<?xml version="1.0" encoding="UTF-8"?>
<VIOLIN>
	<pathogen pathogen_id="pathogen99">
		<pathogen_name>Cancer</pathogen_name>
		<taxon_id></taxon_id>
		<pathogenesis refs=""></pathogenesis>
		<disease_name>Cancer</disease_name>
		<protective_immunity refs=""></protective_immunity>
		<host_range refs=""></host_range>
		<introduction refs="reference1475">Cancer is a class of diseases in which a group of cells display uncontrolled growth (division beyond the normal limits), invasion (intrusion on and destruction of adjacent tissues), and sometimes metastasis (spread to other locations in the body via lymph or blood). These three malignant properties of cancers differentiate them from benign tumors, which are self-limited, and do not invade or metastasize. Most cancers form a tumor but some, like leukemia, do not. The branch of medicine concerned with the study, diagnosis, treatment, and prevention of cancer is oncology.

Cancer affects people at all ages with the risk for most types increasing with age. Cancer caused about 13% of all human deaths in 2007 (7.6 million).  Cancers are caused by abnormalities in the genetic material of the transformed cells. These abnormalities may be due to the effects of carcinogens, such as tobacco smoke, radiation, chemicals, or infectious agents. Other cancer-promoting genetic abnormalities may randomly occur through errors in DNA replication, or are inherited, and thus present in all cells from birth. The heritability of cancers is usually affected by complex interactions between carcinogens and the host's genome.

Genetic abnormalities found in cancer typically affect two general classes of genes. Cancer-promoting oncogenes are typically activated in cancer cells, giving those cells new properties, such as hyperactive growth and division, protection against programmed cell death, loss of respect for normal tissue boundaries, and the ability to become established in diverse tissue environments. Tumor suppressor genes are then inactivated in cancer cells, resulting in the loss of normal functions in those cells, such as accurate DNA replication, control over the cell cycle, orientation and adhesion within tissues, and interaction with protective cells of the immune system.

Definitive diagnosis requires the histologic examination of a biopsy specimen, although the initial indication of malignancy can be symptomatic or radiographic imaging abnormalities. Most cancers can be treated and some forced into remission, depending on the specific type, location, and stage. Once diagnosed, cancer is usually treated with a combination of surgery, chemotherapy and radiotherapy. As research develops, treatments are becoming more specific for different varieties of cancer. There has been significant progress in the development of targeted therapy drugs that act specifically on detectable molecular abnormalities in certain tumors, and which minimize damage to normal cells. The prognosis of cancer patients is most influenced by the type of cancer, as well as the stage, or extent of the disease. In addition, histologic grading and the presence of specific molecular markers can also be useful in establishing prognosis, as well as in determining individual treatments (Wiki: Cancer).</introduction>
	</pathogen>

	<host host_id="host55">
		<common_name>Baboon</common_name>
		<scientific_name>Papio cynocephalus</scientific_name>
		<taxon_id>9556</taxon_id>
    </host>
	<host host_id="host43">
		<common_name>Bank vole</common_name>
		<scientific_name>Clethrionomys glareolus</scientific_name>
		<taxon_id>447135</taxon_id>
    </host>
	<host host_id="host31">
		<common_name>Bear</common_name>
		<scientific_name>Ursus americanus</scientific_name>
		<taxon_id>9643</taxon_id>
    </host>
	<host host_id="host51">
		<common_name>Birds</common_name>
		<scientific_name>Passeroidea</scientific_name>
		<taxon_id>175121</taxon_id>
    </host>
	<host host_id="host35">
		<common_name>Brown Trout</common_name>
		<scientific_name>Salmo trutta</scientific_name>
		<taxon_id>8032</taxon_id>
    </host>
	<host host_id="host30">
		<common_name>Buffalo</common_name>
		<scientific_name>Bison bison</scientific_name>
		<taxon_id>9901</taxon_id>
    </host>
	<host host_id="host53">
		<common_name>Carnivores</common_name>
		<scientific_name>Vulpes</scientific_name>
		<taxon_id>9625</taxon_id>
    </host>
	<host host_id="host37">
		<common_name>Cat</common_name>
		<scientific_name>Felis catus</scientific_name>
		<taxon_id>9685</taxon_id>
    </host>
	<host host_id="host52">
		<common_name>Catfishes</common_name>
		<scientific_name>Siluriformes</scientific_name>
		<taxon_id>7995</taxon_id>
    </host>
	<host host_id="host12">
		<common_name>Cattle</common_name>
		<scientific_name>Bos taurus</scientific_name>
		<taxon_id>9913</taxon_id>
    </host>
	<host host_id="host8">
		<common_name>Chicken</common_name>
		<scientific_name>Gallus gallus</scientific_name>
		<taxon_id>9031</taxon_id>
    </host>
	<host host_id="host42">
		<common_name>Chimpanzee</common_name>
		<scientific_name>Pan troglodytes</scientific_name>
		<taxon_id>9598</taxon_id>
    </host>
	<host host_id="host26">
		<common_name>chinchillas</common_name>
		<scientific_name>Chinchillidae</scientific_name>
		<taxon_id>10150</taxon_id>
    </host>
	<host host_id="host24">
		<common_name>Copper Pheasant</common_name>
		<scientific_name>Syrmaticus soemmerringii</scientific_name>
		<taxon_id>9067</taxon_id>
    </host>
	<host host_id="host29">
		<common_name>Deer</common_name>
		<scientific_name>Cervus elaphus</scientific_name>
		<taxon_id>9860</taxon_id>
    </host>
	<host host_id="host32">
		<common_name>Deer mouse</common_name>
		<scientific_name>Peromyscus maniculatus</scientific_name>
		<taxon_id>10042</taxon_id>
    </host>
	<host host_id="host36">
		<common_name>Dog</common_name>
		<scientific_name>Canis familiaris</scientific_name>
		<taxon_id>9615</taxon_id>
    </host>
	<host host_id="host9">
		<common_name>Ducks</common_name>
		<scientific_name>Anas</scientific_name>
		<taxon_id>8835</taxon_id>
    </host>
	<host host_id="host19">
		<common_name>Ferret</common_name>
		<scientific_name>Mustela putorius furo</scientific_name>
		<taxon_id>9669</taxon_id>
    </host>
	<host host_id="host48">
		<common_name>Fish</common_name>
		<scientific_name>Hyperotreti</scientific_name>
		<taxon_id>117565</taxon_id>
    </host>
	<host host_id="host41">
		<common_name>Gerbil</common_name>
		<scientific_name>Gerbillina</scientific_name>
		<taxon_id>10045</taxon_id>
    </host>
	<host host_id="host13">
		<common_name>Goat</common_name>
		<scientific_name>Capra hircus</scientific_name>
		<taxon_id>9925</taxon_id>
    </host>
	<host host_id="host47">
		<common_name>Gray wolf</common_name>
		<scientific_name>Canis lupus</scientific_name>
		<taxon_id>9612</taxon_id>
    </host>
	<host host_id="host7">
		<common_name>Guinea pig</common_name>
		<scientific_name>Cavia porcellus</scientific_name>
		<taxon_id>10141</taxon_id>
    </host>
	<host host_id="host16">
		<common_name>Hamster</common_name>
		<scientific_name>Mesocricetus auratus</scientific_name>
		<taxon_id>10036</taxon_id>
    </host>
	<host host_id="host18">
		<common_name>Horse</common_name>
		<scientific_name>Equus caballus</scientific_name>
		<taxon_id>9796</taxon_id>
    </host>
	<host host_id="host2">
		<common_name>Human</common_name>
		<scientific_name>Homo sapiens</scientific_name>
		<taxon_id>9606</taxon_id>
    </host>
	<host host_id="host39">
		<common_name>Macaque</common_name>
		<scientific_name>Macaca fascicularis</scientific_name>
		<taxon_id>9541</taxon_id>
    </host>
	<host host_id="host40">
		<common_name>Mongolian Gerbil</common_name>
		<scientific_name>Meriones unguiculatus</scientific_name>
		<taxon_id>10047</taxon_id>
    </host>
	<host host_id="host5">
		<common_name>Monkey</common_name>
		<scientific_name>Platyrrhini</scientific_name>
		<taxon_id>9479</taxon_id>
    </host>
	<host host_id="host3">
		<common_name>Mouse</common_name>
		<scientific_name>Mus musculus</scientific_name>
		<taxon_id>10090</taxon_id>
    </host>
	<host host_id="host59">
		<common_name>None</common_name>
		<scientific_name>None</scientific_name>
		<taxon_id></taxon_id>
    </host>
	<host host_id="host50">
		<common_name>Parrot</common_name>
		<scientific_name>Psittacidae</scientific_name>
		<taxon_id>9224</taxon_id>
    </host>
	<host host_id="host15">
		<common_name>Pig</common_name>
		<scientific_name>Sus scrofa</scientific_name>
		<taxon_id>9823</taxon_id>
    </host>
	<host host_id="host6">
		<common_name>Rabbit</common_name>
		<scientific_name>Oryctolagus cuniculus</scientific_name>
		<taxon_id>9986</taxon_id>
    </host>
	<host host_id="host45">
		<common_name>Rainbow trout</common_name>
		<scientific_name>Oncorhynchus mykiss</scientific_name>
		<taxon_id>8022</taxon_id>
    </host>
	<host host_id="host4">
		<common_name>Rat</common_name>
		<scientific_name>Rattus</scientific_name>
		<taxon_id>10114</taxon_id>
    </host>
	<host host_id="host34">
		<common_name>Raven</common_name>
		<scientific_name>Corvus corax</scientific_name>
		<taxon_id>56781</taxon_id>
    </host>
	<host host_id="host54">
		<common_name>sei whale</common_name>
		<scientific_name>Balaenoptera borealis</scientific_name>
		<taxon_id>9768</taxon_id>
    </host>
	<host host_id="host17">
		<common_name>Sheep</common_name>
		<scientific_name>Ovis aries</scientific_name>
		<taxon_id>9940</taxon_id>
    </host>
	<host host_id="host28">
		<common_name>Squirrel</common_name>
		<scientific_name>Spermophilus richardsonii</scientific_name>
		<taxon_id>37591</taxon_id>
    </host>
	<host host_id="host44">
		<common_name>Tree shrew</common_name>
		<scientific_name>Tupaiidae</scientific_name>
		<taxon_id>9393</taxon_id>
    </host>
	<host host_id="host49">
		<common_name>Trouts, salmons &amp; chars</common_name>
		<scientific_name>Salmoninae</scientific_name>
		<taxon_id>504568</taxon_id>
    </host>
	<host host_id="host38">
		<common_name>Turkey</common_name>
		<scientific_name>Meleagris gallopavo</scientific_name>
		<taxon_id>9103</taxon_id>
    </host>
	<host host_id="host33">
		<common_name>Vole</common_name>
		<scientific_name>Microtus ochrogaster</scientific_name>
		<taxon_id>79684</taxon_id>
    </host>
	<host host_id="host27">
		<common_name>Water buffalo</common_name>
		<scientific_name>Bubalus bubalis</scientific_name>
		<taxon_id>391902</taxon_id>
    </host>
	<vaccine vaccine_id="vaccine5304">
		<vaccine_name>(H115D)VHL35 Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4597">A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. In (H115D)VHL35 peptide, histidine is substituted for an aspartic acid in position 115. It might be used to elicit or boost cellular immunity to cancers that expressing the von Hippel-Lindau mutation. (NCI04) (NCIT_C28776).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4071">
		<vaccine_name>1(SOCS1)-silenced dentritic cell (DC) vaccines</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Dendritic Cell Vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3002">To obtain SOCS1-silenced DCs, DCs derived from mouse bone marrow cells ex vivo were induced to differentiation in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4, and then transduced with Len-SOCS1-shRNA or control Len-GFP lentiviruses. The SOCS1-silenced DCs were loaded by TRP2 peptide to prepare the DC vaccine, which was induced to mature by LPS. The DCs were analyzed by flow cytometry (FCM) for surface expressions of MHCII and CD86 and by real-time PCR for the expressions of SOCS1, IL-10 as well as IL-12p40. B16 or IL-10-silenced B16 (IL-10(-/-);) cells were inoculated into C57BL/6 mice (Wang et al., 2013).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1696" host_id="host3">
			<immune_response refs="reference3002">SOCS1 expression in DCs was down-regulated by 80% after Len-SOCS1-shRNA lentivirus infection. In the DCs with down-regulated SOCS1 expression, the expressions of MHCII and CD86 increased a little, which did not differ significantly from the control DCs, and IL-10 level dropped and IL-12p40 went up significantly compared with the control DCs (Wang et al., 2013).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5414">
		<vaccine_name>117-126:FGF-5 Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4271">A fragment of fibroblast growth factor-5 (FGF-5). Originally isolated from a renal cell carcinoma cell line that overexpressed FGF-5, FGF-5:117-126 peptide is recognized by tumor infiltrating cytotoxic T lymphocytes. Overexpressed by several cancer cell types, this peptide is being tested as a potential target for antineoplastic immunotherapies. (NCI04) (NCIT_C28780).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5418">
		<vaccine_name>12 Melanoma Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="">NULL</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine3978">
		<vaccine_name>12MP</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Multipeptide</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs="reference2900">2 class I major histocompatibility complexâ€“restricted melanoma peptides (Slingluff et al., 2011).</description>
		<adjuvant refs="">6MHP (a mixture of six melanoma-associated helper peptides) or tetanus helper peptide</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1641" host_id="host2">
			<immune_response refs="reference2900">Vaccination with 12MP plus tetanus induced CD8(+) T-cell responses in 78% of patients and CD4(+) T-cell responses to tetanus peptide in 93% of patients. Vaccination with 12MP plus 6MHP induced CD8(+) responses in 19% of patients and CD4(+) responses to 6MHP in 48% of patients. CY had no significant effect on T-cell responses (Slingluff et al., 2011).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4070">
		<vaccine_name>12MP, 12MP/Tet, 12MP/6MHP, or 6MHP</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>multipeptide</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs="reference3001">4 treatment groups, vaccinated with 12 MHC class I-restricted melanoma peptides to stimulate CTL (12 MP, group A), plus a tetanus peptide (group B), or a mixture of 6 melanoma helper peptides (6 MHP, group C) to stimulate helper T lymphocytes (HTL), or with 6 melanoma helper peptide (6 MHP) alone (group D), in incomplete Freund's adjuvant plus granulocyte macrophage colony-stimulating factor (Slingluff et al., 2013).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5290">
		<vaccine_name>27-35(27L):MART-1 Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4325">A synthetic peptide consisting of amino acids 27 through 35 of the melanoma differentiation antigen MART-1. 27-35(27L) MART-1 has a leucine substitution at amino acid position 27 to improve binding to HLA-A*0201. Vaccination with this agent may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against melanoma cells expressing MART-1. (NCIT_C28784).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5076">
		<vaccine_name>3'-Aminomethyl Nicotine-P. aeruginosa r-Exoprotein A Conjugate Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4550">A hapten-carrier immunoconjugate composed of the hapten trans-3'-aminomethyl nicotine conjugated to a recombinant P. aeruginosa exoprotein A, rendered nontoxic through amino acid depletion, with potential immunostimulating activity. Upon vaccination with 3'-aminomethyl nicotine-P. aeruginosa r-exoprotein A conjugate vaccine, the immune system may produce anti-nicotine antibodies. Antibody-bound nicotine cannot pass the blood brain barrier (BBB) to activate brain nicotine receptors. Nicotine, a small organic molecule that is not immunogenic, must be haptenized and conjugated to a carrier protein, such as nontoxic recombinant P. aeruginosa exoprotein A, to induce an antibody response. Aluminium hydroxide may be used as an adjuvant for this vaccine. (NCIT_C88341).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4986">
		<vaccine_name>851B Gel</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4668">A topical gel containing a peptide derived from the human papillomavirus (HPV). Application of 851B gel may stimulate the host immune system to trigger a cytotoxic T-lymphocyte response to cells that express HPV. (NCIT_C48637).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5244">
		<vaccine_name>Abagovomab</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4401">A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125, with potential antineoplastic activity. With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host immune system to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation. (NCIT_C26449).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5543">
		<vaccine_name>Ad CMV I kappaB alpha</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="">NULL</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5179">
		<vaccine_name>Ad-sig-hMUC-1/ecdCD40L Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4258">A cancer vaccine consisting of a recombinant adenoviral vector encoding the tumor-associated antigen (TAA) human MUC-1 (hMUC-1) linked to the extracellular domain (ecd) of the co-stimulatory molecule CD40 ligand (CD40L) and an adenovirus signal sequence that encodes a secretory signal peptide (Ad-sig) with potential immunostimulating and antineoplastic activities. Due to the presence of the secretory signal peptide expressed by Ad-sig in the vaccine construct, transfected cells may secrete a fusion protein composed of hMUC-1 and the CD40L ecd. The CD40L moiety part of the fusion protein binds to CD40 receptors on dendritic cells (DCs). Subsequently, DCs may be activated and migrate, T-cells may expand, and a cytotoxic T lymphocyte (CTL) response against tumor cells that overexpress hMUC-1 may follow. MUC-1 is a hypoglycosylated TAA overexpressed by epithelial cancer cells. (NCIT_C77910).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5303">
		<vaccine_name>Ad5-yCD/mutTKSR39rep-hIL12</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4585">A replication-competent oncolytic adenovirus encoding the murine pro-inflammatory cytokine interleukin-12 (IL-12) gene and two suicide fusion genes, a yeast cytosine deaminase (yCD) and a mutant form of herpes simplex virus type 1 thymidine kinase (HSV-1 TKSR39), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration of Ad5-yCD/mutTKSR39rep-hIL12, the adenovirus selectively infects and replicates in tumor cells, which results in direct tumor cell lysis. Synergistically, IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma (IFN-g) and inducing cytotoxic T-lymphocyte (CTL) responses against tumor cells, which may result in immune-mediated tumor cell death, inhibition of tumor cell proliferation and inhibition of tumor angiogenesis. In addition, Ad5-yCD/mutTKSR39rep-hIL12-infected cancer cells express yCD and TKSR39; upon administration of the prodrugs 5-fluorocytosine (5-FC) and valganciclovir (vGCV), the yCD and HSV-1 TKSR39 activate these prodrugs to form 5-fluorouracil (5-FU) and ganciclovir, respectively. 5-FU gets converted to 5-fluoro-uridine monophosphate (5-FUMP) and subsequently to 5-fluoro-deoxyuridine monophosphate (5-FdUMP); 5-FdUMP irreversible inhibits thymidylate synthase, inhibits deoxythymidine triphosphate (dTTP) formation and halts DNA synthesis. Once phosphorylated intracellularly, ganciclovir triphosphate competitively inhibits deoxyguanosine triphosphate (dGTP) incorporation into DNA and inhibits DNA synthesis. (NCIT_C123930).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5456">
		<vaccine_name>Ad5CMV-p53 Gene</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4578">A replication-defective adenoviral-CMV vector that encodes a wild-type p53 gene. Ad5CMV-p53 induces tumor cells that have been transfected with the vector to produce wild-type p53, a tumor suppressor gene that is deleted or mutated in a significant number of cancers. In transfected tumor cells, the wild-type p-53 gene product exerts an antitumor effect by blocking cell cycle progression at the G1/S regulation point, activating DNA repair proteins in the presence of DNA damage, and initiating apoptosis when DNA damage is irreparable. (NCI04) (NCIT_C2471).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5324">
		<vaccine_name>Ad5F35-LMP1/LMP2-Transduced Autologous Dendritic Cells</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4363">Autologous dendritic cells (DCs) transduced with the replication-deficient adenoviral vector Ad5F53 encoding the Epstein-Barr virus (EBV) transmembrane latent membrane proteins 1 and 2 (LMP1/LMP2) with potential immunostimulatory activity. Vaccination with Ad5F35-LMP1/LMP2-transduced autologous dendritic cells may stimulate a specific cytotoxic T-lymphocyte (CTL) response against LMP1- and LMP2-expressing tumor positive cells, resulting in tumor cell lysis and inhibition of tumor cell proliferation. LMP1 and LMP2 are expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkins disease. (NCIT_C73995).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5523">
		<vaccine_name>Adenovector Encoding MDA7</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4320">A nonreplicating adenoviral vector (adenovector) encoding the melanoma differentiation-associated 7 gene (MDA7) with potential antineoplastic activity. After intratumoral injection and adenovector-mediated gene transfer of MDA7 into tumor cells, the expressed MDA7 transgene may inhibit tumor cell proliferation and induce tumor cell apoptosis. (NCIT_C48368).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4999">
		<vaccine_name>Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4380">A genetically-modified, dendritic cell-based (DCs) vaccine in which the autologous cells are transduced with an adenoviral vector expressing the tumor antigen prostate-specific membrane antigen (PSMA) and a fusion protein composed of synthetic ligand inducible adjuvant iMC composed of a drug-inducible costimulatory CD40 receptor (iCD40) and the adaptor protein MyD88, with potential immunomodulating and antineoplastic activities. The iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to the FK506 modified drug-binding protein 12 (FKBP12). Upon intradermal administration of BPX-201, these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination, the dimerizing agent AP1903 is administered. AP1903 binds to the drug binding domain, leading to iMC oligomerization and activation of iCD40 and MyD88-mediated signaling in iMC-expressing DCs. This signaling pathway activates the DCs and stimulates a cytotoxic T-lymphocyte (CTL) response against host tumor cells that express PSMA. PSMA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed in prostate cancer cells and is used as a tumor marker for both diagnosis and treatment evaluation. MyD88 is involved in interleukin 1 receptor (IL1R) and toll-like receptor (TLR) signaling. (NCIT_C106242).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5137">
		<vaccine_name>Adenoviral Vector Ad5-CEA(6D) Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4178">A replication-defective, E1- and E2b-deleted oncolytic adenoviral serotype 5 (Ad5) encoding an epitope of human carcinoembryonic antigen (CEA) with potential antineoplastic activity. Adenoviral vector Ad5-CEA(6D) vaccine expresses a highly immunogenic analogue of CEA [CAP1-(6D)]. Upon administration, this vaccine may induce both humoral and cellular immune responses against tumor cells expressing the CEA antigen, thereby resulting in the immune-mediated inhibition of tumor cell proliferation and tumor cell death. CEA, a tumor-associated antigen, is overexpressed in various tumor cell types. Deletion of early genes E1 and E2b in Ad5 potentially circumvent pre-existing anti-adenovirus immunity and is capable of inducing strong immune responses. (NCIT_C91373).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5529">
		<vaccine_name>Adenovirus 5-CD40 Ligand</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4416">An adenovirus vector engineered to produce CD40 ligand. For use as a possible gene therapy agent. May induce apoptosis through the TNF pathway. (NCIT_C2493).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5489">
		<vaccine_name>Adenovirus 5-Fibroblast Growth Factor 2</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="">NULL</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5147">
		<vaccine_name>Adenovirus 5-Human Guanylyl Cyclase C-PADRE Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4339">A replication-defective, recombinant adenoviral serotype 5 (Ad5) encoding human guanylyl cyclase C (hGCC) and the synthetic Pan DR epitope (PADRE), with potential antineoplastic and immunomodulating activities. Upon intramuscular administration, the Ad5-hGCC-PADRE vaccine expresses hGCC, which may induce both humoral and cellular immune responses against tumor cells expressing the hGCC antigen. This results in the immune-mediated inhibition of tumor cell proliferation, and leads to tumor death. The hGCC protein is normally restricted to intestinal epithelial cells but is overexpressed by metastatic colorectal tumors. PADRE is a helper T-lymphocyte epitope that is able to augment the magnitude and duration of the cytotoxic T-lymphocyte (CTL) response. (NCIT_C112005).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5435">
		<vaccine_name>Adenovirus B7-1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4341">A gene-viral vector complex comprised of an adenovirus vector and B7-1 gene targeting the CD80 antigen. Adenovirus B7-1 is used as a component in antineoplastic vaccines to elicit a cytotoxic T-cell response. (NCI04) (NCIT_C2204).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5388">
		<vaccine_name>Adenovirus Encoding Rat HER-2/neu</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4342"> A replication-defective oncolytic adenovirus, encoding rat Her-2/neu (ErbB-2), with potential antineoplastic activity. Upon administration, adenovirus encoding rat HER-2/neu may induce an immune response against tumor cells expressing the HER-2/neu antigen, which may result in the immune-mediated inhibition of tumor cell proliferation and tumor cell death. Her-2/neu, a tumor-associated antigen and member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in various tumor cell types. (NCIT_C62527).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5370">
		<vaccine_name>Adenovirus Encoding Tyrosinase/MART-1/MAGEA6-transduced Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4591">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a recombinant adenoviral vector encoding three full length human melanoma associated antigens (MAAs), tyrosinase, melan-A (MART-1) and the melanoma antigen A6 (MAGEA6), with potential antineoplastic activity. Upon intradermal administration, adenovirus encoding tyrosinase/MART-1/MAGEA6-transduced autologous DC vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tyrosinase/MART-1/MAGEA6-positive tumor cells, which may result in tumor cell death and decreased tumor growth. Tyrosinase, a melanoma-specific differentiation antigen, catalyzes the first step of melanin synthesis in melanocytes. Vaccination with multi-antigen modified DC may improve the efficacy of the DC immunotherapy. (NCIT_C102753).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5082">
		<vaccine_name>Adenovirus HER2-Transduced Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4335">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a replication-deficient adenovirus vector encoding HER-2 with potential antineoplastic activity. Upon administration, adenovirus HER2-transduced autologous dendritic cell vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against HER-2-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by some breast, ovarian, and gastric cancers. (NCIT_C61098).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5122">
		<vaccine_name>Adenovirus RSV-TK</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4607">A gene viral vector complex comprised of a replication-defective adenovirus and a herpes simplex virus thymidine kinase gene that activates ganciclovir, causing inhibition of DNA synthesis and apoptosis. (NCIT_C2545).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5285">
		<vaccine_name>Adenovirus-mediated Human Interleukin-12</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4627">A replication incompetent adenovirus encoding human pro-inflammatory cytokine interleukin-12 (IL-12) (Ad.hIL-12), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, the adenovirus selectively infects and replicates in tumor cells, which may result in tumor cell lysis. Synergistically, IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma and inducing cytotoxic T cell responses against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. (NCIT_C37515).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5256">
		<vaccine_name>Adenovirus-p53 Transduced Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4628">A cancer vaccine consisting of autologous dendritic cells (DCs) transduced with a recombinant adenovirus encoding p53 peptide, with potential immunomodulating activity. Intradermal vaccination with adenoviral-p53 transduced dendritic cell vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing mutant p53, resulting in tumor cell lysis. p53, a tumor suppressor gene, is mutated in many tumor cells, resulting in the loss of apoptosis regulation and abnormal cell proliferation. (NCIT_C90542).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5010">
		<vaccine_name>Adenovirus-PSA Prostate Cancer Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4372">A cancer vaccine composed of a genetically engineered, replication-deficient type 5 adenovirus carrying the human prostate-specific antigen (PSA), with potential immunostimulating and antineoplastic activities. Upon subcutaneous vaccination with the adenovirus-PSA prostate cancer vaccine, the adenovirus infects cells and expresses PSA. In turn, PSA may activate the immune system and may induce a cytotoxic T-lymphocyte response against PSA-expressing tumor cells. PSA, a tumor associated antigen, is expressed by prostate epithelial cells and is overexpressed in prostate cancer. (NCIT_C102541).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5545">
		<vaccine_name>Adipose-Derived Regenerative Cells</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4362"> A population of cells derived from adipose tissue with stem cell and wound repair activities. Adipose-derived regenerative cells (ADRC) consists of several cell types, such as adult stem cells, vascular endothelial cells, and vascular smooth muscle cells, among others. These cells contribute to wound repair through a variety of mechanisms by promoting blood vessel growth and blocking apoptosis. In addition, ADRC can differentiate into several tissue types, such as bone, cartilage, fat, skeletal muscle, smooth muscle and cardiac muscle. (NCIT_C73997).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5203">
		<vaccine_name>AdRTVP-1-Transduced Prostate Cancer Cell-Based Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4396">A cell-based vaccine comprised of prostate cancer cells transduced with an adenoviral vector encoding human RTVP-1 (AdRTVP-1), with potential antineoplastic and immunostimulating activities. RTVP-1, also referred to as glioma pathogenesis-related protein 1 (GLIP1), is down-regulated in prostate tumors. Regulated by tumor suppressor p53, the expression of RTVP-1 functions as a tumor suppressor, and is abundant in normal human prostate epithelial cells as well as in differentiated macrophages. Administration of this vaccine leads to an induction of apoptosis through the expression of RTVP-1 and results in a reduction in cellular proliferation in prostate cancer cells. In addition, this cancer-cell based vaccine may induce a cytotoxic T lymphocyte (CTL) response against prostate specific tumor associated antigens, resulting in an immune-mediated prostate cancer cell death. Furthermore, RTVP-1 stimulates CTL and natural killer (NK) cell activities. (NCIT_C64785).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5436">
		<vaccine_name>AE37 Peptide/GM-CSF Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4118">A vaccine containing HER2/Neu-derived epitope (amino acids 776-790) linked to li-Key peptide (li-Key/HER2/neu hybrid peptide or AE37), and combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunoadjuvant activities. Upon vaccination, AE37 may activate the immune system and stimulate T-helper cells against HER2/Neu expressing cancer cells. GM-CSF may potentiate the immune response against cancer cells expressing the HER2/Neu antigen. The Ii-Key moiety, a 4-amino acid (LRMK) epitope from the MHC class II-associated invariant chain (Ii protein), increases T-helper cell stimulation against HER2/neu antigen when compared to unmodified class II epitopes. HER2/neu, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types and is highly immunogenic. (NCIT_C91719).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5275">
		<vaccine_name>AFP Gene Hepatocellular Carcinoma Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4321">A cancer vaccine composed of naked plasmid DNA of the gene for the tumor-associated antigen alpha-fetoprotein (AFP), a macromolecule that acts as a specific immunologic target for hepatocellular carcinoma. This agent exerts an antitumor effect by inducing cytotoxic T-lymphocytes to attack AFP-expressing tumor cells. (NCI04) (NCIT_C2512).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5402">
		<vaccine_name>AIM2(-1)/HT001(-1)/TAF1B(-1) Frameshift Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4547">A cancer vaccine containing the three frame shift peptides (FSP) AIM2(-1), HT001(-1) and TAF1B(-1), with potential immunomodulating activity. Upon administration, the AIM2(-1)/HT001(-1)/TAF1B(-1) FSP vaccine may induce an immune response against microsatellite instability (MSI) colorectal cancer-associated antigens. Frame shift mutations of AIM2 (absent in melanoma 2, an interferon-inducible protein), HT001 (asteroid homolog 1 or ASTE1, with an unknown function) and TAF1B (TATA box-binding protein-associated RNA polymerase I B, a transcription factor) are seen in MSI-positive colorectal cancers and may be associated with malignant transformation, tumor progression and the presence of tumor-infiltrating lymphocytes. These FSPs all have one-base deletions. (NCIT_C99129).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5422">
		<vaccine_name>Algenpantucel-L</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4191">A cancer vaccine comprised of irradiated allogeneic pancreatic cancer cells transfected to express murine alpha-1,3-galactosyltransferase with potential antitumor activity. Vaccination is associated with the expression of murine alpha-1,3-galactosyl (alpha-gal) carbohydrate residues on cell membrane glycoproteins and glycolipids of the vaccine pancreatic cancer cell allograft; murine alpha-gal epitopes, not present on human cells, then induce a hyperacute rejection of the vaccine pancreatic cancer cell allograft. The hyperacute rejection involves the binding of pre-existing human anti-alpha-gal antibodies (which naturally occur against gut flora) to murine alpha-gal epitopes, resulting in the rapid activation of antibody-dependent cell-mediated cytotoxicity (ADCC) towards allograft cells. The host immune system then attacks endogenous pancreatic cancer cells, resulting in ADCC towards endogenous pancreatic cancer cells. (NCIT_C61082).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5020">
		<vaccine_name>Allogeneic AML Antigen-expressing Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4469">A cancer vaccine consisting of allogeneic, immortalized dendritic precursor cells derived from a patient with acute myelogenous leukemia (AML), with potential immunostimulatory and antineoplastic activities. Upon ex vivo stimulation and expansion of the precursor cells into mature, fully functional dendritic cells (DCs) and subsequent administration, the allogeneic AML antigen-expressing DC vaccine may elicit a potent cytotoxic T-cell (CTL) and antibody response against AML antigen-expressing cells, resulting in tumor cell death. (NCIT_C97265).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4998">
		<vaccine_name>Allogeneic B7.1/HLA-A1 Transfected Tumor Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4170">An allogeneic whole cell vaccine, derived from irradiated allogenic tumor cells manipulated to express human B7.1 (CD80 antigen) and human leukocyte antigen (HLA) A1, with potential antitumor activity. Vaccination with allogeneic B7.1/HLA-A1 transfected tumor cell vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor cell proliferation. (NCIT_C70985).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5257">
		<vaccine_name>Allogeneic Cellular Vaccine 1650-G</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4499">A pluripotent, allogeneic, tumor cell vaccine composed of irradiated tumor cells from the non-small cell lung cancer (NSCLC) cell line 1650 and the immunoadjuvant recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) (1650-G), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic cellular vaccine 1650-G may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against tumor-associated antigens (TAAs) expressed on NSCLC cells. GM-CSF potentiates the antitumor immune response. The 1650 cell line is used as a source for TAAs. (NCIT_C119759).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5446">
		<vaccine_name>Allogeneic Dendritic Cell Vaccine COMBIG-DC</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4574">A cancer vaccine consisting of allogeneic, immortalized dendritic cells (DCs) loaded with tumor specific antigens and activated, with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration of the allogeneic dendritic cell vaccine COMBIG-DC, these activated DCs attract natural killer (NK) cells, induce an anti-inflammatory response leading to the induction of NK-cell-mediated tumor cell death. Upon release of tumor associated antigens (TAAs) from the lysed tumor cells, these antigens are taken up by antigen presenting cells which activate the immune system to elicit a potent cytotoxic T-cell (CTL) response against the TAAs, resulting in the death of TAAs-expressing tumor cells. (NCIT_C99902).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5102">
		<vaccine_name>Allogeneic Dendritic Cell-Myeloma Idiotype Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4366">A cell-based vaccine composed of allogeneic dendritic cells pulsed ex-vivo with an autologous myeloma idiotype with potential antineoplastic activity. Upon administration, allogeneic dendritic cell-myeloma idiotype vaccine may stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against myeloma cells, resulting in cell lysis. (NCIT_C61434).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5023">
		<vaccine_name>Allogeneic Glioblastoma Stem-like Cell Line Lysate-pulsed Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4275">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from an allogeneic glioblastoma (GBM) stem-like cell line, with potential immunostimulatory and antineoplastic activities. Upon administration allogeneic glioblastoma stem-like cell line lysate-pulsed autologous dendritic cell vaccine exposes the immune system to GBM stem cell antigens, which may result in cytotoxic T lymphocyte (CTL) and antibody responses against GBM cells. This leads to GBM cell lysis. GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells. (NCIT_C113296).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5327">
		<vaccine_name>Allogeneic GM-CSF-Based Myeloma Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4141">An allogeneic tumor cell vaccine containing myeloma cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Upon vaccination, allogeneic GM-CSF-based myeloma cellular vaccine secretes GM-CSF, which may potentiate a tumor-specific cytotoxic T-lymphocyte (CTL) response against myeloma cancer cell-associated antigens. (NCIT_C90540).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5059">
		<vaccine_name>Allogeneic GM-CSF-Secreting Breast Cancer Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4475">An allogenic vaccine consisting of irradiated breast cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene. Upon vaccination, the genetically modified cells secrete GM-CSF, thereby potentiating a tumor-specific T cell response against breast cancer cell-asociated antigens.A vaccine that is being studied as a way to help the body's immune system kill breast cancer cells. To make the vaccine, the GM-CSF gene is put into breast cancer cells in the laboratory. The cells are then treated with radiation to stop them from growing and injected into the same or a different patient. The GM-CSF protein made by the changed breast cancer cells may help the immune system kill breast cancer cells in the body. (NCIT_C48371).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5075">
		<vaccine_name>Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4497">An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 10.05 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 10.05 tumor cell line. (NCIT_C101892).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5515">
		<vaccine_name>Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4498">An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 6.03 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 6.03 tumor cell line. (NCIT_C101891).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5269">
		<vaccine_name>Allogeneic Large Multivalent Immunogen Breast Cancer Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4164">A cancer vaccine, containing human-specific large multivalent immunogens (LMIs) isolated from the membrane fraction of cells from a breast cancer cell line, with potential immunostimulatory and antineoplastic activities. Upon administration, allogeneic large multivalent immunogen breast cancer vaccine may stimulate a cytotoxic T lymphocyte (CTL) immune response against tumor cells that express the breast cancer cell-specific LMIs. (NCIT_C79799).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5423">
		<vaccine_name>Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4313">A cancer vaccine, containing human-specific large multivalent immunogen (LMI) isolated from plasma membrane fractions of the melanoma cell lines MSM-M1 and MSM-M2, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic large multivalent immunogen melanoma vaccine LP2307 may stimulate a CD8+ cytotoxic T lymphocyte (CTL) response against melanoma tumor cells that express melanoma-specific LMI. (NCIT_C78862).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5376">
		<vaccine_name>Allogeneic Melanoma Vaccine AGI-101H</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4150">A cancer vaccine derived from two gentically modified human melanoma cell lines with potential antineoplastic activity. Allogeneic melanoma vaccine AGI-101H consists of a 1:1 mixture of cells from two genetically modified human melanoma cell lines, designated as Mich1H6 and Mich2H6, that have been gamma-irradiated to render the cells non-proliferative. Upon administration, this vaccine may stimulate a cytotoxic immune response against melanoma tumor cells. (NCIT_C78861).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5440">
		<vaccine_name>Allogeneic Mesothelioma Tumor Lysate-pulsed Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4228">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a mixture of lysates from five allogeneic mesothelioma tumor cell lines, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, DCs are loaded with allogeneic mesothelioma tumor cell lysates. Upon re-administration of the allogeneic mesothelioma tumor lysate-pulsed autologous DC vaccine, the immune system is exposed to an undefined amount of mesothelioma-associated antigens, which stimulates the induction of a specific cytotoxic T-lymphocyte (CTL) response against mesothelioma tumor cells and leads to tumor cell lysis. (NCIT_C121640).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5054">
		<vaccine_name>Allogeneic Multipotent Adult Progenitor Cells</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4196">A biologic product that consists of undifferentiated stem cells, obtained from adult bone marrow or other non-embryonic tissue sources, that are expanded in vitro and deposited in master cell banks for &quot;off-the-shelf&quot; use, with potential hematopoiesis-inducing and immunomodulating activities. Allogeneic multipotent adult progenitor cells (MAPCs) are non-immunogenic due to the lack of major histocompatibility (MHC) molecule expression, and so elicit no immune response upon administration. In vivo, bone marrow-derived adult stem cells are capable of maturing into a broad range of cell types and may help restore the immune system by producing multiple therapeutic molecules in response to inflammation and tissue damage. (NCIT_C77874).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5358">
		<vaccine_name>Allogeneic Renal Cell Carcinoma Vaccine MGN1601</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4136">A whole cell vaccine comprised of irradiated allogeneic renal cell carcinoma (RCC) with potential immunostimulating and antineoplastic activities. Allogeneic renal cell carcinoma vaccine MGN1601 contains two active ingredients: 1) genetically modified allogeneic RCC cells that are transiently transfected with four different MIDGE (Minimalistic Immunogenically Defined Gene Expression) vectors encoding IL-7, GM-CSF, CD80 and CD154 and 2) the synthetic DNA-based immunomodulator dSLIM-30L1, a TLR9 agonist.. Vaccination results in expression of IL-7, GM-CSF, CD80 and CD154, which all contribute to the activation or enhancement of immune responses. Furthermore, administration of this RCC vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor growth. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity. (NCIT_C95213).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5339">
		<vaccine_name>Allogeneic Tumor Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4466">A vaccine composed of tumor cells isolated from the tumor of one patient, killed and processed, and administered to another patient to stimulate cytotoxic immune responses to a similar tumor cell type. The cells found in this type of whole-cell vaccine express many cell-surface tumor-associated antigens. This vaccine is frequently administered with an adjuvant immunostimulant. (NCIT_C1983).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5119">
		<vaccine_name>Allogenic Glioma Cancer Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Inactivated or "killed" vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4608">A vaccine composed of killed glioma cancer cells from another patient for use in immunotherapy. (NCIT_C2055).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5313">
		<vaccine_name>Alpha Fetoprotein Adenoviral Vector Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4477">A vaccine consisting of a recombinant adenoviral vector encoding alpha fetoprotein. After vaccination, expressed alpha fetoprotein may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein, resulting in tumor cell lysis. (NCI05) (NCIT_C48372).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5534">
		<vaccine_name>Alpha Fetoprotein Plasmid DNA Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4618">A vaccine consisting of plasmid DNA encoding alpha fetoprotein. After vaccination, expressed alpha fetoprotein may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein, resulting in tumor cell lysis. (NCI05) (NCIT_C48373).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1789" gene_id="gene315">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response2367" host_id="host2">
			<immune_response refs="reference3903">This patient had a weak AFP-specific T cell response, a strong AdV-specific cellular response and recurred with an AFP-expressing HCC at nine months (Butterfield et al., 2014).</immune_response>
			<host_strain refs="">male, 80 years, Caucasian, HBV-/HCV-, with stage II HCC</host_strain>
			<vaccination_protocol refs="reference3903">This patient was vaccinated intramuscularly between 11/2010-2/2011. Before vaccination, patients received 650 mg acetaminophen and 50 mg diphenhydramine. For each of the three monthly plasmid injections, 2.5 mg of pAFP and 2.5 mg of pGM-CSF were mixed together in the syringes before injection. For the dose of 109 pfu of AdVhAFP, the virus was diluted in sterile saline in the IMCPL before preparing the syringe for injection (Butterfield et al., 2014).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5349">
		<vaccine_name>Alpha-1,3-galactosyltransferase-expressing Allogeneic Renal Cell Carcinoma Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4192">An allogeneic renal cell cancer (RCC) vaccine composed of cell line-derived RCCs that are genetically engineered to express the murine alpha-1,3-galactosyltransferase (GalT), with potential immunostimulatory and antineoplastic activities. Not naturally occurring in humans, GalT catalyzes the expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate epitopes on the cell membranes of the allogeneic RCCs present in the vaccine. This induces a hyperacute rejection reaction involving pre-existing human anti-alpha-gal antibodies, which bind to the foreign alpha-gal epitopes expressed by the allogeneic RCCs. This results in complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) towards endogenous RCCs with unmodified carbohydrate epitopes. (NCIT_C113647).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5315">
		<vaccine_name>Alpha-fetoprotein Peptide-Pulsed Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4184">A cell-based cancer vaccine comprised of autologous dendritic cells pulsed with four alpha-fetoprotein (AFP) peptides, with potential immunostimulatory and antineoplastic activities. Upon administration, AFP peptide-pulsed autologous dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against AFP-expressing cancer cells, resulting in tumor cell lysis. AFP is overexpressed in a variety of cancer cells. (NCIT_C91378).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5288">
		<vaccine_name>Alpha-Galactosylceramide-Pulsed Autologous Dendritic Cells</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4433">A cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with the marine sponge glycolipid alpha-galactosylceramide (alpha-GalCer) with potential immunostimulatory and antimetastatic activities. Upon administration, alpha-galactosylceramide-pulsed autologous dendritic cells may result in the activation and proliferation of a subset of endogenous natural killer T (NKT) cells, B cells, and CD4+ and CD8+ T cells, and the production of interferon-gamma and interleukin-12; these cascade events may result in a T helper-1 cell-biased proinflammatory antitumor immune response. The NKT cell ligand alpha-GalCer was originally isolated from the marine sponge Agelas mauritianusis. (NCIT_C78489).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5198">
		<vaccine_name>Alpha-type-1 Polarized Dendritic Cells</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4300">A mature polarized dendritic cell with potent immunostimulating activity. Treating dendritic cells (DCs) with interferon-alpha (IFN-a) and polyinosinic:polycytidylic acid (p-I:C) in addition to a cytokine cocktail (tumor necrosis factor alpha/Interleukin-1beta/IFN-gamma) produces mature but not exhausted alpha type-1 polarized DCs (alphaDC1) that are capable of: 1) high responsiveness to other lymphoid chemokines, and 2) producing high level of interleukin-12p70 (IL-12p70). Therefore, alphaDC1 has a much more significant capability of inducing helper T cell (CD4+ T-cell) responses in comparison with the &quot;gold standard&quot; DCs. When pulsed with specific tumor associated antigens (TAAs), alphaDC1 is able to induce a potent cytotoxic T lymphocyte (CTL) response against TAAs; as a result it can be used as a cancer vaccine. (NCIT_C64846).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5334">
		<vaccine_name>ALVAC Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4551">A derivative of the Canarypox Virus, ALVAC can infect mammalian cells but it can't replicate. Thus, it produces a self-limiting infection which does not produce symptoms or harm the host. When carrying foreign genes it will cause transient expression of protein. (NCIT_C1479).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5394">
		<vaccine_name>ALVAC(2) Melanoma Multi-antigen Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4528">A therapeutic cancer vaccine, based on a replication-defective recombinant canarypox virus (ALVAC) encoding multiple melanoma antigens, with potential immunostimulatory and antineoplastic activities. Vaccination with ALVAC(2) melanoma multi-antigen therapeutic vaccine may stimulate the host immune system to mount an immune response against antigen-expressing melanoma cells, resulting in inhibition of tumor growth and/or metastasis. (NCIT_C73998).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5268">
		<vaccine_name>ALVAC(2)-NY-ESO-1 (M)/TRICOM Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4284">A cancer vaccine consisting of a replication-defective recombinant canarypox virus [ALVAC(2)] encoding the cancer-testis antigen NY-ESO and the TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3; also called TRICOM), with potential immunostimulatory and antineoplastic activities. Upon administration, ALVAC(2)/NY-ESO (M)/TRICOM vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against NY-ESO-expressing cancer cells, which may result in the inhibition of tumor cell proliferation. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cells, including bladder, breast, hepatocellular, melanoma, and prostate tumor cells. TRICOM may enhance antigen presentation and activate cytotoxic T-cells. In addition, ALVAC(2) encodes the vaccinia virus (vv) E3L ad K3L genes, which may potentiate the translation of the NY-ESO and TRICOM genes. (NCIT_C79832).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5444">
		<vaccine_name>ALVAC-B7-CEA</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4424">A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus. ALVAC-B7-CEA expresses carcinoembryonic antigen (CEA), a protein that is overexpressed by many tumor cells, and B7.1 (also known as CD80), the natural ligand for the T-cell antigen CD28, to augment the host immune response. This agent has been shown to stimulate a host immune response against tumor cells that express CEA. (NCI04) (NCIT_C2742).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4995">
		<vaccine_name>ALVAC-CEA (6D)-B7.1 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4138">A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus. ALVAC-CEA (6D)-B7.1 vaccine expresses both a highly immunogenic analogue (6D) of the immunodominant epitope of carcinoembryonic antigen (CEA) and B7.1 (also known as CD80), the natural ligand for the T-cell antigen CD28. This agent was designed to stimulate host immune responses against tumor cells that express CEA. (NCI04) (NCIT_C29982).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5003">
		<vaccine_name>ALVAC-CEA (VCP248)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4423">A replication-defective recombinant canarypox virus (ALVAC) that contains the entire human carcinoembryonic antigen (CEA) gene. Vaccination with ALVAC-CEA (VCP248) may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against CEA-positive tumor cells, thereby decreasing tumor growth. (NCI04) (NCIT_C2743).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5125">
		<vaccine_name>ALVAC-CEA B7.1 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4501">A cancer vaccine that uses a viral vector system derived from the canarypox virus engineered to target the carcinoembryonic antigen (CEA). It causes infected cells to temporarily display CEA and activates the immune system to attack the tumor cells. (NCIT_C1977).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5051">
		<vaccine_name>ALVAC-CEA Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4453">A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus, encoding for the tumor associated antigen (TAA) carcinoembryonic antigen (CEA), with potential antineoplastic activity. Upon administration, ALVAC-CEA vaccine expresses CEA and may stimulate a host immune response against tumor cells expressing CEA. This may result in the inhibition of tumor growth and/or metastasis. CEA is overexpressed in a variety of tumor cell types. (NCIT_C1648).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5332">
		<vaccine_name>ALVAC-ESO-1 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4471">A cancer vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) encoding the cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon administration, ALVAC-ESO-1 vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against NY-ESO-1-expressing cancer cells, which may result in the inhibition of tumor cell proliferation. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cells. (NCIT_C90558).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5181">
		<vaccine_name>ALVAC-hB7.1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4406">A vaccine comprise of a canarypox viral vector that carries the gene for human B7.1 (CD80 antigen) with potential use as an autologous therapeutic cancer vaccine. Tumor cells harvested from a patient are infected with ALVAC-hB7 1, thereby producing an autologous cell line that exhibits increased expression of HLA class I and class II, CD54 (ICAM), and CD80. Increased expression of these proteins by this autologous cell line may activate an antitumor T-cell response when the modified cells are administered to the patient. (NCI04) (NCIT_C2485).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5124">
		<vaccine_name>ALVAC-MART-1 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4359">A cancer vaccine containing a replication-defective recombinant canarypox virus (ALVAC), encoding an epitope of MART-1 (melanoma antigen recognized by T-cells), with potential immunostimulatory and antineoplastic activities. Upon administration, the MART-1 epitope is expressed by the ALVAC vector in ALVAC-MART-1 vaccine; a host cytotoxic T lymphocyte (CTL) response against MART-1-expressing tumor cells may follow, resulting in tumor cell lysis and decreased tumor cell proliferation (NCIT_C73999).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4225">
		<vaccine_name>ALVAC-P53</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004739</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3257">Several canarypox virus recombinants expressing human or murine p53 in wild-type or mutant form were constructed (Roth et al., 1996).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1682" gene_id="gene313">
			<type>Recombinant vector construction</type>
			<description refs="reference3257">Several canarypox virus recombinants expressing human or murine p53 in wild-type or mutant form were constructed (Roth et al., 1996).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1746" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference3257">Mice were immunized with the viruses constructed (Roth et al., 1996).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3257">The tumor protection was equally effective regardless of whether wild-type or mutant p53 was used for the immunization, indicating that the immunologic response was not dependent on any particular p53 mutation and that immunization with this live virus vaccine works effectively against mutant p53 protein expressed in a tumor cell (Roth et al., 1996).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3257">Mice were challenged with an isogenic and highly tumorigenic mouse fibroblast tumor cell line expressing high levels of mutant p53 (Roth et al., 1996).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5533">
		<vaccine_name>AML mRNA Positive Lysate Loaded Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4168">A cancer vaccine consisting of autologous dendritic cells loaded with separate preparations of acute myelogenous leukemia (AML) cell lysate and AML-specific messenger RNA (mRNA) with potential immunostimulatory and antineoplastic activities. Upon administration, AML mRNA plus lysate loaded autologous dendritic cell vaccine may elicit a potent cytotoxic T-cell (CTL) response against AML cells, resulting in tumor cell death. Autologous dendritic cells doubly-loaded with AML cell lysate and AML-specific mRNA may elicit superior primary, recall, and effector lytic immune responses compared to autologous dendritic cells loaded with tumor lysate or tumor mRNA alone. (NCIT_C74000).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5243">
		<vaccine_name>Amolimogene Bepiplasmid</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4394">A plasmid DNA-based vaccine consisting of small biodegradable poly(lactide-co-glicolide) polymer microparticles encapsulating plasmid-DNA vector encoding a chimeric protein comprising epitopes derived from the E6 and E7 oncoproteins of the human papillomavirus (HPV) types 16 and 18, with potential antineoplastic activity. Upon intramuscular vaccination, amolimogene bepiplasmid may elicit the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV-16 and -18 E6 and E7 and may result in a reduction in tumor cell growth. HPV types 16 and 18 oncoproteins E6 and E7 are most commonly involved in cervical cancer. (NCIT_C90592).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5331">
		<vaccine_name>Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4117">A cancer vaccine containing pTVG4 plasmid DNA encoding the human androgen receptor (AR) ligand-binding domain (LBD) (pTVG-AR), with potential immunostimulating and antineoplastic activities. Upon intradermal administration of AR LBD-encoding plasmid DNA vaccine MVI-118, the plasmid DNA vaccine expresses AR LBD and may stimulate the host immune system to generate a cytotoxic T-lymphocyte (CTL) response against AR LBD-expressing prostate cancer cells. This reduces proliferation of AR-expressing tumor cells. AR, a tumor-associated antigen (TAA) overexpressed in prostate cancer cells, plays a key role in the development and progression of prostate cancer; its expression is correlated with poor prognosis. (NCIT_C121777).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5199">
		<vaccine_name>Anti-CD19/CD3 Tetravalent Antibody AFM11</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4639">An anti-CD19/anti-CD3 bispecific tetravalent antibody with potential immunostimulatory and antineoplastic activities. Anti-CD19/CD3 tetravalent antibody AFM11 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B-cells. Upon bolus infusion of AFM11, this bispecific antibody binds to CD3-expressing T-cells and CD19-expressing cancer cells, thereby crosslinking CD19-expressing tumor B-cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD19-expressing B-lymphocytes. CD19, a B-cell specific membrane antigen, is expressed during both B-cell development and B-cell malignant growth. (NCIT_C115101).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5411">
		<vaccine_name>Anti-CD3 x Anti-CD20 Bispecific Antibody-Armed Activated T Cells</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4297">Autologous activated T cells that have been coated with bispecific antibodies (BiAb), with potential antineoplastic and immunomodulating activities. In vitro, T cells are activated through exposure to the anti-CD3 murine monoclonal antibody OKT3 and low-dose interleukin 2 (Il-2) for 6-14 days and then armed with anti-CD3 x anti-CD20 bispecific antibody (CD20Bi). Upon administration, anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells (AATC) attach to CD3-expressing T cells and CD20-expressing tumor cells, selectively cross-linking T cells and tumor cells. This may result in the recruitment and activation of cytotoxic T lymphocyte (CTLs), CTL-mediated specific tumor cell lysis, and the secretion of antitumor cytokines and chemokines. CD20, a cell surface phosphoprotein, is found on normal B cells and most B-cell tumors. (NCIT_C95751).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5536">
		<vaccine_name>Anti-CEA TCR Retroviral Vector-Transduced Autologous Peripheral Blood Lymphocytes</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4414">Autologous human peripheral blood lymphocytes (PBLs), transduced with a retroviral vector encoding both the alpha and beta chains of a T cell receptor (TCR) specific for the carcinoembryonic antigen (CEA), with potential immunostimulating and antineoplastic activities. After transduction, expansion in culture, and reintroduction into the patient, anti-CEA TCR retroviral vector-transduced autologous lymphocytes bind to tumor cells expressing CEA, which may result in cytokine expression, activation and proliferation of T-cells, and a specific cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells. The tumor-associated antigen (TAA) CEA is overexpressed by a variety of cancer cell types, including those of the gastrointestinal tract, lung, and breast. (NCIT_C79842).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5375">
		<vaccine_name>Anti-CTLA4 MoAb RNA-transfected Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4561">An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. Anti-CTLA4 MoAb RNA-transfected autologous DC vaccine is prepared by transfecting DCs with RNAs encoding humanized heavy and light chains of the anti-CTLA4 (cytotoxic T-Lymphocyte-Associated Antigen 4); expression of anti-CTLA4 blocks the inhibitory effect of CTLA4 on the activation of T-lymphocytes. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses (NCIT_C94217).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5149">
		<vaccine_name>Anti-CTLA4 MoAb RNA/GITRL RNA-transfected Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4566">An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. Anti-CTLA4 MoAb RNA/GITRL RNA-transfected DC vaccine is prepared by transfecting DCs with RNAs encoding humanized heavy and light chains of the anti-CTLA4 (cytotoxic T-Lymphocyte-Associated Antigen 4) monoclonal antibody and tumor necrosis factor (ligand) superfamily, member 18 (TNFSF18 or GlTRL); expression of anti-CTLA4 blocks the inhibitory effect of CTLA4 on the activation of T-lymphocytes, while expression of GlTRL modulates T lymphocyte survival in peripheral tissues. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses. (NCIT_C94218).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5405">
		<vaccine_name>Anti-GnRH Vaccine PEP223</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4176">A peptide vaccine derived from the synthetic peptide pyroEHWSYGLRPG, corresponding to amino acids 22-31 of mouse gonadotropin releasing hormone (GnRH), with potential immunocastration activity. PEP223 is dimerized and contains a D-lysine (k) substitution at position 6 (pyroEHWSYkLRPG) to increase its immunogenicity. Anti-GnRH vaccine PEP223 may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GnRH, neutralizing its activity. In turn, testosterone production and tumor cell growth may be inhibited in testosterone-sensitive tumors. (NCIT_C85464).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5175">
		<vaccine_name>Anti-idiotype MUC-1 Monoclonal Antibody</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4356">A monoclonal antibody that functionally mimics MUC-1 antigen, a tumor cell surface antigen. Administration of anti-idiotype MUC-1 monoclonal antibody may elicit an anti-idiotype antibody and corresponding T-cell response against MUC-1 expressing tumor cells. (NCIT_C2709).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5301">
		<vaccine_name>Anti-Idiotype Specified Monoclonal Antibody</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4152">A synthetic antibody produced by a genetically homogenous population of hybrid cells (hybridoma) against determinant idiotypes (Id) which usually mimic human epitopes. Anti-Id vaccines may be effective in the treatment of B-cell lymphomas, resulting in tumor regression. Anti-idiotype vaccine therapy is less likely to induce autoimmunity if the target antigen is not normally expressed on normal tissues. Monoclonal antibodies have become powerful tools for tumor targeting, recognizing different protein markers on certain cancer cells and may be used alone or as delivery agents for drugs, toxins or radioactive material targeted to tumors. (NCI04) (NCIT_C28330).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5433">
		<vaccine_name>Anti-idiotypic Monoclonal Antibody BEC2</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4552">A murine anti-idiotypic monoclonal antibody (anti-Id MoAb) that is directed against an idiotype mimicking a disialoganglioside GD3. GD3 represents a major surface marker on most human melanoma cells. Due to poor immunogenicity of GD3, anti-Id MoAb BEC2 (Ab2) was raised against a mouse anti-GD3 MoAb, R24 (Ab1). This anti-Id MoAb was shown to be functionally mimicking GD3 in stimulating an immune response to produce Ab3 that may be used in combination with other adjuvants for treatment of melanomas. (NCIT_C2382).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5485">
		<vaccine_name>Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4409">An immunotherapeutic agent targeting the tumor-associated antigen (TAA), cancer/testis antigen NY-ESO-1, with potential antineoplastic activity. (NCIT_C116847).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5081">
		<vaccine_name>Anti-NY-ESO1 TCR-transduced Autologous CD62L+-derived T-Lymphocytes</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4512">Human autologous CD62L-positive T-lymphocytes transduced with a retroviral vector encoding a T cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, the anti-NY-ESO1 TCR-transduced autologous CD62L+-derived T-Lymphocytes bind to NY-ESO-1-overexpressing tumor cells. This may result in cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types. CD62L, also called L-selectin, is a lymphoid homing receptor and differentiation marker and is expressed on a subset of CD8-positive T-lymphocytes; it is involved in the migration of T-lymphocytes to lymph nodes and may improve the efficacy for ex vivo-expanded T-cells following adoptive cell therapy. (NCIT_C114295).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5447">
		<vaccine_name>Anti-p53 T-Cell Receptor-Transduced Peripheral Blood Lymphocytes</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4263">Human autologous peripheral blood lymphocytes (PBLs) transduced with an anti-p53 T cell receptor gene with potential antineoplastic activity. PBLs are harvested from a patient and pulsed with a retroviral vector that encodes the T-cell receptor gene specific for a mutated form of p53. The transduced PBLs are then expanded in culture. When reintroduced to the patient, these modified PBLs express the anti-p53 T cell receptor which binds to mutant p53-overexpressing tumor cells; PBL-mediated tumor growth inhibition may follow. Many tumor cell types overexpress mutant p53 proteins, which are associated with the loss of apoptosis regulation and abnormal cell proliferation. (NCIT_C64773).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5361">
		<vaccine_name>Anti-PRAME Immunotherapeutic GSK2302032A</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4278">An immunotherapeutic agent targeting the tumor-associated antigen (TAA), preferentially expressed antigen of melanoma (PRAME), with potential antineoplastic activity. (NCIT_C116848).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5138">
		<vaccine_name>Antigen-targeted Personalized Breast Cancer Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4480">An individualized, therapeutic cancer vaccine (IVAC) composed of liposomes containing RNA encoding two or three tumor associated antigens (TAAs) that are specifically expressed in the patient's individual cancer selected from a warehouse (&quot;off the shelf&quot;) and p53 RNA, with potential immunostimulatory and antineoplastic activities. Upon administration, the antigen-targeted personalized breast cancer vaccines are translated by antigen presenting cells (APCs) and the expressed protein is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL) and memory T-cell immune responses against the TAAs. The RNAs in the vaccine are specifically selected for an individual patient after RNA profiling of the patient's tumor. (NCIT_C120039).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5420">
		<vaccine_name>APC8015F</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4649">A cell-based vaccine composed of previously frozen autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCIT_C48640).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5222">
		<vaccine_name>Apoptotic Autologous Tumor Cells-pulsed Alpha-type-1 Polarized Dendritic Cells</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4560">A cell based cancer vaccine composed of mature polarized dendritic cells (DCs) and pulsed with apoptotic autologous tumor cells that has potential immunostimulating and antineoplatic activities. Dendritic cells (DCs) were treated with interleukin-1beta, tumor necrosis factor alpha, interferon-alpha (IFN-a), IFN-gamma and polyinosinic:polycytidylic acid (p-I:C) to produce mature alpha type-1 polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70 (IL-12p70). The alphaDC1 are subsequently pulsed with apoptotic autologous tumor cells. Upon administration, these DCs are able to induce a potent cytotoxic T lymphocyte (CTL) response against tumor associated antigens (TAAs), resulting in tumor cell lysis and inhibition of tumor cell growth. Apoptotic tumor cells contain an array of TAAs (NCIT_C102978).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5382">
		<vaccine_name>AS03-Adjuvanted H1N1 Pandemic Influenza Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4308">A split-virus, inactivated influenza A (H1N1) vaccine containing H1N1 immunizing antigen combined with the adjuvant AS03, with potential immunostimulating activity. Upon intramuscular vaccination, AS03-adjuvanted H1N1 influenza vaccine may elicit an immune response against the H1N1 virus and the production of anti-H1N1 antibodies. AS03 is a stabilized oil-in-water emulsion adjuvant containing DL-alpha-tocopherol, squalene and polysorbate 80 that non-specifically stimulates cell-mediated immune antigen responses. (NCIT_C88320).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5455">
		<vaccine_name>Attenuated Chimpanzee Adenovirus 5T4 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4282">A cancer vaccine comprised of a recombinant, attenuated, replication-defective simian adenovirus vector (ChAdOx1) encoding the human 5T4 fetal oncoprotein (ChAdOx1.5T4), with potential immuno-activating and antineoplastic activities. Upon administration of the recombinant attenuated chimpanzee adenovirus 5T4 vaccine, the viral vector expresses 5T4 and stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing 5T4, which results in tumor cell lysis. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness. (NCIT_C121544).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine3081">
		<vaccine_name>attenuated Listeria expressing cancer antigen vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004250</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector>Listeria  Î”actA/Î”inlB-AH1-A5 [Ref1936:Brockstedt et al., 2004].</vector>
		<route>Intravenous injection (i.v.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intravenous injection (i.v.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response911" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference1936">Female BALB/c mice were implanted i.v. with 2 Ã— 10^5 CT26 cells on day 0. Four days later, mice were randomized and vaccinated i.v. with the indicated Listeria strains or Hanks' balanced salt solution (HBSS) as negative control (Brockstedt et al., 2004).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1936">Therapeutic vaccination of CT26 tumor-bearing mice with Î”actA/Î”inlB-AH1-A5, but not with the Î”actA control strain, resulted in a significant prolongation of life with 40% long-term survivors (P &lt; 0.0001)  (Brockstedt et al., 2004).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1936">Female BALB/c mice were implanted i.v. with 2 Ã— 10^5 CT26 cells on day 0 (Brockstedt et al., 2004).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5319">
		<vaccine_name>AUT-OV-ALVAC-hB7.1 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4147">A vaccine comprised of autologous epithelial ovarian cells infected with ALVAC-hB7.1. (NCIT_C28682).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5053">
		<vaccine_name>Autologous Ad-CD154-Transduced CLL B Cells</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4537">An autologous tumor cell vaccine containing chronic lymphocytic leukemia (CLL) B cells transduced with an adenoviral vector carrying chimeric CD154 (ad-CD154) with potential antineoplastic activity. Administration of autologous ad-CD154 transduced CLL B cells may result in increases in the numbers of leukemia-specific CD4+ T cells and high serum-levels of IL-12 and IFN-gamma. Due to ligation of CD154 to CD40 on CLL cells, this agent may induce CLL cells to express the proapoptotic molecule BID and death receptors CD95 (Fas) and DR5, rendering CLL B cells first resistant and then sensitive to Fas-mediated apoptosis. In addition, autologous ad-CD154 transduced CLL B cells may induce MHC class I-dependent cytotoxic T lymphocyte (CTL) responses against autologous leukemia cells. CD154 is a type II membrane glycoprotein and ligand for CD40; both molecules are important in cognate co-stimulatory cell-cell interactions. (NCIT_C68842).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5507">
		<vaccine_name>Autologous Anti-gp100:154-162 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4611">Human autologous peripheral blood lymphocytes (PBLs) transduced with a glycoprotein 100 (gp100) epitope-determined T cell receptor (TCR) gene, with potential antineoplastic activity. PBLs are isolated from a melanoma patient and pulsed with a viral vector encoding the TCR specific for amino acid residues 154-162 of gp100 (KTWGQYWQV). After expansion ex vivo, the transduced autologous PBLs, expressing this specific TCR, are reintroduced into the patient and bind to melanoma cells expressing the gp100 protein, which may result in specific cytotoxic T-lymphocyte (CTL) killing of gp100-expressing melanoma cells. gp100 is a melanocyte lineage-specific antigen overexpressed in melanomas. (NCIT_C71748).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5293">
		<vaccine_name>Autologous Anti-MART-1 F5 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4182">Human autologous peripheral blood lymphocytes (PBLs) transduced with a melanoma antigen MART-1 epitope-determined T cell receptor (TCR) gene, with potential antineoplastic activity. PBLs are isolated from a melanoma patient and pulsed with a viral vector that encodes the TCR specific for an epitope of MART-1 (F5 TCR). After expansion ex vivo, the transduced autologous PBLs, expressing this specific TCR, are reintroduced into the patient, and bind to melanoma cells expressing the MART-1 antigen, which may result in specific cytotoxic T-lymphocyte (CTL) killing of MART-1-expressing melanoma cells. MART-1 (melanoma antigen recognized by T cells 1), also known as Melan-A, is a melanocyte lineage-specific transmembrane protein. (NCIT_C38587).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5463">
		<vaccine_name>Autologous CD133-Positive BTSC mRNA-Pulsed Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4404">A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with CD133-positive autologous brain tumor stem cells (BTSCs) -derived mRNA with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, autologous CD133-positive BTSC mRNA-pulsed autologous dendritic cell vaccine may elicit a cytotoxic T-lymphocyte (CTL) response against the CD133-positive BTSCs from which the autologous tumor mRNA is derived. CD133, a tumor-associated antigen (TAA) and neural stem cell marker, has been found on a specific subset of glioblastoma multiforme (GBM) stem cells; its presence has been correlated with resistance to conventional chemotherapy and radiotherapy. (NCIT_C85445).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5174">
		<vaccine_name>Autologous CD40L-expressing B-CLL Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4243">A cancer vaccine consisting of autologous, B-chronic lymphocytic leukemia (B-CLL) cells harvested from a patient and transduced with an adenoviral vector encoding the gene for the human CD40 ligand (CD40L; TRAP; CD154), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous CD40L-expressing B-CLL vaccine expresses the co-stimulatory molecule CD40L, which binds to its cognate receptor, CD40, on antigen presenting cells (APC). This induces apoptosis, stimulates maturation and proliferation of APCs, and facilitates a cytotoxic T-lymphocyte (CTL) response against tumor cells. CD40L is a type II membrane protein that binds to CD40, which is a cell surface receptor that belongs to the tumor necrosis factor (TNF) receptor superfamily. (NCIT_C118852).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5150">
		<vaccine_name>Autologous Colorectal Tumor Antigen-pulsed Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4333">A dendritic cell (DC)-based cancer vaccine composed of autologous DCs pulsed with tumor cell lysates from a colorectal cancer patient containing tumor-associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous colorectal tumor antigen-pulsed DC vaccine exposes the immune system to colorectal tumor cell antigens, which may result in cytotoxic T-lymphocyte (CTL)-mediated immune responses against the colorectal cancer cells. This leads to cancer cell lysis. The tumor cell lysate contains a range of antigens that are essential for the neoplastic growth and survival of the cancer cells. (NCIT_C123918).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5128">
		<vaccine_name>Autologous CT7/MAGE-A3/WT1 mRNA-Electroporated Langerhans-Type Dendritic Cells</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4617">An autologous tumor cell vaccine containing CD34+ hematopoietic progenitor cell (HPC)-derived Langerhans-type dendritic cells (LCs) electroporated with mRNA encoding the full-length cancer-testis antigens, CT7 and melanoma-associated antigen 3 (MAGE-A3), and the self-differentiation tumor antigen, Wilms tumor 1 (WT1) with potential immunomodulating and antineoplastic activity. The autologous CT7/MAGE-A3/WT1 mRNA-electroporated Langerhans-type dendritic cells are prepared by drawing a blood sample containing the CD34+ HPCs from a cancer patient. The CD34+ HPCs are treated with a combination of cytokines which specifically support LC development, and the LC population is enriched and expanded ex vivo. The cultured LCs are allowed to mature for one day and then electroporated separately with CT7, MAGE-A3 or WT1 mRNA before final maturation. Upon intradermal administration into the patient, the mature LCs may activate cell-mediated immunity and induce both cytotoxic CD8+ T cells and CD4+ helper T cells against cancer cells expressing CT7, MAGE-A3 and WT1 tumor antigens. This may result in the immune-mediated inhibition of tumor cell proliferation, leading to tumor cell death. CT7 and MAGE-A3 are tumor-specific proteins overexpressed in a number of cancers but not in healthy tissues other than testis and placenta. WT1 is a transcription factor important in development and cancer pathogenesis, which is overexpressed in a variety of cancers, including multiple myeloma, leukemia, ovarian cancer, malignant mesothelioma, neural tumors and renal carcinoma. (NCIT_C113174).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5117">
		<vaccine_name>Autologous Cultured Chondrocytes</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5085">
		<vaccine_name>Autologous Dendritic Cell Vaccine ACT2001</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4441">A cell-based cancer vaccine composed of autologous, immature dendritic cells (DCs), with potential immunostimulating and antineoplastic activities. Upon leukapheresis, immature DCs are isolated and re-administered intra-tumorally. The immature DCs internalize and process the tumor-associated antigens (TAAs), migrate to the lymphatic system, and then expose the immune system to the TAAs. This induces a specific cytotoxic T-lymphocyte (CTL) response against the cancer cells leading to tumor cell lysis. (NCIT_C121856).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5030">
		<vaccine_name>Autologous Dendritic Cell-Adenovirus CCL21 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4285">A cancer vaccine comprised of autologous dendritic cells (DCs) that have been transduced ex vivo with an adenoviral vector containing the CCL21 gene with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration, autologous dendritic cell-adenovirus CCL21 vaccine expresses the chemokine CCL21, which may induce an antitumoral cytotoxic immune response in the tumor microenvironment. CCL21 [chemokine (C-C motif) ligand 21] has been shown to attract antigen presenting cells (APCs), like leukocytes and DCs, and natural killer (NK) cells and their T-cell effectors to induce a cytotoxic immune response. (NCIT_C74015).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5088">
		<vaccine_name>Autologous Dendritic Cell-Adenovirus P53 Vaccin</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4398">An autologous vaccine composed of dendritic cells (DC) that have been transduced with a p53 tumor suppressor gene-modified virus. When the autologous dendritic cell-adenovirus p53 vaccine is administered, the host cytotoxic T lymphocytes (CTL) are directed against p53-positive tumor cells, which may result in tumor cell death and decreased tumor growth. (NCI04) (NCIT_C26445).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5495">
		<vaccine_name>Autologous Dendritic Cell-Allogeneic Melanoma Tumor Cell Lysate Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4257">A cell-based vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from heat-treated allogeneic melanoma tumor cells. Upon administration, this vaccine may stimulate anti-tumoral cytotoxic T-cell and antibody responses to melanoma cells bearing shared melanoma antigens such as MelanA/MART-1, gp100, MAGE3, resulting in tumor cell lysis. (NCIT_C48376).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5066">
		<vaccine_name>Autologous Dendritic Cell-Autologous Tumor mRNA-Human CD40L Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4148">A cancer vaccine consisting of autologous dendritic cells transfected with autologous tumor mRNA and the human CD40 ligand (CD40L) gene with immunostimulatory and antitumor activities. Vaccination with autologous dendritic cell-autologous tumor mRNA-human CD40L vaccine may elicit a cytotoxic T cell response against tumor cells from which the autologous tumor mRNA was derived. When expressed by dendritic cells, tumor antigens and the co-stimulatory molecule CD40L, which binds to CD40 receptors on antigen presenting cells (APC), facilitate both humoral and cellular immune responses against tumor cells. (NCIT_C61077).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5284">
		<vaccine_name>Autologous Dendritic Cell-based Immunotherapeutic AV0113</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4415">A therapeutic interleukin-12 (IL-12)-expressing dendritic cell (DC)-based vaccine composed of autologous monocyte-derived DCs loaded with autologous tumor cell lysate and exposed to the microbial cell wall component lipopolysaccharide (LPS), with potential immunomodulating and antineoplastic activities. The monocyte-derived immature DCs are loaded with autologous tumor cell lysates and are subsequently exposed to LPS and interferon-gamma (IFN-gamma). Upon administration of autologous DC-based immunotherapeutic AV0113, the mature DCs migrate into the lymph nodes, express the immune stimulatory cytokine interleukin-12 (IL-12) and activate the immune system by promoting the activation of natural killer (NK) cells and induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. Exposure to LPS and IFN-gamma allows the maturation of DCs and optimizes the presentation of tumor-associated antigens (TAAs) by DCs to T-lymphocytes. (NCIT_C123928).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5056">
		<vaccine_name>Autologous Dendritic Cell-Tumor Fusion Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4326">A therapeutic cancer vaccine consisting of autologous dendritic cells (DCs) fused with autologous tumor cells with potential immunostimulatory and antineoplastic activities. Autologous dendritic cell-tumor fusion vaccine is generated in vitro by mixing DCs and irradiated tumor cells harvested from individual patients and treating them with polyethylene glycol (PEG) to produce DC-tumor cell fusion hybrid cells. Upon administration, autologous dendritic cell-tumor fusion vaccine may elicit antitumor humoral and cellular immune responses. (NCIT_C74016).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5537">
		<vaccine_name>Autologous Dinitrophenyl Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4465">A vaccine consisting of autologous cancer cells modified with the hapten, Dinitrophenyl. The treatment program consists of multiple intradermal injections of irradiated DNP-modified autologous tumor cells mixed with bacillus Calmette-Guerin. (NCIT_C1982).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5459">
		<vaccine_name>Autologous Dinitrophenyl-Modified Ovarian Cancer Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4519">A cancer vaccine consisting of autologous ovarian cancer cell peptide antigens conjugated to the hapten 2,4-dinitrophenol (DNP) with potential immunostimulating and antineoplastic activities. Administration of autologous dinitrophenyl-modified ovarian cancer vaccine may induce a cytotoxic T-lymphocyte (CTL) response against ovarian cancer cells. DNP conjugation may enhance the immunogenicity of weakly immunogenic antigens. (NCIT_C78193).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5118">
		<vaccine_name>Autologous EBV-Transformed B Lymphoblastoid-Tumor Fusion Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4478">A cell-based vaccine composed of autologous tumor cells fused with Epstein-Barr virus-transformed B-lymphoblastoid cells. Upon administration, this vaccine may stimulate a cytotoxic T cell response against tumor cells, resulting in tumor cell lysis. (NCIT_C48377).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5225">
		<vaccine_name>Autologous Epstein-Barr Virus-Transformed B-Lymphoblastoid Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4185">A cell-based vaccine composed of autologous tumor cells fused with Epstein-Barr virus-transformed B-lymphoblastoid cells. Upon administration, this vaccine may stimulate a cytotoxic T cell response against tumor cells, resulting in tumor cell lysis. (NCIT_C53443).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5491">
		<vaccine_name>Autologous Expanded Mesenchymal Stem Cells OTI-010</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4486">Multipotent self-renewing adherent non-hematopoietic stromal cells harvested from a patient's bone marrow and grown in vitro. When injected back into the patient, autologous expanded mesenchymal stem cells OTI-010 may differentiate into various mesenchyme-derived cell types and, in some instances, may augment bone marrow engraftment after whole-body irradiation. (NCIT_C2534).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5250">
		<vaccine_name>Autologous GM-CSF-Secreting Breast Cancer Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4673">An autologous tumor cell vaccine containing irradiated breast cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Autologous breast cancer cells are transduced ex vivo with an adenovirus vector encoding the GM-CSF gene and irradiated and then reintroduced into the patient. Upon repeated subcutaneous administration of the vaccine, autologous GM-CSF-secreting breast cancer cells secrete GM-CSF, which may stimulate a tumor-specific cytotoxic T-lymphocyte (CTL) response. (NCIT_C82388).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5188">
		<vaccine_name>Autologous GM-CSF-secreting Lethally Irradiated Colorectal Cancer Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4227">A lethally irradiated, autologous colorectal cancer vaccine consisting of patient-specific colorectal cancer cells genetically modified to secrete the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon vaccination, the autologous GM-CSF-secreting lethally irradiated colorectal cancer cell vaccine releases GM-CSF. In turn, GM-CSF may increase the body's immune response against tumor cells by promoting the maturation and activation of dendritic cells (DCs), and enhancing tumor-specific antigen presentation to both B- and T-cells, which leads to better recognition of tumors by the immune system. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function. (NCIT_C111991).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5240">
		<vaccine_name>Autologous GM-CSF-Secreting Lethally Irradiated Leukemia Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4159">An autologous cancer vaccine composed of lethally irradiated leukemia cells that are genetically modified to secrete the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon intradermal injection, the autologous GM-CSF-secreting lethally irradiated leukemia cell vaccine secretes GM-CSF. In turn, GM-CSF may stimulate the immune system to attack tumor cells by enhancing the activation of dendritic cells (DCs) and promoting antigen presentation to both B- and T-lymphocytes. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function. (NCIT_C104419).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5266">
		<vaccine_name>Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4235">A recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes. HSP70 associates with antigenic peptides, transporting them into antigen presenting cells (APC) for processing. Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models. (NCI04) (NCIT_C37448).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5043">
		<vaccine_name>Autologous HNSCC DNA-transfected Semi-allogeneic Fibroblasts MRC-5 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4116">A vaccine consisting of lethally irradiated human fetal lung fibroblasts (Medical Research Council 5 or MRC-5) transfected with autologous tumor DNA derived from a head and neck squamous cell carcinoma (HNSCC), with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the autologous HNSCC DNA-transfected semi-allogeneic fibroblasts MRC-5 vaccine expresses HNSCC tumor-associated antigens (TAAs), which may activate the immune system to induce a cytotoxic T-lymphocyte (CTL) response against HNSCC cells. The MRC-5 cell line, established in 1966, is a human diploid lung fibroblast cell line derived from the human lung tissue of a 14-week-old male fetus. (NCIT_C117725).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5228">
		<vaccine_name>Autologous IL-2-expressing B-CLL Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4242">A cancer vaccine consisting of autologous, B-chronic lymphocytic leukemia (B-CLL) cells harvested from a patient and transduced ex vivo with an adenoviral vector encoding the gene for the human cytokine interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous IL-2-expressing B-CLL vaccine expresses IL-2, stimulates natural killer (NK) cells, and may enhance the cytotoxic T-lymphocyte (CTL) immune response against the patient's B-CLL cells. (NCIT_C118851).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5057">
		<vaccine_name>Autologous Immunoglobulin Idiotype-KLH Conjugate Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4629">A cancer vaccine composed of tumor-specific idiotype determinants derived from an individual's tumor cells which are conjugated to keyhole limpet hemocyanin, an immunostimulant carrier protein. When injected into the individual from whom the tumor cells were isolated, this vaccine may stimulate an antitumoral cytotoxic T-lymphocytic immune response. (NCI04) (NCIT_C38715).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5248">
		<vaccine_name>Autologous Lymphoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4259">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysate from autologous lymphoma cells with potential immunostimulatory and antineoplastic activities. Upon intranodal administration, autologous lymphoma cell lysate-pulsed autologous DC vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against lymphoma cells, which may result in lymphoma cell lysis. (NCIT_C85452).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5503">
		<vaccine_name>Autologous Lymphoma Cell/Allogeneic Dendritic Cell Electrofusion Hybrid Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4267">A cell-based cancer vaccine consisting of hybrid cells created by electrofusing allogeneic dendritic cells (DCs) and autologous lymphoma cells with potential immunostimulating and antitumor activities. Upon administration, autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine may stimulate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against specific autologous lymphoma-associated antigens, resulting in lymphoma cell apoptosis. (NCIT_C85451).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5431">
		<vaccine_name>Autologous Lymphoma Cell/Autologous Dendritic Cell Electrofusion Hybrid Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4638">A cell-based cancer vaccine consisting of hybrid cells created by electrofusing autologous dendritic cells (DCs) and autologous lymphoma cells with potential immunostimulating and antitumor activities. Upon administration, autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine may stimulate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against specific autologous lymphoma-associated antigens, resulting in lymphoma cell apoptosis. (NCIT_C85450).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5148">
		<vaccine_name>Autologous Melanoma Lysate-Pulsed Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4161">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysate from autologous melanoma cells containing tumor associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate-pulsed autologous DC vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against melanoma cells, which may result in melanoma cell lysis. (NCIT_C90571).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5213">
		<vaccine_name>Autologous Melanoma Lysate/KLH-Pulsed Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4158">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysate from autologous melanoma cells containing tumor associated antigens (TAAs) and conjugated to the immunostimulant Keyhole limpet hemocyanin (KLH), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against melanoma cells, which may result in melanoma cell lysis. KLH is an immunogenic carrier and serves as an immunostimulant to improve antigenic immune recognition and T-cell responses and can be used to evaluate vaccine efficacy. (NCIT_C90572).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5158">
		<vaccine_name>Autologous Melanoma Lysate/NY-ESO-1-pulsed Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4261">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with both a lysate from autologous melanoma cells containing tumor associated antigens (TAAs) and a synthetic peptide derived from the tumor associated antigen human cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate/NY-ESO-1-pulsed autologous DC vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody-mediated immune responses against melanoma cells, which may result in melanoma cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival. (NCIT_C111900).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5377">
		<vaccine_name>Autologous NSCLC DNA-Transfected Semi-Allogeneic Fibroblasts MRC-5 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4346">A vaccine consisting of irradiated human fetal lung fibroblasts (Medical Research Council 5 or MRC-5) transfected with autologous non-small cell lung cancer (NSCLC)-derived DNA with potential immunostimulatory and antineoplastic activities. Upon administration, autologous NSCLC DNA-transfected semi-allogeneic fibroblasts MRC-5 vaccine expresses NSCLC tumor-associated antigens (TAAs) in addition to MHC class I-determinants and the co-stimulatory molecule B7.1, which may induce a cytotoxic T-lymphocyte (CTL) response against NSCLC cells. The MRC-5 cell line is a human diploid lung fibroblast cell line extablished in 1966. (NCIT_C82416).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5311">
		<vaccine_name>Autologous NSCLC Peptide-specific Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4605">A personalized cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with immunogenic peptides derived from autologous non-small cell lung cancer (NSCLC) cells, with potential immunostimulating and antineoplastic activities. During leukapheresis, mature DCs are loaded with autologous NSCLC-derived peptides. Upon re-administration of the NSCLC peptide-specific DC vaccine, the immune system is exposed to NSCLC-associated antigens. This results in the induction of a specific cytotoxic T-lymphocyte (CTL) response against NSCLC cells and tumor cell lysis. (NCIT_C121848).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5368">
		<vaccine_name>Autologous OFA-iLRP RNA-Transfected Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4264">A cancer vaccine consisting of autologous, mature monocyte-derived dendritic cells (DCs) transfected with oncofetal antigen immature laminin receptor protein (OFA-iLRP) RNA, with potential antineoplastic activity. Upon administration, DCs in the OFA-iLRP RNA-transfected autologous dendritic cell vaccine express, process, and present OFA-iLRP to the host immune system, which may mount a potent cytotoxic T-cell (CTL) response against OFA-iLRP-expressing tumor cells. As a highly conserved protein, OFA-iLRP is preferentially expressed in fetal tissues and in many types of cancer, including hematopoietic malignancies, but is not detectable in normal differentiated adult cells. (NCIT_C78830).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5427">
		<vaccine_name>Autologous Ovarian Tumor Cell Lysate-Pulsed Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4298">A cell-based cancer vaccine composed of autologous, irradiated dendritic cells (DCs) pulsed with ovarian tumor cell lysate containing tumor associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, autologous ovarian tumor cell lysate-pulsed dendritic cell vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against ovarian tumor cells expressing the patients ovarian tumor cell-specific TAAs, which may result in ovarian tumor cell lysis. (NCIT_C95759).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5220">
		<vaccine_name>Autologous Pluripotent ALDHbr Stem Cells ALD-451</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4437">A specific population of autologous, pluripotent bone marrow derived cells that express high levels of the cytosolic enzyme aldehyde dehydrogenase (ALDH) with potential protective and neuro-cognition improving activity. Expression of high levels of ALDH is an indicator of the biological activity in heterogenous early stage stem cells. Upon intravenous administration, these ALDH bright cells may protect normal cells and may repair damaged cells. These cells may also protect brain cells from damage and may improve neurocognition. (NCIT_C78466).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5282">
		<vaccine_name>Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4344">A genetically-modified autologous dendritic cell-based vaccine expressing a drug-inducible costimulatory CD40 receptor (iCD40) with potential immunomodulating and antineoplastic activities. Autologous dendritic cells (DCs) are genetically modified to express the iCD40 receptor and are pulsed with the tumor antigen prostate-specific membrane antigen (PSMA). Upon intradermal administration, these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination, the dimerizer agent AP1903 is administered; AP1903 binds to and activates iCD40 receptors presented on DC surfaces, thus activating the DCs and stimulating a cytotoxic T-lymphocyte (CTL) response against host tumor cells that express PSMA. This delayed activation strategy optimizes DC accumulation in local draining lymph nodes prior to DC activation. iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to a drug-binding domain. (NCIT_C82361).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5018">
		<vaccine_name>Autologous Renal Cell Carcinoma Tumor Lysate-Pulsed Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4328">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with renal cell carcinoma (RCC) tumor cell lysate containing tumor associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, autologous renal cell carcinoma tumor lysate-dendritic cell vaccine may stimulate anti-tumoral cytotoxic T-lymphocyte (CTL) and antibody responses against RCC tumor cells expressing RCC TAAs, resulting in RCC tumor cell lysis. (NCIT_C85479).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5189">
		<vaccine_name>Autologous Sarcoma Lysate-pulsed Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4492">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from sarcoma cells with potential immunostimulatory and antineoplastic activities. Upon administration, the autologous sarcoma lysate-pulsed dendritic cell vaccine exposes the immune system to an undefined amount of sarcoma-type tumor associated antigens (TAA), which may result in the induction of both specific anti-tumoral cytotoxic T lymphocytes (CTL) and antibody-dependent responses against the sarcoma TAA-expressing cells, resulting in sarcoma cell lysis. (NCIT_C105806).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5024">
		<vaccine_name>Autologous TARP Peptide-Pulsed Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4330">A cell-based cancer vaccine comprised of autologous dendritic cells pulsed with autologous T cell receptor gamma-chain alternate reading frame protein (TARP) peptide with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, autologous TARP peptide-pulsed dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against TARP-expressing cancer cells, resulting in tumor cell lysis. The highly immunogenic nuclear protein TARP is commonly expressed in breast and prostate cancer cells. (NCIT_C85470).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5238">
		<vaccine_name>Autologous TriMix-DC Melanoma Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4314">A dendritic cell vaccine consisting of dendritic cells (DCs) electroporated with mRNA encoding three adjuvants, CD40 ligand (CD40L), a constitutively active TLR4, and CD70 (all together termed TriMix); coelectroporated with full-length mRNA encoding MAGE-A3, MAGE-C2, Tyrosinase and gp100; and linked to DC-LAMP, with potential immunostimulating activity. Upon vaccination, the DCs may stimulate the immune system to mount an antigen-specific cytotoxic T-lymphocyte (CTL) response against the melanoma antigens. This may decrease cellular proliferation of melanoma cells expressing these antigens. Electroporation with the adjuvants CD40L and TLR4 allows for the generation of mature and active DCs; electroporation with CD70 provides a costimulatory signal to CD27+ naive T cells thereby supporting T-cell proliferation and inhibiting T-cell apoptosis. (NCIT_C90560).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5108">
		<vaccine_name>Autologous Tumor Cell Proteoliposome Chronic Lymphocytic Leukemia Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4146">An autologous chronic lymphocytic leukemia cancer vaccine consisting of patient-specific membrane proteins directly extracted from patient autologous tumor cells and incorporated into liposomes along with Interleukin 2 (IL-2) to produce membrane-patched proteoliposomes, with potential immunostimulating and antineoplastic activities. After subcutaneous injection of the autologous tumor cell proteoliposomes chronic lymphocytic leukemia vaccine, liposomes deliver the encapsulated tumor antigens into the cytosol of antigen presenting cells (APCs). Subsequently, the APCs process the antigens and present antigen-derived peptides to the immune system. This may enhance recognition of tumors by the immune system, and activate both cytotoxic CD8+ T cells and CD4+ helper T cells against tumor cells. IL-2 is incorporated into the vaccine to leverage its ability to expand activated T cells. (NCIT_C112206).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5396">
		<vaccine_name>Autologous Tumor Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4463">A therapeutic agent produced by isolating tumor cells from an individual and processing these tumor cells into a vaccine formulation in vitro; the vaccine is then administered to the individual from whom the tumor cells were isolated. Typically combined with an adjuvant immunostimulant, an autologous cell vaccine may elicit a cytotoxic T-lymphocytic immune response to cell surface-expressed tumor-associated antigens (TAAs), resulting in tumor cell death. (NCIT_C1980).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5035">
		<vaccine_name>Autologous Tumor-associated Peptide Antigen-pulsed Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4516">A dendritic cell (DC)-based cancer vaccine composed of autologous DCs pulsed with specific tumor-associated peptide antigens (TAPA), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous TAPA-pulsed DC vaccine exposes the immune system to the specific TAPAs, which may result in cytotoxic T-lymphocyte (CTL)-mediated immune responses against the TAPA-expressing cancer cells. This leads to cancer cell lysis. This vaccine is specific towards peptides derived from the following proteins: sperm autoantigenic protein 17 (SP17), ropporin, A-kinase anchor protein 4 (AKAP4), pituitary tumor-transforming 1 (PTTG1) and SPANX family member B (SPANX-B). (NCIT_C126797).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5404">
		<vaccine_name>Autologous-Cell Leukemia Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Live attenuated vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4378">An autologous therapeutic vaccine for the treatment of acute myelogenous leukemia. This vaccine is prepared from blood samples of patients following their first relapse. Tumor cells extracted from blood sample are modified with hapten, a process that makes the cells appear foreign to the patient's body and results in stimulating immune response against the cancer. (NCIT_C2023).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5110">
		<vaccine_name>Autologous-Cell Melanoma Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4464">An autologous-cell vaccine for melanoma. (NCIT_C1981).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine3698">
		<vaccine_name>B-cell lymphoma DNA vaccine VCL-1642.XXX encoding a chimeric immunoglobulin molecule onsisting of tumor-specific variable (Id) regions</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004427</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>VCL-1632 [Ref2341:Timmerman et al., 2002]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference2341 reference2530">GM-CSF (Timmerman et al., 2002) (Syrengelas et al., 1996)</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1509" gene_id="gene1683">
			<type>DNA vaccine construction</type>
			<description refs="reference2341">The DNA encoded a chimeric immunoglobulin molecule containing variable heavy and light chain immunoglobulin sequences derived from each patientâ€™s tumor (Timmerman et al., 2002).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1458" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2341 reference2530">Immunization with 10â€“100 Î¼g induced specific anti-ld antibody responses and protected mice against tumor challenge (Timmerman et al., 2002), (Syrengelas et al., 1996).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3701">
		<vaccine_name>B16 melanoma DNA vaccine pCMV-hTRP-1 encoding TRP-1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004430</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pSport-hTRP-1, based on pSport-B-gal [Ref2343:Leitner et al., 2003]</vector>
		<route>Gene gun</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Gene gun</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1510" gene_id="gene293">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1461" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2343">To test the efficacy of replicase-based TRP-1 plasmids, gene-gunâˆ’immunized mice were challenged subcutaneously with B16 melanoma. This vaccine provided strong tumor protection, with around 50% of mice still tumor-free 21 days after challenge (Leitner et al., 2003).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3700">
		<vaccine_name>B16 melanoma DNA vaccine pSin-hTRP-1 encoding TRP-1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004429</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pSin-B-gal [Ref2343:Leitner et al., 2003]</vector>
		<route>Gene gun</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Gene gun</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1511" gene_id="gene293">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1460" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2343">To test the efficacy of replicase-based TRP-1 plasmids, gene-gunâˆ’immunized mice were challenged subcutaneously with B16 melanoma. This vaccine provided strong tumor protection, with around 60% of mice still tumor-free 21 days after challenge (Leitner et al., 2003).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3869">
		<vaccine_name>B16 melanoma DNA vaccine pSin-mTRP-1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004518</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pSin-B-gal [Ref2343:Leitner et al., 2003]</vector>
		<route>Gene gun</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Gene gun</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1512" gene_id="gene1360">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1512" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2343">To test the efficacy of replicase-based TRP-1 plasmids, gene-gunâˆ’immunized mice were challenged subcutaneously with B16 melanoma. This vaccine provided strong tumor protection, with around 70% of mice still tumor-free 21 days after challenge (Leitner et al., 2003).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3066">
		<vaccine_name>B16 Vaccine  adjuvanted by Loxoribine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intraperitoneal injection (i.p.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intraperitoneal injection (i.p.)</route>
		<antigen refs="reference1892">Irradiated B16 cells (Pope et al., 1994).</antigen>
		<host_response host_response_id="host_response896" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">C57BL/6J</host_strain>
			<vaccination_protocol refs="reference1892">Mice were injected i.p. with 0.5 ml irradiated cells 21 and 14 days before challenge, and were injected with loxoribine prior to challenge (Pope et al., 1994).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1892">Mice treated with loxoribine had significant inhibition of tumor growth following challenge with live B16 cells (Pope et al., 1994).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1892">Mice were challenged i.v. with live B16 cells (Pope et al., 1994).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5467">
		<vaccine_name>Bacteriophage phi X 174 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4452">A vaccine composed of the bacteriophage phi X 174, a virus that infects the bacterium Escherichia coli (E. coli), that can be used as a diagnostic agent to measure immune function of immunocompromised patients. Upon administration of the bacteriophage phi X 174 vaccine, the bacteriophage may activate the immune system to induce bacteriophage phi X174 specific antibody responses. The clearance of phage from the blood and the measurement of phage neutralization by antibodies can be used to assess the immune status of patients with suspected antibody-mediated immunodeficiency and to measure the response to certain therapies. (NCIT_C116736).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5230">
		<vaccine_name>BCG, Cell Wall Skeleton</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Live attenuated vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4360">A mycobacterial cell wall material and serves as an immunoadjuvant that induces both cell-mediated and humoral immunity. (NCIT_C2339).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5399">
		<vaccine_name>Bcl-Xs Adenovirus Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4195">A vaccine consisting of replication-defective recombinant adenovirus that encodes for Bcl-Xs with potential antineoplastic activity. Vaccination with Bcl-Xs adenovirus vaccine induces apoptosis in Bcl-2 and Bcl-XL positive cancer cells, resulting in decreased tumor growth while leaving normal cells unaffected. Bcl-Xs block the function of the protooncogenes Bcl-2 and Bcl-XL which are overexpressed in a variety of solid tumors and promote cancer cell survival by inhibiting apoptosis. (NCI04)A vaccine consisting of replication-defective recombinant adenovirus that encodes for Bcl-Xs with potential antineoplastic activity. Vaccination with Bcl-Xs adenovirus vaccine induces apoptosis in Bcl-2 and Bcl-XL positive cancer cells, resulting in decreased tumor growth while leaving normal cells unaffected. Bcl-Xs block the function of the protooncogenes Bcl-2 and Bcl-XL which are overexpressed in a variety of solid tumors and promote cancer cell survival by inhibiting apoptosis. (NCI04) (NCIT_C28860).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5374">
		<vaccine_name>Belagenpumatucel-L</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4270">A transforming growth factor beta2 (TGF-beta2) antisense gene-modified allogeneic tumor cell vaccine with potential immunostimulatory and antineoplastic activities. Belagenpumatucel-L is prepared by transfecting allogeneic non-small cell lung cancer (NSCLC) cells with a plasmid containing a TGF-beta2 antisense transgene, expanding the cells, and then irradiating and freezing them. Upon administration, this agent may elicit a cytotoxic T lymphocyte (CTL) response against host NSCLC cells, resulting in decreased tumor cell proliferation; vaccine immunogenicity may be potentiated by suppression of tumor TGF-beta2 production by antisense RNA expressed by the vaccine plasmid TGF-beta2 antisense transgene. Elevated levels of TGF-beta2 are frequently linked to immunosuppression in cancer patients and may be inversely correlated with prognosis in patients with NSCLC. (NCIT_C73438).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4992">
		<vaccine_name>Berzofsky Ras/P53 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4421">A synthetic vaccine combining the peptide antigens of two proteins, ras oncoprotein and tumor suppressor p53. (NCI04) (NCIT_C2746).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5483">
		<vaccine_name>Bordetella pertussis Vaccine Adsorbed</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Live attenuated vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4388">A vaccine containing acellular antigenic components of Bordetella pertussis adsorbed on a mineral carrier with active immunizing activity against pertussis infection. (NCIT_C96399).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5439">
		<vaccine_name>Brachyury-expressing Modified Vaccinia Ankara-TRICOM Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4318">A cancer vaccine composed of a replication-deficient, attenuated derivative of the vaccinia virus strain Ankara expressing both a CD8+ T-cell epitope from the brachyury protein and a triad of T-cell co-stimulatory molecules (MVA Brachyury-TRICOM), with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration of the brachyury-expressing modified vaccinia Ankara (MVA)-TRICOM vaccine, the expressed brachyury protein induces specific CD8+ and CD4+ T-cell responses against brachyury-expressing tumor cells. This causes both tumor cell lysis and a decrease in the growth of brachyury-expressing tumor cells. Brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance and cancer progression. TRICOM, a triad of three human T-cell co-stimulatory molecules, B7.1, ICAM-1 and LFA-3, enhances antigen-specific T-cell activation. (NCIT_C116777).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5210">
		<vaccine_name>Brain Tumor Initiating Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4197">A cell-based cancer vaccine comprised of brain tumor initiating cells (BTICs), with potential immunostimulating and antineoplastic activity. BITCs are from the glioblastoma multiforme (GBM) cell line GBM-6 and contain glioma stem-like cell-associated antigens. Upon administration, the BITC vaccine may stimulate a specific anti-tumoral cytotoxic T-lymphocyte (CTL) response against brain tumor cancer cells and brain tumor stem like cells, resulting in tumor cell lysis. BITC have unique antigenicity and have the ability to self-renew; vaccination against BITC antigens may kill these cells and may prevent tumor recurrences. (NCIT_C97666).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5309">
		<vaccine_name>C29561</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5544">
		<vaccine_name>Canarypox-hIL-12 Melanoma Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4485">A vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) that encodes the gene for human interleukin-12 (hIL-12). Produced mainly by B-cells, IL-12 is an endogenous cytokine that activates natural killer (NK) cells, promotes cytotoxic T lymphocyte (CTL) responses, induces the release of interferon-gamma (IFN-gamma), and may exhibit antitumor and anti-angiogenic effects. Vaccination with canarypox-hIL-12 melanoma vaccine may stimulate the host immune system to mount an immune response against tumor cells, thereby inhibiting tumor growth and/or metastasis. (NCI04) (NCIT_C2442).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine1048">
		<vaccine_name>Cancer DNA Vaccine encoding Endoglin Boosted with Recombinant Endoglin Protein</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011367</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcDNA3.1(+) [Ref1318:Tan et al., 2007]</vector>
		<route>i.m. injection for DNA, s.c. for protein</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">i.m. injection for DNA, s.c. for protein</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering534" gene_id="gene721">
			<type>DNA Vaccine Construction and Recombinant Prot</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response801" host_id="host3">
			<immune_response refs="reference1318">CTL response against endoglin-positive HUVECs, but not against endoglin-negative tumor cells was found in the mice combined DNA with protein vaccination. In addition, combination of endoglin DNA and recombinant protein vaccination significantly induced IFN-gamma secreting cells (Tan et al., 2007).</immune_response>
			<host_strain refs="">BALB/c, C57BL/6</host_strain>
			<vaccination_protocol refs="reference1318">The method of ppEDG DNA immunization; mice were injected i.m. in both quadriceps. A 1-ml insulin syringe was used for all injections and each single dose consisted of 100 Î¼g that was diluted in normal saline of a total volume of 100 Î¼l and split between both legs. The method of pEDG protein immunization; mice were injected s.c. and each single dose consisted of 10 Î¼g that was also diluted in normal saline of a total volume of 100 Î¼l. To investigate the protective anti-tumor effects mice at 6 to 8 weeks of age were randomly divided into the following 4 groups of 10 animals each. Group 1 (DP) mice were vaccinated with pEDG and ppEDG simultaneously once weekly for 4 continuous weeks. Group 2 (DD) mice were vaccinated with pEDG alone at the same time-points as in the group 1. Group 3 (PP) mice were vaccinated with ppEDG alone. Group 4 (NS) mice were injected with 100 Î¼l normal saline.  (Tan et al., 2007).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1318">The results showed that combination of endoglin DNA and protein vaccines could enhance both protective and therapeutic anti-tumor efficacy in both colon carcinoma and Lewis lung carcinoma models. Significant inhibition of tumor angiogenesis was found in the tumor tissues (Tan et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1318">One week after the last vaccination or saline injection all the experimental mice were subcutaneously injected with 2Ã—10^6 live tumor cells (Tan et al., 2007).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1052">
		<vaccine_name>Cancer DNA Vaccine MIDGE/hNIS encoding hNIS protein</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011364</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>Minimalistic immunogenically defined gene expression (MIDGE), derived from hNIS plasmid, pcDNA3.1-hNIS [Ref1306:Choi et al., 2007].</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering538" gene_id="gene716">
			<type>DNA vaccine construction</type>
			<description refs="reference1306">Human sodium iodide symporter (hNIS) is a transmembrane protein that actively transports iodide ions into thyroid cells. hNIS is over-expressed in some cases of the thyroid cancers compared with the surrounding normal tissues and has been considered to be an attractive target for immunotherapy. Minimalistic immunogenically defined gene expression (MIDGE) was used as a vector system (Choi et al., 2007).</description>
		</gene_engineering>
		<host_response host_response_id="host_response806" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">Balb/C</host_strain>
			<vaccination_protocol refs="reference1306">mice (4 per group) were vaccinated i.m. with 100 &amp;mu;g per mouse of pcDNA3.1 or pcDNA3.1/hNIS in a 100 &amp;mu;l volume. The groups primed with MIDGE/hNIS or MIDGE/hNIS-NLS received 54.8 &amp;mu;g/100 &amp;mu;l per mouse, which is an equimolar concentration of the plasmids. One week later, the mice were boosted with the same amount of DNA (Choi et al., 2007).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1306">Immunization with the hNIS encoding vectors induced antigen-mediated antitumor activity against NIS-expressing CT26 tumors in vivo, with the highest tumor free rate (100%) and lowest tumor growth being observed up to 40 days after the CT26/NIS tumor challenge with MIDGE/hNIS than those resulting from other immunization groups (Choi et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1306">One week after the final vaccination, the mice were challenged subcutaneously (s.c.) with CT26/NIS tumor cells at 5 Ã— 10^4 cells/mouse in the hind-right legs (Choi et al., 2007).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3695">
		<vaccine_name>Cancer DNA vaccine p.DOM-AH1 encoding fragment C</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004425</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcDNA3 [Ref2339:Buchan et al., 2005]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1228" gene_id="gene1332">
			<type>DNA vaccine construction</type>
			<description refs="reference2339">This DNA vaccine expressed the first domain of fragment C (FrC)3 from tetanus toxin (DOM; TT865â€“1120) with sequence encoding the AH1 CTL epitope fused to the 3  terminus (Buchan et al., 2005).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1455" host_id="host3">
			<immune_response refs="reference2339">Vaccination was rendered effective by electroporation, priming higher levels of AH1-specific CD8(+) T cells able to protect mice from tumor growth (Buchan et al., 2005).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2339">Delivery in a suboptimal volume (2 Ã— 10 Î¼l) did not mediate protection. However, protective efficacy was completely restored when suboptimal volume was combined with electroporation (p &lt; 0.003).  Therefore, this vaccine was able to protect from CT26 tumor in vivo (Buchan et al., 2005).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1059">
		<vaccine_name>Cancer DNA Vaccine pLXSHDmB7-2 encoding Cd86</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011373</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pLXSHD</vector>
		<route>Intraperitoneal injection (i.p.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intraperitoneal injection (i.p.)</route>
		<antigen refs="">Cd86</antigen>

		<gene_engineering gene_engineering_id="gene_engineering547" gene_id="gene304">
			<type>DNA vaccine construction</type>
			<description refs="reference964">A DNA fragment encoding the entire open reading frame of murine B7-2 was amplified by reverse transcription-coupled PCR (27) from RNA prepared from LPS-activated murine spleen cells (15). The sense primer (Sâ€™-TCGATAGGAATTCGTAGACGTGTTCCAGAACIT3â€™) consists of an oligonucleotide corresponding to 64 to 83 nucleotides of murine B7-2 cDNA, plus a restriction site for EcoRI. The antisense primer (5â€™-TACGATACTCGAGTCTCACTGCCTTCACTCTGCAT-3') corresponds to 1018 to 1039 nucleotides of murine B7-2 cDNA, plus a site for Xhol. The PCR product was cloned directly into the vector pLXSHD (provided by Dr. D. Miller, Fred Hutchinson Cancer Research Center, Seattle, WA) (Yang et al., 1995).</description>
		</gene_engineering>
		<host_response host_response_id="host_response817" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference964">For immunization experiments, mice were injected into the shaved right back with live tumor cells by using the same procedure as described above, and tumor nodules were removed surgically at day 10 (Yang et al., 1995).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference964">A plasmid containing murine B7-2 (Cd86) cDNA was transfected into the immunogenic mouse mastocytoma P815 of DBA/2 origin. In contrast to the lethal growth of the wild-type (wt) P815 tumor, B7-2-positive (B7-2+) P815 cells inoculated into syngeneic mice regressed, and immunization of mice with such tumor cells protected them against the challenge of wt P815 tumor (Yang et al., 1995).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference964">Two weeks after tumor removal, the mice were challenged into the left back or the frank with wt tumor cells at 1 X 10^5 /mouse (P815) or 2 X 10^5 /mouse (Yang et al., 1995).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1053">
		<vaccine_name>Cancer DNA Vaccine pSURV encoding Survivin</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011365</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pVAX [Ref1313:Lladser et al., 2010]</vector>
		<route>Intradermal injection (i.d.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intradermal injection (i.d.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering539" gene_id="gene719">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response808" host_id="host3">
			<immune_response refs="reference1313">Intradermal DNA EP of mice with a human survivin encoding plasmid generated CD8+ cytotoxic T lymphocyte (CTL) responses cross-reactive with the mouse epitope surv(20-28), as determined by intracellular IFN-gamma staining, suggesting that self-tolerance has been broken. Survivin-specific CTLs displayed an activated effector phenotype as determined by CD44 and CD107 up-regulation. Vaccinated mice displayed specific cytotoxic activity against B16 and peptide-pulsed RMA-S cells in vitro as well as against surv(20-28) peptide-pulsed target cells in vivo (Lladser et al., 2010).</immune_response>
			<host_strain refs="">C57BL/6</host_strain>
			<vaccination_protocol refs="reference1313">C57BL/6 mice were anesthetized with isoflurane and injected intradermally with 40 Î¼g (40 Î¼l of PBS) of plasmid DNA at two sites (20 Î¼g each) near the base of the tail using a 29-gauge insulin-grade syringe. Mice were immunized two times either at days âˆ’21 and âˆ’7 (early setting) or at days +10 and +17 (late setting) with respect to tumor challenge, referred as day 0 (Lladser et al., 2010).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1313">Intradermal EP with a survivin DNA vaccine suppressed angiogenesis in vivo and elicited protection against highly aggressive syngeneic B16 melanoma tumor challenge (Lladser et al., 2010).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1313">Mice were challenged with a lethal dose of syngeneic B16 melanoma cells (Lladser et al., 2010).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1064">
		<vaccine_name>Cancer EPCAM protein vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011370</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>subcutaneous injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="">Alum</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">subcutaneous injection</route>
		<antigen refs="">EPCAM (GA733)</antigen>

		<gene_engineering gene_engineering_id="gene_engineering552" gene_id="gene317">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response821" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference976">Mice were immunized with 100 lg of Ab2 BR3E4 in CFA/IFA on days 0, 12, and 33, or with 5 lg alum-precipitated GA733-2E on days 0, 14, and 28 (Maruyama et al., 2000).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference976">The full-length GA733 (epcam) antigen expressed by recombinant adenovirus inhibited the growth of established tumors in mice (Maruyama et al., 2000).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference976">Immunized mice (4Â±6/group) were challenged s.c. with 4 x 10^7 CT26-ALGA710-3H cells expressing the GA733 antigen or with parental, antigen-negative
CT26 cells 2 weeks after the last immunization. Tumors were measured with a caliper twice each week for up to 2 months after the challenge (Maruyama et al., 2000).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1051">
		<vaccine_name>Cancer Her-2/neu Protein Subunit Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011363</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference1471">Gerbu Adjuvant and recombinant IL-2 (Wagner et al., 2007).</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering537" gene_id="gene296">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response804" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">FVB/N, BALB/c</host_strain>
			<vaccination_protocol refs="reference1471">FVB/N transgenic mice spontaneously developing c-neu overexpressing breast cancers were used. Mice were immunized with the combination of the three peptides P4, P6, and P7 coupled to tetanus toxoid (TT-conjugates; BALB/c and FVB/N n = 5/group, MMTV-c-neu trangenic mice n = 8/group) using 15 Î¼g of each peptide conjugate or with co-applicated IL-12 (BALB/c and FVB/N n = 5/group, MMTV-c-neu trangenic mice n = 7/group). Control BALB/c and FVB/N mice (n = 5/group) received TT and control MMTV-c-neu transgenic mice received TT (n = 8) or IL-12 (n = 5) alone or remained unimmunized (n = 8) (Wagner et al., 2007).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1471">At the time all untreated mice had developed tumors about 40% of peptide-immunized mice and nearly 60% of mice immunized with the peptide vaccine co-applied with IL-12 remained tumor free (Wagner et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1049">
		<vaccine_name>Cancer recombinant vector vaccine encoding H-2Kb</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011368</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector>Recombinant adenovirus [Ref952:Campbell et al., 2000].</vector>
		<route>i.t. injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">i.t. injection</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering535" gene_id="gene292">
			<type>Recombinant vector construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response802" host_id="host4">
			<immune_response refs=""></immune_response>
			<host_strain refs="">Fisher 344</host_strain>
			<vaccination_protocol refs="reference952">A study was conducted to examine the growth inhibition of LN-4 tumors in vivo with an intratumoral (i.t.) injection of AdV-H-2Kb adenovirus. Fisher 344 rats were injected s.c. in their right thighs with 0.5x10^6 LN-4 tumor cells. At 2 weeks after tumor inoculation, when tumors grew to ;3â€“4 mm in diameter, rats were injected i.t. with a single dose of 2.5x10^9 PFU of the AdV-H2Kb virus. The i.t. injection of the AdV-H-2Kb virus was given two more times at 5-day intervals for a total of three injections. As a control, rats were injected i.t. with a single dose of 2.5x10^9 PFU of the AdV5LacZ adenovirus (Campbell et al., 2000).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference952">The expression of xenogeneic MHC class I antigen completely abolished the LN-4 tumorigenicity in rats, whereas the expression of allogeneic MHC class I antigen only partially reduced the MCA-26 tumorigenicity in mice. The immunized rats that experienced LN-4/H-2Kb tumor regression further developed protective immunity against a subsequent challenge of LN-4 cells. Adenovirus-mediated H-2Kb gene transfer in vivo can further significantly inhibit pre-established LN-4 tumors (Campbell et al., 2000).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1058">
		<vaccine_name>Cancer Retroviral Vector Vaccine encoding Cd40lg</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011372</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector>Gla retroviral vector</vector>
		<route>subcutaneous injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">subcutaneous injection</route>
		<antigen refs="">CD40 Ligand</antigen>

		<gene_engineering gene_engineering_id="gene_engineering546" gene_id="gene305">
			<type>Recombinant vector construction</type>
			<description refs="reference965">Murine CD40 ligand (mCD40L) gene was cloned from a c D N A library generated from activated T cells (Coleclough, 1993) using seminested P C R primers that incorporated a Kpn I site at the 5' end of the gene and a Cta I site at the 3' end of the gene using AmpliTaq (Perkin-Elmer, Branchburg, NJ) according to the manufacturer's protocols. The polymerase chain reaction (PCR) product was inserted into p G E M 7 Z (Pharmacia Biotech Inc., Piscataway, NJ) and the correct D N A sequence of a full-length clone as compared to published data (Armitage et al, 1992) was confirmed. The m u C D 4 0 L gene was then subcloned into the Gla retroviral vector derived from Moloney murine leukemia virus (Genetic Therapy, Inc., Gaithersburg, M D ) using the Xho I and Hind II sites (pGla.mCD40L) and used to manufacture a producer cell line (Grossmann et al., 1997).</description>
		</gene_engineering>
		<host_response host_response_id="host_response815" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">A/J</host_strain>
			<vaccination_protocol refs="reference965">A/J (H^'') female mice (Jackson Labs) received a single subcutaneous (s.c.) injection consisting of 2 X 10* cells total unless otherwise noted in the figure legends. The cells were either neuro-2a/neo cells ( 0 % C D 4 0 L positive), neuro-2a/CD40L (70% CD40L positive), or neuro-2a/neo cells mixed with various
numbers of neuro-2a/CD40L cells to the appropriate percentages of CD40L-positive cells (Grossmann et al., 1997).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference965">Transgenic expression of the CD40L (Cd40lg) increased immune responses against a weakly immunogenic murine tumor, neuro-2a. Tumor cells were transduced with a retroviral construct containing the CD40L gene and co-injected with variable numbers of non-CD40L transduced cells into syngeneic mice. Mice injected with cells that expressed CD40L had a significant reduction in average tumor size as compared to controls (p &lt; 0.0001). In addition, survival of the neuro-2a/CD40L mice was 48 days versus 34 days for the neuro-2a/neo controls (p &lt; 0.02). Expression of CD40L by less than 1.5% of neuro-2a cells was sufficient for significant antitumor effects (p &lt; 0.001). These antitumor effects protected mice from subsequent challenge with parental neuro-2a cells (Grossmann et al., 1997).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference965">Antitumor effects were tested with subsequent challenge with parental neuro-2a cells (Grossmann et al., 1997).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine894">
		<vaccine_name>Cancer Subunit  DC (Tat-CEA) vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011510</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector>Dendritic Cells [Ref1295:Bae et al., 2009].</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering368" gene_id="gene316">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response652" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">B6</host_strain>
			<vaccination_protocol refs="reference1295">To establish a CEA-positive tumour-bearing mouse model, 6-week-old B6 mice were injected in the right flank with MC38-CEA2 cells (1 Ã— 106) each. At 7 days after tumour cell injection, mice were immunized at the tail base with DCs pulsed with CEA or Tat-CEA proteins (1 Ã— 106 cells/mouse in 100 Âµl PBS) at weekly intervals for 4 weeks. Control mice were injected with PBS only (Bae et al., 2009).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1295">In vivo, the DC (Tat-CEA) vaccine delayed tumour growth significantly and prolonged survival of tumour-bearing mice (Bae et al., 2009).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1295">To establish a CEA-positive tumour-bearing mouse model, 6-week-old B6 mice were injected in the right flank with MC38-CEA2 cells (1 Ã— 106) each (Bae et al., 2009).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine891">
		<vaccine_name>Cancer Subunit GV1001 Protein Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011507</vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route>Intradermal injection (i.d.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference1294">Granulocyteâ€“macrophage colony-stimulating factor (Bernhardt et al., 2006).</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intradermal injection (i.d.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering365" gene_id="gene705">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response650" host_id="host2">
			<immune_response refs="reference1294">Overall, a vaccine related immune response was detected in 63% of the evaluable study population (Bernhardt et al., 2006).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference1294">Forty-eight treatment naive patients with non-resectable, histologially confirmed adenocarcinoma of the pancreas were enrolled in the study (September 2000â€“March 2003). he vaccine was administered by intradermal (i.d.) injection in the right para-umbilical area following the schedule; three injections in week 1and one weekly injection in weeks 2, 3, 4, 6, and 10. The three different doses of vaccine administered were; low dose: 60 nmole (112 Î¼g) GV1001 in 0.10 ml saline, intermediate dose: 300 nmole (560 Î¼g) GV1001 in 0.125 ml saline, and high dose: 1.0 Î¼mole (1.87 mg) GV1001 in 0.20 ml saline. From 5 to 15 min before each vaccine injection, 30 Î¼g granulocyteâ€“macrophage colony-stimulating factor  in 0.10 ml saline was injected i.d. at the vaccination site (Bernhardt et al., 2006).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1294">Median survival for the intermediate dose-group was 8.6 months, significantly longer for the low- (P = 0.006) and high-dose groups (P = 0.05). One-year survival for the evaluable patients in the intermediate dose group was 25% (Bernhardt et al., 2006).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1047">
		<vaccine_name>Cancer Subunit NY-ESO-1 Protein Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011366</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference1321">ISCOMATRIX adjuvant (Maraskovsky et al., 2004).</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering533" gene_id="gene724">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response800" host_id="host3">
			<immune_response refs="reference1321">The NY-ESO-1 vaccine induced strong NY-ESO-1-specific IFN-gamma and IgG2a responses in C57BL/6 mice. Furthermore, the NY-ESO-1 vaccine induced NY-ESO-1-specific CD8(+) CTLs in HLA-A2 transgenic mice that were capable of lysing human HLA-A2(+) NY-ESO-1(+) tumor cells (Maraskovsky et al., 2004).</immune_response>
			<host_strain refs="">BALB/c and C57BL/6</host_strain>
			<vaccination_protocol refs="reference1321">Mice were immunized s.c. with 100 Î¼l into the scruff of the neck with the NY-ESO-1 vaccine (5 Î¼g of both NY-ESO-1 and ISCOPREP saponin), or with NY-ESO-1 protein (5 Î¼g of protein) or with the ISCOMATRIX adjuvant (5 Î¼g of ISCOPREP saponin) (Maraskovsky et al., 2004).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1321">C57BL/6 mice, immunized with the NY-ESO-1 vaccine, were protected against challenge with a B16 melanoma cell line expressing NY-ESO-1 (Maraskovsky et al., 2004).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1321">B16 melanoma cells were transfected using electroporation with the mammalian expression plasmid, pCDNA3, encoding the cDNA for NY-ESO-1 (Invitrogen, Carlsbad, CA). Selection with G418 (800 Î¼g/ml) and limit-dilution cloning yielded a clone expressing NY-ESO-1 (B16-NY-ESO-1) as determined by IHC and quantitative real-time PCR. C57BL/6 mice were vaccinated twice (at 0 and 4 weeks) with the NY-ESO-1 vaccine, or with the ISCOMATRIX adjuvant alone as a control. Four weeks after the second immunization, mice were challenged with B16-NY-ESO-1. The tumor cells (1 Ã— 10^4) were injected s.c. on the back, and tumor volume was measured over time (Maraskovsky et al., 2004).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3053">
		<vaccine_name>Cancer Vaccine using E7 protein of human papillomavirus 16 and Algammulin</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004227</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>subcutaneous injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">subcutaneous injection</route>
		<antigen refs="reference1871">Peptide GF001, comprising the H-2Db-restricted minimal CTL epitope  of HPV16 E7 protein (Fernando et al., 1998).</antigen>
		<host_response host_response_id="host_response883" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">C57BL/6J</host_strain>
			<vaccination_protocol refs="reference1871">Mice (8 to 10 per group) were immunized s.c. at the base of the tail with 50 Âµg of E7GST protein, or 50 Âµg OVA as control, and 10 Âµg of Quil-A or 50 Âµg of Algammulin as adjuvant (Fernando et al., 1998).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1871">Immunization with E7 and Algammulin (an alum-based adjuvant) induced a Th2-like response and provided no tumor protection (Fernando et al., 1998).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1871">Mice were challenged with 3 x 10^6 cells of EL4.E7 tumor or 2 x 10^6 cells of C3 cells 14 days after the last immunization (Fernando et al., 1998).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3054">
		<vaccine_name>Cancer Vaccine using E7 protein of human papillomavirus 16 and Quil-A</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004228</vo_id>
		<type>Subunit vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>subcutaneous injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">subcutaneous injection</route>
		<antigen refs="reference1871">Peptide GF001, comprising the H-2Db-restricted minimal CTL epitope of HPV16 E7 protein (Fernando et al., 1998).</antigen>
		<host_response host_response_id="host_response884" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">C57BL/6J</host_strain>
			<vaccination_protocol refs="reference1871">Mice (8 to 10 per group) were immunized s.c. at the base of the tail with 50 Âµg of E7GST protein, or 50 Âµg OVA as control, and 10 Âµg of Quil-A or 50 Âµg of Algammulin as adjuvant (Fernando et al., 1998).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1871">Growth of EL4.E7 was reduced following immunization with E7 and Quil-A (an adjuvant that induced a Th1-type response to E7) or with GF001 and Quil-A (Fernando et al., 1998).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1871">Mice were challenged with 3 x 10^6 cells of EL4.E7 tumor or 2 x 10^6 cells of C3 cells 14 days after the last immunization (Fernando et al., 1998).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1066">
		<vaccine_name>Cancer VEGFA protein vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011371</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>subcutaneous injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="">Aluminum hydroxide, VSSP, and CAF01</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">subcutaneous injection</route>
		<antigen refs="">VEGFA</antigen>
		<host_response host_response_id="host_response823" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">C57BL/6</host_strain>
			<vaccination_protocol refs="reference1304">Immunization was done subcutaneously (sc) with 100 Î¼g antigen in 200 Î¼l of the antigen-adjuvant preparation. The immunization scheme included weekly immunizations for six consecutive weeks. Control mice only received vehicle or adjuvant (Morera et al., 2008).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1304">A protein vaccine candidate, based on a human modified VEGF antigen that is expressed at high levels in E. coli was developed. With respect to controls, immunization experiments in C57BL/6 mice using weekly doses of this antigen and three adjuvants of different chemical natures show that time for tumor development after subcutaneous injection of Melanoma B16-F10 cells increases, tumors that develop grow slower, and overall animal survival is higher. Immunization also prevents tumor development in some mice, making them resistant to second tumor challenges. Vaccination of mice with the human modified VEGF recombinant antigen produces antibodies against the human antigen and the homologous mouse VEGF molecule. We also show that sera from immunized mice block human VEGF-induced HUVEC proliferation (Morera et al., 2008).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1304">Animals were challenged with a sc injection of 2 Ã— 104 B16-F10 melanoma cells, 4 days after the third immunization (Morera et al., 2008).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5329">
		<vaccine_name>CAP-2 (CEA Peptide 9-mer)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5380">
		<vaccine_name>CAP-3 (CEA Peptide 9-mer)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5356">
		<vaccine_name>Carcinoembryonic Antigen Peptide 1-6D</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4503">A 9-residue human leukocyte antigen (HLA)-restricted fragment of carcinoembryonic antigen (CEA). Vaccination with carcinoembryonic antigen peptide 1-6D, which has the amino acid sequence YLSGANLNL, may elicit a cytotoxic T lymphocyte (CTL) immune response against tumors expressing CEA. (NCIT_C2622).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5129">
		<vaccine_name>Carcinoembryonic Antigen Peptide 1-6D Virus-Like Replicon Particles Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4491">A cancer vaccine, consisting of alphavirus vector-derived virus-like replicon particles expressing the 9-amino-acid carcinoembryonic antigen peptide (CAP) 1-6D, with potential antineoplastic activity. Vaccination with this agent may elicit a cytotoxic T lymphocyte (CTL) immune response against CEA-expressing tumor cells. (NCIT_C70644).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5209">
		<vaccine_name>Carcinoembryonic Antigen Peptide-1 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4450">A cancer vaccine comprised of an epitope from the Carcinoembryonic Antigen obtained from cancer cells that can stimulate an immune response against tumor cells. (NCI) (NCIT_C2060).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5041">
		<vaccine_name>Carcinoembryonic Antigen RNA-pulsed DC Cancer Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4641">A vaccine comprised of autologous dendritic cells pulsed with mRNA-encoded Carcinoembryonic Antigen (CEA) targeting tumor cells expressing CEA. (NCI) (NCIT_C2439).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine3696">
		<vaccine_name>Carcinoma DNA vaccine pVAX/E2A</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004426</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pVAX [Ref2340:Lindencrona et al., 2004]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference2340">GM-CSF   (Lindencrona et al., 2004)</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1513" gene_id="gene1684">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1456" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2340">Eighty percent of B cell competent Î¼MT+/âˆ’ mice immunized with pVAX/E2A and GM-CSF plasmids were protected from HER-2 expressing tumor challenge. All mice challenged with the HER-2 negative untransfected control line developed tumors. Of note, protection was equal or better in B cell deficient animals, as 90% of the Î¼MTâˆ’/âˆ’ mice that were immunized with pVAX/E2A and GM-CSF plasmids rejected the tumor. All mice immunized with pVAX/E2A without the GM-CSF plasmid developed tumors. Thus, this HER-2 specific resistance to tumor challenge is entirely dependent on co-administration of the GM-CSF plasmid. None of the Î¼MTâˆ’/âˆ’ mice immunized with pVAX/E2A or the combination of GM-CSF and pVAX/E2A were protected from challenge with the HER-2 negative D2F2 control line (Lindencrona et al., 2004).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5193">
		<vaccine_name>CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4251">A plasmid DNA vaccine containing the mammalian expression vector pUMVC3 (pNGVL3) encoding epitopes of CD105 (Endoglin), Y-box binding protein 1 (Yb-1), SRY-box 2 (SOX2), cadherin 3 (CDH3), and murine double minute 2 (MDM2) proteins, with potential immunomodulating and antineoplastic activities. Upon intradermal administration of pUMVC3-CD105/Yb-1/SOX2/CDH3/MDM2-epitopes plasmid DNA vaccine, the plasmid transfects cells and the peptides are expressed. This generates a specific memory Th1 (T-helper) cell immune response, stimulates secretion of cytokines by the T cells and leads to a cytotoxic T-lymphocyte (CTL) response against CD105/Yb-1/SOX2/CDH3/MDM2-expressing tumor cells. CD105/Yb-1/SOX2/CDH3/MDM2 proteins are highly immunogenic tumor associated antigens that are overexpressed in breast cancer. Additionally, these antigens are associated with breast cancer stem cells and with epithelial to mesenchymal transformation (EMT). (NCIT_C116321).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5107">
		<vaccine_name>CD133 Antigen Peptide-pulsed Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4177">A cell-based cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted peptides derived from the CD133 antigen, with potential antineoplastic activity. Upon intradermal administration, the CD133 antigen peptide-pulsed autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against CD133-expressing tumor cells, resulting in tumor cell lysis. CD133, a cancer stem cell marker, is expressed on hematopoietic stem and progenitor cells and overexpressed on many types of cancer cells; it is associated with resistance to chemotherapy and increased cancer survival. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T-cells. Epitope design that is restricted to those epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity. (NCIT_C113794).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5476">
		<vaccine_name>CD80 Breast Cancer Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4173">A vaccine comprised of CD80-transfected allogenic breast cancer cells to induce T-cell response. (NCIT_C2464).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5045">
		<vaccine_name>CEA RNA-pulsed Autologous Human Cultured Dendritic Cells</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4531">Autologous human dendritic cells pulsed with RNA encoding the carcinoembryonic antigen (CEA) are being studied for possible use in the treatment of cancer expressing CEA. (NCIT_C2710).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5367">
		<vaccine_name>CEA/Tetanus Toxoid T Helper Epitope Fusion Protein-Expressing DNA Plasmid Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4473">A plasmid vaccine encoding wild type human carcinoembryonic antigen (CEA) fused to a tetanus toxoid T helper epitope, with potential antineoplastic activity. Upon vaccination and subsequent intradermal electroporation, CEA/tetanus toxoid T helper epitope fusion protein-expressing DNA plasmid vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells. CEA, a tumor associated antigen, is overexpressed in a variety of cancer cell types. The tetanus toxoid helper peptide epitope, obtained from the bacterial Clostridium tetani toxoid, binds to class II MHC molecules and increases the helper T-cell response thereby inducing an increased and long-term immune response. (NCIT_C90555).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5316">
		<vaccine_name>Chimeric Ad11p/Ad3 Oncolytic Virus</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4332">A complex, replication-selective, E1B and partial E3 gene deleted, adenovirus type 11p (Ad11p)/Ad3 chimeric oncolytic virus with potential antineoplastic activity. Upon intralesional injection of enadenotucirev, the adenovirus selectively and rapidly replicates in cancer cells; however, it is unable to replicate in normal, healthy cells. This induces a selective adenovirus-mediated cytotoxicity in cancer cells, which leads to cancer cell lysis. Following the lysis of infected cells, the replicated virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate the immune system to kill the infected tumor cells. The E1B protein causes p53 inactivation in host cells, which promotes viral replication. Deletion of E1B prevents replication in normal, healthy cells that express wild-type p53. The mutation and subsequent inactivation of p53 in cancer cells enables the E1B-deleted adenovirus to selectively replicate in cancer cells. Partial deletion of the E3 gene, which encodes the adenovirus death protein, enhances the safety profile of the administered adenovirus. (NCIT_C113786).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4985">
		<vaccine_name>CMV pp65 Peptide-pulsed Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4140">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with the human cytomegalovirus (CMV) phosphoprotein pp65, with potential immunostimulatory and antineoplastic activities. Upon administration, the CMV pp65 peptide-pulsed autologous DC vaccine exposes the immune system to the CMV pp65 peptide, which may result in a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells leading to cell lysis. The CMV pp65 protein, also called the 65 kDa lower matrix phosphoprotein, is the primary component of the enveloped subviral particle of CMV and is expressed in certain tumor types, such as glioblastoma (NCIT_C116740).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5306">
		<vaccine_name>CMVpp65/gB Plasmid Vaccine ASP0113</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4262">A poloxamer-formulated, bivalent DNA vaccine containing two plasmids encoding both the human cytomegaloviral (CMV) tegument phosphoprotein 65 (pp65), a major internal matrix protein, and glycoprotein B (gB), an important CMV component responsible for attachment and entry into cells, with potential immunostimulatory properties. Upon intramuscular injection of CMVpp65/gB plasmid vaccine ASP0113, the expressed proteins may activate the immune system to mount both cellular and humoral immune responses against CMV-positive cells. This results in cell lysis of CMV-infected cells and prevents both viral replication and the development of CMV disease. This vaccine also provides active immunization and protective immunity against CMV infection in CMV-negative patients exposed to infected donor cells or tissues in transplant recipients. CMV infection can cause serious complications in patients receiving either allogeneic hematopoietic cell transplants (HCT) or solid organ transplants. The poloxamer-based delivery system enhances DNA delivery. (NCIT_C111903).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine3699">
		<vaccine_name>Colorectal cancer DNA vaccine pCEA/HBsAg encoding carcinoembryonic antigen and hepatitis B surface antigen</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004428</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcDNA3 [Ref2342:Conry et al., 2002]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1229" gene_id="gene1333">
			<type>DNA vaccine construction</type>
			<description refs="reference2342">Vector pcDNA3 expressed the small and middle proteins of the Hepatitis B surface antigen (Conry et al., 2002).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1230" gene_id="gene1351">
			<type>DNA vaccine construction</type>
			<description refs="reference2342">Vector pcDNA3 expressed the carcinoembryonic antigen (Conry et al., 2002).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1459" host_id="host2">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2342">Repetitive dosing of pCEA/HBsAg induced HBsAg antibodies in 6 of 8 patients, and 4 of these patients achieved protective antibody levels (&gt;10 mIU/ml) (Conry et al., 2002).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5267">
		<vaccine_name>Conjugate Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4255">A category of vaccines created by covalently attaching an antigen from an organism to a carrier protein from the same organism to aid in the delivery of the immunogen. (NCIT_C1455).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5372">
		<vaccine_name>CTP-37-DT Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4357">A vaccine composed of synthetic peptides derived from beta-human chorionic gonadotropin (hCG) conjugated to diphtheria toxoid. Vaccination with this peptide may elicit the host immune response against hCG-producing cancer cells. (NCIT_C30000).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5139">
		<vaccine_name>Cyclin B1 Peptide-pulsed Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4198">A cell-based cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with cyclin B1 peptide, with potential immunostimulatory and antineoplastic activities. Upon administration, cyclin B1 peptide-pulsed autologous dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and anti-cyclin B1 antibody responses against cyclin B1-expressing cancer cells, resulting in tumor cell lysis. Cyclin B1, a key regulator of the cell cycle and cell division, is overexpressed in a variety of cancer cells. (NCIT_C97665).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5070">
		<vaccine_name>Cytokine-Induced Killer Cells</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4675">A preparation of autologous lymphocytes with potential immunopotentiating and antineoplastic activities. Cytokine-induced killer (CIK) cells are CD3- and CD56-positive, non-major histocompatibility complex (MHC)-restricted, natural killer (NK)-like T lymphocytes, generated ex-vivo by incubation of peripheral blood lymphocytes (PBLs) with anti-CD3 monoclonal antibody, interleukin (IL)-2, IL-1, and interferon gamma (IFN-gamma) and then expanded. When reintroduced back to patients after autologous stem cell transplantation, CIK cells may recognize and kill tumor cells associated with minimal residual disease (MRD). CIK cells may have enhanced cytotoxic activity compared to lymphokine-activated killer (LAK) cells. (NCIT_C71757).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5163">
		<vaccine_name>Dendritic Cell Tumor Cell Lysate Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4468">A vaccine composed of dendritic cells pulsed with tumor cells lysates that stimulate a potent and specific cell mediated anti-tumor immune response. (NCI) (NCIT_C1988).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5161">
		<vaccine_name>Dendritic Cell-Autologous Lung Tumor Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4397">A cancer vaccine consisting of lymphocytes harvested from a patient with lung cancer and induced to become antigen-presenting cells (APCs) known as dendritic cells. The dendritic cells are transduced with the gene encoding an antigen specific to the patient's cancer and then returned to the patient. In the host, the altered cells stimulate the immune system to mount a primary T cell response against lung tumor cells expressing the target antigen. Dendritic cell-autologous lung tumor vaccines have been investigated for use in cancer immunotherapy. (NCIT_C26446).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5417">
		<vaccine_name>Dendritic Cell-CEA Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4580">A cancer vaccine consisting of dendritic cells harvested from a patient with cancer and pulsed or transduced with a peptide fragment of carcinoembryonic antigen (CEA), a tumor-associated antigen expressed by a wide range of cancers. When the altered dendritic cells are returned to the patient, they may stimulate the host immune system to mount a cytotoxic T-lymphocyte immune response against tumor cells expressing CEA. (NCIT_C2473).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5067">
		<vaccine_name>Dendritic Cell-gp100-MART-1 Antigen Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4203">An autologous dendritic cells vaccine with antineoplastic property. Dendritic cells harvested from cancer patients are pulsed with human gp100 melanoma antigen and MART-1 (melanoma antigen recognized by T-cells) antigen; both antigens are up-regulated in melanomas. Vaccination with this vaccine may elicit the host immune response against MART-1 or gp100 expressing cells. (NCIT_C2214).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5494">
		<vaccine_name>Dendritic Cell-Idiotype-Keyhole Limpet Hemocyanin Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4302">A cell-based vaccine composed of allogeneic dendritic cells (DC), pulsed with patient-specific non-Hodgkin's lymphoma idiotype (Id) determinants conjugated to keyhole limpet hemocyanin (KLH), with potential antitumor activity. Upon administration, this vaccine may stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against Id-expressing lymphoma cells, resulting in tumor cell lysis. (NCIT_C71760).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5524">
		<vaccine_name>Dendritic Cell-MART-1 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4246">A cancer vaccine consisting of dendritic cells harvested from a patient with cancer and pulsed or transduced with a peptide fragment of MART-1 (melanoma antigen recognized by T-cells), an antigen expressed by melanoma cells. When the altered dendritic cells are returned to the patient, they stimulate the host immune system to mount a cytotoxic T-lymphocyte immune response against tumor cells expressing MART-1. (NCIT_C2426).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5000">
		<vaccine_name>Dendritic Cell-Recombinant Prostate-Specific Membrane Antigen Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4568">A vaccine comprised of autologous dendritic cells pulsed with a recombinant prostate specific membrane antigen. (NCIT_C2576).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5493">
		<vaccine_name>Dendritic Cell-targeting Lentiviral Vector ID-LV305</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4625">An engineered lentiviral vector targeting dendritic cells (DCs) and containing nucleic acids encoding for the human tumor-associated cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the DC-targeting lentiviral vector ID-LV305 targets and binds to dermal DCs via the DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) receptor. Upon internalization of the vector, the NY-ESO-1 protein is expressed, stimulates DC maturation and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against NY-ESO-1-expressing cells, which may result in tumor cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival. (NCIT_C115976).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5346">
		<vaccine_name>DEPDC1/MPHOSH1 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4402">A cancer vaccine containing HLA-A*2402-restricted epitopes derived from DEP domain containing 1 (DEPDC1) and M phase phosphoprotein 1 (MPHOSPH1) with potential immunostimulatory and antineoplastic activities. Upon administration, DEPDC1/MPHOSH1 peptide vaccine may elicit a specific cytotoxic T lymphocyte (CTL) response against tumor cells expressing DEPDC1 and MPHOSPH1, tumor antigens that are overexpressed in bladder cancer cells. (NCIT_C74023).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5338">
		<vaccine_name>Dinitrophenyl-Modified Autologous Renal Cell Carcinoma Tumor cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4470">A cancer vaccine consisting of autologous renal cell carcinoma (RCC) tumor cells modified with the hapten 2,4-dinitrophenol (DNP) with potential immunostimulating and antineoplastic activities. Administration of DNP-modified autologous renal cell carcinoma tumor cell vaccine may induce a cytotoxic T-lymphocyte (CTL) response against renal cell carcinoma tumor cells. DNP conjugation may enhance the immunogenicity of weakly immunogenic antigens. (NCIT_C85456).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5409">
		<vaccine_name>Diphtheria Toxoid/Tetanus Toxoid Vaccine Adsorbed</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Toxoid vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4220">A vaccine containing detoxified tetanus toxoid and detoxified diphtheria toxoid adsorbed on aluminum phosphate with active immunizing activity against diphtheria and tetanus. Intramuscular injection with this vaccine activates the immune system to develop antibodies against tetanus toxin and diphtheria toxin. (NCIT_C91718).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5289">
		<vaccine_name>Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Adsorbed, Recombinant Hepatitis B/Inactivated Poliovirus Vaccine Combined</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Toxoid vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4218">A vaccine consisting of detoxified tetanus toxoid, detoxified diphtheria toxoid, acellular pertussis antigens, inactivated poliovirus (IPV) types 1,2 and 3 and hepatitis B (HBV) surface antigen, with active immunizing activities against diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis. The acellular pertussis components in this vaccine, produced by Bordetella pertussis, are detoxified pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN). Upon intramuscular injection, this vaccine activates the immune system to develop antibodies against tetanus toxin, diphtheria toxin, B. pertussis antigens, polioviruses and HBV. The diphtheria and tetanus toxoids and pertussis antigens (inactivated PT, FHA, and pertactin) are adsorbed onto aluminum hydroxide; the hepatitis B antigen is adsorbed onto aluminum phosphate. (NCIT_C91716).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5462">
		<vaccine_name>Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Toxoid vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4217">A vaccine containing detoxified tetanus toxoid, detoxified diphtheria toxoid and acellular pertussis antigens, adsorbed on aluminum phosphate, with active immunizing activity against diphtheria, tetanus and pertussis. The acellular pertussis vaccine components, produced by Bordetella pertussis, are detoxified pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN) and fimbriae types 2 and 3 (FIM). Intramuscular injection with this vaccine activates the immune system to develop antibodies against tetanus toxin, diphtheria toxin and B. pertussis antigens. (NCIT_C91717).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5328">
		<vaccine_name>Diphtheria Toxoid/Tetanus Toxoid/Inactivated Pertussis Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Toxoid vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4216">A vaccine containing detoxified tetanus toxoid, detoxified diphtheria toxoid and inactivated pertussis antigens. (NCIT_C97122).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5539">
		<vaccine_name>Diphtheria-Tetanus-Acellular Pertussis-Inactivated Poliomyelitis-Haemophilus influenzae Type B Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Toxoid vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4546">A vaccine consisting of detoxified diphtheria toxoid (D), detoxified tetanus toxoid (T), acellular pertussis (aP) antigens, inactivated poliovirus (IPV) types 1, 2 and 3, and Haemophilus influenzae type b (Hib) capsular polysaccharide (polyribosylribitol phosphate; PRP) covalently bound to tetanus protein, suspended in water for injection and with active immunizing activity against diphtheria, tetanus, pertussis, poliomyelitis and H. influenzae type b. The five purified pertussis antigens in this vaccine are pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN) and fimbriae types 2 and 3 (FIM). Upon intramuscular injection of the diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae type b vaccine (DTaP-IPV-Hib), this vaccine activates the immune system to develop antibodies against diphtheria toxin, tetanus toxin, B. pertussis antigens, polioviruses and Hib, thereby providing active immunization against these diseases. The diphtheria and tetanus toxoids and pertussis antigens (inactivated PT, FHA, PRN and FIM) are adsorbed separately onto aluminum phosphate and then combined with IPV and PRP. (NCIT_C122399).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5019">
		<vaccine_name>Disomotide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5116">
		<vaccine_name>DLK1/EPHA2/HBB/NRP1/RGS5/TEM1 Peptide-pulsed Alpha-type-1 Polarized Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4241">A cell based cancer vaccine composed of mature polarized dendritic cells (alphaDC1) pulsed with six human leukocyte antigen (HLA)-A2-presented tumor blood vessel antigen (TBVA)-derived peptides, with potential immunostimulatory and antineoplastic activities. Dendritic cells (DCs) were treated with a &quot;type-1 polarizing cytokine cocktail&quot;, including interleukin-1beta, tumor necrosis factor alpha (TNF-a), interferon-alpha (IFN-a), IFN-gamma and polyinosinic:polycytidylic acid (pI:C) to produce mature alpha type-1 polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70 (IL-12p70). The alphaDC1 are subsequently pulsed with TBVA-derived peptides, including delta-like homologue 1 (DLK1) 310-318, EPH receptor A2 (EPHA2) 883-891, beta-globin (HBB) 31-39, neuropilin-1 (NRP1) 433-441, regulator of G-protein signaling 5 (RGS5) 5-13 and tumor endothelial marker 1 (TEM1) 691-700. Upon administration, these DCs are able to induce a potent cytotoxic T-lymphocyte (CTL) response against the TBVAs expressed on tumor-associated stromal cells, which results in stromal cell lysis and inhibition of angiogenesis. Disrupting the surrounding tumor vasculature inhibits tumor cell growth and survival. alphaDC1 are able to induce a potent tumor antigen-specific CTL response due to their high co-stimulatory activity and the secretion of anti-cancer cytokines, such as IL-12p70. (NCIT_C113807).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5016">
		<vaccine_name>DNA Plasmid Encoding Interleukin-12 INO-9012</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4634">A plasmid DNA vaccine encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) with potential immunoactivating activity. Upon intramuscular delivery by electroporation of DNA plasmid encoding interleukin-12 INO-9012, IL-12 is translated in cells and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma and promoting cytotoxic T-cell responses against tumor cells. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation. (NCIT_C116709).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5136">
		<vaccine_name>DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4334">A DNA-based combination immunotherapeutic, INO-3112, composed of VGX-3100, a preparation of DNA plasmids encoding the E6 and E7 genes of human papillomavirus (HPV) subtypes 16 and 18, combined with INO-9012, a DNA plasmid encoding the immune activator and pro-inflammatory cytokine human interleukin-12 (IL-12) with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery by electroporation of VGX-3100, the HPV E6 and E7 proteins are translated in cells and elicit a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the E6 and E7 antigens, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are associated with the development of certain types of cancer. Upon intramuscular delivery by electroporation of INO-9012, IL-12 is expressed and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and promoting CTL responses against tumor cells. This boosts the immune response and results in increased CTL-mediated tumor cell death as compared with the administration of VGX-3100 alone. (NCIT_C123919).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5207">
		<vaccine_name>DNA Vaccine VB10.16</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4312">A therapeutic DNA vaccine composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), the second is a dimerization entity and the third part encodes a protein that specifically binds to antigen presenting cells (APCs), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration, the DNA vaccine VB10.16 expresses HPV16 E6/7 and a protein that targets receptors on APCs. Upon binding to APCs and subsequent internalization, the APCs mature and the HPV16 E6/7 antigenic protein is presented by the APCs. This attracts and stimulates B-lymphocytes, CD4-positive T-lymphocytes and elicits a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing HPV16-associated E6 and E7 oncoproteins, which result in tumor cell lysis. HPV16 E6/7, a viral antigen, plays a key role in the development of certain types of cancer. (NCIT_C123923).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5407">
		<vaccine_name>DNA Vector pPRA-PSM Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4226">A cancer vaccine consisting of a DNA plasmid encoding epitopes of the human preferential antigen of melanoma (PRAME) and the prostate specific membrane antigen (PSMA) with potential immunostimulating activity. Upon direct administration of this vaccine into lymph nodes, peptides expressed by DNA plasmid vector pPRA-PSM may activate the immune system, resulting in a cytotoxic T-lymphocyte (CTL) response against PRAME- and PSMA-expressing cells. PRAME and PSMA are tumor associated antigens upregulated in a number of cancer cell types. As part of the MKC1106-PP regimen exploiting the 'prime-boost strategy', this plasmid is responsible for priming the immune response and is used in conjunction with a peptide vaccine consisting of PRAME and PSMA that boosts the immune system against PRAME- and PSMA-expressing tumor cells. (NCIT_C67089).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4987">
		<vaccine_name>E1M(184V) Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4467">A proprietary lipid emulsion containing five vaccines: diphtheria, pertussis, tetanus (DPT), Bacille Calmette-Guerin (BCG), measles, Serratia marcescens and pneumococcal, with potential immunostimulating activity. Subcutaneous administration of the DPT/BCG/measles/Serratia/pneumococcus vaccine activates the immune system and may both abrogate tumor-induced immune tolerance and induce an antitumor immune response, which may eradicate the tumor. (NCIT_C62801).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5509">
		<vaccine_name>EF-1 Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4579">A synthetic peptide derived from the protein ESW/FLI1 type 1 with potential use in cancer immunotherapy. EWS/FLI1 is a fusion protein frequently found in patients with Ewing's sarcoma or primitive neuroectodermal tumors (PNET). Vaccination with EF-1 peptide may stimulate the host immune response to elicit a cytotoxic T-cell response against tumor cells that express this EWS/FL1 type 1 fusion protein. (NCIT_C49063).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5432">
		<vaccine_name>EF-2 Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4577">A synthetic peptide derived from the protein ESW/FLI1 type 2 with potential use in cancer immunotherapy. EWS/FLI1 is a fusion protein frequently found in patients with Ewing's sarcoma or primitive neuroectodermal tumors (PNET). Vaccination with EF-2 peptide may stimulate the host immune response to elicit a cytotoxic T-cell response against tumor cells that express this EWS/FL1 type 2 fusion protein. (NCIT_C49064).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5531">
		<vaccine_name>EGFRvIII Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4130">An antineoplastic vaccine directed against a peptide found in the epidermal growth factor receptor class III variant (EGFRvIII), a constitutively activated mutant of the wild-type tyrosine kinase. This protein variant is present in a substantial proportion of malignant gliomas and other human cancers. (NCIT_C114755).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5103">
		<vaccine_name>Emepepimut-S</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4610">A liposome-encapsulated peptide vaccine consisting of a synthetic peptide derived from the mucin 1 (MUC-1) antigen with potential antineoplastic activity. Upon vaccination, MUC-1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against MUC-1-expressing tumor cells, resulting in growth inhibition. MUC-1 antigen is a high-molecular-weight transmembrane glycoprotein that is overexpressed on the cell surfaces of many epithelial tumor cells as well as on the cell surfaces of some B-cell lymphoma cells and multiple myeloma cells. (NCIT_C2195).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5264">
		<vaccine_name>ESO-1 (161-180) Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4598">A recombinant 19-residue peptide vaccine consisting of amino acids 161 through 180 of the cancer/testis (CT) antigen. ESO-1 (161-180) peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for ESO-1, resulting in decreased tumor growth. ESO-1 is expressed in a variety of cancers, including melanoma, breast, bladder, prostate, and hepatocellular cancers. (NCI04) (NCIT_C28775).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5178">
		<vaccine_name>ESO-1 Reactive Autologous Peripheral Blood Lymphocyte</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4248">Human peripheral blood lymphocytes (PBL) isolated from a patient, exposed to the tumor-associated protein ESO-1 in vitro, and then transferred back to the same patient to target tumor cells expressing ESO-1. ESO-1 is a human self-antigen expressed by melanomas. The ESO-1 gene encodes several MHC class I- and MHC class II-restricted epitopes that may activate cytotoxic T-cell-mediated tumor destruction (NCIT_C38119).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5473">
		<vaccine_name>ESO-1:157-165(165V) Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4588">A 9-residued peptide vaccine consisting of amino acids 157 through 165 of the cancer/testis (CT) antigen ESO-1. Modified at position 165 (cysteine to valine) to improve immunogenicity, ESO-1:157-165(165v) peptide administered as a vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for ESO-1, resulting in decreased tumor growth. ESO-1 is expressed in a variety of cancers, including melanoma, breast, bladder, prostate, and hepatocellular cancers. (NCI04 (NCIT_C2754).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5378">
		<vaccine_name>Falimarev</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4587">A cancer vaccine comprised of a recombinant fowlpox viral vector encoding the carcinoembryonic antigen (CEA), MUC-1, a transmembrane glycoprotein secreted by glandular epithelial tissues, and TRICOM, comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3). This agent may enhance CEA and MUC-1 presentation to antigen-presenting cells (APC) and may activate a cytotoxic T-cell response against CEA- and MUC-1-expressing tumor cells. (NCIT_C29316).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5151">
		<vaccine_name>Fas-Chimera Transgene-expressing Endothelial Tumor Cell-targeting Adenovector VB-111</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5317">
		<vaccine_name>Folate-FITC</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4571">A conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic activity. Folate-FITC binds to folate receptors, which are overexpressed on the surfaces of many cancer cells including kidney and ovarian cancer cells. Once bound to the cancer cell through the folate moiety of the conjugate, circulating anti-fluorescein antibodies may recognize and bind to the FITC moiety, resulting in antibody-dependent cellular cytotoxicity. (NCIT_C62479).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5031">
		<vaccine_name>Fowlpox Virus Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4488">A recombinant virus-based vaccine that contains various peptide antigens. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it does not multiply in human tissues. Strong CD8 T cell responses may be induced after prolonged immunization and have been associated with tumor regression. (NCIT_C2521).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5042">
		<vaccine_name>Fowlpox Virus Vaccine Vector</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4558">A recombinant fowlpox virus-based vaccine vector designed to express various tumor-associated peptide antigens. Strong CD8 cytotoxic T cell responses may be induced after prolonged immunization with fowlpox virus vaccines and have been associated with tumor regression. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it does not multiply in human tissues. (NCI05) (NCIT_C48390).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5300">
		<vaccine_name>Fowlpox-NY-ESO-1 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4622">A cancer vaccine consisting of a recombinant fowlpox virus vector encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1, an antigen found in normal testis and various tumors, including bladder, breast, hepatocellular, melanoma, and prostate cancers. Vaccination with NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis. (NCI05) (NCIT_C48465).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5038">
		<vaccine_name>Fowlpox-PSA-TRICOM Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4635">A cancer vaccine consisting of a recombinant fowlpox virus encoding human prostate-specific antigen (PSA) and TRICOM, a combination of three immunostimulants (i.e., B7.1, ICAM-1, and LFA-3). Administration of this agent may induce a cytotoxic T cell response against PSA-expressing tumor cells. Dendritic cells infected with TRICOM vectors greatly enhance naive T-cell activation and peptide-specific T-cell stimulation. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. (NCIT_C38708).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5236">
		<vaccine_name>FrSh61 (MEA) VHL33 Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4299">A peptide derived from the tumor suppressor protein Von Hippel-Lindau (VHL). This peptide, sequence: MEAGRPRPCCAR, was constructed based on a frameshift mutation of one of the VHL gene products; the more abundant protein VHLp18(MEA) (where MEA stands for three amino acids, Met-Glu-Ala). Vaccination with FrSh61(MEA)VHL33 peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein. (NCIT_C29065).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5498">
		<vaccine_name>G250 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4482">A naturally occurring 9-residue peptide of fibroblast growth factor 5 (FGF-5). Recognized by tumor infiltrating cytotoxic T lymphocytes originally isolated from a renal cell carcinoma that overexpressed FGF-5, FGF-5:172-176/217-220 peptide activates various cytotoxic CD8 lymphocytes in an HLA-restricted manner. Overexpressed in several cancer cell lines, FGF-5 is a tumor-associated antigen that may be useful in cancer immunotherapy. (NCI04) (NCIT_C53410).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5249">
		<vaccine_name>Gag:267-274 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4601">A cancer vaccine containing of a synthetic form of the renal cell carcinoma (RCC)-associated antigen G250 with potential antineoplastic activity. Vaccination with G250 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the G250 antigen, resulting in decreased tumor growth. Found in the majority of renal cell carcinomas, G250 is a cell surface tumor-associated antigen (TAA) that contains an HLA-A2.1-restricted epitope that is recognized by CTLs. (NCIT_C102982).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5410">
		<vaccine_name>GITRL RNA-transfected Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4562">An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. GITRL RNA-transfected autologous DC vaccine is prepared by transfecting DCs with RNAs encoding tumor necrosis factor (ligand) superfamily, member 18 (TNFSF18 or GlTRL); expression of GlTRL results in modulating T lymphocyte survival in peripheral tissues. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses. (NCIT_C94216).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5096">
		<vaccine_name>Glioma-Associated Antigen Peptide-Pulsed Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4569">A cancer vaccine comprised of autologous dendritic cells pulsed with synthetic glioma-associated antigen (GAA) peptides with potential antineoplastic activity. Upon administration, this vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against GAA peptide-expressing glioma cells, resulting in tumor cell lysis. (NCIT_C74036).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5073">
		<vaccine_name>Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4438">A cell-based cancer vaccine comprised of dendritic cells (DCs) pulsed with various, synthetic glioma-associated antigen (GAA) peptides, with potential antineoplastic activity. Upon subcutaneous administration, the glioma-associated peptide-loaded DC vaccine SL-701 exposes the immune system to various GAA peptides. This may stimulate both anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against the GAA-expressing glioma cells, which may result in tumor cell lysis. (NCIT_C114496).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5055">
		<vaccine_name>Globo H-DT Vaccine OBI-833</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4657">A carbohydrate-based vaccine comprised of the Globo H hexasaccharide 1 (Globo H) antigen conjugated to DT-CRM197, a non-toxic, mutated form of diphtheria toxin (DT), with potential immunostimulating and antineoplastic activities. Upon administration of Globo H-DT vaccine OBI-833, the carbohydrate antigen Globo H may stimulate a cytotoxic T-lymphocyte (CTL) response against Globo H-expressing tumor cells, thereby decreasing tumor cell proliferation. The hexasaccharide Globo H is a tumor-associated antigen (TAA) commonly found on a variety of tumor cells. DT-CRM197, also called diphtheria toxin cross-reacting material 197, is used to increase the immunogenicity of the Globo H carbohydrate antigen. (NCIT_C119745).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5104">
		<vaccine_name>Globo H-GM2-Lewis-y-MUC1-32-mer-TF(c)-Tn(c)-KLH Conjugate Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4391">A multivalent vaccine comprised of the epitope antigens of Globo H hexasaccharide 1 (Globo H), GM2 ganglioside, Lewis-Y, MUC1-32-mer, TF(c), and Tn(c) conjugated with keyhole limpet hemocyanin, with potential antineoplastic activity. The antigens included in this vaccine are associated various cancer cells. Vaccination with this multivalent vaccine may induce production of IgG and IgM antibodies as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumors expressing these antigens. (NCIT_C28503).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5229">
		<vaccine_name>Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH Conjugate Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4624">A heptavalent vaccine consisting of the tumor-associated carbohydrate antigens globohexaosylceramide (globo-H), GM2, Lewis-y, MUC1-32(aa), sTn(c), TF(c), and Tn(c) conjugated with keyhole limpet hemocyanin (KLH), an immunomodulator. This vaccine may induce the production of IgG and IgM antibodies and an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumors expressing these antigens. (NCI04) (NCIT_C28551).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine3643">
		<vaccine_name>Glypican-3-derived peptide vaccine for human hepatocellular carcinoma</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004400</vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="reference2382">A peptide from carcinoembryonic antigen glypican-3 (GPC3) (Sawada et al., 2012)</antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5111">
		<vaccine_name>GM-CSF-encoding Oncolytic Adenovirus CGTG-102</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4381">A recombinant, oncolytic serotype 5/3 capsid-modified adenovirus encoding the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) with potential antineoplastic activity. Upon administration, the oncolytic adenovirus selectively infects and replicates in tumor cells, which may result in tumor cell lysis. Synergistically, GM-CSF (sargramostim) expressed by the oncolytic adenovirus enhances antigen presentation, promotes natural killer (NK) cell-mediated killing and causes a cytotoxic T cell (CTL) response against tumor cells harboring the oncolytic adenovirus, resulting in an immune-mediated tumor cell death. CGTG-102 is designed to replicate only in cells with defects in the p16/Rb/E2F pathway, attributed to a mutation common in many solid tumors. Replacement of the Ad5 capsid protein knob with a knob domain from serotype 3 causes higher transduction in cancer cells as compared to normal cells. (NCIT_C98287).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5532">
		<vaccine_name>GM2/GD2/GD3 Lactone-KLH Conjugate Trivalent Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4181">A trivalent cancer vaccine containing the ganglioside lactones GM2, GD2 and GD3 conjugated with the immunostimulant keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Vaccination with GM2 lactone/GD2 lactone/GD3 lactone-KLH conjugate trivalent vaccine may elicit antibodies against tumor cells expressing any of these epitopes, resulting in an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing these gangliosides. GM2, GD2 and GD3 are tumor associated antigens (TAAs) that are overexpressed in a variety of tumor cell membranes. (NCIT_C91377).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5292">
		<vaccine_name>Golnerminogene Pradenovec</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4399">A recombinant agent consisting of a genetically-modified adenovirus 5 vector encoding the protein cytokine tumor necrosis factor (TNF) alpha. TNF exhibits potent anti-tumor cytolytic properties; the adenovirus 5 vector efficiently infects tumor cells, delivering tumor-specific TNF. (NCIT_C26444).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5133">
		<vaccine_name>gp100 Adenovirus Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4589">A vaccine consisting of a replication-defective recombinant adenovirus that encodes the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. Vaccination with gp100 adenovirus vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth. (NCI04) (NCIT_C2757).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5084">
		<vaccine_name>gp100 and GM-CSF DNA/Gold Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4122">A vaccine consisting of microscopic gold particles coated with plasmid DNA encoding the glycoprotein 100 (gp100) melanoma antigen and granulocyte-macrophage colony-stimulating factor (GM-CSF). Vaccination with gp100 and GM-CSF DNA/gold vaccine may stimulate the host immune system to direct cytotoxic T lymphocytes (CTL) against gp100 positive cells, resulting in decreased tumor growth. GM-CSF is thought to increase the induction and activation of antigen-presenting cells (APC), allowing for a reduction in the dose of gp100 administered. (NCI04) (NCIT_C2760).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5482">
		<vaccine_name>gp100 Protein (184V)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4614">A peptide vaccine containing the amino acids 267 through 274 of the human immunodeficiency virus type 1 (HIV-1) gag core protein (gag:267-274), with potential immunostimulating activity. Upon vaccination, the immune system may exert a potent cytotoxic T-lymphocyte (CTL) response against the xenoantigen gag:267-274 and produces pro-inflammatory cytokines. The concomitant administration of a cancer peptide vaccine may benefit from an already activated immune system and may augment an immune response against the administered tumor associated antigen(s). Gag:267-274 peptide is highly immunogenic and may potentially be used as a cancer immunoadjuvant. (NCIT_C29555).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5153">
		<vaccine_name>gp100 Vaccinia Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4329">A cancer vaccine consisting of a recombinant vaccinia virus encoding the gp100 melanoma-melanocyte antigen. gp100 human antigen is a wild-type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas. (NCI04) (NCIT_C29068).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5135">
		<vaccine_name>gp100-Fowlpox Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4121">A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the melanoma antigen glycoprotein 100 (gp 100) with potential antineoplastic activity. The expression of gp100 may generate a cellular immune response to melanoma cells; this effect is enhanced by the co-administration of interleukin 2 (IL-2). (NCI04) (NCIT_C2761).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5007">
		<vaccine_name>gp100-Pulsed Peripheral Blood Mononuclear Cell</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4124">Peripheral blood lymphocytes (PBL) harvested from host blood and stimulated in vitro with tumor-specific gp 100 antigen. 'Pulsing' PBL with gp100, a tumor associated antigen (TAA) commonly expressed by melanoma cells, may increase melanoma-reactive cytotoxic lymphocytes (CTL) in the PBL cell population. Autologous gp100-pulsed PBL have been administered to melanoma patients in order to augment cytotoxic immune responses to melanoma. (NCIT_C2762).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4990">
		<vaccine_name>gp100-Reactive Autologous Peripheral Blood Lymphocyte</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4187">Human peripheral blood lymphocytes (PBL) isolated from a patient, exposed to the tumor-associated antigen gp100 in vitro, and then transferred back to the same patient to target tumor sites expressing gp100. gp100 human antigen is a wild-type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas. (NCIT_C38124).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5095">
		<vaccine_name>gp100: ES209-217(210M) Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4123">A cancer vaccine comprised of 11 peptides associated with glioblastoma multiforme (GBM), with potential immunomodulating and antineoplastic activities. Vaccination with glioblastoma multiforme multi-antigen vaccine IMA950 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response as well as a T-helper (Th) immune response against tumor cells expressing these peptides, potentially resulting in decreased tumor growth of GBM. Peptides in IMA950 consist of the following: brevican (BCAN); chondroitin sulfate proteoglycan 4 (CSPG4); fatty acid binding protein 7, brain (FABP7); insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3); neuroligin 4, X-linked (NLGN4X); neuronal cell adhesion molecule (NRCAM); protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1); tenascin C (TNC); Met proto-oncogene (MET); baculoviral IAP repeat-containing 5 (BIRC5); and hepatitis B virus core antigen. (NCIT_C2763).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5145">
		<vaccine_name>gp100:154-162 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4125">A peptide consisting of amino acid residues 154 through 162 of the melanoma-melanocyte antigen gp100. Vaccination with gp100:154-162 peptide may enhance tumor-specific T-cell immunity. gp100 antigen is a self-antigen expressed by melanocytes, pigmented retinal cells, and most melanoma lesions and is recognized via class I and II HLA-restricted mechanisms. (NCIT_C2764).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5050">
		<vaccine_name>gp100:209-217 Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4127">A synthetic peptide vaccine consisting of amino acids 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen with an endoplasmic reticulum signal sequence (ES) to increase binding activity. Vaccination with gp100:ES209-217(210M) may stimulate the host immune system to mount a cytotoxic T lymphocyte response against tumor cells positive for gp100, resulting in decreased tumor growth. (NCI04) (NCIT_C2766).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5526">
		<vaccine_name>gp100:280-288 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4163">A vaccine consisting of the amino acids 280 through 288 of the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. Vaccination with gp100:280-288 peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth. (NCI04) (NCIT_C2767).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5438">
		<vaccine_name>gp100:280-288(288V) Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4331">A peptide vaccine consisting of the amino acids 280 through 288 of the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. gp100:280-288(288V) peptide has a valine substitution at amino acid position 288 to improve immunogenicity. Vaccination with gp100:280-288(288V) peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth. (NCIT_C49042).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5033">
		<vaccine_name>gp96-secreting Allogeneic Bladder Cancer Cell Vaccine HS-410</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4336">An allogeneic urothelial bladder cancer cell vaccine expressing a recombinant secretory form of the immunoadjuvant heat shock protein gp96 fused with an immunoglobulin Fc domain (gp96-Ig) protein, with potential antineoplastic activity. Upon administration of the gp96-Ig-secreting allogeneic bladder cancer cell vaccine HS-410, the live, irradiated tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs). This enhances antigen cross presentation to cytotoxic T-lymphocytes (CTLs) and, upon expansion, leads to the induction of a potent CTL response against the TAAs on the endogenous bladder cancer cells. This vaccine also induces a memory T cell response that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL endoplasmic reticulum (ER) retention sequence of gp96 with the Fc portion of the IgG1 protein. This allows for gp96, normally an ER-resident chaperone peptide, to be released from cells. (NCIT_C113653).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5211">
		<vaccine_name>GVAX Cancer Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4496">GVAX cancer vaccines are autologous cell vaccines comprised of tumor cells which have been irradiated and genetically modified to secrete granulocyte-macrophage colony stimulating factor (GM-CSF), a hormone which plays a key role in stimulating the body's immune response to vaccines. (NCIT_C1978).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5453">
		<vaccine_name>GVAX Lung Cancer Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4495">An autologous lung cancer vaccine consisting of patient-specific lung cancer cells genetically modified to secrete granulocyte-macrophage colony stimulating factor (GM-CSF), an immunostimulatory cytokine. GM-CSF modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function and may augment host antitumoral immunity. For safety, cells are irradiated prior to vaccination (NCIT_C1979).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5062">
		<vaccine_name>GVAX Pancreatic Cancer Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4609">An irradiated, autologous pancreatic cancer vaccine consisting of patient-specific pancreatic cancer cells genetically modified to secrete the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon vaccination, GVAX pancreatic cancer vaccine secretes GM-CSF. In turn, GM-CSF may stimulate the body's immune system against tumor cells by enhancing the activation of dendritic cells (DCs) and promoting antigen presentation to both B- and T-cells. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function. (NCIT_C91707).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5454">
		<vaccine_name>Haemophilus Influenzae B Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4371">A vaccine against serotype b of the Gram-negative bacterium H. influenzae (Hib). Hib vaccines contain polysaccharide-protein conjugate antigens that produce greater host immune responses than first-generation purified polysaccharide vaccine. These vaccines may differ with regard to use of protein carriers, polysaccharides, diluents, and preservatives. (NCIT_C1126).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5002">
		<vaccine_name>HCV DNA Vaccine INO-8000</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4144">A multi-antigen DNA vaccine consisting of plasmids encoding the hepatitis C virus (HCV) nonstructural proteins 3 (NS3), 4A (NS4A), 4B (NS4B) and 5A (NS5A), with potential immunomodulating and cancer preventive activities. Administered via intramuscular injection followed by electroporation, cells transfected with the HCV DNA vaccine INO-8000 express the encoded HCV proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against HCV-infected liver cells expressing the NS3, NS4A, NS4B or NS5A proteins. This results in the eradication of HCV-infected cells. HCV, a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, is associated with the development of hepatocellular carcinoma (HCC). (NCIT_C121570).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5457">
		<vaccine_name>Heat-Treated Varicella-Zoster Virus Vaccine V212</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4656">A heat-treated varicella-zoster virus (VZV) vaccine with potential immunomodulating activity. Upon vaccination with heat-treated varicella-zoster virus vaccine V212, this vaccine may activate the immune system to generate specific anti-VZV antibodies and an active immunity against VZV infection. (NCIT_C91085).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5113">
		<vaccine_name>Hepatitis A Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4534">An inactivated virus vaccine that provides active immunization against hepatitis A virus (HAV). Immunization with hepatitis A vaccine induces the formation of anti-HAV antibodies which provide protection against hepatitis A infection. (NCIT_C29090).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5134">
		<vaccine_name>Hepatitis B Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4533"> A non-infectious mixture containing recombinant hepatitis B surface antigen (HBsAg) in a liquid vehicle. Immunization with the hepatitis B vaccine induces the formation of specific anti-hepatitis B antibodies and an active immunity against hepatitis B infection. (NCIT_C29091).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5442">
		<vaccine_name>HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4644">A cancer vaccine based on virus-like replicon particles (VRP) packaged with an alphaviral vector encoding the extracellular domain (ECD) and transmembrane (TM) regions of the human epidermal growth factor receptor 2 (EGFR2, NEU or HER2), with potential antineoplastic activity. After immunization with HER2 ECD+TM virus-like replicon particles vaccine AVX901, the VRPs infect cells and express HER2 ECD+TM protein that may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against HER2-expressing tumor cells. The alphaviral replicon of this vaccine is an attenuated strain of the Venezuelan equine encephalitis virus (VEEV) in which 3 of the 7 viral genes were substituted with a truncated HER2 gene to create a self-amplifying replicon RNA. HER2, a tyrosine kinase involved in several cell growth signaling pathways, is dysregulated or overexpressed in a wide variety of cancer cell types. (NCIT_C99903).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5237">
		<vaccine_name>HER2-pulsed Autologous Type-1 Polarized Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4210">A dendritic cell (DC)-based cancer vaccine composed of autologous, type-1 polarized dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted HER-2-derived peptides, with potential immunomodulatory and antineoplastic activities. Autologous DCs were treated with GM-CSF, interleukin-4, interferon-gamma and bacterial lipopolysaccharide (LPS), a toll-like receptor type 4 agonist, to produce highly polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70 (IL-12p70). Upon administration, HER2-pulsed autologous DC vaccine may stimulate a potent cytotoxic T-lymphocyte (CTL) response against HER-2-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by a variety of cancers. (NCIT_C114293).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5299">
		<vaccine_name>Herpes Zoster Vaccine GSK1437173A</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4310">A recombinant, subunit herpes zoster (HZ) vaccine containing varicella-zoster virus (VZV) glycoprotein E (gE), that can potentially be used to prevent HZ infection, also called shingles. Upon administration, HZ vaccine GSK1437173A stimulates the host immune system to induce both specific CD4-positive T-cells and antibodies against VZV gE, thereby protecting against infection with HZ. VZV gE, the most common antigen in VZV viral particles, plays a key role in VZV infection. Compared to live-attenuated vaccines, the subunit vaccine prevents the risk of vaccine-induced HZ in immunocompromised patients. (NCIT_C88288).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5357">
		<vaccine_name>HIV Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4650">A vaccine intended to prevent or treat infections caused by human immunodeficiency viruses (HIVs). (NCIT_C1325).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5360">
		<vaccine_name>HIVgP160 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4364">A synthetic HIV vaccine based on a recombinant canary pox virus vector expressing the human immunodeficiency virus (HIV) glycoprotein gp160. HIVgP160 vaccine has been used to generate in vivo primary T lymphocyte response against HIV antigens. (NCI04) (NCIT_C29086).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5355">
		<vaccine_name>HLA-A*0201-Restricted TRP2-gp100-EphA2-HER2 multipeptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4306">A cancer vaccine containing four HLA-A*0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Vaccine peptide epitopes are derived from the tumor associated antigens (TAAs) tyrosinase-related protein 2 (TRP2), glycoprotein 100 (gp100), Ephrin receptor A2 (EphA2) and human epidermal growth factor receptor 2 (HER2). Upon administration, HLA-A*0201-restricted TRp2-gp100-EphA2-HER2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against TRP2-gp100-EphA2-HER2-expressing tumor cells, resulting in tumor cell lysis and decreased tumor cell proliferation. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. (NCIT_C84844).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5017">
		<vaccine_name>HLA-A*0201-Restricted URLC10-VEGFR1-VEGFR2 Multipeptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4281">A cancer vaccine containing three HLA-A*0201-restricted peptide epitopes with potential immunostimulatory, antiangiogenic, and antitumor activities. Vaccine peptide epitopes are derived from the tumor associated antigen (TAA) URLC (up-regulated in lung cancer 10) and vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A*0201-restricted URLC10-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URLC10-expressing tumor cells and the tumor microvasculature expressing VEGFR 1 and 2 peptides; this may result in tumor cell lysis, the inhibition of tumor angiogenesis, and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. (NCIT_C77900).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5413">
		<vaccine_name>HLA-A*0201-Restricted VEGFR1 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4194">A cancer vaccine containing an HLA-A*0201-restricted vascular endothelial growth factor receptor 1 (VEGFR1) peptide (sequence: TLFWLLLTL) with potential immunostimulatory and antitumor activities. Upon administration, HLA-A*0201-restricted VEGFR1-derived peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing VEGFR1, resulting in tumor cell lysis and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. (NCIT_C77878).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5112">
		<vaccine_name>HLA-A*2402-Restricted VEGFR1 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4367">A peptide vaccine consisting of the amino acids 280 through 288 of the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. gp100:280-288(288V) peptide has a valine substitution at amino acid position 288 to improve immunogenicity. Vaccination with gp100:280-288(288V) peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth. (NCIT_C77869).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5294">
		<vaccine_name>HLA-A*2402-Restricted VEGFR1/2 Multipeptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4134">A cancer vaccine containing two HLA-A*0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from: vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A*0201-restricted VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing VEGFR 1 and 2 peptides, resulting in tumor cell lysis and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. (NCIT_C95211).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5429">
		<vaccine_name>HLA-A*2404-Restricted RNF43-TOMM34-VEGFR1-VEGFR2 Multipeptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4539">A cancer vaccine containing four HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from ring finger protein 43 (RNF43); translocase of outer mitochondrial membrane 34 (TOMM34); and vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A*2404-restricted RNF43-TOMM34-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing RNF43, TOMM34, and VEGFR 1 and 2 peptides, resulting in tumor cell lysis and decreased tumor growth. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. (NCIT_C77867).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5120">
		<vaccine_name>HLA-A1, A2, B35-Restricted Survivin Peptides/Montanide ISA-51 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4556">A peptide vaccine comprised of synthetic HLA-A1, -A2 and -B35 restricted survivin epitopes combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. Upon administration, HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine may stimulate a cytotoxic T cell response against tumor cells that overexpress survivin, resulting in tumor cell lysis. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens. (NCIT_C48393).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5185">
		<vaccine_name>HLA-A1-Binding MAGE-1/MAGE-3 Multipeptide-Pulsed Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4160">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A1-binding melanoma-associated antigen peptides MAGE-1 and MAGE-3 with potential immunomodulating and antineoplastic activity. Upon vaccination, HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount an anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against MAGE1- and MAGE-3-expressing cancer cells, resulting in tumor cell lysis. HLA-A1 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A1 may improve antigenic peptide immunogenicity. (NCIT_C90570).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5465">
		<vaccine_name>HLA-A2, A3-Restricted FGF-5 Peptides/Montanide ISA-51 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4555">A peptide vaccine comprised of synthetic HLA-A2- and HLA-A3-binding peptides, derived from amino acid sequences of fibroblast growth factor-5 (FGF-5), combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. HLA-A2, A3-restricted FGF-5 peptides contain motifs recognized by the MHC class I molecules HLA-A2 and HLA-A3 and may stimulate a cytotoxic T-cell response against tumor cells that overexpress FGF-5. Montanide ISA-51, a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant, non-specifically stimulates cell-mediated immune responses to antigens. (NCIT_C48394).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5034">
		<vaccine_name>HLA-A2-Binding TYR/MART-1/gp100 Multipeptide-Pulsed Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4311">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted melanoma-associated antigen peptides tyrosinase (TYR), MART-1(melanoma antigen recognized by T-cells) and melanoma antigen glycoprotein 100 (gp100), with potential immunomodulating and antineoplastic activity. Upon vaccination, HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount an anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against Tyr-, MART-1 and gp100-expressing cancer cells, resulting in tumor cell lysis. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity. (NCIT_C90569).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5202">
		<vaccine_name>HLA-A2-Restricted Synthetic Glioma Antigen Peptides Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5093">
		<vaccine_name>HLA-Matched Donor Mononuclear Cell-Enriched Leukocytes Apocell</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4139">A preparation of allogeneic HLA-matched leukocytes treated with a derivative of placental protein 14 (PP14) with potential immunomodulating activity. PP14 derivative-treated HLA-matched donor mononuclear cell-enriched leukocytes contain at least fifty-five percent early-apoptotic T cells; after infusion and when processed by recipient dendritic cells, early-apoptotic T cells may help induce a decrease in the donor effector T-cell responses against the recipient of an allogeneic hematopoietic stem cell (HSC) transplant, thereby minimizing allogeneic HSC transplant-related graft-versus-host disease (GVHD). PP14, a 162 amino acid glycosylated protein secreted by the late secretory phase endometrium, binds to T cells in a carbohydrate fashion and has been shown to induce T-cell apoptosis; maternal immune tolerance to the fetus and pregnancy-related remissions of autoimmune disease may involve PP14-induced T cell apoptosis. (NCIT_C71162).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5246">
		<vaccine_name>Host Dendritic Cell Vaccine-001 MSSM/BIIR</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4524">A dendritic cell (DC) vaccine containing ex vivo expanded autologous DCs obtained from a patient with leukemia with potential immunostimulating activity. Upon reintroduction into the host, the host dendritic cell vaccine-001 MSSM/BIIR may stimulate the immune system to mount a leukemia-specific cytotoxic T lymphocyte (CTL) response. (NCIT_C84845).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5474">
		<vaccine_name>HPV 16 E6 (18-26) Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4249">A peptide derived from the oncogenic human papillomavirus (HPV) early gene product E6. The HPV 16 transforming protein E6 is expressed in precancerous and malignant cervical lesions and has a high affinity for the most common human lymphocyte antigen (HLA), HLA-A2. Immunogenic peptides from the HPV 16 E6 may be used to trigger a T-cell-mediated immune response to HPV. (NCI04) (NCIT_C38117).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5079">
		<vaccine_name>HPV 16 E7:12-20 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4383">A peptide based vaccine consisting of amino acids 12 through 20 of the E7 gene of the Human Papilloma Virus type 16. HPV-16 E7 12-20 peptide vaccine may elicit a specific CD8 T-cell response to the E7 oncogene protein, thereby inhibiting the abrogation of p53 and pRb function and thus prevent tumorigenesis. (NCI04) (NCIT_C2419).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5184">
		<vaccine_name>HPV 16 E7:86-93 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4230">A synthetic peptide vaccine consisting of amino acids 86 through 93 (TLGIVCPI) of the viral oncoprotein human papillomavirus (HPV) 16 E7. Vaccination with HPV-16 E7:86-93 peptide, which binds to HLA-A* 0201 molecule, may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV-16 E7. (NCIT_C38761).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5520">
		<vaccine_name>HPV 16 L1-VLP</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4564">A vaccine consisting of human papillomavirus-derived noninfectious virus-like particles (VLPs), containing the L1 major capsid protein. Vaccination with HPV 16 L1-VLP results in increases in T cell-proliferative response to HPV 16 L1-VLP, as well as significant increases in cytokine (interferon-gamma, interleukin-5 and -10) responses to L1 VLP. This agent may reduce the incidence of persistent HPV-16 infection, which may be responsible for half of all cases of cervical cancer including high-grade cervical intraepithelial neoplasia. (NCI04) (NCIT_C29088).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5159">
		<vaccine_name>HPV 18 E6:13-21 Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4369">A synthetic peptide vaccine consisting of amino acids 13 through 21 of the viral oncoprotein human papillomavirus (HPV) 18 E6. The HPV 18E6 peptide cross-reacts immunologically with both HPV type 16 and HPV type 18, the most common HPV types involved in cervical cancer. Vaccination with HPV-18 E6:13-21 peptide may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV 16 and 18. (NCIT_C26681).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5247">
		<vaccine_name>HPV 18 L1-VLP</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4169">Noninfectious, synthetic, virus-like particles (VLP) containing the major viral capsid protein, L1, of the human papillomavirus type 18 with potential immunoprotective activity. Vaccination with HPV 18 L1-VLP may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) response against cells positive for HPV 18, thereby preventing cervical infection upon exposure to HPV type 18. (NCIT_C49275).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5226">
		<vaccine_name>HPV DNA Plasmids Therapeutic Vaccine VGX-3100</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4505">A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus (HPV) subtypes 16 and 18, respectively, with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, HPV DNA plasmids therapeutic vaccine VGX-3100 expresses E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 proteins, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are the most common HPV types involved in cervical carcinogenesis. (NCIT_C77909).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5083">
		<vaccine_name>HPV E6/E7 DNA Vaccine GX-188E</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4541">A therapeutic DNA vaccine encoding the E6/E7 fusion protein of human papillomavirus (HPV) subtypes 16 and 18, plus the immune-enhancer, Fms-like tyrosine kinase-3 ligand (FLT3L), with potential immunostimulating and antineoplastic activities. DNA vaccine GX-188E is administered using a proprietary delivery system that electroporates the vaccine into cervical cells. Expression of the E6/E7 fusion product may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 oncoproteins, resulting in tumor cell lysis. FLT3L is a ligand for the FLT3 tyrosine kinase receptor, which upon activation stimulates the proliferation of hematopoietic progenitor cells. HPV type 16 and 18 are the most common HPV types involved in cervical carcinogenesis. (NCIT_C102787).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5227">
		<vaccine_name>HPV-11 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4449">A vaccine directed against Human Papillomavirus Type 11 that causes majority of the genital warts and anogenital cancers. (NCI) (NCIT_C2063).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5464">
		<vaccine_name>HPV-6-targeting Immunotherapeutic Vaccine INO-3106</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4666">A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus subtype 6 (HPV-6), with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, HPV-6-targeting immunotherapeutic vaccine INO-3106 expresses the HPV-6 E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells that are expressing those proteins, resulting in tumor cell lysis. HPV-6 infections are associated with aerodigestive malignancies. (NCIT_C123378).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5191">
		<vaccine_name>hTERT I540/R572Y/D988Y Multipeptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4303">A peptide vaccine consisting of multiple epitopes derived from the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, with potential immunostimulating and antineoplastic activities. hTERT I540/R572Y/D988Y multipeptide vaccine contains strongly antigenic peptide epitopes I540 (9-mer), R572Y (9-mer) and D988Y (10-mer). Vaccination with this agent may elicit a cytotoxic T cell (CTL) response against telomerase-expressing tumor cells. Directly linked to tumorigenesis, telomerase is expressed in the majority of human cancer cells but is infrequently expressed in normal cells. (NCIT_C71761).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5121">
		<vaccine_name>hTERT mRNA/Survivin Peptide-double-loaded Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4455">A cancer vaccine containing autologous dendritic cells (DCs) that are pulsed with mRNA encoding human telomerase reverse transcriptase (hTERT) and survivin peptide, with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT mRNA/survivin peptide-double-loaded autologous dendritic cell vaccine may elicit an immune response against cancer cells expressing hTERT and survivin by activating cytotoxic T-cells (CTLs), natural killer cells (NKs), and B-lymphocytes. The tumor associated antigens (TAAs) hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types and play key roles in tumor cell growth and survival. (NCIT_C99116).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5516">
		<vaccine_name>hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4630">A therapeutic cancer vaccine consisting of four epitopes derived from the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, including hTERT (540-548) acetate, hTERT (611-626) acetate, hTERT (672-686) acetate and hTERT (766-780) acetate, emulsified individually in the adjuvant montanide ISA-51 VG and administered with the immune response modifier (IRM) imiquimod, with potential immunostimulating and antineoplastic activities. Each hTERT peptide emulsion is administered individually by intradermal injection. Subsequently, imiquimod is applied topically to the injection site(s). Vaccination with GX 301 may elicit a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells. Telomerase is expressed in the majority of human cancer cells, infrequently expressed in normal cells, and is directly linked to tumorigenesis. Imiquimod stimulates cytokine production through the activation of toll-like receptor 7 (TLR-7), and also exhibits antiproliferative effects. Montanide ISA-51, also known as incomplete Freund's adjuvant (IFA), is a stabilized water-in-oil emulsion containing mineral oil with mannide oleate, which contains vegetable-grade (VG) oleic acid derived from olive oil. ISA-51 non-specifically stimulates cell-mediated immune responses to antigens. (NCIT_C119616).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5065">
		<vaccine_name>hTERT Vaccine V934/V935</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5276">
		<vaccine_name>hTERT-LAMP mRNA-loaded Autologous Dendritic Cell Vaccine GRNVAC1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4620">A cancer vaccine containing dendritic cells (DCs) that are transfected with messenger RNA (mRNA) encoding human telomerase reverse transcriptase (hTERT) and survivin in addition to patient-specific melanoma-derived mRNA with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT/survivin/melanoma tumor cell-derived mRNA-transfected dendritic cell vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against melanoma cells expressing hTERT, survivin, and patient-specific melanoma-associated antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival. (NCIT_C116888).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4997">
		<vaccine_name>hTERT/Survivin/CMV Multipeptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5270">
		<vaccine_name>hTERT/Survivin/Melanoma Tumor Cell-Derived mRNA-Transfected Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4395">A cancer vaccine containing dendritic cells (DCs) that are transfected with messenger RNA (mRNA) encoding human telomerase reverse transcriptase (hTERT) and survivin in addition to patient-specific melanoma-derived mRNA with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT/survivin/melanoma tumor cell-derived mRNA-transfected dendritic cell vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against melanoma cells expressing hTERT, survivin, and patient-specific melanoma-associated antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival. (NCIT_C84755).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5511">
		<vaccine_name>Human Myeloid Progenitor Cells CLT-008</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4674">Early-to late-stage myeloid progenitor cells derived from adult human stem cells with potential hematopoietic activity. Upon infusion, human myeloid progenitor cells CLT-008 proliferate into mature myeloid cells, including granulocytes, macrophages, platelets, and erythrocytes. These myeloid progenitor cells die within forty-five days after a burst of hematopoiesis. This agent cannot create lymphoid cells, including T cells associated with graft-versus-host disease (GVHD). (NCIT_C82381).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5449">
		<vaccine_name>Human Papilloma Virus L1 Virus-Like Particle V504 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4538">A vaccine formulation consisting of several types of human papillomavirus (HPV)-derived noninfectious virus-like particles (VLPs) with potential immunoprophylactic activity. Upon administration, HPV L1 VLP vaccine V504 may generate humoral immunity against various HPV L1 major capsid proteins, thereby preventing cervical infection upon exposure to the associated HPV types. VLPs are composed of self-assembling L1 major capsid proteins or functional L1 major capsid protein derivatives. (NCIT_C71526).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5162">
		<vaccine_name>Human Papillomavirus 16 E7 Peptide/Padre 965.10</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4405">A synthetic agent derived from human papillomavirus (HPV) E7 nuclear protein which is used to produce vaccines against HPV infection and HPV-related neoplasms. HPV E7 oncogenic protein binds the retinoblastoma tumor suppressor protein, pRB, as well as a number of other cellular proteins, and serves as a transcriptional activator. This protein is important in the induction and maintenance of cellular transformation and is co-expressed in the majority of HPV-containing carcinomas. PADRE(R) is a proprietary family of molecules that enhances the immune systems response against an administered immunogen such as the HPV E7 nuclear protein. (NCI04) (NCIT_C2569).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5233">
		<vaccine_name>Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4554">A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective and antineoplastic properties. Upon administration, HPV 16/18 L1 virus-like particle/ASO4 vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens, thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection. (NCIT_C48395).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5279">
		<vaccine_name>Human Papillomavirus Tumor Antigen Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4522">A vaccinia viral based vaccine, encoding epitopes of E6 and E7 proteins from human papillomavirus (HPV) types 16 and 18, with immunostimulatory and antineoplastic activities. HPV types 16 and 18 account for approximately 70% of cervical cancers. Vaccination with this HPV-TA (tumor antigen) vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for E6 and E7 from either type 16 or 18 HPV, resulting in decreased tumor growth. (NCIT_C2403).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5167">
		<vaccine_name>Human Papillomavirus Vaccine V503</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4435">A vaccine consisting of noninfectious, recombinant virus-like particles (VLP) containing the major viral capsid protein L1 of nine strains of human papillomavirus (HPV), with potential immunoprotective activity. Vaccination with HPV V503 may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against cells positive for any of these nine strains of HPV, thereby preventing cervical infection upon exposure to certain HPV subtypes. (NCIT_C71520).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5262">
		<vaccine_name>Human Prostate-Specific Membrane Antigen Plasmid DNA Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4553">A vaccine consisting of a plasmid DNA encoding the human prostate-specific membrane antigen (PSMA). Upon administration, expressed PSMA may stimulate a cytotoxic T cell response against tumor cells that express this antigen, resulting in tumor cell lysis. (NCI05) (NCIT_C48396).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5090">
		<vaccine_name>hVEGF26-104/RFASE Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4582">A therapeutic cancer vaccine containing a truncated, synthetic peptide mimic of the human angiogenic activator vascular endothelial growth factor (VEGF), consisting of 79 amino acids (amino acids 26-104 of VEGF), and emulsified in the immunoadjuvant RFASE, with potential immunostimulatory and antitumor activities. Upon intramuscular vaccination, the hVEGF26-104 moiety of hVEGF26-104/RFASE acts as an antigen and induces an immune response against VEGF, which results in anti-VEGF antibody binding to and neutralization of endogenous VEGF. This prevents the binding of endogenous VEGF to the VEGF receptor (VEGFR) and blocks VEGFR-mediated endothelial cell signaling, resulting in an inhibition of both angiogenesis and tumor cell proliferation. VEGF plays a key role in angiogenesis, tumor cell proliferation and invasion. RFASE, which belongs to the group of sulpholipopolysaccharides (SLPs), is a synthetic polysaccharide covalently coupled to lipid groups and sulphate groups, and is able to induce a strong humoral immune response upon antigen administration. (NCIT_C118364).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5277">
		<vaccine_name>ICT-121 Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4621">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with purified peptides derived from the tumor-associated antigen (TAA) CD133, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, monocytes are differentiated into DCs and are mixed with the CD133 peptides. Upon intradermal re-administration of the ICT-121 DC vaccine, the DCs present the CD133 peptides to the immune system, which stimulates the immune system to induce a specific cytotoxic T-lymphocyte (CTL) response against CD133-expressing tumor cells and leads to tumor cell lysis. CD133 is overexpressed on various types of cancer cells; its overexpression is correlated with increased resistance to chemotherapy. (NCIT_C124652).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5298">
		<vaccine_name>IDH1R132H Mutation-targeting IDH1 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5461">
		<vaccine_name>IDH1R132H-Specific Peptide Vaccine PEPIDH1M</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4231">A peptide vaccine consisting of a peptide derived from isocitrate dehydrogenase 1 (IDH1) containing the point mutation R132H (IDH1R132H), with potential antineoplastic activity. Intradermal vaccination with the IDH1R132H-specific peptide vaccine PEPIDH1M may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the IDH1R132H protein. The IDH1 point mutation of amino acid residue 132 is highly expressed in gliomas and is associated with increased production of the oncometabolite R-2-hydroxyglutarate (2HG). (NCIT_C117235).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5344">
		<vaccine_name>Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4671">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with tumor-derived clonal immunoglobulin (Ig) with potential immunostimulatory and antineoplastic activities. Upon administration, idiotype-pulsed autologous dendritic cell vaccine APC8020, containing idiotype (Id) protein structures that can be recognized by antibodies and by CD41 T lymphocytes and CD81 T lymphocytes, may stimulate antitumoral cytotoxic T lymphocyte (CTL) and antibody responses against Id-expressing tumor cells. The Id represents the unique antigenic determinants in the variable regions of the clonal Ig. (NCIT_C74042).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5168">
		<vaccine_name>IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4280">Human mesenchymal stem cells (MSCs) transduced with a retroviral vector encoding a modified form of the cytokine interleukin-12 (IL-12), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, IL-12-expressing MSC vaccine GX-051 secretes IL-12. IL-12 activates the immune system by both promoting the secretion of interferon-gamma, which activates natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased cell proliferation and increased cell death in tumor cells. (NCIT_C114385).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5173">
		<vaccine_name>IL-2/Lptn Gene-Modified Allogeneic Neuroblastoma Tumor Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4434">A cancer vaccine consisting of allogeneic neuroblastoma tumor cells have been genetically modified to secrete the human cytokine interleukin-2 (IL-2) and the human chemokine lymphotactin (Lptn) with potential immunostimulating and antineoplastic activities. Upon administration, IL-2 and Lptn are secreted by the IL-2/Lptn gene-modified allogeneic neuroblastoma tumor cell vaccine, potentially enhancing the cytotoxic T lymphocyte (CTL) response elicited by vaccine neuroblastoma tumor-associated antigens (TAAs) against host neuroblastoma tumor cells. Produced by activated progenitor T cells, Lptn belongs to the C chemokine subfamily and is a potent chemotactic factor for lymphocytes; IL-2 stimulates natural killer (NK) cells and may enhance a vaccine-elicited CTL immune response against tumor cells. (NCIT_C78487).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5343">
		<vaccine_name>Immunotherapeutic GSK1572932A</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4676">An immunotherapeutic containing a proprietary adjuvant system combined with a melanoma-associated antigen peptide MAGE-A3 epitope with potential immunomodulating and antineoplastic activities. Intramuscular administration with GSK1572932A may stimulate the immune system to exert both humoral and cellular immune responses against MAGE-A3-expressing tumor cells. MAGE-A3, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types, including non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, and bladder cancer. (NCIT_C91714).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5048">
		<vaccine_name>IMT-1012 Immunotherapeutic Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4365">A multi-peptide cancer vaccine with potential immunostimulating and antineoplastic activities. IMT-1012 immunotherapeutic vaccine contains twelve different synthetic peptides or tumor associated antigens (TAAs), including cyclin I (CCNI), cyclin-dependent kinase CDC2, EDDRI and TACE/ADAM17, each of which is involved in a different pathway associated with tumor growth, survival, and metastasis. Each antigen in the vaccine elicits a specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing that antigen. This multi-antigen/multi-pathway targeting strategy provides broad immunotherapeutic coverage with respect to tumor complexity and heterogeneity and may result in enhanced vaccine efficacy. (NCIT_C77863).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5170">
		<vaccine_name>Inactivated Poliovirus Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4615">A vaccine consisting of inactivated poliovirus (IPV) types 1,2 and 3, with active immunizing activity against poliomyelitis. Upon intramuscular vaccination, inactivated poliovirus vaccine (IPV) activates the immune system to develop antibodies against polioviruses. (NCIT_C91715).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5130">
		<vaccine_name>Inactivated Vaccinia Virus</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4436">A poxvirus made non-infectious by ultraviolet light or other inactivation methods in order to reduce its pathogenicity. In cancer gene therapy, inactivated vaccinia virus may be used as a vector to express a protein that kills tumor cells or elicits specific anti-tumor immunity. In a cancer vaccine application, tumor cells taken from the host may be adsorbed with inactivated vaccinia virus and returned to the host, where the modified tumor cells may stimulate an anti-tumor immune response. (NCI04) (NCIT_C29918).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5099">
		<vaccine_name>Inalimarev</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4472">A cancer vaccine comprised of a recombinant vaccinia viral vector encoding the carcinoembryonic antigen (CEA), MUC-1 (mucin-1), a transmembrane glycoprotein secreted by glandular tissues, and TRICOM, comprised of the three co-stimulatory molecule transgenes B7-1, ICAM-1 and LFA-3. Upon administration, inalimarev may enhance CEA and MUC-1 presentation to antigen presenting cells (APC) and may activate a cytotoxic T lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells. (NCIT_C29317).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5212">
		<vaccine_name>Indium In 111-Labeled Autologous Peripheral Blood Mononuclear Cells</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4236">A preparation of autologous peripheral blood mononuclear cells (PBMCs) radiolabeled with indium In 111 with radioisotopic activity. Autologous PBMCs are isolated, expanded ex vivo, radiolabeled with indium In 111, and then infused back into the patient. Gamma scintigraphy may then be used to image gamma ray-emitting indium In 111 PBMCs localized in lymphoma tissue. (NCIT_C67085).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5273">
		<vaccine_name>Indium In 111-Labeled Autologous Polymorphonuclear Leukocytes</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4225">A preparation of autologous peripheral polymorphonuclear (PMNLs) radiolabeled with indium In 111 with radioisotopic activity. Autologous PMNLs are isolated, expanded ex vivo, radiolabeled with indium In 111, and then infused back into the patient. Gamma scintigraphy may then be used to image gamma ray-emitting indium In 111 PMNLs localized in lymphoma tissue. (NCIT_C67086).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5144">
		<vaccine_name>Indoleamine 2,3-dioxygenase Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4563">A peptide vaccine against the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO), with potential immunomodulating and antineoplastic activities. Vaccination with indoleamine 2,3-dioxygenase peptide vaccine may activate the immune system to induce an immune response against IDO-expressing cells. This may increase and restore the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and may eradicate IDO-expressing tumor cells. IDO, a cytosolic enzyme responsible for tryptophan catabolism and conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs) and plays an important role in immunosuppression; Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and suppresses the immune system (NCIT_C94215).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5540">
		<vaccine_name>Interferon-gamma-expressing Adenovirus Vaccine ASN-002</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4507">A replication-defective adenoviral serotype 5 vector encoding a recombinant form of the human cytokine interferon-gamma (IFN-g), with potential antineoplastic and immunoregulatory activities. Upon intratumoral administration, the sustained expression of IFN-g by IFN-g-expressing adenovirus vaccine ASN-002 promotes a T-helper type 1 (Th1) immune response and inhibits the Th2-mediated cytokine production observed in many cutaneous lymphomas. IFN-g also mediates interleukin-12 (IL-12) production by antigen-presenting cells (APCs); activates macrophages, cytotoxic T-cells, and natural killer (NK) cells; upregulates major histocompatibility complex (MHC) molecules; and stimulates antibody-dependent cellular cytotoxicity (ADCC). Altogether, these IFN-g-mediated effects may result in both an inhibition of tumor cell proliferation and tumor cell death. Compared to IFN-g injections, the prolonged local production of IFN-g at the tumor site allows for higher efficacy and a reduction of systemic toxicity. (NCIT_C66972).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5352">
		<vaccine_name>Interleukin-2 Anti-Idiotype Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4500">A vaccine based on anti-idiotype (Id) monoclonal antibodies combined with interleukin-2 (IL-2). Anti-Id vaccines have been shown to be effective in treatment of B-cell lymphoma in animal models and in clinical trials, resulting in tumor regression; the addition of interleukin-2 (IL-2) may augment the therapeutic effect of anti-Id vaccines. (NCI04) (NCIT_C29112).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5258">
		<vaccine_name>ive-attenuated Double-deleted Listeria monocytogenes Bacteria JNJ-64041809</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Live attenuated vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4382">A proprietary, live-attenuated, double-deleted (LADD) strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding multiple, as of yet undisclosed, tumor-associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, live-attenuated double-deleted Listeria monocytogenes bacteria JNJ-64041809 is taken up by antigen-presenting cells (APCs), including dendritic cells (DCs). The TAAs are subsequently expressed by the APCs and then processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to the recruitment and activation of cytotoxic T-lymphocytes (CTLs) against the TAA-expressing tumor cells, eventually resulting in tumor cell lysis. Two genes contributing to the virulence of Lm have been removed to minimize the risk of infection. (NCIT_C125631).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5146">
		<vaccine_name>KLH-FITC</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4570">A conjugate consisting of keyhole-limpet hemocyanin (KLH) and fluorescein isothiocyanate (FITC) with potential immunostimulating activity. Vaccination with KLH-FITC may elicit an immune response against fluorescein and the production of anti-fluorescein IgG antibodies. KLH, a natural protein isolated from the marine mollusk keyhole limpet, is an immunostimulant carrier protein. (NCIT_C62478).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5519">
		<vaccine_name>KLH-Lymphoma Ig Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4290">A chimeric lymphoma vaccine generated by combining the recipient's Ig idiotype (Id) protein with keyhole limpet hemocyanin (KLH), an immune stimulant, with potential antineoplastic activity. Vaccination with KLH-Lymphoma Ig Vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against lymphoma cells, resulting in decreased tumor growth. (NCI04) (NCIT_C2771).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5472">
		<vaccine_name>KSA-KLH Conjugate Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4489">A peptide vaccine containing an epitope of human tumor-associated KSA antigen (Ep-CAM) conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. KSA antigen, a type-I transmembrane glycoprotein and a cellular adhesion molecule with a molecular mass of 40 kDa, is overexpressed on the majority of epithelial tumor cells. KSA antigen is conjugated with KLH, an immunostimulant and a hapten carrier, to enhance immune recognition. Vaccination with KSA-KLH may result in the production of antibodies as well as eliciting a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the KSA antigen. (NCIT_C2520).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5538">
		<vaccine_name>Lapuleucel-T</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4606">A cell-based vaccine targets tumors expressing the HER2/neu marker. HER-2/neu is a growth factor receptor, and its overexpression has been associated with a number of cancers including breast, ovarian, colon and lung cancers. APC8024 comprise of autologous antigen-presenting peripheral blood mononuclear cells (APCs) that have been exposed to HER2/neu protein and can be administered to the patient. These cells may stimulate an antitumor T-cell response to cancer cells expressing HER2/neu. (NCIT_C2057).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5004">
		<vaccine_name>Leukemic Apoptotic Corpse-Pulsed Autologous Dendritic Cells</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4183">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with corpses of apoptotic leukemic cells, with potential immunostimulatory and antineoplastic activities. Upon vaccination, autologous dendritic cells pulsed with leukemic apoptotic corpse may activate the immune system to mount an anti-tumoral cytotoxic T-lymphocyte (CTL) response against leukemic cells expressing leukemia-associated antigens, which may result in leukemic cell lysis and inhibition of tumor cell growth. Apoptotic tumor cell corpses contain an array of tumor associated antigens (TAAs). (NCIT_C91379).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5385">
		<vaccine_name>Light-Emitting Oncolytic Vaccinia Virus GL-ONC1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4536">An attenuated oncolytic vaccinia virus encoding the light-emitting fusion protein Renilla luciferase-Aequorea green fluorescent protein (RUC-GFP) with potential bioluminescent and antineoplastic activities. Upon administration, light-emitting oncolytic vaccinia virus GL-ONC1 specifically enters tumor cells due to the permeable nature of the tumor vasculature. Once inside the cell, the virus replicates, resulting in tumor cell lysis and the release of mature viral particles into the tumor microenvironment. Released viral particles may then infect and destroy neighboring tumor cells. In addition, the release of tumor-associated antigens (TAAs) by lysed tumor cells into the bloodstream may activate the immune system to mount a cytotoxic T lymphocyte (CTL) response against the tumor. The expression of RUC-GFP by this agent allows for both detection and monitoring of virally infected tumor cells in vivo and vitro with luciferase-mediated bioluminescence imaging and fluorescence imaging techniques. (NCIT_C79833).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5408">
		<vaccine_name>Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5488">
		<vaccine_name>Liposomal MUC1/PET-lipid A Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4132">A cancer vaccine comprised of a 43 amino acid epitope from glycoprotein MUC1 (mucin 1) and the synthetic Toll-like receptor 4 (TLR-4) agonist PET lipid A encapsulated in cholesterol/dipalmitoylphosphatidylcholine (DPPC)/dimyristoylphosphatidylglycerol (DMPG) liposomes, with potential immunostimulatory and antineoplastic activities. The MUC1 epitope is composed of two 20 amino glycosylated VNTR (various number tandem repeats) from human MUC1A and including 6 glycosylated sites modified by Tn (alfa-N-acetyl-D-galactosamine). Immunization of liposomal MUC1/PET-lipid A vaccine results in an antibody as well as a cytotoxic T-lymphocyte (CTL) response against hypoglycosylated MUC1 expressing tumor cells. The tumor associated antigen MUC1, a type I transmembrane protein, is overexpressed and aberrantly glycosylated in a variety of tumor cells. As a vaccine adjuvant, PET lipid A, also known as penta erythritol lipid A, stimulates both cellular and humoral responses to the vaccine antigen. (NCIT_C101262).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5383">
		<vaccine_name>Live Attenuated Influenza Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Live attenuated vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4647">A vaccine that contains live attenuated influenza virus (LAIV) particles. This vaccine is administered intranasally for influenza prophylaxis. Not all populations are good candidates for LAIV; the very young, elderly, asthmatics and those with health impaired may be better treated with the trivalent inactivated vaccine that is administered intramuscularly. (NCIT_C96402).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5512">
		<vaccine_name>Live-attenuated Double-deleted Listeria monocytogenes Bacteria JNJ-64041809</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Live attenuated vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4382">A proprietary, live-attenuated, double-deleted (LADD) strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding multiple, as of yet undisclosed, tumor-associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, live-attenuated double-deleted Listeria monocytogenes bacteria JNJ-64041809 is taken up by antigen-presenting cells (APCs), including dendritic cells (DCs). The TAAs are subsequently expressed by the APCs and then processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to the recruitment and activation of cytotoxic T-lymphocytes (CTLs) against the TAA-expressing tumor cells, eventually resulting in tumor cell lysis. Two genes contributing to the virulence of Lm have been removed to minimize the risk of infection. (NCIT_C125631).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5384">
		<vaccine_name>Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Live attenuated vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4229">A live-attenuated, double-deleted strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding a mutant form of the tumor associated antigens, epidermal growth factor receptor (EGFRvIII) and the cancer/testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, live-attenuated Listeria monocytogenes encoding EGFRvIII-NY-ESO-1 vaccine targets dendritic cells and expresses EGFRvIII and NY-ESO-1. This promotes both a potent innate immune response and an adaptive immune response involving the recruitment and activation of T lymphocytes against EGFRvIII and NY-ESO-1-expressing tumor cells, which results in tumor cell lysis. (NCIT_C111998).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4991">
		<vaccine_name>Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Live attenuated vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4229">A live-attenuated, double-deleted strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding a mutant form of the tumor associated antigens, epidermal growth factor receptor (EGFRvIII) and the cancer/testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, live-attenuated Listeria monocytogenes encoding EGFRvIII-NY-ESO-1 vaccine targets dendritic cells and expresses EGFRvIII and NY-ESO-1. This promotes both a potent innate immune response and an adaptive immune response involving the recruitment and activation of T lymphocytes against EGFRvIII and NY-ESO-1-expressing tumor cells, which results in tumor cell lysis. (NCIT_C111998).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5466">
		<vaccine_name>LMP-2:340-349 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4408">A peptide vaccine containing amino acids residues from 340 through 349 of the latent membrane protein-2 (LMP-2) of the Epstein-Barr virus (EBV) with potential immunostimulating and antineoplastic activities. LMP-2, an EBV transmembrane protein, is expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkin's disease. Vaccination with the LMP-2:340-349 peptide may boost the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against LMP-2 producing cells, resulting in cell lysis and inhibition of cancer cell proliferation. (NCIT_C62767).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5479">
		<vaccine_name>LMP-2:419-427 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4407">A peptide vaccine containing amino acids residues from 419 through 427 of the latent membrane protein-2 (LMP-2) of the Epstein-Barr virus (EBV) with potential immunostimulating and antineoplastic activities. LMP-2, an EBV transmembrane protein, is expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkin's disease. Vaccination with the LMP-2:49-427 peptide may boost the immune system to mount a specific cytotoxic T-lymphocyte response against LMP-2 producing cells, resulting in cell lysis and inhibition of cancer cell proliferation. (NCIT_C62768).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5143">
		<vaccine_name>Long Peptide Vaccine 7</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4575">A peptide vaccine consisting of a combination of seven synthetic long peptides (SLPs), which are each about 30 amino acids in size, and derived from cancer-testis antigens (CTA) and melanocytic differentiation proteins (MDP), with potential immunostimulating and antitumor activities. Upon administration, long peptide vaccine 7 may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL) response against tumor cells expressing these peptides. CTA and MDP are overexpressed in a variety of cancer cell types. (NCIT_C116067).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine3723">
		<vaccine_name>Lung metastasis DNA vaccine pCEP4-MUC1 encoding MUC1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004437</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pCEP4 [Ref2359:Kamata et al., 2002]</vector>
		<route>Intradermal injection (i.d.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intradermal injection (i.d.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1244" gene_id="gene703">
			<type>DNA vaccine construction</type>
			<description refs="reference2359">Vector pCEP4 expressed MUC1, a transmembrane molecule whose major extracellular domain is composed of tandem repeat units of 20 amino acids (Kamata et al., 2002).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1469" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2359">The number of lung metastatic nodules three weeks after inoculation of F10-MUC1-C8 cells was significantly lower in mice immunized with pCEP4-MUC1 DNA vaccine 3 times at weekly intervals than in mice immunized with the vector DNA alone or with a single immunization of the DNA vaccine (Kamata et al., 2002).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5164">
		<vaccine_name>LY6K/VEGFR1/VEGFR2 Multipeptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4269">A multipeptide vaccine consisting of peptides derived from lymphocyte antigen 6 complex locus K (LY6K) and type I and II vascular endothelial growth factor receptors (VEGFRs) with potential antineoplastic activity. Upon administration, LY6K/VEGFR1/VEGFR2 multipeptide vaccine may elicit an antitumor cytotoxic T-lymphocyte (CTL) immune response against LY6K-expressing tumor cells and/or VEGFR-expressing vascular endothelial cells involved in tumor angiogenesis. LY6K is a tumor-associated antigen (TAA) that occurs singly in glycosylphosphatidyl-inositol (GPI)-linked cell-surface glycoproteins or as three-fold repeated domain in the urokinase-type plasminogen activator receptor; VEGFRs are cell surface receptors that stimulate endothelial cell proliferation, invasion, angiogenesis, and vasculogenesis upon ligand binding and receptor activation. (NCIT_C74056).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine3617">
		<vaccine_name>Lymphoma DNA vaccine VÎ±VÎ²VÎ²-FrC</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004398</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcDNA3 [Ref2295:Thirdborough et al., 2002]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1514" gene_id="gene1332">
			<type>DNA vaccine construction</type>
			<description refs="reference2295">This vaccine encoded T-cell antigen receptor Valpha, Vbeta, and Fragment C (Thirdborough et al., 2002).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1435" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2295">Vaccination with the DNA construct VÎ±VÎ²CÎ²-FrC induced strong protection against challenge with C6VL, compared with nonvaccinated control mice and mice vaccinated with FrC alone (P &lt; 0.001). Vaccinations with VÎ±VÎ²-FrC, VÎ²CÎ²-FrC, or VÎ±VÎ²CÎ² alone were also completely ineffective. The protective response generated was specific for C6VL, with no protection induced against TCL-1, an unrelated T-cell tumor. The pattern of protection has been confirmed in two subsequent experiments, with survival rates of mice vaccinated with VÎ±VÎ²CÎ²-FrC ranging from 50 to 80%, whereas the other constructs were ineffective at prolonging survival (Thirdborough et al., 2002).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5157">
		<vaccine_name>MAGE-1 Vaccinia Contaminated with BVDV</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4211">A cancer vaccine consisting of a recombinant vaccinia virus encoding the tumor-associated gene MAGE-1 that is contaminated with bovine viral diarrhea virus (BVDV). The MAGE-1 gene is a member of the melanoma antigen-encoding gene family which is expressed in various malignant tumors such as hepatocellular carcinoma and germ cell tumors in addition to melanoma. Vaccination with vaccinia virus expressing human MAGE-1 may generate antitumoral T-cell responses. BVDV is an RNA pestivirus that may contaminate vaccines due to its presence in the fetal calf serum used as a growth supplement in the tissue culture of mammalian cells used in vaccine production. (NCI04) (NCIT_C29187).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5021">
		<vaccine_name>MAGE-3.A1 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4667">A synthetic peptide cancer vaccine consisting of human leukocyte antigen HLA-A1-restricted peptide derived from human melanoma antigen 3 (MAGE-3) with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-3.A1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-3, resulting in tumor cell lysis. MAGE-3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types. (NCIT_C48632).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5263">
		<vaccine_name>MAGE-A1/MAGE-A3/NY-ESO-1 Peptides Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4351">A cancer vaccine comprised of synthetic peptides derived from human melanoma antigen A1 (MAGE-A1), human melanoma antigen A3 (MAGE-A3) and cancer-testis antigen NY-ESO-1 with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A1/MAGE-A3/NY-ESO-1 peptides vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A1, MAGE-A3 and NY-ESO-1, resulting in tumor cell lysis. The MAGE-A1, MAGE-A3, and NY-ESO-1 tumor-associated antigens (TAAS) are overexpressed by a variety of cancer cell types. (NCIT_C84854).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5395">
		<vaccine_name>MAGE-A3 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4214">A peptide cancer vaccine comprised of a peptide derived from the human melanoma antigen A3 (MAGE-A3), with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A3 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A3, resulting in tumor cell lysis. MAGE-A3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types. (NCIT_C91710).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5336">
		<vaccine_name>MAGE-A3-expressing Adenovirus Type 5 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4612">An oncolytic adenoviral vaccine composed of a replication-defective, E1- and E3-deleted adenovirus serotype 5 (Ad5) with a transgene encoding the human melanoma antigen A3 (MAGE-A3), with potential antineoplastic activity. Upon administration, MAGE-A3-expressing adenovirus type 5 vaccine selectively replicates in cancer cells and expresses MAGE-A3. This induces an immune response against tumor cells expressing the MAGE-A3 antigen, which leads to tumor cell death. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types. (NCIT_C119614).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5345">
		<vaccine_name>MAGE-A3/HPV 16 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5215">
		<vaccine_name>Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4268">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from malignant glioma cells with potential immunostimulatory and antineoplastic activities. Upon administration, malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine exposes the immune system to undefined malignant glioma tumor-associated antigens (TAAs), which may result in anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against glioma cells and glioma cell lysis. (NCIT_C74057).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5166">
		<vaccine_name>Mammaglobin-A DNA Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4239">A cancer vaccine containing a plasmid encoding the mammaglobin-A gene with potential immunostimulating and antineoplastic activities. Upon administration, mammaglobin-A DNA vaccine may induce both humoral and cytotoxic T lymphocyte (CTL) immune responses against tumor cells that express mammaglobin-A, which may result in decreased tumor growth. The 10 kiloDalton (kD) glycoprotein mammglobin-A is expressed in over 80% of human breast cancers. (NCIT_C82675).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4193">
		<vaccine_name>Maraba virus MG1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004708</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3230">An attenuated Maraba strain, defined as MG1, was used to express a melanoma-associated tumor antigen (Pol et al., 2014).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1715" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000287</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3230">Once applied for treating syngeneic murine melanoma tumors, our oncolytic prime-boost vaccination protocol involving Maraba MG1 dramatically extended median survival and allowed complete remission in more than 20% of the animals treated (Pol et al., 2014).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5398">
		<vaccine_name>MART-1 Adenovirus Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4289">A vaccine consisting of recombinant adenovirus vector encoding MART-1 (melanoma antigen recognized by T-cells 1), an immunogenic protein of unknown function that is expressed by certain types of melanoma. Vaccination with MART-1 adenovirus vaccine may stimulate the host immune system to direct cytotoxic T lymphocytes (CTL) against MART-1 positive melanoma cells, resulting in an antitumor effect. (NCI04) (NCIT_C2773).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5254">
		<vaccine_name>MART-1 Fowlpox Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4291">A synthetic cancer vaccine derived from a melanoma-associated antigen, MART-1. Antigenic peptides derived from MART-1 are recognized by CD8+ T lymphocytes and have been used to immunize patients with advanced melanomas; prolonged immunization may result in a reduction in tumor size. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it does not multiply in human tissues. (NCI04) (NCIT_C2776).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5204">
		<vaccine_name>MART-1 Vaccinia Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4292"> A cancer vaccine consisting of an attenuated recombinant vaccinia virus expressing the melanoma-associated antigen MART-1. Vaccination with this agent may stimulate cytotoxic host immune responses to melanoma cells. (NCI04) (NCIT_C2774).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5028">
		<vaccine_name>MART-1/gp100/Tyrosinase/MAGE-A3 Peptides-loaded Irradiated Allogeneic Plasmacytoid Dendritic Cells</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4526">Irradiated allogeneic, HLA-A*0201 positive, plasmacytoid dendritic cells (pDCs) loaded with 4 melanoma peptides derived from the tumor associated antigens (TAAs) MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the irradiated allogeneic pDCs may trigger functional multi-specific T cells from peripheral blood mononuclear cells and tumor-infiltrating lymphocytes, and activate the immune system to mount a cytotoxic T-lymphocyte response against HLA-A*0201 positive melanoma cancer cells expressing the TAAs MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3. These TAAs are upregulated in a variety of tumor cells. The pDCs are derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology and express a characteristic set of surface markers and may increase the anti-tumor immune responses. (NCIT_C107159).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5141">
		<vaccine_name>MART-1:26-35(27L) Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1840" gene_id="gene706">
			<type>Recombinant protein preparation</type>
			<description refs="reference4020">MLANA, also known as MART-1, was used as one vaccine antigen for the cancer vaccine (Keller et al., 2015).</description>
		</gene_engineering>
	</vaccine>
	<vaccine vaccine_id="vaccine5450">
		<vaccine_name>MART-1:27-35 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4293">A natural or synthetic peptide cancer vaccine consisting of amino acid residues 27 through 35 of the melanoma-associated antigen MART-1 with potential antineoplastic activity. Vaccination with MART-1:27-35 peptide may induce cytotoxic host immune responses against melanoma cells that express this peptide. (NCIT_C2775).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5142">
		<vaccine_name>Melan-A VLP Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4208">A vaccine consisting of the melanocyte differentiation antigen Melan A (also called MART-1) encapsulated in noninfectious virus-like particles (VLP) with potential immunostimulating and antineoplastic activities. Upon administration, Melan-A VLP vaccine may activate the immune system to exert a specific cytotoxic T lymphocyte (CTL) response against cancer cells expressing the Melan A antigen, resulting in tumor cell lysis. Melan A is an antigen that is upregulated in most melanomas. VLP stimulates the immune system and promotes the CTL response. (NCIT_C61495).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5318">
		<vaccine_name>Melan-A/MAGE-3.DP4 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1844" gene_id="gene706">
			<type>Recombinant protein preparation</type>
			<description refs="reference5096">Functional T cells targeting NY-ESO-1 or Melan-A peptides are associated with the survival of patients with distant melanoma metastasis (Weide et al., 2012).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1845" gene_id="gene708">
			<type>Recombinant protein preparation</type>
			<description refs="reference5096">(Weide et al., 2012)</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1846" gene_id="gene296">
			<type>Recombinant protein preparation</type>
			<description refs="reference5096">(Weide et al., 2012)</description>
		</gene_engineering>
	</vaccine>
	<vaccine vaccine_id="vaccine3727">
		<vaccine_name>Melanoma DNA vaccine gp75 DNA encoding melanosomal membrane glycoproteins, gp75</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004440</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>WRG/BEN [Ref2363:Weber et al., 1998]</vector>
		<route>Gene gun</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Gene gun</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1515" gene_id="gene1685">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1473" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2363">Mice immunized with hgp75 were significantly protected from lung metastases compared with control mice (mice immunized with a null vector).  There was an 86% decrease in lung nodules (Weber et al., 1998).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3729">
		<vaccine_name>Melanoma DNA vaccine hTRP2 encoding TRP-2</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004442</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pCR3</vector>
		<route>Gene gun</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference2365">GM-CSF (Hawkins et al., 2002)</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Gene gun</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1248" gene_id="gene1342">
			<type>DNA vaccine construction</type>
			<description refs="reference2365">Vector pCR3 expressed human-tyrosinase-related protein-2 (hTRP2) (Hawkins et al., 2002).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1475" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2365">Immunization of mice with xenogeneic hTRP2 DNA results in tumor immunity against intravenous tumor challenge with a syngeneic mouse B16F10LM3 melanoma known to exï¿¼press TRP2. All mice (100%) immunized with hTRP2 were protected from challenge with B16F10LM3 melanoma while all control PCR3 vector immunized mice (100%) developed tumors (P &lt; 0.0001).  However, growth of established tumors was not inhibited (Hawkins et al., 2002).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3724">
		<vaccine_name>Melanoma DNA vaccine hugp100 encoding gp100</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004438</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pWRG1644 [Ref2360:Rakhmilevich et al., 2001]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference2360">GM-CSF (Rakhmilevich et al., 2001)</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1245" gene_id="gene1341">
			<type>DNA vaccine construction</type>
			<description refs="reference2360">Vector pWRG1644 expressed the human melanoma-associated antigen, gp100 (Rakhmilevich et al., 2001).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1470" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2360">Particle-mediated delivery of the gp100 plasmid resulted in substantial protection against B16-gp100 tumors, with 40% of the mice remaining tumor free for at least 2 months. Importantly, co-delivery of mGM-CSF DNA with hugp100 DNA resulted in complete tumor protection in all five vaccinated mice (Rakhmilevich et al., 2001).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3717">
		<vaccine_name>Melanoma DNA vaccine pCR3.1-VS-HSP65-TP-GRP6-M2 encoding 6 tandem repeats of GRP</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004433</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pCR3.1 [Ref2355:Fang et al., 2009]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1516" gene_id="gene1686">
			<type>DNA vaccine construction</type>
			<description refs="reference2355">This vaccine encoded six tandem repeats of a fragment of GRP from amino acids 18 to 27 (GRP6) flanked by helper T-cell epitopes for increased immunogenicity, including HSP65, a tetanus toxoid fragment from amino acids 830 to 844 (T), pan-HLA-DR-binding epitope (PADRE) (P), and two repeats of a mycobacterial HSP70 fragment from amino acids 407 to 426 (M) (Fang et al., 2009).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1464" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2355">B16-F10 cells injected subcutaneously formed large solid tumors in nonimmunized mice (saline) or in mice injected with a non-GRP-containing plasmid (pCR3.1-VS-HSP65-TP-M2). The tumor sizes decreased progressively in mice immunized with the anti-GRP vaccine (pCR3.1-VS-HSP65-TP-GRP6-M2).  B16-F10 tumor cells were implanted intradermally at two sites in the abdominal region. It took approximately 7 days for the cells to form âˆ¼4-mm intradermal tumors in the two control groups; however, the growth of intradermal tumors in pCR3.1-VS-HSP65-TP-GRP6-M2-immunized group was slightly delayed and required almost 11 days to form âˆ¼4-mm tumors.  The total number of blood vessels around each implant site from pCR3.1-VS-HSP65-TP-GRP6-M2-immunized mice was significantly lower than that from the saline group (22 Â± 4 versus 72 Â± 14; P &lt; 0.01) or from non-GRP-containing plasmid-immunized mice (22 Â± 4 versus 63 Â± 19; P &lt; 0.01).  To further test the efficacy of the anti-GRP vaccine, the extent of lung metastasis by intravenously administered tumor cells in the tail vein of immunized mice was evaluated. Metastatic tumor nodules were often detected in the lungs 21 days after injection of tumor cells. The average weight of lungs of mice immunized with pCR3.1-VS-HSP65-TP-GRP6-M2 was significantly lower than that of the saline group (0.215 Â± 0.020 g versus 0.301 Â± 0.068 g; P &lt; 0.05) or the pCR3.1-VS-HSP65-TP-M2 control group (0.215 Â± 0.020 g versus 0.289 Â± 0.087 g; P &lt; 0.05), which indicates that fewer metastases were formed in the lungs of the anti-GRP DNA vaccine-immunized group. In addition, the average number of metastatic nodules in mice immunized with pCR3.1-VS-HSP65-TP-GRP6-M2 was significantly less than that in mice that received saline (37.2 Â± 9.4 versus 88.0 Â± 22.6; P &lt; 0.001) or in mice in the pCR3.1-VS-HSP65-TP-M2 control group (37.2 Â± 9.4 versus 79.3.0 Â± 16.8; P &lt; 0.001) (Fang et al., 2009).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3719">
		<vaccine_name>Melanoma DNA vaccine pN4a-MAGE-1-GM</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004435</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pNGVL4a [Ref2356:Sun et al., 2002]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1242" gene_id="gene1338">
			<type>DNA vaccine construction</type>
			<description refs="reference2356">Vector pNGVL4a expressed GM-CSF and MAGE-1 (Sun et al., 2002).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1400" gene_id="gene1600">
			<type>DNA vaccine construction</type>
			<description refs="reference2356">Vector pNGVL4a expressed GM-CSF and MAGE-1 (Sun et al., 2002).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1465" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2356">C57BL/6 mice were immunized on days 0, 7, and 17 with the different MAGE-1 plasmids. After 6 days, the mice were challenged with B16 melanoma cells that express the human MAGE-1 antigen.  Mice immunized with plasmids co-expressing MAGE-1 and GM-CSF had significantly fewer tumor colonies on their lungs than mice from any of the other immunization groups. In fact, 60% of the mice immunized with DNA vaccines that co-express MAGE-1 and GM-CSF had fewer than five tumor colonies on their lungs, whereas this was true of a little less than 20% of the mice immunized with MAGE-1 alone vaccines or co-inoculation with MAGE-1 vaccines and GM-CSF expressing plasmid (Sun et al., 2002).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3718">
		<vaccine_name>Melanoma DNA vaccine pNL3-MAGE-1-GM</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004434</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pNGVL3 [Ref2356:Sun et al., 2002]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1241" gene_id="gene1338">
			<type>DNA vaccine construction</type>
			<description refs="reference2356">Vector pNGVL3 expressed GM-CSF and MAGE-1 (Sun et al., 2002).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1401" gene_id="gene1600">
			<type>DNA vaccine construction</type>
			<description refs="reference2356">Vector pNGVL3 expressed GM-CSF and MAGE-1 (Sun et al., 2002).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1466" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2356">C57BL/6 mice were immunized on days 0, 7, and 17 with the different MAGE-1 plasmids. After 6 days, the mice were challenged with B16 melanoma cells that express the human MAGE-1 antigen. Mice immunized with plasmids co-expressing MAGE-1 and GM-CSF had significantly fewer tumor colonies on their lungs than mice from any of the other immunization groups. In fact, 60% of the mice immunized with DNA vaccines that co-express MAGE-1 and GM-CSF had fewer than five tumor colonies on their lungs, whereas this was true of a little less than 20% of the mice immunized with MAGE-1 alone vaccines or co-inoculation with MAGE-1 vaccines and GM-CSF expressing plasmid (Sun et al., 2002).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3730">
		<vaccine_name>Melanoma DNA vaccine pUB-TRP-2 encoding a fusion protein linking murine ubiquitin (UB) to the N-terminus of the full-length mTRP-2</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004443</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcDNA 3.1 (-). [Ref2366:Zhang et al., 2005]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1517" gene_id="gene1345">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1518" gene_id="gene709">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1476" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2366">A week after the last immunization, mice were challenged subcutaneously with 2  105 B16F1 cells. Control mice and mice immunized with pTRP-2 showed rapid tumor growth, whereas 85% of mice immunized with pUB-TRP-2 were free of tumors and the remaining 15% of the mice exhibited almost complete suppression of tumor growth. Strictly, all mice immunized with pUB-TRP-2 survived over 80 days after implantation of tumor cells, although all mice of the other two groups died within 60 days.  Furthermore, immunization with pUB-TRP-2 was also effective in suppressing the growth of B16F10 melanoma cells, a more virulent type of melanoma (Zhang et al., 2005).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3720">
		<vaccine_name>Melanoma DNA vaccine SINCp c-muMUC18 encoding MCAM/MUC18</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004436</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>SINCp [Ref2357:Leslie et al., 2007]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1243" gene_id="gene1339">
			<type>DNA vaccine construction</type>
			<description refs="reference2357">Vector SINCp expressed murine melanoma cell adhesion molecule (MCAM/MUC18) (Leslie et al., 2007).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1472" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2357">Mice vaccinated with SINCp c-muMUC18 had significantly (P=0.037) fewer lung colonies than mice vaccinated with SINCp -gal. The number of lung metastases was reduced in mice vaccinated with SINCp c-muMUC18 (range 0â€“100; median 1.0) compared with SINCp -gal (range 18â€“200; median 26). Thus, mice immunized with SINCp c-muMUC18 were significantly protected from lung metastasis formation (Leslie et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3705">
		<vaccine_name>Melanoma DNA vaccine TA2Mâ„¢ encoding tyrosinase peptides</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004431</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1234" gene_id="gene1335">
			<type>DNA vaccine construction</type>
			<description refs="reference2345">This DNA vaccine expressed two peptides, tyrosinase 207â€“216 and tyrosinase 1â€“17, both of which are derived from human tyrosinase (Tagawa et al., 2003).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1462" host_id="host2">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2345">The fact that, at a median follow-up of 1 year, 16 of 26 patients still were alive is notable, because the median survival of patients with Stage IV melanoma in recent trials was 7â€“9 months from first treatment.  The 11 patients who had detectable immune responses to tyrosinase 207â€“216 had appreciably fewer deaths and superior survival compared with the 13 patients who had no immune responses (Tagawa et al., 2003).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3713">
		<vaccine_name>Melanoma DNA vaccine VR-S8/VR-IL2/AD-S8 encoding survivin</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004432</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>VR [Ref2351:Zhang et al., 2012]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1238" gene_id="gene1336">
			<type>DNA vaccine construction</type>
			<description refs="reference2351">Vector VR expressed novel truncations of survivin, is overexpressed in major types of cancer and is considered an ideal â€˜â€˜universalâ€™â€™ tumor-associated antigen (Zhang et al., 2012).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1463" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2351">Tumors were significantly inhibited in mice boosted with AD-S8 compared with those in mice given VR-S8/VR- IL2 (P &lt; 0.01).  Moreover, complete tumor rejection occurred in 5 of 15 mice, while no tumor rejection was observed in the control group.  A Kaplanâ€“Meier plot showed that 53.3% of the mice in the AD-S8- boosted group were alive at 50 days with survival prolonged by 35.6%, whereas only 6.7% of the mice in the VR-S8/VR-IL2 and VR-S8 groups were alive with survival prolonged by 17 and 10.5%, respectively (Zhang et al., 2012).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3726">
		<vaccine_name>Melanoma DNA vaccine VR1012/mPmel17</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004439</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>VR1012 [Ref2362:Wagner et al., 2000]</vector>
		<route>Intradermal injection (i.d.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intradermal injection (i.d.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1519" gene_id="gene1687">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1471" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2362">More than half of the animals that had received VR1012/mPmel17 pDNA were protected completely (eight of 15 = 53.3%) against the highly tumorigenic dose of 1X10^5 M3-7 cells. None of these protected animals developed a tumor at a later time point during an entire observation period of 4 months. By contrast, control animals that had been injected with vector VR1012 pDNA alone consistently failed to reject Pmel17high M3-7 melanoma cells (Wagner et al., 2000).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3768">
		<vaccine_name>Melanoma DNA vaccine xenogeneic DNA encoding murine tyrosinase</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004465</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pING plasmid vector [Ref2401:Manley et al., 2011]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1294" gene_id="gene1377">
			<type>DNA vaccine construction</type>
			<description refs="reference2401">Vector pING expressed murine tyrosinase (Manley et al., 2011).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1203" host_id="host36">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2401">Overall median survival time (MST) for dogs treated with loco-regional control and xenogeneic DNA vaccine was 476 days with a 1-year survival rate of 63%.  The xenogeneic murine tyrosinase DNA vaccine was safe and appears effective when used in conjunction with local and regional disease control (Manley et al., 2011).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3728">
		<vaccine_name>Melanoma recombinant vector vaccine rVVmTRP-1 encoding TRP-1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004441</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector>pSC65 and recombinant vaccinia virus [Ref2364:Overwijk et al., 1999]</vector>
		<route>Intravenous injection (i.v.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intravenous injection (i.v.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1247" gene_id="gene1360">
			<type>Recombinant vector construction</type>
			<description refs="reference2364">Vector pSC65 and rVV expressed tyrosinase-related protein TRP-1 (Overwijk et al., 1999).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1474" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2364">Challenge of vaccinated Î²2m knockout mice with B16 melanoma revealed robust protection against melanoma growth (Overwijk et al., 1999).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4989">
		<vaccine_name>Melanoma Theraccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4417">A synthetic allogeneic cancer vaccine. Melanoma theraccine typically consists of lysed melanoma cells obtained from several melanoma cell lines combined with an adjuvant (such as DETOX or RIBI). This agent may be combined with immunomodulatory cytokines such as interferon alpha. Melanoma theraccine may induce a rise in the level of cytotoxic T-lymphocyte precursors. (NCIT_C1830).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5014">
		<vaccine_name>Melapuldencel-T</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4586">A therapeutic melanoma vaccine consisting of autologous dendritic cells (DCs) pulsed with antigens from lethally irradiated autologous tumor cells derived from a patient-specific, continuously proliferating and melanoma-initiating cell line and suspended in a solution containing the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, melapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the patient's repertoire of melanoma-associated antigens, particularly tumor stem cell antigens, found in the irradiated autologous cancer cells. As an immunostimulant, GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes. (NCIT_C120183).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5261">
		<vaccine_name>MELITAC 12.1 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5337">
		<vaccine_name>Meningococcal Conjugate Vaccine MCV4</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4389">A conjugate vaccine of meningococcal polysaccharide used for active immunization against invasive meningococcal disease caused by Neisseria meningiditis serogroups A, C, Y, and W-135. (NCIT_C96391).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5291">
		<vaccine_name>Meningococcal Polysaccharide Vaccine MPSV4</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4307">A polysaccharide vaccine used to prevent contraction of meningococcal meningitis. (NCIT_C96519).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5094">
		<vaccine_name>Meningococcal Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Live attenuated vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4165">Any vaccine derived from Neisseria meningitidis whether in whole-cell or acellular form used for prophylaxis against meningitis. (NCIT_C96397).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5187">
		<vaccine_name>Mesothelioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4219">A cell-based cancer vaccine consisting of autologous dendritic cells (DCs) pulsed with mesothelioma tumor lysate with potential immunostimulating and antineoplastic activities. Upon administration, mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount a specific cytotoxic T lymphocyte (CTL) response against mesothelioma tumor cells, resulting in tumor cell lysis. (NCIT_C78448).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5235">
		<vaccine_name>Methanol Extraction Residue of BCG</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Live attenuated vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4602">A cell wall fraction of bacillus Calmette-Guerin (BCG) obtained by menthol extraction with immunomodulating properties and potential use in cancer immunotherapy.  (NCIT_C1159).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4255">
		<vaccine_name>MG1-hDCT</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004764</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3230">(Pol et al., 2014)  an attenuated Maraba strain, defined as MG1, to express a melanoma-associated tumor antigen.</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5015">
		<vaccine_name>MiHA-loaded PD-L1/L2-silenced Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4419">A dendritic cell (DC)-based vaccine composed of program death ligands 1 and 2 (PDL1/L2)-silenced DCs and loaded with the recipient's minor histocompatibility antigens (MiHA), with potential use for graft-versus-tumor (GVT) induction following allogeneic stem cell transplantation (allo-SCT). Donor DCs are electroporated ex vivo with MiHA mRNA and small interfering RNAs (siRNAs) designed to silence the expression of PD L1/L2. After allo-SCT and upon intravenous administration of the MiHA-loaded PD-L1/L2-silenced DC vaccine, the DCs induce the expansion and activation of MiHA-specific CD8-positive T-cells. These tumor antigen-reactive T-cells exert their GVT effect by killing miHA-positive tumor cells. PD-L1/L2, co-inhibitory ligands expressed on DCs, play key roles in preventing MiHA-specific CD8-positive T-cell expansion; silencing enhances MiHA-specific CD8-positive T-cell expansion and activity and improves the GVT effect. The MiHA are human leukocyte antigen (HLA)-bound peptides and are exclusively expressed by the recipient's hematopoietic tumor cells. (NCIT_C123921).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5347">
		<vaccine_name>Mimotope-P10s-PADRE Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5036">
		<vaccine_name>Modified Vaccinia Ankara (Bavarian Nordic)-HER2 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4222">A cancer vaccine consisting of a proprietary, recombinant modified vaccinia Ankara (MVA) viral vector encoding an epitope of human epidermal growth factor receptor 2 (HER2) with potential antineoplastic activity. Upon administration, modified vaccinia Ankara (Bavarian Nordic)-HER2 vaccine may stimulate the host immune system to mount humoral and cytotoxic T lymphocyte responses against HER2-expressing tumor cells, resulting in tumor cell lysis. HER2, also known as ErbB-2, is a tyrosine kinase growth factor receptor and a member of the epidermal growth factor receptor family; it plays a significant role in the pathogenesis of some breast cancers. (NCIT_C71758).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5412">
		<vaccine_name>Modified Vaccinia Virus Ankara Vaccine Expressing p53</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4474">A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the wild-type form of the tumor protein p53 (wt p53), with potential immunostimulating and antineoplastic activities. Upon subcutaneous vaccination with MVA vaccine expressing p53, the expressed p53 may stimulate the host immune system to mount a p53-specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing p53, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attentuated, replication-defective vaccinia strain and is incapable of virion assembly. The p53 gene, a tumor suppressor gene, is mutated in many cancer cell types. (NCIT_C116868).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5195">
		<vaccine_name>Monoclonal Antibody 105AD7 Anti-idiotype Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4126">A cancer vaccine consisting of a humanized monoclonal antibody that mimics a tumor-associated antigen 791Tgp72 (also known as CD55). Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing CD55, resulting in tumor cell lysis. (NCI04) (NCIT_C2648).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5286">
		<vaccine_name>Monoclonal Antibody 11D10 Anti-Idiotype Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4204">A vaccine consisting of a monoclonal antibody (MoAb) directed against an idiotype that mimics a human milk fat globule (HMFG) membrane epitope. Vaccination with monoclonal antibody 11D10 anti-idiotype vaccine induces anti-anti-idiotype antibodies (Ab3) that may react with breast cancer cell lines expressing the HMFG membrane epitope. (NCIT_C2606).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5452">
		<vaccine_name>Monoclonal Antibody 3H1 Anti-Idiotype Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4247">A recombinant monoclonal antibody in which the heavy and light chain variable domains mimic a specific epitope of the tumor-associated protein carcinoembryonic antigen (CEA). This agent is used as a cancer vaccine against tumors that express CEA. (NCI04) (NCIT_C2424).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5039">
		<vaccine_name>Monoclonal Antibody 4B5 Anti-Idiotype Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4661">A humanized anti-idiotypic (anti-Id) monoclonal antibody (MoAb) that mimics the disialoganglioside GD2 with potential immunostimulating and antineoplastic activities. Upon administration, monoclonal antibody 4B5 anti-idiotype vaccine may elicit both cellular and humoral immune responses against GD2- expressing tumor cells. GD2 is a glycosphingolipid (ceramide and oligosaccharide) that may be highly expressed by melanomas and other neuroectodermal tumors, while only minimally expressed by normal tissues. (NCIT_C2227).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5308">
		<vaccine_name>Monoclonal Antibody A1G4 Anti-Idiotype Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4640">An anti-idiotypic (anti-Id) rat monoclonal antibody (MoAb) that mimics the disialoganglioside GD2, a cancer-associated antigen present on melanoma, small cell lung cancer, sarcoma, neuroblastoma, and other malignancies. GD2 is a highly expressed glycosphingolipid by melanoma and other neuroectodermal tumors with only minimal expression on normal tissues. Vaccination with anti-Id A1G4 MoAb may elicit cellular and humoral immune responses against GD2 expression tumor cells. (NCIT_C2436).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5469">
		<vaccine_name>Monoclonal Antibody GD2 Anti-Idiotype Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4266">An anti-idiotypic (anti-Id) rat monoclonal antibody (MoAb) that mimics the disialoganglioside GD2, a cancer-associated antigen present on melanoma, small cell lung cancer, sarcoma, neuroblastoma, and other malignancies. GD2 is a highly expressed glycosphingolipid by melanoma and other neuroectodermal tumors with only minimal expression on normal tissues. Vaccination with anti-Id A1G4 MoAb may elicit cellular and humoral immune responses against GD2 expression tumor cells. (NCIT_C26450).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5239">
		<vaccine_name>Montanide ISA-51/Survivin Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5386">
		<vaccine_name>Mouse gp100 Plasmid DNA Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4355">A vaccine consisting of a plasmid DNA encoding the murine melanoma-associated antigen gp100. Upon administration, expressed gp100 antigen may stimulate a cytotoxic T cell HLA-A2.1-restricted immune response against tumor cells that express the gp100 antigen, resulting in tumor cell lysis. (NCI05) (NCIT_C48410).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5105">
		<vaccine_name>Mouse Prostate-Specific Membrane Antigen Plasmid DNA Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4154">A vaccine consisting of a plasmid DNA encoding the murine prostate-specific membrane antigen (PSMA). Upon administration, expressed PSMA may stimulate a cytotoxic T cell response against tumor cells that express PSMA, resulting in tumor cell lysis. (NCI05) (NCIT_C48411).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5335">
		<vaccine_name>MOv-PBL Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4213">Peripheral blood lymphocytes (PBL) transfected to express MOv have been designed for possible use in autologous adoptive cellular immunotherapy of ovarian adenocarcinomas that overexpress folate-binding protein. MOv-PBLs express MOv-gamma (MOv), a chimeric receptor gene product derived from a recombinant gene encoding the variable region of murine monoclonal antibody MOv18 against folate-binding protein (FBP), often overexpressed in human ovarian cancer cells, and the human gene encoding the IgG and IgE Fc receptor gamma subunit. Autologous vaccination with these PBLs stimulates a host cytotoxic T lymphocyte response against ovarian cancer cells that overexpress FBP. (NCIT_C2781).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5369">
		<vaccine_name>mRNA-Derived Prostate Cancer Vaccine CV9103</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4459">A prostate cancer vaccine containing mRNAs encoding prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostate stem cell antigen (PSCA) and six-transmembrane epithelial antigen of the prostate (STEAP), with potential antitumor activity. Upon administration, mRNA-derived prostate cancer vaccine CV9103 may stimulate the immune system to mount a cytotoxic T lymphocyte response (CTL) against PSA-, PSMA-, PSCA- and STEAP-expressing prostate tumor cells. The mRNA used in this vaccine is modified and formulated to have enhanced translational potency and adjuvant activities. PSA, PSMA, PSCA and STEAP may be upregulated in prostate cancer cells; their expression in prostate cancer has been correlated with disease progression. (NCIT_C82654).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4054">
		<vaccine_name>mRNA-Electroporated Dendritic Cells</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004614</vo_id>
		<type>Dendritic cell</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference2972">Monocyte-derived DC, electroporated with mRNA encoding gp100 and tyrosinase, were pulsed with keyhole limpet hemocyanin and administered intranodally (Aarntzen et al., 2012).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="">tumor-associated antigens: antigen G250 with gp100 and tyrosinase protein, and pulsed with keyhole limped hemocyan (KLH) protein.</antigen>
		<host_response host_response_id="host_response1685" host_id="host2">
			<immune_response refs="reference2972">Vaccination with mRNA-electroporated DC induces a broad repertoire of IFNÎ³ producing TAA-specific CD8(+) and CD4(+) T-cell responses, particularly in stage III melanoma patients (Aarntzen et al., 2012).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5362">
		<vaccine_name>MSCV-MGMT(P140K) Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5517">
		<vaccine_name>MUC-1 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4137">A cancer vaccine comprised of a synthetic peptide derived from the mucin 1 (MUC1) antigen with potential antineoplastic activity. Upon administration, MUC1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the MUC1 antigen, resulting in decreased tumor growth. Overexpressed on many tumor cells, MUC1 antigen, a mammary-type apomucin, is a high-molecular-weight transmembrane glycoprotein. (NCIT_C53290).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5126">
		<vaccine_name>MUC-2-Globo H-KLH Conjugate Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5169">
		<vaccine_name>MUC-2-KLH Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4174">A peptide vaccine containing human mucin 2 (MUC2) protein conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. MUC2, a secretory or gel forming glycoprotein expressed predominantly in goblet cells of the gastrointestinal and respiratory tracts, is overexpressed as an aberrant or deglycosylated form in various tumors such as gastric carcinomas and some hormone-refractory prostate cancers. MUC2 protein is conjugated with KLH, an immunostimulant and a hapten carrier, to enhance immune recognition. Vaccination with MUC2-KLH may result in the production of antibodies as well as elicit a cytotoxic T- lymphocyte (CTL) response against tumor cells expressing MUC2. (NCIT_C2465).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5123">
		<vaccine_name>MUC1 Antigen/SB AS-2</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5251">
		<vaccine_name>MUC1-KLH Conjugate Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4515">A peptide vaccine, containing human tumor-associated epithelial mucin (MUC1) conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Vaccination with MUC1-KLH conjugate vaccine may stimulate humoral and cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing the MUC1 antigen. In this vaccine, MUC1 antigen is conjugated with KLH, an immunostimulant and a hapten carrier, to enhance immune recognition. MUC1 antigen, a membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed in an aberrant or deglycosylated form in various cancers such as those of the breast, prostate, and ovary. (NCIT_C2232).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5160">
		<vaccine_name>MUC1-KLH Vaccine/QS21</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4162">A peptide vaccine containing the human tumor-associated antigen epithelial mucin (MUC1 antigen) conjugated with keyhole limpet hemocyanin (KLH) and combined with the nonspecific immunoadjuvant QS21, with potential antineoplastic activity. MUC1 antigen is linked with KLH, an immunostimulant and a hapten carrier, in order to enhance immune recognition; the co-administration of saponin-derived QS21 potentially amplifies the total immune response to the MUC1 antigen. Administration of MUC1-KLH vaccine/QS21 may result in both the production of antitumor antibodies and the stimulation of a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the MUC1 antigen. MUC1 antigen, a membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed as an aberrant or deglycosylated form in various cancers such as breast, prostate and ovarian cancers. (NCIT_C11845).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5068">
		<vaccine_name>MUC1-targeted Peptide GO-203-2C</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5522">
		<vaccine_name>Multi-epitope Folate Receptor Alpha Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5224">
		<vaccine_name>Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4540">A cell-based vaccine composed of autologous-monocyte-derived dendritic cells (DCs) loaded with five immunogenic peptide epitopes, derived from the tumor-associated antigen human folate receptor alpha (FR alpha or FOLR1), including FR30, FR56, FR76, FR113, and FR238, with potential immunomodulatory and antineoplastic activity. Ex vivo treatment of the DCs with a p38 inhibitor decreases p38-mediated signaling and enhances ERK activation. This may allow, upon intradermal administration of the multi-epitope FR alpha-loaded DC vaccine into the patient, for decreased activation and expansion of CD4+ regulatory T-cells (Tregs), increased differentiation and expansion of interleukin-17 secreting T helper cells (Th17) and activation of CD8+ CTLs, which induces a strong anti-tumor T-cell immune response against FR alpha-overexpressing tumor cells. FR alpha is a high-affinity folate-binding protein and a member of the folate receptor family; this receptor is overexpressed in the majority of ovarian cancers and in about approximately 50% of breast cancers. (NCIT_C114990).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5421">
		<vaccine_name>Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4145">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with six synthetic glioblastoma (GBM) peptides: absent in melanoma 2 (AIM-2), melanoma-associated antigen 1 (MAGE-1), tyrosinase-related protein 2 (TRP-2), glycoprotein 100 (gp100), epidermal growth factor receptor 2 (HER-2), interleukin-13 receptor subunit alpha-2 (IL-13Ra2), with potential immunostimulatory and antineoplastic activities. Mononuclear cells obtained via leukapheresis are differentiated into DCs, and pulsed with the GBM-associated peptides. Upon administration, multi-glioblastoma-peptide-targeting autologous DC vaccine ICT-107 exposes the immune system to GBM-associated antigens, which activates a specific cytotoxic T-lymphocyte (CTL) response against GBM cells. This leads to GBM cell lysis. The six peptides are derived from tumor associated antigens (TAA) expressed on GBM cells and cancer stem cells (CSCs). GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells. (NCIT_C124054).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5200">
		<vaccine_name>Multi-peptide CMV-Modified Vaccinia Ankara Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5064">
		<vaccine_name>Multipeptide Vaccine S-588210</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4265">A cancer vaccine composed of a combination of the injectable formulations S-488210, which contains the three HLA-A*02:01-restricted peptides up-regulated lung cancer 10 (lymphocyte antigen 6K; LY6K; URLC10), cell division cycle-associated protein 1 (kinetochore protein Nuf2; NUF2; CDCA1) and insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3; KOC1) and S-488211, which contains the two HLA-A*02:01-restricted peptides DEP domain-containing protein 1A (DEPDC1) and M-phase phosphoprotein 1 (kinesin-like protein KIF20B; MPHOSPH1), with potential immunostimulatory and antitumor activities. Upon administration, multipeptide vaccine S-588210 may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing KOC1, CDCA1, URLC10, DEPDC1 or MPHOSPH1 peptides, resulting in tumor cell lysis and decreased tumor growth. (NCIT_C125692).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4064">
		<vaccine_name>Multivalent immunotherapeutic vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004616</vo_id>
		<type>multivalent</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs="reference2995">The approach focuses on the use of five primary patient derived melanoma cells (MEL-2, MEL-V, 3MM, KFM, and GLM-2). These cells display differential in vitro migratory and invasive properties as well as have the ability to form solid tumors when implanted into BALB/c nude mice. The retention of the innate phenotype of these primary patient derived cells together with the expression of a multitude repertoire of melanoma associated antigens offers a novel opportunity to target melanoma so as to avoid immune evasion (Suriano et al., 2013).</description>
		<adjuvant refs="">live vaccinia virus</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="">MART-1, gp100 (Pmel17), NY-ESO-1, MAGE-A1, tyrosinase, TRP-1 (gp75), TRP-2, CD146 and CD71, melanotransferrin</antigen>
		<host_response host_response_id="host_response1690" host_id="host3">
			<immune_response refs="reference2995">gp100 was only expressed by GLM-2 while the cancer testis antigen, NY-ESO-1, was only expressed by 3MM, all of the primary cells expressed tyrosinase, TRP-1, and TRP-2, The cell surface antigens, CD71 and CD146, were expressed by all of the primary cells except for 
GLM-2, which did not express CD71, melanotransferrin 
(p97), was only expressed by MEL-2 (Suriano et al., 2013).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5310">
		<vaccine_name>Murine TYRP2 Plasmid DNA Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4199">A plasmid DNA vaccine encoding the mouse tumor associated antigen tyrosinase-related protein-2 (TYRP2) with potential immunostimulating and antineoplastic activities. Upon administration, murine TYRP2 plasmid DNA vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing TYRP2; this vaccine may also induce an immune response against tyrosinase-related protein-1 (TYRP1). TYRP2 and TYRP1, melanosomal membrane glycoproteins upregulated in melanoma cells, are involved in melanin synthesis. (NCIT_C77877).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5364">
		<vaccine_name>Mutant p53 Peptide Pulsed Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4672">A cancer vaccine consisting of autologous dendritic cells which have been pulsed with a mutant p53 peptide. Vaccination with mutant p53 peptide pulsed dendritic cells may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing mutant p53, resulting in tumor cell lysis. Many tumor cells overexpress mutant p53 proteins, resulting in the loss of apoptosis regulation and abnormal cell proliferation. (NCI04) (NCIT_C2540).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5314">
		<vaccine_name>MVA-EBNA1/LMP2 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4439">A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the gene for the CD4 epitope-rich C-terminal domain of the Epstein Barr Virus (EBV) antigen EBNA1 and fused to the full-length of the EBV-associated antigen latent membrane protein 2 (LMP2), with potential immunostimulatory and antineoplastic activities. Upon administration, MVA EBNA1/LMP2 vaccine may elicit a cytotoxic T-cell immune response against cancer cells expressing EBNA1 and LMP2. Multi-antigen vaccine therapy may be more efficacious than single-antigen therapy vaccine therapy. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation. (NCIT_C91076).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5312">
		<vaccine_name>MVA-FCU1 TG4023</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4142">A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the suicide gene FCU1 with potential antineoplastic activity. FCU1 is a bifunctional yeast cytosine deaminase (CD) / uracil phosphoribosyltransferase (UPRT) fusion gene. Upon intratumoral administration, MVA-FCU1TG4023 enters tumor cells where FCU1 is expressed. Subsequently, the noncytotoxic prodrug 5-fluorocytosine (5-FC) is administered systemically and is deaminated by CD in FCU1- transduced tumor cells into 5-fluorouracil (5-FU), which is then directly metabolized to 5-fluoro-uridine monophosphate (5-FUMP) by UPRT; 5-FUMP may then be further transformed to 5-fluoro-deoxyuridine monophosphate (5-FdUMP), an irreversible inhibitor of thymidylate synthase and, so, DNA synthesis through deprivation of deoxythymidine triphosphate (dTTP). 5-FU and its active metabolites may then selectively kill tumor cells, avoiding toxicity in nonmalignant cells. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attenuated, replication-defective vaccinia strain incapable of virion assembly. (NCIT_C88279).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5091">
		<vaccine_name>MVA-MUC1-IL2 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4403">A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. Originally developed for the eradication of smallpox, MVA is a highly attenuated and replication-defective strain incapable of virion assembly and exerts potent immunostimulatory activity against antigens. Vaccination with MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against MUC1 expressing cells. (NCIT_C2241).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5460">
		<vaccine_name>MVA-PSA/PAP Prostate Cancer Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4392"> A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding genes for prostate specific antigen (PSA) and prostate acid phosphatase (PAP) with potential immunostimulatory and antineoplastic activities. Upon administration, MVA-PSA-PAP prostate cancer vaccine expresses PSA and PAP peptides, which may elicit humoral and cellular immune responses against prostate cancer cells expressing PSA and PAP. Multi-antigen vaccine therapy may be more efficacious than single-antigen therapy vaccine therapy. (NCIT_C74064).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5400">
		<vaccine_name>MVF-HER-2(597-626)/MVF-HER-2 (266-296) Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4493">A combination peptide vaccine of 2 chimeric peptides of the promiscuous T cell epitope derived from measles virus fusion protein (MVF; amino acid residues 288-302) co-synthesized with B-cell epitopes derived from the HER-2/neu a.a. 597-626 and HER-2/neu a.a. 266-296, with potential antineoplastic activity. Vaccination with MVF-HER-2(597-626)/MVF-HER-2(266-296) peptide vaccine may be capable of inducing an active specific immune response, mounting a cytotoxic T-lymphocyte (CTL) response and an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress the HER-2 protein. The oncogenic protein HER-2, a member of the human epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in a variety of cancers and is correlated with increased tumor growth, progression and a poor prognosis. HER-2(597-626) corresponds to the binding site of trastuzumab on the extracellular domain IV of HER-2; HER-2 (266-296) corresponds to the binding site of pertuzumab on the dimerization loop of domain II of HER-2. (NCIT_C97344).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5305">
		<vaccine_name>NA-17/MAGE-3.A2/NY-ESO-1 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5323">
		<vaccine_name>NA17.A2 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4348">A peptide cancer vaccine comprised of human leukocyte antigen HLA-A2-restricted peptide derived from a metastatic melanoma cell line of patient NA17, with potential immunomodulating and antineoplastic activity. NA17.A2 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. This NA17 specific antigen, encoded by an intron sequence of N-acetylglucosaminyltransferase V (GnT-V) gene, is expressed in about 50% of melanomas. (NCIT_C2680).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5026">
		<vaccine_name>Natural Killer Cells ZRx101</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4175">A population of activated, immortalized, interleukin-2 (IL-2)-dependent, cytotoxic natural killer (NK) cells with potential antitumor activity. Natural killer cells ZRx101 are derived from NK-92 cells, having been modified to target tumor-associated antigens (TAAs) upregulated in certain types of cancer. The NK-92 cell line was originally isolated from a patient with large granular lymphocytic (LGL) leukemia/lymphoma. (NCIT_C85466).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5363">
		<vaccine_name>Nelipepimut-S Plus GM-CSF Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4233">A cancer peptide vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (ERBB2) peptide from the extracellular domain of the HER2 protein (E75 peptide) and combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating and antineoplastic activity. Upon intradermal injection, nelipepimut-S plus GM-CSF vaccine may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cell types. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types. GM-CSF potentiates the antitumor immune response. (NCIT_C99228).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine3731">
		<vaccine_name>Neuroblastoma DNA vaccine HuDsec</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004444</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcDNA 3.1  [Ref2367:Carpentier et al., 1998]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1249" gene_id="gene1343">
			<type>DNA vaccine construction</type>
			<description refs="reference2367">Vector pcDNA 3.1  expressed Hu proteins which are the human homologues of the Drosophila protein elav, including HuD (Carpentier et al., 1998).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1477" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2367">Immunized animals were challenged by s.c. implantation of a neuroblastoma cell line that constitutively expresses HuD. When compared with controls, mice immunized with the secreted HuD showed significant tumor growth inhibition (51% reduction volume; P = 0.0012), and 14% of them had complete tumor rejection (Carpentier et al., 1998).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4025">
		<vaccine_name>Newcastle disease virus lysate</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004612</vo_id>
		<type>lysate of cell lines</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference2943">possible value in delaying the progression of malignant melanoma with palpable regional node disease (Stage II) to disseminated melanoma (Stage III). This Phase II study was carried out in a group of 32 patients following therapeutic lymphadenectomy (Cassel et al., 1983).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5501">
		<vaccine_name>Non-Adjuvanted A(H1N1) Influenza Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4583">A monovalent vaccine containing hemagglutinin (HA) of influenza A (H1N1)-like virus with potential immunomodulating activity. Upon administration, non-adjuvanted A(H1N1) influenza vaccine may stimulate the immune system to mount an antibody response against H1N1. (NCIT_C88334).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5206">
		<vaccine_name>NY-ESO-1 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4527">A cancer vaccine consisting of an immunogenic peptide derived from the cancer-testis antigen (NY-ESO-1), an antigen found in normal testis and various tumors. Vaccination with NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response to cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis. (NCIT_C2657).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5283">
		<vaccine_name>NY-ESO-1 Plasmid DNA Cancer Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4327">A plasmid DNA encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1 with potential immunostimulating and antitumor activities. Upon administration, NY-ESO-1 plasmid DNA cancer vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the NY-ESO-1 antigen, resulting in tumor cell lysis. NY-ESO-1 is a tumor associated antigen (TAA) found in normal testes and expressed on the surfaces of various tumor cells, including melanoma, breast, bladder, prostate, lung, ovarian, and hepatocellular tumor cells. (NCIT_C62452).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5100">
		<vaccine_name>NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4279">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a peptide derived from the tumor associated antigen human cancer-testis antigen NY-ESO-1 (NY-ESO-1(157-165)), with potential immunostimulatory and antineoplastic activities. Upon administration, the NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount both an anti-tumoral cytotoxic T-lymphocyte (CTL)- and an antibody-mediated immune response against NY-ESO-1-expressing tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival. (NCIT_C114380).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5445">
		<vaccine_name>NY-ESO-1/GLA-SE Vaccine ID-G305AmN</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5379">
		<vaccine_name>NY-ESO-1/LAGE-1 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5366">
		<vaccine_name>NY-ESO-1/MART-1 Peptide-pulsed Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4167">A cell-based cancer vaccine composed of dendritic cells (DC) pulsed with peptides derived from the tumor-associated antigens human cancer/testis antigen NY-ESO-1 and melanoma antigen recognized by T-cells (MART-1/Melan-A), with potential immunostimulatory and antineoplastic activities. Upon administration, the NY-ESO-1/MART-1-peptide pulsed DC vaccine may stimulate the immune system to mount an anti-tumor cytotoxic T-lymphocyte (CTL) response against NY-ESO-1/MART-1-expressing tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal testes and on the surfaces of various tumor cells. MART-1 is expressed by melanoma cells. (NCIT_C120129).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5428">
		<vaccine_name>NY-ESO-1b Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4543">A recombinant nonapeptide used as an antineoplastic vaccine. NY-ESO-1b peptide vaccine contains the amino acid sequence SLLMWITQC, derived from the cancer-testis tumor antigen (NY-ESO-1), which is expressed on tumor cells of many different types, including melanomas. Vaccination with this peptide vaccine may elicit strong humoral and cellular immune responses to NY-ESO-1-expressing cancers. (NCIT_C68999).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5182">
		<vaccine_name>NY-ESO-B</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4370">A tumor-associated antigen belonging to the family of immunogenic testicular proteins that are aberrantly expressed in human cancers in a lineage-nonspecific fashion. Reverse transcription-PCR analysis showed NY-ESO-1 mRNA expression in a variable proportion of a wide array of human cancers, including melanoma, breast cancer, bladder cancer, prostate cancer, and hepatocellular carcinoma; and restricted expression in normal tissues, with high-level mRNA expression found only in testis and ovary tissues. The gene for NY-ESO-1 maps to Xq28 and codes for an 18-kDa protein having no homology with any known protein. NY-ESO-1 elicits a strong, integrated humoral and cellular immune response in a high proportion of patients with NY-ESO-1-expressing tumors and is under investigation as a cancer immunotherapy agent. (NCIT_C26680).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5475">
		<vaccine_name>Oncolytic Adenovirus Encoding GM-CSF</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4155">A recombinant oncolytic adenovirus encoding the immunohematopoietic cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential antineoplastic activity. Upon administration, the oncolytic adenovirus selectively infects and replicates in tumor cells, which may result in tumor cells lysis. Synergistically, GM-CSF (sargramostim) expressed by the oncolytic adenovirus may promote a cytotoxic T cell response against tumor cells harboring the oncolytic adenovirus, resulting in an immune-mediated tumor cell death. (NCIT_C48412).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5541">
		<vaccine_name>Oncovax-ID/IL-2 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4376">A cancer vaccine consisting of a mixture of a murine lymphoma-derived idiotype and interleukin-2 (IL-2) encapsulated in dimyristoylphosphatidylcholine liposomes. The use of a liposomal carrier confers immunogenicity to the naturally non-immunogenic idiotype. (NCIT_C2783).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5486">
		<vaccine_name>ONYX-015</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4487">An E1B-55kDa-deleted adenovirus that is able to selectively replicate in and lyse TP53-deficient human tumor cells. After tumor cell lysis, released viruses infect neighboring tumor cells, tripping a chain of ONYX-015-mediated tumor cell cytotoxicity. (NCI04) (NCIT_C2830).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5528">
		<vaccine_name>OSE 2101</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4613">A proprietary cancer DNA vaccine that contains multiple natural and modified epitopes derived from the four tumor associated antigens, CEA, HER2/neu, p53, and MAGE 2/3. EP-2101 also includes CAP1-6D, a heteroclitic CEA analog, and PADRE, a proprietary universal T-cell epitope that serves to enhance the immunogenicity of the epitopes. This agent has been shown to elicit cytotoxic T-lymphocyte responses against tumor cells expressing these multiple epitopes. (NCIT_C26645).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5481">
		<vaccine_name>Ovapuldencel-T</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4337">A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with autologous, lethally irradiated cancer cells and mixed with the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon vaccination, ovapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the repertoire of tumor associated antigens (TAAs) found in the irradiated cancer cells. GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes. (NCIT_C113651).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5502">
		<vaccine_name>Ovarian Cancer Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4156">A cancer vaccine comprised of synthetic peptides corresponding to naturally-occurring peptides derived from ovarian cancer cell antigens. Ovarian cancer peptide vaccine may elicit a cytotoxic T-cell response against tumor cells expressing the related ovarian cancer cell antigens. (NCIT_C48414).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5403">
		<vaccine_name>Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4484">A cancer vaccine containing autologous dendritic cells (DCs) that are transfected with mRNAs extracted from amplified ovarian cancer stem cells, and mRNAs of the universal tumor antigens human telomerase reverse transcriptase (hTERT) and survivin with potential immunostimulatory and antineoplastic activities. Upon administration, ovarian cancer stem cell/hTERT/survivin mRNAs-loaded autologous DC-006 vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against ovarian cancer cells expressing hTERT, survivin, and specific ovarian cancer stem cell antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival. Ovarian cancer stem cells contain a specific range of antigens that are essential for the neoplastic growth and survival of ovarian cancer cells. (NCIT_C96739).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5280">
		<vaccine_name>Ovarian Tumor Antigen-activated Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4457">A dendritic cell (DC)-based cancer vaccine composed of autologous dendritic cells (DCs) activated with an ovarian tumor cell lysate containing tumor-associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, the ovarian tumor antigen-activated autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against ovarian cancer cells expressing ovarian tumor cell-specific antigens, which may result in ovarian tumor cell lysis. (NCIT_C115105).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5392">
		<vaccine_name>Ovine Crotalidae Venoms Immune Fab</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5165">
		<vaccine_name>p.DOM-WT1-126 DNA Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4353">A fusion DNA vaccine containing the first domain of fragment C (FrC) of tetanus toxin (TT865-1120) (p.DOM) fused to the human Wilms' Tumor gene-1 (WT1)-derived MHC class I-binding epitope WT1.126, with potential antitumor activity. Upon vaccination with p.DOM-WT1-126 DNA and subsequent electroporation, this vaccine may induce a WT1 epitope-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing cancer cells. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. The FrC of tetanus toxin contains the MHC II-binding sequence, p30, which induces T-helper cell activation for long-lasting immunity. (NCIT_C96738).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5471">
		<vaccine_name>p.DOM-WT1-37 DNA Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4352">A fusion DNA vaccine containing the first domain of fragment C (FrC) of tetanus toxin (TT865-1120) (p.DOM) fused to the human Wilms' Tumor gene-1 (WT1)-derived MHC class I-binding epitope WT1.37, with potential antitumor activity. Upon vaccination with p.DOM-WT1-37 DNA and subsequent electroporation, this vaccine may induce a WT1 epitope-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing cancer cells. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. The FrC of tetanus toxin contains the MHC II-binding sequence, p30, which induces T-helper cell activation for long-lasting immunity. (NCIT_C96737).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5255">
		<vaccine_name>p53 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4462">A peptide-based cancer vaccine composed of amino acids 264 to 272 of the wild-type protein encoded by the P53 gene. p53 peptide vaccine may elicit an HLA-A2.1-restricted cytotoxic T lymphocyte immune response against tumor cells that overexpress p53 protein. (NCI04) (NCIT_C1986).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5278">
		<vaccine_name>P53-Synthetic Long Peptides Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5245">
		<vaccine_name>PA-1-STK Ovarian Carcinoma Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4250">A cell-based cancer vaccine with potential antineoplastic activity. PA-1-STK ovarian carcinoma vaccine is produced by transducing the ovarian cancer cell line, PA-1, with the herpes simplex thymidine kinase (HSV-tk) gene, resulting in a cell line, PA-1-STK, that permanently expresses the HSV tk gene. Upon transfection into malignant cells, this vaccine is capable of sensitizing tumor cells in response to an antiviral drug such as ganciclovir, which is readily phosphorylated by the TK enzyme to its active form. Administration of ganciclovir following PA-1 STK transfection results in enhanced cytotoxicity of the transfected tumor cells. Additionally, adjacent non-transfected cells are also killed by the activated antiviral drug, a phenomenon referred to as the bystander effect that occurs with this type of suicide-gene transfer technique. (NCIT_C2428).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5441">
		<vaccine_name>PADRE-CMV Fusion Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4654">A peptide-based vaccine containing a pan HLA DR-binding epitope (PADRE) fused to a cytomegalovirus (CMV) peptide epitope, with potential anti-viral and immunomodulating activities. Upon administration, PADRE-CMV fusion peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against CMV in the CMV-infected host. The synthetic peptide PADRE is a universal helper T cell epitope. (NCIT_C78820).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5484">
		<vaccine_name>PAX3/FKHR Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4581">A synthetic peptide vaccine based on the sequences of a translocation mutation of 2 transcriptional factor genes, PAX3 and FKHR. PAX3/FKHR fusion proteins are frequently found in patients with rhabdomyosarcomas. Vaccination with PAX3/FKHR peptide may stimulate the host immune response to elicit a cytotoxic T-cell response against tumor cells that express this PAX3/FKHR fusion protein. (NCIT_C49023).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4057">
		<vaccine_name>pcDNA3-MCC/ST</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004615</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference2988">Developed a MCPyV ST-expressing tumor cell line from B16 mouse melanoma cells. The DNA vaccine we generated encoded MCPyV ST aa 1-186 (pcDNA3-MCC/ST (Gomez et al., 2013).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="">MCPyV ST aa 1-186</antigen>
		<host_response host_response_id="host_response1686" host_id="host3">
			<immune_response refs="reference2988">ST-expressing tumor-bearing mice, this vaccine, pcDNA3-MCC/ST, generated a significant number of ST antigenic peptide-specific CD8+ T cells and experienced markedly enhanced survival compared to mice vaccinated with empty vector (Gomez et al., 2013).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5451">
		<vaccine_name>PCLUS 3-18MN</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4511">A synthetic HIV-1 envelope peptide that was developed for use as a vaccine. Vaccination with PCLUS 3-18MN may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) and T helper cell responses, and induce the production of neutralizing antibodies. (NCI04) (NCIT_C2786).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5443">
		<vaccine_name>PCLUS 6.1-18MN</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4510">A synthetic HIV-1 envelope peptide that was developed for use as a vaccine. Vaccination with PCLUS 6.1-18MN may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) and T helper cell responses, and induce the production of neutralizing antibodies. (NCI04) (NCIT_C2787).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine3987">
		<vaccine_name>pCR3.1-VS-HSP65-TP-GRP6-M2</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004609</vo_id>
		<type>anti-GRP DNA</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="">GRP</antigen>
		<host_response host_response_id="host_response1647" host_id="host2">
			<immune_response refs="reference2355">inhibition of the proliferation of B16-F10 cells invading the lungs and suppression of tumor-associated angiogenesis, downregulation of PKC, resulting in antimetastatic effects, upregulation of wild-type p53, leading to the induction of apoptosis of B16-F10, which has very low levels of endogenous p53, or antigenic epitopes in degenerating B16-F10 cells engulfed by immune-activated antigen-presenting cells could be presented to cytotoxic T lymphocytes, leading to a potent immune response against the remaining tumor cells (Fang et al., 2009).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5480">
		<vaccine_name>PEP-3-KLH Conjugate Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4240">A cancer vaccine consisting of PEP-3, a synthetic peptide encompassing a tumor-specific mutated segment of the epidermal growth factor receptor type vIII (EGFRvIII), conjugated to the naturally-occurring immunoadjuvant keyhole limpet hemocyanin (KLH) with potential immunostimulating and antineoplastic activities. Upon administration, PEP-3-KLH conjugate vaccine may induce a cytotoxic immune response against tumor cells that overexpress EGFRvIII; this antitumoral immune response may involve antibody-dependent cellular cytotoxicity (ADCC). (NCIT_C74070).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5259">
		<vaccine_name>PEP-CMV Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5348">
		<vaccine_name>Personalized Synthetic Long Peptide Breast Cancer Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4232">A cancer vaccine consisting of one or more long, synthetic peptides derived from patient-specific breast cancer tumor-associated antigens (TAAs), with potential immunomodulating and antineoplastic activities. Upon intramuscular administration of the personalized synthetic long peptide breast cancer vaccine, the peptides stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TAAs, which results in tumor cell lysis. (NCIT_C121947).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5078">
		<vaccine_name>Pexastimogene-devacirepvec</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4153">A thymidine kinase-deleted vaccinia virus expressing human GM-CSF (hGM-CSF) with oncolytic activity. Upon intratumoral or intravenous administration, pexastimogene-devacirepvec may selectively infect and lyse tumor cells. While vaccinia displays a natural tumor cell tropism, deletion of the thymidine kinase gene increases the tumor selectivity of vaccinia by limiting viral replication to transformed cells. hGM-CSF expression by this agent may help recruit antigen processing cells (APCs), such as denritic cells and macrophages, to virally infected tumor cells, initiating a systemic antitumoral immune response. (NCIT_C71533).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs="reference2972">(Aarntzen et al., 2012) hGM-CSF ID:1437</antigen>

		<gene_engineering gene_engineering_id="gene_engineering1848" gene_id="gene4411">
			<type>Recombinant protein preparation</type>
			<description refs="">[gene ID: 1437]  CSF2 colony stimulating factor 2 [ Homo sapiens (human) ]</description>
		</gene_engineering>
	</vaccine>
	<vaccine vaccine_id="vaccine5032">
		<vaccine_name>PF-04948568</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5006">
		<vaccine_name>Plasmacytoid Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4557">A whole cell vaccine derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology that exhibits immunomodulating activity. Plasmacytoid dendritic cells (pDCs) express a characteristic set of surface markers, such as CD123 (interleukin-3 receptor alpha chain), BDCA-2 (blood dendritic cell antigen 2; CD303) and BDCA-4 (CD304), as well as intracellular toll-like receptors 7 and 9. Upon stimulation, the activated pDCs produce substantial amounts of interferon (IFN) alpha, and to a lesser degree IFN-beta, as well as other cytokines and chemokines, such as tumor necrosis factor alpha and interleukins 1, 6 and 8. In addition, these pDCs, directly or indirectly stimulate T-cells, B-cells and natural killer cells. This may potentially lead to increased immunity against tumor cells. (NCIT_C103192).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5381">
		<vaccine_name>Pneumococcal Conjugate Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4513">An active immunizing vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. It consists of a solution of saccharides of the capsular antigens of Streptococcus serotypes individually conjugated to proteins. (NCIT_C97123).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5071">
		<vaccine_name>Pneumococcal Polyvalent Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4454">An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years. (NCIT_C1643).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5040">
		<vaccine_name>pNGVL3-hICD Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4626">A plasmid DNA cancer vaccine encoding the intracellular domain (ICD) of the HER-2/neu proto-oncogene. Upon administration and after cellular uptake by skin or muscle cells, the pNGVL3-hICD vaccine plasmid expresses the HER-2/neu protein, which, after intracellular processing, may elicit both antigen-specific cytotoxic T-lymphocyte (CTL) and humoral immune responses against tumor cells expressing HER-2. The HER-2/neu ICD protein is highly immunogenic and, as a subdominant epitope, may be associated with decreased immune tolerance. (NCIT_C61146).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5011">
		<vaccine_name>pNGVL4a-CRT/E7(detox) DNA Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4309">A cancer vaccine consisting of the DNA plasmid pNGVL4a-A encoding calreticulin (CRT) linked to a detox form of human papillomavirus (HPV) type 16 E7 antigen, with potential immunomodulating and antineoplastic activities. Upon administration, this vaccine may generate a potent cytotoxic T-lymphocyte (CTL) response against E7-expressing tumor cells, resulting in tumor cell death. For E7(detox), the amino acids in E7 at positions 24 (cysteine to glycine) and 26 (glutamic acid to glycine) were substituted. CRT, a 46 kDa protein located in the lumen of the cell's endoplasmic reticulum (ER), may potentiate MHC class I presentation of HPV-16 E7 to E7-specific CD8-positive T cells. In addition, pNGVL4a-A contains two short immunostimulatory DNA sequences (ISS) in the noncoding region, which may elicit the production of IFN- and IL-12 in transfected keratinocytes and dermal antigen presenting cells (APCs), resulting in a potent T helper cell type 1 response. (NCIT_C88289).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5069">
		<vaccine_name>pNGVL4a-Sig/E7(detox)/HSP70 DNA Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4343">An antigen-specific DNA cancer vaccine consisting of the coding sequences of a signal peptide (pNGVL4a-Sig), a detox form of the human papillomavirus type 16 (HPV-16) antigen E7, and the heat shock protein 70 (HSP70). Upon administration, this vaccine may generate potent cytotoxic CD8(+) T-cell responses against E7-expressing tumor cells, resulting in tumor cell death. (NCIT_C48418).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4190">
		<vaccine_name>Poliovirus vector expressing model antigen H2-Kb-restricted CTL epitope</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004705</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3227">A segment of the chicken ovalbumin gene, which includes the H2-Kb-restricted CTL epitope SIINFEKL, was cloned at the junction of the P1 and P2 regions (Mandl et al., 1998).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1714" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3227">Transgenic mice expressing the PVR (26) were infected i.p. with 100 Î¼l of 5 Ã— 10^5 pfu of the recombinant viruses in PBS solution. The mice also received 2â€“3 booster shots of 1 Ã— 10^6 of the same virus (Mandl et al., 1998).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3227">Inoculation of mice with recombinant poliovirus that expresses ovalbumin elicits an effective specific CTL response. Vaccination with the recombinant poliovirus expressing H2-Kb-restricted CTL epitope SIINFEKL of ovalbumin induced protective immunity against challenge with lethal doses of a malignant melanoma cell line expressing ovalbumin (Mandl et al., 1998).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3227">Mice were challenged by s.c. injection of 1 Ã— 10^5 Ova expressing or parental B16F0 melanoma cells in 100 Î¼l of PBS (Mandl et al., 1998).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5176">
		<vaccine_name>Poly Microsphere Encapsulated HER2/neu Oral Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4529">A cancer vaccine consisting of Her2/neu peptides incorporated into microspheres of poly (lactide-co-glycolide) (PLGA), a biodegradable polymer. Poly microsphere encapsulated HER2/neu oral vaccine has been investigated for use in immunotherapy for tumors positive for HER-2/neu, a tumor associated antigen that is overexpressed in various cancers, including breast and ovarian cancer. (NCIT_C2718).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5272">
		<vaccine_name>PR-151 Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4190">A tumor-specific peptide encoded by patient-specific mutant p53 oncogene with potential immunostimulatory properties. The peptide (LPTGQDL) contains a frame shift mutation at amino acid position 134. It was used to pulse dendritic cells, which are then used in the adoptive immunotherapy setting and may stimulate the host immune system to mount a specific cytotoxic T lymphocyte response against tumor cells expressing the p35 mutation. (NCIT_C38121).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5140">
		<vaccine_name>PR1 Leukemia Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5205">
		<vaccine_name>Primary Prostate Cancer Tissue/hTERT/Survivin mRNA-loaded Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4604">An autologous dendritic cells (DCs) vaccine targeting prostate cancer with immunostimulating activity. The autologous DC vaccine is prepared via transfecting DCs with mRNAs extracted from primary prostate cancer tissue, and mRNAs of human telomerase reverse transcriptase (hTERT) and survivin. Upon administration, this DC vaccine may elicit a potent cytotoxic T-cell (CTL) response against prostate cancer cells, resulting in tumor cell death. Both hTERT and survivin are essential in neoplastic growth, and are considered to be universal tumor antigens. (NCIT_C95771).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4074">
		<vaccine_name>prime/boost DC-TRP-2 melanoma vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Dendritic cell-based vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs="reference3005">Prime/boost vaccination proved to be of no advantage or even detrimental in therapeutic settings in B16F1 and transgenic adenocarcinoma of the mouse prostate (TRAMP) models, respectively (Ricupito et al., 2013).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3005">assessing the ability of dendritic cell (DC)-based vaccines to induce a long-lasting tumor-specific CTL response in either prophylactic or therapeutic settings by taking advantage of transplantable and spontaneous mouse tumor models(Ricupito et al., 2013).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1699" host_id="host3">
			<immune_response refs="reference3005">DC-based vaccine induced a long-lasting CTL response in wild-type mice, and homologous boosting better sustained the pool of central memory T cells, a tight boosting schedule hindered persistence of IFN-Î³-competent memory CD8(+) T cells and mice survival in prophylactic settings (Ricupito et al., 2013).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3745">
		<vaccine_name>Prostate cancer DNA vaccine encoding PSCA</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004451</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcDNA3 prime, Venezuelan equine encephalitis virus replicons boost [Ref2376:Garcia-Hernandez et al., 2008]</vector>
		<route>Gene gun</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Gene gun</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1261" gene_id="gene1349">
			<type>DNA vaccine construction</type>
			<description refs="reference2376">Vector pcDNA3 expressed prostate stem cell antigen (PSCA) (Garcia-Hernandez et al., 2008).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1484" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2376">Eight-week-old TRAMP mice displaying prostate intraepithelial neoplasia were vaccinated with a heterologous prime/boost strategy consisting of gene gun-delivered PSCA-cDNA followed by Venezuelan equine encephalitis virus replicons encoding PSCA.  PSCA-vaccinated TRAMP mice had a 90% survival rate at 12 months of age. In contrast, all control mice had succumbed to prostate cancer or had heavy tumor loads (Garcia-Hernandez et al., 2008).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3737">
		<vaccine_name>Prostate cancer DNA vaccine hPSMAt encoding PSMA</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004446</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pVAX1</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1253" gene_id="gene1303">
			<type>DNA vaccine construction</type>
			<description refs="reference2371">Vector pVAX1 expressed human prostate-specific membrane antigen, PSMA (Mincheff et al., 2006).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1479" host_id="host4">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2371">Only two of the 10 animals immunized against human PSMA developed tumors. In contrast, 17 of the 20 animals in the control groups developed tumors. The tumors, developing in the group, immunized with the human construct, were smaller than the ones in the control group (Mincheff et al., 2006).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3736">
		<vaccine_name>Prostate cancer DNA vaccine pcDNA3-STEAP encoding six-transmembrane epithelial antigen</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004445</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcDNA3 prime, Venezuelan equine encephalitis virus-like replicon particles boost [Ref2386:Garcia-Hernandez et al., 2007]</vector>
		<route>subcutaneous injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">subcutaneous injection</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1252" gene_id="gene1346">
			<type>DNA vaccine construction</type>
			<description refs="reference2386">Vector pcDNA3 expressed six-transmembrane epithelial antigen of the prostate (Garcia-Hernandez et al., 2007).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1478" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2386">Survival was significantly prolonged in mice vaccinated with mSTEAP using DNA, VRP (Venezuelan equine encephalitis virus-like replicon particles), or a combined strategy after tumor challenge compared with control mice. Although all STEAP-based vaccination strategies significantly slowed tumor growth in tumor-challenged mice, DNA vaccination followed by boosting with VRP was the most effective way of inducing protective immunity (Garcia-Hernandez et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3746">
		<vaccine_name>Prostate cancer DNA vaccine pmPSCA encoding PSCA</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004452</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pIRES2 DsRed2 [Ref2377:Ahmad et al., 2009]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1262" gene_id="gene1349">
			<type>DNA vaccine construction</type>
			<description refs="reference2377">Vector pIRES2 DsRed2 expressed murine prostate stem cell antigen (PSCA) (Ahmad et al., 2009).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1485" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2377">These experiments demonstrated 37% relative risk reduction of tumor development in the pmPSCA group, but importantly vaccinated tumor bearing mice also had significantly less tumor burden than the control groups. Tumor growth kinetics indicated slower tumor growth in the pmPSCA treated group (versus empty vector P = 0.04, versus untreated P = 0.01). These results demonstrated that the pmPSCA could provide either complete protection or result in containment of the disease (Ahmad et al., 2009).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3744">
		<vaccine_name>Prostate cancer DNA vaccine PSCA-HSP encoding PSCA and HSP</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004450</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcDNA3.1(+) [Ref2375:Zhang et al., 2007]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1259" gene_id="gene1350">
			<type>DNA vaccine construction</type>
			<description refs="reference2375">Vector pcDNA3.1(+) expressed heat shock proteins (Zhang et al., 2007).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1260" gene_id="gene1349">
			<type>DNA vaccine construction</type>
			<description refs="reference2375">Vector pcDNA3.1(+) expressed prostate stem cell antigen (PSCA) (Zhang et al., 2007).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1483" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2375">The growth of RM-PSCA tumors was significantly slower in the groups vaccinated with PSCA-HSP, HSP-PSCA, and PSCA + HSP plasmids compared with that in the groups treated with PBS or pcDNA-HSP (P &lt; 0.05).  Furthermore, the survival time of mice vaccinated with PSCA-HSP (range 40â€“69 days) was significantly longer as compared with that of groups injected with HSP-PSCA and PSCA + HSP plasmids (P = 0.016 and P = 0.015, respectively) (Zhang et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3742">
		<vaccine_name>Prostate cancer DNA vaccine psig-3P-Fc encoding 3P(hPSM, hPAP, or hPSA)-Fc fusion protein</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004449</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcDNA3 [Ref2373:Qin et al., 2005]</vector>
		<route>Gene gun</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Gene gun</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1520" gene_id="gene1303">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1521" gene_id="gene1352">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1522" gene_id="gene1334">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1523" gene_id="gene1688">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1482" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2373">Vaccination with psig-3P-Fc by gene gun inoculation induced strong antitumor response in a mouse tumor model, which significantly inhibited tumor growth and prolonged survival time of the tumor-bearing mice (Qin et al., 2005).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3740">
		<vaccine_name>Prostate cancer DNA vaccine pVax-PSA</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004448</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pVAX1 [Ref2372:Roos et al., 2005]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference2372">IL-2 and/or GM-CSF (Roos et al., 2005)</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1256" gene_id="gene1348">
			<type>DNA vaccine construction</type>
			<description refs="reference2372">Vector pVAX1 expressed prostate -specific antigen (Roos et al., 2005).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1481" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2372">The pVax-PSA vaccine alone protected 40% of the mice from tumor growth. When either of the cytokine adjuvants (IL-2 or GM-CSF) was co-administered 60% of the mice were protected and when both adjuvants were simultaneously co-administered 80% of the mice were protected.  All groups of mice that received the vaccine pVax-PSA (with or without cytokine adjuvants) were significantly different from the control group pVax (P &lt; 0.01) (Roos et al., 2005).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3738">
		<vaccine_name>Prostate cancer DNA vaccine rPSMAt encoding PSMA</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004447</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pVAX1 [Ref2371:Mincheff et al., 2006]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1254" gene_id="gene1347">
			<type>DNA vaccine construction</type>
			<description refs="reference2371">Vector pVAX1 expressed rat prostate-specific membrane antigen, PSMA (Mincheff et al., 2006).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1480" host_id="host4">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2371">Only five of the 10 animals immunized against the rat analogue developed tumors. In contrast, 17 of the 20 animals in the control groups developed tumors. The tumors developing in the group immunized with the rat construct were smaller than the ones in the control group (Mincheff et al., 2006).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5351">
		<vaccine_name>Prostate Cancer Vaccine ONY-P1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4652">A cell-based vaccine derived from prostate cancer with potential immunopotentiating and antineoplastic activities. Prostate cancer vaccine ONY-P1 is derived from three irradiated allogeneic prostate cancer cell lines that represent different stages of prostate cancer and express a broad range of prostate and prostate cancer antigens. Upon administration, this vaccine may stimulate a host immune response against prostate cancer cells; in the vaccination schedule, the first two vaccinations are co-administered with bacillus Calmette-Guerin (BCG) as an adjuvant. (NCIT_C71723).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5132">
		<vaccine_name>Prostate Tumor Antigen-activated Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4460">A dendritic cell (DC)-based cancer vaccine composed of autologous dendritic cells (DCs) activated with a prostate tumor cell lysate containing tumor-associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, the prostate tumor antigen-activated autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against prostate cancer cells expressing prostate tumor cell-specific antigens, which may result in prostate tumor cell lysis. (NCIT_C115106).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5260">
		<vaccine_name>PROSTVAC-Contaminated W/ BVDV</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4234">A vaccinia virus carrying a copy of the human gene encoding prostate-specific antigen (PSA), contaminated with bovine viral diarrhea virus (BVDV). (NCIT_C29334).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5087">
		<vaccine_name>PSA Prostate Cancer Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4273">A peptide vaccine containing the prostate specific antigen (PSA) with potential antineoplastic activity. PSA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed in prostate cancer cells and is used as a tumor marker for both diagnosis and treatment evaluation. Vaccination with PSA peptide vaccine may produce anti-PSA antibodies as well as elicit a cytotoxic T-cell (CTL) response against prostate cancer cells expressing this antigen, thereby decreasing tumor cell growth. (NCIT_C2497).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5022">
		<vaccine_name>PSA RNA-Pulsed Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4517">An autologous dendritic cell vaccine with potential immunostimulatory activity. Dendritic cells harvested from a prostate cancer patient are transfected with the mRNA encoding for prostate specific antigen (PSA), a tumor marker secreted by prostatic epithelial and ductal cells. When reintroduced back to the patient, these PSA RNA pulsed autologous dendritic cells may elicit a cytotoxic T-cell (CTL) response against PSA-positive prostate cancer cells. (NCIT_C2236).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5234">
		<vaccine_name>PSA-OP Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5353">
		<vaccine_name>PSA-PAP/KLH-pulsed Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4207">A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with the prostate-specific tumor associated antigens (TAAs) prostate specific antigen (PSA) and prostate acid phosphatase (PAP), and conjugated to the immunostimulant Keyhole limpet hemocyanin (KLH), with potential immunostimulatory and antineoplastic activities. Upon administration, prostate cancer antigen/KLH-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against prostate cancer cells expressing PSA and PAP, which may result in prostate cancer cell lysis. KLH is an immunogenic carrier and serves as an immunostimulant to improve antigenic immune recognition and T-cell responses and can be used to evaluate vaccine efficacy. (NCIT_C92573).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5109">
		<vaccine_name>PSA/IL-2/GM-CSF Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4660">A prostate cancer vaccine containing prostate specific antigen (PSA) combined with the cytokines, interleukin-2 (IL-2) and granulocyte macrophage-colony-stimulating factor (GM-CSF), with potential antineoplastic activity. Upon intradermal vaccination, PSA/IL-2/GM-CSF vaccine may activate the immune system to induce a cytotoxic T-cell (CTL) response against prostate cancer cells expressing this antigen, thereby decreasing tumor cell growth. PSA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed by prostate cancer cells. IL-2 stimulates natural killer (NK) cells and cytotoxic T-cells against the PSA-expressing tumor cells. GM-CSF promotes antigen presentation to dendritic cells and further stimulates a tumor-specific cytotoxic T-lymphocyte (CTL) response. (NCIT_C114289).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5252">
		<vaccine_name>PSA/PSMA DNA Plasmid INO-5150</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4514">A plasmid DNA vaccine encoding the tumor-associated antigens (TAAs) prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA), with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery and electroporation of the PSA/PSMA DNA plasmid INO-5150, both PSA and PSMA are translated in cells which then activate the immune system. This induces cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing PSA and PSMA. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation. PSA and PSMA are overexpressed on a variety of cancer cell types. The DNA encoding the TAAs in INO-5150 is based on both human and other primate antigen gene sequences. As the plasmid genes differ from the human gene sequences encoding these antigens, INO-5150 may overcome immune tolerance to human TAAs. (NCIT_C123283).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5106">
		<vaccine_name>PSA:154-163 Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4131">A synthetic peptide based on sequence corresponding to positions 154-163 of the amino acids of prostate-specific antigen (PSA), VISNDVCAQV. Upon administration, PSA:154-163 peptide vaccine may elicit a cytotoxic T-cell response against tumor cells that express PSA. (NCIT_C2798).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5155">
		<vaccine_name>PSA:154-163(155L) Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5052">
		<vaccine_name>PSMA/TARP Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4544">A peptide-based cancer vaccine containing epitopes of T cell receptor gamma-chain alternate reading frame protein (TARP) and prostate-specific membrane antigen (PSMA) in combination with a Poly IC-LC immunoadjuvant, with potential antineoplastic activity. Upon administration, PSMA/TARP peptide vaccine may stimulate a host cytotoxic T-cell (CTL) response against TARP- and PSMA-expressing tumor cells, resulting in tumor cell cytotoxicity. The nuclear protein TARP and PSMA are commonly expressed in prostate cancer cells. (NCIT_C78819).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5535">
		<vaccine_name>pTVG-HP Plasmid DNA Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4521">A cancer vaccine containing plasmid DNA encoding human prostatic acid phosphatase (PAP) (pTVG-HP) with potential immunostimulatory and antineoplastic activities. Upon administration, pTVG-HP plasmid DNA vaccine may stimulate the host immune system to generate a cytotoxic T lymphocyte (CTL) response against PAP-expressing prostate cancer cells. PAP or prostatic specific acid phosphatase (PSAP) is a tumor associated antigen (TAA) that may be overexpressed in prostate cancer. (NCIT_C82407).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5365">
		<vaccine_name>pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4375">A recombinant plasmid DNA vaccine containing mammalian expression vector, pUMVC3, encoding epitopes of human Insulin-Like Growth Factor-Binding Protein 2 (hIGFBP-2) with potential antineoplastic activity. Upon vaccination, pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine may produce IGFBP-2 that binds to cell surface, likely via integrin complexes. This results in the dephosphorylation of the focal adhesion-kinase (FAK) and of the p42/44 MAP-kinases, thereby inactivating them; both kinases are involved in cell growth regulation. Furthermore, IGFBP-2 promotes de-adhesion of the cells in a dose-dependent manner, hence impeding cell proliferation. The primary effect of IGFBPs appears to be modulation of IGF activity and control of IGF-mediated cell growth and metabolism. (NCIT_C95727).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5092">
		<vaccine_name>pVAXrcPSAv53l DNA Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4212">A cancer vaccine containing xenogenic DNA from rhesus macaque (Macaca mulatta) that encodes prostate specific antigen (PSA) with potential immunostimulating and antineoplastic activities. Upon repeated intradermal administration via electroporation, pVAXrcPSAv53l vaccine may induce a cytotoxic T-lymphocyte (CTL) response against PSA-expressing prostate cancer cells. Rhesus PSA is 89% homologous to human PSA. (NCIT_C82352).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5406">
		<vaccine_name>Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4193">A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) types 6, 11, 16, and 18 with immunoprophylactic activity. L1 proteins are produced by separate fermentations in recombinant Saccharomyces cerevisiae, self-assembled into VLPs, and adsorbed onto amorphous aluminium hydroxyphosphate sulfate adjuvant following purification. The immunoprophylactic efficacy of L1 VLP vaccines, such as quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine, appear to be mediated by the development of humoral immune responses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts. (NCIT_C61087).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5201">
		<vaccine_name>Racotumomab</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4600">An anti-idiotype murine monoclonal antibody (MoAb) specific to P3 MoAb with anti-metastatic effect. Racotumomab binds to the idiotype region of P3 MoAb and functionally mimics the three-dimensional structure of N-glycolyl ceramides of mono-sialyl lactose, the antigenic target of P3. As a result, this anti-idiotype antibody may stimulate the host immune system to elicit humoral and cellular immune responses against tumor cells expressing NeuGc-GM3 gangliosides, which are expressed in a wide variety of tumor cells. (NCIT_C95024).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5320">
		<vaccine_name>RAS Peptide Cancer Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4642">A cancer vaccine containing a RAS oncogene-encoded peptide with potential antineoplastic activity. RAS peptide cancer vaccine may stimulate a RAS peptide-specific antitumoral T-cell cytotoxic immune response, resulting in an inhibition of tumor cell proliferation and tumor cell death. (NCI04) (NCIT_C2438).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5504">
		<vaccine_name>RASVAC-C</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4451">A synthetic vaccine used for cancer immunotherapy also known as Ras(cis 12)-Vaccinia Vaccine, RASVAC-C is based on a mutant peptide epitope of the Ras oncoprotein at codon 12 that induces recognition and induction of tumor-specific, cell-mediated immune responses. Ras is an intracellular GTP-binding protein involved in signal transduction and regulation of proliferation and differentiation. (NCIT_C29401).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5497">
		<vaccine_name>RASVAC-V</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4448">A synthetic vaccine used for cancer immunotherapy also known as Ras(val 12)-Vaccinia Vaccine, RASVAC-C is based on a mutant peptide epitope of the Ras oncoprotein at codon 12 (valine instead of glycine) that induces recognition and induction of tumor-specific, cell-mediated immune responses. Ras is an intracellular GTP-binding protein involved in signal transduction and regulation of proliferation and differentiation. (NCIT_C29402).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5044">
		<vaccine_name>RCAS-Akt</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4603">A recombinant retroviral virus derived from SR-A strain of Rous sarcoma virus carrying a constitutively active form of the AKT Gene. The viral vector RCAS harbors a Replication Competent ALV Splice acceptor. This recombinant virus was use in animal model to study gliomagenesis. (NCIT_C29908).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5500">
		<vaccine_name>RCAS-Ras</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4633">A recombinant retroviral virus derived from SR-A strain of Rous sarcoma virus carrying a human gene encoding the G12D mutant form of K-Ras. The viral vector, RCAS harbors a Replication Competent ALV Splice acceptor. This recombinant virus was use in animal model to study gliomagenesis. (NCIT_C29910).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5397">
		<vaccine_name>Recombinant Adenovirus 5 Encoding Tumor Necrosis Factor-related Apoptosis-Inducing Ligand</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4316">An adenovirus type 5 (Ad5) encoding human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), with potential apoptosis-inducing and antineoplastic activities. Upon administration of recombinant Ad5 encoding TRAIL, the adenovirus selectively infects tumor cells and expresses TRAIL. The virally expressed TRAIL binds to and activates its receptors TRAIL receptor-1 (TRAIL-R1, death receptor 4, DR4) and TRAIL receptor-2 (TRAIL-R2, death receptor 5, DR5), which subsequently activate caspases and induce apoptosis in TRAIL-R1/R2-expressing tumor cells. The pro-apoptotic cell surface receptors TRAIL-R1 and -R2, members of the TNF receptor family, are overexpressed by a variety of cancer cell types. (NCIT_C116879).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5530">
		<vaccine_name>Recombinant Adenovirus-Cre Recombinase</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5510">
		<vaccine_name>Recombinant Adenovirus-hIFN-beta</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4368">A recombinant replication-defective adenovirus which encodes the gene for the cytokine human interferon-beta (IFN-beta). Once inserted into and replicating in host tumor cells, recombinant adenovirus-hIFN-beta expresses human IFN-beta, which may stimulate an antiproliferative natural killer (NK) cell response against tumor cells and induce caspase-mediated tumor cell apoptosis. (NCI04) (NCIT_C28550).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5047">
		<vaccine_name>Recombinant Adenovirus-Interferon/Syn3</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4573">A non-replicating recombinant adenovirus type 5 (Ad5)-vector encoding the gene for interferon alpha-2b (IFN alpha-2b) and the gene transfer enhancement agent Syn 3, with potential antineoplastic activity. Upon intravesical administration, recombinant adenovirus-interferon with Syn3 transfects both cancerous and normal bladder cells, and the adenovirus secretes interferon (IFN alpha-2b) into the bladder. IFN exerts a direct antitumor killing effect and a bystander effect, thereby killing adjacent, non-transfected cancerous bladder cells. Syn 3 enhances the ability of the adenoviral vector to transfect cells. (NCIT_C104743).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5074">
		<vaccine_name>Recombinant Adenovirus-L523S Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4619">A replication-defective adenovirus containing a gene that encodes the human protein L523S with potential antineoplastic activity. Upon administration, recombinant adenovirus-L523S vaccine expresses L523S, which may stimulate antibody and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing L523S. L523S is an RNA-binding protein that belongs to the KOC (K homology domain containing protein over-expressed in cancer) family of proteins. As an oncofetal protein, L523S is normally expressed in early embryonic tissues and certain normal adult tissues such as colon, fallopian tube, gall bladder, and ovary tissues but may be overexpressed in squamous cell cancers of the lung. (NCIT_C49289).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5192">
		<vaccine_name>Recombinant Adenovirus-LacZ</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5470">
		<vaccine_name>Recombinant Adenovirus-p53 SCH-58500</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4245">A genetically-engineered adenovirus that contains the gene that encodes the human tumor-suppressor protein p53 with potential antineoplastic activity. Recombinant adenovirus-p53 SCH-58500 delivers p53 into tumor cells, which may result in p53-mediated cell cycle arrest and apoptosis. (NCIT_C2423).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5297">
		<vaccine_name>Recombinant Anti-WT1 Immunotherapeutic GSK2302024A</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4623">An immunotherapeutic composed of the Wilms tumor 1 (WT1) and an as of yet undisclosed adjuvant, with potential antineoplastic activity. Upon administration, the immune system may be stimulated to exert a cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells. The adjuvant stimulates the immune system's response to WT1. WT1, a tumor-associated antigen (TAA) and transcription factor, is overexpressed in a variety of tumor cell types. (NCIT_C116880).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine3074">
		<vaccine_name>Recombinant Colorectal cancer antigen GA733 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004245</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>subcutaneous injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">subcutaneous injection</route>
		<antigen refs="reference1900">Recombinant GA733-2 Ag (Basak et al., 2000).</antigen>
		<host_response host_response_id="host_response904" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference1900">BALB/c mice were immunized s.c. with BV GA733-2F (full-length) proteins (25 Î¼g) in theramide adjuvant (25 Î¼g), 3Ã— at 3-week intervals (Basak et al., 2000).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1900">1 out of 7 mice was tumor free after immunization and challenge with tumor cells (Basak et al., 2000).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1900">Seventeen days after the last immunization mice were challenged with 2.5 Ã— 10^7 CT26-GA733 tumor cells (Basak et al., 2000).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5241">
		<vaccine_name>Recombinant dHER2 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4422">A cancer vaccine consisting of a truncated recombinant HER2 peptide (dHER2) with potential antineoplastic activity. Upon administration, recombinant dHER2 vaccine may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against tumor cells that overexpress the HER2 protein, resulting in tumor cell lysis. The HER2 protein is a tumor-associated antigen (TAA) that is overexpressed in a variety of cancers. dHER2 includes the extracellular domain (ECD) and a part of the intracellular domain (ICD) of the HER2 protein. (NCIT_C49177).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5156">
		<vaccine_name>Recombinant DNA-L523S Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4224">A plasmid DNA encoding human L523S, an RNA-binding protein that belongs to the KOC (K homology domain containing protein overexpressed in cancer) family, with potential antineoplastic activity. Vaccination with L523S DNA may stimulate a cytotoxic T lymphocytes (CTL) response against tumor cells that express the L523S protein. As an oncofetal protein, L523S is normally expressed in early embryonic tissue, but is overexpressed in certain cancer cell types. (NCIT_C49290).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4994">
		<vaccine_name>Recombinant Fowlpox GM-CSF Vaccine Adjuvant</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4349">A cancer vaccine adjuvant consisting of a recombinant fowlpox virus encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF binds to specific cell surface receptors on various immuno-hematopoietic cell types, enhancing their proliferation and differentiation and stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Administration of recombinant fowlpox GM-CSF vaccine adjuvant may induce an immune response against tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. (NCIT_C2686).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5424">
		<vaccine_name>Recombinant Fowlpox-B7.1 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5049">
		<vaccine_name>Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4502">A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the carcinoembryonic antigen (CEA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). This agent may enhance CEA presentation to antigen presenting cells (APC) and activate cytotoxic T-cells against CEA-expressing tumors. (NCI04) (NCIT_C2620).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5274">
		<vaccine_name>Recombinant Fowlpox-gp100p209</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4412">A viral vaccine comprised of a recombinant fowlpox vector construct encoding a modified epitope of the melanoma antigen glycoprotein 100 (gp100), ES-2092M(gp100), containing an endoplasmic reticulum signal sequence targeted to the endoplasmic reticulum apparatus. Vaccination with recombinant fowlpox-gp100p209 vaccine may stimulate the host immune system more efficiently to mount a cytotoxic T lymphocyte response against tumor cells expressing the gp100 antigen. (NCIT_C2806).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5499">
		<vaccine_name>Recombinant Fowlpox-Mgp100 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4411">A vaccine consisting of a replication-defective recombinant fowlpox virus that encodes for the murine melanoma antigen glycoprotein 100 (mgp100) with potential antineoplastic activity. Vaccination with recombinant fowlpox-mgp100 vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth. (NCI04) (NCIT_C2805).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4988">
		<vaccine_name>Recombinant Fowlpox-Prostate Specific Antigen Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4286">A cancer vaccine consisting of a recombinant fowlpox virus encoding human prostate-specific antigen (PSA). Administration of this agent may stimulate a cytotoxic T cell response against PSA-expressing tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. (NCI04) (NCIT_C2675).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5434">
		<vaccine_name>Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4446">A cancer vaccine consisting of a recombinant fowlpox virus encoding fragment of human prostate-specific antigen (PSA), PSA:154-163 (155L), and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). Administration of this agent may induce a cytotoxic T cell response against PSA-expressing tumor cells. Dendritic cells infected with TRICOM vectors greatly enhance naive T-cell activation and peptide-specific T-cell stimulation. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. (NCIT_C29560).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5253">
		<vaccine_name>Recombinant Fowlpox-TRICOM Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4430"> A vaccine comprised of a recombinant fowlpox virus vector encoding a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM), which may enhance antigen presentation and activate cytotoxic T-cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. (NCI04) (NCIT_C2667).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5518">
		<vaccine_name>Recombinant Fowlpox-Tyrosinase Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4304">A recombinant fowlpox virus vaccine with potential antineoplastic activity. Binding to the melanoma antigen tyrosinase, recombinant fowlpox-tyrosinase vaccine generates cellular immune responses against melanoma cells expressing the tyrosinase antigen; this effect is enhanced by the co-administration of interleukin 2 (IL-2). Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. (NCIT_C2807).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5190">
		<vaccine_name>Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4393">A peptide vaccine preparation, containing recombinant human epidermal growth factor (rEGF) linked to the Neisseria meningitidis-derived recombinant immunogenic carrier protein P64k (rP64k) and mixed with the immunoadjuvant Montanide ISA 51, with potential active immunotherapy activity. Recombinant human EGF-rP64K/Montanide ISA 51 vaccine may trigger a humoral immune response against vaccine rEGF and rP64K and, so, against endogenous EGF. Antibody-mediated inhibition of endogenous EGF binding to its receptor, epithelial growth factor receptor (EGFR), may result in the inhibition of tumor cell proliferation. (NCIT_C70674).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5219">
		<vaccine_name>Recombinant Human Fusion Protein L19TNFalpha</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4565">An immunocytokine consisting of human pro-inflammatory cytokine tumor necrosis factor alpha (TNFalpha) fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), with potential immunopotentiating and antineoplastic activities. The L19 moiety of recombinant human fusion protein L19TNFalpha binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the TNFalpha moiety may locally induce an immune response against ED-B fibronectin-expressing tumor cells and may specifically decrease the proliferation of ED-B-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth. (NCIT_C94210).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5359">
		<vaccine_name>Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4428">A recombinant chaperone-peptide complex-based vaccine composed of a complex between heat shock protein hsp110 and the human melanoma-associated antigen gp100, with potential antineoplastic activity. Upon vaccination, recombinant hsp110-gp100 chaperone complex activates the immune system to exert a cytotoxic T cell immune response and antigen-specific interferon-gamma production against gp100-overexpressing cancer cells. Gp100, is overexpressed in a variety of cancer cell types. Hsp110, binds to and chaperones full-length proteins during heat shock; as an immunoadjuvant it is able to enhance an immune response against antigen(s) and stimulate T-lymphocyte activation. (NCIT_C103830).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5077">
		<vaccine_name>Recombinant Human MUC1-Oxidized Polymannose-pulsed Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4542">A cancer vaccine containing autologous dendritic cells pulsed with a fusion product of an epitope of human tumor-associated epithelial mucin 1 (MUC1) antigen and the vaccine adjuvant mannan (oxidized mannose), with potential antineoplastic activity. When the modified dendritic cells are returned to the patient, they may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the MUC1 antigen, resulting in tumor cell lysis. Addition of manna in this vaccine, enhances immune recognition. MUC1 antigen, a high-molecular-weight transmembrane glycoprotein, is overexpressed on many tumor cells. (NCIT_C102782).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5342">
		<vaccine_name>Recombinant Human Papillomavirus Nonavalent Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4584">A non-infectious, recombinant, nonavalent vaccine prepared from highly purified virus-like particles (VLPs) comprised of the major capsid (L1) proteins from human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58, with active immunizing activity. Upon administration, the recombinant HPV nonavalent vaccine activates the immune system to produce antibodies against the 9 HPV types. This protects against HPV infection and HPV-related cancers. Altogether, HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 account for the majority of the HPV types that cause cervical, vulvar, vaginal and anal cancers. (NCIT_C119664).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5058">
		<vaccine_name>Recombinant Modified Vaccinia Ankara-5T4 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4274">A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the 5T4 fetal oncoprotein (MVA-h5T4). Vaccination with recombinant modified vaccinia Ankara-5T4 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing 5T4 fetal oncoprotein antigen, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attenuated, replication-defective vaccinia strain incapable of virion assembly. (NCIT_C49087).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine3085">
		<vaccine_name>Recombinant NY-ESO-1 ISCOMATRIX Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004254</vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="reference1950">Full-length recombinant NY-ESO-1 protein (Nicholaou et al., 2009).</antigen>
		<host_response host_response_id="host_response915" host_id="host2">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference1950">All patients received three injections of the NY-ESO-1 ISCOMATRIX vaccine at weeks 1, 5, and 9 (cycle 1) and were then evaluated for immunologic and clinical response. All patients had histologically confirmed stage IV (metastatic) or unresectable stage III malignant melanoma with measurable disease using Response Evaluation Criteria in Solid Tumors. The vaccine comprised 200 Î¼g/mL of NY-ESO-1 protein formulated with 240 Î¼g/mL ISCOMATRIX adjuvant and was administered in a 0.5 mL i.m. injection to deliver an intended dose of 100 Î¼g NY-ESO-1 protein and 120 Î¼g ISCOMATRIX adjuvant  (Nicholaou et al., 2009).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1950">No objective confirmed responses were seen in this study. These results were unexpected based on observations from patients in the prior LUD99-008 study of the NY-ESO-1 ISCOMATRIX vaccine in the MRD setting. In the LUD99-008 study, patients receiving effective vaccination had a significantly reduced probability of relapse compared with those who received placebo, suggesting that the vaccine may have had clinical efficacy in the setting of MRD (Nicholaou et al., 2009).</protection_efficacy>
			<side_effects refs="reference1950">There were no serious adverse events deemed to be related to study drug reported for this study and no grade 3 or 4 toxicities were observed. Only minor toxicities were reported in relation to administration of the NY-ESO-1 ISCOMATRIX vaccine, NY-ESO-1 protein, and peptides (Nicholaou et al., 2009).</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3078">
		<vaccine_name>Recombinant NY-ESO-1 Protein vaccine adjuvanted with Imiquimod</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004248</vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route>Intradermal injection (i.d.)</route>
		<location_licensed></location_licensed>
		<description refs="reference1915">Recombinant, full-length NY-ESO-1 protein was administered intradermally into imiquimod preconditioned sites followed by additional topical applications of imiquimod in patients with malignant melanoma (Adams et al., 2008).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intradermal injection (i.d.)</route>
		<antigen refs="reference1915">Recombinant, full-length NY-ESO-1 protein (Adams et al., 2008).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering609" gene_id="gene724">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response908" host_id="host2">
			<immune_response refs="reference1915">NY-ESO-1-specific Ab responses were detected in 4 of 9 patients (44%). However, Ab titers were significantly lower than those described in a previous study using i.m. injection of NY-ESO-1 protein with the saponin-based adjuvant ISCOMATRIX (Adams et al., 2008).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference1915">Patients with histologically confirmed, resected malignant melanoma (American Joint Committee on Cancer (AJCC) stages (39) IIB, IIC, and III) were eligible, and 9 patients were enrolled in the study. Imiquimod cream (5%, 250 mg) was self-applied topically by patients to a 4 x 5-cm outlined area of healthy extremity skin overnight on days 1â€“5 of each cycle. Application and removal times were recorded in treatment diaries. Recombinant human NY-ESO-1 protein (100 Âµg in 4 M urea and 50 mM glycine, provided by the Ludwig Institute for Cancer Research) was injected intradermally into the imiquimod-treated site on day 3. Cycles were repeated every 3 wk for a total of four injections. Imiquimod was omitted on day 5 of the last cycle to avoid biopsy site irritation (Adams et al., 2008).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs="reference1915">NY-ESO-1/imiquimod was well tolerated, and all patients completed the study. Treatment-related adverse events were mild and transient. Local reactions at the site of imiquimod application or vaccine injection were seen in 8 of 9 patients (89%). Four of 9 patients (44%) reported fatigue, and 2 of 9 patients (22%) experienced flu-like symptoms. All adverse events were grade 1 (CTC version 3.0) and were likely related to the immunomodulatory effects of imiquimod and vaccination (Adams et al., 2008).</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5152">
		<vaccine_name>Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Inactivated or "killed" vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4520">A whole, heat-killed, recombinant Saccharomyces cerevisiae yeast-based vaccine genetically altered to express the carcinoembryonic antigen (CEA) peptide 610D with potential immunostimulating and antineoplastic activities. Upon administration, recombinant Saccharomyces cerevisia-CEA(610D) vaccine GI-6207 may stimulate a host cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells, which may result in tumor cell lysis. CEA, a tumor associated antigen, is overexpressed on a wide variety of human cancer cells including colorectal, gastric, lung, breast and pancreatic cancer cells. CEA 610D encodes for 9 amino acids (605-613) in which aspartate is substituted for asparagine at position 610 (610D) in order to strengthen the induction of the CTL response against CEA-expressing tumor cells. (NCIT_C82371).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5281">
		<vaccine_name>Recombinant Vaccinia DF3/MUC1 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4323">A vaccinia virus based vaccine expressing human tumor associated epithelial mucin (DF3 antigen; MUC1). MUC1 antigen, a membrane bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed in various tumors such as breast, prostate, and ovarian cancers. This vaccine could be used in development of immunotherapeutics against cancers expressing MUC1. (NCIT_C2510).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5154">
		<vaccine_name>Recombinant Vaccinia PSA Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4637">A vaccine consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA). Vaccination with recombinant vaccinia prostate-specific antigen vaccine stimulates the host immune system to mount a cytotoxic T-cell response against tumor cells expressing PSA. (NCIT_C2433).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5208">
		<vaccine_name>Recombinant Vaccinia Viral Vector RO5217790</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4209">A vaccine consisting of recombinant modified vaccinia Ankara (MVA) viral vector encoding mutated forms of the genes for the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV) type 16 and the human cytokine interleukin-2 (hIL2), with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, recombinant vaccinia viral vector RO5217790 may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against cells expressing HPV E6 and E7, resulting in tumor cell lysis. Oncoproteins E6 and E7 have been implicated in the tumorigenesis of cervical carcinoma. (NCIT_C88326).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5401">
		<vaccine_name>Recombinant Vaccinia-CEA</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4418">A recombinant vaccinia virus encoding carcinoembryonic antigen (CEA). CEA is overexpressed in several cancer cell types, including gastrointestinal, breast, and non-small cell lung cancers. Attenuated vaccinia virus is a highly effective immunizing agent that evokes both humoral and cell-mediated responses. Vaccination with this agent may evoke a cytotoxic immune response to CEA-expressing cells. (NCI04) (NCIT_C2809).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5037">
		<vaccine_name>Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4593">A vaccine consisting of recombinant vaccinia virus encoding the tumor-associated antigen carcinoembryonic antigen (CEA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1, and LFA-3; also called TRICOM). Vaccination with recombinant vaccinia-CEA(6D)-TRICOM vaccine stimulates the host immune system to mount a T-cell response against tumor cells expressing the CEA antigen. The use of TRICOM in the vaccine may elicit a greater antitumor cytotoxic T lymphocyte (CTL) immune response compared to the use of vaccinia-CEA alone. (NCIT_C2619).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5393">
		<vaccine_name>Recombinant Vaccinia-gp100:209-217</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4490">A recombinant vaccinia virus encoding a modified peptide of the gp100 melanoma-melanocyte antigen with potential use in cancer immunotherapy. gp100 human antigen is a wild type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas. gp100p209 is a fragment epitope of gp100 in which the threonine in position 2 is replaced with methionine; this modification may stimulate tumor infiltrating lymphocytes (TIL) more efficiently. (NCI04) (NCIT_C29566).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5505">
		<vaccine_name>Recombinant Vaccinia-Mgp100 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4384">A recombinant vaccinia virus encoding a modified peptide of the gp100 melanoma-melanocyte antigen with potential use in cancer immunotherapy. gp100 human antigen is a wild type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas. This recombinant vaccinia Mgp100 encodes a fragment epitope of gp100 bearing 2 amino acids substitution; T-&gt;M at position 210 and 288 A -&gt;V at position 210. This modification may stimulate tumor infiltrating lymphocytes (TIL) more efficiently. (NCIT_C51978).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5321">
		<vaccine_name>Recombinant Vaccinia-MUC-1 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4215">A vaccine containing a recombinant vaccinia virus that encodes the gene for human mucin-1, a tumor-associated antigen. Upon administration, recombinant vaccinia-MUC-1 vaccine may elicit a MUC-1-specific cytotoxic T cell response against tumor cells bearing MUC-1. (NCIT_C2732).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5326">
		<vaccine_name>Recombinant Vaccinia-MUC1-B7 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4444">An admixture of recombinant vaccinia virus encoding MUC-1 and recombinant vaccinia virus encoding the murine T-cell co-stimulatory molecule B7.1. MUC-1 is a glycosylated mucin that is overexpressed in breast, lung, pancreatic, prostate, stomach, colon, and ovarian carcinomas. Vaccination with MUC-1 in combination with B7.1 may enhance the cytotoxic T cell (CTL) immune response to tumors expressing MUC-1, compared to vaccination with MUC-1 alone. (NCI04) (NCIT_C29409).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5232">
		<vaccine_name>Recombinant Vaccinia-Multiepitope Melanoma Peptides-B7.1-B7.2 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4669"> A cancer vaccine consisting of an inactivated recombinant vaccinia virus encoding epitope peptides derived from melanoma-related HLA-A2-restricted tumor-associated antigens (TAAs), including Melan-A(27-35), gp100(280-288) and tyrosinase(1-9), and two co-stimulatory B7 proteins, B7.1 (CD80) and B7.2 (CD86). Upon administration, recombinant vaccinia-multiepitope melanoma peptides-B7.1-B7.2 vaccine may stimulate a cytotoxic T-lymphocyte response against melanoma cells that express TAAs which share epitopes with the epitope peptides expressed by the vaccine viral vector, resulting in tumor cell lysis; vaccine viral vector-expressed co-stimulatory proteins B7.1 and B7.2 may enhance the cytotoxic T-lymphocyte immune response to the TAAs. (NCIT_C48638).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5389">
		<vaccine_name>Recombinant Vaccinia-NY-ESO-1 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4345">A cancer vaccine consisting of a recombinant vaccinia viral vector encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1, an antigen found in normal testis and various tumors, including bladder, breast, hepatocellular, melanoma, and prostate cancers. Vaccination with recombinant vaccinia NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis. (NCI05) (NCIT_C48419).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5302">
		<vaccine_name>Recombinant Vaccinia-Prostate Specific Antigen</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4143">A recombinant vaccinia virus encoding prostate-specific antigen (PSA). Vaccination with recombinant vaccinia-PSA may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for PSA, which may decrease tumor growth. (NCI04) (NCIT_C29945).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5307">
		<vaccine_name>Recombinant Vaccinia-PSA/PSMA</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4447">A recombinant vaccinia virus encoding prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) with potential use in cancer immunotherapy. (NCI04) (NCIT_C29563).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5063">
		<vaccine_name>Recombinant Vaccinia-TRP1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4442">A recombinant vaccinia virus encoding the melanocyte differentiation antigen tyrosinase-related protein-1 (TRP-1) with potential use in cancer immunotherapy. (NCI04) (NCIT_C29564).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4993">
		<vaccine_name>Remestemcel-L</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4223">Human mesenchymal stem cells (MSCs) harvested from bone marrow of healthy adult donors and expanded ex vivo, with potential immunosuppressive application. Allogeneic adult MSCs are hypo-immunogenic due to lack of major histocompatibility II (MHC II) molecule expression, and thereby elicit none or minimal immune response upon intravenous infusion. MSCs are pluripotent, and are capable of being recruited to damaged tissue sites and differentiating along specific lineages when stimulated. Infusion of MSCs results in: a) increased production of anti-inflammatory cytokines, such as interleukin-10, prostaglandin E, and hepatocyte growth factor; b) decreased mononuclear phagocyte expression of indoleamine 2,3,-dioxygenase, which catabolizes L-tryptophan into its metabolites, which in turn contribute to inflammation; and c) modulated dendritic cell maturation and disrupted activities of natural killer cells, CD8+ and CD4+ T cells. (NCIT_C67082).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5013">
		<vaccine_name>Renal Cell Carcinoma Peptides Vaccine IMA901</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4295">A multipeptide cancer vaccine targeting renal cell carcinoma with potential immunopotentiating activity. Renal cell carcinoma peptides vaccine IMA901 consists of 10 different synthetic tumor-associated peptide (TUMAP) antigens (9 HLA-class I-binding and 1 HLA class II-binding); endogenously, these TUMAPs are expressed by the majority of renal cell carcinomas. Vaccination with this agent may significantly increase host cytotoxic T-lymphocyte (CTL) immune responses against tumor cells expressing these peptide antigens. (NCIT_C70968).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5373">
		<vaccine_name>Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4283">A cancer vaccine in which autologous dendritic cells are transfected with patient-specific renal cell carcinoma (RCC) RNA and a synthetic, truncated human CD40 ligand (CD40L) RNA with potential immunostimulatory and antineoplastic activities. Individual RCC-specific RNA, encoding a unique repertoire of tumor-associated antigens (TAAs) (including telomerase reverse transcriptase, G250, and oncofetal antigen) is electroporated into autologous dendritic cells (DCs), transfected with synthetic RNA that encodes a truncated version of the T-cell protein CD40L; the transfected autologous DCs express and process both patient-specific RCC TAAs and the truncated CD40L protein. When reintroduced back to the patient, renal cell carcinoma/CD40L RNA-transfected autologous dendritic cell vaccine AGS-003 may elicit a highly specific cytotoxic T-cell (CTL) response against RCC cells expressing the patient-specific RCC TAA repertoire. The signal cascade initiated by stimulation of the truncated, ectopically expressed co-stimulatory molecule CD40L results in the secretion of the inflammatory cytokine IL-12 downstream. (NCIT_C77907).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5196">
		<vaccine_name>Renal Tumor-Reactive Autologous Peripheral Blood Lymphocyte</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4221">Peripheral blood lymphocytes (PBL) harvested from the blood of a renal cancer patient and exposed in vitro to renal tumor-associated antigens (TAA). Introducing these renal tumor-reactive autologous peripheral blood lymphocytes back to the same patient target tumor cells expressing these TAAs and could induce a cytotoxic T-cell-mediated immune response against renal cell cancer. (NCIT_C48816).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5437">
		<vaccine_name>Retrovector Encoding Mutant Anti-Cyclin G1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4277">A replication-incompetent, pathotropic, tumor matrix (collagen)-targeted, retroviral vector encoding an N-terminal deletion mutant form of the cyclin G1 gene with potential antineoplastic activity. Under the control of a hybrid long-terminal repeat/cytomegalovirus (CMV) promoter, retrovector encoding mutant anti-cyclin G expresses the mutant cyclin G1 construct, resulting in disruption of tumor cell cyclin G1 activity and decreased cellular proliferation and angiogenesis. This agent preferentially targets collagen of the tumor matrix because of the incorporation of the collagen-binding domain of von Willebrand factor (vWF) on the retrovector surface. Exploiting the collagen-targeting mechanism of vWF permits delivery of the retrovector to tumor sites where angiogenesis and collagen matrix exposure occur. (NCIT_C49082).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5131">
		<vaccine_name>Retroviral Vector MFGS-MOv18-gamma</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4599">A recombinant retrovirus containing the modified murine retroviral vector MFG-S encoding a chimeric construct, MOv18-gamma. MOv18 is a murine monoclonal antibody developed against epitope of human folate binding protein, which is overexpressed on more than 90% of non-mucinous epithelial ovarian neoplasms. The chimeric construct (MOv18-gamma) encodes the variable region of MOv18 antibody, and the gamma chain of human T-cell receptor. This virion might be used to transduce autologous T lymphocytes, and reintroduced back to the patient after expansion ex vivo to invoke specific immune response against ovarian cancer cells. (NCIT_C29192).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5477">
		<vaccine_name>rF-MUC1(DF3)/TRICOM Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4317">A fowlpox vaccine containing the tumor-associated antigen mucin-1 (MUC1), found in pancreatic tumor cells, and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3; TRICOM), which is designed to enhance antigen presentation and activation of immune responses critical for tumor destruction. Vaccination with this agent may elicit a host immune response against MUC1-expressing tumor cells. (NCIT_C29558).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5005">
		<vaccine_name>rF-PSA/PSMA/TRICOM</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4616">A synthetic fowlpox viral vaccine containing the tumor-associated antigens prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3; TRICOM). Vaccination with this viral vaccine may enhance antigen presentation and activate cytotoxic T-cells against PSA- or PSMA-expressing tumor cells. (NCIT_C29559).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5183">
		<vaccine_name>Rilimogene-galvacirepvec</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4651">A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA. (NCIT_C38681).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4201">
		<vaccine_name>rMCMV-TRP2</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004716</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference2996">An unmodified melanoma antigen, mouse tyrosinase-related protein 2 (TRP2), in mouse cytomegalovirus (MCMV)(Xu et al., 2013).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1744" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference2996">Prophylactic vaccination of the mice with a single dose of MCMV-TRP2 (Xu et al., 2013).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2996">Therapeutic vaccination with MCMV-TRP2 prolonged the survival of the mice challenged with B16 cells. Furthermore, vaccination with MCMV-TRP2 five months before tumor challenge still induced tumor rejection, which indicated that the vaccine induced long-term protection (Xu et al., 2013).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference2996">Mice were subcutaneously (s.c.) challenged with 2 Ã— 10^5 B16/F10 cells in 100 Î¼l PBS in the shaved right flank (Xu et al., 2013).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4198">
		<vaccine_name>rMeV- SCD</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004713</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3238">A measles vaccine virus (MeV) vector expressing super cytosine deaminase (SCD), a fusion protein of yeast cytosine deaminase and uracil phosphoribosyltransferase (Lange et al., 2013).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1743" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference3238">When tumors reached a volume of about 100 mm^3, mice were randomized into four treatment groups: control, control+5-FC, MeV, and MeV+5-FC. Mice received intratumoral injections of MeV (either 1Ã—10^6 pfu/dose of MeV P-SCD for TFK-1 or 2Ã—10^6 pfu/dose of MeV ld-SCD for HuCCT1 in 100 Î¼l Opti-MEM) or Opti-MEM alone once daily on days 0â€“4. Mice randomized to the 5-FC groups received daily intraperitoneal injections of 5-FC (500 mg/kg body weight/dose in PBS) on days 5â€“11 (Lange et al., 2013).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3238">In vivo, intratumoral application of SCD-armed MeV together with a systemic 5-FC treatment showed a significant reduction in tumor size in a TFK-1 xenograft mouse model when compared with virus-only treatment. In a second animal experiment employing a HuCCT1 xenograft tumor model, an enhanced SCD-armed MeV vector, in which the SCD transgene was expressed from a different genomic position, led not only to reduced tumor volumes, but also to a significant survival benefit (Lange et al., 2013).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3238">FK-1 cells (1Ã—10^7 cells each in 100 Î¼l PBS) were injected subcutaneously into the right flank of 4â€“6-week-old female CanN.Cg-Foxn1nu/Crl mice . In a second experiment, HuCCT1 cells were implanted subcutaneously in Hsd:Atymic Nude-Foxn1nu mice (Lange et al., 2013).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4251">
		<vaccine_name>rMVTT- HPV16-E6/E7</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004761</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3277">(Zhi et al., 2002)   In this vaccine, the HPV16 early E6 and E7 genes were expressing by  a vaccinia virus TianTan vector.</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1745" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">C57 BL/6</host_strain>
			<vaccination_protocol refs="reference3277">Mice were vaccinated with VmE6E7 (Zhi et al., 2002).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3277">The mice vaccinated expressed retarded or prevented tumor development (Zhi et al., 2002).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3277">Mice were challenged by syngeneic HPV16E6 and E7 transformed tumor cells (Zhi et al., 2002).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5194">
		<vaccine_name>Sargramostim Plasmid DNA Melanoma Vaccine Adjuvant</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4636">A vaccine adjuvant consisting of a plasmid DNA encoding sargramostim (a granulocyte macrophage-colony stimulating factor). Upon administration, expressed sargramostim may stimulate a cytotoxic T cell response enhancing the host immune response to a concomitantly administered melanoma vaccine. (NCIT_C2430).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5340">
		<vaccine_name>Sargramostim Plasmid DNA Pancreatic Tumor Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4483">A whole cell vaccine comprised of irradiated allogenic pancreatic tumor cells transfected with a plasmid DNA encoding human sargramostim (GM-CSF). Vaccination results in expression of GM-CSF, which induces proliferation and differentiation of hematopoietic lineage cells as well as stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Furthermore, administration of this pancreatic tumor cell vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor growth. (NCIT_C2445).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4079">
		<vaccine_name>short overlapping peptides and full-length recombinant protein</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004617</vo_id>
		<type>peptide</type>
		<status>Licensed</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs="reference3010">In this study, we finely mapped linear antibody epitopes using sera from melanoma patients and shorter overlapping peptide sets. We have shown that melanoma patients' humoral immune systems responded to NY-ESO-1 differently in each individual with widely differing antibody specificity, intensity and antibody subtypes (Komatsu et al., 2013).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="">NY-ESO-1</antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5425">
		<vaccine_name>Sialyl Tn-KLH Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4374">A vaccine containing a pancarcinoma carbohydrate antigen conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Sialylated Tn antigen (sTn) is a monosaccharide glycan usually O-linked to serine or threonine residues of mucins found on most epithelial cancers. Conjugation with KLH, a hapten carrier and an immunostimulant, improves host immune responses. Vaccination with sTn-KLH vaccine may produce antibodies and elicit a cytotoxic T lymphocyte (CTL) response against those tumor cells expressing sTn, resulting in decreased tumor growth. (NCIT_C1690).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5216">
		<vaccine_name>Sipuleucel-T</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4461">A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCIT_C1985).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4155">
		<vaccine_name>SL3261-GFP expression and mIL-12 gene integration</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004673</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3134">A live attenuated AraA- autotrophic mutant of Salmonella typhimurium (SL3261) was used as carrier for eukaryotic expression vectors EGFPN1 and pCMVmIL-12 (Qi et al., 2006).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1742" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">C57BL/6 and BALB/c</host_strain>
			<vaccination_protocol refs="reference3134">Mice were vaccinated orally with SL3261 carrying expression vectors for EGFPN1 and pCMVmIL-12 (Qi et al., 2006).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3134">GFP expression and mIL-12 gene integration could be detected in the liver, spleen, intestinal, kidney and tumor tissues of the mice. The serum level of mIFN-gamma, mIL-12 increased significantly in mice with oral mIL-12 administration, which resulted in the survival prolongation of the mice as compared with the control mice (Qi et al., 2006).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3134">After 6 weeks, the mice were challenged with 4T1 or Lewis tumor cells, respectively (Qi et al., 2006).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4044">
		<vaccine_name>smallpox vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004613</vo_id>
		<type>Vaccina virus</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference2962">patients with proved metastases from malignant melanoma treated by inoculations of smallpox vaccine (Hunter-Craig et al., 1970).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4001">
		<vaccine_name>SRL172</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004610</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs="reference2921">This trial provides preliminary evidence of a new, non-toxic, immunotherapeutic regimen in the management of malignant melanoma (Nicholson et al., 2003).</description>
		<adjuvant refs="">IL-2</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1659" host_id="host2">
			<immune_response refs="reference2921">no responses were seen in the first 16 patients receiving SRL172 alone (Nicholson et al., 2003)</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5061">
		<vaccine_name>STn-KLH plus Detox Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4166">A vaccine comprised of a synthetic Sialyl-Tn antigen linked to the protein carrier, keyhole limpet hemocyanin (KLH), administered with immunostimulant, Detox. Vaccination with STn-KLH plus Detox may elicit an IgG-based anti-STn antibody response and ultimately a cytotoxic T-cell response against STn-expressing cancer cells. (NCIT_C2501).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5525">
		<vaccine_name>Streptococcus pneumoniae Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Live attenuated vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4157">A bacterial vaccine used to prevent contraction of Streptococcus pneumonia. (NCIT_C96393).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5371">
		<vaccine_name>Survivin Antigen Vaccine DPX-Survivac</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5265">
		<vaccine_name>Survivin Sur1M2 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4296">A modified recombinant nonapeptide (LMLGEFLKL) derived from the anti-apoptosis protein survivin with potential immunopotentiating and antineoplastic activities. Upon administration, survivin Sur1M2 peptide vaccine may elicit humoral and cellular immune responses against survivin-expressing cancers, resulting in decreased tumor cell proliferation and tumor cell death. The survivin protein inhibits caspase activation and apoptosis; it is undetectable in normal adult tissues but is expressed by several human cancers including lung, colon, breast, pancreas, and prostate cancer as well as hematopoietic malignancies and skin cancers. (NCIT_C71741).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5180">
		<vaccine_name>Survivin/p53/HER2 Antigen-loaded Autologous Dendritic Cell Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4665">An autologous dendritic cell (DC) vaccine loaded with tumor-associated antigens (TAAs) derived from survivin, p53 and human epidermal growth factor receptor 2 (HER2 or ERBB2), with immunostimulating and antineoplastic activities. Upon administration, this DC vaccine may elicit a potent cytotoxic T-cell (CTL) response against tumor cells expressing these TAAs, resulting in tumor cell death. Survivin, p53 and HER2 are essential in neoplastic growth, and are considered to be universal tumor antigens. (NCIT_C114285).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5008">
		<vaccine_name>SVN53-67/M57-KLH Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4631">A peptide vaccine containing a 15-mer peptide (DLAQMFFCFKELEGW), with C to M alteration at amino acid position 57, derived from the anti-apoptosis protein survivin, and conjugated with keyhole limpet hemocyanin (KLH), with potential immunopotentiating and antineoplastic activities. Upon subcutaneous administration of SVN53-67/M57-KLH peptide vaccine, this peptide is able to bind both HMC class I and II molecules and may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) as well as a T-helper cell response against survivin-expressing cancer cells. This may result in decreased tumor cell proliferation and ultimately tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family, expressed during embryonic development while absent in most normal adult cells, is upregulated in a variety of human cancers; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy. KLH may enhance immune recognition and may promote an enhanced response. As SVN53-67 is weakly immunogenic in humans, the M57 alteration may lead to greater affinity towards HLA-A*0201 and thus an enhanced antitumor immune response. (NCIT_C95705).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5218">
		<vaccine_name>Synchrotope TA2M Plasmid DNA Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4530">A recombinant plasmid DNA vaccine encoding epitopes of tyrosinase with potential antineoplastic activity. Synchrotope TA2M vaccine contains a plasmid encoding 2 epitopes, amino acid sequences 207-216 and 1-17 of tyrosinase, a protein frequently expressed by melanoma cells. Vaccination with the TA2M plasmid DNA vaccine may induce the production of anti-tyrosinase antibodies as well as elicit a cytotoxic T-lymphocyte (CTL) response against tyrosinase-expressing tumor cells, resulting in decreased tumor growth. (NCIT_C2650).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5506">
		<vaccine_name>Synchrovax SEM Plasmid DNA Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4456">A bivalent DNA vaccine encoding epitopes for both Melan-A (MART-1) and tyrosinase with potential antineoplastic activity. Synchrovax SEM plasmid DNA vaccine contains a plasmid pSEM that encodes 4 epitopes: Melan-A (26-35), Melan-A (31-96), tyrosinase (1-9), and tyrosinase (369-377). Both Melan-A and tyrosinase are tumor antigens associated with melanoma. Vaccination with this plasmid DNA vaccine may induce both humoral and cytotoxic lymphocyte (CTL) responses against cells expressing either or both of these antigens, resulting in decreased tumor growth. (NCIT_C28549).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5271">
		<vaccine_name>Synthetic Breast Cancer Peptides-Tetanus Toxoid-Montanide ISA-51 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4149">A cancer vaccine comprised of multiple synthetic breast cancer peptides and the adjuvant tetanus toxoid helper peptide emulsified in the adjuvant Montanide ISA-51 with immunopotentiation activity. Vaccination with this cancer vaccine may elicit a specific cytotoxic T-lymphocyte response against breast cancer cells. Synthetic breast cancer peptides may stimulate the immune response against cells that produce breast cancer markers such as erbB2 (HER2/neu) while tetanus toxoid helper peptide binds to class II MHC molecules as a nonspecific vaccine helper epitope, resulting in a long-term immunopotentiation by increasing the helper T-cell response. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens. (NCIT_C61076).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5086">
		<vaccine_name>Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4385">A personalized peptide-based cancer vaccine comprised of one or two de novo synthesized patient-specific tumor-mutated peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB mutated tumor-specific peptides vaccine therapy APVAC2 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the selected mutated tumor-associated peptides, which results in decreased GB growth. These peptides are specifically selected and synthesized based on the expression of the patient's own mutated tumor-associated antigens, which were detected during individual tumor genome sequencing. (NCIT_C116332).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5231">
		<vaccine_name>Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4386">A personalized peptide-based cancer vaccine comprised of five to ten peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB tumor-associated peptides vaccine therapy APVAC1 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the tumor associated peptides, and results in decreased GB growth. The peptides are derived from a glioma actively personalized vaccine consortium (GAPVAC) warehouse and are specifically selected based on the patient's expression of tumor-associated antigens. (NCIT_C116331).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5171">
		<vaccine_name>Synthetic hTERT DNA Vaccine INO-1400</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4272">A DNA vaccine consisting of a plasmid encoding the full-length sequence of the tumor-associated antigen (TAA) human telomerase reverse transcriptase (hTERT), which is the catalytic subunit of human telomerase and synthesizes telomeric DNA at the chromosome ends, containing two immunogenic mutations, with potential immunostimulating and antineoplastic activities. Upon intradermal vaccination of the hTERT encoding DNA vaccine INO-1400 in combination with electroporation, hTERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, telomerase is expressed in the majority of human cancer cells, but its expression is low or non-existent in normal cells. (NCIT_C120118).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5186">
		<vaccine_name>Synthetic Long E6/E7 Peptides Vaccine HPV-01</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4525">A therapeutic peptide vaccine consisting of thirteen synthetic long peptides (SLPs), which are 25-35 amino acids in size, derived from the human papillomavirus (HPV) type 16 oncoproteins E6 and E7, with potential immunostimulating and antitumor activities. Upon administration, synthetic long E6/E7 peptides vaccine HPV-01 is taken up and degraded into small pieces by dendritic cells. The processed viral epitopes are presented by dendritic cells, which may stimulate the host immune system to mount both cytotoxic T-cell lymphocyte (CTL) and helper T cell responses against HPV E6/E7-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased tumor growth. The E6 and E7 oncoproteins are implicated in the tumorigenesis in a variety of cancers. The SLPs allow for optimal presentation by antigen-presenting cells. (NCIT_C111037).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5217">
		<vaccine_name>Synthetic Melanoma-Associated Antigens Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4670">A cancer vaccine containing synthetic epitope peptides derived from melanoma tumor-associated antigens (TAAs), including melanoma-melanocyte antigen gp100(280-288), melanoma-associated antigen tyrosinase(1-9), and melanoma-associated antigen melan-A(27-35). Upon administration, synthetic melanoma-associated antigens vaccine may stimulate a cytotoxic T-lymphocyte immune response against melanoma cells that express TAAs which share epitopes with the vaccine epitope peptides, resulting in tumor cell lysis. (NCIT_C48639).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine3091">
		<vaccine_name>Synthetic MUC1 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004258</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>subcutaneous injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">subcutaneous injection</route>
		<antigen refs="reference2022">The 140-aa synthetic MUC1 peptide (Soares et al., 2001).</antigen>
		<host_response host_response_id="host_response920" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">MUC1-Tg mice (4â€“6 wk old) on a C57BL/6 background</host_strain>
			<vaccination_protocol refs="reference2022">Three different immunization protocols were tested in vivo. Mice were immunized with: 1) synthetic MUC1 peptide (100 Âµg/mouse) coadministered with soluble murine GM-CSF (2 Âµg/mouse; a generous gift from Immunex, Seattle, WA) injected s.c.; 2) synthetic MUC1 peptide (100 Âµg/mouse) coadministered with SB-AS2 (50 Âµl/mouse; a generous gift of SmithKline Beecham Biologicals, Rixensart, Belgium) injected i.m.; or 3) murine DC prepulsed with 20 Âµg/ml of synthetic MUC1 peptide in AIM-V medium (Life Technologies, Grand Island, NY) overnight (2â€“5 x 104 DC/mouse injected s.c.) (Soares et al., 2001).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2022">WT and MUC1-Tg mice that had been immunized with MUC1 peptide admixed with either GM-CSF or SB-AS2 also had to be sacrificed because they failed to reject the tumors (Soares et al., 2001).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference2022">Ten days after the last boost, the mice were anesthetized with Metofane (Schering-Plough Animal Health, Omaha, NE) and 5 x 10^4 RMA-MUC1 cells injected s.c. in the shaved right hind flank. Tumor growth was monitored every 2â€“3 days and tumor size determined with calipers (Soares et al., 2001).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5496">
		<vaccine_name>Synthetic Peptides E-PRA And E-PSM Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4361">A cancer vaccine consisting of E-PRA and E-PSM, two synthetic peptide analogs of PRAME (PReferential Antigen MElanoma) and PSMA (Prostate Specific Membrane Antigen), with potential immunostimulating activity. Upon direct administration into lymph nodes, synthetic peptides E-PRA and E-PSM vaccine may stimulate a cytotoxic T-lymphocyte (CTL) response against PRAME- and PSMA-expressing tumor cells. PRAME and PSMA are tumor-associated antigens upregulated and expressed on the cell surfaces of certain tumor cell types. (NCIT_C67098).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5448">
		<vaccine_name>TARP 27-35 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4171">A peptide-based cancer vaccine, containing amino acid residues 27 through 35 of T cell receptor gamma alternate reading frame protein (TARP), with potential immunostimulatory and antineoplastic activities. Upon administration, TARP 27-35 peptide vaccine may stimulate a host cytotoxic T-cell (CTL) response against TARP-expressing tumor cells, resulting in tumor cell cytotoxicity. The nuclear protein TARP is commonly expressed on prostate and breast cancer cells and is highly immunogenic. (NCIT_C85462).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5242">
		<vaccine_name>TARP 29-37-9V Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4172">A peptide-based cancer vaccine, consisting of amino acid residues 29 through 37 of T cell receptor gamma alternate reading frame protein (TARP) with a leucine-to-valine substitution at position 9, with potential immunostimulatory and antineoplastic activities. Upon administration, TARP 29-37-9V peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against TARP-expressing tumor cells, which may result in decreased tumor cell proliferation. The leucine-to-valine substitution at position 9 of this peptide improves its immunogenicity. The nuclear protein TARP is commonly expressed on prostate and breast cancer cells and is highly immunogenic. (NCIT_C85463).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5295">
		<vaccine_name>TBC-CEA-Contaminated W/ BVDV</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4301">A cancer vaccine consisting of a recombinant vector encoding the tumor-associated carcinoembryonic antigen (CEA) that is contaminated with bovine viral diarrhea virus (BVDV). The carcinoembryonic antigen (CEA) is a prevalent tumor marker expressed by a number of different cancers such as colorectal, breast, lung and ovarian carcinomas; vaccination with vaccinia virus genetically engineered to express CEA may generate antitumoral T-cell responses. BVDV is an RNA pestivirus that may contaminate vaccines due to its presence in fetal calf serum used as a growth supplement in the tissue culture of mammalian cells used in vaccine production. (NCI04) (NCIT_C29476).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5101">
		<vaccine_name>Telomerase Peptide Vaccine GV1001</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4322">A synthetic peptide vaccine, containing 16 amino acid residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), with potential antineoplastic activity. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Vaccination with the telomerase peptide GV1001 may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against telomerase-expressing cells. (NCIT_C62756).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5072">
		<vaccine_name>Telomerase-specific Type 5 Adenovirus OBP-301</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4324">A replication-competent oncolytic, telomerase-specific adenovirus serotype 5 (Ad5), with potential antineoplastic activity. OBP-301 contains the human telomerase reverse transcriptase (hTERT) gene promoter sequence that drives the expression of the E1A and E1B genes, and is linked to an internal ribosomal entry site (IRES). Upon administration, OBP-301 selectively infects and replicates in cancer cells that are expressing telomerase, which causes cell lysis. This adenovirus does not infect or replicate in normal, healthy cells. OBP-301 may also potentially be used as a chemosensitizer. hTERT, which encodes for the catalytic protein subunit of telomerase, is overexpressed in a variety of cancer cell types but not in normal, healthy cells. The insertion of an IRES further improves selectivity towards telomerase-expressing cancer cells. (NCIT_C119617).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5098">
		<vaccine_name>Telomerase: 540-548 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4120">A recombinant peptide consisting of the amino acid residues 540 to 548 of the human telomerase reverse transcriptase (hTERT). Telomerase expression has been directly linked to tumor development; its catalytic subunit is expressed in the majority of human cancer cells, but infrequently in normal cells. Vaccination with telomerase:540-548 peptide may stimulate cytotoxic T cells to recognize and kill telomerase-expressing cells. (NCI04) (NCIT_C2640).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5527">
		<vaccine_name>Tergenpumatucel-L</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4377">An allogeneic lung cancer vaccine with potential immunostimulating and antineoplastic activities. Derived from allogeneic lung tumor cells, tergenpumatucel-L is engineered to express the murine alpha-1,3-galactosyltransferase (GalT), an enzyme humans lack. GalT catalyzes the expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate epitopes in glycoproteins and in glycolipids on the cell membranes of the allogeneic lung tumor cells present in the vaccine, essentially producing a 'xenograft'. The hyperacute rejection involves pre-existing human anti-alpha-gal antibodies that bind the foreign alpha-gal epitopes expressed by the vaccine tumor cell xenograft, resulting in complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) towards endogenous lung tumor cells with unmodified carbohydrate epitopes. (NCIT_C66985).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5514">
		<vaccine_name>Tetanus and Diphtheria Toxoids Adsorbed</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Toxoid vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4648">A sterile, intramuscular suspension of alum (aluminum potassium sulfate)-precipitated toxoids indicated for active immunization for the prevention of tetanus and diphtheria for use in persons 7 years of age or older. (NCIT_C96405).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5287">
		<vaccine_name>Tetanus Toxoid Aluminum Phosphate Adsorbed Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Toxoid vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4254">A vaccine that contains detoxified tetanus toxin of Clostridium tetani. Aluminum phosphate is an adjunct that adsorbs the tetanus antigens to increase the half-life and immunogenicity of the vaccine. (NCIT_C2814).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5009">
		<vaccine_name>Tetanus Toxoid Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Toxoid vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4431">A preparation of formaldehyde-deactivated toxin isolated from the bacterium Clostridium tetani. Tetanus toxoid is used for booster injection and can stimulate the production of antitoxin antibodies. This agent may be used as an adjuvant in cancer vaccines. (NCIT_C2660).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5221">
		<vaccine_name>Tetanus-CMV Fusion Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Toxoid vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4655">A vaccine containing an inactivated epitope of tetanus toxin fused to a cytomegalovirus (CMV) peptide epitope, with potential anti-viral and immunomodulating activities. Upon administration, tetanus-CMV fusion peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against CMV in the CMV-infected host. Tetanus toxin contains universal T cell helper epitopes. (NCIT_C78821).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5114">
		<vaccine_name>Tetravalent RNA-lipoplex Cancer Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4481">A RNA-lipoplex (RNA-LP)-based cancer vaccine containing four naked ribonucleic acid (RNA)-drug products (DPs) RBL001.1, RBL002.2, RBL003.1, and RBL004.1 encoding melanoma-associated antigens (MAAs) encapsulated in liposomes, with potential antineoplastic activity. Upon intravenous administration of the tetravalent RNA-lipoplex cancer vaccine, the liposomes protect the RNA from degradation in the bloodstream, travel to the spleen and are taken up by antigen-presenting cells (APCs); RNA is translocated to the cytoplasm and translated into the four tumor-associated proteins. The expressed proteins are processed and the human leukocyte antigen (HLA)-peptide complexes are presented to the immune system. This induces antigen-specific CD8+ and CD4+ T-cell responses against the four selected MAAs. (NCIT_C122396).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5458">
		<vaccine_name>Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4440">A lipid-based multi-peptide cancer vaccine targeted against multiple cancers with immunopotentiating activity. Therapeutic breast/ovarian/prostate peptide cancer vaccine DPX-0907 is a lyophilized liposomal proprietary preparation comprised of 7 tumor-specific HLA-A2-restricted epitopes (TAAs): Topoisomerase II alpha, B-cell receptor-associated protein 31 (CDM protein), TNF-alpha-converting enzyme (TACE/ADAM17), Abelson homolog 2 (Abl2), gamma catenin (Junction plakoglobin), epithelial discoidin domain receptor 1 (EDDR1) and integrin beta 8 subunit. Upon vaccination, the lyophilized antigen/adjuvant/liposome complex is re-suspended in Montanide 1SA51 VG to create a depot effect, thereby presenting the TAAs to the immune system for a prolonged period of time. This may stimulate a potent cytotoxic T-lymphocyte (CTL) immune response against cancer cells that express these 7 TAAs and share epitopes with the vaccine epitope peptides, resulting in tumor cell lysis. The 7 TAAs are overexpressed on the surface of breast/ovarian and prostate cancer cells and play an important role in tumor cell growth and survival. (NCIT_C91077).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine351">
		<vaccine_name>TICE BCG</vaccine_name>
		<proper_name>BCG Live</proper_name>
		<brand_name>TICE BCG</brand_name>
		<manufacturer>Organon Teknika Corp</manufacturer>
		<vo_id>VO_0000103</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>intravesicular infusion</route>
		<location_licensed>USA (License #0956)</location_licensed>
		<description refs="">TICEÂ® BCG induces a granulomatous reaction at the local site of administration. Intravesical TICEÂ® BCG has been used as a therapy for, and prophylaxis against, recurrent tumors in patients with carcinoma in situ (CIS) of the urinary bladder, and to prevent recurrence of Stage TaT1 papillary tumors of the bladder at high risk of recurrence. It works against cancer as a biologic response modifier. Specifically, TICE BCG has no direct antitumor effect but is able to stimulate inflammatory immune response in the bladder wall that, in turn, destroys cancer cells within the bladder. TICE BCG vaccination may cause a false-positive reaction to the TST (Tuberculin Skin Test), which may complicate decisions about prescribing treatment.</description>
		<adjuvant refs=""></adjuvant>
		<storage refs="">This vaccine should be kept refrigerated.</storage>
		<virulence refs=""></virulence>
		<preparation refs="">TICE BCG is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis. The TICEÂ® strain was developed at the University of Illinois from a strain originated at the Pasteur Institute. The medium in which the BCG organism is grown for preparation of the freeze-dried cake is composed of the following ingredients: glycerin, asparagine, citric acid, potassium phosphate, magnesium sulfate, and iron ammonium citrate. The final preparation prior to freeze drying also contains lactose. The freeze-dried BCG preparation is delivered in glass vials, each containing 1 to 8 x 10^8 colony forming units (CFU) of TICEÂ® BCG which is equivalent to approximately 50 mg wet weight. Determination of in-vitro potency is achieved through colony counts derived from a serial dilution assay. A single dose consists of 1 reconstituted vial.</preparation>
		<route refs="">intravesicular infusion</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response434" host_id="host2">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference767">A large scale trial evaluating the efficacy of BCG was conducted from 1956 to 1963 and involved almost 60,000 school children who received BCG at the age of 14 or 15 (FDA: TICE BCG).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference767">The efficacy of this vaccine has been shown to vary between clinical studies.  For example, in this study, the efficacy was found to be 84% up to 6 years after immunization but in another study, a US Public Health Service trial, of BCG in Georgia and Alabama published in 1966 showed an efficacy of only 14% (FDA: TICE BCG).</protection_efficacy>
			<side_effects refs="reference767">Side effects of vaccination include: headache, fever, hardening of skin at injection site, and swelling of the lymph nodes near the injection site.  The most common side effect is large scars that remain on the skin at the injection site (FDA: TICE BCG).</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine5025">
		<vaccine_name>Tn(c)-KLH Conjugate Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4576">A vaccine containing a clustered pancarcinoma carbohydrate antigen conjugated with keyhole limpet hemocyanin (KLH) with potential antineoplastic activity. Alpha-N-acetylgalactosamine (Tn) is a monosaccharide usually O-linked to serine or threonine residues of mucins found on most epithelial cancers with the highest expression on prostate cancer. This vaccine contains the Tn epitope cluster (c) that is synthesized by linking 3 copies of the Tn epitope on a threonine backbone to achieve the essential immunogenic structure. KLH is a hapten carrier and serves as an immunostimulant to improve immune recognition. Vaccination with Tn(c)-KLH vaccine may produce antibodies and elicit a cytotoxic T lymphocyte (CTL) response against those tumor cells expressing Tn antigen, resulting in decreased tumor growth. (NCIT_C2474).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5426">
		<vaccine_name>Toxoid Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Toxoid vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4387">Any vaccine that contains an inactivated toxic substance used for disease prophylaxis or to vaccinate against snake bites. (NCIT_C96398).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4996">
		<vaccine_name>Trivalent Influenza Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Inactivated or "killed" vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4119">A synthetic vaccine consisting of hemagglutinin (HA) antigens derived from three inactivated influenza viruses, two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine (TIV) is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season. Upon administration, the TIV provides active immunization against the three influenza virus strains, thereby protecting against influenza infection. A form of TIV containing higher concentrations of HA antigens may be used in older patients to elicit a more effective immune response. (NCIT_C2643).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5080">
		<vaccine_name>Trivalent Live-Attenuated Influenza Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Live attenuated vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4549"> A weakened live virus vaccine containing three seasonal influenza reassortants with prophylactic activity against influenza subtypes A and B. The trivalent live-attenuated influenza vaccine (LAIV) contains 2 strains of the influenza subtype A, one for H1N1 and one for H3N2, and one strain of subtype B. Upon intranasal administration by sprayer of the trivalent LAIV, the live viruses replicate in the upper respiratory tract and induce an immune response leading to active immunization against influenza subtypes A and B. (NCIT_C101094).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5325">
		<vaccine_name>TRP-2: 180-188 Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4253">A recombinant peptide consisting of amino acid residues 180 to 188 of the tyrosinase-related protein 2 (TRP2). Expressed by cells of melanocyte origin, TRP2 is an enzyme involved in the process that converts tyrosinase to melanin pigments. Vaccination with TRP-2: 180-188 peptide may induce cytotoxic T lymphocyte (CTL) responses to melanoma cells. (NCI04) (NCIT_C2815).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5487">
		<vaccine_name>TRP1(0RF3):1-9 Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4252">A recombinant peptide consisting of amino acid residues 1 to 9 of the tyrosinase-related protein 1 (TRP1). Expressed by cells of melanocyte origin, TRP1 is an enzyme involved in the process that converts tyrosinase to melanin pigments. Vaccination with TRP1(0RF3):1-9 may stimulate cytotoxic T cell responses to melanoma cells.(NCI04) (NCIT_C2816).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5387">
		<vaccine_name>Tumor Cell Derivative Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4443">A lipid-based multi-peptide cancer vaccine targeted against multiple cancers with immunopotentiating activity. Therapeutic breast/ovarian/prostate peptide cancer vaccine DPX-0907 is a lyophilized liposomal proprietary preparation comprised of 7 tumor-specific HLA-A2-restricted epitopes (TAAs): Topoisomerase II alpha, B-cell receptor-associated protein 31 (CDM protein), TNF-alpha-converting enzyme (TACE/ADAM17), Abelson homolog 2 (Abl2), gamma catenin (Junction plakoglobin), epithelial discoidin domain receptor 1 (EDDR1) and integrin beta 8 subunit. Upon vaccination, the lyophilized antigen/adjuvant/liposome complex is re-suspended in Montanide 1SA51 VG to create a depot effect, thereby presenting the TAAs to the immune system for a prolonged period of time. This may stimulate a potent cytotoxic T-lymphocyte (CTL) immune response against cancer cells that express these 7 TAAs and share epitopes with the vaccine epitope peptides, resulting in tumor cell lysis. The 7 TAAs are overexpressed on the surface of breast/ovarian and prostate cancer cells and play an important role in tumor cell growth and survival. (NCIT_C2341).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5197">
		<vaccine_name>Ty21a Typhoid Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Live attenuated vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4508">A live attenuated bacteria oral vaccine used to prevent typhoid, which is caused by Salmonella typhi. (NCIT_C97126).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5492">
		<vaccine_name>Typhoid Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Live attenuated vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4390">A bacterial vaccine used to prevent typhoid fever, which is caused by Salmonella typhi bacteria. (NCIT_C96392).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5060">
		<vaccine_name>Tyrosinase-KLH</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4664">A peptide vaccine containing a tyrosinase epitope conjugated with keyhole lymphocyte hemocyanin (KLH) with potential antineoplastic activity. Tyrosinase, one of the melanoma differentiation antigens, is the rate-limiting enzyme for melanin synthesis. This tyrosine epitope is conjugated with KLH, which serves as an immunostimulant and a hapten carrier, to enhance immune recognition. Vaccination with tyrosinase-KLH peptide vaccine may produce anti-tyrosinase antibodies as well as elicit a cytotoxic T lymphocyte (CTL) response against cells expressing tyrosinase antigen, resulting in decreased tumor growth. (NCIT_C2384).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5177">
		<vaccine_name>Umbilical Cord Blood-Derived Mesenchymal Stem Cells</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4632">Multipotent stem cells of mesenchymal origin isolated from umbilical cord blood. Umbilical cord blood-derived mesenchymal stem cells can differentiate into a variety of cell types including fibroblasts, osteoblasts, chondrocytes, myocytes, adipocytes, and endothelial cells. (NCIT_C82688).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5046">
		<vaccine_name>Unconjugated Lymphoma Ig Id</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4646">A vaccine consisting of lymphoma-specific immunoglobulin that is not conjugated to a carrier molecule. Vaccination with unconjugated lymphoma Ig Id may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against lymphoma cells, resulting in decreased tumor growth. (NCI04) (NCIT_C2821).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5391">
		<vaccine_name>Unconjugated Myeloma Ig Id</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Conjugate vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4645">A vaccine consisting of myeloma-specific immunoglobulin that is not conjugated to a carrier molecule. Vaccination with unconjugated myeloma Ig Id may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against myeloma cells, resulting in decreased tumor growth. (NCI04) (NCIT_C2822).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5115">
		<vaccine_name>URLC10 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4594">A cancer vaccine containing URLC10 (up-regulated lung cancer 10) epitopes with potential immunostimulatory and antineoplastic activities. Upon administration, URL peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URLC10-expressing tumor cells. Up-regulated in lung and esophageal cancers, the function of URLC10 is unknown. (NCIT_C74087).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5350">
		<vaccine_name>URLC10-CDCA1-KOC1 Multipeptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4135">A cancer vaccine containing multiple peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from, URLC10 (up-regulated lung cancer 10), CDCA1 (cell division cycle-associated protein 1), KOC1 (IGF II mRNA Binding Protein 3). Upon administration, URLC10-CDCA1-KOC1 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing URLC10, CDCA1, KCO1 peptides, resulting in cell lysis and decreased tumor growth. (NCIT_C95212).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5001">
		<vaccine_name>URLC10-TTK-KOC1-VEGFR1-VEGFR2 Multipeptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4595">A cancer vaccine containing five peptide epitopes with potential immunostimulatory and antitumor activity. Peptide epitopes in this vaccine are derived from: URLC10 (up-regulated lung cancer 10), TTK (TTK protein kinase), KOC1 (IGF II mRNA Binding Protein 3) and VEGFRs (vascular endothelial growth factor receptors) 1 and 2. Upon administration, URLC10-TTK-KOC1-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing URLC10, TTK, KCO1, VEGFR 1 and 2 peptides, resulting in cell lysis and decreased tumor growth. (NCIT_C74088).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5478">
		<vaccine_name>UV1 Telomerase Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4662">A synthetic, peptide cancer vaccine directed against the human telomerase reverse transcriptase catalytic subunit (hTERT) with potential immunomodulating activity. Vaccination with the UV1 telomerase peptide may stimulate cytotoxic T-cells to recognize and kill telomerase-expressing cells. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. (NCIT_C104747).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5296">
		<vaccine_name>Vaccinia Virus DD-CDSR</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4596">A highly tumor-selective vaccinia virus (vv) with an engineered double deletion (DD) of the thymidine kinase (tk) and vaccinia growth factor genes and additions of both a cytosine deaminase (CD) gene and a somatostatin receptor (SR) gene with potential oncolytic viral activity. The tk and vaccinia growth factor gene deletions in intratumorally administered vaccinia virus (vvDD-CDSR) help to restrict its replication and cytolytic activity to tumor cells with large nucleotide pools and tumor cells with activation of the EGFR-Ras pathway. Addition of the CD gene to the viral genome allows control of oncolytic viral infection through the administration of the prodrug 5-fluorocytosine (5-FC), converted by CD to the antimetabolite 5-fluorouracil (5-FU) in cells infected with this agent. Addition of the SR gene allows anatomical localization of vaccinia virus (vvDD-CDSR) through the use of octreotide scintigraphy. (NCIT_C74089).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5508">
		<vaccine_name>Vaccinia-GM-CSF Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4287">A recombinant vaccinia virus that encodes granulocyte-macrophage colony stimulating factor (GM-CSF). By activating T-cells and macrophages, vaccination with recombinant vaccinia GM-CSF may enhance the host immune system response to poorly immunogenic tumors, resulting in decreased tumor growth. (NCI04) (NCIT_C2674).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5223">
		<vaccine_name>Vaccinia-Tyrosinase Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4479">A vaccine consisting of recombinant vaccinia virus, based on the modified vaccinia virus Ankara (MVA) that encodes the melanoma-associated antigen tyrosinase. Vaccination with vaccinia-tyrosinase may stimulate the host immune system to mount a cytotoxic T-cell response against tumor cells expressing tyrosinase. Tyrosinase is a melanoma-specific differentiation agent that catalyzes the synthesis of the melanin precursor L-3,4-dihydroxyphenylalanine (L-DOPA). (NCIT_C2531).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5390">
		<vaccine_name>VCL-CB01 Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4202">A vaccine consisting of two plasmids encoding the human cytomegalovirus (CMV) tegument phosphoprotein 65 (pp65), a major internal matrix protein, and glycoprotein B (gB), an important CMV component responsible for attachment and entry into cells, with immunostimulatory properties. Vaccination with VCL-CB01 may stimulate the host immune system to mount cellular and humoral immune responses against CMV positive cells, resulting in cell lysis. (NCIT_C61327).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5521">
		<vaccine_name>VEGFR-2 DNA Vaccine VXM01</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4432">An orally available DNA cancer vaccine containing an attenuated strain of the bacterium Salmonella typhimurium encoding murine vascular endothelial growth factor receptor 2 (VEGFR-2) (VXM01), with potential immunomodulating, anti-angiogenic and antineoplastic activity. Upon oral administration and successful transduction, VEGFR-2 DNA vaccine VXM01 expresses VEGFR-2 in addition to inducing the expression of T-cell activation markers, such as CD25, interleukin-2, the early T-cell activation antigen CD69 and the lymphocyte function-associated antigen LFA-2. The immune response targets the fast growing VEGFR-2 expressing endothelial cells found in the tumor vasculature, thereby blocking angiogenesis which may ultimately inhibit tumor cell proliferation. VEGFR-2 is a receptor tyrosine kinase overexpressed on proliferating endothelial cells in the tumor vasculature. (NCIT_C99378).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5214">
		<vaccine_name>VEGFR1-1084 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4358">A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor 1 (VEGFR1 or Flt-1) with potential immunostimulating, antiangiogenic, and antineoplastic activities. Upon vaccination, VEGFR1-1084 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR1-expressing endothelial cells of the tumor microvasculature, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR1, a receptor tyrosine kinase, may be overexpressed on endothelial cells of the tumor microvasculature and is associated with tumor cell proliferation, invasion and tumor angiogenesis. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenicity. (NCIT_C77895).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5419">
		<vaccine_name>VEGFR2-169 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4201"> A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor (VEGFR) 2 with potential immunostimulatory and antineoplastic activities. Upon administration, VEGFR2-169 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR2-expressing tumor cells. VEGFR2, a receptor tyrosine kinase, is overexpressed by a variety of tumor types; overexpression is associated with tumor cell proliferation and tumor angiogenesis. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. (NCIT_C74090).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5542">
		<vaccine_name>Verpasep Caltespen</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4659">A recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from Mycobacterium bovis, and the human papilloma viral (HPV) protein E7. Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers. E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes. (NCI04) (NCIT_C2811).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5097">
		<vaccine_name>VHL-42: 65-76(V74G) Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4189"> A peptide vaccine consisting of amino acids 65 through 76 derived from the tumor suppressor protein Von Hippel-Lindau (VHL) with a glycine substitution at position 74. As a cancer vaccine, VHL-59: 65-76(V74G) may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein. (NCIT_C38122).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5172">
		<vaccine_name>VHL-59: 116-128 Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4188"> A peptide vaccine consisting of amino acids 116 through 128 derived from the tumor suppressor protein Von Hippel-Lindau (VHL) with a frameshift mutation. As a cancer vaccine, VHL-59: 116-128(FrSh116-128) peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein. (NCIT_C38123).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5012">
		<vaccine_name>VHL14 Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4425">A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL14 peptide is a point mutation variant of the VHL protein; the mutation is in amino acid position 166. It might be used to elicit or boost cellular immunity to cancers that expressing the von Hippel-Lindau mutation. (NCI04) (NCIT_C2741).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5333">
		<vaccine_name>VHL16 Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4426"> A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL16 peptide, also known as S111I, is a point mutation variant of the VHL tumor suppressor protein; the mutation is in amino acid position 111. Vaccination with this agent may stimulate a cytotoxic T-cell response in patients with VHL-associated cancers that express this variant of the VHL tumor suppressor protein. (NCI04) (NCIT_C2740).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5490">
		<vaccine_name>VHL2 (Y12M) Peptide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4643">A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL2 (Y12M) peptide is a point mutation variant (from tyrosine to methionine at amino acid position 12) of the VHL protein. Vaccination with this peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein. (NCIT_C2824).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5322">
		<vaccine_name>Vi Capsular Polysaccharide Typhoid Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Live attenuated vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4509">A live attenuated bacteria injectable vaccine used to prevent typhoid, which is caused by Salmonella typhi. (NCIT_C97127).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5513">
		<vaccine_name>Viagenpumatucel-L</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4151">A proprietary, allogeneic tumor cell vaccine expressing a recombinant secretory form of the heat shock protein gp96 fusion (gp96-Ig) with potential antineoplastic activity. Upon administration of viagenpumatucel-L, the irradiated live tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs) into the blood stream, thereby activating antigen presenting cells, natural killer cells and priming potent cytotoxic T lymphocytes (CTLs) to respond against TAAs on the endogenous tumor cells. Furthermore, this vaccine may induce long-lived memory T cells that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL retention sequence of gp96, normally an endoplasmatic reticulum-resident chaperone peptide, with the Fc portion of mouse and human IgG1. (NCIT_C61073).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4019">
		<vaccine_name>VMCL</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004611</vo_id>
		<type>vaccinia viral lysates of an allogeneic melanoma cell</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs="reference2937">VMCL treatment appeared to benefit patients irrespective of the number of lymph nodes involved and whether surgery was carried out near to (synchronous metastases) or some time after removal of the primary (delayed metastases) (Hersey, 1992).</description>
		<adjuvant refs="">cyclophosphamide</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5127">
		<vaccine_name>Von Hippel-Lindau Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4276">A cancer vaccine composed of peptides derived from a tumor-associated protein encoded by a mutated Von Hippel-Lindau (VHL) oncogene. VHL peptide vaccine may stimulate a cytotoxic T cell response against tumor cells expressing the VHL tumor-associated protein. (NCI04) (NCIT_C2492).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5430">
		<vaccine_name>WT1 124-138 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4200">A synthetic peptide vaccine consisting of a HLA-DR15-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 124 through 138, a HLA class II-restricted WT1 peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 124-138 peptide may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. Activated helper T-cells stimulate dendritic cells, and activate the proliferation of other T-lymphoctes and B-lymphocytes. This causes tumor cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing tumor cells. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers. (NCIT_C104738).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5089">
		<vaccine_name>WT1 126-134 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4535">A synthetic peptide vaccine consisting of the amino acids 126 through 134 of the human Wilms' Tumor protein-1 (WT1) with potential antitumor activity. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. Vaccination with WT1 126-134 peptide vaccine may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. (NCIT_C61442).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5029">
		<vaccine_name>WT1 235-243 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4205">A synthetic peptide vaccine consisting of a HLA-A24-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 235 through 243, a MHC class I-restricted peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 235-243 peptide may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers. (NCIT_C104734).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5468">
		<vaccine_name>WT1 247-261 Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4206">A synthetic peptide vaccine consisting of a HLA-DRw53-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 247 through 261, a HLA class II-restricted WT1 peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 247-261 peptide may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. Activated helper T-cells stimulate dendritic cells, and activate the proliferation of other T-lymphoctes and B-lymphocytes. This causes tumor cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing tumor cells. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers. (NCIT_C104737).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5341">
		<vaccine_name>WT1 Analog Peptide Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4315">A peptide vaccine comprised of an epitope of human Wilms tumor 1 (WT-1) with potential antineoplastic activity. WT-1, a transcription factor, is overexpressed in most types of leukemia and in some solid cancers. Vaccination with the WT-1 analog peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against WT-1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. (NCIT_C64635).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5330">
		<vaccine_name>WT1 Peptide Vaccine OCV-501</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4545">A peptide cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, WT1 peptide vaccine OCV-501 may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in some solid tumors. (NCIT_C106257).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5027">
		<vaccine_name>WT1 Peptide Vaccine WT2725</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4590">A peptide cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon administration, WT2725 may induce a specific cytotoxic T-lymphocyte (CTL) response against WT1-overexpressing tumor cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in a vast number of non-hematological solid tumors. (NCIT_C102751).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5354">
		<vaccine_name>WT1-A10/AS01B Immunotherapeutic GSK2130579A</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4354">An immunotherapeutic consisting of the recombinant fusion protein WT1-A10 combined with the adjuvant ASO1B with potential immunostimulating and antineoplastic activities. Upon administration, WT1-A10/AS01B immunotherapeutic GSK2130579AWT1 may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells, resulting in cell lysis and the inhibition of cellular proliferation. The tumor-associated antigen WT1 (Wilms tumor protein-1) is overexpressed in most types of leukemia and in a variety of solid cancers. WT1-A10 is a 292 amino acid recombinant fusion protein consisting of a 12-mer truncated tat sequence (leader sequence) and amino acids number 2-281 of the WT1 sequence; ASO1B consists of a combination of the adjuvants monophosporyl lipd A (MPL) and Q21. (NCIT_C78865).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5415">
		<vaccine_name>XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Other</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4592">A cancer vaccine containing immunogenic, HLA-A2-specific epitopes derived from X-box-binding protein 1-unspliced (XBP1-US), XBP1-spliced (SP), syndecan-1 (CD138), and CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 may stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens. The tumor associated antigens (TAAs) XBP1-US, XBP1-SP, CD138 and CS1, are overexpressed on the surface of multiple myeloma (MM) cells. (NCIT_C103823).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine5416">
		<vaccine_name>Xenogeneic Tyrosinase DNA Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>DNA vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference4244">A plasmid DNA vaccine, encoding an epitope of mouse tyrosinase, with potential antineoplastic activity. Administered via intramuscular electroporation, vaccination with xenogeneic tyrosinase DNA vaccine may induce both humoral and cytotoxic lymphocyte (CTL) immune responses against melanoma cells that express tyrosinase, resulting in decreased tumor growth. (NCIT_C68839).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs=""></antigen>
	</vaccine>
	<gene gene_id="gene315">
        <gene_name>AFP</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>174</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>4501989</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AC108157</gene_refseq>
        <protein_refseq>NP_001125</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>4</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>73436218</gene_start>
        <gene_end>73455784</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>transcript variant 1</protein_name>
        <protein_pi>5.43</protein_pi>
        <protein_weight>65698.6</protein_weight>
        <protein_length>609</protein_length>
        <protein_note>Also known as FETA; HPAFP</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000004.12:73436218-73455784 Homo sapiens chromosome 4, GRCh38.p12 Primary Assembly
CATATTGTGCTTCCACCACTGCCAATAACAAAATAACTAGCAACCATGAAGTGGGTGGAATCAATTTTTT
TAATTTTCCTACTAAATTTTACTGAATCCAGAACACTGCATAGAAATGAATATGGAATAGGTGAGATATT
TTGTGTTTTTCTTGTCTTTTCTCTATATCAAAATTTTTTAAATTATAAAATTTGCATTAATTTGTCTTGA
TTTATTATTCATATTTATTATTCCACATGGAGAAAAAATATTTAACTGATGGATATATTTAAATGAAAGA
TAAACTTGTAACTTTACAAGAGGTTTACAAAGTTATAGCAGTGTTTAATGGATGAATGGTTTGTATGTTT
CATGTTGAATTAATTTTTACACTTCAATGGTATGCATATTAACTTTGAAAAATTATATATATACACATAT
ATGTACATATATATGAATATAAATAAAATTTTATATGTGAAGAAGCCAGAATTATGCTCCTTCACATAAC
TCCCTCAGACTAGTAAAATAGATAAAATCTTTGTTTTTAATACAGAAAAATGGGTCATTATTTGATGGTC
TGAAGAAGAAATATTGTGACTGGGATATGAATGGCAAACCGTAGTATAACTATGTTCAAAAGAATGCCTG
AAATATATTTTTAACCATTTGACTTTCAGGACAGTTACAGCACTACAGTACAGGGAAAAACCAAACAACT
GGAAGACAAAATCTGGATTTTAGTGATAGGTCTACTATAAATTATGCTTGTTAACTTCATTCCTTAGTTT
CCTAGTTTTCTTTTCCTCAAGTATAAAATTAAGATGCTTAGGTTATCCCTAATGTTCTTTTAATTCTGAA
ACTGTACAGTTCTAACTGAAACACAAACATTCATATGTAACAATGATTACTTTCTTGGTTGCAGTTGAAA
ACACGTTTCATGAAGTTTATTTTGCTTTCCAGCTTCCATATTGGATTCTTACCAATGTACTGCAGAGATA
AGTTTAGCTGACCTGTAAGTTTTGCTTATATAAATGTACTTTAAATGTGTAAAGCAAGGATAAGTAAATA
CTTAAATAAAATTGGGTACCCCTGTGAGCTCTTAAAAGCACAAAAGCAATTTGGACAATTTCAAGAAAAG
TTACTCATACTGAATATCAACTTGATGTTGAAGAGGTTAAACTGTTGACTAATGTCTTCGACATTGACCT
TTTGATTCCTTGAAATCTCATGAGTCAAACCAAATCAGATTTTAGAAACTGAAGATTAGTGTCTGATCAG
TGACAGCCATATACTAATTCAGGAATTTTTCTCATCAGTACCAACAGGGTGATATTATAATGTTTTCTTT
TCTGTATACTATTTAAATCTTAGCAGCAAACCATAGGTGATAAAATATTCTATTTGCTGTTATTTGTGGA
GAGTATGTTAGTCTCTTGGATGTCTTTCCATTCCACATTTTAAAAATTTCTAACAAAGAATTTAAAGTAG
TGTGTTGCTGTTACTCCTTGCACATCCAAACCTGCATAAGGATTGCTTTGAGTCAATCCATGAGCACTGT
AGTCTTGGGTTTTAGACCTTGATCATACTGGGAATAGACACTGTTAGAGGTCTGTCTAATTACCAATTTT
TTTTTGCTTAAATTTAAAAGTAACCATAAAGAATATAGATACCCTCAATTATGGGTACATTACAGTAGAT
GGATGGTCACAGAAGGAGAAACCACTCTTATGGGAAATCCACTTATTTTAGCCTTTAACATCTATATGTA
TATTTATGGCAAAAGAAAACAAGAAAAAGACTAAAGTTTCTTCTCAGATGACCTGGAAGCTAATTTTACA
TAATTTTACAAATCAAATGTCTAAACAGATTACAACATAAATAGAAAACAAAACAAACAAATGAAAAACT
ATACTTGAGAAAAATAAGCTTGCTGCAGGTCTGTTCCTTAAGGATTCACACGTATTTTTGTTTCAGGGCT
ACCATATTTTTTGCCCAGTTTGTTCAAGAAGCCACTTACAAGGAAGTAAGCAAAATGGTGAAAGATGCAT
TGACTGCAATTGAGAAACCCACTGGAGATGAACAGTCTTCAGGGTGTTTAGAAAACCAGGTGAGTGAATA
ATTTTAAAAAAGCATTGTGATATTTGACAAAAATTTAGCATGCTGAAGAGAAGATACAAAAATAGCAGTG
AAAAATGCATTTATATATTTGAAGAGCTATTGTATGAAAGAGGGATTAGATTCATTCTGAATTGCTAAAG
AGGGCAGAAGAGAACAATAGGTAGTTATTATAAAGAGACCATATAAATATGATGACTGAGAGCTAAGGTT
CTGAAATAAGATTATCTTGATGACTATGGGCATATTAACTTTTTTGAGCTTCAGTTTTCTTATCTGTAAA
ATAAGGGATGATAATAGCTCCCATTTCATAGTTAGCATGGAAATTGATATAACAGCAATAGTAGCTAACT
TTTATTATACACACAATGTGACTGGCATTATTCTAGGGAGCATAATGTGTATATTGATAATAAAAATATT
TTATGACATAGGGGATAGATAGCACTGATGAATCAGAATGGTTGTCCAGTGAGTCAAGAGATGCTGGCTC
GGGCTTCTGGGCAGGATATCAGCTTTGCTTACCTATATTTATTTATTAAACATTTAAAATAATCCTTGAA
GATAGATGCTAATCTTCCAACTGAGGAAGCTGAGGCTCAGAGAATTTAAGTAACTTTCTTATGGGAACCA
CCAAATGGCAGAGCCAGGATTTGAACTAGACCATCTGGCTTAAAATTGACAGTCTTAGTAGCTTCATTAC
ACTATAACTATAGTGAATGTAAGATGCATAGCACATCGTTAGGGTTGCCAGGTTTAGCAAACAACAACAA
AACATAATACCCAGTTCAATCTGAATTTTAGATAAACACTAAATACTTTTCTTAGTATAAGGATATTTCA
TTGTAGAAGCTCAACAAATAATATTTATTATTTATTTTATCTCAACATAGAAACAAACTTGATAATGATT
AGAACTCTCCAATTATAAAACAACATGCCCAGAGAATACTCTGTTATGGTGGGGTTAATTAGGTGGCTGA
AAGACAATGTACCTGGAATATCATAGAAGAGATGCTCCTTTAAGGATATAGTTTAAGTTCTTTCCAACTT
TGAAATTTATGAATTGACAAAAATTTCTGTTTTGCATCTCTATTTTTGTCTTGTTCTGATAATCTTTTCA
AAATGTGTATAAAAAAACAAGAATACATTATCTATTGCAACTTTACAACCAATTAGAGGTTCAAGGTAAT
GTTACAGATCGCTGATTTATTCTTGTAAATTCAAAGGTATGTCTTTTAAATGAGGATTGGGAATTAGAAA
TCTTACGTAAGCCTTCCAGGATTCTCTAAATATTACTGTAGCAGCTATAAAAGCTACATAAAAGTTCCCT
CAGATACATGAAACACATGTATTCCTCAGATGCTTTCTGTGGAATATTGATGCTGTCATCTGAGTTTGGT
AAGGGTAAGTCACAGAGGAGGAAACACATACATTTTAAAACATTTTAGCTAAATATGTAATTGTGGCCAA
GAAAAGTGTTTTTTTAAAAAATAATTATTTCATTTCAAAATCATTTTTATTTATAATTGAAAATAATATG
CAGTTTTTTATTGTCTTGTAAGGATGGCATGTAAAATGAGCATTTATGTCTGAAATGTGGTATGTCTGTG
TGTGTGTGTGTATATGTATATATATGTATGTATATACCATAATATATACATATGTATTTGCAATTCCAAA
AGTTACATCTTTAATGAGAATCATGAAAATATTATTTTGCTCAGTTTCTTTTTTTATTTAAATTTAAATT
TAAAGTTCTGGTGTACACGGGCAGGATGAGCAGGTCTGTTACATAGGTAAACACGTGGCATGGTGGTTTG
CTGCACCTACCAACCTGTTGCCTGGGTATTAAGCCCAGCGTGCATTACCTATTTTTCCTAATGCTCTCCC
TCCCTGCACTCCACTCCCTGACAGGCCCCAGTGTGTGCTGTTTCCCTCCCTGTGTCCATGAAACATGGTT
TATATATTTATAAAAGTTTATATATCCTAGTCCAAATTTTTGATAACACAAAAAGGAAAAATAAAATAAT
TCAAAATTGGGAAAGAGAAACAAAAGATTGCATGGCTTTTTTCCTTTTATTGTTTGGACATTAAAGTCTC
ATTTTCCATAAGGCAGCAAAGAAATCTATTTCATCAGGCTGAAACAAAATACATTAGAATTTGTATGGAA
AATTTTTCAGAATCTATAGTTCTGATTTTAGACATTAGAAAATGTTTCATGTGTCTTATAGATTTTTAAA
GCAAAGTTAGTTGTCTTTCTCCAAACATAAAATATTTCTTATAGCTACCTGCCTTTCTGGAAGAACTTTG
CCATGAGAAAGAAATTTTGGAGAAGTACGGACATTCAGACTGCTGCAGCCAAAGTGAAGAGGGAAGACAT
AACTGTTTTCTTGCACACAAAAAGCCCACTCCAGCATCGATCCCACTTTTCCAAGTTCCAGAACCTGTCA
CAAGCTGTGAAGCATATGAAGAAGACAGGGAGACATTCATGAACAAGTAAGGATCCAGTTTAAAGGTAGA
TGCAAACCTCAGAAACACAGCAATGGCAAGCCTAATTTAGTATTTTTGCAATGTACTCATGTACTCCCAG
TAAGAGGTATAATGTTTCTTTGGTGTTGTGTCTGCTGAGGTCCCAGACAAGGTAATTAGGAGAGCAACAT
TCAATGTAACTTGGTTTCCATAGCACGCTAGATGTAGTACAAACCACAGGACAAACCTACCAGAGGTTCC
ATTAGTCCCTTGAGAGATATACACCTTTTTTTTTTCTTTTTACCCATTCTACTCTCAATTTTACCTTGTT
CAAGAATATATTAGTATTGCACCAAATTGATGCTTTCCAGAGCCATATATTGGTGTTTTGTGTTCACCTA
ATTGCCTAGAAATAAAAGTTAGAGATCCAAGCATGGTCAAGCATGGTCAAGATACACAGACATGGCAAAG
GTTTACTGAACACTTAGGATGTTGTGGGGCCGGGCGCGGTGGCTCACGCTTGTAATCCCAGCACTTTGGG
AGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACATGGTGAAACCCCGTCT
CTACTAAAAATACAAAAAAAATTAGCCGGGCGTGATGGTGGGCGCCTGTAGTCCCAGCTACTCGGGAGGC
TGAGGCAGGAGAATGGCGTGAACCCTGGAGGCGGAGCTTGCAGTGAGCCGAGATTGCGCCACTGCACTCC
CGCCGGGGCCACAGAGCGAGACTCCGTCTCAAAAAAAAAAAAAAAAAAAGGATGTTGTGGAAACATGTCT
GCTTGCACAGAGGATCAGATTAACACTCACAAACAAACTTTGAAGCCTCCTTCTCCTCTTCCTCTTCATT
CTTCTTCTTTCCCCCATTTTGTTGATAGGAAATTGAAGGTTGGAAGGCTAAAACAACTGGCTAAGGGCAC
ACAGCTAGTACATTTGACCCCAGGTTCTCTGTTGGAGAAGCCTGTACGTAACTCTTCATCACTTCTGCCT
TCCATGTTACTTCCTAAACCAGATAAATAGAGAGATTGCCCTTAGAACATCTCTGCTATGGCGACTATCC
AGGTGCATAACCCCATTCTGCACTGACAAGGGATAAAATGTCCATCTTTCTGTTGCACTTAGCAGAAGTC
TGGCTTTGCTGATCCCTGAAACATATCTGAGTAGGCTTATTGAAAAGGACCTTTTAATAAGAATCATGGT
TAGCATGTCTGCCTATTTTCTTCTCATAATAGAATCTGGTACCATCTGTCAGATATTTTTCCCCCCAGGA
TCTTTAGTGAGGAAAATTTTGACAACATGTGGAAAAAATATGATGATTTTCCCCTTAGGAACACAGTAAA
GACAAAGTCAAATGCATTTTGTTGTTGTTGTTTTTGAATCTTTAAATAAATCCCAGTGTCCAGTTCCAAG
CAGTAGTAGTCCTATTTTTAGGTGTTTATAAATCTTCTAGCTCTATTTTATTTCACAGATTCATTTATGA
GATAGCAAGAAGGCATCCCTTCCTGTATGCACCTACAATTCTTCTTTGGGCTGCTCGCTATGACAAAATA
ATTCCATCTTGCTGCAAAGCTGAAAATGCAGTTGAATGCTTCCAAACAAAGGTATCATATTTGCGTGGAT
ATCTGAACCAGTACTGTAGTCTATGACTCATTAAAACAAAACAAAGTTAAAAATGAAAACGTGCTTAATT
GTGGAGAGTATCGTTTTTGGAATAGAGAAATAGTTCAGCAGTCTGATATTCTTCGAGTGAACAAAACTGG
ATTTGCTGGTTTTTATTATCTATTCATTAAGTCAACAATAATTTTATTATTAAGGAAGTGAGTTTGATGG
GATAAAGAAGGAAAGACAGACAGACAGAAAGAGAGAAAGAGAGGGTGCTATAAATGGGAAGGAGTAAGTG
AAAGAAAACGGAGAAAAGGAGGAGCAGAGGAGAGAGAAAAAATGAAGAACTATGATAAATGCTTTATACT
TACTGTTTTTTTAAACCTTAGAACAAATTTGAGGTGTAAGTATTTTTGTCCTTTAACAAACTAGGAAAGA
GGTTTAGAGAAGAAAATTTTTTTTAGGTTTAGAGAGGTAGAATAATATCCACCATTAACTACTTGCTACC
AGCAGTCCTATAACAAAAATTTCCTGAGAACTGACTACTCTCAGTGTCAAGCCGTGATACAATCGTATTT
TTTGTAACTGAGAAGACACTTAAGAAATTAGCAGGCTTCAATTTGTCTTTAAGCTGTTTAAAGGTACAGT
TGTTCATTTATGATCCCCAGTATAAAAGTTATGTTTTTGTTTCAAGGTACTTTGAGTAAATTTGTCTGGC
ACAGATGCATATAAACTAACCCAAAAGAATAAATGAGTCAATAATATTCTGCGATAATGTATGACATTTA
TAATTTTTAGTAAAAAACATATTTTATGGAATTTCATTTTACCTATACTTGTTGTTTTTCTAAATATTAG
AGCTTGTAAAGAAAATGTTAGTATATGCTTTCATGACATTTTGTTTCCTCTACATCTAGGCAGCAACAGT
TACAAAAGAATTAAGAGAAAGCAGCTTGTTAAATCAACATGCATGTGCAGTAATGAAAAATTTTGGGACC
CGAACTTTCCAAGCCATGTAAGTTCAAGTTCTATCTAGGGAAGAGGGTGAGAGCTACAGAACTACCATTT
TGCAATTTGGGTTCGTTTTTTTAATTGTTGCTGTTTTAGAGAATGAAGACCCCTTTGTGACCCCTTTGAT
GAGGGCTAATGGGATTAGAACCATGAACTCTTAGGATCAGAAGGAAGCTAACGGATAAGTCAGTTTAACA
CTTACTAAAGCCTAGCTGAGATAATACATAGAAAAGACTTTTAAAGTTTATGTTATTTACCTGTTCTTTA
AGACACTTAAGTTCTGGCCTGCCATCAAATTATACCTCATCACTAGACCATATTTTTCTAGCTCTTCTAC
AAAATAAGTCAGCCTTCACTGAGTGTCATTTAAAACTTTTGCCTTAACAAGAAATTCTTTATATTAATTG
TGTTTCTTAATCTTCTATAAGGCTCTTTATAGCATTTATTGCTTCCCATAAAAATATTCCTTTGAGGCAA
TAATATTAGAATCTAGTGTCAGGAGAAAAGAACATTTTAAATTATATAACTTCTTTAAAGTACTCATCAA
CTCTTTTATGATAAAACATTTCTAGTATATGAAAATATCTGAGCTGCTAATCGAATAGTAGTAAGTATAT
ATATTCAGAGTTTATTTGATTGCTGTTTGGTTAAATAACACGTTAAAGCATATTGTAGACAATGGAAATC
TAGAATGAAGTTTTTAGTAATAGAATTAGTTCTAAAGACTGAAATTTCTTCTTGTAAGAAGTCAGATTTA
TGCCTTAACTACCCTCCAACTCAATTAGAAATTGAAAGATTAATTTATGACCTACTTTAAAAAAATTTAT
CTTAGTAATAAAATAGAAATTGAGATAGTATTATAATACCCTTATCATTTGCTATCCATAAGTGAAAGCT
AAGTGGTCTAAATTTATAGAGAAGATCCATCTTTATCAGAAGCAGGAGTAACACTATTTTCTCTAGGAGC
AATGGTTTTACAAAGACAACTCTTAAAATTTAATGAAATATGCAGAGGAAACCAGAATTTTTATTTCTTA
CTTCTTTTTTGGCCACATTACTCTCTTGGCACACTGGTATGCCTGAAATGTTTAATCTGCTCCACTTTCT
TGTCCCATTTCATTGATTTGCACATACGCCTCCTTTCCTGGATTCTCAGAAGTATTTTTTACCCCAGTAA
AAAATGGTTCTCATTTTCATGGAATTTTCCATTTCTTAATTGTTTATCCTTTTAAAGTTTTATGTCCACT
CAATACAAATGCTCAGCATAAGGGTTGAATGGCAAAAATAATTTACCTTAATTCTTAAGACATGTTTTAG
GAAAAGATAAATTATTTCTAAACCATTTGTGGGGCCAGCTCACAGTTTACAGAGCTACCACCTTGAAAGA
TATGGCTGGAATCAAGCCTTAAAACATGTTTCCTTTTCTTTTTAAACAACAAGGGAATTTCAGTCATTTC
TCTTTGAAACTTCTACTGTAGTAATACTCTATAAATTCTATTTTATTTTGACAGATAACCAAGAAATTAA
TTTCTAATTTCTTTTTTTTCCCTAGAACTGTTACTAAACTGAGTCAGAAGTTTACCAAAGTTAATTTTAC
TGAAATCCAGAAACTAGTCCTGGATGTGGCCCATGTACATGAGCACTGTTGCAGAGGAGATGTGCTGGAT
TGTCTGCAGGATGGGGTGAAGAGTCTTGCTTCTTAAAATAGAAGATTTTCACTCCCTTTTCTTTCTTTTT
GTCTCATTCTAAAAGGGAGAAGGTTGTTTGACTTGAATTGGTTACAGAGTATGTAAACTAGGTGACTCCT
TAAATTTGCAGAATTCTCGGTAGTAAAACTTAAACCATCTTTTGTTGATCCTGGCTTTCACTTTAGCTAT
ACCCCTTTTTGTGAAACCAAGGCTCATCTATTTCTTACTTCTAAAAAAACCGTGGGAACTTCTCAGAAGG
CTTCTCCATAGTTACTTGGAGGACGGGAGGAAACTAAGGTTTAATGTATTTATTTTTTCATTCATTTATT
CTTTCATTTGACAAATAAATATATATTAAATACTTTCTATCTGCTAGCCACTATGACAGACACTTGTTTT
AAAAGCACAGGCTGACCTCAAGGAATTCACAGTCTGATAGGAGAGATAAGACAGTGACCTCCTTGGAGTT
AGGGACTGCCTTGGTTTACTGTTATCTCCATAGCACAATGCCTGGCACATGGAAGGCATTCTATAATAGT
TTGTTAAATGAACGAATGCAATAAAAATTGCACAAGTAACTGTCCTACCAGGTAAAAAGCTAGCCTTGCC
AAAGACAAGTGTGAATAAAGTGGTCTCGGAGAATTAGAAAACAAAATTTAAAAAACCCAGCAACAGTTTC
TTGAGTGTGCTCTAGTCAGTGGTGGTTTAAGCAGTGTGGCATTGGCTTATTTTGGCTAACCCTAGACTTC
CTAGATTTTACAAGAGAGGACTGTTGACCCTCAGATTACTCTGTCTCTGTGGGCTCCATGACATACCAAA
GAGATTAAAATCCAAGGAGCTTAAAAATTACTGCTCTTAGGTACTCAAATGGCTTGATAACCAGCACTGG
ACTATGGTTTCCAGAAGGCTGAAAGTGAAGATAAAATGCTCATTTCAGCCCATCCGATGGCAATTCAGTG
AGATGCTTGAAGTAAGCAAGAAGCCAAGGCTGCAGAGGAGGCCTGAGAGTGACAGTCCCTGAGGAGCTGG
GGAAGAAGTGGGAGGAGGCAGCCTGGCAGGCGACTGTACTACTTTACTTGTTTTTCTTCTAAAAATATGG
CATACTAGGAAAACCAACAAGAAGTATTTTGTTTTTCTTTGAGCTCAGTTTTCCCATTTTGAACGGACAA
TTTTACTGTTTCTCGTTGTCATTTTTAAAAAGTTAATTTTTTCAATTTTTGGAGCTCATAACCACCCTTT
TCCTTTAAAGTGGAAACATTAATTTCAGCATGATATGTAAGTTGGATTTTGATAGCTGAATAATGGGTTC
TAATTATCTTTGCTGAGAATGTACAGAATTTTCAGTCCCATGACAGGTATATATGTAAGCTCTGCCTCTC
TCTGGCCACTTAGGTGCATTGCCATTTTATTATCTATAGACTGCCCTCTGAAGGTCATAGTCAGTCACTG
CAGTATGTTCTGATAAAGATGATTATCATTCTTACGGAATTTCTCGTGGAGCAGAAAGTTTGCTCTCCAT
GTTATGATAAAGATGATTATCATTCTTACGGAATTTCTCGTGGAGCAGAAAGTTTGCTCTCCATGTTATG
ATACCAGTTGCAAGTGTTGTTTAGGGGCAAATTTGAATGCTAATAGAAATACATATAGCAACATGCATCC
TATTTTATTTGAGCACATTTCCCTCTTATTTGTAAAGGTTTTCAATTAAAATAACATAGGATTTAGCTTA
CAACTATGGAAAGAAGAATTGAACAAACAGGTAAGTGGAAAGGAATGAGAAAAGGCAAAAGTGGGGAGAA
AGCACTAAAACGGGAGACAAGTTAAAATTTCTTTTTAATTGATAGGTCACGTTCTCACTCTATTTGCCTT
TAAGGGAAGAAAGCAATCAAGTTAATATGTTTTCCTTCATTGTATAGTATGTAACTACGGACACTATTAG
AGGAGGGATTTGTGTAGCACTTAGGACATTATACTTGATAATTTCCAAGGGTCTTTCTAGATTTAAAAGT
CTGATTCTAACGTAGTAATAAAAATAAAGGCCCAATTTTCTCTTTAATATTGGCTGAAGATATTACTCTA
TTATTGCATTAAAATTAAACATTCACACATTGTTTGCACTGCTAAATAAAATTATGTAATTTCTTCTTCT
TTCCTTCCTCCTTCCTCCATCCCTCTCTATTTCCCTTTCCCCTTCCTTCTTTCCTGGCCTTTTTTCCTTC
TTTCTTTGTTCCCTTCTCCCTCCCTCCCCTTTCTTCCTTTTTCTAAAGCTGGCTTTGAGATCCTTTATTA
AAGAATAAATCTTTAAAACTTATACTTTATTTTCTCTGTTGCAGGAAAAAATCATGTCCTACATATGTTC
TCAACAAGACACTCTGTCAAACAAAATAACAGAATGCTGCAAACTGACCACGCTGGAACGTGGTCAATGT
ATAATTCATGCAGAAAATGATGAAAAACCTGAAGGTCTATCTCCAAATCTAAACAGGTTTTTAGGAGATA
GAGATTTTAACCAATTTTCTTCAGGGGAAAAAAATATCTTCTTGGCAAGGTAACACACTCTGTAAATGCA
TGTTCATGCAAGTAAAAATGATTATGTGGCTGACAGATTTGCGTTGTTGAAATGGAGAGTGATGATTATG
GTTTTTGAGTTCAATATGTGAGGATATTTGGCTAGAATGTTCTGAGCCAAAATAGATTTCAGTAGATAAC
CAGGGAATAAGTAATGGGATTTGGTGTTTAACGGTGAAGCGTTCACCACTGTGACTCATTAACTGCTTTG
CTTATGAAGCTGAATTTTATTTCACATCAATTTCTCTGGAATCAGAAGCATTGTCATCCTGTAAAGATTA
CTCATATCAAGGCCACCATTGAACTCTCAAATAGGATATGGATATTTTTGTAATAAGAAGAGTTCATGAT
TAAGAATGAACTCTTGCTACGCATGTTAAAAAAAAAACTTTTCTCCAAAAGATAACACAAGAGATAATGC
TAGGTAGAAGAACTTTTATAGGAACAGCTTATTGGCTATGTATTAAATACATGTTTTGTATTTTTTAAGA
AAATCAAAACATGTTTAGAGACATTTGCAGTACAGTAGTTTGTTTTAATACAACTGATAGGTCACGTTCT
CACTCTATTTGCCTTTAAGGGAAGAAAGCAATCAAGTTAATACGTTTTCCTTCATTGTATAGTATGTAAC
TATGGACACTATTAGAGGAGGGATTTGTGTAGCACTTAGGACATTATACTTGATAATTTCCAAGGGTCTT
TCTAGATTTAAAAGTCTGATTCTAACGTAGTAATAAAAATAAAGGCCCAATTTTCTCTTTAATATTGCCT
GAAGATATTACTCTATTATTGCATTAAAATTAAACATTCACACATTGTTTGCACTGCTAAATAAAATTAT
GTAAGCTAGAATAAAGTTCAGATTTAGGAGACACATAGTGACAACTGATTGGTGACAGAACTAATCCTAT
AATCTGGGAATACGGTTAGTAAAGTCAAGAATTACCTTTAAGTTTACACATCCATGCACATCTAAATCTA
ATTGTTTAATAGAAGCAGTTCTTCAGTTGCAAAGGTTCTTTGCAGTAGAATTTTCTCAGCCAGGAATGAT
CTTCCCCCAGATATTTGCATGGCTTCTTTCACTTAGCTGATCTCTGTTCTGATATCAGCTGCCTAGAGAG
AATTTTCTTGACCACATTCAAAGTTAGTGGCCTCTCCACCTTGGGTATCATCCTTTTTTCTCTTTTTCAT
CTTTATTTATTTTCATTGATTTATCGCTAACTGAAATGAGATGGCCTATTTCTTGTTTATTTGTTCTGCC
TCCCTATAATGTGTGCTTTTCAGAGGGCAGGTATTTATCTTAGACATCATTGAGTCCGTTCTGCTTAAAG
CAATGCTAGCAAAGAGTGGACACTGGAAAAATATTTGTTGAATAAATGAATATAAAGTCCGTAATTGAAA
AGTCAAATTGAGAGATGCAGGAGAAAACAAAAAGCCATTTTACAGGACAATTTGAAGGATCACAGTCTGT
ATTAACAGTTTTGCCATTCATATAATTCAAATCATATTTGATTTTCAGGTTTATTTATTTGAATTTAACT
TCCACATGCCATATTATATAGGAATAACTGGAGAAGTGATGGCTCCTTTTGTCTCTTAGTTCCAATAACT
TGAAATATTTTTCTCCACATATTTCAGTTTTGTTCATGAATATTCAAGAAGACATCCTCAGCTTGCTGTC
TCAGTAATTCTAAGAGTTGCTAAAGGATACCAGGAGTTATTGGAGAAGTGTTTCCAGACTGAAAACCCTC
TTGAATGCCAAGATAAAGGAGTAAGTTGCTCTAGAATTTTAGGGGAGTATGAAAAACTGGATTGATATCA
TCTGTTAAAAATGCTGTTTGTTTGAAAGCCTCTAGTTTTCAACTAGTTGTTAGCCAGTTATATCTATTTG
TCTAGATATTAAGCTGTTATTAACTAGCAGTCAGCAGCTAGTGGCTTGCTTTAGAAACAAAAATGTTAAT
TGCTTCTCAGCCTTTTGGCTAAGATCAAGTGTAGAAATAAAAATGTTAACCAAAAGTCCTTTGATCCACA
AATAAAGGTAGTATTCATTATTCATTTTTGGATAACTTCAGAAAGGCAAGAATTTGGTACAGAAAGAACT
GTAACCATTTATCCAAAGATTGAGTTTTGCCATTAAATGATTTTGTGATTTATAAAATGTTAAACTTAAT
CTCCCCAAAATCCATTTTCTGTAATTATCAAAATTTACACTTTACCATATTTAATATTTAAACATCTCTG
ATTGGTTTTATAATAGTATATAATATTGATCAATTTTATATACAAAGTTATGCATCCAAGAAAAGAAAAA
TGTATATGTAATAATTCTTCATTTTCAGGAAGAAGAATTACAGAAATACATCCAGGAGAGCCAAGCATTG
GCAAAGCGAAGCTGCGGCCTCTTCCAGAAACTAGGAGAATATTACTTACAAAATGCGTATGTTTTTGTAA
ACAGTATTTTTAGTGAATTAAAATTATTAAAGAGAATGTAGCCTTCCCCATTCTCCTCCTTTGGAAGCAA
CAAGAATGACCTGTGAGGTCTGATCTGTGGTATTGACTTTAAGTTCCCCATACTGTGCAAATTTTTGCAG
TAAAGATATCCATTCTGTCATAGTCTGTCCGAGTTAAAGCACCAAAAGATCACAGTTAAAATCAATGAAG
CTCCGAGGTTGAGAATACAAGTCAGGCTTCCTCCTGGAGTTTGCTTTTTCATTGTGATATGCTTCTATAA
TAGGAGTACAGGGAGTGGTTGTTAGAGTAAATGCATCTCAAAAGTTGGTTCAAATACCATGTAGATGAAA
CAAACGAGCTGACCTCATGTCTTCTGGCATGAGAGTAGAGAGTCTGTGAGAAGAAGCAAGGCGGCTAAAA
ACTCATGAATGACTCAGCAGGACTTAGTTAAAAAATGCTTCTTTCAGGTTTCTCGTTGCTTACACAAAGA
AAGCCCCCCAGCTGACCTCGTCGGAGCTGATGGCCATCACCAGAAAAATGGCAGCCACAGCAGCCACTTG
TTGCCAACTCAGTGAGGACAAACTATTGGCCTGTGGCGAGGGAGCGGTGAGTGTCTGCTTGGTTTGGTCC
CATCTCATTTCTGCCCTGTTTGACTTGAAATAGCCTCATAATTCCCCTCTAGGGAAGACGGTAAAAACCA
ATGTAGAGATGGCCTTAGGAGGCTTGTTTGATTAGTCACGGTTGGAGGGGTGTGAGAACCCAGCTCTGGA
TGGCTGGCATGTGGCCATGCTTCCTATTCCTCCAGGGTGGCTGGTGGAAGTTCAGCCAGTTTAGTCAACA
ATATCTGAGCCAACTTTATATATCGGAAAGACAGAACGACCAACATGTAACTCATAATTCATAACAATTC
ATAATTCATAACTTCAAATCATAATTTCTGCTTTTTGTTCATATACTTACTTTGATGTTTTAAAAAAGCT
TTATCTTTGATTGATTAAAATTAGTCATGCTATTTTAGCCATATTTATATTTTCACCTTTTGTAACATGA
TATTATTATTATGACATCAGGAATAATTGGTTCCCTTTCGCAGGGTATAGGGTACAGCACAGGATAAGTA
TTATGTTCTGAATAGTAAAATGACTTTCGAGTCAGTAATGCCAATATTCTTTACTTCCTAATGTCACTAG
TATCATACATAAGATTACAGGATGAATTAAAAATATTTTTCCTATAAAGTCATAATTGCAAACAAAATTG
TCTATTTTATCCTTTTTCCTCTTTTTCATAATGGGGAGTTATTTGCTGTTAGTCTTCATGTCATACATTT
TTTCCCCAAAGGTTAAGAGTAAAAGGAGAGTTCTTGTGATTAAATGTCACCTCAATTGTTTGTTGAATTT
CCCATGCTGGGAGGCTGCAGGGATGCAGGATGGTGTAATGGTTCAGGAGTGTATGTTCCGGAGGCCACCA
GCCAACAACCGCATTCTACTTTCACTATTCTTTAGTTGTATCACAGTGGGAAAGCAACTTATGTCATTAA
GCTTGAGTTTTTTCATCTGACATTTGAGAATACAAATTATACCACCCTCATACGACAGCTGTTTTAAACA
AGATAATCTGCATAACTCACACAGCACTAGTCTGACAGATAAAGTGCACACAAAACATATTATTTCTTAT
TACAAGTTATTACTAGGTGATTAAGAAATATCTCCTAAGTAGGCAAGGTAGCAAGATTCTACATTAGGAA
AGTCTTAAAAACCCACAAAATTGCTCTTACTTCTTTTCAATTAGGATGATATATTAGCTGCAAGTGTATA
CATGTGTATATGTATGTGAATAAAAGGGGTAAGTTTGTGCTATTCTTACCTTCAGATAGTGATTATCAAA
AGAAAAATGGAAAGTTCAACTAAATACACATGGGAAACATAAAGGCAGAGACATTTTTGTCCTTTAGAAG
TGTGTATGTAACTGGAAGCATGTTTCAAATAGCTGACACAAATAGCTAAATGACTATCCTCAACATCACA
TATGGACCATCTGCTACTACTTGCTAAGGCTTAGCCCAAACAAATGGGTAAATCCTGGAATTTACAATAT
AATGTCACATGATCCTACATAGCAAATTTTCCTGTAATATTAATTATAAATTGCTGGGCATTAGAAATTA
TTGCAGCAGTTTTCTGAAAAACTGAACCAACTTTGTGACTAATGCCCAATCTCCTTACTTTTTTTTCTCA
TTCTCCTAACCAGGCTGACATTATTATCGGACACTTATGTATCAGACATGAAATGACTCCAGTAAACCCT
GGTGTTGGCCAGTGCTGCACTTCTTCATATGCCAACAGGAGGCCATGCTTCAGCAGCTTGGTGGTGGATG
AAACATATGTCCCTCCTGCATTCTCTGATGACAAGTTCATTTTCCATAAGGATCTGTGCCAAGCTCAGGG
TGTAGCGCTGCAAACAATGAAGCAAGAGTAAGAAACTGTTACTTGCTAGCATGGAAAAGAATGACAACCC
CAAAGAGTAACTGAGACTTCTACCTCGCTCACCTAACACTATTGGGCTCACTAACAGAGCGTTACTCCCA
AAACACTTAAAATGCCTTTGAAAATAGTTTTGTCTCAGTGTCTTCACAGTCTCATTGGGGAAGCAGGTCT
AGAAAAATTGACGAGGGTGGACAATTTCCTGTTTGTAAAAATAATCTCTGTTGTAACTGTTATTGTGATA
TGTATTTGGGGGTTGAGGAAAAGTGGGCAATCTATTCTGAGGAATTAGAGTGTATCTTTGCAGCAAATTT
GGGTACTTCCATTCCAAGCACAGGAAACACATCATTGAATCTTTTTTTACACTATTTACACTTTGAAGAG
AATAACCATCTTATTTAATTCAACCATGCAGTTTGGGTGTTAAGAAATGACATGTACATTTCAGTTCATT
GTGGGAGCTCTTTTGTAATGGTGATGGTCATGCAAGTCAATGGAGCTTATGTTCTTCAAACTCCCATGCA
TTTTAATCCTCACTTGTTTTGTAAATAGTCTTCCTTCATTGGAAAACCCATTCTTCTCTTTTTTCCTCTA
TCACAGTCTGAGGTATGTTTCACAGTATGATAAGAATGTTGCCTGTTCTGGCAAGCTTTTTCTATTGCTC
TGGTCTACTTTCTATTGCTCTGGTCTAAGTCCAACATGAAAGGCTTGCTAAGTGAGCAGTGCAGGCAATT
AGTGCTGCCAGTGCCCAGATAAGGGGTGTGATAACTGGATGGGCAGGATTCGGAGATCTGGGTCTTTGAG
TGTAGATAAGACACAGTTAAGAAGAGCGGACAGGAAAGGATATTCCTGGGGGATGAGGGGAGATTGCCTT
CCACTACACATAAGTATGGTCAAGTATGAAATAGTGTTTTATCCACAACCTGCACAACTCCAGGCTGGTG
GAACACTTGGCATGCTTTCAGCCTCAATCTTTCTACTGAAAGTACTAGACAAGGTGTGTGTGGTCAGTCT
GGTGATAGGTTGATGGAGTAAGGGTTTAGGCTCTGAAAATTCTCTACTAGGAAGGCTGTAGAAAAATAGC
ATTGCATAACAGACTTCTCTTGTATTTTGTTTTGTTTTAAATCACAGGTTTCTCATTAACCTTGTGAAGC
AAAAGCCACAAATAACAGAGGAACAACTTGAGGCTGTCATTGCAGATTTCTCAGGCCTGTTGGAGAAATG
CTGCCAAGGCCAGGAACAGGAAGTCTGCTTTGCTGAAGAGGTACATGCAGCTCATTTCATACTCAAAATA
CTTGCTATGGAATTTTCTGTAGTGGATAATGAAAGGAAGACCCTACAAATTTATAACTTTAAAATATTTT
CAGAGAGATTTAAATTTCATTGAGAAGCAGATTGAGGGATTCTATAAGATTTAAAAAATAATCACATTTT
CTTGCTTAATATTAGGAAAATTTATAATATTAAAATATATTAATAGAATTAGTAATTTTAATTTATTTCC
TAGTAGAGAAACCCATAAAGTGAATGTGTAAATAATTGACGGTAATTTAGATAGTTTCTGGCCTAAAATT
GATCAATTCAGCTAAATGGATTAAAGGATTTAATAGCAAATTAATTGTGCAAACAGAGTATTAGGAGTCT
ATTTGTAGAAAATGTTTTTGAACTCATTTAGAAGCTTGCTTTTGTACATCAACAGAGTAGTATTTAGGAG
TTATTTTAATTACATAGTAATTTTAGCTGGATAATTAGCCAGATTTTCTTTAACCAGGGGATTCTACCTA
ACATTTAAAAAAATTACCTTTTTTCAGCTTTATTGAGGCATGATTGACAAATACAAATTATATATGTTTA
GGGTGAACATGTGATGTTTCAATATATTTATACATTGTGAAATGATTATCACAATCAAGATAATTGGCTA
AATTTTACAAATCTTTAGTTTGTATTGCTACATATATTTGAATATAGCAACACTATACTTTAAAAAGATA
TTCTATAACTTAGCGTTTTTGTCAATTTTACCTTTCTCACCATGTAAAATCCAAAGACAGATATATTTAG
AAATGTAGAGTTTTTCTATAAATAATATAATTAGATGCATTTGAGTGTGTGCACTTACCAGTATATGTGT
GTGTTTTTGGTGGGATCAGGTAGGGTGGGACATAGATAACCAAATTAGATAAAACTGGTGAAACAGATTT
GATGTGAAGCATTTCTGAAAAACATGACACAAGAAGATTAATGTTCTCTAATCTGAGAAGACATTTATTT
AGATATAGAGAACATGAACAAATAGTAGCAGTGCTTTATCTGCAAACCTTTTAATTTCTAATAACTTGTA
ATTTGTAGAGGAAGGGGAAAGATTGAGAATACGCATTGATTTGGAGATTGTTATAGAAGAAAACTGTTGA
TGTGAAAGAATATTGTTTTCTCCCTGGCTTTTACTATCCCAGGTTGTTGGCATCAGAGATGTGTTTCTTC
ATTTTTAACTTAGTTAATCTACAAACCTATGAATTCACCCCGGATTGTAGAGTGTTAACTGTATGATTGG
TATAATAATCCATTTCTTTATCTGATTATGTTTATTCTTAATTTTCAGGGACAAAAACTGATTTCAAAAA
CTCGTGCTGCTTTGGGAGTTTAAATTACTTCAGGTAACAAAACATTCAGACAAGCCTGAATACAATGTTG
TTTCTCCAGAAATATCAATCCATAATGAGATAGATCATGAGGAGTGCCATTAATTCTCTTAAAAATACAT
GGAATTCAAAAAAAAGTTTATTTTAAAAACACTTGAACAAAATTACGCACACAATGTTAAATTAGTGGCT
CAACTATGCAAAATCCTTTTTGGTTATTTAAAAGACTTCAACAAATGCTATCAGAAGACTTTCCTACGTA
TCCAATATTTCTCTGATATAAAATAATAGAACCAGTTACTTACTGCACCTATTAGTTTAATTAGTATTTA
ATATATTTTTGCTCATATTGCAGGGGAAGAGAAGACAAAACGAGTCTTTCATTCGGTGTGAACTTTTCTC
TTTAATTTTAACTGATTTAACACTTTTTGTGAATTAATGAAATGATAAAGACTTTTATGTGAGATTTCCT
TATCACAGAAATAAAATATCTCCAAATGTTTCCTTTT

</dna_sequence>
        <protein_sequence>>NP_001125.1 alpha-fetoprotein isoform 1 precursor [Homo sapiens]
MKWVESIFLIFLLNFTESRTLHRNEYGIASILDSYQCTAEISLADLATIFFAQFVQEATYKEVSKMVKDA
LTAIEKPTGDEQSSGCLENQLPAFLEELCHEKEILEKYGHSDCCSQSEEGRHNCFLAHKKPTPASIPLFQ
VPEPVTSCEAYEEDRETFMNKFIYEIARRHPFLYAPTILLWAARYDKIIPSCCKAENAVECFQTKAATVT
KELRESSLLNQHACAVMKNFGTRTFQAITVTKLSQKFTKVNFTEIQKLVLDVAHVHEHCCRGDVLDCLQD
GEKIMSYICSQQDTLSNKITECCKLTTLERGQCIIHAENDEKPEGLSPNLNRFLGDRDFNQFSSGEKNIF
LASFVHEYSRRHPQLAVSVILRVAKGYQELLEKCFQTENPLECQDKGEEELQKYIQESQALAKRSCGLFQ
KLGEYYLQNAFLVAYTKKAPQLTSSELMAITRKMAATAATCCQLSEDKLLACGEGAADIIIGHLCIRHEM
TPVNPGVGQCCTSSYANRRPCFSSLVVDETYVPPAFSDDKFIFHKDLCQAQGVALQTMKQEFLINLVKQK
PQITEEQLEAVIADFSGLLEKCCQGQEQEVCFAEEGQKLISKTRAALGV

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Dendritic cells engineered to express AFP produced potent T-cell responses in mice, as evidenced by the generation of AFP-specific CTLs, cytokine-producing T cells, and protective immunity.  DCs transduced with an E1-deleted replication-incompetent AdV vector (AdVmAFP) were used to immunize naive mice to a subsequent challenge of EL4(mAFP) lymphoma cell line. Mice receiving one or several weekly s.c. immunizations of AdVmAFP/DC were partially or completely protected from a challenge of EL4(mAFP) [Ref974:Vollmer et al., 1999].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene305">
        <gene_name>Cd40lg</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>21947</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>15011846</ncbi_protein_id>
        <gene_locus_tag>RP23-153G22.3</gene_locus_tag>
        <gene_refseq>AH006031</gene_refseq>
        <protein_refseq>NP_035746</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>X</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>57212142</gene_start>
        <gene_end>57224041</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>CD40 ligand</protein_name>
        <protein_pi>8.31</protein_pi>
        <protein_weight>27087.92</protein_weight>
        <protein_length>260</protein_length>
        <protein_note>Also known as IGM; IMD3; Ly62; TRAP; gp39; CD154; Cd40l; HIGM1; Ly-62; T-BAM; Tnfsf5</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000086.7:57212142-57224041 Mus musculus strain C57BL/6J chromosome X, GRCm38.p4 C57BL/6J
GCTTTCAGTCAGCATGATAGAAACATACAGCCAACCTTCCCCCAGATCCGTGGCAACTGGACTTCCAGCG
AGCATGAAGATTTTTATGTATTTACTTACTGTTTTCCTTATCACCCAAATGATTGGATCTGTGCTTTTTG
CTGTGTATCTTCATAGAAGATTGGATAAGGTAAGGTGACCTACAAGCCTTAATTAGCTAAATTGGGGGTT
CTTATTGATCTAGGACGGTTTGAATTAAGTTCTACCTAAATGATGGAGAACAGTAGAAAGTGGATAATGT
TTGTTGTGGCATAATGTTTGTTGCCTAGAAAGTAGAACCTTACCTCTGACTAAGATCTTGGAATGTGCAA
TCAGACAGCCTGGCTTCAAATCTTAGCTTAGCTCTTAACTGCTCTGAGATTCTGCACATGTCACTTCATA
TTTTCATTTCTTTTTCTGTCCCAGGGAAATAGAGGTAGACATAGTACCCATGGCACAGATCAAATGATTC
TAGCCCTGAAGAGGAGATAAACTATGCCTGGCACATAGTACATGCTAGTTAGTTCCTAAAAGTTGCTCCC
CAAAGTGAACTATTTCCCCCCACGAAGACAACTTTAAAAAAATGAGCCCCATGAAAACAACTTTAAAAGG
TGAGCCAGAAAAAAAGGAACATTGATTTGATCTGAAATTCCATTGTGTTTTGGATGAGTACAGACATGAA
CTATGCTCCCAATCTGCCGATTGATTTTTAAAGTCAGAATGGTGCTATCTGTGCAACTCTTCAATGCCAA
CTGCCACTGTAAGCTGCTCTGTGCTCCGCGGAGGAGATTTTCCATGCTTAAATGATTAGGAAGGGAGCAG
ACTAGCTAAGAACAGTAACTTCAGGATCTACGCTGTTTCCATGTGCTGGCTCATATCCACTGAGGGCCAT
ATGGGCTGTGTTATGAAATGCTAAGGGATAATGGGGAAGTTGTAACCCATATAGACTCAAATGTGCTGTC
AAATTTAAGTGAACTTTAAATGACAGGCAAAGCTATTGGCAAACTCCACCTTATATTTTGTTTTGATTTT
ATTTGGTTAAGTTTGGATTTTTCCCCCCTTTTTGAGACAGTTTCATACTGTAGCTCAGAATGGTCTGGAA
CTCTCTAGATAGACGAAACTGGCTTCTAACTCACAGGAACACTCCTGCCTCATCCTACAAATATAGAGAT
TACACACATGTTCCACTATACTTGTATTGGTTCTTGTTTTGAAAGTTAAGAATTTGCCCTTAAGACAAGA
AGAAATTGTTCAGAATTAGTTGACAACACAAGTTAATTGCATACATTTAATTACTCACATATAAAAAAGA
AAATATTGCATTCACTTTGGGGATAAGAGATAATTTCTTTTAAAATGCAAAGCATTTCTACAAGTACAGA
AGAAATGAGAGATGTAATTATAAATCCATGTTGTGAATGAATGCCGCTGTAATGCCTCGTGTCATGAACA
CTACCATGAAGCAGGCAAACTAGCTCGGCAGCAAACTACTTTATGGCTGGTGGGAAACATGACAATTATA
GGACACTGCTGTTGTGGTACACTGAGATTAAAAGTCATTAGAATAGCTATGATTTCTATTGAGAGGCACA
GAAAATATGCCATCGGAATCACCGGCTTTTTAGGCTGTTAAATGGCAAGTGCCAAACAGCAGTAATCCAG
CATGATACCTTTTAATATTCCCCCATTTACACTGTCAAAGTCCCCCTCTCGTCGGTGCCATGGAAGTGGA
TGTGGAGGCAGACGTGATTAGCTGCATTCTTCTTCACTATGACATTTCTCACCAGTCTCCTATTTCAAAA
CAGGTCGAAGAGGAAGTAAACCTTCATGAAGATTTTGTATTCATAAAAAAGCTAAAGAGATGCAACAAAG
GAGAAGGATCTTTATCCTTGCTGAACTGTGAGGAGATGAGAAGGCAATTTGAAGACCTTGTCAAGGTAAG
GTGCTCAGCTCCTGGCAGATTTCACAGAGAAGTTTTCTTACATTTCCCAGTCCTGCAAACTGAATTCTGA
CCCTGGGAAGCTTTAACGTATAAGCAGGGATAGTGGGCACAGCTGCGATCTCAGCGCCTGAGAGGCCAAA
GTCAAAGGACGACTGCTGTGGGTTCCAGGTCAGCTTGGTCTACAGAGTGAGACATGATCAAAATGTACTG
TATATAAACATACTCGTACATATATATACATGTACACACATATGTGTAGGTGTGGAAATGTGTACATACA
AAAAGAAAAGAAAAGACAAAGCCTTACAATAAAATGAAGAAGAGAGCTGAGTTGGCTATGTGCATACTAC
TGCAACAACAAAAAAGTTTTCATTCTTTTGTACAGATAATGTGTAATCCAATAATAGAGTAAAGAAGTCA
GGATCTTACTTCATTTATAAATTCATGACACATATGGAAGTCACAGGACAGCTTTCGAGTCTTGCTTCTT
TCCTTCCACTGTGTGAATCCTGCAGATTGAACTCACATCCTTAGGCTTAGCCTTTACCCACTGAGCCACT
TCATTGTTCTCTTCAAACCTTATTTCAGAACTTAATATACATCCTCCTATTTGGTCAGCAAGGTATAATT
TAACCTAGTGAAGAGGAAGATTCTAAAAACTTACTCCTAGGCCACTTACTGGGATCAGAATTCAGTTCAA
ATCTGCCTGACTTTATTTTAAGCTAGAATGTATTTTTTTTTAATTTTTCAAGACAATCTTGAGTAGCATA
GGATGGTCCTCAGCTTGTAGAAGACTTGTATGTGGCTGAAGACCTGCTCTCCACATCCTTCTGCTTCTAA
CCTCAGGCATGCAGCACTATGTCCAGTTTAATCTAGATTTTATTGTTTTAGTTTTGTACAATGCTCAGTT
GTTTGTACCTTGTGTATTAACCCTCCCCATTCTATAATCTAGGATTTCCATAAAATTCTTAACACTTTAT
TTGCAAGACTGGTGAGTTTAGAAAATGTCTTAGGTTTCTCCAGTGCTTACATGTAGAGTCCTAGGGACTG
AGACTCTATAAGGACACAACCAGCTCTGGTCTTCTCTCTGTGATCAGTCTTCAGTTTCTTTGAACGGCAG
TGAAAGTGGCTTGTTCTTTTTTTCCCTTTTCTCTCTGTTACAGAGAGGTTTCCCAGGTGACCTTCCAATT
CCCTTCATCCTCATTCAGGCCAGATGTAGAAAGCTTCCAGAATCATCTACCTAGGATAGGAGGGAAAGAG
TCTTTTCGGCTTTTATGAAAAAAAAAAAAAGTAGAACTTTTAAAGCTTATCAGCCAAGGCTGTAGGAGTG
TACTGTTTACCTGTCAGGGTATATAGAATTACTGTTTACCTGTCAGCTATGGAACTCCAAGCAATGCCAT
CTTTACCTAGGCTATAAAAAAGCTAAACTTCAAAGTTTTCCCATCAGCTAATTGTCCTCTATCTAAGGCT
CCCCCTTTAGGTCGCCATTTTCCTAGAGTTCTCGCTCAGAAACACAATTTGGAACTGTTGAGCCCAGCAA
GTCAACTGTAGACTAATTCCAGATTAGATTTGTGTTTTCTCAGCTAATGTGAGCAGACTTTGGACCATGA
GGTGGCTGGCCCAGAATAAACTTGAAGTCACGGGGCCTTCTGGGGTTTTAGAAACACTCCGGTGTAAATC
TCAATTCTTAGAATTCCAGTCTTCTCTTTACCATCTCTACAAAGTGGTCAGCCAATATTCATTTAAATAG
CTCTCATGACAAAGAGCACCTTAACTTCTGAGACAAGTATCATGGAGGTCTCATGGTGCATGGAAGATGG
GGGTCAGGGCTCGTGTTAGGGCAAATGCAGGCACCACTTTAAACAGTGTAATTACATAGTAAAATCTACT
TTGCTCCCGGTCTAGTATGGTCAGTCTCATGGTTATCTGTCTACCAGTTTCTGAAGTGTCTTTGATTGGC
ATCAAATCACTTCCATTTCAGGTTAAAGAGCTCATTATAACCTTATCTGCCATGTAGAATTTCCATGTAG
AGAGAAATCATTAATGTAAGATATTTATTTTTGAAATTTGACTTTAAAAACCCTTTCAATTGAAGTGAAG
AGTGAAGCCACACAAAAAAAGAAAAAAGGGCTCTGGGAGTGTGAGTTGGGGAAAGTTCACAAAAGTCAAG
GCTAGGTTCAGAAAAGACAAACTTTGCTGATTTCACGTTTTCATCTGGGCCAGGCCCCAACACCACTGCA
ACCACCTAGCCTAAACGTATCTCGACTTCAATCATCACACACTAGTGTTTGAAAAGCCACCAAAGAGTCC
TTTGTTTACTTGTCAGCTCGCAAACATTTTCCTGTTGCTGCATTGTCACGGTGCCCCCACCACAGCTCAA
ATGGAAAGTTGATCTGTGGGGCTCTCTGTGCTTTAAGCCCTCACTCACAGCTGGCAACCAAGCTGAGTCT
ATAGTTGCATTAGGCAAAAGTAACAACACAGACACCTTCTTGGGGTGAAGAATGTGAAGGAAAGGCCCAC
AATGCATTAGGTTCCAGGACTGAAAAGGAGCATAAGACTATCAGATCTGAAAGCACTGTTTTTTTTCCCT
GCCTGTTCTGAAGAGAGTGATGTAACAGATTGAGCCAGGTCTGTGAATTCTACTTTCTGTACTTCGTGTA
AGCCTCGGGCCCTTGGTTGATCTCATACTCACCAGGCCTTTGATTCAGACTTCTTAAAATGGCGGCAACA
GCCTTGATCATCTCTCGGGCTCCATAGAAGGAAGTCTGTGCTAGCTTCCTCAAGTATGTCCAGCATTCTT
TCATGTTATAAATAAAAGAAATCTTTCAGTGTTGCATTTAATAGGCATTGTGGAACATGCCTGCTGTCAG
CATTTGGGAGGTAGAGGCAGGAGGGTCAGGCATTCAAGGTCTTCCACAGCTTCATAACAAGTTCAAGATT
AGCCTAAGCTTCATGAAAACTCATCTTAAAAGCATAAAACAATGTGCATGGAATTTTCAAAGAAAAACTA
AAATAAAAATAAGAAACTAAGTGTTCTGAACACCATCACCAGCATTAGAAGTTCTATCTCTGCTGAATGT
TAATTACTCTAAATATTATATGCCATACAGAATAAGCACCCACAAAACACACTCAAAGCAAAGTGTGTAT
TTCTCTCCCATGATCATAGTCAAATCTTTTCTTAAGAGGTTTCAAACTAACCTTATTCTAAGAGATCTAT
GTCCTGAATTTTGTTTGATAATATTCCATATACCAGTTTCAGTGGTTGAATTATTACCCCATTCAGCATT
ATTTATCAATATCTGTCAAAAGACAGGGAGGTCAGGGTCATAGAAAGGGTCAGAGTCACAACCTCTGATC
TGGGGAGAGCACTGTAATGGAGATAATAAGGCCTGGATTTTGCTTCCAGGGTCTCCCCTGGGTTTTCTGG
GCTGTCAGCTCATCTGTCAGAGCCAGGGATTCCCAATTGCTATGGTGGAATTAATGGCTGCATCTTAAGC
TATATTATAATCCTTAGCAGAAGCAGACAACACAGTACTGAGAATCGCCAGATGAATGATACCTTTAAAA
CTCCTAAAACAAGCTTCGGTCAACTGATCTTTTGCAATGACTCTTCTTTTAGGATATAACGTTAAACAAA
GAAGAGAAAAAAGAAAACAGCTTTGAAATGCAAAGAGGTAGGTTGCTATTACCAATTTTGTTAAATGCTT
TAAGAGTGAAAAGAAGCTTTGGATTGGGCACATGAAACAGGGAATGCTTAGCCCTGCAAATAAAATGCAA
GACATTTGTTAAACTGCTACCTTCTCAGGCCTCTGTGATACAGAAAGGCCATGTGGATGAGGATATGTTC
CTGTTAATATTGATGATAGTAAATATGAAAAACAAAACACATCCAATACCTTTATCCAAAGGACCACACA
ATTGGCTCCATCTTCAGAGGACCAAGTGAAACAAAAGTCATCGTTTGGTAAAATTGGCATTCATCTTTCA
ATGATAACTATTTTGTGGGAGGACAGTAACCCAGTGGGTCTTCTGGGATCAATGAATACAGAGTGGCTAC
ATTCTAATCTTTGTCTGTTCTTAACATGAGAGCATCCTGGACATCTGGAGGTCATGAAAGGACCTTGATG
GCTCTCAATTCCAGGACAGCCCTGAGAATATCAATGAAGAAATTACTGAACTTATGGCCTCTGCTTAGAT
ATGCCTTGAGATAAGATACCTTATACTCAATAACACATTCCAGTCTATCTTTGAATAGCTCTAATAATTA
TATTAAGGTCAATATCTACTCAAAAAAAGGTCTTACCTCCTAACTGTGTTCCTCAGAAATTTCCTGGAGT
ATCTAATTTTGGGGCACATTTCTGTTCTTTGGAGATGTACTGAGCAAAGAATAATTACTTCTCTATATAG
CAGCGGTCTCAACACTGGAGACAGCAGCCATGGTCCCAAGTTTCCATTGAACACATACTTATTTAGGCTA
AACACACCCAGCACCTTCTACTTTATGTTCCCTTTATGATCCTTTGTAATATACCTACACAGTTTGCAGC
AGCAGGCACATAACTGGAAAGAAAGTAACCACAGTTTCTACATTAGGAGATGGGCACTTTTAATTTGGAA
GCAAGGCTCTTGCATAAGAAACAGAGCTAGATTTGAAAGTCTGGACACCTTCTTAGAATTGGGAACAAAA
CACCCAAAGAAGGAGTTACAGAGACAAAGTTTGGAGCTGAGACAAAAGGATGGACCATCTAGAGACTGCC
ATATCCAGGGATCCATTCCATAATCAGCCTCCTAACGCTGACATCATTGCATACACTAGCAAGATTTTGC
TGTAAGGACCCTGATATAGCTGTCTCTTGTGAGACTATGCCGGAGCCTAGCAAACACAGAAGTGGATGCT
CACAGTCAGCTATTGGATGGATCACAGGGCCCCCAATGGAGGAGCTAGAGAAAGGACCCAAGGAGCTGAA
GGGGTCTGCAACCCTATAGGTGGAACAACAATATGAACTAACCAGTACCCCGGAGTTCTTGACTCTAGCT
GCATATGTATCAGAAGATGGCCTAGTCGGCCATCAGTGGAATGAGAGGCCCATTGGTCGTGCAAACTTTA
TATGCCCCAGTACAGGGGAACGCCAGGGCCAAAAAGTGGGAGTGGGTGGGTAGGGGAGTGGGGGGAGGGT
ATGGGGGACTTTTGGGATAGCATTGGAAATGTAAATGAGGAAAATACAAAAAAAAAGAAAGTCTGGACAG
TCACTTGACCCAAACAGATACCATGATCATATCACTAACTCAGTTTGCAGGTACAGTGTTGTCCACTACC
ACACCAGTATATGGAATCTGTTCTTAAAAGCAAGATTCAAGGCAGCTTTAATGAAGACCAATATTTTAGT
CTGTGTCTATTTATGTTAAGTGGAATGGAGTATTGAATACCAATCAGGAAAAAGACCAATTCAGTTTTTG
AAGTACTAGAAACCACCTTTTCCTTCAGTAGGAAGGATTCCAGACCAGTTATCCTTCCTTTAACATAAAC
TACTTTAGCATAGTCACTATTATGCAGTTATAGAACTGAACCCTTTAATCTCATGAGCTGTTGTATATTT
CTTTGGCCTGACAGTTTGCTTTTGGTTTCACTCCAGGTGATGAGGATCCTCAAATTGCAGCACACGTTGT
AAGCGAAGCCAACAGTAATGCAGCATCCGGTAAGTCCCATCACTTCGGAGTGAAAGCTACCCAAGTGTAT
GAGCATGTGTGTATGTGTATGTTGGGTACTCCAAAGCCATTCGGCCTAATCATTAGGCACTTTTCTTCCT
CCAGGGACCAATTTACCAACCTACCCATATAACTCTTCATACACTGTCCTTTGTTATCAGAGTCAGCTCA
AACGCACAGATGGGACTTAGGGGGACAAAAGGAGGTGGAAACAGTCTCTATGTTCTCATTATGCTTTTTC
TCAGTGGCTGCTTCTAAATGATGAATGACTAGGTGGAGGAACCATTATTTTGCAAGTATAAAAAGAGATG
GCAGGTAGTGACCTCCTCGCTGGGAACATCTCTTCTTCTGAAACCTCTCCACTGTGTATAAATGGGCCTC
AGGAGGTCTTTTCTGTCATCTGTCAATCCCTGTATGATTAACCCCAGGCTCAGTGGGGCTGACCTCGGGG
AAATTAAAGGTAAAAATCATTTTGTAAAGATCAATAGGCGCTGAGACGTTAGATTTTTCAATGAAGTAAC
AACAGATGGCATACTGTGGTCTTTTCAACACCAATGCTTTTATTTCTATATGTATTCTACCATCATCCAG
CCCTTATTTTTTCCCCAAATCTCTACCCTGTAATAGCTAGTACTATAAAATGAATCCCCTCTCTAGATGA
ATGGAAATGTGTATGTATGCTAGCATAAAATTTCCCATATACATAAAGGCATGAGCATGGGATCAGCCCT
AGAAAGCTTCAGCAGAGTAGTTTACAATGGAGTTCTAAATCATGTGTGTGCATTTGTGCATGTGCACATG
CACACACGAGAGAGAGAGAGAAAGAGAGAGAGAGACAGACAGACAGACAGACAGACAGAGAGACAGAGAG
ACAGAGAAAGACACAGAGACACAAAAGAAGACACTGATACTGGGTTGGGTTGTTTTTGAGGTGACATGAG
CTCCTTGGTGACTATAACACAGAAGCACATGCATGATATTGTGGCTCATGGTATATAAGTAAGAGTACTG
GTTAGGGAGTTTGTGAGCACAGGGGTTTAAAAGCTAAGAATTTCTTGCTAAATGACGTTAGGCAAATCCA
ATTTATCCTGTGGCAGTTTTCTTTCTCATCTACTTTATAGAGTAGTTTTGAATATCAAATCAACTAACTA
GTGTGGAAGAAGGTTATATTATTAAGCAATATTATACACGAACAACATGCCAGGACTTAGATTCCTTCAT
TGTGATAACCAGAGATTGACCTAACATTCTTCATGGATTCCAGTTGCTCTTTTATTATTTATTGCTTTTG
TCATATACTGTTCTCTCAAAATTATGTTTATGGGAAAACACCACAATATTGCTGTGACAGAGAAACCATT
TACATATTATAGCAACAAAGAAACCTCCTAGAATCATCTCCTATAGGTCTTTATCCACCTGTACCCAAAT
CTTTTGGTCCTTGGATATATTTAATAGAATTTTGAATTTTTCAAAAGGCATAGAACTGGTACTGCCTGCC
TGTGAAATATGTCACAGTCTATATCACAGTAGATCTGTATAGGACAACATAGGGAAGATAGTACAGTACA
CTGCCACCCCAAATTTCTTATTCCTTTCTGGACATGATGCTACAAACTTGACCTAAATCCCCTAGTAATA
ACCAAAATGAAATAAGGAATTAACCAAGTGGCACATGATCTCAGTGCTAGGGAAGAAGCAAAAATATTAT
ATGTTTAAGGTCATCCAAAAGTACAAAGTGAATTCCAGGTCAACCTGGGTTCCATAAAATCTTGTCTTCC
CCCAAAAGGGGATAAATTCAGTAGACAGAGGCAGGTAGATCTCTGTGAGTCCCAAGCTAGCCTAGTCTGC
ATAACAAGTTGTAGGCCAGCTTCTGTTTTCTTTTCTGTCTCAAAAAAGAAAGCAGAAGTGTAAGTGGGTA
ATGTATTTATTAAACTGAAAAGAATCTGGTCCTTTTTTTCTCATTCAAATGGTTCAAAAGTGAAAACATC
ACAAAACAAACATCCTTTATAGAGAATTTGGGGTGCAATGTATCAGGTGCAATGCCTTCCTGTGCAAAAA
GAGGAGCCTTAATCAGTAGTATCTTATGCCATAACACATGTAAGACCATCAAATAAAACAATTAAATACC
TCAAGAAAGCAAATATATCAATACTTTTACTTCCCCCTGCCTCCCACCTTTCACCCCCATCAAATCTAGC
TGTGGAAGCTGAGATTTGAAATCGGGTGCACACACCACTTTGAACCCACTCAACAACTTGGCAGAGAAAA
GGGCACACTGTTGGTGGGGACTCTGCCCTAGCCGCAAGAATATGGGTACTTTCAAGTTGGTGGCACCCAC
TACAATGGGAGATCAAAACACAGTTAAATGAACACATGGTTTATTTTCATACTTCCCTGCCTATTTTAGG
CTTGGTCGTGGGAGGCAGGTCAGGTTTGCAACAGCATGAGGTAGAAGGAAGAAGTGGGGTCTTGACTCTG
AGCTGACGCTAATCTAGGTAAACTGACAACTCTAGCTATGTAACATTCATGATAAGTTAAATGTTTGCAC
TCCTGTTTAGCAAGAATTTTATAACATTCATAAATCTCAAGTCATTTATGCTTCATTTTAAAACCATGTA
TTTATTTATGTTTGAGTATGCCTGTCTGTGTGAATGTATGTACACATATAAGAAGGGTAGTGGAGGTACA
CAAAGATCAGATGACGGTGTCCTTGTCTTAGCACTCTCCACCTAGTCTCCTGGACTAGGAGCTTTCCTTG
AACCTGGGACTCAAGTCTTCTCATGTAGGTTGGGTACCAGCGTGTCTCAGTGATCTCCTCTATGCCTGAC
CACCCCAGTCCCTTTTGTGTTGTTGTTGTTTTGAAACAGGGTCTTGCTTAGCCCTGATAGGTCTCAAAGT
CAGTATGTGGCCAAGGATGACGTTGACCTTGCCTTCATGATTCTCCTGCTTCAATGTTGTCTGGGAATTT
TAGGTGCATATCACCAAGCCTGGCTAATCATTTGCACTTTCTTAAATTCAATGGTAAATTGGTTTGGAGA
ACTCGAAAGGGAGGAGAAATTTTGCTGTTACATGCCATTTTATTTAACCTTTTCAGATCTCTGAAACATG
CTGTAATACTGTCCCTGTTCTGTTGATTCAGAGTTAGTGTCAGGTTCCAATCTGGGGAGATCACGTGATG
TGCCCAAGTTTGAAGAAAACCAAGGGGGAAAAAAAAAAACAAACCTCTGAAGCCCATATAAACTTGGTCT
CTGTAATCCCTTGTGCCTCTGAGGGCCATAAAGTGCGTTGAGAATTCATTCTCACATGAAGTCGGCATCT
GACCTTAAACCTTATTTCCTGTTAGAATATATGCCGTGCTGTGCTTAAACTGACCAGCGATTCCCTCTCT
TTCTTACAGTTCTACAGTGGGCCAAGAAAGGATATTATACCATGAAAAGCAACTTGGTAATGCTTGAAAA
TGGGAAACAGCTGACGGTTAAAAGAGAAGGACTCTATTATGTCTACACTCAAGTCACCTTCTGCTCTAAT
CGGGAGCCTTCGAGTCAACGCCCATTCATCGTCGGCCTCTGGCTGAAGCCCAGCAGTGGATCTGAGAGAA
TCTTACTCAAGGCGGCAAATACCCACAGTTCCTCCCAGCTTTGCGAGCAGCAGTCTGTTCACTTGGGCGG
AGTGTTTGAATTACAAGCTGGTGCTTCTGTGTTTGTCAACGTGACTGAAGCAAGCCAAGTGATCCACAGA
GTTGGCTTCTCATCTTTTGGCTTACTCAAACTCTGAACAGTGCGCTGTCCTAGGCTGCAGCAGGGCTGAT
GCTGGCAGTCTTCCCTATACAGCAAGTCAGTTAGGACCTGCCCTGTGTTGAACTGCCTATTTATAACCCT
AGGATCCTCCTCATGGAGAACTATTTATTATGTACCCCCAAGGCACATAGAGCTGGAATAAGAGAATTAC
AGGGCAGGCAAAAATCCCAAGGGACCCTGCTCCCTAAGAACTTACAATCTGAAACAGCAACCCCACTGAT
TCAGACAACCAGAAAAGACAAAGCCATAATACACAGATGACAGAGCTCTGATGAAACAACAGATAACTAA
TGAGCACAGTTTTGTTGTTTTATGGGTGTGTCGTTCAATGGACAGTGTACTTGACTTACCAGGGAAGATG
CAGAAGGGCAACTGTGAGCCTCAGCTCACAATCTGTTATGGTTGACCTGGGCTCCCTGCGGCCCTAGTAG

</dna_sequence>
        <protein_sequence>>NP_035746.2 CD40 ligand [Mus musculus]
MIETYSQPSPRSVATGLPASMKIFMYLLTVFLITQMIGSVLFAVYLHRRLDKVEEEVNLHEDFVFIKKLK
RCNKGEGSLSLLNCEEMRRQFEDLVKDITLNKEEKKENSFEMQRGDEDPQIAAHVVSEANSNAASVLQWA
KKGYYTMKSNLVMLENGKQLTVKREGLYYVYTQVTFCSNREPSSQRPFIVGLWLKPSSGSERILLKAANT
HSSSQLCEQQSVHLGGVFELQAGASVFVNVTEASQVIHRVGFSSFGLLKL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Transgenic expression of the CD40L (Cd40lg) increased immune responses against a weakly immunogenic murine tumor, neuro-2a.Tumor cells were transduced with a retroviral construct containing the CD40L gene and co-injected with variable numbers of non-CD40L transduced cells into syngeneic mice. Mice injected with cells that expressed CD40L had a significant reduction in average tumor size as compared to controls (p &gt; 0.0001). In addition, survival of the neuro-2a/CD40L mice was 48 days versus 34 days for the neuro-2a/neo controls (p &gt; 0.02). Expression of CD40L by less than 1.5% of neuro-2a cells was sufficient for significant antitumor effects (p &gt; 0.001). These antitumor effects protected mice from subsequent challenge with parental neuro-2a cells [Ref965:Grossmann et al., 1997].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene304">
        <gene_name>Cd86</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>12524</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>161484599</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AC117662</gene_refseq>
        <protein_refseq>NP_062261</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>16</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>36568955</gene_start>
        <gene_end>36666076</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>transcript variant X2</protein_name>
        <protein_pi>6.36</protein_pi>
        <protein_weight>32680.65</protein_weight>
        <protein_length>309</protein_length>
        <protein_note>Also known as B7; B70; MB7; B7-2; B7.2; CLS1; Ly58; ETC-1; Ly-58; MB7-2; Cd28l2; TS/A-2</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000082.6:36568955-36666076 Mus musculus strain C57BL/6J chromosome 16, GRCm38.p4 C57BL/6J
GTTCATTATCCATGGTTTATTGTCACAGATAGAGTGAGAAAATACTCGTTGAACTCAAATGGCCACCACT
TGGAAAGTCCCTGTCCATAAAAAGACGCCAAGGCTTTGTACACAGATCTGCTTGTTTTCCCATTCTCTGT
CTCCTGGTGTAGGGTGTGGGGACCACTCTGCTCACTGGTCAGCTCTGCTCAGTCGGCCTTTGATGCTCAT
CCCTCTCTGCTCATCCCTGGCTTCTGCTATTTCTCTCAGCATCTGCAGACGGCTCTGCCTTCTTCTCCAT
CTTCATAGGGACCATCATTCTTGCCTCTTCTCTAAGACCTAAGAGATACAAGATAGTCATGCCTAAGGGA
TACAAGATAGTCATGCCCATAGTTATATGAGGCATAACAGCATTTTACTGAAACATACCACATGTGTCTG
TGAACCTATAAGATTATAACAGAGCTGAAAAGTTCCTGTCACCAATGGTTCTATACTGTGCCTTTCCTAT
GTTTAGCTATACAGATAGTTATTATTGCTTTACAATTGCCTATGCCCATAACAGTATCATCTACACAGAT
TTGCAGCTTGGAGCAACAGGTTATGTGCCTAAGGGTGTTGCGGGCTATACTGTCTAGGTTTGTGTCAACA
TGATATACTCTGCTTTATTTATGCATTGACAAAATCATCTGCCCACATGTTTCTTAGGCCATCAACCATC
GTTAATCACATGACTGTACTAAATTCTTACAGAGCATTTAGGAGGGGGCAAGGTACAGGAAATGGAGGAT
TGAAAAGAGTGTTGAGTGTTGAAATGAAGGTATGCTACTGTTGATCAATTGAGCTGTTGTCTTCCCTCGG
TGGGATGCTGGTGCCAACTGTGAAGAAAGTAAGGTGGCTTTCCCCTTTCAGGGAAGAAAAGCACGTCCAT
CTTCAGACTGAAGAAATGAATTAGCCATTTAAGTCTCTGTCCACCATCATGGGTGGTACTGCCAAGAGCT
TTTGTCTCCGAGGTTAGGCCCGGTTTTAGGGCATAGATTTCTGCTGTCTGCTGTGTTCAGCAGGGTCTCA
AGTTGAGCCGTCTTTGTCAGATGAGAGTTAATATTCTGAGGCTGACTGGGAGCTGTGTGTTGCGTCTATC
ACCACAGGTAAGACAGGAAATCAGAGCCCCCAGCCTCAACTTTACACTGTCCAGGCCACATTAGGAGAAA
TGAAATAGACCTGTGTCTTCCTGAGACATAGTTGCCCTCACATCCAAATGGTAGAAGAAAGATGAGTCAT
GTGGCTCTGTGCCCTGGTCAGCCATGTCCACAGGCTGTGGCCAGCACCCGGGAGAGGGCAGGAAGTGACC
CCAAGCTGCCCACCACCGTTTGCTTTGGAGGAAGAGGGCGGCAGTGTCTCCAGGGTATCTGAGGGTACAA
TCTTATTAAGCCTCTGTTAATAAGCACAGCTTCCTTATTTATCAGAGTAATGTATTCTGGGTTTAGAGAA
AGAAAGCAGCTTTTATTTTCCAGGACTATTTTTATAAACTATGTTTTTTCCATCTGGCCTCACAGCTGTG
AACCCAGGATTAACTACCTTACTGTCACAGGCCTGACCTTTACTGTAAGCAATAAGCTCATATCCAGGTG
GGCATTTGACCCAGACCTTGGTTTTTGAAGTTGTTTCTGAATGATTGCTAAGAAACTTGTGATTGGAAAT
ATCAGACTCCCTTCCCAAACAACGGCCAAGATAATTTGGAGAAGAAACATTCCAACTTTATCCTCTTTTC
TGAGTAACTCTCCTTGGGTTTTATAGATGAGCTGTTAATTGAAGTCACCAAAACATTTTATTTTATTTTA
TTTTATTTTATTTTATTTTATTTTATTTTATTTTACTTTTGAGAATGAACTTCAGGTAGAAAAACTTGCA
GGATTTACTTGTCTAAGAATCCCTCGGTATTCCATGCCCTGGCTGATTGAGGGCCATGTGTAGTTCAGGC
AGAGTCCCTCTCTACTGCGGGTGACAGTCTTCTGCAGCAGTGTGCTATGCCACTTTAGCAGGGAAGCTAA
AGTCACCCTGAATACCCAGGGAAGGGTTCAGAGGTGGTGCCACACATCATCAGACAGTTCCTAGTTTGGT
GTTTTGTACCTAGAGGAGAGAAGGCAGACTGACAAATAGAAGAGTCCAGGTTGCAGGACAGAGCCCTGGG
TTTGAGTGTGAGGCCTGGCACCATGTTGGGGAAAACCTAAGCCAGGCACTCTTCCATGCCATGAACTGGG
TGATGAAATGCTGTGGCTGGATTTTCTTCTTTTTATCCTGAGCCTGACTGAGGAGGCATATGTTCAAGTC
TTACCATTGCTTTATGTTTAGCAAGTTATAATCAATACTCTGTTTGCTTGTTACTTAGAAGATGGAAGAT
TAATAGGGCCAGCTGAGTCAGAGATCTGCTTTCCACTCAGGTTCCTGTAAGGTCAGGACTGCAGACTATG
AAACTTATCTCAGGTTTCTGGGAGCCTCTGCGAGGTTGCAGAGACCAGCTACACATGCACTGGGGAGTTG
TACCCTCAGTACTTGAGGAAGCCCCCAATAAGGAAAGCATAGCTAGTCAAAGAATCAAGTCTCTATTGGT
CATTTACACTTGTGCTAGGCAATAAGCTAGGGGCCAAAAGTTTGTAAAATAATACATATAGTGTGTTAAG
TGTTCAAAGAGTCAAGGAGTCCATTGCTACTACCACTGTCCCATGTGGAGAGACAGGCTGAGTGAGTGAG
GTTACACAGCCTCTCAAGGCAACATGAGGAAGATGTGAGAGAGTCTTCACTTGCCAGTTTAGACTTTCTT
CTAGGGTCATGAATCTTGCAGCAGAGGGTGACTTGTTCATAAAACAGAAGAGAAAGTGTGGGTTTATAGA
TTCTGTGTCTGGTTTCACTGAGAACTCAGACATTTAGGTTTTGTTTTGTAACAAGGTCACCATTACTACT
CTAAGGGGTTCCTGAAGGCATTTGCATGTCACTGTTCCTTGCTGCAGTCAAAAAGCACTTTTATTTACTT
CATTATCTACTTGTTCATCTGGCGCCCAGTGTTTTATCTGGATCAGGTTCATCTGACAAGTTCAGGGTGC
TTTTTTTTCCACCCCTACATGTTCCAAATCCCTTACGCCAGGAGTTTGCTGTTTCTGTCATCTGGCCGTC
GTCTTGGTTTCTCAGAACTTGGTTTCTCTCTGAGAAAGTGACTCACGATGTGCTTAGTCAGCAAGCAACC
CAGGGAGAGAGGGGTGCAGTCGATCCTGTTAGGTAAGGTGACTCTGAAGACAAACAGTATGTTGGTGGCT
ACCATTTCAAAGCAAGAGAGGTCAGTCAGCAAGCAGAATGTAGAATGGAGAGAGTTGCCACGGAGGTAGC
CTTGCATCCGTCTCTGACAGCACTCTGGCCTTTCTCATGCTTGTTGCAGTGAGTCAAGAATATACACTTT
TGTGTCAGGAATATACATGTTTGGTGTATGTTTGTTCCAATAGACTCCATGAATCCAGGAACACAGGGCC
TGGTCTCTTTCACTTCCTACTGCATCTCCACAGATGCACACAGTACTGGGTCTCACCCAGAGAAGTGTGC
AGTAAATGTTAATTGAATAAATAAATATATGCAAACTATTTCTCCCTGAAAGTAACCAAGGATTGCATCT
CACAGTGGGAGAGAAACTCAGCAAGAGAATTATAGGGAAAGGCAGCCCTTCTGTGACTTGCCTAGTATAA
CACATTCATATTTTTTAGAGAAAGCCTTTTCCAATAAGATACTGAAAGAAAGTATCTTAATGACTTTTTC
TATTCCAGTCATAAGATATAATGACCAATGCAGTTTATAGAAGGAAGAGGTTGTGGGGGCTATGGTTTCA
GAGAGTTATAGAGTCCATGGACACAATGGCAGCAGGCATGGCACTGGCTCAGGAACTGAGAGTTTACATC
TTGAGACATAATCATGAAGCAGAGAGAAAGAGAAAGACAGAGACACAGAATGAGAGAGAGAGAGAGAGAG
AGAGAGAGAGAGAGAGAGAGAAGGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGA
AGAAGAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG
GAGGAGGAGGAGGAGGAGGGAGAGGAGGGAGACTGAGAATATGAATCTTGAAACCTCAAAGCCCACATTC
AGTAACACACTTCATTCAACAAGACCACACATTTTTGTTAAACTTTATTCTTCCTTCACACATTGCATCC
TGATCACAGTTTCCCCTCCCTCTATTCTTCCCAGTCCCTCTCCCTACCTCCCCTCTCCCCTAGACCAAGT
CCTTTATTTCCCTTCAAAAAAAAAAAAAGAAAGAAAGATAAAAAGGAAGGAAGGAAGGAAGAAGAGGAGG
CCTCCTAGGGAGATTCACCAAACACAGCATAACAAGATACAATAAGATTAGGCACAAACCCTCATATCAC
ACAGCTGAACATGGCAACCCAGTAGGAGAAAAAGGGTCCCAAGTACAGGCAAAAGAATCAGAAACATCCC
CACTCCCATTGTTGGGAGACTCACAAGAACACCAAGCTGTAAAACTATAAGGTATATGCAGAGGACCTAG
CTCAGACTAAATGGTTTGTCAATTAAGTTGCTCTGAGCTTCTATGAGCCCAACATAGTTGATCCTGTGAC
CCATGCTCTTATGGTGTCCTCCACCCCTCTTGCTTCTACAGTCTTTCTCCTCTTTTATAGGGTTCCCCTA
AAACCGTACCTCTTAATCCTCCCTGAACAGTTCTGCTAACTAGGAACCAAGTAAGTGTTTAAATGTATGA
GCTTATGGGAGCCAGTCTCATTCAAACCACCACACTAGGCCAAAGAAACATTGATAAATTTGACGATATT
AGAAATGAAAACTTAAAATCTCTATATACTATCAGTATTAGTCAGGGTTCTCTAGAGTCACAGAACTTAT
GGATAGTCTATACATAGTAAAGGAATTTATTGATGACTTACAGTCTGTAGTCCAATTCCTAACAATGGTT
TAATAGTAGCTGTGAATGGAAGTTCAAGGATCTAGCAGTTGCTCAGACCCACACGGCAAGCAGGTGAAGG
AGCAAGAGCCAGACTCCCTTCTTCCAATGTCCTTATATGGTCTCCAGCAGAAGGTGTAGCCCAGATTAAA
GGTGTATGCCACCACACCTTTAATCCCAGACGACCTTAATCTTCTGGAATCCATAGCCACTATGCCTCAA
GATCTCCATACCAAGATCCATATCAGAAACTTCTATCTCCAACCTTCTGATTAGGGTCACTGGTGAGCCT
TCCAATTCTGGATTGTAGTTCATTCCAAATATAGTCAAGTTGACAACCAGGAATAGCCTACAATATCTTT
CTCTTTTCTTTGGTAGAGCTTTTTTTTAATTTTATTTTTTATTAAACTAATAAAATTTATTTTAAAATAC
ACAACTCAGTATTGACATTTTTTAAGTCATCAAGTAATTTATAATAGTTAAATGCCTCTTAAATATACAT
GATATCTCCTGAAGCTAAAAGTAATATGCACTCAATCAGTTTTTAAATCTATTTTGAGCATTAAACATGT
TAGAAATAGAAAAAAAAATTACTTATGATGTCCTCTCTGAAAGAAAATTGTGAAAATTTCCTGAGTAGAC
AAAAACTGTTCTATCTCCAAGGGAGAATACTCAGGGTAACTGTGGCTTCATAAAATGAATTAAGCAGTGT
TCTTACTGTTTCCATTTTGTGGAATAGTTTGAAGAGTATCGGTATTATATTTCTTTGAAGGTCTGATTGA
ATGCTGCACTAAAACCGTCTGGTCCTGGGCTTTTTTTTTTGGTTGGGAGACTTTTAATGACTGCTTCTAT
TTCTTTAGGGGTTATGGGACTGTTCAGATGGTTTATCTGGTTGGGAATTAACTTTGGTATTTGATATCTG
TCTAGAAAATTGTCCATTTCATCCAGATTTTCCAGTTTTATTGAATATAGGCTTTTTTTTTTTTTTTTTT
TTTGCAGTAGGATCTGATGTTTTTTGGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAA
TTTCCCCAGGTTCTGTTGTTTTATCTCCTTTTTCATTTCTGATTTTGTTACTTTGGATACTGTTTCTGTG
CCCTCTTTTTAGTCTGGCTAAGGGTTTATCTATCTTGTTGATTTTCTCAAAGAACCAGCTCTTGGCTTTG
TTGATTCTTTGTATATGTCTTTTTGTTTCTACTTGGTCGATTTCAGCCCTGAGATTGATTACTTCCTGCT
GTCTACTCTTCTTGGGTGTATTTGCTTCTTTTTGTTCTAGAGCTTTCAGGTTTGCTGTTAAGCTGGTATT
GTATGCCCTCTCTAGTTTCTTTTTGGAGGCACTCAGAGCTGAGTTTTCCTCTTAGCACTGCTTTCATTGT
GTCCCGTAGTTTGATCTTTTCATTAAATTCTAAGAAGTCTCTAATTTCTTTACTTCTTCCTTGACCAAGT
TAACATCAAGTAGGGTATTGTTCAGCTTTCATGTGTACGTGGGATTTCTGTTGTTTTTGTTGCTATTGAA
GACCAGCCTTAGTCCGTGGTGATCTGATAGAATGCATGGGATTATTTCAATCTCCTTGTATCTGTTGAGG
CCTGTTTTGTGATCGATTTTATGGTAAGTTTTGGAGACCGTACCATGAGGTGCTGAGAAAAATGTATATT
CTTTTGTTTTAAGATGAAATGTCATATAGATATCTGATAAATCCATTTGGTCCATAACTTCTGTTAGTTT
CACTGTGTCTCTGTTTAGTTTCTGTTTCCATGATCTGTCCATTGATGAGAATGGGGTGTTGAAGTCTCCA
ACTATTATTGTGTGAGGTACAATGTGTGCTTTGAGCTTTAGTACAGTTTCTTTTATGAATGTGGGTACCC
TTGCATTTGAAGCATGGATGTTCAGAATTGAGAGTTCATCTTGGTAGATTTTTCCTTTGATCAGTATGAA
GTGTCCTTCTTTATCCTTTTTGATAACTTTTGGTTGAAAGTTGCTTTTATTCAAAATTAGAATGGCTGTT
CCAGCTTGTTTCTTCAGACCATTTGTTGGAAAAATTGTTTTCCAATCCTTTGCTCTGAGGTAGTGTTTTT
CGTTGACACTGAGGTGTGTTTACTATATGCAGCAAAATGTTGGGTCCTGTTTCTGTATCCAGTCTTGTTA
GTCTATGTCTTTTTATTGGGGAATTGAGACCATTGATGTTAAGAGATATTAAGGAAAAGTCATTGTTGTT
TCCTGTTATTTTTGTTGTTATGGTCGGAATTCTGTTCATGTGGCTATCTTCTTTAGGTTTGTTGAAAGAT
TACTTTCTTGCTTTTTCTCAAGCTTAGTTTCCCTCATTGTGTTGAAGTTTCCCCTTTATTATCCTTTGAA
GGGCTGGATTTATGGAAAGATATTGTGTAAATTTGGTTTTGTCATGGAATACCTCAGTTTCTCCATCTAT
AGTAATTGAGAGTTTTGCTGGGTATAGTAACCTGGGCTGGCATTTGTGTTTTCTTAGGGTCTGTATGACT
TCTGTCCAGGATCTTCTGGCTTTCATAGTCTCTGGTGAGAAGTCTGGTGTAATTTTGATAGGTCTGCCTT
TATATGTTACTTGACCTTTTTCCCTTACTGCTTTTAATATTCTTTCTTTGTTTTGTGCATTTGGTGTTCT
GATTATTATGTGATGGGAGGAATTTCTTTTCTGGTCCAAACTATTTGGAGTTCTGTAGGCTTCTTACATG
TTCATGGGCATCTCTTTCTTTAGGTTGGGAAAGTTTTCTTCTATAATTTTGTTGAAAATATTTACTGGCC
CTTTAAGTTGGAAATCTTCCTTCTCATATATACCTATTATCCTTAGGTTTGGTCTTCTCATTGTGTCCTG
GATTTCCTGGATGTTTTGGGTTAGGATCTTTTTGCATTTCACATTTTCTTTGATTGTTCTGTCAATGTTT
TCTATGGTATCTTCTGCACTTAAAGATTCTCTCCTCTATCTCTTGTATTCTGTTGGTGATGCTTGCACCT
ATGATTCCTGACCTTTCCCCTAGGTTTTCTATCTCCAGGGTTGTCTCCCTTTGTGATTTCTTTATTCTTT
CTATTTCCATTTTTAGATCCTGGATGGTTTTGTTCAATTCCTTCACCTGTTTGGTTGTGTTTGCTGCAAT
TCTTTAAGGGATTTTTGTGTTTCCTCTTTAAGGGCTTCAAGCTGTTTAACCTGTGTTCTCCTGGATTTCT
TTAAGCTATTCGTGTACTTCTTAAAGTCCTCTATCATCACCATGAGATGTGATTCTAAATCAGAGTCTTG
CTTTTCTGGTATGTTGGGGTATCCAGGGCTCACTGTGGTGGAAGAACTGGGTTCTGATGACACCAAGTAT
CCTTGGTTTCTGTTGCTTATGTTCTTGCCCTTGCCTTTTGCCATCTGGTTATCTCTGGTGTTAGCTGGTC
TTGCTGTCTCTGACTGTGGCTTGTCCCTCCTACAAAGCTGTGTGTCAGCACTCCTTGGAGACCAGTTCTC
TCTAGGAGGAATTTGGATATGGACAGCTGTGGCACAGGGTCAGCTCCGAGGCGCAGACAGAAACTAGAAG
CCTTTTCCAGTGGTTTTCCCAGAGAGTATCCAATCAGTTTCCAGTTATTTAAGACTTCTTCAACTTTTGA
AATAAACCTTTCCCATTCTGAGGCTGTAGTGAAGTTTGTGATCTCAAACAGTTCAGGCTCTAGCTCAATG
TCCACCATCATCTTGCAGAGTGGAGCATCAGCCATACTGTTTTTCTTCTCCAGTAATTTGCTCCTTTTTC
TTCTTAATATTTATTTTTAAGGAGTGGGAACCCATCTGTTCCCATAGAGGCCAAGACCATGCCATGAGTA
TTAGCATTGTTCTTTCATCTACATCATGGTATTGTAGACAAAATCTCTACATTTCATTAAAAATAAAATA
ATGAGAATGTAATACAGTTCCATAGACAGAGCTAAAGGGCAACATGACTTATACCTTATATAAGTAAGAA
AAATTCTTACAAGTCAGTAAGTAAGAGAGAATTGGCTAGGGAAAATGGGAGGTAGAAGAAACATCCAGGT
TCTCTGACATGAACATGGAGCTGGAATTCACTGGCTATCAGGGATACTCACGCTCAGACAACATCCATTT
TCATCCTGTGCTTTGTAAATGATGGATAATGTCTAGCAGCTGGGAACCTGAGAAGAGAGCTGCTATCATA
TGCTACTCAGAGAAGAGTTAGTTGGACCCCCAAAGGCCTACCTACACAAGGAAGCTGGAGGCTTTAAGAG
GTGAGGCATAGTTGGAGACTTGTGATCTCAATAGGAATGTTCTTAAGGTGATAGTGGGACTCCATGCCCT
CCTCCGACTCTCTATTTCAGTTCCTGGCCATGGGGTGCGCAGTGTGGCTCACCGCATTTTCATATGCTTT
CCTGCCTCAGCACAGGCCCAAAGTCATAGGGAATCTCTGAAAACATGATCCTGGAATAAACATTTCTTCT
TCTTAAGTTGATTATTTCAGGTATTTCGTTAGAAGTGTATACAGCTGACTAACATAGAAGGCAATTTGAC
AAGGCCATTAAAAACCCTATTAAGTCTCTAGTAATTCTCCTTGTCAACAATGTAGAGAAAAACTTGCTTG
TGTGCCAGAGAGGCATACACAAGGACAGTTATTAACAGTATTTTCAATGTATTTCAATAATTTATTTCAA
GTCTTTGTGTATTTTTAAAATAGAAATATATAATGAATAATAAAATCAAATTTATCTCATAATTTCAACC
ATTCCCTAGAATAGGTATGCTTCTGTAGACCAATGAACAATGTCTATGCCTAAGGCATGCCTTGGCCTCT
ATGGAAACAGCTGGTTTTCACAGGTGTGTTTCCATTCCTCAAAAACAAGCTTTAAACAGTAGGTTGAGGT
GACTTCTAAAAATATGTGGGAGAGTTGAATCCCCAAAACATGTGGACTCAGCCCAATCCAGAAAATGCTG
TTTGTAAGCATAATTAAGGAGTAAAATCCTCAGGAGAAGAAATAGTTCTGCATTACTGTGAGTAACATAA
GACCAACAACAAGAGCCCTAGCAAGCAACAGAAGGGAAGCAGTCAGATGTAGTAAGGGTTTGGGTTTCTT
TAAAAACCCAGTTCTGCTAAGTGAATATGTTTCTGTTTTAATCGCAGGTGTGGGATAAGAGGCTGCTTCA
CAGAAGGTGACTATGATTTGCCTCATGCATTAGCAGGGGCATGATTTTTGCCAGCTGCAGATACTTTAGT
TTTGAGGACTCTGGAGAGGATAAAATTGGGAGAGTCCCAAGAAGGCTTGTAGTGGCTGCTGCTCCCCCTC
TTGCTGGTGGTTCATCTTGCTGCTGTGTTTGCTATTATTGGTTTACTGGTTTGCTGGTTTGCTTGATATA
CTGACAACAAAGATTAGACTTGCCCCTAGAAACACATTCCTAGTCAGCAGGAAGTAGTCTATAGTGGTTT
ATGCCCCCTTTCCTCTCTAACCTTCTTTCTCTGCTACCTAGTATTGGTTGGGGTTGGAAGGGATTAGGAT
GGAATAAGGGTTGGAAGGGAGATGGAGGTATAAAAACTCAGTAAAATAGCAATATACACATTGGCCAGAA
GCCAATGAATGTCTGGAGCCACTAGAAGCTTGATGGAACAAGGGAGGATTGTCTCTTAGAGCCTTATGAG
GAGCACAGCCCTGCTGCCACAGTTACCTTCTGACCTCTACACACATGCTGTGGCACAGGTGCGCACACAC
ACACACACACACTCCAAATATATCTTTAAAAAAAGTTTAAAGGAACTTCTGTCCTTTAGAAATGTTAGAG
AATAAATTTCTGTTATATTAAGCCACCAATTTTATGGAAACTGATACAAAAAAATTAGGCATTTGTATTT
AGTGAAGGATAAACTTGCTTTTGTTTTTAAGTAAAAACGTTGGCCTTATAGAGGCTGATTCATCTTTTTC
CTCTGGAACCCTAACAAGACTGTCCTTGTATGTGTCAGAAGTGAGTTAAGACTTTCAGGAGCCAAAGGCA
GAAATGAGTTATATGTTCCTAGATGCTAAGTTCTCTGTCAAACTCTGTCGCAGAGACATTACCTTTTAAA
AGACAGATAGGCTGGTGGGTGAGAATATCTGGCTAGTTCTTCAGTTTACTTAAATTTTAACGCAAAGACA
AAGAATAACACAGGGGAGGTGTAGTTCGGGCTGCGCAGCAATGGAGTCTTGGTGGGAGTTGAGGTTCTGG
GGAACAGCAGAGGCCTGAAAAGAGATTTCAATAGTGACTTTAATCTCAGCACAGGAAGCATCTGATTAAT
GAACGATTTACCCATTGAGGACCCTTAGATCCTGTGGATACCTGTGAATTGATTCACCTGCTTGTAGCTA
AGGCTTGGCACCCACAGCTTTTCCTCTCCTGACATTTCACCAGCCCACAGCTCACGGGCTCTGGCTCCCC
GGAAGTCCTGGGTGACTTCAATCTGCTGCAACGGAAACCAGCCTACCTGGAGCTCAAGCTCGGCGACATT
TAGGAGTTTGGGAACATTCGGAAGGATCTGGAGGCCTGTAAGAAGCAGAAGGAAGATGTGGAAGGTGTAG
GAACCAGCGATGGAGAAGGAGCTGCTGGGCTCAGCAGTGACCCCAAAAGCCAGGAACAAATGATTAATGA
TTGTATTGGTTATAAACCCCAACTCAAGAGCAACAACCGCACATCTCAGTTCAGAAACTTTGAATTTTAG
AGATGGATTCTCTTGCATGCTAGACGCCTAGGACAGAATACAATGATGACAGAAGTACCAACCAGATTTA
GAGAATTAAGTGTGTGCACCCAAGCAGAAGGTTTTCTGTCTCCTGCGGGGAGAGGTGACGTCTGTGTGAA
ATTACTGCTGTCCAACCTTTCTGATAGGCTGGAATTTTGGCTTCCTGGAAAATTGGACCGCAGAAGGCTT
ACCTGGTTTTTGTTTTTAAAAATAAATTTATTTTTTGGAAAAAATGTGAGATGTCCTTAAAGGTAGTAGC
ACTGCTAATCGCCACCTCTGACAGGTAACTGCTACAAGTGACATTGAAGGAAGATGAAATATTGTAACTT
GTGAGTTGTTTAGGAGCCCATTGCCCCGGCCTGAGACTGAGAACAAAGCAGAACAGCCCCCAGCCCACAG
GAACAAAGTCCTGATGCCCTTTCTGTTAATGTTTGAATAAGCCAATAGTGTGTCGCTATGCGGAATTCCA
CACCCCTAAGCCCCTTACCCCATAAAAACCCCTAGCTTTCAAGCCTCGTGGCCAACATCCGTTATCTCCT
GTGTGGGATGCATGTCGGTCGGAGCTCCGTAATTAAACGTCCTCATGTAATTACATCAAGAGATGGTCCT
TCGTGATTTTTTTTGGGTGCACACCGAATCAAGAGATGGGTGGGGGTTTCCCCACTAGGTTCTATCAACA
TCATTCTCCTTGTCTTTACAAAAAGACCCCAGACCCCGAACCCTTGCAGTTGATCCCCTGGGCTGACTTA
ACTTGTTTATTCACTGTCTGCTGACCATCCTTCAAGCAACAGAGATCCCAGATGAGTGTGCTCAGGCTGC
AATCCAGCACTTGGAAGGCTGAAGTAGGAATCTCAAAGAGTTGAAGGCTAGTCTGGGCTACAGAGTAAAA
CTCTGTCTCAAAATGTCAAAAACAAACAAACAAAAGGAAACCAAACAGAGATCCCTGCCCTCATGGAGAC
TGGATTCAAATGATCAGATTGTCAGAATCAAATCCACTTCCAGGAAGGCTTTACACAGGGGAAAGCACAA
GCAGCTGTCACAGTGAGAGACATTCTATTCTTCACTTGGGACTCCACTTGCGCAGCACCCATCTGAGAGC
TACTCTGGATACTTTTTCCGCACCATGCCCTATTTTTACCATAAAACCCAGGGACAGAACCACCAGCTGT
GGAAGCCAGAACATCTGGAATCAAGTTTCAAAGAAACGCCTTAGCTGGGATTTACCCAGGATTTTGGGTA
GTTCCTGAGTGATGTGAATGGGAAGGTAGAGACAAAGGGGAATGGATAGTTCCCTCTTCTACTCCAAGCT
TTTCTACAAAACCTTTATTCTAGTTTTATTGATGACTCCTAAGTCCTGTTATCTTCCTGTCTTAGAACAC
AATAAACCCCCCAAGACACAGGCTGTCCATAAGACTCTTTATTATTGCAGCCTGCAAAGGCCTTCCAGCC
GGCAAAGGAAACAAAGAAAAGGATCAGCCTGCCTCAGTCCTTCACTGCAACTCCCCAGTAGGATTCCCCA
CAGTTGTTTTTGTGCCTCTCACATGTACTGACAGCTGCCATGCAGAGGCCTGTATGAGAGTGCTGAGTGA
TTTATGTGGATTCTCTTAGTTCCTGAGAGGGCACACCTTTCTGAGTTTCCAGATGTGAACCACACCTTTC
TGAGTTTCCAGATGTGAACCAGAGCTCAATCACGAAGTGGAAGCTATGGGGCCGCCTGCTTTCCAATCCC
ATGCTTCTAATGGCTTCAAACTACATTGCTCTCTAGGTGTTCTCAGCTGAGTCTTTAAGAAAGAAGTGTA
TGGGGGAGAGGAAATTTTCTATGTTCAAGTTTCCAAGATTTTCTATGCTTTCTTATTAACAGAATGAGAC
AATTATTCATTAGTAGACCAGGACTTGCTGCAATTGCTAATCTATTTTGGGCATACCTAAATTATATGTA
TCAATCTTGTGTTCCCTAGGATCTGTTTGTTTTTGGACCACCAACACCCAGGAGGTTAGTCACTTTATTC
AGAAGAGTGACCTTTCATTTTCCTGAAGCCTTCAGGTGTAATATAATCAGTGCACAGTAAAAATGAAGTA
AGGCTTGGGGAAAAAAAAAGAATATAATAACACAGGAGAAAATATGCTGGTGAAATTTGAGTAGTATCTC
CATGGGGAAAAGAAGACCCAGAAACAACTCAGCCCCTGGAGCTACAGCTGGGGTTCCTATCCCTTGCATC
AGCCATGTATTGCTATCCATAATCTTGGTCTGGATGTGGATCCTCTCCACTCCAGAAGAAGGGATTTTCA
TTCTAAACTAAGTATTTCAAGAATTCTGAGCCCACAAAGTCCAAGACAGCCATAAGCAAAGAGGAAGCAT
GATTCAAAGACATTTTCACCTGGATTTTGAACATTTTCACCTGGATTTTGGGCATCTGTCACTGTCCAAA
TAAAGCAGCTGTGTCTGTACACCTTGACTTTTTAAAAATTAGGTATTTATTTCATTTACATTTCTAATGC
TATCCCAAAATTCCCCCACACCCTCCCCTACCCACTCCTACTTCTTGGCCCTGGCATTCCCCTGTATTGA
GGCATATAAAGTTTGCACGACCAATGGGCCTCTCTTTCCACTGATGGCTGACTAGGCTATCTTCTGATAC
ATATGCAGCTAGAGACACGAGCTCCGGGGTTACTGGTTAGTTCATATTGTTGTTCCACCTATAGGGTTGC
AGATCCCCCCAGCTTCTTGGGTACTTTCGCTAGCTCCTCCACTGGGGGCCCTGTGATCCATCCAATAGCT
GACTGTAAGCATCCACTTCTGTGTTTGCTAGGCATAACTTTGCCCCTTCTTAGAATTGGGAACAAAACAC
CCATGGAAGGAGTTACAGAGACAAAGTTTGGAGCAGAGACGAAAGGATGGACCATCTAGAGACTGCCATA
CTCGGGGATCCATCCCATAATCAGCCTCCAAACGCTGACGCCATTGCATACACCTTGACTTTTGTGTTGC
TCACATTCATAAGTTGAGAATCTATCTCTAGAGCAGCAATATTTAAAGGGGACTTTGGAAGGTGACTGTG
TTATGAAAAAAGAAACCACATGAGGAAGATTCCATGCCCTTACAAATGTAAGTTTAGAGAAATCCTTTGT
TCTCCCCTCTGTAGTGACTGAGAAGTTGGTCATCTATGAACCAGGAGAAGGCTGACATCAGATGTTGAAT
GAAGACCTTGCTCTTAGGTGTCCTAGTTTCCAGATATGTGAAGAATATGTTTCTGTTGTTTGTAAGCCAT
CTAGTTTATAGTTGTCTTAGTTAGGATTTCTATTACTGTGAAGAGACACCATGATCAAGGCAAATTTTAT
AAAGGCTAACATTTAATTGGTGCTGACTTACAGTTCCAGAGGTTTAGTCTATTATCATCATGGTGGGAAG
CATGGCAGCATCCAGGCTGACATAGTACTGGAGAAGGAGCTGAGAGTTCTATATATTTATCTGAAGGCAG
CAGAAGAAGACTGTGTGCCACACTGGGCATAGCTTACGTATAGGAAACCTCAAAGTCTACCTCCACAGTA
ACATACTTTTCCAGCAAGGCCAAACCTACTTCAACAAGTCCACAACTCCTAATAGTGCCACTCCCCATGG
GCATTCAAACGCATGAGTCTGTAGGGACCAAACCTATTCAAACTACCACAATGGCATTGTGTTATAGTAC
ATCAAATGGGCTAAGAAACATCAACAGGAACAGGAAGTATGTATGCACCCATGCATATGCACGCATGCAT
ACACACACAGCAGATAAATCTTTAAAATTTATAAAGGAGGATAACATGGGAAGTTCCAAATCACTTTAAA
CTGTTTTAGTAGAAAGAGAAATAATATCTAAGACATACTGAAAAGTCCTTACTGACAATGGAAAAGAGAC
ACCATATTGACTCAGAGTGAATGACCTGTGTATATTATAAACAAAGAGAAATCTACATAGAGATCTAATA
ACGCTGAAAAGTTTAGGACTCTAAAGACAAAGAAAAGATTTGAAAAGATCCAGAGAGAAAAACTTTGCTT
TTTTTAAAATCACAAACAATATCATGCTTTATTAATAACATGTGAGGTGATTCATGATATTCAACACAGT
TGGAAATATTTACTACTTACCAATCGCTAAAAGAATCAATATGGCTATAGAAGTTAAGAGTGAGGAATCA
AGGAAGTATACTTTAGAGGTCCAGTGGGCTCAGTGGAGATCTAATCTAAACTTTTAAATTTATGACAGTT
TTAGTTGGGGGACTGCATACAATACTGCCGTTTTTATTAGATAATTTCTTTATTTACATTTCAAATGCTA
TCCCGAAAGAACCTATACCATCCTCCGGCCCTGCTCCCCTACCCACCCACTCCCACTTCTTGGCCCTGTA
CTGGGTGGGGCATATAAAGTTTGCTAGACCAAGGGGCCTCTCTTCCCAATGATGTCCAAGTAGGCCATCT
TCTGCTACATATGCAGCTAGAGACACGAGCTCTGTGGATACTGGTTAGTTCATATTGTTGTTCCAACTAT
AGGGTTGCAGACCCCTTCAGCTCCTTGGGTACTTTCTCTAGCTCCTCCATTGGGGGCCCTGTGTTCCATC
CTATAGATGATTGTGAGCACCCATTTCTGTATTTAAAAAATTTAAAAATTTAAAAATTAAAAAACTATGC
TTTTAAAACAGCAATAATCTGTCAGCTGAGTCCCAGATATCATGGGAAGCTAGAGGACAGGGGGATATTT
TTAATACAGGGGAGATAATTGCCAACACGAACTTTTATTCTCTACAGACAAGGTTAAATGCATTAAAATA
AAGGGCATCTTCCTATAGCTGGTCTTCACCAAACTGAATTCTCCTGCATATGTTTCAGACAGTAGTGATG
TCAGAGGCAAGCTTAGAGTGTAGAAAGAAACAGGGTGGCCAAGTCCAAAGGTGAAAGTGATCTAAAATAA
TAGTGTGTGTGTTAAAAACTGAAATATATGGCAAAGGGATATGTGGGCTAGTGGTGTAAATAGTATTAAA
CTGTTCTTTGGACTGTGTGCTTTATAAAAAGACATGGTCTTTAACTGAAGATATTTAAAGTTTAACTTTG
CATGTTTTAATGTGTACAGCAGCCTTTAATAGAGACAGGATGTTTTATTTTACACATAATAAAGAACAAA
AAAATCTGGAAGACTGGAATACAATTGAAAAGAAGGCAAGAAGGAAGAGAAAAATATGTATATAACAGGT
GGGATAAATAAGTTCTAATTAAAATGATAGATTTAATCAGAAATACACTAGTAATTACAATGAGTAGAGT
AAAATTGATGTTTAGATTTATAAATAGCAAGATTAAGTGTTAGACATATGTAAAACATAAAAATACTGGT
AAGTTAAAGTAAAAGTCTAAAAAATAAAAAGGACACAGCATCCAAGTGCTTTTTAATTAAAAGCAATTTC
ACATAACATATTTTGAATGTATTTCCCCTCTTCCAGATGCTCTCCACCTTAGTAGCCAACCAACTTCATG
TTCTTTTACTATCTCTCCCTGAGGGAAAAACAAAACAAAACAAACAAACAAAAAAACAAAACCTAAAACC
CAAACAAAAACAAAAATAAAAACAAAATATAAAAATCAAAACAAAAAACAAAAACTCAATAAGACTAAAC
AAACAAACAAACAAATAAGTAAAGTTCATGAAACATGGAGTCTGTTTTGTGTTGGTCAAGTATCCGTGGG
CAGGGGACCTACCCTGGAGTGTGATGGATATGCCCAGAGATACTCCATTGAAGAAAAGTACTTTTCCTTT
TCTCAGAAGGTAGGTATCAGCTGCAAACAGCTTCCTGATCAAGGCCAGGATTTTGCATCCTCTTCCCCTA
CTCGGTGCTGCTATTTTTGTCTATGGTATACAAATGCTACCCAATTAAAAATATAGCGTTAATTAACACC
ACAAAGTAGGATTTAAGGCACGAGAATTACTGGCTGTACTGAGGATTACTCCATAATAGCAAAAAGCTCA
ATTCACCAGGAAAGTATAAGTTAAAATTTAAATGTACCCAATTGCATTTTCTCAATATATCCAAAGTCAG
AAATTGATGTAATTGTAATGATGAAGAAATCCATAATTTAGGACCACAATTTATGGTAGATTAAAAAACT
TCTCACAGAGAAATAAAAATGGTTTAAAAATATTTCAAAAAAATGTTCATTGGTACTAGCATTTAGGAAA
ATGAAAATAAAAACAACCTTGAAATCTCACCTTGCCCTACTCGGAATGGCAAAGATAAACAGAACAACCA
ACAGCAAACACCAGAGAAGACTCTGGGGAGAAGGGAATTCTCATTAACTCGGGGAGATTGCAAACTGGTT
AGCTACTGTGGAGATCAGTATGGAGAACCGTGAAAAAGCTAAAAATCAATCTATCATACCACACCTTGGC
ATATGCCCAAGGTACTGGACATTCTACCCCACAGATCCTCGCCCAGGCGGGTTCACTGCCACTGCATTCA
CAATAGTACAACCTAAATGTCCTTCAACTGACAAATGGAAAATAAAAAATGCAGTATATGTGCACTATGT
AATACTATTTAGCTGTCATGAAAAATGAAATCATGGAATTATGGTAAATGGATGGACTGGAAAATATCAA
ATCCAGAGCCAGAAAGATCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCAGACCAGCTTTCA
TGGCACCATGATGTGACACACACGCTGCCAAGGGAGGAAGCAAACCCATACTTATGCCCAGTTATGATGC
TTATGAACCGAGGTGACCAGCACATCATGGCATCCCTAAGGGTGCAATAGTGCCTCACATAGCTTGGTTG
TCTACAACAGCACTCTAATTGGACTTACTGCTTGCTTAATAAGGAGATCATATCTGGTATCAGAAAACTT
AGCCAAGTATTCAGGGCTAGTGAAACCATGAATCTTGGAGGAAAACATACAAACACTACTTTACTACAAC
AGCACAATTCCCAACTACATTCTAAATATGTATTTTCTTTGAAGTTACAGTTTCAGAGGGTTAGAGACTG
CCCCCCTTTTAGATTTATTTATTCATAGATTTTATGTGTATGAGTACTCTGTCTTCATGTACATCAGAAG
AGGGAATTGGGTCTCATTATAGATGATTTGGGGCCACCATGTGCTTGCTGGGAATTGAATTCAGGACCTC
TGGAAAGAGCACTCAAGTGCTCTTAACCTCTGAGTCATCTCTCCAACCCCCTAAATAAGTATTCTTATAC
CCAGAGATAAGAATATGTCTCACCCCTCACTAAAGAAATGTCCCTTTGTAACAGACAGAGACCATTAAGA
GAAAACCACAGTGGATCAAAACGTAAGAGAACAGATGACCTTGTGGTGAGCAGCCCCACTGATTTATCTG
CCACAAGGTTCCTGTATCTAAGGCTCAGGAATCAGAGAGGAAGAGGGGTGGGGAGATTGTAACAACCACA
AGAACAGGAAGTCGGCTGTGAGATTGTATCTCCTAGAAATGGCAGGGAGGTATTCCCCATGGTGCCTTAA
CAATGTGTCTGCCTAAAGAAGACCGGAAGAAGCTCAACACCAGCAAATATATTAACATGGAAGGGAGAAA
TCTCATAGGGCCCCATCCGTAGAAAAAGAACTACACAAAGCTAGGGAATATTGAGAGTGGAGAAATGGTC
TTCCCCAGGGAAGGGTCCTCAGATTGGCTACTAATACCAAGTAGTCAGTGCTGAAATCCCATATATACAT
ATATGTGAGTGTAAAATTGAGAAGATGAAGTTCAAATAGAGACTCCAGGATATCAGAGATGCCAGAGCCA
TGGGAAATATGCTGCAGAAAGCTATAGGCAAGGAGCAGAACTAGTCATATATATGTATATGTGTATGTGT
ATGTGTATGTGTATGTGTATGTGTATGTGTATGTGTATGTGTATGTGTATGTGTATATATATACACACAT
ATACATACATATACACACATACATATATATACATCTATATGTGTGTGTATGTATATATATATGCATGTGT
ATGTAGAGATAGAGATAGAGACTGACAGTGACAGGGTGAGGTACAAAAGAAGGGTTGTAAGAGGGAAAAG
GAAGGGAGAAAATGATGTAAATATATTTTAATTAAAAATACTCTGTAGCTGGGCAGTGGTGACATATGCC
TTTAATTCCAGCACTTGGGAGGCAGAGGCAGGTGGATTTCTGAGTTCGAGGCCAGCCTGGTCTAGAGTGA
GTTCCAGGACAGCCAGGGCTATACAGAGAAACCCTGTCTCGAAAAGCAAAACAAAACCAACCAACCAACA
AACAAACAAAAACCCCTCTGTAATAAAGAAACTTCTCTTAGATATGTATAGGATAACAATATCAAACCCC
AGTAATAATACAGACACTTGACAGATATAATTACTATATGGCTCATGTAGTACCATATGGACACATGGAG
AACACACTTTCCAGTGACTGTAGGGTACATTTCCCTTCCAAGTCTATAAAGAATACATGAAAACTTTTGA
TCATATATTGAACCACAAAGAAGTCAGAACAAAACCAAAGACTGGAATGCGTGCAAATTGTGTGTGTGGT
CACAGCGTAGTTAAGCTAATCCTTGGAAAACTAAACACAACAGTCTGAAATCTCTAAATGTTTACATGAC
ACAAAATATAAAAATTATAAAAATCCCATGGTTAATACAAGAAATCACAAGGAGCTTTAGAAAATATTTT
GAAGTGAGTGATAAGGGAAATGCTGTGCAGTATACCTTTTAGATGCAGTTAAGGCAGTTTTTAGGGGAGG
GGAAATGATAAACTTAAGTAGAGCAGTAAAGAATTCTGAAAATAGATTTATCAATCTAAATTGTTAAAAA
AAAAAAAGCGGTGGTGGCACAGGTCTTCAATCCCAGCACTCAGGAGGCAGAGGCAGGTGGATCACTGAGT
TTAAGGCCAGCCTTTTCTACAGAGTGAATTCCAGGATAGCCCAGAGCTACACAGAGAAACCCTGTCCCCA
AAACCAACTCTCCCAAATGTTTTTTACAAAGAGATAACTATGTAAGCAAGAGAAAGCAGAAGGCAATGGA
ATTGCTACTAAGTAGTGCACCTGTTGTTTGTTGCTGTGATAGACCTATGAGTTTTAGGCCTTTGGAAAGG
GTGGAATAGCTTGGAACTTCAGCTAGAACAGACCAATTCAGAGAGACAATGCCTAAAAGAGAGATCCAGC
TTGTGGGGTTTCAGAGAGGAGCAAGGGACCCATTGGCGAGATTTGTATCATGGTTTCTGCTTTCCACTCT
TAGTGAGAGGAGCAGTGGATGGAGCAGAAAGAGGAAAACTACAGTTTGTGGGCTGAGGGGGGTGAGTTTA
AAGTTCCATTTAGTACAGGAACTGAGGAAGTAGTTGCAATTGCTCAAGACCTGGGCCCTGGGAACAGAAA
GGTCTCATTTTGCACTGGGGCAATAGAAAAGGGGGCTTAAGGGCAAGATCCCACCCATTAAAGTTTCCAT
CTTGTGCAGCTGCACATGCCTTTAAAGGAAGAGTTTAAGGGAACAGTGCTGTTGGAGGGACTTCCTCCAA
AACCCTCTAAGAAAAGATCTCAGAAGATGGAACGATCTCCCATGCTCATGGATTGGCAGGATCAACATTG
TAAAAATGGCTATCTTGCCAAAAGCAATCTACAGATTCAATGCAATCCCCATCAAAATTCCAACTCAATT
CTTCAACGAATTAGAAAGAGCAATCTGCAAATTCATCTGGAATAACAAAAAACCTAGGATAGCAAAAACT
CTTCTCAAGGATAAAAGAAGCTCTGGTGGAATCACCATGCCTGACCTAAAGCTTTACTACAGAGCAATTG
TGATAAAAACTGCATGGTACTGGTATACTGACAGACAAGTAGACCAATGGAATAGAATTGAAGACCCAGA
AATGAACCCACACACCTATGGTCACTTGATCTTCGACAAGGGAGCTAAAACCATCCAATGGAAGAAAGAC
AGCATTTTAAACAAATGGTGCTGGCACAACTGGTTGTTATCATGTAGAAGAATGCGAATCGATCCATTCC
TATCTCCTTGTACTAAGGTCAAATCTAAGTGGATCAAGGAACTTCACATAAAACCAGAGACACTGAAACT
TATAGAGGAGAAAGTGGGGAAAGCCTTGAAGATATGGGCACAGGGGAAAAATTCCTGAATAGAACAGCAA
TGGCTTGTGCTGTAAGATCGAGAATTGACAAATGGGACCTCATGAAACTGCAAAGTTTCTGCAAGGCAAA
AGACACCGTCAATAAGACAAAAAGACCACCAACAGATTGGGAAAGGATCTTTACCTATCCTAAATCAGAT
AGGGGACTAATATCCAATATATATAAAGAACTCAAGAAGGTAGACTCCAGAAAATCAAATAACCCCATTA
AAAAATGGGGCTCAGAACTGAGCAAAGAATTCTCACCTGAGGAATACCAAATGGCAGAGAAGCACCTAAA
AAAATGTTCAACATCCTTAATCATCAGGGAAATGCAAATCAAAACAACCCTGAGATTCCACCTCACACCA
GTCAGAATGGCTAAGATGAAAAATTCAGGTGACAACAGATGCTGGCGAGGATGTGGAGAAAGAGGAACAC
TCCTCCACTGTTGGTGGGATTGCAAGCTTGTACAACCACTCTGGAAATCAGTCTGGCAGTTCCTTAGAAA
ATTGGGCATAGTACTACTGGAGGATCCAGCAATACCTCTCCTGGGCATATATCCAGAAGATGTCCCAACC
GGTAAGAAGGACACATGTTCCACTATGTTCATAGCAGCTTTATTTATAATAGCCAGAAGCTGGAAAGAAT
CCAGATGCCCCTCAACAGAGGAATGGATACAGAAAATGTGGTACATTTACACAATGGAGTACTACTCAGC
TATTAAAAAGAATGAATTTATGAAATTCCTAGGCAAATGGATGGACCTGGAGGGCATCATCCTGAGTGAG
GTAACCCAATCACAAAGAAACTCACACAATATGTACTCACTGATAAGTGGATATTAGCCCAAAACTTAGG
ATACCCAAGATATAAAATACAATTTGCTAAACGCATGAAACTCAAGAAGAATGAAGACCAAAGTGTGGAC
ACTTTGCCCCTTCTTAGAATTGGGAACAAAACACCCATGGAAGGAATTACAGAGACAAAGTTTGGAGCTG
TGACAAAAGGATGGACCATCTAGAGATTGCCATATCCAGGGATCCACCCCATAATCAGCTTCCAAACGCT
GACACCATTGCATACACTAGCAAGATTTTGCTGAAAGGACCCAAATATAGCTGTCTCATGTGAGACTATG
TCAGGGCCTAGCAAACACAGAAGTGGGCCATTGGTAAGTATGTCAGATCGATATGCAAAGGTCTGGTTTG
CATGGGTACAGTCTGAAGATGTGAAATGAATGTAGTTCACAACATCATCATCTTTAGTCCATAAGGAAAT
GGGAGAACATATGATCTGATTCTATGTATATAAAACTGGAAACTGGGCAGATTAAATTACTGTTCAGAGT
GGACACAAAGGCTTTAAGACAAATAAAACCAGGACTATGAAAACAAGATGGAGATAACTTGGGGGCCTTC
CTACAGGCCACCTTGGTTTCTTTGCTCCCATTCTTGCCCCAAGCCCCCACTATTATGTATTTTCAGCAGG
ACACTGATGGCTACCTATTTCCTTGCCCATAGAAACACGATGCTCTGTGGGGCTAAAGCTCCCTGGCTGC
TGCCCATCTCACAGACTATGCCATTTTTGGTGCTCAGTTGCTGCTTCTGCCTGACTATCCCAGGATCTTG
TTATTCCCATAAACATGAGAAAGAGCCATCTATCAATCATGCCTAAAGAGAACAGAAATCCCAGGACTCT
CAACAGTGTTTATCCCATGCCCCCTCCGCGTCCCCTCCCCCGACAGCTTATTTCTTCTCAGTTTGGTTAG
GGAAGCATCTTTCCTCCAGAAAATAATGAATGGGCCATTGTGACATTCCTAATTCCAGTCCCTCTCATCC
TGTTTTGCTGCGTTCACTGTACCACTCTGGCATCTCTATCTCACTCACTGTGGCCAGTCTTCTAGTCTAG
GCCTCCAAGAGTTATGCCAACAGTGTACTGGAATTGTCCCTTAGAGCCCTTGCCAGGGCAAAGTCCTCAT
TCGGACATTCCCTGTCCTGCTTCTGACCCAACAGCCCCAGGATTCCCTTTCAGGCTTGCTTTTCTAGCCT
GTGACTGTGAGCCAGAGCCTGCAACTCCTTTGACATATTTCTGTAGCAAGCACCATATTACTTCCCCAGT
CAGATTCATCTCACAATGACCTCAACAAAGCACCTGTAACCAGACAGGATCTAGAGGGTGAGCATATGAA
ATTGCCAGATCCAGCAAATAAAATTGCAGTATATAAAAGACTAGGGCACTAAAATTTATTCATTGTTTAT
TACTTATCTAGAATTCTAATTTAACAGAGAGTTCTGTATTTTATCTGGCTAAGCACTAGCTTACTAACAC
TTCTTCAGAGCCTTCAAACAGTGGGAAGATCCCATTTCCAATAAGAAAAAGTTTGTCTCTTCTGCAGACC
CAGGGGCTGAGGAAATTCAAAATGCCCATCAGCTTCTCAGGTTTGTGTTCAAGGGTGCCTACTCTCCCAC
TGCAGGAAAGCAGTGTCCTTAACGCTGGTGAAGATGTTCAGATTCTCACATTTGACTTCTGTGGATTTTT
TTTTCTGTCTACAGAGTCAGTGGTAATTACCGACAGCTATCCAACTCCATGGTCTTCCTTTAGACACTTT
CCTTCAAACTCCTCACATACACCTTGACTAGATCATAGCTCCTAAACCTATCAATGCAGAGCAACCACCC
AGGAGCTCCTACGATGCTCAGAGCTGAGTCCTGCTCCAAGAAAGTTGATGTGACTGGCCATAGGTGCGGT
TGGGCTTCGGCAGTTTTAACAGCATCTCAGGTGACTTTACTGGAAGTCATCTGAGCCACAGGCCCAGGGT
AATGCACCAATTACAGCATCCCGTTACACTGCATCCCGTTACACTGCATCCCATCATAGTTCAGGTAAAT
GTCTCAGAAAGCCACTACCATGGTGTATCTTTTCCTGTTGCTACAATGAAACACCTTAGAACAGGTAACA
ACAGAGACTCATTGCTTACAGTTCAGGATACAGGAACACTGCAGGTCTGGTGAAAGCGTGCTCTCTTTTT
CCTAATACAGTGCTTTCTGGCCATGTCCCCACCTGGGAGAAGGCAGAAAGACAAAGGAAGTACAGCTATT
CCTTCAACTTCCTTTCTAGAGCACTGACCCTGTACCTGATGGGAGAACACCCACGGTGTGATCATGTCTC
CCAAATCCCCACCTCGGACAGAGTTACTATGGATGGTAGGTTTCAACATATGTGTTTTGGGAGAACAGGT
ACGTTCAAGGTACGTAGCATCCAGGTAACAGCATCTGGTTGTTCTGCTGTCTAGCTCAAAAGCCAATGAC
AAAGTCCTCCCCTTAGCATCTCTTTTGTAGAAACCCTCCTGGCACCAGCTTTCTTAGGTAGGCTCTCCTA
GAAGCAGAGTCTATGGGGATGCTATCCCTGTGATTTCTGCAGAGTGATCTAAGGAAGAGGGAGTAAGGGA
GGCAGCCACAATGCAGGGATAAAACTCATCAAAAAATGTGATCCCAGCTGGAGACCAGTGTTAGAGGCTC
ACTTAGGGGTGGGGAACTATGGCGCAGCAATTCCACCAGAGTCATCCCTACCTTGAGGCAGAGGGGGTGC
CTTTTTGTACCCCTACACTTATTAATCACTGTCTGTGGTCTGCCCTTAGAGGTGCAATGGGAGCCAGGAG
CACAGTTCCTTACCAGGCCTGGGCCTAAGGTGAGGAGAACAACATACAATTTGAGTGAGTTCTCCAAACC
CAGAAATGAAGATGATGTTATTTTAAAGCAATATTTTGAATAAATCAAATGAATCCAAAAAATTATGATG
AGCAAAATCAAATTTTAAAGCTGGACTAAAGAAAGGCGGAAGGGAGAAGCTTCCCGTTTGGAAAAGGCCA
GTTCTCAGAGAGGAGGGAGCTGTGGACTCTCCGTGAGCACTCTCAGCCTCAGAGGGATGACTGTGTTGGT
CCAGGGAAGCGAGTCTGGGTGAGAACCAGCAACATTTCATTTTAGTACTGTCACCCAAGTCCATATAAGT
TTGGTTTGTCCCCATTCCCCCAGGGTTCTTTGGAGATAGCTGGGAAGAATGACACTCCAGCTGTTTAAAA
ATGTTTAAATCTATGGATCTGGAGACTGCTTCTAGAACTTGTAATCCAAACAGCTCTCTCTTAAGGAGAC
CTGTGTTGGAGCAAACACACACACACACACACACACACACACACACACACACACAAAGTGATCAGAGAAA
CAGGTGCTGGGGCTCTAGGGTCATCTTTCCCAGCTGAGTGACAGCTGTTAGTGTTCTAAAAGTCCACTCC
TCCTTGACAACAGTTCCTCATTCCTAAGTCAAGCACCTATACATAAGTCTTTCCAAGCCCCCTCCCGACT
CCACATTTTTCTGACACCACTTTGATGATGGCTAGTTTTTTTGTCAACTTGCCAAAAGCTAGAGTCATCT
AAAAGGAAGGAATCTTGATTGAGAAAAACTCCATAAGATCCCACTGCAGGGCATTTTCCTAAGTAATGAT
TGATAGGGGAGGGTCCAACTCATTGTAGGTGAGGTCACCTGGACTAGTCGCCCCAGGTTCTATAAGAAAG
CAGGCTGAGCAAAACATGTAGAGCAAGCCAGTAAGCAGCACCCCTCCATGGTCTCTGTATCAGCCTCCAG
GTTCCTGCCCTCACTGCTTTTGATGATGAACTGTTATATGGAACTGTGAGCTAAATAACCTCCTTTTCCC
TGAAGTTGCTTCCAGTCATGGTGTTTTATCATACCCTAACCAGGACGACTTCTCATGTCATCATCACTTA
CAACTCTCTTAATGTAGAACCAATTGGTTTTCCTCATCCTTCCCAGACAGCAAACACAACAAACATTGCC
CCTGTGTTCTACCACAATCAGAAGTTCCCTTCTGTTCTTAGTGAAGATAAAATAAAAGCCCTTTCAGGGT
AGCGTCAGATTCAGGAGTTGGTATAAGTCAGGCAAATGAGGTATCATTGAGCCACACCCAGCCCTCCTTA
TGTTTCCTCCTATCTGATGCCCCTTATTTCTCTTCCCTTTCCTGGCTTGTGCTGGCTAGCTTTATGTCAA
CTTTACACATTTGAGAAGATGAAATCTCAATTGGGAAAATGCCCACACCCTTTGGATTAGGCTGTAGGCA
AGTCTGGGGTACATTTTTTTGATTGGTGATCAAGGATCTAGTAGCCCACTGTGGTCCTGGATGCTATAAA
AACAAAACAAAACAGGCTTAGAAAGCTAGGAGGGGCTAGCCAATAAGCAGCACTCTTCTGTGGCCTCTGC
ATCAGTTCCTGCCCTGACTTCCTTCAGTGATGGAGTGTAACCTGAGAGCTGCAAAGTGAAGAAACCCTTT
TCACCCCATTGCTTTTGGTCACAGCAACAGAACCCTAGTTAAGTTACCTACTCTTCTTAAATGACTTTAA
AAGATTCTAAAGACCAGGCCAGGCTTTCTTCTTTTTTCACCAAGATGATGCTTATAGATTTGTTTAAGAT
TTATGTACTTTCATTTGTATGTGTGTATGTGAGCACCACATGAAGGCAGGAGCCCATAGGGGTCAGAAGA
GGGCATCGGATCCCCAGGATTGTAGTTATAGGTGGTTATGAGCTGCTATTGTGAGTACTAGAAACAAGCC
CAGGTCCTCTGCAAGTGCTGTACCATTTCTCTAGCTTCCAATACAGCTGTTATCACACATGGTGCCCAGC
TCTGTGCTCAGTGCTGCTGCTGGCACTGATGGTGATAGAGACAATGGCCCTCTGCTGTCTCTTGACCCAG
ACTTGGAAAGACATGACAACCGTTTCCAATGCTTCCTCCCAAAGAGCAAAATTATAGGTGCTTCCTTGGA
GAGAATGAGAATTCTCAAGATGCACAGATCTGCCCTCTGTTTAATAATTCTTACAAAACCCCCTTCCCTG
TGACTCTTGCTAACCAGAACTCTTTAAGCCCCGAGGACATTCGTGCCTGTTAATATGCATGGCCAGGCTG
GACGGGGATTATTTTAACATTAAAGGTGGCATTCCTTTTCCTTCTTTTCTCTGTAATTACCTAGCAGGAG
TCTTAAATATAACCCTTACACTAAGAGTCTTGGAGGCCAACAACTACATTGAAGACCGGAGAAAAAAACC
CGAGTAGATCACTATGAAGTATGTGAACTCATTTGTTTGGGTCCTCCTACCCACTTTTCTCACAGTAGGA
CAGACTTGTTGTCTTCCCACTAAATGGACACAGCTTGACTATTCTTGATGAGGTTGGAAGGTCTGAAGCC
CGGGGGCAAATATTTGAAGTGTGTGGTTAAAAGGGGGCAGGTGGACTGGTGGAAACAGCATGGAACTAGT
TTGTGTAACAGTCAACACAGGGGCATAGCCTGACATGGTCTAATAATAAGCCTCAGCTGTATGCGTGGTT
GGCAATGATCTGAAGAAGTCAGGCGCTATACCCTGCTCTGCTCTTGGTGTCCAATGGTTCGTACCTGATG
TTAACCCCTGCCCTGGTCCTGGGCTGGATCTGTGAATGACAAAAGATCCTTTCACCTTTTGACTAAACTG
AAGAGTATGGTTTCTAACTCTTTCTCCAGTCTGCCAACTCCATCAGGATTACCCAGACTTTCCAATGTCA
GGTTTGAGGATTTCATCCTTCTTGCTCTGATTTCGTACAGAACGCTTTGTGGCCCCCAGTTTCCACTGCC
CTCTGTTCACATCTGTTTTGAAGTCCATCCTGTCCTTTATCTGGCCGGGCATACTTAGGCACCCAGATCC
ACGTGTAAGGGTCGGGTGGCTTGTCCTACCTCATTAGCAGGGATTCGGATCTTGTTAGCCTAGTCGGGCC
AGCTTCCTTGCTGATTTCCCTGCCCCGAGACATGGCTTCCCCACAGGCCAGTGGTTCTCAGTCTGTGGGT
TGACCCTTTCACAGGGGCACCTAAGACCATAGGAAAGCACACATATCTACATTTAAATTCCCTACTACAG
TAGAACAGTTACAGATGAAGTAGCAACAGAAGTAATTTTATGATGGGGGAGCAGGTCACCACAACAAGAA
GAACTGTGTTAAAGGGTTGTTCTAGCATTAGGAAGGTTGAGAACCACTGCTCTAGACAATGGTCTTCTAT
AATCTTGCCTGATAGCCTCTGAGCTTTGGACCCTTCTCCTTTTTCTTCAGCCTAACCACTTAATTACTAA
ATATAAATGTGTGCTATATTCAGTAAGGACAGAGCCTCTTGTCACTTTAACAGAGAAGTCTTGGAGGTCA
GGGAGGAAATGACAAAAGGAAGATAGAGAGATTCTGGAAAGGTGGCCTCAGTGGAAGGGGTAGGGAAGCC
TGGAGTCCTCAGTGAGCTCATGAGTCATGTCTGGTTGAGGGGCTAAGAGACAGACCTACCTTGACACTGG
TGTAGGAGGGATTGTGGGAATACTTCTGGCTTTCAAAAGGATGTTCAGACCTTCTGGGTTTCGAGTAACA
TGAATGAATCTGCAGTGTGGGCTGGGCTCTTCTCCTTTTATGGCACTAATTCTCATGCGCCACCCCCAGC
CCCACCCTGCCGAAACAAATGATCTAACTGCTCCTTGGATAAGGCTCTTTCTGTTTCACTTTCTCTCCCC
TCCTCTTACTTTCTTTTCTCCGTATTTGAACTATAGTCATCACCTTTTTTGTTGTTGTTGTTGTTCCCTA
GCAGTCCTGGAGATGGAACCCAGGGCCTTGCACATGCTAGGAAACCATTCTGCTACTTAGTGACTGGACC
ATTACATCTTTAGGATTAACTTTGATCTCATGATGTAAGCAGGCGTTATTGACTCTGTTTTACAAACGAG
GAACCAGAGTCAGAGAGATGAAGTTCACAGTCAGGTCACACGACACTGTCATATGTGGCTGAAAGGCCAT
GCCCTTGCTAGATTAGATGTATCCATGTCAATATTCCCTTTCTAGCTCTCCTAGATAATAGAATCATGGA
AGGTCAGACATAGTAGGGTGTAAAGTGCCCTACAAAGATAAAAATGGAGTTCTGCTCCTGTCGTTCTCTG
CTATCTGGTGATTACTTTGTAGTCTTTGTTTCTTAAACAGGGTGGCTGTTTCTTAAAATAGGATGGCTTT
CCGGATGCTCTGCACATTTCTTCCATTTGCAATAGACTGTAGGAACAACTTAATGCTTTTTTATGCTCTC
AATTCTGGCAGTTAGGAACCTCATGAATTCACAGTGTGTAATTATGGGATCGATGGTATATATACAATCA
AATCATAAGAAGAGAAATCACAGCCACATTCAAGCCATCAGCATGGCTAGGGTAGAGGGCCATGTTCTAA
GCCAGGATCATGTCTATTTTTCAAAGGAATGTTTTCAAAATACTAACATAATAATTTTATCATGTCACAC
TTGTTTATAAAAAATACTCCATTGTGTCTGTGTATATATAAATAGGGGAGATGGGGGGGTGGTTCTAGAA
TGAGGAATTTGGGGGCATTTTGTTTGTCCTGGAAACATCATTAGTAGACACAGTGTCTATGGTTGCCTCA
ACCTTACCATTCTGAATTAGACACTTCATGTATAGAGTGTACTTAAGAATACTAGAAGGTATGTCAGGTG
TGAGTTCTCACGGATGCTAGTAAGAGTTTAATCAATTACTGTAATTGAAATTGTGGATAAATAGGAAACA
CTTTGAAAAGTGGGGACTCTTAAGTGCTGATTCGTAATATGCAAAACCTACTGATTTGGCTCTCTTTGCT
GTCTTCTTCATCATTCACACCTTTTATCTTTAATGTGCTGGTCACAAGAAAATACCTTCTTAAAAATTCA
CAGGGAACATTCAGAAATGACTGTCTTTACAAGAAGCTGCAAAACAGTCCAGTCAGTCCCAGAAATCTTG
CTGTAAATGGGTGGTTTTTCTTTTCTGTTTCACCCTTGACAAACCACACAGATCCTCCTGCATCCCTGCC
TCTGGATATTTGTTTTTTATGTCTTTCCTCTTTAGACCCTGCTTCTCAATACCTGTAGTGCCTCACCTGC
ATCTTCTGAGAAGATAAAGCACAACTGGGACTCCCCCCTTTCGATTCCTAAAAATATATGATACCATGAT
ACGGAAGTCTTTTTTTCTTTACTTAATATTTTACCAAAATGGAGTGCTAGATAGACGGTACAGATTTTCC
TCCTGAATAGAGGGTTATCTATTCTATTATCCTGATGTTACCACTGGCTGGGGAGAGCAGAACTGGTGTG
AATACTGATATGAATACTCATACCCCTGAGATGACTGCCCTGTTTGATCAGAGCAGATTTTTGGGGCTCA
TAAATCATATTTAGGTCATATTTAGGTGGCCCCTGGGCTGTACAAAAAAGACAGCTGGCTGTAAGCGGCA
TCCCTCTGTGCTCTCTGCTTTAGCTCCTGCCTCCAAGTTCCTGTGTTGAATTCCTACCTTCACTTCCCTT
ATGATGAACTGTAACCTGTAAGCCAAATAAACCCTTTGGTCAGGGTTTCATTATAGTCACAGAAAGCAAA
TGAGGATAGAAATCAAGGAGGAGTTAGTGATCAGGGCCAAGTGATACAGCAAGCAGAGGTCAGACACCAA
GATGGCAGGAGAAGGGTTGGACTGTAGAATATGAAGCCCCCCCCCCCAGATCAAGAGCTTTAGGGTGGCT
TCTGTACCCTACACAATTTGCTCACTTGTCCAGGGTCCTCGTGCTCCTTCAGCAGGCTGAAGCCCTTCTA
AATATTGACTAATGGACAGAGTCAAGAATCCAAGTGGGAAAGGTGAGCACTGAGACAGAAACTGAACACT
CTTGGCGGAAGCTGTCTGTGATTCAAGGACACAGTACCAACTATGTGCAGTCTTGCCAGGAGTGTAGTGC
ATGGTCTAATAGGATTTGTTCTATGCAAGGCTTTGTTTTAAAAATGAGCAAAACAGAAGGCTGGGAAAAT
AGCTCAGTAGGGTAGTAAAGTGTTTGCTGTGTAGGTTGAGGGCCTGAGTTTGAATCCTCAGAACCTACAT
ATAAAAATGGTAGGACAGTCCCAGCAGCTTGATGCTTATAATCTCAGTATGGATAAAGTGGAGACAGGAG
GTTCCTGGGGATCTCTGGACATCCAGCTTAGCCAGATGAATGAGCCTTAACTCCCTCTCTCTCTCTCTCT
CTCTCTCTCTCTCTCTCTCTCTCACACACACACACACACACACACACACACACACACCACAAACGAGTAG
GACTGTAATGAACAGAGACAGATGATGAGAAGTATTTCAGAATGAAGGGATAACATAGGTGGTTGACAAC
TCAGATAATATAAGCCAATTACATCTAGTAGCATCATGGTTTGCTAATAGAATGAGGGGGAAAATAAGGT
GGGTAAAAAGTTAGATTTAAAGTCATATTGTTGATGACATTGGATATAAGACTGAAGGCTTAGAAATGTG
TCTAGGAACAGCATGGGAATCCATCTTTTTTATCTCCTGGGGTGAATAGGTCAACATTGAGAAAACCCAT
GGTGTTTCACTTTAAGTTCTAACTGTTCTAACTTCATTTGTGTTGCTGTGATAAAATACTCTGACACAAA
GAAAATTACAGGAGAAGGGGATTATTTTTGGCTTACAATTCTAAGTTATAGTTCATCGCCGTAGGGAATT
CAAGGTGGAGTCTTAAAACAGTCAGATCACACTCACAGTCAAGAGCAGGGAGAAATAGATCCATGCATGC
TTACCTGCTTGTTTGTTTGCTTTTGCTCAACTAGGCTTCTCCACTCTTATACAGTTCAGGAGCCTCTGCC
TAGGGACTAGTGCTGCCCATGGTGGGATGGCTCTTCACATATCAATTAACTTAAGACAGTTCCCCACAGA
CACAACCATAGGCCATCCCAACCATGTGGATACTATCTTATGCAGACTCTTCCAAGGTGACTCTAAGTCA
CATTAAGTTAATAGCCGAAGCTAAGCATCACACTAACAATATTGGTAAAATTGAACATGGATACAATAAA
GATGCACAGGGTTTTGCCATTATTCCATTTTATAAATAAATAAGTAATTTATCCAAGGTGATTCAAACCC
AGATCTGCTTGAATCAGGAAATTAATATTATCTTGGTATTTTTGTTGTCATTAGTCTTTTAATTTTATTT
GCTTATATATTTATTTTTAACACACTGAGTCTAATGCTCCTTCTATACACATATGGGTGTGAAATCATCT
CCTGGGACATGGGAAACCTACCAATGGCCAGCCCCAATAAAGAAAAGAAACTTTTACTCTTTCAGCAAAC
ATCACTACCCAATAACTCCTCAACAAGGGTGGGGCCTCAGTAGGTTCTCCTTGTACATGCTGAATTTTTT
TGCAGATAACCACACCAAAGCTGCTGTCAGATCACATGTGAGACTGACCCTTTTCTTAATCATCCTAGCA
GGAATGTTCTGCCCGAAGAGAGGCTGCACATGTGTGTGTATGCATGTACACATAGATAGATAGATAGATA
GATAGATAGATAGATAGATAGATAGATAGATAGATAGAGATTGCGTGTGTCTATAGATGGGTTTGTAACA
TCAGAGTGGCATGTCTAGGGAAAAAGGAATGAGAGGGATAGTTCCATTTCTTTGGGCATTTTGATTAAAG
GACAGTGAGAGAAACGGACTGATCAGTTGGAATGAGTAGACAGGGCAAGTCCACCCTGGAGGAGTGCTTT
CCCCAACCATCATCATCTGGTGATGAGCCAGAAGGAGGGTAGGTTTGAAGTGGGTTCTGAGGGAATGTCA
GAGGGTTGGTGTCAAAATGACTCTTGGCTTTCAGACTTAGATTAGAAAATGTGAAGACAGGGCATAGGTG
AAGCTGTCTCAAAAGGCAGGGGGTGGGGAAGATGTCAACTGGAGGACAACAAATGGCAGGCAGAGGAAGC
CGTGGGAGGCTTTCAGGATCAGTAATGAATATGATGTGCAGACTCCTCTACGTTTCACTTTCCCTATGAC
AGAATCTCCTAATACTTATCTCCTCACGTGCCTCCTTAGCCACAGCCTCTGACTTCATGGTTACCTCCTC
TGGGAACTTGGAGTGGGTAGCACAGGATGTGGACTCATGTAATCAACCTGGGCCAACAAAATGCTGTTTC
TTCTATGTCTGGAGAGAATAGAAAGTGGGGTGTCTGTGAATGGGGTGGGGGGGGCTAAACAAGAGGGTTC
ACAGGAGACACCAAATTCCTCTGACATCCCTCTGCTTAGATTTATTCATGAGCAAAGTGGGCACAGTGCT
TCATGAGCTACAACTCAAGAGTCATTGGGAGGACTGGGTGGAACAGTAATATCAAAGAGCCGAGCCCACG
ACCAACAGGCAGTGTTTGCTGGTGTGCTCCCTCATGACCGGCTGCAGCTCTCTTTTGCTTTTCTTAGCCC
TCACACTTGGAGCACAAGAAGTCTAGAAAATGTAATAAGCAACGGAGAGATGTTTTCACTAAAGGGTGTA
TTAATGTTTCATCTAGTCTTCAAAAAATGTATTTTGAGGCACTGTCTTCAGTACCTGGGTTTCTCTAGTG
AAGAACTTAGACATAGTTCTGCCCCCCATAGTTCAGACAAGCTCTCTGTTGCAGAATAATTGGCTCTTCT
TGTGTTTTTTTTTTGTGTGTGTGACATATATTATTAAATTATTAACTTATCAAGGGTGTGTTTTCAGGCA
ATCATTTTACATTAAGCTTTTTTTCTCATATATATATGCACATAATTTTAAAGTTGCTCAGCTTGAAAAA
TAACAAGCTGAAAAGCCTTGTTTCCTTATTCTGAGGGTTCCTACTAACACTCAGAAAATAAATATTACTC
AATTTTTAGAGAAGTCTCATTATTGAGATATATATTTAGACAAACAAACCTCATTTCTTATACAGTACAA
AGAGAAGAAGGAAAGAAAGGAGGATTGGGGAGGAGTCAGAGACTTTTAGCCACAGAGATGTGAGAGGTGA
ATAGGAACATTATTTCATAATATTACTACTGACATGGAACAAAAAAAAAGTATACTTGAAAAAATTCAAG
AAAACTTTATTGAAATCCACTCTGTACAGAACATGTTGGTAACTGGCCAGATCTTAAGAGTCTGCACAGG
GTGAATCAAGATGGACACATTACAAGCATGAGCCCTGCCAGCGGAATAGTCTATAGCCCTCCAGGGCCCT
TTATGTAAAATGGAAACAACAATATTTTGCTGCTCAGACCTGCCAAAGTTCTCTTTAAGTCTGGGTGATG
ACTATTCCATGCCGTATAGATACACTATGTGCTTTCAGCATTAGTTGCTCTTTGTCCTTTGAAAGGCCAA
GCCACACCCACTCAGGTATCTGCAGACTACAGTAGTCTCAGAGTGTTGTGATTTCTGCTTTCCCTCCTTC
CACACAAGCCATGAGCTGAAAGAGTCCTAGCCTTTCATCAATGTGACTGCTCTCTCCCTAGTTCTACATC
TAGATGAATTTGAAACAAGGAGATCATAAAATACCTGTTGAGCACCGAGGTGGCTGATATCTACATCCAT
TGAGACACACACTGGTCTATCTCTGACCTCTTGACTTTTCAATGGACTGGGCAGATCAGTCCTTCCATAA
ACATTTGTTGGTTGGATTCTAGTGATGTCTCCTGGTTTTGAGTGCTTGGCTGTCTTATCCTTGCACAGCA
TTCTCCAGACCTTTCCAGGCATTTTCTTAAAAGGGCATACAGTACATCTTGCTTTCTTCAGTGCTGCCTG
CTAAGTTGTGACTTGCTGGCCAGGCAGGTGGATTCTTCCAGTATCTGTGGCAGCCCAGGTAGGAGTGGCT
CTTGGATCTAGAGATGGTTCCATATTTGTGTTTCTTGATTTGCCAGCACTGAGAACTCTGTGCTGTTGCT
GTCACCTGTATATTACTTAGGTCATTGTATTCATTATTGACCCTGATGGAGGGACAGTGTTTCTTATAAG
TGCTGGGTCTTTCTCTAGATCATTGTAGTTGAGCTACTATAGTATATGCTCTTTGCTGTTTTAAGATAGC
AACACGAACACATCAAATAACATCACCAAATATACCACTCCCATCCTGACTGAAGAGGTAGCTGTCCAGG
TATAAGTATATAAGTATGCAAGTGTGCAAGACAGATAAAAGCCAGTATTCCTACAACAAGGAGTTCCATA
TAAAAACACACTATGCAAAATTAGAAGAAGAATCTGATCTCAAGTAGGAGAGATTGATCCAAAATGTTAT
TCCTGGGAAAGAAGCCATTTCAGTGCTCTTGGCCTATGAGTGTGCACTGAGTTAAACAAAGCAAGACAAA
ATAGATGTCTGCTCCTGGCATAGGGGACACAATTGACATTGCCCAAAAACTTGGAAAGGAAACAGGATAA
AATATGGACACTGTTGTGTATTTTGTTCTTTAATTATTCAACTGTAGAATTCCAATCAGCTGAGAACATT
TTTGAATTCTGAGAAACTCTGCACTTCTTATTTCAGGCAAAGCAATTTTTAACTCTGAAAAAAACAAACA
AACAAACAAACAAACAAAGAAGAAAGGTTGGGTGAGATTTCAAAGATAAGATACAAGTAGGAGACCACAT
AATGTTGATAAATAGAAACAAAGTATTGTAAGACAGGAAGAGAAAGCCCGAGGAAAGCCATCCAGGCTAC
ACTGTTACCCAAGCTTCCAGCAACAACCACCCTTTGCTTTGGCCTGATGCTTTCTGGTCCTTGCTCTGCC
ATTGTGCCAACTCCTCTATTTCTTCCCTCTGCTGGCCTTTCCCGATCATTTCTGAACCCAGTCTTACAGT
TAGTAGCACCTCAACAGTGGCTTTTTTATGCAAAACTCCAGGGGTGAAATTTCTTGCTAGCACCTGCTAA
GTGCAGAGCTCTTTATGGCCCCTGCATCCTGGATTTATAACCTGTCTCTTCAACCAGGCTCATCCCCATA
ACCAGACAGTCAATGTCTTGGTGTTCCCAAGCTCCCAGCTCCTCAGTGTGGATGGAGGGACAGACAACCC
AATTGTGTCATGCTGTCAGAAGCCTGGTCACCAGAAACCTTTAAATATGCCCAGCATTGTAATAGCTTCT
GGGGTCAGAGCACAGCACTGTTTTCAGCTGCTGAGGTTCCTGCCATCTACAGAGTGCAGTGAGTAACAGT
GGTTCCTAAGATGGTTTCCAGTAAGTAAGCAAGGATTCACAGAATAATATAGCAGGTGGTCATGAGTAAG
TTTAGGCTTTTAAGAAAGTGTTAATTGTTAAGAAGGGCAAGAGCTGAGGAACGAGGGGGAGAGATGGTAG
AAGATACTTTCAAGTGCTGGGCACAACAGGTGCAAAGGCACTGGGGTTAAAGGGAACATGTTCTCACTCT
CTGCTTCCTCGTTTTATTCATTCTATGTATACCAGGAATGTTCTAGTTCACTTTTAGTTGCCATGGTGAG
TGAGACTCTGGGCTATGCTTGCCAAATCTCAACCCTATATACTGTTTATTCCTTGACCTTGACTGACTCG
GCATGCCCTTGGGCACTGTGCAGCGGACACTGCCACCTGTTTATGGCTACTTTCCTCCCTGCTTTCCCTT
GCTTTCTCCCCCATCCCGGCTAGCTTTATCATAAGTCCCTGCTGTGTCTCAGGAGTTAAAGCCTGCGCAA
GTTACAGGCACTGGGGAGATCAAACCTGTTTCAACAGAGATGCAGTCACAACTCACCTTTCCTCAGGCTC
TCACTGCCTTCACTCTGCATTTGGTTTCTGAAAGAGATCGAAAACAACTTCAGAAGCCAGGAAAGCCCTC
GGACAGAGAAAGAGGGGACAGGATGAGGCATTAGACTCTTGGGTCTCAGAGAGAAATTACAAGTGTGGGC
TGGGAAGTTTTTCTGCATCCCCAGGATAAAAGTATCCTTTTGATGACTGTATCTTAACTTCTAATGTTGG
ACATAAAACCACCCTCATATAGTGGTATCCTTATGGAAATAGAGAGGCATGAGGGTAACACATGCAGTTT
TACCAGTCATTTAATGACCAGGAAAGAGTTGCCTTTGTGTGTCTGTGGAGGGGGTGTACATATGGGTTTA
GAAGATAGAGGAGAGAAAATCAACCCCAAGGCTGATGCCTAGAAGGGTTAGATGGTGCTGCCCAATACTA
TCATGTGTTGGTTGCACAGACAGGCTAAAGTAGGAAACCTCCGGCCAGCTAGCTCTCCGAAGGCCGAGTT
GCTCTTTGAATGAACTTACTGCTGAAGCAATTTGGGGTTCAAGTTCCTTCAGGTTGATAGTCTCTCTGTC
AGCGTTACTATCCCGCTCTAACTTAGAGGCTGTGTTGCTGGGCCTGAAATGAAAACACAGGGAGCACTCA
ACAATATCCTGGTGCTTTTATGATGCAGCCTTTCCCAGAGTCTTCCAGAACACTTCCTGTCATTGGTGTT
CTCTTCTATGTGCGTACACATTTAAGAATGACCACCCTCATGGGTGTGTAGCCATGGAAAAGATTTGATA
AGTTTAACAAACGATCATGGTATATAACTCTGGCCCAAGTGAGACAGAAAGCATTGTGGAGATTCCTTTC
TGCATCTGTTCAGCCAACCCCTTTAATCCCACCCTGCTGTTCCTGATCGTTGATTTGTTTAGCTTTTCTT
TATCTCGAACTTGAGATAAACGGGATTACACACTGCAGTCTTCTCTTTCCTTCATTCAGCAGACAGCTTT
GGAAATTGGTTTCTATGGCTAGGTGGTTTTTCACTACATGACTGTACCTGTTTTTGCAGATGGACTGTCT
CTGATTAGTAACATGTAACTGTATATTCTCTCTCTATATATATATTTCCTTTGTCAAGTGTATATGTAGA
AATATTTATATTTTCTCCAAGTTTGTGACTTTCTGTTTTCTTGACAAAGTCAACGGACAAATATTTTAAT
TTTGATGAAGTTTACTCTATCCATTTACCCTTTCCTGTTTGTACTTGCTTAATTAATCTAAAGATACAAA
GATTTTTTTTTCTTTCAGAAATGTTTAACTTCAGCTCCTTTATTTAGTCTATAATTTATCTTATTTTGTG
TAAATCGTATTTTCCCTCCTGAATTCTAGCTATTCCAATACCAATAGTTGAAAATATTGCGCTTTCAGCA
TGGAATTACTTGGTATTTTTTTCTTATCAAAAGCAATTAACCATTTGATTTTATCTTCTTTTTTTACCCC
TTTTCCCTCATTGACTGATATCTCTGTCCTTTTATTAGTGCCACACGGGTCTATGACCACTCTTTTGGAA
TTATTTAGTTTGTTTCTTTTATGAGATACAGGTCTTACCATATAGGGCAGGCCTTAAACTCAATCTTCCT
GTTTCCATCTCCTGACTGCTAGGATTATAGCCCTGTATCACCATGTCTGACTCCAATTTTGCTCTTAATT
TTCAAAATCATTTTACCAGCTGTGGGTTATTTGCACTCCTCTCTATCTTTATACATTTGGCCTTTTAATT
TTTACTAATAAACCTTCCAGGCTTTGGATTTAGATTACTTCAATCCATTCATGAATTTGGAAAAAAAATG
TGATCTTAATAATATTTTGTCTCCTAATCCATGAACCCAGTATATGCTTCCATCTAATTAGGTCTACTTC
CATTTCTGTCCACCGTAATGTTTGCATTTGTCTTGTTAAATGTATAGCCAAAACTTTATTAGTATTTGAT
GATCCTAGAAACTGGATTTAAACATTTACTGTGGCCTGGTAGTGGTGGTGGCAGGGAAAGCCTGTAGTCT
CAGCACTTGGGAAGCAGTGGCAGGCAGACCTCTGTGAGTTCAGGACAGCCTTTCTTGAAAAACAAACAAA
ACCTCATTTCCTAAGTGTTTATTTATTGTTGGTTTATAGAGTACAATTTCAAGAGAGCATTAGTAGTTAG
GCAGGTTGCTCTGCTGTCCTCATAGAATATAGTCTCTCCTTCTGAGATGCATTTTGGAGTACAGTTTTGA
GTATGACCTTTGCAATTGGAGACAGCTACTCCTTCTGATATTTGAGAGCAGACTCTCTCTTCCTTAGGCC
TTTTCTCGGGTTGAGCATTCTTTGGTTATTTGATGCCCTGTTTTCTAACTTTAGAGGCTTCATGTACTTT
GAAGCACATTGTGGGGGCAAGAACAAGTTCCATAACCTTGAAAGGTGGGAACTGATTGGAGGGGATTTGG
CCATGGGGCCACACTTGGGAGAATTAATGTGCACCATGAGTTAGGTCTCAGGTATTGGAACTGTAGAAGC
AGGTTGTTATAATGCCCCCCTCCTCACCTTGGTATCTCTTACACACACACACACACACACACACACACAC
ACACACACACACACACACACACTCACATACACTGTTCTTGCTCTACCATCTGTATGTCACAATGCAGCAC
AACATAGCTGCCTGATCCTGTTCTGCCCCAAACCATAAACCATGATAAACTTTCCCTTAAGGTATCCAGT
CTTTGATATCTTGTTTTAGTCATACAAAGGAACTGAGGCATTTGAGCTGTTTCTTATTTGAGCTCCTGGA
TTCTTTATAAATCTGATTAGATTTTTACAATTGCCTAGATTCCTCTTTAAAAGTATGGCGCTTTATAGCT
AGGTATGGTGTCCCAGATAAATATAGAACAGAAAATAATCAAATGATCTTTTCATACCCATGGCAAAGGC
AGCATCATTACAAGAAGCCTCAGTTTAAAAATGAAAGCAGACAAAAGACACAAAAGTGTGACACACACTT
TTGGAATGGACGTTAACTTCAGTATTTTGAAATAGAAATGCGATGAGATCCCCAACTTTCAGTTTTTAAA
CTCTGTGGAGATTTCTGTTTAAATGATGATGAAGATGAGTCACTTTGGAAAGGACACTTGTTCTTTAAGA
AATTTTAACTAGCCTGATATGGTAGCATAAACCTTCAGCCTTAGCACTCAAGAAGCAGAGGCAAGAGATG
CAGATGAAACAGCTGGGAATGAGTGATGTACGTGATTGTGAGCCCAAGCACAGCCTGGCCTACATAGTAA
AGTCTGCGATAGCTAGCTAGAGCTATGTGGTGAGACTTTGTCTCCAAAACATAAAAAGTAACTACAAGAG
CCGAGGCTCTTCTAACTTTGCTGTATGGAAGCAAACTGTAAAAACTATTAGCTTCATACACACTAGTATA
TACATTTTTTAGTCAAGCCAATTCCCAAATGGGCAAACTGATAGGATAACTTCAGATTAGACGAAGGCAA
TAATTCATAGTTACACATCTCCTCCTTTTTCTTTCTTATCAATCCAGGTCTGGGGTAAGAAATTACCTAG
AGATACCCAAGATATAAGATACAATTTGCTAAACACATGAAACTCAAGAAGAATGAAGACTGAAGTGTGG
ACACTATACCCCTCCTTAGAATTGGGAACAAAACACCCATGGAAGGAGTTACAGAGACAAAGTTTGGAGC
TGAGATGAAAGGATGGACCATGTAGAGACTGCCATATCCAGGGATCCACCCCATAATCAGCATCCAAACG
CTGACACCATTGCATACACTAGCAAGATTTTATTGAAAGGACCCAGATGTAGCTGTCTCTTGTAAGACTA
TGCCGGGGCCTAGCAAACACAGAAGTGGATGCTCACAGTCAGCTAATGGATGGATCACAGGGCTCCCAAT
GGAGGAGCTAGAGAAAGTAGCCAAGGAGCTAAAGGGATCTGCAACCCTATAGGTGGAACAACATTATGAA
CTAACCAGTACCCCGGAGCTCTTGACTCTAGCTGTATATGTATCAAAAGATGGCCTAGTCGGCCATCACT
GGAAAGAGAGGCCCATTGGACTTGCAAACTTTATATGCCCCAGTACAGGGGAACGCCAGGGCCAAAAAGG
GGGAGTGGGTGGGTAGGAGAGTGGGGGTGGGTGGGTATGGGGGACTTTTGGTATAGCATTGGAAATGTAA
ATGAGCTAAATACCTAATAAAAAATGAAAAAAAAAAAAAGAAATTACCTAGAATGGACTTGGTATTGCCT
TTTTAGTATTTAAATAGGATAAATGTACACAGCCAAGGCAGAATAAACAAATGAACCCTGGACAGGACTT
TTAATGCCAGGTTAGTTGTTTTGAAGGTTCTCTTCTGAGAAGTGGATTTAATGTCATTTTTGGAGGAAGT
TCCATTCGGGAATGTATTCCTACTGGTTGTCAATGAGCTTAGGTCTTTGTGGGTAGGTCATGCTCACTCC
TGATTGGCCTGTTGGCAGAATTCAGTTCTTGGAGGTTGTAGAGCTGAATGGACTGCTCGTTTCTTGGCTA
TCAAGTGAGAACCATTTCTAGCCTCTCGAAGTGATTCGAATTCCTTGTTTATGTCCTTCTTTTTCCAAGT
TCAAAGCCAACAATGATGGCTGAGCTTTCTCCAGATCTCATATGCCTCTCCTTTCTTTTAGCATAGCTTT
CTAACCTACCTGGGTATGTTTCTGCGGCTCATATAAATTTGTGCCTTATAAGATAACATCCAGAGGGTCT
GGAGGGGTGGCTTAGTGGTTAAGAACACTTGGTGCTTTTGCAGAGGACCGTGGTTCAGTTCTGAGCCCCC
ACATAAGAGCTGATGGTTACCTATAATTCTAGTTCCAGTGGTTCTGTCATCCTCTTATGGCCTTTAAGGG
TACCAGGATATATATGCAGTACACATATACATGAGTGCAAAATGCACACACATGTAGAATAAAAACAAAT
CCATATTTAAAAGGTAACATGATAGTTTTAGGTATAAGAAATAGAAGCTTTGAAATAGAAGCTCAGCCAT
CATTGTTGGCTTTGAACTTGGAAAAAGAAGTAATTTACTTATTGCAGTGGAGATCAGAAGAAGAATCTAC
AAAGCAAAGAAAGTTATTATAGAACTCAAATGCATGAGCATGGTATATCTACATGGCTTGATTATTCATG
GTATGTCTCCTTCTTGGATCTGTCAAGGTTCCTTTCTTTGACCAAACTCACTGTCATGTCTAAGTGTCTG
ACCGCATAACTTTTTGCTATCAATAATTGTACCCCATTCTTTTGGGGACCATCTATGTGCTATGCTCTCC
TGTTCTCTGCCTTCTGATAACATAGTTTAATGTGACTATCTTACACATATTTAGCTTCTGTGCATCCCCC
TCCAACTTCTTTCTTGCATGTACACATATCATCCTTGACTTTCTTATGTAGTTTCGAATATTTCTGGTTG
CCTTATGGAGAAAGAAAGTTTTTTTTTTCCTCCTTTATTCCATCTCTCCTTTGTTCTCGTTGCAAACTGT
TCATTCCACTGAGAAAGGAAACTTGGCGAGCTACTCATTCACATCTAGAAATCGCTTCTACTTGTATGGC
TAATACTTTAAGTGCTGTTGGAGTCTGAGCCATCAGGGGAAAGCTGCCTGCCAAGCAGAAGTGACATCCA
TCCCAATGGATATTACACCACACCCAGAGGCAAAGGAAATACATTAAAACAAGGTAGCAGCATGGTACCT
CTAAAAGATCGTAATTCCTTAACTTCTGAACACAAAGATATTTGGGGCAAATAATCAAAAAACCTGCTAG
CAAAAAAAAAAAAAAATGATTAATGACCTCTAAGAAGGCATTAAACAAGTAACCCAATTATTTAAGGAAA
TTAATTCAGGACACGAATGTGGAAGTCAACAGCATACATAGAAAAACCCAACAAGCAAACACATTTTGGG
AAAGAAAAGAAACAGAAATGCTGGAAATGAAAACCCAATGAATTGAATTTTAAAAGTCCCATGGAAAGCC
ACTAGACTAGACAAGGAGGTAAGGCTTGAGGAGGAGCATCAGGGGCTTAGGAGAGGGCTCAGTGGGTGAA
AGGGCTTGCCGCACAAGCGCCAGGACCCAAGTTCAAATTCTTGAACCAATGTAAAATACAGATGAGTAGC
AGGAGAATCTGCCACCCTGATGCTTCTGTGGCGAGAAGGGAGCTGGAGACAGGAGACTCCTCACAGATTC
ATGGGCTAGCTAGCCTGGTGTACACCGTGGAAAAGCAATGACGTGGCACTGTCTTGCAGGGCACGTGAGT
GTGCACTCCTTTAATCTCAGCACTTGGAAGTCAGAGGCAAGTGGACCTCTGTGACTTTGAGGCCTGCCTG
GTCTACATATTGAGTTCAACTAGCACTATCAAAAACAAACTACAACAAAACCCCAAATCAAGCAACAACA
GCAAACCTAGGTGGATGCCCAACTCAGAAGGTGAAGGACCTCAAAATGAGAGCACTAAAGCACTGAAGAG
AAAAAGAACTGAAAGGAGGTACTAGAGGGAGAAACTCTCCATGCTCACAGGCAGGCTGGAAAATGGTGGA
AAATGGATATATTACCAAAAGCACTGTACAGATTCCATTCCATCTCAATAAATTGACAATATTATCATAT
AAATAGGAAGAAATTCATAAAATTGATATAGAAAAAACCCACATAATTGAAATATATCACAATATCTGAT
CTCAAATCATATTGTATAGGCACAGCTACAGAACTAGCATGATACTGGCACAAAACTAGACAGGCAGGAC
AATGGGATAGAATGAAAGATTCAGAAATTAGCCCGTGCAACTATAGGCTAATTTTTTTTAACAAATGTGC
CAAGAACATATATTAGAGAAGAAGAGAATAAATGATGCCCAGAGAATTAAATATCCATGTATTGACCACA
ACTAGATCTCTACTTTGCACCTTGTAAAGAAAACTCTATTTAAAATGGGTGAAGATCTTAATGAAAATAA
ACTGCCTTCTTGGACACTTTAGGGGAACGCATAGGATAAACACTCAAGATAGGGCCAGGCAAGTTAGGGC
CAGAAAGAACTCCTGTAACTCAGGAAATAACAGCATGACGTGACAAATGCAACTGCACACAGCTAAAGGG
ATGCTGAACAGTGAAGCCAGCAGGGTGGAGAGACAGTCTTCTGCATGGAAAAAACTGGACAGGACAGTTC
CATAGAAGATACACAAAGACCCGGTTTTGGGTTTTTTCATCCAGGAACACCTGAACTGAATAGGGAAACA
TGGCTTCCCCTGAACATTGTAAACACCTCCATTGAAAGAGGTGACCGGAACAACAACAACAACAACAATA
ACAATGACAAAGAAATAAAAGAAAGGAGGCAGGCATGTCAATCAGCAGGTCACTTTGCATATGTAAGACC
CACCCAGTGCAGAAAAAAAGGAAAGCAGCACACACACACACACACACACACACACACACACACACACACA
CACACCAAACCCAAGACAACATACCTTATTCCCAAATCCCCAACCCCCTAATAGATATGCCTCTAATGAA
AGCAGCCTGAAGAACCACACAAAGAATTCCATTGATTATGTTCAAACAAGTCATAGAGGATGTGAACAAA
CTTTAGGAGAAAAAAAAAAAGCAAAAACTGAATGAAATAAAATTTGTCAGAGAGACCTAGGAACATCCAA
AACAATGCTCATCTGAACTGGATAGTCAGATTCTATTGCTGAAGACACAACATACTGTGGTTTCAAGTCA
TGAAGAAATCAATTTTGAACTGCCCAGGAAACTCTCTCCCTGCCAGATAGCTTTCATAGTGCTAGAAGGT
GTTTGAAAGGCTGCTCAGAGAGAAAAGCCATCAATGGTCTTAGCAAGCACTGGTCTCTGCATGCTACCAC
ATCTGCTTTCTAGACCAAATATGCCCACTGCACAACTGTAACCTTATGGACATTTCCAACTGCTCTATTG
GTGGGATTTGAGGTCTGTTTTGTGGGGATAAATTCATGCCTAGTACAGTGAAGTGGATGGAGGAAGTCAC
AGACTCTAGGAGGGAATCTACTGATCTTGTTCTATGAAATGGTTATGTTATCAAATTGCCTTCTAAATAT
TTATATTTATATCTGTAGACTTATATTGCCCCCAACGTTGGCCAGAGAGGTTTGTTATTGGTGTGGGTAG
TGATTAGTGCAGAGACACATTGTTGTTCAAAGTGCTGAAAATAAGTGACTTTGTTTAGCCATCAATGAGA
CATCTATATCTACCAGCACATCCCTACCCCAAGGCTCAGGGACCTTCACAGAAGATGGGGCAGAAAGAAT
GTAAGAGCCTGAGGATGGAACAACCATCTATCTCCTGAGAATTATCAAGAAGAGGGTAACTGGTATGTGT
GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTATGTGTGTGTTGGGCAGGGACAGGAGATGACAAT
GAGGAGCTAAGTACAGCATTTGCTTGTGTGAGTGTCACAACAAAGCCCATTGTTTCATATTCTCATGTAA
AAACACTTTCTTCAGTGTTGGAGACCAAATTGCTAAGGAACACCTTAACACTAACACCGTAACACGGAGC
TACCTCCTCCTCCTCATCTCATATGCTCATTAAAACACATTTTACATGGTGATCTTTAGACAGAACAAAG
ACACTCATCACCTGCTAGGCTGATTCGGCTTCTTGTGACATACAATGATGAGCAGCATCACAAGGAGGAG
GGCCACAGTAACTGAAGCTGTAATCTCCTTCCAATACGTTTGAGGAGATGGAAACTCTTGAGCTAGAAAT
GACCACAAGTTTTCCATTAGTAAGAAACTCACTTATGAAAGGTTCAAATTTACAACTTGCCTTCCTTCCT
TCCCTCTTTCCATCCTTCCCTCCCTCCTTCCCTTCCTTCCTTCCCTGCCTTCATCATCCCTCCCCTCTTC
TATTCTTCTTCCTTCCTTCCCTCCTTCTCTCTCTCTGTGTCTCTCTTTGTCTGTCTGTTTCTCTCTCTCT
CTCTCTCTCTCTCTCTCTCTGTCTCTGTCTCTGTCTCTGTCTCTGTCTCTGTCTCTCTCTCTCTCTCTCT
CTCTCTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAGATCTCCCCCTGGGTCCT
AGAGCCATAGGAAACTGAAATCAACAAGAGGAACTTAGAGGAGCTTTTGTAATGGTTCCTCCATCCACCA
TCATCTTGAAGTTACTCTCTAGATCACCTCTCATTTGAGCAAACAGAACAAATACTTCAAAGTATTTGAT
TATTAATTTTACTGAGCTAACCCCAGGCTTCCTCATCCTGACTTTCAGTATGCTTTCTCTGTTAGGAAAC
CTTTGCTATTTCTTCATTCCCTAGAGAATCAGATCCCTGAAGGCCAGCAACTACTTCCTAGAATAGGAAA
GCCTAAACTGCAGTAGTGGAAATTAATGGAAAACTAAGTAGTTCAGTTAATAGACATTTAAAGAACAACC
CTTCTGTTTAATCCTAAATTATAGGAAAATTAGGATCAAAATATACCATAGTTTAGATACAATTTTTAGG
CATGTGCTCTCTTCCTAGAATAGTAAGGAAAATAATTATTGGCATTGTGGACCATATTTAATACCTTTTG
AGTGTGTCCCTGTTTGTCTCACTTGAATCTATTTGGGATTTCCAATAAAGGAGGTTATGGCTCTTATATG
GAGACTTCTGCCTTTTGATACACAAAAAGATTCAGTAACTGCGGTGGTTTGAATAGTAATGGTCACCATA
GATTTATGTGTTTGAATGCTTGGCCATAAAGAGTGGCACTATTAGAAAAGAGTAGCCTTGTTGAAGTAAG
TGTCACCTTGTTGAAGAAAGTATGTCAGTGGGGAGGCAGACTTTGAAGGCTCCTATGCTGAAGCTATGAT
CTTTGATGCCTGTGGATCAAGACGTAGAACTCTCAGCTCCTTTTTTAGCACCATGTCTGCCTGCATACCA
CTGTATTTCTTGCCATGATGATAATGGACTAAACCTCTGAAACTATAAACCAACCCCAATTAAATGTTTC
CCTTTATAAGAATTGCTGTAGTCATGGTGTTTCTTCACAACAATAAAACCATAACTAAGATAATAGCTAA
CCTATCTCTGGTCAGGGCAAGGATTTAGGGACACAGATATGCAAGTTCTTTGGATGAGGTACCCAGGGCT
GAAGCATTTCGGATGGTAGTACCTGGGCAAGTTCTAAGATAGTTAACTAGTAGAGGTGAGTCACGATGAG
CTTACCAGTGCCTGCTCACTTGTAGACAAGGGTGGGGAAGCCTGATGCTGGTGGTTACCTGAAGGCGATA
AGCTTCAGGTATGGCTTAGAGTATCTTCTATATTTCTAGAAAATGTTTCAGTGGGAGCAACCAGGACAGC
TGAATGACCACATCTTTTACTAGATTCTGAGTGGCTGCGATATCTGAGCAAAAGGAAATCAGTACTGGGA
GAGGGGGTAGGCTCAGTTGTAGGGTGTAGGTGCTAGCCATGGGGATGTTTCTCAGAGTATGCCCATAGGC
CAAGTTCCTGAGGGAGCCACCAGGATTAAGGACGAGGCAAAGCCAGGGGAGGAAGAAAGAGATGGATGGG
TGCCATCAGAAGGAGCAAATAATAGTTAGAGGGCTGGAAAAGGGACCGTAGAAGCAGAAGGCAGGTGGCT
GTGGGTTTGGGGGTGGGGTGTGGAAGGGGATGAACCTTAGAATAAACACCAATGAATGATGAGCATCAAG
TGGGAACCGAGTGCCTTCATTCTAGGAAGAATGGTGGCTTGTCACAAGTGGGGTACAGGTTAGGCTAGCT
CTCTATGGGGCAAAGCTGACACTGAGTTTCAACCTCTTCTTTCATCACTGTGGAAGCACATCAAGAAGAT
GCTGCAAGCATGCCTTCACTCAGTCTTTTCTTGAACATATTTCCTGCTCCTTTTGGGTACAGCTAATTTG
CTGTGGTTCTCTCACTGGCTGAGCATGCAGAAAGTCACTGCAAATGTGAGGGTCTTTCATAGAGAACTCT
ATATCGCCCTCCCTTCTATTTTTGTCATGTTTACTAAGTCCAATAGTCTGTTATCAGTATCAGTAACTGT
TTTACAGTAGGATAAGGCCCCAGTGCCTTTAGGAAGACTTACATGACTTTCAAAGATCTTGCCTGCCTCT
GAATGCTCATAGAACTGATGATCAGCTTGTTTTAAATTTAGGCAGTTGTTTCCATGAGCTATAATTTAGA
CTTGAATTTCATCTTTTAAAAAAAACTTGGTTGTCATATATGTACATCGTGGATTTCTTATTTTCCTGGG
AGAGTCTCAAGAACTAGAAGATATCTTCTGAGTTTTCAGCTTTACAGCCAACAATGACTACAATGAGTCT
ATATGCATAATAAGTACCATTGAGAGGCAGGTATATATGATTGTCATATATATATATTTGTGTGTATGTG
TGTGTGTGTGTTTTAGTCAGTTGAAAGCTTCTTGCTAGGAAATATCCTCTATTTTGTATCCACAGCATCT
CATTGTCCTCCATCCAAGGATAATTCCAAAGACTGGGTCAGTTTCAGGGCTAAGACCATGTTTCTTCAAG
TATAGCTTGGATCTTGAGTCATGAAAATGTAAAAATAGCCTTCTATTTGGCTCCTTCCTAGTGGTCTGCT
AGAAGGTTTTTCAGCAATCAGTAAACATTGGATAATTTGGATAAAAGATTTGCTTATAGCACCTTGTGAA
ATAAATACTTAGGAAGCAGACTTACTGAAATTGAGAGGTTTGGAGGAAATCTTCATTGACTCCGTTTCCA
GAACACACACAACGGTCATATGCCACACACCATCCGGGAATGAAAGAGAGAGGCTGTTGGAGATACTGAA
CAGTTCTGTGACATTATCTTGTGATATCTGCATGTTATCACCATACTCATTAGTTGAATTAGTTATCAGA
AAATACATCTTCTTAGGTTTCGGGTGACCTTGCTTAGACGTGCAGGTCAAATTTATGCCAGAATTTCCTG
TTACATTCTGAGCCAGTTTTATTTCAGGTTCACTGAAGTTGGCTGGAAGCAGAATAAAGATGGAATCAGT
CAACCTAAATGTAGATGTCGATACAAAGGAATGACAAGTGACTGACAGCCAGTTTTCTGATCAGAATAGA
CCTGACCATCTCAAGGTATATTCCATGTGGGCCTCAGCCCATAGTGAGGGCTGCATAATAAACGTACAGT
TATCTTTCAAGACATCTACTTGTTCCTCTAGAGAATGCTCTCTGAGACATAGGCTACCTAAAATTATCTT
ACCAAGGTCTATAGTGAAGCCACTACTCTAAGAACTGGGGTCTCAACTCTAACTATCTGGCCTCCATTCC
CACAGGGAAACATCTCACCTTCCCACTCAGGGATGAGGTAAATTTCCATCAAGAACTCACAGGGTTTATG
GTCCTTGCATGCTCTGGGTCTCATCTTTAAGAACCTACAAGTAAGAGTAATAAGGGAGGTCTTTCTGCTT
ACAAACTTAGATTGTTGGTTTTTGACATGACTATCATAGTCTAACTTTATGTGCTGTAACAGTGGTAATT
CTCAACCCATGGGTTGTGACCCCTTTGCGGGGGTGGGGGGTGTTCATGTATTAGATATTCTGCATATCAG
ATGTTTACATTATGATTCATAACAGTAGCAAAATTACCATTATGAAGTAGAAACTAAATAATTGTATGGT
TGGGGGTCACCACAACATAAGGAAGTATATTAAAGGGTCACAGCATTAGGAAGGTTGCAGACCACTCTGC
TGAAAAAAATGATTCATATGGAGGCAAATTCAAAACTCTCTCCTCTTTGTTTACCACTGTGTGTTTTTAG
GGCTGAAGTACACTGGCACAAAGATCCTGGACCTGACACGTGTGGATTCTACATATTAGTTGATAATTGA
GTACGAAACTGGAGAGATGGCTCAGCCACTAAAGGCGGAACTCATAAGCAAAATGATTGTACCATGTAAC
AATGTAACATGTAACAATGTAACAATGGAAGTCATTTGCATGCCATCCTCTTTTGAGTTTTTGCAATCTC
ATTGTGCTCCCTGAACATTCTGCTGATGTTTGGTAAGAATTGCTAGAGTCCATTCAGCTTCATCAACAAT
CTCTTTTGCAGTCATGAGTTAAGTTGTAGTACTGATACACATTATAATGAATAGACAACCTGTTTTAAAG
GCTGGTCTGTGCCCCCTCCTAAAACACACTGTTTCTCCAAAGGGGCCTGCCACACCCTGAGAACCCAAAC
TTAGCACCTTGTTAAATGGAAGCCCTGTAGCCACGACTGAATCAAGTCACGCTCAAGGAGAGCAACCCTC
CATGCTGTGTCTGGGTTTGCCTGTTTTATCCTGTGGTTTATCCTGTGGATTTAGAAATGGTTCATTCTAG
GAGGATTATTTCTCAAAAGGTGTCAGTCTGCCTTTTCCAAGTTCGTGAAGAATTCATTCGAGTCCAGCAA
CATTATGCCTCAGAATGAATCTACACTAGAGAAATACAAATACATCCACACAGAGGCTGACACTTGCATA
GCAGCTCAGTTTGTCACAGCTTCAAACTGGAAACAACCCAGTATCTTTCAGTGATTGACAGTATAATGGA
ATTCATCAATTAAAAAAAATAAAACTTCCAAATTTTTGATACACTCAACTTATATGAAACACAAAAGGCA
TTTTGCTGAATAAAAGAAGTTCATCTTAAAGATTAAAGTTCAGCTCCATTTATACGCTATTCTCAGAATG
ACAGAACCCTAAGAGATAAAGCAAGAGACCCAGATTACTACGGGTGGAAAAAAATCTTAGACTAAAAGGA
GAAAATAGAAGGAGTGGCTACATTGTCCATTGTTATAATCTGTCTGTGTTGCTTTGTTCACCTAGCCCTA
TCTTATCTCAAAAAATTCTCACTGATCTCCAAGAAACAAGCTGTCAAAGTACAAAGGGCTTTCAGCTCCC
CACTCTCAGACCCCACATTCCCTCCAAATGGACTTTCTAGAAGTGACTCTCTTCTGCCTTCATTTCCAGT
CTGTTCAAATATCCACCCTCAATGTTTCTTTGCTCAGTCATGGTCTCATCTGAGCAGCCGACAATCTAAA
CACAGCACTGACCACATACCGATCACTGACAGTTCTGTTAATGTCTGTTGGAGGATAATTGATCCTGTGG
GTGGCTTTTTTTGTATAAAACAATCATACGAGCCCATGTCCTTGATCTGAACATTGTGAAGTCGTAGAGT
CCAGTTGTTCCTGTCAAAGCTCGTGCGGCCCAGGTACTTGGCATTCACACTATCAAGTTTCTCTGTGCCC
AAATAGTGCTCGTACAGAACCAACTTTTGCTGGTCCTGCCAAAATACTACCAGCTCACTCAGGCTTATGT
TTTGAGCCTTTGTAAATGGGCACGGCAGATATGCAGTCCCATTGAAATAAGCTTGCGTCTCCACGGAAAC
AGCATCTAAAATAGAAAAACTGAGAATTAGGAAAGAGGAGACAAGAAGAGGAAGATCCCTTGCTCTGAAA
CAGCACCCAGCTTCCAGCTTGTCAGGCAGTGATAGTACTGGAGAGGTGGGTGCTAGGATCTGGAACCAGG
CATCCATGCTGGACGTCTGAAGCTCAGGCTTTCGTTTTGCTCCACTTGGTTCACATGTGCAGGCTGCAAA
CTTTGTGAATCTGTTTTCTCACCAGATTAAGGAAGTGGTCTGTAGTAATGTTCTAGGATTCTCTCTGTGC
TTCTGCGAATTTCAAAACCAGAGCATTGACTACCATCATCATAATTGCTACAGGCCTCCACAACTGCTAT
GCCATCTGCCTAAACCCTGCCTGCCCCATGCAATCCCTTTATACTTTGGTCTGCTATGTTTTTGGTTTTT
TTGGGTTTTTTTGTTTTTTGTTTTTTGTTTTTTTAAAGATTGTTGATGATGGATGGTTCCTCACTTGCTA
CCACCTTTTATTAGTCTCCATTATTTGGGAGCCCTACTGAGTCACTTCTTTGACATTCAACTAGTTCCTG
CCCCCACAGCCTCCACTCCCAGAGCCAGAGAAAAAGGGGGTTTGAAGTGACTCAAGTGTCAAGCAATGTC
TCTATTCTCAGTGACCTCTCTAGAATCTTTCAGGGACCAGAAAGGAAGCTGGGCAAATGTAATGGCTCTT
GGGAGATGATAGAGGTCAGGATATTTAAGGAAGATGAGCAAGCTGCTGGGAGAGAACTGTATGTGGGAAG
GTGAGGATGAGCCTTGTCATACTGCAGAAACCCTGAAGAAACCAATGGCTACTCCTGGGCTGCAGTGCCC
TGGAAACTTTTAGAACCCAAAGGGAGCAATGATGGAAAAGTTCAGAGAGAGGACGCACTGGCATAAGCCA
GCTTATGGGACTTTTTCTAGGCCACAGAATTGCTGGAGACTCAGCAAAGAAAATAAATAGAGGGAGATGA
GAGGCGAGAGGTGAAAGGTGAAAGGTGAAAGGTGAGGTGGGTGTGCCTTTTAAAGGCTCATATGAAGCTG
GAGGCTGCAATGGGGAGAAGAATGGAGGAGAGTCTTCATAAAAACAGCTCGTCCTTCGGGACTTCAGGAA
GGGAGGGAAGGGAGGGCCAGTGATGGGTGAGGGAGATGAGGAGTCCCACTCACAGTGGTGGTGAGTCAGA
AGTTAAACTGACCTGACCAATTAGCCTCCCTTTAAACAGGAAATAGTATAGGCAGGTACGATGGCATGGA
CTTGGCAAAGCAGAACACCCCATGAGAACCTACAATCAAGGGGTCTCAGAGGATACTCCAGACATCCGTG
AAGGACACATGCATGTCTGCATCAGAGGGAAGAGGGAGATCACTGAGTTCCCACAATACCAAAAAATTGA
CCTAAGAAAAATTTATTGTATTTGGCTTTTTGTTCCACCTCTGCTAATCTCTTAAGTGAGAGGCAAGAGT
GCCACCTACTGTAAATGTTCGAAGTTTGGTGAGGACTGGTGGACTGTGCGGAGGGCAGGACATATTCTGG
TTTGGCTCTAACTTATTGTGATTCTGGGCAAATGATTTCTGATGGAGAAACCAAGCAGGCAGCTGAAGCA
AAGCACTGGCCAGCTATTGGTTGGTGTGTTCTTATATTGCCCAGTTTTTAGTTGCACTTCCTGGGTCTAG
AAGTGAACTCACTCTGAGATTCTTACATCCGCTCAACACACAGACTCTTTTTCTTCTGTGGAGACCCAGA
GTACCCAATCTCCTTTCCATTCACTCCCTCTCCAACTTCTCTGACCCAGTCCCCCTCTCCCACAAAGTAA
CAGGGACTTCATCTTCCCTCAGTTCCCTCTTTACCTACCAATAAAAAGTAGACCAAAGCCTTTGGCCTCA
CCTGAGGGCTGGTCAGAAACACAGACTCTCTGGTTCCACACAAGATCTGAATCAGAACCTGCATTTTACC
ATGAACTTCTATTTGGGAAGCTGAGGGGATCAGAGCTGATAACCAGCCACATACACTTCTACCTCTCCAG
TCCCCTTCTCCTCCCCACGGGGCGAGAAACTACTCTGTAGCCATTCTGAATGGAACTGAAAGTATTTCAC
ATTCCACATGCTTGGTTTGTCATCAGACCCTGATTGTCTTGATTGTACTCTGAACCAAGCAGACATATCT
TAGCTGTGACCATATCGGGAAGATTTGACTCAAGGTCTGTTCTTTCCCAGTGCCTTCAGGCCTCCACTGT
TATGGTCCCCAGAACTTGGGGCCTCAAAGCAAGTGAACTCCCTAGAATTCCATTGGTGGAAAGCACTGAG
AAATCCTCCCTCTTCTAACATGTGGGTTAAAGAAATGCTTTAGACTTAGCTATGACTGATTGTTATGATG
CAGCCAGGAGCCAAGGACACAAGAATTCAGCCACATATCTCCCCACTCAGGAACCAGTGATCAAGAATAC
TGAAGGACCTCTGCAGACAGAAACCCCTGGAGTGTCCCACTTTGTGAGTCTATGACCTCACCAGAATATC
AGTCTTCCCTGGTCGGTTACCCCAAACTCATCATCTCTTCTGCATTTTCTTTGCTTGTTACACTCCAAGG
TTCTTGTTCTTTCTGTAAACTTCGCCCAAAGCCTTTCTAGGCCCGCTGAAAGTCCCGTTCCATTGTACTA
GATCCCACTATAGCTGATCCTCTTCAATAAATATTACCCTCTATGTCCTTTCCATGGAATCTAGTTCTAC
CCAAAGGACTCCATGTGGCCCACAAGACACTCCTGGCTTCCTCAGCAAGGGCTTTGAGGAGCACCTCTCC
ACTCAGAGGTGTCTCCTATCTCATGGTTATGAAGTACTAACTATTGGTCACTGTGTCCTCATTCAAGGAG
GATTTCGGCATTATATTCAAGGCTCTTCTCTCTAACCAATACTCAACATAACCACCAAGATAATGTAACA
GTTTATTCATCAATAACAAGTCTGCCAACAACCTTGTGTCAAAGTTCCTTACTTTATCTACCACAGAGAC
CTTCACCCACAGACCTGCTCAGCAACCCTCCATTTCCCATGGCACAATCCTGAGCAGTGTCCCAGAGGGC
TTAATACCTCAGATCTGACCCCCAGTGTTTACTCTCATTTTCTTCATAGCTGTTCTTCAACTTTGTTGAG
ATGTTAGCTCTCTTAGACCCCAGTCTTTGATTTCACAGTATTATTCCTCCGAAAGAATACTTTGAGAGGA
GAGAATTCTTCTCTGGTTTTGCACAATGTGAATCCTCAACAAGTAGTAACTGTGACCAAGAAACTGGATC
ATTTTTTACAGTGCTGGAGAGGGAAATTGAATTTTTTTTCATCTTGTTTAATCTTAATTAATTAAAACTT
AATGAGTCACATATGGATAGTGGCTATTATACTGGACAGCACACACACACACACACACACACACACACAC
AAAATAAATCCATAATACAGCTTTTTAACCATTTCTCACCAGTAAAAAGCCACTAAATATATCTCTTGGC
CCTGGTAGAAGTTATGCTAAAGAAACTTTTTTCGAATCTACAGATCTGATCTTACAGCTGGGTGGGTAAG
TACCCTTACAGGAAATAATCTCACTGAACAGATAGGTAACATTTGAAATTTGTGATAGTCTACTTCTCTA
AACACAGCCTCCAGGCTCATCATCCTGTCTCAACAGGTCCCCTCTGCCCTTGCTTTTCTTTTCTGTTCGA
TTCCCTAGTGAGCAGAGACAGCTTTCTCCCCCTACACGGCTCACTCCTGTCTCTCCTGAAGCTTTTCTGA
CAAAAGGTGTTACCAGTTTTCATCAAGAAAGCTCTGTGCTCTTTTGGACCTCACCCCATCTGGCCATTGT
ACCAAAAGTAACATGGCTTTAAACTCCAGTTTACTTGGAATTAACTTCCTCAGTCTGACTTCCTGGTCCA
TGTGTCTGTTTACTCTGGGATTTATTCTGTATGCCCACTGATTGAACTCTCAGGGATAAGCTACAAGGTG
CGTATCTCCAGTCCATAGCCATTAGTCAAGTCCCAGGCACCATATCCGATGGCTTGTTGGATGTTTTCAA
GTAGATAGCAAGAGATACACTCTATTTCCTCTTAAATCTGAAAAGGCCCCAAGACAGCAGCTGAACTAAT
GGCTCTTTGAGTAGATTAAGTTTGAATTGTTAGTTTACCCCAGGTACTTGATTTAGTGTTGGTAGACAAT
GACAAGAGATAGAGCTAAAAGGAGACCCATGAATGCTATTTTCATGTACCACCCAAGCCAGAACCTACAG
AATCTGGGGGAAGAGAGTCCGCCTCTCCACAACACAAGAATCTGAAGCTGTTTAATGTACGTCTTTAAGT
GAAGGAAGACTCTCCCACTCCAGGGTTATTGTTGACCAGTGGTGTTGGTCAGGCGAAATAAGAACCCTAA
AACCTGGAGATTCAGACAAGAAGAGAACAACTGCCAGATGTCCAACTGGACTAAGCATGGTGGATGCACC
TATGGTCATAGCTACTCTAAGGCCAGTCTGGAGCATTCCCAGAGTGAAGGGCCCATGAGATGGCCTAGAA
GGTTGTTGTGCAAGCCTGATAAGCCGAGTTTAACCCTCAGGACCCACTTAAAGGTGGAAGAAGAGAACAG
ACCCCACAGGGTTGTCCTTTGCCAGCCACACTGGTAGCAATTGATCAGGGGCATAACAATGGTATCTAAT
TTCCAGGCAAAGCATGTGGGAGGTGTAGGGGGCAGGGCAAAACTATTTTGCTCTATGTCTTATGTGTTAT
CTTAAGTTATCAGCCTTGTAATTCCCCCCCTCCCCCCGTGGATTATTAGTGCCAACTGTGTCTCCTTTCT
CTCTTTGGATGCCTGCCCTGGGGTAGGTCTCTACTCCATAGCTCAAGAAGAGGCAGATTCAAATTAGATA
TATTTTCCATGTTAAAAAAAAGGTGGCTTTTAATTTAATAATACACTCTAAGGCCATTTAGTGTTGTTCA
TAAGCGCACCTGTGTGGGTCATCTACTAGGCATAGGTACCAATGTCCCCACCCCAAGAAAAGAATTTCTC
CCTGTGGTTATCTTGTGCAGATAACCACAGCTTCTGAGAATTTGCATGTGAAACAGCTATGTCCTGCCCA
GTGGCCAGTGGTCACAGAACTCCTCCCCATCCTCTGGCTCTTAAATTCTTTCTTCCCCTCTTGTCTCCAG
TAATGTTTGCTGAGCCTCTGGGATTAGGGTTGTGGACATAGCAGTTCCATGTATGTGTGTTCAAAGTTGA
GAGGCAGATGGGGGGTGGGTTTTTTTTGTGTGGGAATGAGAGGTTGGAGGGGGAAAAATGGGATGGATAT
AACCAAGATATATTTGTATGCATGTTTGAAACTAAAAAATAAGCTAAAGAAGCATATTTATCAATGATTA
TACATGATTAAGAGTAAAAAAAAAAATGAAAGGTTAGAAATAGATGCTGACTGTTTTATCATTGCGTTTA
TTGATGAGTGAAGTATTGGCAGCTTCATTTTCTGGCGGTTGAAGCAGATTGCCTGCCATCTTTATATCTG
TTCGTCCCAAGCTATATCCTCTTCCCATACATCCCCTTGCTACAATGAAACCTACTCAGTTTTCACTCAA
GATATTTTTTTCTTATGGTTTCAATATCATCGACCCCCTTTTCCGGAGCTAGGAGTTTCCACATGGTTTC
AGAGCAGGTCAAAAGAGAAGTGGCACCTGTCCTTGGTTTTGATGGGTTTCTCAGCTCTATCTACTCACTT
TCAAAGGGCTGAGCCTGAAAGTTTGGGGACAGGAAAGGTGTCTCAGTCAAGCTGTTACTGAATTATTTGT
TTCCAGGACATTTCTCTCCCAGATCATAAAAGCTAAACTTGCCATTCTAACCTGTAGTGCTAAGGCCTAA
GGTTTAAGGACAGCTGGGGTGTGGCTTAAGATAAAAGCAGGAAGTGGAAGGAGGCCACACAAGGAGGGGC
CAAGCTGAAGCAAAGCTGAGTCATTCAGAAGCAGAGCCACTTGTCATTGCCTCAGGAGGAAGAGCTAGGA
GGAATAGCCTGGTAACGCGCATCCATGACCTTCAGCCTGCACTGCTAGGCATGAATCTGGCCTCTCTGTT
TAGGAGCTGTGTTGATCTTAGTCAATTACTTAGCTGTCTCAGCACTTTAGGGACCTTGTCTTAAAATGAG
GAATAATGATGAAATCTAATGCAGCAAGTTATTGTGGTTTTTAAATGAATTGCTATTTATAAAGTGCTCA
GAACTTTATAAGTACCTGAACTAAACACACACACGTACACACAACGTACACACACACAAGTGTAGATGCG
CACACATGTATACACCACACACATACACACACAGATGTATACACAAAGGCACACACATGCACACACAGGC
AAACATGCATGCAGATACATATATACATGACACACAAACACCACACACACACAGACACGCACAGAGACAT
GCATGCATGCATGCACACATATTGAGTCACGTCCAGATACATAGACAGACAGAGAGAGAGAGAGAGAACA
CACAAATGCATACACACATACAAACTATCTTTATGTTCCTCACCTCTGATATTTGTGTGTGTACACATCT
CCCCAGGAGCTGAGACTCTGGGTCACTGGCCCTGGCAGGTGAAAGCTGCCATTCTCATCTACGTTGATGA
ATAGCTAGGTGAACACCTGTAGACATCATCTGGTGGCCTCTGCAAGCCTTGAGTGCTAAGCAGAAAGCAC
AAATCACAAAAGGACTGTATCTGCTGAGGTCTAAAGGGATATCTCTTCATAATACTCAACTCCTCCTCTT
TACCCTGCCAGGGCTAGGGGCAGTGGCCAAGGGACTGTTGTGTGACAATTATAGAGGAGGTGATTTTGTG
GCTGAGCTGGTTAGTCAGAGGCCAGGTGGTCAGGGGTGGCCTGCAGCTGCTGCAGGCACACCGGAAGCTC
ACCTATCCTGTCTGCTGATCACCAAGACTGAGATGGCTTCTCTGTCAGCACTGAGGTAGAGAAAGTGAGT
ACAGGAAAGAGTGGGCCAGCAGAAACAAAATGGCATTCAGTTGCAGGATGCATGGCAAGGCCTCCAGCCA
GCTGTTTATGGGTGCATCCCAGAGAGCAGAGAGCCAGGAAGGGCTGAATTCAGGGAGGCCTCACAGTTCT
AAACTTTAGTGAGCTTTTTAGAAAAAATAACACATAATTCAAATGCAAGATGTCACCCAGCAGGAGACAG
TGATGTCGGGGGTGGGGGGGAGGCAATCGTAATTAATTGTGGCTATCTTATCCAAATCTTACCAAGTTGT
AAGATATGTGATATAGTGCTGAGGTCCTCCTGGGGTCCTTAGGGGTTAGAAAGGGGGAGCCTGTGTGAGG
GGGAGCCCTGAAGCATTAGCTTAGTTAACTTTAGCTTGGTACAGTGGCTGGCATGATTAACTGGAGGTCC
AGAGTCACAAAGCATGACCAGTATGAGTTAGGGCACAGGCTAAGGAAGAAGGATGTGGTGGTGAGCCAGT
ATTACAAGAAGAAGCCTTTGAAAGCTGTCAGCAATTTTCTAAGGGCTTGAGAATACTGAAAATGGGGACT
GAAAAGACCAGATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGGAGTCA
AGTTAGAGGCTTTACTGTCATGGCTCTCTTTACCCCTCTAAGAGTCCTGGACAGGACACTCCACCTTGTG
CTGTGTGTTGAGGTCCTGGGGGTTTGGTTGTAGAGGAGGAAGATGCCCAGACAGCTGGCCATGGTCCTGA
TCCTTCCGTACTCTCTAGGAAAGCTATTTGCTATGGAGTCTTCGGCAACTCAAGTCAAACGTGAGCAAAC
CATACCAACAACTCTCAGGCCTGGGCTTTCAGTGCTCTGACTCACTGAATGACAGCAGAAGGACTCCAGG
ACTTTACACAGAAAAGGGTTCTTACCTGAGATCAGCAAGACTGTCACAAAGATAAGGATTGCCAAGCCCA
TGGTGCTGGAGTTTAAAAAGACAAGATAAAACTTAGTTAGAAAGTGAGACTGAAAACAATTGTTCACTGA
AACATGAACTAGAAAGAGTATTTAAAATTCGTGTAGGTTCCCACATTCACTGAAGTCATTTCTCCCCACC
TAGCTCCATACACAGGCCATATTTCCCAGCCTCCTTTGCAGTGAGGCAGGCCATGATACTGGGGGCAGAA
AATATGTCTGCTGCTTCTAAACATGGTAACAGCGGTCTCCTTCCTCCTCCCTCTTCCTTCCTCTCTCCCC
CTACCTCCTTCCTCCTCCCTTCCCTCTTCTCCCTCCCCACTCCTCTCTCCTTTTCCTTCCCAGACTCAGG
AAATCTCAAGAAAAAGTGCAAGGGCTAATACGATGCCCACGTCTCATAAAGGCAGAGACTTAAGTTTCCA
GACTGAAGTAGTATAAAACAGCGTTCTCCACCCCTCCACACCCTTCCCATGCTGATCGAGACTGTGACAT
TAGCCAGAAGTACTTGATGTTAGATGACAAAGCTGTGGGACATTCTATGGTAGAGCAAGGCATTACTTTT
GTCTCAACCAATGCAGGGAATATGAGAGAATACCGAGACCCTTGAGTAAAATCGAACTTCCTTTGATTTT
CCCGTGGTTTTCAAAGTTTCGCGTGCATGGAAAGTCACCGGGAGAGCGTGCCAAACACTTTCCTGGGCCT
CGTGCACAGAGCATCTGGCCATAAGTTGAAATGAAGCCTATGTCTAACTACCTGACATACTCACTTCATC
TGTAAGGCATGCTAAAGAAAAAACGTCAGGCAAGACTTTATAATGTCTAGTTTCTTCTTCCTCTCGCTTT
CTCTCTGCTTCTCGACTCAACCGCTCGATATAGACCAAAAAGATGTTAGAGCTTACTAGAAGCACAGGAT
AAAGACCAACATTAGACTGGTGGGGAAACAAATCGATTACCAAAGTTTGGAGCAGATCCCAATACAAGGC
CGACGCTAACTGCTTACCCTAGGAATGAACCACCTAGTATTAGGTGACACTCAAATTTGGCTTGCAGCGT
TTTAATGGCTAATATAAAAGGGGAAACCTAGCAGGTGGATTACTACTCAGCTTTGTATATAAAAGGAAAG
TGGTGCTTTGGGAAGACACACAAGTATTATTCATTCAATAGCAGAAATTTCTCCCTTGGAGGGTGGACTG
TCTACAGCCATTCTCCATCCTTCAGGTCGTGTCTGTATACTTCCTTCTTTTCTTATAGTGCTTGGCACAG
GGCAGTGGGCTAAAACAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTATTTGTGTGTGTGCT
TTAATCCTTCGAGACGGTAATTTTTTTTAATTAAGAATTTTTAGAGATTATATCTGAACATAACATGAAA
ATGCTAAAGTAAAGCTGAGTCTTGGACATGGTAGCAGATGCATTTTAATCCCAGCACTTGGGAGGCAGAG
GTAAATGTTCATCTATCTCAGTGAATCCTAGGCCAGGCTAGTGAGCTTTAAGCCAACAAGGGTACATAGT
AAGACCTTGGTTTTTTGTTTGTTTGTTTGTTTGATTGTTTGATTGTTTAAAGTAATGGTGAGGTATCAGT
TAATTCTTCTGTTGTTGCAACAAAATATCTGATAAAACAACATAAGGAAGGGAGGGAAGGCTTGTTTTGG
CTTACAGGTTTGGGTGCAGCCCATAATTTCAGGGACATCATGGGGTGGGGGCAGGGGTGGGAGGCACCCA
GCCTCATTGTACCCTCAGTTCAGAAAGCAGAGGAAGATGCTGGTACTCATCTTGCCTTCCCATTTTTATT
CAGCCTGAGACCCCAACCCACGCAATGATGCAGGCTGCATTGAAGATGGCTTGAAATAACCCAGTCACTT
ACAACATCCCAGAATTCTAGATTGGTGATTCAAGTTGGCAGCCATTATTAGCTATCAGAGTGACAAATAG
TTGAAAGCCAGGATCCCTATGGACTCTGGTCCCTGGCCATCTAACTTTCTTCCAAAGTGTGCCTGGAATG
ACCAGTTACCTATTTCAGTTTCTTGCCTTCACTTATTTTAGACAAAATACAACAAAGTAATAACTCAGAT
CCACATGTATTAGCGTTTGATTTTAAAACACAAATAGAAGCATTCAATACATACTTTTACATAGATGCTA
CCAGCTTAGGGATTATTTTATATCCATAATAATTAGCACTATCATATTAGCAGTTGCATACTATTCTGCT
GTAATCTACTTGATGCAAATAGCCTGATTAGTTGCTCCTAATTTTCTGTTGTAAAGAAAAACCCAAATTA
TATTCTGCCTCATACCTGCAGGAGCTGGCCACTTCTCAGAAGGAGAATCTCTTGACCAAGAGCTGACGAG
TAATGGAATTTTAGTTTTCACAGATACAGAAAGATTTTCCTCCACAATTATACGTTAAAACTTCCACCGA
CAGGAGACTACTTACTTTCACATGTTTTGGGGGGGGAATGTTTTCAAATTTGTGAATTTTTGATCTGTAC
CATTTAAAGATTAAAATGACGCTTCATTATACATTTTTGACAGTGCTTGGAATTGAGCCCAGGGCCTTGC
GCTAGCCAGGCAAGTGCCCCACTGACTGAATTCCTCAACCCTCTCATCGTAGTTTTTTTAAATATGGTAA
AATACATACAATGTTTACTAGACTGATCATTTCCAAACATGCAGCAGCACATGAAAGATTTGCATTGTGC
AACCATCAACATCACAGTATCCCCAAGTCTTCTCACATTGCAAGATGGAAACTCTGGACTCAGTCAACAG
CGATCGTTCCTCATTTTTCCTTCCTGCCCCCCACTCCCCACCCCGGTCTCAGAAACCACCTTCTGTCTCC
ATGGACCTGAGTTCTTTAGATGGAAGTGGAATCTTACAGTATTTAGCTTTCTGTGGTGGGTTTGCTTCAC
TTAGCGCTGCCTTAGGGGCCCATCCTCATTGTAGGACCTGCTGGGATCCCTGCTCTTCTGAAGATGCTCA
CACCGGGTTCAGCGTCTGTGCCCATCTGCAGAGGGCTGCTTGAATTATGTACATCTTTTTAGTGCCGTGA
AGACTGCTGCTGTGAACATGAGGTGTACGAATTTCTCCCCAGTTTTCTGCTTTCACTTCTTTTAGATACA
AACCAAGAAGTGGAAGAGTAGGTCATATGGAGATTCTATTTTAAACCCTCTGAGGAACCACTGTCCACCA
GAACTTCACATTCCCATCAAAGGCAACCAATAACGGATTTCTCCATATCCTGGGCGACATTTTTTTTTTT
TCTGATTTGCTTTTCAAAGTCTAAGCCACATCTGGTAGGTGGTTTCCACTGTTATTTCAAAACAAATTTC
TCTTATGAATCTGAGTATCCTGCCACATGATTAATACGTTTGTATTCTTACGCCACGTATTCGTCACACA
GCCCTCTCCGCCCCACCTCCCCGCATCCTGTCTTGAGTCTGACTTTCTCTTGTTAAACTGTAGAAGCTCT
TTTTTTTTTTCCCATATAGAAATTTAGCAGTTTGTGATAATGTTACAAGTAAGTTCAGCTGCCAAAATAT
TAGATGTTTGGTGTGAGAACCAAATGTCTAGCTCCCAGTAGCTTTCTCCCTCTCTCCCAGTAACTGTAAT
GGATGTTAGGGTTTAGCATTGTCAGTTGAGCTATAGCAGACATGGCACGTGGGCAGAGCCTGGGGACCCT
TGCCTATTTTGTCACAGTAAGTCACTCACAGTATCCTATTTATCATGGATCTGAAGGCTGGGGCCTTGTT
AGGTCTGAATTCCTCCCTAAATATAGGAGTCTGTATAATACCTGAAAAGTCAACACACTGGATCTAATCA
GAGAACTTTTCCCCACCTGACATGTCAAACACACGAGGTCTCCAAATCAAATGACCCTATGCTATAAACT
TAATTGATTAGTTTAACTCAGGTAATCACATGGAACCATTACGGCAGCGTTCTCAATCTGTGGGTTGTGA
CCCCTTTGTGGGACTAATGACCCTTTCACAGGGCTGCTGAAGAGCATCAGAAATATCAGATGTTTACTTA
CGATTCATTGCAGTGCCAACATTACAGTTATGAAACAGCAATGAAAACAATTGTATGGTTGGGGGTCACC
ACAGCTTGTATTAAGGGGTCTCAGCATTAGGAAGGTTGAGAGCCCCTGCATAATAGCCTTCCAAAATCTC
GAACAAATAGTCCCTGAAACTCACTGGGTGGGGCAAACTCTGGCCCTGCCCAGGAAGTCCATACTGTTGC
AAACTTCTCTGTTTGGAAACTTGTCTTTCCCTGATTAGAAACATCAGCCTCCTTCACTACTTCTGAGTTG
ACTGATACCAGCTTTGTGAGTATTTTGCTTTGTTTTGTTTGTTTGTTTTTTGTTTGTGTGTGCGTGTGTG
TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTTTGCAGGGTAAGGATTTGAGAGAGGGTCTTGCT
CTATAGCTCAGGTTTGTCTCAAATGCATGATCCCTGAAACTACCCACAGTAAGCCAGGCTTCAGCAAAAG
CCATTTAGGAGCTTGAGGATGGCAAAGTTCTACACCTCACACTTTGGCCTTGCCAGACAGTCCCAGTTCC
CTAGAGGAGCATCACGAATGCTCACAAGGAGACTGCATACCAGCCTGGCAGACACTCCATTGCCCGTTCC
TAAAACACGGACACAACCTTCCTTTAGAAATTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT
GTGTGAGGAAGCTAGCTTCTCCACTCTTGTTGGCTCAGAACAGAGCTGTCACTTCCCCAGGAATGAACCG
TCCCCCAAACTCCAAACACCAGCAAGGCTTTTACCAGATGGCCCAAGAAATGGAAATTCTTACTATCAGA
GCGGGTGTTCAGCAGACGCAATGGGAGAGGAAAGAACCTAAGAATTTATGGGGGGATTCTCTGACAGATT
TCTGTCACTAGAAGCAGAATCGGGTCTGAGGGGTGGGTGAGCTAGCGAAAAGCCTAAAAAGGAAGACTGT
TCACACAAGAAGAGTTGTTTGCCAAAATTTTGGTAGTATCTTTAATAAAGATGTTTGTCTTCAGCATCCA
AAAACGAAGAGGAGGAGGAGGGGGAGGGGGATGGGGGGGAGGAGTTACAGTCTAGAAAGCAAAGTGCCCG
GTAATACCATCTTCGCTGACTTTATATACACTCTTACACAAGTAAGAGTGGTGGGGTGAATGACCAAGCA
CCCTGGTTTCTGATGTCTGGGTGAGATTGTTAACCCCCATAATACAGATGAAGAACCAGTTTCAAAGGGT
GAAGATATGTTCAAGGCCATGAAACTGGTAATAGCAGAACTGAGATTCAAACTGATCCAACTTTACTGAT
TTTTCTTTAACACAATGCCAACCAGATTCAGTAGTGCATGGGCAGCAAGCAAAGAGATTCCAAATCTGCC
CACTGGCAGGATAAGAGGAGACAGGGCACTACCAGAACATACCCTAAAATCATTACAGGACCCTTGGGAG
ACCCTGAGGTGGGGTAGAATGGGGTCAAAGCCTCCATTTGCATCATGGGAGGTTTTGTTCTAGTAGGCAA
ATCATTCCACAGATGCTGCTTGAGCACCTACTATGTGCCAGGTAGAACACTACCCTGTTCCACACCTCAC
AGGCAACAGGCTTTAGCGTAGGCACTGGGATCTAGCTGAGGCAGAAGAGGGGAGATGAGGTGGCACAAAG
GACCACGCTGTTCTGAAAGAGAAAGTGGGAGAATGGTTCCCTGGGAGCAATCAGGAGGCCATCAATGGAA
AAGACTTTGCCCTGAACTTAGCGGTAACCAGGTAGTAGGAAAATGCTACTAAGAGGAGCATTGTCTCAGC
TAGGTTGCTCATTCACTGTCTTAAAGGCAAATATTTACTGAGTATTTTCAGCATTAAAGTTCTTCTAGAG
GTCTAGGGAGATGTAAAGATACATAGGCCTGGATCCTTCAAATAGCACTAAAAAGAAAGGCAGGGTGTCC
AGGAATAAGTCAAGCTGGAAAACACCGTGGAGAGCCGCAGCACTTAGCTCCTCCCGAGGTGTACGGTGTT
CTTGCTAGGAGCAAATCAGCAGATGGCATGGCCACTAGAGGAAGGACCCAATCCGGTCGCGCAAGCGCAC
TAGGGCCTGGTCGCTCCTCTATGTCTGTACATACTTACGGCTCAACAAGCCTACTGTGGGTGGATCCATC
TGCTGGCAGAGGGACATAGATCCCAAGAACACTCCTTGCTGGAGCCTCTGTTGGCCTCTACTGCGCCATA
AAGTACTGGGGTTCTTCACAGAGTCCCAAAAGCTAAAGGCGCATGCTAACAGCAGCTAGTGTTATCGTTG
AGACGCTGAGAGGAAAAGGGTGGGGCTGTTTCCTTTCATCTGAAGTTTCTGAACTGTGAAGGATAGGCAT
CGCTTGGGATCCTGTGCTTTCGACTGTTAACAAGGCTCCGGCACAATGACGCGCTTGAGAACAGTGCGCA
ATCACTGCCGTCAAGGTTCGGGTGGTGCTGTGTTCATTCACGCTTCAACAGACATTCATTGAGCCAGACA
CTCTGCTCAGTGCTGGGGACAGAGAGATGAGCAAAGTCAGAGATGGCTTTGCTTAGTACAGCTGCTTAGT
TTGGCCAAGGAGCAAAATAACTGTCAATTAAACATAAACAAATATAAAATTTTTACAATGAAGAGTGCTA
CCAAGAGGTCTGCGTGGTGCTGAAGAAAGTTTTCATGTGACTCGTCTAAAGTGCTATTTGAAGGATAAAG
TGGCAGCTTCAGTATTGCCACCTGTGTCCTGATACCCTCCCACAAAGAGGTGGAGTCTAATCACTTCTCC
TGACTCCAAGGTTGGCCCTTAACTAACTTAGGATGAAGCATTAAAAATGTTCTGAAACTTCTGAGACACA
AAAAGCCTTCCCACCCTACATGACCTTCTAAAAATGTATTTTTCTAAGGATTGAGCCCACCGTGTAAGAT
ATTCCTCTGTCCTGCCATCACAGTGCCAGAGCTCCCATGTGTAAGTTTAGGTCAAAAGTCCTAGCTCAGC
GTAGCCTGCTAAGCTACCAGCATCTGCTAAGCTACCAGACAAATGCCATCCACTCATGGCAGTCAAATCA
GGCCCTTGTTACCACAGAGAATGGGAGAATCCCCCTGAGGCCAAATTCTGAACCCCAGAACTGTATGAGT
GAAATGGTCCAGCCTTGCCTCTAGGAACGTTTGTAATGTACATCTAAAGGAAACAGAGCCAGAGGCACTA
ACCAGGCGAAGGGCTGGGAGGGGTGACAAGGTAGAAAGGTTCTGAGCCAAAGTAATATCACATACAAAGG
CACTGGGGCAGGGGGAAGATTTGAGAGTATCTGTGGTTGACATGCAGGTGAGTGAGAGACAAGGCAGAAG
AGCTCAGCATGGGCCAGAACACACTTGCCTTGTGGGTTAGTTAAAGATTTTGTTCTTTATTATGACTAAA
GTAATAATAGCAGAGTGACATAATCAAAATTCTACATCAAAAAAGATTTGTTTTTGTTATAACATTTGAG
TATCAGAGAAGCCAGAAAGATTCGAGAAGCCTGTCTCACAGTGAGTGTTTGAGTGAAAGTGATGGCTAGT
TGATCTGTGGTGGTTTAAAAAAAAAAAAAGTAGAAGTGGATTAATCAAGAGATAAGACTACAACCAATGG
GCTATGCTGATGGATTAATATCATGACCAAGGGTTAGTTCATTCATTCATTTATTCATTCATTCATTGAG
CAGTTGAATCATTCTTAGCATATCTGTCTGGGTGTCCTAGTTTGTCTTTTACTGCTGTGATAAAAGGCAC
AAGAAAAAGCAATGTAGGGAGGGAAGGGTTCGTTTGGTTTACATGTCACAATCACAGGCTGTCATAGAGG
GAAGTAAGGACAAACAGGAACCCCGAGCAAGGCAAACGTGAGGCAGGGGCATGGGAGGACACTGCTTCAT
GGCTTACTCCTCAGGCTCTCATTTCTTACTCCCCAGCACCACCTCCCACAATTGGATGGACCCTCCCACA
TCAATCACTAGTCTAGAAAGTGCTCCCACACACTTGCATACAGGCCAATTTAAGGGACCCAGTTTCTCAC
TCAGATGACCCAGTTCGTGTCAAGTTGACCAAAACCTAACAAGAGCTCTGGGTACTATGGGACTCTCCAT
TTTTTTTATTGTTGTTGTTGTTTTATTTTCACACATTTATTAAAACTGTAAATGAAAGCAATAGAAAACA
CCATTCATTTCAAATATGCAAATGACTTAATAATTAACCTAAAGCTAGTCAAGCAAATATTCATGAAACC
TAAGGAGAGATAGGAATACGACCAGCCCTGTAAGGGTTAGCTTGGGTTTTAAGATAACGACTGTGTAAGT
GGAGTAACAGAACTAGAGAAATACCTTATGCATAACAAACTATGCCGTATTAGTGTGACATAATAGCCAT
CAACATTAATTTGGTCCTTCTCTTTGGAGGCAGAGGACGATGGAGATAGCACTCAGGGCCTGAGGCACAC
TAGTCAAGTATCCCACCACTGAGCCACACCCCAAGCCACATTAATTCTGTCTTAACTAGCATCTGTCCCG
CCGTCATCTGTGATGATCAGACCACATCACTGTGACCTCTTGTACAGCAAGGTGAGGGTTGGACTTGAGT
GACAGTGACAGAAGTGGAGCTTATCAAGTGAAAGGCAGCACGGTTCACTAGAGGATGATGGGAAAATATG
AAATGAGGAACACTGAAAAGACCCAGGTAAACAAACCTGAAAGAGAGAGGGCTGCAGATCTGTGAGAGCC
AAGGGCAGAGAGTGAGAGCTCCCCCAGAAGAGAGGGGGGGACGCTGCTGCTGAAGGACACACAGCTCCGC
TAGAAGTCACAGGGAGCCAGATTTCAGCTCCAGGGAAAGAACTTGTAACAGCCACAACCAGAGTCTGGAC
TTCTGACCTATATGCACCCCACCAGCTGAACAGCTCAAGTAAAACCTAGGCTGATGATATGGAATAGACC
TTTTAAGGAGGAGATTCTTGAATTGCTGTGTGGTTGAGCGCTATAACTTTAAAATCCCACAACCAAGCGT
CTCATCACAGTCCTGGGAAAAGGCAAAGGTAAAAGATGGTCCCTGGCATCCCGTCTCCCTCTGTCCCACC
CGAGCCCTTCTTTTTTTTTTGTTTTTTGTTTTGTTTTTTTTTTTTTAGTTTAACACAACTGGCAGTATGG
TGTCTTCTTGTCTTCTGAGGATGTTCCCAACTACAGAGAGACCATGAGCTGACTACCAGTGATCTTCCAC
GAGTCAAGGGCAAGAGCAAGCACTCCTACCTACAGTCATCCTAGCCCCGCTCCCCAATAAAGACAATGGC
AGTTTTAGAACTGGGCCAGGACAGTGGCTGGTTTCAGAGCCAGACAACTGAGTGGCTGCTGGAGACAGTT
TCTGTCTGGGCAGATGAAACCCTCCCTACGTAGTGTTGGCTCTGGCCACTCATTCTGAGACTTTTGCCCA
TGAGGGTTTTAGGCTGAGCCACCGCACTGTTCAAGAATTCTCCTCTGAGAGTCGATCTCTTCCTTTACCA
TCAACAACCGTTAATTTCCAACTTGATATGGCTGGCACCTGCTTTGACTGTGAAAGGCTTTTCAAGCTTC
CAGTAACTCTTTCCTCCAAGACAGTCTATGACGTGGTCCTCACTCTATGACACCCTACACATCTGCCTAA
CATAAATCAAAGAGGCTCCGTCAGCAAGTCACTTTTAAATGCCGATGACTTCACACGACTAAATGTTACA
ATTACAGTCTTCATACACACACACACACACACACACACACACACACGTAATCCTGAGTTCAATGATCAAA
GTTTTTTTTTTTTGGTATAATATTCTTTGAGAATTTTTTTTTTTTACTCAAATTGTTCGTTCTGCAGTGC
CAGGAATGGAGCCTAGGGCTTGTACAACAAGCTAACATTGAACAACACCTCCAGCCCAATCTCTTGTTGT
TAATTGATATATAATGGTTGCATATGTTTTATAATATGTACATTATAAATACAATGTAGTACTGTAAAAC
ACTTATACAAGAAGTGATGATCAGATCCTGAGAAGTCTTACAACTATCACTTCAAATCTTCGTCATTTCT
TCATCTTAGGAACATTTATGCTTAATGTTCTATGACTTTCATAGTTCTGAGATACAAACAAATAGAATCA
CTTTAGAATACATTTGAAATATTTATTGTTTTCTATTTGGGTGCTTTACCTGCATGTAAGTCTGTGCAAC
ACATGTATGCAGTACTCTCAAAAGCCAGAAGAGGGTGTCAGATTCCCCAAAACTGTAGTTACAGGCAGTT
GTTAGCTACAGTGTTGGTGCTGGGAACAGAACTAAGGTCTTCTAGAAGAGCAGACAGTGCTCCTATTCCC
TTAGCCCCAAAATTAATCCTTTCAGCCCACAGAATAGCCTTTAAGGAGACTTGGAAATGAAGGGATAACC
AAATCCTTCATAGCAAGTTTTTATTTGTTTGTTTGTTTGTTTGTTTGTTTATCTGACTGAACTTGGAGAA
AGTCTAGACTAGACAAGTAATGGGAAATTCATTTCTGTAAATAGTGCAAGAGAGCTTATCAAGGCTGGAA
AGTCAGATAAGAAATTTGCATCTGGTTCAATAAATTGGAAGTTTGGAATTAATGTCTCGGAAAGGAAAGA
CAAACAAACAACCACAAAAAAAAACCAATGCAGAAAGCTTAAGATAATAGCCCATCCGTGGCCAGGCAAG
AGTGAGTGACACTATCAGGATGACTGGAGACCCATGAGGCTAATAGTCAAAGGCTCAGGGACCAGAAAGA
GGAGGGAAGGAAACCAGAGGAGGAACTGTGGGGCGTTTGGAAGGAGCCGAGTACACAGGATGCTCACTGA
GACTCAAATGCTTCCTGGTTTCTGGCGGGCACTGGAGATGGAGTCCATTGGCTATGGCCAATCGTCACTC
AGTCTGAGCTCTGCTTCCTCTCGCCCCGCCCCACCCCCAGCCGTGTCTCCTACCATACCCTAGTCATCTC
TGAGACTCTCATATCCCCTTGGAGCAAATCCCCTTTGGCTCTTTTCTTGCCTGCGTTTTGTTTTCTGTTC
TTTAGCTGTTGTTTTCTGCACTCGTTCGGGAACAGAGTATGCCCACACATGAGGAATATTAGCGGATTCA
CAAATAGCAAAGGAGTGTTTTCACTCCCTTTTGCTATAACTAAACTCCTAAAACGTAGGTTACTCCCCCT
CTTTGACCCAGATGGAGCACAGCAGCATCATTTAGCTTCTCCTGTCCCCTAACAGTAGATTGAGCATAGG
ACAGATACTCAGCTCTCTTAGCCAAATCTACAATCGGGCTTCTTTGAGCTGACGATTATTTTCCCCTTTA
AAGTATTAATGGTTTTTCAAAGCCAGCTTTCCGTTTTTACCAAAAAGTACCCAAAGGTGAACTCACGACC
CAGGTATCTCCCTAGGTCTCTGCCCTGCCACTCACGAGCTCTACCTTTCGGGAATAAGAGTCACAAGATT
CACCCAAAGGCAACGGCCCATCCTGGTGCCCAGGGCAGCCCCTTTCTCTTTGTCTCAGAACTAAAACCAT
GGTCACACAGAAAAACCAGTGTTGTCAGGGCATAATTTATGGGACAGCCCCTTCTCTCTTTACTGAGCAC
CATGATATTCTCCAGTGTCATTCAGTTTTGGGATTCCCTATTAATCATCCCTTGAACCAAGGCAGGTTTT
GAAAGCCCCCATAAGATGCAAGTGCTGTGTGGAAGAGAAAAAAAAAAAGAATATGCTTTTAACTCTCAGG
AATTATATTCTTATATTCACGTTAACAGAACATGAAACTCAGAAGGGAACTGCATGGTGTGCTAGATAAG
GAATGGGAGGGATACTTAGAGTGATTCAGGTCTCAAGACCTTGGCGGGGAAATACTATGCACTCAAAGTA
CATTTTGTCTTCCTCTTCTCCTGTTGAAAATGGCATCTCTTTCCCAGCCTCATTCTAAGGGCATCCAACA
TGCCATTCAGAAACAACTTTCTACAAGAGAATAGAGAGGTCACGGGTCTGCTGAAAAGCTGTGTGCCTGA
GCTGTGGTCCCATCCTTCTCCCCTCGTGCCCTAAGACTTTGCCTGGCCCTGAAATGTGATTGGCCAGCAC
TTGCAGGAGTTGCCAAAGTCTTCCTGGGAGCTTCCCCTTTCCTGCGGGCCTGTGTCAGACTTTTTCATAC
TCCTGTTTTCAGTTGCAGTTCTGCCCCGGAGATCCCTCCCCTTAACTCCCACGTCCACCTCAGTTTGAAA
CTGGATGAGCTTGGAGCTTTTGATGCTTCTATTGAAGAGTCTGCTGTGTTTTAACAGTTTACCTTTCACG
ATTTCCCCGTCTCCCCATCCTTGTCAAATTAATACAATAGAATCCTCCTCTCCACCCGGGGGTGATAAGA
GAAGCAGACTCAGTAGACACCGTTTCAGTCAGTAGTCACCCAGAACCATTTCCTCCTCAACCAAGGCTTC
TCTCCATGTGATTAATACTACCTTCCCCAGTAGATGCTGCAGGAATAATCATCTCCCTGCATGTCACGGA
TACTCCCTTATACCTAGGACATATTAAGAAGCCAGCAAACATATGCTAAATGCATAAATGAGCTGACATT
TCATACAGATTTCACTTAAGCTTCGTTGAGTCACACCCACAGTGTATACAGCAGCAGCAGCAGCAGCAGA
CTCGGTGCGGAGCCACCAGATCTGAGCATGGACACAAACTCATTTTAGTCCTGAGATGAACGTTCCATCT
AAGGAGAGCAGGCCGACTCCTAAATTATTATAATTTGAGGAGTGGGAAGTTCCCTCGGCCAAAAGTTCTT
TTTCACCTCTCTCTCCAGAAGCTTACAATGCTATTAATGGAAGCAATATTTTAAGCCTATTTGCAAATGC
AAATGTGTACACAGCAAGAGGAACACATCAAACCACTGCCTGGACTCCTTTTTAACCTAAAAGCATTTTT
CCCCCAAATGAGTTGCAATGTTGAGACGAGGCAGCTGGATAGGAAGGAAGAAGAATTTCTGGGCCTGTCA
TGGAAAACTCACACAGGCAATCAGAGGCCACTACAGAGAGAACTGTGGGAGTTTTCCTCTTCCACATTGC
CCCGGTATAGGAGCTCTGGGATTGCCAGTGTCCACCAAAAACTTTTTCTGTAGCAGAATTGCTGGGAACT
CCCAGCACCCCAAAACCAAGAGCAACTGCCAACTATTTGGTATATAACCGCTTCTATTTCCTGCTTGTCC
TGTCTCTCGGCTCCATTACAGCACATATCTGGATGGAGGAGACTCATTTCTGTAATGCCCCACATCTGAT
GTGGACGGTCAGAAACTCAAGTGGTGATTGGCAAAAGGTTTAAGCACTCACCCTCTGCCCTCTCCCGCCC
GCCCGCTCCCTCTCCAGCTGACAGCCCACCTCTGCACATCTGCCCCAGCTGCAGCTCCTGTATCCCGTGC
TCACCAGGTTGCACATGTCTTGATGACATACATGTCACCAGTGCCTCTCCACCTCGGCGCTCAGGGACCA
CACACACAAGCACAGCAGCATTCCCGAAGATCACAGGAACATGAAGAAAAAAATAGAAGGTAAAAAAAAT
AGAAGAAGAAGAAAAGTAAAAGGAGCCTTGTCCGCTCCCCAGGCCTCCTGGGCGTCCTTATACAGGAGAA
ATAATCTGGGGACTGAAGAACTCACATACAGAAAGGGGAACTGACTAGAGAGACTGACACCACAGACAGG
GGCTGTGTCGTGCTTGGTTCCAGATAACTTCTGCTGGTAGGTGGGCATTTCCACTGACGAGAATGACTAG
ACCTGTGCCCTTGGTCAGCCAGCAAGTGTAAAGCCCTGAGGGAAACCCCAAAGACAGCCCCTTCCACAAA
CACAACAGACACATCCCCAGGCACCAAGAGTCCCAGGAGTACAATCTGTGAAGTCTGTGGCTAACAGTTT
AAGCTCTGTGCAGCGTCTGTCTCACTCCCAACCAGAGAGCCGAGGAGGAGTCCTCCATGAAGGGCCTTTC
CATAGATCCTTCTAGAAGCCAGTTTGCACTACAGATTACACTGACCCAACCCTAGCTGTCCAACCCTAGA
ATGCTTCTATGACTTCTCTCCACCATGCCTGGCAAGAGCGGAGGGGTTCTTCTGAGCTAGGAGGGAAGTC
ACATGCATAAGTGTAAGTACAAAGTGTGCTCTCTGAATCTGGGTCTTCTATAGAGTTTACACATCTGGGA
ATATGACTCTTCCTCGGGTACTTGGATCCTTTTCCTGCCAGGCTTTGGCCTTCTAGCCAGCTGGGTTGGG
TGGGGCATTTATATTTCTGTGAGGTGAACTCAGGACAGAGGTAGCCTCACCAGCCTACCTTAGAAGGCAC
CTCACCAGCTTTCTTAGAGGCTAGCTCTGGACCCCTGGAGGGCTGCAGAAACTATCAAGGTTGTTTGTTA
TCTTCTGGTTGATGGACTCAGAGCAGGGGAGGGAGTGTGGTTTGGGGTGGGTAGTTTCGGTGGTCCCCCA
TCGAAGCCTGGCTTGACTGCTGGACTCTGGACAAATCATTGGATATCCTGGAGTCTGACTTCTGACCTAT
GGGGTGCAGTGCGCAATAGATGTCCTTGCTGCATGGTCACGAGAAACAAAGGAGATGGTGAAACTTGCAG
GTAATTCACCTGGCGTGCCACGAATTTAATTAGCCTTCATTATTCCTCTCCCATTTCCTTCTGAGTATTT
TTCAGTCCTCTGACCTTTCCACAAACGTCCTCATTCTGTGAACAAGATCCAGGTTGGTTCTTCCCAGACA
GATCTGAAAAGCCAGTTACCTTCAGTCCAGGGCTGCTCAAATCCCTGGGTTCCTGCTGGGTTGTGGGTCA
TCACTTCCAACCAGTGATGCTGCATACTTATTTTGGAAACATTCTTTATTGGACAAGCACTACTGGAATT
AGGGGTGTCCTCTGGATTTTAGGAGCGTCCTTTTTTTTATTTATTTGAAAAGATCCATGGTGGTTTCTTT
GTTGGAGCATACAAGATCATGCACTTATCACAGTATAGGGGGATTCTTGAATATGACATTTAGTTTTTAA
GTGTTCTTTTTTTTCCCACGAACTCACCAATCCAAATACAAGATGGGGACTGGAGAGATGACTCAGTGGT
CAAGAGCATTTAGTGCTGTATTGGAGAACTGGAGTTTGGACCCCAGCACTCATGCCAAGCAGCTCACGAA
TGCTTGCAACTCCAGTTCCAAAGGATCTGACATTTCCTTTGGCCTTTATGGGCATCTAAATGCACAGACA
CATACACAAACAGACATGGGCACACAGATGCACACACACACACACACACACACACACACGGGCACACAGA
TGCACACACATACACACATACACACATGAAATAAATCTTTAAATATGGATATTAAAATACAAGGTAAGTT
ACATTTAATATGCTGCTATCGAGTTCCCTTCCCCACCCCACCCCACCCCTGGGGATTGAACCCAGGGCCT
TGCCATACTAGCACTTGTCATACTAGAAAATACAACACCTGTTAAGAGAACTAGATGAAAAGGACATTTT
GAGAACACTCCTAAGTCCACCACTCCTCGGCTCTGGATGGACCCATAAGTGCCATTTAGATACTCATCCT
TGTCCTGCTTCCTAGAATCACCAGAATATATCCCTGCACTATTTTAGATTGCTGAAAGCAGATACAAAAT
CCCTCCGTAGATCTGCCTCTCAGCCAGTTACCAGAATTTTGACCCAATCACTCCCCACTAGTTATGGTCT
TTAGGACCCTAATCGACAGCCTCTTTCCGACCAGCACCCTCTCCCACAGTGAGCAACATACATTTCAGCA
GGGCCATTTCAGAAACATAGAATCAGCATCATCTCTGATGCGTCAACGCTCATGTTGTCTTAAAAAAGAG
GTGGAGGCTGGCTTAATGTGATTTCCTTTTAACACATTGGGTTAAGTCTCTACCTCCCCACCCCCCAACT
CTTGTCTCTGTGTCAGTGTTTAGGGCTAGCTCTCAGTCAATTAAAAGTCCTCTCTGACTCTCATCCGTGC
CATCAGAGGTGAAGGGGAAACAGGGTGCCAGAGAGATGGTGCTGGCAGAGTGGAATGATAGGTTCCTTGT
GCTTGTCGAGGAAGAAGTTTCTGCAACCTCGGGAAGCTGCTCTCTGCCCACTCACTCCCAGATGTTCTCA
GCTCAGCCCAAAGCTACAATAAAAACAGGGGAGGGAGAGGAAGCAGAGATGGCATTGGGCACTCGCAAGG
AGTGTGCCTTCCTGAAGCCACACCCAATCATTGCCCAAGAGATGGCCGCTGGGAGTACCTACTTGAGACT
TATATCCTGAGTGACAGAACCAGAAACCCAAAGACATTTAGAACACCCAAACAGGTGTCTAGCTCCATTT
TCCAACTATAGCCACTTGTTTGCTAAGTGGCCCTCTGTCGCCTGTGTCGGAAGATAGTCTAAAAGGATTC
TTGATGATGTAGAAATGGTTTCAATACAGAACAAAGAGGTTCCCAGAAATATTTATAATGGCATTATTTT
TTGTGGTGTTTGTTTGTGTTTGCATTCTGAGTATTCTTGATACAGAGATGTGTGCTGGGGCAAGGGGACA
TGAGAATTGAATACCCGTGGTATAGGTGATCCTTGTAGGTGCCCCTGCAACCCTAGAATATTTCTTCCCT
TTGAACTGCAAGAGAAAGAGAAGACAAAGGAGACGTGTGGGTTGAAGGGGCAGTGGACACCCAAGCACCC
TTCCCTTCATGTTCCCATGGTAGTGATTTCCTAAGGGCTGGATGACTCACACCTAGAGAGGCACTAGCTT
CAGCTCAGATTGCAGTCTCAACAGATATTCCTGAAGTAGCGCAGGTTCTCTTATCCCCATAGCAACCAGC
ACAAATGCAAGATCTTTTATCAGACACCAGATAAACCTCTTGGATCTTGAAGCATGGGAAGGAATCTCTT
GTATGACCAGCAGAATGGAATCTGCTGCCCCAGGGGCATGTGATGGTCTATATATCCTTAGCCCAGGGAG
TGGCACTATTAAGAGGTACAGCTTTGTTGGAATAGGTGTGTCGCTATGGATCTGGGCTTGGATACCCTTG
TCCTACCTGCCTGGAAGTCAGTCTTCTCCTGTTTGCCTTCAGAACAAAATGTAGAACTCTCAACTCCTCC
TGCACTATGCCTGCCTGGATGCTACCATGCTCCTGACTTGATGATAATGGACTGAATCTCTGAACCTTTA
AGTTAGCCCCAATTAAATGTTGTCTTTGTAAGAGTTGCCTTGGTCATGGTGCCTGTTCACAGCAGTAAAA
CCCTAACTAAGACAGGGCAGAATGCTGGTTCAGTAGTAGGATTACACTGAGTTAAAAGAAACATAGGAAC
TGGGCTTCCTATACTTTGGAGGCAGGAAGATAGCAAGTTCAAGGCCTGCCTGGACTACAGAAGGAGTTCG
AGACCATCATGGGTGACACATTGAGACCATCTCAAAGCAAAAAGTGAAAATAAAGTTGAGAGTGTAGCGT
GCTGATGAAATATTTGCCCAGAATCTGCAAAACATTGGGTTCAATCCCAGTACCCCCAGTACACCCTTAC
ACCCCTGCACACACACTCACAAACCTACCCCACATACACACACATACGCACACTCACACACTGCATAAGG
GAAGTAAAGGTTTCATGTGTACGTATATGTTCCTAAACAGAGTTTAGACACATTCACCCATGCAAGGTCA
ATGAAATGTGTTTGTGAACAGAATTCCTGAACTGTTCTTTTTTAAAAATGAATTATTTATTTATTTTTCT
ATGTATGTTGAGTGTTTTCCATGAATGTGTATCTGAGAACCATGTGTTCAGTGCCTGCAGAAGCCAGAAG
ACAGTGTAGAATCCCCTGGGACTGGAGTTTTAAAAGATGGTTGTGAGCCACTAAGGTGCTGGAAATCATC
AAATCTTGGTCCTCTGGAGGAGCAGCCATTTCTCCTAATTAAGAATTAGTGCAGTCTAGAGGTGAGCATC
TTTCTAGCTCTCAACTCTGCAACACGAGTTCTAATAAGTCAGGATAGCTGTCACCATCCCTAGGACATAA
CTCGGCCCTTTTAATGAACCTCTGATGAGTCCACACTTCCCTCCTATACTCTGGGACAACACACAAAACA
TTCACAGTGAATTTTCCTTTTATTGTTACTGTAAAACTGTACATGCAGAAGCCTTCCTCCTTAAGGCATA
CACACACGCTACTAAGAGGGAAAAATATAAACCACAGACTGGGAGGAAAATAGTTGCAAAAGACCTAATA
TGATGAAGAGGCTCTGATCTAAAATATGCAAAGAATGCTTAAGATACAATGACAATGGGTTGGAGAGATG
GTGCAGTGGTTAAGAGCACTGTTTGCTCTTCCAGAGGTCTTGAGTTCGATTCCCATCTGGTGGCTCACAA
CCATCTGGGATGTGTTGTGCAGGCATACATGCTAATAGAGCACTTATGCACATGAATAAAATTTTAAAAT
ATTTTAAAAATATAATGACAAGGAAACAAATATCCCACGGTGAAAACTGGCAAAAGATCTGATTATGTAC
CTGGCTGAAGAAAGGGTACAGGAAACAAATAATTTGTGCAAAGAAGACCAGTGCCATGCCACCACAGAGC
TGCCAGTCAAAATGATGACAAGATTAATACCAGAGACTATCAAATGCTGATGACCATATGGAGAAACAGC
AGCATCCACTCATTTACTTTGGAAAAACAAATGATAGAAATGCCAGGGAAGACCATTTACAAGTTCTTAA
AAACCGCAATATTTCCAATGTATGAATGGCAACCACACTTCAGAAAGCATTGATTCAGTGGAGTGAAAAA
CACCCACACAAACACCTACTCACAAATAGTAATGCCAAATTTGTTTATAATTGCTTAAAAGCTGGGCACA
AAAGCACCCAAGTCTGATTTCCAGCACTGGTGTCAGGCAGTTCACAACTGTCCATAGCTCCAGCTTCAGG
AGACTCTGTCCTCTGTTGGTGTCTGCACTCACATGTACATGAGTGCACACACAGTTACATGCATATAATT
AAAAATAAAAATAAGTCTTAAAATTTAAAAAAAAATGCTTAAGTAGACTTCTTCAAAGAAGACATTCAAG
TTGTCAACATGGAAAAAAAAAAGATACTCTTCAATAAGTGCACGGACAACTTATACATCCATGCAATGAT
GTAATGATTAATGATAAAAGGAAAGAAGCCACCAGGATATGAAATACATGGAGAAAACTTAAATGTTTGC
AACTTGAGTAGAGAAGCCAATCTGAACAGCCTACATACTATACAGTTCCAATAGCATGATATCATGAAAA
AGAAAACACATGGAGACCGTAAGATACAAAGGTGGGGGAATAAACAGATGGTGCATACCATCATGTATGA
TAGGGTAATGGCGGTCATGGCAGTACACATTTGATAAACCCATGTAACGCATAAGAAAGAAACTTAGTCT
TCTAAATCATGAGCTTGGTCAATACTAATGTCTTAACACCTGTTGATTGGTCCTAACAACTATACTACCC
ACTGAAGATGGTAATAGTAGAGGAAGCTGGGTGCTTGGTAGATACAGCGAGGTGGGAATTCTCTGTACTA
TCTGCTCAATTAAGGAAAAAAAAGAATCTAAACTGTTCTAAAAATAAAAGCTATTAATTTAAAGACACAC
ACACACTAACCACACATACTGATTCCTGGCAAAGCGACTAAATCAATAATGTGACATTTTAGCTCCTGCA
CTGGTGGGAAAGTGAATTAGCATTCGAAGGCTCACTTCCCCATGGTCCACTCAGGGCATCAAAATGCCAT
GCATACAGCCTCTCTGAGAAAAATCTCCAATGTTGTATTTATAGCTGCTCTCGATAATTTATGCATATTT
CTGGTGCAGAACCATAAACCTATGTCAATTCCTTAAGTAAGTGAAAGAAAAAAAAAACCCACCATTTTCT
GTGGGTCAGATACATTTAAGAAAAGTAAAAGTTCCAAGTATCTATCTTTCTCCCTCTCCCTCGCTCTCTC
CCTGCCCCCTCCCTCTCTTTCTCCCTCCCCTCTCCCTCTCCATCTCTCTCTCTCTTTCTTTCTCTCTCTA
GAGGTACACTATTAGAAATGTGGTAGATTTCTCTTTGAGAGAGGATGCTTTCTTTGTCTATCCCATGAGC
ACATCTTATATAGTTAAAAGCATTTGAGGTTTCCGTTTTTCTTTCCCGGTATTTTTTTTCAGCCTTTATT
TTTGTTGTACAAGTAAGTCACTGACATAGGAAGGGACCCTCTTTTTCATAAGCTCCAAACAGATTTCTGC
ACTCCCCACCCCACCACCTCCCGATCTGCCCCACTAGCCCCATGCTGGCTTCTCTGTTTCCTTAGCTGTC
CTTTATTCACTTTCTTGTGATGCAAATTTACACTCATTAATCATTCGGTCTAGGAAACCAATGTCTATTG
TCTGTCAGATGCATTCTAACAGTTTCTGAACCTAATACCTACCACCCAGACCCAGGGACATACTTCACCT
GGATGTTCTCAAGGGAGAAATCAGAAAAGGCAAGCCACCTAGGGTATTTGCAGGGAGTTTTCAATTGAGT
GCAAAGACTCTGTTTTCTTCCCCACACACGATAGCTTCAAAACCTATAAACTTTAACAGCAGCCTACAAT
TAGGTGAACTGAAGACATCGTTCACTTTACTGAGGGGACTTATATTAAAACCTGGAGCTCATGGTTGAGT
AGATAAAAATTGCTGTGGGGGTGTGTATACTCCAGGCAGGGTGCGGCTGAGCTGGAGCGTCTGCAGAGAT
GTAGTTACATTAATGCTATAGGCAGCAGAGAATATGAGAAGGGTTGGCCTGGTGGACCTCGGGCTAGTGA
CTATAGCTGCAGCAGATGAGGCCTGAGATCCCAACATCCAGGGTCTGAGGGAGGGAGGATTGCAGCCTGG
TGAAGACACAGCAGAATAGAATGGGGGCTCCTGGGAAGCGTGTGTAAAGCACCCCACTGGTTCATAGGAA
ACAAGACAGACCATAGGTCAGGGAAGCAAGGATAAGGTTGAGAAGGACCATGTGGGGAGTAATGGGGAGA
TCACCAGTCACCCCAGGGACACTGGAGACCAACCAGGGTATTCTAAGAAGACATTCAAGGGACTTTTCCT
ATCTTGCCTGCCTTACTGGGCATCCAGACATGTCGTGGAAGGAGCTACTCAGGACCTTGGGTTAACTGCA
GACTCTAGAGACACACAGAGGCACACACAGGCCTGATTTCTCTTTATTCCTTTGTATTCCTGAAATGTTT
TCTGTCTTCCAACAATACATGACATCAAAGATGTCATTACACCATTTGAGATATCTGGCCTTGGGCCCAA
GGAGAGCTGGAGAAGAATAGTCCCTGCCCTCTTGGGACCTGGAGCTGAAGCAGGAAACCTGTCCCCATCC
AGCAAGGTCAGGTGTCTGACCAGGTGATTGTGAACATGCCTGGGGACTAAGAAAACTCAGGCTCTGCATA
CCGAGTGCCCTCTTGGCTTATCCATTCTGAGAAATTGCCATTTCCCTCAGACCCTCTTTTAGAAAACGCA
GAATGAGGTAATATTCTAAATGTCAAAGTTGCTGGAAGACATCGGTCCATGTTTTTTCTTTACAGAGGAG
GGCAGAACATGCATAACAAAAGTAACACATTTTTTGAAATGACAGTATATTTCAAATTTGAGGAAGCCAG
GATTTTTGAAAGTACCTTATGCAAAAATATCTGGGCAGGGGTCTAAATAAGATGTGAATGGTAAAGTAAA
ATAAAATAGGTCGGGGCACATAGAACACAGACTATATAAATGACTAAATTTTTTAAAGCTATTTTTTTAA
GCTTCTATTTCACCACAGGGGTGGGAGAAGGACCTCTGAAGATCCTAAAGCTCACTTCTGCATGACATCT
TTAAAGCCAGAAGCAATGAGCGGGACATTGGTGAACCCTTTGTATGTGCATTCACACACCTGGATTTAGT
TTTCAAGTTAGTGGTGCAGGACCACTGAGGTGGTTTTTAATTAATTAGTTAGTTATTAGTTAGTTAGTTA
ATTAATTCATGAAAACTTTTGCAGCTCCTTTCTACTCCCTTCACACTCTTCTATCTTCTTAGAAGATTCC
ATTGGATGATGCTACTTAGAAGAGATCTTGATGAAATCCACAGTCACTCATCCTGAGCCTCACTTCTGAA
GAGGGCTTCCCTTTAAGCTCTCTTTAGACTGAAAACAATCAGAAACAAGCCTTACACCGGGTGGTGCTCT
TGTAATGGGAAAAGCTGAGATTTTGAAGGACATTTCTAAACCAACCGTGACCTTTGTGTGTCTTGTCCTG
GAGATAAATACTGCTTCTAAGTGGCTTTCACTGTGTCTGGCCTATTTGCATACAATACAAACAAAAGAGG
TTATTTTTAAAAAGAAGTGTCCTCTTGTTTTTGTTTTTGGCCCCCTGGGATGGCGGTGGTCAGGCAGACG
TGTGCGGGTCATTTTCATGCAGTGACTCCTGTGTGAGCTTGGGTTTATGTCACTTTCCCTTGCCTTTCTT
ACTCATCAACCACTTCTGGTTCATTAGTGGCCAGTTTTGGAGTTCTTGTCTCACCTGGTGTGGACTATGA
CATCTCCGTCTCTTGGCTATGAAACTTCCTTACTTAAAAGACCCTTTCTTTTAAAAGCTAGGTCACACTT
CTGAGCAATGCTGTTCACAATCTAAATCCAGTTTTACTTTTCGATTTTTATCACTCTTCTATACAAATTA
CCTGCTAGTTATAGCCCACAGCTACTCTTTTCTGACCTCCAGGCTCTCTGAAGACTTTTTGCTTCCATGA
ATACCACATAAGCTGTTCCTGGTGCCTGGGGCTCCTTCCCTTGCCTTCACAATGACAAATCTCTACATGC
CTCAAAATACTCTTTTCAGGATGCCTGTGTCTTCCTCACAAACAGAAAACAGTGTTTATTCATCCCCACA
ATGGCTTCTCATTGTGTTCAATTTTCTTGGCTTGAGAGCCTTAGTGTTGCAGGATATTTGATCACACTGC
CCCTTGAACCCTGATACTGTATTGTTTACTGAAAAAATCTGTTTCTAGTTGTGGCGTGGCTCAACTTTAA
CACACACCTTTCTTTCCTCTGGCTGGAATACAGACACACCCTTAGCACACACCTTTGATCCCAAACAATG
AAGGTAAAGTTAGTTTGAAGGAAGAAGCACCCATGTTTAGAAGTGATGTCTAATTGAGTGGTAGACAAAG
TGATGAATCAGAGAAGGATTTGACAAAATATGATATGCCCAGCTCTCATGAGAAGAGACAGAAAAGGGAA
GCTACTTATGAGAGAGCAGCACACAGACAAAAGAGGCAACTTTAATGGGACATTTGTTGCAGAGAGAGAA
CAAGCTAGACACAGGTAAAGATAGAACGTACCAGAGAATGAGAAGGAGCCAGAAGATTAGAACAGATTGC
CAAAGTTAGTATGAGGCTAAGCAGAGCAATTCAGTCAGAAATTGAGAGAAGCCAGATTGCATCAGTCAGC
TTGGAGAGGAGTTTGAGCCAGAAGAACTGAGCCGAATCATTTAGCCGGAGAGGGGAAAGAACTAGGAATG
GGTGAGTTTATTCATCAGTAAGTCTTAGAGGCTGAAAACATAGATAAGATTATAGATAAGATTATACAGA
GGCTAGAAGCTTCCAGGACTAGGCCTAGCTTAGCCGACTGAGGCAGTAAGCCTTGGAGATGATAATTATA
TCAGGTAAATAACAATTATTTACACCTTAGGGTAGGGCCATATTTCTCTCCCCTTGGCATTCATTCTACT
TGATACCTAGTTGTAGGTCCAGCCTGTGGCTCAGTGTATCTACTAAGTCAGGATCTGCCAACAAATGAAG
TAGGCTCCTTGCTGTTATTGTATGCCTTCAGTCCTTCATTTAATCTTTACAATGTATGTAAAATGTTTGA
CATATGAGGAAACTGAGTTCCAAGGATGACACAGCCTGTGTACCCTTCAGTAGGGTATAGAATTGAATCT
ATTCTATTTTATGACTGTTGTCAGAGAGACAGATGGATGCACCATGCCATTTATTATTATTATTATTATT
AATATTAATTTCCTGAATGCTGTATGACTTGGCACTTCTCAAGTGATTCTATCTTTCTATTCTGGTTACT
ATCTGTGCGACCTTGAGCTAGCGGCTGAACCAGTTTCTCATTCTTTTCCATTGTTGGAAAAGCTCTAACC
CATTTGGCCCCTGTCAGGATTGGAATGACAGCTATAGGAAATTCTCAGCATGGACCCTGCCCATCACAGA
AACTCCATGCTCCATCCCACTCCACTCCACTTTGATCTTCTTCCTCTTACTCCTTATCCTCACAAAGTCT
GGAACCATTCAACTTTCTTCTTTTTTTTTTGTTTTTGTTTTTGTTTTTTGTTTTTTTTTTGAGACAGGGT
TTCTCTGTGTAGCCCTGGCTGTCCTGGAACTCACTCTGTAGACCAGGCTGGCCTCGAACTCAGAAATCCG
CCTGCCTCTGCCTCCCGAGTGCTGGGATTAAAGGCGTGCGCCACCACGCCCGGCTCCATTCAACTTTCTA
ACAGACAAAGAAGCTAGAGCTCTGTGATATTAACGACCTATGCAAAGTTCCTTTAATCTGAGGAAATATC
TTTCCTGAGGCCCCCTAGAACTTAATAAGACCCTCCAAAATAGCCAAATAAATAAAGGGACCATGGTATG
AGCTCATGTACAAATACATGTGTAAGCATTTAAGAGTCTGAGTTTGGCCACCCCACCCCACTCCTCCTTT
TCTGACTTTTCTTTTCCCTGACAGTCATGACCGTTGAAGGCAGAGAATCCTGGAAACAGAAGCAGTGATC
AGCCAGTGGATGAGCAAGCTCACTTCTCTGATCTCTGCTTTCTGAAATCTCCATTCATTGATTTCTCAAT
CTAGTTCCCTTCTTCCTGAGAGACGCTTTCTTCCCCCCTTCCCTCCTTCTAGGGCAGAGATCTCAGATGA
GAAGGACCTGGCTTCCCTGAGGAGGTGGGCTCACAGGATCCTCACTTGCATTTCACAGGGCTGTCTCTGA
CAGGCTTCCTGCCTTCTTTGCCCTGGTAAGTGGTCATTCCTGCTCTCAACGTGAGGGTTCTTAGACTCAG
GTCTGAAAAGCCTGAGCAAGGTCATATTCTCAAGTGAAGGCAGCCAAAATGGAGGAGGAGCCAGGCTTCC
ATTGAAGGTGGGCAGCCTCTGTTGACTAGCTGAATTTTCCATGGGGAATGTGGCCTCCTGCTAATAGGCA
CTGTAATTCTTCAGAGGAAAACAGGACCTGGGTTTATGCAGATTCTCTGGATGTATGTATATATACCTAT
AGGTATATATATGTATACGCATATACATGTATATATGTATATATATGTATATGCATATATACCTATAGGT
ATATATATGTATGTATGTATGTATGTATGTATGTGTGTGTATGTGTGTATGTATGTGTGTGTATGTGTAT
ATGTATGTATATGTAAGCAATTAATCTTGATGAAGCTTTTGTTTTATTACTTAGTTAGTTAGTTAGCTTT
ACTCTGCTATTTCAATGACTGGGGGGACCACTTTTAGTTTACAACCTTTAATTTCCCTACTTCCTCTGTA
CTTTTGTTCTTATTCAAGGCTCCCTCTCAGCTCCTGCCTTTATTGCTTGGTCACCAGGGCATGTTTTGCA
CCATTGTCTCTGTGGTGTGAGTATGTGAGTACGTGAGCACTTGTGCTTGTGCGCACGTGTATGAGAGTGC
ACATGGGAACCAGAGGTCAATCTTTGGCGTCTTCCTCCATTGTTTTCCACAGACATTTTTGAGACAGCGT
CTCTTACTGACCCTGGAAGTCACAGATTCTGCTAGACTGATGGCCACAGAACCCCTAAGATCTACCTGTC
CTTGGCTTCCCAGCTCCAGGATTTCCGGCATGTACCACGTGGCTTTACAAGGCCATTGGAGATCAAGTGA
AGGTCCTCGTGCTTACACAATAGGAAGTTTACCCATTAAGCCATTTCCTGAGCCCTGGGTTCAAATCTCT
ACACAGAACCACGGTCTTTTGTGCTGCTAAAAGTACCCCTCCCCAACACACACACACAAGCCAAGACTTA
TATGCACATACACACAGACATACATGCACACTTGTATACACACACACTTCTAAGTAGACATATAGGTAGA
TTGTCTTAACAGAGAGTAAGAGATGTCTGCTCTGGTGATTTGCCCTCCCTATAGTGGCAGTAGCGTCTAC
ACAGGATCCCTATCTGATCCATCTTCACCTCTCCAACATCACTGGGTAAATTAATAAAACATAGTCCCAG
CCTCCCCCTTGCTGCCTCTGGCTCACCACATCCTGCCTCCACTGTAGTATCTTCCTAAACCTTTCTACTA
ACATTTGCCTCAATCTCCTGTGAGTCCATGTTGCCCTAACAGAGGTCAAGAGGTCAAGGTAAAACTGGTA
GAACAGTGGCCAAACCAAGACCTTCCAGACCCTGAACCATTACACAAAACCAGGGCATTTCATCAAATGT
TTACAAATTTTACTTTCTGGCTCTTTGTCATGCAAGACCAGTTTATACTGCTTTGTCCTTACACGCAGAA
CAACAGTGTGGAGACTAATGACTGGCAGGAACCATTAGTTTTCACCATTTGTACCCCATAGGCTAGACAG
AAACCATACACTCAAACCATGCACTTCCAGCATCTTAGAATCTCTGACAGCCAGTCCTGTTTAGAAGCTC
AACTTCACCACAAGAGTACTTCACACTTAAATTTTCACTTTACTTTATATGTATGGGTGTTTTGCTCACA
TGGATGTCTGTGTACCATGTGTGCCTAGTGACTGAGGAGGTCAGAAAAGGGTATCTAATCTTTTAGAGCT
GCAGTTCTATGTGGTTGGGAGCCACCCTTGGGCGCTAGAAATCAAATCCAAGTACTGTGGAAGAGAAGTA
CGTGGTGCTCTTAATTGATGAGCCAACTCTCTGGTCTAACCACAAGACTGCTTTATACTTCATTGCACTG
AGTTTGCAGGATGACGTAAATTTGCTGTAGATTTGGCAATTGCTACCAAAGAACCTGTTTTTCCTAACCG
TACAATCTAGAGGGAGCCATGCTTGCTGCTTCTGGCTGTGTACTGTTTTCTTTAAAATCACATGGTCTTG
TGTCACATTCTGTTATTAAAATGTTACTTTCAATTTCATGATTAGTTCACTGACCCATCCATTGACTATT
AAACACCTTTAACCATTTAGGCTGACTCTTAGTTTTCATTATGTTAAATAATGATGTGATATTCGTTTCT
GTGCAAAAATCTGTGCCCCCACGGAGGTAAGAAGATTATAGCAAGATATATAAGCATTTCTATAGTAAAT
AAAATGGTCATTCATGGATCTTTTAGAATTAAAGTACGACTGTGAATTTAGTCATTAGTCATTCGTAGAA
ACTAATGCAAAAAAAAGAAAAGAAAAGAACAGAAAAGGAAGGAAAAGGGAAGGGGAAGGAAGGGGAGGGG
AGGAGAGAGAGAGGAGAGGGAGAGGGAGAGGAGGGGAAGGGAAAGGAAGGGAAAGGAAAGGAAAGGAAAG
GAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAATAAGAAA
AAAAAAGTCATCACAGCCTTGAAATAGAGAGCTGAGCACAGTTCCTGCAGGTGTAATATCAGATACTTGT
CTGGATTACTTGTGAGTTTGAGGCCTGGGCAACTTAGCAGGATCTTATCTCATGTTAGCCTGGCAGCAGA
GTGATTGATTACTCAGCATGCACCAAGCCTTAGGTTCAAAGAAACTTAGAAGTGCATGTAAATATCTATG
GTCCAAAAGGTTTAAGAGCAGATTTTCACGAGCAGTTCTTGAAGCTACTTACAGGGCTACCAATCCCAGG
ACAGGATTTTATAGCAGTGTTTTAGGCATTCTACCTTACATAAAATGAAGTTAGGTGGCTTTGTGGTTTG
GCTCAGCATCTTCATCTGCATTTGGCTTGCCCTCGTGGCTATAATTAGGAGGTCACCTGTCTTATATTCT
AGGTAAGATTCCATTTCCTGGAACTCATCAGAAATGATAAAGCTCAGTGCTGGGGAAATGGATCCATTGT
TAAAAACTTTTGCTGCTCTTCTAGAGGACCAGTATCTCCTGGCCTCCTCAGTGGTTTGATCTATTTACTA
CCAATGAGTTTTTTGAAGAAAGAAACATATTTGCTCATCTTTAATGTCTTCAATGTGGACCAAAGTGCCT
GGAATTATAGGTCTGTGTCTTAGCCACTGTTCTATTACTGTGCAGAGACACCATGATCAAAGCAACTCTT
ATAAAAGAAAGGACTTAATTGGGGCTGGCTTACAGTATCAGAGGTTTAGTGGACTAGCATCATGGCAGGG
AGCATGGTGGCAGGCAGATGTAGTGCTGGAACAGTAGCTAAGAACTATATCCTGATCTGCAAGTGGAGTG
AGAGGAGCTGGGCCAGGCATGGGCTTCTGGAACCTCTAATCCCACCCTCAGTGACACACTAGCTACATCT
TCTAAGTTTTCTAATCCTTTCAAACAGTTCCATTCCCTTGTGACAAAGGATTTGAATATATAAGGTTATG
AGGACCATTCTTATTCAAACTACTACAGGCTTAATGAATTTTTTTAAAGCTATTATGAACAAGAGAAGCA
GGCAGTGACCAGACAGATACCCTCTGTTGTGACTGAGCACTGGAGAACTTGAATACATGTTGACACATGT
CTCTCCTGTCCATGAGGAAGATAATCATTTAGAGTTTCACAACCAGAGGCACAGGAGAGCACTGCTAATG
TGTGCTCATTTGCTTTCAGACTCTTGCAAACTCCACAAATTGATAATTCAATAAATGGAAATTACTTGGG
AAGGGGCTGGATTGTCATGTGTTCAATACTTAGTGAAGATGAGCATTTTCAGTTTTTAAAAATTATTTTT
TTAGAACCCATTTTTAAAACTTTCAAATAATTGTAGATTCAAAGGAAGCTAGAAAAAAATATACAGGGGA
ACCTTGAACACTCTTCTACCAGTTTCCTCCAATGGTAGTGTCTTGCATAACTGTTTTAGAATGCCAAAGC
CAGGAACTCAGCAATGAACAATCGGCAAACTCGAATCCAATTTCACCAGTGTTTCATGCTCTCACCTTTC
TCTGTGTGACGCTCTACAAAATTCTATCACCTCTGTAGGCCCATGTGATATGTGCCATTGCCATTATGCA
GAGCATGGAGCTGAAGAGATGAAGCAGTGGTTAAGGTGGGATCGTTCTTCAGGGGATCTGAGTTAGGTTC
TCAGCGGTAATGTCAGGAGGCTTATAACTGCCCGTAACTCTCAGGCGATCCAATTCTATCTTCTGGCCTC
CTTGGGCCCCTGCATTCATGTCCATGTACACACACACACACACACACACACACACACACACACACACACA
CTATAGACTGATGGTATTCCCAGAGGTACCCTGTGCTGATTTTTGATAACTGTTCCAGGAGTCCCTCACT
TCTACCTTCTACCTCATCATACCCATGGCAACCACCAGTCTGGTCCCTGTCTCTGTTACAATAGCAGGTA
AGTGGAAGAAGCAACTTGTAACTTTTGGGGGCTGGCATTTCAGGTAGGGTAATTCCTTAGCAATTCACTG
GAGTTTTTGTGTGAACAGATAGGTCATCTCTCTCTATTGTTGAGCAGTACTCCATGGTGTGCCAGAGCTT
GTTTTACTACTCACACTAAAAGTCATTTCTCTTTTTCTGGAATCTGACTATTATAAATAAAGCAGGTATG
AATATTTATGTACTAGTTTCATGTAAACATGGGTTATTTCTCTGAGATAAATGGTAACTATTGGAATCAT
ACAGTTACATGATAAGAATATGATTATCTTTGTAAGAAACCACAAAAGATTTTTCCAGAGGGTCTGTACC
ATTTCCACACTTCCCAAAAGAGAATGATCTTGTTTCTCTGCAGCCTACCAGCACTGGTGGGAACATTATT
AATTTTTAAATACTCTTCAGGGATATGGTAATTGTTCACTTTGATCTCAACAATATTTAATGATGCTGAT
CACCCTTAATGTGGTAATTTATCATTTATACTCTTTTTTTGGAGAAATCTCCTGTTACATGTTTTGCCTG
TTTCTCGTTGGATTATTTGTTTTTCTGTTCTGTCTAACAAACGAAAATGTGTTCATAATGTTTGATTGCT
GTCATTTAATATCTGGGAAGATGAACTTTTTATTTGTATTTACTTTTTTAAAATGATCGAGGCACAGTAG
AGAGAGGCATTGTGGGTCAGGCCTGGAGTCCAGCCCTTGAGAGGTAGAGGTAGGAGGATCTTATAATGGG
GTCCCCTGTCTAAACACACACACACACACACACATACACATCACACACACACACACATCACACACACACA
CACACATACACACACACATACACACACATACACACCACACACACACACACCACACACCACACACACACAC
ACACACACACACACACATACACACACACACACACACACACACACACATAAAAACACACATCACACACATA
CACACACACACACATACACACACACACACACACACACACACACACACACACACACACACACACATACCAC
ACGGAAGAAGAGAGAGAGAGAGAGATTGCCTACTGAGTAATTGACCACATTGGGTTTCCTTGACTATTTT
ATGAGCATCGTTTCTATTCCAAACCACAGTATAAAATAGCACAACATCCATTTCGTCTGTATTCCTTCTG
GTGCTTTCAAATTCTCACAGTCTCAAATTCTCCATGAATACTTGTTTAGTTGGTTAAAAATCACTATAAG
ATAGGGGTGGCAAACTAGGTTTACTTTCTGGTTGGTTAAGTGTTTTAGCTTTCCCCAATTTTACCATTTC
CAAGCTGTCGTTTACTAACTAGCTCAGATAAACTAAATGTTGAGTCATTTTTATTTCTTATTAGATCTCT
TCTCTCATTAAATCTGGTAGCTTTGAATCTAATAATATAGTGCAGACTCTTCCCTTTTAAAAGATTTATT
TTATTTTATTTATATGTTTGAGTGTATCTGTCTGTCACCAGGTGTGTGCAAACACTTTTAAGGAGTCTAG
AAAAGGGTGTTACATTCTCTGGAGCTGGAGTTACAGGTAGTTATACACTCCCTGTAGTAGGGACTGGGAA
CGAACTCAGTTGCTACGAACAGAATCTAGACTTTTAACCTCTTGGTTGCCTCTCCATCCCATATTTTGGA
GTTAAGTTGAAATGGTTTCTCTGTGTAGCTCTAGTTGGCCTAGAACTCACCAATGTACAGCTGAGTGTCC
AGTCACTCAGAGATACCCCTGCCTCTGCCTTATAAGTGCTGGGGTTAAAAGCCTAGGCTAGGCCGGGTGG
TGGTGGTGCACGCCTTTAATCCCAGCACTTGGGAGGCAGAGGCAGGCAGATTTCTGAGTCCGAGGCCATC
CTTGTCTACAAAGTGAGTTCCAGGACAGCCAGGGCTATACAGAGAAACCCTATCTCGAAAAACCAAAATG
CCTAGGCTATTATTATACCTGATTGTGGATTCTTCTGGATTCAAAAATTTTCAAGCAAACACATATATTT
CTGTTTTCCATTTCTACTGAGTTATACTATGGGTTTTTTTTTTTTTTGTCTGCTTATTGATATAAAGAAT
GAATGCTCCCTACGATTCTAGTTATGTTTGACCCATCCAAATCCTTCTTCAAGAAATCTTGGATAAGCAA
GTTTCTCTAAACTCCACAATGCAAATTGGACTCTATGTTGGTACAAAATCCACCATGTGAAATGGTAGCT
TCACAATGTTTGTTTGTTTGTTTCTGAAATCCTTTTCAAACAAGTTTTGGTTGAAAAAGAAATATCGACT
TCTCTCTTTGCTTAGCTGGTAAATGTGGGGAGAGGGCCCTTCCGGGTCCAGCTGACGACTTATTGTCATT
TCCATGAAGATTTATGTTAGATCATCTTTATTTGTGTGTGGCTATGCGTGCCTGAGCACTCAGAGACCAG
ACTATTAGATCCCTCGGGAGCTGGAGTTACAGATGTTTGGAAGCTGCCTGGCATGGGTCTGGAAAGGTCA
TCTGCAAGTCTGTGCTCTTAACTGCTGAGCCATCTCTCCAGCTCCCAACTCTGTGTCATTTTAAAAGGCA
GAAGGGAGTTGATGGAGGTGTCAGGTGTTATTTTTGCATCAAACTTTCTTAAGAAGGCGTCCATCCCTCT
GGGCTGCCTCCCCGTTCTTGGCGTTCTGAGGCCAGTTCCCTCTGTTCACCTGAGAGTGTCAAAAAGGCCA
CCGAGAGTCTCCGGATAGTTTTGGCCATCACACCTTTCTGGAGAATTGGACACCGTGACTACCTTCTCCC
TTGTGAAACATTTTTGTTCTCTTAGATGACCTCATCTCTTCTCAGTTTCTCTCGAGTCTCTCAGATGTTC
TTGCTCGGTTTCTCTCACTCGCCACTCTCACAGGCATTTGCTGACCAGGGCTGTGGAAACCGAGGACCAG
ACACCAAATGAAGAAACCATACAGGTGGTTTTTAATTTTTTTCCTTTCTTTCTTTTCTAGAAGCCAAATG
TACCAGATGAAGGTTATCAACTGTGTTGGCACCTTTAGAGAACTGTCAGGGAGGACTCTGCTCCCAACCG
CTTTCCTTACCACATAAATATTTGTTTTTCTTCTTCCTCTACAAATGTTTCTCCACCCAAATTTCCTCAT
CTCATTTACAAGCTTAGATTAAGACACCCTCTAGTGATCCCATATTTATCTTATCTTTGTAAAAAGTCCT
GTCTCTAAATATGGTCCTATTCTGAGATAATGATGTGAGAGGTGGGAGAAGGGCCCTTAGCACAATCATT
TAATCATCTTTCCCGTTATTTATCATGGGCATATATCTCAATGCAGAGTTTTGGTCAGTATGCTTTGTCC
CTCCATGAACACGTCCTTGTTTTCTTACACTTGGTTTCTAGGATAACACTTTTGTCCTGGTTTACTCCAA
CTCTCCAGCCAGTCTTTCCTGTTCATTCTAGACTGTTCTTCCTCATCCTTGGCCCCGCTGAGATTTTCCA
GGTTCCATCCTGGACTCCTCAATCTACTGTTCCCTGAGAACTCACGAACAGGAGAATTTTGACTACCAGA
TTCTGAGGACTCTCAATGTCCGCCATGCACCAAGCCTTTCTTGGGCTTGGCACTGGCTTGTGTTCTATCT
CCTCAGGCATCTCCGTCTAACTGCTTAAGTCCCCCGCGAGCAAATGAACTCACCACTTGTTCCCTCTCTC
CATTTGCTCCAAACTCATTCCAGTTCCAATGTCTTTCATTATGAAAGATGACACCCCACACTTAAGTATT
CTCCCATCTCCAGTCTCCACACAGGTTAAAAAGCAAAACAAAACAAATCTCAGCAAGGTGGCACAAGCTT
TTAATCCCAGAACTCAGGAGGCAGACGCAGACAGATCTCTGTGAGTTCATGGCCACCCTGGTCTACACAG
TCAGTTCCAGGACAGCAAGGGCTATGTAGAGAGACCTTATCTCAAAAAAAAAAAAAAAAGAAAGGAAGGA
AGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGAAAGAAAAACAAAAGCCCACAACAACAGCAAC
AACAACAAACCCAAATCACAGCAAAACTAAAAACAAGCAATCACCCTGGATTCTAGTGCTCAGGCAATCT
TTTCCTCTCTGATGTCACCATAACTGGTCTCGGAGCCATTTCCTGTCTTCCATTAACCCTTTGCTCATGC
TTTCTCCCTGAGCCCGACTTTTCCCTCAGTCTTCTTTTTTTGCACCATTTTTTCCCCCAGTGTTTAGCTT
CCCACGGGAACCAGCCACTCAATGGAGGCTGCTCTTCTCCTTGGGCACAGCTTGTTTCAGGCCAGCCCTT
TAGGTTCGTAGCCTGGGATCCCTCTACCAAGGCCAGTGAACATATCAGGGAGGGAAGACAGGACACAGGA
CACATTAAACTTCCTGAATTCTAGTCCTAAGAATATCATTATATAGTTATTTAATTTTTAATAAGTAATT
TCTCCTCTGTTTCTTAACCACAAAATGGTAATAATAAAATGACTAATAATAGTAATTACTAAGTTCTTAC
TAGAGCAAAATTCTAAGCACTTAATATAAATTATCCCATTCAAACCTCACAACCACATATGACCTCACTG
TCAGCCACATTTGACAGGCAGGAGACTAAAGATTAAACTAGCTCAGCAGCTTGTTTAAGGCCCACACCTA
GAAGATGTGTCAATGTGGGGTATGGTATTCAAATATACAACAACCACCAAAACCAAAAAAGCATAATTCA
AAACAAGACAAAAGGCTGAAGTCCTTGGCAGAGGGCTCCTACAGAATCAGAGCGATCACAAGCAGACACA
GGAAAGTCAAGTGTAGTTGCTGGTTTCTTTCTTTTCTTTTAATTTTCTCCCTACAGAAATGGTTCAAGGC
TGAGAGCATACAGTGAAAAGTAAAAGCCCTTACACATTTGGTGAATTTTGTGCACGTGCACATCCTGTCT
ACAAAAGGGATAGCACCATGCCTCCCACTTTTTCCATAAGCTAAGCACATTAGAGACTGTTCTTTAGCCG
AGTTTCCCTTTTTAAAACGATTTCATAATATTCCATTACGGGTGTTTCATAGATAACCAGTCATCTATTT
TTAAACAAGTGTTTCTAAGATTTCCCACATTATTAAAAAAAATAGCAAGAAAAATATCCATGTCATTAAA
CCTTTACTAACATCTATCATTGTGTAGTAAAAGATAAACCGGTCTTGTTAGACAGCATATATCCTTGAGG
AAAGCTATGTATTTCAGCAGATTTTTTTGATCAGAAGGGGTGCATAACCATCAAGGGACAATATAGGCGT
ATATTCCCCTCTCCTTAGTAGCATCGGAAATTCTTGTTTGCTTTTGTTTGTTTGTTTGGTTGGTTGGTTG
GGTTTTTTTGTTTGTTTGTTTGTTTGTTTTTGTTGTCTTTTTGTTTTTTTCCGAGACAGGGTTTCTCTGT
ATAGGCCCGGCTGTCTTGGAACTCACTTTGTAAATCAGGCTGGCCTCGAACTCAGAAATCCACCTGCCTC
TGCCTCCCAAGTGTTAGGATTAAAGGCATACACCACCACGCCCGGCTACTTGCTTGCTTTTGAAACAAGA
ACATTTATTAACATTTTCATTTTTTAAAAAATGATAATTTACTGTTATGATTTGCATCACTTTTATCTCT
AAGATTCAACATTGTTTGTTGCTATTTATTGCTTGTTACTGGCTTGGGGCATCAAAACAAAGAATATCTT
AAACAAGCACCATCTAGACAGCGGCCTGTGACCCAAAGCAGCGCCAGCACAATTCAGCACTATGGCTTCT
ACAGCTCCGTGGAAACTCTAAGGTATGACACTTTTTCATATACATTTATTTATATGAAAATTTAAAATTA
TGCTCGAGAGGAAAGAAATTGTTTTAACTTGGAAATTAATCTGTAAACTTTTGAAATAAAAGCAACAAAG
GGGCTTCTGAAACCAGTTGGCACTGGGTAGAAGAGAGAATCCCAAAGTGCAGGAATAAATAACAAAGGGC
AGAAAAACAACTGTGCCTCGAACCGACCATGCCTCCAGCCGCCCAAGCAAAAGAAGGGCAGGCATAGCTG
CTTCTAGGAATCCTGTGCCCTGAGAACCTGCCACAGCAAAGAGGACAAAAAGGATTTCACTTCCATCCTC
AGGAGCCTGGGAGCCTTGCTCAGCTATTAATTAATACAATGATACTGCCTGTCCGGATACCACTGTGAAG
TGTGACATTAATGAAATAATATTAGCGAAGTGCACAACATGCCAGGCATCCCACAGACACTGGGTAACTG
AGTTACTCCCATTGCCTATTTGTGTCTTAGTTTGTTGTTATTGTTGCTGTTGTTTTCTTGAATACAGTCA
CCCCTCAGAATCTGAACAAATTCCAAAATCTTGGGTACTCACGTTCCCAGTATAAAGTGAGGTCATAATT
TGCATGTACTTTAAATTATCCCTAGATTACATACAATGCATACATAATTACATATACAATGTAAATGAAT
AACAACAAGAGCCCTGTGCCTGTTCAGTATAGGCACAGCTATAGGCGAGCTGCATTTCTATCTTAAATGG
GAAGTTGCTCACAGGTGGCCCGCTGAGTCCATGGATGTGGAACTTGTGCATTGAAAGAGCTGTCTGTGCC
TTTTCTCTGCATTTTCTTTGACCTTTCTTCTTTTGCCTTCTCTATTTGACTTCTTCACTTTTATATCAAA
CTTTAAAAAAAAAGTGCCACCTCTCTTTTCTCATACTTATACAGATATTTAAAAACCCAATCCAGACTTA
AAAATCAACGACTGTAGATATTTAATATCTGAAACACAAATCAATCACCTTTGGGGGGGGAAACTATCAG
CTGCTTTCTTTTGGTACCTCAGATAAGTCTTACCCCCATGAAGGAAAAAAAAAGTCATTGTAGGAAAAAA
AAGGGAAAGGAAGAAAGGAAGGGAGGGAGGGAGAGAGGGAGAGAGGGAGAGAGGGAGAGAGGGAGAGAGG
GAGAGAGGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGCTTCCTGATGTGGGAGCCAGTTACCATTTTC
ACATAAATAGCACCTTCCCTTCTGCGCTCTCACTTTGGGTCATTAAATAGACACATTGCACACGAGAGCT
GTCTAGGGCGGCTGGCTCGAAGGACAGAAATGAGAGTGTGGTCTCCAGTCTCAGCCTCCCGCTGAGGTCA
TAATTCACAAGTCATACTGCAAATAGTAGAAGCGACCACTTACCATCTGGGGTCCATCGTGGGTGCTTCC
GTAAGTTCTGGAACACGTCTACAGGAGTCTGGTTGTTCAAGTCCGTGCTGCCTACAGGAGCCACTCTTAC
GCGTCTGCTTGCTCCTCTTTCTTCCTCAGCAA

</dna_sequence>
        <protein_sequence>>NP_062261.3 T-lymphocyte activation antigen CD86 precursor [Mus musculus]
MDPRCTMGLAILIFVTVLLISDAVSVETQAYFNGTAYLPCPFTKAQNISLSELVVFWQDQQKLVLYEHYL
GTEKLDSVNAKYLGRTSFDRNNWTLRLHNVQIKDMGSYDCFIQKKPPTGSIILQQTLTELSVIANFSEPE
IKLAQNVTGNSGINLTCTSKQGHPKPKKMYFLITNSTNEYGDNMQISQDNVTELFSISNSLSLSFPDGVW
HMTVVCVLETESMKISSKPLNFTQEFPSPQTYWKEITASVTVALLLVMLLIIVCHKKPNQPSRPSNTASK
LERDSNADRETINLKELEPQIASAKPNAE

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>A plasmid containing murine B7-2 (Cd86) cDNA was transfected into the immunogenic mouse mastocytoma P815 of DBA/2 origin. In contrast to the lethal growth of the wild-type (wt) P815 tumor, B7-2-positive (B7-2+) P815 cells inoculated into syngeneic mice regressed, and immunization of mice with such tumor cells protected them against the challenge of wt P815 tumor [Ref964:Yang et al., 1995].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1351">
        <gene_name>CEA</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>1048</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>612407802</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AC008999</gene_refseq>
        <protein_refseq>NP_001278413</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>19</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>41708584</gene_start>
        <gene_end>41730432</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>transcript variant 1</protein_name>
        <protein_pi>5.44</protein_pi>
        <protein_weight>71932.24</protein_weight>
        <protein_length>702</protein_length>
        <protein_note>Also known as CEA; CD66e</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000019.10:41708584-41730432 Homo sapiens chromosome 19, GRCh38.p12 Primary Assembly
TGATGCTGAGAAGTACTCCTGCCCTAGGAAGAGACTCAGGGCAGAGGGAGGAAGGACAGCAGACCAGACA
GTCACAGCAGCCTTGACAAAACGTTCCTGGAACTCAAGCTCTTCTCCACAGAGGAGGACAGAGCAGACAG
CAGAGACCATGGAGTCTCCCTCGGCCCCTCCCCACAGATGGTGCATCCCCTGGCAGAGGCTCCTGCTCAC
AGGTGAAGGGAGGACAACCTGGGAGAGGGTGGGAGGAGGGAGCTGGGGTCTCCTGGGTAGGACAGGGCTG
TGAGACGGACAGAGGGCTCCTGTTGGAGCCTGAATAGGGAAGAGGACATCAGAGAGGGACAGGAGTCACA
CCAGAAAAATCAAATTGAACTGGAATTGGAAAGGGGCAGGAAAACCTCAAGAGTTCTATTTTCCTAGTTA
ATTGTCACTGGCCACTACGTTTTTAAAAATCATAATAACTGCATCAGATGACACTTTAAATAAAAACATA
ACCAGGGCATGAAACACTGTCCTCATCCGCCTACCGCGGACATTGGAAAATAAGCCCCAGGCTGTGGAGG
GCCCTGGGAACCCTCATGAACTCATCCACAGGAATCTGCAGCCTGTCCCAGGCACTGGGGTGCAACCAAG
ATCACACAAATCCCTGCCCTCATGAAGCTCATGCTCTCATGGGGAGGAAGACAGACATACAAAGAGATCT
AGAATGTGAGGTCAGGTGTTGACAAGAGCCCTGGAGGGAATAGAGCAGGGAAAGGTCAGAAAAGGAAGAC
CCAGGGTCTCTAGAGGAGGTGTCAGGGAAGGGATCTCCCAAGAATGCCCTGATGTGAGCAGGACCTGAAG
GCAATGGGGAGGGAGCCGTGAAGACCCCTGGAAAAGCAGATTCCACACAGGGAAATGCCAAGGTCAGAGG
TGCTAAGGAAATAGGAGACACACTGCTGACCTTGACCTAGTAGGACACACACACACACACACACACACAC
ACACTCACTCACTCCAGGGCTGGGGGATGAAGAGACCTGCTCAGGACCCAGGACCCCATTTTTCCACCCT
AATGCATAGGTCCCAATATTGACCGATGCTCTCTGCTCTCTCCTAGCCTCACTTCTAACCTTCTGGAACC
CGCCCACCACTGCCAAGCTCACTATTGAATCCACGCCGTTCAATGTCGCAGAGGGGAAGGAGGTGCTTCT
ACTTGTCCACAATCTGCCCCAGCATCTTTTTGGCTACAGCTGGTACAAAGGTGAAAGAGTGGATGGCAAC
CGTCAAATTATAGGATATGTAATAGGAACTCAACAAGCTACCCCAGGGCCCGCATACAGTGGTCGAGAGA
TAATATACCCCAATGCATCCCTGCTGATCCAGAACATCATCCAGAATGACACAGGATTCTACACCCTACA
CGTCATAAAGTCAGATCTTGTGAATGAAGAAGCAACTGGCCAGTTCCGGGTATACCGTGAGTGATTCCCC
CATGACCTCTGGGTGTTGGGGGTCAGTTCTACTTCCCACACACAGGATTATCAGGCCTGGGCTGTGCCTG
TGGCCCCCTCTGCATTACGCACCATGTTAGGGTTTGGGCATTTAGTGCAGGATACACACAGAAGAGACAA
ACTTCAACAGATCAGAATTCCTTTCCGGCATCCAGACCCTGCAGACACTCACTGCAGAGGAAGGACAGTC
TGATGTGGGGGACTTAGCAGGGGGAGGTCAGTCTCAGCCAAGCACCCCGTGCCCTCCCCGTAAACCTGAC
CCTGAGAAAGACCCTGGAGAACTGCATCAGAGCCTGGCCTGAGGGACCCCTGGGATATTCACAGAGAAGC
TCAGCCCCAGGGCTCCTGGTTCCAGGTGACTCAGGGGAGCCTGTGCCAGGGCTGTGTTGTGGCCTCCTGG
GCAAGGCTAACTGGAAGCAAGGACTTAGCAGCTGTCCAAGGGCTGTGGCTCCTGGAGCTGGATTCTGGAT
GCAGAATCGGACTTTCTGGCCACACTTGTTCCCTGTCCCCAGAGTCTCATTTGGACAAGGACAGAGCCTT
GTCCTTTACTTGAGACTCAATGTGGGGAGGATAGATAGACAAGGTTATTAGGGTGTCAGTCCATTGCCCT
GGGGACATAGGTGACTCCATGGGAAGCTCAGTGTCCCCAGGAAGAGGAACAGAGGAGAGAAGATGCTCCC
GGCAGCTCCTTGTCCACCAGGGATCAGGCCCAGGGCCTTCTCTCTTGGAGGCAAATAAACATAAATGATG
TTCATTTGAGCAGCTCCTCTGTGCAGAGCTGAGATCAAGTAATTGTAAATATTTTGAGGTTAATTCACAA
ACAACCTCACAGCCAAATAGCACTTATCCTACTTATTGAAAGGAAATTGAGGCACAGGGAGACAGTCACT
AACAAGGGTCACACAGGCCATAGGTGTCAGATTGAAGTCACATGAGGTCTGTCTGTAGCCACAGCCCCCT
CCTCTCCTCAACTGGGGGTGGGTGGGGCTGTTTGTTGTTAGGCATCTGCATCTGAGACCAGTCATGGGCT
TGCGTTCTTTTGTCTTGGGCATCCACAGCTCAGAAGCGGAGATTCTGGTCTGGAGAGTGATAAGTAAATG
GAGAAATAATCAGTTTTACTCTAGAACTAGATCACCTCAACAGTCAGGGTCAGTGCCGGGATTGTCCAGG
CCTCTCCCTGAGATCCACAGCCCCCTCACATGACCTCAAATCCTGTGTTTCCCGATGTGTCAGTGTCACT
CCCACGGAAGGATAAAGGAAAGGACTTCGCTTTCTCTCCCCACTCACACCCTGTGCCAACAGAGGCCCAA
AGTGAGACACACGCTTGCTCAGTAGCTCTCTCATGAAGGGGGGAATGAGTGAAGGAATGATCCATAACCT
CTATAGAGACTGGATCCTGGATGCAGAATCCTGGGAGGTTCTGACCACACCTGTTCCGTGTCCATCAGGG
GCTGAGATCCATGTACCATTCCTCTGACCCCCTGTCCCGAAAGCCACCCTATCTCATGTGACTCTGGGGT
TCCTTGGCCATGGGAGGGTTTTCAAGGCTCCCTGGTCCTGGTCGGGACAGCCAAGGGACTCCTAGTCCTG
GGGTCTCCGAGGTCACTATACCCCGCATGGCTCATTGCCATGGGCATTTCTGACTTTCTTCTATTCCTCC
ATGTTCTTCGTCTTCCTCCCTCTTCATTCCAGCTGAGATGCCCATCCCTGAACATCTTCCTCCACTCTTA
GGCCTTCCCCAGACACTCCCTTGAACAAGGCTGGCTGTCCTGTTTTCTTGCCGCTCACACTGTGTCCTGG
CCCACTTCCCAGGCAATAGGGAAGGCACAGAAATCACAGGCAATAGGGAAGGCACAGATGGAGCCCCTGC
CAGGCTCCATCACAAGCCAATGTCAACAGGTCACCAGGAGAATGAGCTTCCGCTGTGTTCCTGCCCAGGG
CTCTTTACTTCCATGAGGCCAACACACGGAACAGGCAGCAGGACGGGAATGAGCGACTCCTCCATCCACT
CCCTACACTGACTCACCAGGGGGTCAGAGGCAGAAGGACAGGTCTGCAGTCCCCAAAGCCCGCATGCTTA
TTTCACTCACTTCACTACCCACTCCATCTTCATCCTGGTGTGGGGCTCACATCCTCCAGTGGATCCTGGG
ACCTCCCCCAGGTGGAGCTGGCCAGGCAGGTGCTGTCTGATAGGTTTGCTGCCCATTCCACATACACCTG
TGTCCTCATGATGATGCCATTGTCATAAGGTGGAGTCCCTTGGACTGAGAAGTGAACCAGCCACTGGCGT
CTCACTTAGACTCTACCCAGTTACAAAAACTTAAACTCTAGTTGTGTTTTCTGAGGTTGATAGGAGAGGA
AGAAAACCTTTCACATGCCTGTTTTGAGGCTTCTCCTCTTTTTGCCTAACTCTGCACAGGAACTAGGGGC
AGGGAGCGCTTTCTAAATTTACTAACATCACACACATTGCTTCTCCTAACTTGGCATCATTTCTCCCTTT
ATGTAATTGACACACCTAAGAGTTCCTCTCTGACCGGTTCTGTCCTCTTAACAGGTCTCACATCCCTCTC
TCTGTTCAGGGAGTCACTGATTTCAAACCACTTTCAGCATCTTCCTTTGAGCATAATGTGATCACTTTGG
AATTCAGAGCAGACCTAAACCTTAGCATAATATTAAAAGAAGTACTACTTCCAGCAATTGATCTTAGATC
TTTAGGCCATTGATAAGAATTTCCACTTATGGAAAAAATTTAATGTTTCCCCCAAATGTCTTTCACTTTT
TTAACTATAGTCAGAAAATAACATGAGATCTAAACTCCTGACAAATTTTTAAGGGCAAATTATAGTACTA
CAGATTGAGTATCCCAAATCCTAAAATCCAAAATCTGAAATGCTCCAAAATCCAACATTTTTTGACCACT
GACATGATTCTCAAAAGAAATGCTCACTGAAGGCCGGGCACGGTGGCTCATGCCTGTAATCCCAGCACTT
CGGGAGGCCAAGGCGGGAAGATCACAAAGTCAAGAGATCAAGACCATCCTGGCCAACATGGTGAAACCCC
GTCTCTACTAAAAATACAAAAATTAGCTGGGCGTGGTGGCATGCACCTACAGTCTCAGCTACTTTGGAGG
CTGAGGCAGGAGAATCGCTTGAACCCGGGAGGTGGAGGTTGCAGTGAGCTGAGATCGTGCCACTGCACTC
CAGCCTGGCAACAGAGCGAGACTCCATCTCAAAAAAAAGAAAAAGAAAGAAAAGAAAAGAAAAAAGAAAG
GCTCACTGGAGCACTTTGGATTCCGTATTTTCAGATTTGGGGTGCTAAACTGGTAAGTATATTGCAAATA
TTCAAAACTCAAAAACAGTCAGAAATCCAAAACACTTTTAGTCCTAAGCCTTACACATAAGACATACTCA
ATCTGTATGAACTATAGGCACCAAGCTGAACAGCAGATCCCTAGAACCTCCTCATCCTGCATAACTGAAA
CTGCAGACCCATGAACAACTCTCCATTCCCCCAGTTCCCAGGCTTTGACAACCACCATTCTACTCTCTGA
TTCCACAAGTGTGACTACTCTAGGGACTTCATATAAGTGGAATCCTACAGTATCTGCCCTGTGAGTGGCT
TATTTCATTTAGCATAATGTCCAATGGGAGAAAATAATTGCAAAACTTCTTCTCAAAGTTCTGTCTCATA
ACTGTCAAACACACATGGTCCTTGAGGGCCAGATTTCCAGCAGTTCATGCTCCCCCTTTTCCACCAGTCA
GTTCTGCATTTGCAAATGTCCACATGTATTTATGGAGAGATCCACAGCATCCTCGCCTGCCCTCTGCAAG
GGGAGAAGGGACATTAAAGACCAAAGACAGGCCGGGTGCAGTGGCTCATGCTTGTAATCCCAGCACTTTG
GGAGGCCAAGGTGGGCAGAACACCTGAGGTCAGAAGTTCAAGACCAGCCTGACCAATATGGTGAAACCCC
ATCTCTACTAAAAATACAAAATTTAGCTGGGTGTGGTGGTGGGCGCCTGTAGTCCCAGCTACTCGGGAGG
CTGAGACAGGAGAATCGCTTGAACCCGGGAGGCAGAGGTTGCCATGAGCCGAGATCGTGCCTGGCCAACA
CAGCAAGACTCCATCTCAAAAAACAAACAAACAAACAAAGACCAAAGACAAAGAACATACATATGGTTCT
GCTGTTAAATCCGGGCAGCTCCTGCCTGTCACCTGAAGTTCTAGATCATTCCCTGGACTCCACTCTATCT
TTAGGGGTCTCTGGCTCAAGTCAGTCATCATCAAACACCTGGGAAAAACTGCCCCACCTTGTGCCTCCAC
TGCCTAACGACTGAGCTGACCTCCAGGCTTGCCTCTGGTGTCCCCTGTGTTATTTCTACTGAAACATCCA
GTCCCAGGCCAGGCTGCACAATATGTACAGGGTTTAAGGACAATGGGAAGACCCATCACTATCCATTTCT
AGGATGTCCTTGCAAAGGGAAACCACAGAAAAAATATACCTAGGGAAACAAAGTAGGACTGAAGGTGGAA
GGGACCCAGCACTTGAATGTTCCAGGTGAGGACCCTACAGTGGGCCAAGTAGTCAACTGGTCAGGGAGGG
ACCAGGAGAGGCACCAGGAGCTGTGACCTCCCCCCCAGTCCTGTGTCTGTTCACAGCCCAATGCTGCTGC
TTAATTCACACTTGAGAAAGTCTGTGCTTCCCCCACACCGAGCAGGCAGCCTCGCAGTCTCTGAGATCTC
AGATCATCGTGCATCTGTCTTGTGACACATGCACCCACCGTGGGTTTTTAAGGGCTCAGGTGGGCTGAGA
GGTGGAAGGTGCCAACTCTGATTGAAAGATGCCTGTGAGGAATCAAAGGTGCCACACAGGGCAATCTTCT
CTCTGTTATCTGCACAGCGGAGCTGCCCAAGCCCTCCATCTCCAGCAACAACTCCAAACCCGTGGAGGAC
AAGGATGCTGTGGCCTTCACCTGTGAACCTGAGACTCAGGACGCAACCTACCTGTGGTGGGTAAACAATC
AGAGCCTCCCGGTCAGTCCCAGGCTGCAGCTGTCCAATGGCAACAGGACCCTCACTCTATTCAATGTCAC
AAGAAATGACACAGCAAGCTACAAATGTGAAACCCAGAACCCAGTGAGTGCCAGGCGCAGTGATTCAGTC
ATCCTGAATGTCCTCTGTGAGTATATCTGCTCCTCTCTGGCCCAGGCTGCCAGCCCAAATCCACAGGGCC
AGAGGCAGGATTTCTCAGTCCCTCTCAGGTTCAAGTACACAGACCCTCAACCCTGGACATCCAGACTGTC
TGTGACTTTCTGCCCCAGAAAAACCTGGGCAGACCAAGTCTTGACCAAGAATAGGAGGGGAGGGGCTGCT
TCTGTCCTGGGAGGCTCAGGGTCCACACCCTATGATGGGAGAAACAGGTGAATATCTCAGACTCAGGCTC
AGTAGATACAAGAGGGGTTTGGCTGAGACTTTAGGATTGTGATTCAGCTTAGAGGGACACTGTGGTCCTT
CCATAGACCAGGAACTTCCACTTCCCTCTGACAATATCACCTGTGGCTTTATTTTGTTTGCTCCAGATGG
CCCGGATGCCCCCACCATTTCCCCTCTAAACACATCTTACAGATCAGGGGAAAATCTGAACCTCTCCTGC
CACGCAGCCTCTAACCCACCTGCACAGTACTCTTGGTTTGTCAATGGGACTTTCCAGCAATCCACCCAAG
AGCTCTTTATCCCCAACATCACTGTGAATAATAGTGGATCCTATACGTGCCAAGCCCATAACTCAGACAC
TGGCCTCAATAGGACCACAGTCACGACGATCACAGTCTATGGTAAGTGGATCCACGAAGCACTGACATCA
TGTTTTGAGGTGGAGTCTGTCTGGTTTTCAAACAAGAGCCAGGAAGACATTTTCTATCCCAGCCTGTGTC
CAGTGGGCACAAGCAAATCCCAGATTCTCCCACTGAACCTCCCCAATATGTCTCTACAGACTCTTTTCTT
CTTGTTCTGATTTCTCATGGCGGGCCCCAGGTCCAGCTTGGAATGTGGGGAGGAGGCTCCCTCAGCCCCA
CAGCCCTGTGTAGTGGAGGAAGCTTCACAGAGCGGGAAGGAGCAAGGGTTCTCAAGGTCAAGTTGCTTCT
CTCTGTCACCAATGTGTCCCTTTCTGTCACCTCTTTGTGTTCTTTTGCCTACTCCATGAGCTACAAGCAA
CATTCAAGGCTTTGAAACAAGCTCATACTTTTTTCCCAAATGAGAGAAGGAAGCCCCTTGGGTGAGGGAG
ACACAGCTCAGACTGCTCCCTGCTCTGCTCTGGGCTCCCCTGGGTGACTGGCCTTGCCTGACTCCACCTA
GGTGGGAACGAGGTGTGTGGAGAAGGAGCCCGGGTGGTCTGTCCTGAATTCGGCTAAATCAAGCTGCCAA
TCAACACCAAAGCTTCCCTTCGTCCCAGTCAGGCTGCAGGAAAATGGAAAGAGAGGGAGCCTCAGGGCAG
ACTCCTGAGCTGCGTCCTGGCTCTGATGTCACCAGCTATATGAGGCTGTGGGCACAGCACATGGGACACA
GCACAGGGGACAGCAAGTGACCCACACTTGGAGAAATCAGGAGATTCACCACAGGGGCTCTGCACGGCAG
GGAATGGCAGTGTCAAAAATCGTGTGTTTATACAGATGGTAACAGTACATATCTAACACAAACTTACCAT
CTTAACTTTTCTACACATGCAGTTCAGTGGTATTAAATATATTCCCCTTGTTCTGCTTCCATCACCACCA
TCTACCCACAGGACTCTTTTCTTCCTCCCAAAATGAAACTCTGTTCCCATCAAACTCCTGGGCAGAGCTG
CCCCATCTATGGCCCACAGTCTGATCCCTGACTTGTCACCTCTAGACATGCTCCTAGTCTCCTGCACTAT
TTCTGCTCAAACATCCATCTCCATCATCACCTATCTCTAGGATGTCCTTAAATAGCAAAGCCTCAGAGCA
AACACAACTTGGCTGGGTGGTGTGGGACTGTGCAGCTGGAAGAAACGCAGCTCCTTCAAATTCCAGGTGA
GGACCCCAATGGGCCAGGCAGCCAGCCAGTCAGGAAAGGACCAGAAGTGCTGGGGGCTGTGACCCCCAGC
CCTGTGTCTGTCCACAACCCAATGCTACTGCCCAATTCACACTTGAGAAAGTCTGTGCTTCTCCCACACA
AAACAGCCAGCCTCATGGTCTCTGAGCCCTCAGATCATTGTGCATCTGTCTTGTGACGCACACACACCTG
CCATGAGCTTTTAAGGACTCAGTTGGGCTGAGAGGTGGGAGATGCCAACTCTGATTGATAGATGCCCGTG
GAGGAATCACAGGTGCCACACAGGGCAATCTTCTCTCTGTTATCTGCACAGCAGAGCCACCCAAACCCTT
CATCACCAGCAACAACTCCAACCCCGTGGAGGATGAGGATGCTGTAGCCTTAACCTGTGAACCTGAGATT
CAGAACACAACCTACCTGTGGTGGGTAAATAATCAGAGCCTCCCGGTCAGTCCCAGGCTGCAGCTGTCCA
ATGACAACAGGACCCTCACTCTACTCAGTGTCACAAGGAATGATGTAGGACCCTATGAGTGTGGAATCCA
GAACGAATTAAGTGTTGACCACAGCGACCCAGTCATCCTGAATGTCCTCTGTGAGTATCTTCTGTTCCTC
TGTGGCTCAGGCTGCCAGCCCAAATCCACATAGCCAAAGTCCAGGCCTCTCAGTCCCTCTCAGGCCCAAG
GACAGAGACTTTTACCCCTGGACATCCAGGCTGGCCCTACCCCCAGCAAATCCATGCAGGCCCAGTCCTG
ACCAAGAATAGGAGGGGAGGGTCTGCTCCTGTCCTGTAACACTCGGGATCCACAGCTAGTGATGGGAGAA
ACAGATGAATGTCTCAGACTCTGGCTAATTGGATACAGTAGGGGTTTGGTTAGGACTTCAGGATTGTGAC
TTGGCTCAGGGGGACACTGTTGCCCTTTCACAGACCAGGAGCTTCCCCTTTGCTCTGATGACATTCACCT
GTGGCCCTATTCTCTTTGCTCCAGATGGCCCAGACGACCCCACCATTTCCCCCTCATACACCTATTACCG
TCCAGGGGTGAACCTCAGCCTCTCCTGCCATGCAGCCTCTAACCCACCTGCACAGTATTCTTGGCTGATT
GATGGGAACATCCAGCAACACACACAAGAGCTCTTTATCTCCAACATCACTGAGAAGAACAGCGGACTCT
ATACCTGCCAGGCCAATAACTCAGCCAGTGGCCACAGCAGGACTACAGTCAAGACAATCACAGTCTCTGG
TAAGTGGATCCCTGGACCGTTAGCAATATGTTCTGGAGCGGAATCTGTCTGGTTTTCAGAAAAGAGCCAG
GAAGAAATTTTCTTTCCTAGTATGCATCCAATGGGCACAAGCAATCCCAAATTCAATCCTGAGCACTCCC
AATTTGTCTCTACAAACACTCTTCCCCTTGTTTTTCTGATTTCTCATGGCTGACCTTGTGTCCACCCTGA
GAAATGTGGGGAGGGGTCTTCATCAGCCCTGAGCCCTATGTAGTGGAAGGGGCTTCACAGAGGGGGAAGC
AAGAAGGGTCCTCAAGGTCAAGTTGCTCCTCTCTGTCACCAATATGTCCCTTTCTGACACCACTTTGTGT
TCTTTTACCTAATCCATGAGCTACAAGGAACAACTGAGGCTTTGAAACAAGCTCACACTTTTTCCCCAAA
TGAGAGGAGGATGCCCCTTGGATGAGGGAGGAGCAGCTCAGACTCTGCTCCCGGCTCCGCTCCGGGCTCC
CCCAGTGACTGGCCCTGCCCTGATTTCACCTGGGGTGGGATCCGGGCATGTGGAGAAGGTGCTCAGGTGG
CCTGTCCTGAATCTGGCTAAGTCAAGATGCCAGATGAAGCCAAGCCTTCCCAGGGTCAGGCTACAGGGAA
ATAAGAAGAGAGGGAGCCTCGGGGCAGACTCCTGAGCTGTGTCCTGGAGTCTGAAGTCACCGGCTGTATG
AGATTGTGGGCACAGCACATGGGACACAGCACAGAAGACAGTCAGTGGCACACACTTGGAGACACACAGA
GATTCACCCATGGGGACTCAACATGGCAGGGAAGGGGCAGTGCCAAAAAGTGTGTGTTTATAGACAGGGT
AAGAATACCAGCCACTATATATATCTAACATAAGACACCATTTTAACCTTTCTATGTATGCAGTTTAGTA
GCATTAAATATTTTCCCATTATTCTGCTACCATCATCACCATCCACCCACAGAACTCTTTTCTTCTTCCT
AAAATGAAACTCTGTTCCCATCAAACTCTTGGGTAGAGCTGCCCACCTGTGGCCCACAGCCTGACCCCTG
AACTCACCTCTAGACTTGCTCCTGGTCTCCTGAGCTATTTCTGCTTAAACACCCATCCCCGTCATCACCC
ATCTCCAGGATAGCCTTGAAACAAAAGGCTCAGAGAAAACACCCCACGGTTGGGTGGTGTGGGACCGTGC
AGCTGAACGGAATTCAGCACCCACAAGTCCCCAGGTTGGCCAGGCCGTCAGCCATCAGGGAAGAACCAAA
GGAGGTGCTGGGGGCTGTGACTCCCAGTCCTGGGTCTGTCCACAACCCAACGCTGCTGCCCAATTCACAC
TTGAGAAAGTCTGTGCTTCCCCCACACAAAGCAGCCGGCCTTACAGTCTCTGAGCCCTCAGATCATCGTA
CATCTGTCTTGTGATACACACACCTGCCATGGGCTTTTAAGGACTCGGGTGGGCTGAAGGGTGGGAGTTG
CCAACTCTGATTGAAAGATGCCTGTGAGGAATCAAAAGTGCCACACAGGGCAATCTTCTCTCTGTTATCT
GCACAGCGGAGCTGCCCAAGCCCTCCATCTCCAGCAACAACTCCAAACCCGTGGAGGACAAGGATGCTGT
GGCCTTCACCTGTGAACCTGAGGCTCAGAACACAACCTACCTGTGGTGGGTAAATGGTCAGAGCCTCCCA
GTCAGTCCCAGGCTGCAGCTGTCCAATGGCAACAGGACCCTCACTCTATTCAATGTCACAAGAAATGACG
CAAGAGCCTATGTATGTGGAATCCAGAACTCAGTGAGTGCAAACCGCAGTGACCCAGTCACCCTGGATGT
CCTCTGTGAGTATCTTCTGTTCCTCTGTGGCCCTGGTTTCCAACCCAAATCCACACAGCCAGAGGCCAGG
ACTCTCAGTTCTCCTCAGGTCCAAAGAGGCAGACTCCCACCCCTGGACACCCAGGCTGGCCATAACTTCC
TGTCCCAGGAAAATTTGGGCAACCTCAGCCTGGACCAAGAATAGGAGGGGAGAGGCTGCTCCTGTCCTAG
GAGGCTCAGAGTCCACAGCCTATGATGGGAGAAACAGATGAACGTCTCAGACCCAGACTCAGTGGACATG
AGGGTTATGGTTTGGACTTTTTTTTTTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTTTCGCCCAGGC
TGGACTGCAGTGGTGTGATCTCGGCTCACTGCAAGCTCCGCCTCCTAGGTTCACACCATTCTCCTGCCTC
AGCCTCCCGAGTAACTGGGATTACACACACGTGCCGCCATGCCCAGCTAATGTTTTTTGTATTTTTAGTA
GAGACGGGGTTTCACCATGTTGGTCAGGCTGGTCTCGAACTCCTGATCTGCCCGCCTCGGCCTCCCAAAG
TGCTGGGATTACAGGCGTGAGCCACCGCACCCGGCCGATTTGGACTTTTTAACACAGGATTGGGACAGGA
TTCAGAGGGACACTGTGGCCCTTCTACAATCAGGAGCTTCCCCTTTCCTCTGATGACATCACCTGTGGCT
TTGTTCTCTTTGTTCCAGATGGGCCGGACACCCCCATCATTTCCCCCCCAGACTCGTCTTACCTTTCGGG
AGCGAACCTCAACCTCTCCTGCCACTCGGCCTCTAACCCATCCCCGCAGTATTCTTGGCGTATCAATGGG
ATACCGCAGCAACACACACAAGTTCTCTTTATCGCCAAAATCACGCCAAATAATAACGGGACCTATGCCT
GTTTTGTCTCTAACTTGGCTACTGGCCGCAATAATTCCATAGTCAAGAGCATCACAGTCTCTGGTAAGTG
GCTCCCTGGAGCATCAGCATCATATTCTGGGGTGGAGTCTATCTGGTTCTCACCAAAGAGCCAAGAAGAC
ATTTTCTTTCCCAGTCTGTGTTCCATGGGCACAAGGAAATCCCAAATTCTATCCTGAGCCCCCTCACTCC
ATCTCGGCCAACTCTCTCCTCCCCGGCTTCTCTGATATCTCACGGCTGACCTCGGGTCCAGCCTGGAATG
TGGGGAGGGGCCTCCCTTAGCCCCAGAAGGCCCCCAATAGTGAAAGGGACTTCATAGTCCAGAAGAAAGA
AGGGTCCTTAAGGTCGAGTTGCTCCTCTCTATCACCAATATGTCCCTTTCTGTCACCTCTTTGTGTTTTT
TCACCTACTCTGTGAGCTACAAGGAACAAGGAGGCTTTGAAACCAGCCCACACTTTTTCCCCAAATGAGA
GGAGGAAGCCCCTTGGATGAGGCAGGAGCAGCTCAGACTCTGCTCCCTGCTCTGCGCCCGGCTCACCCGG
TGACTGGCTCTGCCCTGGCTCCACTTGGGGTGGGACCGGGGCATGTGGAGAAGGTGTCCAGGTGGCCTGT
TTTGAATCTGGGTAAATCAAGCTGCCAATCCACAGCAGAGCCTCCCTTGGGTCAGGTTGCAGGGAAATGG
GAAAAGAGGGAGCCTCGGGACAGACTCCTGAGCTGTGTCCTGGCTCTGAAGTCACTGGCTGTATGAGGCT
GTGGACACAGCACATAGGACACAGCAGAGGAAAGTGAGTGACACACACTTGGAGAAATAGGGAGATTCAG
CCATAGGGGCTCTGCATGGGAGGGAACAGGCAGTGCCAAAAAGTGTGTGTTTATAGAGAGGGTAAGACTA
TCAGCCACTATATATATCTAACATAAAACTTACCATTAACCATTTCTAAGTGTACAATTAAGTGAAACAG
CATAAATATCAATCAAGTATATTGCCCGGTGTGGTGGCTCATCCCTGTAATCCCAGCACTTTGGGAGGCC
AAGGCGAGTGGATCACCTGAGGTCAGGAGTTCAAGATACAGAAAAAAAAAAATAGCTAGGCATGGTGGTG
GGTGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTCGAACCTGGGCGGTGTAGTTTG
CAGTGAGCCGAGATTGAGCCACTGCACTCCAGCCTGGGTGACAGAGTGAGACTACATCACAAAAAAAAAA
AAAAAAAGGAAAAAATAAATCAAGTCTTTTTATACTCATGTCTAACCATCACATCACACTATCCATTTCC
AGAACTTTTTCATCTTACCATACTAAACCTCTGTACCCAATAAACAGTAACTCCTTCTCTCCCCTAAACT
CTGGTAATCTCCATTCTACTTTCTGTCTCTAGGTAATCAACTATTCTAACGATCTTACAAAAATGGAATT
ATATAATAGTTGTCCTTTTGTGTCTGCCCTATTTCACTTAGCATAATGTCTTCAAGGTTCATCCATTTTG
CACCATGTATCACAATTTCTTCCTTGTTAAGGTTGAAGAACATTCCATTGTATGGATACACCTCATTTTT
CTATCCACTTATCTTTCAATGGACTTTTCAGTTGTTTCCACCTTTTGGCTATTGTGAGTAATGCTGCTGT
GAACATCAGTGTACAAATATCTGTTCAAATCACTGCCTTCAATTCTTTTTGGTGTATGTCCAGAAATGGA
ATTGGTAGATCAAATGTTAATTCTTTTTTTTGTTTGTTTGTTTGTTTGTTTGTTTGTTTTTTGAGATGGA
GTCTCGCTCTGTCGACCAGGCTGGAGTGCACTGGCGCGATCTCGGCTCACTGCAAGCTCCGCCTCCCGTG
TTCACGCCATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGACTACAGGTGCCCGCCAACAAGCTTGGCTA
ATTTTTTTTTTTTTATTTTTAGTAGAGACTGAGTTTCACAGTGTTAGCCAGGATGGTCTCGATCTCCTGA
CCTCGTGATCCGCCTGCCTTGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACCGTGTCCGGCCCC
AAATGTTAATTATTTATTTAATTTTTTGAGGAACCACCATACCATTTTCCACAGTAGCTAATATTTCACA
TTTCTATCAGCAATGCACTAGAGTTCCAATTTTTCCACCTCCTTGAAAACACTTATTGTTTTGTGGCCAT
CCTGATGTGTGTGAGGTGGAGTATCATTGTGGCTTTGACTTGCATATCTCTAAGTGTTAGTGATGTTGAG
CATATTTGCATGTGCTTGTTGGCCATTTGTATATCTTCCTAGGAGAAATCTCTACTTTAGTCCTTTGTCC
ATTTATTAATTGGGATTTTGGATTTTTGTGGTTGTTGATTTGTAAGAGTTCTTCATATATTCTGGAAATT
AATCCCTTATCAGATATATGATTTGCAAATATATTTCCCATTTCATAGGTTGCCTTTTCACTTTCTCGAT
AATGTTCTTTAATATATAAAAGTTTTTAATTTTCGAGGCCCTGCACGGTGGTTCCTGTAATCCCAGCACT
TTGGGAGGCCGAGGCAGGTAGATTACAAGGTCAGGAGATCAAGACCATCCTGGCTAACACAGTGAAACCC
CGTCTCTACTAAAAATACAAAAAAAATTATCCAGGCGTGGTGGTGGGCGCCTGTAGTCCCAGCTACTCAA
GAGGCTGAGGCAGGAGAATGGCATGAACCCAGGAGGCATAGCTTGCAGTGAGCTGAGATCGCACCACTGC
ACTCCAGCCAGGGTGACAGAGCGAGACTCTGTCAAAAAAAAAAAAAAAAAGTTTTTAATTTTCATGAAGT
CCAGTTTATCAATTTTTTTCTTTTGTTGCCTATTTGTTGTTATAACCAAGACATGACTGTGAAATTAAAT
GTCATTAAGCTTTTTTCCCTATGTTTTCTTCTCAGAGTTTTATACTTTTCACTCTTACATTTAGGTCTTT
GATCCATTTTAGGTTAATTTGCATATATGGTATCAGGCAAAGATTCAACTTGTTCTTGTGCATGGATATT
CAGCTTTCCCTATATCATTTGTTGAAAAGACTGTCCTTTCCCCATTAAATGGTCTTGGCACCGTTATCAA
AAATCATTTGGCCATATATGCAAGCATTTCTTTCTGGGCTCTATATTCTATTGCTTTGGTTTCAATATCT
TCCTTTATGCCAATACCACACTGTATTGATTACTGTGGCTTTATAGCAAATGCTGAAATCAGGAAGTGTG
AGTCCTCCAGCTTCATTCTTTATTTTCCAGGTTGTTTGGCTATTTAGAGTCCTGAGATTCCATATGAATT
TCAGGATATGTTTTTCTATTTCTGCAAAAAATGTCACTGGGACTCTGGTACAAATTGCGTTGAACCTGCA
GCTCACTTTGAGTGGTATTGTCCTCCTAGCAATATTGAGACTTCCCATCCATGAAAAAAAAATGTCTTTC
CATCTATTGATGTTGTCTTTAATTTCCTTCAGCAGTGTTTTATAGTTTTCAGGGTACAATCCTTTCACCT
CCTTGGTTAAGCTTATTTCTAACTATTTTATACTATTTTATGTTAATGTGAATTGGAAATTTTTTCTTAA
TTTCCTTTTAGATTGTTCATTGTTAGTGTGTAGAAGTACAACTGATGTTTGCGTGTTGATTTTGTATCCT
GCAACATCACTGAATTTATTTATTAACTCTAACAAGTTTTTTAATCTTCAGGGTTTTCTACAGAGAAGTC
CAAGTTATCTGAAAACACAGATCATTTTACTTCTTTCCAATTTGGATGTCTTTTTTTTTCTTGCCTAATT
TCTCTGGCTAGGACTTCTAATACTGTGTCGAATAGACGTGGCAAAAGCAGGCATTCTTGTCTTGTTCCTG
GTCTTACAGGGAAAGCTTTCAGTCTTTCTCCATTGAGTATCATGTTAGCATTGGGCTTTTCACACATTGC
CTTTATTATGCTGAGGTGGTTTCCTTCCATTCATAATTAGAGTGTTTTTGTTGTGAAAGAATGGTGAATT
TTGTCAAATGCTTTTATTGGTTCTATCTAATTATAGGCCTATTAAATTTTTTTGTGTTTCCAGGAATTTG
TCCATTTCATCTAGGTTATTCAACAGTTTGTTGGCATACAATTATTCATAGCATTCTTGTAGTCCTTAAT
ATTTCTGTAGAATTTGTAGCATTGGTAGCAATATCTCCATTTTCTTTTTTTTTTTCTTTTTTTTTTTTAA
GAGACAGGGTCTCACTCTGTAGCCCAGCACAAGCTAGAGTGCAGTGGTGCCATCATAGCTTACTGCAGCC
TCAACCTCCAAGGCTCAAGTGATCTTCTGCCCCAGCCTCTTGAGAAGCTGGGACTACAGACATGTGACAC
CAAGCCTGGATAGTTTTTTAAAGAAATTTTGTAGACACTGTGTCTGCCTATGTTGCCCAGGCTGGTCTTG
ACCTCCTGACCTCAAGTAATCCTCTTGCTTGAGTCTCCCAATGTGCTGGGATTAAATGTGTGAGCCGCTA
TACCTCCATTTTCATTTCTGATTTTAGTAATTTGAATCTTCTCTCTTTTTTCTTAGTCAATCTAATAAAT
GATTGTCAATTTTGTTGATCTTTTTTGAAGAACCAACTTTTGGTTTCATTGATTCCTTCTATTGTTTTTC
AATTTTCCATTTTATTTATTTAAACTCTAATCCTTATTATTTCCTTCATGTACTATCTGTGGTTTGAGGT
GGTTCTTTTTCTGTATCCTGAAGTTGTAAAGTTAGGTTGTTGATTTGAGATCTCTCTTTATATTTAATGT
ATTTACCATTAAATTTCTCACACAAGATTCTTAACTTCTCTGAGCCTTCAATTCTTCAACTGAAAATTGT
AATAATTCTCATCACCAGGAAATGGAGGAAAAATGAAAATTGCAATAAGAATGACTGTTTAACAGTATTG
TTTTAAAGATTTAATGTAATATTCGATTAAGCTTTCAGCAAAATGCTACACACAGAGGGAAACTTCATAA
ATATTAGCTGCTATTATCACTACTGTTATTATTAGCTTGAAGTTAGGCAGTTCTAGAGCCAAATCCTAGA
TCCACTTCTCACTAATTATATGACTTTGGATAAGTTTTTTCACCACTCCAAGTCTCTGTCATTTCATCTG
TAAGATGGAAATCATGCCTACCCAACAGGGTTATTGTATGGATCAAATGAGATGCCAGAAAAGCATTTAC
AGTAGCTAACATAGCATTAATCATCAGCCTGAGTTGACTAGTGAGAGCCAAGCCCCAAATGAAAACCCAC
TAGGACATGGTTACTGGCTAAAAATGGGGGAGAGAAAAAAAAGTTAAGTGCAAAGAATCAAGCCTGGTAT
GTTAGTTTTCATCCACTGAGATTCAGCCAAGATGGAATTAGAGGTGCAAGATAATTTACCGGGGGGAACC
ACCATGAGGAAAAGTGGAGTAGAAGTGGGAGGAGCCTGAGAGAGCCCTCAGACCACGATGCAGATCTGAT
TCCTGAGAAGGAGAAAGAGGAGAGAGTTTTAGATAGTGATGCAGTTCTCAGAGTTTCCACAAGGCTGGTG
GGGCGTCCTCAAGCCCCTCACCCATGAGAGAGAAGCAGAGTCCCCCAGAACTGGGCTTTTCATTCCCCTG
GTGGGAGCCCATGAGAAGCGAGTTCTCTGTGCAACGGACTTAGTAAATACAGAATGCACTAGCCTGGGCC
TTCTGCCAATCAAGTCCCTGCCACAGAGACCCAACAGACTTATTTATGCCTACCACAACTGAGACACTGA
GAAAAAGATGCAACCATGAAAAGATAGAAAGTTCTAATGACACGCAAAAATAGCAATCAGACTTTCTCAA
ATTTCAAAGCCTTCAGAAATAGCTGAGTGCAGACAGGCCAGGGTGGAATTGACAGAAGACTGATCACCAA
CTAGCAACACAGTGAGAGAGAAAAAATTGCAACTTTCCCACAAAACTAATGCATTCCTTGAAGCAACAAG
TAGAGACTGCTTCATGCTGAGAGCTGGAACCTGGGGCACCCCACTGTAAAATAACATCACATTCATTCCT
TCTCTTTTCTTTCCATGACGGACGATTCAGCATCTGGAACTTCTCCTGGTCTCTCAGCTGGGGCCACTGT
CGGCATCATGATTGGAGTGCTGGTTGGGGTTGCTCTGATATAGCAGCCCTGGTGTAGTTTCTTCATTTCA
GGAAGACTGGTAGGTATAATGGCCTTTCCTCTTGTTCTGTTTCCTGCAGTGCTGACTGCCATGCTTGGGA
GAGGGAAGGGATTTCTTCACCTGTATCTGGGACTGGATCTCTTCCTCCTACCCCCAAGCTCCTGCTTCTC
AGCACTAATTCCTGCAGGTCTCTTCTTCCCTGGTCTTCATGCTCCCTGTACGCCACTGTCTCTTAGATAT
AATTATCCCCACCCTCTGCTCATTTGTTTCCCAGATTCAATACATTGTCAAAGCCTCTTGGTCCTTTTTT
AACATCTCACACTTGTGTCATTCTCTCCATTCCCATAAACCTCAACAACTGCTCAAAGTCCTGCTTGACC
CCTTGTTGCCAGTCTTTGAAATCTTTCTTGCATATGACTGCCTCATTACCTTCCTAAAATCTAGTTCACT
CGCCTACTCAAGAAGACACAGGGGCCTACTGTGGTGTATTAGATAAGTTCACATTTCTTCTCTTTACTAA
TCTTTTTTACTTCCTTTACCACCACTCCCTTATATAATTCCATCATCCTAATAGATCTGTTTCCCTACAC
ATCCCTGCCTCTCCACCCCACATGTACACAGAATTCTTAGTTCCGGTGTTACACCTAAAAACATGTCAAA
CAGGGTGACCTCCTTCCACTGTCTGCACTGTGGAGTTACCCACACCCTTAATCACAAGCAACTTCTGACC
TCATGAAGAACAAAGACTGTAGCATTAACCTGTGAGTCTTAAGCTCAGGACACAACTGTGCCTGTGACTG
AGAACCTTTTCCTGATAACCAATTCATATGTTCATAACAGATACAGAAATGAAGAAGGCAAGGTCCTTAA
TTCTATAACAGGAGACAAAACCTGAAAAATAATCATAATGCCAAAATAGAAAGGAGTGAACATCACAAGA
AATTAGAGAAATCTGACGGAAAATATAGCTACACATTGGAATCACTCAGAAACATTTTATAAAATGGATA
CTTAAGTCCCACCGATAAATTCCGATTTACTGGTCTGGAGTGGGACCCAGGCATTCGTAATTTTTAAGCC
TCCCCAGATGCTACTAATGTGTAGCCAGGATGGAGAAACCCTGTTCTAAATAGGTAGGACTTGGGGCTAA
ACCCATGACTTTCAGCTAGGAGGATTAGAATTGCCCATGGAGTTTTTCTGGCTGGGCACGGTGGCTCACG
CCTATAATCCCAGCACTTTGGGAGGCCAAGGCGGACGGATCAGGAGTTCAAGACCAGCCTGACCAACATG
GTGAAACCCCCTCTCTACTAAAAATACAAAAAAATCAGCTGGGCATGGTGGCACGTGCCTGTAATTCCAG
CTACTCAGAAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGTGGAGATTGCAGTGAGCCGAGATCGT
GCCACTGCACTCCAGCCTGGGCGACAGAGCAAGACTCCGTCTCAAAAAAAAAAAAAAAAAAAGAATTGCC
TGTGGAGTTTTTCAACATACGTAAGCCTATACTTTGTTGGCCCTGTTCATTAATGGGCTCCACCAGGAAA
TTAGGAATCTAGTTGAGAAACAGAAGCTGAATGGAAAGGCCACCTTATTTGATATGTTAAATTATATGGG
AAGCACTGTCAAATCATTAGTGATGTTAAACCTTCTCTAAGTTATATTTATGAGTATGTTATTGATGTAT
TCCAAAAGTTATATAAGAAATTCTAGAAATCTAATTGGTTATCAGCCATAATGTCATATGCCACAGAAGT
AACTAAATTTCTATGTGAGTTGTGTTCTTATTATAATAAATTATCATCAGATTTTTAACTGTACTCATTT
TAAATCTTTGTCATTCACAGACAGTTGTTTTGCTTCTTCCTTAAAGCATTTGCAACAGCTACAGTCTAAA
ATTGCTTCTTTACCAAGGATATTTACAGAAAAGACTCTGACCAGAGATCGAGACCATCCTAGCCAACATC
GTGAAACCCCATCTCTACTAAAAATACAAAAATGAGCTGGGCTTGGTGGCGCACACCTGTAGTCCCAGTT
ACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGTGGAGATTGCAGTGAGCCCAGATCGCAC
CACTGCACTCCAGTCTGGCAACAGAGCAAGACTCCATCTCAAAAAGAAAAGAAAAGAAGACTCTGACCTG
TACTCTTGAATACAAGTTTCTGATACCACTGCACTGTCTGAGAATTTCCAAAACTTTAATGAACTAACTG
ACAGCTTCATGAAACTGTCCACCAAGATCAAGCAGAGAAAATAATTAATTTCATGGGACTAAATGAACTA
ATGAGGATAATATTTTCATAATTTTTTATTTGAAATTTTGCTGATTCTTTAAATGTCTTGTTTCCCAGAT
TTCAGGAAACTTTTTTTCTTTTAAGCTATCCACAGCTTACAGCAATTTGATAAAATATACTTTTGTGAAC
AAAAATTGAGACATTTACATTTTCTCCCTATGTGGTCGCTCCAGACTTGGGAAACTATTCATGAATATTT
ATATTGTATGGTAATATAGTTATTGCACAAGTTCAATAAAAATCTGCTCTTTGTATGACAGAATACATTT
GAAAACATTGGTTATATTACCAAGACTTTGACTAGAATGTCGTATTTGAGGATATAAACCCATAGGTAAT
AAACCCACAGGTACTACAAACAAAGTCTGAAGTCAGCCTTGGTTTGGCTTCCTAGTGTCAATTAAACTTC
TAAAAGTTTAATCTGAGATTCCTTATAAAAACTTCCAGCAAAGCAACTTTAAAAAAGTCTGTGTGGGCCG
GGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGATCCGCCGAGGCGGGCGGATCACGAGGTCAGGAG
ATCCAGACCATCCTGGCTAACACAGTGAAACCCCGTCTCTACTAAAAATACAAAAAAAGTTAGCCGGGCG
TGGTGGTGGGGGCCTGTAGTCCCAGCTACTCAGGAGGCTGAGGCAGGAGAACGGCATGAACCCGGGAGGC
AGGGCTTGCAGTGAGCCAAGATCATGCCGCTGCACTCCAGCCTGGGAGACAAAGTGAGACTCCGTCAAAA
AAAAAAAAA

</dna_sequence>
        <protein_sequence>>NP_001278413.1 carcinoembryonic antigen-related cell adhesion molecule 5 isoform 1 preproprotein [Homo sapiens]
MESPSAPPHRWCIPWQRLLLTASLLTFWNPPTTAKLTIESTPFNVAEGKEVLLLVHNLPQHLFGYSWYKG
ERVDGNRQIIGYVIGTQQATPGPAYSGREIIYPNASLLIQNIIQNDTGFYTLHVIKSDLVNEEATGQFRV
YPELPKPSISSNNSKPVEDKDAVAFTCEPETQDATYLWWVNNQSLPVSPRLQLSNGNRTLTLFNVTRNDT
ASYKCETQNPVSARRSDSVILNVLYGPDAPTISPLNTSYRSGENLNLSCHAASNPPAQYSWFVNGTFQQS
TQELFIPNITVNNSGSYTCQAHNSDTGLNRTTVTTITVYAEPPKPFITSNNSNPVEDEDAVALTCEPEIQ
NTTYLWWVNNQSLPVSPRLQLSNDNRTLTLLSVTRNDVGPYECGIQNELSVDHSDPVILNVLYGPDDPTI
SPSYTYYRPGVNLSLSCHAASNPPAQYSWLIDGNIQQHTQELFISNITEKNSGLYTCQANNSASGHSRTT
VKTITVSAELPKPSISSNNSKPVEDKDAVAFTCEPEAQNTTYLWWVNGQSLPVSPRLQLSNGNRTLTLFN
VTRNDARAYVCGIQNSVSANRSDPVTLDVLYGPDTPIISPPDSSYLSGANLNLSCHSASNPSPQYSWRIN
GIPQQHTQVLFIAKITPNNNGTYACFVSNLATGRNNSIVKSITVSASGTSPGLSAGATVGIMIGVLVGVA
LI

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene316">
        <gene_name>CEACAM3</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>1084</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>461496471</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AC022516</gene_refseq>
        <protein_refseq>NP_001264092</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>19</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>41796589</gene_start>
        <gene_end>41811552</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>transcript variant 3</protein_name>
        <protein_pi>5.89</protein_pi>
        <protein_weight>20869.17</protein_weight>
        <protein_length>212</protein_length>
        <protein_note>Also known as CEA; CGM1; W264; W282; CD66D; MGC119875</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000019.10:41796589-41811552 Homo sapiens chromosome 19, GRCh38.p12 Primary Assembly
CAGAGCCTAAGTCACAGTAGCCCTGACTACAGCATTCCTGGAGCCCAGGCTCTTTTCCACAGAGGAGGAA
AGAGCAGGCAGCAGAGACCATGGGGCCCCCCTCAGCCTCTCCCCACAGAGAATGCATCCCCTGGCAGGGG
CTTCTGCTCACAGGTGAGTGGAGGATTCCTGGGAGTGGGCAAGAGGAGGGATCACAGAGAATGGCTGGGG
TCTCCTGGGGAGGATGGGGCTCTGATAGGGGACAGAAGGCTTCTGCTGAAGCCTCAGGGGAGAGAACATC
AGAGAGGGACACGGGTCACAACAAGACAATCACATTGAACTGGGATTGATAAGAGGGAGGAAAATCCATT
GATCATGTTTTCCAAGTTAATCATTACTGGCCACTACAATTAGAAAATGATAAGAATAAGAATTACATCA
GGGTGATACTTTAAATAAAAATATAACCAGGGCACTAAAACCTGTCTTTGACCACCAACCACAAGTTGCA
AAATAACCACCACTCCTTAACTCATCCACCAGTATTTGCAATCAAATTTTAGGCACTGGCGTACAACAAA
TATCAGACAAGTCTCTGTGTTCAAAGAGCTTACACTCTTGCAGAGATGAAGATAGACACCCAAAGAGATC
TAGAATGTGAGTTCAGGTGTTGACAAGAGCCCTGGAGGGAACAGAGCAGAAAAAGGTCAGAAAGGGAAGA
CCCAGGGTCTCTAGAGGAGGTGTCAGGGGAGGGATCTCCCAAGGATGCCCTGATGTGAGCAGGATCTGAG
GGCAGTGGGGAGGGAGCCATGCAGACCCCTGGGGAAGGGGATTCCACACAGGAAAATGCCAAGGTTAGAG
GTGCTGAAGAAAGAAAGGTCACGTTACTGACCTTGACCAAGTGGGACACACATACACTCTCCAAGGCTGA
AGGGTGAAGAGACTCTCTCAGGACCCAGGGCCCCATCTTTCCATCCCAATACATGGGTCCCAATATTGAC
TGATGCTTTCTCCCTCCTAGCCTCACTTCTAAACTTCTGGAACCCGCCCACCACTGCCAAGCTCACTATT
GAATCCATGCCGCTCAGTGTCGCAGAGGGGAAGGAGGTGCTTCTACTTGTCCACAATCTGCCCCAGCATC
TTTTTGGCTACAGCTGGTACAAAGGGGAAAGAGTGGATGGCAACAGTCTAATTGTAGGATATGTAATAGG
AACTCAACAAGCTACCCCAGGGGCCGCATACAGCGGTCGAGAGACAATATACACCAATGCATCCCTGCTG
ATCCAGAATGTCACCCAGAATGACATAGGATTCTACACCCTACAAGTCATAAAGTCAGATCTTGTGAATG
AAGAAGCAACTGGACAGTTCCATGTATACCGTGAGTATTTCCACATGACCTCTGGGTGTTGGGGGTCAGT
TCTACTTCCCACATATGGGATTGTCAGGCCTGGGCTGTGCCTGTGGCCCTCTCTGCATTACATTCTGTAT
CAGGGTTTGGACATTTAGTGCAGGACACACACGGGGGAGACAAACTTCCACAGATCAGAATTCCTTTCCT
GCATCCAGACCCTGCAGACACTCGCTGCAGAGGAAGGACAGTCTGATGGGGGGACTCAGCAGGGCAAGGT
CAGTGTCAGAAAAGAACCCCATGGTCTCCCCATGGACCTGACCCTAAGAAAGACCCTGGAGAACTGGATC
AGGGCCTGGCCTGAGGGGTCCCCCTAGGATTCTCAGAGAGAAGCTCAACTCTTCCCAGAACTGAGCCCCT
GTGCAAATCCCTGTCCCAGATTCCTGACTCCAGGTGACCCTGGGGACCCTAGGGATCCTGTGCCAGGGCT
GAGTGAGGCCTCCTGGGCAGGGCTGACTGGGAGCAAGAATTTACCAGCTGTCTGAGGGTCGTGGCTCCTG
GAGTTGGTCACCAGCCAGGGTCCAGCCCCAAGAACCTCTCCTGGGCAAGGACAGGGCCTCATCCTTTACC
TGAGACTCAGCATGGAGTGAACAGATGGACAAGATTACTAGGGCATGAGCCCACTGCCCAGGGGAACTTA
GATGACTCCATGGGAAGTTCAGTATCCCCAGGGGGAGGAAAAAGAAGAGAGAAGATGCTCCCAGCAGCTC
CTTTTCCACAAGGGATCAGACTCAGGGACCTCTCTTTTGGAGGCAAATAAGCATAGATGCTGTTCCTTTG
GGCAGCTCCTCTATACACAGCTGAGGTCAAGTAATTGTAAATATTTTGAGATTAATTCACAAACAACGTC
ACAGCCAAATAGCACTTATCCTACTTATTGAAAAAAAAAATTGAGGAACAGGGAGACAGTCACCGACTAG
GGTCACACAAGTCAAAGGTGTCAGATTAGAGTCACACGAGGTCTCTCTGCAGCCACAGCTGCCTCTTCTC
CACCAGGGGACGGCTGGCGTTATTATTAGACATCTGCAGGCCTGAGACCAGTCCTAAGTTCTCTTTCCTT
TTTCTTGGGCATCCACATCTCAGAGGGGGAGATTTTGGTCTGGAGAGTAAGGGGCAAATGGAAAATTAAT
CAATTTTTCCTGATATAGTTTGGATGTTTATCCTCTCCAAATCTCATGTTGAAATGTGATCCCCAACATT
GGAGGTGAGGCCTGGTGGGAGGCGATTGGATCATGGGGGGCTGTTTCTCATGAGTGGCTCAGCACCATCC
CCTTGGTGACAAGTCAGTTCTCACTTTGAGTGCACAGGAGATCTGGTTCTTTAAAAGTGTGTGGCGCCTC
CACACTCTCTCTTGCTCCTGCTTTTGCCACATGACACCACCTGCTCCCCCTTCTCCTTCCACCATGATTG
TAAGCTTGCTGGGTCTCACCAGAAGCCGAGCAGACGCTGGTGCCATGCCTGTATAGCCTGCAGATCCCTG
CATCAATTAAATCTCTTTTCTTTATAAATTACCCAGCCTCAGACATTTCCTTATAGTAACAAAAAATAGC
CTAACACATTAGCCTAACCTAGAACTAAATCCCTTGTGTCAACAGAGTCAGTGCCAGGAATGTCCGGGCC
TCCCTCTCAGATGCGCACCACTGCCCTCACTCGACCTGAAATCCTGTGTTTCCTGATGTGTCAGTGACAC
TCCCACAGGAGGATAAAACACTCCCCACTCACACCCTGCACCAGCGCAGGGCCCAGTGAGAGACACACAC
TCAGTAGTTCTCTGACGAAGGAGGGAAGGAATGAATGATGAATAATTCTTAAACTCTTCAGAGACCGGAT
CTTGGATGCAGAATCCTATAAGGTTCTGGCCACACCTGTTTCCTGTCCCTCCAGGGGCCGGGATCCTTGT
TGCATTCCTCTAACCCCTGCCCCTAAAGCTACCCCAAGAACCGCATCTCATGGGACTCTGGCACAGCTCA
CCTGTGGGAAGGTTTTCAGGTCTCCCTGGTCCTGGTTTGTGGGCGGCAGGTCACCCAGGCGCCGAGGCAA
GAGACCAAGGACACGAGCTGTTCCAGTATAATAAAATATAAAACAAGAAAAGTTATACCAGATATAGATC
TTAGATATGATTATATGTGAATATCATTAATCATTAGTTGGTAGCAATTACTCTTTATTCCAGTATTATA
ATAATCCTCGCTCTATAATCACAACCTAGGAAAAGCCAGGCCATACAGAGATAGGAGCTGGGGAGACATA
GTGAGAAGTGACCAGAAGACAAGAGTGCGAGCCTTCTGTTATGCCCAGACAGGGCCACCAGAAGGGCTCC
TTGGTCTAGCGGTGACACTAGCGCCTGGGAAGACGCCCGTTGCCAGGCAGACCGAGGTCTAGCGGTAGCG
TAAGTGTCAAGGGAAAACACCCGCTACTTGGCAGACCGGGAAAGGGAGTCTCCCTTTCCCCGGGAGAGTT
TAGAGAAGACTTTGCTCCTCCACCTCTTGTGGAGGGCCAGACACCAGTCAGGTCCACTCGCAGTTATCCG
GAGGCCTAACCGTCTCCCTATGATGCTGTGCTTCAGTGGTCACGCTCCTAGTCCGCCTTCACGTTCCATC
CTGTACGCCTGGCTCTGCCTTCTAGATAGCAGTAGTAAATTAGTGAAAGTACTAAAAGTCTCTGATATGC
AGAAATAATGGCATAAGCTGTCTTTCTCTTTGTCTCCTCTCTCTCTCTGCCTCATCTGCCAGGCAGGGAA
GGGCCCCCTGTCCAGTGGACACATGACCCACGTGACCTTACCTATCATTGGAGATGACTCACACTCTTTA
CCCTCCCCCTTTTGCTTTGTATCCAATAAATAACAGCGCAGTCAGACATTCGGGGCCACTACCAGTCTCC
GCGCATTGGTGGTAGTGATCCCCCCGGGGCCCAGCTGTCTGTTCTTTTATCTCTTTATCTTGTGTCTTCA
TTTCTACACTCTCTCGTCTCCGCACATGGGGAGAGACCCACCGACCCTGTGGGGCTGGTCCCTACACTGG
TTCTAGAATAACCAGGGGTCTCCTGGTCCCTAGGGTCTCTGAGGTCACTGTAGTCCCCACAGCTCACTGT
GATGTAATCTCTGGCTATCTCTGCTACCCCTTGTCCCTTATCTTCCTCCCCTTTCACACCAGTGAGGATG
CCCCTGCCCTGCACAGCTTCCTCCACCCTTAGGTCTTCCCCAGGAACTCCCTCTAACAAGACTGGCTGTT
CTGTTCCCTTCCCACTCACACTGTGGCCTGGCCCACCTCCGGGGCAATAAAAAAAGGCACAGAAATCAGC
TGGATCAGAGCCCCTGCCAGGCTTCATCATGAGCCAGTGTCCCCAGGCCACCAGGAGAACGAGCTTCCAC
TGTGTCCCCACCCAGGGCTCTTTCCCTTCTTGAGGCCAACATGTGGAAAAGGCCACAGGACAGGGACGAG
CGACTCCTCCACCTACTCTTGTAATTTCCCAGCAGGTTTTTCCTGCCACTGCACAGACAAAACCAATTCA
CTGAGACCACGATATTGCAGTCAAGAAAGAGTTTAATTAATGCTAAGTAAGCCAAACAGTAAGACAAGAG
TTTATTATTACTTAAATCAGCCTCCCTGGAGGCTTGAGATTAGAGTTTTTCATGGATAGTTTGATGGCAG
GGGACTAGGGAATGGGGAAAGCTGATTGGTTGGGGATAAAATCATAGGGATGTGGCAACTGATCCTGGTG
TGCTGAAACTGCCTCTGAGTGGGGGCCACAAGACCACTGAATCATGGGTCACAGTCCAGGTGGAGTCAGT
CAGTTGCCAGAATGCAGAAGTCTGAGAAACATCTCAAAAGACCAATCTCAGGTTCTACAATAGTGATATT
ATCTATGGGAGCAATTAGGGAAGTCACAAATCTTGTGACCCTCCCATAATGCTGATCTCGTAATGTTTCA
TTAGTTTACAAAGGCAATCCCTGACAAAGAGGAAGTTAGTTTTAGGGAGGGACTATAATCATCCTTGCTT
CAAAGTTAAACTATACACTGAATTTTTCCCATGGTTAGCCTGGCTTGTGCCCAGGAATGAGCAAGGACAG
CCACCTTGAGGCTAGAAGCCAGATGAAGTCAGCCATGCTAGCTTACTCTCGCCATCTTAATCCTTGCAAA
AGTGGTTTCACTCTCTACAATGACTCACCAGGGGTCAGAGGCAAGAGGAGAGGTCTGCAGTCCCCAAAGC
TCATGGCTCATTTCACCCATTTCCCTCCCGACTCCACCCTCATTCAGCTATGGGGCTCCCATCCTCCAGT
CATTCCCTAGAGACTTCTGGTGTCCAATTTGGCATGTAAGAAGCTTGAAATCTGTCACTCAGTTATAACA
AGTATAAAACTGAACAAACTGAAAAATCAACAACTCTTTTAGATCCCTCAGAGAAGCTAGGCCTCGGTGT
TAATTGCCCCGCATATTGGAGAGACCGACAGGCAAAGATGGAGCAGCACACCTCACCTGGGCAGAAGCCC
AGGGACAGAAACCCTGCAGAACCAGCGCTGGGGTCAGAAATCTGAACTGTAACTGACAAATTGCTGGAGG
CTCAGCATGGACATGCCCCAGAGTTAAACTAAACACTCCAGGGGAGGGATCAATCTTGGGGCTGGGACAA
GGAGGGACTCTTTTGTGAGTCTTAACTCCTAGAGCTACCAGATTCTCATAGTGAATAGGCAACAAAGATC
CCCTCCTCCTTCCTGAAGCGGGAGGGGGAAAGGAATTATTTGGAAAGATCTCCGTGAATTCTATTCTTCT
TAGCAACAGCTGCCTTTAAGAGAAACTTTTACCAGAGCCTGACCTGCTGGGGTTTTATGGGAGCCTAACT
GGCCTGGCAGTGGGTAAATGTCCAACTCCAGCCCCCTGTAGCCATCATGTCCCACCTAAGGGGGCAAAAA
TACAGAGAGTCACTTATGAAGTTCACAGCCCAGGCTGCAGACCTCATCCAGGACCACAGAACCCTTCCCT
CCCAACACTCACCACAGCGTCACTGAACACCTGCTCACCCAAGTTCCTTTTACCCAGAATATCATGTCTG
GCTTTCAACAAAACTGCACAAGACAGACTAAGGCAAAAACAAAAAAAAATGCAATTTGAAACTCAGAACA
ACAATCAGAACCAGACTCAGATGTGGCAGGGATGTTGAAATTAGCAGAACGGGAATTTAAAACAACTCTG
GTTAATACAGTAAAGGTTATGATGGAAAAAGTAGACCCCATGCAGGAACAGATGGGTGATGTAAGCAGAG
AGATCGATATTCTAAGACAGAACCAAAAGAAATGCTAGAGATAAAAAAAGAAACCCTCCTGTAAGGTAAA
TGAAGAATGCCCTCAATGGGCTTACTGGTAGCCTGGACACAGCTGAGGAAAGAATCTCTAGCTTGAGGGT
GTGTCAGTAGAAACTTCCAAAACTGAACAGCAAAGTTTTGTGTGTGTATGTGTGTGTGTGTGTGTGTGTG
TGTGTGTGTGTTGTTTTGTTTGTTTTTTTTTTTTTTGAGACAGAGTCTCGCTCTGTACCCCAGGCTGGAG
TGAAGTGATGCTATCTCAGCTCACTGCAAGCTCTGCCTCCTGGGTTCACGCCATTCTCCTGCCTCAGCCT
CCCAAATAGCTGGGACCACAGGCGCCCGCCACCATGCCCGGCTAATTTTTTGTATTTTTAGTAGAGACGG
AGTTTCACCGTGTTATCCAGGATGGTCTCGACCTCCCAACCTCATGATCTGCCCGCCTTGGCCTCCAAAA
GTGCTGGGATTACAGGCATGAGCCACCATGCCCGGCCTGAAACAGCAAAGCTTTAAAAGAGTGGGAAAAG
GCCGGGCGTGGTTGTTCATGCTTGTAATCCCTGCACTTTGGGAGGCTGAGGCGGGTGGATCACCTGAGGT
CAGGAGTTCGAGACCAGCCTGGCCAACATGATGATACCCTGTCTCTACTAAAAATACAAAAAATTAGCCA
GGCATGATGACAGATGCCTATAATCCCAGCTACTCAGGAGGCTGAGGCAAGAGAATTGCTTGAACCTGGG
AGGTAGAGATTGTAGTGAGCCAAGATAGCGCGATTTCACTCCAGCCTGGGCAACAAGAGCAAAACTCTGC
CTCAAAAAAAAAAAAAGAGTGGGTAAAAAAAGTGGAAAAGCAGATTCAACTTCACATTCAAGATTTTGTA
TTGACAATGGCATATTTTATATTTTCTAAAAGCTGTAACATACATGTAATGGGAATACTGGTGGTTCCTG
GGACCAGGTGGAGCTGGCCAGCCCTGTGCTGTCTGATGGGCCCACTGCTTGTTCCACACACATGTGTCCC
TCATGATGATGCCATTATCATAAGATGGGGTCTTCGGGTGGGGAGATGCACCAGCCACCGGCATCTCACT
TAGACTCTGCCCAATTCGGGCTAATTTAATCAAATTCTAGTTGTGTTTCCTGAGGCGTAAAGAAAAGGAG
GAAGGTGTTTCATATGCCTGTTTAGGCCCCTTCCTATTTTGCCTAACTCTGCACAGGAAATTGAGGTGAG
GGCTCTTTTGACATTTACTGACATACACACATCACATCTCCTAATTTGGTATTTTTCTTTTCTGTGTATT
ATTGAGACATCTCAGACTTTCCCTCTGACCAGTTCTGTCTTCCTAACAGGACTCACAATTCTCTCTCTAC
CCAGAGAGTCACTGATTTCAAACCAAAGTCAGCATCTTTCTTTGAGCTTAACATGATTATGCTGGTCTTC
AGCATTTAGCAGACCTAAACCTTATTATGTTATCAAGAGAAATGCTACAGCAACCAATTGACCTCAGACC
TTTCGACCATTAATAATAATTTCCACTGATAGAAAAAAAATTAATTTCCCCCAAATTTCTTTTTTTTTTT
TCACTATAGTGAGATCATAACTCCTTTGTCTAAACTCCTGACAAATTTTTAAGGGCAAAATGGACTATTA
CAGATGGAGAATCCCAAATCCAAAAATCCAAAATACAAAATGTGCCAATATCCAAAATTTTTTGACCACT
GGCATGATGTTCAAAGGAAATGCTCACTGGAGCATTTTGAAATTTTAGATTTTCAGATTTGGGATGCTAA
ACCGATACTTGTAATACAAATATTCCAAAATAAAAAATAATTAGAAATCCAAAACACTTTTGCTCTTATG
CATAAGAGATACTCAAACTCTATTAATTATAGACACCAAGCTGTACAGCAGATCTCTAGAACCTCCATAT
TTTGCATAATTGAAACTGCACACCCAAGGAACAACTCCCTGCCAGCCCTTGGAAATCACCACTCTGCTCT
TTTATTCTTTTTTCTTCTTTTTTTTTTTTTTTTTTTTTTTTAGATAGAGTTTTACTCTTGTCACCCAGGC
TGGAGTGCAATGGTGTGATCTTGGCTCACTGCAACCTCCGCCTCCCAGGTTCAAGCAATTCTCCCTAGCC
TTCTTAAGTAGCTGGGATTACAGGCATGTGCCACCACACCTGGCTAATTTTTGTATTTTTAGTAGAGACG
GGGTTTCACCATGTTGGCCAGGCTGGTCTGGAACTCCCGACCTCAGGTGATCCGCCCGCCTCAGCATCCC
AAAAGGCTGGGATTACAGGCATGAGCCACCGCACCCGGTCTGCATTCTACTCTCTGATTCCATGAGTTTG
ACTACTCTAGGGACCTCGTATTCGTGGAACCGTACAGTAGTTGTCCTTGTACGACTGACTTCTTTCACTT
AACATAATCTCCAATGGGAGAAAATATTTGCAAAGATTCTTCCCAAATGTCTCTCTCATATCCATCAAAC
ACAGAGTCCATGAGGACCAGATTGCCAGCAGCTTCATGCTCCCTCTTTCCACCAGTCAGTTCTGCATTTG
CAAACGTTCATATGTATTTCTTATTAAGTTCCACGGAGTCCTCACCTGCCCTCTGCAGGAGGAGAAAACA
CATTAAGGACTGAGGACAGAGAACATGGTTCTGCTCCAAAGCCACCAGCTCCTGCATGTCCCCGCCCTCT
TTCTAAGTTGGGATTCTACTCTTCCTGTTGTTGTTGTTTGTTGTTGTTGTTGTTGTTGTTGTTTGTTGTT
TGTTGTTGTTACGGAGTCTTGCTCTGTCACTCAGGCTGGAGTGCAGTCGTGTAATCTCGGCTCACTACAA
CCTCTGCCTCCCAGGTTCAAGTGATTCTCCTTCCTCAGCCTCCCGAGTAGCTGGAATTACAGGCATGCTC
CACCACACCCAGCTAATTTTTGTATTTTTAGTAGAGACTGGGTTTTTCGCCATGTTGGTCAGGCTGGTCT
CGAACTCCTGACCTCAGGTGATCTGCCCACCTCGGCCTCCCCAAGTGCTGGGATTACAGGTGTGAGCCAC
CGCACCCGGCCTTCTACTATACCTTTTACTGACTCACTGTCTCATGTCAGTCACCATGATATACCTGGAA
AGAATAACCTCACCTTGTAATTCTGAGACCTCAGCACCAGCATGTTCCAGGTGAGGACCCCAAGGTCAGC
CAGGCAGTCAGCCATCAGGGAAGGAACAGGAGAGGTGCCAGGGGATGTGACTCCTGGTCCTGTGTCTGTC
CAACACCCAATGCTGCTGCTTAATTCACAGTTGAGAAAGTCTCTTCTTCTTTCACAGGCAGGCAGCCTCA
CAGTCTCTGAGCCCTCAGACGGTCATGCATCTGTCTGTGACACACACATCTGTCTTCGTCTTTTTTTGTT
TGTGTGTTTGTTTGTTTGTTTGCTTGTTTGTTTTGAGAGACAGAGTCTCACTCTGTCGCCCAGGCTGGAG
TGCAGTGGTGCGATCTCGGCTCACTGCAAGCTCTGCCTCCCGGGTTCACACCATTCTCCTGCCTCAGCCT
CCCAAGTAGCTGGGACTACAGGCGCCTGCCACCATGCCTGGCTAATTTTTTGTATTTTTTAGTAGAGACG
GGGTTTCACCGTGTTAGCCAGGATGGTCTCGATCTCGTGACCTCGTGATACGCCCGCCTCGGCCTCCCAA
AGTGCTGGGATTACAGGCGTGAGCCACCGCACCCGGCCTTGTCTTGGTCTTTTAAGGAGTGGAGTTGGCC
AAAGAATAGGAGATGTTGATTCTGATTAAAATATGCCTGTGGAGGAATCACAGGTGCCACACAGGGCAAT
CTTCTCTCTGTTTTCTGCACAGCGGAGCTGCCCAAGCCCTCCATCTCCAGCAACAACTCCAACCCCAAGG
AGGACAAGGATGCTGTGGCCTTCACCTGTGAACCTGAGATTCACAGCACAACCTGCCTGTAGTGGGTAAA
TGGTCAGAGCCTCCCGGTCAGTTCCAGGCTGCAGCTGTCCAATGACAAGAGGACCCTCACTCTACTCAGT
GTCACAAGGAATGACACAGGACCCTATGAGTGTGAAATACCGAACCCAGTGGGTGCCAGCTACAGTGACC
CAGTCACGCTGAATGTCCTCTGTATCTTCTGTTCCTCTGTGGCCCAGGCTTCCAGCCCAAATCCACACAG
CCAGAGGCCAGGCCTCTCAGTCCCTCTCAAGTCCAGGGACTCAGACTCTCACCCAGGCTGGCCATCACTT
CCTGTCCCAAGCAAACCTGGGCAGACCCAGCCTTGACCAAGAATAGGAGGGGAGAGGCTGCTCCTGTCCT
GGGAGGCTCAGGGTCCACAGCCTGTGATGGGAGAAACAGGTGAATATCTCAGACCCAGACTCAGTGGACA
GATTGGGTTTCGTTAGGACTTCAAGGTTGTGACTTGGCTCACAGGGACACTGTGGCTCTTCCACAGACCA
GGAGCTTCCCCTTCCCTTTGATGATATCATCTATGACTTTATTCTCGCTACTCCAGATGGACCGGGCATT
CCCACCATTTCCCCCCCAGACTCCTATTACCATCCAGGGGCAAATCTCAACCTCTCCTGCCACATGGCCT
CTAACCCACCTGCACAGTACTCCTGGTTTGTCAGTGGAATGCTCCAGCAACACACACAAAAGCTCTTTAT
CCCCAACATCGCAGTGGATAAGAGTGGATCCTATGCTTGCCTCGCCCATAACTCAGCCACTGGCCTCAGT
ACAATCACAGTCAAGACAATCACAGTCTCTGCTAAGTGGATCCCTGGAGCATAGGCCCTGAGCCCTGGGT
AAAGCCACTCAGTTTTCTGAAAGAGCCTAGAAGTTTATTTCCCAGCCCATGTCTTGGACACAAGCAAATC
CCAAACTCTACCCTGAGCCCTCTCACTCCACCTCTGCAGGACCCCTCCTCCCCTTGTTGTTCTGATTTCT
CACAGCTGACCTTGGGGCCAGCCTGGAATGTTGTACAAATTTTGTTTTATCACTTACGAGTTCTGTGACC
TTCCTTGACTTACTGAGGTGCTTTAAGTCTCAGATTCTAACTCTGCAGCTGGGGGTGATGCCCCCTCTCC
CTCAAGGTGATGTAAGGATGAGATGAGTTGTAGGTAGGTTGGTGCCCACTGGAACTGGCACATGGAAGGC
CCCTGAAAACAGTCAATGAACATCATCCCTGCTTATCAGCATTGAGTTGATGCCAAGGGCCTGCCCTTTG
TGAGTGTCATGGGATGGAAAAGGAGAAACAGAGGGAAGAGGCATGATGCGAGAGGAAGGAGGGACTAAAA
GGCACAGGAGCAGGGTGAGGTGCAGGCACCTCTGGGACAATGTATGAGTTGGTGCCGCCCAGTGTGTCAA
GCCTGCAGAAAATGGTGCCACCATGGAAAGCAAGGGAATCTGTGATGAGGACAACACAAGAGACTACACT
CAGGCCCCATGGCATCTCCTTCTTCCCTGACTGCACACCTTCCCTGCAAGGCCCCTGTGGTTTCCTCTGG
GATAGACTTGGGCCTCTATCCCCTTTGCCTTCTTCTTTCTGCAGAAGAAAATGCCCCAGGCCTTCCTGTG
GGGGCCGTCGCCGGCATCGTGACCGGGGTCCTGGTCGGAGTGGCGCTGGTGGCCGCGCTGGTGTGTTTCC
TGCTCCTTGCCAAAACTGGAAGGTACCACAGCTTTTTCCCATCCTTCTCCCACCCCCTAGGCTGACTCCA
GGCCAAAAGAAAGGAGACCTTGTCCTGTATTCAGGGCCAGGCTCTCCACGGCCTCCCAAGTCCCCAGGGA
TCCTTCCCTCTTATTCCACGGCTCCTCCCTCGTCAGCTCCTGACCCTGGGTTGCTGCCTCAACAGCTTCC
TCCTCTGTGAATTTGGCCCAATTAAGGCCCCACCCCTGAGTGTGGCCCTAGTTCCCTCACACAGCAAAGC
CACAGCTGCCTGGAGGGAGGGAGAGAAGGAGGGAGGGAAGTAGGGAGGGAGGGAGGGAGGGCGTGCTCTG
TACTTGGTACCTCCCATTGTTCATTGAATCCATCCACACAGTGAGGGGGATTTGCAGGCTCCGGATCCTG
GGCACCGTCACACAATGGGGAGTGGACCAGCCTGGACAGGCTGGGTGGGGTCAGTGCCCCCCATGGCTGA
TGTGGTAACCATAGGCCCTGAGGTGTGAGATGGGAGAACCTGGGCCTCAGAACAGCATGTCCTGGAGCGT
CCTTTGTGTCTCTTGCCAAGGGGTTGAGAGAGAGGACAAGGACACTGTCCCATTTCAGCATCACCAGCCC
TGAGTGCAGGGTCTGGCCACAGCAGGGACACTGAGTTCCAGGAGAATCCAAGACACTTGCGGTCCCCTCC
GTGTCCTGCACACGTGGCCCTGCTTTGCCTCTGGGGACTTGACCCTTCCTCTCAGGCAAACCCTCGTGGT
CTGTTTCCTTCCTTGGGTCCTCAGTCCCTTTCCTGGGTCCCTGGGTCAATGTTCTCCTGGCCCGGCATCT
GCCTGAGGGTCCTTCCCCTCTGCTCAGGACAGATGTGGGTTCCTAAAGCCTTTCCTCAACTCCCCTCTGC
TGGGCTCCCCCTAACACAAACCTGAGGGAGACAGGAGGTCTCCATGCCCATCCTTGAAAATGGGTTTCCC
TTCTTGTCCCCTGTTCGAACTCCAAAGTTGTGGCTTTTAACCTGGCACCCTCCCAAATGACCCTGACCTT
TCCTAGAACCAGCATCCAGCGTGACCTCAAGGAGCAGCAGCCCCAAGCCCTTGCCCCTGGTGAGTGTCCT
CTCAGCCCAGGTGTGGCTGGGAACCCCTAGGACAGCCCCACAGTGTCCGCTCCTGCCAGTCACTGCCAGG
CAGACTCTGATCCTTTCCCGGGGGCTGCAAGGAGGATCTCATAAAACATCACACAGGGGACCCCAATTGC
TTGGGTCAGCCCTCACCTGTGGGCTCTGGGTCATGGGTCACCTCCCCAACCTCAGCTGCTCAGGTATCTT
AGAGCTGAGGACCCCCTACGCCTTCCTGGAGAGGGGATAAGGCTCTCCTCCCACCCTGCTGCTCACTCCT
GTCTCTGTTTCCAGGCCGTGGTCCCTCCCACAGCTCTGCCTTCTCGGTAAGCCTGTCCCCTTCCAGCCCC
TTTCTACTGGGGTCCCAGCTGTGCAGGCTCTGGGCAGAGGGACCATCAGCCCCCCAGCACAGAACAGACC
CACCTTCCCCCAAAACACACAGGACAAGGCTAGCCCTGCCCTGGCCAGGAGCTGGGCCTCCCTACAGGGT
CAGGACCACCCACGCCCTGTGCTGACCCCTCCCCGGGACCCTCCATCACCTGAGGAGACCCCTGGAGTGC
AGCAGGTGCAGAGTGGACACTGGGACCATCAGTCAGGGGCCCACATTAACAAGGGTGCAGGGTGGGCCCA
GCCAGGAAAAGGGTCAGGGTGCTGTGTCCACACTGGGAGGCTGAGCTCAGGGGCAGAGCTGGTCACTCCT
GAGGGGAAATGACCAGAAGTAAACACAGAGAAGTAAATCCTGGCCAATCAGAGACAGGAAACTTCCAGGC
TGGGCCTCCATGACCCTCCCTCCCTGTCCACAGATGTCCCCTCTCTCCACTGCCCAGGCCCCCCTACCCA
ACCCCAGGACAGCAGCTTCCATCTATGAGGTGAGTGTGGGCCACGGATGTTCTGGTCCCACAGGCCCCAG
GGGACCCAGGATCTTCCCCTACTGGCATCGGCTGAGCTCTGAGATTCAGGAAACTGCTGTGAAAATAAGA
ACGGGGGTGGCGAGCAGAGGAGGGAGGGGCTTGGGAGCAGGAACCCCCTGAGCACAGCCAGGTTCAGCCC
CAGAGCAGCCCTGGATGGGCCCAGAGCCTGGGAGACGCCACACCCTGTTCTGAGGAGACTAGAGGGGTCC
AGGCCTCTTCTCTGTTTTAACAGGAATTGCTAAAACATGACACAAACATTTACTGCCGGATGGACCACAA
AGCAGAAGTGGCTTCTTAGCTTCCTCCAGGAGCTGCTCCTGTGTGTTGATGGAGAGTCCCCAAGGCCCCC
AGCCCTGGGGATGGGGAAGGACATGAAGCCTGAGCCAGAGAACCAGCTATAAGTCCTGAGAAGACACTGG
TGTCTGGGGGCAGGGAGGGATGGGGGTCCCTGATGAATATCTGGAGACCTCGACAGCCTGCCCTAGGCCC
TGGGTGGGTCAGGACAAAGGCCTCTCATCACCGCAGAAAGCGGGGGCTTGCAGGGAAAGTGAATGGGCCT
GTGGCCCACCTGGGGTCACTTGGAAAGGATCTGAATAAAGGGGACCCTTCCTCT

</dna_sequence>
        <protein_sequence>>NP_001264092.1 carcinoembryonic antigen-related cell adhesion molecule 3 isoform 2 precursor [Homo sapiens]
MGPPSASPHRECIPWQGLLLTASLLNFWNPPTTAKLTIESMPLSVAEGKEVLLLVHNLPQHLFGYSWYKG
ERVDGNSLIVGYVIGTQQATPGAAYSGRETIYTNASLLIQNVTQNDIGFYTLQVIKSDLVNEEATGQFHV
YQENAPGLPVGAVAGIVTGVLVGVALVAALVCFLLLAKTGRPWSLPQLCLLDVPSLHCPGPPTQPQDSSF
HL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>The immunogenicity of the nominal antigen, carcinoembryonic antigen (CEA) has been studied, as well as that of an anti-idiotype antibody, 3H1, which mimics CEA and can be used as a surrogate for CEA. It has been demonstrated that immunization of CEA transgenic mice with bone marrow-derived mature dendritic cells (DC) loaded with anti-idiotype 3H1 or CEA could reverse CEA unresponsiveness and result in the induction of CEA-specific immune responses and the rejection of CEA-transfected MC-38 colon carcinoma cells, C15 [Ref975:Saha et al., 2004].
To improve the antigen delivery into DCs,   CEA conjugated to a protein-transduction domain, human immunodeficiency virus transactivating Tat was utilized. Furthermore, the truncated non-glycosylated CEA from Escherichia coli was purified to overcome the safety concerns and immunosuppressive functions associated with the native CEA protein.CEA-specific T cell proliferation and cytotoxic T cell responses were enhanced significantly in mice immunized with Tat-CEA-pulsed DCs [DC (Tat-CEA)] compared with those immunized with CEA-pulsed DCs [DC (CEA)]. T helper type 1 responses were more prominent in the DC (Tat-CEA) immunized mice whose splenocytes secreted more interferon-gamma and less interleukin-4 than those from DC (CEA) immunized mice. In vivo, the DC (Tat-CEA) vaccine delayed tumour growth significantly and prolonged survival of tumour-bearing mice [Ref1295:Bae et al., 2009].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene4411">
        <gene_name>CSF2</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>1437</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>27437030</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AC004511</gene_refseq>
        <protein_refseq>NP_000749</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>5</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>132073788</gene_start>
        <gene_end>132076169</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>colony stimulating factor 2</protein_name>
        <protein_pi>4.93</protein_pi>
        <protein_weight>15698.85</protein_weight>
        <protein_length>144</protein_length>
        <protein_note>Also known as CSF; GMCSF</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000005.10:132073788-132076169 Homo sapiens chromosome 5, GRCh38.p13 Primary Assembly
CAGTACACAGAGAGAAAGGCTAAAGTTCTCTGGAGGATGTGGCTGCAGAGCCTGCTGCTCTTGGGCACTG
TGGCCTGCAGCATCTCTGCACCCGCCCGCTCGCCCAGCCCCAGCACGCAGCCCTGGGAGCATGTGAATGC
CATCCAGGAGGCCCGGCGTCTCCTGAACCTGAGTAGAGACACTGCTGCTGAGATGGTAAGTGAGAGAATG
TGGGCCTGTGCCTAGGCCACCCAGCTGGCCCCTGACTGGCCACGCCTGTCAGCTTGATAACATGACATTT
TCCTTTTCTACAGAATGAAACAGTAGAAGTCATCTCAGAAATGTTTGACCTCCAGGTAAGATGCTTCTCT
CTGACATAGCTTTCCAGAAGCCCCTGCCCTGGGGTGGAGGTGGGGACTCCATTTTAGATGGCACCACACA
GGGTTGTCCACTTTCTCTCCAGTCAGCTGGCTGCAGGAGGAGGGGGTAGCAACTGGGTGCTCAAGAGGCT
GCTGGCCGTGCCCCTATGGCAGTCACATGAGCTCCTTTATCAGCTGAGCGGCCATGGGCAGACCTAGCAT
TCAATGGCCAGGAGTCACCAGGGGACAGGTGGTAAAGTGGGGGTCACTTCATGAGACAGGAGCTGTGGGT
TTGGGGCGCTCACTGTGCCCCGAGACCAAGTCCTGTTGAGACAGTGCTGACTACAGAGAGGCACAGAGGG
GTTTCAGGAACAACCCTTGCCCACCCAGCAGGTCCAGGTGAGGCCCCACCCCCCTCTCCCTGAATGATGG
GGTGAGAGTCACCTCCTTCCCTAAGGCTGGGCTCCTCTCCAGGTGCCGCTGAGGGTGGCCTGGGCGGGGC
AGTGAGAAGGGCAGGTTCGTGCCTGCCATGGACAGGGCAGGGTCTATGACTGGACCCAGCCTGTGCCCCT
CCCAAGCCCTACTCCTGGGGGCTGGGGGCAGCAGCAAAAAGGAGTGGTGGAGAGTTCTTGTACCACTGTG
GGCACTTGGCCACTGCTCACCGACGAACGACATTTTCCACAGGAGCCGACCTGCCTACAGACCCGCCTGG
AGCTGTACAAGCAGGGCCTGCGGGGCAGCCTCACCAAGCTCAAGGGCCCCTTGACCATGATGGCCAGCCA
CTACAAGCAGCACTGCCCTCCAACCCCGGTGAGTGCCTACGGCAGGGCCTCCAGCAGGAATGTCTTAATC
TAGGGGGTGGGGTCGACATGGGGAGAGATCTATGGCTGTGGCTGTTCAGGACCCCAGGGGGTTTCTGTGC
CAACAGTTATGTAATGATTAGCCCTCCAGAGAGGAGGCAGACAGCCCATTTCATCCCAAGGAGTCAGAGC
CACAGAGCGCTGAAGCCCACAGTGCTCCCCAGCAGGAGCTGCTCCTATCCTGGTCATTATTGTCATTATG
GTTAATGAGGTCAGAGGTGAGGGCAAACCCAAGGAAACTTGGGGCCTGCCCAAGGCCCAGAGGAAGTGCC
CAGGCCCAAGTGCCACCTTCTGGCAGGACTTTCCTCTGGCCCCACATGGGGTGCTTGAATTGCAGAGGAT
CAAGGAAGGGAGGCTACTTGGAATGGACAAGGACCTCAGGCACTCCTTCCTGCGGGAAGGGAGCAAAGTT
TGTGGCCTTGACTCCACTCCTTCTGGGTGCCCAGAGACGACCTCAGCCCAGCTGCCCTGCTCTGCCCTGG
GACCAAAAAGGCAGGCGTTTGACTGCCCAGAAGGCCAACCTCAGGCTGGCACTTAAGTCAGGCCCTTGAC
TCTGGCTGCCACTGGCAGAGCTATGCACTCCTTGGGGAACACGTGGGTGGCAGCAGCGTCACCTGACCCA
GGTCAGTGGGTGTGTCCTGGAGTGGGCCTCCTGGCCTCTGAGTTCTAAGAGGCAGTAGAGAAACATGCTG
GTGCTTCCTTCCCCCACGTTACCCACTTGCCTGGACTCAAGTGTTTTTTATTTTTCTTTTTTTAAAGGAA
ACTTCCTGTGCAACCCAGATTATCACCTTTGAAAGTTTCAAAGAGAACCTGAAGGACTTTCTGCTTGTCA
TCCCCTTTGACTGCTGGGAGCCAGTCCAGGAGTGAGACCGGCCAGATGAGGCTGGCCAAGCCGGGGAGCT
GCTCTCTCATGAAACAAGAGCTAGAAACTCAGGATGGTCATCTTGGAGGGACCAAGGGGTGGGCCACAGC
CATGGTGGGAGTGGCCTGGACCTGCCCTGGGCCACACTGACCCTGATACAGGCATGGCAGAAGAATGGGA
ATATTTTATACTGACAGAAATCAGTAATATTTATATATTTATATTTTTAAAATATTTATTTATTTATTTA
TTTAAGTTCATATTCCATATTTATTCAAGATGTTTTACCGTAATAATTATTATTAAAAATATGCTTCTAC
TT</dna_sequence>
        <protein_sequence>>NP_000749.2 granulocyte-macrophage colony-stimulating factor precursor [Homo sapiens]
MWLQSLLLLGTVACSISAPARSPSPSTQPWEHVNAIQEARRLLNLSRDTAAEMNETVEVISEMFDLQEPT
CLQTRLELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWE
PVQE</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene724">
        <gene_name>CTAG1B</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>1485</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>4503119</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AC244107</gene_refseq>
        <protein_refseq>NP_001318</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>X</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>154617608</gene_start>
        <gene_end>154619270</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>cancer/testis antigen 1B</protein_name>
        <protein_pi>8.51</protein_pi>
        <protein_weight>17594.6</protein_weight>
        <protein_length>180</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000023.11:154617608-154619270 Homo sapiens chromosome X, GRCh38.p12 Primary Assembly
ATCGTAGCTCAGTTTTATTTTCTACAGAAACAAACATGTAAGCCGTCCTCCTCCAGCGACAAACAATCAG
GCCCCCACAATGAACTGGCCACTCGTGCTGGGACCATTCCCTAGGGGAGGAGGCATGACCTAGGAAGGGG
CGCCAGGCTGGGCTTAGCGCCTCTGCCCTGAGGGAGGCTGAGCCAAAAACACGGGCAGAAAGCACTGCGT
GATCCACATCAACAGGGAAAGCTGCTGGAGACAGGAGCTGATGGAGAGCTGCAGTTGGCGGTGGTCTGCA
GCAGTCAGTCGGCTAAATGTGAGGGGCAGAGAACATCACGTTAAAGGCGACACCTCTGCACCCATCTCCC
TGGGCTCCCTCGGGTGGCGGCGGGCCTGGTGTACCAGGTCTCTGTTCTGAGACCCTGTGCTGGGGTGTTC
CCAGGTTTCTAGCAGCCTGACCGTGGGGTGTAGGCGGATCCCAGCCCCCACCCTGCCACGCTGTGACCGC
CACCCACCCAGGCCCCATCCCTGTCCTGGTCCTGAACTGACATAGTCAGTATGTTGCCGGACACAGTGAA
CTCCTTCAGAAGCACCCCTGGCACGGGAAGCGGTGGGGCATCCTGGGCCAGGCTCCTGCGGGCCAGCTCT
GCTTCCATGGGTGTCGCGAAAGGCATGGCGAGGTAGCTGGTGGGGGCCCAGTTAAGGCATCCTCTCCTAG
GACTTGGCCTGTGGCTCCGGCCTGCTGCTTACCCCAGGCCAGCTTCCCCCTCCCCCACTCCCCCACCCCT
CCCCCCTACCCCGGATTGCCCAGCCCATCCCCCCCAGGCTGTCTCCCCAGGCACTGGCCCAGTAGCACAC
CCCACCCAGCTGTCTTGGTTCCCCACTTTCCTTTGCTGCACCCCAAGCTGACTCCTCCATGCCCTTACAA
GACCCCTCCCCACCCTGCCCCCTGTGGCATCACCCGGCCCCCTCCTCATCACTCGACCCTCCATCCCAAC
CACCTCCCGCCACCCGCTCCCATCTTGCCCCCTTCCCCCCACCTCCTGATCCCCTCCTACACCTGGGTCC
CCCTATCTCCTGGCCCCTGCTCCCCTCCCCGCATGACCCGGTGCCCCTCACCCAATCACCCAGCCCCTCT
CCCCCACCCCCACCCCCTCTACCTCCCAGCCCTTACCTCCTCCCCTCCTCGCAGCTGGCCTCTCATATCC
CCACCTCCCAACCCCCACCCCCACCCCCACCCAACCACTTACTCGCATCTCCCCCGCCTCCTCCCCCACC
TGGCCCTGCCCTCCCCATCTCCCGGCCCCCACCTCGCCACCAGAACTGTCAGAACAGAACAGAACAGAAC
AGAACAGAATACAACTCAAGCAGGCGGCTCTCCGGCCCCCTGGCCCCGCATCTGCAGCATCCATTCAGCC
CTGAAGCCGCGCCGCCATGCGGACCCCGCGGGGCGCCTCCTCCCGGCCCCGAGGCCCTTGCTGCCCCTGC
GCCCCGGGGACCTCTGCCGCCCGTGGCACCCGCCTCTCCTGGGCCGCCAGCATTGCCCCCTGGGCCATCA
GGAATGCCAGGGCCTCCTGGGCCATCAGCATCGCCCGTCGAACCCCCTGTGCCCCGGCCTTCGGCCTGCA
TGGCTCCGGAGCCTCTGCCCGGCTCTCAGAGAGAAGGTCAGGGCCCACGAGGA

</dna_sequence>
        <protein_sequence>>NP_001318.1 cancer/testis antigen 1 [Homo sapiens]
MQAEGRGTGGSTGDADGPGGPGIPDGPGGNAGGPGEAGATGGRGPRGAGAARASGPGGGAPRGPHGGAAS
GLNGCCRCGARGPESRLLEFYLAMPFATPMEAELARRSLAQDAPPLPVPGVLLKEFTVSGNILTIRLTAA
DHRQLQLSISSCLQQLSLLMWITQCFLPVFLAQPPSGQRR

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>The preclinical immunogenicity and efficacy of NY-ESO-1 protein formulated with the ISCOMATRIX adjuvant (NY-ESO-1 vaccine) is described below. The NY-ESO-1 vaccine induced strong NY-ESO-1-specific IFN-gamma and IgG2a responses in C57BL/6 mice. Furthermore, the NY-ESO-1 vaccine induced NY-ESO-1-specific CD8(+) CTLs in HLA-A2 transgenic mice that were capable of lysing human HLA-A2(+) NY-ESO-1(+) tumor cells. Finally, C57BL/6 mice, immunized with the NY-ESO-1 vaccine, were protected against challenge with a B16 melanoma cell line expressing NY-ESO-1 [Ref1321:Maraskovsky et al., 2004].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1684">
        <gene_name>E2A</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>21423</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>255918153</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AB095606</gene_refseq>
        <protein_refseq>NP_001157619</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>10</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>80409164</gene_start>
        <gene_end>80433959</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>transcript variant 8</protein_name>
        <protein_pi>6.35</protein_pi>
        <protein_weight>65318.03</protein_weight>
        <protein_length>653</protein_length>
        <protein_note>Also known as A1; E12; E2A; E47; ME2; ALF2; Pan1; Pan2; VDIR; Tcfe2a; E12/E47; bHLHb21; AA408400; AW209082</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000076.6:80409164-80433959 Mus musculus strain C57BL/6J chromosome 10, GRCm38.p4 C57BL/6J
GGAATCCTACAGGACTCCAGCACTGAATTGGGACTGCTGGCACACTGAATAGCTACAGTATTCTTGGAGA
CAGTCGCTTTGTCGCTGTTGAGAATACCCAGGTCATGGCCTGTAAGCCATTCTAATATCCTTACACACAC
ACACACACACACACCTTATTCTAGCAACTTTTCTTTAGAGGTCCCCTAATGCATGACACCCAAGTATTGA
GGACCATGAGGACGGCCCACTTCACATGAGGAGGGCATGGTTTAGCCAAGGAGCACATGCCTGGCACAGA
CAGGCCTTGGGTTCATGTTCATGGGAAGAGGAAGGGGCAAGCATCTAGATCTTGTGCCAGGCCTCAGGGT
AGGGGTGACCCTTAGATCAACACTGGGTCTTTTGAATGCTACTTTAATAACCTTGTAGACCATGAAATAT
GACGATAAATTCTAGAAACAGAAACAGACATGAGACTTTTATACAAAAATTTGTTGCTTACAAAACATAC
GGAAAAAAAAGCTAAGGGAAAAAAAAAAGACACGGAAGGCCTCGTTCTTGCTAACTTTTGTCTACATTTA
AAAAAAAAATCTGAAAACTAATGTTCCTTTATTCTCCTTTAAAAAAACGAAAAATGCTTAGGCACGATGT
GCTGGTGGCTCTGAAGTAGAAGCCAGTCCCAGGCCGCCCTGCCAGGGCACGGTCCGACTCTTCCGTCTTA
CATAGTTAAGGCATCTTTCTTTCCTTTTTGAAAAGGGAGCATGCTGCTTTGTTTCCAGTTCTGGTTAACC
GAGAGGAAGGAACTTTTCTGCTTGGTCACTGGGGCCAAGCAGGGAGCTGTTCAGTGCCACCCTCCCCAGG
CCCTGAAGTGTCCCCAGAGCCCTCTCTCTGCTCATGCTTCGATGGAGACCTGTCTCATCCAGAACCGTCC
TGATGCACCCCGGGCAGAGATATGGTGGTCCCTGGTCCAACGAAGAAGCTGTGACGGCTCACAGGTGCCC
GGCTGGGTTGTGGGCCTCACCCAGGCCCGGGTGGGCGGCTGACAGGGCCAGCTGTGGGTCCCCGACCACG
CCAGACACCTTCTCCTCCTCCCTCCGCTTCAAGCAGGCTGCTTTGGGGTTCAGGTTGCGTTCTGGGGGAG
TGGGGAAGGAGAGAGCAGTGGGAGACGGTCCTCAGGTGGGGTCAGAGAGGGGCGGGGCTGTGCCGAGGCT
GCCCTGGCCAGCAGGATGGAACAGACGGGGCGGGCGCAGCCTACCTCGCACCTGCTGCTCCAGGCCCAGG
ATGACCTGCACCGCCTGCTGCAGGATGAGCAGCTTGGTCTGCGCCTTATCCGACTTGAGGTGCAGCTGGC
ACATGCGGCCCAGCTCCCGGAAGGCCTCGTTAATGTCCCGCACGCGCACCCGCTCCCGAGCGTTATTGGC
CATACGCCTCTCCCGGTCCCTCAGGTCCTTCTCCTCCAGGGACAGCACCTCATCTGTACTGCTGGGTCAC
AGCACCGAGCCTCCGTCAGCGGGGGCCGGGCCACTGCGTGCTATGTGTATGTAATGTGTGAGGGTAGAAA
GGGTGTCATGGGTGACTTGGTGGCAGTGGTGTGGTGCTGTAATGGGTGTCGTGGGTGGCAGCCAATGTGC
ACAGTGATAGCAGCTCTGCAGTGTGGACAACTGTGCCTTGTGCAGGTGACACACCCCTATGGGCATCTGC
CTGTATGTGTGTCCTTAGACCATGTCTCCGGGAGGCCAGGTGGTTACTCTGGGAAGGACAAAGGCCTCAC
TGTCTCCCAGCATGTACAGAGGGAGGCAGAGCCTTAGAGGGCAGCGGGGCCTCAGTTGTCCCTGTCTTTG
CTGACTAGTTTCTTGCTGTCCCTGCTCATGGCTTGGGTAATAGATTCAGGGCTGTACTGCCCTATATAAG
GCAGAAGCTGAAGCTTGGCCCCTGAGCCAGAGCTCATGGACGCAAACAGCACTTGGGCCCAAGTCCTGCA
CCCCAGCTGGGCCTGAGCCCCACACCCCAGAGCCAGTCACCCTGGCTGGGCCAGGAGGGTCGACTCATAG
GTCCAGGGACTTATGTCCTCCACTGTGATGGACACTCATGACAGTGACTCCAAATGACCAAACTCAAGGG
TAATGCTGTCACTGTCTGTGGTCGCAGACTGAGCCAGGCCTCTCTTGTGCTGAGCCTTCTGCTATCCAGC
TGAAGCCCAGCACCATGCCCCTCGCTACTCCTGTCTCAGGCCACCCTTGAACCTATCAGATCCTAGGTGG
TGGCAGTGGCCCCAGACCTCAGGACAAGCGCACAGACCAAACTGCATGTGGGCACCAAAGGCTGTGTGCC
CAGAGGGCCTTTTCCTTCCCTTTAGAAACTGCATGGCCTATGGGACAAAAGGCCCCTAGGTCACGGTGCG
ATCAGCCCTGTCCAAAGGGCAGCAGGTGCGAGGTGAGGGGCGGTGGTGGCAAGCGAAGCCAGGGGACAGC
CAGGGTAAAGGGGACAGCATGAAACACAGACAGCAGATAGACGGGCTTGGGAGTCACAGGGTGGGCTGCG
CACTCAGCCACCATAGAGACCTTGGAGTCAAGGGGAGAGTGGGTGGCTGTGCAGATCACACCATGCTGCA
GGAGAGAAAGGGTTAAAGGCAGGCAGGCAGGCCAGGGCAAGTGCAGGTTAAGGAAGCAGTGGGGTCCGAG
CTGTTGTCCTCCCTCATCAGCCCCGGGTCAGGTGGATTAACACCATTAGATGGGGAAACTGAGTCAGGGA
GAAGCTACTGTGGGGTAGGGAGCCTTCTAAGTTGAACAACAATGGTGGCTTAGACACCAGCTAGCACCTT
TGGGCTGGGGCTGGGGCTGGGCTAGCAAGAGCCTGGGGATGGGAAAAGTCAGGGTTGAAGTCCTCAGGCC
AGTGAGGCCAGTGTGGCAGACTCCAGGCCTGTCAGAGGCAGGCCCAGGATCAGCAAGGCAGGAAGGAGGT
CAGTCAGTCAGAACTGGGGCCAGCAGGTATGAAGGAGATCAGGGGGGTGGGGGGGGACGGGGACAGTCGA
CCTAGAGTGTGACCGGCAGAAAGACAACCTGTGGGACAGTGCAGAGACAGAGTAGGTACAAGGGACAGCT
GACATTGGGAACAGCTGGTGTGGAAGAGGGTGGATGTGATGTTAGGTAATGAGGATGAGGACAGTCAGTG
TGGATGGTGACAGAGTAGATGGGGACAGTCAGAATGGTTGGGGACAGTCAGTATGGATGGGAACAGTCAG
TATGGATGGGGACAGAGTGAGGACAGTCAGTGTGGATAGGGACAGTCAGTGTAGATGGGGACAGACAGTG
TGGATGGGGACAGTCAGTGTGGATGGGGACAGTCAGTGTGGATAGGGACAGTCAGTGTGGATGGTGACAG
ACAGTGTGGATGGTGACAGAGTAGATGGGGACAGTCAATGTGGATGGGGACAGAGTGGATAGGGACAGTC
AAGAGTGGATGGGGACAGTCAGAGTGGGGACAGCAGTATGAGGCAGGACTGGTCATTAGTGCCACAGTGT
AGCAAACTGGGCAGGGACAGTCAGTTCAGAGAGCAGCGAGTGCAGGGAACCTCCTGTCTGGAGGAGGGGT
GCAAGGACTGGTCGGTGAGGGACTGTCACTGCTCTGGCTTGGGCAGCAGGGAAGGAGCATCGCGGAGGCG
CGGGGCGCGGGCCGCCCACTGACCTCGCACCTGCTGCTCCAGGCTGAGGATGACGGCCACGGCCTGGTGC
AGGATGAGCAGTTTGGTCTGCGGCTTCTCGCTGCTGAGGTGCAGCTGGCACATGCGGCCGAGCTCCTTAA
AGGCCTCATTGATGTCGCGGACCCGCAGGCGCTCTCGGGCATTATTGGCCACCCGGCGCTCCTTCTCCCG
CTCCGCCTTCTGCTCTGGGGGGAGAAGGTCGTCCTCGTCCTCGTCTGGGCTATGGGGGAGGGGAGCCGGG
GGCCAGAGGGAGACAGTGAGGTGATGTGGTGGCCTGCAGGGCCTCCCGGGGTCTGTGTGCACGTGTGATG
TGTGTAACATGTGATGTGTGCGTGTATGGCCCAAGGGGTGGGGTTTGGCACCTGGTGCGCGTGCGTGGGA
CCTTCAGGTCCTTCTTGTCCTCTTCGGCGTCGGCTACTGATGCGATTTCCTCATCCTCTTTCTCCTCCCG
CTTGATCTCGCTGGCACCCGCTGTTGTGCCTGCCCTCCCGAGTCCTGAAACAAGCCAGGGATGAGGGGCC
CCTTGCCAGGACGCAGCTCCAAACAAACTGAGAGAGGCAGGCTGGATGGCTGCCCTCAACTGGGAGCTGG
CTCCCTGCCTGACACTGAAGTCACACTAGACCCTTCACAGAACCAGCAACTGCAGACCTGCTCTGTTTGA
AAATGGCAAACCAGCAACTGCAGAACCTGCTCTGTTTGAAAATGGCAAACTCACAAGTTTTAAAACTAGG
GGAACAGCTGTCCACTGGTAGCACACACCTTTAATCCCAGCACTTGGGAGGCAGAGGCAGGTAGATTTCT
GAGTTTGAGGCCAGCCTGGTCTACAGAGTGAGTTCCAGGACAGCCAGGGCTACACAGAGAAACCCTGACT
CAGAAAACCAAAGCAGTGGGAGGAGCAATCCCTGCTATAACCATGGGGCAGGGGGAGAGTCTGTGGACTG
GTACAAGAACACACCTGTCACCCCAGCACTGGGAGGCTGAGGTAAAGGGGTTGTAAGTTCAAGACCAGCC
TATGATACACAGTGAGGTTGTCTAAAAAAAAAAATCAAAATCAAAATCATAAACCTGGTTGTTGGCACAC
GCATCAATCCTGGACTTCGGAGGCCAAGGCTAGAGACCAGAAATTCAAGGTCATTCCAAAGCCAGCCTGG
GCTACCTGAGAAATTGGGTCAGGATATCAATAACAAGAACTGCCTAGAAAATGTCCACAACAAACATTGA
AATACAACAGGCACAATTCGGAGTGCAGACACAGTCTAGGGATTAAGAGCTGAGGGGGGCCTGCATAAGA
TCATGCACAGCAGACACTGCGTGGGCCTGGGGCTTCCTCTGTGGACGTCATCCTTAGTCTCACCCACGCC
CAATCCACCGAGCCCCTCACACAGCCAGTGCTAGCCTTATGGCTCCCAGCGTCACCTGAGGGTGCAGAGG
CCAGACATTCCTACCCTGCTCTCTGCTGGCAAAATGTTCCCCACACCCACAGGCCACTGCACACTGGCTT
GTCAGAGCTTCCCGTCTCTTCCACCCTCTCGTTCTCCCTACGAGGGCTCTGCTCTGCCCACAGGCCTGTG
CACAGGCTGCCTCCTTGCTGGAGGCTCCTCTGTACCCCTGTTCTATTCCCTCCACGTGTGCTGGCCTAAC
ATCTCTACAAGCACTGCATCCCCTATGGGACCGCGCCTGTCCTAAGCCCTCATGTGAAAAGCAAGCACTC
CATTTTGCCAGGTTCCTGAGCCCTGCCGTGTGCCTCAGTGCTCCCCAAACAAACCAGCACACAGGCTACA
TTGAGGACCTGAACAGTCAGTCTACCTGATGGCTCTTGGTCACAAGTGTGTGTGTGTGTGTGTGTGTGTG
TGTGTGTGCTCAAAAGGCAGGCAGGGACCAGGGAAAGACATCAAGTGTCCTGTTCTTGTCACTATGACTT
ATCCTGGAAACACAGAGATTTTCAGCAAAGCTGGCCACCACGCTCACCCTTGTAACATGGATTACGAGGT
CAGCACATTCATGTGAGAAGCACCAATCTTGGCTCCCCAACATCAGCTTTCAGTTTTGAGGCAGGGGCTC
ATGGGAACCTAGGGCTTGCCAAGTGCAGCTTGCTGGCCTGCGAGTCAGCCTGTCCCTGCATGCCCAGCAT
GGGTGCCCAGGCACACATTTGTGCTTTTTACACAGGCTCTAGGGTATCCAGTTCAAACCAGTTCAGGTCC
TCACGCTTCAGCAGATCAAGTATGGACTAAGTCACTCTTCAGCCCTGAGGGACACTCATGTCCTCCCCCT
CTCTGCGACAAGGACTGGGAAGGCCTTCAGCTCCCTGCTGGGACTTACCACTATAGGAGTCGGGAGGTCT
CTGTGAGAGGTCAGGGAGGGAACTGGGCTGGCTGGGGAGGCTGGCATGGTTATGCAAAAGACTGGCCCCA
CTTGTGAGGCCCTCCTCAGGATGGCTTCCCCCGACCTACAGAGGAGAATGACATGTCAGGGTGGCTGGAG
TCCCTAAATGTCACCATTCCCTGACCTAAGCTGATACTCACCAGGCCGGCATGCCGCCCGCCCAGTGACA
TGGGGCCGGTGAAGCTCGTGGTCAGTGCGCCATGGCCAGGCAAAAGCCCATGGAGATCGCTAGCGGTGCC
AACAGCGTGGCTTCGCAGGACATGGATGGCCTCGTCCAAGCGGTCCTCCATCTTGCTCTGCTGTGAGAGG
GTGAGGCAGGCACTGAGGGGCACGCACATGCATGTGCACATCTGCACTATTTGCTTCACACAGGACATTT
CGCTGCGGCCTACTCAAAACGTGTGATCGATCCCCTTGCCTTGCTCCTCCTAATTCTCCTGCCTCCACCC
CCCAAGCACAGAGAGGACAGGCAGATGTCATCAGTGTCAGTTTCTGCAGTGCTGATGAGGGGACCCAGGG
CTTGGCACACAACAGCAGGCACTCTGCCCACTGAGCCCCAGCCAGCCCAGCAGCAGTGGTGGGACAGAAT
AGTGCCTGGTGCCCTGGCCAGCAGGGAGGGAACACTCACCAGGCCATGGAGACCTGCATCGTAGTTGGGG
GATAAGGCACTGGGCGCTCCTGCCCGGGGCCACTGTGATGTCCCTGGAGAAGGAAAGGCACAAGTGGGAA
GACAGGCAGTGGGGACAGGAAGTGCAGCTGACCCACAGCACTCAGAGATGCCTGGCTCGGCCCAAACACC
AGACACTGCTCAACCTTCCAAGCTCCCTCTTTCCTGACTGAACACTACCCCTGATCCTAGAGGAGCCAGC
CCTGGCACACCTAGCCTGCAAGGGCACAGCAGAGGGAGGCCTCAAGGATGGTTTCTCTCTGTCCCTCCTT
GTCTGGGCTCACTGCTACAAACACAAACAACAGGTAGCTCCAGGAGGCCCAGACAGGTCAAGGTGAGGAC
TGGTATGGGACTCCCTCTGTAGACAGGCTGGCCTCACACTCAGAGAGATCCATCTGCCTGTGCCTCCCGA
GGGCTGGGATCACACAGTCCTGTGCCAACATGCCAGGCAGAGCAGGTTACTGTTACCCTCAACCTCCCAG
ACCTAGAAGCCCCCAGCCCCCATTTTCCTTTGCTCCTCACCGGTGCCCCAGCAACATCCACCCTGGAGGG
GCATGCCTGAGGTGAGCCCGCCTCCCTCAGATGCCACCTCTCACTACCTGACCAGGTCTATAGACTGGGG
ACAGCCCTGAGGTAACACATGGAGCCCATGCCCATCACCTACACACCTGGCAGGCCCTGGGGTGAACCCA
CAGGCGTTGAGGGGCTAGGTGAGAAATTATTGCTGGAGTGATCCGGGGAGTAGATCTGCAGTGGTGCGGA
CAGAAAGATGGGCAATCAGGGCCACAATGAGGCTACCAGAAGTCCCCCCCACTGCCACTGCCCAGGCCCC
TGCTCACCGAGGCCAGTGCCTTCCCAAGGGCATCCCCTGAGCTGCTGGCTGTAGTCCCTCGGGTGCCTGT
GGGGGAAGAGAAAAGCCCTAATGCTGTGTGCCACCATAACTGTGCCCCACCCCCTATCCACTCAAGACAC
CTGTATCCGGGTCTTGCCTAACACTGACACCTGCCTCCCGGGTGAACAAGGACTCCTTTCTGCCTCAGTT
TACCCCAAAATGAAGTGGAAAACCTTGTACCAAAGTCAACCTGGCTCAGACACTGACCACACCCTCTGGC
TCCAGCCTCTGGACCCTCTCCATGGAGCGCTGATGCCTGCCCCATGGGTCCCAGCCAGGCCCAGCAAACC
CCAGGTGTAGGCTCACCTAGGAGGCTTTCAGCTGCGGCCCCACTCACAGGGGGCGTGTGGCCGGAAGTCC
CACTGTAAGTGCCAGGGGCAGCCGAAAAGCTGGATACAGCTGGGAGCGAGCCATTAACCTCAGATCCATG
CAGCTGGTAGCCCTGAGGGGAAAATCAGTCGTCAAAGAGCAGGTCAGCAGGACAACACAAGTGTTGGCAC
TCCCCAGGTCCCCAAACCATGACACCTACCATGCGATCCTGCTGCTGGAGGCCCCCAAAGGTACCACTGC
CCACGGAGCTGCTGCCCGGTGCAAGGGGCAGAGGGGAAGAGCCGTCACCTAGCATGGGCCCAAAGCCCAC
CTGGCTAGGCGTACTCCAGAGCTCAGCTGATGGGTGCAGGCTGCCATCTGTGTAGAGGGGGGTTGTGAGA
CGAGACCCTGGCCCCACAGAGCCCCCCCAGGGAGCCCCACGCACCTGCCACGTAGAAGGGGGAGGGGTAA
GCGCTGCTGGGGGTCTTGGCGGAGGGGTAGGCTGCAGCATCCCTGCTGTAGCTGTCACCTGAGCTGGGCG
GATACACCTGCAGTGGGAGGGTACAGTCAAGCCAATGGCGGGGGACAGGCAGCTCCATGCCTAGGCCCTG
GAGGTCCTAGAAACCTAATGTCCCTTCACTACCTCTGAGATGATGCTTCTGCTTCTCCGGAACACCTTGG
CCTGCCTCACGTAGCAAACTCATAGTAAATCCCCAAAGTCCCACCTCCAGTGTTCAGCTCTATTGCTCCC
TATTTAGCATTTAGCAGTGCGGGAAACCTCCCTGTCCTTCTGGCCATAGGACCCTGGGCCAGAGTCAGAA
TCCCAGCATAGCATCTGGTCCTGGTGCCCCCCACAGCAGAGAAGGCACAGAAGAGAGCACAGCATTGACC
CTGACCAGCTAGCATTGGCTGGAACTCTGACAGCTTGAAGTAACAGTGGGGATCTGCCACCAATGTCTGC
AGTAGCCCATGGCTCAGGAGGGGATCAGCTGCTCATGTCTGCTTTGGCAGAGGAACAGAGAGCAAGTCTG
AGCTAGCTCCAGAGTTAACTTGACTTACCTTAAGTAGGTTCTATTGGTCAGTCTGACCTAAGCTTTGCCT
CCTATACCATATGTGTATTTCTGGACAGCCCCCACCCCCATGGCCCATCCTAGTCCTGATGTCAAAGGGA
AAACTATAGTGTTCTGGGGCCACAAACTTTTATATATGAGGTGACACTTTGACTCTTCTGCCTTTACCTC
CCAAGTGCTGCGGGAGGCATCCAGGTTGGAGAATCCAGCATACCACCTTTCTTAACGTGATTAAATCACA
GGCCCATGGTGCCATGAACCACTGAAGGCCAGTAACCATCTGCTGGGGTTGGCAATTTGCCAACTGCCAA
GCCAATGGGCGGAGACACTTACAGCTTTGGCAGGTGGGTGTGGCTTAGGAATAGGCAGGATCTGGCTACT
CAAGCACAAGAGGCCCCAGGCAGCCCCAGCTTAGAGGAAAGGAGGGAGTGAGGTGGGACCTGAGAAAGGG
CTTCCCTAGGGAACAGGGGAGGAGCACACACATTTTGCTGCAGCAGCCCTCAGAGCTCAAAGCCTGCTCA
ACTTCAGGATGTAGCCACAGCTTCTGGACTGGGAAACCCAGGAAGCTGTGGCAGCTAATGGCTCTAGGAC
TGTCCCACTCACCGAGGAAGGGAGACCAGGCGGAACCTTCCGGACCTTCTTCGGCTGAGTATCTGCTGGG
AGCAAGAGCAGAGAGGAAGGTCTGGCCACTGCCATCTCCACATGCCCTCATGTGGCCCCCTACCATGCTG
TAGTCAGGTTCCAAGGATGCCACATCCCTGACACTTGAGGGGCCTTGTTAATGCAGCCACTAAAAACCTG
TGCTCTGCCAGCATAGAGGAGACAGAGGCAGGCAATCTCTGTGAGTTCCAAGTCAACCTGGTCTACAAAG
AGTTCCAGGACAGCTGGGGCTACATAGAGAGACCCTGTCTCAAAATCAAAAAAGATCTAAAAAATCCAGA
TCCCACCCACTGGGACACCAAAGATGTAAGGAAACATCCTGGGGGGGAGGTGGGGGAAGGGGCACACAGA
ACTTGGAGTGGGGGCAAAACAGCCTGGTTGTCCCAGGCCAGTGCACCCCATAACTCTGGTCAGCAGCCCC
GGGGCCAGCAGATCTGGCCACCAAGTGTGTGGCCCTCACTTCAAGTATGATCCCAGTTCATGCTGTCCTA
GGGGAGAGCACCCCAGTGGCCACTGCGGCTTAGTGGCACCCACTCTGGCCTGGCTACAGGTCTTTCTCCT
GTTCATGGCTGGTGCCCAGCCCAGGCGTCAGTCTCTTCCACAACGGCCCCTCCAGCATCTCCCTGTCCCC
AGCCCTCACTCACCCAGGCCACCATCTGCAGCTCTCCGACGAGGGTTGCTGGGGAATGAGGGGTAATACT
GGGAGCTGCTCTTGATGCCCGATGGGGACAGTGGCCCGGGACTGCTGAGGCTCAGCTCACCTGGCAGGAA
GCCAGCCTGAGAAATGGGGACACCAGGAAGCTGAGGCTCATGGTCAGACCATACCGATCCCTGCATGGAG
ACCCTGCGGTGCCAGCTGTAGCTATCACTGGCACAAAGCCAGGCGGGGCCCATAGGCCTCACTGGTGCAC
AAACCCTCAAGACACACCCTCTTCTCAACCATCATGCTCCACTTCACAGCCACAATCACACAAGGGTAGA
GTCCACCCTGGGGCCTTGTCTGCGGGATACCCTGTAACAGCCGGGTCAGGGCTCTGAGACCCATATCCCA
AACTGCCCAGCTCTGTTATTCATGTGGTTGAAAAGCCTCCTTGGGGACTTGAGAGGCGACATGAATGTGA
CCATCCTTGGTGCACAGCTTGGCCCCTAACAGTCACTGTGGAAGTCAGGCTAGCTCTGCCCTTCTGCCTC
AGTTTACCTGACTCAAGGTGCCAACACTGGTGTCTCTCCCAAAGGTGGCATAGGCATTCCGCTCACTGCC
CTTGCCTGCAAGGGACAGAAAAAGTCACAAGAGAGCCCAGGAATGTCCCTCAGACAGTGGGGGTCCCACA
TGGGGGAGCTCTGGCAGAGCCCTGCCTGTGCAGTCGTGGCTGCCCAGGCCCCTGGATAGAGGACAGAGAA
CACAGATTCTCCCTAGCAACAGTGGGACCAACTGACCAGCAAGTGTCCCTGCTACTCTTCTCAGTTAAGT
TTATTCATTATTTCATGTATATGAGCACTTTGCCCGCATTTATATATGTATGTACACCATGTGCATGCCT
AAAAGAGGGCATCCTATCTCCTGGGCCTGGACTTATGTGTGTTGTCAGCCACCATGTGGGTTGGGTGCCT
GGTGTGAACCTGGATCCTCTGCAAGATCAACAAGTGCTCTCAAGCCCTGAGCCAACCTCCAGTCTTTATT
TGTTTTGCGGCAGGATTTCATGTAGCCCAGGCTAGCCATGAACTTGCCACCTTCCTGCCCGAGTGCCTGG
ACACTGAAGGCTGCTGACCCCGACAGACCTCAGTGCTGTCACAGGGTCCACCCTGGGGATTGGGGAGGCT
GGCAGAGACAAGCTGGAACGGACACAGCTGAACTCTATGGGAACTGCCCGAGGGCCCTGCCACCCTGTCA
GGCAGGACACCCGAGGGAGAGGCGGAAAAAGGAAACCCAAAAGAGAACATGTAGCCCACAACTGCAGAGG
CCACTTTAGGCCATGGTGGAAGGAGCCAGGGTCAGCGCTATCCAGTTCCGGACTTGGAGCAGAAGCAACT
TTCTCAAGTTATAACCACCGCCTTCATGCCTTTCAGGCCTCCTGACCCAATGCCTGGTGACTGTCCCCAC
AGTGCCCAGGGACACAGACAAGGCTAACGAGCACCTCTCATGACAAATAGCATCCGACTCACTGCCTGCC
GATCCCAGCCTGGGCTACTGACGTGATGGCTGGTGCTCCCCTATCTCACTGTGTCAAGTCCCTCATGGGA
TTAGCACAGGGTGGCCACACTTACCTCCAAGCCCAGCTCCTAGGAACGTGGAAGGCGGCAGGCTGCTGTG
GGAGTCACTGAAGTGGGCACCTTCGCTGTATGTCTGGGGGAGACAGCCAGGGTGAGAGGTGCAGGCACCA
CGCACACATGTGCACAGGCTAAGCCCTGTAAGCGCCTCACTGTGGTTGGGCACAACTGACAAAGGGTACC
ATGCGCTGTCTCCTCACCTCCTGCCCAGGAAAGGAGACCCGGGGCCCAGGCGTCTTACCCGGCTAGGGTC
AAAGGAAGAACTGTTCTGGTCACTGCTGCCCCAGGAGCCTGAGCTGGGTCGGTCCTCCAGTCCTGTAGGA
GGCAAAGAGAAGTCAGTCTAGTTCAGTCTTATTCCTCCTTCACCCAGATATGCTTAAGAGCAATATGGTC
AGACTTCTCCAGCCTACATAGCCTAGGATTCTGTCCCTACGAAGGCTGCTGTAGCTCGGTAATGTGACCA
CTAGCAATCTGTCTCTCCTAGAAGACTCCTACTCACCTGTCAAAACCTCAGCTATTGTCCCCACTTTTAG
TCCCATGGCCCAGCCTCTTGCTCAGCCCTATGTCTGATCATGCAAGGCTGGGCATGTGAGTCAGAAATGG
TCAACAACGGCTTCTAGGGCCTCAAGGACTTCAGGAGCAGTGTCTCCCTGGTACAGGCCCTCCTGGCGAG
GCCGACCAGCTCAGCGGGTGGGTAAGCAAGGCAGATACTGTCAGATGTGGACAGGAGGCACAGCTGGCTC
AGGCTCCTGCATCCTCAGAGGAAGGGTGAGGGTTAACCAGCCTGGAGACCAGAGGACCTTGTCCTAAGGG
GTGGGGTAAAGCAGGGCTGGGCCCTTATCTCCCCAAACACTCCTCACAGGCTGCTAACGGCCTATACCTC
TAGAATCCTCTTCTCCACTGCAGTGAATCTGCTTCTTCCTGGGCCCTGTCCCCATGCACAGAGGCCACAG
GGGCCACACTTCCAACTCCTCCCTGACAACCTGGCTGTATGGCTCTTCTGTGTGCCTCGGTTTCCCATTT
GTGAAGCTGGACAGGGGAGTCCATGTTCCCATCCCAGACTCCAGGGGCTCCCGCACTCAACTTCACACCC
TACAGCCCAGGACCCCTCGTCCCCACCTCCACACCAGAGACTTCCAAACCCCAGAGCATGAGCCTTTGTG
CTCATCATTCCCTCCTCAGAGAACCTGCTTAATCGTGGTCTAATTTGCATAATTGTGCATATTAATCTCC
CAACCTCATGAATATTCACTCCAATTATACCTTCCTGTGTCCTGATAAAGTTCCAATGTGTTGGCAGTGG
GGGGCTGGGATACAGCCATTGGGGGCTTCCAGGAACCCCTCTAGCATTAGGTGCAGTCTGTGGGTGTCTA
TACTCCCAAATTTTAGCTTTCCACTAGGACTTATGGTGAGGCTCAGGAGGGTAGGGTGCCAGCATCCACA
CTGGTTGCAGATCCTAGGAGCACTCGGCACTTGAGAAGCCCAGACCCAAAATGGCCTGCCCATGTGACCC
CTGCACTTGGCAAACACAGCCCCACTCCCTCAGAGCCTAGTAATACTGAGGATTCCACAAGACCCCAAGA
CCCTCTAGCACAAAAGCCCTGTCTTTTTCCATTCTATAAATAACAAAACTCAGGAGACCCCTCCCCCACC
CTATTAATACAGTTATTAAAATCACCCCACTGATAAATTATGCATCTTAATAACCCCAACATGAATATTC
ATAGCAGTTTCACTGCGTACTAATTAAAACGTTCTAACAGAAGATGTCGATGTCAGGCTCCCTCGCGCGC
TCTCTTCCTCTCTCTTAATCTTTTCCTGTCCCTCAAGGTGAGGTATTACAGGAAGTTGGAAAGAAATAGG
CACCTCCTTGGAAAGAGGCACAGGGTCCACTCCTAGCTTGGTCAGTCAAACCCAACCCATGTCAGGGGAG
AACCAAAGGCTTGGAGTTCTATTCTTTCGATGGGATTGTTGGCTCTTTGGCTATGACTTGTTCTCATAAA
TAAAGTTTTAGTGGCACACAGTTCTGTTCATATGTGATATATCTACAGCTATATTCAAGACAGGGATACT
TTTTTTTTTCCCCTTTTTCGAGACAGGGTTCAGGCTGGCCTCGAACTCAGAAATTCACCTGCCTCTGCCT
CCCAAGTGCTGGGCTTAAAGGCGTGCGCCACCACGCCCGGTGACAGGGATACTCTTACTACCTATTTGTA
TACGTTTATATAAGGCCCACTATGGAGAGAACCAGCTGCCCTGGTGTGGAGGACACTGTTTCTTGGACAT
GAGCTCACAGCACCAGCTTTGCTTGAGCCTGCAAGCACGCTCCTCACTCCACAGCCCATCACCAGGGACC
ATGTCAACCGCTGTGAGAGCACACCCACCCAAGTCCAGCAGACAATGTCAAGCCTGACAAAGCTCTCAAA
CAACACCTGCAGTCTGTCCCACGAGCTCCTCCCAGGACTACTGAGGTCAAAAGCAAGTTTGGGACCAGCC
TAGTCTTTACAACACACCTCAAAAACCCAAAAGTAACCAAGGAAAAAGTTGACCTATGCCCCAGCAGAGA
ACAGCAAATCCAGGATTCTACCCAAGCTCCCACTGGGGGATTCTGGGCCGTGCCACCCTGACCACGCCCT
AGGCCCTCCAGTAGGGGGATTCTAGGCAGAGGCTCCACCCCTGACCACGCCCCAAACCCTCCCTGGGGAT
TCTGGGTGAGGCCTCACCTCTGAGCTATGCAAGCTTCAGCTCTCACCTCACAGTGAAATCTAGGGCTGAG
GCCCTGGGCTCCATCCTAAAACTCGCTCCCCATCAAATCAAAAAGATTATCAAACATTTGGATTTTAAAG
TCCAGGAAAGAAAGATAAGAACTTTAAGAGGAGGAATCAAGATTAAAGTAGAGAGGAGTCAATGTTTGCC
ATCGATTCTCCAAGGCACAGACTCCACAGCACAAAATCAATACGGCAGACGCAGGACGGAGCAAGGACAA
AGGGACAGAGGCAGAGGCAACTTTACTGGCAGCAGGGGAATAGTCACACCTGATGGGAACAGATGGCCCT
GCTTTTGTTTTGAGGGCCAGGGCTCCCCTAGCCCAGGCTGGCCTCCTCCTGAGTGCTGAGATGGCCAGCT
CACACCCCACACTGCGCTTGAGTGGATTTTTTTTCCTTCTCCTAAATAATGCAGTGGTCGAGTGGAGGGG
ACAGATGCAGCCTTTGGGTAGGGTTGGCTGGCCAGACAGATCAGGAGATGCTAACAACTGAGGGACGGTA
TGTGATAAACAGAGTCAAGTGTGGGCACGGGGGAGGGCTCAGTTGGGAAATGTTTGCTGGCACAAGTGAG
AGGACCTGAGTTCGAGTCTCAGAACCCACCTAAAAAGCCAGGCACAGTGCTACATAAACTTGGGATCCCA
ACACTGGGAAGGTGGACAAGGGAGGCTCCCTGGAGCCCACTGGCTGGCCAGTTTAGCTAGATAGGTGAGC
GCCAGATGGAAAGACAGACTTTGATCCAAAAAATGCAGCACAGAGTGATTACAGAAATCGCCACTGTCAA
CTTTTGGTGTACACAGACAGACAGACGAAAGCACCCTGACACACACACATACACACACACACACGCAAAC
ATATCCAGATACACACAGTCAGACACTAGCACACTGATACAGATGCACACATAGAGCAACATGATAGTCA
CAGAAAGAAAAGCCACCAAGAACAGCAGGTCACAGAGGCACAAGAACAGCAGAGTTCAGACTCTGCTCAG
TTTTTTTCAACTTGACACAACCCAGGGTCACCTGGGGGGAGAAATCTACACTGAGAAAACCACATGAGGA
CACTCTAAGACGACTCACTGTGACACTTGTCACCCATGTGGTTCGTGACAAGGTCTCACTATATAGCCCA
GGCTAGCTTGCATCTATGTAGCCCAGGCTGACGATCCATTTGTCTGCCCAGTGCTGGGATTAAAGGTATA
GCCACCATGACTGACAGCAACTGAGTTCTTGCCTTCCATTCTGGAGTTTCTTGATTCAGTCTCCAGTGAC
CAAATAAAACAAACTAATATAAAATAAACCCCATTGGGTCAGACATTTGACTCAGAGGGTAACAGCACTG
GCTGATCTTCTAGAGGCCCCAGGATCAGTTCCCAGCACCCACATACAAGATGCAGGGGATCTGATGCCCT
CTTCTGGCCACCGTGGGTATGAGACACACATGTGAAGCAGATATACATGCAGGAAAAACACGAAATGCAT
AAAGTAAAAGAAACACCCCCCCAATACAGCTTCTTAGAGAAGGAAGCTCTCGGGGGCATTTCTTCACTGT
AAGAACCTTCCCCAAGTTCTTCTGTTGTCTGACTCAGCGTCCCCTGCTCTTCCGCTTTTTACTCCAGAGA
TGAAAATGCTAGTGAAGCCTTCCTATGTAAAGTGTGAGTACAAACCAACAAGGGTTGTGTGGGGTGGTGT
ATGGGCAGCCCTATTCAGTGAGAAGAAACCCTAAGTTTCAGGCTCCTACTGGAGTAACTACTTCATCTAT
GTCCTGCATCTGTGAGAAACGGGGACTCAAGACTCTGTGATCCCAGGTCATCATGTAATATGGAGCTAGA
AATTCTTCTTAAGACGTATTTTTCTGCCGGACGTGGTGGTGCACGCCTTTAATCCCAGCACTTGGGAGGC
AGAGGCAGTCGAATTTCTGAGTTCGAGGCCAGCCTGATCTACAGAGTGAGTTCCAGGACAGTCAGGGCCA
CACAGAGAAACCCTGTCTCGAAACAAAACAAAACAAACAAAAAAGATGTACTTTTCTTTCTTTTTCTTAA
AGACAGGGTCTTACTACAGCACTCTGGAGGCCTGGAATTCCCCATGTAGAACAGGCTGGCCTCTGCCTCC
CCAGTGCTGAGATTAAAGGTATACACCCACAACTGGCCTAAAATGTGTCTTTTAAAGTTGATCCGAGCCA
GACGGTGGTGCATACCTTTAATCCCAGCACTTGGGAGGCAGAGGCAGGTGGATTTCTGAGTTTGAGGCCA
GCCTGGTCTACAGAGTGAATTCCAGGACAGCCAGGGCTACACAAAGAAACCCTGTCTTGAAAAGTCAAAT
AATTAAAGTAATTTCACAGAAGTGACAGCTGGACAGGTCTCCGGGGACCTTCCTGAGCTCCCTGAGGCAC
CTGTCTCACAAGACGATTCCAGCTGGGGGGCAGCAGGGGATGGGGGGGGTTCAGTCAAGGATGTTAGAGA
GAGTACAATCAGAGCCCCTTGACCTTTCCTGCAAACCGAACTGTGTCACACAGTTCCGTCGTAAGGAGCG
ACTACAGACTACAGGTGGACATGAGTTGTGAGGCGGGGCTGTCTACAGCATGTTGATGGACAAGTGGGGT
GTCACACGGGACCTGGCACTTGGGTCCTTAAATGTTATCAAGAAAAAATGCTGACCAAATGCAGGAGGGC
TGAAGCTGTGGCACCAACTCACCGAGAGTGATGGGCCTCTAAGGCCTAGCTACCACCCACGTTTGAGCAC
TGATTCTGCCTTCCGTGGTCCTATGTGGGATTGCCCCAGAGTGGCAGGCTCCAGTCTTGACTGTGCCAAC
AGGGCCTGGGAGACCCGCTCTGCACACCCCTCCTGTGTGCCTTCATCATCAAGAATGGGGCGAATATCCT
TTCTGCCACCCAGGTTGAAGTGACGTCCCCTCCCAGGTGACACAGCTCTAGATGTGCCACCTACTGAACT
AAACTGATCATGATGGGCAATCAACATGGTCCCTGTGACAGGTCACACAGCCCAAGGCAAAAGGGCTGCA
TGCTAGGCTTCTCTGGACCGCACACGAGCCTGGTACCCAAGGGTCCAAGGTTCGGATGAGGGTGGGTCGG
GAAGGCTAGACAGCCTGGACAGAAGCCAGCGGGTGTTCTGCCAGGCCAGGCTTACAGGAAGAGGTCCGTC
AGGCTGTCCCACCCCCGGGGGCCACCTCCATGTTCCCACACAGGTGTTGATGACGAAGGGTAAAGGGTCT
GGAGAACCATCACTATGAACAGGCCAGCCCTCTCAACCTGACCTTACCCACTGGTGCGGCAGGAAGCCTG
GGCATTACGGATTGGGGGCTGCTTCCGGGGTGGCGGAAGCCTCTGGGGATTTCCAGGCCTCCAGCAGTAC
CCAGATGGCCCTCCGTTCACTTCCTCAGTCCAAGGGGAAGACAAGGCACAGCAGTGACTGATAGCCCTGC
TTTCAGGGAGGGTAAGCAAGAACGACCCACATCAGCCTTCCAAGTCTGCCGCACGGTCGTCACCTCCATC
CAGGGCAGGCTGTCTATGTGCTGCTTCTCTTATAAGGTCTTACGTGTCCTAGCTCCTAGGCAGTCCTAAC
CCCATGGTCCCGGGCAAGCCAGACTGACCGTGGTTATTCCAGGTGTCTAATACTTGTTCAAAATCCAATC
ACCGGGGGAGGCCAGGCCTGGATTCACAGTTGGAGCAGACAAAGCATGGAGGCCTGGGTTCCAGTTCACC
CAGCCCAATGGGTTCTAGAATGACCACACTCCCACCCACCAGACAGATCTCCGCCACCGTCCCCATGAAC
ACCCCCCCAAGAGCCCCTCAGTCCTACCTGAGCCTGCAAACTGGGTTCCCCCGAGGGAGGCGGGCCGGCT
CTTCCCATTGGCCACAGGTAGCGGGAACATCTGTGGGGACAGAGAAAAGTCAGGTGAATGGAGGCTAGAG
CTGTGAGCAGTTGGGGTGTCTGGCTGAGGCCCAAAGACTAGGTTTCCTGGAGTTAGGCTGGAACAGAGCT
GTGGGCAGGGATAGGGTACCCCAGCTGGAGGACAAGCATAGAGAGAAAAATCACACTCAGTAGAGGACAT
GGCTTCCGATTGGTTTTTGTGCTTATACAGCTTTGAGTGTCACTTGTTTTTGAGGCAGGGTCTCACCTTG
GCTGACCTGGAAATTGCTATGAAGCCTAGGCTGGCCTCAAACACACAGGGACCCGCCTGCTTCTGACTGA
GTGTTGGGGCTACAAGTGTGTGGCCAGCGGGACATGGTGGCGCACACCTTTGATACCAGCACTCAGGAGG
CAGAGGCAGGTGGATTTCTGAGTTCGAGGCCAGCCTGTTCTACAAAGTGAGTTCCAGGACAGCCAGGGCT
ACACAGAGAAACCCTGTCTCGAAAAAAAAAAAACCAAAACCAACCAAACAAACAAAAAACAAAAAAACCA
AAACAAAACAACAACAACAAAAACCCAAGTGTGTGGCCATTTTTTTTCTTGAGACACCATTTCTCACTGG
CCTAGAGCTTGCCAAATAAGCTAGACTGGCTGGCCGGAGGGCCCAGGTGATCTCTGGTGCCCATCTCCCC
AGTGCTGGGTTACAGATGGGTGCCTCTGTGCCCCACTGGCTGCTGGGCTTGACTCAGACCCCAACACTCT
ACCCACTGAGCCATCTCCCCTGCCCTTTTTTTGTTTCTGAGATGGGCATTCCGTAGCCCAGGCTTACCTT
GAATTTCTGATCCTCCTGCCTCAGCCTCACAGAGGTACCCCAATGCCACAATGCCTGGAGGTGATATGTT
CTCTCCTATCCCAGCTGGACTACAAAAAAACGCTTGCTCAACAGGTGGTCTGTGAGAAGCCCAGGCAGGT
CTGGGAAGCTCACTCCTCGGCCAGCACCCTATAGATCCAGACATCCCTAGATATCATGCAGGGCCCCCAC
TTGTCTGAGTGGCTCACTTAAAGCCATCATGGGAGGATATACACTGTGAGGAGGTGTGGCCACCTGCAGT
AAGGGGAGAGTGAGGCTGTCAGCCCAGCACTTGGGAGGCAGAGGCAGGCAGATTTCTGAGTTTGAGGCCA
GCCTGGTCTACAGAGAGAGTTCCAGGACAGCCAGGGCTGCACAGAGAAACCCTGTGCTACACAGAGAAAC
CCTGTCTCGAAAAACCAAAAAAACAAAAACAAAAAACACTCAGAGGCACAGACAGACAAACCATACACAC
CAGCCAACTCCCAACCACCGAGGGCCATATTTTACCTGTGTGTGGAGCCTAAGCAACTGAAGGGACAGGA
AGGCCCCAAGCTGCCCACACTGTCCCCTAAGTCATCCCACAGACAACTAGGCAGTGACAGTGTAGCCCCA
CAGCCAGCGGGTGGGGGGGTCACCATCCCTACCTCTCATTCAGGAGGAGCAGTGGCCGAAGTGGGGCCCT
GTCTGGGACCAGCATGGGGTTGCAGAGGGAGGCTCTGTCTCAAATGCTAAGATGGGGACCAGAGAGCGAG
CTCTGAGGATAACATGCTCTTCCAGAGGACCGGGATGAAGTTCCCAGCAACCACATGACTGCTCACAACT
ATCTGAAACTGGAGCTGCAGGGTGGCTAATGCCCTCTTCTGACCTCCAGGGTACCCTGCATAAACAAGGT
GCACAGGTGCTTTCTCTCAAGTGCATGCTCTCGCTCTCTTGCTCGCTCGCACTCACACACACTTAAATAA
CTGAAAGAAAAAGAACAAATTCTAGCCAAGGGGGCACAGGCTTCTCCATACTTGCAGACAGGAGGATTTA
GGGTATCTAGACCAACCTGGGCTCCAGGAGATGCTAGCTCACAATCAAAAGAATAAAAACTACGACCCCC
ACCACAGGCCCTGCCATCCTCGCCCCCGTCCCCCGTGCTTTCACCCCAGTTTCTCATCTATCCCACAGGA
CGCCCTCTCTTGACCTAAATCGGGGGAGATCCTGAGCCCTGCGACTGAAGGGGGTGGCCCTGAGGCTCAG
GGTGCTCCCCTGGGTCCACTGGGCTGAGCTGCACCCCCAAGCTGCTGTGTTCCAGGCCACTAGGCCGTGA
CCTGACAGTTTAACAACAACAAAAACCAGGGGCCAGGGCCTCTGTCTGTTCAGCCTGGGGCAAACCAGGA
GGCAACGACAGAAAATGGGCCTTAAAAATACCAGCGGGGCCTTCCGGAACCCAGTGGCTCTGTCCCTAGG
GCTGCATTTCCGTAGGGTGGCTGGGGCCGTTTCAGTGTGAGCATGCTTGTTATTTGGTAGAATTCTGTGG
CCTGGAGCCCTTGTGGGGATGGGCAGGGGAGCTCAGACCGAAAGTCGTCCTAGAAACCAGGGCTCAGTAG
TGCTTCTGGGGGTGGGGCCAAGATTTCAAGAATCCAGAGTTTAGAAAAACATGCTGGTTCTTGAAGGACA
GGTCCACTGCCCCCGCCCCCAGGGTGCCCACTGCACAGATGGGTAAACTGAGAATCCTAGGCTGTGGAGA
TGGCCACCAGGAGGCTCCTTATTGGGTGTTCTGTGACTTCTGTCAGCCAGCAACCTCTCTGGGCATTTAC
ACAGCTGGAGGAGAAGAGCCATCACAGAGGGTGGGAACAGCCACTGCAGGCTGTATGCTAATGCGGCAGG
GCTGCTAACAGCCTTCCCAGGCCAGAGTCTCCCTCACTAGCAGAGCACCCAGACTGAGGAGGGTAAGTCA
CCAGCGGTACAGGGGGTTGGTGGCTTCCTTCTCTAAGGCCCCAGCACGTGTCAGAACAGCTTGGGACTTC
ATTCTCACAGCCTGTAACTTCGATGGTCACTTTTCTAACTCAAGGCCACCAGCCCCCACAGGCACTTCTG
CAGTGAACACTGGGGAACAACCACAGCTCTGAACAGCCCTTCCCTCTCTCTGGGCTCCGTTCTTCTCCTC
ACTGGTGAGGTGCCAGGTGGGAGCACTTCTTTGGTGGATGTCACCAGGCCTACGGTAGGGGGCTCCATTT
CCTCTGAGATTTCCCCCACTCTTGCAAGCTGGGGGCTCCACTCCTACTGGCAGACACTCCCACTTCAACC
CTACCTTCCAGGCCAGGAGTGGTGGGGTGGGTAGGCACTGAGGGGCGGGGGGGGGGGGGGGGCGCTAGCT
CACCATGCTGAAGTCCAGGAGGTCACTCAGTTCCTTGTCAGAGCCCACGGGTGCCATTCTCTGAGACTGG
TTCATCATCCACCCAGGACAGCAGGTGTTGGAACTGGGGTGCGTCCCCCAGATCTAGAGACAGCCCTGTG
GTGACACCAGGGGACAGAAGGGGAGAAACAGAGGGACTGAGAGCGTGGACAAGTGGGCATTAGAAGTGAG
GCCCTGGGGTCAATGGGGGTCCTGAAGGAAGAGGCAGGAGCCTGGGTTCTGGGGGGATCCTCTGTAGATC
CTTCTCATGAGCAAATGAGTAGCTTGAACAATGGAGAGAAGGGGTACACATATGAAATCTCCCAATTCCC
AGAGGCCCACCAGAGTGTCAAATTGCATTTTAAAGGGGTGGGGGGGGGACTGTCTATGGGCCCTGTCCAG
GAAGAAAGGGGTGGCCCAGGCTCTGCCTCCTCCAAATAAACTTGGTGGAACCTTCCCATGCAGCAGCTGT
CACAGAATACCCAAGACCCTGGTCACCCCAAATCCAAAGCAAAACAAACTGTGAACCTCAAGGCTCTAGT
GGGTGGAAGAGGTGTTATCCCTGGGACCCACAACTTCTCCCTCTCACCCCCAAAACCCAACCTCATTCAA
GAAAGCTAAAAAACAAAACAAAATTAAAACAAAACAAAACACTCAAACCAAGTGGGCCTCTTATTGTCAG
GATATATCCGGGAATTATTCCCAGTCAAGTTTAAAAACATCCTTTTACCAACATCACCGGGGGGGGGGGG
GGAGGTCCCCAAGACCTGGGATTCCCCTCAGGTCCCAGGGGCTCTGCTCCACCAGTGGGGGAGGGGTTCC
ACCTGCCAGGCCCAATCCACCCACCCCAGGAAAGACTGAGGGGCCAGCACGCAGTTAAACCATTAACTTT
TTTTTCCAGTGTTCCCCAGAAAGGAGCTAGGGCAGCAGGGATCCGGAAGCCACAGGCTGGGGAAGGCGAT
TCTGGGGTTGAGGGAAGACCCACGTCCAGAAGCTCAGGAACCCCAACTCTTTTGTTTGTCAACTCACACA
GGGTGTGAAACAGGCACCTCGGGCACCCCGCCCCCACTGCTTTTTGTCTTTTTTTTTTTTCATCCTTTTT
GGAGGATGTGTGAAACTGACTCTTTTCTTCTTCTTCTAAGTTGTACGAAACCACACTTTTTTTGTGGGGT
ATTTGAAACCGATTTTTCTGGGTAACCCCAGGAGAGGTGAAACACTGCTCCAGTGGGGGCGGGTGCCACA
AACACTCTTGGGAGGGGAGGAATGGGACAACCTGGGTCATCTTGGATTGGGGGTAGGGAAGCAGAATTGG
GGATGACCCCCCCCTTCTCCTCCCTCCCCCATTCCAGCAGCCACTGCGGGAGGAGGAAGGTTGGAAGTTC
TGAGGCTCGCAGAGGCCACCATCGTGTCCCAAACCCTGAGCTGTGCCGCGCCCCACATTAACACAGAGCA
GATGTTCCCATCTCGGGGTCCCTGTGTCTCCCCTCCTTCTCTGTACCCAGAGATCCCTTTCTTGTAGCAG
ACAAAAGGACTTGCTCTCTTTCCTCCAAACTCCAGTTTAAATCGGGGGGGGGGCATCCTTAAGTGGCAGG
GGGGGTCTTCCAAGATCTCCAGGAGTTGGGGAACCCCAAGTTAACGAGGTGAAGATATTGGGTTCACTCT
TCCTTCCAAATTCCAGTTTGGATGGAGATTTGGAGACTTCCCTGGGTGGGGGTGGGTTGGAAAGGGACAC
CTCCCACAAAATCCCCAAGAATTAGGAACTCTAAATTGTGGAGTGCGATATAATCCTCAGCCTTCCAAAC
TCCACTAGGATCAAGGGGACACCTCAAGTGAAGAGGTGAAGGTGGGTGATAAGGGGACACCTCCCCTAAG
ATAACCACGAGTTGTGGAACCACTAGCTAATGGAATGAGGAGGTGGCCCTCTCTCTTCCCTCCAAACTCC
AGCTCCGATCAGGAGGACCCCCTCTCTAAGGGCAGATGGAAAGGGAACACCTCCCCTAAGATCCCCACGA
GTTGGAGAATTCCTATCTGATGAAGTTGGGTGACCGTCCACAGAGAACCGTCACAAAAGAGGCCTGGGCA
AAGTTTGCTCTCAAGTGCGCGCGTCCCCTCCACGTCGCCCCCCTCTCCAGGCGCGCAAAGTTGAAGACAG
AGAACAATGCGCCGCCGGGCCCGGGGCCCTGTGCAAGGGGGACGCGTGCACACTCCCCCGGGGGCTCACC
CCAGCCCTAGCCTCCCCGCGGACCCGAGAGAGACCCAGAGGCAACTTTTTTTTTCTCATGCACTAAGCAG
AGGGGGGGGGTCCCCACCGTGCGCGCGTCCCCGTGAGCCCCACGCGCGCGTCCGGGGCCCCTCCGCGTGC
GCTCACCTGCTGGGCGGGGGCATGCACCGGGTGCACCGGGGCTCCCTGCTGCCCACCGCCCTCGGGGACC
CCGGGGACAAAAGGGTGGCGGGCGCGTCCCCGAGGGTCGCGCGTGGGCGGCGGGAGCGCGCAGGGCTCGG
GGTCGCGCGTCCTTCCTCCTCCCCACTCGCGTTCGCGTCGCCTGGTCTCTCTCGAGCTTCTCTCAGAGCA
GGCCCCGCGGGAAGGGACTGTAGCAGAGGCGGCGGCGCGCGGCGGTGGCCCGCGGTGGCCCGCTACGCCC
GCAGCCGCCGGCGCTGCCTCATCTTCCTGCGGCGGGAGACATGTTCCGCCCCCCCACCCCGCCCCGCGCC
GCCCGCGGAAGCCACGCCCCCAAGTGACCACGCCCACTGTCGCCAAAAGCCACCTCCCCTAAGTCGCTGC
AGCCGCGCCCCGACCGGATACACAGATCCCTCCACTACCTCTTGAGGCGATAGTAACATACACCACCTCA
CAACAGTCACTGCCAGAACACCCACAAAGATTACCATGACACCAAGAATCAACCCGTATCTAATACTAAA
GTACTTCCGGCAGAGATAGTCTCTATCAAACCGAGGGAAAGACTTAGGAACTATCTTCCTACGCGGCGGT
ATACACGCACTGAGCG

</dna_sequence>
        <protein_sequence>>NP_001157619.1 transcription factor E2-alpha isoform 1 [Mus musculus]
MMNQSQRMAPVGSDKELSDLLDFSMMFPLPVANGKSRPASLGGTQFAGSGLEDRPSSGSWGSSDQNSSSF
DPSRTYSEGAHFSDSHSSLPPSTFLGAGLGGKGSERNAYATFGRDTSVGTLSQAGFLPGELSLSSPGPLS
PSGIKSSSQYYPSFPSNPRRRAADGGLADTQPKKVRKVPPGLPSSVYPPSSGDSYSRDAAAYPSAKTPSS
AYPSPFYVADGSLHPSAELWSTPSQVGFGPMLGDGSSPLPLAPGSSSVGSGTFGGLQQQDRMGYQLHGSE
VNGSLPAVSSFSAAPGTYSGTSGHTPPVSGAAAESLLGTRGTTASSSGDALGKALASIYSPDHSSNNFSP
SPSTPVGSPQGLPGTSQWPRAGAPSALSPNYDAGLHGLQSKMEDRLDEAIHVLRSHAVGTASDLHGLLPG
HGALTTSFTGPMSLGGRHAGLVGGSHPEEGLTSGASLLHNHASLPSQPSSLPDLSQRPPDSYSGLGRAGT
TAGASEIKREEKEDEEIASVADAEEDKKDLKVPRTRTSPDEDEDDLLPPEQKAEREKERRVANNARERLR
VRDINEAFKELGRMCQLHLSSEKPQTKLLILHQAVAVILSLEQQVRERNLNPKAACLKRREEEKVSGVVG
DPQLALSAAHPGLGEAHNPAGHL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene721">
        <gene_name>Eng</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>13805</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>226437649</ncbi_protein_id>
        <gene_locus_tag>RP23-17P12.4</gene_locus_tag>
        <gene_refseq>AL772271</gene_refseq>
        <protein_refseq>NP_001139820</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>2</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>32646594</gene_start>
        <gene_end>32682668</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>transcript variant 2</protein_name>
        <protein_pi>6.15</protein_pi>
        <protein_weight>63897.93</protein_weight>
        <protein_length>652</protein_length>
        <protein_note>Also known as CD105; AI528660; AI662476; S-endoglin</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000068.7:32646594-32682668 Mus musculus strain C57BL/6J chromosome 2, GRCm38.p4 C57BL/6J
GCGCATTTCCTGCCTCTCTGGGCCGGGCTGGATGAGCTGAGCTCCCTGCCCTGACAGTCAGACCCCTGCC
TTCATCTGTGTCCCGTCCCCAGGCCAGGACCGCCGACAGCTGCTGCCCGAAAGAGCCCAGTGACTCTTTC
CCACCACCCAGTCAGCTAGAGACTCCTGCCCTGCTGTGAGTCTCGAGCCCACTTCTCCTGACTTCTCCGC
CGCCACCTCAGAAGGCTGGAGCAGGGACGTGGTCGCTCCGGCCGCCTGCTCCCTTCGGATCCCCGCGCGA
ACCCACGCAGGCCCCGGCGCCCGCCCGCAGCCTTACCTCTGGATACCGGATAAGGCCCAGCGCACAGACT
CCCGGGTGGACAGCATGGACCGTGGCGTGCTCCCTCTGCCCATTACCCTGCTGTTTGTCATCTATAGCTT
TGTACCCACAAGTAAGTGTCCAGCGCCCCTGGGTGGGAACAAGCCCAGGCTAGACCCTGGGTGTTACAGG
TCTTATTCCCATGTCCCAAGCTACTAGCTGATGAAGCCACCCCCAATGTATTAGGAGGTAGAAATGGGAT
CACCAACTATTTTGGTTCAGTGGGAGTAAAATGTTTCATAGGATGCCAAACTTAAGCATTAGACGTCTGG
GGAGAAGTGGGATAAGCTATTTAAGTTAGCGTTGGCACCTTCCTGTTATCCTTCCTGCTGTGTTCAGCTA
TCAAGAAGGCCAGGAGCTACACTGCTATGCATCACTGAGAGTATTCCCTCCCATCTCTGAGCCTTGAGTT
TCCCATTTGAGGAAGTTTAGGAAGGAGGATGCAGAAGTAAATTTAGGCTCTGGGTCCAACTTTGACCTCC
TTGTTTTCTTGTATGAGCCTTGAGGCCTCCGTGCCAGAGGATGCTTAGAGCAAAGACTGGTGATGAGATC
ATTTGTCCGAAGAGTTTCTGTTTCACTAGCTTCAAGTTCTCCCAGCATTCCCGGGCTTTGCCCGCTCCCG
GAACCCCCCAAGGGCACATGCTCTGGCCTTCTCCATTTGCCTTTCTGAGAAGGGTACAGGCTCCATTAGG
GACTCTGTGGATCTTCTCAGCCAGGGTGACTATTGAAAGTGATCTGAGGAGGGTCGGTGAGGAGCCTGGA
CCCCAGTCCTACTCACGAAGGGTCACAGCAGGGCCTGGTCCCCAGCCACCTCCCTGAGGATCCCCGCCTA
CCAACCTGCAGATTCAGGGGCATGTTCAAGGGTTGGGGTGGGCAGCCTGGAAGAAAGAGTATGGGAAATG
ATGGGGCCATCCTGGCACTCAAAGTCCACAATTGATGGGAAATCTGTCATCGCGGGTTAACCGGAAATTG
AGTCTCAGAAACACTGAGTGACTTATCAGGGATTTGACTCAAGGCCTGTGGCCCCTCAGAACCCTTATTC
TGACCACACATGACCCTGCAAGATGGCTGCCCCAATTACCCCATTTCCCAGAAGAGAAAATGAAGGCTCT
AACCTTCCAAATCCACCTACTCCAACAGAGTCTGACCCCAGGCTGGGACAGGATTCCAGGCCCTCTTCCC
CCCGGCTTGGGGAAACCTGCCTTGTAGGATGGGAAGTGGGGTGTCAGTGTCTAGGTGACTGTTCAGAGGA
TAGACCAGTAGACTGTGGTGGTATGCATATTTCCTCAGAGCTGATTTCAGGTCACAAACACTCAGTTCTT
ATTTGGAAATCAGAGTACAGTGGCACACAGCAATTGCCTCTCTCCCCTACAGAGCTGAGAGGTACAGGTG
CCCGCAAGGGTACCTGAGGGTAACGTGGCTAAAAGAATTAGGAAATATGAGTTCTCATTGTGACTAGCTG
GGTGTGTAGTGCCATGGTAGGGCTCTTACCCGCCATATGGAAGGTCCTGAATTTTAAAAAAAATTATACA
CATTTATATTTACAGATGCATATGTATACATATATACATATATACATACATACATACATACATACATACA
TACATAACTTATTTTCTTTCTTGAAACCAGGTTTCACTATGTAGCCCTGACTGGCCAGGGCACAGAATTT
AGCTTTTCAGTGCATAGGGTGAGGGACTGGGCACAAAAAACAGGCCCAGTCTCCCAGAACACAACACAGC
AGAATTTTCTAAATCTGTAACTTGTGTGTAGCGCCTTACCCTCACAACTCAAAGCCAGCCCTAAGCTGGG
TGTGGTGGTACACAGCTGTAATCTCAGCACTTGGAGGTTTGAGGCCATACTGTCCACTCAAGTCCTGGGC
CAGCTTAGATTATGTGGTGAGTTCGAGGCCAGCCTGGGCTACATAGTAAGACTCTATCTAGAAAAGAAAA
GAAAGCAAAGTCAGTCCTTGAGAGTTACCTGTCTACTCCACTGTAAGGATATGTGGCCCACAGGTACCAG
ATTCTACCCAAATGTCTGTCAGCAGGGGTATCATTGAAGAAGTCTTGTCACAGAATGTCATCCAGCAGCT
ACCACAATGGATCCAATCACCATGACACATGTGTATGGGACACATCACACCGTAAAAACCTTACACAGAC
ATCCGTTTCTACTGATAAAACAGCACTGATGCCATTTGCACAGAGAAACTTCTGGAAGGTTGTGCACTCA
GTGTGGCCGCGCATTCGGTGTGGCTGTTTTCCAGTGTGCGATTTTCTCTAGACTCTGGAGAAATCGAAGA
CGTGGATTTGTTTTATTAGTTTATCTGTATGTTTGTTTTGCCTGTATGCATGTCTGTGTGTCCAGGGAGG
TACAGACAGTTGTGAGCCTCCAGGTTGGTGCCAGGAATCGAACCCTGGTCCTCTGGAAGAGCAAGTGCTC
TTAACCACTGAGTCAACTCTCTGGCCCTGGAATTCCTTTAAAGAACATGCGTGTGGAGATTCTTAAAGAA
CAACTTAACCATGTGTCTGTTCCCCAAGGAAAACAGATGAATGAGGGGCTCTGGGGTACAGCTATGTGGC
AAAGCACTTAGTAGGCTAGGAGGACAGAGGGAGGCATGGCGGCCACACCTGTCATACCAGTAGTCAGGGG
GTAGAGGCGGGATCAGAAAGTGGATCACAAGCTCAAGGCCAGACTGGACTAGATGAAGACCTGTCTTGAG
AGAAGTGGGGGGCAGGGGAGCAAGGGAATGGAGTGGGGGAGATAAGAAGAGATGGGGGAAATGAATTTTA
AAATCTTAGGTCCAGGCCGGGTGTGGTGACGCACGCCTTTAATCCCAGCACTCGGGAGGCAGAGGCAGGC
AGATTTCTGAGTTCGAGGCCGGCCTGGTCTACAGAGTGAGTTCCAGGACAGCCAAGGCTACACAGAGAAA
CCCTGTCTCGAAAAAAAAAAAAAGTCTTAGGTCCATGGGCCAACAAAACAGCTTAGCGAATAAAGACCTG
CCGCCAAGGCTAATAACTTGAGTTTGATTCCCCAGAATTTATATAATGGGAAGAGAGAGCCTTATGTTGT
CCTCTGACCTTTGCATGCGGTGGTAGACACACACACACACACACACACACACACACACACACTCACACTC
CTTCTGATTAAGGCTAGCATATCAATGGCAGTGTTTTTTTTTTTCTAGAATATTCCATGTCCAGTCTTCA
GTACTGCAGACAAACACTCCGAGCTCTGTTGGCATCTATAGGCAGCCTCCAGGGCTTCACCAAGTATTCT
GGTCCTTCAGATGAGCATGCGAGAGTCCTGTGGACCCTTCTGAACTGCCGTATTTTTTTCATGGCATTAT
TTGGACTCTATCACAGTTTGTCTGCAGTTCTGGAATATTCTGTTGCATCTGCACGCCACCATTTGAACAG
CAAGTCCCTGCTTGAATATCTAAGTGGTCTCCCTTCTGTTCCAGTTTGGCGCACGCACCCATCCCCGTAT
TTTGGCTTATGGCATTTGGAAGCTCCTGGCACTTGTGGCATGAGCCTGGTGACTGGGGTTAGGCACCTGT
GGCTGAGCAGTGTCTCAAACAGTAGGTGTCATTTGCCTGCGGCTGGGGCGGAGAATGACCTGAAACTTCC
TTACCGATGGCTGGGAATCTTGGATTCAGTGCAGAAGGAGCTGGTGGCAAAGGGCAGAGATTGAATCTAT
GGTTTCGAGGTCACATTCCAGAAGGAAAGAGGGATGAACAAAGAACTGCATTAGTCAGGACAGTAGCTCC
CTGAGACCTATGAGGACATGACCACTCCTGCGACCACTATTGGGACATTCTCTCTCCACACCCAGATTCA
ACTTATTCACATTAAAACCACCTGTAACTCCAGTTCTAGGGAATCCCATGTCCTCTGGCTGCCACAGTCA
CATGCACACATCCATGTAGTGCGCATAAGCTCATGCAGGCATGCACACATACACACGAATAATAAAATAA
ATCTTAAACAGTTAAAAAAAAAAAGATTTTCTCTCACCTCAGCCAGAGAGACAGAGGGACAGAGGACTTG
CTCTGTGTCACATGTGGACCAGTGCTGGGACCTTGGAGGACAGGCCTGCTCCGTGTGCTCTGGGGTCTTC
AGGCAGGTCTGGCAGTTCTCAGTGACAGGCCCTGATTTCCACCCCAGGCTGTCTGCTCTAACCCAGCCTC
CTCTCTGGGCCGTTTGGTGGCTAGGCACAGGAGATTTAGAACTCTGGGGGCCCAGTTCTGGGTTCTACCT
TTTCCTCCAGACCAGGCGTTGGGGCAGCAATTCTGCAAGTTGAGGTGGGGTGCCCATTCCAGAGTAAATT
GGATTTAACATGGATGTGTAAGTAGGGTGCTGGGTATGCCAGTTGGCATTTATGTGGCGCTTACTGTATA
CCAGCACTGGCACTAGTCTAGGCTGTTACCCCTCTGTTGCAGATGAGGAGACTAGGAGATAAGAGCAATT
GCTAAGTAACACAAATTAGAGTGGATAGCCATGTCCCTGAACCTTGGACCAGCCGTTTCCATGAGTTACC
TAAGGGGATGGACAAGCATCTTCCTGTGGTTTGAGATTTGCCCCCGTGCCCCCACCGTCTCAGCCCGGCA
ATGGCCGTCCCTCTTAGACAAAGCTAAACAGCTGCAACCAAGTATGGGTGCACTTGGGAGACTGAGACAA
GAGAATCAAGAATTCTAGATGCGTTCCACATCCATAGTCAGTTTCAGGGCAGCCTGGGCTGTGGGGAATC
CCGTCTCACAAAGCAACCCAGCACTGGGGAGCATTTGGAGGACATGAGTTGGGTTCCCAGAATCCATATC
ACATAGTTCGCAATTGTCTTTAACTCCAGCACTAGGGGATCCAGTGCAGGCACCTGTACACATACACACA
CACACACACACACACACACACACACACATACACACACACACATTAATTGAATCTTAAAAAGAGAAAACCA
GAGGTTGGGAGATGGCTCAGTGGTTAAGAACACTTGTTCCTTCAGAGGACCCAGATTTTGTTCCCATGGT
TATGGCGCACATACATACAAATACATACACACATACATACATATGTACATAATACACATACATATAAAAA
TAGGTACATATATGCATACATACACATGCATGCACACATATACATATATACACACATGCATGCATACACA
CAATACATGCATACATACATGCATGCGTATATACACACATGCATACCTATATACATACATACATACATAT
AAAAGACTCATACAGAGAAAAATAAATGCATGTGAAACAACACAACAAGAACACAGGCCAGGAGTGGTGG
CACACACCTCTAAAGCCATCACTCAGGACAAGGAGATGGCAGGTGAGACTGCCTGAGAGGTCAATGAGGT
CAGCCAGAACTGCAGAGTGAGACCCTGTTGTTTGTTTGTTTGTTTGAGACGGGGTTTCTCTGTGTAGCCC
TGGCTATCCTAGAACTCACTCTGGAGACCAGGCTGGCCTTGAACTCAGAGATCTGCCTGACTCTGTGTCC
TGAGTGCTGGGATCAAAGGTGTGCACCACCGCTCTCTGGCTAAGACCCTGTCATAAATGGGGAGAATGTT
CATCTAGTAAGCATTTGCTATGCAAACACTGAGGACCTGCATTCCGTGCCCAGAGCTCACTCAGTAATGT
TGATGATGATGATGACAATAATAATAATAAATAATAGTAATAAATTTAATAAAAACAACCGGGCGTGGCG
CTGGGCAGAGCAATCCACATGCTAGTGAGTAGGAGCTGGGAAGCTCCCTGGGGGTCACTGGCTATTCAGC
TCAGTCTGCCCAGTGAGCCCCAGGCTAGTGAAAGACTATCTCCATCAGCAAGGAGGTGGTGCTGAGGATC
CTGGGTGTAAATTGCACACATGCACAAGCACGCATACACCCTTACACACTTACCCACACACACATGAGAA
ACAAAACTGCCCAAACCATCAAAACAGATAAAGGCAGTGAAGTACCACCTGACTCTAAGACATCGGGGAG
AGGGGGGGCCCACAGACCTAAGGAAGTACCTCTCCCCTCTCCCCTTCCTCTTTCTCTCCCTTTTGTTTTG
GTGGTGGTCGTCGTGGTTTGGGTTTTGTTGTTTTTGTTGTTTGCTTGTTTGTTTTGGCTTTTTTGAGATA
AGGTTTCTCTGTGCAGCCCTGGTTGTCCTTGAACTCACCCTATAGACCAGGCTGTCCTTGAATTTAGAGA
GATCCATCTGCCTTTGCCTTCCGAGTGCTGAGATTGAAGCTGAGTGCTGTCTCCCCGTTGCTACCACCAG
CAGGAGGCTAGGAGGCACCTGCTTCAAGAAGAGGCCACAGTGGGTTTTTTTGTTTGATTATTTTTGTTTT
TGTGTTTCTTTTTGTTTTTTGAGACAGAGTTTCTTTATGTAGCCCTGGCTGTCCTGGAACTCATTCTGTA
GACCAGGCTGGCCTGGAACTTAGAAATCTGCCTGCCTCTGCCTCCCGAGTGCTGGGACTAAAGGCGTGCG
CCACCACACCCGGCCAACAGTGGTTTTGACAGTTGAGACAAGTTGGTCAGGCTATCAATAAAATGTGGTC
ACTAGGGTCTAGACAGGTGACTCTGCAGTAGCCAGCACTTGCCATTCTTGTAGGGGACCCAGATTTGGTT
CCCAGAGCCCACATGGCAGCTTACAACTGTCCATAGCTCCAGTTCCAGTGGTCCTGATGCCCCTTTTTGC
CCTCTGAGGGGCACTGCCAGCACATGGCACACAAACACACATGCAGGTACACACTTATGCACATGACACT
AAAATAAATACATCTAAGAGGACAGCCGTTGGCCTGAGAAGGGGCAGAGGCAGGCAGGGTGTGTTTGGAG
GAAATGTTCACCTCTGACTGGAAGGACACAGTCCCCACAGCAGTTCCTGAGCCATCTCCATTCATTAGCG
GATGGCTTAGCGCTGTGCATGTGACCAGCTCTCTGAAGGTGACAGAGGGTTTTTACCACCTCAGTGTAGG
GATCATAATTGGGAGGCATAAAAAGGAGCCTGGCCGGCGGCTGCGGCACAGTTAGGATAGGAATTTGTGG
AATGTGTCAACCTCGCCATCCTTTGACCTCACTTTAGACCACAGCTTGTGAATTTGACTCAGTGGCTGTT
GGGAAATTCTGGGAAAGGCATACAAGCGGGGATCTGTGTCTTGCTGGTGGCCTGGCTGGGAGATGGGACA
GCTATGAGGTTGTGATTGGACTCTGAAGAGAGTAGAGGGTGCCTGAGTCGGGTGACTGAAGAAGACTTTG
GTCTGAAAGTGCCCTCCTCGGTGTCGCAGACACTCATAGCACCCATGGGAACCACGGAGATGAGCATCAG
AACTGACTTACAGAAAGCACACGCTGGGGCTAGAACTAGACCCTCAGAGTTCACGACCAGGGCCTGTTGC
TGAAAGTCTGGGTCTCCTAGGGAAATTCTTTAGCCTCCCTAACTACCCATGAGATGGGCATAAGAACCCC
CCCCCCACTGCCCTCCAAAGGCTGCTGTAAGGATCCAAGGAATGTAGTCATACAAAGCTTCCAGACAGGG
ATCGTGATGGGACTTACTGTGTGGTTATTATGCCTACCAATAAGGAGAGCGAGGCCTTTATGACCAGGCC
ATCGGGCCCCAGAGCAACTTGATGACCTCCGGGAGCTATTTGGGGTGGAATGGGGACTGGCTGTGTAAGG
CCTGTGATTGTGGGGTGAAGGAGGAGGAGGAGTAGGAGGATGGTCCAGACGTTTCCTCGGGAGGTCAGGG
TCACCCAGTTCTCCAAAGGTGACTTGTAGGCCCCCAGCGGCCCTTCCTCCAACAGTTCCCTGGAGGCCCC
GGGCAGTTCCCTTGGTACCAGGGGATTGTTTTCAGCTGGCCTGGGCCCGCCTTGGGCTGCTGGAGACAGG
CTCAGGCGTCACACTCCCTCCTGTCTCCCCATTCTCGTCTGTGGGGTGGGGGCAACCAGTATTCGAAAAG
GCCCCAAAATAAATGGGCCTCTTATCTGATCTCCCAGCCTGGCCTGTTATCTGATCATTACATAATGGCC
AGGCCCGCGGCCTCTCCTGCTGGCGCTGGCTGACGGCATGGAGGAGGCGGCCCCAAATGCCAGAGGAACT
GGGGTTCCTGGAAGTCTGGGGAGGGGGGGTCAGGAAAAGTCCGAAGATCTGTAGGCCAGATGGTGGGCCA
TGTGGAGGGAGTAGTCGGAGACCCAGAGGGCAGCCATACGCATGTATGACCTTGATGTGAGTGTCCTGTC
TCTTGAGGTTGCAGCCTCCCCTTCTAGGTAGGAGTGGGGACAGACCAGATGGGAGACTGACAAGAGGAAA
TGGTGCCAACCCTTAGTCTGTTGGGGTGAGGGAAACCTCAAAATTAGTCCTGTCCTCAGCTTCACCCCCA
CCCTTAAATGCAGACAAGAAAACTACAGAAATGAAACTACCACATGCCCTGTCTCACAAATGGCTCCCAA
CAACCTCCAGGGCCGGGTGCTTTCTCTTCCTATTGCCATTGTAGAGATCAGGAAACTAAAGCCCAAAGTC
CTGAAATCATTCCCTCAAACCACACAGCTAGTCAGAACTAGTTGGGCCTGGGATACTGGGCCTGGCTCCC
AGGGACTTGCTTTGAACCAAACTCCCGTATTGCTCAAACACACAGATGTCTCTTGCAAGTTGCTACTGCG
ACTAGAGTAATGGCTGCTAAGTTTGGGCTCTTACAGCAGCAGTAGATACCTGCTCCTATTCTCCTCCCAA
GATGGAGATATCTGAGGGAGGGTGTTGGTGGGGTGTAAGGTAGCCATCTTACCTCCTTCTCTGACCTCAG
TGGCTTTGGGCCCAACAAGCTAGCTACAAAGGTGGGGGAGAAGGCTGGCCAGGCCACAGGCGCCTGGGGT
TCAGGAAGAGCCGGCCTGCCCCCCATCCTCAGCACTGGCGTCAGCTGGACGTGAAGCCTGGCCCTCCTCG
CCCATCTTTGATCTCCAAGAAAACAGGAAGTGAACACGACAAGATGGAGACATAAACTTCCAAACAGCCT
CCCCTTCTCTGTCCCTCCTCCACAGCCCCCCTTCCCCTCAGCACATTCCTTAGGACGAGGTGTAGGGGCC
TCATTTCCTCTTCCTCCTCTGCTGGGTCAGGGTGAAATTCCATTCCTCTCCCTTGGGACCCGTGTTTCCG
GGCCGCCCTGCAGCCGACTGTGAGGCCTGCTCTACATCACCGCCTTTAACCTGGGCTGCTCCCCCTGAGG
CAGGAAATTCCCTCCTCAGAAACGGCCTCTCAGGAATGGACACCTTGAGGTCTGAAGAGGGAAAACCGTT
TTTCCTCCTCAACGCCACCCGGTACACACACTCCTTCCTTTGGATTGAACTGGCCTTAAGACTTGGGGTC
CACCATGGGCCCTACCCCTTGGGTCACCCTGCCAGCAATAGATAGCTGGGCACGGTGGCACTTGCCTTTA
ATCCCAGCACTGGGGAGGCAGAGACAGGCCATCTCTGTGAGTTCAAGGCCAGCCTGGTCTACAGAATGAG
TTCTAGGCCAACTGAGATTACACAGTGAGATCTTGTCTCAAAAATACAAAAAGAACAAAAAACAAACAAA
TACTTCTGAAAATTAGCTAAAATTTCATTTCAGGCAAACTGTTTTTGCAATATAAGTATATAATTATATA
TTTAAAATTATACCTTGAAAAAGGATTCCCGTTTATCTGAAATTCAGACTTATTGGTACCCTGGCTCTTA
CCTTCCTTCCAACATTATACCTACTAACACTATGATCCTAGGAGAGACTTTCTCCGGCTGTGTCTCAGTT
TGCCCATCTGTGGAGAGTATGAAATGATATCTACCATGTAAGGTAGCTATGAAGATGTCATACGCCTTGA
GCTCTGGGCTCATACGTGTACCTGGGAAATGTTCAGAAAGTGAACGTGGTTGTATCCAGGCGTGGTGGGG
AATCCTAGCATTAGGGAGGCAGAGGCTGGAAGACCTGAAGGTCAAAACCATCCCTGGCTACATTGAAGCC
AGCCTGGGCTACCACAGCTCTGCCTCCAAATAACAACAACAACAACAACAACAATAACACAACAATAATT
CTTTTTTTTTTTTTTTTTTTTTTTGGTTTTTCGAGACAGGGTTTTTCTGTAGCCCTGGCTGTCCTGGAAC
TCACTCTGTAGACCAGGCTGGCCTCGAACTCAGAAATCCGCCTGCCTCTGCCTCCCAAGTGCTGGGATTA
AAGGCGTGCACCACCACGCCCGGCTAGCAACAATAATTTTTTTTAAGATTTATTTATTATTACATCTAAG
CACACTGTAGCTGTCTTCAGACACAGGTGTTAGATCTCACTAAGGATGGTTGTGAGCCACCATGTGGTTG
CTGGGATTTGAACTCATGACCTTTGAAAGAACAGTCAGTAATCTTACCCACTGAGCCATCTCTCCAGCCC
CGCAACAATAATTCTTAAAGAGACTAGGAATACAATTAGTACTCTTCCCTCCCAGTGCCAGGGACTGCCT
TGCCCACACTAGACAAACATTCCTGCCCCATCCTCCTCTGACCTAACCTGCTTTCCCACTATGCTTTCCC
AGCAGGTCTCGCAGAAAGAGTCGGCTGTGATCTACAGCCTGTGGACCCCACAAGGGGTGAGGTGACGTTT
ACCACCAGCCAGGTCTCCGAGGGCTGTGTAGCTCAGGCTGCCAATGCTGTGCGTGAAGTCCACGTTCTCT
TCCTGGATTTTCCCGGAGTGAGTACCTCAGGCAGGTTTGGCGGGGTCCCTTAAGAATCGGAGTAGACTGG
GTGAAGGGTGACTTCTTACAGCTTTACTAGCACCTCAGCCATGGGGCTGATGGGGCAAGTCCTGGGAGGG
CCCTTAAGAGGTAGAAGGTATGATTTTCTGGAACACATCACAAGAGCCAGCTGGAGGGCCGGTGACATGG
CTCATGGGTAAGGGAGCTTGTGGCTCACCGGGTGAGGGCACTTACCACCATACAGGATGACGTGAGTTCA
AGTCTCTGAACCTACATAAGCAAAGAACATCTTCCTCAAGTTGTTCTCTGACTCTCGTGAGCGCACACAC
ACACACTTTTTTTTTCAAGACAGAGTTTTTCTGTGTAGCCCTGGCTGTCTTGAAACTCACTCTGTAGACC
AGGCTGTCCTTGAACTCACAGAGATCCACCTGCCTCTGCCTCCAGAGTGCTGGGATTAAAGGCATACGCC
ACCACACCTGGCAAAAAACAAAAAAGGAAAGGACCCAGATAGAAAAGAGCTAGTTAAATGTGTTAGTGTG
AACTAGGGAAGCTTGTGTCTAGATGCAGCTAGTGACAGGGCTCTCAGAGCTTTTCAGAGGACATGACTCC
ACTCTAAGCTGGGCTTTGGAGAAAGGGTTGAGTTCTAGTCTACCTCACCTCAAACATCTGCGAGTCCACT
AGGCATCCTTTGAGATCCAAACCCCGCAAGCCAGCCTCAAGTCTGATCTCCAGCGGCTTGCCTCCAGTTT
GTCTAGATGTAGAGCAGCCATAGCCCATTTGTCAAATGCTTGCTGCATGCTAGGTGTTAGGCTGCAGCCT
ACCGTCACCTAGGAAGCCACCAGCTTTGTCTGGTTGATTAGTTCTTTTTTTGAACTAGGATTCATGTAGC
CCAGGCTGGCCTCGGTTTTGCTATACAGCTAAGGATGACTCTAATCCTCCTATCTCCAAAGTTCTGGGAT
TATAGGTACGTGTACCACATCAGACTTACATGACCCTGGGCTTCAGGGTCAGAGTCTCATGCCTGCCAGG
CAAACATTCTACCAACTGAGCTACATCCCTAGCCATGGATACAGACATGGCGGGGGCTCATTAGGGTCCC
GTATTATTCTCATTTCTTGGAGGAGGAAACTGAGTCCACCCTTGAGAAGTAAAACATGAACTGAAAGTCA
GAGGACAGACACACCAGAATCCTAGGGACCTCAGAGCCAAGGTCAGGTTCACTGGCCTGCCTGGGCTGCA
GCCCACGCCTAGCTGATGTAGACTAAGGCCACAAGAATGAATTAGGAGCATGGGATGAATTTGTAGCCAA
CCTGCCCCTAAAACTGTTGAGTTACTTTGCATTTTGTGTAGTGATAAGAAGGTGCCCAGACCACCAATAT
CGGGGGGCCCTGCCTGCCACAAGGACTGTGGGCTTTGATAACCCCCAAGGTACAGATAGTACCAAATACA
TTTTATTTGGCTTTCATAAGCATAGCAATTGTTTTTCAAGTCAGTAATGATATGGAAAAATAAGAAGCTT
TCCTGTAAGTTCATTTTGTTCTCAGGTTTAGGCCCTTGCACCTCTTCTGGGTGATCCTGGGGTCTCCTGA
CAGCAAAGCCAGGCAGAGGAAGATCCCAGCCAGATGGCCAGGTCTCTGGGCCACAGGTGTGTAGACAGTT
CCAGCCAGGACACAGGAGACTGGTGTTGTGGCAGGGTACTTCAGCTGCTAAGCTTAGGCAGGGCTTCCTG
GAGGACGTGACAACACAGAGGAGCTGGACCCTCCCAAGTGTGGGCACAGCCGGGGAGAGGATGTAAGCAG
AGGGAGGGAGCTGCCCGCTCAGACTCTGACAGGACCTTGAGGTTCACCTAGGAGCAGAACTGGAGAAATG
GCAGTTATTGAGAACTTGGTTTTTAGTCTATGAGCAATGGTGACCACTGAAGGAGTTTTAGGGCTGTGTT
GTGTGTGGGGTGCCACAGTAACTCATGGCATAGTCCAAGGATTCCAGCATCTGTGACAAGAGAATTTCCT
TGTAGCCCTCTGCCCCTTCCAGAGAACTTTATAGATCATGGGACATTTTTATTTTTACTTTTTTTGGTGT
TTTGGAGACATGGTTTCTCTGTGTAGCCCTGGCTGTCCGGGAACTCACAGAAATCCACCTGCCTCTGCCT
CCCAAGTGCTAGGATTAAAGGCTTAGGGAGCTGCTGCCACCTCTCTTCCCAACCGACCTTGTGACATCTA
ACCCATCAGGCCAGGCCTCCAGCCCTAGGACTATGAAGGATATGCATTTTGAAGGGGTAGGAAAGAGAGC
TGGGGTCCCAGGGTTCAGTCCTGGACCTGTCATTGGCCTGCACCTTGCATAGAGCTTGAGCTGCTGAAGG
GGCACCTCTTATATTTTTCTTGGGTTCAGAGGCTCGCTCAAGAATTATGAAACTATGGAACCTGGTTCAG
GACCTGGTCTATTCCAAATAATTAATATATTCCATAAATGAATGCATATTTGTGTAATAAATGCATTCAA
ATGGGACCACGATACAGTGTTTAGGAGCACGGCTTTTAGTCAGGCATTGTAGTGTGAGACTGAGCTCCCA
GTTACTCAGGAGCCTGAGGCAGGAGGATGGCTTGTAACAGTACACGTTTTAGGTCATCCTGGCCAACGTA
GTGAGAGTTTGCTCAGAAAACAAACCAAGGAAAGAGGACGTAGCGTCTGGAGCCAGTCAGTCCTCATCTG
AACCTCAGCTAATCTCACGGCCACATCGCTTTGTTGGCAAAGCTGTCTGAACCCTGGTCTTCCCACGGGA
AACATGGAGACAATGATAATCTTTCCTACCTCACAGGTTACTGTGAGACTCCAGGATAAAGAAAGCAGAA
CACAGAACACAGAACCTGCCCACAGTGAAAGCTCTAGTTTGGCTGTTATAAATTTTGTCATTATTACTAT
GTCTCCTGGACTCCATTTTTCATCTGTAAATACTTGGACATGACCCAGTTTCCAAACATCTTCCATTTAG
TTTATTACTCTTTAAACCTCACACTAGTTCGAACTCAATGGAGAAGAGGCAGAGACTGAAGATCCATTTT
CAGGCAGGCTAATGGAGGTGGAGGCTCGTGGAGTTCCTGGCCTATCTGTCCGTGATCCTGGTCAGTCTTG
GTGCTTTGACCACCAAGAGCCTGTGACCTGCTGAGCACTGACTTCCCTTCCTGGGAGTCTCCAAGAACGA
GATCCATGCCACTCCCTCACTACCAACTCTACAAGGGTGCTTGCTGTTGTCAAGGGTAGAGATAGGAAGT
AAAGCTGAGCCAATCACAGGCCAAGAATTGATATGAGTGAGTGAGTGAGCGAGTGAGTGATGGAGTTAGC
CATCTTGGGAAGGATGAGAGGCTGTGGGTGACAGGGAGATACTCACCCGTTGTAGAGAGGAAGGGATTTG
GGGGCTGCACATGGAGCTCAGTTGTTAGGGTGCTTGTCCATCATGAGGCCATGGGTTTGATCACCAACAT
CTCATAAACAGCGAGTAGCTCAGCACCCAAGAGGCAGATGCAGGAGCATTAGAAGTCCAGGTTAGGCGAG
AGCGATCGCTCAGCAGCAAAGAACACTTGCTGCCCTTTCAGAAACCCCATGTTCTTTTCCCAGCACCCAC
ATCAGGCAGTTCACACCCGCCTGTAACTCCAGCTCCAGAGGCCCCAACACCCTCTTCTGGCCTCTATGGG
CACCCACATACAGACACATACACATAATTAAGAATAATTGTTTTTAAGTTCAAGGTAGCATGGCACGTGT
AAAGGCCTAAAGGCCAATTGCGTGGGTGAACAGGCCTAGTGGGGGAGGCACTGCCTCTCCTGACCTTTGG
CCTCCTTTGTCAGTCCCTGGCACAGAAAGATGGCTTTCTCGTCCATCCCCACATGGCTTTATAACCATCA
GATTTCCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGGCAGATGAGTGGTGG
CAGCCAAGAACCCCAGGAAAGTGACATTTGAAGTGTCTGTCTGTCTGTCTGTCTGTGTGAGTGTGTGTGT
CTGTGTGTTGAGGAAGTCTGTAGACAAACTAGGGGCTGCTGGGCAGGGGTTATCTCACTGGGTCCCCAAA
GGACAGGCCGGAGCCTGGATTCCGGGAGGGGCCTAGGGTCACATCCTGACCTTCAAGACAGGAACAGGCC
TGGTGCCTCAGCGATTCCCATCAGCTGACTACCCTGTTCTGCTGTCCCAGACCTAGGCAGCCAAGCTTGT
TTGGCTGCTGATTTGCTCCCCCCCCCACCTCCCCCTGCCCTCGGCCTGGGCAAACTCAGGGAGCTCCTTC
CTCAAGATAGGAGCCAGCCAGGCTCTGACTCACGCCTAGCCAGAGGGGGCATGGAGACAGCGAGCCAGGG
GAACCTCCACTGATTGTCCTCAGCTATCATGGGAGACAGTGAGGGGCTGGGAAGGCAGGGTGGCTCTGAG
AAGTGGTATCACACTGAACAGCCTCTCTGTCACCCATTTCCGGCGACACCTCTGCTCCACAGTGGGAAAC
TTGCAGCACTGAAGGGATGTACCTAGAATCCTTCTCTTACACCGCAGAGCCTGCTCAGGGTGCCCAGAAC
CCCTGAGTGTCTTGCTCAGTTGTGTCTGAGCCTATTGTGCAGGCTGCAGGGGAGTGGCTTTTATTATTGT
CCCCAGAAAAGAACCCTGCCCGGCTGATGTGAGTTCTTCTCTACCTGAAGAGTGGCAGAGCTGGCTCTGG
GGGAGGCAGCCCAGAGGATTCTGGGCTGGGTTTCTCCCATCTGGACGCATGAGCACACTCACTTTGCTCT
CAGAAGCTGAAGAGACCAAGGGGCCCTGGAGAGGGAGCTTCCTTTGTGTCTTTGTGCCTTGCAGGTGATG
AGCAGGGAAGGGAACCGGTGTAGCAGGGTCAGGTGGCTGCACAGGGGCTCTCATCATCTCCCCGGCTTCA
GCACTGAGTCACCCTGAGAGGACATATTTATTGGATAGACAGACAGATAGGTAGTAGACGATCAAAAAAG
GGGGGGTCCATAAAGCCTGGAGAAAATCAAATGAAGTCTTTTAAGTCCTGAAAGTAAACAGCTGTGAATC
AAGAACACTGTACTCGCAAAACTATCTTCCAACACTGAAGAATAAAAAAAGGCATTTTGATGCTGGGCAG
TGGTGGCGCATGCCTTTAATCCCAGCACTTGGGAGGCAGAGGCAGGAGGATTTCTGAGTTCGAGGCTAGC
CTGGTCCTACAGAGTGAGTTCCAGGACAGCCAGGACTACACAGAGAAACCCTGTCTCCGAAAAAAAAAAA
AAAAGAAAGAAAGAAAGGTAGGTATTTTGAGACAGACACAAATGAAGGTAAGACATGATTAGTAAGGACA
GCAGGCAGTCCTCGGTGGGATACTTTACAGGAAAGAACCTGGCAACTCAGCAAGCCCTAAACCTTGTATG
AAAGCAAGAAAAGAAATACCAATAACTTCACAAAGCAGAACAAACCTAGCACATTTAAAGGAAGAAGCAA
AACCCCCCCTTACAATTCTCTTACAAATAAATTGTTTTGGCTTATAGTTTAGTGCATCACAGTTAAATAG
GACACTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTCTGTCTCTTTCTCTCTCTCTCT
CTCATTTGTTGAGTCTTGACTTGTGTCCTAAGGCTGGTCTTGGAGGAGAAGTTTCTGAGAAAATCTGCTG
AGGAAGACATGTGCGTTCCCTTCCCCTTTGGGTGGAATGTTCTGTCCGTATGTTAAGTCCAGTTCATCCA
CACTGTTCTTGGCTCCCGAGTTTCTTTGCTAGCTTTTAGTTTGGAAGACTTGCTGAGTAGGAGAGTGAAG
GATTGAAGTCTCCCGGTGTTACTGTATCAGGACCTGGTTGGTCTTTGTATCTTGGAGTGTTTGTTTTATG
CAATTGGAGGCTCCAATGTTTGGTGCATAGAAGTTAGAATTGTTGCATCGTCTTGAATTGTTTCTTTTAT
TAATCTATGCCTGGCATAGTGGCCCGCATCTTTAATCCCAGTACTCAGGAAGCAGACATAGGCCAATCTC
TGAGTACAAGGCCAGCCTGGTCTACAATAGTTCCAGGACAAACAGAGCTTCATAGTTAGACCCTGTCTCA
AAAATAAACAGGCAAACAACACCAAAAGGTAGAGTCCTTTTTATCTTCTTTAACTAGTTTTGGTTTGAAG
TTGACTTTGTTTAGCATAAGAATAAATTTCCATTGGCTTGGCAGTTTGTTTTCCATGCTTGGAGATGAAG
TTTTGGGGTATCTTTGTTGACTAAGTATGCTTCTCGGAGAGCGCATATAGCTTGTTCTTGTTATTTATCC
AGCCCGTTAGTCTGTGTCATTGAACTTGCAGGAGTTCTTGTGCCTCCTGAGGGCCAGACTCACAGGCATG
TGCCACTGTATGTAGCTCAAACACATTGTGTTTAAATATATTTAAACATTTTAAAGGTTTCAGACTAGAC
ATGGTGGTATATCTCTTCAGTCCCAGCAATTGGGAAACAGAAACTTGAGGCCAGCTATGTCTACATAGTG
AGTTCTAGGCCAGCCATAGTTACCCAGTAAGACCTGGTTTCAAAAAAGAAAAAAAAAAATCAGACTTGGG
CTTGGAGAGATGGGGCAGCCCTCAAGAGCACATTCTGGTTTTGTAAGAATTCCAGTTTGATTCCTAGCAC
CCATGTTAGGTGGCTGTGAGCCGGGGACCTGACTCCCTATTCTGGCACATTCGTGCACACATACACATAC
ACACTATACACACACCGCATACAGACACACTATATACACCACACACATACACATACACACACTACACCCA
CCATAAACACACACATACACACACTACACACACCACACACACACACACACACACACACACACACCATACA
CACTCACATACACACATACTGAAAACATTTCATTCAGAAATCAGTCATGATGGCACATACCTGTGACCCC
AATATCCAAAGACTGAAGATGTTGAGTTTAAGGCCAAACTTGCACACAATGAGATTCTATCTCAAAATGG
GGTGGTGGCACATCCCTTTAGGGCTACATAGAGAAACCCTGTCTCAAAAACAATTATTATTATTTTATTA
AGTTAAAATATTGGGGTCAACAGCAGTGTCACATTCCTGCTTCCCAGTTCTATGGGAAGTTGAAGCAGGA
GAATCACTTGAGTGCAGGGCAAGGTGCCATCTCTTAAAATAAAAATAAAGAATTTTATCTGCATTAGTAG
AATCTATCAGTGGACCCAGAGGGGCTGAGCTAGGCATCGTAAAACCAGCTATGAGGCCGGATCCCTGCAT
CTTCACACGTACGTGAGCAGGTAGGTTGTCTAGCTCCTGCTCCAGATCAGGCCCAGAGAGGAAGACAGAA
CGTCCAGACTCACAGAGCCACGTTTAATTCAGGTCTGTCTGGCTCTGAACTCTTTGCCTGCGACACTCTT
CCTGTGTGCACCATCACAGTCTGCTGAGGCCGACTTGGGCCTCCTCTGGGCTGGCCCTGGGAGGGTGGGG
GCTGCAGGCAGACCCAAGGCTCCACTCCTAGAAGAATTGCTGGAAACGGCTTTCTATAAGTGGCTACTAA
TACTCAGGGCCTCTTCACCGAAATCCCCCTTTCCCGACACCAACCACTGGGCTAACAATGGCATCTAAGG
GACAGCTGGTACCAAAATAGCAACTGGTCTCCCACCCACCCACTCAGGGAAGGAGTCACACAGGCCCGTG
CTGGCAGGCCTGGGGTCAAGGAACTGGCACATACGTCATCCTTGCTGGGCCTCCAGATGCCCAGGAGCCC
ATGCTGAAGACGGGCAGCCCCTCAGGGGACGAAAGAGGGAAATCAGCATGCATGCGTGCAAATGGCTGGC
GTAGTGACTCAGGGTGGAGGGGAAGGGAAGTGTTTACTGTGGAAACCCTGGCTGAGTGATTCTGGTAACT
GGTCGTCATCAGTTAGGCCTGGGAGCACAGAGCCCCCAGAAGCTCTGCTTTCCAGTCTCCCCGTGTCTCA
CACTGCTCACTCTGGGGCCTCAGTTTCTCTCAGCCCCTTCCTCTGTACATAAGACCCTGGTGACAATGGA
GTGGGAATTTGCCTTATGAATTCGGGAAGAATTGCTGAAACTTGTCACAAGTGTCCTGAAGCCACAGCCT
CTTGACCCGTGGTACAGCCCCCAACACCCCCACCCCCCACCCCACCCCCTGCGGCATGACCGTGCCCTGC
CCTCCGATTTCTTTTCTTCACTTCCTCTATCCAGGGCCCCTCCTGGTCTTGGTTTCCAACCCTTTCCTGC
CCCCATTTCACAGATGAGTAAAGGGAGGCACCAAGGGATCAGAGCTACGGTAAAGTAGCTGCAGGGTTCA
TGTCCAGGGCACTTTCCAAATCCTCCTCATAGTTCCAGCTGTGTCAACCTGTGGTGTCCTCCCAGAGTGA
CATTGCCTCATCTCCCTGTCTGCGCGAGTCTCCTGGCATAGTCTGCCAGATAACTGACTCCATCTATTTG
CTCTCTGGGTGGAGCTGGTAGCAGTCTGTTTGGGGGGACAGAGAAAAGGATCTACTACTGGGCAGCCAAG
TGCCGTACGCTCCACTCAAGTGCTGGTCCCGGACTGTGGGCTCCACACTCTCTTTGGGTGACTTCCATTC
TAGAGCCTGGGAGCTGAGAAATCCCTGTGCCTGCTTTAGTCAGCCTGCACTTGCTGTGCGCTCAGCACAG
AGCATAGCATGAATTCCATTGGACCATAACACATTACAGGCACACAATTGCTTTACTGAGGTAAAACCCA
CTGATTTGAAGTGTGCAGTCTAACTGAAATGAGAAGTTTTAGGTTCAGGGAGAGACTCTGTCTAAGAAAA
TATAGACACATAGCTGTGTAACCAACCTGTGGTGTTCAAGCTACTGGTACACAGAAATCAATCAGGGTGA
TATGTTGCATGTGAATATATTTTCGGAGACAGAGTCTTTTTTTTTTTGGATATATGTAGCTATCCCAGAA
CTCACTATGTAGATCAGGCTATCCTTGAACGTACAGAGATTTACCTGCCTCTGCCTCCCAAGTGATTGGG
TCAAAGTTATATACCACTTCAGCCATCTTAAAATGTATAATTTTTAAGATTAATAAAACAAGATACTTAT
GAAATTAAAATGTAAACCCATTAGTAAACATTATGTGGGCTGGAGAGACAGCTGAATGGTAGGATGTTTG
TTAAGCATGCACAAGACTGGGTTTGCTCCATAACACTGTAAATTATTATTATTATTATTATTATTATTAT
TATTATTATTATTGGTGGTAGTATTTCCACATGTCTGAAATGCATTTTTTCATTATACTATAAGTTACTG
TGAGGATACTTATTTAAGAATAATAACCTAGGGGGCTGGAGAGATGGCTCAGCGGTTAAGAGCACTGACT
GCTCTTCCAGAGGTCCTGAGTTCAATTCCCAGCAATCACATGGTGGCTCACAGCCTTCTGTAATGGGATC
CGATGCCCTCTTCTGGTGTGTCTGAACAGAGAGACAGTAAGAAACCCTGCCTCAAAAACTAAAATGGAAA
ATGGCAGAGAAAAATATCCAGACTGGATCTCTGGCCTCTACGTGTGCACACACAGGCAAGTGAGTCCGTG
CGTACGCACATGCACTACACACACTACTAAGATAAAGGGGCTGGAGTCTTCTGGCCTCCATGGGGTCCAG
GCATGCACATAATACACATACATACACATACACACACACACACACACACACACACACACACACACACACA
CACACACGTTTAAGTTTTTGTTTTTGTTTTTTCGAGACAGGGTTTCTCTGTGTAGCCCTGGCTGTCCTGA
ACTCACTTTGTAGACCAGGCTGGCCTCGAACTCAGAAATCCGCCTGTCTCTGCCTCCCAAGTGCTGGAAT
TAAAGGCATGCGCCACCACGCCTGGCTTACGTTTAATTTTTAAAAGAATTAAAATAAAGATCACCTAAAG
GGATCGAGCACCATCAGGACAAAACCACTGGGCACACGTTGAAAACAAAGCGAGACCGTTTGCTCTTCTC
CTCTGTGGCTGTAAAGAGTAACCCCGAACACAAAGAGTGATTAAGAGGGTCGTTTACCGAGTAGCGGAAA
TATTTCTGAGCAGATTTTTCCAGGGACTGAAACGCTTGTCTCTGGCTCTGTGACATCAGTCAGGGAAACA
ACAGTGAGTCGATTAGAAGCCAGACCCTAAAACTTTCCACTGATGTCTCTGTGCTAAGCCCATGCTCTGC
TTTCTGACAGAGGACAGAGCTTGCTTGCAGTCCGCTATCGGACTTCATGCTGCTGGCAGGAACTGCCAGA
GACCGTGTCTGGGAGGATTTCCACTTGTCTTTGTTCTCTGAGACACCACAAGGTTTCTGAGGCACCGATC
TGGGCCAGGCGCCTTTGTCTCCTGCTCATTCCCCCTCCCTCACCATCTCATGGGCCCAGAAAGCTCTCGG
AATAGCTTTGATCTGGCCATCTTTTCTTTTCTTCTTAGTCTTCTTGACAGAGCTGGACATTGCCAGCCTT
CCGTGTGATCATGGGGCAAGCAACCTCACTTCTGTGACTCGGTTTCCTAATTTGTGAACGTTTTACCAGT
ACCCACTTCTTAGGTTGTTTCCATGGAGCTCATAGGTAAATGTGGGTGGAACCAGGTCATGCGCGTGTGA
TCTGCCACTGAGCCGCCATGCCAGCTCTAGGAACAATTGTGAATGGTTGGAGTGAGCTGGCATCAGAGTG
GCCTCCCAGAGACAACTAGAAAAGGGGAGAGGACAGTGAGAGAAGGCTCGCTGCTTCCATGCATAGCTTA
ACCTTCAGACATTTACAGGCCCAGGTTACAGCAGACACTCAGTGGAAATCATCCTGACTGGATGTGCTGG
CATGTGCCTGACATTCCAGCACTGAACTAGGTAGGAAGAGTCAAGAGTTCGAGGCCAGCCTGGGCACAAA
GCAAGAACCTATGAGGAGAAGGAAGTGGAAAAGGAAAGGAAAGGAAAGGAAAAATGAATCTCGCAATCCT
GAATGTTACGTGAAGCACAGATCTGACTTAGTTTGTCCTCTTTTTTGCTTGGTTGGGACCAAGCTCATTC
ATTCATGCATGCATGCATGCCTTCTTTCCTTTTTTAAAAAAAATTATTTATTTATTTTATGTATATGAGT
ACACTGTCCCTCTCTTCAGACACACCTGAAGAGGGCACTGGATCCCATACAGATGGTTGTGAGCCATCAC
GTGGTTGCTGGGAATTGAATTCAGGACCTTTGGAAGAGCAGTCAGTGCTCTTAACCACTGAGCCATCTCT
CCAGCCCCCAGCCTCCTTTCCTTATTAATTTACTTATCTTTTGTTTAATTTGTACTTATTTACTTAGCGT
GTTTGTGCATGCATGGGTGCATGCGTGTGTGTGCCTGTGCATGTGCGTGTGGGCACATGTCACAGTTCTG
GTGCAGAGCTCAGTGGATAACCTGCAGGAGTTGGGACTCTCCTTCCACCAGGTGGGTTCTGGGAATTGAA
CTCAGGACCTCAGGCTTGGCAGTCATGCTTGCTGAACCAGTCCCTCTTATGTTTCCAAGGGGTGTGAGGG
ATAGGTGCTACTTTGCAGATGGGTAACTGGTGAGAGGGTGGGTAGGTCAAGCCACAGAGGGACAGAGGAA
TAACCATCAACCATAAAGCATCGCTGCCCCACTGGCTGCAAACCTGACTGATATATCTACGTCCATGGTT
CTTCTCCAGATGCTGTCACATCTGGAGCTGACTCTTCAGGCATCCAAGCAAAATGGCACGGAGACCCAGG
AGGTGTTCCTGGTCCTCGTTTCGAACAAAAATGTCTTCGTGAAGTTCCAGGCCCCGGAAATCCCATTGCA
CTTGGCCTACGTGAGTGTGTGACCCTTAACTCCAGGCAGGCTGTGGGAAATCTCTGCCTGGTGTCCCTCT
CTGTGAGCAACATGGCACACCAGAAAGGCAGAGGCAGATAGGAACAGGACCAGAAGGTGCCAGAGGAGGC
AGAGGTGGGCAGTAGAGGTGAAGATGGCTCACAGATGGACACATAGACCAGCATGGTGGAGACACCATGG
AAAATCCCCTCCCAAGTTCAAGGGTCCGGCCTCCCTTCCCAGAGTGCTCTTCTCCTTCTCATTGAGAGGG
GAAGTCAGGTCCCAGAGATCTTCCCATGGTGCCTCTCCAACCAGTCCCTTCCCCACTTGCTACCCAGGGT
TGAGGAGCTGCCAGGGTCCTGAATGACACTTGGAATGCAAGCTCTGGCTGTAGGGTTGCAGCTGCAGCCT
AGCCTGGTTGCATCTTTTTACTTGCTCTGAACACACACAGTGACAGCCCTGAATCATCTGTGTGCAGATC
ACCACTCAGAGGCCAGAGGCCGTAAACCAGGGGCCTGATAGTCACGGCTGTAACCCTGTTTTACAGGGGT
TAATGCCTGCAGAGTAGGCAGTGTGCGCTATTATATCTCTTCTGACTGTCATGCAGTCCTCCTTAATATC
TAATCTGAAGCCCTCCTGCTGCTGCTGCTGCTACCTCAGCTCAAAGTAGCTTGGAGTCAATAGTCCTAGC
TGCTTCCTCTAGATCACCTCCTCCAGGAAGTCCTCTTCATTTCCTTCCTTAGCCCAACAGACCCCAGAGG
AGCCTAAGGGAGGTAGTAAGGTTTGGGATCTCTCCAGACTCCCCGTCCCCAGAATAAATTTAATCTAATT
TTATGTATAGGTGTTTTGTCTGCATGTGCGTCTGTACCATATGTGAGCCTTGGGCCTGAGGGGGCCAGAA
AAATGTTGCATTCCCTAGGGCTTTAGTTACAGATGGCTGTGAGCCACCATGTGGGTGCTGGGAATTGAAC
CTGGGTTCTCATGAGAGAAGAGTCAGGGCTCCTAACCACTGAGCCATCTTTCCAGACCCTCTTTTTGCTT
TTCATGATAGGGTTTCTCTGTGTAGGCCTGGGTGTCCCAGAACTTGCTATGTAGTTCAGGCTGGCCTCGA
ACTCACAGAGTTCTGCCTGCGTCTGTCACTCAGGTGCTGGGATTAAAAGCACGAGCCACCACTACCTGGC
TCCAGCCTTGGTTTTTGTTATTTATTAAATAATGTCCTCTATCTTCTATTACTTCAACTAATGATGTCTC
TCTAGTTTCTTAATGGTGAGCTCCCAGAGTTGGCAGAACCCCATCTGTCTTCATTCATTTACTCATTCAT
TTTTTTCTCACACCTTTCTTCCTTTCCCCTTCCACTGTCCCCTTCCCCGTGCATTGAGAGTACCTAATAT
GTGGCAGGTCTCAAGGTGCAGCTGGCGTATCAGATCCCCAATGAACAAAGGCTCAGAGCCTTCAATGAGT
CAAGTGCTATGGGCACCAAGATTTCCCTCCCATACCCTCAGAGTGCAGACAGTTACAGACAGTAGCTACA
TTGGTGCCATTATATATGGTTTGAATGAGTGCCTCATGGTGAGGGTAAAGCAAGGACAGACAGACGAACA
AATGTGTGTCTCTGTACAGCCATCACATGCAGGAGGGAGATGGAGCAGATCTGGCTATGCTAGAAGAGGT
ACCGGGGGCTCTGGGCTGACTGACGACTTCCGAGCCTTGTCATTTGAGGTCCCGGCCTCTTTGCTGCCAG
ATTGGTAGGAAGTGACCCAGCACTCTGTGTCTCCACAGGACTCCAGCCTGGTCATCTTCCAAGGACAGCC
AAGAGTCAACATCACAGTGCTACCATCCCTTACCTCCAGGAAACAGATCCTCGACTGGGCAGCCACCAAG
GGCGCCATCACCTCGATAGCAGCACTGGATGACCCCCAAAGCATCGTCCTCCAGTTGGGCCAAGGTCAGC
TCCCTCAGTTGCTTCTGAGTTCAGGTTCACTTGCAGAGGAGACTGAGCAAACTCCTGATATGGGCACTAC
CAGCTTGTGGTGGCATGTGATTTGCCCACAGTCAAACGTGACTGGCTGGTGCCCTTTGCAGTTAGCGACT
GCTTCTGCATCATATAGCAGATGAGAAATGCCAGATTTTTTACTTGGGATGTGGCTTGGTTGGTAGAGCC
TGTGCGTAGTGTTAAGCCCTAAAGCCCTAGAACCCTAGAGCATGGTGGCATGGACCTGTGGTGCCAGCAC
TCAGAGGGCAGAGGCAGGAGAATCGGGAGTTCAAGGTCATCCTCTGCCACATAGCAAGTTCAAGGCTTCC
CTGGAGCTTGCTGGTCAGCCAGTCTAGCCAAGTCTTCGAGCCAGGTTCAGTGAGACACTGTGTCTCAAAA
AAATAATATGGAAAAAAAACCAAAAAAACAAAAAAATAATATGGAAAGCAATTAAGGAAGATACTTGACC
TGTGCTGGCGTGCTGGGTGGGGGTGGGGGAATGCACTCTTGACACATGCCATGGGCTCACTTGCTATGTT
AACCCTGTGCTGACACAGGCGGAAACAAAGGCCGGCTACTCAGTGGTGAGTCATCCTCAGCCCTGTTAAG
CTTTGTCCTGAATGTCCTCATCAATGCCTTGTCTGGAAGTGGGGTAGGACCCTCTGATATATCTGTCTCC
ACAGACCCAAAGGCACCATTCTTGTGCTTGCCAGAAGCTCACAAGGACATGGGCGCCACACTTGAATGGC
AACCACGAGCCCAGACCCCAGTCCAAAGCTGTCGCTTGGAAGGTGTGTCTGGCCACAAGGAGGCCTACAT
CCTGAGGATCCTGCCAGGTTCTGAGGCCGGGTAAGCTAGCCTTTGTGTGTATTACCCAATCAGATCCTAG
TCTCCAAATGCATTACCCAATCAGATCCCAGCCTCCAGGCGTATTAACTTTCCTATTGCTGAGATAAAAC
ACCATGACCAAGGCAATGTGTAGAAGAGTTTATTTTGGGCTTGCAATTCCAGAGCATCAGTTCTGCATCA
GCATGAGTTCACGACAGCAGAGTGAAGGTTGCAGGCAGCAGGCAGCTGGAGCAGCAGCTAAGAGCTCACA
TCTTGAACCACACAGATAGGAGGCAGAGAGCTCACCAAAGCCTACCCCTTGTGTTCTACACCCTCCAGGA
AGGCCCACTTCCCTAAGCCTTCCCAGACTGGGATCAAGTATTCAGATGCTCATACAGATGATGTCTCATC
CAAACCAGCACACCAGGTCTGTCCCCATACTAAAGCCACAACCCATCTGCCCGCCCGCTGCAGGCCCCGG
ACGGTGACCGTAATGATGGAACTGAGTTGCACATCTGGGGACGCCATTCTCATCCTGCATGGTCCTCCAT
ATGTCTCCTGGTTCATCGACATCAACCACAGCATGCAGATCTTGGTGAGCCTTGTACTCCCACCCCAGCC
GAGACCTTACACACACACCTTCCCCAGCTTTCTACCTTCATCTAAGTTGTTAAAGTAAAGGCCACTTCCA
GGAAGCTTGTCTTGATGGGCCAGGGAATCCGTTAACCTAGCCTGGTAGGCCAAGGAAGACTCCTGGAGAT
ACAAACTCTGAGCTGGGTCAGAGGTCAAAGGGGAAATGGAGAAGGTGAGGGGAAGGGACGGCAAGGCACA
GGCGAAGGGCAGGGGTCTCCGTAGGTAAGATGCCAGCTCTCTTTTTCTGCCTTCAGACCACAGGTGAATA
CTCCGTCAAGATCTTTCCAGGAAGCAAGGTCAAAGGCGTGGAGCTCCCAGACACACCCCAAGGCCTGATA
GCGGAGGCCCGCAAGCTCAATGCCAGCATTGTCACCTCCTTTGTAGAGCTCCCTCTGGTCAGCAATGTCT
CCCTGAGGGCCTCCAGCTGCGGTGAGCCACAGCCCTGTGCCCCTGTCCCAGACCTGTTGCTCCTCCTCCC
TTTCCATTACTTTGTGCCTCTCTGTTCTTTGAGCTTGGCTGGTTTCTCTGAGCCTCACTGGCCTCATCTG
CCACCCGTAGTGCACACCCAGTGACGGTCTACTCCACCCACTCCATAGGTGGTGTGTTCCAGACCACCCC
TGCACCCGTTGTGACCACACCTCCCAAGGACACATGCAGCCCCGTGCTACTCATGTCCCTGATCCAGCCA
AAGTGTGGCAATCAGGTCATGACTCTGGCACTCAATAAAAAACACGTGCAGGTAAGTAAAGCCCCGCCCC
TCCACCTTGAGATGGCATGGACAGCTGGTCCCTTGCCAAGAATGTCAGGGGCCCAGCCCAGGCAGTAAGA
GCAAGTCACATCCCTGTGCAAGCCTCGGTTTTCTCACTTGTGAAATGCAGTTTGAACAGAGCACAGAGCC
GTGCACTGGTATTCTCAGAACCTGGGAGGCTGAGCGAGGAGGATGGTGAATTTCAGGTGGACTAGGCTAC
ATAGAAGGTATAAAATAGAGTCATCCTCAACTACATAGGGAGTTTGAGGACAGCCTAGGCTACATGAGCC
CCAATCTCAAAACACAAGTAATAATCATACCAACATTAGGTAGTCATTATTAATCTTTGTTTATTTGTTT
TCTTTTTAAGACAGGGTTTCTCTGTGTAGCTCTGGCTGTCTTAGAACTCACTCTGTAGACCAGGCTGGCC
TTGAAATCATAGAAATCTGCCTGTCTCTGCCTTCTGGGTGCTGGGATCAAAGCTGTGTGCCACCACTGCC
TGGCTTAGTCATTATTATTAATCTTAATGGTGGTTGAGCCAGGTGGTCACAGAAATTTGTATTATGTGGC
CTTTGCATGATTGATAAATCCAAAAGACACTGTGCAGGGCTGGGGTGGTGCCCAGGGAATAACGTGTTCG
CCGTGGAGTAATGTGTTTGTTTGCCGTGGAGTAACGTGCTCGCCGTGCAAGCAAGAGGGCCTGAGTTTGG
ATTCCCAGCACTAGGAGGCAGAGAAAAGGAAGCCCTGGGGTCTCTCTATCCAGGCCAGCCAATCCGTGAG
GTCCAGGTTCAGTAGGAGACCCTCCCTGTCTTGCCAGGTGTGGTAGCTTGTGGGTCCCCACCCCCCTTGG
TTTTCTTTGGAGACAGGGTTTCTCTGTGTAGTCCTGGCTGTCCTGGGACTCACTCTGTAGACCAGGCTGG
CCTTGAACTCAGATATCTGCCCGCCTCTGCCTCCTAAGTGTGGGATCAAAGGTGTGCACCACCACGCCCA
GCTAGCTTGTGCTTTTAATCCCAGCACTTGGTCGGCAGAGGCAGGCAGACCCCTGTAAATTCAAAGGCCA
GCCTGGTCTACAGAGTGAGTTCCAGGCCAGCTAAGGCTATGTAGTGAGACCCTGGAGAGAAAGAGAGACA
GAGACAGAGAGACACAGAGAGAGACAGAGAGAGACACAGAGACAGAAATCAATGGAATGACCCAGTGGTG
AAACATTTGCACACAGCCTGCTTACCTGAGTTCAAGCCCCAGAACCCACAGGAAGGTGGAAAGAAGAACA
GCTCCATTAAGCCGTGCTCTGACCTTCACCTGTGTACCCTGCCCAGGGCACACACTAGATAACCATAATA
GGTTAGTTTTAAAAGCAAGGTGCTTTGCACTGCATGGTATCTGCACTCAGCAGTTCTTTCCTGTTGGGTG
TTCAAAAGACAGTGTGATAGAAACTCACTATCTGGCATCGTTGGTTTCTTGGCTTTGTGCGTGTTAAACC
TGGTATTTCTAATGATACAGTTTAAAAAAAAAAAAAAAAAGCAAGGTGCAGTAGTAAAAGATGCCCGATG
CCTGATAGCAAACTCTGTGCTCCACACATGAGCACCTATGTGGGGGTGTACATATGGTAGATAGGCCACA
CACACACAGAGTATATAAACTGCACACACAACACACATAGAGAGTATATAAGCTGCGCGCGCACACACAC
ATACACACAGGGTATATAAACTTCACACACATACACACACACACACACACAAAGTATATAAACTGCACAC
ACAACACACACAGGGAGTATATAAACTGCACACACATACACACACACACACATGCACGCAGAGAGAGAGG
CAGAGAGAGGTACTAATACCTTCACTATGTATTCCTTATTGGACTAGAGCCTTAAACTCACAGAGATCCC
CCTGCCTCTGCCTCCCGGGTGCTGGGATTCAAGGCGTGCTCCACCCTGCCCTACACAGAATGGAGGAAGT
CTTCATCTTCCCTTCTGAACTTGTGACCCTCCTGACCTCCCCTCCTGGATGCTGGATTATATTATATTAT
ATTATATTATATACAATGCTGGATTATATTATATATTATATTGTGCATGCGGCACTGTGCCATTCTCAAT
TTGCTTTTGAGCAAACAGAACATATGTACGCGCCCACTCCGATTTGTTTCACTCATTCCTCCCCTCCCCC
ACCCACCTCCCAGTGCTGGGGGTGGAACCCACCTGGAGTCCCAAAAAAGTCTCGTCTGTTCTGTACCTAC
TCAGTAGAGCTGTGTCCCCACCCCCCTACAATAACTTGCTTTTATTTGGGGAGTCTGAATCTGGCTATGA
ACCATATAGTGTGGAATTTGCTATATGGACCAGGCTGGTCTTAAACTCAGTAGAGATCTGGCTGCCTCTG
TCTCCTAGGGGATGGGAATTAAAGGTACACACCACCATTCCTAACTTTTAACTTATAAGAAAAAACCCAA
ATAAAAAAAATTAAATATTTTTTAATGTATATGGGTGTTTTTCCTGCATCAAAGTCTATTCACCACACTT
GCCCACAGAGGCCAGAAGAGGCCATTGGATCCCTGGACCCAGAGTTATAGACGGTTGTGAGATGCCATGT
GTGAGTTGGGGACTGAGCCCAGGTTCTATATAAGAGCAGTCAGTGCTCTTAGGCACTGAACAGTCTCTCT
AGATTCTTATTTTAACTTTTGAGCTTTTTGTTGTTGTTGTTTAATTTTTTTTGAGACAGGGTTTTTTTTT
GTTTGGTTTTTGTTTTTTTGAGACAGGGTTTCTCTGTATAGCCCTGGCTGTCCTGAAACTCACTTTGTAG
ACCAGACTGGCCTTGAACTCACAGAGATCTGCCTGCCTCTGCTTCCCAAGTGCTTTGATTAGAGGTGTGT
GCTGCTACCACCCAACTTAAAAAAAAATTTTTTTTTAAATGTTAGATAGGAGCTGGGCATGGTGGCGCAC
CCCTTTAATCCCAGCATTCGGGAGGCAGAGGCAGGTGGATTTCTGAGTTCTAAGCCAGCCTGGTCTACAA
AGTGAGTTCCAGGACAGCCAGGGCTATACAGAGAAACCCTGTCTCGAAAACCCAAAAAAAAAAAAAAAAA
AAGAAAAGAAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAAAAAAATTTAGAAAAAGTTAGATAGGGTGG
AGAAATGGCTGAGCAGCTAAAAGCTGTTCAGAAGACCTAAGTTTGATTCCTAGCACCTATACGGTGGCTC
ACAACCATCTGTAACTCTAGTTCCACGGGGTCTAATGCCATCTGCTGGCCTCTGAAGGCACTACATGTAT
GTGGTGCATACACACACTTAGGCAAAACAACACACACACACACACACACACACACACACACACTCACGTG
CCCTGGGTTCAGTTCCCAGCAATGGAGAAAATAAGAAGACATTCTAGTTGCCCATCCACTACTGAATAAT
TTTTTCCTGGTTTTTCTGAAGTCTCTGTCAGAGCTTTGATGTCCCCTTGGAAAGGTTTCAATAAGGATTC
ATTTTACTTATTTTTAAACTATGTGTAGGGTGGGGGGGGGGTATGTGCACGTGGCTACAAGTGTCTACAA
GGCCAGTAGTCATACTCCCGAGCTGGAGTTACAATCGGTTGTGAGCATTCTGACATGGGTTGGGTGCCGG
GAACTGAACTCGAGTCCTCTGCAAGAATGGCCGGGGCTCTTAACCGCTGAGCTATCTCTCCAGCCCCCAT
GAGCGGTACTTACAGTGTTTCAGTAGTGACAGCGAGGCCTGAGGGAATGCCGGGCCTCCTGATGATTCAG
CCCTTCTCCCCTGGGTCAGACTCTCCAGTGCACCATCACAGGCCTGACTTTCTGGGACTCCAGCTGCCAG
GCTGAAGACACTGACGACCATCTTGTCCTGAGTAGCGCCTACTCCAGCTGCGGCATGAAAGTGACAGCCC
ATGTGGTCAGCAATGAGGTAAGGCCTGGGAGTAGGAAGGTGTCATGTCCAGCAGAGTCGGTGTCCCCTCA
GACACCTCACTGATCCCGGGGCTGAGGGACATTTTGGGGAGCGGGAAGCAGCAGTGAGTAGGAGCCAAAA
CATAGATGCTGCTAGCTTGGCCCTTCCCACCCATCAGTCAGGCCTGGGAGACAGGATATCCTCTGGGGTC
TTTCTGGCTCTGACCGGCTTCTTGGCTCTGTCTTTGCAGGTGATCATCAGTTTCCCGTCAGGCTCACCAC
CACTTCGGGTGAGATGGACGGTCCTACAAGGCTCTCCAACTGGTGCAGGGTGGCCTGCTGGGGTGGGGCC
ACTTTCTGGCCTACCAGGGAGCAGACCTCAGGAAACTCAGGCCTGAACCCTGACAAGGCCCGTGTTTCCA
GTGTGCCTCAGTCTCCCCTTCCATACAATGGGAGCAGTGCTGCTGAGGGTTAAGCTTTCGGCCTCTTAAA
TCCAGGCAACCAGCTCACAGTGGCTGTGTCACCTTGGGCAAATCATTTAACTCTCCCCGGGGCTCAATGG
TCATTGGCTATAAACTGTGGCATAAAAAAAGTCCCCACCCCATAGGGGTCTTTAAGGAGCAGTACCGAGA
GGTGTGAAGTTTCTCTCCACTAGCCCAATGCCAAGTGATTTCTTCATAAATGTGAGAACTATGAGTTTAT
TATTTAAAAGGTGAGGATGGTGGTCAGGCGATTCCTGCTGTCACTCCGTTCAGACCGCCCGCCTCCTCGT
GTCCTCCCACAGAAAAAGGTACAGTGCATCGACATGGACAGCCTCTCCTTCCAGCTGGGCCTCTACCTCA
GCCCGCACTTCCTCCAGGCATCCAACACCATCGAACTAGGCCAGCAGGCCTTCGTACAGGTACTGTGCAC
CCCACCTAACTATCTCCTTGAGTCTTCTATGGGCCTTTCTTCCCAACGTTGCTAAAGAGAAGATCGGATG
CCACCTTCCAGAGGAAGGAGAAGGCCAGCCCGGGTGTGTGTGTGGAAGGCACAGAGAGAAAACGACTTGC
ACTTTGGAATGTCACTCTGTCCTGCCTGCTTGTTCCTGGAGCCTGTGGGGCTCCTTCTTGTCTTTTATTC
AGAGGGGTCCCTTTCTAACTGACGTCAAGAGGGCGAGGGCGTCAGTGAAGAGCCAAGGATACCTGCGTGT
ATCTCCTCCGTCTGTCTGTCTGTGCAGGTGAGCGTGTCTCCATTGACCTCTGAGGTCACAGTCCAGCTAG
ATAGCTGCCATCTGGACTTGGGGCCCGAAGGGGACATGGTGGAACTCATCCAGAGCCGAACAGCCAAGGG
CAGCTGTGTGACCTTGCTGTCTCCAAGCCCTGAAGGTGACCCACGCTTCAGCTTCCTCCTCCGGGTCTAC
ATGGTGCCCACACCCACCGCTGGCACCCTCAGTTGCAACTTAGCTCTGCGCCCTAGCACCTTGTCCCAGG
TGAGTGGACATGGCTTGAGACTAGTTTCACTGAAGCTGTGATGTCAGTATATACACACACCTGCAACTAT
CCACCTACACGTTTATCCTCTACATATTTTAACATCCATCCATCACCCATCTGCCCACATATCAGGATCC
CAACCATTTATCCACATACCCATCAATCTACCTACCTATTCATGGACTCCACCTACGCACCCACCAGAAG
CCTAGCCATTCATTCATAGACCTACCCACATACCCAGCTATTTACTCACCCACCCAAACAACCCACATAC
CCAACCATCCACCTACCCACACACACAGCATTTACTGCCTGTCAATCCATGTACCTATCCACCCATCCAT
CATCTATCCACCAATCTACCTACCTATCCACACGCACACTCCTGCATCCACCTACCTCCCCTCTCCCTAC
CAGCCGCTCACCCATCACCCACCACTTGCCCTTCTATCTACTCATCCACAAGCATCCATTATTCTCAATA
CTTTCACTAGCTCACCTAGTTACTCACTTACTCTAGAATCCCACCCACCCACTAACCACCCACCTACCCA
CCCACATGGCGATCACCAATGTGACTGATCTCAGGAAACTTGACACTCTGCCCTGCTGGTATCACACGTT
GCCCTCAGTCCTGACACACTCACAAGAACACTCCAGGTGTCTGCACACAGATTTCTTTCTTTTTTTTTTT
CCATTTTTTATTAGGTATTTAGCTCATTTACATTTCCAATGCTATATCAAAAGTCCCCCATACTCACCCA
CCCCCATGCACACAGATTTCTAGGACTCAAAACCTCCTGAAGCTGGGCCCCCACACAGACAGCTATACCT
GTCTTCCAGGCCCTGAGCCTCCAAGCATCTGGGCTGACCTGGCTTGTGGCTCACGGCTTGCACAGGCTAA
CAGATGCTGGGCTCCTACTGGAGACCATTTACAGTAGCCGCAGGCTACCCTGCTGCTCTCGCACACCATG
TGCCTCCCTAGGATTTGCCTGCAGCCTCCCAGCCTGAAAATAGCGGACAAATGACTCAGCCAAGGGCTGG
GATGGCAGCAAGGGAGAGCTGCAGACAGGGAGAACCGCATGCTGCCAGCTGAAGGCTGGGTCACTTACCA
GACTCCTCCCTCCTCAGGAAGTCTACAAGACAGTCTCCATGCGCCTGAACATCGTCAGCCCTGACCTGTC
TGGTGAGCAGAGAACAGGGCTGGGAATGGAGCCCAGATATGGGGCCCTTGGGAGGAGAGGAGGGTTTCTC
AGGCCCAGCAGCCCGAGGAGCTCACAGTAAGATGCCAGGTGCCATAGACAGCCCTCCACTCTCAGACCCC
TCCTGGGCCTCATCTCTGTCCCGTTAGTCACTGGTTGCCATGATGGAGGACTTAACCTCCTGGACAGAAC
ATAAGGCACCTTAGCTATGGTATAAGACCCCACATTCCTTGACATCTCAAGGGTAGAGGAAGCCCCTTGA
GCCTAACACCCTCTGGTCTCTATTGTTCCCCTGGGCCCAGGCACTACCAGGCAAGAGAGTCCTGTTGCTA
GGGGCAGATACAAGCGGTGTAGCCTAGGATGGGCCTAGCCTAGGGCTGAGAATGCAGGGCTCCTAAACTC
CCTGCACAGACAGTAAGTCTAAGGAGACTAAGGGCCCAGAACTATGTAGAAACAGGAGGGAAGCCTGCAG
TAACCCGAGCAGCACTGGTTTTAAAAAGATGCTCTGGCCCATTTGAATCTGGTGTAAGGTGCAGAGGTGG
GGCGGCTGGTTGGAGAGGTCACACAGCATGGCAGAGCAGGCCCCTTCATTCTTTGCACCCACAACACCAT
CCATAAAGGAATTACCTGCTGGGCTTTGGAGACAGGAGGGTGGCCCAAAGAGCCTGGCCGGCTGGGCCCT
CGGCTTAGTACCGAACTAGATGAAGAGACCTCTGTCCAGAGAAGTCGAGTCACTGACCCAGTTGAATCTA
GCTAATACCCGTGACCAAGGCCAGCATGAGAGGGTAGGGACAGGCCTGAGGCCACAACACACTGACTATC
TTGGCCCTCCTTTGTCACACAGGTAAAGGCCTTGTCCTGCCCTCTGTACTGGGTATCACCTTTGGTGCCT
TCCTGATTGGGGCCCTGCTCACAGCTGCACTCTGGTACATCTATTCTCACACACGTGAGTATCCCAAGCC
TCCACCCCATTCCCACAGCAAGCGCTCAGGGCCCGTCCACACCACCCCGGGGCACACCCAGTGGAGCCTC
TGAAGAAGCGGGGAGTCCTGGCTGGGGCCCTGACCTTCACCCACGCCCCTCAGGTGGCCCCAGCAAGCGG
GAGCCCGTGGTGGCAGTGGCTGCCCCGGCCTCCTCTGAGAGCAGCAGTACCAACCACAGCATCGGGAGCA
CCCAGAGCACCCCCTGCTCCACCAGCAGCATGGCGTAGTGCCCAGCCTGGAGCCTCGGGGAGCCCCCCAG
CCAGCCCTTGCCCTGCAGGAGAGACCGAGCAGCCACAAGCTGGAAACCACCGGCCATGAACTTGTCCCAG
GAACCAAACACCTCCCCTGCACCTGTTCATTCCTCCCAGTGGAGACTTCAGATTGGAATACCTTGGGATC
TCCTCACCCCACTTTACAGAACTGCCCAATCCAGGGGCTCTGGGATATGGCTGCCCGGGATTACAGAAAG
ACACGGCACTGCCGTGCACACCCATGCTGCTTAGAAGCCTAAGCCTCTGCCTTCAAGCTGGATCCTGTGC
AGGGTGGGCAGGCAAGAACTCAGACATGCCCAGCCTAGCCCAGGGCGGCCTGCATCTGGCCCCAGAAGCC
TCCTCACCTGGACTGGCACAACTTCGGTTGGGGAAACAGAAGCTGAGGGAGCTTAGATGGGGTGGGGGAT
CCAAGCCCCTCCCAGCCCACCCATTGGCCAGGCAGCAGGGGGGAGTGGCCAGGCGGCTGGTTGTGGGCCA
AGTCCTGCATATTCACTAATAAATCAGACATGAAACCAGTGCCCCTCTGGGTTGTATGGGAGAAGAGGAA
GATGGGCAATTATGTCACAGAACAAGGGTGCACACCCCTTTGGTCGGCATGGTAGCAGACAGCCAGAGCC
CATGTGTGGAGGAAGTCAGTTCTCTCTGCTGCTTGCTCATTTGGTAGCCCAACCTTGGGTCAGAGGGGAC
AGAAACCAAACACTAAAAAGCCCTGTCTACAGTCTCTGGGACACAGCTACCCCTATAAAGTTCTGGGTTC
TAATCCTGTACATGACTCTTGTGGGCAATGAGCCTGTGGACAGCTCCAAAGTCAGCCACCCTCCCTCATC
TGTAAGATGGGCGTCCAACTTGAATGCATTGTCACCAAGGAGGCTTGCGATGCAGTGCCTTGGTGTGTGA
CACACAGTGTGCCAGTCTTTCATGACATGAGAGGACTAATCCTAGGCCATACTGTGTTAAACTCCAACCC
CCAAATGTCTGATGAGGGAGCTAGGAGAATAGGAGTCAATCAAAAGTTTTGTCATTTATTTACAAAAAAT
AAAAAATAAAAGGGTTTAAAAGCTT

</dna_sequence>
        <protein_sequence>>NP_001139820.1 endoglin isoform 3 precursor [Mus musculus]
MDRGVLPLPITLLFVIYSFVPTSLAERVGCDLQPVDPTRGEVTFTTSQVSEGCVAQAANAVREVHVLFLD
FPGMLSHLELTLQASKQNGTETQEVFLVLVSNKNVFVKFQAPEIPLHLAYDSSLVIFQGQPRVNITVLPS
LTSRKQILDWAATKGAITSIAALDDPQSIVLQLGQDPKAPFLCLPEAHKDMGATLEWQPRAQTPVQSCRL
EGVSGHKEAYILRILPGSEAGPRTVTVMMELSCTSGDAILILHGPPYVSWFIDINHSMQILTTGEYSVKI
FPGSKVKGVELPDTPQGLIAEARKLNASIVTSFVELPLVSNVSLRASSCGGVFQTTPAPVVTTPPKDTCS
PVLLMSLIQPKCGNQVMTLALNKKHVQTLQCTITGLTFWDSSCQAEDTDDHLVLSSAYSSCGMKVTAHVV
SNEVIISFPSGSPPLRKKVQCIDMDSLSFQLGLYLSPHFLQASNTIELGQQAFVQVSVSPLTSEVTVQLD
SCHLDLGPEGDMVELIQSRTAKGSCVTLLSPSPEGDPRFSFLLRVYMVPTPTAGTLSCNLALRPSTLSQE
VYKTVSMRLNIVSPDLSGKGLVLPSVLGITFGAFLIGALLTAALWYIYSHTRGPSKREPVVAVAAPASSE
SSSTNHSIGSTQSTPCSTSSMA

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>A study which combined endoglin plasmid DNA and recombinant protein as vaccines and used them to prime and boost, simultaneously, as a vaccine strategy was conducted. The results showed that combination of endoglin DNA and protein vaccines could enhance both protective and therapeutic anti-tumor efficacy in both colon carcinoma and Lewis lung carcinoma models. Significant inhibition of tumor angiogenesis was found in the tumor tissues. The titers of autoantibodies against murine endoglin were significantly increased and the antibody levels lasted longer in the mice with combined endoglin DNA and recombinant protein vaccination. CTL response against endoglin-positive HUVECs, but not against endoglin-negative tumor cells was found in the mice combined DNA with protein vaccination. In addition, combination of endoglin DNA and recombinant protein vaccination significantly induced IFN-gamma secreting cells [Ref1318:Tan et al., 2007].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene317">
        <gene_name>EPCAM</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>4072</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>218505670</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AC079775</gene_refseq>
        <protein_refseq>NP_002345</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>2</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>47369147</gene_start>
        <gene_end>47387027</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>epithelial cell adhesion molecule</protein_name>
        <protein_pi>7.53</protein_pi>
        <protein_weight>32154.08</protein_weight>
        <protein_length>314</protein_length>
        <protein_note>Also known as ESA; KSA; M4S1; MK-1; DIAR5; EGP-2; EGP40; KS1/4; MIC18; TROP1; EGP314; HNPCC8; GA733-2; TACSTD1</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000002.12:47369147-47387027 Homo sapiens chromosome 2, GRCh38.p12 Primary Assembly
CAACTGCAGCGCCGGGGCTGGGGGAGGGGAGCCTACTCACTCCCCCAACTCCCGGGCGGTGACTCATCAA
CGAGCACCAGCGGCCAGAGGTGAGCAGTCCCGGGAAGGGGCCGAGAGGCGGGGCCGCCAGGTCGGGCAGG
TGTGCGCTCCGCCCCGCCGCGCGCACAGAGCGCTAGTCCTTCGGCGAGCGAGCACCTTCGACGCGGTCCG
GGGACCCCCTCGTCGCTGTCCTCCCGACGCGGACCCGCGTGCCCCAGGCCTCGCGCTGCCCGGCCGGCTC
CTCGTGTCCCACTCCCGGCGCACGCCCTCCCGCGAGTCCCGGGCCCCTCCCGCGCCCCTCTTCTCGGCGC
GCGCGCAGCATGGCGCCCCCGCAGGTCCTCGCGTTCGGGCTTCTGCTTGCCGCGGCGACGGCGACTTTTG
CCGCAGCTCAGGAAGGTGAGGCGCGGATTGGAGCAGAGTTGTGGAGCTGGGCTGGGCTGGGGGGCAGCGG
CCCCCGGCCCTCGGCCCCCGAAACGGGCATAATAGGGAGGGGACCAAGAGGCCGCGCTTTCCAGCGTGGA
GACCGGACGGTGCGGCCGTGCTCCGGCTCAGGCCCTCCGCGCGGTAGGAAACGGCGAGGGCCGTCCCGGG
GAGCAGCCTCACTTCGCAGCTTTGCTCGCCTTGGTAGGGAAATGGCCTTGGGCGGAGGCGGGGGACAGGC
AGGGAACGGAGTGGCCACGTCCAGGTTTCCTGCGGCCACCGAACCGGTGCCTCGCGCCCTGGCGCACCCA
CGTCCTCGGTTCGGGGTGGACTTGGGGTTCCAAAACAGCCCCAGCCGGTGGCGGAGTCTTTACGACAGGG
ACCAGCGGGCTCGCCCTTGTCCTTGCAGCGGGCCCCGGATGTGGGCCTCAGGCGGGGACAGGCGCCCGCA
GGGAGGCCTCCAGGGCCGCTATGCACCTGCGCGCGGCAGGCGGCCCGGACCACACAGGGCGTGTGGGTGT
TTTCCCTTTTCTAAGGATCATATGAGTAATGCCAGGCTTATTGTAGGGAACGCAGAAATAATAACCGTAA
AGAGTAAAAACATATAATCCCAGCATTTTGAGAATCCCATAATTAGTAATTAGGTGTATCTTTCTTTCTT
TTTATTTATTTATTTAATTTTTTGAGACTGAGTCTTGCTCTGTCGCCCAAGCTGGAGTGCAATGGCGCGA
TCTCGGCTCACTGCAACTTTCGCCTCCCGGGTTCAAGTGATTCTCCTGCCTCAGCCTCCTGAGTAGAGTA
GCTGGGATTACAGGCGCGCGCCACCACCCCCCGCTAATTTTTGTATTGTTAGTAGAGACGGGGTTTCTCC
ATGTTGGTCAGGCTGGTCTCTAACTCCTGAGCTCGTGATCCGCCCGCCTCGGCCTCCCAAAGTGCTGTGA
TTACAGGCGTGAGCCACCGTGCCCGGCCTATTTTATTTTTTTATTTGAAACAGCCTTGTTCTGTCACCCA
GGCTGGAGTGCAATGGCAAGATCTTGACTCATTGTAGACTACGCCTCCCGGCCTCAGACCATCCTTCTGC
GTCAGCCTTTATGCCTGGCTAATTTTTGTATTTATTATTTATTATTATTATTATTATTTTTGAGACAGAG
TTTCGCTCTTGTTGCCCAGGCTGGAGTACAACGGCGCGATCTCATCTCACTGCAATTCAGGCGATTCTCC
TGCCTCAGCCTCCCGAGTAGCTGGGACTACAGGCATGCACCACCACGGTCAGCTAATTTGTATTTTTTGT
AGAGAGGGGTTTCGCCATGTTGGCCAGGCTGGTCTCGAACTCCTGACCTCAGGTGATCCACCGACCTTGG
CCTCCCAAAGTGCTGGGATTACAGACGTCAGCCACAGTGCCAGCCGAATATTTGTATTTGTAGAGACGAC
ATCTCACTATGTTGCCCAGGCTGGTCTCGAACTCCTGGGCTCAAGTGATCACTCCGTCTGGGCCTCCCAG
AGTGCTGGGATTACAGGCGTGCATCACCACACCCGGCCTTAAAAACAAGATTTAAAATGGTGACTGGTAT
GTTGCACCGTTATTCAAATGTTAGACATGTAGTTTGATTTCAGTTTCTCTTAACTGTGGAATAAACAACT
TGGCTGCCGTCTCTCTCTCTCTCTTTTTTTTGGAAACAGTGTCTCCGTCTGTCGTTCAGCCTGGAGTGCA
GTGGCACATTTACATGTCACTGCGTCCTCCATTTCCCAGGCTCAAGCGATGCTCTTACTTGGACCTCCCA
AAGTGCTGGGATTACAGGCATGAGCCACCGGTCCGGCATCTCTTGGTTTATTTGTAAGATGGTGCCTAGA
AGTGGAGTGGCGTTTGCCAAAGGTCTCTGGAAGGGCTTTTACACTTTCACCAATGGAGTGGCCTAAATTC
AGTAATTATACTCTCAAAGTAATGCAGTTTTAGTCAACTCATGTTTTTCTGGCTTCAATCTGGGACTACG
TACTTAATGTTAAATTGCTTTAAAGTGGTCATAGCTGCTACAGGTTTGTGCTCAGAAAGTCTGCACCTGA
CTGGTCTGATTTAAATTTTACGCCCCTTAGGTATGAACAGTGTGTTTTAAACAAGTACAGGATGGGGCTG
CAGAAGATTTAAACGCTTGAGAACAAGTGCTGTATTTTCCCCTTTTGTGACCCCAGTATTGAGTTTAGTG
TTGGGCAGATTAAAGGTGGTTCATATCGACTATAACTTGAACAGGGAAAAATTGAAATCAACTTAGGGTA
CTTGGGATACGAAGGATCAATATAAAAACTCTGGTTTGTCATGCTAGCTTTTTCTTTTTTTTCCTCTTCA
GTTGAACTGAGGAGATAGTTTTTGTTTTTAATGATTGTGCTCTTTTAACTAGACAAAAGGAATTAGATAG
TCTTGCCTATTCGAAGTTAAATGAACTTTTGAGGTTGTTAAGGACAAAACTATTAAACTGACATCAATAA
TACAGAATGGGCTGCTTAGTATCACTTTCCTTATCAGGTACTAGGATTTAATTTAGTTAGGAAACTCACT
TAAAGGGAGGACTATAACTGCAGTTGAAAGTGTAATTTTTCCAAGATATAAAATTGTTTAAAGATTGAAT
ATATTCCTGTTAAGCCCCAAAGGAAACATCCCTCATTTAAGAAAATGGGGTGGGAGAGCAAGAGAAGGTG
AGGATTCACAGATCCTAGAATTGGAATAGTTGATTTTTTTTTGTAAAAGAGGCGGTGACAGCCGGGCATG
GTGGCTCACGTCTGTAATCCCAGCACTTTAGGAGGCCGAGGTGGGTGGGTTACCTGAGGTCAGGAGTCCT
AGACCAGCCTGACCAACATGGTGAAAACCCGTCTCTACTAAAAATAGAAAAAAAAAGCCGGGCGCGGTGG
CTGACACCTGTAATCCCAGCACTTTGGTAGGCCGAGGCGGACGGATCATGAGGTCAGGAGTTTGAGATCA
GCCTGGCCATTATGCTGAAACCCCGTCTCTACTAAAAATACAAAAATTAGCCAGGTGTGGTGGCATACCC
CTGTAGTCCCAGCTACTTGGGAGGCTGAGGCAGGAGAATCGCTTGATCCTGGGAGATGGATGTTGCAGTG
AGCTGCGATTGTACCACTGCAATCCAGCCTGCACGACAGAGTGAGACTCTGTCTCAAGAAGAAAAACAAA
AAAAGGCAGTGACTAACAGGGATGTTACTTAGCAGGACAGGACTGTGGAAGGAGCTAAGACTGGGAGTTT
CACAAAGACAAAGCTAGAAATGATACTTGGAGAGCTGTGTTCTTGTTTTAAAAAAATTGTAACAGGAGGC
CAGGCACAGTGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCTGAGGCAGGAGGATTGCTTGAGGCCA
GGAGTTCAAAACCAGCCTGGGCAACATGGCGAAACCCCGTATCTACAAAAAGTTAAAAATTAGCCAGGCA
TGGTGGTGCATGGCTGTAGTCCCAGCTACTTGGGAGGCTGAGACAGGAGGATCACTTGAGCCCTGTAGGT
CCATGCTGCAGTAAACCAAGATTGTGCCACTGCATTCCAGCCTGGGCCACAGAGTGAGACCCTATCTTTA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAACAGGAATGCATGCAGATTAAACTATGTGTCTGTATACAGTA
TGCAAACTTTAGCAAGTGCCAGGCACTTAGGCAGTAGTCTATAGCTGAAAAATAAAACATTCAGAACCAC
TTTTTAAGGTTTTGTGTCCTTGTAACTTTAGGCATTATTATTACAATATAACTTAGCTGGGACATGAGAG
TTAATAGATCCACATTTTAAAGTAGATTTTTTTTTTAATTTTCTAGAATGTGTCTGTGAAAACTACAAGC
TGGCCGTAAACTGCTTTGTGAATAATAATCGTCAATGCCAGTGTACTTCAGTTGGTGCACAAAATACTGT
CATTTGCTCAAAGCGTGAGTAAAATATCCTAATTACCTGTAAGCTTTATTTTGACTTAATACTTCTTTAA
TTGATGTGCCTTGAGTTGGAAAGAGTTTTATTGGCTTAAATCTGAATCATGTTACAAAGTAAGTGTGGGA
ACACATAAATTTCAAATAATCTTTGACCCTGGAACTTTAGAGTTAATTTTTTTTTTCCCGTAATCATGAA
ATCAGTTATTTTTCAGTTTGGCATTAAGGTTTCTTTTTCAGTGGCTGCCAAATGTTTGGTGATGAAGGCA
GAAATGAATGGCTCAAAACTTGGGAGAAGAGCAAAACCTGAAGGGGCCCTCCAGAACAATGATGGGCTTT
ATGATCCTGACTGCGATGAGAGCGGGCTCTTTAAGGCCAAGCAGTGCAACGGCACCTCCATGTGCTGGTG
TGTGAACACTGCTGGGGTCAGAAGAACAGACAAGGACACTGAAATAACCTGCTCTGAGCGAGTGAGAACC
TAGTGAGTGGGGCTGCCTATACTACTTGTTTTCATGCTGTTCAGATTCATTTAATTAAATTTATTTTTGA
TTATGTAATATGATTTCATGGTTTAGAATTCAGAAGATATGAGTGTCCAGTGAAAAGCTTCCTTCTCATT
CCAGTCCCCCTCGCTACCCATTGGACCTCCACAGAATTGATGTTATTGATTATTCTATAACCTTCCAGAG
ATAGTTGATGAATTTGTTATATATCTGTTTTATTATTTTTACATAAATGATAGCATACTAGGTATAATTT
TTCTTTTATATCTTTACTTAACATTATTCAGTATTTCATTGTTGCATTAGTAGTAAATGTATGTAATTTA
ACCTATGTATTTGCTTATTGATTGTGTTTTAAAAGTGAGATATGCTTGTTTTAGGGATTGTTTAATGAAA
AGGCACAGAAACCCACTCAAGCTAGCTTAAGCAAAAAAAGACTTCATTGGAAGGGACTAGAAACTGGAAA
GGATGTCAGGACCAAAGTGGGCACTTTGTTTTTCTGTTCTGGTCTTCTGGAGCCTCGTTGTCAGTTTTCT
CTTTGTGCCCTTTCTTTTGTTTTTTCTTTTTTCTTTTCTTTTCTTTTTTTTTCGAGATGGAATTTCCACT
CTTGTTGCCCAGGTTGGAGTGCAGTGGCACAATCTCAGCTCACTGCAACCTCTGCCTCCCGGGTTCAAGC
AACTCTCCTGCCTTAGCCTCCTGAGTAGCTGGGACTACAGCTATACCACACCTGACTAATTTTTGTATTT
TAGTAGAGATGGGGTTTCACCATGTTGGCCAGGCTGGTCTCCAACTCCTGACCTCAGGCAATCCACCCAC
CTCCACCTCCCAAAGTGTTGGATTACAGTTGTGAGCCACCATGCCCGGGCCTTTCATGCCTTTTCATCTT
TTTAGTTGAACAGGGCATGACACTGCCAGCTAAACTTTGACTTAATGTGACTTTATGTATTGTGTCCAGA
GAACAGAGGGTCAATATTAGAAAAGGTGTTCCCTCCTGGGTGTGTCCTTTATGAAGGATGTGTAAGGGAA
GAAATTATAGGAATAGCTACTGCATAAATTTTTTTTCTCTTAGTCCTTATAATTCGAGAATTTTAGGATT
AGCTTATTAGGAAAATAGTATGGAAGACTGAGTTATAGTCAACTGACATTGTCTTTTTACTTTATAGCTG
GATCATCATTGAACTAAAACACAAAGCAAGAGAAAAACCTTATGATAGTAAAAGTTTGCGGACGTAAGTG
CAATTAAATGCATCATATTCTTGCACAGTTGGTGGCTCAAATCTTCCATCCTACACCATTAGAAAAAGCA
AGTCTAAATGCTTTTTTATATTTCTGAAAAATAAAGTTACTTGAAATAGAGTTGCAAGAATAGCACAGAG
ATTCTGGGAATACACTTCACTCAGATTCACCAATTAACATTTTGGCACATTTGCTTTTTATATGTGTATG
TGTGGATGAATATGTGTGTGTGCTTTACATCAGTGTATCTATGCATGTATAAATATTTTTCCCAGAAGCA
CATGAGAGCAAGTTGTAGACATCAGGCCCCTTTACCCCTAAGTACTTCAGTGTATGTTTTCCTAAGAACA
AAAGGCATTCTTTTATATAAACCACTATACAACGATCAAATTTAGGAAAAATTTTTTTTTTTTTTTTTAG
ACGGAGTCTCGCTCTGTCACCCAGGCTGGCGTGCAGTGGCGTGATCTCAGCTCACTGCAACCTGCGCCTG
CCGGTTTCAAGCGATTCTCCTGCCTCAGCCTTCCAAGTAGCTGGGACTACAGGTGCCTGCCACTACGCCC
TGCTAATTTTTGTAGTTTTAGTAGAAACAGGGTTTCACCATATTGGCCAGGCTGGTCTCGAACTCCTGAA
CTTGTGATCCTCCCGCCTCTGCCTCCCAAAGTGCTGCAATTACAGGTGTGAGCTTCCGCGCCCGGCCAGG
AAATTTAACGTTATATCACGTTGTGCCCATTTTCCCAATATTGTCCTTTGTAGTAATTTTTCCCCTCTGA
TTCAGGACCCAGTCCAAGATCCATGTATCACATTTAGTTGTCATGACTCTTTAGTCTCTTAATATCGAAC
AGTTTCTTGGCCTTTCTTTGTCTTCCATGAACTTGCTATTTTTAAAGAGCATGGGCAAGTCATTATATAT
AATGTCCCTCAAATTTTGATTTGTCTGATATTTCCTCCTTTTTTTTTTTTTTTTTTGAGTTGGAGTTTTC
CCTTTTGTTGCCCAGGCTGGAGTGCAATGGTGCAATCACGGCTCACCGCAACCTCTGCTTCCCGGATTCA
AGCGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGGCGTGCGCCACCATGCCTGGCTAATTT
TTTTTGTATTTTTAGTAGACACGGGGTTTCTCCACGTTGGTCAGGCTGGTCTCGAACTCCCAACCTCAGG
TGATCTGCCCACCTCAGCATCCCAAAGTGCTGGGATTACAGGCATGAGCCACCTCACCCGAGCCTTGATG
TTCCCTCTTAACTAAAAGCAGGTTATGCATTTTTGACAGGAAAACTACTTAAGCGATCTTGTGTCCTTTA
TAATACTTCACATTAGGAGTTGCATGATGTCAGCTTGTCCCTTTACTAGTAAAGTAAACTTTGGTTAAAG
TGGTATCCACCAGGTTTTTCCACTGTGAAGTTACCATTCTCCCTTTGTAATCCATAAATAATCTATGGGC
AGATACTTGGATACTAAGTAAATGTTCTTTTTCTAATTAAACTGGTACCCAGCAGTTTGAATATCAATGG
ATGATTCCAGCCTGAATCAATTATTATTATGATAGTTGCAAAATGGCAGAAAAATTTTAACTTTAATGAC
AGTTTTAGACCCTGAGCTGTCTGCTTAAAGAGTAGTGCTTCTTACTGTTGTGTGGTACAAACATTTTTTT
TTAATACAGATTTTAAATTCTTTACAGTGCACTTCAGAAGGAGATCACAACGCGTTATCAACTGGATCCA
AAATTTATCACGAGTATTTTGGTATGATTTTTTAATAAGTGAGCTTTAGCAGACAGTTGGTGAGACAGTA
TGTTTTGAGTATAAGGACAGCCAGTGATTTAAGTGGTGGTTAAATGCACTTACTGGAGCAACAGTTTCGG
ATCTGGGTACTTAATGTGAATTTCCTGTTACTGTTTTTTTTTGTTTGTTTGTTTCTTTAAGACAGACTAT
TGCTCTCTTCCCCAGGCTGGAGTGTCATGGCAAGATCTCGGCTCAATGTAACCTCTGCTTCCAAGGTTCA
AGCAATTCTCATGCCTCAGCCTCCCGAGGAGCTGGGACTACAGGCACATGTCACCATGCCCAGCTAATTT
TTGTATTTTTAGTGTCGGCGGGGTTTTGCTATGTTGGCCAGGCTGGTCTCGAACTCCTGGCCTCAAGTGA
TCTGTCTGCCTCAGCCTCTCAAAGTGTTGGGATTACAGGTGTGAGCCACCACGCCCGGCCCATTGTTTTT
GGTTATCGTTGTTTTCCTTCCATAGCCTTTGAAAAGCCTAGTTTTACTCCTAAAGAAAACGTAGTATCTC
TTAGTATCCCTAAAACATTTGAGTTTTCTTATCCTGGAGAACCTGTCCCTGTGGATGAGCTCCAGTAACA
TCTTAAAGTAAATATGCACCAAAATTACTTTTGGTAAATACAGTTTTGGTGCATATTTACTTTAGGATGT
TACTGGAGCTCCCATCTTCTCTGCTTTAAGGAACTAGTCCTTAACTAGTTAGCCCTTACTTAACTCTTTA
AACTCTGGTTTAAAAAATAAAAAGAAGCTTGAATAGTGTGACGGAACTCTTTAAAGGTAGTATGAATTTA
TTCAAGAGTCTTTAGAAAGAATGTACTTTTTTTACTCTTTAAAAACAAAATGATGGCCGGGCACGGTGGC
TCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCAGGTGGATCACAAGATCAGGAGATCGAGACCAT
CGTGGCTAACACAGTGAAACCCTGTCTCTACTAAAAACATACAAAATAGCCGAATGTGGTGGTGGGCACC
TGTAGTCCCAGCTACTCGGGAGGCTTGAGGCAGGAGTATGGCGTGAACCTGAGAGGCGGAGCTTGCAGTC
AGCTGAGATTGTGCCACTGCACTCCAGCCTGGGCGACACAGCAAGACTCCGTCTCAAAAACAAAACAAAA
AAACAACATGGAAAATGCATGCTGCGTTTTACCTTGCATTTCTTTTTCTTTTCTTTTTTTTTTTTTTTTT
TTGAGACGGAGTTTCGCTCTTGTTGCCCAGGCTGGAGTGCAATGGCGCCATCTCGGCTCACCACGACTTT
TGCCTCCCAGGTTCAAGCGATTCTCCTGCCTCAGCTTCCCTGGTAGCTGGGATTACAGGCAATGTGTCAC
CACGCCTGGCTAATTTTGTATTTTTAGTAGAGATGGGGTTTCTCCATGTTGGTCAGGCTGGTCTTGAACT
CCGGACCTCAGGTGATCCGCCCACCTCAGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACTGCACC
CGGCCTTACCTTTCATTTCTTTAGTAATTTAGTTTTAAAGTAGTTCTAATCCAAATAAAATACTTTCATA
TCTTATTTAAAAATCTTTTCAATATAAGAAAATCCTCTTAGGAAAAATTGTACATTGTAATTATGTTTGG
TTGCATGGCTGTCTTATTTCCCTTTGATAGATTTAGAGACCTCCCAAAGATTTCTTGATTAGTGATAAAC
TTAGTTATCCACTAATGGAAAGGAACAGTGATGCATGTAGATTATAGAAAATCAAACACTGAATATTCTG
ATTCTCAATTAATGTTATTTTCAAATGATTTTGATTATATTAGTATTAATTTGTATTATTCAATTTTTTT
CCCCAGTATGAGAATAATGTTATCACTATTGATCTGGTTCAAAATTCTTCTCAAAAAACTCAGAATGATG
TGGACATAGCTGATGTGGCTTATTATTTTGAAAAAGATGTGAGTATCATCTTCTTTATTCCTGTGTTCAG
GAATGTAGTCTATCATGCCTCAATGAATTAAATATATTTCATCACCTTTTTATCCACTTACAGATCAACC
AAATGGTTCGCTGCTGCCGTTAATTTTGTCCTCCCTGTCACTCACATGCATCTTGCTTGTTTGTATATTT
ATGCCTCTTATCAAATTGTTCTGCCTAAAATATCTCCCCTCTTTCTTATAATTCTTATTTATTATCTACT
TGGTGGTTACTTAGTTTGTGCATATATGCTCCCCTATGATATTTATAATTTACACAAATAAAAGTCTGTT
AAAAAAGACTGTAACTGATATGATTAAAATATTTTGTTGAAACTTTAATATATTATAGTGAGGTATTTTC
TGCTGAAATATGAGGTTTGCTTCAAAATAATCTGGGCGGGGGTGAAAGGATGAAAGGAAGAAAAGATGAA
GTAAGAGAGGCTATGTGTTGTTGGCCTTGCATCTGGGTGATAGGTACATGGGCATCATTGCACTACTCTT
TCTACTTTCGTGTATGTTGAAAGGTTCCTGTAATAAACAGTTTTTTAAAGTTCCAATAAATTAGATTGTT
ATCACTAAAACCATAAAGATTCTTGGCAGCGGTTCTTTTGGCATACAATTTGTATGTAATTATATGTGGC
CATGGTTGGTTTCCTTAAATATTTTTAATTCCTTTTCTCCTTTTCAATACAGGTTAAAGGTGAATCCTTG
TTTCATTCTAAGAAAATGGACCTGACAGTAAATGGGGAACAACTGGATCTGGATCCTGGTCAAACTTTAA
TTTATTATGTTGATGAAAAAGCACCTGAATTCTCAATGCAGGGTCTAAAAGCTGGTGTTATTGCTGTTAT
TGTGGTTGTGGTGATAGCAGTTGTTGCTGGAATTGTTGTGCTGGTGAGTACAGAACAAGTAAAATTTCAT
TTAAGGGTATATTTTTTCAAGAAAAAGTAATAGTGGCTGGGCGCGGTGGCTCACCACACCTGTTATCCCT
ACACTTTGGGAGGCTGAGACAGGTGGATCACTTGAGCCCAGGAGTTTGAGACCACACTGGGCAACATGGT
GAAACCTTATCTGTAGTAAAAATACAAAAATTAGTCAGATGTGATGGCTTGCACCTGTGGTCCCATCTAC
TTAGGAGGCTGATGTGGGAGTGGTCAGTTGAGTCCAGGAGGTCAAAGCTGCAGTGAGCCATGATCACACC
ACTGCACTCCAGCCTGGGCAACACAGCAGGACCCTGTCTCAAAAAGAAGAAAAAAGGAAATATGAAAAAG
TAACATCCATATTCCAAAACATTCAGGGAAAAAAATCTTCATTTTTAAATAATTTTTTTATGGTGAATGA
ATCTATTGTATCTCTGGTCTCTTTTTACAAAAGTCATTTTATGAAGCAAGAAAGGATGCTAATATTAAAA
AGCTTGTGGCTGTGCACCTCACAGGCCAGTTAAATTGCCATCTAGCAGCAAGCGTCTTTCAGTTGTCACT
GCAAACAATTCAACACCTAGTGCAAAATACCTGAACCCCCAAACCACTCAATAAGATGGAACAACAGAAC
ACAAAGTTAACGTTAGCCATACAAAAGAGTTAAAAGTGATATGTGAATCAATACTTCCAAGTAAAGATGA
GCAAATTGAATTTAACAGTGCTTCAGCAAAAGAATGTATTGCTTGAAGAAGTGAAAGGTTTATTTTAGGA
ATGTAAGGATGCTTCGGTATCAAGAAATCTTACTAACACTGGCCAGGTGTGATGGCTCAGGCCTGTAATC
GCAGCACTTTGGAAGGCTGAGGCGGGTAGATCACTTGAGATCAGAAGTTCGAGACCAGCCTGGCCAACAT
GGTGAAACCCTGTCTCTACTGAACATACAAAAAAATTAGCTGGGCGTGGTGGCACATGCCTGTAATCTAT
TCGGGAGGCTGAGGCAGGAGAATAGCTTGAACCTGGGAAGCAGAGGTTGTAGTGCGCCAAGATCATGCCA
CTGCACTCTAATCTGGGTGACAGAGCAAGACTCTGTCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGG
CCAGGCACAGTGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCTGAGGCGGGTGGATCACCCGAGGTC
GGGAGTTCGAGACCAGCCTGACCAACGTGGAGAAACCCCATCTCTACTAAAAATACAAAATTATCCGGGC
ATGGTGTCTCATGCCTGTAATCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATCACTTGAACCCAGGAGG
TGGAGGTTGCAGCTGAGATCATGCCATTGCACTCCAGCCTGAGCAACAAGAGTGAAACTCCGTCTCAAAA
AAAAAAAAAAAAAAAAGAAATCTTACTAACACAACAGAATTCAGAAAGAGGTTTGAGGGTATTTAGGAAC
TTAGATTTCCAGTTCAATCAACCATGTTTGGCTATCCATCTGGAACAAAATGAAAGTTGAATTCCTATTT
CACTCCACCAGGCTGGCCATATTGCCCAGCTGTGTGAGGGTGGCATGTCCAGAGCACAGTAGTAGGAAAG
GCGTTGGGCAGTGTATCCATTTTCAAAGACATTTACATATTTAAAAATACAAAAAAGTAAACTCCCAAGA
AAATTAATTGAGGGAATGTTTGTACAACCTTGTGGTAGGGGAAATTATGTAAGGCAAGAAATCTGGAATC
CATGAAAGAAAAGATACATATATGTGTATGTATATTTTGAGAGAGGGTCTTGCTGTGTCACCCAGGCTGG
AGTGCAGTAGCATGATCATAACTCACTGCAACCTCCAATTCCTGGACTTAAGTAATCCTCCTGACCTATC
CTCCCAAGTAGCAAGGACTACAGGTATGTGCCACTATACCTGGCTAATTTTTTAATTTTTAGTAGAGACG
AATTCTTGCTATGGCTGCCGAGGCTGGGCTTGAACTCCTAGGCTCAAGCAGTTCTTTTGGCTTAGCCTCC
CAAACTGCTGGGATTACAGGCATGAGCCATTGCACCTAGTCCTATATATATATATTTTGGCTTCATTAAA
ATTAAGCATTTTATATGGCAAAGAAACTGTAAAGTAAAAAATAACGATGGGCATGAAAAAAATATGGCGC
ATAAAGCAAAAATGGATATTATACATAATATACAAAGAGTTCTTACAAATTGATGAGGAAACCTAAAGAA
AGAATGACAACAGGTAGGGATAGACAGTTAATAGAAATTTCAGATGGCAAATGAACACAAGTGGTTAATG
CTGGAAGTCTAATTGTTCTGTAGAAATAAATGAAAACACAAGTGCAATAAGGAAGCACATTGTTATTGTA
TCATAGCATTGCTTGTAAAGGTGAATCTGGCCAGGCGTGGTGGCTTACGCCTATAATCCCAGCACTTTGG
GAGGCTGAGGTGGGCAGATCACCTGAGGCTGGGAGTCCGAGACCAGCCTGACCAACACGGAGAAACCCCG
TCTCTACTAAAAATACAAAATGAGCCAGGCATGGTGGTGCATGCCTGTCATTCTGGCTACTCAGGAGGCT
GAGGCAGGAGAGTCACTTGAACCCAGGAGGCAGAGGTTGTAGTGAGCCGAGATCATGTCATTGCACTCCA
GCCTGGGCAACGAGAGCAAAACTCTGTCTCAAAAAATGAATAAAAACAACAACAAAAGTGAATCTGGAAA
ATAGCCTGAGTGTGTATCAGTAAGAGAGTAAATTATGTTTATTGTATCTACGATAGGGAATAATGTGAAT
GGTGAATGAGTTCGATCTTTATCTTTGGATCTGGAATGGTTGCTATGATGTTGATACAAGCTGTGCACAG
GTGGTGATGATACTGCATGGTCCCATTTTTAGACCCCAAAACTTAGATGCATGTGTTTATATATGATATT
TGTATTAGTGTGGAAAAGGAGGATGTGGAAGAATGCACACCAAACTGTTAAATTTCTTTCTTTTTTTTTT
TTGGAATGGAGTCTCGCTGGCCGGACGTGGTGGCTCACTGCTGTAATCCCAGCACTTTGGGAGGCCAAGG
CAGCTGGGTCACGAGGTCAGGAGATCGAGGCCATCCTGGCTAACACGGTGAAACCCTGTCTCTACTAAAA
ATACAAAAAATTAGCCAGGTGTGGTGGCGGGCACCTGTAATCCCAGCTACTTGGGAGGCTGAGGCAGGAG
AATGGCGTGAACCTGGGAGGCGGAGCTTGCAGTGAGCCGAGATTGCACCACTGCACTCCAGCCTGGGTGA
CAGAGCGAGACTCCATCTGAAAAAAAAAAAAAAAAGAAAAGGAGTCTCTCTGTGTTGCCCTGGCTGGAGT
GCAGTGTCATGATCTCGGCTCACTGCAGCCTCCACCTGCCGGGTTCAATTGATTCTCCTGCCTCACCCTC
CCGAGTAGCCGGGACTACATGCAGAAGCCACCATGTCCAGCTAATTTTTGTATTTTTTGGTAGAGACAGG
GTTTCACCATATTGGCCAGGCTGGTCTCGAACTCATCACCTCGTGATCCGCCTGCCTCGGCCTCTCAAAG
TGCTAGGATTACAGGCATGAGCCACTGTGCCCGGCTTCTTCTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTGAGATGGAGTCTTGCTCTGTTGCCCAGGCTGGAGTGCAGTGGCACGATCTCGGC
TCACTGCAACCTCCATCTCCCAGGTTCAAGCCATTTTCTTGCCTCAGCTTCCCAAGTAGCTGGGACTACA
GGCGTGCACCACCATACCTGGCTAATTTTTTTGTATTTCTAGTAGAGATAGGGTTTCACCATGTTGGCCA
GGCTGATCTCGAAATCCTGATGTCAGGTGATCTGCTCACTTCGGCCTCCCAAAGTGCTGTGATTATAGGC
GTGAACCACCATGCCTGGCCTAAACTGTTAAATTTCTTTAAAGATTATTCATTGTTTCCTTTTTTTCTTT
CTCTTTCTTTTCTGTTGTCCCATTGGATCCAGCATTGTTTTTGATTTTGATTTTTGTTTGTTTGTTTCAC
TTGTCGTGGTAGACTTTTTTTTGTTTAGTAGTGAAAGTTTTTATTTTATTTTATTTATTTATGGAGACAG
AGTCTCCTTCTGTTGCCCAGGCTGGAGTGCAATGGTGCATGATCTTGGCTCACTGCAACCTCTGCCCCCC
AGGTTCAAGCTATTCTCCTGCCTCAGCCTCCCGAGTAGATGGGATTACAGGCGCCTGCCACCACGCCTGG
CTAATTTTTGTATCTTTAGTAGAGATGAGGTTTCACAATATTGGCCAGGCTGGTCTTGAACTCCTGACCT
AAAGTGATCCACCCACCTCAGCCTCTGAAAGTGGTAAGATTACAGGCATGAGCCATCATGCCTGACCTAT
TTTATTTTATTTTAATTTTTTTTTAGAGATGGAGTCCCACTCTGTCGCCCAGGCTGGAGTGCAATGGCGC
CATCTCGGCTCACTGCAACCTCTGCCTCTCGGGTTCAAGTGATTTTCCTGCTTCAGTCTCCCAAGTAGCT
GGGATTACAGGCGACCACCACCGCGCCTGGCTAATTTTTTTGTTTTTTTAGTAGAGTCGGGGGGTTTCAT
CATGTTGGCCAGGCTGGTCTTGACCTCCTGACCTCAAGTGATCCGCCCACCTCGGCCCCACAAAGTACCG
GTGAGCCACCACGCCCAGCCCACCTTATTTATTTTTAAGAGACAGGGTCTTACTCTGTAGCCCAGGCTGG
AGAGCAGTGATGCCATCTCCACTCACTGCAACCTCTGCCTCCTGGGTTCAAGCAATTCTGGTGCCTTAGC
CTCCTGAGTAGCTGGGACTACAGGTGCGTGCCATGACACCTGGCTAATTTTTGTATTTGTAGTAGAGATG
GGGTTTCACCGTGTTGGCTGGGCTGGTCTGAAACTCCTGACCTCAGATGATCTTCCCGCTTCGGCCTCCC
AAAGTGCCGGGATTACAGGCATGAGCCACTCCACTGGTGTGAAATTTTTAATTTAAGAAGCAATAAATGT
TTATGGATAGATGTTAAAATTAGTTTTTTTTCAGATCAAAATTATGTCCATTAAAAGCATATATGTCTGT
TTAGATAATCTTTTTTTGAATAGCAGTCCTAAAACAATAGTTGTCTTTCTTCCACTCAGGTTATTTCCAG
AAAGAAGAGAATGGCAAAGTATGAGAAGGCTGAGGTAAATGGATTACTTACCTAAATAGAAAGGCCCTGT
TGAATCTCTTACTCCTAATCACTCTACCTTCCTACACACTGATGCATTTCAGTTATACTGGAGTCCCTTT
ATACTGTTGTCTTTAGGGTCTTAGGGACAGTCTTAGAATGTACTCTTACCTAAATATTCTTGCGTGAGTT
CCATGGCAGATCACCATCTGTTTTCTGCCTCATAGAAGAGTGGAATGGGAAGCCTATGGTTTTTATTCTA
CAAAGAGTCAACATCTAACAGAATCTTCTGAAGGCATACTCCAGTGGATTCACCTTGGAGAAACTCATTG
TGACTGATGATCTGATTTATTATCTCTATGCCAGTGAAATAATCATTTAATATGAACTTAATTTGTCATA
ATCTATTGTGTACTAACTAGTCTATACTAGTGTGACATCAAAGTGTCAGATTGTTAGTGTGTTTCAGTCC
CTTGGAATTGAATATGAACACTTATCCTTGAACCCTATCAATAACATTTTTCACATATCTCAATTTTTGT
GTGTCTTTGTAGTTGTATGTGGGCCACTTACTAATATTTTAGCAAGTAATAAAAATAGAAACGTAAAGGA
ATATTGGAAAAAGTCTAATGGAACCAGAAAGTTCTAGCATTTTTTTCCCATTCTGTAGTAGGTCATCTGG
TTTATTTGGTTTGGTGACCGCAAGTCTAGAAGACTAACCCTGAATTGAATGGTAACAGACAGGCAGAATG
ACAATGTAGTGTTGCAGTGCAGAGCAGTACAGACCTGGGTTTGGCTGGGCAAAATTATATAACTTCTTTA
AGCCTCCATGTTTCCTCATCTGTAAAATGAGGATAATAGATAGTATGGACCTGTTGCAAGGATTAAACAT
AATCAGTGTAAAGTGTTGGTCCCATGCTTGCCACATAAGAAAATATTTGTCAACAGAGTGGTAGTTGTCA
TTATCATTGTCTCAGTTTGCCTGTAACTAGTTGTGTGATCTGAGACAAACACTAATTTTGAACTTGAGTT
TCCCCACATGTAAAATGAAAGATTGATAATAGAAAGTAAATCAATTTTTTCTAGCATTAAAAATAGTATG
CATTTAATAAAAATCTTATTCTTAATGATCTAGCTTACCTCCAACTTGCCCTAGTCACTTTGGCGATCTT
GTCTCTAAATAGAACCTTGAAAACACTTAAATGTGTGTTTCCTTGCAATATAACTTTTTCTTTTTTTATT
TAAATAAGTCTTATAAATGTGGGAAAAAATTATCTTGTGTTCCTTTAATTTCATTTTTATTTAATACTAT
TTTCAGAATGAACAAAAGATTGAAAAATTATTTAGAATTTTTTTCTGTGCTTTTTCCTGTTTCAGATAAA
GGAGATGGGTGAGATGCATAGGGAACTCAATGCATAACTATATAATTTGAAGATTATAGAAGAAGGGAAA
TAGCAAATGGACACAAATTACAAATGTGTGTGCGTGGGACGAAGACATCTTTGAAGGTCATGAGTTTGTT
AGTTTAACATCATATATTTGTAATAGTGAAACCTGTACTCAAAATATAAGCAGCTTGAAACTGGCTTTAC
CAATCTTGAAATTTGACCACAAGTGTCTTATATATGCAGATCTAATGTAAAATCCAGAACTTGGACTCCA
TCGTTAAAATTATTTATGTGTAACATTCAAATGTGTGCATTAAATATGCTTCCACAGTAAAATCTGAAAA
ACTGATTTGTGATTGAAAGCTGCCTTTCTATTTACTTGAGTCTTGTACATACATACTTTTTTATGAGCTA
TGAAATAAAACATTTTAAACTGAATTTCTTA

</dna_sequence>
        <protein_sequence>>NP_002345.2 epithelial cell adhesion molecule precursor [Homo sapiens]
MAPPQVLAFGLLLAAATATFAAAQEECVCENYKLAVNCFVNNNRQCQCTSVGAQNTVICSKLAAKCLVMK
AEMNGSKLGRRAKPEGALQNNDGLYDPDCDESGLFKAKQCNGTSMCWCVNTAGVRRTDKDTEITCSERVR
TYWIIIELKHKAREKPYDSKSLRTALQKEITTRYQLDPKFITSILYENNVITIDLVQNSSQKTQNDVDIA
DVAYYFEKDVKGESLFHSKKMDLTVNGEQLDLDPGQTLIYYVDEKAPEFSMQGLKAGVIAVIVVVVIAVV
AGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>The full-length GA733 (epcam) antigen expressed by recombinant adenovirus inhibited the growth of established tumors in mice [Ref976:Maruyama et al., 2000].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene296">
        <gene_name>ERBB2</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>2064</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>54792098</ncbi_protein_id>
        <gene_locus_tag>RP23-355L10.8</gene_locus_tag>
        <gene_refseq>AB025285</gene_refseq>
        <protein_refseq>NP_001005862</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>17</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>39688083</gene_start>
        <gene_end>39728661</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>transcript variant 3</protein_name>
        <protein_pi>5.82</protein_pi>
        <protein_weight>126717.24</protein_weight>
        <protein_length>1225</protein_length>
        <protein_note>Also known as NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000017.11:39688083-39728661 Homo sapiens chromosome 17, GRCh38.p12 Primary Assembly
GAAGTTCCTGTGTTCTTTATTCTACTCTCCGCTGAAGTCCACACAGTTTAAATTAAAGTTCCCGGATTTT
TGTGGGCGCCTGCCCCGCCCCTCGTCCCCCTGCTGTGTCCATATATCGAGGCGATAGGGTTAAGGGAAGG
CGGACGCCTGATGGGTTAATGAGCAAACTGAAGTGTTTTCCATGATCTTTTTTGAGGTAGGGCTGTTTAC
TGTCACCACCCCTGTCGGATTTTACTTCCTAAACGTACCTGTAACTATCCACTTCTCTCCATCTCTTCTG
GCACCACCCTGGTTAAAGACACCATCATGTGTCGCCAAGACAGCCGCAGTAGCTTCTTAATGGCTCTCCC
TGCCTCTACTTTTGCCTCTTCCAACCTGCGCTCCATTTTGAAAAATTAAAATTTGCCCATATCACTTTTT
TTTTCTTAAAATTATTTACTGGCTCCCAATTACCTTGGGTAAAATACAGTCTCCACAAACCCTGCCTGAT
TTGGCCCCTGTCCACTGGTCTCCCTCACTCCCTTGCTCCAGACCCGCTTCAGAGGGCTATGTCCCTCAAG
CTTCCTGACTGCCTGGCCTGGTCTGAATCACTCACTCTTCTTTTTTCTTCTAGTCGCAATTGAAGTACCA
CCTCCCGAGGGTGATTGCTTCCCCATGCGGGGTAGAACCTTTGCTGTCCTGTTCACCACTCTACCTCCAG
CACAGAATTTGGCTTATGGTAGGCGCTAACTGCGTTTGTTTGTTCTTCTGTTTAATGAATGAACAGCATA
CATCAACATAAGAACTTGACAAATCCAGGGCTGTAAAATCATCAGTATGGTTCTGCACTGAGATCGGAGA
GAAGTAATATTTCTAGGAAAATTAGGAACCCTGGGAACAGGACGCTTGCTTTAGTATCCTCTCCCTGCTC
ACCTCCCCTGCACTCCCATCAGCACCGACCCACACCCAATCTCATAGAAGCCTTGTAGCTAAGGATCACC
CTTTCTCCTCCCCCACTCTCCTCACCCCTTGTCAACTTTTCTTTTTCGTCCTGGGGGTTGGAATGAGTAA
GAAGTAGCCTGGGATTCCATTCACTCACTTAACAAACATTTCTGAGTCCTTAGCTCTAGCACCTTGCTAA
GCAAGGCAAAATCTCCAGGAGGCACCATTCACATTGCATTTTCTGTGAATGGTGCTCTGGGGAGCAGCAT
TCACATTGCCTTTTCTGTGAATGGCAAATTCTTCCAGTTAAATATAACATGAATAGTGTCCCCTGGAGTT
GACCACCCAACTGATACTGACTGAGAAGCTGAAATGAACAAAACAACCCCTTAGCCCTCCAGGAGCTGAC
CGGAAATCCAGTGCTAATACTACTTTGCATCTTACAGATTAGTTCTTTTACAATACTGTTTTTTTTTCTT
TTTTCATTTCATTTTGTCCTTTCTGTGACTCTGGGATGAGTCTTTTTATGAGGATCCTCATATAAAGATG
GACATTTAGGATTAAAGAGGATGAAATCCTGACAAAATAGGGAGTCTCCCCTTTAGAAAATTCCTAAGTA
AGGCTGGGGGTGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGACGGATCACCTGAG
GTTAGGAGTTTGAGACCAGCCTGACCAACATGGAGAAACCCCATCTCTACTAAAAATACAAAATTAGTTG
GGTGTGGTGGTGCATGCCTGTAATCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGG
GAGGCAGAGGTTGTGGTGAGCCAAGATTGCGCCATCGCACTCCAGCCTGGGCAACAAGAGCGAAACTCAA
AAAAAAAAAAAAAAAGAAAAAGAAAATTCCAATTTTGAAGGCCTCATCCTATATTATGTCAAACATACTG
AAATGCAGTAACGCCCCACATTAAATAAGATTTATAAATAACTATACATATATATAATTCAATCTAATTG
CTGTTAATAGTTGACATATTGCTACATTTATATACATTTAGTTAAAAAAAATTTTTTTTCCCAGACAGCC
TCTCACTCTTTCACCTAGACTGAAGTGCAGTGGCATGATCACGACTCACTGCAACCTCAACCTCCCAGAC
TCAAGTGATCCTTCCATCTCAGCCTCCTGAGTAGCTGGGACTGCAGCATGCGCCACTATGCCCTGCTAAT
TTTTTTAATTTTTTGTAGAGACACGGTCTTGCTATGTTGCCTAGACTGGTCTCCAATTCCTGGGCTCGAG
TGATCCTCCCGCCTCAACCTCCCAAAGTGCTGGGATTACGGGCGTGAGCCATGCCACACGGCCATAAAAT
ATTAATTTTCGCAGCTTTCTTATATTTTAGAACTAACAATGGAAATTTGTTCGGGTCTAAAGTATTTCAG
AGGTCCTTGAAAACCCATGCCTACATACCTGATGGAAAAAGCAATCCTAGGTTAATGGTGGAAGTGGGAG
TAGAGACTTCTGTTCTGTTGACTTCTTGGAAGATGGGGTACTGTCTCTCTGGGACAGCTCTTGAGAATTT
CCCTGCCAGCACAGCCCCAGATAACAATCTCTAGATGGCGATTACCTGGCCTCTCTTCCCAACTTTCTAG
CCTGGAGCCCCTAGTTCTCCCCTGAGCCTCCTTAGCTTGTCCTTCTTCCTAACTTGTATTTGGCTTCAGA
TGTGATCCACAGTCTGAAAAGTCACTAATTCATTCCTTCAACTCAGGCTTATTGAGTCCTCCTGTGTATC
AGCCATTGTACTCATGGGGGAAAAAAAAGACAAAGCATATGTTAATAGTAGAGTGTGCTGGACAGGCACA
GTGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGGCGAGGCAGGTGGATCATCTGAGGTCAGGAGTTCG
AGACCAGCCTGACCTAACATGGAGAAACTCCTGAGATCGTGCCATTGCACTCCAGCCTGGGCAACAAGAG
CAAAACTCCGTTTCAAAAAAAAAAAAAAAAGTATAGTGTGCTAAAGGCTCAACGGCAAGCTGACCATGTT
CTTAGATCAAAATTGGTAGAGAGTCTACAATGTGGGTTCCTTATTCATCAAATGTTTATTAAGTTTACCA
TGTGCAAGTCTCTGGGAACAGAGTGATGAACAAGGCACTGTACTTTTCATGGTCAGAGGAGGGAAACAGG
CCATAAACAAGTGTCAAACAAAAGACTGAAGCCAGGTGCGGTGGCTCACATCTGTAATCCCAGCACTGTG
GGAGGCCAAGGCAGGCGGATCATGAGATCAGGAGATCGAGACCATCCTAGCCAACATGGTGAAACCCCAT
CTCTACTAAAAATACAAAAAAATTAGCTGGGCATGGTGGCACGTGCCTGTAATCCCAGCTACTCCGGAAG
CTGAGGCAGGAGAATTGCTTGAACCAGGGAGTTGGAGGTTGCAGTGAGCCTGGATTATGCCACTGCACTC
CAGCCTGGTGACAGAGCGAGACTCCATCTACATTAAAAAAAAAAATATATATATATATATATACACACAC
ACACACACACACACACACATACCCTCTAACCCAGGAATTTCACTCCTAGGTATACCTACATAAGCTCCAG
TATACCTAAACAAGTGCAAATTTGTTTAAGTACAGTTATTTGTGGTAGCATTAGTCATTGTTTTCAATAG
CAAGAAGAAAAAGGAAACAACTAAATGTCCATCAATAGGGAATGAATTATATTAATGGAGGGAGAGCCAT
ACAATGGAAGGCTGAACAGAAATTAATAGGAATGGGGCAGATTTGTAATGTACTAGCATGGTAAAACCTT
CATGATAGATATAGATATAGATATAGATATAGATATAGATATATATACATATACATATACATATACATAT
ACATATATATATATATATATATATATCTCTTGTGTCTCAGCCTCCCGAGTAGCTGGGATTACAGGTGTGT
GCCACCACATCCGGCTAATTTTTGTATTTTTTAGTAGAGACAGGGCTTCACCATGTTGGTAAGGCTGTCT
TGAACTCCCGACCTCAGGTGATCCACCTGTCTCAGCCTCCCAAAGTGCTGGGATTATAGGCATGAGCCAT
CACACCTGGCCAAATATTTTTGATAAGTATCAAGTGCACAGTGCAGAACAAAATATGTGTGTGTGTATGC
ATGTGTATGTACACCTATACACTTATATACAGTACCCCATGTGAAGAAAAATAAGGGTACGTGTTATGCG
CGTAGTATTATGGTTGTTATTTTTGAGAATATATCTAGAAAGATAAAAAAGAAAGTGGAAATAGTTCTTG
CCTCTGGTGGGAAGTGGGACTATGTGCCTGATCAATAGGGAAGTAAGGAACACTTTTTTTTTTTTTTTTT
AAACGGAGTTTTTGCTCTTGTTACCCAGGTTGGAGTGCAATGGCGCGATCTTAGCTCACTGCAACCTCTG
CCTCCCAGGTTCAAGCGATTCTGCTGCCTCAGCCTCCTGAGTAGCTGGGATTATAGGCATGCGCCTCCAC
GCCTGGCTAATTTTGTATTTTTAGTAAAGATGGGGTTTCTCCATGTTGGTCAGGCTGGTCTTGAACTCCC
CACCTCAGGTGATCCGTCCGCCTCAGCCTCCCAAAGTGCTAGGATTACAGGCGTGAGCCACCGTGCCTGG
CCAGGAACGCTTTTTATTTTTGTACCTTTAAAAGTGTGTACCGTCTGTGTATATAATCAGTTAAAAACAA
AGAAAAGCTGAGTGTGGTGGCTCATGCCTGTAATCCCAGCCCTTAAGGAGGCCGAGGCCGGCGGCAGATC
ACCTGAGGTCAGGAGTTCAAGACCGGCCTGACCAAAACGGTGAAAACTCATCTCTACAAAAACATAAAAA
TTAGCCAGGCATGATGGCAAGTGCCTGTAATCCCAGCTGGTTGGGAGGCTGAGGTGGGAGACTTGCTTGA
ACCTAGGAGGCAGAGATTGCAGTGAGCCAAGACTGTACCACTGCACTCCAGCCTGGGCAACAGAGCAAGT
CTCTGTCTCAAAACAAAAACAAAAACACAAAGAAAAAATGTAAAACAATTTCATGCAGTAGCAAGCATCG
AGTTAAATACAGTTGACCCTTGAACAACACAGGTTTGAATTGCACGGGTCCATTTATACTCACATTTCTT
CCACCTCTGCCACCCCCAAAATAGCAAGACCAACCCCATCTCTTTTCCTTTCTCTTCCCCCTCCTCAGCC
TACTCAATGTGAAGATGATGAGGATGAAAACCTTTGTGATGATCCACTTCCACTTAATGAATGGTAAATA
TGTTTTTTCTTACTTATGATTTTCTTAGTAGCATTTTCTTTTCTCTAGCTTCCTTTATTGTAAAAATACA
GTATATAACACATATCACATACAAAATGTGTGTAAATGGACTGTTTGCTATTGATAAGTATTCTGGTAAA
CAGTAGACTATTAGTTTTTTTTGTTTTGTGACAAGGTCTCCCTCTGTCGCCCAGCCTGGAATGCCGTGGT
GTGATCATGGCTCACTGCAGCCAAAAACTTCTGGGCTAAAGCAATCCTCTACTAAAAATACAAAAATTAG
CCAGGCATGGTGGTGCGCTTCTGTAATCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATTGCTTGAACCC
GGGAGGCAGAGGTTGCAGTGAGCTGAGATTGCACCGTTGCATTCCAGCCTGGACAACAGAGCGAGACTCC
ATCTCGAAAATAAAATAATAATAATAATAATAATAATAATAATAATAATAATAGGGCTGGGTGTGGTGGC
TCATGCCTGTAATCCCAGCACTTTGGGAGGCCAAGGTGGACAGATCACCTGAGGTCAGGAGTCTCAATTA
AAAAATAAATAGGCCGGGCACAGTGGCTCATGCCCATAATCCCAGCACTTTGGGAGGCCGAGGTGGGCAG
ATCACCTGAGGTCAGGAGTTTGAGACCAGCCTGGCCAACACGGAGAAACGCTGCCTCTATCAAAAATACA
AAAATTAGCTGGATGTGGTGGTGCATGCTATAATCCCAGTAATACCAGCTACTCGGAAGGCTGAGGCAGG
AGAATCACTCGAATCCGGGACACGGAGGTTGCAGTGAGCCGACATCATGCCACTGCGCTCCAGCCTGGGT
GACAGTGAGACTCTGTCTCAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATATATATATATATAT
ATATATATATATATATATATATATATGTGTGTATATATATATATATACACATATATATGTGTATATATAT
ATACACACACACATATATATGTGTATATATAAAATAAAATAAATAATAATAAAACATTTACTTTGGCTGC
TGTTGCTGCGGGGAGAATTGCAGGGTGTCAAAAGTAGCACTGGTGGAGGGGTAGTGATCAAAGTCTGGTG
CTTTAGCCCAAAGGAGAAATGATAGAGACTCAGACTAGCTGGTGATGGAGGTAGAATAAGCATAAATGTA
TCAAAAAGAGGAGTTGATAGATCTTAAAGAATGATTGGATTTGAAGGGCAAAGGAAGAGAAGAATCAACC
AGGTGGGTTCAGTGAATGAAACCATCAGAAACGAATTGTCCCCTGAAATCAAGACTTTGTGATTGCCATA
GTTGTATGCTTCTCAAAGGTTCCTCGTCTCCTCTTCCTTGGACCAAAAGTCAGAGGCAAGAATGCCCTCA
TTCATACCCCAGTGGTCTATACCTCCAGCAGCAAGTCGAGTGAGCAAGTGATGTCCTGAAAGGCCCAGTG
GATCAGTGGAATGAAGCGGGCAGGAAGACTTAGTGCTCCTGAAACAAGGAATCCAGAATCCAGGAGAAGG
ATGGCTCAGTGGGGCTTTCAAGGGACAAGTATGGGGGTTGAAGGGGTCACTGTCCCTATACCAAATCCGA
AAATATTGTGACCAGGAACCATTCTGTCCAACTCTTCTATTTCAGGTGGCAAAGCAAAGCTATATTCAAG
ACCACATGCAAAGCTACTCCCTGAGCAAAGAGTCACAGATAAAACGGGGGCACCAGTAGAATGGCCAGGA
CAAACGCAGTGCAGCACAGAGACTCAGACCCTGGCAGCCATGCCTGCGCAGGCAGTGATGAGAGTGACAT
GTACTGTTGTGGACATGCACAAAAGTGAGGTGAGTCGCAGGACAGAAGAGTGCTTTTTGTTTCAGCAGAG
CAGCCTGGGGAGAGATAAAAGCTACTCCTGGGGCCTGGGCCTGCATTCCTGAGATGTGGGTAAGAGGGGC
CCAGGGTCAGAGTGTCTGGCAAGCTTGGCTCTGCCCCTTTGCTGTCCTGGAGACTAGGGCTAATCCTGGG
CTCAGGGAGTGGCCTCCCCATGGTTAGGATACAAGTGCTCATCAAGGGCCACCCCTAGGAAGGACCAATT
TTCCTATCAGAAGCTTCTAAGTTATCCTCCTTTGGCCCAAAGGGACACCTCAAGCCTACTCTGAGGAACT
CTTTCCAATGAACTAATTCCTACAGTCACTTCCCCAGCAACCTGTGCCTCAGCCTCAAGGCACTGTGGGG
TAGGCCTCAGTTTGTGGCCTGGACATCGGACTGTGGACCAGACGACTCCTCCCGATTTCTGTTTGTTTTC
AGTCCTCTGACCCCAAGCTGGCTGGTGAAGTAGGTAGAGGGAGGAGACTTTGGTGCATGCATACACACAC
ACACACACACACACACACACACACACACACACACACACACACACACGTCTCCTGTGCCCCCCAGTCTCCA
TGGCTGGTCAATGATTGACTGGCATTTCACAGGCCGCTGGTTGCAGCCCCAGCCTGTTGACTTAGAGGTC
ACCCTCGGAAGCTAGAGCCCTGTCCTGCCTCTTCAGTGTCAGTGGTCACTCCACTGCCCACAGGCTGGGG
TCTTGGGCAAAACACACGCATCTGCCCTGATCTGAGTTTGCTGCCCTCTGTCCCGCAGTCAGCCCCACTC
TGTTCCCACTCCCTCTCCCCAGCCCCCTAGCTAGACCCCTCTCACCAGCACCCCTTTCCCTTCCCTGAGG
GTCCCCCTCGCTGTCTTTGTCCCTCAGACATCCTCTTTCCTGGGCTCTCCTGCCAGGCCCTGCTGGAGGG
ACAGTTAAGGAGGAAATCGAATCAGCAGCGCCCACCCCTGCCCCCCTTCCTCTCCTCTTGTCAGACACCA
GACGAGGTTTTTTCCTCTGGCTTCCCAGCTCTGAATGGGCTCATTCTTTTTCAGAGGCTCGGCCCCTCTC
GAGCCTCCTCCCCAGGGCGTGAGTTCTGACCCCAGCTCCTCCCCCCATCCCCACTCCAGCCCCCTCTCCA
GCTTGCTCCACCCTCTCTACCGCCCACCGGGACTGGGCATTGTCTGCCAGTCCGGGTTTCTTCCTGGGAT
TTGGGATGCAGAGAGGATGGGTTTGCTTGGGCGGGGGGGTGGAGAGTGAAGGGGGGAAGCAGGATCTTTG
TAGAGGGAGGGACCTACAGTTACCTGGACTTCTTTCCTCTGTCTCCCCTCTTGGTACCCTTGACTGGGGC
TCTTGAGGGTAATGGGTGAAGCCAAATCTGCCATGGCTCAGTTCCCAGCTCAGCTCTGTGACCTTGGGAA
AGTTCCTTTAGCTCGTGGAATCTCAAGGCTCAAGGTTCCTCTTCTGCAAAATGGGGAATGATAACACCTG
CCTCCTCTGGAGTCTTGGGGACTCAGTGTTCTGAGGAACGTGGCTGTAGGTCAGAGTGGCACAGAGTAGG
GTCCAATGAAGCATGGCGTCCACAGTAGCTTTCCTGACTGGACTAACCTTTCCGGACACAACAGCAGGGC
AGGGGTGGGGCCTGGGGAGAAAGGACACCTCTAACCCTGATCCTAACATCCCGATGGCCTCTAAGGCTGC
CTGCACACTCATCCAGGTGCAAGCCCTCCAAGGTGTGGTGTGATGAACCAGTGACTCCTGGAGCCAGGTC
AGCGCATCCTCTTCCCGCAGGGCTGTAAGCTGCAGGACTGAGAGGCAGGTTGACCAGGTCCTGGGCTGGA
TGATGGGGTGAGAGTAAGGGGTCAGTTTTGATACATGCCCAACTTTTCTCTCTAGCCCTAAGACATCCTG
GGCAAATTGCTTACCTCAGTTCCCCTGATCCTCACCCTAACCCTAACACCAGCTCAAGAGAAAATAGGGA
TATTGATGGCCATCCAGAAGGGCTGCTGTGTTCCATACACAGCAATATTTCTCGAATGTTTGTGACAGCG
GTCCAAGGAATAAGTTAATTTTACATTATCACTCTGGATACCTGTACAAAACTCCACCTTATCCTTACTA
TATGAATGTGCTAGGGTTGTTTTTTTGTTTTGTTTTTTTTTTTTTTTTTTGAGACAGAGTTTCGCTCTTG
TTGCCCAGGCTGGAGTACAATGGCGCGATCTTGGCTCACCGCAACCTCCGCTTCCCAGGTTCAAGCGATT
CACCTGCCTCAGCCTTCCCGAGTAGCTGGGATTACAGGCATGCGCCACCATGCCCGGCTAATTTTGTGTT
TTTAGTAGAGACAGGGTTTCTCCATGTTGGTCAGGCTGGTACCAAACTCCCGACCTCAGGTGATCCACCT
GCCTTGGCCTCCCAAAGTGCTGCAATTACAGGCATGAGCCACCGCACCCAGCCGTGCTAGGGTCTTTTTC
TGTTCAATTCCTTTCTCTCTCTTGCTCTCTTTCTTTCTTTCAATGGAGTCTTACTCTGTCACCCAGGCTG
GAGTGCAGTGGCAAGATCTCAGCTCACTGCAACCTCTGCCCTCTGAGTTCAAGCAATTCTCCTGCCTCAG
CCTCCCGAGTAGCTGGGATTACAGGTGCCTGCCACCACACCTAGTTAATTTTTGTACTTTTAGTAGAGAT
GGGGTTTTGTCATGTTGGCCAGGCTGGTCTCGAACTCCTGACCTCGTGATCTGCCTGTCTTGGCCTCCCA
AAGTGCTGGGATTACAGGCATGAGCCGCCATACTCGGCCAACTTTGTATTACTTTCTTAAAGAGAGTTTC
CCAAATTATATAAGCTTCAGGCCCCACAAAACCTAGATCTGCCCCAGTATAACTAAATCTGGGACCATTT
ATTGAGCAATTATTATGTGCCAAGTATTGCGCTGAGTGCTTCCAGAGCATTATCTCCTTTAACCCCAGCA
TAGTATGTCAGATGCTGTTTTACAGATGAGCCAACTGAGACCAGAGATGCTCAGTCACTTGCCCAAGGTG
ACATGACTGATATGGAATAGAGTCAAGATTTTTTTTTTTTTTTTTGACACGGAGTCTCACTCTGTCTCCC
AGGCTGGAGTGCAGAGGCGCAATCTCAGCTCACTGCAAGCTCTGCCTCCCAGGTTCACGCCATTCTCCTG
CCTCAGCCTCCTGAGTAGCTGGGACTACAGGCACCCGCCACCACACCTGGCTAATTTTTTGTATTTTTAG
CAGAGACAGGGTTTCACCGTGTTAGCCAGGATGGTCTCGATCTCCTGACCTCGTGATCTGCCTGCCTCGG
CCTCCCAAAGTGCTGGAATTACAGGTGTGAGCCACCGCGACTGGCCAGATTCAAGATTTGAACCCAGGTC
CTCTTGGTCCCAGAGGCCCCTGTTTCTCAACTCCCTAGGATGGCATAGCAACCTGTCCCACAAGAGGTGC
CTGCTTTAAGTGTGCTCAGCACATGGAAGCAAGTTTAGAAATGCAAGTGTATACCTGTAAAGAGGTGTGG
GAGATGGGGGGGAGGGAAGAGAGAAAGAGATGCTGGTGTCCTTCATTCTCCAGTCCCTGATAGGTGCCTT
TGATCCCTTCTTGACCAGTATAGCTGCATTCTTGGCTGGGGCATTCCAACTAGAACTGCCAAATTTAGCA
CATAAAAATAAGGAGGCCCAGTTAAATTTGAATTTCAGATAAACAATGAATAATTTGTTAGTATAAATAT
GTCCCATGCAATATCTTGTTGAAATTAAAAAAAAAAAAAAAAGTCTTCCTTCCATCCCCACCCCTACCAC
TAGGCCTAAGGAATAGGGTCAGGGGCTCCAAATAGAATGTGGTTGAGAAGTGGAATTAAGCAGGCTAATA
GAAGGCAAGGGGCAAAGAAGAAACCTTGAATGCATTGGGTGCTGGGTGCCTCCTTAAATAAGCAAGAAGG
GTGCATTTTGAAGAATTGAGATAGAAGTCTTTTTGGGCTGGGTGCAGTTGCTCGTGGTTGTAATTCCAGC
ACTTTGGGAGGCTGAGGCGGGAGGATCACCTGAGGTTGGGAGTTCAAGACCAGCCTCACCAACGTGGAGA
AACCCTGTCTTTACTAAAAATACAAAAAATTAGCTGGTCATGGTGGCACATGCCTGTAATCCCAGCTGCT
CGGGAGGCTGAGGCAGGAGAATCACTTGAACCAGGGAGGCAGAGGTTGTGGTGAGCAGAGATCGCGCCAT
TGCTCTCCAGCCTGGGCAACAAGAGCAAAAGTTCGTTTAAAAAAAAAAAAAAGTCCTTTCGATGTGACTG
TCTCCTCCCAAATTTGTAGACCCTCTTAAGATCATGCTTTTCAGATACTTCAAAGATTCCAGAAGATATG
CCCCGGGGGTCCTGGAAGCCACAAGGTAAACACAACACATCCCCCTCCTTGACTATCAATTTTACTAGAG
GATGTGGTGGGAAAACCATTATTTGATATTAAAACAAATAGGCTTGGGATGGAGTAGGATGCAAGCTCCC
CAGGAAAGTTTAAGATAAAACCTGAGACTTAAAAGGGTGTTAAGAGTGGCAGCCTAGGGAATTTATCCCG
GACTCCGGGGGAGGGGGCAGAGTCACCAGCCTCTGCATTTAGGGATTCTCCGAGGAAAAGTGTGAGAACG
GCTGCAGGCAACCCAGGCGTCCCGGCGCTAGGAGGGACGCACCCAGGCCTGCGCGAAGAGAGGGAGAAAG
TGAAGCTGGGAGTTGCCACTCCCAGACTTGTTGGAATGCAGTTGGAGGGGGCGAGCTGGGAGCGCGCTTG
CTCCCAATCACAGGAGAAGGAGGAGGTGGAGGAGGAGGGCTGCTTGAGGAAGTATAAGAATGAAGTTGTG
AAGCTGAGATTCCCCTCCATTGGGACCGGAGAAACCAGGGGAGCCCCCCGGGCAGCCGCGCGCCCCTTCC
CACGGGGCCCTTTACTGCGCCGCGCGCCCGGCCCCCACCCCTCGCAGCACCCCGCGCCCCGCGCCCTCCC
AGCCGGGTCCAGCCGGAGCCATGGGGCCGGAGCCGCAGTGAGCACCATGGAGCTGGCGGCCTTGTGCCGC
TGGGGGCTCCTCCTCGCCCTCTTGCCCCCCGGAGCCGCGAGCACCCAAGGTGGGTCTGGTGTGGGGAGGG
GACGGAGCAGCGGCGGGACCCTGCCCTGTGGATGCCCCGCCGAGGTCCCGCGGCCGGCGGGGCCAGAGGG
GCCCGGACGAGCTCTCCTATCCCGAAGTTGTGGACAGTCGAGACGCTCAGGGCAGCCGGGCCCTGGGGCC
CTCGGGCGGGAGGGGGCAGTTACACGGCAGCGGCTCGAGATGGCCCATCCAAGAGACTGGCGCTTTCCAG
GCTCCGAGGGGCTCCGGGAACTTGTCAAAGAAGTTCTCTGAAATTGTTCAGAAAGTTTTCCCGCAAAGGG
TGTATTGCGTAGAGCGCGCGCGCGCGTTTCCCCCCTTCTTGAGCCCCCTCAAGCTTTCTCAAAGCCTTTC
CAGTTGGCAGCCTCCGCCTCCGGACTGGCCTGGGCTGGATTCCTTGGGGGGGTCCTCTGCCCTGCCCCTC
CTCCAGCCCCTCCCCGCTCCCCTTCAGACGATTTTGGTTTGGTTGCTCCTGCTTCTGGCGGGGTCGGGTG
TGTGTGTGTGTGGTGGAGTGGAGGGTGGCATAGCAACCTGTCCCAACCAGAGCCGGGGAGGAAAGGGTGG
CCCGGAGGGTGGCCTCTTGCTGGGGTCTGGGTTGGGGGCGGGGGAGACGTTTGCTTTGAACAGATTCTTG
GGGCCAGCTTAGGGACTGTGCTCTGTGACTTTTGGAGCGCGTGGACCATGGAGGGGTGGGGGTGGGTTTC
TTGGGGTGTAAAGTGGGAGAGTTCCCAGAGAAGGAAGCTAAGAAATAAGGCCAGATGGGAGCCTAGGGAG
GGCTGCGTTGTTCTGCTGCCTTTTCCTTGGTGCTGTGCGTGGGGAAGGGTGAGTGGGGGCAGTGTGTATC
CTGACCCATCTGTCCACCTGTGTGCATTAATCATAAAAGCTAACATATAGCCTGGGCCAGGTATACTCTG
CCAGGAACTGTTTGTGGTGTTTTGCATGCATTCTCCTTTAATCCTAGAACACCCCTATAGTGGAAGTTCT
GCCAGCATTCTGGACTGAGTAGCAGTCCAGAGGTTGAGTAGCAGCTAGTAAGTGGTGGGGTCAAGATGGG
ACCCCAGGCAGTGCGACCCCCAACCATGCATTCGAAATCGCTATATGGATGAGTGCACCTGGAGCAATGA
GGGACACTGCTCCCTGAGTCACTGGGCTGCAGGGGAGACAAAATGAAAGTGTTCTGGGAGTCGTGGGTGG
TCTCCATAGGTCAGAGGGTCTGGGGAGGGAGTGGGTGTCATCGTGGCTGTGTGTTGCCCGAGGGGCCCTC
TGTGAGTGAGTGCATGGCCGTGTTATCTCTGCAGGTCTACGCCAGGGTGTTCCTCAGTTGTGTGGTCTTT
GTATTTGTGTGTCTGGGCTTTGTGTTGCCAAACAGCAGTCTCTCTGCTGACTTGGGGACACAGGCTGAAC
TCTGTCCTCTGCAGGAACTCCCTTAAGGTGCTGGGCCAGATCTGCCATAAACAGAGGGAGGTAGCCTTCT
ATGGCCACGCCTTCTTGCTGAGGAAGAAGGTTCCTCTCTTCCAGGGAGTACATCCTTGCCCTCCCTGTTT
CCCAGACAAGCATCTTCACCTCTCATCTTCTGATGAGAAGGGTGAGGCCATACTGAGCTGTCAGGCTGAG
CTGCTGCCCTTCCTCACCTTGGGCTGGGAGTTGATCAGGGAATGGCAGTTGCTGCAGAGCTGGATTTGAG
GGCTGGGTTCTCTGGATGGGGCCTCCTCATGTCCTCACCCCTCAACCTGCACTATTGATTGTGTTGTGCA
GGAGTTAGTTAAAAAGTCATTGCACAGCCTGGGCAACAAGGCAAAACTCTGTACAAAAAATACAAAAATT
AGTTGGATGTGATTACACGTGCCTGTAGTCCCAGCTACTCCGGAGGCTGAGGCAGGAGGATCACCTGAGC
CCAGGAAGTTGAGGCTTGCAGTGAGCTGTGATTGCAAATGCTCTCCAGCCTGGGTGACAGTGTGAGACTC
CGTTTCAGAAAAAAAGTATACCACCCAGCTGCCTCCAGCACCCAGATTTTACCCAAGGGGTGAGGTCTGG
GGCAGGAATGTGGGGGAAGGGGAGGCCTAGGGGGAGCCCCAGAGGGGTCAGGATTTTTCTGAAATCCTTT
CTTAGAGGTATGGGTTTTACAAATTGCAGCAAATACATCCTTTTAATCTTGCAGAACTCCTTCATATTTT
AATTCCAGTATGATTCTTCCAACAGCCTCCTCTCTTTACTATACTTGGGGAAAGTACTCATTTTATTTGT
CAAGAAAAAAACAATTGAAAAGATAGGGATCAAATGTAAAAAGAAAAAATACGTGGCATTCCAAAGTCAA
ACACAAAGCATGTTTAATTTTCTCGTGGTTTGGGATTACCCATATTCCTGCTGTATGAACCTGTCTTGTC
TTAACTTTTAAGAAATGTACGGTGTACTTCCTATATGCTAGGTTTTTATCCATGCTTTCATTTAATCTCT
GTGACAGTCCTGTGAAGTAGGTGCACAGATGAGAAAATGGAAGTTCAGAGAAATGAAGCAACTTATCCAA
GGCTCCCAGCTACCCAGTAATGTCCAGGGAATTTTTGGACTCTGAAGAGGAGGCATTAAGAGGTGGTTAG
AGTCTTATTCCAGCCAACAATAATGGGTTGAACAAAGCCTTAGGGGCAGGCAGGTGGCCAGATGGGAGGA
GAAGCGCTCCTCTTGTTCAGGCGAATGACCTTTCCATCCACTTCTCTAGGCTGTAGAAAGTGGAGCTGAG
CTGGGGGCCCTGAGGTTCCCTCTTGACTTCAGAGTCCTCTCCCTTCCTGTCCAGCCAATGCCTGTCTTCC
TTTTGGGCCCTACCAGCATGACAGGGGGCTGCGGGCAGGAGGGGACAGAGGCCACGTTGACACACAGGGC
TGTGGGTGAGAGAGACAGCTGAAGTGTCAGCGTGAGGGGCCAGTGTGGGGCTGCGGCTGGGAGGGCTGGG
GTGGGGCCCAGGGTAGTTGTGCCTGTCCTTGGGTGATGGAATGATCTGGAAAGAGATTCCTTCCCTGCCC
TCCACCTGTGAGAAGCCCCTCTAGAGTGACATCTCCATCTTATGTTTGGCCACCCATCCTCCCCCTGGGA
AGAGAGCCGAGGTGGGGTAAGGGATGTGTACTCTTTCAAGGAGTGGGAGAATTATTCTAGCGAATGTTTG
TGTTGTCCCAGTTCTGTTTACAAAGCCTCGTCATGTTTACAGATGGCTGCGCAATTCATTACCTCATTTA
ACTCTCATGTACCTCCTCTGAGGGAGTAAGAGCTGTTACAGCCAAGTTTAGGTCAGTAAATATTCACCAA
GTTGCAGGTACTGCAGGGCATAGAGATGAATCCGATTTAGCTTCTGCCCTGGAGGTCTGGGAACTTGCTC
AAGATCACTCAGTGAGCAGCTGAGCTAGGGTTCTCAACTAAAGACCCTGGGCCCAGGCCCTGGTCTGATG
TCAGGCCTGATACACCAGGTGTTTGTGGTCGGGGAATCCCAGTGTCACTTGAATGGGCTGTGACATTATG
GGTCTGGGAGAGCTGAGCTTTGGGGACACAGGTCATTTTACTGTAGTATTCATGGAAACCAAGGGAAGTA
TTGGCTTTTCTGCTGTGAGCAAGAGGAGCAGCTGGGGCTGCAAGCTGGTGGGGAGGAGAGAACCCACCTG
AGAGAAACCTCAGGACTGGGGTCAAGTCCTGACCACCAGAGTCCAGAGAGACATGAAGGACTGTGACCAG
CTCTGAGCAGAGAGATGGATTCCATGACCTCAACTGGTCCCTTTTGTTCGGAGACTCGTGACTGGACTTC
ATTCATCCACTCATTCATTCATTCACTCAGCAGACACTTATCTAGCGCTCCCTGTGGCTGGTCCTGCCTC
ATACTGTCTTTGCTCTGGAGAATTGGAGGTTGGGGTTCCTGAGGGGCAGGGTCCTGGAGACAAGGACACT
CCTGGGTAGAATTAGGACCTACCCCCCAGGAAATCAACGGGGACCAGGTGCCGTGGCTCACACCTGTAAT
CCCAGCACTTTGGGAGGCCGAGACGGGCGGATCACAAGGTCAGCAGTTCAGGACCAGCCTGGCCAACATG
GTGAAACCCGCCTCAACTAAAAATACAAAAATTAGCCAGGTGTGGTGTCAGGCACCCGTAATCCCAGCTA
CTGAGGAGGCTGAGGCAGGAGAATTGCTTGAACCCGGGAGGCAGAGGTTGCAGTGAGCCGAGATTGCGCC
ACTGCACTCCAGCCTGGCGACAGGGCGAGACTCCATCTCAAAAAAAGAAAACCAATGGGACAGGGCAGAT
ATGGGGACAATGGTAAGGAGATGGGAGAGTGGGAGGGAGGTGTCAGGAAGACCTTCTTGACTTCATGTAG
GCTGGTGGGGGTGTTAGCCAGCAAGCCTCCAGTTCCCTGGGAACCGTTCTCAGGGTACCAATTTTACCAC
CTGTCTGCAAACACTTTAAGATTCTTAATCAGACTCAAATTGGCCACAAATCAGGTAAACAAACTCACTA
GTGGGGTGGGGCTACCACCCGTTCTGACCCTCCAGCCCAACCCAGCCCAGCCACCCTGCCCTCCGTAGAG
CCTGTGGTGTTTATCGGTGGCATTGGGAGAATTAGTGTGTATTTATGTTGGCGTGGGGTGTGGGGTGGAT
TTGTGTGTGTGCAGTTAGGCCTAGTGGAAGGAATGTGGGATCTGAAGGCAGGCCAGCCTGAGTTCCAGTC
CTGCCTGTTGCTCACAAGCTTTATGAGGCGAGAGCTAACCCCTGCCAGCCTCAGTTGTCTTCTTTGCAAG
ATGGAGGTTGCAGCCCCAGTCTCTGGAGCATGTTATGCAGATCCACCGAGAGTGCCTGCCAGGCACACAG
TAGGTGCTCAGCTCAGTTACTGTGGCGGCCCCCACTCCCCATTGTTGTTGTTTTCCTATTGCCTGGCGGC
CACAGCTGGTATCCCTTGAAAAGGGCTACAGGGGGTGGAGTCGGACCCTGCCCCAGCCCTGTGGAGACCC
TGGGCTTGGGCCAGGGCCTGGGGTCTGGGCCTGCAGACAGCTGTGTCTATAAAGCAGCTGAAGGGCTGAG
GCCGGGGGAGGTCCTGGCAGCAGGGCGTTATTTTGGGCCTGGCCTGCCACCCCCAGCTCCTGTTTCTCTT
GGGAGTCTGTTGGGGGAGGAAGTGTGGGGAAGAGGAGGGGGTGCAAGTGGGTGAGGCATGGAGTGGGGAG
GCCTCCCTCAGGGACATGGACCCTTGAGTTCTATTTCTGTTCCTCCCTCCTGTTCCTCCCTCTTTGTCCT
TATCTGCCTAGAGAGGTGGGAATAGAGGCCATTCTGAGTATCACTAGGAGACCACCAGTTTGTGGCCACT
GGCCACTGGCCCAGGCAGGGAACCTGGGGGCTTGCCCTACCAGCCTCTCCCAGCAATCTGAAGGCAGGGG
GTACCTCGTATTACCCCCTAGGATTTGACCTTAGGCTCCAACTTGCTGGGAGAGCAGTGCCTCTGGTGTC
AGACCCCAAGCCAGCCCTTGTGCTGTCCCTGAATCTGCATGTAGCCTGTGGGAGGCGGAGCAGTGACCGG
CAGGAATTCTGGGCAGCTCAGGCACCTGTGGGCCTGAGGGTGCCCTCTGCCCCCACCCTTCCGATCTCCT
GGGCAAGACACGCCAGGTGATTCATCTCACCAGAGCAGAAAAACAAGTTCAACTGGGCACTTTAATCTCC
CCTCACTGGCAGGCCTGGTGTGAGCTGCTACCCCGGCGCCCCTCACCAGGGGTGCTTTACCTCCTCTAGT
ATTCCTGACCTTAGTGGGCATTTCTGGTCTCAGGGATACCAGGCTGGGGTCCAAGTGGGCCAGGTGTGGC
AGTTCAGCCCTATGCCCCATGGCTGATGGCTCGCGCTGGGCAGGTATGCAGGGCTGACGTAGTGCCTTTG
TGGCAGCAGTTTCGTGGCACACATTCTGCCAGCTGGTTCTGGAGTCTTGCCCTGAGGAGGTGGCCAGGGT
GAGGGTGCCAGCGCAGGAACCTTTGGCGCATGCTTCACCCTGGCCTGGGATCTGCAGCCTGGGTCCAGAT
GCCCACAACTGGAATCTGACGCTCCTTTTCTCTTCATGGGGGACTCCCAGAGGTCTCTGCAATGACCAGA
GCCCCGGTTGTCCCATGCCTCAGCTGCAACTCCAGCTGACCCTCCTTCCCCACTCTCTGGGTGGCATTAC
GGGGGTGTGGATCCCTTGCCAAGAGGTTGGCATGTGGGTGTGCTGGAATGGCATAGGGAGAATGCACCGA
GTTTGTTTGCTTGGGAGAGGGGCAGGGGGTATCCAGAAGATTCATGATTCGTCATCGCCTCTCTTGGGGG
ATTTTTACCCCTTTGCCCTGAGTTGTGCCTTTGGGACAAAGGAAGCCTTTCTTTGCCAGCCAACACCCTG
TACTGGCGGGCGAGCTCCCCAGGGCTGGCACGCTGGGGCAGCCTCTGAATGCACAGGGTGGGCCTAGTCA
GAAGAAGCCTTTCCCCTGAAATCCCTCTACTTCCCAAGCACGCAAGCTTTCTCCTGCTGTTAAACCTGCA
GTGTGCAAGGGACATGGGCGGAGGGGTCCTTCAGTCAGGCTTCTCCCTGTCTGAGGTGGCATGACTTGGA
GTGAGTTTGGATGGGGTGGCCAGGTCTGAGAAGGTCCCCCGCCAGTGTCCTCTGACCCATCTGCTCTCTC
CTGCCAGTGTGCACCGGCACAGACATGAAGCTGCGGCTCCCTGCCAGTCCCGAGACCCACCTGGACATGC
TCCGCCACCTCTACCAGGGCTGCCAGGTGGTGCAGGGAAACCTGGAACTCACCTACCTGCCCACCAATGC
CAGCCTGTCCTTCCTGCAGGTGAGGCCCGTGGGCAACCCAGCCAGGCCCTGCCTCCAGCTGGGCTGAGCC
CTCTGTTTACAGGTGGGTGGCAGAAGAAGGTGCCCTGCCCTTCTGTTTCCTCTCTTGTTGTGGTTTCTCA
ACCAGGAAGTCCTTTCTAACATCTAACCCCCATTCATTTTACTGCAGAATCAGTTGACTCTCTCTATAAC
GTGGCTGGCCGAGGTCATGTCTGGATGGGATGCGTCTGTGTTTCCGCTAAATCTTGTGCTCTCTTGCCAG
CATGATCATGTCCCCTGTCCACCTGCTCCAGCCACTATCCCTCTCCCACTTACAGCAGAAGAAAGGGCTG
GTGAGAAAGGTGGATTACAGGCCCACTTCTGCCACTGACGAGCCCTATGAATGTGGCCTACACCCCCTTA
GCTTCACTGGGTCTCAGTTTCCCTATCTGTATATTGGGAGCAGTTGTGAAGCTCAGAAGAGAAATGTCTG
TGAAAAGGTTATGAACAGGAGGGAGAGTGGAAACCAACCTGCTGGATCGTGTCCACAGACCCTGGAATGG
GGCCACATGCTTGGTTTGTCAAATTGCAGACGCCGGCCGGGTGCGATGGCTCATGCCTGTAATCCCAGCA
CTTTGGGAGGCCGAGGCGGACAGATCACTTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGAGAA
ACCCCGTCTCTACTGAAAATACAAAATTAGCCAGGCATGGTGGCACATGCCTATAATCCCAGCTACTTGG
GAAGGCTGAGGCAGGAGAATCACTTGAACCTGGGAGACGGAGGTTGTGGTGAGCCTAGATCGTGCCATTG
TACTCCAGCCTGGGCAACAAGAGTGAAACTCCGTCTCAAAAAAAAAAAATTTGCAGACGCCATCCCATCC
AGGCCTTTGCTTTCACTGATGAAGAAACTGAGATACAGAGAGGGCAGGGCACCTGTTCGGAGTTTATGAA
ATGCCCCCCCACCATTATCTTTCTTGATCATATAAGAATCTGGTGAGGCAAGGTAGGGCGTGATCTTTAT
CTCTATTTTATCGTTTTATTTAAGCGGGAACAGGACTGCTCAGTGGCTGGGGGCCTTGCCCAAGATCTCC
AAGTACTGGGGAACCCCAGGGAGGCCCTGGGGGGTGGCAGTGTTCCTATTTCAGCCCCACTCTGCTTCCC
CCTCCCAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTCACAACCAAGTGAGGCAGGTCCCACT
GCAGAGGCTGCGGATTGTGCGAGGCACCCAGCTCTTTGAGGACAACTATGCCCTGGCCGTGCTAGACAAT
GGAGACCCGCTGAACAATACCACCCCTGTCACAGGGGCCTCCCCAGGAGGCCTGCGGGAGCTGCAGCTTC
GAAGCCTCACAGGTGGCCTTCACCGTCATTGAAACCTTCTCTTGGTTATTCAGAGCTGACCAGGGCCACT
GCTAACCAGGGGGAGGCTTTGTGTGCATTAGAAATGGTGTCCCTTCTGGGCAGACGCAGGCAGAGCCCGG
GAAGACGCCCTCAGAAGATTGGAAAAAGATTCCCCTTCTTCCTGGGAAGTTGTAGCTTGCGTCAGCACAT
ATAATTCAATCGTGAGAATGCAGGCTGGGTTTTTGCCCCCACTTGGCTGAGTGAAGTGTACAGTGAACAA
CCTATGTAACTATTTGCTGGCCCTGGAGCCGACTCTGCCCCAGAGTCTGGGTGCCAGGTGCTTTGCCCGC
ATGGCCCATTTCAGTCACGCTGCAGTCCTGTCAGGAAAAAATCAGTGTTATTCTCATTCTACATATGAGA
AAACTGAGGCTTGCAGATATAAGGGCCAAAAGTTACACAGCTAGTGAGTGATGGGGCTGAGTTTCAGACT
CCACAGTCTCTTAACCACCAAGCAGCATGCCCAGAGTAGAGGTGAGAAGGAAGGAGAGAGCTGCGGTCCA
CATGAGCATCTGGACCTAGCATGGACAACTCACTCCTCCCTGGCTCTCGCTTTGTTCTTGTTGCGGGTGT
GGTGGTGGTGGGACTCAAAGACGGTAAAGATAGCTTTCTCTCCTCCCTGGGGAATCTGGGGGTTGTTTAA
AAGGCCTGCTCCTCTTTTAGAAGGCAGGAGGGCCCCAAGGGAAGCAGAAGGTGACAGAAGGGGAAAGGGT
CCTCTGATCATTGCTCACCCCACAGAGATCTTGAAAGGAGGGGTCTTGATCCAGCGGAACCCCCAGCTCT
GCTACCAGGACACGATTTTGTGGAAGGACATCTTCCACAAGAACAACCAGCTGGCTCTCACACTGATAGA
CACCAACCGCTCTCGGGCCTGTAAGCCATGCCCCTCCCTGCTGCCTCTTCTCTCAGACAGCCTGACCCCA
GCCGCAAACTCCCAACTTACAACCCAGTGCCTGCCCGCCACTGCCCCAGCCGCCTACACCACCCATTTCC
TCCCTCTCTGTCCCTCCTGCCATCTCCCTGTGCCTCTTCATCTCTGGGGTTCTCTGTCTTGTCTCCCTCT
GCTTATAGGTTGTGCCTCTGGTTTGGGGGCCTCTCAGCCTGTCTGGGTCCCTCCCTTGCTGTGCAGTTGG
CCTCGTGGCCTCTGCTGCTGTTTGTGCCTCTCTCTGTTACTAACCCGTCCTCTCGCTGTTAGACATCTCT
CTCACTGCCTGTCTCTGGTTCTGTCCTCAGGCCACCCCTGTTCTCCGATGTGTAAGGGCTCCCGCTGCTG
GGGAGAGAGTTCTGAGGATTGTCAGAGCCGTGAGTCTCAGGGAGGCCTGGAGTCAGGGAAGGGGAGGGCT
GGGGCCGGGTGGAATGCAGGTGTCATACAGGTGACATGGGAGGGGTGGGATAACAGGCTTGGGATGTCTC
CCCTGGGCCAGGTAGTCTCCCTAGAAGGTGATGCTGATGAGGGTCTGGTGCCCAGGGCGCCACTCAGCCC
TCATCCTGCCCTTTGCCCAACAGTGACGCGCACTGTCTGTGCCGGTGGCTGTGCCCGCTGCAAGGGGCCA
CTGCCCACTGACTGCTGCCATGAGCAGTGTGCTGCCGGCTGCACGGGCCCCAAGCACTCTGACTGCCTGG
TATGTGCCTCTGCTTTGTGCCCAATGTGCTCTACCCCCCAGGATGCAAGGGGTGGGCACCCTGCCTGGTA
CTGCCCTATTGCCCCTGGCACACCAGGGCAAAACAGCACAGTGAAAGCCAGCCACCTGTCCCCCCAGGCC
TGCCTCCACTTCAACCACAGTGGCATCTGTGAGCTGCACTGCCCAGCCCTGGTCACCTACAACACAGACA
CGTTTGAGTCCATGCCCAATCCCGAGGGCCGGTATACATTCGGCGCCAGCTGTGTGACTGCCTGTCCCTG
TGAGTGCCAGGGAGAAACACAGTTTTCTCATTTTGGTGGGGAGGTTTGTTTCTGTAAATGGGAGCATATG
GGGAGCACTGTCTGCATCTTGCTTTGAGAGCTGGTCATGACAGTTCCTGCCGAGCTGCCTTGTTCTTTCA
ACAGCTGTGGAGCAGGTGGCAGTAAGGAGAGGCAGCTAAGAGCCCAGACTTGGGAGCCAGACTGCCTGGG
TTTGAAACCCAGCTCTATCAATTAGTAGGCACGTGACCCTCTTGCTGTGCCTCAGTTTCCTCATCAGTAA
AATGGGGGCAAGAATAGTCCCAACTGCATAAGATGGTTATAACATTTGAAAGAGTTAATATTTGTAAAGC
TCTTAGAACGGTGCCTGGTATGTACTAAGTGCTCCTAAATGTTAGCTTTTATTCTATAGCCTGGTGAGGT
CAGTTTTACCTTTCGTTTTGTTTTTGAGACCGAATTTAGTTAGCTCTATCGCAGTGGCGCGATCTCGGCT
CACTGCAACCTCCGCCTCCCAGGTTCGTGCTATTCTCGTGTCTCAGCCTCCTGAGTAGCTGGGATTACAG
GCGCCCACCACCATGCCTCGCTAAATTTTGTATTTTTAGTAGAGACAGGGTTTCACCACGTTGGCCAGAC
TGGTCTCGAACTCCTGACTTCAGGCGATCCACCTGCCTCGGCCTCTGAAAGTGCTGGGATTACAGGCGTG
AGCCACTGCACCCGGACTTTTTTTTTTTTGGCAGAGTCTCGCTCCATTGCCCAGGCTGGAGTGCAGTGGT
GCAATTTTGGCTCACTGCAACCTCTGCCTTCCGCATTCAAGCAATTCTTGTGCCTCAGACTCTTGAGTAG
GTGGAACTACAGGCATGCACCACCATGGCTGGGTAATTTTTGTATTTTTAGTAGAGACGGAGTTTCACTA
TGTTGGCCAAGCTGGTCTCGAACTCCTGACCTCAAGTGATCCACCCGCCTTGGTCTCCCAAAGTGCTGGG
ATTACAGGCATGAGCCATCGTGCCTGGCCTAGCTCAGTTTTATTTAACAGATCACCTATTTACTGATGGG
CGTTTATGGACTGGGCTCAGACCTGGGGAACCTCTTTCCTCCTCTCACAGGAACAGGAGTGGGCCTTCAG
ATCCTGGCTGACTGTGTTAGGGAGAGGACAAAATGTAGAGCCAGACCATTTGGGTTCAAATCCTCGCTCC
TCCACTCACTAGCACAATGACCTTGAATAATTTACAGAACTCTCTGCTTTGGTCTCCCTTTTTGCAAAAT
GGGAATCTCACAGTGCTGATCCCGTCTGGTTGTTGTGAGGGGTAAATGGATGTCAGGTGCTGATGCGTGG
TAGGGCATTTAAGTATTGGTTGATATTATTCTTCTTGTGCCTGGGCACGGTAATGCTGCTCATGGTGGTG
CACGAAGGGCCAGGGTATGTGGCTACATGTTCCTGATCTCCTTAGACAACTACCTTTCTACGGACGTGGG
ATCCTGCACCCTCGTCTGCCCCCTGCACAACCAAGAGGTGACAGCAGAGGATGGAACACAGCGGTGTGAG
AAGTGCAGCAAGCCCTGTGCCCGAGGTACCCACTCACTGCCCCCGAGGCCAGCTGCAGTTCCTGTCCCTC
TGCGCATGCAGCCTGGCCCAGCCCACCCTGTCCTATCCTTCCTCAGACCCTCTTGGGACCTAGTCTCTGC
CTTCTACTCTCTACCCCTGGCCCCCCTCAGCCCTACAAGTGTCCCTATATCCCCTGTCAGTGTGGGGAGG
GGCCCGGACCCTGATGCTCATGTGGCTGTTGACCTGTCCCGGTATGAAGGCTGAGACGGCCCCTTCCCCA
CCCACCCCCACCTCCTCAGTGTGCTATGGTCTGGGCATGGAGCACTTGCGAGAGGTGAGGGCAGTTACCA
GTGCCAATATCCAGGAGTTTGCTGGCTGCAAGAAGATCTTTGGGAGCCTGGCATTTCTGCCGGAGAGCTT
TGATGGGTAAGAGTGGGCACGATGACCTGAGACAGTGTCAGGGCAGACAGAGTCCTGAGGATCCAGATGT
GGCAGCATCTCTTGGGGATGGCAGGAGACAGAAGTGGGGGGATCAAGAATGCAAAGAAAGCAGATGGGAG
ACCAGAGGAGCAGGGCCTTTGGTGGGTGGGGGTGATTATTTTTGTAAATGACATGCTATCCGTGAACAAG
GACTTGTATGGAGGTCAGACCATCTAGATAAAGTAAAATTCCCTTTGAGTTCATAGCAGCTTTATTCAAA
ATATCCCCAAATTGGAAATAACTCAAATGTGCATCACTAGGTGAAGGAATAAACAAGTGGCAGTGTATCC
ATTTGGTGAAGTTCTACTTAGCAACCAAAGGAAATGAACTACCGATACAACATAAATGAATCTCAGAAAC
ATTACATTGAGCAAAAGAAGCCAGAGACAAGATTCCATACTGTCTGATCCCCTTTATGTGAGGCTCTGAA
CCGAAAAAACCACTCTGTGGTGGGAGAGATCAGAACGGTGGTTGCCCCAGGGTGGGGGGCTTCAAAAGGG
AGGCACACAAGGACATTTCTGGGGTAATAGAAATGCTCTGTATAGTGATTGGGGTAGTGGATACATGAGC
GAATCCATTTGTCAAAACTCATCAAACTGTGTGATAAGAGTCTGTGCATTTTATTTATTTCATTTTATTT
TTTGAGATAGAGTCTCACTCTGTCAGCAGGCTGGAGTGCAGTGGTACGATCTTGGCTCACTGCAACCTCT
GCCTCCTGGATTCAAGCAATTCTCCTGCCTCAGTCTCCTGAGTAGCTGGGACTACAGGTGTGTGCCACCA
TGCCCAGCTAATTTTTGTATTTTTAATAGAGATGGGGTTTCACCATGTTGGCAAGGATGGTCTCGATCTC
TTGACGTCGTGATCCGCCCACCTCAGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACCACACCCGG
TGCATTTTATTGTATATAAGTTATACTTCAATAAGAAATGAATTGGGGCCAGGCACGGTGGCTCACGCCT
GTAATCCCAGCACTTTGGGAGGCCGAGGCAGGCAGATCACTTGAGGTCAGGAGTTCAAGACCAGCCTGGC
CAACATGGTGAAACCCCATCTCTACTAAAAAATATAAAAAATTAGCCAGGCTTCCTGGCATGCGCCTATC
ATCCCAGCTACTTGGGAGGCTGAGGCAGGAGAATTGCATGAACTCGGGAGGTGGAGGTTGTAGTGAGCTG
AGATTTCGCTATTGCACTCCAGCCTGGGCGACAGAGTGAGACCCTGTCTCAAAAAGAAAAAAAAAAAAAA
GGGTCAGGCGCCGTGGTGCACACCTGTAATCCCAGCACTTTGGGAGGCTGAAGCAGGAAGATTGCTTGAG
CCCAGGAATTCAAGAACAGCGTGGGCAACATAGTGAGATCCCATCTCTACAAAAAAACACAAAAAATTAG
CCGGGCATGGTGGTACGCACCTGTAGTCTCAGCTACTAGGGAGACTGAGGTGGGAGAATCACCTGAGCCT
GGGAGGTGGAGGTTGCAGTGGGTTGAAATCATGTCACTGTACTCCAGCCTGGGTGACAGAATGAGACCCT
GTCTCAAAAAAAAAAAAAAAAAAAAAATTCCCTTTCACACTTCCTTTACCTCCACTCCCCTTTCCAGAGG
GGGCCATGGTTAACAGTGTGTGTGTTCACCTAGACCGTTTATGCATCTGTAGACACACACACAGTGAAGT
GTGGTTTTCGTCGTTTTGGTGGGGAGGTTGGTTTCTGTAAATGGGAACATATAGGGAGCACTGTCTGCAC
CTTGCTTTGAGAGCCGGTCATGACAGTTCCCATTGAACTGCCTTGTTCTTTCAATAGCTGCAGAGCAGGT
GGCGGCAAGGAGAGGCAGCTAAGAGCCCAGACTTGGGAGCCAGACTGCCTGGGTTTGAAACCCGGCTCTA
CCACTTACTAGGCATGTGACCCTTGTGCTGTGCCTCAGTTTCTTCATCTGTAAAGTGGGGGCAAGAACAG
TCCCAACTTCATAAGATGGTTATACCACCATGCCTGGCCAGATGATTATAAAGTTTGAATGAGTTAATAT
TTGTAAAGCTCTTAGAACAGTGCCTGGCAGATACTAGGTGCTCCTAAATGTTGGTTTTTATTATGTGGCT
GGGTGGCTCGGGGTTTTATTTAACAGCTCCCCTATTTACTAATAGACATTTAGATCATGTTCCATTTTCA
CTCTTACAAACAGTTCCACTTTGTGTGTGGCTCTGGGAACATGGGCCAGTGTCTCCCTAGGCCACATTCC
TAGAAATAAGATTTCTTTTCTTTTTTTTTTTTTTTTGAGACAGAGTCTCGCTTTATCGCCAGGCTGGTGT
GCAGTAGTGTGATCTCGGCTCACTGCAACCTCTGCCTCCCGGGTTCAAGTGATTCTCCTGCCTCAGCCTC
TCGAGTAACTGGGACTATAGGCGCGCGGCACCACACCCAGCTAATTTTTGTATTTGTAGTAGAGATGGGG
TTTCACCATGTTGGCCAGGATGGTCTCCATCTCTTGACTTCGTGATCCGCCCGCCTCGGCCTCCCAAAGT
GCTGGGATTACAGGCGTGAGCCACTGAGCCCAGGCAGAAATAAGATTTCTAGATCAAAGGATATAAATAC
TGTTTTGATAGATGTTGCCGAACTAAGGCCTGGGCTTTGAAGCCCAGGATGGGAACAGCTGGGCTCGATG
GGCAAAGGGTTTGAGTGAAGGCATTCATGGTGGGGAGTGGCTGGCATGGCCAGTGCTGGGAGTGATGTCC
ACCCTGTTCCTGGCCCTGCTGACTCCTCTCCTGACCCCTCCAGGGACCCAGCCTCCAACACTGCCCCGCT
CCAGCCAGAGCAGCTCCAAGTGTTTGAGACTCTGGAAGAGATCACAGGTGGGCTCTGTCTCTGCATCCTG
TTCTGCAGGGGCTGGGAGTCCTTGTCCTGTCCCCACTCCTTTAATCTCACCCTCTGCCTGCAGGTTACCT
ATACATCTCAGCATGGCCGGACAGCCTGCCTGACCTCAGCGTCTTCCAGAACCTGCAAGTAATCCGGGGA
CGAATTCTGCACAAGTGAGCACTGAGAAAGAGGGGGCCTGATGGGGAGGAGTCCCAGGGAGGAGTCCCTG
TGGGAAGCTTTGGGCCTGAGGGAGTACTCCTGTAGCAGTAACCTTTCCATGAAAGTCTGCAGAGTGTGCT
GGGGATGGAGGAAGATGAGAATAGCCTTTGCTGACCGGGAAGGGGTCCGTGGTAAGGTGCCCACCTTTCT
CCCATAGTGGCGCCTACTCGCTGACCCTGCAAGGGCTGGGCATCAGCTGGCTGGGGCTGCGCTCACTGAG
GGAACTGGGCAGTGGACTGGCCCTCATCCACCATAACACCCACCTCTGCTTCGTGCACACGGTGCCCTGG
GACCAGCTCTTTCGGAACCCGCACCAAGCTCTGCTCCACACTGCCAACCGGCCAGAGGACGAGTGTGGTA
AGACAGGGAGCCCAGTGTGCGCACTCCCCATCTGCCAGCACACAGCAGTGCCCAGGGGGCCCTGGCAGCA
GCGTTCTTGGACTTGTGCAGACTGCCCGTCTCTGTGCACCCTTCTTGACTCAGCACAGCTCTGGCTGGCT
TGGCCTCTTGGCATGGCTTCTCTAGCTGGGTCCTACCTGCCTTGGCATCCTTCCCTCCCCCTCTGTTTCT
GAAATCTCAGAACTCTTCCTCTCCCTACATCGGCCCCACCTGTCCCCACCCCTCCAGCCCACAGCCATGC
CCACAGCCAGTTCCCTGGTTCACTTGGACCTGGGGCCTCCCCTAAAAGTCCCCTGCGGTCCCTTCCTCCT
CACTGCAGTGGGCGAGGGCCTGGCCTGCCACCAGCTGTGCGCCCGAGGGCACTGCTGGGGTCCAGGGCCC
ACCCAGTGTGTCAACTGCAGCCAGTTCCTTCGGGGCCAGGAGTGCGTGGAGGAATGCCGAGTACTGCAGG
GGTATGAGGGGCGGAGGAGAGGGTGGCTGGAGGGGTGCATGGGGCTCCTCTCAGACCCCCTCACCACTGT
CCCTTCTCTCAGGCTCCCCAGGGAGTATGTGAATGCCAGGCACTGTTTGCCGTGCCACCCTGAGTGTCAG
CCCCAGAATGGCTCAGTGACCTGTTTTGGACCGGTGAGCTGCTGGCGGGCTCAGAGCTGGGTGGAGGGGG
GCAGCGAGGGGGATTGCCAGGGACTTGGCAGGATGGCGAGATGCAGTAGGGTGTGCTATCTGGTAAAATA
TCCCTGGAGAGGGCTCAGCGCTCAGACCTGAACAGCAACAGAGTGGCAGAAAAGGGGCCTGGGGGACACT
GGGGCCCTTCAGACTATGAAAAGGTTCTAAGGAGGTCTGTGTTGGTGGCTGTGACTGTGGCTGTGCTAGG
GTGGTGAGCCCTGTGGGCTCAGGCGTCAGACTACCTGGATTCAGACCCAGCTCCTGCTTCCAACCTTGGT
TTTTTATTCCTAAAATGGGTATTGTAATAATACCTACCTTGCTGGGGTGTGGCAAGAATGAAATTAAACA
GGGCTTGGCACAGTGAAGCACGGGAAAGGCTTTCTACAGAGCAGTGACTGTTGTTACTCGCTGTTACACC
TTAGGTAATGCGTTTTCCTCTCTGGGTGCCTCCCATTTTCTGGCTCAAGTCCCTGCCCAGGATCAAGCTT
GGAGGAGGGCCCCGAGGGAGGGGCCACAGAGACTGGGTGAAGAGCAAGGGTGTTTGTCCCAGGAGCATGG
CGAAAATTGCTGCTGGGTGGCCTTGGGAAGCACAAAGGGGACCCAACTAAGGGCCTGATCCTACTGCCCT
GGGGGTGTCAGTGCCAGCCCCCCACAAATCTTTTCTGCCCCCCCCAGGAGGCTGACCAGTGTGTGGCCTG
TGCCCACTATAAGGACCCTCCCTTCTGCGTGGCCCGCTGCCCCAGCGGTGTGAAACCTGACCTCTCCTAC
ATGCCCATCTGGAAGTTTCCAGATGAGGAGGGCGCATGCCAGCCTTGCCCCATCAACTGCACCCACTCGT
GAGTCCAACGGTCTTTTCTGCAGAAAGGAGGACTTTCCTTTCAGGGGTCTTTCTGGGGCTCTTACTATAA
AAGGGGACCAACTCTCCCTTTGTCATATCTTGTTTCTGATGACAAAAATAACACATTGTTAAAATTGTAA
AATTAAAACATGAAATATAAATTAATGCCCTAGCAGTTCTATCCCCACTGTTAATAATTTGAAATATTTT
TCCTCTAGTTATTTTTGTCTGTGCACATTCTAATATGTATATATAAGTTAACATATATTAATATTATTCT
CCAGTTATTTTTATCTGTGCACATTTTAACACACACACACACACACACACACACACACATATGTATTTTT
AGACGGAGTTTCACTCTGTCGCCCAGGCTGGAGTGCAGTAGTACAATCTTGGCTCACTGCAGCCTCCACC
TCCTGGGTTTAAGCAATTCTCCTGCTTCCGCCTCCTGAGTAGCTGGGATTACGGGAACGTGCTACCTTGC
CTGGCTAATTTTTGTATTTTTAGTACATAGGATTTCACCATGTTGGCCAGGCTGGTCTCGAACCCCTGAC
CTCAGGTGATCTGCCAGCCTCGGTCCCCCAAAGTGTTGGGATTACAGCGGTGAGCCACCATGCCCAGTCA
TATATTTCTTTTTAACAAATAGAATCATAGATCATACATATTGTTTGCAAATTGCTTTTTCTCACTTTCC
AGAACCTTGAAATGTTTTTCCATGTTCTAACATGGTGATCTACCTTATTCTTTTAATTTTTCTTATTTAG
TTGTCTTTACACATGAAACACATGAATACATCCTTGTGATAAACATTTTCAGTAACATAAAAGTATAAAT
GTTACAAAGCCAACGTGCCCTTTCACTCAACTCCCTGTCCACCCAGTCTCTCCTGTCTGCTGGGAGAACC
ACCGCATTGACTTGTGTGTTCACCCTTCCAGGCTCTTTTCTGCACACTTATATAGACATACTACATTTAT
ATTAGGTCGAGTCAAATAAGATTGCTGTTTGTGTAAACCAAAAAGTGTCAAGAGCCTGGGCGCAGTGACT
CACACCTGTAATCCCAGCACTTTGGGAGGCTGAGGCAGGCAGATCACTTGAGATCAGGAGTTCGAGACCA
ATCTGGCCAACATAGCGAGACCCCGTCTCTACTAAAAATACAAAAACTAGCCAGGTGTGGTGATGCTGTT
CTGCACTTTGCTTTCCCCCCGACTTGAGGTATCCTTTCTTGTGAGTACAGACGGATCTACCACCTTTATT
TTTTTTTTAATTACTCAACCTGTAACATGGATGTAATTTCACTTTGTTTTTGAGGGATATTGAGCTTGTT
TCCCTGTTTTTGCAGTTTATTGCAATTGAGCTCCACACACAAGTGAGCCCTCTTTTGTATGCCCCCTAGT
GGGAATACAGTGCTGGCAATGTTTATCACAAGGATATATTCATGCATTTCAATTTAAAGACAACTAAATG
AGAAAAATTAAAAGAATATGGATCCAGGCTGGGCATGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGA
GGCCGAGGCAGGCAGATCACCTGAGGTCAGGAGTTCAAGACCAGCCTGGCCAACATGGCAAAACCCCGTC
TCTACTAAAAATACAAAAATTAGCCAGGCGTGGTGGTGGGCGCCTGTAATCCCAGCTATTTGAGAGGTTG
AGACAGGAGAATTGCTTGAACCTGGGCAGCGGAGGTTGCAGTGAGACGAGATTGCACCAGTGCACTCCAA
CCTGGGCAACACAGTGCAACTCCTTCTCAAGAAAAAAAAGAAAAAAAAAAAGAATATGGGTCCAGATCCA
TATGGATCCTAGATCCAGATCACGGTGTTAGAACATGGAAAAACATTGCAAGATTCTGCTAAGTGAAAAA
AGCATTTGCAAACAGTATGTACAGTCTATATTCAGAGGAGGAACTGCTGGGTCATAGATGATATTTCATA
GGTATTGCCAAACCGTTCTCTGGAGAAGTGGTATGGGTTTACCCTGGGATTCTTCTATGGAGGGAATAGT
TGAGCTCCCGGGCTTGCTCTTCTGGGTGCCCCTCCCCGCTTCCTATCCACCACAAGGAGCTGCAGGGGAG
CGGGGCATGCCGGTTCCTTGGCTGGAGAAGGAGTCTCCTTGTGAGGTGGTAGAAGGAGCACTGACGGCCT
TGAGCCCAGTTTCTGCCTTTGTCAAATGGGGATAATGACCCAGCCACACCCCTCCCAGGGTTGTTGTGAG
GCTGGAAAGGTGGTTCCCAAGAGGGTGGTTCCCAGAATTGTTGATGAGACTGTTTCTCCTGCAGCTGTGT
GGACCTGGATGACAAGGGCTGCCCCGCCGAGCAGAGAGCCAGGTTGGCCTGGACCCCAGGATGTACCCTT
CATTGCCCTTCACTCCCCCACTGGATGCTGGGTGGTCACTGCTGTAGGGAGGGGACCCCCTGACATATGT
CCCTTCCCACCCACTCTTCCACTGTGGAACCTCCTGTCATTTTCCACTTCACCAAGTGACAGAGGACCTG
CTCAGATGCTGAGGGGAGGGGACTGCAAGGAAAGATGGCTAGGAAACCCAGTCCCTCCACACCCTAGAGT
AACTTGATGCCTTGTGAGGGACACAGGCAAAGTTCAATTCCTTGGAAGTCAAGGGAGACTGAGAAGAGTA
CAGCTGCAGCACTGAGGGAGTGATGAATTCTTAACTGGGGATGGTGGGAGGCTTCGAGTGGGAGGTGGCA
TTTGAGCTAGGCTTTGAGAGAGGAGCAGGTATTGCACTTGCATTTAGGTAGAAAGCATTGGGGTGCAAGG
TGACACTGGAGGGGGAGGCATCAGGAAATCCAGGATGTCTTCAAAGTTCTGGTGTCGGGGGCTGTTGAGT
AAGCACAGGAATAAGGGGGTCAAGTTAGAGTCAGGGTGGGGTCTGACCTGGATGCCATAGGACCTGATCC
CCAAGCCACAGGGTGGGACTTGACTGGGCAGTGGGGACCTTTGGAAAGGACTTTGGGGAGAAAAACAGAC
TGGAGTCTGTCTTAGGCGATCATCGGTCCGTGAAATGAGCATGTGTTACAGGCTTGGTATGTACCAGACC
CTGTGCTAAGCAAGGGGGTATGGAGAGGAGAGGGTGACAAGAATATTGGATCAACACCCGGGAGCTCCAT
CTATCCCAGGATGCACTATCTTTTTTTTATTTTTTTGAGACGGAGTCTCACTCTGCCTGCAGGCTGGAGT
GCAGTGGCTCCATCTCGGTTCACTGCAACCTCTGCCTCCTGGGTTCAAGCGCTTCTTGTGCCTCAGCCTC
CCAAGTAGCTGGGATTACAGGCACATGCCACCACACCCAGCTAATTTTTGTATTTTTAGTAGAGACGGGG
TTTCACCATGTTGGCCAGGATGGTCTCGATCTCTTGACCTCAAGATCCGCCCACCTTGGCCTCCCAAAGT
GCTGGGATTACAGACATGAGCCACCGTGCCCAGCCAGATACGCTATCTTTTTATTGAGTGATTGAGACAG
GGTCTTGCTCTCTTGTCCAGTCTTGAATGTGGTGGTGTAATCACAGGCTCACTGCAGCCTTGACCTCCTG
GGCTCAAGTTACCCTTCTGCAGTAGCTGGGACTATAGGAGCGTGCCACCACGCCTGGGTAATTTAAAAAA
TTTTTTTTGTATAGACAGGGTCTCACTATGTTGCCCGAGCTGGTCTCAAACTCGTGGGCTCAAGTGATCC
TCCAGTTTTGGCCTCCCAAAATGTTGGGATCACAGGAGTGAGCCACCACTCCTGGCGATGAGCCAAGTCT
TTTTTTTTTTTTTTTTTTTTTGATATGGAGTCTTGCTCTGTTGCCCAGGCTGGAGTGCAATGACACGATC
TTGGCTCACTGCAACCTCTGCCTCCCAGGTTCAAGCAGTTCAAGCAATCCTCCTGTCTCAGCCCCCCAGT
AGCTGGGATTACAGGCATGCGCTACCACGTCCGGCTAATTTTTGTATTTTTAGTAGAGATGAGGTTTTGC
CATGTTGGCCAGGCTGGTCTTGAACTGCTGACCTCAGGTGATCCACCTGCCTCGGCCTCCCAAAGTGCTG
GGATTACAGGTGTGAGCCATCGTGCCTGGCGGAGCCGAGTCTTAAAAGATGACCCTGTGGAGAAATGGTG
GTCCAGGCTGAAGGGACAGCCTATGCAAACACTGGGAGGTGTGGAAAATCATGACCTGTGGGTGGAAATT
TTGGCTAGAACATCAAAATCATCAGGTGTACATTCCTGTACCCATGCAGCAGTCAGAATCTCTGGGGGTG
GGGCCCCAAAATTGTATGCATACAGACTGTGTGCTGATTTGTGATATTACTTAGGATTTTTTGACTTTAC
AATGGTGGAAAAGCAATAATATACATTCAGTATAAACCGTACTTTGAATACCCATACAGCCATTCTGTTT
TTCACTTTTATTTTTATTTATTTATTTATTTATTATTTATTTTGAGATGTCATTTTGCTGTTGTTACCCA
GGCTGGAGTGCAATGGCGCAGTCTTGGCTCACCGCAACCTCCACCTCTCAGGTTCAAACGATTCTCCTGC
TTCAGCCTCCAGAGTGGCTGGGATTACAGGCAGGCACCACCACACCCGGCTAATTTTGTATTTTTAGTAG
AGACGGGGTTTCTCCATGTTAGTCAGGCTGGTCTCGAACTCGAGAGCTCAGGTGATCTGCCCATCTCAGC
CTCAAGCCACCATGCCCAGCCCTACTTTCAGTATTCAATAAATTACATAGCCAGGCACCGTGGCTCACAC
CTGTAATCCCAGCACTTTAGGAGGCCAAGGTGGGAGGATCCTTTGAGGCCAGAAGCTCGAGACCAGCCTG
GGCAACATAGTGAGACCCCATTTCTACAAAAAATAAAAAAACTAGCTGAGTGTGGTGGCGTGTGTCTGTA
GTCCCAGCTACTTGGGCAGCTGAGGTGGAAAGACTGCTTGAGCCCAGAGGTCAGGGCTGCAGTGGGCCAT
GATCTCACCACTGCACTCAGCCTGGGCAACACAGCAAGGCCCTGTCTCAAAAATAAATAAATAAATAACA
CAAACTTATTTAACAGTTTACTATAAAATAGGCTTTGTGTCAGATGATTCTGCCCAACTGTAAGCTGCTG
GCAGTGTAAATGTTCTGAGCACGTGTAAGCCAGGCTAGGTGTCTTAAATGCATTTTCAGTTTCAACTTAG
AATTGGTTTATCAGGACGTAGCCCCTTGGTGTTGAGGGGCATGTGTATTAACAGTCTCCTTAGTGACTTT
TTTTTTTTTGAGATGGAGTCTTGCACTGGCCGTAGTGCAGTGGCACAATCTCAGCTCACTGCAACCTCTT
GTCTCCCGGGTTCAAGCGATTCTCCTGCCTCAGTCTCCCAAGTAGCTGGGATTACAGGCACCCACACCAC
GCCCAGCTAATTTTTGTGTGTGTGTATTTTTAGTAGAGACGGGGGTTTCACTATGTTGGCCAGGCTGGTC
TCGAACTCCTGACCTTGTGATCTGCCCACCTCAGACTCTCAAAGTGCTAGGATTCCAGGCATGAGCCACC
GCGCCCAGAGTCCTTAGTGATTTTTACACCATGAATTGTTGAAGCCCTAAGCCAGAGCCAAGGGCAAGAG
TATAGAGAATCTGGAGATGCGGAGAGGGTTCTGATTGCCTACAAGGAGTTTGGACTTTATTGTGGAGGCA
GCGGGGAGCCAAGGCAGGTTTTAGAGTAGGAGAGGGTCCAAGCCTGTGGGTCACCCTTCCGACTTCCCTT
TCCGAATGCCAAACACCTTCATGTCCCCCGTGGGCCCCCTTTGTCCCTCCCACCCCAAACTAGCCCTCAA
TCCCTGACCCTGGCTTCCGCCCCCAGCCCTCTGACGTCCATCATCTCTGCGGTGGTTGGCATTCTGCTGG
TCGTGGTCTTGGGGGTGGTCTTTGGGATCCTCATCAAGCGACGGCAGCAGAAGATCCGGAAGTACACGAT
GCGGAGACTGCTGCAGGAAACGGAGGTGAGGCGGGGTGAAGTCCTCCCAGCCCGCGTGGGGTCTGCACCG
GCCCCCGGCACTGACCCACCACCCCCTCACCCCAGCTGGTGGAGCCGCTGACACCTAGCGGAGCGATGCC
CAACCAGGCGCAGATGCGGATCCTGAAAGAGACGGAGCTGAGGAAGGTGAAGGTGCTTGGATCTGGCGCT
TTTGGCACAGTCTACAAGGTCAGGGCCAGGTCCTGGGGTGGGCGGCCCCAGAGGATGGGGGCGGTGCCTG
GAGGGGTGTGGTCGGCAGTTCTGATGGGAGGGGCAAGAGCTGGAGGCAGTGTTTGGGGGAGGGCAGTTAC
AGCGGAGAAGGGAGCGGGGCCAAGCCCTAGGGTGGTGAAGGATGTTTGGAGGACAAGTAATGATCTCCTG
GAAGGCAGGTAGGATCCAGCCCACGCTCTTCTCACTCATATCCTCCTCTTTCTGCCCAGGGCATCTGGAT
CCCTGATGGGGAGAATGTGAAAATTCCAGTGGCCATCAAAGTGTTGAGGGAAAACACATCCCCCAAAGCC
AACAAAGAAATCTTAGACGTAAGCCCCTCCACCCTCTCCTGCTAGGAGGACAGGAAGGACCCCATGGCTG
CAGGTCTGGGCTCTGGTCTCTCTTCATTGGGGTTTGGGGAGATATGACTCCCGCAAACCTAGACTATTTT
TTTGGAGACGGAGTCTTGCTCTGTCACCCAGGCTGGAGTGCAGTGGCGTTATCTCGGCTCACTGCAACCT
CCACCTCCTGGACTCAAGCGATTTTCATGCCTCAGGCTCCTGAGTAGCTGGGATTACAAGCGCCCGCTAA
TTTTTTTTTTTTTTTTGAGACAGAGTCTCGCTCTGTCACCCAGGCTAGAGTGAAATGGTGCGGTCTCAGC
TCAGCCTCCCAGGTTAAAGCGATTCTTCTCCCTCAGTCTCCTGAGTAGCTGGGATTACAGGCGCGAGCCA
CCACGCCCGGCTAATTTTTGTATTTTTAGTAGAGATGGGATTTCACCATGTTGGCCAGGTTGGTGTCAAA
CTCCTGACCTCATGATCCGCCCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCACCGTGCC
CGGCCTAATCTTTGTATTTTTAGTAGAGACAGGGTTTCACCATGTTGTCCAGGCTGGTACTTTGAGCCTT
CACAGGCTGTGGGCCATGGCTGTGGTTTGTGATGGTTGGGAGGCTGTGTGGTGTTTGGGGGTGTGTGGTC
TCCCATACCCTCTCAGCGTACCCTTGTCCCCAGGAAGCATACGTGATGGCTGGTGTGGGCTCCCCATATG
TCTCCCGCCTTCTGGGCATCTGCCTGACATCCACGGTGCAGCTGGTGACACAGCTTATGCCCTATGGCTG
CCTCTTAGACCATGTCCGGGAAAACCGCGGACGCCTGGGCTCCCAGGACCTGCTGAACTGGTGTATGCAG
ATTGCCAAGGTATGCACCTGGGCTCTTTGCAGGTCTCTCCGGAGCAAACCCCTATGTCCACAAGGGGCTA
GGATGGGGACTCTTGCTGGGCATGTGGCCAGGCCCAGGCCCTCCCAGAAGGTCTACATGGGTGCTTCCCA
TTCCAGGGGATGAGCTACCTGGAGGATGTGCGGCTCGTACACAGGGACTTGGCCGCTCGGAACGTGCTGG
TCAAGAGTCCCAACCATGTCAAAATTACAGACTTCGGGCTGGCTCGGCTGCTGGACATTGACGAGACAGA
GTACCATGCAGATGGGGGCAAGGTTAGGTGAAGGACCAAGGAGCAGAGGAGGCTGGGTGGAGTGGTGTCT
AGCCCATGGGAGAACTCTGAGTGGCCACCTCCCCACAACACACAGTTGGAGGACTTCCTCTTCTGCCCTC
CCAGGTGCCCATCAAGTGGATGGCGCTGGAGTCCATTCTCCGCCGGCGGTTCACCCACCAGAGTGATGTG
TGGAGTTATGGTGTGTGATGGGGGGTGTTGGGAGGGGTGGGTGAGGAGCCATGGCTGGAGGGAGGATGAG
AGCTGGGATGGGGAGAATTACGGGGCCACCTCAGCATGTGAAGGGAGGGAAGGGGCTGCCTGTGCCCCAC
CTTGCAGGGTCTGTGCACTTCCCAGGATTAGGGAAAGACCGGGTAGGGTCTGTCTCCTGGCATCACATCT
CCCCCTGCTACCTGCCATGATGCTAGACTCCTGAGCAGAACCTCTGGCTCAGTACACTAAAGCTCCCTCT
GGCCCTCCCACTCCTGACCCTGTCTCTGCCTTAGGTGTGACTGTGTGGGAGCTGATGACTTTTGGGGCCA
AACCTTACGATGGGATCCCAGCCCGGGAGATCCCTGACCTGCTGGAAAAGGGGGAGCGGCTGCCCCAGCC
CCCCATCTGCACCATTGATGTCTACATGATCATGGTCAAATGTGCGTGGCTGAGCTGTGCTGGCTGCCTG
GAGGAGGGTGGGAGGTCCTGGGTGGAGGAGCCCACAAGGGGCATGAAAGGGGACCAGGATGTATGTAGAC
CCAGGAGCCCTAGTATGTTAGGAGCCTCAAAACCTTCTTGTATCCCTTTTACAGTCAAAGTCCAAAGCCA
CTCTTGAGGAACACTCTTGTACAAAATTAAGCTGGGCACAGTGGCTCATGCCTGTAATCCCAGTACTTTT
GGAGGCTGAGGTGGGAGGATCCCTTGAAGCCAGGAGTTCAAGACCAGCCTGGGCAACATAGTGAGATCCT
ATCTCTACAAAAAATAAAAAAATTATCTGGGTGTGGTGGTGTGTGCCAGTAGTCCCAGCTACTCAGGAGA
GGCTGAGGCAGGAAGATCACTTGAGCCTAGTTTAAGGTTGCAGTAAGCTATGATTGCACCACTGAAATCC
AGCCTGGGTGACAGAGCGAAACCTCATCTCAAAAAAATAAAAAAGCAAACAAAAAGAAAAAAAAAATTAA
AAGGGAAACTAGAAGAGATGCCAAAGGTTCTGGCTGAAGACCCCAGAGTCTGGTGCTACTTCTCTACCAC
CTGAGGGCTTTGGGCTGTCCCTTGGGACTGTCTAGACCAGACTGGAGGGGGAGTGGGAGGGGAGAGGCAG
CAAGCACACAGGGCCTGGGACTAGCATGCTGACCTCCCTCCTGCCCCAGGTTGGATGATTGACTCTGAAT
GTCGGCCAAGATTCCGGGAGTTGGTGTCTGAATTCTCCCGCATGGCCAGGGACCCCCAGCGCTTTGTGGT
CATCCAGGTACTGGGCCTCTGTGCCCCATCCCTGCCTGTGGCTAAGAGCACCCTCCTGCAGAGGGTGGGA
AGGAGAGATGAGTCCAGTATGCCAGGCCCCTCACGGAAGGCTGCATGCTGGGCTGGGGAGGGGCCACCAT
CCTGCCTCTCCTTCCTCCACAGAATGAGGACTTGGGCCCAGCCAGTCCCTTGGACAGCACCTTCTACCGC
TCACTGCTGGAGGACGATGACATGGGGGACCTGGTGGATGCTGAGGAGTATCTGGTACCCCAGCAGGGCT
TCTTCTGTCCAGACCCTGCCCCGGGCGCTGGGGGCATGGTCCACCACAGGCACCGCAGCTCATCTACCAG
GGTCAGTGCCCTCGGTCACACTGTGTGGCTGTCTGCTTACCTCCCCCAACCCCGGTGGACTAGGGTCCCT
TTCTCTGATGTTCCCTCAACTGTCACCTCTCAAGGAAACCCCATTATCCCTACAAAAAATTCTTACTGCC
TTCCAACCCCTGTGACCCCATTCTCTCCACGGTGACTGTGTCATACCCCAAAGGTGACCTCTGTTTTTCT
CCTGTGACCCTGTCACCTTCCATGGAGTCCCCATCCCAGATCCGTGAGTGACCCCCATCATGACTTTCTT
TCTTGTCCCCAGAGTGGCGGTGGGGACCTGACACTAGGGCTGGAGCCCTCTGAAGAGGAGGCCCCCAGGT
CTCCACTGGCACCCTCCGAAGGGGCTGGCTCCGATGTATTTGATGGTGACCTGGGAATGGGGGCAGCCAA
GGGGCTGCAAAGCCTCCCCACACATGACCCCAGCCCTCTACAGCGGTACAGTGAGGACCCCACAGTACCC
CTGCCCTCTGAGACTGATGGCTACGTTGCCCCCCTGACCTGCAGCCCCCAGCCTGGTATGGAGTCCAGTC
TAAGCAGAGAGACTGATGGGCAGGGGAGGTGGGACCTTCAGCCCAGGGTCCACTGTGGGGGCAGAGGGAG
TGGCAGAGACACCGGGGTTCCTTCCCCTAATGGGTCACCTTCTCTTGACCTTTCAGAATATGTGAACCAG
CCAGATGTTCGGCCCCAGCCCCCTTCGCCCCGAGAGGGCCCTCTGCCTGCTGCCCGACCTGCTGGTGCCA
CTCTGGAAAGGCCCAAGACTCTCTCCCCAGGGAAGAATGGGGTCGTCAAAGACGTTTTTGCCTTTGGGGG
TGCCGTGGAGAACCCCGAGTACTTGACACCCCAGGGAGGAGCTGCCCCTCAGCCCCACCCTCCTCCTGCC
TTCAGCCCAGCCTTCGACAACCTCTATTACTGGGACCAGGACCCACCAGAGCGGGGGGCTCCACCCAGCA
CCTTCAAAGGGACACCTACGGCAGAGAACCCAGAGTACCTGGGTCTGGACGTGCCAGTGTGAACCAGAAG
GCCAAGTCCGCAGAAGCCCTGATGTGTCCTCAGGGAGCAGGGAAGGCCTGACTTCTGCTGGCATCAAGAG
GTGGGAGGGCCCTCCGACCACTTCCAGGGGAACCTGCCATGCCAGGAACCTGTCCTAAGGAACCTTCCTT
CCTGCTTGAGTTCCCAGATGGCTGGAAGGGGTCCAGCCTCGTTGGAAGAGGAACAGCACTGGGGAGTCTT
TGTGGATTCTGAGGCCCTGCCCAATGAGACTCTAGGGTCCAGTGGATGCCACAGCCCAGCTTGGCCCTTT
CCTTCCAGATCCTGGGTACTGAAAGCCTTAGGGAAGCTGGCCTGAGAGGGGAAGCGGCCCTAAGGGAGTG
TCTAAGAACAAAAGCGACCCATTCAGAGACTGTCCCTGAAACCTAGTACTGCCCCCCATGAGGAAGGAAC
AGCAATGGTGTCAGTATCCAGGCTTTGTACAGAGTGCTTTTCTGTTTAGTTTTTACTTTTTTTGTTTTGT
TTTTTTAAAGATGAAATAAAGACCCAGGGGGAGAATGGGTGTTGTATGGGGAGGCAAGTGTGGGGGGTCC
TTCTCCACACCCACTTTGTCCATTTGCAAATATATTTTGGAAAACAGCT

</dna_sequence>
        <protein_sequence>>NP_001005862.1 receptor tyrosine-protein kinase erbB-2 isoform b [Homo sapiens]
MKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLR
IVRGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWK
DIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQC
AAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACPYNYLSTDVGS
CTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPES
FDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLPDLSVFQNLQVIRGRILHNGAYSLTLQGLGI
SWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHC
WGPGPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHY
KDPPFCVARCPSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVG
ILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGA
FGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQL
MPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLL
DIDETEYHADGGKVPIKWMALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGER
LPQPPICTIDVYMIMVKCWMIDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLE
DDDMGDLVDAEEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEG
AGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYVNQPDVRPQPP
SPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQGGAAPQPHPPPAFSPAFDNL
YYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Three peptides representing B-cell epitopes of the extracellular domain of Her-2/neu each of them inducing Her-2/neu specific immune responses with anti-tumor activity in vitro were identified. A study was performed to evaluate the in vivo protective capacity of a combined vaccination with these three peptides in FVB/N transgenic mice spontaneously developing c-neu overexpressing breast cancers. The three Her-2/neu peptides coupled to tetanus toxoid were administered with or without addition of recombinant IL-12. At the time all untreated mice had developed tumors about 40% of peptide-immunized mice and nearly 60% of mice immunized with the peptide vaccine co-applied with IL-12 remained tumor free [Ref1471:Wagner et al., 2007].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1332">
        <gene_name>Fragment C from tetanus toxin</gene_name>
        <strain>Clostridium tetani</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>8132375</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:285228
CDD:285226</xrefs>
        <taxonomy_id>1513</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>tetanus toxin</protein_name>
        <protein_pi>6.27</protein_pi>
        <protein_weight>49733.83</protein_weight>
        <protein_length>515</protein_length>
        <protein_note>Clostridium neurotoxin, N-terminal receptor binding; pfam07953</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAF73267.1 tetanus toxin, partial [Clostridium tetani]
KNLDCWVDNEEDIDVILKKSTILNLDINNDIISDISGFNSSVITYPDAQLVPGINGKAIHLVNNESSEVI
VHKAMDIEYNDMFNNFTVSFWLRVPKVSASHLEQYDTNEYSIISSMKKYSLSIGSGWSVSLKGNNLIWTL
KDSAGEVRQITFRDLSDKFNAYLANKWVFITITNDRLSSANLYINGVLMGSAEITGLGAIREDNNITLKL
DRCNNNNQYVSIDKFRIFCKALNPKEIEKLYTSYLSITFLRDFWGNPLRYDTEYYLIPVAYSSKDVQLKN
ITDYMYLTNAPSYTNGKLNIYYRRLYSGLKFIIKRYTPNNEIDSFVRSGDFIKLYVSYNNNEHIVGYPKD
GNAFNNLDRILRVGYNAPGIPLYKKMEAVKLRDLKTYSVQLKLYDDKDASLGLVGTHNGQIGNDPNRDIL
IASNWYFNHLKDKTLTCDWYFVPTDEGWTND

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1338">
        <gene_name>GM-CSF</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>12981</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>110625658</ncbi_protein_id>
        <gene_locus_tag>RP23-309E16.1</gene_locus_tag>
        <gene_refseq>AL596103</gene_refseq>
        <protein_refseq>NP_034099</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>11</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>54247269</gene_start>
        <gene_end>54249898</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>transcript variant X1</protein_name>
        <protein_pi>5.91</protein_pi>
        <protein_weight>15098.22</protein_weight>
        <protein_length>141</protein_length>
        <protein_note>Also known as Csfgm; GMCSF; Gm-CSf; MGI-IGM</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000077.6:54247269-54249898 Mus musculus strain C57BL/6J chromosome 11, GRCm38.p4 C57BL/6J
CAAAAGTTTTAATAATTTATTATTCTGGTAAGACATTCTCAATAAATAGAGTTGCAAAAATAAATAAATA
AATAAATAAATATTTAAAAAATATAAATATATAAATAAATATAATGGTCCCTATCAGTAGAAAATATCTC
TCGTTTGTCTTCCGCTGTCCAAGCTGAGTCAGCGTTTTCAGAGGGCTATACTGCCTTCCAACTGTGGCTG
TGCCACATCTCTTGGTCCCTTTAAGGCAGAAATTCCAAGTTCCTGGCTCATTACGCAGGCACAAAAGCAG
CAGTCTGAGAAGCTGGATTCAGAGCTGGCCTGGGCTTCCTCATTTTTGGCCTGGTTTTTTGCATTCAAAG
GGGATATCAGTCAGAAAGGTTTTAAGGCTGTCTATGAAATCCGCATAGGTGGTAACTTGTGTTTCACAGT
CCGTTTCCTGGAGGGAATGGAAAAAAATAAACAGCACTTGAGTCCAGGTAAGTGGGCCACGTGGGGAAAG
AACTGTGTATTTCTCTCTCGCTGCTGAGAACTCAGAGGCCAGAAGCCCATTTGTAAGGATCAGGTGACAC
TATAGCTGCCCGTGTGCTGCCTAAGGCATGCACAGCTCTGCCAATGGCACCCAGGGACTGTGCCCTTACA
GAAGGACTGTCTCAGGTCTGCCTCTTTGGTTCCCACCGAGAAGCAAGCAACCAGCCTGAGGCATCTCCTC
ACCTCTAAAAAGACACAAGGCTCACTGTCTTTGATGAGGAAAGGAAATAGGAATGTTTGGGGTGTCTGCC
CATTCTAGGAGCCTCCTCCTTGTATCCATGGAATACAGGCATCCTTACAGGAAAGTCCTGCCAGGAAGTG
GCATCTGGGTGCTGGCTCTTGGCTCTCCTGGGCTTGGGCAGGCCCTGAGCTTCCTTGGGTTTGCCTCACC
TCTGACCTCATGACTGACAATGGCATGTGTGACATGGGCAGATGGTTCCTCCTAGGAAGAGCAGTGGGCT
CTCTGCTGTTTCTCAGCTTAGGGTCTAGGGATGAATAGGAGCTATGGCCTGTTCTTGGGGGGCTCCTAGG
AAACATCTAACAATACAGAAACCACTTACTGGGGCCCTGAACAGCTACAGCCAGAAGTCTCTCCTTACTG
GCCGCACCCTCCCAGACTAAGACCTGGGGCCCTGATGCTGTGTACTCACCGGAGTTGGGGGGCAGTATGT
CTGGTAGTAGCTGGCTGTCATGTTCAAGGCGCCCTTGAGTTTGGTGAAATTGCCCCGTAGACCCTGCTCG
AATATCTTCAGGCGGGTCTGCACACATGTTAGCTTCTGTGGGAAGCATCCATTTGTTGATAAGCAAAAGC
CAAGTGTCCATAGAATACAAGCTAACTTCTCCCTACTCCCTTCTGCTCCCACCAAGTGGTACAGGTTGGG
GCTAGTCATAACACTGTCCTGAGCACTGCCCTTCTTCTTGCCTGGTCCAGGCCACCTCAGCTACCACAGC
CATGTTTATAGTCTGGTACCATAGAGGTTCCCAGTTCCAAGTGCTGTCCCCCCCCCAAAAAAAAAATTTG
TAAGCAAAGGCTACTTGCTGCCATTCTAGAAGAAGGAGATGGCCAGAGCCCAAACTTCTGTGTGGGGAAG
CACTATTTCAAAAGCCCCTCTGTGCCCTGTATAATCAATACCCTCTGTGCCCCTGTATAATCAATACCTT
CTCTCCATGGTCACGGGGCACAGAGAGAACTTGAAGGCAACAAGGCCAACTCATAAAGTGACTCTCATGC
TCCCATCAATCCCTGAAGACCTCTGACCTTTGAAAGCTAGCTCTGCCCAAACTTATTGCTCACTTGATAA
AAAGAGTGCACATGACTGCCACAGGGGCATGGCTCTGGACGATAAAAGAGTGCACGTGACTGCTACAGAG
GAATGGATATAGAGATCTTGACTACCCAGATTCTGCCCCCTCCCGCTGGCAGCCACTGGCAGGGAAGAGT
GTAGAAAGCCTTGCAAGAGGCTATTTAAAGCAGCCCTGCAGGGCAACCCGGGAAGCTACACCAAAAGAGA
AGAGCAAAAGAGAAGCAGCTTACCTTGAAGGAGAACTCGTTAGAGACGACTTCTACCTCTTCATTCTGTA
AAAAGGAAGTGCCGTGTTACCAAGCTGAAAGGCAGGGCAAGACAAGGGCCAATGGGTGGCCTGGGAACAA
CCCAACTCTCTCCCTCACTCACCAACGTGACAGGCATGTCATCCAGGAGGTTCAGGGCTTCTTTGATGGC
CTCTACATGCTTCCAAGGCCGGGTGACAGTGATGGGTGAGCGGGTGGGTGCTGAGAGGCTGTAGACCACA
ATGCCCAGGAAAAGTAAATTCTGCAGCCACATCCTCCTCAGGACCTTAGCCTTTCTCTCTGAGTACTGGG
CTCACTGCAAAAGAGCTCTTATATACACAGTTAGAGGAAATGATTAATGGTGACCACAGAACTCCAGGGG
GGCGGGGGAACTACCTGAGTTGTGGAATCTCCTGGCCCTTATCAGCTATACATGGGGCCAGTGAGCCTTC
CCCCAGGTTGTCAGGCTTGGGGGGTTTTCATTAATAAGCCCTTCCAAGAACTGGCAGCCCACCTGCGGGC
TGCTTTAAAGGCCTTTCCCACCCTGCCTGGGCAGTCTGAC

</dna_sequence>
        <protein_sequence>>NP_034099.2 granulocyte-macrophage colony-stimulating factor precursor [Mus musculus]
MWLQNLLFLGIVVYSLSAPTRSPITVTRPWKHVEAIKEALNLLDDMPVTLNEEVEVVSNEFSFKKLTCVQ
TRLKIFEQGLRGNFTKLKGALNMTASYYQTYCPPTPETDCETQVTTYADFIDSLKTFLTDIPFECKKPGQ
K

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1341">
        <gene_name>gp100</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>6490</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>318037593</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AC025162</gene_refseq>
        <protein_refseq>NP_001186982</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>12</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>55954104</gene_start>
        <gene_end>55966711</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>transcript variant 3</protein_name>
        <protein_pi>4.92</protein_pi>
        <protein_weight>55125.13</protein_weight>
        <protein_length>575</protein_length>
        <protein_note>Also known as P1; SI; SIL; ME20; P100; SILV; ME20M; gp100; ME20-M; PMEL17; D12S53E</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000012.12:55954104-55966711 Homo sapiens chromosome 12, GRCh38.p12 Primary Assembly
ATCAGGCTCTGAGTATTTATTTCAGTTAATAGTAGTCTCCCAGGGAAGACTGGGGGAAATATAGGTGTTT
CTGTCAACTCCAGGAAAATCACAGCATCATATGAGAGTACTCAGACCTGCTGCCCACTGAGGAGGGGGCT
GTTCTCACCAATGGGACAAGAGCAGAAGATGCGGGGTAGACGCAGCCAGTGACTGCTGCTATGTGGCAAC
TGGGGTACGGAGAAGTCTTGCTTCATAAGTCTGCGCCTGATATTGGGAGAAGGGGTAAACTGGTTAGCAA
TGGACAAAGGTAGCTTGTCTGTGCTTCTCCAAAGAAGGGAACACACCCATATCCCAGTCTGCTTAGCCTT
GATCCTAGCTTCCTCCCCTTCTCCTCACCTCCAGGGTTTACCCTCTCTTATTTCTGTGGTAACCTCTGTC
CATTCCTCCCTCACCCCGTAAGCTTTCCTGCCTGAGGACCATGCCACCCCAGGCCTGGGGGATCTGCCCT
TCTTGCAGGTAGAAAACTCAGTTCACCCCAGGCCAGGCACGGTGGCTCATGCCTGTAATCCCAGCACTTT
GGGAGGCCAAGGTAGGCAGATCACGAGGTCAGGAGTTTGAGACCAGCCTGGCCAACATGGCGAAACCCTG
TCTTTACTAAAAATACAAAAATTAGCCAGGTGTGGTGGCAGGTGCCTGAAATCCCAGCTACTCGGGAAGC
TGAAGCAGGAGAATCGCTTGAAACTGGAAGGTGGAGGTTGCAGTGAGCTGAGATTATGCCACTATACTCC
AGCCTGGGCAAAAAGGGTGAAACTCCGTCTCAAAAAAAAAAAGAAAACTCAGTTTACCCAAACTGCCCCC
ACTCTTCATATTATTAACAACAGTCATTAATATCAATTATTGCACTCTTGCTTCAGAGCCAGGTGCTTTA
CTCATTGTTTCTAATCTTTACAACAGCCCCACAGGGCAAGTATTAGTTTACCTACTTTTCAGAGGCTTAG
ACAGGTTAAGCTACTTCCCCCAGGTCCTACAAGCAAGACTGCAACCCAAGTCTGTCTAACTTAAAAGCCT
GGGCTCTTTCCTGGACACCATGCTTCCTCAAAGGGAGAGGTGGTTTCTTCTCCCCTTGAGGAAAAGTGAG
TAGTGATAATAAGGGATAAGGGGGTCTGAGCTGTGTGATGAGGCCCTTACCTATATATCAGAGATGCAAG
GACCACAGCCATCAACACCAGCAAGATGCCCACGATCAGCGGAACCTGCCCAAGGCCTGCTTCTTGACCT
GTGAGAAGAATCCCAGGCACTGCTTCACTCAGTGTCTGCTGCTTGCCAGCTGCCCTCTATCCACTCCCTT
CCTCATCTTAGCTCTTGTCCAAGGACCTACCAGGCATGATAAGCTGGGTGCTGACCACTGCCAGGCTGTT
GGTATCAGCCAGAGACACATTGAGGCAGTATGTCCCCGAGCCACCCTTCAGTATCTGGTGCAGAACCAGC
TGGCAGGCTGGGCTGGGTAGCACAGGCTGGCACAGCCGCTGGGCAGGGGGCTGGCACCCTGGCGATGAGA
TCTCCATGCAGGCTTCCTTGGGCAGCCTGGAAGAAGTGTCAGCATATATAAGGGGATCTGGGAAGGGACA
CTAAATGCCAGAGAGCGGAGAAACAGTCAACCAAAGAGTTACCAGCACACTAGTGAGACACTCACCCGCC
TTGGCAGGACACAGTCAGCTCAAATGCATCCCCCTCACCGGACGGCACAGCCTGCAGGATCTCGGCACTT
TCAATACCCTCTGCAGAGTTGCAAGCTTATCAAATTAGGATTCCTCTACCTGGCCTCCCCAAAAGCCCAG
AGACAGAAAAGCCCCAGGGCTGCTCCACCAATCCCATCCCTGTGCTTTCAAATGAGGACTCTGGCATTTG
GGTATTCTTCCTATCTAGGTGAGTAATTCCTCCCAAGGTGTGCTTCCACTGACCAGCCCTAGGTAGCACA
CAGCTGCCTCCATCAGCCACCAAAGTAGGCAAGACTCACGGACAATGTCCAGGGTGACGGAAAAGGAACC
ATATCGATACAGAACACAATCCAGGGGGACTTGTCTCTTCACCAGCCTTAAGGTGGCTGTACCATCCAGC
AGGGGGCCCAGGGAACCTGGCAGGAGAGGATCAAGGAGGCAAGATCAAGAGACAGATGACTCATCTGGAG
GCAGAGGCCAAGCAGGCATTTTTTCAGGTTGAACCAGAGTTACTGGATTCTGGAGTCACAGGCTTGGAAT
CAGATAAGACCTGGGAAACCTTATTCTATAGATAAGGAAACTGAGGCCCAGAAGAAGAAAATGACTCCTC
CAGAGTCACAGTTAGGGGTGGCATTGGAGTTTTAAAAAATCCTCAAATGTTTATCACACCCCACACTATG
TCAGGTCCTAGGCTAGACATTCAACGTGTGTTAACTCATTTAAGCATCACTGTTTCATTCCTCCCTTTTT
GCTTTGGGATGGGAATCCAGGGTTGGGAAATGGAAGGATCAGGATCTCGGAATCTGGGAAGGATTTTCGT
GCATTTATGCTTGAACAGAAAATGAGCTATAAATATTATATAAATGATCACAGTCTGTTCCCTGGTCTCG
CCAACCGTTCTCAGCAGTAGAGAAAGCAACAAGCTCTTTCCTCATGGCCTAGGGGAAGACCTTGGTTTCC
TGAACTCCAGACCTATTCCATGTCATTAAGAGAGACTGGAGGGCTTTATAGCCAGGCCAGTGAGAACTCT
GAGGGGACCATAGTGCTAAGCAAAGGATTGGGTAACATCTGAGTCCTGGGTAAGACTTACAGAGTAGAGT
AGGGTACCCCACCTCCGTGAACCTCATTCGCACTGATACTCTTACCTGTAATACTTTCCGTAGACATGAT
TGAGCTGGCATCTGGACCTTCAGGCTCAGGGATAGGTAGCTCTCTAGCTGTGGTCTCCACCCACTCTGTA
GTTGTTACCTGTGCAGCTGTGGTTCCAGAAAGCACCACAATTGATACCTCTGCAGGTGTCATACCTGTAG
CCTCTGGAGTTGACATCTCTGCCAGTGTGGTACCCATGACCTCTGAAACTGGCACCTTCTCAGGTGTCAT
ACCTGTGCTCTCTGCAGTTGGCATCTGCACAGGTGCAGTGCTTATGACTTCAGTGGTTGGCACCTGCACA
GATGTGGTTCCAGAGGGCTCTGCAGTTGGCGCCTGACCAGGTGTAGTACCCACAACTTCTGTAGTAGGCA
CTTGGCCAGCTGTGGTGTTAGGGGCCTCTGCAGTTGGCCTGTGCCCATCTGTGGTGCCTGGAACTGGGGA
GGAGCCACAGGAGGTGAGAGGAATGGCAGCCTGCAGGACCACCTGGGCAGTGACTGGGCCAGGCTCCAGG
TAAGTATGAGTGACCACAAGTGCCCGAGAGATCAGGGTTCCACTACTGTCTCCAAAGTCCCAGGTGTAGG
AGAGGTCAGCTTCAGCCAGATAGCCACTGGGGTCATGGAGCTGGAGGGCAAAGGTCAGAGGCTGATTTCT
CAGGAAGTGCTTGTTCCCTCCATCCAAGGCCCGCAACTGGGACACGCTCACGGAGAAAGGCACCTGGTCT
GGGATTGGAGCCAGAAAAGGTGAGAACCAGGCCTGAGCCACAGCTTCTCCTTTCACAGCCACACCCTCCA
ACTCCAAGCTGACTGGCTGGCCCTTCACTGGCACTAAGCCTCACATTTCTCTGCCTAGGTCTTCCTGGCC
CTTCTACTTTAAGTTTGCACAGCATTTCACCTTTCTCCTTTCCAGTCCATCCAAGCCTCCCTGCCTTCTC
TTGCCCTACAACTGGCCTTGCCCCTTCCTAAACCCTTACCAGTAATGGTGAAGGCTGAGCTGGAATGAGC
AAGAGGCACATAGCTCCGGGATCCCCGGCGATGGTAGACAGTCACTTCCATGGTGTGTGTGCCCAGCATT
GCCCTGCCTGTCCCAATGCTCAGCCCAGACACTGGGCCCCCTAGAACTTGCCAGTATTGGCCTGAAGTTT
TTGGAATGAAAAGCAAGGAAGAAGAGATTACTGGTCAAAGGGGACTGAGGGACAGGCTTCGAAACGGCAC
TGGAGATGGGAGGTCAGGAAGTATGATTACTTCTGAGGGTGTTTGGAAGGCTGTGATATGGGGGGACAGG
GAAGGGGTCCTAATGAGGCATTCCATGGGGTAGGACTACAATTGAGGAAGAGTTGCCAGAAAGAATTATG
ATAGAGTTGAAGGGGGCTAGGTGCTAAGAAAGAGAAAAGATCTAAGAGGAAAATGAAGATTAGAGAAAAT
CACAGAAGTTAAGGTGGAAGGGGCGGCCAAAAGAAAGGTGATCAGGTAGAAAGAAGTAAACACAAGTGTG
GATGATAGGCTGAGAAGGGAGTCCCTCACCCCAGGTCTTCCAGACATAAACAAAGCTTCTCTTCTGAGAC
CAAGAGCCAGATGGGCAAGGTCCACCATCAGGGAAGATGCAGGCATCGTCAGTTTCCTGGGGATACACTG
GCTGTCCTCCCCACACCTGGCTCCCTGAAAGATAAATACAGAGTCACTCTCAAACCCTGGCATTCTTTTT
TGTATATCAAAACCCCTAAAATTGCTCCCAGGGTATCAGAGAGGGGCTCTGGGAATATTCCCTAGCTAGA
AAGTACATTCTCCATGATATAACCATTTGGGGTGGTAGTTGGGGGTTGAGGGTGTGGAAACTACATTTTT
TTTTTAGAGACAGGGTCTTAGTCTGATGCCCAGGCTGGAGTGCAGTGGTGTGATCACAGCTCACTGGAGT
GTCAACCTCCCAGGGTCAAGCAATCCTCCCACCTCAGCCTCCCGAGTAGCTGGGACTACAGGTATGCACC
ACCATACCCAGCTAATTTTATTTTTTTGTAGAGACAGGGTCTTGCTATATTGCCAGGACTGGTCTTGAAC
TCCTGGGCTTAAGCAATCCTCCCACCTCAGCCTCCCGAAGTGCTGGGTTTACAGGCGTGCACCACCATGC
CTGGCCAGAAGCTATAATTTAATTGGCCAGGTGTGGTGGCTCATGGCTGTAAACCCAGCACTTTGGGAAG
CTGAGGTGGGAGGACTGCTTGAGGCATGGAATTCAAGACCAGCCTGATCAACATAGCAAGACCCTGTCTC
TACAAAATACATTTAAAAAAAATTAGCCAGGTGTGGTGGTATGCACCTGTAGTTCCAGCTACTCCAGGGG
CTGAGGAAGGAGGATCACTTGAGCCCAGGAGGTTGAGGCTGCAATTAGCTATGATCACACCACTGTACTC
CAGCCTGGGAGAGAGAGAAGGACCCCGACTTTAAAATAAATAAATAAATAAATAAATAAAATAAGAAAAA
TAAAAGAAAAAGAAGATATATGTATATATATATAGCCACATATCAAAATATTTAGAGTGATTTGCTCTAG
CTAGTGGAATAAAAATAACAGCACTAGGGGGCCAGGCGCAGTGGCTCACACCTGTAATCCTAGCACTTTG
GGAGTCTGAAGCGGTTAAATCACCTGAGGTCAGGAGTTCAAGACCAGCCTGGCCAACATGGTAAAACCCT
GTCTCTACTAAAAATACAAAAATTAGCCAGGCGTGCTGGCGGAAGCCTATAATCCCAGCTACCCAGGAGG
CTGAGGCAGGAGAATCGCTGGAACCTGGGAGGTGGAGGCTGCAGTGAGCCAAGATCGCACCACTGCACTC
CAGCCTGAGCGACACAGCGAGACTCTGTCTCAAAAATAAATACATAAATAAATAACAGCACTAGATAGCA
TTTATTTAGCCTTTACTGTAGGCTAGAGCAGACACTACATTAAGTACTTTACACATATTATCACATTCTA
ATCCTTACAACAATCCTTTTATCTTCGGAAATGGAAACACAGTGAGGTGGGCAGATCACTTGATCTCAGG
AGTTTGAGTCATCCTGGATAACATGGTGAAACCCCGTCTCTACTAAAAATACAAAAGAATTAGCCGGGCA
TGGTGACATGCGCCTGTATCAGCTACTCGGGAGGCTACTCCCAGCTACTCAGGAGGCTGAGGCGGAAGGA
TCACTTGAACCCAGGAGGCAGAGGTTGCAGTGAGCTGAGATCCTGCCACTGCACTCCAGCCTGAGCGACA
CAGCCAGACTCTGTCTCAAAAAAAAAAAAAAAGAAAAGAAAAGAAAAGAAAAGAAAAAAAAAGAAATGGA
AACACAAAACAAGTAACTTGCCCAAGGTCACATATCAAGGACAAGTTTAAATATAGGTCTGTTCAACTTC
TAGGTCCCCTGAATTCTGCTGTCCTCCACTTTAGGGACTGTAATTTTCTTTTTTCTTTTTGAGACAGGGT
CTCACTCTGTCACCCAGGCTGAAGTACAGTGGCGTGATCATGCAGTCTCGACCTCCCAGGCTCATGATCC
TCCCACCTGAGACTGCTAAGTAGCAGGGACTACAACTGTAATTTTCTTTTCTTTTTGCTTTCTGTTTTTT
TTTTTTTTTTTTTTTTTGAAATGGAGTCTCGCTCTGTCGCCCAGGCTGGAGTGCAGTGGCATGATCTCGG
TTCACTGCAAGCTCCACCTCCTGGGTTCACGCCATTCTCCTGTCTCAGCCTCCCAAGTAGCTGGGACTAC
ATGCGCCTGCCACCACGCCCGGCTAATTTTTTGTATTTTTTTTTTAGTAGAGACAGGGTTTCACCGTGTT
AGCCAGGATGGTCTGGATCTCCTGACCTCGTGATCCGCCCGCCTCGGCCTCCCGAAGTGCTGCGATTACA
GGCGTGAGCCACCGCGCCCGGCCTTCTCTGTGTTTTTAAATTTTAACTACAATGAGTATGTATTACACAT
ATAACTTGTTTTAAAAATTAAAGGAGGAGGCCGGGTGCGATGGCTCACGCCTGTAATCCCAGAACTTTGG
GAGGCCGAGGCGGGCGGATCACAAGGTCAGGAGATGGAGACTATACTGGCTAACACGGTGAAACCCTGTC
TCTACTAAAAATACAAAAAAAATTAGCCGGTCATGGTGGCAGGCGCCTGTAGTCCCAGCTACTCGGGAGG
CTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCAGAGCTTGCAGTGAGCCGAGATTGCGCCACTGCACTC
CAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAGAAAAAAAAAAAAAAGTAGAGAAGGAAGGGGCA
TTCCCTGAGCTCACTGGGCATACCAGGGAACCTGAGCCCTAGGAATAAGGACCTAGAATAGAGAAGTACT
CACCATTGATGATGGTATTGTTGACCCAGATAACCTGCCCATCTGGCAATACCTTTTGGCTTCCAGGGAA
GTTCAAGGCAATAGAGAAGGAGGCATTTGCACCAATCAGTGTAGGCCCATCATTACTGACCTTGAGGGAC
ACTTGACCACCTGGGAAGGAAAGCTACATTAGCTGGGACTCCTGGGCTTCCCCTCCCTGTATACGTTTCC
CCTCCTTTTCTTCCCAAGCTACACTCGATGCAGTTCAGCTTGCTTTTTTCCTCATCCCACTCCCACCATG
CCCTCCCCTGGAACTTCCAAGTTCCTACCTCTCCAGCAGTCAAGTCTCTGGGCTTCTGTCCACTCTGGAT
ACAGCTGCCTGTTCCAGGCTTTGGTTCTGAGTTGCCTTGAGACACCAAGCCAGTCCTGGTTTCTGGGTAC
TAAAAGGAATGTGCCATGAAGGGCCCTAGGATCCTTTCAGTTCCTTCTCAGGGATAACACTCTATTCATG
TCACTCCATTCATTCTCACATTCGAAGTGCATTTTTTTTTTTTTTTTTTTGAGATGGAGTTTCGCTCTTG
TTGCCCAGGCTGGAGTGCAATGGCATGATCTCGGCTCATTGCAACCTCTGTCTCCTGGGTTCAAGCGATT
CTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGGCATGTGCCACCATGCCAGGCTAATTTTGTATTT
TTAGTAGAGATGGGGTTTCTCCATGTTGGTTGGTCTGGTCTCGAACTCCCGACCTTAGGTGATCTGCCTG
CTTTGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACTGCGCCCGGCTGAAGTGCATTTTTAAAAC
TCATTTATTTGGCCGGGTGTGGTGGCTCACACCTGTAATCCCAGTACTTTGGGAGGCTGAGGCGGGTGGA
TCATGAGGTCAAGAGATAGAGACCATCCTGGCCAACATGGGGAAACCCTGTCTCTACTAAAAATACAAAA
TTAGCCGGGCATGGTGGTGCGCACCTGTAGTTCCAGCTACTTGGGAGGCTGAGGCAGGAGAATTGCTTGA
ACCCGGGAGGCAGAGGTTGCAGTGAGCTGAGATTCTGAGATTGCACCAGTGTACTCCAGCTGGCGATAGA
GTAAGACTCCATCTCAAAAAAAAAAAAAAAAAAAAAAACACAAAAAACCCCTTATTTATTTGTTTATTTA
TTTATTATTACTCTTTTTTTTTTTTTTTTTTTTTTTTTGAGATGGAGTCTCGCTCTGCCCCCTAGGCTGG
AATGCAGTGGCGTGATCTTGGCTCACTATAGCCTCCGCTTCCTGGATTCAAGCAATTCTCGTTCCTCAGC
CTCCCAAGTAGCTGGGACTACAGGCACCCACCACCACACCCAACTAATTTTTGTATTTTTAGTTTCGCCA
TGTTTCATGGTTTCTCCATGTTGGCCAGGTTTGTCTCAAACTCCTGACCTCAAGTGATCCAACCGCTTCG
GCCTCCCAAAGTGCTGGGATTATAGGCGTGAGCCACTGCGCCTCGCCTGTTTTGTTTTAAATCAAGACAT
AATTCACATACCATAAAATTTACTTTTAGCCAGGCATGGTGGCTCACATCTGTAATCCCAGCACTTTGAG
AGGCCGAGGCAGGTGGATCACAAGGTCAGGAGTTCGAGACCAGCCTGGCCAAGTGAAACCCTGTCTCTAC
TAAAAATACAAAAATTAGCCGGGCGTGGTAGTGGGCACCTGTAGTTCCAGCTACTCAGGGGGCTGAGGCA
GGAGAATTGCTTGAACCCAGGAGGCGGAGGTGGCAGTGAGCCGAGATCACACCACTGCACTCCAGCCTGG
GCTACAGAGCAAGACTCCGTCTCAAAAAAAAAAAAAAATTTACTTTTGAACATGATCAAATTTGTGTTTT
AGAAAGATCACGATGGCAAGCAGTGAGGAGGATGGATTAGAGGCTGGCAGAGATTGGGGATGGGGACAGG
GAAGACAAAATTATTGTAACTGACCAAGAGAGGTCTGAGAAGAAAAGGATATGCTGGACCTCCATCTGCC
CCACCCAGGTCCAACAACTATCAACACCTTGCCACATTTGCTTTGTTTATCCTTACTAGTTGTTGTTTTT
GTTTTTGTTTTGGCTAAAGTATGTAAAAGCAAATCCCAGACATCGTGTTATTTTAACCCTACAAATTTAA
AATGTATGAGTATTTTCTTGCATAAGCACAATGTCATTTCATGCTAGACAAAATTATCAAACTCAGTCCA
TATAAAATTTCATGAATATCTGGAAAAATGTCTTATGATTTTTAAAATCAGGATCCAAAATATAAGTACA
GTCTTTTTGTTAAGAGCCTTAGGTGGGTGGGTGTGAACAGACTCTTTCCAGGATACATTAAGGAATATAG
TAAAAGAAAAAGACTTGAAACTGCAGCACAGCGAGGAAAGTCACATCAAGGAGAACTTCCTAGAAATCTG
TGACACTAAACATCTAGGGAGAAAGCAGGGCTGGGATATAATGTATGTATTTCAGCACAGCAGAAACTAC
CCTCACCCCATTTTTCCCTTTCCTGCAGAAACCTCTCTCCCCTCCCCTTCCCTCCCCTCTCCTCTCCTTT
CTGTATATAGTTCAGCACAGCAAAAACTACCCTCACCCCATTTTTCCCTTTCCTGCAGAAACTTCCTTCC
CTTTCCTTTCCCTTTCCCCTTTCCTTTCCTTTTGATACAGGGTTTTGCTCTCTCACCCTGCGTGCAGTGG
CACGTTCATCACTCACTGCAGCCTCAAACTCCTAGGCTGAAGCCATCTTCCTCATTAGCCTCCCAAGTGG
CTAGGACCACAGGTGCTCACCACCAAGCCTGGCTAATTTTTTTTTTTTTTTTTTTTGAGACAGAGTTTCG
CTCTTGTTGCCCAGGCTGGAAGGCTGGAGTACAATGGCACGATCTCAGCTTACTACAACCTCCGCCTCCC
GGGTTCAAGCGATTCTCCTGCCTCAGCCTCCTGAGTGGCTGGGATTACAGGCATGCACCACCACGCCCAG
CTAATTTTGTATTTTTAGTAGAGACTGGGTTTCTCTATGTTGGTCAGGCTGGTCTCAAACTCCCAACTTC
AGCTGATCCACCTGCCTTGGTCTCGCAAAGTGCTGGGATTACAGGCGTGAGCCACCAAGCCTGGCCTAGG
CCTGGCTAATTTTTTTACGTTTCGTAGAGACAAGGTCTCACTATGTTGCTCAGGCTGGTCTTGAACTCCT
GGGCTCAAGCAATCCTATGACCACGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCACTACACCCGG
CCTCCTTATCTCTTTTCTTTTCTTTTCTTTTTTTATTTTTTTGAGACAGAGTCTTGCTGTTGCCCAGGCT
GGAATGCAATGGTGTGATCTCGGCTCACTGCAACCTCTGCCTCCCAGGTTCAAGCGATTCTCATGCCTCG
GCCTCCCAAGTAGTTGGGATTACAGGTGCGTACCACCATGCCCAGCTAATTTTTGTATTTTTAGTAGAGA
TGGAGTTTCACCATATTGGCCAGGCTGGTCTGACCTCAAGTGATCCACCCGTCTCAGCCTCTCAAAGTGC
TAGGATTACAGGCATGAGTTACTGTGCCGGGCCTCATCCCCTTTCTTTTTTTTTTTTTTTTTGAGACGGA
GACTCGCTCTGTCACCCAGGCTGGAGTGCATTGGTGTGATCTTGGCTCACTGCAACCTCTGCCTTCTGGG
TTCAAGTGATTCTCCAGCCTCAGCCTTCTGAGTAGCTGGGACTACAGGCATGTGCCACCATGCCCAGCTA
ATTTTTGTACTTTTAGTAGAGACGGGGGTTTCACCATATTGGCCAGGCTGGTCTCGAACTCCTGACCTCG
TGATCCACCTGCTTCAGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACGGCGCCCGGCCTCATTCC
CTTTCTAATGTGTGCTGTAACCCTAGTTGATTCTGCTGGGGGAGGATCTGGAATCATCTATTGAGCATCC
CACCACTAGAACAAGAGAAGTCATAAGATACCCCATTCTTTCTCCACTTCCAACTCTCCTCAGAGCAGCA
CGGGACATTCCAGACCCTCTCACCACCCCACCCCCGCCCCTTGCTCCTGTCACGAGGCCCAATCCCCCAG
AGCCCTTTCATGTGATGCTCAGCTGAGACCCCTCTGCCTATCTCTCCAGCCCCAGAACAAAAGGTCTGGG
CTGTGTTCACCCGTACCCATCCCAAGAGGAGAGGATTGTATCTCCTTAGTGTTCTTACCCAATACCACAT
TCTCTGACTCCCCACTTTAAATCTCCTACCCCAAGAGACGTTTCCTAAAAGAGTCTCCTGCACATTTCAC
CCCTTTGGAGCCCGTGCTCCAGCTCACTGCCAAGGAAGCCTCAGAATCAGTGCCACAGAGACCTTCTATC
CTTCTGCCCCTCCAAGCATATGAGATTATTTTCAGGCAAAATCCCAAATCTCCATGTAGGGAGGGAGCCC
AGGTGCCCACATCCTCACTAAATCAAATGAGTGGGAGACGCCTGAAATATTGCCGCTATCTCCCATTAGG
AGGACAGAAACCAGAGCAGGGGGAATTCATCCCCAAGTTCACACCTGCTCATGTCCACATATCCACACAT
ACCTTTTGTAGCCCCCACAGCCAGCAAAGCACCTATCACAGCCAAATGAAGAAGGCATCTTTTTAGCACC
AGATCCATTGTGTTCTTCCCTCCAGCAACCAAAGGCACTGGGGGGACTGGGATAGGCCCCTATATAAGAA
AAGGGTGCTCATTTGCATAGCCCTTCCTCTTCTCCCTCAGAGAAGGCCTGGGAGGGGCCGGAGGAGAGGA
AAAAGGAAAAACTGACAAAGGGATCCTGGTCCCTAGACATTGCTTTCCCATCCTGCTACTCAATGACAGT
TTCTGGTTTCACTGGGTCACTCTCATCTTGATGCACTCCCGGGCAAGAGCTAACTGAAAGGCAGCTGCGT
AACACATACCAGACACAACAGTTTATCATGGGAGAGTGAATTAAACCAGGAACTTCTCAAAAAGACAGAA
ACAGAACCCTGCATCCCAAAACAGAGACAGTGTCGGGGTATGCTATGAGGCAGAGGCAACGACTCCTCTG
AGGCCCAGGATTCCTTTGCAACGAGATTCCCGGCTTCCTGGTTTCCAAAGGAGGCTCCTGGGCCAGGTGG
AATTTAACCTTAGGTCGATACATATTTTCCCCAGGATTGGTGAAAATAGTGAGTTAGAAATCAAGAAATC
CCTACAGACTAGAGACATAGGTAGGAAACTTGGACCCAAAGCAGGTACTTGGGAAGAGTGTTCAGCCGCC
CCACCGGGGAAGAAACTTGTCTAGCCCCCAAGAACCAAACTTGCCTGGGGCGGGATCATTTGCGGGGAGG
AGCGCTGG

</dna_sequence>
        <protein_sequence>>NP_001186982.1 melanocyte protein PMEL isoform 2 precursor [Homo sapiens]
MDLVLKRCLLHLAVIGALLAVGATKGSQVWGGQPVYPQETDDACIFPDGGPCPSGSWSQKRSFVYVWKTW
GQYWQVLGGPVSGLSIGTGRAMLGTHTMEVTVYHRRGSRSYVPLAHSSSAFTITDQVPFSVSVSQLRALD
GGNKHFLRNQPLTFALQLHDPSGYLAEADLSYTWDFGDSSGTLISRALVVTHTYLEPGPVTAQVVLQAAI
PLTSCGSSPVPGTTDGHRPTAEAPNTTAGQVPTTEVVGTTPGQAPTAEPSGTTSVQVPTTEVISTAPVQM
PTAESTGMTPEKVPVSEVMGTTLAEMSTPEATGMTPAEVSIVVLSGTTAAQVTTTEWVETTARELPIPEP
EGPDASSIMSTESITGSLGPLLDGTATLRLVKRQVPLDCVLYRYGSFSVTLDIVQGIESAEILQAVPSGE
GDAFELTVSCQGGLPKEACMEISSPGCQPPAQRLCQPVLPSPACQLVLHQILKGGSGTYCLNVSLADTNS
LAVVSTQLIMPGQEAGLGQVPLIVGILLVLMAVVLASLIYRRRLMKQDFSVPQLPHSSSHWLRLPRIFCS
CPIGENSPLLSGQQV

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1686">
        <gene_name>GRP</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>2922</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>60498997</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AC067859</gene_refseq>
        <protein_refseq>NP_001012530</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>18</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>59219187</gene_start>
        <gene_end>59230773</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>transcript variant X3</protein_name>
        <protein_pi>10.74</protein_pi>
        <protein_weight>14837.71</protein_weight>
        <protein_length>141</protein_length>
        <protein_note>Also known as BN; GRP-10; proGRP; preproGRP</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000018.10:59219187-59230773 Homo sapiens chromosome 18, GRCh38.p12 Primary Assembly
AGGGACAGTTTGAGCTTTCAGGTAGAGGCAGCCTAGGGAAACTGGCATAAAGCAGTTTCTTTCTCTATTC
CATGGAAGTTGCATGCTTGTGAAAAGGGCCAGCTATCTTCTGTCTTGCCATACAAGTGGGCAGAGCTGCC
TGGGAATACCAGGTGGGTTAAGGATACTGCCCTTAACCTTAAGGTGGAGGGCAGCAGAGGGGGAGAGAGA
GACAGAGAGAGAGAGAGATTGGGGAGGAGGGGAGAGAGAGAGGGATGGGAAGGGGAGGAGAAGAGAGAAG
GGGAGTGGAGGGGAGGGGAGGGTATGGGAGTGGAGAGGAGGGGAAGGGAGGGGAGAGGAGGGGAGAGGAG
GGGAAGGGAGGGGAGAGGAGGGGAGAGGAGGGGAGAGGAGGGGAGGAGATCTGCAAGAAAGAGGCAAGGT
CCAGAAAAAGAGAGAGAGATCTGCAAGGAGGCAAGGTTCCAAAATCTATGGGCTGGGACAGCAAAGATGT
GGCCTACGAAGAGAAAGGTCTGGAGAATCAGAAGGCCTTCAAATGGTGGTTCCAAATCCCTCCAGCAAAG
CCCATCCATCTTTAGAGCTCACCCGTCTCCAGCTACACCCCCCACCCCTCCCGGCCCAGATCAGGCAGCG
GGGTCGCCCTCTCCAGGACTCTCAAGGCAGCTAAGGCTGGAGGCGCCGGCGAGCCTGGAGAGGGAGGAGT
TCACTAAATTGTGTTGGATGGAAGGCGTCGAGGACCGGAGGAATTAATCCGATGTGGGGAAGGCGGACGG
GGCTACGAGGAAAAAAGAGGGGGCAATGTACACTCAGCCTTTTCATCACTCGGCGGGGAGATGGATGGTT
TTCCGGACCGGGCGTCCCAGCGCCCCGGTTAGCTATAGGGAGACGTCAGAGCGCTCTGGTCCGCGATAGA
AGAGCCCCCCAGCCCCCCCGCCCGGGCTTCCATATAAAGTAGGGGCCCTAGTGGAGGCCGCAGCAGTAGC
ACCAGCGGCTGCGGCGGCGGAGCTCCTCCGAGGTCCGGGTCACCAGTCTCTGCTCTTCCCAGCCTCTCCG
GCGCGCTCCAAGGGCTTCCCGTCGGGACCATGCGCGGCCGTGAGCTCCCGCTGGTCCTGCTGGCGCTGGT
CCTCTGCCTGGCGCCCCGGGGGCGAGCGGTCCCGCTGCCTGCGGGCGGAGGGACCGTGCTGACCAAGATG
TACCCGCGCGGCAACCACTGGGCGGTGGGTGAGTGTCCTGGCCGCGGGAGCCGCGCGCTTGTCCTCCTCT
GGATCAGCCAGCCGGAGGGGACCTGTCTCCCCATTTCTTTGCGTTTCCCTGGCCCAGCTTTGGGAGCTGG
GTTTGTTGTGACCTTTCTATCGGCAAACACCTTCCCCGTTCTCCTAAAACTCCACCCCACCTTTCCCCAT
TCTAGGGAGCCCATGAGTCCCTAGTCAGCCGCAGGCTGGTCCGCTGATCCTTTCCCGCTCGCTTCCAGCC
TGTCTTCCCCAGGGCACCCGAGCTCCCAACAGCCAACCCCGGTGCAGATCACCTTCCCTCTGCGCCCATC
CTACATCTCCTTTTGTCCGCCTAGTCTCAACCTGTCTGGCACGGTACTCTCCTAGAATAATCTTGGGGAG
CGTTGTCCCTTGAAAGCATCTCAGAACCCTGGTCCAGCTCGGTGGCCTCAACAGCGACTGGCATGGGCTG
AAATCTAAGCTGCGCCTATGCTCCCCGCAAAGCCACAGGTGTGGGGACCTAGGGTGCAGCGCTCCCGCCC
CGGGTTTCACATCTGTTCAGTGCGCAGTGCCCTGAATCCCGCCTGTCTGTGACTCTCTGGAGTTTCCTCA
GTCCTTCTCTTCGCTTTGCAGCGATATTCTTTTCCCTGCCCTTTTGCCCTCCCTCTTTCCAGCCAGCAGG
CTCTGAGCTTGGGGAATCTCGCCTGCTCTCCAAGCTCATCCCGATCTCTCTGCCCCTCTGAGCTCCGCTC
TTTCTCCGCCCTTCTTGACCCACGACTTCGCCCTTTCCCCTCGCTCCTTTCCCATTCCCTCTGCAACAGG
TCCTGCTCTCTAGGCACCGGCTTGGAGGCTCCCTCGCCATGGCCCCTAGAACCCAGGCGGAGAGGACGGC
CGCGCTGCGGGTGCGGAGGGCGCCTGCGGGTGGGGTCAGGATTCCGCCCTGCGCGCACTCGCTGCTTTCG
CTCAGCTGGGAGGCAGGAAGCGCCTGGCAGCCTCGGCTCACCCAGCATCACCCCAGGGCTCTCGGCGTCG
CCGAGCATAGCTTCCAGCAAACGCAGAGCGTCCAACTTCCTCACTCCCCCACCTACCCGCCCCACAAAAG
CCAACTACAACAACCCCAACCAGCTTCTTGGGAAGCTGGTTAATCCCTGAAGAGATTTAAGAGTGTGTAT
GTGTGTGTGTCTCTGTGTGTGTGTGTCTCTGTGTGTGTGTGTGTGTGTGTATTTCCTTAGCCATCTACTT
AGAACGGGCGCTGGGGAACGGTGTGTTGAACAAGTACTTGCTAATTCATATATCGGCTGATTCACAAATC
TTGATAGAAGATAAATAATTTGGGGGAAGGAGTGGGACTGGAACTGTTGCTTCCTCAGCTCGTCTGTGTC
GTGTGTGCTTTTGTGAGGGAAGTCGAGATCTTTGGGCTGCAATAGAGTGGTTTCCACTGTTGCTAAAATA
ATCATTTGCCAAGTCTTGACAGTTCCAGAGATGAGAGGATGTGTGATCGCTGAGGGACAGGAGGAACCCA
GCAGTCTGGTGTGGAGAGGAGAGGTTGGAATGGGTGAAGCTGAAAAACCCTCCATTTCAAGAATGAAGGA
TGCTTAGCAGGTGTTGAAGAATCCAAACTTAGAATTGATGCTTCTTAAAGAGGGCTTCTGGGAGCTTAGA
TCAAGTGGCCATTATCTGGCCCAGCCACCAGCCAATGGGGCTGGAAAGATGGAATGAAAGTTCTGGATTC
CCAATCTCTTTGTACTCATCTATATTATTGCACTAATAAAGCTTATTATTAGGTAACGCTTGCAGGCCCA
AAGGAGGACAATAGAGTTAACTGGGGAGTGGCATCGTGTTATTTCTGGTGCAAGTCAAGCCAATCTTGAT
TTGCTGTAGTTCCGCAGAACATCTGTCTCCAGGTATTTAGGGTGTCTGCCGTTTAATTGCCCTTCATAGT
GGTACTTGAGCATTCCTAACCCAAAAGAATACCAACCAGTGGTGACCCCAAATACCATTTTCATATTTAT
TCTCAAATGCACTTTTTTCTCTCCCTTTGATAACTGTGCAGAGTTGAGGAGGAGCAAGGGAAAGAGGGAG
GTGAAGTAGAAACTCACATTTTAGCCTAAAATTACCTTGCGGTTGAGAAAACGTTTGCTTTGAGTAACAT
GCCCTCTGTTGGAATATGAGCATTGACAAGGATGAATGATGTTACACTTCAAATTTAGCTTTCAGTTATC
TCAAGAAAATGCTTATCCTCTTCAATCACCAAAGACATGTAGTTTAGTTTTAATTATATAAAACCAAAGC
TACATGCTGCTGTCCATGAGGATGCTGTCAGCACACATTTACAGGCTTGGTAAGTAAATTGCTTCTTCTA
GCTGAGAGAAGCATGGTGCAGCAATGGAAAAAAGGTTAACAGCTTGAAAACTTAACAAATTTTTATCTGG
CTTGATGTTCGTGGAAATGTTTTGTTTGTGTGATGAAAATATATGACAACACTTATACTGGCTACTATTC
CCTGTGCACCCATGAAATGCTCCTAACTGTGGTTCTAACTTGGACGTGAGACATATCCCAGAAGGTTGAA
TTTGGAAATACCAGTATTCCACTGCAGAATGGCTTGTTATGGCCCCAGAAACTGTGGAATAGAATTTAAG
TGTGGGTCCAAAAATACTACTTCTTAGTAGTACTCAACACTTTCATCTATGTCTTATTCATTTCTGTTTC
AAACCTTCCCTTTAGTAGTATCTTTAAATGATTAATAAAAAGAACAAAAGCTCTTTTTTTCTCTGATCAA
GGTTTTATTTTTTCAAGTGCCTGTCTTTTGTCTATGGTGAGGTTTCCATTATTATGATATGGGCACTTGA
CAGATGATGTTGGGAGAAGAGGTGGAAGTGGGCGTATCATCCATGTTGCCATGGAGATGACGATTTGGTT
GACAGTCACTAGCTCAAAAGCAAAACTGGACCCAGGGAATGTGTACTTCCCTGGGATGTTACAGATAGCG
TGCTCTCCTTAGCAACCAGTCTATGGAACTAGAGATAAAGAACTGATCCCCACACATTCCCCATATATGC
AAGTACTGAAAGTTAGTACAATCACAGAATGGAGAATAACTTTCTCCTCCCATTTTAGAAAAGTCCACAA
AATTATTCAGGCATGACAAAAATGAGGTTCTTATGTGTGATATCTGCATCACTTCTCTGTTTTACTGGCA
ATAACTCTTTCTCATTTCCAGCATTCTAACTAGATGATAGTCAGTTAGAAGGGCAAGGTGATCTAGGTCA
TCACTGGGAGTATCAGGATTCTAATCCTGCCTTCCAACCATCATGATTTAATTTCCTCCATATAAATAAA
GTCAAATGCATCACTACTTCCTGGGAAGTTGCACAACATAATCACCGTTATGGCTGAATGCAAGGTTATT
GAGTGGCTATCTGAGCACCATGTGACCAAGCTGATACGTGAGGAGCCAGTCATTCAGGATTCCAGGTCTT
CACTTGGGACAGTATCCCCAGTTAGGATCCTGAAATTGTGTGAAGTCTCATGTCATAAGCAATTTGGCAA
ATGCTCACACTGCAATGCAGTAAACCTGATTTTAATGCTCCTTAATACTCATAGAATTAATTTTTCTCAA
TTACATAATGCATCATGATATATTGGCATATAATCCCTATTTTTATAACATTAGAAAGCCTTTTGTAGAC
CTTATCCTTATTTCCAGATCCCAGAATGATTTTAGCTACCTTATATTCTTAGCAAGTTAGAAGACATTGC
CAAGCAGTGTAATAATGTAGTCTAGATTGTGAACTGATTTTAATCCTAAAATAGTTGCTTACATCTATGT
GACCTCTGGCAAGTCTCATTTTCACCAAACCAATTAGCATATGGATCAAATGAAATCCAGCACATTTAAA
CATCCCATAAACTGCAAATCGCAATACACATAAAAGCAATAAAGTTAAAGTGAGGGCTTCTCTGTTGGTG
GATAGAACTTCTGGGAAGGGGCCTCTTTCCATTTTAAGACTGAAGATCTTTCAAATTTTATGTTTGCCTT
AAATACTTCTAATGCCAGTCAGTGTTGGAACCACAAAGACCTTTTTCCTTGCACACTTTAGATCAAAAGC
ACCATAGTTTTGTTGACGTTAGAAATTTCAAAGTGCTACAAAGTCCAACTACAGAGAGAGGAAAAATCAA
CTGTAAGAAATAGAGAACATGAGAATATTCAAGCAAGGGTCTAAAGTGTTAAGAATGCAGACCTTGAATT
CTGTACCCACTTCTGACTCCAAGTTATCCTCTCTTGCATACATAAATTTTCATGTTTTTGATGGTTTGGC
CTCCTTAACAGCAGCTTTTTAAAAAAATTATTTACAAGGCTAGTACACATTCCTGGAGCCACTGATAGAC
TTTCAGACACCCAAGAGAAAATTCTGCATTTATGCGGCTGTAAAGTGTTACTCAGGGCTTGTTTTCAACT
TGTTTTTCACTACACTCTTAACAAACAGTAAATCTGGGTAGTTTTCTCAGTTCAGTCTCAACTAAAACTC
TGAGAAAGTTTAAATGAAAAATTCCTTTGGTATTTTTTTTATTACGATAAAAGGAAAGAAATATTTTTAA
AAAACCACACAAAGAAAAGCATGGAGACTTTTATTTTCAGCAGCAATTCAAAATTGGCTGGGGAAGATGT
TTAAACTCCATCTTTCAGCTGGAAATAGAATTTGGTGCACACAGAATTGATGATAGAATTTTAGATATGG
AAGCCTCCTTAGATTTAATCTAGTCTACCCTGTTCATTTTATAGTTGAGAAAATTGAAGACTAGGGGTGC
TAAACGACTTGGCAGAGGTGACCTAACTAGTTAGGAGAGGTGCTGGAACCAAACCCAGGGTTCCTGGGTT
GCAGTTCTGAATGCTGTCTAGCTCATTGCACATTTTGAACAGAGAGCAAAATCTATCTGTCGTTTATGAA
CTAACTCTTAATAAAACATGATTTATTCTGCATTTAGGAGGAAGCAGCACAAACACAATTAGCTTTAAAT
TTCTTTTAAATTTCTCATTCATTCCCTTTGGTTAAATTTGTGGCATTCTGAGTGTTTTTGTTTTTGTTTT
TACAGGGCACTTAATGGGGAAAAAGAGCACAGGGGAGTCTTCTTCTGTTTCTGAGAGAGGGAGCCTGAAG
CAGCAGCTGAGAGAGTACATCAGGTGGGAAGAAGCTGCAAGGAATTTGCTGGGTCTCATAGAAGCAAAGG
AGAACAGAAACCACCAGCCACCTCAACCCAAGGCCCTGGGCAATCAGCAGCCTTCGTGGGATTCAGAGGA
TAGCAGCAACTTCAAAGATGTAGGTTCAAAAGGCAAAGGTAAAAGAAACATACATGCAAGATGGGGTGGG
AGGTATCTGGGGAGAGGTGGAAAGAGGGCAAGTTCAAAGGAGGAAGAATAGAATTGCTTATGATATAAAC
CTTCACAGTCACTACATTAGGCTAACACATGCTAAGCACATTGACAGACAATTTCTACATTCTCTTCTTT
TTGACATATAGTCAAAAGGATATTGATTCCAAACTCCAATTTAGGAGTTTTTTTCAGCAATTTTGTCTAT
TTGCCATTACGCATTGATGGGATTTTTTTTTTAACACACAGGCCCTACAAGAATGTTTTGATAGTGAGTC
TGCAAACTATTTGAGTAAATCCTTGTGGATCTACAGATTTTATTTTATTTCTGGTGAACACTAGTGGAAG
TTCCTGTTTTTAGAAGACAGCATTCTTGTTTGCTACCTTTGACACAAAGTAGCACTTCTTCATATTTGTT
CCAGGAGTACCTAGTTCAGGTTTCATCCTAATATTTTAAAACTCAGTGAACATGTCTGAGATCAACAAAT
CCATCCTGTATATGATTTTATAGAGGATAGGGGAAAATAATTATACTAAACTGGCAATGCTTAAAGACAG
TGAGCAAGATAAGAGAGAATAAAATTTACAGGAAGAAAGCAAGGCAACTGAAAATGAGGTGATTATCACT
AACTTTTAAGTTTCCATGAAATGTATAATAAAATACAAAATAATAATTACAATAACAACGGTGGCTAGTT
TTACTGAATATTTACGATAATCCAAGTATTGGGCTAAGCAGTTTACCTCCATTTTCTCGGCTTATGCTCA
CAGAAGTCTTAGACGGAAGATTCTATTATTCTCTCCATTTTAGAGGTAAGGAAACTAGTCCCATAGCTTT
TCACTGATAAAATCAGGGTAAGGGCCTGTGTTCAGTCGGCCTCAGACAGTCTGTACCATGCCAGACATCT
TCCAGAAATGGTCCTCATTGATCTTAATATAAAGGATCCAGGCTGAAGGCCTTGCTACTTGCTGCTTCTG
ACAATAAATAATATTGCTTTCCACTCACAGTACTGGAGAGCTTCCTTCTTCACTCTTTCATGGTGAAGAC
TGATGGCCCCTTTAGGGGCTCAGAGCTGCCTTTGCCAAGCCTCGGCTGGCTTTCTGGAGGGAAGCTTTCT
ATTTCACTGCCCTTTGGGTCTATTCTGGTCTTTCTCTTTCTTTTTTTTTCTTTTTTCTTTCTTCCTTCCT
TTCTTACAAGTTCTGGCTATGTGGTTTCTTTTCTTCCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCT
TTCTTTCTTTCTTTCTTTCTTTCTTTCTTCCTTTCTTTCTTTTCTTTCCTTTCTCTCTTGCTCTCTCTCT
CTCTTTTTTTTTTTGACAAGGACTGGCTATGTTGCCCATGCTTGTCTCAAACTCCTGGGCTCAAGTGATT
TCCCTCAGCCTTGGCCTCCCAAATGTGGGTTTCTATGCTAAATGGAAACTGAAGTTCACTTGTTGCACTA
AGCACCTAGAGGGAAAGTCTTTGTAGCTTTTATTCAGAAAAAAAACAAAAACCAAAAACAATCCTAGATT
AAATAAACCAATACAGAAATAAATACCAACTTTGTACAAAACCCCAAGCGATTGTCTGGTCCATACCTGT
GTCATAGGTGTTATGTCATCAGCCCCCTTCTTTACTGATTGATCCCATACTCTGAGGGTTCTGTGAACTT
GCAGGTGACTTCTCAGATTCTAGCTGCCATGCCTTTTTCATGGTCAGGTGCTTTGCCAGAGTTCCTGTAG
GTGGATATCCAACAGCAGTACCCTTCTCATTTGTCTGAACAGTAATAAAAATTGCCACCACAAAACCCTT
GAAAATAATTTTTGCAAACATTGAACTGGACTTGCCCTCATAGCTCGTTCATGAAATACTCCCCTCTACT
AACACACAATCATGTTACTATTCTATAGTGCCTCATTTTTGAAACAAACAGCAGTGTCCAGTTTGTTATT
TTATTTCCTCAACCTGGCTCTGCATATCTTTGGAATCTTTTGGCAAATTCAACTCCTTCCTTAAGGATCA
AAAATTTTCCACCACATTCAGAAGAATATTCTGTAAGCTTCAAAGGCAACAGCAAAAAGAATAGCTCCAC
AAAGGTGTCTGAGTAGCAGTATAATAGGATGGGTTGAGTGGGCAGCTGCCGAGAGTGACTGCTTAAAGGG
GGCAGTCCTTATCCCAAGTGAACTGAAAAAGGTCATCAAAAAGATGATAAAAAAAATCAGGCTTTGCTTT
TCTATTATTTTTATGCATTGTTTTTCTTTTTACAGGTTTAGAAAGCCCATCTCATTTAATTCCACCTCCA
GTTGAATAATTAGTTATCGCACACATTGGTACTATTCTTTTGGCTATATTTCCTAGTAACACAAAAACAA
GTTCCACAGTTAGTGTTTGCAGAGACCAAAATATTTTATTGCTTCTCTTGCACTGGAAATTCCACCTCAA
TGAAAGTATGCTGTTATGAAAATTGAAAACACCTTACAATGATCTTATTCAAAAAGAAGGGGTGCCAAGA
GAGTAGTTCTATTAGAACCCATATATCTCCCATATCTTAGAGTTATGGGAGTGTTAGAGGGAAACTTAAT
AACTTAGCTAAGCATTGCCAGAATTAGCAGCAGGAGTTTTCAGAGGCTGAAGGACTGTTCTTAAAATTAA
AAACTATCTACATATGCTCTCCTCTCTCATTTTAGTAATAAAACATCAAGTACTGTTGCCAACTCTCTTG
GAGCTGTGGTTAGAAACTCCAAGCATTTCCTATGTTTTGATGACAAAGATATTTACTTAATTCATAAAGG
ATGTGTGTAATGTGCACTGAAACTAGATTGCTCGACCATGGAAACAGCTCCAGAACTTTCAGAGCAATTA
TGCCCAGCAATGTTCAAGGTTAACCTTAATCCTTTTAACTGTGCCCTTCTCACAAATCTTTTAATTCTAT
TCTGCAATTAATGGAACTTTTCCCCCATGGTTTCTGCAACATGAAACTCTGTTCTGTTTCTGCAACATGA
AACTCATCCCCATGGATGAAGCTCCAGGGCCTCATCCATGATCCTGGATGTGGTTGTTCACTGTCCTGGG
TTTCAATGGAGGTTTTAGTTGGCCTTTGGTCTACCTTTATAATTTGGACTTAGTCCCTTATTCTTTGCAG
CTTAGGTCTCTCCTTTTATTTAGTGGACATGAAGAGGGCAAGGAAGTGAGCTACAAAGGCTGTTATGGAA
AGAAAGTAAATGTGTTCGTTCTTCACTTTTAAGGGACTGCTCTCACTGTCTCATCAAATCAGTACAGAGA
ATAGGAAGGTCTTTTTTCTGAATATTTGAAATGCTCCAAAGGAAGTGCCAAATATAGAAAAAGCAACATA
AAATCAAGAATCACTCATAACCTTCTGATTACCCTGGCACTTTCTATGAAGGAGTAGAGTAAAGTTGGCC
CCCACCTGGAATATAGCTCCTCCCTACCCCCAACAATGGACCCTGCCCATTGCCTCCCAGTTCCTTGATC
TTCCTAGGTTCCACAACTCTCTTTTTCCTTTTAGTTTTATTCCCTCCAGCCAAACCTCTCTTATTCAATA
TTTTGAGCCAATGGGGGAGTTATGTAGATTTTTTTCCCTACACATTAGCTGGCCCCTTTTATGACCAATG
ACTCATAAGGCAAGATGTGTGGTGGCATCTTCGGACAGGCAGCAGGCTTTAATAGGGCAGCCTGGGTTGG
TGGAGGCAAGCAAAGCTAATTGGCATGCGTGGGAATCAAACCCCAGGCCCTGGGCTCATTAGCCCATGGT
CAAAACAACTGAGCCAGAGGAGGTAATAATTTGCCCAAGAATATCAGTAGTTCCTTTATTAGAAGAAAAT
GGCTGATATGGAAGTTGGGGAATCTGAATTGCCAGAGAATCTTGGGAAGAGTAATAAGCTCTTAGTCTCA
ACAAAAAGTGTTTTTTCATCTCAGCGCGTAAAGGGTGCTATATGGGAACAAAGAAGTATTTTAAAATTAT
AACTACTCATTCTTTCTTTAGCCTTAGTTAATTTGAGCAGAAGCCACAACAAGCAAACCACAATAAATTT
AGAATTGGCAGAAATCCACATTAACTCCTCTTCCCAAGTTTCCACACTACTACCATTTACAGTTGTAGGT
TTGTAATGTATAATTATGTAATGCAGAAACTAGCTTTGACTTGTGTAACGATGCACTGTCAAAGTAAGCA
AAGTAAGAATTGAAATTCCACATTCCCAGAATTTAACACTCAGCTGCTCCTCTAGTAATAAGTTCCTGGG
GATAATACATTAACCAACATTGGTTGAAACATACCTGAGTAATCATATCAGGATGCATGTTAAGCTGATA
AAACAATAAGATCCCAAAATGCAGTAGCTCAAAAAAAAGTAGAAGTTAATTTATCTCCTGGGGGACAGCT
CTGGTTCTCAAATTTTACAGGCTCAGAATCACCTGCAGGGCTTGTGAAAGTACAGATTGCTGCGCTCCGC
CCCCAGAGTTTCTGATTTAGTAGGTGTTAGGCTGAACCAAGAATTTGCCTTTCTAACAAGCTCCCAAGTG
ATGCTGATGACTTGTAGGAATGGATTTACTTCTAGGATTAGACTTCAGCTCACTCTGTTTGCTGAACTCT
TTCTAATATTTCTTAAGTTGGTAGACTCTCTGCTCCAGGTTCTCAACGTGAAGGAAGGAACCCCCAGCTG
AACCAGCAATGATAATGATGGCCTCTCTCAAAAGAGAAAAACAAAACCCCTAAGAGACTGCGTTCTGCAA
GCATCAGTTCTACGGATCATCAACAAGATTTCCTTGTGCAAAATATTTGACTATTCTGTATCTTTCATCC
TTGACTAAATTCGTGATTTTCAAGCAGCATCTTCTGGTTTAAACTTGTTTGCTGTGAACAATTGTCGAAA
AGAGTCTTCCAATTAATGCTTTTTTATATCTAGGCTACCTGTTGGTTAGATTCAAGGCCCCGAGCTGTTA
CCATTCACAATAAAAGCTTAAACACATTGTCCAAAGG

</dna_sequence>
        <protein_sequence>>NP_001012530.1 gastrin-releasing peptide isoform 2 precursor [Homo sapiens]
MRGRELPLVLLALVLCLAPRGRAVPLPAGGGTVLTKMYPRGNHWAVGHLMGKKSTGESSSVSERGSLKQQ
LREYIRWEEAARNLLGLIEAKENRNHQPPQPKALGNQQPSWDSEDSSNFKDVGSKGKGSQREGRNPQLNQ
Q

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene292">
        <gene_name>H2-K1</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>14972</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>133922588</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AB114280</gene_refseq>
        <protein_refseq>NP_001001892</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>17</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>33996011</gene_start>
        <gene_end>34000340</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>transcript variant X11</protein_name>
        <protein_pi>6.35</protein_pi>
        <protein_weight>38523.57</protein_weight>
        <protein_length>369</protein_length>
        <protein_note>Also known as K-f; H-2K; H2-K; H-2K(d); MGC7052; MGC184092</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000083.6:33996011-34000340 Mus musculus strain C57BL/6J chromosome 17, GRCm38.p4 C57BL/6J
ATAGTGACCCAGATTCTGGAAGTTTATTCATCTATCATTTATTTCTTCAAAAAAACAAATCAATCAAACA
AACAAACAAAACCTCTAAGCATTCTCAATCCATGAAATTAACAAGAAATCAGCCCTAGGTCAAGATGATA
ACAATCAAGGTTACATTCAAATTATTATTCTCAGTGTGGAAGTGAGGAGTTGCAGGTCAGGGTAGCATGG
AGCTGACAGGCTACAGATGTCCCTCAGTGTTTGGCTGAACCAGCAAGGTTGGCTGTGGAAGGGAAGACAG
AGCAGTGCAGGGACAGGGTCCTGGTGTAGAGGGGTGGACTGGGCTCCACAGTTCTTCACATTGAGTCCAT
AGGCTCACAGGGAACATCAGACACTTGACTAAAGAGAACTGAGGGCTCTGGATGTCACAGGAGATATGAG
AAGACATTGTCTGTCACCAAGTCCACTCCAGGCAGCTGTCTTCACGCTAGAGAATGAGGGTCATGAACCA
TCACTGTGAAGACAACATTCGAACAACCCATCACTCACTCACAGGGGATTCTGGGAGTTCCTGAAACCCA
ATCATGTCCACATTGCCCCTCCCCAATCAGACCCTAGAGTGTCACCTTTACAATCTGGGAGAGACAGATC
AGAGGTCTGGGAGCCTAGGGTAAAACAAAACAAATGTATATGCATATGTACATGTACATATTCATTTCAT
GGCACAACTCAGGCACCTAGAAGATTTCTCTGGAGGAGCTATTATGGATTCCCAGAGCTCCCATCATCTC
CAACTTCACTCCAATGTCCCCAGGACAACTCTGTCCCCACACTAACCTGGAGCCAGAGCATAGTCCCCTC
CTTTTCCACCTGTGAGAAGAAAAGCTGTGAGAGTTCCAGGAAGATCTTGACACTAGGAAGTTCCCAGAAC
TGACAGCAGACCCAGTTAGAGACAGTAGCAATGTGGGGTGTGCCTGTGTTCCCCATTGATGAGCAGAGCA
CACTCTAAAGGAGGCTGAGAGAAAACTCAGACTCTGCCCTTTCCTACCTGTGTTTCTCCTTCTCATCTTC
ATCACAAAAGCCACCACAGCTCCAGTGACTATTGCAGCTCCAAGGACAACCAGAACAGCAACGGTCGCCA
TGTTGGAGACAGTGGATGGAGGAGGCTCTGGGAAGGACAGGTACAAGAAATGAAGGTGAGGGTCATGACC
CCAGCTCTCAGCCCTGAGCAGCTCAGGGTCTGCAGAAAGCTCCAGCTTTCCCTGACCCCAGCTCTGCACC
CACACTCTCCTTACCCCATCTCAGGGTGAGGGGCTCAGGCAGCCCCTGATGGTACACATGGCATGTGTAA
TACTGCTCCTTCCCAAGAGGCACCACCACAGATGCCCACTTCTGGAAGGTTCCATCCCCTGCAGGCCTGG
TCTCCACAAGCTCCATGTCCTGGATCAGCTCCTCCCCATTCAACTGCCAGGTCAGGGTGATGTCAGCAGG
GTAGAAGCCCAGGGCCCAGCACCTCAGGGTGACTTTATCTTCAGGTCTGCTGTGATGGGTCACATGGGCC
TTTGGGGAATCTGTGTGGAAGATTTAAGAAATCACACAATTAACAAGACAAACTGAAATCTACCCAAGAC
TCAGTTAAATCAATGATGACAGTGAACTATGTGTCTGTTTGACACTTCAACTGTCATCGCACTAGTGACC
AAAAGCAGAGCTGGTCCCCTCAGCACAGGACTGCACATTTTCTTTTGGGACTCAGAAGCTAAGAGGGAAT
CCACATGAGCCATTGGGTAAACATGGCCATCCTTATGTGATGTTCAATAGCATGAGAGAGGTAGTCAAAG
AATGGAGGAGGGAATGGAAAATAACTAATTTAATATGTGTTTGAGTTCATATTAAAATTAGGGCTGTATG
ATCCTGGAAGGTGACACCATTGAGACTCAACCATTGTAGTCACCTTGCTGACCAACATTAACTGTCAGTC
CAAGTGAACAGCCATCACTAAGTGTGTAGCCAGAGAAAATGACTCCCAGCCCCTGACTCTGGGGGACAAG
GTACAGGTGTGTCACACAGGATCCCTGGAGTGTGCTGTGGACCCCAGTGCAGCACTCACTGGAACACAGT
GGGCTCACAGGGTGTGTGGTCTTCCCTCTCACTCAGCCCTGGATTGCAGAAGACCCTGCCTCTCAGAGTC
CAAGTCCTGATTTACTAGCGGGAGGGAGCACTGTAACTTGTGGGGCAGAGGAAGAGCAGGAGGCTTCTGC
ATGTTTAGTTCTGACAGGAAACAGTCTAAGTTCACAGGAATCTCTTCTTTAATTCGAACCCTGATTTAAC
TTGTCTAATTATCCAGGTTAGCAGCCTTCCCTGGCACCTGTGGAGACTGAAACAAATGATAATAGGAGGG
CATGGAGAGACTGGATCACTCCAATGCAGACAAAAGCTGACTAGAAACAAAATAAGCCCCCCCCCCCACC
AAAAAAAAAGTTAAGAAAAAAGAAAGGCCAGGAGTGGTGGCACATGCCTTTAATCCCAGCACTCGGGAGC
CAGAGGCAGGCAGATTTCTGAGTTCAAGGCCAACCTGGTCTACAAAGTGAGTTCCAGGACAGCCAGGGCT
ATACAGAGAAACCCCGTCTAGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACGGAAAGAGA
GAGAGAGAGAGAGAGAGAAGAAAATCCACGATTTATATTCCTCCAGGGTAGCCCATAAGGGCTCATGTGA
CCATTCACCACTGTAGGAATAGATAGAATTGGGTTGTTAAGGGGTGCAAAACCCCACAGACAGGGAGGGA
TCTGTGAGAATGTATTCTTTGGAAAATTCTAGAAACTAGGTGAACCGTCCTAGTGTAGAGGAGTCCATGT
CTCTTATCAGGTAAGGAGACTTCCGGTCCTGAGGTGTAAGGGCTGACACATTCAGCAGGACAGGAGTCAG
TGTCTACAGACAGTGGGCGTGGGCAGAGAACCCGGCCTGGGAGAGGCCATGGCTGACAGAGGCTGCAGGG
GAACTGAAGGGAGCAGCTGTTGTTACCTCAGGGAAATTCTCTCCTTCCCTCCTGAGACAGCCTGGGCACT
GTCCAGGGAGAAGGCTGAGCCCTGGGAGAGTCAGTGCAGTCACTGTGATGAGGGATCAGGAGACCAGCGA
CACTCTCTCCCCTCTGAGACAGGGGCATCACCCCAGCTGAGGGTTTCTTCTTCCCCAGGACTGAGCCCCA
GCCCGAGGGCAGAGGGAGGAGCTGCCCGCGGCCCCTGCACCTGTGCGCAGCAGCGTCGCGTTCCCGTTCT
TCAGGTATCTGCGGAGCCACTCCACGCACGTGCCCTCCAGGTAGGCCCTGAGTCTCTCTGCTTCACCAGC
CTGCTCCCACTTGTGTTTGGTGATCAGCGCCGCCATGTCCGCCGCCGTCCACGTTTTCAGGTCTTCGTTC
AGGGCGATGTAATCGCAGCCGTCGTAGGCGTACTGCTGGTACCCGCGGAGGAGTCGCCCGTCGGACCCCA
CTTCACAGCCAGAGATCACCTGAATAGTGTGAGAGCCTGCGGGACCCCGCGGTCAGCCCCGCTCACCCGC
CCCGGCCCCGCCCGCCCGCGGACTCCTCCAAACTGAAAGAGAAACCGGTTCCGGGTCCGTTCTGTTCCCG
AACCTCGGACTTGGGACCCGGGACGTCAGCGTCCCTGTGTCGGGACGTGGAGGGGTCGTGACCTCCGACC
CGGGGTCACTCACCGCCCTTGCTCTGGTTGTAGTAGCCGAGCAGGGTCCTCAGGTCCACTCGGAAACTCT
GCTCATTGCCCTTGGCTTTCTGTGTCTCCCGCTCCCAATACTCGGGCCCCTCCTGCTCCATCCACCGCGC
CCGCGGCTCATATCTCGGATTCTCCGCGTCGCTGTCGAAGCGCACGAACTCCGTGTCGTCCACGTAGCCG
ACTTCCATGTACCGGGGCTCCCCGAGGCCGGGCCGGGACACGGCGGTGACGAAATACCTCAGCGAGTGTG
GGCCTGGGGGCGGCGCGCGGTGAGACCCGGACCACCTCACCAGACCCCGGGCGGCTGCGCGGGCTGAGAG
GGGAGCAGGGCGCGGGACTCGGGTGGAGAAGGGGCGGAGGGTCCGGTGGGCGACCCGAGGACGCGGCTTC
CCCGGTGCCGCCCCTCCCCTCAGAGGCCGTTTCCCTCCCGGCCCGGTACTCACCCGCGCGGGTCTGAGTC
GGAGCCAGGGCGGCCGCCAACAGCAGGAGCAGCGTGCACGGTACCATCGCACCTGTCGGCGATTCGCGAC
TTCTGAGTTCTGCGGGCTGCGTGGACTTTATATCCAGCGTCCGCGGCGACACTGATTGGT

</dna_sequence>
        <protein_sequence>>NP_001001892.2 H-2 class I histocompatibility antigen, K-W28 alpha chain isoform 1 precursor [Mus musculus]
MVPCTLLLLLAAALAPTQTRAGPHSLRYFVTAVSRPGLGEPRYMEVGYVDDTEFVRFDSDAENPRYEPRA
RWMEQEGPEYWERETQKAKGNEQSFRVDLRTLLGYYNQSKGGSHTIQVISGCEVGSDGRLLRGYQQYAYD
GCDYIALNEDLKTWTAADMAALITKHKWEQAGEAERLRAYLEGTCVEWLRRYLKNGNATLLRTDSPKAHV
THHSRPEDKVTLRCWALGFYPADITLTWQLNGEELIQDMELVETRPAGDGTFQKWASVVVPLGKEQYYTC
HVYHQGLPEPLTLRWEPPPSTVSNMATVAVLVVLGAAIVTGAVVAFVMKMRRRNTGGKGGDYALAPGSQT
SDLSLPDCKVMVHDPHSLA

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>A mouse H-2Kb (H2-K1) gene was introduced into two poorly immunogenic tumor cell lines, a mouse colonic carcinoma cell line, MCA-26 (H-2Kd), and a rat mammalian carcinoma cell line, LN-4, in an effort to stimulate tumor rejection. Results showed that the expression of xenogeneic MHC class I antigen completely abolished the LN-4 tumorigenicity in rats, whereas the expression of allogeneic MHC class I antigen only partially reduced the MCA-26 tumorigenicity in mice.  The immunized rats that experienced LN-4/H-2Kb tumor regression further developed protective immunity against a subsequent challenge of LN-4 cells.  Adenovirus-mediated H-2Kb gene transfer in vivo can further significantly inhibit pre-established LN-4 tumors [Ref952:Campbell et al., 2000].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1350">
        <gene_name>HSP47</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>51450</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:239001
GOA:P19324
InterPro:IPR000215
UniProtKB/Swiss-Prot:P19324</xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>heat shock protein</protein_name>
        <protein_pi>9.16</protein_pi>
        <protein_weight>44286.67</protein_weight>
        <protein_length>470</protein_length>
        <protein_note>Heat shock protein 47 (Hsp47), also called colligin, because of its collagen binding ability, is a chaperone specific for procollagen. It has been shown to be essential for collagen biosynthesis, but its exact function is still unclear. Hsp47 is a...; cd02046</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>CAA43091.1 heat shock protein [Mus musculus]
MRSLLLGTLCLLAVALAAEVKKPLEAAAPGTAEKLSSKATTLAERSTGLAFSLYQAMAKDQAVENILLSP
LVVASSLGLVSLGGKATTASQAKAVLSAEKLRDEEVHTGLGELLRSLSNSTARNVTWKLGSRLYGPSSVS
FADDFVRSSKQHYNCEHSKINFRDKRSALQSINEWASQTTDGKLPEVTKDVERTDGALLVNAMFFKPHWD
ERFHHRMVDNRGFMVTRSYTVGVTMMHRTGLYNYYDDEKEKLQMVEMPLAHKLSSLIILMPHHVEPLERL
EKLLTKEQLKAWMGKMQKKAVAISLPKGVVEVTHDLQKHLAGLGLTEAIDKNKADLSRMSGKKDLYLASV
FHATAFEWDTEGNPFDQDIYGREELRSPKLFYADHPFIFLVRDNQSGSLLFIGRLVRPKGDKMRDEL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1343">
        <gene_name>HuD</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>1996</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>221316767</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AL583843</gene_refseq>
        <protein_refseq>NP_001138246</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>1</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>50048013</gene_start>
        <gene_end>50203785</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>transcript variant 7</protein_name>
        <protein_pi>9.83</protein_pi>
        <protein_weight>38195.22</protein_weight>
        <protein_length>366</protein_length>
        <protein_note>Also known as HUD; PNEM</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000001.11:50048013-50203785 Homo sapiens chromosome 1, GRCh38.p12 Primary Assembly
GAGGTGGGCAGGGGGTGGCGGCGGCGACGGTGGCGGAGCCGCAGAGCGAGCTAGAGAGCGAGAGCGGTGA
GACTCTGCGGACGTCTTCCCGCCCGCCGCGCTCCGCCCCACCCAGCCTCCGCAGCCTCGGGCCGGATCGC
CCGGCGGGGAAGATGCGCCTCAAGAACCAGGTAGAAGCGCCTCGGCGCAGGCCCCGCACCCCCGACTCTG
CCCGCCCTCTGTTACGGACACCCGCTGGGCCACGTGGTCGCGACTGGCTTCTCCCAGCGGCCAGCCTGGC
CACCCCGACTCCCAGGGAGGGGGAGAGGGCCCTTGCAAGAGGATCCTGCCCCCGCGCTGCCCAGACCTGA
GGGCTCCTGGCGACCCCACCCGCAGCCCATCTGGCGGCTCTGGCCCCGCAGGTCAGGGTCACACCCCTGC
CGGCCTCCTGAGACTTCCCGGCCCCAGGGGAGAGAGCTGAAACTTGGGTTGACGCGCGCCCCCTCCCCAG
CGACAGGCGACCCCGCAGCAGCCCCGCGCCACTCCTCTCTGCGCCTTTCCGTAGTTGTCCTCGAGGTGGC
TTTGTTGAACGTCCTGGTGGCGCCAAAAAGTCCAGGCAGCTTCGGGCGATCAGGGTCCCGAGGCGCTGGG
CGCGCGGACTTGGATCCTCAGGGGGCCCCTCTGTGTGACTTTCGCTAATTGTCTCACAGGGAGGGCAGCA
CCCTCCCCTATCTTTCCTCTATTACACCCCGCTGTGGACCTGGGACTTGGGTATTTCTAGACGAGATTGG
GAAGGCGCGTGTGTTACACTAAGCAGTGCTCATGTTTAGCTGAGGAAGAAGGAGCCTCAAGTGTTCGTAG
GGTGTACCTGTGTATGTTGTAATTGTTGTCTCTCTTTGGGCTGGGGGCTGTTATACATGTAGGATTTAGT
AAACACAGGTCTTGAAGTCTTGAACCTGCAGGAGACTCATTTGTTTCTACAAGGAGAGAACCTCCCCTCC
CCCAACATATGTTAAGGGACTTGAGGAGACCACAGGGAAACCGAAGGGAGGGACTTCTAGAAAACAATTC
CAGGTTTGGGGGAAAATGAGTCATATTGATTCCCAAGCTGTTAGCCAATACCACTCAAGGGTAATAATTT
TCATAAAATCTTCCCACTGGGGACTTAAATACAGGGCTCCACAACACAGTTTGTTGAGAGCTCTCTGGTG
CCTTTAAGCCTATCCATGCCCCTTACCTAAATGCTTTAATTTAGTAGAGCTCCTTGAGAAGCTGCCTCAC
ATTATCCTCCTGCATTTGTGCGCCTAGCTTTTAATATTTTATAATACTTGCAAATTGACACTGAACAAGC
TTTAACCTCCATCATTTCAGAATAAGTTTGATGTTTTAAGTGAGATGTGAATGGAACTCCATTCATGAGG
GAAGTAGTCTGTGTGAAGTGTTTTGTAAATGTGAGTGGGTTGAGTTTAAAACACTGAATAAAATTAACGT
AACAAGGAATCAAAAGGTTCAATCCAGATGTTTGCCTCCTTGCTTCTTCAATAAAGTGACAGTACAATGC
TGCATGACACCACTTGCTTCCTTAATAAAGTGACAGTACAATGCTGCGCGGCACCTCTCCTTTCAGTTTT
TAGGTAGGGTAGACTGTGGCACTGTGGCTTATGGGGTCAACCATGAGCAAGTGGATGGCTGGATTCCTTC
CATTCATTTTTTAAAGCACTAACAAAATCCTTGGGGCCGATGGGGTTGTGACCCACCCACCTATACAGAG
GATTTTCCTCCTCTACTAACTACTCTAGAAATACATGAGGGATTTACATGCAGGTTTTTAGTTGAAGAAC
TAAAGTAATCCTCTTTAGTTATCATTAGTATTAGCCTCTGAAACCTTTACTTGCTTGCTAAGATAAGGTA
CTTGGGTGTGGGTTGTAATAGAGGTGGAGTTGTGAGTTAGAGCTGGTGGCCTTACTAATTCCTCTACTTA
CTGTGTGCTTTGGGTTGACAGAAAACTCCTTAGCATTTGTGTAAGTGCAATATAGTTTAGCATGAGAGAT
TTTAAATTAGATATTCTTGGTTCCGGTCTGACCTCACCACTCAGTAGTTATGTGACTTGCATAATTAATT
TTTTGGTCCTTCCTGCCACTTTTTTCGCCATAGATACATGGGGTTAATACCAACCTCGTAAAGTTGACAT
GAGAATTAATATTATATATGTACAGTGCCTGCCATATGGGCATTCAGTAAATACTGCTATTATCAACCAA
ACATAAACAGTAGCTATTACCACCATTGCTACTACATCTGCTTAAAAATGGCTCCTTGTAGTTGGGGAGG
GAGATTTGGCTACAAAGGGACAGGAGGGAGCTCACTGGGGTGACTGAAATATGCTTTATCTTGATTGGGG
TGTTGGTTACAAAGGTATATCCATTTGTCAAAACTCATCAGAGTGAACCTTTATGATCTGTGCATTTGAT
TTTATGTGCATTATATATCAATAAAGTTCATGCTTAAAATTAACATCCAGATGTGTTAAGTACATGCCTT
TGGGAGGCCTAATTCTGCATAATAGCATACCTTCTTCGTAAGTTTATCCTGAGCCACAGGAAAGTTAGAG
AAGGTGCTTTAATTTTTCAGGTTGATGTCAGGAGTGATGGTCCATGGAAAAAAGTGATTGTCTTGTGCCA
AGATTATATTTAATTTGGTACTAGTTTTCATTAGTAGCTTAAAAAAAATTGAAATGTTTTATTTGAGCAG
TACTGCTCATTTGCATAATATGATAATGGATATTATAATATCCATCCATTATTCACAGTTGCTGAAAAAT
CATAGTGATTTTGCATCCCTTTTCCTGCTTTCAATAAATTCTATGCATTGTTTTAGCTAAGTGAAATATG
TAAAGTGTGTTTAGCACAGTACCAGGCACATGGTAAATACTGATACATGCTAGCTGTTAGTTTTTAAGTT
GATATATTCAAATTCATCTTTTTTATAGGGCAGAATCAACACTATATAGATTATAATATCAATCTATCGT
AAATATGCTGTTAAAAGTTTTTGAGGTAGAAACAAGCCAAAAATTATTAATAAAATGTTGTAAAACTGAA
ATCTCACTTATCTAAACTTAGTAGTCATGAACTTTTTACAACATTATGTCTTGGGAATATAGGCAAATCT
GTGAGGGAAGCAAAAACTTTTCTCAAAAGCAAACATATATCCACAAAGAGTATGCTAACTCATTTACTTA
GAGGCAAGCTCCTCTCATATTCCCTCAAGCCTTTTTATTTTTACTTCAGACATAGTTCTAACATGTTTAG
TTCCTTAGTTTCTCAGCCTATAGTAGTTTAGAAGCCTTGCTAGATACAAGTTTCAAGAAATATTAGCTGA
ATGTAAGGGGCGAATGAATTATAAAGATAAGACATGAGAAATCAGTCTTATTCTTGGGCCAAAGTAAAAC
TTGAATTAGAGTACTGAATAGTATTGCTGATTTATTGGACATTTTAATTTTTATTCTTTAAAAAAGTTAA
ATTGTATATTCTCTCTAAAAAGTGGGGCAGTATATAATGATGTATTTTAGAAACATTTCCATCTGATAGG
ATTAGATTACAAACTTAGGCTTGTTAAGGGCAAGCTTCAGTTATCTGGATATCTTACTTAATGTGGAATG
ACTTATTCACTCATGGTACTGCATAAATGAGGCATCTATCAACTTGTGATTTTTTTATTGGGAACTGGAT
TTTTAAAATCTATTTCATCTTTTGATAGAACAATATGATGAGATGAATCATACATAGAGTATTAGTTTGC
TAGGGCTGCCATGACAAATATCACAGACTGGGAGGCTTAAACAACAAAAATTTATTTTCTCACAGTTCTG
GAGGCTAGAAGTTCAAGATGAAGGTGTTAGCAAGGTTGTTATTCTGAGATCTGTCTCCTTGGCTTGTAAA
ATGGCTGTCTTGTCTATCTCTTCATATGTTCTTTGCTCTGTTTACGGCCTAATCTCTTCTTTAAGAATAC
CAGTCCTGTTGGATTAGGGCCCACTCACATGACCTCCTTTTACCTTAATTACTTTTTTAAAGGCCCTATA
TGAAAATACAGTCACATCCTGAGATACTGGGGGTTAGCACTTCAACATATGAATTTGAAGGGACTTAATT
TAGCCAGTAACACATGGTTTTAGTAAAAAGCTGTATTGATTCTTTCAAAATAATTCAGCATGCAGAATAT
GAAACAGGTGAGATTTTAATTCTTGTTTTAGAACAGTTCAATTTGGATTTACATGTGAGAAACCCCAAAA
TACTCATCATGTACCAACACACACACATACAGATACACCTACACATACACACCCCACACTTTTTGTGTGT
AAAGCTGATTATAACTGAAGCTGAGTTAGGGTCATTGTCCAAGCTGAGTTTAATCTGTGATAAGGTCCAC
TAGCAATGTCTTTCATTGATCAAAAAAGACAGCTGTGCAGTAGCTTCCTAATCTTTCTAGTTTTATAGTA
TCTTAGGTGATGGAAGCAGAAGGTTTGACTTTCTCAGAAGAAACCATTTACCACTTTGATACTTTCATAC
CCCCTTGTCATTTGAGCTCTTTGACCCTCTGGTATCTCTGAAACAAAATAATTATACTAATCCCTTGATG
CATCTTTTCCACATATTCAAACCATGAATTTATGGACCAAAATTTGCCACACAAGCACCTTTGTTCACTC
AAATCAGAGTCTGGCAATAGTTTACTCAGAGGAACCTAAACTGCCTACTACACAGTTTATTCTCCTCACT
AGTTTGAAGTTCATCTCTGTTCCACATGTTCATGCATCAGAGTATGATATTTTATCCAAAGAAAAGAAAA
AACTGCTAAACTTATGTTGTGCAAAAATGACTCCCAAAAACCCTATGTGTGTTACTGTTACTACCAGTTT
GTGCTAATTTGCACAGCCTCTGAACAACTGGCAAAGTGGCTAGTGTTGACATTGCAACTGCTACGGAGTT
CCCAGTTGCTGTAGGAATTTTTAAATTTTATTAGTATAATAACAGAGTTTACAGTTATTCACAGTATGTT
AATTGCAAACGCTTATTATCTATAGTACCAGCTTGATACTTGATCTTATGTTTCTTTTAATAGAAATACT
GCAGCTTTTACTTTTCATTGTAATGAAGGTTAATCATCACTATGAATTTTCACCTATGAGCAACAATTTT
GCAACAAGTTATAGTTGGGGTGAGTCTATTATATTTAAAATATAACACCAAAATAGCTTCTTTTTGTACT
TTTAATACTTCCATTGACAAACAATTGCTCATGTCTCTGAGCCTCCTACAACCATTTCAGATGACTGATG
GATGATTGGTTTTTGTTTTTTATGTTTTGTGTTTTTGAGACGGTCTTGCTCTGTCACCCAAACTGGAGTG
TAGTGGCATGGTCACAGTTCACTGTAGCCTTGACCTTCTGGGCTCAAGCAATCCTTCAACCTCAGCCTCC
TGAGTAGCTGGAACTACAGGTTCACGCCACCAAGCCTAGCTAATTTTTGCATTTTTTTGTAGAGACAGGG
TCTCTCTATGTTGCCCAGGCTATTCTCAAACTCCTGGCCTCAAGTGATCCTCCCACCTCAGCCTCTCAAA
GTGCTGGGATTATAGGCAAGATTGATTGATAGATTCAGTGAATGTTTATTGAGTGTCTGGTATGGACCTG
GCCCAGTTGTAGCTGTTTAGGATGTATCAGTGAACAAAACTCAGCTATCCCTGTCAGCAAAGGAACAAGA
GAAAGTAGACATTAAAAATAACCATAATCAAGAAGTGCGTCATAGAGCACGTTAGACAGTTATAAATGCT
ATGTGGGAAAAAAAATAGAGTAAGATAAAGAGGGATAAGGATTCCAGTGGAGGATTGCAGTCTTGAATAC
AGTAGGCCTCACTGGTAAGTGATATTTGAACAAAACTTGATGAAGATGAAGAAGTTTTAGTTGTGTGGCT
ATCTGGGGGTTATAAGCAGAGGGAACAGCCAGGGCAAAGGCCATATGGCAGGAGTATACCTAGAGGGGTT
CAAGTTACAGCAAGGAGGTCAGTGTGGCTTGAGAGGAGTGAGCAAGGAGGAAAACTATTGTAAATTGAGT
TATAAGTTTTATATACTGAGTAAATGTTGACGTAAATATTGTCTACCAGTAAGTAGATGCTTAGCATAGT
GATTCTCTCCAAATGCTTGTTGAATGTTTCTTTGGCAAATGAATTTGTGCTTATAAGAACTGGTTCTGAA
GTGCAATAGAAAATGGACTTCTGCTAATTCTGCTGCTGGCAGAAGTTAGATTAGGATCTGGAAAAGGGAG
GAAGGCAGGAAAACAACCTGGTAGATGCTGATGTGTAGGTGTCTGAGTCCTGCCCAACCATTGTCACTCC
CATCTTGCCAGGGGAATTAATTTTTCACTTATTTAATACTGAAAATTCCCTTTTCTGTTTGATTTTTGTC
CTCATGATTGGAACTTTTAACCAGAAAGAATAAATTCCAGTGTAAAGAATATACTAGATTTAAAAGTGTG
AGATCTGTCAACCTTAGAAGACTCATACCATAGATTGGTATTATTCTTTTTTGTTTATTTCTTATAGGAT
AGACCTTATAATTATTATATTTGTGTATTTTGTTTACAGTTTACAAAGTATTTTTACATATATTAATATT
ATTAATTTGATCCTCACAGCAAATCTATGTGAGAGGTGGACAGCCATTATTAAGTTTTGGGCTGAGTATC
TTTCATTTGCCCTTGAGATGTTACTCTCTACCCTTTTCCCAATCCTTTCTGTGGCCTTAGGGCTGACCTT
CATAGCTTCATCAACAAGCTCCCTTGCACTCTTGCTTCTGGAAGGATTCAGCCAATACGGAGCACTTACA
GGATATCTCAGACAGAAGAAAAGTGAGTTTGGAATATTTACTTCTCCAGCTCCCTCCCTTCCAGGTTACT
GGCTAGCAGTGGCTAGCAGTGGCTGCGTGGAGGCCACATCACCTATCCAATCTACAGCTACAGCTTTCTC
TCTCTCTATGGGTTCTCTCAAGATCTAGGGCTGGGTCTCCACTGTTTCTATCTTCAATGACTTATCTTCA
TTAAATCCTGCGCAATTTCCCTTTTTGAATATGCCTTCTGTTTCCTGTTGAGACCCTGACCAAGACACCA
CTTTAAAAACGACAGTCTTGGAGAAGTTGGATGACTTGCCCAATAATAGATATCCAGTAAATGACAAGAA
TAGGGACTTAAATCCTGGTTTTGTGACTTCAAAGCATGATCAATTTGTTTTGTTTTTTTTTTGTTTTGTT
TTTGTTTTTGTTTTTGTTTTTGTTTGAGACAGAGTCTCGCTCTTTCTCCCAGGCTGGAGTGCAGTGCCGC
GATCTTGGCTCACTGCGAGCTCCGCCTCCTGGGCTTACACCATGCTCCTTCCTCAGCCTCCCGAGTAGCT
GGGACTACAGGCGCCCGCCACCACACCCAGCTAATTTTTTGTATTTTTAGTAGAGACGGGGTTTCACCGT
GTTAGCCAGGATGGTCTTGATCTCCTGACCTCGTGATCCACCCGCCTCGGCCTCCCAAAGTGCTGGGATT
ACAGGCGTGAGCCACCATGCCCAACAATCAATTTTAAATATACCACAAAGGAACTTATCCCAACTGGTGG
ATAGTGTTGAAAAAATCTTTCTACTTTGACCTTCAAAATTCTATATAGGCCAGGCACGGTGCCTCACGCC
TGTAATCCCAGCACTTTGGGACGATCAACAAGTTATTTATTGAGCAAATGACTTAGTATGAGGCTCCTTC
AACGAAAACCTTTACAGGAAAAGTTTTGAAGTTGTGCTGACTTGAGTTAAAATTTCAGAGAGGTAGGGTG
GAGATGGGAGTAAGGAGAAAATAAAAAGCAAAAGTTCTGAGTAGTCATCAACTGCAGACTGCCTAAATAG
GAAGTCTACGCCAGGAAGTCATGTTTTTGCTGCTGGAGGTTTGAGTAGGACTCTGTATAACTTTGCTCTC
TTATGCAACTTGTGATTGATCTGGGTTAGTTGGCTCTGCTGCTATTATAAAAGGGATTTCCTTTTCTTTC
CCTGGAGATTGGGTGCCCATCTTTTTCCCTACATTTCTGATAGTAAAGGTCTTTTTATTCTCACAGCATG
AGTTTCTGGACAAAGGGTCATCTGGGAAGCAAAAGTTGAGGATCTTACTCAGGTCACTGGAACTAGTGTT
CTAGAAGTGCCTGGTGCATGATGGTAATAATATAAGTCACACCCCAAGTTTGTATTACTAATAAGAGTTT
TGTACTACAAACTTTCCCTGTCTGTTCTTGTTGAGGGGGAAATGGCACTGAGTGTAATACTGTATGGTCA
TGCACCACATAAGTACGTTTAGGTCAACAACGAAGTTCATTTATGATGGAGGTCCCCTAAGATTATAATG
GAGCTGAAAAACTCCCATTGCTTAGTGACATCATAGCCATTGTAACATCGTAGCATAATACATTACTCAT
ATGTTTGTGGTAATAGTGGTGTAAACAAATCTACTGTGCTGCCAATCATATAAAAGTATAGCACATACAA
TTATGTACAGTATATAACACTTGATAATGTTAATACATTACTAGGTAACTGGTTTATGCATTTACTATAC
TATATTTTTATCATTATTTAAGAATGTACACCGGCCGGGTGAGGTGGCTCACGCCTGTAATCCCAGCACA
TTGGGAGGCCAAGTCAGGCGGATCACGAGGTCAGATCGAGACCATCCTGGCTAACACGGTGAAACTCCAT
CTCTACTAAATATACAAAAATTAGCTGGACATGGTGGCGGGCGCCTCTAGTCCCAGCTACTCAGGAGGCT
GAGGCAGGAGAATGGCGTGAACCCGGGAGGCAGAGCTTGCAGTAAGCCAAGATCGTGCCACTGCACTCCA
GCCTGGGTGACAGAGCAAGACTGTATCAAAAAAAAAAAAAAAGCACACCTACTTATTTTAAAAAATAGTT
TATTGTAAAACAGCCTCAGGCAGGTCCTTCAGGAGTTATTTCAAAATAAGGCATTGTTATCACGGGAGGT
GACAGGTCCATGTTTGTTATTGCCCTTGAAGACCTTCTAGTGGAACAAGATGTGGAGGTGCAAGACAGTG
ATATTGGTGATTCTGACCCTGTATGGGCCTAGGCTACTGTGTGCATTCTTATCTTCATTTTTAACTGCAA
AGGTTTTAAAAGTAAAAAAAAAAATAATAGAAAAAAGCTTATAGAAAAGGATATAAAGAAAGAAAATATT
TGTGTACAGCTGTACATGTGTTTGTGTTTTCAGCTAAGTGTTATTATAAGAGTCTAAAAGTTTAAAAATT
TATAAAGTAAAAAAGTTACAGAAGCTAAAGTTAATTTATTATTAAAAGAAAAAACATTTTTATAAATTCA
GTGTAGCCTAATTGTACAATGCTTATAAAGTCTACAGTAGTGTACAGTAATGTCCTAGGCCTTCGTATTC
ACTCAGCACTCATTCATTGACTCACTCAGAGTAATTTCCAGCCCTGCAAGCTCCATTTATGGCAACTGCC
TATAAACATGTACTGTTTTTAATCTTTTATTCTCTATTTTACTGTACTTTTTCTATGTTTAGATACACAA
ATACAAGCATTGTGTTACAGAGGCCTACAGTATTAACTAGTCACATGCTGTCCAAGTTTGTAGCGTGTGA
ACAGTAGGCTATCCCATATAACCTAGGTGTGCGGTAGTCTATACCACCTAGGCTTTGTGTAAGTGCATTC
TGTGATGTTTGCATGATGACAAAATTGCCTGACGTATTTCTCAGAACGTATCCCCATTGTTAAGCAACAC
GTGACTGTACTATAATATGATGTCAAGTTACCATGTTGTTTGGGACATATGACAAGAACAGAGCTCAAGA
AACTTTTGTATACATGGGACAATCTTGTGAGTTGAAATAATATTTCTCTCACCTTCAAGGGTGTGATTTA
TTCTTTTTGGGTATAAATTATGCAAGCAAAGCTAGAGTATTCTTACAATAAAATAATTTTAAAAGACAGC
ACCGAAACATTTTTCCAAATTAAAGGAAGCTTGAGTTATTTTTTTCTGATTTTTGAAATGGAAGAACCAG
TCCACGGGGGGAAGTGATCAGAGTAAACTAAAATTTAGTGCTATGTCCCTCTAATCACAAAGTGGTGTCA
TATAGGGGTCACAGTGGACCATGATCTGCTTTTATAGATAAATGATGTTCTGTGGGAGACGTTCTCCAAT
TCATAAGCTAGAGAACAGATTTAAATTTACAAAACCAAATTGGGATAACCAGTACTGTAAACACTGTCAT
TATAACCATGGAGCACTAGATTGATGTGAGATGGATTGACATTCAGCAGGGGTAAGGACAGGATAGGATA
TATAGGAGGAAACCAAACCACAAAAAAATTAAATGGGAAATTTTGAAAGGGGCAGCATTCTTACCTTATG
TTTCTATAGCACCCTTTCACTTTTCTTTTACACTTATCCACATGGAAAGGTTGTTATAAAGGGAGCATGA
AAATTGAAGATTAAAAAGTAAAAATGACTTCACTTGACTAGCCTAAAGAAAAAAAAAAAGTAAAAATGGA
CCTCCGCATTAATGGTAAGAATTCTAAGATAATTCCTTTTTTTTTTTTCCTGACAGTGTCTTACTCTGTC
ACCCAGGCTAGAGTACAGTGGCACGATCAGGACTTACTGCAGCCTCCACCCCCCAGGCTCAGGTAATCCT
TCCACCTCAGCCTCCTTAGTAGCTAGGACTATAGGCATGCACCACCATGCTTGTATTTTTTTTTAGAGAT
GAGGTTTCCCCATGTTGCCCAGGCTGGTCTCAAACTCCTGGGCTCAAGCAATCCATCCCCCTGAGCTTCC
CAAAGTGCTGGGATTACAGGCATGAGTTACCGCACCTGGCCCAGGATAATTCTTTTATTATAAGTGTTCT
TGTTCCTTTATTCACTATTCTGGTTAATGGCACCACCATTTACCCAGTGGCCCTAGGCAGAAAAATATTG
AATCTAGAAATTATCCTAGATTCATTTTTCTTCCTTACTGCCTGCATTAAATTTTTCAGTCTCTGGGTCC
AGGTGGTCAAACTGATACCTTTAATTAGCCAACATTTATTGAGTGCCTAGTAGAGTGGTATAAATAAAAA
TTGCCACCCTTGTAGAGCTTGCATTTTCTTAAATATCAATCATATTTCTCTGATTCTAAGATAAGATTTC
TGAGATGGAATGCATTTTACAATAAAGTTTAAAAAATACTACACTAAAACTTAGCAAGTTGTGATGCAGT
TGTCATTGCCTATACATGCACGGACTTAGTGGAGCTCACAGAAAGTACCTGTTAAACTGTCACTTCAGTT
CATTTATTTGCATTTGGAAGCCTCATATAAAATGAAATTTTAACTGAAATTTGGATCCCTGATTGTTATT
TAAAATGTTAAGAAATAGCCAGCAAACACATAAAAAGATGTTCAGCGTCATTAAAACCATAATGAGATAC
CACTTTACACCTACTAGCATGGCTATGATTTAAAAAAAAAGTATTGGTGAGGAGGTTTTTTAAAAAAAAA
AACCGTTGGAGAAAATGGAACCCTCCTGTTTTGCTTTCAGTCCTTGGCATATATACCCAAAGGAATAGAA
AACAAGTATTCAAGTACAAGTACACACATGTTCATAGAGGCATTATTCATAAATGGCCAAAAGGTAGAAA
CAGCCCAGATGTCCATGAATGGATGAATGCATAAACAAATTGTTTTATATAATGCAGTGGAATATTATTC
AGCCATGAAAAGAAATGAATTCTGATATATGCTACAACATGGATGAACCTCCAAAACATAAGTGAAAGAA
GCCAGACACAAAAGGTCACATATTATATTATTTCATTTATGAGATATCCAGAATAGATAAATCTATAGTG
TCAAGGCAAATTGGTGGTTGCCAGGGGTTAGGGAGCAGGGGTGAATGGGGAAAAACTGCTTAATGAATAA
GGGGGAATAATGGAAGTGTTTTGGAACTTGATAGAGGTCATGATTGCACAAAAATGTGAACCTACTAAAT
GCCACTGATTGTTCACTTTAAAATGGTTAGTTTTGTTTTATAAATTTTATCTCAATAAAGTATTTTTCAA
ATATTCCACTGTGCTACAGAATTGAAATGAAGTTATTGTATGCCCTAAAGTTTACCTGTCATATACTGTT
CATTACAAGTAAAAACAGAATAGTCAAATCTCTTTATACAAAACCTAGAATTTCAGAGTTCAGAGAGATT
GTTATGACCTTTTCAAGTGTCATCAAGGAATGTCATTTAGGCACCTGCCGTCTGTTTATCAAAAGCTCGA
CTTCCAACAGAAGCTGTATGACTTTTCATGATACATAATTGGGTATAACAGGAGTGTCCACATTCCTTTT
CCCCTCAGCAGCTCAAACTACATCAATATGCCACAATCAGGAATCATAAGTGATGTCATGCTTTGCAGCT
AAGTCATAGAGAACTGGTGGCAGAGTCACAACTTGGCTCAGGATCAAGATCCAGAGCAGTGACTAAGGAC
TTCATGAAGCAGAATCTCCTGCTCTTACTATGGAGGAGGGCCTGGGTCGGCCTCTAGCTGAGAAGGTGCT
ACACTGGGTCCTCTGTTCTAACTACTGCACTGCCACCAGTATGATCCTACTTGTAGGAATACTTTCCCAC
TGTCACCTGCCAAGTCTCAAACAAGTCTCAGAACTCAGTGAGACTCATAGGCACAGTGAGCCTATGTCTC
CACACTTTACAGGCCCAGAACCTGATTTCCCCACACCACTCCATCTCTTCTTTGTCCATTGTGGCTGGAC
AAAGTTGTCTGCCTACTTCCTCTGGCCAGGTACCCTGAGTGCCTTGTAGCACTCAAGCATGATTTACATC
CCTCATTCAAGATAATTTTTCTTCTATTTCCCTTGTTGGAGAGGAAAAAGAAATAGACATGTGTTTAATA
TCCAGCACAGAGTATCTCTATACATTTAAAAAATCAAAGCTTTGAATAACCAAATGCAGAACAAACCTCA
ATATTCCGTGATACCTCTTGAGATTGTAATATCAATCCTAAAGTATCAAAGAGGTCAAGTTCACCAGCAT
GGATTTTGAAAAGTAAGGTCCTTATGATGCTCTGCGCTTAACTGTCAGTGAACAAAAGTGATGGAGAAGA
TATTTACATAATAGCTTTGGTTTGTTCATAAAATTATATGCCAATTTAGTTTTCAAGGTTTGACTCTTTG
CTGGGCTTGAATAGTGGCTATTTTCTTTGGTATTGTTTTTAACCTGAATCCCTTAAGGCAAGGCATGTAC
TCTCCAGTTAGGCTATAGAGACCATGGGCCTCCTTTCCTCTTTTTTAGGTCCATTTACACATTTATGTTT
CCTACCTATCCCCTGTAGTCATTTGAGTTTATAATTACTAACATAGACTCAAGTTTTAAAATTACATGTA
GTTGTATAGATAACTCACAGTAAGACCAAATCCTTAAATAATGCATACTAAATTCTGGGCACTGTTTAAC
ATGTTTAATCCATAGTAACTAATGGAAACCTCACAACCCCATCAGGTAGTGTGGCCCTCATGGAGGTGCA
CCATTCAGATCTGCCTTTAAGAGGAAGCTTATGTTTGTTTGCAAGGAGTGCAGTTAGATGACAGTCTCCA
GTTGCAGTGCCTGTAGGCCATGCTTTTGCTGGGCGGTCCTAGCCAATGACTGAACACTCTGGGAGTACTA
AGGCCTGGCCATTTCTGCCCAGTGTGGGAACTCCCCTAATGGGTAATCTTTATTTCAGAGCTCTCCATTA
GGTTGGCAGGCCTTTGTCTGATTTGCCTCATAGTCTGAGACTCTGTCTCCAATTCTACTTTCTTCACCCT
CCTCGCCCCAAAATTTTCACAGCAAACTAATAAATCTCTTGCACTTCTGTCTGTCTCATTGTCTGTTTCT
GGGTAGACCCAACTAATACGGATAAGTATTATTATTATCCTCCTGTCACAGATGAAGAAACTGAGGCACA
GAGAAATGGCTCAAGGTGTCACAGCCAAGTGAGTTTCAGTGTTCTTCATCATGTTTTTAACCATTATGGT
ATGTTGCCTTCCCTTTCTGAAGTTCATGTTCATCCAGTTAAGTATCCTTTGTATCCCAGAAACTTGGCTG
GATGCTAGAAGTATATAGATGAATAACATAGCCTTTGATCTCAAGGAGTCCACAATCTTGTGGAGAAAAC
AAGGAGAATAAGCAGATAGCATCGGTCTTTGCTCTAAATGCAATGATGAGATATGTGCAGGGTGCCCTGA
GAGCCCAGAGGAGGGACCTAATTTGTGTCATTTCTCACTTCTTCTACCTCTGAATGGACTACTCTTCCTC
CTCTTGTTCCTGTAGCCATGCCATCATATTTATCTGGGATGCCTGTTATGTCTTTGGACCACCCCAAATT
GAGTTGGGCATGACTATTCTGTATTCTTACAGGAACCCTCTGCACTTACCATACCACACCCACCTTAATT
GATATTTCCCAGCCTGTGTCCTGCTTGTCTGTGTGCTCAGTGCTACTTCATGCCTGCCTTGGGCCCTGGC
CCCTTGAGGAGCTTAGGAAGTGTTTGTTGAATCAATGAATGAGGAGAATCATTTGTTTGCTTGGCCTGTA
AGATGTGAATAGAAAAGAGATTTGAAATAGAATACACAGGAGGGAAAAGGTGGGGGCAGATGAATTCTAC
CATTCTCTTGAGAGTATCTCACCTTATTTCTCACTGTCATCAGCAGGTGTGGATTTGGGATGTTTCCATT
CCCCTTTAAATTTTTGGTTCAAACATGGACACATGCTTTCTATCTTGCTTCCCGATGATACAAATATGTT
AAGCTGAGTTTTTATCCATTAATCCATCCATCCATTCACCCATCCATACTTGTTTGTTAAGTCTACCAAC
CCATATTTATCTAGTACTCTCATGTGTCAGGCCCAGTGCCAGGTTCTGTTCACACAGTGGTGAACAAAAA
GCACAGTCTCTGTCCTCAAGAAGGTTTCATTCTGGTAGGATAATTGGATTCTAAACAAATGTAACCTGAA
TGTCCTCTAGACCCCTCCAGTTGGATCCTAGGAGAGGTCACTTTAAATATTTCCAGTGGATATATAGTCT
TCCACCTACAAAATGGCACACTGTCAGCCTTGCTCCTTTCTTGTATCTCTCTGGACATCCTCGAGGCCAT
TTTTTCCATATGAAATAATGCATATTATTAATAGATTCTTGGTAATTGAGTAAACGCTTCATACATGGTG
AATATTATTTTTATTATTAATGATATTTATATAATGTGTTCTGCTACTTACAGTTTTGCCTTTCTTTTCT
TCCGATGACTCTTCTCACCATATTTCCTGGTCATTGTCTACTGTTGTTTTGTTTGTTGCTTTAAAGCTGC
CTGTACCTTTCTCCTATGCTACTGCCACTGTAGGAAACACGTACATGTTATATTACCTGATGGTTTTTTA
GCTTCCTCTATGGCCACTGTCTCCAGATCTCTGTTCCTATATCAGCATTTGCACTCATCTATTTTGATAA
GCTTATCTCTCTGGCTAACCACCCTCTTTCTGTAAGACCTCTTCGAGCGTTTCCACCATCACTTGGGGAC
TTTTGCCATTTTTCCTGCTTCCAGATCTCAGGTGCTCCTCTCTTCCCAGTTCTTGGTGAAGCATTTTCTT
CTTGTCTGGACTGCCTTCATGGTAGTCCCATAGCATTGTGACATGCGACCCTAGTAACAGAATTATTTCA
TTCTTTATCACACTGCCTTCCTTTTCTCAGACTGTTAAATGTGGCTTTCAGTTAGAACCTCTTACTGGAC
CTGGAACCACCAATCTCATCTAGCTTCAGGCCCACTGTATCAGCCTCTTTCCTCATGTATGGTCTTTTCC
CACCCAGGGATTCCTGTTTTCCCTATTTTCAACTGGAAGTGACATTTAAACTAAGGAATAAAGGAAAATT
AGGAATTATCTAGGGGAAGAGGGAAGGCAGGATTGAGTATGGTACATAGAACAAATGAGGAATCCCAGAG
AAGGAAAAGCTTGTGCCAAGTCCCAGAGGCCAGGAGCAGCATGGGTGTGTAATAGAGAAAGGTGTGCTGA
GAAACTGCAGTCATTACAATGTGTCTGGTGTGTCATAGAGTGCAAGGGCATAGGTGGCAAGAGGTACCCC
TGGGAAGTTAGGTTGTGTTAGATCAAGGTGGGTCTTTCCTGGGTATTGAGAACAGAAAGAAAATAATCTG
GAAGTGAAACTGGTTGAATTTTCTCAAGTGCAGGTGTTTTATTCTTACCGATTTTTTCCCTGGCCCCTAA
GGGCTAGAACACCACCTGCTGACATTCTGTATGTATGATGCATGGCTTGCATTGCTTCTTGGCCCTTTTC
TCTATCTTTTTTTCTACTCCCTGGACTAGACTAATCTTACTATTCATTTTCTAGATCTATTGATTGGCAT
GACGTGGTAGTTGTTTCAAGTTTCCAGGATCCAGCTATCAGTCCTGCCAACTTCTGGATATGTTGGAACT
CTCAGATGAATCTTTTTTGTCTACATACTAGGAATTGGCCTTGTCCAAAGTCACCAGATTTAAATAGTCA
CCACATGAATATCTTGAAGATACAGTCACCATGACAACCCAAAACAAGAATCATACACCTATGGCAGTGA
CAGGCTGTGTTCCCACAGAGAATTTCCCATCCTATTATCCCTCCCATGTGAAGGCTTGCTGGATAGATCT
AACATACTTTTCTCTCACTCCACTTTGAACTCTGGAATCTGACTGTTTATTCCATTCATTTGACAATTAG
TAATACCCTCTTACTTTTCATCTCTTACTGTTCCTTTAGCCTTTTGTATATTTCTGTCTTGCATCCCCAA
GTGGTGTTGAGTTCCATGAGGGCAGGGAATATGGGTTTAACTGCTTTGAAGCCTCCTCAAGGGCCAGTCT
TGTGCCTAGAGACATAGGGGATATTTGGTATATGTTCAGTAAGTGGAACTGTCGGCTGGCAATTAAGCCT
TAAGGAAGGCATGGAGAACCTGGAGACCATTCAGAAGAGTGGCCAGGCAACATGGGTGTTGGCTGTGGAG
TTACTAGACTTGGAGTTACAGCCCAACCAGTCTGCTCACCCCCCACCTTTTCCTCTCACCTCTATAAAAC
AAAGGTGATGGTGGAAACTTAATGCTTATTGTAAGGATCAAATGAAATAACATATCAACAAATGAAGTCA
GTTTTTGCTGTTATTTATAGAAATGGCCTTTTGAGTTAGAACAATCAGAAGTGAAGGAAAAGGTTAGAAC
AGATTATACCGGAGAAGACTGGGAAAAGTTCCTATTTGTTGGATTAAGGAAAAGATGCTCTTTCTTAGAT
TAAGTGCTGCTCTGAGGTTGGACTGCCAGATTTGAATTTCGGTCCCATTGTTTGCTAGCTGTGCAACACT
GGAGCAAGTTAACTTAACCAATGTGCACCTTGATTTTATTATAATCTATAAAATGGGAATAATAATATTT
ACTGCATAAATTTATTGTGAGAAACAAATGAAATAATCAAATAATCCCTGCAAAGTGCTCATTAGCAGAA
TGCCAGACACATAGTATGTCTCGGGGTGGACTGGTTTATTTATTGTTACTTGTATCAGTTACCTATTGCT
GTATAATTAACCACCTCACATGCAATGGTTTGAAACAGTGAATGTTTATTATTGCTCATGAGTCTACAAG
TCAGTTCTTTTTATCTCAGTTGGTCTTATTCTTATGTTTTAGTCAGCTCTTGGGCAAGAAGGTAGCTCTG
CTGATCATGACCAGGTTCTTTCACATGTGTCGGGGTTGAGGGCTATAGGCTATCTAAGGATGGCCTTGGC
TGGGCTCACTGGACTATCTTCCATGTGATCTCTTTTCCTCTAGAAGGAGAACCAGGGCTTGTTCATATGA
CAGCTGGGCAGGGTACCAAGAGAGAGCGAAAGTAAGGAAGAAGTGACACGGTGGAATTTCTACTGCATCC
TATTGGCCAAAGCAGATGACAAGACCAGCCCAGATACAGGAGTGGGGAAAGAGATTACATCTCTTTTAGG
AAGATCTGCAAAGTCACATTGCAAAGGGCATAGTTATAGGTAAAGATTGTGCTAGTTTTGCAGTTGATCT
ACCCTACCACCCTTACATTCCTTCTAGAAATAAGAGAAACAAATCGTTGTATCATGTTTTACAGATTACA
AAGACCTTTTGCCTGTAACCACTGAGTCTTGCAATGAGACTGTGAGTTAAGGATGTTTTAGCCTTCATAA
CATGCTAGATACTATCTTAGGCACATACTTCTTTTGAAACCTTTTTCTTGTCCTTCCAGCACACATTGAT
CGCTAACATTTGAATAGTAAGTTTTCCTACTAATCCTACTGCTTTCCTGATTCTTCAAGGCTTATGTTAT
TTTCTTTCATCATTTCATGTTCTACCCATATGCAGAGAAATTGATACTCCAGCCTAAATCCCCCAGAGCT
TTGTTTTTCCATGTCTAACTGCTGTTGGCCAACTCTTCATACTTGTCACATGGCTGCCTCAAACTCAGCA
CGTCCAGATGCATAACCAGACATCTTATTATTTTAAAATATAATTAGACTCATAATTTGCAGAGTAAAAA
ATACTATGAAGATAAAAAATACATGTAGTAATTGTTTGACTCTTTAAGTCCTGTCTGTATGATTTTTCAC
CCTCTAAAGTTTTGGATACACTGAAAATGGCTTTCTATAATTAATATTCTTAGGAAAATACTCTCTACAC
AAAAGCATTTTTTACTCAGCCTTAATCTTAGGTCAGTAGGTAGGGTCCTGAATGCAGATGCCAAAGAGCT
TAGGAAATTTTCAGAGTTTTTATTTAGGGTTTCAGTGGTGCTTCTAAATATAGCATGTCCCATTTTTCCT
TTTCCCTCAAACTGTCTCATTGATGTAACATGAAACCAAATAGAACAGTGCCGAACAGCTTGAAAGAGTG
AATATCATGTGTTGAAAAGGAATATCACAGTATCACCTGGTAAAAATAGCTTGTACCCACAGCAAGCAGA
GATTGGTGCACTCTGGGAGAGTGCATGTTTTTTAAAGGTTTTATTCACTTTCCCCTCCCCAAGAAATTGA
CAGGTGTTTGCAAAAGCCCTATCAAGTAAGAGGTTGATGGATTGTAGGAGGTGGGAGGAAAGAACCTTTA
AGCTTAGTGGCCAAGTAATTCTTAAAAGGAAGCAACAGAAATGTGGTTAAAATGGTCCTTTACTTTTCCT
TGTCACCAATCAAATATGTTCGTATTCTTGAGGATTGAGGTAGTGATTTGACAAAGTTAAGATTAAGAAG
CCTGCAGAGGAACAAGTAGGGAACCATATCATGTATTTATTCCATTTAACAGGCATTAACCAGGAAACAC
TCTACCTCAAGTGTCCAGAAGATACAAAGGTGAAATAGACATGGATCCTCAAGGAGTTTCCAGCCATGTA
GGGAAGATATATGTATGTATATAAATATGCATATAAATACTACCAAGTTGAAAGGGACAGATGTAGTCAG
AAAGATATAGGTAAACCGATACAGGGTTTGTATGTTCTGTCATTTATTTATTCTGACAAAAATTGATTGA
GTACCTATTGTATCCAGGCACTGTGATAGGTGCTGGGGACAAAGTTTACATTCTAGCAGTGCATGTAAAT
AACAAGCTTATTGTATTAGTCCATTCTCATGCTGCCATAAAGGAGTGCCTGAGACTGGGTAATTTATAAA
GAAAGAGGTTTAATTGACTCACAGTTCCACATGGCTGTGGAAGCCTCAGGAAACTTACATTCGTGTCAGA
AGGCGAAGCACACATGTCCTTCTTCACATGATGGCAGGAAGAAGTGCCAAGCAAAAGGTGGAAAAGCCCC
TTATAAAACCATCAAATCTCCTGAGAACTCACTCGCTATCACAAGAACAGCAGCATGGAGGTAACTGCCG
CCATGATTCAGTTACCTCCCACCGGGTCTCTCCCACAACACGTGGGGATTATGGGAACTATAATTCAAGA
TGAGATTTTGGTGGGGACATAGCCAAACCAGCCAAACCATATCACTTATAAACCACTAAACAGACAAAAT
AATGCAGTTTCAGATCATCATTAAGTGCTGTAAGGAAAATAAAGCAGGTTAAGGGGGATAGGTTAGGGGA
ACTTGTTTTTCAGTAGGTGGTCAGGGATATGTAGAGATAGGGGTGGCAAATTGAAGATCTTCCTGAAATC
TAAGACCATGCATAACTAGACATGGGAGAATAAGGATGTCTTCATGCAAGAGCAGTCCACTTTGGTATGG
CGGTGGGTGAGAGGGGGTAACAAAGCTCAGAAATGTAGTGAATCTCCATATTCTAGTATTTTGAAGGATT
TTCAAGAGGTAGAAGACAGGACCAAGCTGGGACCAATGGCTGGAGGTTTCAAAAGTGAAAATCTATGCTG
TCTAGTAGTAGAGTGTAGAAGGGCTTCTGGCACACTGTTGTTAAAGCCTGGTCAACTGCTTATGAACTCC
ACAGGGGCACAGGAGTGGTGCCTTTGTCATTGTCAAATCCTTGTCATCTGCCTCAGTGTCTGGCATGTAG
TAGATGATCAAGGGTTGATTTTTGAACTGCATTTCTGACCGTCACATGTCTGGTTGTGTGAAATCTGTGG
ATATTCTAGGATATAGTAGGTGATTAAGAACTGATTTTTGAATTGCATTTCTGAACATCATGACTGGTTG
AGTGAAATATACGGATAAGTTAAGATGGCTATGGATTTAAATGGAAGTCTGCAGATAACATTTTCCAAAA
AGAATGATCTATTCTGGTTTCAGCATCCCTGGATGAAATGAATTAATAACAACGCTTTACTTAATAGACA
GTTTCTCTTTCTAGGATCACAGAGTGGTTTTATTGACCATAGAGCTGTACCTGATTTAAACAGGGTATGG
TAACTGAATTTCATTTATTCCACTTATTCACAAAACATTTATTTATTTTAGAGAGAATAAGTATTTTACC
CAGGATTTCACAGGTAGTAATCACTGAGGCCTTGTGGCTCTAAGTCCATGCTCTTTCTACTACATCCTGC
TGTCTTACATGAAACAGATTTTATTTCATTTTATGCATTTCTGTTTATGTATCTCTATGTCATATTTTAA
TTTCTGTAACAGCAGCATCATTTACCAGCTAAGAGGACTGCCTGCTTTGGATGGAGACCTAGCCACTGTG
GTGACAAGGACACCTCATTCTCTGTGAGGTCTTCTGCTTAATGAAGCCCTTCTGGACCTCTCTGGCCTCT
ATTATTGTCTCCTGTCTCTGATTACCTATAGCATTTGTATACTGCTCCACACCTCACACTTAGCTTATTT
TCTTGTTAATTCTGGTTGAGTCTTGTCTCCCTAGATGTAGAAAATCCAAAGGCTGTTTTTTAAACCAGAA
GCTCCATTGTCCAACACTAGACATGGGTGCCTGTGATCTATTTGTTTGATTTAGAATCATTCATGGCTGA
AAGGAAAGTTGAACTCTGGCCCAGAGAAGTTGTTCAATAAATATTTTTTGGATGCATAGTCTTGGTTCCC
CTACAACCTTGCAATTTATTCTTGGCATCATTGTTTTCCGGTGTTCCTCTTAGTGATGTTGTTAACCTCA
CCATCCTTGAATCAACGTCTGGGGTTTATCTCTGTAATAATAATAGCAGCTTATTTTTTAGCATTATTAC
TGCATATAAAGCATCATACTAAGTACTTTATACAAATTCTCTTATTAAGCCCTTATCATCACTCTCTGAA
CCTAGACAGCCTGACCCCAGAACCCACACTCCTCACCTGGGTACTATATTTCCTTTGTAGACCCTTCTTG
TGCTTACCAACTCACAAGGGTTCAGCCCTTATGAATTTCTGGTGAAGGTGTGTTGAAGATATTACCTAAG
TATTGTAAACATTTCTAAGTCCTTTCTATTTTAGTGTCAAGGCTGTTTTTAATATCTTCTATAAAATTCT
GTGGTTTCTTTTTCCTCTTAGGTAGATTTGCTAAGTATAGAAGTGTGCAGGGAATAGCTAGACTAGCATA
GAATTGATATATTTGCCACTCCTGGATTTGCCAGGCAACAGGATTCCTTGTTTTCCTGAGCTTTCTTGAC
ACTGTTAATGGTGTTGGACATAGAAGGATAATGTGGGATGTAAATAATGAACACTGGAATGAAGTGGATA
GCAGTTCTTGGGACAGTGTTTCTAGTTTTTAGGAAATAGAATAAAACTTCAAAGGCCAGAGAGGGCTGAA
GACTGCATTTATTTTCCTGAATCCTTATTTGGATTCCCACTCATTTATTACTATTTGACAGTGACTTATT
GGGGATAGGGAGAATGGGGTCCTCTATGGGACTCCCTGCCTCATCATTTTCATTTTCCTTTTAACTACCC
TGTGCTTTCATTTGATAGCAAGACTAAAGAACATGAAAATGCCACCGTGGCTGGGCGCAGTGGCTCATGC
CTGTAATCCCAGCACTTTGGGAGGCCAAGGCGGGCGGATCATGAGGTCAGGAGTTCGAGACCAGCCTGAC
CAACATGGTGAAACACCGTCTCTACTAAAAATACAAAAAATTAGCTGGGCATGGTGACAGGCACCTGTAA
TCCCACCTACTTAAAGGGTGAGCCAGGAGAATCGCTTGAACCCAGGAGGCGGAGGTTGCAGTGAGCAGAG
ATCGTGCCACTGCACTCCAGCCTGGGTGACAGAGTGAGACTCCATCTCAAAAAAAAAAAAAAAAAAAAGC
CACTACTAAACGGTGACGTTTCAGAAGGGCAGATAAAGTTACATAATATTTTTAGGCTTCAACTTTTTGC
TTTGGAAATACCACATACTCCATAGGACTGTTGGTGGAATAAATAAGATCCAAATTCCTAACTGTGGCTT
GCAACATCCAGTATTATCTGATCTCAACCTGCCTCTCAGACACTCAGATCTTGTTGACGCTTGCTCACCC
CACTTCAGTCTCACTGGCCCTCTTGCTCTTGTTCCAGGATGTCCAACTGGCTCCTTAGCGCCATCCTGCT
ATACCTGCACCTCCAGACCCTCACACGGCTTCCTCCTTCACTTGGCTCAGGCTTCTGCTCTCAAGGACCC
CCCCTCAGAACAGTCCTTCTCTCATCTGCAGTCCAGAAGAGCTCTCCCTCCCTCCATCATTCTGCCTATC
CACCTTATCCTGCCTTGTTTTCCTTATACTACTTATTGCTATCTAAAACTATTTTAATTTTTTATTACTT
GTTTGTGCTACCTTCATTTGAATGTAAACTCTATGAGGGCAAGGATTTTGTCTATCTAGTTTCCTTGTCT
CCTCATTACGCCATGGACATAAATGTGCCTGGCACTATTCATTCCACAAGGAATGTTTAGACTTCCTAAT
TTCAGCTTTGTAACAACTTTTTTTCTTGAGTCGTGCATCTTTTATTTTTGCAAATGTAGCCAATAAAACT
TAATTTGACAATTTGACTAGCCTCAGAGTCAAATTGAAGTTCATCGTGAATGCAGCTTCCTACTGGACCA
CATAGCCACATACACAAAAGATGCCTTTTGTGTAGGAAACATTAGGGGCAGGCCTATCACTAGCAGGTGA
TTTTGAGAGAAGCAGCTAAGGTAAGATGGAAAGAATTGAATATGAGTAAATCAAGAGAACACCAAGAGCT
GTATCTGAACATGACGGAAACTGTAACCAAACTGGATGGGCAAGGGGTACCAGAAGCCCTATACTTATAG
GGTGACTTTGATCAAGTCCTTTTACCTCCTCTGCATTTCAGTTTCCTTGGGTGTAAAATGAGGCCCATAG
GTGGAGAAATGGGAGGAGGAGAGGCTCCCTACCACATAAGGGTGTTGAAAAACTGTTGAGAGAACATACG
TGATAGCAGTCTATATTGAGTAGCACTCACATAAATTGACATAAATGCATATAAAGTGCTTGGCATCCAG
TAAGTAGTCAACAAATAGTACCTATTACTATTAATATTAACATTATTAAATCACTTGGAAATGATTTGAA
GCACTTGTAAAGATTTGGATCTCTTACTAGTGTTAATGATTATTTTCTTTGAATTTAAGCAAAATTTCGA
ATTGTCTTCTGTTCCTGTTTGCATTTATAAGCATGGGAGGGCCCATGAGTGCAGTGAGTAAGAATCTAGA
CTCTAGAGTCAAGACAGAAATGGGTTCAAGTCCTGAAGTAAATGAATAAATAAATAAGCAAATTGACTAA
AGTTCAAACCTAATCTTACCCCAAGCAAGCTTTTATTTTCTTTCTCTATCAAATTCCTGTCCATCTTGTG
AAGGAGACACTGTGGCCAAAAACTAGGAGCAAGAGAAACTGTAGGCTGGGTAATTCATGGATGCCTTTTG
TACCTCTCTATGAACGTGAACCCCCTGTATTCCTTCTCCAGCAGAGACATGAGCATGCTTTGTCCACACA
GCCCCGCTGGGCCTTCTCACTGTTTTATGAGACAGATACCAAGACACATCAGAGTGGCAGCCCCTCACTG
CCATCATCACTGATGAATGACAAAAGTTTGGAAAAGAAAGAGCTATGGACAAATAACTCTCTCCCTCAAG
CTCATCAAGTGGGGACACACATCCTCCTTGTCTCAGTGGTTTCCTGATGTACCTTGAAGGTCCTTCACAT
CTGTGGTCCTTGCAACTGCTGGGAATGACATAAATCATAATCCTGATATAAAGATTGATTGAATTCTTGC
CAAATGCCAGACATTGTGCTTAATCCTTTATCTGAATCCTTCTACAGCACTAGGAGTTGTAGGTACTATT
ATTGTCCTCATTTTTACAGATGAGGAAACTGAAGTTTCAAGAGATGAAATAACTTTCCCAAGGTACCCCA
GTTAAAAAGTAGAAGAGTTAGGCTGTCAATCAAAGTCATCTAACACCAGAGCTTGTCTGTTTTCTGCCAG
ACTGTAAACTCTTTGGGAGGAGAGACAACCCTCTCATTCACCTTTAGTCCCCATCTATACCCAGTTTCAC
CTCAGTTAGTAGTTATTAAGATGAAATTTTAAAATCTTTTCATGTGGATGATGCCCTAATGTACCATGAG
TGTATCTTGAGTTGCAAGGTAGAAGCTGTCTTCACCTGTGCATTCTACTCAGCCTTTGCACAGACACACA
GTCTCCCTCTAGCCTCATGGTACCAGGGAGTGGAGGGTACATCTCTACAGAGGAAGAAACATTCTGCCAG
TCCTTCATAGTAAGTGGTGGAGTTAGGATATAAGCTGAGGGCCCTCAACTTCATATTTGGCCATTTTCCC
TCTTCTGTATCTTTAAACTTTAAAGAAATGTGGAGATTTTGTGGATGGGGACAATGATATTTGACAAATT
CTTTTTTATTATTTTAAAAAATCCTAATTGTGAGGCAAAAGTTATTTTAATCTCTAATACAGGCAAAAAT
GCTTCATTGATTTTTTTTTTAAAGCAAAGTAATAAAAACCCATGTCCTTTTTTTTGGAATAAATATTATC
ACTAGGTGTTGAGGTCTGCAAGATGCTAAATAAGGATTCGAGTAAAATGCTTTGCAAAACCATTTCAATG
CAAAATCAATAATATGCATTAAAATTTATGAAAAATGAATTAAGAAAAAACAACCCCTTACCTTTTAGTG
GATACACACACACATGCACAAACACACACGTACACACACATACACACGAAACATTAACATGAAATGTTAA
CTTTTGGTCGTCCACTGGAGTTTGAGGAATAATGGCTTCGTAAATGAGAAAAACACCAAGAGCTTTGTAT
GAATATAATGATTGCCATAACTAACTAGATACGCAAACTAAATGCACAAAGACTAAGTGCATAAGAAAGT
AGAAGTCTAACACAGGATCCTAGAAATCCCAGAAACTCTAGACTTTCAGATAAGAATCCTATACCTTTAG
TTGCCTTCTGGACATCTTCATTGGATCTTGTGAATGAGACTGTGAACTGGTATTTAGCTAAGCATGGCTG
CAAAGCATGCTGAGTCATCAGCATGGTAGGTAAGGAGAGGTGAGTGGTGGCCAGCAGTCCAGAAAACATT
ATTTTGAAAGGTTTTACTGGTAAAGCTTCAAGATCAAGGGTCCTGGGGCCATAGATGTGCTGGCCTGGCT
GGCTGGCTGGGCTGTGCTTCTCTAGTTTATGGCTAAAGCCCAGCCAAATTCCCTTAGAGTAACTTAAGAT
TTGTTTTATAGTTACTTATATTTTTTGTCTTATCTCTCTGTGAGTTCCTTGAGGAGCCAGTCTCTGACCG
GTTCATTATTTTAACTGTTCTTGCTGTATTTACTTCAGAGTAGGCACTCTAGAAATCTCTCTTGAGTGAA
TTAAAGGATGATTTAAAGAGCATTCACAGGAAGATCGGGTACAAAAATGGTACTACAATAATAATGACAA
TAATTGCTACCATTTACTGAGCACCTTCTATATGCCAGGTGCATTGTTCGCATTTCTGATTCCTGTCTTT
CAGGTCAGCAACCTTTTGTCAAATATTCACTGAGGCTGATTATATGTCCGGTTTTGTATTGGCTCCGGAG
TTTTCAGGGAAGAAAGGGACCCAGTCTGTTGCCTTGAGGAATTCACAGAAAAGATAAAGTGCAATTACTA
TATGGTGAGCTCAGTGCTTCAACAGCTGTGGGAGTTTATGCACAGTGACCTAATAACCTTGGGAAAAGAG
GGGTCATGGTGGAGCTAAATCTTAAAGATGAAATAGGAATTTGCCAGATGAAGACACTAGAGGAAGGCAG
GGGACAGTGGATCAGTCTGGGTAGACAGAACAGTAAAGGCAGAGGTAGGAAGATGCTCAGCTATGTGATG
GGTTTATGGAACATTAATTAAGAAAATATATAGAACACTGGCTGTGTGCTAGGCACTGGGGATGTAATTA
TGAGCAAATCCTCATAGAGCTTATAATCTAGTATTTATGTTATCTAGGGGATAGCATAAATAATAGTAAA
AAGACAAACATTTATCTACAAATTATAGTAAGTTCTATGAAGGAAATGAATTAGATTCTAAGAGAATAGA
ACATAATTTGGATTTGGTCTTTGTGAGAAAGGTACATTTAAGCAGAGACATAATGGAATAACAAGGAAGT
GAGTAGGATGAAGTGTGTGTCAGATGGGGAATTCCATGTGAGTGTAAAGGCCCTAGGGCAGCCATGTTTA
AGACGATGTAAGGCCACCAGGGAGACAGCTAGAAAGAGATCACATCAATTCCTTTAGGAGACATTTTAGG
GAATTTGCATTTTATCCGAGGTGCAAGGAAAAGGTATTGAAAGGTTTTAAGCAGGGGAGCAGCATGAGTT
TTTTCCTTCATTTTTAAATGAAAATTTTGAAGCATACATCAAAGTTAAAGGAATTTTAAAGTGAGCTCCT
GTATACCCATCACATAATACCATTTTCATTTTATTGGATACAAAGATGTGATGTATTTTTAAATGCTCTG
TCCTCTTTGTAGAAGAGTACTGAAGAGGAAGGAGAAGGGGAAGTGGGAGCTCTAGCCCTAGTCTCATCAT
TTACTGTCATCGCAGGTAAAGAAGAGCTCCAGCATGGAGGCCTGGAAGGCTGCTCTGCACAGTGTGTGGC
AGAGGCCAGACCACAGTGGGTTTTTTGTATCATGCCAGAGTACAGGTGGTCCTATACTTACAATGGTTCA
ACTTACTATTTTTTGACTTTACGATGGTGTGAAAGCAATACACATTCAGGAGCCCCTCGACTTAACAGTG
GGGCAACATCTTGATGAACCCGTCATAAGTTGAAAATACATATTGTCAGCTGAAATTGCTTTTTGACTTA
TGATATAGATATAGATAGAGAGAGAGAGACAGAGAGACAGAGAGAGAGAGAGTCTCACTCTGTCACCCAG
GCTGGAGTGAAGTGGCATGATCTCGGCTCGCTGCAACCTCCACCTCCCGGGTTCAAGCGATTCTCATGCC
TCAGCCTCCTGAGTAGCTGGGATTACAGGCATGCACCACCACACCCAGCTATTTTTTTTGCATTTTAGTA
GAGATGGGGTTTCGCCATGTTGGCCAGGCTGGCCTCAAACTCCTGGCCTCAAGCGATTGTCCCACCTTGG
CCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACCGCACCAGGCCAACTTATGGTATTTTCAATTGAGA
TGTACCCCGATCATAAATCAAGGAGCAGCTGTATATGTAGGCCATGGGGAGATTGTAGAGGATTTCAGTT
GAGAGTAAGGTAACCTCTTATCAGTGGTTTTACTTTCCACAGTTTCAGTGACCCTTGGTACTTGACCTTG
ATCCCAACCTTCGTCAAAAATGCTACATACAGTAAGATATTTTGAGAGAGAGAAAGAGATCACGCTTACA
TAACTTTTATTACAATATACTGTTATAGTTGTTCTATTTTATTATTAGTTATTATTGTTGATCTCTTACT
GTGCTTACTTCATAAATTAAATGTTATCATAGGTATGTATGTATGTATGTATACAAAAACACCATAGTAT
ATATTGTGTTAGGTACTATCTCAGTTTCAGGCATCCACTGAAGGTGTTGGAACATATACCCAGTGGAGAA
GAGGGAACTACTGTAGTGTGAGCAGGCTTGCATATTCCAAGGGTCCTGGAGGCAAAAATGTGTAAGGAAA
TGTCTGACATGAGATAGACCTGGGCCTGGGAAGTGAGTCTGGAGCCTTTAGTCCTATGCAAGAAAGAGGA
TAAGCTGTGTTCTGTAAGGCCAGGGAGAATGGGAAGAAAGAGAGAGGGGGAGGGGAAATATTTGACGATT
ATTTAGGGGTATAATGCCTGAACCATAATAGTTGCTTGATAAGCATTTATTGAGTGAATTAAAGTACAAT
CAGCAGGACTTAGAAAGTCCTGGTGATGAAAGACAAGGAGATGAGTTGTAACCTGTGCAAGTCACTCAAC
TTCTCTAAGCCTCAGCTCTTCATCTGTGAGAGGGGAAAGCTAAGGGTACTTCCTATTATATTTGTCAAAA
ATCTCCAGAGAAACAAAGTAAATGGGATGTTTCTCTCTCTCTCTCTCTCTCTCTCATACATATATGTTAG
ATACATGACCCTATACTGCACAGCTTATCCTCTTTCCTAAAGAAGACTAAAGCCTCCAGATTCACCTCCC
AGACCCAGTTCTATCCCATGTTAGATACATGTATATAAGTAGATACATGTGTATATGTATTAGGTGTAGG
GGAGACATATAGGGAATTGGCTCACATGATTGCAGAGGGTCACAAATCCCAAAATCTGTAGTCAGCAAGA
TGGAGACCCAAGACAATTGATGGTATAGTTTTAGTACAGATGCTGGCAGGCTTAAGCCTGGAAAGAGCCA
ATGTTTCAGTCTGTGTTCAATAGCAGGAAAGAATTGAAGTCTCACCTTAAGACAGTCAGGCAGGAGGAGT
TCCCTCTTACTTGAGGGAGGGTTGGCCATTTTGTTCTATTCAGGCCTTCAACTGATTGGATGAGGCCCAC
CCAAATTAGGGAGGGCAAATGACTTTTTTCCGTCTAGGGAGGGCAAATGACTTTATTCAGTCTACTGAGC
CAAATGTTAATCTCATTTAAAACACCTCACAGACATATCTAAATAATATTTGACCAAATATCTGGTCACC
CTGTGACCCAGTCAAGTTGATACATAAATTAACTATCATACTTACCCTGCTTGCTGTGAAATGCTGTTAA
GTTTTAAAATACTGTACACATGAAAGGAAGTATCACTATTGATTCAAAGAGAAAAGGTTACTTTAATGAT
AATAGCTTAATTTTATCCAGTGCTTCCCATATCCCAATTATTATTTGGTCTTACTAGCATTATCTCATTT
AATTCTCTCAATAACTTTATCCCTCTGTTTACCCGTTAGAGAGTCCATGTCTACAATTGTTGCTGCACAC
AGATTCCCTGCATTAAGACATGGTGAAGAGGAGCACAGTCTCTGGAGCCAGACTTCCATGGTTTCAATCC
CAGCTCTGTCACTAGCCTACATGACCTTGGGAGCAAGTTACTAACTTCTCTGTCCCTGTTTCCTCTTCTC
TGAAATGGGATAATTGCAAAGTGCTTAGGACAGAGCCTGGCATTTAGTATACAAATATATACCTTGTGTG
TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTATATAGTATTTGTGTGTTTATATATCTATGTGAATATAT
TGCAGTAGTAGTGGTGGTGATGACGACAGTGATTACACAGAGAGCAAACTCTCATGCCTTCAGGCACCAG
TCAGGTAATATCAGTGTGTGAAGCGATAAATAATAGGTCAATATGGAGTGGGGGAAGTGAGTGGAGAACT
AGGGAGTGTCCTCTTAACTTGAAGGCATTAAAATCCAGGAATTTCCAAAACACTACTTGGGCCACCTAAA
ACTCATTTTTTTTTTACCCTCAGGTTGCCGTCTGCCAAACTGTAATGAGTGTTTCACAAGTACTTCCCTT
AACAATTGTGCTAGCAGAGTGGCCCATTTTACAGATGTCAAATTCGAAGCTCACTTACAAGGTAGTCAGT
ACCAGGGGAAACTGGGACTGAACAAAGGGAACAGAGGTCTGACTCCAAAGCCAGTAGGGCTATTTGGATG
GTCTCAAGGTTCCTAGGTGAGTGGAACTGGAACATTCAGTTCGTCCTACTGTCTGTCATCTCTAACCCCT
TTGAGGATACGATCTCTCACTGATCTGTGGCAGAGGTAGAGCAAGTGAAAGAGGAAAGGTGCCTGTGGTG
CTTGCAGTCTCCCTGGAATGTCTTCTGTGCTCTCCCTGTGCAAATCCCACATCCTGCTGACACCACCCTC
TCTTCTCCATTCCCGTGCCTATCACATGTGCGTCTGTTGGTGGCCATGCAGGTTATGGCTGTTTATGTTT
GTGATGCTCCTTCCATTGTGAGCTCAGAAGGGTTAGACCCATATTCATTTTTCCATCTCCTACCTGTTTG
AGTTTCCATTGAGTACCATCCATTAAATACCATCTGCTGGATCTGAGTTCTAGTTATTATCCATCTCTCA
TCAAGTGATGAAGTCTGGGTGATTCATTTGCCATCTAAGATGTTCAGTTTCTGCAACTTTTAATTTGTAA
TTATTTATTATTATTTTTTAGATGGGGTCTTGCTTTGTTGCCCAGACTGGTCTCGAACTCCTGGGCCCAA
GAGATCCTCCTGCCTCAGCCTCCCAAGTAGCCAGAGCTACAGGTGTGTGCCACTACACCTAGCTCTCCAT
CTTTAAAACTGGGATAATAACTGTCACAAGTTGTATTCCCCAGGAAGTAGATTCTGATGTAGACTAGCAT
GTAGGAGATTTATTAGGGAGCGTTCTTGGGATCATCACAGGGGAAGAGAAGGGAAGGAAGCAGGATCAGG
CAAAGGGAGAAGAGAGGTTACAGTACATTTTTAATGAAGGCCTCAGCCCCTTCCATGAGAAGCTCTGAAG
CTAAGATAGCCTTTCAAAATAGTCCTGAGTCAGGGTGAGGGTGTCAGGTCTTTATACCCTATGTTGATCA
CTCACTGGATGTGGACACCTCAAGAAGGGGGCATGACCTTGGGAAAGACAATTCTCTCAGTCAAGGCAGT
TTCAAAGAGAGTTGACAGTTGAGGGTTGTCTAAACTAAAGTTATTCTGTTTCAGAGGAGGACTTGGAAGG
CATCACAGCCTCCCAGTAACCCAAGAAACCAAGTTGGTTAACCCAGTTACTCAAGTAACAACTTCACAGG
AAGGTTGATACATGTAAAAGCATACTGTAAGGTGTTAAACTTAAGGTTTTAGTTGTTGTTAATGTTAAAA
GTAATATTACTGGGGCTGGGTAAATACTTCTTCAACTGAGTTGATTCTGTGTTTTTAGAGCAGCTTCTCA
ATAAAACTCATGCAGTTAGTATACACCCTTGTTTTATTCTTCTCACTTCCCAAAGACACCCTTCTCCCTC
TCTCTTTTGTTATTAAGCTCATCTTAAACGTGCGTATGCCATCCTATTTTAAAACCTCTAGGGTTGGTTT
GATTTGATTTCCTTTCCACTGAAATGACTGTTCTGAACTCTGACCTTAATCTGGGATGGTTAGAACAGCT
GGAAGCACTTTCTTGACTGTCTATCTATCTTCAGACTTTATATTCCATACAGTCTCAGAGAAAGTTTAAG
TGCGGTCTTTAAACATTGCTAACATTAACAATTCCCATCAATGAAGTTAACTAAATGTAAATCAGTACTG
GCACTAGCATTCCCAACTTTGTACTGATCCTGGATAGGCTTGTAAGGCTCAGACGTCAGAATATCTTAGC
AGAAGCTGACAACAGGAAAAATGAATGTTCTAAAGATCAAGAATATTGAGCAACTATGAGTCAATTCCAG
GGACTAGCTGCTTATAGAAAAGAACTGTGTATGGGAGTTCAAAGGTGTAATATGTTGTTGATTTCACACA
CACACACACACACACACTCACACACATACTGATGTGGTCAGGCAATCATTCTCTGAATTCCATCATCATT
TGATTTCTCTCAAATATATATGTGTATATATTTCTAACTCACAAATCTCATTGTGTCATTTCCCTGATGA
AATATCTTCTGTAGCTCCCTGACATCTCCATCAGAAAATCTAAAGTCTTAGCAAAGCTCTTATGTTCCCT
AAATATGCCAGAATTTTTATGCTGCTGTGTCTTTGGGCATGTCGTTTCCTTTCTGCAGAAAGCTTTCTCA
TTGCTTATGCATCCTTCAGGTCTCAGTTCAGATGTTACCTCCACTGGACAGCCTTCCCTGGCTTCCCCAC
AATGACACTTGCTGTTCTGTGCTGCCTTTCCTCCAAGACAGTGAGCTGCAGGATGGAAGGAAATAAATTC
GTGGACTAGTTGGAGGGGTGAGAAGATCAGGGTAGAGAGAGAATGGGAGAAGTTATATGCAAAGCCTTTG
TACTTAAAACTTTCATCTTGCAGAGTCGATACTCGGTTATATGTATCTCTAAAAGTGTGACTTAATATAT
CTGATATTTCATTTTGTTCTTGGCTTTAAGAAGAACCAGAATCTTTTGATTCAAGGATTAGAAGAGCTTC
TAAAGGTAGGCTTTCTGACAAAAGGAAAACTTTCCCCTGACTGCCCTCTTGTGGAGGTGCCAAAATAGCC
CAAAGATGGCAAGTCCATAAAATCATCATAAACCTTAATTGAGAGAGCAGTTTTCTGTACTGTCTGTTGT
ACTGGTTAGTCAAGCTGCCATATGCATATAATTACATATTTTTAAAATTTGAATGTGGCAAGGCATGCCC
CAAACTGAATTCAGTTTGTCTCTGGTAAATCAGATGGTTCTTCAAGAATACAGAATACCCAGAGTGAAGG
TTATGAACAGCACATGGAGACAGGCCACATGTGATTAAGAGCGGTCTCTGGTGGATGAAGTGCTAGATGC
ACACTAGCTTTCACTAGCACTTTAAGTTCCATTTCCCCTAGGCTCATGCCATGCCTAAGAATCATCTGCT
GACCTATGTTAAAATGCTGATTTCTGAGCCATTCATCCAGATTCTGATTCAGTGTGTCTGGGCTAGAGCC
CAGGAATCTGCCTTTAATAAGCACACCAGGGTGATGCTAATGGATGTAGCCCTTTTGAATCTTGCAGTGG
GGATGGGTTTTATAGAGTCATTTACATGCTTTTCTACAACTGGGGCAACTTTCTTATTTTATTTTGAAAA
TTTTTTATTGTTATACTTTAAGTTCTGGGATACATGTGCAGAATGTGCAGGTTTGTTACATAGGTATACA
CGTGCTATGGTGGTTTGCTGCACCCATCAACCCGTCATCTACATTAGGTATTTCTCCTAAAGCTACCCCT
CCCCTAGTACCCCCACCCCCTGACAGGCCCTGGTGTGTGATGTTCCCCTCCCTGTGTCCATGTGTTCTCA
TTGTTCAACTCCCATTTATGAGTGAGAACATGCAGTGTTTGGTTTTCTGTTCCTGTGTTAGTTTGCTGAG
ACTGATGGCTTCCAGCTTCATTCATGTCCCTGCAAAGGACATGAACTCGTCCATTTTTATGACTGCATAG
TATTCCATGGTGTATATGTGCCACATTTTCTTTATCCAGTCTATCATTGATGGGCATTTGGGTTGGTTCC
AAGTCTTTACTATTGTGAACAGTGCCACAATAAACATACATGTGCATGTGTCTTTATAGTGGAATGATTT
ATAATCCTTTGGATATAAACCCAGTAATGGGATTGCTGGGTCAAATGGTATTTCTGGTTCCAGATCCTTG
AGGAATTGCCACACTGTCTTCCACAGTGGTTGAACTAATTTACACTCCTACCATCAGTGTAAAAGCATTC
CTATTTCTCCACATCCTCTCCAGCATCTGTTATTTCCTGACTTTTTAAAGATCGCCATTCTAACTGGCAT
GAGATGGTATTTCATTGTGGTTTTGATTTGTATTTCTCTAATGACCAGTGATGCCTTTTTTCATATGTTT
GTTGGCCACATAAATGTCTTCTTTTGAGAAGTGTCTGTTCATATCCTTTGCCCACTTTTTAATGGGGTTG
TTTGTTTTTTTCTTGTAAATTTGTTTAAGTTCTTTGTAGATTCTGGGTATTAGCCCTTTGTCAGATGGAT
AGATTGCAAAAATTTTCTCCTATTCTGTAAGTTGGACTAGGACAACTTTTTATAGAAGTCATGATTTTAC
CTATTCTCATCTATTGTCTCCATTAGAGCACTCTTTTTAGAACTTATGCCTTGATTTTTGGCTTGAAAGA
CATGGTCTTCATTTCCATACATGAGATTGCTAGTAAGAATTAGGCATTTGATCTATAACTATGGAACAGA
CTTTCTTTCCTGTCTCCTTTCCTCCTTCCCTCCTTTTCTCTGTAGCTACCTACCTGTCTGCCTAACTATG
TACCTATGTACCTACCCACCTGTATTTACAAACCAACCTTCATTGTGCCTTGTACCCAGTGAACCAATGT
GAACTTCAGAAAAGCCAGCCTTTCAGAATGGGGATTACCCTGGGATTTTGACCTTTTTGATAGGGAAAGA
TGAAAAAGCATTGGCCAGGAAGTTTAGCTCTCCTAGAGAATAATACCAACAGCCATTTTTTTAAGATATG
GAGTCTCACTCTCACTCAGGCTGGAGTGCATTGGCATGATCATAATGCCCTGTAGCCTCAAACTCCTGGG
CTCAAGTGATCTTCCCACGTAATCCTCCTGAGTAGCTGGGAATACAAGCACACAACACTTTACCTGACTA
ATATTTTTTATTTTTTTTATTTTTTGAGACACTGGGTATTGGTTTGTTGTCCTGGCTTGTCTCAAACCCC
CAATGTCAAGTGATCCTCCCAACTCAGCCTCCCCCAACTGCCATTTCTTGAACACCTGCCAGATACCAGG
CATTCTATAAGACTTTTTAGGTACATTATTACTAATTCATCAAAGTAGTTCACAGGTGAGGAAATTGGAA
GCTTAAAGAGGTTATGTACTATGTAAGTCATCTAGAGTCTTTAAGGTTGAACTATAACTTGAATCAGGTA
TGTCTGACTTCAAAGCTCCTTCCTCTCTCACTGGATGAGCATGTATCTAACTACCTGCAGGTGGATACCA
ATGGTCATCAGCCTTCTCTGGGTCTACTAGTTAGTTTTGTTGTCATTAAACATAAAATTTGGGGAGAAAA
CTCCATATTCAAAAAAGTAAGTTAGCAAATCAAGCATTTCTCCAGGGCACAGCTGCTATTTTCCCACTTT
CTGAGAAATCTGAAAATCAGTATTGAAATAGAAAGGAAAAGAATGCTTACTGTGAATTTTTAGAAGTTTC
TGAAGATTGTTTTAGGACCACACTGGGCAGCCACGTATCTTAATTTTGCATTTTGTAAAGAACCTGTGGC
ATTGTTGACACTCCTGAAAGGTCAATAACTACTTGTTTGGTATTTCAAGTTAATTGTGAGTTTCTGCATT
TTGCATAGCTGAGTCTTTATTGTTAAAAGGTCCCTCATAAATGTTGCATTCCCCTCATTGTTGAGAGCTG
CCTTGAATGCCTAGTAGGCCAATGGAAATACATTTGTTGCAGTGGAAAGGCATTTGACTTAACACAGCGT
AATTAATTTTTCTTTAGCCATCAGGACATTTTTAAAAATCAAGTTTGTGTTTTTCTGATTATGAAAGAAG
CACATGTTCAGTGTTAACAATTAGGAACATATAAAACAGTATAAAGATGATAAATCATCCATGATCTTCT
TACCCAAGAGTAATTATAGTAGTAATTTTTTTAAAGTTCTTTAAATAAGGCATGTTTACCATGTGTCAAC
TCTGTTGTAGGGTAGGTGACATAATTCTAATTTTATAGATTTGGTAACTAAGCTTAGAAAGGTTAAATAA
TTGTCCTGCTTAGTTTACAACATTCTGTTTTCCCCTAGTTCCAAAGCCTATACTGTCCCACATAACCACT
GTTAACATTCTAGATTGTTTCCTCCAAGTCTTTTTTTATGCATATTTTTTCATGGCTGAGATCATACTGT
GAACACAGTTTTGACCCTCCCATTTACCCTTCACATAATGGTATAAGCATTTTCCTTATATAATATGGCT
CTGCCTCCCTCCCTGCCTTCATCTCATACCTGCCCCCTTCTGTCTTGTATGCCACACTCCAGTCACATTG
GCCTTTTTTCTGTTCGTGGAACAAGTCAAGAATGTTCTTGCCTTGGGACCTTTGCACTGGCCATTTCCTC
TGCCTCAAACACTCTTGTCTTAGATCTTAATGGCTCATTGGTTAGTTTTTTCTCATCCTTTAGGTAGGTG
TCAGCTTCAATATATAGGTTTTCCCTGAAAGTCTTATCTCACATAGGTCCTGTTTTCTTTCTTAGCACTT
GGTGGATTTCCTTCATAGCACTTCTTATAACTTACCATTAGTTCATTTTATTTGCCTTTTTATTGTGTTA
TTGTATCACCTTCACCTTTATAGGTCTGGGCCTAACATGGGCTTATACATGATGCTGCATTGAACATTTT
TCTATATAAAACACTTTCTCTATCATTATGATAGTTTCATAGAAGTTCAAACTAGATCAAAGTGTAGGAA
CATTTTGAGGGCTCTTGCTTCACATTACTGCAAAAATTTCATCCCAGCATCCCAAAGTGTATACAACTAT
AAGCACTGTGTGGGGGTGCCAGTTTCACTGCATCCTTGCCAGCATCATCAGTTTTTAAAGTCTTAGCTAT
TTTGATAGGTGACTTAAACCATGCCTGCACACTGTAGGTGCTCAGTAAATTTCATTTGCTAAAGAGATGA
TATATAAAGTTGACATTTGGCCAGAGTTCCAAGAACACACACATCCTTTCCTGGACTCCTTTTCCTTTGA
GGTCACACAGAGAATGTAATACAGAGAACAGCAGTAGCCAGTGCCATGGCGTACACCTATAATCACAGCA
CTTTGGGAGGCCAAGGTAGGAGGATGGCTTGTGGCCAAGGGTTCTAGAGAAGAGCGGCAAGTAGAGGTGC
CCAGATTGGCTCTATTTTCAGCCTTCATAATCTGGGCAGGATCTTCTGAAAACTTTATTTTGCTAGGCCT
AGAGGTAGCCATTGTCTAAAAATACAGTTGCCCCTTGCTCCTTTTCCTCTAAATCTATATCCAAATAGTA
AGGAAGGACCTATTCAGAGCAAAGAAAGCATATTTGCGTTGTCATTGCTGGCATAGACCTGTCCAAATGC
CATTTCAATATTATCTCCTTGACAGATGAGGTACCATTTTTATTCAGATATCTAATTAGCAATCGCTTTA
AAAATTCATCATATTTAATGCATGGCATAGTAAATACTTTATCCTCTGAGACTTTAACCCAATATAAAGC
TCTTGAACCTGACTGTATTTACAGCTGCAAGCCTCCTTCTTAGGGAGGCAGCGAAGGGGGAGATAGATGC
AGAGATATCCCCTTAGCATTATTTTCATGTATGAGTTTTAAAACTAGTTGTGAGGGTAGATGTTTTCCCA
CATGTTTGTTCACCAGTTGTAAGTCCTATTTGGGGTAACTGTTCATGTGTTTTGTCTGAGTCTGTATTGT
GTTTTGTAATACATTTATGTGAGTGCTTTAAGTAGTAAAAGCAGTGATCTTTTTTTTTGTATCTTTGGTA
AATATTTTTCCAGCTTGTCTTCCCTGAAACTTTTTCTGTTTTAGACTTCCTGAAGTTTTAAATGTACATG
TAGGCCATTCCGTCAATATTTTTCCTTGTTAATTGCTTTTAAGCTTATAAGAGTCCAAGATTGGCTAATG
GGTTACTTTTTTTTCCTAGTTATTTTATGGTTTGATAAGCATGTCTTGCTTAGAAGGTCCTTTCTACTTG
TATAAAGGAATGTTGAAATTGTATGAAATGTAAATACCTGGTTCCACAGCATTTTCCTTGAAATTGGGAA
ATTTTTCTAGTTTGGCTTTGAAAAAAATAGATTTCAAAATAAGGTATAACTAGATAAGATTTAAAGGTAT
TTCTTTGTTTAGTTCCTTGGAACCATTCAGCTTTTATATATATATATATATATATATACTCTCTCTGCTC
TGCCTCCTGGAATAGTATGCGGAGGAACCCTTTAGCATACTAATATAATAAGGATGCTTTTTATGGCTTA
AGAGATCTTGGGAATCCTTGGGAAATTGTTCAGTGACTCTCTGCAATGGAATTAATGTTTTAAACCCAGA
AGCATGCATTCTATATAAGAGATATATTTTCAGAGCTCTTCTTGCTATGAGCTTTCCAACCCTTGCCTCC
TACCACCCTGGGAGTGGTGCACCCTCCACACCCCGCACCCTCCACCCCCAGATAATTGGATTGGAGCTAG
TGTTCTTTGTTGTTTGCTTTTCAGAGAGGGGTGGTTGTGTATTATATTCTGGAAGGAATAGGTACTGCTG
TAGTGTGAGTGCATTCTCTCGGGGACTCTGCAGATCCAAGGCCAGTTCTTCATTCTGAGCCCCTCAAGTC
ACTCCTTGGCCTCTGCTGTTCTTTAGCTAAAGGAAGAGATTCCCATTGTTCCCATCTATTTTTCCAAAGG
GAGAATGCCAGTACTGAGGAAGAGGGTGGGCTTAGAGAGTCAATCAATTATCTTTTGGGCTTAAAACTAA
AGAAAATGAACCCATGGTTCAAGGATATCTACTTCATCATTTATTATTTTCCATGTGAAAACCCCCTTGG
AGCAGGATAATCTTTTTCTAATCACTGTACTGAATGGATCCCCAAAACAGCCAACCAGAAATGGAATTTT
AAAACATGGCTTATTTTAAATTAATTTATTTTCTTTTTTAAACCAATATAATGAGGAAGCAGAGAGGTAC
AGAAAGGGCTAGGGACTTAGCCAAGGTGACAGAGCTAATTAGTGACAGAGCAAAGATGCTTGCTGTTCAT
GTCTTCCACTCTAGTACTTTCTACTGTCTCTTTTCTCACAATCTTCAGAGGTGTATAGTTTACAACTGTG
GCTATGTACAACAGACTATGTCTTCTAGATTGTAATTTTTTAAACTTAGCTAAAATAACCTATTGAAGAT
AAATATATTTTAATTTTTATAAATTTCACCTTAGCGATGTGACCTAAAATGTAACCACCTCAAGTAGACA
CTGAATTTTCTACACGAAATTTGCTGTGGACTAAATTGTGTCTTCAAAATTTGCATATTGAAGCTCTAGC
TCTTGATGTGACTGTATTTGGACATAAGGCTTCTAGGGGGTAATTAAGGTTAAATGAGGTTATAAGGGTA
GGGTCCTAGTCTGATAGGATTGTTGGCCTTATAAGAAGAGGAAGAGAGAGATCTTTCTCTCCACCATGCA
AGGACACAGTGAGAAGGCAGTCACCTGCAAACTAGGAGGAGAGTCCCCTCTAGAACCCAACCATGCTGGC
ACCCTTATCTCAGACTTCCAGCCTCCACAACTACAAGAAAATACATTTCTTTTGTTTAAACCACCCAGTC
TATGGCATTTTGCTATGGCAGCCCAAGTTGACTAATATAAAAGCTTTATTGCCTCACTAAATTCTGGTTT
CTAGACCCAGTAGACATACAAATTACAAGATCATTGAGGCTGATCTGTGTTTTAGAAAAATCATTCTGAT
AGTTCCTTTGAGGCTCTGTGTGCCTTTTGTGTGATTGAGTTGTGAGTGCTTCAGAGCACTTGCTTTAATT
GTAAGGAATAGCTTATTGTTGACTGGAAACATCCTGGCTCACAAATGAAATTGATGAAAGCTGGCCTGTC
CTTCACTGAACCAGGAGTGAAGGATATATTAGCATTGTGATGTCACTGTGGCCAGAGGCCTTTGCTGGAC
TGGGAACTCACTTCTGAGTTCCTGAAATCACTTAATTATAGGCGAATACACATAATACCTGAACAGCATC
ACTGCACTATTTTTGTCTTCCCTTCCATGCTGACTTATTCATTAACATTTGTGTAAACCATCTGAACCAT
AGAATCCTTTTGGGAGGTCCTCCAGCTCATCTCTTCTATCTGTAGACCAACTTTTCCTCGAGCATCTCTA
ACAAAACTCAGAGGCTCTCATCTTCCCCACTGAAGAGTTGGTGCCCTTGAACTGATGGATTCAGCTGATG
TCAAAATTGGAAACAAATATTAACGAATATTTAATTCAATCTCGGACAAAGTAAGAGATCTAAAAATGTG
TGGTCCCAAGCCTCTTAAACTTCTTGAAATCAAAGAAAGCCAACTGCTGGCCTGAAGGTCTTGGCAGAAT
GGTAATGCTACTTCTATAGCATTAACCACCAAAAGCCCTTCATCTCCAAGGATAGACAGGCTCCTTCAAT
CACTCGGTGCACTAGAAGCCAGGAAACAAGAAAGGGCACCCACCCACACAGCCAGTCAGCACCTCTCATA
TCCTCCCACAGACCCTGTTCTCCAAATACTAGACAGCAGAATAATCAGTTAAGCCTTAGTGACTGCCAGG
GTGTTTCAGATCCATTCAAATGACTGTGTTGGTTTTACCAGGCTTGGCAATTGTTCTTTGCAGAAGGCTG
AGTCTAGCAATAGCCCCATTTCACAGCTGATGGTGCTAACCCATGGCAAGGCTTGAAGTCTCCACAGCAA
AGGAATTGAGCAGCTCTGACTACAAGCCACCTGAAAGTGAATGAGCTCCTCAAATATTATCCGCCATTCT
GCCACACTGCCAGTCACTAGGATAAAGAGAACCAGAAATGGTCGCTGGCTTTGTAGAATTCTCAATGTAG
CAGAAAAGAAAGACTCATAAGAACTTATCATTACAGTGTGAAAAGGGCTGTAATGTTGGAAAGGAAGCAA
GGAGGCTACAGGAGCAGAGAGGAGGGTAACCTAATGCAGATTCTTAAAAACTGGCTAAATTAAATTAAAG
ATGTAAGGCATTGTTAACTTTAAAGGTTTTCCTTTTTAGATTCCAGGATGATCTCTGTACCTTCTAATAT
AGTTTTTTTGAAAAAACAAACTTGATTTTTAAAAACTTTGGTTTAATTTCAACATTCTCTCATGTTGGCT
TTTTAAAAACCTCTTTCTGGCTAGGTGTGGTGACTCATTCTTGTAATCCCAGCATTTTGGGAGGCCAAGG
TGGGCAGATCAATTGAGCTCAGGAGTTTGAGACCAGCCTAGGCAACATGGCAAAACACCATCTCTACAAA
AAAGTTTTAAAAATTAGCCAGGCATGGTGGCATGTGTCTGTGGTCCTGGCTACTCAGGAGGCTGAGGTGG
GAGGATCACCTGAGTCCAGGAGGTTGAGGCTGCAGTGAGCCATGATTGCACCACTGCACTCCAGCCTGGG
CGACAGAGTGAGACTTTATCTCTAAAACAAACAAACAAAAAACAAAAAACCATCTTTCTAACCCTTTCTG
TTTTTAGCGTGGGCTTGGGGAATGAGGTGTATTTTCTCAGTGATACCATCAGGGGTGGGAAGGATAAGGC
CAAGTACAGTGGGAATACAGACGGTTCCTAGGGTCACCTGCAGAAGAATAGCCAGATGGGGAAACTCAAC
GCCTAAGAGATTCAGATGTTTAAGAGTCATGTAAAAGCCTCAAAAGCATTTGAGGTCCCAACATGTAAAG
TATAGGAATTCTCAGGTTGGTATTTGGGCATCAGAGAGTTGGGTGGAGGTTGTAAAAAGGTCTGCCACAG
AGGACAGTTGGAAGGTTCTGGTGCTGAAATCAGTGGGGAATGACAGAGGCTAAACAGGCTCAGGCAGAGG
TTATGTATGACAACTGAGTCTCTTTTTTCCTCCTGTTAAAAAGTTAGTGATTTTATCTATCTCAAGTTTG
TTGTAAGCTATAAATGAAACTCTCACATATAAAAAGACTAGTCCTTGAAAAAATCCCCACCTCTCCTTTC
TCCTACCCCCTTCCTCTGCATTCTCACACTACTCTTTTTCACTTTTCAGAAGCCAGTAGTGTAGAGAAAG
AGCTATTCTAAAATATTCTATACAATGTGTGCCACTAGGCTTCTAAGGGAGATGGTGATGTAGTAACTTT
CAAGACACTTAGTCTAGTATTGCAATTGAAAAAAAAAATTGAACAGTATATATTAGTCAGAATAGGCCAA
TTACTGTAACAAACAACCCTGAAATCTCAATGGTTTGACACAGTCAGGGTTAGCTCTTGCTCATTTCACA
GTTCAGCATGGGTCCATAGGATGCTATACTCCACTCAGTCATTCAGGGACCCAGGTGCCTCTCATCTAGT
GGCTCTGTTCTCCTTTAGGGCCTCAGAGTTCTCCTTTGTACCCTTTGCATCTACTTGGTAGGCAAAGGAA
GAGAGAGAGTGAAGATGGCACATCATAGAGAAATTGTTAGAGACTAGTCTTAAAAGTGATGTGCATCACT
TCCACCCACATTCCAATGGCCGGAGCTCAATCACTCAGCCCCACTGTATTCTAGCTGTATGGCTAGGCAG
AAAAGGAAATAGGACTGGGTGGACACTTGGCAGTCCCTGCACCGCAGTCAGAGGTAGCCCAAAATGAGGC
AAATTATTGGAAAAGTAGTGAATGAGCTCCCTTTCACTGAAGGTATGTAAGCAGAGTCCAGTGACCCCTT
ATTTTCCAAGTCCTACTGGAGTAAGGTGGGGGAAATTTAAGCTAGAAGAATGCAGAGGACCTTTCTATCT
TTGAGGTTCTCTGATTCAGTAAAGCAGAAGGGAATTGGAGCTGAATTACCCATCTGAATTTCCGGTGACT
TAAACTGAGTTCTTGGAGTAGAAATAGAATGTTGAATTTCATTTCATGAATTGTTCTTCCAGCTTGACGT
ATTGGAGATTTTTAGCACGCACGCTCACACCTGGCTGCTCGCCACCTTCTGCCATTGCAGATACGCTTAC
AGGAAACCGTAAGTGGATCTGCTTTTGATGCTGGCAGCGTCTTACTAAAATGCTTTTGCTGGCATCATGG
AACAGGAGCAGAATTCAGCTGGGACCAATAATGAGGCTATTTAGAAAGTTCTCTCCTCCACCCCCTGACA
AGGCAGATGTGGTAGGGATTTTTCCACTCCCATTCTGTCGATGGTGGCCAAAATTAGTTCAAGGCCATCA
GAAGTGTTTAGACCTCAAGAGTTGAAACCCCAGACCCATAAAGAGGACAAATCCTCTTCCTCACGTCTAG
CAAGAGAAGAAGAAACTCACCCCCAAAGACTCCCAACACAGAAATTTGTCACCTATTGTTCCGTAACAGA
CTTTAAAAAGGCACAGCCATGTGTCAGTTTGGAAGGAAAAGAAGCACTGACCTCCATTAAAAATATCTCC
AAGTAAGTTAAAGTTGCTAATGCTTTCCTTTTCCTGAAACCATGTTGTATTGAAACAACATTTTCTTCTA
AGCACTTTCACTTCTATCATCTCATGTTAAAATCCCCAGCCATTGTAGTGTGAGGTAGGGATGTCATGTT
TTATCCCCATTTAATAGATGAGACTTCTTGAGGTGCAGAGAGATTAAGTGGCTCGCTTAAGGTCTGTGAG
ACATGTATGCAAGATGAGTACCCAAATCTCTATACTTCCAAACTCTTTCGCCTAGACCACACAAGATTGT
ATCAGCTGATGGGTTTTTTGGCCATTCTAGTTCACTGTAACTGACTCTGTCCATCTGTTGATCCATTAAT
CCATCTGTCCATCCACAAACTGTACCAGGCATTGTGCTTCAGATACAGAGATAAATAAGGGTCTTTGCCT
TCACAGCTTAGTAGGAAAGATGGAAATAGAGATAAATAAATGATGGATACAAGTACATATATAGACAAGT
TATGATGGGTATATGTGTGGGGAAGGGCCAGGATTGGAAACACAAAAAGAGCATGGTAAGTTCTTCCTTA
GAAGGTCAGGGATGATGTCACAAAGGTGACATTTGAGCTGAATCTTATAGGTGTATGACCATCAGACACA
CAAGGGGTCGGGGGCATCCCAGGCGAGACACCAACTTGTGCAAAGGCATAAAATGTGGCCTATGCAGGGA
TGTTCTGGCATGTTTCGGGATGGTTTTAGAGAGTAATGAACCCAACGGGGGCACCCTGGCAGCATTGCTG
AGCTAAAAGTAAAAGAAGATATTCTGTAATACTTGTGTGCACCCTTGTTCCTGGACTCATGCGACATCTC
AATTCTCTGACTTTAGGCAGTGGTTTGGGTCTGACCCACACAATTTAGTCTTTGATTATGTACTCTTGCC
TTATTCTGCCCATGTTTTCATCATTAGGCGTGGGCTCCCTAGTCTGACTGTAAACACTAATAACAGTACA
TTGTGAGTGCCAAGGGACTGCTTGGTGATTTTTAAATATTCAGAAATCAAGCAGTGAGCCCAAGAGAATA
TGAGCAGGATGTAGCACCATGAGAGGAAAAATATATGGACTTTAGTTCAGTTAGGTAAACCAGCACCATG
CCAGGCATGGAGGGCACAGAAGTTGTTGACGTCAAAGAGCTTACAGTCTTGAGTGGAAGGTAGACAGGGA
AGCTAGTAATCACAATTCAATAAGGACAAGAGTAACCTGTGGAACAAGTTCTGTGAGAGCTCAAATAGGG
AACCATTAATTCTGCCTATTCTCACTCCAATATAAATTCCCAGGGCAGGGGATTTTGTGTGCCTTGTTTA
CTGTTGAATCCCCAATGTCTGGCACATAGTAGGTGTTCAATAAATATTTGCTGAATGAATTTATTGAAAT
TAATTCTTGAACTTGATTTATGATCATCAAGGATAAGTGGGGACAAGTGTTCCAGACAGAGAGAGAATAG
CTTGGGCAAAGAAACATACATAGGTGCAAGTTTTAATTTGCCCAAATGTTGTTTCCCTAAATGTACTGCC
AGAGAGTGTTCTTATAAAGTTTGGATATCATTGAGATTTCTGGATGGTGGCCTTTCTTTCTTTTCTTTTA
TTATTGTTTGTTTGTTTTTAAACTTTTGATTGAATTCTCCCCACACATTACTGTGCTCAGTGTCTTGAGA
AGATTGACCATACTGGCACATTTTAACCAGGGCTTCTGTCAACTGATGTCCTTTTGAACCACCTGCATTA
GGGTGCACATTGTTGCATCCTCTACCCTCATCCCTCTGTTGGAAACCATAGTGGCTATCAGGTAAAATTG
GTCATAGGTAATGTGACCATGTGACCTGGTTTGCCATTACTGGTTTATGCCTGTTGTCTTGTTGTAATTA
TTAATAGAGACTCCTTGCACTCTCAAAAATATCTGGGTTTGCCCGAGAGAAGCATCAGTCAAGAAAAGTG
GTTGATGTAGAAAGCCCCATTACCAGACATTGGGAGCACTAATTCAACACTTACTTAGCAGATATTTATT
GAATGTGATTCTATTCTGGACACTTCAGGGACCCGTAAGTATGAACAAAACGTGGTCTCTCCTTTGCCCT
TAATTCAAAGTGATGATTGTACATATCCTAGCTTTCTCGTGGTTATAAGAATAACACAGTAAATACTCTG
TGAATATTTGTTGAATGATTATAATGAGTAAATGATGTATGTTATTTAACCTCTTTCTTAGTTTTCCTTA
TATGTCAATGCAGAGATAATAATAACAGTACCTACCTTATAGGATTGTTGTGAAACTAAGTGAGTAAATA
CATATAAAGAGCTAAGAGTAGTATCTGACACAGTAAATGCTCAATAGATAGCAGTATTGTCTGAAAGCAC
TTTGCAAACACAACAGAGCTACCTATAGCTTTCTGCAGCTTAAAAATGAGAAAAGCAGCGATTTGGAAGC
TTTGTCTAGGAAAGGTTGCATTTGTTAATTTATTTAACTATCATTTATTATGAATCAGATATAAGCCCCA
TCCTCAAGGAGCTCAAGTGGGACAGACATGCAAAAGAAGACTATGAATCTACATACATTTATGTCATAAA
ACCATGTCCTATAAATTTGTGGGTTTTGTTAGAGGTCTGCTGGGTACCACTTTATAGACCATTCATTGAC
AGTTTCAGCAGAAGGGGTGGATGTTGATTGCTATTAATCAAGGAAGCAATGTGGTTAGATTGGAATTTAA
GAAAGGTTACTGTGGCTGGTAGATGGTATTCATTTAAAACTGAAGGTAAAGATACGTTGATGGTAATAAT
TCAAGACAGGATCAAGATACCAGCTTTATTTTCCCAGCCCTCTCTCAGTATTTGTGAAACCTGTGTTGTC
AAACTTGAGTGTTTCCATTGTTAATTGTTGTACTTCATGTTTCTATAAGTAAAGAATAATTAGCTGGGTG
TGATGGCTCATGCCTGTAATCCCAGCACTTTGGGAGTCCAAAGTGGGCAGATCACCTGAGGTCAGGAGTT
CGAGACCAGCCCGGCCAACTTGGTGAAACCCTGTCTCTACAATAAATAAATAAATAAATAAATAAATAAA
TAAATAAATTAGCTGGGCTTGATGGCAGGTGCCTGTAATCCCAGCTACTGGGGAGGCTGAGGTGAGATAA
TCTCCTGAACCCGGGAGGCAGAGGTTGCAGTGAGCCTAGATTGCACCATTGCACTCTATCCTGGGCGACG
GAGTGAGACTCCATCTCAAAAATAAAAAAATAATAATAAAAAAAATTATTCGGAGGAAGATTAATTGTGA
AGCATTCAGGTAGGTGAAAAGTGTGAGAGGAGTAAGCACTGTTATCCTGTATGCTTGGGAGGCCTCAGCA
ATGGAGACATTCCATTTGGGATTTCAGATAGCAATGACTGAATGCTTCAAAATGAAAATAACAGACAAGG
AGGCTTGAGTTCAGTGGAAGTGCTCAGGGACTTGCCTAAGGTCACATAGCTAGTTTACGGCAGCATTGGT
GCTCAAACCCGTCTTTTGACTCCCAGTTCACTTTTCTTTCATTATAGTATTATTTATACTAGACTAGATA
AGTCCCTTTACTGATTGCTGAGTTCCTTAGGAACTGCGTGGGTGTGGGGTAGGCATTAATGAGGCCCACC
CTTCCCCCAACTAGGAGAACAGCACTGTTCTATTTGTTTATATATTGAGGGTTTTCATAATATTTTGCTT
AGAAAAAAGCACTTGCTATAAAAAAGAAAAAAAAGGTTGAAAATAAATCATCTGAAGCTACAAATTAGCT
AAATAGCCTGATACTCCTGTAGTGTAAAACTATATAGTCTCCTTTTAAACTAATTTTATATTTATATAAT
ATATAATTTTTACACACACACACACATACAGCCACACATATTAACTAATGTCACTGCCTATATAGATACT
CTGTTAAGTACTTGCACTTCCTAGGGTTTTCCCAGAGACCTGGTTGTATAGATCTGAGAATATGGGCTAC
AATATCAGCAGTGCCTTCCTCTTTTCCATAGCTTTCACACCATCCAGACCTATTGGAGTTCTCTGTGACT
AAGACTTTCCAGCTATGGAAGCACAAATTCAGGGGGCAAACCGTCACATTATTCACCAAATAAGGTTGTA
GCCAGAGCATCCCCATCTCTATCAATAAAACAGTGCCTGTGTTGAAAGCTCATAGCATGAGCTCAATGGA
TTTGTTGAGTTTGAAGAGCAACTTCCACTTTCGAGTTTCTGATTTTAGTCACTTGAACATTTCTAAGAGG
AATAATACCTTCCGTTGGTAGAGCTTTCTCACAACAGAAAAAAATGATTTTGTGGAAAGGTGGATTCCAA
AAGTTTTTGAGTCATCCTTGGGATTCATCTACTCTTCATGTATTTCTAAGAGAGGCCATATCTCAGCCTG
CCATATGAATATATTTATTTTACTTTAGCAAATATTTATTGAGCACCAACTATGACAGCCACTGTGCTCA
GCTGGAGGGAAACAAAGACAAATAAGAACAGTCTTTGCTCTTGAGTACCTTGAAAACAGGTGGGAGAGAC
AGACCCGTAAACAACTGTGGTAATGCTCTGACATGAGTTCTGTGGAGTCAGAAAGAACAAGCTAGTATGA
AAGCTCAGATAACAAAGAAGATCATTTTGCTTAGTGAGGCTGAGGCCTTGAAGGATGAATATGATTTTCC
ATACAGAGAAGGCATTCTAGATGGAAGAAATTACAGGCATAAAGACAAGTGTTGTGAGAGAATAGATGGT
CATATCTAGAGCTGTGTATAGGGAAAGGAATGTCTTGGAGGTATCAGGAAACTTAAATAAAGACAAAATT
TTAAAGAGCCTTGAATGCCGTACTGAATAATTGGCCTTGAAAAAAGCAATAAGGATCTTAGAAAGATTTT
TAGGCAGGGGAGTAACAGAACATAGGGCAAACCATAAGAAATTGACCACGTTTGACTGCTTTTAACCTAA
AAAACAATTTCATGTTTCAACCTAATAAAAAATAGTGAACATTTTTGAGTAAGTAGCAGCATGTTACACC
CCACAATACATGCCTTACATGGATTATCTCATCTAATCCTCACAAGTTTAGGCATTATTGTTGTCCCCAG
TTTAAATATGACACAAAATTCAGAGAGTATCTTTGGACTTAATCAAGGTCCTGGTCCCTGACTTTTAAAA
GCCCATGGTTTTAATGATTTTAACCAACCATCTCCAGTTCTGCATTTTATTAAAATAGCTTGGTTAGGCA
CAGTGGTGCATGCCTGTAATCCCAGCACTTTGAGAGGCCAAGGCAGGAGGATCGCTTGAGCCCAGGAGTT
TGAGACCAACCTGGGCAACATAGTGAGATCTTGTCTCTACTAAAAATAAAAATAAAAATTAGCTGGGTGT
TGGGGAAAAGGCCTGTAGTCCCAGCTACTCAGGAGGCTGAGGTGGGAGGATGACTTAAGCCTGAGAGGTC
CAGGCTGCAGTGAGCCATGATCATGCCACTGCACTCCAGCCTGGGTGACAGAGCAAGACCTTCTCTCAAA
AAGAAAGAAAAAACAAAACCTCTCGTGACCAGACTGGGCATTAGAGGAACATGCTACTACCCCGGCTCTT
TCTTTGAGGCAGATTTAAAAATCTTCTTCAAAAGCTTAATTTCCCTTTAGCCAGCATTATTACAGTGTAA
AGTCAGTTGAAAATCTGAGTAAACCCTACTGAAAATGTTGTTTGCTAATTAAAAACTACTTATTTATAAA
CTCTGACATATTAGAACTGGCAGAGACTTCAGGAATCATCTAGTTTCATTTCTTATTTACTCAAGAAGGT
TCTGGTCCAGAGAGGAGAAGTGGTTTGCCTGAGGTCATAGAATTACTAGTAGCAGAGATGAAACTGGCCT
TGATGTCTCCTGGCTCTTCCTTTATGTTCCCTAGTGAATTAAAATGGATCTTACTTTCACAAACATGCAC
TAAGCACCTACTGTGTATAAGGCCCATTGTTCTAGGTATGTTCTTCTGTTCTCTTACACATGCAAATGTG
TACAAATTCATGTTAGGTAGATGGTTCAGTTTGGCTAACTACTGACACTACGTCAAAGATATAGGGGGAA
TCTGTCTTTTAGCTATCCATATCATGGAATTGGCAAACATACATTGATAATAAATTTTTAATAGTGAAGA
TATCCATTAAGATTACTGTTCTAAGTCCTTGTGTGTTTTGTTTCCTTTTGCCCCAAGGTACCCATGTGCT
AACAAATAATAAAGAAAAAATTTCAAGCAGGAGTTTTTACATTACTTGAGTTGTGAAACCTTGAAGATGA
TGTAAGCATTTCAAAATCCTTGAACAAGATGTAAGTTTTAATGGTATGCATAACATATATGACACACATT
TACATTCATAGGATTTTTGAAGGCTAGCAAAATTTTTTGCAAGCATTCTTATTTCACTGACAATGGAAAA
ATCATCAATGTGATGATTATTTGATTATCCCACTGTCCATTTTATGGATAATGAAGTGGGCAAAGTAGGT
ATCAAATAATAAAATTAGTAAATACTCTTTATTCACTCTTCTCAGTAAGGGAGGAATAGCAAGTGGTTAG
ACTGAATAGTGAGTTCAATATCAATAACCCTTTTAAAATAACTTAAGTGTAATTTCTATAATGACCTAGG
ATTAATGATAACTTGGTTAAAAAAATGAAAAGTTATGTTTGTGAGTAATTTTAGGGAAGGACCAGGGCTT
TTCTAGACACTCAAATTTTGTAGAAGCCTAGCATCATTGTGGTTACCTCATAATATCATAAAGGAAGGTT
AACATGAAATAAGCACTTGTAGCAAATAAGGCTTTGGGTGTTGTAATGTTAAAACTTCTGTTCAAAAACC
TTACATTAAAAAAGTACTCATCTTCATTAAAGATGTGATCCTTTTCACAGAGGTATTTTGAACTTCAAGC
TGCTGTTGCTAAGGGGTTGCTACGGGAAATGAGCTACTCAGCATTAATGTGTAACTTTACTCTTCTGCTT
AAAAGTAGTTAAATCATTTCCCCAGCTTTAGAGTCAGAGAGGGGAAGAACTAAAAAGGGTCAAGTGGAGA
GTTGCCTCTTTCTGACAGTTATATAGCATGCCTCTCTTGTTTTTCACATTTTTTTATTTGCCTCTCATAG
AGAAAGGAAGCATCCTTTCTGGGCATAAGAGGGTTGAAAACTAGACTACCAAGTAGGGCAGGGCTTATAA
TAAATGTAGAATGTCCCTGGCTAAGGCAGAAGGGAAGTGCCTGACCACTGAAAGAAAAGCAGCCGTGGGC
TGTTGATCTAAGGCTTCTGCTGGTGACCAACCTCAGGAAAGGGCTTTTTATAATAAGTCAGCATTGAGGA
TGACTTGATAAAGAAAGTTATGTATTAGTGAATAGAGCATTGACCACCAAATAATTATATCCTAAGCAGT
TGGTTCAAAAGTTTTTCTGAATTATTTGAAATCAATAATTTATATCTTTTCTTGAGTGCCCACCATATTC
CAGGTACTGTTATTCCATGTGCTGGGGTTATAAGGCAAATAACGTACAATTTCTGCCATGCAAGCTCACA
GTACAGTGTGAAAGTAACAATGAACTGGCTGGGTGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGA
GGCCGAGGCAGGTGGATCACCTGAGGTCGGGAGTTCAAGACCAGCCTGACCAACATGGAGAAATCCTGTC
TCTATTAAAAATACAAAATTAGCCGGGCATGGTGGCGCATGCCTGTAATCTCAGCTACTTGGGAGGCTGA
GGCAAGAGAATTGCTTGAACCAGGAAGGCAGAGGTTGCAGTGAGCCAAGATCACACCACTGCACTTCCAG
CCTGGGTGACAGAGCGAAACTCCGCCTCAAAAAAAAAAAAAAAAAAAAGAAAGAAAAAGAAAGAAAGTAA
CAATGAACTATAATCCATTGAATGCAATCTGTAATTGAATTGTTTGAAAATTACTGAAGTCTGGAATTAT
GTTCTCAGTGGATTTTTAATAAATAAAATTTGGAAATATTTGTAAAGATTAATGCTTTGGGACTTTAGCA
GACAATTTCATCTGAAGATCAGTCACTCTCTACACCACTTCCAAGCCTGGAGAATGGAATAGCACATGCA
CGAAATAATGTAGACAAAATGTTTCCCTTGTAATCCTCATAGGACCAAGGTTCTGTTATCACCTGGTGGC
AGAATACAGAATTTACAGGCATAGATTATTTTGATTGTTACTGTTTTAAATGTCAATAGAAGTCAAAGAC
ATTATTTTGAATGTTAGTTTTTGAGTATAGAGTAACACAGAAAATAAGACTTAAATATCTTTAGATTCAC
ACTTTTCTGTGTAAGTTGGTATGTTATAGAGAAAAGACTGTGGACTGAGGTTGGGCATACGTAAGCATGA
AACTTAAATTGGCCTCTTACTAGTTACATGATCTTGAGAAAATCAGTTAAATTATGTAATCTCTAGTTTT
CTTATTGGAAATCTCAGAGTTGTGAGATTAAATGAGATTTATAGGCACAGCACCTACCATAATGTTCAAC
ACACAGTGAATGTTCCGTCAATATTAATTCTGGTTCCTTTTATAAAGAACGTACTGAATAAGAGGTCTGC
CCGCCCACAGTCGTCATATCATAACATCCCTCTGTTTATAGCTTTTAAAAATGGAGGAGGTTGGAATAGA
TTCAGAGGAGCCTTCATAGGGGTTCTGGCTAGGATGCGATGGCTGTCAGTATTTCTTTCCTTTCCCCCTA
CCCCACCTCTATTCTTATATGAAAAATATTCTGCATTTTCCTAGCCAATTCTTATCATTCTTTGGATCTC
GCCTCAGTTCAGGCTTCTCCCACGAAGCCTTCCCCATCACTCCAGATCTCATCCTCATTATCAACTATCT
CTAACACTTAATTTTGGTATTCTTTTTACATCCTTCCTTAGGCTATTAGGATTCATGCATAAAAAGGAAA
GCTCCTTCCCAATCAGATTTTAAGCTCCTTGAAGGTGGGGACTATGACTTCTATTTCTTTTTATTGTTCA
CACCAATAATTTAGCACTGAACTTTGCTCACAAGATTAAGTAAATGTTGATTTGCAGCAGGCACTTTTTT
ATTAGAACTGGAACAGACCATTCAGCCTTTGTTAGTTATGATTTTCTTGTTATTCTCTAGTTGTTTTGAG
AGTCTTTATATCATATCTTCCTCAACAAGACTGAATTATCCTGAAACTAATACAAATTTATGCATTTCCT
CCCCATTCTACATATTAGTAATAATTGCTGCCATTTAGAGTGATGCCTCCACCAAGTTTTTTTTTTTTCT
GGCAACAAACTATAAGTGAAGTATTATTGTGCCCATTTTACAGATGAGGAAATTGAGGCTTATGGAGCCT
AACATATCATTTTTCCCTAAGGAGATGTTCAGCCACCCCTAGTTGAATCAAACAAAATGGGCCTTGGGAT
AGTACTTGAAGTGTTAATGAGTGGGACTATTGATCTTCGTTCATTCCCCATAACTCAGCACTACTTGGAA
ATAAGGACATATAACTTAATTCAACTACTGCTTGTTGAGCAACTACTGTATGTAAGGGGTTTTTTCAGGT
TTAAAAGAGGAAAAACGGGTAGGGTTGGGGACCCAATCAGGTACTCATCCTGCTTTCTAAAATGCTTTGC
TTTCCAGCTTTAATCTTTTGTATTTCTCCTATTCCAAATTTACAGCCTGATTATAATAATAGATTAAATG
AGATATCTTGAGGACATACCTAGCTAAAAGCATGTCACAAAGAAATCTTTTTAAGAAAATTTTTTTAAAG
AATATTTTTTAAATTTTTTAATCTTGCTATTTTTTAGTTGAGAAAAAATTGAGCATGACTTTCACCTTCC
CTTTCCTTTCTCTTCTAGTCTGTGCCCATCTTTCTCACTGATTTCAACAAATATTTACTAAGGCTGGGCA
CAGAGGCTTATACCTATAATATTAGCACTTTGAGAGGCTGAGGCAGGAGGATCTCTTGAGGCCAGGAGTT
CAAGACAAGGCTGGGCAAAATACTGAGACCCCTATCTCTACCAAAAAAGAAAAATTCTTAATTAATAAAC
ACAAATATTTACTAAGCATATTCTTCTGTGACATAAAGGAAGAGATATCTTACTTTTAGATAAGGAAAAC
ACATTTCTAGAAGTATGCTTAGATACTATAATTGTCACTACTGACAATTTACTGGGTTGAGTAAAATTGT
GTATGTCAAGTGCCTAATACAGTGTTTGGTATACAGTAGACTCCCGGTAAAATATAGCGTTTTCATTTGT
GCTTTAGAATTCCTGTTAATTTCATCCAGGTGCGGTGGCTCACGCCTGTAATCCCAGCACTTGGGGAGGC
CGTGGCGGGCAGATCACGAGGTCAGGAGATTGAGACCATCCTGGCTAACACGGTGAAACCCTGCCTCTAC
TAAAAATACAAAAAATTAGCCGGGTGTGGTGGCGGGCACCAGTAGTCCCAGCTACTCAGGAGGCTGAGGC
AGGAGAATGGCTGAACCTGGGAGGCGGAGCTTGCGGTGAGCCGAGATGGCGCCACTGCACTCCAGCCTGG
GCGTCAAAGCGAGACTCCATCTCAAAAATAAAATAATAAAATAAAATAAAATAAAATAAAATAAAATAAA
ATAAAATAAAATAAAATAAAAACTCTGCCCTAACTGGCAAGTCAAAGAATTCCTGTTAATTTCGTTATTT
CTTCTTCTCCTCCCTTTCTCCCCTCCCCTCCTCTCCCTTTGACCTTTTCTTCCTTCTTTCTCCTCCTCCT
CCCTTCTTTTTCCATGGATGTACCTTCTTTGCCTTTTACATCTATTCCTTTATTATTAGTTACAGAATTA
TAAATGAGTCCAGAATTTTTTTAAATTCCATATCAAGTCATTTTCAAAAATTTATTAAACTGACCAAACA
CTATATCCTTTAATGGTATGAATAGCTACTCCATACTTTACCTGCTCGTGCACTTAGATTTATAAAAATT
TATACATATACCAGGGTTGTTTGTTTGTTTCTTTGTTTTGGTTTTTTATTTTTAGTAAAGCTCATCTGAA
CTGATATGAAGAGGCCCCAAATCCCTTAATGCAGGGATCTTCAGAAATCTCTGTGTGTTTTCACATTGAC
CCTGCTGAGTTTTTTGGGGGTTATGATGAAGAATATATCAGGGAAAAGTCCAGACAGCCATTCCACCTAA
ATCAGATGCTTGGATAAATGTGTATTTACCTTTTTTTTTCAGAATTTTGTAAGTAAGATAGTTTTCCTGT
ACTTCAAATTTTCTTTCCCAGAAAGACATCCTAGTGCTTTAAGAGTATGGTCAAAGGCACATTTGAAAAA
GTAAGCATACACTGACTCTGGAAAGGAAACTTTTACTTTCAGCTACTGTTCTTGCATAAGGCTTAGGAAT
ATGAAGAGAAAGCAGGAAGATGAAGTATGAATCTACTCTTAGGTCCATTTACCTGCACAGGTGAACTCTT
GGCGATTTAGACAGGTTAGACATCCATTTGTCACATTTCCCCCCACAGTAGCATTCTTCTAGCTTTCCCA
CAATCTGTAGTAGACAAAACTACTTAGGAAGGAGAAAGGCATTATTGACTATCAGGTCATATATCTCACA
GAGAACATTCGACAGTGAATTTCTGATAGACTCCTTCACATCAGTCTGGTGCATCTTTCTTGCCTCTGTA
GTATGTTTGCATTTTCCTATAAAAATTGATTTAATGTTTCTACATGATAAAGAAAAAAAAAAGACAGAAA
CCAACACCACAATTCAACAAAGGAAAATTAAGCTTTAAATTTTCTCAAAAGCTTTTACATATAGTATACC
ATTTTCTGGGCAGACTGATTGTATTTTTCCTAAAGAAGGAAATGCCAGCAGTCTAGGTTTATTTTTCAAG
GGAAGAGGTAAAGGATGAAAATAAATTGAACCACAGGAAAATGTCAGGTCATAGTCACTGATGACGCTAT
TTAAATGGTGTGCTATAATCATATTAGGGCAGAGCACATGGAATTCCTGATTTCTGCATGACAGTGAAGA
AGGGCCAGCAATTATCTATATGTGTGTGTGTGGATATGTGAGTGTCTGTTCACTCTACCTTCCCACCCCA
TTTTGCTAATTCAATTGAGGGGCAAGAAGAGGTAATCCAGACAGCCGGAACAGGAGGAAAAGGTCTGCAG
CTGTGTTCGGAGGGACTGGTGTGAAGAGAGAGGCTCAGTCTGACTTGGAGTTTTGTGCTGTTGCACGTGA
ATGCTCTGGAACTGCCCTAATCGACTGAAAATGAGCCGGCTACAGTCATATGGAACAGGTCTGTTTAGCC
ACATCACTGGATAGCCTGGCAGATGGTAGACCGTCAATGGGTGGTATTGATTGGCTGGATTTGCCTTAGG
GTAACAAGACTATGGGTCCTTAAAAACCCGCTTCATCTTATTTTCCTTTGTGCAGCTTCATACAGTAGTG
GTTTTCTCTTCTCTCTCCCCCCAGTCCCCAGTATCCCCTTTTACCCTTTTCAAATTAAAAGTCTTCCTTG
GTAATCAAAATAGAGAGGTTACCTTGAGATAAACACTCTTTAAATTAGCACCAAGGCAAGAAAACTTGAG
AATATTTTATTTACTAGGCTGATTACATTTTAATGTTTGAAGAAAGTGACATTTTTTAATTAGTGTTTAA
GACATATGGTGAGTGTACAAATTAGCTTATTTCATACAACCAGAATTTGATGAGAGCAACTCCTCCTTCT
CACTCCCCAGTTAAAAATTGTCACTTGAAACTTAATATATGCAAGGAGGTTAAATGGTATTAAGTGATGC
CGTCTTGACTTAAAGATGAAGGACATAGTCACTATTGTGTATGGCTAAATACGGCCTGGATGGGCTGGGA
AAATATTACTGTCAACACCTGTGTTTGCAAGAAAATGTGGAGGTTCCAGACCTTTAATTTTGTCCAGCCA
AGAAAAGAAAATCCCAGGTATCTGTGTGTGTTGGTTTCTGTTTTAGACACATGTGGAACATAGAATGGTG
TTGCATGCTTTATAAGTAATAAGATCCTCCTTAAAATCAGGCCATATAACAATATAAGTGATGTAATTTA
TTTTTGTTCAGGTGGTTCTATATCCTTTTAACATACCCCCAATCACTTGGAGCTTTCAACTTGGGACATT
CTGTTTATTCTTGGCAGAGGAGCAGATTAATTGGAATAGAGTGATACAAAGGAGATGCCAAGTTAGCTAT
ACATCCAAAATAGTATACGACAGAAATGTTCCACTTCGAGGCAGATCTTCGGGAAAAAGAACAGCAATGG
GTAGAGACATGTGATTGGCTTGCTCTTGTGGTTGTTTATCACTATTCATATAATTGTATTTTTAAAAGAG
AGGCTTAATATTTTGTATTTTTTTTCGGTGTCTTTACTTTTAAGCTTTCAGTTATTTCTTATCAGGAAAG
ACCCACATTAAATAAACCTAATTTCTACCCAGAAGAAAAGTTGCACCCTTAAACTCTTGCCTCCATCTTG
TATGTGCTTCATCCACATGCACACTTTTGAGTTTTCATCACTGTGTGTGAATATTTTTCTGTTTTTGCTA
AAGAGAAATATTTTCATGAGGTTTTTGGCCTTCCCCATTGCTCTGTGTTGATTGTATTTTCCTTGTTCAT
CCTTTGCTGAATGAAACAAAGCTTGTTTGTGTTTCATTCTTCGCAGTTCTTATTAGAATTTGTGGCAGTG
TTTTGTTTTGTTTTGTTTCATTTCCTTGCTTTAAGTCAAGAGAAGGAATTTTATTTATTTATTTTGACAA
GATATAGTGAGAGACAATCTTGCCTGTTAAGATGCTAGTGTTTCTCATGTCACATTTTACACCCAAAAGC
TATTCCAAGGGGAAAAAAAAAAGAAATCTTTTAAGATGGTTCATTTGAATCTGTGCACTCTACCCACCTG
GTGGTTATATAGTGAACTGTTACTTTAAAGAGTAGTTTAAACACCAGCCATGTTTGGGGCAGGCTGCTCT
TGCAAAGAGAGCAGTACATATAACAGGAGTCTACTGTGTGTGAGATAAGGGGAAAATTCAGCTCACTGAC
TAGAGGTTTTAATGTACGAACTCTAGGGAAATAATATATTGACTGTTCCGTGGTGCGCAAGAAAATTGAA
GAACCCTTTGCAGACGGAGTGCTTTGCAAAGGATTCTATCTGTTTCTCTTAAAACAAAATCTGTGGCAAG
ATGTTTGAAATCAGCAGGACGCTTAATGCTGCTTTGTTAAATAATGAGGTAATATTTTGTCACTTTTTTC
TGGGCAGCATCTGTTTTTCCCCCCTCTTCTTTTTTTTCCCTATATTTATGAAGGATTCCTTTTTTTCCGC
CTCATGGAAGTCAAGGAAATACAATTCACGCTTCCATTTCTGTTCCTTCCTTTTGGTGCTTTTGGAGAAT
TTGGTTGTCTTTTTTTATTTGCAGTTTCAGCCGGCTGCTGTTTCCTAGCCCATTGTGCCACGTAAGGCTT
CTCCACTGCGCGGAGTAGGTAGTTATTAACGCTGAATTGGCTTCTGGTACAGTCCATCTGGACTCTGTGT
GGGAAAGCTGGCTGCCGGCGACTGATGCTGAGATATCTGCAACCTTTGGGATGTGTGCATGGTGGCAAGG
GGCTGACTGATATGAGATTACTTCTTTTAAGGGAAATTGTCATTAATGAGTCAAGAAACTGCTCATTTAT
GGTAAGAGGAATACAGCGGCGCTGGCAGCCCCACAGTGCTGGGATATCATTTTTAGGTTGCCTTAGCTGC
TTGAGTGAGACAAGTTTCTTTCTGTGGTGGTGGATTGTGGCAGAAAAAAAAAATCATGCATGACTGGGAG
ACTCGCCTGCCTGATTCTTGAGATAATATATTGAGAATCTGTTGCTTTACAAATGTCACATCACTGATGT
AGCGGTCAGCCCCTCACTCTGAAAGATGAATTGTACTATTGGAAATGCGATAATAAGGTTGACTTTTCCC
AACAATAGGATTCTGCCTTTGTCTTTAGAGAAAAGGCCTCTGAGGACATTTGTGCATTTGTTTGAGGATT
CTGTTGAAAGACTTTAAAGTGGAGGTTTGTGGAAAAGTGATCAATATACAAAATGCATGAATTTTTAGCC
TAGCAAAACCAGCTAGTTATTTATACTGTATATACAGCTACTATTTTGGAAAAGTGGCCAGAATACCTTT
TAATATACCTAATGTTAATTTATGGTTCAATAAGTGTACTGAGGTTAGTATGGATGGGAGAAAAGGGTTT
TTAAAATTTTTATCTTTTATAACCTCCAGAGAAATCTAAGTAAATATTTTGTTCCAAGTGAGCTGTTTTT
ATTTGTGTTTGTCAGCATTGTCTTAATGTTTACTTTTCACAATATTTTAATATTGGTGAAATTGCACTCA
GAGTTTATGTTGTTGATTTGGGGCACACATACCTACTCTGTGTATATATGCTGAACCATTTAGAACACTT
TAACCTGTGAATTCACCCTCAGTACACAGTTCAACAGATACTGTAGTACTATTGTGACTCACAGGACATT
TTATACATTTGCTAAAGAAATTACTTTAAAAGTTTACTTAACTGAGTATTGTTCCACCTTAAGGAATTAT
AGTTTTAACATTTGTACTTTTCTATTTCATGTATTTTCATTTCTAATAGCTGAACGTATTCATACTCAAG
TCTAATGGATTATGCAGTGTACCCAACACATATTGTTTTATGATGTATCTGTATTTTCTGAAGTGTGAAT
ATATATGTATGTTTATATGTGTGTGTTCATGAAACAGCATCTTGGACAGAATAGTTTTAATCTTGAAAAA
TGTAAGGTTATTTTCTTTCCTAATAATTTTTCACAAACCCATTTATTCTTGGACTTTGAAACCCAGAAAT
ATAGCTTATTTTTTGGTCTGTATGTCTACTCTGCCTAGTTCTGTCTCACTGTCAACTCTAGTCAAAGATT
AAAGATTACATTGAATTTTGTATTTGGTAATATGTGTTACCACTGTGTATTTATTGAAGAACAAATTGAT
TAAATTATGAGTTAAATAAATAGTGACACATTAGTCTTTTGCATAGGTGTGAAGCATGAACTTCTCAGGT
AAGCCACTTAAAAAACCCAAACCAGAACAAAAAATACACTACTGAAGGCTTGGTAGTGTAGAGGTTGTTA
AATGTGTAAATAGGCAGACAAACTGTATACCTCACCATACACTTGCTAAATGTCTCTTTGCAAATCTCTT
AAGAGGCCAAAGAAAAAAAGACATCCCTTTGAAGGAGAGAAGCAAAATCACTTATTTAGTTAAGCAAAAT
GAACACTCTGCACAGGTTTTGAAATGAGGCTGTTGTCAAAAGCATGTTTTACCTTTCTCTAAAGGGGTAG
GAGAATGTGTTTTAGTGGATTTTTAAAAATTCAGATCATGTTCCTATCCAACTTGAAAAATAAATTCATT
TAAGTAAATCATTCATCATCCTCAGTTTTGAAAAGCTCAGACAGAAGGCAGAAAGGTAGAGGCTGACAGC
TGCCCCTCCCTTACCCCCACCATTTTTTTTCTTTTTGTTTATTAGGAAATAGTTTTCTGAGACAAACTTG
TATGAACCTAGTTCACGGAGCAAGCTTAATCCCCAACTTGCTTGCTTTTGAAATGTTGGCCATGTTAGCT
GGAGAAGGAGCATTACTTACTAAAAATCAGCAATATCTGGAAATAATAAAGTTAAATTGTAGATGAATTA
GCACATTAAAGTGCTTTTGTTGTACCTTTAAGCCTACAGGCAGATCATTAAATATGCATTTCGCTAGAAA
GCAACTGTCTAGAAAGATAAGGTGGTTGAAAATATTCTACGGTGGAAAAGCCCTCCATCAGAGAGGTGGC
ACGGTTCGGCCCTCAGGATGGGAAAAGAAGGACCCTCCCACTGTTAGTTTAGGTTTGCAAGCCTCCAGTG
ACCTGCAGTTGTTACAGTACTTTTGAGCTGGGAGGAGGGAAAAGGTAAAAATACAAGTATGGCTGTTGTT
GCTTCAGCCGGGCCTTAATTACCAGACACAAGAAGCAGTTCAGAAATCTGGTCTCTGTTGTTGTAGAGGT
CACCAAATCATTAACATCGTCAATCTGGCAGTAGCTAATTTAAATAGCACCTGATGTTGCAACGCCTCCC
TTCGTTTCCCCAGCCAATCAGATCCAGGCTTCGGCTGACAGATGGTCCCATAAATGGATGTAAAAAGGGG
AAGCTTCGAGCCAATTTCAGCAAGGCTCTGTTCAGTTGTTCTTATCTACATCCTAGAATCGGGGGTTTCA
GCTCACTGCTCCTTTTCTTTTTTTTCTTTCTCTCCCCCGCCCACCCCCCCAAAAATAATTGATTTGCTTT
ACAATCATCCACACTGTGTTTTGTGGATCTTTAATTATATATAACAATAGTAGTCATTTTAAATATATAT
TCTGAAATCTTTGCAAATTTTAACAGAAGAGTCGAAGCTCTGCGAGACCCAATATTTGCCAATAAGAATG
GTTATGGTAGGTATGACTAGATTTATAATCTGTTGTTTGTGTTGCTGGAGGGAAGAAAAGCATCTACACC
TTGACCAGTCTTATGCTTGCACAAGAGTTTAGTTCTGTGCTGCTGTTTGGTTCCTACATTTACTATCTCT
TTTGTGTAGAGAGTGCGGGTAGGTCCTTTTATTGAAAAGCAATGGGGATATAAGATTGTCATTTTTAGCA
AGTCGTTGTCAGTTTTCCCTTCAACATAAAGGCAAGGGGTGGAGGGGGAGGGCTGAAATAATTGCTGGTT
TATTGAAAGAGGTTATATTACTTGAGACATAATGGCAAAAGAAGGGTTTTCTTTTTTGTAAGGGAGAGGG
GGTTTGTCTACGTGCCTGGGTTTTGTGGGGCTGGGGGTGGATGCAGCGGGGTTAGGAATCTCTCAATTTC
CGTGCTGGAAATTTAAACCTCGAGAGGCAGCTCCTGGATACTGAACACTGAGATGGGCAGTTGTGTTTCG
GGGGACTGCGCAGTCAAAACGGCAAAGAGAGTGATTTATTTGGGCTTCAGTAAATGCTGCATCTTGTATT
TCAAAGAGTTTCCTGTCATGACCTCATAAAAAAGAGGAGGCGGCTTGTATGTGTAGCAGTGCCTGGCGTG
TTGAGTTGTTGCTTCCTTCTCTGGGCAGCAGCTCTGTAAGAAGGAATGTCAGCTTTTACATAACGTTCCT
TTCCGCTTTTGACACACTGTGTGAGGGTCCATCTTCTTCTGATCACAGATGGAGTGGAATGGCTTGAAGA
TGGTAAGTGAAAAGAGGAAGGCAGCCTGGAGGTCCCAGCCCTGTGTGTGTGTGTGTGTGTGTGTGCTTGT
ATGTGTGTATGTGTAAGGATGCTGGACTGTGCATCGTAAATCACTGTGCTGATCGTTTGTGTGTGTATGT
ATGTGTGTGTTTATTAGTATTTCTCTTTTCTGAAAACCAGAATCCATCTCCAAGTGTAATGGCACTGCAT
GCACACAAGGCACACACACTGCCTCTTCCAGCAAACACACATTTTAGCCAAGGAAGGTTGGTGTCTTTTT
TGACAATCAATGTCACCGTCACTGTTGGCTGGCGTGTCCACCGCCTCTGTGAGCCTTCAACGGAATTACA
CGACTGCTAAAGTTAAAGGCACATTTCTTTTTCAGTCTCATGCTAGGAGTGATGGGGAAGGATGGGAATG
AGGGGTGGAGGAGGTGAGATTCAGTACCAGCCGATGCAATTGTGAAACAGGACTTTCGGATGTGGAAGGG
GAAGTGGAAAACCTTTCTGCCGAAGTAGTAAATCTATTTTTAGCATCATCTTTTTCTGAAAAAAGAAGCA
GGGAAACTCCTTGAGTGCCGCTTCTGTCGCCTGATGTTGACCCTGAAGATATGGCACAAAATGGCATGAT
TAGATGCCACGAGTGCCCACTTTGACTTTGAATTTTCACCAGCAATAGGTTTCACAAGGTTTCAGAGCTG
GGTATGGGGGCAGGCTGTAAATTCATAACCATCTTACTTATTTTTCCCTAGAAAAGCCTGGGGAGGACTT
TTTGCTCTGCATAGATGTTATAACAAAGCTGTGGTCTTTTTCCCATTCTTAGAGGATTGCCTTTGTCTGG
CTGCTTGTTTTGATGGGTGTAAAACAAATAAGATTAGACCGAGCAGCCCAACTGAAAGCGATAGCTGGGA
GGAAAACCCAATGAAAGGTTGCCGGGGAAACGAACAGAGGAGAAGCCGAGTAGGGAGCAGGTGGCTATCA
TGAGAACACACTGCAAACAGTGTAAAAAAAAAGGGGAGGGGGACAGGACCTCGATTATCTTTGCTGTTCT
TTGTGGCCAGCCCAACTTTAATTATTCGTTATTAATAGGTGTTAATTACATTTCTAACTCTGGTTTACAG
TGATTTTTAGAAATCTATTTTTAAGCATCTGTTCTGTCTCCCCTGTTTTTGTGTGTGTGTGCGTGTGTGT
GTGCGCGTGTGGTTTTTGTTGTTGTTGTTGTTGTTTAAAAAACCCAGAGAGGAGGTGAGGGGGAAGGGAG
GGTAGGGAATCTTGCTTTTTTTTTTTTCCTTTTTCCCCCTTTTCCCTGGTGTGAAATTGTACATGCGAAA
AATCGCAAGGAATCCTGTGAGACCATTTGAAAAAATGTAAATTATATTGAATGAAGTTGACGGAAGCATA
ATAGTGAACTCCCACAGCTGATAGGTTCTGCAAATGATTTCTTAGAAATTTCCAGCAAATATTCATAGGA
AAAATATAGGTAGAATAGATCTACCCTAAGCAATGATTTGGGGTTAGGTGATTTTGGTATTTTTACTAAA
TCGGATGTTGATACTATAGTTTCAGGGGAATTCATTGTACCTCTCATTTTTTTCCTCAGTAGAAATTACT
TTACAAAATAATAAATGAAGAGCTTTTTGCTTTCCTTCTTTCCCCATGCCCACAGTCACAGGATCCATCA
GGCTTGCACTCTCATAACCACTGCCTTCCATTTGGCATTTGGTCCTGATTCTGGTCTTGGCACAAACTGA
GTGAAAAGCTGATTTTTATATTAGTGTCTTTGGACGTCTGGGACCCATGTGTGCACTGGGTGACAAGCAT
CTCTCTTTTTTCTCTAAATGTGCTTTACTAATAGTCTCTTTTTCTCATGATGGTGGGTACCATAAGGATT
GAAAGGTGTAGTATTTGGGTGAACAGGAGATAGCGTAAAAACAATTGAAATGGTGATCTGTTAGGGTTTT
TTACTAAAGGACAAAATAGATGCATGATCAGGGAGCTAATTGTAAGCCCAAAAATGAGAGATTTAAAAAT
GCTGAAATACACTAAAAGATTAGGAAATATAATTGGCTTTATTGAAAGTACACTTAATTTTTGCTCTCTT
CATTGCAAATCCCCCCAATTCTTTTTTCCTTGCAGATGCGTCTTTTTGTTTTCTCTTCTTATTAGGGGAT
TTAAAAATTTTATTTTCACTCTTGAGGTAAAAATAAATAAACTTGTATTTTTTGTCATACACTTGAAACT
TGCGGCCATATGTTGAGTGCATAAGCCTGTGTCACCTTTAAAAAAATAGAATTTTTTTAAGTCTCCAATA
TAGTTTCTTTTTTTATTTTCTGAGAATTTTCTGGCAATTTTTAGTTAGGGGAAAATAATTTCTGTAAGAA
GTGTCATCTTGGCTTGGGTTGTAAAAAAGACACGTGGTTCTGATGCTGACCTTTCTCGATCCTTTGTCTT
AAAAATATTAATGCCTACTACCTTCATGTGGAGTTGTGCTCTTATGGAAGCACAAGGCTGAATGTGCATT
TATTAAGAAGTGAAAATCCAATTGGAAATATTTCTGCAAAAAACATCTGACTAAGTAGCAGTTTTAATGA
TCAGAATGTCCATATATCTCATAGTAACATAACAGCTAAATCATTTAATATTTAAATTTTTGAAAGGGTA
AAATTAACATAGATGAGGAAGTAGCTGAAAAATTACTTTGAGAATTGTTGATTTACAAGACAATTTAATA
TCTCATTTTTTAAAAAGCTAACAAACAACTTAACCATTCATTTGTGATCTCAGTCCCATTCATTTTTACC
TGCCATTCATTCAAGTCATTCTCCTGGCCAGATGTAGATGGCCTTGCTTCTGTTTGATGGTTTGCACAAA
ACCTTAAAACTTTTTCTCTCCCAATACTCCTTCCTTGGTCCTTTGAAAATTAGGGTGTTGTTATGAGAGG
AAGGCCAGATTGTTGTGAGATAATAACAATAGAATATTTAGAAAGAGAGAGAGAGAAAGAAAATGAACTG
CGCATTTGCCTTTTAGTTCTAAACTTAGTCTTGAAATTGGATTTGGGACACTTTGGACTTCAGATATTTT
AAACTTAGGATTTCTATTAGGTATAAGCTATTTGAAATTTCACATCTAGAAATTATTGTTTGAATGGTGC
TTTGTATGTGTGTGTTCAATATCTCTAAAAGGACTTGTGGATGAATTGAGATGTTTTTCTCAAGTTAGAG
TTACTGTGAACAACAATGGGATTTCCTCAGAGTAAGTCTTTTTTTTTTTGGTTTGATTTCTTCCCTTTAC
ACTTATTTCCTTATTATAGGTGGGTTCTTTTCCTATATGTAGGCCAAATACTATTTCTTCCATGAGGAGA
TATGCTGCTTCATTTAGCCCTGAGCATCTTAACACCTTATTTTAATTTTTTTAAAAAAAGAAACAAATTG
TCTGTATGTACCTCAAGTAAGAAATGGTTGTCTTCATAGAGGTCATCATACATAGACGAAAGTACTTTGG
CCTTGACAAATTTCTTCATTAGCTCCAATGATCTGTGGCCACCAGGCAGTTAATTTATATGCCTAGACAT
TTAATATGTACATTTGTTGGTGAGCTGGCCAGAGGATGCTAAACACACGAGTATGCGCTGGCAAATGCTG
CAATGCAGTATTTTTTTCCCAATGTCATTGGGAATTTTGGGGCTAGGAAGGGACATGAACATTTTCAAGC
TTTTATCTTACTATTGTCCAGTCGATGGGCCATGTTGTACAGATTTGGTCAATTCTCCTTTTGAAAGTAA
AGTCAACCTTTTATTTACCACTATCCATTCCCCCATCCATGTAATGTATATGTGGAAAGTGTGTGTGTGC
GAGAAAGAGAAGCAGAGAGACTCTGTGTGTATCAGTATAAGTGTGTTGCAGATTCCTGCACCTGTCTTAG
GCTTTCCTTATTTGGTATTACTAAACATGTATACACACTTACTTGCAAGTATATGTGCATCTATAAATGG
AGAGAAAACCAAACTGGGCTGCTTCCCATAAGAACTGGTTTCTCTTCATGACTCCAAGAGTTCTCATATT
AGAAAAATATGAAATTTCAAATATTCATTAAAAAATATATATTCAGACCCTGCAGTCTGTTAGTAACCAA
ACACCTTTCTTTAGCTGCCACTTAAGAAATTATAAGTGTGCAAATGCATAACAATGTTTGTGAGCTAAAA
GCCATCCCTTCAATCAAGGGCCTGGGTATGAATTAAAATGTGTGTATGTGAGTGTATATGGATATGTGTA
TATGTATGGGGGGCGGTGGGCAGGATGTTTTTCTTTGAGGGCATTTGAACCTAGTCTTTACCATTGGTAA
AAATAAGGAGGCGGTAAGATGGAAGTGTTAACATCTGTGCTTTGCTTTGTAAGTTGGTGTGCAAGTGTGT
GTGTATTAGGAACATCCTTATATTTGTGAAATCTCCACGTATTTTAGGGGTAAAGGGCTTTTATAGGTCA
CTGGCTTTCTAAGGGTAAAAAAAAAAGAAAAGGTGATCTGTGGGTGGGTGGGAGTCACAAGCAGTAATTG
TCTTAAATTAGCTATTTAGCAGTGAAAAGGAAAAAAAGGCTGGAAGACAAGAGTGTAGAAGAGTACCAAC
ATGTGGGTCTGCATCTTTCCGGTATAGGAGATAATGAGTGATAAATTTGAACTGGTGCAGTGCAAGATGC
CCGATAATTTCTCTGAACCTTGACTTTGCAGGTCCATTACTTCCTTGCTTGCTTGTTCACACCTTTAATT
ATATCCAGTTTGGGATGCTAGCTGGGGGCACCACAGATAAGCCATTTTGTTTGTTGTTTACTTCATTAAG
TATTCAGGCAGTGTATTCACAGTAGCTTTGGAGCATCAGTGTTAGGAATTGAGCAGTTTGGAAATGGAAT
TGTTAAAAAAGAACAAAAAAATAAGACAGCAATCAGCCAGCTAGCTTGCTTTGGATGTTCACATCCACTC
TGCTTAATGGTAATATTTATGCTTTCCCTTGCACATTAATTAAGAAATAACTTACGCAGTGTCAGGGCTC
TTAATAGGCTGGTGACTTTCTCTCTCTTTCTCTGTCTCTGTCTCCGTCTCTCTGTCTCTCTCTCTCTCTC
TGTCTCTCACTCTAGCTCCAGCTGTCTCTTTCTCTCCACCCCACCCTTGAGACTGTCTTTGCTCAGAACA
TTTTAAGACCAACCAATTTTGCTTTAGGGGAGCTCATATTCAGATCCTTGTTGTATCTAATACCAAAGGT
ATTTCTCCCCTCAATAAAGATCCCCCTCTACAAGGATCAAGAAATGCTGAGAGCCCTAAAGGAATCCTTA
AATAAATTTTGGTTGAGAAAGCAGTAGAAGTGTTGAGGAAATAAGGTCAGTGTAATTTTTGTGCTTGCGT
TTTTGTTTTTTGTTGTTTTTGGAAAGTCTTATTTTTAACCCCAAAAGTAAAATGCAAAACTAGCATATGG
GATTTTTTTAATGAAAAAAATATATATGTCTTAGGTCTCTCCTGAAAATAACCTCCCTTGGACTCTTCAT
TTGAAAAATAACATGTAAACTTTAGCTTAATTTTTGAATTACTCATTTTAAACTATAAAATATAGTTCAT
AAATATTTTTTCCATAGGAAGTTTAGTTCTTTTTTCAGGCTATGGGGAAGCAGAGAAATGACCCAGCGAA
GATGGTGAATTCTGAAAAAAACACAGCATGGAGGTTTCCTCTGTTTGCACTTCGTAGCATTGAATCTTCT
CCTGCTTCTATGAGTTATCCTTTAGCCCTTAAAGTTGTTTTGCCAACAGTGTTCATAATAGAGACTGACT
GTCATTCCTTGTTGGGTGAAGATGTATTTGTTGAGGACTTACTATGTGCATTTCTTTGGAACGTGGAATC
CAAGGTCACCATTTCTTTTTCTTTTGACAATGATCAGAAGACATAATTAATTAGAGGATAAGTCCCTGTG
ATTGGAGATGAAGTTAGGGTGAGGGATTTTTAAGGTGGCACATTGCACAATGAGGTTTGTGTCAAATAGT
AAGAAAAGGTCTGCTGGAACATTCAAGTACATAAATGTCTTTCCTTCTGTATTTATAAGCATCTAGGTGT
GACTCCAAAAGATAGAAATAAGAGATCTTTTGGACATTTTAGTCTATAAGGTTTCATGTGTCCACATCTT
CAGCCTCAGGAAGAAATATAGAAGTTTGGACTGTTGAAAGGAACTTGTCTTTCAGTCAGCAGCCCATGAA
GCTTGGCTGAAACTGGTTAATTTTACAGAAACACGAATGTCTTGCCTCCTTGCTTCTGATGTAAGTGGCT
TTTTGAATTCCTTTTCCTCTGTTACCTCCCAGGAGCATCTGAACAGATAGTGACCGTTTTGGCATGCCAA
ATTGGAAGTTTGCTAGTGGAGCAGAAATCATAGTTACTTTGTCATATACATCTAAATACTGTGGTGTGTG
TGTGTGTGTGCGTGTGTGTGTGTGTGTGTGTGTGTGTCATGTGTTGTAGACAGCTGGGAGCCCCGGTGTG
CCGTGGGATGTGCCAATAATGGCTTCTAAAGTACTCTGTGTTTTCCTAAGCTGCCAGTCTAAACCCTTTA
AAGGTTTGCTTTCTAATTTGTACATGAAAAATAACAGGCTGAGTTGAACTTTTTTTTTCAAGTGCCCCCT
TTGAAGATGCAGCAGTAGTAAATACTGCTCTAATGATAAACTTTAGTTCTAAGTGCTACTTAAAAGTCTG
TAGTAGAAAGGCTGAGAACTTGCCATCTTTACTAATGAAGCTTTCCTTAGGAAAATGCTCACTTAAAAGG
GAGTAAATGACCAAGTCCCTGAAATTTGTGATTTTTACCAGATTTGACTTATCTTTTCTTATTTTACTTT
TTGTAATGCAGCCAACCACACATCCAAAATTCTTGGTATTATACATGTCTTCAACATTAATTATCTCTGT
TGATGCACTGGGTACAGATAGTACAGTTCCCACAAGTCCAGATTCTTACTGTAACACCAAAACAAAAGTG
ATATTTATGAATAATATTGGGAAAGTTGTCCTCATAGTAACCATTCCCCAAAGGAAGCTTTACATAAATG
TGCACTTATTATTCAGGATATTAAAAGGGAATCGTTAGCTTTTACTTTTTAATTTGGGCTAAAATATGTA
AATTGGTTTTATTTTGGAGTTTCTCTGTTTTAGGTGACTTTGGGGGAGGATAACTTTCTAGCTTGATTAT
ATTTTAATCACCTCTCTAGTGGAAAAGTTAATCTTAAAAGCAACCTGCTTATTGTGATTAGGACCCAGAG
GGCCTGTGTTCAGATGGGGCTAAAAACATATTATATTGACCTGTACACACGTAGAAAAATTAGATTTATT
TCTACTAGATACCGCTATTACCATGCCTTTGTTGGCAAGGCTATCTCAGAGACCAGAGAACCGTGAGTCT
GCCTCTGGCCTCCGAGGAACATCACGGTGTGCCTGTACAGGCAAGCCTCTAAAAAGATTGTTCTTTGTCT
TAAGAAACTGGCAAGTGCAAAGGACTTCAGAGTCAGTTGAACTTAAGTTGGAATCCTAGCTCTTCCAGTT
ACTAACTGGGCAATCACAGATGAGTTACTTCAACATGAGCCACAATTCCTCATCTTTAAATGGTGATGAC
AATATCTAACTCACAGGGTTTCTGCAAGAATCAGATGAGAAACAGTATTTGAAGGCACCAGTCATACATA
GGACTTGAAAATTGAAGGTGCTTTGAGGGTGTTAAGTCTCTTTCAGTCTGTCAGTCTTTCTGTCCCTTGG
CAAAAGCCCTTCCCCAGAAAGAGGCCCATCTGCCCATGCCAGATGTCCTGGGCAGTGACATTGTATGCTA
CCCTCACTGTCTCCATACTGTCCCCAGCATGCAAGAAGGGTGGCACACAGTGTTGTTGTTTTTTTCTATA
TAGACAAGCCCTCAGTTCTTCCTCGGAATTGTATGGCTTTATTAAGTTTTCTGCATCCTCCTAGGATTTC
ACAAGCTGTATCCATGATCTCCTTTGGAATTAGAATTCACTTGGGATTTAGTTGTCAAAAGAGAAAAACG
ATGAAGATAAAATTAATTTTAACCAGTGCTGTTTTTTTAATTTCATGAAAGAGCCTGTTAGGAAAGTTAA
AAGTCAGCCAGAAAGAAAATAAAAATAGGCTGAGCTTAATTGATATGGTCCCATCTTTGCTGTCTGTATA
TTGTAACTTGCAAATTATTTGACTTTTTCCCAGAAACCAACTTACTTCAGATCTATTTTTTTTCCTTTTC
ACTGTATCAGCTGTTTTCCTCCTTTCCCCTTGTTTTCCCAATAGGCTGAACTTTGAAGTTCTGTTTCTCA
CGGAATGGTGAAGAGGTTGAGGCAAAAAGTGGCTTAATGAGATTTTTGTAACTTGCCATCAGTTTTCCTT
CTGCTTGGCAAGGCAGCATGATGGATGGCTTTGGCAGTGTGAACACCTCTAGAAGTGATCAGATTGACTG
AAGAGATGTGCAGGATGTCAGCAGAATGCTGACCCTCAATTCATTACCCTCCCATTTGAAGGAAAAAAAA
AGAGAGAGAGAGAAAAGAGGAAAACAACCACAAAAGCCTTGGCGTAGTTGTTGATTACACACACTTGGGA
AGGGGTAATGGGTCGCGTCAGGACTGGTGTTAGGTTAAACCTAATTTTGTACCTTTTCCCCAAGGGTCTG
AAGGGGGAAATAAATAAATAGGCACCATAAATTAATTCACAAATTGTTCTAAATGGGGACCTGTTGCTGT
GACCTGTTGCCGTTATGAAGAAATAATACAAATTGTCCTGAAGGGATTCAAGATTCAAATTGAAAACACA
ATCTTGAAACACCGATTTTGAATTCTACTTCATATGCTTACAGGAAGGATATAAAGGGAAGTCGATTTTT
TTCTTCAATGTAATCCTTAAAGTAGGGGAAGGGGTTATTAGTTGATCTGATATCCCAAATGCCATTTTGC
AGGTCCTATGCTAAAAAAAGAAAGAGAGAGAGAGAGAGAGAGGGAGGGAGGGAGGGAGGGAGAGAGAGAG
AGAGACAGAGAGAAAGAAAGAAAAGAAAGGAAAGAAAGAAAGAAAAAGAAAGAAAGAAAGAAAGAAAGAA
AGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAAAGAAAAAGATCCTTTGCTATGGAACAGGCAGACAAT
AAAACTTTTCTCTTTCCATATGAATCTATTTTAAGTCTTCACCAAGAATCTTTGGAGGATTTTGCAGGTG
TGTGTCTATACATATTGTATGTGATGTGCAAGCTCTCTGGAAGAATTTGGTTGGTTTTTAGACTGTGTTT
GTATGGGCAGAAATATATCTGTAAAAAGCGGGAGGGACTTGATTTTGGAGAAGGGATGGTATAGAAGATG
TTTGTCCATATTTTAGCCTTGGAAAATCTCATGCCTATTAATGAAGGACAAAAAAGAAATGATTTACTGA
TTTGAGCAGGCAAATGAGAAGGTTGGATATTCTTAGGACCTTCTTGCTAGGTAGGTGTTTGTTTATTTAA
AAGTTAAAAATTCATCCATATTTAGGTCAATACTTGAATCTCAGTTCCTTCTTTTTTTTAGATTTCTGGC
TGAAGTTTTTCATGAGAAGAAAAAAGACTTGGAGCTTAGAACTGCTTTAGTAAGAACTATTAAACAGGTC
TCCAGTCATTGAATTTTGGAGGCATGGGCTTGCAGTTGGTATAATCTTAACAGTATTCTTCCTGAACTAT
CCCATGTCCATTTCCCAAGAACAGAAGAACAAGTTCGCATTCTAGAACTTCAGCTGTTCTCAGCATAGTT
CTGCTTGTAACAGATCTGTGACCATAGAGATCATCTTTCATGTTCACTCAGCCTTGTATAATTTTTGCCC
TATGGTGTCAGTTTGATCTCTTTAATGTAATTAGGGCAGGTACTGTTAACTCTTTTTTATAGAAAATAAA
GCTTAGCCACTTGACTAAGCTTGCACGTTTAGTAATATCAGAAGTCTTCGCTCCAGAGTGTTTGGGAATA
TGTCCAGCTCAGCCAAAGTTTACTTTTCTTGGGGGAAAAATAAGGTAATTTCTCTTCTATATCAAATTTT
TCGTTGGAGAATCAACAAATATATATATATATATATAGCATGTCTGTTGCATATAAACCATATTCTAGAT
GCATCCTGGAGCATCATAGTATTTAAAATATATTATAGTAAGCAAGGACAATGGCAAGCAGAATGATGTG
GACAGTGTCTCAGCAGAGGAGGTACAATGTACAAAAGAGGGAGACATTAGTTCTTGTTGGGGGAAGGAGA
CAAGCTTCATGGAGGAAATGCCATTTGAGTAGAGCCAGGGAAACTGGATAGATGGAAAAATTAGAAGAAA
GGGGAATTCCACATGGAGAGAATCATATGAATAAAGGCATAGAGATGGGAACTTACAAGGCCTACTTAAG
AAACTGTAAGTAATCTGGTGTGAATGCAGCATATGTTGTGTAAAGATAAAGCTAGAAAGAGATAGGTAAA
AGCTATGATTTAGGAAGGTTCAGTTGTTTTGACTTGGTTTTGACTTTGAATTGGTAGCTATGGAATGTCT
TAGGTCAGAGGACTGTCCTTTCTTAATTCTTTTTCAGGGTCAAGACCTGTCTTTATTAAGCCATTATTTC
TCAGAAGTTGAAGTCACCCTAAAGATACTTCTAAATTAGACATTGGTTAGGGGAATCAGCATTAGAGCAC
TCTTCTGGTCATAATGTGATGTTATGATGATGATGCTCATTGGTGAAGTCACATTAAGGACTGCTTTTAG
GGTTATAGTGGCAGAAAGCAGTAGGAGGAAAAATATCGACTTTACTTCAGATTGTAAAGAAGTGTGCTAT
TAGAGGAGTACACTGCATTCTCTCACCAACAGGTCTCCAGTGCTCATTTTGTGGGATAATGTGTGGCCAG
AGAGAAGATGGTGGTGAGTGGGGAATATGCTTATTTTCTCCAGTATAAAAATGTACCCACTTCAAACTTG
CAAGTACACGTACCAAAGCATGCTTGTCTTGACTGGTCATCTGTTAGCCCTGGAGGGCATAGATCATGTC
AAATCCTCTCTTACTTCAATGTCTAATACATAGTAAGTACTCAAAAAAAATGTTTATTGAATTAGGTTGT
CATAATATGGCTTTTGTTGGGGGTTTTGTTTTTATCTCTGATTTTTAAAGAGACTGAACTACAGAGTTAG
ACTTGTGGATCTTGGATCTGTCATCAACTTCTAGGAGCCTATTTAGCCCAACTAACATAACCTTTCTGAC
CTTCAGTCTCTTAATATGTAAAACAGAATGAATACAACTTCATGGCTTAATGGGAGGATCCATTGAATTG
TATCCTTGATACACTCTATTGGACAGGATAATAATATTAGTAAGTTACTAGATTCTAGTTTTACCTATGG
ATAGTTTATTGGGTCTCGACCGGCATTAAAAATTAAAACAATGGAATGATAGAATTGAATGAAATAGAAA
AGAAAGTATCATTGGGTGGTACTTATTAAGGGTTAGTATTATTTCATGAATCTTTGCTTCAGTTACCTAT
GTTATGAGTTGTGATATGAAGCTGTGGTGTTCCATATGGTGTTCAATATGTTCCTTACTTTTTTATTTTA
CTTTGTTGGGTCATGGTCAGAAAAGTTTGAGAAATACTGGTCTAGATAATAGTGAGCTCTGTATTATACA
AAGGAAAAATAACAGTCAGCTTTTTTAGAACTATGCAATGCAAGATCTCTAGTATCTTCTGAGTTATTAA
AGAAAGGATGACTTCTAGTTGTTTTAGATTTAATATGAAGCATCATATCCTACATCTTTGATAACTACTG
ATGTCTGCATGATATATGTTGGGGCTCTTTATTAACCAAAGTATTTATTAACTAGGAAACCTTATGCCTT
GGTTGTGCTACATAGCAAAACCTGGAATGTAATAATAAAAGTGACAATAATCAGTAGTGAATGTGACCTA
GAGGTGGGACTAGAAATAATAAGATTAGTTTTCATTTCTTGAGCTCTTGATATGAGTCAGACACTGTGCC
TTACAAACACCATCCCTTTTAATCCTTAGAACAAACTTAAAAGGTAAATGTTAATTTCTCTATTTTATGG
ACAAGCTAACTGAGGTTTTGGTGGGTAAATTACAGCCAGTAATTGGTTGGGCCAGGATTTGATTTGAACC
CAGATTTGTCTGACTCCAGAATAAAATTTCAAAAATTTATTCAGTTCCATGAAAATGTATTAAAGTGCCT
ACTATGTGTTAGCTCTGTACTCCTCTACAAAGATAAGTCAGTCTCTGTCCTTGAGGCTTTACTAGCTGCC
CTTTGTATTTTACTATGTAAGAAGATGAATAAGGATTTATTTTATCACAGCAGGAGATAGGACAGGCACA
TAGAGTACTGTATATTTTACTTCAGAAGTGTTAAGAAAAGTGCCTGACACACAGTAGGCATTCACTAAAG
ATTTATTACATTGAATTGAAGTTGGATTAATTCTCCTCTAGGGATTAGGGAACCTTTGTACTAAAGAAAC
ACTGTACATTTTTATATGTTTAGCTGTATATGCCTAGTGGCATGGGTATTCTTACCTGCAATGTGGGCAG
ATCCATCTGTCCCAAATCCATTCAGTGCCTTTTGGAGCTCCTAAAACTGGCAGCACAGAAAAGCCAACAA
GAGCTCAAGAACTCAAATTGTAAACTTCAAGTTTCATTCAGCCAGAGAGAACATTTTCCATCTTAGTGTG
AAAAGCAAATCCCATGGCAGAGACATTTGGAGAATGATAAATGGAAGGTGGGCTTCCTTAGAATGGAAAA
TTGTTATTATCATTGTTAATGTTATTTTTACAATGCCATTTACTAGCTTTATAAATTCAAGCAAGTTATA
TTACCTCTCTAAGCCTCAGTTTCCACATTTTTAAAAGGATTAATACCACTCAGGATTGTTAGGATTAAAT
AGACCCATTTGATAAAAACTTACTGAGACTTACTATTTGGTAGTCTGTAAATATGTAGTAGTAAAGGAGA
CATGGCCCCCCGTCCTCAAAGAGCTGAATATCTGGTGAATGTGCTGTGAGAAGTGGGATTCAGACTCCCA
CCACCTGCACAGGTCACTATTGATAGGATGCAGCACTCTACAGTCCTCCTTGGGGTATGTATATATTGTC
ATATACATGTCTCAATTGCATCATCAGAATTTCAAGTTTATTGAGGGTGAGTGAGCTCAAATATTCATCT
GTTTATCTCCACCTACCCCTAAGTTTCATCCTTGCCTGTTGACACAATGTTACCTTATACAGTAGTTGCT
AGATGAATCCAGCCCAATTCAGCAAATATTTACCAAGTGGCTCAGGGTACAGTGCTGGGAAAGGGAGGGT
AACATTTGCTGAACAGAGTTGAATTTAAAACAACTTTAGAGCATAAAAGGGGAACAGTGTCATGAAGTGG
TGATATACTACACTAGTGCTAAAAATACCTGTGATCTACTCAGGAAGAAATTAGGGCTCTAAAGAAAATT
CGGCAGTAAGCCTAAAAATAATGTATTTTTTCACTCTCCCAGTGCTGTTTTGTTTGTGTTTCATGGAGAA
ACAGTGTATTTGCTATAAGCACACAATTAAGATGAGATTTCAGAGATGGCTACTTAATTCATCTGTGGCT
CAGGACCAAGTCTAGGTAGCTTCACAAAACCCAGGAGCCCCTCTGTGGCCAGACTCCTCTCCTTTCCAGC
CTCCCATCTTGGGTCTCTTTGCCTTCTGTTCATGCTCCACTGTAGAACTGCACCACGGTGTTCCCTACTG
TTGCTCACACAGATCCCTCGGTCTCCAACATCTTTCTGCTTTCTTCACCTGGCTTCATGAGACAAATAGG
AGGCCTGTGTCACCCAGAAAGGCTTGCCTTAACTCACTGTGGGTTGTAGCCATCTCTGTTAACACTGCCA
GCATCATTCCATCATTGGTCTTCCACACTCCATAATCAAATGTTTATTTTTCTAGGTTTCACCACTGCCT
CAACAATCAGCACTGAGTTTATCTTTATGCTTGGCACCAAGTAGGTGCTCAGTAATTGATTGTTAACTGA
TGTAGTCAGATATTAATTAGGTGTTTCATAATGTGTTCCCATCAGGTGCCCCCTAGCTTATGAGTGGGAT
ATTGGACCCAAATCCCCCTTGTTGTGAAGACTGGTTTTGACACAGCTATTGCTCACCAACCCCAGTTCTG
TAACTTTGAGCTGAAGATCTTGAGTATATCTATTTACATTAAACTTTTTCCCTGATCACCATGACTCACC
TGTAATTCCTCAGTAATTCTTCTTTCCTCTAGACTCCTTTATGTCACTTGCTGTCTGTACCACGCAGTTA
ACAATGACACATCACAATAATAGTGACCCTTTATGTAATGTGTGTGTCAGACTTTGCAGAAAGAACTTTA
CTTAGGTTATCTCATTAAATCTCACAACGATTCTAAGAAACAGATATTTTTATTCCCATTTTGAAGAAAG
AGGACAACGTAGTTTAAGTAACTTGTACAAGGTTACATGGCTAGGAAAATATCAGACTGGGAATTTAAAA
CCTAGTTTGTTTCATTCCAAAGCCCATGTTCTGTCTCCTATTTTATCTTACTCATCCCTTAAAAGGTAGG
AATTAATGAGAAACATTTAGCCTAGTGGTTATTAATAGGGATATTTTTGAGATAGGGTCTCACTCTGTCA
CCCAGACTGCAGTGCAGTGGTGCAATCACAGCTCACTGCAGCTTCAACTTCCCAAGGAAATAGAGACTTT
TGATCAAGACTACCTGGATTCAAATCCTGGCTTTATCAGTTGTGACCTAGGGGAAATCATTTCCACTCCC
TATGCCTCAACATTTTCATCTGTAAACTAGGGTTGTTGTGAGGATGTGATGGACCAATGAATATTAAGGA
TTTAAAACAGTTACTTGGCATATAAAGTGATAATGATCATCATCATTATTGTTATCATACAATATTAATT
TGTGTCCCATTCTTCAAATTTTTGTTGAGTGCCTGCCAGACACTGTTCTAGGTAATGGTGATAGCAGTGA
CTAAGACAAGTCCTTGCCTTTATGGAGCTTTCATTTTAGAGGAAGAAGACAGAGAATAGAGTAAGTAAGT
AGTAAGTAGAACATGGCATAGTAGTGTGTGCCTGTAGTCCTAGCTACCCAGGAGGCTGAGGTAGGAGGAT
CACTTGAGCCCGGGAGTTTGAGGCTGCAGTAAGCTGTGATCACACCACTGCACTCCAGCTTAGGTGGCAG
AGACTCTGTATCTTTATTTAAAAAAAAAAAATAAAAGTAGATATTATATATTATGTCGTGTTTTATAATT
TCACATAGTGAAATGATGTTTAAAAAATAAAAGATGCTAGATTAGAGAGTTACACTAACGAGTCCTTGTT
TGTGGCACACAGTGAGGCCACAATAGTTCAGCCAGTGCCTTGCTTCTGCTTGATGAGCTGGAACCGTCAA
TGCCCTACTCTGAAAGGCTGAGCTTCATATGTCCAACTACTAACTCTTGGAGACAGGCTTGCCTGACCTG
CATGTGGTGTAAGGTGGTCATCTGTGGAATGATTGGACAATTGGACTGAGGTGTCTGAGCCTCAGGAAAA
CTTAAGATAGAGAACTCATAAAGAGGCCAGGGGTCCCAGCCTTTGAAGAGAGGTCCTATTCTGTGAAATG
GGACAAATGTTCCAGGAGGGTCAGGAGGAGGATTTGGCCAATCATTCAACTAAGAACAGGGTCAGCCAGA
ATGTCTTCTCAATTAAGGCTGTTAAGATCTCCTGATGGCTCCTTGCAGGAGCCTGAACCTAGAAGGTGAG
TTAGCCTTGGCATTATCATAGGATTCTACCTTTCCATGAGTGTTCTGCTGGTTAAGGGCATCTTAGGAGT
CTGCAAAATGGGGTGTTTTTTTCCTTCACTTACTTGTAGTGGGGTCTTGGTAAAGTCATTAGCCTGTCTG
AGCCTCAGTTTCCTTATCTGTAAAATTGGGCTAATAATACCTTCCTCCAAAGCTTGTTTAGAAGATGAAC
TAATTAACATGTGTAAAGAACCTGAATCGGGGCCCGGCACCTAGTAGGCATCTAATAAAGGAAGATTTTT
AAAATAAGCTCAGTCCCCCTAGGGTGTGCATTTTAGGTATTGGTAATTTATTTTGGGGCTCACAGGGAGA
GAAGAGAAAAATGAGAGCTACTTCCCATTCTATAACTTTCAAAAAAGTGAGCAGATAATCTCAAAACCAA
AGATATGTCATCTCAGAAAGGACTGTGAAGAAAATAAAATTAGATTTGCTGTAAATCAGTATGATTGAGA
CTGGTCTCTGTCAAAGACTGTGTTGGCCCCATCCTCTTGGTGTCACAGGCTTTTAGAGGCCTGGGGCTCT
GTGAAGAAAAGCACTTGGTTAAAATGGCTCTGGAGTCTTAAATCCTGAGTCCAATTCTTTCTAGTAATAA
GTTAGAGTATTTACTTTTTAGTGGGGGATGAAGGGGATGGATGATTTGGTTATTTTCATATGTCAAAAAT
TTCAAGGAAGGACTCCTGTGCTAACTGGAATTATACATAAACCTAATTGATGCTCTGGTGAGAGCAACTG
GAAAGCACTAGTTTTAGAATGTAGACATAAACCTTTATGTATTGTATCTCCTGTCTCCATTGTGTATACT
GTTACATAAAATTAAAGATTAAAATTAAACTTTTAAATTTCACTGATTAAAATCAATTTACCTGATTAAA
ATTAAGATTGAAGAGAAAGAGAGAAAAAAGCACAGTTTATTCTCATCCCAAACCTCCTTTGTTTTCATTA
GCAATGTGTAGACCTGAAATTACCTTAAAAACAAAACAAAACTCCCCCATGAAACACATTTAAGAATAAA
AGAATGATTTTCCAAATATTTGTCAATGCACTTTTTGTACAGGGCACTGAATGAAACTTTAAATATTTTT
TTCCTCTTATGGTTAGTGACATGTTAGTATTGTGATTCACTCAGAATTTATTTGACCCCCTTGATCACTA
GTTCACATTTGTTTTAATCTTGATGGCTACACTCATCTAAAATAAACAGAGCAGGAAGAGTAAGAGAACG
CTTAAAAAAAAAGCATTTTAAAATAAAGAGTCACCCATTCCTCTTACGATTATCTCAGCATGCTGAGAAA
GAAGCCTGATGGGTTGGAGATAAGGATGTCTCCTCCTATGTCCCCGTGTGCTCTGCCTCTAAACTCTCCT
AGCACCCTGCACCTGCCTCTGATAGCTGATCCATTCAGTGGGCATTGGTTGAATTCCCCATGTACTGCCT
GCTGGGAGTAAGAAGTCAACCAAAATTCAGGCCTTATTTTCAAGGCATTCCCTGTCAGTGGGGAGACAGG
CAGGTAAAAAGCGACTCAATATAGGGTGGTAAGTACCAGGACAGAGGAGAGAGAGGAGTTGTCTGAAGCT
ATGTAGGTCAGGGAGGTGGACTCCAGGGAGTCTTGCAAAATGGCAGGGTAATTTAGATGGTGATGGCGAA
AGCATTTCAGTGGACATATATGCAAAGACATGGAAGGGACATACTGCCAAAGGCATTCAGATTATGGTAC
TTGGCTCACTGCATCTGGAACTTTGTTTTCAAATGTCTACTAACCTTCCAAGACTAAATTCCTAGAGGGC
AGTGATCAAGTGCCATGGAACTCAGTTATCCAACAGTAATAGATTTAATCTTTGCCACATTCCTGTGAAC
CACATTTCTGTGAAGCCTATAACATTATCCTATTGATATGCCCCAAGTTACATTTGGAAAACCGAGACAC
AGAATGGTTAAGTGACTTGTCCAAGGTCACACAGCTAAACAGGAATTTAAACCTGGGCAGTCAAGCTCTA
GTGACTGTTTTCTTAACTATTATGCTATGCAATTAGTATTTAATAAATGTTTGAATTGATGTTAATTGAA
TGGATGTAGAAGTGATTATGTGATAATTTATTTATTCACTTATTTAAAAGAAATAACATGCCAGGCGTGC
CCAGATCTAATAGTTGTTGCAGGAAAATGTCAAGAGCCCCCATTGGCTTTGGCTTTGGCTTTGGCTTTGT
GACTTACAGAAACTCTTAAAGGTAGAAATGTTCTGCAGGGCTGTGAACCTCAAGATGGTACTTCAGATTT
CAGCCAAATTCAGACTCAACGTGGAAATAAAATATGAGTTTAGGCCTGAAACAGAGGAGATCTAATTTCC
TATGTGGAGATGAAGAAACAAAGGCTGTAAACATGGCCTTACTTGGAAAATGGAAGGCCCTAGGTTTTGA
AAACAGCCTCTTGGGATAGTTTGAAGGAAGTTGAGTGAGACAACAATGATGAGGGCAATATAGCTTTAAA
AGAATGAATTCACTCTTACTTTTGCATTGATTCTGAAGAGGAGAGATAAGCGAGGTTTATGGTGAGAGCA
AAGTGGTGATGAACAGGCAAGGGAAGCAGATTTGGCTATAGAAAGCAGGTGAGGACCTAGAGAGTCATCC
ATTTATTCATTTATTCTACCAGCAAAATCATGAGCTCTGCGCTGTTCCCTGGGATTACAAATGAATCAAA
CACAGTCGCAGTCCTCAAGGAGCTCACAGTCCAGTGATAGAGAAAGATAGGAGGCTGGAGAGTTTCAATG
CTATGTGGCACATGTCCGTAATGGAAATGTGTGTGAGAGACAAAGGTAAGAGCCATGATGGGGGATTGGA
GAAGGGGCATGCTAGGTCTGATGGCAGAGAGAGGAGGGCTTTCCAGGCCAAGGGAGTGCTTATGTGCAGA
GTGTGGCACAGGAGAGAACACAGTGTGTTCTGGTTTGTCATTGCTGGCTGCAGAAGCCTACAGAAGGCTG
TGGCCTGGAATGTGCATTCCAGGGCTTATGGAACTTGTAGTGGGTAAAGAAGGAAGATGGGAGTCAGTGA
CCAGAAGATGTCAGTTCAGATCCAGGCTCTGCACCATGTGAATATTGGCTAGTTAGCTTTACCTTTCATT
TGCTCCTTAACCCTTAGTTTGCTCACCTGTAAACTGCAAGTGATGGCAAGGGAAGACACCACCTATCTCT
CAGGATCTTCAGGAAAATTAAGTGGGGTGGTGAGTGTGAACGTACTTACAAAATCCTCTGAGTCCAGCAT
GTAATTTAATTATTATAAATTATTATAAAAAATTATTTTATTATTTTGTAAGTGAGGGTTTTGTAAGGGC
TTTGTAAGAGTCTCATTTCTTCAGGGGGAATGACACTTGCTCTGTTATCTCTACACTTCCCACCACACCT
TTCTGACTGTGCCCTGGAAAAATCCTCTGGAAGTGCATTCTGTCAGTTTAGCTGCTTATTGGGGTATACA
GTAAGAAAGGAGCAGTCCAAGTGGAGGATGGACCAAGAACAACCCTGCTCTTCCACCCTGAGTTTCCTTG
TGGGGAGCCGGAAAAGCCCTCTGCTGTCAGTATGCAGAGTGCACTGTGGCAGTGATCTGAAATTTCCCAG
GAAAACATGATGGTTTTCCTTGTAGGAAAGCAGAAACCCTAATGACTCTTATTAACATTTGAAGTACCTC
ACTTGGGCCATTCACAGTGGATGGCTTTTTGAAAGGGCAAAAGATACCAGAAATTGTGTTTGTAAGTGTC
AAACATGCTACTTTCATTATTTCTTTTTTTAGAATCCACATAGCCCCTCCCCCTTTGCTATGTGTTTACT
GGTTTGGCATTATTGTGAGAGCTTATTAGTGGATGTTTGTGGAGCATTGTGAAGATGAATAGCTATTGGC
ATAGGTGATGAGTAGTAATGTTTTTAAGTATACTTTTCTATTTCAGAAATTAAATTCCAAGGATAAATCT
TACCAGCTCTTAGATTAGTCAACTTTGCCACCTGCAGCACATTTTAATGGGCACATATTTCAGAATGTTA
CCTTTTGGACAAGGAAAATGAACATGTACTGAGTGCTTACTGTGTACTGAGCTCTGAACCAGGTGCCTTC
AGATTTGTTGTTTTTCTCACAGCAACCCTGCAAGACAGATAGAATTGTTCACATTTTTCAAATGAGTAAA
CTTAAATTGCACTGCAGAGAGTCTGAACTGGCTAAACCAAGGTCAAGGCTGGTGGTGGATTTCCAACCCA
AGTCGGATCACCTCCAAATCTCATGCTTTTTCCATTATACCATGTAGAATTTTGAATTTTGAATTATGGT
CTTTCCTGTAACACCCATTTATTGGGCAGTATTTACTGACTAATAAACAGCAGATACACAGGCTAGTTGA
TTTTAATAGGGTTAGATAATTTACATTCTCTAAGATTACTAGGTTGCATTTCATAGTGATAGGAAAAGTC
CTCAGACTTAGAGATTGAAGAAAGGGCACAAATTTGGTTTCAGCCTTGGGTTCAAGTTACAGTCCTAGTT
AAGTGACAGTGGACTCTGCCTGAAGACTCATTACTCCATCATGTGTAGAGTGACAGCACTTCTACATCTG
TAAATGAGAGGAATGACAATACCCACTTCTCAAAGTTGTGTGAGAATTAAGTGAAGTGATGTATGTAAAG
ACACCTCTCACCATTTCTTATTAGTACCATTGGAAGGACTTAATGATAATTACTTGCCTAAATATTTTCC
TGTGTAACTCAAAGCACTTTTTAATCAGCATTATAACAGGATTTCCCTTTACTGAGTGTTTGTCATATTC
CAGGCACTTTGTATGTACTTTTTCCATTACTACACTTATGACATTAGACAGTAATTTCTTATTTACTTAT
TTATTTACTTCCTTGCAGGCAGGAACTCTTTCTCTCTCCTTCATATCTCTGGCATTCAACATAATGGTTT
CTGGCCCATCGAAGGAACTCATTAATGTTAGGAAACTTAGCTTGGCTTTTGTTCCTTCTTTTGAGAGCTA
ACTTCAGTTTGGGGGAGGGGCTGCTCCAATGAAGTACTAAATTAACATCATTAAATTGTGTCTCATAACT
TGCCCTCAAATATATACCTGTAACTAAAGAAATTTTAGATTGCTCTAATTGACAATGGATGATTCTGAAT
ATGTGTTAACATTTTACTTTTTAAAAAAGGTAAATTTCTGGGATAAAAAGAATATATTAAGAGTTGCAAG
AGTTTACCAAACAAATTTTCTTTGTATCTGTGATTCAAAGGACAAGCTTACCCTACTCAGAAAAGTAATG
TTTTAGTTTCAAAATACATGTATTATATCCATTTGATAAATATACATGATAATATACATGTATCATATAC
TAAATATTCTTAGGGACATAGTAAATTAATTCTAAAAGGGTCTTATCTGAGAATTGTAGATTATGCAGCT
TGAATTATAATACAAATGTAATTTTTGAAATTTTATCATGTCTTTTTTATAATTTAAAAGTTTTATTTTT
GATTTTTAAAAATGCCAACTTGACTTTTGCCCAATTAGTGAGTGTGACCTTTCAAAAGCATATTTTGAAA
AGGCAAAAGATTGTGAAGACAGAAATACTAACTTATTTATTCTCTTATAATCTAAAATTCTATTTTTATG
TGGCAAATCATAAAAATACATACAGTAGGAGTTTTTTTAAAAAAATAGAACAATGGGCCGAGTGCGGTGA
CTCACACCTGTAATCCCAGCACTTTGGGAGGCCGAGGAGGGCTGATCACAAGGTCAAGACATTGAGACCA
TCCTAGCCAACATGGTGAAAACCTGTCTCTACTAAAAATACAAAAAAATTAGCTGGGCTTGGTGGCGCAT
GCCTGTAGTCCCAGTTACTCAGGAGGCTGAGGCAGGAGAATCACTTGAACCTAGGAGGCGGAGGTTTCAG
TGAGCAGAGATCACAGCACTGCACTCCAGCCTGGGGACAGAGCAAGACTCTGTCTCAAAACAAACAAACA
AACAAATAGAACAATGAAGAAAGTGAAATTAAGGGAAACTAAGAGGATTTTAAAAAGATAAATTCAGAAG
TAAAATTTATGTTTAAAAAAAAAAAAAAAACCAGAAGTTTGCAGTGAGGTCCCATGCTCTTTACACACAG
AAAACTATAGATTTGGCACCCATTTTCCTAATATTGAAAACAAAAGCAAACCCATCATGCAGAGGACAGA
GAATATTAGTGGTTTAATGTCATAAAAAGTGCTTGCCTCAGAGCAGACGTAAGTATTCCGATACTTGTGA
TTTCTGGATTTTGTTTGTTTTTTTCCATTTCTACTTTGCTTGCTTCTTGTTCATGATATTTTTAATCGAT
ACGTATTAGAAGGATGTTCAAATGCAAGAAAGAGAGAGAGAAGCTTAAAAAGCGTGGTATGGAATGCCAC
TTGACAGTGTCATACATTCACAAGATGTCCTTGAAGATGGAGCACAGAACAGAGATCAGGGAAATTTTGT
CAGCTGCAGTTGGGAAAATAAATGGCTGTTGTGTGATTGGGCAGATCCTGAAAGCAGACTCCTGCTCAAA
CCATGTAATTAACAAAAGTGGGAGCTTTTGTCCAAGTGCAAAATGTTCATAATATCAGAGTTTGTCAGCA
GGAGCTTTTAGAACGGATCAGTACTTTTCACTCCCTGATCCAGGGAATGGTTTTCTTATAAATCATCTTC
TCTCCTTGCTGTCCTCATGAAGGTTGCTGCCGGGCGATAGGCAGACTTAAGATTGTAACCTTGCTAATTC
ACAGTGATTTAGGTGAAGGGGAGACTGAACCAGAGACTGTTTCTAGAAATGTGATTTTTATTCATTTGGG
CTCCCATGAGTACTCTAATGTAGGAACAAACAGAGTGTGTCCAAGGAGAGATCCTACAGGATAGCTCTGG
GGAGGAGACAGAATCATTTTTAATACTGTGACTCCAAACTGGTTTGAAGGACTTGACATTTTCTTTCTTT
TTTAAAAAACAACTTCCTTTCAGATTATAAAACTGCTGTATTCTCACTGTAAAAACAAAACAGAGTTGAC
AAATAAAGATGGAGAAAAGTGTAACAATCACCTGTAATTCTGCCATTTATTCTAGTGTTTTTTATTTTTC
CCTCCTACTCTGTACTTGTTTATATAATTGAGATAATCAATCTTTTATTTCACTTCTTTTTCTACATTGA
TCATATACATTTTCTCACATTATAAAAACCCATTATAAACATAACTTTAGCAATTGCAGAATACTGTATC
AAAAAACTGCACAATGAGTTATTTAGCCATCCCCCTTGTTAGACTCCTGGGCTGTTTCCGTTTTTCTCAC
TCCTCTTAATATAACTCATTGTATGTACTTCTGGTCTGCAGAATTTTGGATTCTTTTCTGAGTTTCAGAA
TGGACCAGTGGGTCCAAGAATATGAACATAAGAAGAGATGTGCCAATTTATCCTTATACCCATAATTATG
AGAAAGACTATTTCACTGCATCTTAGAACTTGACAGTTGCAAACCTTAAATTTCTAGTTTCCATGTAAAC
ATGTTGCCCACAAATAATTCAAAGGCACACTTCTCCTCACCCAGGCCTGAATTCTCACCAACATTGATTT
GGTGGAGTCCAGTTTTACTCCTGCCTCCACTACCTTCCCAGGGAATGTTTAGGGGCAATGGTATCCAACT
GGCCCTCAGAGGAAGTTTGAGGGATAAAGTTCTCCTATCAAGTCAAAATGTTCTTTTTTTCTAACATTTA
TCTCTTATAAAAAGAAAGAAAGAGAGAGAGAAAGAAAGAAAGAAAGAAAAGAAAGAAAGAAAGAAAGAAA
GAAAGAAAGAAAGAAAGAAAGAAAGAAAGAGAAAGAAAGAAAGAAAGAAAGAAGCAGTGAAGGGAGAAAT
TAACAATAAACTTTCAAGTGTGATAAAGTAATTTTCAGATTTAAAACTACTCTATCAGAATAACATTCAG
GATCTTTTCATGAATGAACATGTAGCTATATGAGGCTATATGAATTGTCCATGAGTATAATTTATCACGG
CCAGTTATATATGCATTGAGGTGCTAAGAACCATTTTATTTCACTTATTATCTTCACCTTCAGAATGACT
TAATTTTTTGAATTGCACAATTAGAAGAGCCATTGACCTTACACAATTTCTCTTAAAAAGAACAAGACTT
CTACACAGATTTTTCTAGACACAAACTCCCTCTACTCCCTTTTACTCCTCCCCTCTTCCTCACCCTGGTT
ATGTTAAGAAAACAAGTGTTAATTTTCAAAATAAAATATATTTCTATGTAGATTTCTGAAGAATTTAATC
TGAGTGTGCATAAAACTTAATTTCAGAGATGTGACCTAATGCTTTAGATCATGATACATATGTGGAATAG
CACATTGCTGTTTACAAGTAAACCTCAAGAGTTTGCTGCGACTGAGCCACTAGCCAGGCATTTTATAAAT
ATACAATACTAATGTTTACATGAATTGTGCCATTGGCTATTGTTTATGCATTTAATTGGAAAGATAAGTC
TGGCTTAATCAGTTTGTGGGCAGTTTTTCAAATGATTCATTAATTATGAGAAAGACTGTTCTTTGTATGG
AAGATGAAGATAATGTATTTCCCATCACAACTGGTTCCCATCCCAACAAGTATCCAGAGATTATTATTAG
GCATTTTAGTTATTTTATCCACATTAAACCTTCAGAGTTCAGAGGGTCTTAGGGAGCAGAATGGGAAGAA
ATTGTTTTCCAATCGATTTTCTTTTTATTAGAGCTGATACTTTTGCAGGAAAGCTGAGCTTGCCCACAAA
ATTGTATTTTTATTAAAATGCAAACATTTGTCTTTTTCAAATCTGACTTAAACAAAGAAAGCTTATTGAA
AGTACGGTACTGTATTTATTTACTGGCCATTTTGGAAAGGAGAACCGAATTGTGGGGGATGAAGGAAACG
TTCCCTCATCTTTATAATGTGCTGAATGATCAAGCTGTCCCTCAGCTATGGAGAGTTTGTTGTAAAAGTC
AGTTAAAACCAAATACCCAGGGGTCTTACCAGAACTGCATCAGGATGGACACACCAGGAAATCATCTTAG
GCCCAAAATGAAGCTCTAAAGAAACACTGTAAAATGTAAAGGAGGCCAGTATTTATTTAGGAGGGGAAAT
GGGTGTGATGTGTCTGGGGAAGAAGATTAAAACTTGGATTTCCGTGAATTTGAGAATGATGCCTATGAGA
AATTAAATTTTGATTATGCTTTTCATATCCGTGCTGGCCCTGCTATTTTAAGTATTAATGCCTCTTGTTC
TCTCCAGTGGCTGCTGATTTTTTAAAAGCCCTGACTACCACCACTGAGAATACTTTTGGCATGCCTGGTG
TTCATCTCCAGAGCAGAAGTTGCTGTTTGAAAGAAGGGATGCCTCACGCTTACCTCATTGTTACAAATAT
AAGTTCCTTTTAGATTATAAAGCGCTATATTCTCATTGTAGAAACAAAACAAAGAGTTGACAAATAAACA
AGTCATTTGTTTAGGATGTAGGCATTTATACCAGGAAAAGGACAGTCAGTTCAGTATCAAAACAGGTAGG
ATTAGTCTGAGTGTATACGATTTATATGCTTTTGCTGAGGAGGGGGTGTCATTTGAGAAACTCTGAAGGA
GACTGCTTAAAACAAAGGGATATACAATTGATTTTAATGAATTATTTGTTTGCCTGCCCTCCTCTGCCAT
CCTCCCAGCTTCAACCCTCTACAGGGAGGGACCAGATTATTTTTGTTTTCCCACCTTCTAGAAGAATGCC
TTGGCTTATAATTGCATTCAATAAACTTGTGTTGAATTGAATACACTTGTTTTAAGGATATGCTGAGAAT
TTATTACCACATAACTTCCCAGAGTAAATAGGTCTTTCAGGTTATTTGTGCCTCTGCCCAAAGGTATTAT
TAAGCTGTCAGCATGTGTTTCTTGGATGGAATTAAATATTTTTTTCTAGAGTTTTCTAGTTACCTTCTGG
CAGAAGCTACAGAAACATGGTATGAATGGTTTTGGGAAACATGAGTGCAGTCTTTAGCCACAGTCCCCTA
GTCCAGTGGTCTTTGTGAGTCATCACCTGTAATTTGGTTGGAAGGGTGGTATTTCCAAGTTCCCTTTTCC
TAGAGTTATCAGATCATCAGTCTCAGCTCCTCCCCTTGGGTCCCATTAATAACATATGTCTCCTTCACAG
TTGAATCATAACCAGGAAAGTGTTGCATTTCAAAAAAAAATATTAACCTGAAGGGACTTGAGCGAATTAA
AGCCTCTTGAAAAGAAGGACGGGAGAGAATAGATTTTATGAGCTGATCTAAGACACTTTAAAGAAATATG
AAATTGGGGAATTGTAACGACATTTTTAGTATCTTTTAAGGAGCAAGAAGAGAAGTGAGGAATTTTACAA
AAAAAAATAATGTCTGTCTTCAGGAACACAGAGCCTGCTGTGTAATTTTCTAACTTTGGGAATTTGTTTT
TCAGGCTTGGAAAGGTGGGTGAGATGCAGTAGTCTGGGCTATTGCATCCACCAGAGTCTAACATACTACA
TGTCAGAATTTTACAAGGGTTAAGTGGGAAATTCCTACAAAGAGAATTAGGACTTTTATTTTTGTTCTCA
TTAATAATTTAAATCTATTTCTTTAATGGTTCAATTCAGTGACTGCCCTTGGTAAACATTATTCTTCATG
CACCTGAGAGAGCTTGTTCTATTACATAAGGGTTAGCTTTATACATATATTTTCAAAAATCCTTCCAACA
TGGTAAAAGAAAACACCTTTACATACTCATTAAAATATTTAATAAAATACATGCATGAGTCTCAGGTGTA
CACACCTGAGACATGTTTGCAATCAGTACATTCCTTTAACATCTTTCTCGTTTCTGGGAATACTGACTTT
TAAAGGTAGCTGAAAGTAGAGGATAAGGGTATTTGTAAAAGAAACATCATGTTCTGTGACCTTCTTTGGT
TCTTTCCTCTTGATCCTTTCGCATGAATTGTGCAGTGAGGCTATATCTCCGCCAGAAAACCAGGAGTTAA
GGACTGCCAAAAGTATGGTGACAGGTGTACAAGAACCCTGCACTGGGCTCTTAGATGATGAATGTCAGTA
CTGAGTTCTGTATCAGGTCAGATTCCTGTAATGTAAAGTTGTAACCTTTGATTTGCCTCATGAAGTAAAT
CCTGAAAGTAGGTGTAGGTTAACTAGATTAAAATATCTAAATGCAAAACAATAACGTGGGGTCGTATGTA
GGTAAAGTGGAGGGGATAGGGTAAGACAGGGTTCTAAACCTTGCTATTAAGAAGTAAAAGAGTGTTAGTC
TACACTGAAGTATTCCAAAAATGTCACAGGCTTGAATGGGAAGGAACAGTTTGTGGACTTTCCATCTTTA
TTTTTATACTACCATTTTTAGGGAAAATATTAGGACAAGGACACAATATGGTGTGGTTGGCAGGATGGTA
AGAAGACTATGGTAGCAACAATGATTCTCCTCCACTGTGAGGAGGGGGATCAATCCTGTAACTCTAGCCT
GATTGCCCCAAACTTGAGAAAATTAAAGCTTTGTGAAGAGTGGAGGATGGAAGGAGGTGTAAGAAAGTCA
TGAGCTAATGGAATAAATATTAACTACTCAGGAGGTTGAGGTGGGAGGATCACTTGAGCCCAGGAGTTCA
AGTCCAGCTGGGGCAACATAGAGAGACCCAGTCAAAAAAAAGGGAAGGAAGGAAGGAAGGAAGGCAGGAA
GGAAGGAAAAAAAGTTTTAAGGGAGCTTTAAATACATTTTTAGTACATCCGTACACTTTTAGATTTTAGA
ATAGTCTTGCTTAATATACTTCAAAGATTTTCCTAGTCACAAGACATGCTGCTGTCTCTTCTCTGACATG
TGGACCCTTCATCAATAAATATTTATTTGATTAGTAAATTAATGAATTCTGAGAGCAAGAAATCATATGA
AAAGAGTGGTTTGGGAAGGAAGGAAAGGTTTTACTTTTGATTATATTGCTAATCAGCTTTTCTTGTCTAA
CTCTTAACCTAGTTTCTTAGGTATTGGTTTTTATCTTTCTCCTTGTTCTCTTCTAATAATATTAGCATCA
GTCACCACTAGCATCTGTGGAGGGATTACCATGCCAGGAATAGTGCTGAGTGCTCCATGTACATTATCTC
ACTGAGTCCTTTTTATACCAGTAAGAGCAAAGGCTGCCCTGAACCACCAGGTTCTATTCTTTTCCTTTTG
ACTCATTAAATAGGGCTGAGATAAAAGTGTGGAGGGGCCGAGTGAAGATGATTGACACTATATGCTGCCA
ACATGCTTAATTAACAGTTCTCAGCCACCTTGGTGTGAGGTAGGTAGAGGGCAGAGGGTAGGTCAGTGGA
AGGGCTGGGGTAAGGCCGTATTCTAAACTTTCCTATCAAGAAGTGAAAGAGTGCTAGTCTACACAGAGGT
GCTCCAAAAATGCTGCAGGTTCGAATGGGAAGGAACAATTTGGGAACTTTCAATCTGGAGATAATAGATT
GGCTTTAGTGAACATAAAATGCTGTTTGAGTGTACATTTTTCTGAGGATATAGGGCCAAGGCATTCAATA
GGTTTTCTGAGGATATAGGGCCAAAGCATTCAATAGTAGACTCATGCCAGCCAAAGCTTTAACCCTCCTG
CTTGAATGAGTGCTTTTTTTTTTTTGAGGTGGAGTCTTGCTCTGTCACCCAGGCTGGAGTGCAGTGGCGT
GATCTCGGCTCACTGCAACCACCGCCTTCCAGGTTCAAGTGATTCTCCTGCCTTAGCCTCCCAAGTTGCT
GGGATTACAGGCACAGGCACCCGCCATCATGCCTGGCAAATTTTTGTATTTTTAGTAGAGGTGGGGTTTC
TCCATGTTGGCCAGGTTGGTCTCAAACTCCTGATCTCAGGTGATCCTCCCACCTTGGCCTCCCAAAGTGC
TGGGATTACAGGCATGAGCCACCACACCTGGCTAATGAGTGCTTCTTAAAATCTGCATTTGACATAGAGA
TGGAAAGTAGAATGGTAGTTGCCAGGAGCTGGGGAAAGTAGGGGAATGAGGAGGTATTGTTTAATGGGTA
TAGAGTTTCAGACTTACAAGATGACAAGAATTCTGCTGGTGGCTGCAAAGCAATATGAAGGTACTTAATG
CCACTGAACTGTATACTTTAAAACTATTTAGTTGGCAAATTTTGCTATGTGTATTTTACCACAATTTTAA
AAATTGAAAAAAAATCTGCATTTGAAAGAATATTTAAGTGTATGCCTGGCATATAATAGGTGCTCAGTAG
GTGACTGGTTGCTTACCTGTCCTGTTCTTTTGTTATCTGTAAAATGGGGATGATATTAGTACTTTATTGG
CTTGTACTTCACAGGGTTGTTTGAGAGATCCAGTAAGCTAATGGACATGTAAGGACTTTCATTCATTCTA
CAGTCCTTTATCTGGGACCTACCGATTGTTAGGCTTTATTCTACATTCAGGAGATGCTGTAATAAACAAA
ACAGATGTGATCTCTGTGCTGTGGACCTCACAGTTCAGGTCATGAATTTTAATGAACTGTAAAGTGCTAT
ACTCAGAAAAGTATGGAGGTAGACATGTCTCCACAAGTCTGTTGAAGTACATTCTGGTCCTCCACTTTAA
AATTACAGGGTTGGGCTTCATGGACCCTAATGTTCTCTGGTATCTGTTGAATTCAAGAAGGGTCTGCTCT
TTGTCTTTGTTATCTCTGTATCCCCAGAGTTCAGCACAGATCTCGGCTCCATCTCTGTTTATCTAACATA
CCCAGATCTAGCCATAGTGGAAGTAAACCCTTTTTAAATGTGCGTATGACCTGACATATCCAGGAACTAG
TGTTACAGGTAACTTGGGTAGATAAAAGGAGCCTGGATTGTGTTGAGAGAGGTGCCAGAAGGGAACAGAG
GGGTGGCTTTTTAGTTTCCAAGAGCAGGAGGCTGGCTGAGCCTCTGCTCCTTACCTCCCCTCTGCAGATA
TAAACGACCCTGGTGATGATCCGGCAGCTGCACGTCTGAAGCCTTCCCTCTTGCTTTTGTTGTATATTTT
GCAGAAAAGAGTGGTGGGAGGGGTGAGGTTAATGCATTGAGTGTGAGTAATTAGTCATTCAAACCATCGA
CATTTACGATGACAGGATTTGAGTGCCTACGTTATTGTGCACCGCTCTAATAGTTTATCCCTGAAATTTT
CTGCCTGTATAATGTTTCTTAAAATATATCACAGAAACATAAAAGATTTAATGTAGTGCTTTGTACATCC
ATTAGAGTTCGAAGTCAACTGAACCTCCTCAATGATCTATCCTGGATGCTGACTGTAATTCTGTTCTTAA
TTGCTATTCAAATGAGGAAAGGAGGGCAAGTCAGGGGCTTGGAACCTGGTCAGCTGCAAAGTTGGCTGTG
AGACCCACACAGAATGTTTCATTAAAGTACATATGCACACTTGAGTAACTGATATATTTATTTGCAATGA
AAATTGTGCTGTTAGAATATCAAAGGCGTTAGCCTGAGGAAGCAAGTGTTCTGATTTTGCCCAGCCAGCC
TCTGTACTTACTGGAGGATGTGCTTTCTACCAACACACATCTTTTCTACTCCTGTTCTGTCCCTCTGTTT
CCCAAGCAGAGAGAACAGGTGTCCTGTCTTTGAGGTCTATCATGTAACCTTAAAATGCTGTAGTTTCATA
TTCGTGCATTTAATATCTTTACATCTTGGCAACTTCTCTTATTTTCCAGGTAATGTTTTAAAATCCTCTT
GTTTCATTCACATGTCAGATTTGATTCTGATGTTTTACATTTCTGATTTTTTTTTTCAGCCTGTGTTGCA
TCCTAAGATGCATCATTAAGACCTGTGAGGGGTCTTATTATAGGATGTATATTAACACATTTGCAAATGT
TTCTCAGCTTTCAGACAGCACACTTTTATTGAGAAAACTCTCTTTGTATGTGTCCATTTGTGTGTTTTCA
TCAGTTCCTTCTGGATACACAAAAGAATAACTGTGTAGTGTAGATGCAGAGCAAAGAGAGCTCCATCTAC
ATTGGATGAGAATGACTTGACCTAATTTATAGATGTGGTCAGCTAAAGTAGCTCAGTAGTGAGCATTGTA
TCTCATGGCTCCTTTTAGAAGCTAGTTGGGACCAGTTGGGCTGTCTAATCTACAGACAGGACTCACCTCC
TGGAGTCAACATAGATTAGGAAATCCACATAGAATGCAAGGAAGGCCACAAAGCTGATGCGGGGACTGAA
ATTACTTTGCTGCAGCCTTGTTACTTCACAGGCCTTCCTGGAGGAGGTGGACCTGTGAGATGTTCACATG
GACAAGTGCTGGCTTTCACCACGTGTCTGAAAACGAAAGATGAACCTGACTATCAGGTGACCTTTATGAG
TTTTGGTCCCACAGAATCTCAACATGAAATTCTTCCACATACTCCATCACTAGCACCAAATAAGCTGCCT
TGGTGTGGGATATTTTCTAGGTGTTTGTTGGGGAGCTGAAAGAAGGGTAACCTGAAAAAGGTAGAAAACA
GAGAAGAGTTTCTAAAGATTGTGGGCCTGGGGGGTTTTTGCCATTAAATCGAATGTAGTAGTCCGGCCTC
CTGAATGGATAAATTCTGATTTTCATGTTCATTATCGAGTTGGCAGTGCTTCTTATGTTTGTTGCCTGGA
CACCTGACTCAGTGAAGCAGTGAGACAACACAGCAAATGGAGGCACTGCAAAGACCCAGAAGGCCCCACA
GCTTGGCAGAGCTGAAACCTGCCTCCTAGCCAGGAGTTGTGCTGATGCTCTGTAATGCCATCCCTTTAGC
ATGCCTCCTTCCCTGGGGACCATCTCCCTGATTCTTTTCCTGGACCCTTGCCTCGAAGGCAAAGTGGCTG
AATAGGCTTTGCTGGGTACAACTTCTATCAGTCCTGAGGGGAGCTTGATTTAAGATTCTTCTCAGAAGCT
TTTTGCTTTCTCCTTGCTGTCTGGACCAGCCTTCTAGAATCCTAAAGTTGACCTGAAGCCAAGAAGAAAA
TTCTGGTGATGGGAGAAGTGGAGCCACTTAAATTACTTACATGATGGTAAAGAATCTTAGATGCTCCCCA
TCTTTCTTAGTCTGCTTTATTTCCTTGGCTCCTCTTGAGCCATGTTTTCCTTTTTGTTTCATTTATCATT
TGTGACCATCAGAAGATGAAAGAATTAGAATAACACTCACCTACGTGGGGCATGATGAGGAATAATAGTT
ATGATGCCTCTGGGCCCTTTGTATTTTAGACATTTAATGTACATTATCTCTCATCCTGAAGATAACCCTG
CGTGGCAAGCTTTTTATTCCAGTTTTGCTGAAGAGGAAGCTGAGGCTCAGAGTATTGAAGTAACCTGCCT
CAGATCACACAGCTAATAAGTGGTAAAACTAAGTTTTTTGTTTTTTTGTTTTTTGAGACGGAGTTTCACT
CCTGTTGCCCAGGCTAGAGTGCAGTGGTGCAATCTTGGCTCACTGTACCCTCTACCTCCCAGGTTCAAGT
GATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGATTACAGGTGTGCACCACCACACACACACAGCTAATT
TTGTATTTTCAATAGAGACTGGGTTTCTCCATGTTGGTCAGGCTGGTCTTGAACTCCTGACCTCAGGTGA
TCTGCCCACCTCGGCCTCCCAAAGTGTTGGGATTACAGGTGTGAGCCACCGCACCTGGCCTAGAACTCAG
ATTTTAAATCACCTGTTGTCTTGACTCAAACACTCATTCCATTTTTACTATACCACTCTGCTTCAGATGA
GAAAATAAACAAAAACAAAAACAAAAAATAGTCTCTGAACATTGATGAGGATGTGGAGCAACTGGAACTT
TCATACTCTGCTGGTGGGAATATAAATGGATACAGCCACTTTGAAATACTGTTGGCAGTATCTACTGAAG
CTAAATATACATACACCCTATGATCCCAAAAACAGAATCCTAGGACTATCCCCAATAGAAATATGTACAT
TTTTGTACCAAAATGTTGTACATAACGCTCATAGCAGCATTATCTATAGTAGTTCAAAATTAGAAACAAT
CCAAATGTTCATCAACAGATAAATAAAATGTAATATTTCCACACAATGGAAATTGCTATAGCAGTGGGAA
GAACAATGCATTGTTACATGTAACAGAGCAGATGACACTCCATACATGTGTGAAAAGGCACAAAAGAGTA
TGTGTTGTATGAGTCCATGTATATAAAGGTAAAAAAATAGGTAAAACAAATCTGTGGACTAGAATTCAGA
ATAGTGGTTACCTTTGAGGGGTGAGGTAAATGACAGGGATGGAGAACCTGAGAAAGGCATTTGGGGTGCC
AGTCATGTTCTGTATTGTGATCTGAAAGGTAATTACCCAGTTGTGAATTGTGTTCACTTTGTAAACATTC
TTTGTGTTGTACCCTTAAGATTTATACACTTTATTACATGTATGTTATAGTAAATGAAAATGCTTCCCCC
CTAAATCCTCTGAGCAGGCAAATGGTAATAATAATGGAAGCTACTAGTTATCAGATGTCTGCTATGCCTT
GGTTTCCTCATCTATAAGACATAGAGAATATTAGAATATGCTTCATTGCCTTCTTGTGAGGAGACAGTGA
GAGAAGTCACATTGGATGATTGGCAGAGTAACTAATAAACATCAGTGATTGTGGTTATGTGCCCACCACT
GTTCTGGTGCTTTACATAAGTCATATCACTGGATCGGTTCTTACCGCTTTGCCATACGGTGGCATTGTTC
CCATTTTTCAAATGAGGAAAATGAAGACTCTTAGGATTTAAGTCCCTTGCCAAGGTCACACAGCTAGTAA
GTGGCAGAGTATGATTTCATTTCCAAGGAGTTGATGATCAGTTTCTGAGGAGATGGAAGCCATTTTATGA
TGGACAAATAGAGGACGGTGTAAGACAAAATGGAAAGTTGCGAATTATGGGCTGCGTTTGGGGCCAGGAA
ATCCGGGTGCAGGCCTGGACTTTGCCCCCATTTTTCTATGATAACAGAGAAGTAACTGGACATCTCTGGG
CTTCATCTCGAATGTGAGTGTTGAGCTAGATTTTGTTCCCTTATGTGCCTTCTGGCTCTGCAATTTTGCA
ATTCTCCATGTTTGTCATTCCATACAGGGCATCTTCATGACCTGACTTCATGAGCTTAAACTCATTTTTC
ATATAAAACCCTATTCCAGCATTTTCTCAGAACTGTCCCTAAATCTCCCTATCCTATAAGCAGAAGTAAT
TGCTTCTGTATTGCATGATCACTGCCCTATACCAGCTGTTTACCTGTCTGTGTCCTCTATAGACTATAAG
CTCCCTGAGGATAGGGATTCATTCATTTCTTTATTCTCATACGTGCTACCTGGAACATTCACACCAGCCA
GAAATCTTTGTTTAATTAAATATTTTAATCAAGAGAAAGTCCTTTTTGAGTAATATGTGAGTGGACAGCC
TCAGGCGGTGCTGGACCTAACGTGGAGACCTAGAGAAAAGTTTGCCTCCATGTTTTTTGTTTTATTAGAG
GTCTGGGAGAAACAATAACAGAATGGCTAGATTAAAAAAAAAAAGACATTAGATGACTTTGCAGCTCCCT
AGAATGTACCTGTAAAATCTAAAATTTGATCAGTGATTAAGCATCAGTGAAAATTTAAACCCTTCCCATA
TTGAACAACCCCACTTAATTTAATGTCATTTTATTTTATGAGATAGTTAATAAACAGGTACTGTATTTGA
TCTTGTGAGTGTAGTCCTCTATATTTAGCTTTTTCAGCTTTAATGGAACTATAATTTTAATCATGATTAT
TACTTTACATTTTAATTATAATTTGGTGTGGCTTAAGTATACATTTCTGAGAGTGATTGTGTAATGAAAA
CAGGAATTAGCTTTTCATTAACAAAATAATGGGAGAGTTCCTACTGCATTCTAGTCTGTGTTCAAAATCT
ATGGGCTGGCCTAAAAATAGAAAGAGGAGTTTAACATTTTGGTTAAAAACATGCTTCTAAATTGGCTGTG
TTCACAACCCAGTCTCTTGCTCCATCTTGCTTTATCTTCTTCTCTTTCTTTTCAAAAAAATTAATAAACT
TTTAAAAGAGACTTTGTGTCTGAGATTTCAAAAGGCTTTTTCAATTGTTTTTATTTTTATTTAGATAATT
AGCACCATGGAGCCTCAGGTGTCAAATGGTCCGACATCCAATACAAGCAATGGACCCTCCAGCAACAACA
GAAACTGTCCTTCTCCCATGCAAACAGGGGCAACCACAGATGACAGCAAAACCAACCTCATCGTCAACTA
TTTACCCCAGAATATGACCCAAGAAGAATTCAGGAGTCTCTTCGGGAGCATTGGTGAAATAGAATCCTGC
AAACTTGTGAGAGACAAAATTACAGGTATGCACAGGATTTGAAGCTATGTTGTTCCATTAGATGTGCAGA
TCTTAGCAGAAATGCACATGTGTGATGGTGCACCTGAATGTCTATATCATGTACCCTGCATGCAAGATGG
CATGGATACACAGTCATAAACTCACACTACATACACCACATAAGACCTTATTGTAGATTGGTACTGCTGG
GGAGCAGATGAAGATTTTGGTACATCTTCATCTTCATGTAAAATGATCCTTTGATTTTGTCTCCTTTTAT
TCTTAATCAGCCATTCCTTCCCTTTGTTCTATAGTTTCCAGTCCCACAACTCTGCCCTCCCTATACTATA
CACTAGTTTTTGCTCATGTATTCTCCTCCTCTCAATATTTGCTTCATGTGTGCCCAGTGTTCTTCCATGT
GCCTGAAACAAGTGTTTTAAAGGGGGCCACTGTGGATGTGTGGACAGTTGACACAACTGCCCTTGTCCCT
GGGGAGAAACAGGCCCTAAGGATAGCAGATTATTCTGGAATACAACTACTCTGCAGTAGGAGGGAAATGC
TTAATGAAGATCTGCATTTGAGGTATTTTGTTTTATTTTATCTGTCTGTTCGTTTTGAAGATACTCTTTG
AGATGTGAGGGCATTTTTACTTGAAAGTGAATCAACACCCTATACAACTTCAATACATGAGATTTTTAGG
TTCTGATTTTCTCCTAATTGACAACTGTTCATTGAGAACCAAATGTTTGCCAGACACTGACACTATAATT
CTTTGGGGGAAAGTTTCCCTATAATCTTATTGGCAGTGAGAATATTTTCTTGGAATATATTAGGCTACAT
AATGATGGCAGTGAAGCTGCTACTCTCTGATACTCCACTCCTGAAATCATTCATATCCAACTTTGAATAC
TTGTCAGTTTTGAGTATTGACTTTTGTTTCCCTTTCCCTAGACAGTTTAATTAATCAGCAACTGTCCTAG
AGTTTTTTTTTTTTTAAAAAGGAAGCTGCATCATTAAAATAGGGATATACATCATCTTTATTTTAAATCA
GAGAATACATTCTATATGTGTGTGTGTAGATATATACATTCTTCTGTTCTCATAATTCACATGTAAATCT
GTTCCCCTTATAAATTAAGTAGTTTGCAAAATCATAAAACTTAAATACCACTGCTACTTTCCAAAATACA
AGTCACCTAACACTCCAGACATAATTTTCTTATTTGAAAAACTGGAAGATAATGCTTGTCTCAAAGGGCT
TATTGTGAGGATTAAATGAGAGACTAGATATATTGCATCTAGCACAATGTCTACTGCACAGTGGTCCCTC
AGTAAATAAATCTATTATTGTAAGTACAGCTAGTATGCTTCAAGGAAAGTGGCCAGAACAGAAAAAAAAG
TATCTATCAAATTCTCCAAATAGGGCCAGGCTTTGATTATCTTGTACCAGAGCACTGGAACATCTATCCT
TAAACAGAATTTCCCATACGTTCAGAAAGCCAATATTTAGATTCCTGAATAATCTTTATATAATAGGATG
ATAATTCAAACCAAATTAAAACCAGTTAACCATATGATTCTTCCTCCTACTCCTATATAGAAAATGTATT
TTTAGTATAGCCTTACCTTCAAAATACAGACTCTGCCAGCTATATTAGTGAATATTATTAATCACCTTTT
CAGAATTCCTTCAGAACTGTAGCGAGATTTTTGAGAAGTACTGATTCATGGTGTTGTTCCTTGTTTTCTA
AAGACACATGTTTAAACAAGCAGATTCCTTTACTGAAAGAATGCTAATTTGGTAGTTCACCGAGTGGATT
TGAATAGGAGTGACAGCTTCGAAGACAGCCTTTAATTTGGTATACAAAACCAAAATTGTCAACTTTGGTT
TGTTTAGCACCCTCTCCAGCACAAGCAGAGACATACAGTAGCATCTGAGCTTAAAGAAGAAGCTTATGGG
GTTGAAAGCAGAAATACAATTCAGGCATAAATTTATAATTATGCATTCTTCTTAAATTCAGGCCCAAAAA
ATTTTTATTTGTAGAGAGCTTATGGGAATGAGGCAGGGAAATATAGAGAGAGACCAGAGATATTTGCCCT
CATTTGACAGCAGTGTTTAATAGAAGTAAAACTTGTGGTTGTAAAGAGTGCTTATTAAATTCTTCATTTA
CACTACCTAATTAATTCTAGCATTTTAAATTAACAGTGAAACTAGTCCCTGCTGTACCATTCCATAGATG
CAGCATATTTCCTCCATCCACCCGTTGTTCAGGTTTAATTGGCTATGCTAAAAGTCAGAGAAGGAGGGAG
AGATAGGGCTGTGGGGAAATGGGGAAGGAGTGGGAATTGCTCTAGCGGAGGACCTCCCCGAGGCCAACAT
TTGGGGTTAGGTCACAATGCAGGCTGGAAGAGGTGAGGTATATCACACCAGGCAAGTGGAGAGGCTGCAG
CTGGTGGTTCAGAAGTCAGGGTAAATGACATCATGGGTATTTTTGTTGCCCTGATTTTTAACATCCTAGT
CCCCCTTTTTCCTCCAACACCTCCTACAGATCTCAATGCATCTCGATCCTGTGAAGTTTACAAGGAGTTC
TAAATATCCAGTGGGAGGATTGGGGGGTGGGAGGTGGCAAAGAGATAAGAATTCAAGATTAAGATTTTCC
AGCCCCAACCACTCCCTAAGAGAATGTAATGGATTCCCTTAGAAGGTTCTGGCTTCTGCAATGTTAAAAT
CTCTTTACAGAGAGAGGAAGTGACTCTGTTGATAGCCTTACCAGCAGGCTAGATTCATCCCTGGCTGTGA
ATTGTCAATGAATTCTCCGTTTGAGAACAGATAGAAGAAATTTGGTCATGGAGTTAAGTGTTATGTGCTG
GGGACATAAACATCACCATTTATCAAGCACTTCATCTGTGCTGGATACTTGCTAAGCGCTGGACATACCC
TATTTCATTTAACACGGAGCCTCCATTTTCTTAGATGAGGAAACTGAAGCTTGGTGATTTCCCCAGGCAG
CATAGTTATTAGCAGGTGGTGGAGCTGGGAGTCACCCCTACTTTCCAAAAGCATGATTTTATTTGGAGGC
ATGTACAGGGTAAAGACCCTGCCTAACCTGCACTTCATAACCCAATGCAACATTGTGTTCTGCTGAGCAG
AGGTTGCTGGGCACCCTCTGGAGAGTCTATCTAATGTACCATGGCTTTAAACAAGACTCATGTGTATAAA
GGGAGCAAAGATAACAATATTTATCATCCTCTGGGGATATAACTCAGCCTTTGTCTTCCTTCAGAGTAGA
ACCAAATTTACTGAAAATGCCAGTTTTAAGATACCTTGCTTTTGGACATCTCTGTTACTTATCTTCTCAG
AGACATTACATTTTTCTTTTTCCAATTGGGAAAGGACACTCACCAGAATAATCCAGGTACCAGGGAGAAG
AAAGGCATATCCTGAGTTGCTTTTGTGTACAGCCGTGACACATCATGGCATTGGAAGCTAAGTCTTTAGC
TTTTCTTCTTCATCTACCTGCAGCCTCTGCTGCTGGGGAAAACAAAGGAAGTGTCATGTGACCCACAGAG
TTCATGCAACCTAGAAACTCAGGCAAAGAACACCAAATACCTGGTAGAAATTATATTATTCCCATGGACT
CCAAGGAGTTGATTTAGTTTCTTATTTTTTTGTTTTGTTACCATTTTGGTTTTGGTTTTGTTTTGTAAAC
ATTGAGATTGCCTTACTGAATCCAAGTTCCTATGTGATCAGTATTTTAGGGGAGAAAACATGTGGCTTGA
CCAGGGCAAGGTTAGGTGGCTCAGGGTATGTCTTGAAACCAGCAGAGCTGAATTATTATTATTATTTCTT
TGCCTTTTTTGCATTTTTATAAGTGTTTATCTTGTTACCGCCCCAAAACAAATAAGGAAAGAAAAAAAAA
GAAAAATCTCTAGAAAGAAATTAGGCCAGGCGCAGTGACTCACGCTTGGAATCCCAGCACTTTGGGTGGC
CAAGGCAGATGGGTCACCTGAGGTCAGGAGTTTAAGACCAGCCTGGCCAACATGGTGAAACCCCGTCTCT
ACTAAAAATACAAAAATTAGCTAGGCGTGGTGGTGGGCGCCTGTAATCCCAGCTACTCGGGAGGCTGAGG
CAGGAGAATTGCTTGAATCTGGGAGGCGGAGGTTGCATTGAGCTGAGATTGCGCTCCAGCCTGGGTAACA
AGTACGAAACTCTGTCTCAAAAAAAAAAGAAAAAGAAAAAAGAAATCAGTGTAAGACAACAAACAGTTTT
GACCTGCCTATTTACATTGTGTGATTATTTGCATCACAGTGATAAAAAAAAGAATTGTATTTTTACTTCA
TGTCACTCTCTGTGTACCCATGCATTGTCCTTTTTTTTTTTTTTTTTTTGAGATGAAGTCTCACTCTGTT
GCCCAGACTGGAGTGCAGTGGTGCAATCTCGGCTCACTGCAACCTCCACCTCCTGGGTTCAAGTGATTCT
CCTGCCTCAGCCTCCCGAGTAACTGGGACTACAGGCACCCGCCACCACGCCTGGCTAATTTTTGTATTTT
TAGTAGAGACAGGGTTTCACCATATTGGCCAGGCTGGTCTCAAACTCCTGACCTTGTGATCTGCCTGCCT
CGGCCTCCCAACGTGCTGGGATTACAGGCATGAGCCACTGTGCCTAGCCACAGTGTACTTTGTTTTTGAG
GACAGGACAGACCAAACTGAACATTATCAATAACAAAACTGAATCTATTAAGAGACAAGTATATGGAACA
TGCTATTAATACGTAAGTGCTATAGGTGGTTGGAAGAGGTGAGGTTGGTGTTAGCTGGAGCTGTTGGGGA
AAGTTTAAAAGATAGGGTAAGGATTTAGGTAGAGGAAAGAAAAGCAAAGGAATAGAGCTAAAATTTTAGT
CAAAGAACAAAAGCATTTTTTATTCCTCTGTGCTTTGGACAAAAGAAGTAGCGCTGGAACATGTCTCTTT
GGAAGCAGTGGTCTAATATGAAGCAGCATGGTCAAATGAAGTTAAGCATACCAAAAAATTCAGTCAGTTA
GAGTTGTACCCCAATGGACAAAGACAACATTTCCTAAACACCACTTCTAATCCGTGTCTTCATTTCTTCC
TTTATAATACGTCTCTTTGGTTTAATTAATATCATTTAGTGGAAAAAGAATAAGGCCAAATAAATGACCT
TCACTACTGTGGGCAAGAGGGTGGATATTTTGCTGCTGCCTTTGTATCTGAATTTACAACTCTAATTAAA
GGAACCAACTCAGTTTTGATGCAGTAACACTGGGTAACTTGTGTTCTTTCTTGAATTTCTGAAAGTGCTA
ACAATCCTGAGCGTGTCTCTCTCAGTAGGTGAGATGTGGGAAATGGACCACAGCGGTGGCCACAGTATCT
ATTAGAGCATCTAGGCTTTGAGTCATGACAGAGTACAGTCTATTGGGTTGAAGAGGAGAGGGGAGTGAGG
GTTCTGGATTGTTTTAATGTACCTTATATACTTTCATGTACTGGACTTATAGGAACACTATGGGAATTTG
GTTGAATTTTACTTCTGAGATAACTATATAAACAATAAAAGGCTCTGAAAAATCCTAAGATATAAAAATT
CCTTGAACTCACTCCCAAAATGTGAATTCAGCCCCAAGGTGAGTTTATTGGCATAATTTCTTACAACACC
CAGCAGACATATAAGAATAACTGCAACAGCTTTTATTTTTTGTGTGTGCCTTAATATGTTTACTGGGCAC
TATAATAATGCTTTAAATATAGTAGCTTATTTAAATAATAAATCAAGCTATCTTGGAGAATCATAATGGC
CAATGCTTTTGAGTACTTACTGTGTGCCAAGCATTGTGCTGAGATCAGTAGACGGAGTCTCACATAATCC
TCATGATGGCCATTTTACAGATGCAGAAACTTGAAATCAGGAGCAGTTGAATTACTGGCCAACGTGACTT
AGCTTCCAAGTTAAGGGAGGTGGTACTTGAACCCAGCACTGACTAATTGTGAATTGTCAAATTTATACTT
TATTTCTGGCAGTTTGCCCCAAAATACTAAACTGACTCCTCCCCTTTACAAACTAACTCAGCTTGTATAC
CTAGGGAATGAAATTTTTGAATACCGGGAAAACATAATTAGAGCTCAGAATCTTTTGTTTTGGAAAATAG
CACACAGTGCATTAAAAAGATAAATTTTTGGTATTAAACAGGTCACTGCTTAGCTAAACAAAGAAGACTA
GACTTGGAGTGGTTTTTTCACTTCTGATATTCTCTTTTCGTGAAATACTCTTCAGTATGTTCACCTTTTC
TTTATTGTGCAGGCACTGTATTGAAATGGATGCTGCCTACAATTTAAGCATAATAAAAACCCAGCCTCAT
TTAGGCATATCCAAGAAAATCCCAAGATATTGATTAGCTAAATGAACTTTTCTACATGCACATAAGACGG
AAAGTGATTAGTGATGGGAAGAGTACAGCAAATGGTAGCATTTATCAGCATATTTTGCTGCTGATTTGGA
AAATGTGCTTAGTACAATGTGATGTATCTCCTGATTTCAGAGGAAAATCAGGCAGATTCGCATCTGTCAT
TTTATTTACCACCTCCCTGCAGTCATACATATTCTACAAAGAAGAATAAAAGAGTTTTGATTTGTTGACT
CGGGAAGAGGGGGTTGGCTATTGTTGGAGGTGAGTGGAAAATTTTTAGGTATGGAGAAGATTTGGCAGCC
TAATGGGGTTGCAAAACAGGAGAATTGGAGTCTGCCTTATTAAGGGGAACTTGAAGAACGTCAGAACGTG
TAGTGCAAACAGTAAACCATGTAATCATTGTGCTTCTTACACACTCATCAGGGGGAATCAGAGACTTTCC
ATCCTTTCTAATTAGGGCAGGTTGGCAGTTGAGTGGAGCTGTGAGGTTTAGGGTTTGTGCAGGTACATTA
TGCATCTTCTGACACAATTTTTTCCCAGGATGTCTGTAGTCAGGATTACAGACCAGGTATGGTTTCCTTT
TGCCTCCTGGCTGTGTTCCCCTTCATCTTACCTTCCAAATCAGACAGTTCTGCCCTGCTTCCGAACTCAG
ATAACCGTAGGAAAGTATTCTCACATCCCAGAAGAGATGTCTCAAAGGATTTTTACCTAGGATGTGAATC
AGGCTGGGTATTTTAAGAATTTTCTATTTCTGTACTTTAGCTGACTGTTTGGTTCGTAAGACCAATTCCC
TGTTCACGCAGCCTTCTCTTCTTCCCCCAACACACACACACACACACACCCACACATTCACTCACTCACT
CCTCCCTTCTCTGTAGAATGCCCTGGTTGATTGAGACTAGGAACTAAGGAGGAAGGTAATGTCAAACTGA
AATTTCCACACATTATCTAAAAATGTAATTCATCAGCTTCAGGGTAGGAGGAAAGTGCTTTCTGAAATGT
GTTAATGGGAAATTCATTTTCTTCTTGTCTTCTGTGAGGTGTAGTAGTGGTGATTTCTTTTTCCAATCTG
CCCCCTCGCCCCCATTCCACATCTCCCTGACTGCTCTTAACTGATAAACTCTGTATCTGTGTTTATTCCT
CGTAAGAACTAAAGATCATTAAGTTGCTTTTTCGTTTTTTCTACAGTCCCAAAATTGAGCTTTGATAGGA
GAAGATATTTCTAGTTTGGAGAGAAGATAAAATTCAGATAGAGATCATATATTTGTATAAGGTTTTTATA
TTTGTAAAACATTTTCAATCAACCAACAGTATTTATTTAGTGTCTACTCTCTCAGACCAAATAGATATTA
TTCCCTTTCCTTCCCTTCTCTGAAATTCTGTATCACAGTCTGTGAGGAGGTCAAAATGGATAAGTCATAG
TTTGTGCCCATGTGTTGCTGCAGGACCAACGAGCCAGGGAAACCAGAACAAATGACAGCCCTTCATGAAA
GTCTGGAAGTGACGGGGAGCTGGCTGCTTATTATGCATATTAACTACACATCTACCTTGCTGTTTTGTGG
GCGGGGGCAAGAGGGAAGTGGAGGTTGTTTTGTTTTGTTCTTCACCAAGGCCCAATCTTACTTTTCCTTG
GTCCTGGCTATTAATGTCATTGGAAGGATGGTGAAAAAGGATTCATAATGATACAATGAAGTTGGAGGTT
TGATGGAATGCCTACTGCGTGTCAGCTACAGTGCTAGGCATATTATAGATGTTATCTCATTGAAGCTTTA
TATCAGTGTTGCCTGATCAGTGATTTTATTCCCATTTTGCAGATGCAGAACCCAAGACCTAGAATTAGTC
AGCTGGTGAGTGGGGTTAGGGCATCTGACTGCAAAGTCTATGGTCTTTCTGTTACCATACCACTCTGTCT
GTGCTGAATGAAGACAACATCAGTTATGGGTGTTCAAAGGAGAAAAAGATGACAATAGACTGAGATTCTC
AAAGCAAGTGTCAAAGAAAAGCGAGCCTTCAACTTGGCCCTGAATTTGGTAGAGATTAGATTGTAGGAGA
CCAGTCCATGCAGAGGAGGCAGCTGAGCGAAGCTTCAGAGACATTGTTATGGAATGAATGTTTATGTCCC
CGCAAAATTCTTATGTTGAAGTTCTAACCCCCAATGTAATAGTTTTTGGAGATAGGGCCTCTGCAGAAGT
AATTAAGGTTAAATGAGGCCATAATGGTAGATCCCTGATCTGATAAGATTAGTGATCTTATAAGAAGAGG
AAGAGAGACTGGAATTTTCTCCATACATATGCAACAAGCAAGAAGGCAGCTATCTGCAAGCCAGAAAAAG
AGCCTTCACTAGAACCCAACCATGCTAGCACCCTGATCTTGGATTTCCAGACTCCAGAACTGTGAGAAAA
TAAATTTCTGTTGTTTAAGCCACCCAGTCTGTGGTATCTTCTTATAGTAGCCCAAGCTGCCTAATACAGA
CATCTTCAAGAGATAATGAATAGAACAGGCAGGACTACTCTGTCGGGTAAATGGGGATACCACCTTTGTG
TCAGTGAAATATCTGAAGCTCAGAGATGTTAAATAATTTATCCAGGGTCACAGTTAATAAGCGGTGGAGC
TGATATTTGAACCCAAGTCTGATTCTGAGGTCTGCGTTCCTTCTACTTTGCTAGTAACTAACTCTACCTA
ACACAGAAGGAAGTTGACAGCTTTCAGACTTCCCATGGCGTCTGTGATCTGAGAACCATTATTTATCTCT
CTAAGGTGATGTACCCATTTGCTCAGTGACTTGCTTTCCACCTACTTAGTTCTTGCGGATTTCTAAGTTG
AGTTTTCTGCATGTCCCTTATTTTGTAGTTGAATGTCTGGTGAGATACAAGGCCTCATAAACACAAAGTG
GATACAGCTAGCTAGGGTAATAACTCTAATTCCTATGGCCGCTAATGGAATTTCTCATCACAAACTTCTG
GAATCAGATTAAATAATTTTATTGGTGATATAAGCATAAAATATACACTTAGCAATCCCTGATATTTGCC
CTTAGTGTTTGTTTTCAGAGGCTTTTATACTCAGTACTTCCTTTGACGAGTCAAGAGCACTTGGCTGCTT
ATTTTTCTTGCTCTTTCTTCCTCTCTTTTCTTTGCCTGGTTTGTTGTTGTTGTTATATTTTGTGTGTGTG
TGTGTGTGTGTGTGTGTGTGTGTTTGTCCTGCTTCCTCTTTCTGCCTTCTTGTTTTTTGACATGTCACTT
TGATCCAAAAAGGATTTTCATTGGCTTATTAGATAGTATGGAAAAAACTAAAATTGAAATAGCCATCAAT
TTTTTTAAAAAACAGAATAGAAGGAAATGGATATAGAATGGTAAAAGGAGACCAGAGGAAATTTAGTAAA
TTAATTGTGGTTAAATGACTCAAACGGACCACCTAGTTTGAGTTTTCTTTTTTTTTAATTATTATTATAC
TTTAAGTTTTAGGGTACATGTGCACAATATGCAGGTTAGTTACATATGTATACATGTGCCATGCTGGTGT
GCTGCACCCATTAACTCGTCATTTAGCATTAGTTATATCTCCTAATGCTATCCCTCCCCCCTCCCCCCAC
CCCACAACAGTCCCCAGAGTATGATGTTCCCCTTCCTGTGTCCATGTGTTCTCATTGTTCAATTCCCATC
TAGGAGTTTTCTTTACATCAATGAAAATGAATGGTGACAACTTTGGTTCCTTTCTCAAGTAGTTACCAGA
ATCCCCACACCCTCTCCCACCACTGGCCCTGTAGCCCTTTCTCTGGAGACAGGCCTCTGATTGTAGAGAC
ACTTGCCCACTGTAATGCAGGATTGGATAGAAAGCCTGAAATCATATACATGGAATTTTCCTCATCTTTC
TTGCCTGGGTCCATTTTGGATTGATTGACTTGCTTTTTATGGCTAGGGCAGGCAGTAACACAGAGAAGCT
GCCTGAGTGGAGTTCTTGTTTTTATTAATATAAGGTATAAACAATGTGCCCTATGGAGGAGGTGTTCTGA
AGCAGGCCTTCCTTGCCTGCTGCCCTGAACTGAGGTATTACTGAAGTATTACTGCTTTCTGAGTCACTTC
AGTCTTTCCTCTCCCTTCAGACCCCAAGGCTGGACATGCAGGAACTTCAGTTTTCAGCTTCCGTCTTTCT
CGTGAGGGTTTCTGCAGTGAGTTCTGTCTGGTTTCTCATTACCCAGAGCCCTGAGCTGGACAACAAACAG
GAAACTCAAATGTCACTCTCATATCCTGGTCCTAACTGTGGAAACTGGAACTAGTCCTCAACCACCTTTG
CTCTTCCCAGTGCCCCTCACCAGTCAATGGACACAGATCACCCTCTAAGTACGAGAGAGAGACAGCACTA
CCCAAGAGCTCCGCACACCCCAGCACACACACACATCCCCCAAACACTTTTCTGGCATGCATGTGCGTGC
ACAGGCACGCACACACACACACACACACATCCCCCAAACACTTTTCTGGCAGGCATGTGCGCACGCAGGC
ACACACACAAACACATCCCCCAAACACTTTCTGGTCAGAAATACCAAACCCAGTGCATCAGACTAACCAG
AATTGAGACAGACTTCACTGAAAGTCCTGCCTTGCCTTCCCCACCCCATACTTGATAGATGTATTTGAAA
CCTTATGTAAGTCATGTTATCCCTTTGGATCTCCATTTCCTCAATACACAGTAGAGAAGATAAATCTTAA
CCCTACCTTCTTTGGATGGTACTTGTGAATTCAAACCAGGTGATACATGCGAAGGCACTTTGTAAATGAA
AGCAGTCTATAAATGGGTTGCTCCTATCTCGTAACTCCTAACCACTTCTCATCAAGGGTGTTAGCCCTGG
GCCAACAGATGGATAAAGGGGGAGGAGAGGGAAGGTGGATGTCTGTTCCTGGTTCAATCCTAGGTTATGT
AATTCCAAGTAGGAAGTAGGAGATGGCATCTGAGAAGGCAGGAGAATAGAATGGAAACTTACGTTTACTA
AGCACCTGCTAGATGCCAGATGTTAGATGCCGCCTTATATTTATCTCATTTAATCCTGACCACATCTACA
GTAGGTACACATTAGTGACCCCCTTATTTAGACAAGGAAACCAAGGTTCCTGGAGTTTAATGTGACTAGC
CTAAGGTCACACAGCAAGCAAGTGGCCAAGCCGGCTGCATACCCATGTCTGTCTGCCAGCTGGGACGAGA
GACCTTCACAAGAGAGGGTTTCCCACATTCTTGCTGTTTCATCCTGAGTCATGAATGTGGCTGTACATTG
TATTCCAGTAAACCTCAGGAATAGCTGCAGAAATAATGAACACCAATTTCAGTGGTTCTGGAAGATTGTA
AATGAAAGCCTTTAGTTCAATAAGATGCTCCTCCATTTACAGTGGGATTATATCCTGATACACCGTCATA
AATTGAAAATATCATAAGTTGAAAATGCATTTAATACTCTGATAAACCCATTGTAAAGTCAAGAAGTCAT
CATAAATCCAACCATTGTAAGTCGGGGACGGTCTGTAGTTGAATATGTCAGGATAATTTCTGAGATTTTT
TTTAAAATTAGGCCACTTCTATAAGTGGTAACATGATAAAGTGGAAGGATCCACTAAGTTCTTGTTCTCG
GGCTAGCTATGGGACTTTTGGTGGATCAAGCCATTCTGTGCCTCAGGTTGTTGTGCATAAAATGGAGATA
ATACTGACTTTTCGCACCTTTCTGTGTGTTGTGAGATCAGATGATTTGCTAATGTGCTGGTAAATTCAGG
ATATTACTGTGGTCACCTATAAGATAGGACATTGTAAGCAGGGGATTTATGAGGGTAAAACAAACCCTTA
AACCCCCTGTGATAAGCTATCTTTCCTTCCTAGTCTGCCTTCCAGAAGTTTTGCTCAGTTATCTGCGTAC
ATCTCAACAAAAGCTGATTAACTCTCTCAGACATCAGTGTCTAACTGTTATTAATGCTCAAGCTGATCAA
ATTACAATGCCACAGATCCTACTTGTGCTGTTAATATTAGATTTTGGATTCCGGTCTATAATGAATGATT
TTTCCTCCATGCATTGGGAAAATTGGTTAGCAGAGTTCATAAGAAAGTTTAATTAGCAGGCTGTTTGTGA
AAATAGCGGCTGTGAGTCATCATTCAGAATGAACTAACATTTCTCAGGCTTGAATTTGTTCTTTTGTTCC
TTGAGCAGCCACATAGGATCCTTGTGTTTGGGAAGCTGGTGTCCACATGTTGCCCATTTGAATGGCACCA
TGTAATAAACTAATAACCAAAACATCAGATTTAAAAAACCAGAGAGGAAGAGGAGGTATAGGGTGTTTGT
ATATATAGATATGTGTATCTGTGTCTGCTAAGGGAATATTTTAGGCCTAAGCTAATCCAGCACGGTGCTA
GACAGGATAGTCTAGTGATTAAGAGCTAGACTACCTATATCTACGTCTCTGCCTTATCATTTACTAGCTG
TGTAACAGGCAAATTTTTAACTTCTCTGGGCCTCAGGTTTATCATTTATAAAATAGTGATACTGATAGGA
TTATTGTGAACATTAATTTATGTAAACTACCCAGAACAACACCTGGCATATAGTAATATAATTCTTACAG
GAGTTCTGTGAGATGTAGGTATTATTAGCTCCATTTTATAGATGAGGAAACAGCTGTGTGATCTTGGATA
AGAAAGTAACTTATCTAAGATCACACAGCTTCTAAGTGGCAAAGTCGAACCAATGTTTATTTGACTCCAA
AGCCTCTGTTTGTATTTACTATACTGTACTAGCTTCCAGGGTCGTATGCCTAGTTCATTAAGTGTAGATA
CTCTGTTTGTGTGTGTGTGTGTCTGCATGTGTGTATGTGTGTACCTATGAGAGTTTGCTCCTGCTTGACT
ATCCATACAGCCACACACAATTGTTTTGCATTTTTTTCCTTGGGTCTTTGGTTCTCCTAGTGAAACTTCA
GGAGCTCACTGCTGACTACTCACACAGTGAGCTAGAACCAGACTTGTACAACTTGTACCAACATGAAAAT
GTGTCTTCAGATGTCTGACTCCCCTCCCCACTATGCAATTCTGTCCTGTGTCTAGATTATCCCAGAAGCA
AGACTCTGTGATGTCATCTGAGAAGCCAAATCATAGACTGTCACAGTGAAAAGAGACCTTAAAAGTACTC
CATGGCAGCCAGGCCTGGTGGCTCACCCCTGTAATCCCAGCACTTTGGGAGTCCAAGGCGGGTGGATCAC
GAGGTCAGGAGTTTAAGACCAGCCTGGCCAAAATGGTGAAACTCCATCTCTACTAAAAATACAAAACAAG
CTGTGCATGGTGGCAGGCGCCTGTAATCCCAGCTATTCGGGAGGCTGAGGCAGAGAATTGCTTGAACCCA
GGAGGCAGAGGTTGCAGCAGTGAGCCGAGATTGTGCCACTGCACTCCAGCCTGGACGACAGAGCAAGACT
CCTTCTCAAAAAAAAAAAAAAAAAAGAAAGAAATACTCTGTGGCTTGGTCTTATTTTCAACTGGCAGGAT
TGTTATTTCAGGAACTATAGTTCAGGTTTGGGGACCAGATCCCCCACCTTAAGTAAAAATCTTGAGACAG
TATTCAGTCCTGTTTCAAAGGGTAATATTCATTTGAGAATTCCATCTAAAAATCTTTTCCAAAGGCGCTT
AATTGATAATGTTTTTTAAAAGGGGTTCTGTGACCAAATGAGTTTGAAAAACTGAAGTGAACCAAGTTTA
AAAGTGATTTATTGGTGGGGCATGGTGCCTCATGCCTATAATCCTGGCACTGTGGGAGACCGAGGCAGGC
GGATCACTTGAGGTCAAGAGTTCGAGGCCAGCCTGGCCAACATGGTGAAACCCCATCTCTACTAAAAATA
CAAAAAATTAGCTGGGCTTTGTGGTGGGTGCCTGTAATACCAGCTACTTGGGGGACTGAGGCACGAGAAT
CACTTGAACCTGAGAGGCGGAGGTTGCAGTGAGCTGAGATCACACCACTGCACTCCAGCCTGGGTGATGG
AGCGAGATTCCATCTCAAAATAAAAAAAAAAAATGGGGGGCTCTTTTTATCAGTACTTCTCTGAACCTGT
GCTAACACGACGTGAAAAGGAATGGCATAATATGGAGCATTACCCAAGGAACCCTTTTCCCTCCAGCATT
TTGTATACTCTCCTTTCTAAGCCAGTAGAGAAGAATGGAGTCCTTGGAGGATAAATTTGAGGGTGGGAGA
CAAGGAGGCAGTTTGCAACAGTTCCTACATGAAGACCTCATTTATTTCATTAAGAAAGAGGGGAGATCTT
CTGCTGCCCCGGGGTGGGCAAGTAAAAGCGTTGGTGTCCTGGGAAAGTCTCACCTACTCCCAGGAGGAAC
AGAAAATGATGCCATATGGATCCAAACTCTAGCATCAGCACAGTCCCATCTCACACTAGGCATTTTTTTG
AAAATTATTGAGTACTGAGCACGTTCTGGGTATGATTCAAACCGTGGGTTCATTTGGTGTCCTGACTGTC
AGGGTGACATTCCATTTTCCATTGCCTGGAAGAGCTGAGCCATTAGAAGGTCTTCGTATTTTGCAATCTC
ACTCGTATTCCTGGGCACTCCTTCATTTTCACATCTGCCACGTACTTGACTCCATGTAATGAAGCTGGTC
ATTCTTGCTTTGTGTAGCCATTCCCCAAGAATCCCGAGCTTTTTAGAAAATCAAAGAAGATGACGTTCCC
CCGCAATTTCTACCCTAAAGACCTATTTCTGCATGAGTTGTTCTTGGGTTTTTATGTCTTTATTTTGCCT
TATTTCCTACCTGCAAGTTAAATAGCAATGAAAAGGGAAAACATACTTTTGTTTCTTGTTTTTTTTCTTC
TTCATGGATCTGGGAATTTCTTTCTTTTTAAACATTTGTTGAAATCAAACTAAGATGTTAGAACATGGTG
GTGAGCTTCATGCCTGGCACTTTACTATCAGCGAACTCCTCGATGATAAGGACAGAGGTGTCCATTTCTG
CATTTCACACAGATATTAGTGGTAGATCCAAGGCCAGAGAGCACCTTAGTGTTATTTCAGAAAGGACACG
CTGACAGAGGTTTTCAAAGTCCTTCAGCTAACATTTGGCATCCTGACTTATCTCTGTATGGACAAGTTAT
TTATCTCATCTCCTTGAGTGAGAGCCATAAATGTCTTTCACTTTGAATAAGGCAGTTTTAATGGATTTAT
ATTCTGTTAATGTTTATGAAGTATTACTCTGTGCCAAGCCCTCTCACATAACTTATCCCTTTTGATCTAA
ATCCCAACATGATATCAGGAGCTTCTACATGCGCTTTGTAAGAATGGTGTCTGGTGGGAGTTTTAGAAGC
CATTGTCTTAGTGTTAAATATAGCAGTTCCTTTCATGCACAGACATTTCACCCACAGAAAGTCTCATTTT
GCCCAAAGGCTAATTACAGTGTATGTAATTAGTATTAACCTGATAATTTTTTCTATCTCTTCCTCTTTTG
TTGCTAAACCCTCGTGGTTAACATCAGCTGCATTGCTGGAATCACCTGTTGGTTTGCATCCACTCTGGGT
GGAATGTCTTGTCTATCTGACACCCAGACCTTTGTTTCATGTGAGAGTAAGCCAACCAAGAATTAGGAAT
TCTGGTTCATTTTTCTGGCTAGCTGGGAGTTTGCCAAAATCATCCTCTTTTTTTTTCAACCCTTGTTAAA
AACATTTTTAAACGTGTGACTATTCTTTCCTGTCTTGTAAGAATATTCTGAACATAATTTAATTTAATGT
TGCTTCGATTAAGAATCTTTCATTGCCCCAGGGTCATCAGTCTGAATACTCCTTCTTTTTGTATGATAAA
TGCTGAAGGTGAGATAGTTGTCACTGAGGCTTCTATTGTCCTAGTGCACTACTTAGAATATCTTTTCCTT
TTCAGTTTTTTTTTAACTAAGTACTTGATACCAGCTTTTATCTTACAAATTTCCTTTCTTTTCTGAACAA
ACAGAAGAAAAATCAAGTTCAGATTAGTTCAGTTTTTCGTTTATTGAGGTGTATTTTTGAAATGTGTATT
TAAAGATCTGTCATTTGGAGCAATTTATTTTATATAACAAACCAAAAGGGTGGGGGAGTGGAAGACAAGA
AAATACCTCCTTTGAGAAATAGTTGGTTGGCCTTTCTTTTGTTTGTTTTTTGAGACAGGGTCTCCCTCTG
CCATGCAGCCTGGAGTGCAAGGGCAGGATCGTGGCTCCCTGCACCTCCTCCTCCCAGGCCCAAGCAGTCC
TCCTGCCTCAGCCTCCCAAAGTGCTGGGATTATACATGTGAGCCACTGCACGCAGCAGTTGGCCTTTCTT
AATGAATAGTGTAGCTTTGTAATTGGTCTTTCTGCTTTTGGGACTGCTAGAAATGAATGTATATAGTCTG
TGCATTTTCATGTTCAGAGACATCATTTTACATCTGTGTGAACAATTTGGCTATCTTCTCTGAAATCAGA
AACTCTATTAAAGGCCTGTATGGGCTTTGGAGCTGGATGGATGTTCAGATCTTGGAATCTGAGGCCTCCT
TGATTATAAATTGCAATGATAATGCTTACCTTGTTGGATTGCTTTAGACAATAGATGAAATGATAGAAAT
AAAATGTTTAGTATACTGACTGGCACTCACAAAATGATAACTGTTTTTGTTACTATTCATTCACTTATTG
AATTCATTCATTCATCCATCCATTCAACATAGATTTCTTGAAAATCTACTATGTACCAGACATTGGTCAT
AACAAGATCCATGTGGGTCATAATAAGACTCACGCGCCCGCCCTTAAGGAACTTAGGGTCTATTGAGAAA
TACATTCAGTTCAACAAGCTTATATTAAATACCTACTGTAGGCCAGGCACTTTGCTTGTTGCCATCTTTA
TGCCACATGATGAGTACAAACATCTACTTAGGAAGCCAGAATATACCCTCTGGAAATAACCAAGGACTGG
CCCAAGGTAATTTTAAATACTTTGGGAATTCGGGTCCTGGGTTTGTTGTTGTTGCGTTGATGTTATTTTG
AGAGAGAGTCTTGCTGTGATGCCCAGGCTGGAGTGCAGTGGTGTGATCTCGGCTCACTGCAACCTCTGCC
TCTTGGGTTCAAGTGAATCTCCTGCCTCAGCCACCCAAGTAGCTGGGACCACAGGCACATGCCACCACAC
CCAGCTAATTTTTGTACTTTTTGTAGAGACAGGGTTTTGCTATGTTGGTCAGGCTGGTCTCAAACCCTTG
ACCTCAAGTGATCCACCTGCCTTGGCCTCCCAAAGTGCCAGGATTACTGGCGTGAGCCACTGCACCCAGC
CAGTCCTGTTTTTTTAAACAATATTGTTGGCAGAGAGCAGACACACTCAAAATTACAGATGCTTAAATGC
TTCCTGAATCTCTGCCAGAGATATAAGGAGATCTCATATACACATCTGAGAATGGATTCAACTTAGAAAT
GGTATTGACAGTACAGGTTGACATCAACAACAAGTGGAAGTGATGACTATAAATTTCGTGACAGTTCTTT
CTTCTCGAGGAATGGGTGCTCATTGTGTCCTCTCCTTCTGGAATGCTCTACTATACCTGTTGCCCTTGAC
TGCCTATTGCCTGGCTGTCTCCTGTCAATTTTTTCAAATTAGTCTCAATTCAGATATCACATCCTCCAGA
AAGCCCTCTCTCATCTCACTATTGTAACACTTAACTATACTCTACTATCACTGATAATTCATGAGTCTGA
CTTTTCTACTAGATCATGAGCTCCTTGCTTCTTTCTTTGTCCTCAGTTTCCACATCTGTAGAAGGGATTT
GAAGATGGCTGATACTAAAGTCTTTTCCAAGATTGTCATTCTATGATGTACCAGATCCAGTTTGAAAGGC
ACAGCCAAGTTGGGAGATGGGAATGGGATACTTTGGGATATATATTGGAATTAAATGGGAGAACAAAGAC
TTGGAGTTGGTACTAGAAAACCCATGCTCTCTCGCCGGGTGCAGTGGCTCACGCCTGTAATACCAGCACT
TTGGGAGGTCGAGGCGGCAGATCACTTGAGGCCAGAAGTTCGAGACCAGCCTGGCCAACATTGCAAAATC
TCGTCTCTACTAAAAATACAAAAATTAGGCGGGAGTGGTGGTTCATGCCTGTAACCCCAGCTACTCGGGA
GGCTAAGGCATGAGAATTGCTTGAATACAGGAAGCAGAGGTTGCAGTGAGCCCATATCATGCCACTGCTC
CCCAGCCTAGGTGACAGAGTGAGATTCAGTCTCAAAAGAAACAACCCAAACAAACAACCGCATGCTCTCT
CAAAGTCTCAGGCATACTATGCTAATGTCAGGTATTTAGCATACAAATGAGCACATATTCAAGAAACCAG
GGCACAGCAGAAAGTACACTGGCTCTAGAGTCAGATGGGCCTAGCCACTATTTTCTAGACAAGAAAGCTA
CTTCTCCCTCTGGGCCGTAATGGGCCTTAATTTCCCCTTTAGTAAAACAGATATCAAAATACCTGCTTCA
GAGGGTTGTAAAGATTATGTAAGTAATGATATAAGTGAAGTGCTTGGCCCATAATGCGTGCTCAAAAAAT
ATTTGCTATTATTTTTATTTTCTCAGTTAGAAATAAGTATAAACTGAAACCCACTATGAGCATTGAGTCT
AAAATAAATATAATTTAGAACCTTTAAAGGGATCTTATGGGTCAGTCTTACCTACTGCTCTAGCATCCTC
AGACAAATAGTAGGTCTGGCTTCTGTTTGCACATGTCTAGGCATGGGGCTCTCGCTACCTCACAAGGCAG
CCCACCCCTTAAAAAAGCATTATTAGAAAGTTATCCTTTTATAAAGGCAAAAATCTGTTCCCTAATTTTC
TTCCACTGCCTGACTCTCATTCTCTCCTTCAGGGCCCCACATAGCAAGTCTACCCTTATTTTCCCATCAT
GACCTTTGAAAATATTAGAAGGGACTTTGAGGTCAGGCACAGTGGCACATGCCAGTGCTTTGGGAAGCCT
AGGTGGAAGGATTGCTTGAGGCCAGGAGTTCAAGACCAGTCTGGGCAACACAGCAATACAATATAAAAAA
TAAAAGAAAGGGCTTTGGATACCTCTAGAGTCTTCTCTCCTTCAAACTAAATGCCCACAGGTCTTTCACA
TGTGTCTTATGGGATCGGGTTCCGCTTACCAACTTCCTATGGACATGGGTAAGGCTCTGGTAAAAAAAAG
ATTTTGCTGCTTTTCCCGGTCCTTTTATGTTTGGTATTTGGGAGACTGAAGGTAGTTAAGAGAATGTAAA
TATCCATGTGAATAGATAATATTCATTAGTTTACCCAACAAACATTTACTGGATATCCAATAATGTCATG
GGCCCTTTGTTAGTTCCTGGGGAAAGAGAAATGAATAAAGCAGCATCTTGTTCCCATGTTGCTCCCAGTC
TAGCGGGGAACAGAGACACATTACCAGACAGTTTTCAAAGGATGTGTCAGTGAGAATGTTCGCCTGATCT
GCAAGACTGAGGGGAGGGGGCCACTGTAGTTTTTTCATACATGTCTTATTCAGCAGCATGGTAATTCAGA
TTGAAGAAACTAAGGGTGCCCCTTTCCTCTTTTCAGTCATTTGACAAGCGTGATGATGGATTGCCCTCAC
ATTCACTTGTGCCACTGCTCCAACATGCCAAGCACGTTCCTGCTTCAGGGCCTTTGCACATGAGATTCCT
TCTCCCTGGAATGCCCTTTTCTCTAACAGAAGTGACTGGCTACCACCCTTCAATCACCCCAGCCCTTTCC
CTCAGATCTCTGCTCTAACATCATGTTAGCAGTGAGGCCTTACCTGACCATCTGTATTAGTGAGGGTTCT
CTAGAAGGACAAGAACTAACAGGAGATATATATATATATAGATATAGATATAGATACACACACACACACA
CTCACATATATATGTGTGTGTATACATGTATATACTATGCATATATACGTATATACATATACCTATATGT
ATATATAGTATATATGCATATACACACATACACGTATATATGTATACATATATACGTGTATGTATACGTA
TACATATATATGCATAAATATATGTATATAGGTATATATATGTGTGTATATATGTATATGTGTGCATATA
CATATATACACACATATACATATATACTTATATATGTATATACATGTATATGTGTGTATATATACATATA
TGTGTATATGTGTGTATATGTGTGTATATATGTGTATATATATGTGTATATGTGTGTGTGTATATATATA
TGTGTGTGTGTATATATATATAAAGGGGAGTTTATTAAGTATTAACATACACAATCACAAGGTCCCGCAA
TCGGTTGTCTGCAAGCTGAGGAGCAAGGAGAGCCAGTTCGAGTTCCCAAACAGAAGAACTTGGAGTCCGA
TGTTCAAGGGCAGGAAGCATCCAGCACAGGAGAAAGATGTAGGCTGGGAGGCTAGGCCAGTCTCTCCTTT
TCACGTTTTTCTGCCTGCTTTATATTCTAAGGCAGCTGATTAGATCGTGCCCACTAGATTAAGGGTGGAT
CTGCCTTTGTTAATCTCTTTTGGCAACACCCTCACAGACACGCCCAGGATCAATACTTTGTAGCCTTCAA
TCCAATCAAGTTGACACTCAGTATTAACCATCACAGGTCCACCCCTTGTCAGCTTGAACCCATACACATC
TCTTGAGGTTATAAATAATCTTCAAATAAAGGTAGTAATAAGCTCATGATTACACCTAACATAATACAAC
TATCCTTCAAACAACCAGAAACGCACCCATCCCCAACCCAAATACCATTATACTGAGTTAACAATACTTA
AATGCTGATATGAAGTCAATAAATCTTATGTCACATGATAAAGGAAAAGGAAATAAAATAAAGACATTTT
CTTAGTACAAGTGTATACATGCACAAACATGTCTTTAGCAAAAGAAGGAGGAAATACCCATGACAATTAC
AGTCCCTGTTTCTGTACCCATTTGTATTCCCTTTGCCTTCAGCAAGCACCTCAGCAGGTCATGGTTTTTT
TCCTGGTGGAATGACCCAAACCTTCATTCCTGAGGTGTCTGGGCCATTTGCAGTCCTGCCTGGATTGGAC
TGTTGTAGCTTCCCATTGACCTTAATCACAGGGCGTGGTAATACTAAGAGACACCCTAATGAATCTCCTG
TATTCCATGTATATTCTTCCTTACCTCCATTGTGGAGTAGTAGACTAATTTCATCTTGATAGTCTGGGTC
AATCACCCCAGCCAACACTGCAACTCCCTTCTTAGCCTGTTGACTTAAAGGTAGGAGGAGCCCAAAGTGT
CCAGGCAGCAATCTTAACTTCTAGTTTAATGGAATTGTTATTGTGTCTCCTGTTGGCAGCGTTCCTCCCT
CTGGAACTAAGACCTCTAGGCCAGCAGAACGTGGTGTTGCAGGAACAGGAACAAAAATTTTGCTAGTGGA
TCACTAGAGGTGATGGTGAGTGGTGCCACTTCCACTTCCACCCCTTGATTCCTGGACCCATGAATCCTGG
CTATGGGAGAAACAGTACCATATATTGGACACTGATTCAGAGCATACACAGCCTTCTGGAGAACTTTGCC
CCAGCCCTGCAAAATATTGTCACCTAGTTGGTTTTGTAATTGTGACTTCAAAGGCCATTCCATCATTCTA
TCAATCCAGCTGCTTCAGGATGATGGGGAACATGGTAATATCAGTGGAATTCCATGAGCAAGAGCCCACT
GCTGCACTTCTTTAGCAATAAAATGAGTGCTTTGGTCAGAGGCAATGTTGTGTGGAATACCATGATGGTG
GATAAGGCATTCCGTGAATCCATGGATGGTAGTCTCGGCAGAAGCATTGTGTGCAGGATAGGCAAACCCA
TTTCTGGAGTAAGTGTCTATTCCAGTGAGGACAAACCTCTGCCCTTTCCGTGATGGAAGAGGTCTAATAT
AATCAACCTGCCACCAGGTAGCCGGCTAATCACCCCGAGGAATGGTGTCATATCAAGGGCTCGATAGTGG
TCTCTGCTGCTGGCCAATTAGGCACTCAGCAGTGGCTGTAGCCAGGTCACCCTTGGTGAGTGGAAGTCCA
TGTTGCTGAGCCTATGCATAACCTCCATCCCTGCCACCGTGGCCACTTTGTTCATGACAGGGGTGGCTGG
GGAAAGAGGCTGAGTGGTGTCCACATAATGGGCCATTCTATCCACTTAATTATTAAAATCCTCCTCTGCT
GAAGTTACCCATTGGTGAGCACTCACATGGGATACAAGTATCTTCACAGTTTTTGACCACTCAGAGAGGT
CCATCCACATACCTCTCCCCAAATTTCTTTGTCACCAATTTTGCAATCATGCTTCTTCCAAGTCCCTGAC
CATCCAGCCAAACCATTGGCTACAGCCCATGAATCACTATATAATTGAACATGTGGCCATTTCTCCTTCT
ATGCAAAGTGCACACCCAGGTGCACTGCTCAAAGTTCTGCCTACTGGGAAGATTACCCTTCACCGCTGTC
CTTCAGGGATGTCCTAGAAAGGGGCTGTAGTGCAACAGCTCTCCACTTTCGGGTGGTGCCTGCATAGTGT
GCAGAACCATCTTTAAACCAGGCCCTAGTTTTCTCTTCCTCTGTCAACTGATCATAGGGAACTCCCCATG
AGGCCATTGGCGCAAACTGGGGAAGAGAAGGCAGGGTGGCAGGAGTGTCCCCAGCTTCATCAGGGTGGCA
GGAGTGTCCCCAGCTTCATTAGGATCCTCCCACACATCCCCATTCCAAGTTTCAGGGTCCCATTTTTTCC
AATCAATGCCCTCACTTTAACAGTAGACACCTGGCGAGGCTGTGCATGCATCTTTAGTTGCGGGTCAGCC
ACTCACATGATAAGAGCTCATGTCTGTTTTTCCGTAATTTCAGCTCTTTCTCTACAAGAGATAAGACTCT
CACTCAAGGCAATCTCAGTAGATTTGAAGCTCAGTATCTGCTTCTGAAGCTGGGAGACAGAATCCCTGAG
TTCATCATTTTCTTTCATCACTTTGTCCACTGAACTTAGGAGCAACCAACCAGCTTCATTATGTTCCTTG
GTTCTCCACATACAGTCAAAGGTATCATGTATAGAGTCACTAAACTCCTTGCCACTCACGAGCGGTGAAT
CAGGAGTATCAAATTCATTTATTTTGCATAACGCTCTAAACAGGTCATGCCAAAGACTGTCAATGTTCTC
TGTGCTATTAGAAGTAGAGTTCTTAGCATTTTGGGGTCTAATCATATTAAGCAGCCAACTCCAAAAATCC
CAAAACTAATTAAAGAACTCCATCCTTAATATTCTGTTCCTCTAGAACCACTCCTGGTACCAAAATCTGT
ATTAGTCAGGGTTCTTTAGAGGGATAGAACTGATAGGAGATATGTATATATATATATATATACACACACA
CATATATATATGTATATATATATATATAAAGAGGAGTTTATTAAGTGTTAACTTACATGATCACAGGGTC
CCACAACAGGTTGTCTGAAAGCTGAGGAGCAAGGAGAGCCAGTCTGAGTCAAAGAACTGAAGAACTTGGA
GTCCGATGTTCAAGGGCAGGAAGCATCCAGCATGGGAAAAAGATGCTGGATCTCTGGGAGGCTAGGCCTG
TCTTTCCTTTTCACATTTTTCTGCCTGCTTTATATTCACTGGCAGCTGTTTAGATGGTGCCCACCAGATT
AAGGGTGGATCTGCCTTCCCCAGCCCACTGACTCAAATGTTAATCTCTTTTGGCAGCACCTTCCCAGACA
CACCCAGGAGCAATACTTTGTATCCTTCAGTCTAATCAAGTTGACGCTCAGTATTAACTATCATACCTAT
TTAAAAACCATCATACCTTTTAAAAATCGCAACTCCACCCCCTACACTGCCTTTCCTTCTTCTCTGCTTT
ATTTTCTCCCTACAACTCACTATCATCTGAAAAACGTTATATTTTATTTATGTATTTCTTGTCCATTTCC
CTCAACCCCAATCAGAATGTAAATTCAGTGATGGCAGAAAACAAGTAGGTTTTGTTCTCTTTTATATTCC
TAGTGAATGGAATATGCCTGGTACATAACACATGCTCACTAAATATCTGTGGGATAAATGTAGTACTTAG
ATTCAGCCCTCAAGTTCGAATGTCATCATTGTGATAGGGAAACTCTATCAAAACTCTGCTTTATCTTCAA
AGCCCAGCTCAAATGTCTCCACCTCCATGAAGCCTTCCCTACTCTACTCAGTCAGAATCAATTTCAACTT
CCTCTCTGTTCTTATATATAGCTTTAAAAGAAAAATACCTGTTATATGTATTATTTTTGCTGGGCTATAT
GTATTATTTTTTCTGGGCTATAATTAGTTTTTATACCTGTGTTTTCCTTCTACATTATAAGCTCCCTGAA
TGCGGGGACAATTTTTTGGTCATTTTGGGGTCTACCCATAGTGTCTAGCATGTGGTAGGTGCTAGTTATA
TGTGGGATTTGTGTGCATGTTAAATATTATATGCTCCAATGTAAAAGAAAGGCATCAGAAGCAGCCTCTA
CCTTCAAGAAGGTTGCGGTTTCATTGAGGAATAACATTCACATAGACCACAGTGTCAGACAGTATCTTGT
GGGGCATGAGAGAAGAAGGAAAAGGAACCAACATCTATTGAGCATCTGTTTTATGGCAGCGACTTTACAT
GCATTATCACTTTTAATCCTCCTATTAACCCCTTGAAAAAAGTAATATTAGCCCCATCTTATAAATGAGT
TTATTGGAGCAGAAAGACGCAAAGTAAGAATGTAAATTCTGGGGACAAAAAGAAATAGCATATACCAAGA
AATTCTGAGAGCTTTCCCATCAGAGCTTCCCTTCTCTGTTACCATGAGTTGGGTGTGTAGTATCCCCAGA
AACCAAGGCACAGGGAGGTTAATTTAACTTAGCCAGAGTCACACAGCAGTAAATTGAAGAACTGGGATTC
AGACACACGTCTGACCAACTCCAATTCCCTTTCTTTCCAGTGTTTCTCATCATACTTTAAACCAATGCTT
CTTAATCCTTCATGTGCATTTGACTTACCTGAGGATTTTGTGGAAGTACAGATTTTGATTCAGTAGGTCT
GGGATGGGACCTGAAGATCTGCATTTCTCACAAGTCCCTGGGTGATGCCAGTGATGCTGATACAGGAACC
ACACCTTGAGTAGCAAGGTTTTAAACCATTCTTAAGCTGGGCATGGTGGCCTGTAATCCCAACACTTTGA
GAGGCCAAGGCAGGAGGAATGCTTGAGCCCAAAAGTTGGAGACCAGGCTGAGCAACAAAACAAGACCTGA
TTTCTTAATAAACAAATAAATTTAGCCAGGTGTGGTGGCATGCACCTGTAATCTCAGCTACCCTGGTTGC
TGAGGTGGGAGGATCGCTTGAGCCCAGGAGTTTGAGGCTGCAGCAAGCTGTGATCATGCCACCATACTCC
AGCTTGCGCAAAAGAATGAGACAAAACAAGCAAACAAACAAAAAAACCCCACATACTTAGTTTGAGGAAA
TTGTGTGAATGACCAAAAGAAAATAAATCCTCTGACTAGTTGGCTGTAGTAACACTGGGCTTGCAGGAAA
TAAGCCAAGACTCATTGTAAGCCTCTCAGAGGTGGGATGGGAGGGAACAATCATAGGTGCTCCAGAACCC
CAAGGGATCCCCAGTCAGTGTGTTAAGAAGGAGAAGAGACCCCCAGTGCAAGTGAATGTATCCCCTTGAG
TAACTGCCTGATGCCAGACACTCTGCTGGACACTTAAACTTGGGCCAGTCCCTGTAGAGAGAAAGTGTGA
ACTGAGATATCCAACAGACTGGAGTTCATTCAAATCCTAGCCTCAGAGCCTACTTGCTGGTTGACTTCAG
ACAGATTATTTAACATTTCTCAAGCCTCACTTTCCTTATCTGCACAGTAGGCCTGATGATACCCATTTCA
CACAGAATTAAATGAGGTAACATTAATAAGCCACTTAGCACAGTGCCTGGCACAAAGTAGGCACTGAATA
AATTGTAGCTGCTATTAGTCCCCATGTTAATATAATCTTCACAGTGATACTTTGATTGTGAGAATTAAGG
GATTATCTCTGTTTTTTCCAGATAAGAGAGCATACTGATAAAGCTTAAATGACTTAACCAAGGTTATACA
GCAAGTAGTTTTGAACCACACACACATTGATACATGCAGTAACAACCATTCATCTGACCCTTTCTTGGGT
GTGTTTGGGTAGATTTAAGCCTGCTGAAAGCAAGAAAGACCTCTCAGAATGGGCAGTGAAGGAGTCCCAG
GATATGGAGTTGGCTGCAATTAACCTAGTATGTGGATTACTGCCATGCAGGTAATTTTGAGGTGACTGGG
GATTTTATCATGCACTTTCAGAACAGGATTTCAGCCTGAACTAGGGGTTCTAACTTCCATAAAAATTCCT
TACTCAACTCAGAAGTTTTCAACAGCAGCTACCCATCTGGCTGCCTCCTCAGGGGCTTTGTAGATGAGGG
GAGTAACTGTTCGGTTTCTGGAGAATGATGGTTTTTAAAAAGCGAAAGAGCAAGGTGTGCAGATTGGCAG
TGCAGAAATGCTGAGGTTCTTTCTGGCCAGCTTCTCTACTGCAGCCATCAACCATAAGGATGTCAGGATC
AGAATAATCTCCAGGATCCTAAAGGCAAGGAAAAGCTACGTCTATCCAGAATGGCTGGGAAAATAAGGGG
TTATAACCAGCTATGCTCTCAACACTTTCTAGAGATTAAATATAACAAAAATGCTTAACACAAACTACTG
GAGATAATTTACTCTTTCACAGCAGATTCAAAAAGCCTCTGATACATTTCAGGGTCTCAGAATCATTGTT
ATTATAATAACATTTTAGTTCAAATGGAGTAACTAGTTGTGGCAGAGAGTACAGGATTTGAAGTCAAATG
ATCTAGATCGGAAGATAACAATCTACAGCTCATGGGCCAAATTGGGCCACTACTGCCTGTTTTTCTAGAA
AAAGTTCTATTGGAACACAGCTACACTCATTTGTTTACATACTGTCTATGGCTGCTACACAATGGCAGAG
TTGTCAGGGACCCTAAGACCTACCAAGCCTAAACTACTTACTGTCTTGCCCTATACATAAAAAAGTTTTC
TAACCCCTGATCCAGACTATGATCTAGCTCTGTGATCTTAGGCAAATCACCATTTTCTCTGAACTTCAAT
ATCCACATCTATAAAATGATAATTATCTCTCAAACAGGGTTGTTGAGAGAATCAAATGCATAGAAGGATG
GGAAAGCATTTTGTAAACTCAGAATCTCTGTGGAAAGGTGGATAAGGGTGATTTTTGTTGTTCATCTGAT
CTGTGCCAGAGGAGAACCTACCCAGGACATTTCTTGTTTGTGTTTTGTTTTCCAGCCCCCGGAGTCAGTT
TATTGTTGTGTCCTCTCTTTCTCACAAATGCAAAATTAATTCCCTGGGTACCCCCTCTTTTCCCCCTCTT
CCCCCAAACTTACCAAACATTCTGGTTATATGCTTTCAGTAATGGAGGACTGGTACAAATGCATACATCC
ATTCTTTCATTTATCAAGCATTTGTTGATGACTTACTATGTGCAAGGATAGAAACTTTTATGAGCTAGTT
ATTATGGGAAGATGTGTTTTGTTTCTAAGGGGAAAAGTTGGATATACAAATTATTATAACAGAATAAAGA
TGTTGCCATGTCATAGTAGGAGGAGACATTGTGTATTTGTGTGTGTGCCTATGTGCCTATGCTTTATAAA
AACAGAAATATTGAAGTTCAGATTTAAGAGCAGCTTGTTAAAAACAAAAACCTGTTTAATTCAAAATACT
CTGAAGTGCTTTAAAGTGTAGCCATTATGTATAGCAGTTTTCTCTTGGAAAGTACATTCTGAATTATAAG
TTTCCATCTCAAACTGCCAAGAATGCATTTCCTGCCCATGCATGATAACTGGTGACCATTCACACATGCC
TGCTGGACAGGATTATTAGGGACTGGTCACAGTAAGGGTTGTAGGTCACCTGGGCACCAAGGGGCCAAAT
GCTCACTATAGTTTCTAAATTTTGGAGGCAGTCTTAATTTCATATCTCATTTTTTAATAAAGAGGATTCA
ATAAATGTAACTTTGATGATTTCCTTTTTATTTGTTCAACTTCCCATCAAAATAGACTCATAAATTGGGA
ACAAAAATACAGCTTGTTTTAATTTTCTGTTCTGAAAATACTGTTGCCATCCCTATGTTCTCAAATCTTG
CTACTGCTGATAAAGGGAGAAGATGTAGCCATTTGGAAAAAAAAAGAAAGAGTAATAAAAAGATATTATT
TCTGGAATACAGATACAGATACACTAGCTCTGGGCTCCAGACTGGATCCCTCAGGCCCTCCCAGCATAGC
ATTTCTCTTGGTCCCCATAGAAAAAGTGTTGCTATTTTTTGTGAATGCGTTTCATCTATTTTTTTCTAGG
TACACTTAGCATACAGAACTGCAAATATAAAACCCATCACCAATATATGGCCACCAAAATTAAAACATAA
AATTTTTCCTCATTTTACTCTCCCTTACTACTGAAATAGTTTCTAAAAGAAGTAAAGCTTGGGTTTTTTT
ATTTTCTACATAGAGATTTAATCCTCTACAGGACATGTTAAAAGAGAATGCTTAGATCCATAGAGTGCTT
TTTATTAGACTTAGCTGAACTCCTATGATGGTGAGAAGCATGTTAAGAAAACCTGTTCATGAACTAGGCT
AACCACAGGTAGTTTCATTGTGGTACCAGACTATCTCATATCTTTCAATTCACAGGCAAGTTTTTCTGCC
TCTGTCCTCCTCTTGTTCTATGCAATGTTCTGTTTTAGAGCTTGAAGTTCATTATTTCATATCAAGGAGA
ATCATCATCATTTTTCCTCTTCCTTTCTGAAATGATGTTCATCTGTTTTTTGTTTGTTTTTTTTTTTTTC
ATTTTCCCAAAAGCACCCTCATTCTTGATGTTAAATGCAGTCTCTCTCTAAAGTTAGAGCAGGTGATAAC
ACAGTTGTGCTAATTGCAGTCAGGAACTAAGGTGATGGTGGATTTGGGACTGATAGAAGCAGGTGGCTTG
ACATGATACATCTTGCTGGGCAGGGCTCCTTTCCCTCATTTGACCTTCAGAATCTTCCTAGGACTTGAAT
GTATTTTCCTTCCTCCAGAAGCAAAGGTCTAAAACAAAAATAAAATATAGAATGTGAAAATTATGCCCAT
TATATTTATTTTAGATTTTCATCAATATATGAGTAATTTTAGAAAGATGGATAGTGTGTCAGGAGCATGT
ACCACTCGTAAGCATGATTCCTCCACATATATTCCATCAGTATAAATAAATCAAGTACTACTCCAATGTG
AGTTAGGTCTAATTTTTGCTGTTAAGTGGTGTTTTGTTTATATTTTTCATAATTTATTTTAATTTTACGC
AAATTAAATTGGGCTGGATAGATTGACCATCTGACCAGTTTCCTAGAACTTATGCATAAGGTTTATCATT
GAGATAATTGTTTTAAAAATATCCTTTAAAAGCAGCTCAACTTGGTGAATGTTTTTAAAAAGTGATTATA
AGAATACTTTTGTACAGCAATTTTTAAAGCTTCTCATATATGCAAGGTAAATATGACTGAGAAATTTGCA
TGATGAAAATGTATTTAATTAGGTGAATTATTTAGCTAGGTTTGATGAGGTGACACCAAATTTCGGATAA
ATGATATTTTTAAACCAATGAAATTGGTCTCTGTATTTTTGTATTTGCAAAATGAAATTTCTGGGAACAT
ATGGCAGGGTCTTGTAATTCACCTCCCCCTGCCCCCACCACACGTACACACACACACACACACACACACA
CACACACACACGCCACTCACACACCATACTTACACAGTGAGATGGAAAGAGAAGGGTCCCAGCAGCTGGA
GTGCACCCAGCATTCTCTCCTTCCTCTTCAGTTACTAATCCTGGCTGGTGAAGGGCATGTCTGGTAAAGT
TTGCCCCTGTCTTTCTTCTTCTCACCCTGTTCTTCCAAAACAAAGGAATATCCTAATGGAAGTGTCATTT
TGGGTTTTCCATTTGGGGTCAAATGCCATTGAGCTTTCTTGTGATTCTCTTTGCTCCATCCTATAACAAA
GTCACCCATTTTCTCATCCAGAACCCAACTTGTTTTCCCAGGTTTCCTCCTACAACCAACACAAACACAG
ACATTTACCAGCAAAACAGAAGCTGTTGGAAAGATTTTTTGGCCGCTGAAATGGGCTCCTGTCACCAGGA
CATGGCAGGCTTTTTGCTGTATTATCTCCCAGCCCTGGCCCCCGTACTCCAAAGAGAGCTTTATGTAATC
AGTCTTTGCTGACATGTGACGTCCTGTCATTTTCCTCCCCTTCGGCTCTGCTGCCGCCCACAAATCAATA
ACATTGCTTGGGAAGTTCAGGCTGGTTTTGCAGCCACCCCAAGCTCTGTGTTTCTTAAAGGGTATGTCAG
AAAATGTAAAGTTTCCTAATGATATTTCTGGCTGATGACACATGGCAGAGCTGATGGACTATTTATAATC
AGTGGCACGATTGCAAGCACATTATTTTTATTTCACTTGGGGGGAGCCCTGTCACTTGCTACCTCTCTTT
GCAGACAAGTTGATGCCATCTCCACCTAAAGTAGCTAAATCCTCTTTTCAGAGTTTATTTGCACTCTTAG
CTTTGTGTTAGGAGCTCCCCAGCTCTTTCCAGTAGAAACCCCCTCTCCTTTTTCTTTATTGTTCTTTGGC
TCAGGGAATGATGAGGGTAAAGAATGATTTGTAGCAACTGCTTTGAATTCTAGCCATGCCTGCATCCTTA
ACTATACACATCTCCAGTCTTTGCTACTCAAGTCTTGCTACATCCCTCTGAATGTGGGTGTGGCTGGCAT
GACCGAGGCAATAGACACTGCTACTGTGTCCAGCACTTGCCTCAATTTTACAGGCCTGAGCAGAGCATAG
CTGTCTTTTGTTGAGCACCTACTCCAATCTAGACAATGTACTTGGTAGGCATTTTATACACAATCTCTCA
CTCTCTCAAACCTACCTGAGGTAAGTGCTGTTATCTCCAGAACAGAGATTGGAGGTGGGAGGGGGAGAGA
GATTAAATTACTTCCTTACAAAGTCGCACAGCTGATAGGGAAAGCTCTAGGACTCCAGTTTAAGTCTCTT
CTGACAAACCACACCTGTTCTCTTTCCGCTACCATGTCCTGCCTCTTCCTGATTATGTGGACACTTGTGT
ATCTCTTGTGTGGCTGTGCAGGGGCACTTACCCAGTTTTAGCTTGCACAGCTCCTAAAGTTTAATAGCCA
ATGAGAGTGAGAGTTGGAGGAATTGGAAACCTCTCAATCTGGGGGTAAACCCTGGTGTAAGAGGAACTGT
ATACCAAAGGAGAGTTTTGACTCACTGCAGTGGGAAGTGTTGCCTCTATAAAGATACTGAGCATGCTCTC
TCTCTCTCTCTTTCTCTCTGTCTGTCTCTCTCTCCCTTTCTCTCTCTCTTTTTAATATTTCCACAGGACA
GAGTTTAGGGTATGGATTTGTTAACTATATTGATCCAAAGGATGCAGAGAAAGCCATCAACACTTTAAAT
GGACTCAGACTCCAGACCAAAACCATAAAGGTAAGAGGTGATGTGCTGGCTCCTGATTCAGGAGGCTCTG
GTTAAATTTCATTCTGTTGATCTGGTAAATCCAGGCTATGTGGGGGCTGGAAGCAGTGTTCTTGATTTAT
TCAAAGAACATTTACCATCCACTATACTAAATGGGAGACACAGAGTGTTACAGAAGAGTGAGGTGAGGGT
TGAGTAGAGGGAAGGGACCACAAGCTGTGAGACCTCCAATTAAGAGGGCAGATGGGATATTTGGGATTCA
AGACCCCACAAAGAGGGCCTGTGAGCCTGAGTCTGCAAAGATGGCCAGAGCTGAGCCAAGGGAAAAGGCT
GAGGCCAGGAAGCTGTTCCAGGCAGAGGAAACAGCACATGCAAAGCTGTGAAAATGTAAGACGTTGTGAG
CAGGGACAGCATATAAATAGTGTGGCCTAAGTTTGGATGGGAAGGTGAAAAGATGAGGATGGGAGGTGGC
AGGGCCAAATCAGGAGGCTTTGTGTGCCAGGCTGCAGCTTGGCTTTACCTAAGGGTGGTTAGGACCCTCC
TAATCGAGACTCGAAAAGGGAGCATCAGTTATAAATAAACGCACCAGTGTAATAGGGATGGGTACTATAA
TAAAATTGATGAGAACATAGTATGGGAATGACAGAAAAAGTAACATTTCAGCAATCTGAAAATAATTAGG
TGGGTAGATAATATCTCAGGAAGGGTTGTTTTAAGTCAAAAAAGAAAAACAGTAACCCAGAGCCTGCTCC
TCTAGAAGGAGGTTTAAGTTTCTGTCACTGGATAGTCATACTCTGGGTCCAGACTTCACCTATGGGATCC
TTCAGGAGGTAGTGCTGTTTGCCTTGGGGGATTCCCTTGGGCAGCCGGTGGTGGTCTAGTGGATGGAGCC
TGCCTCCTCCTCGGCCTTCCTTCCCTTTCTTCCCCTACCTCCAGGCAGCGTCCTGCTTAGGGGCAGCTGC
CAGCCAATTAATGAGTCCCCATCTTTCATAGCCTATTAAACTGCAGGGAAGTGTCTCCTGGGCGCTCTTA
TCCTCACGACAGCAGGTCTGACGCAAAGTAGGACAAAAGAGAAACCTCTCCCAGAATGGAAATCTATAGA
TGGCACCAGCTCTCAGCATCTGAAAACACAAAACCAGAACTTTTTAGTCCAACAAAGCTACTTTTCCAAC
ATCCAGCCTGATAGAGGAGACTACTGGTATAAGATAATCTTAGCTGGAAGGTAATCAAAACAAAAACAAA
GCAAAACCTTTCTCTTTTTAGAATATGTGATTATCTTTCTTTCTTTTTTAAGCAGCTTTACTTTTGCAAT
TGAGTTTAGCTTATTTCTAAAGATGATTGCTTTCCCTGATCTCATACAGCCTGATACACAAAGATCCCAA
AATGGACCTGATTCAGGCTCCTCAGTCTAGGCTTAGAATCATTTCCTATGAGTTCTCTAATGAGGAAATA
ATCAAGAGTTGTTTAATTATGGGGTAGTCCTCTGAGAGGCAGGAGGATTAATTTCTTTCAAAGTAAAAAC
ATACCTATTTTCATGCTTTAAGTAAAGACGGATGCTCATGTCACCTGACTCTTTGATGAGGCCACACTAG
ACTGAGAGCTGTATTTGTAGGTTTGATTGATTTTCTGTGCTATCCAGTTCAGCATTAGAATGTCAGATGT
CTACTCTTCCCTTGACAGACACCCTGACCTTGAACTGAAAAAGGTACTTTTCTTTACAGTTTTCTTGAAA
CCCCAACTCTTCTCCAGGGGCTTAGGATCAAATAATCAACTTTCCATTTTGCTTTTTTTTTTTTAAGTAT
TCCATAAGGCCACTGTGGTTCCCCAAAGACTGAGTAGACCTGGCTTTTCTGGTCTCAGATGTACCCCCTA
GCCCATCATGCCATCAGATGCTTTATCTAAGTGGATCTTAGAGACAAGGATCATTGATTATTTTCTTTCT
GTAAAGAGTCAGTCTGCCTCCTTCCGTTATCTATATTCCTTTCCCCACCCCCTCACCCACCCTGTATCAA
AACGCTGCCAACACATTTGCACCCAGCGGTAATGTGGGCTTCTGAGACACTGTAGGATTCAAAATGCACG
ATGCCATGGCTGAATCAATAATTTCCATTCTCCTCTACAAATGAAAATTTAATGTGCAAACCTGGGGACT
TCAGCCCTTTCATTAAAGCAGTTTATTTGCTGTACTAAAAATTAAGTTTGAGTGATAGGTTCCTTTATTA
ACTTTTCTTCCCTTTTCTAAAGGGACACAATGTTTAAGGTAAAAATCATATTAAAGGAAAGAAAAAAGCA
AACCCCTTTTGTATGCTGTTTAATAGTCTCATCATTTATTAATTTTTTTAAATTGCTTTTTTGTCTTTCA
GGCCACTGTTTACCTCTGCTTCAGTTTGCTTTGATAAGTGACATGAGATCTATCTCTTTGCTCTGACTCC
CATGAAGGAATAGTTAACTTGCCTATCTGGAAAAAAACCAAGTATCTTCTTTGGAAGCGTACATTACAGA
GGTCTCAGGACCATCTAGTACATGTTTGTGAACTTTGGTCAAATTTCCCCCTCCTTTTCAAATTTCTGGA
GTGCAAAACACTCTACTTTAAATGTTATGCACAAAGTAGGTTCAGGCAAATCAATAGTTAATTCCAAAGC
TGTGAAGGTTAATGATTAACAGCTGGATTCAGGGAAGGTTCTGGAAAGCTCTAAGGCATCGGTGGAGACT
GTAGTGAGCTGTAAAGAAGACAGCTATTCTGCTGCTGCTGCTAACTGTTTAAACCCAGATTGTTGCCAGA
TCTACCAGTTGTCCAATACACATGAAAATCTAGATTTTTTTCCTGCCAATCTCCCAATTTTTAAAAGCTA
GAAAATAACTCAAAGAATTTTAAGAATTATGTAGGTGGGCCAAACAGAACTTAATAGTTGACCTTTTGAC
AGGCAGTTTGCAAACCACCCCCCAACCCACCCCCACCAAAAAAAAAATGAACTCAAATTTAAATATGAAA
ACATCGTTTTGCCAATTGGTAGTGAATGGCTCATTACAGGTCCACTACAGGCTGAGCATCCCAAATTGGA
AAATCTGAAACCCAAAATGCTCCAAAATTTGAAACTTTTTGAGCACCTACATGACACTCAAAGGAAATGC
TCATTGGTGCATTTTAGATTTCAAGTTTTTGGATTAAGGATGTTGAATCAGTATAATGCAAATATTCCAA
AATCTAAAATTTGTGGTCCCATTTCTGATAAGGGATACTCAACCTGTACTAGGAGGTACCCACAAATGAT
GGTTCCCAGTCAACAAATATCCATTTCCCTTTTATTAGGGGCAGTGTTACATGACTCTGTGTGAATACTG
ACAGCATTCAGAGAGCAATCTGACCTCTGTTCTCCAGAAGCATGCAATCTAGGCATCGGCACAGCACCAA
AGCAGAGAAAGAGCATGATGTGTAATTAAGCTTCCAATGCATAGTGTGGATGGTGACTCCAGGGGAATTG
TTCTTTGGGTTATAACTTCTTTAGTGGGAGAAAGTTCCCACCACACATCTTGGAGATCAGGCTCAGAGAC
ACTAAGTGACTTGTCCAAAGCCATACAACAGGCCAGCAGTGGAGCTCAAGTTAGCTTCAAAAGGGCCTCT
GAAGGATTCTGCCAGAAGAGGAGCTGCTTAATATGTTAGCATGAGCTTGAAATAATAATAATAAAGATTA
ATAGTAATGCTAATTTATAGTGAGTATTCACTCTGTATCCAATACTATTATAACCCTTTTACATGCTTAA
TATCATTTCATCTTTGAAATATCCCTGGAGCTAGGTGCTTTACACACATCAACTCTAATTCTTAAAATAG
CCCTGTCAGGAGGTACTATTACCTCCTTTATACAGGTGAGGAAACTGAGGCCCAAGGAGGCTTAGAGACA
CACCCAGGATGACACAATTGATAAGCAAGACTTGGAGTAAGAAAAAATGTTCTAAAAATAACTCTCTGGC
AGTAGGTCGTAAGTGTTGGAATGTCACACTGCCTGCTTGCTCAGCAACACGTGCATTCTGTGAGGGTGTG
TGGGTGTGTATTTGGCTCTGTGCACACATGGGTTATACTCTCTGGCATGGGAAGGAGAATAAAAAGCAAA
CAAATGAATTGTGTGTCTCCTCCAGGTTCTTTAGTAAACAGACATGGCTCAGGGCTTCTGCTATCAACCT
AGGGACAGACCTGACTTCATTTCTTCTTGGGTCCCTGCTTTCCAGGCTCTGTGCTAGGTCCTCGGATTTA
GGTGAATCAGAAATGACAGTGCCCTAGAGATTCTTCCATCCATGTGAGTCAGAGAGCTATGGAGTATGGA
CCATGGGCTTACATTCACTAGCCTGCCAGAGCAGCCTGGAACCCCACTTAGGAAACTGGGTCATTGTTCA
GTGTTTCAGCCCTGAGCCCAGCCCAGTGGAGATGACTTGCCTCATGTAGGAGTTTGGGATGCTATTTGTT
TAGCTTTGTTTTTGGTTTGTGTGTATGTGTGTGTTTGTTTTGTTTTGTTTTGTTTTTTTAGACAGAGTTT
CACTCTTGTTGCCCAGGCTGGAACGCAATGGTGCGATCTGGGCTCACAGCAACCTCTGCCTCCTGGGTTC
AAGCAATTCTCCTGCCTCAGCCTCTGGGGTAGCTGGGATTACAGGCATGCACTACCACGCCCGGCTAATT
TTGTATTTTTAGTAGAGACAGGGTTTCTCCGTGTTGGTCAGTCTGGTTGCGAACTCCTGACCTCAGGTGA
TCCACCCGCCTCAGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACCGCGCCCGGCTAGCTTTGTTT
TTAAAAGTCGTCTCCAATAGGGATCATTTTAGACTCTGCAAATGGCTGTGGATTCTGAAAAATTATTCCT
GGTACTCCTTGACCCCACACCTGATGCCTGTCCCAGGCCTGACCTTCTGTTGGGCTCCAAAAGAACAGCT
TCTGAATTTACATTGTAATTTTATCCTTTTACTAAGAACTGCTTCAGTGAAGTTGCATTTGGTCCAGCTC
TGTCACATTAATCAGGAACAAAGAAAATTAGTACCTTCAAAAGAGAAATACGTTTACCAAAGTTTTGGAT
TGATGTTCAAATTACATTGAGAACCTTCAGTAAAAAGTGATCCAAAATGGAATGTGAGGGTTTGGTATCA
CACCCACTAAACCTTTCAGAGTGTTGGGACACCTGTTTGCGTTTTGACCTAAATGTCAGGAGTAGGATTA
AACAAGCGTTCACTGCTGGCTCTGCCTCCAGAAGCTCCTGTCTCATGGGGGACACAGACATGCAAAGGAC
CAACTCTAAAGCAGTGGGACAGGGCAGTCATGGGGCTGCAGAGGTTTCTGTTTGATATTGGGGTTGGGGA
GATAGGGAGCTGTGCAAGGTTTGAGTGAGCAAAAGATCTGATCAAAGTAAAGTTCCAAGAAAGTTCATCT
GTCAACGACGTGCCACATAGAATGTTTGACAGATGAAACCAGAGCTTGCAGGCTGCTGTGGTAGGTTTTT
GTCAGCCTTAGACATTGGTTTTCATCAGCTCTATTAGGAGCCTTATCCACTCATTTTTAAAGCAAAACAT
GCTTCTTTGTAAATAATTTGGTATGTACAGAATCATATCGTGAAGGCAATATCAGCCATTCCTAAGCCAA
CAGTGTTAACATTTTTATATATTTATATATTTCCATCCTTTTTTTTTTTTAAATTAAGACAGGGTCTCGC
TTGGGAGTGCAGTGGTGCAATTCCAGCTCACCATAACCTCCACCTCCCGGGATCAAGCAATTCTCCTGCC
TCAGCCTCCCGAGTAGCTGGGATTACAGGCACCTGCCACCACGCCCGGCTGATTTTTGTATTTTTAGTAG
AGACAGGGTTTCATCATGTTGGCCAGGCTGGTCTCAAACTCCTGACCTCAAGTGATCTGCCCACCTTGGC
CTCCCAAAGTGCTGGGATTACGGGTGTGAGCCACTGCGCCCGGCCGATTTCCATCCTTTTTTTATTGTAT
TATATGTGCACAAATGACTTAGTGACTTACCTTTTTCTAATAATTATATTAAGCTATTACCCAAAGGATT
AAAATATGATTTTAAATGAAATATTTCCAGAGGACAGGTATTGTGAGTGATTGCAGCACTGGATCTGGGA
TGAAGGGGTAAAAGAGCTGCTCCTGCCACTCTGAGCAAATCTATGAGAGTTAGCACTCAGGCAGGCAGCC
GGTGAGAGAATAAGAAAGACACTTAGCCATGAGGCAGTGGCCCAATTCTGGAGGGAGCAGGAGTAGAGAA
GGGGAAGGTGTGTGAGGGAAGGCTTTTCAGAAGGAAACACCTTCCTTCTCTGGGAAGGAGAGTGAGCTCC
TTCATTTCCACCTCTTCCTGTTGTGATGCTGCTTAACCACTTCTCCATTTTCGCTTTATTCTTCTAATAC
CACTAACAGTGCCTCCGGGGGTCTTTCCACACTTGAGCTTTGCAGGTTCCAGTTTGCCCCTCCCACTTCT
TTCTCTTGCCAGGGGTCGTCAGGGAGCTGCGCCTCCCCCTCTCCTCCCTGCATCCACCTGCCTTGCTAAG
GGCCTCCATTCCGCTGAGGCATCTTTTCTTTGCATTCGGCATAAGCAATTATTTCTCCTATCACTGCTCT
TAATGCTTCCTGGAGAGTTAGCAGATCATTTTTTGCTGATGGATATCACCCCACACAGAAATGATGGACT
GCCTCCCTCAGTCTTGTTAATAGTAAAAAGGCATTTTCTCTCCTCCTCCATTACCGCTAGTCACAACCTG
GGCGAGAATGCTTCTCTGCCAAGGTCAGCAGGGGCGGCTGGATCACTGAATCCCCAGGGAGCCAAGAGAG
AGCACGTGGCAATGCCAGCAGAAACCAGAGACACGTTTACCCCAGTTGTGCTAGCAGCCCTCTCTTGTGG
GAGATTTTATTTGGCTGCTCTGCTTCCCAGTGCCCTGTTCACTTCCTTTGAGTGAATAATTTCAAATACA
AGGATAGGAGTTGGAGAAATGGAAATACAATTCCCCTCTTCTCTCTGCTCAGTGAAGGTGATACGTTCCC
AGTATCTTGAAGTTCATTCATAGTGTCCTGTGTCCACATCTAAAAAGGAAATTAGACCGGTATGGGTTGG
GAAGGCACAGGTTTTCAGAAGTACATGGAATGGGGTCTGGGGGCTTTAGCTGTCTTCAAGTGTAAAAGAA
GCCAACAATGTGATGTGAGCTGCTTCAAAAAAAAAAAAAAAATCAGCACAACTTTAGTTGTGTTGGGAGA
ATTATGGACTCCATATCACAGAAAATAGTGGTCCTTTCTTGTCCACTCTGGTCAGCCCATCCTAGTGTCT
TATGTCCCATTCTCGGCTTCATATTTTAAAAGATTGTCTAAAGGTGAATGACAAAGATGGGAAAGAAGTC
TCTGCACCCACCCACAGATTCACCTCACAATGGTTGCTTTTCTATTCTCTAGGAAAGAAAATTCTGCAGT
GACCCTGAGGCATTAGTTTGATCCTATATTTCAAGAATCTGGGAAGAGAACCTGTGTAGCTATCAGAGTA
GAATGTTTGCCTTGGGTGGTAATGAGGCTCCGATCATCGGAAGCATTCAGATGAACTCATAAGGGATGAT
GTAGACAGGATTTCAGTCCCACAGTGGAGTCTGACTAAATGATCCTAAAGGTCCCTTCTAGCTCTAAGAT
GCTATAATTTTGTGTTATTTCTGATTGTAGAGCTGCTCTGTCCAGCATAGTAGCCACTAGCAATATATGG
CTATTTATATTTGAATTTAAATTAATTAAAATTTAATAAAATTCAAAGTTCAGTTTCTTAGTCACACTAG
GCATGTTTGAAGTGCTCAGTAGCCACTTGTAGCTAATGGCTACCTATATTAGACAGCACAGATAGAGAAC
ATTTTCCTGATCCCAGAAAATTCTGTGGGACAGTGCTGGCCTAAAACATCAGTGGCCCTGCGGATTAAAG
ACTCATTTCTCCATGGTGCTCCTGCAGCCTCTGGGCAGGATGGCTGGTCTGTCAGTGATCATAGAGCACC
ACACTCCTCTTCCTTCTCCCCTTTTGTCCATTCAAAAGAGCTCTGAGTTCAGATGGAAAGTCAAGTTCCA
GCTCTGTCAAAAACTGCTAAGGATGACCTTGGGCAACTTACTTTACTTCTTTGGACTGGTTTCCTCATCT
GCAAAATGATTTTTTCCAGTTCCAACAGTATAACTAACAAATTATAGTGTGATCTTTCTGGCTTGGTAAC
CTTTCAGGGAAAGTAACAGTTTGTGCCAAGCACACGGCTTTTATTTCACTGTCTGGATTAGTGTGCCATA
GTGGAAACATCCCAGAACATGGAATTATATCCCAGTTTGTCTCTTAGTTCAGCTGTGTGACCTTGGATAA
GTACTTGATCTCACTGAGCCAGAGTTTGTCATCTGGAAAATGGAACTAATGATATCTTACTTGTAGGGAA
TCGTAGCTTACAGTGGATGCTCAAGAAATGCTCCCCAGGATGAAGATGATGGTGAATGGTGCTATCCCTA
AAGTGAACATTACATGAGGAGAGGGGGGGACTTTTTTCCATCTACATGTTTCAGTGATGAGTAAGGGAGT
AAAGAATGAGTCTGAATTTTACTAAGATTCGGGCAACATATATAAAAAGCTTTGTATAGGGGAAAGTATT
ATGAAGCTTCCAGCTGGCCACAGTAATCGTATCAGTCTTTTATAAAGCAGGAGCCAGGAGTTGCAGTCTA
GTGAAGAGACTGAATCTGGGGCCCTGAGCCCAAGACCAGATATTCCACTAACCAGGCCATGAGACCTTTA
CACAGCTCTCCCTTCTGAAGGCCACTAGATAGACAGAGAGAACTTAGTACGTACTAAGTATGCCTCTTTG
ATAATTTGATAGATATTTTAAAAGAAGTTGCAAGACACATGAATCTATCGTCACATCTTTTCTATTCTTT
AAAAGAAATACTTGTCTGGCCTACTAGGTGCCAGACACCCTTATGATATTCGTAGATACCCTTTAACTGC
ATGATTCTTTCTGGCTTCTTCATCACATCAGAGTCAGCTCTTAGAAAAGAAGCTAAAATCCGCGGCATAA
AGTATATGATACATTTCATTTCACTTGAGAGAGCATTTTTTTTTGAGCTCTTGCCCTGATAAAGCTTTGA
GACTAGGTGCCACAGGGGTCTATGGAGATCACCAGAATGCTCAGACTCATAGGGCAGGTAAGGTGTTATC
ACACTTGTAGTGCCTGGGATCTGGGATCAGGATGCCTGTAGTGGGAGGTAGGGTAAGTGTAACTATTGCC
ACTGAAATATACTGCTGTGTATCTTCTGTGGAGTCAAAGGAGAGGAGAGTCATTTGTGCCTGGGACTCGT
GGAGGAGGTGGCATTCAGTATGGGCTTAGAAAGATGGGCAGGAGTTTATTCTGCCATGATGGTGAACAAA
CAGCAAAACAAAGACATAGAAATAGAAATTTTCTGGACATATTCAGAAAACTGTGACATGTTTTTGTCTG
AACTGGAGCATAGGGTGCATGAAGGGGTTGGCAGGAGATGAGAGGTTGGGCCAGATTCCAGAGGGCTTTG
AATGCCCAGGTAAGGGGTTTAGACTCCCATCACAAAATGGCACAATCGGAACTCATTAGAACCATTTCCA
TGAAGTTTCACCTCTGATAAAATAGCACGTATCAGGTGGCAGGTAGGGGAAGTGTAAAGAGTGGTGCTAC
ATAAGCAGATGCCTGTCCTGCCTGTGAACAGGCCTACAGCCACAGGCACAGAGGTAAACTGATCCTCACA
ATCAAAGCTGCGGTTTCCAGGAACCAGTTGGCTTCTTTCTTCTGTCCCTGCTCCTAGAGGTGGGATTGTA
GGTCCTTGAGAGGATTTGTTCCTAGAAGGCCCTGGCAGCATCAGAATCTGTTCCCTGATTCCATTCTCCT
CATCTCCCCAGGGACTTGTCTGCTCTGGGGAGTTTGTATGCACTCAGAGAAAAGGGTGTTACAACAGATT
GGGGAAAATCTGCAGCCTGATCTTCTGAAATGATTGGTTTGTGTGTGTGTGTCTCCTCTGCTAGACTAAT
AGTCCTACATGTCAGGGACTGTTGTATTCATCTCTACACCCTTGGTGTCTAGCATAAGGCCTGATTATAC
AGCAAGTGTATCAAAGCCATTGTTTATTGAGCATTTACTGTGTGCCAGGCATTGTGCCTAGAAGTCTTAA
ATGCATTTTCTTGTTTAACCCTCAAACAGCTCTGTAACAGAGCTTCTAAACTATGTATTCAAGTGATGCA
GCTCAGAAAGGTTAAGTGACTCACCCCATAGTCACACAGCTAATAACGGTCAGGTTTCAAGTCCACATCT
CTCCAACCCCAAAGCACTTGCTCTTAATTGCTGCCTCCTTTTCATTCTAGAGCAGGTGCTCACTTTCAGT
TAAAGTAACATAAACAAGAACTTCTTTGGAGTGATTTGTCTCAAAATATAGTTACCCAATACTCTAACTA
GCACCTATCAATGAGACCCATAGGATAAGGGGTGGTAAGGACAGAAAAGATGGCCCTGGGGTGTGAAGCT
AGAATAATAATAGAAGAATGGAAGCTACAGGGGAGACAGATGTGAACTCAGTAGAAGGAAAAACTTTTCA
ACAATTAATGAGGCTGGGCATGGTGGCTCTCATCTGTAATCCCAGCACTTTGAGAGGCTGAGACGAGCAG
ATCATCTGAGGTCAGGAGTTCGAGACCAACCTGGCCAACATAGTGAAATCCCTTCTCTACTAAAAATATA
AAATTAGCTGGGCATGGTGGCGCATGCCTGTAATCACAGCTACTTGGGAGGCTGAGGCAAGAGAATTGCT
TGAACTCAGGAGGCAGAGGTTGCAGTGAGCCAAGATGGTGCCACTGCACTCCAGCCTGGGCAACAGAGTA
AGACTTGGTCTCAAAAAAAAAAATTAATCATGGCCAGCAATAGTGTAGGATGCCTCATGAGGTGGTGAGC
TTCCTGTCCTTGGAAATGTATACATTGAATGGTCGGCTGTCTTGGATCATGCCATGAACTTTTGGGGCCA
CTTCCAGCACCAAATTTCTGTGAAGCAGATTTCAGGAATATAACTTTCTGCTGAGTTCCCCATTGCCACT
GTATGTCACCTTTATGTGACACTTACTATGTCTCCACTTACTATGAACCACAGTTATAGAAATTTGCAGT
TTTGTGAACAGAATGCCTGGCTCATGAAAAAAATCCAGTCAATGATAGAGGCCACGTCATTACTCTAATC
CACAGGGGCCCAACAAATGGCGTTGCTGTTTTCCACATCCAAGTTCTAAACCAATTGAGAAGTAAGACAA
AAGAGAAAAGTGTATGGAATCCTAAGGTCATCTTTATTGCCAATTAAGGCCTGGATGGGTTGCATGGACA
CAGTGGGCTCCATAACACTGAACTTTACACTTTGACAGACTGACACACCCTGTCACAAGTGCTCTAGACC
CCACAGGCCGAGAGCAGAGCCTGCCCCCATAAGACTGAGAGCCTGGAACAGAATGTGTGCTTCCAGCTGG
CGTCTGGCTCCCAGAAGGGAAGAAGCAGGCAGCATTTGAGCCTCACATGCCCATTTCTTTTATTGAAGCC
TCCATTCAGAGGAGTCACTTCTTTTCCCTGGGGAAGAGTGGATGAAGGGATAGCAATAGGCCTGGTCTGT
TGCTGCAGGGGGTTCTCTCCACATGGAAGGAAACACTGGGAGTGGGAAATGAGTATCTCCCTGTTGGAAG
CAGCCCTCTGTATTGCATGCTTCATTTGTTTACTTTCCTTTCCAGACTGGGATTCGTGAAGCAGAGACAT
TCCCAACACCCATCCCAGGGCCTGGCACATAGTAGATGTTTAGGAAGGGGAGGAATGAATGAACTCCCAT
CTTCTAATGCCAGTGTTTTTCTAAAGGAGCAATTTTCTGGGGCTAAAAAGGATGCCTTTTCCCTCTCATT
TTATCCTCCTCATTGCACCCAACATGCCTTTATCGTGTTTTCCATGTCCTCTCCCTTTTCTGTATTATGG
AGGACAGACAAGGAGTGAGGTATTGCTGGATGATTCAGGGAACATTCTTCCTCAGGTCATGCTGTTCTTC
CCACCCTGCCCAGGCCAAGCCCTGTGTATGAACAGGTAAAGGGAGTTGTGGGTGCTGCATGGGAAGAGGC
AGCCCTCAGCCCTCGTCCTGATGCCCCATCTGTGATGAATGACAACGCCTGCTTTACCCACCTTGGTGAG
ACTTGCTGAGAGCAGAATTGGGAAGTCACTTTGGAAAGTGGAAAGTACTTTGTCGGCATAAAGCAGTGGG
ATCTGTGGAAATGTGTTAGAGGACATTCATGTCAGTAAAGTGGTAAAAGATGGTCCAGACCCCACCAGGG
TGGCAGAGGAGGGCAGTGCCTCTACAGGCATTCCCTGGTAGTGTTCCACATGTTTTTTTTGTTTGTTTTT
TGGGGGTTTTTTTCCGGTGAAATTGGAGGGTATGTCCCAATGGGAGCTAGATTCCCAGGCTGGCCCACAA
AAGCCTGTATGACTCATCACATAATAATATGTGTAAGTATCTACTAAGTTCTAGGTATGTGCTAGACAAA
TATATCAACTCAGTTCTTACAATAACCCATCAAAGGATAATTGACCCCCTTTTTACGAGCAAAGATGTTG
AGACTTATCAAGATCAAATTACTTGCCTAAGGTCATGCAGCTAGTGAGTACTGGAGCTGACCCACAGTCA
GGGATCATAAGCATGATGCTATAGCATCCTTCTGGTGGAGGATGGGAAGACTGTGAGCACCAGGGATGGG
GAGAGCTGAGGAGCTTGGAGGGACTTCAGATCTTCCATAGAGATCATCTGTAAAGTCAGCTGCTTACAGT
CACCTGGCTTTGAGCCACCCCTACCCAGAGAGAGGAGTGGCTTCTTCACTCCCAGCCCTTTCTGAGTTCC
AGAAGGAGGTCAGTGCTGGCCTAGAGATGCCAGTCTTGTCTTCAGAGATTCTGGATGAATGAAGCAAACA
GGATCCTGACTGAGGCAAGGGGGGTTCTCCAGGGCGCTGGCTCCAGTGTTGGAAGCCCTGTGACTCCAGG
CCACTGGCCCAGGGGCATTAATATGCCATCAATGCTGACCCTGAAAATTGGCAATTTTTTGGAAATCTTT
CAGCCTAACCAAGGGCCTGACCACTGTAGTCATTCAGTTAGAATTTAATACATGTATATGGAAAGTTGAA
AATTTTAGGTACTAGGATGAACATTTGGATATTCAATGCAGGAAGATCTTTTTTCTGTCATTTTTGTTTA
TCCATACGCCACAGGTTTCATGGACAGGAAACTGAGAGAACAATAGACTTAAGGTTCCATATAGGTGAGA
AATACTAAACAGGAATTAGACTTGGTAGAGAATGATTGATGTGCTGTTCACCTTTGGGATTTGTTGCTGC
CTTTGGGGATTTAGGGTCTGTCTCTGGAGATGTGTTGCAGTAATTCTCCCTAGCTGAGATTCTACCTATG
TTGGAATCAACTTTTGGGGAAATGGTTTTTGTTGTGTCACCAACTTTCAAGTGCCAGCTCCTCTTCCCTG
GCAGGGTTCACCCTGTTCCCTCTGTACCCTAGCTCTGGCTGTGCAGAACTAATGGGAGTTAAGGTCATGA
CTATCCATTATGCATTTATTGGGTGCCAGGTACTGTGCTAAGCCCTTGATCTTCATCACCTCATTTGTCC
TCGTGACAGAGGAAGGCTATTATCAGGCCACCATTACCTGACTCCACCACCACCTTTCTCACCACCAGTC
TCAGCTCAGCTGTGTCTCCTTCCCGGCCCTTTTAACCTTTGATTAATCTCTCCCTCCTCTGTGTTTTAGT
CACACTCATATGTATCCCTGGCATAACACACACATCTTGTGGCACTGTGATAATTGGTCTGTATGTTTAC
TCATCCATTCTTTTGTTCAACACATTTTATTGAGTGCCTCTTATGTGTTGTCTGTTGCCCTCTTTGGACT
TGGAGTTCCTTTACAGCAAGAGACTATGCCTTGTTCTTGCTGTGTTGCCAACACATACCACTGTACCTGG
CTCATAGTAGATCCTCAGGAAATATTTGCTAAGAGAAGGCCTCTATGTGAGGTCTAGTCCTAGAACAATC
TTCTTTCAGTCCTTCCAGCCCCAGGCATTGGAAAATGGGAAATATGTCCCTTAGCTCTTAGCTTGGTGGA
GAAACACAGCTGGGATTCTGGGTGCCTGACTCTCAGTGGTCCACCTTACTGGAGTTACAGTTAACTCCAA
AGAGCCAATAATATCAACATCATTTCTCATGAGCTGTGGGTGTTTATTCATTTTTTCAGTAGGTGTTGAA
CACTTTATAGGTATCAGGCTATGTGCTGGGAGCTAGAGTCACAGAGTTGAATAGGACACACACACACACA
AGACCTACAACCTAAAGAGATCATCAGCCTAGATGGAGAGGTGGTCAGTTAAGGTTGAAACGGGTTAAGT
ACCATGGTTCATTGAGAACACTGCTGGGGAGATTTTTAGGAGAAGGTGAGATTAGAGAAAGCTGCCTAGA
GAAGATGTCATTTGATCTGAGCCCTGAAGAGGAGTAGGATTTGGACTTGAGGAAGTAGGTATAAAAAAAA
TGTCTGTATGAGCAAAGGTATAAAGGTGGTAGGTTGTGTTTTGAGGGAGCACAAATGTCATTCGGATAAT
TAATTTGTCAGTAATTGGCAAGGTGAAACAAGGGTGACCCTCATTGCCATGGGCATATCACTATGATGTT
TTTATTTCCTTCTTCCACTTCTTCCTCTTACTCAAAAAATAGTTCTGCTATTGACACACTTTGTCCCTTA
AAGAACAGGGGTGGGAGAACCTTCTGTGGAGTGAAGCCCTGTCCAGACAGTCACATGGGGTTCTTAGTCC
TTCAGCCCACACTGCAAATGCACACACTGGGACCCCCTATATAAAGGCCCCTCTACATCTCAGCCATGTG
CTGAGAAGGAGCCCACAGAGGCCTCCCAGCCCACCCGTGAGTTTCTAGAAGATGGAGATACTGAAGGCAG
CTGCCTCACTCCATCAGCAGGAGGAGGCCAGGGAGGCAGATTAGTCACTCACATCATTTTATCTGTTGAG
TCAACATCTATTTTTAGGCATGGAACCCATAAAGGGACCTGGCATGTCTGTCATGGAAAGGGGGAGAGTG
CCATGGATGAGGGTTCTGCTCATCCTTCATCTTCTTTGCTAGACCCATTCTCTCCCCTGAAGGTCACAGA
AGCAGGGTCCACATTACTGCTGGAGGTTTAGGTCTTAATGTCAAAGGTCTGGTTTAATGTGTTCAATTCC
TTTTGCACACATGCTTTTGTGTGCACGCACACACACACACACACACACACACACACACACACACACACAC
ACTCTCACCCCTACAGTCTTAATAGGTCTTATGAATCAGTTGTATGGATTAAATAGAACTTCCAACTGAA
AAACGCTAAGGCATATAGGTCTCTTCCTGTCCAACGTTGTCAGATGTGCTCTGAAATGACTGTTTTCATC
ATCTATTCTGAGCCATAACCACCCCAGAAATAGCTTTAGCAGGAAAGTGCTTTTGTTAGACTAGCTGTAA
ATTATATTTCAAATGTCTGATGTTGTTTTCTTAAAAAATAAATAAATAAGTAAATGAAAGTCTAAAATTA
ATGACTGCTGGGGTTTGCTTTGCTTATGTGTACTGCTACAGATTTGGCTTCTTGCAGATGGAATTTCAGA
TCTGTTTACACTTCTGTGTTAGCTTTTGGGGGGAAGAAAAGCAGTTGAGAGATCTGGGAGGACAAATTTA
CAAAGTCGAACTTATTATAACCATTGGTGAGGCTCTCTTCTCTCTCTCTACTGCCCTTTCCCTCCCTCCT
TTCCATCTTGCCCCCATTTTATTTGTTGTGGTTTTTATCTGCCCTGCTTCAAAGTTAGAGGCGACTGGTC
CTTGCAGATGTGACGACAAGGTCACATATCCAGTTTCGCAAGCAGATGTTCATTCAGCCCTATTTCACCA
GCACTTTGTCATTTGGTGAGAGCAGACCTCATGGGAACAGACTGGAGCAACACAAAGGATGGAACATAAA
AAAATCTTGCAGAGAACCTGATTGCTTTTATGTATTCAGGAAGAAGGGGATGGGGGTAGGGAGGGTGGCA
AGGAGAGAAATGTGCAGAGCAGAATTTCATGAGGTTTTTTTTTTTTTTCTGGTTTATTCAAAGATTATTA
TGTGTTGGATACAGTAAATCATCTATACACCCACTTCCAGGAGGTAAATCTTCAGAACTCCATGTGTGGG
TAGCTCTGCATTTAACAGCTGCCATACAGTAGCTATTTTGTTCTGCACTTAGAGACCCTTATCTGTGCAT
TTGTTTTAAGTTATTGTCAACTCTCCTGTTGTTCCTCTATTGTTGTTCTCCTGGTTCTCATTACTATTAC
AAGGGTAGCTAAAAATCTGAACTACTGAGTGATTTAAACTGACACCATGAGTTGTAACGGTAGATGAGGG
GCTGTCATCTTGGTTGTGGACTCAGCATCTACTCTGAGGGTGATTGCCTATAATGGAATTAGCTCCTCTT
GCCTTTTCCTAGGTCTCATATGCCCGTCCGAGCTCTGCCTCAATCAGGGATGCTAACCTCTATGTTAGCG
GCCTTCCCAAAACCATGACCCAGAAGGAACTGGAGCAACTTTTCTCGCAATACGGCCGTATCATCACCTC
ACGAATCCTGGTTGATCAAGTCACAGGTTAAGTGTTTCTTTGTAATTTCTTTCCTTGTATATCAATGTCA
TCAGCCCTGTTACTCATAAGAGCAGAAGGCTGATGGCTGCTTAAAGCAGATGATATGGATCATGAATAGA
CAGATTTTTGACTTGGAAGAAAGACTTCTTATCGGTCAACTGCCCAAATTTAAAATGGGCCATCTTGGGA
GGTAGGAGTTCTCCATCATGGGACTTGTTTTAGCAGCAGCTAAACTACTTGCCAGGGTTGTAAAAAGGAT
TCAGGCATCAGGCTGAGAGTGGAACTGTATGACCTTCAAAGTCTGATTCAGCCCTCAACCAAATAACATT
ACTTTTGTATGTGAAAAGAACCTGTATGCATAGCTGTAACTCCAATTCATAGCATTATAGAGTTAGAAGG
AATTGTCCCATTTCACACTTGAGGAAACAGGTTGAAAGTGGGGGATCTGACTCCCCAAAGCTAGTTAGTA
GCAGTACAAGGATCTGAACCGAGGATCTGGTACTGGTGTTCTTTGTCCATAATAAAGAAAGGCAGCCACC
ACCTCTCAGTAAGAAATGTCAGGTACTCTGGGTTGCACTTTTAATGACAAGGTGTTTTCGCCTACCTCCA
ATTTGATTCCAATTTAGAACTCACCCCCTGAGAATAGTTTAGCACGTTTATCATGTGATTCATGAGACAA
ACCTTCACAGAAGTCTGCTCTGCCCTAGACATTGTGCAGAGGGACCCTGGAGACCAAGAAAGAAGCAGGC
ACTGCCCCACCCTTACAGGACTCCAGTGTGGAGTCCAAATACTTGCTAGAAGCTGTCAAGTGCCCCTGAG
AGCTCAGGAGAAGGTGTGCCATGCCTGGTGGGAATTGCTAGGAGGGCCCCATTGAGGAGGCAATGTTTGA
ATAGGAGTTTGGAGGATGTTTCAGAGGTATCCAGCAAAAAGGAGGGACAGAGCAGTGTAAGTGGAGAGGA
GAGCATATCCCAAGGCATGGAATCGAGGAAGAACAGTCTATTCGAGGAGGATCAGGCAGTTCAGGGTGGC
TGGTGTGAGCCTCAATAGGGAATTTGGGGCCAGATTGCCAGAGGCATTGAATGCTGTGCCAAGAAGTCTG
GACTTTATCTGGGTGCAGAATGGAGCCATGGAAGGGTATTTTGTAGGTTTTGTTTGTTTGTTATTCATTT
TAGAATGGGAGTCAGTGAAGAATAGGTACTATGCACAAGGTACAAAATTCAAAAAGTACAAAAGAGATAC
AGAAGATGTTTTTAAAGCATATCATGTGGTCAGAGTTCACTTTTCAAATAGATTGCACACTAGCTACATG
TGGAGGACACATGAGAAGACTAGAAACTGGACAGTGAGTGATCAGTTATAGTAACTTTTGGGAGGTGATG
ATGGGGCAGAGCAGTGATAGAGGACTAGAGGGGCCAGATGCAAGAGAGCCCTGTGTTCTGTGGCTGGGAG
GCATCAGTCCAGAGCCATGATAGCAGGAATGCAGGTAAACGTGTTTTGATTGGTGAGAGAGATCAGGGAG
CTGGGCTCAGCCCTGGCACCACAGGTGGGCTTACTCCTCACACAATATCCACAGGACCCATCTCTTCCCA
AAGATGTTTACCAGTTTGGTGTGTTCACTCTTTACAAAGGCTCTTTCTCTTTCCCCAGGAGTGTCCAGAG
GGGTGGGATTCATCCGCTTTGATAAGAGGATTGAGGCAGAAGAAGCCATCAAAGGGCTGAATGGCCAGAA
GCCCAGCGGTGCTACGGAACCGATTACTGTGAAGTTTGCCAACAACCCCAGCCAGAAGTCCAGCCAGGCC
CTGCTCTCCCAGCTCTACCAGTCCCCCAACCGGCGCTACCCAGGTCCACTTCACCACCAGGCTCAGAGGT
TCAGGTAGGCATGCCCAAAGAGGAAGAAGCCCTGCTACAGGGGTTCATAGCTGGGCAAGAGCCAGGGAAG
CCCATGGTCCTGACAAATGGGGCAAGGGTAAAAGCTTCCACCCCCAGGAATCACTGTGCAAAACTCCCCC
CGAGCCTCAGTTTCCATTCCTGTAAAATGAGACAGTTGGAGCAGATGCCCTTCTAAGCCCTCTTCCAATT
TACTACTGTGACTGTATAAACTTTAGATTCTTTGGTAGAAACAAAATGTCTGTATTTAACCAAACATGAA
GGTTCAGTTTCAACAAGAGTTAATCACAGATCAGTGACCACATTCAGCAGATTAGACTTAAGGCTGGACA
GTGGCTTTTAATAAATTCAAAAAATAGACCATAAGGCAGATCCTTGCCAGAAGGAGTTGTTTTTCCTATC
TTCTTTTCCCTCGGCAGGTAACTCTGTTGAGTTCAGGGGAGGGGGAAGTGCCTTTGGTGTTAACCTTATT
ATGTTAAGTCAGTAGATTCTGGGAAGATAGGGAGGAAGATCCTGTCCAAGCCTGATTAGTGTTTCCTTCA
AGTACCCAACCCCCAGGAAGCTCCTGGGGCAGGGGGGCATTGCCCTTCTCCTGGGACTTTTCTAAAAGAC
AGGTTTCTCTCCATGAAGGCAGTATGACCTTGACTGGTCTCTATTATACAAGAGATAAAAATATGTTTGA
CTTACCCATGATAAATTCTAAACAATTACTTTATTCCACACCACAGCCCAGCTTCCCTTTGATGAAAATG
TTTTTCTCTTTGAGAAACTTCACATGGGAAATAGTAGGTCCTTCTATCTAGGATAGTATGCTCCATCTGG
CTACATGAGGAGAAAAATCATCCTCTTTCGTGTCCTCCTATGCCCTGTGAATTTGAAATGGTTAATGATT
TCATGAAGAGTCCAAGTCATCTAATTTTTATTTTGCTTGAGAGCACATGCAGTATTTATGTAAAAAGCCT
CTCCAGCAGACTTCTAATGGTGGAAACTATCGTTACTACTGCCCTATGGTGTGAATAGCTTGTCCCCAAG
TAAGGTAGTGAATGTGAGGAAGATTATAGCGTAATGGCAGTTTGCTGGGAGGTGCTATCAGGCAGTAAAC
AGTAAGCCACTTTTTAAAAATCTTAACCTGCAAACTCCCCCTGCCTCCCAAAAATGTGTGTAGTAAGATG
ATTTAGTTAATGTAGCAAGGCTAACAGAAAAGATCTGTTCTGATACATATTGTGTGCCTGTGTATTGTTA
ATCTGGAACAGAGACCTTTATTTACAAGTTTAATTATAGTAAAAAGGTGAACAATTTAAGAAGCCCCCGC
TTTGAACAATTTCACTACAATATAAAACAAAATCCACACAAATGTTCTGAGAGGTGGGGGGAATGGTATT
AATTCAGACCTTGAAAGAAAGGGAGACTCATTAGACACTTGCTTTAAACTCTAGCAATGACCTGAACATG
AATTACTTGCAGTTAGAGACAGAAAAGGGGGAAACTACCGGTGGATAGACTCCTAAGCAGTGGGGAAAGT
TGTTGAGCTTTTCTTCTTTGAAAATGGAGCATTCTTATTAATAGTTCCATTGAGCGATCTTGCCATCTGT
GAGGCATTAACCCAGAGACCCTCCTTCTCTTTGCAGGCTGGACAATTTGCTTAATATGGCCTATGGCGTA
AAGAGGTAATTAAAACTCCACAGATTGCCAGATGTCCATGTTGGCACAGACTGGGGCTAGAATTTTTTTT
TTTTAATTCACTAACTTTACTTTAAAAGAAAAAAATTCTTCCTTTTTCTTCCACCAGCATGTCAAATTCT
TAATTTTAATTTCGGACCTCAGTTGATTTTGTTTCTTTTAGGGCACACAAAATGTATTTGTGTGTTTCAC
TTTTTCTTTTATTTGCAGGTGGGCTTCTCCTATGGTTCAGGTGCCACAGCTACCAAGCCCTTAATAATCT
GGTCCTTTGAATGGCTCCCCTAAGGGGAAAGGCTCCGACTCTTTGCTGGCTGGTTTTGCAAACTTGCAGA
GCAAACTGTTTTGCATTAGCAATGCCAAGATTCAGTTAAGAGGGCAGATTCCAGCAAATCAGAATTAGAA
CATTTTGCTAATTGTGGTTGACAATCTTATGATTTTTCAGTAGAAAAATTAGATTTTGGACTACCAGCTC
TGGCCAAAGGATAAACAAACACGTGGATGACTTTCTAACTCCTGCCCCCACTTCAGTGTGCATTTCAGAG
CACATCCTGAGAATGAAGTGTATCTGTGTGCACCTCAACCAGGGGTTTCTTTTGTTACAGGTTTTAACAG
TTCTTATAAATCCTCCCTTGGTTATATGTTATGTGTGTTTTAAACTTGCTGTTCCTGTCACTGAAAGGCT
TTTTGTGGGGTTGGGGGCCCAGAGTCAAGGCTTTTGGGGCTCTCTGAATGCAGATTCAAAGTTTTCCAGA
CCCAGTATGAAATCTGAATCTTGGAAAGTTGGGTGTGTGATGTCACTGTGTCCATGAGATTCCCATATGT
GCTTCTGATAAGCTCCACTGCACTGCTAGGGACATAGTGTCTTCATCATCTTGCTCAGTAGAGCTGCACA
CTTTAATTCCCCTTCCTACAGTCAAGGGAAAGAGATGTAGTCTTTAATAGTCCACATCACACCCCCAGTT
CTTTCACTGGCCATCCATGGTAAGTACCCTGACTCTGGGAACTGGTGCATGGTAGAGGAAGTAACCTGAC
TGCAGACTTCACTATCAGAGGACCGGCCTTTCAAATCTCAATCCCAGCATCAATGAGGATAACTATGAAT
TATCTCCACATTTCCAGCACACTGTTTGCCTGTTCCCAGGGATTTTACATCTTTCCTAGCTCTATCTCAT
TCCTTTGCTCCTCTCTGATGTTAGTGAGGTAGTGCTAAATGTTGTGAAAAGAGAAATGCTTATAAATAGA
TAAGATAGGGGAAGACACAGCTGTAGTAGGCCTGCCACCACCTCCTCCACTGCCCCACCCAGAGTAAACA
TCACTAGCTGATAATAGCATTCTCTTTTCCTATTGAACCCAGATTTGGATTTAGAACGCTTCCTACCAAA
ATGCTGCAATTAACTGTCACCAACTAGGATAGAGGCTGTACTTGCAATCTCTTTGCTGGCCCTGACCTTT
GACTTATAATAAATACTTAGCTGTTTTCTACCTATAAACAGAAAGAGGTCAGTTCACCAGGGTCAACTCA
CTTGGTTGGAGGATAGAATATTAAAAAGACAATCTTCAGAAATGATACAAGTTACAAATAGACATGGATT
TGCACGTCTAAGGATCTACACCATGATATTTTTTGGCTTTTTCTTGTTAATTGTTTTTAAACAAGAGGGA
AGATTGACTTAGTGAATAATAGCAAAAATATTGTCTATTGAGTTGTTATATTTAGCATATATTCAGTAGC
CATTTGATTATCCAAATTCTAGTTAGATACAGAACTATTCTTTAATAGGACTTTCAAATCTCCAAGAATA
TTTGCTTATTTTTAAAAACAGTTGTAGCTCACACTTTACACCATGCTCTTCCCTAGTTTTTGCTTTCTCT
CCTTTTCCTATCTCCCCCAGTAAAACCCTGGCCAAATGAAAAGCAAGAAACTATTCAGTGTATAGCATCA
AAAATCCGTATATAAGCTCATGCCTGTAATCCCACCATTTTGGGAGGCCAAGGTGGGTGGATCACCTGAG
GTCAGAAGTTCAAGACCAGCCTGGCCAACATGGCAAAACCCCGTCTCTACTAAAAATACAAAAAAATTAG
TCAGGCATGGTGGTGCGTGCCTGTAGTCTCAGCTACTCAGGAGGCTGAGGCAGGAGAATCACTTGAACCC
GGGAGGCAGAGGTTACAATGAGCCAAGATAACGCCACTGCACTCCAGCCTGGGTGACAGAGTGAGACTCC
ATCTCAAAAAAAAAAGAAAGAAAGAAAGAAAGAAAAAAAAAGAAAAAAGTCCCTATGTAAGTTTGATATG
AAACAAAACATTAACAAATATTGTTCTGCTATAGGCACTGGTAACCTAATTGTTTCATCTGGTACATCCC
TCACAAATTACACAAGGATTTATTTCATCAGACAGTGAATAGAATTTAAAGGGTCATTTTTTCTTTTCAG
GATTGCACAAAAACTGAGAAGATTTCTAAACCTAATACAAAAGCAGTTGTAATAGGGCAAATAACAATTC
TATGCTTTTCTAATGTATAGCGATTCAAGATATATAAATGCACAAACCACTTGCAGTCTTGCTTCAGTGA
TACTTAGGAATAAATTCCAGATAACATAGCATAAAGGAGTAATACATCTTTATTATTATTGCTTGAGTTT
GTGGGGGAAACCCTTTTGAATAAATGCTAAATGAAACATGAACCACCCATCTGTTTAATAGCAAGAAAGG
CCTGTTCATTGTCACGTATCTCCATCCTCACCAAGAAACATTTGACAACCGTAGGTCAAGGGAGTGCAAA
AATGGTAGACTTAAGCACTTTAGGGCCATCTCCTAATCTGCCTTTAAAAAAAAAAACAATGAAATTTCCC
AAGCACTGGCCAAAGTGAGTCACTTATTCAACCAATAAATATTTATTGAGCATTTTCTATGTGTCACTAT
ATCTGTGAGATTCCCATATGTGCTCCACTGAATAAACAAATAGAGCCACAGAATGAATGAAATAGACCCT
TTCCTCCAAGAGCACATTGTCTATTGTTGGGGTGGGGTGGAGTCGGGGTGGGGTGGAGTCAGGTTGGGGT
GCGCTATGAGCATATACTGTGATAGAACTGTTACAGAGCCTTGCTCTGGGAGCCCTGGGAGTCCCTTATG
GTTTTTAGAAATTGACCTAGGTCTTTCTCTCAGCATGAACATGCCCTAGCCAGTCAAGCCATTCCCATCA
GAGGAAATGACATAGACATTAGTTTTTACATTTTGGTTTTTGAACCCTGAAGACTCTCCTGTAAACACTC
ACTCAGCCCTCTGCCCCATGTCTGTGTCTGTGCATCTGTGTGTTATCCTTGGTCAGACTGATGTCTGGAC
CAGTCCCCCCTTCTGCTTGTCCCCCCAGGTTCTCCCCAATTACCATTGATGGAATGACAAGCCTTGTGGG
AATGAACATCCCTGGTCACACAGGAACTGGGTGGTGCATCTTTGTCTACAACCTGTCCCCCGATTCCGAT
GAGAGTGTCCTCTGGCAGCTCTTTGGCCCCTTTGGAGCAGTGAACAACGTAAAGGTGATTCGTGACTTCA
ACACCAACAAGTGCAAGGGATTCGGCTTTGTCACCATGACCAACTATGATGAGGCGGCCATGGCCATCGC
CAGCCTCAACGGGTACCGCCTGGGAGACAGAGTGTTGCAAGTTTCCTTTAAAACCAACAAAGCCCACAAG
TCCTGAATTTCCCATTCTTACTTACTAAAATATATATAGAAATATATACGAACAAAACACACGCGCGCAC
ACACACACATACACGAAAGAGAGAGAAACAAACTTTTCAAGGCTTATATTCAACCATGGACTTTATAAGC
CAGTGTTGCCTAAGTATTAAAACATTGGATTATCCTGAGGTGTACCAGGAAAGGATTTTATAATGCTTAG
AAAAAAAGAAAAAAAAAAAACAAAAAATACCTTTGATGCATTGAATGTTCTTTCATAGCTGTCGTTGTTG
AATATAATATACATAGATAGCGATGTGCAGGGATTTTTACCCAGCCAGCTAACTTTACTACCTTCCTTGA
AGGTGGATCTTTTTAAGATGACCATTCGCTCATTTGAAGAAGAAAAACAAAAAACAAAAAAAATAATAAA
AATAAAACAATTTTTACAAAGTAATGGGATTCAAAGAAAGGAAAAAAAGATTTTTCTTTTTTGTCAAAAT
ATCGATCCAATCAGATTGGTAAAAACCCCCACACAAATTAAAGAGGAATAATAAAAATTGCAAAAATAAA
AAAAAACTTTTGCAAATTTTTTTATTTTTCCTTCTTTCTTTTATATCATGTGAACTAAAACAGTCTTCTG
TTAGGGGATGGGGGCAAGGGGGATACCTGATGACATTAACAATTTAATAACATTAACATTGTTGCCAAAG
AGGTGGTCTCTTTGCTGAAAATGGGTTTCAAGAAAAATCTATTTTTATAAAATATAAAGAATTTTTACAA
GAGAATCTGGATTTGAGAAAAAAATATTTTGACTGGCTAATTTAGGGGAAATTGACAACTTTGTCGCGTT
CATACTGCACTGGTAACTTTTTAGAGATCAAGATGTGTGTTTTAAACTGGATTCGTAGACTGTTTTTTGA
AGGATGGGCTATAAACAGATGATCTTCATATCTTTTCATAGCATGTAATAATAATTAAAAAACAATTATT
AATTACTAGGGGAAAGGAGTGTTCGTTCTACCCAGGGTACCACAGTTCCCCACAGTCAAAACCCAAAAGC
AAGGAGATGAGTTGAAAGACAGTTTTTCTTTAAGTCATCAGTATGGGATGTCAGCAGAACAAAAATTAAA
AAGATTAATTTTCCTTTTGATCTAAAACTTCCTTAGTTTGAGCAGTAGGTGCTACAAAATTATTTACATA
TCTTAGTATCATAGTTAAATGTAATGTGTTTAGGAGAGGAAAACAAAAGATACATTTGCTTTAAATTCAT
TAAGAAATTTTCAAATTCACTTTGTAGCCCATGCTGATAGAATTGGGCTGTGTTGGTACATTTGAAACAC
TGTTTATGTTGCTTGAAACACTTATTTATTTAATCGCCGATGTGATGATGCCTATGGCCGAGATCAAATA
TAGCTAGATTGGCTAGACTACTTATTTGTTTACTTAAACTATGGGAAGAAGCATATTATTGTGTCATTCT
GTTGTGTGTGTATGTGTATATACAATATAAATATATATATATAAAGTTATTTTTTCTTTGGGTTAATTTA
TTATAAGTTGTAACACTTGGCTAGTTTTGTTTGTATATGTCTTAAAATGTTTTCTTATGATATTTAAGTG
ACAGTTAAAGAGGTATCAAGGTAACTTGTGTAGAACTATTCTTTGATATATTGTCATGTTTGTTGTGAAT
ATTTTTTCTTACTGCACAGTAGAAAAATAAAAACAACTGAGTCTTTATTTTAATGTAACTCAGATTGGGG
AAAACAAAACAGAGCTAAGGGAACAAAATGACTGAGGGAGCACTCTCCCACGTCCAGTGCACTGATCATT
TTAGTATGTTTGTGCTTTGTACGGTTATATATTTAAAACGAAAACAAAACAAAAAAATACAAGGGTTCAT
GCTCTTCCCTGGGTAATAGAAACAGTTACTCGCTATGCATAATCTAGTTGATAGTTAAATTTGCTATTGC
TTTTCTTGTCTTGTTATATAAAATCTTTTCAATACAAGTTTAGTCTTAATGGTAATAAAACGTTATGGTT
ATTTATAACTTGTGCTTATTTTGTGCATTTTTTCCCATGCTGAACCCACTAAGTGCATGTAGACAGGACT
GTTGTTTTCACACTGAAAAGGCAAACTTTGTAGTAGTCGTTGTAGTGGTAGACAGATAACGAATACCAAG
GCTGCATCATAGACTCCTCCTTTAAATTTTTTTTCTGTTTTTTTTTCCTCTTTTCGGTTTTGGATATAAC
ACCAGATTTCAGTTCAGAGAACACTCGTTCAACATTCAGGGAAAGCTTTTTACGTCACCTGCTATGAATG
AACGTAGTTTGCTGGCAAAGTTTTGATGCATTTGCTAAGCATTAGTGGGAAAGGCATGCCAAAATCTTCT
CTATAATGTGTTCAATCTTGGGGGAAAAAAAAAGGAAAAAAAATCTTAGGACCAGGCAGTTGTATACTTT
AGTTATTAATGAATGACTTCATGTTAATCTTGCTAGTTTAGATGATTTCCAAGGGAAAGTATTGTAAATG
TTTTTTTTTCATAATCTTGTTGTGTTTGAATTATTTGTACTTTATCTGTCCAGACAATAAATGAAAGTGT
GTAGAATGGATTTGACTTCCCAA

</dna_sequence>
        <protein_sequence>>NP_001138246.1 ELAV-like protein 4 isoform 2 [Homo sapiens]
MVMIISTMEPQVSNGPTSNTSNGPSSNNRNCPSPMQTGATTDDSKTNLIVNYLPQNMTQEEFRSLFGSIG
EIESCKLVRDKITGQSLGYGFVNYIDPKDAEKAINTLNGLRLQTKTIKVSYARPSSASIRDANLYVSGLP
KTMTQKELEQLFSQYGRIITSRILVDQVTGVSRGVGFIRFDKRIEAEEAIKGLNGQKPSGATEPITVKFA
NNPSQKSSQALLSQLYQSPNRRYPGPLHHQAQRFRLDNLLNMAYGVKRFSPITIDGMTSLVGMNIPGHTG
TGWCIFVYNLSPDSDESVLWQLFGPFGAVNNVKVIRDFNTNKCKGFGFVTMTNYDEAAMAIASLNGYRLG
DRVLQVSFKTNKAHKS

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1685">
        <gene_name>HUMGP 75</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>1067130</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:278682
GDB:126337
GOA:P17643
HGNC:HGNC:12450
InterPro:IPR002227
InterPro:IPR008922
InterPro:IPR015559
UniProtKB/Swiss-Prot:P17643</xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>melanoma antigen gp 75</protein_name>
        <protein_pi>4.59</protein_pi>
        <protein_weight>27124.87</protein_weight>
        <protein_length>312</protein_length>
        <protein_note>Common central domain of tyrosinase; pfam00264</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>CAA35820.1 melanoma antigen gp 75, partial [Homo sapiens]
PAFLTWHRYHLLRLEKDMQEMLQEPSFSLPYWNFATGKNVCDICTDDLMGSRSNFDSTLISPNSVFSQWR
VVCDSLEDYDTLGTLCNSTEDGPIRRNPAGNVARPMVQRLPEPQDVAQCLEVGLFDTPPFYSNSTNSFRN
TVEGYSDPTGKYDPAVRSLHNLAHLFLNGTGGQTHLSSQDPIFVLLHTFTDAVFDEWLRRYNADISTFPL
ENAPIGHNRQYNMVPFWPPVTNTEMFVTAPDNLGYTYE

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1688">
        <gene_name>IgG Fc</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>8857</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>154146262</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AC006950</gene_refseq>
        <protein_refseq>NP_003881</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>19</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>39863322</gene_start>
        <gene_end>39934625</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>Fc fragment of IgG binding protein</protein_name>
        <protein_pi>4.99</protein_pi>
        <protein_weight>526566.43</protein_weight>
        <protein_length>5405</protein_length>
        <protein_note>Also known as FC(GAMMA)BP</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000019.10:39863322-39934625 Homo sapiens chromosome 19, GRCh38.p12 Primary Assembly
ATGCAGCTTAGCTTAAGATATTTATTCAATGCTCTCACATTTGGCCTCTGTGACCCAGAAAAGCGGTAGA
GCAGGGTAGGAGCACATGATGCATCCTTCAGCCACTGCAACCTCCAGAGGGACCAGGTCTTCTTCAGGAA
ATCTTCGTTCCTGGTGGATGACTGATCAGCCATAACTGCAAGACACAGACATTTAGCACCTCCGCTTGCA
GACTAAACACCCACCCTGACTGCCCTCATCCCATGAGGATCCAGGTGCCTTTGCCCCAAGAAGCCTGGTT
TCCATACTACATCCCTCACCATGGGGAGAAGTCCTGCGCTCTCCATTTCTCCATCGCTGGCTTCTCCTGG
GAGTCATGCCAATCATTGGTCTGGTCCCCGTCAAAGTTTCCACAGGCCCCACACAGTTTCCCAGCATGGT
CATTGCTGACAATCACAGCCACCTTCCCATTGGCTCCAAGCCACACCTGGACCCCTGCCTTCTGGCGGAC
TAGCAGGGAGCCATCAGGTGTACGACTCACGGACACAGATGCTAACTTCTCAGCTGGGAGATCCACTCGG
AGACCATTCACCTGGTGGGGGATGCCCAGCAAACACAGAGGTGAGGCCACAGCCCCAGAATAGCTGGGTG
TTACCAGGATGGAGGATGGAGACCCCAAACAAGATAAGTTCATGGAGCTAAATCAAAGAGGCAGGTGCTG
AAAGAGATGAAGACCTGGATGTTTGCACTATTTGGAGCAATGGATACATGAGAAGATAGCTAGAGATCTG
GATAGACGGATAAAAGGATGGAGAGTGGAGGGATGGAGAGACGTACCCATGGATCTACACAACACCCCAA
AGTCGGTGGGGGAAGCATTTTGTACCAGACAGATAAGCAAACAGACAGACAAACAATCAAACCCCAGGGT
CATCCTTATGGTTCTAGTTTTCTTTTTCTTTTCTTTTTTTTTTTTTTAAGATAGGGTTTTGCTTTGTCAT
CCCAGCTGGAGTGCAGTGGTGCAATCACAGCTCACTGCAGCCCTGACCTCCTAGACTCAATCAATCCTCC
CACCTCAGCCTTCTGAGTAGCTGAGACTACAGGACTACAGATGTGTGCCACCACACCAGGCTAATTTTTG
TATTTTTTTCTAAAGATAGGGTCTCACTGTGTTGTCTAGGCTGGTCTTGAACTCCTGGATTCAGGTGATC
TGCCTCCCTCAGCCTGGTTCTAGTTTGCAAAATAAAACAAACTTTGAGCACATCCTGTAAGTTATTGGTT
CCCTAACCAAAACAACGTTATCCTTTATTTTTGCAATGCTGATGTCTGAAGATAAGTAATGACTTTAGCA
AATATAATAATCATGTGAGAAAATTACTTTTTCTTCATCATAGGCTGCAGATCCAGTAACTTTGTGAGTT
TTTCCTTTACATAACTGTTGTCTATGTTAGTTGGTGAATTAACCCTTCTAAAGTTAGATTCCCTAGAGAA
ACTTCCTTAAAAGACTTGTCTTTTTTTTTTTTTTTTTTGTAAATCCTTCTTTTGTTTGTTTGTTTTTTGT
TGTTGTTGTTGTTGTTTTGTTTTTTGGTTTTGGTTTTAGTTTTTTTTTTGAGATAGAGTCTTGCTCTGTC
GCCCAGGCTGGAGTGCAATAGCGCGATCTCAGTTCACTGCAACCTCCGCCTCCCGGGTCCAAGTGATTCT
CCTGCCTTAGCTGGGACTACAGGCATGTGCCACCATGCTCGGCTAATTTTTGTATTTTTAGTAGTGACAG
GGTTTTGCCGTGTTGGCCAGGCTGGTCTCTAACTCCTGACTTCAAGTGATCTGCCCGCCTCGGCCTCCCA
AAGCGCTGGGATTACAGGCATGAGCCACCATGCCCAGCCCTCTAAATGCTTTTGTATCTGAGTTTTCCTC
TGCCAGATGATTGGAGAGATAGGTAGATAGATCTGAAAAGACAGATGGGTGGGTGGGTGGGTGGGTGGAT
GGATGGAGGGATGGATGGGTGGATGGGTGGATTGGTGGGTGGATGGATGGATGGACAGATGGGTGGGTGG
ATGGAAGAAAGAAGGAAGGGAAAAAGACTAGAAGGAAGGAAATAGGAAAAAGAGAAGGGGGTAGAATAGA
TGCTGGAAGGAAGGAGGGGAAAAGGGAGGATGGGTGTAGTGAAGGACAGATGAAGACTAGTGGATGGAAA
GTCTCAGTAGGGTGCAAGCTTTCCAAGTATAACGACTGAGTCCGAGTCATCTCTGTTACCCAGCACATGG
CCTGGCACAAAAGGAGCAGGGCTGAGTTTATTCACAAAACCAGCCTTTTACTGAGTACCCTCTAGGTGCC
ATGCCCTGATCTGGGTACTGGGAACAAACTGGTGACCAAGATGGACAGGATCCCTGCCTACCTGCGGCTT
ATAGTCCAGTGATGAACAAAGATGCTGAGCATCTTCTGGGAGTTTCCTTCTAGGAGTCTGGAATTTTGGT
AGGTGGATACCAAAACCCCAGGCACTGAGACTCTATGAATTTCCCTGGCAGATGACATTTCATGTTTCAT
CACAACTTTGTTGCTGGAGGAATTAAGCACATCCTGTGTGACTCTACCGAGAAAGGACTCTCGGAAGCTT
GCACATGATTTCCCCTGGACTTTGTGCGATGCACCTTTTCCCTGTGTCAATTTCACTTCGTATCTTTTCC
CTATGATACATCTTAGCCCTAAGTACAACTATATGCTGAGTCCTGTGAGTCCTAGTGAATCACTGAACCA
GGTTATGGGAAACCCTGACACATTATGTGACCCCCCACCCCCAGCCTTGACCAATCACGGAACTTCCTCC
CTAAAGTCACAGTGATTGGCTCCAGGGGTGGGCATGTGACCCAAACTGGCTCAGTGAGATATAATCCTGG
GTCTTTTATTGAACCATTTTCTGTTAAGGTAGATAAGCTGGTGGGGTGTAGGCCTGGGCAGCTGGGCGGG
GGTCGTCTTTACACCTGTAAGTGGAAAGCCTGTTTGAGAACAAAGCTGATTTGGCAAATAGCAAGTCTCA
AAGACGGAAGTACAAATTTCTGATAATATTGCCAGGGCACCTAGATCCAGCCATTCCTGAGGCTCTATCC
TGGGATTTTCTAGCTACATGGACTAATAAATTCAATTTTGCTTAAGGCAGTTTGAATTTGGTTTTAAGTC
ACTTGCAACCCATAGAGTCTCGATTCATACTAATGTCAAAACTATTAAGTTGCTTGAGTATGTTTTTGCT
CCTCTAGAACTCAGCCAGAACAGAGGGACCAAGTTTGAAATATTGAGATAAATACAAATCCAGAGACTAA
ACCGCAGAGACCTGGATAAAGAAAACAGATCGCAAGACAGAAAGGAAGCCAGGAATGTGGGGACACTGTA
ATCAGAAGAGCAAAAGCCCAGGGAGACATTCCCTACCCCCTACTCACAAACTTACCCACACACCCTTGTT
TGGAGTCAACGTCACCATCCCATCCTGGAAGAAGATGTGGACCTGGCCCACAGCCTCCGTTTTGCCATGG
CAGATCTGGACTTCGGCAACTACACGGTACCAGGGGATGGTATTCTGTAGTCCTGGGCAGCGGGAAGAGA
GCTCATAGACACCAGGAGAGGTGGTGGCACCACGGGCCCCATCAAAGGTGGTGAGGTTGGCACCCACAGA
CAGGACACAGAGACCACGGGTGGCCCAGCAGTTCCGGGCTTCAGCCTTGACCTCACATACACGGCCTGGT
GGGCAGCCAGCTGCCTGGCATGTCAGGCCAGAGCTTGAGGAACAGGAACAGCGCTCGCTGCAGTCTGAGG
TCAGCAGGGAGGAGTTTACCTGTGCACAGAAAGGGGCCAGGTTATGGTGGTGGGATGGATCGCAAAAATG
GCCACACTGCTTGAACCCTCTGTATCCATGCAGAGTGACTTTACAGACTCCCATTAAGAAATAGAGTTTA
TTTCCCCCTCCCTATGAATCTGGGTTGGCCGTAAGACTATATTTAGGTCAATGAAACACAGAAGAAGCAA
TGTTGTAACAGGTTTAAGCCTAGACCTCAAGAGACCTCACAGCTTCTCTTTCCTTCTCTCTCTCTCACAT
ACACAGAATCCTGCCCAGCCACCATGAGAACAAGCCTGGGCTAGCTCCCTAGAAGATGAGTGACCCCATG
GAACATAGATAACTCTTCCAGCTCAGGCCACCCTAGACCAGGCAGCCTTCAGCTGACCCACCAGCTGACT
ACAGATATTATACATGAGTAAGCCCAGAGGATAGCAGAAGAACCACCCAGCCAAGTCCAGCCTAAACTGC
AGTCACAAAATTGCAAACTAAATGAATAATTGTTTTAAGCCACAACGTTTTGGAGTGATCTGTAACCCAG
CAAAAGCTAACTGATACAGGTAAGAAATGAAGAAATGTAATTAACAAAATAAATGCCATCTCTACAATGA
TGATTTCCACATCTCTAGGCCAGACCTCTCCCATGAAGGCCAGACTCACAAATCCAAGACTTCGGGCATA
GGCAGAGGGGTCAGGGCAGAGATGGGGAAGCATAGGGAGCTGAGGGGTTCAGAGGAGGCACCTAACCCAG
CCTAGGGGATCAAGGATGGCTTCCAGTAGGCAGTGAGACCTCAAGGAAAGAGCAAAATTTGGCTCCATTT
GCAAGCAATGCAAGTTAGTGCTGCATGTTAATGGCTAGCCTCGGGCTGACTTCTCTATGTCACAATTTCT
TCATCTGTAAAATGGGGAAAATAGTCATAGTATCTATTGCATAGGATTGTTGTGATTATTAAATGAATTA
ACATCCAGAACATGGCCGGGAGAGGTGGCTCATCCCTGTAATCCCAGCACTTTAGGAGGCCAAGGCAGGA
GGATTGCTTGAGCCCAGGAGTTTGAGACCAGCCTGGACAACATAGCGAGATCCCATTTCTACATAAAAAT
TAAATAGTCAGCCAGGGATGGCAGTGTGAGCCTGTGGTCCCAGCTACTCAGGAAGCTGAGACAGAAAGAT
CGCTTGAGCCCAGGAGTTTGAGGCTGTAGTAAGCCGTGATCATGCCACCGCACTCCTGCCTGAAAGACAG
AGTGCAATCCTATCTCAATAAATAAATAAATAAATAATAACACCCATAACAAACATGGTGCATAGTAAGA
GCTCAAAAAAATTATTAACAAGAATAAATCAATTCTTCAATTTAATTCATATTATTAAACAATTATTAGC
TGGGCTACCTATTTGCACTGTTGTAAACTGCTATTTCTTTTTTTTTCTTTTTGACATGGAGTCTCGGTCT
GTTGCTCATGCTACAGTGCTGTGGCACAATCTCGGCTCGCTGCAACTTCCACTTCCCGGGTTCACGGGAT
TCTCCTTCCTCAGCCTCCCGAGTAGCTAGGACTACAGGTGTCCACCACCACACCCAGCTAATTTTTGTAT
TTTTAGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCGAACTCCTGACCTTTTGATCCGCCCG
CCTTGGCCTCCTAAAGTGCTGGGATTACAGGTGTGAGCCACTGCGCCCCGCTGTAAACTGCTCTTTCTTT
TTACTGAGTGTGATGAACATGCAGGGCAAGGCCCAGTGCTCAGTGGGTATCTTTCCTGTATAATCGGGCC
TGATCCTCAGATACCTATGGTACAAAGATGGTGATTAGTCCCATTTTACAGGTGAAGAAAATGCAGTTCA
AGGAGGGGCCAAATGATGCCCCCGCCCCAAGATATCAGGTCCTAATCCCTGTAATGAGTAAATGTCACCT
TATATGGGAAAAGTGTGTTTGCAGATGTGATTGAATTAAGGATCTGAAGATGGAAAATTTCTCCTGGATT
ATCTGAGTGAGCCTTAGATGCAATCACGTGTATCCTTATAAGAGAGAAGCAGAGGGAGGTGTTATGACAC
ACTCAGAAGAGGAGGCAGAGGTTGGTGTGATGTGGCCACAACCAAGGAAAACCTGCAGCAACCAGCAACT
GGAAGAGGCAACAAACAGATTTTCCCCTAGATTTCTTTTTTCTTTTCTTTTCTTTTCTTTTTTTTTTTTT
TTTGACATGGAGTCTCGGTCTGTCACCCAGGCTGGAGTGTAGTGGCGCAATCTCGGCTCACTGCCACCTC
CGCCTCCTGGGTTCAAGTGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACATGCACGCACCACC
ATGCCCGGCTAATTTTTGTATTTTTAGTAGAGACAGGGTTTCACCATGTTGGTCAGGCTGGTCTTGAACT
TCTGACCTCGTGATCCGCCCGCCTCAGTCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCACCGTGCCTG
GCTCTTTTCCTTTTTTCTTTAGAGGTAAGGTCTTGCTCTGTCACCCAGGCTGGAGTGCGGCAGCGTGATC
ATAGCTCACTGCAGCCTCCAACTCCTGGGGTCACGCCATTGTCCCACCTCAGCCTCTTGAGTAGCTGGGA
CTATAGGTGTGCACCACCATGCCCAGCTAATTAAAAAAACAATTGTATGTTGCCCAAGCTGGTTTTGAAT
TCCTGGGCTCAAGTGATCCTCCCGCCTTGGCCTCCCAAAGGGCTGGGACTGCAAGTATGAGCCACTGGGC
ATGGCCTCCCCTAGATTTCTCTGGAGGGAGTGCCACCTTGCCAACACCTTGATGTCAGCCCAGTATTCCT
GATTTCTGACTTTTGGCCTTCAGAACTGTGGGAGAATGAATTTCTCCTGTTTAAGCTACCATGTCTGCGG
TAATTGGTTACAGAAGCTGCAGGAGACTAATAGGGGGAGGTTGCCTGCATCAAGTCACATAGCTGGGATA
TGGCGGTACCTCCTCTGTCCCCAGCCTTGAAGAGGTCAGCACAGAATCTCTGGGTCTCTCTCAAGCTCTT
CTACCCTCTCTGCCCACCCCAAGCCCCTACTCACCGGCAAGTATCGGCCATTATGGGTGCAGCCACAATC
TTGGACAGGGATGCAGACACCCTGGGAAAGCAGGAAGCGGTCGTCGCACTCACAGCCCTCAAAACAGCGG
GTGGTGCAGCCCGTGAGGCCGGAGAGAGCCGCACAGGATCCCTGGCAGGTGCGAGTGCAGATGGAGTAGT
GGCTGTGGGCGGGGCAATGGAGCGCTGCAGAGAGAGGAGGCAGGGCTGAGTCACACCTCCAAAGGGTCCT
GGATAACCAAGGGGGCCTACTGCACACCCAGCCCTGTTTTAGGCGGTGCTGAGGACACAAATACTGAGAA
AAGTCTCAACCCCAGTCCTACAGAGCTCACTTCCAGTGGGACAGACAGGAAGAGCCCAAAGTGAACATGC
TGCATCAGGGAGTGTAGACAGAGAGGTCAGGGTCAGGGTGGGGAGGCACAGGCAGAGGGGTCAGGGCAGG
CATGAGGGGGCAAAGGCAGAGGGGTCAGGGCCAGGGTAGGGGGCTACAGACAGAAGGGTCAGGGCTGGGA
TGGGGAGGGCACAGACAGAGGGTTGAGGGCCAGGGTAGGGGGCACAGGCAGAGGGGTCAGGACCAGGGTC
GGGGGCACAGGCAAAGAGGTCGGGGCCAGAGTGGGGGCACACAGGCAGAGGGGTCAGCGCCAGGATGGGG
AGGGCACAAACAGAGGGTTGAGGGCTGGGGTTGGGGGCACAAGCAAAGGGGTCAGGGCTGGGGTGGGGGG
GCAAAGGCAGAGGGGTCAGGGCCGGGATGGGGAGGGTACACACAGAGGGTTGAGGGCCGGGGTAGGGGGC
ACAGGCAGAGGGGTCAGGGCTGGGTAGGGGGCACAGGCAGAGGGGTCAGGGCCAGGGTGTGGGGGGCACA
GGCAAAGGGGTCAGGGCTGGGATAGGGGGGCACAGGCAGAGGGGTCAGAGTTGGGACAGGGGCTATATGG
ACCCAAGGGAATTATCTGTGGTAAGTCCCTGGTCTCTGGCTAAGCAATTGGTGGAGGTGTGGCTGTTCTG
CAATGCCCACCAGGTTTGGGGAAGGAGCATCAGGCTGGGGGTGAAATGCTGATTTTATTTGGGAACACAG
CAGGTAAGAGGGACGGTAAGGACACCCAGGGGAAGGTGTCTTGGACACCCTAACAATTACCACAGACTTT
GTAGCTTAAACAGGGGAAATTCATTCTCCCACAGTTCTGAAGGCCAGAAGTCAGAAATCAGGATCACTGG
GCTGACAGTCAGGAGAGAGTTCAGGGCTTGAGACAGACAGACCAGGTCCATGGTCAACAATGAGAACAAA
TCTAAGGCCGCGGGTGTGGATGACCGCCCTGGGTATAGGTCCTGCCCAGGGGAGACCTGGCTCTGACCTG
GAGCCGAAGGGGCCATTGCTTTTTCCTGAGAGTCTCTGGTGATGTCCCTCCCATGGGGAATTGAATGAGA
GGTACAGTCCTAGTTTAGCGGGGTGTTTAATAGCCTGCAGCCTTGTCTTGGGGGGATCTGAGGGGATATG
GTCTTGTCGGGGGTAGAAGGAGGGTCTGTGTGAGCCACAGATCTCCCAACCCATCCAACTCTCCCTTTCA
GGTCACTGCAGAAAGAGTCCAGAATAGAACACTAGGGAAGAAGAGAATTTGAGGTTTGAGCAGAGTGGGC
CCAGACAGGAGGCTGAGAAGGAACAGTCAGAGGGATAGCAGGGAAGCCAGTGGACTATGCCGTGGGAGAA
GAAGTTGTGTGGGTGTGGGGTGGGAGGGGGTGGGGAGGGAGCGCTTTTACAGGGAGAAACCACTCCGACA
TGCAAATAGAAGGAATGGGCCAGGAGGGGCCCCTACACCTGGTCTAGAGTCCTGCGAGGGACCCACGGAC
ACTCACGGCAGAAGCTGTCTGTCCTCCAGGGCTTCACGGCCACGCCAGCTGCCTGACAGGCCGCCGTGTA
GGCTGCCAGGCTGCGGCACAGGAAGGCTTTGTCACCCTTTTGCGCGCACAGGTCGTATACGCATTGGCGG
AAGTACTCAGAGGGACTCAGCACCGCCTGGCAGGTCGCGAAGGGGCCCTGGGGGTTCCGGAGCTGCCCGC
AGGCCTCGTTGCTCTCATAGGGTGCAGTCTCCTCTGCCAAGCACACTGGGCAGCCTTGGGGCCCGCAGCC
CTCGCCACAGCCCTTGGAGGAGCCGGGCGCCCGCCATGCAGCCCCGAAGGTCTCCACACTGGACGCTGCT
GAGCCATTGGGCAGGACAAAGTCGTCACTCCAGTTGCCATTGAAGTTCCCACAGAGGCCACAGAGCCGTC
CACGGAAGGGGCTGGGGATGGACATGAGGAGGTGGGCATCGCCATCAAAGAGAAGCCGCAGCCCCTTGGT
CGTCTGCAGAACCATGTTTCGGCCCTCGGCGGTCACCCGCACGCGGCCCACAGCCACAGGCAGGGCCACA
GCCTCGCCGTCCACGGTGACCTGGGTGGAAGGGTCGGGTAGGTCAGGAACTCACAGAACCACAGGCAAGG
CTGTCCTGTCCCACTCCCAGGCCAGAGCTGCATCTCCCTCAGTCCCATTAACGTCAGGTCATGTTTCCCT
TAAACTTCTTGGGCCCCAGGCCTGGCGTGGTGACTCACACCTATAATCCCAGCACTTTGGGAGGCCCAGA
CAGGTGGATCACTTGAGCCCAGGAGTTCGAGACCAGCCTGGCCGTGACAGCAAGACCTCATCTCTACCAA
AAATAAAAAATTAGCTAGGCATGGGGGGCTGAGGTGGGAGGATTGCTTGAGCCCAGCAGGTTGAGCCTGC
AGTGAGCTGTGATCACGCCAATATACTCCAGCCTGGGTGACAGAACAAGACCCTGTCACAAAACAACACA
AAAATCTCCCACGGTGGGACCATTCACCAAACCTTCCAGGGTAGGTACCAGAGTTCCCATGTTAGAGGAA
TGTCCCTCTCATACCTACAGGGTGGGGTCGTGTCTCCCTCAGAACCCCCTAGATGGGGCTGTGTTGCCTT
CAGACCCCCAGGGCAGGCTCACATGGACTCACCTGCTGCCCCTGAGCTAGGCTCACAACCTGGCCAGCCA
CAGTAACCAGGAGGCGTTGGAGATCTCCAGCTGCATTCTTCTCAAGCACGATGGAAAAGTCCTCGTCCCC
AGGCTTTGGGTGGCAGACTTGGGCCAAGACATAGGAGCAGGAGCCATGCAGGTCGTAGACACGGCCATCA
AGGGTGATGTAGTGGATGCCCCCGTTGGCCAGGCAGCGGCCACAGCCTGTGGCATGACAGGCCTGGACAC
CATCCTCTAACCGGCACTCCTCATGGGGCCCACAGGCTGCGCCCTCCTGGCAGGTGACATGGCCACCTGG
CCCACACTCACAGCGCCGCTCACACTCAGGGCCCGGGTAGAAGACCTCGCCCAGTGGGTAGTAGCGGCCA
TCATGGAGGCAGCCACACTGGCCCACGGGTACGCAGGTGTCACCACTGAGTACGAAGCCAGCATCGCAGA
CACAGCCTTCACGGCAGGCCGACTCACAGCCCTCGGGTGCTGAGAGGCTCGGGCAGCTCACAGGGCAGGA
GTCACCGCAGAGCTCATAGTGGCTGTGGGCAGGGCACTGCAAGGCTGTGGGGACAAGGTGGGCATGAGCC
AGGTAGGTGTTCGAGTCGGGGTCTTGGGAGGCCCTGAGTGGGAAAACTGCTCAGGCCAACTTGAGTGTCT
CTGTGTATGCACATGTGATCCAGGACATCTAACTGGGGGACTCAGTGTGGGACCTGGAATGGGAGGGGAC
ATGCCCTGGTCTCTCTGACCAGGTTATGTGTTAGCCTGACCAAATATTTCTGAAGATCAAATGACTCTGC
TTGCCTGATTTTTATTTATTTATTTATTTATTTATTTTTTATTTTTTTGAGACAGGGTCTCACTCTATCT
CACCCAGGCTGGAGTGCAGAGGCGCGCTTACTGCAGCCTCCACCTCCTGGGCTCAAGCGATCATCCTGCC
TCAGCCCCCCGAGTATCTGGGACTACAGGTATGAGCCACCACATCTGGCTAATTTATTAGTAGTTTTCTG
TAGAGATGGGGTCTCACTATGTAAGCCAGGCTTACCTGGGTGAAATGGATCACTTATATCTATTCGGGGT
ATGCAAGATCAGAACTGACTATGGGTACCTCAGCGTGTGAATGTGACTGGGGTGTGGGGCCACATGTATC
TCAGGGTATGGCTCTGCCTGAGGGCACCCAGCTGTGGGTGTCTGACATGCAGCATCTCCCAGAGTCCTTC
TGACATGGTCTGCCTAAGGGTGTGCCTGGGTGAAGTTGGCAGGATACCTGTGACCAGGAGACCTGCCTGA
AGGGAACCGCCTAGGACTATCTAACCATGCATCTGTGTGGATCTGCCCAGGGCTATGTAAGAGTCCTGAT
TCTATCTGAGTGTATCTAACCAGTTAGTCTCAGTACAAAATCTGAGCAGATACCACTGAAGGTATGTGAC
TTATTCTATGTGACTAGGTGTATTTCAGTGTGTGCAACAGACCAAGGGCCTCTGACCAGCTGTAACTCAC
TAGGTCTTCCTAACCAGGGGTACCTTGCTGTGTGACTGAGGCAGAGTCAGCCATCCCAATCTACATGCCT
TGGATATCTGAGAGCATGGATCACCAATCCTCAACAGTGTCCTGGACCCCAGGTTTCTGACTAGGTGTTT
CTTTTCTTTCTTTCTTTTTTTTTTTTTGAGATGGTGTCTCACTCTGTTGCCCAGGCTGGAATGCAGTGTC
ACATCATGGCTCACTGCAACCTCTGCCTCCTGGGTTCAAGTGCCTCAGCCTCCTGATTAGCTGGGATTAC
AGGTGCCCACCACCACGCCCAGATAAATCTTGTATTTTTAGTAGGGACAGGGATTTCACCATGTTGGCCG
GGCTAGTCTCAACTTCCTGACCTCAGGTGATCCACCTGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGC
GTGAGCCACCACGCCCACACTCTGACTAGGTGTTTCTAACTCTCTCTCACTGCAGTACCTTTCTTGGGGC
ATTTCAGTGTGTGAGTGCCAAGGTGTTTGGTGACAGGAGATACCAAGCTCAGAGGAAGGAAAGTGGCCCC
TGAGCCCCATGGAGGAGGAAGGGGCTGCTGTCCTACAGTCCTGGGAAGGGCAGGGAGAGACCCAACCATG
TGGACCATGCATGGAGCAGTACTCACGACAGAAGTCCGGCCGCCTCCACTCGCCGAGCTGGGCCCCAGCG
GCCTGACAGGCTGCCACGTAGGTAGCCACTGCAGGACAGAGGCCTCCAGGATGGCCCTGAACTTGGCAGG
CGTCCAGCAAGCAGCCCTGGAAGTACTGCGCGGGCGGCACAAGGCCGTGGCAGGGTGCCAGCGGGCCGTC
GGTGGCGGAGATCACGCCGCAGGCGTCCGGGCCGCCGAAGGACTCCTGCTGCTCTGGGGTGCACGGCGAC
GGGCATGGCTTGGACACACATTCCCCGCAGCCCTGGGCCCCGCCCACCTGCCATCCAGCGGGCTTCCCGC
CCACAGCCTTGAGGTCGTCTGCGGGGTCCTGGTTGTAGTTCCCGCATAAGCCACAGAGAGAGGCCGCGTA
CGCCGCCGGCACGCGCAGGCGCACGAAGCTGTCCCCATCGAAAGCCAGCGAGAGCCCTGAGGTTGTGGTC
ACCACCACGTCGGCGCCGCTCAGGTGTGCGTGCAGGAGCGAGTCCAGCTGGAAAGGCAGAGCCACGAACA
CGCCGTCGACCTGCGGGCGGGGGATGGCGGCGGGGGGATGGGGCGCGGTGAGTGGAGAGAACACGGGTTT
GAATCCTGGCCCCACCACCTACTAGCTGTGGGACCCAGAGCATGTCACCTCCCCTCTGAAAATAATAATG
AGCATCTATAGGCCGGGCCTGGTGGCAAAGCCTGCAATCCCAGTACTTTGGAAGGACGAGATGGGAGGAT
CACTTGAGGTCAGAAGTTCAGACCCGCCTGGGCAACATAGTGAGACCCCCATCTCTACAAAAAAAATGAA
AAATTAGCCAGCATGGTGGCCTGCGCCTTTAGTCCCAGCCACTTGGGAGGCGGAGGCCAAGGCGGGAGGA
TGGATTGAGCCCAGCAGTTCCAGGCTACAGTGAGCCCTAATCCTGTCACTGCACTCCAGCCTGGGCAACA
GAGTCAGGCTAAGAAAAGAAAGAAAGAAAGAAAAACAGAAAAGAAAAAACAAAGAGCCTCTATAGGCTCA
TGTCACTGACTCCTCATCCTTCTCAAAAACAGGTACTTTCTTAGACCAGTTTACAGAGGAATACACTAGG
CTCAGAGAGGAAGAAGCCGCTGTGCCAAGCCACCAGGCTCCTAGGCGTACACTCTGACCCTTCCATCATG
CCCCAGCTAAGCTGTGAAAGGGGCCCAGGGGAATGGTGAAGCCCTTACCATCTCAGGCAACCCCAGAGCT
GGCACTTGCTCCTGTCTGGCCCACAGCCCTCCTCACCTGTAGCTTCCGGGGCCAGCGGGCACTCAGTGTC
AGGCTGTGGTTGTAGATTTGCAGGGTGACACTGCGGGTGTAGCTGACAGCCTGGCTGCCCCGGTGCTCAT
TGGCTACAGTGACAGTGAAGTTCTCAGCCCCCAAGGGTGGTCCGTGGCAGGGTGCACTCAGCAGGTACTC
GCAGGTGCCTTGGAAATCGAATCGGTGCCCATCCAGAGTGACGTAATGGGGGTCACCCCACGCCTGGCAC
TCAGCTGTGCTGACGGGCTGGCAGCCGTGCTGGCCGGATGGCAGGAGGCCACACACTTCACCCAGCCCAC
AGCTGGCAGGTGTGCAGACCAGCGAGCCACCCCCAGGCCCGCAGCGACACCACTGGGAGCAGGTGCCATC
AGCCCAAAACTCACTGCCCGCCTCGTGGTAGGTGCCATTGGCCCAGCAGCCGCAGCCGTTGTTGAGGGGA
ACACAGCGGTCAGCACTTAACACGAAACCCGCGTCGCACTGGCAGCCCTCCACACAGGGGCCCTCACATA
CGGCTGGCGTCGTAAGGGGTGCAGGGGACGGACAGCTGGCTGGGCAGGGTGGGCCACAGACCTCATAGTG
GCTGTTTTCTGGGCAGGTGATCTCTGTGGGCAGACGAAGGAGCAGGAAGGAGAGAAATAGAGAGAAGGGT
GTCAGGGGTGGGGTCCCAGGACAGGGTGGGAGGAGACAGAGATACTAGGGAGCAGACAGAAAAAGGGAGA
GACAGAAAACAAGACACAGAGAGGACACAGAGAAAGAAATGGGAGAGGGCGAGACACCAGGAGACCCAAG
CAGAAACTGAGGGAGCTAGAGAATGAGAAACAGACAGATAGACACAAGCAAAGCGAGGCCCAGAGATGAG
CACCAAGAGACAGAGAGACAAACAGAGAAAAAAGAAAACAAAGAGACCCAGAAGGACCAGAGTGAAACCA
AACCAGCCCCGAAGAGACGGGACCCCGCCCCCCGCCCCACCTCTGCTCCCCCAACACTCACCACAGCCAA
CCTGTGCCCGCCAGTCTTCGATGACAACCCCAGCGGCCTGGCAGGCGGCCACGTAGGAAGCCAGAGCCTT
GCAAAGAATGTCACGGTCCCCACCACCCATGCAGACGTCCAGAACACAGCCCTTGAAGAAGCTCTCAGGT
GGCACATGAGCATGGCAGGTGGTGAAGGGGCCCCCTGTGCCAGATGAAAGGGGTCCGCAGAAGCCAGGGC
CCTCGTACTGCTCCAACCGGTCCTCAGGGCACGTTGGGCAGGACCCCCGACATTCGTCCCAACACAGTGG
GTCCCAGCCTGGGGCTCGCCAGCTGCCGCCCCAGATGGGTATGGAGGGAGCCAGTGTGCCATTAGGGAAG
ACCTGGTCATTGTTGGGGTTGCGGTCCATGTTACCGCAGAGCCCGCACACTGCGCCATGATAGCTGCTGG
GGAGCGTCACGTCTACCCGCCAGTTCCAGTCATAGCTGACTTGCAGTCCAAAGTCAGCCACCAGCAGTGC
CTTCGATGCACCCTGGGCCACTGAAATCCGCCCGTCGGCCACGGAGACAGGCAAGGCTGTGAGCACACCG
TTCACCTGGGGGAAGGAGGGAAGGCAAACGGGTCACTGGAGGTTTTACGGCCCCAGCTCTGGCCCTCTGC
CTCCCTCTCTCTCATCCCACCGGGGGCTGGGAGAGGCCAGGGCCTTCCCCCGAGAGTTGGATTGTCATCT
GACACACTGTGGACAGTTGTTCTAGCCCAGGTCTTGGGGAACGAAACCTCACTTTACTTTTTCTAGATCT
TCTCCCTTCATCTCTATCTCCCTCTTCTGTCTCTCTGTCTCTCTGTCTTTCTGTGTCTCTCTCCCTCTGT
CTTCACCTAAGTCTATATCACTTGGTCTTCTCTCTCTCTCTTTCTGTCTCTCTGTCTATCTCTCCCTCCT
CTTCCCTTCCTCCCTCCTACCCTCATTCTCTGTGTGTCTCTTCCACTCACTCACCATCATTTATCCAGTG
CCTACTCTGTTCCATCCCTCATTTTCTCTCTGTGAGCTACCATTAAGCTCTATCTCCATTTCCCTGGGCA
GAAAGGATAGCCCATCTGTCTCCTCTGATCTCCCTACATATCTCCCTATATTTCTTTCTTTCTTTCTTTT
TTTTTTTTTTTTTTTTTGAGACAGATCCTCACTCTGTCACCCAGGCTGCAGTACAGTGTCGAAATCTTGG
CTCTTGTAACCTCCACCTCCCAGGTTCAAGTGATTCTCCTGCCTCAGTTTCCAGAGTAGCTGGGATTACA
GTAGCACCACCACACCCAGCTAATTTTTGTATTTTTAGTAGAGATGGGGGTTTCACCATATCGGCGAGGC
TGGTCTCGAACTACTAACCTCAGGTGATCCACCCGCCTCGGCCTCCCAGAGTGCTGGGATTACAGGCGTG
AGCCACCGCACCTAGCCCGATCTCCCTGTATTTCTCTCTGTGTCCTGGTCTCTGGGTCTCTCACTTGTTC
CCTCACAAACACTCAAACGACTGTTCACCTGGACTAGACTCTGAGCTCAGCATGTGACATGCACGGCCTT
GCTGTGGGGGAGGCCCTGATACGATGCCCACTTCACAGATGAGGAAACTGAGGCCTACCAAGTGAACTGC
CCAGCATCACATAGCTCATAAGGAGGAGAGGCTGGATTGAAACCCAGGTCTATAAAAAAGGCAAATGCTG
AGGTCCTATGTTAAAGCCCTTTGCCAGGGGCTAGGCTCATTTAATTCCCAGTAACAGGGTGACATTTTTG
CTGCAATTATTCTTTTTGTTGACAGTTTGTTTCAGGCCCAGGTGAAGACAAAGAGCCTTGAGCTGCTAAC
TGTGGTCGTCAGGATCCCTCCTGCCCTCCCGGGGACCTCAGGGGACCATCCTGCCACACATACCCGGACT
TTGCCGATCTCGTCCTTGTGGATGGAGATGTTGGTGCCGAGGGCAGCCACGGTGACGACTCTCACGTAGG
ACACAGCAGGGTTGCCCCGGTTCTGGTTCTTGGTGGTGACGGTGAAGGGTGTCAGGCCCTGGGTGCTGAC
CCCCGGGCAGCCAGTTGTTGCCAGCACATAGTTACAGGTGCCCTGGAAGTCAAACTTCCGGCCATCGAAG
GAGTGGTAGTGTGGGTCGCCCCACAGCCAGCACGTGGCCTCATAGTTGGGCAGGCACACGCCCTGGCCAC
CCTGCTCCTTGCATGTCTCCTGTGGCCGGCATGTCACGCCGTGGCACGGGTCTGGGGACAGAAGAGGGAG
GAGGACCTTGAGGGGCTGCCCATTGTAAAGCATGGCCGCTCCCTCCATATCTACCCAGTCTGTGCCAGGG
ATCTGAGGGTTACTGCAGGCAAGACCACATTCCAGAGTCCTCATGTCTAGGACCCACTTCCTATAGTTTG
CTTTTATATTTTCTTTTGTTTTGTTGTTTTTTTGAGATGGAGTCTTTCTCTGTCACCCAGGCTGGAGAGC
AATGGTACAATCTCGGCTCACTGCAACCTCTGCCTCCTGGGCTCCAGTGATTCTCCTGACTCAGCCTCCT
GAGTGGCTGGGATTATAGGTGCCCACCAGCATGCTTGGCTGATTTTTGTATTTTTAGTAGAGACAGGGTT
TCACCATGTTGGCCAGGCTGGTCTCGGGCTCCTGACATCAAGTGATCAGCCAACCTTGGCCTCCCAGAGT
GTTGGGATTACAGGCATGAGCCATCATGCCCAGCCTGCTATTTTCAAGACCAGCCCCTGGGAGTCGCACA
CAGCTGACACTGAGGCCCCATGGGGGACTGTGTCTAAGTCTCGGCTGTCAAAGGTCCCATACCGGAGACC
TGGGCCCCAGAGGTCTGTACAGCCAAGACCCAGTACCTAGAGTTCCCCTACCTCTGAGACTGAGGCCCTG
CCATTTGCTGTGTGAGACTGAGATCCTGGAGTCCACGCACCTAAGACCAAGGCAAAGACCAAGGCTCTGG
GTCTGTGTTTAAGGTGCACTTTCCATGGTGCCCTTGCTTGAGATTTCACCCTGTTCTTGTATTTTAAGTT
TTATAGGAACCTCACCGTCTTCACTTACATAGGCTACGGCTGCTTTCACACCACAGTGGCAGAGTGAGTA
GTTGTGATCCAGAAGGTATAGCCTGCAAGCTTAAACACTTACCATCTAGCCCTTTAGAGAAAAGGTGCAC
TTGACCCCAGTTGAGATCTGTGCCCCAGGGGTCCTTGTGTCTGCGATGCCAGCCCTGAGAGCATCCATGT
CTGAGATCCCAGCCCCAGGGTTCTCTGTGTTCAAGACCTGGGCCCCAGGCCAGGTGTGGTGGCTCAGGCC
TGTAATCCCAGCACTTTAAGAGGCTGAGGTGGGAGGATAGCTTGAGCCCTGGAGTTTGAGACTAGCCTGG
GCAACATAGTAAGACCCCATTTCTACAGAAAGATTAATAAATTAGCCAGGCGTGGTGGTGTGTGCCTGTA
GTCCCCCACTACTCGGGAGGCTGAGGCGGGAGGATTGTTTGAGCCCAGGAAATCGAGGCTGCAGTAAGCT
ACACTACACTCTAGCCTGGGCCACAGAGTGAGACCTTAGCTCAAAAAAAAAAAAAAGATCTAGGTCTCAG
GGTCCCCCATGCCTGAGACCTCAGCCCCCTGGACATCTCCACATTTGATAGAAATTGGTCTCCAATTTCT
CTAGGTCCTGGAGGCCTCTATGCCCAAGACTAGGGCCCTGGGGTGATCTTCTGGCAAGAGCCCAGTGCCA
GGGTCTCAGCAGGATTTGAAATGTTTGAGACCCTAACTAGCTAAGTCTCATGGGCTGGGCTCCCTCAGTG
CAAGACTCCATCCCTGAGGGTTGCTGTATTCAAGACAGTAGCCTTCATCGTGTCTCACTGCTGAGGCCCT
GTCCTGGGGGGTTTCTGTGTCCGAGACCCTGTTCGTACAGTTACTACATCTGTGACCCCAGCTTGCGGAA
CCCCTGTGTGGGAGAGGCCAGCCTTCAAACGTCTCCTTCCTCCTGTGTCCATTATCAATGTACCGCCTCT
CAGCTTCAAATACACCCACGGAGTTAAGCTTTGTCAACAGAGGGCGCCGGAGAGTCACTGCAGGAGGGAG
GGTCTCCGGGTCTGGCTTCTAGCCAGTTTGGTCCTTTCAGCTCTGGCCAGGGTGCGGGGCCACATTCAGC
GAGTGCCACTGGCCGCAGCTGGCTTCCCAGTGAGGGGTTCCCTTCTTGCCAAGTCCAGCCTGCAGAAACC
TCTGTGCCACCCAGTGGGCTACAGCTGCAGTGAGACTGGACTCAGCCTTGGGGCTGATTCTCCCCTCCTT
GAAGAGGAGGGACCAATTTCTCCCTTCCATGAGGCTTTTAACTTAGCCCTAGAGTGGCGGCTACTTCCTG
TGTGTGCTTTGGTGGTATTCTTTAGTGCTCTCTTTACCGTTTCTTATTTCTGTTTATTTGTTTGTTTGTA
AAGAGACAAGGTCTTGCTGTCTTGCCCACGCTAGAGAGCAGTGGTGCAATCATATAGCTCACTGCAGCCT
CGAAATCCTGGGGTCAACTGATCCTCCTACCTCAGCATCCTAAATAGCTGGGACCACAGGCACGCATCAC
CACACCTGGCTAATTTTCAATTTTTTGTGGAGACAGGGGTCTCGCTATGTTGCCCAGGCTGGTCTCGAAC
TCCTGGCCTCAAGTGATCCTCCCAAAGTTCTGGGTGTGTGAGCCACGGCACCAGACCCTCTTTACCCTTA
ATAGTTAATCTCCTATTAATAAGTAAGTGATTCTTTAATTAAACTTTCCTCATTCAAATGGCCATACGCT
TTCTGTCTCTCGACTAGATGCTGAGTGATATACCCCCCATTCCTGGGAGTCCCCATTATCCTGCTCATCA
GCCCTGAGAGTCTTAGCCCCCACTCCTTGGTGCTGGAGCTCCCATTCTCTTATCCTTAGGGGGAGGAGAG
TTCTCTGCTCTTCACCCTAAGAAATGAGCCCTGGGGGTGGCTGTGTCCCAGATTTAGTCTGGGGGATTCC
CACATCAGAGACTATACCCCTAGAAATCCTGATCTTCCAGTTAAGAGGGGTCCCCATATCCAATGTCCTG
CCTTGGTGAGGTCTCCGTGCGTGAGACTCAGAACTCTGCTCTCTGTCCCTGCCCCTGGGATCCCAATCTC
TCCCCTGCCCTTTGGTGCTAGTGTCTGAACCCCAAGCCCGATCCCACACATCAGTGTTCCGCTCATGATG
GAACCCTAGGCTGCTGCTCTTGTATTCTAAAGTCTTATAGGAACCTGACCTCTTCACTTACATAGTCTAC
GGCTGCTTTCATGCCACAGTGGCAGAGTGAGTAGCTGGAACGAGAACCTACAGCCTGCGAGCTTAAACAT
TTACCATGTAGCACATTAGAGCAAAGGCGCGCCTGTCCCTGCCTTATACCGAGGGTCTCTGACATCCACC
CTGAGAAAACTATCTCTGAGGGTCCCCACAGCCTGGATTTTCCCTAAGGGTCCCTACCTCCCAAAGTAGG
TGGCCCTGGCCCTGTGAAACCTGGTCTAGGGTTCCCCAGGTCTGCAACCTCAATCATTAGTCCTGTACAC
CTCCCGCCATGGACACCCCAGTTACACTACCCTCAGCCCCAGAGTCCCCATCCTCCATCCCTAGTCCCAT
CAGCCCCAGTCCCAGCCCAGCCCAGCCCAGCACCTTTGGTGACGCAGCTCAGGATGCCTCCGGAGGGCTG
GCACACCTGCCCCGGCTTGCAGCTGTGTTCCTGGCACACCACGACTTTACCCACATGGCACGTGCACTGC
TGCCGACAGTTGTCAATGAGGACTGTCTGCTCCGGCTGTGGGGAGAGAGGGAACGGCCATCAGGGACACC
ACGGGTGGGAGCCGACTCTCACATCTCTGGCGTTCTGGCACAGAGGGGTTTGGCAGACATCACAGACAAG
GGACATCTCTCAGCAGGATGGCCCCTTGTCTGTGAAGCTGAGGCACAGCATGGCTTTGGGGCCATCATTC
ATTGGTTCATTCACTTTTCTTCATTTACTCATTCATTCCAAAATATCCACTCAACGTCTGCTGTAGGAGA
AATGGTGTGACACAGTAACTAAGGGCAGATCGCCTGGGCTTGAAGCCCGTTTCTGCTGTTTCCAAAGTGT
GTGACTCTGGGCAGTTACTTCACCTCTTTATGGCTCAGTTTCATGATCTGCAGATTGCAGATGATAGTAG
CGCCTGCCTTTGGAAATATAACTGAGTTATATTCAGATAATAACCAAGTTATATTCAGATAATAACCAAG
TTATATTCAGACATGTAAAATTTAGATAAAATGAAAAGGGTAGGCCGGGCGCGGTGGCACATGCTTGTAA
TCCCAGCACTTTGGGAAGCCGAGGCGGGTGGATCACGAGGTCAGAAGATTGAGACCATCCTGGCTAACAC
GGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGTCGGGCGTGGTGGCGGGCGCCTATAGTCCCAG
CTACTCGGGAGGCTGAGGCAGGAGAATGGTGTGAACTCGGGAGGCGGAGCTTGCAGTGAGGCAAAACTGC
GCCACTGCACTCCAGCCTGAGTGACAGAGCGAGACCCCATCTCAAGGAAAAACAAAAACAAAAACAGAAA
AGGGTTTCCTTTAAAACATTCAGATAGGAGAGATACGTGGGGTAGACATCAAACAAGATCGGGAGAATAT
GGCTTATTTTTGAAGCTAAGTGATGGGTAAGTACATGGACAGTCATTCCACTATTCTCTTAATTTTTGCA
TGTTTGAACGTTTTCAGAATAAAAAGTTTTTAGATATGTAATGCATATATAAAAATATGCACACATAGCA
CTTAAAACGGTACCAGATACATAGTAAGCACTATCTACACATTTTCTGTTATTATTAATATTATTTATGT
GAGGAGAACAACAGAGAGAGGGTTCCACCCCTAGGAGAGCTCACAGTCCCCAAGGGAGATGGACATTAGA
CAAACACATGCTCCAGTCAAAGAAAAAGGACCTACGGGGACAGAGTGGGAGAGGGAAGTAGAGGGTGTTA
GCAGCTGGTATAACACATGGAAATCTTGTCTTTGTGGTCAGAAAGGCTCCCTTCGTCCAGACCTGGAAGG
CAAAGCCACAACTTGACCTGGGGAGTCAGGGGAGGGTTTAAAGCTTCAGAGCCCGTGGTCATATTTAGAA
AGATCTTTACCACTGCCACGTGGAGGGTGGACCAGAGGGAGCAGAGGTAGGAGCTGGGAGGGACCCAGGT
AGGAGAGGACCAGCTGGACCAAGGGAGGGCCATGGGGACGGGGAAAGGAGTGGGTACAAGAGACACTGAA
GAGACTGAGTGGACTAGCTGTGGTGGCTCCCGCCTGTAATGCTCGCACTTTGGGAGGCCAAGGCAGGAGG
ATCACTTGAAGTCAGGAGTTCGAGAGCAGCCTGGCCAATATGGCAAAACTCCACCTCTACCAAAATACAA
AAAAATTAACCGTGTGTGGTGGCACGTGCCTGTACTCCTAGCTACTCGGGAGGCCGAGACAAGAGAATTG
CTTCAACCTGGGATGCTGAGGTTGCAGTGAGCTTGAACCCGAGAGGCGGAGGTTGCACTCCAGCCTGGGC
AACAGAGCAAGACTATATCTTTAAAAAAAAAAAAAAAAGAGGCTCAGTGGGTCGGGCATGGTGGCTCATG
CCATTAATCCCAGCACTTTGGGTGGCCAAGGCGGGACGATGGCTTGAGGCCTGGAGTTCACGACCAGCCT
GAGCAACATAGTGAGACGCCCCCATCTCTATGTGTCCACAGGAAAATTAAAAATTCGCTGGGCTTGGTGG
TGCGCACCTATAGTCCCAGGTACTTGGGAGGTGAGGTGAAGGATTGCTTGAGCCAAGGAATTTGGGGCTG
CAGTGAACTATGATGGTACCACTGCACTCCAGCCTGGGTGACAAGAGTGAGACCCTGACTCTAAAAGAAA
TAAATAAGAGGCTAAGTAGACAGGCCGTGGGGCTGATGAACAGTGGGAGGGGTGAGACCCCATATTCTGC
CCCAGATGACTAGGTTCCTACCTCATAGTAGACACCATTGTGGTAGCAGCCACATTGCTGGATGGGCACG
CAGGCTTGGCCGTTGTAGAGGAAGCCGGAGTCACACTGGCAGCCCTCAGCACACCCATCTGGGCACTGCA
GAGGGGCACTGAGAGCCGAGCAGCCCAGGGAGCAGGTGTCCGCACAGAGCTCGTAGTGACTGTTCTGAGG
GCATTCCATGGCTGCAAGGAGGGGGTGCCGATCAGAGCCCTGGGGAGGGAGGGGCTGCAAAGCCCAGGGT
CTACCCCTTCTGTGCCTCAAGCTCTCCCCTCCCTGCCCCTCCGGCTCTCCCTCACTCACGACAGAAAGTT
TCATTCCTCCAGGGCTCCACGTGGCCTCCAGCCGCCTGGCAAGCACTCACGTAGGCATGGATGTTGCTGC
AGAGAATGCTCAGGTTCCCACCACCCAGGCAGAGATCAAAGATGCAATCTTTCAAGGGACCCTGGGGATC
CACCAGCTTGTGGCAGGAGGACAGTGGCCCTGTGGGGCTGGAGAGGAGCCCACAGAACTCCTCCTTCTGA
TACTTCTTCTCCAGCTCGGGAGGACACTTGTCGCTGGGGATACAGCCCGCGCTCCCCGGCGGGCAGGTGG
GCGGCGGCAGGCAGGGAGAGTCGGGCACCACCTCCTCCCAGGAGTTGCCGAACTCATTGGCGTTGCCTGC
CTGCGAGCCATTGGGCTTCTGGAAGTCATCCTTGGGGTCGCCGTTGTAGTTCCCACACAGGCCACACATC
AGCTGGTAGTAGTTTCCAGGGACGGTGACCCGCACATAGTACACAAGGTCGTAGGCCACACGCAGGCCGA
AGTCGGTCTCAATCACAACATCTGAACCATGCTGGGAGGCACGGATCTGGCCGTTGGCCAGCACCACGGG
CAGCTTCATGTCCACACCGTTCACCTGGGAGGGGAAGAGAGGCAGGCCACGCTTCAGAAAGTATACTTTG
AGTGAGGGTGGGACCCTAGTTCAAGCCCATGCCTGATGCTGATCTTTGTGACCTCACCTCTTAGGCCCTC
AGTTTCCTATTTATTAAATGGATATAATAACAGGGCCTGATAGTAGATTGAATGGTGGTCCCCAAAAGAC
ATATTCACACAGAATCCCATAGCGTGAGCTTACTCGGAATAAAGTTCTTTGCAGATGTAATCAGGGTAAT
AATCTCAACATGAGATTATCCTGGATTAAATTGGGCCTTAAATCCAATGACTAGTATCCTTATAAGAGCC
AGAAAGAAAAAGGCAAAGAGACACACAGAAAAGGCCACATGAAGATGAAGGCAGGGATTAGAATGGTGTT
GTCACAAGCCCAGAGAACCTGGAGTCTGCAGAGCTGGAAAGGGAAAGGAAGATCCCCCAACCAGTGTCTT
TGGAGGGGGTGCAGCCCTGCCCACACCTTGATGTTGAACTTCTGGCACCCAGGACTGTGGAACATACATT
TCTAGTGTTTTAAGCCACCAAGCTCGTGGTAATTTGTTATGGCAGCCATGGGAAACGAATACAGGTCTCG
ATGAAGTAACAAGCCTCCAGCTATCCTTTGTTTACCGCTTGCTGCAGCCATTAATAAGCAATGATCGCCC
CCGGAGCCACTTGCCCGAGTTCAAACAGTTTCCCCCTTACCCTCTTTGTGACCTTGGGCAAGTGAGTCAC
CTCTCCCTGTTTCTGTTTCCTCATCTATCAAGTGGGAATAAGGCGTTTGCCCCATGGAACTGTTGTCAGG
ATCACATAAATTAGTATCTGTAAAGTGCTGAGAAACGTGGCTGGCATAGCATGCATGCTTCAGGAGCATT
TGCTGTTATTAGCAGCTATGAGTGGAAGTTTTTCTTCTGAAGAGTAAACAGAACCACAGGTTTTTGCTTT
AAAGCATCAGCGAGTGGAAAGTTAGGCTAAATTCTTGGGGAAATGAACTTAAACCTATGAGCTGAGGACC
AGTGGTTTCAGTTAAAGATTTACTAGGCTCCAACAAAGCCTGGTAAATCCACCCCTGGACAGGGCACAGT
GGCTCATGTCTATAATCCCAGCACTTTGAGAGGCCAAGGCGGGAAGATCACTTGAGCCCAGGAGTTCAAG
GTCAGCCTAAGCAATATATCGAGATCCTGTCTCTACAAAATAAAAAAGAAAACAAATTAACTGGGCATGG
TGGTGCATGCCTGTACTCCCAGCCACTCAGGAGGCTGAAGTGGTAGGATTGCTTGAGAGCAGGAGTTTGA
GGCTGCAGTGAGCTAGGATCACACCACTGCACTCCAGCCTTGGTGATAGAGCAAGACCCTGTCTCTAAAA
AATAAATAAATACATCAACCCCTGATTAACATGCTTTCTTACCCTTCCTTATCACAGACAGTGCACACCG
GATTCTTTTGGAAATGTGAAGAATCAGAGGAGAAGGCAGGAGAAAGACATGCTCCTGGCTGAGTCTCCTA
AAAAGATGGTCAACTGCCACACTTCCCAAGCAGGGCTGGGCGGTGGGTAAGGGCAACTGACTTAGCCTTG
CCTCAGTTTCCTCAGCTGTAAACTGCGGGGTAATAAGAGCTCCCACATCTGTAGGGAAGCTGGGGGTTTC
AGTAAGAAGCAACTAACAAGAACATCAACAACTCCTGTGTATTTAGGCGCTGTATGTCAGGGGCTATTCT
AGGAGCTTGGGAAACATTAGGGAATATATTCAATTAAGTCCTGCATGTCGGCCGGGCACAGTGGCTCATG
CCTCTATTCCCAGCACTTTGGGAGGCTGAGGCCGGCAGATCACTGAGCTCAGGAGTTGGAGACCAGACTG
GCCAACATGGTGAAACCCGTCCCCACTAAAAATACAAAAATTTCCTGGGCATAGTGTTGCACACCTGTAA
TCCCAGCTACTCTGGAGGCTGAGGCAGGAGAATCACTTGAACCAGGGAGGCAGAGGTTGCAGTGAGCCGA
GATCGCGCCACTGCACTCCAGCCTGGGTGACAAAGCCAGACTCTGTGCCAAAAAAAAAAAAAAAAAAGTC
ACGCCTGTCCAGTTCGCCAGATTAAGTCAGTAATTGATCAGCACCTTCGCCAATACTGCCACTAGAAAAA
CAGCTGCGTGTCTGTTTCAGTGGGATCTCAGGGGAAACCCCTCCACTGTAACTCAGATGCCAGTCTCCAC
ATGAGACCAAATCTTCTCAGTAAGAAAAGCACTGCAGAGCAGCACGGGGTTCAAGCTCCACCTTTGCTGG
GGGACTATGGGCCAGTGATGGGCCATCCCACTCTGAAAAATAAAGCAAGTCATAGTGCCTGCAGTCCCTG
TTGCAAGCATACAGACACCATGGACGTGAAGTGCCTGGCAGCCAAAAGGTGTGCAGTCAGCTGTATAGAA
ACTATAGCTGCTGTTGTTGTTGTTAAGGCGGTGAGAGTGTCACCCACAGATTGTCCTCTGTCCATGAAGC
TTCTCAAACTCGGACTTTCTCAACCTCTGATGGCACCACGTCCTGCCAATAAGTGGCAGACTAGGGAGGT
GAGTAGGGCAGAATCCAGGACTGAGGTGGAGAGAGGATGGAGTGGGAGGGAGGAGAGGGTGGGAGAAATT
TGGAGAGAAAAGTCAATGCATGGAGGTAAAGAGAGGGTGGAGACTGAGGGACAGAGATGGGGGAGCAGCT
CCCAAGTCCCTGATGACACCTCCCTCATTGGCTTCCCACTCGGTTCTGACTGGCATCTTCTGTCCTCAGA
GACCCCAGGCCTCGCACATGCACTCTCATCTCTTGTGCCCCCAACTCCTGGGCTGAGCGCTGCCTGTGCC
CCACCTACCCACAGGCCCCTCGCCCCCTGCTCCCCATCTGCTCTCACCGTGACCTTCCACTGTCTCTGCT
CCAGCCGCAGGGTGAAGTTTGCCACCTGGACCGTGATCACCCTGGTCACACTGACTCGCCCATTACCCCA
GGCCACGTTCTCCTGCAGGACGGCAAACCGATGCAGGCCAGGCCGGGTGCCGCAGGTCTGAGCCAGCACA
TACACGCAGGTGCCCATGAAGTCGAAGCGGTGGCCATCGAAGGTGGTGTAGTGGGGATCTCCCGACGCCT
GGCAGGTGGTAGAGCCCACGGCCACGCAGCCCAAGCTGCCACCGGATGGCCGGCAGGTCTCATGCGGGCC
GCAGCTGGAGGGCTCACAGGACACCTCACCGCCCTCCCGGCAGCGGCAAAGGGAATCACACCCAGGGCCA
GGGTAGAAGGTCTGGCCCAGTGGGTAGTAGCGGTCATCGTGGAGGCAGCCACACTGGCCCACAGGTACAC
ACGTGTCACCACTGAGCACGAAGCCAGCATCGCAGACACAGCCTTCACGGCAGGCCGACTCACAGCCCTC
GGGTGCCGACAGGCTCGGGCAGCTCCCAGGACAGGAGTCACCGCAGAGCTCGTAGTGGCTGTGGGCAGGG
CACTGGAAGGCTGTGGGGACAAGGTGGGCATCAGCCAGGTAGGTGTTTGAGTCGCAGTCTTGGGAGGCCC
TGAGTGGGAAAACTGCTCAGGCCAACTTGGGCGTCTCTGGGCATGCACATGTGATCCAGGACATCTAACT
GGGGGACTCAGCGTGGGACCTGGAATGGGAGGGGACATGCCCAGGTCTCTCTGACCAAATATTTCTGAAG
ATCAAATGACTCTGCTTGGCTGATATTTTTTTTTTTTTTTTTTTTGAGACAGGCTCTCACTCTATCTCAC
CCAGGCTGGAGTGCAGAGGCGCAATCACAGCTCGCTGCAGCCTCCACCTAAACCTCAAGCAATCCTCTGG
CCTCAGCCTCCCGATTAGCTGGGACTACAGGAGTAAGCCACCACATCTGGCTGATTTATTATTATTTTCT
GTAGAGATGGGGTCTCACTATGTAAGCCAGGCTTACCTGGGTGAAATGGATCACTTATATCTATTCGGGG
TATGCAGGATCAGAACTGACTATGGGCATCTCAGCGTGTGAATGTGACTGGGGTGTGGGGCCACATGTAT
CTCAGGGTATGGCTCTGCCTGAGGGCACCCAGCTGTGGGTGTCTGACATGCAGCATCTCCCAGAGTCCTT
CTGACATGGTCTGCCTAAGGCTGTGCCTGGGTGAAGTTGGCAGGATACCTGTGACCAGGAGACCTGCCTG
AAGGGAACCGCCTAGGACTATCTAACTATGCATCTGTGTGGATCTGCCCAAGGCTATGCCAGGATCCTGT
TTCTTTCTGAGTGTATCTGACCAGTCAGTATAAAATTTAAGCAGATATCACTGAAGGTATGCGACTAATT
CCATGTGACTAGGTGTATTTCAGTGTGTGCAACAGACCTGGGCCCTCTGACCAGCTGAAACTCACTAGGT
CTTCCTAACAAGGGGTACTTTGCTATGTGACAGAGGCAGGGTCAGCCATCCCAATCTACATGCCTTGGAT
ACCTGAAAGCATGGATCACCAATCCCTAAGAGTGTCCTGGACCCCAGGTTTCTTTTCTTTCTTTTTTTTT
TTCTGTTGTTTGTTGTTTGTTTGTTTTTTGTTTTGGAGATGGAATCTCTGTCACCCAGGCTGAAGGGCAG
TGGCACGATCTCGGCTCACTGCAACCTCTGCCTCCTGGGTTCAAGTGATTCTCCTGCCTCAGCCTCCTGA
GTAGCTGAGATTACAGGTGCCCGCCACCACGCCCGGATAATTTTTGTAGTTTTAGTAGAGGTGGGGTTTC
ACCATGTTGGCCGGGCTAGTCTCGACCTCCTGACCTCAGGTGATCCGCCCGCCTCGGCCTCCCAAATTGC
TGGGATTACAGGCGTGAGCCACCGCGCCCACACTCTGACTAGGTGTTTCTAACTGACTCTCTCTCACTGC
AGTACCTGACTTGGGGCATTTCAGTGTGTCAGTGCCAAGGTGTTTCCTGACAGTAGATACCGAGCTCGGG
AAGGAAAGTGGCCCCTGAGCCCCATGGAGGAGGAAGGGGCTGCTGTCCTACAGTCCTGGGAAGGGCAGGG
AGAGACCCAACCATGTGGACCATGCATGGAGCAGTACTCACGACAGAAGTCCGGCCGCCTCCACTCGCGG
AGCTGGGCCCCAGCGGCCTGACAGGCTGCCACGTAGGTGGCCACTGCAGGACAGAGGCCTCCAGGATGGC
CCTGAACTTGGCAGGCGTCCAGCAAGCAGCCCTGGAAGTACTGCGCGGGCGGCACAAGGCCGTGGCAGGG
CGCCAGCGGGCCGTCGGTGGCGGAGATCACGCCGCAGGCGTCCGGGCCGCCGAAGGACTCTTGCTGCTCT
GGGGTGCACGGCGACGGGCATGGCTTGGACACACATTCCCCGCAGCCCTGGGCGCCGCCCACCTGCCATC
CGGCGGGCTTCCCGCCCACCGCCTTCAGGTCGTCTGCGGGGTCCTGGTTGTAGTTCCCGCATAAGCCACA
GAGAGAGCCCGCGTACGCCGCCGGCACGCGCAGGCGCACGAAGCTGTCCCCATCGAAAGCCAGCGAGAGC
CCTGAGGTTGTGGTCACCACCACGTCGGCGCCGCTCAGGTGTGCGTGCAGGAGCGAGTCCAGCTGGAAGG
GCAGAGTGACGAACACGCCGTCCACCTGTGGGCAGTGGGGGAGCGGTGAACGGAGCAAACACGGGTTTGA
ATCCTGGCCCCACTACCTACTAGCTGTGGGACCCAGAGCATGTCACCTCCCGCTGAAAATAATAATGAGC
ATCTATAGGCCGGGCCTGGTGGCAAAGCCTGCAATCCCAGGACTTTGGAAGGCCGAGATGGGAGGATCGC
TTGACGCCAGAAGTTCAGATCAGCCTGGGCAACATAGTGAGACCCCCATCTCTACAAAAAAATGAAAAAT
TAGCCAGCGTGGTGGCGTGTGCCTTTAGTCACAGATACTTGGGAGGTGGAGGCCAAGGCGGGAGGATCGA
TTCAGCCCACGAGTTCCAGGCTGCAGTGAGCCCTAATCCTGTCACTGCGCTCCAGCCTGGGCAACAGAGT
CAGGCTAAGAAAAGAAAGAAAGAAAGAAAGAAAAGCAAGAAAGAAAAAAAGAAAAGAAAAACAAAGAGCC
TCTACTGGCTCATGTCACTGACTCCTTATCCTTCTCGAAAACAGGTACTTTTCCTAGACCAGTTTACAGA
GGAATACACTAGGCTCACAGAGGAAGAAGCTGCTGTGCCAAGCCATCAGGCTCCTAGGCGTACACTCTGA
CCCTTCCATCATGCCCCAGCTAAGCTGTGAAAGGGGCCCAGGGGAATGGTGAAGCCCTTACCATCTCAGG
CAACCCCAGAGCTGGCACTTGCTCCTGTCTGGCCCACAGCCCTCCTCACCTGTAGCTTCCGGGGCCAGCG
GGCACTCAGTGTCAGGCTGTGGTTGTAGATTTGCAGGGTGACACTGCGGGTGTAGCTGACAGCCTGGCTG
CCCCGGTGCTCATTGGCTACAGTGACAGTGAAGTTCTCAGCCCCCAAGGGTGGTCCGTGGCAGGGTGCAC
TCAGCAGGTACTCGCAGGTGCCTTGGAAATCGAATCGGTGCCCATCCAGAGTGACGTAATGGGGGTCACC
CCACGCCTGGCACTCAGCTGTGCTGACGGGCTGGCAGCCGTGCTGGCCGGATGGCAGGAGGCCACACACT
TCACCCAGCCCACAGCTGGCAGGTGTGCAGACCAGCGAGCCACCCCCAGGCCCGCAGCGACACCACTGGG
AGCAGGTGCCATCAGCCCAAAACTCACTGCCCGCCTCGTGGTAGGTGCCATTGGCCCAGCAGCCGCAGCC
GTTGTTGAGGGGAACACAGCGGTCAGCACTTAACACGAAACCCGCGTCGCACTGGCAGCCCTCCACACAG
GGGCCCTCACATACGGCTGGCGTCGTAAGGGGTGCAGGGGACGGACAGCTGGCCGGGCAGGGTGGGCCAC
AGACCTCATAGTGGCTGTTTTCTGGGCAGGTGATCTCTGTGGGCAGATGAAGGAGCAGGAAGGAGAGAAA
CAGAAAGAAGGGTGTTAGGGGTGGGGTCCCAGAACAGGGTGGGAGGAGACAGAGAGAGACACTAGGGAGC
AGACAGAGAAAGGGGGAGACAGAAAACAAGACACAGAGAGAGGACACAGAGAAAGAAATGGGAGAGGGCG
AGACACCAGGAGACCCAAGCAGAAACTGAGGGAGCTAGAGAATGAGAAACAGACAGATAGAGACAAGCAA
AGCGAGGCCCAGAGACGAGCACCAAGAAACAGAGAGACAAACAGAGAAAAAAGAAAACAAAGAGACCCAG
AAGGACCAGAGTGAAACCAAACCAGCCCCGAAGAGATGGGACCCCGCCCCCAGCCCCGCCTCTGCTCCCC
CAACACTCACCACAGCCAACCTGTGCCCGCCAGTCTTCGATGACAACCCCAGCAGCCTGGCAGGCGGCCA
CATAGGAAGCCAGAGCCTTGCAAAGAATGTCACGGTCCCCACCACCCATGCAGACGTCCAGAACACAGCC
CTTGAAGAAGCTCTCAGGTGGCACATGAGCATGGCAGGTGGTGAAAGGGCCCCCTGTGCCGGGGGCCAGG
GGTCCGCAGAAGCCAGGGCCCTCGTACTGCTCCAACCGGTCCTCAGGGCACGTTGGGCAGGACCCCCGAC
ATTCGTCCCAACACAGTGGGTCCCAGCCTGGGGCTCGCCAGCTGCCGCCCCAGATGGGTATGGAGGGAGC
CAGTGTGCCATTAGGGAAGACCTGGTCATTGTTGGGGTTGCGGTCCATGTTACCGCAGAGCCCGCACACT
GCGCCATGATAGCTGCTGGGCAGCGTCACGTCTACCCGCCAGTTCCAGTCATAGCTGACTTGCAGTCCAA
AGTCAGCCACCAGCAGTGCCTTCGATGCACCCTGGGTCACTGAAATCCGCCCGTCGGCCACAGAGACAGG
CAAGGCTGTGAGCACACCGTTCACCTGGGGGAAGGAGGGAAGGCAAACGGGTCACTGGAGGTTTTACGGC
CCCAGCTCTGGCCCTCTGCCTCCCTCTCTCTCATCCCACCGGGGGCTGGGAGAGGCCAGGGCCTTCCCCC
GAGAGTTGGATTGTCATCTGACACACTGTGGACAGTTGTTCTAGCCCAGGTCTTGGGGAACGAAACCTCA
CTTTACTTTTTCTAGATCTTCTCCCTTCATCTCTATCTCCCTCCCCTGTCTCTGTCTCTCTCTCTGTGTC
TCTCTCCCTCTGTCTTCACCTAAGGCTATGCCTCTGGGTCTTCTCTCTCTCTGTCTCTGTCTCTCTCTCT
CTCTTTCTGTCTCTCTGTCTCTGTCTCACCCTTTTCCCTTCCTCCCTACCTCCCTCATTCTTTGTGCATC
TCTTCCACTCACTCACCATCATTTATTCAGTGCCTACTCTGCTGCATCCCTCAGTCTCTCCATGTGAGCT
GCCATCAAGCTACATCTCCATTTCCTTGGGCAGAAAGGATAGCCCATTCCTCTCCCCCATCTCCCTATAT
TTCTTTTTCTTGATTACTTTTTTTATTTTTCAGACGGAGTCTCACTATGTCACCGAGGCTTGTGTGCAGT
GTTGCAGTCTCGGCTCTTGTAACCTCTGCCTCCCAGGTTCAAGCAATTCTCCTGCCTCAGTGTCCTGAGT
AGCTGAGAATTCAGGAGCATCACCACACCCAGCTAATTTTTGTATTTTTAGTAGAGACGGAATTTCACCA
TGTTAGCCAGGCTTGTCTCGAACTCCTGACCTCAGATGATCCATCGGCCTCGGTCTCCCAGAGTGCTGGG
ATTACAGGCGTGAGCCACCGGGCCCAGCCCAGTCTCCCTGTATTTCTCTCCATGTCCTGGTCTCTGGGCC
TCTCACTTTTCCCTCACCGACACTCAAACGACTGTTCACCTGGACTAGACTCTGAGCTCAGCATGTGACA
TGCACGGCCTTGCTGTGGGGGAGGCCCTGATACGATGCCCACTTCACAGATGAGGAAACTGAGGCCTACC
AAGTGAACTGCCCAGCATCACATAGCTCATAAGGAGGAGAGGCTGGATTGAAACCCAGGTCTATAAAAAA
GGCAAATGCTGAGGTCCTATGTTAAAGCCCTTTGCCAGGGGCTAGGCTCATTTAATTCCCAGTAACAGGG
TGATATTTTTGTTGCAATTATTCTCTTTGTTGACAGTTTGTTTCAGGCCCAGGTGAAGACAAAGAGCCTT
GAGCTGCTAACTGTGGTCGTCAGGATCCCTCCTGCCCTCCCGGGGACCTCAGGGGACCATCCTGCCACAC
ATACCCGGACTTTGCCGATCTCGTCCTTGTGGATGGAGATGTTGGTGCCGAGGGCAGCCACGGTGACGAC
TCTCACGTAGGACACAGCAGGGTTGCCCCGGTTCTGGTTCTTGGTGGTGACGGTGAAGGGTGTCAGGCCC
TGGGTGCTGACCCCCGGGCAGCCAGTTGTTGCCAGCACATAGTTACAGGTGCCCTGGAAGTCAAACTTCC
GGCCATCGAAGGAGTGGTAGTGTGGGTCGCCCCACAGCCAGCACGTGGCCTCATAGTTGGGCAGGCACAC
GCCCTGGCCACCCTGCTCCTTGCATGTCTCCTGTGGCCGGCATGTCACGCCGTGGCACGGGTCTGGGGAC
AGAAGAGGGAGGAGGACCTTGAGGGGCTGCCCATTGTAAAGCATGGCCGCTCCCTCCACATCTACCCAGT
CTGTGCCAGGGATCTGAGGGTTACTGCAGGCAAGACCACATTACAGAGTCCTCATGTCTAGGACCCACTT
CCTATAGTTTGCTTTTACATTTTCTTTTGTTTTGTTGTTTTTTTGAGATGGAGTCTTTCTCTGTCACCCA
GGCTGGAGAGCAATGGTACAATCTCGGCTCACTGCAACCTCTGCCTCCTGGGCTCCAGTGATTCTCCTGA
CTCAGCCTCCTGAGTGGCTGGGATTATAGGTGCCCACCAGCATGCTTGGCTGATTTTTGTATTTTTAGTA
GAGACAGGGTTTCACCATGTTGGCCAGGCTGGTCTCGGGCTCCTGACATCAAGTGATCAGCCAACCTTGG
CCTCCCAGAGTGTTGGGATTACAGGCATGAGCCATCATGCCCAGCCTGCTATTTTCAAGACCAGCCCCTG
GGAGTCCCACACAGCTGACACTGAGGCCCCATGGGGGACTGTGTCTAAGTCTCGGCTGTCAAAGGTCCCA
TACCTGAGACCTGGGCCCCAGAGGTCTGTACAGCCAAGACCCAGTACCTAGAGTTCCCCTACTTCTGAGA
CTGAGGCCCTGCCATTTGCTGTGTGAGACTGAGATCCTGGAGTCCACGCACCTAAGACCAAGGTAAAGAC
CAAGGCTCTGGGTCTGTGTTTAAGGTGCACTTTCCATGGTGCCCTTGCTTGAGATTTCACCCTGTTCTTG
TATTTTAAGTTTTATAGGAACCTCACCGTCTTCACTTACATAGGCTACGGCTGCTTTCACACCACAGTGG
CAGAGTGAGTAGTTGTGATCCAGAAGGTATAGCCTGCAAGCTTAAACACTTACCATCTAGCCCTTTAGAG
AAAAGGTGCACTTGACCCCAGTTGAGATCTGTGCCCCAGGGGTCCTTGTGTCTGCGATGCCAGCCCTGAG
AGCATCCATGTCTGAGATCCCAGCCCCAGGGTTCTCTGTGTTCAAGACCTGGGCCCCAGGCCAGGTGTGG
TGGCTCAGGCCTGTAATCCCAGCACTTTAAGAGGCTGAGGTGGGAGGATAGCTTGAGCCCTGGAGTTTGA
GACTAGCCTGGGCAACATAGTAAGACCCCATTTCTACAGAAAGATTAATAAATTAGCCAGGCGTGGTGGT
GTGTGCCTGTAGTCCCCCACTACTCGGGAGGCTGAGGCGGGAGGATTGTTTGAGCCCAGGAAATCGAGGC
TGCAGTAAGCTACACTACACTCTAGCCTGGGCCACAGAGTGAGACCTTAGCTCAAAAAAAAAAAAAAGAT
CTAGGTCTCAGGGTCCCCCATGCCTGAGACCTCAGCCCCCTGGACATCTCCACATTTGATAGAAATTGGT
CTCCAATTTCTCTAGGTCCTGGAGGCCTCTGTGCCCAAGACTAGGGCCCTGGGGTGATCTTCTGGCAAGA
GCCCAGTGCCAGGGTCTCAGCAGGATTTGAAATGTTTGAGACCCTAACTAGCTAAGTCTCATGGGCTGGG
CTCCCTCAGTGCAAGACTCCATCCCTGAGGGTTGCTGTATTCAAGACAGTAGCCTTGATCGTGTCTCACT
GCTGAGGCCCTGTCCTGGGGGGTTTCTGTGTCCGAGACCCTGTTCGTACAGTTACTACATCTGTGACCCC
AGCTTGCGGAACCCCTGTGTGGGAGAGGCCAGCCTTCAAACGTCTCCTTCCTCCTGTGTCCATTATCTAT
GTACCGCCTCTCAGCTTCAAATACACCCACGGAGTTAAGCTTTGTCAACAGAGGGCGCCGGAGAGTCACT
GCAGGAGGGACGGTCTCCTGGTCTGGCTTCTAGCCAGTTTGGTCCTTCCAGCTCTGGCCAGGGTGCGGGG
CCACATTCAGCGAGTGCCACTGGCCGCAGCTGGCTTCCCAGTGAGGGGTTCCCTTCTTGCCAAGTCCAGC
CTGCAGAAACCTCTGTGCCACCCAGTGGGCTACAGCTGCAGTGAGACTGGACTCAGCCTTGGGGCTGATT
CTCCCCTCCTTGAAGAGTAGGGGCCAATTTCTCCCTTCCATGAGGCTTTTACCTTAGCCCTAGAGTGGCG
GCTACTTCCTGTGTGTGCTTTGGTGGTATTCTTTAGTGCTCTCTTTACCGTTTCTTATTTCTGTTTATTT
GTTTGTTTGTAAAGAGACAAGGTCTTGCTGTCTTGCCCACGCTAGAGAGCAGTGGTGCAATCATATAGCT
CACTGCAGCCTCGAAATCCTGGGGTCAACTGATCCTCCTACCTCAGCATCCTAAATAGCTGGGACCACGG
GCACGCATCACCACACCTGGCTAATTTTCAATTTTTTGTGGAGACAGGGGTCTCGCTATGTTGCCCAGGC
TGGTCTCAAACTCCTGGCCTCAAGTGATCCTCCCAAAGTTCTGGGTGTGTGAGCCACGGCACCAGACCCT
CTTTACCCTTAATAGTTAATCTCCTATTAATAAGTAAGTGATTCTTTAATTAAACTTTCCTCATTCAAAT
GGCCATACGCTTTCTGTCTCTCGACTAGATGCTGAGTGATATACCCCCCATTTCTGGGAGTCCCCATTAT
CCTGCTCATCAGCCCTGAGAGTCTTAGCCCCCACTCCTTGGTGCTGGAGCTCCCATTCTCTTATCCTTAG
GGGGAGGAGAGTTCTCTGCTCTTCACCCTAAGAAATGAGCCCTGGGGGTGGCTGTGTCCCAGATTTAGTC
TGGGGGATTCCCACATCAGAGACTATACCCCCAGAAATCCTGATCTTCCAGTTAAGAGGGGTCCCCATAT
CCAATGTCCTGCCTTGGTGAGGTCTCCGTGCGTGAGACTCAGAACTCTGCTCTCTGTCCCTGCCCCTGGG
ATCCCAGTCTCTCCCCTGCCCTTTGGTGCTAGTGTCTGAACCCCAAGTCCAATCCCACACATCAGTGTTC
CGCTCATGATGGCCCCCTAGGCTGCTGCTCTTGTATTCTAAAGTCTTATAGGAGCCTGACCTCTTCACTT
ACATAGTCTACGGCTGCTTTCATGCCACAGTGGCAGAGTGAGTAGCTGGAACGAGAACCTACAGCCTGCG
AGCTTAAACATTTACCATGTAGCACATTAGAGCAAAGGCGCGCCTGTCCCTGCCTTATACCGAGGGTCTC
TGACATCCACCCTGAGAAAACTATCTCTGAGGGTCCCCACAGCCTGGATTTTCCCTAAGGGTCCCTACCT
CCCAAAGTAGGTGGCCCTGGCCCTGTGAAACCTGGTCTAGGGTTCCCCAGGTCTGCAACCTCAATCATTA
GTCCTGTACACCTCCCGCCATGGACACCCCAGTTACACTACCCTCAGCCCCAGAGTCCCCATCCTCCATC
CCTAGTCCCATCAGCCCCAGTCCCAGCCCAGCCCAGCCCAGCACCTTTGGTGACGCAGCTCAGGATGCCT
CCGGAGGGCTGGCACACCTGCCCCGGCTTGCAGCTGTGTTCCTGGCACACCACGACTTTACCCGCATGGC
ACGTGCACTGCTGCCGACAGTTGTCAATGAGGACTGTCTGCTCCGGCTGTGGGGAGAGAGGGAACGGCCA
TCAGGGACACCACGGGTGGGAGCCGACTCTCACATCTCTGGCGTTCTGGCACAGAGGGGTTTGGCAGACA
TCACAGACAAGGGACATCTCTCAGCAGGATGGCCCCTTGTCTGTGAAGCTGAGGCACAGCATGGCTTTGG
GGCCATCATTCATTGGTTCATTCACTTTTCTTCATTTACTCATTCATTCCAAAATATCCACTCAACGTCT
GCTGTAGGAGAAATGGTGTGACACAGTAACTAAGGGCAGATCGCCTGGGCTTGAAGCCCGTTTCTGCTGT
TTCCAAAGTGTGTGACTCTGGGCAGTTACTTCACCTCTTTATGGCTCAGTTTCATGATCTGCAGATTGCA
GATGATAGTAGCGCCTGCCTTTGGAAATATAACTGAGTTATATTCAGATAATAACCAAGTTATATTCAGA
TAATAACCAAGTTATATTCAGACATGTAAAATTCAGATAAAATGAAAAGGGTAGGCCGGGCGCGGTGGCA
CATGCTTGTAATCCCAGCACTTTGGGAAGCCGAGGCGGGTGGATCACGAGGTCAGAAGATTGAGACCATC
CTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGTCGGGCGTGGTGGCGGGCGCC
TATAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGTGTGAACTCGGGAGGCGGAGCTTGCAGTGA
GGCAAAACTGCGCCACTGCACTCCAGCCTGAGTGACAGAGCGAGACCCCATCTCAAGGAAAAAAAAAAAC
AAAAACAGAAAAGGGTTTCCTTTAAAACATTCAGATAGGAGAGATACGTGGGGTAGACATCAAACAAGAT
CGGGAGAATATGGCTTATTTTTGAAGCTAAGTGATGGGTAAGTACATGGACAGTCATTCCACTATTCTCT
TAATTTTTGCATGTTTGAACGTTTTCAGAATAAAAAGTTTTTAGATATGTAATGCATATATAAAAATATG
CACACATAGCACTTAAAACGGTACCAGATACATAGTAAGCACTATCTACACATTTTCTGTTATTATTAAT
ATTATTTATGTGAGGAGAACAACAGAGAGAGGGTTCCACCCCTAGGAGAGCTCACAGTCCCCAAGGGAGA
TGGACATTAGACAAACACATGCTCCAGTCAAAGAAAAAGGACCTACGGGGACAGAGTGGGAGAGGGAAGT
AGAGGGTGTTAGCAGCTGGTATAACACATGGAAATCTTGTCTTTGTGGTCAGAAAGGCTCCCTTCGTCCA
GACCTGGAAGGCAAAGCCACAACTTGACCTGGGGAGTCAGGGGAGGGTTTAAAGCTTCAGAGCCCGTGGT
CATATTTAGAAAGATCTTTACCACTGCCACGTGGAGGGTGGACCAGAGGGAGCAGAGGTAGGAGCTGGGA
GGGACCCAGGTAGGAGAGGACCAGCTGGACCAAGGGAGGGCCATGGGGACAGGGAAAGGAGTGGGTACAA
GAGACACTGAAGAGACTGAGTGGACTAGCTGTGGTGGCTCCCGCCTGTAATGCTCGCACTTTGGGAGGCC
AAGGCAGGAGGATCACTTGAAGTCAGGAGTTCGAGAGCAGCCTGGCCAATATGGCAAAACTCCACCTCTA
CCAAAATACAAAAAAATTAACCGTGTGTGGTGGCACGTGCCTGTACTCCTAGCTACTCGGGAGGCCGAGA
CAAGAGAATTGCTTCAACCTGGGATGCTGAGGTTGCAGTGAGCTTGAACCCGAGAGGCGGAGGTTGCACT
CCAGCCTGGGCAACAGAGCAAGACTATATCTTTAAAAAAAAAAAAAAAAAGAGGCTCAGTGGGTCGGGCA
TGGTGGCTCATGCCATTAATCCCAGCACTTTGGGTGGCCAAGGCGGGACGATGGCTTGAGGCCTGGAGTT
CACGACCAGCCTGAGCAACATAGTGAGACGCCCCCATCTCTATGTGTCCACAGGAAAATTAAAAATTCGC
TGGGCTTGGTGGTGCGCACCTATAGTCCCAGGTACGTGGGAGGTGAGGTGAAGGATTGCTTGAGCCAAGG
AATTTGGGGCTGCAGTGAACTATGATGGTACCACTGCACTCCAGCCTGGGTGACAAGAGTGAGACCCTGA
CTCTAAAAGAAATAAATAAGAGGCTAAGTAGACAGGCCGTGGGGCTGATGAGCAGTGGGAGGGGTGAGAC
CCCATATTCTGCCCCAGATGACTAGGTTCCTACCTCATAGTAGGCACCATTGTGGTAGCAGCCACATTGC
TGGATGGGCACGCAGGCTTGGCCGTTGTAGAGGAAGCCGGAGTCACACTGGCAGCCCTCAGCACACCCAT
CTGGGCACTGCAGAGGGGCACTGAGAGCCGAGCAGCCCAGGGAGCAGGTGTCCGCACAGAGCTCGTAGTG
ACTGTTCTGAGGGCATTCCATGGCTGCAAGGAGGGGGTGCCGATCAGAGCCCTGGGGAGGGAGGGGCTGC
AAGGCCCAGGGTCTACCCCTTCTGTGCCTCAAGCTCTCCCCTCCCTGCCCCTCCGGCTCTCCCTCACTCA
CGACAGAAAGTTTCATTCCTCCAGGGCTCCACGTGGCCTCCAGCCACCTGGCAAGCACTCACGTAGGCAT
GGATGTTGCTGCAGAGAATGCTCAGGTTCCCACCACCCAGGCAGAGATCAAAGATGCAATCTTTCAAGGG
ACCCTGGGGATCCACCAGCTTGTGGCAGGAGGACAGTGGCCCTGTGGGGCTGGAGAGGAGCCCACAGAAC
TCCTCCTTCTGATACTTCTTCTCCAGCTCGGGAGGACACTCCTCGCTGGGGATACAGCCCTCGCTCCCCG
GCGGGCAGGTGGGCGGCGGCAGGCAGGGAGAGTCGGACACCACCTCCTCCCAGGAGTTGCCGAACTCATT
GGCGTTGCCTGCCTGCGAGCCATTGGGCTTCTGGAAGTCATCCTTGGGGTCGCCATTGTAGTTCCCACAC
AGGCCACACATCAGCTGGTAGTAGTTTCCAGGGACGGTGACCCGCACATAGTACACAAGGTCGTAGGCCA
CACGCAGGCCGAAGTCGGTCTCAATCACAACATCTGAACCATGCTGGGAGGCACGGATCTGGCCGTTGGC
CAGCACCACGGGCAGCTTCATGTCCACACCGTTCACCTGGGAGGGGAAGAGAGGCAGGCCACGCTTCAGA
AAGTATACTTTGAGTGAGGGTGGGACCCTAGTTCAAGCCCATGCCTGATGCTGATCTTTGTGACCTCACC
TCTTAGGCCCTCAGTTTCCTATTTATTAAATGGATATAATAACAGGGCCTGATAGTAGATTGAATGGTGG
TCCCCAAAAGACATATTCACCCAGAATCCCATAGCGTGAGCTTACTCGGAATAAAGTTCTTTGCAGATGT
AATCAGGGTAATAATCTCAACATGAGATTATCCTGGATTAAATTGGGCCTTAAATCCAATGACTAGTATC
CTTATAAGAGCCAGAAAGAAAAAGGCAAAGAGACACACAGAAAAAGCCACATGAAGATGAAGGCAGGGAT
TAGAATGGTGTTGTCACAAGCCCAGAGAACCTGGAGTCTGCAGAGCTGGAAAGGGAAAGGAAGATCCCCC
AACCAGTGTCTTTGGAGGGGGTGCAGCCCTGCCCACACCTTGATGTTGAACTTCTGGCACCCAGGACTGT
GGAACATACATTTCTAGTGTTTTAAGCCACCAAGCTCGTGGTAATTTGTTATGGCAGCCATGGGAAACGA
ATACAGGTCTCGATGAAGTAACAAGCCTCCAGCTATCCTTTGTTTACCGCTTGCTGCAGCCATTAATAAG
CAATGATCGCCCCCGGAGCCACTTGCCCGAGTTCAAACAGTTTCCCCCTTACCCTCTTTGTGACCTTGGG
CAAGTGAGTCACCTCTCCCTGTTTCTGTTTCCTCATCTATCAAGTGGGAATAAGGCGTTTGCCCCATGGA
ACTGTTGTCAGGATCACATAAATTAGTATCTGTAAAGTGCTGAGAAACGTGGCTGGCATAGCATGCATGC
TTCAGGAGCATTTGCTGTTATTAGCAGCTATGAGTGGAGGTTTTTCTTCTGAAGAGTAAACAGAACCACA
GGTTTTTGCTTTAAAGCATCAGCGAGTGGAAAGTTAGGCTAAATTCTTGGGGAAATGAACTTAAACCTAT
GAGCTGAGGACCAGTGGTTTCAGTTAAAGATTTACTAGGCTCCAACAAAGCCTGGTAAATCCACCCCTGG
ACAGGGCACAGTGGCTCATGTCTATAATCCCAGCACTTTGAGAGGCCAAGGCGGGAAGATCACTTGAGCC
CAGGAGTTCAAGGTCAGCCTGAGCAATATATCGAGATCCTGTCTCTACAAAATAAAAAAGAAAACAAATT
AACTGGGCATGGTGGTGCATGCCTGTACTCCCAGCCACTCAGGAGGCTGAAGTGGTAGGATTGCTTGAGA
GCAGGAGTTTGAGGCTGCAGTGAGCTAGGATCACACCACTGCACTCCAGCCTTGGTGATAGAGCAAGACC
CTGTCTCTAAAAAATAAATAAATACATCAACCCCTGATTAACATGCTTTCTTACCCTTCCTTATCACAGA
CAGTGCACACCGGATTCTTTTGGAAATGTGAAGAATCAGAGGAGAAGGCAGGAGAAAGACATGCTCCTGG
CTGAGTCTCCTAAAAAGATGGTCAACTGCCACACTTCCCAAGCAGGGCTGGGCGGTGGGTAAGGGCAACT
GACTTAGCCTTGCCTCAGTTTCCTCAGCTGTAAACTGCGGGGTAATAAGAGCTCCCACATCTGTAGGGAA
GCTGGGGGTTTCAGTAAGAAGCAACTAACAAGAACATCAACAACTCCTGTGTATTTAGGCGCTGTATGTC
AGGGGCTATTCTAGGAGCTTGGGAAACATTAGGGAATATATTCAATTAAGTCCTGCATGTCGGCCGGGCA
CAGTGGCTCATGCCTCTATTCCCAGCACTTTGGGAGGCTGAGGCCGGCAGATCACTGAGCTCAGGAGTTG
GAGACCAGACTGGCCAACATGGTGAAACCCGTCCCCACTAAAAATACAAAAATTTCCTGGGCATAGTGTT
GCACACCTGTAATCCCAGCTACTCTGGAGGCTGAGGCAGGAGAATCACTTGAACCAGGGAGGCAGAGGTT
GCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGTGACAAAGCCAGACTCTGTGCCAAAAAAAAA
AAAAAAAAAGTCACGCCTGTCCAGTTCGCCAGATTAAGTCAGTAATTGATCAGCACCTTCGCCAATACTG
CCACTAGAAAAACAGCTGCGTGTCTGTTTCAGTGGGATCTCAGGGGAAACCCCTCCACTGTAACTCAGAT
GCCAGTCTCCACATGAGACCAAATCTTCTCAGTAAGAAAAGCACTGCAGAGCAGCACGGGGTTCAAGCTC
CACCTTTGCTGGGGGACTATGGGCCAGTGATGGGCCATCCCACTCTGAAAAATAAAGCAAGTCATAGTGC
CTGCAGTCCCTGTTGCAAGCATACAGACACCATGGACGTGAAGTGCCTGGCAGCCAAAAGGTGTGCAGTC
AGCTGTATAGAAACTATAGCTGCTGTTGTTGTTGTTAAGGCGGTGAGAGTGTCACCCACAGATTGTCCTC
TGTCCATGAAGCTTCTCAAACTCGGACTTTCTCAACCTCTGATGGCACCACGTCCTGCCAATAAGTGGCA
GACTAGGGAGGTGAGTAGGGCAGAATCCAGGACTGAGGTGGAGAGAGGATGGAGTGGGAGGGAGGAGAGG
GTGGGAGAAATTTGGAGAGAAAAGTCAATGCATGGAGGTAAAGAGAGGGTGGAGACTGAGGGACAGAGAT
GGGGGAGCAGCTCCCAAGTCCCTGATGACACCTCCCTCATTGGCTTCCCACTCGGTTCTGACTGGCATCT
TCTGTCCTCAGAGACCCCAGGCCTCGCACATGCACTCTCATCTCTTGTGCCCCCAACTCCTGGGCTGAGC
GCTGCCTGTGCCCCACCTACCCACAGGCCCCTCGCCCCCTGCTCCCCATCTGCTCTCACCGTGACCTTCC
ACTGTCTCTGCTCCAGCCGCAGGGTGAAGTTTGCCACCTGGACCGTGATCACCCTGGTCACACTGACTCG
CCCATTACCCCAGGCCACGTTCTCCTGCAGGACGGCAAACCGATGCAGGCCAGGCCGGGTGCCGCAGGTC
TGAGCCAGCACATACACGCAGGTGCCCATGAAGTCGAAGCGGTGGCCATCGAAGGTGGTGTAGTGGGGAT
CTCCCGACGCCTGGCAGGTGGTAGAGCCCACGGCCACGCAGCCCAAGCTGCCACCGGATGGCCGGCAGGT
CTCATGCGGGCCGCAGCTGGAGGGCTCACAGGACACCTCACCGCCCTCCCGGCAGCGGCAAAGGGAATCA
CACCCAGGGCCAGGGTAGAAGGTCTGGCCCAGTGGGTAGTAGCGGTCATCGTGGAGGCAGCCACACTGGC
CCACAGGTACACACGTGTCACCACTGAGCACGAAGCCAGCATCGCAGACACAGCCTTCACGGCAGGCCGA
CTCACAGCCCTCGGGCACTGGGAGGTCTCCACAGGACAGCGGGCAGCCGTAGGAACACGCCTCATAGTGG
CTGTGGGGTGGGCAGCTCAGTGCTGCAGGGAGAGGAGACATCAAGATCAAGAATTCCTGCTCCCAGGTCA
GGAGTTCGAGACACACTCACATACAAGTGGTCCCTCAACACATTCGTATGCACACAAACACTCAAACACA
CTCACACACAAGTGGTCCCCCAAGACATTCATATGCACACACACGCTCAAACACACTCACACACACACAA
GCGGTCCCCCAACACATTCGTATGCACACACAGATGCTCAAAGACACTCACACACAAGCGGTCCCATTGC
AGGGTGCTTGGGGAACACATTACATCGCAGTTAATCTGATCCTGATAATTAAGATTCTTTCCCAATTTAA
CTATGGTTTGGAGTTATCTATTATGGTTTTTTTTTTTTTTGAGATAGGGGTCGCTCTGTTACTCAGGCTG
GAGCGCGGTGGTGCTTGCTATCACAGCTCACTGCAGCTTTGACCTCCTGGGCTCAAGCAATCCTCCCACT
TCAGCCTCCTGAGTAGCTGGGACTATAGGCGTGCACCATCATGCCTGGCTAACTGTTCAAATTTTTTATA
GAGATGCGGTCTCGCTATGTTGCCCAGGCTGGCCTCAAACTCCTGGGCTCAAGCAGTCCACCTGCCTCAG
CCTCCCGAAGTGCCGGGATTGCAGGAATGAGCCACCACACCCAGCCTTCTATTATGTCTTTAATGACCTT
ATTCAAGTTGGATACATGGTGTTGATATGTGGCATATATTTTAAACATGCATATGCATATATTTCTGTGT
TTGTATAATCTATGCAATATTTGTGAATGCAATACTTTTAGCTTCTTCCTTCTATAGCAGTAATTAAAAT
ATTTAGCCAGTGTTATAAAGAAAAAAAGAAAAACCTCCCTGCTCCCCTCCCCAAACTCCAGTCACTCCAT
AAAAAGCAAATCTAAGTGACTAAAACTAAACCACATTAAATCTCTATCTGTGCTGTCAAATACAGTAGCC
ACTAGCCACTTGTGACCATTTGGATGTAAGTTAATTAAAATGAAACAAAATTGAAGATTTAGCTCCTCAG
TCACAACAGCCTCATTGCAAGTGCTCAGCAGCCACATGTGACCTGTGGTGACCTGGTATGTATTTGAACA
GCTCAAATATGGAGCTGTCATCATTGAAGTTCTGCTGGGTGGTGCTGTTCTGAAGCTGACATCCAGCTTA
CAGGAGAATCATGGGGACATAGGGACAAGTTCAATAACACTCCAAAATAGCAACTAGCCAGATCCTGAAA
GTATGAAATTCTGCAGGATAAATAACCTATCTTTCCCAGTAAATAAGTGACATAGACAAAAGGAAGAGCT
GGATGGAGGGATAGCTATGTGATAAGGCAAATGAATGAATTAGAATTAGAGTGAAGAGGCCGGGCGCGGT
GGCTCACACCTGTAACCCCAGCATTTTTGGAAGCCGAGGCAGGAGGATCACTTGAGGTCAGGAGTTCGAG
ACCAGCCTAGCCAACATGGTAAAACCCGTTTCTACTAAAAATACAAAAATTAGCTGGGCATGATGGCGCA
CATCTGTAATCCCAGCTACGTGGGAGGCTGAGGTGGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCA
GTGAGCTGAGATTGCACCACTGCACTCCAGATTAGGCAACAGAGTGAGACTCCATCTCAAAAAAAAAAAA
AAAGAAAGAAAGAAAGAAAGAAAAAAGAAAAGAAAAAGAATTAGAGTGTAGAGTCCAGGTGGTAGGTTTA
TGGGTCTTCACTGTAAAATTCTTTCAACTTTTTTGTATATTTGACAATTTTCATAATACTATGTTGGGAG
GAACAAAGGAAGGAAATTCTGACAGAGTAAAAGCAAAGAGGTAGATCAATCCAATGCAGTATGTGTATTT
GGTTTGGTTCTAGAGCCAAACAAAATAGAAAAAAACCTTTTTTTTTTTTTAGACAATTGGGAAAATTTGA
ACCCAGATTGGGCTTTACATGATGTTAGGGAATTAATGTTATTGTTGTTACTGGTAATTACCACATGCCC
TCATATCTCTTTCTTTCTTCCTTCCTTTTTTTTTTTTTTTTTTTAGAGACAGGGCCTCACTGGAGTGCAG
TGGCACAGTCTCGCCTCACTGCCACCTCCACCTCCTGGGCTGAAGATATTCTCCCACCTTAGCCTCCTGA
GTAGCTGAAATGATAGGCACTAGTCACCATGCCCGGCTTATTCTTTATTTTTATTTTTGTAGAGACTGGG
TTTTGCTATGTTGCTCAGGCTGGTCTTGAACTCCTGGCCTCCAGCGATCCTTCCACCTAGGCCTCCCAAA
GTGCTGGGATTACAGGCATGAAAAGCAAACTCCTGTGCCTTAAAAGTCCTTTTTTGTTGCTGAAAAGCAG
ATGCTTACTGAAGTAGTTAGAGGAGAACTGATCTGCCTAGAATTTGATCTAAAATATTCTACCAAAAAAG
AGGGGGTGGAGTGAGAGGTAGAGGAACTAAGAATGGCAAAATACCAATAATTGTTCAAGCTGGGTCAGGC
CTCCGTCTGCATATCTAAGACCTCATGATCCAGTCTTCTAGAACTTCCAGGTGGTACAAGGAAAGGAGTA
GTTTTAAGGAAACAAGAGATTCTCAATTTCCACACAGGCCACAGAGTCTGATAATTAACAGCACAAAATC
AGGAGCCAGCCTGTTCAAATCACCCCACCGGCTGTGTGACCTCAGGCTAGTTCCTTAACATCTCTGTGGT
TCAGTTTCCTCGTCTTGTAAAATAGGAATAAGAGCAATTCTGCCTCACGGGGTGGTTGTGAGGATTCAAT
GAGAAACCCTTAGAACAGGACCTGCCCAGTGGGATGCGTGTCACACAACTGCTAGCTGGAATTATACGTG
TCCTGCCTAAAAGGACAGCCCAAGAATGCTCTGTTAGAAGAGCATTCCCACTTCCCATTGTCCACCTGTC
CCCTTCACAAGTGTGCTTCCTGCACTTTACAGAAGAGAACAGTGCAGTCCCCCACCCATCCTGAATCTTT
TTTTTTTTTTTTTTGAGACAGGGTCTCGATCTGTGGGCCAGGCTGGAGTGCAGTGGTGCGATCTCGGCTC
ACTGCAATCTCTGCCTCCCAGGTTTAAGCTAAGATTCTCCTGCCTCAACCTCCCAAGTAGCTGGGATTAC
AGGCGCTCACCACCAGGCCTAGCTAACTTTTGTATTTTTTGTAGAGACAGGGTTTTGCCATATTGGCCAG
GCTGGTCTCGAACTCCTCACCTCAAGTGATCTGCCCGCCTCAGCCTCCCAAAGTGCTGGGATTACAGGCA
TGAGCCACCACACCCAGCCCCATCCTGAATCTTAACACATGGCACAGTGCCCTGGAGTGTGAAACCTCTG
AGGACATAAACGGACGATTTCAAATATTGCTATCGCTGTGAACACAACGAATGCTGAATCATTATTGAGT
AATAAATCAAAAGGAGGGCCTAATAGAATTGGCTGCTCACAGATAATATAAAATAAATTTGTCGTGTCTC
ACTGTGTGCCTTCCCTATGACTCAGAAGGGGTTCAGAGCACGGAGTGATGTTACTCCACCTGCACTCTGT
CCACTCCCACCCACTTATTAATATCATGTAAGCCAGGAGCTGTGGCTCAAGTCTGTAATCTCAGCACTTT
GGGAGGCCAAGGCGGGAGGAAGGCTTGAGCCCAGGAGTTTGAGACCAGCCTGGACAACATAGCGAGATCT
TGTGTCTACAAAAAATAAAAAATTAGCCAGGCATGGTAGTGTGCACCTGTAGTCCCAGCTACTCAGGAGG
CTGACACAGGAGGACTACTCGAGCCCAAAGATGGAGGCTACAGTAAGCTGTGATCACACCACTGGACTCC
AGCCTCGGTGACAGGATAATACCTTATCTCAAAAATAAATAAATATCATATCTACAAAAATGAAAGATAG
GATTAGAATTGATGCTGAACCCTGTCTCATTCTAACAATATATGTGAAATATTGGGTGGGGGTAAGCTCA
CTGAGTGATGCCATTACAATGGCCATTACAATTTACTTCTGTTTAATATTTTTATCAATTGTGCACAAAC
AATTCTTGCAATGATATCTTACTCCATTAAAAAAACCACTTAGAGTCTTAGAGTCTCAGGAATTTCTAAA
ACTTCTTATATCTTTTATAAGAAGGCTGTTTTGTCCTGGGAGGTTTCACACCCCAGGGCAACATGCCACG
TGTTGAGATTTGGGATGAGTGGAGACTGCACTGTTATTATTTTATTTTATTTTATTTTATTTTATTTTAT
TTTTTGAGACAGAATCTCGCTCTGTTGCCCAGGCTGGAGTGCAGTGGCTTGATCTCGGCTCGCTGCAACC
TCTGCCTCCTGGGTTCAAGCGATTCTTCTGCCTCAGCCTCCCGAGTAGCTGGGATTATAAAAATTCTGAA
ATCTTAGTCATAGATGTGTATGTTTGTGGCAGAGAAGTGTGATGGCGATTGTGACACAGGCTGCCAATGG
TCACGTCTTGACTCTGGGCATGACCATGGCACTTGCTTTGGCCAATGGGACATTGGCCACCATGATACCA
AGTAGAGCCTTGGAAAGTGCTTGCACACTGGGGCTTGTGTGCTCTTAGGAATCTTGAGAGCACCTTGGGA
AGAAGCCTTGGCTCACCTGCTGGAAGATGAGACCAAGTAGAGCAGAGACAAGAATTCCCAGCTGAGGGCC
CCCCAAACCAACCAGCTTGACAACTGCCAGATGTGTAAAATCACCCTAGATTACCCGGCCTTGGCTGAGC
CTCCAACAGACTGCAGAGATCAACCAAGCTGGCCCAGGCTGGGAGAACAGCTCAGCAGCCCCCAGAATCA
TGAGAAAGAATAAATACTTGGCCGGGCATGGTGGCTCACACCTGTAATCCCAGCACTTTGGGAGGCTGAG
GCGGGCAGATCACCTGAAGTCAGGAGATCGAGACCAGCCTGGCTAACATGGTGAAACCCCCATCTCTTCT
AAAAATACAAAGAATTAGCCGGGCATGGTGGCACATGCCTGTAATTCCAGCTACTTGGGAAGCTGAGACA
GAAGAATCACTTGAACCCAGGAGGCGGAGGTTGCAATGAGCCGAGATCACACCATTGCACTCCAGCCTGG
GCAACAGAGCGAGACTCCATGTCAATAAATAAATAAATAAATAAATAAATAAATAAAAATAAACACTTGT
TTTAATGCACTCAGCCACTAAGCCTTGGGTTGTTTGTTAGGCACCAAAAGCCAGCTGATACAGTGACTTT
AACAAAAGACTTCCATGCATTCAAATGTGTTACATTAGGTTAAATTCTGTTAGAACTAAAAAGCATTAGA
AAATCAGTTCAGAAAGGCAAGGATTTGTTTTCTTATTCTCTCCCCTATTGTATCCGGAGTGTTTAGAATA
GTGCCTGGAATACAGAAGGTATTTTTGAATGTTTTGGATATTTGTTGAATGAATGAATGTAAGTTGAAGG
AGAAAAAGGAATGATGTATTTATCCTGTATTTTTCAGTGGACAATGATGTGTACCACTGTGTGCTATGTA
TCTGTTGAATACATTTAAAAGAGGAGCATAAGTCAAGTAATGGTTTCATTTTGAAATACCAATATTATGT
TGATAATTGTGGAAACTAAATGATGGATATATGCTGGCTCACTATCCTAGTTTACTTTGGATATGTTTAA
ATTTTTCCCTAATAAAAATGTTCTTAAGGCCATGAGCAGTGGCTCACGCCTGTAATTCTAGCACTTTGGG
AGACCGAGTTGGGCGGATCACTTGAGGTCAGGAGTTCGAAACCAGCCTGGCCAACATGGTGAAACCCCCT
CTCTACTAAAAATACCAAAAAAATTAGCCAAGCATGGTGGCGGGCGTCTGTAGTCCCAGCTACTTGGGAG
GCTGAGGCAGGAGAATTGCTTGAACCCAGGAGGCGGAGGTTGCAGTGAGCTGAGATCGTGCCACTGCACT
CCAGCCTGGGTGACAGAGTGAGACTCCATCTCAAAAAAAAAAAAAAAAAAAGGTTCTTAAAAGTCAAAAG
TTACCATTTGTTAGAAATTATAAGTTTTATGATTATTTCAGGTGAAAAACTAGACATGTATGCTTCTATT
AATTCCAAAATTCAAAAACTTTAGAAGTCAGAATAGTGGTTACCTCTTGGGGTTGGGAACCTGGATTTTT
TTTTTTTCTTGAATTTGGGACAGTTCACACAGGTTTGTTCTCTTGGTGAAAACTGATCAAGCTGTTAGCT
TATGATATGTACATATTTTTAAATATCTGTATTATATTTCAATAATAAATTTTTTAAATTAAAAATCGGG
TGAGAGGAAACTGGTACGATGGCTCACACCTGTCATCCTAGTATTTTGAGAGGCCGAGGCAGGAGGATTG
CTTGAGCCCAAGAGCCCGAGACCAGCCTGGGCAAAATATCAAAACCCTGTCTCTATAAAAAATATTTTAA
AAATTAGCGGGGGATGGTGGTGCAAGCCTGCCGTTTCAGCTACTCAGGAGGCTGAGGCAGGAGAATCGCT
TGAGCCCAGGAGTTCCAGGCTGCAGTAAGCTATGATTGCACCACTACACTCCAGCCTAGGCAACAGAGCA
AGACCCCATCTTAAAAAAAATCAGGTGAGAGGATGCATGGCTTTTCAAACTTCTTTCATAGGCAAGCAAA
GGTGTTGGAAAACCATTCATGCACCCACCTCTGAAACAAGGCTCTCAAACTGACTGCCCAAGGGGTCAGG
CAGATGTAAATAAGCGAGGTAGGATAGATGGGGACCAAAAAGAACCAGAGAGGGGATGAGACTCCTAATG
ACAATACTGTTGCTCATATCTCAATGACAGCTGTTATGTGGGAATCAGACCCTGGGCCACCAGGTGTACT
CAGTCATTTTACAAATACCAACTGCCGCTGGGCACGGTGGCTCACGCCTGTAATCCCAGCACTTTGGAAG
GCTGAGGTGGGCGGATCACGTGGTCAGGAGATCGAGACCATCCTGGCCAACATGGTGAAACCCCATCTCT
ACTAAAAATACAAAAATTAGCTGGGCTTGGTGGCGCATGCCTGTAATCCCAGCTACTCTGGAGGCTGAGG
CAGGAGAATAGCTTGAACCAGACTCAGAGGTTGCAGTGAGCCGAGATCATGCCACTGCACTCCAGCCTGG
TGACAGAGCAAGACTCCATCTAAAAAAAAAATACCAACTGCATGCCCACCATCTGTGATTTTCTAGCTAT
CATGATCCCAGGTGTGTAACTGAACCTTTCTGAACTTCAATTTCTTCATCTGTTAAATGGGTATAACCAC
AATCCCTACCTCATAGGGCTATTATAAGGATTAAATGAATTAATGATATTTATACATTAATGAATATATA
TAAGGCTGAGTCCCCCAGTTGCCACTTCCGATACTCACGGCAAAGTTCTTCACTCCTCCAGGGGTGCACT
GTGGCTCCAGCAGCCTGGCATGCAGCAGCATAGGTGGCCAGTGCGTCACACAGTGGCCCAGACTGGCCTG
GCAGCAGGCAGCGGTCATAGACACAGTCGCGCACGGCACCCTGGGGGTCCAGCTTGCTATGGCACTCCCG
GAAGGGCCCCTTGGGGTCGGCAAGGATTCCACACTCATTCTTGCTCTGCAGCTGCTGGGCCACCAGGGAG
TCCAGCTTGGGACAGTCACCCGGTTCAGTTGCTCCACAGCCGGGCCTCGTCTCTTCTTGCCAGCTGTTCC
CAAAGGCCAGTGCATTGGCAGCTTGACCCCCACCCCGCAGAGCCAGGTCATCAGCTGGGTCCCCGTTGAA
GTTCCCACAGAGTCCACACAGGGCCTCAGCATAGCTGCTGGGCACCTTGGCAGTCACTCGTGCATTCCAG
TCATAAGTGACAGTCAGGCCAAAGTCCGTGCGCACGACGGCATCCCTGCCCTGTCGGAACACCTGCACCT
GCCCATCTGCTGCTTGGAAGGGCAGATACTGAAGGACGTCATCCACCTGGGTGGAGATGCAAGAGGGCCA
CCTGGTCAGGGTATTCACAGTTCTGTGGCCCACCCTTCAATTCACTCACCTCCAGCTACCCTGACCTCCT
TGCTATTCTCTTGGACATATTACGCTCAGTCCCACCTCGAGGCCTTTGCACTTGCTGTTCCCTCTGCCTG
GCTCACCATTCACCCCTCTTCATTCCTAAAGCACCAGCTTAAATCCAAATCCCTCACCCATGGCCTTCAA
AACCTACATGATCTGTCTATCTCCCCATTACCTCCCTCGCCTCACCTCTTCTCACTGTCCCTCTCACTCA
GGCTGCTGCAACCATACTAGCTTTCTTTTCTTTTTTTTTTTGGACAGGGTCTCACTCTGTTGCCCAGGCT
GGAGTGCAGTGGCACAATCTTGGCTCACTACAACCTCTGCCTCCTGGGTTCAAGCGATTCTCTCTCAGCC
TCCCTAGTAGCTGGGATTACAGGTGTGAGCCACTGCACCTGGCTAATTTTTTTTTCTATTTTTAGTAGAG
AGGGGGTTTCACCATGTTGGCCAGGATGGTCTCAAACCTCAGATGATCCACTCGCCTCAGCCTCCCAAAA
TGCTGGGATTACAGGCGTGAGCCACGGTGCCCAGCCACTAGCTTCCTTTTTAAAATAGAGACAGGGGTCT
CACTCTGTCACCCAGGCCAGAATGGAGTGGCACGATCATAGCTCACTTCCTAGCACTTCAGGAAGCTGAG
GCGGGAGGGTCACTTGAGCCCAGGAGTTGGAGACCGGCCTGGGCAACTTAGTGCGACTCCGTTCTGCACA
AAAAGGAAAAAGGAAAACGAAAAAAATAAAATCTTCTAACAGGCCTCCCCCACCCTCAGGCCCATCCAGA
ACTCCAAGTCTTCAGAGGGTATTTCCTGCTCCGTCACCCAGCCCTGGGCGCCACGTCGCTCACCAGCACT
TGCCCGGGGTACTCCCGGCGCACGGCCACCTTCACCCCGCGGGCCTCCACCCGCACGGCGCGCGTGTAGC
TCACAGTCTGGCTGCCCCGATGCTCGTTTTCCACCAGCACCCGGAAGGCAGGCAGCGCTGCGTTCTGGCC
GCATGAGCCGACCAGCAGGTACGTGCAGGTGCCCATGAAGTCGAAGCGCCGGCCGTCGAAGCTCACATAG
TGTGGGTCCCCGGACCCCTGGCAGGTCCCGAAGCGATCGGGGTAGCAGCCCAGGAGGCCGTTCTGGACGC
TGCAGCGCTCACCCGCCGGGCAGCTCTGCTTGTCGCGGCAGGTGACCTGATGGGTGGCGCCGTTGCAGGT
GCAGCGCCTTTGGCACAACTCGTCCGCCCACACTTCCTGGCCCGGAGCGAGCTGGAGACCCTGGAAGGTG
CAGCCACACGACGAGGCCGGCACGCAGGCGCCGCCGCTGGCCACGAAGCCTGGGAGGCACACGCAGCCCT
CCACGCAGGGGCGCCCGGAGCAGTTGGACGGCGCCGCAGCCCCGTTGCAGGAGGTCGGGCAAGCAGGGCC
GCAGAGCTCATAGCGGCTGTTGGCAGGGCAGGACAGGGCTGCGGGGAGATCAGAGAGGGTGGATCAGGCC
CGCGTAGCAGGGGCCGTCGAAGAGCGCCCTGTCGGGGACGGCGCCCAGGAATTCCATCCCCAAACCCTGC
TCCTCTCTCAGAGCTCGCCATCTCAGATAATGGCACTGCCATTCTTCTGGGTGCTCCTGCGCCACACCCC
AGCGACGCAGTTAATCTCCACCCCGCCAACCCCCTAACGCTCACTGGACAACCAATCTGTCAGCAAGTCC
TGTGAGCTCCATATTCAAAATCTACCCAGATTGGCCGGGAGTGGTGGCGCAGGCCTGTAATCCGAGCTAC
TCAAGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGAAGGCGGAGGTTGCAGTGAGCTGAGACCACACTA
CTGCACTCCAGCCCGGGCGCAGAGCAAGACTTTGTCTCAAAAAAAAAAAAAAAAATCCACCCAGTTACAG
AATCTGCCTCTGATCCTATCCACCGCAGCAGCCTCCTGCCTGGGCTCCCTCCTGCCCCCACAGCCTGTTC
CTCACACCAGGCCGAGGAATCTGGGAACATCTGGGTCAGATCAGGTCCCTCCCCATCTCAGAGCACTACT
GTGGCTTCCTCTCACTCAGGGTAAACGCCAGAGTCCTCCCCATGCCTCAGGAGGCCCTGTGCCATCTGTT
CCTCTCACCTCTCAGCCCTCACCTCTTCTCCCTCTCCCTCGGGCTCACTCTGCCCCAGCCCCAGCTGCCT
CCTCCTCCCGGGTCCTCACCCTCCCACCTCAGGGCCTTTGCATTGGCTGTTCCCTCTGCCTTCCCTTTCC
CCAGAAAGCCCACTGGGGCCCAGGTGGCCTGGGTTCAGATCCCAGATCTCTCCTTCTCGGCCACTGACTC
CAATCTCCCCGTGCCTCAGTTTCCCCATCAGTAAGATGGGATAATGTAGTCGAGACCTCACAGGGTTGTT
GTGAGGATTAAATGAGTTGATCTATGGGGAAACATTCTGTGGACATCACTGTTAGTTAGTACTTAGCTGA
CTCCATTGCCTGACCCTGGTCTCAGCTCCAATGTTACCTGCCCAGAAAGGCCTTCCCTGATCACCCTCTT
CACGAGCCTCACAGTCACTGTCATTGAATGAACTTGTTTCTTTGCCTCTCTGAAGATACTTCCTAGTTCA
TCTGCTCACTGTCTGTGTCCCTCCCCTGCCGCTAAGAGAGAAGTTCTGCGGGAGTGGGGACCTGATCTGT
CTCAATCACTGCTGAGTCCCCAGCACCAAGGACAGGGCCTGGTACGCAGCAGGTGCTCAGGAAATACTGC
AGAAGTGAAAGGGAGAATAAATGAACTCTCTGATTCCTATTTTGCGCCAGGCATGGGGTTGGGGGGGTGC
TTACTGGGCAGTGGGGACACAGAACTGGCCAAGACAAACACCTAGTGGCCTCTATGTCTGCCCTGTACTT
ACTCCCCCTCCCTCTGGGCCTGGGCCTGGATGCCTCTTCCTCCCTCCTACCTGTCCTTTCTGCCTCTGGG
ACATGTCTCTAGGAGCCTCACTCACAAGGGCAGGAATAGATTTATGCTGGTCTTCACTGTGTCTTCAATA
TCATTAGCATGCACAGGGGGCAGGCAGGGGTTCAAGGAATGCTTGTGGAATGAATGAGTGAACGATTAAG
CAGACGGACACCTGGCTAAAGAGCCTGGACTTTATCTAGAGGGCAATGGGAGTCATGGGAGGGCTATAGG
CAAAGGAAGAGACGTCACGTCTCTGTGTTGGGATTCTGCAGACAAGAATTCCCGTCCTGCCAAGCCTTTG
AGCATGCTGTTCTCTGGGCCTGCAACTCACTTCCTCCTCTTTCTCTTGGCAACTTCCAGCCCCTCTTATG
GGTTTCAAATTGGACATCTTTCTCTAGAAAACCCTCCCTGACCACCCCTGCTCCCCAGGCTGGGCCAGGA
ACCTCCTCTGGTTTCCCATAGCCCCACTGACTTCCTCCATCCTGGCCCCAACCCCTCTGCCTGTGTCCCC
CGCAATCCCAGCCCTGACTCATCTGCCTGTCTCTCTCCCATCCTGGCCCCAACCCATCCGAGTGGGCCTC
CCCATCCTGCCTGGACCCCTCCAGACTGTCAATGTCTAGTGAAACGTCTCTCCAACCTTAGGCTCATTGT
GGACAGAGCTGGCTGTCTTGGCCATCACTAGGCCCCTGGCATTGCCCAGCACCAGGCTGAACCATAATAA
CTTCTCAGATATTAAGCAGATGCTAGGGATCTCCTGCCCCTCACTGTATGCTCCCAGCCCCCACCCAGGG
CATCACTCACGGCAGTTGGCTGGTGATCTCCAGTCCCCAACCGAGATGCCAAGCTCCAGACAGGCCTGGG
CATAGGCGCTGAGGCCACGGCACAGGCTGAGCCGCTCCCCACCGACCACACACAGGTCATATACACACTG
CTCCAGGAAGGGCCTGGGGTCCAGGGTGTCATGGCAGACAGCGAAGGGGCCATCGAGCTTGGTCAGCATG
CCACAGAGTCGGTCGCCCTCATAGTGTTGGGCCTGGCCTGGGGTGCAGGCGGGACAGTTGTTCTGGCAGC
CATCCTCACACAGGTAGTCCCCATCATCCAGCTTCCAGCTACTTGCGAACTCCACAGCGTCAGGAGCCAG
AGCCCCGTCAGGCGTGAGGAAGTCGTCTGCTGGGTCACCATTATAGTTGCCACACAGCCCGCACACCTGG
TCTTGGAAGCGTGCAGGCAGGCTGAGTGCCAGCTGGCAGTCCCAGTCATAAGTGACCACCAGCCCAAAGA
CCAGCTCCACCACGGCCCGTGGTCCGCTCTGGTACACACGCAGGCGACCCTCACTCAGGGAGACTGGCAG
GCGCGAGCGCTGGTTGTCAACCTGCAGAGTGGGTGAAGAGGAGGTGGTCAGGCCCCTGTGCCATCTGGCC
TCCAGCCCTCATTAAAGTACTTTTTAATTAAAAGTTTTAAATAGGAGAATATAGAAAAAGAGTATGTGCT
CAAACGTCACTGACTCAAGCCTTCCCTGACTGCCCTATTTTATGATTTTATTTTATGGTTTGTTTGTTTT
GTTTTGTTTTATAGAGATGAGGTCTTGCTATGTTGCCCAGGCTGATCTCAACTCCTGGCCTCAAGCAATC
CTCCTGCCTCAGCCTCCCAAAGTGCTAGAATTACAGGCATGACCCATGGGACCCAGCCTACACCCCTTTT
TAAATGGCAGCCTTGGGCCGGGCGCAGTGACTCACACCTGTAATCCCAGCACTTTGGAAGGCTGAGGCGG
GTGGATCACTTTATGTCAGGAGTTTGAGACCAGCCTGGTCAACATGGTGAAACCCTGTCTCTACTAAAAA
TAAAAAAATTAGCTGGGTGTGGTGGGGCACGCCTGTAATCCCAGCTACTCAGTTGGCTGGGGCAGGAGAA
TTGCTTTAACCCAGGAGGTGGAGGCTGCAGTGAGCCAAGATCGTGCCAAACAGAGTGAGACTCTGTCTAA
AAAAAAAAAAAAGGCAGCCTCTCCCTATTCCATAGCCTCCTTCCCTGCTTTCCTTTTTTTTCTATAGCAT
CTGGCCTTCTGAAATATAATTCACAAATTGACCATGTTTATCATCTGTCTTACTCCATCAGAATGGCAGC
TCCACAAAGACAAGGGTTTGGGTCTGCTTTGATCACTGCTTTATCCCCAGTGCATAGAACAGGGCCTGGT
AGAATCCCAGGCACTCACTAAGTGAATTAAGTCACTGCTGCATTTAATAAACATTCACTGGGCACTCACT
CTGTGCCTGGCCTTGAGCTGGGAGATCCTGGGAATACGAAGGTGGCGGAGACAGCCCCAAGCCCTACCCT
CATGGGGCTCCCAGTCCATTGGGAGAAACAGACACATCACCAGACAGTGAGAGCTCAGAGGGGTCAGGGC
AGAGATGGGAGAAGCACAGGCAGAAAAGTCAAGGCCAGGATCAGAAAGGCCCAGGCAGAGGGGTCAAGGA
TGGGATAGGGGAGGTACAGGCTGAGGGTTCAGAGCTGGGATAGTGGGGAGATAGGAGGCTGTGAAAACCT
AGAAAAATGGCCAGATCTAACCTTGCTGGTCAGGGATGTTGAAATCTTAACACCCAACATGATGGTATTA
AGAGTGGGGGGAGGCCTTTGGGAGGTGATTAGGTCATGAGGGTGGCACCCTCATGAATGGGATTAGTGCC
CTTATGACAGAGGCCTCAGAGAGCTCTCAGATCCGCTTTCCACCGTGTGAGGATACAAGGAGAAGTAGGC
CATCTGCAACCTGGAAGAGCACCCTCACCTGAACCTGGCAGTGCTGGTGACCTCATCTTGGACTTCCAGC
CTCCAGAACACAGAGACGAGGTTGTGTTGTTTATAAGCCTCCCAGGCTCTGGAGAAGCCTGAAGTCTGAC
TAAGAACCAGGAGATAAGAACTATGTCTCTCTGTGCCCTGGGGCATCTTTTTTTTGAGATGGAATCTTGC
TCTGTCACCAAGGCTGGGCTGCATTGGCACGATCTCGGTTCACTGCAACCTCTGTCTCCCAGGTTCAAGT
GATTCTCCCACCTGGGATTACAGGTGCCTGCTACCACGTCCAGCTAATTTTTGTATTTTTAGTAGAGATA
GGGTTTCACCATGTTGGCCAGACTGGTCTTGAACTCCTGACCTCAAGTGATCTGCCCACCCCTGCTCAGC
CTCCCAAAGTGCTGGGATTACAGGCATGAGCCACCGTACCCAGCCTTTTTTTTTTTTAATTAATAAAAAA
ATTTTTTAAATTAGATATGGGGGTCTCACTATGTTGTCCAGGCTGGTCTGGAGCTCATGGCTCAAGCAAT
CCTCCCACCTCGGCCTCCCAAAGTGCTGGGATTATAGGTGTGAGCCACCGCACCCAGCCTGGGCATCTCT
TTCTTACTCTTTCCTTACACATTCTCTGAGCTGTGCCAGAGCTGAGACTTGAAGTGGAGAAGTCTTAGCC
AAGAGGATGGAATATGATAAAAGGAGCAACAGGAGAGAGGACAGCATGAGCAATGGCCCAGAAGGAAGAC
AGAGCATTCACTCATTCCGGCTCCCAGCAAAGCTTCTGTGAGTCCCACTGTGTGGCCTGCTCTGTGCCAG
CTGGTGCTTTAGACACTGCAGTGATGGAGACAGGCCATGGCCCCATGCTCAGAGCTCTCAGTCCAGCATG
GCTGCTCAAATCTGTTTCTCCCCTAAGTCCAGTGATCTCCATTTTAATTTTTCTATTTTTTTATTTATGT
ATTTTTTTGAGACAGTTTTGCTCTGTCACCCAGCCTGGAGTGTAGTGGCAGCATCATAGCTCACTGCAGC
CTCGACCTCCTGGGCTCAAGCCATCTTCCTGCCTCAGCCTCCCAAGTAGCTGGGACCATAGGCAGGCGCC
ACCACACCCAGCTATTTTTTTTTTTTTTTTTTGGTAGAGATAGGGTCTCCCTATGTTGCCCAGGCTGGTC
TCAAATTTCTGGGCTCAAGTAATCTTCCAGCTTCAGCCTCCCAAAGTACTGGGATCACAGGCGTAAGCTA
CCATGCCCAGCCAATCTCCATTTTTAAATGACACAAATAATATTCGTTCATTACAGAAAACTGAAAATGC
ACAGGAGCAAAAATGAGAAAAGAAAATCACCCTGTAGGCAGACACATACAAATGTATAGATCCTGTTGAG
TTTTTTCCTACCTTTAGATATATTTACACTTAAAAAAAAAAAGACCATGCTGAAGTCACTATTTCATTAA
CTCCTCTCCTAACAATGTCTTGTGAGTATCCTACTATGATTCTGACAGTAGCTCTGCACCTTTGTCAAGT
CACTGACCTCTGTGAGGATCTGACGGAAAAAAAAATGAAAGGCCGGGTGCGGTGGCTCATGCCTGTAATC
CCAACACTTTGGGAAGCCGAGTTGGGCGGATCACAAGGTCAGGAGATCAAGACCATCCTGGCTAACACAA
TGAAACCCCAGCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCATGTGCCTGTAGTCCCAGCT
ACTCGGGAAGCTGAGGCAGGAGAATCGTTTGAACCCAGGAGGCGGAGGTTGCAGTGAGCCGAGATCACGT
CACTGTACTCCAGCCTGGGCAACAGAGCGAGACTCCGTCTCAAAAAAAATAAAAAGTAGTTTTCAGAGAG
AGGTATAAAATTCTGTATATAATTTCAAGGGATCTGAAGTCCGCCTGAACTTGTGCTCAACCCCTCCAGG
GCTGAAGAACACCTCCTTTCACCAACTGATTATTAATCGCAGAGATCTACCTGCACACTCACAAAATCAG
GGAGGTACAAGAATATTTATTTCAGGTCAGATACAGGGGCTTACGCCTCTAATCCCAGAACTTTGGGAGG
CCAAGGTGGGAGGATCACTTGAGACCAGGAGTTCGAGACTAGCCTGGGCAACATAGCAAGACCTTATCTC
TACTAAAAATAAAAATACTTAGCCCAGTATAGTGGCATGAGACTGTAGTCCCAGCTACTTGGAAGGCCAA
GGCTGGAGGATTGCTTGAGCCCAGGAGTTTGAGGTTGAAGTGAGCTATAATCACACCACTGCACTTCAGC
CTGGGCAACAGGGCAAGACCTTGTCTCAAAAAAAAAAAAATCAAAAAAATATTCATTGCAGTATTGTTTG
TAATAGTGAACAATGTGTCCATCCACAGGGGACTGGTTGAATGAACCATGGTGTTCATATCCATATAAAG
AATTGTGCAGATGTTAAAAAAAAATAGAGGCTGATAGAGAAACTGTTGATAGAGAAACTGTTTCAGAATG
TATTGCTAAATGCAAAAAGCAAAGTAGAGAACACAACATATATATACACATATACATGTATATATGTGTG
TGTATATATGTATATATATATATATACACATATATACTCTCTCTCTCTATATATATATATATTTTATTTA
TTTATTTTTTTTTTTGAGACAGAGTCTTACTCTGTCACCCAGGCTGGAGTGCAGTGGTGCAATCTTGGCT
CACTACAACCTCTGCCTCCTAGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGTGTAGCTGGAATTACAG
GCATGCGCCACCACGCCCAGCTAATTTTTGTACTCTTACTAAAGATGGGGTTTCACCATGTTGACCAGGC
TGGTCTCTAACTCCTGACCTCAAGTGATCCACCCACCTAGGCCTCCCAAAGTGCTGGGATTATAGGCATG
AGCCACTGCGCCTGGCCCTGAAGTTATTGAACAGGCAAAACTAATCTATGCTGGAAAAAAAAAATCAGAA
TTGTGATCATCTCCAGGAGTAGGTTGGGGACTGTTTGGTAAGGCACATGAGGGAATTTTCCCAGGTGATA
AAAATATTCTGTATCTTAATGGGCAATTTGGTTACACATTTGCCAAAGGTGAACTATACAGTTAAGATTT
GTGATTTTTGTTATATATAAATTTCACCTCCAAAATCAGCCAAAAGAAGTGTGAAAATATTATATTCTAG
TTAATGACATGGTGAAGTCTTTTGGGTGATATGTACTCATGTCTGGAACTTTGAAGTGCATAAAAAATAA
GAGAGATTGTGGAATGGACAGAGGGATGAACCGATGGATCAGTGTGTGATCAATCAAGAAGAGTACAGTG
TTTAGAATCTAGATGATTGGCACCTGTAATCTCAGCACTTTGGGAGGCTGAGGCAGGCCGATCAGTTGAG
GCCAGGAGTTCCAGACCAGCCTGGCCAACATGGTGAAACCCCTCTCTACAAAAATACAAAAATTAGCTGG
GCATGGCGGCACATGCCTGTCATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCTGATC
CTGCCGCTGCACTCCATCCTGGGTGACACAGCAAGACTCTATCTCAAAAAAAAAAAAAAAAAAGAAAGAA
AGAAAGAAAGAAAACTCTAGGCGATTGGCATATGAGCATTCACTGTATAAGAATTTCAACTTTGGACATT
TTAATATTTTCATAATAACATGGCGAGAAAAAGGAAGTAATTGCTCTAGGCTGCTGTTATTCATATGAAC
TGAATAGAAATGCATTTACCAGAGTCAGGACAGCTGAGGGATTAAGAACAAGGACTCCAGAGCCAGCATG
CCTGTGCCCTTAGCTCCACCTCTTACTAGCTCTGAGCCCTGGGGAAGTCACTAGCCTATCTCAACCTCAG
TTTCCCAATCTGAACATGTTCATAATAATAATGCCTCCTGCACTGAGTTTGTGAGCATTAAATTCGTTAA
GATGAGAAAAGTGCTAAGAAACATATCTGGTGCATAGCAGGTGCTCATTAAATTTAGTTATTTGGTCAAC
GTAAATCCCCCATTGCTGGATAATTTTTTGTTTGTTTGTTTTTGTTTTATGCTATTATAAACCATGTTGG
CATGTTACCCCCCAGTCTCTGTCTCTGAATATCCTTTAAATTTCTAGACGTGGGATGGCTGGAGGGCAGG
GTTCTAAGGTCCTGCTACTGATTTTCAAATCCGCCTCCCCACCCTCCAACTCCATGGCCCACTTCCCTGC
ACCCTGGTTTGAGGTCGGCCATTGGGCTTTGCCTCCGCCTTCGGACCCGCAGCTCATGGATGTTAACCCC
CCAAAGCCCCCAGGTACTCACCAGGACGAAGCCAACTTCACCGCGGGTCAGCGACACAGAGTGGCTGTAG
GCGCGCACAGTGACGAGGCCCACGTAGGAGACGCGGCGGCTGCCCCGGTGCTCGTTCTTGGCCTCCACGC
TGAAGGCGGGCAGGGTGTCGTCCTCGCTGCACAGCTCCACCATCGTGTACGAACAGGTGCCCATCATGTC
GTAGCGACGGCCGTCGAAGGTGGTGTAATGGGGGTCGCCCTGGGCGCGGCAGACAGCGGTGGACTCCGCC
ACACACCCGGCCTTCCCGCCTACCACCTGGCAGCGCTGCCCGGCTGCGCACTGCATGCCTTCGCAGGAGG
GCTCCACTGGGGACAGTACAGCTGGGGAGGGAAGGGAACGGTGAAAAGAGAGAATCAGAAGTGTCCGCGG
GGTTGTAATCCCAGCACATTGGGAGGCCAAGGTGAGGGGGGCGGATCACTTGAGGTCAGGAGTTCGAGAC
CAGCCTGCCCAACATAGTGAAACCCCATCTCCATTAAAAACACAAAAATTAGCAGAGCATGGTGGCACAT
GCCTGTAATCCCAGCTACTTGGGAGGCTGAGGCAGGAGAGTCTCTTGACCCCAGGAGGCGAAGGTTGCAG
TGAGCTGAGATGGCACCACTGCACTCCAGCCTGGGTGACAAAGTGAGACTCTGTCTCACAAAGAAAAAAA
GAAGAAAGAAGAGGAAGAAGAAGAAGAAAGAAGAAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAG
AAGAAGAGGGAAGGGGGAGGAGGAGGAAGAGGAGGAGGAGGAGGAGGGAAGAAGAAGGAAGAAGGAAGAA
ACCGCCTCAGGCCTCAGAGGGAGGCATCCTGGAGCCCACCTTGCCGGGGAAGCTTGAGCAATTCGCTCAC
AACTGCCCATTTTTGCCCATTTTTGCCCATTTTAAAGGTGGGGAAACCGAGGTCTGGAACCCCACAGGGA
GAGAGTTGCTCAGGCCTCTCTGAGAGCCCCATGTTTTCTGATTCTCCAGTTTAACACAGGGCAGCCTAGA
AGAAGGGAAGGCAGTAAATAAGAAAAGGCAGAAACGGTCATTAAAATGTTAATTTGTGTTTTTCTCTCCC
CCTTTTCCCCTCTTCCCTACCTTCCCTCCAGGGTCAAAAAGAGCTAAGGGATTTTTTTAAGGACAGAAAA
TGGAAGACAGCCTTCAGCAGGATGAAAAGGACTATGGAGTCAGGCCGCCTAGGTAGGAATCCTGGCTCAA
CCAACTGGCTCTGAGACACTGGGCAAGTGGTTTTAAACTCCCTCTGCCTCAGTTTCCTCATTTGTAACAT
GGGGGTGATAATAATACCTCCTTCGTAGGGATCTTGGTGGGGGGTGTTAGGATTAAATAAGCTAAAACTC
GAGAAAGCTTTAGAACTGAACCTACGTGTTAAGTGGAGTGTTACCCATTATAATTAATCACCCACCGCTC
CCTCATTCTATTTCTCAAGCCCAAAGTGGCTCCTTGAAGTTGGGTGGCTTCCATGCCTTGGAGGGGAGGG
GAGGGGCATTTTTGCCAGGTCCAGGAATGCCAGAGTCTTAGCGTGGCAGGGACTACATGGGAAGAAACAG
CTTTCCTCCATCTGCCTCCCAGTCCTCAAAAGTTTTTGCAGCTGGGTGTGGTGGCTCAGGCCTGTAATTC
CAGCCCTTTGAGAGGCTGAGGCAGGAGGATCGCTTGAGCCCAGGAATTTGAGACCAGCCTGGGCAACATG
GAAAGACCCTATCTCTACAAAATATAAATTAAAAATTAGCTGGGTGTGGTGGTGCATGCCTATAGTCTCA
GCTACTTGGGAGGCTGAGGGAGGATTGCTTTAGTCCAAGAGTTCGAGGCTACGGTGAGCTGTGATCACAC
CACCGCACTCCAGCCCGAGTGACAGAGTGACACCCTGTCTCTAAAACAAAGTTTTGAGGGAGAAACAGTT
ATCCCCATTTTACAGATGTGGAAACTGAAGCCCAGAGAGATGAAGTCACTTGTCCAAGATCACACAGCAG
AGCTGGGATTTGAACCCTGGGACCCTGCACTACACTGACAGCGTCTCATGGGCTGAGCCTGAGGTCACAC
AAACTGCCAGGTCATATACATTAACTGTGTCAAAAACACGTGAAACACCTAGAAAGATTGCAAGATACTC
CCCTCCCCAACGCGTAGTCATCTTATTATCATACATTTAGATCTCCTAAGTTTGGGTATCAACATTCCTA
CATGAGGTGTGGAGAGTGGCTTAGCAACTGGTGTGGCTATGTCAGTTGCTAAAATATCAAAATATTTCCA
AACTGGTTGGTGAGAAGCTGCTGACCTGACTGTCCCCCACAACCCCAAAGATCCCTCCTTCTCAGCACCC
TGGCTCTCCCCTAGGGCCCTTTCCAGAACAAACCAACAGACAGGGGCTGATGCCAGCATGATGGGGGCTT
CAGGACCCTGTCACAGTGCTTTGGCTGCTGTCTCTTCTGACTGGTAGTGCCCCAGCTCTCCCTGGTTGCT
AAATATTTAGAATATTGTTTCTGGGCGGATGGGAGGGGCTGAGAAGACTTGAGGAAGGATGTCGCGGAGA
AGAGAAGTGAGGGGAGGACAATCAGGATCCCGAAAGCCACAGAGGAGTAGGTGGGTGGAAAAGCGGTCAC
CAGGTGGACAGGACCAGGGGACATTTCCATTACTTACTCCGGCCGCAATCAGCAGCTGTTGCGTAGCCTA
TAGCCTTGGCCAGCCCGAAGGTGAGCAGTCCCAAGTTGGTGGTGGCCTCGGCCGTGTGGATCATGTCAGC
TGTGCCGAGCTCCACTTCAGCATACGAGAACTCACTGCCTGGCACAGCCTCCCAGGTGAGCTTGGCCCCC
ACTGCATGCCCATCTATGGTCAGCCCGCTGATAGCCTTCGTCTGTGCCACTACCAGGGCCACGCCCTCAC
AGCCTGGTACACTCTTGACCACATAGGCTGGGCAGTAGGCCGCCACATCTGGGATCAGGACCAGGTAGGG
GTCATAAGTCACTTCATTCCTTATGGCACCTGTGCCAAACAACAGGACCTGGATGCCCACATTTGCAGAC
AGGTAGAGTGGCCAGGATGGCCGGACCTCAAACTCTACCACATCACCTGCCTGGAGCCCACGGGAGCCAG
TGATACCCCCATGGTTGTAGGTCAGCTTTGTGGCCTGGCTGGCCACAACGAAGGCCAAATCATAGCGAGA
TTGGGAGGCCAGCGTGGGTACTACATAGTGGGTGCCCCAGGCAGACGTGGGTAGCAGCTGCTCAACCACA
TGGTTGCAGGTCGTATGTTTCTGCGCACAGCTGTGGCCAGAGAGGACAGCCACGGGGCTACTAGCTGTGA
CCTTTGACCCCGAGAGATCCACTGAGCTCTGTAGCTGGGCCACATTGTAGGGCTGTAGAGTCACTCTTAG
GACATCGCCTGCTGGATAGAACTTGCCATTGAATGTCACTGACCCCTTCAGCGTGACACTGACCGAGGCA
CCTGCGGCACCGGCCACCACGGCAAACTCCTTGACATTCCTGGCTGAGGTGCCGGGGGGTGTGAGCACAA
AATACTCGGTGCCTAGGGCCTGGATGGGCCGCAGCAGTGTCAGCTCCGCTGTGTCAGGCTTGGCATTTAG
TGCCTGCACAGAGATGGCATAGTCAGAATGGATCACCACCGCATGCTGGAAGATCTTGCTGCCTATCATC
TCAGCCTTGGCACTGATGTTGACCATGACCGACTCCCCGGGCCTCACTGTGACCTTCTTTGAGGTGTTGT
CTGCCTGGCTGAGGATGGAGACTGAAGCGGGGCTCTCTGACAGACTGGAGATAAGGAGGCGGGGGTAGGC
CTTGCTGTAGGCCAGCTGATAGTTCTGCAGGAAGGCTGTGAGGAATTCCTCTCTGCCAGTGTTCTTGAGG
TCCACTGAAGCCTCCTGGGTCAATCCTGGTTGAGAAAATACAGTTGTGGGTCCACTTATCCAATCCTCCC
CACTTTTGCTCTGCACCCAGAAACATGTTGAAGTATTAACTTGGGCTTTCCCCCACCACCCTTCTCTTTC
CTTTCTTCTGATTCATGCAGCTTTCGTCTACAAGCCTTCCTGGCTTTTGTTTTTCAAAAATCTAAACACC
TTAGACAGGGCCCTCAAACTCCAATGCTGATGGGGCCAGGCAAGAAATATAAATGTGTGAAACAGTCCCG
GAGGGGCGACTGTGGAACTGAAGCACTCCTATACCATCTAAAGTGGGTTGTTGCTTATGCAAATCCATCA
GTGTGATACATCTTATCAACAGAATAAAGGACAAAAACTATGTGATCACTTCAATTGATGCCAGAAAAGC
ATTTGATAAAATTTAACATCCTTTCGTGATAAAAACTCTCAAGAAAGTAGACACGGAAGGAACACACCCC
AACATGATGAAATCCATGTACAACAGACCCACAGCTGGTATCATACTGAATGGGGAAAAACTGAAAGCCT
TTGCTCTAAGATCTGGAACACAGCAAGGATGTCCACTTTCACCACTATTCTTCAACATATTATTGTTAGT
CCTAGCTAAACCACTTAGACAATAGAAAAAAATAAAGGGCATCCAAACTGGAAAAAGGGCATTCAAATTA
TCTTTGTTTGCAGATGATATAATCTTATATTTAGAAAAACCTGAAGACAGCTGGGCTTGGTAGCTCACGC
CTATAATCCCAGCACTTTAGGAGGCCGAGGTGGGTGGATCACCTGAGGTCAGGAGTTCAAGACCAGCCTG
GCCAACATGGCGAAACCCAATCTCTACTAAAAAAAAACCAAACATTAGCTGGGTATAGTTGCACATGCCT
GTAGTCCCAGCTACTCGGGAGGCTGGGGCAAGAGAATCTCTTGAACCCAGGAGGTGGAGGTTGCAGTGAG
CCAAGATCACACCACCACACTCCAGCCTGGATGACAGAGCAAGACTCTGTCTCAAAAAAAAAAACAACTT
TGGCTGGGTGCAGTGGCTCAAGCCTGTAATCCCACCACTTTGGGAGGCTGAGCTGCACAGATGAAGAGGT
CAAGAGATTGAGACCATCCTGACCAACGTGGTAAAACCTGTCTCTATTAAAAATACAAAAAAATAATTAG
CCTGGCATGGTGGCAGACACCTGTAATCCCAGCTACTCGGGAGGTTGAGGCAGGAGAATCGCTTGAACCT
GGGAGGCAGAGATGGTAGTGAGCTGAGATGGCACCGAGCTGAGATGGCACCATTGCACTCCAGCCTGGGC
AACGAGAGCAAAACTCCATCTCAAAAAACAAAAAACAAAAAACAAAACAAAAAAAACAGAAAACCTAAAG
ACTTCATCAAGAAGCTATTAGAACTGATAAACAAATTCACTAAACTTGCAGGATACAAAATCAACATACA
AAAATCAGTAGCATTTCTATATGCTTACAGCAAACAATCTGAAAAAAAAAAAGGAAAGTAATCCCATTTA
CAATAGCCACAAATAAAATAAAACACCTAGGAATAAACGAAAGAAATGAAAGATCTCTACAATGAAAACT
ATAAAACAGTAATGAAAGAAATGGAGGAGGACACACACCAAAAAAAATGGAAAGATATTCCATGTTCATG
GATTGGAAGACACAATATTGTTAAAATGTCCATACTAACCAAAGCAATCTACCGATTCAATGCAATCTCT
ATAAAAATACCAGTGACATTCTTCACAGAAATAGAAGACTAATCCCAAAATTTGTGTGGAAACACAAAAT
ACCCAGAATAGCTAACGCCATCCTGAGCATAAAGAACAAAACTGGAGGAATCACATTACCTGACTTCACA
TTATACTACAAAACTATAATAACCAAAACAGTGTGGTACTGGCATAAAAACAAACACATGGACCAGTGGA
ACAGAACATAGAACCCAGAAACAAATCCACCCACCTACAGTGAATTCATTTTTGACAAAGATCCCAAGAA
CATACATTGCATTTATTGAAGATAAATGGTACTGGGAAAACTGGATATCCATATGCAAAGAGTGAAACTA
GACCCCTATCTCTCACCACATACAAAAATCAAATCAGAATGGATTAAAGACTTAAATCTAAGACCTCAGA
CTACGAAACTACTACAAGAAGACATTTGGGAAACTCTCCAGTTCATTAGTCTGGGCAAAAATTTATTAAG
TAATACATCAAAAGCACAGGCAACCAAAGAAAAATGGACAAATGGGATCACATCAACCTAAAAAGCTTCT
GCTCAGCAAAGGAAACAATCCACAAAGTGAAGACACAACTGACAGAATAAGAGAAAATATATACAACCCA
TCTTAGCTAAAGCAATTAGACAAGAGAAAGAAATAAAGGCATCCAAACTGGAAAAAAAAAAAAAAGAAGT
CAAATTATCCTTGTTTGCAGATGATATAATCTGATATTTAAAAAAAACCTAAAGACGCCATCAAAAAGCT
ATTAGAACTGATAAACAAATTCACTAAATTTGCAGGATACAAAATCAACATACAAAAATCAGTAGCATTT
CTAGATGGTACTGACAAGGGATTAATAACCAGAATATAAAAGGAGCTCAAACAACTCAATAGGAAAAAAA
TCAAATAATCTGATTTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTATGTGTGTGTGTTTGAGATGGGGT
CTTACTCTGTCACCCCAGGCCGGACTGCAGTGGCACGATCTCAGCTAACTGCAACCTCCGCCTCCTGGGT
TCAAGTGATTCTCTTGCCTCAGCCTTCCAAGTAGCTGGGATTACAGGCATGCGCCACCATGCTCGGCTAA
TTTTTGTACTTTTAGTAGAGACAGGGTTTCCCCATGCTGGCCAGGTTGGTCTCGAACTCCTGACCTCAAG
TGATCCGCCTGCCTCGGCCTCCCAAAGTGCTGGGATTAGAGACGTGAGCCACCACGCCCGGATTAATCTG
ATTTTAAAATGGGCAAAAGATCTGAATAGACATTTCTCAAAGAAGACATACACATGGCCAGCAGGTATAT
CAAAAAATGCTCAACATCACTAATCATCAGAGAAACACAAATTAAAACCACAGTGAGATATCATCTCACT
CGAGTTAAAATGGCTTTTATCCTAATGAAAGGCAGTAATGAATGCTGCTGAGCATGTGGAGAAAAGGGAA
CCCTGTTACCCTGTTGGTGGGAATGTAAATCAGTACAATCACTATCGATAATAATATGAAGGTTTCTCAG
AAAACTAAAACTAGAACTACTGTATGATCCAGCAATTCCTTTCCTTCCAAGTCAGGAAGTCAGTATATGT
AAGAGACATCTGCTCTCCCATGTTTATTGCAGCACTATTCCTAATAGCCAAGATACGGAATCAACCTAAG
TGTCCATCAACAGATGAGTGGATAAAGGAAATTTGGTACATACAAACAATGGAGAATTATCCACCATAAA
AAAGAATGAGATCACCCGGCACAGTGGCTCACACCTATAATCCCAGCACTTTGGGAGGCCAAGGCAGGTG
GATCACTTGAGGTCAGGAGTTCAAGACGAGCCTGGCCAACATGGTGAAACCCTGTCTCTACCAAAACTAC
AAAAATTAGCCAGGAATGGTGGCATGTACCTGTAATCCCAGCTACTCGGGAGGCTGAGGCACGAGAATCA
CTTGAACCTGGGAGGCGGAGGTTGCAGTGAGCCAAGATCGCGCCACTGTACTCCAGCCTGGGCAACAGAG
TGAGACTCGGTCTCAAAAAAAAAAAAAAAAAAGGAATGAGATCCTGTCATTTGCAACAACATGGATGGAA
CTGGAGGACATGATGTTAAGTGAAATAAGCCAGTATAGAAAGACAAATTTCACATGTTCTCACTCATAGA
TGGGAATTTAAAATTTTTAACTGATGAACTCATAGAAATAGAGAGTAAAATGATGGTTACGATGATTACC
ACAGGCTGGAAAGTGTAGCGGGGACTGGGGGATAAGTAGATATGGTTAATGGGTACAAAAATACAGTTAA
ACAGTTAGATAAAATAGATAAAATCTAGTATTTGGTAGCAGAACAGGATGACTATTGTTGACGATAATTT
ATGGTATATTTTAAAATAACTGAGAGTGGAATTGGAATGTTCCTAACACAAAGAAATGACAAATGCTTGA
AGTGAGGGATGCCCTAGTTACCCTGATTTTATCATTACACACTGTATGCCTGTATCAAAATATCACAGGT
ACCCCATAAATGCAAACCCATAAAAATTAAAAATTTTAAAAATATATAAACTAGTAAAAAAAAAAAAAGT
GGATTGTTGGTACTAGCTTTCACCTGTTATAATGAAAGAATGTGAGCTTTTTTAAATTGTAAGACCTTCC
TGTTTTTCTTTTTTTTTTTCTTCTGAGATGGAGTCTCGCTCTGTCACCCAGGCTGGAGTGCAGTGGCACG
ATCTCGGCTCACCACAACCTCTGCCTCTCAGGTTCGAGTGATTCTACCACCTCAGCCTCCCGAGTACTGG
GACTACAGGTGTGCGCCACCAGGCACAGTTAACTTTTGTATTTTTTCTTTTTTTTCTTTTGAAATGGAGT
CTCACTCTGTTACCCAGGCTGGAGTGCAGTGGCGCGATCCTGGGTCACTGCAACCTCTGCCTCCCGGTTT
CCACGCCCAGCTAATTTCTGTATTTTTAGTAGAGATGGGGTTTCACCCTGTTGGCCAGGCTGGTCTCAAA
TTCCTGACCTCAGGTGATCCACCTGCCTCGGTCTCCCAAAGTGCTGGGATTACAGGCGTAAGCCACCACG
CCTGGCCGTTCTTTCTGTTTTTAAAGAGAATGTGGCTATCTGAATTTTCATGTGAAATCTCCAACCCACA
ATTGTTTTAAGCACTTTGGGGCTCAAGGTGGATGTACTCTGCTGCCAGTGTATGATTTCCATCTTTTTAC
AAACTGGAGTGCAGTGGCTTAAACACAACACACTGCAGCCTCAACCTCCTGGGCTCAAGGGATCCTCCTG
TCTCAGCTTCTGGTATAGCTGGGACCACAGGCACGCACTGTGTGCCTGGCTCATTTTTTAATTTTTTTCT
AGAGGCAGGGTCTCACTTTGTTGCCCAAGCTGGTCTTGAACTCCTGGGCTCAAGTGATCCTCCTGCATCA
GCCTCCCGAAGTGCTGGGATTACAGACGTGACCAACTGTACCCAGCTGGTTTTTGTCTTAATAGGACTTG
TGGGGGCCAGGCGCGGTGGCTCTTGCCTGTAATCCCAGCACTTTGGGAAGCCAACGCGGGTGGATCACTT
GAGGTCGGGAGTTCATGAGCAGACTGACCAACGTGGTGAAATTCCATCTCTACTAAAAATGCAAAATTAG
CCGGACATGGTGGCATGGGGCGCCTGTAATCCCAGCTACTAGGGAGGCTGAGGCAGGAGAATCGCTTGAA
CCCAGGAGGTGGAGGTTGCAATTAGCTGAGATCACACCATTGCACTCCAGTCTAGGCAACAAGAGTGAAA
CTCCATCTCAAATAATAATAATAATAATAATAATAATAATAATAATAATGGGACTTGGGGGTTTGTGAAA
AGGGGATAAAGAGAAGAAGGGGATTATGGAAGGGTGAATGAATTGTCTCCTAGAAATAGATGGCAGTGGG
GGCTTCTGACCACCCCCAACTAGGAAGAGCGTCCCTGGGGCTGAGGAGAGAGAGGTCTAAGGAATCTTGA
AGAGAGTGTGGGGGCTATGGAATGACCACCTTCCATATAAAGGGGGCTTTGAAGGATATCCCAGGGGGCC
AGGGGATCAGGAACAATGGACATTTCAAAAGTAACCTAGATGGATGCTGACTGGTGACGAGAGGGTCCTC
ATATCCCATCCTCCCCCCAGTACTTTGGCTTTATCCAAAATTTTAGTTCTGGACACATCCCTGGGAGAAG
TGGGGACAACACCCTCCAAGAATGACTTTCGTGAAATTTTCCATCAACTTAGCAGAATGAGGCTCAGAGT
CAAAACCTTAGTTGAGTTGCAGAAAACCAAGAAAGTTCTTGCACACTTGAGTTTGGGGACTAAGGTTTTT
GCCTGTGCTCCCATCCAGAAAAGGGTGAGAATTGGTGAATTCTACCACATCCCCCTGCAGAGCCTAAGGG
CCTCTCTCCTGTCTCAGCTAGCCTGGGGTGACATGTGGAGGAGGCACACATGGAAGGCGTGGACCCACGC
AGAGTTCCCCAGATTGGAACAAGGACATGGAGAGGGTCTTGGTCTGACTTACCCCACAGGAGGGTTGCTC
CAGCCCAGAGTATCCACCAGCTCCATAGGGCACCCATGGCTGCA

</dna_sequence>
        <protein_sequence>>NP_003881.2 IgGFc-binding protein precursor [Homo sapiens]
MGALWSWWILWAGATLLWGLTQEASVDLKNTGREEFLTAFLQNYQLAYSKAYPRLLISSLSESPASVSIL
SQADNTSKKVTVRPGESVMVNISAKAEMIGSKIFQHAVVIHSDYAISVQALNAKPDTAELTLLRPIQALG
TEYFVLTPPGTSARNVKEFAVVAGAAGASVSVTLKGSVTFNGKFYPAGDVLRVTLQPYNVAQLQSSVDLS
GSKVTASSPVAVLSGHSCAQKHTTCNHVVEQLLPTSAWGTHYVVPTLASQSRYDLAFVVASQATKLTYNH
GGITGSRGLQAGDVVEFEVRPSWPLYLSANVGIQVLLFGTGAIRNEVTYDPYLVLIPDVAAYCPAYVVKS
VPGCEGVALVVAQTKAISGLTIDGHAVGAKLTWEAVPGSEFSYAEVELGTADMIHTAEATTNLGLLTFGL
AKAIGYATAADCGRTVLSPVEPSCEGMQCAAGQRCQVVGGKAGCVAESTAVCRAQGDPHYTTFDGRRYDM
MGTCSYTMVELCSEDDTLPAFSVEAKNEHRGSRRVSYVGLVTVRAYSHSVSLTRGEVGFVLVDNQRSRLP
VSLSEGRLRVYQSGPRAVVELVFGLVVTYDWDCQLALSLPARFQDQVCGLCGNYNGDPADDFLTPDGALA
PDAVEFASSWKLDDGDYLCEDGCQNNCPACTPGQAQHYEGDRLCGMLTKLDGPFAVCHDTLDPRPFLEQC
VYDLCVVGGERLSLCRGLSAYAQACLELGISVGDWRSPANCPLSCPANSRYELCGPACPTSCNGAAAPSN
CSGRPCVEGCVCLPGFVASGGACVPASSCGCTFQGLQLAPGQEVWADELCQRRCTCNGATHQVTCRDKQS
CPAGERCSVQNGLLGCYPDRFGTCQGSGDPHYVSFDGRRFDFMGTCTYLLVGSCGQNAALPAFRVLVENE
HRGSQTVSYTRAVRVEARGVKVAVRREYPGQVLVDDVLQYLPFQAADGQVQVFRQGRDAVVRTDFGLTVT
YDWNARVTAKVPSSYAEALCGLCGNFNGDPADDLALRGGGQAANALAFGNSWQEETRPGCGATEPGDCPK
LDSLVAQQLQSKNECGILADPKGPFRECHSKLDPQGAVRDCVYDRCLLPGQSGPLCDALATYAAACQAAG
ATVHPWRSEELCPLSCPPHSHYEACSYGCPLSCGDLPVPGGCGSECHEGCVCDEGFALSGESCLPLASCG
CVHQGTYHPPGQTFYPGPGCDSLCHCQEGGLVSCESSSCGPHEACQPSGGSLGCVAVGSSTCQASGDPHY
TTFDGRRFDFMGTCVYVLAQTCGTRPGLHRFAVLQENVAWGNGRVSVTRVITVQVANFTLRLEQRQWKVT
VNGVDMKLPVVLANGQIRASQHGSDVVIETDFGLRVAYDLVYYVRVTVPGNYYQQMCGLCGNYNGDPKDD
FQKPNGSQAGNANEFGNSWEEVVPDSPCLPPTPCPPGSEDCIPSHKCPPELEKKYQKEEFCGLLSSPTGP
LSSCHKLVDPQGPLKDCIFDLCLGGGNLSILCSNIHAYVSACQAAGGHVEPWRTETFCPMECPPNSHYEL
CADTCSLGCSALSAPPQCQDGCAEGCQCDSGFLYNGQACVPIQQCGCYHNGVYYEPEQTVLIDNCRQQCT
CHAGKGMVCQEHSCKPGQVCQPSGGILSCVTKDPCHGVTCRPQETCKEQGGQGVCLPNYEATCWLWGDPH
YHSFDGRKFDFQGTCNYVLATTGCPGVSTQGLTPFTVTTKNQNRGNPAVSYVRVVTVAALGTNISIHKDE
IGKVRVNGVLTALPVSVADGRISVTQGASKALLVADFGLQVSYDWNWRVDVTLPSSYHGAVCGLCGNMDR
NPNNDQVFPNGTLAPSIPIWGGSWRAPGWDPLCWDECRGSCPTCPEDRLEQYEGPGFCGPLAPGTGGPFT
TCHAHVPPESFFKGCVLDVCMGGGDRDILCKALASYVAACQAAGVVIEDWRAQVGCEITCPENSHYEVCG
SPCPASCPSPAPLTTPAVCEGPCVEGCQCDAGFVLSADRCVPLNNGCGCWANGTYHEAGSEFWADGTCSQ
WCRCGPGGGSLVCTPASCGLGEVCGLLPSGQHGCQPVSTAECQAWGDPHYVTLDGHRFNFQGTCEYLLSA
PCHGPPLGAENFTVTVANEHRGSQAVSYTRSVTLQIYNHSLTLSARWPRKLQVDGVFVTLPFQLDSLLHA
HLSGADVVVTTTSGLSLAFDGDSFVRLRVPAAYAGSLCGLCGNYNQDPADDLKAVGGKPAGWQVGGAQGC
GECVSKPCPSPCTPEQQESFGGPDACGVISATDGPLAPCHGLVPPAQYFQGCLLDACQVQGHPGGLCPAV
ATYVAACQAAGAQLREWRRPDFCPFQCPAHSHYELCGDSCPGSCPSLSAPEGCESACREGCVCDAGFVLS
GDTCVPVGQCGCLHDDRYYPLGQTFYPGPGCDSLCRCREGGEVSCEPSSCGPHETCRPSGGSLGCVAVGS
TTCQASGDPHYTTFDGRRFDFMGTCVYVLAQTCGTRPGLHRFAVLQENVAWGNGRVSVTRVITVQVANFT
LRLEQRQWKVTVNGVDMKLPVVLANGQIRASQHGSDVVIETDFGLRVAYDLVYYVRVTVPGNYYQLMCGL
CGNYNGDPKDDFQKPNGSQAGNANEFGNSWEEVVPDSPCLPPPTCPPGSEGCIPSEECPPELEKKYQKEE
FCGLLSSPTGPLSSCHKLVDPQGPLKDCIFDLCLGGGNLSILCSNIHAYVSACQAAGGQVEPWRNETFCP
MECPQNSHYELCADTCSLGCSALSAPLQCPDGCAEGCQCDSGFLYNGQACVPIQQCGCYHNGAYYEPEQT
VLIDNCRQQCTCHVGKVVVCQEHSCKPGQVCQPSGGILSCVNKDPCHGVTCRPQETCKEQGGQGVCLPNY
EATCWLWGDPHYHSFDGRKFDFQGTCNYVLATTGCPGVSTQGLTPFTVTTKNQNRGNPAVSYVRVVTVAA
LGTNISIHKDEIGKVRVNGVLTALPVSVADGRISVTQGASKALLVADFGLQVSYDWNWRVDVTLPSSYHG
AVCGLCGNMDRNPNNDQVFPNGTLAPSIPIWGGSWRAPGWDPLCWDECRGSCPTCPEDRLEQYEGPGFCG
PLAPGTGGPFTTCHAHVPPESFFKGCVLDVCMGGGDRDILCKALASYVAACQAAGVVIEDWRAQVGCEIT
CPENSHYEVCGPPCPASCPSPAPLTTPAVCEGPCVEGCQCDAGFVLSADRCVPLNNGCGCWANGTYHEAG
SEFWADGTCSQWCRCGPGGGSLVCTPASCGLGEVCGLLPSGQHGCQPVSTAECQAWGDPHYVTLDGHRFD
FQGTCEYLLSAPCHGPPLGAENFTVTVANEHRGSQAVSYTRSVTLQIYNHSLTLSARWPRKLQVDGVFVT
LPFQLDSLLHAHLSGADVVVTTTSGLSLAFDGDSFVRLRVPAAYAGSLCGLCGNYNQDPADDLKAVGGKP
AGWQVGGAQGCGECVSKPCPSPCTPEQQESFGGPDACGVISATDGPLAPCHGLVPPAQYFQGCLLDACQV
QGHPGGLCPAVATYVAACQAAGAQLREWRRPDFCPFQCPAHSHYELCGDSCPGSCPSLSAPEGCESACRE
GCVCDAGFVLSGDTCVPVGQCGCLHDDRYYPLGQTFYPGPGCDSLCRCREGGEVSCEPSSCGPHETCRPS
GGSLGCVAVGSTTCQASGDPHYTTFDGHRFDFMGTCVYVLAQTCGTRPGLHRFAVLQENVAWGNGRVSVT
RVITVQVANFTLRLEQRQWKVTVNGVDMKLPVVLANGQIRASQHGSDVVIETDFGLRVAYDLVYYVRVTV
PGNYYQLMCGLCGNYNGDPKDDFQKPNGSQAGNANEFGNSWEEVVPDSPCLPPPTCPPGSAGCIPSDKCP
PELEKKYQKEEFCGLLSSPTGPLSSCHKLVDPQGPLKDCIFDLCLGGGNLSILCSNIHAYVSACQAAGGH
VEPWRNETFCPMECPQNSHYELCADTCSLGCSALSAPLQCPDGCAEGCQCDSGFLYNGQACVPIQQCGCY
HNGVYYEPEQTVLIDNCRQQCTCHVGKVVVCQEHSCKPGQVCQPSGGILSCVTKDPCHGVTCRPQETCKE
QGGQGVCLPNYEATCWLWGDPHYHSFDGRKFDFQGTCNYVLATTGCPGVSTQGLTPFTVTTKNQNRGNPA
VSYVRVVTVAALGTNISIHKDEIGKVRVNGVLTALPVSVADGRISVAQGASKALLVADFGLQVSYDWNWR
VDVTLPSSYHGAVCGLCGNMDRNPNNDQVFPNGTLAPSIPIWGGSWRAPGWDPLCWDECRGSCPTCPEDR
LEQYEGPGFCGPLSSGTGGPFTTCHAHVPPESFFKGCVLDVCMGGGDRDILCKALASYVAACQAAGVVIE
DWRAQVGCEITCPENSHYEVCGPPCPASCPSPAPLTTPAVCEGPCVEGCQCDAGFVLSADRCVPLNNGCG
CWANGTYHEAGSEFWADGTCSQWCRCGPGGGSLVCTPASCGLGEVCGLLPSGQHGCQPVSTAECQAWGDP
HYVTLDGHRFDFQGTCEYLLSAPCHGPPLGAENFTVTVANEHRGSQAVSYTRSVTLQIYNHSLTLSARWP
RKLQVDGVFVALPFQLDSLLHAHLSGADVVVTTTSGLSLAFDGDSFVRLRVPAAYAASLCGLCGNYNQDP
ADDLKAVGGKPAGWQVGGAQGCGECVSKPCPSPCTPEQQESFGGPDACGVISATDGPLAPCHGLVPPAQY
FQGCLLDACQVQGHPGGLCPAVATYVAACQAAGAQLGEWRRPDFCPLQCPAHSHYELCGDSCPVSCPSLS
APEGCESACREGCVCDAGFVLSGDTCVPVGQCGCLHDGRYYPLGEVFYPGPECERRCECGPGGHVTCQEG
AACGPHEECRLEDGVQACHATGCGRCLANGGIHYITLDGRVYDLHGSCSYVLAQVCHPKPGDEDFSIVLE
KNAAGDLQRLLVTVAGQVVSLAQGQQVTVDGEAVALPVAVGRVRVTAEGRNMVLQTTKGLRLLFDGDAHL
LMSIPSPFRGRLCGLCGNFNGNWSDDFVLPNGSAASSVETFGAAWRAPGSSKGCGEGCGPQGCPVCLAEE
TAPYESNEACGQLRNPQGPFATCQAVLSPSEYFRQCVYDLCAQKGDKAFLCRSLAAYTAACQAAGVAVKP
WRTDSFCPLHCPAHSHYSICTRTCQGSCAALSGLTGCTTRCFEGCECDDRFLLSQGVCIPVQDCGCTHNG
RYLPVNSSLLTSDCSERCSCSSSSGLTCQAAGCPPGRVCEVKAEARNCWATRGLCVLSVGANLTTFDGAR
GATTSPGVYELSSRCPGLQNTIPWYRVVAEVQICHGKTEAVGQVHIFFQDGMVTLTPNKGVWVNGLRVDL
PAEKLASVSVSRTPDGSLLVRQKAGVQVWLGANGKVAVIVSNDHAGKLCGACGNFDGDQTNDWHDSQEKP
AMEKWRAQDFSPCYG

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1683">
        <gene_name>Immunoglobulin</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>1945467</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:299845
CDD:214653</xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>immunoglobulin heavy chain</protein_name>
        <protein_pi>8.49</protein_pi>
        <protein_weight>12543.09</protein_weight>
        <protein_length>185</protein_length>
        <protein_note>Immunoglobulin domain; cl11960</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAB52596.1 immunoglobulin heavy chain, partial [Homo sapiens]
ELQLVESGGAFVQPGGSLKLSCAASGFNFSDSTIHWVRQASGKSLEWVGHIEKKSKNCATIYRASVKGRF
TISRDDLKNTAFLQMDSLRPDDTALYYCTPPPEVESLRSWGRGTLVTVS

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1334">
        <gene_name>KLK3</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>20520643</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:238113
GOA:Q546G3
HGNC:HGNC:6364
InterPro:IPR001254
InterPro:IPR001314
InterPro:IPR009003
InterPro:IPR018114
UniProtKB/TrEMBL:Q546G3</xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>prostate specific antigen</protein_name>
        <protein_pi>7.5</protein_pi>
        <protein_weight>26588.32</protein_weight>
        <protein_length>319</protein_length>
        <protein_note>Trypsin-like serine protease; Many of these are synthesized as inactive precursor zymogens that are cleaved during limited proteolysis to generate their active forms. Alignment contains also inactive enzymes that have substitutions of the catalytic triad...; cd00190</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>CAD30845.1 prostate specific antigen [Homo sapiens]
MWVPVVFLTLSVTWIGAAPLILSRIVGGWECEKHSQPWQVLVASRGRAVCGGVLVHPQWVLTAAHCIRNK
SVILLGRHSLFHPEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDDSSHDLMLLRLSEPAELTDAVKVMD
LPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVDLHVISNDVCAQVHPQKVTKFMLCAGRWTGGKSTCS
GDSGGPLVCNGVLQGITSWGSEPCALPERPSLYTKVVHYRKWIKDTIVANP

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1600">
        <gene_name>MAGE-1</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>416115</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:289225
CDD:279759</xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>MAGE-1</protein_name>
        <protein_pi>4.54</protein_pi>
        <protein_weight>32600.49</protein_weight>
        <protein_length>349</protein_length>
        <protein_note>Melanoma associated antigen family N terminal; pfam12440</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAA03229.1 MAGE-1 [Homo sapiens]
MSLEQRSLHCKPEEALEAQQEALGLVCVQAATSSSSPLVLGTLEEVPTAGSTDPPQSPQGASAFPTTINF
TRQRQPSEGSSSREEEGPSTSCILESLFRAVITKKVADLVGFLLLKYRAREPVTKAEMLESVIKNYKHCF
PEIFGKASESLQLVFGIDVKEADPTGHSYVLVTCLGLSYDGLLGDNQIMPKTGFLIIVLVMIAMEGGHAP
EEEIWEELSVMEVYDGREHSAYGEPRKLLTQDLVQEKYLEYRQVPDSDPARYEFLWGPRALAETSYVKVL
EYVIKVSARVRFFFPSLREAALREEEEGV

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene708">
        <gene_name>MAGEA3</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>4102</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>4885467</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AC244102</gene_refseq>
        <protein_refseq>NP_005353</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>X</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>152698741</gene_start>
        <gene_end>152702346</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>transcript variant X2</protein_name>
        <protein_pi>4.25</protein_pi>
        <protein_weight>32564.28</protein_weight>
        <protein_length>314</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000023.11:152698741-152702346 Homo sapiens chromosome X, GRCh38.p12 Primary Assembly
CAGAAGACCGCGAGATTCTCGCCCTGAGCAACGAGCGACGGCCTGACGTCGGCGGAGGGAAGCCGGCCCA
GGCTCGGTGAGGAGGCAAGGTAAGACGCTGAGGGAGGACTGAGGCGGGCCTCACCTCAGACAGAGGGCCT
CAAATAATCCAGTGCTGCCTCTGCTGCCGGGCCTGGGCCACCCCGCAGGGGAAGACTTCCAGGCTGGGTC
GCCACTACCTCACCCCGCCGACCCCCGCCGCTTTAGCCACGGGGAACTCTGGGGACAGAGCTTAATGTGG
CCAGGGCAGGGCTGGTTAGAAGAGGTCAGGGCCCACGCTGTGGCAGGAATCAAGGTCAGGACCCCGAGAG
GGAACTGAGGGCAGCCTAACCACCACCCTCACCACCATTCCCGTCCCCCAACACCAACCCCACCCCCATC
CCCCATTCCCCATTCCCATCCCCACCCCCACCCCTATCCTGGCAGAATCCGGGCTTTGCCCCTGGTATCA
AGTCACGGAAGCTCCGGGAATGGCGGCCAGGCACGTGAGTCCTGAGGTTCACATCTACGGCTAAGGGAGG
GAAGGGGTTCGGTATCGCGAGTATGGCCGTTGGGAGGCAGCGAAAGGGCCCAGGCCCTCCTGGAAGACAG
TGGAGTCCTGAGGGGACCCAGCATGCCAGGACAGGGGGCCCACTGTACCCCTGTCTCAAACCGAGGCACC
TTTTCATTCGGCTACGGGAATCCTAGGGATGCAGACCCACTTCAGCAGGGGGTTGGGGCCCAGCCCTGCG
AGGAGTCATGGGGAGGAAGAAGAGGGAGGACTGAGGGGACCTTGGAGTCCAGATCAGTGGCAACCTTGGG
CTGGGGGATGCTGGGCACAGTGGCCAAATGTGCTCTGTGCTCATTGCGCCTTCAGGGTGACCAGAGAGTT
GAGGGCTGTGGTCTGAAGAGTGGGACTTCAGGTCAGCAGAGGGAGGAATCCCAGGATCTGCAGGGCCCAA
GGTGTACCCCCAAGGGGCCCCTATGTGGTGGACAGATGCAGTGGTCCTAGGATCTGCCAAGCATCCAGGT
GAAGAGACTGAGGGAGGATTGAGGGTACCCCTGGGACAGAATGCGGACTGGGGGCCCCATAAAAATCTGC
CCTGCTCCTGCTGTTACCTCAGAGAGCCTGGGCAGGGCTGTCAGCTGAGGTCCCTCCATTATCCTAGGAT
CACTGATGTCAGGGAAGGGGAAGCCTTGGTCTGAGGGGGCTGCACTCAGGGCAGTAGAGGGAGGCTCTCA
GACCCTACTAGGAGTGGAGGTGAGGACCAAGCAGTCTCCTCACCCAGGGTACATGGACTTCAATAAATTT
GGACATCTCTCGTTGTCCTTTCCGGGAGGACCTGGGAATGTATGGCCAGATGTGGGTCCCCTCATGTTTT
TCTGTACCATATCAGGTATGTGAGTTCTTGACATGAGAGATTCTCAGGCCAGCAGAAGGGAGGGATTAGG
CCCTATAAGGAGAAAGGTGAGGGCCCTGAGTGAGCACAGAGGGGATCCTCCACCCCAGTAGAGTGGGGAC
CTCACAGAGTCTGGCCAACCCTCCTGACAGTTCTGGGAATCCGTGGCTGCGTTTGCTGTCTGCACATTGG
GGGCCCGTGGATTCCTCTCCCAGGAATCAGGAGCTCCAGGAACAAGGCAGTGAGGACTTGGTCTGAGGCA
GTGTCCTCAGGTCACAGAGTAGAGGGGGCTCAGATAGTGCCAACGGTGAAGGTTTGCCTTGGATTCAAAC
CAAGGGCCCCACCTGCCCCAGAACACATGGACTCCAGAGCGCCTGGCCTCACCCTCAATACTTTCAGTCC
TGCAGCCTCAGCATGCGCTGGCCGGATGTACCCTGAGGTGCCCTCTCACTTCCTCCTTCAGGTTCTGAGG
GGACAGGCTGACCTGGAGGACCAGAGGCCCCCGGAGGAGCACTGAAGGAGAAGATCTGTAAGTAAGCCTT
TGTTAGAGCCTCCAAGGTTCCATTCAGTACTCAGCTGAGGTCTCTCACATGCTCCCTCTCTCCCCAGGCC
AGTGGGTCTCCATTGCCCAGCTCCTGCCCACACTCCCGCCTGTTGCCCTGACCAGAGTCATCATGCCTCT
TGAGCAGAGGAGTCAGCACTGCAAGCCTGAAGAAGGCCTTGAGGCCCGAGGAGAGGCCCTGGGCCTGGTG
GGTGCGCAGGCTCCTGCTACTGAGGAGCAGGAGGCTGCCTCCTCCTCTTCTACTCTAGTTGAAGTCACCC
TGGGGGAGGTGCCTGCTGCCGAGTCACCAGATCCTCCCCAGAGTCCTCAGGGAGCCTCCAGCCTCCCCAC
TACCATGAACTACCCTCTCTGGAGCCAATCCTATGAGGACTCCAGCAACCAAGAAGAGGAGGGGCCAAGC
ACCTTCCCTGACCTGGAGTCCGAGTTCCAAGCAGCACTCAGTAGGAAGGTGGCCGAGTTGGTTCATTTTC
TGCTCCTCAAGTATCGAGCCAGGGAGCCGGTCACAAAGGCAGAAATGCTGGGGAGTGTCGTCGGAAATTG
GCAGTATTTCTTTCCTGTGATCTTCAGCAAAGCTTCCAGTTCCTTGCAGCTGGTCTTTGGCATCGAGCTG
ATGGAAGTGGACCCCATCGGCCACTTGTACATCTTTGCCACCTGCCTGGGCCTCTCCTACGATGGCCTGC
TGGGTGACAATCAGATCATGCCCAAGGCAGGCCTCCTGATAATCGTCCTGGCCATAATCGCAAGAGAGGG
CGACTGTGCCCCTGAGGAGAAAATCTGGGAGGAGCTGAGTGTGTTAGAGGTGTTTGAGGGGAGGGAAGAC
AGTATCTTGGGGGATCCCAAGAAGCTGCTCACCCAACATTTCGTGCAGGAAAACTACCTGGAGTACCGGC
AGGTCCCCGGCAGTGATCCTGCATGTTATGAATTCCTGTGGGGTCCAAGGGCCCTCGTTGAAACCAGCTA
TGTGAAAGTCCTGCACCATATGGTAAAGATCAGTGGAGGACCTCACATTTCCTACCCACCCCTGCATGAG
TGGGTTTTGAGAGAGGGGGAAGAGTGAGTCTGAGCACGAGTTGCAGCCAGGGCCAGTGGGAGGGGGTCTG
GGCCAGTGCACCTTCCGGGGCCGCATCCCTTAGTTTCCACTGCCTCCTGTGACGTGAGGCCCATTCTTCA
CTCTTTGAAGCGAGCAGTCAGCATTCTTAGTAGTGGGTTTCTGTTCTGTTGGATGACTTTGAGATTATTC
TTTGTTTCCTGTTGGAGTTGTTCAAATGTTCCTTTTAACGGATGGTTGAATGAGCGTCAGCATCCAGGTT
TATGAATGACAGTAGTCACACATAGTGCTGTTTATATAGTTTAGGAGTAAGAGTCTTGTTTTTTACTCAA
ATTGGGAAATCCATTCCATTTTGTGAATTGTGACATAATAATAGCAGTGGTAAAAGTATTTGCTTAAAAT
TGTGAGCGAATTAGCAATAACATACATGAGATAACTCAAGAAATCAAAAGATAGTTGATTCTTGCCTTGT
ACCTCAATCTATTCTGTAAAATTAAACAAATATGCAAACCAGGATTTCCTTGACTTCTTTGAGAATGCAA
GCGAAATTAAATCTGAATAAATAATTCTTCCTCTTC

</dna_sequence>
        <protein_sequence>>NP_005353.1 melanoma-associated antigen 3 [Homo sapiens]
MPLEQRSQHCKPEEGLEARGEALGLVGAQAPATEEQEAASSSSTLVEVTLGEVPAAESPDPPQSPQGASS
LPTTMNYPLWSQSYEDSSNQEEEGPSTFPDLESEFQAALSRKVAELVHFLLLKYRAREPVTKAEMLGSVV
GNWQYFFPVIFSKASSSLQLVFGIELMEVDPIGHLYIFATCLGLSYDGLLGDNQIMPKAGLLIIVLAIIA
REGDCAPEEKIWEELSVLEVFEGREDSILGDPKKLLTQHFVQENYLEYRQVPGSDPACYEFLWGPRALVE
TSYVKVLHHMVKISGGPHISYPPLHEWVLREGEE

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Vaccine- and tumor-specific immune responses of 10 melanoma patients treated with autologous GMLs expressing the cancer germline gene MAGE-A3 were analyzed. Three of 10 patients treated with MAGE-A3-GML showed an increase of circulating anti-MAGE-A3 T cells, and developed skin delayed-type hypersensitivity to MAGE-A3. Interestingly, in 2 of these patients, with progressive and measurable tumors at study entry, anti-MAGE-A3 T cells were detected not only in the blood but also within tumors resected after vaccination. These results demonstrate that the infusion of MAGE-A3-GML elicits antitumor T cells, which are capable of trafficking to inflamed tissues and of infiltrating tumors [Ref1298:Fontana et al., 2009].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1339">
        <gene_name>Mcam</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>84004</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>1327848422</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AC148328</gene_refseq>
        <protein_refseq>NP_001346459</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>9</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>44134580</gene_start>
        <gene_end>44142726</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>transcript variant X2</protein_name>
        <protein_pi>5.64</protein_pi>
        <protein_weight>61047.95</protein_weight>
        <protein_length>606</protein_length>
        <protein_note>Also known as CD146; CD149; Muc18; s-endo; AV025631; 1-gicerin; s-gicerin</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000075.6:44134580-44142726 Mus musculus strain C57BL/6J chromosome 9, GRCm38.p4 C57BL/6J
TACGCGGGGCGGGGCCGGGCGGCGCCCGGGGTCCCCTCCCCCGCCCCCCTGACGTCAGCCCCCGACAGCG
GCGAGTTCCTCACTTGGCTCGCGCCCTCCGTCGGGGAAGCATGGGGCTGCCCAAACTGGTGTGCGTCTTC
TTGTTCGCTGCCTGCTGCTGCTGTCGCCGTGCCGCGGGTGAGTTCTTTATGTTGAGGGGGCTGTGGGGGG
CCCGACCCGCGTCCCTCAGAGCCCAGGCGTTGGGAGTTTGGGGATGTCTTCGACGGAGCCGGACTGTGCC
GCCTGAGTGTACCGGAGATCAGAGCTGGTAGCAACGTAGAGTCGGGGCTCTGCACCCCAGTGGGCGCTCC
TTCTTGCCAGAGTCCCCGATTTCCAGGCGCCCCGCGTGCGTGCAACTTCTTTGCGGGTGTGCAGCCTAGG
TTTTAGAGTATTCTGGGAACGGACTAGTCGGGTTGCTGCAGCAGCGAGCGGGAAGGGGTGGGGCCGAGCT
TCTGCAGGACGCTGGGCCCGGCCTCCCGCAGGTGTTCGCTCTGGGTGCTGGATGCTGGGTGCTGGAGTCC
CGGCAGAGAGGCGCAGCCGGGGCGCATCCCCAACCCGTGCATCCCGCGCCCGCCTGTTGCTGGAAAAGGC
AGTTTCCCTAGCTGGAGGGGGCCGCCGACCCCTCCCCCTCCGCCTGGGCCTCACGCCAGTTTGGAGGTGA
GCGAGGGAGGAGGCCGCTCCTGCTGGGGCTGGGCGTTGGCAAGGGCAGCGGGTGGTGTGGGTCTCCTTGC
GCCTCCGGGTTTGACGGGATTACAGGGGAAAGACAACAGATGGAGAAGTTCTACAACAGTAACAGCTTCT
GTGGTCCACTAGAGTCAGGTGGAGAGAGCCTGGCACCTCGGAGCTTTCCTTTAAGCCATCGAGTAGACAT
GCTTTCCTGGGTCCGGGCTTCCCTTGTAGGGCACACGCAGCGGTGTCGTGTGTTATTCTTGGCTCTTTCT
CGCGTCTCAGCCACTGGTCAGGCTGGGGAAGGGGAGGACTGGGCATTACCCACTTCTCTGGCCTCTTGCC
CAGTGCCAGCCACGTCCCTGGGGTACTCCAGTCTAGTGCCTCCCAGACTGACCTTATTTCTGGGGAAAGG
GCTAAACCCAGCTAGGCAATCGCAGCACAGAAAACTCAGTTTCGCTCTGCCCTGCTCTTCTGGCCCTTAG
AAAGCAGGGATTCAAAGTTCCTGCTGTTGGTAGAAGGCTATTCCCACCTTCCCTCCAGTCTGGAAGCCAC
ACAGTCCAGACATCCCAGGGTCCAGGCAGATTGTGCTTAGTGACATCACCTCTTCTAAGAGCTGGCAGCA
TGCTGGCACCACTGACGTCACTCCTGCCCACTCTCTGGTTTTTGACCTAACCCTTGGCGGAGACTGACCC
CTCTAGACTTGGATGGGGTCTTCAGATTGTATTGCAGCGTTTCTTGACATGCTACTGTGGGAACATAAAT
CATAGCCTCTGGCTAGAGTTGGCTCACTGTGTCTTCCAGAGGATTTGGGGGACAGAGGGTAGAATAGTGA
CGTCTTCGTGGAGGGGGGGCACACAAAGGGGCCTGTGTGCCCCAGCCTGGCACATGCCTTACATTCCCCT
AGTCTGAGCTCACCAGGACTAGGAAGGGGCCCAGGAGCAAAGGGGCCTTCATCTTGGCCCAGAGCCCATG
TTGCTCTTATCTGTCTCTCCACCAGCTTCTTCTAAGATATACCCAGTCACTCTGTCTGTGTTTCACTCCG
TATTACACTGGGAGAGGTCTGACCCAGGTTGGGGGTGTGGGCTTGGTGAAGTTGAGGGTAAGGAGAGGGT
AAGGCCCTCCCCAGACCCTTCAAGTGGGACAGCTGCAGTGAACCAGGAGAGGGGAGGGGACCGGACAGAA
CACCTGGAGCTGACAAAGCTGCCTGGGCATGCCCCTCTCTTTCCCCAGGTGTGCCAGGAGAGGAAAAGCA
GCCAGTACCCACGCCCGACCTGGTGGAGGCAGAAGTGGGCAGCACAGCCCTTCTCAAGTGTGGCCCCTCA
CGGGCCTCAGGCAACTTCAGCCAAGTGGACTGGTTTTTGGTGAGCGCCTGGACTTTGGAGGGCAGTAGTT
GTGTGGGAAGCAACTGTCTCTCTGGCAGGTAGCTCATCTCTCAGCTCCTTTCCCTCAGATTCACAAGGAG
AGGCAGATACTGATTTTCCGTGTGCACCAAGGCAAGGGCCAGCGGGAACCTGGTGAATATGAGCACCGCC
TTAGCCTCCAAGACTCGGTGGCTACTCTGGCCCTGAGTCACGTCACTCCCCATGATGAGCGAATGTTCCT
GTGTAAGAGCAAGCGACCACGGCTCCAGGATCACTACGTTGAGCTTCAGGTCTTCAGTGAGTGCCCCCCT
CGTTTCTGCCTTCAGGGTCGTGTGGACCATGTAGCAAAGATGGGTCTCCATGTCCCTGTTCATTCCCCTT
CCACTGTAGAAGCCCCAGAGGAACCAACTATTCAAGCCAATGTCGTGGGCATCCATGTGGACAGGCAAGA
GCTCAGGGAGGTGAGAGGCACTCGGTCAAATGATGGTGGATAGAGGCTAAGCAGGGACGGGGGTGGGGGG
GGGTGGTATGTGGCAGACGCAAGGAGACTCTCGTCCTGTCCTCCTTAGGTTGCTACCTGTGTGGGGAGAA
ACGGCTACCCCATTCCTCAAGTCCTATGGTACAAGAACAGTCTGCCCTTGCAAGAGGAGGAGAACCGTGA
GTAACCCTTACTGAGAAGGCTCAGGAGGACCATCTAGCATGTCCTTGTAGAGCTTTTACTAAAACAAACA
AGCAAACAAACAAAAACCATACAGGTGATGCTGAGTAAGTCAGACTGTAGGCTGGACAGTTAGCTCCATG
AACATCACTGGTTGCTTTTGCAGAGGACCCAGGTCAGTTCCCAATACCCACTTGGTGGTTCCCAACTCCA
CTTCCAGGGGGATCTGATGCCTTTTCCTGACCTCGACCTCTGAGGACAGAAGGCATGCATGTGGTGCATA
TACACACGAAGGCAAAACATTCCTGCACATTAAACAAACAAACAAACAGCCAGGTGTGGTAGCGCACGCT
TTTAAACCCAGCACTTGGGAGGCAGAGGCAGGTGAGTTTCTGAGTTTGAGGCCAGCCTGGTCTACAAAGT
GAGTTCCAGGACAGCCAGGGCTATATGGAGAAACACTGTCTCAAAAAAAAAAAAAAACAAACAAACAAAC
AAAAAACTGTTATAATTAAATAAAGACCTGGCTACAAAATCTTTTAGAAGAAAAATTTAGACTATAAAAA
AACTTAGGAATTCCTTTCTGACCCAGGCTTCTCCCAGAAGTGACTTCTGCTATCAACTGATATTTTCCTT
CATTCTTACTTCTGTGTCCATCATGTAAACAAATGCTTGCAGACGTGTAGAGAGGGCTGTCTGCGGTGTT
TTGAGACAGGAAGTCATGCAGCTCGATGACCTAACTGCAGATCCTCTCTGCCTACCCCTCAAAGCGCTGG
GATCCATGCCTGTAACACTGTTCCTGGCTCAAACAAGGCTTGTGTTTTGTTTTTTGTTTTGTTTTTGTTT
TCCTGTCTTTAACCAGGAGTGATTTTTGCATACACACTAGTCTGGGGATACTTGGCAGTGTCTGTGGGCA
TTAGTGGATGTCACAAACAGGGAGGCTGCTGTTGACATCTGATACGTAGAGGTTAGAACTACAGCTCAGC
ATCCTACAGTGCACAGGATGGGCCCCACCACAAAGGTTTAATTCCACCCCAACACATCAATAGTGCTGAG
CCGAGAAGCCCTGACCCCAGTGGCCATGCTGGGCACACATCCCTTTGTGTAACTTTCCCAGGTCAGTCTG
TTCAGATAGACTCACCTTGCTTCCTAGCCTCGTATTGCATATGATGTGGCTGAGTTTCCACTCTTCCTTT
AGCATTTAATGTCTCAGTGTCTCAGCACCTTGGGGCATTTGTTTTGGATTCTGTATTGAACCTAAGGCCA
TGCACATGTTAAGAATTTGCTCTACCACTCAGCCTTTCATTCAACTCCATTTTTCTTTGTCTTTGGGGTG
TTCCTGGCCCCATCCTTGTACATATGCTAAGGTGTAAGTGCTTTCTAGGGTAAATACCAAGCAATAAAAG
TGCTAGGCTGAAGGGTCGTCATTCTGTGTTCGGCTATGGGCCTCTCCTTTAGACATCTCCCTGCTGACCC
CCAGGGGAAGTCTGAGGGGTCCTGAGGCCAGGCCTTGCTTCCTCCTTCTGCCCAGGAGTTCATATCCAGT
CATCACAGATTGTCGAGTCCAGTGGCTTGTACACCTTGAAGAGTGTTCTGAGTGCACGCCTAGTTAAGGA
AGACAAAGATGCCCAGTTTTACTGTGAACTCAGCTACCGGCTACCCAGTGGGAACCACATGAAGGAATCT
AAGGAGGTCACTGTCCCTGTTTTCTGTGAGTGCTGACTTCCTAGCGCCTCTGGATTTTTTTTGAGGGGGG
GAGGATTGGGGTGGGCCTGGTGGGAACTCCTGCTGGTCCCTCTGTGTCAAATTCGGGGCCACCTCTTGGA
CTGAGAGCCTTCTCCTTTGCCCAAACAGACCCTGCAGAAAAAGTGTGGGTGGAGGTAGAGCCTGTGGGGC
TGCTGAAGGAAGGGGATCATGTGACAATCAGGTGTCTGACAGATGGCAACCCTCAACCCCACTTCACTAT
CAACAAGAAGGTACAGAGAGAGCGAGCGCTCCATGCTGGGTGCACGGAGTGGGCGTAAGGGTGTGGGCAG
GAGGTGGGGACAGTAGCTGGAGGGCATCAGCTCACTCTCACCCCTTTGTGCTCCCCCCAGGACCCCAGCA
CTGGGGAGATGGAAGAGGAGAGCACCGATGAAAATGGGCTCCTGTCCTTGGAGCCTGCCGAAAAGCACCA
TAGCGGGCTCTACCAGTGTCAGAGTCTGGACCTGGAAACTACCATCACACTGTCAAGTGACCCCCTGGAG
CTGCTGGTGAACTGTGAGACCCTGGGATGGATGCAGGCTCCATCTGGGCAAAGAGGGAACTGGCTCGTCC
TGTCAGGCTGACATTTTTTTGCTATGCCTCCAGATGTGTCTGATGTTCAAGTGAATCCAACTGCCCCTGA
AGTCCAGGAAGGTGAGAGCCTCACGCTGACCTGCGAGGCAGAAAGTAACCAGGACCTTGAGTTTGAGTGG
CTGAGAGACAAGGTACCCAGACACCTTTGAGACTGGGGGAGAGGGGGGACAATGAGAGCTTGCTCCTTTT
CAGACCCCCTGACCCACCTCTCACCCCTAGACAGGCCAGCTGCTGGGAAAGGGTCCCGTCCTCCAGCTAA
ACAACGTGAGACGGGAAGCAGGGGGACGGTATCTCTGCATGGCATCTGTCCCCAGAGTTCCTGGCTTGAA
TCGTACCCAGCTGGTCAGCGTGGGCATTTTTGGTGAGGCCCTTTGTACAGTGACCAGGTCACCCTGAGTT
GTGTGGTTTTGAGCTGTTGGCCAGCTTGTACTGTGGGAGCTGAGCGGGGAGCAGGCTATTTGGTATTTGG
GGGGTCTAACCCTTCCCTGCCCCCAAGGGTCCCCATGGATGGCATTAAAGGAGAGGAAGGTGTGGGTGCA
AGAGAATGCAGTGCTGAATCTGTCTTGTGAGGCTTCAGGACATCCTCAGCCCACCATCTCCTGGAATGTC
AATGGTTCGGTGAGCCGGCTTGCTTCATCTCCCCATTCTCTTAATCCCTGCCTAGGCCTTGAGGCCATGG
CCAGAGATGCTTCCGCCCTCTGAGAGGCCCATTTACTTCTAGGCAACTGAATGGAACCCAGATCCACAGA
CAGTAGTGAGCACCTTGAATGTCCTTGTGACGCCAGAGCTTCTGGAGACAGGTGCAGAGTGTACAGCCTC
CAACTCCCTGGGCTCAAACACCACCACCATTGTTCTGAAGCTGGGTGAGAGCGGACTCCCTGCAGAGGCT
GGCAGGGGCATGCCCAGGCACAGGCATTAACTTGTGCTACTAACCCCCCAACTCCTTCTGCCTCCTAGTC
ACTTTAACCACCCTCATACCTGACTCCAGCCAAACCACTGGCCTCAGCACCCTCACAGTCAGTCCTCACA
CCAGAGCCAACAGCACCTCCACAGGTAAGCCGGGCCTGCGCAGTGGTACCCAGTCAGTCTCCCCTTTTGA
GAAAGTTAACGGCCCATCTGTCCCCCTGGGCTGGAGAGGGTGGGGCAGCAACAGCAATTTGGCAGCCAGG
AGCAGGGAATGACTACAAGTGTCTTTGTTTGACAGAGAAAAAGCTGCCACAGCCAGAGAGCAAAGGTGTG
GTCATCGTGGCTGTGATAGTGTGTACCTTGGTGCTTGCTGTGCTGGGTGCTGCTCTCTATTTCTTCTACA
AGAAGGGCAAGCTGCCATGTGGACGCTCGGGAAAACAGGAGATGTAAGCCAGGCTTATGCCCTCCTCCCA
CCCCACCCCCATTTTTGGCTGCCCAGCTTGCTGTCTTATAAGGGCCCTGCCTACCCAGTGCCCATTACCC
TGGAGAGCAGAAACTGGACCTGTTTTTATTGTCCACTACCAAACTGCCACCAACCACACCATCTTCCCCA
ATTCTCCCTTCCTGAGCCGGCCCCAAAGCACCAGAGTATCCATTCCTAAAAGGTCCCCCCCTCCCCAGCC
TCCCCCAGCCCCCGAGTTGCCAACCTCTCACCTCCCTTCTCCCAGCACGCTGCCCCCGACTCGTAAGAGT
GAATTTGTAGTTGAAGTTAAGTCAGATAAGCTCCCAGAAGAGATGGCTCTCCTTCAGGGCAGCAACGGTG
ACAAGAGGGCTCCAGGAGACCAGGTAGGAGGCAGTTCCTGAGGCCAGGGCTCTATTTTCAGGAATTGGGG
GTAGTGGGGTAATGCTACTTGTTCCTGAACACTAACTCTTTCTGTCCTTCATCCTTGGTTAGAGATGGGG
AGCAGACCTCTCTTGCCTTAACATTACTACAGGTGGCAGGATGAGGGAAACGGTGGAGGGACCCTAGAGA
AAGACAACGCCCCAGCCACCTTCTGTTAAACGTAGAGACTTAGCTGGGGGACTTCTGTCTTTTCCTCCCC
CACCCCATTCCTGCTGCTTGCTTTAAGGATGTTGCAGCCCATCAGCTTTTGCTTCGGCCTTTTCTGTCTG
GTGGTCACGCTGTAAACCTTGCTGGCTCTCCATGTTCTGGTGACTTCTCTGTATCCATTTTCAGGGAGAG
AAATACATCGATCTGAGGCATTAGATGGCTCCCATTGCACTGCTCGCAGCTCCCTGCTCAGACTTCACCC
CAAGCTGAAGCCTCCAGAGGGACAGCAGGGACGAGCCACACTCAACCCCCCCCCTGCACATCAGGTCTGA
GAGCTAGGAGCTGGGACAGGAGTCGTCTGCAGGAGCTCAGTTGGCTACAGAGGCCTGGTTTTAGAGACCA
AGCCCTCCTCTGTGTCCAGTAAATAATGCTTATCCCAAGGGGCCCGTCTCCCAGGGCATTTCCCCCTCCC
GTGCACAGCCATTGGTGGCAAATCCTTCTGCCATCAGCTGTGTGGGCTTGCCTCTTTGAGCTCATCTCCC
CTCACAGGCTGTCTTCATGATGCAGGACCTGGGCACATGGTCACATTATTCCGTTCACATTGGTCCTTGT
GAGAACCTCACAGTCTGGAGGCGGCTGCTTTTGTACCTTCCTGCCTGCTACTAATTCAGGGTCTCATTTG
GAACATTTTTCCTTTGGGTAGTGGTCAGGAACTGGTGTAAGTCCTCCAGACACATCCCTGTGTAAGGAAG
CCAGGCACTGTTTCTCTGAGTTTTGTTGTTTTGTTTTCTTTGAAGGCTACTGAGCCCAAGCTTCCCGCAT
TCCCTTAGTAACAAGAGACAGGACAGAGAGAAGGTCTACTGTTCATGGGGATTAGGCTTATAGGAATGTT
AGTACCAAATTTCTACATGTGAGCTTTGGGGGCCAGGTCCTAGAGAGCCCAAGTGGGAGAATGGTATTTA
GGAGATGAAAAACCTGGCCTAGCAAGAGCTTTTGAGGTGTGTGTGTGTGTGTGTGTATACATATATGTGT
GTATATATATATATATATATATGGTTTTGTCTGTAAATTTGCAAATTTTTCCTTTTATATGTGTGTTAGA
AAAATAAAGTGTTATTGTTCCAAAAGC

</dna_sequence>
        <protein_sequence>>NP_001346459.1 cell surface glycoprotein MUC18 isoform 2 precursor [Mus musculus]
MGLPKLVCVFLFAACCCCRRAAGVPGEEKQPVPTPDLVEAEVGSTALLKCGPSRASGNFSQVDWFLIHKE
RQILIFRVHQGKGQREPGEYEHRLSLQDSVATLALSHVTPHDERMFLCKSKRPRLQDHYVELQVFKAPEE
PTIQANVVGIHVDRQELREVATCVGRNGYPIPQVLWYKNSLPLQEEENRVHIQSSQIVESSGLYTLKSVL
SARLVKEDKDAQFYCELSYRLPSGNHMKESKEVTVPVFYPAEKVWVEVEPVGLLKEGDHVTIRCLTDGNP
QPHFTINKKDPSTGEMEEESTDENGLLSLEPAEKHHSGLYQCQSLDLETTITLSSDPLELLVNYVSDVQV
NPTAPEVQEGESLTLTCEAESNQDLEFEWLRDKTGQLLGKGPVLQLNNVRREAGGRYLCMASVPRVPGLN
RTQLVSVGIFGSPWMALKERKVWVQENAVLNLSCEASGHPQPTISWNVNGSATEWNPDPQTVVSTLNVLV
TPELLETGAECTASNSLGSNTTTIVLKLVTLTTLIPDSSQTTGLSTLTVSPHTRANSTSTEKKLPQPESK
GVVIVAVIVCTLVLAVLGAALYFFYKKGKLPCGRSGKQEMERNTSI

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene706">
        <gene_name>MLANA</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>2315</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>5031913</ncbi_protein_id>
        <gene_locus_tag>RP11-546N22.1</gene_locus_tag>
        <gene_refseq>AL365360</gene_refseq>
        <protein_refseq>NP_005502</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>9</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>5890908</gene_start>
        <gene_end>5909821</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>melan-A</protein_name>
        <protein_pi>8.21</protein_pi>
        <protein_weight>12561.33</protein_weight>
        <protein_length>118</protein_length>
        <protein_note>Also known as MART1; MART-1</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000009.12:5890908-5909821 Homo sapiens chromosome 9, GRCh38.p12 Primary Assembly
CAGCAGACAGAGGACTCTCATTAAGGAAGGTAAGAGCGTTGCCTTCTCGCCATAATCATAGTCCTCTTCT
CCCAGAATAGGATTTGGGAAATTCTGGCTAAGTCCTCTGCCTACCCTCATTGCCCCGCTGATGTGTGACA
TCAACAGAATTTCTCCGCAACGTTTGTCAGTCTCCAACCTCAGAGGGCTCACAAAGCCTCCTCCTGAATC
CTCTCTCAGTCCTCCAACACTACCAAGAAGAAAAGCAATTATTCAGGATGGCATCTTGCTGGGGAGAAGC
AGCCTCCCTGAGGTAGATGTGTTCTCCTGTCACTTAAAGAACCACTTCTCCTGGTCTGAGTAGTAAGAGG
CGCATTTGCTGTTGCTGCACCATTTGCCAAGGCTCTGAGTTTGAGGTATGGGATGTATTAAAACAATTTA
ATGAAGAATTAAGATTCCATTCTGTCATTTTGAACACAGGGTTCAGTCCTATATTATTCACTTGAGAGGA
CTGGTGAGTTTGACTTTCATTTCTTTTTTACAACTGGGAAGGGCAAATTACACATAAAATGTCCCAGTGG
AAAGGGGTCATGTGTCGAAATCCCCACTCTTCTGTCTCACCTCTCCCTGTTGTTTTAAACTGGGGCTCAT
TAATATAATTCTATGGGGATCACACCTTTGAAATTCATGAGGACAGTAAGAGAGCAGAAAAATACACAAT
AATAAGGAAAGGAGCTTCCATTATTGGTTTTTAATGAGCGTACTTGAATTACGGCCACTGCAGTTTATGG
ATATTTTTTGTTGTTCATTTGTATGTGTTATAGTTAGAAAAAAAAAGAATCCTAGCCAAGGGACTTGAAC
CAGAGAGAAGCAGAAATTGACTTAAGTAGGAAGGGAAACACATTGTTAGATAAAGTCAGGTCCTGGGCTT
CCTCGGCTTGTTTTGGGTGGAGTGCCTGGGGACAGGCTGAAGCCCCTGTGTGGGGTGGTTTCCTTTGCTG
AAAAGCTGGGCTGGAAGATGTTGTGCTCAGTGCTCAACCTCATGCACCCTCGCGAGGCACAGGCAACGGG
TGCTCTGGGAAACACACGTTATGTATCATAGCCTCTGTTTGTCTGTGGGATTGATATCCAACAATAACTT
TGGAGAAAAATAACTCCTCTAATTTTGTTAGCCACAGCCCTGGGCCAGGGAAGGTGGAGAATCAGTGAAA
ATGCATTTTGTTTGTTTCTCTAGAAGTTTATGGTGCAGAGTCAAATTGAAGGCAAATGAGGAATATTTTT
TCACCAAATAATAACTCAACTTGCAAGTCTTTTTTGCTTTTGTTTGTAGTTTCTTCTTTGAACTTAATTT
TCAGTTAGTAGGAGGGGTTAGAAACCTGAGCTATTGCTAAAGCCCTTGATATGAATGAAAGAAGCAGGTG
CAAATCCCCTCACAGAGAGAAACCAAAGGGTCCTGGCTATGGATATTGGTCACCTAGTGAGGATGCTGTT
GTGGGTCTTTATGAGATGATGAATAGGGTGGCTTTGGATGCATTAATGATGCCCACATGCTCCTTCTGTT
AGGTGTCCTGTGCCCTGACCCTACAAGATGCCAAGAGAAGATGCTCACTTCATCTATGGTTACCCCAAGA
AGGGGCACGGCCACTCTTACACCACGGCTGAAGAGTAAGTTCAAAACCAGACCCAGCAGGGCTTCCAGTT
TGCCGTTTGCTGACACAGCCTGCTGACTTCCACCAGTACATGCCTGCTCGTAAATCTCCCTAGTGTTTAT
CTCCCCAGACAGTAACATCCCTGGCAACAAGGGGAGGAGATTCTGTGCTTCTATAAGGGGCTCAGTCAAG
CTTCTCTGAGGCCAAACAGGCAGGAAGATGGGAATGGTATAAGGTTGGATCTTGCCATTTTTGGGTGCAC
TTTTGACTATTGGGTCTTATCTGTAGGTTCCCAAGTGGAAAAACATCTGTTCAGGATCACAATGCCTCTC
TCCTCAATCCTTGTTCTGTCTCCTCCACTCAAATTCCTGAAGGTGGTTTGCAGACAGAATAAAAGTGAGT
TGCCAAGGAGCCAGTAAGGATGACGGGCAGGTGTGTGTGACTCAGCCCACAGCCAGACTCGAGAGGAAGA
TGGAGGTCACAGCCTTTGCAGTATAACTTTATCCTAAGGAAAGACATTGGGTTTTATGAGTGAATTAAAA
ATAAGTATTTATATGATTAAGCATTTCTAAATGCTAAGCATTGTATACTGGCGTGAGACACTGTTTTTAT
CTTTGAAAAAACTCACAACTTAGTGGGAGAGTTAGGCATGAGATTAATTTCAGCAAATGTAAGTGCGGTA
ATGAAAACCCAGAGGCTGCAGGGACATACTCTGTATGTGCTGGGAGTGGGAAAGGGACATACTCTGTACG
TGCTGGGTGGCAGGGGCAGGGGAGGCCCCACCCTCTGCGTGGGACTCTAACAGGACAACACCCTCTTATG
TGGTCTGTCCAGAACTCCCTGTGAACCTGCTCTTTCTTTGGAAAGAGCTGTTGAACAATCTTTGTTAACA
GTCAACCGCAGGGACCAGCAAGATGTAAAGCCCAACAAAGGCACTGAGGAAGAGTTCAGGCAGACAGCAT
TTCCTCAGAAGACCCTGGTATAGGATCCTCTAATATCCCTGGCCAATTGGAGATGAGGGCGGCGGTATCT
TCTCAGAAAATGTCCTGACAGCAAAAACATACTCTTTGAGGGAGGGGAGCCCATTGCCCGTGCTATTAGT
TAGGGTATCGTTTCAGCTTGTGTATAATCACTCAACAGACTCTTTAAAATATACTTTTATGTCTCGTGTA
AAAATTCAAGAGTAAAGAGTTCAAGGCCTGTTCGTTTTCTTCTTGCTGGTTACTCCCTTGGGATGTCACT
TTTGTCCCCATGGCTGAAGATGTTGTGCCATCACCTCCACATCTTGCCAACAGAAAGCAGGAGGTGAAGG
AGAGGCTAGGACCGTTCCTTTCAAGGGGCACACGTCACTTCTGCTTATTGCTCCACCCCCGCCCCCCGCC
CCGTGGCACCCACCCTGGTGGGTATCATTCTTGCTGTGTTGTAAATGAAGAAAGGTTTAGAGAAATTAGG
AAATGTGTGGCCAGACATGGTGGCGCTGGGATTTAAATCCAGGTCTGTTTGCCTCCAGAGTCCATGCTCT
TAAGTGTTATGCTGCAGGCCAGCAGAGGCAAATATTTGCACAATCCCATCCGACGAGAGGCTAGGGCAGA
GGTCAGTATCTCTCAGTGTGAAGCTGGAGGCTGATGCTAGTCAGCTCAGTAGGCCGAAAGTGGAGTTGTC
CTTTGCCATGTAGGGCCATCATGCCCAGCTGGGGAACCTCATAGCCAGGTGTACCCACAACCTGAACAAG
GTAACTTTCAGGGTCTAGTCAGGAAGAAACCAACTAGATGGTTCAACATAGAGACTTTAATATAAGAAGC
TGGTTAAACAGGCATGGGACTGAGACTGAGGAGGCAAAGAAGGCATCGGGGCAACCAAGGCTGTACCCAC
AGAATGCTGCTTCTACCCCCGTGTCTGGGGTAACAAACGGAAGGGTGAGGCCATCAGGACCTAGAGTTGG
GAGGAGGGACGCCACAGAAATGGGACCCAGATCTCTAAGGAGAGATTTTTGTTTGGCTGGTTCTGGTGTC
TCAAGAGCTTAGAAGTGAGGGGCATGAATCAAATACTCAGGCCTCTGAGGTCAGCCAGTGCTCTGCTGGG
GAGGGGCATAATGAAGCTGGCTCTGACAATGCCGGAAAACGAGCTGGTGCTTGGCATATACAGACAATGT
GAGCATTGCTGGGGTGATCCTGACAGGAGCCAGAAGCACACTGGAAGGAGCTGCTCCTTCTTGATGCCCC
AGGTTTGTAGGCACCCTCTAGAGTACTCTAATGGGAGCCAGTGGGCAAAGGAGAAGTGGCATTTGCAGAG
TCCAGTCCCAGCATCACAGAGCAGAGCATAGAAAGGTAGGTTTGGAGTTGAGGGACAATGGCTTAATAAA
GGGCAAAGGGGGTTATGACCACTATCATGTGAAGGAACCCCTTGACTGAAGGCACAAGCTTTCTGTGTCT
TGCAACCTGAATGACGTGCATAAGCAGGGTCAGGTGGGTTATCTGACATTTTCCTTGAGAACAAGAGGGA
GCCTCTGGATTCCAGCACAAAAGAAAAATACCCACTCAACCCGTATGCGTGGGAGCTATCCTTTAAAGAG
AAAGTAATTCCTTTTGACATTTTGCTGTCTGTAGAAGGGTCAGATGGCCAAAGCTTCCAGCACAATGAAA
CACTTAACTTCAGTCTGTGAGTGTAGGAACCCCTGAATACATGGAACATCATCATCTTGTGCAGGTACTG
AAGGAGATCGGTCCAGAAAATAAGTAACTGCACATGGCCACCAATGTCAAAAGTCATTCCTCTCATGAAA
AGTCCCTGCCCCCATTGCTGTTTGTTTAAATAGGTGGGATGGAGGTAGGGGAATGGGGCCATCTTCTTTT
TTTTTTTTTAATTTTTTTGCATAAAATCCAGATCCTGCACAATGGGGCAATCTTCATTAAAACAATGCAT
CCCTAAGATCTGAGAATATTTATCCTTCTCACAATTGTGCCAGCAGGTGGAATGAAGAAGAATGATGCAA
AATAAGTTCCCACATCCAGCCAAGAAGGACTACATACCTGCTTTGGGTATTATGTATCTCTTTGAAACCT
CAGTGGAGAGCAGTTCTCACAGTTGGGTGGACACAAGTCATCCATGGAACTTGTTAAAATGCAGATTTCT
AGGTGCTGCCACCTAAGAGGCTGATTGGGTAGGCCAGGGGTGGAGTCCTATGATCTGCACCTTAACGTGC
ATCTCAGGTGATTCTGCTGCAGGTGGTATTTGGAAGACACTCTGAGGCGCCCTGCCAAGCTGGGCAGTGG
GTTCTTCCAATGTGTCAGGCATACCCTGGTGCTTTTCGCTCTCAGTTACTTGGGCATGTTGTGAGTACCA
CGTGACCATGCATAAAGTGCTGTAACAGAGCTCTGACTGTGTCAAGATATTCAAGTGGACGCCACAGGGT
AAAATGAGAGCACAGGCATGTTGGGAGTTGAATCAGCTGCCTTCAGTCACGAGAACACACTGAACACTCC
TTGTGACAGCTTCAGTTCAGGAAAGAGTGACTCTGCAGGAAAAGCACTGGCCTGGGAGACCTGGATCTGG
CCCAAATTCTGGTGCTCACTTGCTTGGTCTCCCGTTCCAGTTGCTGTGAATGTTGGTTCTGCCACTTGCT
GGTTGTGCAGCCCTGGGCACTTGACCAGCATAATGTCAGCTGTAAAATGAACATCATTCCTAACTCCGAG
GACTGTGGTTAGGATGAAATAAAAGCATATATGTGGGGGTGCCTAGCCCAGTGCCTGGCACAAATTGGTG
CTCAATGAATGGTAGTCACTATGGTTATGGTAATGTTGATGAATCTTCATAGGTCTCAGCTTCCTGATCT
ATAAAGCGGGTGGACTGACCTACATAAGTCAGAGTTTCCATCTAGCACTGTCATCCCATGGTTCGCTCTA
TCCTGTTTGGAGACGGACAGGATAAGCTTGATGTCTCCTCAGCCTTGAGACAGAAGTTGTCCAGTAGATG
GTACTGAGCAAAAGTCTCTCCAGCAGAAGCCTTAGTTAAACCTTGCTTCTCCTGTAGCTGCTCAGTCTCT
TGTAAGTCACTCAGCTCTGCAGAAACTTTCTTAGCGAGTTGACAACCACAGATAACAGAGTCAGTTCTGT
CGATTTTGATCATGCTGTGATCAGGCAGATGTTAGCTAATTGATGATGCTTGCCCGGAGTGAACAGCTCC
AGGCCCTGTTTCCAGGGTCTTTGTGGTAACTTTGTGGTAACTGTAATGCTTCCCAGGGGTCACTGAACAC
AGGGCCCAAGAGGCTGGTGTAGACCCCCAGATTGGCACCCTGCTGCTTAGACAAGATCCTTCTCAATAAG
TAATGCCACAGCTTTGCTGTAGGTTCAGCCCAGACACTTCTCCCTAGGGCTGCAAGGAGCAAAGCGGGGA
GTTTAGGGAAGGGAGGGCACGAACATAATTGAGACGGATTCAGGTTCAAATCCAGCCTCTGTTTTGTGCT
AGCTCTGTATGATCACCAGCGAGTCATGTATCCTCTGCCTTTTATTTCCTCTTCTGTGAAAATAGGGGAT
GATAAATTGTGTCTACCCTCCAGTGTTGATGTGAGAATTGAATAAGCTAATGAATGTTTAGCACAGCACC
TGGCTTTTAGTAGATGAGTCAGTGTTAATTTCTATTTTCTCTTTGTGGGCTGAGTTGGAGAAAATGTTTT
AAAACAGCCTGATGAGAAGAAAAGATAATTTAGCCCCAATAAATACATTGTCCACATAAAGACCAGTTAC
TATGGCACTTCTCATACCTGGAACTTGGGTGCCTGGGCCATGCCAATTAGCAGAGTTCCTGTGGGCACAC
ACTTGAGAGGCTCCTAAAGACCTGGGTTAGATCCAGGTGCTGGAGGCCTGGTGGGGTGCCCAGTGTGGGA
GGTGGGAAACTACTTGGACACTGGGAGATGCTGCTCTGGGTCGTCAAAGTCCATATGAAGAGGAAGACTG
ATTTATGCTTCATCATAATGTAGAACAATGTTTCAATGACAAAGTGGATTTGTCTATCTCTTGGGCCAGG
GCCGCTGGGATCGGCATCCTGACAGTGATCCTGGGAGTCTTACTGCTCATCGGCTGTTGGTATTGTAGAA
GACGAAATGGATACAGAGCCTTGATGGTTGGTAAAGTTCCCACTGCTGAAATCCCTCCAAGTCCAGGGCC
CTCTTTCCAGTTCTTTCCTCTGAATCTCTGGAGAGTCAGATAATTGCCTCATTATAACCTTCAGCTCTGA
TTCCGGCTTCTGATGCCTCTTTTGCTACATTGTACTTTGGCAACTCTACCTTTGCCTCTGCTCAGGCATG
AACCTCAACCAGGAACTTGCCCTGTGTCTTAGTCTGTGATTATAACATAATACGAGAGACTGTAATTTAT
AAATAAATGAAATTCATTTGGTTTACAGTTGGGAGGCTGGGAACTCCAAGATCTAGGGGCCACACCTGGT
GAGGACTTCTTGCTGTGTCATATCATAGTGGAAGGCATCACATGGGCAAGGGAGTGAGAGAGCAAGAGGG
AGCTGAACTCATTTTTTTTTTTTCTTGAAACAGGAAATCCTGGGATGGAGCGCAGTGGTGAACATGAGTC
ACTGTAGCCTTGACCTCCTGGGCTCAAGCCATCCTCCTGTCTCAGCCTCCAGAGTAGCTGGGACCACAGG
CACGTGCCACCACACCGGCTAATTAAAAAAAAACTTTTTTTTGTAGAGACGAGGTCCCACTATGTTGCCC
AGGCTGGTCTCAAACTCCTGGGCTAAAGTGATCCTGCCTCGGCCTCCCAAAGTGTTGGGACTACAAGTGT
GAAACACTCCACATATGGCCCAAACTCACTTTTATAACCAACCTACTTTTGCAATAACAAACACACTCCT
GCAATAACAACATTAATCCATTCATGAGGACAGAGCCCTTGTAACTTAATCACCTCTTAAAAGTCCTACC
TCTTACCATTGTTGCATTGGGGATTAAGTTTCCAATACACGAATTTTGGGGGACACATTCAAACTATAGC
ACCTGTCTCTTTGGTTCTACTCATAGCAGACTTGGGTACCTGGATGTTGTGTGTAGCTAAGCACTGACGG
TTTATAGGGCACAGGGGAAGGGGTTTGAGGTTCCCTTATAGCAAACAGGAGTATATTAGACACCTCAGGT
TTTACCACTTCTGGGAATTCTTGCTGGTTCTGTTACTCCACTTTGTGACCTGCTCTTCCTACTTTTCTTC
TTCACCCCTTTCCTCACTGGTTACCTGTGAATTCCAAGTTCTTCTGACTCTACACTAAGCATCCCAGGAT
ATCATCAGTGCGATGAGGAAACCATCCTTCCTGCATCAGCACAAAGGGTCACTTGTGTGTTTTTTAACAG
GCTGCATCCTTCTTAGATGGCCAAAGGTTTTAATAGTATTTTTTTCTTCTTTACCCAAATATGCAGGAAG
CTAACACAATTACACAATCCAATCTTCTGGTACCAGTATCCTCCATGAATGGGAAACATCAACTGAGTTT
ATAAGCTATAAAAATTACAGGTTTCAGCAATCTTGCTTAAAGCCAGGTAGCACTTCAGCACTTCAGCACC
CGAAGGCATTCTCCATAGATCTCGCTGTCTCTCTTTCTTGTTATTACAGATCTGAAAGCTTTTCAGGTTG
ATGCATAATGGAAAAAAAGTATCTTTCCAAAAGATGTTGGAAAGTCCCATTCCTCATTCAGCAAGCACTT
CATTTAGAGGAAAAGGTCCTGTGAAAGAGAGGAGGGTTGGTGTGGGGTGGGGATTGAAGCTTGGCAAGCT
GATAAGGAGAAGGTGAGAGATACAACTCTGGATTCTTTCCCTCTTTGCCAAGAAACTTGGGCAGTCTCAT
GTCTCATGTCTCCTGTTCCCCAATGTCTTTCCAGAGCATAAATACAAATACAAACCATCAAAGGCAAGTC
AAGTCTGGGGGCTGACACACCCACCGAGCATAGCCCTCTAGTGTGCTGACATCTAGTGGGAAGGAGGAGG
AGTTGATGAATCTGAACAAGACTCCAATATTGGAGGAAATACTTGAGGAAAGCCTTGGGTTAGAAAGTTA
GGGATAGAATTCCTGCTCATACGGCTGTCCACAACAGGTTAGTAGGGGAGGACTTTAATCTCTGCCATAG
AACTCCATTTGTAACTCTAGCATGGGGTTATGACATTGCCTTGTAATTGGCTATTTACTTTTTGCCTCTT
CGACCCCTCCGCTTTCCCCTATGTATGAACCACAACAGAGAATATTTCTAACTCATCTTCATATCTCCAG
TGCCTAGCACAGTGCCTGGCACATGGTAGTCACTCAATTGTGTTGCATTAGGACTTGGTCCCATTGTCTG
CCATTGAGTTGCTTGGAGACTAGAATTCAACTTCTCCAAGATTCACTAGCTCTATTTTACACCCAGACAT
GTTGGAAATCTGTGATGTAACACAATGTATATCCATTTTTATTTAATACATATTTTCTTCTATATTTTGA
TTTCATTATATATTTGTATATCAAAAACAAAATGTTTAGTCTTTCAAGAAGTAAAGCTATACAAACTCAA
TATGTTGGTACTCATTTCCTAACTATAATTATTAGTTTGATCCTATTGAACACAAATGCAGTAATTTTTC
TTTTCTGCTTCAATGCTCTCATCTTAAATTCATTTAATTGAAAAATAACAGAGAGTCTTAATGTCATGTG
CTCAGACACTGTGAACATTTTGCTTGGTAAGTTTCAAATTCAAACTCTATGCCTCCATTCCTCTAGGATT
AGATCAGTGGTTTGTAGTTTCTGAGACTTTTTATTGAGAGGGAATCGTGTTTAAATTTCCTGGTTTATTT
AATTTCCATATTTATTTTTTAAATTAATATTAAAATCTTATTTTGAGATTTTCATATATCTAGAAAAGTC
AGTTTGGAGATCAGCAGTCTAATAAGTTTAGGCAAAATTATGTAAAATAGTGCATTAAGTATTGCATTTA
ATTACATAATTACCTCCCTTTCTGTCTTCAGTGATTCTATTTTCATTTTAAAGCAAAGGGATGTAAATGA
CATTAAATATGAGCTTTGGGCATGTGAATTACTCCACCTTTAACAATCTTCATTAAGCTTGAAATGTCTA
CTTTTCAACTTCCATTTGTCCACAGAGAGGCTGGTTGGAATTTAGATCTCTTAAAATTTCTCCCTTGGTT
AACAATTCCCCTGAGCCCTGGAAAACATCTTTTGAAAGGAAAGGCTGCTTTTTGTAGCAACAGGAAGTGG
GAAATGATTTGTAATAAACTGAACAGTGGTTTTTATATTAACCAGTTTTACATCTTCACTTGGAAGTTCA
AGGACAAAATACTTTTGATTCTTGGAGAATTTCATGGCCCTTGCTCTCAGCTCAGTTTACACTCATGTGT
CAGGGCACTGTGTTTTTCAATGCATGGTCAGTGGTCACCTGCACTGGAATACTTTGGGGTTCTTGCTAAA
AGGCAGATTCTGGGATCATCTCTGGTGGTGGGATTCAGGAATCTATATTTTAAAATGTACACCCAGTTTT
AATGTAAATACAGAGAACTGGCAGTGAACCGGTAGAGTGGATCATACTCTTAACCTATGGTGAGTGAGAG
GCTTAAAAAAAAAAGAAAAAGAAAAAAATGGTAATTGACAAGGGCAGTTTTATTTTTTTTTCCCAATCAG
TACACCTTTTATATCCTTTTCCAGTTTATTGCATTAGTTATTTGCAACTTCCAGTATGATGCTGAAAAGG
AGTGGTGAGACAGGACATCCTTGCCTTGTTCCTGATCTTAGCAGAAAAGCTTCAAGTATGATGTTAACTG
TTGATTTTTTGTACCTAGATATTCTTCAGCAAACTTGAGTAAGTTTCCCTTTATCCCTCGTTTATTGAGA
GTTTTAAATTATGAATGGGTGTTTGATTTTGTCAAATGCTTTTTCTACATCTATTGATACAATCTTGCAA
ATTTCTTCTTTAGTCTATTGATGTATCAGAATAATTCATTTCTCTTTTTCTTTTTTTTTGAGATGGGGTC
TCATTCTGTCACCCAGGCTGGAGTGCAGTGGCTCAATCTCAGCTTACTGTAACCTTCACCTCCCAGGCTC
AGGTGATCCTCCCACCCCAGCCTTCCAAGTAGCTGGGACCACAGGTGTAAGCCACCACGCCTGGCTAAAT
TTTTTTGTATTTTCGGTAGAGATGGGGTTTCACCATGTTGCCCAGGCTGGTCTCAAACTCCTGAGCACAA
GCAATCCACCTGCCTCAGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACCACGCCTGGCCTGATTT
CTCAATATTGAACCAGGTTTGCATACCTGGCATAAATCCTATTTTGTCATGGTATGTAATTCCTTTTATA
CATTGTTAGTTTGACTTGCTAATATTTTGTTGAGATTTTTTGCATCTGTATTCATGAGTGATATTGAGCT
GTAGTTTTCTCTTTTTGCAATATCTGTCTGGTATTAGGGTAATGCTGGCCTCATAGCAATGAGTTACAAA
GTATTCCCTTTGCTTCTATCTTCTGAAAGAGGTTATAGAGAATTGGTATAATATCTTTCTTAAATGTTTG
GTAGAACTCACCACTGAACTCATCTGGGTCTGGTGCTTTCTGTTTTGGAAAGTTATTATTGATTCAATTT
TTATAATAGATATAAATCTCTTCAGATGGTCTAGTTCTTCTTGCGTGGATTTTGACAGATTGTGTCTTTC
AAAGAATTGTTACATTCACCTAGGTTTTCAAATTTGTGAGCATAGTTCATAGTATTCCTTGCTTATCCTT
TTCATGTCCATTATTATTTCTGATAATAGTAGTTTGTGCCTTTTTATTTCTTAGCCTAGCTAAAGGCTTA
TCAATTTTATTGATCTTTTCCCAGAATCAGCATTTGGTTTCATTGATTTACTCTACTGACTTTTTTTTCT
TTCTTTCTTTCCTTTTTTTTTTCTAGAGACAGGGTCTCATTCTGTCATCCAGACTGGAGTGCAGTGGCAC
AATCATAGCTCACTGTTACCTTGAACTCCTGGGCTCAAGCACTCCAATCCTCCTGGCTCAGCCTCCTGAG
TAGCTAGGACTACAGCTAGCTACCATAGTAGCTAGGATTATAGCATGTGCCTCCAGGTCTGATTAATTTT
CTTTTTTTTTTTTTTAATTTGTAGAGACAGAGTCTCACTATGTTGCTCTGGTTGGTCTCAAACTCCTGGC
TTCAAGCAGTCCTCCTGCCTTGCCCTCCCAAAGTACTGGCATTATAGGCATGAGCCATTGTGCTCTGCTG
ATTTCTTGTTTTCAATTTCATTGATTTCTGCTCTAATTTTTATTTTTCCGCTTACTTTGGATTTAATTTG
CTGTTCTCTTTATTTTCCTAAGGTGAAAGCTTAGATGACTGATTTTAGATCTTTCTTCTTCTCTAATATA
CACATTCAATGTCATACATTTCCCTCTAAATACTGCTTGCACTGCTAAGCAGTATCCCACAAATTCTGAT
ATCATATTTTAATTTCATTTAATTCAAAATATATTTAAATTTCTCCTGAGATTTCTCCTTTGACTCATGT
GTTATGTAGAAGTGTGTTGTTTAATCTCCAAGTGTTGGGAATTTTTCAGTTATCTTTCTGTATTGATTTC
TGCTTTAATTCTATTATAGTCTAAGTGCAAACATGGTATAATTTCTATTCTTTTAAATTTGTTAAGATGT
GTTTTGTGGCCCAGAATGTGGTTTATCCTGGTTAATGTTCTGAGCTTGAGAAGAAAGTGTATTCTGTTGT
CGTTGGATGAAGTAGCCTACAGATGTCTATTATATCTAGTTAATCGAAGATTTTGTTGAGTTCCACTCTG
TCACAGTATATAATTCCTTTTATATATTGTTAGGTTTGATTTGCTAATATGTTGTTGAGTTTTTTTGCAT
CTATATTTATGAGAGATAACGAATTGTCATTTTCTTTTCTTGTAATATCTTTGTTTTTGATATTAGGGTA
ATGTTGGCCTCATACAATGAGTTAGTCCTTACTGATTTTTTACCTGCTGGCTTTGTGTTATTTCTGATAG
AGAGATGTTGAAGCCTCCAACTGTAACTCCAACTTCATAGTGGATGCAACTATTTTTCCTTGCAGTTCTA
TCAGTTTTTATCTCATGTATTTTGATGCTGTGTTCTTAGGTACATGCAATGTTAGGTGTTCTTATGTCTT
CTTGGAGAATGAACACCTTTATCGTTATGTAATATCCCTCTTTATCCCTGATAACTTTCCTTGAAATCTC
CTTCTGAAACTAATATAGGAACTCCTACTTTCTTTTCATTAGTGTTAGCATGGTATATCTTTTTCTATGC
ACTTACTTTTTTTTTTTTGAGACAGAGTCTCGCTGTGTCACCTAGACTGGAGTGCAGTGGTGTGATCTCA
GCTCACTGCAACCTCCACTTCCTGGGTTCAAGTGATTCTCCTGCCTCAGCCTCCCAAGTAGCTGGTATTA
CAGGTGTGCGCCACCAAGCCTGGCTAAGTTTTGTATTTTTAGCAGAGATGGGGTTTCACCATGTTGCCCA
GGCTGGTCTTGAACTCCTGAGCTCAGGCAATCCGCCTGCCTTGGTCTCCCAAAGTGCTTGGGATTACAGG
TGTGAGCCACCATGCCTGGCCTCTATCCACTTACTTTTAATGTACATGTATGTGTCTTTATATTTAAAGA
GGGTTTCTTGTAGAGAACACATAGTTGGGTCTTGTTTGTTGATCCACTCTGACAATCTGTCTTTTAATTG
GTGCATTTAGACCATTGATATTCAAAGTAGTTATTGATATAGTTGGATTGATATCTACCATATTGTTACT
GTTTTCTACCTGTTGCCTCTGTTCTTTGTTTCTATTTTTGTCTTTACTCTTTTTCTGCCTTTTGTGATTT
TCACTGGACATTTTATATGATTCCATTTTCTCTCCTTTCTTGGCATATCAGTTATACTTTTTTCTTTTTG
AGACAGAATCTCACTCACTCTGTCGCCCAGGCTGGAGTGCAGTGGCACGATCTCAGCTCACTGCCACCTC
TGCCTCCCAGGTTCAAGTGATTCTCCTGTCTCAGCCTCCTGAGTAGCTGAGATTAAAGGTGCATACTACT
ATGCTCATCTAATTTTTGTATTTTTAGTAGAGACGGGGTTTCATCATGTTGGCCAGGCTGGAACTCGACC
TCAAGTGATCCACCCACTTGGCCTCCCAAAGTGCTAGGATTACAGGCGTGAGCCACCGCGCCCAGTCCAG
TTACACTTCTTTTTTTTTTTTTTTGAGACGGAGTCTCACTCCGTTGCCCAGGCTGGAGTGCAGTGGTATG
ATCTGGGCTCACTGCAAGCTCTGCCTCCTGGGTTCATGCCATTCTCCTGACTCAGCCTCCCAAGTAGCTG
GGACTACAGGTGCCCGCTACCATGCCTGGCTAATTTTTTGTATTTATAGTAGAGATGTCATTTCACTGTG
TTAGCCAGGATGGTCTCAATCTCCTGACCTCGTGATCCACACGCCTTGACCTCCCAAAGTGCTGCGATTA
CAGGTGTGAGCCACCGTGCCCGGCCTTATACTTCTTTTTTACTTTTTTTCAGTGGTTTCCCTAGAGTTTG
CAACATACATTTACAACTAATTCAAATCCACTTTCAAATAACACTATACCATTTCATAGGCATTATGAGT
ATCTTAAAATAATCCTAATTCCTTCCTCCTGTAAACTAAAAACAAAATCCTAAATCCTCCAAACAACTGA
ATGGACCCCCTCTTCACCAAGGGGACCCCAGGGAAACCTGAAAAACTGAGTGTTGGCCATGACGGGAAGG
GAGGTGAGAGATGCCTCATTATACTCCCTCCCTTTTAGAGTTTTAGGTACAACTGACCAGCATTAATTTT
AAAATAGAGATTACAGGACTGACAGAATGAACTCTTTGTGGCAATATCAAATTAGGAACAAGACAATGCA
AGGAAAGGGTTAAATCATGCCCTTCAAACCATAAAAAAATTTTTTTTTAATTAACCCCATATAATGTGGT
ATACTTTCCAAACTGACTCTGGTATAGCATCACATGACAGATTGCAGACTCCCTTACCTTAAGCATTCCT
TTATACTGACTTCAAGTCTTAAGACAGAGCTGAACTCTTTCAACCAGCTGCTAACTAAAGAATACCTAAA
ACCCACCTGTGACTTGTAAGTCTCTGCTTTGCCATGTCCTGCCTTTTCAGGCTGACCCAATGTATACCTT
CCGTGTATTGATTTATGATTTTTACCTACAATTCCTGTCTTCCTGAAACATATAAAACCAAATCATAACC
CAACCACCTCAGGCACACTTTCTCAGGACCTCTTGAGACTATTCTCCCGGCCATGGTCATTCATATCGGC
ACAGAATAAACCTCTTTAAAATATTTTGCAGTTTTTTTCTTTCTGTTAACATTCCTTTCCCTTGTATCAT
TGCTGTTATTAATTTCAAGTATATATAAGCATACCTAATTAAATACATTGTTGCTATTATTCATTTTTGA
ACAAACTATTATCTGTTAAATCAACTAAGAATAAGACAAATATGTTGGGTGCAGTGGTGCATGCCTATAG
TCTCAGCTACTCAGAGGCTGAGGCAGGAGGATTGCTTGAGCTCAGGAGTTTAAGACCAGCCTAGGCAACT
TAGCAAGATCATGTCTCTTAAAAAAAAAAAAAGAAAGAAAGAAAAACAAAGTTTTAGGAGGCTGAGGCAG
GAGTATCACTTGAACCCAGGACGCAGAGGTTGCAGTGAGCCGAGATCGTGCCATTATACTCCAGCCTGGG
CAACAGAGTGAGACTCTGTCTCAAAAAAAAAAAAAGAAAAGAAAAGAAAAGAAAAAAAAAGTTTTTATTT
TACCTTCACTTATTCCTTCTTGGATGTTCTTCCTTTATGTAGGTACAAGGTTCTGACCTATGTTATTTTC
TTTTTCTCTAAAGAACTTCAAAAGTTTCCTGCAAGGCAGGTCTACTGGCAATGAATTCCCTCAATTTTTG
CTTGACAAAGTCTTTATTTCTGCTTCACTATTGATGGATAATTTCACAAGAGTGTTCCTTTTGTAGATTC
ACTCTTCTTATCCTTCCCTTCAGAAATATTCTTTGACCAACTATTGGGTCCCAGGTACTGCACTAGAGCT
TTACTTCTAGTTAATTCCCACAGCAATTCTGAGAGGTAGGTAGGTATTATATTCCTAGATGCAAACTCAG
AATTCAGAAGGTAAAGTGATGAGACTGAAGGCACACAGCAAGTAAGTGGCAGAACCTAGATTAAAACTCA
TTCTTAAAACTTTGGCTTCCTTCTCTTTTCTTTAATGGATTCAGTTACTTCTTCTCACCCACTCACCTTT
ATCAATTTACATTTCAGGATAAAAGTCTTCATGTTGGCACTCAATGTGCCTTAACAAGAAGATGCCCACA
AGAAGGGTTTGATCATCGGGACAGCAAAGTGTCTCTTCAAGAGAAAAACTGTGAACCTGTGGTAGGTTAA
GATCCTTCATAAGGGTATTTTCATGAATGGCTGTTTTTAACTCAAGTGAATACAATTATTTCCATTTAAA
AAGCAAGGACAATGTGAATGTACTCATTGCCACTGAACTATATACACCTAAAAATGGTTAAAATGGCAAC
TTTTATGTGTATTTTATGAGAATAAAAAATAAATAATAATAAAAAACAAGGGAAGTACAGATATTTTCTT
AATTGTGTTGTCACATACCCAGTGTTTCCAGGGTCAATAATGAGAGCCCTACATGTAAGATTCAAAGGAA
GAATTTAGTCCTGGATACAATATTCTTTTATGTTTTTAGTTATATTTGCCTTTTTAATGGATGCAGATAT
ATACAGAGGGAAGGGATAAAGTACCTATTATTTATTGTATAGAGCTGTGCTGTCTGATGGCTTAGCCACT
AGTCACATGGTGCTATTGAACACTTAAAACACAGGAGTTTGAAATAAGATGTATTATAATACATATCATA
TTTCAAAAATATTAGTATGTAGAAAAGAAGATAAATGGTTCATTAATGATTTTTATATTGATTCACCTTG
AAATAAATATTCTGAAAATATTAGGTTAAACAAAATATTTTAAGATTAATTTTACATGTTTCTTCTTTTA
AATGTAGCTACTAGAAATTTTAAAATTACATATGGCTGGGCATGGTGGCTCACACCTGTAATCCCAGCAC
TTCGGGAGGCCGAGGTGGGTGGATCACCTGATCTCAGGAGCTCGAGACCAGCCTGGCAAACATGGTGAAA
TCCTATCTTTACTAAAAATACAAAAATTAGCCAAGCGTGGTGGTGCATGCCTGTAATCCCAGCTACTTGG
GACGCTGAGGCAGGAGAATCACTTGAACCCGGGAGGTGGAGGTTGCAGTGAGCCGAGATAGTGCCACTGC
ACTCCAGCCTGGGAGACAAGAGCAAAACTCCATCTCAAAAATAAATAAATAAAATAAAATTACATAAGTG
GCTTGTACCATATTTCTATTGGACAGCACTAGTACATATACAACACAGCATAATGGTTGAGAGCACTGAC
TCTGGAGCCAAATTACTGTGTTTGATTCTTAGCTCCACAACTTACTAGTTGTGTGACCATGGGCAAGCGA
GTTAACCTCTCTGTGCCCCAGTTTCCCATTCTGTAACATGAAAATAATAAAAACACTCCCAGAATTGTTG
TGAGCATTAAATGAAGCCCTGACACATTTGTTCTGGATACAATATCCTCTTGTTTTATATTTGGTAGTAT
CAATGTGCCTTTAGACACAATTACAACGATCTCTGTGGTAAAGATGCAATGTATATGGTGTCTATAAATA
GCATTCAATGATTCGTTAGTTAGGGCTTGAGACTTTTACTGTCATGGAAAATCTAGGTATAGCTAAGCTT
TTGAGATTTTGGGAACTCCTTAACCCTATTTTTCTCTACTCTTGCCCCCAACAATCAGCCTATATACTTG
TGAAATTTAACAATTACTTCACTGGGCAGAAATTATATGGGAACACTTAGAAATTTCAGTCCACAGGGAA
AGTATAAATATGTTAACTATTTTAACTTAATCCCTTCCTAGAAACACATACACTGTTGCCAAGCCCATAT
TCTCCCTTTCTTGTTCTCACAGGTTCCCAATGCTCCACCTGCTTATGAGAAACTCTCTGCAGAACAGTCA
CCACCACCTTATTCACCTTAAGAGCCAGCGAGACACCTGAGACATGCTGAAATTATTTCTCTCACACTTT
TGCTTGAATTTAATACAGACATCTAATGTTCTCCTTTGGAATGGTGTAGGAAAAATGCAAGCCATCTCTA
ATAATAAGTCAGTGTTAAAATTTTAGTAGGTCCGCTAGCAGTACTAATCATGTGAGGAAATGATGAGAAA
TATTAAATTGGGAAAACTCCATCAATAAATGTTGCAATGCATGATACTATCTGTGCCAGAGGTAATGTTA
GTAAATCCATGGTGTTATTTTCTGAGAGACAGAATTCAAGTGGGTATTCTGGGGCCATCCAATTTCTCTT
TACTTGAAATTTGGCTAATAACAAACTAGTCAGGTTTTCGAACCTTGACCGACATGAACTGTACACAGAA
TTGTTCCAGTACTATGGAGTGCTCACAAAGGATACTTTTACAGGTTAAGACAAAGGGTTGACTGGCCTAT
TTATCTGATCAAGAACATGTCAGCAATGTCTCTTTGTGCTCTAAAATTCTATTATACTACAATAATATAT
TGTAAAGATCCTATAGCTCTTTTTTTTTGAGATGGAGTTTCGCTTTTGTTGCCCAGGCTGGAGTGCAATG
GCGCGATCTTGGCTCACCATAACCTCCGCCTCCCAGGTTCAAGCAATTCTCCTGCCTTAGCCTCCTGAGT
AGCTGGGATTACAGGCGTGCGCCACTATGCCTGACTAATTTTGTAGTTTTAGTAGAGACGGGGTTTCTCC
ATGTTGGTCAGGCTGGTCTCAAACTCCTGACCTCAGGTGATCTGCCCGCCTCAGCCTCCCAAAGTGCTGG
AATTACAGGCGTGAGCCACCACGCCTGGCTGGATCCTATATCTTAGGTAAGACATATAACGCAGTCTAAT
TACATTTCACTTCAAGGCTCAATGCTATTCTAACTAATGACAAGTATTTTCTACTAAACCAGAAATTGGT
AGAAGGATTTAAATAAGTAAAAGCTACTATGTACTGCCTTAGTGCTGATGCCTGTGTACTGCCTTAAATG
TACCTATGGCAATTTAGCTCTCTTGGGTTCCCAAATCCCTCTCACAAGAATGTGCAGAAGAAATCATAAA
GGATCAGAGATTCT

</dna_sequence>
        <protein_sequence>>NP_005502.1 melanoma antigen recognized by T-cells 1 [Homo sapiens]
MPREDAHFIYGYPKKGHGHSYTTAEEAAGIGILTVILGVLLLIGCWYCRRRNGYRALMDKSLHVGTQCAL
TRRCPQEGFDHRDSKVSLQEKNCEPVVPNAPPAYEKLSAEQSPPPYSP

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>a recombinant adenovirus vector encoding the melanoma-associated antigen, MART-1, was used to transduce murine DCs, which were then tested for their ability to activate cytotoxic T lymphocytes (CTLs) and induce protective immunity against B16 melanoma tumor cells implanted intracranially. Using the B16 murine melanoma, which naturally expresses the MART-1 antigen, all the mice were then challenged intracranially with viable, unmodified syngeneic B16 tumor cells 7 days later. Splenocytes obtained from representative animals in each group were harvested for standard cytotoxicity and enzyme-linked immunospot assays. The remaining mice were followed for survival. Immunization of C57BL/6 mice with DCs transduced with AdVMART1-DC elicited the development of antigenspecific CTL responses. As evidenced by a prolonged survival curve when compared with control-immunized mice harboring intracranial B16 tumors, AdMART1-DC vaccination was able to elicit partial protection against central nervous system (CNS) tumor challenge in vivo [Ref1297:Broder et al., 2000].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene703">
        <gene_name>MUC1</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>4582</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>67189007</ncbi_protein_id>
        <gene_locus_tag>RP11-263K19.2</gene_locus_tag>
        <gene_refseq>AC234582</gene_refseq>
        <protein_refseq>NP_001018016</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>1</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>155185823</gene_start>
        <gene_end>155192914</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>transcript variant 14</protein_name>
        <protein_pi>6.67</protein_pi>
        <protein_weight>26222.24</protein_weight>
        <protein_length>264</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000001.11:155185823-155192914 Homo sapiens chromosome 1, GRCh38.p12 Primary Assembly
GTTGGCGCAGTGGGAGACCACGTTTTATTCAGTCCAGTTCAGGATCCCCGCTATCTCAGGGCTCTCTGGG
CCAGTCCTCCTGGGAGCCCCCACCACAACACTTCCCAGGCATGAGCCCTCAGGGGCCCACATGAGCTTCC
ACACACTGAGAAGTGTCCGAGAAATTGGTGGGGCCTCTGAAGGAGGCTGTGAGCAGCCCACCTGAACTCC
CAGCTCACCAGCCCAAACAGGGTGCAGGGGCTCTGGCCCTGAAGAACCTGAGTGGAGTGGAATGGCACTG
GCTGGCCACTCAGCTCAGCGGGCGACGTGCCCCTACAAGTTGGCAGAAGTGGCTGCCACTGCTGGGTTTG
TGTAAGAGAGGCTGCTGCCACCATTACCTGCAGAAACCTGGGTGGAAGGAAAAGAGATCCAGGGTGAGGA
GCAAAAGGTACCTCCTAGAGCCCCTGGATGCCACCCCAGGCTGGGGTAATCAGTCCAGAGTCCTGGCCAG
CTCTCAAAGGGTTAATTCAGAGAGAGCACCTGCCACCCCACCAGCCAGGTGACTGTAAACAGGGCTGCCC
TCCTCCCTCTGCTCTCCTTCACTCCCTCTTCTTGGCTCTAATCAGCCCCCTTGTCCCTCCATTCTCTGCT
GTTCCAGCCTAAGGAGGTGTGTGTGTGTGTGTGTGTGTGTTTTGGGGGGCGGGGTGTATCTGTGTCTTTG
TAAAGCCGAGAGAGGGAGGTCTCCAGGAGGAGGAAAATAGGAGCAAGAAAACTAAACTCTCTCCTCCCCC
ACCTGGAGTGGTTTTCCAGCCTCAGGTGGCTGCAGTAATTATTTACTAGGTCCCATAGAGAAAGACCAGG
AGAGGAAGGAGGGAGCGTTCCTTGCTTCCTTGAAGCTCCCAAGAACCCCACTGGCACCCACGCTCACCTG
GTCTGCTGACACTTCTTCTTCTACCTGGGAAACCTCCCCCTATGCCAGCCTTTCTCGGTCTACCCTCCAT
TCCTAGGAGATGATTAGGGGCACAGAGGCTCACCCCTGGGACTCCTCGGGAAGGGCTCCCCTGGGCATAG
TGCTCCACCCATTTTGCCTCTGGGTGCAAAAAAGCAAAACAAAACAAAACTGCCACGGTGGCACCAGTTC
AGCCAGCGCCAGCCAGCATGAATGTGGACGGCCAATGATCTTTTAGGAATTCTGGCAGTGGGGCCACTCC
CTCTTGAGGGCCCCTTTCTTCCATAGTCTCCTCCCAGGCCTGTCCCCCAAAACTCCTCTGACCTCTGCCC
CTCATCCTTGCCAGGCCCTCCCCTGCTCACTTCACGCCACTTCTCACCTCTTCCAAGCTCTTTGGGTTTT
CCAAGTACCCCCTTCAGAATCCTTGCCCAGCCAAACCCTCTGCTTCCCCTGGCCTGTGGGGCCCAATCTC
ACCTTCTCATAGGGGCTACGATCGGTACTGCTAGGGGGCACATAGCGCCCATGGGTGTGGTAGGTGGGGT
ACTCGCTCATAGGATGGTAGGTATCCCGGGCTGGAAAGATGTCCAGCTGCCCGTAGTTCTTTCGGCGGCA
CTGACAGACAGCCTGGGGAGATAGGAGGTTATGGCAGGCCATGGAGTGCCTTCTACCGGGGGGCTCTGAT
CAGGGCCAGGGACTGCACTCACCAAGGCAATGAGATAGACAATGGCCAGCGCAACCAGAACACAGACCAG
CACCAGCAGCGCGATGCCCCAGCCTGGCACCCCAGCCCCAGACTGGGCAGAGAAAGGAAATGGCACATCA
CTCACTAAAAGGAAAAGCAGTGGTCAGGGCAGTCTCCCAGAGGAGGCGCCCCTCCCGCTGCCAGCACTAA
GGAAAGAGCGGGGACCCAGACACTGGAAGGAGAGGGGCCCCGGCATGGTGCTGGGCTGCAGCCAGGGAAG
TAGCCTCACCGCTGACGTCTGAGATCGTCAGGTTATATCGAGAGGCTGCTTCCGTTTTATACTGATTGAA
CTGTGTCTCCACGTCGTGGACATTGATGGTACCTTCTCGGAAGGCCAGAGTCAATTGTACCACCACAGAT
CCTGGCCTGGTCACAGGGAAATGGGCACTTCAGCCACGGGTCCCAGCTCTGGCTCAGCACTCTTCCCCCA
ACCTTAAGTGCACCAGTCCCTCCCTACGGTCATGACCACCACCCACCCTCCAACCACCACACTGGGTCCA
CACCCAGAACTGTACCTGAACTTAATATTGGAGAGGCCCAGAAAACCCCCTTGTTTATAAATCTGCAAAA
ACTGGGGTGAGAGGGAAAGGACTCAGGCTTGATGCAAAGGGTGTGGACAGTTCTGATGGCTGCTTCAGGG
GAGCATGGGGAAGGAAAGGCCGATACTCACCATTTCAGAAATGTCTCTCTGCAGCTCTTGGTAGTAGTCG
GTGCTGGGATCTTCCAGAGAGGAATTAAACTGGAGGTTTGAAATGTGAAAAGACAGGAAAAAGAAAGAGA
CCCCAGTAGACAACTGGGGAGAAGTGCTGTGATTGGAGGAGGTGAGAGGAGGTACCGTGCTATGGTGAGT
GCTACTGGCATCAGTCTTGGTGCTATGGCTGGCAAGGGTGGTAGGAGTATCAGAGTGGTGGCTGGGAATT
GAGAATGGAGTGCTCTTGCTGGCTGGGGTTGTGGTAGCCCTGGCAGAGGTGCCGTTGTGCACCAGAGTAG
AAGCTGAGCCTGATGCAGAGCCTGAGGCCGAGGTGACATTGTGGACTGGAGGGGCGGTGGAGCCCAAGGC
GGGCCTGTTGTCCGGGGCCGAGGTGACACCATGGGCTGGGGGGGCGGTGGAGCCCGGGGCCGGCCTGGTG
TCCGGGGCCGAGGTGACACCGTGGGCTGGGGGGGCGGTGGAGCCCGGGGCCGGGGTGGAGCCCGGGGCCC
GCCTGGTGTCCGGGGCCGAGGTGACACCGTGGGCTGGGGGTGCGGTGGAGCCCGGGGCCGGCCTGGTGTC
CGGGGCCGAGGTGACACCGTGGGCTGGGGGGGCGGTGGAGCCCGGGGCCGGCCTGGTGTCCGGGGCCGAG
GTGACACCGTGGGCTGGGGGGGCGGTGGAGCCCGGTGCCGGCCTGGTGTCCGGGGCCGAGGTGACACCGT
GGACTGGGGGGGCGGTGGAGCCCGGGGCCGGCCTGGTGTCCGGGGCCGAGGTGACACCGTGGGCTGGGGG
GGCGGTGGAGCCCGGGGGCCGGCCTGGTGTCCGGTGCCGAGGTGACACCGTGGGCTGGGGGGGCGGTGGA
GCCCGGAGCCGGTCTGTTGTCCGGGGCCGAGGTGACACCGTGTGCTGGAGTGTCGGTGGAGCCCGAGGCC
GGCCTGGTGTCCGGGGCCGAGGTGACACTGTGAGCTGGGCTGCGGGCGCGGTGGAGCCCGGGGCCGGCCT
GCTCTCTGTTTTAAATATACACCGTGGGCTGCGGGCGCGGTGGAGCCCGGGGACGGCCTGGTGTCCGGGG
CCGAGGTGACACCGTGGGCTGGGGGGGCGGTGGAGCCCGGGGCCGGCCTGGTGTCCGGGGCCGAGGTGAC
ACCGTGGGCTGGGGGGGCGGTGGAGCCCGGGGCCGGCCTGGTGTCCGGGGCCGAGGTGACACCGTGGGCT
GGGGGGGCGGTGGAGCCCGGGGCCGGCCTGGTGTCCGGGGCCGAGGTGACACCGTGGGCTGGGGGGGCGG
TGGAGCCCGGGGCCGGCCTGGTGTCCGGGGCCGAGGTGACACCGTGGGCTGGGGGGGCGGTGGAGCCCGG
GGCCGGCCTGCTCTCCGGGGCCGAGGTGACACCGTGGGCTGCTCTCGCGGTGGAGCCCGGGGCCGGCCTG
CTCTCCGGGGCCGAGGTGACACCGTGGGCTGGGGGGGCGGTGGAGCCCGGGGCCGGCCTGGTGTCCGGGG
CCGAGGTGACACCGTGGGCTGGGGGGGCGGTGGAGCCCGGGGCCGGCCTGGTGTCCGGGGCCGAGGTGAC
ACCGTGGGCTGGGGGGGCGGTGGAGCCCGGGGCCGGCCTGGTGTCCGGGGCCGAGGTGACACCGTGGGCT
TGGGGGGCGGTGGAGCCCGGGGCCGGCCTGGTGTCCGGGGCCGAGGTGACACCGTGGGCTGCGGGCGCGG
TGTAGCCCGGGGCGGGCCTTGTGTCCGGGGCCGAGGTGACACCGTGGGCTGGGGGGGCGGTGGAGCCCGG
GGCGGGACTGGTGTCCGGGGCCGAGGTGACACCGTGGGTTGGGGGGGCGGTGGAGCCCGGGGCCGGCCTG
GTGTCCGGGGCCGAGGTGACACCGTGGGCTGGGGGGGCGGTGGAGCCCGGGGCCGGCCTGCTCTCCGGGG
CCGAGGTGACACCGTGGGCTGCGGGCGCGGTGGAGCCCGGGGCCGGCCTGCTCTCCGGGGCCGAGGTGAC
ACCGTGGGCTGCGGGCGCGGTGGAGCCCGGGGCCGGCCTGGTGTCCGGGGCCGAGGTGACACCGTGGGCT
GGGGGCGCGGTGGAGCCCGGGCCAGAACTGCTTTCCGGGGCCGTGGTGACTCCGTGGGCTGCGGGCGCGG
TGGAGCCCGGGGCCGGCCTGCTCTCTGGGGCCGAGGTGACACCGTGGGCTGCGGGCGCGGTGGAGCCCGG
GGCGGAACTCTCCGGGGCCGAGGTGACACCGTGGGCTGGGGGGGGGGGGGAGCCCGGGGCCGGCCTGGTG
TCCGGGGCCGAGGTGACACCGTGGGCTGGGGGGGCGGTGGAGCCCTGGGGCCGGCCTGGTGTCCGGGGCC
GAGGTGACACCGTGGGCTGGGGGGGCGGTGGAGCCCGGGGCCGGCCTGGTGTCCGGGGCCGAGGTGACAC
CGTGGGCTTGGGGGGCGGTGGAGCCCGGGGCCGGCCTGGTGTCCGGGGCCGAGGTGACACCGTGGGCTGC
GGGCGCGGTGGAGCCCGGGGCGGGCCTGGTGTCCGGGGCCGAGGTGACACCGTGGGCTGGGGGGGCGGTG
GAGCCCGGGGCGGGCCTGGTGTCCGGGGCCGAGGTGACACCGTGGGCTGGGGGGGCGGTGGAGCCCGGGG
CCGGCCTGGTGTCCGGGGTCGAGGTGACACCGTGGGCTTGGGGGGCGGTGGAGCCCGGGGCCGGCCTGGT
GTCTGGGGGGGCGGTGGAGCCGGGGCCGGCCTGGTGTCCGGGGTTGGAAAACTGGGCTGGGGGGGCGGTG
GAGCCCGGGGCCGGCAGGGGTCCGGGGCCGAGGTGACACCGTGGGCTGGGGGGGCGGTGGAGCCCGGGGC
CGGCCTGGTGTCCGGGGCCGAGGTGACACCGTGGGCTTGGGGGGCGGTGGAGCCCGGGGCCGGCCTGGTG
TCCGGGGCCGAGGTGACACCGTGGGCTGCGGGCGCGGTGGAGCCCGGGGCGGGCCTGGTGTCCGGGGCCG
AGGTGACACCGTGGGCTGGGGGGGCGGTGGAGCCCGGGGCGGGCCTGGTGTCCGGGGCCGAGGTGACACC
GTGGGCTGGGGGGGCGGTGGAGCCCGGGGCCGGCCTGGTGTCCGGGGCCGAGGTGACACCGTGGGCTTGG
GGGGCGGTGGAGCCCGGGGCCGGCCTGGTGTCCGGGGCCGAGGTGACACCGTGGGCTGCGGGCGCGGTGG
AGCCCGGGTCCGTCCTTCTCTCCGAGGGCCGAGGTGACATCGTAGACTGCGGGCGCGGTGGAGCCCGGGT
CCGGCCTGCTCTCCGAGGCCGAGGTGACACCGTAGACTGGGGGGGCGGTGGAGCCCGGGGCCGGCCTGGT
GTCCGGGGCCGAGGTGACACCGTGGGCTGGGGGGGCGGTGGAGCCCGGAACCGGCCTGGTGTCCGGGGCC
GAGGTGACACCGTGGGCTGGGGGGGCGGTGGAGCCCGGGGCCGGCCTGGTGTCCGGGGCCGAGGTGACAC
CGTGGGCTTGGGGGGCGGTGGAGCCCGGGACCGACCTGGTGTCCGGGGCCGAGGTGACACCGTGGGCTGC
GGGCGCGGTGGAGCCCGGGGCGGACCTGGTGTCCGGGGCCGAGGTGACACCGTGGGCTGGGGGGGCGGTG
GAGCCCGGGGCGGGCCTGGTGTCCGGGGCCGAGGTGACACCGTGGGCTGGGGGGGCGGTGGAGCCCGGGG
CCGGCCTGGTGTCCGGGGCCGAGGTGACACCGTGGGCTTGGGGGGCGGTGGAGCCCGGGGCCGGCCTGGT
GTCCGGGGCCGAGGTGACACCGTGGGCTGGGGGGGCGGTGGAGCCCGGGGCTGGCTTGTTGTCCGGGGCT
GAGGTGACATCGTGGGCTGGCGGGGTGGTGGAGCCCAGGGCTGGCCTGGTGACTGGGACCGAGGTGACAT
CCTGTCCCCAGGTGGCAGCTGAACCTGAAGCTGGTTCCGTGGCCGGGGCCAGAGTGACATCCTGTCCCTG
AGTGGTGGAGGAGCCTGAACCGGGGCTGTGGCTGGAGAGTACGCTGCTGGTCATACTCACAGCATTCTTC
TCAGTAGAGCTGGGCACTGAACTTCTCTGGGTAGCCGAAGTCTCCTTTTCTCCACCTGGGGTAGAGCTTG
CATGACCAGAACCCGTAACAACTGTTGCGGGTTTAGGGGCTGTGGTAGCTGTAAGAAGTTAAAGTCATAG
GGTTGGGTCTTTATGAAGGAAAAATAAGAGCAAGAAGAAAATATAAGCTCTGGCCACCAGAGAAATAATA
CCAGGAGGACTGGGGAGTGGGCAGCCTCAGTAACCCCTGGGTTGGCCGCCTCCTTCCCTGCAGCAGCCTC
CTTCTCTCTGCCCATAGGCCTTGGCTCATGGCCCCTGCATTTCTTCCCCTCTTAAGCCTTCCCTCTCCCT
ACTCTCTTCCCCCTAGACTTCTCTACAGGACATTTGCTTGCCCCTGGTACCCACTCTCAGGGTTGGGGGC
AACTCTTCTCAGCCTGTCCTTAGCCTCTCCCTCCTTCTGGCACAGACAGGGCAGCCTCTGTCTGCAATTC
TTACCTTAACTTCATGGTGCCATCTGCCAGGGAGCAAAACCCACAGAAAGACCACGAAGACCACCTAAGC
AGGGCAGCCCACTCCCCACCTCGTGCCCCTCACCTGTAAGCACTGTGAGGAGCAGCAGCAGGAAGAAAGG
AGACTGGGTGCCCGGTGTCATGGTGGTGGTGAAATGGGTGGGGAGGGGGCAGAACAGATTCAGGCAGGCG
CTGGCTGCTTGAGAGGTGGAGC

</dna_sequence>
        <protein_sequence>>NP_001018016.1 mucin-1 isoform 2 precursor [Homo sapiens]
MTPGTQSPFFLLLLLTVLTATTAPKPATVVTGSGHASSTPGGEKETSATQRSSVPSSTEKNAFNSSLEDP
STDYYQELQRDISEMFLQIYKQGGFLGLSNIKFRPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASR
YNLTISDVSVSDVPFPFSAQSGAGVPGWGIALLVLVCVLVALAIVYLIALAVCQCRRKNYGQLDIFPARD
TYHPMSEYPTYHTHGRYVPPSSTDRSPYEKVSAGNGGSSLSYTNPAVAATSANL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Vaccination of wild-type mice with MUC1 RNA-transfected DC induced anti-MUC1 immune responses against MUC1-positive MC38/MUC1, but not MUC1-negative, tumor cells. Mice immunized with the transfected DC were protected against challenge with MC38/MUC1 tumor cells. Furthermore, mice with established MC38/MUC1 tumors were eliminated after receiving the vaccination [Ref1292:Koido et al., 2000].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1352">
        <gene_name>PAP</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>56318</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>46575784</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AC127422</gene_refseq>
        <protein_refseq>NP_062781</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>9</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>104288239</gene_start>
        <gene_end>104337721</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>transcript variant 1</protein_name>
        <protein_pi>6.19</protein_pi>
        <protein_weight>42128.24</protein_weight>
        <protein_length>381</protein_length>
        <protein_note>Also known as Lap; PAP; FRAP; Ppal; 5'-NT; A030005E02Rik</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000075.6:104288239-104337721 Mus musculus strain C57BL/6J chromosome 9, GRCm38.p4 C57BL/6J
TGAAACATTTCAGACAATATTTTATTAGTTTGGCCAAAGATTAAAAAACAGTGAAGACACAGGATAAAGG
TGACCTGTTGTGTTTGTTTTACTTGACTTTATTGTGGTACTGGGGATGGAACTCAGGGCTCACCTATGCT
AGGCAAGCACTTTGTTGGTGAGCTACATTCCAGTCCTAAGGATGATGTCTATTTCTTCACAATAACCCAA
AGTGTATTTTACAAATAAAGGATGTATGTGTTCTCTCTGCTTTAAAAAAAAGGCTGTCATCGAATGGCCT
AGGCCAGAACTATTCAGCATGGGAGCCACTAGTGACTCCCAAGTCCTCAAAGGTGGCTACTCCAACTTGG
AACAAAACATCACATCACATTTTTAAATACTTAGTATGAAACTCATCTTAAAAATATTCCATGAACACTT
TTTGTTGAAATGTTATTTTACATGCATTATGTTAAATAAATTTTTATATTATAATTCATCTCACCTAAAA
AAGTTTTCCATTACAAACGTGGCTGTAGGCCATTTAAGACCATGAGTGTGACCATATGTGTCTCTTAGCC
CTATCTAGGGTGCCAACATTTCACGATTGTTTGGATAGTTTCTTGGAGAGGGTTTTAAAAGAGAAAGCCG
TTATAATTTGGCTTTTATTTACCCAGAAGCCCCCATGACTGTGAGGAATCAGTGCTAAGAGTATTAGAAC
AAGACAGAAAAAGGACAGGAAGACAGGAAACACAAGTGAATTCAGGGAAGAGAATATCAGCTTTTGTGTA
AAAAGCTGCCCAGTGAATGCCAGTCGGAGCCTCATGTACGCCATTCCTTAAGCAGTGGGATTTTTTTTTT
CACAAGTTCTCCAATTCTCTGTCTGTGCTTTGCCACTAAAGCTCGGAACAACCTAGCACTCGAGCGCTCG
CTCTCTCAGTGCTTTCCTGTATAGGCATCACTAGTGTTTTTGTGTAATTACTATCAACACGCTAATGACT
GCTTCATGGAAATTCTCCACAAAGGCTTCTCAAATGACACGGAGCACACATCACAACAGAGGTGATCGCA
GCTCTAGTGACGCTCTTGCAACATCACCATGACAACTGGAATGGTCACATCTGTCTCATCTACCAAGTAG
TTATCAGTATCGGGAGTTCACATGCCCTGTTGTTGACGTTGCTTATTTTCTGGGACACCCCACAGTTCCT
TTGTGTTCTTTGCATGATTCCTATAGCTCATCTGTCACTTGGGATTCTGCCACAGTGTATGAAAACTGCT
TATAGTATTTACCAACAGAAGATAAAGGGCACTGCGATATTGAGCCTGAGAGCTTTCCATATAGTAATCG
AAGCAATGGTAGGAACTGGGGATTGAGCAGATGGGTAGGTGGGTAAGAGCCCTTGTTGTCCAAGCATGAG
GACTTGAGTTCAAGTCCCAAGCACCTATGTAAAATGCTGAGTGTGGCCCTTGTGTCCCTGTAACCCCAGT
GCTGTGGAGACAAGCCAGGAGGATCACTGGGGCTTGCTGGATGTCAGAGTAGCTTTGGGTTCAGTGAGAG
ATCTTCTCTCAAGGTAAGAAAAGTAATAGAACAGGACACGTGACATAATCCTTTGTTCTCTGCGCATGCG
TGAGAAGACAGCACCCACCCGTGTGCACATTATCACATGCTACATAAATACACACATATGAGAGGGGGGC
TCCGAGTTTTGTTTTCAATGACCTTGGCTCACTGAGAATGGTATTAAAAATACAGACTATAGATGTGAGC
GAGTGGCATTTAACAGAAGGGCTTCCGGGGCTTGAGGGATGCGCTGGGGATCTGCGTGGAGAGCAGGTCA
AAGGTCCCAGCATCCCACATCTAGACAGCACTGCAAAGTGAATTCTGAGTGTGGCCTTGGGAGCTTGAAT
GTCTACGTTTTTCTGCAGAAGAGCACATGTGGGTGGAGAGTGAGCATGGACTCAGGTATATTTCGAGATC
TTTAAGCAACCCCAAGGAAGTAGGGCAACCCACTGAAGAATGAGATCGAATTTATCACCAGTGGAATGCT
TGTGTGTCCAGAGCAGTTTGTCATGCTATAAAGTACATTTTGGCCTTTTTTCCTAATGACTTCATGGGTG
GTGCCAGTCATGGAGGGGTTTGATGGGGCCCTGACTCATCTGTAGTAAAAGCAGAATAAAACTGGTCACA
GAAAATGAAATCTGGATGTGACTTCTGCATTCCTCTTGTCTAGAGTTTTCTACTTTAGAATAAGAAATAC
GACTTAAGCCAGCAGGTTGTCACCCCCCCCCACAGGGTACTTTACTTTCTGTGTTGGCACCGTATAAAAG
TCAGAGAGGACTAAGGGCATAATTCAAATAGAGTACTCTCCGAGCTTGTGTTAGACCCAGGGATTTTGAA
GTCTGGCACGACAGTAAAAAATAAATAAGTAAAAACAAAAATCATTTCATAGTAGCAACAAACAGCCCTT
AAGTATAAGATATCGTAATTTTAAAGTGAATGTACTACCCACTGCATAAAAATAAGGTAGTGAGGGGCGT
GAGGAAGGTGAACTCATCTCATGGGTTTTTCAGTTATTTCTCTGTACGAAAATGAGAGAAAATGACCGGA
GCTGTGCTTAAAGTGAATGATGCTATGGTTTCTGAGAATCGAACACGTCACCTAAAGACATTCTGCATAC
GGATATATGTATGTGTGTGTTGGATGTACACACAGAAATTTGTCAGTTATGAAGTGCTGGGTTTGAATTG
CTTGCGAGTGAGTGAGCGAGAGAGAGAGAGAGAGAGAATGAGAATTAAGCATATTACATAACTAAAGTCA
TTTTTCTGTGGATCTTCTAGTCTAACATTCCGAGTTACCTAGTGCGTTCTAACCTAAATCCTGACCCCAC
TTTCTCTCCCTTTCGTCTTCATAGTCACAAGGTGGGTTGGAATTTGGCTTCTTCTTTCAGGACCTCTGTG
TAAAAGAGCAGAGGCATCCCTTGCAAGAGTCCTATCTTAGCCCTGTGAACAGCTCAATGGTAAGGAGACA
TAACTGACCTGCCAGCTCTGCACTCTCCCCCGTGGCAGTGAGCTCACACCAACTCTAGGTAAGTTCTAAA
GGGAGGGCATGGGCAGGACAGAGCCTGCATGGCAGAAGAGCTTCTTGCCGGTGCTGCTTCATTGAGAGAC
GTCCCCAAGGTCAGCTGTCTGTTCAGATGTTCCGATACACATCTCTCTGCCAGCAGGGCCCATGGCGGAT
GAGGACAAGCAGAAGTATCACCAGGATCCCGGTTACCAGGCAAAATGTAGTGGCAAGGATAACCCTCAGC
ACTGCGAACCGAGAAATACACGCGAAATTAGGACGTTAAGAACGCATGACGATCACAACAAAAAACTCTA
AAGAAGATGAAGATCATATATCATTGTTGACTTTGGGCCTTAATTTAAAAATTAAAAAGATGCTTATTTC
ATGTACAAAAAAAAGTTTATATAACTTTTGCCTTCTTTGTCCTTCTGTTTTTGTTTACTTGCTTGTTTTC
AGAGACAGGGTCTCACATAGCCAGAGGGGCCTTGAACTCCCTATGTAGCCAAAGGTGAGCTAGCTTCAAC
TCGTGATCCTCCTGCCCCAATCTCCCAAGTGCTGGGATTACAGGTTGGGGCCATCCTATCCAGCTTGCCT
GCCTTAATTGTAAATTCTAGAGGAATTTCTGAAGTAGCCTTGGATTCCGAAGAGCTAGGGGTCAGGAGGT
GACCCCTAGTTTCAGCATGACCTTTGACATTTGGCCTCAGCTCTCTACTACAAACGGAAGGAAACTGGCT
GGAGAATCTCCAAGGTCATCTCATAATAACTGCTTTCGCGCCGTTCTCCCTTTCCTTCTTTCTGCCCTGA
CTCTCTTCTCCCCTCTCACCTCCATGGAGTGGACTCAGACTTGCAATCCTACTGCCTCAGCTTCCTCACT
TGAATTCTATGCATTTTCATATGGTTAAATTATCAATCGAATCTGCTCACAAGTTCAGAGGAAAATCTGA
ATAATTCAAGCAATTGACTAAAAGAGGTTGAATCATCCCATTTTTAAAAATCGATCTTTCGAAAACCACG
TTTTATGGAGAAACTGAGCATAGGTTGACCTTGGGAAGCGTCTTTTTTATATTTTTGCATAAGCACGTAG
TAGCACCGAGTCCGTAATTATTGAAAAAGATCCCTTGATGGATAATGGTCCCGATGGCTCATCTGTAGAC
ACTAGTGCTTTAGGAATGCAGATGAGCATCACTGATTTAGCCTAACCTTATCCCAGAGGGAGGAAAGGAA
GAAGCAGAGAGCGTTTGGTCAAGGCTCAGCAGATAATTTTGTTGTTGTTGTTGTTTTGTTTTTGTTTTTC
AAGACCGGGTTTCTCTGTGTAGCCCTGGCTGTCCTGGAACTCACTCTGTAGACCAGGCTGGCCTCAAACT
CAGAAATCCGCCTGCCTCTGCCTCCCAAGTGCTGGGATTAAAGGCATGCACCAATACCACCGGGCAATTT
TATTGTCCTAGAAACACAGGATCTCATCAGTCTCACGATTCCAAATCCATCTATATGCGTATGACTTCTG
AACCGACCCTCATCTCCAGCTATGACTTTTTGCTTAAGCTTGACTCGTACCCAGTGTGTTCTTGGTACGT
AGTAGTCTCCCTTACATATGGATTCACTCTCCGTCAGGTACCCGTGACAGTCAACTATTGTATGAACGTA
TTAATGGAAAATTCCAGAAATAAATGAGTCATCCATTTTAAATGCTACACCTCTCTGCGAAGCATGATGG
CATTTCCTGATGTCCCATCCCATCCCCCTTCCCCCCATGATGTAAAGCAAGTCATCCTTTGTCAATCAAG
TCTATGTCCTGCCCACCAATGACACCACAGCACCTTGCTTCCCAGGCATTGTCGTGTATTTCAGTGCCTA
TGTTCGTTCAAGTAACCCCCATTTTACTCAGTAATGGCTAAAGACACAGGAGTCGTAATGCCGGAAACTG
GATCCATAAGGAGAACCTGCAGTATATACCCTTCGTTGGCTTCATTAGTTTCTAATTCATTTACATAATT
GTTCTATTTCTGTTTCGTTTTTGAAAGCATGTCTCATGTGGCCCAGGTAGGTAGGCACTTGTGTAGCAGC
CAAGGAAAATCTTGAACTTCCGACCCTTCTGCCTCCATCTTCCAAGAGTATAGCAGAGCATCATCTCTAC
GCTGGGATTTATGAGGTCGTGAGGATGAGTCCTCAAGTGTGCCAGCCATTGAGCCACGTCTCCAATTTTG
TTGTGTGCTCTTGTTCATCTATACCATGCCTAATCTATAAATTAAACTTTAACATAGGTGTATATGTACA
GGGAAAAGCATTGCTATGTACAGGTTGAATATTCTCTGCTATGTCAAGTATCTGCTGGGATTTGGCACAT
GGGCTCTTGGATAATAGAGGCTACGGATTCCTCTGGGCATCCAATAGGCACTTCAATCTTAAGGTAAAAA
GACAATACCCAAGCCTCCTCCAGCCGGATCTGTTTTTCTCATAGCCACTCTCCCCTTGGATGATTAAAAA
CTGCCTTCTGTTGGCCTGGGGAGGAGGGGTTAAAAACGAGTCTTCCATGATTCCTTTATTTTCCAAATAA
TCTACACCTGACCTTCCAGGAAAGCCTGTCAGTTCTACTGGGAGGAAAGAAATCCAGAAACCAACAGCTC
TCTCCATCTCTGCCACCATCTGCTTTGAGCTGCCCCCGATTGCCAGGACCACTGTAATGGACTCTTTACC
TATCCCCAGCTTCTATCCTTGCTATTCTGTTCACGGTCTGTTTTAAACACAGCAGCCAAATGTTTACAAG
TCAAGCCTTGTCATTCGGCTCCTTCAGGTGAAGTGTGCTATGGATACTCGTGTCTACCTGAGCAGAAGCT
GAGGACCTGATGGTGACTCTTCCAGCCACACTGCCCTTCCAGATTCTCTTTAAACACCCCTTAGCATCCT
CGCTTGGTGCTATTGTTTCAGCTTTTAGCATTGCTGGAATGCTCATCCTACAGACCCCCGGATGGGGTAC
TGCTTTCCTGTGTTTGCACAAGTCTGCTCTTTTCAATACATTCTTCCCAGTTCAAAGTTTATACAGCATT
CTCCACCCCCTTTTACCAACAAGTGCTTATAATCTGAATCTTTCAAAAACTCTTACTACATTTATTATAT
ATCATCTGTCTCTCGTTTCTTCTAATTGACTATACATTTCAGGGCACAAGAACTATATCTATTAGTATCT
ATGGATCATAGATTAGTACCTGGGACATAGGTGTCAATATATTAATGTTAAAATGAGAGACTAAAATGAG
GGTGTGGCCCAACTGGTAGCATGCTTGCCTGTCAGGAGCAAAGGCCTGGGTTTGAATCTTGATACTGCAT
AAATTGGGTATGGGTGGGGAATGCACCCATAATCTCATATGTCAGGGGATGGAGCCAGGAGGGCCAGAAG
TTCAAAGACAATCCTCAGTTACATGGGGAATTTGAGGCTACCCTGAGATATATGAAACCATGTCTCAAAC
ACAAAACAACCTCCCCTCCCCTGCAAAACCCACTAAAAATAATGACTTAGAACTCACAAAGTGTCAACTT
ATAGCTCAGTGTTTCCCCCATGATCAGGATGCTTTTTAGTGGCATGAAAAATATAATTTTAGGAAAGTTA
AACCCTAACAGACAGTTTATTAGCACTGTCCATGGAGCTGGGATAAAGTTGGAGAGAACCAAGTAGACTT
GAAGAACAGAGAGACTAGATGAAATGAAGGAAGAGGGACAGGTACTAATGATTTGCAGACACACACAGAC
ACATAGACACACACACCCCTTAGATGTCCTAAAAGGCTGTTTTCACTGGGCTGGGAATGATGACACAGCC
TGTAGTCCTACCATTTGGAATGCTAACTTAGAAGGGTTTTAAGCTCCCATCCAGCTTGTCTACAATAGTG
AGTGAAAAAGGTAAATTAATTTTCATGGTTAATTTTCTGACTTTAGAAATTTAATTTTTAATTAGCCCAC
TAATTTTGCCTATGCTACCACAGCAGTCCCATGAAATAAGCATCCCCAGACTTTCATGCAGTGAGCACAC
ACACGTCCTGTGCCAGGCAGGCTTTGGGAGGTGCTGAGACCTCATAAGCTCTGTTCCTGAGAAACCCAAC
ATGTAACAAGACAATCAGACAGACATGTATGTGATAGGTGACACATTGAAATGGAGATGTCACCAATGCC
ATTCCAAGAGAGAAAAGTACAATCAGAAGAGTATATTGAATTTGCAAAAAGGGGAAAATTTGGAAAGCTT
ATGAGATTTGAGGTGGCTTGTGAGAGGAATAAGATTTTACACGAGACAGAAATTGCTACACAGGGTATGT
TTGGGACACGATGAATGGTTATATATGGGCACACAGGAGTCAGGGCTGGGGTTGAGACTGGATGTGCATA
CTGGGGCCCAGTTTTTATGCTTTCAGTTTAGTCTTGTTCTGAAGCACACAAAAATGATTAGCAACTAAGA
TGTCTGGAAGCCAGACACTCTAGTCTGTGTTTAAGAAAAGTAACTAGGGATGTCAAGATGGTGAAGAATT
GGCAGATTTGGTAGGGAGCTATTGAAAGCTCAAGCAAGATAACCAACGCTCTGAACTGGAGTTGCAGATG
TGGTGGGGACACGAGGAAGGGGACTAGAATGCTGATTAATCTTGTGTCTGAGTTGAAAAGTCAGAGTAGA
CACCCCAGTCAAGGGGAAGAAGATGCGGGTGAGATAATCTCCTGGGTTTGCGCTGTGATCAGAGATGGAC
ACCACAAAAAAGGACCGGTACAGACACTAGGAGGAAATGACCTTTATTTTCAAAGTGGTCGAGATGAGCT
CTTCGATGGATAGATGTGACCAAGAGGTAGCTGCAAACAACAGGTCTGTGATTCTTCACTTAGGTATGGC
AGTAAGGATTGTAGATGTGGAAGATTGAGGCTGTGGGTAAGCGTGGGATGAGGGCAGCAGCTATGGGATC
TTGAAGGGTGATTATTTAAAGGGCTGGTGGAAGAGATCTATCCAAAAGAAGCTAGCAAGGGACTCAAGAG
GACAAACAAACACCAAACTAAACCCAACCCACCAAAACAAAAGACAGACAGACAGACAGGCAGGCAGACA
GACAAAACTCCCAGGAAAGACACCCAGCTCTGTCCATTATCTTTTCATCTTTCAGTACTGAGTCTTGAAC
CCAGGGCCTGAGGCATGCGAGCCAAGCACTCTGCCAATGAGGTGCATTTCCTCCCTTGAACGCAAGATCA
TCCTGCCTCCAAGTGCTGAGATTTCAGGCATGCACCACCACACCAGCCTGCCTGTGAAACTTTCCTTTTT
TTTTAAAATTAAAAATTATCTGCTCATTTGAACTACAGACAATTTTAGAAATTTGGCAGTGTTCCGTTCT
AGAAGCTGAGAAATGACGGTGATCCGTGTTTCTTATTGCAAAGAGGTCTAGAGCAAGCAAGGGCTGAAAA
GAGACTCCATCGCATGGGGACACACAAAAGCTGCTGAAGGCAATGTGCCAGACACAATCTTTCTAGCTGA
ATATATAGCCAAGGATGGCCTTGAATTTCTGCTTCCACCTCCCAAGTACCAGGATTATAGGCATATACCA
TCACACTGAATCAAACTGAGCTATTCCTGCATGCTGTATCAGCACCCTACCTGAACTACATCCCTAGCCC
ATTCTTTCTCTCATTCTCGACCTTGGTCACTATAGTAACTACCTCAGCGTCCTTCCCATCCAACCCAGTC
TTTCCCTGTAGCCAGGGTCTTCCTAAAACAAGAAGCCAACAGCAGCACCAGTCCTCTGCCTTTTAAATGA
CCAGGACAGTGCAGCTTCATCAAAGGCACTCTGCACCTAACTCTTCCTAAAATGCCCCATGTTGTCTTCA
GCTTTCTGACTTCTGTACCTTCTCTGTCCCCTTTCTTTAGGGCATTTCCTTCCTGCTCAGCTCCATTCGA
CTGGCTGATTCCTTTTCGCCCTCAGGTTTCTGTTTAAACATTACCCCACTGGAGAAACCTCCTGGACGCC
TTAGCTTTAGCTAATTGCTTCTGTGGTGTGTCTTCAGTGTTGCCTGTGTGTCCTTCATCATGGCTCCCCT
GTATGGCTAGGGCCTGCTGGTTTGTTTCTTTCTTTTTATTTTATTTTTTAGAATTATTTATTTAGTTTAT
GTATGTGAGTACACAAGTTTTCAGACACACCAGAAGAGGCATCGGATCCCATTACAGATGGTTGTGAGCC
ACCATGTGGTTGCTGGGAATTGAAATCAGGACCTCTGGAACAGCAATCAGTGCTCTTAACCTCTGAGCCA
TCTCTCCAGCCCTAGAACCTGTTTCTTAACTCTTTCCCCACTTGTCTTGTCTGTCTTGGGTGTAGACTTG
GTTGGCAGGGCACAGACTAGGTCATAATTGCCAATGGCACAGTTGCCTTCACTGAGGGCAGAAATAGGCA
TGGGGTTGAATTACTGCATAAGCAAGTCATTCTGCCAAGGGCCAAGCCCTTTAATGATGGCCATGTCCTG
GGAAATCGAAGGCAATGGCAACTGGGTGAGAAAAAGATGTTTTAATCACTTGGCCTCGTCTCTCAGGGAG
GGGAGAATGATGCAGGGGGGGAGGGGGCCCCAATGGAGCAGGGGCTCTTAACTATGACTACGAAAAACAG
ATGCTAAGTGACAAAGAGTAGGTTTGCAATTATGGCCAATGACTGGGTCTTTAACAAAGCAGTCACACTT
GAGACTCATTCATAGCTTCTGTCTCCTATGGCTGACCAGCTAACTTCCATGAGGAAGTCTGGTTGCATCT
GGAGGGTTAAACAGTTATCCAGCCCACAAACATCAATTGCGGGGCTGCCAGCACCTCATATATGTAGAAA
ACATCTATGTCATTTTTGTCTTGCTTTAGGTATTGGCTTTCTCAGAACATGTGTTCCGTAGCTATTCCAC
CACCGGACCTCCGACCCCTCCATCCCAAGATCACAGTTCAGCTGTTAGAGCTACTTGTCAAATTGATCTT
GGGCTCCTCTACCCTTTATTTGCTAAATCATGTCCTAAAATTGCTGCTCTCACTAAAATGGCATCCACCC
TTACTGCCCACCATGCTTAGCCTCTGCCATATAGTACCTATGCTAAGGCAAGGGCTTGCCCAACCACGTG
GTCACTTCCCATATCCAGACCATCTTAATTTCCACCTACCACCTCCAGCATCACCCTCTGAGACTTTCTT
GCACAGTGGTGGAGTCTAGTCCTTTTTCATTAGGAAGTTCATGTATGGAGTTTATTCTGTCAGAGGCCAT
CTTGTCCTACAGACTCCTAACAAGCTTTCTGCTAGCTAGAACCAACAGGGTGTTGGCAACTTGAAACAGA
AGCAATCCCCTCTGGTTTGTGTCACTTGCTGAGTTCTGTGAGGAGGAGCTATGACCAATGTCAAGCTACC
AAAGAAAAGTTGTGGAAGTCAGCGTCAGGAAGAGACTCACACGTTTCACCCTTGGATCTACGTGGGATGC
TACAGCATGGTAGCCACTGCTCTTTCTTCTGGCTGATACGATCTGATAATATAGTCACATTTCTCATCCC
TTGGGTATTGAATTGCCAAGGCCACTGTGTTGAAGGGGAAATTCTGTAAATACGCTGCAGATAGGTTTAA
CAAGATGAGACAAACTGGCTAGGGAATAAAACACAGAGCAGGCTAAACAGGACTCTCAGGCTGCTGGGTA
TCGTGTCTAATCAAGAGAGGGAGGTCAGGGGGAAAGATAACTAATTATACACCAGTGGGAAAATATTTAT
TGAGCACCAAACAATGTCCTGTACTGGCTCTCTGAGGTATTGAGGACACAACAGATAAAATTCTTGCTTT
GTAGAACTGATATTCTATCTTATAAAATTCTTATATCCTATAATTCTTGTTCATACCTTAACCCATAGAG
TTACAAAACATGTTCTTGTTCCGAGTAAGACATATCACTTCTTTAACACATTGTAAACTTCCTAAAGGAT
GCTTTGTTGCCAAATTCTACCTTGGGTAGATGAGGTAGAGCTATTTATTGCTTACCGTTTATCGGAAGAA
ATTCAAACTATATTTTAATGTAAAAAATTAACTTAAAAACCCAGCTGAGTAATTTTATATTATATTAGCA
GTCACTTCTGTAACAAGACCATCCCCCCTCCCAAGCAGAAAGAGAGCCCTCATGTCTGATTGCAGGAATT
CTATTCTAATGAAATAAACACAAGCTTTTCAAAGTTCACTATGAAAGTATCTCCCTTTGAACTTCCTAAT
CACAACACTTTTATTCCCTGCTTCTCACTTGCCTTACTGCGAGGCGACAGTTATTTCCACGGGGAAGAAG
TAACACAAAGAAGCTCGTCAGTTCCATGACTGACCCAAGACGGGGTGGCCATGGTCTAGGTCTGGCTTCC
AGTGGAGGTCACTTCCGGCAGCCATCTTGTCTCTATCCAATTTAGAATCCCAGGCGTGTTCTGCCACATG
GCCAGTCAGGCTCTAAAGAGCATCATCGGGGCACAGCTCCGTGTGCAGTGGCTGTAGACCTGGTACTTGG
CTTACGGCTTCTGAAGGTTCCAGAATCAAAGCCTTGAACATTGTTTGTTCTCTGAGAGGATTTTGTAGCC
TACACTCAAAGTGCCAATTAGTTTTGGACTTGGAGGCATTTTGTTTCAGTGGTGTGTGTGTGTGTGTGCG
TGTGTGTGTGCTTGTGTGCCTCCCCCATAGCTCCTCTATGTATTAGCTCTTGATTCTGCATGTTAGGCAC
TGGAGGCTTGGGAGACCCTCTGCAGAGCACTCTGACCTCTGAGGTGCTGTGTCTGATATCTTGCTCTTGT
CAGGTTGTTTATTGACTACAACGCGCCTTGGAGGAGCTGCTGTATGGAAGCCATGTACAGAGCTTCCCAG
GAAGCTTGAGTTTTAGGTTCTTTGAAAGGAACATGAAGGGACACAGAGAGGCTTTTATTTTTCAGTTCTG
CTACCCAGCGCGTTCTAACATCCACATAAAATCTGATCGGTCTAGGCTGGGTATGCAAAGCTTCCCCAGG
TGTCCTCCTGTCTCATCTTTTTGCCTTGAGAGAGAAGGCAGGAACAGGTGAGTGCTGTTGGTGGGGAAAT
CAGTCCTTCGCCCCTTAGCCTGGGATCAGCAGCTTCTTTTTCATGCAGGTGCGCTAACTGGTAGGCTTCC
TTTGAAACCCGCTTGACATCAGGCATTTCCAGCGGGGCTTTAATTCCGTCCTGCTCAAGCAAAAAACTCT
GAGTCCTTCAACAATGGAGTTCTTTGTGCTAATCCTGGATCCCACGACAGCCCCACAACTTTGACCTAAC
TCTTATTCCTGATTACACTGGCACTGAAAGAAACACCAACCGAGTTAGGGATGACGGCAGGTAGGAGTAA
GGTTAGATAGATAGGCGTGGCTTACAGTGAGAGGCTCCTAAAATATACAGTTATCAATCTCAACCCACTT
CCTTCCAAGCCGGGGACAAAGGTGAAAGAACTTTCTGGAAGCCCTAGTTGCTTGAGCAGGCACCCTGCAC
TTCCTGCTGAGCTCCGCAAACTCACTAACCCAAAGCGCCCACAGTACCTTGGTGGCTGCTTGTGGCCATA
CACTCCGTGGCCCAGTCCTGGGAGATCACCGGGTCCAGTAGCTCCGCAAACTTCTCCAGAGGGCAGCTGT
GGGTGCAGCCTGGCAGCGTGAGTGGGTAGGGCTCGTTCTGGGTCTCATTCCGATAGTACATCTCCACAAA
GTGCCCCCTGGTGCGACAGGCAGAGAGGGCGGAGCTGTTAGTCCTGCAATGCTAAGTTGTCCTGTGAGAT
TTCTTCCCACTCAGCTGTAACATATTCCTAAGAACCAGTAGAAGAGCTCGTGAGGAAGAAGGGATTCCAG
CCAGTTCGTGTGGGGTTGGAGGGGGGCGGGGATGTAGAGATTAAGACAGGGGCAACAGGCTTGGGGAGTG
GAATTGGGAGGGCTGACTCATTAGATAAACAGGGTACAGAGGGTGAGGACCAGCATCCTTCATCAATGAA
GATGCTGATTAGTAAAGCTGGGTGTGGCTTTAAGAATGAGCATCTTTATCGGGCTCCTGTCAGCAAGCAC
TTGTTAGCATCCACAACACTGTCTGGGTTTGGTGATTGTATATGGGATGGGTCCCCAGGTGGGGCAGTCT
CTGGATGGCCATAGCTGTCTCCAGAGAGGCTCTGCCAGTGCCTGACAAATACAGAAGTGGATGCTCACAG
CCATCCATTGGACTGAGCACAGGGTCCCCAATGGAGGAGCTAGAGAAAGGATCCAAAGAGCTGAAGGGGT
TTGCAGCCCCATAGGAGGAACAACAATATGAACTAACCAGTAACCCCAGAGCTCCCAGGGACTAAACCAC
CAGCCAAAGACTACACATGGTGGGACTCATGACTCCAACTGCTTATGTAGCAGAGGATGGCCTAGTCGGT
CATCAATGGGAGAAGTGGCCCTTGGTCCCGTGAAGGCTCTATGACCCAGTGTAGGGGAATGCCAGGGCCA
GGAAGCGGGAGTGAGTGGGTTGGTGAGCAGGGGGAGGAGGGAGGGCATAGGGGGAGGGAATTTTTGGAGG
GGAAACCAGGAAAGGGGATAATATTTAAAATGTAAATAAAGAAAATATCTAATAAAAATAAGAAAAAACA
AGAATGAGGATCTACTGGTTGGTTTTTGCTTTTGTTTTTAAGACTTATTTTATTTTATATGTGTGTATGC
TTATGAGTCTATGTCATGTGTGCATGGGTATCCACGGAGAAAAGAAGAGGGCTCAGGTCTCCTGGAGCTG
GAATTACAGGCAGTTGTGGGCTGCCCGATGTGGGGCTGAGAACCAGCCTCAAGTCTTCTGTAAGATCAGG
ATGTGCTCCTAACTGCAGAGACCTCTCTCAAGATAGGTTCTATTGCTGTATTTTTAATTAATTAATTAAT
TATGAGTTCCTGTTGCATCTGCACTTAATCCTTGGTATAGCTTTCTTCACTTCTGTGTTGAGGGAATGAA
CTGGCCTAATTTCTTAGCTCTCAGATATTATACTGGCCTCATATAAGATCCTAAGCAACAAGTTTGAGGC
TCCATGTAAGACAGGTATTCTCAGGTCATGGGTCGTGACCCCTTTGTGGTTGAGCTATCCCTTTCATAGC
GGTGTCTGGGAACATTGGAAAAACACAGATACTTACATTACTACTTATAACAGTAGCAACATGACAGTTA
TGAAGTAGCAACAAATAATTTTATGGTTGGAGGGGTCATCACAACATGAGGAACAATATAAAAGGGGACA
TTTCTGTTAGTGACAAGCTATAGCAATGGGTAAAGTATTACTCATTTCCAAAGAGGGGAAAATGTGGGGG
TCTGCCGAGATGCCGGGACTCACTTCCACATTCTGTCACTTCTGGGGTTTTCATTCACTCCTCTCTCCTT
TCTCTCCCCTCGGGGATTACTTCAGTATTCTAAATATGTCCTCTCCCTCAGCCATAAACACAGACATGAA
CAACACAGACAACTGGGGGTAGGCCAAGATGTCAGACCAAGTTCTATCGGAGAGAAACTGGATGTAGATT
CGATTCCTGAGTCGTTCTAAGTAGGGCTCTCCCCAAATCTTACTTCTGAAACCAAAAAGCTGGAAGGTTG
AATGGCCCTGCACCAACCTGTTTGTGGAATTAACTCGCTTATGAAAGAGTCAGGAGAGAAATTCAAGTAG
GCTTTAATGACCTGTCTCATTGTAATGACCTCATATTTCAACATGTAGATGCTGTTTCATGCGTGCCTTT
AAAGAAGTACTTTAAAGAATGGACACAGTACTGCGAATGTTCATTCATGAGATATGTTTTGTTTGTGTGT
CTATGCGTGTGATACGGCATGTGTGTGTGTGGGCACACGCACACCTATGTGTTCATGGGTGGAGATCAGA
GGACAATGTCAGGCATCTTCCTCGCTTGCTTTGCCCCGTAATTTGGAACCAGGGTCTCTCAGTGATGGAC
GTGGAGCTGGCTGTTTTGGCTATCGTGTCTGGCCGTTTGTTGCCAGGATCTGCCTATGTTTGACATCCAG
GAGGACTGAGGCTCTAAGATGCACACATACACAGTTTTAATGTGGATGCTGGGATCTGAGTTCAAGTCCT
CACATCTGCATAGCAAGCACTGCATCCTTTAAGCCATTTCTCCATCCCTTAAGATACATCTACTTAAAAA
AACAAAACAAAACTCTCCACTATGGCATGAGTTGGTACTTATATCTTGGAGTGACATTTTCAGAAACAGC
CTTCCCCTTTCCTCCTCCTCAAGTGGCCTTGATGACCAATAGTCCAGCAAAATCATAACTATCTTTTCAA
AGACTAGAATTATGGCCCAGAAGTGACTGCATTTTGAAGACTCCCTTGTAGCTCATGGGATCAAGTGTGT
CATTTTAACCAGTAAAGTATCAACAAAAAAGACATGTTTCTTTGGGACTGAGGGATTTGATACAATCGCA
TTTCCACTCCCTAACTTCTTTGTAAAAGCTGCCTACAGGTGCTTCCAGCTGTAGGTCAAAAGCCCAGTGC
CTGATTCTCATCAAATGCTATCGCAATGCAAAACACCAGCCTTGACCGAGTGACCAGTGCTGGAGGCTTA
GATACACAAGGCTTAATTTCCATTGTGTGAAGCCTCTAAGAGCCTGATCTTCACTGATGCAGAAGGGAAA
GCTAATTTTGTGAATTAACATATCTAATTAATTAATTAATCAATCAATGTAGAGTAGTATCTACATAGGA
TCTCATGGTGAAGATGCCTACTAAAGGCACACAAAGGATAAAATTGTGGCACATAATGCGAAAATGGGGG
ACTGGAGAGATGGCTCAGTGTTCAAGAGCACTGACTGCTCTTCCAGAGGTCCTGAGTTCAATTCCCAGCA
ACAACACGGTGGCTCCCAACCATCTGTAATGGGATCTGATGCTCTCTTCTGGTGTGTCTGAAGACAGCTA
CAGTGTACTTATATACATAAAATAAATAAATCTTTAAAAAATGGAAAAATATGGCATTTTAGCACAGGGA
ATCACTATATATTATCTCCAGCTTTAAACTTATATGCCAAATCAGAGAGAAAAACCCTTGAAGTAGATCA
GGTGTGGCACTGAGGCCTGTAACTCCACCACAGGGACCCAAAAGAGGACTTGCAAGCTGCAGTCCTGCTT
GGGTTACATTGCAAGATCCTGTTTCTAGAACAACTCCTTTAAGTGCAGGGTAGCCATGCCACCTACAGTT
TCAACAGCTCTCGGATTAAGAACGGCCAGGAACTGAAAACAGCCTTCCTTTGTGTTGTTATCTTTTCTTC
TTTCAGTAGAAAGTCTAGGGTGACCTTGGAGCCAGGACCAGGTAATAAACAGCTAAAGCCTATGTTAACT
TTGGAAACCGCCCCCACTCCCTTGTTCTAACTTAAAAGCAAGCAATCACTTTTAACCTTTGATTCGTTCC
TGGAGTAGAGAAAGTTATCCTAGATTAACCTGTGGGTTTGTGTGTGACTTTTTGTTAAAGTTTGTGTATG
TGTGTGTTTTTTTTTTTTTTTTTTGGTGAAAAAGTTAATATTAGGGACTTGATTGAGGCCTTTAGAGAAA
GTGAGCCGGTGAGAACATACTGTAGTTAGTGCCCCAACAATTTATGACTTCACACCCCGATAAGCAAGTT
CAGGACTGCACCCCCAATAAATCAAGTTTAGAACTGCACACCCCAATATGCCAGCCGAGGACTTCACACC
CCAGTAAGCTCAGGACTGTGGTGCAGACCCCAGAGAGGAGAGAGAGCTGAGGAGAGCTGACAATGCCTCT
TGCTTTAGATCTGAAGAGACAGCCTACGCCTAGAGCTGACGCTAGGGTTTTAGCTAGATTTCTCAACTCC
ATGCTCAGAGGGGCCTTCAGACTCGGCTGTGAACGGGAGAGCGTTTGTTTCCAAGCGTTTACTGATCTAT
TCACTAGTTTCCACGGTGGGGGTTTTCTCTCCCTTCATGTGAGGTGTTTGAGAGCAAGAGAAGCTAAGGT
GGCACTTTACTTTTTCATGCCTGGCACCCAGTCAGAGGTTCAGGAAAGAATGTCTACCTCCTCCTGACCA
TGATGGACCCACTTTCTTTGTAAATAGTTAAGAAATTGGCTGAGGATGAAGTCTGGGTGGTGTCTTAATA
TTTCCTTCCAGGAAAGAGTCTCCCTGCTAAGAGATTCTGAACAGCCTGCAAACCTGTGAGAGGAGAGGTA
TGTGGACCAATCACAGTGCACCTCATATGTAAATGAAGGCATGGATCTGGGCCAATCAGAGCACACAGCT
CATGTGAAAATGAGAGTTTCATCAGTTAGTCTTGCCTTGCTAGCACCAGTTGCAGCTATGCCTCCAGGGG
AGGTGCTCTCTGCCTTTGGCCTAGGTTGAAATGGTAGTAAGTTCCTATCTAGCCAAGTCTTGTGATAGCA
AAATGTATGATATAAACAATGTGAAACCGTCCTGCTGGCGCTGCTCCTGAGGGGCTGATGCAGCCGTTGT
GTGTCTTCCAAGGTATTCATAGAATGTTCAAAATGGCCGAAGTCCCAGTAAACTAGGACATCTGACATCT
CTAACCTGACTTTTCTTTGCTCTTTCTTCTCTCAGAGGCCAAGCTAGTCATTGGTGGAGGGTCATACTAA
GCCACCAGTGGGTTAATACTGCTTAGCAGTAGGACTTTATGACCATCAGCTGACAGATATGAGTCACAGG
AACTGCGGTTTGCACTGTTTAATTGAAAGATATTTTACATACCCATCAAGCATCTTTCTTTCCCTCTTGG
TGTCTTGTACCAGACAGTTTCTTCCCGCAAGGAAAAAAAAATGTAATGTCTGCCTACTCATTATATTGCC
TTCATTTAAAAAAAATTAATTTCTTTCACTTTGTATGTTTCTCTCAATCTATCTTCTGTGTGTACATTAT
TTCCCAATAAAAGGCTCACAGAATTGAAAGAGTCAAAGGTATTGTTATCACTATCCCTGCCCTCTGAGTA
TAAAGCCAAACCAAGTAGAGACTGACACAATGGCCTTAAGCCAGCAAGACTCAATAATAGCAGGCTGGGA
TAGCAGCACAAGTCTGTAACTCCAGCAATCTGAAGGCTGAGGAGGGAAGATCAATGCCAGCTTGTGTTAC
AGACTGAGTTCAAGACCGACTGACCCCAGCTATGTAGTGAAACGCTGTCTAAACAAGCAAGTCAAGAAAG
AAATGCCTAGCTGAGAGCTTAGAGGGTTAATGGGTTATAGAAGAGGAATAGTTAGTTTGCTTTGGAGGTG
TGGTCCTGGAAAATGACGCTCTCCAGCAGATAGTCCCACATCCATGATTAAATGGCCATCGTAAGTGACA
TGATGTTGGGAAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTTGGATCCAGGAGGAGTTCAGGAGAA
GATGAAGGTGAACACATCCAAAATACATTGAATGCATTTATAAAAGTCTCCAAGGATTAGTAATAATAAT
AATAATAAAAAAAAGGATAAAAAATATAAAGGATAATAAAAAAAATCTATGCGTTCCAGACAGCCAGGTT
TGCATAATGAGTTCCAGGGTAGCCAAGGATACATAGTTGGACCCCATCAACACAAACAAACAGACCCAAA
CTGATAAGAGCAAAGCAGGCACTTACCCCTTATCATGGTACAATTCCATCATGTGGCAAGAAGCGTAGGG
AGGCAGAACTCCATTATAAACATCTAGCGCCATCTGCAGGCCACTCACGGTAGTGTCGTGCTGCAGAGAT
TGGAAACAAGCAATTTTACTGTTTGCTCCCTGATTCAGGTGTACAGACTTCAAGCTGTGTAGGATACAGT
GACGGCTCCTGATTCCTCCACACTCCCAGTGAAAACATAGAAGAGGGGAAAGAATGAGCTTCTCTTGTGC
GTTTGGGCAGTAGGATGGACTCATCTATTGGTTTTGTTTAAAAGATGAAAAGAAAATGGCTATCCAGAGA
AATTAGGCACCTTGCTTAGTTTCCTAAGTAGAATAAATGCGAAGCCCATCTTCTTATTTTAAGTTCCATG
CCTGTAGAGGGCCTTCCTGCTTCTACATGATGTATTGACTTTCAACACATTAAAAAAAAAAGTCCAGGTC
ATGTGCTAAGTTACATTTCCCACATAGTTGCAACATCTTTGATTTTAAAGTTGAAGAAGAGTATAGGAGA
CCAAGGATGTTGAGGGAGGTTAAAGATGTAGGGAAGTAGCGAGTGTAAGGTTTAAAAAGTAAATGATGAA
TGCCATGGTTGTTTACATCAGAGTGGTTTTTGGTCTTTTGGCATGGGAGAGCTATGTAATCTTAGGTAAA
CGGTACCTTGCATTTCTATAAGATGGAAGAATATTTGAACTGTCTGAGGCCTGGGCTATAACTCAGTTGG
TACAGTGCACAAATCCCTGGGTTTAATCCCAGTATTGGGGAAGGGTTTTACACACACACACACACACACA
CACACACACACACACACACACTTAGTGCATACGTCACTCTCTGTAGGATGCACACAGGTTAGGACTGGAA
CCCCATTTAGAAATGTTACACAGCTGTCAGCATTGTCTAATCTCAGGCCCACTTCTCTCTCTCTCTCTCT
CTCTCTCTCTCTCTCTCTCTCTCTCTCTCAGAAGCGCTTCCCTTCCTGTGTGGGCTGTTTCTCTAGCCAT
TTGCATTCAGAGTCCCTGATGGGCATAACATCCCTGTGTCTTCAGGCACCTTTGCTTTTCTCTAGACAAA
CCATAGCTTTCTGCATAACCCAGCTGACCCTCCCTTCTCCCGTTGTCATCCTAGTTTTGTGCCGCACCTC
CATTTAGCCCTCAGCAGGCACAATCTTCTACACCATATCCATCTTCAGCTTCCAGCCACCTACAGGAGGA
TGCGCGCCCACAGTGCTGACCCGTTATTCCTCCCCTGAACAGTCTTCCCCTTCCTGTGGCTCTTCACACA
TTACCACAACTGGCATGGAGAACAAGATGGCCCTTAAAAGCCTTCTAGCTCGAATGGTCCCATTGTTTGA
AGGCTGTCCAAAAAAACAGGGATGCTAAGAAGGCTCCGTGTCTGTACTGTCCAGCCCAAGAGATGCTGCC
TGCGTGGCTGCGTGGCTGCGTGGCCTCATGGCTGCAGGACTGCGTGAGCTCCAAAAATGTGGACAGTGCA
ATTGAGGCCCGTAAGCCTTCTTTTCTTCTTCCTTTTCTTTTTTTCCCTTCTCCTTCCCTTCCTCTCCCTC
CCTCCCTCCCCAACCTTTGTGTGTCTTTCTGTTTTAAACAGGGTTTCAGTATACAGCCCTGACTAACTTA
GAACATTCTCTGTCAGTGAGTCTCAACTTTCCTAGTGGTACAACCCTTTAATACAGTTCCTCGTGTTGTT
TTGACCCCACAATAACAACCTTATTTCATTACCATTTCATAACCGTAATTTTGCTACTGTCATGAATTGT
AACATAAATATCAGATATGCAGGCTATCTGATATGCAGGCTATCTGATATGCAGGCTATTGGATATGCAG
GCTATCTGATATGCAATCCCTGTGAAAAGGTCATTTATCCCCAAAGAGGTCTCAACCCACAGGTTAAGAA
ACACTGTCCGGTGGGGTCCAGACTTGCCTTGGACTCGGCAATCTTCCTGTCTCAGCCTTCCGGTTAAAGG
CTGGGATTACAAGCAGGAATTACCACACTTAGCCTGATGCTTTGTTCTATGTAATTATGGTCGACTTAGG
CTTAAACAGTTGCATGTAGCGACAAAGTTCTTTATCAGGTAGACCAGTGTTATTTGTTATTTTTAAATTC
GATGCCAGAGTCTCCTCTGGAGTTCTTTTCACGAGTCCCACGTGCCCAAGAGGAAGTGCTTACTGTCCCC
TTTCTCTTAATGATTGAGGTCTGTCTAATTCAGGATGCCTGATGCATCTCTTTCCCATGCCCTGCGGCAG
AAGGCTGGCTGGCTGCCTCCTTGGAAATGCAAAAGCACTTGCTTGTGGTGGATTTCCTGTTGCTTGTCTG
GTGTGTGTATGACTGTGACTATCTTGTCATCGGTATTAGTATTACAGTGTAACTTCCACCAGGGCAGAAA
GATGTATTTAATTCTAGATGCTTTGTGATGAAGTCACCAAGATGACGATGTCCTACACTTGAACATGGAT
GTCTATGCTAAATGCACACAGAGATACTTACTGCGGAATACATGACCAGCTTTTTATACTTCTGTGGCTG
AGTTGCAAGCTTCATATTCTTGAGGATTTCATTGACCAGGACGCCTTCAAGGAGACAAGATCAACAGAAC
TGAGTCAAGCATAGGCTTATACAGCGGTCTGTGGGCTTCTTGTCCAATCACAGCTGACAGTTCTATCTGT
TATCAGACTGGGCAAAGACTTAATCTTGGCTCATAATCTGCTGCATGCCAAGCTGTGTGATTTAGGTCTT
GTGGAGCTGAAACTCAGAGGCATCAGTGCCTTACACAGCTTGGAGAGGGGAGCCGAGTGGGCCCCTGAGC
CCTCTCCTAGATTTGCTTTCATCAAAGCCCAAGTTAGGAGACTGATACCCTTGGAAGTTTCCATGCTTTT
CAGACTATATAGACAGTTCTGTTGTTAGCCTTTTTCTTTTCTTTTTTTTTTTTTTTTTTTTTTTTGGTTT
TTCGAGACAGGGTTTCTCTGTGTGTAGCCCTGGCTGTCCTGGCACTCACTTTGTAGACCAAGCTGGCCTC
GAACTCAGAAATCCGCCTGCCTCTGCCTCCCGAGTGCTGGGATTAAAGGCGTGCGCCACCATGCCCGGCT
GTTAGCCTTTTTCAAAGTCAGCCTGAGATGATGGCACGACAGGTACTTGAATCTTCACCTCTGGCTTCTA
CTCGTTATTAGCCAGACCTGTGGGAGGCCATGGGAGAAAGCAACGCTCCATATATACATAGACATAGACA
TAGACATATATATACATACATACATACAGATCATGGACTATCTCCTGTGGACCATTTCTTTAGCTTAGCC
AGGGGTGTGTGTGTCTCACCACATCACCACACCCACACACACCCACACCCAGAGAGAGAGAGAGAGAGAG
AGAGAGAGAGAGAGAGAGAGAGAGAGAGAGACTACATGTGGTCAGCCAGCCTTGTTAGCTTCCACATAGC
ACATTTGCAGACTCGATCTTCATTTCCTTCTATCCAAACCCTGGACTCTTCTGAGGGGTTGAGTGAGGTA
GACTAACAACTGCCACTTCCAGTTTGTCTGTAGACAGTGAAGGCTGGGGATGGGGTAGGGGTGTAGACAC
CCAGCAATGGCAGAGTCTACTTTGAGGATATACTGCCTTAGAGACGCCCCCTTGCTCCCAACCTTCTCTG
TTGAGGAATCTCCAGAGAGTTGAGTCCTTGAAGCCTTGTTGGTGTGTGTGTGCCCTGGCTCAGGAGTGGG
TCGTGGTGATGTTTATTTTTGGTAAGGAGCAAAACTGAAGGCTCTGACTGTAATCCCCACAGTCTGTAGG
GCTTTCAGAAATGCATAACAAACAGTTATAACAAGACAGGAACCATGCTAAGTGAACCAGACACAGTCCC
TGTCCCCTAGAAGGCTCATGAAATAGTTAGACTTAGGCATGTGGGTTGGTAACTTAGCAAAGGTGACCTC
TTCTCTTTGTGGATGCTGGAATTTCTTGGTTGTGAGTGGAAGAAACTGGATGCTGCATGTTGAACAGGTC
CAAGTCTCTGGCCCAGGGAAGGCTACCCCATAGAATACTTAGGGCATTTCATATTGTTCTTCGAGCCTCA
TCAACCCTAAACTCGCTGAGTTTCTGAGAACCATAAAAACTGCCTTCAAGGAGCCGTTGGCCCTTTGTCA
ACAGGGGCCTTGCGTCAGGCTATAGCCTGGCAGTGAAAATGGTACCCCCTTTAAGTTCTGGGGAAGTTCT
CTTCTTGTTCTGACTACTGTAAGTACCCTTAGGGCTGGAATTCTAATACACTGATGGATATGTGGGGGAA
TGAGACTCGGCAAGGCTTAGATGGATATGTGGGGGAATGAGACTCAGCAAGGCTTAGCAACATGCCCAAT
GTTATGTAGTGTGTAAGCAGAAATGCTGGGCGTTGGACAGTGTAGCAAGACGCTCATCCTAGGTTTCTTG
TATCCATTCTTTACTACATCAATAAGTCAGACAACAATCACTGTTTAAGAGACATAAACCCTACTTATTA
GACTCCTTATCTACATACAGCAAAGATTAGCAAATTTTTCTTTTCCATACAAGGCCAGATAGTAAATGCT
TTAGATTTTATGAGGCACAGGTCTGTTGCCGCTACTCCGTTTTATAGTGGTACCTGGGATGTCGCTATAG
GCAAAACAGAATATGAGTGGGGCTGTTTCAGGAAAACCTTATTAGAGCTCCCTCTGTAGCCACTGCTGGA
GCATCAGCCACCAATCCCTTTGTGACTTCTGACTCCAATGGGTCTTCTCCATTTGGAGGAGGAATACTGA
CTTCCTGTCTCTCCAAAGGGCTAGGCAGAAGTGCTGGGTTCATCTTTGCCCACCAGAAAGGGCAATGATG
TTCAGTTTGTACAAGGATGCCATCAAGGTCAGGTGACTGGCACGATAGAGGGTAGAGCAGGTTCTCAGGA
AGGAATGGGTGTGGTGCAGCGGGGAGAGGCTAACAGCACAACTGTCCAAGTGGATTAATGGCACTTATCG
AGAGGCTGAAACTATACAAAGCTCTGAAACAATCCTGGAACGGAAAGCCAGATCTCGCCAAGTAGGAGTA
GAAGATGAGAGGCTAACAGCACAACTGTCCAAGTGGATTCATGGCACTTATCGAGAGGCTGAAACTATAC
AAAGCTCTGAAACAATCCTGGAACGGAAAGCCAGATCTCGCCAAGTAGGAGTAGAAGATGAGAGGCTAAC
AGCACAACTGTCCAAGTGGATTCATGGCACTTATCGAGAGGCTGAAACTATGCAAAGCTCTGAAACAATC
CTGGAACGGAAAGCCAGATCTCGCCAAGTAGGAGTAGAAGATGAGAGCACCAGGAATGAGCAGTGGGGCA
AACACAGGGAGAGAGCAGTAGTGTAGATGGCCTGGTGTAGACAGCCTTCACTAAAGCTGGATAAATGCAA
TGTAACGGGGACTTATTTACAAAACCAGGCTCAGGGCTGAATTCAGCTCGCAGGCAGTTATTTGCCAGTC
CCTAGTCTATGGCAAGAATAGACAAATGTTCCTGAACTACACTTGGGAACTTGGGTTTGGGAGGTGTGAT
GGTTTGTATATGCTTGACCTAGGGAGTGGCACTGTTTGGAGGTGTGACCTTGTTGGAGTAGGTCGGTGTG
GGCTTTAATACCCTCACCTTAGCTGCCAGTATTGTGCTAGCAGCCTTCAGATGAAGATGTAGAACTCTCA
GCTCCTCCAGTGCCATGCCTGCCTTGGTGATAGTGGACTGAACCTCTGAACCTGTAAGCCAGCCCCAATT
AAATGTTGTCCTTATAAGAGTTGCCTTGGTCATGGTGTCTGTTCACAGCAGAAAACCCCTAACTAAGCCA
GAAGGTATGTATGGGTACATCTTACTGAATACTGTCATCCACAAAACCAAATATAAAACAAAAGTTTCAG
CAAATGTGAGATGACACTGGTCACCCCCCACCCCAGGTGTTCTGTGTTGCTGTGTCCTGGAGGCTTTCTA
CATAGGCCTGTGCCCAGCTGCTTTATCATTCAATCACCACGCAGTTGACAACTCTCCCTCCCTCCTGCCC
CTCTCTCTGTCTCTCTCTGTCTCTCTCTGTCTCTGTCTCTGTCTCTGTCTCTCTCTCTCTCTCTCTCTCT
CACACACACACACACACACACACACACACACATACACACACACACCTAACGGGATTGTAATAACAGGCTA
AGAGGATGTATTGTAAAACACCATACAGGAAGCTGGACATGGTGGTACATGCCTCTAATCCCAGCACTTG
GGAGGCAGAGACAGGCATATCTCTGTGAGTTCAAGATCAGTCTGGTCTATGTAGAGACTTTAATGCTATC
CAGAGCACAGTGAGATCCTATCTCAAAACAACAACAACAACAACAACAACAACAACAACAACAACAGAAA
TCTCATGCAGGAAACAAGTTTTCTAGCTAATCAAGGGCTGACCAGAAAACAGGTCAGGTGTGTTCACATG
AGTGCCAGCCTTTATAATCCAAGACCAGACATCTCAGAGAAGGACCTTTCTGAAGCTGACTCTCCCTAAT
TCCTCTCTTGGCCTGCTTACATCAACATCCTTGCAGGACCCCGTATCCATTCATCCTGGCTTCTTTCTTC
TACTTCCCTATCCTGCTTTTTTTTTTTAAAAGATTTATTTATTTATTAGATGTAAGTACACTGTAGCTGT
CTTCAGACACTCCAGAAGAGGGCGTCCGATCTTGTTACAGATGGTTGTGAGCCACCATGTGGTTGCTGGG
ATTTGAACTCTGGACCTTTGGAAGAGCAGTTGGGTGCTCTTACCCACTGAGCCATCTCACCACCCCCCCC
CCATCCTGCTTTTAAGGGCCCAGCACCCTTTTTACTGGCTTTGCCTTCATGATGGGAAGGTGTCAAAGAC
TACAGCCGTGAAGTGGGGTCACTGATCAATATCTCGATGTCTTTCAATGCCAGCGGACGAAGTCATTTAA
ACTTGTCTACTGTTTGTGAAACATATCCAGCTTTTGCCAAACGTCGCACTTGTGCTTTACCCTATCGGCT
ACCAGACACAATCCACTCTCCTGGAACCCAGACATAAGTCCTTAATCATTTTCTCTGGAAGAGATGGAAA
AGACCATTTTGTCTTTAGCCCAAAACTTTCATTTCCAGAAGTAAACATTACACCAGAGTGGGCAGTGCCA
GCACAGTGTTGGAGGACAGTGTGTTAGGCACCAGGCGCTGTTTGTGCTAAGTCTCTTAAACATACATTCG
CTTTAGTAGTCAGTGTCTCCAGCATACTGTTCTTAGCATATCTGCAAGACGATAATAAAGTGATCTGTGT
AAAACCAATCACTGGGTGGGTGACGGGACTAGAACTCAGACCTAGACTGTCCAACCCCAAACCCAACATT
CTCTTTTTGTTTGAAAAAAAAATACTCACCCCCTTGGAGTCGAGATTTCTCTTTCTGCTTGTGAATTCCA
TAAAGTGATAGCAGAGATAATTCTGATAGCTCTTTCAACTTAATCATGGCGTCCTCGGTGGCCCAGGAGG
GCAAGGTGAAATTGTGAACACTCTGCAGAAAAGGGAACAGAGGAAAATATGTGCACACAGTTGTGAGTTA
TGACCTCCTTTGTTGAGTGCCATTCCCCACTTCACCCTACAAGTAGGGCGAGCAAGCCTGGCAGCCTCAA
CCCAGGAATTGCCACCTTCATATTGGATTGGCCTTAGGTAGGTCTATGATGCATTTTCTTAATTGGGAAT
TGATGCGAGAGGGGCCAGCCCACTGTGGGCAATGCCAACCTAGAAGGTGGTCTTGGGTTGTATAAGAAAG
CTGGCTAAGAGTGAGTCAGAGGGAGAAAGGCAGTAAGCTACATTCCTCTGTGGTCTGTCTCTAAGATAAA
GGCAAAAAAAGCAGAGAGGGTCAGATGCTGTAGCCTGAAAATCAGAAGGACTTTCTTAAGAGGCCAGTTT
TAGAAGTCTACCTGTTTCTGGAATTTTCACAAGTATAATACAAGCTTCTAGTTCGCTGGCTGGGGGAGCA
TCCGTACCCCATGCGCAGTGAACATTTACTAGTAAATGTTTGCTAATTGTATGATGGATCTGCAAGCAAC
AAAGATACAGGACCTTATGCAGATGTTTATTACCTATTAGGAAGCATTGTTAGGGTTCCTTTGGTTTCAA
AAGTTGAAGAATGGGAAGGAGGAAGAAGAGGAAGAGGAAGAAGAAGATAGAAAGAGAGGGGGGAGAACAA
GGAAGAGAAGAGGTTATGAGAAGAGCAGAGTGAAGTAAAGAGATGCAGAAGGAAGATGCAGGGAATGTGA
CAATGACCCCAGGTAACATGGGCTCATCACAGAATAACTCAGGTCAAACCATATGAAGTTGCTGGGGTGT
GGCTCAGCAGTAAGGCTTGCAGGAAGCATGGCCCTGCCTTGGCCTTAATCTCCAGGACAAGCAAATGAAC
AAATAGAAAACTAGAGTAAAGGGGAAGGAGAAGAGGAGGAGGGAGAGGAAGAGGAGGAGGAGGGGGAAGA
GGGGGAGAAAGAGAAAGAGGAGGGGGGAGAGGAGGAGGAGGTGGAAGAGGAGGAGAGGAAGCAGCAGCCA
TCAGGACAAAATGAGGAGCCTTAAAAAAATGCTGATGATAAAGAGAAAGGATGGGAGAGCGCATGGTTGG
GTCACCTGACTGCCACAGAGATGGGTAAACTGTGTCATCTCTCATCAAGACGGATGTAGGAGGGGAGCTC
CTGCCCTGCACACTCATGGTGACCTCCATGTCAAAAGTGGGCATGAGGTATGTATGCAGTGGTCAGAACT
TTGCGCCAAGATACAGGAATAAAAGTTACTCCGTTTGGCCAGAAGGTGGAGCCCGGTGAATGAAAAGCAT
CGCATGCGGACTATCTAGTGCTCTATTATCCATCTAGGAAGACGATTTCAGTTGCACCACACAGGGAGTT
CTTTCCTTGGAAGCCACGTCGGGCAGCCTGGCTTACAGTTGTCTGGATTATTTTAATATCCAGAAAGCTG
GCAAATTTCCTCCCCCATATATAAATAAAGCAACATCACAATATTGCTCCCCCCTTCCCCCATTAAATCC
AACGACAGGAACCTGGCATTCCAGTGTGACTGCGAAGTAAATGACTGGAAATGTTTTGAAGAAAAGCACA
TTTGTTTGCCGTTTCATAAAGGGCAAACGCATAAGTAATGGGAGAAGAGAAGTGCAGATTCTCGAGTTTA
TATACGGAAACCCTGAGCCGCACTGCAATACCAAAGGCCATCTAAACAGCACAGAGTTTACCAGATTCGG
TGTATGTATCAAATCACAAAACCAGATTGCAAATGAATCTTTGATTAGTTCTCTTACCTCGCAGAATAAA
GGGTCATAAACTTTACTCCAGATTCCAAAAAGATCCTGGTCATCGAATCCCGACAGCGACGACAAGGTGT
CCAGGAAGCTCTGCAACACAACCAAATAATTGCGGCTAAGGAATCTGACCTGAGCTTACTCCTCATAGCG
CCTTAAAGTGGCAGGTACAGCTTGGGTTATGGCCACGTGTTCCTGGTTTGCGCTAGTGGCTGATGGGAGC
ACTCTGCCTGGGTGAAGTATCACACATGCAAAGGAGTATCCCTAAGCGAGAAGAGAAAGGATGGGCAAAG
CACCGGAAGTGCACCGGAAGTCTCTGGTTACAGAACTGAGCTCTGGATGGAGTGCAAGCATTTCCCTCAC
TAGAAGGGTCTACGTTGTCATCACGTGACTCGCGTTGGCCCGTGAGCTTGGCAGCCATTTCTAGGAAGTC
TTTTGGAAAACAGTTTAAAGGATAAAATTTCCAAGAGACTATCTCTTTTCAATGTTAACCTCAACAGACT
TCCATCAAATAAACAGAAATAATTGTTAAAAAATATTCCATTGCTGAGGCTGGAAAGATAGCTTGGTTTC
TAGAACTTAATGTGAAAAGCCACACTTGGTGGCATGAGCTTGTAACACGGCATTGAGGAGGTGGAGACTG
AGGGTCCCTGGGGACTTCTAACCAGCCAATCCAGGCAAAGGGTAAGCCTCAGTTCCCAGAGAGAGACCCT
GTCTCAAAAAAACAAAGTGGGTGGTCTTGAGGACTCGAAGTTGAATATGATTCTGGGCTCTCTATATAAG
TGTACACAGATGGGCATAGAAGAACACACACACACACACACACACACACACACACACACACACACACACA
GAAGAACACATATACCTGCACATGTGTACACACACCTACCCCCAAGATACGAAAAATAGTTCCTATCCTT
TCTGGCTAAAACACAAAACTCCAGAGTGCATGATTTCTTAGAGGAACTCTGTCAAGCTCTTCAAGGGCAA
CTTATTCTAATGCTAGTTTAACTGCTTGGGACCATTAAAAAGAGAGGAAAAACTTTCCAAGTGTTTATGT
GTTAGTCCTGATACCAACGCTAACGGAGAGTGCTCAGAAATTAAAATGGGTTCAGCGTCACTTGTAAATA
CCAACACAGAGCAAAAACATTAGCAAATACTATAATTTCACACAAAAGGAAAAGGCTTGATTTGAGAAAT
GTAAAGATAGTTCAATTCTAGTAAATCTTAGAGTACAGTAATAAAGTCATTGATCCAAAGAAATTAATTG
GTTAAAACACTCATGACATCAGAGAAGATAGATAAATTTAGTTTAGTTTTAGTTTTGTTTTTTAAAGATT
TATTTATTTATTATATGTAAGTACACTGTAGCTGTCTTCAGACACTCCAGAAGAGGGTATCAGATCTCAT
TACAGAGGGCTATGAGCCACCATGTGGTTGCTGGGATTTGAACTCAGGACCTCTGGAAGAGCAGTCAGTG
CTCTTAAGCGCTGAGCCATCTCTCCAGCCCTAGTTTTAGTTTTGAGACAGGGATGTCATTTTTACCCTGG
CTTGCCTAGAATTCTCTGTGTAGTCCAGGCTAGCCTGAAACATATGATTTTCTTCCTGCCTCTGCCTCCT
ACAAGCTGAGATTATAGATGTGTTACCACCATGCCGAGGGATTGGCTACATCGTCAGCTTAATAACAATA
AAGAAAGAACTACTATATTTTGACTCAAAAGTTAGTGCACTTAACGGTAGACAATGTATAAATTAAGAAT
ATGACAAATGAAGCTGACTAAAACAGTGTTGTGTAACATTGTGCTGTAGCTACTGGCCATTACAAGCAGG
CAAGAGAAGCAACCAGAGAGGCAGATACTGGAAAACTGGAGATAAACCACTGCTATTTACAGATATTGTA
AACTGGAACAGATAGACCAAATGTAGAAAGACTGGCTGGAGAGATGGCTTAGCGATAAACGTGTTGCTTT
GTCAAAGGATCCATGGTCAGTTCCCAGCATTTACCTGGTGGTTTAACATCATCAGGAACTCTAATTCCAA
GGGAATGGAGGCCTCTCTGACCTCTGCAGGCAGCAGGCTTGCATGTGGTACACACTCATATGTGTAGGCA
AAGCAATCATACACATAAAACTAAAAAGTCTTTTAAAATATGTTTAAAACATTTTAAATTATGCAAAAAT
ACATGGCAAGAGCCTAAAATGATCTTTAAGACAAGTACAAAGATACCATTTTTTTAAGAAAAAGTTCCAC
ATCTAATGGTTATAGATCCTCCCTAATTTAGCATAAATTTAATATTATCTCCATAAAACCACCAAAGAGT
TTAATGTTTGAAGCTAGGGAAACATGAATATTCAGAGAAGAGTAAATCTCCCTTTCACAGCCCATATTTC
TCCTAGCATCCCTTGGCTTCCTTTTCCCTGTAGTATATGTGATTGTAGTATATGCTATTGTGGCATATGT
GATTGTAGTATATGCGATTATAGTATACACTGTTATAGTATACTGGCTGATCCTACAGTTTAAAACGAAG
CTAAAAGTACATACATGAAAATTCAGAACAGAGAGGAGCTGGGTGTGGAGGTGCAGGCCTTTAATCATAG
CACTTGGGAGGCAGAGGTGGCAGATCTGGGAGTCTGAGGCCAGCCTGGTCTAGGTATGAGTTTCAAGGCA
GTCATGCTATATAGAAAAATCCTGTTTCAAAAAAGGTAAAACAAAAACAAAAACCAAGCAAACAAACTAG
TAAGAGAGGGGTGACAGGTGACTTTAGATACTCAGACAGCCCACTAAATTCCAATAAACCATGGTCTAAT
AAATAATCAGAACAAGAAATAGAATTTAAGTTCTAGAAACAGCCTCCATCCATGAGGAGATTTTAATATA
TAGGAGCTCAGATTGGTGAGAAAAGATGAGTCGGTTAACAGAGAATGGCAAACCACAAAGTGTTTGTAAA
GGTAATTGATCACAAGTGAGCCACACTTCCAGGAAATAAATAAAAATACGTTACGGTAAATCAGTAAATT
AAGATACTGCACATTTAACCAAAAAAACAAAAACAAAAACAAAAGCCAGGTGGTGGTGGCGCACGTCTTT
AATCCCAGCACTTGGGAGGCAGAGGCAGGCAGATTTCTGAGTTTGAGGCCAGCCTGGTTTACAGAGTGAG
TTCCAGGACAGCCAGGGCTACACAGAGAAACCCTGTCTCAAAAAAAAAAACCAACCCCCCCCCAAAAAAA
GATACTGCACATTTGCCAAAACCTGAGGAAATATTTTCCCTACAAATATAAAACATTTTATTAAGCAATG
ATGATGATCATCATCACTTTCCTGTGCATGGGAGAACTAGAAAACCCCACAGAAAACAATGTCACTAGTG
ACCTTCGTGGGGTCATTGAGAGACCACCATATTCTACTGTGCTTTTGATGTTTTCTAATTCTTGGACCGT
AGAGATATGTAACTGACTCAAATGGTTACTTTTAAAAAAAAAAATCTAAATTATTATGCCTACCTTATGC
GTTATCCTGAAAAGCGAGTCCTTCCCAAAAGGGAAGAACATACTCGGGCTTAGGAAGATGAGGGTCTCCG
TCCCTCAGCCTCCTCAGAACAAGCATTCATTCTCACACACCAGGTACCTGTCCAGGACATGGGCGAAACC
TGGGAGGGACCGGCCCGGCCTCTGTGCTGGCTGGTGACCACCACACAGGGAAAAAGACCCAGGTCACACC
CCAGAACATGCTAGAGGGCACTAACTTTATATGGATGAAGCCTCTTCAAGAATTCCTCAGATTCTAAAGT
CTCACTCTTGAGTTCTTCAAAACGAGGGCAGTCTCTGAAAGGCAGGTACAGCAACTGTGGACAAAAGAAA
AAACAAAACAGAGCAAAACAAAATGTAATCCCTTGATTATTCAAGCGAGAGCCCGCAGAGACTTGGTGCC
AACCTTTTAAGCCTCATTAGGTCTAAAGCAACCTTAAAAGATCCACGTGTCCTTTGAACAGAAATTCCAA
AATCAGACACAACAAGGCAAATGGTCTCCAGGTCCCCAGACAATAGGGCGTGTACCCTGATGCCGAAACT
GATTTATTTATTTTCCTTTCGTGAACTTGTTGCTTGTAAATATCCACAGGGGCTCATTTTCTGTGTGGAT
GACTGTTATCTTGTGCTAAGTGCCCATGTGTGCGTGCCCTCTCTTCCCCGGAAGTGAGGCAAAATAAATT
AGAGGCTTGGGATAGAATCTTAAAGGAATCAACTGTTCATCGATTTCGTTCTAGGCAATCTACACTGTCA
AAATAAGAGTGTGTGTTAGATGTGTGGAAGATATAATTAAGAAATCTATTAGGAGGGCAAAATGATCGTC
ATAAAATTGGTGTGGGTTTCACAATCGCTCTGAGCTCCAACTGCGACTCGTGAGTTTGTTTCGTGGCTCT
AAGGTTCACCCACTCTCTTTCTGTAGCCCTTCATGAGGAGCGCCATCCTAAGGCCGCCTGCTCTTCAATC
CCTGAAGTTCTGAAACTCAGTGTGAAGAGGGTCAGCCTCATCTTCAATCATTTCCTTTTGCCAGTCTCTC
GATTTCTGCCTGCGATCAAGTTTATAAACCTGCTTGTGTAGGCAGTCAGGAGAATCAGTCTACTTCCAAA
CTAGATCTAAAACAGACCCTTCTGTCATCTCCATTGTCCACCCCCAGTCTGGACTCAGGCTCTGTGTTTC
AGTCACTGTCCATGCATGCTTCCTGTCTGGTCAATTTCGGTCCATCCCACTGACTTCTCAGTCCCTTGTC
CCAACAGAAGCCACACTCCTCTTTAAAGGAGTCCCAAAGACCAAATCATTTGGGTGGGTCTTAACTACCA
CAGACTTTCATTTTGGATCTGCAGTCAGATCCAAACTTGCCATGGCTTCTAAGGGTCCTTGTGAGGTGAC
TGGTGAACGACAGCTAGTTCTCTACCCTGCTTCCCCACAGCCTAATTCCTCACACTGTCCTGTCTTCCAA
GCCGTCCAGTCTCAGCCACTACAGTAACTTATTTCCTTCTTCCAAAGCTCTTATCACAATCTGAAAGCAC
GTTATTGCTGTTCTTCTTTATTGTCTATTTCCAATAAGATAGTAATCTCAAGTGAACTACACTCCCCTTT
GTCACACTCTCCGCTGCATTGTCTACAACCAGAACTAGGATGCTGTTGTGTTAGTCGATGCTCAGAAAGC
TTTTAAGTTGCGTCCGGTCTGTCCTCTCTGACTCTGCCTGCCACCTGGTTTTATTTTTGTTTCCTTCCTT
TTTACGACCATGGAATCTCAGACATTCGCTTCGTCATCCCTGAATGACATCAACAATTAGCCTCCAGGGC
GCCCACATCTTTTCCTTCTAAGCATTGTTGGGACAGTGGCTCAATATACCACACATCACACCCAGGCAGC
TCTGAGAAATACACGCTGTCACATCCTCTCCTACCTCTGAGGTCTAGTCAGTCTCACCTTCTGTGAGGAC
CTGAATCCCTGCCCTGTGGCCCTTCTTGGAACTCCTTCAGTATGTGCAGCTGGTGTTGAAATCATCACCC
ACCAGCCTGTAGTGTGTCATGTGGTTGATACATGCTGAGTTTCTTTCATCAGACTGATCTAGGCACGGAG
CTTGATTGGATATGCGTCGTTCAGCACAGCCGGGAGAATAACCTAGTCTTTTCATCAATTATGTTAATTT
TTTTCATTGATCAGAGAACCTGGCTTCCCTTAATGAAAAAGTAGCTATAACCTGTGGATAGATATTTTAT
TTTCTGTTTTCCTCTTCATCTCCCTCGCTCTCTGTTTCTTTTCTCACCTTCCAATAGCCCCAGCATCTTT
ATTGTGTAATTTGGTTACCAACTGTCTGGATTACAAGCTGACTAGCTCCTTTGCTTTGCATTGGCTATGG
TTTGATACTCCACTCCAGGCATTATTTCTATAGAAAAGCCTGTGGTAAACATGATTTTTTTTTTTTTTTT
TGGTAAGTATTGTTCACAACATTTTTAGACCACTGGTAATATGATGCTCCCCTGCTGGTTCTGTGAAGAT
ATGGATATAAATACATTATTCTGGTTTTTTTTTCCCCTGAAATACCAGGAAAATGGTTATAGTACATCAA
CTTTGAGTAGGGTTTACAGGGGAGGCACTGCTTCTACACAAAGCATTTCGAAAAATTCTACAAAGCAATC
GTAGAACTCATATAGCCATTAAGTCAAATCTCTAGGAGTATTGACGGCAGAGGAGACTAGTATGTCCCGC
AAGTTCCTGGGAAAGGTTCTGGTCAGTGCTAATAAACAGAGTCTGAGATGCCCTTGCGATTTGGATGTTT
TCTAGAGAAGTCATGAGTTGGAAGCTTGGTCTTCTGTGAGGCTATGCTGAGAGGCTGAACTGTGAGAAGT
GACTGGGCCACAAGAGCTCTGCCCTCGGGGATGGATTCATGGATCTCTATGGGTAGGAGGGGATTTATTA
TAGAAGCAAATGTTCTTGGCTATACTTGCTCTGCCGCACCATCTGACATCCTCTGCCAGGTCACAACCCA
GCAAGAGGCTTTCGCCTGATTCTGAGCAGATGCTGGTCTCGTGCTTTGAACCTCAAGTCTTCAAAAGTGT
GACCTGAATGAACCTCTGTATTTAGATAAGTTATCCAGTCTACACTGCTCAGTTATAAAAACATGCAATG
GTTAAGTCTATAATTAAGGAGTGACTCTTTGTTCCAAACTGGCTAATCTGTATTACATTCTTACACCCTA
CAATGGAAGGTTAGACTTATTTATTCATTTTTTTTCCTAAATACCAGTGCCTTTGAAAAGGTTAGATTTC
TTGGTCAAACCTCACCCCGTATGAGTAAAGTTGAGTTTCTCTCAAATAGTTCCTTTTAAGCAACTTGGCA
CAGGATGCTATATCTCAAACTTGGCTGCCCATAAAATTATTTAAGGGAGATTTAAAAAACACGGATGTTG
GGCCTGAGGAGATGGCTCAGCAGAAAAGAGAACTTGTTGCTCTTCTACAGGACCAAGGTTCTATACCCAG
CATCCACACGGCAGTTCACAACCACCTATAATTCCAATTCCAGGAGATCCAACTCCCAAGGGTACCAGTC
ACACCCATGGTGTATGCACATGAGGTGAAACACTCATAAACATATAATAAAAGAATTTTAAAAGATACTG
ATGTAAGGACCCCCACCCTCAGAGACTGACTTGTGAGGAGTGTCCCTGTCATTGGACATTCCGAAAACTC
TCAAGGTGGTTCCTGAAGGCTGCTACGCCTGAGAGCAACAGTTTCACAGGAAGCAGATACTTCTGAATGG
GAGAGGCCCACGATTGATCGTTGTTAACTAGCAATGGCTACTAGAAAAAAGTTTTATTTATTTCTTTTGC
TCCAGAATGTAAACCTCTCACGAGAGAGGAGTGTTTGATGGACAGGGAGATCTTTGGGTGTTTGGGGGAG
ATAGGAAACCTATGTTGGGCTCTAAAATCTTAAGGATTGAAGGCAGAACACTGGTTTTGTGTGTGTGTGT
GTGTGTGTGTGTGTGTGTGTGTGTGTGTGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG
TGTGTGGTGTGTGTGTGTGTGTGTGTGTGTGTGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG
TGTAGATAGAGAGAGGGAAATTACCAAAAGTTGGAATGGCAATAAAGCAAAATAAACCCAAGGAAAAACT
CAGCTCCTAGCCTTGCTTGTCTGGGCCCTTTCTTGTCCTATGTATCCAGCCTGCTTCATCTGTAAGTCCC
CAGGAGCCCGATTGTCTCCTCCTGGATTACCCAGGATACTGACCCGATCCTCAGAGAGAGACACGGTGTG
CACTGGGATGGGCTGCCAGAGCAGTCTAGGATTCCAGATGCTGATCCCCTCTGGAGGAAACAGGGCTGCA
AGGTTTGTCATAGCACTCATCAAAGTCCTGTCCACATCTGTGCTCCGGATATAAATCTAGAGTGGGAGAA
TTCAACGCAGATGGAAAATTAGAGAAAACTCGAGGTTTTCTTTCCGTGGGGTTGACAGGGTGTCAGGGAA
AGAGCTGGAAAGGGGCATAAGCTATCAGCAAGCACAGTGGGACCATCGTCATCCTATCTGTCACGGGAGG
GATAGTACTAGGAAAATGCAATGAGATGAGGCAATCTGTAGTCCAACAGTTGACCCGTGACACTAAGACA
AAGTATTTACACAGGTACCCATAAAGACTTGAACTAAGATTCACCAATTTTTAGGGAAAATAGTTCCACA
AAAAGAAGTACGATTATAAACAAGACCTCCAACTTGTATAAATTCTCTAGAAAATAGGCAAAGGTGTAAA
TTCATCATATGCATGAGGAATTATTTTAATTTTGTTCAGGAGTCAAGTTTCAAAGTTCCGGTTCCCCAAC
TTGCCTGATCATGCTTATAGGTGTCGTTCAAGAATCTTCCGTATCTTTTCCTTATATAACTTCCAAGTTC
GTAGTGCTGTTCCATGCCCCACTATGGGGAAGGAAAATAAAAAGGAAGGTTAGGAAAAGTATCCATTATC
GTAGAAGTGTATCTCTTCTTGTTATATACAACATGATCATGGTGTGCACCACAGTTTCACAGTAAAACCA
CCTATTGAAACTAAGGCAAGAGAGAACAGTTGCTGTCGTCGGGACTCCCCGAGAATACTCCTTCATCTTT
GTTAGCACACAACGTAGAGGCTTGTGTATAGCACGCATCAGTTGATAGTTGGTGATGTATCTAGGTAAAG
CCTTCATCTCAGGTGTGATAGACGGAACCATGAAGGTAGAACATTCAGAGTGACTGGATGACCATTTTGT
AGGGATTTTTGTGAATGAAATCCAGCCATCGGTTGAAGTTGAGCTGGCTGACTCTTAAGGCCCCTCTCAA
CCTTATTAGCAAATGGGCTGATTTATTACAATCACTGTCTATTGCTGGCTCACAAAAAAGAAATTAGAGC
TTGTGACTCAGGGTGTGGTTTCTGGATCTGCAGGACTGGTATCACTTGGGAGCGTGTTAGAATCAAATTG
TTGGGTTCTACTCTTGATGTATTTGGGAGTGGGGCTCAGAAATCTTTTTAAAAGATATTTATTTTTGCCG
GTCGGTAGTGACACATGCCTTTAATCCCAGCACTCGGGAGGCAGAGGCAGGCGGATTTCTGAGTTCGAGG
CCAGCCTGGTCTACAAAGTGACTTCCAGGACAGCCAGGGCTACACAGAGAAACCCTGTCTCAGAAAAAAA
AAAGATATTTATTTTTATAATTTTATGTGTATGAGTGCTTTGCCTGCATGTGTATCCGTGCAGCACACGT
GTGCCTGGTACCCACAGAGATCATGAGATCACATCCCCTGGAGTTAAAGATGGTTGTGAGCCATCATGTG
GGTGTCACTGATTAGACCTGAATCACCTCCCAGAACAGCAAGTGGTGTAACCACTGAACAAACCCTCCAG
CCCAGGAATCTGTCTTTAACCCCCTCTCTCAGAGAGTTTGGTGGATCGTGGAGAGCGGTCTTAGCTCAGT
GGTTCTTGAGCATTGGCATGCAATAAAAGTATCCAAAGCACCGTTTGAACTTAGATTCCTTCAAATCTCC
CCCTAAGATTCTAGCTCCCTGTATCTTGGATGTGGCCTGGAATCGGCTTTTAACAGGGACCCCAAATGAT
TCCAGCTCAGGGAACAACGTGCCATGCTTTGAGAAGCACTGCATTTAGGTTTGTCGTTCATCCAGGGCCT
CACCAGAGAGTCACAAGCCAGAGAGGTTGTGGTTACCCCAAGCTATTGCTTGACAGACTTGCTCATTTGC
TCATCTCTTGGAAGCATCTCTCCCATCACCTCTCATCAAAGACAAGGATAACTGTTGGGCAGGAACAATA
TACCATGACAGAAGTAACTGTAGAAGGAGCGGCTTTGGGTCCAACTGTCTTCTAACTTACAACCCACTTT
TGGAATCTGATTGCTACTTAAGAGATTTCTAGGGTTGAATCCAAACCTCTTGATCCTTGAAAAATCTTTT
GGTCTCCCTGGAAAAGCATAGCAAGGAAATGGGAGCCTTATACTAGGAAAACACTCTGTGGATCTTAGTG
ATGTTCTCTCATTAGAGAGAAAGATGGATAGGCTATGGTGGGGAGGGCTCTGGTAGATACTGTCTTTCCT
TGGCTCCTCTGAGTTTTAATCTCTACAAAACCATGGCTAGGGCCATGACTCTTGGCTTTGGCTGAGCAGT
AAAAGGAGACAATCAGGTAAAGATGTTCCAATGTTCCAAACATCCTAATGTCCAGACCACGACCTATGCC
AATTAAATAAAAATATTGTCGATGTTTTAGACACATCTCTAGACAATCTCCATGGAAACCCCTCACACTG
AAAATATAGTCAGCGGGATAAATACATCAAAGTGAAAAATCCTGTACTTATTTTCCCTTCACTCAAAAAT
TTAAGCAGAGCTTTGGCTCACACCTGAAATTCTCGCTCTTGGGAGGTGGAGGGAGGAGGATGAGGGGTTT
CAAGGTCACTCTTGGTTACATAGGGAGTTCAAGGTCAGCTTCAAGGTCACTCTTGGTTACATAGTGGGTT
CAAGATCAGCTTGTGCGATATGAACCCGGCTTCAAAAAAATGCAAAGTAACAGCAAAATAGATCAAACTA
ACCTGGGTGAGTTGGCCAAATCCTTGTGGCCACGAGGATTCTGTAATGGGGTCGGTAGGAAAGGTCTCGA
TGGGACCTCGGTCTCCATGCCGAAACACCTAAGAAAAGATGTGCAGCAACATTACAAATGTCACTCATGT
GTTTTGTTTCTACTCGTCATAACAGAGTTTCTTAAACCACGGCCACCACCTTGTCTGTCCACTGGAATCA
CCTGGGGAGCTTTAGAAAGTTAACGATAAAGTGCTTCCTCTCCAGTGATCTTGGTTTTGTTAGTTGGGTT
TATGACCAAGGGTACCAGTCTTCTAAAATTCTGTTCAAATAAAACTCATGTGAAGAACCACTAACATTGA
GCTTGAGGTAATAAAACTATAGCATCAAGCTAACTGACCACTGGGAAGCAAATATACATATATGTATCCG
TACACATATATATTTGGAGATAGAGTCATGTATCTAAGACAATAGACTGGCGCATGAGCATACAAGATCA
CTTGGTGCAGACAGACTGAATAGAAATATTTTTCTCTGTGGCTGGAGAGACGGCTCAGTGGTTAAGAGCG
CTGACTGCTCTTCAGGAGGTCCTGAGTTCAATTCCCAGCAACCACATGGAGGCTCACAAGCATCTGTAAT
GGGATCCAATGCCCTTTTCTGGTGTGTCTGAAGAGAGTGACAGTGTACTCACATACATAAAATAAAGAAA
AAGGATTTTTTAAAAAAAATCAATATTTTCTCTTAACGATGGCAATAGCAACAATGCTCTTTAAACTTTA
TGTATAATAGTTTTGAAGTGACCCACTGGATTGTGGACACGTTGGCTCGGAGATTGGGCTCCGGGGGTTT
GAGGCAGATGAATTACAGATTAGGGAGATTAGGAAATGCAGGTCTCAGCACTTTAACAATACGGATTTTA
GATCTGCACAGACACTTTGTTATTCTTCACTTTGTTATCCTTGAACCTCGGAAACCTTGGTACTTCGATT
CTAAAACACCTTTAGAGCAGCGTGCCAGGACAAACTCCATGCAATTTTATAGTCAAAACACAAGGCAAGA
AAAGCTCCCAAGAAGGAAAAGATGAAGTCTGACATGCAGAAAATATTTAATAACACAGAGGATGTTCGCC
TAACCCTTTGTCTGATCTGAGGTCACCTTTACCTGTCACTTGGATTACCTACTGGGAGACCCTCTTGTAC
ACAAGCATGGGGGCTGTATTTCAGAACAGTTCAGGAGACTCAAGGAAGGAACAACCTCAAACTTTATTAC
CTCTATGAAGGAATTCCAGGATAGCAGGGAAGGTTTCTGAATCCTATGCTATATCTCTGGTTTCTCAGTA
AAGTGAGTCTTTTCTACTCCAAACCAGTGGGACATTAAAAGCTCACATGACAGCCTACAGAACATAGAGG
GGAACAGGGCACAGGGTGCTAAAAAGCCCTTGGGGCAGGTAGGGAAATACAGCTTGAAAGGTCCCCTTTC
TGGCAGGAAGAACAGCTTCTGGTGCCAGTCTGTAGGAGTGACTTGGTCATGAGCAAGAACCACCAAGGTT
AGCCAGTAGTGACTCCGTGTCTACAACCAGGCCCGTCTTAGAACTGTTGGGACTCCACTCAGTGTTCGAT
GAACCTTCTTAGGTCCGAGGAACTGAAATGGTGACATGGGGTTCGAAGATTTGTAGCCTCACCTTCGTTT
TTCAATCTCAGCACCGGACATTTTCAGGGGAAGATAATTCTCCAGGTAGGGAGCTGCCGAGAGCACTGGC
CTCTTGCTGCCCATAGTACTTTCTTATTACGGCAGTTGGAAAGGCCAAACATCTCACCACTGAGCTAGCC
AAAGAGAAGTCTGATAATGGGCATTCCACCAAAACAATGAACAGCCCTGCCTGCCAGGGCACAGCCCTTC
TTACTGCATCCAACGACAACAATCCTTCCTCCACGTCTTTCACACTTGCTTTGGCTTGAGAAGCCACTAA
GTGCTTCTCATGTTTCATCCCCTCAACCAGTTCTGCAACTTAGCCACAGCTCTTGTTATATATACTTCCC
AGCTTATTTTAATAAGCCATGAGTCCAAGCCTGCAAGCGGTAGAACTAACCAGGCATTGGCCATGTGTCT
TTCACAACAGTATCTTTCTTGGTGTGTGTGTATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG
TGTGTGTATGTCTACAGGCATGCGTTTGGATGTCCTGTCCCTTGAACCCATGTGCCCATGCCTGTGTGTG
CAGATGGCAGTCTTTGAGCTCAGAGCTTCTCAATTCACTTGGACTATGTCTAGGCATTCTTGAATCTACA
GAGGGGCCAGTCTCTCAACTCCACTACATTATTGCTTCTGACCCCAGGCAAGTAATTCTACTTATCAAAA
CCTTTAGAAAACCAAAAAAACGTGTTATTAGAAGTCAAAATTTTCCACAGAACTAGTGAAGACAGGAACA
GGAAGAGCGCTGAGACCATGAGAACCCCTCAAATACACACCCCACTATGTTTGAAAGAGCCCTCCCCGTC
ACTCCTTTTGACTGTTTGTTTTTGATAGAGTCTTCCTCTCTATACCCGGATCTAACTAGGTAACCCAGGC
TGGTTTGAACTTGCAATGATCCTCCTGCTTCAGCCTTCCCAAACACTGGGACTGCAGGTACGAGAGACCA
TTTCTGGATTTCCTATTATCTCTCGTATTCTTACAACTCCCTGCCGTGCAGCTTGACATTATTTCTGCGT
AGACCAAGTCAGCAAACAGGCTCAGAGAGATTTGATGAGCTGTTCAGATCTACTGATTCCCAGGATGGTT
GGTCCTCTATTACTGCTGGGCCCCTGTGCCCTCCAACCCCTATATTCAACTACTTTCTTATGAATTACAA
GAACTTTCTTTTAGTTAGGGTCTCACTCTATTTCCCATGTTGCCTAGTGGCCTTGAATTCTTGTCCTCCT
GCCCTAACCTCACTTGTGCTGGGATTAGAGAATACTCAATCCCCACCCTGTCTAACTTTTTAAAGGATTT
TAAGAGTTTTGACAGTCATGTGTGTATAGAGCATATTGTAGCCACACTCCCTATCACTTCCTCTTGTTCC
TCTCCCAGGATTGCTAATGCTCTTCTTGAGATTTTTTTTTATAAAGAGTCCCTGCGGGCCCTGCCAGCTC
CAACAGTCAGTCTGTATATAGTCAGGGTTAACTTACAACTTCACTTTTAGGAATTATATCATGTTTCACT
GCTCTTCCCCCCAAACCTTACCCCCAGACCAGGTCTCTCTTTCACCCCAATGTCCTCATCCCACATTCTT
GCTAAATGTGCTTAGCCATGGGAGCCCTCCCAGTCCCAGTGCTTTGAATGCCCAGCGCCTGCTTCTCCTG
ACACATACTCCCTTTCTCTGCATCCAGGCTTGTCCAGGGAAACGCAAGGGCCCTTTCATACTAAGTATGC
AGTCTCTACTTTCTCTTACTGTTTTGTTTCCATCTCTAGTATTTTCTGCTTGTATTCATTAGAACTTTAA
AAAAAAATGACATGTCTCTTCTTCTATACTATTTTCTCCTTGCTGTGACAAAATCCTTGGCAGGAACACT
TCAGGAAAGAAGGGGGATTTAACTTCAGTTCTTGGTTTGATTACAATCTATCGCAGTGAGAGCATGGAAG
TAGGAAGTACAAGCAGAAGGTCACGTTGCATACGTAGTCAAGAAGTAAAGATGGGGTGGAGGAATGCTAG
CACTCGGTCAGATTTTTCTTTTATCTTTTTCTTTTCAAACTCTTCGTTTTATCCAGTCTGGGGCAGTGGG
CCGTAGGATGGGCCTGCTGGTATTTAGAGTGTGTCTTCTCTCCACAGTTAAATCTCTCAGGAAACACTCT
GGAACATTTCCAGGGTGTCCCTAGGTAAGCCCGGATTAACACTGCCCGGATTAACAAAGATGTAGGAAGT
CCTTGGATGTAGAATCCCTATGGAAATGGCCACTGTCTACATTACAACAACATACAGAAGCCTGGTCTGG
ATGAGCAATGGACCCTGGGCTGGGTCCCCATCCTCTAGGCTAGTGATAACACCTCCAGCCCTCTGGTTTC
ACGAGAGCTTTTGATTCTCATCATCACGTATTGACAAGCAATGGTGCACAATCCTGTTTTCTTCCTTCCT
CCCCTGCCCTCAACTCTCCCTTCTTTCAGCCCAATTTCTGCCTTTGATTTCAGAATAGTGAGTTTCCCCT
TGGAATATGCTGGAGTCTAACCAACCACCACGTCGCCCTGTCAGGTTTAGAACTCAAGACAACAGGAAAA
CTTTGGGATGACCTTGGATCCAAACTCCAGTTGCTCACACTCATAAACAAGCATTTTAATACTGAGCCAC
CTCCCTAGTCCCATTTTCTTCTTTTAAATAACTAAGAAATAAATCCATTAGCAGATAATTGGAACGGAAG
ATAGTTTGAGTGGAAACAGTGATCTCCATAGACATGCTGTGAGAGGAAAGAGGGACAGTCAGCTGTGAAA
AGAGTCAGTATGTAGCTACATCCTGCACTGGCCATGAGGACCACATAAGAGGCCTAGCAAGCTCTTTGTT
CAGGGCCCAGGAAGAACAAGAAGCCAGCAGGAAAGGGAAGTGGTGTAAACTGTGTGCTACATCGCGTGCG
AGCTGTAAACAGCAATGTCTGACACTCATTTTGGTTACCCAAGGCAAGTTTCAAACACCAGCTTTGCCAA
CCATTGCCCAAGCGACACTGAGAAAACAACTAAACTCCAAGGTCAGTATGTCTCAATTTCTCTTTCCAGC
TAACCACAAAATCATTTTCTAGCAGGCTAAAGCAACGTAAGAATTGTAGTGTGTGTGAGAATTGAGCACA
CAGGATACATCCAGCCATCAGAATGTATTATGTTACTCATGTAGTCACACAATAACTGTCCCATATGTTT
CCTTTCTTGCTGAAAGTAGTTTGCAGCATCCAGGGCATTACCCATTGAGCCCTAGAAAACAGCCTTCTCT
TTCAAGAAACATCTCTATTAATATATAATCATCTCCCTGTCTTCCATTTACCTAAGAGCCATATTGCTTT
TGCCTCTGCATTCAAGCCACTTTGCAATCTTGACATGTCTGGAGAGGCAACCTAAAATGTTTTGAGCCAA
ATACAGTCTCTCTAATGAGTTCAGTGCCCTGGAAATTCTCAAAGTGTGTGGATAAACAGGTAGAGACAAT
TTCCTGAGCTCACAAGCTTAGATGGATGACCCCCTGCCTGGCCAATACCAGCTCTCAGGACCACCAACTT
CTAGCAGATATCTCTGGGGAACCTGTTGGTCGCCAGAGACACCTGCTACTCCTGTACTCTCATGACTAGG
GAGTCACACATGAGGGAGAAAGAACAAAAGGTGGTGAGCAAAAGAACCTGCTTTTTCTTTTCCAGTGGGG
CATTTTATGTAGTGGCTCTCTTCATAAGCCAAGCCATTAGTTCTACATGATTTTCAAGAATAGGATTTAT
TGGATCCTACGCTGTGAAAGACAAGGTCTAATTCTTAAAGAAATAAAACAGTACGAAGAATCAACAACAA
AAACTTTTGATTCTCCTGTAACACTGAAATCATTATATATATATGTGCCTTTGGGTAATTGGGAAAATTC
GGTGTAAAAAGAGTGCCTGTCACCTGGCAGATGCCTACAACCTATTACGTACATTTGACATTCTACTTCA
ATTGAAGTTAAAAAGAAAAAAAAAAAAGGGAACAGGTCTTGGAAAGTCCATGCCTGTGGCCAAAGGCATA
ACCTCAACATGAACACTGGAGATGAAGGCCACCCAAAGGTGTCTTCCAACTGAAAGCCAGGAAGGAACCC
AACGGGTCCGTCTACTGAGTAAAATAGCAATAGGTTTTGGGAGTCTGAATCACTCACCGATACACGCTTC
TCTTGTTTATATTGGGCCAAAGATGGAACTTAAAAGATATGGAGATAGTTACTTGACCTTTTTGAGAATA
AAATTAACAACTAGAACAAATAAAATGAAGCCTGGCACTGCAGTGAACTGGTCCCGTGAATGATTAGAGT
GTGGAGATTGGTGCTTGTCAAATGATCTGTACCCTCAGCAGAGGGACTTAAGGACCTTTCATGCATTTCC
ATGAGCAGCATGACAACTCCACGAGGCGTTATTGGCCCCATTTTCAGTGATGAATCACAGACTGGTTAAG
TGGCTCAGTAGAGCCGCACGGCTAGCACCTGGTTGAGTTGCCATTGCTCAACCAATAGTCTGATTCTTGG
GTCTGCACTACTTGCTACGTTGATAAGTAGGATGCTGCACAGAACCATGTCAATTACTACTTTCTGACGC
TCTCTATACACGCTACCTCCGTGGCATCCTCATCTCTCCAGTGACCCAAATTAGAAATCATGGGGGTCAC
TAGCTAATCACTACTTCCTGTAATATTCACAGCCAACCCACTGGATTCTGTTCGAGTTAAAACATTACCA
CTGCTTTCCCATTCTGGTTGTGATCCCCAACTTTAAGTTCGGGGAACTTGACACTCAGTTTTTTTCCTTA
AGTGGCCTGGATCTGCTCCCAGATCTGGTCAACAAGAATGGAACTGAGTTAATAAAAATTCTGTGCTTTT
CTAGGTATCGCCTTTGACGTCTATTCTAGGAGAATGCATTAGAAAACTAACTATGGGGTTGGTTGCTAAC
CCTTGAGAAGACTGAATGAAGAAGATGGGTTGGTCCTGGAGATATGCGATGGCTAGCCTCACGTCCAGGT
CCAACCTTGACTGGGAGGCGACTCAGTCCTGGAGGCTTTTTGAGCCAAAAATATACTACGACTCAGGTAA
AACCCTGCAGAAATAAGGTCATCCATGAAGAAGAAAAAGAAGCTCTGTATGGCGAGTCATTATTCCTTTC
TTTATAAAGGCCCAGAGGAACAACACAGAATTTTTGTCTGTCTGAGATCACCCGATTTGTTTTTCTCTTG
TTGAAGGGACGGAGGCTTTACAACAGCATTCTCCCTTTCTGATAGGGAAACATGACATACGAAATCATTG
TAAAAAGGAAGACAGGTGAACACGTGCAGGAAGTGAGTAGGTATGGGGAGGGGGTGGGGCAGGGGAGGCT
GGGGAGGGGGAGCAAGACTGACCTAGAGTGATAATTACCCAAGCTGGCTGATGCATGCACGGAGACTCAC
AGCCTTATTATCTTCTCTCTGCAAGGTTACAAATACCAATTCTACAGACAGTTTGGGGAGGTGGATGCCT
TTGTCATCCCAGGAAGCAGTCTACAGGTAGATTCCTCCCTTGGAATCTATAGTCTCTGTTCAGGATGCAC
TTCATTAAACACTGTAAGGAGACCCTTTTTAAACCCATAATAGAGTTCATTTTTTCCCATACAACTATTA
ATAAGAGGTCAAAACGGATTTTCATGGGAAACACTTTTTTTGGGGGGGGTCTAGTTTTTGTAAGATCATG
TGGCAAAGTAGGGTGGTGGTGGCTCATGCCTTAAACCCCAGCACTTGGGAAGCAGAGCAGGAGGATTTCT
GAGTTCGAGGCCAGCCTGGTCTACAGAGTGAGTTCCAGGACAGCCAAGGCTATACAGAGAAACCCTGTCT
CAAAAAACCCCCCAACAAACAAACAAACAAACAAACAAACAAACAAACAAACAAAACCAAAGATCAACCA
ACCAGCCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACTGATCAAT
CAATCAAAACAACCCACAAAAGATCATGTAGGGTTGTTGAATGATAAATGGCTCAATAGATAAACTGTGC
AAATCTGATTTCTTGACTTCAGTCCCTGGAACTCAGTGTTGGGAGGAGAGAGCAACTCCCAGGAGTTGTC
CTCTGACTTCTCCACATGCTCTGTGGTATGTGTGTGTCTGATGTAGTGCTGGGCTGAGGGTGTTTGTTTT
TTGGCTGCTTCCCTGGCGTGTACAAGGCTTTGGATTCATGCATGAGACCTTGGGTTCAGCCCCCCAGCAC
TACAGAAAACAACCAACCAACCAAAATAAAATAACCATTAAGATAATCATGGGTGACTGACTGTTCACAG
GCAAGACCAAGAACCAGGGGCAGCCTTCTTTCCTTTCTGCCAAAAACAGCCTTTCAAAATTAAGAGATTT
ATTTTTCTTGGATTATGGAGGAAAACAAGGAAATGATTTATAGTGTCTGAGTCAAGGTAATGCTACAAAC
CATGTAGTCATCTCAGACTAGCTCCAGGTTCTAGGGTATACACACTCAACAAAAACCCGGTCAGGGCAGT
GTGGGTTCAAGACTGTTTTTCTATCTGTGTGAACATCATTAAATTGCCTAGCTACTTTTACTTATGCCTC
TATCTTGAAAGTAGGATCAAGTTTGGTTGGGTTGTTTATTTGTTTGTTTGTTTGTTTTTGTTTCTGTTTC
TGTTTTTTTGAGACAGCATCTCATGTAGACCAGGCTGGCTGGTCTTGCACTAGCTATGAAGAAATTCTGA
TCCTGCTGCCTCCACCTCCTGAGTAATGGGGTCACTAGATTTTTGGGTATGTATTACCTAGAACTCACTA
TGTAGACCAGGCTGGCCTGAGATTAAAGGCATGCACCACCATGCCAGACTAGACTTTTTTTTTTTTTTTT
TTTTGAGACAGGGGTTTCTCTGTGTAGCCCTGGCTGTCCTGGAACTCACTTTGTAGACCAGGCTAGCCTC
AAACTCAGAAATTCACCTGCCTCTGCCTCCCGAGTGCTGGGATTAAAGGCATGCGCCACCATGCCTGGCC
CCAGACTAGACATTTTAAAATTTGTTCTCTTACTAATCTTCTGAATTAGCCGGGCAGTGGTGGCACATGC
CTTTAATCCCAGCACTTGGGAGGCAGAGACAGGAGGATTTCTAAGTTTGAGGCCAGCCTGGTCTACAGAG
TGAGTTCCAGGACAGCCAGGGCTACACAGAGAAACCCTGTCTCGAAAAAACAAGCAAGCAAACAAACAAA
CAAACAAAAAAATCTTCTGATTCAGAGAAATCTTCTGAGGATTTCTCTGAATGTTCAAGGTTACTATTTA
TATACAATAGTCTTTACAATCAATCAAAAGAAGAAAATGAGACCTTCTGGCTGATATCATCAGAGAGAAG
ATGTTTTGCTAAGGCCAAGGAAGATGCATTAAATTGCCCATTGTTTAACATTCCTAGAAGCCGCGGTAGA
AAACATAACATTTGCTTTATACAGTGTTGGTTAACTTTTGAGTTGTAAGACAGCTACCTTCGTAGCTTGG
TTCTTCTTTAAGGAAGAATTTACCAGCTGGCCACTGACCGTATTTTAACGGAGACCGGAGAGGCAGACAG
GAGGGAAAGAAGACCCACAATCTTTGGCAGCCAAGGCAAGTTACCTGGGCTGTGGCTGGGACTCAGAGGG
CCACTCTAATGCCTCAAAGAAGGTTGCCTTGAAGCCAGCTGTTTCCGAGCCCAGTATGGCACGACCAACA
GAACACAGCCACAATGCCACGGTCCCTATCCTCTTCTAAGGAGCTTGTTGGCAAGGATGCCATGCGTGGA
AGGGAAAGAATAACTCGCATAGGTGTTCCTGCAGAAGGTAGGGGGTGTCTTGTTGCTTTATGGACACAAA
AGCCACACAGCTGGCAAATGGCTTGATGGGTCTTTGTCTTTCTTCCATTTCGTTCCTGACTCACGACTGG
TAAAGATCTACTGTACTAAGAATCATAATTTATGTAAAATTAAAGATTTTTTTTTCTGTAGAAAGAAAAG
AATCTCCTGAGTACCTCACCTTGGCAGGAAAGGAACATCATATTTAAGTGCAAACTAAGAGGCGTCCTTC
TCTAAGTCATGAAAATCGTTTCTGGGAATTCTCTTGCAGGGAGGAAGAGGAGGTGAATCCTCCTGACTTT
GAAAATGCACTTCCCATATATTTTTTTAAAGAATTATTTATTGATTTTATGTATATAAGTACACAGTACC
TGTCTTCAGACACACCAGAAGAGGGCATCAGATCCCAACAGACGGTTGTGAGCCACCATGTGGTTGCTGG
GATTTGAACTCAGGACCTCTGGAAGAGCAGTCAGTGCTCTTAACCATGGAGCCATCTCTCCAGCCCTTTC
CCATATGTTTTTTTTTTTTAACACCCGACTGTATATAATTTTTTCCTTGACAACAGGCAAGTCACAGATC
TCTTCTTTTCATGGCTTGTCTCAGTTACCATATGCACGGAAAATCATGGTTTTAATGGTCAACTGAATCT
TTTATCTGATAGTCACTCTGAAACTCTGTTCAGTTTGTCTTTTGTGCTATCAAACACATAACTACAGGCA
TATGTTCCAGAGTCATGATAAACACGAGAGACTTGACTTCAGAAACTGACTGGTCCTTGGTTTGCGAACT
AATGATCACTGAATGGAAAGAGGCCAGGCTAGCTCCTGAATATCTGAACTGTGCTCTACGCTGCCTGTTC
TCCTGAAGTAACCTGTCAGTCCGAAGGCATTGGACTTGAGGGCAGCTGTAAAGGAACAGTACCATCGATA
GCACGTGAGACTGTTGTTGTCTTTAAAACAAACTCGTGCGACTCCTCACTTTCTGAGTCTGAACAGTGCC
TGCCCTCAGGCAGACAGCAGAGAGGAAACACGAAAGGCAACACTTAACCAAGTGTTCTCGGAACAGGAAA
AACAATGAGAAAAGGTGTACTTACCAATGTCACAAACTTCAACTCCTTGGCTTGGCCTGGGTCCAGGCAG
AGAGAAAGCAGGAGCAAGAAGCCAAGGCTGAGGCTTGCTGTCCGGCTCAGGGGCAGAGGAACGGCTCGCA
TGGTCGGGGAGAGAGCTGCTTTGGGCAGCCTTAGGAGGTGCTGCACTTCAGAAGCCTTCGGGA

</dna_sequence>
        <protein_sequence>>NP_062781.2 prostatic acid phosphatase isoform 2 precursor [Mus musculus]
MRAVPLPLSRTASLSLGFLLLLSLCLDPGQAKELKFVTLVFRHGDRGPIETFPTDPITESSWPQGFGQLT
QWGMEQHYELGSYIRKRYGRFLNDTYKHDQIYIRSTDVDRTLMSAMTNLAALFPPEGISIWNPRLLWQPI
PVHTVSLSEDRLLYLPFRDCPRFEELKSETLESEEFLKRLHPYKSFLDTLSSLSGFDDQDLFGIWSKVYD
PLFCESVHNFTLPSWATEDAMIKLKELSELSLLSLYGIHKQKEKSRLQGGVLVNEILKNMKLATQPQKYK
KLVMYSAHDTTVSGLQMALDVYNGVLPPYASCHMMELYHDKGGHFVEMYYRNETQNEPYPLTLPGCTHSC
PLEKFAELLDPVISQDWATECMATSSHQGRN

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1687">
        <gene_name>Pmel17</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>20431</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>31981217</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AC117232</gene_refseq>
        <protein_refseq>NP_068682</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>10</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>128705143</gene_start>
        <gene_end>128720237</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>transcript variant X1</protein_name>
        <protein_pi>6.27</protein_pi>
        <protein_weight>60349.2</protein_weight>
        <protein_length>626</protein_length>
        <protein_note>Also known as Si; Silv; gp87; gp100; Pmel17; D12S53Eh; D10H12S53E</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000076.6:128705143-128720237 Mus musculus strain C57BL/6J chromosome 10, GRCm38.p4 C57BL/6J
GCCCCGCCCTGGGCGGGCGAGCCGCGGGGCAGCTGCACAACTTTCCCGCAGTTCCTGGTTTAGGCTCCGC
AGGCCGGAACTGGTGGTGTTTCTGGTCTACGGATTTCCTTACCTTTCCCTCACAATTTTCACCACCCCTT
GGGTGAGATTAAAATTCCACCTGGACAAGAGAGTCTCTTTTAAAAAGCAAAACCTGGGAATCTTTAAAAG
AAAAAGAATAATGTATTTTATTTTAAATGGTGTGTGGGTCTGTGTGTCTGCATTTAAGTTTTCACAGAAG
CAGCAGGTGCCCTGGAGCTGAGGTTCTAGGCGGTCGTGAGCCTAACTTGGGTGCTGGAGCTGAACTCTGG
TCTTCTGCAAGAGCGGCTTGCGCTCTTAACAGCGGTGCTGTTTCTCCAGCACTCTCGCCTGCTTTTTGGA
AACATCTCATAATGCAGCCCTTGTTGGCTGGAATGCGTTCAAAAGTCCAGGTTGTCTTCGAACTCACAGA
GATCCGTTTGTCTCGGTCTCCATGTGGGGCACAAAATCCGGTCTCTCTCTCTCTCTCTCTCCCACACACA
CTCCCTCCTTCTCGCCTCCCTCCGCTTTCTTTTTATTTTTCTGAGACAAGGTTTCTCTGTGTAATCTTGG
CTGTCCTGGAACTCTAGTCCAGGCTGGAAAATCGGGACTCTTATTGTAAAGGATTCTTTGGCTAGATAAT
AGAGTCGTTTCTCAGCCTAGCTTAATACTGTCTCACTGTTTCGGGGTTCATTGGCTGCCTGTGTTGTTTT
ATTGCTGGCAATCTACCCTCCCAGCCCCTTCTGGATGCTTTTGGATAAAGGTGCTGTTTCTGTCTTAAGG
ATCTCTTGGTTTGACACAATTCTCTTCACTCTGTCTTGCTGAATTGTGACTGTTAAGTATGTGAATTGAG
GCTGCCCATCAGTGAACTCTTTCCAGAATAAGTGTGTCAGTGAATGTGACCCAGCGAAACCAGAAACTGT
CATTGAGCTGTGTGGGATGAAATCAGTTCTGGCCCTTTCCTTCTTCCCAGGTTTCCCCTCCTCTGGAGGG
AGAGGAGGAAGGCCTATGCAAATGACCATCCCTTTCTATATAGGGGCTCGCTCCCACCCCCTGGTACCTT
TGGCTGCTGGCAAGAGGACCACTATGGGTGTCCAGAGAAGGAGCTTCCTTCCCGTGCTTGTGCTGAGTGC
TCTGCTGGCTGTGGGGGCCCTAGAAGGTGAGTGTGGGTGGGTGGTCAGGAGCAAGTGCTATTAGCAATTG
AACACCAGCTCTGGGTTTCCCCCTTCTAATCAGACAAGTCAAAATACTTTAGGCTTGTCCTATTTGATTT
TAGTGAAGATATGGTTTTGTTTGGTTTTTTTATTTGTTCAAGACAAGGTCCAGTGTAGCCCAGGCTAGCC
TCAGATTCACTGTGTACCCACGGATGAACTCAAACTCCTCATCTACCTCCTAAGTACATACTTAAACCGT
TGTGCCCAGCTTTAGATGTGAACCTTAGGATCAAGCATAGAGGTATCCCTATCTGATGCAGGGGGCAGAA
GGCATGGCACTAATTCTGAGGCTGCTTGGAGCACTCAGCGAAATAGGGGCTCCAAGGAGGTGACATGGTG
ACATGTCCATGGTGACATGGAGATCCTTTGGGTAATATCTTAAATGCAGTGATAGGAGATGTAAAGTAGA
GAGAAAAAGAGTAGGGTATTCAGGAAGGCCAAACTGACAGACCACCTCTGCATCAGGGGTGCGGATGGAT
GAATGTATCCCAGGCTTGTCTCAGAAGGGTCTCAGCTGAGCATCACATGAAAGGACTCTGGGGGATTGAG
ACCTCGTGACAGGAGCAAGAGGAGGGAGTTAAGGATGGCGAGAGGGTCTGGAATGTCCCGTGCTGCTGAG
GAGGGAGAGTGGGCAGTCAAAAAGAATGGTGCGTCTTATGACTGTTCTTGCTTCAGTGGTCAAGCGCTCC
CTGAGATGAACATAGAACAGCCCCCCCCCTCCCCCCTCCCAGCAGAACCCTGGGCTTCCTGTGGACGTTA
GAATTGGGTTAAGGACACTTCTCTGTGCTGTAATATATTATATATATATTACATACATACACATTATATA
TATCTGGTTTCTTCACTTGTACTATAATTTCTCTTTTCTTTTCATTACTTTTCTGAGATGTTGTTTGCGA
TGTTCTGTTCATACCCACACATCTGAGTGAGGCCCTTAAGATACTCTGCTTGCATTTCACACACTGACTT
TAGTTTTTGTTTGGGGGCTGTCCCCCCACCACTACCATGTGAGTCTGGGGAACAAACTCAGGTTGTCAGG
CTGGGCAGAAAGCCTCTTTACCCCATAAGCCACCTCACTTGTCCAAGAGTTTCTTCTAAATACATATTTT
AGACAAAAACAGCAACCAAGAAGGATAGAGCAAATGTGTCCAAATGTTGGTGGATTTTGGATTTGGGTGA
AGGGATGTGGACATCCATTTTATTCCTTTCTTTTCAGACATCTGTTTTAGCTCTGGTCTCCCAACGTAAC
CCCAGCTGGCGTCCAACAACTTGCAGTGATTTTCTTTTTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT
TTTTTTTTTTTTTTTTTTTTCCAGTCAGGGTTTCTCTGTGTAGCCCTGGCTGTCCTGGAACTCACTCTGT
AGACCAGGCTGGCCTCGAACTCAGAAATCCACCTGCCTGCTTCTGCCTTCCTAGTGCTGGGATTAAAGGC
GTGCGCCACCACACCTGGCTCTTCTTCTTCGGAGTGCTGGGACTACAGATGTGACACACTGTACCCAATT
AAATTATAATAATTATATCTGCTTTGTCCCCCACCTCCAACCTGTACAGGCTTCTTCTCAATCGACCCTC
CTCTCTCTCCTCCTCCTCCTCCCCCTACAGCTGCCCCTCTTCCTCATTCCCCTCCTCCATTTTCTGAGAC
AGGGCACGCTGCTCTGGGATACACTCTGTAGTCCATGCTGTCAAGCTCATGGTGTTCTATGCTGGTGACT
CCTGAGTACATCATGCCTTGATGCCACAGTGGCCTTTCCATCATGTTAAAAAAAAAAAAAAAAAAAGGCC
GGGCGTGGTGGCGCACGCCTTTAATCCCAGCACTCGGGAGGCAGAGGCAGGCGGATTTCTGAATTCCAGG
ACAGCCTGGTCTACAAAATTAGCTCCTCAGTGGCTATTCTTGTAGAATACCCATGTTCAATCCCCAGCAC
ACACACATGCAGCTCACAACTGTTTGTAACTCCAGACCTAGGAGATCAAACATTCTCTGCTGATCTCGGG
GGTCACTAAGTGTGTGCTTTGGTGCACAGACATACATACATACAGACAATAGACTCTCTCTCTCTCTCAC
ACACACACACAAACAATAAAAAATATTCTTTTCTTTTTGTTTGACAGTATTTCTCTGTGTAAAAGGCATG
CACCACCAGCATCCAGCAATAATGAATATTCTTTTAAAAATTATCTGAGCAGGCCATGGTGGTTTGCCTT
TAATCCCAGCACTCAGGAAGTAGAAGCAGGTAAACCTCTGAGTTCAAGGCCAGCCTGGTCTACAGAGCTC
CAGAACAGTGAGGGATACAGAGAAACCCTGTCCAAAAAAATATATATATATATAACAAAAAAAATAAGAT
GAATCTGAAGGATGGGATGGGGATAGAGCTTAGCTGGTAGAGAGTTGGTCGAATACACACAAATCCCAGG
TTCTGGTCCTAATGTCTTTCTAGCACATACCTAAGCCTAGCATTTAGACAGTAAAAACGGGAAGATTGGG
ACTTAAGGGTCATTATCTACTACAATGAAAGTTTGAAGCTAACCTGGGATGCAGAGATAGAGAAGGAGTG
GGAGCTGAAGGGCAGATTTTATGGTGATTATGGGCCAGTTTAGAAACGAAGCCATGCATTCCAGGCTGCC
TGGTGGCACACACCTTTAATCCCAGCTTTTGGGAAGCAGAGGCAGATGAATCGTCTCTGTGAGTTTGAGG
CTAACTTGGTCTTCATAGAAAATTATAGGCCAGCAAGAGAAAATAAAAACAAACAAACAAACAACCCTCT
CCCCACCCCCAGCAGTCAGGCACAGTGTCATGGGCCTAGAATCCCAGATTGAGGCAAGAAAATCACCTGA
GCCCAGAAATGTAAGACTAGTCTATGCAACAACATATAAAGTCTTCATCTCAAACAACAGGCTGTTATAT
AGTTCAGTGATAGAGTGCTTCTCTAGCACTTACAAAGCTCCGCATTAGAGTCTAAATACCACCCCAAGCA
AAATAAAACACCAAACAACAACAACAGAAACAGAGAGGAGGGTGTCTTAGGTTACTATTGCTGGGATGAA
ACACCATGACCAAAAGCAACTTGGGAGGAAAGGACTTATTCAGCTTATAATCCAACATCACTGTTCGTCA
CTGAAATAAGTCAGGACAGAAACCTGAAGGCAGGAGCTGATGCAGAGGCCATGGAGGGGTGCAGCTTACT
AGCTTGCTCATTATGGGTTGCTCAGCCTGCTTTCTGATAGAACCCAGGTCCACCAGCCCACAATTGCTGG
GCCTTCCCACATCAATCACTAATTAAGAAAATGCCCAACAGGCTCCCTCCATTATGCCACCAATCCTATG
GAAGCATTCATTTTCTCAGTTGAGGCTCCCTTCTGTCTGATGACTCAGGAGGGAGTTGACATAAAGCCAA
CCAGTGAGTGGTGAATAGCACCTGGATTTCCAGAGGACCTGAGTTCCTTCCAGGTAACCCCCTCCAGTCA
GTGTGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAATAACTACAGC
ACCAGGGAATCCAATGGCTGTGGCCTCTATGGACACCTATACTTACATAATTAAAATTAATAAAAATAGC
TGGGCAGTGGTGGTGTACGCCTTTAATCCCAGCATTCAGGAGGCAGAGGCAGGCGGATTTCTGAGTTCGA
GGCCAGCCTGGTCTACAAAGTGAGTTCCAGGACAGCCAGGGCTATACAGAGAAACCCTGTCTCGAAAACC
AAAACCAAAAAAAAAAACCCAAAAAAATTAATAAAAATAAGCTGGGTTTGGTAGCACACGCTATTAATCC
CATCACTCTGGAAGCAGAGGTAGGCAGATCTCTGTGAGTTGGAAGCCAGCCTGGTCTACAGAGTGGGTTC
CAGAAAAGCCAGTGCTATTACAGAGAGAAACCTCTGTCTTGAACCACCCTCACCCCCAAATAATAATAAA
AATAAATCCTTAACAAAGGAAGAGAGATAGAAAGAAAGAAATAAAAAGAAAGAGAGAGAGAAAGAAAGAA
AGAGAGAGAGAAAGAGAAAAAGAGAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG
AAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAAGGAAAAACACCGGGTGTGTGGCATCTGTGATTGTACTC
AGTAGGCAGGGGCAGAAAAATGGTAAGTTCCAGAAGTTCCAGGCTGGCCCAAGCTACATTGCTTAAGGTC
CAGGCCAGCCTAAGCTACACAGAAGGCCTATCTCAAACAAAACCACAACCACTAACCAAAATCCCCAAAG
AAAAAAGGTCACATACCTCAGCCTGTCGCTGAAACCCCTAACTCAGCCGAGGTCAAACAACCCTTTCACA
GGGGTTGCCTAAGACTCTCAGAAAACTCAGATATTTACATTACAGTTCATAACAGCATGAGGAACTAACT
ATTACAGGGATACAGCAGCATCAGGAAGGTTGAGAATGGCTGCCCTAGCTCATTTTCTCAGCCTCATTTC
TCACAGTGTCTATCGATCATCACTTGCCATGTGGCTAGTGATCTCTAACTTGCCAAATAACTGTTTGACT
CCATGTGTTAGCTTGTGCTAAGCCTAGCTCAGGTCCGCACTCTGCTAGGGTGGAATTAACCAGTTCATCT
GCCATTTTGTGACACTGTGCTCTTATGGCAGATGCTAGCAGTGAGTGGTGTGGTGACAACTTGTGTACAT
GCTCATTCCTTATGCTTAGCTTTACATCTCTCCAGAGCCTTATCTCATTCACTTCTTAAGACCTTCGTAC
TTAGAATAATGCATAATATAGAATGAGTATCTGTTGCGGTAAATCTCCAACCCAAATATGCCCCGGCAAT
GAAAACACAACACAATTAATATGAATACATGCTGTGCGCCTAGATTGGGCAGATCTACCGCTACACTACC
ATCTTGTCCATTAGAACTTGCAGTTTCTTCAGGCCTTATGCTTCTGCTCCGCTTTTCTTCTTCTTCCTCC
TCCTCCTCCTGAGTCCCCTCCCTCTTCCATTTTCTCCTCCTTCTCTCTCACCTTCAGTTCCACCTTCCCT
CTATCTGCCCAATCATCAGCTCTCCTTTATTTTCCAAATTAAGGTGGGAAGCAGGTTTTCAGGAAATCAC
CTGAGTGCTGACTTATTCCTTGTTAGAAGCCACTCACAAGAGAGAACAGAATTAACATAAAAAATAATTA
AAAAAAAAAAAAAGCTGGGCGTGGTGGCGCACGCCTTTAATCCCAGCACTCGGGAGGCAGAGGCAGGCGG
ATTTCTAAATTCCAGGACAGCCTGGTCTACAGTGAGCTCCAGGGCAGCCAGGGCTATACAGAGAAGCCCT
GTCTTAAACACCCACCCCCCCAAAAAAAATAGCCCCACGGCTATCCACAAGTATCCAGTAAATCAAAATG
CATTTTGAGGAGTTGAAGAGATGCCTTATAGGTAAAGAGCACTTGCTCCTCTTCCAGAGAACACAAGGTC
AGTTTCCAAGGACCACATAAGGTAGCTCAAAACTGCCTGCAATTCCAACTTGGGCAGTCAGGTCTGATTA
AATAAATAAATATGCACTCTGAAAGCTGGGCATGGTGCTATCCACTTGTAATCTTAGTTCTTGGGCCACT
GATGTAGGAGGATGACAAGTTTAAAGATAGCCTGAGCTGTAGAGTGAGAGTTCTCACAGAAGTAGATAGT
GGGGGCTGGTGAGATGGCTCAGGAGGTAGAGGCGATTGCTGCTAAGCCTGATGGCTTGTGTTCAACCCAC
ATGGTTGGAGGAGAGAGCTGAATCCCATGGTCAGTGTTTTCGCCTCCATACATAGACTGCGGCACTCACC
ACACACACACACACACACACACACACACACACACACACACACACAGTTACATAAATAAGTTCATGGTGGC
TTGCCTGTAATCCCAGCATTTGGGAGGCTGAGACAGAGGACTTCCATGGACTTCAGCAGTCTAAAATCTT
GTCTGGAAATATGTGTGTGCAGTGGCTGGGAAAGTTCTCAGTGCTTGTCCCAGGGGCTGGTAAAGTAGCT
CGTCTTGTAGGAAACTTGTGTAGCATGTGTAGCATGTAGGAGCCTCCTTCCCAGCACCATGCGACCTAGG
CACAGTGGTGCAGGCTTGCGATCCTAGTGCTTGGGAGTGCCAGCAAAAGGACCAAGGCCATTCCTGTCTT
CACAGTGAGTTTGAGGCTAACCTGGATTATAAGATGCCTTGTCTGAAAAAAGAAAAAGCAAAAACTAAGT
GTTTCCCTGGTGTGCTTATAACCCTGGGTTCATCTTTAGTATCATAAGCTTTTAAATTTTTAGTTTTTTT
TTTAAGTATAGAATAGAATTTATTTAGGGCATGGGAAGGGGAGTTAAGAGGGTAGCAGAGGCAGAGAGAA
GGAGAGAGTAGAGAAGTAGAGGCTGGCCATGGCCACGTGGAGAGAGGGAGGAAGGGAATGGGGAGCAAGG
GGGCAAGAGAGAGGCAAGAGCATAAGAGCTTTTTTTTTTGAGACAGGGTTTCTCTGTGTAGACCAGAACT
CAGAAATCCACCTGCCTCTGGGATTAAAGGCATGGGCCACCACCGACAAGAGCTTAAATTTTTAACTAAA
AAAAATTTTAAAAGATTTATTTATTTTATGTATATGAGTACACTATTACTTTCTTCAGACACACCAGAGG
AGGGCATCAGTTCCCATGACAGATGGTTGTGAGCCACCATGTGGTTGCTGGGAATTGAACTCAGGACCTC
TGGAAAAGCAGTCAGTGAGTGCTCTTAACCACTGAGCTATCTCTCCAGCCCCTTAATTAAAAATTTAAAT
CTAACATCCACACATACACAATCATCTGGTGTGAGCATATGAGTGTCCATGTGTGTGCATGCATGTGTGT
GTGTGTTTGTAAATAATAAATAGTTTAAATAAAAGCCATATTGGGTGTGATGATACATGCCTTTAATCCT
TGAACTCTAGAGGCAGGCAGATATCTGTGAGTTTGAGTCAGCCTGGTCTGCAAAGTGAGTTCCAGGCCAG
GCAAGCCTGCATGGTGGGATCCTATCTCAATTTTTTTTTCTAGGATGTTTTTGTTTTTGTTTTGTTTGTT
TTGGTTTCATTCGGTTTTTGGTCTTGTTTTTGTCCTGGAACTCAGTCTGTAGGCCAAGCTGACCTGAACT
CAGAAATCTGCCTGCCTCTGCTTCCCAAGTGCTGGATCAAAGGCGTGCACCACCACCATCCCGAATTTCT
AGGATTTTTAAAAGACAGGCTCTCGCTATGTAGCCCTGAACACCCTGGAGCTCTATTTGTAAGCCTGGCT
AGCCTTGAACTCACAGAGATCCACCCACCTCTCTCTCCCAAGTGTAGGCACCACTATACCCAGCTTTAAT
AAATTAATAAAAGCATTTAAAGTAAAGTAAAAAGAGGGTTGAGGATATGGGTCACTGGTAGAGTACAGGT
GTTGGGTCCTCAATTCAGTCTCAGTGCTGCTTTCCATACCGCCAAAATTAATAAATTTCACTTTGAATTT
AACAGTGAGATGACATGGGACATAGCCCTCTCCTCTGAGAAGGGACTAAGGATCCCAGGATCTTATGGTA
CATTTCTTTTAGGATCCAGGAATCAGGACTGGCTTGGTGTCCCAAGACAACTTGTAACTAAAACCTGGAA
CAGGCAGCTGTACCCCGAGTGGACAGAGGTGCAGGGGTCTAACTGCTGGAGAGGTAGGATTTGGAAATTC
TGGAGAGATGGGATTACGGGAGACTAAGAACAGGGTTAAATTTAAGCAGGTTGGGAGAGAGGTTTGGAGA
GGGGAAACCAGAATCCCAGCTAATGGCGTCCCTTCCCAGGTGGCCAGGTATCTCTGAGGGTCATTAATGA
TGGGCCTACACTGGTTGGTGCAAATGCCTCCTTTTCCATTGCCCTGCACTTCCCTGGAAGTCAAAAGGTA
CTACCGGATGGTCAGGTTATCTGGGCCAACAACACCATCATCAATGGTAAGTACCTTTCTCAGTACCTCC
TGAGCCTTATTCCTGGGACTCAGATTCCCAGGTATCCCCAGTAAGCTCTGGGAAAGTCCCCTCCCTCTTC
TATTTTTTAAACAGTGCTGGGGTTCAAACTTAGGGCCTCATGCATGCTTGTCAAGTGCTAGTCCACAGGA
CCTTTATTCCCCAACACCACCCCCATAGAATCTTTAAAAACCAAACCAAACCAAAAAAACCCTAAATGAT
GTTTATACTCATTATAGTCAATATATACTGTAAGTATACAAAAATGATAGTTTCCGAATCGGAGGACAAC
AGATTGCTAAAGTCACACAGGCTTAGATGTAAATCCATCAGTAGCTCGGACCCTGGATGGGTTAAGTTGC
TGTGTGCCTGTTTCCCCCTCTGTAAAGTGGGTGTGGTGCCTTGACAGAATTAAGAAGCTGAAAAAGGGCA
TATCTATGTAAAGTCCTCAGCACAGTTGTCTGGACCTACAGCACATATTCACCGTTCACTGCTGCTGTTG
ATGCTGCTGCTGCTGCTCTGAATCTGACTAGAGAGTCACTATAAACATTTTATTCTATGGACATCCAATC
TTCTATTTAGATTCTCTATGATATGAATCTCAAGTTGTGGTGTCCATAAATCCCCGCTCTCCATGCCATC
TTACATGGGTTATAGTATGGAGACTGTAGTTACAGCTAAGGCTTACTCCTACAGCCCCATCCACCAGGAA
CTCTTTAAGGAGTTTGAGCATACCCGGAGGAATGACAGAGCTTGAGGTTGACTGTGTCTCCTTTCTAGGG
AGCCAGGTGTGGGGAGGACAGCCAGTGTATCCACAGGAGCCTGATGATGCCTGTGTCTTCCCTGACGGTG
GACCCTGCCCATCTGGTCCTAAACCTCCGAAGAGAAGCTTTGTTTATGTTTGGAAGACCTGGGGTGAGGT
TCCCTAGCACCTCTTCCCAACTGAAATCCTATGAGAGGAGCCCTGGGCCCGCCCTTCCAGACACCTTCTG
GAGGACACCCTCGACCTCCCTTCTCTGAAGCCTTTTCAAACTACCTTTCCGTTCTCTTTGACCAATTGCC
TTCTCTTTCTTGCTTTTCTCTCAGGAAAATACTGGCAAGTTCTGGGGGGTCCAGTGTCCAGGCTGAGCAT
TGCTACGGGCCACGCAAAGCTGGGCACACACACAATGGAAGTGACTGTCTACCACCGACGGGGTTCCCAG
AGCTACGTGCCCCTTGCTCACGCCAGTTCAACCTTCACCATTACTGGTAAGGGCTTAAAGAGGAGCTAGG
CCAGTCGGGCATAGGGCAGAAGGTGGGGAGGCTGGCTTGGACTGGAAAGAGGAAGTACCCAACCTTCAGA
GGGGAGGGGCAGAAAGACCTGGGCGGAGAAATGTGAGGCTTAGAGAGAAATAAAGACCTGGCCAGGCAGC
TTGTACCTGGAGAATGTGGCTGTGAAAGAGATGTGACTTGGTCCTCGTTCTGATTTTTCTGGCTCCAACT
GCAGACCAGGTACCTTTCTCCGTGAGTGTGTCCCAGCTACAGGCCTTGGACGGAGAGACCAAGCACTTCC
TGAGAAATCATCCTCTCATCTTTGCCCTTCAGCTCCACGACCCCAGTGGTTATTTGGCCGAGGCCGACCT
CTCCTACACATGGGACTTTGGAGATGGTACTGGGACCCTGATCTCTCGGGCACTTGATGTCACTCACACT
TACCTGGAGTCGGGCTCAGTCACTGCCCAGGTGGTACTGCAGGCTGCCATTCCTCTTGTTTCCTGTGGTT
CCTCCCCAGTCCCGGGTACCACAGATGGCTACATGCCAACTGCAGAAGCACCTGGAACCACATCTAGGCA
AGGAACCACTACAAAAGTTGTGGGTACTACACCTGGCCAGATGCCAACTACACAGCCCTCTGGAACCACA
GTTGTACAAATGCCAACCACAGAGGTCACAGCTACTACATCTGAGCAGATGCTGACCTCAGCGGTCATAG
ATACCACACTGGCAGAGGTGTCAACTACAGAGGGTACAGGTACCACACCCACAAGGCCTTCTGGAACCAC
CGTTGCACAAGCAACAACCACAGAGGGTCCAGATGCCAGCCCATTGCTGCCCACACAAAGTTCTACAGGT
AAGAACACGTGAATATGGAGGTTCTTGGAGGCGGGCTGTCAGTTTTCCACTCTGAAGTCTCACCCAGACT
CAGATGCTAAGCAATCCTTTCTTTAGCATCGTGGCCACCTCAGAATTCTCACTAGCTCTAAGGCCTACAG
ACTGTCTTAACCGCATGCAAGAGCTGTGGAGTTCAGTATAGGAGTTTTCCCTAGTCCACCAGGGAAGAAT
GGATTGGTTTTATTTACCTCCAAGGATAACAGCCAGGAAGCCAAGGGAACACCTATGGTTATTAACAGTT
GTATTACATTTTCTGTTCAAGCATGAATACAGATATGTCAGATTCTAACACCCTGATCCTGCCATTTCTT
TTTTTTTTTTTTTGTTTTTCGAGACAGGGTTTCTCAGTATAGCCTTGGCTGTCCTGGAACTCACTCTGTA
GACCAGGCTGGCCTCGAACTCAGAGATCCACCTGCCTCTGCCTTCCCAGTGCTGGGATTAAAGGCATGCG
CCACCACGCCCGGCTTAAAAAATGTATGTTTAATAGTTTTACCAGCATGTTTGTACACTCTGTGTGTGTG
TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGCCTCATGCTCATGGAGAACTCAAGAG
GGCATTGGATCCCCTGCCCTGAATCTAGACTTACAGATGGTTGTAAGCCACCATGTAGGTCCTGAGAATT
GTACCCAGATTTTCTATAAGAACAACCAGTATGTTAAGCCACTGGGCCATTTCTCCAGTCTTGAAGTGTA
TGTGTGTGTGTTCTCTTTCCCTATGTGGGGGAAAAACAAACAAACATTTTTTTTCCCTAACATAGCTTCC
TTATATATGAGACCTACCAGATCTTTTTTTTTTTTTTTTTTTTTAAAGATTTATTTATTTATTATATGTA
AGTACACTGTAGCTGTCTTCAGACACTCCAGAAGAGGGAGTCAGATCTTCTTACAGATGGTTGTGAGCCA
CCATGTGGTTGCTGGGATTTGAACTCCAGACCTTCGGAAGAGCAGTCGGGTGCTCTTACCCACTGAGCCA
TCTCACCAGCCCGACCTACCAGATCTTGGCTGATTCAAAGCAGTCATTATAGCATCCTGTAGCTCTGGTT
GTACTTGGGACAATGCCTGCTTGGTCTCTGTCTCTAAGAGAGTTCTTGACTCTGCCCCCTCAAATCTTCT
CCTGACAGGGTCCATTAGCCCTCTACTGGATGACACCGACACCATAATGCTTGTGAAGAGACAAGTTCCC
CTGGACTGTGTTCTATATCGATATGGTTCTTTCTCCCTCGCCCTGGACATTGTCCGTGAGTCTTGCCTAT
GTTGGGGACTGAGGCAATGAGGCATAAGCTGCCCAGGCTAGCCAGTAGTAATGTACCTTGGGAGAAATTA
CTTGAGAATACCCCAATGGCAGAGATAGTTTTGGGAGAACACCCCCTGGGCTTTCTTTCTGGTCTTGGTA
GAGGAATCCTAACTTAAAAAGTTGCAACCTTGCAGAGGGTATTGAAAGTGCTGAGATCCTGCAGGCTGTG
CCATTCAGTGAAGGGGATGCATTTGAGCTGACTGTGTCCTGCCAAGGCGGGTGAGTGTCCTGCTGGTTGT
CCTGGTAACCCTTGAGGATGACTGTCACTCTTTCTGGAGTTCTGTCCCTTTTCAGATCCTTTGATGCCAA
CTCGTACTCTTATTTATTTGTTTGTTTGTTTATTTATTTAATGTATATGAGTACACTGTAGCTGTACAGA
TGGTTGTGAGCCTTCATATGGTTGTTGAGAATTGAATTTAGGACCTCTGCTTACTCTGGTCAACCCCACT
CGCTCTGGTTGGCCTCTCTTGCTCAGGCCCAAAGATTTATTTATTATTGTATCTAAGCACACTGTAGCTG
TCTTCAGACAGCACTAGAAGAGGGCGTCAGATCTCATTATGGGTGGTTGTGAGCCACCATGTGGTTGCTG
AGATTTGAACTGCTCCAGAAGAGCAGTCAGTGTGTGCTTACCCGCTGAGCCATCTCTCCAGCCCGCAAAC
TCATCCTCTTCTCAGGCTACCCAAGGAAGCCTGTATGGACATTTCATCACCAGGGTGCCAGCCCCCTGCC
CAGAGGCTGTGCCAGTCTGTTCCACCGAGCCCAGACTGCCAGCTGGTTCTACACCAAGTGCTGAAAGGTG
GCTCAGGGACATATTGCCTCAATGTGTCTTTGGCTGACGCCAACAGCCTGGCAGTGGCCAGCACCCAACT
TGTTGTTCCTGGTGAGTACTTAAACATGAACTAGAAGAAACGGAATGGACAGAGGCTAGCTGGGAGGGAA
CAGACAGTGATGCAGTTTCTGGAATTCTCATTTATAGGTCAAGACGGTGGCCTTGGGCAGGCTCCCTTGC
TTGTAGGTATCTTGCTGGTGTTGGTGGCTGTGGTCCTTGCATCTCTGATACATAGGTAAGACACAGCTAT
CCAGTATCCAGGTCCTCACCCATTATTACCACCAACCACTCTTCCTTTAGGGGTGCAAAACTACTGCTCC
CACTATTACTCCCTTGAGGAAGCATGGTGCCCAGGAGAGAGCCCAGAAGTGGAGCCAGACAGGCCTGGGC
TGCAGGCTTCCTGTGGTGCCTTTGAGAAGTAGTTTTAAACTTCTGAAGATTATTGGCATTAGAAGCTATG
TGGGCAAGCCTCCTGGAGTAGAAACAAGAGTGAAGCAATTGTCGATATGCAGCTGTTGTTGATATTAAGA
GTTGTTAATATTAAGTGTCTGAAGACAGCAACAGTATACTCATATACATAAAACAAATAAATTAAAAAAA
AAAAAAGAGTGAGTCCGAGGCCAGTGATTTGGCTCAGTGGGGAACCACCAAGGCTCACCACCTGAATTCA
ATCTCTGGTGCTAGAAGAGAACACATTCCCCAAAATTTCCCTCTGACCTCCACATGTGGACCGTGCACCC
CCACCCATAAGTAAATAGAACTGTAAAATATAAAACAAAACAAAACAAAAACAAAACAGGGCAGTTGGGG
TAAAGCATATTAGTCACCTATGAAAAAGGTAAATTTTGCAGGACATGACAGTGAGGTCTACATAGTGAGT
TTCCAGGACAGCCAGAGCAGAGCTACTCAGTGAGACCCTGTATTGAGAGGGGGTGGGGCGTGGAGAAATG
TATAGAGGTTAGGGGGAATGTATGTCAGTGACTAGAGAGACAATGGAAGATGAACACTAAGTAGGGTAAA
GAAGAGGGGAGAGGGTTACAGTCAAAGCCAAGCAAACCTGGGATATAGGATTAGCGTAGGCAGGTTGCCC
TTGCTGACTGTTTCCCCCCTCTTCTCTCTCTTTCCATACTAGGCATAGACTTAAGAAGCAGGGCTCAGTT
TCCCAAATGCCACATGGTAGCACTCACTGGCTGCGCCTGCCTCCGGTCTTCCGCGCCCGCGGCCTTGGAG
AAAACAGCCCGCTCCTCAGTGGACAGCAGGTCTGATCATTCTCAAGGCACCGTGGATTTCCTGGGGTTGA
CAGCAGTGCCTGTGTTTTCTGCAGTCTTCCCTTCGAGACTACCAATATCTGAAATAAATTCTCAGAACCT
TGCGGGAGGGCTTTTGTTGCTGTTCGTTTATTTGTTCTGTCTGCTTTTAAATCTGTCTGTAGAGGGGTAA
GGGTAATGGAGAAAGTCACTTTATTAGAATGAGGCATTTTTTCAG

</dna_sequence>
        <protein_sequence>>NP_068682.2 melanocyte protein PMEL precursor [Mus musculus]
MGVQRRSFLPVLVLSALLAVGALEGSRNQDWLGVPRQLVTKTWNRQLYPEWTEVQGSNCWRGGQVSLRVI
NDGPTLVGANASFSIALHFPGSQKVLPDGQVIWANNTIINGSQVWGGQPVYPQEPDDACVFPDGGPCPSG
PKPPKRSFVYVWKTWGKYWQVLGGPVSRLSIATGHAKLGTHTMEVTVYHRRGSQSYVPLAHASSTFTITD
QVPFSVSVSQLQALDGETKHFLRNHPLIFALQLHDPSGYLAEADLSYTWDFGDGTGTLISRALDVTHTYL
ESGSVTAQVVLQAAIPLVSCGSSPVPGTTDGYMPTAEAPGTTSRQGTTTKVVGTTPGQMPTTQPSGTTVV
QMPTTEVTATTSEQMLTSAVIDTTLAEVSTTEGTGTTPTRPSGTTVAQATTTEGPDASPLLPTQSSTGSI
SPLLDDTDTIMLVKRQVPLDCVLYRYGSFSLALDIVQGIESAEILQAVPFSEGDAFELTVSCQGGLPKEA
CMDISSPGCQPPAQRLCQSVPPSPDCQLVLHQVLKGGSGTYCLNVSLADANSLAVASTQLVVPGQDGGLG
QAPLLVGILLVLVAVVLASLIHRHRLKKQGSVSQMPHGSTHWLRLPPVFRARGLGENSPLLSGQQV

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1348">
        <gene_name>Prostate specific antigen</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>53320</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>228008369</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AC099606</gene_refseq>
        <protein_refseq>NP_001153178</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>7</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>86718975</gene_start>
        <gene_end>86776053</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>transcript variant 2</protein_name>
        <protein_pi>8.08</protein_pi>
        <protein_weight>76668.23</protein_weight>
        <protein_length>719</protein_length>
        <protein_note>Also known as GCP2; mopsm</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000073.6:86718975-86776053 Mus musculus strain C57BL/6J chromosome 7, GRCm38.p4 C57BL/6J
ACAAAATTATGTATATATTCAAGATATGTAATGAATACAGCCATGTTTGATGACTTCTATATAAACAAGG
AAATCATAAACATAAAATTTAAGACCAGGATTATATTTGATATAAATGATGCAATTGTTTAGAAGTACAT
GGTTATTGGGACTACAAATTAATTATTGGTTGTGCATTTATATTTTATACATTTTCATAAAATGATATTT
TCCTAAGTCTAAATAATTAAACGTTATAATTCAGAGTGCTGAGTTTTACAAGATATGAGAATAGATTATA
ACTTGTCAGCTATTGTGGCTAATATGATCTTCCCAGCCTTTCGTGGCCAGAGTGTATCTAGTCCCCCAGA
TGAAGCAGACTTGTGAACTATTCCAGCTGTGTTCCATAAGGAATTGATACTTGTTTTTATTGAAATGACA
GAGTAGATCTGGGAAGGCTGTATTATATTTCTGATAATTGTCTGATACTGTCAAATGTATCACTTTATTA
GACTGTTCACCTTAGTTTTAATACTTATTTGAATTTTAAATTTTATGAATACATGTTGAAATTTAAAAAA
TAAATTATCCACTTTTGGATTTTTTGATGCATATGAAAAAAATAAGAATATATGTATGCATGTGTATATA
TATATATATAAGCTCCATAGTTCCATAGGGATTTTGTGATTCTGTAGAATGTGTTTAAGCTACTTCCCTC
AGAGTCTCTGCTGCAGCTTGCACTGTAAAGGTTGCAATAGAAATCTGTCTCTTCACTTCGTTCCAGGCCT
TAGAAGCATTGACTTTGCTACTTATATCAAAAAGGGCATCATAAATCCCAGGGAATGATTCTCCTGCATA
CTTGTTGTGGCTGCTTGGAGCATAGATGATATGCCTGTTGATGAAACATATCTTTGTCCATTAATTGCAC
AAGCAACATACAAGAGAATAAAGGCACTATACACACATGTCATACTCCTGATTTCCTGGCTTGAATAAGT
CACTTGTTACCTGAGTTTAAAATGCAATAATATCCAGGCACATAAATACATATAATTTTTGCTTTAATGA
ATAACTCAAAGTGGTTCAGATAAATAAAAATAACAGTAAGGACAGTTGATGTTAATTGTGCTTAATACTT
AAAAACGAAACTTATATTTTTATAGTTACTAAAAATAAACTCTATAATGCAGATATTGATGTTGCTTAAG
GAGACAAATAATCTGAGAGGAAAAGTGAAAAGCTAATTTTTCTTAATCATATTTGCAGTAAGTGATGATG
TTTATATCATACTCCATGCTCAGACAGTGTGATCATGAAATCATGTGTATAGCCAGCCTACTGTGTAGTA
CATTTTTATTCTTTGGAAAAGATGCATTCATAATTTACTTACAGTTCACTTAAATCATAACCAATCATTA
TAAATGACCTAGGTGTATGACTATTTTTGAAGTGGCCAAAGAACTTACATGTATTGATTCAGGAATAGCA
TGGGCCAGGATAGAATCCACAGAACTTAAGAAGTTTAACAAGCCAAAGGGTCCAAGTAAGGATATTTCAA
TCCCACTTTGGAGGGAGAATAAAGCAATCATGGGGGCATAGGCAGGGAGGGACTTGGGTGATAGAGGGGA
AGAGGAGGGAAAGGAGGATCATAATCAGAAATGGGACCAGGGCAGAATGAAGACCTGAGGGTCAGCAGAA
TGAATGGAAACAGGCAACCTCTGGAGGTGGGATGTAGGGTGACCCTCTACAATGTACTAGAGACCTGAGA
GGTGAGGGATTCTGAGGACTGAAACGGAGGGACCTTAGATGAAATGCCCAACAGTGCAGAGAGGGAACTT
GTAGAGTCCACCTCCAGTAGAAAGACAGGGTATCAAGTCGAGGGATGAGGTTGTCATCCCACAGTCAATA
TTTTGACCCATATTATATCAGTCTGAAAGAATTGGAGGGACAAAAGTGGAGAAGAGACTGAAGGAAAGGC
AGTCCAGAGACAGGCCCAAACTAGGATCCATCTCAAGGGGAAGCTCCAATGCCTAACAGTATTACTGATG
CTATGGTGTACTTATAGACAGTAGCCTAGCATGGCTGCCTTCCAAGAGGCCCAACAAGTATCTGACTAAG
ACTGATGCAGATACACCAAACCAATGGACTGAAGTCGGGGACTGCTGTGGTTGAATTAGAGAAAGGCTGG
GAAAAGTTTAGGAGGGCAGCCCTATAGGAAGACCAGCAGCCTCAACTGCCTTGGACTCCTGAGATATCTC
AGACACTGAACCACTAAGGGAGGCCTTGCAAATTCAGATGGGGTGGGGTGGTGGGGTTTAGGGGATTGGG
ACATAGTCTTGGAGACTGGAGGAGGAATGGGATGAAGCACTGCAGGAGTGCAGACCAGGAGAGGGATAAC
GACCAAACTGCATAAAAATGATTTTAAAAGAAAAAAAGACTAAAGAGTTTATTTTTTAATTGCCAAATTA
AAAAGTCTCTAAAAGGGGTGAAAGGATCAGGGGTTAAACCAAGCACTGTAATCCATTATCATCTGAATTC
TGCCACATTCAATCATTCAATTTCATAAAACTTAGCCCAATAGTGTCAACCTTCTAATGCTGAGACCACT
TAATTAACTACCTCACATATTTAAACATCTCATGTGAAATGAACATATATTCTTTATTCCTCTAGTCATA
TTAACTCTCAATAAAAGGGGCTGCTTACCCTATTTTAGGACTTTATCTTCAAATTATCCCACATTCTACC
AACAAACTTATTCAAAAGACCATGAACAACAGTGAGATTATCGGAGCAACAATTCCCTATCTGCACAAGT
TTTCTGTATGACTTTCTTTTTCTTGCTGTGACAGTATACCTGCCAAAATCAACGTAAGGAAGGAGAAGTA
TTCTTCTCTCACAATTTAAGGGTACAGACAACTATGGTGGAAGAGACATGGTAATAGAAGCTAAGCATGT
TGCATTCATAGTCAGACAGCAGAGAGATGAAGGCTGGGGGTCATTTCATAATACTGCCTACACTAAGTGT
GTGAGACCCTAATTTTGTTAAAAATGTTAGTTAAAAATAAATGACCTCACACTCAGAAGTTTGTTTCTTG
TTGATTCTAAAAGTCATCAGGTTGACTATAAATAAAATTAACCATCATAGTCTCCAACAATTCAAATGAT
TTGGAGAAAAAGGAATAAGGCTGCAGGTATCACAAAACTTGATTTCAAGGCACACTACATGGACTTTTGG
AAAAGAACTCCAATTGCTAACAAATAGTGCCAAGAATTAGAAAAAGTGATTTCATGAAATTTTAACAGTT
CTGGGAATCAAAGAGAATGATCAAATGAGGGGAATGCCAATGAAATTTGAGGAAAATCTTTACTAAATAA
ACATCTATCAGATCATTGAAATCTAGAATATACAAATAAAACATTTATTGCATGTCCAAACCCTGGCAAA
TGAAATAGAAAATGTTCTCCAAAGATGAACAACAAATATCCAATAAGCAAGGATAGTGTTCAGCATATTA
ATAATCAGAGAAATTTGAATCATAACCAGCTTGGGATTCTTTCTCTCTCCAGTAACTATCAAATAAGAAC
AAATGCTGGTGAGGATGTTCAGAGATGAGGAAACATATACAATAATAGTTGGGGTGCATGTAGTGTATTT
ACTAAGGGAATCAATATGAAGGTACTTCAAGAAATCTATGAACAGAAATACCATATGAGTCACCTACACC
AGTTCTGGGTGCATGACCGACGAACTCTCTAATTATGACAGAGATAACTGCTTAACTGTGCTTATTGTAG
CACTATTCATTGAAGGCAAGTTATGGAACCACCCTGGATATCAGTCAATGAATTAATTGAAAAGAAGATG
ATATATATGAACAGTGGAATTTTATTCAATTACAAAGGAAAATGAAATTATGCTGTTTGCTAAAAAGTGG
GTGCAGCTAGATATCATCATACTAAATAAAATAAAGAATACACAGAAGAACAAATACATGTTTTCTCTAT
CTTGCATTTTCTAGAATCCTATAAGATGGGACACAGGAGGAATTAAGGAGGGTAGAAGGACTGGGACAAG
GGACAACTTACAGAGGGTAGTGAATGAGAAGGGATGAAGAACAATGTGCATGTAAAATCCCAAATAAAAT
ATTTATGTGCAACATAATTCTGCATAACTCTACATAATTCTATATAAACTCTAAGTACAGTGAGTTTGTA
TCACTAAAGTAGTTTGTATATTAAAAACAAACATACTATATTTTTTATACACTGTAAACAACTTTTAACT
GATATTAGACTATAGAATCATTTTTCTGTACCTGTAGAAAGGCCTTCCTGGTAAGCCTAAAGGATCAATG
AATGCACGTTCCAGATACATCAGCTGGTCATTCATAATTCTCAGTAATATGGGGCTAAAAGCAAAATTAA
TAAAGTTATATCTTTACGACAATATAAATACTACCTAACATACTAAAAAGTTACAACAAAATAAAGCTCA
ATGGTGCATTTTAAAACATTATAGCATGCAAATTAAGAACATCAGTAACATTACAGAAACTGAACAGGTT
GCATTTATATATTCAGAAATATTTGTAACAACAATTAGTGATAAAATGAGGTCATGACCAAAGGTATCCA
GTAGGTACCCAGGGAGGACTACTCCTTCTAAGAGGTGAAAGGAAGGGATAGTGGTGTAGGGTCCTTATAT
CAGGGAGGGCAGGGAATTAGCAAGCTGTTTGGAATGTAAAGTGAACGAATAAAGAAACTCATGGCAAAAA
AGATTTTAAGTAATATTATTGGAAAATATAATGTTGAACAGGTGATACTTATAAATTTAGAAATATGATA
ACAACCTTACTGAAAACTGAGGTCCTGCTTTCTAAAAGTGGGCAAAGGAGTTTTAGAATGTTTGAAGGGA
AGTAAAGATAGAGATAATGTAATTATATTCTAATCTCAAAACCTAAAGTAATAAATTAAAAGCAAATATC
AGCATGTATTCTCGCCAAATACCAGGAATTCAATAAAATATTATTCTACTAAAACATAAACTATAAAGCA
GTAACATACTGGTGAAAAATGTGATATTAAATTTAATGTGTACAGAAATGAGACTTACTCAGTCTGAGTT
TATAATTACTGTCAAGATTAGAGATCCTCATCAAAATTGAAATGAGAAATGCTGCTAATTTCTATTAAGT
TTATACAAACTACGAATATTTAACAGGTGACACTGTATAATATTCCTTCTATTAAAGAAGAATTTGTCAA
ATATATCATCCTTACTTTCTATTTTCATCAGCATTCAAATATCATAGAGCAAACACTAGATTTCAAGTTC
ATATCATAGAGCAAACACTAGATTTCAAGTTCCTAAGGGCCATGTGTTATTAAGGTTGTAATTGTAAATA
AAAATTTACACCAAAAAAAATTCCACCAAAAATCCCTTGGGTAGCTCACCTGAATTTAGCACAACAATTG
AGCCATGATACAGTTTAGTGAAAATTATCACTTTAATAAATAGGGTTATTTTATCCATTAGTTTATCTAT
ATTTTCATTTTATATTACTTTTAATGAGAATAATATGAAACTGTCACTGATACTTTTTTGTTTTGTTTTG
TTTTGGTTTTGTTTGTTTGTTTGTTTTGTTTTTTTCAAGACAGGGTTTTTCTGTATAGCCCTAGTTGTCC
TGGAAATCACTTTGTAAACTAGGCTGACCTCGAACTCACAAATCCACCTGCCTCTGCCTCCCAAGGGCTG
GGATTAAAGGATTGCGCAACCATGCCTGGCTGATTCTTATGACTGCTTTTATAGAAAGTTTTAAAGCAAC
CCTGCACATTATACAAGATTGTAACTTCATTTTGCAAACTAAGGATCTGTTTGCCAGTTTATATTTTTGC
GAAGAAACAGGGTAAATATTGTAATATTTTAAAACTCTTCTTATGGTTCAGTGGTTCAGTTTTACACAGA
ATTAATATTTGTTTAGGAATTCTACAAATTTTAACTTCACAGTATTTATTATTATTATTATTATTATTAT
TATTATTATTATTATTATTATTATTATTATAGAATTTTTACTAGAGTTGGAGAGGATGGTCTGTGTGTAG
ACATAATGACTTCTAGTAGAAGTTGAGAAGCACCCTGCAAGAATAAAGGAATCAGGATGGAGAATGATGC
AAAATGAAACCAAATTATATTTGAGCCAACACTGAAGTTGCCAAGTTGCATCCCATAGTCTGGCATGAGG
AAGGCACTGCCATCTAGCTGCAATTCATGTAAAATAAAATCTGAATGACAGGCAATACTGAACACAATGC
ATTAGAGGGAAGACAGAAATATAAAACAATTTTCTAAGGTATTTCAGCAATGCAAATGTGAATTAATGAT
ATTTTACATATATAGTAACATATATAATTATATATTTTAATTAATTGATTGATTGAGGACATACTTGCTT
TTGTCTAACTCTTGCAGTCTCTGATTGAACTTAGATGCAACATCTGTAAAATTATTGACTGCAGAAAACA
GTGAATCTGAAACAGAAATCCAAGTTAGCAAAAATTTTAAAAACATGGTTTCTAAAGCAGGTAAGGTGGT
AATGTCTGCAGTCTCATCATTTTGGAAGCCAAAACAGAAAGATCACTCCAGCCCATGAGTTTAAAACTGG
TTAATGTAAGATTTGCAAACTCATTTCAGTAAAAGAAACAAAGCCTCGGGGTTTTTAATGGTCTCTATAC
AGATAACGATGTGGAAACAATATAGAAAACTATTTTATGAAGTATTTATTTTTATGAAGTATTTTGAACA
TCTATGTAATTCAGAACAGATCTCAAGAGAAAAGGAATATCTGATCTAGTACAATAGAAATAACAATGAG
AAATATTTAGAACACAGGAGTCAAATTGAAAGGTAAACTGCAACATACCAAATGATATCATGTAAGCCTT
CATTTCTTGTGGATGTTTCATTGAAATATTGTAGATAGTGTCAGCATACTTCTTCAGAGCTACAGCATAA
CTTTGGCAGTCAAAGGGAAGCACTATAGAATTGGCAAGTTCAAATACCATCGCTCCTCGAACCTGGGCCA
CAGTGAGGTGGTATTTAAATGTTGGGTCATAAAATTTTACTACCAGCTCATATGTTTCATAGACACTGTG
ATAGAGAGGATAGCTGCTGACTTTGTTAGTTTTCTAGGAGAAAAAAAACAAAAAACAAAAACAAAATGCA
TCTCTTTAAAATGGCTTATAACAACCCCTATTCCATGATATTTAATGCAGTGTTATTAAGGTGGTTTGAA
AACTAGCGGACAGGGATCATGTAAACTTAGATTCCTAGAACTTAGTAAAGGACTACCCTAGGCATGTACA
GATAGATACACATGTACACATGCTGCAAAAATAATATGAAAACATTCTGTAAGAAACACACCTGAGACTT
GTCAACCAAAATATAAGAGATATAGAAGTTTGTAAAGAGGCCAAAGAAAGGACTATATAGTGCTGCATTA
GAAAATAAATTATTTAAGGAGAAAGTTGAGTAATTAATAAACACCAGTGGAGAAAATTTATGAATTTATG
AAGTAGAACCATGTATCACTGAAAATCTCCCAAAGAAAACTCTGAGAGATAGTATGCTGACCAGTGGAGA
AACAAACAGAGAGAGCCCCATAGTGAACTTGGGGTATTTCTAAGGAGAGAGAGGTGATGCTCATGAGAGG
CCAAATCTTTTAAGTTCATACTCCATTTTAGAAAACCAAACCTAAGTAGAATTTAGTTAAACTAACAGGC
TAGTATCTAGGAGTAGTTTCCAAGTTGACTTGCAACAAAACCCAGTCTCTAAGCTAATCCCTAACAAGAC
TAGCATTTCCATACTACACCCTCAACAAGACCGGTGTCTCCAGGTTATTCCCCTAACAAACCTGCACCCC
TCAGATTACAAGTCCACCCCCTGCTTAAAGACCAGCAATGCAGAGGGGAGCAGAAATTAAGTTTATGATA
TGACTCTCAGCACCAGACAATTTTGTTAAAGACCACAGTAGCTTTCCAATTAGATGCTTGTACACTTATC
TCCTGCTTGCTGCTTATTTTAAAGTCTTCCCCTGATAGACATTTGGGAGCTCCCCACCATCAAAACCCTC
CTGCATGTTGGAGGAGTGTGGGGATGGGGAGATGCGGAGGCTAGCTCAAATAGAATACTATAGAATAAAT
AGAATAAAATAGAATAAATATCCTTATATAAAGAACACTTTATTTGGTATAATTCTGAGAGACTGAGAGT
ATGACATTATTAATTTTGGATGAGTTTAATTCTGAATTCAAAGTTGATTCATTTGGCAATTCCCTGGATT
TGATTGGTTTAGTTTCATATGTCAAGTATATTTATTTTCATCTTAACCCCCCAAAAAACTCAACTTTTTA
CCCCCAAAAGATCTCTGGCTGAGGGCAAGTAACTTGATCAAGAGAAAATACATACAAAGATTCACTGATG
TCTGAATAATCCCCTCTGACTTTAGAGTTTAAGCACAATGGGAATTTAGAGTTGGGTCCAATCTTTTTTC
CTGTGACTATATTCTCCCTTTCAATCATCTTTAGTGAATTGAATAATCAGTTTAATAATTGTGCTGGCTA
GTTTTATGTCAACTCGACAAAAGAAGGAGTTATCTGAGAGGAGGAAAACTCAACTGAGATATTGCTTCCA
TAAGATCAGGCTGTAGACAAGCATGTAGGGTCTTTTATTAATTAGTGATTGATGGAGGAAGTACCAAAAT
TATTGCGGGTAGATGCCATCTTTGGGCTGGTGATCCTGTTTTTATAATAAAGCAGGCTAAGCAAGTCAGT
AAGCAGCACCTATCTATGGATTCTGCGTCAGCTCTGGGCCTATAGGTTTAACCCCTGACTTCCTGTGATA
ATGACCAGTGACATGGAAGTGTGAACCTATTAAACCTTTCATTCCCAAGTTCATTTGGTCATGATGTTTC
ATCACAGCATTGATAAACCTAAGTAAGACAATAACTATTGTTTTTTTCTTTAATACCATATATTTGGAAA
TGAAAGTATATGTATAAGATATTACTTACAAATTAAAAATTAAAATTAGGTTAAAATTAGAACAAAATTA
AAAAGAAAAACCTCAGTATAAAACAGAAAACATGGGTGCAGTTAACATATGATTAATAAATTGCTAGCAA
GAAGCTTTTACAGAACTAATACAGATTTTATAATGTATACATTTTTTTTTTTAATGGTTTTTCGAGACAG
GGCTTCTCTGTGTAGCCCTGGCTGTTCTGGAACTCACTTTGTAGACAAAGCTGGCCTCAAACTCAGAAAA
CTGCCTGCCTTTGCCTCCCGAGTTCTGGGATTAAAGGTGTGTGCCAATACACCCAGCCTTAATCTATACA
TTTTTAAAGCTTACTAAAGATTTATCAATCACCAAATAAAAGAAATAAAAATGATTTATGGTTTTGTTGC
ATTATATCAATATTTATTAAATGATTTCTTTTGTTTGATGAACTGAGCTACAGTAACAGACAGAAGTCCA
AATATTGTCATGTCTTACTTGGTTTGATGAATTTGGAGTGAACATAAGTAAAGATGAGCCCAACATAATT
CTCAGGAACTTAAATTACGAAGTAAATATTGAGTCACTGAATCAATAAAACATAATATATTTAAGGCAGT
GTTTTTCAACCTTACAACTGTTATGACCCTTTAACAGAGTCCCTCATATTGTGGTGACACCAAATCATAA
AACTGTATTTGTTACTACTTTATAACTGTAATTTTGTTACTATTATGGATCATAACATTAAGATCTGATA
AGAAGGATATATAATAATGACCTCTTAGAGGGTCATTTGACCCACAAGGGGTCAAGACACACAACCTGAG
AACTGGTGATTTAAGAGAAAACATTAGGAATAGGTCAGGGGAAAAGATGAGTGCAACTGGAATGTGAATA
CAGGCTCAGTGTAACAAAGGCAGGACAAAGAACCAATGAGACATCTCTATATGAGTTTCCAGTGCTCCCT
TTCCTCTAATAAGTCTTAAAGTAAAACTTATTAATTTGGTTAAAACATACCCATACTTAATCTATAAGGA
TTCTCTAATTCAGACTTACCCAATTTTTAGTATATCGGGCTCTGCCTGAAGCAATTCCAAGTCTTTGGAA
GAACACTTCAAAATCATTGCCAGACCCCAGCTTGCTAATTCTGAGAGACAAAATCATTATAATTAGTTCA
GAGTACTCTGTTCATTCTATAAAGACCAAAGATCAGTTTCTACATTCTAGTCATACTATTTCAAATATGA
GAGCATTAGACATACAGTTGAAATAAGATTTTTTTTTTCTGGTACTGAAAAATGTGCTTCCTCTTCAATA
CTATTCCATGGAAGGTCACTTTCATAAATCACAATTTATTTAAAGATTTTGGAGGTTGGAAAATACTTTT
GCTCAAAATATTTGTTTCATTTTTGTTTTACAAATTAGTGAATGCAAAAAGTCTTTTTCAGATTAGGATA
TAAATTGGTCAGATCAACATATTCACACTGTAGATCTCTACCTATACGAACTATTGAGATATTTGTTTCC
CTTCTCTTGCATGTAAAGATACAACCACTAAGTCATAGTTATAATATTATCAGAGTAGACACAGTATTTG
TTAAATGCATGGTATTCAGTAAAAGAAATAGTTATAGACAGACATGTGAGAAATGTTTGGCAGGAATTGT
GTTCCATTTTCTCCATTGTGACCATTAACATGGACCATGTACAAATATCAGGTATCCTAATGGGCACCAT
AGTTCTCCCTTTTCTTTATAAAATGTTAGTTATTTCTCACAGTATAATTTGAAGGGCCCTTGGCATTAGA
AACTTGGCTGTCAAGGCCTTTGAAAGAGGAACAACAGTTTAACTCATAGAATGCAGGCCACCCAGTTAGA
ACTAAATACATGTATGTTCTTCAGAAAGGCAGAGACCCAAGTACTAAGTGTCCTGAGTAATTGATGCTGT
ATTGGTGCATCTCTCTGCTGGTTGTTCTTATGGTCTTCATGTCCTTTGTAGTTTATGTGTCGGATGAAGA
TTCTAAGCGGGCTCCAGCTGTCCACTGGGCCATATGTTTAGCAGTCAAAGTAATAGTGCTTGGTGATTTT
TCCAGCATTGCTTCTGGAACATATCTATGATTCAGTCACCACCCTTGGTTAGATCTTAAACATGTAGATT
GTTAGCAATGACCTCCACCCTTAGAAAGAATTTTGAGAAGATTGTTAAGATGTTTTTGTCAATGGCTCTT
ATGTAGAAAATCTTAAAAACAAACTGAAGTTCAGGAAGGCAGTTCCGCTAAATAGTTGAACTGGGGATTT
TTTAAGCTTAGGGAATAAGAGCAATGGCAGCTCAAATAGAACTGGCTTACATGACTTTTGCTGAAGGTAG
GCTAGGGATCAAATGTGATAATTTCTTATTTCCATTTTTTTCCTCAGCTTCCTGATAAGATTTAATAAAA
ACTGTTAATGAGTATTTATGTACCTTGAAGATTTAAAATAGGAATGACTGTTTTTTTAAAGATTTATTTA
TTTATTATATGTAAGTACACTGTAGCTGTCTTTAGACACTCCAGAAGAGGGAGTCAGGTCTCATTATGGA
TGGTTGTGAGCCACCATGTGGTTGCTGATGATTGTGAGCCACCATGTGGTTGCTGGGATTTGAACTCAGG
GCCCTCAGAAGAGCAGACAGTGCTCTTAACTGCTAAGCCATCTCTCCAGCCCCTGTAATGACTGTTTTTT
AAATAAATGTTTACATTTGTAATTTTTTAAAATTTTTTATATGATTACTTCTTTAAATAATTACTGAGAT
ATCTGATTCTTTCTTTGTAACCACAAAATTTAGCCTGTAAGTCAAGAGGACCTGCTGAGAAAATTACCTT
GTTTGCTTAAACTTTTGTTAATTTATAACAAGTTGCTTAGTTATAAATGTATGTAGGTTCTTGGGAACGA
TTTTCTGTTTCTTCACCTGTATTACATAAAGTGTTTTTTTTTTTATGTAAAGGTATTGAGGAACATACTT
TTTAAAACAATAATCATTCACTAAAAGAAAAATAGAATGTAGTTGCATTGTAATTTTTATGGTCCTTGAA
AGGTTTTGAAGGGATGTATATGATATAAGAGAAAAAAAATAAAGTTCTTAGAACTTGTTGAAGATTGCTT
CATTCATCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGCGTGCGTGTGCGTGTGCATGTGAGC
AAGGAAGCGAGAGAGCGAGAGCGAGAGTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGA
GAGAGAGAGAAATTCTTATACTATCTTTTTATTTCTTTCTTTATGGCCCAAAAAAAGGATTTTATTGCCT
CTTCTGAAGGAATTTTTTATTCTGGCCTTTAGCAATCACTCAAGATAATTTCACAGGCACACTCTACATG
TCACCTCAGTTTGCACTAAATGTCAAATTTGTTCTTTGATACTTGGATGCAGCCTCTTGCATATAGCTTG
CTTAAAAATGAATTTTGAAACCATCAGAAATATTTTCAAAACATAGAAAAATATTTTATTTTAAACACAA
CCTTTTATTTTGAAGACACATATTTCTTTGTCAGATATTAGAGCATTTTGAAAGCTACTTCTCAATAAAA
TATTAAGGCAAATATACACTTTTATATCCAAAACATTCACCCAGTGACCATCTTGGTAGAATGGTTGTGT
TGTTGCTGTACCTGGGCATTCCAATGAACTCAGGTGAAGGACTCTTTTCTTTCCAGCTGTCATAAAGAGA
TTTTCCTTCAAAACCTTCATCTGGGCTTTGCAGCTATACAAATTATAAACAGGAGAATTCTCAAAAATCT
GATGCATAAGCTTAAATGTCCATTAGTAAGAATGTGAAGAGTTAAACTACATTTCAGCAAAATAAGAGAT
AAGATCTCTATATTAGAAGTTGTGAATTATTTGGTTGCTATATGGTGATTCCTTGATAAACTCTTGGTTT
TGGGATCAATAAAAAGCATAGGGCTCAGAGGGTTACAATAAAAAGTCCTGAAGAGAAAATGTTTGTATAT
GTATAGTGTGCAAGTGTGAAGATATGGGATATATAGAAAAGAATTCACAAATTAGCAAGTCATTGTCTGT
GGAGAAAACAATCATAGGCCAATTTTCCTAGATCAAAGAAAACTATTTTCAAAATCATATCCTTCTCCTA
CTAAAGAAAATATTTCTTTATTACTGCCTCTTATTTGTAGGACTGCAGAAGTCTTACATGATCCATAATG
AAATCATTATATAACATAAATAAAGGAATGTAATGACTAGTTCTTTTAATTGATTGCTCTTTATAATTTT
GCTAAGCATTAGGGTTTAAAATCATTGTCTGGTTTTATGAGTGAAAAAAAGAAGTAAAAAAACCCCAATA
TTATTAAATTTTAGAATTAGAACATATAAAATTGCACCAAGAGTGTTTAATAAGTTGAACATCACTAAGG
TTCCATAGTTATTTAAGTTCAATGGAAGAATCTTTGGAATGTTTTATACCTAATACCTAAGTGTAATAGT
TTAAAACATTTGAAATGTAAATAAAGAAAATATCTAAAAAATAAAAAATATTTTAAAAATATAAAAATTT
ATTGAACACTTACAATATTTAATAGTTTGTATAAAAATGTAGAGGTTCATGTAGTATATACTGTAATAAA
TGTATCCATTAATTATTATATATACACAAGTTAGATTTATTTCACATTAGAAGAGAATTAGAAGATATAT
CTATATCTTAACAAATAAGATAGGAATAAAGAAAAAAATTATTTTATTCACATTTATAAACTCACTTCCT
TTTTCTTAAGGAACATAAATTTAAAAGAACAATACTATATTATTAAAAATATGTCTATCAAATAAACATA
TTTAAATAATAGCAAAAACTCTCTTCAAACAAAGAAAATAAAGAAACAAGGAAAGGAAGAAGGAAACAAA
GAAAGAAATAAAGAAAAGTTTTATAAATTACAAATATTAAGCCTGACCCAGCAGTGTTTTCACAGCTGTA
GCAGAAGGTCACTAACTCAGGAGATGAACAAAACAGTCAAACTTCCTCATAATTTGCCATAAATTATTGA
ACAGATTTCTCTGAAACACTGGGTTTAAGGCATTAAAGTTTCACATGTTATATAGTAACTAATAAAACTG
CCTTTAAATGATACAGATCTTAAAAAACTAAATGCTAATACTAATTAATATATTTCTTATACCTGTAGAA
GGAATCATGTTTTCTGACTTAATTCCATGTTTTGAATACAAAGATTTATTTATAAGTCCTATGTAAATTA
ATTATGATTTTTTTTTTAGAAATGCATTTGTATTAGTAAATATGTCCAATGACCGGGTTTTGTGGGTTGC
TTGATTTTTGCAGTAATTTGAGAGTCAGTCTCAAAAGTCTGTCATGCAGCTAAAATGATGATACACGCCT
GCAACTCTGGAAATCTGAAGGCTGAGTCAGGAAGATCTGGATCTCATGTACAGATAGACCTGAACTACCT
ATCAAAACCCTCTCTTAAAGATGCTTTCACATAGAAGTGTAAGCAGTGCCTCCAAACAACTTCAGTATCT
GTTGCAGCTGAGAGCTAGAAGGAAGGTCAGACCCTATGGTAAAGTCAAAGATTGGAGTACTAGGAAAAAA
ATCAAGAAGGGACCACCTAGTTTTTGTCCACCAATGGGTGCATTTCATTTAATTCAGTCATCCGTACCTC
GTGAGTTACCTAATTTTACCATACAAGGGAGCATAAAGTAATTATAGAGTAAAGGAATTAAACAGTAGTT
CCAGCTACAGTGTGACTCTAGTGGCTGCTTTGTAAGGTCTATTTTGTCATTTCCAAAGTACAGATGATAG
ACAGAATGCAGCCTATAGGCTGACTCACAGAGGTGGGAGAAATAGCATATAGTATATGGAGAAATAGTTG
GTTAGCTGAGAAAGTTCTGAAAGAATATTTTTCATGAGAAAAGAAAGTTAGCTACAAACAATATAAATAT
TGAAAATAACAGTTGCATCCAAAATATCATTTTCAGAGTTTCTGCAAAGATTTTCCCACTACTTTACCTC
TTTTGTTAGGTTGTACACTAAGCTGTACATCAGTGGTGTGCAATCAACTCTTAGAGTGTAATTTCCTGAA
ACAGAAGGAATTGGCTGGTTTATTTCTTTCATTTATGTTATTTATTTACTCAAAGACCATTGTTAAACTG
TACATAAAATTATTCCTTCAAAAATACAGTTTATAAAAAACCCTCTATTGTTCTCAATCTTCAGCTATAA
AAACAAATTTTATGACACTGACTGCTAAATCTTGTCCTGAAGATTAGGGAGAGAGCTCAACAGGCCATCT
CTCCAAATCTTTACTTCCTATTCTACCTAAAAACTTTTCCTTAAGCCTCTTTCAAATACTGTTCCCTCAG
CTTGAATCAGTATCCTACACCATATCTGCATGACTTCTTCAGCCTTTGGGCTCATGTTAAATTTTCAGAG
GGATCTCAACTCCTGAGCATAACACTCCATAGAATCTGTTCTCTTTTTCTTGTCCTTGGTCTTTTTTTCA
CATCACTCAAGATCTGGATCACAGGTGAGCCATTCAATTCTGGAACGTAGTTCAATCCAGATATAGTCAA
GTTGACAACCAGGAATAGCCATTACATGTGCCCTGAACATAAGAGTACTTCCAGGACTGTTATGTATTTT
CTATTCACAAAGTAAGATCCAGGTCACTGAAGGCTGAGTGGCGTGGGCTTTTAATCCCAGCACTCAGGAA
ACTGAAGCAGAATGTTCATGAGTTCTATGCCTCATATACATATATACATACATACATATACATATATATA
ATATTTATACACAAGTGTTTTATATGAATGACTAAGAGGGAGACAGGCATTTCTTACAATATAGATACAC
ATAATATGGGATCAAAAATTACATACATGGCTCTCTATTCAGTTGAAATTTCATATAGAAAAGTACATAT
GCATAACTGGACAATCTCTACAACATCAGCTACAGAAATGAAATGTAAAGGCACTATTAAATGTACTACA
AAAGTTCTATTGTTTTACTGTAGTGACTTTGCTTTTTTTGTGTGAGGTGGTTTGTTTAGGCTGTTATACT
ACATAAGTATAATAAATCAATGTATACTCATTAAATGAAACATTTTATGTTTTCTGTGTGAAAATGTGGA
TTTCCAGCCATTTACTTATAATACCAAAGTTCTGTAAGATATAACAGGAGGTAAGAAAGCATAATAGATA
GGAAAGACTGAACTCAGCCCTCTCCTCGCAGGTAACCCATGGGAAGTTAATTGACATCCGAGTCACAGCT
TCCTCTTCTGTACAGTATGGAAAATAAGTACTTATATCACATGAGATCTATATCACATAAATATTACATG
GGCAAGAATTAAGTGAGCATTAAATACATTTCTGGCATATTACTCAGATAAATGAGAGCTCATAGGACAG
AAACACTACAATTCAAGGAGAATAGATGTTTTGGAGAAGACATTAAGGGTAACCTGAGTAAAGCTTTAAT
TTCTTTTCAATATTACATACTTTATTATTTATACAAACTTTCAAATAAATAAAAATATCACTTTAGTTTT
TGTGTTATATTTATGTTTATATTTTAACATATATTCACAGGTATGTGTTATTACATCCCTTGAGAAATAA
ACATTTAACCAAAGAATGGAGGGTTGTATATCTCAATCATATTGAACTTATGCATATTTGTTCTTAATCC
TGAAAATTATGGTCCAGTTTCAAATATGACATAATTATCTAAGCCCAGTGATTGCTAAAATACAGGACAA
GTCAAATGTTCAAAATTATCAATAATAATAGTAACATCATTTAGCTATACCTCCAGATTCCAAATCATAT
GATTTGAGAATGGTCATTATTTATCACATACAAAATGTGTGTGTGTGTGTGTGTGTGTATGTGTGTGTGT
ATCATTGTGTATACATGGAAGTCAAAATAAAACTTTTTGGAGTTAGTTCTCACAGTCCATCTTTAAATAG
GTTCCCATGATACACCTGAGTTTGTCAGGCTTCTCTCAAATTGCCTTTGATGGTTTATCCATTTCACTAG
TCCCTAAACATAAATGTCATATATGTAATTCAGAAACAAAAGATTCTTCAAGTTTGTGACTTAGGCATTC
AACAGGTAATAACCATATTTAAGAGACTGGTAGAAGAGGCATGTTAAGTAATGCAGTCTTCGTGAACTAG
CATTGATATACAGCGGGGGGGAAATTCCTCTTAATTACTCATGAAGTCAGTCCTGAATCAAAGGGAAAGA
TGTGAAATCAGCCATAGGTATCTTAACTTCATCTTAATGGGCTTCTTTCTGTGCTAGGATGAAATTCTAC
CTCCAGAATAACCATTGTTCTCTAATAGGGCCAATAATATTCACCTTCTATGGAAGAATCAGCATTAATA
TAAGCCACACCTCGCTCTTGTAGGAGTCTTGAATGTTCCTATAACAAGAAACTTAATAAACTATAAGGAT
AAATTTAACTCACTCCCACCCAAGGCATTTCTGCCATTCTTTAATGTATATATTTTAATGAAATAGTGAC
ACAGTTCCCACAAGTTTGGCATGTAAAGTCTCAAGAAAAAAAAATGTACTTTACAATGAGAAACAACACC
AATGGACAGATCTTCTAGACAGAAACTAAACAGAAACAATGAAACCAACCGAGGTTAAGATGTAAATATA
CCTACCAGATAATTATAGAAAAATTAACCCAAACACAAAAGAATAGACCTTCTTCTTGGGACCTAATGGA
ACCTTTTCCAAGATTGACCATAAAATTTGTCTCAAAAGAATTAAACCACAACAGATAAAATAAAATGGAA
ATAACCCCTTGCATCTTGTCAGAACACCATGGATTAAAGATAGTTTCAACAACAACAGTAATTGTTGGGG
ACTGGTTTGAGTACTTTGTCTTAATTTGGCTCCCAAAGCTGCACTTCAGGTGCTGAGGGTCCCTGCCCCC
AGCTGGATTTGATTGGTAATAAAGAATTGCCATAGAGACAATGGCTGGGCAGGAAGACTGAGGTGGGACT
TTTAGATTGCATGGGCAAGGGACCAAGGGGGTCAGGGGGTAGGATGGGGGAACAGTGATATTAGAATTAA
AGGCCCACTGACATGTAAGGATTCTGGGAAGTGGTCCCAGGGACAACTTTCCTGCTTGGGTCTAGGAAGC
CAAAGATTAAAACAAATAGATTTAGAAAATGTTAACCCAGGAATACTGGAGGAAGTATATGCTAGATGTG
GGGAGGTTTAGAAGTATGCAGACACTGAGCTAGTTAGACATATTAAAAATTAAGCCGATATGTGTTTGTG
TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGCGTGTGCGTGTGCGTGTGCGTGTGCGTGTGCGTG
TGCGTGTGTTATTTTTTAAACAAAAGAGCTCTGGCAGGTGGCTAGAATTCAAAATTTACCACTACAAGAA
ACAACAGAAGGCCGAAATACTCCTGGAAACTGAACTCTCTCCTCCATGATCACTGAATCAGGGAAAAGAA
TAAAGAAAGAAATTAAAGACTTTCTAGAATTCAGAAAAATGAGGGCACAGCATTCTCAGACTCATGGGAC
ACTATGATATCAGTGCTAAGAAGAAAGTTCATAGCACTGTCTTCATAAAGGAATTGGAGAGTTTTCTTCT
TTTCATTTTTTATTGGTTATTTTATTTATTGACATTTCAAATGTTATCCCCCTTCCATGTTTCCCCTCCA
CAAGCCCTCTACCTCCTCCTCCCTCCCACTGCCTCTATGAAGGTGCTTCCACACCCCCACACTCAATCTG
CCTCAGTGCCCTAGCATTCACCTAACCTGGGTCATCAAGCCTCCACAGGACCAAGGGGCTCCCCTCCCAG
TGATGCCAGATAAGGCCATCCTCTGCTACAAATCCAGCTGGAGCCATGGGTTTTCCCTGTGTACTATTTG
GTTGGTGGTTTAGTCCCTGGATGATTTAGGGCATCTGGTTGGTGGATATTGTTGTTCCTATGAGGTTGCA
AACCCCTCCAGCTAGAATTCTTATACTAATAAATTAAAAGTATGCCTGAAAGCTCTAGAAAAAGAAGAAG
AAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGA
AGAAGCAAACACACTGGAGAGGAGTAGATGCCAGGTCATAATCAAGCTGAGAGAAAAAGAAAAGAAAAGA
AAAGAAAAGAAAAGAAAAGAAAAGAAAAGAAAAGAAAAGAAAAGAAAAGAAAAAAAAGAAAAGGGAAAGG
GAAAGGGAACGGGAAAAGAAAAAGAAAAAGAAAGAGAAAGAGAAAAAGAAAAAGAAAAAAACTTTGGGAA
AAAATAGACAATCCCTTAGCCAAATTAACTGGAAGACAGAGATACAAATTTAAAAACTGAATCAGAAATT
AAAATGAATACATAAGCATGGACAATGAGGAACTTAAAAAATCAAAAGGTATTATGTCAAAAGCCTTTAC
TCCACAAAATTGGAAATCTAAGTGAAATGGATAATTTTCTATACGGATACTAAAAGCAATCCACAGATTC
AATAGGATCTCCATTAACATTTCATTAAAATGCTTTACAGAAAAATTCTCATCTTTATATAGAAAAGCAA
AACACCCAGGGTACCTAAAACAATCCTGAACAATAAAAGAACTTTTGAGATACCACAATCCTTGACTTCA
AGCTGTACTACAGAATAATAGTAATAAAAAAAATTAAAAACCACACGGTATTGTTATAGAAATAGACAGG
TGGATCAATGGAATCAAATTAAAGACCTAGAAATAAACCCACATTTCAACAGACTACTGATTTTTTACAA
AGAAGCCAAAACTTTACAATAGAAAAAAGAAAGCATCTTTAGCAAATGCTTCTTGTCTAAATGGATGTCT
GCATCAAAAAGAATGCAAATAGATCCATATAATCAACCTGTACAGAACTCAAGTCCAAATGGACCAAAGG
CCTCAGCCTAAAACAAGATACACTAACAGAAACTGGGGAATGGATTTGCACTCATTGGTACAGGAGACAA
CTTCCTGAACAGAACACTAATGATGTGGCGCTAAGATTAACCCTTAATAAATGGAACCTCATGAAGTTGA
AAAGCTTCTGTAAGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTACCATCATTAGAACAAAATGA
GAGCTTACAGATTATGACAAGATCTTCCCCAACCATACATCTAAGAGAGGGATAAGTATCTAAAATATGT
AAAGAACAGAAGAAGTCAGAAACCAAAAAAACTAACAATCAAATTAAAAAATTGGATACAAAACTAATCA
GAAAATTGTAAACAGAGGAATCTCGAATGTCCAAGAAGCACTTAAAAATATTCACTATTCTTAATCATTC
AGGGAAATGAAATGAAACCATTGAGATTCTTCCTTACACACATCAGAATAGCTAAGGCCAAAACCTCAAG
GGGTAGCTCATGGTGGCAAGGGTCTGGAGCAAGAGACACACTCTTCTATCAGTGGTGGGATTACAAACTT
ATACAACCACTATGGAAATCAATTTGCCAGTTTCTGAGGAAATTGGAAATAATTCTACCTGTAGACCCAG
TTATACCACTTCAGGGCATACACTCAAAAGATGCTCCACTTTCCTATAAGAACACTTGTCCAACTATGTT
CTTAGCAGCTTTATTTGTAATATCCAGAGACTAGAAACAATCTAGATGTCCTTCCACTGAATAAAAGATA
AAGAAAATGTGGTTTATTTACACAATGCAATACTACTCAGTTATTAGAAACAAGGACACCATGAATTTTT
CAGGTAAATGGATAAAACAAAAAAATCACCTTGACTGAGGTGATATTTCACCCCAAAGCCATGCATGGTA
TGTTCTCACTTACAAATAATATTAGCAATAATGAGGTAAGCCAGACACAAAAGGACATCCATGGCATGTA
CTCACTTTTAAGTGGATATAGCAATAAAATACGGGATAGCCACTCTATATTCAACAGACCCATACAAACC
AGATAACAAGGAGGGCCGATGGAAGGATGACTCTTTCTCAGAGGGGGAAATAAAAGAGAAATCTGAGGTG
GATAGGAGGGAAGTGGGTTGAAGAAAGAATGAAGAGTAGAACAGGACAGAGGTCAGGGAACAGATGCAGG
AAGAGTGAGGGAGAGAGAAGGGGAACTGGCAGTGGGGGACTCTAGATTGTGGCAGAGACCAAGGATAGCT
AAGCCTTGGGCCTCTATGGGAGAAACTCTAGTTGAGACTCCCAGCAGTGGGGGATATTGATTGTGAACTA
CTTCCTGTAGCCAGGCAGGACCACCAGTGGAGGGATAAAGACAGCAACCTATTCATAAAGCCTTCAACTC
AAAATGTGCCCTATCTACAAGATGTACAGAGACAAAAAGCAGATACTGATCACATGGCCAACCAATGACT
GCCCCAAGTTGAAACCCATTGCTTGAGTAATAACCAATCCTTGACATTGTTAATAATACTACGTTATGCT
TGCAGATAGGGGCAGAGCATAACTGTCATGGGAGGCTTCATCCTGCAACCAGTGTAAAAAGTCAAACATT
AGATGGAGCTCAGGGAGTCTAATTGAAGAGTTGGGGGAAGTAATGAGGGAATGTAAAAGGACAGATACTC
CACAGGAAGATCAACAGTCAACTAACCTAGACCCCTTTGGCTCCCAGAGACTGAAACACAAACCAAAGAG
CAATCATGGATTGTATGGAACTACGGTCCCTGCATATATGTGCGTGATAACAAGATAACAAGGAGGGCCG
ATGGAAGAATGACTCTTTCTCAGAGGGGGAAATAAAAGAGAAATCTGAGGTGGATAGGAAGGAAGTGGGT
TGGAGAGAGAATAAAGAGCAGAGTATATATATATATATATATATATATATATATGCATGTGTGTATATAT
ATATATTTGTGTGTGTGTATATATATATATATTTGTGTGTGTGTGTTTATACATCAGATGAAAAGCTTCC
TCTTCATGTCAGGGCCCCCCAACAACAGAAGGGGCTCTCCCTGAATTTGTTTCCTGCCTGCATGTGGATC
TCATTCCCCTAAATGCGCCATTTTATCTGGCCTCAGTGGGAGAAGATCTGCCTAGTCCTAAAGAGAATTA
ATGTGCTAGGGTGGTACAGGGGTGACAATATAGGGTTTATATCAAGAGGGAGCTCCTCCTTCTTAACGGA
GAAGGGAAGGGAATAATAGGAGGAGTTTCTCTGTGAGGGAATAGTGGGAAGAGAGAGGGGACTGATATCA
GCATGTAGAGTGAATAATAAATTTAATTTAAAAAAGAAATTGCCAATTTTTTGTTTGGTTGTTTTGTTTT
GGCTTTGTATTTTGATTCCAGTACACTGATTTATTTATTATATTACATTATCTAAAACAAAATTAAATCT
CAATAATTGAAATGAGGTGTTTCTAAAATTGGAACAGAAGTGAATTCTTCAAGTGAGATAATTTTGTTGA
TTTTTTAAAACAAATTATATTTTTATTAACATATTTATGTATTTAGTGCCTGTATGTGTGTTTTGTGAAC
ATGCATGTCATCTCATGTAAGTGGTGGTCAGAGGAGAGAATGTCGGTTCTCCAATAATTAGTGAAATCTA
GGTACCAATAATTAGTGAAATCATCAGCTTGGCAGCAAGTGCCTTAACCAGCTGAGTTATATTTTTGCCC
TCTTGTAGATTTTTTAACAATAACATAATCCTTTTGCATAATAAGATGTCTAAGCTGTGCCCTTGGGCAA
CATGCAGCCAAGTAATAGGTATGAATGTAGTCCAACACAAAATTGTAAACATAGTTAAAATATGCTGAGA
TGGTTTTTATTTGGTCGCTTATAAAGTAACTTGATGTGTGAGTCTGAAACATGAATTTTGTATATAGAAC
ATTCTGTTGTAATAGTAAAAGGTTGAGCGCACATCCAAGAAATTTTAGCAAAAATCAAAGCATTGTCTCA
CTAGATTTACTTGTCATTTTTTTTCAAGCTTCAAAGTAAAGTCCCAACTCTTTTGTCACTTTGGAAAATT
TATGTGTAAGAAAATTATCAACCAACCTCTGCCCACTCAGTAGAACCAAGAAGGCCAAATTCTTCTGCAT
CCCAGCTTGCAAACAAAATTGTCCTTCTAGGCCTCCGTCCTAAAAGACATGGAAATAACACATAAATTCC
TGAAAAATGCATAGCCCCCAAGACAAGGAGAATTCTCCAAGATGGGAAATCACAAAATGCTGAAGACTTT
TATTGTGATAAAGTAAGAACTTTTGTTCTCACCCTGAGTTACACAAATTCATTTTCTATGTTTTTAAAAT
GATACTTGTTAGAATCAAATAGTATAGTTGTACTATAAAAGGAAGAATTTAGACAGTGAGAAAGTCTCAT
GAAGTCAGAAAATATTTTCTATAATTTAGAATTTCCCAAGAGCAAGAAAGCCCTCTCATCTGCATGTGCC
TGACATGGAGGGAGAAATCCCTGGCACAGCCAGTGCTGCAGCGGCAGGCAGAAATGTGGGAAACTATTTA
GAAACCTCCCGTGTTGTTCTGAAATAGCATGATCATCTGCTTCTGTGATTTTTTTCCCTCCATTATTATG
TAAAACCAATTACCAAGGGCTCACTTTTAGATAGCAGTATCCATTGATAGTGAAAACTTTACACTTTGAT
AAGTAAGCTCTGAGGTAATTAACAGTGACATTGGAGGTGAAGAAAAATGTGGCTTTAAACTCTGATTCTC
ACACTTCCCAGATGCTGGTAAGTCTGTGCCATAAAAACGTACTTTTTGTTTTTGTTTTTTGTTTTTTTGT
GTTTGTTTGTTTGTTTGTTTGTTTGTTTTTTGAGACAAGGTTTCTCTGTATAGCCCTGGCTGTCCTGTAA
TTCACTTTATAGAACAGGCTGGCCTCAAACTCAGAAATCCGCCTGCCTCTGCCTCCCAAGTGCTTGGATT
AAAGGTGTGTGCCACCACCACCGAGCTAAAAACTTACTTTTATGAAGATAAAATCCACTATAGTAGAATA
AGGAGAAGAAGATATGATTTGACTATCAGGATCATTAAATGGAATACTATTTCAGAAGAACTTAGTAAGT
GCTATAAGGTCCTTGTAAATATCTCAACTATATTTATGAAATATTATAAAGGGGATGGGGAGATGGCTCA
GCAGTTAAGAGCACTGTCTGCTCTTCCACAGTTCCCAACAACCACATCTGTAATGAAATATGATGCCCTC
TGCTGGTGGGTAAGAAAGCAAAAACTGAGCAGTGGTTGTGCACACCTTTATTTCTAGCTTGTAGGCAGCA
GAGTCAGGCTAGTCTCTGAGTTTGAGACCAGCCTGGTCTACAGAGTAAGTTCCAGGTCATTCAGGGCGGT
TACACAGAGAAACCTTTGCACAAAACAAACAAACAAACAAACAAACAAACAAAAACAAGGAAAAGAGAAA
GTGTGTGTGAGAAAGAGAGAGAATATTTCCTATTTCCCTATAACTATTGAATTCAATAGTTTCTTTTTGT
CTAATGTGTTATTTAATTTCCCTATTCACTCATTCCTTATCATCTCATTCTTTCAGTACATTCCTTACTT
TTGACAACGCTGATTTGCATTCATTATAAAAAAAAGTCTTGTTAAATCATGATACCTTTTGTATAGAGAT
TAAATACAACCAATTTCATGAACAATGTACACACTTATCTGGCAAATTTCATTTGTTAAAGTGTAAATGG
TGCACCTCTGTCTTATTTGGAACAAAGATAACGTGAGTTTGCAATGTGTCAACCCTAATTTTGAGCTCTG
TCACACATTACATAGCTAATATCCATAAAATGGGAACAGACCTCACAAAATATCTCAAAGGTTGCTTATG
GTATCAAAATAGATGACACATGTGTAAACAATTTCTCAGTATGCAAAGTAAATATTTGTTGTTATTGTTG
ATTTATAGCTAAGAGCTACAAGATGTCTCTGCTTATAAATGAACTTAAAGTGTCCTATAAATTGAATAAT
CTAATAAAATTTAAACAAGTATAATTAGACAACCTTAATATTTGTACTATTATTGTTACTTTTTCACTGA
CAATATTGAGTTGACATGTGTCTATTTGTTTTTTTACTGTGTACTAGGGATCTAGGAAAGTGCTTTTGGC
CCACAAGACACATGCTATAACACTTAGGCACTTCCCAGGTCCTGAGATAATATTTTCACACTCACTTTAC
AAAAGATTAAGATGAAGTTACCAGAAGTTGGTTTTCCCACTCACTGTTTCTCTTACCTTTCTTCTTCAGG
GTTCCAAAGCTCCGCACAATTTCATGAACAACAGCTGCTCCACTCTGAGGGTCAATGCCACCAAATACCC
AAGCATCTCGGTGACCTCCAAGAATAACATATCTGTCTACAAATCAACAGACCACTGATATCAGACAGAG
GAACCTGCAAATGACTCAATAGTTTTCACAACTTGAGAAAAGGTATTAAGGTTCCTAAGGCTTGTGCCCA
TTGGTTATTTGCACAGATTTTACTGTTTGTTTCTTCTATCTGCTGAAAGTATGAATCTAATTTAAAAATC
AATTTGATGTATTATTGAAGGTATACACATATGGGTAACAGAAGCATAGAAAATTATCTGCCTAGCTCCT
CACAGGTCTCTAAACTTGTTTCTACAATGTGCTGATCATTTTCACAGAGAACACAGCTCTTCCCTTCTTA
GACTTATTCTATAAGCCTCTCAATAACTGTCTGTGACCATTTCTGTCTGCTATAGGAAGGAAAAACTGCA
TGGGTTGAAAGTATGGTGAACAATCTTTTCACATTTGTTTAGGTATTTATCACCCTTAACTGACAAATTC
TTCTTTTAAATCATGATAACCTTGACCTTGATTTAGGAGTGCTTCAACACTCCCCCAATTCCAATGTGTG
TCACAGATCCTGTACAAAATAACCATCTAATAATATTCAATATGTCACTTATGTATATACATACACATAT
ATATGTACTCATATATTGCTAAACTATACTTATTTATATATATACATATATGCATATATATGTATAAACT
AAAGTATATATATATATATATATATATATATATACATATATGTATGTAGAGCACATATAGTTTAGTACAT
ATAAGTATTACTTTTATAAAACTCTTGGTCTTAAGTGAAAGATTGTTTATTCTTGTTACAGTATTCCACA
TAACAGCAATTTCCACACTTGGAAGGAAATAATAGGAGTCCAATTATATGAGAACTTGTCTCAAAAAAAA
ATAACATATGTTTGTAAGAATATATGTGACTAAATTGAACTATTTATGTTAAAACTAATAATAATCAAGC
AAATCGTAAGGAAGCAAGAACCAAACCCTAAAGGATCAAAAGATATAATAAAATATGCATAATTCTCCAA
CTCTCACAATGTTACACCTAAGAAAGGCACCATGCTCAGCAGTAGATAGCCAACAGAAAATTAAATTAGC
AGTACTTTTGGAGATTGTTTTGTCTCATATGGCTATGATTGGACATTTTTTAACTTTTCTGATCCTTTAT
TTATCAATGATGTTTTTTATTTTTATCAGTTTTGTGCGTGTGTATCTTTACATATATGTACTGTTCATCA
TTCTTTTTTCTCTTCTTTAAAATTTTCTTTTATTCTGATTTTATTTTATTTTATTTTGTTTGTTTGCATG
TCTATTTATTTTATAAAAACAGAAAAGTAAAGTATGGAGATGTATGGATAGGAAGGGAGGGAGGATCTGA
GAGAAAATGAGGGATGCAAAAATGTGTTTAGAACACAGTGTATAAAACAGTTTTCATCAATAAACAAACA
AACAAATAAAGCAGTTTATCACTCTCACTTGTCCCCATACTTTCCTGTTTGTGTTCTTTCAACACATGTG
ACAAATGATACACTATAACTGGAATGTGTTACTTTGACTTTTGATGAGCTTCACTTAGGCAGCAGTGGTT
CAAGACATTTGATTCACCAGTATTTTCAAAACACATACTCCATTTACCTGGTTCCAGAGCTCCTTTGAGG
GTGCCAATGACATTATAGATTCTTGTCACTTTAGTGTAAGAGTGAATATGCATCTTGACCTTTCTAGTTC
AAGTATAAAAAATATGTCATTAGAATACTAGTTAACAGATTTAACACTCACATTTCTTAAATCCTCCATC
ATTATTTTAAAAGATTTATAGTTGTTTCCAAAAGAAAAGTAACCCAATTTTTTAAAATCATTTTTACAGT
CCAGTTATTATCCCCTTTCCAATATGTCCTCTGATAGTTCCTCATCCCATTCCTTCTCCCTCCTATCTCA
AGAGGATGTCCCCATTGCCAACCCCACCCCACCAGACCTCCGCACTCCCTGGGGCCTCAAGTCTTTAGAG
GGTTAGGAGTATCTTCTCTCATTGAGGCCAGACCAGGCAGTCCTCTATTGTATATGTGTTAGGTGCCTCC
AGACCACCTAGTATGTGCTGCCTGGTCAAGTGGTTCAGTGTCGACAGATCTCAAGGCTCCCAGGTATCTC
AAATAACACTGATTAATTCTAATGATTCAAAATTATTGTCTTTTTCAATTTCTGTTTTTATTGCTCAATA
GTAGTAACTAAGCTTTATATTTTTCTTCATCTTTGATAATTGTCTTCTTTTAAAGTATTTTGAACAGAAT
CATTAGAAAAATATCTCAACTGTGTTGAAAAGTTTCCAGCAAAGCCAGGTCCCACGTTGTAAGGCACTTT
TAATCCTCCCTTCCAGCTACTGTCAGGGGGTGCTGGACCACCCATGTGTCTGTTGGACATGAAAAGAAAT
TATTACATACAGAAAATTTGATACACCATGTTAAAAGGCCAGATCATTTACTGGTCTAGGTTATCTTCTC
ATAACAGCTTCTATAAACAAACAGTAGAACAAGGTGCTTTGCATGTAATAACCATTGACCTTTCTTGCCA
CTCCTGCATGGTAGTGTCCACTATCAAATCAACTTTGCAGATGAGTAACATGAGGACAAGATTGAACAAA
TAGCAATGGCCAAACTTATTGTGGTAAAAAGTGCAACTGATATTGAAATTATTTACAAGAATCTAAACTT
AGTTACTACTGTATAATGGGAAACCATATTTTAAAACTCTGACTCTCTAGCACATGTACTAAAGGAAGAA
TCTGAAGGCTGTCTGGAGTCTTTCACTATGCTTTCTCCTACTGAAAGATTTCTCTCTCTCTCTCTCTCTC
GCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTATATATATATATATATATATATATATATATATATGTA
TACACATATACATATATATATACACAGATATAGATACATGTATGTTTGTGTCTGTAAGGAGAGGAATCTT
TTAATATATAGTATTATATTACTATATATACATTAGATATATATGTAGTCATCTTTCATTATCATTAAGT
GTTTTCACACATACCTATTAGGAAGAAACAAAGAACAAAGAAACAGATAATTTTATTCCCAGCAGAGGTT
CCTAAAATTTCAAATTATCATTTCACACACACACACACACACACACACACACACACACACACACACACAA
AACCTAGGTAGATCAAAAGTTTTGGGTGAACCAGCTACCATATAGCTCTAGCCTTCAAGTATCTACCTAC
AACAAATCTGAAAAGCTGATATTTTAAGATTTCTAATAAAAATATGTCTTCACATCTCTGTAACTGCTAC
TTGAGAATGGACTATTTTTTAAATTTTGATATGAAAATAAAACATACCTTCACTAAGTATGAATGTAGTT
ATAGAAAACTGGAACTTAGAGTTGAATAATAATAATAAATGATTCCTTTTGTTTGTTTTGTTTTGTTTTG
CTTTGTTTTGTTTTGTTTTGTTTTGTTTTGTGTATAGCTCTGGCTGTCCTGGGTCGAACCTAGAAATCCT
CCAGCCTCTGCCTCCCAAGTGCTGAGATTAAAGGTGTGCAACACAACTGCCCAGCCTAAATATGATTCCT
TAATCCTAATTAATTTTGTTTGCATTCTGCAATAAGGACAAAATAGTATTAGGGAGCCTGCCAAGATCAT
CTTTTACTTCTTTAAAGATTGTTCTTGTTCTTAGATGCAGTTCTAATTACTCCTGGCCTGTAAAAATAAA
TTTTCTTACTTAAAATGATATAGAGTCCCTGAAATTTGAAATGTAGAGTTGGAAAGCTCCATCTGCTTTT
TTGTTTTTGTTGTGTGCGTTTTTGTTATGTTTTTTTTTCTCACCAGACCATGCGTGCACACTTATTGCAT
ACACTAAGCTTTGTAAGGTTCTATGCTCTACAGTTTGCTTGTTTTGTTTGCTTGTCTGTTCATTTGTTTG
TTTTTAGTTATACGCAAGTGCTTGTCCATTCCTCATATGCTTGAAGAAGTTTTAATATTTCAGCTTGGTT
TATATTCTACTGTATTATGCAATAATAAATTATGTCTCTGGGGTATTTCATCTTGTCCATGATCTATTAA
AACAATGACAGCTGATGCTGGTGAGGATGTGGGTTAACATTAACACTCATTCATTGCAGGTGGGAGTAAA
AATTTACTTTTATACCTAGACCACACAAGATCCCAGCATAAAAAGAGAACTTCAGACCAGTTTTGGTTTT
TTTCAAGACAGGGTTTCTCAGTATAGCCCTGGCTGTCCTGGAACTCAATTTGTAGACCAGGCTGGTCTTG
AACTCAGAAATCCGCCTGCCTCTTCCTCCCAAGTGCTGGGATTAAAGGTGTGTGCCACCACACCTGGCTC
CAGATTGGTGAATTTTAAGCACCATAATCAAAACTATTCAACACTAAACAGAGAAGAAAAATGATTTTAA
AATAACAAACAAAGGGCTGAAGAGATGGCTCAGCTGTTAAGAGCACTGACTGTTCTTCCAAAGGTCCTGA
GTTCAAATCCCAGCAACCACATGGTGGATCACAACCATCTGTACAGCTACAGTGTACTCATATACATAAA
ATAAATAAATCTTTAAAAAAAAAAAATGAACAAAGTATCAGTGAACTATGGAGCAACCCCAAAGGGACTT
ACATACTAATTATTGTCTTTAAAGGACATGAAAGAGGGCAGGATAGAAAAAGAATATTGAAAATTTAGTA
CTCAGATATAGTAGCATATTCCTGTAATTCCATCACTTTGGAGGCAGAGGCAGGAGGATCCCCATGAGCT
GAAGGCTAGCCTCATCTATGTGCCAAGCCATAGGCTAGCCAGAGCTATAGAGAAACACCTGTCTCAAGGA
GGAGGGAACAGAGAGAAAGAGAAAAGAAAAAGCAAAACCCAGTGACTCAATTTGATAAATACTATAAATC
CACAGGAGAAAGATTAATAGACATTAAGAAACATAAAGAAAATGATACAGTATGTCAAGTCATAGCATAG
TCAAAAATTTCAGAACCAGCAAAAGAGAAAAAAAAATATTGAAACACAACCAAGGTTGCTCCTGACCACA
CATGTTCTTCCAGGGAGGCCGAGGCAGGGGAGTCATGAGTTTGGGGCCAGCCTGGTCTATATAGTGAGCT
CAGTATGAAAACAAACAAGCGAAAACATAAGGCCCAAGCAAACAAAAAACAGATCCTTCCCTCTGCTCCC
TGCCTCCTAGTGCAAGCTTACCTTACTTCACACTCCACTGCTTGCCCAATTAACCATGAGCTAAATCTCT
GTTCACCTGGAGTGGCTTCTGTCAGGTGTATTGCCAAAACAATGGAGAAAGTAACTAATTCACAAAGTTG
GTATGAAGAAGTCAGGCCACTGCTGTGGTAAATCTGATCACATGACTTACACACACACACACACACACAC
ACACACACACACACTCAGAAAGAGACTGGATTTCACAACACTGGGCAGAGCTTGAGCATAGGAGAACTCA
AAGCAAGCCATCACAGTGACACATTTCTTCCAACAAGCCCATACCTACCCCAACATGGACACACCTCTTA
ATAGTGTCATTCCCTATGTCCAAGCATTCAAACACATGAGTCTAAAGGGACAATACCTATTCAAAGCATA
CACACACTCACACACACACACACACACTCACACACACACACACACACACACACACACACACACACACACA
TGCACTGGCTGTCTACCAACAGAAAGTCCAAGAATCTAGTAATTATTCCGTCACTACAGAGTGATAAAAA
ACTGGATGGTATTGGTATAGAGACAGACAGGTTGCTCAATGGAATAGAATTGAAGACCCAGAAATAAAAC
CACACACTTATGGACACTTGATCTTTGACAAAGAAGCTGAAAATACACAATGCAAAAAGAAAGTATCTTC
AATAAATTGTTCTAGTCTAACTGGCAGCCTGTATGTAGAAAAATGAAAATAGATCCGTATTTGTCACCTT
GCACAAAGCTCAAATCCAAGTGGATAAAGGACCTCAACATAAATCCAAATACACTGAATATAATAGAAGA
GAAAGTGAGAAAGAGCCTTGAACTCATTACCATGGGGTGGGAGTGGAGATTTATTAAACAGAGCTCCTAC
TATAAATCAGCAACCTACAGATTGGGAAAAAAAATTCACTAACCCCACATCCTATAGAGGTCTAATATCT
AAAATATATAAAGAACTAACCACCAAAAAACAAACAAACCAATCAAAAAATGGGGTATAGAACTAAAGAG
AGAACGCACATCAGAGGAATTTTGAATGACTAAGAAACAAAGAAAAATTCAAAGTCCTTGGTGATCAGAG
AAATACAAATCAAAACTTAAAGGCTCTGAGATTCCACCTTACACCAATCAAAATGACTAAGATCAAAAAC
TCAGGTGATAGCACATGTTGGCAAGGATGTGGAGAAAAAGAAAGAGATCTTCCTTGCTGGTGGGATTACA
AACTAGTACAACTACTCTGGAAATCAATCTGGAGGTTCTCCAGAAAATTGGAAATATATCTACCAGAAGA
CCCAGCTACATCACTCTTTGGAATATACCCAAATGATGCCCCAACATTCCACAGGGACACATGTTCTATT
ATGATCATAGTGGCCTTATTTGTGATAGCCAGAAGCTGGAAAGTATCCATATGTCCAACAAAGGAAGAAT
GGATAAAAAAATAATGGTGTTCAATTACACAATGGAATACTACTCAGCTATTAAGAATGAGGACATCATG
AGTTTTGCAGGCAAATGGATAGAACTAGATAATATCATCCTGAGTGAGGTAACTCAGACCCAAAAGGGCA
GGCATGGTAAGTACTCACTGAGAAGTGGATATTAGCCAAAAATGTACAGAATACAATCCACAGAACTCAT
CAAGGTTAACAAGGATAAGAACCCAAGTGAAGATGCTTCAATCTCACTTAGGAGGAAGAAGGAAGCAATC
ACAGGGGCAGAGGGAGGGATCGACTTGGGTGGGAGAGAGATCAAGCAGGGCTCAGGTATTGGGGGATGGG
AAACAGGACTGAATACCTGAGTTCCAGCAGAAAAACTGGAAACAGGCAACTTCGGGAGGCAGGAGGTAGG
GTTACCCTCCAGAATGTACTAGAGACCAGGGAGGTGAGACACTCTCAGGACTCAAAGGGAGGAACCTTGG
ATGAAGTGCTCTACGGTGGGGAGGATGAACTAATAGAGCCTCCTTCCAGTAGAGGGACAGGATGTCAACT
GGAGGAAAGGGACTGCCATCTCACAGTCAAAAGCTCTGATGCAGAATTGTGCCTGTCTGAAGGAACGGCA
TGGGGAAAAAAAATAAAGAGTCCAAGAGAACAGAGGGCCAGTGACAGGCCCAAATTGGGATCCATCTCAT
GGAGAGGCCTGGCACCTATCACTGTTGCTGATGCTGTGATGTGTTTTCAGACAGGAGCAGCCCTTTGAGA
GGCCTAACAAATAACTGAAAGAGTCAGATGAAGATATTAGCACCCAACCAATGATCAGAAGCGTGAACCC
CTGTCCTTGAATTGGGGAAAAGCTAGAAAAATTGAGGGGGAGGACAGCCCTACGGAAAGAGCAACAGTCT
CAACAGACCTGGACCCTGGAGATCTCTAGGACATTGAGCCACCAATCAGGCAGTGTACACCAGGTGATAT
GAGACGCCTTATGTATGTATATGTATGTATATAGCAGAGAACTTCCTTGTCTGGCCTCAGTGAAAAAAGA
TGCACCTAACCCTGGAGAGAGTTGAGGCACCAGGGAATGGAGTGGTTTGGTAGGGTGGTGATGGTGGGTG
TGAACATCCTCTTGGAAACAGGGAAAGGAGGCATGGGGAGGAGTGCAAGTGATGGGCAGACTGAGAGGGG
GGTAATGACTGAATTATAATAAAAGGATTAAGGAATAAAAATAAATAAATTAATATATAAAATTAAATTA
AAATATTAGTTAATATTTTCAAAATATTTTTTAAAAACAAAAGGAAATTATGGGGAGAGGGTTTGGGGGT
AGCATTGGAAATGTAAATGAAGAAAATAACTAATCAAAAAAATGAAAAAAGTTCTAATGAAACTAAACAA
AAGGAAGTTATGTATCAGGACTGAAGTAATAAAGAATAAACTGTAGAGATATAAAATTATAAAATAGACA
AAATTAGTGATAGCATATTTTCTCAAAATATCAACAGACAAACCATAGTGAATGGTTTGAATGTAAAAGT
AAAACTCTAATTACTAATCCCAGAAACACAAAAAGGGACACAACTTCTGACTTTATAGAAATAAAGAGAC
TTATCAAGAAATACAAAACAGAATTATATAATGATAAATTGAACAGCCTATATGAAATAAATAAATTCCT
AGAAAGTTGCACACTCACAAAACTGACTGAAAAAGAGAAAATATGATCAGACTATTAGTAAAGGCTTTAA
GTAAGGAATAGATACCTTCAGGATGGAAAATTCACTTCACTATTTCCTATGAATTTGCTTTAAAGCACAA
GCAACAATTCTTCAGGAATTGCTCCAAGTAGTAGAATAAGAAACATTGCTAAAGTTATCCTGTGTGTAAT
ATGCTAACATGACACTATAAAGAAATAATGAGAATAGATGATTTTCAAAAGCTCATAGAACTATTAATAT
TTAAAGAAAATACAAAATCTACCTATTAATTTGAGATATTACTATATAAAACGTGCTTTCATAAAAACAC
GTAAAGAATGTGAGTGTGCTATTCATATATTGATGAGAAAGTTATAGTAATACAATCTCTCTTACTTGTT
AGTTTCTTTTTTTTTACATTAAGTATTTAAACATTTTATTTTTACTTAAAAATTTCCTTACATTACATTA
AAGGAATATATATATATATATATATATATATATATATATATATATATATATATTGCCATACAATATACAT
ATATATCATGTACATATAACCATATATATCTCCATGTGTGTATATCTATATATCTATATATCTATATCTA
TACCTATACCTATACCTATGCCTATACCTATATCTATATAAAGAAGTTGTAATAGTTAAACATAAGCAAA
GGAGTATTCCCCCTTTCTCTGCATCCTTTTCAGCATTTGCTGTCCCTTGAGTTTTTTATCTTAGCCATTC
TGATTGGTGTAAGGTGGAATCTCAGGGTCATTTTGATTTTCATTTCCCTGATGACTAAAAATGTTTTGAA
CATATCTTTAAGTGCTTCTCCATCATTAGAAATTCCTTTGTTGAGAATTCTCTGTTTATCTCTGTACCTC
ATTTTTAAAATTGAGTTATTTGGTTTTTGGAGACTAACTTTTTGAGCTTGTTCTATATTTTGAATATTAG
CCCTCTATACAGAGGATGTAACATTAGTGAGGATCTTTTCTTAATCTGTTGTGTGCCATTTCGCCCTATT
AATTTGTTAGTTTCTTATGAAAGTAAATGTATTTATGTAACTCAAGAATGTACACTAGAAAATAATGAGG
ATTACAGTGGCAAGAAATCAATGCACAATTTTCCATAATGTCTTTTTTCATAACAGCAAAGATAGGGAAC
AGTCTCAATTGTCCTTCAACTCGTGAATGGTTAAACACACTGCAGTATCATCATGTGATGATAAACTCAG
CAAAACAAAAAAGGTTACTTCATACACAAAACTGCCTTCTTAGAAGCTAGATGTAATTTGTGATAAACAT
CATTTATAATTTCCTATTCAAATAATTACATTGCCTCAGTTAGGACACAGCTAATATGTACCTGTTGATC
TAGACCAGAGAACTAGTAGACATGACAAGATAAGATTCAATTGAATTCTATAAAATGCCATACATTCTCT
TTCTAACTACAAGGAAATATGTGCTCATTTTAATTTGCTATATAACTGGAATCATTTAATATATTATTTT
CAAGAGTCTGCTTGTTAAGTTAATACATCACAAACACACTCCATTTTATTAAATATCCTTGCTCAATATT
ATTCTGCATTTTATAACTTTTATAGTATTTTAACCAATAATATATTTGAAGGTGCTGACACTGTTCATTA
TTTGTACTACATACTAAATCTTGATACAAGTGGCACAGCTAACATTTCCAAATCTAAAAATGATCTGCCC
ATAGATTGGACACATACTTCCAATTTCTAGACATCAGGATCCTCACATGTGAAACTGTAGGCCTCAAACT
AGCACAAAAAGTGTTCTCTAACAGATATGATAATGAAATGATTAAAAATGTTTTGAGAACAGGCATGATG
GAGGGACCTTGTAATGCCAGAACCTAGGAGTCAGAGCCAAGAAAAATCAGAAATTCAGGAGTAGCCTGTG
CTATATAGTTAGACCCTATAATAAACCCAATACAATCCAACCTATGCAAACTAGGGGAGTGTTTTCAATT
AAATGAAAAACCTGGGTAATTGGTAAAAATGCTTTGAATCTATAACATTTCCTTTTAGAGAACTTCCTTT
CTCTTACTTACAGAAGGAGGTAAAGTAGGAGGGGCATGCAGATGGAAGAGAGTAGGACAGGAAAAAACAA
TGATGGCAGAAAGGGAACATAAACACAGATTAAAGATTGATGACATAGTCAATAAGACAAATCAGCAATC
TACAGATTGGGAAAAAAAAAACAAAACAAAAACGAACAAACCGTCACTAACTCCACATCCAATAGAGGGC
TAATATCTAAAATATATAAAGAACTCAAGAAGCTAATCACCAAAAAAACCAAACAACACAATCAAAACAT
GTGGTATTGAACTAATCCGAGATTCACAACTGAGGAATCTCAAATGACTGAGAAACACCTAAAGAAATGT
TCAAAGTCCTTAGTGATCCGAGAAATGCAAATCAAAACGACACTGAGATTCCACCTTACACCAACCAGAA
CGGCTAAGCTCAAAATTTCAGGTGACAACACATGTTGGAGAGGAGGTGGAGAAAGAGGAACACTCCTTCA
TTGCTGGTGGGATTGCAAACTGGTAGTAGCACTCTGGAAATCAATTTGTTAGGGTTCATCAGAGAATTGG
AAATAGATCTACCTGAAGACCCAGCTATACCACTCTTGGGAATATACCAAAATGATGCCCCATTATGCCA
CAGGGGCACGTGTTCCACTATGTTCATAGCAGCCTTATTTGTGATAGCCAGAAGTTGGAAACAACCTAGA
TGTCCCAGGACACAAGAATGGATACAGAAAATGTGATTCATTTACATAACAGAATACTACTCAGAACAAG
TATATCCTGAGTTTTGCAGGCAAATGGATATAATTAGAAAATACCATCTTGAGTGAGGTAACTCAGGGCC
AAAAGTACATGCATGGTATGTACTCACTAATAATTACATATTAACCAAGAAATAAATAAAAAATAAAAAG
TACAGAATACTCAAGATACAGTCCACAGAACTCAAAAATGTTGACAAGCTGAAGGGCCCAAGTGAGGATG
CCTCAGTCCCTTTGGGAGAGAGAAAAAAAGCAGTTACAAGTAAGGAGGGAGGGAGGGACTTGAGAGAGAA
TGTGGACAGGTGCTAGGGGGTGGGGAAGGGAGAATAGGTGGGGAGAAGGAGACCTGATCTGGTATTGGGC
AAGGTAAAAGGTCTGAAACCCTGAGAGCTAGCAGAGTGAATGGAAACAGGCATTTCAGGAAATAAGAGGT
TGGGGAGTGGGGGTGGGGGCTGGCTAAAGAATGCACCAGAGACCTGGGAGGTAAGAGACTCTCAGGAATC
AAAGGGAGGGACCTTAGACTAAATGCCTGACAGTTGGGAGAGGGAACTTATAGAGCCCACCTCCAGCAGG
AAGACAGGGCACCAAGTGAAGAATGGGTTGCCATCCCATAGTCAAATCTCTGACCCATATTTGTTCCTGT
ATAAAAGAATTACAGGGATGGAAATGGAGAGTAACCCGAGGGAAAGAAGGTTCAGCAACAGGCCCAAAGT
GGGATCCAGCTTAAGGCAAGGTCCCAAGCCCTGACACTATTATTACGGCTATGGAGTACTCACAAAAAGG
GACCTATCATGGCTGCCCTCCGAAAGAGCCAACAAACAACTGAAAGAGTCAGATGCAGATATTTACAACC
AACCAATGGACAGAAGAACCTGACCCGTGTTGCTGAATTAAGGAGGACTGAAAGAAGCTGAGGAGAAGGG
CAACCCTGTAGGAGGACCAGCAGTCTCAATTGATCTGGACCCCTGAGATCTCTTAAACACTGGAGCACCA
AACAGACAGCATGCACCAACTGATATGAGGCTGCCAACACACATACAGTAGAAGACAAAACAAATTCCAG
AATTAGAAGCAGTATTCTTTAAATTTATGAAAACATTTGTACATTGCATCAATCAACTAGAGTATAGTAC
TAAAATTTGAACATTCCCAAATATGTGAAAATTCTCAAGAATGAGAAATAAATACCAAAAGAAGTGTTTT
TTTTTTTTTTCTGTCAAACTTACTCTAAGAGTTTCTGTGCATCATCATATCCAATAGGATGGACAGGAAT
ACTTGGAAGGCCAACAGCGTTTGTCAACTCATGCCTATAAGCATGTTCTGAGAAAATAAAAAGACATAAT
TATCCATTAAAAACAGTATTTTTCAAATGGGGTTTTATAAGTAAGATTAAACAATTCTTCCACATATTCT
AGAAATAGTAAAATTTCAAGTGTCAGAAAGAATGTGGGGAAATTGAAACTCTCATACATGTTTGTGGGAC
CATGAAGTCACATGTTGTCCTAGAATAAGTCTCTTAAAATAGCCAAGCAGTGGGTAGAGAGATGGCTCAG
TAGTTAACAACACTGACTGTTCTTACAGAGGTCAGTAGTTCAATTCCCAGCAACCACATGTGATCTGATG
CCCTCTACTTGCATATAGGTGTACATGCAGATAGAATACTCATATGCATAAAACTAATAAATACATCTTT
AAGAAACTTTTATAATAGAAAAGAAAAATGAATGGGAAGTCCAAAAGTCTAGTAGTTGCTCAGTCAATGA
GGCTAGTTGTTTCACCTGGTCTTCTGTATAAGATTGAATACTGAAGAAGTAGATTCCAACAGATGTTGTG
GCAAGTAAGTATTCCTTCTTCCAATGTCTTTATGTAAGCCTCCAGCAGAACGTATGTTCCAGATTAAAGG
TGTGTACCATCATGCGTGGATCTTGAACATGCTTTGTCCCACATTGACCTTGAATTCAGAGATCTCCTTG
CCTCTGTCTTCTGGGATAAAAGGGGTGTACTACCCTATCAGGGCCTAAACTTTTCATGGCCAATATGCTT
CAAGATCTCCATATCAAGATCTGGGTCAGAAGCCTGTGTTTTCCAGCCTCAAGTTCTGGGTTACAGGTGT
ATGTCCATTTCTGGATTGTAATTCATTCCAGATGCAGCCAAATTGACAATGAGGAATAGACTTCAAACTT
GAGTTTTGTTTTGTGCAGGATGATAGGTATGGGTCTTTTTTGCATTCTTCTATATGTGGACATCCAATTA
GACCAGCAACATTTGTTGAAGATGCTTTTTTTCCCCCATTGAATACTTATAGCTTCTTTATCAAAAATCA
GGTGCCCATAGTTGTACAGATTTATTTCCTGGTCTTCAATTTGATTCCATTGATAAACCTGTCTGTTTTT
ATGATAATATTATCCATTTTTTATAACTCCAGCTTTGTAATACAGCTTAAGATCAGGGATGTTCATACAT
CCACAAGTGCTTTTGTTGTACAAAATAGTTTTAGCTATCCTAATTTTTTTAAATCTGACTTTGAGTATTG
TTCATTCAAGTTCTTTAAAGAATTGTGTTTGAATTTTATGTGGGTTTCATTGAAACTGTATGTTGCTTTT
TGTAGGATAGCCATTTTTCTAAGTTAATCCTACAGATCCATAAGCATGGGAGATCTTTCCATTTTCTGAT
ATCTTCTTCAAAGACTTGAAATTGTATCATAAAGGACTTTCACTTGCCTGGTTAGAGTTGCTCCAAGATA
TTTTATATAATTTGTATCTACTGTGAAGGATGTTGTTTCCCTGATTTCTTTCTGAGCCCATTTGTCATTT
GCCTATAGGATGGCTATTATTTTTTTTAATTAATCTTGTATTCAGCTATTCATGTAAACTTGGCAAGATC
AGGGGAGCCTTTAAGGTTCTGGCCTAAGTCATCTTCATATATATTATGACTATATAGCTTGGTGTTCTTG
TGGAAATCCTAACAGTGGGAACAGGGGCTGTTCCTGACTCTTTTGCCTACTTGTAAGATACTTTTCCTCA
TACTTGTTGCCTTATCCAGCATTGATATGATGGTACATGCCACTTTTACTGTATCTGGTTAAGCTGTGTT
TGGGTGCTGTTCCATAGAGGCTTGTTTTTTCTAAGATGAGGCAGAGGGCAGGTGGATCTCAGAGGGGGCA
AAGGGGAGAAGTGAGAGGTTTTAAGGAGGAGGAGAAACTTTGCTTGGGATGTAATGTATGAGAGAAGAAT
TTTTAAAAAGTAAAATGAAAGTGTAATTCAAAAAACAAAACAAACAAAACTGTTAAACAGAGAAGTACTC
TATTGAGCACTTCCATTGCTAGTTCTTGACCCAAGAAGAAAGGTGAGGGAATATGGAATAGGGAGGAGGA
AGCTAAAACTAAGGGTCATTTGAGGAGCTATTTGGAAACCTAACACGTATAAGCTTCTTAAAATGTATAC
ATATGTGACAAAAATCTAAATGGAATCACTTAATAATGATGGAGACAAAGCCCCAACAGACATCTTTCTT
ATTCAAATGAAACTTTCAGTGCTATGAATAGGTTATATATAATCTAGTTGCTGGCCATTCTGGGTTCCAT
GGAAAACCCCAAACTACCTAGTTTATTGTGGTGGCTATTAACTGCTCCCCACCAACTGATGATAAGGTCC
TATTGCTGAAGACAATATCTACAAAAGTCATTGAACATGGAGAATTTAAGCTGGTGCCTACCTAGAGTCT
TCACTTCCACAGACTATTGTTCATGGTTTTGGAAGGAACTCTGCATGCTACAAAAGAAGAAAGGTAAACA
CCAACCCAGCTACACACCCTTCAATCTACAATAATGACCTGCCTGCAAAGGTGCTCTAGGAAATAGAGAC
ACAAATATTGTGTGAACAATAAAATAATATCTGATTGAATTTAATGCCCACTCCATGAAATAGAACCCAT
TTCTGACACAGCTTACATGGCCAAAAAACCTGAATCTAGATAGGTCTGGGACTGAAAGAAAGTCAAATAC
TACTTTTCTGTTAAAAGAGTGTAGCAATAAAATGTCTATAAATGTCATTCTGATAGTCTTATATCAATGC
TTCTCTCAGACATCATCAGAGAAGCTTATACCTTCAATAGATTCACAATGGGACAATATGCAGAGTGAGA
GATCTTGGAACATTCAATCTTTAAAAGAATGTTTACATTGCTTCCTTCCTTCATGTATCAGGGAACCCTC
CAGAAGAGGAGACAAAGAGTTTAAGAACCAGAGGGGATGAAGGATACCAATGAAACAAGGTTTTTAAATA
CAACATAAATGATGCACATATGAACTCACAGAGACTGGGGCAACATACACAGTGTCTGTATAGGTCTATG
ATCGATGGGTTCTTAGAGCTGAAAGGAGAAGGAGGCAAAAGTCTCTATCCCTAACCCAGAAGTTATCTCC
AGCAGATAATAAATCACAAAGGAAAAAATTTTTTTCTCCAAGAGAATTTCACTGGGAATACAAAACATTC
TTAAGAGCACTCACAATGTCTGACAAAAAATGATTAATGAAAAATGTACTCAACAATATCCTCGAAGTTT
CTACATCTTATAATTCTTTTTAACATCATGGAAGAAACTTGTTTTAAGTGTAGAAATAGAAAAGTTAGAG
TAAATAAAAATTTTATTGCATTTCTTTCCATTTACACGTCCCTTTAAATGTTTATATTGGAGGGTTCTTT
TCTTTTTAATATTTTTTGAAAATTTCATGAATGTATACATATATTTTGATTGTATTAATTCCCACTCCCT
CCCTCCAACTCCCATGAACCTAGTATTAATAACTACTGAGCCCATTTAATACTGCTCCTATGTAGATGAG
AGTGGGGCCATATACTGAATCATGAAAAGCCTACCAGTGGTTGCCTACCACAATGTGACTCTGCTTAACA
GTATAGTAATATGAAGTTATTTTAAATAATTGTCAGTGCTCTGTATTTTAATAATAGGTTCAAGAACAAA
CCCTCCAAACATAAGCTTTTCAGATATATATTATTTGATAGATCAGAGATGAAAAATCAATATGTAAACA
TCATAGGTACTTGAGCAAACTTTTATTTGAGTTATAAAAACTTGCTCTGTTCCAAACTATGCGAACAAAG
TGAACACAAACTTTGTAGACATCATCTAATATCTGAATACAGTCAAAACAATTTAGCTTGTTTGTTAATG
CTTGACTAGGCAGTGTTTCATCAAAAGACAAGAATGTGGACTCTGAGACCACACTGTGACTTTGAACTCC
AGTGCTCTACTTAGTGGCATAGTGATAATGGCCATACTCTTAACACTTAGTCTCATTTTCCCCCAAGACA
GAGATCATAACACCTCTTGCCTGTAAGGTTCTTAAGGTATTCAGAAGCTGTCATTTAGGAAACATTATTT
GGCAATTTTTTCTAACATTGCAAAGCAGCAAACACTTCTCTATCATTATTGCACTGTCTAGACTCTGTAT
CCTAGGTGAACTATTTAATCACTTTTTGAGGCCTTTTGATTTTCTATTCATTACTAGAAAATTAAAAATT
ATCCTCATGAAAAATATATATTCTGAGTACATTCTTTTTCATACAAATGGCCAACCTGGACAAAACTCAT
CATCAGAAATAAAGCAGAGTAGAACAGACATAAGTCCACTCATTTTTAACCCACATTCAAAGTTGGTATT
CACACATGCTGCTGCAAAATTATTTTAAATATATCCTTGGTATGCTCTGTTTCTACCCACATGTGTCATG
TATCATATTAACCATGGACTATATAACATTTTAATATTTCAAAAAGTCAGAGTTCCAAAGTTGCAGTCTT
AAATTATGAGGTGAGGAACATAATTAAATAATTTTCAGAATTTTAAACATTTTTATTTCTAGCATGAAAA
ACAATAAGAAAATATGTTCTTAGTTATTTTGACAATTTTTTTTTTACATCATTTGAAATGGTCAATTGAT
ATGATGGTTGGGATCTAGCCACTCACCATTTGCTGGGTAACCTGGTGTGAGCGGGTCACCTGCACCATTA
AGATTTAAGACATTTCCACGTTGGACACCACCTCCAGGGAGGTTCCAGCCATCTGGATAGGACTTCACCG
CAGGAACAAAGTAGTCAGCAGGGTCTGAGTACAGAATCATTCCTTTTGCCCCTGCCAGTTGAGCATTTTT
AACCTAGAAAACATCATGTTTCTTTTCTCAGTTTAGGTAAGTTGTTACTTAATAATGGCAGATCCCAAAA
TCACATTACACACATAGTTAAGTTTCATCTTCTATTTTAAAGATCAGGTCTCAGTGAGATTTCAAGGCTG
AACATTAATTCACTTTGTAGTCTAGGAAGGGCTTAAACATGTTATCTTCCTGTCTCAGAGTCTCAAGTAG
CTACAGCTAAGTGCCAGTAGGCATGGATTCCATTAATGGTTTTGCAGAGCAGCAAATGTTGAACTCTCTC
ATCACAGTGGGAAAAAGAATTTGGTATCCCCTCTTGTTTTCTAGAAGCAGAATAAGAAGAATGTAGAATC
CCTAAGCTAAGTTCCCATTAAATATATGGCTGAAAATGAGTAAAGACTTCTTGCACTACTTATAATAATG
ATCCATATTGAATTTAAATAGAAAATCTTTGAAGGTGATATGTAAAACAAAGGTACTGGAAACTAGTAAG
AAACCCATTGTGAATTTCTTTGTGTATGTTGGTAGGTCACAGAATCTTGCAGGTACAGAATACCTGCTGC
ATCCACTCTGGCAAATACAGACAGAATTTCAACAGCACAACTCAAAAACACTTTGTTAGTGTGTCTTCTT
TATAAAATGGAATGTACAGAGATAAGAAAATCATGATCTCAGAAAAATTGTAAAATATATCATTTTATAA
TATTTTAGATTGGCGAGAGATGAACTTTAAAAACATTATCAACTTGTATGAGTTGTAAAAAACAGTGGAG
TTAATTATAACAAATCCAAACATGAATAGCATGTGCTCAGATTATACTCATCCACCTATGATCCTATCTC
CCTCCATCCTTTCTATTTCTCCCCTACTTACTAACAAATAGGCGCATCACTCCTATTGATCTGTGTATGT
TTTGTTCTTGCTTTTTTGAAAGAAGATTTTACTTATAAGGAAACAATGCAGTATTAATCTATTTAACTTA
ACCCTATGCTCGTCAGCCTGTCAACTATCCTGAAAGGACATCATTTCTTTACCATATTTCCTCTGAACAC
TTTCCCATATCTGGCAATCACAATCTTCCCAGAACAACTGATCTTCATTTCCCGTTCCAGTTTAAAGAAG
TCTTCAGTTCGTGCATAGTTGACATACACTAGATCACCCTGTTGAGATCAGGAATGATTTAATATAAAAT
GTAGCATATGGAGGTATCTCTGAATGACAGATGTTTGATCTCTAAAGAGGGATAAAGCTAAAACACCACG
AGTGCCATGACACATGAACCTCAAGCAGGGCAGTCAATGGAAAGGTTAACTTAAATTAAAAACGTTATTT
GACAGGTTGGGAGACACATGAATTAAATGATAAATTTCCCTTTACTTTTCTTGATAACTAAAGATGTAGA
AATACCCCCAAAAGAATTACATAAGTATTCAAGTTGCTACATGTAATCTGAAAAATATCAGTCACCATAC
ATTGAGCAGGTGAAAGAAAGTTTTCCTCTCTTTAAAGTGCATAGTGAGTCTTCACAAACGTCAGAGACCA
CAAAAGGCCCTGTGATTCAGGAGGACCTGTTTTAATCATTTGTATGGTCACATGCAAGCATCACGGCATC
CTTATTACACTGTTATTTGTAAAGGGATTTTCCAAAATTCTTTTCACCCTTTAATCTAGTCCAAAAGGAA
TTCTGAAAAGTAACATACACATTCATTTTTTTTTTGCACAAATAGCTAAAAAAAAAATTTATCATACTTT
TATGAAAGCAAATGCTTGCATTGTAATATCATTTCCAGCATACTATAAATAGCAATGTTTTAGAAACCAT
TACATAGGTGTTCACTTACATGTGAAGGAATTTAAAAACAATCTGTAAATATTTATTACTTAACTACTTC
CATTTTAAAAATATGAACAAGGTGTGCAAACATAGCTTAGTGGTGTAACATTTATTCAGTATGTAACAAG
CTCTAGGCTCAATAAACACTACCACAAAAAGATTAGTTTTAATCAAAACCACAAACCACCTGACTATATT
TTGCTGTGCTGTTATAATTTTGTCAATTCCTTTTTTCCTTAAACATTAACTTCGAAACTTTTGCTATGGG
CTTGCTCTAAAATGTACTGCCAAGATTCCTCTTCAGTGAATGATCTGCTTCAGATTTATGGAAAACTCTT
CAAAAGAATGTAAGATCTGGGGATGGAGATAAATACTCTAAAATGTTTTCTCCTTGAGGCAATGGCAGTT
GCATTCAGGTACTGTGAGCCCCATGATTACCAGCAGAAGAATATGCCAGCCAAAGTTCTTGCGTAAATGG
ATGAAGCCCTGACTTTTAGGAACTATTGGCAGTTGTTAACTGAAAAAAAAAAAAAAAAAAGAGGGAGAAT
CATTCTTTCATGAAAGAGTGGTCATGAGTAGGTTTCCTATGCTCCAGTAGATGACCTCACAACTATGCAT
GTATTGGTACCACTAACTTATCATTAAAAAAAAAAAAAAAAAAACACGGAAAGAAAAAGAGAGAGAGACA
AGAGAGAAAAGAAAGGAGAGTGAGATACAGAGGAAGAAATATTAAATTGCTCTACTCACACTTCTTTACC
AGTAAGTTCTCACTTACAAAAAAAAAAAAAAAAAAAAAAAAAAACACTTAAAATTTTGGGAAATATATCC
CCTGTAAAGGTTACAAAATAATAGCTATCTTTTGATAAAACTGCACTCATCATAAAAGAAATTTGTTATA
GAAATGGGATTAATGGGATTAGGGGAAATATTGGTTTAAAACCTTGCAAACAAAAGTAGCAAATATATAA
CCCTCTATGCAAATTATATTCTGAGTTAGAAAACCACTTTGTTTTTAGACAATGGGCTTCTTGTATGATT
TACACTGTGCTATTGTTCTGACTGTGAATAAAATGATACCCTTGGCTTAGAATCCTTTCTTATTCCTTCA
AGCTTCTATTTGCCTGCCCTTATCAACATGAAAATTTTGGTGAGAAAATCAGTTATTCTCAGAGAATGGT
CCTGGAGAGCTCCATCACAAAGGACTTTGTGAGAACCAGAATCTGGGCTTTGCAAACCCTCCACTTATGT
CACACACAAAGGCCTGAGGAATACTACAGTATTTTTAAACACATTGTGGAGTTACAAATTTTAAATCACC
TAATGCTTGGACCAGTGTTATTCCTTCTACAGAATTTAGATAACATAGATTCTAAAATGAGTAATAGAGA
CATATACTGCATATACACAAAATATATATAATTAATAAAGAATAAATTTGCTACTGGCTTGGTTACAATT
GGCCCAAGACTTACAGCAGTCAACACTAGCCTTCTCTTGGTGCGCATATATCAATCTCATGGAGAATGTG
CTCCTTCTATCTATGTTCAATGTGAAAGAATTTAAGCATATTTGAAAGAAAGAAAAATAATTATTTTTAG
GATTTTTTTTTAATTCTAAACTACATTTCATTGCTACAAGTGCTATGATCTGATGGTATTTGTAATATAT
TTGACACTGATATGGCAAATGAACCTTATCTTTGAAATTAAGCTTTGTTAGTATTTGGAATATTATACAT
GTAGTCATATGCTTCTCTTGGTGGAGACATATTACAAATAATGTAGCCAATTTTTGAATGTTTATAGTAT
AAAAATATATGAAGAAAATTTGACAAAATCAGTATTTGGCATGTTTTGAAATAAAGAGAGATGTAGAGAA
AATGAGCCAGACATTGAAAATTTAGAAGATAGTTGCAAAATCTAAAAGTGTTAGGGCTGTGTCATATATT
TAAAATAGTGAATAAACTGACAAAATTCAATAGTAAAAATATCAGACACTCACCAGGAAAGAAAAGGGCT
ACAATTAGTCATTTCAAAAGTAAAAAACCTGGTTAGCTAATAAATATGTATACCTAAGTATGAGCAACCT
ATTTGTAATCAAAGAAACATCAATTAAAAGAGATTAAAATAAGCAAAATTATAGTTCCATAATTTATGCA
TTTATGAAAATGTGAGGGGAGAAGTATACTTAAATATTACAAATAGATAGGTGGCTGCTGGTTAGATATT
AGACAATTCCTTATTTATGACAACATTACAATCTCATTCTATGTTTACTGTATACAGAAAAACCCTCAAA
AGCAGTATGATACCACTGTAAAATAATGGAGGTTTAGGAGAAAATTATGTATTTGACACCAAAATATTCA
GTAAATTACTTGCAAGGAGCCTAAAAGAAAGGACTAACACAAGTGATCATTACAATAGACACTATACCTA
ACCACCACAGTGATAATGACAGCTGGTCATCACAATTAGCAGTGTGGATGACCATCACAGTGACCACTAC
AAACGACCATGACACCTACTTCTACACATGAGCACCTGCTTCTGAGGCCAAATCTCCACTTCCTTCTTCC
AGGGCCCTGTGCTTCCCAGGAAGGATTGGTTTACTCTCACACTACATTAGGGGAAGGCTCTGAGGCTTAA
GATACTCATGGCTTGGCTGAAGCCACTCAGCCACCACAACATATCCTTACTGTTGTTCAGGTGCCTTGTC
CAGGTGACTAGGGGTCTGCTTGTCCTCTGAAAACTAGGGAAACTCCATGCTCTGATAATTCTCATCATTT
CTCTTTACTCTGCCTCAAGGCAGGGAGCTGAGGCTGGAAAACACAAGGCTTTCAACCAATTGCTTTCTAT
AGCATGAAACCCATCTCCACAATGCTGCCCAAATAGGTATAGACCAGGACCTTTCCTTTGCTATCTCTTC
TAGCAGGAAAGACCAGTCCTCAGTGAAAAGAAAGATAATAAAATAAATAATAAAAATGAAAATAAAATTC
GGGACAGCATGGAATAAAAAGAGAGAAAGAACAAGAAGTCAATGATTTTCCTTTTAGCTAAGATACTTCA
GTTGGATCAGAGAGGCCTCTTTCCTGATCCCTTTCTTCTCACCAGATTGGTTGGTGGTGTGTTTGGACTA
AGGGATGCTTAGTTGGACATGAATTCAACAATGCATGGTGGAAGCACAACTCTACACTGTCACCCTGAAC
AGAACAAGACTGAGTATCTATTAAAACATGTCTTTTTATATTATCTTGGGACTCAAGTAATGAGGACAAG
CAATCATGGATCCAAATCTTCAAAACTAAACATCAAAATAAATCCTTCATCTTTTTGCTTACCTTAGGCA
TTTTACTTTGTCATAGTGATTAAAATGAACACACACACACACACACACACACACACACACACACACACGC
ACACACACCAGAGCAATGACTGCCTCAATGGTGTAAGAAATTGAGAAGTGGCTTGAGGTAATTTTCTGAA
CTTATGTCAACACTTTATACATCAGTGGAGTTTTGAATACACAGAAGTGGATGTTTGAAGACATGGCCCC
TAGTTGAGCCAGACAATCTACAAAATTTTTAACCAGAATTGTTCCTGTCCAAAGGAAATGTAGGGACAAA
AATGGAGCAGAGACTGAGAAAGACCACCCTGTTCCTGGCCCAAATTGGGATATATCCCAAGTGCACACAC
CAATTCCTGATACTATTACTGTGGCCATCTTGTACATGCAGACAGAAAAAGTTCTACTAACAACTGACTG
GATCAAATGCAGGTACTTTCAACCAACCATTCGATTAAGATCTGGGACAAATATGGAAAAGTTAAGGGAA
ACACTGAAGGAAATGAGGGGACTGCAACCCCACAGGAAGAACAGCAGTGTCAACTAACTCAGAACCATCA
GAGCTCCTACAGACTAAGCCAAAAAACAAGTAGCATACTTGGGCTGGTTCATGACCCCAAGAACATGTGT
AGCCGAGGGCTGCCTTGTATGGCCTCAGTGGGAGAGGATGTGCTTAATTCTGTGGAAAGTTGATGTCCCT
GGGAAGAGGAATGTTTGTGGGGGTAAGAGGGGAGAGGATAATGTGAAGAACTCAAGGAGGGGGACAGGAA
AGGGGGTAACTTTTGGAATGTAAATAAGTAAAGTAATTTAATAAAATGAAAAGTGGGTGTTTATGAAATG
TCAATAAATGTGTAGATTTGTACGTCTTATTGCAGCATATTTTATTTTCAAAAGCACCATGAAAAAATTA
ATACTTTTTTGATATTAAGGAAGCCTAGTTTCTTAAATGTGGAAATGGTATAATTTTGAATTACATAGTA
ATCCCTCTTGTTACTTTTTAATTATTGGCTAAATATGGAAGCAAATGGGGCTTCTGCTTATCATTTGTAT
TGTGCTGTGCTCCATTGTTACCTCTGGTGTCCCTTGTGGAGAGAAGGCACTGTATGGTGGCACTACATCT
GATATATTCTCATATCCTGGGGGTGGCTGTTCAGATAATGATGTTTTGAAAATCTAGAGAAATAAACAAG
AGAAATAAGAGTGATTCAGTTAAAGATAATCACAAGCAAGCAAAAACGTGCATCCATGTCTCCTTCCAGT
TATCATTTAATGATTTCAAAATTTATATCAACACCTAATTCTGTTAGCAATGCGCAGAGAGGGAAAAATT
TAGACCTTCTTCTCAGAATAAATTCAGGTATAAATCTATAATAATAATGATAATAATATTAATCCTTAGA
ATTGCCAGGAACTAACTATATTCTGTTTGTGAGTAAATAAAAAGGAAGTTCAAACAGACATGGCTTCCCC
CAAAAGGAAGACAGCTGTATCATAAGGAAAGGACGAATTGATGACAGTCTTTATAGAAAAACACACATCC
CTGTCTGCTATAAACAACAAATACACAGCCCAAATACCAGGTGTTACATATATCTTTAGTTATTGCATAC
ATTATAAAACATGAGAATATGTGAAGAATAATGTTTGCCAAAGCCATTAAAATCTAGTCAAAGTGGAAAA
GTGCATCTTACTTTTATTTATACTTTTTAAATTTAAGTTTGTATTTCTGTACCTCACTGTAGTGATATCT
GTTGTAGAAAGTATTTAATCCTTTCTTTTGAAATTTTAATATTACATTATTTTTATTGTATATTTTCTTT
ATTTACATTTCAAATATCCCTTTCCTAGTTTCCCCCCAAACTCCCTTCCCCCCTGCCCCCAGTTCCCAGA
TAAAAAATATACAATCTTTATAATTATAAAAAGTCTAAATCATCAATAAAGCTGGGCAGATATCTACCAT
CAATGCTATTATGTTATGTATACTTTCCTATCAAGAACCCCAAGTTATAACTTGCTATGTTCCTACTGTG
CTGCTACTAACTCCAATTGGCCAGCCCTTATGGCCAAGTTTTGAGGATGCTTACCCTGTGACATCTTTCA
CTCACTCTACCTTCTCCCTTTTCCCCTAGTGGTTCTCCTCTGACCCCAATTCAGAAATCCCAAACCCTAT
CTATGTATTTTCTCCCCAGACCTTGACTGTTGGCATTTTTATTTAACCAATAGTTTTAAAGTAAGGAGCA
ACGTTACATTTTGTGTTCAGATACTCTGGATTTTTTGTACCTGTGAGCAACCAGGCCTTGGGGGTCAATA
CTTAACATAGTAAAAGACCAAACCTCAACAGATGCATCAACAAAACATCTTTGTACCAGCTTATTAATAC
ATCAGCAGTAAGATTAACTTCCCAATACACCACTATGACTGTTACAATAATCCTTTTGTAATCCAAGTTA
GACTACAATTTATGAGGTAGTCAATACTGTCCTTGAACCTCAAGATTAACATCCTTACACAGGGTTCCTA
ATTCTGGGAATAGAGACAGATAATATCACAACTGAATAAAATAGTGATTAAAAATGAAAGCTCATATAAA
ATATGTATTTTTAAAAGATCAATATTATGTCAACTTGAAATTATACTGGGTATTTTAGTTCTTCCATACA
ATACATGTGTCAGAACCAGCTGATTTTTTTGAATTTGAAATATTAAAGAAAAATGTCATGTTGGAGATGT
AGTTTGACAAAAATATTTTTTAATTGTAAGAAATATGTGATAGTACATGAACATTGCATTAGATCCAAGC
AATAAACCTGGATGTGAATGATCAAAATGCAAATGAGAGTGCATATATCTGAAATAAAAGCAATGCAAAC
ATGCTGCTTACAGAAAATAAGCACATGGTTAAAAGAACCATGTCATAGTTGAATAATGTTTGCCCTAGAA
AGGGGAACAGAGCAAGAAGCATGATGTACTGTGGAACTGTGATTAAAAGACTGATGCATTAGTGTAAGAA
AAGTTTAATAGCAATTTGAAAAGAAAGTCAAATATGAAACTGATCTAACTTGTAGATAGCTTGGACAATG
CTATTTATAATATAATAACCTCAGTTACAAAATAACTATTGGAAGTATTGTAGACTGTACTAGATATATC
AAGTTGGCTCCAGAAAATGTACTGATATAAATAAATGTTTTAGTTATAATTTATTGTTTTCCTATTGAAC
ATACATCTTTGTTTGATCAGTCTCAGCTGTATTATAATGTCTTAGGCAAGTATGCACCTGGACTTATAAT
AAGTATTGTAAATTCTTTGCTATAACTATACTGTTTCCAGTTTGCGTTTTGCTTCCAGAGGACTAACATA
AAGTCTTAGTAAAAGCCTATGTACAGGGTCATTTCAAAAATAATTATTCAGTGTGTCTAGGTTTTTGGCT
AAGATCAAGTGAAAATACAAAGTTTTCAACCAGCAGGTCCTTGCTAGCTGAAAACCCACACTAGGTCTCT
AAATATCCAGCTTAACTCTAAATCTAGTCTTTATGATTTAAATCTGTGATGAGTGTCTGTTTAGATATTG
AAAATCATAACCTTATATTACTTTTGAAATTCAGATATAATGCTAAATATACAGAAAGTAACTGTAATGA
AGCTTCCTTTTAAAAAATATTCCCCAAATCACACTAAGTTCAAACACTCTAAGAAATAAACTGACATTGA
TAAAGAGTTTTTAAAGGTAAATCACAACAGTCTTAATTAATTTGGATCCCCGATATCTTTCAAACACTGG
ATCACCAAATAGACAGCATATACCAGCTGATATGGGACCACCCAGCATACATGTAGTGGAGAACTTCAGG
GTCTGTGTTCATTCAGGGATGGTGCACCTGACCCTTGGGAGACTGGAGGCCCCAGGGAGTTTAGAGGTCA
GGTGGGTTCAGGGTTGGGGAATCTATGTAGAGATGGGGTGGGCTGGGGGGGAAGTGTGGGACTTGGGACA
GTCAGAGAGTAGATGGGGGAGTGTGGGGAGTGGTATATGGAAATAAAACTGATTCATTTTAGTAAAAATA
AATGCACATGAAAATGTTAACTTACTGAGGAAAAATCTTCCCTTAAGAAAAAAGAGATATGGTATCGATG
AAATATACAGTAAAACCTTTTTTCTCGAATCAAATGAAAGAATGTAGAGAAAGGAAAAGAGGTACAAAAC
AGGTAGAAATGTATTTCGTTTTTATATTTTTCAAGATCTTTAAAAAAGTTAGGGCTGGAGAGATGGCTCA
GCGGTTGAGAGCACTGACTGCTCTTCCGGGGGTCCTGAGTTAAATTCCCAGTAACCACATGGTGGGTCAC
AACCATCTGTAATGGGATCTGATGGTCTCTTCTGGTGTGTATGAAGAGAACAATGGCGTACTCATATACA
TAAAATAAACAAATATTTTTTAAAAAGTTTAAAAAATGAATTAAAAATAAAATAAAAATAAAAATAAATA
TTCCCCAAATCACACTAAGTTCAAACACTCCAAGAAATAAACTGACATTGATAAAGAGCTTTCAAAGGGA
AATCACAAATGTCCATAATATTGAATTCAATAAATACATGGAGATGATGCAACTAAAGTGAAATCTTTCT
GCTTATCTTTTTACTTACCTCATTTCCATCTTCATTAATTATTGAGATATAGTTAGGATGAGTTTTATTT
GGATAGGACAGCAAGACATCGTAATGGGATAACTCAACCAAATCCAGGCCAAATTCTTTCCACTGGTCAT
GAATTTGCTTTGCAAGCTCAAAATTATTTTGTGTTCCTGCCAAGTGTGGTGTCCGTGTGAAATTGCTGGT
GAAGGAAAATTGAAAATGTTTAAACATTACTTTTAGTCTGTCTGCGTTTTCAATAGGCACCCCAAAAACC
CTACATTTTTCATGCCTATAATATATAATAAATGAAGTAAATATAAGATGTGGGGACTTTTCATGAAGAA
GTTTAAGCCTAATGCCTCTTACTCAATGGGGCACTCCTAAAAGCAATAGCTCTCATAGATTTTAAATCTA
TTGTAATTAACGTACACACACACACACACACACACACACACACACACACACACACACACACACACATATA
TATATATATATATATATATATATATATATTCCTACAGATATGAAACTTTTAACCATATGTGAATATTTAA
TAGTCTTTTATATCAAATCACTCTGTGTTCATTAGGAAATCCTATCAGTAGAGGAATTTTTTAAAGACTT
TTGACATATATATTAACCTGATTTTTTGAAAACCTATAATGTGTTCTAGGTGATTAGATAATACTAATCC
TATATACATCCACATATTGTATTTTAACTAAATATAAATCTAACTTTGTGTCTATGATTACGTTTTATGT
TCTTGTACTAATGAGAATCAAACTAGTGCCTTGTACATATTCAGGAATATAGTTTAGGTCTAGCATGTGC
AAGGGCCAATAATTTTACAATATATTCATTTATCTCTTTTGCTTTACACTCTTTTGAAAAGAATAGAATT
AGTTTTTAGTGTTTTCAGAACATCTAATTCCCAGGTTCACCCTTATCACTGCAGTATCATTATCCTTATC
TCATAGATGAGAATAGAAGCTTGGTCAGTTTCATTAGTCACTCAAAGTTAGTTCCCTCATAATGAGCAGA
GATGGAGCTCAAACTAAACATCGTGCGATTTTTAAATCAGCTTTTTCTTAAATAAAACCTATTATCTCTC
CTTAAAGGATAAGTCACCAAAGTACGTTCCTCAGTCCAAATCTGGCCATAATTTGTTTTTGTATTCTCCA
CAGGCAAAGACCAGCTTTATAATTTAAGTAGGTGAGGAAATAAGATGGGATTTTGTAATGCATCAACAAA
TAATAATCAAATTTCTCTGCTCCTGAATGCAATTTTATCAGAACCTGCATTTGTCAGATACTTCCTATGG
CTTCTTTTGCTCTTATGGAGCTAAAGTTAAGTAGTTATGGCAGATATTTGTTGGCTTGCAACAACTGGTC
TTTCCCCCTACAGGAAATGTTTTCTGGGTACTACTCAGAAAGCTTTGTGAAGATATGAAGTTAAAGCTGA
AGGTATAATCACCATATGGAATGTAATACAAGTATATTCTTACTATAAAAATTTTTTGATGTTCTCAGCC
TTCAATTCATGCAAAAACTCCTTCTTCATGCCAGAATGGGAAACATTACCAGTAGCTTCATTGGAAGGTT
TTATAAACCACCCTGAAAAATACAAGCAAAAGTATGAATGATATACGAGCTCATGTCAGGATCTTTTGGT
TTTTTTTTTTTTTATGAGGGACACAGTTAATAAATTATTTCTTATATGATCTGTGCTTCTCATGTTTTCC
CCTTGTTTTTTTTCTACAAAGAAAAGAGCATATCTGTATTGCTTTTAATTGCAAAGCAAGTACAACATAT
TTTACCTAATTTCAGTTATATGTGTTGCTCTTATTTCTAAGAAAAGTTGAATGTGAAAATTCAAGTATGT
AGTGTTGTTTCAATTATTAGAGATAAAATGCTATGAAAATGTAGTTTCTCTACACTTGCTTCTCTTAATA
ATTTCTTGCTTCTCTGTAGAGCTAAACAGAAGCTCACAATGAATTATTTATGAGTACAGTGACTGGAGAG
ATTGCTCAAGCAATTAAGAGAAGAATGTAATATTCTTGCAAAGGGGCCTGACTTCGATCCTTAGCACACA
TTTCCCAACACAAGCCCATGGACATCTCCTCTCACATCTACATACATACGTTCTCAAAGATATAACATAT
GAAGTTATTGAAAACTAAAGAGGATCTTAATTATGAATATATTTCATATATATAAATTATCTCAAAACAT
TTAAAAAACAGACTTCAATTTGCTTTGAATTGGACACTAAGGCAAAATGCAGGGATATTTTTGTTTCTCC
TTTAAAATTGGCTTGAGAAACTGAAGTTCTGAGAACTATAGTAAACTGCAATATACTTCGTAGCTCTGCA
AGACATCCAATGCACAGAAAGCCACAGACAGGTTATAACCTGTGCCTTGACCCCTGGCCTCATAAATTGA
TTTTAATCTGAGAGGGAGAGAACATCCTTATAGAGTTTACAGAGTACCTTACCTGAGAATAAAGAGAGTT
ACTGAACCAAACCTCATGGTGCTTTACCACTATTGATAATATATTTGAAGACATATATGCACACAAATAT
GCACATTGAGACATATGGCTGAGCAAAAGGCTTAACTAAAGGCCCTAGTGTTCACTGTGAGATTAGGAAA
GAACACCCTAGGCCTGAAATAACTCACAAGTAAGAAAGATAGAGGCCTGTGGTAGAGACAGAATACTAAG
AAACTAACAAACTGGGTTATTGAACAGTGAAACCAAGGGATAGTGGGTGTAACAAAGTAGAAATGACTTG
CTTTTAGGATATGTAGGCTTTTGAATCCCATGCTAACCGTTCCAAAACTTGATTCTCATTTCAAGCTGAT
AACAGAAACTCAATTTAATTCAATCTCATTGGGGCTCACAGCAATCATAGGTAATTACTGATATCTTTGT
GTTTAGTTTGATTGAAGTCTCTGGCCAAAGGCTACACAATTGGTTCAGAGCCTGTCTTTACCAATGACAT
AGAAGTAATTCAAAATGCAGAGCAAAGACGGATGACTTGATGACAAGTTAGACTGGCCTGTGTACTAAAG
TCCAGTAGGAAACAGATCCCTCATCAAAGACCCAAGTAGTTTTCTAGTAAAGCTCCTCCTGCTAAATAGT
GTCCTATTATCTGTACGTTTCTCATTCAAGTTTCATCATAAATATGGGGAAAATTAAGGTTGAAAGAGAA
TGGGTAAATTTTTTTCACAGTAAACGAGAATTAGTGATACAAACTCTGAATTTGTAAATCAGCTATGCTC
TGCTACTGATTTCTGATGCAGATGGTTTCTTACAGAGTTGGGCTAAATCTGAACTAAGGTCAGGAGGCTC
CTGTTAAGGATGTGTTCAGGCAGTGCTGACAGTAATTCACATTTCCCAGAATGTCTCTCTGCTTGTCCAA
GGAAGAATGTGAACAGAAAGAGAATCCTTTCACAGAGATGTCCTGGATGCCATGGTATCCTTGAAATTGA
CACAGGTAGGAGACAGGTGAACCTTCCCCCACCACGTCTCCCCAGCCTCCCCACCCCACCCCCAAAGGCA
AAAGCCACTAAAACCAAGCTTACTGGTAGATCTGGATCAGCAGCCACTGGGAATCAGCACTGAGAAGGGT
AGTGTCCTGCAGGGTCCCAATGGGTCAGACCTAATTCTAGTTACTGTTTCTGGTTTTTGTTTATTTTGTT
TTGTTTTGTTTGTAATCTGACTTTAATCTATGCAATTCTATATACAGATAATTTATTCCTAATTCAATCC
TGCTCAGACCCCAGGAAACCTCTGCTTAACTCAGATACTAAAGGTTCCTTCCTCCATGCAAATCACTGCA
CCCCGGGGAAGACCCGAAACCTCTCCTGCGGGAAGAGCAGCTACAAGAGTGCAGAAGCGAAGGAACAGGG
AGATTATGCACTTTGCCATGCAAATGCACCATACCAAAGAGGAAGCCAATGAGGAAGGTTCCGGTTAAAG
CCAGCACCAGTGTCCCAACACGGAGCCAGCGCTGGCGGTGTCCCAGGACCTCCGCGGAGTCTCTGTCCTG
CAGTGCGTTCCACATCTCTGGCAACTTTAGTTTTCCTCAGCAGTTCTCTTCTACATCCACTGCAGAGATT
CTGCGGGTTAAAATTTCCTCCCACTGCTATTCCCCTGGGAAATAGAAGTCTCTCCTAAGACTTTCTCCGC
CCCCAAATTCTGGCGTACTGTGAGCCAATTGTAGTTAGGCTAAGGGAAACTGCCTACTCTGGCTTCTTTG
GAGTGAGGCTTCAGTTTCTCTTTGAGACTTTATTGACAGGGGCTAAATAGAGAGATAAACAAGAATATCA
GAAAGCAATGATAACTTGCCAAATAGTAC

</dna_sequence>
        <protein_sequence>>NP_001153178.1 glutamate carboxypeptidase 2 isoform 2 [Mus musculus]
MWNALQDRDSAEVLGHRQRWLRVGTLVLALTGTFLIGFLFGWFIKPSNEATGNVSHSGMKKEFLHELKAE
NIKKFLYNFTRTPHLAGTQNNFELAKQIHDQWKEFGLDLVELSHYDVLLSYPNKTHPNYISIINEDGNEI
FKTSLSEQPPPGYENISDVVPPYSAFSPQGTPEGDLVYVNYARTEDFFKLEREMKISCSGKIVIARYGKV
FRGNMVKNAQLAGAKGMILYSDPADYFVPAVKSYPDGWNLPGGGVQRGNVLNLNGAGDPLTPGYPANEHA
YRHELTNAVGLPSIPVHPIGYDDAQKLLEKVKMHIHSYTKVTRIYNVIGTLKGALEPDRYVILGGHRDAW
VFGGIDPQSGAAVVHEIVRSFGTLKKKGRRPRRTILFASWDAEEFGLLGSTEWAEEHSRLLQERGVAYIN
ADSSIEGNYTLRVDCTPLMYSLVYNLTKELQSPDEGFEGKSLYDSWKEKSPSPEFIGMPRISKLGSGNDF
EVFFQRLGIASGRARYTKNWKTNKVSSYPLYHSVYETYELVVKFYDPTFKYHLTVAQVRGAMVFELANSI
VLPFDCQSYAVALKKYADTIYNISMKHPQEMKAYMISFDSLFSAVNNFTDVASKFNQRLQELDKSNPILL
RIMNDQLMYLERAFIDPLGLPGRPFYRHIIYAPSSHNKYAGESFPGIYDALFDISSKVNASKAWNEVKRQ
ISIATFTVQAAAETLREVA

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1349">
        <gene_name>Prostate stem cell antigen</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>72373</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>21312316</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AC118022</gene_refseq>
        <protein_refseq>NP_082492</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>15</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>74714838</gene_start>
        <gene_end>74717064</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>prostate stem cell antigen</protein_name>
        <protein_pi>7.83</protein_pi>
        <protein_weight>12881.57</protein_weight>
        <protein_length>123</protein_length>
        <protein_note>Also known as 2210408B04Rik</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000081.6:74714838-74717064 Mus musculus strain C57BL/6J chromosome 15, GRCm38.p4 C57BL/6J
AGGTGCTCACTGCAACCATGAAGACCGTCTTCTTTCTCCTGCTGGCCACCTACTTAGCCCTGCATCCAGG
TAAGCTTCAGACAGCCACGGGACAGGGCTCAGAAAGGAGTGATGGAGAAATGTCCAAGGGGTAGACAGAT
TAGGAGAGGGAAGGGGAGAGAGAAGACTGGGGACACCAAAGCCCCTTTGCGGTGTGGACTCTTACTAGGG
TCCTGTGAGAGGCAGGCTAGGAGGGACTGAAGGGCTTCAGGAAGGAGAGGCTGCCAAGGGACAGACACAC
AAGGCTACAGGGCCTTAGTCAGGGAAGCCCAGGAGACAAATGGCTTAAGCTGAGAAGTGTCACAGAGGGA
GGGGGAGGAACGTAGCAGGACAGGGTCCTCAGGATGTCTTGGAAAGGGTCTCACTGGTCCATCCCCAGCT
ACTTTTGCCTCCAGTGTGAGAGTCCACTGGGGGTGGGCAGTCTGTGATGAACTAGTGTGCTGAGCCCTCC
TATCAAGTAAGTCCAGAAAGGTCACTAGACTCCTAGAGCCTCAGCTTCCAGTTGCAGAGAAAGAAAAAGA
AGAATGTCCCCAAGGCCCCTGGAGACCTAAGCAGAACAAAGCTTGTAGCCACTGAAGTCAGATGTAAGCA
CCTATTCCTACAGATGTGACTTTAAGGACAGCTTTGCCAGCTTTTGAAAAGAGAAGGTGACCCACATGCC
CTGACATCTGAAGCTACTTGTCCCAGGCACGGAGCAGGACTTCCCCAGGGGCCCCACAGCATAGTGGAGG
CGTAGGAAGCCTAAGAGACAAGCTGGGCTCAGAGGACAGGTGGCCCTCAGAGCCAAGTAGCATGAAGAAG
TCGTATGTCCCTCCAGCCTAGTGCCCGGCGGGGCTTTTTCCCTGTGTGACCTGTCACTAGGCCCCTTGTC
CCTCTCAGGGATCACAGGTACTTTAAGTTCCTGAACAGTGAATAACAGAGCAAAGTGTGGGTTTTGGGTG
ACCAAAGCGGAGTAGGCTGGCACAGAGCCCTCCGTAAAGGGTATCTGAGAGTTTTGGGTTTTAGTCTCCT
CTATGCTTCAGCAGTCTGGAGGGGACTGGGCTGTCTCTCTCCACTCTGTGTTGGAGATGGGAAGGCCTGG
TCCGTCTCTCTTGAGGTGCAGCTGGCCAGCCTCTGAGCCTCAGGCCTCTTGCCTCACCCACAGGTGCTGC
TCTGCAGTGCTATTCATGCACAGCACAGATGAACAACAGAGACTGTCTGAATGTACAGAACTGCAGCCTG
GACCAGCACAGTTGCTTTACATCGCGCATCCGTGAGTGCTCTGCCGCCCCCCACCCCCAGTGCTCTGCTG
CCCCATCCCCGGTCCTCACTGCCTGCTGCCCCACCGGGCGGCCTCCCTCCCCACTCCAGCCAGACATCAA
AGCTTTGCTCACCCATTCACCAACCATTTCTGGTCTTTGTGGAGTGGGTCCAGAAGTTTAGCATGTTCCG
GAAGGGGCCCTGAGCCAGGGGCAGAGAGGTGGCTATCAGGACCTGGCTTTAATCCCAAGTGTCACTCTCT
CTTCCCAGGGGCCATTGGACTCGTGACAGTTATCAGTAAGGGCTGCAGCTCACAGTGTGAGGATGACTCG
GAGAACTACTATTTGGGCAAGAAGAACATCACGTGCTGCTACTCTGACCTGTGCAATGTCAACGGGGCCC
ACACCCTGAAGCCACCCACCACCCTGGGGCTGCTGACCGTGCTCTGCAGCCTGTTGCTGTGGGGCTCCAG
CCGTCTGTAGGCTCTGGGAGAGCCCTACCATAGCCCGATTGTGAAGGGATGAGCTGCACCTCCACCCCCA
CCCCCACACAGGAGCAACCACCACCACCACTCTTAACTCCCACATAGGGCTGGCCTCCCTCACCCCAACC
CCTTCCACCAGGGCCCTTTCTCCTCTCTGCTGCTATTTCCACAGCTAGCGCTTGGCCCACCCCACCCCAT
CAGCACTGTGCCCTACCAAGTTCTGCTCAGATGCTTCAGCTGAAGGACTCCCTCGCCACCCTACTCTCCA
GGGCCTGAGCCAGTGTGCACAGCAGCACTTGGGGAGGGGCCTGGTAGAGGCTGAGATGGGATGGACTGAG
CAGAAATGGAGCTGGGAGGTGGGTGTGAGGCACCAGGAGTCCCAGGAGATGATGCCTGGTGGGGGACATG
CTCTCCGTTTATAGAGCTCCAGGATACAACAGTCGTGTAATAAATACCTGCTGAGTA

</dna_sequence>
        <protein_sequence>>NP_082492.1 prostate stem cell antigen precursor [Mus musculus]
MKTVFFLLLATYLALHPGAALQCYSCTAQMNNRDCLNVQNCSLDQHSCFTSRIRAIGLVTVISKGCSSQC
EDDSENYYLGKKNITCCYSDLCNVNGAHTLKPPTTLGLLTVLCSLLLWGSSRL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1303">
        <gene_name>Prostate-specific membrane antigen</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>2346</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>62548858</ncbi_protein_id>
        <gene_locus_tag>GIG27</gene_locus_tag>
        <gene_refseq>AC110742</gene_refseq>
        <protein_refseq>NP_001014986</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>11</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>49145093</gene_start>
        <gene_end>49208669</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>transcript variant 6</protein_name>
        <protein_pi>7.11</protein_pi>
        <protein_weight>75932.97</protein_weight>
        <protein_length>719</protein_length>
        <protein_note>Also known as PSM; FGCP; FOLH; GCP2; PSMA; mGCP; GCPII; NAALAD1; NAALAdase</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000011.10:49145093-49208669 Homo sapiens chromosome 11, GRCh38.p12 Primary Assembly
ACACCAGCAGAAATAAATACATTTTATTATTCACCAGTTATCCAAATTTGGGTTATCCACTCCAAACTCC
CACTTGATTGTCTTCATAAATAGATCTGGGCCCATTAAATAGTTCTTCTTTGTCACGTGTTAATGATGTT
AAACTTTGTGAGTAGAAGGCATTGGAGAGATGTTCCAAGAGGGTGCTTTTCAATCTGCTTTCTGTGTGCA
CCCTTGGCAAACTCTGGCAATGCAAATGACATCTCCAGCATCTGACACGGAGGGCATACAGAGCTACACC
AGTGCCCAGATTCTGTAGTTCAGGCTGCTGCTATGGCACCCACTTCCTGAAGTTCATGGTGGCCAGGAGA
ACCCAGCGGCCAAGAGCTTCTCCTGAAATTGTCCTTTGCCAAATTTGTAGTAGAGCCCCTCTGGCTTGAC
ATTTCTTCATAAACAGCTTTACACATTGGCCCAGAAGACAAGTTTCTGGGGAGTTCTGAAGTGTCAATTT
GAAGCAGATTCTTCAAGGGCAACACTACAGCGACTTCTTAACTTTGAGCGAGGCCACAATGTGAGGGGAC
TCTTCATTGGCTGCTCCAAATTCACCATGGAGACAAGAGCAATTCCTTACATCTGCTCATCACATATTCT
TGAGACTTCTCTTTACATATTACTAGACAATATTTCATTGTTCCAATGCTGTAACAATTAATAATTCTTC
ATATTAACTTTCCCTATTCACATTACTGTATGTTTTCTCTGTCTTGATGGACCCTGAATCCTACCCTCAT
GTGAATGAATGCTCTATATCAGCAAAATATGGCAAACTACAGCCACAGTGATAATATATTTGAACCCTTA
AAAGTCAATGAAAAAAATCAAGTCCCTGAAAATTACACATGGTATGATTGTCTTTACAAAAAGTTCAAAA
ATACATAATGCCAAAACATGTAAAGGATACAGCCATGTGTGATAAAATTATAAATAATGACAGAGGAAAG
ATAAATAAACATAAAATTCAAGAAAATGCAAAAGCATAACTGTCATTAGTACATGGGGCATCCAAAGATA
TTAGAAATGTTATTTTCTTCATATGGCTATTAGGTTCACAAGTGTTCATTTAATTACTATACATATATTT
TATACTATAGCCTTTTATATAAATAAAAAATAATTATTTCTTATGCTATAGAGTGATAACATTTACTAAA
AGTGTGATTTGATCCATTTCCCAAATAGTGTGCTGAGATAGTGATCCTCTCAGCCCAGGCTGGCCAGGTA
GGCCGTGAGGCCTCTGGCTTGGGATAATCTTGTGCATATTCCCCAGTGTGCTCTCTGACATACTGATGTT
TTCTTCTGTGTGAAGTGACATGAATAGATTAGACTTGATTCCCTGATAATGCCAGATGAGAGTTTTACTA
TATTAGGCCATTCTCCTTAGATTTAATACTGAGTTAAATTTTTCCACTTCAGAATAACCTCTTATAATTA
TGAAATTCAGTTTTAATCCATAGGGAGAAGATAAACAATATAAACACACACATATATAAACACTCACATA
ACTATATATAATATTCAACTTTATTTCAAATATACCAATTTTAAAATTTATCAATATACCCATTACGATT
CTTTCTGAGTGACATACCACACAAATTCAATACGGATTCTCTAAAGAATCCTCTTAGGCTACTTCACTCA
AAGTCTCTGCAGCTGCCTGCACTGTGAAGGCTGCAACATAAATCTGTCTCTTCACTTCTCCCCAGGCCTT
GGAAGGGTCCACTTTGCTTTCAATATCAAACAGAGCATCATAAATTCCTGGGAATGACTCCCCTGCATAC
TTGTTGTGGCTGCTTGGAGCATAGATGACATGCCTGTTGATAAAATCGTTTGCTGTTTATTAGGTGCCCA
AATGATATACAAGAGAAACACAAGAGCACTCTGCAATTCCTGGATTGCATATTCCTATAACAATTTGAAC
AAGCCACTTGTCAACTGAACTTCCAAGTTCAATCATCTCTGAAGACTATTATATGAAATCTATAGTAATT
AATTATATTTTTATTTCAAACAAATAAATTAAAGTGGTTCAGTGCTACAAAACTAACAATGATGATAGTA
ACCACAGCAATCATTCTTGGTATTTAATGTTTACTTGCAATTTTTCTGATGTTTAGAAATAAACTCTACA
CAGTTGATATTAGTATTTCACAGAGAAGGAAACTGAGGTCTGAGAGATCAAGTAACTAAATGATTTGTCT
CAAGGCACACGACAAGTAACTGCTGATTTTTTAATATATCATGCTACCCCCTATATTATAGCACAATTGT
AATCATTACAGTCTTGCTTGTGATCAGCCAACCCTCTATTGTGGTTTTTTTTTTGTCTTTTTTTAAAAAG
TCACACTACCATGTTAGAATACTTAATATAGAGTTTGAAGAATCATCAAAAACAATTTTGTAATGTTCCA
TGTGACCAAGGCAGAAAATGTTTTATAGAATGGGCTATGACAGTTCATGTAATAGCCCACAGAAGAGAAG
GACAAACTCCATAGTAAAGATGTAAATAAGGCCAGAAGCAGTAGCTCATGCCTGTAATCCCATATATTAG
GGAGGCCAAGGTGGGAGGATTGCTTGAGGCCAGGAGTTCTAGACGAGCCTGCGCAACATAGGGACACCCT
GTCGCTACAAATGAACGTACAAATATTAGCTGGGCATGGTGGCATGTGACTGTAGTCCTAGCTTCTTTGG
AGGCTGCTGCAGGAAGATTGGTTGAGCCCAAAAGTCTGAGGCTGCAGTGAGCTAAAATTGCACAACTGAA
CTCTAGCCTGGGAGACAGAGTGGGACCCTGTCTCTTAGGAAAAAAAGGGGGGGTGGGGGATGGATAAAAA
TATGCTGCTACTGGTGATCTGATCCAGTCAACCTGCTTGGAAGATGCTCTTACTCCCAAGCCCGACCCTT
TGATAATCCCTAGAAAGAAAGTTAGGGCCATTTCTGGCTGTCCAATGATCTATCTCATTCTGCAATATTT
AGAAGATCAACCTGGGGACAGTCAATGTTTGGCAGAAAAAAATCCAACTGTCAGGATTTAGGAGGAAATA
AAATATCTAAATATCAACATTAGGGAAAAGAATAAATAAATATATATTTATTATATACATTATATATAGA
GAGATGTTTGGGTTCTGTGTATACATAAGTAAAAATATATTTAAAATAGAAAAGGAGCTAAAATTATACA
CACCAGAATATAACAATGATTTTATATTTTTCTGATAAAATTGGGGAGATTTTTATTTTTTGTCATGGCT
TTCTGGATCTTCTATATTTTCTAAAATAAATTTATATTCTTTTATAATCAGAACAAAGATACTCAAAATA
AAGATATGCAAAAATCATATTACATTATATGAAGAAACAATACAACTATCACTTACTACATATATTTTGA
AATTTTCTATTTGCTTGCAAGAAATCAACTACAATATTTTTTCCACAGTGAAAAAAATAAAAATAATTAG
AAGAAAAAGTGATATTACAGAAAGGAGTCATATTTTCTTTTCTTACCTATAAAAAGGCCTGTCTGGTAAC
CCTAATGGATCAATAAATGCTCTTTCCAGAAACATGAGTTGATCATTCATCATTCTTAATACTATTGGGC
TGAGAAAGAAAATGAATATAATTATAACTTCATGAAAATATGTTTCTACTCAGAAAATAAAAATTTCAGA
ACAAAACTGAATTTAGTTATCTCCGGGGATTGGTTTCAGGACCACCCTCTACACCAAAATTTGTGCATAC
TCAAGTCCTGCAAGGAGGACACATGTATGTGAAAAGTCGGCCCTCCTCCTTTGTGGAATTTTTTTTTATT
ATTATACTTTTAAGTTCGAGGGTACATGTGCACAACGTGCAGGTTTGTTACACATGTATACATGTGCCAT
GTTGGTGTGCTGCACCCGTTATCTCACTCATAGGTGGGAATTGAACAATGAGAACACTTGGACACAGGGT
GGGGAACATCACACACCAGGGCCTGTCGTGGGGTGGGGTGAGGGGGGAAGGATAGCATTGGGAGGTATAC
CTAATGTAAATGACGAGTCCTCTGTGGAATTAACAGGGTGAAAATGAACAAACTACCAAACAAATTAAAT
TGATCTCTCGGTATAATGATCCAGATTTAAGTCTAAAAGTTACTTAAAATTATATCGTTTCAAGTGATTT
TCAGAATGGTTTAAGTACAGCGTTCTTGGAGCCTGATATGACTTTCTGGATTAACTTGCTCTGCCTCAGT
GAGGAAATGTAGCTGTGTATGTGGAATCTGAAGCCACATCTGATCTCCCTTGGGTTAGCTGCCCCCAGTA
TAACTCTTACCACATGCTTAATCCCCCTTTCACATCTTAGTCTTCATGTTGTTAAGACAATGAGATAGGC
AATTATATAAAATAGAAAATGTTTGTGGAACACATGGCTAGTAGTCCAAATGGAATGTAACAGTTTTTTT
TTAAGTTTCTATAATTCTCTTACTTTATATTTTTCATTAGTTTTTCATTAGCTACATCTGAGTTTCTCAG
ATTCAAGCTTGTAGAGTGAGCATCATTCTGTGATAAAAGTTCTAATATATCAAAGCTAAAAGAAAGATGC
TTGTTGAGATTTTTTCCACATAAATGAATTTTCTCAGTTAAAATACTTTTGTTCTAGATTTATGTCCATC
CTACTTTTAGATATTTTTAATGAAATCATTTTATGTATGCAATGCTAACATTTTCAAATGTAAGCTTGAA
AATAAAAGATTTAATTTGGCAAAATAAAAAGTTTTCCATATTTAAAAATAACAAGAATAGTCAGCCCTCC
ATATATGTGGGTTTTAGTCCTTCAATACTGTATTTTATTTTGTTTTCTTAAGAGATGGAGTCTTGCTCTG
TTGCGCAGGCTGGAGTGCAGTGGCTTAATCATAGCTCAGTATAGCCTTAAACACCTGAGCTCAAGCAATT
CCTCTGCCTCAGCTTCCTGAGTACCTGGGATTACAGTGAATAATACTGAATTTTCCATCTGTGTTTGCTT
GCTAATGTGAAATCTATGGATAGAGAGGGCTCACTGTATTAATTGAAAAAAATTCGTAAATAAGTGGACC
TGTGCAGTTCAAATCACTGTTGTTCAAATGTCAATTGTAAATTTTAACATTCTGTAATATGCAAATTAAG
AACAATAACATACATAGCTATGACATCTTTAAAATCTTATAAAATACTATACTGCTCAGGCTTATAAAAG
CACAGAAACAGTTGTATGTGCAAATGGAAAAAATAATAGTGATTTTTATTTACATTGGCATAATTAACTG
ATCAACCCAGATATACAAATATAGGCAAGATTTTCTTCACCTTAGGTATCCTAGCAATCTACTCACTGAA
GTAATATCAATATTAAAATAAGATGACTTGCTAATGTTTAGTAAGATGCCTGGCAAATTATAAATATTTA
CCAAGTGATAACTAATAATATTCCTTTTATTTTTAAAGCTAAACCTATTATGAACACAACAGATGGTGAT
TACTTAAGTCTTTCAACAATATTTGGATACCTGCTATTTATCAAACACTCCCTGCTTTTACAGAACTTAC
ATTCTAAAAGGAGTGTTGGGGTTGTTATTATAATAAGAATGATTCAATATAATTGAAAGTTTATCAGCAA
GCTCTGAATACTTCAACAATGAGTTACTGAATTTAATATACCAATTATTTCACAATTTAATTAACTGAGA
AAAATCATTACAATAAGAAAGCATGAATCATCTTGTTCATTAATTTACTTCTTGCTTTTCATAATTTAGT
TTTACTAAAAGAGCATTTAGTGATCATTTCCTATGTGCCAATTACTGTTCTGAATCTTTATACAAAATGT
GATTTTTAATTTTCAGAGCAATTCTGCAAGTTGGGTAGGGTAACAGCCCCATTTTGTAGATGAGATAACA
AAGGATCATGAGTTAAATAACTTGCCTAAATTCACACTAGAAAGTTTTAGAGTGAAATAGGAGATTGATA
TTGTTCTTTCAACTGCACCTTGCCGACAAAAGGAAAATAGGAACAACTTAAACTCCCATAATTTGGATTT
GAGCTATTTTTAACATTTATGTATTTGGCATCATGAATTCAGATTCTGTGATAGTATAAAGGTAAATGAA
ACACAGAATACCTGTTAGCAACTCCGATAAACAGTTGAGACAATCGAATGAAGGATAATTTCAATAAGAT
GCAATGGGTTTCGGAATCAAATTCACAAAGAATTGCTACAAGTACAAAAACTCGTGGCCACACACACGTA
AATGCGCGCGTGCGCGTGCGTGCACACACACACACAGACACACACACACACACTTCTCTTTCTCTGTATC
CTGTGTTAACGTCTTATATTCTTTGATGGGGCAAGAAGTGATACAAGAAAAGCAGGATAAAGTCATGTCT
CTTCCTTAGATTTCAAAGTTTTGGTTGAGAAATTCAACATTCAGTTTAATTTACTTAGTCAGAATTTACT
ATTATGTGCAAAGCACTGCTCAGGTGTTTCAGAATTTGTAAGTATCATATAGGGAACAGAGTGTATCTTT
ACTATCACTTACAGAAAATAAAACAAATATAGAAATACTAAAGGAAGGGGAAGCTGAGTGTGCCAAACAA
TAAGTGTCCTAAACAAACCACAATTCAAACCATGAGACATTTTGTCAGAGGGAGAAAACATTTTTTCTTT
TAAATACAAAAAGAAAACCAGTTTTATAGGATACATGGTGTTTGGGATCTCCTTAAAATGTATTTCTTAT
TGTTGACTTTTTTACTCACATATAAAAATTATAAAGAATTGAAAAGAATAGGAAAACAATTCTTCCAATA
TTCCCTGAGGATAGCACAATTATTATAATAATTCATTAATTCCCTTAAAGTTTTTCCTGTATTTGTTAAA
TAAAAATTAATCAAATTATATTTACAATTTTACAACCTTTTTGCTTACTTCATATTTTATTCTAAGTATC
TTCTATTATGTTGTATTTCTAATAATCCATTGTTAGGATTATAAAATGTTCAAATTGGTGAATATCAAAT
TTTTTAGTAATTTCTCTTCTCTTAGGCATTAGGTTATTTTGAATTACTTGCTATTATAATTTTATACTTC
AAATCTTTCTCCAGGCAGCCTTTCTTTTCCAAAATTGAGACTTTTTCCTAAGAAATAATCCAAGAAGTGG
AAATACTATGTCAAAGCACAGGACTCTGTGACAGCTCTTGAACACATTAGCAATATGTATCTATCTTTTT
CAAAAAGGCTAAAATAATTCATAATGCTATCAGAAAAGCATGGAGAGCATATGCTTCAGTGTACCAGCTA
CAGCAATGGGCAAACCAAGGTTTAAATTGTTATTAATGTGTTATAAAAATAACATCACATTACTTTCATT
TGTATTTCTGAATTATGCATTAGTGAACTGCAATATTTTGCCATGTTTCTTTGCAGGTGTATCTTTGACA
ACATTTGTAAAATTATTTGTCTTGTTTCTTACCGATATTTTCAGCTGGTTCTTTTGGACTGTTTAAATTA
ATTTTCAAAAAATATTTTTATAATGTATATATTACTCTCCATTTTTGCTAGAAAATAAGTTTTCAACTTT
CTTAATTTTTCTTGTGAATATTAATTTTCGTATTCTGAACCATTTCAAATGGTCTCAAATCTGATTGCAT
CATTTCCCCATTGCTTCTAAACTTGGCATCTTTCAAGAAATTTCCATTTTTACTAAATAATTCTTTACAC
CTGTTGTTTATGTTAGCATACAATGTGAAGTGCGATTCTGAATTTACTTTTATAGCAGTTATAGCAGGTA
CTAACATAGTTCATATAATATTATGGTTGAGTAATCTTTCCCCATTAATTTTTGCTGTATCATTTATTAC
TAATATTTCCTTATAGATCACCAAGCCTATTTCTACATCATCTACTGTAATCTTTTTATGTGTCCTTACA
TCAGCTCCTGGGGATTTGATATTTATATCATGATACTATATTTAATACACAGATCTCTGCCCTCAAAATT
ATACTTTAAAAAAATTACCTTAGTATTCTCACCAAGTATTTTTCCTTCCATCTTAAAATTTTGTTCAAAT
TGTGTTGTACTTGTGTAATCTTACACAGAATTAATCCTAAATGTTTAACATTTCCAAAATTAATGGCTTC
ACAATATTTGCTATTCTGGATAAACAGAATTTTGCCAGATGGAAGTGGAAATAAGGAGCTCTATGTGGAG
GTAATGACAAAAACAAAGGAGGTAGAAAGAAATCATGTTTTGAAAAATAAATAGTCTGGCTGAGTTATGA
TGTACAGATACTGAAAAAGCAAGAAATAAAACTGGAAACAGCTGGGGTCACACAGTAGAGGACCTTCAAT
GTTAAGCAGAGTATTTTGTAACTGATCAAATGTCAGGAGGGAGGGACTGACATTTCTGAGCGGCACAATT
GCCACTCAGAATGTCGAAAGTAGGTCTTTTGAGATGGGGCAGCCCTACATAGGACGTGCTAGAGTGGAAA
GACAGAAAACAGCAGGAAACGACACTTGTATACCTATGTAACAAACCTGCACGTTCTGTCCATGTATCCA
GCAACTTAAAGTAAAACAAATTTAAAAAAAAGAAAACAGCAAGAAATTCCCAAAGCTAGTTCAGCAACAG
TCATGTTAGTTTACTTTTAAATATATATATATACACACACATACACACATATGCACATATATGTAGAACA
TACTTGCTTTTGTCAAAGTCCTGGAGTCTCTCACTGAACTTGGAAGCAATTTCTGTAAAATTCTTTACTG
CAGAAAAAAGTGAATCTGAAATAGAAATTGGGATCATCAAATGCTTAAAGAACATAATTTCTAATGGCAC
TGCTCTATAGTTCAAGAAAAGGAACAATATAGAAGCCATCATCTTTTGTGTTTTACAAGGTATTTATATT
TTTATATTATAAGACGTGAGCATCCATAAAATGGAAAATACATTTATAGACATAAACAGAATATTGGATC
ACTTGAAATAGCAATAAATAATAAATGACCTAAGATAGCCCATTATATTTAGGAGATTAATAGAACCATA
CAGATGAGGAATTTGAAAAAGGAAGGGTAACATACCAAATGATACACTGTATGTCTTCATTTCCTGTGGA
TGTTTCATAGAAATACTGTAGATTTTGTCAGCATACTTTCTTAAAACTACAGCATAATCTCGACAATCAA
AAGGGAGCACTATGGAATTGGCTAGCTCAAACACCATCCCTCCTCGAACCTGGGCCACAGTGAGGTGATA
TTTAAACATTGGATCATAAAACTTTTCCACCAACTCATATGTTTCATAGACACTGTGATACAGTGGATAG
CCGCTGAATTTGTTTGTTTCCTACAGAAAAAACAACAAAACATATCTCTTATAGGATAGCTTACAAAAAA
TGATTAGCACCATATTTACTATTAGTATTAGTAAGATTGGTCAGTGATGGATCAAGGAAAGTACTTAAGC
ATCTCAATAAGCTACATCCTAAATGGCTAATATTATGATACATAAACACATTCCAGGCTTGTATCAATTA
AAATATGTGTATATGATATAACAAATATTATTTAAAAATTATTTGAAAGGGACCAAACTGGCTTGCCTCT
AAGAATGCAGAACATTGCATTCTTAGATTCATGTTTTAAGAATCTGAAAAAAAAGACAAGACAATCTTGC
ATTTGGATAAAAAGAAGACGAATTGTTAAAGGCAAGTACATAAGTATTACACAATATTATATAGGAGAAG
ACACTAAATTGCTTAATCACTAAAATTCCATGGATAAATGATTGTCTGACAAGCAGTGTACTGAAGGCTG
GAGAGTCTGAGTGGTGAGGGGTGCAGTAGTGGATCCAAAATCTCACTAAGGAGAGAGAAGGGAGGCCCAG
ACAGGTGTCAGGAAAACCAAAAGTATAGGTAGAAGGAAGGACTTTTCAAACTGTGAATTGCTGGTTTATC
ACTTTTGATCATCTTAAGATGCTTATTTTTTATTATTAATATAAAAGGACATTTTATGTACTGATGTGTT
GAAGAGACTGGGATTCTGGAATTACCCTGCCAGGGTTTGAATCTAGGCTTCAGGACTTACTACCAAAAAC
TTTAGGTGGTCATTTGACTTTTCTTTGTTGTAATTTTTTCGTAGTAAAATGTAGACAATATTAATATTTA
TCCTCACTATCACCTCCTGCATAACTCTGCCTAACCTCCTACCTCACAGACAGGAGACTGAAGATTTTCC
ATCTGGGAAGAATAGCCCATGAGGAAAGGCTTACAGAAACTTAATGTCAACTCTAAATCACCAAATGTCT
TTTCTGTATTTGGAGTTGAGCTCGATCTCTTATTATTGCAATATTCTTATTGGAATAGTTTTGAATGAAC
TCTTCCTTACCATTTTTATAACTGTGAGAATGATTTTTCTTTATAACATAAAATTTAAAATTGAAAAAGT
ATCAGGATTAAAATATTACTTATAAATATGGATGTATCATAAAAGTTGACAAAGGTTTCATCTGATGAAC
AGAAATCAGGGGTGGTATGAATATGAAATGGAAATAAGAAACAACTGTTTTTAATTATAAACCACTGTTC
TTATAAAACTACTTGACATTTTATAAACTATGTACCCAATTTACTTTGAAGAAAATGAAAACCATATATA
TATATATATATATATATATATATATATATATATAATCAACAACAAAAGAAAGGGAATCATGACTTTTACA
CGTACACAGTGTATTATACTGATATGATTTGACTCTGTGTCCCCACCCAAATCTCACCTTGAATTATGAT
AATCCCCACGTGTCATGGGAGAGACTTTATGGGAGGTAATTGAATCATGGGGGACGAGTTTTCCTGCACT
GCTCTCGTGATAGTGAATAAGTCTCATGTGAGCTGATGGTTTTATAAAGGGAAGTTCCCCTGTATATGCT
CTCTTGCCTGCTGCCAGGTAAGATGTAACTTTGCTCCTCACTCACCTTCAGCCATGATTGTGATGCCTCC
CCAGCCATATGAAACTGTGAGTCAATTAAACATATTTCCCTTTTAAATGACCCAGTCTCGGGTATGTCTT
TATTAGGAGCAGGAAAACAGACTAATATATATATCATTTTTCATTTGTTTAATGACTTGTTATTTGTTTA
ATAATTGGAGATACAGTAAGAGATGGAAATCCAAATACACTCATTAATTTTGAATGATAATGGGGAGATA
CTAATTTTGAATAAGGAGGAGGGTGAAATCAAAGACAATTCCTACATTTCCAACTTAAATGACTGAGTGA
ATGCAATGCCACCAAATGAAACAGAAAATATGTTTAAAGGAGTACACAGAAGTTCACATTTGCAGACATG
AGTATTGATACCAACTGACACTTGAATTTAGGGTTGGAATACAAGATATAGGAGTTATCCTACGTAGTAG
TGATACTGTCAACCATTGAGACTTCTCCCTCTGCTTTCAAATTTCTCTATTCCTCTAATGCTTGAGTCAC
TTTTTGGAGTCAGAATTATTTGTTTAGTTAAAACATATTCATAAATAATCTTAGATAATTTGAGATTCAC
TTACCCAATTTTTAGTATACCGTGCTCTGCCTGAAGCAATTCCAAGTCGTTGGAAGAACACCTCAAAATC
ATTTCCAGATCCCAATTTGCTTATCCTTTTAGAGATAAAACAACAGAATTATTTCAAAGTAATTTGTTCA
TTAAGCACAGATTACATGTCCATTAAACTAAACCCCATTCTTACTATTATAAATGTAATTTTAAACATAC
AGCTTTAGACATGCAGCAAAAACATGAAAAGAATATTAATTTTGATCACAAAATATCTCCTTCTATGAGA
CTATTTCGTGTAGGAATGACTATTTTATGTCACATTTTGTTAAAGGTTTCTGAAGTTGGAAAACATTTTC
CTTAAGATTATTTCATTCCATTTATCATCTTTATTTGTTGTACATAATAGAGTGAAAAGCAAATATTTTT
CAGATAATTTGGACATAAATTTTGCCCTTAATAATATAAATAGTGCTGTTGACATCGATAAACTCAGAGC
ACTGAGATATTTATTCTTCTTCCCTTGCTTGTGAAGATACAACCAATGTTGAAATGATGCTTGCATTTTT
ATTGCAATAAGCAAAATATTTGTTAACTATATGATATTCAGAAAAAGGATAATTACAAGGTGATGAGGTG
GCAGAAAAACGAGGAAAATTACTTTTCACCATTATCTCTATCATGGGTTGAGTATCCCTAATCCAAAAAT
CCAAAATCTGTATCAAAACATTTCATGCACCCCAAAAATAAATACACCTACTACATACTCACAAAAATTA
AAGATTAGAACATTTTAAAAAATGCTGCAAAATCCAAAAGTTTTTAAGCACCTACATGACACTGAAAGGA
AATGCTAACTGAAGCATTTCAGATTATGAATTTTCAGATTAGGCATGTTCAACCAGTAAGTATAATGCAA
ATATTCCAAAATCTTAAAAAAATCCAAAGTCCAAAACACTTCTCATCCCACGCATTTCATATAAGAAATG
ACCAATCTTTATAATCTGCTGAAATGTTCCATATGTATATATTACATATTCTAAAGAGAAATCACATTTT
GATATCCTGCAGATTTAACTACAAAACACATAGTAATATTTTATTTGTGAACCAAAGTAATGCTTTTCTT
TATCAGATTTTAGACCATTTTGAAACTTAATTTTTCACTTAATGATTGAAAGAAAATGTGCTTTTATTTT
CAAAACAATCCCACACTGAATTCAGTGGAAACTTCATTCATTTGTTTACCTGGGCATGCCACTGAACTCT
GGGGAAGGACTTTTTTTAGTCCAACTTTCATAAAGAGATTTGCCTTCAAAGCCTTCATCAGGGCTTTTCA
GCTACACAAATTAAAAGAAAAAAAGAGAATACTTACAAATCAGATATATTAAAAACTAGATGTCCATTAA
CCAGAAGTGAGTAACTAAGCCACAATTCAGCAAAAACAAGGGATGCTATCCATACATTAGCAGTCATCAA
GAATTATAAGTTTCTGACAAGTGGGAAAATACTCATGTGATTATATATAGGTGAACTATATTATAAAAAT
AAATGTATGAAGTGCATAGCATAAACAGGCTACACCAAATTCATACCAAGCCATTGTCTTTAGATGAATG
GCATAGCATATGATCTTTTTGTCTATTTTTCTGAATTAAAAGATACTACAGTCAAAACTATTTCTCATCT
CACAACAAAGAAAATAAAAAGAAGTAAGCTGGTTAAGGGTAAGGATTCAATTTAATATTGTTTCTTGCCA
GTAGGGTTGCCAAAGTCATTCAATAATATACAATAAACCGCAATGTCTGTTCTTGTACCAGTATCATGCT
GTTTTGATTACTGTAGCCTCATAGTATAGTTTGATGTCTCCAGCTTTGTTCTTTTTGCTTAGGATTGCCT
TGGTTATATGGGCTCTTTTATGGATCCATATGAATTTTAAAACAGATTTTTCAAATTCTGTGAAGAATGC
CAACAATAGTTTAATAGGAATAGCACTGAATCTATAAATTACTTTGGGCAATATGGCCGTTTTAATGATA
TTGATTCTTCCTATCCATGAGCATGGAATGTTTTTTCCATTTGAATATGTCATCTCTGATTTCTTAGAGC
AGTGGTTTGTAGTTCTCCTTGTAGAGATCTTTCACCTCCTGAGTTAGCTGTATTCATAGGTATTTTGTTC
ATTTTGTGGTAATTGTGAATGAGTGGTAATTTGTGACTTGGCTCTTGGCTTGTCTGTTGTTAGTGTATAG
GAATGCTAGCAATTTTTGTACATTGATTTTGTATCCTGAGACTGCTATAGTTGCTTATCAGCTTAAGGAG
CTTTTGGGCTTTGACAATGGAATTTCCTAGATATAGAATAATGTCATCTGCAAACAGGGATAGTTTGACC
TCCTCTCTTTTTATTTGAATGAGCTTTATTTTTTTATCTTGCCTGATTACCCTGGCCAGCACTTCCAATA
CTATGTTGAATAGGAGTGATTAGAGAAGAATCCTTATTTTGTGTCGGTTTTGAAAAGGACTGCTTGTAGC
TTTGGCCCATTCAGTACGATGTTGGCTGTGGGTTTGTCATATATGGCTCTTATTATTTTGAGGTTTGCTC
CTTCAATACCTAGTTTATTGATAGTTTTTAACATGAAGAGATATTCAATGTTATTGAAAGCTTTTTTCTG
CATTTATTGAGATAATCATGTGGTTTTTGTTTCTAGTTCTGCCTATGTGATTAACTGCATTTATTGATTT
GCATATGTTGAATCAACCTTGCATCCCTGGGATGAAGCCTACTTGATTGTGGTGGATAAGCTTTCTAATG
TGCTGCTGGATTCTGTTTGCCAGTACTTTATTGAGGATTTTTGCATCATTGTTCATCATAGATACTGGCC
TGAATTTTTGTTGCTGTTGTATCTCTGCCAAATTTTGGTATTGGGATGATGCTGGCCTCATAGAATTAGT
TAGGGAGGAGTCTCTCCTCCTAATTATTTGGCAATAGTTTCAATAGAAATAGTACCAGCCCTTCTTTGTA
CCTCTGGTAGAATTAAGCTGTGAATCCATTTGGTCCTTGGCTTTTTTTGGTTGGTAAGCTATTTATTACT
GCCTCAGTTTCAGAACTCATGATTGGCCTGTTCAGGGATTCAATTTCTTTCTGGTTCAGCCTTCAGAAGG
TGTATGTTTCCAGGAATTTATCCTTTTTTTTCTTTTTCCTTTTCTTTTTTTTTTTCTGTTTTTGTTTTGT
TTTGTTTTTTGATGAAGTCTTGCACTGTCACCTGAGCTAGAGTGCAATTGCGCGATCTCTGCTCACTGCA
ACCTCGTTCACGCAATTCTCCTGCTTCAGCCTCCCGAGCAGCTGGGATTACAGGCACCTGCCACCACACC
CAGCTAATTTCCATTTCTTCTAGATTCTTTAGTTTATGTGCATAGAGGTGTTTATAATGTTCTCTGATGT
TTGTATTTCTGTGGGGTCAGTGAGAATATTCCCCCTTATCATTTCTGACGGTGTTTATTTGAATCTTATC
ACTTTTCTTCTTTATTAGTCTAGTTAGCACTCTATTTTTTATTAATTTTTTTCAAAAAATCAGCTCCTGG
ATTCGTTAATATTTTGAAGGGTTTTTCATGTCTCCAACACCTTCAGTTCAGCTGTGGTCTTGGTTACTTT
GTGTCTTTTGCTAGCTTTGGGGTTTGTTTGCTTTTGTTCTCTAGTATATTTAGTTTTGACACTAGGCTGT
TAACTTGAGATCTTTCTAATGTTTTTTTCTTTTTTTTTGAGACGGAGTCTCTCTCTGTTGTCCAGGCTGG
AGTGCAGTGACGTGATCTCAGCTCACTGCAACCTCCACCTCCCGGGTTCAAGCGATTCTCCTGCCTCAGC
CTCCCGAATAGCTGGGACTACAGGCACCCGCCACCACGTCTGGCTAATTTTTTGTATTTTTAGTAGAGAC
GGGGTTTCACTGTGTTTGCCAGGATGGTCTCGATCTCCTGACCTTGTGATCTGCCCTCCTCGGCCTCCCA
AAGTGCTGGGATTACAGGTGTGAGCCACCACACCTGGCCAGATATTTCTAACTTTTAATGTGGGCATTTA
GTGCTATAAATTTCCCTTTTAATTCTGCCTTAGCTGTGTCCCAGAGATTCTGGTGTGTCATATCTTTGTT
CTCATTAGTTTCAAAGAACTTCTTGATTCCTGCTTTTATCTCATTATATACCCACAAGTCATTCAGGAGC
AGGTTATTCAATTTCCATGGAATTGCATAGTTTTGAGTGAATTTCTTACTCTTGATTTTGAATTTGCACG
GCAGTACAAGAGACGTTTTTAATTTCATTTCTTTTGCTTTTGCTGAGGAGTGTTTTACTTCCAATTATGT
GATCAATTTTAGAGTAAGTGCCATGGGCTGATGAGAAGAATGTCTATTCTGTTGTTTCTGGGTGGAGAAT
TTTGTAGATATCTATCAGGTCCATTTGATCCAGTACTCAGTTTAGGCCATGAATATCTTTGTTATTTTAT
GTCTTGAAAATTAATTAATATTTTCAATAGGCTGTTAAAGTCTACCACTATTATTGTGTGGGAGTCTAAG
TCTCTTTGAAGGTCTCTAAGAACTTGCCTTATGAATCTGGGTGCTCCTGTGTTATGTGCATATATATTTA
GGACAGTAAGCTCTTCTTGTTGAATTGAATCCTTTACCGTTACGTGATGCCCTTCTTTGTCTTTTTTTTT
ATCTTTGTTGGTTTAAAGTCTGTTTTGTCAGAAACTAGAATTGCAACTCCTGCATTTTTCTGTTTTCTAT
TTGCTTGGTAGACTTTCCTTCATCTATTTATTTTGACTTATGTGTGTCATTGCATATGAGAAGGGTCTCT
TGAAGACAGGATACCAATAGGTCCTGGTTCTTTATCCAGCTTGCCACTCTATGTATTTTAATTGGTGTAT
TTAGACCATTTACATATAAGATTAGAATTGAAATGTGTGGATTTGATCCTGTCATCATGATGTTAGCTGG
TTATTCTGCAGACTTATGTGATTGCTTTATAGTATCACTGGTCTGTGTACTTCAGTGTGTTTTTGTCGTG
GATGGTGATAGTCTTTCCTGTCCATATTTAGTACTTCTCTCAATAACTCTTGTTAAGACAGGTCTGGTGG
TAACAAATTCCCTCAGCATTTGCTTGTCTTGAAAGAATCTTATTTCTCCTTCACGTATAAAGCTTAATGT
GGTCGGATATGAAATTCTGGATTGGAATTTCTTTTTTCTAAGAATGTTGAACATTGGCCTCCAATCTCTT
CTGGCTTGCAGGGTTTCAGCTGAGAGGTCCACTGTTAGGCTGATGGGCTTCCCTTTGTAGGTAACCTGGC
CTTTCCCTCTAGCTGCCTTTAACATTTTTTCTCTCATTTTGTCCTTGGAGAATCTGATGAGTATGTGTCT
TGGGGATGATCTTCTCAAGTAGTATCTTACTGAGGTTCTCTGCATTTCCTGAATTTGAATGTTGGCCTAT
CTAGCTATGTTGGGAAAGTTCTCATGGATTATATCCTGGAATATGTTTTCCAAGCTGGTTCCATTCTTCC
TATCTCTTTCAAGTACACCAATCAGTCATAGATTCAGTCTCTTCACATAATCACATATTTCTTGGTGGTT
TTGTTCATTCCTTTTTCTCTATTCTTGTCTGCCTGTATTATTTCAGAAAGACAGTCTTCAACTCTAAGAT
TCTTTCCTTCACTTGGTCTATACTGCTATCAATACTTGTGACAGCATTTGTAGTATTTTTCAGCTCTATT
CTTCTCTAAACTGGCTCATTTTACTGTCAGTTCCTGCAATGTTTTAACATGATTTTTAGCTTCCTAGAAT
TGGGTTACAACACGCTCCTTTACCTCAGTAAACTTTGTCCCTATCCATATTATGAATTCTACTTCTGTCA
TTTCAGGCATCTCAGCCTCAACCCGGTTCCGAAACCTTGCTGGAGAAGTGATGCAGTCATTTGGAGGAAA
GAGGGCACTGTGGCATTTTGAGTTTTCAATGTTCTTGTACTGATCCTTTCTCATCTTTGTGGGCTTATCT
GCCTTCAATCTTTGAGGTTGGTGACCTTTGAGTGGAGCTTGTCCTTTTTTTTCTTTTCTTTTTTTTTTTT
TTAAACAGTCTAGCCACTTTTCTGCAGGGCTGCTGTGTTGTGCTGGGGGGTCGACTCCAATCGCTAGTTG
CCTCAGATTTTACAGTACCTGGAGGAATCATCGGTGATGGCTGTGAAACAGTAAAGAATGCAGCCTGCTT
CTTACTGTAGGACCTCCGTCCAAGGGAGTTATAGACATGTTGCCAGCCTGAACAGACCTGTAGGAGGTGG
CTGGAGACCCCACTAGGAGGTCTTACCCAGACAGGAGGAAAAGGATCAGGGACCCAGTTTAAAAAGTAGC
CTGGCCACGTTTTTGTAGAGCAACTGTGCTGTGGTGAGGGTCCACTTCAGCCCTCGGTTGTCTTGGACAC
TCCGAAGTCTGAAACCTGGGATGGCTAAGTCACCCAAACAGCAAAGATGGTGGTTTGCCCCTCCTCCTGG
CAGCTCCATCCCAGGGTGTCCTAAAACCTCTGTTAGCCAGAGAACACCAGTGGGGGTAGCCAGAAACCCT
AGTTGGGAGGCTCCACCCATTGATGAGGAACGTAGTTGGGGATCTGCTTTATAAGGAAGTCTGGCCACGT
TTTTGTGAGGCCACTGTGCTGTGCTGGGGTACCGCTTCCACCCCCAGTCATCTTGGGCTCTCCAAAGCCT
AAAGGTGGGAATGGCTAAGCCACCCAAACAGCAAAGATGGCAGCCCACCCCTCCACCCCCACCTCCCTGC
CCCCCACCACCACCCAAGAGCTCTTTCCCAGATAGGCACAACACTGCTACCAGTGGCTGGCTGGAAATCC
AAGCCAGTGGGTCTTATCCTGTGAAGTGCTGTGGAAGTGGGGCCTGCAGACCATCACTGCTCAGGCCCTT
GAATTCAGCCTCTTTTTTATGGGTATGTATGGGGGTCTAACCTCCTGCTGTGCTGGAGTTGCAGTTACTT
TTGCCATGAAGCCTGGAAAGCTGGTGTATCTAAAGCTCCTGTGTCTCTGTGCATGCCTGAGTGGCTGTTC
TGCTAAGACTCCATGCACCTGTGTATCAGACTGAAGGCCCTGGTGGAGTGGGTTCACAAGGGTATCTGCT
GACCTAAGCGTTGCAAAGATCCATGGAAAAAGCATGGTTTCCTGGGGTTGCACATTCGCTCATCATTTTC
CTGGGTGGGGGAGGTTCCCTTGACTCTGTGTCATTCCCAGGTGGGCCATCGTCCTGCCTTGCTTTTCTCC
ATTCTCCTTGGGTTGGGTTGTTTCCTTGATTAGTCCCAATGTGAGTATCTGCTCGTTTCAGTTGAAGGTG
CTGTATTTACTTGCCCCTTCAATTTCTCTTTGTGAGAGCCACACACCATAGTTGCTTCTAGTCAGTCATC
TTGGTCACTCCTCCATTCCATTCTTTTGAAACCAAAGCTTAATGGCATTTAAATTTTATTTATAATCCCT
ATCTGAAAAAATGTAATTGTGATCTCATCTAGCCTCTGTCCCTGGAAGCCAGCACCTGGTATTCTTATGA
ATATTCTTTCTCAATCAGTTAGAACATTTAATGATTCCTGTGTTCTGAATTAATTGGTATCACTATACTG
AAGAGTATAAACAAGTTTTTTAATTAAGGAGTTGAGCCATAGGACCAAGTCTTGGTTCGGCTACCGTACA
AGTTGTGTGTGACTTTGGTGGCCAATGTTCTTTGAGCTCAGTTTCACTGTTTTAAGAATGGAGATGGTAG
ACATGATGCTACTAATGGGCTACCTCACACTGGTGTGGTGAGAAATGAGGCAATCTGTGTAAACAGTTTA
CTAGATGTGATGGTCTGTGAAGATGTGATGTCATATATGTTATATGAAATGAAGACAAGAAGTTATAAAA
CACCACCTATGTTTAACATAATACCTCAAGAAAACATCATTTGTAGAATTTGGGTTTTCTTAAATTATAT
GTAATTATATACCTCTTTTGTTAGGTTGTGTACCAAGCTGTACATCAGCGGTGTACAATCAACTCTCAGA
GTGTAGTTTCCTGAAAAATAAGAAAAGAATAGATTTTAAAATTTAATTTCTTTCTGTTATTATTTTCTTC
AAAGACCACTGCTAAATTCCTACCAGAATGATTGTTTTAAAACCTGATTTCAACTGTAACTCTCCAATGG
CTTCCCAACTAACTCTGTAAAGTCCATCATTCTCACCATGGCCCACACTGCCATATATGAAACCCTAGGT
CACCTCTCAAAATCTGCATTTTACATTCTGCCCAAGAATACTCCCTCAGCATCTTTGCACACACTGTCCT
TCCAGCCTGGAACAGTATTCTGCATTATATCTGCATGACTTACTCCTCCTCCTCTGGTCTAATGTCATGT
TTTTCTGAGAGATTTCCCCTGATCACCCTACCTAAAATAGCACTCTCTTACCCCCTAATTTTAGCCACTC
TCTCTTTTAACCTTGGCTCTTGTTTCTCTATATTACTCATCTATTTAACATAAAACATATTAAGTACTTG
TCTTTTTATTATTGGCCCTCCCACTAGACGATAAGTCCCCTGGGATAAGGTGCACTCTCTTGTTTGCTGC
CATACCCCAAGTGTTTAGAACAATCCTAGAATCTGGCATTTAACCAATCAATATTTGTTGTAACAATGAA
TTTGTGAACCAGGTGCTCTTCTTAGAGTTTCAGTCCCCATTCCTCAGGAGGGGGCTGGTGGTTGTGACAA
TCAAGTGAAGCACCCAGGAGAGGTGTTCTTGGGAAGCCAACACAGCACAGGGAGGGGCTGCTGACTCAGG
AGGAGTTTTGGGGGAGGGAAGTCAAGACAAATTCACAAACTTGGAGAGGGGACTCTTGAACTGGGTTTTC
TAGAACCAGGACACAGTTGGGGGGAAAAATGGTATTTGCAGCTAAAGGCATAGCCTGTGCGAATGCCCAG
AAATGTAAAAGCACATGAAACACTCAGAGGATGGCAACTAGCTTTTATCCCAAAGCCTCGGATCCATGTT
TGAGAACAGCAAAAGTTGAGGCTTTTAAAATAGTGACACCACAACAGAATTGTTTATGGAACTTAAAGAT
TTGATTTTAGATTCTAAAATTTATCTGGAAGAATAAATATGTACAAACAGCCAATGTAATTTTTAAAACA
GAAGTGCTTATAAGAGTGGAAATTGGGGAGTGGAGTAGTTTGGCAGCATTTATTACAATTTAATTGCCCA
CATCTGAAGACCAAATAAATATACTTGTAGCTCTCTACCCTCTCCTCACATTATACCAAAAAAGCATGCA
AATAAAATAATATTAACCACAACAAACTGAAGCAAGCTGTCCAGCAGCTAGAAAACTGATACAAAATTTG
TCCTATTGAATACATTGTAGATTTTTGTTGTCTGGTGGTAGTGTTTGTTTTTTAAGTGAAACCGAGATAT
GTGCTGATATGGAAAGTTTTTCATAATGTGTTGCTGAATGAAAAAGGCAAGTTGTAGAAGCATTTAGCTG
TAATATGATACCAAATACCTGTATAAGGTGGTGAGAGACAATAGAGTGTAGTGGTTAGAGGGGTAAAGTT
GGAACAGACCAGTCTGATTTGAGTCTAAGCTCAACCCTTCACTAGCTGTGTGGCCTTGGGAAAATTACTT
AACCTCTCTGAGTGTCAGTTTCTTCTTTTATACAAAAGGGATAATAAAAATATTTACTTACTTATCTCAG
AGAGTTATTGTGAGTACTGAATAATTTTTTTACGTGTAAAGCACCTGAGATAGCACCCACTACGCTCTTG
GTGCTTTGTGAAGCTAAATTCTATATATTAATGCCAACATGATGGAAACACCCAAAACTGAGGACAGTAA
TACCTTTGGAGAGAGGACTAAGTTTGAGAGTAGTTTGCATTGGGGAGTTTCGCTTTATTTGTACATTTTA
CATTTTAACATTAGAAATTTCAGAATCTATGATTATTTGTATTATTTGAGAAAGAAACATTAATACAATG
TAAAAATATAAAACAAGTGAGATGAATGGTGTCCCAATCATATAGTACCTCCTGTCCTTTGTTCTCGATT
TTGAAAATTATAGAGACACAATGGAGCAATTTCAAGCCAGGGATGACATAAGTAGCAAAGCTTAATGAGT
TTTTAAAATACATTAAAATATCAAATCTTAAAAAACTATGGCCAAGTATGGTGCCACACACCTGTTTTCC
CAGCTACTTGGGAGGCTGACGGGGGAGGATCAGTTGAGCTCAGGAGTTTGAAACTATCCTGGACAATACT
ACAAGATCTCATTTCAAAACAACAATAACAACAACAACAACAACAAAAAAAAACAGAAAAAAACTATCAA
TAAAGAGAACGTTATTCTATGTTTCAAGAAAATATATTTGGAGTATTTATTCTGGGTGGGCATATAATAT
ACATATATATACATGTATATATTTCACCTTATGTGTTTTAAGTAGGTGTAATGATACTAATCAAAGTTAA
CTTTTTTTGACATTTACTCTGTGCAAGGCACAGGTCTGGGAGATTTGCAAATGTAACTTTTTTTGCCCTT
ACAGGAGCCTTTGAGATAGGAGCTCTTAGAAGTTATATTTAGAAGTGAGAAAACTGAGGCACAGAAAGTA
AGTAGCTTGGGTCACACAAATAGGAAGTTGCAGGGCCAGGAATGAATCCAGGCATCTGACGCCAAAGGTC
AAGCTCTTAGCCACTACCCTAAGAGAAGGAGAAAAGAATAACCAAATGCACTGTGTAAACTAACTTTCAG
AACAGTGTAGCTCAGAGGCATTGACAAAGAAGAAAAGGAAGGTTGGGAGCTGTGGCTCAGACCCGTAATC
CTAGCATTTTGGGAGAACAATGTGGATAGACAGCTTGAGCCCAGGAGTTTGAGACCAACCTGGGTAATAT
GGTCAAATGTCATCTCCACTAAAAATACAAAAATTAGCTGGATGTCTAGCGTTTGCCTGTAGTCCCAGCT
ACCAAGGAGGCTGAGGTTGGAGGATCACTTGAGCCTGGGAAATCAAGACTAGTGAGCCATGATCGCTCCA
CGCACTCCAACCTGGGCTGCGGAGTGAGACCCTGACTCAAAACAAACAAGCAGACAAACAAAAAAACAGA
AGAAGAACAGAAACAGAAAAAAAAAACAAACAAACAAAAAACAGAAAAAGAACAGAAACAAAAAAACACA
CACAAAAAAACCAGAAAAAGAAAATGCCAACGTGACTCCATCAAGGTCTCATGTTCCAAGTGTTGACATG
GCAAATTTACTAATACACTAAAGAAAATATTCTAAAAAATTCCCCCTTCATTCATTTAGTCCTTTTTTTT
TTTTTTTGCAACCATACCACAAATATTTATTTAATAAGACGTTAGGAATCTAGGAGTGAATAAGCAAGAT
ACTGTCTGTTCCTTGTTAAAGAATACAGTCTATTACTTGTAAAACAAATAATTACTTAATAATGACAGTG
ATGAGTGCCATGAAGACATGTCTTCCCTGAAAAAGTAACATTTCAAAGGAGGGTCTAAGGATAAGGATTA
AACACATAAAGAGGTGTTGAAGAGCAATCTGAGTGTAGAGAACAGGAGAGCAATGGCTGGGATGTTGCAT
ATGGTCAAGATATAGATATATTAGTGGAGCTGGATTGTAGTGAAAATGGACTCTTTCATTTTCATGAAAA
TCAATCTGAGATTTCCTTTAGTTTGGTCCTTTGCTTATTAAATATATTTCCATTCTTCAAAGTCAGCCTC
AAATGCCTATTCCCTTTCTCAAGCCTTTCCTGAAGTTTCTATTATTCTTTCCTCTGAACTCCCAGAGTGG
TTTTATCCTACCCTTTCTAAAGTACCTGCATACATTATAATTCAAGATTGATTTAGTATATTATCTATAC
TGAGTGCGCCACCACGCCCGGCTAATTTTTGCATTTGTAATAGCTATGGGGTTTCACCATGTTGGCCAGG
CTGGTTTCGAAATCCTGACCTGAAGTGATCCACCCGCTTCAGCCTCCCAAAGTGCTGCGATTACAGGCGT
GAGCCACCGCACCCCACAAATGATACTTTTTTTCTACACCATTCTAAATTATAGAACTCTTTAGGTCCCT
GAGTTAATCATTCAACAGATACTTACTAAATTCCTGCTGTATATAAAAAGAAATCTGCCAGATGAAGCTA
ATCAAAGAATGCTGCTTTTCTGAATTAGTACTCTATACTTCAAAGCAAAAAAAAAGTAAGAAAAGAAAGA
AAAGAAAAGAGAAAAGAAAACAAAAGGAAAGGAAAGAAGAAAAGAAACACCTGTTCACCTAGGGCTCACC
CAACTCTCAACTAGGGTTCATACACTGCTTCCTGTCAGAGGTTGCAGTAGATTCCCTAACCACACATTAA
TGCATAGCCTTCCTTGTTAGTGCATAATTTATTAACTAGACTGCTGCTCCTAGTTTAATCACATCTTTTC
TTATGAGACCAACGATATTCACCTTCTATAGATGAGTCAGCATTAATATAAGCCACGCCACGCTCTTGAA
GGAGTCTTGAATTCTCCTATAATAAAAAGGAAAACTATAAATATAAAGTTATAACCCACTCCCCCTCCCC
CACAAAATGCACATCTACATTTAATGTATGTAGATTTCTAATTGAGCTGACCCATATTAACGACAAATTT
GACATAAGAAATTCTCATAAAAGAGCTGCTTTGAAAGAATTTCAATAAAGATTACTCGTAGGAAACAACA
AGCAAAACTTGTTAAAAGCTAATATTTAAGATGAAATTGTCCATATACTTATGGTAAGTGGAAAATGAGT
TAATTTCTTAACCATACTGTAGTTTATCTTTCAAAAAGTTGTCTTAGCAAACATGAATGACCTAAGAGAC
TTTTCAGTGAAAATCTTCCTATAAACATCTCATTATTTAAGCAGAGAATCTTGTCTGATTCATATGGAAT
GAAGGTATTTTAAGTGTATGAAATTTTAAGTTAAATTTCATGTTACGAAAAATAAGTGAACTTAAATCAT
CTCCTGACCAGAAGTCAGGCTCTCCTGTAGGATGGTACCATCTCCTGGTCAATATTGATAATTGCACACT
TTTAGAACAAAGCGTAGCAAAGTTTTTTTGAGATATCAATGTGAATTCTGAGTCTCTAAAATACATAATT
TCCTAAGCATTCTGACTATAAGATAAAAAATGAAAAAAATACAACTGTAAGTGAAAAAAATAATTTGAAA
GACACAAATTACACCGTCAAAATATTAGGTTCTTCCAGATAGTGGCAAAATTCTTTCTTATAAAACTTTG
ACTAAGTCTACAGGAGCACCATTTTTTTTTTCAAAGAAAATTAAAGTCCACAGGGTTTCACATAATATCT
GGAGTATGAAAGGAGCCAGTAAATATTTACAGCATGACTGGAAATTAATGGAATAAACATTGACTTTGCA
TATATTTACTTTATAGCTAACGTTTCTGTTATATAAAGCCAACAATACATGCAGGTAAAATTACTTTTCA
AATGGCTTAGTAAATATTCTGTGGTGGAAATTTCTGCCTTACTTTTAGCATAATTTAACATAGAGCAGGT
CATTATGAATTAAGAAAGATAAATGAAAAGTATACCTTACGGCCAGGCATGGTGACGCACGCCTGTATTC
CTAGCACTTTGGGAGGCCGAGGCAGGCATATCACTTAAGCTCAGGAGTTTGAGGCCAGCCTGGCCAACAC
AGCAAAACCCTGTCTCTATTAAACATAAAAAAATTAGCCAGGTGTGGTGGCACATGCCTGTAATCCCAGC
TACTCAGGAGCCTAGGGCAGGAGAATTGCTTGAACCCGGGATGCTGACGCTTCAGTGAGCAGAAATCACA
TCACTGTACTCCAGCCTGGGCAACAGAGCGAGACTCTGTATAGTTAGCTTTAGGAGATATTTTGGAAAGC
GTAATAGAATCATGATAGAAATCAAACATGATACAGGAAAATTTGGCTTCATGGTCAGGAAATAGAGACA
ATTTAACTTCATATTTTTCATAAATTTGAAATAGCTTAATTCCCTTTGAATCAGACAAGATTCTCCATTT
AAATGACATGTTTATGGCAAGATATTCACTGAAAAGTCTGTTAAGTCGTTCATGTTTGCTAAGACAATAT
TTTGAAGAATAAACTACAATATGATTAAGAAACTAACTCCTTGTTTTGATGTTTGGTTTCTAGCATATCT
ACTTATTTACTCTCATACTCCCAGGAAATAAAGATAAATTAATTTTGACAATTGACATTAAGTGGCTCTA
AAAGGTTCAAACAAAACTTAGTTCTTTAGCAACAGAGATTTTTATTGCTGATTTTTGAACAAGAATATGT
TACTTCAGATTTTGGGGAAAAAACTTTGAATACTTTCTCATTATATTCACTTCTTATTTTTATGTGCTTG
GCAAATAAGTCCTGGCTACTTTATTTTATAAAAATTTATATTATAGCAAATTACCAACTAACCTCTGCCC
ACTCAGTAGAACCAAGAAGACCAAATTCTTCTGCATCCCAGCTTGCAAACAAAATTGTTCTTCTAGGTCT
CCACCCTAAAATGTATGTGTATATATAAATGATAGAAAAAAAATTCATAATATACCCAGGACACTACCAA
GCCCAGATTGGAAAAAAAAAAAAAAAAGTCATTGATGGTTTGGGAAGGGCAAATTGTAGTAAAAAATCTT
TACTTACGTAACTTTTTTTGTAAGATTTTAAAGTTGTCAATACAAAATAGCACAATTACATAGAAAAGGG
GGGACATGTGACAGTAAAAATCTTGCAAGATCATAAAACATTCTAATAGGTTTATAATGATTCGCTATGC
ATAGGAAGTCATTGGTGGTCTGCAACTGCCTAGAACAAAGAAAGAAATTTCTAGATGCATTTGGTATTCT
GAAAGCAGATATAACTGAAAGAAAATCCTTTAGAACTCTTTCCTGTTGTTCTGACATCAAATGAACAATT
GTTCAATATCAGCTGGTCCGTATGATTTCACACCATTCTCTGCCAGAATTAATCAACAAGGGCTCAGTTA
GCAACAGCAATGTTTGCTGTTGCTGAAAACCACATAATTCAGCAGAGGGGTGATGTGTCTCGGAGGTTAT
AAACACTGACCTTGGAGTTAAGGCAAGATCTTGTTTCAAACCCTGGTTCTCTCACTAGCAGCGTGACTGA
GGGAAAGTTATTCAAACCTACTAAACTTCCATTTCTTCATCTGTATACAAGGAACAAGAGAGTAAAGATG
AAGACACCACTTGATTGTGGGAGGATTAAATGGAATAATGTTTAGAAAGCACTGAGTAGGTGCTTTCAAA
ATTGCGAGTAGTCATCATCTTAGTAAATATTCATGTGTGCTTAAGAATGTGTATACTATAGCTGTTAACT
CGAGTCTTTTGTTTTTGTCAATAGTATTATTCAAATTTCCTATTATTATTCATCAGCATTCCATTTCTTT
GGCATATTCTGTAATTGTCACAGTGATGTTTTGTATAGTTACCACAGGAATTTCCTAGAAAAATCATGAA
ACATTTTTGTAATAAAATTAAACACTACCTACTTCATGAATTATGTAAATTTAGGTCTCCATTGTTTGTT
TTCTTCAAATATAAGATAGCTGTGTAGAAAAAAGAACTGAGCGCCTTTACATTTTATTTTAAATAGAGAC
ATCATGGTTTTGAGGACTGGTAGTGAGAAATTTGAGTTTCAGCCCTGATTCTCTTATGCTGCCACATGCT
AGCTACATAATCCTGGGGAAATTACTTGATTCTCTAAACCTTGGTTAACCTATCTGTAACATGAGAAGAT
AAGTAAATATGTCTTCTCCCTAGTTGCTATGACTTCAAAGAAGATAGGACATATAAAAAGTTTCTCAAAA
AAAAAGTAAATACTATGCAAACAACATACATTATTGTTTTTATGGTTGATAAAAATATATAGATTACATT
TTACAGCCCCAGACACCTTGTTTGCAGGGTCAATAAAGAGAATGAACTTCCTGCTCTCAATGTGTAATTA
TTATTTTAAAAAGCAAACATTTGAACTAAATTTTACTTTGGCTTTCATATGAAGATTCTAAAATGACTAA
AGTGGTGATGTTACGAGTGTAAACCTAATTTTTGTGAGAGCACACCAGGGCTCAGGATGTGAGAACACAG
ATTCCAAACTTTTGACAGAATCCCATTAGACCTAAGACCTGTATTTCTCTGAATAGAGCATCTATCTCCT
TAATTACTTTGTACACGTAATCTGAGGTCTGGGGTTAGAAGAGACGGAGGAACGTCTGCTTACAGTCTCT
GACTAGGAAGCTTTGGCTTATAATCTAATTTCAGTGTGTTTTCTCTAGTGATGTAACCCATCTTCATCTT
CTTAGTTGCCAAGAACAACCATTAACAGTATAATTCCTTTATTTCAGATTATCACTTAATACATAAATAT
CAATAATATATGTGTTATATAAATAAATGCAAAAATAAATAAACAATATAATTAACCAACCAACACTGAA
AATTGTATTAGTATTTTTACCAAACACATGTAATGGTTGAGGTAGTATTTTTATACTCCCTTTACAGAAG
ACTAAACTGAGACTCAGATAGGCTGTTTTTTTTCTTGCTGTTTGTTTGTATTACCTTCCTTTTTCAGTGT
TCCAAAGCTCCTCACAATTTCATGAACAACAGCTGCTCCACTCTGAGGGTCAATACCACCAAACACCCAT
GAGTCCCGGTGACCTCCCAGAATGACATATCTGTCTAGAAAGCATAGATACAAGATTATTTGTCATTTCA
GGTCAATAAAAGAGAAAATTGCAAATGACTCAATAGCATCTAAATACAAAGCACTCACGCCTCAGAAAAA
AAAAAAAGGCTAGGTTCCCCAAGATTTGTGAAAATATGTTATTTCTGATTTTAATATGTGTTTCTTCTAT
CTGAGAAAGCATAAATGTGATAAAGCAAATATATATTTCAATGTATTACTATAATTATAAGTACTACATT
AAGTAATTAAGAAAGTTTAAGGTTATCCTTGTTCACATTTTTTGTAACTCTATTACTTCTCTTACCTAAC
TTACCACTTTCTAATATATTCAAAGTAAGAGAACATAGTGGCCACATAGGAAGTTCTCCAATTCCTATTC
TTTCTATTCAGTTTTTAAGGTACAGCTCAAATATTTTCTCCCTCCATTCAGTTTTTAAGGTACAGCTCAA
ATATTTTCTCCCTCTATGCAGTTTTTAAAGTACAGCTCAAGTATTTTCTATAGAAGAGGGAATTTCTTTG
CCTACCCAGCTCTCAGGAGTGATAAAGCATTGATCACCCTTAAGCATATGGCTCCCTTCACAAACTGTCA
GTTGTTTGTCTTGGGTCTGTGTCTTCTTTTATCTCCCCATTTCCAATGCTTATCATGGAACTGGCACAAA
ATAGGTACTCGGTATTATTCAACAGTAGCCACTTATATATTGTTTAGTACTCTTTAGAATATGCAAACAA
CAAGGATATCAATATTCTTGATCTAAAATAAATCACTGGCTGCTTGTAAGAAACATGCAATTAATATGTT
TAATATGCATTTAATAGTATCTGTTTTGGTAAGAAATACAGAACAAAATAGTTCATAAGAAACTGAGCCT
TCATGAACTAAGACTATGTATAAAATGTATTAATCAGTAGATCATCTGAACTTCTATGGAAATCATATGT
CCATATATTTTATCAGTGGCTTTAGTGGTAGAAAATAAAACTATGAAAGGATTCATTAATACAAGATTAT
CTTAATTTTCTAAGAGTGTGATATTTTATATAGATGTTTATAGTTATCATGAAGATATTTATGCAAAAAT
ATGGTAAAAAAAAATTCAGAAAACTCGGAAGAAAACACATCTTTCCCTACCCTGCTTCCCTTGATCCTTT
AATTGAGGCCTGCACAATTTATCATTCACCTTGGTCATCTGCCCAGCCTAGCACCAAACATTCACTTTTA
TTCACCACCTGTACCACAATACAAAATTATTTCATACTTATTTCCTTTGTTTTTAGGTGAGTTCCACCGA
TTTTCTTCGTTTGTTTGTTTGTTTGTTTGTTTTGATTCACTTTGCACTCCCAGAGCTTGGTAGTATCCAG
CACATAACAGTTACTTGATCAATATTTGCTAAGCAAACGATTCCTTTACCTGGTTCCACTGCTCCTCTGA
GAGTACCTATCACATTGTAAATTCTTGTCACTTCATTGGTAGAGTGGATGTGCATCTTGACTTTTCTAAT
GCAAAAATAAAAGACATTCTTAAAAAAAAAAACTGGTTAACAGATTAACACTATAAGGTTTAAGGGAATT
TTCCCCTCTGCCTTTGAAGGTTCAAGTCTGGTAAAATAAACTGAAAACTGATTAACAGGAGAAAAGGCAT
ACAAACTTACTAACACACCAGTGTATACAGGAGCCAAACAAAATATGAGACTCAAACAAAGGCCAAATGG
CTAAAGTTTAACTAGCACCCTCTTCATAGAGGAGGGGGAAGTGGGGGAGTGCAGGTGGTTTTGAGGGGTG
GTAAATGGTTTTCAAGAGAGTTAAATGGGCCCAAAGAGCAGGCAATAGTTTATAAATAATTCTCTTTGGA
ACTTGAATGGAACTAGAGAACAGTCAACAGCTTGTGACAAAGCCTGTGCAGATAAAGTGATATGCCTCAG
TCTTCCTTCCCACTACATGAGTTCAATCTTCCCTGGTTAATAAAATTTCAGGGAGGGGAAGGAAAGTCAT
TGTCTTCCTTCTGCAGGAGCTTCAGATAAGGGAACTTCAGAGAGAAACTTACACTCTGCTCTTGTGGGGT
GAAGTAAGAGGTCAGAATTATTGATTCTGAAGCTGCATCTAAGGACTTTTATCCTTTAGTTCAAAGTGCT
CAGCATGTCAAAACACCATACTTTGGGTTATTCATTTTCTGAGTTCCAGCAACACTCATAATTTTTAAAT
CTTCAATCTTGCTTAAAGATTTCTAATTGTTCACAGGCAAAAATTACACTGGTTCTAACTTGCAGTTTTG
TTTCCTGCTGGTATTACATAAATTTTACTTTTTCTGTCATCCTCTATAGTATTTTTTTCTTTAAGTCTCC
CCCTTAAAAGAGTTAAAATTAAAATAGTCTCTTAACTGTGTAGAAAAGTTTCCAGTAAAGCCAGGTCCAA
CATTGTAGGGCACTTTGAGACTTCCTCTCCAGCTGCTATCTGGTGGTGCTGAGCCACCCATTTTTCTATT
GGACACAAAAAAACATTATTAGCCACAAAAAAACCTTGAAGTAACGCATTAAAATGTTAATGGATTCACT
TTATTGAGCATCTGCTCATAATATCTTTAATGAGTGCAAAGTGCTTTGAATATAATACGTCATTTAAACC
TTACCATAATTCTGAGGAATTGCTACCTCCACTTCACAGATGGGGCACAGGAGGCTTAGATAACATGCCC
AAAGTCATGCAACTAGTAAATGGTATAATTAAGATTCAAATTATTGATAAGAATTTGATCTGCCTTACCA
GTATCTAGTAGTAAATCTAAAAGTGCTTTCCAGAGCATGTGCTGAAGAAAGAGCTTGATGTCTAACTCTC
TGAAATTTTCCATTCTTATTTGTCTCACTGGTATATAGTTATTTTTTACAAAGTACTTTCATACACACCT
ACTAAGAAGACAGGAGGATCAAAAGAAAGGATTTCATTTCAGAAGCCCCTAAAAGCTTCACGCTATTTTT
TAAAATTCAGAAATAAAGATTCAGGCAGACCACCCAGTATATGCCATGGTCCCTGGTTATCTTTCAGCAG
GTGACTGAGAAAGAAAACATGGTAATGTTTATGAAATGGTGGGGTTCTTGTAGTTTCACTTCAACATATC
TGCCTTTACTGTATTAAGATGATGGATTAACTTATTCTTGATATGGGCATGTAAAACAATATACTTTTAC
TAAACAGCTACAGAGAGACAAATGTGTTTCCAGACAAACTTAAGAGACTGAGTGTTCAAACTGAATAATC
TCGACCTTAATTGTAACTATATTTTTATGAAAATCCAGCTGTAAGGCAAAAACAGACTTCTTTGGGCCTA
CCACGGGCATTTTGTTCCTTAACAATACTCCAAACCTTAAACCCAGCTCCACTTAAATAATGGCCTGGAA
AAATAAATGTCATTATCTGATATTATACTGAGATGTTTAGTTATGAAATCAAAAGTGGAGAATTTCAATC
TGTCCTGTAAGGCTTTCTCTGCGGTCACGCACCCTCATGCACTCCAGGCTGTGCGGTGCAGCATGCTCTG
TCATGTCCTGTTTTCTTCTGTGCCTGTACACGGGTGCTTGTTCCCTGTCTACCTGTTTGAGGAAATATGA
ATAGCTCAACTTAACCTAGAATCTACTGCACATGCAATAAGGAAACAATCAGTAAGATCACTTTCTCGTG
GAAAATTCATTAGAATTAACATCTCGTTTTAAAATGCTCTATCAAAGTGTAAATAATTCCTCTCTCTTTT
CCCTTTTTCACTAAGGAGTTTGTATATTAAACAGAATTTCAAGTAATGTATTATAAAATTTATTTAAACT
ATTTACAATAAAATGCCACGTATAAAGCATCAAGCAACATGAAGAGGCATTTTACATTGGTAGAAAGCAC
AATACATAGCCAAAACAGCAGAGTATTAAATAAACAGAAAATTTGCAAAAGGCAAGTAAAGAATATACAT
ATACTTAATTATACATAAAATATTGATACAGGAGGTAGAAAGAAATTTAGTAAGCAGATAATGGGGGCAA
CAGAGTCCTCAGCAGAGCTTCCCTTCTAACAAAAAGCAGCCCAATAAATTATTTTTTTTTTCTAACAAAA
AGCAGCCTGAAAAATCGAGCTGCAAACATAGATTAGCAAGCTGAAAGTGCGGGAGAATGCTGGCAGCTGT
GCCAATAGTAAAGGGCTACCTGGAGCCGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGG
CGAGGCAAGCGGATCACCTGAGGTCGGGAGTTTGAGATCAGCCCGACCAACATGGAGAAACCCCGTCTCT
ACTAAAAAAAAAAAAAAAAAAAGGCAAAAAATGAGCCGGGCATGGTGGCACATGCCTGTAATCCCAGCTA
TTTGGGAGGCTGAGGCAGGAGAATCACTTGAACCTGGGAGGTAGAGATTGCGGTGAAGCGAGATCACGTC
ATTGCACTCCAGCCTGGGCAAAAAGAGCAAAACTCAGTCTCAAAAAAAAAAAAACAAAAGAAAAAAAAGG
CTACCTGGGGGCCAGGCATGTACACATAGAGGGTCTATCTTCCGTGGTTTTGTTATCACATGCACAGTAA
CAGAGAAATGAGCACTATGACGCAGCTCAGGCAGAGAACTCACCTGAAGAATAAAAGATTAGGGTGGGGC
CACCAGAAATTCACACCCTATGCAAATGACACACCTGGTCTAACCAGTTTGTCCATGACTTATATAAATC
AGACACTACCTCTTCACCAGCTCATCTATAAAACCCTCTGCATTTTGCAGTGGACCAGCAACACACTTTT
TCCGGGACCTCTCTCTGCAGCAGAGAACTATGCTAATACACTATAAACTAATAACATCAGTTGCTTTGGG
GGTGTAAATGGATGAGAGGAAAACTTTACTATAAATCCTTTTGAATTGTGAACTTTGTAAATGTATTTCC
TTTTCAGAATAAAAATTAATAGTCCATATTTCCATAAAACAACACAATATAAAACCACGATTGTAGTGTC
CCCACAAGGAGGTAGACAAATAACTAGAAGAGAACATAATAATAGTTATATATAAGAATCTAATATACCA
ATGAAAAAAATAATGCACATACATGGAGAAGTTTCAGTTGAAAAATGTTACTGAAATTTCTCTTTAGGTT
CTCTTTAGGTTCTCTTTAGAAATAAATCTCTTTAGGTCATTTTCTCACTTTATAAATAAAAAATAAATTC
CACAAATATTTAATAGTTGAATATTAAAATTTCAAACCACAAAAATATTAGAAAGTACCATTAAATGTTG
GAAAATGTCTCCGAACATATTTGGTAGATGGTAGATGTCCAGTAATTAATGTATAGACAGTATTGAGTTT
ATAATTCTGTATCTTGTAGCATATTAATTTTGATTTGACAATTTGGAGAAGACTTGTTGTCTACTATGTT
TAAGGCACTGTGTTTTATTCACTAAAAAATATAAATATATACAAGACTCAGTCTTTCCACCAAAGAGTTT
ATAAATCACTCAGAAGAAAATACATATAAAACCAATCATAATATAAAACAGAACATCACAGAGCAAAGGT
AAAATTCTAAAAAATTTGGACAAAAGAAAGCTTGAATCAGCTTGTGAGATCAGGAATTACTTTCTAAAGA
AGGTTTCACTTGATCTGGATTTTAAAGATGAATAAGGGCCGGGCATGGAAAAATGAGGGCGAAGAGCCTT
CCAGGCACAGAGGCAGGCAAGCATAGAGCAAGTGTAAGGCATGATGACTATTCTGGCTGGGATATAAAAT
GACTAAGATTCCTTGAGAAAGAAATTGAAAAATAGTGTAACTCAAGTGCACATGGAGCATTTTTCATAAT
AAATCACGTCTGTAAAACGAGCCTGGATAAATTTAAAAGGTTGAAATTATACAATCATTTTATTACTCAT
ATACTTCTTTTACTAATCCAACCACAATAAAAGGAATTTAGCAATCAATAACAAAAGTAAATTTAGGAAA
TTCACAAATATATGGAAATTAAACAACTAACTCCTAAATAACCAATGGGTCAAAGAAGAACTTGCAAATA
CAATTTAAAAATGCTTTGAGATGAATGAAAATGAAGACACAACATACCAATATTTATGAGATGCAGCAAA
AACAGTGCTTAAAGGAAAATACATAGCTGTAAACACCTATATAGAAAGAATCTCAAATCATTAAGCTAAG
CTTTCACCTTAAGAAACTGGACAAAGAAAACTAAACTAAACTCTAAAGCATAAGAAAGGAAATTACAAAG
ATTGAAAGAGAAATAATAAAATAAATAGAGAAAATCAATGAAACCAAGGGTGATTCTTTAAAAAGATCAA
CAAAATCAGCAAACCATTAGTTAAACTGACCAAGTTTAAAAAGTAATTACTAAAATCAAGAATACAAGAT
AGGACATTACTACTGACTTTACCTAATTCCTACTTCTACCACAGTGCCTGAAATATAAAAGTCATTCTAT
AAATGTTTCTTGAGTGAGTGGGCTGTGAGACGCCATTAAAGGTCTCCCGAGCAGAGGCATAAGAATGAGC
CAATACTATAATCAACAGAGGTGGCTACTAAATGCTTGCGTCATTGAGTAGAGAGTAAGTAGTGTTTACC
AAAGTGTCTTTTGCATCAGACATCAATTTGGGCCCCGGCTCTCTCACTTACTCTCTGAACATTGGTTACA
ATGAGTATCACAATACTAACTCATATTGTTGTTTTATAGGTTAATTGAGGAGATGTGTGTAAAGCATTTA
GCACAACAGTAAGTGCTAAAGCGTAATTAGCCCTCCATGCAGGATACATGCTATTACTGTTGCCGTTGGC
ACTATAATTATCGTCCTGGAAGTTACTGTAGAAGGCAAATTAAAACCACATAATCACACTGTGTTCAGGG
TACATGTAAAGAAAAATAGGAAACAGTATATATGGTGTCCCCTTTCTGTCCCACTCAAGTCAACATTGAA
GTTTTTAACATCACTCACATTTCATCAACTTTTTATTTAAGTTCTCAGCATTCTTCGGCCATTATATGAC
TTTATATCTCTCCTCATTTACTCACACATTTATTAATAAACTTTTATTTCATGATATATTCCATTTGTAA
AACACTGTCTTTTCTAATTAGTGCACAATGCTAAACTGCTAACCACTTGAGAGAACCTCAGAATTGAGTA
TCTTGGCACACTCCCAAGGTACGTGTGCCAAGAGAGTAAATTTTCACAGTGAAATTCATAAACAAACCAT
ATGTTCTTTTAAACAATTTTTTAAAACTAAATTCCACTTATATGGACTGTTTCATTATGGCTTAGAAAGT
ATAGGTGGATAAATAGTGTCTATTTTTAATTATGAAATTTTGAATGTAAAATGCACTTTTTCATGAAAGT
TATGTTATTAACGGTGATTGTATTTGTAAAATGGCTTACAGAGGCTGACACAGTAATGTCAGATGAATTG
TGTTTGTTATTTTTCAATCAATCAGATAATTCCATTACACAATCAGAGCACAGCTGATATTGACCTAGTA
AACCAGACCAAATCGTAGACGTCTAAATAAATCTCACATCTAATTCCATAATATTATGCATCCCTCTTTT
GTAATTACAAAGATAATACAGGTTCATGTTTTAAATTTTTTTTTTTTTTTTTTGAGACGGAGTCTCACTC
TGTCGCCCAGGCTAGAATGCAGTGGCGCGATCTCGGCTCACTGCAACCTCTGCCTCCCGGGTTCAAGTGA
TTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGACTACAGGCATGCACCAGCATGCCCAGCTAATTTTTGTA
TTTTTAGTACGGACGGGGTTTCACTGACCATGTTGGCGAGGATGGTCCCCATCTCTTGACCTCATGATCT
GCTCGCCTCGGCCTCCCAAAGTGCTGGGATTACAAGTGTGAGCCACCGCGCCCAGCCCCATGTTTTAATT
TTTTATAAAACTGAGATAATACTATATATATATAGTTTTGAAATTTGCTTTTCTTCACTTAATAATATAA
GCATTTTTCTATATTATTAATTATTCTGGTACTACATATAATATCTTTTAATCACTTCATTTACTATCAG
AGTAATTAATGTATTATTCGAGTACATATAAATTGTTGAAGATTTGTGTTGTCTACAGTTTTCCACTATT
ACAAGTAATGCTAAAATCACTTTTATCTTTTAAATGTCATGAATACTTAGTCTTTATTTATACATATTTT
TAGGCAAATGCATAGTCTATGGTGCTATCAAAAGTTGTGCCTGGTCCTGAATCTTAACCAATGCAGTAAA
TCTTATAGCCCCAAGGAAGAAAGACCAGGGTACTTTCTTAATCTGCCCTTAAATTGAACAGATGTGTCCT
ACTCCCCAGACGTCAGCCTCCTCACCTCTAAAAATGAGTGCCTTGCCCTTGGTCAAAAAGTGCTTCCTCA
TAGATACTGGAATAAAATTAGTAAGAAAGGCTTGAACTTAAAGAAGAAAAGGGACTACCTGGCCAGACGC
TTTGGTCTCTATCAATTTCACTTTTAGAAAAGCCAGTGTTCTCTCACCTCTAAAGAATAATGGTGGCTGG
GCGCAGTGCCTCATGCCTGTAATCTCAGCACTTTGGGAGGCCAAGGAGGGCGGATCACCTGCGGTCAGGA
GTTCGAGACCAGCCTGATCAGCATGGTGAAACCCCATCTCTACTAAAAATACAAAAATCAGCCGGGCATA
GTGGTGGGCACCTGTAATCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATCACTTGAACCCAGGAGGCGG
GGGTTGCAGTGAGCCAAGATTGCACCATTGCACTCCAGCCTGGGCAACAGAGTGAGACACTGTCTCAAAA
AAAAAAAAAAAAAAAAAAAGGACATGGCAATGGGAGAAAGCAGCACAGGGAAGAGGAAACAGTTCCAATG
CCAGGTTAAGCAGAACAAATCTGGGAAAGTTTCAATAATGAAAGCAGAAAGTTTCAATAATGAAAGCAGA
AGGGGAAGAAGAATAGAGATAAAAACAAAATGGAAGTTGCTCTCATAGTGTGTTATTCTGGGTCCTCCCA
GACGTAGCCAGTAAGAGGAATACATGAGTAAGAGATTTACTAGGGAAAAGCATGTGTGGAAAATGAGGAG
AGAGCTAGGAAACCCTGAGAAAGTCCTTAGACTGCAAGGTAGGTCTAATATTGAATAAAGGAAAAAGGGA
GGAGGAAAAGAAAGAGGAGTGTTGGGTGCAGCATCTATTTAAGCGAGGCTATCAAGGAGTCCCTGGGCCA
AAGTTTTGCATCAGAGGAGTCCAGTGCCTTCCAGAAACAGGCCTGCAGTAGTATCCTTGCCACACTGAGT
CATTGCCCGAGAACACCTACAGGAAGCATGGTCTTGACAAAAATATAGTGGGGTTTCAAAGCACAATGTC
TGGAGCAATTGATCAATTAGGTTCCCTGAAGTTAAACATCTGAAAGGTTCATTTTCATGGCTGTCATACA
CTAGATACTCATGTATATACTAAATTCCAGAACAGAACCACTCTTCTATTTTATACTGATAAAATTACAA
GCAACACCCATGTTGGAAAATTTAAGTACTAAAAAATGGAGATAAAAGCCTAACATTTGAAAACTGTCAA
TAAGAAAATTACCCAAATAGCCATCCATGGTTTCTTACAAACTTACTCTAGGAGCTTCTGTGCATCATAG
TATCCAATTGGATGAACAGGAATACTTGGAAGACCAACAGCCTCTGCAATTCCACGCCTATAAGCATATT
CTGAAAAAAAAAATTGCCATATTTCCAGTAAAAACTCAGTTTCATTCAAACGGTTCTCTATAAATCACAT
TAAATACATTCTAATTTCACATTTGCTAGAATTGTTAAAGTAAAACAGATTAACAATTCAAATGTTAGCG
AGAATGCAGAGCAACTGAAATCCTCATACATTGCTTGTGATAATCTAGGCTAAAATTATACAATCACTTA
AGGTAACTCTTTTGAAAAGCAATGTCAAGCAGAAATGTGCACTATGGCACAGCAATTCCACTCCTGGGTA
CTCTAGAAAGATGAGCACATGCCCACAAGAAGACGTGTACAAAATTGTTCATAACAGCCACATTTATATT
AGCCAAATATTAGACAAAGTCTAGGTTTCTAACAACAGAAGAATGAATAAACAATCCGTAGTATAATCCC
ACAATGGAATGCTACTCAATCATCAAAAGAAAAAAACTAATACATACAATATGATAGAAAATCTCAAATT
ACTACACTGAAATAAGCAAGGCTTTAAAAAAAAATCTACTGTTTGATTCCACTTACTTGAAGTTCAAACC
CAGGCAAACGAATACACGATGCTAGATACTAGATAGTGATTGCTTCTAGGGGACACAGAGAAAATTGACC
AGAAAGGGGTACAAAAGAACTTTCCAGAGTGATGGAAAGGCCCTTATATTCTATTTTAAGTGACATAAAC
ACATGCAATTTGCAAAATTTATTGAACTGAACTCTTGAGATCTATGTATTTTATTGCATGTAAACTGTAC
CTCAAAATAAGCACACACATCCTATCATTTCTTCAGACTTAAGAAAAATCAGAGTTGTTTTTCCATTTTT
TTCTCTGTTTTTAAAACAATCTAATAAGAAACTTAGGTAACTGCAAATCCTTGTTTTTATGGGTAAAATG
ACACAATGATATGCTGTGTGGGATTTGTTTTCAAATTCTTTAGAATAATAGCAAAATAAAATTGGAGAGA
TAAACAAATAAAACAAGATTGACAACATGTTGATGACTGTCTCTACTTTTGTATATGTTAGAATTATGCC
ATAATAAAAAGTAAAATTAGAAAGAAAATAAAAATGTATAGAGCACAAAATATAATTCAATAAACATTAG
CCCCATAGAAATAACATAATTTCTCCCTAAAATACCATCATTCAAATTTGAAGAAAATCAACAGAAACAT
TCCAGTTAATCTCATTTTATTTTCATTATTTTGACTTTGCATAACTAATAAAGCTTAGGCTAAGCTGCAT
TTTTTAAAACTTGGAAATAAAAAGGTGGAGCAAATGAAGTTCAGGTAGATTTATATAATTTTACTATAGG
GTAATATGTGTCATTTTTTAAAAAAGAAAAAAATCTCTGACAATGTATTATGTTCTAAGAAGATTTACAA
AGCCAAAAAAAATACATACTCTTTACAGGAGTCTACAATTTAAGAGTAAAACCAGATGAAGACATAAATG
TCATAGAAAACTTGGCAAAGTATTTTATACAAGTTTTAAAAATTTAGTTAGCTTTAAACCACACAAACTT
AATGATCACAGATTTTTGTAAACATCATTAAATAGTTGAGCACATTCAAAATAAATTAGCTCCCTTTGTT
AATGTTTTACAGGGGAGCCTTTCAGCATAAGACTACTATGTGGACTCTGTGAGCCAGACTGCCTGAATTT
GAATCCAACTGCCCATTCAGAGGAGGGGTGATCTTGGGCTGACTTCTAGTCTCACTTTCCTCCCTGTGAA
TAAGAGATAATAACACCCCCTAGCTTTAGGGTTGTTAATGCAAGTAAAATGCTGGCATTTAGGAAACACT
CTTTGAAAGTTATCTCTGTTATCTTACAGAAATGAAGCAATATGCATTTCCTGGGCCCTATATCCTAAAT
TGGCCATTTAAAAAGTTTATGGAACTTCTGCTCTCCTGTCCCTTACCCACACTGTGAAATCTGTAAATCT
GGGGGGAATTTATTTAACAGCAAAACCTGATCTGACCTGAACTCATTTGAAAGCAAAATTTGACTTGAGT
AGACATAAGTCTGTTTATATTCCTTATTCCCCGCCCCCCACTTACTACTTAGCGTAAGTATTCATACACT
CTGCAACAAAAATATTTATATACTTTTTCCCCATATTCTGTCCCAGCCCCCTATGTCACTGTTATGCAAG
TTATGGTATATGTGTAACACCATAATGTTTTTTAAATAGCTGAATAAGTCTGAATTTGAAAGCCCACCAG
GCCCAAGTTTCAAAATAAGGGGGTAAGGGGCCTGAACCAATCACTTTAGAGTTCAAAATTCTTTCATTCT
TAAATGCAAAGAGAATAAAAAAAGACATGCTTAGTCCATTGTACCAAAGGAAATTCTTTAATAAAGTCTC
TTTCAAATGTTAAGTTTCCTATGATATTCAAGGATTGATCATTCACCATTTGCTGGGTAACCTGGTGTGA
GAGGGTCTCCTGCACCATTCAGATTTAGGATATTTCCACGCTGGACACCACCTCCAGGAAGATTCCAACC
ATCTGGATAGGACTTCACCCCAGGAGCAAAGTAGTCAGCAGGGTCGGAGTAGAGAATGACTCCTTTGGCC
CCTGCCAGCTGGGCATTTTTAACCTAGAAAACACAGTGTCTTTCTTTCCTTATTTTAAATTGGTTGTTCC
AGATTCGGTAATATCAATTTTCAATATTACACTTAAATGAGTACCAGAACTTTATCTTCAACCTTTTCTC
ATTAGGCCTACAACAAAGGACATCTCGGATAGAATTTCCCTTTTCTTTTTGCTACTATAAGCTCTAAAAA
TCCTCAGAACATCAGATTTAGAAATGTTCTTATTAGTGGTAGTGAGCATTTGCTATTTCCTACCACTAGC
TTACAAATATAATAAGCAAGTAGACCCCACAGGCCAAATTCCTATTTGTTCTACAGTCGAAAGGGAATTT
TTTAAAATTTAATTTCCCACTAAAGAGAAAAATATATTAACAAATCAAATGACAGTAATTTTTAAATTTG
CTATGTGTAAATTGTTTTCCCTCATTATTTATAACAATTCATACTACAATTTAATTTAGTAAACATTTTT
GTAGAAAATATTTAAAACAAAGATACTGAAAGTTAATAATAAACCCAGTGCATGCTTCTTTGTAGGCCAC
AGCCATAACCTGTAAGCACAGAAAAATTTGTTCTGTTCACTCTAAACATCTACACTGGCCAAATTCCAAT
GCTCGAATTTAACCCCGGGATATAACCTAGTAAATGTGTCCTCTCTGTAAGGTGGGCATGTCACAGAATA
CAAGAAAATAATGGTATTCATAAAGTTTTAAGAAAATGATTCTACACATGTAAAACCCACTATAACTTTT
TACATTGGGGGAGAGAAAAAAAGAGATAATTTTTACCTTACCTTATTTCCTCTGAAAACTTTCCCATATC
TGGCAATTACAATTTTCCCAGAGCAATTGATTTTCATGTCCCGTTCCAATTTAAAGAAGTCTTCAGTTCG
TGCATAGTTAACATACACTAGATCGCCCTGTTGAGATCGGGAATGACTTAATATGAGTCAGATATAAAAC
AAGGAGGTTTTTCTGCATGGGGACTGTTGGACATTTTTGAAAGAGGGAAGAGGTCAGAGCACACAGGAAG
GTCAGAAATGCATGAGCTCCAAAGAAGAGATTCAAGGGAAAAATGAATTTAAATTGAGAATGGAATTAGA
TGGGCTAGAAGCACATGAATAAAGTAATATTTGTTTGTATTTGTCCCATATTTAGTGGCTACGAAGCTGA
AGCTACAGAAGCACCCCCCCCACACACACACAGAAAAGCATATACGTGTACACATTGCTGCACGCAACTT
GAAGGTGTCCAGATACCCTAGGCTAAGAAGCCCTTAATGAGACCTTTTCTCTCTTCAGTGTGTGTTCACA
GGGAGTAGCTTAATGGTTCTTAACAACCACCAAGTAAAGAAAAATGCACAGGTAACATCATTGCTTCACA
GGTCTGATTTCAATCATTAAGTGATTATGTGCAAATCTTATAACATATTTGAGTCTCGATATTCTCATTG
GCTCAATGATCTGCTAGATTAAATCAGTGATCTTCCAACCTTTTTTGCTCACCTATTCCCTAAATTAATT
TTGACAATGTCCCCCTTCATCTAAAATTTAAAATTTTTTATCATACCTTTAAGTAGCTGCAAAGCATGCA
ATATCTAGCTTACTATAAATATTAATATTTTTAGAAGAAATTGTATACAACTTTTATATTGATCCAAATG
ATTTAAATACTGTATTTATTTACTATTCAACATCATCAATTTTAAAAAATACATGAACATGCTGTTCTTT
ACAGTCAAAATTTTGTCATCTCTTTTTTTTTCTTGAACTTGTATATTGTCCATCTTCCCCCACAGAATTT
TACTCTAAAGTAAAATATATTTGTGCTGGGCACCAGATGAGCTGTCCAGATTCACGGTCAATGAAGGACT
TTTTGCTCCAGCTGCAGGGAAGGCTCTCTGCAGACAATCTTCATCTGTCAGCCCCTTCAAGGATTGCCTC
AGCTGTAGACAGCCCCCTTGCTCAAGGTCATGTCCCTTTCTAGAATGCCACACATTCAGTGACTGATTGA
TGTGAGGGTACAGAGACCTGGACATCTCAGTCTAACGTAGGACAATTCTGAGAAACTATTCCAGACCTCC
TTATGGGCTTAGCCAAGGCTATCCTTCAGCTGGCATTGCAGGGTGACTTCTCCCTCTGCCTAATCCAGCT
CTGCTTTTCACAGATGTTGATCCCAAGAGAACACTCCACAATTATCAACTAGCATTCTAAATTTCAATTC
AGAATCTATTACCTTAAATATGGGTATGCTTGAAAGTCTTTTATTAATCACTGTCAAATTTCCTTGAATC
AGTATATCTTTATAAGTCAAATTTTTTAAAAAATTTATTTTTGTGACAGATTGTGTTAAGAAACAGCTTC
AAGAGTAAGTTATAATTATAGGCCAGGCATGGTGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCTGG
GTTGGGTGGATCACTTGAGGTTGGGAGTTCAAGACCAGCCTGGCCAACATAGTGAAAACCCATGTCTACT
AAAAACACAAAAATCAGCTGGGCGTGGTGGCACCGCCTGTAATCCCAGCTACTCGGGGGCTGAGGTATGA
GAATTGCTTGAACACGGGAGGTGGAGGTTGCAGTGAGCCAAGATCATACCACTGCACTCCAGCCCGGGCG
ACAGAGTAAGACTTGGTCTCAAAAAAAAAAAAAAAAGATAGATTAAGTTATAATTATAATTACTAGCAGT
ATCAAATTAAGTCTAACAACATCATTGCAATTCTTATATATAATGCATAACCATAAAATTTGATTAGAAA
TATATCTTTGAATGCAATGAGTGGGACAGTGAAGCGTTATCTTAACACATTTGTTCAGTGGGTGAACAAA
TTATTGCTAGAATGAGACTGGGATCAGCAACAACAGTTCAATTTACATTTCTTGTTTTTACAGTAAGTTC
TGAGAAAACTTGGATAGGAATGAAAGATTTGTTATGGAATTGTTACTAACTTATTTAAACTTCTTTCAAG
TTATAATCTGAAAATCACAAATTGATCCATCATTCAAGTGTCTTTTAATGATATTAGCTGGAAACTCAAT
TGGGTTTACCTTTAATTTTGCTCAATTGTAAACCATTTGAATTGCTAAGAATTTGTTACATAGCTATTAG
AACCATTCACTATCTTAACATTGAAAACAATATTTCTAATTGTCTCTTTTTTTGAAGCCCCAGAGATTTT
TACAACACAGATATATGCTTCATATTGACTTAGAATGGGTAGGAGATGTTTTTCATTTATAAAATAAGAT
GAAAATGCTTGTAAATAGGGAGCAGGACCTCACGACAGGCTAGCTTTCAATACCATGAAAAAGCGCACAG
GGTAATTGATGATCTGCAAACTGATCTCTTTAAAACCATGTCATGCTTGCCTTTCGAAAGTCTTTACACA
GCCTAGTTTGAAACCCCTGTCCCAGATGATTTCCAATATCCTATCATTTTATTTTGGTTATTGTTTTCCT
TTTTGACTACATTTTTCATAGCATGTACACGACAAATATACATAAGATATTAAAATAGAATTGTTTCCAA
GCTGATTCTAGGATTAATTTGACAAATTGGTGAAGATCTATTATGTGTTAGGCAGTGCCCTATGTAATAC
AACAAATCTCTGCCCTTGAAGGAACTTACACTGCAGGTCCTCCTTCACTCACAATGGAATTAAGTCTTAC
TAAACTCACCTAAGTTGAAAATAATTATACACCTAAAGTGTGTTTTTGACTTAGGATATTTTCAATTTAT
AATGGGTTTATCCAGACATAACCTCATGGTAAGTTGAGAAGTGTATTGAATGAGTATGGCTATTGCACCA
TCATGAAGTCAAAAAATTTTAAGTAGCCATCTTAAGTTGGGGGTTTCCTGTAATGTGGATGGGATAATAC
AATAATGAGCATTAAAGTTAATAACTAAGCAAAGCATACATTATATTAAAAGGTGATAAGTAGTATAGAA
AAAATTAAAAAGCATTTAAATAGAGTATACAAATGGTGAACTAGAGCTTAAGTGGGTGTAATATTAAATA
AAATGAGGAAAGTCTAATTGGGAAACTGACATTTGAATCTTTGCCTCTGTAAAAGGATTACATTTAGCTC
TTGTATTTCTTCCTAAGACCAATGTAATATTAATGCACTATTAATCATAACACTATATGTCTGATTTATC
ATTGTTAACCCTCTCTGGAGCACACTCATTCTATTTTAACTGTGGCTACAAAGTCATTAACCAATGTGAT
TTCAGCAAAATAATTTTTTTAGTGTAAATATCCTACTTTCTTTACCCTTAATATAAGTAACTTTGAGGAG
ATTGTACCTTTAAATGTCTCTAAATGTGGCTGTCTTTTGATATATCAGCAATCCTCACAAAACAAACTGT
GAGGGAGAGAAAACTGAAAAACATATTAGCTTAAAAATGAGAGTAAACTTTGAAAATGAAAACAAGTGTG
ACAGATATTCCCTCTCAGCACTTCTCAAATGCAAGTTGTCACTGTTAGAAAAGAGCTTTGTTTTTAGACA
AAGACCTTCTTGTACAACTTACACTGTACCATCCATTGTTCTATGACTGTGAATAAATAGAATCTTGCAC
TCTTAGCCCGGAATTTTCTTTGTTTCCTTAAGCTTCCATCTCCCTAACTCTTATTTATAGAGACAGAATT
GGGAGGCAAAACCAGTGATTCTCAAAGATGGTCCTTGGACCCTCAGAAACAATATCACGCTTGTTACAAA
CACAAACTCTCAGGCTCCACCCCATTAAACTTAGGGAGTGGAAACTAGAATCTGTGTTTTACAAGCCATC
CAGATTATTGTGACAGACACTAAAGCTTGAGAACCACTAGATAGACTATATTTTATGAACATCGCAAATT
GCTAATTTTAAATAGCATAAAGCAGAGTCCCATATTTCATATTCCACAGGATTCAGACGTAAATTCAAAG
ATTACTGATCGTGAATTTTTGTTTTGTTTTGTTTTTTGAGACGGAATCTAGCTCTGTCGCCCAGGCTGAA
GTGCATACATTTAATTTAAAATAGCTAAAAAATATAAAATATACTTTAAAAATCTTAAATGAATGTGATC
TATTGAAGAAGCTGAAGTGTGAAGTGTGAAATTGAAGAACCCTGAAATGTATTGAGCAGTGAAAAGATTA
TGTATACAAAAACAGGTTGGCCGGGTGCGGAGGCAGGCAGATCACCTGAGGTCAGGAGGCGCGATCTCGG
CTCACTGCAAGCTCCACCTCCCGCGTTCACGCCATTCTCCTGCCTCAGCCTCCGGAGTAGCTGGGACTAC
AGGCGCCCGCCACCACTCCCGGCTAATTTTTTTGCATGTTTAGTAGAGACAGGGTTTCACCGTGTTAGCT
AGGATGGTCTGGATCTCCTGACCTCTTGATCCGCCCCCCTCGGCCTCCTAGAGTGCTGGGATTACAGGCG
TTAGCCACTGCGCCTGGCCTGTAAAACGTTTTAAACACACATATGGACATACATAGTTTTGAAAGAATTG
ACATTCCACTGGCTGGGTTACAGATGATCCAGTGAGGAACACCGATCAGCAAACTCATCTGATATTTGAA
CATAAACAGCAAACCCATACAACATGTGTGCTCTTTGTATTTAGCCATTGATCTGGAAGATTTTAAGTCT
ATTTGAAGGAAATAAGAGACAACGGTCTTTATAACTCTTTCTTACGATTAATAGTAATGTCAAAGTCCAA
AAATTATTTGGAAGATTTTAATTGGGTATGCAGTAAACCTACAAACTAATCTAGGTGTAATTTTCTCCTT
ATAATATGATGTCTTCTCAGCCAGAAACATAAACGGTTTAACTGTTTTTTCTTTTGTTTTGTTTTGTTTT
TCTAAGATGGAGTCTCGCTCTGTCACCTAGGCTGGAGTGCAGTGGCACAATCTCAGCTCACTGCAAGCTC
CGCCTCCCGGGTTCACGCCATCCTCCTGCCTCAGCCTCCTGAGTAGCTGGGACTACAGTTGTGTGTCACC
GCATCTGGCTAATTATTTTGTATTTTTAATAGAGATGGGGTTTCCCCATGTTGGCCAGGCTGATCTCGAA
CTCCTGACCTCAGTTGATCTGCCTGCCTCCGCACCCGGCCAACCTGTTTTTTTATACACAGTCTTTTCAC
TGCTCAATACATTTCAGTGTTCTTCAATTTCACACTTCACACTTCAACTTCTTCAATAGATCACATTCAT
TTAAGATTTTTAAAGTATATTTTATATTTTTTTAGCTATTTTAAATTAAATTTATTCATTATACTTTCTG
CTATCATATACTATCTGGTCTTTTATATTTAGCTTCAATCTGATAATATTAATACTATTTTTAAATAAAA
ATGTATTGTTAATTTTTGGTATACATAAGTCATGAAGTTATATCACTGTAAATCATAAAGAAGGAGAATA
TTAATAAAGAAGGCCCAAAGTGCAAAAACATAAGGAAAATAATTTGACAACGTCAAAATTAAGGATCTCT
TTTCAACAAAGGAAAACACAGAGTGAACAAAAAGATGAAAAATTAGAATAGGCAAAACTAATTTATGGTG
GCAGAAATGTCAAAGAAAGATATCCTCTGGGGTATGTAGAGTTGATTAAGAAGAACCATAAGGGAACTTT
CTGAAGTGAAGGTCATATGCTGTACATTGATGGGATTTGGATCACCCAGATGTTGGCATTTGTCAAAAAT
CAATAAATGTGCATTTGGGATTTGTGCATCTCATTGCAGTAAGTTGTATCTTTAAAAATACCATTAATAA
AATATAATCAATATTCCTTCTTCTTACTAAGACATTCTCATTACTTAAATGTGGAAAAATGAATTGGATT
ACATTAAAAGTCCCTTTATGACCCTTTAATTATCGGCTGAACATATGAAGAGAAGGAAGGCTTCTTTTTG
TCATTTTTATTTGTTGCACTGTGTTTTTACCTCTGGCATTCCTTGAGGAGAGAAAGCACTGAAAGGTGGT
ACAATATCCGAAACATTTTCATATCCTGGAGGAGGTGGTTCAAATAATGATGTGTTGAAAATCTAGAGAA
ACAAAATATTATAATCAAAATAAAACAGTTAAAGTTTGATTACTGTAATCAAACACAAAAAAAATGAATA
TTATCTTTTATGTCAGTAGAGGGTGAATGAATCCTTCAGGATTTTGATGATAGTATCAGATACCCAGCAC
TATGCTAGAAGTTGTGAAGAATTCACGAGATGAATAAATCACAGATTCTGTCCTCAAAATGGTTAGATCT
ATTCAAGGAAACAAAGCTAAAAAAACCCCACCAATAACTAAAAATCAACCAAATGAAAAACAACAATCAT
AAAATAAGTAAGTACTATAGAAAGAAAAGCTCAGAGGAGGTAAAAAGATACTCTTCCAAAAGGAATACTA
TATACTGTAAACTGTGTACTGATAGAAGGAAGAATTAGAAATTTATTTTTTGTAAGTGGCATACATACTA
AGCTAGTGTGAACACAAGCCTAAATATGTAGTTGCTTCACAGAAGGTTAGAAGTAAATTAACCTCATGAA
TTTCTTGAGAGAACTTGTAAGGACTAGCTTTCGATTTTGGAGAAAGATTTTAATCACCAAATAAAAAGTA
CCTTTGTTTGGTAATCTCAATCATTATAATAGTGCTTAGATAATTACCTAGGAACAAATTAAATATTAAA
TTTACTTTAAAAAAAAGTACATGATTGGGGAATCCACAACTGGCCTTATCTAGATTCTCTGAACAACATA
TGCACTGAAAAGAATGAAAAACACTGAACCAAATATATGTTTTTTTAAGTTTAAAATTAAATTGGAAAAA
AAATAGTAAGGAATATTCAGAAGCAAAAAAATAAAATGAAAGCAAGAATCCTCAGAGGTAGCACGAAATT
TGGCTTTGCCTTAGATGGATCTATCAAAGCCTATGGCCCCATGAAAAGGATTCAGGAGTTAGTTTAAAGC
TGGTTCACATAATGGAATCTAGCAGAAGACTGTGCATAAAGCTGGTCTAAGAACAACAATATCCTGGCCA
GGTGAGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGCCCAAGGTGGGTGGATCACGAGGTCAGGAG
TTTGAGACCAGCCTGACCAACATGGTGAAACCGCGTCTCTACTAAAAATACAAAAATTAGCCGGGCCTAC
GTGCTTGTAATCCCAGCTACTCAGGAGGCTGAGACAGGAGAATCACTTGAACCCAGCAGGCAAGCTTGCA
GTGAGTGGAGATCATGCCACTGCACTCCAGCCTGGGTGACAAAAAAAAAAAAAAAAAAAAAAAGAACAAC
AATATCCTTCAGGGTTAAGGATAAATTCAAAATAAACTTGCTCCATGGAAAGTAATGGCTTAGCGTAAAG
CAGGAAAAAAGGGTTCCAGATAATTCATAACCCTACAAATTTCCATTCACTGTTTATATAGTATGCCTCA
AGCGAAAATATTTATTTTAAAGCAGTGCCAGGTTTGTAGTGCTCCCTGGGGCCTAAGAGAAATGATCAGG
AGGAATCAGCCTTCAAATTAGCCTTAAAGAATTCCCAAATTCTTATTACTATCATATTAATAAACATATT
TATCAAGTTTATGAAACAAGACTGAATTAAAATTATGCATATAAATTGGTAATATATAACAAAAGTGAAA
GTGTTCTAAGGTTTCTATATTGTAGAAATATTGATTGAATTATGACACCAAAGCTTTAGGGGAAAAAAGG
AAGAGTAAAATTCACACTAGAGGAAGGTAAAAGTGACCTAAATATTGTATATCAGAATTATAAAAAATGA
AAATGGAAAAAAGAATAATTAAAAAGCGTAGCATGTCTAAATAAAATCAGCTGTGTACCAATTGACAAGC
AGTGACATAAACCCGCTGAAAAAGAAATACCAAACAAATATTAATTAAAAAAAATTTTAGGACAAAGTCA
AATAACATTATGACGAGATAAAAAAGGCTACTACATAAGTATAAGTCTGTCATTTCATCAACAATTCTGT
TTATATATGATAATAGGTCTCCAAATTATACATAACATAAATTTATGGAATTATAAATTTTATATATATA
GTATAAAACAGACATCACTATAGTGAGGTGAGATAATTTAACATTTATCTCTAATTAATAAAGGAAGCAG
ACAAAATGAGAGAGCACATTAAGGATAATGGAGATTTCAGCCAAATAATAAGCAAACTCAAACTAATGTA
CAAATACAAAATATTAAACCAAACAACCATCAAATACATGTTTTTCCCAAAGAAACACAGAACGTCTATA
AAAACTGAGCACATATTAGGTTCCAAAGGAAGCCTCAACAATTGTCAAAGGATTAGTGTCCTACAAACCA
CATTATCTGATCTCAATATATTCAATTTAGAGATCAGATCAAACAAATAACAATAACAATCTTTATATTC
AGGATTTTAAAAAATACTTGTAAATAGTTGCAGGATCAAAGAAGAAAATACAGAAATTAAAAAATATTTA
GATACTAATGATAATTAAACTACTCCTAATCCAAATTTGTGAGATGTAGTTGAAGTGGAAAGGGAAGTTA
AAGGGGAAATTTATGGCTCTAAATACTCATAATAGAAATGAAGAAAGACTGAATGTCAATAAGTTAAGCA
TTCTACTGAGGATTTTACAAAGAACAGCAAAGTAAACACAAAGAAGATAAAAGAGGCAATTATAAAACAA
GAACAGAATTAATAAAATATAAAGCAAAGATAGATGAGAAAAGATTGCCAAAGCCAAAGTTTATTCTTTG
GATACACTAGTAAATTTGACATATCCCTCTCAAGAGCAATAAGAAAAAAAAATAGCAAAAGCGCAAACAA
ATAATATTATTTATTAAAAAGAGGCACATCTACAGACGCTGAACAGATTACAAAAGATAAGAAAATACTA
GGAACAACTATACTATAAATTTGAAAGCTTACATCAAATGGAAAATGCATTTTAAATAAAACTTATGAAA
ACTGACATAAGAATACATTTTTTAAAAAATCGGCCAGGCACAATGGCTCACGCCTGTAATCCCAGCACTT
TGGCAGGCCGAGGCGGGTGGATTACAAGGTCAGGAGTTCGAGATCAGCCTGGCCAACATAGTGGAACCAC
GTCTCTACTAAAAATACAAAAATTAGCCGGGTGCGGTGGCTCATGCCTGTAGTCCCAGCTACTTGGGAGG
CTGAGGTGGGAGAATTGCTTGAACCCGGGAGGCGGAGGTTGCAGTGAGCTGAGACCATGCCATTACACTC
CAGCCTGGGTGACAGAGTAAGACTCGGTCAAAAACAACAAAAAAATCTAGTTGTATAGCCATATAACAAT
AAAGTCATATATCAAGCAATAAAAATTGTTCTATGACATAAAATTATCATATGACAAACAATAAAGTCAT
TTAACAAACAATAAAAATTGTTATATGACGTAAAATAGTCATATTACAACCAATAAAGAAATTAAACCAG
TAGTTTAAAATTTTCCACAAACAGAGTCAAGGCCAACTGGTTTTCCTTGAGTTTGAAAGGTTAAAGGAAA
AAATAATTTAATTGCAATAAAACCTACTTCAGAAAATATTAAAAACCCAACTCATTTTAGAAGGCAAGTA
GAATATTGAAATTATAACCCAACAAATAGATTGCAAAAACACAGACTAAACATGCTATGAGTATAAACAT
AATATATATCAATATATGAATTTAAAACCCTAATGCTAATATTACAAGTTCAAAAAATATAAGATTATTC
TAACATTAGAATACACTGAATGTCATCTTCAGATCAAGAAAGAAAAATCGCATGCTCATCTTAAAGAAAA
ATGTGTTTAATATAAATCCATACAGCAAAAAATTTTAGTATATGTGGAAAGGATGTACTTTAAGATAACC
AGAAAAAGAAAACAGTAAATACCATAATTAATGGTGAGAAAGAATTAAAGGTATTTCCTTCAAGACCAGA
AGAAAGTTAAGGATATCTGCTATCAAAACTTCTTTTCAACATTATATTGTATAGGTCTTGGTCAGTGCAG
TAATACAAATGGGAGGGATTTGGAGATGAGGAGGGGATCTGGGCAGATTTTACATTGTACTGACTAGAGC
AGTAGTTATTTCCCTTTTCTGACATGGATAGAAGCTAAAATGAAACCAAATCAACTACGACTTGCCACAT
CCCCACATATTCCAAATTTCCCATATTTTTTTCTGTGATTCACATGAGAAATGAACTCATCTGAATCACT
AGGTAAGATTAAAAGAAAAATTATGCTGAGGTGCAATAAAAATCAATAAAGGAACAAAGTCATTATATAA
GCATGTCTTTCAGGCAAGGGAATATTCAAACTTGTCTCACTTGATTTGCCTTTATGGTAATCAATTTTGC
AGCACCACTATGCCACACTGAATTTTACAGCAAGTTTATGAGCTATTCTAACAAGTAAGAAAAGTTTTTA
ATGTCAAGGAAATGCCTTTTTGGTTGACTTTATCAAAGTTAGATTAAATTTCAGTCTTAGAGTATTTTTT
ACTTTCCAAAATGCACTGGTAGCCTCAAATTATATATTCTGAGTATAACTAAAACAATATTAGTTTATAA
TTTCTGTTTACATTTTGTGACATAAAAAAGTCAATATATAGTTAAATCTTTATGGGATGTTATTTCTGCA
TAATCAAAGGTGAAACAATGTCTCTGTATACATTAAAAATATTTCTCATAGGATCCACAAAATACTAATC
ATATTTGTTGCCTACGGATGGAGAACTTGTCTGTTTTGTGCAGGGGTATAAAAGAAATCATAGTTTACCA
CATAGCTCAGCTGTGAACTGTTATTCATAACAATTAAATTGTACTGGGAGATGGGAGGTAGTAAGAGAAC
ATGGTGGTTGGGGCCAAGGGATGAACAGGGAGCTGACTTGTCACAATGTCAATAGATAATGCCTGCATCT
GAAATAAAAGCCATATAAGCATGTAATTTATAGAAATAGATGTAAATATAAAAAGAATTAACTTATAGTT
GAATAATGATTGCCTCTGGAAAGAGGAAAATAGAGAAAAAGCAAGGCACTCAGGAAAATTATGTGGTTAT
GTACATATATAACTTGGATAAAAATAAAAAAGAACTAATGATATAAATTTAAAAAATTAAGAAACTAGGT
ATCTAACACTATTCAGGAAAATCTCCCAAGTGAAACTTTTACATGATTCATTTTGTATTATGTAACAGGC
TTTGGTAACATTATGCATGTTTGTAATACAAAAGTAAATAATGAAATAAAATAAGCAATGGTATAGTCAA
AACTGGGAAGTGAGGAGGAACGAAAAAAGAAGAAAAAAACGACAACATAGCAAGACCCCATCTTAAAAAA
AAACTAACCAGCACTTTGGGAGGCCGAGGCGGGTGGATAACGAGGTCAGCAGATCGAGACCATCCTGGCT
AAAACTGTGAAACCCCGTCTCCACCAAAAATACAAAAAAATTAGCCGGGCGTCGTGGCGGGAGCCTGTAG
TCCCAGCTACTAGGGAGGCTGAGACAGGAGAATGGTGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCGGA
GATACCGCCACTGCACTCCAGCCTGGGCGACAAAGCGAGACTCCGTCTCAAAAAAAACAAAAACAAAAAC
TAAAATATATTATATGTCTGCTCTTTTCCACATTGTACCTAGACAATTCTCAAATTTGATAGATCAAAGA
GACGTTTAAGCATATGTATACATTTTAACATTGTCAATATTTTATTTCTTTAAATAAATTTTCTGAACAT
GTTTTAAAGACCCCTCGGTATTTAACTGTATAGATATGCCACCACTTATTTAACAAACATTCTGAGACTA
TATGACGTGTAGTGGTATTGCCTTTTCAATATAATATATTTTAGGGTTTTTTTAGTTTGTTTTTCTTTTT
TTTTTTTTTCCTTTTAAGGTGGAGTCTTGCTATGTTGTTCAAGCTGGTCTGCAACTCCTGGCTCCAGCAA
TCATCCTATCTCAGCCTCCCAAGTAGCTGAGATTAGGGGAACATGCCACCACGCCTGGCTTAATAATATT
TTTTAAAGTTATATTGTTAACTACTATGATTGAGAACAGTAGTTAATATGAAAAGCTCCAATCACATTAG
AAAATTTAGTATGGAATTATATCACTGACTGTAAAACATAACAACATATTAATCATTAAGAAGAGACTGA
TTCATTAGTCAATAAAAGGAGGTTATTGACCTACTATGAAAAAAAATTATATATGTACTTAAATCACATG
ACATTTTCAGTTCACTGATCAAACTGGACATATTTCAAGCTACATGTAATTAAGAGTGCCCAGTAATAAA
AGGACTAAAGGAACTTACCTAAATAGAAATGGACTCTTCTACATACGGTAGCTCTAAAACTGAGGTATGT
TAAGTAAGGATGAATGTATGTTATATTTTGTGATCTTTCATATTGAACATACATCATAATAAATATATCA
ATTTATCTGCATTGTCTTCTCTTTCTCAAGTATATGCCCCAACTTGCAAACAAGATTGCAAATTCTTTAA
ATACCATGCTAAAATACCTTGCCTCCAAACTTGTCCTCTCCAAATGTCCACACACAAATTCTTCGCACAG
AGTTCAACCTGATCAATTGAGACATAATCATTAAGTACCAATAAAAACTTGCTGGGTCAAACTGCATACT
GGATCCGTGCATTTCCCAGCAACTCCAAATCTGTGCAGTGTCTTTATAAATTAAACCTATCAAAAATGTA
TCTCCTGGCCAGGCGCAGTGCCTCACACGTGTAATTCTACAACTTTGGGAGGCTGAGGCGGGTGGATCAC
CTGAGGTCAGGAGTTCGAGACTAGCCTGGCCAACATGATGAAACCCTGTCTCTATTAAAAATACAAAAAT
TAGCTGGGTGTGGTGGTGCACACCTGTAATCCCAGCTACTCAGGAGACTGAGGAAGGAGAATCCCTTGAA
CATGGGAGGTGGAGGTTGCAGTGAGCCGAGATGGCACCACTGCACTCCAGCCTGCCTGACAGGAGTGAAA
CTCCATCTGGAAAAAAAAAAAAGAAAAAAAGAATCTCTTTTATAAAGTATCTCTTTTTATGCTTGGAGGT
TTACAAGTATATCATATTTGATATTGGTGTGTAGTACTAAAAACTAAAAAACAGCAGCTGTTATCAAGCA
TTAATTTCTCGAATCTTTCTAAAACACAGTAAACTCAAACATCATAGGAAAGTAGTTGACACGGATAATG
AGATATTAAAGGTATTCACAAGATCCAATAATATTGATTTCTATTAATATTTAGAGATGGGATAGAACAT
TATTTCATAGAAGGTATTTGAAAAAGAATAAATGGGGGGAATGTTTCTTTTATTTATTTATTTATTTTTT
ACCTCATTTCCATCTTCATTAATTATTGAGATGTAGTTGGGATGAGTCTTATTTGGGTAGGACAACAGGA
CATCATAATGTGCTAGCTCAACAGAATCCAGGCCAAATTCTTTCCACTGGGATTGAATTTGCTTTGCAAG
CTGAAAGTTTTGTTCTGTTCCTGCTAAATGTGGTATCTGTGTAAAATTACTGGTGAACAAAAATTGAAAG
TGGTTAGATATTAATGTTTAATCAACTTTTATTCCAAATCAACAAAGTAAAGCAGAGTTACACAAAAGTA
CTTTGAAGTGTGATACGTTAAAAAATTAAAGTGGTAGTATTATTGCATGAAATAGATTTTCAAAGTCTGC
TTTGAAATTTTTATGCTCTAATTTGTACTAAATCAAGAGAAAAATCGGAGAAACTGATTTTTGTATCATT
ATGTGTAATCCTATTACTATAACCTCGTATGGTAGATTATCATATTCTTTCTTAAGACCTATACTTCTTG
GAACTTACATGGAATTATCTGTTTATATCACTGTGTAAAATATTGAAACAGACAAAAATATTTTATCCAA
AAGATCAAGGTGTAACATGGCAAGAATTACTAATAATTACATTTATTTAAATACTGAGAGTTATAGACAA
GTGATAAACTTTTTGATTAGCAACCATTTATAAAGTATCTTCATCAAAGAATAATCTGAACATACCGATA
CAAGTTCAGAATGAATCTCTTGCACTCCATCTATCATACAGAGTGACACACTTAAAATCAATGACAATAA
TTAGTCTGAAGAGGAATATCTTTAACAAAGAAATTATGTGGCCAAAATTTGGCTACCAGAAATATTTTCA
GGAGTAGACTAATTTCTCATTTAATATATTTAGATTCTGGTGCTTTTGATTGTTTTAAATTTCTCCCTCC
TGGGAAATTTCTTGTTTCCCTGAAGAGCTCATTGGTAAGTATTTTTAACTTAAGCCCTTAAATACATGAC
AAGATATTATGTAGCATGAAAAGATATATATATATATATATATATAGTTCATAAACTTTTGGAACTTCAT
AAATTTCTAGTTTTAAATATGTAGCTTTATAAAATCAACATAATTCCATCCTTATGGTGATTTAAAAAAA
CTAATAACCAACATGACTATGATAATTCCAGTTTCAAGTTTCATTCTACCATGTATTTTAATTTTTTTTA
TTTGATGAATCAACAATGAATTAAAGTAACTCAATTTTTTAAAATTGGAATTTCCTGTAACTTGTTTACT
TTAATAATTATATTAAAGTTATTTAAATTGTATTTATAAAAATAGTATTAAAATCCTCGTTTGGTAAATG
TTTAGGGGCAAAATATCTTACACAGAATTTCTAATATGGAAAATATTGTAACAAAAAGGACACAAACATA
AGAGGCAGCTAAGGAGTCTCTATCCCTTATCAGTGAGCACCTGCAGGGAAAACAGAAAAACAGCCAACAT
ATCGCTATTTTCTTGAATATTACAAAGATCACAAACTGCAATGTAACTAATGTAGGATGCAGATATCCTG
AAGTGCCAGCTATGCCTCTGTCCCTATAAGCAAAAGGAATTACTATGGGGAATCTTGAACCTACTCACAA
AAAAGTGGGAGAAAATCATTATAAGGCTTTGCTACTATTAAGTGAATTTTCTTGTAACAGTCTTGTCACT
ACCAACTAGGAAACAACATTTTGCTATTATCAGGGTTGGGACTCACTCATTTGAACAAAACACATCCTGG
AAAAGATTAGTAGGAGAAAAAAAGATCCATTGCAAACACTAAATAAATTAATTAGCATAAATCATGTACG
TGGTATAATACAGGTGTTGTCATTAACTCAGTATGTAACCCTAGCTGTGTCTTGAGTTTCTCATCTGTAT
ATGGGGAGAACATCACTGTCTCACTACTTCACAAAGACTTGAGGCTCAATTAGATTGCGTATTAAATAGC
ACTTCTCAATGATTTTAATCATTTGAGATGTGTGTCACAAGTTGTTGAACCTACCAGAATATCAAATTTT
GTAAAAAATAAACAAGAATAAGAATAAAAATATGAATTTACAAATTTTCCCAAATAGCCAAATTCTGTTT
ATATATCACTGTAGGGCTGCTTTAAATGTGTTTCTAGTATTGTCACATTATCTCTTTTTTTTTTGTAAGA
GACAGAGTCTCATTCTGTTGCCAGGCTGGAATACAGTGGTGCAATCATAGCTCACTAAAACCTGGAACTC
CAGCTTCCTGAGTAGATAGGACTACAGACACATGCCACCATGCCCAGATAAGTTAAAAAAATATTTTGTA
GAGACAGAGTCTCACTCAAGGCATCTGCCTGCCTTGTCCTCCCAAAGAGCTGGGATTACATGGGTGAGCC
ACTATGCCCGAATACATTATCTCAGTCCTTTAAAAGAGCTACTGTTGTTTCTGTTTCAGTACATTTCATC
TTGTTTACAAATAATTTGGCAGTGTTTCCAAGACTTCAAGATGACGAAGGTATTTAGTAAAAGGTGGAAT
TAGCTGGGCACGGTGGCATGTGCCTGTAGTACTACCTACTGGGGAGGCTGGAGCTCCAAGCTGCAGTGAG
CTATGATTGTGCCACTGCACTCCAGCCTGGCAACAGAGTGAAACCTTGTCTGAAAATAATAATGATAATA
ATAATTGAGATAATGTGACGATACTTGGAATATATTTAAACCAGTCTGAGAGAGATCTATGAATGGATTT
TTGCTATTCTGGAAAATGTGTAAATTCTTATTCTTACCTTTTCTTTTTAACAAAATTTGATATTCTAGTA
TCAACAAATTACTTGTGACACACATCTCAAGTGATTAATAGATTAAGAAGTGTAGTTTAATATGTGATTT
CATTGGGCCTATATATTCAAATACAGACCTATGTATTCAAATACAGACCAGTAAAATTCTGAGACCAAAA
GTCTAAAACACCTTTTAAAACAATCTTATCTTGCAAAACAATGTGGAAAAGGAAGAATCCCTCTAGAGAG
ATGCAAAATGGTAAACAGATCTGTGAATTCAACTGGGTGTTTTCAAAGAAGGGAAAACACAGACAACCCT
GTACATCAAGGCAGAGTGAAAAAAAGCTGCTCCTAATTAATCTTCCCATTCACTACTGAGGCAGATATTT
CAGAGGCAGTGGGGGCTTTTAAGAGCAGAACAAAAGATTTTAAAGGGGGACCAGATGGAAGGTCAGAGGT
TTTAATAGTCTCTGACCCATGGGTATATTTTAATTGAAAGCTCTCTGATGGACAAATGGCAAATTGAAAA
TCTGGAGAGTTTAGGAGGCTTCTGGAGATTCTGTGGTCCTTGGAGGAATGAGAGGGAATTCTTTCAATTT
CTTTCTTTTGTGTGTTTATGCTGAATATCCCCCTGTGTTCTGGTTAGAGGAGCTTGGTTAGAGACATGGA
GAATAAACAAGAAGCTGACTGCTTAATCTTGCTGAGGGTCCAAAAAGAGAAATAAAGGCATTTATTTTTC
TTCTTTGTTGGTCAATCTATGTCACAAGTTAGTGTTACAAGTAGTTAGACAGGAGCAAGTCAGGAGGGGG
CTCTCCCCCCACCCTCTAGAATGTCAGGTGATGGTTCAGTTCAGCATTGATCGCATTGCCTCTCTAAAAA
TGATTTAGCAGTGCCAGGGAGAGGCCAGCTCTTGATGGTCCACACCTGTTAACACCAAAATGTTAACTGA
ATGCAGACTCCAGGGAGAAGCAACTTCCTGGGCATGCGTGTTAGAGACAAAAATGGTATAGTATAATCTT
CCAGGTACACTCCACCAGAAAAAGGAAGAGAGACTCAGATGGGCCTGTGTATACTTCCCTAAACACATTG
CGGGTGCTCTTTTCCCAAGGGTTAGGAGGGCTGGGCAGCCCACCCTAAGAGAAGAATCATGGGAAAGAGG
CAAGCGTAAAGAAGTCCTACGATCACAGTTAAGTGGGGCACTTGGCCTTCTCTCACCTTCATGTGCCTGC
TTGGCTCTCTTCCAAGCACACCTTCCTTTCTTTCCTGTTATAAGGCCTTTTAAAATAAACTTCCATTCCT
GCTCTGAAACTTGCCTTGGTCTCTTTTTCTGCTTTTGCCCCCAGTTGAATTCTTTCTTCTGAAGAGGCAA
GGACTGAAGTTGCTGCTGACCTTATGGATAGGCTGCTGATAACTTGGAGTAACTTGGATCTCTTCCACCA
CTAATATTGGGAAAGGAAGAAAGCTGGAACAGCAGCTCTGTCAAGGAGTAAAGACCATACCTTGCCAGAC
CTCCACTTTTATTATACCTACTATACATTATTAGAGTGGAATAAGCACAACAGGCAGAGGAGGGTTTTCC
ACAAAGATAAAGAAGTTCGAGCTTCAGAGTCTCACATTTAAAACGGCCCTTCCAAAGACCTGAGAGGTAT
CCTATCAATTTGTATTTATACTTTTAATTCTGTTGTAATTAATACAAACATATATATGTTTGTATGATTA
TATGTGTGCACATCTATGCATACCTATGTGCATGTGTGTGTGTGTAATGGTCTTTTAATTTAGAATTACA
ACCTTTATTCACCAGCGAATCCTGCAATCATTAGAGGGACTTCAAGTATTTTAGGACACATGAGCTAACT
CAATTTGTAAAAATTCACAAAAGGATCTCATGCTTAAAAAAAAAGCAAGTATTCTGGGCTGGGTGTGGGG
GCTCACACCGGTAATCCCAGTACTTTGGGAAGCCGAGGCGGGCAGATCACCTGAGGTCAGGAGTTTGAGA
CCAGCTTGACCAACATGGAGAAACCCTGTCTCTATTAAAAATACAAAATTAGCTGGGTGTGGTGGTGCAT
GCCTGTAATCCCAGGTACTCAGGAGGCATGAGAATCGCTTGTACCTGGGAGGCGGAGGTTACAGTGAGCT
GAGATCACGCCATTGCACTCCAGCCTGGGCAACAAGAGCGAAACTCCATCTCAAAAGAAAAAAGGAAAGA
AAAGAAAAGAAAAAAAAACAAGTATTCTAATCAATTATATATAGTAATTCTATATAAGTATTTTCTTTTT
GGTTGCTTTTTAAATTTACTTATTTATCTCTTTCGTCCTACACTGGAAATAGCTATTTCAGGAAGTAGGG
AGCTAGTTTTTAAAATATGCCAAATTTATGCTAAATATATGCTCTTTGACTTCATCCATATCATAATAAG
ATCATTATTCCCATTTTACAGATGTGGAAAAGAGAGCTCAGAAAGGTTAAGTATTCATCCAAAGTATTAA
TAGGCAAAGATGGAATTCAAACTCAATTCTAACTCAAAGTCCATTTTTTTAACTGAAATGCAATATCTTT
CTCTAAAGCATTAATCAGCAAACTAGGTTCCACTGGCCAAATCTGGACCACTAACTGTTTCTGTACAGTC
CACAAGCTAAGAATGGTTTTTATATTTTAAATTGGTTTTAAAAATAATATTTTTGACACATCAATTATAT
GAAATCCAAATTTCAGTGCCCATAAGGAAAGTTTTATCAGAACTGACTGTTTATGTATTTTCTATGACTT
CTTTTGTGCTGCAATAGCAGAGCTGACTAGATGTGACACAGATCAGCTGGCCTACAAAGGCTGGTCCTTG
TACAGAAAAAGTTTGCTGACTCCTGCTCTAAACCTCTGTAATGACAAAATTTAGCTGAAAGTATAGTCCT
CCTCAGATGAAATGTGATCCAAGATCTTTAATAAATAAAATTTTAAGAAAAAAGTCCAGTTCCTATATAT
AAAATATTGGACCAAAACAGAATGATAAATTTTTCTAACAACTTGTCCATATAAACTTTCGAGGATGTAC
TTACTATAAGAACTTCTTGATGTTCTCAGCTTTCAATTCATCCAAAAATGCTTTCATATTATGCTTTGGA
GTAATGTTAGTAGCTTCATTGGAGGATTTTATAAACCACCCTGAAAAATACATCCAAAAATAGGCATGAG
ATACGAGCCTATAGATAGGACTTATTTTTCATTATTGTTGTATGTATTATTTGTAAAACACAAATTATCA
ATATTACCTCTGACATTAGGTGAGATATTTCTGAATTTTAATTTCTCTTGCCTACTTTCACTGAAAAAGA
GTCATGCAAACAGATTTTTAAGTTGCAAACCAATTGCAAAATATTTCTTATCCAACTTCAATGATAGGTA
TTGCTGTTATTCTAAGAAATGTTTTATGAGATAATCAGGACGAAAATAAAATGACATTAATGTTTCAACT
AATGGGTGTAAACGAGATGTTCTGAAAATGAAGGCAAAAAGGAGATCCACCTTCTACTTTCATAAAGTTT
CTATCTTCCTCTGCTGACTCAAATAAGCATTTAATACATTTTTATAACGAATTAATTATGAATATATTTC
AAATAAATAAATTATTTCCAAGTGTTGAAGGAAATTCAGACTTCTAATTTGCTCTGATTCTGAAACTAAA
ACAAAATGCTGTGAGAGTTTGCGTTTCCAGTGAAGTAGGCGTGAGAAATCCAAGTTCAGACAGCTACAAT
GAAACTACAATTTACCCAGCCTCTCTGCCAGACACCCAGTGCACGCATAGGCGGCCAGAAACAATGGATA
GCTAGATCCTGCAGTCATTAGACCTTGCAGTTGGCTTTTAACCTGAAGGAGATAAGGCAAGATTCCAGGG
TTTATTTAGAGAAATTACAGGATCTGGGAATAAAGTAGTTACAAAATTAGTCCCCAACCAGCTTTCATGG
AGCTTTCCAATTATTAATTATTCTAGTTCTTAATCGCATGCATACAAATGCACATACATATATACATGCA
TATTAAAATACATGATTGCACGCAAACGGAAATAAGATTCCACCTGTGCATAAAACAGAAAGACTTGGAT
TAGAGTGAGGGATCAGGAAACACCACACTGAGGACGAGATGCTTGAACTGAGATCTGAAAAATGAACAGG
ATGAAGAGGATGGAGGCCTGTAGGGGGAGGGGAGAGCAGAGAATCCTAGTGGGTGGGGGGCGGACATCAA
TAAAGAACTCTTCTGTGTCAGCCACTGAGCACGGAATACAGGGATGAGAGTGAGGGCAATACCAGGAAGA
ATAAAATCCTTTTAAGAGATGAAGATTGTTATGAGCACAGTGTGTGGTTCAAAAATCTTTTAACAACCCC
AAGGTGAAGCTAGTGGAAGATATTGAATTTGTTTAAACCCATCTGGTCCATGCCCTGTTCTTCTAAATCC
CGAAAGAGGGTCAAGAATTCCGAGCAGGAGTGGACTACCTGGTGATACCTTAGACTAGTCCTGTGTATTA
AAGTCCAATGAGGAGTATCTTGGTAAAAGAAGAAATAAAGTGGCGAAAATCCCAGTACTGTGCTAGGAGA
TTTACATGCTATATTATTTACTATTACCAATAATTTGCAGATAATATTATCCTCATCATAAAATAGGGTA
ACTAACGCTGAGAGGGACTCGGTAACTTGTTCAAGGCCACTAAGAAGTGGCAAAGTCAAAACTGGAATTT
AATAAAAGAGTCTGAGCTTGCCTGTGTGGTTCTGCTTTTCTTAGAAAGTTGGATCAAGTCTGCAAATCAG
TACCCAGGAAAAACAGCAAAAGACCCGCTGGTAAAGACCTGTCCAGATTGCTGACCTGGTTCACACAGTT
CCCAAGCTTGCCTCTGTTACTTCCAAGGAAGAAAGAATGCACAGAGAGGTAAAAAAACAAACAAACAAAC
AAAACAAAACAAAACAAAACAAAAGCAAAAAAAAAACTTCCTCTGTCTTGCAGGGCTCCAGCACTTGGAA
CCTTCCTACGCCCAGTTTCAGGTTCTCTCAGTTCTACCCTCAACCTGAGTGACTGTCCTACCAGCAGCTT
GTCGAGAACTCAGCCCTGCACCGTTCCCAGCTACCCTCCTCCTAACTCGAGGGGTGCTCACCCCACATTA
CCCCGACCCTAATCGCCGCCCCTGGGGAAGACCAGCAACAGGATCCCACTCGGCAGCTGACCCGCGAGTC
CCAGCACCGCGGCACCACGGGGAAGACTCCGAGGTTTGCTCCGCGAGGCGCCCCCCTACCGAAGAGGAAG
CCGAGGAGAAAGAAGCCACCCGCCAGCACCAGCGCCCCAGCGCACAGCCAGCGCGGGCGGCGCGCGGTGG
CCACAGCCGAGTCGGTTTCGTGAAGGAGATTCCACATCTCGGCGCGAGCAGAGCCGGCCTCCCGGGACCC
GCGCCTGTGCTGCTGCTCTACTGCGCGCCCTCCAACCACCACGGCGGGGTAAAGTCTCTCTCAATCTCAC
TAATGCCTCGCTTATCAGCCCTGCAGGCTGGAATTCGCTCCAGACCTGGGGTCCAGTTTCTCCACCACAG
CAGTGTTTCTAGAGTGCACTGAACCAATCCGAGCGAGAGAGAGAGGCAACATCTGCCTCCAGGAGAAGGA
AATCCGGCCCCTTTTGA

</dna_sequence>
        <protein_sequence>>NP_001014986.1 glutamate carboxypeptidase 2 isoform 2 [Homo sapiens]
MWNLLHETDSAVATARRPRWLCAGALVLAGGFFLLGFLFGWFIKSSNEATNITPKHNMKAFLDELKAENI
KKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFN
TSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVIARYGKVFR
GNKVKNAQLAGAKGVILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYR
RGIAEAVGLPSIPVHPIGYYDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTN
EVTRIYNVIGTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGWRPRRTILFAS
WDAEEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKELKSPDEGFEG
KSLYESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKNWETNKFSGYPLYHSVYETYE
LVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDYAVVLRKYADKIYSISMKHPQEMKTYSVSFD
SLFSAVKNFTEIASKFSERLQDFDKSKHVIYAPSSHNKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQ
IYVAAFTVQAAAETLSEVA

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1347">
        <gene_name>Prostate-specific membrane antigen</gene_name>
        <strain>Rattus norvegicus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>85309</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>17105334</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AABR07071938</gene_refseq>
        <protein_refseq>NP_476533</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10116</taxonomy_id>
        <chromosome>1</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>150323767</gene_start>
        <gene_end>150395414</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>folate hydrolase 1</protein_name>
        <protein_pi>7.54</protein_pi>
        <protein_weight>79875.19</protein_weight>
        <protein_length>752</protein_length>
        <protein_note>Also known as Naalad</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_005100.4:150323767-150395414 Rattus norvegicus strain mixed chromosome 1, Rnor_6.0
AAATAGAAGATAACAATGAAAAATAGAAAATTACATATATTTCAAGACATGTAATGAATATAAAACACAT
GTAATTCTATATAAAAAGAGACATTATAAACATAAAATTCAAGACCATGATTATATTTCATATAAATAAT
GCATTTGTTCAGAAGTTCAGTTACTGAGACTATAGATGTTAATTAGTAGTTGTACTTTTACAATTTATAG
AGTTTTAGATCATAAATACCTTAAAACCATGGACTGCCGCTTTTTATCAGGATCCTCCATAGGGAGCCAC
AGACAAGACCTTGGCCTATATACTTAAACTTTTCAATAAAGAGGAATTAGGTTTACAAGAAGAGAGAATA
AATTAGAACTCGTCTGCTAGGGTGACTATAATGATCCTCCCAGCCTTTGGTGACCAGAGAGCATATAGGC
CCCCAGGTAGAGCAGAATTGTGAACTATCCAAGATGTATTCCATAATGAAGTAAAACTACAGGGTAGATT
TGGGAAGGGTGTATTAGATTTCGGATAATTATCTAATACTGTCAAATGTGTCATTTTATTAGGCTGTTTA
CATTAGTTTTAATACCTATTGAATTTTAAATTTTAGTAATACATGCCAAAATTATAAGTCATTATGAAAT
TATTCACTTTTGTCTTTTGATCCACAAATCAGTTTTTTATGAATTCTGTAAAGACTGCTTAGTCTACTTC
TCTCAGAGTCTCTGCTGCAGCTTGCACTGTGAAGGCTGCAATAGAAATCTGTCTCTTCACTTCTCTCCAG
GCCTTAGAAGTGTCGACTTTGTTATTAATATCAAAAAGGGCATCATAAATCCCTGGGAATGATTCTCCTG
CATACTTGTTGTGGCTGCTTGGAGCATAGATGATATGCCTGTTGATAAAAAAAAATCCCTGTCCATTAAT
TGCATAAGCAACATACAAAAGAAGAAAGACATTATACATGAATGCAACACTTCCAGTTTTCTGTCTTCAT
AAGTCATTTGTTACCTGAACTTGAAATGCAATAATCTCTCAGAACATTACTACACATACTGTTTGCTTTA
ATGAATGACTGAATGTGGTTTAGATCTAGAAAAATAACAGTAAGGGCAGTTAATAGGAACTGATATGTGA
CCCCTAAAGGAGTCACTGACCTACAGATTGAAAACCAATAGCTTAGCATCATTAAGAGAGCTACTTTTAA
ATATGCTTTATTAGAATAAAGCACAAAGATCCCTGGCCCAGTTTCTAGTAGTATCTTTCTACTCCTCTGA
AATTGGCAAGATGAATACCTATTCTCTATTTCTTTAGTCATCCTAACTCTTAACAAATGGGGCTCAATAA
AGTCTGCTTACACTATTTTATGATTTTATCCCCAAACTTTCACACATTGCACCCATAAACTTATTCCAAA
GAATATAAATGATTTAGAAGAAAAGGAATAAGTCTGCAGGTATCACAAAACTTGATTTTAAGACACACTG
TGGAGCCTTGTACAAAAAGAGAATATGATACAAAACAACTTATGTGTACATGAAAATAGAAGAGGTGACC
TAGAAACAGGCCTTCACATTTACAAAGATGTCAAAATATTTCATTGAGAAAAAAATGCCTCTTCAAAAAG
TGGTGCTGTGTAAACTAGATAAATGAATACAATTATAACTATATCTCACTGAGTGGAATAATCAATTTCA
TAATCAATAAAGGACCATATGACCTAAAACTCTAATATTGCTATAAAATATGGAGAGTATTTCAAGATAT
GGATATTGATATAGACAAGGACTTTTGGAAAAGGACTCCAATAGCTAGAAAATAGTACCAAGAATTATCA
AAATTGATTTAATGAAATTTTAACAGTTCTAGGAAGCAATCAAATGAAAAGAATGCCAATGAAATTTGAG
AAAAATCTTTACTAGTTAAACACCTGTCAGAGCATTGAAATCTAGAATATACAAATTATACATCTATTAA
ACATCCAAACCCTGGCAAATGAAATAAAATTACACTTTTCACAGGATGAAGACCAAATACCCAATAAACA
TAAAACAATGTTCAGCATTTTTCTAATTGGGGAAATTTTAATAAAACCAGCTTGGAATTCTGTCTCTCTC
CAGTAAATAACAAGAACAAATGCTGGTGAGGATGTATGGAGATGAGCGAAATGTATACAGTAGTAGTATT
GGAGCATTTAGTCTACTTACTATGGGAATCAATATGAAGGTATTTCAAGAAATCTATGAATAGAACTACC
ATAGGGTACAGCTACATCCCTTCTGGATGCATGCCTGTAGAGCTCTCCACATATGGCAGAGATAACTATA
TAAGTCTGCTTATTGTAGCTCTATTAATTGAAGGCAATTGTGGAACCACACTAGATATCAGTCAATGAAT
TAATGCAAAAGAAGATGGTATATGTGAACAATGCAATTTTATTCAACAACAAAGAAGAATGAAGTTACAC
TGTTGCTTAAAAATGGATGCAACTAGAAGTCATAATAATAAATAAAATAAGCAATACACAGAAGAATACA
TATTTCTCTAACTTGTATTTTCTAGAATCCTAAAATACCCATAAATATCAGATGGGACACTGGAGGAATA
AATGATGGTAGTAGGACTGGGACAAAGGACAACATACTGAGAGGTTTACGAATGAGGCTAGGAAGGACAA
AGTATGGTATCTCCCAAATAAAACGTTTATGTATAACATAATTCTAAATAAACTCTACGCATAGTGAGTT
TATGTCACTAAAATAGTTTGAATATTAAAAATAAACGTACTAAAATATTTTTATACACTCTAAAACAGCT
TTAAACTGTTATTAGAGTATAGAATCATCGTTTCTTACCTGTAGAAAGGCCTTCCTGGTAATCCTAAAGG
ATCAATGAATGCACGTTCCAGATACATTAGCTGATCATTCAAAATTCTCAGTAATATGGGGCTGAAAGGG
AAATTAATAAAGTTATACCTTCATAAAGATATGAATACTGCCTGACAAAGTAAAAGATTGCAACAAAATA
AACATCACTGGTGAATTTTAAAACATTATACCATGCAAATTAAGAAAATCAGTAACATTATAGAAACTGA
ACATAATGTATTTATATATTTATTAATATTTATAACAAATATTATTGAAAAAGTGAGGTCTCTTAATTTT
TAAAACACCAAAGGCACCCGATGTCTGACAGGTAACCAAGGAGGACTTCCCCTTCTCAGAGATGAAGGGA
AGGGGTAGTGGAGGAGGGTACTTGCAAGGGAGAGGACTGGGAATTGGTAGGTTATGTTTGGGATGTAAAG
TGAATGAATAAATAAACTCAGGGGAAAAGGAATATCAGTAATGTTATAGGAATATATAGTGTTGAACATG
TTGTACTTATGAATTTAGAAATATTATAACAACTTTAGGGGAAAATGAAGTTCTGATTTCTAAAATGAGC
AAAAGGAGTATGGAAACTTTGAAGGGAGGTTAATGTAGAGATGATGTAATTATATTATAATCTCAAAAAA
ACCTAAAGTAATACATTAAAAGTGAATATCAGCATGTATATTTGCCATATGTCAGGAATCCAGTAAAATA
TTATTCAACTAAAACATGAACTATAAAACAGTAACATACTGATGGGAAAATATGATACTAACGTTAACAC
ATACAAAAATGAGACATCATCAGCCTGGGTTTATAATTATTGTCTAGATTAGAGATCCTCATCAAAATTG
AAAAGATGGAGAATCTATAAATTTCTAATGACATGGTATAATATTCTTTCTGCTTAGACAAGAATTTGTC
AAATATATCATCTATATTTTATATTTTATCAGCATTCAAATATCATGAAGCAAAAATTCTTCCAGATTTC
AAATTGTTAAGGGCCAGTATGTTGTTAAGGGGGACATTGTAATTGTAAATAAGAATGAATCAATGCAACT
AAATATTCATCAACAAAACTTGGTTAGCTCAACTGAATTTAGTACTACAACTATGCCATGATACAATTAG
TAAAAATTATCAACTTAATAAATAATATTATTTTATTTATTAATTCATCTCTATTCTCATTTATATTACT
TTAAATGACAATAACATAAAAGAGTCCCTTACTCTTGTGAATGATTTTATATTGTTTTAAATTTAGAGCA
ACCCTATACATTACTCAATGTTATAACTTCATTTTGCAAACTAAGGGTCAATTTGCCAGTCTATATTTTT
GCGATGAAACTGGGTCAATATTGTAACATTTTCAAATTCTTCTTATGTAGAGAGGATGGTCTGTGTGTAG
GCATAATGACTTCCAATAGAAGTTGAGAAGCACCCTCCAGGAATAAAGGAATACAGATGGAGAATGATGC
TCAGGAGTGAAACCAAAACTTATTTGAGCCAATACTAAGGTTGCTAAATTGTATCTCCTAATCTGGCAGA
GAGGAGAGACTGCCATCTAGTGGCACTTCACGTCCGAAATGAAATCTGAACAGGATGCATTAGAATGAAT
ACGGAAATATAACACAATTCCCAAAGGTATTTCAGCAATGAGAATGAGTTAGTGATATTTTATACATATT
TACACATATAATTATATATTTTGATTGATTGATTTAGTACATACTTGCTCTTGTCTAAGTCTTGCAGTCT
CTGATTGAACTTGGATGCAACATCTGTAAAATTATTTACTGCAGAAAACAGCGAATCTGAAATGGAAATC
CAAATTAACAAAATATTTTAAGAACATGTGTGGGACTGTGAAAGGTAACTTAGTGCCCGGTTGAGCTAAG
GCTTGAATCTCCAGAAAATCTGAAGGGACAGTAGGTGCTTCGCCTGTTTCCAGGCACCAGGCCCCTGTCA
CCACCCCCCTTTCCTCCCCCAGATTGGTCATCAGTTATGTAAGGGCAACTCCCCAAGCCCCTGGACAGGT
AGGCGACATGACTACAGGTCACATAGACTCAAGGCAGATCTCCATTTTAATGAGGTACATAAAGGCCTAG
ACGGCTTTGCCAATAAACTTTCCTTCCCAGACACTTCTCCCTGCAAAAGGAATTTAACCTCAGTTCCACC
GTGAGAATTGGGGTATGGTTTTACACATCTAAGTTTCACCATGATAATAAATACCTTAAAACCATGGACT
GCCGCTTTTTATCAGGATCCTCCATAGGAAGCCACAGACAAGACCTTGGCCTATATAGCCACTGTGTAAT
CTCCCATAGAAGGCCTCTCTGTGCTCCCAACCACCACCACAACCAAGACCTAGCCCAAGACTGCAAAGGT
CAAGGCAAGGACTCTCCCCACAGAACTAGTTGGAGTTCTCCACTTTTCCCCTTGGCACTAGGCTAAATCC
AAACCCATGGATCCCCACTCTATTCTCAGCTCCTCTACAGCAACCAGTGGCACATGGATGTCAAAGAGCT
TAAAAATCAGATGGCCCTGGCCTCCTTGAAGGCCCAGCAACCCCTGAGCCAGCTCCTGCTCTCTGCCTTA
GATTGTGCTTACCCAACCACAGAGCGGTGTCCTGGGGCTTCCGTACAGCCCAACACCTGCCTGGTCACAG
TGTGGTGTAAGCTGGGTCAACCTCCCACATTCTGCCAGAGCAGACCCAGAACCCTACAAACATAGTTTCA
AAGGTAGGTAAGGTGGCAAGATCTGCAGTCTCAGCACTCAGGAAACCAAAACAAGATGATCACTCCAGTT
GGGGTTTAATACTGGCCAGTGTGAGATGTGCAATCTCATTTCAGTAAAAGAAACAAAACTCTGGTGATTC
TAACACTCTCTTTGTAGATACTGATGGGAAACAATATAGAAATCTCTTTTGAAGTAGTTATATATTTTTG
AACATCTGTGAGATGAAGAACATATCTCAGGAGAAAAAGACTATCTGATCTAGTATAATAGAAGTACCAA
TGAGAAATGTTTAAAAAACACAGGTGTGAATTTGAAAGGCATATTGCAACATACCAAATGATATCATGTA
CGCCTTCATCTCCTGTGGATGATTCATTGAAATGTTGTAGATAGTCTCAGCATGTTTCTTCAGAGCTACA
GCATAACTTTGGCAGTCAAAGGGAAGCACTATAGAATTGGCCAATTCAAATACCATTGCTCCTCGAACCT
GGGCCACAGTGAGGTGATATTTAAATGTCGGATCATAGAATTTTTCTACCAATTCGTATGTTTCATAGAC
ACTGTGATAGAGAGGATAGCTGCTGACTTTGTTGGTTTTCTAGGAGGAAAAAGAACAAAATGCATATCTT
TATGATAGCTTATAACCAACCCTATAGCATGATATTTACTGTTATGTTATTAAGGTGGTTTTAAAACTGA
CAGACAGGGTTCATGTAAACTTAGATTTTTGAAAACTTAGAAAAAGACTACTCTAGGCATGAACAGCTGA
ATACGCACGCACACATGGTGCAAAACCAATATAAGAAACATTCCTTGGGAAACACCCCAGACAGTTGTCA
ACCAAAATGTCAGAGATGTGGAAATTTGTTGAGAGGCCAAAGAAAGGACTGTGCAGTGCTGCACTAGAAA
ATAAATTCTTTAAGGAGAGAGTTGGGAATTATTAAACACCAGTGAAGGAATATGATAGAGTAGAATCATG
TATCACTGAAATCCCACAGAGAAACTCTGAGAGGCAGCATGATGAACAGTGGAGAAAACAAGCAGGGAGG
ACCCCGGTAGTGAACCTGGGATCTTTCTAAGGAGAGAGAAGTGATGCTCAAACAGGAACAAGGGAACTGC
ACATGGGGAAATAAAGAACTTTTCTCACAGTGAACTGCTGACATTGTGTCTTCATTTTTTTCTCATTATG
TTCTTTCATTGCTGATACAAATAACACTTTATTTAGTATAATTTTGAAGAGACAGAGACTTGGATATTAT
TAATGATAGATGAGCTTAATTCGGAATTCAAGACTGGTTGCCAAGGACATTTGGCAACCCCATAGATTTT
GGTTGGTTTAGTTTCATCTACATCAAATGTATATATTCTCATCAACCCCCTTCTCATGAAACCCCACACA
ACATTTTATCCCCCAAAGATCCCTGGCTGGGGGCAAGTAACTTGATCTAGAGAAAACACATCCAAAGATT
CACTGTTGTCTGAATATTCCCATCTGACTTTAGGATTTAAGCACAATGGAAATGTATAATTGGGTCCAAT
CTTTTTCCCGTAGACTATATTCTTCCATTAAATCATTTTGAATTAATTGAATAATCAATTTAATAATTGT
GCTGGCTTAGTTTATGTCAATTGACACAAGCTGAAATTATCTGAGAGGAGGGAACGTCAATTGAGATAAT
GCCTCCATAATATCAGTCTGTAAACAAGCCTTTAGAGCCTTTTATTAACTATTGATTGATAGAGGAAGTA
CTGAAATTATTATGTGTGGTGTTATTTTTGGCTGGTAATCCTATGTTCTATAATAAAGCAGTCTAAGCAA
GGCAGAAAAAGCAAGCCATTAAGCAGCACTCCTCCATAGATTCTTCATCAACTCCGTGTCTATAGGTTTA
TTCCCTGAGTTCCTGTGAAGGTGACCAGTGACTTGAAAGTATGACCCTAATAAAACTTTCCTTCCCAAGC
TGCCTTGGTCATAGTATTTTATCGCAGCATTGATAAACATAAGTAAGACAATAACTGTTGCTTTTTTCTT
AATAACATATATCTGAAAAACAAAAGTACATGTTTAAGATATCACTTATAAATTAGAAACTAAAACTTGA
TTGAAATTAGAAAAAAAATTAAAGAGAAAAAACTCACTGTAAAACAAAACATGGGTGCTTTCAACATAAG
ATTCATAAATTGCTAGGAAGAAACTTTAACAGAATTAATTCTGATTTTAAAAAGAACACATTTTTAAAAT
TTACTAAAGATTTATCAATCACAAAATGAAAGAAATTGAAGATGATTTAGGGTTTTGTTGTAGTATATCA
ATTTTTATTCAGTGAATTTTTATTTATTTGACAATCTGAGCTACAATAACAGACAAAACTCCAAATATTG
TCATGTCTGGTTGGTTTTGATGAATTTGGAGTGCAAGAGAGGACAGATGAGGCCAACATAATTCTCAGGA
ATTTAAACAATGAAATAAATACTGACGAACCAAATGAATAAAACAGAATGCATTTAAGGCAGTTTCTCAA
CCTTCCTAATGCTTCAACCCTTAAATACAGTCCCTTTTGTTGTGGGGACCCCAAATCATAAAACTTTTTT
TGTTGCTACTTTATAACTTTAACTTTGTTATTGTTATGGATCATAATGTTATGGATCATAAGAAGAATCT
GATAGGTGACCCCTGTGAAAGAGTCATTTGACCTGCAAGGGATCAGGAAACACAGCTTGAGAACTGGCGA
TTTAAGAAAAAACATTGTAAAGGGTCTACTGACAGCAGTCTGAGTGCAACTGGAGTGTGAATAGTGTCAG
GGTAACAAAGGCAGGACAACCAACCAGGAAGACATTTCTATATGTCTTTTCAGTCCACCACTTCCTCTAA
CGCCAAGATATTTCTTGAAGTAAAACTAATTAATTTGGTTAAAATAAACCCACATTTAATTTGTAAGGAT
TCTCTAATTTAAACTCACCCAATTTTTAGTATACCGGGCTCTGCCTGAAGCAATTCCAAGTCTTTGGAAA
AACACTTCAAAATCATTGCCAGACCCCAGCTTGCTAATCCTAAAAGACAAAGTTAATGTAATTAGTTCAG
AGTACTCCGTTCATTCTATAAAGAGCAAAGGTTAATTACTAAATCCTAGTTATATTATTTCAAATATGAG
AGCATTAGATGTACAGTTGAAATTTTCTCTGGTACTGAAAAATGTGCTATGCTATGGAGGGGCTCTTTCA
TAAATCACAATCTATTTAAAGATTTCAGAGGTTGGAAAACATTTTTAATGCTTTTGCTCAAAATATTTGC
TTCATCTCTGTTGTAGAAACTACTGAATAGGAAGAGCCATTAATAGATTAGGATAAAAATCTTGTCAGAT
CATTATAATATATACATACTGTAGAATTCTACCTCTACAAAATAATGAGATATTTATTTCCCTTCTCTTG
CATGTAAAGATACAGCCACTAATCATAGTTATATGTTATCAGAGTAGACAAACTAATGCACTCATCCAGG
AAAAAGAATAGCAATAGACTGACATGTGATAAATGTTTGACAGAAATTGTGTTCCATTTCCTTCATTGTG
ACCATTTACATGCACCATGTACAAATATAAGGTATCCTAATATACACCATAATTCTCACTTTACTTTATA
AAATATTAGTTATTTTTCACAGTCTAATTTGAATGCCCTTGACATTAGAAGCTTGGCTGTCAAGGTCCCT
GAAAGAGGAACAACGAACGGCTTAACAACTCATAGAATGCAGGCCCCAAGTCAGTACTAAATCGATGGGT
GTTCTTCAGAAAGGAAGAGAACCAAATACTGAGTGTTCTGCGAATTTGATGCTGTTTTGGAGCGTCTCCC
TACTTGTTGTTCTTGTGGTCTCCATGTCCTTAGTAATCTGTGTTGGGTGAAGATTCTAAGGGGACTTTAG
CTGTCCACTAGGCCATATCATTGACAGTCAAAATAATAGTGCTTGATGATTTTTGAAGCATTGCTTCTGG
AACACACTAATGATTGAGTCACCACCCTTAGAAAGAACTTAAAAAACTAGATTGTTAGCATTGACCACAA
CCCTTAGAAAGGATTTCGAGAAGATTGTTCAGATGTTTTTGTCAATGGCTCTGATGTAGAAAATCTTACA
AATTAAACTGAAGTCCAGAAAGGCACACTCCTAAGAGCTGAGCTAGGAATTTTTTAAGCTCAGGGAAGAA
TAACAATGGCAACTTTAATAGCACTGGGTTACATGACTTTTACTAAAACTAGGCTACTGATCAAGGAGAT
AATTAATTATTTATTCCTAATTTTGTCCTCAGCTTTCTGATGAGATTTAATAAAAACTGCTAAGGTGTCC
TTATGCACCCTGAAGATTAAAATAGGAATGACTGTTTTTTAAATAAAAGTTTACATTTGCTACAACAATG
TCAAGCAACCAGAGCTTCCAGGGACTAAGCCACTACCTAAAGACTATACATGGACTGACCCTGGACTCTG
ACCCCATAGGTAGCAATGAATATCCTAGTAAGAGCACCAGTGGAAGGGGAAGCCCTGGGTCCTGCTAAGA
CTGAACCCCCAGTGAACTAGTCTATGGGGGGAGGGCGGCAATGGGGGGAGGGTTGGGAGGGGAACACCCA
TACGGAAGGGGAGGGGGGAGGGGGATGTTTGCCCGGAAACCGGGAAAGGGAATAACACTCGAAATGTATA
TAAGAAATACTCAAGTTAATAATAAAAATTTACATTTGCTACTTTTAAAATTTCTATATGATTAACTTTT
AATATACTCACTAAATAACTGATTCTTTCTTTGTAACCATAAACTGTAACCTGTCAGTGAAGACAACCTA
TTGCAAAAATTGCCTTGCTTGCTCAAACTTTTGTTAAATTATAACGAGTTGCTTAGTTATAAATGTATGT
AGGTTCTTGGGAATGGTTTGCTGTTTCTTCATCTGTAATACATAAAATGTTTGGTTTTATGTAAATATTT
ATTGAGGAACACATGTTTTAAAAATAATCATTAAGTAAAAGAAAAACAGAATGCAGCTGCATTATAATTT
TTATGCTTCTTGAAAGATTTAGCTGGGGTATATAACTTATAGCAGAAAAAATAGCTCTTAGAGCTTGTTG
AAGTTTCCTTTATCCATTGAGTGACTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTTTGTGTGT
GATACTATCTTTAATTCTTTTTTCATTGGACTACAAAGCATTTTCTTGCCTCCTCTGAAACAATTTTTTA
TTCTGGTCTTTAGCTAGCAGCCAAGGAGATAATTTTGCAGGCTTCAATCAATTGCTCACTCTGCATTTCA
CCTCAGGTTACATTAAGTGTGAAATTTGTTCTTTGATGCTTCAATGCTGCCTCTTGCATATAGCTAGATC
AAAAATAAATCTTTACCAATCCTACATCTGATAGAGGGCTAATATCCAAAATATACAAAGAACTCAAGAA
GTTAGACTCCAGAGTGCCAAATAACCATATTAAAGAATGGGGTACAGAGCTAAACAAAACATTCTCAGGT
GAAGATTATGGAATGGCCGAGAAATGTCTAAAGAAATGTTCAGCATCTTTAGTCATCAGGGAAACGCAAA
TCAAAACATCCCTGAAATTCCACCTCTCACAGGTCAGAACAGTTAAGATAAAAAAAAATTCAGGTGACAG
CTGTTGTTGGCGAGGATGTGGAGAAAGAGGAACACTCCTCCGTTGTTGGTGGGACTGCAGACTGGTACAA
CCACTCTGGAAGTCAGTCTGGAGGCTCCTCATAAAATTGGACATTTTACTACCTGAGGACCCAGCTATAC
TTCTCCTGGGCATATACCCAAAAGACGCTCCAACATACAACAAAGACAACATGTTCCGGTATGTTCATAG
CAGACTTATTTTTAATAGCCAGAAGCTGGAAAGAACCCAGATGCCCTTAAAGAGAAGAATGGATTAAAAA
ACTGTGGTACATCTATACAATGGAGCTATCAAAAACAATGATTTCATTATATTCATAGACAGATAGAATG
AACTAGAGAATATCATCCTGAGTGAGGTAATCCAAGCATAGAAAAACACACATAGTGTGCACTCTAATGA
TTGGATATTAGCCCAAAAGCTAGAATTACCCAAGATGCAATCCACAGACCACAGGAAGCTCAAGAAGAAG
GATGACCAATATGCAGATGCTTTCACTCCTTCTTGAAAGAGGGAAGAAAAATATCTATAGGAGGGGATAT
GGAGGCAAAGTTTAGAGCAGAGACTGAAGGAACAGCCATTCAGAACCTGCCCCACATGTGGCCCATATAA
TATATATACAGACACCAAAACTAGATAAGATTGATGAAGCTAAAAAGTACATGCTGAAAGGGACCGGATA
TAAATCTGTCCTGAGAGACACAACCAGAGCTTGTCAAATACAGAGGCAAATGCTACCAGCAGACCACTGA
ACTGAGAACAGGACCCCCTTTGGGGGAATTAGAGGAAGCATTGAAAGATGTGAAAGGGCTTGCAACCTCA
TAAGAACAACAATGCCAACCAACCAGAACTTCCAGGAACTAAACCACTATCAAAAGACTATACATGGACT
GACCCAGGGCTCTAACTGCGTATGTAGCAGAGAATATCCTTGTTGGTACACCAGTGGAAGGGGAAGCCCT
TGGTCCTGCCAAAGTCAGACGTCCAGGGCAGTGGAATGTCGAAGGGGCATTAAGGGGTGATGGTTGAGGG
AATACCCTTATGAGTAAGGGGGAGGGGATAGGGGTCTTATGGACAGGAAACCGGAAAGGGTATAATAGTT
GAAATGTAAATAAAGAAATATATCCAATGAAAAAATCCTCAGATTTAATTTCAAAACACAGGGTAATATC
TTACTTTAAACATAGTATTTTATTTTAAACAAAAATACATCTTTGTCAGATGTGAGAGCGTTTTGAAATT
ATTTCTAACAATACATTTTAAGAAATATACCCATTTACACCTAAAACATTCAGCCAGTAACCAAACTTGG
TAGAATGGCTGGATAGTTGCTGTACCTTGGCATTCCAATGAACTCAGTTGAAGGACTTTTTTCTTTCCAG
CTGTCATAAAGAGATTTGCCTTCAAAGCCTTCATCCGGGCTTGGCAGCTATACAAATTATAAACAAGAGA
ATACTCACAAATCCAATGCATAAACCTAAATGTCCATTAATAAGAAATTGAAAATTTAAACTACATTTCA
ACAAAATAAGAAAAGAGATCTGTATATTAGAAGTTGATGCAAATTATATGACTGCTCTGTGGTTCTTTCT
TGATATATTCTTGGCTTTGGGATCAATGTGAAGCATAGGGATTAAAGAGTTACAATAAAAAGTTCTGAAA
AGTATATATTTGTATATGTGCATTTTCAAGTGTGAAGATGTGGCATATAAAGAAAATAATTCAACATATT
AGCAAATCATTGTCTGTGGAGAAACAATCATAGGCCAATTTTCCTGGATCAAAGAAAACTATTCTCAAAA
CCATATTCTTCTCCTACTAAAGAAAATATTACTTTATTATTGCCTTTTATCTGTAGGACTGCAGAAGTTT
TACATGATACATAATGAAGTCATTATATATTATAAATTAGAGAAGGCAATGACTGTTTTTTTTTAATTGA
TTGCTTTTTGTAATTGTGCTAAACACCAGGGTTTAAAATCATTTTCTGGTTTATGGGTGAAAACAAAATG
AAGTAAAACAAAACCTATATTATTCAATTTTAGAATTAGAAGATATAAAGTTGAGCATCACTAAGTTTCC
ATAGTTATATAGGTTCAGTGGAAGAGTCTTTTAAATGTTTTATACGTAATAACTATCAAGTGTAACAGTT
CTTAACAAACTTAATTTAAAAAATTTACTGACATAATATTTAATAGTTTATGTACAAAAATGTAGATGTC
CATGTAGTGTATACTATAATAAACTTATCCATTAATAATTATATGCATACAAGTTAGATTTATTTCACAT
TAGTAGAAAACTAGAAGATATATCTCTATCTTAACCTGTAAAATATGAATAAAGAAACAAAATTATTCTA
CTCACATTTGTAAACTCACTTTCCATTTTCTTAAGAAACACAAATTGAAAAGTAAAATACTATATTATTA
AAATTATCAGTTTATCAAATAAGCATATTTAAATAATTGCAAAACTCTCTCCAAACAAAGAAAATAAAGT
AACAAGAAATGAAAGAAAACAAAGGAATGAAACAAAGAAAATTTCTATGAATTACATATTTTAAGCCTGA
CCCAGCAGTATTTTTACAACTATGTCAAAAGGTCACTAACTCAGGAGATAAACAAAACAGTCAAACTTCC
TCATAATTTGCCTGAAATTATTGATCAGTGAGATTTCTCTGAAACACTAGGTTTGAGTCATGTAAGTTTT
ACATGCTATCTAGTAACTGATAAAACTGCATTTAAATGGTTCAGATCTTATATAACTAGATGCTGATTCT
AATTAATATATTTCTTATACTTGTAGAAGGAATCATATTTCTTGATTTAATTATATGCTTGTAATACAAA
GATTTATTTATAATTCCTATGTGAAGTAGTTGTGATTTTCTTAGAAATGCATTTGAAATGGTTAATAATG
TTCAATAATCAGGTTTTGTGGCTTGTTTGAATTTTGTAGTAATTTTTAGGTCAGTCTCAAAAGTTTGTCA
TGCAGCTAGAATGACAGTACACTCCTGCAACTCTAGTAATCTGGAGGCTGACACAGGAAGATCTGGATCT
CACATCCAGATCTATCTGGACTACCTATCAAAACCCTCTCTTAAAGAACCTTTCACATAGAAGTATATGG
TGCCTCCAACCAGCTTCAGTATTTTTTATAGCTAAGAGAGCTAGAAGTAAAGCCAGGCTCTTGTGATAGA
GCCAAAGATTGGAGTAGTAGGTGAAAAATTAGAAGGAATTACCTAGGTAATAATTGAATTCATTCAGTCG
TTCTTACATTGTGAGTTACCTAATTTTCCATATAAGTGGTAATAAAGTAGTTATAGAGTAAAGGAATAAA
GCAGTAGTTCCAGCTACTATGTTACTCCAGTGGCTGCTTTCTAAGGTCTGTTTCCTAATTTTCAAAGTAC
TCATGGTAGAAAGAATGCAGCCTATAGGCTGACTCACAGAGTTGGGAGAGATGGCATCATATACTATATG
GAGAAATAGGTTAGCTGTAGAAGTTCAGGAAAGAATATTTTCATGAGAAAAGAAAGTTAGCTGTAAACAA
TATAAATATTTAAAATAATAATTGCATCCAAAATATCATTTACAGAGTTTCTGCAAAGCTTTTTCCATCA
ATTTACCTCTTTTGTTAGGTTGTATACTAAGCTGTGCATCAGTGGTGTGCAATCAACTCTGAGAGTGTAG
TTTCCTGAAACAAAAGGAACTGGCTGATTTGTCTTATATGTGCTATTGATTTTATTCAAAGGCCATTGCT
AAATTCCACATAGAATTATTCCTTTTAAAATGCACTTAATAAAAATCTTTAATGTTCTCAATCTTAAACT
ATAAAAACAAACTTTTATGACACTGACTGTTGAATCTTGTCCTAAAGATTAGGGAGAAAGCCTGATATAT
CTGTCTATTGAGAGGTTCTGCCAGAGCATGATAAGTAAAGAGGCAAATGCTAGCAGCAAACCATTGAAAT
GAGAACAGGGTCTCCATTAGAGGCTTTGGAGAAAGGACTGGTGGAGCTGAAGGAGCTTGCAACCCCATAA
GAACGACAAGCAACCAGAGCTCCCAGGAACTAAACCACTACCCAAGTAGAACTCATGGACAGACACATGG
CTCCAGCTGCATATATATAGCAGAGGATGGCCTTGTTGGGCACCAATGGGTCTTGCCAAGGCTGGAACCC
TCAGTGTAAGGGAATGTCAGAGCAGGGAGGCAGGAAGGGGTGGGTGGTAGGGGAGGGGGAATACCCTCAC
AGAAGAAGCAGGTGGGGGATAGGATAGAGGGATTATAGATGGGAAACCAGAAAAGGGGATAACATTTGAA
ATGTAAATTTAAAAAATCCAATAAAAAAGTAAAATAAGATACATTTAATAAAATGCCTCTAATATTTTCA
ATCTTAAGCTAAAAAAACAAACGCTTATGACATTGACTGCTGAATCTTGCCCTGAAGATTACGGAGAGAG
CTCAATAAGCCACATCTCCAAATCTTTACTTCCCATTCTACCTAAGAACTTTTTCTTAAGCTCCCTTATA
ATACTGTTGCTTCAGCTTGAGTCAGTGTTCCACATAATATATGCATGACTTCTTCACCCTTTGGGCTCAA
GTTAAATTTTCAGAGGGATCTCATTGAGTCCTGGATGGAACACTACAAATGGCTTCCACTCCATAGAATC
TATTCTCTTTTCTTGTCCTTGATCTGTTTTCCACATCACTCAAGAGCTGGATCATAGTGAACCCTCCAAT
TCTCTATTGTAGTTCATTCCAGATATAATCAGATTGATAACCAGGAAATAGCCATTACATTTGTCCACAA
CCTAAAGTTACTTCCAGGATTGTTATATATCTTTTATTCCCAAAGTAAGATCCATGTCACTAAAGGCTGA
GTGGTGTGGGCTTTTAATCCAAGCATTCAGGAGGCTGAAGCATAATGACTTTGGATGAGGACTGTAAAAC
TATAACCTACCTCTATCAAAGGTGAATCAACTGCTTTAATTAAGCTAAGACTAGATTGGGCAATAATCAA
AACTATGAAAATTTAGTTAACAGCTAAATACCCTACATCTTGCTTCAATCTACTTCTTCTGCCTGTCAGA
AAGGGGATAAGAGAAGCTTAGTAGAGAAATATATCTACACCTTTGAATTTGTATTGGACAAGATTATCAC
CTTAAGGCTTGGAAAAAAGGGATTCAACCCTTGTGTTTAGATTAACAGTCTAATGCCTACTCTGACATTT
TACTTTCATAAACCACTGATTATTTTCAACTAGCCATAAATATATTGTGCATATATATATATAATGTATA
TATATTATATTTTGATAACAAGTGCTTTTATTTGAGTGACTTACAGGGAGATGGTATCAAAGCATTTATT
CCAATATAGATACACATAACATGGGTCCAAAGAATTACATATATGACTCTTTATTCAGTACAAATTTCAT
GTAGAAAAGTACATACGCATAAATGGACAATCTCTATAATAGCAGCAACAGAACTGAAATGCAATTGCAC
CATTAAATGTGCTACAGAAGTTCTACTGTTTGATCGTAGTTACTTTGGTTTGTTTTGTTTGGGGATTTGT
TATGGTTGTTACATATATATGCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTATAATAAGTC
AATGTGTATCACTAAATGAAACATTTTATGTTTTCTGTGTGAAAATGTGGATTTACAACCATTATTTGGA
GTACAATACAAATCTTGTAGGATTTAAGAGGAGGTAAGATAGCATAATAGATAGGAATGACATTGAACTC
AACCCTCGCCTAGCAGGCAACATTTGAAAAGTTTTTTTTACTTCTCTGAGTCACAGCTTCCTCTTCTATA
CATTGTGGTAAATAAGTACTCACATGACATGATAGTAGCACCACATAAAGATCTGATAGGCAACAATTAA
GAGAGCATCAAAACCATTTCTGTTAAATGCAGCAGATACATAGTATGCGAGTTCACAGAACAGAGACACT
AGAATTCAATGAAAACAAAATTTTGGAGAAAAAATTAAGAGTGATTTGGGTAAACCCTTAATCTTTTATA
AATTTACAAATTATATTATTTACAAAAACTTGCAAATAAATAAAAATATTATTTCAGTTTTTGTTTTTAT
ATGCTTATATTTTAACATAAATTCACTAATATGTGTTGTATTATATTCCTTGAGAAATGAACATTTAACC
AAAGAATGGAATATAAATTGAGGGTTGTATATCGCAATCACACTAAACCTATATGTACTTGTTGTTAATC
ATAAACATTATGTACCAGTCCCAGATTTGACATAACTATCCAAGCCCAGTGATGTGATAAAATACTGGAG
AAATCAAATGTTCAAAACTATTAATAATAATAACAACAACATTTAGCTATACATCTAGCTTCCAAATTAT
ACGATTTATGTAAGTAAAGAATGGTGACTATTTATCAAAGTGTGTGCGTGTGTGTGTGTGTGTGTGTGTG
TGTGTGTGTGTGTGTGTATCATGGGATACAAGTAGAAGTCAAAATACAAATTTTGGAGTCAGCTCTCACA
GTCCATCTTTAAATGGGTTCCTAGGATACACCTCAGTTTGTCAGGATTCCCTCATAGTGCCTTTGATGGC
TTATGATTTTCACCAGTCCATATAGATAAATGTCATATATGTATTCAAAGACAAAAGAATCTTAAGGTTT
GTGACATAGGCTTTCAAAGGGTAACTGTAACCATATTTAAGAGAATCTGGTAGAAGAGGCATGTTAAGGA
ATGCAGTCTTCCTGAATCAGTCCTGATACACAGAGGGGGAAATGTCTCTCTCTCTCTCTTTTTTTTTTCT
TTTCATCTTCATTAACTTGAATTTCTTATTCACACTTCGATTGTTATTGCCCTTCCTGGTTTCCTGACCA
ACATCCCCCTAACCCCTCCCCCTCCCGTTCTCTATGGGTGTTCCCCTTCCCATCCTCACCCCATTACCGC
CCTCCCCCCAACAATCATGATCACTGGGAATCCGGCCTTGGCATAACCAAGGGTTTCCCCTTCCTCTGGT
GTTCTTACTAGGCTATTCATTGCTACCTATGAGATTGGAGCCCAGGGTCAGTCCATGTATAGTCTTTGGG
TAGTGGCTTAGTCCTTGGAAGCTCTGGATGGATGGCATTGTTGTTCATAAGGGATCTCAAGCCCCTTCAA
GCTTTTCCAGTCCTTTCTCTAATTCCTTAATCGGAGGTCCCGTTCTCAGTTCAGTGGTTTGCTGCTTGAA
TTCGCCTATGTATTTTCTGTATTCTCGCTGTGTCTCTCATCCTGCCAATCCATGAGCATGGGAGATCTTT
CCATCTTCTGATGTCTTCTTCAATTTCTTTCTTCAGAGGCTTGAACTTCTTATCATACAGATCTTTTTCT
TGCTTGGTTAAAGTCACACCGAGGTATTTTATATTATTTAGGACTATTATTAAGGGTGTCGTTTCCCTAA
TTTCTTTCTCAGTTGTTTCTCTTTTGTGTAGAGGAAGGCTACTGATTTATTTAATTAATTTTATACCCAG
CCATTTTGCTGAAGTTGTTTATCAGGTTTAGTAGTACTCTGGTGGAACTTTTGGGATCACTTAAATATAC
TATCATATCATCTGCAAATAGTGATATTTTGACGTCTTCTTTTCCAATCTGTATCCCTTTGATCTCCCTT
TGTTTTTTGATTGCTCTGGCTAGAATTTCAAGAACTATATTGAATAAGTAGGGAGAGAGTGGGTAGGCTT
GTCTAGTCCCTGATTTCAGAGGGATTGCTTCAAGTTTCTCTCCATTTAGTTTAATGTTAGCTACTGGTTT
GCTGTATGTGGATTTTGGTATGGGCCTTGAATTGTTATTCTTTCCAGGACTTTAATCATGAAATGGTGTT
GAATTTTGTCAAATGCTTTCTCAGCATCTAATGAAATGATCATGTGGTTTTGTTCTTTCAGTTTGTTTAT
ATAGTGGATTACGCTAATGGTTTTCCGTATATTAAACCATCCCTGCATGCCTGTGATGAAGCCTATTTGA
TCATGGTGGATGATTGTTTCGATGCCTCTTAATTACTACTGAAATCAGCCTTAGGTTGAAGGAAAATATG
TGAAACCAGCCACAGTTATCCTAACTTCATTTTAGTAGACTTCATTCTGTGCTAGAATGAAATTCGTTGT
CTAAATTGTTACTTCAAGAAAAATCATTATGTTATTTTATGAAGACAACAATACTCACCTTCTATGGAAG
AATCAGCGTTGATATAAGCCACACCACGTTCTTGTAAGAGTCTTGAATGTTCCTACAATAAGAAATTTAA
CAAACTATAAGCATAAATTTAATTCCCTCCTACCCAAGGCACATATGCCATTCTTTACCGTAAACAGTTG
AACGAAATTACATCATGATTCCCACAGGTTTTACATATAAAGGCTAAAATATGTGCTTAGTAATGAGAAA
CCATAGCAAATTCTTCTAAAGTACATTCAAGCGGGTGAATAGTTCAAATACAGTAGATGAAAGAAAATTA
GGAATTTAAACATGTACAAGCATCAATCACTGATTTTTAGTGAACATCTGTTTGAGACTTTTTAGTAAAA
ATAAACTTTTATACATCCAGTCATAATGTAAGCAGAAATGATTTCCTTGATTAACAGGAAATGAGCAATT
TACTAGTCAGGAAATTTACAAAGAAAACTTGACCATGGGGGCAATTTCTATTCTAGGATAATACCACCTT
TGGGTTATTATGACTGATTGCACATTTTTAGAACTAAGAAGTGTAGCAGGAGTCCATAGAGACTTTTGGT
CTCCAAAATATTGAATTTTCTAAAAAGTTTGATTGTCAGAAAAAAATCAGGAATGTATGTGTAATTCTGA
ATGTTAAAAAAATATTGATCAATGTATAGTGGCTCAAGGGGCCAATGTAGCAATATTGTGAAAGTTTCAG
GGCAGTTTGAGCTAAATAAAGAGACCATCTGAAAATAATGATAATAATGATATCAAATAATAATATTATT
AATAAAAATTCTATAGAGAAAACTGTATTCTGAAATATTCATGGATTTTTTCTGATACTAGCATGAGACT
TTTCTGTGGATAAAAAAATTAATCTTGATCGACAGTAATATAGCAACTATTTGGAGAAACCTGTAATATC
TATGTTTAACAGGAACTGCATGAGCCTTAAAAGCACTATAGTAAGCTAATGAAACAAATATCAAAACGCC
ATATGTTTATTTCTCTGTCACACTAAGCTGACACACATTTGAATGGATTTACTATTCATGTTACCAGGTA
AATATTCCTCCTACATCATTTTTTTGTGTGTACAATAGTGATGAGACCACTGAGGTAAGAAAATAAGTAC
AAACCAGGTCTTACTGTGGAATCTGAGGTCTCAATGTGACTGGTTCTTGGAGTTGATTGAGGAGGTATGT
AAGAATCATACTAAAAATTGTCATGTTTTAAGTTGTGTGGTTCTCTGACCTCCACTGTATAGATCTGGGC
TTGTCCTTCAGTCTTAAGGACACTTCTGGAACTCCAATTGTATTCTGCTTCCCTGTTGAAGAGAGTGGGA
CCCAGGAATAATCACCTTAAAACCAGGTCCCACCAATCCTCTCCTAGTAGTGTCTGCCAGGGGCCCAGCC
TACAGAGACAAGTTGTTCATGGTTCCTTGACTTCAGTTGTCTACTTCTGGAATCAACCTTCAGTCCTGAG
GAGCCCTGGGAGAACCCAAGAGGATCCTGCTTCACTATGGTGTCCTGTGGAGTGTCCTCAAGAACTACCA
GCTTGGAACATTGCTTCACCATTCCCTTGACAGAAGGGTCCACCTGAAGCACAGCAGCCTGGTCAGGTAC
CTGACCTTTGCTGCCTGGCCCTTAGCTCCTCTGTGCCATCAGTGTCATGAATCCATCATCAGGGAAAATC
AGATGCCTAAAGGACAATGTAAAAACCCAGTCAAGACTCAGGGCAACATGGCACCAACTATCCTAATACA
ACAAACTTTGGATATCCTAAGGAAAATAAAACACAAGAAAATGATCTTAAATCAAATCTTATAAAGATGA
TGGATACCTTTAAAGAGGAAATGAATATATCTTATGAAGAGATACAGGAAAATATATTCAAACAAGTAGA
CGTATTAAAGGAGGAAGCAAATAAATATAATGAAATACTGAAAAAATAGAATCAAATAGGTGAAGGATAT
GAATAAAACTATATAAGACATGAAAAGGGAAGTATAAGCAATTAGGAAAACACAAACTGAGGAAATCCAA
GACATGAAAAATCTAGGGAAAAGAACAGAAATTACAACACCAACACAATATTAAATATGGAAGAGAGAAT
CTAAGACATAGATATGATAGAAGAAATACATACATTAATAAAAGAAAATGCAAGGTCTAAAAAGTTCATG
ACACAAAATAATGAGAAATTTGGGATACCATGACAATGCCAAACCTAACAACAATAGGAGTAGAAGAAGG
AGAAGATTCCAGCTCAAAAACTCAGAAAATATCTTCAATAAAATCATAGAAGAAAATGTCCTTAATGGAA
AGTAAAACATCCCTATAAATGTATAAGAAGCTTACAGAACAGCAAAGAGATTAGATAAGAAAAGAAAATC
TTACTGCCACATAATAATCAAAGCATTACATGTACAGAGAAAAGGAAGAATATTAAAAGGTATAAAAAAA
AGCCAAGTAATACATAAAGACAGTGCTATAAGAATTACACTAGACATATTGATACAGATTCTGAAAGCTA
GAAGGCCCTGGACAGATGTTCTATAGACCATAGGAGTCCACAGATGTCAACCCAGACTACTATACACAGT
GAAACACCAATAACCATATATGGGGAATCCAAGATATTTCATGACAGAACCAAATATAAACAATATCTTT
TAAAAGCACAGCACTACAGAAGATAGCAGGAAGAAAACACCAACCAAAAGAGGCTTACTACAATCAAGAA
AACACAGGAAATAAATAATTGTCCACCATTAATACAAATAAAAATAAAACACAGACACACACATATACAC
ACACACAAACACAAACACACACACACACACACACACACACACATCTGTACACTACCACCACCAACATAAA
AATAACAGGAAGTAACAACCATTGGTCATTAATATCTCTAACACTGATGGACTCACTTCCCTAGTAAAAA
CACACAAGGTAAAAGAATGCACTTGTAAAGAAAATCCATCATTATGTATATACAAGAAACACACCTCAGC
AACTAAGATAAATACTACCTCATAGGAAATGGATAGAAAGAGTTTTCCAGGCAAAGGGACACAAAAAGCA
ACCTTTAGTAGCCATTTTAATATCTTATAAAAGATATTTTCAGCCAAAAATAACCAAAAGACATAGAAAA
GGACAATTAACACACATTAAAGGAAAAATCTACCAAGAGGTCATCTCAGTTCTTAACATCTGTGCCACAA
ATGCAAGGGCAACCACATTCATAAAAGAAACATTACTAAAGCTTGAATCACTCATTGAATCCCACATATT
AGTTGTTAGAGATTTTAATACCCCATTTTCACCAGTTGAAAATGGAGGTAGAAACTAAACCGAGAAGTAA
TGAAACTAACAGAGATTATGATTCAAATACACTTAACAGATATTTATAGAACAATTAGCCCAAACACAAA
AGAATAGACCTCCTTCTTAGCACCTAATGAAAACTTCTCCAAAATTGACCATATAATTTGTCACAAAACA
AGCTTCAACAGATAAAAGAAAATTGAAATAATCCTTTGCATCTTGTCATATCACCAGCTTTTGTTGTTGA
ACTGTTGAGGGATCTTTCTAATGCTTTGTCTTAATTTGACTCCCAAAAGCTGCACTTCCAGATGTTGAGG
GCCCCGGCGCCCAGCTGGTTTGATTGGAAATAAAGAACTGTCTTACTGAAAAGGGTTGGGCAGGGAGATG
GAGGTGGGACTTTAGATTATATGGGCAATGGACTGAGGGGGAAGAGGAAGAGACAGAATGACCATGATGG
TGGAGAAGTGAGATTAGAGTTAAAGACCCACTGACATATAAGCATCTTGGAAGGCATTTCTGGGACTACT
TCCCTGCTTGGTCTCAGGAAACAAAGATAAAAAAAATTATTTAGAAAATATTAAACTAGGAATACTGAAG
GGGAGTGTTTGCTAGACATGAGAAAGTTTAGAAGTAACAAGATATTGAGCTAGTTAGGCATATTAAAAAT
TAAGCTGACGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTATTTGTGCGTGTGTCTAGAATTAACAA
TTTACTGGTACAAGGAACAATATAAGGTCCACATACTCATGGAAACTCTCTCCTCCATAATCACTGAATC
AGGGAAAAGATAAACTCAAGACTTTCCAGAATTCAGTAAAAATGAGAGCACAGCATTTCCAAACTTATGG
GACACTATGATACTAGTGATAAGAGGAAAGTTCATAGCCCTAAATGTTTTCATAAAGAAATTATAGTATT
CTATAATAGCTAATTAAAAGTATACCTGAAAGCTCTAGGGAAAGAAGAAGCAAACACACTGAAGAGGAGA
AGATGCCAGGTAATAATCAAACTCAGAGATTAAAAAAAAATCAATTAGAAACAAAGGGAACAATACAAAA
TTCAATAAAACCAAGAGCTGGTTCTTTGGGAAAAATCAACAAGATAGACAATCCCTCAGCCAAACTAATT
TAAGGGCAGAGAAATAGTACACAAATTAAAGATAAGAATAAAAAATGAAAAGGGATACACAAGCATGGAC
ACTGAGGAAATTCAAAACATTAAGAGGTCTTATGTCAAAAGTCTTACTTCACAAAATTAAAAGTCTAAGT
GAAATGGATGATTTTCTGTACAGATACCAATTACCAAAGTTAAATCTAGATTATGTAAACTATCTGAATA
ATCCTGTGACCCCTAAAGAAATAAGCACAGTCATTAAGTATCTCCAAACCAAGAAAAAAAAAGAAAGAAA
CAAAAGAGGTGCTTGGTCAGATGATTTCAACACAGAATTTGACCAGATCTTGAAAGAAGAGCTAATATCA
ATACTCCTCAAAGAATTTGCAGAATAGATCAGAAGATAGAACGGTTTCTCATGCTCCTAGATTGGAATGA
TTAATACAGTGAAAACATATATCTTACTAAAAAGAATCCACAGATTCAATGGAATCTCGATGAAAATTTC
GTTGAAACTCTCTACAGAAAAATTTTCAACTTTAAATGGAAAAGTCAAACACCTATGAGACCTGAAACAA
TTTTGAACAATAAAGGAACATGAGGTTATAGCACTATCCCCGACTTCAAGCTGTAATATAGAGCAATAGT
AATAAATATCACATGGTACTGGTATAGAAACAGATAGGTAGGTCAATGGAATCAAATTGAAGATCCAGAA
ATAAACCCATACACCAATGGACACTTAATTTTTGACAAAGAAGCCAAAACCATACAGTGGAAAAAAGAAA
GCATGTTTAACAAATGGTGCTTGTCTAACTAGAAGAATGCAAATAGATCCATATTTTTCACCCAGAACAA
AACTCAAGTCCAAATGGATCAAAGACCTCAAGATAAAACAAGATACATAAAACTAGAAAATAAAATAAAA
ATAAAAATAGAAAAAAAATGGTGAATAGCCTTGAACTCATTGGTAGAGGAGAGAACTTCCTGAACAGAAC
ACCAACAGCATAGGAACTAAGATGAACCATTAATTATGAAATGGAAAAGCTTCAATAAGGCAAAAGATAC
TATCATTAGGACAAAATTGGAGCTTACAGACTGGGAAAACATCTTTGCCAACCATACATCTGATAGAAGG
ATACTATCCAAAATATGTAAAGAACACAAGAAGTCAGAAACCAACAAACCAAATTGCCAAATTTTAAAAG
GGGATAGAGAGCTAATCAGAAAATTCTCAACACATGAATCTTGAATGACCGAGAAGCACTTAAGAGTAAT
ATTTATTATACTTAGTCATCTGGGGAATGGAATGAAAACAACTCTTGAGTTTCTTTTCTTTTTTCTTTTT
TCTTTTTTTGGTTCTTTTTTTTTTTTTTTTTTTTTTTTGGAGCTGGGGACTGAATCCAGGGCCTTGCACT
TCCTAGGCAAGCGCTCTACCACTGAGCTAAATCCACAACCGTTGAGTTTCTTTTCTTACAAACAGCAGAA
TGGCTACAGTGAAAACCATAAAAGGCAGCCCATGCTGGTGAGGTTCTAGAGCAAGGGAAACACTCCTCCC
TTGCTGGTGTGATTACAAACTTATACAACCACTATGCAAATCAATTTGTCAGTTTCAGAGACTTGAAAAT
AATTCTACCTGAAGTTATACCAGTTATACCACTCCAGAGCATATACTCAAAAAAGTTTCTTCATCCTACA
AGGACCCTTGCTCAACTATGTTCATAGCAAATTTATTTGTAATATCCAGAAACTGTAAACAATATAGATG
TCCTTCTACTGAAGAAAGGATTAAGAAAATGAGATTCATTTGCACAATGCTATACTATTCAGCTATTAAA
AACAAGGACACCAAATGGCTGAGACATACCTAAAGAAATGTTCAACATCTTTAGACAAAGGGGAAATGCA
AATCAACCCTGAGATTTAACCTCACACCACTGAGAATGGCTAAGATCACAAACTCAGGTGACAACAAATG
CTGGAGGATGTGGAGAAAGAGGAACACTCCTCCTTTGTTGGTGGGATTGAAGACTGGTACAAATATTCTG
GAAATCAATCTGGAGGTTCCTCAGAAAATTGGACATTGAACTACCTGAGGATCCAGCTATACCTCTCTTG
GGCATATACCCAAAGGATGCCCCAACATATAACTAAGACACATGCTCCACTATGTTCATAGCAGCCTTAT
TTATAATAGCCAGAAGCTGGAAAGAACCCAGATGCCTTCAACAGAGGAATGGATACAGAAAATGTGGTAC
ATCTACACAATGGAATACTACTCAGCTATCAAAAGCAATGACTTTATGAAATTCATAGACAAATGGAGGG
AACTGGAAAATATCATCCTGAGTGAGGTAACCCAATCACAGAAAAACACATATGTATGCACTCAATGATA
AGTGTATATTAGCCCAAATGGTCAAATTACCCTAGATGCACAGAACACATGAAACTCAAGAAGGGTGACC
AAAATGCGAATGCTTCACTCCTTCTTTAAAAGGGGAACAAGGATACCCTTGGGAGGGAATATGGTGGCAA
AGTCTAGAACAGAGGCATAAGGAACACCCATTCAGATCCTGCCCCACATGTGGCCCATACATACACAGCC
ACCAAACTAGATATGATGGATGAAGCAAAGAAGTGCAGGATGACAGGAACCGAATGTAGATCTCTCCTGA
GAGACACGGCCAGAATACAGCAAATACATAGGCGAATGCCATCAGTAAACCACTGAACTGAGAACGGGAA
CCATGCTGAAGGAATCTTAGAAAGGTCTGAAAGAGCTTGAAGGGGCTTGACACCCCATATGAACAACAAT
GCCAACCAACCACAGCTTCCAGGGACTAAGTCACTGCCAAAACACTATACATGGACTGACCCTGGGCTCC
AACCTCATGGGTAGCAATGAATAGCCTAGTAAGCGCACCAATGGAAGGGGAAGCTCTTCGTCCTGCCAAG
ACAGAACCCCCAGTGAATGTGATTTTTGAGGGGAGGGCGGTAATGGGGGGAGGATGGGGAAGGGAACACC
TATAGAGAAGGAGAGGGAGAGGGGCTAGGGGGATGTTGGCCTGGAAACCAGGAAAGGGAATAACAATTGA
AATGTAAATAAGAAATACCCAAGTTAATAAAGATGAAAAAAATTTTTAGCAAAAATAAAAAAAAAAAACA
CAAGGACTTCGATCTGCATTCTTCTCCATGCTGACCTCCAGTTGAACCTGAGGACCCAGCTAAATCTCGC
ATGTGCTTATACTCAAAAGATGCTCCAACATATAACAAAGACACATGCCCCATTATGTTCATAGCAGCCT
TATTTATAATAGTCAGAATCTGGAAAGAAAAAAGATCCCCTTCAACAGAGGAATGGATACAGAAAATGTG
GTACATCTACACAATGGAATACTACTCTGCTATCAAAAACAATGACTTTATGAAATTCATAGACAAATGG
ATGAAACTGGAAAATAACATCCTGAGTGAGGCAACCCAATCACAGAAAAACACACATGGTATTTACTCAT
TGATAAGTAGGTATCAGCCCAAATGCTTGAATTACCCTAGATGCATAGAACACGTGAATCTCAAGAAGGA
TGAACAATTTCCTAGACAGATACCAGGCACCGAAGTTAAATCAGGAACAGATAAACCAGTTAAACAACCC
CATAACTCCTAAGGAAATAGAAGCAGTCATTAAAGTTCTCCCAACCAAAAAGAGCCCAGGTCCAGACGGG
TTTAGTGCAGAATTCTATCAGAAGATAGAAGACCTCGTACCAATATTATCCAAACTATTCCACAAAATTG
AAACAGATGGAGCACTACCAAATACCTTCTACGAAGCCACAATTACTCTTATACTTAAACCACACAAAGA
CCCAACAAAGAAAGAGAACTTCAGAACAATTTCCCTTATGAATATCGACGCAAAAATACTCAATAAAATT
CTGGCAAACCGAATCCAAGAGCACATCAAAGCAATCATCCACCATGATCAAGTAGGCTTCATCCCAGGCA
TGCAGGGATGGTTTAATATATGGAAAACCATCAACGTGATCCATTATAAAACAAACTGAAAGAACAAAAC
CACATGATCATTTCATTAGATGCTGAGAAAATATTTAACAAAATTCACACCCCTTCATGATAAAAGTCCT
GGAAAGAATAGGAATTCAAGGCCCATGCCCAAACATAGTAAAAGCCATATACAGCAAACCAGTTGCTAAC
ATTAAACTAAAGGAGAGAAACTTGAAGCAATCCCACTAAAATCAGGGACTAGACAAGGCTGCCCACTCTC
TCCCTACTTATTCAATATAGTTCTTGAAGTTCTAGCCAGAGCAATCAGAAAACAAAAGGAGGTCAAGGGG
ATACAGATCAGAAAAGAAGAAGTCAAAATATCACTATTTGCAGATGATATGATAGTATATTTAAGTGATC
CCAAAAGTTCCACCCGAGAACTACTAAAGCTGATGAACAACTTCAGCAAAGTGGCTGGGTATAAAATTAA
TTCAAATAAATCAGTAGCCTCCCTCTACACAAAAGAGAAACAAGCCGAGAAAGAAATTAGGGAAAGGACA
CCCTTCATAATAGACCCAAATAATATAAAGTACCTCAGTGTGACTTTAACCAAGCAAGTAAAAGATTTGT
AAAATAAGAACTTCAAGCCTCTGAAGAAAGAAATTTAAGAAATCCTCAGAAGATGGAAAGATCTCCCATG
CTCATGGATTGGCAGGATGAATATAGTAAAAATGGCCATTTTACCAAAAGCGATCTACAGATTCAATGCA
ATCCCCAATCCAATTCTTCAAAGAGTTAGACAGAACAATTTGCAAATTCATCTGGAATAACAAAAAACCC
AGGATAGCTAAAAATATCCTCAACAATAAAAGTACTTAAGGGGGAATCGCTATCCCTGAACTCAAGCAGT
ATTACAGAGCAATAGTGATAAAAACTGCGTGGTATTGGTACAGAGACAGACACATAGACCAATGGAACAG
AATTGAAGACCCAGAAATGAACCCACACACCTATGGGCACTTGATTTTTGACAAAGGAGTCAAAACCATC
AAAGGGAAAAAGATAGCATTTTCAGCAAATGGTGCTGGTTCAACTGGAGGTCAACATGTAGAAGAATGCA
GGTCGATGCATGCTTATCACCCTGTACAAAGCTTAAGTCCAAGTGGATCAAGGACCTCCACATCAAACCA
GATACACTCAAACTAATAGAAGAAAAACTAGGGAAGCATCTGGAACACATGGGCACTGGAAAATTTTTCC
TGAACAAAACACCAATGGCTTATGCTCTAAGATCAAGAATCGACAAATGGGATCTCATAAAACTGCAAAA
CTTCTGTAAGGCAAAGGACACTTTGGTTAGGACAAAACGGCAACCAACAGATTGGGAAAAGATCTTTACC
AATCCTACAACAGATAGAGGCCTTATATCCAAAATATACAAAGAACTCAAGAAGTTAGACCGCAGGGAGA
CAAATAACCCTTTTAAAAAATGGGGTTCAGAGCTAAACAAAGAATTCACAACTGAGGAATGCCGAATGGC
TGAGAAACACCTAAAGAAATGTTCAACATCTTTAGTCATAAGGGAAATGCAAATCAAAACAACCCTGAGA
TTTCACCTCACACCAGTGAGAATGGCTAAGATCAAAAACTCAGGTGACAGCAGATGCTGGCGAGGATGTG
GAGAAAGAGGAACACTCCTCCATTGTTGGTGGGATTGCAGACTGGTACAACCATTCTGGAAATCAGTCTG
GAGGTTCCTCAGAAAATTGGACATTGAAATGCCTGAGGATCCAGCTATACCTCTCTTGGGCATATACCCA
AAAGATGCCTCAACATACAAAAGAGACACGTGCTCCACTATGTTCATCGCAGCCTTATTTATAATAGCCA
GAAACTGGAAAGAACCCAGATGCCCTTCAACAGAGGAATGGATACAGAAAATGTGGTACATCTACACAAT
GGAACATTACTCAGCTATCAAAAACAATGACTTTATGAAATTCGTAGGCAAATGGTCGGAACTGGAATAT
ATCATCCTGAGTGAGGTAACCCAATCACAGAAAAACACACATGGTATGCACTCATTGATAAGTGGCTATT
AGCCCAAATGCTTGAATTACCCTAGATGCCTAGAACAAATGAACCTCAAGACAGATGATCAAAATGTGAA
TGCTTCACTCCTTCTTTAAAAGGGGAACAAGAATACCCTTGGCAGGGAATAGAGAGGCAAAGATTAAAAC
AGACACAGAAGGAACACCCATTCAGAGCCTGCCCCACATGTGGCCCATACATATACAGCCACCCAATTAG
ACAAGATGGATGAAGCAAAGAAGTGCAGACCAACAGGAGCCGGATGTAGATCGCTCCCGAGAGACACAGC
CAGAATACAGCAAACACAGAGGCGAATGCCAGCAGCAAACCACTGAATTGAGAATAGGACCCCCGTTGAA
TGAATCAGAGAAAGAACTGGAAGAGCTTGAAGGGGCTCGAGACCCCAAAAGTACAACAATGCCAAGCAAC
CAGAGCTTCCAGGGACTAAGCCACTACCTAAAGACTATACATGGACTGACCCTGGACTCTGACCCCATAG
GTAGCAATGAATATCCTAGTAAGAGCACCAGTGGAAGGGGAAGCCCTGGGTCATGCTGAGACTGAACCCC
CAGTGAACTAGATTGTTGGGGGGAGGGCGGCAATGGGGGGAAGATGGGGAGGGGAACACCCATATGGAAG
GGGAGGGGGGAGGGGGATGTTTGCCCGGATACCGGGAAAGGGAATAACACTCGAAATGTATATAAGAAAT
ACTCAAGTAAATAAAAAAAAAAAGAAGGTCAATAAATCTTTGTAGATTCCTAAAAAAAAAAGAAGGATGA
CCAAAATCCAAATGCTTCACTCCTTTAAAAGTGGAAAAAGAGTACCCTTGGGAGGGAATAGGGAGGCAAA
TTTAGAACAGAGGCTGACGGAAAGCCCATTCATAGCCTGTCCCACTTGTGGCCCATACATATACAACCAA
GAAACTAGCTAAGATGAATGAAGCAAAGAAGTGCTGGCTGACAGGAACCGGATATAGATCTCTCCTGATA
GACACAGCCCACAGCCAGAATATGGCAAATACATAGGCGAATGCTCCAGTGAACCACTGAACTGAGAACG
GGACCCCTGTTGAAGGAATCAGAGAAAGGACTGAAAGAGCTTGAAGGAGCTTGAGATCCCATATGAACAA
CAATGCCAACCAACCAGAGTTTCCAGGGACTAAGCTACTACCGAAAGATTATACATGGACTAACCCTGGG
CTCCAACTCCATAGGTATTAGTGAATAGCCTAGTAAGAGCACCAGTGGAAGGGGAAGCCCTTGGTCCTGC
CAAGACTGAACCCCCAGTGAACAGGATTGTTGGGTGGAGGGTGGTAAGGTGAGGAGAATGAAGAGGGGAA
CACCCATCGAGAAGGGGAGGGGTAGGGGTTAAGGGGATGTTTGCTTGGAAACCAGGAAAGGTAATGACAA
TTGAAATGTAAATAAGATATAACCAATTTAATAAAGATGGAGAAAAGGAAAATAGTTATTAAAAACAAAA
CAAAACAAGGACATCATGAATTTTTCAGGTAAATGTATGGAACTAGAAAGTATCACTCTGAGTGAGGTGT
TATTTTATCCAAAAGTCATACATGTTATATTCTCACTTATAAACATATATATTAGCAATAGTGAGGTAAG
CCAGCCACAAAAGTACATGCATGGCATGTACTCACTTATAAGAAAATATTAGCAATAAAGTACAGATAAC
CAAGCTATAGTCAATAGACCCAAACAAGCCAAATGACAAGGAGGGCTGAAGGAAGGATGGGGCATAAGAG
AAATCTGAGGTGGATAGGATGAAGAGGGGATGGGAAATGTGGCAGGCAGGGATGGGATATCAGATGCAGG
GAGAGTGGGAGAAGGAGAAGGGAAACGGGCAGTGGGGTGACTCTAGATTGTGACAGAGACTTGGGATGGG
TGAAACCCTGGGGGTCTATGGGAGCAGTGGGGGATATAGAATCTGAACTATTTTCTGTAGCCAGGCAGGA
CCACCAGTAGAGGGATAAAGATAGCAACTTATCCACAAAGCCTTCATTTCAAAAAGTGTCCTGCCTCTGA
AATGTGAAAAGACAAAGATAAAGCAGATACTAAGGGGATGGCCAATGAATGACTGCCCCAAAATGAGACA
CATCTCTTGTATTAGAACCATTCCTTGACACTATTAAAAATATTCTGTTATGTTTGAAGATAAGAGACGA
GATTAACTGTTTTTCATTATGGAGAAGCTCCATTGTGTACCCAATGGAAAAAGATGCAGAGACACACAGT
CAAAAATTAGATGGAACTCTGGGAATATTGTGGGAAGGAATGAGGGATGAAAAAGGACAGGGACTCCATA
GGAAGACCAACAGAGACAACTAACTTACACCCTTTTGGCTTCCAGAGCTGAATCCTGAACTGAAGAGTGA
GCATGGGCTGTAACCAGTGCTCCTGCATATATGTAGCAGATGAGCAGCTTATTCTACATGGGGGGCCCCT
AACAAGAGTGAAGGGGTTTTCTCTGAATTTATTGCCTGGAAGCAATTGGATCTCATTCCTCTAAGTAGGC
CACCTTTTCTGACCTCAGTGGGATAGGATATGCTTAGTGCTATAGTGACTTACTATGCTGGTGTGGCAGG
AGTAATACAGGGGTGGCAGTATAGGGATTATAACTAGGAGACTCCATCTCCTCCTTTGAGAAGGAAAAGA
AGTAATAAAGGGAGGTGAGGGGTTACTGGGAGGGGAGGGGGGACTGATATTAGTATGTAAAGAGAATAAA
TTAATAAATTTAATTTAAAAAAGAGATTGCCAATATTTGTTTGTTTGTTTTGGCTTGGTTTTATATTTGT
ATTTGATTTGTTTACTATATTACAATGTCAAACACAAAATTACATTTCAATAATAGACATGTGATTCTAA
AAATTTGAACAAAAGTGAATTCTTCAAATGTGATAATTTTGTTGATTTTTAAAATATTATATTTTTATTT
ATGTATTTATGTATTTAGTGTTTGTATGTATGTTTCTGTGAGCATGCATGTCATGTCACAGAAGCGATAG
TCAGAGGAAAGAATGCAGCTCTCAGTTCTCTCCTCCTACCATCTAGGTCCCAATAATTAGAGTCAAATCA
TCAGTTTGGCAGCCAGTGCCTTAACTAGCTGAGTCATATTATTGACCTCTTTTAGGTTTTTGAACAACAA
TACAATCTTTTTGATAAATAGACATGTCTAACCTTTGACCATGGGATGCATGCATCCAAGTTTAGGTAAG
AATGTAGTCTAACACAACATTGTAAACATGATTAAAAATGATGAGATGATTTTTATTTGGTAGTTTATAC
AGTAATTTTATGCATGTGTCTTAAACATGAATTTTGCATACAGAATATTATGTTGTAATAGAAAGAGGTT
GAACACACATGCAAGACATTTTAGAAAAAGTCAAAGTGTTATCTGATTGGATTCACTTGCTATTTTTTCA
TGCTTCATAGTAAAGTCTCAGCTCTTTTGTCACTTCAGAAAATTTATACAGAAGAAAATTGGTAACCAAC
CTCTGCCCACTCAGTAGAACCAAGAAGGCCAAATTCTTCAGCATCCCAGCTTGCAAACAAAATAGTTCTT
CTAGGCCTCCAACCTAAAATACATGTGAATGACATATACATTCTTGAAAAATATATAGCATCTAAGACAT
GGAGAAGTCTCCAAGAAGGAAAATCCCAAAATGCTGAGGATTTTTATTGTAAAAAGTAGGAATTGTTGCC
CTCACCTTTAGTTACACAAATTTATTTTGTATTTTTTTAAAAATGAGACTTGCTAGAATCACATAGTATA
ATTGAATTCTAAAAGGAATAATGTAGACAGTGAAAGTCTCATGAAGTCATACAAAATTTTATGTTTTACA
ATTCCCCATGAACAGGAAATCATATTCCTGACACAGAGGGGGAAACCACTGGTACTGCCAGTGCTGCAGT
GGCAGACAGAAATGTGGGAAACCATTTAGAAACATCCCATGTTGTTCTAAAATAGCATGACCATTTCTTT
TTGTGATGCTTTCCTTCACTGTCTTGTAAAATTATTTATCCAGGGCTAACTTTTAGATATCAGTATCCAT
TGATAGTGAAAACCTTACACTTTGTTAAGTAGGGCTTGGAGTTGGAGAAAATCTGATTCTCTTACTTCCT
AGAAGCTAAAAAGGCTGCGCCATACAAACTGACTAATCCTTCATGTCTTCATCTAAAGTCCACTATAGCA
GAATAAGGGAAAGATATCACTTGTTTATCAGGAGCATTAAATGGAATATGATTTCAGAAGCACTTAACTT
AGTAAATGTTATAAGGTCAAAAATATTATATTATATTATAATATATATAATATTATATAATATATGTTAT
ATTTTTGAGGGGCTGGAGAGATGACTCAGCAGGTAAGAGTGCTGATGCTTTTCTTCAGGTTCTAAATTCA
ATTCCCAGCAACCATATTTTCAATCAACCATCTGTAATGGGATGCGATGCCCTCTGCTAGTGGGTCAGAA
ACTGAAAGCAGGGCAGTGGTGAGCACATCTGTATTCCTAGCTCTCAGGCAGCAGAGTGAGACTAACTTCT
GAGCTTGAGATCAACCTGGTCTACATAATGAATTCCAGGACATTCAAGGCTGTTATAAGATAAACTTTTG
CACCCTCCGAAGAGAGAAACAAAAAAAGAAAACAAAACAGAACCAAAAAAGAGCAAAAAACAAAACAAAG
CAAAACAAAAAAACAAAAAACAAAAAAAGGAAAAAAAATTTATAACTATTGAACTTAATGGTTTCTTTTT
GTCGAATGTTTTATGTATCATTTAAATTCCCTATTCTCCTATTCTTTATCACTTCATTTTTTTGAGTACA
CTGCTAAATTATGACTGCTGATTTGCATTCAATGTAAATATTTTCTTGTGAAATCATGAAACCTTTTGTA
ATAAGATTAAATACAACCAAGTTCATTAACAATGAACATGGTCATCTGGCAAATTTTGTTTGTTAAAATG
TAAGCAGTGCACTTCTGACTTATTTTGAAAAGAGATTACATAAGTTTGCAATGTGTTAACCCCAATTTTG
AACTCTGTCACACATCACTTGGCAATTATCTATTAAATCAGAACAGAACTCAGAAAATGTCTTGGGGGTT
GCTATGGCATTAAAATAGATCAAAATGTGTAAAAAATTTCTCAATATGCGAAGGAAACATACATTGTTAT
TGTTGATTTATAGCTGAGGGCTACAAGATATCTCTGCTAATAAAGGTACTTGCTGCCAAGACTGACAGAC
TAAGTTCAAACCCTCCGTGGAATTCATAATTGCTTATTTCAAATTGTCAGTTTACATACAAATATTCTAT
TAACTTTATAATATAATGAAAATAATAAAAATATAATTAACTGACATTAATGCTTGCACTGTTATTGATA
CTTTTTCATTGACAATGTTGAGTTTTCATTTATTTATTTGGCTTTTCTTTTGTGTACTCTGGATCTAGGA
AAGTGCTTCTGGCACACAAGGCACATGCTCTAACACTGAGCTACTTCACAGACACTGAAATAGTTTTTTC
AAACTCACTTTGCCAAGGATTAAGGTGAAGTTCCCAGAAATTGGGAGTTTGCTCAGTTTCTCTTACCTTT
CTTCTTCAGAGTTCCAAAGGTCCTGACAATTTCATGAACAACAGCTGCTCCACTCTGAGGGTCAATGCCA
CCAAACACCCAAGCATCTCTGTGCCCTCCAAGAATAACATATCTGTCTACAAATCAACAGATTGCAGATC
TCAGGCAGAGGAATATGCAAATGACTCAACATATTTCACAACTTCCAGGGACACGGGAACCCCACCAAGT
CACATGCTCCACTATGTTCATAACATCCTTATTTATAGTAGCCAGAAGCTGGAAAGAAACCAGATGTCCT
TCAACAGAGGAATGAATACAGAAAATGTGATACATTTACACAATGGTGTACTACTCCTCTATTTAAAACC
ATGATTTTATGAAATTCTTAGGCAAATGGATGGAACTAGAAAATATCATCCTGAGTGAGGTAACCCAATC
ACATAATAACACAGATGCTATGTACCCACTGATAAGTGGATATTAGCCCAAAAGTATATCCACAATACCA
CTCACAGAGCTTATGAAACCAAGAAGAAAGAAGAGCACAACAAAATGTTGATGCTACAGTCCTACTCAAC
AAAAGGGAGAAGAAATTAATTTCAGGGAGTAGATGGAGAGGAGGATCTGGGAGTGAGAGAAGAGGAGGAT
GTAAAAAGGCTGGTAGGATCAGGTGTGGGCAGAAAGGTAAGAGAAGTACAGAGGATCGCGAATTTGAAGT
TGTGTAGCAATGGAGGAGGGGGAATTTGGGGGAGCCACTAGAAAGTCCCAGATGTCAGGGTCTTAAGATG
TTCCTAAGACCCAATATGGAGGGCATTAGCCAAAACACCCAACAAAGGGGATATAGAACATAATAATGGA
CAGTCACAGCCTCTGCTAGAGGGGTGGGGCCACCCACCCACCTCAAATATATTAACTCAGAATTTCTCCT
TGCTAAAGGAAATGCAAAGACAAAGAGTGGAGCGGAGACTGAAGGAAGGCCATCCAGAGACTGCTCCACC
AAGGATCTATCCCATCTGTAGACACCAATTCCAGACACTATAGCTGAAGCCAAGAAGAGCTTACTGACAG
GATCCTGGTATAGCTGTTCCCTAAGAGGCTCTTGTGGAGACTGACCAATTCAGATGGGGATGGATGCAGC
CAAACATCAGAAGTTAGGAACTGAAGGAGCTGAAAGGGATTGCAACACCATAGGAAGAACAATAATGTCA
ATCAACCAGACCCTCCAAAGCTCCCGGGGACTAAACCACCAACTAAAGAATATATATGGGAGAATCCATG
ACTCCAGCTGAGGATTGCCTTCTCCTCAATGGCCCATAGTAGGAGAATGCTAGGGAACTAAAGAAGTAGT
GGGTGGGCTGGTGGGAGAGCACCCTCATAGATTCAGGGTTGAGGGGACACAGTGTTCATGGAATGGAGAC
TGGGAAAGGAAATAACATTTGAAATATAAATAAAGAAAATGACCAATTAAAAGCAAAACAAAAAAAGAAG
CACAGGAAACTATCTGCCTCGCTCCTCACAGTTCTCTAAACTGTTGCCACTTTGTGTTCATTGTTTTCAC
AGAAAATACAGCGCTTCTTTCTTTTTTTTCTTTTTTTTTTTCTTTTTTTCTTTTTTTTTTCCAGAGCTGG
GGACCGAACCGAGGGCCTTGCGCTTGCTAGGCAAGCGCTCTACCACTGAGCTAAATCCCCACCCCCAGCG
CTTCTCTTCTTAGACCTCTTCCATATGACATTCAGTAACTGTCTGTGACCATTTCTGTGTACTATAGGAA
GAAAATACTGCTTGGGTTTATAGTTTGAGGGACAATCTTTTCACGTTAGTTTAGGTATTTTTCAACCTTA
AATGGCAAATTCTTCTTTGAAATCATGATCACCTTGACCTTGGTTAATGAGTGCTTCAATACTCCACAAT
TCCATGGTTTGTCACATACCCTGTACAAAATAATCACCTAATAATATTCAATAAGTCACTTATGCATGCC
CATATACATGTATATACTCATGTTACTAAATTACATATGTTTATATATATGTATAAACTAACTTATTTAC
ATGTGTAAACTAAACTTTTTTGTAAATATAAGACACATATAACTATAATATATATATAGTTTATATAATC
ATTAATTTTATAAAACTCTTGCTTCTTTAGTAAGAGATTGTTTATTCTTCTTACAGTAAGTCACATAACA
GCAATTTCCACAATTGGAAAGAAATAATATAAAATCGAGTCAAATTACATGAGAACTTCTCTCAGAAAAA
GAAATAAGTAGCATATTTGTAAGAAATATATGCGATTAATTTTTACTATTTATGTTAAAACTAATAACAA
TCAAATAAATCATGAGGCATCAAGTCCCAAATCCTACAGAATCAAATCACATAATAAAATATGCCCAGTT
CCCCAACTGAGTCTCACAATGTACCCAAACTACACTTAAGGGAGGCACATGCCTAGCAGTAAATAGCCTA
CAGAAAACGAAATTAGCAATACTTTTGGAGATTGTGTTTCTCATATTGCTTTATTTGGGCAATTTTCAAC
CTTTCTGATCCTTTGTTTATGAATGATGTTGTCTGATTTTTTTGTTTTTATGGTGTGTGTGTGTGTGTGT
GTGTGTGTGTGTGTATTTTCACATGTACATGTACTGCTCATGTTTCTTTTCTCTCTCTCTTCTTTTAACT
TTTGTTTTATCATGTTTTTATTTTATTCTATTTTGTTTGTTTGTTTGTATGCCTAATTGTTTTGTAAAGA
AAAAAAGTAAAGCATGGAGATGTATGGATAGGGAGGATCTGATTAGAAATGAGAGATGGGCAAATGTGAT
TAGAACCTAGTGTATAAAATGGTTTTCAGCAATAAACAAAGAAACAAAGCAGCTTATCACTCTCCCTTGT
CCCCATATTTTCCTGTTACTGCTTTTATAACACATGCTACGAATGGTACACTGTAACTGGAATGTCTTAG
TTTGTGCTCTGATGAGCTTCACTCAGGCAGTAGTGGTACATGACATTTGATCCACCAATATTTGCAAAAC
ACATACTCCATTTACCTGGTTCCACAGCTCCTTTGAGGGTACCAATAACATTGTAGATTCTTGTCACTTT
ATTGTAGGAGTGAATATGCAGCTTGACCTTTCTAAATCAAATATAAAATTTCAGTCATTGAGAATACTAG
TTAACTGATTCAACACATTTCTTAAATCTGCCATCATTATTTAAAAAGATTTATATTTGTTTCCAAATGA
AAAGTAACACTGACTTTTTTATCTTTTTTTTACAGTTCATTCATTATTCCCCTCCTAGTACACACTCTGA
TAATTCATGCTGTTCTTCCTCCCCTGTCTCCAAGAGGATGCTCTCCCCAACTCCAGCCCACCAGACCTCC
CCATGACCAGGGCCCCCAAGTCTTTATACGGTTCGGTGAATCTTCTCTCACTGAGGCCAGACCAGGCAGT
TATCTGCTGTATATGTGCCAGGGGCCTAGGACCAACTAGTGTACGCTGCTGGGTTGGCAGTTCAGTGTCA
GAAAAATCTCAGGGGTCCCAGAAGTCTCAGCTAACACTGACTAATTTTAATGGTCCTAAAATCATTGTCT
TATTCAACTTCTGGTTTTATTGCTTGATGGTGTTAACTAGGCCTTACATTTTTTTTATTTTTGATAATTG
TCTTCTTTAAAAGTATTCTGAATAAAAGGATTATAAAATATCTCAACTGTTTTGAAAAGTTTCCAGCAAA
GCCAGGTCCCACGTTGTAAGGCACTTTTAGTCCTCCCTTCCAGCTGCTGTCAGGGGGTGCGGAGCCACCC
ATATGTCTGTTGGACATGAAAATTAATTATTACCTACATAAACTTTGAAACAACATGTTAAAATGCCAGG
TCTTCTTTTGGTCTAGATCATCTTCTCATAGAAGCTTCTATGAACAAACAAAAAACAATTGTCCTTTCCT
GAAAGGTAGTGTCCACAATCAATTCAATTTTGCAGATGAGTAATACAAGGATAGGAATGAACAGAGAGCA
ATGACCAAAGTTATGGTGGAAAGAGGTGCAGCTGATATTTAAATTATTTATAAGAATCTAAACATTGTTA
CTACTGTATAATGGAAAACCATATTTTAAAACTCTGACTCTCTAGCACATGTACTAAAGGAAGAATCAGG
AGTCTGTCTGGAGTCTCTCTCTCTCTCTCTCTCTATATATATATATATATATATATATATATATATATAT
ATATTCATCTTTATTTAAGTATTTTCATATGTAACTATTAGGAAGAAACAAAGAACTAAAGAACAGAAAA
TTTTATTCCAAGCAGAGATCCCTAAATTTCAGTTCATTATTTCACAAAAGAAAAAGCTACAACAACAACC
AAAAATAAAATAAAATAATAAAATAAAACCCTAGACAGACCAAAGGACTTTGGTGAAGAGCTACCATATA
GCTCCAGCCTTCAGGAATGTGTCCACTAGAGACCTGAGGAGCTGGTATTGTAAGATTTCTAATGGGATTT
TATGTTCACCACATCTCTGTAACTTCTAGCAAAGAATGAACTTTCTTTACTTTGAAAGGAAAATAAAGCA
TAACCTCACTGACCAGGTTGATGTAAGTACATTTACTTACAGAAAAATATGTAAATTATAGTTGAACAAT
AATGATTTCTTTCTTAACCCTTTACTAAATTTTGTTTACATTCTGCTATAAGAACATAAGAGAATTATGG
AGCCTGTCGAGCTCATTTTGGATTTCTTTTTTTTTAATTACTGGTTATTTTATTTATTTACATTTCAAAT
GTTATCCCCTTCCACGTTTCTCCTACACAAATCCCCTATTCTGTCCCTCTTCTCCCCAGCTTCTATGAAG
GTGCTCCCCCATAGGGTCAGTCCCACCCACTCCTGCCTCACTGCACTAGCATTCTCCTAAGCTGGGGCAT
TCAAGCTCCACAGTACCAGGGGCCTGCCCTCTCATTGATGCTAGGAAAGGCAATCCTATGATGCATACAT
AGCTGGAGCCATGGGTTCCTCTTTCGTTGGTACTTTAGTCCCTGGGAGCACTGAACAGTGGGGTGGCGTC
TGGTTGGTTGCTATTGTTTTTCTTTCTATGAGGATTCAAACCCCTTCAGTTCCTTCAGTTCTTTCTCTAG
CTCTTCCACTGGGGTTCCCAGGCTCAGTCTGATGGTTGGCCATGAGCACCCACATCTGTATTGGTCAGAC
TTTGGCATAGTCTCTCAGGGTAGAGCTATACAAGATTCCTGAAGCAAGCCCTTCTTGGCATCAGCAATAG
TGTCTGGATTTGGTGTCTGCAGATGGGATGGATTCCTAGGTGAGTCTGTCTCTGGTTGGCCTTTCCTTCA
GTCTCTGTTCCACTCTTTGCACCTGCATATCCTTTAGACAGGAACAATTCTGGAATAATACTTTTGAGGT
GGGTGGGTGGCCCCATCCCTTAACCAAGGGCAGTGTGCAACTTCTGGATATGGTCTCTACAGGTTCTGCT
CCCTCTTTGCTGGGTATTTAAGCTAATGTCATATCTATTGTTTCCTGGGAGCTTCCTGCTTTCCTGGAAT
CTGGGACTTTCTACTGTCTTCCCCCAGTAGCCCATCCCTCACTAGTACAAACCTTCCTTCGATTTCCTGA
CCATCTGAACTTCTTCCCCATCTCCTCCCACAACTGATTCTGGTCCCCTTCCCACCTCCCTCTCAGGTCC
CTCCCATCTACCTCCCATGATTATTTCATTGCCCCTTCTAATTAGGACTAAAGCATTCACACTTTGGTTT
TCCTTCTTCTTGAGCTTCATATGGACTGTGAGTTGTATCGTGGGTACTCTGAGCAAGGTAGTAAAGAACA
GACTTGCCTCCACAGTACTATACTCCCAGAACACATCTATACTATTATCCTTAACACAATCAGCCATTGC
CTGACTGAAAACATGGTGGAAGCTTTACTGTGTCACATATATGAAGATGGGACATTTGACATCATAGTTC
CAATAATTAATCCATGATCATTTTCGTAACTGTCAGATGTTGATTATCCAAATACAAAATAAATTCCAAA
ATTAGAAACAGTATTTTTAAATTTATGAACATATTTGTATATTGCATCAATCACTTAGAGTATAGTACTA
AAAACTGAACATTTTCAAACATTTGAAAATTATCAAGAATGAGAAATACAAAAAGAGGTATTTTTCTAGC
AAAAACTTACTCTAATAGTTTCTGTGCATCATCATATCCAATTGGATGGACAGGAATACTTGGAAGACCG
ACAGCTTCTGTGAATTCATGCCTGTAGGCATATTCTGAGAAAAAGAAAGAACTTAACTATATTAAAAACA
ATGTTTTCAAATGGGATTTTGTAAGTATGATTAAACAAATTCTTCCATACATTCTAGAAATGGTAAAATT
CCAAGTGTCAAAATGAATGGGGAAAAATTGAATTCCTTATGCATACTTGTGAGAGAATGAAGTCACATGA
TGGTCTAGATTAACTCTCTTGAAACAGTCAAACAGATGGCTGGAGAGATGTCACAGTGGTGAACAGAACT
GGCTGCTTTTTTAGGGGTCATGAGTTCAATTCCCAGCAACCACATGGGGTCATAACAATCTATATTGGAT
TCTGATGTGCTCTTCTGGAATACAGTTGTACAAATAGATGGAACATTCATTTGTAAAATGTTGTTTTAAG
AAAATTAAAAAAAACTCTATAAGATGGAAGATTGGTAAAGACCTTTCCCTAACATGTTGGTTGCCATTTT
GTCCTAATGACAGTGTCCTTTGCCTTACAGAAGCTTGTAATTCTACAAGGTCCCATTTGTCAATTCTTGC
TCGTAGAGCATAAGCCATTGTTGTTCTATTCAGGAAATTTTCCCCAGTGCCTATGTATTTGATGCTCTGC
CCCACTTTTTCTTCAGTTAGTTTGAGTGTATCAGGTTTTATGTGGAGGTCCTTGATCCACTGAGACTTGA
GCTTTGTACAGAGTGATCAGAATGGACCAATCTGCATTCTTCTACATGCTGACCTCCAGTTGAACCAGCA
CCATTTGTTGAAAATGCTTCCTTTTTTTCCACTGGATGGTTTTAGCTCCTTTGTCAAAGGTCAAGTGAAC
ATAGGTGTGCAGATTCACTTCTGGGCCTTCCATTCTATTGCATTGATCTACATACCTGTCTCTGTACCAA
TCCCATACTGTTTTTATCACTATTGCTCTATAATACAGCTTGAGGTCAGGGATGTTGATTCCCTCAAAAG
TTCTTTTATTGTTGAGGATAGTTTTCACTATCCTGGGTTATTTGTTTTTCCAAATGAATGTGAAAATTGC
TCTTTCTAACATTATGAAGAACTGAGTTGGAATTTTGATGGGTATTGCATTGAATCTGTAGATTGCTTTT
GGCAAGATGACCATTTTTACAATATTAATCAAGTCAGTCCACGAGCATGAAAGGTCTTTCCATATTCTGA
AATCTTCTTGAATTTCTTTCCTCATAGACTTGAAGTTCTTGTCATACAGATCTTTCACTTCTTTTAGTGA
GAGTCACACTGAGGTAATTAATGTTGTTTGTGACTATTGTAAAGGGTATTATTTCTCTAATTTTTTTCTC
AGCCTGTTTGCCCTTTGAGTAGAAGAAGGTACTGATTGGTTTGAGTTAATTTTATATCCAGCCACTTTGC
TGAAGTTGTTTATGAGGCTTAGGAGTTCTCTGTTGGAACTTTTGGGGTCACTTAAGTATACTATCATATC
ATCTGCAAATATTGATATTTTGACTTCTTCCTTTCCAATTTGGATCCATTTGACCTCCTTTTGTTGTCTG
ATATTCTAACTAGGATTTTGAGTACTATATTGAATATGTAGGGACAGAGTGGACAGCCTTATATACACCT
CATTTTAGTGGGATTGCTTCAAGTTTCTCTCATTTTAGTTTGAGGTTGACTACTGGTTAGCTGTATATTG
CTTTTACTGTGTTTACTTATGGACCTTGAATTCCTAATCTTTCCAAAATTTTTAACATGAAGACATATTA
AATTTTGTCAAATGTTTTCTCAGCATCTAATGATCATATGGTTATTTTTTAGTTTGTTTATATAGTGGAT
TATGTTGATGGATTTTCTTATATTAAATCATCCCTGCATCCTTGTGATGAAGCCTGCTAGATCATGATGG
ATGATCGTTTTGATGTGCTCTTGGATTCAGTTTAGGAGACTTTATTGAGTATTTTTGTGTCAATAGTCAT
AAAGGAAATTGGTCTCAAGTCCTCTCCTTGTTGGTTCTCTATGTGGTTTAGGAATAAGCATAATTGTGGC
TTCATAGAAGGAATTAGGTAGTGTTCCTTTTTATATTCTGTGAAATAGTTTGGAAGTGTTGTTATTATGT
CTTCTTTGATGGTATGGTAAAATTTTGCACTAAACACATCTTATCCTGCGCTTTTATTGGATGGGAGACT
TTTAATGACTGCTTCTATCTCTTTAGGGGTTAAGGGACTAATTATATGCTTTATCTGACCGTGATTTAAC
TTTGGTACCTGATATCTGACTAGAAAATTGTCTATTTCATCCAGATTTTCCAGTCTTCTTGATTACCAGC
TTTTGTAGTAGGAACTGATGTTTTTCTTTAATTTCCTCAGATTCTGTTGTTATGTCTTCTTTTTTCTAAA
AATCTTTCATTAGAAGAAGGATGACCAAAGTCTGGATGCTTCAGTCCTTCTTAGAAGAGGGAACAATAAT
ATTAATAGGAGGAGATATGGAGACAAAGTTTGGAACAGAAACTGAAGTAATGGCCTTTCAGAGCCTTCCT
CACCTGGGGATCTAGCCTATATACATACAGCTACCAAACCCAGACAAAATCATTGATGCCAAGAAGTGAA
TGCTGACAGGAGACTGATATAGCTGTCTCCTGAGAGGCTCTGCTAGAACATGACAAATACAGAGGCGAAA
TCTCACAGCCAACATTTGAACTGAGAATAGGGTCCCCATTAGAGAAGTTAGAGAAAGGAATGAAGGGTTG
AAGGGGTTTGTAACCCCATAAGAACAAAAATACCAACAACCATAGCTCCCAGGGTCTAAACCACAATCCA
CAGAGTACACATGGAGGGATCCAGAGCTCCAGCTGCATATGTAGCAGAGGATGGCCTTGTTGGGCACCAA
TGGGAGGAGAAGCCCTTGGTTCTGCCATTGTTGGACCCCATAGTAAGGTGGAATATCAGAGTGGGGAGGC
GGGAAGGAGTGGGTAGATGAGGGGTAACACCCTAATAGATGAACAGGGGGATGGGATAGAGGGTTTATGG
AAGGGAAACAGGGAAAGGGGATAATATTTAAATGTAAATAAAAATATCCAATAAAATATAATATTTATAA
AAGAAAAGCAAAAATATCAGGGTTTTTTGTTTTTGTTTTTGTTTTTTATTCTTTGCTTTATAGAAGCTTT
TCAGATTCATGAAGTACTATTTACTAATTGTTAATCTTAGCACCTTTGTTATTAGTGTTCTGTTCAGGAT
GAAGGCCCTGTGCCAATGCATTAAGGAGGTTCTTTACTTTTTCTTCTAACAAATTCAGTGTATCAGGTTT
TATGTTGAGGTCTTTGATCCACATTGACCTGAGGTATTATTCAGGGTTCTCTAGAGTCACTGAACTTATG
TAATATCTCTATATATTAAGGGAATTTATTATAATGACTTAAAATTTATATTCCAACTACCCAAACAATG
GACACTGTGAATGGGAAGTCCAAAAGTCTATTAGTTTCTCAGTTTATAAGGCTAGTTGTTTCACCTGATT
TTCTTTATATGTTGGAATCCTAAATAAGTTTCAACAGATGTGCTGGTCATTATGTGCAAGAAGGTAAAGA
AGAATAAGTCTTCTTTCTTTCAATGTCCTTATGTAGACTTCCAGCCAAAGGTGTGGTTCAGATTAAAGAT
GTATGTCACCACACCTGGATCTGGAAGTTGCTTTCTTACAGTCTGACCTTGAACTCAGAGGTCTCCTTGT
CTCTGTCTTTTGTGAATAAATGAGTACACTACCTTGCCTGGACCTAAGCTTTTCATGGCCACTATGCTTC
AAGGTCTCCACATAAAGATTTGAGTTGGAAGCCTAAGTCTTCCTGCCACAAGATGTAGATCACAGGTGTG
TGCCTTTCATTTCGAGATTGTAGTTCATAACAGATATAGAGAGTTTGACAATCAGGAATAATCAGCACAC
TTGAATTTTATATGTGGGGATAAGAATGGGTATTTTTGCATTCTTCTATATGCAGTCATCCAGTTAGACT
ATCAGCAGTTGTTGAAGATGCTTTCTTTATCCCATTATATATTTCCAGCTTCCTTATCAAAAATGAGGTG
TCCATAGTGGGTTTATTTCATGATCTTCCATTTGATTCCATTGATGAACCGGTCTGTATTATGCTAATAC
TATTCAGTTTCTATAACTACAGCTTTGTAATACAGCTTGAGATCAGGGAAGTTGATACATCCACAAGTTC
ATTGTATAGGATGTTTTAGCATATATACTGCTTACTTGTATGATACTTTCCTTCAAACTGGTTTGGTATT
TCTAGCCTTGATATGACAATTCCTGCCTATTTTACAGTAGCTTGCTATGCTTTCTTTGGGTGCTGTTTCT
CAGAGGTTTGTTCTTTTGAAAGGTGAGGCTGAGGACAGGTGGATCTGTAAGGGTGGGGGCGGGGTAAGAG
GTTGTAGGGAGGGAATCCCTGTGGTTGGGATGTAATATATGAGAGAATTAAAATAAAAGAAAACTTAAAC
TGTAATCAGGGGAATTTTTTTTCCGAACTCACAACAAGTGTCACATGCAGGCAACCTGTGGTTTCAGACA
GAACACTAGAAAGGAGAGTGGTGTTCCTAAGCTGGGGGCGGGAGCATGAAGATTCTGAAGCAGAGAGCAG
AGCCCAGGAGCCTGGAAGGGTTGTAAATGAGTGACTTCTAGCTATGTGGAGGGTCCCTGTGAGCCTGAAA
GCTTTAGGAGCCAAGAGTGCCATGAGTTGAGGCTAAGACAGGATGGACAGAGCTAAAGAGATGAGGTTGG
AGAGAAAAGTATGTAGAGGGCTAGCAGATGTGAAGAGATGATACAGAGAAGCCGTTTAGATTGAGGGACC
AGAGAAGGCCCTAGACATGAGCTGGTGGAGAGAAATTTTTAAGGACCTAGAAGTATGAGAGTCTTCAGAG
AGGGGTATAGACGTGAAATGGTAGTATATTGGTTAGGGATGAAGTAGCTATATACAGGCACGATAGGTGA
TTAAGAAATGTGGTACATCTAAACAATGGAATATTACTCAGCTATCAAAAACAATGACTTTATGAAATTC
ATAGGCAAATGGATGGAACTGGGAAATATCATCCTGAGTGAGGTAACCCAATCACAGAAAAACATACATG
GTATGCACTCATTGATAAGTGGATATTATCCCAAATGCTTGAATTACCTTAGATCCACAGAACACATTAA
ACTCAAGAAGGATGACCAAAATGCGAATGCTTCACTCCTTCTTTAAAAGAGGAACAAGAATACCCTTGGG
AGGGAAAAAGGAGGCAAAGTTTAGAACAGAGGCATAAGGAACATCCATTCAGAGCCTGCCTCACATATGG
CCCATACATATACAGCCACAAAATAGATAAGATGGATGAAGCAAAGAAGTGCAGGCCAACAGGAACTGGA
TGTAGATCTCCTCTGAGAGACATAGCCAGAATACAGCAAATATATAGGCGAATGCCATCATTAAACCACT
GAACTGAGAACAGGACCCAGGTTGAAGGAATCTTAGAAAGGACTGAAAGACCTTGAAGGGGCTGGAGACC
CCATATGAAAAACAATGCCAACCAACCAGAGTTCCCAGGGACTAAGCCACTACCCAAAGACTATACATGG
GCTGACCCTGGGATCCAACCTCATAGCTAGCAATGAGTAGCCTAGTAAGAGCACCAGTGGAAGGGGAAGG
AAGCCCTTGGTCCTGCCAAGAGTGAACCCCAAGTGATCGTGATTGTTGAGGGGAGGGAGGTAATGGGAGG
AGGATGGACCCCCATATGGAACACCCATAGAGAATGGGAGGGAGAGGGTCAAGGGGGATGTTGGCCCGGA
AATTGGGAAAGGGAATAACAATCGAAATGTAAATAAGAAATACCCAAGTGAATAAAGATGAAAAAAAAAA
AAAGAGTTGTGTTCGTATTATCCAAACTATTCCAAAAAAATTGAAACAGATGGAGCACTACCGAATTCCT
TCTATGAAGCCACAATTAATAATCTTATACCTAAAGCACACAAAGACACAACAAAGAAAGAGAACTTCAG
AACAATTTCCCTTATGAATATCGACACAAAAATACTCAATAAAATTCTGGCAAACTGAATCCAAGAGCAC
ATCAAAACAATCATCCACCATGATCAAGTAGGCTTCATCCCAGTCATGCAGGGATGGTTTAATATATGGA
AAACCATCAACGTGATCCATTATATAAACAAACTGAAAGAACAAAACCACATGATCATTTCATTAGATGC
TGAGAAAGCATTTGACAAAATTCAACACCCCTTCATGATAAAAGTCCTGGAAAGAATAGGAATTTAATGC
CCATACCTAAACATAGTAAAAGCCATATACAGCAAACCAGTTGCTAACATTAAACTAAATGGAGAGAAAC
TTGAAGCAATCCCACTAAAATCAGGGACTAGACAAGGCTGCGCACTCTCTCCCTACTTATTCAATATAGT
TCTTGAAGTTCTAGCCAGAGCAATCAGACAACAAAAGGAGGTCAAGGGGATACAGATCGGAAAAGAGGAA
GTCAGAATATCACTATTTGCAGATGATATGATAGTATATTTAAGTGATCCCAAAAGTTCCACCAGAGAAC
AACTAAAGCTGATAAACAACTTCAGCAAAGTGGCTGGGTATAAAATTAACTCAAATAAATCGGTAGCCTT
CCTCTACACAGAAGAGAAACAAGCCTAGAAAGAAATTAGGGAAACAACACCCTTCATTATAGATCCAAAT
AATAAAAAGTACCTCGGTGTGACTTTAACCAAGCAAGTAAAAGATCTGTGCAATAAGAACTTCAAGACTC
TGAAGAAAGAAATTGAAGAAGACCTCAGAAGATGGAAAGATCTCCCATGCTCATGGATTGGCAGGATTAA
TATAGTAAAAATGGCCATTTTACCAAAAGCGATCTACAGATTCAATGCAATCCCCATCAAAATACCAATC
CAATTCTTCAAAGAGTTAGACAGAACAATTTGCAAATTCATCTGGAATAACAAAAAAACCAGGATAGCTA
AAACTATCCTGAACAATAAAAGGACTTCAGGGGGAATCACTATCCCTGAACTCAAGCAGTACTACAGAGC
AATAGTGATAAAAACTGCATGGTATTGGTACAGAGACAGACAGATAGACGAATGGAACAGAATTGAAGAC
CCAGAAATGAACCCACACACCTATGGGCACTTGATTTTTGACAAAGGAGCCAAAACCATTCAATGGAAAA
AAGATAGCATTTTCAGCAAATGGTGCTGGTTCACCTGGAGATCAACATGTAGAAGAATGCAGATCGATGC
ATGCTTATCACCCTGTACAAAGCTTAAGTCCAAGTGGATCAAGGACCTCCACATCAAACCAGATACACTC
AAACTAATAGAAGAAAAACTAGGGAAGCATCTGGAACACATGGGCACTGGAAAAAATTTCCTGAACAAAA
CACCAATGGCTTATGCTCTAAGATCAAGAATCGACAAATGGGATCTCATAAAACTGCAAAGCTTCTGTAA
GGCAAAGGACACTGTGGTTAGGACAAAACAGCAACCAACAGATTGGGAAAAGATCTTTACCAATCCTACA
ACGGATAGAGGCCTTATATCCAAAATATACAAAGAACCCAAGAAGTTAGACCGCAGGGAGACAAATAACC
CTATTAAAAATGGGGTTCAGAGCTAAACAAAGAATTCACAGCTGAGGAATGCCGAATGGCTGAGAAACAC
CTAAAGAAATGTTCAACATCTTTAGTCATAAGGGAAATGCAAATCAAAACAACCCTGAGATTTCACCTCA
TACCAGTCAGAATGGCTAAGATCAAAAACTTAGGTGACAGCAAATGCTGGCAAGGATGCGGAGAAAGAGG
AACACTCCTCCATTGTTGGTGGGATTGCAGACTGGTACAACCATTCTGGAAATCAGTCTGGAGGTTCCTC
AGAAAATTGGACATTGAACTGCCTGAGAATCCAGCTGTACCTCTCTTGGGCATATACCCAAAAGATGCCC
CAACATATAAAAAAGACACGTGCTCCACTATGTTCATAGCAGCCTTATTTATGATAGCCAGAAGCTGGAA
AGAACCCAGATGCCCTTCAACAGAGGAATGGATACAGAAAATGTGGTACATCTTCACAATGGTATATTAC
TCAGCTATCAAAAACAATGACTTTATGAAATTCGTAGGCAAATGGTTGGAGCTGGAAAATATCATCCTGA
GTGAGGTAACCCAATCACAGAAAAACACACATGGTATGCACTCATTGATAAGTGGCTATTAGCCCAAATG
CTGGAATTACCCTAGATGCCTAGAACAAATGAAACTCAAGAAGGATGATCAAAATGTGAGTGCTTCACTC
CTTCTTAAAAGGGGAACAAGAGAGGCAAAGATTAAAACAGACACAGAAGGAACACCCATTCAGAGCCTGC
CCCACATGTGGCCCATACATATACAGGCATCCAATTAGACAAGATGGATGAAGCAATGAAGTGCAGGCTG
AAAGGAGCCGGATGTAGATCGCTCCTGAGAGACACAGCCAGAATACAGCAAATACAGAGGCAAGTGCCAG
CAGCAAACCACTGAACTGAGAATAAGACCCCCGTTGAAGGAATCAGAGAAAGAACTGGAAGAGCTTGAAG
GAGCTCGAGACCCCTTATGAACAACAATGCCAAGCAACCAGAGCTTCCAGGGACTAAGCCACTACCTAAA
GACTATACATGGACTGACCCTGGACTCTGACCTCATAGGTAGCAATTAATATTCTAGTAAGATTACCAGT
GGAAGGGGAAGTCCTTGGTCCTGCCAAGACTGAACCCCCCAGTGAATGAGATTGTTGGGGGGAGGGTGGC
AATGGGGGAAGCATGGGGAGGGGAACACCCATACAAAAGGGGAGGGGGAGGGATTAGGGGGATGTTTGCC
CGGAAACCGGGAAAGGGAATAACACTCGAAATGTAAATAAGAAATATTCAAGTTAATAGAAAAAAAAGAA
GAAGAAGAAGTTTGAGGAAAGATGAAGAGAAAAGCTAGCAATAGTGAGTTCTCTCAGTTCCTTGTAGAAG
GCTCCTAGGTCTGGCCTAGTGAAGATTCTAACCCAGACACCAAAAGTTTTTATAGTAGTGGCATCCCACT
CCATTAGGAATTAATGTGGCTCCTTCTCTGAAGTGCATAAGCCTCTGGATCTGCTGCCACTGCATGGGGA
ATGGGTGGTGAGGAGGGGCCTGCTTGGGCCTGTTTTGAATCTTGACTCCAACCCCTCCCCACAGAAGGTA
CAGAAAAGAAACACTCCCAGCCTTAGAAGTACCAGTGTTGCCTCTGACTACAACTGAAATCCACCAATAT
TTACAAGCTCATAGGACCCCCTTCCAGGATGGCCACAGCTGCCTTCAAGCACCAAGTCCTTTTGTGGGAT
CCTTAGATATCAAAAATCAGAAGAGTGCTAGCAATTCCTTCTGCCTCTTCAATGACAAGACCACAGGGCA
CTTCCTTTGCATGACCAGCCTAGCAGAAGGGAACTGGGAAGACTTCCAGGCCAGTGTGAAGGGATGAGGG
GATAGGGCCAAAGAGGGAATCCTACTTAGGGAGGGCCCAAAAGCTGAGGAAAGGTAGGAGTTCTTGAGAA
TCTGGAACGGAACCATACTTCTTTTGGAGCTGCCTGAACCCTAGGAAACCTAGGTAGCTCATGTGATGTT
TGGCCTTACCAAGGTGACAGATGACACACTTAGGAAATTTTGTCTACTATCTTCAATCTACTCAAGTCTG
CTGTTCCCTTGGTTCACCAGTGGGAGCTCAGGATTATGTGGCTTGAAGTTACTAGGGGCTGAGAGTCAGG
AAAATGGAGTACAGTACGTAGAGAACACCTTTACTGGGCCTGGTGTCTCTCATAACCTATTTGGATTACC
AGTGAACAGCAGCTATAGAGATGCTGAGGTGGTTCAGACAAGTCACAAGCTGGACAACTTGGTCTTGAGC
CAGGCTACAAGGATACCCACTTTTTTCCTACCCCAGGGAACACTCTGTTTACTCTTAACCTTTTGCCCTT
AACTCGAACAATTCCATAGGATTAGATCCTGAGAAGCTGCCAAAACTGTTTGCCTGAAATGTCAACCCCA
AATGATGTTCTTGGGTGAGGTCTAAGAACCAGCAACCTCATCCCCTGGAGCCCTTAAACCAAGGCTTAAA
TCTTCTCCATATTCTTCATACTGCTTTCCCTGCCTGGCATGAGTCTTTTTGTGTCTTTTTGCCAGCTTTA
AGAAGAGGTTTTTGAGAGTATCAGATGTGCAACAAGCAGCTGGTGTCTGTTCGAGCAGATTCCCAGACCT
GAATCATCTGCTGAACATGATGAGGTGGGTGAGTTGACGGCCTTTACAGGGCCAACAGGAAGCAGCAAGA
CAACATCCATCAGTGAGTATGCCCTGGAATTGTCTATCAAGGGAGTGAACACACTGTGGGGTATCATTGA
GATCAGCAATTTGAGAAAAGCCCAGGTCATGCTAAGATTGCTATGACATATCTGGAAGAGCAACTGGACA
AGTATGAAGAGTGGGCAGACAGTTTTGAGGACCTGCCTCTCTATTCCATGACTTTCCATGGACAACACAG
CATTAGGTCTCTCACAGACACAATGCAACATGCTGTTTCCATCTATGACATTTGTCATATAGTCATGATC
GGTCATGAGCAGCTCTCTACTGACAGGATTGCAGCTCAAGACTACATTATTGGAGCCTTTTGGAAGTTAT
CTGCAGAAAGTAGCTGCCATGTGACTATGATTAGAAAGAAGATGATGACAAGGAACTACAGACAGCATCC
ATTTTTGGCTCAGCCAAAGCAAGACAAAGAAACAGACAATGTTCTAATCTTACAGGATAGGAAGTTGGTG
AGTGGGCCTGGGAAACAGTATCTGCAGGTGTCCAAAATCACTTTAATGGAGACATAGGTGTCTTCCCACT
TGAGTTCAACGAGAGTTAGTTGTCTTACCTTCTCTATCCCATCCAAGGGCAAAGCCCGACTCAAGACGAT
CAAGAATGACAATGAACTTGTGGCCAAAAGTCCTCTTCTAGTGAAAAAGGGGCTGTGCACCTGAACCCTG
AGACTTTCTTAGGCCAGGAACCCAGCCCTAAAAGTCAGATACCTCTAAGTTGTCAAGGTGAAAGCTGAGC
ACAGCTGCTTGCTGAAATGACCCTTGTGGACCAGGCTGACACACAGACTCTTGGCCTTCTGCTGGGGCAC
TTCCATATAGTCTTGAGTTATGGAACTTTTCCAAGCCCAGGGCTGAGTTCCACGGTGACATTTTTTTCAG
TCAGCAGCTACTAAGGATATCATGTATGCTAGTTTGGTTTTCCCCCATAGGTTTTCATTTATAGCACTGA
AAAAACAAGGTCTTTTTCTAGAGAACCAACATGTTGGTGACAGCAACAAAGCAAAGTGAAGAATGCTGGA
CTGCTCAGCTAGTTTATATTAGTCAGTCTAAAAAGGTGGCTGATCAGTGTTCATGTAAGAACTAGACATG
GGCATTGTGTACTTTTGGAGAAAGGGATCCAGGCAGAGAAGCAGACCAAACCTCAGGTGGCAATGTGTAT
GTCAGATAAAGAAGGTGGGCTCCTGAACCTGCCATGAAACATGAGGTTTGCTGAAACTCTGGCATGTTGG
CATCCAGAGCTAAAGAATGATGCAACGGTCACCTCTCTGCTCTGCTTTGTAGAGCCAGGCAGAAAGAATT
GATCTGAGGTGATTATCCTGTACTATCAGGGTATCAATGAGGGAAGCTGCTTCCCATTTAAGGAGGGAAA
GAAGCTGTGAACCTGCAGTGCCTCCCCACTGGGTACAAACTCCACTGTATGCTGCCTCTGACTGCTGAAG
GTAAGACTCTTTGTAGAGCCTTTTCCAGTTTGAATGAAACATTTTTATTGCCTTTGGAAAAAAAAAACTG
TAATGTGGAAGCAAAAACAAAAACAAAATTTGTGAAACAGAAAATTGCTCTAGCTAGCATTTTCATTGCT
AGTTCTTAACTTAAGAAGAAAGATGAGGGAAGAAATATGGCATAGGAAAGAGATAGCTAAAACTAAGTGT
CATTTGAGGAGCCATTTGGCAGCCCAGCACAATGCAAGCTTCTTACAGTGGTAGAACTGGGTTATATATA
ATGAGTTCTTGGCCATAGTGGGTTCTAGGGAAAACCCCAAACTACTTAATTTATTGTTGTGGCTATTAAT
TGTTCCCACACACTGATGATAAGCCCTATTGCTGAAGACAATATTTACAAAAGTAATTGAATATGAAGAA
GTTGACTTGGTGCCTAGCTAGTGCACTCACTCCTACAGAATATTTGTCGTCTATGGTATAGGAGTGAACC
TTGTATGCTACAAAAAGAGAAAGGTAAACACCAACCCAGGTACAAACCCTTCTATCTACAATAATGATCA
GCCTACGAGGTGCTCTAGGGAATAAAGGCATAAATGTTGTGAAAGCGACAAAACTATACCTGATTGGATT
TACTGCCCACACCATAAAATAGAACCCATTCCTGACACTGTTCACATGGTAAAGAAACTGAAACTGGATA
AGTCAGGTACCTGGAGGAAAATAAAATACTTATTTTTTTAATTAAAAGAATGCAGCAATAAAATGGCACC
TAATATCATTCTGCTATTCTCTTAGATAAAGGCTTCATTCAGACTTCTTTAGAGAAACTTACTCCTTCAA
AAGATCCATAATGGGACACTGTGCAGAAAGTGAGAGATCTTGGAACATTCAGTTCTAAAACGAATGTCTC
CACTGCACCTTTCCTTTATGCATCAGGGAGCTCTCAGGAAGAGGAGGCCGAAAGGTTCTAAGAGCCAGAT
GGAATGAAGAATGCCAAGGAAACAAAGTTTTCTAAATACAACACAGCTGGTGCACATATAAACACTCAGA
GACTGTGGCAGCATGCATCTGGCCTGTGCCAGATTGGTTCTTAGAGCTCAAAGGAGGAGACAAAAAACCT
CCATTCTTAACCTAGAAGTTATTTCCAATAGATAACCAACCACAAATGAAAAAGTAGTAGTTTTCTCTAA
GAGAATTTCATTGGGGGTACAACGAATTATTATGAAGAGTCTCAGTGTCCATCAGGAAAGAACTAACAAA
AAATGTACTCAATGGCATCTTTGTCTATTCTTTTGGGGGATTATTTTTACTCTATGGGCCCTTCATATAT
ATGTATGGCTTCCAGTTTTGTGTTTTTATGGATTTCCTGTAGGTGTCTCTGCATCTGTATGGGTTTGTCA
TTCTTTTTCTTTGGCATTTTATCTTCTGTTTGTTTTGATCCATTCTGATTTATTTGAATTTCTTTTATCT
TTTTTATATTTTAGATAACTATTTGTTTTTGAATAAGGCAGGAAGTGTTCAGATGGGAGAGAAGATGAGC
ACAGCTTCACCTCAAAGTAACTGAGAAAGAGAAGGCATAATCAGAAAAGGCTGTGTGAAAAATAAAATCT
ATTTTCAGTGAAAGAAAAGAAGAGAAAAGGTAAAATTTAAATGAACATGAAAATGTAAGGTCACAAAAAT
TGACTAATGCTATCCATTCAAATTACATGTTTTCCCACAAAATGTCCATCATTTTAAATGTTGAGATCAT
AAATAGAAGTTAATTTTATTTTATTTTCACAATTCTAGTTTAATAAGAGTAACATGTTGGAAGAAAGAAT
TTTAAATGTGGAAATGGAAAAGTAAGAATAAAAAAAACTTATGGCTTTTCTTCCCATTTCTAAGTCCCTT
TTTATGTTTATATATGAGGGCTTTTCTTTTTATATTCTTTGAAAATTTCATACATGTATACATGTATTTT
CATTGTATCAATTACAATTCCCTTCCTCCCACTCCCCATAATTCTCCAAACACGTTGCTCCCTCTATTTT
ACATGTTGTATTAATAACCACTGAGCCCATTTAATATTGCTTCTATGAAGATGGGAGTGCGGTTATATAA
TGAATCATGGAAAGCCTACCAATGTGTCTATGCTTTACAGTAGAGAAATATAAAGTTATTTTAAATATTG
GAAATATCCATGACAGTCTTCTGTGCTTTAAGAGTGATTTACAACCCTCCAAACATATAAGCTTTACAGA
GGTATACGATTTGGTAGATCAGAGATGAAAAATCAATATGTACACATCATAGGTACAGAAAACGTTGCTC
TGTTCCAAACTATGCAAACTAAGGGAACACAGTATAGACACCATCTGATATCTAAATACACCCAAAACAA
TTTAACTTGTTTGTTAATGCTTGGCTAGGCAGCATTTCAGCAAAAGACAAGAATGTGGACTCTAAGCCCA
TAATGTGACTTTGCACTCCAGTGCCCTGCTTAGTGGTGTATTAAGTATGCCCGGACTGTTAACAATTAGA
CTCATTTTCCTCCAAGACAGAGGTCGTAATACCTCTTGCCTGTAAGATTATTAAAGTATTCAGAAGTTAT
CATTTAGAAAACATTACTTGGTAATTTTACTTATTATTGCAAAAAAACAAAAAGGTTTTGTTTTCTTAGT
GCACTCTCTAGGCTCCATATCCTTAGTGAACTATCTAATCATTTTATGAGGCCTTTTGATTTTCTATTCA
TTACTAGAAAATTAAAAATTTTACTCATGAAAATTAGGTTTGCGTACATTTCTTTAATAAGGATAGTCAA
CCTGGCCAAACTCATGTTCAGACTAGAACACACGTGAGTCCACTCATATTCCTCTTCAACCACATTCAAC
GTTAGTGGTGAGTGTTCACACATTCTGCTATAAAATTATTTTAAATATATTATTGCTGTATTCTGTTTCC
ACCCACATGTGTCATGCAAGCTATCTGATTGAGTTCTTAAATTATGGGTAAGGAACATGATCAGATAATT
TTCAGAATTTTAAACATATTTTATTTCTAGGAAGAAAATAAGAAGAATATGTTCTTGGTCCTTTTGACAC
ATAAATTTTCTACATCTTTTGAAATGGTCAATTGATATAAATGGTTAGGATCTGATCACTCACCATTTGC
TGGATAACCTGGTGTGAGTGGATCACCTGCACCATTAAGATTTAAGACATTTCCACGCTGAACACCACCT
CCAGGGAGGTTCCAACCATCTGGATAGGACTTCACCCCAGGAACAAAGTAATCAGCAGGGTCTGAGTACA
GAATGATTCCTTTTGCACCTGCCAGCTGAGCATTTTTAACCTAGAAAATATGATGTTTCTTTTCTCATTT
TAGGTAAGTTTTTACAGGCTGAATAATGTCAGATACCAAAATCACATTGCACAAATAGCTAAGCTTCATC
TTCTGTTTTAAAGGCCAGGTCTCACTGAGATTCCAAGGCTGAACAATAATTCACTCTGTAGCCCAGGAAG
GCCTTAAACTTGTAATTATCTTAGCTCAGAGCCTCAAGTAGCTACAGCTAAATGCTACTAGGCATAGATG
CCATTTTAGATCTAAAAATTGATGGTTTTGCAGAGTGACAAATGTAGAACACTCTCATAACCATGGGAGC
AAGGAATCGCTATCTTCTCTGGCTTTCTAGAAGGATAATAAGAAAGTAGAATTCCTAAGCCAAATCCCCT
TTAAATCTATGTCTGGGAAAGAATAAAGACTTCTTGCACTAACTATAGTAATGATCCACATTAAATTTAA
TTGAAAAAAGTGAAGATAATATATAACACAAAGGTAGTAGAAACTAGTAGGAAACCCATTGTGAGTTTGT
GTTTGTTGGTAGGTCACTGAATCTTGAAGGTACAGAATATTTGCTACATTCACTCTGCAAAATACAGGCA
GAATTCAACAACACAATTCAAAGACACACTCTCTCTCAGTGTATCTTCTTTGTAAAGTGGAGTGTACAGA
GATAAGAGAATCATAATCTGAGAAAAAATGTAAAAATCTATCATATTACAATATTTTAGATTACAGAAAG
AGGTGAACTTTCAAAATGTACAAATGTATGAACTGTACAAAACAGTGGAAAAAATTATAGCAAATCCACA
CATAAATAGCATATGCTCAGATTATACTCATCCACTTATGATCCTATCTCTCTTAATCATTTCTACTTCT
CCCCTACTGACTGGCAAACAGGCCGATCTCTCCTACTTTCATGTGTATCTTTTGCTCTTCCTTTTTTGAA
CGAAGATTTATGTATAAGGAAATAGTACAGTATTTATCTCTTAACGGTTATCTCCAGTCTATCTACTATT
CTGAAAGGACATCTTTTCTTTACCTTATTTCCTCTGAACACTTGCCCATATCTGGCGATGACAATCTTCC
CAGAACAATTGATCTTCATGACCCGTTCCAGTTTAAAGAAGTCTTCAGTCCGTGCATAGTTAACATATAC
TAGATCCCCCTGTCAAGATCAGGAACGGTTTAGTACAAAATGTAGATTATAGAGCTATCTCTGATTGAAA
GATGTTTGATATTTGAAGAGGGAGAGAGCGAAAACACATAAGAGGGTCATGACAGATGTGCCTTAACTGA
GACAGTCAAAGCAAAGGTTAACTTAAATTGAAAATACAATTTGATATCTTAGGAGGCGAGTTGATTAAAT
GATACATTTTGCTTTTTCTTTTCCTGAATAAATCAAGATGTAGAATAATGTAAGTATTCAAGTTGCTACA
TGTAATCTGAAAAATATCGGTCACCATAGGTTGAGAAGCATTTGATAAAAGAAACCATTCTTCTCTTTAA
AGCACTCACTCAAATTGGAGGATAGTGAGTCTTCACAAACCTCAGAGACAAAAAGGCCCTGCTTTTCAGG
AGGCCTTGTTTTAATGATTTGTGTGATTACATGCCAGCATCACATTATCCTTAATTCTCTATAAGGGTCA
TTTGTAAAGTGATTTTATAAAATGCTTTTCATCCTCTAATTTAATCCTAAGGGAACTCTGGAAAGTAATG
TACATGTTCATTTATTTTGCACAAATATAAAATGTTCTAAAAAACATCTAAAACATCTTCTTTATACTTT
TAGGAACCTAAGTGCCTACATTACATGACTTCCAGCATGCTCTTAATAGCAATGTTTTAGAAGCAATTGC
ATAGTTGTTCATATATATCTGAAATAATTTAAATACTATTTGTATGTATTTACTATTTAACTTCTTTCAA
TTAAAAATATGAATATGGTATTGAAATGTAGCTTAATGGTATAATATTTATTCAGTATGTACTAGGCTCT
AGGCTTAATCAACAATACCACAAAAATATTAGTTAAACCCAAAACTAAAAACTAACATATGACTATATTT
TGCTGCACTGTCATAATTTTATTAATTAATTTATCCCTTAAGTATTAACTTAGAAATGTATCTGTGTGAC
AAGTACTTCAAGTATCTGAAGAAAGAAATTGAAGATGTCAGAAGATGGAAAGAACTCTCATACTCATGGA
TTGACAGGATTGTTATTGTAAAAATGGAAATCTTGGTAAAAGCAACCTACAGATTCAATGTAATCCAGAG
AAAAGTTCCAACTCAATTCTTTATTGTGTTAGAAAAGCAATTTGCAAATTCATTTGGAATAACAAAAAAA
ATAGGATAGTGAAAACTATCCTCAACAATAAAAGAAACTCTGGGGGAATCAACATTCCTAACTTCAAGCT
GTACTACAGAGCAATTGTGATAAAAACTGCATGGTATTGGTACAGAGACAGGCAGGCAGATCAATGGGAT
AGAATTGAGGATCTAGAAATGCACCCAAATAGCTATGGTCACTTGATCTTTGACAAAGGAGCTAAAACCA
TGCAGTGGGAAAAAGATCGCATTTTCAACAAATGGTACTGGTTCAACTGGTGGTCAACACGTAGAAGAAT
GTAAATATATCCATTCTTATTGCCCTGTGCAAAGCTCAAGTCCAAGTGAATCAAGGACCTCACATAAAAC
CAGATACACTAAAACTAATTGAAGAAAAAATGGAGAAGAGCCTCAGATATATGGGCACAGGGGAAAATTG
CCTGAACAGAACACCAATAGCTTATGCACTAAGATCAGCAATCGGCAGTGGCTGTCGTATTTAGTAAATC
AGAGCCCCCATGATTACCAACAGAACTAGAAAGCCAAGATTCCTGCATAGATGGGTGAAGGCCTGCCTTA
TAGAAACTATTGGCAGTTGTTAACTGATGAGGGGGAGAATCATTCTTTCATGAAAGAGTAGCCACAGATA
GGTTTATTATGCTCCTGGAGATGATCTCACAATCTTTTATGTATTGGTACCACTGATATATCATCCAAGA
AGAAAGAAGGAAGGGAAAAGAGAGAGAAGAGATGAGAGAGAGAGAAAGAAAGAGAGAGAGAGAGGAGAGA
AAAGAGAGGGAGAGAAAGAGATATTAAATTGATCTGTTCACATTTCTTAACCTTATCAGTGGCCAGGAAG
CACCTAAAGAAATATTAAACATCCTAAGTCATAAGAGAAATGCAAATCAAAACAACCCTGAGATTCCACT
TCACACAAGTCAGAAGAGAAAAGGATGGTTAAGATAAAAAACTCAGGTGACAACAGATGCTGGTGATAAT
CTGAAGAAAAAAGAATACTCCTCCATTGTCAGTGGAATTGCAAGCTGGTACAACTACTCTGGAAATCAGT
CTGGCAGTTCCTCAAAAAATAGGACATAGTATTATTACCTGAGGACCCATCTATACCACTTCTGGGCCTA
CACCCAAAAGATTTTCCAACATCTAACAAGGACGACATATGCTCCACTATGTTCTAAAGCAGCCTTATTT
ATTATAGCCAGAAGCTGGAAAGAACCCAGATGTCCTTCAACAGAGGAATGGATACAGGAAACATTTACAC
AATGGGGTACTATTCAGCTATTAAAAACAATGATTTTATGAGATTCATAGGCAAGTGGATGGAAGTAGAA
AATATCATCCTCAACAAGAAAAGAAAAAAGAAAAAAATCCAGGTGTTATGTACTCACTGATATTAGCCCA
AAAGTTTGGAATACCAAAGATACAATTTATAGACCACCTGAAGCTCAAGAAGAAGGATGACCAAGGTGTG
GATGCTTCAGTCCTTCTTAGAAGGGAGAACAAAATATACTCACAGGAGGAAATCCATATACAAAGTATGG
AGCAGAGTCGAAAAGGTGATCCAGAGACTGCCCCACCTAGGTATCCAGCCCATATACATACAGGCACCAA
ACCCAGACAATATTGTTAATGCCAAGAAATGCAGGTTGACAGGAGCCTGATATAGTTGTCTCCTGAGAGG
CTCCTCAAAAGCCTGACAAAGACAGATGCTCACAGTCCAATATTGGACTGAGAAAGGAGTCCACAAGAGA
AGCATTGGGGAATGGAGTGAAACAGCTGAAGGGGTTTGCAACTCCATAGGAAGAACAACAATATCAACCC
ATCAAACACCCCATATCTCCCAGGGACTAAACCACCAAATAAAGAGTTCACAGGAAGGGACCCATTGCTC
AAGACACATATGTATCAGAGGATGGCCTTGTTGGGCACCAGTGGGAGGAGGGGCCCTTGGTTCTGTGAAT
GCTAGATACCCAAGTGTAGGGGAATGCCAGGACAGAAAGGTGGGAGGAACAGGTTGGGTAGGTGGGAGAG
TATGCTCATAGAAGCTGGGGGAGGGAGTATGTGTAAAGGGGTTGTTGTTCTTACACAAAATTTTTTTAGA
AAATTACCCAGATATAAAACTTTTACACAAAATGTGAGTTAAAGAAGAATGTTAATATTAAGTTCAAAGC
AGTGTCTGATTCCAATATGCTCACTATAACTTCATAGCAACAGCTTTTGCATGCCCTTACCTCTTCACAA
TGAATACTTGAGGTTTTATCCTTGGAGCTAAATTCTTTTTCTTGAACACAAATTTGTGCCAAAACTATTC
CTCTTTTATTCTAATTATGAAAGCCCATTGTACTTCTTATCATGAAGTCTGAGCTTACTATATGAGGAGT
GGGCACTTTGTATTTTTGATTCTAACTTTTTTATATCTTTCCAGCAATATAGTTAAGACCATCTCTTAAA
ACTTTCCTTGTAAAATTATTTCAATCAAACAAGGGGTTATACAGGACCATTAATTATTCTAAAGAGCATT
AATTCATGAAAGTTTAACTTTATGTTAATCCCCAGGAAATCTGACCAATAGGGTGGGCTAGTGCCTGAGG
ATGATTATATTAATTTAATAATGACAGGAAGGGTATATCAGCTGCAAGAAGCAATCTTGAGATGAAGTTT
CTTTGGGAACTTGCCATTGAGTTCACTCATTATAGACTATGCAATGATAGTTAGCCACCTACAGGAAGGT
TATCTGCCAGCCTTAGCCTATCCAAAATAGCTCCTGAACACTTAATAAAGGATCTCCTTGCATTTGTTTT
GCGATTGGAAGTTAATGTTTGGATGTTGTCTGTGTTTTGTCTGGGGTCCCCGAGGGGAAAACCCAATAGT
ATTTGCATCAATACCCTGTACACGTTGATATGATTCACGTAATTTCAAAGCACTATGAGTTCCACAAAGA
GTCACAGGGCACAGTGTATCTCTTTTCCACTTAAGTTTTTAAGTTTGTTGTATTGCATTAGTTGCTTTAA
TGTCTACAAATGATTTGCTTGCATGCATGTATATGTACCCGGTATGTGTGTTTGGTGCCTGAGGAAGACA
GAGGAAGCCTTTGATAACTTGGGACTGGAATTGCAGACAGTTGTGAACTGTGTTGATGGGAGGTCCTCTG
AAAGAACAGAGTACTTTGAATCACTTAATCAGCTCTCCAGTCCCGCTTTCACTTTTAAACAAGGATCCTC
TTATCAGGTTTCTCTTGAGAGGTAATATCCCACTACCACTCAAGGGAGAAAATAGGCCATAGCAACACCA
CCATCAAATCAAGTCATATGCAGAAACACAGTAAAATGCAGTTAACAGTAACCACAGCACTTCAGTAATG
GCCACAGAAAGGAGCAAAAGTATACACAGAACACACTAAAAGATTAAAATCTAGAAAAGAAAAAACTAAT
AAAGTACTTCAACATAAATATAAGTATAAATATAGACAAAAATAAATATAGCTGTGAATATGAATATAAA
CATAAACATAAGCTTAAATATAAATAAAGAAAAGTATGAGAAATGTAAAAAGAAACAAAAGTTAGATTTT
TAAGAGAAAAGGCACATGAAAAAAAAGTAAGGAAAAGCATAAATAAAGAATAACAGATAAAGATAAAAAT
AAAGTTTGGGAACAGTGTGGAATGAAAAGAGAGAAAGTAAAAGAAGTCAATGATTTTCATTTTAGCTAAC
ATACTTGGGTTGTCTCAGAAAGGCATTCTTTCTGTTCTCTTTCTTCTCACCAAATGTGTTGGCTAAGTGA
TGCTTGGATAGTCACAGATTCAATGGTGCACAGTGGAAGCACAGCTCTACACTGTTTCCCTGAGCAGACC
AAGATTGTGTACCTATTCAAACATGTCTTTTTAACTTACTTTGGGCCTCACGTTATGAGTACAAACAATA
ATGGACACAAATCTTTGAAATTACATGTCAAAATAAATAATCCAGCATCTTTTCAGTTGTCAGCTTAAGC
ATTTTATTTTGACATACTGATGAAAATTAACACACACACACACACACACACCCCAGAGCAATGATTGCCT
TAATGGTGTATGAAATTGAGAAGAGGTTTAAGGGAATTTTCTGAACTAATGACAACAATCTTTACAACAG
TAGGGTTTTGATTACATAGAAGTGGGTGTGTATAGACATGGATCCCAGTTGAGGCAGGAGATCACACAAC
CATTTTCAGAATTTTTAAGCCAGAATGGTCCCTGTCTATAGGAAATGCAGGGACAAAAATGGAGCAGAGA
CTGAGAAAAGCCACCCTGTCCATGTGCACACACCAAATCTTGGTGCTATTATTAAAAGTCTCTACTACCA
ACTGACTAGGACAAATGCAGATACTTTCAGCCAACAGTTGGATTGAGGTCTGAGGCCATTATTGAAGAGT
TAGAAGAAGGATTGAAGGAGCTGAGGGGATTTCAACCCAATAGGAAGAACAACAGTGTCAACTAACCTAG
ACCCCTCAGATCTCGCAGAAACTCAGACAAAAACCAAATAGCGTACAGGGTGGTTAGTGGCCCCAGGCAC
TTTTGGCAAAGGAATGCCTTGTCTGGCCTCAAAGGGAGAGGGTGCACTTAATCCTGTGGAAGCCTGATGC
CCAGTGAAGAGGAAAGCTTTTGGGGGTGAGTGGCAAGAGGGATGAAGTGAAGTACTCAGGGAGGGGGACA
TGGAAGAGACAACTTTTGGAATGTAAATAAGAATAGCAATTTAATAAAATGAAAAATGATTGTTTATGAA
AAGTCAATAAATGTGTAGGTACATCTCATTGTAGCATATTTTATTTTCAAAAGCACCTTGAAAACTTAAT
ATTTTTTTTACCAAGCAAGCCTAGTTTCTTAAATATGGAAAAGGAATAATTTTGAATTATGTAGAAATCC
CTCTTCTTACCTTTTAATTATTGCCTAAATATATAAAGAAAGTGGTTTGTGCTCATCATTTGTATTGCGC
TGTGCTGCATTGTTACCTCTGGTGTCCCTTGTGGAGAGAAGGCACTGTATGGTGGCACTACATCTGATAT
GTTCTCATATCCCGGGGGTGACAGTTCAGCTAATGATGTTTTGAAAATCTAGAGAAACAAATAAGAGAAT
TAAGAGCAAATCAGTTACATTTTATCACAAGCAAGGAAAAAATATGCATCCATGTCTCCTTCCAGTTATC
ATTTAGTAATTTCCAAATTTATATCAACACCTGATACAATGTGAACAATGTGCAGAGATGGAAAAATTTA
GACTTTGTTTTCAGAATCCATTTAGGTATAAAGCTATAATAAATGACAATAATAGTAATAATAATAATAA
TAATAATCCTCATTATAAGGAAATAAATAAGCTCTGTTTGTGAGTGAATAAAAAGGAAATTCAAACAGAC
ATGGCTTTTCCAAAAAAGACAGTAGTATCATAAGGAAAGCAAGAATTGATGATGGACTTTATGGAGAAAC
ATACATCCCTATCTTCTATAAATAACAGCACAAATAATACACAGGTAAGGTAGAGAAGATTTAACCTCAT
GCTGGTGCTAGCAAACCTCACAAGCACTAACTTCCATTTAAGTAGAAATACCACCAGACTTTTTTAAAAA
GTCCTTGTATACATAATCTTGCATAGTAAAGGTTGTCACTTGTAATAATGTTACAATAACTATTTAGAGA
TCATATAAATATCATATTTGTGTTAGTATAATTTTTATATTTTAGGGATCCATCCTTAAAATTATCTGGA
TACCACAAACAACATTCATGCTTAAAACAATAAAAACACTAACCAAAAATATGTATTTGTGTATCTGCTT
AAGTATATTGTCATTCAATTTAAACATCAAAAGAAAAATTAAGAAACTCCCAGAAATAGCAAACAAATGA
AAATAGATATGCAACAGGAATTCTGAGAGGTAACATTAAAATCTGTATTATAGGTTTGGATACTGAACAT
TCCTCAATGCCCATATGTTAGCTCATTGGTTGTTTCCGAAAGCAGTAGAGATAGAACCTTGTAGGTGATC
CTTTAATTGGAAAATATGAGCTTAAAGGACTCCTAGCACCATCCTCAATCTTTGCTTTCTTGTTGTGACA
TCAGTAGTTTGTACTTCCATTCCCTTCTCTGTTATGCACTGCCTCATTAGAAGTTCAAAAAAATGGAACC
CTTCGATTATTGACAGAGACCACCCAAACCTTAAGCTAAAATAAAGTTTCATAAGTAAATACAAGTGATG
AAGCTGACTAGAATGTGAGTCCCTTTTTTTCTCACTTGGACTTATCAAAATGGAAATTTAAGAAGACATG
TAAATTAGAAATCATTTTCAAAATAATGATTACTGAAATATCTCTTATCTAAAATTGTAAGGTACTTGAA
GCAGTTAGAAGAGAACTTGAAAATCAGGAAAGGTAATAACATTTGAAATGTAAATAAAAAAAACAGGAAA
GGTAATAACATTTGAAATGTAAATAAAAAATCCAATAAAAGAAAAGAGAACTTGAACCACACATTTTATT
ACAAACTGGATATCAGCAAGCTAACATTATTCAGAAGATGCTACAATGACTGGCATAGTAACTACAAAGA
TGGTAATAAAGGAAATCTACATAAGCACATAATTAATAAAAGAAGAATTTAAGGTATAAAATTATGATAA
ATTTAAGAATTAATAAAATTGTATGTTTCTGTCAAAAGCACTAAGGATATAATAGAAAAAATCAATATTG
CACATATATTTAGCTGTTGCATAGATTATAAAATGTGAGAATATGTGAAAAATAATGTTAGCCAAAGCAA
CAAAAATGTAGGCCTTTGATTATTCGGTTCCGAAGTAAAAGATATACAACATTTATATTTATAAGAAGTC
TTGATCAGCAATAGAGCTGAGCAGATATCTACCATCTATGCTATTATGTCTACTTCCCTATCAAGAACCA
CAAGTTATAACTTGCTATGTTCCAACTGGGCTTCTAGTAACTCCAATTGGCCAACACTCTTGGCCAAATT
TTGAAGATTCTTATCCCTTGGCATCTCCTGCTTACTCTACCTTCCCCATCTCTTCCTAGTGGTTCTCCTC
TGACCCTAATTCAAAAACCCAAAACCCTATCTGTGTCTCTTCTGCTCAGATATTGCCTGTTGGCATTTTT
ATTTAAACAAAAGTTAGTAGCAAGATTACATTGTATGTGCAGATTCTCTGTATTTTTTGTCCCTGTGAGC
AACCAAGCCTTGGGAGTCAATATGTAGATTTATAATACATAGCCAAAGAACAAACCTTAACTGATGCATC
AATGAGATATCTGTGTACCAGCATATAGATACATCAGCAGTAAGGTGTAACTTTCCATTACACCACCACC
ACTGTTGCAATAATTGTTTTGTAATCCAAGTTAGACTACAATTCCATGTTGGCTTTGAACCTCATGATTA
TCATCCTTACACAGGTTCAATAATTCTGGAAATGGAGACAGACAGTATCACAATTGAATAAAATAGTGAT
TAAAATGAAATGTATATAAAGAATATATATTTTAAAAATATAGCATTATTCTGCCAATTAAAAATTATAA
TAGCTATTACATGTATCAGAACCAGTTAATTTTCTTTGAATTTGAAATACTAAAGAATGGTGTCATGTTG
GATATATAGTTTGACAAAAAAATATTTTTAAACTGTAAGAAATATGTGATAGTGCATGAAGATTGTGTTA
GACCTGAGCGACAAACATAGACCTGAATGATCAAACTGCAAGTGATTGCAAATATGTGAAATAAAAGTAA
TAAAAACATGCTACTTACAGAAAATAAGTACATGTCAAAAGAATCATCTCATAGTTAAATAATGATTGCC
CTCGAGAAGGGAACACAACAAGAAGCACAATATGCTCTGGAATTGTGATTAAATTTATCATGATATCATA
TATATTATTATTATAGTATATGTTAATTATAAGAAAAGACTGAGACATTATTAGTACGAAAGGTTTAATA
GCAATTTGAAAAGAAAGTCAAATAGGAAAATGATCTAACTTGTAGAGAGTCTGAAAAATGCTACTTATAA
TATAAAAATCTCAGTTGCAAAATAGCTATTTGAAGCATTGTAGACTATACTAAATATATTAAGTCTGCTG
TAGAAAATATACCAATAGAAATCAATGTTTTACTTATACTTTATTGTTTTAATATTAAACATACATCTTG
GTTTGAACAATCCCAGACAACTGTACTATAATGTCTTAGGCAAGGATGCACCTGGACTTATAATAAGGAT
TGTAAATTCTTTGCTGAAACTATACTATATCTCCAAATTGCCTTTTGCTTCCAGAGGCCTAATGTAAGGT
CTTATACAAAGGCCTGTACACAGGATCCTTTGAAATATAATTATTGAATGTGTCTAGGTTTTTGGCTAAG
ACCAAGTGAAAATACAGTGTTTTCAAACAATAAATTCTTGCTAGCTAAAAACTCACACTAGGTTTCTACA
TATTTAGTTTAACCCTAAAACTTGTCTTTTTTTTTAAAGATTTATTTATTATATATGAGTATACTGTAGC
TGTCTTCAGACACACCAGAAGAGGGCATCAGATCTCATTACAGATGGTTGTGAGTCACTATGTGGTTGCT
GGGAATTAAACTCAGGACCTCTGGAATAGCAGTCAGTGCTCTTAACCACTGAGCCATCTCTCCAGCCCCC
TAAATCTAGTCTTAGTGGTTTAAATCTGTGACAAGTGTCTGTTTAGGTACTGAGAATCTTAACCATATAT
TACTTTTGAAATTCAGATATACTGCTTAAAAAACAGAATGTAACTATAATGAAGCATCCTTTTAAAAAGT
ATTCCCCAAATCACACTAAGTTCAAACACTCTTCAGAAATAAGCTGACATTAACAAAGAGCTTTTAAAAT
CACAAATAAATAATTCTGAATTCAATAAATACATGGAAGTGATACAACAGAAGTGAAATCTTATTTTTTC
TTACCTCATTTCCATCTTCATTAATTATTGAGATATAGTTGGGATGGGTCTTATTTGGGTAGGACAACAG
GACATCATAATCAGATAACTCAACCAAATCCAGGCCAAATTCTTTCCACTGGGCATGAATTTGCTTTGCA
AGCTCAAAATTGTGTTGTGTCCCTGCCAAATGTGGTGTCCGTGTGAAATTGCTGGTGAAAGAAAGTTGAA
AGTGTTTAAACATTAATGTTTGGTCTGTTTGCATTTTCAATAAGCACCATGAAAAACCAACTTTTGACAT
GCCTATAATACACAGTTTTATGAAGCAAATACAAGATATGGAGATTTTCCATGAAGAAGTTTAAGCCCAA
TACCTCTTATTTAATGGGGCACTCCTAAAATAAATAGCTCTCTCAGAGTTTTACCTCTATCATAATTAAT
GTAGGTATATGTATTCAAACACATGCAACTTTATCCATATGTGAATATTTAATGGTCTTTTATATCAAAT
CACTTTGTGTTCATTAGGAAATCCTATTAGTAGAGGGATATCAAATATTTTTGACACATATATTAATCTG
ATTTGTTGAAAACTGATGTGCTCTAGATGATTAGATATGCGAATTCTATATGCATCCACATATTTTAATT
TTAAATAAATATAAATCTGACTTTGTGATTATGTGTAAGTTTTATTTTCTTGCACTAATGAGGATCAAAC
CAGGGCCTTGCACATGTTCAGGAGTAGAGTTCAATGGCCAGTACTTTTAAAATTTCTGTGTTTGCTTGAC
ACTCGTTCAATAAGAATAGAACTAGTTTTTAAATTTTCAAGATATCTGCTTTCCAGGCTTATCCTTACTG
CAGAAGTACCATTATCCTCATCTCATAGATGAGAATAAAAGCTTGGTAAGTTTCATTAGTCACTCGAAGT
TAGTTCCCTTATAATGAGCAGAGATGGAGCTCAAACTAAATTCTGTGTGACTTTAAATCAGCTTTTTCCT
AACTACAGCCTACTACCTTTCCTTATAGGATGAGTCACCAAAGTATGTTTCTCCATCCATATCTGTCCAA
AATCTGACTTTGTGCACTCCACAGGCAAAGGACAGCTTTATAATTGAAGTAGGTGAGGAAGTGAATAAGA
TGTGATTTTATAATGCATCTACACATGAGAATCAAATTTCTGTGCTCATGAGTACAATTTTATCAGAACC
TGAACATGTATTTTTCAAATACTTCTTATGGCTCCTTTTGTGCTGCGGTGGGTTAAGTAGTTGTGATAGA
TAATTTTTGGTTTGCAACAGTTGGTCCTTCTTCCGGAAATGTTTTTGGAGTTCTACTCTGAAAGTTTTCT
AATGATATAACGTTAAAGCTGAAGGTGTAATCCTTACCATATGGAATGTATTAAAAGTATATACTTACTA
TAAAAATTTTTTGATGTTCTCAGCCTTCAATTCTTGCAAAAATGCCTTCTTCATGCCAGGATAGGAAACA
CTGCTAGTAGAATCATTGGAGGGTTTTATAAACCACCCTGAAAAATACAAGCAAAAGTATGAATGAGATT
TGAGCTCATGACAGGGTCTTATTTTTATGACATACATAGTTAATCAATTATCTCTCATATTAGCTGATAT
TCATAGTTTTTTCCCTTTCCTTTACAGAGAAAAGCAGCATATCTGTATTCCTTTTAATTGCCAAGCAAAT
ACAATATATTTTAACCCAACCTCAATCTTATGTGTGTTGCTGTTACTTCTCAGAAATATTTAAAGTGAAA
ATTCAATTCTGTGTTTTTGTTTCAATTATTGGACATAAAAATGCTGTGAAAATGTACTTCTCCTGCATTA
GCTTCTCTTGCTAAAAATTGCTTGTTTCTCTGTGGAGCTAGAACAAACATTTAACAGAAGGTTATAATGA
ATAAATTCTTAGTAAAGTGACTGGAGGGATTGCTCAAGCAATTTAGAGAATGTTATGTTCTTACAAAGAA
CCTGAGTTTTATTCCTTGCATTCATATCACACATTTCCCAACAAAACTCTGTGGACACCCTTCCTACATC
TACACATACACATATATAAATATGAAATTATTAAACAATAAAGAGTATTTTAATTGTGACTTTTAAATAT
ATAAATTATCTCAAAACATTTAAAAAAAACTCAGACTTTGAGTCTGCTTTGAAATGGACACTAAGACAAA
ATGCATTGATATTTTTGTTTCTGCTTGAAAATTGGCATGAGGACCTGATGTTCTGAAAACTACAGTATAC
TACAATGTACTTCATAACTCTGCAAGACATCCAATATACAGAAAGACACAGACAGGTTATAAGAATCTCC
TTAGCCCCTGGCCTAGTGAGTTGATTTTAATCTGACAGGGAGAGAGCATTATTATAGGCTTTACAGAGTA
CCTGAACTGAGAAGACAGAAATCTACTCAGTCAACCCAAGTGGAGCTTTAATGTTATTGATACCATATAT
ACAGAGTTGGGCTTAATCTGAACTAAGCTCAAGAAACAACCATAAAGGATGTGTTCAAGCAGTGCTGACT
AATTCACATTTCCCAGACTGTGTCTCTGCTATGTCCAAGGAGGAATGTAAACAGAAAGCGATTCTTTGCA
CAGAGATGTCCTGAATGCGTTAGTATCCCGGAGGTATCTCTGAAACTCTCCCAAGTATGAGCTAAATGAC
ACCCCCTTCCCCACTCCCCCCAAACAGGGAAGAGCCACTAAAGCCAAGCTTATCGCTTGATTTGTATCAG
CAGCCACTAGGGATCTGAACTGAGAGATGCTGTGTTTGCAGGATTCCAGTGGGTCAGACCTAACTCTAGT
TCCTGTTCCGGGTTTTTTGTGTTGTTTTGTTTGCAATTTTACTCTAATCTGTGCAATTCAAACTCACTGG
CAGTTTATTCCTAAATCAAATCTGCCCAACCCCAGGAAACTTCAGCTTAACTCGGATACTGCTGGCCCCT
CCCCCCATGCAAATCACTGTATGGCGTCGGTGTGGTGGGGGAGGGCGCTAACCTCTCCTACAGACTCAGT
TGCTGCTGATTGCAGAACGGAAGGAAATGGGAAGTTATGCAGTTTGCCATGCAAATGCACCATACCAAAG
AGGAAGCCAATGATGAAGGTTCCAGTGAAAGCCAGCACCAGTGTTCCAGCACAGAACCAGCGTTGACGGC
GTCTCAGGGCCTCCGCGGAGTCGCTGTCCTGCTGAGCGTTCCACATCTCTGGCAACTTTGGTCTTTCTCA
GCAGTTCTACTGCGGCTCTACTGCAGAGTCTGCAGCCT

</dna_sequence>
        <protein_sequence>>NP_476533.1 glutamate carboxypeptidase 2 [Rattus norvegicus]
MWNAQQDSDSAEALGRRQRWFCAGTLVLAFTGTFIIGFLFGWFIKPSNDSTSSVSYPGMKKAFLQELKAE
NIKKFLYNFTRTPHLAGTQHNFELAKQIHAQWKEFGLDLVELSDYDVLLSYPNKTHPNYISIINEDGNEI
FKTSLAELSPPGYENISDVVPPYSAFSPQGTPEGDLVYVNYARTEDFFKLERVMKINCSGKIVIARYGQV
FRGNKVKNAQLAGAKGIILYSDPADYFVPGVKSYPDGWNLPGGGVQRGNVLNLNGAGDPLTPGYPANEYA
YRHEFTEAVGLPSIPVHPIGYDDAQKLLEHMGGSAPPDSSWKGGLKVPYNVGPGFAGNFSKQKVKLHIHS
YNKVTRIYNVIGTLKGAVEPDRYVILGGHRDAWVFGGIDPQSGAAVVHEIVRTFGTLKKKGWRPRRTILF
ASWDAEEFGLLGSTEWAEEHSRLLQERGVAYINADSSIEGNYTLRVDCTPLMHSLVYNLTKELPSPDEGF
EGKSLYDSWKEKSPSTEFIGMPRISKLGSGNDFEVFFQRLGIASGRARYTKNWKNNKVSSYPLYHSVYET
YELVEKFYDPTFKYHLTVAQVRGAMVFELANSIVLPFDCQSYAVALKKHAETIYNISMNHPQEMKAYMIS
FDSLFSAVNNFTDVASKFNQRLQDLDKSNPILLRILNDQLMYLERAFIDPLGLPGRPFYRHIIYAPSSHN
KYAGESFPGIYDALFDINNKVDTSKAWREVKRQISIAAFTVQAAAETLREVD

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1333">
        <gene_name>S</gene_name>
        <strain>Hepatitis B virus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>128168861</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:279085</xrefs>
        <taxonomy_id>10407</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>hepatitis B surface antigen</protein_name>
        <protein_pi>8.11</protein_pi>
        <protein_weight>14446.5</protein_weight>
        <protein_length>204</protein_length>
        <protein_note>genotype D</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>BAF48754.1 hepatitis B surface antigen, partial [Hepatitis B virus]
NFLGGTTVCLGQNSQSPTSNHSPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPL
IPGSSTTSTGPCRTCTTPAQGTSMYPSCCCTKPSDGNCTCIPIPSSWAFGKFLWEWASARFS

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene716">
        <gene_name>SLC5A5</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>6528</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>4507035</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AB032811</gene_refseq>
        <protein_refseq>NP_000444</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>19</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>17871393</gene_start>
        <gene_end>17895174</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>transcript variant X1</protein_name>
        <protein_pi>7.43</protein_pi>
        <protein_weight>63209.43</protein_weight>
        <protein_length>643</protein_length>
        <protein_note>Also known as NIS; TDH1</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000019.10:17871393-17895174 Homo sapiens chromosome 19, GRCh38.p12 Primary Assembly
CCCACTCAGAACTTGAGCTCTGAATGTCTCCCACCCAGCTTAGCCCAAGAGCGGGGTTCAGTGATGCCCA
CCCCCTAAGGCTCTAGAGAAAGGGGGTAGGCCCACATGCCAGTTTGGGGGTGGTAAAGCCAGGTAAGTTT
TCTTTATGGGTCCCCTGAAACCCTGAAAGTGAACCCCAGTCCTGCATGAAAGTGAGCTCCCCATAGCTCA
AGGTATTCAAGCACAATACGGCTTTGAGTGCTGAAGCAGGCTGTGCAGGCTTGGATAGTGACATGCCCTC
TCTGAGCCTCAATTTCCCCACCTGTCAACAGCAGACAGTGACAGCTGTGATCAGGGGATCACAGTGCATG
GGGATGGGTGGGTGCATGGGGATGGAGGGGCATTTGGGAGCCCTCCCCGATACCACCCCCTGCAGCCACC
CAGATAGCCTGTCCTGGCCTGTCTGTCCCAGTCCAGGGCTGAAAGGGTGCGGGTCCTGCCCGCCCCTAGG
TCTGGAGGCGGAGTCGCGGTGACCCGGGAGCCCAATAAATCTGCAACCCACAATCACGAGCTGCTCCCGT
AAGCCCCAAGGCGACCTCCAGCTGTCAGCGCTGAGCACAGCGCCCAGGGAGAGGGACAGACAGCCGGCTG
CATGGGACAGCGGAACCCAGAGTGAGAGGGGAGGTGGCAGGACAGACAGACAGCAGGGGCGGACGCAGAG
ACAGACAGCGGGGACAGGGAGGCCGACACGGACATCGACAGCCCATAGATTCCTAACCCAGGGAGCCCCG
GCCCCTCTCGCCGCTTCCCACCCCAGACGGAGCGGGGACAGGCTGCCGAGCATCCTCCCACCCGCCCTCC
CCGTCCTGCCTCCTCGGCCCCTGCCAGCTTCCCCCGCTTGAGCACGCAGGGCGTCCGAGGACGCGCTGGG
CCTCCGCACCCGCCCTCATGGAGGCCGTGGAGACCGGGGAACGGCCCACCTTCGGAGCCTGGGACTACGG
GGTCTTTGCCCTCATGCTCCTGGTGTCCACTGGCATCGGGCTGTGGGTCGGGCTGGCTCGGGGCGGGCAG
CGCAGCGCTGAGGACTTCTTCACCGGGGGCCGGCGCCTGGCGGCCCTGCCCGTGGGCCTGTCGCTGTCTG
CCAGCTTCATGTCGGCCGTGCAGGTGCTGGGCGTGCCGTCGGAGGCCTATCGCTATGGCCTCAAGTTCCT
CTGGATGTGCCTGGGCCAGCTTCTGAACTCGGTCCTCACCGCCCTGCTCTTCATGCCCGTCTTCTACCGC
CTGGGCCTCACCAGCACCTACGAGGTACCGGACAGAGGCCCGGGGGTAGGACCTGCCCCACTGGCAGTGC
TGGGACCCCGTGTGGGGGAGGCGCTGGGGCTTTGGGCCGCTGTACAGGAGGACGCGGATGGCACCTCGGT
GCTTTAACGGAAGGGGCCCCTAGGCAGACACGTGGGGAGGGTTCTAGGAAGAGGCCCCAGGCGCCCGGCG
AGGGGCAGGAAGGAGGAAGAGAGAGCCTGGCGTCCTGCTCCTTCGGTGGAAGCGCGCGCGGGGCGGGGCC
CGGCTCGACCAGGTGTGTCCTCACGGGTGGACACACACCTGCCCCCCACCTGCCCGGGCGTGCAGACCCA
CGTGTGCGCGCTAGAGGGGACTGCTGACGGCTCCGGGGTTCGAAACCTGGCTTCACTGCTTTCTTGTATC
TTGGGCAAGGGGCGTGCCTCTCTGTTTGGGTTTCCCAGCTGTCCAATGGGCGAATTACAGGACCTCCCTC
CAGGGGAGAGGGTAAAGCGATTAAAATCGTGACCGGGGCCCGGTGCGGTGGCTCACGCCTGTAATCCCAG
CACTTTGGGAGGCCAAAGCATGCAGATCACCTGAGGTCAGGAGTTCAAGACCAGCCTGGCCAACATGGCG
AAACCCCGTCTCTACTAAAAATACAAAAATTAGCCGGATGTGGTGGTGGGCACCTGTAATCCCAGCTACT
TGGGAGGCTAAGACAGGAGAATTGCTTGAACCCGGGAGGTTGCAGTGAGCCGATATCGCGTCACTGCACT
CCAGCCTGGGCGACAGAGCGAGACTCTTGTCTCAAAGGAAAAAAAAATATTGTGGCAGGGCGCAGTGGCT
CACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGTGGGTGGATCACGAGGTCAGGAGTTCAAGACCAGC
CTGGCTAACATGGTGAAACCCCGTCTTTACTAAAAATACAAAAATTAGCCGGGCATGGTCGCGCGCGCCT
GTAATCCCAGCTACTCAGGAGGCTGAGGCAGAAGAATTGCTTGAACCTGGGAGGCGGAGGTTGCAGTGAG
CCGAGATCGTGCCAGTGCACCCTAGCCTGGGCGACAGAGCGAGACTCCGTCCCCCCTCCCCCCCAAAAAA
ATCGTGACAGGTATATCCTAGGCGGCCAACACCATTGGCCCGGGGCACTGTCTACACTGTGCGCTTGCGG
GCCACGTCGGTGTCTGCTGAGCGGTGGCTGCTCCAGGAGCCCGCGCCCGTCAGGCGCAAGTGGGAGGGCG
CGTGCACACGCATGGACCAGTCCTCCAGGTCCACGGGGTACGCACAGGCACGGGATGGCACCTGTGCACG
GGTGTGTGCGTGCGGCGGGGCCCCCACGTGCAAGAATCTGGCGGGCGCGGTTGGCTTCCGGAGGGAGGGG
CCCACCTAGAGAGCAGACCAGGGACCCGAGAGGCCTCGGCTCCTGGGTAAGGACTGTCCAGGTGACCTCG
AGTCCCTCCTTGCAGTACCTGGAGATGCGCTTCAGCCGCGCAGTGCGGCTCTGCGGGACTTTGCAGTACA
TTGTAGCCACGGTGAGTGGCCTCGGCCCCGCCCTCCGCTCAGGGCCCCGAGAGCGTCAGCCTTCACTAGC
CCGGCCCCCACCATTCAAGACCCCGCCCAGACCCCGCCCCCCATGCTCCCGTTCTGACCCCGCCCCCATC
AGTCCCCTCCCACACCACAGCCGGCCTGACCCCGCCTGCACTCTGGAAGACCCGGCCTATCTGCCCCGCC
CATATTCTGGGACCACCCTTCTGCCTCCTCTCCCCATCCCCAACTCGCCCAGACGCCCTCCCTGCTCACC
CGCCCCACACTCTGTCTACAGATGCTGTACACCGGCATCGTAATCTACGCACCGGCCCTCATCCTGAACC
AAGGTGTGACTCTGGGAGATTAGGGAAGCATGTCTGGGAAGAGAAAGGGAGGGAGAGGAGAACCCAAGAC
TAAGTTTGCGCCCCGCCCAGGGGCCTAACAGGGGGACCTCTTTTTGCATAGTGACCGGGCTGGACATCTG
GGCGTCGCTCCTGTCCACCGGAATTATCTGCACCTTCTACACGGCTGTGGTGAGTGGCCCTGGGAACTCA
CTCCATACGGGGGATCGGGCCCACTGTGTCTCTTGTGGGGAGACTCTGGGCTTGCCCCTTTCTCCTGAGG
AAGCCTCTGTCCCAGCTGGGACCCAGTGTCCTCATCTTTATAGTGAAAAATGATCTGAAAAGCTTATTGC
TGAGAATCTAGAGGTATGGTAGCTTCAGGCATGGCTGGATCCAGGCTTCCACCTCTTCTGGCTTCCAGTC
CAGCAGGAAGTGAGCTCCTGCTTCATCCTGGGGCTGGCTGAGGTCCCAGGGAGGGCTACCTTTGGCTGGC
TCAGGTCTGACCTTGATGGCGATATTATCATCGTAGTGATAATAATAGTAATGGCGGCCGGGCGCGGTGG
CTCACGTCTGTAATCCCAGCACTTTGGGAAGCAGAGGCAGGCGGATCACCTAAGGTCAGGAGTTCGAGAC
CAGCCTGGCCAACATGATGAAACCCCGTCTCTACTAAGAATACAAAAATTACCTGGGCGCAGTGGCACGC
GCCTGTAATCCTAGCCTCTCAGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGTGGAGGTTGCGG
TGCGTGGAGATTGCGCCATTGCACTCCAGCCTGGGCGACAGAGCAAGACTCCATCTCAAAAAAATATAAT
AATAATAATAATAATAGTAATGGCAGCAATCACTCACTGACACTCGTATATGTCAAGTCATATTCCAAAT
CTTTTTCACTTATTAACTTGTTTAATTCTACTGGGCACAGTGGCTCATACCTGTAATCCCAGCACTTTGA
GAGGCCAAGGTAGGAGGATCACTTGAGGCCAGGGGTTCGAGACCAGCCTAGGCAACATAGTGAGACCCCC
CCCCGCCCCCATCTCTACAAAAAAAATTTTTTTTAAATTAGTCGGGCATGGTGGCACCTGCTGTAGCTCC
AGCTACTCCGGAGGCTGAGGCAGGAGGATCACTTGAGCCTAAGAGTTCCAGTCTGCAGTGAGCTGTGATC
ACACCACTGCACTCCAGCCTGGGCAAAAGACAGAAACCTTTTCTTTAAAAATAAAATAACTAACTTAATT
CTTACAACAACACAGTAAGAAGGTATTATTATTAATCCCACTTTAGAGAGGAGGAGACTGAGGCATAGAA
GGGCATCAGTCCTAGGCACCACTGAAGGCCAGGTCCCCCATCTAACCGCCCCTCTCCCTCTCTCTGTCCC
ATGCTGCAGGGCGGCATGAAGGCTGTGGTCTGGACTGATGTGTTCCAGGTCGTGGTGATGCTAAGTGGCT
TCTGGGTTGTCCTGGCACGCGGTGTCATGCTTGTGGGCGGGCCCCGCCAGGTGCTCACGCTGGCCCAGAA
CCACTCCCGGATCAACCTCATGGAGTGAGTGAAAATGCAGAGGATACTCCAGCAGGATGGGGCTGGGACC
AGTGCGGTGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCAGATCACTTGAGCTCAGG
AGTTCAAGACCAGCCTGGGCAACATGGTGAAAACCCATCTCTACAAAAATACAAAAATTAGCTGGGCGTG
GTGGTGCACCTGTGGTCCCAGGTAGTTGAGAGGCTGAGGCTGGAGGATTGCTTGAGCCCGGTAGGTGGAG
GCTGCAGCAAGCTGAGATCACACTACTGCACTCCAGCCTGGATGACAGAGCTAGACCCTGTCTCAAAAAA
AAAAAAAAAAAGAGGCTGGGTGCAGTGGTTCATGCCTGTAATCCCAGCACTTTGGGAGGCCAAGGCGGGG
GGATCACCTGAGGTCAGGAATTTGAGACCAGCATGACCGACATCGAGAAACCCCATCTCTACTAAAAAAT
ACAAAATTAGGCTGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCAAGGATGGCAGAT
CATGAGGTCAAGAGATTGAGACCATCCTGGCCAACTTGATGAAAGTCCGTCTTTACTAAAAATACAAAAA
TTAGCTGGGCATGCTGGCAGGCGCCTGTAATCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATTGCTTGA
ACCCAGGAGGCAGAGGTTGCAGTGAGCCGAGATGGCATCACTGCACTCCCGCCTGGTGACAGAGAGAGAC
TCCGTCCCCCCCCTAAAAAAAAAAAAAATTAGCAGGGCGTGGTGGCGCATGCCTGTAATTCCAGCTACTC
GGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGGCGGAGGCTGCGGTGAGCCGAGATCACACCAT
TGCACTCCAGCCTGGGCAACAAGAGCGAAACTCCATCTTTAAAAAAAAAAAAAGAGGATGGGGCTGGGCT
CCCTTTGTGCCGTGGGATGGTAGAAATCAGCCAATGCCTCCTGCTCCAGGAGGCCCTCGCTGCTCTCTTC
TCCTCCCCTCAGACCAGATTGGGGGCTAAAGCCTCTCTGAACTCTCAGCTGGGCAAAGAAAGGTTTTTAA
GTGCGTGGATAGATGATTCAGTAAACAAATACGTGAATTTTCAATCTGGCAAATGCCTATGCATATGTCA
AACCCACTCCATTTATTATTTATTTATTTTTAATTTAATTAATTTTTTTTTTTTTGAGATGGAGTCTCGC
TCTGTCACCCAGGCTGGAGTGCAATGGCACGATCTCAGCTCACTGCAACCTCCGCCTCCTGGGTTGAAGT
GATTCTCCTGCCTCAGCCTCCCAAGTAGCTGGGATTAGAGGCACCCGCCATTATTCCCAGCTAATTTTTG
TATTTTTATAGAGATGGGGTTTCACCATGTTGGCCAGGCTGGCCTTGAACTGTGACCTCAGGTGATCCAT
CCGCCTTGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACTGCGCCTGGCCAACAAAACCCACTCC
AAATGTCCCCTATAAGGTCCAGAAGCGCTGTCTGGGGCCCTTGGGAGGGTGAAGTCAGCGTGACATCTCC
ACGTGGCTAACTTGCCCTGTCCCCACCCAGCTTTAACCCTGACCCGAGGAGCCGCTATACATTCTGGACT
TTTGTGGTGGGTGGCACGTTGGTGTGGCTCTCCATGTATGGCGTGAACCAGGCGCAGGTGCAGCGCTACG
TGGCTTGCCGCACAGAGAAGCAGGCCAAGCTGTGAGTGTTTCGGGGAGCAAGGTCGGGGTTTCTGGGACA
TGCTGCCCCCCTCCACCAGCCTGAGGCTATCCCCTAAGCCTGAGGCTGCCTCTTCCCCCAGGGCCCTGCT
CATCAACCAGGTCGGCCTGTTCCTGATCGTGTCCAGCGCTGCCTGCTGTGGCATCGTCATGTTTGTGTTC
TACACTGACTGCGACCCTCTCCTCCTGGGGCGCATCTCTGCCCCAGACCAGGTGAGTCCCACCCAGGCTC
CTGGTTGGCTCTGCACTCCCTCACTAGCTTGGTGGGATTGAGGTCGAAGAGCATTCCTAGCAGAGGGAAT
GGCCTGTGCAAAGGCCAAGAAGTAGGAAAGAGCTGAGAGGAGGCCAGGTGCGGCGGCTCATGCCTGTATC
CCAGCACTTTGGGAGGCTGAGGCGGGTGGATCACCTGAGGTCAGGAGTTTGAGACCAGTCTGGCTAACAT
GGTGAAACCCTGTCTCTACTAAAAATATAAAAATTAGCTGGACGTGGTGGCACGCACCTGTAGTCCCGGC
TACTCAGGAGGCTGAGGCAGGAGAATCTCTTGAACCCGGGAGGCGGAGGTTGCGATGAAGGGAGATCGCA
CCACTACACTCCACCTTGGATGACAGAGTGAGACTCTGTCTCAAAAAAATAAAATAAAATAAAATAAAGA
GTTCAGAGGAGGATCTGCAAGGAATGGGAAAGGTGAGTCTGGGAGGCAATGGACCGCCCTCAGTAGGTGT
GAGCAGACAAGGGCCACATTCAGATCTAGAGTTCCAGAGAGTTCCAAAGATCCCCTGGGAGATGCTCAGG
AGGAGATGAAACCATGACCCAGGCCGGGCATGTTGGCTCACGCCTGTAATCCCAGCACTTTTGGAGGCCG
AGACAGGCAGATCACTTGAGGTTAGAAGTTCGAAACCAACCTGGCCAACATGGTGAAACCCCCCTCCACT
AAAAATACAAAAATTACCTAGGCCTGGTGATGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAG
GAGAATAGCTTGAACCCGGGAGGTGGAGGTTGCAGTGAGCAGAGATCGCGCCATTGCACTCCAGCCTGGG
TGACAGAGAGAGACTCCATCTCAAAAAAAAAAAAAACAAAAAAAAAAAACCAAAACAAGGCTGGGCGCGG
TGGCTTACGCCTATAATCTCAGCACTTTTGGAGGCTGAGGCAGGGGTATCACCTGAGGTCATGAGTTGAA
GACCATCCTGACCAACATGGAAAAACCCCGTCCCTACTGAAAAATACAAAATTAGCCGGGTGTGGTGGTG
CATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATAGCTTAAACCTGGGAGGCGGAGGTTG
CGGTGAGCTGAGATGGCGCCATTGCACTCCAGCCTGGGCAACAAGAGAGAAACTCCGTCTCAAACAAAAA
TAAAAACAAAACAAAACAAACCCACAAAAACAAAAACAAAAACTGTAATCCAGCGGGAACTAATCATGTT
GGTGATAATAATAATGACAGCTCTGGTCTCCCATGTCCCAAGCGTCCACTCTGTGCCTCATGCTGTTCCC
TTCACCAGCAGTTAGTTCTCCATCTAATCTTTCTTCTGAGAAAGGCAGGGCAGTCACGGCTCCAACTTTA
CAGATGAGGAAATTGAGGCTCGGGGGGAAGTCACTGCCTGAGGTCAATGGGCAAGTCGGGGGGCGGTGCC
AGGACCCATGCCTAGGTCACACCCCAAGTAGAGTTCTGACCATGGGGTTCAGAGTTAGCAGAGGGTACGG
GGGACCACCCCATCTGCAGTCCTCCCTGGAGGTCAGATCCGGGACTGCTGGACTGTGTAACTTCAGGGAG
GGACTGTACTCTCTGCCTCACAGTCTTCATCAATAAAATGAGGATGACACGGGTCCCTGCTTCACAGGGA
TCCCAGGGCTCAGAACACAGTGGGGCTCAGGGACAATTCTCAGGTTCATGCAGTTGATCAACAAATGCAC
ATTATAGCCTGAGGAACATAGGGAGACCCCATCTTTACACAATTTTTTTTTTTTTGAGCCAGAGTCTCAC
TCTGTTGCCCAGGCTGGAGTGCAGTGGCGCAACCTCAGCTCACTGCAACCTCTGGCTCCCAGGATCAAGC
CATTCTCTTGCCTCAGCCCCCGAGTAGCTGGGATGACAGGCATGCGCCACCATGCCCAGCTAATTTTTTT
GTATTTTTTGTAGGGGTGGGGTTTTGCCATGTTGGCCAGGCTGGTCTCAAACTCCTGACCTCAGGTGATC
CACCTGCCTCAGCCTCTGAATGTGCTGGGATTACAGGCATGAGCCACTGTGCCCGGCCTTTCTTTCTTTT
CTTTCTTTTTTTTTTTTTTTGAGACAGAGTTTGGCTCTGTTGTGCAGGCTGGAGTGCAACGGCGCGATCT
CCGCTCGCTGCAACCTCTACCTCTCAGATTCAGGCAATTCCTCTGCCTCAGCCTCCCAAGTAGCTGGGAC
TCCAGGTGCCAACCACCACACCCAGCTAATTTATGTATTTTGGGTAGAGATGAGGTTTCACCATGTTGGC
CAGGCTGGTCTTGAACTTCTGAGCTCAAGTGATCCACCCGCCTCGGCCTCCCGAAGTGTTGGGATTACAC
GCGTGAGTCACCCTGCCCGGCCAGACCCCTATCTTTACACAAAAATTTAAAAAAATTAGCCAGGCATGGT
GGCGCACACCTGTGGTCTCAGCTACTGGGGGACTGAAGCAGGAAGATCGCTTGAGCCCAGGAGTTCTAGG
CTGCAGTGAGCCACATTCATGGGACTGCACTCCCGCCTGGGCAACAGAGCAAGATCTTTTCTCAAAACAA
AACAAAACAAAACAAAACCACAGACAAAAACTAAATGCATATTAAATGCCGACTCTGAGCCCTGTCCGTC
TTGGGTGCTGGGGACGTGCAGCATCAGGACAGATAGATGCCCCGGTCCTCGGGGTGCAGCTGTCTGGGAG
GCTGACCCCCAGTTCTCCCCAGTACATGCCTCTGCTGGTGCTGGACATCTTCGAAGATCTGCCTGGAGTC
CCCGGGCTTTTCCTGGCCTGTGCTTACAGTGGCACCCTCAGGTGAGCACCCCTGCTTGTTCATGGAGCAT
TATTTCAGCCCCTGGGAGCCTCCTTATCCTGGCCTGCCATCCCTCTGGGGCATGGAATGTTCTGGACCTG
TCCATCAGTCCCAGTTCCTGCTTGATCCCTAGAAGACAGCTCAGGTAGGCGCTGGCAGAGAGCATGCCCT
GGGCACAGGGACCCCAACTGCAAGGGTTTACCTTCTTATCACCTGTCAGGGCCACGCCTGACTCTCCTCT
CTTCTTCTTCCTTCTTTCCTTCCTTCCTCCCCAGACAAATATTTGTTGAACATCTACTATGTGGCAGGTA
CTGTTTTTTTTTGTTTTTTTTCCGGATGGAGTCTTGCTCTGTCACCCAGGCTGGAGTGCAGTGGTGCCAT
CTCGGCTCACTGCAACCTCCACCTCCTGGGTTCAAGCAATTCTCCTGCCTCAGCCTCCCAAGTAGCTGGG
ATTACAGGTCCACGCCACCACAGCCGGCTAATTTTTGTATTTTTAGTAGAGACGGGGTTTCGCCATGTTG
GCCAGGCTGGTCTTGAACTCCTGACCTCAGGTGATCTGCATGCTTTGGCCTCGCAAAGTGCTGAGATTGC
AGGCATGAGCCAACGTGCTCAGCCCAGGTACTGTTGTTCTAAACCCTGGGGCACAGCCATGACCAAGCAG
TCCCCTGCTTCTGCCTTCCAAGGCCACACACTCAGGTGGTTTCCACTCTTCCGGGACTTCTGGTCACATG
CCCTCACTGTCCCTTTTGCAAATCTCCCACATGTGACTGCAGTCCCTCTGGAACCAGAACCCACCTGTCT
GTCCCACCTGCCCTTGGTCACAGGTGTCCTTGCTCCTGTAGGGATGTCTCAGGTCTTCGGGGAGGGGAGG
GGCAAATATCTCCTTCACCTTTGCAGGACTGGGTTACCCCCACCGTTGCCCTCAGGCTGGGTGAGGTCTG
GCAGGCCAGATGGTGTGGACGGTCTCTCCATATGGCCTGAGGACCCCCCGCTGCCTTCCTCACACAGCAC
AGCATCCACCAGCATCAATGCTATGGCTGCAGTCACTGTAGAAGACCTCATCAAACCTCGGCTGCGGAGC
CTGGCACCCAGGAAACTCGTGATTATCTCCAAGGGGCTCTGTGAGTTTCAGGGAGACCTGGGTGGGAGGC
CAGGGCAGTCCCTCCCCGTTGACCGTGCCATCCTCATCCACTACAGCACTCATCTACGGATCGGCCTGTC
TCACCGTGGCAGCCCTGTCCTCACTGCTCGGAGGAGGTGTCCTTCAGGTGAGACCCCACCTGCCCCCTGC
CCTGGTCTCCTGAGAGGTGGGGGCACCTTTCCCTCTTTCCCATTAAACTGAGGCTCAGAGAGGTCACATG
TGTCAGTGGCAGAACTCACTTCTATGTTTTTTTTTTTTTTGAGATGGGGTCTCACTGTGTTGTCCCAGGT
TGGTGAGCAGAGGCCCGATCATAGCTCACTGCAACCTCCAGCTCCTGGGTTCAAGCCATCCTTCCACCTC
AATCTCCCAAGTAGCTGGAGTTACAGGTGTGTGCCACCATGCCTGGCTAATTTTTTTCTTTTTTCTTTTT
TTTTTTTTTTTGAGGTGGAGTGTCACTCTGTTGCCCAGGCTGGAGTGCAGTGGCATGATCTCAGCTCGCT
GCAACCTCCACCCCCTGGGTTCAAGGAATTCTGCCTCAGCCTCCAGAGTAGCTGGGATTACAGGTGCATG
CCACCATGCCCGTCTAATATTTTTGTATTTTTTTTTCTTGAGACGGAGTCTCGCTCTGTTGCCCAGGCTG
GAGTGCAGTGGCACCATCTTGGCTCACTGCAAGCTCAGCCTCCTGGGTTCACGCCATTCTCCTGCCTCAG
CCTCCCGAGTAGCTGGGACTACAAGCGCCCGCCACCACGCCTGACTAATTTTTTGTATTTTTAGTAGAGA
TGGGGTTTCACCGTGTTAGCCAGGATGGTCTCGATCTCCTGACCTCGTGATCCGCCCTCCTCGGCCTCCC
AAAGTGCTGGGATTACAGGCGTGAGCCACCGCGCCCAGCTTATATTTTTGTATTTTTATTAGAGATGGGA
CTTCACCATGTTGGCCAGTCTGGTCTCGAACTCCTGACCTCAAGTGATCCACCCGCCTCTGCCTCCCAAA
GTGTTGGGATTACAGGTGTGAGCCACCACGCCTGGCCTGGCTAATTTTAAAACTTGTTTTTAGAGACAGG
GTCTCGCTTCGTGCCTAGGCTTGTCTTGAACTCCTGGCCTCAAGCAACCACCCGCCTCAGCCTTCCAAGT
CGCTGAGATTAAGAACTAAGTTCTATTTGATGCCAGAGGCCATCAGGGGACTTTTTTGCAGCTGGCTGGC
TTGGGGTGGGGGAATTGGGAAGGGGGAGGTGGCGACAGAAAGGGCCTCCCTATGGAGGTTGCAGTGAGCC
AAGATCGCGCCACTGCACTCCAACCTGGACAGCAAAGTGAGACTCTGTCTAAAAAAAAAAAAGAAGAAGA
AAGGGTCTCCCTGGCTTGAGGGTGGGACTGCCACCCCCAAGAGATAATCAGTGTCTTTGCCTCCAACCCA
AGGGAGATAGGCAGGAACAAGGGGGGGGGGTCCTCTCCCCTTTAGGGAAACTGAGACACAGAGGAGTCCT
TGAGACCCACATTGGAGTTCCTGAGGTCTCGCTTTCCCAGCGGGTAAACTGAGGCCCAGAGCGGTGGGAG
GGCTCCGCCCTCAGCCCCACTTCCACCTACTCTCCCAGGGCTCCTTCACCGTCATGGGAGTCATCAGCGG
CCCCCTGCTGGGAGCCTTCATCTTGGGAATGTTCCTGCCGGCCTGCAACACACCGGTGAGTGGGGGCGGG
GCAAGGGGCGGGGAGGGGCGGGGCCGGACAGGCCCCTCCCCTTCCCTGACGCCGGCTCTGCCCCCAGGGC
GTCCTCGCGGGACTAGGCGCGGGCTTGGCGCTGTCGCTGTGGGTGGCCTTGGGCGCCACGCTGTACCCAC
CCAGCGAGCAGACCATGAGGGTCCTGCCATCGTCGGCTGCCCGCTGCGTGGCTCTCTCAGTCAACGCCTC
TGGCCTCCTGGACCCGGCTCTCCTCCCTGCTAACGACTCCAGCAGGGCCCCCAGGTGAGCAGACTTGAGG
GTAGGGGGGTACCCGAGCCCTGGATGGTGTGATCTTGAAGGGAAACTTACTTGCCCTGCACTCTGTGTAA
GAAGCCTGATTAGTAAAATGCATTCCTGGGGGAGGGAACGGTAGGTGCAAAGGCCCTGAGGCCACAATCG
GGTTAGTCCCAGTCCAACTGCACTGAGGTTAGGGTGCATTTAATGGGAGGAGAGATGGGTGGGAGATATG
GTGCAGCCAGAGGAAGCTAGTACTTTTTTTGTTTTGTTTTTCTGAGACAGAGCCTCGCTCTGTGGTCCAG
GCTGGAATGCAGGGGTGCAATCTCAGCTTACTGCAGCTTCAACCTCTCAGGCTCAAGCAATCCTCCCAGC
TTGAGGGAGGCCCAGAATTTGGTTTGGTTCTATTTTTTATTGAGATAAATTAGCCATTTAAAAGTGGCAT
TTAGGCCAGGCAGGCACAGTGGCTCACACCTGTAATCCCAGCACTTTGGGAGGCTGAGGCAGGTGGATCA
CCTGAGGTCAGGAGTTCAAGACCAGCTTGATCAACATGGGGAAACCCCCGTCTCTACTAAAAATACAAAA
CTTAGCCAAGCGTGGTGGCAGGTGCCTGTAATCCCAGCTACTCGGGAGGCTGAGACAGGAGAATCGCTTG
AACCCAGGAGGTGGAGGTTGCAGTGAGCTGAGATCGCACCACTGTATTCCAGCCTGGGCAACAAAAATGA
AACTCCAACTCAAATAAATAAATTAAAGTGGCATTTAGTATATTTGTGCAACCATCACCACTATCTAAGT
CAAGAACGTTTCCTCTTTTTTTTTTCTAATTTTGTATTTTTAGTACAGATGGGGTTTCACCATGTTGGCC
AGGCTGATCTTGAACTCCTGACCTCAGGTGATCCGCCCACCTCAGCCTCCCAAAATGCTGGGATTACAGG
TGTGAGCCACTGTGCCTGGCCCCAAAAACATTTTCTATTTTTTTTTTTTTTTGGAGCAGGGTCTTGCTCT
GTTGCCCAGGCTGGAGTCCAGTGGCACGATCATAGCTCACTGCTGCCTCAACCTCCTGGGCTCAAGGAAT
CTTCCTACCTCAGCCCCCCTAGTTGCTGGGACCACAGGTGCACACCATCATGTCCTGCTTGTTTTTATTT
TTATTTTTTGTAGAGACAGGGTCTGGCTATGTTGCCCAGGCTGGTCTGGAATTCCTGGGCTCAAGCGATC
TGCCCACCTCAGCCTTGCAAAGTGCCAGGATGACAGGTGTGGGCACCCAGCCAACCAAGAACATTTTCTG
TTTTGTTTATTTATTTATTTATTTATTTTGGTTTTTTGGGTGGGTTTTTTTGCTTTTTGTTTATTTGATT
TTTTGGAGACAGGGTCTCACTCTAACACCCAGGCTGGAGTGCAATGGCACAATCACAGCTCACTGCACCA
TTGACCTCCAGACTCCGATGATCCTCCTGCCTCAGCCTCCCAAGTAGCTGGGACTATAGGCATGTATCAC
CATGCTGGGCTAAATTTTTTGTATTTTTTATAGAGACGAGTTTTTGCCATGTTGCCCAGGCTGGTCTCAA
AGTATTGGGCTCAAGTGATCTGCCTGCCTCTGACTCCCAAAGTGCTGGGATTACAGGTGTGAGGCACTGT
TCCTGGTCATAAGAACATTTTTATCACCCCAGAAAGAAGCCCTGTCCCCATCAGCAGTCACTTCCCACTT
CCCCCTCTCCCCAGCTCCTGGCAAGCACGAATCCACTTTCTGTTTCTATGAATTTGCCTGTTCTGGGCAT
TTCATGTAAATGGAATCATAAAATATGTGATCTTTTGTGTCTTAGCATAATACATATATATTTTTTGAGA
CGGGGTTTCACTTTGTCGCCCAGGCTGGAGTGCAGTGGCGTGATCCCAGCTCACTGCAACCTCTGCCTCC
CAGGTTCAAGCAATTCTCCTGTCTCGGCCTCCTGAGTAGCTGGGGTCACAGGCATATGCCACCACGCTTG
GGTAATTTTTGTATTTTTAGTAAAGATGGGGTTTCACCATATTGATCAGGCTGGTCTTGAACTCCTGACC
TCAGGAGATCCACACATCTTGGCCTTTCAAAGTACTGGGATTACAGCAGAGTACAGTGGAGCCACTGCAC
TCCAGTCTGGGTAACAGAGTGAGACTCCACCAAAAACAAACAAAACCAAAAACATTTGTGAACAAGTTTT
GGTATGGACATATGTTTTAATTTCTCTAGGTATATACCTATGAGTGGAATTGCTGGATCATATGGTAATT
CTTTAACTTTTTTTTTTTTTTTTTAGATGGAGTCTTGCTCTGTCGCCCAGGCTGGAGTGCAGTGGTGTGA
TCTCCACTCACTGCAACCTCCGCCTCCTGGGTTCAAGCGATTCTCCCGCTTCAGCCTCCCGAGTAGCTGG
GACTACAGGCATATGCCACCACGCCTGGCTAATTTTTATATTTTTAGTAGAGAAGGGGTTTCACCATGTT
GGTCAGGGTGGTCTCAAACCCCTGACCTCAGATGATCCGCCTGCCTTGGCCTCCCAGGGTGTTAGGATTA
CAGGCCTGAGCCACCACGCCCGGCCTATGTTTAACTTTTTGAGGAACTACCAGACTGTTTTCCACAGCGG
CCACATCATTTTACATTCCGACCAGCAACATATGAGGATTCTAACTTCTCCACGTCCTCGCCAATACTCA
TTATTCTCCATCCTAGTGGGTGTGAAGTGATACCTCACTGTGGTTTTGATTTGCATTTCCCTGATGAATA
ATGATGTTGAGCATCTTTCTTTTCATTGGCCATTTGTGCATCTTCTTTGGAGAAATGTCTATTCAAACCC
TTTGCCCATCCAGCCTGGGTAACATAGAAAGACCCTATCTCTATAAAAATAAAAATGAAAAAATTAGCTG
GGCATGGTGGTGCACACTTGTAGTCCCAGCTCCTTGGGAGGCTGAGGCAAAGAGGATCGCTTGAGCCTGG
GGGGCCAAGGCTGCAGTGAAGCATGATCCCACCACTGCACTCCATCCTAGGCAACAGAGCAAGACCCTGC
CTCAAATTAAAAAACAAACAAACAAAAAAACACCCTTTGCCCATTTTTAAATTGGGTGATTTGTCTTTTT
ATTGTTGAGTTATAATTTACATATTTTTATATCTTTATGTATTCTGGGTACAAGCCCCTGATCAGATGTA
TAATTTGCATGTGATATTTTCTCCCATTCTGTAGGTTGTCTTCATTCTCTCGATAGAATCCTTTGATGCA
CAGAAGTTTTTAATTCTTTTTTTTGGTGGGCGGATGGAGTCTAACTCTGTCACCCAGGCTGGAGTGCAGT
GGTGCGATTTCAGCTCACTGCAACCTCCACCTCCCAGGTTCAAGGGATTCTCCCACCTCAGCCTCGTGAG
TAGCTGTGACTACAGGTGCACACCACTATGCCAGGCTAATTTTTATATTTTTAGTAGAGATGGGGTTTCA
CCATGTTAGCCAGCCTGGTTTCAACTCCTGACCTCAGCCTGCCTCAGCCTCCCAAAGTGCTAGGATTACA
GGCATGAGCCAACATGCCTGGCCAGAAGTTTTTAATTTTTTTTTTTTTTTTTTGAGATGGAGTCTCGCTC
TGTTGCCCAGGCTGGAGTGCAATGGTGTGATCTCGGCTCACTGCAAGCTCCACCTCCCGGGTTCATGCCA
TTCTCCTGCCTCAGCCTCTCGAGTAGCTGGGACTACTGGCACCCGCCATCAGGCCTGGCTAATTTTTTAT
TATTTTTTTATTTTTAGTAGAGACAGGGTTTCACCATGTTAGCCAGGATGGTCTCGATCTCCTGACCTCG
TGATCCACCCGCCTTGGCCTCCCAAAGTGCTAGGATTACAGGTGTGAGCCACCACGCCCAGCCAGTTTTT
AATTTTTGATGAAGTCCAATTGATTTATTTTTTTCTTTGGTGGCTTTTGCTTTTGGCGTCATATCTAAGA
AACAATTGCAGTCACGAAGATTCCCACCTATGTTTTCTTCTGAGAGTTTAATTTGGTTTGATTTTGAGGG
TGACAGGGAGCCACAGAGGGTGACGGGCAGCAGCAGGTGATCTGAGTTACATTTTAGTAATGTGCCCTTT
GGCTGTGTGTGGAGGACGTCTAGGGTGGGGATGGGATACCTGGAGGGAAGGAACATTGGCTACTGCACAG
ATCTGGGCAGACAGTAATGGAGGTCTGTGCTAGGCCATGGCAGTTGGGGGAAGGAAGCAGGGGGTGAGGT
TGGAACAGCTTTTGAGTGCAGGCAGGGGATAAAAGAGGAGGTTCAAGTCTGTCTCTCCCAACCTGCAGCT
CAGGAATGGACGCCAGCCGACCCGCCTTAGCTGACAGCTTCTATGCCATCTCCTATCTCTATTACGGTGC
CCTGGGCACGCTGACCACTGTGCTGTGCGGAGCCCTCATCAGCTGCCTGACAGGTAGGTAAACAGAGCAT
GTGGCCTCAGAGGTCATCCCATTCATCTCTCTGCCTCAAGGCTCCACCCAGCAGGGAGGGGAGAAAGGAC
GCTCCCATTGGCCAAACTGCCACTGTGTGCTGTACACATTTGTACCTTATTATTATTATTATTATTATTA
TTATTATCATCATCATCATCATCATCATCATCATTTTTGAGATAGAGTCTCACTCTGTCACCCAGGCTGG
AGTGCAGTGGTGTGATCTCAGTTCATTGCAACCTCCACCTCCCAGATTCAAGCGATTCTCATGTCACAGC
CTCCCGAGTAGCTGGGATTACAAGTGTGTGCCGCCATGCTTGGCTAATTTTGCATTTTTAGTAGAGACGG
AGTTTCGCCATGTGTCTCGAACTCCTGGGCTCAAGTGATCCGCCCACCTCGGCCTCGCAAAGTTCTGGGA
TTATAGGTGTGAGCCACTGCACCTGGGCTGTACCTATTTTTTTAAAAGGAAAAAAAAAGTTTGTGAGGAA
AAAAGAAGTGTGTGTGTATATATACACATACATACACACTTTTATGTGTATATATACATAAAAGAAATTA
TGAATATATATAAAAATTATGACTATATATATACATAAAAGAAAGTGTATATATATATAGTTTCTTTTAA
AGGGACGGGGTCGACTGGGCGTAGTGGCTCATGCCTGTTATCCCAGCACTTTGGGAGGCCGAGGCGGGTG
GATCACCTGAGGTCAGGAGTTCAAGACCAGCCCGGCCAACATGGTGAAACCCCGTCTCTACTAAAAATAC
AAAAAAATTAGCTGGGCATGGTGGCAGGCGCCTGTAATGCCAGCTACTTGGGAGGCTGAGGTAAGGGAAT
CGCTTGATCCTGGGAGATGGAGGTTGCAGTGAGCCAAGATTGCGTCACTGCACTCCAGCCTGGGCAAGAG
AGTGAGACTCCATCTAAAAGAAAGAAAGAAAGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAAGAGAAAG
AGAGAGAGAGAGAAGGAGAGAAAGAGAGAGAGAAAGAAAAGAGACAGGTCTCACTGTTACCCAGACTGGA
GTGCAGTGGCACAATCATGGCTCACTGCAACCTTGAACTCCTGAGCTGAAAGCAATCCTCCCACCTCATC
CTCCCGAGTAGCTGAGACTACAGGTGCGCGCCAACGTGCCCGGCTCACATTTACACCCTTTAAAGCTATG
TTGCTTTCTTGACAACCCTGCACCTCTCAGAGCTTGCCCTATTTTGCAGAGGCAGAAACGGAGGCATTGC
CTGCAACTCCTCTCCCCAACAAGATTAAGTCCTCAGTAGAGGATATGGGTTGGGGCGGGCGGCGCTATCC
CTGGTGCTGAAATATCTTCTAAAGCTGCCGGTGACTCCGCACTTGTTAGGGAATTCTAAATTCCACGGAA
AAGTAGAAGGAGACAAAGAGGGGAAAGTCAGTAGTGATAACAGTACCTGCTCACACTTCTTGAGTCTCAG
ACTTCACAGTCATCAGGCCTTTATCGAGTCCTCCTCTGTGCTGGACGCTATTTTAGGCACTGGGGATGCA
GCAGTGAATGGAACCGTGTGCTGGACCCTCCCAGCCATCCATTAATGTCTTTGTTTTGTTTTGTTTTGTT
TTTTTGAGATGGAGTTTCACTCTGGTCGCCCAGGCTGGAGTGCAATGGTGCGATGTTGGCTCACTGCAAC
CTCTGACTCCCGGGTTCAAGCAATTCTCTTACCTCAGCCTCCCGAGTAGCTGGGATTACAAGCGCCCACC
CCCACGCCTGGCTAATTTTTGTATTTTTAGTAGAAATGGGGTTTCGCCATGTTGGCCAGACTAGTCTCGA
ACTCCTGACGTCAAGTGATCCCCTGCCTTGGTCTTCCAAAGTGCTGGGACTACAGGCGTGAGCCACCGTG
CCCAACCTCCAATGATGTTTTTGTTTTGTTTTGTTTTGTTTTGTTTTAGAAACAGGGTCTCACTCTGTCA
CCAAGCTGGAGTGCAGTGGCACAATGACGGCTCACTGCAGCCTCGACCTCTTGGGCTCAAGCAATCCTCC
TGCCTCAGCCTCCCAAGTAGCTGAGACTAGAGGCACACACCACCATGCCTGGCTAATTTTTTAATATTTT
GTAGAGATGGGTTCTTGCTATGTTGCCTAGGCTGGTCTCCAACTACTGGGCAACTCTAAGCAATCCTATT
GCCTTAGACTCCCAAAGTGCAATTATGAGCCACCATACCTGGCCTCACTGATGTTTTATTACAACTTCAC
TGTGTAGATGAGGAAACTGAGGCTCAGAGGCTTGCCAGGGTCCCTTAGTGGGACTGGAGCCTGTTAGACT
TCATAGACCAGGGATCTCCTTTCTCCTTCCCAGGACCTGGTCTCCAACCCCCATGACCCCTTCACTGAAT
GCCTGGATTTCTCCATTTCTCCCCGCCTCTCAGGCCCCACCAAGCGCAGCACCCTGGCCCCGGGATTGTT
GTGGTGGGACCTCGCACGGCAGACAGCATCAGTGGCCCCCAAGGAAGAAGTGGCCATCCTGGATGACAAC
TTGGTCAAGGTCAGTCTTAGGCTGGGTTCCCAGATCTAGAGGCAGCCAAGTGACTTTAGGACGTGACCAC
AGCTCAGGGGAGGGACATGGTATATCAGCACCTTTCTCCATCGCTCATTATCTCCAGTCAAAAGACTCTA
TTGGGAGCTGATTCATCCTCAACAGTTTTTATCTCCCTTCACAAGGACTGAACAGAGTTTAATACTATTC
CTTTTTGTTTGTTTGTTTTTTGAGACAGAGTCTCGCTCTGTTGCCCAGGCTGGAGTGCAGTGGTGCAATC
TCGGCTCACTGCAACCTCCACATCCCGAGTTCAAGCGATTCTCCTGCCTCAGCCTCCTGAGTAGTTGCTA
CTACAGGCGCATGCCACCGCACCCAGCTAATTTTTATGTTTTTAGTAGAGATGGGGTTTCACCATGTTGC
CCAGGCTGGTCTCGAACTCCTGACCTCAAATGATCCACCCACCTTAGACCCCCAAAGTGCTGGGATGACA
GGCATGAGCCACCGAGCCCAGCCTCATCTTCAAGTTTTTGTTATCTCCCTTCATAAGGACTGAACAAAGT
TGAATACTATTCCTTTTTGTCGTTATCTGTTTTTACAGTGACTTCCAATCTTTGGCAGGTGAAACTGGTG
TGCTGTTAGGGTATTGATGTAAAGTCTCTTCTTAAAATAAAATTACTTAATTCAAAAGTGAGTCAACTTG
GGGAAAAAATCTTACATAAGAAACACAACAGATGGTAAACCGATTTTGGCTAAAACCGCGTGGTTGCTTT
GTGAATTCCCAGAGTTTGGAAAATGCTGTCCCTGGGGGACCTGATCCCATGCCTACCCCTGTTTTGGAAT
CCCTGTTCCATTCTCTCATTTATTGAGCACCTGCTGTGTACCCAGTCCTGCTCTGGGCTATGGTCTAAGA
CCCCCACCCCACCCTCATCTAGCAGGGGCAGGTGAAAACTAAAAAGAGAAACATGTAGGGTCTGTCTCAG
TATGTGATAAGCATTCAAAAGATAATACAACCAGATGCTGTCAGGCCGGGCACGGTAGCTCACGCCTGTA
ATCCCAGCACTTTGGGAGGTTGAGGTGGATCGCTTGAGGCCAGGAGTTCAAGACCAGCCTGTCGAACATG
GCAAAACCCTGTCTCTACTAAAAATACAAAAATTAGCCGGGCATGGTGGCGTGTGCCTGTAATCCCAGCT
ACTCAGTGGAATGAGGCAGAAGAATTGAACAATTGAACCCGGGAGGTAGAGGTTGTAGTGAGCTGAGATC
GCGCCACTGCATTCCAGCCTGGGTGACAGAGCAAGACTTCGTCAAAAAGATAGGAAAGCAGGAAGGGAGG
GAGGGAGGGAAAAGAAGGAAGGAAAGGAAAGAGCCAGGCGTGATGGCTCACCCCTGTAATCCCAGCACTT
TGGGAGACTTAGGCAGGTGCATCACCTGAGGTCAGGAGTTCGAGACCACCCTGGCCAACATGGTGAAACC
CCATCTCTACTAAAAATACAAAAAATTAGCCGGGTGTGGTGGTGCATGCCTATAATTCCAGCTATTCGGA
AGGCTGAGGCAGGAGAATCGATTGAACTCAGGAGGTGGAGGTTGCAGAGAGCAGAGATTGTGCCATTGCA
CTCCAGCCTGGGCAACAACAGCCAGACACTGTCAGAAAGAAAGAAAAGACAGAGAGAGAGAGAGAGAGAG
AGAGAGAGAGAGAGAGAGAGAGAGAGCAAGCTAAAAAGAAAAACGTGTAGGGTCTCAGCATGATAAATAT
TCAAAGGATAATAAAACCGGATGCTGTGATGGGGAGCAACTTTAGCCAGGGAAGTCAGGGGTGGCCTCTT
GGGAGAGGTGACATTGATTGACCCTGAGTTAGGAGAAGAGGAACCAGCCACAGACAGGAACAGCTTTGAC
TGAGAAGGGGATTGGGAGGGGAGGGGTTTGCCTGAAGGTGTTTAAAGCTCCCTCCAGCTGCCCTAGAGAA
GTGTTTATCTTTTCTTTCTTTCCTCTTTTCTTTTCCTTTCTCTTCTTTTCTTTTTTTTCTTTCTCTCTCT
TTTTTTGTTCTTTATTATTTTATTTTTCTTTTTTGTTGTCTTTGTTTTATTTGTGTGTTTTTTTTCTTTT
TTGTCTTTTTTTTTTTTCCTTTTTTTGAGATAGGGACTCACTCTATTGCCCAGGCTGGAGTGTAGTGGCA
TGACCATGGCTCACTGCAGCCCCAACCTCCATGGTCCGAGAAATTCTCCCATCTTTCAACCTCCTGAGTA
GCTGGGATTATAGGCATGCACCACCGAGTCTGGTTAATTTTTTTATTTTTGGTAGAGATGGGGTTTTGCC
ATATTGGCCAGGCTGGTCTTAAACTCCTGGGCTCAAGTGATCTGCCCACCTTGGCCTCCCAAAGTGCTAG
GATTACAGGGGTGAGCCACCGTGCCCGGCCAGAAATATTTATTTTCTTGAAGGTGAACAGGCAGAGAAGC
AGAGAAAGGAGGGAGGAACTATAGCAGGCATCTGAGAAAGCGTTGATGGCCTGGGCTGTAGGTGACATGT
GAGTGGGGAAGAGAAGCGCATGGAAATTTTGGAGGCAGAGCGGGCAGGACTGGCCCGTGCACTGAGCAAG
GGGATAGTATGCAATTCTGTGCACGCCCCGTCCCGCCAGGTCATCAGTAGCCCATCTGGGAGATGAGCTG
ACACGGAACAGGGTGGGGACAGGGTCTCTGATGGGGTCTCTTTTTCCCACTTTTCCCCAGGGTCCTGAAG
AACTCCCCACTGGAAACAAGAAGCCCCCTGGCTTCCTGCCCACCAATGAGGATCGTCTGTTTTTCTTGGG
GCAGAAGGAGCTGGAGGGGGCTGGCTCTTGGACCCCCTGTGTTGGACATGATGGTGGTCGAGACCAGCAG
GAGACAAACCTCTGAGGACAGGGCCAGCCGCGGGACTGACACCCTGGGATGGAACCTCAGGATGGGCCAA
ACCCAGACAACGGGCCCATGGCCTTGGGCTCTGATTGGCTGGATTGCCTTGTATGCAAATGAGTTCAGGA
CTACAATACCCTACCCTATGGGGAGGCCCTGCCTCCGGGAGGTCATTTTTTAAATCCAGCCCCTTGCTTC
AACCGTCCCCAGTATTAGACGCTGCAGCCCTGACGGCTCCCCCCAAATAAGGCTGGGTTTTTCTCTCTCT
CTTTTTTTTTTTTTTTTTTTTTTGAGACAGGGTCATGCTCTGTCACCCAGGCTGGAGTGCAGTGGTGTGA
TCTCGGCTCACTGCAACCTCTGCCTCCCAGGCTCAAGTGATTCTCCTGCCTCAGCCTCTTGAGTAGCTGG
GATTGTAGGTGCCCACCACCATGCCCAGCCAACTTTTTGTATTTTTAGTAGAGACAGGGTTTCACCATGT
TGGTCAGGCTGGTCTCGAACTCCTGACCTCAAGTGATCCACCTGCCTCGGCCTCCCAAAGTGCTGGGTTA
CAGGCGTAAGCTACCATGCCCAGCCTACCGTTTTTCTCAATCTATAATAGAAAGCCACCACGCCCAGGTA
ATTTTTGTAATTTTGTATTTTTGTAGAGACGGGGTTTTGCCATGTTGGCCAGGCTGGTCTCAAACTCCTG
ATCTCAGGTGATCCTCCTGCCTTGGCCTCCCAAAGGGCTGGGATTACAGGGGTGAGCCACCGCGCCCCAC
CTCTTTCTTATTTTCTTCCTGGGATTGGGGAGGGGATGATTCAGACCCCACATGGCCTCCAACCTTGGCC
CACACACCTGCCATGGCTCCCATCATCCTGAGCATGCTAGCGTCCCCTCCTCACCTGACAATGGAGGCTC
TCGAATTGGGTTGTGTCCCCCCAAAATTTATGTCTACCCAGAACCTCAGAACATGAGCTTACTTGGAAAT
AGGGTCTTTGCAGGTGTAACTGGTTAAATTAAAAGAGGTATTACTGGAGGAGGATGGATGAATCCAGTGA
CTGGTTCCTCATATGAAGTAGAGAAGAGATGCAGAGAAACACATGGGGAAGATGCCACGTGAAGACAGAG
GCAGTGGTTGGATCAATGCATCTACGAGTCGGAGAACCCAAGGATTGCCAGCAACAACCAGAAATCAGGA
GGGGGGCATGAGATGCATTATTTCTTAGAGCCTTTAGAGGGAACATGGCCCTACTGACACCTTGATGTCA
GACTTCTGGCTGCTAGAACTGTCAGAGAATAAATTTCTGTTGTTTGATGCCA

</dna_sequence>
        <protein_sequence>>NP_000444.1 sodium/iodide cotransporter [Homo sapiens]
MEAVETGERPTFGAWDYGVFALMLLVSTGIGLWVGLARGGQRSAEDFFTGGRRLAALPVGLSLSASFMSA
VQVLGVPSEAYRYGLKFLWMCLGQLLNSVLTALLFMPVFYRLGLTSTYEYLEMRFSRAVRLCGTLQYIVA
TMLYTGIVIYAPALILNQVTGLDIWASLLSTGIICTFYTAVGGMKAVVWTDVFQVVVMLSGFWVVLARGV
MLVGGPRQVLTLAQNHSRINLMDFNPDPRSRYTFWTFVVGGTLVWLSMYGVNQAQVQRYVACRTEKQAKL
ALLINQVGLFLIVSSAACCGIVMFVFYTDCDPLLLGRISAPDQYMPLLVLDIFEDLPGVPGLFLACAYSG
TLSTASTSINAMAAVTVEDLIKPRLRSLAPRKLVIISKGLSLIYGSACLTVAALSSLLGGGVLQGSFTVM
GVISGPLLGAFILGMFLPACNTPGVLAGLGAGLALSLWVALGATLYPPSEQTMRVLPSSAARCVALSVNA
SGLLDPALLPANDSSRAPSSGMDASRPALADSFYAISYLYYGALGTLTTVLCGALISCLTGPTKRSTLAP
GLLWWDLARQTASVAPKEEVAILDDNLVKGPEELPTGNKKPPGFLPTNEDRLFFLGQKELEGAGSWTPCV
GHDGGRDQQETNL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>The aim of this study is to determine the feasibility of utilizing the hNIS antigenic protein in enhanced-antigen-associated immunotherapy using image analysis with a gamma counter. To accomplish this, minimalistic immunogenically defined gene expression (MIDGE), either plain or coupled to a nuclear localization signal (NLS) peptide, was used as a vector system. Vaccination with MIDGE/hNIS, MIDGE/hNIS-NLS and pcDNA3.1/hNIS produced a significant increase in the number of hNIS-associated IFN-gamma-secreting CD8(+) T cells, with MIDGE/hNIS having the strongest effect. In addition, immunization with the hNIS encoding vectors induced antigen-mediated antitumor activity against NIS-expressing CT26 tumors in vivo, with the highest tumor free rate (100%) and lowest tumor growth being observed up to 40 days after the CT26/NIS tumor challenge with MIDGE/hNIS than those resulting from other immunization groups [Ref1306:Choi et al., 2007].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1346">
        <gene_name>Steap1</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>70358</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>254553462</ncbi_protein_id>
        <gene_locus_tag>UNQ6507/PRO23203</gene_locus_tag>
        <gene_refseq>AC092404</gene_refseq>
        <protein_refseq>NP_081675</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>5</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>5736321</gene_start>
        <gene_end>5749316</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>six transmembrane epithelial antigen of the prostate 1</protein_name>
        <protein_pi>9.55</protein_pi>
        <protein_weight>36316.01</protein_weight>
        <protein_length>339</protein_length>
        <protein_note>Also known as Steap; Prss24; 2410007B19Rik</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000071.6:5736321-5749316 Mus musculus strain C57BL/6J chromosome 5, GRCm38.p4 C57BL/6J
AAACGATCCCAAAGTATTCATTTTATTAACAAACACAAATTTGAAATGCTTATGATAGGACATCAATAAC
AAGCAAATATGTGCAAACAGTAGTTCTACAACCTGGAGGCCATCTCAGTCCTGTTAATTTTGCTGACATC
TTCCCAACCACATCTAATCTTCAGTATCTTCTTCCTCAGACAGGGCAGGCACAGGGCGATTTTACATATC
AGGACAAGAGTTGGAAGGAAAACAGCTATCATAAAAGTCGGAGGCATGTACCATACAAATTGACTGACAT
CTACCCATTTATTCCAGGCAAAAACCAAAGCGTGTACTGTGCCCAGAAGAAGAGAGACAATTCCTAGTTT
GCTCTGCAAAAGAAAACAACAACGTGATCCTAAGTAAGGGTTGATTCAATAGCAGCCAATTCTACCCTAT
CCCATTGGGGTTGCTCTGTTGCTTGGAGATGCTTTCATTCATCTACAATTATCTTCCTGTAACATGTTGT
TTGACAATGTCCATTCACACCTTGTTATTCCTTTTACAGGTCCTGCTCATCACACTGCCTTTGGGCAATT
GTTCTTGTTTCTATACTAAGTGGAAAAGTCACGTGATTTTCAGCCCCATCAGTGCTTTCTCTACTATTTT
GTTGAAGACACCATCTTTCATAAGACATTTTTGTGTTATTGGCAGTGATGTGGATCAAAGCCAGAGCCTT
GTGCATGCTAGCTAGGCAGTTTATCATTGATGGACATCCCTGGTCTCATTATGGCATTTGCATTATGATA
TTTTGTCTTGATTTTATTTTAACTTTGCTCTCAGGCAGTGCCTAAAATAGATATTGTCTTATTGTAGGGT
CTTTGTAAAAGCAACAGGATGATTTGAACATGTTTGGTGCTCAATGAATATTGCTGAACTGACTAAAGAA
TACTGTAAAAAATATCAATCGGATCTCAGTGATGTTGATCAACTGATGTTATTCTAATTTTATGAATGAA
TATGAAAATAGATTCTATATATGTACACACACATATACATTCACACACACACACACACACACACACACAC
ACACACACACACACAACACACACACACAGAAAGAGAGAGAGAGAGAGTTTTCCAATTAATCATTTTTTAA
ATTCTAAGCATAACGTTTTAGTAAGGGAGATGAAAGAAGCTGGTATGGCTTTTTCCCTTCACACATAATA
AAGTCTTCTTGATATTTGATATAAGTCTCCCTAAATATACCACTTTCTTCAGTTATTATTTCTAAACTCT
TTCTGATGCCCTAGCCTGGAAAAAAAAAAGACATAAAATCACTGATCCACCAACACAAGAGCAGGTCTAT
TGAGATCACAATTGTAAGTTTTAGGGGATATAAGAAAAAGTAGTAAGGAAAACATGAGGCCAGAGAAAGT
ATTTTTTAGTGATGTCAGGAAATGATTGTTGGTAAATATCTTCTCTCCTGTGTCTGGGTGCTGTCAGAGA
CAACTGGTATGTCTACAAGTACTGTAAAACACATTCTAGAAAATGACTGGGCATGGATCTGTGGAGCAGA
GGGTTGAGTTCGTTTTGCATAAGTCAAGGAGTGGTATAGCTGAGACAAACGCTTGCTTTATTTTTAGCTT
TTTGAGAACCCGCCACACTGATATCCAAAGTGGCAGTGCCAGTTTGTAATCCCACCAACAGAGGATGAGG
GGTTTCTCTTTCTCTGAGCCAGGGTCCTCCCCATGCAGCCCCCACTAGCCTGGAACTCACTATGTAGATT
AAGCTGTCTGTGAACTCATAGAAATCTATGTTTTTAAAAGATCATAGATTCGGATACAATGGGAGAACAT
TGGGAATCATTTCAACGTCTGAACAAAGTAAATCTAAATGAAGAACAATTCCAACTTGAAACATTTTGAC
ATCAGACAGAGAAAGCTGCTCAGGGATCTTTCTGTTCACCAGCATAAATTTAAGGCGTTCTGACAAGATT
CTTCTAGATGACTCCAGACTTGGATTTACTTTGTTGGAAATGGTCATTAGGCTGACAAAATGAATATAAC
TCAGTTATTCAGCTGTGTTCTTACGCCTCAACTAAATAGCTAAGTTTATATTTTTAGGCTATGAATTGTG
GAGGTTAAAAAAACTGTTACCAACCGTCATCTGTGGATGGAGGGTCTAGAAATGCTCTTGATTGTTTGGA
GACTAATTTCTTAAAGGGGTATTCTGTGATTACAGTCACGTGTTGTACATAATAGCAGGGTGGACTTGTC
AGGGCCCAACAAAAACCAATGTGAACGAGAATAGCAGGAGGGAGAGAGGACTGCAGGGGCTACTGTCTGA
ACACAAAGAAAGTCTAAGGCAACTGAACTAAATGGGCCTTCTCAGTCTCATGAGAATGCTCAGCAGTCTC
TCAGACAAACCTATGGACATGTGCAAGCGACAATAGAGAAGTGCCTCACTGTACGGAAATCTCCAAACCT
CCCCACTCATAAAAGTTAAGAGCATGAGTCTAAAATGTTTTGGCAGATACTTATGACTGGATTAAGTGAG
CTCCTGGCTGTTGTTACATGGGCCCTTTCTGGTACATTGTTCTTTTTAAATGTGTGCTCCTACCTAGAAG
ATATGTAAGCTTGTGACAGGGTTCTGTATCCCAGAGATATTGTGAAACTTCAAGTGATTAACACAATTTA
TTTATTTATTTTTTATTTTTATTTTTTATTTTTTTTGGCTTTTTCAAGACAGGGTTTCTCTGTATAGCCC
TGGCTGTCCTGGAGCTCACTTTATAGACCAGGCTGGCTTCGAACTCAGAAATCCACCTGCCTCTGCCTCC
CCAGTGCTGGGATTAAAGGCGTGCACCACCACGCCCGGCGATTAACACAATTTAAACATAACTTAGAAAT
ACCATCTTTAAAACTTAGATAGCAGAGGCAGGTATGGTGGCTCATGTCTGTAATTGGCAGTATTTGGGAG
GTGGACATAGAAGGAACACTGGCTTATATACCAGACTCGCCTGGGCTACATAATAAATCCAGGCCAGCTT
GGGGTAGAAATGTGGGGCTCTGTCAACAAAAATTAGGTATCACAATACATTTAGTTAATAAAAATTTGAA
TTTTAGAGAAAGATTCATTTTTGTCTTAGAGAATACAAAACTATGTAACTTTAAAGGCACAACTAAAGTC
AAGGGATGGGTACAATAATGTTTTGACGTGTGGGGGGTACTACTAAACCATTGATATTCCTAAATATATT
TGTAGTTATTGATGGGAGCAGCAAATTATCTACAAAGTTTTAAAGGTGAGAAACAGTATTTCTGTTTTAA
TAATGTCTTTTATTTATATCTACAAAATGTGTCCCAGAATTTATAAACGTAATGGAAAAACAGTAAGAAA
ACTTACTGAATGGAACAGTGTGAGATCTTTCCTACTGGGAAACATTATTTTAATGGGGTAAGTCAATATA
TTTAATATTATAGGCAGGCTAGGATTGTTTCTATGCACGACTTACCTGAATATAGTGAAATTCTCTCCAG
GTTAAAGAGTCGCTCACAGATGGAATAGATGTCACAGCCAAGAGAGCCAAGATGGCCAGCCCCACAATCC
CCAGGGACACATAAATCTCCATTCTCCAGACATCATGCTCTACCCAGGCATCCTCTTTGTTTTGTTGAAC
CTTAGAAAAAGAGGAATCCAAATCGCACTTATGAATATGTGGACTTACTTGATGGCTTACTCAGAAGTGT
AAAACGCATGGAAACACTGCTAAGTAAGTGGAGGATAGAATCGATCGGCCCTCAGAAAGCCACACTGCCG
GAATGCTACGATTGAACTATGACCCCACCTATGCAAAAACACTTCTTAATGCTAAAGGTATTGTTTATTT
TCAGTTTAAAAACATTCTTCAGTATAAGATGACAGGTGCTGATAAAATTATCGTAACGGCTATCAAAAAT
GCAGAATAATTTCTCAGAGCATCAATCTTGCTATGAGTACAAGAAGAAGGGGTTGTTAGGTAATGTAGAC
GTCTTAGTTTGTTAGTTTTGTGGCGTGTCGCTTTCCTACCTGTTTGTAAGCCCAGTTGAGTAGCTTGTAT
CTGTAGGATCTCCTCATTGGGTATGAGAGACTGTAAACAGCGTGCAGCACAGCAAAAAAGAAGCTGAGGA
GACCAAACTGCTTCCTGGCCAGCATCCATCTATCTAACCAGGGTGGGAACTTCTTGTACTTGGTTCCATT
GCGAAGCTGTACAACTGCCGCTAACTCTCCTGGCAAATAGACCAGTGCCAAGAGGGTAATGGCGACCATT
GGCAAGACTTTGTTAATAACCAGGATTGGAATTTTATAAAAATATTGTTCACGGGAAGTTACTAACGGGT
AGATGATTTCCCTCAGAAGTGTGTACAGGAAAGTCAGGGATGATATGATGGCAGCGACTTTCACTGGCAA
GCGCCAGTTTGGAAAGAATTCCTGCGTGTGCTGAAGCTCGGAGGGGCAGTCAAAGGCATCGACGTGGACC
GCGTGCTGCAAGTGCGAGAGCCCCGGTCTTTTCAGCATGCTCGTCTCTCCCGAGTCCTTAGTCTACGAAA
GAAAGGGAACATCTTAACACTGGACAAAGCATGGGATTTCTTTTACCTGCTCCATCGTTGTGCTTCTTGG
TGAATAGAGCATTCAGAAGCTCGCTTGTGGATACCAGGCAGCTAAAGCCAGTATAGTCTGTGTAAGACTG
ACCCAGGATGCACCCCGATACACTGGTGTTCCGCACTTGCCTATTTATTTCCCTCTTTGTGTTAGAGCCA
GGGTCTGTAGCTCAGGCAGGCTTTTCTCCCACTGCTGGGCACGTGCTGGGTTAGCAGCATATGCTACCAA
ACTGGGTTCCATTTCTCTTTAAAATAAAAGAGATACATGCCCACACACCAAGGTTTACACAGTTCCTTCT
CTTTTGAAGACTTGAAATAATGGAATAATTTTTTTTTTTTTTGGACAGGTTTTCTCAGTGTAGTGCTGGC
TATCCTGGAACTTACTCTGTAGACCAGGCTTAAACTCATAGAGATCTTCCTGTGTCTGCCTCCCAGTACT
TGAAATTAAAAGTGTGTACCAGCACCCAGAGGGATAAGCTTAAGAAGTCCCCCCCCAATATATATACATA
CACATACACATATATATATCTTTAAATAAGTCCAGTATTCTTTGGAAAAATCAGCTAATATGCATATCAT
AATAGTGTTTTGTAATATTTCTATTGGTTCCTGGGCAATTATGCAGAGCAGTAGCAGTGAATTTATTAAG
TTAAGTGCAAAGGAGCTGGAATAATAGCGTCAATCAATCCTAGTAGAGAAAAATGTGAATTTCATTATGT
GGTTGCGGTTTTAATGAGAATGGCAGGAATAACAGGGTGATTACGAAAAGGCGAATATGAATTTCATTGT
GTAATTTTGCTCTTTGATTATATATATATATCTAAAACAGATAAGTTAATGATCAGAAAGCTAAAAAGAA
CAAAAAGCTACTTAACTACCTAGTGAACTCCTGCAGACACATCTGCTTCCTGACAAGATAATACTTCTCT
GTCCACCATGTTTTGTGCTGGTCAGTAATTCAAAAGAAAGTATGTTGGATAATGTTTTGTTTGCACAAGG
GATAAGGGGAAACAAAGTTTGTAAAAATCCAAATGAAGACCCCAGAGCGTTTCCGCTGGTGTTCCGTTTC
CGTTTCCGTTCTCAGAGCTCCAAGTGTGCTGAGAAGAAGCTCCGATGCTGGGCTCTCCTCATCTCACACA
GAGCGAAACCACACAGTACTCCACAGTGGCCAGCGTCCGGCATCAGTCAGTCTTCCATCCAATGTCTTTC
TAATTACGCCACCCAGAAAGGAAAGGGCTCTGTAATTCCTGCATGTTAACACAGCCCTAGTGAACCGGCT
GAGAACAGCTTTCTGGCTAAAAGTTATGAGTAAGAGAGTAAGAGAGCTAAATTGAAAAATGAAAAGCATT
TTGTTTTACAGGGTATATGCATGTGATTCTCAGAACTGCATTTTAAATATTTTATAAAGGTAAGTGTTTG
GAACCAAAAAAATTCCTGCCACTTTAAAAATGATGTAGCAAGAAACATTTAACCCTGCGATGACCAAAAG
TGACTTCTGCACAGACAACGTATGTGGTTAAACAGCGACTCACCGTTTCCTTGGTGGACTCTCTGGTAAG
CTGCCCTAGTGCCTACCAAGATGCTTACAAAGCTACTCTACAGGCCGTCATGACTTTTTTTAAATTTTGA
AGCACCGGTGTTAGAAAGGACTAACGGGGCTTTGGAGAGGGTCTGGTCCAGGTCGCTCACTTCATACAGA
AATGCAAGACCCAGGAAACTCAGGGCCCCGTGGAACGTTAAGCCCCAATCAAGTCACCTCAATTATCCCA
TACAGCTTCAGTTCCAGGCATCTGAGCTCAGAGCAGCAGATTAGAATGCAATGGCGTTTGCAACACGAGT
AGATTCAGAATACACGCTTAGTATGTATACATTTTAATTATTGGCTATTACAGTCATTATTTTACCGAGT
AACTGTCATCTTCCAGGTTTCCCTTTGGCTTCATTTTCCAAAGTTGTTCTGGGTTTGTAACATCGTCACT
GATCTCCATGACTGCTATAAAATAGTACGGCTTCAGCCACCTAGAGAAAGAAAAAGAAAGTCTGCTCCAT
TTATGATACTATTGTTTTGGTTTTTTTTTTTTTGAGACAGGGCTTTTCTTCTCTGTGTAGCCCTGGCTGT
CCCGGATTTTGCTCTGTAGACCAGGCTGTCTTCAAGCTCAGACATCTGCCTGCCTCTGCCTTTCCAGGGC
TGGGATTAAAGGCATGTGCCACCGTTTGTCTGGCTACAATACTTTTGTTTGATGGAACAATATAAAGTAT
TTATTCTCTTGAGAACCAGAGCAGAAAAATCCAATTAAGATTCAAATAGTGAATAACTACATATTTAGCA
AGCCTCCAATCAGTTCACTAATGTCTGGTACTATTTGTCCAATGGATGACCTACCAATCATTTACATGAA
ACTTAATGTCAACTACTTGCCCAATGGATGACCTACCATTTACATGAAACTTAAGAATTAGCCATTACTC
TGCTCTTCAGGAAGATTTTACTCCAGTTCTCAGTTGGACAAAGGCCTGCTGCCCTTAAAGGTAAATGGAA
TTAGGAATGCATTTTTCAGTTTTGGGAAAGGATGCTAACAGCAAGGCTTGAGGCAGCGGATAGAGAACTT
CAGGAAGATGTTTCCTAGGCTTCCAGGGATGCTGATGGAATCTGGAACAATAATTAACTGCTTTGTATGT
TGAAACGTTCCTCAAGACAGTAATCAGAAGAGGTACAATTATTAAGGTGAGTCCCAATAGTTGCTTCAAG
GGCCAAAAGGCTGCATTGCCAGAGTATCTCTTGGGCGTGTTTTGTTGGTAAAAATGGCTGCTCATCTATT
TCCAATGGGGTATGGAGTTGTGTTCAGTCACTGACCAGCCCACTTTCTTAGTCAACCCCGTGGAGAGGAG
CTTGTTAAAAAATTTCCCCAAACAAAGAAAATTATTCCTTAACAGCTTTCATAGAGCCTAATCCAGTCTT
GGCTTCACATATCTTACGCAGGACAAACAGGACGTCATATTCTCCATTGTTCCTAATGAGCTCTAAATTC
ACTTCTAGAAGATTATACCTCCAACTTGTACCTTGTCCAACAAAAGAGAAAAACAAGTTAAAAACAACAG
TTAGGTTGCTGGAAAATATTCCAAGTACTTTGGGATTTTGGACCACCTGTGATGCTGTATTAAGTGGAAA
ATTATTTTCAGGAGTAGATTATATTATTTAGACTATTTATAACTTTTCAAGGTCAGCCTTTCCCTAACAG
CATTTTTTTTTTCTCATTAAGGTGCTCTGGGAATTCTAGAATTACCTATCTTGGAACATTCAGGAGGAGA
CTATAGGTTGAGCATCCCTCATGTGAAAACTCGCAAAGTTGAAATGCTCCACAGTGCAAAACTGGACCTC
ACACGATGGCTTGCACGGAAACTTCAGGCATAGTGAGTATATTCTAATTGTACATTTCTTCAGATGGGGC
TTCAGTATGTAGACCTTGCTGACCTGGAACTTGCTATGTTCAGCAGACCTCAAACTCAGAGATCCACTTG
TCTCTGCCTCCTGAGTGCTGCGATTAAAAGCGTGGACCACCACATTTGATAGTAAGCACATTCCTCTTTA
AACTTTCATCTTATCTGCAAGATACCTTATTGTGCTTATATAAATTATTATATCTGTATGTTACATCTGT
GCATAATCCCAGCACTCGGGAGGCAGAGGCAGGCAGATTTCTGAGTTCGACGCCAGCCTGGTCTACAAAG
TGAGTTCCAGGACAGCCAGGGCTATACAGAGAAACCCTGTCTCGAAAAAAACAAAACAAACAAACAAACA
AACCAAAAAAAGAAAAAAGGAAAGAAAAAGAAAAAAGCCTACCACACAAAATATTTTTGGTTCTAAGTGG
TTTTTTGTTTGTTTGTTTTGTTTTTGTTTTTGGAGACAGGGTTTCTCTGTATAGCCCTGGCTGTCCTGGA
ACTCACTTTGTAGACCAGGCTGGCCTCGAACTCAGAAATCCCCCTGCCTCTGCCTCCCAACCAAGTGCTG
GGATTAAAGGCGTGCACTACCACTGCCCGGCTGCATTTACTGTTTTGATTGGGCCATGTAACAGTCATCC
CCTGTTATAACAGGCAGATAACACAGGCTTGGCTATCCAGGGATAATTCCTGTGATCACACTCAGTAGCT
TAGGGATGGCAGCCAAATCTAGTTGGCAAATTACAGTCATCTTCTGATATCGTCTCCAATGGAAGAGAAC
GAAGAGATACCCTGGACATGTTTGCTAAGTTAGGATGGTGTAAAACTACCATGCCACCCTTTGGGTAAGT
CAGAAGATGTCTTCATATGCACATAAGAAAGTGAACACAGAAAAGCCAAACAAGAAATGAAGAAGAAGAA
GGTATATCCTTTTGTTTTAGGATAAAATGTTCTCTCCCATGCTCATGGATCAGCAGGATCAATATAGTAA
AAATGGCTATCTTGCCAAAAGCAATCTACAGATTCAATGCAATCCCCATCAAAATTCCAACTTAATTCTT
CAACGAATTAGAAAGAGAAATCTGCAAATTCATCTGGAATAACAAAAAAACCTAGGATAGCAAAAACTCT
TCTCAAGGATAAAAAAAACCTCTGGTGGAATCACCATGTCGGACCTAAAGCTGTACTACAGAGCAATTGT
GATAAAAACTGCATGGTACTGGTATAGCAACAGACAAGTAGACCAATGGAATAGAATTGAAGACCCAGAA
ATGAACCCACACACCTATGGTCACTTGATCTTTGACAAGGGAGCTAAAACCATCAAGTGGAAAAAAGACA
GCATTTTCAACAAATGGTGCTGGCACAACTGGCGGTTATCATGTAGAAGAATGCGAATTGATCCATTCCT
ATCTCCTTGTACTAAGGTCAAATCTAAGTGGATCAAGGAACTCCACATAAAACCAGAGACAGTGAAACTT
ATAGAGGAGAAAATGAGGAAAAGCCTCGAAGATATGGGCACAGGGGAAAAATTCCTGAATAGAACAGCAA
TGGCTTTTGCTGTAAGATCGAGAATTGACAAATGGGACCTTATAAAATTACAAAGCTTCTGTAAGGCAAA
GGACACCGTCAATAAGACAAAAAGGCCACCAACAGACTGGGAAAGGATCTTTACCTATCTTAAATCAGAT
AGGAGACTAATGTCTAATATATATAAAGAACTGAAGAAGGTAGACTCCAGAAAATCAGATAACCACATTA
AAAATGGGGTGCAGAGCTAAACAAAGAATTCTCACCTGAGAAATACCGAATGGCTGAGAAGCACCCGAAA
AAATGTTCAACATCCTTAATCATCAGGGAAATGCAAATCAAAACAACCCTGAGATTCCATCTCACACCAG
TCAGAATGGCTAAGATAAAAAATTCAGGTGACAGCAGATGCTGGCGAGGATGTGGAGAAAGAGGAACACT
CCTCCATTGCTGGTAGGATTGCAGGCTTGTACAACCACTCTGGAAATCAGTCTGGTGGTTCCTCAGAAAA
TTGGACATAGTACTACCGGAGGATCCCGCAATACCTCTCCTGGGCATATATCCAGAAGATGTTCCAATTG
GTAAGAAAGACACTTGCTCCACTATGTTCATAGCAGCCTTATTTATAATAGCCAGAAGCTGGAAAGAACA
CAGATGCCCCTCAATAGAGGAATGGATACAGAAAATATGGTACATTTACACAATGGAGTACTACTCAGCT
ATTAAAAAGAATGAATTTATGAAATTCCTAGGCAAATGGATTGACCTGGAGGGCATCATCCTGAGTGAGG
TAACCCAATGACAAGAGAACTCACATGATATGTACTCACTGATCAGTGGATATTAGCCCAGAAACTTAGA
ATACCCAAGATACAAGATACAAAGTACATGAAACTCAAGAAGAACGAAGACCAAAGTGTGGACACTTTGC
CCCTTCTTAGAACTGGGAACAAAACACCCATGGAAGGAGTTACAGAGACAAAGTTTGGAGCTGAGACAAA
AGGATGGACCATCTAGAGACTATCAAATCTGCGGATCCATTCCATAATCAGCTGCCAAACGCTGACACCA
TTGCATACACTAGCAAGATTTTGCTGAAAGGAGTCTGATATAGCTGTCTCTTGTGAGATTATGCCAGGGC
CTAGCAAACACAGAAGTGGATGCTCACAGTCAGCTATTGGATGGATCACAGGGCCCCCAATGGAGGAGCT
AGAGAAAGTAACCAAGGAACTAAAGGGATCTGCAACCCTATAGGTGGAACAACAATATGAACTAACCAGT
ACCCCCTGGAGCTCGTGTCTCTAGCTGCATATGTATCAGAAGATGGCCTAGTCAGCCACCAGTGGAAAGA
AAGGCCCATTGGTTGTGCAAACTTTATCTGCCTCAGTACAGGGGAATACCAGGGCCAAGAAGTGGGAGTA
GGTGGGTAGGGGGGTGGGGGGGAGGGTATGGAGGACTTTTGGGATAGCATTGGAAATGTAAATGAGGAAA
ATGCCCAATAAAAAAATTTAAAAAAAATGAAGAAGGACAGTGACAAATCTTGCTGGCAGTAGTTCATGCC
TTTTTGTTTGTTTGTTTGTTTGTTTTTTTTTGAGTTTGAGGTGTGTGTTGACCATTTCCATTTGAAAGAA
TTCTGGGTAAAGTCTAGGTCATTCAACAAGTTCTTACAAGGCCAATATCAAAGAGGAAAAAGAGAAGGAG
ATTTCAAGGCTGCCCTTGAGGGGCTAACAGTCTGTCTTCAAAATGTATTACCCATGCCATTTTCTGACCT
TAACCAGTACTATAAAGTGAGTAGGTTGGTGTTGGGTATCTAGGAATAGGGTAGCATGCACTGTAGTAAC
AAGTATAAGAAACAGTTTGCTACGTTTAGAGTGTATTTTAAGTTTTGTGATTCACAATGTTTAAGATAGT
GAAGCATAAATCTATAGCTGTTCACTGTTAATTCATTAATCACACTGAACAATGATGGCAGACACGGGAA
ATACAAAGTTAAATGATAAGTCTGTTCTCAAAGAAAGTTTAGGACAGGGAAACGCTCCATTAAGACCTGT
GTGGTAATGCCATACATCTTAAAGGATAATAGTGTATAGACAGATGGTGGCTCTGGAAAGGAAGTGGAGA
AAACGGATGAGAGCCCCTTTCTTTACCCAGTCCTGTGACCTGCAGTGAGTTGTTGGTGCTTGCTGACATG
ACAGACAGCCACTGCTGAGAGATTCTGGGTGGAAGGACAGAGTGGCCCAGAGGAGATGCCTAGCCATTTG
TTTGCATGGTACCACTCTGAGGAGCATCGCTAAGGAAAAGAGCCAATGCCCGTAAAGGTGATTGTTGACT
GTATGCCCAGAAACCAGGAAAACAAACTATCAGCTAAATAAATCATGCCTTCTTCCACCAGACCTTAGCT
ACACCTATAATTACACTTCTACAGGAGAGGTTTCATCAGGCTGTCCAGCAAACTCAGCAGGAAACAGCAT
AGTGCAGAGATGTCAAGAACTCCAGGATTTGAACCAACATTCTCCAGCTTTCTTCCCCATTAAATAGTGA
TTTCTGTTTTCCTGGATTAGGTTGGCTGGCTTGTTGTTCCTGCTAAATATTGACACAGCCCAACAGACTC
ATGTTTATGGGAAGGAGTTTAGAATCCAAGAAACCCAGTGACTGGAATACATTGTGGGTTGCAGTGCATG
TCCCACGAGTCTTTCAAATGTATTTTTTTGCTTTGCCACAGTTAATTATTGGAAGAGGGGAAGGTGTTCT
ACAGCGGGCTGTTTCTTAAAGCATTGCTTCCCCAAGTGCTTAACATTAATATTAAATACATTCCCTTGAT
TTTATATCGAGATGTGGATGTATCCCCCACCTCAACGGAACAGCATAACTAAATTTGAAGTGGACTTAAA
TTCTTGGACTACAAACGTCTGTTAGTTGCTTTCACCAGAGTGCCTTATTTAAAAGCTCTGACTATTTTAA
ACCCGAATCCTACTCAGATCCCGAAAGAGTAGGACCGGTGTTCCAAAGACTTAAAATGAAAAAAAAAAAA
AAAAAATTCCATGAAGAAACCAGCTCAAACAGCAGGACGAGTCATTCATCCAGCGAGGCAAACTTGCGGA
AACTGCCAAGTTGGCAAACTTACCGGGGGAACCCAACCTGACTGCAAAGTTGACCTAAGCTCCAGAGCCG
GGACCGCGGAGACCTGCTCCCCGCGGGGCTCGCCGAGATCCGCGAGGGGCCGAAGGGGCGCCCCGCTGCC
CGGAGCACCACCGCCCGCCCCTGAGACCCGCCTCACCCCTTCCCCGGCCCGCAGCAGATTCCCAAGGCCC
GCGGAGGCGGGGAGCAAGCGGCCTGCGAACGAGACTCGGGACTCACCGGCTTCTCCGTGGGACCCGACGG
CGAGGCGCTCGCTGCCCGGACGGACTCCCAGTCCCACGCGGAGCCC

</dna_sequence>
        <protein_sequence>>NP_081675.2 metalloreductase STEAP1 [Mus musculus]
MEISDDVTNPEQLWKMKPKGNLEDDSYSTKDSGETSMLKRPGLSHLQHAVHVDAFDCPSELQHTQEFFPN
WRLPVKVAAIISSLTFLYTLLREIIYPLVTSREQYFYKIPILVINKVLPMVAITLLALVYLPGELAAVVQ
LRNGTKYKKFPPWLDRWMLARKQFGLLSFFFAVLHAVYSLSYPMRRSYRYKLLNWAYKQVQQNKEDAWVE
HDVWRMEIYVSLGIVGLAILALLAVTSIPSVSDSLTWREFHYIQSKLGIVSLLLGTVHALVFAWNKWVDV
SQFVWYMPPTFMIAVFLPTLVLICKIALCLPCLRKKILKIRCGWEDVSKINRTEMASRL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene719">
        <gene_name>Survivin</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>2315863</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id>1XOX</pdb_id>
        <xrefs>CDD:306999
CDD:237989</xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand></gene_strand>
        <protein_name>apoptosis inhibitor survivin</protein_name>
        <protein_pi>6.02</protein_pi>
        <protein_weight>16571.66</protein_weight>
        <protein_length>202</protein_length>
        <protein_note>Inhibitor of Apoptosis domain; pfam00653</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAC51660.1 apoptosis inhibitor survivin [Homo sapiens]
MGAPTLPPAWQPFLKDHRISTFKNWPFLEGCACTPERMAEAGFIHCPTENEPDLAQCFFCFKELEGWEPD
DDPIEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFEETAKKVRRAIEQLAA
MD

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>The efficacy of a human survivin DNA vaccine delivered by intradermal electroporation (EP) was tested. The CD8+ T cell epitope surv(20-28) restricted to H-2 Db was identified based on in-silico epitope prediction algorithms and binding to MHC class I molecules. Intradermal DNA EP of mice with a human survivin encoding plasmid generated CD8+ cytotoxic T lymphocyte (CTL) responses cross-reactive with the mouse epitope surv(20-28), as determined by intracellular IFN-gamma staining, suggesting that self-tolerance has been broken. Survivin-specific CTLs displayed an activated effector phenotype as determined by CD44 and CD107 up-regulation. Vaccinated mice displayed specific cytotoxic activity against B16 and peptide-pulsed RMA-S cells in vitro as well as against surv(20-28) peptide-pulsed target cells in vivo. Importantly, intradermal EP with a survivin DNA vaccine suppressed angiogenesis in vivo and elicited protection against highly aggressive syngeneic B16 melanoma tumor challenge [Ref1313:Lladser et al., 2010].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1336">
        <gene_name>Survivin</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>11799</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>59859890</ncbi_protein_id>
        <gene_locus_tag>RP23-268N22.2</gene_locus_tag>
        <gene_refseq>AB036741</gene_refseq>
        <protein_refseq>NP_001012273</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>11</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>117849236</gene_start>
        <gene_end>117855742</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>transcript variant 3</protein_name>
        <protein_pi>4.99</protein_pi>
        <protein_weight>13855.81</protein_weight>
        <protein_length>121</protein_length>
        <protein_note>Also known as Api4; TIAP; AAC-11; survivin40</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000077.6:117849236-117855742 Mus musculus strain C57BL/6J chromosome 11, GRCm38.p4 C57BL/6J
AGCGGGCGAGGGCGTGGGGCCGGGGCTCTCCCGGCATGCTCTGCGGCGCGCCTCCGCCCGCGCGATTTGA
ATCCTGCGTTTGAGTCGTCTTGGCGGAGGTTGTGGTGACGCCATCATGGGAGCTCCGGCGCTGCCCCAGA
TCTGGCAGCTGTACCTCAAGAACTACCGCATCGCCACCTTCAAGAACTGGCCCTTCCTGGAGGACTGCGC
CTGCACCCCAGAGCGAGTGAGTCCCAGCTTCCAGCGACTCCACCCTGGGCCCGACGGTGCCTTAGTTGTG
TGACCCGGGATCAGAACCCGCTATCCCCACCCTCGCTTCGTACTGTTAGCCAGGCTGCTTTGCTCTGCTC
TGTCCTCCACGAGGCCACCCCCCCCCCCCGCTCTCCCCACCCTCTGCCTGAACCACTGTTAGCCTCCGGG
CCTCTTCCCACTGTCCTCAGTTCTCGGCCCGGAACGATCTCTGGGAATCATGGGATAAGGTCAGACTGTT
GATCCCGCTCACGAGCTGTCATTTTCAGATGGCGGAGGCTGGCTTCATCCACTGCCCTACCGAGAACGAG
CCTGATTTGGCCCAGTGTTTTTTCTGCTTTAAGGAATTGGAAGGCTGGGAACCCGATGACAACCCGATGT
AAGTCCCACAGGCTACTCTCGGTGGGTTTCCTGGTGTTCCCCTTCCATTGAGAGCCTTTTGGGTTGAACT
GGAGTTGGGACAAACCATTTGTATTTAGTAGAAGAGCATGCTTCTTGCTCAAGTGTTCCAGTTATACAGC
TCAGACTAGTCTTGAATTCTCAATTTCTGCCTTGGTTTCCTGAGTGTTGCCAACATGCATGGTTTTGCCT
GAGGTTTTTTTGTTGTGTTTTGTTTTTGTTTTAAAACAGGGTTTGTCTGTGCAGCCTTGGCTGTCCTGGA
ACTCACTCTGTAGACCAGGCTGGCCTCGAACTCAGAAATCCGCCTGCCTCTGCCTCCCAAGTGCTGGGAT
TAAAGGCGTGCAGCACCACTGCCCAACCAAATTTTTAAATATGTTATTATTACTTAATTTATATTTCTAT
TTGTGTATGTTTGGATGTGGGTGTCATGGTGGATGTTGGTGTCAAGACAGCTTGGGGGGATAACTTCTCT
CTTATTGTGTTGGTCCCTGGAATTGAGCTCAGGTGAGCAGGTTTGGCAGCAAGCATCCTCACCTGGGCCA
TTTCAGTGGCCCCTGTTTGGTTTCAGACCCCAGGAGTAGGAACTGAGGTGCTTATTCTACATATCAAAGC
AGACCTGGACTCCAGGCTCTCCCAGCATCCCTCACTCCCTCCCTGGCATACTTTGCCCCCAACTCTGAAC
TTCCAGCCCAGGAACTGGGCAGCCCTTCCCCCCAGAGGCTCCACCCTATATAATCCAGGCATTTTGGACT
TCTCTTCTTCTCTCTCTACATGTGTTCTTTCTCTCACCTTCCCATGGTGACTCCCCTGGCCTCAGTCCTT
GAGCCCAGTGAATTCACCTGGGAGCAGCTTTCCAATAAACCTGCATTTCATAACATCTAATCTGGCTTGA
ATTGGTTCATTTAACCAGCAGAGAAATAATTTATAATCCTGGACTATGATTCATTAAAAACAGGTCTATT
GAAATATAATCCATCTACTGCAAAAATCAGTAGCTTAGTGACTTTTTAAGGTCTTTTTAAAAATCTAAAA
AAAAAAAAAAAATTAAAAAAAAAAAAAAGGCTGAGAGCTGGCTCAGAGGTTAAGACCACTTGTTGCTTTT
ACAGAAGACCCAGGTTTGGTTCCCAGCACCCACCTGGTGGCTCACAATCAATTACAACTCCAGTCCCGGA
GGATCTGAGGCCCCCTTCTTGCTTCTGAGGACACTCAGCACACATGGGACACATCTACACAGAGCACTCA
TACATGCAAAGCAAAATTTAAAAAGAAAAAAAAAAGACTTAATGTTGTCTGTCTTTAGAGCTTACAAGCT
GTGTTCTAACTGCAGTCCTGCATTGAATGCTGTGACGTACCATATGCAGGACAAGTCCTCTCACGGGCGT
GTGTGAGTTAGCGGAGTTCCCTGAGTAGACGTGTGCTAAAGCTTTATGAACATTCCTGTAAAGTGGAATG
ATTTCTAGCAGGTCTTTGGAGGAATTCAAACAATCTTGTGTGTGTGTGTGTGTATGCATATGTACATGTA
TGTATAATATACATGCGAAGGTTGAGGGACAATTTATAGACATTGGATCTGTCTGTCTCTTCTGTCTTTC
TACTATGAGAGTCCTAGGATGGGACTCAAGCTGACAAGCTTAGTGAATTTTATTTTAAAAAAATGTTTAT
GTTGGGTATGTCTTAGGATTTCTTTTGTTTGTTTTTATTTATTTTATTGGTTTGTTATTTGTGGGTTTTT
TTGTTTTGTTTTTGAGACTGGGTTTTTGTTTGTTTGTGTGTGTGTGTGTGTGTGTGTTTGTGTGTGTTTT
TGTTTTTCTTTTCTATGTAGCTCTGGCTATCCTGGAACTTTGTAGACCAGGCTAACTTGAACTCTGCCTC
CTGAGTGTTGGAATTAGGGGCAGTCACCACCACTGCCTGGTCTTAGGGTTTCTGTTGTAAAGAGACGCCA
TGGCCACTATAAAGGAAAGCATCTAACTAACTGAGGCTGGCTTACAGTCTAGAGGTTTAGTCCATTATCA
TCATGGTGGTGGAGAGGTAGCTAAGGGTTCTACAGCTATATCAGCAGGAAGAGAGAGTGACACTGGGCCT
GGCTTAAGCTTCTGAAACATTAAAGCCTGTCTCTAGTGACACACTTCATCCAACAAGGCCACAGCTCTTA
GTGGTGCCACTCCCTATTAGCTAATGGGGCCACTTTCATTAAAACCACCACAGGGTAAGGCGGTGTCTCT
GGTGGCGCAGGTCTTTAATCCCAGCACTTGGGAGGCAGAAACAGGCGGATTTCTGAGTTCAAGGCCAGCC
TGGTCTACAGAGTGAGTTCCAGGACAGCCAGGGCTACACAGAGAAACCCTGTCTCGAAAAAACAGAAAAA
AAAGAGAAAAGAATGGGGAAGACGGGGGCTGGTGAGATGGCTCAGTGGGTGGGAGTGCTGACTGCTCTTC
CGAAGGTCCTGAGTTCGGGTCCCAGAGGCCACATGGTGGCACACAGCCATCTGTGATGAGGTCTGACCCC
TCTTATGGAGGGTCTGAAGACAGCTACAGTGTACTTACATATAATTAATAAATGGGTGAATCTTTAAAAA
AAAAGAAAAGAAAAAGAATGGGGAAGACATAACAGAGAGAAGATATGCTGTGTGGGATGTTCCTAGGACA
TGTTTGAGCCTCAAATCTTGTCCTTGACACAGATCAGGGTGCACCAAGAGACAGCCGTGGAGATGGGAGA
TAGACTGTGGGTGGTGAGTAGCCCTGGCACTTTTGACATGTACGTCTATTTTTTTTTTTTTTATTAGAGA
GGAGCATAGAAAGCACTCCCCTGGCTGCGCCTTCCTCACTGTCAAGAAGCAGATGGAAGAACTAACCGTC
AGTGAATTCTTGAAACTGGACAGACAGAGAGCCAAGAACAAAATTGTATGTATGATTGAGAATAAGGACT
GAGCAAATTCTGCCCCCAGAAGCCCTAGGGATCTGCTCAGGAAGGGTGCTTCAAAGGTGGTTCCTGAGCA
GGTCACCTTCCCACCTGAGTGGCAAGCATTGTCAGAAGCCCTTGTCACAGGCTGAGCCCCCAGTGGTAGC
ACTGGTATAGGTAGAGGCTTGGGGACATGGCAGAGAGTATTGGCTGAAGGGGACACTGAGCAGACAGGTC
AGCTGAGCTTTGCCTCCTGTCACGTGAAGTTGATTGGGAAGCAGGAGGCACAGGTGAGTCCACAGGGAGG
TGGCTCCCATGCAGCCAGGCATGAAGAGTCAGGGTGGCCAGAGTCCAGAGCTCAGAGTAAACCTGGGTCC
ATTTTGACTGAGAACACCCCACATTTTGCATTGGTTATTCACTGCAATTGTTCGTTTATCTGAAGTTCAA
CTCTAAGCAGGCAGCCTGGGTGCTCATCTGTTACCCTCGAACTGTTTTAGTGGGAGGAGTCGGGGAGGGG
TTCACTGGCAAACACTATACCTCATCCTCGAAGGATGACCCACAGCTGACCCTGGCTCAGGTAGAGGCTC
CGACCTGCTGTCTTGGTTGCCACGGTTTCTCTTCAGCTGTAAGTTACGTTCCTTGGTGGAGGGCTTTGTG
AAATAACTGACTGATGCTCAACATAGAGGATGATGGTTTGCTGTCAGGAGGAGAGGGAGCTGAAGATGGT
GTTTGGTCAGCGTGCTCAGACACTCTGGGGATGGTCAGGTGAGGTGGGTCCTGCTGCTCAAGTCCCTCTT
ATATAGCATTCTTTTTTATTTATTTATTTATTTTTTTGAAGCAGAGTTGAGGTTCAATAAACATATTTAA
TACAAGCTTAGGCACAGAGTCAAAAGAACCATCTATCCAGACTCAGACCCCTCTCCCAAGGTTTTTTTTT
AAGGCATGATTCTCTGTGCAGCTCTTTCTGCCCTGGAATTCACTCTGTAGCCCAGCCTGGCCTCAAACCT
CTGCCTCCTGGGTGCTGGGATTAAAGGCATGCTCTCCCACCACCAGGCATCCCTTCCTGTGTTTAAGGTT
GTAGCTCTGGGTCTGTGGAGATCCTACCATAAGGAGCACAGCCATATTTCAGTCTTTTTTTTTTTCTTGT
CAATTTATTAATTTTAAATTAAGTTCTCTAATCTGTGAAAGTAACTTTTATTCTTCTGTAATAATTGTCT
CACAGGCTTACTGCCCCTGTCTGCTAACCTAGGCCTAGTCCTGGAAGCTTCTAACCTCTATACAATCTAA
TCTAGGTCTAGAATGTTTTCAGCCTCTGAGACTCACTGCTGAGTAAACTCACACTTTCTAGTTCTTTCTG
GGCTCTAACTGACTGGTTCAACTCAGCTGTTCTGACCCAAACTCTTCTCCAAGCTGACTGATTCAATCTG
GCTTTTCTCTTCAGCCTTTTCTGAATTGCTCTGTTTGGCTTCATACTGCCGTTGGCAATCTGTTCTAATC
CGGCTGCTTCTCATTCTCTGGCTTGTTCTGTCCTCACCTGTCTCTCATTTGTGCTCTTCAGTCTGTCTGC
GCACAGCTGTGCTAGTAAGACGGCCTCCTCTCTTTTCTGCGCCCTGCTCCTTACTTCGCCTCCCCTCCGC
TCCCTTCTCAGGAGAGCTGGGCGTGACCTAGTCTCTCAATCTTCCTCTGATTCGTCACTTTGTCTGCCAC
TCAATTAGACATCACTTGCAAGCATGGGTGCTTCCTTCTACAAACTACCTTCATTGTTTGGGATTAAAGG
TGAGTGCTAAGGGCTGAGCCACACCACAACTAGAAACAGTTTTTTTCCAATAAACAACACAATCTTGGGG
GTCACAATGTGATCAAATATCCTACAAGACTAACCCGGGCTTGGTGCCACAGGGTACAGTCCTAGGATAC
TAGGGTACAATCCCAAATAATTTGGCTATTTGGCTGGCTGAAGGAGGACTGAAAGTTAAAAGCTATCCTG
GGCTACATGAAAAAACATGTTTTTTTTTGTTTTGTTTTTTTTTTTTGTTTTTTTGTTTTTGGTTTTTTGA
GATAGGGTTTCTCTGTATAGCCCTGGCTGTCCTGGAACTCACTTTGTAGACCAGGCTGGCCTGGAACTCA
GAGATCCACCTGCCTCTGCCTCCCGAGTGCTGGGATTAAAGGCGTGAGCCACCACGCCCGGCTTGAAAAA
ACATGTTTATATATATATATGTATATATATAAAAAATCAAGGAAGGAAAATTCCAGTTTGTAGCTCAGTA
AGTATTTGCTTATTACTATTGAGGCCCTAGGTTCAATTCCCAGCAATACAAAAATAATAACTTTCCTTTT
AATGATTTATCTTGCCACGATGGTGATGAAACTAGCATCTCACCCTGGACAGGCAAGCCTGGCCCTCTGG
GCCACACCCCAGCCCCTTCGTGTCTGTTCATCATTCCAGGCAAAGGAGACCAACAACAAGCAAAAAGAGT
TTGAAGAGACTGCAAAGACTACCCGTCAGTCAATTGAGCAGCTGGCTGCCTAATGCTGAGCCTTTGCTGA
GATAACTTGGACCTGAGTGACATGCCACATCTAAGCCACGCATCCCAGCTTTTCCAGCCAGGGCCTCCTA
GCAGGATCTTAGAGAAGGAGACAGTGGTATTTTGAAACTGGATATCAAATATTTTTGGTTTTGCTTTAAA
GTGGCTACCTCTCTTTGGTTTTGTGGCTTTGCTCTATTGTGACGTGGACTTAAGCAATAAGGAAGTGATG
AAGGGACAGTGTTCTCTGACAGGACCTGTGGGGGTCGGGGTGCCTGTGCAAGGTCTTGGTTCTGATTGTG
ATATTTCCATACAGGGCTGCTAATGCAGCCCATGGGTAAGTGTGGTTATATGTGTTTGTGCTGATAATTT
TGTCCTGATGAGTTTTCCTACCACGGGGTAACGGAATAAAATCACTTGAAAAAGTGGACTGTAAGCT

</dna_sequence>
        <protein_sequence>>NP_001012273.1 baculoviral IAP repeat-containing protein 5 isoform 3 [Mus musculus]
MGAPALPQIWQLYLKNYRIATFKNWPFLEDCACTPERMAEAGFIHCPTENEPDLAQCFFCFKELEGWEPD
DNPIEEHRKHSPGCAFLTVKKQMEELTVSEFLKLDRQRAKNKIVCMIENKD

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene705">
        <gene_name>TERT</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>7015</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>301129200</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AB016767</gene_refseq>
        <protein_refseq>NP_001180305</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>5</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1253166</gene_start>
        <gene_end>1295046</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>transcript variant 4</protein_name>
        <protein_pi>11.27</protein_pi>
        <protein_weight>112208.51</protein_weight>
        <protein_length>1069</protein_length>
        <protein_note>Also known as TP2; TRT; EST2; TCS1; hEST2</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000005.10:1253166-1295046 Homo sapiens chromosome 5, GRCh38.p12 Primary Assembly
ATTTTTTTCAAAACTGAAAAACTCATATATTCAGTATTTTACTCCCACAGCACCTCCCCCCAATTTGACC
CACAGGGACCCCCATCCAGGTGCAGGGTCCTCGCCTGTGTACAGGGCACACCTTTGGTCACTCCAAATTC
CCAGAGCTCCCAGGGTCCTTCTCAGGGTCTCCACCTGGATGGTGGGGGTGGAAGGCAAAGGAGGGCAGGG
CGAGGGGTGAACAATGGCGAATCTGGGGATGGACTATTCCTATGTGGGGAGTGGAAGCCGGGCTCCTGGT
GAGGAAAAGCTGGCCCTGGGGTGGAGCCGAGCGCCAGCCTGTGGGGAAGTGAAGACGGCAGGTGTGCTGG
ACACTCAGCCCTTGGCTGGACACTCGCTCAGGCCTCAGCCGGACACTCAGCCTTCAGCCGGACATGCAGG
CCTCGGCCAAACACTCACTCAGGCCTCAGACTCCCAGCGGTGCGGGCCTGGGTGTGGGCCGCCCCTCCCT
CCCTGGGACGTAGAGCCCGGCGTGACAGGGCTGCTGGTGTCTGCTCTCGGCCTGGCTGTGGGCGGGTGGC
CATCAGTCCAGGATGGTCTTGAAGTCTGAGGGCAGTGCCGGGTTGGCTGCGGCCTCCAGGGCAGTCAGCG
TCGTCCCCGGGAGCTTCCGACTCAGCTGCGTCTGGGCTGCGGGGCCAAAATCAGACTCCGTTCCAGAAGA
GGCCAGAGGTGGCATCCTCCAACCCTCCTAGGACGTGTGGGTGGCCGGGCAGGCAGGGCCTGCACCTCGT
GGCCCTGGCTGGTGGGAACCTCAGTGAAGGGACAGACACCCCTCCACCGGGGCGAGCAGACAGGCAGCCC
AGTGACGCTGGAGCGGCGGGGCGGGGAGAGAACTTGCTCAGGACCCCAGGAGCTCAGGGCAGCAGCCAGG
GAAGAGGCTGTGAGAGGACACAGGTCAGGGGTCAGAAGGCTCCCAAGCGTGGGGAGCCATCGCCCCTGAG
ATGGGAAGCAGGGGTTCAAGAAGTTGTGGACCCTGCCAGGCTCCGTGGCCTGGGGACACCAGCGTTTAAT
CACATAGGGCTGCCAGCGTGGCTCCAGGCCCCCAGGGTCAGGCCCGGGGGCGTCTGCACTTCAGCAGCAT
CTGAGGCTGCTCGCCCCACACAGGGCGTTCAAGGATGACCCCTGGGCAGGTGGGGCCCGCACTGGCCTCC
ACCCACACTTGCCTGTCCTGAGTGACCCCAGGAGTGGCACGTAGGTGACACGGTGTCGAGTCAGCTTGAG
CAGGAATGCTTGGTGGCACAGCCACTGCACGGCCTCGGAGGGCAGAGGGCCGGCGGCGCCCTTGGCCCCC
AGCGACATCCCTGGGGGAAAACAGAGGCTGAGGAGTCACAGGCCCAGCCCAGCTCCCCTCCCAGGAGACA
CCGGAAAGCTGCCCACACCCGACGGTCTGCGGGGTGGCTCCATCTCTGGCTGTCCCGACCCAAGCACCGC
AGGAGTCACGACAGAAATGTTTTCTTCGGCTTCTCCAGGTGAAATTTCCACAACACAGAAAGAACAGAAA
GTAGAAGCTGTTAAGCTCAGGACCGCAGGTTCGACATGGCTTGAATTTCAGACGGATCAGAAACCTCCCT
GATGCTGGACAAAGTGTCCAGGGGCAGAGGACGGTGACTGGGAAGCAGAGGACGGCGCGGGGCTCTGTCG
TGGTGATACGCGGCCTCTGCTCCTGAGAGGGGTGGGGTAGCCTGGGCCTGGCCTCCTCCTAAGCCCTTGG
CCTGGGTTTGCACAAGGGCCCTAAGTGCCATGGACGGGAGACAGCCCAATCCCACCACAGGGCAAACAGG
AGAGGCCAGGCCCCCCAAATCCCACCATGGGGCAAACAGGAGAGACCAGGCCCCCCAGCGCTTCCCCAGG
CAGAGCAAGGTGGGAAGGATGGCAGCTCCCAGACAGCTCCTGTCCCTTCCATCAGGTGCTCTGCTCACCC
CACGAGAGGGCGGGCAGACGAGCCTGACAGTGGTTGGGTTAAACCACTTCCTGATGCGAAAAGGGGTAAG
AACTTCCTAAGCCCAGATTCACTCAGTCTCCTGACACACTAACACCAGCAGGCAGGCACTGCTGCCACTG
AGGCCAGGCACCTGCACATACCTGCGTTCTTGGCTTTCAGGATGGAGTAGCAGAGGGAGGCCGTGTCAGA
GATGACGCGCAGGAAAAATGTGGGGTTCTTCCAAACTTGCTGATGAAATGGGAGCTGCAGCACACATGCG
TGAAACCTGAGAGGATGGCGGACAGCGTCAGAGGAAAGGCCTCCTAATCAGACGGTGCTCGTGGGTGTGG
GCATGGGCCCACCGGTGCCTGTGTGCGTGCATGAATGCACATGCATGGGTTTCCTCATGGGCACAGGTGC
ACACACACGGATGCATGCATGCATGTCTGTGTGTGTGCTTGTGTGTGCGAGTAGCTGCGTGTCTGTGTGT
GCACAGGTACACTGCGTTTCTGTGCACCATCTGTATGAACACGCATGTGGAGGCTGAAGCAGCTCCATCC
TGGATGCCAGCCCCCCATGCTGGCTTCTGATTAGCCCCTGTTCCGGGAAGGCCTCTAAGGTTTCCAGTTT
ATCCATTGTTCCTTGTGTACCAGCAGGTACTTATCATGAATCCTGCCCTTCGTCAGACAACCTTGATGTC
ATCGTATATCAACGTCCTGCGCATCCCTTCTGAGCCACCCGCCCCTGTGGTGCATAAACCCTGGGTCTGG
GGTGATGGTGTGAGGACCCATCATCTCATCTCACTGACACCGAGACACCGACTTGGCTTCTGTGTGTAGG
TTAAGTTCCTACTAAATGTTTCTTTCCAAGAAACTGCATTTGTCAGTCTTCTTTGTTGTTGTTGAGATGG
GCTCTCACTCTGTCACCCAGGCTGCAGTACAGTGGTGCAATCTCAGCTCACTGCAGCTTCCACCTCCTGG
GCTCAAGTGATCCTCCCACTTCAGCCTCCCAAGTATTGGAACTACAGGCGCACACCACCATGCTCAGCTA
ATTTTTGTTTTTATTTTTCATAGAGATGGGGTTCTACTATGTTGCTCAGGCTGGTCTTAAACTCCTGGGC
TCAAGGGATCCTCTCGCCTCGGCCTCCCAAAGTGCTGGGACTACAGGTGTGAGCCACCGCGCCAGCCCTG
TCAGCCTCCATCTTTGGCCTCTCAGCTTCCTGGGACTTTGGGGCAGGTGTGCACAGACCTGGCTACCATG
AAACAGCACATGTGCACATGTGCTCATATGTGCGTGTGATCAGAGCCCCCGTGTACCTGGTCTGACCCTC
TGCCTGAGCCCCCCGTGTACCTCATCTCACCCAGTGCCTGAGCCCCCCATGTACCTGGCCTCACCCACTG
CCTGAGCCCCCCGTGTACCTCATCTCACCCACTGCCTGAGCCCCCCATGTACCTGGTCTCACTGACTTCC
TGAGCCACTTCTGGAATGACCTGAGATCACACCAGTCAAGCCAGCACCCCGGTTTCAGCCTCTCAGTAAC
TCTGCTGAGGTGGGATGTCTTTTCCCCATTTAGCAACAACGGAAGCCAGGCCCAGAATGTTTTTAAACAA
ATAAATAAGCCTAAGGTCCCGGGGTTGCCACACGGCCACGCTCCTGACCCAGGAGGGAAACACCTAGCAT
GGGTGAGGGGCTCTCTTCCAAAGGGAGAAATAGCCACCTGCTAGAGGTCGGGGCGTCCACCCCAAGCCCG
TGTGGAGGCGCGGCCAGCACGGGCCAGGAAGGCCGAGCCCCAGCGGATTTGAATCAGACCCCGCCCCCAG
CGCCACGTGGACCACCACAGCCTCGCCCACTGCAGCCTGGCTGCCGTGAAATCGGGGCCCAGCTCTCCGT
TCTCCCACTCCTGCCTCGAGGGAAGGGGATTCCTGGGCCTTCCACGTGCCTGACTCTGTGTTTGGAAACG
GCCCGTGGCCCATCGCATCTCGGCCTCCTCAGGGCTACCCAATCAAGCGACTACCCAAGGGTCCCCACAT
GGGTGGGGAAACTCAGCCGCCCTGCCCTGAGCCCAGGCCCTCTACGGGAGCTCCTCGGAGCTAGAGACCC
TGGTGGGGAAATGAGGACAAGACTGAGCTGAATATGGGAGGAGCAGGTGGCAGGTCACATGGCCCTGGGA
GTTTCCCAGGAGTTTTCACCTGGGAAAACTCCTCTGACCTCATCATGGCCCAAGGAGGCCCCAAGCACGC
CAGCTGGACCCTGGGGTCAACCACAGTGTCAGACACCTCCAGTCCTCAGTGGCACCTGTATCCAGCACAC
CCCAAGGGTTTCCGGAAAGGAGTCAAGCAGCTTGCACGAGGGCCCAGGCACGCGTCAGGGAGATGCAAAC
GAGGGAAGATTTGAGGCAGAGAGAGAAGGCAGAGAGGAGGGCGGTCTGAGCCGGACGCACCCTGGAACTG
AGACAGCCTGGTCCCAAGCCTCTGGAGCTGGTGCAAAGGCGGTAACATGCAGCTGTGGCTCTGCCCTCCC
TGCCAGAGCATGAAGGCGCAAGCACTCGGGTTAAAAACCATTTTCATGGTACGACCTTGTAATGGAAAAC
TCTCCCGTGAGCCCTTGCTGGGTTTCCACGATAGACGACGACCTCATTTCACATCAAGTGTGCACGGTAA
TTCGCGCAGCCTCGGCCCTGGGTAACACAAATGCTCACACTCCTTCTCAGCCCTCATGGGGCGAGGGCTT
CGGCCTCCTGGCATTCAGCTCCCAGTGGCTCGGGAGGCCTGTTGAGGTGGAGGCCCGGGCCTGTGGTGCC
CGACTGCCCTTTGGTACAGCCCCGAGGCTTGTGCCACCACCTGCCCTGACTCCAGGCAGAAGCTGGCCCT
GTGGCCTCCACAGATTGGCCCTTCCCTCTGTGATAAAGTTGTCGATTCTTGGCAGGGGCACCCCCTGACC
AGCCAGGACAGGGAACGTTCCAGGAGCACAGCCATGCCCAGAGCACAGGTGCTGGCCGGGCTGTGTGGGG
AGCCACAGCTCTGCTGCACCTTCCCGGGGGTGGGGCCAGCGACCCTCACCTGCACCCACCTCGGCCCTCT
TTGCTGAGACCCCAAATCCTCCGGGCATCTGATCTCCCATCTACTGTTCAGACACCTTCCCAGCCTCCTC
TGCTAAGACTCCCCATAAACATCTCTTTACCCCATGCCCCTGCTGCCCTGGGATGGCCTCCATGACGTCC
CACGGCCAGTGCACAGGCACAGTGGGGACACCTGGGGCCACACCGGCTCCTACCACTACCCAGAGATGGA
GAACAGGTGCTTTGCACAGAGCCACGCGAACAGAACTGTGCACAGGCAGCAGCACCACTGAAAACGTAAG
ACATTCCTTGCCCCTAAAACCCAGGAGTTCCAAGGTGAAGCCCCGGGTCAGAGGTGAGCAGAGCGCGGAG
GGTCCCTGGAGGCTGGGCCTGCACCCCTTGGTGGCGGCTCACCTGTACGCCTGCAGCAGGAGGATCTTGT
AGATGTTGGTGCACACCGTCTGGAGGCTGTTCACCTAGAGTCGCCAAGAAAGAGTGAGAAACGGTAGAAA
CCTCTCTGGGATTTTAAGTTTTTACTTTTTGCTTTATCATCCATTCAGATGGAACAAGAAAGAGGAACAT
TTTGACAAGAAACTATCCCTCTTCCCAGTGAAATCCGGCCTGGCCCTCACCCGGCAGCTGCGAACCACCC
TGGGCGAGTCAAGACTCTGTGTCATCTGCCTGCCCCCGAGGCTCGGCCAAGACAGGAAGGAACCAGGAGA
GGGAGTGGACGCAAATGCCCACAGAGAGGGGAGGTGGACGCAGATGCCCACAGAGAGGGGGAGTGGACGC
GGATGCCCACAGGAGAGAGGGAGTGGAGTGGATGTAAATGCCCACAGGAGAGGGGGAGTGGACACAGACG
CCCACAGGAGAGAGGGAATGGAGTGGATGTAAATGCCCACAGGAGAGGGGGAGTGGACACGGACGCCCAC
AGGAGAGAGGGAGTGGATGCAGATGCCCACAGGAGAGGGAGTGGACGCGGATGCCCACAGGAGAGGGGGA
GTGGAGTGGATGCAGATGCACACAGGAGAGGGAGTGGACGTGGATGCCCACAGGAGATGGAGTGGATGCA
GATGCCCACAGGAGAGGGAGTGGACGCGGATGCCCACAGGAGAGGGAGTGGACGCAGATGCCCACAGGAG
AGGGAGTGGACATGGACGCCCACAGGAGAGAGGGAGCAGACGCAGATGCCCACAGGAGAGGGAGTGGATG
CGGACGCCCACAGGAGGGGGGAGTGGACACGGACGCCCACAGGAGAGAGGGAGCGGACGCAGATGCCCAC
AGGAGAGGGAGTGGACGCGGACGCCCACAGGAGGGGGGAGTGGACACGGACGCCCACAGGAGAGAGGGAG
CAGACGCAGATGCCCACAGGAGAGGGAGTGGACGCAGATGCCCACAGGAGAGGGAGTGGACATGGATGCC
CACAGGAGAGGGGGAGTGGACACGGATGCCCACAGGAGAGAGGGAGTGGACGCAGATGCCCACAGGAGAG
GGGGAGTGGACACGGACGCCCACAGGAGAGACGAGTGGATGCAGATGCCCACAGAAGAGGGAGTGGACGC
GGATGCCCACAGGAGAGGGGGAGTGGACACAGACGCCCACAGGAGAGAGGGAGTGGATGCAGATGCCCAC
AGGAGAGGGAGTGGACGCGGACGCCCACAGGAGGGGGGAGTGGACACGGACAACCACAGGAGAGAGGGAG
TGGACACAGATGCCCACAGGAGAGGGAGTGGATGCGGATGCCCACAGGAGAGGGGGTGTGGACGCCCACA
GGAGAGGGGGAGTGGACACAGAAGCCCACAGGAGAGGGAGTGGACGCGGATGCCCAGATGGGACAATGCC
CTCAGGGCTGCAGCTTCAGAGCCTCAGCCCACCAAGGCCTGGGACCCCGTCTCATCCTGTAAGGAGTGGC
ACTGGTGCTGAGGACCTAGCGGGGTGAACACGAGGACCCCTCAATACATGTTATGTGCACACATGCTACT
CACACTGCACACCCACACGCATGCACCTCACGTGAATGCCCACACGACTGTGCACGAACACACATGCATG
TCAGGTGTGCATTCGCATGTGCACACACTTGTGCCCTTGCACACCTGTGCACACACTGCCATGCCTTCAT
GTACACACATGCACACATGTATGTGCTCACGTGTATATGCGTACATGTGCACTCTTACGTGCAGCCAGTC
ACCATCAGCCTTGCAGGCACGCGCGCACACACACACACACATACTTGCGCACACACCTCCTGAACTCTGA
ACTCTGTGCTGACCATCAGCCTGCTCACCTGCAAATCCAGAAACAGGCTGTGACACTTCAGCCGCAAGAC
CCCAAAGAGTTTGCGACGCATGTTCCTCCCAGCCTTGAAGCCGCGGTTGAAGGTGAGACTGGCTCTGATG
GAGGTCCGGGCATAGCTGAGACACAGGGGGGAATGTCAGACACAGGTGCCTGCCCCACACCCAGCCCCCT
CCTGCAAAGCTTGCTCCAAAGAGCCTCCTGCCTTCCTCCCGCTTCCTTGTCCTGCCTGGGGCATGCGCTG
CAGCCCGAGGGGGCTGGGTGCTCACTCCATGGACTCCAAATGCTACATGCCATCCAGACTCTGCATGACC
AAACTCCACCAGGACCTGGCTAGTGATGTTGAGTGTATCCAAACCTCGCACGGCCGTGTTTGTGCACTCA
TCATCTGCCCTGATGAGATCTGCACATAACTCAGCCAAAAACACATAATAAACTGTGGAGCCCTGGCTCC
CGGGCGTCCCTCGAGTGAACACAGGTGTGACTCAGGTTTTTTGTGGGAGAACACTGAGTTGGGCGTGGGG
AATCTCACTGTGTTTGAATCTCAGGGATGGAAGAGCCAGGTGGCACCAGCTAAACAGGGCTCCAGTGAGT
GCACGTGGCACACATGGTGTCTCCAGAGGGGCAGGATGGAGGCATCCCACCGATGTCCTCCAGGGCCTCA
CCACCACTCACTGCCCATGTATGTCCATGTCCAAAGATGAACACACATGACATCCACGGCAGGCTCCTGG
GGTGTGTTCTTTTACATCCAGCTTTGAACACTGCTACATTGAAATAAACGTTTTGTGCCATTAAACATTC
TTCAAAAATTCTTTGAAAAATGTTTAATGGCAGAGCAAGTTTTGTGATGCATAATATCTCCTTAGCCCTG
TATTTGGGCAGGTTCGTGACTTGCTGTGGCAAGTCCCCCTGCCTGGAACACTGGAAATGGTAAATAAGAC
CCGTGATAATGTCTGGTCACTTCAGAAGTGGAATTACTGGGAAGACACAGGACATTGTGAGGACTTCCAT
GCAAACAAGCTGCTTTCCAGAAAAGTCTTTCCAGCTTGCCTCAACCTGATGCTGGCTCTTGGCAAGCCCA
GAAAAGGAGCCAGCATGAGGGATGGGGACAGGTCTCGCCATCAGTTTCACGTGCGTTTCTTTGAGGGATG
GGTCTCGCTGTCAGTTTCACATGCATTTCTTTGACGCTGCTGGTAGGACCTTCCCAAGTGTGCATCAGAC
GTCCATTTCTTCTTTCACAGCCATCCCCAACACGACCTTGGGCTCCGGCTCACCCTGAGCCTATGGGTCT
GACTTGTGTGGGGTCCTCGGGCAGAGCAAGGGCCCCGGAGCAGGAGGCCAGGCTGCAATCATGCATGCCC
TTTGCCAGCTGGGTGACCAAGGGCGGCTGCTCCCCTGGAGCCTTTCCTCCTCTACCTCTCAGGTGGTTAG
GAGAACAAAGTGAGAGGATGAATGTGCAGGACCTCACAGGGCGCCTTAAATAAATCACGTGCACAAACGC
TCCAGGGAATGGCCATTTTCACTGTGGCTCAGGCAAGCTGAGTTTCTCTGCAGTGAAAGCAATGCCCGTT
GCCTCACTGGTTTCATCCGCCTCCCTGTGTGTCCTTCCCCAACACCAAACCAGGGAACGTTCACCTCCCT
TCCCTTTGAGTCTTTTGTTTTATTTCTGTTGCTGGTGTTGTTTGCATGTGTCTCCTCTTCTACCTAGAAT
CTGCTCTGGTATATGCTGTAAAGACACAACTTATTTGCTTCCAGTCAGTTTTCTCAGAAAAAAAAATTAC
ACACACACTCTCTTTTCCATCAGCTGTGCCACATACCACATTAACACACGTTTCTGAGAGATAGGGCTTC
CGTTTTGTTCTATTGTTCTGTCCATCAGTTCTGACCACATTCTACCATCTGAGCTGTGGTTTGGGAGACT
AAAATCTGGACAAGAAAATTCCCATCTTACCACTTTTCCTTTTTCACTTTTCTTAATCATTTTGCCTGTT
TTCTTCTCCCAGATGCCCTTCAAGCCTCTGCTGTATACTTCAGACACAGAGGATGTGAGTTCACCCTGAG
TATGGCGAACCACTGCCTCCACTGCTGAGCTTTTAGAGCCACCTCTGCAAGCACACACTCTGACCAAGTG
GCCTTTGGGAGCACAGAATATTCTGGCATTGGACCCACATCTGATGACCTGATGCCCACCCATCCTGCAC
TAGCCTCTGTGGCTTTGCAATGTGTTTAGAGAGAACCCATTTTCCTGATTTGTTTGTCTGTCCTTTGTCC
TTCAATAACATTCACTGATGCTGTGCCAGAGGCTGGAACCAGGGGTGCCTGTCCTAAAAAATACATTTCA
TGGGGAGCAAAATAAGCAGTGGACAGTTCACAGCTGACTGGTATGGCCAGCACTGCAGAGGTGCCTGGGA
GAGGCGAAGAGGTGCTGGGAGCCCAGGAAATGTGGAAATCATGCAGACAAAGCCAGTGGAGGCCAGGACC
AGGTAAGGCTGTGAGAGGGAAGCAGGGACTGTGGGGAGCACAGGAGACCGGCATCCTTGTGGGGAGGGAG
CTGCAACAGGGACATGCTGGGCACCATGCACAAGGGTGTCTGCACCTGCCACTCCCCCATCATGAGGGCG
TCTGCACCTGCTGCTCCCCCATCACGAGGGTGTCCACACCTGCTGCTCCCCCATGAAGCAAACCCCAGGG
AGCATTCTGGAAAGAGGCAAAGTCCAGATCTGGACTGTTAACTCAGAACGACAGGACCCCAGTTTAAACC
TCTGGTTTAACAACCATCCACCACTTATTTCTCTTCCCATGAAGGTGTGCCTTTCAGAGGAAGGCACCCC
CAGTTCCGGCCTCTAGCACAGCACCAGTAAATATTATCGAAGGACAGAATAAAAAAACACCTGTCCACTA
TGGTTTTGGAATGCTGATACTTTTTTTTTTTTTTTTAAGATGAAGTCTCACTCTGTTGCCCAGGCTGGAG
TGCAGTGGTGTGATCTCGGCTCACTGCAACCTCTGCCTCCTGGGTTCAAATGATTCTCCTGCCTCAGCCT
CCCGCATAGCGGGGACTACAGGCGTGTGCCACCAGGCCAGGCTAATTTTTGTATTTTTTAAGTAGAAATG
GAATTTCACTATGTTGGTTAGGTTGGCCTCAAACTCCTGGCCTCAAGTGATCCACCCACCTCGGCCTCCC
AAAGTGCTGGGATTATAGGTGTGAGCCACCTTGCCCTGCCTGGAATGTTGATACTTTTTATTCATAAAAG
AAACAGCACAGATTTCTGCATCTGTGTCCATCTTCAATTCATTTGTGTCTGAGCCTGAGACGGGGCCTTG
AGCTCTCGGGCTCTGGGGAAACAAGACCCCAGAATTTTGTAGAGACCCCCCCCACACCATGGCCCTGTCC
CCTGATGGGTCACACGTGATCATGAACTCATGGCATCCTGTAGACTGTGGATGAGCCTTGGAGTGTGGGG
CTCACAGCGGAGAGACTCACGCCCAAAAGGGCCCTGAAGTCTCTGGGTTCGGAGAGACTCACGCCCAGCA
GGGCCCCAGGGTCTCGGGTTCAGAGGGACTCATGCCCAGCAGGGCCCCTGTGTTTCGGGTTTGGAGAGAC
TCACGCCCAGCAGGGCCCGGGCGTCTTGGGTTCGGATCCAGACTGCTTTCTGAAGACACCTCAGTGCACC
CAGGTCTGGTGCACCATTTCCTTTTACCAAAATAGCACAGAAAACTGCTCCCGTTGTGAGCACCCTCACT
CCCACAGAAAGATGCATTTCTGCTCAGCCCCAGATGGGACGAGGGGCACCCTGTGGCCTCTGACCCTTTG
GGATTGGCAGTCGCCTGCCCCACACGGAAGCAGAGGTGGACGCAACGGCCCTGCAGCAGCACCTGCCCCA
GCCGGGCACAGGCTCCACTTCCGGCCAGGTGCGCTCACCTGGAGTAGTCGCTCTGCACCTCCAGGGTCCG
GGTATCCAGCAGCAGGCCGCACCAGGGGAATAGGCCGTGGGCCGGCATCTGAACAAAAGCCGTGCCACCC
AGGGCCTCGTCTTCTACAGGGAAGTTCACCACTGTCTTCCGCAAGTTCACCACGCAGCCATACTCAGGGA
CACCTCGGACCAGGGTCCTAAGGCAGAGGGGCAATGTCAGCCCCAGGATGCGGGGCCGTCACCCAGGAGG
TAACCTGACACCCTTGTTAAATGCTTTGGAAAACCCCAGAGAAGTGGTGATTTGGAGCAGGGTGCTGGGC
CTGGCAGGAGCTCTGAGGAGCCTGGACCCAGCCCTGCTCCAGACTTCGGGGTGCTTTCCCTGTCTCCCGG
GCAGGACAGGTAGGTGAGCATGCAAGAACCTGGCCTGGACCCGGGACAGCCAGGACTCAGATGGGAGGTG
CAGCCCCAGTGGCCTCTGTGATGGTCCATCTCATGTGTCCCCATGGCAACACCACAATCCCGTTATAGAC
TCATCTGTGGTCCGGGGCAGACTAAAATCTGGACAAGAAATTGCCACCATCCCACCTTCTTTTAAGACGT
TTCTCAACGACTTTGCCTGTTTTCTCCTAGATGCCCTGAAGGCATCTGCTGTGCTTTAGACAAAGGGGAG
GGTTCTGAGTTCCTGCTCAGGCGCGGGACCTGGCTGGGCTGTGAGCTGGGCAACACCAGTCGTCAGCTTC
ACGTCAAGGAGGTTCCCTCGCCGAGTCATGAGCCTCGCTCACCCAGCTCAGGGAGCCCCCCTGTGCCCGG
TAGCCTCTGCTCTGGCCTGGGCATCCCCTTCCCTTCCTGCGGCCTCTGCTGTGGCCCCGGGCGTCCCCCT
GCCCTTCCTGTGGCCTGGCCCTGGGACCTCGGCCAGCTGCGCAGCTCCCCTGGTGCATTCCCAGCTCCCT
GTGGCCACCCCTTCCTGTTACATGGCTGCCGACTCATCAGAGACAGAGTTCTGCCCCCGGTGGGACCCCA
ACATACACTCTGAGCCACCTCCCTGGCCAGCACCCTCAGGAACTTGCCACACAGAAGCAGCGTTCCCCGT
CTGCTCTGTCCCCTCAGCAGCCTCAGGACTCCTGAGCCCTCAGTTGCTTGGGACCTGGGCTCCCCCCGAG
TGAATCTTAGTGGATTTAAATGTGCACAGCCTGCTGTGCTCCGGGCTGCGGCACAAGGAACGCCAGGCAT
ACCCCCAGCCCAGGGCGGCCCTGGAGGGTGGACCTGGAGGGTGGACTTGGAGGGCGGGTCCAAATGGGTT
TTCACAAACACAGCCCAGCAAAGCACCTGAAACCACCCCTGGCGGCCACATTTTCTGAGGGTTCCCTTTA
CAGCTTTCAAGGTTTCTCGTCCCTCGTCAAATCGCACTTTAAAACAAGCCCACCGGCTCTGTGGGGCGCC
CTTGAGGGGGACCACATTGGACAATCCCCTGTGCTGAGGCCAGGTCCCCTGTGCCTGATTTTAGTTTGAT
TCACAAAAATCAACTCTGAAACCCACTCCTAGCCATCTCCGTGGTTCAAGACAGCAGCACTCAGCAAATC
CAAATTCTCCCACCGATCCCAAACAACCCCACGCAGGAACGTGACCGCAGCGAACGCTGTGGGCCAGCTC
ACTCAGCAGCTCCTGCTCTCCGCAGGCTCAGGTGCACCCTGGGGAGGAGGCTGCCGCCTCGGCCCTGCAG
GCCCTGTGCACAGCTCCTGGGGGTCTCACTGGGGCCCCAGGAGCCGCCACTCTTGACTTTCCAAAGAGCA
GCAGGAGCCAGGTCACCGCCTGCACTCACCACGTGTGTAACCTGGGTGCGTCTCTGCAGGACCAGGGCCT
GCACGGTACCCACTCCCTCCCGAAGGTGCCCCTGCGCCCCCAGGCCTGGGTGCACGGCCAAGCGCCTCTG
CTCTTGCGGATCCAGCACCGGCAGAGAGAGAGGACTTGGCAGAGACAACGCTGCGGTGCCAGGGGCAGGA
CACGGGGGGCTCAACTGCAAAGCCCACAGGCTGTGGAGGTCCCCACAGACACACGGCACGGGCCTCACCT
GAGGAAGGTTTTCGCGTGGGTGAGGTGAGGTGTCACCAACAAGAAATCATCCACCAAACGCAGGAGCAGC
CTAAAATAAGGGAAAATACACAGCAAGGTTAACTTTACACTTTTTACGTAGTATCTGTCTACGAGGGACT
GAATGTCAAACAATTTACACAGCCATAAATAAAGTAACATTCTCCAAAGCGGTTAAATGAAAAACTTAAA
TTTCTTTCCAACAGACGAGCTCTCTACAGTTAACTGCTACAGCAATTCCTCATTCATTATAAGTACTCAG
TGTTTACCATCAGCTTGTGCAATTCTGTGCCAGCTGAAGACGAACGAAGGCCATCAGGCGCGGCCCCACT
TCTCAGACTCTTAGGGAAAAATAACTGAAGACGGTAAGAAAGCTGGGGCTGGGAACCTCGCCCCCTCTGA
GCCACGTGGTGCCCTTTACCAGCATGGCAGCTGTGGTCCTCAGCATGATCCGAGACCCAGATCCTATCCA
CAGGAAGCTGGGCATGGTGCACTGTGTGACCCTCAGGCCCAAGCCCAGCGCCCCATGACCATGGGCCAGA
GGTATCCTGTCCCAGAGGGCTGACCAGTGTGCCGCCAGCTCGAGGACACTTTCCTCCAAATCCCAGAGCA
AGTTGTGTGTACAAGAAATTTTTGTTTCTGTTACATAAACTTATTTCAATCTAGAACTTGAACCTTAATG
AAGAAGAACCTTGATCCACTGTACATGCTATAATTGGAGCTAGAGTTTCAAAAGATGCACAGGAAAAACC
CGGAGTCTTCGAGAGAAATGGCTGTGTGGCCTGCAGGCTTCCTGACGCATCCTTCACTAACTGTCTGCTT
GTTCAGTGATACTATTTTCATAAAAAAATAACTGCTGTCCACATCCTCTCCAGCACCAGAACACTTTTAC
ACTGTTGGTGGGAGTGTAAACTAGTTCAACCATTGTGGAAGACAGTGTGGTGATTCCTCAAGGATCTAGA
ACTAGAAATACCATTTGACCCAGCCATCCCATTACTGGGTATATACCCAAAGGATTATAAATCATGCTGC
TATAAAGACACATGCACACGTATGTTTATTGCGGCACTATTCACAGTAGCAAAGACTTGCAACCAACCCA
AATGTCCATCGATGATAGACTGGATTAAGAAAATGTGGCACATATACACCACGGAATACTATGCAGTCAT
AAAAAAGGATGAGTTCATGTCCTTTGTAGGGACATGGACGAAGCTGGAAACCATCACTCTGAGCAAACTA
TTGCAAGGAAAGAAAACCAAACACCACATGTTCTCACTCACAGGTGGGAACTGAACAATGAGAACACTTG
GACACAGGGTGGGGAACATCACACACCAGGGCCTGTCATGGGATGGGGGGAGTGGGGAGGGATAGCATTA
GGAGATATACCTAATGTAAATGATGAGTTAATGGGTGCAGCACACCAACATGGCACATGTATACATATGT
AACTAACCTGCACGTCGTGCACATGTACCCTAGAACTTAAAGTATTAAAAAAAAAAAAGTAACTGCTGTC
AATAAAAGCCAGCTGAGTTGAACCACATTAGGTTGGCACGATATTTAGGTGTGTGCGTCCTTGGGTGTAG
ACCCCATGCAAGTGGGATGGGCAATGGGCTGAAGAGGCGCCCAGTCCAGGCCACCTGTCGAGGGCCTGCT
GGGAGATGTGGGGCCTCAGGCTGCACCAGCCCCATCTCCCCAAGGACCCTAACGGAACCTGGGTGACGTG
ACAGAAGCTGGTGTGCTTCCTCGGTGTTGAATTCACATGCTCATCATGCAGGGCAGCGGCCCTCCCGCCT
GCTGAGCCCTGAGGCCTCTGGACATGGCCGCTGGACAGAGCCTGCGTGGAGCCCGCAGTCCTCAGGCTGT
GCAACCCCTCCCGTGCGGCTTCATACCAAGAAGGGGCTGCAACCTTGTCTGGTTCCTCAAGACAGAGCAG
TCATGGTCTCCAGAGCACCAGGAATATTAACACTGAATGCATCAAAAGCAAATCAACCCCCACCCAAGCC
CCCCTGGGGAAGAGGAGGCCTCACCCGTCCCGCCGAATCCCCGCAAACAGCTTGTTCTCCATGTCGCCGT
AGCACAGGCTGCAGAGCAGCGTGGAGAGGATGGAGCCCTGCGGGATCCCCTGGCACTGGACGTAGGACCT
GGGGCGGGAAGACACAGGTGAGAGACGGGCAGGGCATGTGCTGGACATGCGTACACTCAAACCGAGCCAC
ACACAGACACAGAACCTCATACACACAAACGACACGTCTACCATTCAGCCGGCAAACACCTCAGAAACAT
ACCAGATGAGACCTCTGAACAAACAATCCCTGCTCCCCACTCTCACCATGCACTGGGGCGGCTGAAACAG
ATCCAGCCACAGGTGTGACCACATCCTTGCTCTGAATCATCAAGGTTTTCTTTCATTAAGGTTTCTTAAA
TCTTAGAGTTTATTCACAGAACCAGACACTTGACCCGGAATGAATGCTTAACCGGACTCCTTTTTTTTTT
TTCAAGGAATTTGTCCACGGTGAAAGACTCATGACCCTACATGTAGCCGCTGCGCGCCAACGGATACAAC
CTTGCCCCTAGTTTCAGCATGACCAACGAGAAGCAGAAACTCTCCAAACAAGGATGCCAAGGGTGCGTTT
TCAGACAAACAGTGAGAGCAGAATAGCCCCGTGGAACCTAAAGGTGCACACAGAAGGCATGGCTGCCACG
CGACCCTCAGCCATCCCCAGAGCCCACAGGACGCCACTCCTGTTGCTAAGAGACGCTTGCAGCCTACTGC
AAAAACAAGACCTGTTATTTTCGGGAAGCGCTATAGGTGGTCACCTTAAAAAGAGGCTTTCCGGCTGGGC
GTGATGGCTCACACCTGTAATCCCAGCACTTTGGGAGGCCGAGGTGGGTGGATCACCTGAGGTCAGGAGT
TCGAGACCAGCCTGGCCAACATGGCAAAAACCCCTCTCTACTAAAAATACAAAAATTAGCCAGGCGCAGG
GGGTGGGTGCCTGTAATCTCAGCTGCTCGGGAGGCTGAGGCAGGAGAAATGCTGGAACCCGGGAGGCGGA
GGTTGCAGTGAGTTGAGATCGCGCCACTGCACTCAAGCCCAGGCAGACAACAGTGACGTTCCGTCTCAAA
AAAAAAAAAAGAAAGAAAAGAAAAGAGGCTTTCCTTGCTGGTGCAGATATCACAGTGATGGGCAAGAGGA
CTGCACTTTTTGCACAGAAGCACACGCACCAACTCTAGGAGTCCGGCCAGCCCAGCGAGTCAACGCAAGC
AGATACGCCCCTGTGAGCACATGGGATGGGAAACTCTCTCTGTTCTTAGTTTTTGGGGCAACAGGTTTTG
AAGACGTTTTTATTCAGAGGCCAAACTGGACCACGATGGGGACTAGAGCTTCGGGCCTGTCCGTGTCCTA
GGGACAGGACAGACACAGTCACCTCCTGTCTGTCAGGGCATGAGGACGCAGTCATCACCTCACATTCCCC
AAAGCCCTGCCACACGTGGACGGTACGTGACTTGATCCATCTTAATAAAATTCACGACCACGAAGGAGGC
CCGTGGTGGCTTCTCTGGGGAGGTGACTTTGTCAGCGAATTCTGTGGGCCTGGGGGCCGCTTACACACAT
GTGCACACGTGTCCCTCGGCCAAAATTCACTCTGCTGCCATGTGCAATTTGTGTTTTTCCAGAACGTGTG
TACTACTTAATATTTCTAATTATACTTTAATAAATATTATAATTGCTGATACCATTAGTGATTACTTATA
ATGCAATAATTAATAGTTATATTTTTAAATAAAAGCTTCCGAAGCTGTGCACAGTCCTTTATCCGCTGGA
GACGATCCCAGAGAGAGGCCTCCACGTTCCACCTGACTGCGGATGACCTTGCTGATGACCTTGAGTGTGC
ACGAATTTCCTCCGTGCTACCACTCTCCCCAGGCACACACAGGGTCGCAGGCAGATGCCTGCCGGGAGGT
GTGTGGTTTTACTTAAAATCCAGAGGACGTGATGTGGCACCAGGCACTGTGGCTCTACCACCGTGAGTGT
GGCTCACCCAGTGGCTGTGTGACGGCAGCTCTCCCAGGCCGCCTGCCCCATGGCCACCACAGGCCCCCCG
AGAGGAGCAAACTACACGGTCAACCCCGCACTTTCCAGATGGGAAATCTAGTCACAGAGAGAAGAGCCCG
CGCCCTCGCGGGGGTCACACGACAGGGACAGGAATGAGAATCGGATAAAATCCTTTTGTATCGGGAGAGA
GAGATACAAGCGTGTGAGAGCCGGGTGTCCAGCGTCAGTAGTAACTTGGAGCTGACAAGCTGCAGGCTCA
AACGCTCGGCGCACACCTGACCCAGACACACCCCCCGCCCCTCGTCCTCCACGCAGGAGCAACTCCACAC
CCCGCTTGCCATTTCCAGGCCTCGTGTGGCACCTGCTCCGCTCCGGCTGCCGCAAGCCGAGCCATGTTTC
CGGGGCCTCGGGAGCCTGCAGCCCAGGAGCCGGAGGGGGCGGGGGCCAGAAAAGGAGACTCTGGTGGCCC
CGGGCAGAAGGGCAGTGGGGAAGGGGCAGGAGAGAGGTGAGCAGAAGCCCTGCCAGCCCGCCCAGCCACC
CGCAGGGCAATGGCACCTGGCCACCTGACTCACTTGCCCCTGATGCGCACGGCGTGGTGGCACATGAAGC
GTAGGAAGACGTCGAAGAGGCCACTGCTGGCCTCATTCAGGGAGGAGCTCTGCGAAAGCAGACGGGAGAC
ACATGGGAGTGAGCCGGTGGGTGCTGAGACAGGCAGGACCACGTGGCCAAGACCCTCCGTCCCTTTTGGG
GTCAGTGTTTGTGATGAAGTGCGGGGCTGGGCTGGAATGCAGGGCCATCGTGGGCTGGCCGGGCCGAGTC
TCTGCAGACACACATGGGCTTAGGCAGAGTGTGTGACACAGAATGTCTCCTCTGGGCCACCTGTGGGTCC
AGCTGGGCTCACACCCACACAGCCCACCGTGGCCCGGATGGCATATGTGATCCAGGAGTTGCTGCCCAGC
TGCCGGGCACAGGGTCTGGGTCCCAGCAGCCCAGGCCACCTCCACCCCCACCCTGGGAGCCAAGGAAATT
CGCCCAGAGGTCTCTGAGCCTCATGCGGTGGACACGACTGTCCCCTAGAGCCGAGCAAGTGCTAACAGGC
ATCTGCAAAGAGCCACAGGGCCACGTGGACAGACCACATCTGCAAAGGGCCACAGGGCCACGTGGACAGA
CCCAGCACTGAGAGGCCCGCTCAGCGGGGCGTGGCTCAAACACGGCCCGTCCTCCTAAGAAGGGGGACAC
GTTTCCTTTGGCCTCAGACCCAGCACTGAGGGGCCAGCTGGGCAGGACACGGCTCAAACATGGCCTGCCC
TCCTAAAGGAGGGGGACACCTTTCCTTTGGCCTCAAGATCAAAACTGGCAGAGAAGACATTTAGCAAATC
ATGAACAAAGGCACTGCGGAACTGGAGAGAGGCCGCGCAGTCAAACGTGAGCAGGTGCCTGAATGCAGCA
GCTGTCGCAGCCTGGCATGGCCCAGCTCAGATTTCGCCAAGGCACACAGCTCATCATGCCCCCATCACAG
CTCATTCCCCCCACTGCCCCCCAGGGCCAACAGTCTGTCCGGTCATGAGCCCAGTGATTGCCCAGGGGAG
GACCCACTGCTGGGAGTCCGTGCCCAACCCTGCAGGGCAGTGCCCAGACCTGCTCGATGACGACGGCATC
CCTCAGCGGGCTGGTCTCCTGCAGGTGAGCCACGAACTGTCGCATGTACGGCTGGAGGTCTGTCAAGGTA
GAGACCTGCCGGCAGAGGAGAGGGCATGAGCCACAAATGTGGCCTGCCCCGGCCAGAGCTGGGCACTTGT
TTCTTCCGATCAGGACGTGTGGACCTGCGGCCAAGCCCGATGGCGGGATGAAGCCCAGAGAGCGCCTGGG
AAGCTTCTGTTTGGGAAACGGGGGCCGGGGGGCCGAGGACGCAAAGTAGCTACAGACACACCTGGGACTC
CACCTGCAGCTACCACACATCAGACCCCTGTGACCGATCACCATCCACAGTCACCACATCAGACCCCACG
ACCGCCATCCACAGTCACCACATCAGACCCTACGACCGCCATCCACAGTCACCACATCAGACCCCACGAC
CGCCATCCACAGTCACCACACATCAGACCCCACGACCGCCATCCACAGTCACCACACATCAGACCCCACG
ACCGCCATCCACAGTCACCACACATCAGACCCCACGACCGCCATCCACAGTCACCACACATCAGACCCCA
CGACCGCCATCCACAGTCACCACATCAGACCCCACGACCGCCATCCACAGTCACCACACATCAGACCCCA
CGACCGCCATCCACAGTCACCACATCAGACCCCACGACCGCCATCCACAGTCACCACACATCAGACCCCA
CGACCGCCATCCACAGTCACCACACATCAGACCCCTGTGACCGATCGCCATCCAGTCACCACACATCAGA
CCCCCGGGACCAACCGCCATCCACAGTCACCACACATCAGACCCCACGACCGCCATCCACAGTCACCACA
CATCAGACCCCTGTGACCGATCACCATCCACAGTCACCACACATCAGACCCCACAACCGCCATCCACAGT
CACCACACATCAGACCCCACGACCGCCATCCACAGTCACCACATCAGACCCCACGACCGCCATCCACAGT
CACCACACATCAGACCCCACGACCGCCATCCACAGTCACCACACATCAGACCCCACGACCGCCATCCACA
GTCACCACACATCAGACCCCACGACCGCCATCCACAGTCACCACATCAGACCCCACGACCGCCATCCACA
GTCACCACACATCAGACCCCACGACCGCCATCCACAGTCACCACATCAGACCCCACGACCGCCATCCACA
GTCACCACACATCAGACCCCACGACCGCCATCCACAGTCACCACACATCAGACCCCTGTGACCGATCGCC
ATCCACAGTCACCACACATCAGACCCCCGGGACCAACCGCCATCCACAGTCACCACACATCAGACCCCAC
GACCGCCATCCACAGTCACCACATCAGACCCCACGACCGCCATCCACAGTCACCACATCAGACCCCACGA
CCGCCATCCACAGTCACCACACATCAGACCCCCGGGACCAACCGCCATCCACAGTCACCACACATCAGAC
CCCACGACCGCCATCCACAGTCACCACATCAGACCCCACGACCGCCATCCACAGTCACCACATCAGACCC
CACGACCGCCATCCACAGTCACCACACATCAGACCCCTGTGACCAACCGCCATCCACAGTCACCACACAT
CAGACCCCCGTGACCGACTGCCATCCACAGTCACGTGGCACAAGTGGCACTCGAGCTCCCGGGCCTCTCC
AGCCCAGTGCTGGAGGGATTGCAGGGATGCAGGTGCAGCCACAGCACAGGCAGGAGAAGAGTCTGAAGAC
GCGGGAGAGAGACCGGCACCCCCACCTCCTATTCTGCAGACTCCCCCAGGACGCTTGTCATTTACTACGG
GACCTGCTAAGCCCCTGCGTCCCCAAGACAGGATGTGAGCAGGCACGTGACACACACTAACACGGACACA
GGAGGCCTCGAGCTTGTGAGGCATCAAAAGACGCGCACGGTGACTCTGTGCTTCAGCATGTTCCCCAGCC
CCCAGGAGCTGGCGGCAGGGCCGTGGGCTAAAACCACATCGAGTACGATTCAACCCTGAGAACCAACCTG
GAAGGCAGTAACAGGAAGGTACATGGGGCCTGCACCCTTCCCAACCCAGGAGCAGGCAACACGCCCACAA
ATAGCCCATGGGTCTGAGGTCGGCGGAAAGCATCACAGAAATCCGTAATTATTCTGGACTCAACACAGAA
AAGCCAATATATCAACACTGACGAGAGGCTGCTGAAGCAGGTCTTTAGCACAGGGTCCCCAACCATTGTG
GTACCAGGGACTGGTTTCGTGGAAGACGATTTTTCCACAGGACAGCAGTGGGGAAGGGGATGGTTTTGGG
AGCAAACGGTTCCACCTCAGATCATCAGGCATTAGATTCCCATAAGGAGCACAGAATCTAGACCCCTCTC
ACGCACAGTTCTCAGTAGGGTGTGTGCGCCTCTGAGCACCGCATGCCACTGCTGATCTGAGAGGGGCGGG
GCTCAGGCGGGAACGCTGGCTCCCCACACCCCACCTAGCCTCCCGCTGTGCGCCGGGTTCCTAACAGGCC
CCAGACCGGTGCCACTCCACAGCCAGGGGCCTCGGGATCCCTGCTTTAGAGGGAAAACGGCAACTTCAGA
TGCTTGTTTAGAAAAGAAAGTTCAAACATCCATAATCGAAACTTTTCCTTCAAGGAGCCGGAAAAACAAC
AATAAACAAAGCCTAAAGGAAATGGAAGGAGGCCATCGATAAACAGCAGACACCAATTACGCAGGAAACA
GCCGGGAAATCAGCACACGTGAAACTCTTCTGTGAAGAGAGTCATGAAATGGAAAGACCCCTAGCGAGAC
CTGGAGAAGGAAAACGGAGGTTGTCAGCACCAAGGCTGCAGGCAGCTATCGCTGCAGATCTCACGGAAGC
TGCAGGAAGCGAGTCTCGGCCGGGCGCGGCGGTTCACACCTGTCATCCCAGCACTTTGGGAGGCCGAGGT
GGGAGGATCACCTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAACATGGAGAAACCTCGTCTCTACTAAA
ATTACAAAAATTAGTCAGCATGGTGGTGGGCGCCTATAATTCCAGCTACTTGGGAGGCTGAGGCAAGAGA
ATTGCTTGAACTCAGGAAGCACAGGTTGCAGTGAGCCAAGATCACGCCAAACCACTCCAGCCTGGGCAAA
AAAGAGCGAGACTCTGTTATCAAAAAAAAAAAAAAAGAAAGAAAAAAAGAAAGAAAGCAAGCCTCCAACT
CGCAGGGGAATTCCAAGGACGGAGCGTAGCCAGGGCCACATCCAGGCCAATGAACACAAGGAGGCCTGGA
AGCCCTGCCCACCGGCCACACACCACAGCAGGCACCACACGACCCCAGAGTGGAAGAAACAGAACAGGGA
GCCCAGGGGAGGCCTCCACACCCCTGACTTACTATAAACCCGACCATAGTTCAAAGGAAGATATGGTCTC
CTCAATAAAGCTGTTGGAGCACCTGCAGACCCACTACAGGAAGAAAGCTCGCCTTGAACTCTGTGTTACC
CCACTCATAAAAACCAATCCCACAGATCCCCACCTATCCCACACATGAAAACCAATCCCACAGATCTCCA
CCTACCCCACACATGAAAACCAACTCCACAGATCCCCACCTACCCCACACATGAAAACCAATCCCACAGA
TCCCCACCTACCCCACACATGAAAACCAATCCCACAGATCCCCACCTACCCCACACATGAAAACCAATCC
CACAGATCTCCACCTACCCTACACATGAAAACCAACTCCACAGATCCCCACCTACCCCCACACATAAAAA
CCAACTCCACAGATCCCCACCTACCCCACACATGAAAACCAATCCCACAGATCCCCACCTACCCCACACA
TGAAAACCAATCCCACAGATCCCCACCTACCCCACACATGAAAACCAATCCCACAGATCCCCACCTACCC
CACGGATGAAAACCAATTCACAGATCCCCACCTACCCCACACATAAAAACCAATCCCACAGGTCCCCACC
TACCCCACACATAGAAACCAATCCCACAGATCCCCACCTACCCCACGGATGAAAACCAATTCACAGATCT
CCACCTACACCACACATGAAAACCAACTCCACAGATCCCCACCTATCCCACACATGAAAACCAATCCCAC
AGATCCCCACCTACCCCACGGATGAAAACCAATTCACAGATCCCCACCTACCCCACGCATAAAAACCAAT
CCCACAGATCCCCACCTACCCCACGGATGAAAACCAATTCACATATCCCCACCTACCCCACACATAAAAA
CCAATCCCACAGATCCCCACCTACCCCACACAAGAAAACCAATCCCACAGATCCCCACCTACCCCGCACA
TGAAAACCAATCCCACCTACCCCACACATAAAAACCAATCCCACAGATCCCCACCTACCCCACGGATGAA
AACCAATTCACAGATCTCCACCTACACCACACATGAAAACCAATCCCACAGATCCCCACCTACCCCACAC
ATGAAAACCAATTCCACCAATCCCCACCCAGGTTTGCAAGCTGACACAGTAAAGACTGTTCTAAAAGGAG
GCGCAGAAGCAACGTCACCACAACCTCAATACCTTGAGTTCCTGCAGAGAACACAAACAGCTTTAGCCAC
AAACAGCTGATAAAGTGGACTGCGTTACTGGACTGTGTTAGTGGACTGCGATAGAAGTACAATCTTCCAG
TCCTCAAAAGGCTTGACTTGAGAGCACAAAAGCAAGACACACACGGCACAGAGATTCACAGTGCACGCAT
GTGATGCCACACTTGCAGCAGAACACACAAAGAGCTCCTGCAAGCCGATGATGGCAGGCAGGCGCCCCAT
ACAGAGCGGGGCAGGACGGACAGCCACCTCCCGCAAGAGCCCCGGGGCGGCCAGCACGGGAACACTGTGG
GCACGTGGGCATCAAGAGAGCCCCCTGCACAATCCCACGAGGCGGCTTCGACACCTTCAGGCCAGCGGCC
ACCGGAGGCATCGCCCTCACAAGCAGCCAGCCGGGGTGTCACTGTCACCCCCCTGGAAACTCCCACAACA
TCCCTAAAGCACGTCTGTGACCCAGCAACCCCACCCCTGGAATTCACCCAGAGGCGAGGGCCTCTGACCC
CTGGGACACTCCCAGAACCCAGCAGGCTCACAGCAGGCGCAGCCGTGCAGTCCGCACCCAGGAGCCTCCA
CAGCAGCGGGAAGGATACATCCACGTGGCGAGTTCCACAACGGATGCCATTCATGGACAGAACGCACAGC
TGAGGCGTTCAGCATAGCTGAGGCTCGAACCCCAAAACCCACCTCCTGCCTGATCTCACTCACATGGAGA
CCGGGAGAGGGAGACCATGGAGGTCGAGGTCGGAACGAGGGTCACGGTGGGGGCGGTAGCTTCCGCTGCA
GCGGGGATGTGGGGGGGGGTCTCCTGGGCTCTGGTGACTTTCTACACCCGGGCACAGGTGGGCGGTGGGG
ACGGGGGGGTCTCCTGGGCTCTAGTGACTTTCTACACCTGGGCACAGGTGGTGGCCATCAGCTTTCCATG
AGGGTAAAATTCTGCTGAGATTTGCAAGTAGCTGCGATAGCTCAAGAAGTCAGAGAAAGAGGTCCTTGTG
GGTTTCCACATGTGCCTCTCCCCAGACCGAAGCTCCAGGGATACTTCTTCACCTCTGCACCCCGGCCTGG
CACGACTTTGAGGGCTTACCCCTCCAGCGTGCTCATGACCACTGGGTGGGAACCCAAGCCCAGGGCCCCT
TTCACCCCTGCCGAGCCCCAAGGCCCCCGGCCGCTCTGGGAGGAGTGTGTCCCGGGGAGCGAGGCCTGAA
TCAGCCTTCCTATATCTCATGGAGCCGGCATAGGCCAGACTGGGGTCCTGGGGGTGCCAGGGGTCCAGGA
AGGTACCACCAGCATCCCTACTCTCCTCTCAAACCTGGCTTACAGTCTCCAAGGCCCAGCCCTGTGACAG
GACAGGGGCACCCATGCTAGAAGTGAGGACCCTGAATGTGGAGCTCCCCAAACCAGCACCCGAGAGCGTG
AGGACAATGGTGCGGACCATGCCTGGAGGAGGAAGGAGTAAGGCCAAGGGGCCACACACACCCATGCCAT
AGACACGCATATGTCACGGACACATGCACACACACACACCACAAATAGGCACATCACAGACATGCAGCAC
ACAGCATGAACATGCACGTGTCACAGACACACACACATGCACACCACAGGCACACACACCATGGACACAC
ACGTGCCACACACACACACACCACAAATATGCACGCCACAGATACATGCACCACGACACACACGTGCCAC
ACACGCATATCACAGATGTGTAAATCATGGAAGTACCTCCACCACAGAAACGCATCACAGACACGACTGC
ATTCTAGACACATTCATATCCCAGAGACACACATCCTGGACACGACTATCACACGTGAACCTTACGTGGC
TCTTGAAGGCCTTGCGGACGTGCCCATGGGCGGCCTTCTGGACCACGGCATACCGACGCACGCAGTACGT
GTTCTGGGGTTTGATGATGCTGGCGATGACCTCCGTGAGCCTGTCCTGGGGGATGGTGTCGTACGCGCCC
GTCACATCCACCTGTGTGAGTGGAGGCGAGGAGACTGACAGTGGCCACGCAGAAACTCAGACATCACCTC
TGCCCTCAGGGCCTGGCCTGGCGGTGTCCCCCACTCTCTCTCTGACCCCCACCACTCCAGACCCCAAGGG
CAGGGCGGGCTGTGTCCCCTCTCTGAGCCTCAGGACAGGAGACCCCTGGCTCAGGACTGGGGTGCAAGGC
ACCGGGGCCTGGTGGCTGAGCCGTTGCGGTTCCTTCTCTGACGGAAACTGGAATCCAGTGGGACCCTCCT
TGGGAATAGGAGCCCGGGCAGTCAGGGTGCACAGTCGGCCCCATGTGCTGCAGGAAAGGCTGAAGGCCTC
CACCCTAGGTGCCAGGTGTGTCCTCAACAGTGACAGGGTCACCTGCACTCCCTGCGGCCCACCCAGGAGT
ACCTCCTCCACCCAACATGAGGTGCCAATCAGGCAGCCACTCCCAAGGTCCAGCAGGGCTGCTCACGGGG
GTCCCCGGCACCCACCTTGACAAAGTACAGCTCAGGCGGCGGGTCCTGGGCCCGCACACGCAGCACGAAG
GTGCGCCAGGCCCTGTGGATATCGTCCAGGCCCAGCACAGAGGCGCCCAGGAGGCCGGGGCGCCGCGCCC
GCTCGTAGTTGAGCACGCTGAACAGTGCCTTCACCCTCGAGGTGAGACGCTCGGCCTGGCGGGGACAGCA
TGGGAGACAGTCAGGAAAGTGGATCCGGCCAAGTGCCCACCCCACCATAGGGACCCAGGGGAGAAGCAGC
CCCTCCCCAGTGTCCCCAGCCACCCAGACCCGGGACCTAGAACCCCTCCCAGCTTCCTCAGACCCTGTTT
GAAACGGGTTCCTGGCCGCATGTGTGTTGCACACGGGATCCTCATGCCACACCTCTGTCCACCTCACCCC
ACACTCTCCTCAGATGACGGGGTCACCGCAGCCACCGCAGCCACAGGGGTGGGGTGCAGGAGCCGTGGGG
CAAGGTCCAGGATCCTCAGAGCCCGGTGGGCTCCTGGCAGTCGTGGCCTGGTCCCCGGGCCCCGTAAGCG
GAAGCGCACGGAGGCTGCGCACCACAGCAGGACACGGATCCAGGACCTCGGGCCGTGCTGCATCCAGGCC
CTGGCCCGGCTGCTTCTTGTGGTCCTCAGAGCCTGTCCCTGCCCCAGGAGCTCCCCCTACACCCCCACGC
TGCTTTTCTGGAGGCACCGGCACCTCGGCCACCTCACTGTGCGCACAAATGGGTTGGCGCCGTGCCATGG
CCCTGGCTGTGTCCCGTGGCCCCTCCTCCGGGCCCTTCATCTAAGCTGATACCAAATGTGGGGCTCAAAC
GCACTTCTGTTTAAAAAGGAAGTTAAACCAAAGCACAGCCACCCTCTTTTCTCTGCGGAACGTTCTGGCT
CCCACGACGTAGTCCATGTTCACAATCGGCCGCAGCCCGTCAGGCTTGGGGATGAAGCGGAGTCTGGACG
TCAGCAGGGCGGGCCTGGCTTCCCGATGCTGCCTGACCTCTGCTTCCGACAGCTCCCGCAGCTGCACCCT
CTTCAAGTGCTGTCTGCAATAGAGAGCCCCTCAGGAGGCTTGCTCAGCCAGACAACAGACTAGGGGGAAG
CTCACGGGAAGCCACAAGCCCCCACCGACTCAGTGAGGGCTCAGGGCACCCACGGCAGCACACGCTGAAG
GCCATGCCCGGGGCCACGTCCACCCATGCCAGCCAGACGCCTCTGAGAGCCCCTCTACTTGCAGGGCACC
TGGACACCTGGTCCTATAGTCAACCCTGGGGACGCCCAGTCCGGCGGTCAACCCCCAGGGTGACTGTCCC
ACCATCAGCACCAGGGAGCCTGGTCCCAGGCTGCATCTGGGGCCACGTGAACCCATGCCCCTCCACACAG
GATGCCTGTCCCTCTGGTACAGCCACTGGGGTAGCCCAAGGCTGGCCCCAGGCAGGACCCCCAGGTAGAA
AGAGCCACATCCCTTCAGATGGAGAGGGCGGGAGAGGCTGCTCAGGGCAGCTCAGCCAAGGAGCAGAATC
AGCTCTCATGAGCCCACCAGTCTCCTGACACCTCTGCCCTTTGGCCTTTTCCCCCAAAACCACCCATGGG
GGCACGGGGGCTGGAGCGGCCACACCTGGACCTGGGCATCTGTGGCTGACAGCCTGGCACTCCGTGGACA
CTGGGGCCGCGGGTGCTCCGGAGCTGGTGCCCTGACCGCAGGCCGCAGGCCCAGCAGAGTAGAAAAGGCA
CGGTACCCTGTCCAGGGAGGAGGGGCCTCCAAGGCCCCCCAGGCAGAACAACAGTCCCAGTAGTGACAAG
GAGCATCTTGGGGACCACCACGTCTGTCTGCTCCTTCCGGTCACCCCAATTAAATTCTTTCCAAAATACT
GGTCAAATGACCATGTTGGGTCGCACACCATTAAATACGTGTAAAGTCTAAGTAAGGTGCATTGTGTATT
AACTTGTTCCCACAGGGAAAGCCCTGACCCTCCCCCAGATGCAAGGAAATGGCCCCAGCACCACGTCGGG
GTCCCCAGCCCAGAGGCTGTGTTACCTCTGACGAGGTCTGCTGCCAGCTCCCTCTGCAGACATCCTGATT
TGGGGCATGGGGTGTCACAAGGCCCCCCAGGGACTCGAGTGTGCAGGGGAGCTGGGGAAGCCCTGATCTT
CTGACTAAAGCCCTCCACAGTCAGCCTGGGCGGGACACGGAGAAGCTAATACCATGGCCTGGGCTCAGCC
AGGCTGGCATCTCCCAGACCAGCGCTCCCGTCCCTCACTGATGCAAATCCAGCTTGAATCTGTCACAATC
TCACACTCTCATCAGCCGAACATTGCAGACAAAATCTCACAGCCATTCAAATGCAGCCACCTAGAAGTTA
GCTCATGGTGGAACTCTCCTATCCCCAGGTGCTCCCTGCACAGGTGCTCCCTGCAGTGAGTCGCCAAGTG
GGTGGGATTTTATCCTCTCATGACCTAAATCCAATAGATTGAAGATTCATACAGAACAGCATGAATTAAA
AGAGAATCGGGGGCTGGGCACGGTGGCTTAGCCTGTAAACCCAGCACTTTGGGAGGCCAAGGTGGGTGGA
TCACCTGAGGTCATGAGTTCGAGACCAGCCTGGCCAACATGGTGAAACCCCGTCTCTCCTAAAAGTACAA
AAATTAGCCAGGCGTGGTGGCAGGTGCCTGTAATCCCAGCTACTTAGGAGGCTGAGGCTGGTGAATCGCT
TAAACCCAGGAGGTGGAGGTTGCAGTGAGCCAAGATTATGCCACTGCACTCCAGCCTGGGCAACAGAGTG
AGACTCCATCTCAAAAAAGAAAAAAAAAAGAGAGAGAGAATCAGACCCACATCCCAGGGAAAGGCAAGGA
GGCTAGTGGTAGTGTTTCCATCTAATTTAAATCCCTTCTGCTTTACAAACCCTAGAGACCACTTGGCACA
AACTCCTGATTTTACAAGTAAGAGAACGTGAGCTCCAGGCAGTCAGAGCCTTGCACAGAATCCACTTGGA
CCAGGCCTGTGACGGGGCCCCTGGCTCCCAGCCCAGAGCTGCACAGCCAGGGAAGCACAGGCAAGTGGAG
ACAGGCGCATGCTGAGGCCGGGCTGGTGTTCCAGGACTTCGAGAAGCAGAGGCCTGGCGTGGGGATACAG
TACCTGATTCCAATGCTTTGCAACTTGCTCCAGACACTCTTCCGGTAGAAAAAGAGCCTGTTCTTTTGAA
ACGTGGTCTCCGTGACATAAAAGAAAGACCTGAGCAGCTCGACGACGTACACACTCATCAGCCAGTGCAG
GAACTTGGCCAGGATCTCCTCACGCAGACGGTGCTCTGCGGCCGGAACACAGCCAACCCCTTAAACGAGA
AGGACATGCCACATCCAGATCACCGAGGGCCTGGTGACCTCACCCCGGACCTGCACCATCCGGACACCGC
ACATCCAGCTCACCAAGGGCCTGGCGACCTCACCCCAGACCTGCACCATCCGGACACGGCACATCCAGCC
CACCAAGGGCCTGGCGACCTCACCCTGGACCTGCACCATTCGGACACGGGGACACCGCATATCCAGCTCA
CCGAGGGCCTGGCGAACTCACCCCGGACCTGCAGCATCCAGACACCACACATCCAGCTCACCGCAGGGCC
TGGCGAACTCACCCCGGACCTGCACCATCCAGACAACACACATACAGCCCACCGCAGGGCCTGGCGACCT
CACTCCGGACCTGCACCATCCGTACACTGCACATCCAGCTCACCGCAGGGCCTGGCGACCTCACGCCAGA
CCTGCACCATCCGGATACAGCACATCCAGCTCACCGCAGGGCCTGGCGACCTCACCCCGGACCTGCACCA
TCCGGATACAGCACATCCAGCTCACAGCAGGGCCTGGCGACCTCACCCCAGACCTGCACCATCCGGACAC
CACACATCCAGCTAACCGCAGGGCCTGGTGACCTCACCCCGGACCTGCACCATCCGACACCGCATATCCA
GCTAACCGCAGGGCCTGGCGACCTCACGCCAGACCTGCACCATCCGGATACAGCACATCCAGCTCACTGC
AGGGCCTGGCGACCTCACCCCGGACCTGCACCATCTGGATACAGCACATCCAGCTCACAGCAGGGCCTGG
CGACCTCACCCCGGACCTGCACCATCCAGACACCGCACATCCAGCTAACCGCAGGGCCTGGTGACCTCAC
CCCGGACCTGCACCATCCGGACACCGCATATCCAGCTAACCGCAGGGCCTGGCGACCTCACCCCGGACCT
GCACCATCCGGACACCCCACATCCAGCTCACCGAAGGCCTTGGCTACCTCACCCCGGACCTGCACCATCC
AGACACCGCACATCCAGCTCACAGCAGGGCCTGGCGACCTCACGCCGGACCTGCACCATCCGGACACCAC
ACATCCAGCCCACCAAGGGCCTGGCGACCTCACCCCAGACATGCACCATGCAGACACCGCACATCCAGCT
CACCAAAGGCCTGGCGACCTCACCCCAGACCTGCACCATCCGGACACGGCACATCCAGCCCACCAAGGGC
CTAGCGACCTCACCCTGGACCTGCACCATCCGGACACGGGGACACCGCACATCCAGCTCACCGAGGGCCT
GGCGAACTCACCCCGGACCTGCAGCAACCGGACACTGCACAACCAGCTCACCGCAGGGCCTGGTGACCTC
ACCCCAGACCTGCACCATCCGGATACAGCACATCCAGCTCACAGCAGGGCCTGGCGACCTCACCCCGGAC
CTGCACCATCCGGATACAGCACATCCAGCTCACAGCAGGGCCTGGCAACCTCACCCCGGACCTGCATCAT
CCGGACTCCATACCTCCAGCTCACCGAGGGCCTGGCGACCACACCCCAGACCTGCACCATCCAGACGCCG
CACATCCAGCTCACAGCAGGGCCTGGCGACCTCACCCCGGACCTGCATCATCCGGACTCCATACCTCCAG
CTCACCGAGGGCCTGGCGACCACACCCCAGACCTGCACCATCCAGACGCCGCACATCCAGCTCACAGCAG
GGCCTGGCGACCTCACCCCGGACCTGCATCATCCGGACTCCATACCTCCAGCTCACCGAGGGCCTGGAGA
CCTCACCCCTGACCTGCACCATCCGGACACCGCATATCCAGCTCACAGCAGGGTCTGGCGACCTCACCCC
GGACCGGCACCATCCGGACTCCATACATCCAGCTCACCGAGGGCCTGGCGACCTCACTCCAGACCTGCAC
CATCCAGACACCGCACATCCAGCTCACCGCAGGGTCTGGCGACCTCACCCCGGACCTGCACCATCTGGAC
ACTGCACATCCAGCTCACCGAGGGCCTGGCGACCTCACTCCAGACCTGCACCATCCAGACACCACACATC
CAGCTCACAGCAGGGCCTGGCGACCTCACCCCAGACCTGCACCATCCAGACACCACACATCCAGCTCACA
GCAGGGCCTGGTGACCTCACACCGGACCTGCAGCATCCGGACACCCCACATCCAACTCACAGCAGGGCCT
GGCAACCTCACCCCAGACCTGCACCATCCGGACACCGCATATCCAGCTCACCGCACGGTCTGGCACCGTC
TGGCGACCTCACTCCAGACCTGCACCATCCAGACACCGCACACCCAGCTCACCGCAGGGCCTGGTGACCT
CACCCCAGACCTGCACCATCCAGACACCACACATCCAGCTCACAGCAGGGCCTGGCGACCTCACCCCGGA
CCTGCATCATCCGGACTCCATACCTCCAGCTCACCGAGGGCCTGGAGACCTCACCCCTGACCTGCACCAT
CCAGACACCACACATCCAGCTCACAGCAGGGCCTGGCGACCTCACCCCGGACCTGCATCATCCGGACTCC
ATACCTCCAGCTCACCGAGGGCCTGGAGACCTCACCCCTGACCTGCACCATCCAGACACCACACATCCAG
CTCACAGCAGGGCCTGGCGACCTCATCCCAGACGTGCACCATCCGGACACTGCACATCCAGCTCACTGAG
GGCCTGGCGACCTCATCCCGGACCTGCACCATCTGGTACAACAGCCATGGCCATGGGAAGCCCAGCAGGT
CCAGGCCGAGATGGCCACGCACGGGACCTACACACGGGATCCCGCAGACAAAGCTCAAAAAATGTCAAAT
GTCCTGTGAGTGATGCTCCCACCAATAACACCCTAAAATGATGAGGTGTGGACATGCTGGGCTTCAGTAA
AATCTATTATTACATTAATTTCACCTTTTCTTTTTTACTTTTTTAATGTGGCTACTAGAATTTTTTTTTT
TTTTTTTTTTTTTGAGACAGAGTCTCGCTGTGTTGCCAGGCTGGAGTGCAGTGGTGCAATGTCGGCTCAC
TGCAACTTCCAACTCCCAGGTTCAAGCAATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGATTACAGGCA
CCCGCCACCACGCCCAGCTAATTTTTGTGTTTTTAGTACAGATGGGGTTTCATCATGTTGGCCAGGATGG
TCTCGACCTCCTGACCTCGTGATCCACCCGCCTTGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCA
CCGCGCCCAGCCTAGAAATTTTAAAATTATCCACATGGCTCACGTCATGCTCCTGTTGGGCGACAACGGC
TCGGAGCCTCATCCTTTGTCCTGGTTCCCAAGCAGAAGGGAGGAAGCAGACACTCCCCCGCCAGGCAGCA
CCGTCAGAGCTGGCGCCACACCGCAGGTTTGCGCGATTTCAAACTCGACACCGCGGAGCCACCAGACCCC
GACATGCCTGGGGTTTTCCAGGCTGAACCCAGGCCGAGCGGACGTTGCTGTCACTCACTGGCTAAGGAAC
GCTGGCCACGTGGTGCTCCAGACACTCACGGGCCAAGATGACCGCCCTCCTCGTGAGTCTCCACATCTTC
ATCTGTGCATCATAAGCAGAGGTCCCCGGACGTCGCTAGATGCCATGGAGGCCAGCACAGGTAAAGCTGG
GGTTTACCAGCAATAACAAGACAGAAGAACCACGCAAAGGACAAGGAAGGGGACCCCAGACGGCGGGCCT
GAGACAGAAGACAGACGGGGAACAAAGGAGGAAAAGCAGGGCGGGGGCAAAGCTACAGAAACACTCAACA
CGGAAAACAATATTAATAATGCTTAGCTTGTGGGGGTGTCAAGATGCCTGAGATAGAACTAAGTCAGCAG
GGAAAACAGCACACAGGCTGGGGGGTGGCCAGAGCTAAAATACACTAAGGGTCTTATTGCTCAGGACAAG
GGTAGCAATGTTTCAGACTTCATTTTAAAAGATCAAGGTATGCCGGGCACGGTGGCTTGCACCTGTAATC
CCAGCACTGTGGGAGGCCAAGGCGGGCAGATCACTTGAGGTCAGGAGTTTGAGACCAGCCTGGCCAACAT
GGTGAAAGCCTATCTCTACTAAAAATACAAAAATTAGCCAGGCGTGGTGGTGGGCGCCTGTAATCCCAGC
TACTCATGAGGTTGAGGAATGAGAACTGCTTGAACCGAGGAGGCAGAGGTTGCAGTGAGCCGAGATTGTG
CCATTACACTCCAGCCTGGGTGACAGAGTGAGACTGTCTCAATAAACAAAAGCAAACAACGACAATAAAA
AGATCAGGGGGTAACACTAAGCAAAGAGAAATAAAAGCAAATGCCCAGTGACCAGGAGGCAACGAGAGGA
TCAACACACACTCGGCAGGAAACGCACATGGCAACCCAAGAGGTGGTGAGAAACAAGGGAACGAGGACAT
GCAACAGGCAAGTGGAGAATCAGAGTGCACCAGGCGGGTCTCTAGTGACAAAAAAATGAAAATAAATCAG
GTTATCCAGTTAAACAACGACTGTCAGACTGGATTGGAAATTCACCTACATGCTGTTAACAGGACATACC
CACACTATAAGAATATAAAAGTGTTGAAAATTAGGCCAGACATGGTGGCTCATGCCTGTAATTCAGCACT
TTGGGAAGCCGAGGTAGATGGATCCCTTGAGTCCAAGAGTTTGAGACCAGCCTGGGCAACACAGCAAGAC
CCTGTCTCCAGAAAAAATTTAAAAATTAGCCAGGTGTAGCGGTGCGTGTCTGCAGTTCCAGCTATTCAGG
AGGCTGAGGTGAGAGGACGGCTCAGGCCAGAAGGTAAAAGTTACACTGACCTGTGATCACACCACTGCAC
TCACCCTGGGCGACAGACCAAGACTCTGTCTCAAAAAAAAAAAATATATATATATATATATAAATTAAAG
GCAGAAAACAGACACAGCAGGAAAATACTAATCAAAAGAAGCCCAGTGTGGCAGTACTAAGAGCAATTTA
AAAAAAGAATTACTAGATTACTAGAGACATAGAAGTCTCCAAAAGATTCACTCATCAGGAAGATAAAAAT
TCTACCACGTGCATGCACCTAACAATGCCTCACATAAATGCTACCAAACGAGAAGAAATGAACAGACCCA
TCCCCCAGGTGAGGGACTATGGCCTCCTTCTTGGAATTTCATGCATCTAGAAGGAGACAGAAGCTTTGCA
CTGGACCTTAATAAGCTGGATATAGTGAACATGCATGCCCACTATTGACAGGATGTCAAATTTACAATGG
ACAGTTCTGGAAACCATGCACACACTAGATCACAAAGCAAGGCTCCGCAAACTTCAAATAATTGGTATTA
TACAGACCACTACACAACTGAGTTAGAAATCAATAATAAAATGATAACTTAAAATACTCTACGTATCTTG
ATACTCTACATATCTTGAACATAAACAGTGTTCAAATAACTCACTGCTCAAAGAAATCACAGAATAAGCT
AAAGAATACTTAAAAGTCACTGATATCAAAATGATTTCACGTCAAAACACAGCGTGCACAAAGAAAAAAA
TCACAGAATAAGAATACTTAAAAGAAGTATTAACACTTTGAAGTATTTTAAGAACACTTGAAAGTGGCTG
ATGTTGAGATTACTTCACATCAAAACACAGGGTGCAGGTAAGGCAGCACTTAGAGGGAAAGGCATGACTA
AACTAAGAAGCTAGAAAAGGAATGAAAGAATAAACCAAGAAAAAGCATACAATGGAGAGATAGAAACGTC
AGAGGTAAATCAGTGAAATTCAAAACTAAGACCCAAGAGGGAAGTCTGACGAAGGCTGGCGGAGACACCG
GCCCTCCACGTGGGTCTCAGAGCAGGAGACAGACAGAGACACTCCAACCTGTGGCTGGACGTCAATCCAT
GTGAGGGGGCGACTGGAGGCAGAGCCCAGCCTAAGCAATGAGCGGCAGGTGCCCAGAATAAGGTGACAAG
CGTTGCCACCCACCCAAGGGGGCCAAGCAGAGGGGCAGCTTGGGAGAAAACAGGACAAGTGAGGGGGCTG
GGGTGACTTGCTTTCCTTCAGGGCACAGAGAACCCTTTCTGGGATGTCTCCAGCAACACGTGGCAGCAGA
CACAGGCAGCCCAGAGTCCAGCCTCGGCATGAGACAAGCTGGGAGAGGAGTATTGGCAGCATGCATGTGG
CGGGCACGTGGTGAGCAAGCCAGGCCCAACAGAGGCAAGCGGACCTGAAGCTGTGGCTGCAGTGCCTGGC
ACGCGGGAGGCGAGAGCCTGCAGTCCCGTGTCCCCGTAGCAAAATGGAACGGAGAGGTGACCAAGAAGAG
CCGAGCATCAGAAAAGATAGGCTTGGGGACCAGCACTGCGCCTGCACCATCTACCCAGGCAATGGGCAAC
CGGCGCAGCTGTGGCTATAGAAAGAGCAAACATTCAGGAGCAAGCTCAAGTGAGCAAACGCCAAGGACAC
CTGGGGACAGAGCCTCACTCACCCTACACGAGACAGGGACACCCAGGGACAGCGCCTCACTCACCCTGCA
CCTGAGAGGGACACCCGGGGGCCGCAACTCACTCACCCTACACGTGACAGGGACACCCGGGGACGGCGCC
TCACTCACCCTACACGTGACAGGGACACCCGGGGATGGCGCCTCACTCACCCTACACCTGAGAGGGACAC
CCAGGGACGGCGCCTCACTCACCCTACACGTGACAGAGACACCCGGGGACAGTGCCTCACTCACCCTACA
CGTGACAGGGACACCCGGGGACGGGGCCTCACTCACCCTGCACGTGACAGGGACACCCGGGGACGGCGCC
TCACTCACCCTACACGTGACAGGGACACCCGGGGACGGCGCCTCACTCACCCTACACGTGACAGGGACAC
CCGGGGACGGCGCCTCACTCACCCTACACGTGACAGGGACACCCGGGGACGGCGCCTCACTCACCCTACA
CGTGACAGGGACACCCGGGGACGGCGCCTCACTCACCCTGCACGTGACAGGGACACGCGGGGACGGCGCC
TCACTCACCCTGCACGTGACAGGGACACCCGGGGGCCTCGCGTCAATCACCCTGCACGTGACAGGGACAC
CCGGGGACGGCGCCTCACTCACCCTGCACGTGACAGGGACACCCGGGGACAGTGCCTCATTCACCCTACA
CGTGACAGGGACACCCGGGGACCGCGCCTCACTCACCCTGAACGTGACAGGGACACCCGGGGACAGTGCC
TCACTCACCCTGCAAGTGACAGGGACACCCGGGGGCCGCGCCTCACTCACCCTGCACGTGACAGGGACAC
CCGGGGGCCGTGCCTCACTCACCCTGCACGTGACAGGGACACCCGGGGGCCGCGCCTCACTCACCCTGCA
CGTGACAGGGACACCCGGGGGCCGCGCCTCACTCACCCTGCACGTGACAGGGACACCCGGGGGCCGCGCC
TCACTCACCCTACACGTGACAGGGACACCCGGGGGCCGCGCCTCACTCACCCTGCACGTGACAGGGACAC
CCGGGGGCCGCGCCTCACTCACCCTACACGTGACAGGGACACCCGGGGACAGTGCCTCACTCACCCTACA
CGTGACAGTGACACCCGGGGACCGCGCCTCACTCACCCTACACGTGACAGGGACACCCGGGGGCCGTGCC
TCACTCACCCTGAACGTGACAGGGACACCCGGGGACGGCGCCTCACTCACCCTACACGTGACAGGGACAC
CCGGGGACGGCACCTCACTCACCCTACACGTGACAGGGACACCCGGGGACGGCGCCTCACTCACCCTGCA
CGTGACAGGGACACGCGGGGACGGCGCCTCACTCACCCTGCACGTGACAGGGACACCCGGGGGCCTCGCG
TCAATCACCCTGCACGTGACAGGGACACCCGGGGACAGCGCCTCACTCACCCTGCACGTGACAGGGACAC
CCGGGGACGGTGCCTCACTCACCCTACACGTGACAGGGACACCCGGGGACCGCGCCTCACTCACCCTGAA
CGTGACAGGGACACCCGGGGACAGTGCCTCACTCACCCTACACGGGACAGGGACACCCGGGGACCGTGCC
TCACTCACCCTGCACGTGACAGGGACACCCGGGGACCGCGCCTCACTCACCCTGCACGTGACAGGGACAC
CCGGGGACCGCGCCTCACTCACCCTGCACGTGACAGGGACACCCGGGGACCGCGCCTCACTCACCCTGCA
CGTGACAGGGACACCCGGGGGCCGCGCCTCACTCACCCTGCACGTGACAGGGACACCCGGGGGCCGCGCC
TCACTCACCCTGCACGTGACAGGGACACCCGGGGGCCGTGCCTCACTCACCCTGCACGTGACAGGGACAC
CCGGGGACGGCGCCTCACTCACCCTGCACGGGACAGGGACACCTGGGGACCGCGCCTCACTCACCCTGCA
CGGGACAGGGACACCCGGGGACAGTGCCTCACTCACCCTACACGTGACAGGGACACCTGGGGACCGCGCC
TCACTCACCCTGCACGTGACAGGGACACCCGGGGACAGTGCCTCACTCACCCTATACCTGGGAGGGACAC
CCAGGGACGGTGCCTCACTCACCCTACACGTGACAGGGACACCTGGGGCCGCGCCTCACTCACCCTACAC
CTGAGAGGGACACCCGGGGACAGCGCCTCACTCACCCTACACCTGGGAGGGACACCCAGGGACGGTGCCT
CACTCACCCTACACGTGACAGGGACACCCGGGGACCGCGCCTCACTCACCCTGCACGTGACAGGGACACC
CGGGGACAGCGCCTCACTCACCCTGCACGGGACAGGGACACCCGGGGACCACGCCTCACTCACCCTACAC
GTGACAGGGACACCCGGGGACGGCGCCTCACTCACCCTACACCTGAGAGGGACACCCGGGGACAGTGCCT
CACTCACCCTACACGTGACAGGGACACCCGGGGACCGCGCCTCACTCACCCTGCACGTGACAGGGACACC
CGGGGACAGTGCCTCACTCACCCTGCACGGGACAGGGACACCCGGGGGCCACACCTCAATCACGCTGCAC
GGGACAGGGACACCCGGGGGCCGCGCCTCACTCACCCTACACGTGACAGGGACACCTGGGGGCAACGCCT
CACTCACCCTGCACGTGACAGGGACACCCGGGGACCACGCCTCACTCCCTGCATAAGCCAGGGGCAGATT
GTGACCTCATCTGAAGTCAGAGAACAGCAATGACAGGCAGAGTCCTGATCAGAGAACTCAAACTCTCCTC
AACGAAGGAAGCTGGAGCACAAAAAGCAAAACTGGGTTGCATGACGCTTATCTGACTCGGCGTGGTCCAC
CTGAGCCGCAGCAGGTGTGAGGCAGCTGCCGTTCGATGGGTAGGGACTTCCAGTCACGCAAGACGCAGCA
TTTCAAGCAACCTGCTGTAAACACCGCCGAGTTAGCAATTCTGCACTGTACACAGAAAACGGTGTTAGGA
GTGCCAATCTCATGTTATATGACTTTTGCCACCATAAAAAGAAAAAAAGAAAAAAAAGAGCCCCAAGAAG
GTCACCCTCCTTGTCTGCATGGCCGGAAGTCTTACATGTCTTGGGAGTTTGTGGGGAGGGGGTGAAATCG
GGACTTCTTCTAGCTGCCACGGTAGGGCCTGGGAGCACTGGGAGCCAAAAGGGGGCTGGAGCGGAGGTTC
CTCAACATCAAATCCAGAAAAACAGGGTGGGGACACGGCAGGGCCCAGCAGCACCATCCCCTGAACACCC
ACAAACACTGTCCCTTCCTCAGCAGGTGGAGCCATCTGCTGTCCTCTGCTCCCATGTGGCCCTCTTCATA
CCTAAAGATGGGACCAGGATCTGTGCTGGAGAACAGTCTTATCTCCCTCCCTCTACCCTGTCCTGGCACA
ATCAACGAACACTTTTTTTTTTTAAAGACAGAGTTTCACTCTTGTCGCCCAGGCTGGAGTACAATGGCAC
AATCTCAGCTCACTGCAGCCTCCGCCTCCTGGGTTCAAGTGATTCTCCTGCCTCAGCCTCCCAAGTAGCT
GGGATTACAGGCACACACCACCATGCCCAGCTAATTTTTGTATTTTTAGTACAGATAGGGTTTCACCATG
TTGGTCAGGCTGGTCTCAAACTCCTGACCTCAGGTGATCCACCTGCCTCAGCTTCCCAAAGTGCTGGGAT
TACCGGCGTGAGCCACCGCACCTGGCCGTCAACACACAATTAAATCTTAAACACAAACCTGCATATTGGC
TGACCACGTGCACCTGCAAAACCCTTACCTCCCACCCCCAGGAAGAGGGGGTTCTCGTCCCCACCTCTCA
TTCCCACCCTTGAAATTGCGAAGAGGATTATAGGTAACCTGCAGGCACCCTCGCCAGAGCGTCTGTGCTT
CCAGACACTTCTCCCCATTGCCGGCAACCCGGCTCCACTGCCGCGCCCAGCCTCCTCTGTTCACTGCTCT
GGCCTCGGCGCCTGGAAACCGCGTGTCCATCAAAACGTGAAGGTGAACCTCGTAAGTTTATGCAAACTGG
ACAGGAGGGAGAGCAGAGGCAGAGATCACCGTGTCCACTCGACGTCCTGAGCGAAAAGCCACGTGTGCCC
ACGTGACGATGGAGACAGGAGGACCAGGGCTCTGCCTGCCCCCTTTTCTGAGCCCCTACTGCATTCAGCT
CTGGGGCCTGGGCCCTCGACGGCCACCACCTCCTCACCTGGGCTCCTGCGCAGCCAAGCGCAGTCCCGCA
CGCTCATCTTCCACGTCAGCTCCTGCAGCGAGAGCTTGGCATGCTTCCCCAGGGAGATGAACTTCTTGGT
GTTCCTGAGGAAGCGGCGTTCGTTGTGCCTGGAGCCCCAGAGGCCTGGGGGCACCAGCCGGCGCAGGCAG
GCCCGCACGAAGCCGTACACCTGCCAGGGGCTGCTGTGCTGGCGGAGCAGCTGCACCAGGCGACGGGGGT
CTGTGTCCTCCTCCTCGGGGGCCGCCACAGAGCCCTGGGGCTTCTCCCGGGCACAGACACCGGCTGCTGG
GGTGACCGCAGCTCGCAGCGGGCAGTGCGTCTTGAGGAGCACCCCGTAGGGGCACTGCGCGTGGTTCCCA
AGCAGCTCCAGAAACAGGGGCCGCATTTGCCAGTAGCGCTGGGGCAGGCGGGGCAACCTGCGGGGAGTCC
CTGGCATCCAGGGCCTGGAACCCAGAAAGATGGTCTCCACGAGCCTCCGAGCGCCAGTCAGGCTGGGCCT
CAGAGAGCTGAGTAGGAAGGAGGGCCGCAGCTGCTCCTTGTCGCCTGAGGAGTAGAGGAAGTGCTTGGTC
TCGGCGTACACCGGGGGACAAGGCGTGTCCCAGGGACGTGGTGGCCGCGATGTGGATGGGGGGCCCGCGT
GGTGCTGGCGGCCCACGGATGGGTGGGAGTGGCGCGTGCCAGAGAGCGCACCCTCCAAAGAGGTGGCTTC
TTCGGCGGGTCTGGCAGGTGACACCACACAGAAACCACGGTCACTCGGTCCACGCGTCCTGCCCGGGTGG
GCCCAGGACCCCTGCCCAACGGGCGTCCGCTCCGGCTCAGGGGCAGCGCCACGCCTGGGCCTCTTGGGCA
ACGGCAGACTTCGGCTGGCACTGCCCCCGCGCCTCCTCGCACCCGGGGCTGGCAGGCCCAGGGGGACCCC
GGCCTCCCTGACGCTATGGTTCCAGGCCCGTTCGCATCCCAGACGCCTTCGGGGTCCACTAGCGTGTGGC
GGGGGCCGGGCCTGAGTGGCAGCGCCGAGCTGGTACAGCGGCGGCCCGCACACCTGGTAGGCGCAGCTGG
GAGCCACCAGCACAAAGAGCGCGCAGCGTGCCAGCAGGTGAACCAGCACGTCGTCGCCCACGCGGCGCAG
CAGCAGCCCCCACGCCCCGCTCCCCCGCAGTGCGTCGGTCACCGTGTTGGGCAGGTAGCTGCGCACGCTG
GTGGTGAAGGCCTCGGGGGGGCCCCCGCGGGCCCCGTCCAGCAGCGCGAAGCCGAAGGCCAGCACGTTCT
TCGCGCCGCGCTCGCACAGCCTCTGCAGCACTCGGGCCACCAGCTCCTTCAGGCAGGACACCTGCGGGGG
AAGCGCCCTGAGTCGCCTGCGCTGCTCTCCGCATGTCGCTGGTTCCCCCCGGCCGCCCTCAACCCCAGCC
GGACGCCGACCCCGGGGAGGCCCACCTGGCGGAAGGAGGGGGCGGCGGGGGGCGGCCGTGCGTCCCAGGG
CACGCACACCAGGCACTGGGCCACCAGCGCGCGGAAAGCCGCCGGGTCCCCGCGCTGCACCAGCCGCCAG
CCCTGGGGCCCCAGGCGCCGCACGAACGTGGCCAGCGGCAGCACCTCGCGGTAGTGGCTGCGCAGCAGGG
AGCGCACGGCTCGGCAGCGGGGAGCGCGCGGCATCGCGGGGGTGGCCGGGGCCAGGGCTTCCCACGTGCG
CAGCAGGACGCAGCGCTGCCT

</dna_sequence>
        <protein_sequence>>NP_001180305.1 telomerase reverse transcriptase isoform 2 [Homo sapiens]
MPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDARPPPAAPS
FRQVSCLKELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLL
LRRVGDDVLVHLLARCALFVLVAPSCAYQVCGPPLYQLGAATQARPPPHASGPRRRLGCERAWNHSVREA
GVPLGLPAPGARRRGGSASRSLPLPKRPRRGAAPEPERTPVGQGSWAHPGRTRGPSDRGFCVVSPARPAE
EATSLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFLLSSL
RPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQRYWQMRPLFLELLGNHAQCPYGVLLKTHCPLRAAVT
PAAGVCAREKPQGSVAAPEEEDTDPRRLVQLLRQHSSPWQVYGFVRACLRRLVPPGLWGSRHNERRFLRN
TKKFISLGKHAKLSLQELTWKMSVRDCAWLRRSPGVGCVPAAEHRLREEILAKFLHWLMSVYVVELLRSF
FYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRELSEAEVRQHREARPALLTSRLRFIPKPDGL
RPIVNMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLDDIHRAWRTFVLRVRAQ
DPPPELYFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVVQKAAHGHVRKAFKSHVSTLTDLQ
PYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQGSILSTL
LCSLCYGDMENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLSYARTSIRASLTFNRGFKAGRNMRRK
LFGVLRLKCHSLFLDLQVNSLQTVCTNIYKILLLQAYRFHACVLQLPFHQQVWKNPTFFLRVISDTASLC
YSILKAKNAGMSLGAKGAAGPLPSEAVQWLCHQAFLLKLTRHRVTYVPLLGSLRTAQTQLSRKLPGTTLT
ALEAAANPALPSDFKTILD

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Telomerase is expressed in 85-90% of pancreas cancer, and immunogenic telomerase peptides have been characterised. A phase I/II study was conducted to investigate the safety, tolerability, and immunogenecity of telomerase peptide vaccination. Forty-eight patients with non-resectable pancreatic cancer received intradermal injections of the telomerase peptide GV1001 at three dose levels, in combination with granulocyte-macrophage colony-stimulating factor. Monthly booster vaccinations were offered as follow-up treatment. Immune responses were measured as delayed-type hypersensitivity skin reaction and in vitro T-cell proliferation. GV1001 was well tolerated. Immune responses were observed in 24 of 38 evaluable patients, with the highest ratio (75%) in the intermediate dose group. Twenty-seven evaluable patients completed the study. Median survival for the intermediate dose-group was 8.6 months, significantly longer for the low- (P = 0.006) and high-dose groups (P = 0.05). One-year survival for the evaluable patients in the intermediate dose group was 25% [Ref1294:Bernhardt et al., 2006].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1360">
        <gene_name>TRP-1</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>22178</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>530537244</ncbi_protein_id>
        <gene_locus_tag>RP23-372M15.1</gene_locus_tag>
        <gene_refseq>AF087673</gene_refseq>
        <protein_refseq>NP_001268943</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>4</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>80834207</gene_start>
        <gene_end>80851735</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>transcript variant X1</protein_name>
        <protein_pi>5.94</protein_pi>
        <protein_weight>57188.15</protein_weight>
        <protein_length>537</protein_length>
        <protein_note>Also known as b; isa; TRP1; Tyrp; TRP-1; brown</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000070.6:80834207-80851735 Mus musculus strain C57BL/6J chromosome 4, GRCm38.p4 C57BL/6J
GTGTGAGAAGGGATTAGTGAGAGCTGGAAGAGAGGACCAGCCCCTCCCAGTGTGAGGAATCTGGCTTGGG
ATTTACTGTCTGGCAGAAAATCTCTTCGGGCAATTAACAGCTGGCATCAGGGGAAAAGCAGACATCCAAC
AACACTAGCTCTGAAGGAGATCAGCAGAGAAACCTTCCAGGGATTCATGGTACTGGTGAGCAGCTCTGTG
GTGGGTACCCTGTGACCAAAGCTCTAGGAACATGAAGGAGATTTGCTTGCTATAAACCTGTTTCCTATTC
TCCTTTCATTTCCATGGTTAACTATTACTATGGTAGTCACCAACTAGTGGATGCTTTTGGTAAATGACAT
CTATGGAAAGTCTTTTTGGATCAGGGTGATCTTTTTATGTATGTGTATGTGCATGGATATGGGTGCACGA
GAGCAGGTGCCCAGATTCTCAAGGAGGGCTTCAGTTACAAGGAGTTGGGAGTGATCTGATGTGGTTGCAA
GGCACTGAAGTCAGTCTCTCTGTAAGAGCACTCTATGCTCCTTACCACTGTGCCTTCTCCCCAGCCCAAG
AATAGTATTCTTATGGGTAGAAATTTTAAATAAGAAAACTCAAAGACCAGGAGAGTGAGTTCTGTCATCT
AGCTATTATGCCTGCAGATATTTAAAGGTGAATAATTGTTTTGACTATTGTTTAGAAATGTTGTTTCACA
TGAAAGATTCCATTTCCGGAGTGGGTTGAAAAAGTATGCAAAAGAACTTTTGCAACTCTGTTTTTGCCTT
TCTGTTTTTCAGCTGTATTTTCATCTGAGCACCCCTGTCTTCTCCATGCAAAGAGCAGCATAGGAGACCT
GTGTTCTGAACTCTTGCTTCGAGAAGAATGAAATCTTACAACGTCCTCCCCCTAGCCTATATCTCCCTTT
TCCTGATGCTGTTTTATCAGGTTTGGGCTCAGTTTCCACGAGAGTGTGCCAATATTGAGGCTCTGAGACG
TGGGGTGTGTTGCCCAGACCTGCTCCCTTCCTCTGGACCGGGGACTGACCCTTGTGGCTCATCATCAGGA
AGAGGCAGGTGTGTGGCTGTGATTGCAGACTCCCGACCCCACAGCCGCCATTATCCCCACGATGGTAAAG
ATGACCGAGAAGCCTGGCCTCTGAGGTTCTTTAATAGAACATGTCAGTGCAATGATAATTTCTCAGGACA
CAACTGTGGGACTTGCCGTCCTGGGTGGAGAGGAGCTGCATGCAACCAGAAAATTCTCACAGGTGAGTAG
AAAGGCGGGGAAGACAGTTTCACTGAGTTAGACTTGATGCTATGTGAATCCTGAATCACATAGGTCAGGA
GTCACCTTAAATCCTAGAGCTCAGCCCACTTCTCCCCGTTTTAACCTACACTTTTTAACTAATTCTATTT
CCATAAATCTGGAGAGATGGCTTTGTGGATGGTAAGAGCATTCTCAGGAGCTGGGCAGTAGTGGCTCATG
CCTTTAATCCCAGCACTTGGGAGGCAGAGGCAGGTGGATTTCTGAGTTCGAAGCCAGCCTGGTTTACAGA
GTGAGTAAACAGGACAGCCAGGGCTACACAGAGAAACCCTGTCTCGAAAATTTAAAAAAAAAAAAAAAAA
AAGCTTCTAAGAAAGAGAACCTAAGATTCCCAGCACCCAGTAGGAAACTGGGTGTGGCCACTTGTGACTG
TATGCTCAGTACAGTAAGGTGGGAGACAGGTTATGGAGCTTTGAAGATCACAGGTCTAGCCAAAAAGAGA
TGAACTCCTTGTGAGAGACTCTGTCTCAAGATAATGAGGTACGGAGTGCTAGAGGACACCTGATACTCTC
CTCTGGTCTCCACATACAGGTAATTTCCTACTTTAGGCAGTTCCTATATGTTAGGGACTGACTTTTGTGA
CCAGAGGTCTGCGTACTAATCCTTGTACATTAGATTCAGAAAGGTCAAACTCATGGATCTGGACCTTTAG
CAAAGAAAGCATGTCCACTGAGATCTAGCTAGCTCTAAGGAAAACAGTCTCTCCTCTCTAAGCAGCCCTG
GTGACTCACGACTCCTCACTTACTGAAGGAGTTCATGCATTTTAGATGAATGATCAGGTACATGCAGTAT
TATACAGTAACAACAACAGCACTTGCTTGGTTTCCATGTGTGAGACATTGACCAAGGCTTCCCAGACTAC
CTTTTGAGACTTTAATATCATCCAAGCACTAGTCTACTTGGTGGGGTGTGTGTGTGGAAGGGGTATATTC
CTTCTCTACATGTCTCTGTAAAGCAAGAGTTCTTTTTATCCAAATATCAAATAACATGAAAAAATAAGCC
TGAAGATCTGTGACAAAAGACAGAAATTCTGTTTTAACCACTATGATGTATTTGCTTGCCTTGTTTTTCT
AAGATTTATGATATTTATAAAGTAGAAAATTCCACTGGTGATGGTAATGCACAACTTTAATCCCAGCACT
CAGGACAGAGAGGCAGGAGGATCTCTGAGTTTGAGGTCAGCCTGATATACAGAGTGAGTTCCATGATAGT
CAGAGCTACACAGAGAAACCATGTATTGAAAATACAAAAGCAAAGAAGTAGAATTTTCTTTAAAAATGCC
AATAATGCACAAAAATAAATATGATAAGCTTTATTTGACAATAAATGATAAATCTCCATGTATTATTAAA
GAAAGCTTTTAGAAATTCAAGAGTAAATTGCTGAGACAAAGAGGGGAAGGAAGAGAGATCAGTCTAAACA
CAGATTTAATTAAGAGTATTTTTAATAATATACAGACTGGACAGCTATGAAATCAAAATTTCAATATTAT
CCAAACTCTGAAATTTTGGAGCCCCAACATGGTGTTCCAAATGGAAAGCTCCACACTGTTAATCTTTGTT
TTAAGCACAAAATAATGAAACTGTGGTTGAAACTGTCTTCAGGCTATGTGTGTAATGAGGTGTATATGAA
ACAAATGGATTTTACATTTAGCTTTGGACCCATTGCCTAAAATATAGTATATAAGAAAATATTTCAAAAT
GTGAAATCTCCAAAATATAACTGGTACCAAGCATCTTGGAAATGATAACCAGCTAAATAATGTACAAAAG
TAATGTACATATGGCCATTAATGGATACTAGAGGCATAGCATGTTGGAATATGATTGTGCTAATTTTCAT
GTCTTAATCTTTTCATGTTTAAAGTCAGGAGAAATCTTCTAGACTTAAGTCCAGAAGAAAAGAGCCACTT
TGTCAGGGCCTTGGATATGGCGAAGCGCACAACTCACCCTCAATTTGTCATTGCCACAAGGAGGTTAGAA
GACATACTGGGACCAGATGGCAACACACCACAATTTGAGAACATTTCCGTTTATAACTACTTTGTTTGGA
CACACTATTATTCAGTCAAAAAAACCTTCCTCGGGACAGGACAGGAAAGCTTTGGGGATGTGGATTTCTC
TCACGAAGGACCCGCTTTTCTCACATGGCACAGGTACCATCTGCTGCAGCTGGAGAGAGACATGCAGGTA
TGCTGATTCTTGGTTTTTAGGTCCCTCCATGTAACTCACATTGTACTGAATGACAAGATTGAGTGTTATT
GGGGTACTCTACACTCTCAGATAAGATCCTTCCCACACTGATTATTCAATAATTTATTAACCATGGTCTT
TTGTACAGTGAAATGAAAGCAATGTTAATGATGAGAGAAAAAAAATGGAGACCTGTTTATGCAAGAGTTA
AAAATTTGGAATTTTTTAATAGTTTGATAACTGAACAAAATTACTTATGAAACAAACAAAAAGCAAAAAA
ACAACTCACTTTCCAGATCTTCTTCCTCTGTGGAATGTTAACAGTTGCCACCCCCTGGAAAGTGGTATAC
TTGCATGTACCCTTCCATCCATGTGTAACCATCAAAACAGCTAATGGTTCTAGATCCCAAATCCTTTCAT
TTTCACGGAACTATATTTTCTATACTCCCTACCATTTTAGAGCTTACAGAAAACCCCACTCAAAAGCATC
ACATATTTCTGTAAAGAAATAATGGATGTGTTCAATTTCTTGGAGGTAGTAATCATTTCACTGTATGTAT
GCGTGTGTGTATGTGTGTGGGTGTCTGTGTGTGTATGTGTACACCTGCATATATATTCCTATTTATAATT
TTACATGCCATTTTTTCTAAAAGGACTTCAAAATGGCATATCTTTAGACATGAATTTTCAATCAAAAACT
AGATTTGTGAAGGAAAATATAAAGTAGACCTCAACTGAAGCAAGTAACATCAAGGGGTTTTTGTCTGGTT
GGTTGGTTGGTTGGTTGGTTGGTTGGTTGGTTGGTTTGGTTTTAAGCAGATGTGCCCAAAACACACTAAG
GTATCTGGTAGCATAAGTATCGAGTTATTGCCCTTTCACTAATAAACTACTTTTTAGGAAAAATATTCTT
ATTCAAAAAGTTAACAGCTGAGGGGTTATGAGCTTATCTCAATGATAGAGGACTTGCTGAGTGAGCACAA
GGCCCTAGGTCTAATCCCCAGTTTTATTTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTT
ATTTATTTGGTTTGTTTTGGTTTTTCAAGACATGATTTCTCTATGAGGTCCTTGAAAACTGCTCTGTAGA
CAAAGCAGGCCTCAAACTCAGAGATCTGCCTGCCTCTGCCGCCCAAGTACTGGGAGTAAAGGTGTGCGCC
ACCACTGCCCGTCTAAAAGTATTTATTATTGGCTCTCAATTATTAACTCTATAAATCAAGCTTTTTTTCT
TATATAAAACAGTCATGAATCTCTACCCTAAAGTTAAAGTCTTAAAATTCATTAAAATTACCTTAACACA
CACGCACACGCATATGCACACGCACACACACAGGCACATGCACACACACATGCACACACACACAAAAGCC
CACCTCTCCAGACTTATTGATTAATGCACTGAGTGCTGTGCTGCTATGCTAGCAATTCAGGGGAAAATAA
TGGTTAGCAGAGACAGAGTGGTGCACTACAACAGAGTCAAATAGTTGACAGGAGTCTGTGAGGGTGATTG
AACAACCCCTCTAGTCCTCCTGGCATCATATTTTAAAGCTCTGATTACAAGAAAGACATTTAATAGATTG
TGAGTAGATGAATCTGTCATCCCTAACTGACTGTAGATCTTCATTCCCTCAAGACGTTTTCCCAATGGCT
CAACGAAATGAAAAGGCAGGTGGTAAGTGTCTAAAAGCTGCAGTTCTGCATGTGTAACTTCCACCTCAAT
GACTTACATATTTTTAGCCGGGAGCACAAGGCATCATCTTGTTCCAGGCTACAAGTGACATGTAGCACCA
TATGAGTGTGTCGAAATGCCAGCAGCCCAACCACAGTTGTTCTTGATTCATAATGAGTTTGGAAGTTGTC
ACTAACTTTTTGGAGGCACAATACTAGTTTTTGTATGTGTGATATAAACCCTTGGAGATCAGTACCTAGA
GATACCCTGAACAGCTCCTGACTTTCTAAAACCCCCAACAATAAGATGCTTGCCAGAAGGGAGCTGCAAT
TAAAGAGCAGAAATCGCCAGGTGCTTGAAAGGCACAGAAGGCAAGAGAAGCTTCACACTAAAACTCCCTC
TCCGGAAGTAACTCCCCAAGGGCTAAAAGAAAGGCAAATGAGAGAAGCAGTGTTTTAAGGAATCTAATAA
TATAAGCATGTGTCCTTGGTCTCATGAATTTTCAATAACATGTGAGATGGTTTCAAAGTGGAAACTAGGT
CATTGGTCTTAAGAACAATAGGCACAGAATTCATTCCACTTCTGCTTAGCATTTTGACTGCTAGCTTCAG
GCAGATGCCTGCCTTCCTAGTTCAGCATTGCAGTGTAGATCTCTAAACAAAACTCCTTTAGTGCTTTGCA
AATAAGTCCGTGTGAGACAAAACAGGCAGTCTGTCAGCAAACCAGAATCTATCTAAGTACTTGCAGTCAT
CCAGACCACATTCTAAACAAAAATTATCGTTACACAAATCATTTCAAAATTGAAGTCATAAACTGCTAGG
AGTTCATGGTGTTTCAATTAAAAATAAGAAAGTGGGAGAGGTAGAAAAATCAAGGATTAAAAAATAAAAC
TCAAGGATTGTGATACAACCAACAGAAACACAATTAGCTGCCAATAATGGAAACTATGTTTTCCTCCACA
TATTTTTGGAGAAGTTTCTTCATGAAGTGAGTTTCGTTGTTTCTACTGCCCATTTGACTCCCCCAACTAA
ATTCCAAACTTTGTTCAATAAGTCTGGGGTCCCAAACATTATTGACACACTCACTGACTCCTTAGCAGGT
AGAGAGCTAAAGGAAAAGGACACCAGGGCTAAGCAAGCCAGGACACAAGATGTTAGCAGAAGCAGAGACC
ACTAATGGATTTCTATGATCTAGGAGATGCTGCAGGAGCCTTCTTTCTCCCTTCCTTACTGGAATTTTGC
AACTGGGAAAAACGTCTGCGATGTCTGCACTGATGACTTGATGGGATCCAGAAGCAACTTCGATTCTACT
CTTATAAGCCCCAACTCTGTCTTTTCTCAATGGAGAGTGGTCTGTGAATCCTTGGAAGAGTACGATACCC
TGGGAACACTTTGTAACAGTAAGACCCAAATGACAGCTACTATTCACAATTCTTTATTCTATAAATGACT
GTGTTGCCTGTAAGGTCCCTCTTCAGAGTGAAATCTGCTATCTCTCTTCAGAGAATCAATGCAGTTGCAC
GTTAAGCACCCAGGAGACTCAAGGCAGTCTAACTGGTGCTCTTGGGAAACACAAAGTACTTGTGTATTTT
ATTGATTTTCTTCAGCATCAGTACGTTTCTAACTTCGTTTTCAAAAAGCCTAGTGTAGATTAATCCTCTT
AATACATCCAGAACTGCTTAGCAGTCATGTGTCTTGGGATGGAATTTCACTGAAAATGTCTCCCAAGAAC
ATCTAAAATGTGCAAAAAATTGGTCAGGAATCTTCTGGGAGCAGAGCAAGAGGAAGAGAAACAAAGAAGG
AAAAGTGTATGTTCAGCCAGAGAACTAAAATCATAAATGGATACCTTTCACAGGTATAGGAATAGGAAGA
TGTAGCAACAGCAATACAGGCAGACTCACTGTTCTCAACTCTCCTACAGAAAGTGCCCACGTGTCTGCCT
ATTGTGCCTCTGCCGTGGAATATGTCTGCTCTGTACCAGCCTGCTCATGTCCTTTTTATTTTCTTCCATG
AATCATAGTTACCCTCCCTGTGCTACTAACCGGATTTTCATTGCTGGGGTTCTCTACTGTTTCTTCTTTT
TCTTCTTCAAGCATTTCCAGATATTTTAAATACTTGGATTTCCATATGAAAATTAGAGTTGTGCTTTAAT
ATTGCATTTGTGATACATCACTCTGCTTGTATTTTATGCATCAACTTTTGTATTGCTGTAGAAGCTTAAA
GAATGAATAGTTATTAATAAATCAAAGGAACTAAGTACATTTTTCCCGTTAGGATAGCATTTAGCTGTAT
TTTAATATCTTTTAAAAATGTAATAATACATGAACGTTTCCTTTAGAAGTCTAACACCTGAGCAACTGGT
TCCACCTTGTGACAGAGGGATGAAATTGAAGGTCAGCATATCCTCACTAACACATTCATCTTTCAAACCA
GACTGCTATATTTAGGGCTGGAGTATTTTAGACATTTTGTAACCATGCTGATACTCTCTCTCTCTCTCTC
TCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTGTGTGTGTGTGTGTGTGTGTGTATGTGTG
TGTGTGTGTGTGTGTGTGTGTACGTTGTACATGCACATGCAAATGCACCCACATGCACACTCATGTGTTC
ATATGTATGTAAGCCATAGAACACTCTCAGCTGTCATTCTTTTGACTTTTTCTACCTTTCTATTTTTAAG
CCAGTGTCTCACTGGCTGGCCTGTTGCCCACTATGTAGTCCAGGCTAGATTCTGACTCATGGAGATTCAA
CTGCCAGACTACTTACTTTCTCTCAAGGGCTAGGATAAACACCAGGCCCCAGGATCCACTTAAGTTTGAG
GGATGGAGGGCAATGTTTATTACCCATCAGTAGCTCATGACCACATCTGTCACAACCTGCTCAATGCTGA
TATTGCTAGTGGGCCCTAAATTATTTCATTTTCTTTTCTGTGGATTCTTCAGTCAAAGTCAGGTCTCAAG
TATTTTACTTTTATAAGCTATCTTTCCAGCTTAGAACAAATAATTTAGAAGAGCAAGTGAAATATAGCAT
AAGAGAAAAACATAGAAGTGGAAGTATTTCATTTTGCCATAGCTTTTCCTGTCATTCAATTTAACAAGAT
TCACAATATCATAAGAAGTTGAAGAGTGCTTATTCGGGGTTAAACAAGTATTGTGATTGCCTATTGTGAC
AATCCAGGATGTAAAAATCAAACATCATATTTATTGAGCATGGTAAAGAGAGCTGCAAAGATGTCTCAAG
TAGAAGCTCGTGTTGCCAAGACTGACAACTTGAATTCAATTCCTAAGAACCACATGGTTGTCTTTTCACC
TCTGTATGTGCACACACACACACACACACACACACACACACACACACACACTTAATTTCAAAACTCAAAA
ATATTAAAGAATAAAGGAAAACAGCCTGTATCAATCACATCATGTGTCTCATAGAGACACAAGATGCCTA
CTGTGTCTTGTTCAACTATTTCTTTTCTCTATTTGTGACTGAGAAGATGTTATTCATTTCTACACTGTCA
TTGACATCTTCTTCAGGAGAGTGGTGCATGCATGTCCTTGGATTAACCTTTCTTTGGTGATCCCATATGT
CCATTGTTTTACTGAATTTAGTGGGTGAGTGGAGTGAGTTAGTGACACTTGTCATTCTTTCATCCCTCAT
GCATCTACAGTTTATCAGATGAAAAGCACTGGTTCATCCTTTCCAGCATTTCTTGAACCTATTTTTCTCT
TGGACATTCTGAACTTCTCATTCATTCTGATATGGAAATTTCATAGGCCTACAAGTCATAGGACACTAAT
GGTTGAGTTGGCAGAGGTTGTCCATAGGCAAACTTATATTCAAAATCACTGGGAAAAAAACTAAAATGAC
TCAGTTGTATCTTGTGCTGGCCAAACTCTCAACCATGAAACTCCATGAATATTAACTAGGGTGCAGTTGC
TTGCAACCAAAATAGACAGTATTTTTCCTTCATTGGACTTACTGATGATAATTCCCCAAACAGCAATCCC
CAAAATACCATCTTAAAGTCAGGTTTAGTGATGCCTTAAGGTTTTTTGAACATAGTTTATAACCCCTAAA
TGCACATGGACACTGCAATCCTAAAACAGGTCTAAGTTTTACTGCTGTGATATTTAATGGTTGTTAGTTA
ATGTAGCAACCAGGCAGAACTGTGCTAAGAACTCAATAGAAGACATTTGTAAATGAATAGGAAAACAAGC
TGAAGTTGCAGTGCTGTCCCTCACGAGCCAATAGATTACTTGCCTCGTCCCTGTAAGGCACTTATGAGTC
TATCAATCACCATGGAATACTCATGAAATTTGCTCTGAACCATTCTTTCCTTGTCCCATTTACAAAGGCT
CCAGTTTTCCTCCACTTCCAGTTGAAATAAATATAACCTTCAGAGCTTGGTATTTCTTCACAATATGGCT
CTGGCCTAGCTTCTCATCCTCCTGACAGTCTGCTCTGCAACTTGCAAGCTCTTTCCCTCAAAAGATCCCT
TTTTACAGCCACAAGAAAGTATGATTCAATTCCTTGTCACCAAGAAAACACAAGGCACTGTGCCAGGGAT
GGTGAGAGGGTTCATGTTCTCATGAGACAAACAGAAGGGAGCTTCTGGGTCTTTGCTACTTCTCTTCCTG
ACTAGTCTTGCAATGTCTCTCTGACTTTACCTATGTAAATTCTTCCCCAATCATTCAGTTGTTCAAAGTT
CCCTGTAAATCTAGTCTTTATCTTCTCTGTCTCTCTGTATCTCTGTCTCTATGTCTCCATTCTCTCTACC
TCTACCTCCCTTCCTTTCTTTCTTTACCTTTATCACCTATTCTATATCACCCTTTAAATGATTTAATGAT
GACAATTGATTTTTAGAAAGGGAAAATATTTGTAGATTGAAATATGCACAATATCCAACAAGATTTGCGG
ATATGTTTTTTCTTATTTCTCTAAAGACTTATAACAGATGGCATTTGAGTGATGTTATGTGTGTGTGTGT
GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAAATACATATTTTCAGTTTTTATTTAGTTAT
TTATAACAAAATTCAGTTTCTCATGTACTTACATTCTTGTAATAAAACTTGTTGCAACTTAGCAGTACTC
AGATCCACGTCGTTCAGCATGATTATATTTTCCTTCCTATGATTTTTATATATCAGGTTGTCTCAATTCA
CAGTAATAGGATAACATAATTTAGATGTGTTTTACAGTAAACATGTCTTTTCATATTTCTTCCATAAGGA
TGTATTTTTCAGTGGTTTTGCTATATAAAGAGAGCATTGCTCAGACCTATAGATATTCTTTAAGTACATT
CCTTTCCTCCCCAGGCACTGAGGGTGGACCAATCAGGAGAAACCCAGCTGGAAATGTAGGGAGACCAGCA
GTGCAGCGTCTTCCTGAGCCACAGGATGTCACTCAGTGCTTGGAGGTCCGTGTATTTGACACACCTCCTT
TTTATTCCAATTCTACAGACAGTTTTCGAAATACAGTGGAAGGCAAGTAAACAAAATTGGTGTTTTGAAT
TAATCCAATTGGAAGAGCAAGTTGAAGTGCCCCAAATTAGATGGCTTTGAAAAGACTTTGAAAACCATTC
TGATCACGTGGGTTCATGTGAACTGGCTGTTGATTTTGATTTAGTTAAAATTTCTGGTTCAAAAATAAAG
GGAGTATCAGACTCCATTTGGCGATGAGAGAAAAGCCATGGGGAGTTGCCAACTTAAGCCTCTATCTAGA
GCCTCTTTAACTTTGGTACCTGGCCATTATCAGGCCAGCGTGTGTAATAAAGCCCTGCCACTGCATTGAC
AGGCGACTTCAACTGTAAAGTGTTTCTTTACAAAATAAGATTAACAGTTCTTTAAGTCCCAATTACTTGA
CAGTCTGTACAGTCTTGTTTGTTGGGAAGTTTTATTTAAGTTACATTGTATCATATTTTAAGGTCTATAA
AAGTTTAAATAAAGGTCTACTGAGGCTTAACTTGATTTTCTTCATTTCATAACAATTAATTTGAAGTTAG
AAAATGCATAATTCAAATAGGTGCAATGACTTTTCTAAGATAGCCAACAATTATATATATACATATATAT
GTGTGTACGTATGTATATATATATATATACATATATATATTCAATTTTCTTAGGGGATATAATTATGTCT
TACTTAATTTGAAGTTTGTCACTGTTGAAATTTCCCTTGAGTTCCTGCACCAACCCCCTTCCTCTCCTAT
GATCTGAAACATGTAAGACATAAATCCAATTGCTACTTTTAATACTGTGCCCTTTAATCAAAATTGTATA
CACTCCTTATGTTTATTTAAATGGTATTAGCTCACTGACAAACGTTGATTCAATGTTTACTTCATATAGA
TAACCAAAATGATATCTACAAAGCTAAAGTGGTCATTTTTAGAGCAATATACTATGTTTTCTGAGTAAAA
AATATGGATTAAATGCATTTAAAATGAGTTAGTGAATATATATATACATGACAGTTCAACCCAATCAGAC
ACATTTAACTTAATCGCTAATCACAAACCCTCTGCCTTCTGACCTACTTGGCATTTATCCTTACCAGCCT
AAACACGTAGAGATACTATGAAAATTCCCTAATACTTTAAAAGTAATCTTTCCGGATGTTTAAAACCGTA
TAGAAAAAGTAGGCAAATGGTGACACATTAGCATTCCCACAAAATTAATTCTCTAAAAATAAATATGCTG
GCTGTCATTGAAAAGGAGAAAGGTGGGAAAGTGTCCAGGAGAGTGACAGCTCCCAGTGGTCACAGCAGTA
ACTGGAGGATTTCCACTGTCTCTGTTTCCATGCAGAGCAAGCTGTGCCTTGTCAAAATTCAGCATTTATG
CATTCTGACTATTATCCTTTGCAGGTCGTTTTGTTAACCTAAAAACTACATTTGGAATGCCATGCTACCA
GCTCAGAACTAACCTAGCTCTGAGTATAGCAAGCAAATGTCACCAGCCATTGCTCTAGAGAGGCAACACT
GTTATAATGAGCTGATATTTAGCCTGGAAAACGTTGACAACCTTTTTACTAATTTAATTACTGCTGCTGA
CTATCAGTGTTGTATACTATTTTCATCCTTACTTTCAAATGTAGGTTACAGTGCTCCCACGGGAAAATAT
GACCCTGCTGTTCGAAGCCTTCACAACCTGGCCCACCTCTTCCTGAATGGAACGGGAGGACAAACCCATT
TGTCTCCCAATGATCCTATTTTTGTCCTCCTGCACACTTTCACTGATGCGGTCTTTGACGAATGGCTAAG
GAGGTATAACGCCGGTGAGATGCTTTCCTATGTTTTCTGCAGGCTTTGCAAAGAGCTTACCCTGAAGGTG
TGGTTATCAATTCAAGCTAGCCCTTGACACCTATAAAATATGCTCCAAAATAAAGATTCAGTAGCTCTCA
TATCCAGCCCTTGCCAAATACTTAAAACCACCTTGAAAGGTGTAGAAGTCTTTCACTACAGTAACCAATA
AGATGACAGACAGTAGAGGAATTTTTGTCATTAAAAATAATGACTATGATGTGTCTCGCATTTTTATATT
TTCCAGCAGACCTTCTCGTTGCTTCTTAGAATAAATGGAAGGATGTTGCAGATCTTTTCTGGGGTTTCAC
AAAAGACTAGACATGCCATCACCATAATCAGCAGTTCTGTGCTATCACTTTACGGCCTCACAGAAATGGA
AAATTTGCTCTACTTGAAAAGTTAACTGTCTTTATGTCCCACCATAGGAAATCTCTTTTAAGCTCATTTC
AATGCTTTCTTTAAAGTGTTATTTTAGAGACCTAATTTACTGCACTCTTACTCAGCTAAGAGAAGTGTGA
TGCTTTTCCAAATCATGGGAGGACTTTCATTGGTTTAAGGAACATAAAATTTCATACTTTGAAATTTTTC
TGCATGTTATCTGCCATACCTTTATCATGCACACACAATGCTGAAGGTTAGCACTCTGTTGCTGTATCTT
TCCAATGAGGGCATTCACACTTCTTTGTGTGTGACACAAACCTCTATTGCAACCTGTCCCAGACTATTAA
TCTATGGGTTGGTCAAAATATATTATTCTGTCAGAAACTGTTAAGAAACAAGTAATTTGCCATATATGGT
AGTGTTTATAATTTTGATAATCAGAAATTTGAGGTAGAGAACTTAGAGTTCAAGACCAGCCTACGCTATA
ATTCTTTTCTTGAGTACTGACTCAAAAAAAGAAAAATCAGACAAGAAGTTTACATATAAATTCTTCCTTA
GCTGTCAATGTTTTATAAATTGGTATATACAATTGGTATCCTGTCTCAAATTTCATGTGTATTTACATAC
ATAACAACAAAAGAACTAGCTACGTAAGATCAGATGGCCTCAAGCTCACAAAGATCTGCCTGTTTCTGCC
TCTCACCACTATTGTTATAAATCTGAGTAACATACAATTCATTATCCCTCTTCCATTGCTTTAGAATTAT
GTATTCTTTCAAACGTAGTGCTCCAGAACTCCGTGCATTTATTTTTTCAGAAAAAGCAGTTTGTACATTT
CCAAAATGATTCCTTCTTCTTGAGCTAGAAAGGAAATGGAGCAATGATAAATCCTTTCCTGAACATTAGG
TGAGCCCTTAATGTTTGCTGGACGACATTCTAAGCACCAGAAGTAGCATCCAGAACTCAGAAGTGCTGTC
CTCCTAGAATTTTCCTACCTATTATGAGATATTAAGACAGATGACTATAAGAAAATACAGTATAGGAGAA
AGTGGAAAGTTGTTGTAGGTAAATAAAACCAGAACTAAGATTGGGAATGAAGTGTAGAAAGATGGAAGAT
CATCCTAAAACAAAGGGATTTGAAGGACCTGATACAGCTGGAGCAGAGGGGCCCTGGGAAGAGGAGGTGA
GAGGAAGTGGGCTCAGCCAAACAATGAGAAGATACTCAAGCTCACCGCATTACAGCCTTGGGGAAATGGG
GGTCGTTAGAAGGATCTTGCAAAGAGAAATTACTTGTGATCCAATTGTGAATGCTGTTTTTGCTATGACT
CCTCTGCCCATTTTGGTGAACTTTATCCCATAGCAGAAGCGAACTGAATTGAGAGTGATCAAGCCAGAAT
TCAATAGACAGGTGGAATGTGAGTTTACAATTCTAATTGAATTATAAGCCTCAACATAGAACTTTCATAG
GCTACTAGTACTACAACAGGATGTGAGACTTTCAGGACTGGAAGGTGGCTTCTTTGGTCAGTGGACTAAT
ACCTAGCACCAGCAGGCACTCCGTATATTTCCATAAGTATTTTACTTCTTGTAGTACATGGTAAAACTGA
AAAGACACAGATATATGAAAGCCATTGCCATTTTGGTACCTGACTTTTTCTCAAAGGAAATGCTGAACCA
TGCTTTCATGACCCCACAGATACCAAGTCTCCTACAAAAGGACACCCTTCACCCTTGCTGTCCTCTCATG
TGCCAGGTGTCCGCAAAGAAGCAGGTAGTGCCCCTCCGAAACACAGATCCACCTGTGGTTTTGGGGGCAT
TCTGCTTGGTGTTTAATAGCACTCATACAAATACAGATTAACAAGAAAAGCATAGACACAGAGAACCTAT
TCTAACTCTCATCCTTAATCACGCAAAAAAGAAAACGCTGAAAAATAAACGCCTTCTGTTTCAATGGCTG
ATTTAGATGGAAGGAAAGGAGACAACAGGGAACAGTGTTCTAGAGATCAGATTCAATTTTTTTTTTAATT
AGGTATTGTCCTCGTTTACATTTTCAATGCTATCCTAAAGGTCCCCCATACCCACCCCCCCAACCCCCTA
CCCACCCACTCCCCCTTTTTGGCCCTGGCGTTCCCCTGTACTGGGGCATATAAAGTTTTAATACTTATTT
CTGTCAAAGTAAATTGAAGAAAATAGAAATATTAAACAGATACGACGGAGGTCAAGGACAACCATCTGCC
AAGTTTGAATTACAGACCATAATAGAGAAAGGGCAGATCTGGCTCTTTATTGACTGAAAAACATGTATTG
CGGATTAATTTGAATTAACTTGTGTGGTTTTAAAACTGAAGAGCTGAGAATTTTATACAGAAGTAAAACT
CACGTTCTCTCAAGACATGTGCTGGAACCACGTTCTCCCTGTTCTGCAGAGACACTTGTCTTGAGACCCT
CCTTGATGTAAACTTTAAAAACACTTTCTATGTGTTTCTTGCCCATTAACCACCTTCAGAACATAGCAAC
TACTTTGATGTCAACTTCCTGTCTGCTAACATGCTGCCTTTGGAATATTTTAGATATTTCTACCTTCCCG
TTGGAAAACGCACCTATTGGACATAACAGGCAATACAACATGGTGCCATTCTGGCCTCCAGTTACCAACA
CAGAAATGTTTGTTACTGCTCCAGACAATCTGGGATATGCTTATGAAGTTCAATGGCCAGGTCGGTTTTG
TCAGGGTATTTTTACTGTGGTGTTCTCCAAAAGCAAAATTGTCATCTTGAAAGTAAAGTCCCACACAGTC
CTGAGATAAGTGTGTTCTATTCGATATGAAGCTCTCGCATGAGTTCTTATTTGGGAATAAAAAAAAAATC
TGAAAAGTTGTCACCTAAGGAGTACTCACTTTGACCCAGTACTGAAATCACTGTACGGCATTCTATCTTA
CTTGATCGTCATAGTCTTTGGAGACGAGTATTTTATTTCTCATTTTGCAAATAAATGAAAGAAAACTAAA
ACATTAGAAATTAGTTCTAACACTGAAAAGGTTATGTTTCAAGTAAAGGACATGATGAGTTTTAAACTTA
GACACCTGTAAAGAAAAAGGTAGTTGAAATATTCAAAGCTTCTTTTCTGGGATTTTAAAATTCAAGACTT
TCAACTCTAAATTTTCCTCAACAAACAGAACCTAGTGAAGGATCACAGAATATGGGACTTGAAAAGGCTA
AGCTCTAAAACTAGCAATGCTTTCAACAGCCCAGTAACCCTGGGCAGGGTCTCAATTCTTTGACCTATCA
TGTCTTTACCTTTAGAATGGCAATAAGGTTGATCTCAGTGTGGCTCACTCAGAGAAGGAAATAAAGAGTA
CTTTCAAGATGGCAGGTGCTAGGCTCAGGTAATATGGCCAATGAAACTTAAACATGAGGGTCTCTCCTAC
AGTGCCTTGAACAGTGCCTAAGTGTAAGCAGACCATTTTGGGTGACAATTATTTTAAATATTTATATTAT
TCTCATCTTATCTTTCAAATAGGTCAGGAGTTTACTGTATCTGAAATCATTACCATTGCTGTAGTGGCTG
CGTTGTTACTTGTAGCTGCCATTTTCGGGGTTGCTTCTTGTCTGATCCGTTCTAGAAGCACCAAGAATGA
AGCCAACCAGCCTCTCCTCACTGATCACTATCAACGCTATGCTGAGGACTATGAGGAGCTCCCGAATCCT
AACCACTCCATGGTCTGATAGCCGCCTGCCCATCCCCGCACGCAGCAGGTTGGGAAGCAACCTGATTGAA
ACACAGCTGTCAACCGTATTTCCTTTGGCTTCCTTCTTTTCTTCCCAAGATAGATGTGGTTTGGAATTAA
AGCATTGCTCTCCAGTGATGACAGTTTAGACTCCTTTTAATGGGTTTTAATAATTAGTTCTATTGAAGAT
GGCAAATTATACCAGTTGTGTGATATCTGAGAGGATAATTGGATGAACTTGGTGGTATTCTAAAGATGGC
CTGTATGCTGTGAAAAAGCAATGCTTTGTTTACACAGGAAAAATAAGTTTGATGTAAAATCTCTATTTCA
AATATATGAGTGCCCATTCTTATGGAGTTAACATGTGAATGCATTGTTATTGTTGGTACTAATCAAAAGT
TATAAAAGCAGCCATGTTGATTAGTTACAACAAATCACATGACATTATAAACAAATAGAATCCTGATTAT
CTTTCTGAAACTGCTCTCATTTTGCTTTCAGCGTATTATTTGGCCTCAGGTGCAAGGCCACCACAAAGTC
ACAGTCCTTGCCACACATGGTAAAGACGAAAGCTTCACTTGCTGGAACACATCTGCTCTTGCATATTTGC
CAATGTGTTCCCTAGCTCAGTTCTCTGGACATGAAACTGCCTGGGCCACAGTTCACCTCTAATTCTCGTA
TCTTAGAGGCCTGCGAGGAAGGTATCAGTCAGAGGACACAATGTTCTGTGCATCTTATCAAATGTTGTAT
TTCATTTCAACAGCATTGTTACACCACTTATCAGCCTTCTGTGTATTTCAAAATAAATATAATAAAATCT
TCTTTCATTGGTTCCAGGTTTTCAAAAAT

</dna_sequence>
        <protein_sequence>>NP_001268943.1 5,6-dihydroxyindole-2-carboxylic acid oxidase precursor [Mus musculus]
MKSYNVLPLAYISLFLMLFYQVWAQFPRECANIEALRRGVCCPDLLPSSGPGTDPCGSSSGRGRCVAVIA
DSRPHSRHYPHDGKDDREAWPLRFFNRTCQCNDNFSGHNCGTCRPGWRGAACNQKILTVRRNLLDLSPEE
KSHFVRALDMAKRTTHPQFVIATRRLEDILGPDGNTPQFENISVYNYFVWTHYYSVKKTFLGTGQESFGD
VDFSHEGPAFLTWHRYHLLQLERDMQEMLQEPSFSLPYWNFATGKNVCDVCTDDLMGSRSNFDSTLISPN
SVFSQWRVVCESLEEYDTLGTLCNSTEGGPIRRNPAGNVGRPAVQRLPEPQDVTQCLEVRVFDTPPFYSN
STDSFRNTVEGYSAPTGKYDPAVRSLHNLAHLFLNGTGGQTHLSPNDPIFVLLHTFTDAVFDEWLRRYNA
DISTFPLENAPIGHNRQYNMVPFWPPVTNTEMFVTAPDNLGYAYEVQWPGQEFTVSEIITIAVVAALLLV
AAIFGVASCLIRSRSTKNEANQPLLTDHYQRYAEDYEELPNPNHSMV

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1342">
        <gene_name>TRP-2</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>1638</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>193788640</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AL139318</gene_refseq>
        <protein_refseq>NP_001123361</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>13</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>94437303</gene_start>
        <gene_end>94549412</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>transcript variant 3</protein_name>
        <protein_pi>7.46</protein_pi>
        <protein_weight>59851.11</protein_weight>
        <protein_length>552</protein_length>
        <protein_note>Also known as TRP-2; TYRP2</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000013.11:94437303-94549412 Homo sapiens chromosome 13, GRCh38.p12 Primary Assembly
ATAATCTGCAAAACAACATTTATTTTTAGTTTCCTTTTTAGTAAGTTTTCTACTTCTTAATAATGAGATT
AAAACTAGTCATTAAAAGTATTATAATTAACAATGTTAAATCCTAAGCAAGATACAAATGTCAATTTTAG
AATTAGAAGGGAATTTAATGCACAAAGGAAAGATGTTATTGCATTTTATCCCATTTCTGAATGTTAGCTT
TATAAAAAGCATTTCTATTAAAATCATACATGCAGTTTTTCTAATACTGAAGATATAAGCAGTAAAGTGA
TCTGGTCATTTTCTCCAAGGTTGAATTCTTCCCCCTATCATTGAGAAATATAGCCCACAGTATTTGGTGA
CATTTTCTGAGTTTATTTGCATGATATTCAATGTAAGTAAATACCAACTTTTTATTCTGTTGGTTTATCC
TACCTTAATATTTGTTAAAATGCATTCATAATTGATTTATTGTAAGGTCAGAAAATGCTAGAAAATTGTA
TTTCTCTTATATGAACTACAAAATTAGGAAATTCTCTCAGGAAGACATTATAAAACATAATAGTTATAAA
AAGTCACCCACACTACAGATAAAAGCAGCTAAGTATAATCGATTACTATTTTTTCCTACCTAAGATAGAT
CTGCTTTAACCAAGTCTTATGAGACTATGATATATGAGAATTCTGATATACCTGACAGATAAGCTAGAGG
TGGTTATTTGCTTTATGAAATTATTCGTAATAGTTCACTTATAAAAAGTAACTTCTGGCGCTTTTAACAT
AATTGATTTATACATAACTTTTCAGAAATATATGTACCATGCACAATTATATCTCCATTTTAATAAATTT
CTCTTTTTGTTTAAAACCAAGATTTAAAAATGTGTTCCCCAACTATCCTGAGCTCAGAGCATAAACCTTC
CAGAGTGGAGCATGTGAAAGACACAGTGCTGTATTTTCCATGAATATTGTTAATGGCAGGAACTGAGAGG
TATCCATGTGGCTGAGGCTAAAAAGCCCAAGCAGGGCTTTACCGGGCTATCTTGATCTTCACCACTGAGC
CTGCTCTCAGATGCACCTGTAGCTTTATGAGATTCAAATTCAGTTCCAACTGGGCTTTGTCCATTTCTCT
GGCTTTAGCAGTCCTTTTGCATGGGGTAAACTGGTTCTTGATGAGTCTTGCACCCTCTAGGACCCCTTAT
GTTGAAGGCAGCTCCAGGGACCTCTTAACACCCATTCTTTACATTCATTCATTCCAGTAGAGAGGGGCCT
CGACAGACAAGCCACGCCCTAGAACTTCAGTCTCACTCCTGATGCACAGAAACCAGATATGAGCAGATGA
AATTTGCCTGGAAATCTCAAGAGCCATTAACTTCTCTGAAGTGGGGTCCATCATGATAAGTCTGAACATC
GTAGTAAAGATTGTCTCATTCTTATTCCTCATGATCTGATGATTGCATAGCAGAATATAACCACTTAATT
CTGAATTGTCATGTTTTGTACAGATGGTTTGCTTTCAAATGATAAGACTTAATTGATCAGCATTCATAAG
TAACTGTGAGTATTCGGCAACATTAATCAATCTAACATCAATGCTTAAAAATAAGCCCAGTGCATTATGT
GGGAATAATTTTTCATCTGAGGCTACCTAGTAAAGAAATTGGTAGAGGATCAGCCAAAGAGACCTCAGAG
TAATGGGACTCAAGTCAAATTGTCTCATGTTCAGGTTTACAGCCTCACCAGCCTTCAGTCAGCCTTCCTT
GGAAAGAGTAATTCTGTATTTGTTAATAGGTTTACAGTAGCATATCAACTAACCAGGAAACTCTATAATT
TTATTATCTTCTCTATTTATCACTATAGAATCAATGTGTATCCAGCTATTGAATCCTGTAATATAGGTCT
ACTGTTTAAAACTGCAGATTTTAAGTAAAATCCGTAAAATCTAGTTTACACAATAGAGTGGAATTGATCC
TTCATTTAGTCATTTTCCATCCTGTAAAGAAAACAAGGCTTATTCTCATCTTCTAAGCTGGAGAGGAAAA
ATATAGAGAAAAGAAGAAAAAGAAGCCCAAGGAAGATAATCAGGAGGGTGCCTAGAAGCAGAGATGTTTA
TAGCTAAAAGGGATCTTGGAGACTCATCTAGCACCTACCAACTCCCACCTCCATGGCATTACCAATAAAG
ACACTGGGGCTAAGAAAGATTGATGTATGGTCTTGGCCAGGTCTCACATTGCACTGACCTGCAAATTTAA
ATGACTCCCCTGGATCAATGTTTTGGGATTTTTTTTGTTTTTTTTTAAATGCTTTCAGAAAAGGAGGAGG
CTTAATCAATATTGGGGGGGGGGTTATTATTAGATATCACAAATTGTCAGGTCTATCTTTATTTGAAGGT
AGAGGTAGCCTCAAGCACTTTAGTTGGGTTTGTTAAACAAGCAAGCAAAGCGGAAACTACAGCTAAGCAT
CTTCTGAATGAGATCATCATCACTATAGAAGAACCTATGTCAAAGATCTTCAACTCAAGAAGGAACAGTG
AGGATTAGTTCCTTTATTGTCAGCGTCAGAACTGTGGCTTGGCCAGCCTCTTCTCTTAGGTAAGGCATGA
GCACCCTAGGCTTCTTCTGTGTATCTCTTGCTGCTTAAATGTGTCTCCATTAGGGGTGTATATCCTTTTC
GAAGTCTTCTATATTGAAGAAAAGCCAACAGCACAAAAAGACCAACCAAAGCCACCAGTGTTCCCATGAC
TACTAAGAGAGTTGTGGGCCAACCTGGAGTTTCTTCAACTGAAACTAAAGCAGAAGAGAAGGGTCTACAA
TCAGGATTTTCATCAGCTGAATACTTTCAGAAGAGAAAAAGAGCAAGCGCACTTGCCTTTCACGTGCTTT
TTGTTGATAAAGCAAAACTACTCATGCTAGACTAAAATTTATCTTCTCCTTTCTCACCATTTATCATATC
CACAATTGTTTTTCTTGGGGTAGTCAGAACTGGCATCCCATTACTTAAATACAGCTTATTGCATTTTAAA
AATTTGTTACAATAAATGCTTATGCCGAAGAAACCTTCTAAGGAAGAATGTAACTACTTTTCTGAGTTAG
AAACTCATTTGTGAAAGTGCATGCTAAAATGGCATCTGGGGAGCTGCAAAATATACAGCCCTTGGGAAGA
GAAATTCTGCTATTGTCTCTACCTTTTTTATAGAATGATAAACCTGTGAGAGGGATCAGACTGGCTATTA
CACCAGGAGACACTCAATAACCAAGCAGATGATATTTATACCCATTCAAATAGTTGTGAATAAAATGTAA
ATCTCCCACATGATAAATCCAATCTTCTACTCTCATATATTTTATAAGCTCTCTTCCACAAAATTAGTGG
ATTTCATTTTTTGGTTTTTTTTTTTTTTTTTTTTTTTAGATAAAGTCTCGCTCTGTCGCCCAGGCTGGAG
TACAGTGGCATGATCTCGGCTCACTGCAACCTCTGCCTCCTGAGTTCAAGCGATTCTCCTGCCTCAGCCT
CCCGAGTAGCTGGGATTACAGGCACCCATCACCATGCTCAGATAAATTTTGTATTTTTAGTAGAGACAGG
GTTTCGCCATGTTGGCCAGGCTGGTCTGAAACTCCTGACTGCAGGGAATCCACCTGCCTCGGCCTCCCAA
AGTGCTGGGATTACAGGTGTGAGCTACTGCACCTGGCCGAATTTCATTTTTAATATACATATGCCTATTT
TTCATTTATTTTAAAAATTATATTCTCCTTGGCCAACTGTTCTTAAATTCAGCTCCTCTGAATTTGTTCT
ATACCTTACACTCACCTAATATAAGATTCTCTTTCTAGTCCTTTTTCTGCAATCCCATGGGAGGTCCTGA
CCTGTCCTGATGGGATTCCTCCAAGAGGGTTTTGATCTGTCTCCTCCTGATTCAACCCAGCAGCACCTAT
TGCCAACTTCATCTTCTTAAAACACATATATTTTTATTCTGCCATTTCTTTGTTCAAGACCAAAAAATGG
TTGCCTTTTGCTTTTGTCCAAATCCTCTTAGTTTTTTAAAAAATTATGTTTTAGAAATTGTTGTAACATA
TATGTAACATAAATTTGACCACCTTGACCATTTTTAAATAGGCAGTGCAGTGGCATTAAGTACATTCACA
TTGTTGTGCGACCATCGCCACCATCCATTCTCAGAACCTTTATATCTTGCAAAACTGATACATTGTGCCC
ACCAAACAGTAACTCCCTATTCTCCCCTCCCAACCCCTGGTAACCAGGGGTCTCTATGAATTTGACTATC
TCATAGTCTAAGTGGAGTCATGCAGTATTTGTTCTTATGTCTGGCTTATTAAACTTAGCTTAGTGTCCTC
AAAGTTCATCCATGTTGTGGCATGTATCAGAATCTCCTTCCTTTTTGAGGCTGAATAATATTCCACTGTA
TGTATGTACCACATTTTGTTTATTCATTCATCCACTAACAGACACTTGGTTTGCATCTACCTTTTGGCTA
TTGTAAGTAATGCTGCTATGAACATGGGTGTGCAAATATCTCTGCTGGACCTTGCTTTCAGTTCTTTTAG
GTATACCAGAAGTATAATTGCTGGGTCATATGGTAATTATTTGTTCCATTTTTTTGAGGAATCCCCATAC
TGTTTTCCATAGTGGCTGCACCATTTTACATTCCCACCAGCAATGCACAAGGATTCCAATTTCTCTACAC
CCTCAGCAACACTTACTATTTTCTATTTTTTTTTGATAGCAGTCATCCCAATGGGTATGAGGTGGTATCT
TATTGGGGTTTCTGCCTGGCATCTAAGGCCCTCTGTACCTAGGCTCTTTCATAAATTTGAACTTAATTCG
AGGTAATTCTCTGCCCAAGCGTCCCACTACAGCCAGGCTTGAAAGACTCAGGTCAAAGAGAGAGAGACTG
AGCTCTGAAATCATCTTGATTGCTTTCTAGGCTGAGACTTTGGGTAAATAGGCTGTGTGATTTTTCACCT
TCTTGATTAAGATTTTTTAAATTGTTTTGTTTTTGTTTTTTTGGGTTTTTTTGAAACAGGGTCTCACTCT
GTTGCCCAGACTGGAGTGCAGTGGCACAAACAGGGCTCACTGTAGCCTCTACATCCTGGGCTCAAGCGAT
TCTTCCACCTCAGCCTCCCGAGTGGCTGAGACTACAGGCATGCACCACTATGCCCAGCTAATATTATTTG
AATTTTAGCAGAGATAGGTCTCAGTATGTTGCCAGGCTCCTAACATTCTTTAAATGGTGTGTGGAGCCAT
ATTGGGGCCTGGGCCAAAAAGAAAAACATGTGCCCTGTATATACTTGTCAAAATATCCTCCCATATGTTG
AACCAAGTGGGAAAAGTTAATAAGAAATCTACAATCTTAAAACATGACTTTAAAAACAGTAACTAATGCA
ACATACACATAGAGTCCCACGTAGCCCAATCTGTTGGTAGACCAATCAATGTCAGCCTTCATGAACCTAT
CCATCGCAGGTGGTATAGGCTAAATGGGAAATGACTGATTCAGTTATAAGACGATGTGGGTATGAAAAAC
AAACAAAAGTCTGCCTTTATTTAAAATTTTGATGATGTATTATTCATGGTTAATTTTTTGCATTAATTTT
GACTTTCCAAAATTTTGTATTATATTATTACTTACCTTGATTACTGAGTTTTCTGGCCTCCTCTTGAATT
TTGTGCTCAAGGCAAATGTTGTACTTTCCTCACCCTAATCCCAGCCCTGCCCTCAAGGAATAATCTCTAA
ATCCAGCTAGTCCCTGTACAGTGTGGCTAGTTCATTTTTATTTCATTGGTTAGAAATTTCAAAGAACCAT
AGGGAGGTTTTTTATTAATCCAATAAACTCAGAGAGAATTGTCAAGTCAGGTGTAAAAGCAGATAGTTCA
TTTAATAAGATCTATTTAAAACTTTCAGTTTTCTAAAACAAGAGTCAGCTCATTAGTCCCTTTCTGATGT
TTAATTGGTAGTTTAAAGGCTCATTTTGCTAAATACGTATATGCTAGAAAAATGGTCAATAAACTTAACT
AGACCTGAAAGCTTCGGCTAAAGGTCTTGGTTTACATTATAAAGAAAGAAAGCAAGAAAGCTAGCTTCTT
TAGAAGATGAATGAATCACCCATTTGGAAGTTGTGTTAGTTACCTGGCAGATCGATGGCATAGCTGTAGC
CAAGTTGGTCTGAGGTTAAAAAGAGTTCTTCATTAGTCACTGGAGGGAAGAAAGGAACCATGTTGTACAT
CCGATTGTGACCAATAGGGGCCAGCTCCTGAGGCCAGGCATCTGCAGGAGGATTAAATCTTTTCATCCAC
TCATCAAAGATGGCATCAGTAAAGGAATGAAGAACCTGCAAAACAGTTGGACACAGCATTTAACATAAAT
CAGTCTGTTCCGATCACACCAACCTGACTGTTGCTTTCTCTAAAGTGGAATAACTTCTTCTTGACATAGG
AACTTCTGTATACCCATGTGTGGAATACCCCCTTCTGTGTACCACCATGAGGAAGCCCAAATCAACTCAT
ATAGAGTGACTATGATGGCGAGGATCAAGATTTCGGGAAGAAAAACAGTTAAGTTTTCAACGATGTATGA
ATCTCTCTCTCCAAGCAGGACTATAAACCCCTTTGTCAAGTGAGCAAATGAAAGTTCATGTTGGATTTAA
CATTGGTTGCAGATTGAACATTTGAGGCCTTCAACATATATGTGTTAATTATGAAATTCAGAAAAAGGCA
AGTATGATAAGATACATGTTCTAGTATTGAGATGATTTGGTTTAACAGGAGAGAAAGAAAAAGTTGTGTT
TACAGGTTGAGTATCTGAAATCTGAAAATTTAAAACCTAAAATCCCCCTAAACCTGAAACTTCTTGAGTG
CCAACATGACACTTGAAGGAAATGCTCATTGGAGCATTTTTGAATTTTTTGGATTTGGGATTCTCAACTG
GTATAATGCAAGTATTCCGAAATCTGAAAAAATTCAAAATCCCAAACACTTCTGGTCCCAAGCATTTCAG
ATAAGTGATACTCAATCTGTATCAATATTATAATATAAAGGAACAGTAAATTTTTCTCACCAGGAATACT
CTTCTGTCTACTCATTTCATAAACTCTCACTTGAATTCTTGCTGTTATGCCAGCAAAAGAAAGTCTAAAA
AGGTAATGTACAAAGTGCTCATTTATGTTTTCTCAAGGAAGCCATTAAAGTCCTTTTAAAATATAGCAAT
TACTATATGTTTTGAAATATTAACAGCAAAATTTCCACATTGATAGCCCTGATTTTGTAACATGATACAA
GTTTGAGAGTTCAGTCCCACCTTGATGGCAGTTGTTGGAGTTCCTTGTTCCTTCCTGGATGGTAAGTTCA
AGGAGCTCAGGGGCAGTGTCCTTTTTTCATTCCCCCTGGATCCCCAGAGCTTGTCACCCCAGGGTGTCTC
ATATGGAGAAAGGGAGGTACTTATTTCAGTAAATACTTATTCAGTGTATTCATTCCTCCATTCACCACTG
TACCTTGTACCTCATTTATAGCACTGATCAAATGATACTATAACTTGTTATTTATGTATCTATGTCCCCT
AACAAGATCCTAACTCCTTAAGGTCTAAGATAAGGACTTTTCACCTTTGAAGTCTCAGGTTTAGTATACA
ACCTGGACAGAGTCAATGTTTACTAACTATGTGTTTGCTGATGACAGTGTCATGCAGACACTTTGCATAC
AGTGCAAAGCTTAGCATACAACCTGGACAGAGTCAATATTTACTAAGTATGTGTTGGCTGATGACAGTGT
CATGCATCTTTATTTACATAAACAGTTTGTGCAAATAAACAGTGTCTAGGGATATACAAAAATATATTTT
CCAAAGAAGGCCACACAATGTTTGTTTCTTGACTAACATGCTTTTCTAGAATCTTGCCACTCCCTCATTG
AAGGTTGGCTTCATCTGGCCTTCCCTTGAAACTTGGTGAGTTTCTGACTCTTTTATAACCAATAAAATGC
AACAGAAGTGACATTTTGTGACTTTCAAGGTTAAATCATAAAGTGTATTGCAGTTCCTATCTTGTGCCTG
AGCCCTGAACCATCAAATAAGCAGTCCAGCTGTCCTGAGGCAGCCATGCTGTGAAGAAGCCCAAACCAAC
TCATATAGAGTGACCATGATGGCGAGGCTCAAGATTTCAGGAAGAAAAACAGATAGCGGGCCAGTCCACA
GCTGTTCCAACACCTATCACCATCTGACTGCAGCTGCACTGAAAGATGCTAGGCTAGAACTGCCTAGTCA
AGCCCTTCCAAAATTCCTGACCCACAGAAATGGTAAGAAATGAAATGGTCACCTTCAAGCCACTGAGTGT
TTGGGTAATCGTAATCTGTTATGCAGAAATGGATAAACACAACAAAGGAAAAAAACCTGAGTAGAGCCTC
CCAGGCTCATGGTTACCAGCACATGCAGGGAAGGGAGTTCCTTGGTCGCTTTCTCTTTTCTGTTGAGACA
CAAAATTTAATAGAAATTTTGTTTGTAGTTCTTACATTCTCAGTGTGAGCTGAATTGGGACCCGCTGCCC
CATGCAGAAGTGGCCCATTCCTGGAGGCAGGGGAGAAACTGTGGGGGGGCGGGGTGAAATGGGAAGAGCC
CCATTCTTCCTCAGTGTTGGGGGGCTAGAGATGCCACCCCCTTTTCCTGGCCCCCTCTGGGTTCCAGGAA
GGAGAACAGATGGAATGTCAGGCCTGAGACTTCTCCTCCACACTGCTGCCCCCTGGGTGGGAGGGTAGCT
AAGAGATCCAGACAGAGAATGAGAAGGCAGAGGTGGTGAAACGGGGATAGTGACGCAGCTTGAGATGAAT
AAAACACAGCCTGTGGAGCTGATGATCCAGGATCACAGAGGTCTGTAAACCTCAACAGTGGACACCAATA
ACATGGCACTGAGAAGGTAGGGAAGATAATATATATTAGGTACCTAGTACACAGCACCTTTCTTGTAGGA
AATGGTTATTCAATGGTTGTTATCACTATGACTATACCATCAGTACTATTATTATTTTAACTTGGGACAA
GGACTTATGGAAGAAGAATGATGGAATTCGCATTTTGCAGGTGGGTGGGGCCTGCAAGCACCTCTGAAAT
CACACACACTGTACATATAGCCAATGAGGAGCTGGGCATTTAGGAATGCATGTGGCACATGCCTAGCACT
TTTTGATAAGTAAATTAGTGAGTATTTATTAGTGTTTGCTCAATTACCCAAAATGACATATTGAATCCTC
AAAGCAGCCTGATTTGGTGGATATTATTTGTTTGCTCAGGCTGCTGTAACAAAGTACTACAGACTGGGTG
GCTTAGACAACAGGCATTTGTCTTACGGTTGGAGACAGTGTCTCGCTTCTAGGCAGCTGGAAGTCCAACA
CCAAGATGTCAGTGGGGCTGGTTCCTTCTAAGCACTGTGAGGGAAAATCTGTTCCAGACCTCACTCCTAC
CTTCTCGGGCCTTGCTGACAATCTTTGGCATTCCTTGCCTTGTAGATCTCTATCTTCATCCTCATGCAGT
GTTCTCCCTGTGTGCAGGTGCCTATGTCCAAATTTTCCCTTTTTATAGGGACACCACTCACACTAGATTA
GGGACCTACTCTACTCCAGTATGACATTTTATGTTAATAAACTATATCTGCAGCTATCCTATTTCCAAAC
AAGGTGACATTCTGAGTTATTAGCTATTAGGACTTTGACATATGAATTTTGTGGGGGACAATTCAACCCA
TAACATTATTACCCTGTTTTACAGATGGGGAATAAAAGGCACAAAAGTGTTAAGTGACTTGCCTAAGGTC
ACACAGCTAATATATGGTAGAGTAAGAATTTGAACCCAGGAAGTCTGGTTCTAAAGTGAGAGTTCCTAAT
CCACATACTCTACTTCCTCTACACCACCGGTCCCCAACCTTTTTGGCACCAGGGACTGGTTTTCGAGGAA
GACAATTTTCACGGACCAGGGGGTGGTGGATGGGAAGGGAGATGGTTTCAGGATGAAATTGTTCCACCTT
GGATTATCAGACATTAGTTAGATTCTCATAAGGAGTGTGCAACCTAGGGCCCTCTCAGGTGCAGTTCATG
ATAGGGTTTGCACTCTTATGAGAATCTAATGCTGCTGATCTGACAGGAGGCGGAGCTCAAGTGATAATGC
TCAATTGCTTACCATCCACCTGCTGTGTGGCCCAGTTCCTAAGAGGCCACAGACCAGCATGGGCCCATGG
CCCAGGGGTTGGGGACCCCTGCTTTACACCACCACACTGTAGTACAACCTTCAGGACCAACTAGAATAAG
AAAAATTGATTTTGAAGGCATATTCTCCAATCTTAACAATGCAGAAAGAGGATACTTTGACCTATGAGTC
CTAAACCAATCATGAACTTTTAGATACTGTCTGAGTTCAAGTCAGGGTTCAAATTGTGATGACAGAAAGA
GACAAGAGACTATCAGGACACAAGGAAGATGCAGAATCAGTGCTGTAAGAGGCAAATAACTTATAGAAAG
TATCAGAATTCACCAAGGGAAAAATGTAAATAATAAAGGAGAAGGCAAGATCCTAAGGCAATTAGTAATC
TGGAGAGATAAAAGAATAGGGGAAAATAATAAGGAGGAATTGAAATTGTAGCTCTCAGGAGGGCTATAAA
ACATACAATAAATGCTCTAGTAAGGCTGCACACAGTGGCTCATGCCTGTAATCCCAGCACTTTGGGAAGC
TGAGGCAAGAGGATCACATGAGCCCAGGAGTTCGAGACCAGCCCCAGCAACAGAGTGAGACCCCATTTCT
ACAAAAATTTAAAAATTAGCTAGGTGTGATAGTGTGTGCCTGTGGTCCCAGCTACTTGAGGCTGAGATGC
GAGGATCATTTGAGCCCTGGAAGTCAAGGCTGCAGTGAGCTATGATTGTGCCACTGCACTCCAGCCTGAG
TGACAGAGCGAGATACTGTCTCAACAACAACAACAACAACAACAACAAAGCTCTAGTAAGAACTATATAC
AGAGTACCCAAATTATAGAATGTAAGTTTTTTTGAAAAGACTGGTACATGCTGAGAAAATGCAAAGCATC
CAATGAACAAAATGCTACAAGCAATAACATATCTACAAGCTAAAAAGAGAAGTAGTACAATCTACGGAAT
AGGTAGTTTTGTTAAAATTGTGGGCATTATTCCTCAATAAGGTACCTTGAATTGCTCTTGAAAAACTAAT
TGTATCTTTGTTAAATACAAGTTAAAAATGTTAAATACAAGTTAATATCTCTGTAAAGGGTCAAATGTCA
TTTGAGGGTAGGAAACAAAAGCAAAAGTTAAATGAAAGTGTATCATTGGGCTGGGCATGGTGGCCCACAC
CTGTAATCCCAGCACTTTGTGAGACTGAGGTGGGAGGATCACCCGAGGTCAGGAGTTCGAGACCAGCCTA
GCCAATATGGTGAAACCCCATCTCTACTAAAAATACAAAACATTAGCTGGGTGTGGTGGCGTGCACCTGT
GATCCCAGCTATTCGGGAGGCTGAGGCAGGAGAGTCACTTGAACTCGGGAGGTGGAGGCTGCAATGAGCC
AAGAACGCACCACTGCACTCCAGCCTGGACCACAGAGTGAGACTCCATCTCAAAAAAAAAATAATAATAA
TAAATAAATAAATTTGTATCATTGGTGCCTTTCATCTGCTCGAGGGCTACATAGCTACGTTTTGGTATTA
GAAACTGAGTACTTCAGAAATGAGGTTCCGAATTTTGGCATATAAACCTATTCTGTCTTGTTCCAACAAA
ATGAGGATAGGTACAGAAAAGGAAAAAAAAAACAACACTAAATTTCAAAGTAGAGGCCATAATGGAAAAA
AAAATGTGATTACATGGGCTTTCAAGGTAAAGATTTTTCATGTAACCCATGCAGGAGAAAGTAATCAACC
AACAAATATTGCACCTGCAGGCATAAAGAAAATAAAATACAAGAAAGTGTGCATTATTTTTTCAAGATCA
TTGGAGGATAAAGTTACTATCAAAGGGCCTTAGCTTAAATGACTATAAATTTGGATTCCCACCACACAGA
TGAAATAAGAAAAGTTTCTGCATCTAGAGAAAGAACCATGGAAATATGAGGCCGGCTGCAAAGATGTGTG
TGCATCATTAAAGACCAGCACAGTGTAGCTTTCACCACTTGAGTTCATGTGTTACTGCCCAGAAGGCATC
CTTTGTCATCAGACTGGATCCTATTGTGGTGACATGCTATTGCTCTGGTCCTCTGAGAGTCAGAACTAAG
TGACAATTCAAATGTGATCACTTAAAAGCCACATGACAGATAAAAGCACACACAGGTCCATATGGGAACT
CTAATTTAAAACTTAAAGTAGAAGGTATACATTAAAAGGTTGGTTTGGACTTTTTAAATGAGAGAATTCC
TAATGGTCATTCCTAAAAAATATATTTCATCAGGCTTGCTATTTTAGGGAAATATCTTGTCTTGTTCTAC
CAAAGATTTGAAAACAAATGTAATTGGGATGCTGGTTTCACACTGCCCTAAATAGGCCATATGTAATAGG
CATGAAATAGTTAAACAACACCCAAGCCTTTATTTAATTAACTAAGCTCTGCCACAAGGAGGTGGGTACT
ACACAGAGAGAATATTTCAGTGACTGATGAGAAACAATCTCCTATGGACTCAATGTGTGTGCCCTACCCC
GAACAAATTCATATTTTGAAATCCTAACTCCCAGTGTGATGGTAATAGGAAATGGGGCCTTTGGGAAATA
ATTAAGCCATAAGGATGGGGTTCTCATGAATGGAATTAGTGCCCTTACCAAAGAGACCCAGAGAGCTCCT
CCCTTTCAGCTACGTGAGGACAAGCAAGAAAATGGCCGTTATGAGCCAGGAAGAAGTTCCTCACCACACG
CTGAATCTGCTAATGCCTTGATCTTCAACTTCTCAGCCTCCAGAACTGTGAGAAATAAATGTTGTTTAGG
CCACCCAGTCTCTGGTATTTTTGTTTTAGCAGCCTGAATGGACTAGGACACAACCACGGAAGAGAAAAAA
AAAGATATTGGAGCAATAATAGCATCTTCCAGGCAGGGCGCAGCAAGGATGGTGCTATAATTTTCTCTCC
CTATATTTCCCTATCCATTCTTTTATAGCACCCTGGGCAGGCAAAACAGAGAGTATTTCTCAGGCATTTT
GGAGGAGTTATATCAGGAACACATTCTCCCACATAGACTTGTATAATAGCCTTGTATACTATATGTGTGT
AAAAATGTACACAATATACATTGTATACAAGCTCTAACAGCACACATACAAAAAAAAATCGAGAGAATTA
GAAATGCTGATTCTAAACCCTTGAGGAAAAAAAGCTTCTTCTTCAAGAATTAAACTCTGAACAGATGCAG
AGGACTACAGAAAGACTCTGCTAGGTCAACTTTAAAAGAAGTGACCAGTTCAACATGCATCATAAGTTGA
CATTACGGATTGGAGAAAGAACCAAGGTGATGCTAGAAGAGATTCTAGACAGAGACTAAGCTACCTCTCA
GGCCATTCTTGACTAAACAATCATGAAAACTCTAGGAGAGAGTTGCTCAACTCAATGCTAGAACCATCTT
AGATTTGTATGTAAGTTGTGGTTTGTTATTATATTCATATTTTATCAGAATGAATTGGATGTAATTCATA
GGTTTAGTTCTTCTCAATATAGTATGCATTTATCCTTATAAATTCTAGAGTTGAAGAGAATCCATTCAGG
TGACATTTAGCACCTGTGAAATTAAAGAAAACAAGCCAGCCCCCAGCCTAGTCCATAGAAACACTGCCAC
CCTGGGGAACCAGAGAGGGGTCCAGCCACCCTCTCTGATTCCTCAGCTCTTATAAAACTCATCAAGATGT
TATGCCACTTAGGAGGTAGTAACTGTGTACCTGCTATTTAAAAACTAGTATTGAATAAGTAAATGTGACA
TTTAAAAAGCATAAATACATGCTCACAATGAAAGCAATGACTATCATTTCAAAAGCTGTGCAAAATTAGT
CAGATCTGCCCTTCACCAATTAGTGTTAATTCCTATTAATATGATCTAACGGGACTTAATTTCCTCAGCT
ATAGTGAATGCAATTGTGAAGAGACTGAGTTAAGAATTGTCTAAACTGACAAAAGGCAAAATTGTAGTTG
AAAGATTGAACACGGGGAGATTTTTGAATAGGAAACTTTTCTTATAAATCTCTGCTCAGCCATTTACTGA
TTGGTGTGACCTTGACACATTTCTTAGCCTCTCTAAACTGTATTTTCCCTGTGTTTAAAACAAGGAGAGT
AGTTTACTATATACAGATTTGTTCATTTAAGAGGTGAGCTTTGCAAGACATCTCGCATAGGGGCCATCAC
AGAATAGATGTACAATAATAGGACATTCTCCTCACAAAAATGTACAGAACATCTACTAAGTGTCAGGTAC
TGTTCTAGAGGTTGAGTATGTTTTCAGTGATCACATTCATTTTCCATAAACTAATAAAACCTACAAAATA
CATCTTTACATGACCAGATTATTAGGTTTTCCAGGAAAATAAAATATTAAAAGAAAATGTTGTATTTTGT
TACTCACACAGAGGACGAATTACTTTCCCTAATTCTGACTTTTTTGAATATTTAGGGTTTTTTTTTTCTT
TTTCCAGAAGTCATGATCACAAACAAAAGTTATGAAGACAGATCACAGAAAAGGAGGTGCAAATGGATTT
TTTCTTTTTGAATGTCTGAAAAGATGCTGGACTTCACTTTTTTTTTTGAGACAGAGTTTCGCTCTTGTCA
CCCAGGCTGGAGTGCGATGGCACGATCTTGGCTCACTGCAACCTCCACCTCCCGGGTTCAAGTGATTCTC
CTGCCTCAGCCTCCCAAGCAGCTGAGACTACAGGTGCCTAACACCACACCCGGCTAATTTTTGTATTTTT
AGTAGAGACAAGGTTTCACCATGTTGGCCAGGCTGGTCTTGAACTCCTGACCTCAGGTAACCCACCCACC
TCAGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACTGCATCTGGCCTAGACTTCACTTATAAGAAG
AGAAATGCAAATTAAAATTTGCTAAAATGCCTTTTCACCTATCACGTTGACAAAGATGAAAAAGTGTGAT
GACACAGGGACAAAGAGCATAATGAGAGGGAATGATGGGGGAACTGTGGCTCTGACACATAGGTGACACA
CAGGTATTAGGAGGGAATATTGTCCAAACTTCTAGAGGCAATTCTGTAACATTTATCAAATTTCAAATGC
ATTTTTTTACCCTTTAAGCCAGGGATTCTATTCTCTTTACTTACCTTACATGTTCAAGGATGTTTGTTGT
AGCATTGTAAAGCAAACGATTAGAAATCACCTAAATGTCCATCAACAGAAAATAGTTTAAAATCTTAAAT
TTAAAATTAAAATAATACATTTCAGGATAAATCCATGCAAAAGAATACTATACAGCTATAAAAAAAGAAT
AAGAATGCCCTTCAGAACTGAAATGATTTGGAATAAGTTAAAAAAAAAGTGGGGGAAAGGCAAAGGGACA
GAGGGGTCTATAATATGCTACCATGTAGATAAATATATAAACATATTTGTTTGTGTATTTATAAAATATA
TCTGGAAAATTAGAAAAAAATTGTATTGTTTGCTGGAAGATGGTAGTGATAATACGGACTTCATTTTATA
CATTTTATATTTTGAATCTTTTATGTGCACTAAGATTTTAAGATGAAAAAATTTAGAAAACTATGCAACA
ACCTAAAAATTAAATAAATTAAGTGATAATGGGATATTATACATAATAGGTGCCTTATAGAGATGGTCCT
CTGAATCCAATTATAAGTAATCTAGACATGATTTAGAGTATACAGAAGGATGTGCGTACCTTATATGCAA
ATATAATGCCATTTTATATAAGGGACTTGAGTAGTCACAGATTTTGGTACCCATGGTGGGGGGTCCTGGA
ACTAATTCCCTCAAGATATTGAGGGATGACTATAATTGCAACTGTATAAAACATATGAGAATATGAAAAG
AAATAAACAAAAAAATTGAGATGGAATTACAGGCATTTAAAAACTATTTTCACCAACATTTCTGTAATTA
TAAATAATATAAAAATCATAAACCAATAAAAATAAAAATTTCACATACAACAATGTTATTTTATTTTTTT
ACAATATTAGTCTAATTATGATTTTTCTTATTTAAAGTAAAGCAAAATGGATCTATCTTTAAATGTTTCA
CTCTTGGGAAGAAAAAAGCAATGCCCTATTGATATGGTTTAGCTGTGTTCCCACCCAAATCTCATCTTGA
ATTGTAGCTCCCACAGTTCCCACATGTTGTGGAAGGGATGTAATTGAATCATGGGGGTGGGTCTTTCCCA
TGCTGTTCTTATGATAGTGAATAAGTCTCATGAGATCTGATGGTTTTATAAATGAGAGTTTTCCTGCACA
AGTTCTCTCTTGGCTGCCACCATGTAAGATGTGCTTTTCACCTTCCACCATGATCGTGAGGTCTCCCCAG
CCACATAGAACTGTAAGTCCATTAAACCTCTTTTTCTCTATAAATTACTCAGTCTCAGATACATCTTTAT
CAGCAGCATGAAAACAGACTGATACACCTATCCTTCTTTTTTTAAATTTCAACTAAACTCACTCTAACTC
AGAATTATTTATACCTGTAATTGTGAGCTTTTGATTTCACTAACTTTGTTGTAGCCTAGAACAGCAGACT
CAGAAGGGCTCTTTCTTACAGGGTTAATTTATGGTAGTCCATCAGCTATGTGTGGTTTTAGAAATTCATT
TTCTCCTGCTGCACATTTTCTAAATTAATGAACTTATTTTATACACTGATTAGTAATAAGACTACTGTAT
GTTGTATTCCATTTAGAATGTCAACGTACAAGGTAGAAAACAGGCACGAGCTGTTTAGTATTAATTATGG
AACCTATGGACCCCCCAGCCACTGATGAATTGAAGGAACGTAGAACTCACCAAATGTACTTTCTAAAAGG
ATAACATCCAAGTATACTCTTAAGAATAGTATCTTTAGGAATTGGGAAGGAAATTACCACTATGTAACAC
AGTTTCTTTCTTGGCATTTAAATAACTTTACAGTCTGTTGGTTTCCTTTTTTTTCTCTTTTCTGGATTAT
ATCTAAATTTAATATTGAAGACAGCACTTAGCATTTCTCTGGCCTAATCTTATTTTCCATGATAAATGTG
TGCATTTGCCTCAATTACCTTAGGAATTACTAGAGATTGCTTCAGAGTTTTTCCTGCACTTTAATGTTCT
GCCTTCTTTTGCTCATTATTGTGATCACATACAATTTTGTAGCTCTATTGCTTGGAGAGATTTCACAAAA
AAAATTTTAATAAATGTCATGTGCAATATATTTGCATGAATTGCCTCATGAATTTGAAATTCCAGAAGCT
ATAACTCTGTTAACTGAAATACTTTAACCTGGATCTCAATATGTGAAAAATCATTTAAGGCTGAATTGGC
TTCAGCATAAAACTCTTTGAAAATAGCCTAAAGTAATGGTGAGTTCTGGAACTAGGCCCAAAACATTATT
CATTCTGTGCCTTTAAAGAAACGCTGTGGCTTTTTGTTTATTTATATGTATATTACACATACTACTAAAG
AAAAATAAAATTTTAACATTAAGCACATTAGAAACAACGAACACAAAGATGATTAAATGTCTTATATCTC
TGAACCACGGGATTTCTCACCCATCAAGTCACAATGTGAGCTTCCACCCTAAAGCAGAAGGAGAAATATG
ACTAAAGGGAAATCCCTACTACAGGCCAGATATGGTGACTCACCCAGTGCTTTGGGAGGCCAAGGTGGGA
GGATTGCTTGAGGCTAGGAGTTCTGAGACCAGCCTAGGCAACATAGTAAGACCTCATCTCTACAAAAATA
AAAAATTTAAAAAGCTGAGCATGGTGGTATGTGGCTATAGTCCTAGCTACTTGGGAGGCTGAGGCAGGAG
GATCACTTGAGCCCAGAAGTTTGAGGCTGCCGTGAGCTATGATTATGCCACTGCATTTCAGCCTGGGCAA
CAGAGAGAGACTGTCTCTTAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGATTCCTACTATCCTTACTACA
AACTAATACAAAGAAGAAAAGTGAATCCTTTACACCACAGGTTGATAAATTAAAGCCTGAGGGCCAAATA
GAGCCTACAACCTGTTTTTGTAAATAACGTTTTATTGGAACACCACATTCATTTGTTTATGCATGATCTA
TGGCTGATTTCATGATACAGGGGCAGAGTTCAGTAGTTACAACAGAAAACATCTGGCCTCCAAAGCCCAG
AATATTTGCTACCTGGCTATTTACAGAAAAATGTTGCCAATTTCTGTCCACTTAGCAGGCTTGTTCAAAA
GAAGGAGATACGGTTTAGCAATCCTGGAGACTTGGGATGCAGAAAATCAAATTACTAGCATCATTTTTAA
TAGGAGAGAAAGAGTTGGGGTATAATCCTTAATTTATCAGAGGATTCCACTGTTCTACTTATAACATATT
GGAGTACTGGATAAGGAGTATTATGACATTTTTCCTTATGAATATGAATTGTGTGTATAAATTGTACAGT
TGACAATGTATGCTTTAATAAATACTTAGAGACGTATAGTATAAATAGATGTACAGATACATGGCTGAGA
AAGCAGACACCAGAAATGCTTGGCATAAGCTATGGCTGAGACGATAGCCAGAAAAAATGATGTGAACTAT
CAAGTTAAAATCATTGAACAAAGCAGGCATTCTAGAGAAAAGCAAAGATCGCTGTGGCGGCGTCACAGAT
AAGCCCCCACCTTGTTAGAGGCTGGGACCATTAATTCAGACTTCTGACAACCCCTTCATTTATTGCTACT
ATGCAAATATGAGGAAAGAAACATTTTTTAGAAGGAAAGAACAACTCTACCAACTAATTCCGTCTCAGGA
TTTCTTGAAGCTCACCTGACTATGCTTTAATCTATCTAGGAGCCCCAGAAAGCTACTTCACACCCATCAG
GCAAGCTTAGAATCATTGAAAGCTATACCTTTACTCTCCCTCTTCATAGCTCCTTTTTTTGTACCCTGGG
TTGAGTAACAATAATAAATCACCTGTGAAATACTTCTGACTTTGTGCTTATTAGTAAAATGTCTTAGGGC
ATTACTGTCTGCTTTGGAGAACAAGATAAGAAATATTAATTAAGGTTTGAAAATCTAAACCTAACATATG
GTTCTCTAATTCTGACCATTATAAAACACATTATTATTGTTATGATAACATTTGTATTGTACTTGACGGG
CTCTAGACCAGTTTCCTATTGTCCTAATCTACTAAGAGTCACTTCACTGAGAACAACATTTTCACCACCA
GATCAGGTCAAGAGACCCACACTTTGCAGAGTGGGAAGCAGAAGCTCCATGTGGTTCAATTACATTCCCA
AGATTGCCCTGGTCTGTATCAAGTAAAACTGATTGACTTGTAATCAGTCATGAAGCCTCCAAAAAGTCCA
GAAAAACAAACTTCTGGCTGGGTGCATTGGCTCACGCCTATAATCTCAGCACTTTGAGAGGCCGAGGCCC
GAGGATCACTTGAGGTCATGAGTTCAAGACCAGCCTGGCCAACATGGCAAAACCTTGTCTCTACTCAAAA
TACAAACATTAGCCAGGCGCAGTGGCACGTGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAA
TCACTTGAACGCAGGAGGCGGAGGTTGCAGTGGGTCAAAATTGCACCACTGCATTTCAGCCTGGATGACA
GAGAGAGACTCCGTCTCAAAAAGAAAAAAGAAAAGAAAAACAAACTTCTATAAACTGATGGTTTGACAAT
GCATTATAAATGCTATATCTGGACTGAACTGTGTTTCCCCAAAATCTGTGTGTTGAAGCCCTAACCCACA
ATGTGACTATACTTGGAGATAGAGCCTAGAAAGAGGTAATTAAGGTTTAATGAGGTCAGAACCATAGGGC
CCTGGATTAGTGTTATCATAAAAGGAGGCATCAGAGAGTTTATTCTCTCTCTCCCTCCACTATATGAGGA
TGCAGCTAGAAGGCTCAGGAAGAGAGTCTTCACCAGGAACCAAATCAGCTGGCACCTTGGTCTTAGACCT
CCTGGCCTCTAGAACTGTGGGATATAAATTTCTGTTGTTTAAGCCATCCAATCTGTGGTCTTTCATTATG
GCAGCCTGAGCAGACTAAGACACATTGCTAAGATTAACATTAAGGTGAGGAAAATTCTGGAGAAAAACAG
AGAGTCTTTGGATATCACACAATCTAACTGGATAACAATATAAACTCAAAATACTGGCAAAATAAAAAAG
GAGAAGAGGTGAAATTTCTTCTTGTAATTGCTCCAAAACTATCTATTCAAGACATACAACTCAGAAGACA
CACAGACAGGGTTAAAATAGACGAGGGTGAGTTGCGTATCTGTAAAGCAGGAGCACTTTTGGGGATTGGC
TGCTGAGACATGAATGTGTATGTTGTCTAAATCTCTTATGACAACTTGAGTGACCTGTACTTAGAAAAGC
AGCCCCTGACATTCAAGAGCTGGCCTGGCGCTATCAACGAGGACTTGATGTCCCCCTATCAGACATAAAC
GATTTCGTAGAACATCGACAGCAGACAAGGCCACTCTGTGACCATGACGGATCAGGACAAAAACAAGAAA
ACCCCATAACCGTGTCTGAGCACAGACAAATTATGAACATTGTCCAAGATGCAAGATGCGTGACACCCCC
TTTCCCGGCTAATATGAGCATCTGCTGCTGTTTTACCAATTATGGCTTTAACCTCAGTCTAGTCTGCCCC
ATATACAGACATAATCACTCTATCAAGATACCCACTCATAGAATCAGGAAGCATACCCCTGCTTCCTGAC
AACATCTGATTCAGAGCAAAGCTTCCAAAAGTCCTCCCCAAATCACCTAGCACAAGCCCAAACCCTTTCT
GTCTTTTCCAACACCCACTGGCTGAGACTTTCCACAGTCCTCCATTCTCTGCCTGCAAGGAGTAACAGAC
CAATGTATTCAACTACATTGTGTTCCTAGAGGTCACAGACTGAAGAGCATTGACTAGGGTAGCTGAACAG
TGTAGCCCTGACTCGTATTTCCCCATTTTGTTTGTCTTAGAAAAGTTCACCAGGGGATGAATATACTTTA
AAAACTAAAGACTGGGCCCAGTGGTTCACGCCTGTAATCCCAGGACTTTGGGAGGCTGAGGTGGGCAGAT
CAGGAGGTCAGGTGTTTGAGACCAGTCTGGCCAATATGGTGAAACCTTGTCTCTAGTAAAAATATAAAAA
TTAACCGGGCGTGGTGGCGTGCAACTGTAGTCCCAGCTACTTGGGAGGCTGAGGCAGAAGAATCACTTGA
ACCCAGGAGGCAGAGGTTGCAGTGAGCCCAGATAGCACCACTGCACTCCAGCCTGGGCAGTGGAGCAAGA
CTCTGTCTCCAAAAACAAACAAATAAACAAACACTAAAAAAGCTCAGAATTGTAAAATTTAGAATCCTAT
TGTCAAGTTTTGTTCAGTTTGTTTTTGTTTTTGAAACAGGGTCTCACCCTGTTGCACAGGCTGGGATGCA
GTGGCACGATCATGGCTCACTGCAGCCTCGACCTCCCAGGCTCAAGTGATCCTCCCACCACAGCCTCCCA
AGTAGCTGGAACCACAGGTGCATGCTACCATGCCCAGCTAATTTGTAAAGGTTTTTGGTAGAGAAAAGGT
CTCATAATGTTGCCCAGGCTGGTCTTGAACTCCTAGGCACAAGTGATCCTCCCACCTCAGCCTCCCAAAG
TGCTGAGATTACAGTCATGAGCCACCATGCCTGGCAGTTTTCTTCTTTTGTTTTAAAGTGAGACAGAAAT
CAAACTGATATACCAAAGGAGTTCATCACACTGAAATTTAAATAACTGTGAGGCTCCTGCACAGTCAACA
GCAATCCTATTTACTGTCTGTATTATTACATGTCAGAGGTATGAATCAGATTAACAAATTAAATTGCCTC
AAATGTGAGTTTTTGTATTAATGCCATCGGTGAAGGCATTTGTCATTTTTTGCTCCTATTAGCCAGGAAA
GGGGATGTCATGCATCTTGTGGCTTGGAAAATGTTCATAATTTGTCTGTGCTTAGACACAGTTATGGAGT
AGTCTTGTTTTTGTCCTGATCCACCATGATCAGAGTGGCCTTGTCTGCTGTTGATGTTCTAGGAGATTGT
TTATGTCCAACAGGGGACACCAAGGCCTGGTTGATTTCACCAGGCCAGCTCTTGGATGTCAGGTGCTGCT
TTTCTTCTTTCTCAAGTAAAGCTCACTCAAGTTGGAGTAGGAGGTTTAAGTGTCCAGCACACCCTCTCCA
TTCTCCTCCCCTTTTCTGGCTAACAGAACCTCTCTTTCCTGCAGGTAACACATTGAAGGTGGTTTGTGTG
GACTACTGAACCTCAACAATACTCACTTAGCCAATGAAAAATCATTTATTATTATGCTAATTTATGAATT
CACCAGTGGAATTGTAAACTCTTGTCTAAGATCACCCAAAAGTGAACCATCCCTGAAGCATGGGTTCTGA
TTAGGGCCTTCAAATGCTACCTAACCATCCCTATGGTATAGATTGAAATTAATTTACATTTGCACACATC
ACATTGTTCACACAGAGAATAAAACACCATCAAACATTAATTGTATGAAAAAATAAATCTGACATATTAT
CTAGAAAATTTTCATGCATTCTGAATCTTTGAACATACCACAAAAATGGGATCATTGGCGGCTGAATGTG
GCAAAGCGTTTGTCCCGTTCAGGAAGGAATGAACCAAATTATGAAGGCTCATCACTTGAGAATCCAGAGT
CCCATCTGCTTTATCAAACCCTTCCAAAGCATTCCTAGGAGAAACAAGTATATCAGTGACAACAGACAAA
GACTGATAAAGGTCTCTTTTTTGTTGTTTTCAGCCTAGATAATAGTTGTCTAATTTGAGATTGGGTAGGG
ATATGGGAAGCTCTGTCATAGCAAATTGACCAAGAATTTGCCCCAAACTTTAATGATAATCCTCTGTAAG
GGGAGAGAACTCCTAAGCAACGCTATTTCTGAATTATATCTCTTTTGTGTACTGTATGACAACTTTCATA
TCTGTCTCTCATTCCCTTGGAGAGCAGGCTCTATGTTTTCTTCAGATATTTATTGCCAGGGTTCAGTACC
ATGCCCAGCAGATTGTCTGTGATCAGTAAATTCTTTTATTTAACATATAATCTGATATTTATATTTCTCA
ACCAAATAGACCTTCAGCTTGACTGAAGGTCCAGCTACTCAGGAGGCTGAGGTAGGAGGATCACTTGAGC
CCAGGAGTTTGAGGTTACAATTAGCCATGATTGTGCCACTGCACTCTACCCTAGGTGACACAGTGAGATC
CTGGCTCTAAAAAAAAGAAAAAAGAAAAAAATTTTCTACCACCATAGAAAGACTTTAAGAATTATGAGAA
ATATGTTTATAAATAAGACTTTAAACAAAGATGGGTCCAAAAAGGGGATGGTAGATAGATTAAAGATCTT
CTCCAAAACTGGATTCTCTCTCTCTCTTAACTGTGTTTAAAGTAGACAATTTGTATGGGCCCAGGGCAGG
GCAGGCTGGACTCAAATGTAGAGGTTGTGCTAAGTGTAGCATGGCTCAGTCTGCTGAGGTTGGACACAGC
CTTCAGAGTAGTGTCAAAGGTGGGGGAAGGGTAACATTTAAGGTTGTTTTGAAAAGGAGGATGAATTAGT
TTTTCATTGTGACAAAAGTGCTATTAAAACAGATTGCATTTTCTATATGTTTGAGTTAGGGGAGTTGTTC
TCAAAATGCAGTGCTCAGACCACCTTAACTGGCATCATTTGGGATTTGGTTAGAAATGCAAGTTGTTAAG
ACACAGCCTACACCTACTGAACCAGAAACTCTGGGAGCAGGGCATGAAACATGTGTTTTTCTTTGGTGAT
TTTGAGATGTGCTTAAATTCTAGGCCTACCTCTACAGGTACATACCACCACACCTGGCTACTTTTTTATA
TTTTTTTGTAGAGACAGGGTCTTGCTCTGTTGCCCAGGTGGTCTCAAACTCCTGGACTCAAGCAGTCCTC
CCGCACTGGCCTCCCAAAGCACTAGGATTACAGGCATGAACACCATGCCCAACCTGTGGTGGAAGATTAA
TAGTTGGTCTTTAAATGTTAAGTATTGTAATGTCATTGCTGTGCTATGATTTGAGTTGAATTTAGTCTGC
AATACTCCTCTGAGATCTCAGACCTCACTATTAAGTTCTATGGCTGATAAATTTCTAATATCGACATTTT
AAAAAATAAGAAAGGAAAGAGAAAGAGCATGGACATTGAAAAAACACTATATTTAATGAAGTACCCTGTT
TCCAAAGACTGGACCTATTAATGTACTGCAATTAGAAATACAAAAGTTGGTTTTGAACAGCTAAGTTAGA
AGGTATTAAAACCACATTGTTAGTCATAGTAGATGGGTAAAGACTTTCCTCACACCAATCCCTTGCTAAC
TTCTCTCGTTAGGCCTCTCTCCATCACTTAGCTTCGTAGACAACCCCCAAAACCTGGGTTTCCTTCCAGT
TCTTTACAATCACAGGCATGAAAACCTGTACTGTACAGGCAGGTCCAGCAGAGCTCAGAGCACCCACCTG
AAACTGAAGGTAGAGTTCTGGAAGAAGGGAGGATTGTCAAACTTCTGGAGAGACAGGCAATCTCGTATGT
CTTTTAAGGTTGGCAATTTCATGCTGTTTCTTCCCATTTGATTTCTTCTCAGCAAACCTTCATAGGTTCC
ATTGCACAAGGTGACCAGGTGGTTGTAGTCATCCAAGCTAAGATTTGTAATAAGATTTAAAATAATATAT
GTTGGCTGGGCACAGTGGCTCACGTCTGTAATCCCAGCACTTTGGGAGGTTGAGGCAGGTGGATCCCTTG
AGGCCAGGAGTTTGAGACCAGCTATGGCAAAGCCCCGGCTCTACTAAAAATACAAAAATTAGCTAGGCTT
GGTGGTGTGTGCCTGTTGTCCCAGCTACTCAGGAGGCTAAGGCAGGAGAATCGCTTGAACCCAGGAGACA
GAGGCTGCAGTGAGCAGAGATCATGCCACTGCCCTCCAGCCTTAGTGACAGAGTGAGACCCTGTCTCAAG
AAAAAAAAAAAATCCCCCAAAACAAAAAATGATATGTCTTAACTTATGTACAGTATTATAAATTTGGGCC
AAGCAAATCAATCAGGGTCACAATCATGGTAAAATTGTATTACAATTACTTTACCAGAGTTAACAATATG
TGGTAAAAAGTACTATACCTGAAAGTCATTATGGGTCGAGAAGTTTCAAAAATGTAGATGCACAAAATAC
GGACATGGGCATAAATATGAATAATCATTACCATTCTGTTGGAAAGACAGTGAGAGGGTTTACAAGGCAA
GATGACTCCTATTGTGTGCATTTGAATCTTGAGTAACTGAAGGGAGAATAGGGTGGTTCGTATTATGCTG
AGCTAAGCCAGTTTTGGCAGAAGTGACATGTAAAGTTACGAAAACCTTTTAGGCAAACTGAAGGCAAACG
GGGAGGTCAGAGTAAAAGCAGATGAAAGTACACAAAGGGGAGATATTAGAAGAAACACTGTGTTGGAAAA
TGTTCCAAGGTAGTAGAGTATCAATAGTTAAGTGCTCAGCATGGGCTGAGAAGGTCCCATGTCCGTAAGA
CATTATATCCTACACGCCTGCTATGGCCTGGATTCCAACATCAGAATAGTATTTCTTTCTTTCTTTTTAT
TTAGTTTTTCTTTTTTAATTTAGAGATAGGGTCTCACTCTGTTGTACAGGCTAGAGTGCAGTGGCATGAT
CACAGCTGACTGCAGCCTTGAACTCCTGGGCTCAAGCAATCCTCCTGCCTCAGTCTCCCCAGTAGCTGGG
ACTACTGGCTAACTTTTTTTTTTTTTTTTTTTGAGACAGAGTCTCACTCTGTAGCCCAGGCTGGAGTACA
ATGGCACACTGCAACCTCCACCTCCTGAGTTCAAGCAATTCTCCTACCTCAGCCTCCTGAGTAGCTGGGA
CTACAGGCACATGCCACCAAGCCCAGCTAACTTTTGTATTTTTAGTAGAGACAGAGCTGTCAGGCTGGTT
GGTCACCATGTTGGTCAGGCTGGTCTCGAACTCCTGACCTCAGGTGATCCACCTGTCTCGGCCTCCCAAA
GTGCTGAGATTACAGGCGTGAGCCACCGTGCCCAGCTAGGCTAACTTTTCAAACTTTTTGTAGAGACAGG
GTTTCACTATGTTACTCAGGCTGGTCTCGAAGTCCTGGCCTCAAGTGATCCCCCTGCCTTGGTCTCCCAA
AGTGCAGACCATTATTTCACTGGCAGAGATAAAAATTTAAAGATGTTATTGTGAGGGTTTTCATGAATTA
GGGATAGGACCCAGTATGTGAGAATATAATCAGCACATCCACAGGGATGAAAGAGGCCAGGACCTAAACA
CTAAGCTGAAAAAGGTCTCCAAGGCCTCCCAGGCAGCGTTTCCCAAAGTGGATTCCAATGGGATGTCCGG
TGAAGTAAGAGTTCCAGGGTTAGGCTCCTCTTGAAAAAGAATACCACATTTATCTATGGAAAGCTTGACG
ACATTCTAAAAATTTAAAAACCTTTTAAACTCAGCCTTCTCTAAATTTACTTGATGACGGAAATCTCTTT
TCACATACCATCCACTACTATTCCAAGGTATGGTGGGAAATGGCGCTTGATGGAATTAAGCTCAGTCACA
GAAAAAGCACTGATGATGTCCCTGCTCGTGGAGCACTGTTCTGAGCACTGTAGGAAATGTACAGGATGTG
GAAGACGAAGTCCCTGCTAGCTGGGCATGGGCCCCTCAAAACGCACACCTATGCAGGCTCAGGGTGTTGG
CAGTGAAGCCTGGGGGCCGGGGGAGCCACAGCTCTGTGCCCTGGAGCAGTCTAAGGACCTGGGACGAAAG
ACAGAGCAGTGGGGTTAAAAACATGGGGATTTTGAGGCCGGGTGAGGTGGCTTACACTTGTAATCTCAGC
ACTTTGGGAGGCCAAGGCAGGCAGATTACGTGAGGTCAGGAGATCGAGACCATCCTGGCAAACATGGTGA
AACCCTGTCTCTACTAAAAATACAAAAATTAGCTGGGCGTGGTTGCGCATGCCTGTAATCCCGGCTACTC
AGGAGGCTGAGGCAGGAGAATTGCTTGAACCAGGGAGTCGGAGGTTGCAGTGAGCCGAGATCACGTCACT
GCACTCCAGCCTGGTGACAGAGTGAGACTCCATCTCAAAAAAACAAAAAAACAAAAAACAAAAAACAAAA
CAAATTTTGGAGGAAAAAAATGAATAAAGGAAGGTGAGGTGAGGAGCCTCTTGGGAAATTTTTGGCTGAA
ATGTGTTCCAGGTGTTCCAGGACAGAGAAACAAATTCAAGGAGCCTTTGAGGACAGAACTCTTCATGGGC
TGCAGGCCAGGCCACTGACCTGTGTATGGTCTTTAGTATGTCACAGATCATCCTTCCCCGGCTGGCCCCA
AGCCCCTGTCCTCCTCAACTCACCAGCATCCTGTGACTCAGCCATACCAGGCTGTTTCCAGAGAATTATC
TAGCTTCACACATGATGTTCCTCCATCAAGGACCCACCCACTGCCCTCCCACACTCCCCTCACCCTCCTC
TACACCTCAGGTCTGTGCCCCTCCCCTTCTCAGAGCCATCATCTCTGCCTCTTGGGGACTTGCCCAGACT
CTCTTCTTGTCTTTGTGTATACATCTATTACAGTACTTCCCACACTCAACTGTAATTTACTTACAAGAAA
TCTATCTCGTTAATACAAGACAATATTCAAAAGGGAGGTTTTATTTCATTCATCTTTGTATTCCCGGCAG
TACCACATCACATGGGATATGATTGGTGCTTAGCAAATGTTGATTGAATGCAAGAACTACTCTTAATTTG
ATTAGGTTGATGCAAAAGAAATTGTGGTTTTTGCTATTACTTTTAAAGGCAAAAACCGCAATTACATTTG
CACTAATCTGATAAAACTAACCTGATCTCAAAATGATGGCCAAGCATAACCAATTCACAAATGTGATTTT
GATATTTTTTTTTTAATTAAAGAGCTTTGAATTTTTGAAATCCCACCTCCCAGAGGAAAACTGTTTTTAG
AAACATGTAAATAGGACACCACATGCATAAGAAACAGCACTATAAAGTGACTTCTCCTCCATGTCTCAGA
CATCAGAAAAGACAATCTCTGGATGCCATTGCAGGTACAGGAGCCATTACCTATCACAGACAGTTTCCCA
GCTGGAGAATCTTGAGTTCCGACTAATCAGAGTCGGATCGTCTGGTCTCGCTGCCCCAAACAGCTGGTCT
GTACACACATCACACTCGTTCCTCCCAGTGGCAAAGTTCCAGTAGGGCAAAGCAAAAGACTCATTGCCAA
TGAGTCGCTAAAAGCAAAGGGCAGGCCTAGTCATTTAATCCATGCCATCAGATACAACAAGAAAGCATAC
AAGGCAAAGGCTGATATGTATCTGAACCAAATATCTACCAAGACAAAGACTACTGGATGGATAAATGAAT
GAAGAAACTGTGACATAAATCAGTGTGTGTATATTTTATATATATATATATATATATATATATATATATA
TATATATATATATATATATATACTGTGTACAATGGAGTATTATTCAGCCTTTAAAAAGGAGACCCTGCCA
TTTGCAAAATGTGAATGAATCTAGAAGACATTGTGCCAACTGAAATAAGACAGATACAGAAAGAAAAACA
CTGCACTATCTCACTTATATGTGGAATCTAAAGAAAAGAAGAAAAAAGAAAAAGAGTGAATACATAGAGA
GTTACATAGTAGTTACAAGGGACTGGGAGAAATGGGAAGATGTAGGCTGAAAGGTGCAAAGTTGCAGTTA
TGTAGGATAAATAACTCGAGGTCTGAGACTATAGTTAACGTTGTATTGTGTACTGGTGATTTGCCAAGAG
AGTAGACCTTAGGTACTCTTACCACACACACACAAAAAGAGATATCTCTATGTGATGCTGAGTATGTTAA
TTTACTTTAGTGCACTAATCACTTATCTTGTATGAGTATCAAGATAAGTATATCAAAATTCACACTGTAT
GCCTTAAATATATACAATAAATTTTTTAAAAAATTAAAAGAACTAAATGCATAGTTTTGACCTACCTGGA
GATCTCTTTCCAGACACAACAAATGGTACCGGTGCCAGGTAACAAATGCAGGTCCTTGATGTGAGAAATC
TATGGCCCTGTAGGGGCGTCCTGGTCCTGAAACAATTGGGAAACATATTAGAGATGACAGAATAGAATTT
TTTAAAATGTTAAATCTTACCTGGGCTGTATCTATAGAGCCAATAAGTCCATGATGTTTTATAGTAGTAA
GAAAAAAAAGTTTTGTTGTTATTTATATCTCCAAAAGCAATAGTAATGACATGAATTTCAGAAGTAACTA
GTACTTTTAGGATAAACCCTCCTTTATCTCTTAAAAGGTTGATTTCTAGCAGAGATCCAGGAAATTCAGG
TGACTTTCAGGATTGGGAGCCCCTGATACATATTTAATTTGTAAGCAACAATCCATTCAGGTGAAATAGA
CTATCCAAAAGAATAGATCATTAAGACCTAAAGGAAATATATTTTTTAAAGGCATTTGCTAACCTATGCT
TCACAAAGATATAAATTTAAAAGGGAGGGATTAATTAATAATATTGTAACTTCAACTGCACTTAGTCCTA
ATGCAGTATTTATGTAACCAAAAAGAACTTTCGCGTATTTTGCCTCACCCATCAATCTGTTATAACTACT
AGCTGACAAGCATGTTCGCTGAGACCAGAAGAGAGAAAAATACATTCAAGCCATTTAGGCTGGACACTGG
AACTGCCAATTTTAGTGAAAAGCTCTGGACGATTTAATGACCTCCTTACTGCCTGGTCCATCCTTCTTCC
CTTTTTCATAACAGCTTTGATGGTTATGTGGAAACTTTAGCTAACTTTAGTTCTTGTCCAAAATACCTAT
AACAACTTCAGAGAGCTGAACAGACGTGAATATAAATTTAATTCGTAGCTATGACCAGAAACTAGGACTT
TCTTTTCCTCTTGAGAGAGTACTCTCTCATAAAGCAATAATTCCTCAGAGTGATAACAGGAAAACTATAA
AGGTTTATAGCCAAAAGAGCCTCCTTATCTATCGATAAAGACAGACAGATGCTTACCTGTAAGGCAAGTT
TTAAAAGACTCACACTGAGAAAAGCACTGCTGTCCCTGATGTTGGCTACACGGCCCTTTTTCATGTTCAA
TTCAGAGCAAGGTTTCAAATTCTCAGAACCCAACAACGAGAGGGTATCAATTGAAGGGGAACAAGTGATG
AGCAGAAGGATGAACCTGTCCAAATCAGAATCTTGCTCTTCAAAGTGAGCTTGATGTCTTCATTCATCCT
GACCCCAATGAAGGACCCCAAAAATGGGGAGAGGTGCACGTGCAGCCATGCATTCAAGAACTGCTATGGG
AAGAATCTAGGATGGAGTCAAGCCCTCCTGGAATACATTGGTGTCTATGGCTTTCCTTTGACTGAAAAAT
AAGGACAAAGCTGAACCTACTTGATACATGAAGTTTGTAACAGACAACCCCCTCATTCCAAGTCCTACCC
AGCCCCCAATTTTTAAGACTTGGAAGGGCAGGTCACCAATTTCTCAAGCATCCAACATGACTGTGTTGCA
AAGAGCTAAGCAGCAGAAACTCTACATTGCTGTGGCTAAGCTTGTACTTTTCCTTGACAATAAAGCTCCA
AGAAACCTGGGGATTCCGGACCATGCAGGAGTACCATAAATGATTATCTGAAAGTCTATCATGTGATAGA
CTGTCTAAAATCCATCCAAAGTTGATCTATCCTGTGAGTTTAACAAGATGCCCACTCCCAACATGAGCAC
TCTAATTCCGCACAAAGAAGCTTCATGTGCCTTAGCACATGTTCAGTTAATTCCTCTAATTTGGAGAAAA
GGTCAGAGAGGGCTTCCATGGCCAGATTCGCAAATATTTTCTTCTGAAATCAAAAGGAATTCGCCTCCAC
CTCACCAACTCACATCTTTGATGATTAACAGCTTCACAGAGAAAAGTTTACACTTTGAACCAAGAACATA
CGGTAGAGGAGAGAACATTTAAAGTGTCTGCATCCAATGCACAGGAAGAAACTGCTTCCTTCTAACTCCA
GGCGGTATTTGATAATTCTACGACTTTCATAAACCTAAGGCTGCCTTGTGGTTGCTCTCTTAATTAACTT
GCATGAAATTACTTCCCACTGCCATACCCTCAACCCAATCACAAACCTGTAATAATATACCTTCAGCCAA
GGAAAAAACCCACCTAATAATGTATCTCTAACAGAATAATAATGGAGCCACACAAAAAAATCATAAACAC
TGCAGTTGGCAAACTGCGGCTGGGTTCCATTGGGCCCAAGCAGGCCCAGCCAGTGTTGTGTGGTGATCAC
GTAGTCGGGGTGTACTCTCTTCTTCGCGAGATCTAAGGCGCCCAAGAACTGCTCTCTTTCCTGAGGACTC
AAGGAATGGATGTTCTGCCGAATCACTGGTGGTTTCTTCCGCTCGCAGTTGGGACCGGTCCAGCCAAACT
TGCAGTCTCCACAATTATAGCCGGCAAAGTTTCCTAGTTCACAAAACAGAAAGATGGAAAGGAAGGGGGT
TTATGTCGTTTGGAAGAAATTTCTGAATTTGTACTCTGAAATTTGAATGGAAGAGAAGATGAAGGTGCTT
ACACAAAGGCAAAGAAAGTCAATTTTCCTCCCATGGTCTCCTCTTAAATGTTTATATCTCCAAGTGGACT
AAGCACTAGAGGGTTTCCTAGACACATTCCCAGCAAAGAAACAGGACATGAAATACACTGTATACTGCAA
TGAGCTAAACCGTGTCCCCGAAGTCCTAGCCCCAGTATACCTCGTATGTGACTATATTTGGAGATAGTGT
CTTTAAAGAGGTAATTAAGGGTAAATGAGGTAATTAGAGTAGGCCCTAATCCAATATGACTGGTGTCCTC
AAAAGAAGAGGAAATTTGGACACAGTTTTGGAAGGAAGACCACATGAAGACACAGGGAGAAGACAGCCAT
CTGCAAGCCAAGGAGACAGCCCTCAGAGGAAACCAACTCCCTGATCTCAGCCATCCATCCTCCAGAACTG
TGGGAGGGTGAATTTCAGTGTTTAAGCTGCCTAGTCTGTGGGATGTTGTTACGGCAGCAGTAGCAGACTC
ATGCACACACTCCTTCCTCCCAGGATCGCAGGCGTGTCTCCTCCTGCGTCCACTCCACGCCCACAAAAAG
GGATGACACAGAACAGTTCATTGATTTAGAGAAGGAAGAAAATACACAGCAAGCTAAAGATGAAACCAAA
ATAAATACATGGCTTGGCCCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCAGA
TCACTTGAGGTCTGGAGTTCGAGACCAGACTGGCCAACATGGTGAAACCTCGTCTCTACTAAAAATACAA
AAATTAGCGGGGCGTGGTGGTACATGCCTGTAGTCCCAGCTACTGCAGAGGCTGAGGCAGGAGAATGGCT
TGAACCCGGGAAGTAGAGGTTGCAATGAGCCGAGATCATGCCATTGTACTCCAGCCTGGGTGACAGAGCA
AGACTCTGTCTCAAAAAGAAAGAAAAGAAAGAAAGAAAGGAAGAGAAAGAAAGAGAGAGAGAAAGAAAGA
AAATAAATACATAAATTAACTGATTTCTAGGAATTTAGAAGAAATCTCACATTTAAAAAGCTGACTTATT
TCACGAAGTTGACAGCATTAAGACAAAATCAACGGAAGCTGTCAAGTCCTCAGGGTGAATCAGTAGCCAT
GATGTCAGGAAGTACAAACCACCACAGGATTTCTGTCAGCTGCACAAAGCTCCCTGCTTTCTCAAAGCCC
AGGGAAGGAGGACAGGACTAATAAGATCAAGCTCTGGGCATCTCTCTGATCAGCATCTAAAGTTTACATC
CTTGTAGCTTGCCCCAGACTTTTCCCTTCTTAGCCTTCCAACTTATTGCCTTTGGGTATGACCAACATTT
CATTCCTTAGGTTAGAGGGTAAAATTTAAATATCATTAGAGCACAAGATTGAAACGAAAGGGGATGATAA
TGCTTATCTCCCAGAAGATTAAAGGGATTACGTAAAGCATTTAAAGAGGGTGACCAGCTCACTTACTCCT
CCTCCTCTACCTCATGCCCTAGGCCTATTTGCTTGCTTTTCCTTCTTCCTGAAACACTTTTCCCTCACTG
TCTCCCTAAATTCCTCTTTACCTGCGTGATCCATTTCTCCTTTAAGCTTCACGTTTGTGCTCTCTAAGGT
CATTCTTGATTCCAAAGGTCGGGGTTCGGGTCAGTTACTTCCTTGCACCTCATACATCCCCTTTCTTCAC
ATTTATTTACACTGATTGTAAACATTACTACACTTGTTTCAGCTCCAGGCAGCTGTAAGGCTGTGAACTC
ACTGCCTAGGCCTGTGCTTAGCCTTGTTCAAAACAAATGTGTGTTGAGTGAATAACAGAAGTATCGAGCA
TGTAGCAGATGATGCCACATACATTTTCTCTCCCTGTTCTGTGGGTTTGCAGAAAAAGCAGCCCCTATAA
ATAATTTTGGTAAACTACAAGTAGCAAAATAGAGGTAAGTAAAAAGTACTATGACCATAGGGGAGGGGGA
GTTATTTGGATCTCTCAAGGAAAGGAAAATTTTCCAACAGCATGAAAACAAAATGATTAACAGCATTCTG
TAAAGAAAATGCACAGGCTTCCTTTTCTACAGTGGATTTTCTGATAGTTAAAGAAAATTTCCTTAAAATG
TAAGTAGGGAGAATTTTTTCTAATTGTAATCGGTTGAGTTTTTTTGTTTTTTATAATATATCATATATCC
CACCTTTTACGTAGCTCAATTATCTGTATTTTTCTTTTACAGCACTCTATGAGAACATAAGTTAAAATAT
TGAAAAAAGGAAAAATTCTACTCTTCCCAAGACTAACAATGTTTTTGAATAGTTTAAGTTAAACATTAAA
ATGTACATTGATTCCTGGAGATAATTAAATACAAACTATTTATTTAACAAATATTTATGAAGCGGCTACT
ATCTCATCAGATGCTATGCAAGATGCTTCGTTTTATGGACCTTGAAGTCTATTTTCCCTGGGGCAACCTT
ACTAAAACTGTATGTATTAAAAACAGATTTGATTAAAACATATCACCTACTATGACAGTACAGGAATGGA
ACACTGTTTTGAGAACTGAGTGAACAAAATGCTGTGTCTAAAGAAGAGTAGCTACCCAGATTAAAATTCA
GTCAAATTTCCAGCTGCCTATCTATAGCTGATTGGAGGTAAATGTCTAGTCACTTCTCTGCAGTAGAAGA
GTAATTCCTTGCTTCATAATGCTGAGAAATTTGGATGATAATAATGTCGGTAGAGGTTCATTGATTGTAA
CCCTGGTTTGCGGATGTTGCTAGTGGAAGATTGCAGAGTGTGGGGGAGAAGGTAGATGGGAATTTTTTGT
ACTTTCTCCCCAATTTCAATGTGAATCCAAAACTGATCTAAAATAATAAAGTCTCAATATTTAAAAATAT
TAATAAATAACACACCTAAAATTTATAATAATAATTTAATACCTTTTTACATTTAAAGGCATAACACTTG
TTTTTGAATTGGGGGCCTGACTGTTGAAACTGAGTCATTCATAACTTATGCCATGAATTTGAAGACTACT
CTTATTTTCTTTGCCATGATTCTTTGTAGTTGGCAGAAACAAAATAATTGGCTCTCTCATGTATTTATTT
AACAAACAATTTATTGAACAGCTACTATCTAAAAGGTAGCCAACACTAAACATGCACTGACAGTGAGGGA
GATGTGAGTGTGTGAGGGCAGGGGGTTGGCAACTCTCTGTACTTTTGACTCAGTTTTGCTGTGAACCTAA
AACTGCTCTAAAGTCTATTAAAAAATACAACAATCAACACATCTTCCTTTATGCTACCATAGCTTTTATG
TTATAAAAAACAAGCACATTAATGTGGAGCACATAGAACTACATCTGGTATACAGTGAGTTAAATATATA
CATACATACATATATATATATATATATATATATATATATATATATATATATATATATTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTGTCAAGACAGTCTCACTCTGTCACCCAGGCTGGAGTGCAGTGACGTGATCTCAG
CTCCCTGCAACAACCACCTCCCCGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCTAGTAGCTGGGATTAC
AGGTGCACACCACCACACCTGGCCAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCATGTTGGGCAG
GCTGATCTTGAACTCCTGAACTCGGGTGATCCACCTGCCTTGGCCTCCCAAAGTGTTGGGATTACAGGCA
TGAGCCACCGCACCCTGCCGTGAGTTCTATATTGTGTTATTATTACTAGTATTATTAGAGACCACTTATC
AAATAGTATAGCAATTGTTTGTCTTCATATCTGTCTTACATATGACTATACTGTGCACATCTTAAGAATC
ACGTCAGTTTTTCCCCCTCTCTGTATCTGAAGGGCCTAGTTGATGCTAAATAAATGTTGCTTGGATGGGT
GGTGAAAGAATCAATGAATAATTGAATAAAAGGGATCAGACACTAGTGAATACAAATACAGATGGCCTCT
GACTTATGATGGTTCAACTTAAAATTTTTCAACTTTAGGATGGTGCAAAATCAATATGCATTCAGTAGAA
ACTCTACTTCGAATATCCATATGACTATTTTGGTTTTCACCTTCAGTACAGTATTTAGTAAATTACATGA
GATATTCAATACCTTATTATAAAATAGGCCTTGTGTGAGATGCTTTGTCCCAACTGTAGGCTAATGTTAG
TGTTCTGAGTGCATTTAAGGTAGGTTATGCTAAGCTGTGATGTTCATAGATTAGGTGTATTAAATGCATT
TTTGACTTAACAGTATTTTCAACTTATGATGGATTATTGGGATGTAACCCCATCATAAGTCAGGGAGCAT
CTGTATAAATGAGGCAATAATACCTTAGTCTAGTGGAAATGAAGGACAAGTACACAATGACATTTCAACA
CAAGTCAAACTGTGGGAAAAGTGAAAACAGAGGAATAAGTCAAGCTCCACTGGATGACAAATGACGAAAT
GATTAATCCTGATTCAGAAAATCAGAGATGCTTCACAACTACAGTGAACAAGAAACTTTAATGTAACCAG
AGTTGCCTCCAAAAGGCAATGTATAAGTTCTAATAAGAAAGCTTTCAACATCTGTGAAAAGAATGGGAAG
TGGGGGGGTAAAGAAAGCTTGTGTCTGTTTTGGAGCCCATTTATGACCCAGAAATTTATTCAATTAAAAA
ATTCCTTTTCCAAGATGTCTCAGAGAAATTATTCCAAAGCTCTGCAGTCAGGTCCCTTTCATTTCTAAGT
TTATAGACCTGACCTGAAGAATTTGTTGAAATGCTGGAGATGACTGAAAAGTGTAACAACATGAAAGCCT
AGCAGACAAAATGTTTATTTCTTTAATTTAGTTTTCCTAATAGCATCTTCCATCAATTTAACATGATTTA
GTTTTTTCTTCTTAATCTACCAATGCAAAAAATATAAGAAGAGAAGTGTTTTAGAAAGAACCGTGTTATC
TTACTGGGAAATGGAGAGAGGAAAAAAAATGATTCCTAGATAATATCAATCTATCGACCATTGAGTATGT
CCTTCAGTGAAAATTAAATTTAAAGAGTCAAAGTCTCATGTTTACAAAGGACTATGATAAAAATGGAAAA
AAGAGTGAGATCATCTAAACACCACACATTCCTACATGAACTGCATCAGCTCAACCTCAGAAAGCCATTA
GACTAAATAAGCTTAAAGACCACCGATTAGTGAATTTACAAGGAACTCTAAATAGCCTATTCCTTTTAAT
TAGAGATTCTATTATTTTAATAACAATACTTTATACTTACATAGGTCCTTTCATCTACAGAAATCAAAAG
GATTTTACAAGTGTGGTTTCATCATTATCCCCATTTCAGAGATTGGAAAATGGAGGCAATTAGTCACTTG
TACAAACAAGAAGTTCACCGTCAACTGTTCAAAAACTATTTGGTGCGCAAGTTTTTCAGAAGCCAAAAGA
CATAGCTGCAAATGGCATATTCTCATAAAGCCAACTGGCAGGTAAGCCTTATAAGGTGAATAGCAAATTC
AAAGTCTCCTGCAATTCAGCTCTTCCTGACAATTAAGCTCAGTGGCTTTTTTGTTTCAATTTATCCCTAC
AGAGACTATAGAGAAGCTCTCTACAGAGAATTTCACCATAGAATTTAGAGTTTTAAAAAACAAATCCCAG
AATTTCTATGTGTTTCTACTTATTAGGCTGAAATTACTTTACCAGCTTCATGATTATGGAAACTATGAGG
TGTTTATTTTCCAAAGAATTAACAACATTTGGGGTCATCAATAGTCTGTTACAAGACACTAATCTACATC
TCTTCCTTGAGAAATTTTGGATCATCCCAGGAGTGCCCCAGTGACTCCATTCGCAAAAGAGTCATCAGGC
TACTGTAGAGGATGTTCTCTGGGAGGCTCAGGATCAGGTTTCAATTCCAAAGATTGCCCCACAAACCATA
AAAAAGCTACCCTAGGAAGGCTAGCAACTTACTCTTTGGGGAATAATTAATTGAAGGACATGTGTCCTGC
TTTGGGACACACGGCTCATCACAGAATGGTAATTATGACATACACAAAATAACTTCCCAGCTCAGTCACT
AAGGACTTAGTCTCGTGCCCTGAGATTCAAAGAAAAAGACCATCTAGCAAGATAAGTAGAGCCATCCAAA
GTTGGTATGACAATACAATGGAATATTATTCAGCCTTTAAAAAGAAAAAAATTCTACCATTTGCGACAGC
ATGGATGGACCTGGAAGACATTTGTGCTAAGTGAAATAAGTCAGTCTCAGAAGGACAAACTCTGCATGAT
TATTCTTATATGAGGCATCTAAAGTAGCTGAACATAGAGAAGTACACGACGGAATTGTGGTTACCAGGGG
ATGGGGGAGGGGCGATAGGGAGTTGTAAAGTTATAATGATACAAGATGAGCAAGTTCCAGAGATTTTCTG
TACAATATAGTGCCTATAGTTAACAATAAGGCATTCGGCACTTAAAAATGTGTTAAGAGGGCAGATCTCA
TGTTAACTGTTCTTACCACAAAAGCAAAAAATAAACAAAAACAAAGAACCACGAGGAACCTTTGGAGATG
ATGAATATGTTCATTATCTTGATTGTGGAAATGGCAACACAACTGTATAGGTATGTCCAAACACCATATT
GTGCACGTTAATTATGTGCAGTGTTCTGTGTAACAATTATGCCTCAATAAAACTGGGAAACATTAAAAGT
CTAGTAAATTGAACTTATAGATACAGTAAATCTTAAGTTACCTTTAAAAAAATGTAGGTGTGGAAAGAGT
TCTGTTCCTGATGAGTTTGGACTGAGCAGATCACGGGGGGAGGTGAGCCACAGCCTGGAGATGGGGCCTC
AGGGCCAGGCCGGGCCTTGACAATGGCTGGAGAGGCAGACCATCTCCCTGGAGGAAGCCCTGCTTCTTTG
GACTGGCTTATGTACATGGGACTTCCTTACAGCCTGGACTTAAAGAACAGGCCCTATTTATTTCTGGCCC
AAGGGCTTTTTAGAGCAGGGGGAGCCTCTTTTTTTTTTTTTTTTTTTTTTTTTTTGAAGGTAGGTCTCCA
TGATCCTAAGTTCCTATTACTTCTAGAGCAATATTTATAAACATTTCCTTACCAAAGGGAAATAGCAATG
ATCCCTTCTATTCTTTCTATCCCTACCTAAAACAAAACAAAACTTGCTAGCCATGGCAAAAATATGAAGA
AGCTGGTAACAAAAAGAGTTTATGGTTATATGTGACTTCCTAAAGTCCTCTGCCTCAGGATTCTATGCAA
TGCAGATTTACAACTTTTTGAAAGTGTTGGCACTTTCTTTTTTTTTTTTTTTTTTTTCTGAGACACAGTC
TCACTCTATTGTTGCCCAGGCTGCGTGCAGTGGCGCGATTTCAGCTCACTGCAACCTCCACCTCCTGGGT
TCAAGTGATTCTCCTGTCTCAGCCTCCCAAGTAGCTGGGATTACAGGTGCCCATCACCACACCTCGCTAA
TTTTTGTATTTTTAGTAGAGACAGGGTTTCACCATGTTGGCTAGGCTGGTGTTGAACTCCTGACCCGTCT
TGGCCTCCCAAAGTGCTTGGCTCCCAAAGGCGTGAGCCACTGCGCTTGGCCAGCACTTTTTCATTGATTG
ACATAGAAATAATTGTTCTAGAAGTATTTTGGGGTTTTGAACAAAGAAGTTACTGTGTTAGTGTGGTTTT
CAATCACGCTAACCACACCAGCAACCTGCTCCTCATTCGTCTAAAACACCATGATAATTTTGAGAGAAGG
TCTATAGAAGCAAATGCTTAAAAAACTTAGAAAAGCTGGATAATATATATCCAATATGTTATTGAAATTT
TTGTCATGATTAATACCCAGGGCAAAACCAGGACCTAGATATTCTTCTGAATGACAGAATTAAAAATATT
ACTACAAAATGATTATAAAGCCAGAACTATTTATTTATTTATTTATTTTTTTGAGACAGATCTCACTCTG
TCACCCAGGCTGGAGTGCAGTGGTGTGATTTCTGCTCACTGCAACCTCTGCCTCCTGGGTTCAAGAGATT
CTCCTGTCTCAGCCCCCAGAGTAGCTGGGATTACAGGTGCCTGCCACCACACCCAGATAATTTTTGTATT
TTTAGTAGAGACAAGGTTTCACCATGTTGGCCAGGCTGGTCTCAAACTCCTGACCTCAAAGTGACCCACC
CACTTCAGCCTTCCAAAGTGCTGGGATTACAGGCGTGAGCCACTGCACCAGGCCTAAAGCCAGAACTCTT
AATGTGAAAAAAGAAATCTAATGTCTGGGCACTCATGGACATAAAGATGGCAACAATAGGCACTGGGGAC
TGCTAGAGAGGGGAGGGAGGGAGGGGTCAAAGGTTGAAAAACTACCCACTGGGTGCTTCGCACACTACCT
GGGTGACAGGATCAATCATATCTCAAACCCTAGCACTGTGCAATATATCTATGTCACAAACCTGCACTTG
TATCCCCAGGATCTAAAATAAAGTTGAAAGTTAAAATTAAAAAAAAAAATCGAATGTCATTCCTACACCA
ACATCACAGGCCTTTGTATGTTCCCTTAGTAATACCTATTCAACCCCTTATGAAGCTCAATGACCTATAT
CCTCCTATGTTCCAGCATCCTATGAGAAGAGAAGTAAAAAGTATTTTTAAAAGGAAAAAGTCTTCTGCAA
CCACCCAGCCTACAACAGTGTCCAAGGGCTTTCCTGAGGTTGCCACTTGTGTTTTTTGTATTTCAGTGGC
CCCCTGCCAGGCTTTGAGTGTTTATTCCCGAAGGGCATATGGCTGCTGGAAACTGGAGGTGGGAAAGATT
GAAGAGGATTTGAAAAAGCCCCAAAGAGCTAGAGGAATGAGAAATGCACAGAGATGTCAAAGCAACAGGT
AATGAGAGAGACCAGAGTCTAAAGGAAGGACACTGAGCAAATTTTGTGATGTCCGGTTCAAGTCCAGAGA
AGAGTGACAAAAAGCCATTGTTATCTAATAACAACCCCCCGCCCGCCCCCCCCACCCCCAGCTCCTCGAG
AAAGCTCTGTCTTGCCACGTCTCGACAATTTTGTCAAAGTTACAACCTGGTCATAAGCTTTAATGAGAAA
CATGCACCCTGCTGAGGTCAGGAGTTCGGGACCAGCTTGGCCAACATGGTGAAACCCCGTCTCGAAATAC
AAAAATTAGCCAGGCATGATGGCGGGTGCCTGTAATCCCAGCTACTTGGGAGGCTGAGGCAGGAGAATCA
CTTGAACCCGGGAGATGGAGGTTGCAGTGAGCTGAGATAGCACCATTGCACTCCAGCCACGGTGACAAAG
CGAGACTCCATCTCCAAAAAAAAGAGAGAGAGAGAGATCTGTTCAAATCATGAGAAATGCTGAGACCAGA
ACACCTGCCTTTGACTCCTGTCTTCCGAATGCCAAGCTTCACCCATCCCTTTTCAACAAGTGCAAACCCA
TTTCAGGAGAGGGCACCGAATCCATCTTGAAAGGACTTGCTCCGAGTTTCAAAGCTGACGCTTTTAAGCT
CTTAAATTCCCCTTCCAACAAACAAGCCAATAGTATGTTGGCATGCATTCATATAAGCAGGCTTGGCCCA
CGCCATATTTATTTAGTCTTCATAACTAGATGTACTAGAGGGTGTGAAGAATAAACCAGCACATCAGCCT
TATTGAATATGCTTCCGACCAAAACCATCATTGGTTTGCCTTTCAAAGCCTAATCTAAGAGTCTCTGTCA
AGAGTCTCATCTCTTCCTTAGAAGGAGCTCTTTCCCCAGCTCTGGCCCTCCCCACCAAGCTTGGAGCATG
GGCCTCACCTGTGCACTTGCAGGTCCGGTGGAAGAATTTTCTTGGCCACAGCTCACGGTCATCCTGGTTT
CGTAGGATGTAGGGACCACTCCAGGGCCTTGTGTCGGCTCGCACCTCTGTGCACTGCCCCCGGCCTTGCT
GAGAGCCACAGACATTGGCCGACTCTGCACCCAGGCGTGGGCAGCACTCCTTGTTCACTAGGCTGTCCAC
CGTCATGCAGACTCGGGGGAACTGACCCTGGGCTCCTGGCAGGATTTTGCAGCCCAAGCAACTGAGCAGA
AACCCCCACCAAAGGGGGCTCATGGCTTTATAATTGGGAGAGCTCTCTCTCTCTCTTACTTTCCTTGTCT
CTGTCGTACTTTTCTCCTTATCTTCTACTCTTTCAGTCTTTTCTTTTCAGTATTTTTTATTTTTCTTTGC
TTTCTATTCCTTTCTTCTTAAAAAAATACCCACAAGAATCACAGAGGTTACATGTGTGCACATGTGTACA
TGAACGTGCACACACAATTTTATGTGATTCAAACAACTAACAGACTTAATTTCCTTAGAAGCGCCTCTAA
CAACCAAATTTAATGAGGGTAGCGCTTCTCACCATCTTCCCCCGTTAAGTCAGGCTTTGTCTAATTGAGT
TAATTTACAGAGCACCCAGTCATACTACTTATTATGCTGGTATTTCTAAACCCTCTCCCTCCCTCCTTAG
CTCTTGACTTTAATTGCCTTGAACTCAGTTCAAAAGCCAAACACCGTGCTGCTTTTATTCTCTCTGGCTT
GCCAAGCCACGGGGCCTTGGGGGCTTGTGTAAGGGCTGGGAGAAGCCTTCATTAGGGGGATTAGTATTAC
AGAAACCCTCATCATTAGCACATGACCCAAAGTGCACAATAAAGGAGATCACTTCTGGCTTTATTTCAGG
AGGGCAAAACCATCTTCTTTATCTGGGCTCATGTGCTCCAGCCAAACTTGTGACCTCAGACATCCTGGGG
AGTCAGTAGATGCAGTGAGCTCTTCGTCAAAGACCCTTTACACAGAAGCTCACATTGCCAACTACAATGC
ACTCATGGCTGCTTTCTGACATGTGTGCAAAAAAGACCACAACAGGGGGTCATGCAACTTCAAAAATAAA
GAAACATTTATGTAGAACCAGGGTACAAGGAATTGCTTTGTTCCACAATTGGGAATCCTCTTCCCTCCAA
ATAATAACTTACTCTTCTCCTATTCAGCACATCTACGCAGCAATTTTTTTTTAATTACATGAAGTAGCAT
GCCACCAGAAACTCACAATTGTCATTATCTGATTGTATGGAAGGCACTGGAACCATTTGGAATGAAGGCT
TGCAAGCAAATCTTTTTGATTAGACTAAAGTGAAGCATGACTGAGCTTCAGTCTAGAAAGCAATGCCTCC
TGGTGCTTCTGGAGAATGGTCAGGTCAGCAATGGTGGCCACCTGTCAGAACATCCATTTATTTTTTCACA
GTGGAAACAGGACTGTCTTGGTAACTGTTTCACAGTGGAAACAGGACTTAGTGCCACAAGGATGCGAAAC
GGCTTCAGCTAGTTTCTAAGAATATACTTGAATGTAAAGACACATATTGTTATGTTTCAAAGCAAATTCC
TAAGGTGAAACAATTATATAGGTATTCCCACCCCCTGTACCTCTGTGCCACCCCTTGATGTTAAGTTGTT
GTGACTAATTAAATGGCAATTCTTATGTCTGACTCTACACCAATATCAGCCTGTACCACAGCCCTACTGA
ATCAGAATCTCTGAGGATGTTCCAGACACCAACCAACCTTTGTTAGAAAACATCTAGGCAATTCTAATGC
TCAGCCAGAGTTGAGAATCACTGAATCAGAATACAGCAGAGCTCCAAAGGAAATATTGCATCAGCATCAG
CTAAAAGAGACCATGTGCAATAGTTTCCTGAGGCTTCTGTAACAAATGACCACAAACTGGATGACTGAAA
ACAACAGAAATCTATTTTCTCACTGTTCTGAAGGCCAGAAGTCTAAAATGAAGGTGTTGGCAGGACTGGC
GTGTGTCAGCCAGGCGGCTGCACTCTCCCTGGAGACTCTAGGCTAGAATCCTCCTTGCCTTTTCAAGCTT
CTGGCAGCTGCTGTCAATCCTTGGCTTGAAACCGCAGCTCCAATGTCTGCCACAGCCCCATGGCCTTCTC
CCCATCTGTCTGTGTTTTTCCTCCATGTCTGTTTCTTATAAGGACACTTATTGGATGTAGAGCCCACTCA
GATAATCCAGGATGATCTCATCTCAAGATTCTTCACTCAATTACATCTGCAAAGAAGACTCTTTTTTCCA
GACAAAGTCACATTCACAGGTTCTGAGACATGGACATATCTTTTGGGGAAGTCACCATTCAACCTAACAC
ATCATGGGTGGGAAGAAACTTGGGGTTCTAAAATCGCAAAATCTCAGGGGTTTTTGAAACCTTTATTTTG
GAGCTCATTCATTCATTCCATGTATATTTATTGACTGCCACTTCATGCCAGCATTGTGACACTTGGGAAT
TTTATTCCAGGTTTTTGTGAAGCCTTGGGGCTCCATAAATGTTAAGATAAAATTTCTTGGATGTTAAAAC
TGATGGAGTCAATAATTCTTATGTCAGAATGCCCCAGGTCGAAGTCCTAGGATCTCTTTTCTTTCATTTC
CACACTTGCTAGATAACTCAGCTAGTCTGAGGCCTTAAATGCAGGCTATCATGACTTTCCAAAATTACAA
CTCTGACTTTGACCTCAGTTGTGAGCCCCAGACTCATATTATCTAACTTCCTACTGGACCTCTCTACTTG
AAGGTTTAGATATTTCTCACCCAAGTTGAGAACTTTTGCTCTCTCCTCCCAAATGTGTTCTCCATTGGTC
TTCTCCATCTCCACAAAGAGCAGCATCACCACAACCCTACAAGTGATCTTTGAGTCTTCTCTTTCCCACC
TCCCCATGTGTGCTTTCCAATGCACTTCAAGTAAAATCCGAGGTGCTTTGCATGTGCTACTCAAAGTGTG
GCCAACAGATCCGTGAATGGTGTGTTCCTGGTTTACATCAAGTTAAGAACAATAAGAATAGAAATTGAGA
GTCAACACTGGGAAATTTTCATAGCAATTTGACATTGGGATAACATTCAGGCATACGATCAGTAGTTTCA
TTCAAGAGGGGAGAGTCCGGCTGTGAGGTTGCCAAACGTGCATGGTGATGATCACGGAGCACAGGCTGAA
TGCAATGAGTCATGTGCAGTTGGATCACGTGTTAGTCTGTGGCTGGAACATTTTTCTTTTTTAATCATTT
ACCATGGATAGTTTGAGAACTAGCTTAAAAGATCCTCCATGATTTTTCCCTCGCCTGCCTCTCAATCTCT
TCTTCTGGATGGCAGACTATTGCAATCACTATTATTCAAACATGCCCCCATTCATTTCCACCTTGGCCTT
TGTCTTGCCATTCCCTCTGTCTGGAATAATCTTGCTCAGAGCCCTCAGCTTCTCAGAGAGGCCTTCCATG
ATATTTTAACACGTCTACAGCCAGCCACCTTCTCTCTACCACATTACCTTATTTTATTTTCTTCATAGCA
CTTATCACCATCTAAAGTTATCTGACTTATTGGTTAGGTGGCTGAAAGACTGTCTCATCTACTGGACTAT
AAGCTCCTTAACTCTGCTGTGTTTTTCCAACATGTGCAACAGTATTTGGCAAATAGAGACTACTTGATAA
ATAGTTGATGAATAAATATTCCCAATTCAAAACTGTATGTTCATCAAAAGGGCCTCATTATTATAGTGAC
TGGCTTTATACAAATTAAATGCTTTTATTTTGAATATATAAAACACTTAGGCTTATAATGACCACTATTA
TATTGGGGGTTTCATATTAGGTTTTATTAAACTGCTGCAAATGTTTGAAAACCACCAACCCAACATCACT
ACAACCCATGAACTCCCCCCTCAGTATTTCCAACAAAATATCACTAGTGAGGAGGTTCTCACAACATTTC
AGGAACAGTTCTAAGGGTGAGGAAATTCTTCCTTTTCAATAAGTTTTTGGCCTGGCACAGTGGCTCATGC
CTTGTAATCCCAACATTTTGGGAGGCCAAGGCAGGCAGATCACGTGAGCCCAGGAGTCTGAGATCAGCCT
GGGCAACATGGTGAAACCCCATCTCTACTAAATATACAAAAATTAGCTGGGCATGGTGACATGCACCTGT
AGTCCCATCTAGTAGGGAGGCTGAGGCAGGAGGATTTCTTGAGTCCAGGAGGTTGAGGCTACAAGTGAGC
CGTGATTGCACCACTGCACTCCAGCCTGCAGAAAGGAGTGAGACCCTGTCTCAAATAAATAAACAAAAAA
AAGTTTTTAACAGTAAGTATAATTTAAATGTAAATTTAAACATAAATGTTAAATAAAAATTTCCTTCCCC
AATTCTTTCATCAAAAGCCTTTGGTAACCCAGTCAGGCTCCATAGACCGGGTACAGTCCATTTCCCACAG
GCGTTTCTCCCTTTTTTTTTTTTCCAGACTAAATATTCTCCATTCCTTTTCATTTTCTTTCATATGACTT
AGTTTGTTTTTTGTTTTTGAGACAGAGTCTCACTGTGTAACCCAGGCTGGAGTGCAGTGGTGCAATCTTG
GCTCACTGCAATCTCCACCTCCCAGTTTAAGCAATTCTCCTACCTCTGCCTCTCGAGTACCTGGGACTAC
AGGCACCCACCACCACATCTGGCTAATTTTTGTATTTTCAGTAGAGACGAAGTTTCACCATGTTGGCCAG
GCCGGTCTCAAACTCCTGACCTCAGGTGATCCTCCCACCTCGGCCTCCCAAAGTGCTGGGAGTTTACAGG
TGTGAGCCACCGTGCCCGGCCCATATGACTTAGTTTTAAATCTCCCCATCAGCATGGTCTTTTTTACGGA
CAACACAGTTCACGATTTGACCTCTGAATGCAGGTTTCCCATAACTTAATTCAATGTTCCTGCTACGATC
TAAGCAAAGATAACCGAAAAAGAATTACCTTGTAAGCTTTGCTAGACAGTCACATCACCTCATCAATTTT
GTCTACATCCACTCAGGCTAACTCACGCTGCAGTTAAGACCTCAAAATGTTATTTGGCTTATAAAAGAAA
TGTTTATTTCTTATGCAGCTGCACATCCACCACATGTCAGCTGTGACTGTGCTGTACACTGTGTTCACTC
CAGGACCCAGGGGGAAACAGCATCTTTTCATTCTTTTCATTCTGCTAATTTTGCGTCAAAGTAGAGGTCA
GTGATGGGCCACTACTTGGAAGAGGTCCACCTTACTCACGTCTGCTCCCACCCCATTGGCAAAAAGCAAG
TCCGCGGGCAAGACAGCTGCTCTCAAAGACAGGGGTTCTGTGAGGATGGCCCCTTTAGGGAGAGTCAAGA
AGTATTTTATTTTTACTGCATTTGAAATCAACTTAAAGCCTTATGTCATTTTCATATAGCTTTCACAAGG
CTGCCTTAAAGTCAGATGCCTCTCATATCCCCATCTGCTCTTCTATTCGTATGGAATTGCCTTTTGAGGT
CTGTATTAGTTTGCTTTGGCTTCCATAACAAAATGCCATAGAGTAGATGGCTTAAACAACAGAAATGTAC
TTTCCCACAGTTCCAGAGGCTGAAAGTTCATGAGCAAGGCATGGGCAGGGTTGGATTCGTCTGTCAAGGC
CTCTGTCCTCGGCTTGCAGAGAGCTTCCCTATTGCTGCCCCATGCCATGGTCTTTCCTCTCTGCACATGC
ACTTCTGGTGCCTTCTCATGTGTCTAAATTTCCTTTTTTTATACGAACACTGGTCAGATTGAGGCCCATC
CTGACGACTTCATTTTTAACTTAATCTCCTCTGTAAAGGCCCTATTGCCAAATACAGTTATATTCTTGGG
TGCTGCAAGTTGGGAATTGAATGTAGGAATTTTGGGGAGGATGCAGTTCAGCTCCTAACAGGGTGTAAAT
GAAAGGGTTTATTTTGCCTCTGTCCAATGTTGTCATATTAAATGGGTGTGATAAGCAATGGGATTTCTCT
CATTCCTGCCTTTGTCCTAACTACACATTTGGTTGACCCGTCTTTATTGTCTTCGTAACCCAATTCATTG
ATGAAAATGACCGAATGTCAAGGTCCATGGCAGGACTTGAGACACGTCACTCAAACAAAAGCGTCTCACT
CTGGCACTCTGCTGGGGGGCGGTGGGGGGGTGGCCACAAGAGGAACTTCAGGGGGATCTTTGAACATCCT
GAAATTGTGAAGAAAATGTAGCATGGGTCTTTTTCTGTTAAGAAGATTCATAGATTTTGTTAGCTTCTCA
AATGGATTCATGACCCTGCCCTTGAGACTTTAGCACAGGTAGAACCTTGGAGGGCTCTGTGAGAGAACTT
AGAGACTCCGAGCATCATCAGTGTTTCCAAAGGATGTCATGGCCATTAACCACCAGTCTGCTTGTCCACA
ATGGAGGCACCTGTATAGTTCACTGCCTTTCTCCTAGAATGGCAGAGCCCCTGAGCTTTCCTGTACTCAC
CTGGTCTTAAAAGAAAAGCCTTAAATACTTAAAGGAAAAGGCTTAAACGAAGCTGCAATCCCATCAACCT
TGCACAAACACAGTGTCTGGCACATAGGAAGCACTTTCAAAATAACTGTTGAGTAAATGAACCATCATCT
ATAGTATCCTCCCCAAATTCACAATCATTCCTAATAAAGGCAGGTCACTCTTTCTCTCACGGAAACACCC
AGTTTGAAGTCCCATATCTTGAAGGAGAGCAGAGAAAACAAAATGGGACAGGAAGTAATAATACTAATGC
TTGATAGGTGAGAAAGGGCTAAAAGTATTGATTATTTAGCCAAGAGAATTGCTAGGGAGTGACTGATTTT
CAAAAAGATAAAGAGATTTCCTTTGGATTTGGAAGGATAAGGCTGCAGGTGATCTATACGTTGTGAAGTG
CTCAATGTCATTGGGTTTGTGGTCTTTTTTAGTTCCTACGCGTTGCTCGATTGCATGATTTTAAAAGTAA
GAAAGCAGCTTAATGTATTAAGTCCCTACTATGCTCCAGGCACTAAGCTAAGGGTGAGTATGTAATGTTT
CTAGTTATTTATTCACTGGTTATTATCCTCATTTTACAGAAGAGAAAACAGAGGCTGCCAGACCTCGGGT
AACAAGCTCTGTGACAGAGCTGTGTTTTCCTGACTCCAAAGTTGTGGTCTTTTCACCATGTCGAGTTGTC
AAACTCATCATTTTCTCTGGGGAAGTCAGCACAGTGCCTCATACAAAGGGACTGATGGAAACTTACAATC
TCTTATCTCCTACTCCATGCCAGGTACTATGCTAAGCTTGCTTTCCTTACCTTTTGTTATCTCATTTAAA
TTCCAAGAAACTGCTGCTTGAAATTTTAGTATTTCTAATTTAAGTGAATTGATTTAATATTGCTACCCTA
GATGGAAGCCCTAAGCACGTCAGAATAGAATTAAGAAATCCTCATTCTGATGGAGGAGATTGATTGAAGT
TGAGAATAAGGGTTGGGCTCCTCCTAGCCTTGCATTAACTAAATTACCCTTTAGTATTAAGCCATCAGCC
TGCATTAGGGCATGATTTGGAAAAACATCCTGTGAAACTTGTAAGGTATTTTTAATATCATCAAACACAT
TTCCCAATGTCATTTTATGGGGATCCAGGGAGAGATTTCTTGCAGGCTTCAGTATCCAGGAAAGCTGTAC
TTCCCCATAGAAAGCAGCTTATCCAGGACTGTTGGACCATGTGAATCTTAGGATGGTGTTTCTTTCTTTA
CCTTGGCCAGTTATGAAGCTTGGAGCCAAATTTGCAGCCCCCACATCAAGCAACTGATTCACGCAGTATC
TACTTTAATATTCTCCTTCCCTTATGTTCCTGGGTTCTGGGATTCTTATTTTATCCTTTTGCAAATTTAT
GTATTTCCCTAGCTTGTCTCAAATCCTTTGAGAAATAAGACAAACACACACACACACATTTCTGTGTAAG
TGCAAAGGTAACAAACACACAGCCAAGTTGTTGTTTACAAAACAGGGCTTAGAGAAGAGTTCAAGAAGAA
TCCCTAAAAATTTGGTATAAGTGAATACAGACCTAAGGACATAAGCTAAGAAGATCTCAAATCATAAGCA
TGACTGTAATTAAACATTGCATTATTTGCAAAAGAGAAAGTCTTTGTTAGAAACTGAATAGCAGAATCCA
AGAGGGGATATCTCATGGGTGTATTGAGACCATTGGTTACCAATGGAAGCCATCGAATCAAGGACTACTA
TAAGGAATGTTCTGAAAGCCAGTAAAGAGAGGCAGCTGTGTATCATACAGCTTAATAGTCTGAGAGTAGA
AAAGTGCCTTATTAGAAAGCAATTCATTTTACTCTCTCTTTTTACAGCTGAGGCAAGACTAAGTGAAAAG
GGATGTTCTGCATACTTTCATTTTGCATGCCGGCACCTAGCACCAACTTGCACATAAGAAGGACTCAATG
TATGTTCATGACATACTGAATTAGATACCTTAGAGAATTTGTAAGTGGATGATGCAGGGCAGACATGCAT
AGCTTTGGAGCTAGGATGCCAGCCTATGCCTTCCTGTGCCAGTCTATGTGTTCAAAGGAGGAAGAAATGG
CTCAAAGCCTGGGAAGCAATTGAAGAGAAAGGTAGATGTGTTAGAGCCATGGCTAAGATTAATACAGAGA
AAACATATGCATCTTTCTCCTGCTTGCCAACGAGTTGCCTGCTCTTTACTCCTGTGCCTCTGAATGTGAA
AATCCTCCCCGTTTTTTAGCCCCCTGCTCACCTTCCCTGTCTGATGGTTTTTGATCTATTCTTTGCTGCC
TCATCATGGGGAAAAGAGATTATTTTTTTCCCTGTGACCAAGTTGTTTCCTAAATGCTGGACATCTGTCC
TGATAAGAGTTTTGCTTTCTACATCTAAGAGCCTTTTTTCTTCTTGGTGGTATGAATTGTTCTTCAGAGG
AATTAAGGGTTAGAAATGGGACGTGTGGTCTGTTATTTCAGTTGAGTGCATTTTTTTCATCTTGAATGCA
TTTTTTATAGTTCATCCTTAAGTCTGTGTTTATACACCAAACACTTTTTAATTTCAGATTTTGCATCATT
TATCTTTATATTAATCTTAGTTATTTGCTATGCACACTGTGCCCTCTAATTCTTATTTTATCATTGTTTT
TTATGCTTCATTCTGGTACATGAGTATTCAATTTGGATTTTTATGTGTACCCTTATAATTTAATGACTGA
TTTGGGTAAGCAATAGAGCTACTCCTTCTTCAAAATACAGTTCTATGGGAGGGAATCACTCTCTTCCTGC
TCAATTCTGATCAAATCCAGAAAATACCACCTATACATTTGTAAGAGGTTGTATGGGCTGAAAAAATATA
TATATTTTTAGACAACTTTAGTACTAATGGATCTACCAGGGTTTATAGATGTACAATTTAGACTGTTCAG
GGTCTAGAAGGATTTCCAAAATATGTTGTCTGCCAGGCACGGTGGCTCACACCTGTAATCTCGGCACTTT
GGGAGGCTGAAGCAGGAGGATCACTTGAGCTCAGGAGTTTGAGACCAGCCTCGGCAACATGGCGTAACCT
ATTTCTACAAAAAATACAAAAATTAGCCAGGCGTGGTGGTGCATGCCTGTAGTCTCAGCTACTCAGGGAA
GCTGAGATGGGAGAATAGCTTGAGCCCAAGAGGCAGAGGTTGCAATGAGCTGAGATCGCATCACTGGACT
CCAGCCTGGGTGATACGGCCAGACCTTCTTGTCTAATATATACACACACACACACACACACACACACACA
CACACACACACACACACGCCATATATATACATACATATACACACACATATACACATACATACACACACCA
TATATATACATACATATACACACACATATGTACACATACATACACACACATACACACACAAACACACATA
TATATATAGTCAAGAGAAAAACATAAGGTATATAGCTATGAACTCACTATGTTTATGCTAACATGTACAT
GTGAGGGAGTGGGGGCAGGGAGTATGTCTGTGTCTGTGACTTGTCTGTGTCTATCTGCCCATCTGTGTGT
GTCAATGTGTAGAATAAACACAAGAAACTGGTTGAGTGCTGTCTGTGGGAATGGGCCTAATGGGGTGAGG
AACAGGAGCAGAAAGAACAATTATTTTCATTCTATATTTTTGTACATTTTGAATTTTGAACCATGCATGT
ATAGTACTTAGTTTAAAAATTTCGTTAATAAAAAAATTCAAGTTAAAAAAATTTGGAATGATGAGGACTT
GTGAGGATGACATTACATAAAGGAGGAGTTTCCTGGAAGTATTAAAAAGAGTATAACCCAGTCAAAATCC
CAGCAAGTTACTTTGTGAATAAGGACAAACAGTAGAGGTTTATATGGAGAGGCAAGAAACTTACCAGTTC
TATGACCCTGGACAAGTGGTTATTCTCTCTCAGCCTCAGATTCCTCATCTGTAAACCCAAGATGAAGATA
TCTACTTAATAAAGCATAATTTTAAGGATTAGATATGGCATTGGATATAAATTGCCTAGCAGAATCTGGC
ACACAGTAGGTACTTAGCACATTTTTATTACTTCCATTAAACAATGCCTCAAATTTCTACACTGGCAAAC
CACTGGTCTGACCCATTATATTATTACTTGTTTGAAAAATTACTACCTTCATAATCAGTAGCCCATATGA
CCTCTATTTCAATGGACAGCCAGGAAGGGGTGAAAGATCTTGCCAGAGTACTGAAAAATCCTCTCCACTG
AGAAAATTTTGATTCTAGGAATGATTAATACACACACACACACACACACACATATACACATGTCTAAGCA
TCTAATTATAAGTACTTCTAATAATTTTTTTCTGGAAACTAAATAAGTATTTATAACTCACACATAGAAG
ATATTCTTGTCCATAATGCAATATTACTACCCAGAAATGAAGTTGTTTTCTTCTTAGATTCTGCTTAGTC
AAATGATGATACGCTATGTTTACAGCTATGCTATTCTGTTAGCCTTGGAACTTAGGAATCTCACTAATTA
TGACAAATATAGGTGGAGGCAAGGTTTAAAGAAGCCACAGAGAATGAATAAACCAGATAGGAGCCCTCTT
ACTAATTTCAAGAGCTGACAAAAATAAATGCTATCATTAAAAATAAGGAAAAATCTTTTTCAAAAATTTC
TTGACCTGAATCTGGTGGTTTTACACCAAGTTCATTACTTTATCATTGCTGTCAAAAACCAACTAACCAA
AGCTGGGCGCAGTGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCTGAGGTGAGTGGATCACCTGAGG
TCAGGAGTTCTAGACCAGACTGACCAATATTGTATAATCCTGTCTCTACTAAAAATACAAAAATTAGCTG
GGCATGGTGGTGCATGCCCATAGTCCCAGCTACTCATGAGGCTGAGGCAGGAGAACTGCTTAAATCTGGC
AGGTAGAGGTTGCAGTGAGCCGAGATTGTGCCACTGCACTCTAGTCTGGGCGACAGAGCAAGACTCGGTC
TCAAAAAAAAAAAAAAAAAAAAAAAAAAACAACTAACCATGGTGTCTGTGTCTGTCTGACATTTGCTTTA
AAAATGGTTCTTCTCATTGAATCTCACCTGCACTCATTCAGTTACTTTTCATGGACCACGTGTGCATGCA
CACACACACATACACAAAGCTAAAAAAACCTCCAAACTTTCATAATAGAAAAGATATATGTACTTACAAA
TCATAGCAGACAGCTGCCTAGTAAATGTAAATTTTGTTGTAATGAATTTTTCATTTCTAAAAAGTATTCT
AGTATAAGAAGGAAGACACACTGAAAAGTAGTAGAAAACAAGATAATTTCATAGAGGTTTCAGTTTACCT
TCAATTATGAGTTTATAATATGTAATATTTTTGTAATCACAAGATCTATTGAATTCAGGAAAGTTACCTA
TTTATTTATGCCATGAAATGGATTTCACCTTGAGCACCAATGATTCAAAGGCCAGGTTGGAGCTCAGCAG
AAGAGTATGTAATAATGGAGGGGTGAGCAACCTTCTTGTGGAAACATTTAGTCCTCACCGAAGACCGGAA
AGAATACAAAGATGTCAGTGAACAAGAAAAGTCAGGGCGCTTTTAGGGACTGGGAACCATAGAGAGTAAA
GAGTTCAGAGTAAAGCTTCCACAAACTGAGTGCCTCAAACAATAAAAATTTATCATCTCACGGTCCTGGG
GCTAAAAGTCTAAGATCAAGGTGTCAGCAGAGCCATGCTCCCTTTGAAGTGATAGGGGCGGATCTTTTCC
AGGCCTGTCTTTCAGCTTCTGGTAGTTTCTTGGCTTGTAATATAGAACTCCAATCTTAATATGATGTTCT
TCTTGTGTTCAAGGCTCTGGGCCTGAATTTCCCCTTTTATGAAGACAACAATATATTAGATTAGGGGCCC
ATCCTACTCCAGTATGACCTCATCTTAATTAATTATTACCTGCAATGACCTGACTCCTAAATAAGGTCAC
ATTCTGGGTTACTCAGGGTTTGGGCTTCAGCATATAAATTTGAGAAGGACACAATTCAACAGATAACAGA
TAATAAACGGTGAAACTGGGCATCAAAACTCAAATACTCATTCTCTTTTTACAACCAAGTCATCCTGAAC
ACATCCTCAAACTTTTGGGATTAGAAGGAGAGTTGGTATGGGTCATGCTGTATGGAAGAGAAACTGAAGA
GAAGTGGGTCACCATCATAAGACTTAGCTGCTTTCTGGTGACATGAAGAATTCTGCTTAATCTCACGGAA
GTGCCAAATTGGGTGTAGGGGAGTCTACTTCTGCAAAGGTTAGCATTTGTCAATCAGTACTGGATCTCCT
CTCAGAATTCTGCAGTTAGTCCTATGCATGGTCTCTGTGAACCATATTACCTCATAAATTTTAGATCTGG
ATGAGAAGTTAAAGATCATTTAGACCAATACTCTCAAGTGAGAAAATCAAAGCCCACTCAGAGTTTAGAA
TAACTCATTCATGACCATGGAGCCTCAGCATCCTGATTCATAGTGCAGTGCTCTTTTCTCTCACTGGACA
ACCAGGGGTGAGTAAAACATGAGATCTCTCTTACCTGTTATGGACACGTTTTTCTCCCCTCACCTTTGTC
TCAAGCATCGCATTTGTAAAACTCACTCTTAGCTCATCGTTCTCCCAACTCAACAGTTAAAGGCAGATAC
ATAGAAAGTGCTCAGTATTTATTGAATGAACTTATAAATGACAGCAGAGAAGCAGCGAGCCTTAAAGATA
AACTTCAACTGAAATATCCAGGTGGCCTCTTGAATCACATGCCCCTCCCTCTCTACAGAGGGGTCCACAG
AACTCTTTTGCTTCTTCTAAGTTGAAGGTGGTTGGGTCTTCTCCTCATAGATGTTTCCTCTGAACTAAGC
TTGAGGTTCCCAGAATGGCAGCAGCTCCTCTTCCTGCAGGAGATTGGACACCTCTTTGTGTTCCAGGGCA
ACATGACTGGCTATGCCTGGGGGCTTCACTCCCTGCCTTCTGTTAATATTTATACCTAATATCTAACACA
GTGCCTAGCACAAGTAACTGAATGATAGACCATGACTATTACTTGGACTACAGGATCCAAGTTAGTTGGG
GATGGGAACTTATTCCAAATTACTTGCTAATGTCTTCCAAATCAAACCCCCAAATTTGAGGTTTAATATA
ATTTTTTTCACATTATTTATAAGAAACATTGATTTTAGAAAAACTGAAGAACACAAAGATGTACAGAAAA
GAAAATGTAAATCACTCATGTTCTCACCATCAAGAAATTATTCTAATTAATCTTTGGGTGTTTATCATTC
CAGATGAAAATATTCATTCCTTCAATAGCTTTTTAAAACCTAATTGGAATTATAGTATATATATTTTCAT
AGTCTATATTGACCCCTGATCGACGTACATATTGAAAATGCTTTTTCCAAATTTGCAGTTGTCAAAGTAC
AGAGGAAGGAAGTCTGAAATCTTTGCTCAATCAAAACATGGCAGTCATAGAGAATGGCAGCACCCAAGGC
ATCCATTGTGCTTGGAACGTTCATTGTATCCAATGGTGAAAAATGCTTCACATCTGTGCTCAAGACAAGA
GAGACTCTTTTGCAACATGACCCCGAAGAAAAGAACTCTGTGGGCTATTTTCAGATCTAATATACTCTAT
AAGATGGTTTTTGATATTAGGGCACATCTCTAATTCCACATTATTAGCCATCATCCTAAGACTTGCCAGC
TTCTCGAAATTTAGACTTCTACAGGATCCAAGGGAAATGCCTGCCCCCCACGACTTATGCTGAGTGAAAA
AAAACCTGACAAAAATAGTACATATAATCATTTATATAAAATTCTAGAAAATGCAAACTAATCTTAAGTG
ACAGAAAGCAGATGAGTGTCGGCCAGAGGACAGAGTGGTAGGTATGGCTGTGAGAAAGGAATTCCCAAGG
CATATGAGGACTATGACAGATAAACATTCATTACCTTGAGTGTGATGATGGTTTCACTGGTGAATTCTTA
GGTGAAAAGTCATCCAATGGTAGGCTTGAAATATGTGCAGTATATTATACATCAGTTATACCTCAGTCAA
GTTATGGTGACATGCACAAAATGACATGGACAGAATAAAATGTATATTGCTAAGTCTGAAAGGGCTACAT
ACGATATGATTCCAACTACACAATATCCTGGGAACATCAAAACTGTGGAGACTGTAAAAAGATCAGTGGT
TGCCAGAGGCTTGTAGGGAGGGAGGAAAAGATGAATAAGTGGAATGCAGCGGGTTTTTAGGGCAGTGAAA
CTATTCTGTGTGATACTGTAACAGTGAATGCATGTCATTATACATTTGTCAAATCCCACAGGGTGCACAA
CACAAAGAGTGAACCCTCATGTAAACTATGGGCCCAAGTTAATGATTGTATCAACAGTGGAAACAGTGGG
GCAGTAAGAGGCTGTATGGGAACTCTTTCTACTTTCGGCTCAATTTTTGTAAAGCTAAAACTGCTCTAAA
GAATAAAGGCTATTAATTTTTTTAAATGTTTAGAGATGCCAAAAGCTATAAAATTAGGAGATTCCACCTA
AAAGTCTGGATCTCAAGCTCATCCCAAAAGACAAGAAGCTCCAGAAATCCTGCATTAAGCCCACTCATGG
CTCCCCAGGATCTCACAGCTAGTGCTCCTCGTCCCCATACATTGCCACCTGGCCCTGCAGGCCTCACAGC
TTTTAACATCTGCCTTCTGTGCTTGGCCTCCCCGATCCTGGCTCCTAGCCAGAGCCCAGGAAACAGTTTC
CTTAGAGGGGCATTTTGATTGCTTTGTCACTATTCCCCAATCTGCATCCTTTCATCATTTTGTTTGTGCT
CCTTAAGTCTATTTTAGGTGTAATCAGCCTCACTGATTTCACTAGGGGTTCTCTGAGACTAGTTTCTCCT
CTATCTTCAGGGATTTCCCAGGCAGGGAACGCCTAATTGGTATTATTTGCTGATCTCCTCTTCCTTCACT
CAGTTTTGTCTCATTCCTGCTGTATACCCATTCTCCTTGCAACAGCAAAATTAGGAAGTAAATGTGTGGA
ATTTTGTTTAACCCTTTACTCGCTAGCCTCCTGCAGGTCTTCCCTAGCACTAAGTTATCATTTACTCTGA
AAACTTTCTATAATATAATGAAGGAATGATTCACTGCATTATAGAAAGTTTTTAAAGTGTTAAAGAAACA
GAAGCAGAAAGTAATTAATCACTACTCCTTCACTCAGAGATAACCACAGCTTACATGTTGATATTTATAC
ATTTAATCTTTATTCTGTGCATATACATAATTGAAACAAAATTATGATATTACATTCTGCATTATTTTTT
CCATTTAACAATATGTTATGCATATTTTTTCATATGATTTTGAAGGGTTATAGAATACTCATTGTATAGT
AGATAATTATGATGTCATAATTGATTTAATTTCCCTGTTTTTGAATATTTAGCATTATTTACAGCTTGTC
ACTTGTATTAATAATTCTGCAACAAACATCCTCGTCAATTAATCTTTGCCCTCCTCTATGATATTTTCCA
TGAGTTAAATTCCAAGAAGCAGACTGTTCAACTACATGCTTATTTATATTTTCTTTTTTTTTAAAACAGG
GTCTGGCTCTGTCACTCAAGCTTGAGTGCAGTGGTGCAATCTTGGCTCACTACAACCTCTGCCTGCCAGG
CTCAAGCCATCCTCCCAGCTCAGCCTCCTGAGTAGTTGGGAATACAGGCATGTGCCACCACACCTGGCTA
ATTTTTGTATATTTTGTGGAGACAGGGTTTCACCATGATGCCTGGGCTGGTTTCGAACTCCTGAGCTCAA
GTAATCCACTCAGCTCGGCCTCTCCAAGGGCTGGGATTACAGGTGTGAGCCACCACAACCGGCCTTACAT
GCTTATTTTTAATGCTTTTGTTATATGTTCCCAAATTGCCCTCCAGAAAGAATGTACCCACTTCTACTCC
CAAAAGCAGAGCGCCCAAGACATAATTTCATCTTTAAGCCAAAACTTCAAATAAAAAATGTATTCCATGT
ATCATCAAAGTTTAAATTTTAGTGAATGTAGGAGCACTTGTCAAAATGTAAGATGCAAAAATTCAAAGAG
AAAAGAAGAATATAACATGCTACCTTTTTGGAAGATGTCATGACACTAATATTACAATATTTCTATTAAA
ATATTAATTTTTACCCTCTCTCCAACTGTATTAATCATTCCACAATTGTGAAGGATGTACTATCTCAAAG
GGAGAGAGAGACATGGTTCAACTGTATAAGCTTTTTGGAGTAATAAGAAGTTGAACACAATAACTTCATA
TTTCAACTGTGAGGGTTTTCTTTTAAATCTGGTTATAAATAATTTGATATGGCACCCCCTTAGAATTCAT
GAAGGGATGGCTCTGCAGGGCTAGTGAAGCTGCATGGTAAGTCTGTTGCATAGAAGTCTATAGAGCAGGC
TCTTCCCAGAAAGGAACAACGCGCCTCTGATCGTTGCCAATTGACTCTTCTCTGCCTTTCTCTGCCCTAT
TCATTGTGCCATCAGTATTCACTTATTGTCAACAACATGCTGATGTTACCCAGCCCTTTCTTCTGACCTC
ATTCTGAACCTTATAAAGTGTGATCCAGCTTAATCAACTCAGAGATTAAGAGCTGTAGTCTATACTTGTT
TTTGGAATGGATCCTGGCATTATTTATTTTTATTTTTATTTTAAGATGGAGTCTCACTGTCACTGGGCTG
GAGTACAGTGCCATGATCTTGGCTCACTGCAACCTCTGCCTCCTGGGTTGAAGGGATTCTCCTGCCTCAG
CCTCCTAAATAGCTGGGATTACAGCCACACACCACCACACCCGGCTAATTTTTGTATTTTTAGTAAAGAC
AGGATTTCACCATGTTGGCCAGGCTGGTCTCCAACTCCTGGCCTCAAGTGATCTACCCACCTCGACTTCC
CAAAATGCTAGGATTACAGGCATGAGCCACCGCACCCGGCCGGATTCTGTCATTATTAACATTATTAACA
TTTTCACTCATCTCAAAGAACTCACAGTGGCATGTACAGACCTTGTTGATCTTCAGGTATGGGCTGGTGG
TAAGGGACATAATTTGGATATGCTAAGGCACAGAAAAATGAGACGTGAAGGAAGATATTTATGTGTGGTA
CAGTTTGCATTTAATAGGTTGAGCATCCCTTTTTAACTGCTAAAGCACTAGAACTGCAACATGCCTAACC
TGCATGTTCACCATGGGAAATGCACAACAGCAGGCTGCAACATGCTCCTAGATACCAGGACTTCAGAGCA
CCATGGATATTCGGCTTCTGCAGGCTCTGGAAATAGTGTCTAGTGGGCTGTGAATACACCTGGAGCAGAG
GAGAGAGAGGAAAGCTGCAGGCCTCAGTGCTCCTTGCTGTGCCCACACAAGTGCTGGACGTCCTTCAAGA
CTCACAGGGAACACGTTAAGAGTTGAACTAAATTGTGTCTCATAAATGTTCTTCAGTCGAGCCTCTGGGA
AATCTGTGTTGGTTAATTTTATGTGTCAACTTGACTGGGCACCCAGACATTTGGTTAAACATTTTTCTGG
ATATTTCTGCGGGGTATTTTCTGGATGAAATTAACATTTAAATGGGTAGACCTTAAGTAAAGCAGACTGC
TCTTCATAACGTAGGTGGGCCTCATCCAACCAGATGACGGCCTGAATAGATCAAAGAATGACCTCCCCTG
AGCAGGAGGGAGTTCTGCCAGCAGACTGCTTTCAGACTTGAACGGTAACCCTTCCCTGAGTCTCCAGCCT
GCCAGGCTACTCTGCAGATCTTGGACTTGTCAGCCTCCATAATCAAGTGATCCAATTCCTTAAAATAAAT
CTGTCTCTCTAGGTGAATAACAGTTGACCCTTGAACATCATGGGGTTAGGAGCACCAACTCCCCATGCAG
TCTAAAATCCAAGTATAGCTTTTAACTCCCCCAAAACTTAACTACTAATAACCTACTGTTGACTGGAAGA
TGTACCAATAACATAAATAGTCAATGAACACATATTTTATATGTATTAGGCACTGTATTCTTACAATAAA
GCAAACTACAGAAAATAAAATTTTACTTAAAAATCATGACGAAGAGAAATATATCTACTAATTAAGTGTA
AGTGGGTCATCATAAAGGTCTTCATCCTCATCTTTGCATTGAGTAGGCTGAGGAGGAGGAGGAAGAAGAG
GGGTTGGTCTTGCTGTCTCAGGGGTGGCAGAGGTGGAAGAGGTAGAGGGGATGGAAGGGGAGGCAGGAGA
GGCAGGCATGCTCCATGTAACTTTTATCAAAAAAAACTCCATGTACAAATGGACCTGTGCAGTTCAAACC
CATGTTGTTCAGGGGTCACCTATATGTGTGTGTGTGTGTGTACACACATGCATGCACATATACATCTTAC
TGGTTCAGTTTCCCTGGAGTACCTTAATATGTCTGCTCTGCACTTTTCAGTGGAGGATATTCTTAAATGC
AAAGAACAAGCTACCTTTTGGAGGCCTAAGTAAGAGCTGCTGTCCTCAGGAAGCAAACTCAGAATCGAGG
ACAACAGCCAGACAGAATCCTAAACCTCTACTCCCTCAGGAAGGGAACAATCTTGGATGAGTGAAATCCC
CAAAGTTGGTGTGTCAAGAATTGCATGTGGATAAAATATGTGAGGAAACCACTAGATGAAGCCCCCTGGC
TACTCCATCAGTGAGTGAAAACAGGTAGACCAAGCATAATAAGAGGGACTTTTATAGACTTTCTCCTCAA
TCCCACAGTTAAAATTGTCAAAGAAGTGAACAAATAAATTAGAGCTGAGCAGAAAATCTTTAGGAGCTGT
TATGGACTGAATATTTGCATCCCCTCTCCCTGCTCCAGATTCATACTGATGCCCTAATCCCAATGGGATA
GCATTAGGAGGTGGAGCCTTTGGGAAATGATAAGGTCACAAGGGTGGAGCCCTCATGAATGGGGTTAGTG
CCCTAATAAGAAAAGGCCAGAGAGAGCTTTCCTCTATAAACCAGGAAGAGGGCCTTCACCAGGAACCTGA
CCCAGCTAGCACACTAAACTCAACTTCCAGCTTCCAGACAGAACTGTGAGAAATCAACACTTGTTGTTGA
AGCCACCCAGTTTACAGTAATTTGTTACAGCAGCCTGAACTATGACAGGAGCTGTGTACATTTGAGAGGT
GAAGCCAACTGGACTTCCTGGGTCGAGTGGGGACTTGGAGAACTTTTCTGTCTAGCTAGAGGATTGTAAA
TGCACCAATCAGTGCTCTGTGTCTAGCTAAAGGATTGTAAATGTATCAATCAGCACTCTGTAAAAACACA
CCAATCATTGCTCTATGTCTAGCTAAAGGATTGTAAATGCACCAGTCAGCACTCTGTAAAAACACACCAA
TCATTGCTCTGTGTCCAGCTAAAGGATTGTAAATGCGCCAGTCAGCACTCTGTAAAATGGACCAATCAGC
ACTCTGTAAAATGGACCAATCAGCAGGAAGTGGGTGGGGCCAAATAAGGGAATAAAAGCTGGCCACCCCA
GCCAGCAGTGGCACCCCATTCGGGTCCCCTTCCACACTGTGGAAGCTTTGTTCTTTCGCTTTTCACAATA
AATCTTGCTGTTGCTCACTCTTTGGGTCCAAACCACCTGTAAGAGCTGTAACACTGGCTGCAGAGGTCTG
CAGCTTCATTCTTGAAGTCAGCGAGACCACAAACCCACCAGAAGGAAGAAACTCCAGACACACCATCTTT
AAGAGCTGTAACACTCACCGTGAAGGTCTGCGGCTTCATTTTTGAAGGCAGTGAGACCAAGAACCCACCA
GAAGGAACCAATTCCAGACACACATTTAGCTTCCTGATTAAAACTTGGCATAAATATTTAGCATAAAGAA
GACTAAAAGCATAAAGATATATGCTCCCATTCCCAAAGCAATAAAAGGACCAAAGGAGTGTGCATGAGAG
TGAGTGTGTGTGTGTGTGTGCGTTCTCTCCAAAGCACCAAGCAGTGGCTGTTGATGGCAGTATAAAAGAA
TAATTTTCTCTTCAGGATGTTCAAAAGCAAACCTGGCAGCATGAATTAGATGGCCTAATTTTAAACATAC
AAAACACCTCTAGTTCTTAATGAACAAATAAGCAAAGTGCACCATCGGTGGCCTAGACACCATTTCAGTT
TTACACTGGAATCAATAAGTTAGGAATGATTTGACTCCCAGAGCTAGCCTCAAGTCCAAGCCATGGAGAA
TATTAAACTGACCTCCCCTCATGACTCTGGCCAACCCTGTGTTCCAGCCCTTCACTCTCTCCATAGGAGA
GGGCTGAACCCCCACCATGCTCTAACCGAAAGCACAGCTGGCCTTCCCTCTTCTCCTCAGCTTTATTGAG
GTTATAACTGACAAACAAATATTGTATATATTTAAGGCATACAATAGGAAGTTTTAATATACCTATATGT
TGTGAAATGATAATCAAGCTAATTAACATATCCATAACATATAGTTACCTTTTTTGTGTGTGAGAGAACA
ATTAAGATCTATTCTTTGGGCAAATTTCAAGTATACAATAGAGTATAGTTAAGTATAGTCACCGGGCTAT
ACACTAGATCTCCAGAGCTTATTCATCCTACACATCTGAAGCTTTTACCCTTTCATCAACATCTCCCCAT
TTCCCTCACTTCCCATCCCTGACAACAACCTGTATTAGTCTGTTCTCATGCTGCCAACAAAGACATAGCC
GAGACTGGGTAATTTATAAAGAAAAAGAGGTTTAATGGACTCACAGTTCCACGTGGCTGGGGAGGCCTCA
CAATCATGGCAGCAGGCAAGAGAGAAAATGAGAGCCAACAACAGGGGGAGCCCCTTAGAAAATCATCAAA
TCTCGTGAGACTTATTCACTACCATGAAAACAGTATGGGAGAAACCACTCCCATGATTCAATTATCTCCC
ACCTGGTCCCTCCCACAACATGTGGGAATTATGGGAGCTATAATTCAAAATGAGATTTGGGTGGGGATAC
AACCAAACCATATCACTACCATTCTGCTCTCTGCTTCTAAGAGTTTGATGTTTTTAGAACCCATATATAA
GTGAGATCATGCAGATTTTGTCTGTCTATGCCTGGCTTATCTCACTTAGCATAATGTCATCCAGAGTCAT
CCATCCTGTTGCAAATGACAGAATCTCCTTGCTTTTAAGGATGAATAATATCCCATTGTGTACCACATTT
TCTTTGTCCATTCAACCGTTTATGGACACTTAGCTTGTTTCCTTTTCTTGGCTATTAGAATAATGCTGCA
GTAAACATTGCTCTTCACTTTGTAAATATATTTTCATTTTAAAAAATCATTCAGATAGGCAAACGGAACA
AAAGCAGAATAGCACAATGCACCACTCTGTGACAACCCCATTAACATTTGGTGACGATCCTTCCAGACTT
TTCTACCACTGCCATCCTCACACAGTGATTTTTAGTTTCTTTTTTTTCTAAATAATTGTTCTTTTATAGA
TTTTAAAAGAATTTGGCACTTTGGGAGGCTGAGGCGGGCAGATCACGAGGTCAGCAGATAGAGACCATCC
TGGCTAACATGGTGAAACCCCATCTCTACTAAAAATACAAAAAAAAATTAGCTGGGCGTGGTGGCGGGCA
CCTGCAGTCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGT
GAACGGAGATCGCACCACTGCACTCCAGCCTGGGTGACAGAGCAAGACTCCGTCTCAAATAAATAAATAA
ATTAATTAATTAAAAATAAATAAAAGAATTTGGAAATGTTCATCTCTCTGAGCATTTATTTTCATTGTTT
ATAAAAAGTGGATGGTGTTCATAATACCTCTCTCTGATCAGGCTGTCGGAAAAATTAAAGAAGTTAGTGC
CTCTAGTACATAAAAAGTAAGTTGTCCTTTCTAGTCACCATCTGTTCCTCCTTTCTACTTTCCTTCCTTT
TTGACTTATTCCTTGAACAAATGTTTATTAAGCACCTACTGTATGCCTGGCCCTGCACTAGGCACCAGGC
TCACAAGGATGGGGAAGAAGACAGCCATGGATCTTGCAGTCACGGTACTTATGCAGAGACAAAGACAGAG
ACAGAGAGAGAGAGAGAGAGAAAGGAGAGAGAGGAGAGAGAGAGAATGAGAACAGGCTTGCAGAAACTCC
TGGCAAGACCACCAAACCTGCGAGAGTGAGGGAGGGTGTCCCAAGCAGAGGGCACAGCATTACAAAAGCC
AAATCATCACAATGTGGCGCACTAGGTGCAAGAAGGGAAGAGTTCATGAGGGACAAGGCTGCAGATTGAG
CAGAGACCATGTCAGGAAAGTCCTCATGTTTCAGCTTAAGGAAGCTGAAGGCAGCCCAAAGTTCGCTATC
TTGTAGGTATTATTGTCTCCCTCACTCTGCCCTTGCTGGGTCTCCCACTGTTTCCATAGCCTCAGCCCCT
ACTTCTGAGGCTCTGCTGAGGGTGCCTTCACTGTTCCATAGCCCCAGCCCCCACTTCTGAGGCTCTGCTG
AGGGTGCCTTCACTGTTCCATAGCCCCAGCCCCTACTTCTGAGGCTCTGCTGAGGGTGCCTTCACTGTTC
CATAGCCCCAGCCCCCACTTCTGAGGCTCTGCTGAGGGTGCCTTCACTGTTCCATAGCCCCAGCCCCTAC
TTCTGAGGCTCTGCTGAGGGTGCCTTCACTGTTCCATAGCCCCAGCCCCCACTTCTGAGGCTCTGCTGAG
GGTGCCTTCACTGTTCCATAGCCCTCCCTGCTGTCCCCCTCATCCCATGAATTTTGCCCCTTTCTCTCAC
CATCATGTTCTTCTGTTGCCTCTGCCATTTCCAGTTGATTCTGTGGTGGGGAAGGACACGGACCTTCCTC
CAGCAGGTATTGCCATAGTTCTCGGCTTACTTTCCCTGCCAGACTCTTTGGGAGAGTGGCCTGAGCTCCC
AGCCTCCACCTGCTCTTTTTCCATTTAATCCTTAACTATTGCACCTGCGTTCAGTCATCAGCCCTCAACA
CTCAGCTGCGAGGAGCTGGTGAACTTGTGATTACACCCAGCAGGCATCTGGCCAGTCCTTCGCTTGCTTG
GCCTCTTTGTAGCTTTCTGACCCCCTCCTCTCCTTTCTTGGTTCACCCCTTTCCCTCAGCTTCTAGGTAC
CTCATTCTCCTTGTGTCCTCCTTTTTTTCTTCATTTTCCTCAGTCATCTTTATAAATCTTTCTCGTCTAC
TAGCCCTTCAACGTGTGGCTGTCCTTTCCTCTCCTCGCTGCACTCTCTCCGAAATCTGTATCTCCAGACC
ACATCTGCTCATGCAGACAAATCCTCTGACTTCCAGCCACTGTGAGCCTGCCACCCCAGGTCCCCACCTT
TCTGTGACTCAGTGAGGCTTCCCAAGTCAGGCTCATTGCAAGGAAAACCTGGTTTAACTAGTAAAGAGGT
GGGTTATAAAATATTGTTAGAAACACCGTGGTGGTTTAAATAATGTCTGCCAAAATGATGTGCTCGAGAC
CTAAGCCCTGGGACCTGTGAATGTCACTTTATTTGGAAATAAAGTCTTTGAAAATACAGTTAGGTTGGGT
GCGGTGGCTCATGCCTATAATCCCAGCACTTTGGGAGGCCAAGGGGGCATGGATTGCTTGAGTCCAGGAG
TTCAACGCCAGCCTGGGAAACATAGCAAAAACCCCATCTCTACTAAAAATACAAAAAATTAGCTGGGCAT
GGTGGTGCATGCCTGTAGTCCCAGCTACTCAGGAAGCTGAGGTAGGAGGATTGCCTGAGCCTGGGAGGTC
GAGGCTGCAGTGAGCCAAGATCACGCCACTGCACTGCAGCTAGGGTGACAGAGACCCCATTTCAAAAAAA
GGAGGGAAGGGAAGGAGAGGAGAGGGGAGGGGAGGTGGGGGAAAGAAAGAAAGAAAGAAAAGGAGAGGAG
AGGAGGGGAGGGAAGAGGAGGGGAGGGGAAAGTTAAGGATCTTAAAATGATACAGTCCTGGATTTAGGGT
GGGCACAAAATCTGACTGGTGTCCTCATAAGACAAAGGCCTCAGAAAACTGGAGAGACACAAGGAAGAAA
GCCATGTGAAGACAAAGGCAGAGATTGCAGTGATACTGTCACAAGCCAAAGACTTCCTGGAGCCACCAGA
AGCTGGAAGACAGGATGGGTTCTACCCTAGAACCTCTGGGGATAGCATGGCCCTGCCTATACCTTGATTT
CAGACTTCTGGCCTCCACAACGGTGAGAGAATAAATTACTGCTGTTTTAAGCCACTCAATTTATGGTAAT
TTGTGACAGCAGCCCTAGAAAACTAATACAGGTACATACCCATTATTCTCTTTTTAAAAATTGCTCATAC
AATTTTCAAGTGGGGGTCCTGGCTTTCATAACTATTAGAGTTATTGATGAACTACTGTTTGCTTTATACC
TGTAAAATGAATGGTGTTGGTTGTGCATAAGTGAAGTAAACATTTTCTTTCTGTTTTGTTTATGTTGTTG
CTTGGTGAACTCATTTATCAAAGTGAAGGCAAAAATAAACATTAGTACATCTTAATCCAAAGCCAAATTT
GCAAGACTTGGAATTAATAAGATGCTGCTGAAAAGTGGTGCAATCCTTGTTATTTTTATAGACTGTGATT
CTTGTGTTTGGCTAATGTAATTAATCTTCAGCTAAAATCATCTGTTCCAAATTTACACTAATTTTCAATG
CTTCAATATGTTTGCAAAGCAGCATTCTGCTTCTGTGTACTGCAGGTAGATTCTTGTTACCTGTTAGCCT
TGGTAGAGCTTATCAACTGATGCAGTGCACAACTTTGGTGGTGCTGGGGCATTTGTAGTTTTTTTGTTGT
TTGTTTGTTTTGTTTTTTCTTTGAGATGGAGTTTCGCTCTTGTTGCCCAGGCTGGAGTGCAGTGGCACAA
TCTCAGCTCACTGCAACCTCCACCTCCCAGGTTCCAGTGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGG
GATTACAGGTGCCTGCCACAATGCCCGGCTAATTTTTTGTATTTTTAGTAGAGATGGGGTTTCATCTTGT
TGGCCAGGCTGGTCTCGAACTCCTGATCTCAGGTGATCCACCCACTTTGGCCTTTCAAAGTGCTGGGATT
ACAGGGGTGAGCCACTGCACCTGGCCAGCATTTGTTTTTGATCTGGGGGGATACTTGCTACTGGCATTCA
ATGGGCAGGTGGCAGAGTTGTCCCACCCAAAATGCCCATAAGCAACCCTCTGAAAAATATTGCTAAGGAT
TTCCAATACAACATTTGTGACTTGTCAAGGTGATGCCATTTATTATTAGGTGTGTGAAAAATAAGAAATG
ACTTGTATTGGCTTATTTTCTTTGTATCCAAGGCACCTTCTGCATAACTCCCTCCTACCTCTTCTCATTG
GACTGTGTGTGTTCACATGTTCATCTTCCTCTAGTCTCTTTGTCACATCAGAACGGAGACGGCACTTCAT
TTGTCTTTGTATCCCCAGCAGCATTTCAGCAACAGAGTGGATGCTCAGTTAGGCTTGATGACTGAAAAAC
GAACAAAAGCCTGGTACACCAAAAAAGTTTAGAAAATGTTTATAAGAACAAATTGTCTCTTTTGTCACAG
AAATACTCTTTGTTATCCTGAAGGCCCTGGTTTGGTCTTGGGGAAAGCACACTAGATCTGGTATCCTGGT
CTAGGGTTCTTGACACACGCATTTTATCATTATCTTACTAGGTCTTAGATTTTTCATCTGGAAAATAAGG
GGAATTAGGGCTTGGTCTGCATTATTCTAAGGTCTCTTTCAGCTTCAAAAATTCTACTTCTTTGTTAGAC
AAAGATAATATTACCTCCAGATTAGACACCATAGTCCTACTGCCAAGTGCAGGCTATTTCTAGATTTTCT
ACTAATCCTCTAACATCAGTCATTATCTTATTTAATGTCAGAGTCTAGATTTGGCCGAAAGTCCGTTTGT
AGAAGCTACATTTTAGAAAAACAAATGTACCTAGCTTGAGAATGTAAGCCATCTGGTCATCTGTTATCCT
GGTTTCCATGGGAGCATATTTTCCTTTTCGGCCATGGAGGAAGACCGGGAGGATACCAACAGCCATTCTA
CATAATCAGAGTTGAAAGAGAGTGAGTATGGCACAAAAGTGGGGAGAAGAGAAAATGGCAAACATGATGG
GACATCACTTTGTGAGTTTGTATAAAAAACTTTGGTTTCCATCTTGCTAGCCAACACTATTGTCTTCTCA
GCTTGAACAATTTGATAAAGCAAGCTGCCTTGTTGAAGAGACCCACGTGGCAAGAAATTGAGAGCAGTCT
TCAACCAACAGCCAGCAAGGAACTAAGGCCCTCAGTCCAGCAATCCACAAGGAACCAAATCTTGGAAACA
TCCATGTGAGCTTGGAAGTGAATTATCTCCAGCTGAGCCTTAAGATTACTACAGCCCAGCTGACTTGACT
GAAGCTTGTTAGAAATGCTGGAGTTGAGAACCAGCTCAGCCCTGCCTGGATTCCTGATCCACAGAAACTG
TGAGATAATACATGTATTTTAAGCTGCTAAATTTGGGGGTAATTTGTTACACAGCAATATATAACTAATA
TACTTGATATTCAGAAATCACGTATAGTTTGTTATCTGCCACCATGGATATCTAAACACCAGTGACTATC
TTTTGTTTCTCCCCCTGGTGTTTACTTAATCGCTTAAAACTCCATCTGGTCATCTAGCCCCAGCTCTTCG
TTTCTAAATACCATTCTCCATTAAAACAACCTAGGCTCTTGGGGAAAGTTGATTCCAGGGTTGGGGCAGA
AAAAGGCAAAAGCAGAGCCTGAAACATTTTTTGATGCAAGAAAGTAAGGAGTCCTCCCTAAAATGATGAG
GCAAGTCAAAAGGATACAGAAAGCAACTTGAAGAGCCCCCAGTGGTAAAATCTGAAACAATGTGAACAAG
AATTTAAATAATGATTGTAATAGATTATAACCCATAGAATAAAATAAATAATTATGAGTTCATACTTATA
TAAATAAACACATAAAAAAATTAATGTGTGAGAAGGGACAGCAGAATTTAATTAGTAAATATAGAAAGAA
TGATGCAAATAGAAAGTAACTATTAGACAAATTCCACAGTAATCATTATGGATTACACTGTTGCATGACA
AAAGAGTGTATTTACATAGTCTCAAAATATCTTCTTATAAGATATTTATTGCTTATAAAGAGAAAAATAA
TTTTTAAAAAGTGGGGAAATCTGTAGGATACCGCCTTAAACTAGTGATCAAATTTAGCATCACCATGATA
AGATATATCAATATCATGTACATCCTGTTATTCACTAAAAAGGGCACAGCATCACTTTGGCAGTGTTCTT
GCCAAAAATGTTTAGCTTCAATCTATTAATATTTATTTTAAAAATCAGGCTGATGCACATTGAGAGTTTT
TACTATTATCTTACTCTATTGAGCTCTTTGAGTCTTGGTTTCTTTATCTGGAAAATAAGGATGTTGGACT
GGCTAGTATTCTTCAAAAGTGTTCAAGTCATAAAAGACAAAGACTAAGAACTGCACAGACCAAGGAGAAT
ATGGAGACACAACTACATGGCATGCCATGCTTAATCAGAAAAGGGACATTAGAAGGAAAACTGGCAAAAC
TCAAATAAGATCTCCGAATGAGTAAATATCATTGTATCAATGCTAATTTCCTACCTTTGATAATTATACT
AGGGTTATGTAAAGTATTGACATAAGGAAAAGCTGGGGGTAAAAAGTAAAGAGAAAGTCTCGCTACTCTT
TTTTGGAACTTTTCTACAAGTCTAAAGTTATTTCAAAATAAAAAGTTTGATAATAAAAAACATCTGGTAT
TCTAAGAGGATATTCTGGTAGCCTTTCAATCTCACACCACAAGCGAACAGGTGCAACACCTTTGATGTGG
GCTATCAAAGAACAGCTTGCTTTTGAACAACAGTTGGAGTTTGCATTTCTGGTATATTGACTTTTTTTTT
TTTTTTGAGACAGTGTCTTTCTCTGTTGCCCAGGCTGGAATGCAGTGGCATGGTCTTGGCTCACTGCAAG
CTCTGCCTCCTGGGTTCACGCCATTCTCCTGCCTCAGCCTCCCAAGTAGCTGGGACTATAAGCGCCCACC
ACCATGCCCGGCTAATTTTTGGTATTTTTAGTAGAGATGGGATTTCAACGTGTTAGCCAGGATGGTCTCG
ATCTCCTGACCTCGTGATCCACCTGCCTCGGCCTCCCAAAGTGCTGGGATTATAGGCGTGAGCCACCGCG
CCCCGCCGTATATTGACTATTTTTTATCTAAACTCTTAGAAGATATTAGCTCAGTTTTAATTAATCACTT
CTAACTTTATAGAGTCAAGAGTCTACATGTTTTAGTCTCTATCCTTCACTTCATTCATGATAGAAGAAAT
TGCTCATCCAAATCTTTAGCAAAGATAAAAATGTGCACATGAAAGGGCCTTATATACTGCTCTTTAGTCA
CATTTTTATAAGTTTACATTGTTTACTATGGCATACATAGGCAAACCTCAGTTATCTGCAAAGATCATAG
CATGCTACATTTCATGATGCTGTTAGTAAAAAGTGATAACTAGTAATTATTATGTATTACGTTGGTGGTA
GAAACTGTCTATCATTGCCCTAATTGTTTGTCATAATAACTAACATTTGATTCCTACTACATATGAAGCA
CTGAGCAGACCACTTTATAGATTATTTATTTTATTCCTTCAATAACACTATGAGTTAGGCACAGATGAGT
CTGCAAACACATATTCGCTAGTAATATCTGGCATCAGAGAAAGAGCTAGGTGGGTTATACTGGACCCCAA
GAAAGGTCTGTGCTGGAGCAGTGACTGAGTTGTCACAGCAACAGGCACTATTTGATCAATTCCCTTCTAT
TTATGTCTTTTCAATCAGTTTACTCTGTTAGCACTGGGGAAAGGGGAGTAGGCATGGAGGGAAAGAGGAA
GAGAGGAAAGAAAGAAAGAAGGAAAAGAAATCTCAAATTGTCTGAAGAGTCTCAACCTTGTCATAAAAAT
GAAACTTTCAGTTTGATGTGTTTCAAATTAGAGAAGTTTCCAATTGGAGGAGAAAGACTCAGGAGGAATA
TGAAAGACAGTTTTTTAAATGTGAAGGGCTGTTCTGGGAAAGGGGGATTCGAATTGTTGTGTGTGGCCTG
AGAAAGAAGAATAGGGGGCCACTGGGTGGAAGTTTACACAGACACATTTTAGCTCATTATAAAGAAACAC
TTTCTAACCAGATAGTCCAATTACAGGAGATGCTGCCTCAGAACTTTCTGAGCTCTTGGTCCCATGAGTG
CTACAGAGGAGGGTGGATGACCAACTCTCAGAGAAGAAGAATAAAAACAGGGGATTGGTACTTAAATTAA
ACGACTTTGAAAGTCTCTTCTAGTCAGGATGCTCTGTGAGGAATTCTGAGCCTTTGCTTTGCCACTGAAT
CAGACACTACTGAGAGAGGTCAGTTTCCAAGCCACTGAATCAGACCCTACTGAGAGAGGTCAGTTTCCAA
CTCCCTCCTCCATGGTGTCTTAGCTCTGGGCTACCTATTATGTTGAGTTGAGAGAAGCAAACTGAATGGG
TATTTGGAAATAAGAGGCTGAATCAGACAACCAGTGCATTGCTGTCAGTCTTTCAGAGCTGAGAGAAAAC
TATGAGATCTAAAATTTGGAAGACTCTTAACTTTGTGAACTTTTCTCCTTTTTCTGTAAGTGGGAGGCCA
TGCAGTATGGTGGGTAGGATGTCAGCTGTGGAGAGCCTGCCTGGGTATAAATCCTGGGTCCCCATCTCCT
GGCTGTGGCAGTCATTGGTGCTGTTCTCTCAAATATTTCCATATCTTTTCTCCTGGGAAGTACTGACATC
TCCCCCCACACCATCACCCCCTCCCCACACACACACAGAGGAGTGTGACCATGTGACACATTCTGGCCAG
TAAAATAAAAGAAGTAAAGCCAGTGTGTGATTTTCAGCCTGGCCCTAAAGTGGGGACAATGTGGAGCACA
GCCCCTTGCCAACCATAATGGATATGCAGTGTGAGTGAGAAATAAATCCTTGTCTTAAGCTACTTAGATT
TTAGGAGTGTTATCTCAGCATAACTTAGCCTACCCTGACTGATACATGGGCTCTGGGCCAGTTACTTGAC
ACTGCTAAATCTCAGACTTATTATACATAAAATGGAATCATAATAGCACCCATCTTCTAGAAGTGCTGTG
AGAATCAAGTGAGAGAGTTAATACATACAAAGTCTTAACACAGTGCCTGGCTTATAAGTAAGTGCTCAAA
AATGTTATCTACTATGATCACTATACCATAAGCTCCACTGGGTCAGGAATCATGTGCCCAGCACTCAATA
GCAATTTGTTGCTATTGGCCAGGCACTCAATAGCAATTTGTTGAAGAATCAAATTAAGTCATTCTTGACA
AGGAGCATCAATGACACCTACCACACTATTGCTAATCTGATGAATGATATTCAGTTGTAATCTTACTCAT
TGGCAGCATCCTCCTTGAAACTCCCCCTTTGTTTTCTAAGATATTCCTCCTGGCTGGTTTCCTCCTAGAT
CTCTGTCCTCTCCTCAATCTCTTTTCCAGTTTCTCTTTCTACTCCCTAACTATCAAGGGCATTCTCTAGA
GTTATGTCTTTGGCCCTCTTCACATCAGAGTCACTGGATGGCTCTACAAAGTCCTAAGGCCCAGGTCCCA
CCTGCAGGTTTCCTGATATAATTGGACTAGGGTGCATCATGGGTATCGGGATATTTAAACCACCCTCCTA
CCACCAAGTGATCATCCTGTGTAGCCAAAGTGGAGAGTTAATGCCCTGCACCTGAACTGTCCACCACAGT
GACCACATAAGACAATTAAGCACTTGCATTGTGGTGAGTCCAAACTGAGGTGTGCTGTCAGTGTAAAATA
CATACAAGGTTTAAAAGACTAGTATGAAGAAAAGCATGTGAAGTGACTCATTCTTAATTTTCATACTGAG
CACATGTTGAAACAATGATACTTTGGATGTAGTGGGTTAAATATATTATTCAAATTAATTTTACCTGTTT
CTTTTTACTTTCTGATGTGGTTATCAGGAAATTTTAAATTATATATGTGGCTTATGTTATATTTCTAGCA
GACAGAGCTGCTTTAGACACTCCTGCTGAGTGGTGCCATCTTTCTCATGGCTTTTACCACTGTACATTAT
GATCCACAAATAGGCTTCTCCAGCACCTACTTCTTTTTGAGCTCCAAGCTCACGCATCCAACCCAAACAC
ACATCTTCCACAAAATTGGCTCTTCCTCTCCTGGTGCTGCCTGTGGAGCATCAACATCTACTTGTCCACT
AGACAAAAGCCTGCAATTCCTTCCACTTCTCCACATCTTCCCCCAACCATGTGAACCACCTCCTGCACAT
TCTACTTCCTAAATATTTCTCAAAACTCTGCATTGCTCTTCATCCCCACTGTTTCTGTCCTCACTGGCTT
TCAGTGGTCTATCTTCCATCTAATTTATTGTAGACACCTAGCAAGAGATGGATCATTTCAAAATGCAAAT
CTCCTCTGTTTAAAAATGCTTTCATGGCATCAGTGGACTTGAGGATAAAACCCAAAGTCCTAACAATGTC
TATCAGGCCTTTCTTGATAAGGTGCTTATCTGTCTCTCCGCCATTCCCACCTGAGAAATGGGGACTGCCC
TGCCCCTCCAGCTACATTGAACTGCTGATTCCTCCAATACACCCTGCTCTCTCAGGACCCTGGATCTTTG
CACAAACTGCTCTCTTCCTGGAAGGCTGTTCGTGTTCCCCTGCACCTACATAACTTTCTCTCTCTCTCTC
TTTTTTTTTTTTTTTGAGATGGAGTCTCACTCTGTCACCCAGGCTGCAGTGCAGTGGCATGATCTTGGCT
TACTGCAACCTCCACCTCCTGGGTCCAAGTGATTCTTGTGCCTCAGCCTCCCAAGTAGCTGGGACTACAG
GTGTGTGCCACCACACCTGGCTAATTTGTGTATTTTTTGTAGAGATGGGGTTTCACCATGTTGGCCAGGC
TGGTCTCAAACTCCTGACCTCAAGTGATCCACTTGCCTTGCCCTCCCAAAGTGCTAGGATTACAGGCGTG
AGCCACCGCATCCGGCCTCATAACTTTCATCATTCAGGACTCCCAGCTTGCTCTCCATGAAAACTTCCCC
AGCCACCCCTTCTCTCAGGCTAAAGGAGAAACTCTTTCTCACCCCACTCCATGTTCTCATACCATAGGTG
TGTTGTCTCCTCCCACTATACACCTCAATGCCCAGCATTGTCAGTGTGTGTGTGTGTGTGTGTGTGTGTG
TGTGTGTGTGTGTGTGTTTGTGTTTTAAGAGATGGGGGTCTTGCTCTGTCGCTCAGGCTGGAGAGCAATG
GTGCAATCATAGCTCACTGCAGCCTCCAACTCTGGGGCTCAAGCAATACTTCCACCTCCACCTCCTGAGT
AGCTGGGACCACAAGTGCATGATACCACACCTGGTTTTTTATTGCCCTTTTACTTTGTCTACTCCCACTA
GACCATAAGGCTTTTAAAGGAAGTAGCCATTCCTGACTTGCCTTTGTATCCCTAGTGCCTCACCCAGTAC
TGGATACAGCATAATAATAACAACAGCAACGATAATAACAATGTTAATAATAGCAGCAGGGATTGAGCAG
TTACTACATGTCAGAAACTGCTCTCTGCTTCACATGGATTGCCTCTTTTAATAATAACTTTATAGAAGTA
TATTGAGATAATAAAATTTGAGCGTGGCCTAGGACTGTGCTAAACACCACAAGACACACTAAGAAGCAGA
TTCTCTAATCTAAAGAAATTGGAAATATCATCAAGTAACAAAAATAGTGCACAATTCTTTCAGGCAAAAC
TACCACCCAAAGAAAGACATTCAAATAACTTCTAATTTATTAAAGGAAGAGTTGTTCTTGCCATTTAAAA
ATAAAAATATGTCAATAGGAATTATAATTATTATGGACAGTTGAGAAGCCAGAAGTGGGAAAAAACGACA
AACTATTTAGTGAAACACATGTAGTATGGCATGGCTTTGTTCACCAAAACATTGACTCAGTATGGAATGT
TTCTATTCAATCTTCAATAATCCCTGTTAGTTCATCAATTCAACAAATCTATGTAATATTTATAATACAA
CATGCCAATGGTTTCATATATATATATATACACACACACACATATATACATACACACACACACACCCCAT
GTGTATTTATGTGAAAATACACAGGAGCTAGAAGAGAAACACATGAAAGATTTAAAACAACAAAGCCAAA
CTAAGTATCCAGACCCATGAGAACTTCAGAGTAGGAAGAGATTAGTGTGGATCATTGTAGCCAGAGGAGC
CTTCATGCAGGTAACAAGATTTGAAGAGGAAGCTGTGGGAGGCTGAATATACAGAAGGTAGAAAGAAGGG
CTTTCCAGGCAGCAGAAATAGCATGAGCAAAAGTTTGGGTGAGGCCATGAACTTTTTCAGAGAACGTGCC
ATTCTGTTAAGTCAAAGTCTTACCCATGTATTTAAAGACACAAAGGGCTGGTTTCTTCATTTCTCCTGAT
TCACGTCTGTGCTTTTGTGTCACTTGTGATGCTGGGTGAAAGAAGGTGCCTCTCTGATGTGTGCTAGTCA
TTCCCAAGGCGACAGCTCTGTCAGAGATAAAAATAAGGAAGTATCCTTTTTTATCTCCTTTGAGATGCTA
ACAGGCTGCTTTCCAGATTGCATTCCAGTCTACAGTTGGTTAGCAGATTTGTGTACTGGTTCCACCTGGG
CATATAAATTACTCTCTCCACTCAAAGTGCTTTGTAGAGCACAAGAATTTATCGTGTGGAGAGGTAACTA
TGGTCTGCTACAGTTTTATCGGTGTCTGTGGAATAATCCTGAGCTTAGAGTAAATTTTAGCACACCAAGC
AATTTATATAACAACCAACCTCCAATTATCTAATTTTCAGAAACAATATATGAAACAATGGGCAGCATTT
GTTAGGCACTTACTATGCCTCTGAGATTTGGTGGGGAATGTTCTGTGACAGGGAGACAAAACAAGCAGGA
AGCAGCCAGAGGTCCACACACTAGGGCTAGGCAGGCTGTAAAGACTCTACTCAGTTCCCAGAGAGTTAGG
CTGGGAGATGGCCTTTAGATAAAGATAGATACCGCTGGGCACGGTGGGTCACGCCTGTAATCTCAGCACT
TTGGGAGGCCAAGGTGGGTGGATCACTTGAGATCAGAAGTTCGAGACTAGCCTGACCAACATGGTGAAAT
CTCGTCTCTGCTAAAATACAAAAATTAGCCAGGCATGGTGGCAGGCGCCTGTATTCTCAGCTATTGAGGG
AGGCTGAGGCAAGAGAATCACTTAAACCCAGGAGGCAGAGGTTGCAGTAAGCCAAGATCGTGCCATTGCA
CTCCAGTCTGGGCAACAAGAGCAAAACTCTGTCTCAAAAAAAAAAAAAAAAAAAAAAAAGATAGATACCT
ATCTCTTTTCTTGATTTAGATGTAAAAGGTCAGGGATTGGCGACGGGGCAACCAGAACCCTGAGACTAGG
ATCATGGGCTGGGCACTTGGGCTTTCCAGAGATGGAAAGCAAAAGCCATCGACACTTAGCTCTAAGACCT
AGCTGCCTACTGTGCCGGGAACATCACCACTTCCATCCTAATGAAATACGGAAAGAGCACAGATGTGATG
TCGTAACAACAGTCCAAGGAAGGGGAGGTGGCAAAATATGAATTTCCTCACAGAGAAAGGGGAGGTGGCC
AAACCACCAAAACGGGGGTGGGCATCAATGGGGTTCACTACATTTGACTTCATGCAGCCTGTCTGAACCC
CTTCCTCTTGTTTCCCTTCCTGCCCTGAAAGGCTATACTGACCATTGCAGAGTCTGAGAGGAGTAAGCAA
AGTTAGCAGCTAGTAAGCAAAGTGAGCAGCCTTGGCTGGGCTGAGTCACTGGAAGGTTCTGAGTGTTCAG
AGGCTGCTGCAGCACAGGGTAAGACGTGTGGCCCAGACTCCAGGGCAGTGTCAGAAGAGGCTGCACTTAC
ATGCAAAAGCTAAACAGGAGTTAACCAGGCAGAGTGGGGAGCACGTGGGCAAAGGGACCAGCAGGAAGAA
AGGCAGGGATGTGAGAAAGGCTGGGCCTTTCGGTTCCCTCAATATGGCTGCAGGGCAAGGCGGGAAGGGG
GAAGACAAAAGATGGACGTGGAGACCTAGCCTCGCATGGCAGGCAAAGGAACCTGCAAATTAGACTGCAG
ACAGTGAGGAGCTCGGCAGATGTAGCATAATTACAGCTGTATTTTACAAAGACTACTCTGATGACAGGAT
GGAAAAAGTTAACTAGGTTTGTTCGGACTGAATGTTTGTACCCCCTACTTCTTGCCCAAATGCATATGCT
GAAAACTCTAAACCCCAATGTGATGGTATTAGGAGGTGAGGCCTTTGTGAGATAATTAGGTCATGAGGGT
AGAGCTCTCAGGAATAGGATTAGTGCCCTTAGAAAAGAGACTGCAGAAAAATCTCTAGCCCTCTCTCTAC
CATGTGAGAACACAACAAGAAGATGGCAGTCTATGAACCAGGAAGAGGACCCTGGGCAGAACCCAACGAT
GTTGGTGTCTTGATCTTGGACTTCCAGCCTCCAAAACTGTAAGAAATAAATGTCTGTTGTTTATAAGCCT
CCTAGTCTATGGTACTCTGCTGTAGCAGCCCCAACTGACTAAGACAAGAGTTCAAGGGGGATACAGAAGG
CAGTAAAATTAGTCCAGAAACTGCTGCAATAACCCAAGTACTAAATAAACAAGGTTCTAAACCAAATTGG
CAACAGTGGGAATGAAGAGGATGGGATAGATTCAAACTGCAACACAGACGTACAAAAGAATACACAGAAT
TTGGAAACCAATTGGATGCGGAAGGTGAGGAACAGGAGAAGTAAAGTAAACACCATGGTTAAGGCTTAGC
TAACTGAGTAGCTGGTAATGCCACTTACCAAATACTGAATCAGTACTTGTCAGTGCCAAGCTGCTATGTG
TATTCCAAGCATCATGGGTTCTGATACAAGGAAGTAGAGGCTTACAAAACCTCAAGAAGGGCTTGGAGTG
GTTTTCAGAAGTGCTACAGCTGCTGTTCAGAAAAAGAGAAGCTTCTTTGAATCTCAAGAACTTCTAGAAA
GCTTGGACCTCAGCTTACAGTAGCAATGCAGGTCATCTCCAAGAAGCCACTGCAGCTGTCTACACTGCCT
ACAGCACTGTAACAAATACTCACCTGGGAGTTCAGCTAGAGAATGGAAAGTTGAGTTGGGGTAGGCGACG
TGATCTCCAAGGAAGGTGTTTGATACACACATCCAGATAACAAGGAAGAGCTCTGAACTAGAAGGACAGA
TTTGAAAGCCATGGGGCTTAAAAATGGAATCACCCAGAGAGAACATATGCAGAAAAGTGAGAAAGAACAG
GACAGTATCCACAGGAGTCCAAATAAGACAAAGATAAGCAGCAACTCAAGCCCCGCCCCCACCCCCACCC
ACCGTCTAACTTTAGGAGCTCCTCACCTCTTATGGTGAGGAGCCAGACTCAGCTGATCCCAGTGCAAGCC
CTCAGCCTCATGTTCTCTAGCGCATGACCGGAGCTGTATATGGAAGAGGTGGCATATGGATTGAGTGTGC
CTGGCAGATATTGTAAGCCTGAATTTTCTCCAAGTAGGAAAAGATGATGGCCAAGTGCAGGTGGGTAGGG
AGGAAAACTTCTGGAAGAATTAAGGCTTGAGGAGGAAAGATACAAATCAGGTAGGCTATTTTCTACATTA
AATTTCAATCCTTGCTATAACTGCTGCCCAGAAAAGAAATACATCTGGTGAAAGTCACATGGTTCAAGCT
AAGTGAAATCAACAATTTTTCTTTGTGCTAAAGATTTCACGGTTTGTCTCATTTGCAATGGGGGAAAAAA
CTTTTTAAGAGAATAAATCATTAGGAGACAACCTGCTATGGTTTGGATATTTGTCCCATCCAAAACTCAC
GTTGAAATTTAATCCCCAATGTGACATTACTGAAAGGGAGGGTCTTTAAGAGGTTGTCAGGTCATAAGAG
CTCTGCCTTCATGAATGGATTAATTCATTTATGAATGAATGGATTCATGGGTTATCATGGGAATGAGACT
GGTGGCTTTATTAGAAGAGGAACAGATACTTGAGTCCACCCCCCCTCACCATGTGATGCCCTGTGCCACC
TTGGGCCTCTGCAGTGAGTTCCCACCACCAAGAAGGTCCTCACCAAATGTAGCCTCTCAACCTTGGACTT
CTCAGCCCCCATAACTGTAAAAAATAAATTCCTTTTCTTTATAAATTACCCAGTTTCAGGTATTCTGTTA
TAAGCAACAGAAAATAGACTGAGACACAACCACATTTCCTAACCAAGTAATTTACAAGATTATTCAAGGA
AAGTCAAAACCAATTTCAAAAGCGTGTTCTAAGAAACAAGTTTGTACAAAGATACATTATTGCAAATAAT
GCACCTCAAGGCATACTAATTATGTAGTTTCTAAAATTTCCCCCCAAATATGGTCATTTCCTAAATATAA
GAGGGTAAGCGAAGTAAGGGATTGAGGAGAATTATATAGGTTGGAAATGATTTTCTAACAATTTCTCTTC
CACCCTTTTTATTCCACCCAACAACATCGTTTCATTTCTGTCTCCTAACATCTAATCACTTTTACTCACT
ATCCAAAGACTGACAATTAACCTCAACAATTTTTGCCATTTTCCAATGAGGCTTCAAGGTCCATGTTGAC
ACTCACCCAATATCCTGGACCCTCATCTTCTTGACTTCATCTCTAGTGAATTCCTCTTTTTCTCTACCTC
AGATACCACCCTCATGATCTCATTCTTGACTCTCATCACCTGAAACTGTGTCATTTTCAAAAATGAGACT
TCTAAAATTTATAACATGTAAATATCCACCTCTGTGACCACACCCTCACATCCTTCCACTTCCCTTGATC
AAGCATTCTGTAACAGGCTGAATAATGACACCCAAAGACAGCAAGTCCTAAGTCCTGTAAATGTTGCCTT
GTATGGCAAAGACTTTGAATATTCAATTAAATTCTGGATCTTGAGATGGGGAGAGTATCCTTGGATTATC
CCAGTGGGCCCTAGATCAAATCACAAGTGTCCTTATATGAGATATACAGAGAGAGATTTAACACGGACAG
AAGACAGGAAGTCAATGTGAAGGCAGAGGCAAAGATCGGAATGATGCAACCACAAGCCAAAGCATGCTAG
TAGCAAAATACGTTGACTAATTAATTAAATTTAAAAATTTTTTAAAGAATGCTGGTAGCCACCAGAAGTT
GGAAGAGGCAAGGAATGAATTCTCCCCACTACAGCCTCAAAGGAAAGCATGGTCCCCACTGATTTCACCC
CATTGAAGATGATTTCAGGGCCAGGCACAGTGGCTCACACCTCTAATCCCAGCACTTTGAGCAGCTGAGG
TGGGACGATCACTTGAGTCCAGGAGTTCAAGACCAGTCTGGGCAATAAAGAAAAGAAAAGAAAAGAAGGA
AGGAAGGAAGGAGAAGGGAAACGAAGGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAA
GGAATGAAGGAAGGAAGGAAGAAAGAAAGAAAGTCCAACCATTGGCCATCTTTGTGTCAGCAACTGGCAA
CTAAGTGTTGTTAAAAAAAAACAATTATACAACCAGGCAGATTGATACCACCCAAAATTGATATCTGGGA
ACCTCAGTTGAACCCTCCACACTGCTTACCCTCAGCCATGTTCTAGACTATATGTATATCACTGTCAACT
CAACATGGAAGTCACAGAGGCACTTTAAATCCAATGTATCCAAAACTTTTCTCATGATCTCACTCTCCAA
ACTTACATCTACATGTTCCACAGCTCAGAAAATACTGGCCCTAATACTGTCCAGTTATTCATGTCAGAAT
CCTTGACGTTTTTCTTCTCTCATCCCCTTGATGAATCCATCATCAAATTCTGTTGATTTTAGTGCCTCAA
AGTTTCTCAAACCTGGTCACATTTCTCCACTTTTTACCAATGTAATATTCAATTCACTGTCATCAATTGT
CTGACCTGGGACAATAGCCTCTGCACACGTCTCTGCATCCATTCTTGCTTTCCTCCTGTTGGTTCATTTG
TTATGACCAGAGTTATTGTTTAAAATACAAGTTTAATCATTTTGGCTCTCTGCTTAAAACTGAATATCTG
AATATATTCCAGTTCTTCATAGAATAATGTCCCAAATCCTTAGCATGGACTCCAGCTCTGCTTCATGATT
TGGCCTCTTCTCTCTTCGGCCTCATTTTGATTTGTGCTTCTTCTTAATCCCTTTAAGTTGCAGTCTTGCT
GGCCTTATCTCAATTCTTAGAATGCACCAAGTTCTTTCCAGCCCCAAGACCTTTGCCTACACTCTTCTAT
TTGAATGGATTGTTCTTTCTTCCTTGCCCCACCCACCATTGCCCCCTCCGCCTAACCTGGTTATTTCTTA
TTCCTCCTTTAAGTTCCAGCACAAATGTCATCTTCTCATGGAAATCTCTACCACCTCCCTGCCTAGGTCA
CATCTGCTAATGATATCCTGCTAAAGCCCCCTATACTTTACCTTCACGGCACATACCCAAGTGAAATTGT
GAACTACTTGGGTAGTTATTTGATTCATTTAATGTATCTCACTTTCCTAGGTTATAATTTTTATAAGGTC
TGGAGCCTTATCCATCTCATTCCTGGTGACTCTCCAGCACCTAGAACAGTGCTTGGGCCCTAGTAGGTAA
GCGAGTGCTTATTCAATTTTGGATGGAATGGAAAACTTAGGAGCTTGGGAGTTATAAAAGATGAGCAAAA
CCTGGTTTTGTACCCAAGGAGTTTGCATTTGGATACTTGTTCAAATCTCATGTCATCTAACCCCATCTCA
GAAAAAAGAAATGACTGTATATCAAGAAGCATATTGAGATGAGTACCTAAGCAATTTAAAAGGGGTTATT
TCAGCATGGCCACTGTAAAGTTATATGGGGTTTGCACTGCACAAGGAAACATTGTCAGGAGGTGGGTTAG
GAGCTTCAATCCAACCATGCTCAGCTTTCCCAGCTACACATTGGTAGGGACTGCATCTGCTGAAGATGTC
CTTTTTCTATCTTGAGAAAAGGTATGGTAGAGGCCAGTGGTTGCCTTGATTCACATCCCAAACATGTGGG
TCCTGGGTGATTTTGGTGGTGCTTAAAGAAATGCAATAGCCTAAAATTCAGACAGGTAGTAGTAGAACCA
AGAAAAAGCCCCAGGCTTGAGACATGTCCATTATTCTATTCAAACAGTTAACTATGAGGGAGAACTGAGG
AGAAGGTCTAAATACATATTGAGTTCTAAGGTGGCAATTAAGGACATCTAATAGAATCTTTAAGTGGTCC
CTATCTGACTCTAAGATGTCTCTCTGAGGTCAAGAAGGGTCAAACAGAGCCTCAAAACACAAATCTTGCT
ATTTAACATTCTCAATAATCTCAATGTTAGCTCCTCAATAGCTTTCAGATATTATACCACTTGCTGCAAA
ATTAAAATTAGAGTCAATACAATGAGTACTCAGTATGCAAAACAATTCAAGGCTCTATTTCAGCATGAAG
TTCCATTTAAGCTGCAGGAATAAAAGGAAAAGACAACCCTTTGTTCTCTTTATTTCACAATCCTGCAAAT
GGTCTCTTAGCCAAAATAGTTCCTCTAATCTTTAAGTTTTAATTAGCTGCCCACAATTCATAAAATATCA
GGAATTAAAATTCTGATACCTCATTCTCCTGAGAAATGGCACACAATTAACCTCTTTTTTCTGGTCAAAG
GCAGAAATTGAGAAAGGGTAATGACAAAATTAATCTATTCTGGTGGCGAGGCCTGCCATAAGGCTGGAAG
ACAGCATCCGACCCTGCGTCGAAGGGGAAAGCAATCTCTAGCACGTTGAGGAGCCTCAGATCAGTTGTGG
CTTTTGTATTCATGGTGAATTCTATCACAAAACATGTGAGCCCCAAATATCTTACAAAAATATTAAATGA
TTCCCCAGGAAGAATCAACCTAGCCTGCCTTCCTTTCTCTCTAAAAAGAGGTAAATACAGAGGCTTTAAG
TGGTCAGAAGCTCTGGCTTTCTAGCAAGGTGGGTAGAGAAAAAAAAGGACTGAGAAACTCACACCTTCCT
GGCATCATCTCCAGATCAAAACATATGCTGGGCAGTAGTAAAGTCAGATGGAGTTTCTGGGACCAAGTTT
ATACCTTTCTATAATAATTAGTCCCCAGAAAATATAGATTCTGCTTTTATTCCCTAATGGTAAATCACAC
GGTAAATATTTAAGCAGAATTATCCGTATCCATTTAAACTCAGTTGAAAGCTCATGGGACAGAATACAGC
CCAGTACTAAGAAGGTAAAGATATTTCAATGGAGGCTGTCAATGAAGACAAAGGCAGGCCTAACTAGCCC
ACATTTAGAAGGTAAAGATGTTTCAACAGTGGCTCTCAATGAAGACACAGGCAGACCTGGGTAATAGGAT
GGAGGCTGTGGAGTCCATCTGCCTGGTTTCAAATGCCAGCTTGGCAACTTACTAGTTGTGTGATCCAGGG
CAACTTGCTTAACCCCTCTGAGTTTCTGCTACATATCTCTAAAACAGGGACAAAAACCTGTGTTGTAAGG
ATAAAAGAGAGAATGCGTATAACATGCTTAGCTCAGTACCTGGCACTTCATGAGTGCTTGTTAAAGTTAG
TTACTATTATTGTCAATAGAGGAACCTAAATATTTTTAATGAGTTTAAAAAAGAAAGATACATTTTCATG
TTAAGAACCCTTTAGTGGCCGGGCACGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGTG
GGCGGATCACCTGAGGTCAGGAGTTCGAGACCAGCCTACCAATGGGGTGAACCCCCGTCTTTGCTAAAAA
TACAAAAATTAGCCAGGCGTGGTGGCCTGTGCCTGTAGTCCCAGCTACTCGAGAGGCTGAAGCAGGAGAA
TCACTTGAACCTGGAAGGTGGAGGTTGCAGTGAGCTGAGATCATGCCATTGCACTCCAGCCTGGGCAACA
GAGTGAGACTCTGTAAAAAACAAAAACAAAACAAAAACAAACAAAAAAAAACCTTTAGTAATTTCAATTG
CTGCTTTTGTTGTTGTTAACAGCTTTATTAAGATATAATTCACAAACCATAAGACTCACTCATTTTAAAT
ACACAATTTGATGGCTTTTAGTATGTTCAAAGAGTTGTGAAACCATCGCCACAATTTTAGAACATTTGCA
TTATTATAAAAAGAAGCCCTATACCTAATACCTAACATGTCCCAATCCCTCCGTTTCTCCCAGCCATAAA
CTTCCTGTGTCTATCGATTTACCTATTCTGGACATTTCATATCAATGGAACCATATAATACATAGTCTCT
TAGGATGGGCTTCTTTCACTTAGCCCAGTGTCTTCAAGGTTCACCCATGTTGTAGCATGTATCAGGACTT
ATTCCTTTTTATGGCTGAATAATATCCTATTGCATGGTGTGATAATTAATACTGTCAACTTGATTGGATT
GAAGGATGCAAAGTATTGATCCTAGATGTGTCTGTGATGGTGTTGCCAAAGGAGATTAACATTTGAGTCA
GTGAGCTGGGAAAGGCAGACCCACCCTTAATCTGAGTGGGCACAATCTAATCAGCTGCCAGCATGGCTAG
AATATAAGCAGGGAGAAAAATATGAAAGGAGGGACTGACCTAGCCTCCCAGCCTACATCTTTCTCCCATG
CTGGATGCTTCCTGCCCTCGAACATCAGACTCCAAGTTCTTCAGTTTTAGAGTTTTAGAACTCGGACTGG
CTCTTTGCTCATCAGCCTGCAGATGGCCTATTGTGGGACCTTGTGCTCATGTGAGTTAATACTTAATAAA
TTCCCCTTTATATATATATATAAATTCTGTTCCTCTAGAGAACCCTGGCTAATACATACGGATGTAGTAC
ATTTTGCTTAATCATTGCTATTATTTTTGGATTAATTGTGAATTCGATGCTAAGTTATAAAAAAAAGTGA
GACGTAGTCCCAACTTTCATCCTTGTGGAGCTGCTTTGGAGCCTACAGGGTATGTTGACACACATGATTT
CATTTGAACATGAGCAATTTCATTTGCAGCTCACCATGATCCTGGGTGACAGATGTCATTTTACACTTTA
GAGATGAGTCCAGACAACTTAAGAGTCTTATTTAGCAAAGGTTATATAGCCATATAGTTACTGGCACCGC
CAGAACTCAAACTCAGGCCTTCTGAATTGAGTCTGTGTTTTTCCTGGTACAGTCAAGCTGCAGGAGCATT
AACCATGCAGTGGTGAGTGTGTGAAGATTGACGGTGTTAGCATACGTGTTTTACATCTGGGAGGAAGTTG
AGAGTAGATAAAAGCCATTTACCATTACCTTCATTTGCTCCCAACATGCAATCACCAGAGAATATGTAGC
CAGTAGAAGGGGGCCTGGGGTCTCCAACCTCAAAGCAAGAATGTCGCAGTTTCTACTGGGGATGACCCAC
TCCTTGGGGAAGCAAATCAACCATTCCTTTGTTAAATGTTTTTGGTAGTGAAAGAAGCTCCATCTTGGGA
TGCTAATCAGCCATACTGACTTCTGATTAACCTGAGTTCCAGGAATGCCTCTAAGATTTCTATTTTATCT
TTTGTTTCTTGTATAAGAGCATGTACTTAAAATAAATCTTGCCCTTAAGTCAAAACAACTTTGACCATAA
ATCCTGCCCTTAGGAAGATTCACAGTGCCTTCTTGCCTTTCCCTGGGGGGTGGACTTCAATTGTCCTACA
TGCCCCTCACCTATGGTATCTAAGCCCTGAGTCTGAGGGTTAGTAGTACTGTGATGCACCATCTAGTCTT
GCAGTTACCTGAGTCACAGACATGGCCTCTGTACATAAGTCCCTATTAAATGTTTCTTTCTAAGAAACTG
GATTAGTCAATCTCTTTCTTTGGCCTCTCAACTTCCTCAGACTTTGGGATAGGTTTGCATAGACCTGCTC
ACTGTGGAACAGTGTTCCGTCTTCATATCTCCCTGGCTAAACCTCTATTCAAGGTTTTACAACTACGCCA
TTCCTAAGCAGCACCATTCTGATCAGAGACACTTTTGCCCTGCCCTAATTGGGGAGAAATGAGATTCTTG
TCCTGTATTTACACCCCCACATAAGCCCCCAACACCTTTCTGAAAATGTATACAATAGCGTGCTTAAATT
TCCCTGCTCCCTGGGCTGGAAAGAAATTACCTAAAATTCTGAGGACTCCATTTTTTTTTTACCATTTTGC
ATTTCCCCCAAGCCCAAATCTAAGTAATTTGCTAACAATAACCATTCATGCACCCAAGTGAGTGCAAACG
TATATATGACATCTGGAAACTACTTTGGGAGAGAAAGAAGAAAAAAGGGATTTGCAGTTCATCTGTGAAC
TTGAATTCAATAAAATGAGCTAATACCTCCCCCTTTATAGCAGGAGGAGATGATCTCCATCCAGACTGTT
TCATCCCCAAAAAAGCTTTGGTTGCAACTCAAGCCGAGCTATGACCGGGGTGTAGAAGGCTGGCATTTGT
AACAATACATTCTAGGTAGCTCCACTTCTCTCAGAAGCTGTGGTAAACCCAAAACAAGCTCCTGACAGGT
GCAGGAAACTCAATGGGCTGTGGCACCTTCGGAATGGCTGAAGAATGAAAAGCAGCACTGACAAGGATGC
CAGGGAGCAGGCTGTGGCTACCGCCTTATGTCTGCTCAGGATGGGGAGATCATGTGGCTACATGGCATCC
TGGGCCGAGGACAGCCTATGACCATCGCCACAGGCCTGCTTGCCCATAGCCGTCCTGGGCCAGCCCAGAC
CCTCCCTGGCAGCAATCCCCTCTGCCACTGGCCTGGAGACCCTTTAGATAGGCAGGCTCAGAGTCCTGTC
TGAGGAGGTGGGAAAGCGTGAGCAAAGCCAGTGATCAAGTGCTGGCTGCTTTGTGATTCTCCTTCCATGA
AAAGAGAGATTTTTATTGCATTTTGTGCGCATGTGCAGAGTGGCTTGCTGTCTTCCCCCAGAATTAAAAG
CGTCTTTTCTTGGTTCAGCCTTGGGGTTGTTTCTGGAGAACCCTAGTAGGGTTTTGTTGTCGGTTGAATT
GTGCCCTCGTGCCCCCAAATTTCAGATGTTGAAGTCCTAAGTCCCAGTACCTAAGAATGTGACCTTCCTT
GGAAATAGGGTTGTTACGAATGTAACTAGTTAAGATGAGGTCACAAGGGCGGGCCCTAATCCAATATGAT
CCGTACCCATTATATTAATAAAAGGGGAAATTTGGATACGTATATGAACACAGAGAGAATACCCTGTGAA
GATGAAGACAGATCAGATAATGCCTCTACACTCCAAGAAACACCAAAGATTGCCAGGAAACCACCAAAAG
CTAGGGAACAGATTCTTCCTGATATAACTGAGAAGAAACCAGCCCCTGAGATCTTCTTAGACTTCGAGGC
TCCAGCGCTGTGAAGTGATACCTTCTTTTTTTTTGGAGGTGGAGTTTCCCTCTTGTTGCCCAAGCTAGAG
TGCAATGACACGGTCTCTGCTCACTGCAACTTCCACCCCCTGGGTTCAAGTGATTCTTCTGCTTCAGCCT
CCCGAGTAGCTGGGATTACAGGCATGCACCACCATACCTAGCTAATTTTTGGTATTTTTAGTAGAGATGG
GGTTTCACCACATTGGTCAGGCTGGTTTCGAACTCCTGACCTCAGGTGATCCACCTGCCTCAGCCTCCCA
AAGTGCTGGAATTACAGGCCTGAGGCACCATGCGTGGCCAAGGTGATACATTTCTGATGTTTAGGCCACT
CGGTTTGTGGCACTTTGTTATGGCAGCCCTGGCAAGCAAATACAGGCTCCATCCCTTGGTGTAGGAATTA
CTTGCCATCTTTATTCTGTCTTTCCCTCATGTCACAGAGACACCCTGCCTCCTTCATTGCGGCCTAATCA
CAGCGAGAGAGGGTGCTCCCTTTGCTTTTGCAGGAGGTTGTGCCTCAGTGGATTGTGTCATATTAAACGC
AACTCTTGAGGCCTCTGCACAGCTAAGATTACTGAAAAGATTTTCTTTTAATGAATTTTCTCAGCTGTGC
ATGGTGGCTCATGTCTATAATCCCAGCCCTTTGGGAGGCCAAGGTAGGAAGGGGAAGATCACTTTAGTCC
AGTAGTTTGATACCAGCCTGGGCAACATAGTGAGACTCTGTCTCTACAAAACATAAAAAATTAGCCAGGC
GTGGTGGTGCCATGAATCTTTCTACCAGGAGTTTGCTTCTGCTAGATGACCACACAAATGTTTGGTTTGG
CTGCATACACGTGTTGCTTCTGTAAACTGCTCTTCATTTAAGCCCAAAGGCCATGATGATTATAGCTACA
AATGGGTCAGCACAACTTCATTCAAAGTCCAATTTGATGAGCACACTGAATTCTGGCCACATGTGCTGTC
TTCAAGGCTTTTAACTCATGGGGCATGATTATCTACAGCAAGCTGACAGAACTATGGGGCATATGGCTCC
TGGGTCCCAACTATGGGTACTATCATGGCAAGAGCCAAATCAGCACTCACTGTATGCCCACTCATTTAGT
TAACACACATCTACTGAGCCAGTACTTGAGTCAGGCCCTGTGGGATGCCCTGGAGCTGCAGTGATGAATA
ATGCACAATTTCTGTCTTCAAGCAATTGAGAACCAGATTAAAGACATTAAAAATCCAGCACAAAGAATTT
CCCAAACTGTATTTGAGTAACACGGATATTCCGAGATATTAAAAGGCAATTCCAAGGCCAAGGTGAAAGG
ATCGCTTGAGCCTGGAGTTCAAGACCAGCCTGGGCAACACAGCAAGACCCCTATCTCTACAAAACATTTA
AAAATTAGCTGGGCATGGTGGCATGCACTTGTAGCTACTCGGGAGGCTGAGGTGGGAGGATTGCTTGAGG
CTAGGAGTTCAAGGTTGCAGTGAGCTATGATTGCACCACTGCACCCTGGCCCAGGTAACAGAGCAAGACC
TAGCCTTCAAAATAAATAAATAGGGGTGATTCCAAGATGGCCGAATAGGAACAGCTCCAGTCTGCAGCTC
CCAGCGAGATTGACGCAAAAGATGGGTGATTTCTGCATTTCCAACTGAGGTACCTGGTCCATCTCATTGG
GACCGGTTGGATAGTGGTTGCAGCCCATGGAGGGGGAGCTGAAGCAGGGCAGGGTGTCGCCTCACCCAGG
AAACACCAGGGGTCTAGGGATTTCCCTTTCCTAGCCAAGGGAAGCCGTGACAGACTGTACCTGGAGAAAC
AGTACACTCCTGACCAAATACTGCACTTTTCCCACAGTCTTAGCAACTGGCAGACCAGGAGATACCCTCC
TGTGCCTGGCTCGGTGGGTGCCACGCCCATGGAGCCTTGCTCACTGCTAGCACAACAGTCTGAGATTGAC
CCGCAACACTGCAGCTTGACTGGGGAGGGGCGTCTGCCATCGCTGGGCCTTGAGTAGCTCACAGTGTAAA
CAAAGAGGCCAGGAAGCACAAACTGGGCAGAGCCCACCACAGCTCAGCAAGGCCTACTGCCTCTATGAAT
TCCACCTCTAGGGGGAGGGCATAGTAGAACAAAAGGCAGCGAACAGTTTCTGCAGACTTAAATGTCCCTG
TCTGACAGCTCTGAAGAGAGCAGTGGTTCTCTCAGCATGGTGTTCGAGCTCCAAGAATGGACAGACTGCC
TCCTCAAGTGGGTCCCTGACCCCTGTGTAGCCTGACTGGGAAACATCTCCCAGTAGGGGCCGACAGACAC
CTCAAACAGGCAGGTGCCCCCTGGGAAGAAGCTTCCAGAGGAAGGATCAGGCAGCAATATTTGCTGTTCT
GCAGCCTCCGCTGGTGATACCCAGGCAAACAGGGTCTGGAGTGGACTTCCAGCAAACTCCAGCAGACCTG
CAGCTTAGGGATCTGACTGTTTGAAGGAAAACTAACAAACGGAAAGGAATAGCATCAACATCAAAGAAAA
GGACATCCACAACAAAACCCCATCTGTAGGTTACCAATATCAAAGACCAAAAGTAGATAAAAGCACAAAG
ATGGGGAGAAACCAGAGCAGAAAAGCTGAAAATTCCAAAAAACAGAACACCTCTTCTCCTCCAAAGGATT
GCAGCTCCTCGCCAGCAAGGGAACAAAACTAGACAGAGAATGAGTTTGACGAGTTGACAGAAGTCAGCTT
CAGAAGGTCGGTAATAACAAACTTCTCCAAGCTAAAGGAGCATGTTCTAACCCATCACAAGAAAGCTAAA
AACCTTGAAAAAAGGTTAGATGAATGGCTAGCTAGAATAAACAGTGTAGAGAAGACCGTAAATGACCTGA
TGAAGCTGAAAACCATGGCACGAGAACTTCGTGACGCATGCACAAGTTTCAGTAGCCAATTTGATCAAGT
GGAAGAAAGGATCTCAGTGATTGAATATCAAATTAGTGAAATAAAGTGAGAAGACAAGATTAGAGAAAAA
AGAGTGAAAAGCAATGAACAAAACCTCCAAGAAATATGGGAATATGTGAAAAGACCAAATCTGCATTTGA
TTGGTGTACCAAAAAGTGACGGGGAGAATGGAACCAAGCTGGAAAACACTCTTTGGGATATTATCCAGGA
GAACTTCCCTAACCTAGCAAAGCAGGCCAACATTCAAATTCAGGAAATAAAGAGAACACCACAAAGATAC
TCCCTGAGAAGAGCAACCCCAAGACACATAATTGTCAGATTCACTAAGGTTGAAATGAAGGAAAAAAATG
TTAAGGGCACCCAGCAAGAAAGGTCGGGTTACCCACAAAGGGAAGCCCATCAGACTAACAGTGAATCTCT
CGGCAGAAACCCTGCAAGCCAGAAGAGAGTGGGGGCCAATATTCAACATTCTTAAAGAAAAGAATTTTCA
ACCCAGAATCTCATATCCAGCCAAACTAAGCTTCATAAGTGAAGGAGAAATAAAATCCTTTACAGACAAG
CAAACGCTGAGAGATTTTGTCACCACCAGGCCTGCCTTACAAGAGGCTCCTGAAGGAAGCACTAAACACA
GAAAGGAACAACCGGTACCAGCCATTGGAAAAACATGCCAAATGGTAAAGAGCATCGACACTATGAAGAA
ACTGCATCAATTAACGGGCAAAATAACCAGTTAACATCATAATGACAGGATCAAATTCAAACGTAACAAT
ATTAACCTTAAATGTAAATGGGCTAAAGCCCCAATTAAAAGACACAGACTGGCAAATTGGATAAAGAGTC
AAGACCCATCGGTGTGCTGTATTCAGGAGACCCATCTCATGTGCAAAGATGCACATAGGCTCAAAATAAA
GGGATGGAGGAAGATCTACCAAGCAAATGGAAAGCAAAAAAAGCAGGGGTTGCAATCCTAGTCTCTGATA
AAACAGACTTTAAACCAACAAACATCAAAAGAGACAAAGAAGGCCACTACATAATGGCAAAGTGATCAAT
TCACCAAGAAGAGCTAACTATCCTAAACATATATGCACCCAACACAGGAGCACCCAGATTCATAAACCAA
GTCCTTAGATACCTACAAAGAGACTTAGACTCCCATACAATAATAATAGGAGACTTTAACACCCCACTGT
CAATATTAGACAGATCAATGAGACAGAAGGTTAACAAGGATATCCAGGAATTGAACTCAGCTCTGGACCA
AGTGGACCTAATAAACATCTACAGAACTCTCCACCCCAAATCAACAGAATATACATTCTTCTCAGTACCA
CATCGCACTTATTCTAAAATTGACCACATAATTGTTAGTAAAACACTCCTCAGCAAATGTAAAAGAACAG
AAATCACAACAAACTGTCTCTCACACCACAGGGCAATCAAATTAGAACTGAGGATTAATAAACTCACTCA
AAACCACACAACTACATGGAAACGGAACAACCTGCTCCTGCATGACTACTGCGTAAATAACGAAATGAAG
GCAAAAATAAAGATGTCCTTTGAAACCAATGAGAACAAAGACACAACATACCAGAATCTCTGGGACACAT
TTAAAGCAGTGTGTAGAGGTAAATTTATAGCACTAAATGCCCACAAGAGAAAGCAGGAAATATCTCAAAT
CAACACCCTAACATCACAATTAAAAGAACTAGAGAAGCAAGAGCAAACAAAGTCAAAAGCTAGCAGAAGG
CAAGAAATAACTAAGATCAGAGCAGACCTCAAGGAGATAGAGACCCAACAAACCCTTCCAAAAATCAATG
AATCCAGCAGCTGGTTCTTTGAAAAGATCAACAAAATTGATAGACCACTAGCAAGACTAATAAAGAAGAA
AAGAGAGAAGAATCAAATGGATGCAATAAAAACGATAAAGGGGATATCACCACAGAAATACAAACTACCA
TCAGAGAATACTATAAACACCTCTATGCAAATAAACTAGAACATCTAGAAGAAATGGATAAATTCCTGGA
CACATACACCCTCCCAAGACTAAACCAGGAAGAAGTTGAATCTCTGAATAGACCTCAATTTCTGAACAGG
TTCTGAAATTGAGGCCATAATTAATAGCTTACCAACCAAAAACAGTCCAGGACCAGATGGATACACAGCC
GAATTCTACCAGAGGTACAAAGAGGAGCTGGGACCATTCCTTCTGAAACTATTTCAATCAATAGAAAAAG
AGGGAATCCTCCCGAACTCATCTTATGAGGCTAGCGTCATCCTGATACCAAAGACTGGTAGAGACACCAC
AAAATAAAGAGAATTTTCAGCCAATATCCATGAGGAACATCGATGCAGAAATCCTCAATAAAATACTGGC
AAACCAAATCCAGCAGCCCATCAAAAAGTTTATCCACCACAATCAAGTCGGCTTCATTCCTGGGATGCAA
GTCTGGTTCAACATATGCAAATCAACGAACGTAATCCATCACATAAACAGAACCAACGACGAAAACCACA
TGATTATCTCAATAGATGCAGAAAAGGCCTTCGACAAAATTCAGCAGCAATTCGTGCTAAAAACTCTCAG
TAAACTAGGTATTGATGGAATGTATCTCAAAATAATAAGAGCTATTTATGACAAACCCACAGCCAATATC
ATCCTGAATGGGCAAAAACTGGAAGCATTCCCTTTGAAAACTGGCACAAGACAAGGATGCCCTCTCTCAC
CACTATTATTCAACAGAGTGTTGGAAGTTCTGGCCAGGGCAATCAGGCAGAAGAAAGAAATAAAGGGTAT
TCAATTAGGAAAAAAGGAAGTCAAATTGTCTCTGTTTGCAGATGACATTATTGTATATTTAGAAAACCCC
ACCATCTCAGCCCAAAATCTCCTTAAGCTGATAAGCAACTTCAGCAAAGTCTCAGGATATAAAATCAATG
TGCAAAAATCACAAGCTTTCCTATACACCATTAACAGACAAAAAGAGAGTCAAATCATAAGTGAACTCCC
ATTCACAATTGCTACAAAGAGAATAAAATACCTGGGAATCCAACTTACAAGGGATGTGAAGGACCTCTTC
AAGGAGAACTACAAACCACTGTTCAACGAAATAAAAGAGGACACAAACAAATGGAAGAACATTCCATGCT
CATGGGTAGGAAGAATCAATATCATGAAAATGGCCATATTGCCCAAGGTAATTTATAGATTCAATGCTAT
CCCCATCAAGCTACCACGGACTTTCTTCATAGAATTGGAAAAAACTACTTTAAAGTTCATATGGAACCAA
AAAAGAGCCCACAATGCCAAGACAATCCCAAGCCAAAAGAACAAAGCTGGAGGCATCAGGCTACCTGACT
TCAAACTATACTACAAGGCTACAGTAACCAAAACAGCATGGTACTGGTACCAAAACAGATATATACACCA
ATGGAACAGAACGGAGGCCTCAGAAATAACACCACACATCTACGACCGTCTGATCTTTGACAAACCTGAC
AAAAACAAGCAATGGGGAAAGGATTCCCTATTTAATAAATGGTGCTGGGAAAGCTGGCTCGCCATATGTA
GAAAGCTGACACTGGATCCCTTCCTTACATCATATACAAAAATCAACTCAAGATGGATTAAAGATTTAAA
TGTAAGACCTAACACCACAAAAACCCTAGAAGAAAACCTAGGCAATACCATTCAGGACATAGGCATGGGC
AAAGACTTCATGACTAAAACACCGAAAGCAATGGCAACAAAAGCCAAAATAGACAAACAGGATTTAATTA
AACCAAAGAGCTTCTGCACAGCAAAAAAACTATCATCAGAGTGAACAGGCAACCTACAGAATGGGAGAAA
ATCTTTGCAATCTACCTATCTAACAAAGGGCTAGTATCCAGAATCTACAAAGAACTTAAACAAATTTACA
AGAAAAAAAAATCCCATCAAAAAGTGGTCAAAGGATACGAATAGACGCTTCTCAAAAGAAGCCATTTATG
CAGCCAACAGACATATGAAAAAATGCTTATCATCACTGGTCATCAGAGAAATGCAAATCAAAACCACAAT
GAGATACCATCTCACTCCAGTTAGAATAGCAATCATTAAAAAGTCAGGAAACAACAGATGCTGGAGAGGA
TGCGGAGAAATAGGAACGCATTTACACTGTTGGTGAGAGTGTAAATTAGTTCAACCATTGTGGAAGACAG
TGTGGCGATTCCTCAAGGATCTAGAACTAGAAATACCATTTGACCCCGCCATCCCATTACTGGGTATATA
CCCAGAGGATTATAAATCATGCTACTATAAAGACACATGCACACATATGTTTATTGTGGCACTATTCACA
ATGGCAAAGACTTGGAACCAACTCACATGTCCATCAATGATAGACTGGATTAAGAAAATGTGGCATGTAT
ACACCATGGAATACTATGCAGCCATAAAAAAGGATGAGTCCATATCCTTTGCAGGGACATGGATGAAGCT
GGAAGCCATCATTCTCAGCAAACTATCACGAGGACAGAAAACCAAACACCACATGTTCTCACTCATAGGT
GGGAGTTGAACAACGAGAATACATGGACACAGGGCAGGGAACATCACACACCAGGGCCTGTCAGGGAGTC
AGGGGCTAGGGGAGGGATAGCATTAGGAGAAACACCTAATGTAAATGACAAGTTGATGGGTGCAACAAAC
CAACATGGCACATGTGTACCTATGTAACAAACCTGCACGCTGTGCACATGTACCCTAGAACTTAAAGTAT
AATAAAAAATAAACAAATAAATAAATGGCAATCCTTGAAAAGGGGGCTCCACAGCAAACTGCTTGGGAAA
TGCTAATTTTTGTGACCTTTCTCCCCCATTCCCTTTCCTCTCTCTGTTATAACACGAAAGAATCCTAAAA
GTAAGACAATAAAAATAAAATGACAAAAAATATTTATTTGGCTTAACCCATCATTTCTCAAAGGTGTAAG
ACCATGCAATTCTTTTTGTCCAAAGGATGCTTATTAACATCTTACCTAAAATATTTACTGGAAATGTTTT
AAAAACTTAAGTGCACTCAGCATTGTGACAATCCTGTAAGACAGGCCAAAACACCATAGGAAAAGTAACC
AGATGGAGAAAAATGGCAATTACTGGATCATACAGGGAGAACACCGTGGTTGAAAGAAATGGGAGTAGTT
ATAACATGAAAGAATCCTAAAAGTAAGACAATAAAAATAAAATGACAAAAATAATTTATTTGGCATAACC
CATCATTTCTCAAAGGTGTAAGACCATGCAATTCTTTTTGTCCAAAAGATGCTTATTAACATCTTACCTA
AAATATTTACCGAAAATGTTTTACAAACTTAAGTGCACTCAGCATTGTGACAATCCTGTAAGACAGGCCA
AAACACCACAGGAAAAGTAACCAGATGGAGAAAAATGGCAATTACTGGATCATACAGGGAAAACACCCTG
GTTGAAAGAAATGGGAGAAAGTCCAGGCACGGTGGCTCACACCTATAATCCCAACACTTTGGGAAACCAA
CATGGAAGGATCACTTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAACATAGTGAAACCCTGTCTCTACT
AAAAATTAAAAAATCAGCCGGGTGTGGTGGTGCATGCCTCTAGTCCCAGCTACTTGGGAGGCTGAGGCAG
GAGAATCACTTGAACCCAGGAGTTGGAGGTTGCAGTGAGCCAATATCACTGCACTCTACCCTGGGCAACA
GAGCAAGACTCTGCCTCCAAAAAAGAAAGAAAGAAAGAAATCGAGCAAATGTCTCTTACCAACTCAATTA
GAATTGGCCAGTAGGTCATTGAAAAAGTTAATCAAAGCAAGGAATCATGACAAATTACACAAGCACCTTA
AATAATTTACAGTATTTTATCTTAAAACATGTAACTGTTCATTCCTTTAAACATCTTTTTATGTATGTAC
ACTTTGAGTGTAGGTTGACTGACCAAAGTTCTTACACTTACTACACCTGTGATGCATCCTCCATGATTTC
CAATAGAACAAGATCAAAACAATTGTTACAAAATAAGTTGGCTGCAGCTTCAGTCCACATTCACAAGTTT
CCCCATATATATTTTATTCATAGGTATATAATTATATATTAAATAAAAATGTATATAATAAATTAAATAA
CCTATTAATTTATCTCTGTTAGTTACCCTATTGTGTCCAACTCTCTCTCTTACTTTTACAAAGAGAAAGT
AATCAAGTAAGTTTCCCTTGAAATCAAACCCTGATGTCTCCTCAAAGGAAGAACTGCTAAGTTTTCAGGT
CAAGTCGAATGGAATGTACAATGAGTCAGGGGGCTGAGCCCTCATTACAGCTAAATGATGTGTTTCAGCT
GATGACTTCATTGTATTAAGTTTTGCCAAGGCATTCAACTTAATTTTCTTAGACCACCAATTATTTCTTT
GTCTTTTGCTTTTCACATTCATATAGTAATAAGTACAACTGGCACAAACAGGTGTGGGAACAAGAGCAGC
TTTTGGCCAAGCATACAAGTCAACTACTGGGAGCAGAAGCCTGCTGGGATACTAGAGAGTGGCCATAGGC
TTTCAGTGGACCCTGATCATAAGTCAGTTTGTTTGAAAGAAAAAATGGAAAGCACAGGCTAAATCAAGTT
TCTGCTCTACTGCCATCGGCTGCCCTGGGCAGGGAGTGAGATCTTCAAAGAGCAATCTGAAGCAATATCT
GAAAGTTACTAAAGTACCTTCTAGGGAGGGTGGGTCTAGCTAACTTAAACACTCTTGTTTGAATGCAGGA
GGAAAATTTGAAGGCAAAAGATAATTTCCCCAACATCACAGCTGAGAGTTGCTATTAGCCGTAACATCCA
TCTTTCCCCAATGCCATCCAAATAAATGTGGTTTGTTTGTTTTAGAGACAAGGTCTTGCTAAGTTGCCCA
GGCTGGTCTCAAACTCCTGGGTTCAAATTATCCTCCCACTTCAGCCTCCCAAATATCTGGGATTACAGGC
AAGTGCCACTGCACCTGGCCCAAATGAATGTTGAGTAAATATTCTGCAAACATCACTTGAAGGGACTGCA
GCCCACTTGATTAGGCTGTCTGGAATGTTCAAATATCTGGCCTTACTTGAGAAATTTGTTTTTAGCTTGT
TAATATATACAATTTAGAACATATACTATATACCTGTTTTCATGCAGACTATTTTATATGTCCACATGTC
CTCAGTTGTATGTATCACAGAGTTTCACGGTATATGGCATGTTTGACTAAATGATGGAAGAGGTTCAAGA
CTAGTCACCTGCATGAGTTGATTGCAAAGGAACGTTTGGCCTTTGGCTAAATAAGGAGGAAGCATTATTG
CTGTAAGTATCAGGGCAATAATATGGAGAAATGACATGGAAATAGTATCTGTCACTCCACCCAGCCCAGT
GGAATGAGGCTCTGCCAGAAACTGAAGGATAGTTTTCATATAAATCTGTCAGATAAGGATGCTTCAAGAG
CTACCAGCAGCTCTCCTATGCAGATATGCAGAGCACAATACTCAGCACCCCTGTAAGCATTAATGTAGGC
AGTGCCTGGAACTATAGCAGAACCCATGAGGCCAAGCAAGAAATGAGGGAAGCTAGTGGACCAGAGGTCC
AATTGTGATGCTAGCAGTCTGAGATTTATTTGTGAAAATACATGCAACATTCCTGGGCAGGTGCAAATGG
GCATCTTTCTAATTGCAGAGGTCGTCAATAAATAGTTGGAGCAAAGACAGAAAATTCTGAGCTATGGCCA
GTACTGTGATTTCGCCTATACCCTCAGATTGGTAGGGCACAGTGAATCACAAAAAAACACTATTAATATA
TTGGTGCTTGTAAATGGCGTAGCCCCTCCCAGGTTTCCCTCTTCGAGGAAGAATGTCTCCTGCCACCCGT
AGAGGCTCTATGGTTAACTAAAGTCAATCTAGCTCCTCATCAGCATCTTAAAGAGGTGTTCACAGGAAAT
AGCCTAACCCCTAATACCACAGAAAAGTTTGCTAGTGCTTCCAAATGATCTCAAGAACTAGCTCAGAAGC
CAGTAAATGACAAAATCTTTCCAGATTTAGAAAAATTTAGCCTTTTATTTAAGGTCCAGGAGACAAAAGG
TTGTGTTCAGAAATGTGGCTGCAACCAGGAGCCAATGGTCGATACAGTTTAGGACCAGGGTTGATAGATC
CGACCCTCAAGGATGCCATGTACCAAAAGGCCTGGACCTGATGATTTAACATTGACATTGGACAGAGTAA
TGTTCTGGGAGCAGCCAGGGCCTGTGATGCCTCCAAGAAGCTGCTCTTCAAAGGGGACCTCCCAAACATG
CCTGCTAAAGACCAACCCAGTGTAACCTAGTGATGTAGTCTGGATGTTTGTTCCCTCCAAATCTCATGTT
TAAATGTGATCCCCAGTGTTGGAGGTGGGGCCTGGTGGGAGGTGTTTGGGTCTTGGGGTGGATCCCTCAT
GAATGGGTTGGTGCCCTCCCCATGGTCATGATTTAATATTCAGTCTATGAGTTTTCACATGAGAGCTGGT
TGTTAAAAAGGGTCTGGTACCTCCTCTCTCTTGCTCCCTCTCCCGCTATGTGACACATCTGCCTCTGTGT
CACCCTCTGCCATGAATAAAAGCTTCCTGGCTGGGCACGGTGGCTCACGCTTGTAATCCCAGCACTTTGG
GAGGCCGAGATGGGTAGATCACCTGAGGCCAGGAGTTCGAGACCAGCCTGGCCAACATGGTGAAACCCCT
TCTCTATTAAAAATACAAAAATTAGCGGAGGTGTAGTGGTGGGAGCTTGTAATCCCAGCTACTCTGAAGA
CTGAGGCAGGAGAATTGCTTGAACCCAGGAGGCAGAGGTTGCAGTGAGCCAAGATTGCGCCACTGCACTC
CAACCTGGGCAACAGAGAGAGACTCCACCTCAAAAGCAAAAACAAAAAAGCTTCCTGACACTTCACCAGA
AGCTGAGCAGGTGTGGGTGCCATGTTTGCCCAGCCTGCAGAACCATGAACCAAATAAATCTATTTTCTTT
ATAAATTTCCCAGTGTCACGTGTTCCTTTATAGCAATGCAAAACAAGCTAACACACCTGGTAACCCTGTA
AGAATAATTGAATTGGTAATTGGCGGATCAAGTAAAATGTTTCCATTATTAGGACATGTATCTATTTGTG
CCAGACTGTTAGTTTCTTTAAATTTCTCTGAACACAAAATCTTTAGTTCTCAATCTCAGTTACATCTGAA
AGGTTTCCCAAATCTCATTTCTCTAGAAAGTTCTTCAAACCTTCCATTTAAAAATAGCAGTCAGAACATC
TAGTAACTTGAAAGATGGGGAGAATGCTGTTGTTGCTAAGACATTTTTTGAATGTCAACCATGTAATGTG
TGACTATGATCCTGGTTCATAGGATTACAACCTAAATTAACCCAAGTTAGTGTCCTGGCAGATGGCCGTT
CCTAAACTGCCTAAACTTGTCTCTGTCTCTGTTAGATTAAGACAATCCCATGATCTTTTTGAAGTACTAA
CAAAGACTTACAGCTTCCTGCTCTCCTGTGCTGCCATGTTGAAGAAGATGTAGAGCCTTTTTTATTGCTT
TCTACAAATTATGCAAGTGAGAAAAAAAAACAAATAAAAACGAAAACACTGAAAATCATCCATAACCTTA
AATTAACCATACAACCTTTTTAGTCCTGAAATAGTTGCTTACTGTTAAGTCAATAGATGTAAACAAGCAA
TTCTTGAGAACCTAAAATGTTTCTGGCACTTGGCTAGGTGACATAAGATGTGGAAAAGGAATAAGAACGT
CAGTGTAGGCTCTCAGAAGAGTTGATTCTCATGTTAGGAAATATAATAAAAACAAGTACAGCCAAGGATT
ATGATGCAGTGGTGACCCACCATTGGCAGGATGAAAAAAGAGGAGAAGTACTCTTACTCATTCAACAAAA
ATGCATTGAGCACCTACTATGAGTTTTCTGCTAGTCATGTGAATCCTGACCTTAAGGAGATAATAGCAGC
CAGTCAGAAAATCAGACCAATAAAATACACAACCAGAAGATGATATCCAGGTTATTGTGTGGATAAGGTA
TAGGGAGTACAGGATGGAAGAAACAGCTAAGTTTTCTCGGGCAGCCAAGATGAGATGTTGCGGAAAGTGA
CTCCTGAAAGAAGGGTGGAGCTTGTAGAGAGTGCTTACTGAGCCTGCAGGACCTGCCTGACTACATGCCA
AGCACTCTTCATGGATTATCTTATTTAATTCTCACACTAGCCCTATAAAATAAGGATTTTTATTTTTCTC
CATTTTACAGACAGGGAGACTGAAACAAAGAAGAGTTACGGAACTTCTGGATATTACACAGGCAGGGGGT
GAGCCTGGAGCTCTGGCCCAGGCAGCCTGCCTCCAGAGGCTGTGCTTCCCACCACCCCTCCCCGCCAAGC
CATATGTATACACATAGCCCCAATACCTTGGTATTAGCCTTCTCCCCTGCCTCCTTTTATACCACATCTC
CCCCTCTTCTTCATCTATTGTAGTGAGAAAAGCAGATGGACTTGGTGCATTATCCGTCTTTGCTACAATG
TAAGAATTCAAGGGTATAAACCATAGACCGTTGTGTTGAGCCCTGAACTTGGATTTTTCAGCCAGGTTCG
TTCAGGTTATGGGCTGTCCACTGCCCATCACAAATACAACTGAGACCTCAGATTGAAAAAGAATGAAGTT
GCATTCAGTCTCTCTTGTTGCAGTTTCTCTCTTTACCTGGGATGAAGATCATTTTCAGAAGCTTCCCCAT
CCTAACATGTTAGATAAACTGTCTAAGCTACTCAGCTGCTTCTCCTCCCTCACTCTTAGGATTTGTCTGT
TTCTATCTGTGCGGTTTGGCTCTCCCTGTTGTCCTTACCCTTTTCCTTTTGTTCTAAGAGCCCAGCACTA
CTCTAGCTTCTAGGGGTTATCAGCCCACACCCCTCCAGCTATTCCAGGTCACACAACATCTTTCAGTCCC
GACCACCACCAGGCGACACATTAACACCTGCATTTCCAAAGAACTCCAATAGACTTTTTATGACTTTTCA
CAAAATTCTTAGTCCCCTGCTTTGTTACTAGAACATGAAAATTCTTCCTGAAATCAAACCCACCTTTTGA
GGGGCAGTAGAATTTTGCTATGAGGAAGAAAGCACACATTCAACACAGAGAATGAAAGTTGGGACAGGAT
CACATGCCCAGAGCATAGCAGACGGCAAGCTCTCAGGATGGTCAGAGTGGGAAGAGCTGGATATTAGCTT
AAACTATGGAAAACTTTTCATGAAGAGGAAAAACCTGAGAGAACTTGAAAGGTAAGTAGGAATTAAGGTG
ACGCTAAAGGAATAAGATATGAAATAAACAGGCATCTGAGTGCATTTCTCTATGAGCAATTTACCAACCT
ATTATTAGAAAATGCTTAAAAGAGGAATGTTTCTTCTGTGTTACTGTACACCTGGATTTCATTCCTGCAT
ACTCAAAGCTAAACCTGCGCAACAAATCAGCTCTTCCTTTTGTAAAAGAAATAAAACCAAATTTTTATGG
TTTTATTTATTTTACAAATGACAAAATTATTGTTTGTAAAATAATTGTTCCTGGGATAAGAGATCAGACT
ATTCAAATAGAGATATAATTTATGGATTTAAAATTAAATTCCTTTCCAACATTATCTTTAGAATTTGAAT
CAATTAGGGAACATAAACATGATTGCTATTGGGTGAGACTGCCTCTGAATACAAAAATATGGTTTGAAAG
CTCAGCTCAGGTTTAGAATCGGTGAGAAAAAAAAAGGGAGAAAGGAAAAGTATGGTGTTGTCAGCATTCA
AAGGAGAAGTAATGTGCATCTTTAGATAAAAGCTTTACAATGGTGTGCATAATAATGATACTGTTTGTTT
TAAATGTGATATATATATATAGAAATGTGTACATAGACATACAACAATTACTTATGAACAAATACACTAA
AAGCCAGTAACAAAGATCGCCTCTGCAGAGGGGAACTTAGAGCTACAGGAAAGACTCTTTTTCATTGTGT
ACTTCCTTTTCTGATTGAATTTCCCACCATGTAGCTCAATTATCAATTCTAAAAAAAAAAATGTGTTTAA
TGTAAAACATTGTTTCAAATTTCCAACTCTTAAATGTGAGAATAGATCTCTGAGGTGGAAGAAAGAGATA
GAAAAAGAAGATAGGATGAGAAGGAAGAAAGAAAGGACAAATCGTGGAATAGATGCTCTGCTCTGGGCAC
TAAGAGTTGCAGAAAGAGAATAAACCTTTGGTCACATTGTCCAAGTGTTAGAAAAACATATTCCTTGGGC
CATTTAAGACACCACCTGAAAAGTAGAATCAATAATTACAGATGCTTTGTAAAGATGAGAAAGACTGTGG
GAGATCAAAGAGAACTAAACATGTAAGGAACTCAAAGAACTCAATAGCAAAAAAGCACATAATCTGATTT
TAAAATGGGCAAAAGATGTGAATAGACATTTCTCAAAAGAAGACAAACGCATGGCCAACAGGTACATGAA
AAAATGCTCAACATCACTAATCATCCAAGAAATGCAAATCAAAACCCAATGAGATATTATCTCACCCCAG
TTAAAATGTGTTTTATCGAAAAGACAGATGCTGGTGAGGATGTGGAGAAAGGGGAACCCTCGTACACTGT
TGGTGGGAACATAAATTAGTACAATCATTGTGGAGGACACTATGAAGGGTCCTCAAAAAACAAAAAAAAT
AGAATATCATATGATCCCGCAATCCCACTACTAGGTAAATATCCAAAAGAACGGAAATCAGTATATCCAA
TAAATGTCTGCACTCCCATGCTTATTGCAGCATTATTCACAATAGCTAAAATACAGACTCAATCTAAGTG
TCCATCAACAGATGAATGGATAAAGAAAATGTGGTACTTACACACTATTCAGCCATAAAAAAGGATGAGA
TCCTGTCATTTGCAACAATGTGGGTGGAACTGCAGGACATTATGTTAAGTGAAATATCACAGGCACAGAA
AGACAAGCAACCCATGTTTGCACTCATATGTGGGAGCTAAAAAATTGATGTTATGGAGATAGAGAGTAGA
CTGATGGTTTCCAAAGGCTCAGAAGAGTAGTGGGGAGGTGGAGATAAAGAGGTGTTGTCTAATGGGCACA
AAAATACAGTTAGATAGTAGGAATAAGATCTAGTATTCAGGCTGGACACAGTGGCTCACGCCTGTAATTT
CAGCACTTTGGGAGGCCGCGGCAGGTGGATCACCTGAAGTCAGGAGTTCAAGACCAGCCTGGCCAACATG
CTGAAACCACATCTCTACTAAAAGTACAAAAATTAGCTGGACGTGGTAGTGGGCACTTGTAATCCCAGTT
ACTCGGGAGACTGAGGCAGGAGAATCACTTGAACCCAAGAGGCAGAGGTTGCAGTGAGCTGAGATCATGC
CATTGCACTCCAGCCTGGGTGACAGGAGCGAAACCCTGTCTCAAAAAAAAAAGAAAAAAAAAAGATCTAG
TGTTGATAGCATAATAAAGTGACTATAGTTAACAATAATTTATTGCATAGGTTGGTGCAAAAGTAACTGT
GGTTTTTGCAACTTTAAAAACTGCAATTACTTCTGCACCCACCTAATATATTTTGAAGTAATTCGAGGAG
TGGATTTGGAATGTTCCCAACAAAAAGAAATGATACATGTTTGAGGTGATGGATATCCCAACTACCCTAA
TTTGATCATTACACTTTGTATGCTTGTATCAAAACATCACATGTACCCCATAAATACGTATGACTATTAT
GTGTCCATAAAAAATGTTTTTAATTCAAAGAGAACCACACAAACGTGGAGGGAAGGGGCTCTGTGCTGGC
TACACACGGGTCATTGCAGCTGGAAGGGACTCCAGAGGCAGGACCATGGATTTTAGGAAAACATCAGTAC
CATCATTTGCCTTCATACAGGTAAATTTATATAGTACCTCAATACCCATTTTCTAGGTAATTTTATGGAG
TCTACTTGCCTATCAAATTTCCCTCCAGGTAATCATGAAACTGACATGAAACAGACTAGCAGCATATACG
CTTCCCCTTTACCAGGGCACATCATTTAAAAGTCTGTGTTACTATACAAGCACTTCAAACATTAACATGT
CTCAACCCTTACCAAGAATTCTCAGGCATTGCATCTCTTTTTTTGAGACAGGGTCTCACTCTGTTGCCCA
GGCTGGAGTGCAGTGGTGCAATATTGGCTCATTGTAGCCTCCACCTCCTGGATTCAAGCAATTCTCCCAC
TTCAGCCTCCCAAGTAGCTGGGACTACAGGTGCACACCACCATGACCAGCTAATTTTTGTATTTTTTTAG
TCGAGTCAAGGTTTCACCATGTTGGCCAAGCTGGTCTCAAAGTCCTGACCTCAAGTGATCCGCCCGCCTC
GGCCTCCCAAAGTGCTGGGATTACAGGTGTAAGGGATTACAGGGCCACAGCACCTGGCCCGTTCCATCTT
TAAATGCCCATTCCCTTCACACAAGGCCACTGAGGATGGAATGGCAATTTTCTTCTCTTAATTCTCATCA
CATACTGCCTCCTGCTTCATGCGTTCAATTCCCCACCTTTCCATTTGCCTGGGGCTCAATCGAAGTTCTC
CGATTTTTACTTTTCTAACACTGAGTCTATCTTTAAGCAGATGTTTTGTTCTGGGACCAGCTCTGTGAAA
AGCATTTAGGAAAACAAAAAGTAATTTACTTGCATGAAAGTTAAACAAGGGTGTCCAGGCTTTCAAAAGT
CTAGCTTAAACACAAAACAAAAACAAACAGGAAACCCTGAAATAAACCCAAAAAACCAAAACACACCCAT
GTTCACACACGAGAGTACCAATGTTGCCAAGGACACAGTTTCTCTGTTCACGGTGGGAAAACAGCAATTT
TGTCACAGTAGCTTATTTACAAAGGACGTTTTCATACATTAGCTTTGAACTGGTCATGGAAAAAATTCTT
TGACATAGAATAAGTAACTTTCAGGAAAGTCTCATGGCTTCATTTATTAAGGGGCCTCTAACCGGACAGG
GTTATCCTGTTGGATGGTTTCTTTTGGTTTATCTCAGGATGCCAAGTGCTTTCTGTTTTTGCCTGACTAG
GGCACATGATTATGATGTGCACACTAACTCATCACAGCCGCAGGGACAGATGCTGGTTTTGCTTCTAGTC
ACTTAGTGTTAAGAGATAACGAGGTAATAGAATTCATCCGGTGAGGCCACCACCCTTTTTGTCTCTACCC
CTGCGCACACCTCATGCCAATCCACACCATTCCTTCCTGAACCATCAGCAGCAGCAAGCACAAAGAAACC
ACAACTCAGAAGATTTTTCAAAAGTGCCAAAAGTTGGCTAGCAGTCCTATTTGAACACAGACGTGGCTAT
TGGACAGCAGTTGTCTAGCTCACCCAATCTTAGATGGATACTTTCCTGTAACACAACTAGGTCAAACAAT
CTTATCACCCTGACAGAACAGTTCCTGTCTTTCTCTAATAGAAATCTCTCCTGCCTTTATCTGAGCCCAT
TCCTTCTTGTGATATCTTCCTAGAAATTATATACTACTGAAAAAATAGTAATCAAATTACCCTTAGCTTC
TTTCCTCTTGGCAAATTTACTTCATATCCATTTTTAAAATGAATCTCCCCTTCCTAATCATGTTGTTATT
CTTTGTTAATCCTTTCCTTTTAAGTTGAGTTAATCAAAACTGAACAAAATGGCCAGGCACGGTGGCTCAC
GCCTGTAATCCCAGCACTTTGAGAGGCCAAGGCAGGTGGATCGCCTGAGGTCAGGAGTTTGAGACCAGCC
TGACCAACATGGTGAAACCCCATCACTACTAAAAATACAAAAATTAGCTGGGCATGGTGGTGGTTACCTG
TGATCTTGGCTACTCAGGAGACTGAGGCAGGAGAATTGGTTGAACCCAGGAGGCAGAGGTTGCAGTGAGC
CGAGATCACGCCACTGTACTCTGGCCTGGGCGACAGAGCAAGACTCTGTCTCAAAAAAAAAAAAAAAATG
CTCTTTATGGATCTCATTAATGCAATGTATGAAAGAAGAACTAATACTTTATACTTAGAGCTCATGTTTC
ATTTTAGTACATCTCAGAATTATGCTGATTTTTCACAACAGCATTCCTAGTAGCATGTATTTTTTTTTAT
TTATTTGTATTCAACTATGCCTCCTATCTCAAAGGATTATTGACAAGTTTAATGGGATTTTGTATGAAAA
GTGCTTATCAGAATGCCCGGCACATAGAGAACACTCCATAAACGGTGACTATCATTTTTCATTATTTTTG
ATACTTTGGACTAGGGAGTCAGTGAAATACGTGGGGAAAGCGGGTTTGCTCAAGATGCATTGTAGGAAAT
ATTTAGGTAGTGAATAGCAAAATATTTGTGCTCCCTGCTTTAAGACAACTCATTATAGGAACACTGGAAT
TTACAGAGCTAAAGTGTGCATTTGGCGTCTGAGATGAAGAGCTGTTCCCTTGCTCAGCCTGTCCAGCTTT
ATTTGCAGGGCTGTCTGTGGGCCCTCGCCTAAGCAGGGACTGCAGACTATCCTCCAAGATGATCCATTAG
AAAAGGAAGTTAAACAAAGTAATCCACTGTGACACTATATATGAAGGATGATTGTACAGGAACTGTATAT
TCCTGGAATCTGTAGTAAATCCACACAGAAGTTTTATTTCTGGCCAAGGACTCAACATCAAATAAATCTG
AGATATGACAAATAGTATAACAAAAGTAAACTATAAACCACCATCCATTTAAAAGAGGAGAATTATGATC
CAAGACTAATGAAATGAGCATTAATATATGTACACATTGATGACACAAAAGGCCTTAATGAATTACTAAA
TACTCATCTGGTTTTATTATGTATAACAATTATAGCAGCTCGGTCTCAAAAAAACAACAACAAAAAAATG
TTTAATGATGATGGTGTTCTTTCCCACTGAAAGCATTCCTTCTCTAAAGTAAGTGGCGACCCTATTCTCC
CACCCTTCACCCTTCATAGCCTCCTAAGTTATAAAGTGTGATCATGGCATCAGTGGGGTTCCCAGGAGAT
ACCTGGTGTTCAGTCTTTCTCAGCCTTCACTCCCGGGAAGTGACAGTGTTTGACATCTATTAGAGCACAT
CACGCTTCAGATGATGATGATAAAAATGATCAGATTACATTTTTAGATGTTACCTCTTCAGGTAAAATAT
ATATTATAAAACCAAAGATCCAAATGGGCCATGGTCAGACCATATATAAAAACAGAACTGTGACCATAAC
CTGCCCAGGAAACCAGCCCCTTATCTACAATAAACAGTCCAGCAAGCCCGTCTGCTAAAGCCAGACTTGC
AAGAAGTCTGGGAAATAACAATCTGAGAAGCTAAACAATAACTTTTATAATAATTAATTCCAAATGACCA
GGAATTGATTAATAACTGACAGCTTTCCTAGTTTTTGTCCTCATTTCCAACTTTAGGCCAACCACAAAAG
GCGCCTTAAATAATCACATGGCTGCCGGCTCCCAGTTAGCTAACTCCAGCTTCCCAGACCAACAGCCTCC
AATCAGGGCACACCTGAAGCTGTCCCTTGTGTCTGCTGTAAAGCTCTCCCACTCCCCTGCCTGCCTTTGA
GTCTCTCCCAAATGCCAGTGATGGTGGCTGACTCCCTCGCTATAGCAAGCTCTGAATAAACAGCCTTTGC
TTTCTCACATGGTGGTCTTCCTTCATTTCATATATATAAGCGGTGTGTGTATTTTTTTAATGCTGCCCAC
CTGCTTCCCGATCACTCCTCCCTGTCACAAGACCTGAAAAGCCTTCTCAACCAACAGGTGGAGGCCTGGC
CTAACTCTTCCCCTTCACCCTCCCCTCCTCACACTTCTAATGACACAGATTTTCTCCTTGACCAAATGCT
AGCCAGGCCTCTCTGAGCCCCCTTCTAGACCAGGCCTCAACCCCCTCAGAGTGCCTGCTTGAGAAAGCCC
AAGACTGACAAAAGAATTCTATGCACCATCTGATGAAAGGCTTCTGGCACTTTCTTAGAGTACTTACTAA
AAAGGGCTTACAATTGTGACTCCTTCCTCTGTGCCTTTGAGATGGCTGTGTATCTCCTACAAAGGCAATC
AAGGACGTAAAAAACCATTCCTTTACAATGTAATCATCAGGAAGGATAGGGCCAGTGTCTCCCAGTCTCT
GGAAGGACAGAATCCAGACTTTGATCATTGCCAGCTAGCAGACACAGCTGCCTAATCAGCATTTACATGC
GTCAATCCTTTGTCAGTTTTCACCTTCCTGACTCTGCTGAAGCCCCACTGGTTCCTCTCCGTTAATCCCT
CATTGTCCCTTAAAATGCCCAGTCACCTCTGTACAAATCAAAGTTCAGTTCACGCTGGACCCTCTTCCCT
ATTGCAATAGTACATTATGATTACCATCTGTCCTTACCACGTTACCTAGTGTCTGGTTTATCTTTGGTAC
TAACCAGGTGTGCGCCTCCATCCTTCCCCCACCCACACCAATAGCCAGTAGCTGGTCTTCCTGTTACAGT
AGGGAGCTAGTCAGGCATGAGCACAGCAGGAGAGCCCCCCTCCCCACCAAGGAATGTCAGGAGACCAACA
GGTGGTGGGCAAGTGGTTGTTACACTGTTTCCCTAAAACGGTAATTGGTCGCAGCCAGCCCTAGGGAAAG
GCAGGCTCCAAACAGAAAAAACCTGAAACTGGTCATCATCAGTTTCCTGATAAGATCTTAGGAGTTGGGC
GAGTAAGCTGAAGCATGCGCACTAAGAGGCAAAATGGCAGCATTTAACTGGTACATGACCTTCTAGGAAC
ATTCAGCTGGTAAAGGAAGAATGCCTCAAGTGAGCATGGGTACAACGCCAGTAAACACACTGTGCATGCT
TCCCTCCCAAGCACTAGCAGGCCACTGTGCATGCGACAGCCCACCCCAAGGGAAGAACTAGGGAAGAAGG
GATGCAAGACCCCAGAAATGCCAGTGTATAAAACCCTAAGTCAGAGGTCAAACAGGGCTCTTGATCTCTC
AATTTGCCCGCTTAGCCCTCTTCCAAGTGTACTTTACTTCCTTTCATTCCTGCTTCTAAACTTTTTTTTT
TTAAGAGACAGTCTCACTCTGTTGCCCAGGCTGGAGCGCAGTGGCATAATCTCAGCTCACTGCAACTTCC
ACCTCCCCTGTTCAACGGATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGATTACAGGCTTGTACCACCA
CGCCCAGCTCATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCATGTTGGCCAGGCTGGTCTCAAACTT
CTGACCTCAAGTGATCCGCCCACCTCGGCCTGCCAAAGTGCTGGGATTACAGGCATGAGCCACCGTGCCT
GACCCTGCTCTAAACTTTTTAAAAACTTTCACTCCCGCTGTAAAACTTGTGTTCATCTCTCACTCTGCCT
TATGCCCTTCAGTCGAATTCTTTCTTCTGAGGAGGCAAGAATTGAGGTTGCTGCAGACCCGCATAGATTC
ACCATCACTAACATTACCTTGGGCAGAGTGCTCAGACCTCAGGTTGTCTGAAATGAAAGTCACTATCACC
CCAGAACCTGCATCCTTTCCCTACTCTTTAGAAATGTGATAGCTGGTGGCACTCCTGTTAAATCTTTCCA
TACCTAAGAAATCTTGGCTGGGCACACTAGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCCAAGGCGG
GTGGATTACTTGAGGTCAGAAGTTCAAGACCAGCCTGGCCAACATAGCAAAAACCCATCTCTACAAAAAA
TGCAGAAATTAGCCGGGCATGGTGGCGGGTGCCTGTAATCCCAGCAACTCGAGAGGCTGAGGCAGGACAC
TCCCTTGAACCTGGGACACCACTGCACTCCAGCCTGGGCGTCAGAGTGAAACTCCGTCTCAAAAAAAAAA
AAAAAAAAAAAAATATATATATATATATATATCTTCTCTGGGTGAGGACCCACTGCTCCATAGAGCCTTT
TCTGGTGAGCCAGACAAAAACTTTTATTTCCCTCATACAAGTACCTGTATGTTTATGCACACCTGTCTTG
ACTACACATCTCAACAGCTTTTCACTTACAGTAACATTTAGGAGGTAGCAATGTTAGCTGTCTAACAGAC
ATAGCTTATGCTTAATTCTTGCAACCCTGGAAAGGCTGTTATGTATAAAATGGGGATAATAATATGTACT
TCATAAGGTTGTTATGAAGAGCAAATAATGCTGGCTCGTAGTGGGAGGTTAGGAATTAATGTCCAATTAG
AGAATGAATGAATAAGAGAGAACACACAGTAGTTCATAAATATGAGTTTCCCTTCCCCCTCAAAACAGCA
GAACCAGAAAACAAGCAAGACCTAAGCATACATCTCACAATGGTCCTTCATCTGCTGTCCAGCAACCCGC
CACCTCACTAAACTGACTATTCTATTTTCCTACGACACAAATAGATAGATATTTCTTATTTTTAAAATTT
AGATCTACATCCCTGCAACTTCTCCCCTTGGGTCCTGGCTCAGTTCCCACCAGCCATACAAGATAACATC
AGGTGCCTGGGCCTCCATTTTCTTTCTAGGACACCCAGTTTGGCCTTGGGGTGGGCTCCCACAGGTAGCT
GGGAAGCTGATGCCCCTGAGTACCCACGTCCACCCACACGTGAAAACAAAAAAAAATCTCAGAAAGTAAT
TTCGAGCACGGGTCAAAGTTCTATTTCACACTTGCAGGGGCAAGACAGCAAAAGGAAAAAGCTGGTTCAC
AGCAACTGTCTTAGGAAAGCAAGGCCTCTTTTAGAAACAGAAAGGAACGTCTAGACCCGTGGCTTGTTTA
AACACCCGCTGCTAGGCCCCACTGCCAGAGCTGCCTATCCAGGGCCGAGAATGTGCATTTCTAAGTAGTT
CTCAGGCGGTGCTGATGCTGCGGATCTGGGGACTGTACTTTGAGAACCACCGGTGCAGACCCTGGCCAAC
GTTCTTTAGTCTGATGCGTCGGGGAGCTGTAAAGCTGCCATCCTTCACCGGTGGGCAAGTAACCTGGTGG
CGCCACCCCAGGGCCAGACCCAGGGCCGGCCTCGGTGCGCCTCTAGCCAGAAATAACCAGCACTGGGTTC
CGCTCACCGGCAACGCCAGGTGGGGGCCATCTGACCACTCAACAGTTTTGCTTTTTCTTCAAATTCGGAT
ACTTAGAAGGAATGCGATGAAATTGGGATGAAGGTGTTTTGCTGGCCCCGTGGACAGACCAGACCTCCTC
CCATCGGAGCCTCGGGTCTCACACCAGCCCCCCAGGCGGCGCGCGGCCCCGTCTCGCCACCGCGGCCCGG
GTCGTTCGCGTCTTCCGGCGCCGAGGGTGCCTCTGGGTCC

</dna_sequence>
        <protein_sequence>>NP_001123361.1 L-dopachrome tautomerase isoform 2 precursor [Homo sapiens]
MSPLWWGFLLSCLGCKILPGAQGQFPRVCMTVDSLVNKECCPRLGAESANVCGSQQGRGQCTEVRADTRP
WSGPYILRNQDDRELWPRKFFHRTCKCTGNFAGYNCGDCKFGWTGPNCERKKPPVIRQNIHSLSPQEREQ
FLGALDLAKKRVHPDYVITTQHWLGLLGPNGTQPQFANCSVYDFFVWLHYYSVRDTLLGPGRPYRAIDFS
HQGPAFVTWHRYHLLCLERDLQRLIGNESFALPYWNFATGRNECDVCTDQLFGAARPDDPTLISRNSRFS
SWETVCDSLDDYNHLVTLCNGTYEGLLRRNQMGRNSMKLPTLKDIRDCLSLQKFDNPPFFQNSTFSFRNA
LEGFDKADGTLDSQVMSLHNLVHSFLNGTNALPHSAANDPIFVVISNRLLYNATTNILEHVRKEKATKEL
PSLHVLVLHSFTDAIFDEWMKRFNPPADAWPQELAPIGHNRMYNMVPFFPPVTNEELFLTSDQLGYSYAI
DLPVSVEETPGWPTTLLVVMGTLVALVGLFVLLAFLQYRRLRKGYTPLMETHLSSKRYTEEA

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene709">
        <gene_name>Trp2</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>104042</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id></ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>tRNA proline 2</protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length></protein_length>
        <protein_note>Also known as Trp-2</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence></protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>The infusion of tyrosinase-related protein 2-transduced (TRP-2-transduced) lymphocytes induced the establishment of protective immunity and long-term memory in tumor-bearing mice [Ref1299:Russo et al., 2007].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene313">
        <gene_name>Trp53</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>22059</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>187960040</ncbi_protein_id>
        <gene_locus_tag>RP23-56I20.1</gene_locus_tag>
        <gene_refseq>AF074575</gene_refseq>
        <protein_refseq>NP_001120705</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>11</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>69580358</gene_start>
        <gene_end>69591872</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>transcript variant 2</protein_name>
        <protein_pi>6.19</protein_pi>
        <protein_weight>40666.98</protein_weight>
        <protein_length>381</protein_length>
        <protein_note>Also known as bbl; bfy; bhy; p44; p53; Tp53</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000077.6:69580358-69591872 Mus musculus strain C57BL/6J chromosome 11, GRCm38.p4 C57BL/6J
CTTTCCCCTCCCACGTGCTCACCCTGGCTAAAGTTCTGTAGCTTCAGTTCATTGGGACCATCCTGGCTGT
AGGTAGCGACTACAGTTAGGGGGCACCTAGCATTCAGGCCCTCATCCTCCTCCTTCCCAGCAGGGTGTCA
CGCTTCTCCGAAGACTGGGTAAGTAATTGATGAGCGTGACGAGACCTCTCGGTCACTGGCTCTCTCCGTT
TGCATCCATAAAACTAGAGAAAACCGTGGGGTTTGGGGGTGGGGCAGTGGGGGGACTCAGCGCGATGGAG
ATGGGCGGAATGGAAGCTTGGCGGGCGGGATGAACGGGAGTGTATATGTCAGATGCTGTAGTGAGGGTAG
CTGATGATGATGATGTTAGGACCGACGAGCCTCACTGTCATGCACCTGCAAAGTAGAGCATATAGGGACC
ACTGAGATGGCCTAAGGGGTTTTCTCTCCGCTACGCGTTGTACACACTTATCTGCCCGCTGCTAGGTGAT
GGAAGCTCCGGAAATAACATGCACAAAGCACCAGGATTTAAGATTTTTCGAGATTCATAGCTTAAGACTT
AAGACCCCCCATAGCATCCTAATGAAACCCTGGGTTCCGTTCCTGGATGAGATCGGGGTGATCCGGGGAG
CCTTAGCTGCTAAGGTCCCGCAACTTCCGGACCTTTGTCCCTGGAGTGATTTCTTTTTTTTTCCAGCCGC
TTCTCGACCCTGCTAGATGAAGAAAATCCAAGAAAAGCCTGAAGCACTAGCGGTGCTAGCCAGAAGTATT
TGCCCTCGGGGCCCGACTCAGCCTCTTGGTCTGAAAGGCCCGCCGGCCCTGTTATTGTTTGGCTCCTTTA
CGTTTCTGCCGCTTGCAGGAGCATTTCCGGTTTCTTGTTTTCGGAGCAGATCACTGCTCGCCCGGCGACG
GGGGAGTAGCGAAAGGGGAGAAATGGATTCTAGGCTGGTTCTGTGGTTTGAGGAGGAAAACTGCTGTCCT
CGACATCTTATTTTTCTGGATTACTTGGTTATTGCTTTTGCAAAGGAGGAGGTGTTTATTTAAAAGAGTG
CGCCGATAGGTCGTTTCTTCCTGCCGGAAAAGCAAATTACCGAGTATCCGGTTTTAGGGTGAGCCATTCC
CTTGCTTAACGCATTCCGCGCGTCCTGAAAGCGGAAGGGGCGGGCTTGGGCCCCGGGCGCCCGGCGGTCC
TAAGTGCAGTCAGCCCGCACCATCCGGTTCTTCCCAGCGGGAGGTGGCGGGACTCTGCCTGGGCGTGGGC
TATGCCTGTCCCCGCCACTTCAATTTTTAGAACAGGTCATTTCATTACAGTTTCTTATCGCGCACCAGAC
ATCGTGCGTGCCTTTTTTTCTTTTGTAAAAATACTATTTCCACACTGCACTTGGATCGGGAAGTAAATTT
TTTTGTCCATCTGAAGATTTAGTTTCGGTCTAAAGAATAAATGATAGGTAGACCGGGAGGCGGGGGGACT
TTGTTTTCGTGGCTTCAGCTGTAAAGCCGTAAGGAAGACTAGATCCTCCAGTTCATTGAGAAAGTATACA
AATGACTTCACTTAAACTTTGACGCGCGAAGGGAACCCTAGCTGTGAAGGTTAGACTGGACAGCCACAGC
GGTCCAGGGATGCCTTCTTATGCAAATAGCCTCCCTGCTCTTGCAATCTCTTTGACTGGATTTAGTGAAG
GACTCTCTTGTGAATGTTAAAAGATCCCAACCCGAAGTCAAAAGGAGGTGCCCCTAGGCCCCATCTTGTT
TACAAATGTAGATATATGTAAATTGGTTTTTTTGTTTTTTTTTTTTTTACATAAAGACAACTTTGGAAGA
TATTTACCCTGCTCTTCCAGTTTCTCTTCTCTGAATAATTTACTGCAGAGGGGTTTGGGAATGTCTGGGA
TGGGTAGTATATGCACTTAAATTATGCTTAAATCATCTGTAGCTTACATATGACCCTGCACTGTAAATGT
TATTCAAATAAATGTTACCGTGTTGACTGAAAAAAGGAGCCAGGCTGGACTGGGACCGGGTGCTGCAAGC
CTTTAACCCCAAAGCTAGGGAGGCCGAGGCAGGTCAATATCAGAGATTCAGGCCAGCCAAAGATATGCAA
GGAGACCCTATCTCAAAAAGAAAAATATGTCACGTATGTTAATATTCACACTGACACAAGATAACCTGCT
GCTACAGTTGAGTAGCAGTGGGAAGCCTCGACAGTCTCGAGTTCCAGACCACAGTGTCCAGACCATACAT
AGAGGGAGTTCAAGGTCATCCTTCCCTGGGTAGTTGTAAGCTGACTTGAGATAAATGAGAGTGTCTTCAA
AAACAGAGAAAGAGTACAAAAGTTAACATTGGCAAACCAGAGCCTACTGGCCTTTCTCCTGATGGGTAAA
TGAGGACGTCTCGATGGCCCGTGCCTTTAATGCTAACACTCTTGGGATGCTGAGGTAACTTGGGCTACTT
AGCAAGACCTTGTCTCAGAAAGGCAAACAGCTGGAGATATGGCTTGGAGTAGATTATTTCACCTGGCAAA
CATGATACCCTTGGTTTAAATCCTGAGACCACAAAAAACAGGTTAAACCCAGCTTGACCAAGTGCCATTG
GTCCATGGATTGCTGTATTGGAATCAAACAGAAATCTATGTCATTCACAGCAGTAACCTCCTGGGAATAC
TTCAAGAGACGGAGAAAGGGCGACTGACTGTGCCCTCCGTCCTTTTTCGCAATCCTTTATTCTGTTCGAA
TCATAATTTGTTTTCCTGAGACAGGGTTTCTCTGTGTAGTCCTGGCTGTCCTGGGACTCCCCTCTGTAGA
CCAGGCTGGCCTCCAACTGTCTCTGCCTCCTATGTGCTGGGATCAAAGGTGCCTGCCACCACCGCCTGGC
TTCTTAGAGTTGGGACAAGCCTCGAAGTAAGTTGGATGCCTAGGATCCCAGCACTACTGTGGTTAAGACA
GTAATGAATTTAAGGCCAGCCTGGGATACATAGTGAGACCCTGTCTCAAGAAAGGGGGAAATAAGTTCCA
AAAGTGACATTTTCCAAGGTGCGAAAGCGATGGTTCCTTAGAGAAAGTGACGTTGGAAGGGACAGAAGTA
AATTTGACTCCTTAGTTATTAATTTGGTATCGATTTGAGACCTGGATAAAAAGCTGGTAAGCTTTAGGAA
GGAAGGTAACGGTGGGCACGCATCTTTACGTCTTGGTTGGTTGGTTTTTTTTTGTCTCTGGCTGATAAAA
GTAAACCCACTGTCTTTGTCTTGGTGCAAGAGAGGGCTACTACTAGGCTATTTCAAAGTTTGCCAAATAA
ACACTTACCATGTTCTCTTGTATCCACGTTTTAGTTACATAAACAGTCTTAAACCAGATGTGGTGGCTCA
CACCTGCAAGCCCAATGGTCAGGAAGCTGCAACAGAAGAAGTGCCATTGTAGCCGAGCCACAGAGTGAGG
CGACTGTCTCAGAGTACAAAATAAAACTAAATCAAACATAATGGTCATCTTTTATCACACTGAGTACGCG
CGCGCGCGTGCGTGTGTGCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAGTG
TGTGTCGAGCTCATGCATACTCATTAGCATGTGTGTCAGAGGTCAGCTGACAACTTAATAGAAATTAGTT
TTGGGGTACTCAGTCTTGGTACCAGGTGCCTATTCTGGCCACACAGACCCACCTATTTTCTGATTTGTAT
AAACTATTTTGAGTTTTTCTACCAATCGTATTCCTCACCCAGTGTGTTTCTAAACGTTTTCCAAAGCCGT
GTTTTATGTGTCTGTTCCCCACCAGTGTGTTGTGATTTCTTCTTGCTCCACACCCGGAATAATGCTGACA
GGAGCAGTTTTTGTGCAAGGCTCCTGCTGTCCGTGTTCTAGGAACTGCACCTAGATGTGGTTTTGCTGAG
TGAGATGTGTGCTTTAAGTGATACCAGACACAGCCTTCTTATTTTTTCTTAGAACCAACAATATATCGGT
CCTTGGCCCCCACCCCCATGCCCCTTTTTTCCAATGCTGGGTGTTGAACCCGGAGCCTTAGACATAACAC
ACGAACTCTGCAGCTGAGCTACCCTGCCAGCTCCGAAAGATTTGTATACTAAGTTCTATGAAACATTAAG
GTCGTTTTATTCAGGGTAAGGTGTGGCTTCTGGCTTCCCTGGGTCCAGTCCTTTGATGGTGGTGGGTAGT
ACTGTTCGTTCCATTCCGTTTGGGGTTTTGATTGACAAGCCTTGCACCTTTCCAACTGTTCTACCTCAAG
AGCCAAAGATAAAGGGTAAAAGATTCCCTTCCCTTATCCCTGTCAATAGCAGCCTGCCTAGCTTCCTCAG
GATCAAATGAGATGAGCCCCTGAGAAGAGCAAGGCCCGCTGGGCCTGGAAGGCCAGCCCTGGTTGTACTC
AAACCTCTCGAGTCTATTGCCTTTCCCAGCCAACATTTTCTTACACATCCAGCCTCTGTGGATACTGTGA
CCCTCCTGATCTGGTTCTTGTGAAAAGTTTCATATTGGCAACTGTTCTTAAGGAAACACTGAAAACCTAA
TTACTACTAACGACCTGGAAGATAGAGCAGGAAGACCTCCTATTGTCAGTGTGGCTATGTCTCCAAGACT
GAGACATTGGGCCGCCATCCCAGCATGTGCGCGCGCGCGCGCGCACACACACACACACACACACAGTATT
CACTAAGCAAGAGTTCCTTGACAGGGTGAACTGGCATTAACGGGTAGTGGTTAGCGCCACAGAAGCACTG
CTAGCTCAGAACAAATGAGGTGCTCATACCCACAGGGCTGAGCTCTTACATGAGTGTGTACTGTTGGGCG
TGGGGTGGGGCTGGACCCAGGGCTTCACAGATGAGCTCCGCCCAAGGCCAAATCTCAAAAAATGAAAAGG
TCAAAAGGTAACCCTTTCAGATAGATACCGGAGATATGATATTTACAAAAAATATGATAATTAAATGCTA
CAGTTTTAATTATGAATCTGAAGCAGCTCTGGGTCTCCCTGACCCCTTTCCAGGGCCAGCCACCTCATTA
CTCAGATGTAGGGGCTATATAATACCCAGTCCTTTGCTTTCTTCATCTAGCTGATTGCAAGAGAACTGTG
CCTAAGAGCCTGTGACGCACTAGATTGTTTGGGTGGCCATCTTTAATAAAGAGTCATTCACCTGCCCAGG
GGCAGATGTGACCATCGAGACAGATGAAATAGCCCATATGGAAAGGTTTCTCAAACTCTTAAATAAATGA
GAACTTGATTGTTCTACATACAAGTGAATATATTAAATGTTGAGATTATAGTCAGTATTAACAGTAATTA
TTCTGAAATGCTTGCCTTTGCTGTTAGAAAGGAAACATGATGTCCCAGGGGGTTGGCCGAACTCAATCCC
CAGAACCCACTTCTTATAAGTTGTCATCTGACCTCCATACGCATGTCTTGGCACCTTTAAATAAGGCACA
ATAAATAAGTAAATGTCTAAGTAAGGAAGATAATAGCTCCGTGGTTAGTAACAAGAGAAAATGAGTGAGA
GAGTATCATACGGCTTAACCTCTGAAGGAGGTGGTGGTGGTGTGGCTGGCTGGAGATTGGCTGGCTGTGA
CTGTCTCCGAGGAGCTATGGCATACAAGATAAGGAAGAGCCTACCTCATAGCCTAGGGAGAACAGAAACT
GTGACTTTGCTCTTGTAGAGGTAACCACACTGATTCAGCCAGGAGGAAGTAAGTGCTCCCTAGAGCCCTT
GGGGAAGAAGGCAGTAGGAAACCTGCTGAATCTTCAGGAATTTGTAAGGCGCTGGGGACCTGTCCCTAGG
GGGCAGATGAGACACTGATGGGCGTACTTAGAGATTTGCCATGAAGTGGGTTTGAAGAATGGAGCTGTGT
GTGAAATGGTGGATGGGGGGGGGGAGTCCCTCCCCAGAGGGAAGGGAAGAGAGATGAGATGTAGGGTGCA
GATGTAGGGGGGCTTGGGGCTAGAAGTACCTCCCTGATTACCTGTTCCTTGAAGCAGTGTGTGGTTCGAG
AAGCTGATAGGAAGCCAGGCCAAGGCTTGAGCAGCCTGAATAAAAGACGGAAGAGCTGCCCCATTCCTGC
TTCTCTGGAAATGGTGTCCCTCACGGCCATCTTGGGTCCTGACTTCTTCTCAAAGGAGCCTGGCCGACTT
CTTGGATACTTGTAACTTTGCGCTTTCCCACCCTCGCATAAGTTTCCTGAAATAATGACTCTGAAACTCA
AAATATATTTACAAACACCTCGGCTGTAGCTTTGGTTTGTTCTCTGACTTGCTTATAACTTAATATCCCT
CTTATTCTAACCTAAGTTCTGCCACGTGGTTGGTTACCTCTGCTCAGCCCCCGGCTTCTGTCCTCCATGT
TCCTGGGGGAATCCCTACACTTTCAGAATTTAATTTCCCTACTGGATGTCCCACCTTCTTTTTATTCTAC
CCTTTCCTATAAGCCATAGGGGTTTGTTTGTTTGTATGTTTTTTAATTGACAAGTTATGCATCCATACAG
TACACAATCTCTTCTCTCTACAGATGACTGCCATGGAGGAGTCACAGTCGGATATCAGCCTCGAGCTCCC
TCTGAGCCAGGAGACATTTTCAGGCTTATGGAAACTGTGAGTGGATCTTTTTGGGGCCCTTAAGATACAT
CCCGCCATACCTGTATCCTCCCCTTGCCTGAGAGAAACAAAAACAGTAGTGTTCAAACATGGTATGGTGT
TGGGTGTCTGTAAATCCTGCGGGGCGGGGTGGCGGGGGGGGGGGGGGACTGCAGGGTCTCAGAAGTTTGA
GGTCATCATTGACTACATAGCAAGTTGGAGGCCAGCCTGGGATAAGTGAGATTCTGTCTTCAAAAAATGG
AAGGAAATCAGGAACTAACTCTCTGCTCTTGTTTTCCAGACTTCCTCCAGAAGATATCCTGGTAAGGCCC
AGAGCAGAAAGGGACTTGGGCTTTGGTGTTGGGCTGGTAGGCTGAGAACACAGTCCTGAGGGTTCTTCTT
TGTCCCATCCACAGCCATCACCTCACTGCATGGACGATCTGTTGCTGCCCCAGGATGTTGAGGAGTTTTT
TGAAGGCCCAAGTGAAGCCCTCCGAGTGTCAGGAGCTCCTGCAGCACAGGACCCTGTCACCGAGACCCCT
GGGCCAGTGGCCCCTGCCCCAGCCACTCCATGGCCCCTGTCATCTTTTGTCCCTTCTCAAAAAACTTACC
AGGGCAACTATGGCTTCCACCTGGGCTTCCTGCAGTCTGGGACAGCCAAGTCTGTTATGTGCACGGTGAG
TGGGCCCCGGGGAGTTGTCTTTCGTGTGACCTTTCAATGCCTCTTTTTCTCTGTCTAGATTTGGGGGTTC
CTCTTCAGCCTGTAGACTGTGCCTCAGAGTTTAGTTTTGCCCTGAACCTTTTTAGCCTCTTCTCCTTTCT
CTCATATTCTCTGCATCTCTCCAGGGGACGTGGAACTCTCTTCCCTCACATTCCTTTCTTGGCTTTTGAA
AATAATCTTCTGAAGCCAAGCACAGAGGCGTGTGCTGTAGGCCCAGCTGCTAGAGACAGTTGAGGCAGGA
TTGCTTAAGGCCAGCCTGAGCATGGAAGTAAGACCCCTTCTCACCAAAAACAAAAACAGCCCAGTGGAGT
GACACACACCTGTAGCTCCAGCACTGGGGAGGCCAAAGTGGGAGGGACAAAAGTTCGAGGCCATCTCTGA
CTACACAGAGAGGTGCCCTCTCAAAAAAAGAGAAGTCAGGTGTGTTGGCCATCTCTGTGAGTTCGAGGCC
AGCCTGGTCTACAAAGTGAGTTCCAGGACAGCCAGGGCTACATAGAGAAACCCTGTCTCGAAAAACACAG
AAAGGGAGGAAGAAGGAAAGGTCCCAGTCCTCTCTTTGCTGGCTGCCCTCTGCCACTGCGAGGGCGTCCA
ATGGTGCTTGGACAATGTGTTTCATTAGTTCCCCACCTTGACACCTGATCGTTACTCGGCTTGTCCCCGA
CCTCCGTTCTCTCTCCTCTCTTCCAGTACTCTCCTCCCCTCAATAAGCTATTCTGCCAGCTGGCGAAGAC
GTGCCCTGTGCAGTTGTGGGTCAGCGCCACACCTCCAGCTGGGAGCCGTGTCCGCGCCATGGCCATCTAC
AAGAAGTCACAGCACATGACGGAGGTCGTGAGACGCTGCCCCCACCATGAGCGCTGCTCCGATGGTGATG
GTAAGCCCTCAACACCGCCTGTGGGGTTAGGACTGGCAGCCTCCCATCTCCCGGCTTCTGACTTATTCTT
GCTCTTAGGCCTGGCTCCTCCCCAGCATCTTATCCGGGTGGAAGGAAATTTGTATCCCGAGTATCTGGAA
GACAGGCAGACTTTTCGCCACAGCGTGGTGGTACCTTATGAGCCACCCGAGGTCTGTAATTTTGTTTTGG
TTTGTGCGTCTTAGAGACAGTTGACTCCAGCCTAGACTGATGTTGACTTTCTAGCAACCCGTTTGCCTCA
CCCTCCTGAGTGCTAGCTAGGCTTAGAGGTGCAAGCTGCCGTGCCCAGCCCAGGGTCTACTTTAACAGCA
GTCTCTGGGAGAAGGGGCTTCCCCATCCAGGCGGGAAATAGAGACGCTGAGTCCGGTTCCCTCCCATGCT
AAGCAAGTGTTGGGCCCCACAGCTCCAGCAGGTGTGCCGAACAGGTGGAATATCCCTACTCTACAACTAA
AACTGAAACTTATTAGAGGCTATAGCCAGCCATTCCCGGCTGCTGCAGGTCACCTGTAGTGAGGTAGGGA
GCGACTTCACCTGGATCCTGTGTCTTCCCCCAGGCCGGCTCTGAGTATACCACCATCCACTACAAGTACA
TGTGTAATAGCTCCTGCATGGGGGGCATGAACCGCCGACCTATCCTTACCATCATCACACTGGAAGACTC
CAGGTAGGAAGGCGCGTGGTAGGTTAGGTTAGCCTGTTTCTTCCCCAGCTTCTGCCTGTTTCTGTTCCAC
GAGTCCCGCCCCCTACCACATGCCCAACGCTCTTTGGTTCCTACCCTATCTACCTAAATGAAGTCTCCTC
CTCTGTTTCCTCTTGGGCTTAGGGACGTCTCTTATCTGTGGCTTCTCGGGGTTCCTGTAACTGGACCTTT
GGCTGCAGATATGACAAGAGGGGTTGGGAACAGGTGGGGGCCTAGTTTACACACAGTCAGGATGGGGCCC
AGCTTTCTTACTGCCTTGTGCTGGTCCTTTTCTTGTCCCGGATAGTGGGAACCTTCTGGGACGGGACAGC
TTTGAGGTTCGTGTTTGTGCCTGCCCTGGGAGAGACCGCCGTACAGAAGAAGAAAATTTCCGCAAAAAGG
AAGTCCTTTGCCCTGAACTGCCCCCAGGGAGCGCAAAGAGAGGTACGCAGGCGGGACCAAGGAGGCGGAG
GAGCCTGTTGAGCTTCACCCCAAAGTCACCTCTTGCTCTCTCCTTCCACAGCGCTGCCCACCTGCACAAG
CGCCTCTCCCCCGCAAAAGAAAAAACCACTTGATGGAGAGTATTTCACCCTCAAGGTACCAAGGCTGGAG
AGTCGCATGCCAGAGACAAGCTGTACCCATTATTGCCTCTGTCTCTCGCATGTATAAAATAGTGTTATTA
GCAGGTTGCCAGGTCTTTTTCAGTGGCTTTATCTCTAGCCGTGACATTAGCTTGAGAGCTCATGCTCTGA
GGCTGTGCCTCCTCCGACAGTGGTTCTCAGTGTAACTAACTTGACAACACCAACTTACACCATAAGACAG
GTGCTCCTCCACTGGGGATGGGAACATGTCCTAGGAAACTCACCATAAATTGAAAATAACACACGACAAA
AATGTGTTTAGAGGCAGGCCTGGTGGCACCTGCCTGTAATTACAGCACTGAAGAGGGTGGTTCAAAGCTG
GCAAGAAAAAGTAACCCAAGGAAAGGACATTGGGGTTTAAGGGTATAACTCAGTTCCAGGATACTTGCCA
AGTGTGTGCCAGGCCCCGGATTAGGTCCCCAGCGGCTCACGGTGCCTTTAGTCCACCTAACCCACAACTG
GACTCTACAGCTCAGCTCCCGGTTGCCCTGTTAAGCGTCTGTTCCCTCTAACTGAAAAGATCCAAGCTTG
TTGTACACGTTCTACTGAATGCCTGTTACTTTCACACCATCTTATTAAAGATGATCTCCCCCCCCCCCAA
AAAAAAAAACAAAACAAAACAAAACAAAAACCTGTAAGTGGAGCCAGCTTAAGTTGGGAACCAACTTTCA
GAAAGAAAGTTGTTAAAATCGTGAAAGTGGTTGTGTGACCTTGTCCAGTGCTTCCATCTCACTTCATCTC
TGCTGCAGATCCGCGGGCGTAAACGCTTCGAGATGTTCCGGGAGCTGAATGAGGCCTTAGAGTTAAAGGA
TGCCCATGCTACAGAGGAGTCTGGAGACAGCAGGGCTCACTCCAGGTAAGTGGCCTGGGGCAGCGCCTGC
CTGTGGTGCTCTACCCAGACCTCCCTCCAGCTCAGCCTTTGTAGTGAAAGATAAAAACCCCACCCTGCTA
GATGCTTAGGGCTGCACCCTACGAGAACTGACTTCTTGACTTTTTAGGCTCTGTTAAGGGGTATGAGGGA
CAAGGTATGGTGTCATGCTCCTATAATCTCAGCAGTAAGGAAGACAAAGTCAGGAGGATTTGGGGAAGTT
TGAAGCCTTCATAAACTATATAAAACTTTAGGCCAGCTAGGGCTAGCTACAATAGCAAGACCCTGTCTCA
TGGTGATGGTGATGATGGTGGTGGTGGTGACAGTTGTGATAATAATGGCAGTGGTGGTGATGATGATGGT
GGTGGTGATGATGGTGATGGTGAAAGGGAGGATAAACTGATTCTCAGAAGTATTCCAGTGTGTTCTGTGA
ATATCCCTACCCATAGTAGAAGCCATCTTAAATTCCTTTTTTTCAGCCTCCAGCCTAGAGCCTTCCAAGC
CTTGATCAAGGAGGAAAGCCCAAACTGCTAGCTCCCATCACTTCATCCCTCCCCTTTTCTGTCTTCCTAT
AGCTACCTGAAGACCAAGAAGGGCCAGTCTACTTCCCGCCATAAAAAAACAATGGTCAAGAAAGTGGGGC
CTGACTCAGACTGACTGCCTCTGCATCCCGTCCCCATCACCAGCCTCCCCCTCTCCTTGCTGTCTTATGA
CTTCAGGGCTGAGACACAATCCTCCCGGTCCCTTCTGCTGCCTTTTTTACCTTGTAGCTAGGGCTCAGCC
CCCTCTCTGAGTAGTGGTTCCTGGCCCAAGTTGGGGAATAGGTTGATAGTTGTCAGGTCTCTGCTGGCCC
AGCGAAATTCTATCCAGCCAGTTGTTGGACCCTGGCACCTACAATGAAATCTCACCCTACCCCACACCCT
GTAAGATTCTATCTTGGGCCCTCATAGGGTCCATATCCTCCAGGGCCTACTTTCCTTCCATTCTGCAAAG
CCTGTCTGCATTTATCCACCCCCCACCCTGTCTCCCTCTTTTTTTTTTTTTTACCCCTTTTTATATATCA
ATTTCCTATTTTACAATAAAATTTTGTTATCACTT

</dna_sequence>
        <protein_sequence>>NP_001120705.1 cellular tumor antigen p53 isoform b [Mus musculus]
MTAMEESQSDISLELPLSQETFSGLWKLLPPEDILPSPHCMDDLLLPQDVEEFFEGPSEALRVSGAPAAQ
DPVTETPGPVAPAPATPWPLSSFVPSQKTYQGNYGFHLGFLQSGTAKSVMCTYSPPLNKLFCQLAKTCPV
QLWVSATPPAGSRVRAMAIYKKSQHMTEVVRRCPHHERCSDGDGLAPPQHLIRVEGNLYPEYLEDRQTFR
HSVVVPYEPPEAGSEYTTIHYKYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRR
TEEENFRKKEVLCPELPPGSAKRALPTCTSASPPQKKKPLDGEYFTLKIRGRKRFEMFRELNEALELKDA
HATEESGDSRAHSSLQPRAFQALIKEESPNC

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>The antitumor activity of a recombinant canarypox virus expressing wild type murine p53 (ALVAC-p53, Trp53) was investigated in two murine syngeneic tumors harboring an endogenous p53 mutation (CMS4 and TS/A). Direct intratumor injections of ALVAC-p53 in CMS4 pre-established subcutaneous tumors induced total tumor regression in 66% of mice. Furthermore, 100% of the cured mice was protected against a contralateral subsequent challenge with the parental tumor cells. The intravenous treatment of experimental lung metastasis by ALVAC-p53 also induced significant tumor growth inhibition in both models [Ref972:Odin et al., 2001].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1335">
        <gene_name>Tyrosinase</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>7299</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>4507753</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AH003020</gene_refseq>
        <protein_refseq>NP_000363</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>11</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>89177564</gene_start>
        <gene_end>89295758</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>transcript variant X1</protein_name>
        <protein_pi>6.05</protein_pi>
        <protein_weight>58703.65</protein_weight>
        <protein_length>529</protein_length>
        <protein_note>Also known as CMM8; OCA1A; OCAIA; SHEP3</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000011.10:89177564-89295758 Homo sapiens chromosome 11, GRCh38.p12 Primary Assembly
GACACTACCTCTCATTTGCAAGGTCAAATCATCATTAGTTTTGTAGTCTATTAACTGGGTTTGCTTAGGT
CAGGCATTATTATTACTAACCTTATTGTTAATATTCTAACCATAAGAATTAAACTATTAATGGTGAATAG
AGTTTTTCACTTTAACATAGGCCTATCCCACTGGTGGGATACGAGCCAATTCGAAAGAAAAGTCAGTCAT
GTGCTTTTCAGAGGATGAAAGCTTAAGATAAAGACTAAAAGTGTTTGATGCTGGAGGTGGGAGTGGTATT
ATATAGGTCTCAGCCAAGACATGTGATAATCACTGTAGTAGTAGCTGGAAAGAGAAATCTGTGACTCCAA
TTAGCCAGTTCCTGCAGACCTTGTGAGGACTAGAGGAAGAATGCTCCTGGCTGTTTTGTACTGCCTGCTG
TGGAGTTTCCAGACCTCCGCTGGCCATTTCCCTAGAGCCTGTGTCTCCTCTAAGAACCTGATGGAGAAGG
AATGCTGTCCACCGTGGAGCGGGGACAGGAGTCCCTGTGGCCAGCTTTCAGGCAGAGGTTCCTGTCAGAA
TATCCTTCTGTCCAATGCACCACTTGGGCCTCAATTTCCCTTCACAGGGGTGGATGACCGGGAGTCGTGG
CCTTCCGTCTTTTATAATAGGACCTGCCAGTGCTCTGGCAACTTCATGGGATTCAACTGTGGAAACTGCA
AGTTTGGCTTTTGGGGACCAAACTGCACAGAGAGACGACTCTTGGTGAGAAGAAACATCTTCGATTTGAG
TGCCCCAGAGAAGGACAAATTTTTTGCCTACCTCACTTTAGCAAAGCATACCATCAGCTCAGACTATGTC
ATCCCCATAGGGACCTATGGCCAAATGAAAAATGGATCAACACCCATGTTTAACGACATCAATATTTATG
ACCTCTTTGTCTGGATGCATTATTATGTGTCAATGGATGCACTGCTTGGGGGATCTGAAATCTGGAGAGA
CATTGATTTTGCCCATGAAGCACCAGCTTTTCTGCCTTGGCATAGACTCTTCTTGTTGCGGTGGGAACAA
GAAATCCAGAAGCTGACAGGAGATGAAAACTTCACTATTCCATATTGGGACTGGCGGGATGCAGAAAAGT
GTGACATTTGCACAGATGAGTACATGGGAGGTCAGCACCCCACAAATCCTAACTTACTCAGCCCAGCATC
ATTCTTCTCCTCTTGGCAGGTAAGATATGCTAGATATACGATGTCAGAGTAGGGAGGAACCTTAACAATC
ACTTCTTCAGGCAGGGTATAAACTTCTCACCTGAACACTCATTGCAGCCCCCATCAAGGACAGAAATGGT
GCCCTGTTAAGAACTCTCAATGTATCTTGTATTTTTCCTTTATAGCACACTTTAGATATTTGTGTAATTA
TTTGTTTAATGACTTCTACTAGGTTTCTAAACTGCAATGAACAGAGTACTTGATTCATTATTGCATTTCC
CAGAACATAGTATGGTGCCTTTAAAAATGGCAATAGTGCATTATGTATTTTGTGAATTGAATAAATGAGT
GAATGAATGAATATCTGGATGATTAAAAAAACAAATGATATACACTAATGTCTCTGAAAAATAAAATTAT
TATTCACAACAGGATTCATATGGTGTACAAATTAAAAATGCAAATTCCTGGCCTTATCCCAGACTAATTG
GTCAGAATCTTCAGGAGAGAGTCCCGAGAAGGCACAATTTACTAAATGTCTATGGTGATTCTTTTAATCA
GGAATGTTTGGGAAATAATTATTGGATTAGATCTTCATTTTTGAAAGTATGAAGATCCTGAGGCTTAAAC
AGGTAAATAATGAAGATGGCTAATATTCATTGAACATCTAGCATGTGCAAACCCCGTGGCAAGTGTTTTT
GTGCATTCGTTCATTTCATGCTCTTATCAGTCTTTCCCTATTTTAGAGGTTATAAAGGTATCAGGTAACT
TGTATAAGATCATACAGCTAATAAGCAGCAAAAAAAAAATCACATTTATTCTCTAATAGTCCAGCTGTAT
GACCACTGTATCCTATTTCCAAGGATGTGACTGCTGTGATATCTTTAGCTAAAGGATCTGGTTCATTCTG
TCTCACTTTTTCTTTAGGCTGCATTAGAAGTTAGCTTTCTTTCTCAGTCCTTGAAAACTTTAGATAAAAT
ATGAAGCATTACTATTTGGAATTGAATTCCTATTTCATCTATTCTGAATTTTTCATTCTGAATTAGGGGC
AAATGGTAACCAAAGAAATATGTGCTTAATTATTTATCATTTTAAAACCATATGTTAAAGGAATGCTTTT
CTGCCTGTCTTCCAAAAATTTCTAATACAGCACTTTTGACTAGCAATGCTCTATGAAATTAAGCCCAATA
TGTGAATGGGATGGGAAGAATCTTGCACTCAATTTCCCACAATCTGCAGTTTTGAAATGTAGATGGCCTT
CTCCGCCCAACCAAGTTTGTACCCCATCCCAATGGAGTCTACTGAAGTTCATTTAAAAAATAGCCACTGT
ATAATTTCTGGTGTTATTAGTCAGCTATTTACCAAATGTAATGGGTTTTGTGCAGGAAAGGCTAGAAAAA
ATGTGCTTGGAAAAAAATCTATTTCAATAAGCTTTCAGACCTCCTACCTTAATCTATAATGTGCAAACTC
TCATCTAGCTCTTATATCCTCTGTTCCTGTTTAAAAAACTGCCAGGATTGGACATGGGATTTTCAGTCAG
TTATGATGCTTTATTTAACTATGTGGCTTAACTTGACCCAGAAAGGTTGGAGGACTGTCTAAATTACCAA
AATAAGCTGCAACATCCACAGGAAATCTTAATAGATAGATACACATTAATTTTTAATTACATGAGATGTG
TAATACCAGATGCTATCCACAACTGTATGAGTATTATTTTCCTAATTACTTATTAATTGTCAAGCAGAAC
TTTTTCCTTTTTCTCTCTTCATGAATGTGTTCAATTTTAATACTCTCTAGAAAAAAAAAAAAGTGTGTCA
AGTCAGTAAGCCCTGAACTGAAATTGATACAATTATCAACTTCAACCTTGTTCTATGATTAAATTGCTGT
GTAGAAACAGGTTTCAAAAATAAAATTAGAAAACAGAGTGGAAGGAAGATGACTGAAGAGAAACAAGCAA
ACCACAGTTTAAGAAAGGTGAAATGAGCATTTGCTGCTCACCTACTATGTTTTAGTAGTGTCAAGGGCTT
ATTAGTGGCAAAGGTGACAGTCAAACCCCACTCACATTGGCTGTTTCCATTCCTTCACACAGCCTCTCTG
GTTACAAAGTCCTTAAAATAGTTAAGATCGATTGCTTACATTGCTTTAATTCAGAGTTCTCAATGTCAAA
ATCACCTAGGAAGCTTCCAAAAAACCATTTAAAAAGTAAAAATAAAAAACTGTTGCAAGGTTTTTATGCA
CCTAATTTCTTGCCAGAAATTCAGATTCAGGTGGTCTCCTGTGAGGTTGTAAAGTTCAAGAGTCTTTTTT
TTTGGCAGTGGTGCAATCTCCATACGCTGCAACTTCCGCCTCCCAGGTTCAAGTGATTCTTCTGCCTCAG
TCTCCCTAGTAGCTGGGACTACAGGGGCCTGCCACCACTCCCAGCTAATTTTTTGTACTTTTAGTAGAGA
TGGGGTTTCACCCTGTTGGCCAGGCTGCTCTTGAACTCTTGACCTCAAGTGATCTGTCCGCCTCAGACTC
CCAAAGTGCTGGGATTGCAGGCCTGAGCCATCAAGCTGGGCCTTCAAGTGTTTGCATTTTTAAACCCTCA
TTTTGTGATTCTAATGTGCAGCCAGCACTGAGAATCATTGAGTTAATGGAGATTGTTTTGGTATCTTTTT
ACTTTCACTTTACAAAAACGCATGTTCTGTAATAAACACACCATTAATTTGAATGCCTTTGTCCAAATTG
AATGCTTAAATTAAGAACTAGACTATTTGTGTGAGATGAGATCAAATAGTTTCTAGATTGAGTTAAGACC
TTCCAAATTAGCTAGGCTGATGCACCTTTCACATAAAGCCTTCTTTTTTTATTGGTTTCAGATATCATTT
TACTTGACCCCAAAATTGAGATTTGAGAGATTTGATAGCATTTATTAACTCTGAGCTGAGAGATCTTCAA
TTTTATTTAGGGTAACCTGTGCATTTTATTAAAAAACTATAGAAAAGCCTAAAATGGTAGGATGATTGTC
CAAAGTCACACATCTGAGGACTAAAACCAAGCGGCTCTGACTGCAGTGCTTTTTAAGTCAACAATGTTAT
TTCTTGTTTATAAGGATCCATTTAGGTTCAGAAGGGGTCAAGTAACCCGCTAATTTCTGGGTGTATAATT
TGACATTTGATCACGTTGACTCCCTTAAAATTGTCCTGCCCCAGACAACATAGGCAGACACAGTGATGTA
GTCCTTTTAATTTATATCATAATGAAAATATTCTGAGACTTTTACTGATCCACCTCTGTTACTCAGGTAG
AGTTGACCCTCTCCCCGTCTTTGTGCTATCATTGTACTTTATACAGATTTGTATCATAGCACTTGTAACT
TTTCATTACATGTAGTGGTTTTCCAGCCTGTCTGTATCTGCCAGCCTGTCAGTCGCTCCAAGGTGGTGAT
CATTTCTAAATATTTTTGTATCCACAGAGCACAGGACTATAATATACACATGGAACAGGCTTTATAAATA
CATGCTGAATTTAACATCAAAGAAACGTTAGCTCCAATGCTAACATACATAAAATATTAAACTCTGCATG
GGTAGATTTCTAGGACCATTCACTGCAGTTTTTTTATAGCACTGGATTCCCAATGCCAAGGATACAACAA
TGTCAACAATAGCCACTTACTCAAATTTGGGTATAATATATCTTGTGTCGTTCTCTCTGGTAGTTCCATA
TGTATGTCTGCGTGTGTGCATGCAAAGAAAGACAATACAAGAGAGAAGATGAAGCAAGGTGCAACATAGC
TGAGTGTGATTTAAATGAAGTTAATATTTATTGGTCAGAGTTTTCTGTTAAATATGTTAAAATCAGGTAA
TTAATTTATTTGGAAATATTGTGTTCCTAATTCATGTCTGTTGTTTGCTCATTTATTTAACTCCCAAAGC
TTTAAATTAGGGGCCATGTTTATCATCAATTAAAATAGTTCATTATATTTGGAGGTGGAGGGTTGCTTAA
TAACATTTAAGTACAAACTACCCATGCTCAATATAATTAGATCTAATGTTATGCAACCAACAGATCAGCT
AGCTACAAAAATAAAAGGGGTATCAGGAATAGGTGTCATCATGAACAGAAACAAAGAGGAAAAAACATTT
CCTAGCTGATACACATGAGTGAATTGTGACCAGGGAATTCACTCATCAGGTGAAAAGCACATCACATGGA
AGCAAAGAGAAGAAAAAAAGTCACATTTCAGCAGAGAGTCATGGGTTTTAGGTAACCATGACGACAGCTC
AGTGAAATAACAGCTTCTCTTTTTTCTTTATGAAAAAGATTTTGTGGAATGTCATACGGTTTACATTTTT
TCCCCCAGATAAACCTCTAATGCTATAACAAAATCTTTGCTCCCAAAAGCTTTTAATATCTGGCAGTTTA
TTGCTATTTCTTTAAATTTAAGAGAACAGTATTTAGGTTCACCTTCCTCATTAATATATCTATTTCTTCT
ATCTCCCCTTTTTTCTTTGACTTGGAACACTTGATCGTCCCCCCAGCATATGTTATAAATCACTTGCGTT
GAAATAGAAAAAAAACAGAGTCATCATCAGAACATCCAGGCTCAAATTCTACCCCTGCCATTTAGTAGAC
GACATTGGACCAGTTATTTAAAATCTTTGACCTTTGTTTTTTCCAAAGAGAAAAAAAATGAGGTAGAATT
ACCATCTATACATGTTTTGTGTGTGTGCTAATAGGAGGATTAAATGGAATGGGAAACAGAATAATGTAGT
GGAAAGAGTATAGTCTTTTCAGTCACATCAGCATGAATTTGAGTGAACTTTCATACTTACTTAGCTACAA
GACCCTAAGTTACTTAATTATTCTGAGACGATTTTTGTCCCTAAAATTAGAATAATATAGGTTAAAGCAT
TACTGTGAAGGGATTCAATAAGATGTGTTTATATGGCTTGTTTAGGATCTGACCTATTGTTTGAGTTTCA
TGTGTGGAAATAATATATTTTTAAATGATACATCAAAGTTAGATATAATAATGAATATTCAAACAGTGTT
ATACACCCAAAGTTAAAAACAATTTGGTGACCTGCCCAATGGTCTTGTTTTCAAAAATAATTATGATAGT
TGTCATTATTAAACACTTTACACTTGGCACTATGCTAAGTGCTTTATACATGTTAGATTATTTGATCATT
GATAGAAACGTATAATTCCCATTTACAGATGAAAAAACTTAATACCCAGAGAGCTTAAGTAACTTGCCCA
AGGCCATGTAACTAATAGGGTCAGTATTGGAAACCAGGTCTTTCTGACTAGAATCTTCATGATCATAAGC
ACAATGCTAATATAATTTCTCCTAGCCTGCCTCCTCTCCTGTATGCAGTGTAAAGACTAAGGTTTGGAGT
TTTTCAAATTATTTCTGGAACCAGGGTAGATTTTCTCCTCGTTAGTAATACCTCCAGTCATCCGAACACT
TAGTCACTTGGCAGTTGGCATTTCAGCAAAAATAGTTTCATTCAAGCCTCTCTAATTTAACTGAGTTGGC
TGTAGGAGTCTTTAAGGCAGCAGGATCTTTTGAAAATATCCTGAGATTACTCAAAGAGGAATAAAAATGA
TTTAGTCTACATACTTGTAGCGTCCAGTTAACCCAAATTATAAAAGCATCCAACATATTACATTCAATGT
AAAAGTTAGGTTAGTTTTATTCAACCATTCCTAAGCCATTAACACGTCATAATTAATGTAGTGGGTATTG
CTTCAGAATAAGGAAACTTGTGTTTCAGTGCTTTGGTTTTGACTCTAAATATCATATGGCCCTAAGACAA
GTCACTCAACAGTTCTAGTTCTCAATTATATATGGATAAAAGGATTTAGGAACGTTATGAGGTATAAGGC
AAACTAGAAACTGGCATTTGTTGAAACAGAAATTATTTGTTGAATAGTTTCTTTTCGTATATTATGTCAT
AGTACAGTTTAAAAAAATTGAGATTTAGCAAGTCTAAAAAACATGTTCATTGCCAGTAAGAAAATTAGCC
AGAATTGAAGTTGCATCTACCTGTATTACGGAGCCCAATTTTTTCTCTACCACACAATGCATAAATTCTT
AAGTTATGTCTTAGTGACCAAAAATTAAGAGTAGGTTCTCTAAGCATTTCTTATCTAACACAGTAGCAGC
CATCTATGGTGGGGGGACTGCCCATTCAATTCTATTTGAGATGACTACATTTGTTTATACATGCTTATAG
ATAGCAAATTCAGTGGGATAGGAGGACCAATAAAATAGTCTTGATTATTTTCAAATGTGATGCAAACAGT
TGACCGGGAAGACATTTTACCTTCAAATTATTATTCTATACGTCTCGCCTACTGTTCACAAAATTATAAA
TCATAACATGGGTCTTTATATCCCGTTAGCCTTTTGTAGTCTTCCACAGTCTGGCTTAGTATCCTCATCA
TGAAAATAGAGATAAAATCATAAAAATCCACAGGGTAGTTGTGAGAATTTCTAATTTTAATGTATATGGA
GATATCTCCCTTATGGCCTAGGACAGAGTAGTGACTCAATATAGGTTTAAAAAAATAAGTTCTAGAAATA
TATTCTATGGTAAAGGTGGTACCAACAACATGACCAAGAAAAATGAGCACTCAACACATACTTTTTGTAG
GAGATTCTTTGGCTCATCCACTGACTCTGTTCATTCATCCAACAAATTCTTACTGCACATCAACAGGGTG
CTAGAAACTGTACTAGATTCTGAGAGAAAAGAAATAAACAACAATGTGAAAATAAATGTGTCTTCATGAA
GGATGCGTTTTTATAAGGGACGTAACAATCATTGTTTATTAGAGACGAAAATGAGTAAGTGTAAGTTGGG
TAAAGAACAATGTTATCTCCCTAGTGGCCCCAAGCCTCCCACGGAAGCATGCACCTGTTGTGAACAGTCA
ATGACGGCAGGGTGGACTCTCCTGAATTTCATCTTTTGCTTCGAATGTATCTCTCACTACCTAATTACTC
TATTTTATTAAATCTAAGGTATCAATGAATTTAAGTGATGCATTCATTTATGTACCACTAAGAAAAATAA
AAAAATATATTTATCTTAAAAGCCCTTTTTGGCTTACGTAGTCACATATTTTTATCATAGTTTATTCTTC
TGCCTCCATATAAATGAAACTACAAGAAAAATAATTTGGTGAAGGATTCCTGAAATGTTTTTACATTCAG
AGTCAGCCCCTTTTGAGTTACTTTTAAAGTCAGAGTCAACAATGCCTGTTTTTACTAATTATTTGCTTTG
GCCTTAAAGAATGGGTAGGATATTAGATGCATGGCAAAGAGTGGGCATGCTTAGCCACAATCAGAGTCAT
GGAATGGAGAAGCACAAGCAGTGTCCAGAGAAAGTAGGCCATCTGACTTTAGCAGCAGGATCACACAGGA
TGTGAGCACATGGAGAATGGTTGCCTGACTCGAGATATTTTTTGGAGGTAGAATTGCCAATATAAAAGCA
GTGCCATCGCACAATGCTCCATGCTCAGAAGCAGACCCTACATTTGAGGTTTAATGATCTGTGGTCTTGG
TGTTGAAATTCTTATTAATCTTATCTTTGGGTTTGTGCTTTATAAGTGAAGTTATAGGGACAATGGAGCA
TATGCTTGGTTCATATGCATCCTGCAGACCTTTTGTTCTTTGTTTTCCTGGGATGGGTCTTGGCTACCAC
TACCCATCCACCAGCCCTACCTAGTTTCCACCTCCTCACCCTCTGCCCAAGGCCACTGGTGGGAGGAAAG
AGGTCAACATTTCACTGTCACTCTCCATCCCTGGTGGGGTCCTTGGTGCAAGCAAAAAGAGGTGTGAGGT
TGGGTGTTGATCCCATGATTTGTTGGTTCAGAGTAAAACAGAGGCCTTCTCTACCGAGGCTGGCTGCACC
TTAGCACGGTGCACAGGTGATTACATATAGACCTCTCAGCCAGTATTATGGACTGAATTGTGTCTCCCAA
AAATGTGTGTGTTGAATCCCTAATTTCCAGTGTGACTATTTGGAGGTAGGTCTTTAAGGAAGTAATTGAG
GTTAAGTGAGGTCATTAACAGTGGGGTCCTAATCCAACAGTACTGATGTCCTCATAAGAAGACAAAAAAG
ACAGAGCCATCTCTTTCTTTGTGTATGCGTAGAGAAACGGCAATGTGAAGACAGAGAAAAGGTTTCCTCT
GCAAGACATAAGAGAGGCCTCAGCAGATACCTTGATCTTGGACTTCCAAACTCATGAACTTTGAGAAAAT
AAATGTCTGCTGTTTAAGCCACCCAGTCTGTAGTATTTTCTTATGGCAGCCTGAACTAATCTACCCACCT
ACTCAAACAAGTCTTAGCATGGAGGTTTCAATCCCTAGGGAGTCACCTATTCACTATAGACTGAGACTGT
GGGATACCTATTCCCTGTAGATTGAGAAAGTGAATATTGATTTCCCTACCCCCAGCCAAGGCCTCAACAT
TTATCTGGTGCTGCAAATTGCATAGCCAGTCCTGCCTAGAGCACCACAATATTTACAGGTAAGACAGACG
AGGAAGAGCTAGTAGGACACACCAAGTAGTAACAGCAAGAGAGAAAGGCAAAAATCAAAGGGGATGTGAT
TATAGAAATCAGTACATAGAGGAATGTGTTTTGTGAAAATGAAAGTGGTCAACTGTGCCTAATGCTATCT
TAACATGGGGACTTGCAGGGATAATTGGATTTTATAATATGGAGTCTTTGAAGGTTCATAACAAACTCAT
TGGCCAAGAGATGACAGGGGAAGATGACTAGAGTGCCTTTATGTGGGAATGGGTAGCCAGGAAATGGAAT
TTTCATTTAAGATACTTGCTAAGATTTAAGCTTTAAATCATGTAGTCTATATTCAAATATTAACTCCCCC
CGTTTTATAAACTATAAATGTTTGATGAAGCCACTTAACCTCTATAAGCCTGTTTTCTCATTGATGAGAT
GGAAATATCAAAAGAACTCCTCTCATAGAATAATTGATTTACTGTTATTGAATTTCAAACCAAAGTTTTC
AAATGTCTTTGTGTCAGGCACCATACCATTACACAATAATACATAGTGAATAGGATACAGTTTATATTTT
GATAGAGTTTATCACCTAACAGGTATGTTTATAAAGATTAAATATATACACCATATTGCCTTATTCATTG
ATTTAAAAATTCATTTACAAAAATATTAGCACTTTAAGTATTGAGTATTTTATGTAACTTATCTTCTAGT
GGAGTAGGTCTAGTAAGTGTGTGTGGTGAGACAGTAAAACATTATATATAATATTTTATTTAAAAAAGTT
AAAGGAGTTAAAAAATATAATAAGTTATATATATTGTTTTACTGTCTCACCCACTCACACTTCCTAGACC
TACTCCACTAGAAGGTAAGTTACATAAAGTACTCAATACTTAAAATGCTAATACTTATTAAAAATGTTTA
AGTCAATGAATAAGGCAATATGGTATAGACATTAAATCTTCATGACCATACTTATTAGACTGTAAACTCT
ATAAAAATAAAAACTATGTTTATCGTGTTCAGTATGTATTCTTGTATTCTGGTATAATGCCTGACACATA
GACATTTTAAAACTTCGGTTTGAAAAGCAGCAACAATAAATCAATCATTCTATGAGAGTTCTTTTGATTA
CATAGTTTGTTAGAAGGTGCTAAGTGCACAGATAAAGCAGAAATTAGTGGTGTACAGTAAATGTTTAATA
ACTTGTTCTCAATGGAGGAGTGGGAAAGTAGGGAGAGATGATTCTGATTTGCCAATTGTTGTGGTGTAAA
TACTGACAATGGTAGATTTCCATCTAATGATGGGATACTGCTGAACATTCTAATATTGAGAAGGGTTACA
CACTTTGAACTTTTGCTAGCTAGTGCTAACCAGCTCTACAACACTGCTAAAGTGGGTAAGGCTGAATATG
ATGTTAAATAGATGTTTAGTGTAGATTTCATTAAGATAATGAAGATATGAATAACCCAAGCAGGTATCAA
GGGAAAACAGTCTACCCAGAAAAAATAACCAGTACAGGAACATGTTGCATAAGAGTGATTGGTGAGTTTT
GGGAAGGGCAAAGAGGCCAGTGAAGTTATAGAAGAGAGGGAAAGGGAAAGATCAGTAGGAAATAATGTTT
GCATCAGTCAGGATCTCAGTAGGAAATAGATACCCAAACCAAGTTATATTAAGACAGTTTATTTAGAAAA
ATTTGATCAAGGTTTAGGGAAACCAACAAAGAACAACATCCTGTTGTCAGCCACAACTGAGATACAGGAC
TAGAACTCTCTATTTTATTTTAACCTAGAACCTACTTTTAAAAATTTTTTAATGTTGAGTTCTGCTAGAC
TAGTTATAAAAGCACAAAATACACTAAAGATGAAGTTGGAAAACTTGGGTTGCCATCACAACACTGCCAT
TTATTTGCCATATAACCTGAGAAATGCCACTTACCCTCTCTGAGTCTCATTTTCCTTATTTGTGAAGCGA
AATGTATTGTTTTGTGATGTAAATGAAACAATGCATGTGCCGTGTTTTCTTAAAAAGTTTTGCTTATAGA
AAGGTGAGAAATTCTTATTTTTAAGACGGTATTTCTACAATGAAAATCACCTTGGTTCTAGCTAAAGGAT
CAGAGAAATTTCTTTTCTTAAAAAACAATCAACCACGAGTATTGTACTGCACATCAAAAAAAAAAGGGAC
AATAATAGGATATTTTATGAACAAAAAGCACAAAATGAAACTATTTCTAGTCCTTGACATTCTGAATATA
ATATAGATTAATGTTTTTAAAGCTACTGTTTATTGAGTGTTTTCTGTTGGTCATGCCATGTGCTATGGGC
TTTATATACAGTAAGATGCCTATCTCTATTGTTACCAACCCCAGCCTCAGCACTTGGCACAGTGCTTAAT
ATATAATAGGTGTTTAATAAATATTTTATTTTCTATAACTATGTGAGGTAGTTGTTATTATCTTCATTTG
ATAGATGAGGCCTAGACAGTTAAATCATTTTCTTAAGTGGTAGATGCAACACTAGAATCCTGTTCCAGGT
TTTAACTTTTATGGCTCATTCTGTAACCTTCAAAAAGCTAATTCTAAAATACAGTAGTATGCCACACAAT
GGCATTTCTGTCAAGGATGGACCACATATATGACAGAGGTCCCACACTACTATAATGGAGCTGAAAAATT
CCTGTCACCCAGTGACATCATAGCAGTCATAATATTATACACAATGCATTACTCATGTCTTCGTGGTGAT
GCTGGTGTAAACCTACTGAAATCCCACTTGTATAAAAGTCTAGCACATAGCATTATGTACACTACATAAT
ACTTGATAATGATAATAAACAACTATGTTACTGGTTTATGTATTTACTATCTATATTTTATCATTATTTT
CGAATGTACTTCTTCCACTTATAAAAAAGTAAGTTAACTGTAAAACAGCCTCAGGCAGGCTCTCCAGGAG
GTGTTCCACAAAACGCCTGGATGTTTTATAGAGATTGTTATAGAGATGATAGCTCCATGTGTACTATTGC
CCCTGAAGATTTTCCAGTGGGACAAGATGTGGAGGTGGAAGACAATGATATTGACAACTTTGACTCTGTG
TAGGCCTATGCTAGTGTGTATGCTTGTGTCTCAGTTTTTAACGAAATTTCAATTATGTTTATAATAAGTA
AAAAATTAAATAGCATAAAGCTTATAGGCTAAGGATATAATAAATATTTCCTACAGTTGTACAATATGTG
TTTTAAGCTAAGTGCTATTATCAAAAGACTCAAAAAGTTTTAAAAAATTAAGTAAAAAAGTTACAGGAAG
CTAAGGTGAATTTATCATTAAAAAAGAAAAATATTTTTATAAATTTAATGTAGCCGATATATATATAGTG
TTTATAAAATCTACTGTAGTGTAGAGTAGTATCTTAGGCCTTTATATTCACTCCTTATTCCCTCACTTAC
TTACCCAATGCAACTTCTAGTCCTGCAAGGTCCATTTATGGTAAGTGTCCTGTATATACAAGTATGCCAT
TTAAAAAAAAATTTTATACTGTATTTTTACTGTACCTTTTACATGTTTAGATAGGTTTAGATGTATAGAT
ACTTGCCATTATCTTACAATTGCCTATAGTATTCAGTACAGTAATGTGCTGGACAGATTTGTAGCCTAGG
AGCAGTAGGTTTTACCAAACAGCCAAGATGTTTAGTAGGCTATACCATTCTAGGTTTGTGCAAGTACACT
GACTATGATGTTCACGCAATGACAAAATCACCTAATGATGGATTTCTCAGAACATATCCCTGTCATTAAA
GACACATGATTGTAGTAATCTCCTCAGGAGAAGTCTAACAACGATAATTAGGAGTTCCAACATTTCTGCC
TTCTCCTACTGACTCAGTGGTGGTGACAATTTGTTTAACATGAGGGTGTTTTGTACAGATTGTCTGTAGC
CGATTGGAGGAGTACAACAGCCATCAGTCTTTATGCAATGGAACGCCCGAGGGACCTTTACGGCGTAATC
CTGGAAACCATGACAAATCCAGAACCCCAAGGCTCCCCTCTTCAGCTGATGTAGAATTTTGCCTGAGTTT
GACCCAATATGAATCTGGTTCCATGGATAAAGCTGCCAATTTCAGCTTTAGAAATACACTGGAAGGTAAT
CTCTTTCTTTTCACTTTTAATTTTTTTTCTGAATTCATATTTACAGTCTCTTATCCAAAGTCCTAGGAGG
TATTTGAGAATTCAGAATTTTCTGAGTTGACCAAGAATATGTGTTGTATATACTTATATCGACAATGACC
CTAGCTGACACTGGTCAGCACGTTATAATTCAACGTGTTAGCTTCAGGAGCCAGGCATGGTGGCTCATGC
CTGTAATCCCAGTTTACTTGGGAGGCTGTGACAGGTGGATCACTTGAACTCAGAAGTTTCAGGCTGCAGT
GAGCTATGATTGTGTCACTGCATTCCAGCCTCGGTAACAAAGTGAGAGACTCTGAGGAAAGAAGCAGCAG
CAGAAGCAGAAGAAGCAGCAGTAGCAGCTTTAGTGAAATATATGAATATATTCATCATGGTAATAAATAC
AGGCAATAGGCAACCTAATGGTGAGTAAAGTCAGTTTTTTCCATTAAAAGAGAAAAATTAATTTCATTTC
CAGAACATTTTGTATTGTGGAATTTCAGATATAAGTCTGTGGACTGATACTATTTTCCTACGTTTTAGTG
TTTTAGTTTTCTCCTGTTTAAAATATTCTAGGCAGTGGGTTCTTTGAGGTAAGTTCATTCATTTAACTGT
AATAAGGACACAGCACATAGGTAAAGCCTCCCTCTCATTATCCCTTAAGTTTTCTGTTCTTCATCAGAGA
TTACATCTCATGATCTTCTCTAACTCCTAAATATTTATCCTACAAATGTTTTCATCTTGCTTGCATTTTG
CATTCAAACATCGATTCATTCTTTTCTGCTTATAGCTGACTCAGTCATGAAACCCATTTCACTCACATAA
ATTTGCATTAGGAAAACAAAATCACAAACAAACACAACAAAACAAAAACAAACAAAAAAAAACTCAATCA
AGTCACAAATTTACCAGGAGTTTGGGGAAGACATAGGCACTGACTTGTGGCAAGGCAGACAACTCAAAAT
TTAACACTAGACATCGCAGCTCCTAAAAGGCCTGTGACACCTTAACATGTAGAAAAACTTTCCTCTCTTT
TGTAATCCTTTCTCCTTGACTTGTTCTTTTTTTTTCCTTTTTGTCATTGTTTTACACCCCAACTTTTATT
ATTGTACTGTGCAGAGTGGTTTTACTGTTTCATTCATTTCCCTGTTTTATTCAAAACCATAATCTCAGGG
TCTTACATCCAGAATCAATTGAAGCAAGGCAAGTCTCATCCTAAAGATGAATTCTGTTTTCCAGCTATGA
AAATAGAAATTAGGTTTATTCTTCTATGGTAATATTCATGATTAACTTTTTAAAGTAATCACCGTATCCA
AAACACCATGTCAAACACTTTGTATGGCATTAATTCACTCAATTCTAATAACTATCCCCTGAGGAAGATT
GTATTTATTATTCCCACTTTTAAGGGAGGAAACATTATCAGAGATATTCATCTTTTGGTTATTGATTCCC
ATTGAAAAGTGGTGGAGATAATCTGCCCCCAGCTTTATCAAGTACCAAAGTCCAAGTTCTTTCCATTGCA
CTCTGATAATCAACAGTGGGTTGAGAGTTTCTTTAAAGTGGACAATACCAGTTTGGTCTTTTGACATAAG
AAGGCAAGACATAATGCCAGGTAATCTCAGAGCCTATATAACAAATCTAAGGTACACAATTTCAAAGTCA
CCATCTGGGAGGATTGGGTGACCCACTGGACTCTTCAGGGATTAACAACAGTACTCAGAATGCTGATATT
AATGACATTGCAAAGCGAAGCTACATCTTTAAGGAAACTGGAGCATTTTGCTGTTTTTTCAGCCATAAGT
GACAAAGCATATATTTTATTATTAAGAAGCATGGGTTAGTTGCAGAAATAAGGCAGGGGAACATCACTCG
TCTAGGGTCTCAAGTCAAAGAAAAAAAGTGGCTCAAGATGTGTCAACTCAGCCAGTGGTTTTCAAGTGAG
AGTCTAATACACACAGGTGAGGAGGGAACAGCAGATTTACTACAAATAATTTGCTACTACAAATAATTTA
TGTTTGTAAATTATTTTTTCCCATAATTTATTCTCATTCTTACACACTTTAGTAGGCAAAGTGTGTGAGA
AGCAAACAGATGCAACATAGCATATTGTCTGGCACACAGTCGTTCGGTAAGTATCTGATAACCGAGTATG
TAAATAATAGCTAGAATCTTTCAAATTGCATCTAAACCACCACTTACCTTATCCATGCCTGTTGTATGAA
GTCCATGTCATGAGAGAAAATGTGAGAAACCATTAAGCTCAGCTGCTAAGAAGAACTTTTCTTTACCAGG
TACACATTTTAAAATTATTTTTTCTTAAATTTGTATTCAGCAATAATTTTAAGCTTACAGAGATGTTGTG
AAAATAAAAGCAATACAAAAAACATGAATATATATTTTACCCAAACTTACTTACATTGTATCCTGTTTCT
CTCTCTCTCTCTCCCAGTCTGAGCCATTTTAAGGGTAAATTGCATAGACTGTAACTCTTTACCCCTGAAT
ATTTTAGTGTGTATTTCCTAAGAATAGGAATAGACTCATATAGCCACAGAACAGTTTTCAACTTCAGTAA
ACTCTATATTGATATAATGCTTTTATCAAATCTACTGTATATCAGTTTTTAAAATTAGATATAATAATAT
CCTCAGTATTTTTCCTCTCCAAAATAGAATCTAGTCTAGGATCAAATAGCATTTAGTTTTCATGGTTCTT
TAGTCTGAAATATTTCCATAACCTTGTACATATGTGTCTTTATGTGCTTGACAGCTCTGGAGGATATAGT
TCCTCCTCTTCCTCCTCATTTTTTTAATAGAACATTCTTCATTTTGAGTGTATCTAATATTTCTTCATGA
CTAGATCCAGGTAATGCACTATTAGCCAAAATTCCACATAGGTGATTATGCATCTTTCTGAGATGGTGTC
ACATCTGGAGGCACATCATGACCATCTGTCTCACGTTGGTGATGTTAATCACCTACTCCAGATGTGGTCC
AATTTTCCCACTGTATAATTATTTCTTCCCCTTGTTTAATAAACTGTCTACATGGAGACATTTTAAGACT
ATGCAAATACCTCACCTCTTATCACAATTTCTTCTACAGTTGGCATCGTCGATGGTTACAAATTTATGAT
TTTTCAACTTCAGCACTGCTTTTAAATTTATTAGCCAATATTCAGGATTCTACTATTAGCAAAAATCCTC
CATTTTTTCTATCTATCTATCTATCTATCTATCTATCTATCATCTATCTATATTAATGGTATGGAGTAAA
GGCTTTCCATTGTTTGATAGTGTATAACTCATTGATGTGCTTAATTATCTTTGTGTTCCAATGGTTCCAG
AATTTGCCCATGGTACACCTTCAAGCTGGTTCTTATGTCTCCATTTCATATACACATTTTTTAAAACACA
CATTCTCTCTGGTAAGCAAATTATTCTAGAGCATCTTGTACCTACAATGCTCCAGGCCTGAAATTAGCCA
TGACTCCAAGGAGTAATGTTTTCTTTCATTGGGAAGGAAACTCAAGATCAAGATTCGGAAGCAAGTTTTC
CTCACCAGAGAGACACATTTTATCTCACATCATGAATAGGACAGGGATGTGGGGTGTCTTGGTCTATAAG
GAGTACACAAGTGAATATAGCAGTGAGGACAGTAGGACTTGAGAGGAGAGCAAATGTCAAAATTATACTC
TGCTCTCTCAATAAATGCATATGAAATGGAATTGTTACTTTTGATTATACCTCAAAGTTATTGCTTCCTT
TTCTTTCTTGGTCTCGTGAGAAGTGTATAATGCACTTCCCATGGAACAAAATATTCATAGTCATTGCTAG
GACAAAGGAACTGTTTTATTTTTGTCTACTGAAGTTATTTAAGTAAACTCAGCTTTCCTCTTAGATTTCA
TTGCTGAAATAGTGAAGATGTGTAATTTGTGAATTGTGTAAGAGAGACCACATGGCCGGGTGTGGTGGCT
CACGCCTGTAAACCCAGCAATTTGGAAGTCCAAGGCAGGTGGATCACCTGAGGTCAGGAGCTTGAGACCA
GCCTGGCCAACATAGAGAAACCCCGTTTCTACTAAAAATACAAAAATTAGCCAGGCATGGTGGCACATGT
CTGTAATCCCAGCTACTTGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGGCAGAGGCTGCAGTG
AGCCTAGATCATGCCACTGCACTCCAGCCTGAGTGAGACTCTTCCCATAAATAAATAAATAAATAAATAA
AAATAAAATAAAAACCTCATGTTTCTAGATAAAGCAAAGAAAAATAAGTCTGTATTATAAGAAGTTTTCT
GATTAGGTTAAATAGGGGACCCTGTGCAGTGTCAGTTGTCACATTAAAACAGAAATTTTCTCTCATGAAA
CTCTCTATCCATTATGTCCTGTATTTCAGAGTTTACAAGAGATTTTTTGTTTACTTTTTCTTTTATTTAT
TTTTTTAATAGCACTGTTGGAGAATGGGACATGGGGACTGAAATTTCAATGAATTGGTTAAAAGTAATCA
AACTGACTAGGATTACATCCTAGCTCAACCACTTCCTAGATGTGTGACCTTGGGTATGTTATTTAACTTC
TCATATGTAAAATGTGGATAACAATAATAATGTATAAGATTCAAAGAATTAAATGATGCAATACATGTAA
GGTAGTTAGAACATTTTTTCAACAAAGGGCACAACAGTATTGTGTTAAGCTGTGGTTAGTTACTGACAAC
TTAGCAATCATTAACTTCTCTGGCAATTAGCTTAACAAAGTAAGTTTACAGTGAGTCCTGAGAAAATATA
TTATAATGGCCTACATTTAGTGGAAAAATAAGGGAAAGGGGAGGATGGAAAATTCATGAAGATAGAACCA
AAAATAAATAATGTTTCTGGAGACAGATAGGATTTCAGGACAAGTTTCAAAAATGAGGTGACAGCAGGAA
CAAAGGTATCTTCTGTTACCCAAAAGGGAAAAAGGAGACAGGAACAAGGAACAACTTCTTGGCGTTTAAT
GGTGTGTTTCCAATTCTGAGCACAGTGGCTGCCTATAGTAGGTGCTCATTAAGTATTGGCTGACAGACTG
ATAAATCAATAAATAAAAGAAAACTACCTTCATTGTAAAACTTACATATACCAAGAATAGTGTAAAATCA
AATTAATCATAGGTAGGACCAAGTCAATCTTGGTTGATCATATATTGTTTCAAACCACCCCCTTCTAACA
AATGCAGTTTATGACTATGGAAACTTACTATTGGAGGAGACTTCTCAGTATATTCAGTCCGACATCCCAC
ACTATGCTAAGATGCCCATTGGGATAACACCACCATGTGACCCATCAAGGGAAAACCTACCCCACAAGGG
AAAACATGAAGTTCTTTAGGCTAAACCAAAATCTAATTCCATTCGACTTAAATAGAGCCATCCATGAACC
TGGTATTATGGTATACTATGGAAGTACAAAAAAATACAAAGATGACTTACACAGCTTATCTTACTGAAAA
GCTCACCATCAAGTGAAGAAACTCCACGTAAATACATAAAATGGTAATTGATATAAAATGAGGTAGGAAC
CCAGATACACCAGAAATATTTCCTAAGGAGGTGAAAATAGAATTGGATCTTGAAATATCAGTAACTGCTC
ACTGAGCAGAGAAGAGGAGGAGAGGCATTTCCAGCAGAGGGAACAACATATGCAATGACACAGAGGTGTG
AAAGTGTGAGATGAGTTACCAAAAAATGAGAAGTTCTACGTGGCTAGAATATTGAGTTTGTAGTGGGAAA
TAACAAGAGATGTAAGGAGTTTAGAAAAATCCGTGTATACCAGTGTCTCTCAATCTTCTTGAAGGAAAAA
AACACATTATAGGCCTCTAGGAATATGTTCACAAATCCCTACAGAATTAAGAAACTGAAGTTTATTCTAA
GATTCTTTCAAATCTTCACTTTTAAAGAGTTATAAATTCATTCGTAATACATTAAATGTTAGCTGTCATC
ACCATAAAAACCCAATGTTTAAAAACCATAACATTCTTATCTTCAAAAGTATGTCTGAAAAATTTGCCTT
GAAAACATGCCATTGACAAGGGTAGTTGTGATAGGTTATTAAACAAGGAATTGATATTATCCTACCTATA
CTTCAAAAGATATGATGTTAGTGGCATTAGTAGAATGCAGAAAGATAATCAGTGAGCTATTGGGGGGAGT
CATGGATGAGAGCTTGATCTAAAGTAGTGAGAATGAGGATGAAGATGAGTTGGTTAGTATACAGAATCAG
AAGCTCTCGGTGACTGACTGTAAGGCAGCAAGGAAAGCAACAAGTTCAGGATGATTCTGACACATCTGTG
ATTGATTTCTAACAATTGGTCCTTGTTTTTGTCCTAGTAAGCTATACGTCATTTTAAAAATGTAATTTCT
CTTCATATAACAGCACTTATAAAGCTGATATTATGCTTCCTTCTCTAGAACCTTAACTTTTTTTCTGCAG
CCCTTCAGCTCTTTTTGTTTCAATGTCACTATCAAACACTTCACTAGGAACTATTTCACCACTTCACATG
CAAGGACTTTTTAAGGAGCAATCTACAGAGTGGTAAATGAGCTGTGGGCTTTAATGAGAAACAAGGGAAG
TTTTGAAATTTTTAATGACATTTAAACAAGAATAGTGTGTGTATTTGCAGAGAAAAGCCAGCTGGAAAAC
TACAATGAAGCCTCCATAGGTAATCTAGTTTTCAGTCTTCCTGCCTGAGAAATGGACTTCCTTAGTTCAT
GCAACAACAACAACAAAAAAAAAGGTCACACAGATTCAAAAAATAAATTCATTTGACACTAATTGTATAA
ACTAGATAGCCAAGGAGATAGTTAACATGGAGTGACGCATTCTAGTAATTGGAAGGCTAAACTATTTCCC
TAGTATCTTCCTCACTAATTCTGAGGGAATCAGAAACTCAGTAGTTTGGTGTACCCTGACTCCGAGAGAG
GCAGAAGGTTTTGAAAGATGATTGCCAGACCAGGAAAACCTTTCCGGGCCTGTTTTAATTAATCCCCCAG
ATTTACCACCTTGATAACCACATTGGTATTCTGATCAGGCAATAATCCTGATAATAACAATAAGAATTCC
TATGTGCCAGACATTAATACTCCTCACATGTTATCTTATTTAGTCCTCACAACAGTCCTAGGACATTTCA
TTGATTAAACTAAAGCACCATTCTCAGCAAAGTAATTATTCTAATAAATTTAGGAGACAGTCTCTGTCCT
TACATTATAAGCTCATTCCACTCATTTTACTCAAAAGGTAACTTTTTTCTCATATATATATATATATTTT
TATACTTTAAGTTCTAGGGTACATGTGCACAACATGCAGGTTTGTTACATATGTATACATGTGCCATGTT
GGTGTGTGCTGCACCCATTAACTCATCATTTACCTTAGGTATATCTCCTAATGCTATCCCTTCCCCTTAC
CCCTACCCCATGACAGGCCCCGGTGTGTAATGTTCCCCACCCTGTGTCCAAGCGTTCTCATTGTTCAGTT
CCCACCTATGAGTGAGAACATGCGGTGTTTGGTTTTTTGTCCTTGTGATAGTTTGCTGAGAATGATGGTT
TCCAGCTTCATCCATGTCCCTAAAAAGGACATGAACTCATCCTTTTTTATGGCTGCATGGTATTCCATGG
TGTATATGTGCCACATTTTCTTAATCCAGTCTATCATTGTTGTACATTTGGGTTGGTTCCAAGTCTTTGC
TATTGTGAATAGTGCCGCAATAAACATATGTGTGCGTCTTTATAGCAGCACGATTTATAATCCTTTGGGT
ATATACCCAGTAATGGGATGGCTGAGTCAAATGGTATTTCTAGTTCTAGATCCCTGAGGAATCTAGTTGT
ACTGGCATATGCAATTTATTGTTCATGCCAAATATGAATATTGACAAAGTAAAGTGAATTTATGTAAGCC
TTGTGTCATCTTCACTCTGAATTAAAAGGTGCAGGTATTATCTTATGGCAAGTACTGTCTTAGGAAGATT
CACTGGAAAGAGAGAAAGAGAGAAACTTCCCAGATTAGTGCAGAGTCCTTTAGGGTCAATGAAAACACTG
ATATTGAAGACATATAGAACTGGATTTCAGTATCAGTTCTAAAATTCTGGGCATCTACTTCCTCATTTAT
AAAATTTCTTCAATAATTACATGCTCAGGTTATCATGAGAATTTATGTACATCTAGCTCCTATTACATAC
ACAAAAAATGTTTCCCTTTTTCTCCTGCCACCTTCTCTGTAATCTTCAATAGTCTTCTCAACTTCTCTTA
TAATTTAGCATAGGCTGTCAGTCTTCATGATGTGTATTTATCCAAGCTAAAGAGCTTTTGTTTAATTTTT
CATGATTTGAACTCACTGCTGTGGAAAATGGCTATTTAAAAGGGATAATGTCATTTTCCAAGAATTCAAT
TGAGGGTCCTAGAAGATCTTTATGGAGCAAAATAATAATACACCTTTTCTAAGTATAGAGTCAGGCATTA
AGACATATAGACATTTCACTTCCTTGGGATAAGTCTTGGGAAAAATATCACTACACATTAGCAATACATA
TTGCAAATAAAATTTATAACTCTATTTTATGCATTTATTAAACAAATACGAGTTAAAAGACTTCAGGAGT
TTTGGTCTGTAGCCCAGGCTGGAATGCAACGGTGCAATCTTGGCTCACTGAAACCTCTGCCTCCCGGGTT
CAAAGGATTCTCAAGCCACAGTCTCCCGAGTATCTGGGACTATAGGTGTGTGCCACCATGCCTCGCTAAT
TTTTTTGTATTTTTAGTAGAGATGGGATTTCTCCATATTGGCTGGGCTGGTCTCAAACTCCTGACCTCAA
GAGATCCACCACCTTAGCCTCCCAAAATGCTGGGATTACAGGCTTGAGCCACCACACCTGGCCTAACTTC
AAGGTATCAAAGACAAATTAACAATGTCTGATGCATACATAGGACTGCTTTGTAATCTTCTACACTAATG
ATTTGTACTATTTTGGTTTCAGAATCCATTTATAACTCTTACAATATATGAAAAATTTCTGCCAGCTTTT
ATTTATGTGGGTTATATTTATGACTACTTCTCATTTGTAAAACTGAAATAAAAAGATCTTGCATATTTGT
ATTAATTTATTTAAAAAATTAATTTGTTATGTGATAGTATAAATAATATAATTTTAATATTTCAAAAATA
CTAAGTGGAATGAGATTACTTTATATTTTTTAAAAACACACTACATCTGACTACTTCTACATTCAATATA
TTATAATTTATTGTTTGGTTGAAGAACTTGATGAAAATCTAGCCTCACACAACTATGTAATCAGAATAGA
GAGAAGTATTTTTAAAAACATTTTCAGATAATTGTAGATCCTTTCTTTTTGATACTAAAACTTCACAAAT
GGTAATTTCCTCAGAGTTTAATTACACTGTCAAATCTGAAATCATATCAATGAACTTTTTGTCCTTGCTA
CATTAAAGTCCATTGATCTGTCTAGCATCATGAATGAGTATTTTACCCATTAGTGATTTTATAATAGCAT
GCATTGGTCATTTGTAAAATACTCAGTTAAGTGATCTTCCAAATGTTAAAATATCTCATTATACAATATT
CAAAATCACATTATTAATATCACCACCAATCTCATCAGAAATATCTTTAAGTATGAAGACATTGACAAGC
TCATAATGATGTTATCAATTTTTCTTAATTTAAATTTTTGCTTGAAAACTCAAATTGTAGCATTGGCAAA
AAAGAAAAAAAATACCATTAGCTTTTTTTTTCTGTTTAAGTGACAGACTTGCTTTGTTCACATAAGAAGT
CTGCCAAATGCCTGTCTAAATAGCCAGTTTATCTCTGAATCCTACATTCAAGTGAAAATGATTTCCTGTG
GGAAACATGATTATTTCAGCTCTCAACACAAATAATGGCACAAATGTTTTTTCCCTAGACGAACATATTT
CAGAATGCAGCATAAATAGTGCATATGTAGGTTCCATTTTGTGAAACAGAAAATTAAAAAGGCATGTAAA
AAAAGATAGTTTAAAAAATTGTTTTGCTTCATTATGGACATTAAGTGAAACTTGCATTTATTCATTTTTA
CTGCAAGTCTGTGGCTGGTGAAGAATATAATAATTACAGTACACTTGGTTGCCACTACCTTGATTTGTGC
TAAGACACCAGAAGATTTGCCCACCATTGCTTTTGCACCATCAGTGCAAATGTGAACACAGAAAAAGGCA
AAATCACATCATAGTATCATTAGGAAAATAGTTTTGACATTGCAAATCCTCTGAAAGAGTTTCAGGGACT
TCAAGGGGTCTGTTGGCCCCATTTTGTTAAGCAATAAAATATTGGGATTGTAGAATAATTTCTTTTTTAA
AAATAAGGGCATCTGGGAAGACCTTATTAATTTCAAATACAATTCTGCATTTTCAGGATGAAATGTCAAA
GAATGTTGATATCTAAAGGCACATTTGCGAAATCCAAAAAGACATGGTGGCTAACAACGTACATTATCAG
GCCTTTCCTCTAGAGATTTTGGTTCAGTAGGTCTGGCAGTGGAAGTGGGGGTGTTTATGACCTCCAGTGA
GCCACAGTGACTTATATAATAATGTTATATATATATGTGTGTGTGTGGAGATATAGATATATCACATAAT
TATTTGTATTTATATATTAAACCTTATTATCAATACAAAGAGCACACACCCACACACTTATTTTTGTGGG
GGCAGGGTAAAAGGTGTTTTCCTGCAATGGTACATTAGTCACCTTGCTTCTCTCTCTGGTGGCTGTTGAG
GTTGTCTACAGTGGATTGGGTGCATCCTGAGGGCCCTCAACAGAATGAGGTCCACACACAACCTTCTAGT
ATTTGGAAAGTTGAGGGACAGCATGAAAATTGCACAGTAAAAGCACACACTGTTGAGCTATGAAAATGAA
GCAGTTTTTTTTTTATAGTAAATAGTAGGTCATTGTGTTTCCCAAACGTGATCTAATTGGCTATTACAAA
TTATCTGGCACATATATTGATTCCAGATGTGATTAGTGTTCACTTGGTTTTAGGGTTTTACATATACGCC
AATTTGGCAGTCCTAACGTGTTGATGTTGATAATGTTTCATGGCCAAAACTAGAATATATTTTCATAATA
CACACACACACACACACACACACACACTGTATAGCTGGATCCTAGGAAACTTTAATTTTAGTAAATGCCT
CAGATGATTTTTATGATCAGGCATACAGGGCAGCTCTGCTCTATAGCTGGTTACTATATTCACATTTCTT
TTCTTAAGATGTAATAATTAATGGAGGGGGAGCAGATTTTATAATCAACTGTAGAAATATGGTTATAAAA
ACTCGTTATTTCATGGCTTATACTTCTCTTCATTGCAAGCTCCTCTTACCTCAAGGACAGAAAAAAATGA
TGCTGTTTCTATGAAAAGATTTTTCTGTTTAGTAAAATCTCTAGTGTAAAAGGAGTGGCCTGTTTTCAAT
TTGCAAGTCTGATCATTAGCCTTTGATTCATATAACATAAATAGACTTCTTTGATATCTAAAAAGCTTGG
CTATATTAAAGTAAGAAAGTAATAGATACTTGCATTTCCACATTACAAGTGAGCAACAGAGAAAACAAAA
TTAGTACTTGTTGAGCACCTGATACCTTGTACATTTTCAAATAAATCACTTGAAATTTGCAATTACACCA
TGAGACAGGTTTTCCCTTGATTTTACGGATAGGGAACCTGATAGTCACATGGTTGATAACAACCATAGTT
AAGTCTACTATTCCAAATTCATCTGACTCCAAGGCTGATACAAATTCCACTTCACTACAAAGCCTTCTTC
AGCCTGCTAAAGTAAAGCTGGGGACTCTGATAAACTCCCAACCCTGCCTCTGGTATATGACCCAACACTA
ACCACTCTGCTCAGAGTAGGTATCTAAAAGAAATTCTTGTGTGAAACAATGAAATTTTGGTGGGAAAACA
GAAACATGATTGTCAATAACAAAAGTATACAACACAGACTTCTACTTCTGGGAAGGTAAAGTAGGTACAC
TTTTCTCTATTAGTCCCTCTAAATACAACCACAATCTCTGGACATGGCATATAAAAGAAACAGAAAGAAT
GTAAATAGTGAAGAGAAGAAGCCAGGTCAGCTAGGAATATTGGGATCTCACGGTATGATGGTGAGTCCCC
TGGGTTTTATTTTCCTCATATATTCAAGATTTGGAGCTGAAGAAGCTTGTAACCTAGAAACACCCAGAGG
TACAAACAAAAGTAAAACAAAACAAAACAGAAAGAAAAAAACACCAACAAAAGCCTTCTCTCTCTAGTCA
AATGACAAAGAAAGGTGCAGAAAAGTTTTAAACAGTAACTACTCTATTTCATTCAAATTCAAAAACAGAA
AAACTGAGGCACAATCCCCACCCAAGTCAGCAAAAGTTGACTGGGGAGACTAGACTTCTACCCTTACTAG
GCTATAACAAGGTGCCTCCTCAATTCCCTTCCAGGGTGATGTAAGAGAAGGCTCAGTTTGCATTCCAACC
AGGGAGGAATTAACCACTCTTCCTACTTTACATGGAGGCAATGTGGAGGACCTGCAATTCTATCCCCACC
AGGCAGTAAAAAGAGGAATCCTTTCTTCCCTTCTGGATTGTTGTCAGAGGAGGCCTACTGGATAGTTAGG
TCTTCTAGCACTGTCTAGTGGTAATTAGGCCACCCAATCCATGGCATTAGGGGAAAGTAGTTGAGGAGCA
GTAATGAGGGGTATTCTTACCTCTCCTAGCAAGGAAGACATCAGTAGAGGCCTAGTGGGGAGCCAGGTCG
GTGGGGAACTTGGACTTCTATTGCTACTTAAAAGTAATAATGCAGTGTTTCCCTTCTGCTGGAGCTGAGT
CAGAGAAAGCCAGGAGATTATACATTTTTTTTTTTTTGAGATGGAGTCTTTGCTGTGTTGTCCAGGCTGG
TGTAAAGTAGCGTGATCTCAGCCCACTGCAACCTCCACCTCCCAGAGTAGCTGGGATTCCCCTGCCTCAG
TTTCCCGAGTAGCTCAGATTGCAGGTGCCCACCAACAAGCCCGGCTAATTTTTTTTATATTTTTAGTAGA
GACAGGATTTCACTATGTTGGTCTGGCTAGCTCCCAACTCCTAGCTTCAAGTGATCCACCCACTTTGGCC
TCCCAAAGTACTGGGATTACAGGTGTGAGCCACTGCGCCCAGCTGAGATTATAAACTTTTATAAAACAGA
AGATTTAATAAGATCTGTAGTCTCATAAAATACCCAAAATGTCCAGGTTGAAAACAGAAAATAATCCCTT
ATCATACTAAGAAAAGTTACATCCTTGAATTAAAAAAAAAAAAAAGACAGCAGACGTTAACACTGAAGTA
ACAGATATGTTAAAATTATCTCAAATAATAGGTTGAAGCAAAAGTAATTGTGGTTTTTGCCATTGAACAG
AATGGTGAAAACCGCAATTACGTTTGTACCAAGTTAATAGATTTAAAACACTCATTTTTGAATTCCTCAA
TGAATAATTATAAACATAGTTGAAACAAATGAAAAAAATAGAATGACTTCGCAAGAAAATGGAAGATATC
ACAAAGAACAAAACAAAATTAGAACTAAAAAATACAGTTACCAAAGTAAAAGTCTCAATACTAGGTTCAA
CAGCAGAATGGAGAGGAAAGAAGAAAGAATAAGTGAACTGGAAGATAGAAAAATAGAAATTACCAAATCT
GAAAAACAGAAAACACACTGGAAAAAAAATTAAAAAGGCTCAAAGAGTTGAATAACTACATGAAAATGAT
TGAACTTTTGTGTTATTAGTGTCCTAGAAAGAGGGGAGAAAAATCAGTTCTAAGAACTCAATGAAATAGT
GACTGAAAACTTCCCAAATTTAGCAAAAGAAACTACAAATTAAAGAATCAGAGTTAAACCCAATTTAATA
AATCCCATAGCAATCCACATCAAAATATATCACTATTAAACTTCTAAAAACTAAAACAAATATTCAAAGT
AGTGAGAAATTAATTATATCTTATCTATTGTGGAAAAAAATGAATGACAGATCTTTCCTTTGACACTATG
GAGGCCAGAAGGTGGCACTGCATTTTTCAAATGCTGAAAAAAATGAACTGTTAACCCAGTGTTCTATGCC
CAGGGAAAATACTCAGGAATGAAGGAGAACTCAAGGTCTCCTCAGATGAAGTAAAATGAAAAGATTTTGT
CACCACCAAGCAGACCTGCCCTGAAAAAAAAATGGTTAATAGAAGTTTCTTAAGAAGAAGGGAAATGATA
AAATAAACTTTCTTAAGCAAAAATATAGGGAATTCAACAGACTTCTGTTGAGTTTTCTAAATTGTGATTT
AATGGTTGAAACAAAAATAAAATTTTATGTCATTCATCTAAATGAACATAAGATAAATATTTAAGACAAA
TAAGGTTTTACACTTAATTTGAACTAGTTGAAGGATGATGCCAGCAGAGATAAATTATGTAAAAATAATG
TAATACTTAGATAAATCACCAATAAAGTGATACAAAGAAATACATTCAAAAAACTTGATAAATAAAAATG
GAATTTGTAAACATTTTCAAGCAACTCAAATGAAGACAGGAAAAATGAACCAAAAAATTCAGAAAAGTAA
CAAACAGGAAAAAAATAGGTTTAAGCCATAACATTATATAATACTTATATTAAATGTGAATAGTCTAAAA
ATACCAATTAAGAGATTGGGAGACTAGATTTTATTTAAAAATGACCTATATTGAGCCTAGAGGAAATTCA
CTTTAGATATAACAATATTTGTGAAAGTTAAAGGATGGAAAAAATCATAAAACATTAATCAAAACAAAGT
TAAAGTGGCTATATTAATATCTAATAAAATAGACTTCAGAGCAAAAACAATTATTGGAGTAAGAGAGGCA
CATTTTATCAAGATTAATGAGTCAATCCAGTAAGAAGACATCACAATCCTAAATGTGTATGCACCAAACA
AGCTTAAAATTTGTGAAGCAAAAGCTGGTAGAGCTAAAAGGAAGAAATAGACAAATTCACAATTACAGTT
GGAGAATTCAATACTGCTGTTTAACCAACAGGACTAGGCAAAACATCTGCAGTGATAAAGAACTTAACAC
CATCAGCCAGAAGAATCTAATCAACATTGATAGAACATTCCATTCAATAACAACAACAAAAAATATTTAT
TTGAAGTGCTGATAAAACATATGCTAAACATATGACTGCCCCTTGAGCCATAAAGCAAATATCAACAAAT
TTAAAAAGATTGGAATTATACAGACTGTGTTCTCCTACCCCAATGGAATCAAACTAGAAATCAATAACAT
GAGGGAAAGATCTTCAAACACTTAGAAACTAAACAAAGCACTTCTAAATAACCCAAGGAGTAAAGAGAAA
GACTTAAGGAAAATAAAATACATTTAAATAAATAAAATTAAAAACCAAACTTACCAAAATTTGTCAGACA
TACTATAAAATTGTGCTGAGAGGGGGAAGTATAGTACTAAATGCACACATGTGGAAAGAGGTAAAGTCTC
AAGTCAGTAATACAAACTCAAACTCCAGAACCTAGAAATAGAAGAGCAAAATAAAACCAAAGCACAGAGA
ATGAAGGAAATAATAAAGATAGGAGCAGAAAGCAGTGAAATTAAAAACAGGAATCAATACAGGATATGAA
TATAACAAGCAGCTGGTTTTTGGGAAATATTAATAAAATTGACGAATTAGCAAGATTGAAAAGGGAAAAA
GAGAAAAGACACAAATTACCAATATCAAGAATCAAAAAAGGGATATCAATACAGATCTTGCAGACATCAA
AAGGGTAATAAAAGCGTACTATGAGCACTCTATGTACATAACATTTGACAACTTAGATGAAATGAACTAA
TTCCTAAAAAAGCGCAAACTATACCACTCACCCAATAAGAAATAGACAACTTGAATAGCCCTATAAATGT
AAAGGAAATTGAATTGGTAATTTTAAAACTACCAAAATAGAAATCCTAAGGAATAGAATGTTTTCCTTGA
GAATCAACCAGGAATTTAACAAATTAACATAAATTCTATACAATCTGTTCCAGAATGTAGAAGGGAACAT
TTCTGAGTCATTTTATAAATCCAGTATTACCTTAATATTGAAACCAGATAAAAGGATGCCAAGAAAATGA
GACAGATCAATATCCCTCATGTACATATATGTAAAAATTCTTAAAATATTGACGAATATAATTCAGCTGC
ATATAAAAAGAATTTTATGCATTGAAACAAATGAAATTTATTCCAAAAATACCAAACTGCTTCAATATGT
AAATATTCTGTATCTTGACCCTTTCAATACCAATATCCTAGCTGTGATATTCTACTATATTACATAATAT
TTTTTCAAGGTTACCATTGAGGGAAATTGAATAAGGAGCACATCAGATTTCTCTCTATTATTTCTTACAG
CTGCATATAATTCTATAATTAACTCAAAATAAAAAGTTTTTAAGGCCAGGGGCGGTGGCTCACGCCTGTA
ATCCCAGCACTTTGGGAGGCCAAGGCGGGGGGATCACGAAGTCAGGAGATCAAGACCATCCTGGCTAACA
CAGTGAAATCCCGTCTCTACTAAAAATACAAAAAAAATTAGCCAGATGTGGTGGCGGGCACCTGTAGTAC
TAGCTACTCGGGAGGCTGAGGCAGGAGAATGGTGTGAATCCAGGAGGCGGAGCCTGCAGTGAGTGGAGAT
CGCGCCATGGCACTCCAGCCTGGGCAACAGAGCAAGACTCCGTCTCAAGAAAAGAAAAAAAGTTTTTAAA
AAGACAAAGTTCTTTAAGGCAAATATTTGAAATTTACATTTAAATAGATAGATGAGATAAAAGACGTATT
AGGAACCCTATTTCAGTCAAGCAAGGAGCAATACTTACTTTTATTTATTGACCTTTCTTGATGCATAAAC
ATCAAGAGAACCAATGTGTAACATCATCCAAGATAATATCAACAGTTATCAATATATGTGAGAAAAGACT
TAGGGAGGACTTCCAATATATATTTTATTCTAAATTTTACATTATACAAACAGCTATTATCACTTTGTTT
TCTGCCAATTTGAGATGAATAATTATTGTGCCAGAGAATAAAATAATTGCTCAGTGAGTATGCAATTCAT
CTGAATCTATGGATCATTTACAGAGAATCTCCTTAAAATATGCATCATAATTTTAATCACTAACATATAC
CCAAATCCCTAATTTTGTAAGTACTTCTAAAACATATCTAATGATCTTTGTAATCATTCTTCTTAGACGT
ATTTACTTTGTTTTTATTTATCCACCAGCATTAGCAATTGCTTATTTTTGTTGCTTACTTTATAAAGAAA
GATTTTCCATATCAATCAATTTTTATGGCCACTATTTATGTTATTGTAAAGTAAGAACAAAGGTAAGACC
TTTTGCTCAACTTTCAGTTGAGTTTAAATCCTTGCTTTGGGAGAGCTTCCAAGATGACTGAACAGGAAGA
GCTCTGGTCTACATCTCCCAGGGAGATCAATGCAGAAGATGGGTGATTTCTGCATTTCCAACTGAGGTAT
CTGATTCATCTCATTGGGACTGGTCGGACAGTGGGTGCAGCCCACAGAAGGTGAACCAAAGCAGGATGGG
GGGTCACCTCATCTGGGAAGCACAAGGGGTTGGGGGATTTCCCTTTCCTAGCCCAAGGAAGCTGTGAGTG
ACTGTACCTGGAGGAACAGTACACTCTTGCCCAAATACTATGTTTTTCCCATGCTCTTTGCAACCAGCAG
ACCAGGAGATTCCCTCCCATGCCTGGCTCAGCAGGTCCTGTGCCCACAGAGCCTTGTTCACTGCTAGTGC
AGCAGTCTGAGATAGACCTGGCATGCTGGAGCTTGGCAGGGAGAGGGGCATCCACCATTGCTGAGGCTTG
AGTAGGCGATTCTATGCTCACAGTGTAAACAAAGCAGCAGGGAAACTAGAACTGGGTGGAGCCCACTGCA
GCTCAGCAAGGCCTACTGCCTCTTTAGATTCCACCTCTGGGGGCAGGGCATATCTGAACAAAAGGCATCA
GACAGCTTATGCAGAATTAAACGTCCTTGTCTGACAGCTCTGAAGAGAGCAGTGGCTCTTGGAGCACAGC
GTTCGAGCTCCGATAATGGACAGACGGCCTCCTCAAGTGGGTCCCTGACCCCGTGTAGCCTGACTGGGAG
ACACTACCCAGTAGAGGCCGACAGCTGCCTCATACAGGCAGGTGCCCCTCTGGGACGAAGCTTCCAGAGG
AAGGATCGGGCAGCAATATTTGCTGTTCTGCAGGCTCCATTGGTGATACCCAGGCAAACAGGGTCTGGAG
CGGACCTCAAGCAAACTCCAACAGACCTGCAGCTCAGGGGCCTGTCTGTTACAAGGAAAACTAACTAACA
GAAAGGAATACCATCAACATCAAACAAACAGGACATCCAAAGCAAAACCCCATTTTTAGGTCACATACAT
CAAAGACCAAAGGTAGATAAAACCACAAAGATGGGGAGAAACCAGAGTAGAAAGACTGAAAATTCCAAAA
ACCAGAATGCCTCTTCTCCTCCAAAGGAACACAGCTCCTCATCAGCAAGGCAACAAAACTGGATGGAGAA
TGAGTTTGACAAGTTGACTGAAGTAGGCTTCAGAAGGTGGGTAATAACAAACATCTCCGAGCTAAAAGGG
GATGTTTAAACCCATCGCAAGAAAGCTAAAAACTTTGAAAAAAGGTTAGATGAATGGCTAACTAGAATAA
CCAGTGTAGAGAAGAGCTTAAATGACCTGCTGGAGCTGAAAACCACAGTACGAGAACTTCATGAAACATA
TGCAAGCTTCAATAGCAGATTCAATCAAGAGGAAGAAAGGATTGAAGATCAAATTAATGAAATAAAGTAA
GAAATAAAGTAAGAAGACAAGATTAGAGAAAAAAGAATGAAAAGAAACAAAGCCTCCAATAAATATGGGA
CTATTTGAAAAGACCAAACCTACATTTGATTCGTGTACCTGAAAGTGATGACGAGAATGACCAAGTTACA
AAACACTCTTCAGGATATTATCCAGGAGAACTTCCCCAACCTAGCAAGGCAGGCCAACATTCAAATTCAG
GAAATACAGAGAACACCATAAAGATACTCCTCGAGAAGAGCAACCCCAAGACACATAATTGTCAGATTCA
CCAAGGTTGAAATGAAGGAAAAAGTGTTAAAGGCAGCCAGAGAGAAAGGTTGGGTTACCCACAAAGGGAA
GCCCATCAGACTAACAGCAGATCTCTCAGCAGAAACCCTATAAGCCATAGGAGAGTGGGGGTCAATATTC
AACATTCTTAAATAATTTTCAACCCAGAATTTCATATTCAGCTACACTAAGATTCCTAAGTGAAGGAGAA
ATAAAATCCTTTACAGACAAGCAAATGCTGAGAGATTTTGTCACCATCAGGCCTGCCTTACAAGAACTCC
TGAAGGAAGCACTAAACATGAAAAGGAACAACGGGTACCAGACACTGCAAAAACACACCAAATTGTAAAG
ACCATCAATGCTATGAAGAAACTGCATCAATTAATGGGCAAAATAACCAGTTAGCATCATAATGGCAGGA
TCAAATTCACATATAACAATATTAACCTTAAATGTAAATGGAGTAAATGCCCCAATTAAAAGACACAGAC
TGGCAAATTGGATAGTCAAGACCCATCGATGTGCTATATTCAGGAGACCCATCTCACGTGCAAAGACACA
CATAGGCTCAAAATAAAGGGACTGAAGAAGATCTACCAAGCAAATGGAAAACAAAACAAAAGAAAAAAGC
AGGGGTTGCAATCCTGGTCTTTAAACTAACAAAAATCAAAAGAAAAAAAGAAGGCCATTACATAATGGTA
ATGGGATCAATTCAACAAGAAGAGCTAACTGTCCTAAATATACGTGCACCCAATATAGGAGCACCTAGAT
TCATAAAGCAAGTTCTTAGAGACCTACAAAGAGAGTTAGACTCCCATACAATAATAGTGGGAGACTTTAA
CACCCCACTGTCAATATTAGACAGATCAATGAGACAGAAAATTAGCAAGGTTATCCGGGAATTGAACTCG
GCTCTGGACCAAATGGACCTAATAGACATCTACAGAACTCTCCACCCCAAATCAACAGAATATACGTTCT
TCTCGGCACCACATCACACTGTAAAATTGACCACATAATTGGAAGTAAAACACTCCACAGCAAATGTAAA
AGAACAGAATCACAACAAACTGTCTCTCAGACCACAGTGCAATCAAGTTAGAACTCAGGATTAAGAAATT
CACTCAAAACCACACAACTACATGGAAACTGAACAACCTGCTCCTAAATGACTGCTGGGTAAATAACAAA
ATGAAGGCAGAAATAAAGTTGTTCTTTAAAACCAATTATAACAAAGACACGACGTACCAGAATCTCTGGG
ACACATTTAAAGCAGCGTGTCGGGAGAAATTTATAGCACTAAATGCCCACAAGAGAAAGCAGGAAATATC
TAAAATTGACACCCTGACATCACAAGTAAAAGAAGTAGAGAAGCAAGAGCAAACACATTTAAAAGCTAGC
AGAAGAAATAACTAAGATCAGAGCAGAAATGAAGGAGACAGAGACAAGAAAATCCCTTCAAAAAAATCAA
TGAATCCACGAGCTGTTTTTTTGAAAAGATCAACAAAATAGATAGAACATTAGCAAGACTAATAAAAGAG
AGAAGAATCAAATATATGCAATAAGAAATGATAAAGAGGATATTGCCACTGATCCCCCAGAAATACAAAC
TACCATCAGAGAATACTATAAACACCTCTATGCAAATAATCTAGAAAATCTAGAAGAAATGGATAAATTC
CTCAACACATACACCCTCCCAAGACTAAACCAGGAAGAAGTTGAATCTCTGAATAGACCAATAACAGGTG
CTGAAATTGAGGCAATAATTAATAGCCTACCAACTAAAAAAAGTCCAGGATCAGATGGATTCACAGCCGA
ATTCCACCAGAGGTACAAAGAGGAGCTGGTACCATTCCTTCTGAAAATATTCCAATCAATAGAAAAACAG
GGAATCCTTCTTAATTCATTTTATGAGGCCAGCATCATCCTCATACCAAAGCCTGGCAGAGATACAACCG
AAAAAGGAGAATTTTAGGCCAATATCCCTGATGAACATCGATGCGAAAATCCTCAATAAAATACTGGCAA
ACTGAGTCCAACAGCACATCAAAAAGCTTATCCACCACAATCAAGTTGGCTTCATCCCCGGGATGCAAGG
CTGGTTCAACATACACAAATCAATAAATGTAAATCCATCACATAAACAGAACCAACCACAAAAACCACTT
GATTATCTCCATAGATGCAGAAAAGGCCTTCAACAAAATTCAACAGCTTTTCATGCTAAAAACTCTCAGT
AAACTAGGTATTGATGGAACGTATCTCAAAATAATAAGAGGTATTTATGACAAACCCGCAGCCAATATTA
TACTGAATGGGCAAAAACTGGAAGCATTCCCTTTGAAATCCAGCACAAGACAAGGATGCCCTCTCTCACC
ACTCCTATTCACATAGTATTGGAAGTTCTGGCCAGGACAATCAGGCAAGAGAAAGAAAAAAAGGATATTG
AAATAGGAAGGGAGGAAGTCCAATTGTCTATTTGCAGATGATATGATTGTATATTTAGAAAACCCCATTG
TCTCAGCCCAAAATCTCCTTAAGCTGATAAGCAACTTCAGAAAAGTCTCAGGATACAAAATCAATGTGCA
AAAATCACAAGCATTCCTATATACCAATAATAGACAAAAAGAGAGCCAAATCATGAGTGAACTCCCATTC
ATAATTACTATAAAGAGAATAAAATACCTAGGAATCCAACTTACAAGGGATGTTAAGGACCTCTTCAAAG
AGGACTACAAACCATGGTTCAAGGAAATAAAAGAGGACACAAACAAATGGAAGAAGATTCAATGCTCATG
GATAGGAAGAATCAATATTGTGAAAATGGTCATACTGCCCAAAATAATTTACAGATCCAATGCTATCCCC
ATCAGGCTACTACTGACTTTCTTCACAGAATTGGAAAAAACTACTTTAAAGATCATATGGAACCAAAAAG
AGCCTGCATATCCAAGACAATTAATTCTAAGCAAAAAAGATCAAAGCTGGAGGCATCATGCTACCTGACT
TCAAGCTATACTACAAGGCTACACTAACCAAAACAGCATGACACTGGTACCAAAACAGATATATAGACTA
ATGGAACAGAACAGAGGCCTCAGAAATAACACCACACATCTACAAACAACAGATCTTTCACAAACCTGAC
AAAAACAAGTAATGGAGAAAGGATTCCCTATTTAATAAATGGTGTTGGGAAAACTGGCTAGCCATATGTA
GAAATCTGAAACTGGATCCCTTCCTTACACCTTACACAAAAATTAACTCAATATGGATTAAAGACTTAAA
TGTTAGACCTAAAACCATAAAAACCCTGGAAGAAAACCTAGGCAATACCGTTGAGAACACAGGCAAAGAC
TTCATGACTAAAACACCAAAAGCAATGGCAACAAAAGCCAAAATTGACAAATGAGATCCAATTAAACTAT
AGATGGTTCTGCCAGCAAAAGAAATATCAGAGTGAACAGGCAACCTACAGAACTGGAGAAAATTTTTGCC
ATCCATCAAACTGACAAAGGGCTAATGTCCATCAAAAAGTGGACAAAGGATATGAACAGACACTTCTCAA
AATAAGACATTTATGCAGCAAATAGACATATGAAAAAATCCTCATCATCCCTGGTCATCAGAGAAATGCA
AATCAAAACCACAATGCCATACCATCTCATGCCTGTTAGAATGGCGATCATTAAAAGGTCAGGAAACAAC
AGATGCTAGAGAGGATGTAGAGAAATAGGAACCCTTTTACACTGCTGGTGGGAGTGTAAATTAGTTCAAC
CATTGTGGAAGAGAGTGTGACGATTCCTCAAGGATCTAGAACTAGAAATACCATTTCACCCAGCGATCCC
ATTACTGGGTATACCCAAAGGATTATATATCATGCTATTGTAAAGACACATGCACGTGTATGTTTATTGC
GGAACTATTTACAATAGCAAAGACTTGGAACCAACCCAAATGTCCATCAATAATGGACAGGATAAAGCAA
ATATGGCACATATACACCATGGAATACTATGCAGCCATAAAAAATGGATGAACTCACAGGTCAGACCCAC
TGAAATAGCACCAAATATCAGAGCCAAGGGATGAACAGAGCTCTAAAGTAAATCAAAAGCCCAGAAATCA
GGAGACTAAGAGGCAGTAAATCATGTGATTAAGAACATAGATTTTAGCATCAAACATGCCTCATTTTGAA
TCCCAAAGCTGCTACATCTAGCTACATAATCTTTGGCAAGCTGCTTATTCTTCCCTAAGCCTTCTTTTTC
TCACCATAAAATGGTGCTAATATTTGTAGCCATCTAAAGTTACAGCTTTGATTTTTAGTACGATATTGTA
AAAATATATATGTAACAACGTTCTTAGCACACAATTACTAGATAGACAAGGAACTTGCTATTAAAATATT
TGCATTCTAGTGAGGAGAAGCATAAGCAAACCAGAAAAGAAATAAGCACAAAATTCAGTTAAGCACTATG
ATGTGATATAATATCTATATATTTTATAAAGAATTACTTGGGAGAAGCTTGCAGTTGAGATAGGCTACTT
ATAGCTGACTTCTCTGATGAAGCTGAAAACCATCATTCTCAGCAAAATATCACAAGGACACAAAACCAAT
CACCGTATGTTCTCACTCATAAGTGGGAGTTAAACAATGAGAACACATGGACACAGGATGGGGAACATCC
CTGTTTGGGGGTGGGGGGCTGGGGGAGGGATAGTGTTAGGAGAAATATCTAATTTAAATAACGAGCTGAT
GGGTGCAGCACACCAACACGGCACATGTACACCTATGTAACAAACCTGCTCATTGTGTACATCTACCCTA
GAACTTAAAGTATAATAATAGTAATAAAATAAAATAAAAATTATTGCTTTGGCAAAGAATAAATGGCTAT
ATCCCATTGGCTTTAAAAATTTGAGTCTAAGCAATCCATTAAAATAATCTATTTTAACTTAAAATTTTTT
ATAGATTTAGGGGTACAATCATGATTGTGTTGCACAGATATATTGCACAGTGGTGAAGTCTGGGCTTTGA
GTGCACCTGTCAATCAAATAGTGTTCATAGTGTTACTAAGAAATGTTTAGAAATGTCATAAGAATCCCAC
CATTTTTGGAGAGAGATCATTAATACTAAAGACGCAAGACCCTCCATAAGTCATTTAACTTCATACAGCT
CATGTTTTTTATTTATAAGGTGAAGATAATATTTCTGTTCTATCTGTTTATGTAATTATCAACTAAGATA
ATGTTTGTTAAACATAGAAAACCTCTGTTACTATATTATTATAATGAAGAAAATAATTTTTAGGATTTAT
ACAACATACTAGGATTTTGGTATCTTTAATCAATAATTTTAATTGAAACCATATTTATTTTTCTTTTTCA
TCCTGCAGTAAATTCAGATTTTGTGCAGTGAGTGACTTCACTTACCAATAGAAGGTGTGAAAGCTTATGA
ACCTGGTGAAAGCTTATGAACCTGGAATTGTGACTTTAGTGTATAAATAAACAGAAGAAAATGCAGTAAG
AAAAAGCATCAGATTTATAGGTGAAATACTTAAAGGATGGCACTTAAACAGAGTAAGAAATATGACTTGT
ATGTATACTAAAAGCAACTGTGGCTCAGATTATTCCTTCTGAGGTTCTATCTGCCATTCATTTCATGGAA
TATTGTGGAATTAGCCTATTTCACCTTCTATTAAATGAGGCCCACTTTATGGTATCATAAGAAAACTCAA
GGCTGAGGTGCACTGATTGCCTCAGCTCTGGAGTTTGACACGAGCCCAGGCAACATGGTGAAACCCCATC
TCTACTAAAAATACAAAAAATTAGCCAGGCATGGTGATGCACCCCTGTAGTCTCAGCTACTCAGTAGGCT
GAGGCTGGAGAATCGCTTGAACCCAGGAGGCAGAGGTCGCAGTGAGCCGAGATCGCACCACTGCACTCCA
GCCTGGATGGAGTTTTTCCATCTCAAAAAAAAAAAAAAAAAAAAAATAGGTAAACCCAAATAATATGCCT
TTTAAGAAAAAGAAGTTGATTTTGCTCTTATGAAACAATATGAAGTTAGATCTTCAAGATCTGGTAGTGC
AATTCTGTCATCCTTAACTCACAGCTTCCATCTCTTGATCTTCATCCTGTTTTCACCCTAATCGAAAGGG
TGAAAGTGGGAAGAATAGCGTATGACTATTTTTCTTTAAAGGAATTATTTAGAAGTGTTTCTTATCATGA
TCAAACAGACATGGTAACATTTAGCTTAAACTGGAAGATGTTATCTCCAGCTAGTGGCCATGTGTCCAAC
AACATTTAGATTATTATTAGGAAAAAGAGAAAAAATTAGCATTTGTGAAAAAAGTAGTAGTCTCTGTCAC
AATCTTTTACCCATGTTTTGTAAAGTATTTAAAACAAAAATCAAGCACTCTTACCATAATGTTCTGTCAC
AGTGTTGTTTTAAATTTCATGTAAAACAACATTAGTTCTGTAGTGGTAAATGAAGTGTTAAAGTCTCTCT
TTAACTCCAGACCTTTCAAGTTATTAAAAATGCGAACATTTATTATCTAACTTAGGAAGTAGAGAATATT
GGAGTAAGTAATACTATGCAGTGTTAACAAACGTATGCCAAAATCTTAGTGATGTAATCCAATAAAAATG
AATTTCTTGCTCATCCAAAATCCAATTTGGATGTTTCTGGTTGGGGAATGACCTTCCCTATGGCTATGTT
AGTGAGTCTACTGTCCCCCACTTATCTGATGTATCTTCTCCATCTTCCTGGGAGACTGAGTATGAGGATG
CATGGAGAATTGTACATGAGAAATATATGGGCCAAGCCTTGAAGTGGCCCACATACCTTCTGCCTACATG
TCATTGACCACTACTTATTCACAGGGCCACATATAAATGTGAGGTTCATTGTGCATCCAGGAGTTAAGGG
AAAGTGGTTTTTTGAACACAGTGAATGGATGTGTCTTGGGTGTTTCTGTTTGAGTCTCTTCGTTGTTTTA
TTTTTCCCTCTAGGATCCAGTAATTCCTGAACTTTAGTTCTGGCCTGGGCTGGCCTGCCTCATTTTCACT
GAAGCCTCGATTCTTAACTGTGAAAGAATAGATAATTTTCTCTTTCTTACCATTGCTTGCTGCCCTACTC
TTTCTGAAATAGTTTCCCATGTTATCCCATTTTCTACTACATGGAAAAAGATCATGCTATTCTGTTTTCC
ATAATCATTATATATTCTTTTTTCCCCATGGTATTTCCCAAAAATTTATTATTCCATGTTTTATGGGTGA
ATAGTTATTTCTATTAACTACTTTTTTAGAGTGAAGAATCATCGACCTCTTCTATCCTAACATCTACTGT
TATCCCCTCCATGCTGAACAACACCAAAACTATTTTTCATGTAGGTTGTTCAGGGCTTTCTCTCTATTCA
CTTAATTATTCCATCAGGAGACTATTGAGAGAGGCCTATAACATAAAAACATAAGGGTTAAATTCAAAGC
CATCGTCAATCTTACTCAAAGACATAAACCTTAGAACATTATAGGAATCTTCAAAAAAGTTAGCTTAATT
GATTTTAAAATTATGCCAGCAACTAAAGCTACATGTTTTAGAAAGAGAAATATATGCCTCATGTTTATTG
ATTAAAAAACATTTATAGATACTTTGCAATATACTAGGAATAAATGACATATTCTGCCCTCTTGAAACTT
AATATAATTAAGAACTAGATTGTGAAAAACTAATTATAATCCAAAGAAAATAAATGATTAAAAGAGGCAA
ATTTAAGTGTCATTAAATGAAGGAAGCTAACCAAATATTTCTTGTCAAAGAAATTTTTATGGATGATCTG
ATATCACCAAGAATGAGCTGGAATAGTTTCAGTAAAGTACAAAGAAGAAAAGGAGGAAAATTGACAAATT
CTTTCCTACATCTTTACAAAATAACCTTACAAATTACCAGATAGCCTCTGTAATTAATAACAACAGTTAA
CATCACTACAATCCTACTTTTCTAAAAACTTTTCACGTCCATTATCTTAATTATTCTTCTTAAATGCCTT
ATACCATATTTATTATTATGCACACTTTATAAATGAGGAAACTGAGATTCTGATAATTTATCCAATTGAC
AATGTTACAGAGCTAACAGGTAGAAAACATGGATCATTAGCAAGGGAGATCATGTCCTCAAGTGTTCCAA
ATAGAAAAGCCAAGTTTTAGATGCAGCTAGAGAAAAGCAGTTAAGAGTTGGACTACCTGGGTTTAAATTC
TAGTACTATCACTTACTAGTTAAATGACTTTTGTAAATTTAACCTGCCCTTGCCTGAGGTCCCTCACTTA
CAAAGTGATAATAATCACAATACCTACCTCATATGCTATTGTGAAGATTACATAAGTCAGTATTTGTAAA
TTACTTAGAACCATCCTTTTATTGCAATAATGAAAGTTCCTTAAAGTTACTGTCTTGCATGCTGATGCAC
ACACTGTAATTTTCTAGCCCTATATAGAAGCCAAATTCCAAACAATAGACTAGGACTTGAGACTCAAACT
GGACAAAAATTGTTTCAGGAAAATATTAGTCCTAAATTAAACTTATATCCAAAGTGTAAAGAGCAGCAGA
ATGACAGAGTGACTTTTTTTTTTTTTTTTTGGAGACAGAGTCCCACTCTATTGCCCAGGCTGGAGTGCAG
TGGAGCGATCTTGGCTCTCTGCAACCTGTGTCTCCCAGGTTCAAACGATTCTCCTGCCTCAGCCTCTCGA
GTAGCTGGGACTACAGACATGCACCATCACCCCTGGCTAATTTTTGTATTTTTAGTAGAGACACCATGTT
GGCCAGGCTGGTTTTGAACCCCTAATGTCAAGTGATCCACCTGTCTCGGCCTCCCAAAGTGCTAGGAGTA
CAGGCGTGACCCACTGTGCCCGGCCTGATAGAATGCTTTTAAAAGCAACCTTTAGGATGAAATTATGTCC
TTCCACAAATTCTTACAATCTAGTAAAAAAATTAAATTTGATAAGAACAAAAATTGGCCATAAGTATGTG
GGTATTGGGTCTTATACAATATCTTGGTGACACTACCAAAAATTCTTGCCTTCTCTGATCCAGTTGACTA
TGTGCCCTGGAGTCCTGTGATAGGAAGCTGATGAAGTTTTCATCCAGAGAGTAAGAACCAGCATGATAGG
GCCTTTTCTACCCCAAGAGAGTACTCTGTGAAAAAGCTGGGTTGCAGCTTTTTATTCCAATGGATATGAC
AAGAATTAAAGGAAATAAAGGAACTATCATAACTGCAACAGAACATCTATTGTCTATTTTAAATTTTATT
GCAACTAATGGCTTTATATCAACTGAAAGAATGTAACAGAATAATTAAGAGCAAAGCTTGGAAGTTTGGC
AGATAATTGGCCAAAATTCTGACCCTGCCACTTATCTGCTTGTGGTAGGCCGTTCTCACATTGCTTTAAA
GAAATCTCAGACTAGGTAATTAAAAAAAAAATGGTTTTATTTACTCACAGTTCTGTAGGCCGTACAGGAA
GCACAGTGCTGACATCTGCCTGGCTTCTGGGGAGGCTGAAACTTACAATTATGGTAGAAGGCAGAGAGCA
CGCACATTATATCGCCAGAGCAGGAGCCAGCGTGAAGGGTAGCAGGTGCCACACACTTTTAAATCATCAG
ATCTTGCGAGAACTCACTCACTATTGTGAGAACAGCACCAAACGGATGGTACTAAACTATTCATGAGAAA
TTTGCCCCATGATCAAATCACCTTCCACCAGGTCCCACCTCCAAAAGTGGGGATTACATTTCAACATGAC
ATTTGGGCTAGGACACATATCCAAACTATATCATTACTGAATGACCTTAGATAAACCACCTATCCTCTTT
GAGACTTAGTTTCAACACCTGAAAGTTGGTTAAATAATATCTTCTTTACAGAGTTACTACGAAGATAGCC
GGGCGTGGCGGGTGCCTGTAATCCCAGCTACTCAGAACGCTGAGGCAGAAAAATCGCTTGAACCTGGGAG
GCGGAGGTTGCAGTGAGCGGAGATCACACCACTGCACTCCAGCGCCTGGGCAACAAGAGCGAAACTCCGT
CTCAAAAAAACAAAACTCAAAACAAAACAAAACAAAACAAAAACAGAGTTGCTATGAAGATGAAGTTCTA
TAAAAACTTAAGGAAATGCAGCCTAGCACCTACCACATAGGAATAGAAGGTGTAGTAATAGCAGTAATCT
TTGTTGTAGAGAGGCAATTAAGTAGTAGAGAAGAGAAAACACAAACACCGAGGTTAACAAGTAGAGAAGC
CCACTTAAAATAATAAACACTTTAATAACACAAAAACCTTTCTTGAATTTATGGAAATGACTTATAATTC
ATTGTGATTTGTCATTGTCTTTGTGCAAACAATGAAAAGAATGAGAGCAGCTGTTTTCAAACCTTATTTG
CATTAGAATCACCTGTAGAACTGGTTAACACACACGATGGGTCCCCACCTGACTTTCTGTTCAGTGACTC
ACTGTTAGGGTTAGAGGATTTGTGTTTGTAACAAGTTTACAGGTGATGCTGCTAACTCTGGGACCACATT
TTTGAAAAACACAAAATATGTGGAGTGTTTGTGCCCTGGGCTCTGCTGTAATAATTACATAGTATGAAAC
ACTCATGCACCACTTCATTTGCTTCGTTACTCTATTCCTCATAATCAAAGAAATCTCCTGAGTCAAATTA
AAAGTATTTTCTAATAAACATAAATGCTAATTAATTACATTTATGGCTGTAGAGCTAGCACTTTGAGCAA
ACTGGAAGTTGGTTGAAAGTTAATGCTTCTCGTGTATCTAGGGACTTGCTTAGATCCAAAAATGTTTTTT
GATCTGCAATTCTGTATTTCTTCTGTAAGTAGTTTAAATTACAAGCCTTTTCAAAGTATTCAGCCATCAA
ATACAGCCTCCTAAAACCATTGTGCATAACCTTTTGAAGCTGTGTACTTAATTCCTCAATCAAGTTGCAC
ATTAGGAGAGTAAATTGGAGGAATATAAGTCAGTGGGTCTTAAGTCACTTTTTAAAAAATCTTCAGATGC
ACTAATGTACATTTTCTATCTTCTTTTTATTTCCTCTTCTCCAATTCCATCTCTGAAACACTATGAAATG
TTAAAATAGGTTAAAAATGCACTTAAATGAAATGCAATAAATTAAATGTGCTCTATTCTTCTGAAGATTT
AACTACACACCTTTTCATATTTCAGACTCTTAGCAGGTATGATTAAAGTGCAACATCTGTAACTCATCTT
CCTCAAAGGAAAGATACGGAATTATATGAGATGATTTATGTGCCAATGCCTAGCCAGTGACTGTTACATA
GTAGTTGCTCAATTTCTTAAATCATAATTTTCAAAGGAACATGGAACAGTTACCAGGAAGAAAATATGTC
AAGGCATAAGTTTATAGTGTAAGATTTTAAAGGCAGAAGGATTTTTGGACTGTCAGAATATAGAAGGTGA
AAATTTCATATCAAGGAAATCATATATTCACAGGTAGTTTTTGAAGCATGAGCTCAGGTTTAGAGAATGG
AGATCAGTCCAGCTTAATTCAGTGCAGTGCAACCCTGGTCACATGTTAGAACGACCCGGAGTGGTTTTCA
AACTCCAAGTGCCTGAGTCCCATTCTAAACCAGTTATATCTGAATCTCTAGGTATGAGAGCTAAGCATCA
ATATTAAAAAGAAACAAACATAAACTTTTCAGAGTAGTATTAGGGAAGAAAAGAGCAAAAGAGATCAACT
AGTTGCAATTTTCTATTGTTGGGTGCCGGGCACGGTGTCTCACGCCTGTAATCCCAGCACTTTGGGAGGC
CAGGGCAGGTGGATCACCTGAGGTCAGTAGTTTGAGATTAGTGTGGCCAACATGGGGAATCCCCACCTCT
ACGAAAAATACAAAAATTAGCCAGGCATGCTGGCTTGTGCCTGTAATCCCAGCTACTCTGGAGTCTGAGG
CAGGAGAATCACTTGAACCCAGGAGGTGGAGGTTGCAGAAAGCTGAGATCACACCACTGCACTCCAGCCT
GGGCAACAGAGTGAGACTCCATCTTAAAAAAAAAAAATTCTATTGTTGCCATTGACCTGAAACTGGGTTT
ATTAATTTCCTATAGGAATGTAGCTTGCAAATGTTAAGGCATAACATAATTTGGGGGAACTCTTACTGCC
TTTCACAAAGAACATTGAGCTATTTTGGCATCTGTGACTAACATGTCTCTACTGGCTCAGTAAAATTTCT
TTCCATGAGGAATTCGTGGACAAGGTTGAGATAATAACACATTCTGCACCTTGCTGTAATTTGGTAGCTA
AAAATGACAAGTCCACAAATTCATTGCAGGGGTATAGTGCAAAGAAATTTCCAAGGGTAAGTCAGTACAG
ACACTACCCAACTGTATATGCAAAAAGGAGCACAGGAATTGGAATCAATTATTCAGTTCATTGATTCCCC
AACTACTAGCTTTAATGTATGTGTTATTTAACTTCTATAAGCTGTAGTTTTCACATTTGTAAAACTGAGG
TAATGATAATATTCATATCACAAGTAGCCCTGAGATTCAAATGAGATTATTTACATGAAAGATATTTGAA
AAGCTGGATATATATGGGCACTATTTTGGGGTACTTAGAATTTCCTCTTTGACTTATTCTTCCAAAACAG
AGTCAAATCTCAGCCAGAGAAGCTACCGATGTTGGAGTAATTATTTCTATTTTTTTTCAAGTTGACTTCA
CCAACCAAGAAAATAAACTCTATGAAAAGATAAAATAGAAAATAGTTTGTTCACATTTTTATATTATTTG
TCATTCATAACATTTTCTCTGTTTTGTCACTTGACAGGTGCCAGAGTAGAGCTCTCTAAAATTCCCTCGT
AGGTTTTTTGGAAATTGTCTCTCTTATTCCCAATCTCTGTAGGATATATAAGTGAAAGATTGAGAGTATT
TTATATTTGTTTATCTTTTAAATATGAAGGTGTTCAAGTCTCTGATTTTGATTATCGGAAATCAAAACAA
ACAATTTGATCTCTAATTCTGAGGTGTCTCTAGTCTATTTGAAGAGACAATATATACATTATTTAAAATT
GTTACTATAATAAAACTGTTTACAACTGTTTATATTAATCTGGTATGTATTACAAAGAATCTTGGTTCAA
CCTGGGCCTTTACATTATTTCTAAGCACATATCACAATGTATTCCGACAAATTCCTTGTGCTTTTTCTTT
AGCTGTTTTTTTTTTTTTCTTAATAATATTAGGGGCTTTTCTAGATGCAACATCTGTCAGGTCAGTATAG
TAGTGAGTAATGAAATACCAGCCTGGCTGAAAACGCTCTTAAAATGTCGGTCCATTCTACTTCCTAAGAC
ACCTAAGAACACCTGATATAGGATGAGAGCAGGCAGCAGGCAGGTTTCTACAGAACAATGAAGTTTAGGA
AGGAGGGAGATGCGTGATGCTAGGGTGGTACCTAATGGTTGCAGCAAAAGAGATACTTTTGCATTGAGAG
TGCACCATATTCTTGGTTAGCAGCAACTATTTACCACATGCAACATGATTATAGAAATACTAGTTACTAC
TCAGGAAGTATTCACTTTGCACCAGATCTGTACTAGGTGCTTTTATACCTGCTATCAAAATTAATCCTTG
CCACCAACTGATAAGTGGACATTATTTACTTCCTCTCTTATCATTGAAGCCCAAAAAATATAAATAACTT
GACAAGGATTATACTTCCAGTATGTAACACAGAATTTAAGCCAAGTTCTACTCAGTTCAAAAATCTTTTT
TACAGCAGTATCTTCAAAGTGGCATAGATACACTACTGCAGGTTCACAAAAACTTTCTAAGGGGTACATG
GTGCAGAGAGTTTTAAGAAAATTTATTTTTAGCTCATCCTTCCAAGCATACTTTTCCAAATGAATCTGAT
TGAGAAGACTCCTGAAGATTCTCCTTCACCAACTCTCCTTTCAAAATCTCCCTTCTCTGATGTTTCAGAA
GAGCCTATCTTCCACCTATCCTGAATTCATTCTCAATACAGTCTGCTCCCAGAATGGGAAAAACTTCCAG
AGTGTTTAACAAGTGGGGAATCCGAAACATTGGTGCTAGTGTTGCCAACATGTATAACTTTAATTACTAG
GCAACAAACTTCTTACAAGTTGGGTAGTTTATAAATAAATTCATCATTTGTGAAATTGCTTTTATCAAAT
AATTCTTGCTTGAGTTGTCAGTTGATGGATCAAATTGTAAAAACTATTTTTTTTTTTGCTGGATTGTATC
ATTATTAGCATATTTAGCTCAAATGAGTTCAAAAAGATAAGTAAAATTTAAATAAAAATTTCTTTACCCT
TATCTAGTTATTTATGGGAACAAAGCTTCTTGGCAGTTATTTATTTTTTTAAAATTTAGAATATAATTGA
TATACCTATTTTTGTTACAGAGAATTTTGGTAGGCTACTTATTCTTTTCCCTTTTTAAAATTTATAAATA
AAAATTGTATATATTTATGGTGCATCACATGATGCTTTGATGTATGTATACATTGGGAAATGGCTAAATC
AAGCTACTTAAAATATCTGTTACCTCACATACTTATTTGAGTAGTAAGAACATTTAAAATCTACTCTCTT
AGCAATTTTCAAGTATACCATACATTATTATTAACTATAATCACCATGTTGTATCATAGATCTCCTGAAC
TTATTCCTCCTATCTAACAAAAAATTTGTATCCTTAGACATAGATCTCCTGAACTTATTCCTCCTATCTA
ACAAAAAATTTGTATCCTTAGACTAACATCTCCTTAATCCTCACTAATATTTTTCAAATATTTTAAGCAT
AACATATATAACATTTAGATATAATTGTGTAGAAAAATAGTATACAAATACAAGTTCAAGTATAAAAAGG
TAACTCCAGAAAGTTACAGACTATCAAAGAAGAGTTTAAGTTGTTTTTGATATGGATGATGGAATCAAAT
AATTATGGTGGATACATTTTTTGAAAGTAATATTATATGTTCATTTTTAAATTGACACTATTTGCAATAT
CCTTTTATTATATCCTCTGAAACTATTTATGATTATGATTAAAACAATTTGATAGTACAGTAGGAAAATT
ATAGTTAACAACAATTTATTCTATTGTATATTTTTAAATAGCTAGAATAGAAGATTTGTAAGATTCCCAA
CACAAAGAAAAGATAAATGATCGAGGTGATTGATATTCCAATTACTCTGATTTGATCATTACACCTTGTA
CATTATAGGCATCAAAATATCACATGTACCCCAAAGATATGTACAATTGTTACATACCAATGAAAAATAT
AAAACTTTAAAAATTCTTTTAAATTAAAAAAATCAGTTTGGGACCTACTTTAAAAAGTGTGAGAGTATAC
ACTTTAAAAAGTGTGAGAGTTTTAAATTTTTCATTTGGTGCTACTCAGAGATAAAATCTTGAAAACAACT
TCTATGAAGAACATTGTCCTCAGTGACATGATTTATTGCTACATAGCAAAGGAAGTAAACCATTGTATTT
AGGAGCATAAGTTCTACACTAAAACAGGCATCTGCTCTAACCTTAATGTCTAATTTGTTATTTTACCTTA
GACAAGTTCTTTGTCCCCTCTAAGCCCTTTCTTTCCATTTCTATAATAATGTAGGTACTTAATTGGTCAG
ATCCTTCTAAATGTCACATAAAATTATGTCAAGATCTAGAAAAATTTCTACACAGATTAAGTGTCATGTA
TGTATATTCACAGAAGTTGTCATAGACAAAACTGTGTAAAGGAGAGGGATGTGCATGTTCTTAGGCTAAT
CTCCCAGAGGGATCAGGGATTGGTATGGTCTCCCAGAATGAATAAAATAAGTTCAAAAGGAGGTAAAAGG
AGGAAAAAACATCACTACCCGAAGGGGCAGAAACACTGTCAGTCACAATAGTGGGAGAGCACAAGGCATG
TGATGCAAAAATTAAGAACTGCACCTTTAATAAGGAAGATATTGCCAATAAAATAGTTCTACTTGTATGA
AATAAAGCTAGAACTTCCCTGCCTAAATCCTGTCTTTTTTCACTGTTTCTGTTGTAACTCTGGTTTACAT
TATGATCTTATTCACAATTTCTGCTTGCTTGATATTTCTTAATTCTGAAATTTAATAATATGCCCTTCGT
CGTGTTCCCCCAACTTGGTTCCTGCTTACAATTCAATTTTGTTATCCAAACTTCTTTTTCTGGTCCTAAC
TCTCAGTTTTGCCTGAGTGGGCACTAAAAAGTTATCTTCCTCTTCCTCTTCTTAATGGGCACATGGGAGA
GAACACAAAATTCTAAGAGCTCATATCTTAGCGTCTAATTGATACGGATTAAAATCCCAACTCTACCTGG
GTAGCTTGGTAAACTCAGAACTTCTCTGAACCTCAGTTTTCTTTGAATAGGGATAATAATTTCTAACCAA
CAGAGTTACTGTAAAGATAGAAGAACATATGTCACAATAAACATTTAGCATACTCAACATTTAGAAAATA
ATTGCTCTTATTAAAATTTTTCCCATTATTACTGTTGCTGATGCAATAAATGGAAATATTTATTGGAGTT
CTGAATATTTTTGAAATGAATGTTTTGTAAAATCAGACACATTATGAACTGATATGAAAGATGTTCCTGT
GAAAGAGGAATTGAAATGTGAAGAGTCACAAATTTTACGCTTTCTCTGGAACCAGAAACCAAACTTAAAG
TGTTCTCCAGAACTGGAAAGCAAGGGGACACATAACAGGCTGAAAAGATCTGCTATGAGTGTTGTTACAG
ACTGAAGTGAAAGTGACTGCTGGTTATTATAAAATGTTCCTATGACTTGTCCATATTGAAACAGAAATTA
TAGGCAGAATGAACAGGAGGGAACACAAATTGGCTCAACCTCTTTTACCTGGTTAAGCTCTCCATTGTAC
CCAAATTTGGGCCATTTAATTCCACAAATATTTATTGAATACACACTGGGTATCCAGAATGTAAAGAGTC
TCAATACGGAATGAATTTTATTTTTGATTTTATATTTTGAAACAGTCTTCAAGTTATAGTTATAAATCAA
ATGGGATAATCACATAGGTTTTCAGTCATTAAAGTAAACATATTTTTTTCATTTTTTTTTAATGAACAGG
ATTTGCTAGTCCACTTACTGGGATAGCGGATGCCTCTCAAAGCAGCATGCACAATGCCTTGCACATCTAT
ATGAATGGAACAATGTCCCAGGTACAGGGATCTGCCAACGATCCTATCTTCCTTCTTCACCATGCATTTG
TTGACAGGTTGGTTAATATTTCTTTATAAATAACGTGCTCATTGGATTTAAATAGAGGGTGCCTATCAAA
TGTGATTTAAGTTATTAAATAAAAGCTAAGAAGTTATGGTAGTCTATTGTCTGTGATCAGGTTGTCACCA
AAACAGACCTTAGGCTAAGAATTTGCATGCAAATGTATAATAAAGAAAGTGTTTATAAAGATAAATTAAA
AGAAGGTGGATTAGGCAGGATACAAAAGAAAGAAAAGTAAAATAAGTGTACAATGTCAGTTGAAATCCAA
GACTCCACTAGATCCTGGTAGAAGGTAAAGTATACCCTAGTTTGTCCTACCTTAAGAAAAAGACAGATGA
GTCTTTGTACTTCCATGCTAAATAGCCATTGGCTACAGGATGCCCTGAGGTAGGGGATGTAAAACTCCCA
GGAGCTTGAGTCCAGATAGGCTTTGTGGCCCCAGTACCCAAGGGCAGCCTTCTAAAGGCTTCAGGAGAAA
GTTGTTAAGAGCAAAGAATGAAAAAGCAGGAGGATGGACACACAGAACTGCTATAGGAATTTAAGGCCAT
GTGGGCCTGGCACTAACCTACTACATCTGTCATCAATACATCTTTCCTTCTGGAAATTGTATTGTTATTT
CTTCTCTTTTTGAACCTAACACACTTTCATATAAGGAAGTACAAACTGATCTCTTCCACTGGCCTGAATA
GTATATGATTAATTCTCCAGACAGAGTGCACTATGGCCCAACTGTCCTATTTAATGTGATTTAATTCTCT
TGGAGCTTTTATTTCCCTTATTAGCCTTCTTCCATTACATTTGTAATGTCTTAGATATATTAGGTTTTAG
ACTTAATTGTAGGTGATGATAGCAGAAAAGAAAGTATTCAGAGGAAGGTCAGCTGTCTACTCTTGAAATT
TTCAAGAAGAAAGGAGAAAATAAAGCATCAAATCATGACTGACAAATGCTATGGAGTGTTCTTTGTCCCC
TCTACAGTAATTTTCTCACCACAGTTAATGAATAAAGGGCACAGATTTATACCTGCCATTAAGATAATAC
TATCATCCTCTTGGGTAAAAATAAGAGGAGTTATTTTTCGTGTTTTAAAGATAAGGAAACTGAAACTGAG
AATTAAAGATTTTACTTAATTTACCAAAATCTTCTCTTCATTCATGTCCACAGGAACATGGACATAAAAT
CAAATAAGAAAGTGACCATTATCCAGGAAAATCATTAGGCAGATTTTTATTGGCTTCATGGCAACTCTCA
TATAATGAGAATTAAGTAACAGTCTGTGTTAAGTTTTATTCAGAAATCAGTGTATAAGAACATGTATGAA
CACCAAAGTGTTGGTGTCAATACCAACATCACAACCACCTATACCCATACATAAGAGAGAAAAGCATAGT
GCTGGAATAAAATGTTATCAGAAAAGATAAATTGAACGCTTTTTAAAGAATCATTTTTATATCACTTTTT
GGTGTAAATTTTTTGCCATTTTTAATATCTAGAACTACCCAGTGAACTCTAAAGATTTAAGTATGACCAC
TCTTGCCACCTCCATTCAATATAGTATTAAAAGGTCTACACAATTAGCAATTAGGCAAAAAAAAAGAAAA
AGAAAAACTATCAAAATATGAAAGGAAGAGGATATTGTTTCTGTTTACTGATGATCTGCCCTTATACACA
GAAAAGCCTGAGAATTCACTGGAAAACTGTTAAAACTGATAAATTAAGTAAACTTGCAAGATACAAATGC
AACATACAAAAAATTAGTAGTGTTTCTGTACACTAACAATGAACTATCTCAAAAAGAAACTAAGAAAACA
ACCCCATGTACGACAGCATCAAAAAATAAAATACTTAGGAGTAAGTTTATCCAAGAAAATGAAAGATGTG
TACACTGAAACTATACAATATTGATAAAAGTAACTGTAGAACACAAAAATAAATAAAAAGATATCCTGTA
TTCATAGATTAGAAAAATTAATGTCGTTAAAATTACTATACTACCCAAAGAAATCTACATATTCAATGTA
ATCCTATCAAAATACCAAGACATTCTTCACAAAAATAGAAAAACAGTCTTCAAATTCATACGGAACTACA
AAAGAACCTGAATAGCCAAAACAATTTTGAGCAAAAAGAACAAAGCATCATATTTCCTGATTTCAAAATA
TACTACAAAACTATAGTAATTATAATGGCATGGTAATGGCATAAAAGAAGATTTATTGTTCATTGAAACA
GAATTGAGAGCCCATAAGTCAATCCAATAATTTACATTCAATTAACTTTTGACAAAGATGCCAAAAACAA
TGGGGAAAGGACAGTGTCTGCAATTAGTCGTTTGGGGACAATTGGATATCCACATTCAGCAGAATGAAAT
TGGACCCATATCTAACACCATATCCAAAACCAATTCAAAATGAATTGAAGACTTAAATATAGGGATTAGA
AATTGTGAAACTGCTAGAAGAAAGCATATGGTAAAAGTTCCAAGACTTTGGTCTGGGCAATGATTTTTTT
GGAGAGGAGCCCCAAAGCAAAGGTAACAAACACAAAAATAGACAAATAGGATTACTTCAAACTAAAAATC
TCCAAGCGACCAAGAAAACAATTAACATGATAGACAGACAACTTACACAATAGGAGAATATATTTGCAAA
CTATACCTCTGATAAGGGGTTAATATTCAAACTATATTAAAAAGTCGATTCAATAGTTAGAAAATAGAAA
AACTAATTTTAAAAATTGGGCAAAGGATGTAAATAGACATTTCTCAAAAGAAGATATGCAAACGTCCAAC
AGGTACATGAAAAGATGCTCAACATCACTAATCATCAGGAAACACAAATCAAAACCACAATGAGATAATA
TTAATGTTACTTCACACCTTTTAGAACAGCTATTAATAAAAAGACAAGGACAAGAAGTATTAGAGACTAT
GTTAAAAAAAAAAAAAAGAGGGACTTTAGGAAGCCAAGGCGGGCAGATCATGAGGTCAGGAGTTTGACAC
CAGCCTGGCCAACATGGGGATACCCCTTCTCTACTAAAAATAGAAAAATTAGCCATGGGTGGTGGCAGAC
GCATGTAATCCCAGCTACTCGGGAGGCTGAGGCACGAGAATTGTTTTAACTTGGGAGGTAGAGTTTGCAG
TGAGCCAAGATCATGCCATTGCACTCCAGCCTGAGTGACAGGGTGAGACTTCGTCTCAAAAAAAAAAAAA
AAAAAAAAGGAAGGAATTGTTGTACTGTTCATGGGAATGTAAATTAATATAGTCATTTGGGAAAACATAG
CAGTTTCTTAAAAAATTAAAAATAAAACTATCATATGATTCAGCAGTTCCACTCCTGGGCATGTATCGAA
AGGGAAATATATCTGAACTTCCAAGTTCATTGCAACATTATTCATATAAGGCAAGATACAAAACCAACCC
AAATATTGATAACGATGGATAGATTAAGAAAATGTGGTATATATACACAATGGAACACTATTCTGCCATA
AAAAAGGAAAACCCTCTCATTTGCAACAACACGGATGAACCTGGAGTTTAGTATGTGAAATAAAATGAGT
CAGACACACAAAGACAGAAACTGCATGGTCTCACTTATTTGTGGAGTCAAAAGAAAATTTAAACTCCTAG
AATTAGAGAGTAGAGGATGGTTACTGGGGGCTGGAGCTGGGGTGGGTTGGAGGGAAGTTGGACAAATGAT
ACAAAATTTCAGTTAAGTATAAGAAGTAGGCTGAGCGCAGTGGATCATGCCTGTACTCATAGCACTTTGG
GAGGCTGGGATGGGTGGATTGCCTGAGCTCAGGAGTTCGAGGCCATGCTAGGCAACACAGTAAAACCCCA
TTTCTACTAAAAATACAAAAATTTCGCCAGGCATGGTGGTGTGCGCTTGTGATCACAGCTGCTCAGGAGG
CTGAGGTAACAGAATCTCTTGAACCTGGGAGACCAAGGTTGCAGTGAGCTGAGATTGTGCCCCTGCACTC
CAGCCTGGGCAACAGAGTGAGATTCCATCTCAAAAAAAAAAAAAAAAAGTAAATTAAGAGATCTGTTGTA
CAGCGTGATGACTAAAGTTAATGACAATATATTGTATTCTTGAAAATTGCTAAGAAAGTAGATTTTAACT
GTTCTTAGCACACGAAAAGTAAAAAGTAAGTATGTGAAGTAATGCAATGTTAATTAGTTTGAATTAGTCA
TTCACAATGTATGTATACAGGCACACATCAAAATACTGTGGGCTTAGTTCCAGGCCACTACAATAAAGTG
AATATCTCAATAGAGACACAAAGTTTTGGGTTTCCCAGTGCATCTAAAAGTTACGTTTATGGAATCAACC
CAGGTGCTCATCAATGGTGTATTGGACAAAGAAAATGTGGTACATTTACACCATGGAATACTATAAGAAA
GAACAAAATGATGTCCTTCGCAGCATCGTGGATGTAGCTGTAGGCCATAATCTGAAGTAAATTAACACAG
GAACAGAAAACCAAGCACTGCATGTTTTCTCTTATAAGTGGGAGGTAAACATTGGCTACATATGAACATA
AAGATGGGAGCCATAGATATTGGGAACTACTAGAGTGAAGAGAGAAGGAGGGGCATAACAGCTGAAAAAC
TACCTAATGTATAAGGTATACTATGTTCATAACCTCGATGATGGGTTCAATCATACCCAAACTTCAGCAT
CATGCAATATACCTTTGTAGCTAACCTACACATGTCCCCCGATTCTAAAATAAAAGTTGAAAAAAAAAAT
TAAAATTAAAATTATGTTTATACTTTAATGTAGATTATTAAGTGTACAATCTCATTATGCCTAAAAAGCA
ATTTATATACCTTAATTTAAAAATACTTTACTGCTAGAAAATGCTAACAATCGTCTGAGCCTTCATCAAG
TCAAAGTTTTGCTGGGGGAGGGTCTTGCCTTGATTTTGATGGCTGCTGAATGATGAGGGTGATGGCTGCT
GAAAGCTGGGGTGGCTGGAGCAATTTTTTAAAATAAGACAAAAAGGAAATTTGTTGCATCAGTTGATACT
TTCTTTCACAAAAGATTTCTCTGTAGCATACTATGCTGTATGATAGCATTTTACCTATAGTAAAACTTCT
TACAAAATTGGACTCAATCTTCTGAAAGCCTGCTGCTGCTTTATCAACTAGGTTTATCTGATATACTAAA
TACTTTGTTACAATATCAAAACATTCACAGTATCTTCACCAGGAGTAGATTCCATCTCAAGAAACTACTT
TCTTTTTTTAACCATAAAAATCAAATCCTCATGTGTTCAAGTTTTATCATGAGATTGCCACAATTCACTC
ATACCTTTAGGCTGCACTTGTAATTCTAGTTCTCTTGCTATTTCCATGATATCTGCAGTTATCTCCACCA
CTGATACCCTGATCCCCTCAAAGTCATCTATTAGGATTGGAATCAACTTCTTCCATACTCCTATTAACGT
TAATATTTTGTTCTCCTTCCATGAATCAGAAATGTTCTTAATGGCATCTAGAATGGCGACTCCTTTCCAA
AAGGTTTTCAATTTATTATGCCCAGATCCATCAGAGGAATCACTATCTATGGAATATATAGCCTTACAAA
ATATACTTCTTAAATAAGATTTGAAAGTCCAGATTACTCTCTGATCCATGGGCTGCAACATAGATACGTG
TTAGCAGGCATGAAAACAGTATTCATCTCCTAGTATATCTTCCTCAGAGATTTTGGGTGACCAGGTATAT
TATAAATGAGCAGTAATATTTTGAATGGAATTGTTTTTCCAGGGAGTTGGTCTCAGCAATGGGCTTAAAG
TATTCAGTAAACCATGCTGTAAACGGATATGCTATCATGCAGGCTTTGTTGTTTCATTTAAACAACAAAG
GCAGAGTAGATTTAGAGTATTTCATAATGGGAGTTTCAGACCAGTAAATGAGCACTGGCTTCTACTTAAA
GTTACCAGCTGCATTAGCCCCTAGCAAGAGTATCAGACTATCCTTTGAAGCTTAATCCTTTATTATCCTT
TGAGCATTAATTTCTCCTTAGTAGCTGTGAAAGTTCTAGATGGCATATTCTTCTAATAGAAGGCTGTTTT
ATCTACACTGAAAATCTATTGTTTAGTATAGCCAACTTCATCTAATATCTAAATCTTCTGGATAACTTGC
TGCAGCTTTCCATTGCACTTGTTGCTTCACTTTGCAGTTTTATGTTATGAAGACTTCTCTTTCCTTAAAT
CTTGTAAACCAAGCTTTGCCACCTCAAACATTGTTTCTGCAGCTTCCTCACCTCTTTGACCCTCCATAGG
ATTAAGAGAGTCAGAGCCTTGCTCTCAATTAGGCTTTAGTTTAAGGAAATGTTGTTGCTGGTTTGATTTT
CTATCCAGACCACTAAAATTTTCTTCATATCAGCAGTAAGACTGTTTTTCTTTCTTATTGTGTGTGTTTA
CTGGAGTAGCACTTTGCATTTCCTTCAAGAACTTTTCTTTTGCAATTGCAACTTGACTAACTTTTGCACA
AGAGGCCTAGCTTTCAGCCTACGTGAGCTTTCAACATGCCTTCCTCACTAAGCTCAATCATCCCTAGTTT
TTTATTTAAAGTGAGAGACATGCAACTCTTTCTTTCATTTGAACACTTAGAGGCCATTTTAGGGTTATTA
ATTGGCCCAATCTCAATATTTTTGTGTCTTGGGGAATAGGGAGGCCCAAGGAGAGGGAGAGATTCAGGGG
AGTGGCTGGTCAGTGGGGCAGTTAGAACACATGCATTTATTAATTAAAGTCACCTTTTTAACATTGGCAC
TGTTTGTGGTGTCCCAAAACAATTACCATGGTCACGTCAAAGATTTCTGGTCACAGATCAGCATAACATA
TACAATAATAATTTAAAACTTTGTAATATTGCAAGAATTACCAAAATGTGACAGACATAAAGTGAACACA
TGTTGGAAAAATGGGAGTAACACACTTGCCAAACACCAGGAGTAGATTCCATCTCAAGGTTGCCAGAAAC
CTTCAATTTGTAAAAAAAAAAAAAATGCAGTATCTGTGAAGCACAATAAAGCAAACCACAATAAAATGAT
AACACTTATATTTCCAAACATAAATAGCTTATAAGCAGATGAAAAAATGCTCAATATCACTAATAACCTG
TGAAATATTAACTGAAACCACAATGGGATATCACCTCTGACTTGTTCAAATACCTCTTATCAAAAAGATA
AAAGACAAATGTTGGAGAGGGTGTGGAGAACACGGAACACATGCACATTTTTGGGTGGGAATGTAAATTA
GTCCATGGAAAATAGCATGGAGCTTCCTCAGTAAACTAAAGATAGAATCATCATATGATCCACTCATTCC
ACTTCTGACTATATATCAAAAGGAAGTGAAATCAGTATGTCAAAGAGTTATTTGTACTTCCATGTTTGTT
GTAACATAATTCACAATAGGCAAGATATACAATCAAACTAAGTGTCCATAATTGGGCAAATGGGTAAAGA
AAATACAGTATATGTACACAATGAAATACTATTTACCATTTAAAAAGAAATTCTGTCATCTATCATAATA
TAGACAAACCTGGAGGACATTACATTAAGTGAAATAAGCCATGCACAGAAAGACAAGTAACCACATAATC
TCTTTAGATGCAGAATCTAAAAAACTTTGAACTCGTAGGAGTAGGAAATAGAATCGTAGTATCACAAGGT
GATGTGCAGGAGTGGAAGGGGATGAATAGGGTCAATGAAAATGTTAGTTGAAGGGTACAAAGTTTTAGTT
AGACATGAGAAGTAAGTTCTACTGGTCTTCTGCACAGCATGATGATTATAGTAAATAATGATATATTGTA
TCTTTTAAGATTGCTGAGAGTAGATTTTAAATGCTCTTACCACAATAAAATGATAAATATGTGAGGTGAT
TGCCATTTTAGCTTGATTTAATCACTCCACAATATATACATATATCAGCATCACATTATGCCCCATACAT
ACCTGTAATTATTATTTGTCAATTAAAAATAAAATTTTTAAAAGTGTCAATTTGTCTAGATGCCTTGATG
TTTCCCACTTGTTTTTATAAATAAGGTTTTATTGGAACACAGCCATGATATTCATTTACATATTGTCAAT
GGATGCTTTCGGGCTACAATGTCAGAGTCGAGTAGCTGTGACCAAGACCACGTTGTTTGCAATGCGGAAA
ATATTTAATAGCTAGCCGTTTGCAGAAAAAGTTTGGGGATCCCTGCCAAACCACAAAATTCCATACACAC
TCACACACACATACACACACACACACACACACACCAGACAAGAGAAAGAGGTTTTTTCTGTAGCCCACCT
ATATTTAAAGAAAGTACTATCATTAAATTCAATGTCTGTAGGCATGTTTGTTTAGTAGAGAGAATGTCAT
TCTGTAGATATATAGCTGTGAAAAGCCACTCTGCAACCTTTGAAAATTAGAATTTTCTGCTCCCTTAGAA
TTCTCTATTAATTCTATTTTACTATTAGACATTTGCATAATTATTAAAATAACTCAAAAATATTAAGCAA
AGATCAAGGTAATTTCTGAGCCTTTGTAACAAAGCTGATGAAGATTCTGATGATTCAATTATCATTATAC
AGAAAGCTAGAGAACTGTGGGTTACCACAGAATATTGTGTGGCATCTGAGCCATCCTCTCAAGTTGCTAC
CTATGAAGACTCATTTTTCCGATCAGACAGGTCTATTGACTGCCATTCAATTATGCACAAATATATTTAT
TGGCAAACTATGTACTGAGTGTATTTTCTTAAACATTCCACATTTATTCCTATTTCTGGGCTCTGATTAG
ACCATTCCTCAAATCTGTAGCCTACTTTTCTTGACCTATCTAGTTTGTACACAAACTTCAAGACTAGTTT
CAGTTTTGACCTCCTCCATAAACTATGCCCAGGTCATGTCTGTCTATAACTATCACTCCAAAATCTAATT
ATGAATACCATTTCCCAACTTGGCATTCAGTGACCTCAGGTCGGTATCCTGAAATCAGCCATGGTGAGAG
TATTTACACCATGAAATTGGCAAATGGTACACGTCAGGGCTTTTATTCCAAAAGACCTAGTTGTTAAAAT
AATGGCCAACACACCACTGCTCTAATCTATTAACTCACAGCACATTCTTTCTATGTCCCTTATTTTGGAC
ACATCAATTATCTTTTTATTTTTATCTCCTCATCTGTTAACTGTTTTCTTGGCTGCAGGAAGCTTTTTTG
TTTAATGTAATCCTGTTTGTATATTTTTTATTTTCGTTGCCTGTGCTTTGAGGATCATTTCCAAAAATAT
TGCCCAGACCCATGTCATGGAGCGTTCCCCCCATTTTCTTCTAGCAGTTTCACAGTTTCAGGTCTTACAC
TTAAGTCTTTAACCCATTTTGATTTGATTTTTATATATGGTGTGAGATAAGTGTCTAATTTCATTATTCT
GAATGTGACTATCCAGTGGTCTCATCACAATATATTGATGAGCCTATCCATTGTGTATTTGTGGCATCTT
TGTTGAAAATCAATCATAAATGCTTGACTTTATTTCTGGGATGTCTATTCTTTTCCATTGGTCAATATGT
CTGTTTCTATGCCAGTACTATTCTGTGATAATTACTACAGCTTTGTAGTATATTTTGCAGTCAGATACTG
TGATTCTCCTGCTTTGTTTTTATTACTCAAGATTGCTTTGGCTATTCAGGATCATTTGTGGTTGCATAAA
TATTTTAGAATTGTTTCATTTCTGTGAAAAACATCATTAGAATTTTGGTAGGGATTGCATTGAAACTGCA
GATTGCTTTAGGTAGTATCAACATTTTAATAATATTCTTTCTTCCAAATTTTGTATTTTATTATTTTTAT
TTATTTATTTATTTATTTTTGAGACAGAGTCTCACTCTGTCACCCAGACTGGAGTGCAGTGACGTGATCT
TGGCTCACTCCCACCTCCACCTCCCAGGTTCAAGCGAGTCTTGTGCCTCAGCCTCCTGAGTTGCTGGGAT
TACAGGCACACACCACCATATCTGGCTAATTTTTGTATTTTTAGTAGAAATGGGGTTTCACCATGTTGGC
CAGGCTGGTCTCGAACTCCTGACCTCAAGTGATCCACTCGTCTCAGACTTCAGATTGCTGGGATTACAGT
CTTGAGCCACTGCTCCCAGCCAATTCTTCCAATTTTTGAAGAAGAGATATATTTCAGTTTATTTGTATCT
CCTTAAATTCCTTTCATCAATATTTTATAGTTTTCAGTGTATAGCTATTTTACTTCCTTGTTTAAATTTA
TTCCTAAGAATTTTTAAAATTTTTATTTTTAATTAACAACTAATGGTATATATTTAGTAAGTACAATGTG
ATGTTTTGATCTATACATTTTTGTGATGCTATTGTAAATTGATTGTTTCCTTCACTTTTTTTGGATAGTT
CATTGTTAGTGTATGGAAATGCTACTGATTTCTGTATCTTGTTTTTGTATCCTGTAACCTTACTGAAGTC
ATTTTTTAATTTTTAATAGAATTTTAGCAGATTTCTTAGGGTTTTCAGTATACACAATCATGTCTGCAAA
CCGGGACCATTTAATTTCTTCCTTTCTAATTTGGATACATTTCATTTCTTTTTCTTAGCTAATTGCTCTA
GCTAGGACTTACAGTATTTGTTGATTAGTCATGGTGAGAGTGGGTATCCTTGTCTTCTTCCTGATATGAG
ACAAAAGAAGTTCTACTTTTTGCCATGAAGTATGATGTTAGCATTGGGTTTGTCATATATGCAAACTTTA
TTGTATTGAGGTACGTTCCATCTATACCTAATTTTTTGAGAGTATTATCACAAAAGGATGTTAAACTTGT
TGAATACTTTTTTCTATTAATACAGCTATTAAAATGATCATATGATCATGTGATTTTTCACAAATATAAC
TGTGAAATTTGTATATTAACTATCCTTGCATCTTTGGGATAATCCCTCTTGATGATAGTGAACCAGCCTT
CTGTTGAATTCACTGTCAAATTCAGTGTTTTAGTATTCTTTGAAGAGTTTTGCATCTATGTTCATTAGGA
ATATTGGCCTGTAATTTTGTTTTGTCATACTCTCCTAGTCTGGCTTTGGTATCAAGGTAAAGCTGGCCTT
CTGAAATGAGTTTGAAAGTATTCTCGCCACTTAAATATTTTGGAAGAGTTTTTGATGGATTTGTATTAGT
TCTTTAAATGTTGGCAGAACTTATCTCTGAAGCCATCAAGTCCTAAGCTTTTCTCTGATGGAATAATTTT
TATTACTAATTCACTCTCTGTACTCATTATTGGTCTATTAAGATTTTCTATTTTTTCATGATTCAGTTTT
GGACATTGTGTGTTTCTTGGAATTTATCTATTTTCTTCTAGTTTACCCAATTCGTTGTTCTTAGTAGTCT
CTTATGATTTTTATATTTCTGTGGTATCTGTTGTAATGTCTCCTCTTTCATTTCTAATTTTATTTATTTG
CATCTTCTTTTTTTTCTTATTCTGGATAAAGGTATGTCAATTTTGTTTACCTTGTTAAAAACCAACTCTT
AGCTTCATTTATCTTTTGTGCTATTTTCATTTACTTCTTCTCTGATGTTTATTATTTCCTTCCTTCTGTT
AACTTTAGGCATAGTTTGACCTTTATTTTCAGTTTTTTGAAGTACAGCATTGGATTATGTATTTGAAATA
TTTTTTGTTAATGTAGGCATTTATTGTTATAAATATCCTTCTTAAAAATGCTTTTGCTGCATCCCATAAG
TTTTAGTAGTTTGTGTTTCCATTTTCTCTTCTCTAAAGGTTTTAAATTTCCTTTTTAATGTTTTAATTGA
CCCATTTGTTGTTCAGAAACATATTTTTAAGTTTCTATGTATTTGTGAATTTTTTGAAATTCTTTCTATT
GTTGATTTCTAGTTGCATACCATTTTGGTCAGAAAAGATACTTGATTATTTCAGTCTTCTTAAATTTGTT
AAGACTTGTTTTGTGTCTAACCATATGATCTATCCTTATGATAAACCATGTGTGTGACAATAATGCACAT
TTTCTGTTGCTGTTAGAATGTTCTGTATACATCTGTCGGGTCCATTTGATCTAAAATGTGGTGTAAGCCC
TATGTTTCTCTATTGAGTAGGGTGGGGTGGAGGGAGAGCATCAGGATGAATAGCTAATGGGTGCTGGGCT
TAATACCTGGTTGATGGGTTGATCTGTGAAGCAAACCACCCTGGCAAACGTTTACCTACATAACAAACAT
GTACATCCTGCACATGTACCCTGAACTTAAAATGAAAGCTGGAAATCAAAAAATAAAAATAAAAATAAAA
CATAAAGGATCCAATTGGTAAAAACTATCTAAAACCTATCCTATCACCTAAAAAATATTCAGAAAATACA
AAAAGTGGAGAAAGAAACAAAATAACAAAATTAATGATATTTCCTTTTTGTGAAATTTCTATTTACTTCC
TTTGCTATTTTATATTACATTTTGGTTTTATTATTGCATTGTATAGGTTGTTCACAATTTTTAAAAATTA
GTTCTTTTTGTCATAAACATTATAAATATTTTTTGGTTATTATCTTTTAATGTTTTAATGGTACTTTTTT
GCTATTCAGAAGTTATTCCTTTTCATATGGTTTCTTTTTAATTCAGTCATTTGTTCATGGCTTTAAGGTC
ATGAACATTTGTTTCTTATACAGTAGTACTATCTGTAAAAAGAGTGAATTGCTCTAAATCTCTAATTTTC
TTTCTGGACTTTGCAACTGGATAATCTCTTTTTGAAGAAATGACAGTAATACATTAGTACAGTTGCAGGT
CTTTATTGGGATTTTTAGTTACAGCTTAATCATGCTTTTAGTTATGATTAATAGGTAAGTTACAAATAGA
GAAGTTCAATTTATAGTTAAAATTATTTTTCTCCTCTATTCAGTTTAAGGTTTGACAAGGGACTCTAAGC
TGTTCTCAGGTTTGTAAAAACAAACAAACAAAAAACTTTCTGGCGTGGATATGGGGTTGAAAAGTTTGAG
AAGGTTGAAGACTCCAAAAGAAAGAATTGGTTGAAGAGTTGTTTATTCTGTTTCTACACAAACATCAGAT
TTGGGAAAAACTAAAGACAAGGGTATCTGGGTCATTAAATCAGCCTAACACTACAACAGCCATCAAGCAA
AGCTGATGGTGTCTGTAAATGCTCTTCAACTTGGATGGTGGGAGAGGGTGTAGAAAGCATGAAGAACTAT
TTAAGAACATACTAAGTTCCAGGTCTTGTGACAGAAATTTTTCATATGTTACTTCTACAGATGTGACCTG
CCTCAGGAAGAAATGTCTGCCTCATACACTTAAATTTACCCTCGTATGTACTCTTGTCTACCCTGTGGAT
CCTCCTCATGCTGTACTCTGCTTACTTGCCTGTTTTCTTAACAGTGTTCACCATTAGTTCTGCATTGATC
ATATCTAGTTTGTTCATAGTTTTATTGCTAGGACCTAACAAAATGTCAAGAAATACGATATGTGTCTGAT
AAATATTTAAGCCCTTTAAATATTATATTCAATCATTCATTCATATTTATTAATTCAATGAATCTATTCA
CTCATTAATTCATTTAGAAAATACTTATTGAGCTCCTGACACTATACTAGGCAATAGGTTATAGCAGTTA
ACAAAAACCTCAAAAGCTTAAGTTATTATCAATATTATTTCAGTTAATTCTTACAATTAACTAAAATTGT
ATCACTACAATTATATAAAGTATTGCAGTCCATTTGTATAGATGTTAATATAATTTAATATATTAATATA
TTTTATATTATATATTACTATAATAGATATTATATAGTACATTTTATATACTATATAATATAGTATATAC
TATACATATATATATTTCATATTAATATAATAGTGAAATTGTCTCACTACAATTATGTAACGTATTGCAG
TCCATTTTTATAGATGAGAAGACTGAAGATAAAGAAAAAATAATTCACTTTTCTTTAAATGGATACTAAA
AGATGATACCACGTTTTGAACCCAGATTTTTTGAGCAATTTAAATCACATTATACTGTTTCCAACCATAG
ATTATATCATAAATATTTTGGCATAGTGAAGAGCATGGAAAGAGTCAGGTTGGATACACTTCTGAAGAAG
ATAAAGATATGTTATTATTTCAGAGAAAGATGAGTGTCCAGGATAAAATTTCAGAAGGGGCTTCTTTGGC
TCTTTATTAACTTTGTTTTTTGGGTTATCTTTGTTTGTTTGTTATGTTTTTTGAGATGGGGTCTTTCTCT
GTTGTCCAGGCTGGAGTGCAGTGGTGCAATCTCAGCTCACTGCAAACTCCACCTCCCGGGTTCAAGTGAT
TCTTCTTCCCCAGCCTCCTGAGCAGCTGGGATTACAGGCACCCACCACCACGCCCAGCTAATTTGGGCAT
TTTTTTTTAGTAGAGGCAGGGTTTCACCATTTGGCTAGGCTGGTCTCAAACTCCTGACCTCAGGTGATCA
CCCATCTCGGCCTTCCAAAGTGCTGGGATTACAGGCATGAGCCACTGTGCCCGGCCTCTTTATTGACTTT
ATAGCACATAGACCTGCTAGTGTGGAAGGACTTTGGTGAAGGTGGTCATTTGGATCTTGGAGATAAACTA
GAGAGCTCTATTCTGACAACTAGCATTTCAGAAATTTTTCCATGTAGAACATTGTGTCAGGAGTGGTTAA
TGGCAGTGTGGGCCAATGGAAGAAAACTTTTTTTACATTTAGAATCTGTTAATTAGTATCCCTGGGAGTT
CAGATAAATAATGTAGCTTTTTTGAGACTTATTTTCTTCATCACTAAAATGGGAATCCCTAAAGAGGTCC
TGACCAACTCAGAAGTTATAGAAATCAAAGAAGGTATGCATCTAAAATGCTCTCTATAAAGAGTAGGGAG
CATAGTGTGGTAATGAATTAAAGAGTCAGAGAGACCTCGACTGAGATATGAGTCAGTTAACCACTCAATC
ATGGAGCCTCTGCTCTATATAATGGATATCACATAATTCCACCTTTGTCAGCGTGTTGGAAGTATTTTAA
ATAACACTCAGGTGATACTGAATAATAAGATGCTACAATAATTATCATTCTCCAACAATTTGAATAACTA
TTCTTCAAAAATTTGTTATTCTCAAAAGTTTGTAGGTTTTGCATTATTCCAGAGCGGGCATGGCAAAGGA
ATACAGTGCTTTATTGGGGTTTAGAGGTCCCAATCAGTTGATATAAATGTTACAGGGTAGTATTAATGTT
TTAGAAGATTCCGTTTTATTGTTTTATCTATTCATTCTACATTCATTCAATAAATACTTATTTAGCATGT
GTGGGCCACTCACTGGACACTTCAGCTTCTGCATTCTTCCTAAACAGGCATGTTAATGTACATGCAAATG
GGGATTCCACCTATACTTATAAGTCAAGAGGTAGTTCAAGCATCACCTTGTCAGTGCAGCTTTCTCCACT
TCCCCAAGGTCCTTACTCCAGTCTTTTGAGTCTCCAAGAATTTGGGGGCTAACCTTTTATGTCAAGCTTA
AGACATTGTATTAGAATTGTATTATTATGAATTATATTATAATTGTCCAGTTTACCTAGCAAGATCTTGA
ATTATAATTTCAATTCTCATTTTATCTATCACATCTTTGTATCTGTAGTTTTCTGTGCTCAGGGTAATTC
CCAGCACACAATGTTTAATCGAATTAATAAAGTGTAACAATGTCCAACTGCAGTGTGTTAACTAGCAAAC
TGGCTAAGAAATGTAGTTGAAATATACTCTCTGCTGTCATTTCTCAAAGCATTCTATAAATACATTTAGT
GAACTCTTGCATACAATGGAAAATTCAGTAACCATTAAAATTATGTGTATTTATAATTGTTGGGTTTTAA
AATATTTATTATTTATTATTAAATAAGGAAGGTTATAGAATAGGATATTTAAAAATATTCCATTTCAAAA
GCATATGCATGTATATTCAAACGCAAATATATCTATTAATAGAGGTGAGAAGGGTATAAAAATGTTGGTA
ATGGACCCCTGGTTGGTAGAATTATGCATAAATTTTATTTCCTTTGTGTTTTACAAATTTTAAAACTTTT
TTGCAACAGATATGTACATTTTTGCAATAATATCAAAAATAGAGGCTATTTCCAAAACTGCACAGATAAA
TAAGCAAACAAACATACAAAAGGGTAGAGAGGGATATTTTATCATTTGCCTATACTCTTAAAGTTGCTTA
AACTTGTGTTTGTTTCCTTTTATCTATTTTTATTAAAGTAATTACTGGTGACTCATATTTTACAGAATTA
TCTCTCTCATAGATTGATTCAATAAAGAGATCTACTAGGCAGTTGAGCTCCAGGTCCTGCATTTTTCCTG
ACATACTCTGTATTTCTCTCTGTCCAGCTCCAGCTTCTGAAATGCCCTCTCAGCTTAGCACGGCCTGCTT
ATGGCGAGAACCATGTATTCAATGGCTCCTCCTTATTTCTGCAAGTCTTCAAATTCTCCTTTTGGTAATT
CTCTGCATGGAATTAACTCTTGCAAATCCATGTCTCACTTTTGTGTGACCTATTTTGTCTTATGCTACAC
ATTGTCCATGTTTTAGCAGTAGATTGGAAGCTTTTATGTGCATAGCCTTCCCAAGAGGAAAGTAAAAGGT
TGGTGCTAGATGGTGCACCTTCGATAAATGTCAGAACAGCAAAAAAAGGGCTTTAGAAATATTTCCTTCT
TTGCACATTCCCATTCAAGAATGGCTTATACAGAAAAAAAACAAGCACACCTCTGCACATATGCATTCCT
TCATCTGTTAATTCAACTAACATTAAGTACCCTTTATGTGTCATGTGTTATATTAGACCATGGGGATGAA
GTGATTACTAAATACTATTATTCTCCAACTAGTTTCCTCGAGGGCAGATATGTCAACAACTAAGTAATGT
AAAGCAAAACGTAACTCTGCAGTAATAGTGGCTCAATAGGACAGGATATTTGGAAGTGAGAAAAAGAGCA
CCAAAGAACGGGGACCACAGGAGTAGTCCTCTTTAACCCCTGAATCTGCAGCACCTATCACTATGCCTAG
CATAAGATAGTCAATGAATAGCCGTTTGATACTATTGTTTGGAATACAATTTTATGACTGGTGGTTCTGT
GAAGAATGAGTAGATTTTTTACTTGTGACATTTGTGTGTAAAAACAGTCAATATATAGAGAACAAAACAA
AAAGGTGTAGAAATATGTGGTTGAAAGAAACTTCAGAAAAGTCAATAGTTACAACATTACAAAAATACTA
AAAACAAAACTAAGGTTTATTGTGTGCTTACTACACACCAAATTCTAAGCGCATCACATGAATTGACTCA
TTCAATCAATAGTTACAGAAGAATAGACTGAAATTCCGAGAGGTTAAGTAACCAGTACTAAATACTGTTT
CATAAAGGGTTTAGATGGAGGCTTAATAGAAGGAAAGTGTATATTGGATATAGACAAAGAAAGTATACTC
TTCCTCCAACAAGGGAGCAGGAACTATCAGGATAAGGGATTATTTTGAACACTAGTCAAGCAGTGCAGTT
ACTGCTGCAGGAGGCATTCCAAGCAAAGCAAGTTGATAAAAAATTTAGCATGCTCAGTTGGGGCAGGCAG
ACAGGGAAATGAGGATTAAGAAGAATCTGGAGGAACAGGCTGGGCGTGGTGGCTCACGCCTGTAATCCCA
GCACTTTGGGAGGCCAAGGCGGGCGGATTATGAGGTCAGGAGATCAAGACCATCCTGGCTAACATGGTGA
AACTCGGTCTCTACTAAAAATACAAAAAATTAGCTGGGCTTGGTGGTGGGCACCTGTAGTCCCAGCTACT
TGGGAGGCTGAGGCAGGAGAATGGAGTGAACCTGGAGGCGGAGCTTGCAATGAGCCAAGATCACGCTACT
GCACTCCAGCCCGGGCGACAGAGCAAGACTCCATCTCAAAAAAAAAAAACAAACAAACAAAAAAAACAAA
ACAGAATCTGAAGAGGAACAAACAGTGGGCCAAAATTTAAGGGTGGGGAGATGTGCCATTTAGCATGCTC
AGAAGCTTGGGCCAGCAGTTTTAACTGATTCTTAAATACTCCGATGTGGCTGGGGCTCATAGGAGTCAAC
CTGACTGGACAGGCACTAGCTTAGGAACTGAGACCGAGGTATAAAAGGCAGGACATGACATCCACCACTA
AAACTCACAGTCTAGATACTAAATTCTAACTGTGAAGAGGAATCCTGTAGTGGAAGGATCATGAAACCTG
GAGTCAGAAGTTCCGTGATTATGTCCTGGGTCTGCTTCATGCTTCTTTTGTGTGATCTTAGGAAAGTTGC
AGATCTCCAAGCCTAATTTTCCTCACTTACAAAAAGGCAGTAATAATACTACTTTCCTCATAAGAACCTG
AGTTCATACTTTATAAACTATAACACATTAACAAAGACTAGCTCCTGTAAAGAGCTAAAGTATAAGGGGC
TTAAAAAAATATTCAATGCTTTTGTTCTTTACTCACTGTACTCTAAATGCTCTCCAGTATTGGCATCACC
TCACTGATTCTCCCTTAGCGTGTCTCTTAAATGTGTAGGAATCTAGTTTAGGTGCAAACCTGAAACAATA
CATTCCAGGAATGGCCAGCCTGCCTCCCTCCTTAGCTACAGATTAATTACATCTTCTGGAGTGACATTTT
GGCTGTATTTTCCAGTGAGGCTTCTCTTCTACTCTACTCCCCAAGCCTCCCCTTGGCCATCCTGCTAAGA
AGACTGTCCTAACCCACATGCCTTCAAACCAGACGCCTTGCCAACTTGGCAGCCCAGAAACAGTCCAACC
AGAAGGGCGGCAGTAAGAAAGGTCCCTGGGGCTTCAGGAATGAACAGCAGATTGCTTCCCTGCTGGTGAC
TGCAAGGCTGAAGCTTGCTCAGAAAGGCAGAAATCTCAGGGTTATGGGGGTAGGTAAGCTTGGAAACCAG
AAAAATGTCTTAAAGTCTATTCTAGCAATCAGATGGGATGGCAGAGGAGGACCTATCTGTTTCTGGGTTT
CTTTTCACACTGTTGGATTGTGACCAGCTTTAAAAACTGCTCCCTGATTTGTTCTCTAAAGCAGAATTAA
TGCCCTAGAACAAAGAGCGGTTATACCATTATAGTCATATTTGTCTATATTCTGACAGCTGTTTTTCTTT
TTGATGTTATTGTTAGATTTAGCTCTTATACCACTCTGTGCTTGTTAGACTGATTCATGGTTTGTCCATC
TCTCCCACTAAATCATGGGTTCGTGGCAGACAGCATCTATGTATCGATCATTTTTAGCACCTAGCACAGA
ACCTAGCACATAGGAGACATTCATTACATACTTATTAGACTAAGTTGTTGTATAATTGATAACTCTGAGG
CAGGCAGGCATCGACTGGGTTATCAGTAGCATTTTGTTGTGGAGTGAAATATTAATCTAAGAGAGTTGAA
TTGCTTTCTATCAAGTGATGAAGACATCATGTACTATAACTAACAACCTAAAGAATGTTCCTACAACAAT
GTAGCTGCTCTTTGTAGGATTAATATATTCTAGTACTAGGAAAGTTAAATTGCTTAAATTAAAATATTGA
TAACTTAAAAAGCTTAAAGGCAGGGGGAAAAAGAAACATGACTTGTCATTATTGCTGAAATCTTAAAGAG
AATTTCAAGATCATAATTCAAATTGTTTATTTTACAAAAAAGGAAATTGGGGCCCAGAGAAGATGATGTG
CCCAAAGGCACACAGTTTTCTGCAAAGCGGAGGGAAGAGTGTCAACCTCTTGCCCTGCAGATTAGGAGAT
CCTGGGGGCAATGTGGAATATACTCAACATAGCAGGAGGATATTTAGGCAGACAGAAGCAGCATGACTGT
AGGATAGATCTTTACCATAATTATTTCGAGAGCCAAATGTCAGACCCACTGAAATAGCACCAAATATCAG
AGCCAAGGGATGAACAGAGCTCTAAAGTAAATCAAAAGCCCAGAAATCAGGAGACTAAGAGGCAGTAAAT
CATGTGATTAAGATCATAGATTTTAGCATCAGACATGCCTCATTTTGAATCCCAAACCTGCTACATCTAG
CTACATAATCTCTGGCAAGCTGCTTATTCTTCCCTAAGCCTTCTTTTTCTCAGCCATAAAATGGTGCTAA
TATTTGTAGCCATCTAAAGTTACAGCTTTGATTTTTAGTATGATATTGTGAAAATATATATGTAACAATG
TTCTTAGCACACAATTACTAGATAGACAAGGAACTTGCTATTAAAATATTTGCATTCTAGTGAGGAGAAA
CATAAGCAAACCAGAAAAGAAATAAATAAGCACAAAATTCAGTTAAGCACTATGATGTGATATAATATCT
ATATATTTTATAAAGAATTACTTGGGAGAAGGTTCCAGTTGAGATAGGCTACCTATAGCTGGCTTCTCTG
AGGAAATGACCTGTAATTTGACACTGAGACCACGGAGAAGAGGTAGCCATAGAAATCCCTCTGGGACAAG
ATTTTTAGGAAGCAGAAGGCACACATTTAAAGGTCCCATGGCATAAAAGAGCTTGTCTTGCTTCAGGTTT
GGAAAGGAGACTAGAAAAGCTAAATACGGTAAACAAGAGGAACTTGGTGCAATATGAGATTGAAGAGATC
AGCAGAGATCAATAGAGCCCTAAGTACAGTATAGAGGAAAGAGTTTAAATTATTTTAATCCAGGTGCTGA
AATAATTTTTAGATTGACATTTTTAAAAGTTGTCTTGGCTATTGTGACAAATAGACTGTTAGAGTGAAAA
CTTCAAAAGTGACATGGATTACTCTATTGCATTGGTCTAAATGAGAAATGATGGTGATTTCAACCACAGA
GGTGACAATGGAGCTATTGGGAAACAGAAAACCGAACCTTATGTATTTCAGAGGTAAAACCAACAGGGCT
TGTTAATGGACTATGTGATAATATAGATGTAGTTAGTAATTTTAAAAATAAAGAAAAAAGAGTAATCAAA
GATTACTCCAATAATTAGAAGCATTAGAGAGAAGAGTGGAGATGTTTACTGAAGTAGAAAGGATGGGTAA
GTAATAAATTTAGCAAAGAAAATGAACTAAAGTTCTCTTTGAACATCTTTGGGTCTTTTTAGGATAGGGC
AAATAGATACCCGAAAGAGGCTGCCAAGTAGTCAGTTGAATCTTGGAGTATCAAGCTCAAAAGAGAGAAC
CAGGTTAGATACATGTATTTGGTAGTTTTAGCCTTATCTATTTAGCATTAATCACTTCGTGTTATTTAAT
CATTTAAGTTTTAAAACTTAATTATTTAGCATTATTTAAAATCAATGGAGTGAATGAGGTCACAGAAATT
GAGTATAAACACAGAAGAAAAGGAAGCAGTCTGGCATACCCCATCATTAAAAGGATGAGCCGATACAGAT
GAGTCAGCAAAAGCAAAGAAGACAGAGGGTCATTGACCAGTGAGGAAGCAGGAAAAAAAGGACATTAAGC
CACAAAAGCCATGTAGCCAAAAAAAAAAAAAAAAAAACAGTGGAAAAATAAATCAGGTACTCTTAAGAGA
TCCATAAAATGAGGAGAGAAAAGTACTTGTTGGGTCTGAAAACACAAGGATGATCATGCCCTTGGCAACA
GAAAAGTTTCAGTAGAATGGAAGCTTCGGGAGCCAGACTGGAGCAGATTCTAAACAAAACTTTTGAAAAG
TTTTCACAAAATAAGGAGCATTTTTAAGTGGGAAGCAGGAAAGAGGATATGAACAAGAAAGGAGGATTTG
AGATTTCCTTTTTAAGAGAGAGGATATGTATTAGAGAATGATTATATGTTGTTGAAAATGAAAACATTCA
GAGAAAGAGACATAGGAGAAAAAGGAAAAAATTGCCACAGCAAGGTACTGGAGATGTGAAATCTAAAGCC
CAATGGAGAGAGGAGCCTTTGCCATGAGTTGGAAGGAAGCTTCCTTCATGCCTGAATGGAGACACAAGAT
AGAGTATAGATGCATGTATTGTTCTTGGACAAATTAGGGTGTACTGATCTAGTTATTTCTATTTTCTGAT
TCAAGTGTGAAGGGAGGTCATCAGTTCTTAAGGGGCTGGGGGCTGACTAGGAGAATAAGAATTAGAAAGG
AAGAGTTTGTGTAAGTTAGAGAAAACAATATTAGACAAATCATCCATTATTTATGTCATTAAATATATCA
GTGGTCTGAATTTAGGAAGCATGTTGGTCTGGACAACAGGAAAGAACTATAGTGTCATGAGTTTCATTAT
TATCTGCTTGATATTACACAAGGCATTTCCATGTAACCATCCTCTTTAATCCTTAAAAATGAATATTAAT
TATTTCCTTTTTTAAAGTCTGAAGGCGGAGGCAAAGAAAGATTAAATAATTCGCCCAAAGTTTTAGCACT
ATTAATTGACTAAAATTAGGACTTTGACTCACTTCTGTCTTACTTTAAATTCCCTGTGTTTTGATTCTGT
CATTATATCAATTAGGAAGTAACTGATAATCATATCAAAAACATTATTTATAGGGTGGTATATTAGTTTT
CTAGGGCTACCATAACAAAATACCACAGACTAGGTGGCTTAAAAAACATAAATTTATTTTCTCACAATTC
TGGGGACTAGAAATCCAAGATCAAGGTGTCTGCAGGGTTAATTTCTTCTAAGGCCTCTCTCTTTGACTTG
TAGATGGCCATCTTCTTGCTATGTCTTCATAGGGTCTTCCCTGTCTGTGTGTCTGTGTCCTAAACTTCTC
TTCATATAAAGATACCAGTCATATTGCATTAGGGTTCACCCTAATAAGGTCTTTAAAAACTTTATCTTAA
AATACACTCACATTCTGAGGTACTTGGGATTAGGACTTCAACATACAAATGTTGCAGGGAAGCAATTCAG
CCTGTTACAAGTAGTGAGAATGAAAGTCAAACAGTAGTGGAATAATGACAGACTTGACGTTGAAAATGTT
AAATCAGACCTAGCTTTTAAAATTGTGATGATAAAATAGAGAAATAAGAAAACAAATCATTTGAAGGGAG
CAAGAATTAAGAAAATAGTATTTTAGAATTTTTTTTATTTTAAGATACAGGTGACTGAATCTATAGTTTA
AGTGAAATTTGCTGAAGAAATGAGAGAAAAAACATTAAAGCATGTTGAAATGTTTAAACAGGTACTATAA
AACATATGGGTTTAATTCCAAAAGATATTCTGTAGGGAAATTATCTCAGATTTTCCTCAAAGGAAAAATG
AATTAAAGAACAATAACTAATGTATAAAATATCTATAAGAAATGCTATTTTGAAAAGCTCCTTTACCAGA
TTATTCATAACATATCTGTTTATCATATGACTGTTTATTAATGTAATTTTGATGACATAAGGGTTTCCTG
AAGTATCAAAACAAATTTCTGCTTGTCGGATTGCCACAGCAGAAAACAAATAATAACATGCATGGACAAT
ACAAATGTTATTTTTATCCTAAAGTAAAGCATGCCCAAGATACATCTTGTTAAGTACAAAATGTCACAAC
AATCTAGAATAACAATAAGGATAAGAATCTGTTGAATACTCAGGAAAGAAATATTACTAAATTCAAAAAG
TCAAAGAGGAAATGGCAGCTGAAAGTTTTCTGTAGCTGTGTCCTTATACAAAGCATATTTATTGAAAGGA
AAAAAGTTTTGTTTCTGTTTTTTTAGAAAAAGTGCTTTCCCAAGAGAAAAAGAAGCAGCACAGCTCCTGT
ACGTCAGGTAAAAAAAGTCAGGAGAAAAAGCTTCAAGATTCACATGATGGGGTATTCTTTTACCAAACCA
GGAATCAATTGCTTTGGAGAACGGAAATAACATTTTTGAAATCCCTTAACACCAATGATCCCTGTTCTGT
GAGGTGCCTTGATGCTAATCAGACAGTTGCTCATATCAGTTAAATCATTGAAATGTAATTACCTCTAGTA
CTCAGTGTTGAGGTATGGAGGTGAGGGAAGCAGGCCTTGAGAAAAGCCCTTACTGTAGTAGTGTCACTCT
TAAGTTGCGTCGCCTTCAGTTATGCCATCCCCATATATTTCCTTTTATCCTCACTACAAAATGAGGACAT
TGGCTTTTCTGATTTCCAATGTCCTTCTATTTTTTCATGTTCTATGAGTAAGGAAGATATTTGATTTATT
TTTAAGATATTTTATGTGCAATTCTTAAAGTTGATATATGGCTTTCTGTTCTAGTGAGATATTAGACTAT
GAGAATCTGAAAATTCCCTTGAGACGATCAGTACCAAGCCAGAAAAATATAATAGGAAAATTTATTTTAC
ATGCATATCTATCTCTCAGAACAGTAAGGCTAATAAGATTCAGAAAGAAAAAATAAATTAAAACAGGAGT
ACTGATCTAGGAAGCTGGCCTGTACCTTACCTTGGCTGTTGGGGTTTTGGTCTCAATAACCTAGGGCATA
AGATTTTAAAGTCCATAATGGGGCAGAAATGAAAGACTTGAGCCCACCCAAGGCTAGGATCAAAATGTCC
ACATAAATCAAAGACCCTAGAAATCTGTATCATTCATGAATGAGTATAGTAGAAAAACAAAATCCACTAC
AAGTCAAAGGAAGATTTTAGCCTTCAAGACCTGGATAGTAAAATAATTCCCTGAAAAATTAGAAACCTGG
TGCTTGCACTCCACATAAGTTTTGTGTTTTGAAATTAAACAAAGTACTGATTCAGAAAAAGCAAGTGCAA
AACCTCTGAAATTAAAACAAACTAAGAATTTCAAGGAACAGATTGATTAGAATAACTGGACCATTGTAAA
CTAGGGAGACTGTACAGGAGAATAAGATCGGGGACGTAATGAGGCTCCTTGAGGATCATTTTAAGGAGTT
TCATGCTTCAACATGAAAAGGAAAGCAACATTCAGGAAATACTCCTTTGTTATGTCATTTAATTATAGAA
ACAGTCTCATACAGTCATTTGTTTTTAAAATAAATAAATAGAGTATTTTGAAAAAGTGCTTCTGAAGTAC
AAAGTGGTTAAGTGGTAAATTGAATCACAATCTGATCCCAAATCCAGGTTAATTTCTCTATATTACATGA
CTTTATTTCTTCTTTCACATAGCAAGCAAATTAGTCATACCTCCAAATTTAAACTTCAGAATTCTAACTT
ATTTCAGCTGGATTAGAATTTCTCTTAATTCTTATGCTCTCTTTCTGTACTTGTCAATGAAAGATCCTTT
CACTTTCTTCCTTTATAGTTAAGTCAGTACCTATTGCAAAAGTAGACTTCTTAGCCTATAAGCATTGCAT
ACAGGTGACAAGAATTTGCCAACTACAAATGTTAACTGCTTGAAGAGTTGTTTTTCAAATATCTGTTTTT
ATTGAGGTATTTATTTAGTATTGTTGAGTTCTGCTCTTACATAATACTTCGTTTCCAGGTAACACACAGC
CCTGCCAAGTATTGGTATCTAGGTAATGCTGACCATTTTAAATGAACGTTTCAATATTGAGTCTACCCAT
CCACGAGCATGGAATGTGTTTCCATTTGTTTGTGTTGTCTATGATTTCTTTCATCAGTGTTTTGCAGTTT
TCCTTCTAGAGGTCTTTCACCTCGTTGGTTAGGTATATTTCTAAGTAATTTATTTTATTTTATTTTTGCA
GCTATTTTAAAAGGGGCTGAATTCTTGATTTGATTCTCAGCTTGGTTGCTGTTGGTGTATAGCAGAGCTA
CTGATTTGTGTACATTAATTTTGTATAACGAAACTTTGCTGAATTCATTTATCAATTCTAGGAGCTTTTT
GGAAGAGTCTTCAGGTTTTTCTAGGTATATGATCATATTATCAGCAAACAGCAACAGTTTGACTTCCTCT
TTACCAATTTGTATGCCCTTTATTTATTTCTCTTGTCTGATTGCTCTGGCTAGGACTTCCAGTATTATGT
TGAATGGAAGGGCGAGAGTGGGCATCTTTGTCTTGTTCCAGTTCTCAGAGGGAATGCTTTTTTCTTTTCT
CTTTCAGTATTATATTGACTGTGGGCTTGTCATAGATAGGCTTTTATTACATTGAGGTATGTCTCTTGTA
TGCCAATTTTGATGAAGGTTTTAATCATAAAGGGATGCTGGATTTTGTCAAGTACATTTTCTGCATCTAT
TGAGATGATCATGTGATTTTTGCTTTTACTTGTGTTTATGTGGTATATCACATTTACTGACTTGTTTACA
TTAAACTATCCCTGCATCCCTGGTATGAAACCCACTTGATCACGGTGGATTATCTTTTTGATATGCTGTT
TGATTCAGTTAGCTAGTATTTTGTTAAGCATTTTTGTATCTATGTTCACCAGGGATATTGGTCTGTAGTT
TTTTGTTGTTATTGTTATGTTCTTTTCCGGTTTTGGTGTTCGGGTGATACTGTCTTCATAGAATGATTTA
GGGAGAATTCACTCTTTATCTTGTGGAATAGTGTCAGTAGGATTCATAACAATTCTTTGAACATCGGATA
GAATTCAGCTGTGACTGTGTCTGGTCCAGGACCTTTTTTGTTGTTGTTGGTAATTTCCTTACCATTTCAA
TGTCGCTGCTTTTTATTGGTCTGTTCAGGCTTTCTAATTCTTCCTGATTTAGTCTAGGAGGGTTGTGTAT
TTCCAGGAATTTATCCATCTACTCTAGGTTTTCTAATTTATGTGCATAAAGATGCTCATAGTAGCCTTGA
ATGATCTTTTGTATTTCTGTAGCATCAGTTGTAATATCTCCCATTTCATTTCCAATTGAGCTTATTTGGA
TTTTCTATCTTCTTTTCTTGGTTAACCTTGCTAATGCTCTATCAATTTTATTTATCTTTTCAAAGAACAA
GCTTTTTGTTTCATTTATCTTTTGTATTTCTTTTGTTTCAATTTCATTTAGTCCTGCTGTGATATTGGTT
ATTTCTTTTGCTGGGTTTGGGTTTGTTTTGTTCTTGTTTCTCTAGTTTCTTGAGGTGTGACCTTAGATTG
TCTATTTGTGCTTTTTCAGACTTTTTGATGTTAAAGGTTGTAAACCTTCCTCTTAGCATCACCTTTGCTG
AATTCCAGAGGTTTTGATAGGTCGTGTCACTATTATTGTTCAGTTCAAAAAATATTTTAAATTTCCGTCT
TCATTTCATTGTTGATACAATGATCATTCAGGATCAAGTTATTTAATTTGTATGTATTTGCCTGGTTTTG
AAGGTTCCTTTTGGAGTTGATTTCCAATTTTATTCCACTGTGGTCTGAGAGAGTACTTGATATAATTTCA
ATTTTCTTAAATTTATTAAGATTTGTTTTGTGGCCCATCATATGATCTATCTTGGAGAAAGGTCCATGTG
CTGATGAATAGAATGTATATTCTGTGGTTGTTGGGTTGAAAGTTCTGTAAGTATCTCTTAAGCCCATTTG
TTCTAGGGTATAGTTTAAATCCATTGTTTTTTCATTGACTTTCTGTCTTGATGACCTGTCTAATGAAAAA
TAAATTAAATAAATAAAATAAAATAAAATGAATGTTCCTTCCTCTTTTAGTTTTAGGAAGGGTTTGTATT
TAATTGGCAATATTCCTTTCTTAAATGTTTGGCAGAATTCACCAATAAAGTCAGCTAGATTAGAAATTTT
CCTTGTAGAAAAGATTTAAAATTAAAACTCAATTGGTTTAATAAATTTAATGTTACCCAACCAATCTATT
TCTTCTTGAATGAACATTAGTAGTTTGTGGTTTTCAAAGAAGTAGTTCATTTTGTTTAAATTGTCAAATT
AGTGGTATACAATAATTCATAATGTCTACTTCTTATCCTTTTGATATCTGTAGGTTCTGTAGTGATGCTG
CTAATTTATTCTTGTTGGTGGTAATTTCTATCTCTTCTAATTTTTTATAACCAGCCTAATTAGACCTTTG
TTCATTTTATTTGTCTTTTTTTAAGAGGCAGCTTTAGTTTACTTGATTGTCTCTATTGTTTTTCCATTAT
ACATTTCAGAAATTTTTGATATTTATTATTATTATTACTTGCTGGTCTAGTATCTTCTGACAAAATAAGT
CACATATTTTAATTAAACAGTGGCATTTTACTTCTGTTCTCATCTTTGACATCATTAAACTGCCATATAT
TGTTCAAAAATTTTACATATGGTTTGTTATAGAATCAGGGTGAAATATGAGTAATAAAGACAATGACCTA
TATCTGCACATGTGGCTAATGAGCACGTAAAATATTGTTAATAAAACTGAAGAATATAATTTTAAACTTT
AATTTAAAATCGGGTATTTGTTTGTTATTGAAAAACTTACAAATATTTTTAGAGCAACTTGGATGTGTGA
ACGTAAGTTATTGCCTGTAAAATGTATGAATTCTAAATACACACGAAGTATTTCTGATACTGTCCTATGT
CATATGCCTTCAATATATACTCTATAATTACTAGGTTTTTCTTAACTTTGTATTAAAAAAAATCACATTA
ACCCACATTCGACTAGCTATAAAGAACTTTGTTTTCTATAGTTTTATACAAAATGATAGAGGTATGTGTG
TGTACTTGTGTATATGTGTGTGTGTGTGTGTGTATATGTGTGTGTTCATGTTTCATATTAGTCAAGATTC
AATGAGAAAAAACAGAAACAATGCTAGTTGTTTTAATAATGTCAGTTGTTTATATAATAATAAATAATAG
CTTAAATAGATATTTGAAAATTCAAAAGTGGAAAAAAAACTGAAAATGCCTAGAGATAGGCATTGGAGGA
AGCAGTACCACTCCTAGGACTGGGTAAAAATAACAAAGTAGTAAGAGATATTAGAATCTAATAGTTTTGG
GAAGGGCTTCAAAAACCTGAACTCAGATTTCTGAAGAGGGGACACTGTTTATTTAGTAGTGATATCTCAT
ATCACCTGACATTGAAGGAGGAGCCTCACAGGGCAGTAATTCAAACTCCTGAGTAGGAGGCTTTAGTCAA
CTGGTACTGATAGCTCATGAGTATACTAGTGCTCTACAGAACTAGATCTCAGATTTTTGAGCAGAGAGGG
ATGTAGGGGTGTGAGGGAATGGGGAATACGGCCTAAAGCATGTTGAAACTTCTTAAGAGGAATGATAATG
CTGATTCTTGGTGTGCTGATAAGAAAGCTAGAAGCTAGACTCTACTGCTCTTCCTAGGGTCAAGAACAGT
CACTGAAATAAACAAGAAGGAACAAGTCCTTTGCTGTTCTAGCCTATATGTAGTGTCTATCAGGGGTTCA
ACTAGCAAAAGAGAAATGCAGCTTACACATTCTCAGCCCCAGTATCCCAAAGTGGAATGTAGTAGGACAT
CGTTGGGGCTGGAAACAATAGCTTAAAAACTGGCACAGTCCACCTCTTGTCTATCAGGCATTGATACACA
TTTACCCTCCCATACATAGGTAAATTTCACACAATAACAATAACAAACTTAAGGTATTTTTTTCAAACGA
AGATTATTTCATTCTATCTTCATGAAGAGGTAACTAATGTCCCAAAAGCCATTTCTGATTAATTATTCCT
TTCTGATTAATAGCCATATTATCCGTCTCTGGGAGATGTTATATAAACTTCAAATTTTGTCATGGTTTAT
ATAAACATTCTGTACTCTAAAGAGGGAATTATAAGATTAAATATCGTTGATCACACATATGAAATAATGA
GACATGAAATGTTAATATATAAAAATACTGTATATGTATACACACAGACAGACACAAATTAGGTTATATG
TGAAAACACAGAAGGACCAGGAAAGAAAAGATGCGTAGCTGCTGCAGACCTCATTTTATTTATGTATTTT
TTTTACTACCCATTAAATGTTATATTTGCACTCAGCCAGCATTTCAGCTGGCCAACGCTCTCTACCTATC
AAATGACTCAAACTTTCTTTCCCAGAGAATTTGAATTCTGAGTGATTTTCACCTTTCTTTGGTTACTGTA
GTCTTCCATTAAATTATTGAACACAGAAATGCTAAAAATTCCTCAAAGAAGGCCTTGAATTTCATGCATA
TAGTCTTTCCTGCACTACTATGTAGCAACACCCCAAAAGTATCTTGAGAATATGGATTTTTTTAAAAAAA
TCATGTTCTTCATAAAACTTAACAATGTGAAATTGTGTTTTGGTGCAAAGTCCCAAAAGATTGTGCTAAT
TGATTCCACAACACTTATTTTTATGCCTTTAAATTCATGTTGAAGGTGTGGCATTATGACAATGGAGTGA
TTGATTGCTATGGTGAAAGGCGGAAAATTTTCTTCTCAAATGGATTCTATCTGAACACAGATGAGAAACT
TTTTTTATGTTTCTTTTAACTATTTATAATTTGAGGAATTATGACACCTGATACCTTGAAAGTAGTGAAG
GAGAAAAATTGTGTTTCCATATTAGCTATCTATATCAAATCAGGCAAGAACAAAAAAGAAAATTGATTTT
TTTTTTGCTAGAAGCCTGATGGATGTAACAACTTTTCCTCAAAGGAAAAATAAAGGAAATCTCTTATTAC
CTATATGGCAACATCTGGCCAAATGAAAATGTGCAAAAAAAAAAAAAGTGAAATAAGTTGGGGCTGTTTC
TGGCTCAGTGTGAAGTATGAAAAGATTTTAAAGTTAGGTGTTAGATTGGAAAAAATGAGGATTTATGATC
ATCTTCTTTGACACTTTTTATAATGTGCATCATAGAATATATGAGAAAAAATTCCCATGAAATTATGAAG
AAACAGATATGATAAGTGGACAGATATTGGGTGAATTTAAGAAAAACAAAGTATTTTTATTGTACATTTA
ATTGTAAACAATGTAAATAGGCACTGGCCTGTTTTCTAAGCCTTTGCATAGGTTCAACAATACGGCTTTC
TTCCTTCCAAAGGCTGACCTATCTATTCCCACTATACAGGGTCAAATCTAATACCAGAGACCAACTATGA
GGCTCTGATAAAACACCATTCCTTCAGAGCAGAGTGGGGAGCAGCCAGTGCCTTTGCCACCCTCACTCAG
CTGGAGTTACTCAATACATTGTTATTATGTCTGTTTCATCTATTTTCTAAGTCATACCTACCGGAATAGG
TAATCTATTGCAAAAGTATTTCTCAATCCTTGCTGCACGAATCAGTGGGTGTCTTTTTTTAATACCCATG
TGCAAGCCCCAAACACAGAAATTCTGAATTAACAGATATGGAAGTCTGGGCATCAGTATTATAATGGGTT
GAGAACCATTGCATTCATGCCCAAAATGAATGAGTCTAGAATTCGTAACATTTACGTAACCACAGATGCG
CTAAAAATGAATTCTAAGAACACGATGACTATAGCACTCTCCTAATCTCTTTTTTTACACAGCCTAGACA
TCTTCCTTGCAAGCTTAGCACTTTCCTTCTCATACTGAGAATCAAATTCTACCCTGTTGTGTAGAATACT
TGGCTAGAACATTAGTATTTGGCCTTATTCTTTTTAGTCTTTTTCTCAAGAAGGTTGACACTATTTAAAC
TTCTATCACTGAGAAAGTAATGCCAAGCAGGCAGACTACCCAAAGCTATAACCTCAACCACCTGTTTCTG
AACAATAGATCTTACGCTAAATTAGGTCCCTTTGGAAATAACATCAAATATTACTACTCTGAAGTAGCGA
ATGTAGTTAGGTTAAAAAAATATATCAGAAGTTGGAAAAAATAGGACCAAGAAATAAAATAGTAAGCCAA
AGTCAAACCAGAGTTCATAAAATTCCTCGAATGTTCATGTTTAGACCCCTGGATCCCCTTTCAGAGGCTT
ACCCTACCTAAAACCAGAATAATATTCTAGGCACAGCTTACTTGTGACCCCACATCTTTCCTTCCAAGCT
GGCATTCTACCAACTTCCCAGCATATCTGCTGGACAATCATCAATGCATAATGACAGAACCATATGTAAC
TTCTTAAAAATACATACCACTGTTGTTATACTGAATCTATCTTAATTTTGATTAATAATGATTCCCTCTT
ATTTAATTATATTATTCTTTTTAGTTAGGAGTTGATGGGCTTAAGAACCAGATTGGTTCTTAAGAACATT
GTTTTAATTCCTGGCCCTGCCATTTACTATTCATGTAACTTTGGACATGTTATTTCCCAGGGGCTATGTT
TTCTCTGATAACAAAAGTTATTCACTTGTAGATATTCTTTGGTGGTTAAAAAGAGATTGTATATTTTTAG
TTTATCTTCTTTTAATTCAATGGAATGAGCAAATAACTGGGTTAAGGCAAGGACGTGTGCAGTAGTTTCT
CATCTACTATCAGACAGTTTTATTACCTTAGACAAGTCCCTGAACTTCTACTTCCATTGAGAGTAGCCAC
TTTGAAGAATAAAATGCAAAAAAAAAAAAAAATTAAAAATGAACAAAACCTAAGAGATCTGAGCAACATC
ATTAAGTATATCAACATATGTGTAACAGAAGTGCTAGAAGGAGAGAAGAGAGAACTGACTTCTTACCAGA
AACTATGAAGGCCAGAAAACAAAGGATTGGCATATTCAAAGTGCTGAAAGAAAATATTGTGACCCCAGAT
TTCTATATCTGGCAATGTTATTCTTCAAATATGAAAGAGAAATAAAGAAATTTCCCAATAAATGAAAAAC
TGAGAGATTGCATTGCTGGTAGACTTCCTCCAACCATGCTAAAGGAAGCAGTTCAAGCTGAAAAGAAAGG
ACACTAAACAGTGACTCATCCACCAGAAAAAGTAAAGAGCACTGTGAAAGATAACTGCATAGATAAATTT
AAAAGACTACAAAAATGCTCTTTGAGTTTGTAACTTATTTTTTCTATCCTATTTAAAAGAAAATATATAA
GGCTATAAATCCAGGTTGGTGGGCATATAATGTATACAGATAAAATGTGGGACAATAACAGCATAAAAAT
GAGAGCATGCTCCATATAACAGGGGTCCCCAACCCCTGGGCCATGGGCTGCTACTTGTCTGTGGCCTGTT
AAGAACCAGGCCACACAGCAGGAGGTGAGTGGTGAAGTGAGTATAACCTGAGCTCTGCCTCCTGTCAGCT
AAGCGGCAGGTGAACTGGGCATGTGAGGGATCTAGGTTGCACATTCCTTATGAGAATCTAACGCCTGATG
ATCTGAGATGGAACAGTTTCATCCCAAAACCATCCCTTCAACCTCCATCCATGAAAATATTATCTTCTAT
GAAACCAGCCCCTGGCACCAAAAAGGTTGGGAACAGCTAGGAATTATGTATTCAACACAAAAGAAGGCAG
TAATGGAAGAACTGAGGAACAATAAAGAAAGACATAACATGTATAGAAAACAAATAGAAAAATGTCAAGA
ATAATGACATTTTATCAGCCATTACATGACATATAAGTAGATTAAGTTCTGCAATAAAAGGACACAAATT
GGCTAACTGGATTTTTTAAAATGACCTCAATATATGTTGTCTACAAGAGACTCACATTAGATGCACAGAT
AGGTTGAAAAGAAAAAGATATTTTATGTAAAAAATATTCAAAAGAGAGCTTGAATAGGTATACTAATACC
AGACAAAACAGACTTTAAGACAAAAATTTTAACAAGTGACAAAAGAAGACATAATATAACAATAAAAAGG
TCAATTGCTGAAGAAGATACAAGAATTATAAATATGTATGCACTTATCAACAAAGCCACACAATACATGA
AGCAAAAACTGACAAACTGAAGGGAAACATTTGCAAGTCAACTATAATAGAGACTTTTTAATACCCCACT
TTCAGTAAGGGATAGGACTAGACCAAAAATCAGCAAGAAAAAACTTGCGCAATACTATATGCCAATGAGA
CCTAACAGATATTTATAGAACACTCTACCCAACAACAGAATGCACATTTTTTTCAAGTGCACATGGAGTA
TTTTCCAGGATTAATTACATGTGAGACCATAAAACAAGTCTCAAAACTTTGAAAAGATTGAAATCATACA
AGGTATATTCTCCAACCACAATGGAAAAAAAATAGAAACTAATAATAAAAAGGAATTTGAAACATTTATG
AATATATGGGGAAATTAAGCAACATACTGCTAAATAATAGTTGAATTAAAGAAAGAATCACAAGAGATTT
AGAAAATGCTTTGAGATAAATTAAAAACAAAATATACCAAAGCCATGGAGAATAGCAAAAGTGGCAATGA
CAGAGATTTTTTATTTTTTTTTGAGATGGAGTCTCACTCTTGTTGTCCAGGCTGGAGTGCAACGGCACCA
TCTCAGCTTATTGCAACCTCTGCCTCCTGGGTTCAAGTGATTCTCCTGCCTCGGCCTCCTGAGTAGCTAG
GATTACAGGCACCTGCCACTAGGCCCAGCTAATTTTTGTATTTTTAGTAGAGACAGGGTTTCACCATGTT
GGTCAGGCTGGTCTTGAACTCCTGACCTCAGGTGATCTGCCAGCCTTGGCCTCCCAAAGTGCTGGGATTA
CAGGCATGAGCCACTGTGCCTGGCCTGAAATTTATGGTTATTAATGACTACATTAAAAAAGGAAATATCA
CAAATTAATAACATAACCACCAGCCTTAGAAACAAGAAAATAAAAAATCAAACTAAACTCAAATAAGAAG
AAAGAAATAGTAAAGACTCGAGTAGAAATAAGCAAAATAGAGAATACGAACACAGTAGAGAAAATCAATG
AAACAAAAAGTTGATTCTTTGAAAAGATCAACAAAAATGACAAACATTTAGCTAGACTGGCCAAGAAAAA
AAAAAAAAGAAGATTCAAATTACTAAAATCAGGAATGAAAGAGGGGACATTACTATTGTCTTTACAGGAG
AAAAAATTACAAAGGAATACTATAAACAATTGTATGGCAGCAACTGATACTAGATAAAGTAGATAAAATA
AATTCCTAGAAGCACACAAATTACCAAAACAGACTCAAGAAGAAATAGAAATCTAAACAGACCTGTAGTA
AGTAAAGATACAAGCTACTCATCCAAAAAAAAAAAAAAAAAAAAAAAAACAACAACAACAACAACAAAGA
AAATCTCAGGACAAGATAGCTTAATTAATTGATTTTCTCACATGTTTAAAGAACATCAATTAAAGTCTTT
CAAAAAAAGTAGAGTAGGAGGGAACATTTCCTGACTTACTCTATGGGGCCAGTATTATCCTGTGAGCAAA
GTCAGACAAAACTATCACAAGAGAAAACTACAGAACAATAACACTTGCAAATACAAATGGAAAAAAAATT
CTAAGCAAAATACTGAAAAACTGCCCAGCAGCATATAAAAATGTTTATGTCAAAGCCAAATTGGATTTAT
TTGAGGAATACAAAGGTGGCTCAACATATTAAAATCAATAAATTTATTATACCACATTAATATAATAAAG
AGAAAATAAAATCCCATGGTCATCTCAATAGGTGCAGAAAAAGATAGTACCTTTCATGATTTAAAAAACA
AACATGCATCAAGCTAGGAATAAAAAAAGAGCTTTCTCATTTTGATAAATAACACCTATGAAAAAGCCAC
AGCTAACACATCATACTCACTTATTAAAAACTGAAAAAAAAAACTCAAATAATTTTCCTAATGTAAAGAA
CAAGGCAAAGATGTTTGCTTAGACTACTTCTGTTTCACATTGTATCGAAGGTTTAAGCCAGGGCCATTAG
GCATGAAAAAGAATAAAAATTGTCCACACTGGAAAGGAAAAATTAAAACTATTTCTGCAGATAATAGTGT
CTTAAATCATAAAGAAGCTACAAATAAACAGTTTGAATGAGTTTAGAAAAATTGCAAGATACAAAATCAA
TATATAAAAATCAGTTGTATTTCTAAACATTAGCAATAAACAAACTGAAAAGGAAATTAAGAAAACAATT
TCAGTAATATCAGAAAGAATAGAATACTTAGGAATAATTTTAACCAAATCAGGGCAAGACTTATATACTG
AAAACTATAAAACACTATTGAAAGAAATTAATAAAGATCTGAATAAAATAACAGGAAGACCCCCCCTTGT
TCACAGATTGGAAGACTTAACTATCATTAACATGACAATACTTTCTAAGTTAGTCTATAAATTCAACACA
ATCTCTGTCAAGTGAGAGGAAGTTAAAAGATCATGATTCAAATGCCACAGAGCCTCACTGCTCTTAATGT
TGTAGTAGATTTTCTTGAATAAATGTTTCAGCATTTGCTGTGTACCCTTAGAATAACTTCTAGAGACTTT
AAGTGGGGGAGTATTATTTTTTCATAATTGTTACTAGTTACACTTGTTTTGCAAAGGAGAAGATCCGTGA
AGCTTCTCCCACTGCCAATCCAGAGGTGGAAATGCAGAAACCCTTTTTAAAAAAAAATTCCTACACTGAA
TGTAATTTCAATATGTAAAACAGATACAAATAGAACTGCTCTAATTGTGATTGGGGTAAAGTCTCCAAAG
TCCATTTGGGTGGCAAGTTCTCAAATATTTCACGGACTCCAGATGACTTATTTATCAAACCTTGGATTAG
ATGACAGTATTCTTTTTTTTTTACCTTTTAAGTTCAGGGGTACATGTGCAGGTTGATTACATAGGTAAAC
TAATGTCATGGGAGTTTGTTGTACACTGTTGGTTGAAGTATAAATTAGTTCAACCCTTGTGGAAGAGAGT
GTGGCAATCTCTTGAAGACCTAAAGATGGAAATACCATTCGACCCAGCAATTCTATTACTGAGTATATAC
CCAAAGAAATATAAATCATTCTATTATAAAGAAACATGCATGCATATGTTCATTGTAGCACTATTCACAA
TAGCAAAGACATGGAATCAACCTAAATGTTCATCAGTGATAGACTGAATAAAGAAAATGTGGTACACATA
CACCGTGGAATACTATGCAGCCAAAAAAAAAAAACAAACAAACAAACGAGATCATGTCCTTTGCAGGGAC
ATGGATGAGCAGTGTTCTTTCAAGCCCTAATATTTGTGAAGTGTCTAATATGTTATTTATATATCTAAGA
ACTCTCCTCTCTCCTTTGTAAGGAAAACTGCTTTTCTTAAGTGCCATTTCTCTTTCACTCCTTCAAGGAA
ATCTGTTCACTTTTCCTTATCTTCTCAGTAAATGATATCTAAGTATTTAGTGCATACTTAATTCTTTTAA
GCTTTATTGACAGTTACGTCAGTTTTGAGTCTAAGCCCATTAGGTAATCAGGCCTCTGAGAAGCTCATAT
TTTTTCAATGAGTATACCTAATAACAACTTCTAAACAACTACAGATTCTCAAATGTTTTGGGCACAACAA
CAAAAAATGATAAATTGGACCCTCACTGATGCTTTTAAAAGTAAATAAGCAAATCATAAGAAATCAGGGA
TATGGGAGATAAAAACAATGATTCTCACTGTCCAAGGATATATAAGTGGGTAGGGGAAAGCCTTCAAACA
AGGAGTTTACTCCTTTGACCTTTGATAAAAGGATAAGCTTTGTCAGACGGGCCCAAAGAGGAGCTTGCTG
ATAAGAGTTGTCACAACCACTCCACCTCTCAGAATTCCTCTGCCTTCGCCACTTGGCTGTGGAGTGAAAT
ATGTCTTCATAGCTCCTATTACCCTTGATTTTTCTTAACTGGGCCTTTCTCATTTCATGAATTTTACTAC
TAATCACTTGGAGAAAATAGATAATAAGTAATCAACTTGGGATTTTAATAGAAATTTCAAAATGTTCACT
ATCACAAGTCCATTTGGTTTATATTCTGGAGTCTTCTTGAGATGTTTCTGAGTTTTCTCCTTTGATGTTC
TACCCTCTGTTATTTGTTTGTTCTCAGAGGGGGTTTCACTAGTCTCTCACTCTTCCACAAATTGTTTGTT
AGCAGAAGAAATAGGAATCCTTTTCTCCATGTTATCTCCCTTTCCATAGTGGAGATTTAATAAAAATAAA
ATAATCCATTTTCCTTTCTTGAAAGTGGCAATTAATATTTTTAACTCCAGATCGAATGATGCTCAGATCA
CTAGCTTTTTTAAGACATACTTTAGTTTGTCAATTTTTCCAATTGGAATAGAGGATTAGAAGAGTAGAAA
AGGAAAAAAACTAAGAAATATTATGTAAATAAAAATTTTGGCTGGAGAAGGAAATAAATGGTAAGTACAT
GGGAGGATATCTAACTACTATTTTGGGGCAAAACGCAAAGAAAATAGTCTGTTTTTTAGCATTTGATCGA
TCTTTTCTTGGGCTCCTTTTTCCAGCAGTCCAGATCATTTGTTGTGATTAAGATGTCAGGTTGTCAGCTT
CAGTTGAATTTGCTCTCTGAAGAATGTTTTACATTATCTTCTTTGTTCATTAGGCTAGACTTTAACACAT
CATGCTTTTTCTTATCTAAATTGCCAATGATATTAGTGTTATTCTTGCATAAATTATTTGTGTATTGGTG
TTCTGTATATTTCTATAATTGTAAACCATAAATACTCTTAGTCATGCATAGAATATTTGCTGTTCTTTGG
AAAGAAGCATTTGAGTTCATAGATAATTCATAGAGAATTTTGCTTCTTTTAGATGGCATCTCTGTGTTCA
CATATTTTTTACTTTCTTTGCTTTCTTGTCTTATCTACAGATATTACCTCTGATTTTTCTTACATTTAGT
ATGGGCCATAGGTACTTAGCCCCATCATATGTATTGGTCCCCTGCCTCTAATCCCTCCAACAACAACAAC
AACAACAAAATCCAATCTGCGTAACACCTCCATATAATTCTTTCTATGCACCATTTTTTCACACAATTCC
ACTCTTCAAAGGGCAATAGTCTTCCACTGCATATATGTTACATACAGAATAAATTCAAATACTTTGGGCT
GATACCCATAGATTTTTGCTATTTTGTTCTTGCTGCCCACTTTTCTACTATTGTTTTAGTCTATAAGCAC
CAAACTAAGCACTAATTTTTCTCATTTTCTGAAGCAGAGGTGGAAACAAACCTTGCCTGTTCATATGCAG
ATTATCATGTAGGTAATTACATGAAGATTATCATGTAGATTATTACATAAAGAATAATTCCTCTGGATTC
CTACCAAACCATGTCAATTACTGGGGAGGCTACAAGTGTTAGAGTTTGTGTCTGAAGGGCCTTATGCACA
ATAGGAATGATATCCTTTTGTCTGGGGGAAAGACTTGTCATTCAAAATAAAGGAGTTCTATATCTGTACA
GATAGTAGATATATGATAAACTTTTCCACTGTAATTCTCAGAATCAAGTGAAATCTACCACAGTTGGGGA
GAGCAGTAAGGCTATTAATGTCACATGAAAGTTGATGCTTAGGGCTTAGGGATATAGTACTGGGAATATT
TCAGTGAGGATGTTGGAAACCAGAAAGTATTGTCTGCTATGACAAGAGTGTTGGGTATGTGAAAGTGTGC
CTGTACTACATATGCTCAGTTTGAACTTATTTAACTGTTATTACCTTGAATAATGACTCTTACTTTATAG
CACTTGAATACACCTTTCTCCATCAGATACACGTTCTTGGTCTTTGACTGAAGATATAAAAATCATATAA
ATGATTAAAGATATAAAAAGAGATAAATAGATATAAATGGTTTAAGTGGCTTTCTTCCCTGAAAATTCCT
TAAGGGAAGGACTCTGCTTTCTGAAGCTTTTCATCTCCCATTTTACTACATACATTTCCTGTACTTGCCT
GTAGGTAATAGCTTGTTAGTATCTATTTTCTGAATATATGTTTTGAAGAAACATAATATATTCTCCTCAT
TCCCAGGGGATACTTCTGAAAACCCTCTGGGATAGTTACTTATCAAATATTTATTATCAACTGTGTACAG
GCACGATTCTCTTTTCTATGGACATAGCAGTGAACAGATGAAGTTTTTATTTGTAATGTAAAATGTCACG
TAGTTTTCCACTCAAAGATCTTTTTCAATGTTTTTCTTTTTCCTGATTAACTTAGAAAATGGGCAAGTCA
TATAGGCTTACTGAGTGTATGTGTGTGTGTGTGTGTGCAGAATACACAATTGGAAGCACTTGGTGTCCTG
GAAAGTGCCAAGTACAAAAGACTCAGGTTTGATTCCTACTGCTCCATTTACTAACTAAATAGAGGAAAGT
TGCCTAAACCCTCACTTTTTGTTTGTTTGCCTATTTTTATATGTATTTTAATGGGAGTACTTTTGTACAA
ATACCTCATTAAGGCTAAGAACACTTATCATATTTAGACTGCAGGTTTCAAATGTTGATTCTGCCACTTC
ACACTTACTGGCTGTGTAACCTTAGGCAAGTTTTATATCCCTTTTGTCCTCCAGTTTTCTCATCTGTAAA
ATACAAGTATAACATAGCTCATAGGGTTGTTCTGAGGTTCAAACGAGTTCCTGTATGTGAAGTACTTTGA
ATAATACCTGGCATACAGTGGTATATGAGCTAACTCTCACTACTGCTACCATACTACATTTCTTGCAGTT
TTGTTGGAGAAATAAATATGATATATATATATATCAAAATTCTCAGCATAGCACTGGATGCATGACTGTC
ATCCAATAAATTGAAATTATTACTGAAGCAATCAGTCATTTTTTATTATTCTAAGAGCCTCAGAAGCATC
ACTCTAGTGAAGAATAGTAGAACAATAATGTATGTTAAATGAAGAGAAATTTTGGAAGAAAGAGAGGCAG
CATAGCCATCTTAAGAAAAGTAATAGCTATTTGTCATATGTAGAAGTTGTCTTAGTCACTATTGCTCCCC
TGGCATACTATGATCTCCACTAAACAGAAGTATTACATTTTGATTTATTATAATTTAATATAATACACAC
ATCCATTATAATCATAGTTCTAAAATTAAAATCCAGGAACAGTTACTTCTTATCTAAACCACTTAGATTC
AATTTAACCCTTGGGATCAAGCCCAGACTCCCCACCCTGATATGCATAAGGCCTTTCACAGTGTGACCCA
CCTCCACCTCTCTGGGCTCACTTGTTGTTGATCCCGCACTGCTCTACATTGCATCCCACACCAGATCACT
TTTATTTTTTCAATTACATCAGTGCCCAGGGTCCCTGTCAGTCTACGCATTCTATGTGATACCTTTCCCA
TAATTTACTCATCCAATTTAAATACCACTTTCTCGTTTCCCATCTGGTTAGCTGCTTCTGCTGTAATCCC
ATAGGCTTTATACACATCTTTAAGAGCATCATTTATATTACCTTAACACTTTTTGTATGTGTTTATCACA
ACATGGAGAGAGATCAATGAGGATAGGGACTATGCTTCTACATCACTGGAGCTTGACATGTCATGATTCT
TAACATGATAGAATATTTATTGAATAAATAAATGGACAACTCAGTGAAGGGAGTAAGGTAAGTTTTGTTA
TCACCACTTCACAGGTAAGAGGGGTGAGGCTTTGAAGGCCCATCAGTAATTCCTACTGAAAGCCAAGTTA
ATAGCAGACCTCCCATTTACACCCAGCATTGTCTGGAGGTCTGTTAGGAGACATTTTCTAGATTCATCTT
GACTACTGTGGCCAGTGTGGCCTGGCTCATTTTATTTGAGTGCAATTTCTGCCTAATGCAGTGTATCTCA
ATCCTGGATGCACATTGAATTATTCATAGCAGGGTGCCTGATACTTAATGATATTAAATGTTTTTTGGAA
AAGGAGAGAAAAAAACACCGAAACTGCCTTTCTTTCTTAAACTTTTAATTATTTAGGCCTTTTTGGTTCT
TATACTAAGTTTCTCCAAGTTTCATCATTAGTTTAAGTATTTTAATCTGATTTTAACTGCCTTACTGATT
CCCCAAGGGTTTGTTTCCCCTTTTTTCAACTAAGTTAAGAACTTCTAGACTATATACTTAAAATTGTAGT
TAATTGAGATCGGCCACAGTTGAATTTCTTAGCTATGTAACAGGATTTTCATTTGAAGCTATTTATTCCT
GACAATCTCTACTCTTAAAGTGTGGAGTTCTCTTAAAGGGGCTGTTTTTCAGTGAAAATTTCCAGATACT
CCTCAAATGTGTTTCAACATTAGCCAGGAATCAGGAGGAAATAGAGCTCCTGGGATGCTATTATTTCAAA
CCCAGGTAGATGCTCCAAGTTTTTCCCAGTGGTCTCAGTAAAAGTAGGCTGTCTATCTACTACCGTGTTG
CTCCCTTTGAGCTCCCAAACTCAGCTGTTGGTCCATTGAATTATACCGTAACTAGGCACGATTATGTCAC
TGCATGGCTTAAAATCCTCCAATGGCTCCTCACAGCTTTTAAACTAATATTGACTAATTACCTTTCATGC
AAACCCTACAGTGTCTGTGTTAAACCACATATACCTACAGATATCCACATAATATCCTTCCTTTCAATCC
ATCTGATCTACTTGCAGGGTCCCAGAAGCGTAATTCTTTTCCTTCATGCTTGTGCTTTACTCCTACTAGA
ATGCTTTTTTTCCCTCTTATTACTTTGCCTAGATCTCTGCTATTCATTTTTTAAAACTTAAGTTCAAGTG
TCACCAAAGGGGCACCTTGACCGACACCACTCAACCCTCATCCAAGTGGATACTAACTCCTCTTTCTCTT
TTTTCCCAAGGCATGAAGGGCCCTTCTCTGCTGGCATTCACACTGTACTGTGCTGAATTATTGACCAGAT
TTTAGCTCTTTGTAAGACAAGCACCTTTCCTCATTTGGCTTTCTACTTCCAGCACTCGGTGCAATGCTTA
TTACATGCCAGGCACTGTCCTAACTGATGGGGGTTAATGAATGGTACAATCTACCAAGATTCAACCCAAA
GTCATCAACATTTCTTAGATCCTTTCTTCTCCAAGTTCTGATATCTAAACACTAAATTAGTGATTCATAA
AATGTTTAAATAATTTGAATAATTTAAAAAATTTAATCTTAAATAATTTAATCTTGAACAATTTGAAAAA
ATTTTGGACTCTCTAGGGAAAAATATACAATTCCTATGTATTTTATATATGATTTATGAGACTTTATAAA
TATACTAATATGAATTCAGTCTCCTGGTTGAATTCATATTGTTTTTAACTGGCAGGCACTGTAATGGACA
CAGGACATATAATGACCAATAAGGCAATATCATTGCTTTCGGCGAATTTCCCATATAGGCAAAAAATTAC
ACATGATCAAATAACTGCAATGCAATATGACAAATGTGATAATCAAAGGAGGAATATGTCAACTCTTAAA
AGTTTTCACAGATGTAGCCATTGAGCTAATCTTAAAGGGGCAAAAGATGTAGGAGAATATAAAAGTTTAA
AGAACCCCTATGGAAGAAAAATCCCAAAACAAAGTATTTATAATTTTAATAACAATAATAATAACATCTA
TACTTACTCTATGCTACACGTTACTCTAATTGATTTTACATACATTAATTCAGTTAATGCTAAAAACAAT
CCCTTGTAGTAAGTACTATTACCTATTGGTTTCTTAGGGCTTCCATAATACAGTGCAAGCATAACTCTAA
GATATGGAAGGTTTGGCTTCGGACCACCACAATAAAACAAACATTCTAATAAAGTTAGTCACATTAATAT
TTTGATTTCACAGTGCATATAAAAAGTTATATTTACACTATATTGTAGTATATTTATGGTGCAGTAACAT
TATGCCTAAGAATAAAATGTACATACCTTATGTTAAAAATACTTTATGCTGAAAAATGCTAAGAATATTC
TGAACCTTCAGCAAGTTGTGATCTTTTTTCTGGTAGGTCAGACCTCTGGTAGGTCTAGCAGGTTGATGGT
TGCTGACTGATCAGGGTGATGGCTGCTGAAGTTTGGAGTGGATGCAACAATTTCTTAAAACAAGAAAAAA
ATAGAGTTTGCTACATTGATTGACTCTTCCTTTCAAAAAATATATTCATGTAGCATGTGATGCTGTTTGA
TAGCATTTTGCCTACAGTAGAACTTCTTGCAAATATGGAGTCAATCCTCTCAAACCCTACTGGTACTTTA
TTAGATAAGTTTATAGAATATTCTAAGTACTTTGTTGTCAGTTCAACAGTGTTGACAGCATCTTCACCAG
AAATAAGTTTCATCTCAAGAAACTATTTTCTTTGCTCATCCATAAGATGCAACCCCTCATTCGTTCAAAT
TTTATTATGGGATTGAATAATTTGTTTCCATCTTCAGGGTCTACTTGTACTCCAGTTCTGGTGCAATTTC
CCCCACATCTGCAGTAACTTTCTCCACTGAAGTCTTGAACCCCCTCAAAGTCATCCATGTGGTTTGGATT
CACCTTCTTCCACACTCTATGAATGTTGATATTTTGGCCACCTCCCATGAAAATTAATGTTCTTAATTGT
ATCTAAATAGTTAATCCCTTCCAAAAGGTTTTCTATTCATTTTGCTCAAATTCATCAGAGGAATCACTGT
ATGTCGGCTATACCCTTATAGCATGTATTTCTTAAATAATAACAATTGAAAGTCAAAATTACTCCTTAAT
CCATGGGCTGCTGAATGGATGTTGTGTAGGCAGGAATGAAAGCAATATTCATCTCCTTGTGTATCTCCAT
CAGAGCTCTTGGGTGACCTTGTCAATGTGCAGTAATATTTTGAATGAAATCTTTTTTTTTTTTTGAAGGA
GTGGGTCTCAACAGTGGACTTGAAATATTCAGTAAATCATGGTATAAACAGATGTGCTGTCACCTAAACA
TTGTTCTATTTACAGAGCACAGGCAGGGTAGATTTAGTGTTTTTGATGGCCTTTGGACTTTTGGAATGGC
TTCAACTGAATAAGCACTGGCTTCAACTTAAACTAACCAGCTGCATTAGCTCCTAACAAGAGAGTTAGCC
CATCCTTTGAAGCTTTAAAGCCAGGCATTGAGTTCTTTCTAGCTAAGAAAGTCCTAGATGGCATCTTCCA
ATAGAAGGCAATTTGTCTACCTTGAAATTTGTTTGTTTAGTGTAATGGCTTTCATCTCTTATCTTAACAA
GATCTTCTGGTTAATTTTCTGCAGCTTTTCCATCAGAACTTATTGCTTCACCTGGCACTTTTATTTTATG
AAGATGGGCTCTTTTCTTAAAACTCTTGAACAACTGCCAGATTCAAACTTTCCTTCTTCAACTTCCTCAC
TGCTCTCAGGACTCATAAAATTGAAGAGAGCTGGGGCCTTGCTCTGGATTAGGCTTTAGCTTAAGGGAAG
TTTGTAGCTGGTTTGATCTTCTATCCAAACCACTAAAACTTTCTTCATATCGGCAATAAGGCTGTTTCAC
TTTCTTATCATTTATGTGTTCACTGGAGTAGCACTTTTAATTTCCTTCAAGAATTTTTCTGTTGCATTTA
CACCTTGACTGTATTTCACATAAAAGGCCTAGCTATGTTGGCTTTGGACATGCTTTCCTCATTATTATTC
TTACCTCTAATATTTATCTAATATTATTCCTACCTCTAGGTAATTATTCCTACCTCTTGATTTAAAGTGA
CTCTTCCTTTCAATTGAACATTTATAGGCCATTGTAGGGTTATTAATTGACCTAATTTCAATATTGCTAT
GTGTCAGAGAATAGGGAGGCCTGAAGAGAGGGAGGAGGACTGTTGGTGATGGGGGCGTGAGGGAAGGAGG
ATGGCTGGCAGGTGGAGCAGTCAGAACATACACAAAACTTCACCATCTTATATGGATGTGGTTTGTGGCA
ACCCAAAACAATTACAAGAGTGACATCAAAAATCACTGATCACAGATCATAATAAGAGATTTAGTAATAT
TGAAAAAGTTTGAAATATTGTGAGAATTATCAGACTGTGAGAGAGACATGACACGAACACATGCTGTTGG
AAAAATGTCACTGACAGACTTCTGCAATTGGGGCTGCCACAAACCTTCAATTCGTAAACAATGTAATATC
CACATAAAGCAATAAATTGAATTGCAATAAAATGTGGTATACCTGTTCCACAGACTGGGTAGCTTAAACA
ACATAATTTTTTTTTCTCACAATTCTGGAAAATTAAAGTCTGAGATCAAAGTGTCACCAGGGTTGGTTTC
TTTTAAGGCTTCTTCCCTTGACTTGTAAATGGCCATCTTTTTCCTATGTCTTCACATAGTCTCCTCTCCA
TCCCTGCCCATGCTCAAATTTCCTCTTCTTCTAAGGACTTCCTTCATATTGGATTCTGGCCTACTAATGT
CTTCATTTCAACTTAATTATCTCTTTAAAGATCTTATCTCCAAATAAAGTAACATTCTGAAGTATTAAGA
GTTAGGACTTAAAAATTTGAATTTTACAGAGACACAGTTTAGCTCATAATATGTTATAATCCCCACTTCA
CTGAAAAGAAGAGTGGAGCACATGAAGTTAAGTAGCTTGCCCCAGTTTGCAGAATTGTTAAGTATCACAA
TCATCTAGCTCCAGAATCTGTGAGGCTAACCTTTAGATTGTATGATTCTCTTTTTATATTTTAAAATAAG
AAATAAAATTCATAGACCTATTGAATTAATTTTAGGACAACTCTTTTATTTGTGGTACACCATAATTCAC
AAATAGCAAAAATTTGCCTATGTCTATACCATAGGCATACCAATTTCTTGAAAGAAAAGCAGGGTCTAGT
CTGGTTAGTACTTGGATGAGAGACCAAATAGCAAATACTTAAAATGTCTTTTCTAAGGAAATTAAATTGG
CTCCTATATTAAGCTGTAGAACTAATGGCTTCTGCTCTGTGCAAGTATAATGGCCACAACTAACCTCACT
GCATGTTAAGTACTGCCCTTAGAGTACCTGATCTCATTTATGTCTTACAGCTCTTTAAAGTTTGTTATTA
TCCACATTTTACAGATGAATAAACTGAGACTTCCAGAGATTATCTTCTCTCTCCTCACAAAAATCAATAA
CAGGAATTTGAAACAAGTTTTCTTATGAGGAGGTTTTGTATTTCTGACTTCTCTTCTTGCTGCCACATCC
CAAGGCCAAAGTTAGGATGCCTTGTATAAGCCTTTGTGCTTGTGGAAATTGGACTTTCCCCTCTTTTGTG
TTCATCTGGCAGGTTCTTCCTACGTTCATAACAAGATATATTGTACGGCTTTCCCCAATTCCCCTCACTT
TCACTGCCTGTTGTCAATGTGAGCTGTTTAGGTCCCTTTCAGCACTCTTAAAGTCACCTCCCAAGTACTC
TGTGGCCCTCCTCAGGAGGGTATTCTAAGTTAGTCATCATAGATACATCTAAGTCCAGATCCAGAATCTC
ATGTTCATGGCATCCTCTTTGACCTACTTAGCTGTTGCCGCCTCATACCCTACTAAGCCAGTGATGGTCT
TTGGCTCCTCATAGCCTGTGAATAAAAAAGGGTTTAAATTCTACAGGGATAAATCATATGTCTTTAGACT
ACTGTTATTAGTGTTTCACAACTGTGCCGTCACCCTTTCTTACATACTCTGAGAGATTTTGTAATCAAAT
TCTGTCACGTAAGGTGAAATCAGAAGATGCCTAGTTCTCACTTCTGTGTATAGCTTTGAAAGGCCTGCTA
ATGCTTGGAACAAAACATGAAAGCCTTGTCCACCTTTCTGTTTTAATTCCTAATTACTAATTTCTTGCAT
GTTAGTGGAAAAGCATTAAACTTGGAACAGAGCACCTTGATTCTGGTCCTAGCTCTGCCACCTGGGTGTT
ATAATAAAAGTCACAGGAATCTAAAATGGAACCCCAGATCTTCTACTGCTTTCTAGTTGAGTTACTATTG
GCAAATTCTTAAATTCTTTGACTCAATTTTTTCTTCTGTAAAATGGAATCAATAAAATATTAAGCAAGAT
ATTGTTCAAAGGAAAACTTTAGCCAAATTAAATTTAAAAGAGTTTAATTGAGCAAAGAACAATTTATGAA
CCAGGTAGCTTCCTCAGCTAGAGTAGGCTCAGATTCTCTAGCACAGCCACATGGTGGAAGAAGATTAATG
TACAGAAAAAGAAAAATAACGTTAAAAAAATGGAAGTGAGGTACAGAAACAGTCAGATTGGTTATAGCTT
GGTGTTTGACTTATTTGAACATGGTTTGAACAGCTGGCCACCTTTGATTAGACAAAACTCGGTGATTGGC
ACAAGAATAGACTATAGTCTGTTTACAACTCCATTTAGGTTATAGTTCACAATGTACAGAGAAACCTTCA
GGCTGAACTTAAAATATGTAGGAGACAACTTTCAGCTAAAGTTGATTTAACAATATATTAAGAGTTTATT
TTATAGACATTGCTTTATTGCTAACTTTGTCATCTGGGTTAGATTATAAACTCAAGATTATTGGGTAGAT
AGTTGGCACCTAATCTGTGTGCAAGGCACTGAGAAACAAAAGATAAAAAGCTGTTGTTCTTCAGCTGGTT
GGCAGCATTGATATTCCTCCAATGTACTTGTGCCTGCTTTGAAAACAACAATGCCTCTGCCTCTATTTGG
ATTTGTTCCCTCACAGTGAAAGAAAAAAGAGTGATTGTGATCCTGAATTTCTGAAATAAGGAGCATGTTT
AACTGACAATCTAGCATCTGTTTTCTGTACCTTTCCCACCCAGTTGACAAATTCTCCTCCATCTGCATCG
CTTAAAACTTAGTCAGAAAGTAACAGAAACCTCCTCATGGAGAGAAAGGAAGGAAAGAACAGAAACCTAG
ATAGGGAACACTAAAGTGTCAGAGAAAGAAGCAGAAGAACTGGGTTCTCATCTTAACTCAGTCCCTTACC
AACTTTGTTCACTACTTTCTCTCTCTCTGCCTTTTTTTTTAAAGTATGATTTCACATTATCTCCTTCGTT
GTATTTCTTATGCTAATACATATCCTTTCCTGATCTTGTAATGTATTCATTGCTGCTTCTTGAGTATAAA
GTGTGTGAGTCCTGAGTCCTCTGAGAAAAGGAACACTTAAGGTGTTTAATGCTAATTAATGCAGGTGTCT
GTTGGATAAACAGCTTACATTTCAAGATGAAGGTCAAGCAGAGCGTCTTCCAAGAGAGAAAATCTACACA
TCAGACTTTGGTAGAAGCATATGCATACTTGCAACTGCAGAAACACCCCTGTCATCCTGTGTAAACACAC
AGAGAACAGGGTACTTACTATTATTAGTAACAGAGTGGTAGCCAAGACCCCTTGATTCCAATGTTGGTTG
TACCGTTAACTGTGACCTTTGGATTCAAATTTTATTTTGCCTCTGTAAAATGAGGGGTTTGGAAGGGAAG
AAAACAAATTACTGCTTTTTCAGAACTAAGCCAATCATTTATATTGTCTCATTTTATCCTTAACTATTGT
TACTTGACATTTCACTTCCTTATTTTATTTTTGTTCTCATAAATACATTAAAATAGATAGTACCATCCCT
TTTCTATAAATGAGCACACTGAGGCTTAGAGAGTTTTATTGGATTAAGTTTAAATGGAAATGTTTATTAT
CATTTAAAAATTACAAGTTTGTTTTAACAAGTAACTGCTTCAAAACAAGTACTACATGAAAAAAATAAAT
AATAATAAAAGAAAAAAAATTTAGGAATGCACTGGCCTTGCTATTATACAACTGCAATTCAATAAATTTT
GAGTGACTAGAAATTCGTGTGGCTGGAGGCATCGCAAGCTGCAGTTCTCAAAGAGAGTGTGATTGTCACG
TCATCTGTCCTGGCCTTTCAGAAAGATGATATCCAAGAAAAATAACTCCAGATTCTCTTGTATTTTCATT
ATCTCATTATTCCCATGGCTTCAGTTATCAGCTAGAGGTTGGTGAGCTGACTTCTCAATTTGTGTTTCCA
AAGTTAATCTTACTCTGAAATCCAGACCCAGATATCTAGCGAATGACCTGACATCCCCACTGAAATGTCT
CAAAAACATCTTACAGCACATCTCATCTAGAATCATGACATCAGCATCCTCCCCTAATATTCCACTTCTT
CAGGGGTTTCTGCATCTGGTAATACAAACACTTTGCTCAGTAGCATAAGCCAGAAAAGTAGGCATTTTCT
GTGGTACCTGGCCCCTCAGTTGTACTGCTTGGATTTCCAGACATCATCTATTTTCCTGGACATCATTTTC
TCACTGATTTCTTTATCCCCCTGATGCGTGCATATCCACCAACTCCTACTCTTCCTCAGTCCCTTCTCTG
CAACGAAATCTGTGTGGTCTTTTACAAATGATAATCTGTTCGTGTTATCATTCACCTTCCCAGATACAAA
CAGTGACTTTCTGTTAGGAAAAAAACACAAATCTCCCTAACATGGCCTCTGCTACCCTTCATGATTTGGC
CTCAGTTCACCTTCCTAGCCTCATCTGGAGCTATTTGCTCCTTGATCCCTATAGACATATTGGTCAATTT
TTAATTCCTTGAATTTGTCGCATACTTCCAATCAAAGATTCTTTCCAAATTCCATTCTGTCCTTCAGAAA
TATTCTTCTACCATTTCTCTAAACAGTCATTCTTCAACTCTTGAAGAATGCACCATCAAAGACTTTTCCT
CAGGCCACAGACCAGATGAGGCTTCCCCATTAAATCCTGTTACCATGTTACATTCTTCCATATTTGCCAG
TCCATAACTATAGGTTGATTTCTGAAATTGCTAGTTACTGTCTATCTCCACCACTAGACTCCAAATACTA
TAGGGCAGAAAACTTCACCAATGCTGGGCCCAGAGCCAGTTTATTATAGATATTTAGAATATATTCATTC
ATTTTTTAAATATATGAATGAATAAATAAATAAAAAGGTCTTCTATTACATATGTGTATGTAAGTTTTTT
TTGTGTGTGCTCATGGTGGTGGTAGATGTGTTACAACGAATCAGTTCCCAAATATCCAACTATCTTAAGG
CTTCCTTGTTTGTTCTTTTTTTAAGTAAATATTTTATAATTATTTTATTTGTAAAAATGTTGTGAAGATA
GAACGGAGAGTTCCTACATTTTCCATACCCAATTCCTCTATTATTAACATCTTCCCTTGGTATGGGACAT
TAGTGGACATTAAAGAACCATGTTGATATAATTATTATCAACCACAGTCAATACTTTAGATTACTTAGTA
CCTAATATCTTCTTCTGCTCCAGGATCCCACCCAGGATACTATATTACATTTAATCATTCTGTCTCCTTA
GGTTCCTCTTGCCTGTGATAGTTTTTCAGACTTTCTTTGTTTTTTTGATGACCTTCACAACTTCGAGGAG
TACTGCTCAGGTATTTTGTAAAATGTCCCACAGTTGATATTTGTCTGATTTTTTTCTCATGATTAAACTG
GGATATGTGTTTTGGGATGGACAACCCTAGAGGTAAAGCACCATTCTCTTCACATCATATCAAAGGTGTA
GAGGGACTCAAAAATGTACCCCAAAGTATGGTGCCTTGTGATGCTGAGTATTTTGAAGTAAAGGAGATTG
GAAGGCCTCAGAAGCAAAGTCTCTGGCCCCTCTTTCTCCTGTGAAATAAACCATAGAAACTAGACTCCCT
CTTCCCCAAGATCATAAAAACTAGAACCTTTCTTTTCCAAAACAAGCCATAAACCCTAAAAATATTACTA
TCATCTTCTCCCACCTTTCTTTGTAGCAGCTGGCCATAAAGAAATACTCTGACCTACATTATTTGATAGT
AGGTCATAAAACCTTCATTGCTAAGGCCCTGCCCTATACGTAGGAGGAGGGACTGCTGCACAGAGAGGTC
AAGAAGAATACAAACAGACAGGGCTTACTGGGTTGTTTCTCTCAGTCTATTACATTAGATCATACTCTTT
TGTCCAAATTTCTGCAACACTGGCCATAAGCATAAAATCTAAGCATAAAATAAACAATTTTCCCTGGGTC
TTTGGCTCTTCTTTTCTGAAGTCTCCCATGTCATATAAAACTTTGATTAAATTATTATGCTTTTCTTTGT
TAATCTGTCTTTTGTTATAGGAGTGTTGGCCATGACCCTTATGATGGGTAGAGAGCAATTATCACACCTC
TATCACCCAAAAAGGGCTATGCTATTAACATAACTTACCATTGTGAATGTTAACCTTGATCACCTGGCAG
AGGTAGTGTTGGTCAAGTTTCTCAAACTGTTAAATGATTTCACCATGTTTTTATACTGCACTCTTTGAAA
AGAAGTCACTGTGTGCATCTCATACTTAGTGAGTGGGGAGTTATATATAGTACCTTCAAGACAGAGTATC
TACATAATTATTTGAATTCTTTTACATGATAGATTCATATATTTCTCTCCATTTATTAATTTGTATATTT
ATAGATTATATCTGTACAGACTCCTCTATATTTATTTTATACAACTTTATTTTGTGGCTCAAACTCTTCC
AGCTTTAGCCTTTAGGAGTGATTTCAGTTGACTACTCTGTTCCTTTGAAATATCTCTAACATTGTGGGTG
GTTGTCGTTTCTTTGAACATATCCTTAGTTTATGGCACTAAAAGATGCTCAACATTCATCTTGTATATTT
CTTACCCCAGCCCTAGAACCTGCCGTTTCTTCGAGGAACCCCAGTTCCCTTTACTGGAGAATATTTCTTC
TGTTCTGCCTACTTTTTCTTCTTCTGGCATTCCAATTATGCATATGTTACATTTTTTGGAAATTATCCCA
TAATTCTTAATTATTTTTTATTCTTTCTCTTTACATTTCAGTTTGGGAAGTTTCTCCTAACCTAGCCTCA
AGCTCACTGATTCTTTTCTTGGCCATATCAATGTTAGTGATATATACAACACTGTTGGAGTGTTTTTGAT
TTCTAGGCTTTCTTTCAATTTTTTCTTAGGGTTTCCGTCTTTCTGCTTACATTATTCATGATTTTCTGCA
TATTATTTACTTTTTCTATTAGAAATGTTATTCTATTAATTTTATATTATGTATAGTTTTTTAAAATTGA
TATTATTCACAATTATTTCAGATTCTATGTCTCATAGTTCCAAAATTTATATCATATCTAATATGATATA
AATGATTCTAATGATTGCTTTATCTCTTCAGATTTTTTTTCTTCTCTGTTGCCATGACTTGTAATTTTTT
ATTAAAAGCCATATGTTTTATTAGGTAAGATAAACTGAGGTAAATGGGCTTTTAGTGTACAAATTTATGT
TACTTTGGCAAGGAGTTGCACAATGTTTAAATGTTTGTCCTAGTTGTTACAGTTTTGAGATGAGAGGCCT
CAAGTTTCTCTAGTGTATTTGTTTTTGTCTCTATTCTTGGTTTTGGGTTTCCCTACATACTCTTCCTCAG
AGATAGTTCATGTATTTCAGCTCTTTTAGCTGTAATCCACTGTTGTTATACTGGAGATTTGTTGGATGCT
GGTAAAGTATGAGAGAGGGGAGTGTTCAAAATATTCTAATTAAATCTTAGTCCTTTAGTAGGCCAGTGCA
TTGGGGCTTCACAATACAGCTTTTTCTTCTTTTGCCTCTGCCCCTCTATTTGCTTCCCTGGTTGCAGTAT
TTCTATTTATTTCCTTGAAACTCTGACCCCTGTGGCTTATATTTACTTCCCCTTAGGTGAGACAGGAAGA
CTGAAAGAGGCTGGACTGAAAGGAATTCTCTTCCTGAAACTGGGATAAGGCTCTAACAATTTCCCCTGGA
TCATAGGGCTTTGATATGGAGAATGTCCTGGGCATATTTCACAACGGTCACTCTCCTCCTCCCTGTAACA
GAGTAAGGAGAGTATCTTTCTGAGGTCTTCACCATAAAAACCTGGTGGAGTTCCTGGAGGTAAAGCCCCA
AACATGTGGAAGTTCCCCTAAGACAGCAGCACCCAGGAATTTCCCACTATCTTCACTAGTCTAGACTCAG
TCTCCAGCCATTCATCGAAGTGTTTCAGTGTTCCTACCACTTTAGGAATCCAGCTGCTCCTGCCCCTGGT
AAGCAGATCTCAGCTATGTACCTCTGGATGAACCCATCTCTCCACTTTTGAGGATGGCAGTTTGCCCCGC
AACTTCAATTCTCTCATGGGTCCAAGAAAATTTGTTGATTATTAATTTGTCTATTTTGTTCTTATTTTAA
GGATAAGGGTGACCAGAGTCTTTACATGTCTGACCTGAAATCAGAGGTCCCATGCCAGCTTTTATTTATA
AAACACATCTTTCCATATTTCCATCTGTGTTCATCTTTACATTTTTCTAATTTTTCTGTTGTGAATTTCA
CTGTCACTCAGATTTTCAGAAAAACTATCTAGATTCAGTTCAAATTAAGTTTTGCTAAAAAGATGACTAC
CCCCTCCTCCCCAAATGTCAATGTAATTATCTGAGTTAAACATTAATATTCCCATGTGAGCTATTCTAGT
CATGGTTTGGTGAAATTAACTGAAGTTGAGAATCACTGGTGAAGAACTTAATCAAGATTAATACCTTCAT
TTGAAAAGGTTGATGAGGTGGGTGAGCACATTAATGGTTTCATCCATTAAATCTTTTGGTGCTGAGAATT
GATGTCCTTGTCCTACTTAGGTAAAGAATTTTTATTTCATGGCAGAAACAAGATTATTTATAAATTGAAC
TATAGAAGTAATTTTTCTCGATTGACAAAAGGTACAATTTTTGCCTCCAGCCCTTATTTAGTGGCTCACT
GTATATCAGGCTGTTCCCAAATCAGTCAAAATTTGACAGGGGTGGTGGAGGGATTATCAGACAGCCTCCT
TCTCATTTTAAAAATTTAATTTACCAATTGAAAACACATGGTTAGTACGAATAAAATGTCTACTAAAAAT
TATCTATAATGTGATTTCCTTTTTTGGTAAAATACAGGTAGAGTGTTGTGGATGCATATTTTAAAAACTA
GATATAACAAAAGCATAGAGCAATTACAGGTGATTTTTTCTTTTCTCCTTTTTCTTTGTATTTTCTCTAT
TTTACATAACAAACAAGTACTGCTTTTGTAGAGAAGAAAACCATAAAAGTTAAAACAAAAGGACTAGTTT
ATAAAATCATAGGACTTTAATAAAATTTGGGGTTTATTGTCAAGCCAGTTTCTAATTTCTTCTGTTGAGG
AAACTGAAGCACAGAAAAACTCATCTTCTTAAATCTTCTAATTTCTCATTTTTGCCTATCAGAATACTAA
CCATCACTAAAGGCACTGCTCACATATGCAAGGCTTTGGCATTTCTAAAACAGCATATGTTATGTCTCAT
CAATTTTAAAGTTTTTCCAGTATAGTCATAATACTTAGGAGGGGGAAGAAGAGAAGAGAGGAGCTGTGAG
AAAGATAATAGCTTTTATGTACCACTTAACTGTGTATTTTGTGTTATTTTAATTAATCCTTACATTACCT
TCATGACATAAATATAATTCCCATTTTGTAGAATAAAGAAGATCAAACAGATACAATTTTACAAATCTTC
CCTGTCTCAACCTATAGAACTCAGATTTTTACACAGTTCTTTGTGTAACTTGACCTACAGTAGATACTCA
GTAAATATTCGTTTAATAATTGAACTAATTTAGAAAGCATTTGGTATGCATGGACCAGATTTTTAGTGTT
TATCAGTGGACTGCCAATTCCTCACTAAATTCACAACTGAAAACCAACTTTGACCACAAGTAGTGTGTTC
AAGTTCAGATCCTCTAATAAACAGAATTGTTTTCTGTCATGGAAAAAATGATCACCATTTCTTCCATTTG
GCTTCCTTGTTCTCTTCATTATTGTGCTTCAAAATGTTGAAAATGGTTTTCTAAAATTGTATTCATTTTG
TTTGAAGCATTATCACTTCTTTTTCAATACCACCTTTTCTACCATGTACCAACCTTTGACCTGCTAGCTT
AAAATGTACAGCTAAGTAACGATAGCTTATTATTTAGTACTTTCACAAAAACTATCATATTGGAAACAGG
TAGGACAGATATTATTACTCTTATTTAAGGATGAGGAGGCTAATTCTCCAAGTTCAGTGATTTTCTTAGA
GTTATACAGCCAGATGAAAACACAGAGCTAGGCCTCAAGAAGAGTTCCCCAACTCCAGCTCTTGTGTTCT
TTCTTCTATGTCATATGACTCGATAATGCAAAGCCATTCTCTTTGTCATATTGTTAATGGCTCTCTATAA
ATTACTCTACAACTTGAGTTTCTACTCCATTCTTACTGGACTTTTTTCAATCCTTTAATTTTTTAGTTTT
TTTCCAGTCAAAGTTTTTAGTTGCATGAAATAGAAACTAACTCTGCCTGATTTAAGTAGGAAAAGAATTT
GCTGAGAGGCTACTGAGTAGCTCACAAAATCATGGAGCAGCAGGTTCAGAAATAGGTGAGAATAAGCAAG
AAGGGCATCAGCTAAGACGGCTGCCAAAACCATGCTATAGAACACAGGGCACTTGCTGGGCAATGGATTT
CTTTGCTGGTACATCTGGCTTTGCTGCCCCTGAAAACTAAATATTGTTATATCAACTGCCACTGCCCATT
TCTAGGATGGTTTCTGATTGTCCCTGCTTATTTGTGTCACTATCTCCTGTTTCGAAGTCATGAATGAGTA
TGTCAGATTGGCAGAATATTTATCATATGGTCATACTCTAACTTTAGAAAAAGCCGAGAAACAAAGTTTA
GGTATCTAAACCATTGTCATTGGAGGTAAGCTCTGTCTCCCATCAAGACTCATTAAGCCCACACTTCACC
TATCACAACATGAATGTTTAAATCATTGAAAGCCTCCCACCAGAACCAAAAAAATGACCAAATTCTAGCA
CTGTTTCCAATTTAGTTTTATACGTTCTTTCTCTGGTCTTTCTTTGGGAATATATTTAATTTACAACTAT
GACTCAATTGTCACTCAACCAATAGTTACCTTTATTTTGCAGCATTCTGGAGGTTCAAAACTCAATGTGT
AAGTTTTATTCACCTGCTAAGAAATTATTTTTTCAAAGCTAGCCTCAATATTTATTTTAAATGAGTGAAC
TTCAAGGCCTGAAAGAATAAACTAATACTTTACGAAATATTTTTGAAGTATAAAGAATATATTCAACATC
TTTCCATGTCTCCAGATTTTAATATATGCCTTATTTTACTTTAAAAATTTTCAAATGTTTCTTTTATACA
CAATATGTTTCTTAGTCTGAATAACCTTTTCCTCTGCAGTATTTTTGAGCAGTGGCTCCGAAGGCACCGT
CCTCTTCAAGAAGTTTATCCAGAAGCCAATGCACCCATTGGACATAACCGGGAATCCTACATGGTTCCTT
TTATACCACTGTACAGAAATGGTGATTTCTTTATTTCATCCAAAGATCTGGGCTATGACTATAGCTATCT
ACAAGATTCAGGTAAAGTTTACTTTCTTTCAGAGGAATTGCTGAATCTAGTGTTACCAATTTATTTTGAG
ATAACACAAAACTTTATGCTTCGACAATGTTATTCCTGAACACTTTAAATCCTGAAAGTGCATTATAATC
CTTAATTTATTACCAGTTTATTATCACAGGAATCAAATTCTGAGGATCTTTAAAGTCATGGTCATTTTGC
TTAACATAGGCCATTTTGTACATGGCAACCATGTGAAGAGCAGTAGAATCAGAAGAAGAAAAAAAAAGGT
TTTGAGACATGACTCTATCAACTGACTGTAAGGTGACCTGGGAAATTCACTCTACATCCCTGAATCTCAG
TTTATTCACCTGAAATACTGGGACCAGAACACATTAAAGAATTATTTAGAATGATACATTAATGAGCCTA
GTACAGTGTAACACAGGGTAAACATCCAGCAGTTTTGGAATCATTTTTGGAAGTTTCTTGCTAGGGTTAC
CAAGAAAATTTGTAGAAATCTTGAACTTAAGTGTAGTTAATAATAATAGCTATTATAATGTTTATTGCTC
TATGATGACGATAGTAATATAAAACCCCAGGATTAGAATTAGATTTGAGCTCTAAATAATCTTCCTGCAT
AGAACCATGTCAGTATCTTCTTGACAAAATGAGGAACAGATAGTAGTGTTTCCTTCTACCTGAAAGTCCA
CTACATGCATATTCTTTACATGTATTATTAATAAACCATATAGGAGGTAAGTTTTATTCTCCTAAGATAA
AGGTGAGGACACTGATACCCAGAGAATTTAAGTGACTTTCTCAAAATCAAACACCAATAATGTGGAGAAG
CAAGATTTCAATTCTAGGAGGTCCTCCTCATCTCACCGCACTGTAATTCACCTAACGCATGAGGGTTAAT
TATCAAAAACAGTGTGGCTTATGGGTAGGAGGTATTTAACAAGCATTGATGTTTCATTGCATTCATTGAT
AATGACACATAAATACATAAATAAATAAATATATAAAATAAACGAATGAAACTCAACCCTCTCACTCTTG
TGCTCAAATCCAGTGATACATGACTAGCATAGTTTCATACCTGAAGAAGCTCCAGTGTGGAAGTAAGACA
ATTGTGCAAGGAAGTAAAAAACATCAGGCTGTGTTATGTGCAGTAAAAGAGTCATAAAGAAAATCCCACA
GCAGTGCTGAAGAGAAAGCCATGACTTTTGAAGGGTTCAACCTAAAAAGAGAAAACAAGGCCTTGAGAAT
GAATAAGCAGGTGGCAGATAGAAAAGGGCAGGGGATATGCTAGGCAAAGAGAATAGCAAGAACAGTAGAG
GTGGAAAATGTACAGCATATTTATGAAATGCTGAATTATTCTATTTGAGTAGTATGAACAGTGGAAAAGG
ACACGAAGAAAATAAGTTGACCCAGTTTATAATAGTTCACACATACTAAGTATTTTTTATTAGCCAGGAA
CTCTTCTCAATGTGCCCTATGCATTACTTCCTTAAATCTTCATAATTACTCTATGAAGTAGGTATCATTA
TTTCTTTTGCTTTTTCATAGATGAGGAAACAGAGTCATAAAGAGTATAAATTGATTTTCCCAGGCCACTT
ACCTAGTATATGGTACAATATATACACAATTTGGGGCTAACAGGAGAGGCTATAGGTCATCAACCTTGTT
CTGCCCTTTGAGGGATGATTAATTGAAAAGATATGGGTTTAATTGAACTTTTCTGCTTTATCTGAAGACT
GTAGCCAATGCACAAAATGCTAACACAGCTGACAAAGGAGATCAGTTTTTGGAAAATCTTAAGATCACTA
AGAACAGAGAAATTTGCAAAGGGTGGAGGTGTGGTAAGAGGAGGGGTTTCCTGTAAGTCTCAAGTGACAT
GTCTTCTCTTTCTTCTATGAAAACCACAGTACATAAAAAAGGGAGCTTATTGGTAACTATTTTTCAAAGA
TTTTCCATTTAGGATTTTATGATTTAGTGTCTGTTTCCATTTCCAAAACACGCTAGACTTTCATGGGTTC
ATGCTTTTAAATATGCTATTGTTTCTGCCTGAATTCTGACTCTCTTTCTCCATTTGTCAAACTCTCAGAT
ATAAAAATCATTTTATACTTATAGTGATGTTTACTCACGCCTTTCTCATAGTTACATAGCATTTCTTTCT
GTGTATGAATCTGTCCTGGGTTTTATTCTTCCCCAAACCCCCAAGATCAGAATTTATCTTGCAAGCTTCT
CCATTCTAAGCATCACATTGTATCTGGTATGGACTGAAATCAATAAATCAGTTTGAGTACAAGTGATATT
TATCATGAAGTGTCATTTCTCTTAACTAATATAAGTGAAGTTTTCTAGAAAAATGCCACACCTCTTAATA
CTCTGGTCACTTTTGGATATATATTTTAAAACACTATAAGTATTCTATCACACCAGGTTTTTTTTTATGT
GTCTGTACTGAGTTGTTTATTCTTTACATACACATTTATTGAATACGTACTTTGAATAACACATTGCCTT
AGATACTATGGATACAATGGTAAACAACATAGTCTCTATCTTCACAAAGTTTACCATGGAAGAGAAAGAT
CTTAACTGCTTGCTGAAAAACTCATTTATATAGAGATATGCCTAACTCCAGGGGTCAATGAAGTGATACT
TCAGATGACATCAATATGACAGGTAGAATTAACTAGTTGAAAAGGAGGACATGGTTATGAATTTGGGCCA
TATTGTTAGAATAATGCAAGCCACTGATAAATTTTAAGCAGGTTATAATCAAATTTGAATTTTCAAAAGA
TTATTGCAGCTTCAGTATGCAGAAAAATTTTAGTAGTTGGAAAGCACATGCAGAAAGCCAGTGAAAATGC
TATTATAAGAGTCTGAGGAAGAGGTAAAGGTAGTTTAAGTTGCAGTGGTGGTGGCAGGAAGGGAGACAGA
AAGCATGATTAATTTGATATTATTTTGAAGGCAAAATTTACAGAACTTGGAAAATTATTTATATATCAGA
TGAAGGAGATTAGGAATGGCTTTACGCTTTCTGGCCTGTGAAAATGATGAATGGTAGTATAATTCACTCA
TATAATAACAAGAGGAGCAAAGAAAGACATGGAGGAAAGCTTATGGTTTTGTTATACAGTGAAATGAAGT
TATATGGGACGGCAAGGTGAATGTCTCTTGAGAAGTTGGATACACAGCCTGAAACTCAAAAGCGGTGTCT
GGCCCTCAGATCCTAATGCGAGAGACATCAGCATATAAATTATTGACTCAGCTAATTTTTAAAACCCCAT
GGAAGGGTGATTTTTATTCTGTTTTACAGGTAAGTAAATTGAGACTCAGAAAGATAAAGTGATTAATTTT
AAACTACAAAGCTAGTAAGTGTCAAATACTGAATCCAAAACTTCATCACTCCATCACTGCACAGAGAAGA
GGGTTCCCTTTAACCCCTACATTGTCTTCTACGCATATGCTCCACCTCTTTGTTCCTTCCCTAGTGTCCC
AATGGATACTTTTTACTACAAAGGCAACAAAATTTCCTGGATGAGCCAGGGGAGAAGAGGCTCAATGAGT
CATATTAGAAGCTTGAAGGTATTTATTTCCAATTAAATTTAAAGAAACAATTTACTTGAAATGCTTTAGA
GTAATTTTCACACGGCTTTGAATTTACAAAGTTAATTTTAGAGAAGTTTGACTTTAAAATAAGCAACAGC
AGATACTTGGGAGGCTGAGGCAGGAGGTTCTCTTAAGCCCAGGAGTGTGAGGCCAGTTTGGGCAACACAG
CAAGACTCATCTCTAAGAACAAAGCAAAACAAAACAGCTAAACTAAGTAACACCAATTGCCTATTTTCTA
TTTTATGAATTTTTCCATATTGTTGCCTCTGTTGTACTTTCAAGGAGTTTAAAATTTATCTCTATTCATA
GCTAAATTTTAAGCTTACTAAAAAATTATTTAAGATTTCTTGATATAATTTTGTTCAAGGGGATTATTAT
TCATCAACCAGGTACTCATGTTTATAATTACTTAAGTGGTTTCTGTAAAAAGGCAGCTGATGTCTGCCAT
TTATCAAACTTTTTCTCTTATAATTGAATTTAGTGATTCTTTAGAAAATTGAGTAGCAGGTGATTTTCTC
ATATGTATAACTAATTTACAAGGGGAGGCCAAAAATCTTTGGCAAAGAAGGGTTATGTCTTCAATGTTGT
TGATAAATGTAATCTTACTTTCTACGTAGCAGAAAAACTCTGTTGAGAGCTTCCTTCTCCCCATACATTA
CAAAAGACCTGGAAATTTGGTTTCAAAAATGAGAAGGGGAAACACTGTTCACAGTAACTGCAGTGCCCCA
TTCTGCCAATGGAATTTGATGACACTTCTATCATTCATGAATTTGTTCAATAGCTCTGTTTGGCTGTGTA
TACCTGTGTGCATGCTGTTCTTTTCTGCCTAGGATGGATTGCCATCAACATTATATGCTCAGAGTCTAAT
TCATTCTTTTACTCAGTGGGACAGTCTTCTGGGGTGCATTCCCTGACTTCACAGAGATGTAGGAAGTCTT
TTCTCCATGATGCCTTTCTATCTTCATCAGAACAACATTACTCTCGAAATGATTTGTTTACCTGCCAGGT
GCTGAGGGTGAAAAGGTAAATGAGACAGAGTGCCCCCCAACTCCCCGCCTACAGGTAGTGTATCTCAATG
AATAAGTGATATTTTAATAAATGAGTTGAAGAAAGATAAAACAAGTAAGACATAATACTTGCTCTTGAGA
GTTTGTGACAAGCTTGAAAAATAAGACATATATAAATAGATATAATTATAATAAATGGACGTTTGTGCCA
AATGTCACAAGGCAGCAAAGAAACTAGTTTGAGAATCCAGAAGAGAATGGAGCTGAGTCAGCAGCTGAAG
CAAGTTTGGAAAGAAAAACTCAAATTGTAAGCTGATTTAGGTGAAATATTGATGAAATTATCATTCTATC
ATGATAAGAATCAACAGCAGTTGTAAATTGTTTTCTATATGGTAGACATTGTACCAAGGGCTATACATAC
ATTGTCTAGTTTAATCGCTCCAGGCAGACTCCTAATTCATTTGAGTAATGGCCCCTAACTACTTCATGTG
TTTGTTTTGTGAATAAATGGGCATGTTAATGCACTTTGGAAATGATAGAGCATAAAACAAAAATCTACAT
AATTATTCTGAAAAGAATGGATGACAAGAAAAATAGGACTTCACAGAGGGAAGGATGATCAAAAAATTAC
GATATTGGGACAGAACAAAAAGGTGCACTATTGGGGCTCAAACGCAGATGGCTTACAAAGAAAGTCTGAA
TTTGAAGGATGTTGAGAAATAAAAGTATCTCAAAGACAGTCCCTTGGTGACAGTAAAAATTGAGACCACT
TGGAATGAATTAAAGTGGAGCAATAGTAAGAGAAGCTGGAGAACAGGACTGACATAGAAATAGTATTTAA
AAGCTGTGAAAGCACTTCAGCCAAGCCTTTAACAAAAAAGAAAATATTTATTATGTAGCCTCTATGTATC
CTGCCTTTTTTTGGACATTTTAAATGTACTATGTATTGAAGCCACTAACAGCAATTTAAGCTAAGTATTG
TAGTCCCATTTTCAAAATAATTTTAATATATATTAAAAACAGTAACTTTCAAGGTCTAGGGTTTACCCTG
GGTTATATAGTCCATGATGGCTCACCAACAACCTGTCTGTATTCTAGCTAGTCAGAAAGGAAAAGGTAAA
TGGTTAAAGATATATTCTTTTCTTTTTAAGGGAACTTCCCCCAAAGTTATACATATATTTTTGCTCTAGA
CTTGAGTCACATAGCCATGACTTGCTGCAAGGTAAGCCCAGGATGCACTCTCTTCTTTCTGCTATGTCAA
AAAGTAAATTTATAGTATCTTCTGTGTATGTTCTACATATATATCTTCTATATGCATTATAGAGAGCATC
TTCTATAAAGGAATTGTTTTGTTAGAAAGAATCCATTTGCTCTTACTGAACAGATATTCAGTACGGACTT
CCTCATTTACTCAAATCTTAATAGTCTCCTAAATAGATTCTATAGTTATATTTACATAAAATTTAAACAT
CTCTCCTTAACTGCTACGTGCCTTAAATATGTAGTTGATTGTGAGAATGAGATTTGTTTTTCATTAAAAC
AAATCTTTCCTTCCCATTTCCACAGCTGCCATTCAGGGACATTCCTTCAACATATCTTCTGGGTCCAATA
ACACATTCAGTCATTCAGTAAACATGTTCATTCTCTCATATGTGTTTCAGACACTGTACCAGATTCTAGA
ATTATATCAATGATGAAAGCACACTATTGGCCTTCAAGGAGCCATTTTAATAGAAACAATAGGTTAATTG
TTGATGTATAGGGAAGTTTAATTTATGTAATACTTATCTAGCCGTATTTTATTTTTTTACTATGCATTAT
CTGATTATGGATTTCCTAAATATATAGTTATATCATCTATTAATTGCATCAGGTACTTTTAGTAGCATGC
TTTCTAATTGTATCAGTAAAAAGACTTTTTTTTTATTTTGGAAAATTAATAGAATAAACCAAAAATAAAA
ATCAACTGTAATCTTATTGTTAGATTGATCACTTGTGCTGTTTTAGTCTCCTGTGTACTTTTTCTTATAC
TTTTTTCCACATACACATAAGTTGTTAAGCATATCTTTTAATTAATTTTGTTTTATCAAATATTATAAGC
ATGTTATTTTACAAGCCAAAGAGTGCTGCAAGTCTTATAACAAAATGTTTATGCCCCTATATCAGCTACT
GTAACCCTTTTACCTATTTATTCTGCTATATTGCCCTGTATTTCTAAATAATAGGGAAATATTACTATCT
GTTAATTCATCAAGTTTATCTTTGGAGTTCCTCATATTTAAATAATGATTTTAACTCTCTTACAGCTTCC
CTGTTCTTTCATTCATCTTCTCAGTATAGTATTATCATATTTGGGGGCAAATCCACATCTAGGAATTTTA
CTGTTTTTACTACTACAATATTATTTACAGTTCAACCAAATAGTATGCTATGATTACGTTTGTTTTCCTG
CATTACTTTTCTATTGGAATTAAGACTTTTTTTTTCATTTTAAAGCACCCATCACTGTTTATACCAAATT
TTAAAAGGAACTGTAAATACTACCTCATAACATAGTGAAATATGAGTAATTTATAAATTTTTTCCCTGGG
TGACATCCTTTTGTATATGTCTGCCCTTCTCATTCCACAGCTGCCATTCAGGGACATTCCTTCACCATAT
CTTCTGGGTCCAATAACACATTCAGTCATTCAGTAAACATGTTTATTCTCTCATATGTGTTTCAGACACT
ATACCAGATTCTAGAATTATATCAATGATGACAATATACTATTGGCCTTCAATGAGTCATTTTAATAGAA
AAAATATTCATATAATAGATAACTGGAATATAATGTGACGGGTATGATAATAGAGGAAATGCTAAGCCAG
TAACATATTGGATGCTGTCTCTCCTCAGTGCCATGTTCTTATGTGGTTTGAAGGAATATAAATAATCAGG
AGGCTAAAGACTTTTCCTTGTTCAGAATTATTGTTTAAATATATGTGGTCAAAATCTGTTGTTGCTTTTT
AAAGTAATGTAAAACGATTGACCACTATTCACCTTTATTTACAATAAAGGAATCAATATACAATTGGATA
ACATTCTGATTACTACCAAGTTATTGTTTTCCCTGGTTTCTGCTGAACCAGAAAATCGAATATTGAAAAG
ACTGAGTCTACCTGTAAGGAATGAGTTAAGGTAAAGAAAAAATATGCAAGTCAATACATTACAAAAGTTG
TTCATCCATTTATGGCAGCAGATTCTAAACTGCCAAATCTCCAACCATCTGATTGGGTTCCTAAAGCCAA
GTCTTAGACATCCCATGAATCATTACCTTTTAGTCAGTATAGCACAGGGATTTCAACTTTTTGTAAAGGA
ATGGCCTGCTAGAGGAATCGTTAAATGTCCATTAAATTAAGTCTTGTTTAGATAATTAAAACACAGCAGG
ATCTGTCTAGTTCCCTCATCTGGTTGGGGAGGTTGTTGGTAGTAATAAAATTATTCCTTTTAGGAATTTT
ACAAACTGTTCATTTATATGACTAAAGGTGTAGATAGGGATTCTTATATGGCTACTATTAAATGATACAT
TTAAATTGTCCAACTAATTATAGAATCATCTGTTTTATTTGAAATGTATGGCTTCAGGAAAATTTTGAAT
TTAATTTGATGTGATTTATTTCTTAGGTTGCTCAGTATGATGGCATCTCAAAAACATGGGCTTACCCATG
ATTTTTGTTTGGTGAATGTTTAAAAACAACACAAAAAGCCATTTATGTACACATTTTATGCATACACACA
CACACACACACACACACACACACACACAACCCAGAATGGTCCTTAGGATAAACGCAAGTTCTGATTGAGT
AATGACTATGGAAATTTTCCCCGACATTTAGAAATGCTGTTCTCTAATGCAGAGGAAATAATACATCATT
TTATGAATACGTTCATAGAAGAATAAGATATCAAATGTTCTTTTATGATAAAGGAAGCAACTACAGAAAG
CTTTTATTTGTTCAAAGTAACAAGTGGTATTGATGAAAAAAAAACACACACACCAAAAAAACCCAACTCT
CCCAATACTACTTTTAAAATGAACATATCAAAACTGATTTTCATTAGAATGTAGTTATTTTTCCACACTA
GTTAATTAAAAGCCAAGACCCAGATATATATATCACAATGCAAACAATTAAGCTTCATCATCTGGACAAG
AATGCCAACTTAGTCTCTCTTTGTAAAAAACAATTACAATTTCAAGACACTTCATATTTGCCGCTTTTGC
CAGCAGCAAGTCGGCCTGATGTGAATATTCCCATTTCAGGAGAAACATCCATTCTCCACTGCTGCCTGTG
GCACCAATTATTCTTTCAGGATCAAGATCTCTGGTGAAGCCTCTTGGTTTGTCGGCAGCATCTCTTTTCT
TTGATTTGCTGTCATTAGATTCATTGTCAGATAAAGACTTTCTTTCTTTTTGTAATTTTTTTTTACCAGG
TTTTTTAGAATTAAGGAATGTTTCAATTAACTCTGGACAATCTAAATTTTCTGCGGGTTCCCAAGTACTG
TCAACATCTGACGTCCCTTAAACTTCAGGAAATGCTCCACCTTCCCTTTTGCTGTAATTCGATCCAGTAG
TTTTTCCACAAATGCTTCAGGCTCTGCCTCTTCGACTTTTTTACCCTTTTCATTCTGTTTTCTTTTTTCC
TCCCTTTTTAAAATTATTTATTATTTTTTGCACTGTAGTTTCATTTCAGGCTTTTGGGGTTTTTTTGTTT
GTTTGTTTTGGTTGTTGTTGTTTGATTTTGGCAGACCCGAAGGGCTATTATTCTTACATATATCGGCTCC
CCTAAGCCCCGCCCCTCCAGGCTTTACTTTCAGAGTCCTGAGGCCTATAAAGGCCAGGCCCCTGCCCTCC
AGCAGGGAGTGCGTCTCTGAGGAGAAACAAAGGCCCAGAGTGCGGACGCTCCAGGGTACCGCGGCACAGG
GCCCACTCCTATGCCACTGCGGCCCGGTAACCAAGAGCGCCCCCAACCCCCGAAGCCTTAGGACAGAGGG
ACGGTGCCCATGCGCCAAAATCTGTTTCAAGATTTAAGACTGTGACCTCTGTGAATACAGAGATTGTTCA
AATGCCCTAGGGTTCTTGGGAGGCTACTAAGATTGCTGAGCATTTGCCAACATTACTATTAATGTCTGTC
AAATAATTAAAAGACTGGATTAGTGAATGGTTAATGATATAACGGTGTTCTATTGATAATCGGAATAGTT
ACAACATCCTTTCACAGAAAAAGATGGAAAAATCACAGCTAACATTTAATTGAGTACACACTATATACCA
GGCCCTGAATCACTTACGGATGTTATCTATAAAATTCAAACGTTCCAACAAGAGGGGTATTATTTTCCCA
TTTTTCTGATGAAGAAACTGAGGCTTTGGAGTATTAGGTGTAACTTTCCCAAGCTCTTACAGTTAATAAG
TAGTAGAGCTGGCCTTCAAACCCAGGTGTCTACTCCAAAGGACTGTGAAAGGATGAAGATGATGGTGATC
GTAACAATGGTGGTAACAATAAAAACAATGGGATGTCTTTTTATTTCAGACCCAGACTCTTTTCAAGACT
ACATTAAGTCCTATTTGGAACAAGCGAGTCGGATCTGGTCATGGCTCCTTGGGGCGGCGATGGTAGGGGC
CGTCCTCACTGCCCTGCTGGCAGGGCTTGTGAGCTTGCTGTGTCGTCACAAGAGAAAGCAGCTTCCTGAA
GAAAAGCAGCCACTCCTCATGGAGAAAGAGGATTACCACAGCTTGTATCAGAGCCATTTATAAAAGGCTT
AGGCAATAGAGTAGGGCCAAAAAGCCTGACCTCACTCTAACTCAAAGTAATGTCCAGGTTCCCAGAGAAT
ATCTGCTGGTATTTTTCTGTAAAGACCATTTGCAAAATTGTAACCTAATACAAAGTGTAGCCTTCTTCCA
ACTCAGGTAGAACACACCTGTCTTTGTCTTGCTGTTTTCACTCAGCCCTTTTAACATTTTCCCCTAAGCC
CATATGTCTAAGGAAAGGATGCTATTTGGTAATGAGGAACTGTTATTTGTATGTGAATTAAAGTGCTCTT
ATTTTAAAAAATTGAAATAATTTTGATTTTTGCCTTCTGATTATTTAAAGATCTATATATGTTTTATTGG
CCCCTTCTTTATTTTAATAAAACAGTGAGAAATCT

</dna_sequence>
        <protein_sequence>>NP_000363.1 tyrosinase precursor [Homo sapiens]
MLLAVLYCLLWSFQTSAGHFPRACVSSKNLMEKECCPPWSGDRSPCGQLSGRGSCQNILLSNAPLGPQFP
FTGVDDRESWPSVFYNRTCQCSGNFMGFNCGNCKFGFWGPNCTERRLLVRRNIFDLSAPEKDKFFAYLTL
AKHTISSDYVIPIGTYGQMKNGSTPMFNDINIYDLFVWMHYYVSMDALLGGSEIWRDIDFAHEAPAFLPW
HRLFLLRWEQEIQKLTGDENFTIPYWDWRDAEKCDICTDEYMGGQHPTNPNLLSPASFFSSWQIVCSRLE
EYNSHQSLCNGTPEGPLRRNPGNHDKSRTPRLPSSADVEFCLSLTQYESGSMDKAANFSFRNTLEGFASP
LTGIADASQSSMHNALHIYMNGTMSQVQGSANDPIFLLHHAFVDSIFEQWLRRHRPLQEVYPEANAPIGH
NRESYMVPFIPLYRNGDFFISSKDLGYDYSYLQDSDPDSFQDYIKSYLEQASRIWSWLLGAAMVGAVLTA
LLAGLVSLLCRHKRKQLPEEKQPLLMEKEDYHSLYQSHL

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1377">
        <gene_name>Tyrosinase from Mouse</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>22173</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>959092340</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq>AC122517</gene_refseq>
        <protein_refseq>NP_001304326</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome>7</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>87424770</gene_start>
        <gene_end>87493511</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>transcript variant 2</protein_name>
        <protein_pi>5.22</protein_pi>
        <protein_weight>42925.77</protein_weight>
        <protein_length>390</protein_length>
        <protein_note>Also known as c; skc35; albino</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000073.6:87424770-87493511 Mus musculus strain C57BL/6J chromosome 7, GRCm38.p4 C57BL/6J
TAAAAATTGTGATACATACAATTTAATAGGGTTTTTGACTTCTTAAAATATCTTTGTTATTCAAGCTTCT
TCATCATTAAAATAAAGTAATATAACCATACTCAGTGTTCATATGACAAGCAGAAATTATATAGAGTAGT
GCTTAGACATGCATCCAGTATATAAATGATGAAAAGGTTCTATTATAATTGTTAAAGAAGAGATTAATCT
AATCTAAAAAATTATGTCTTAGAATTGAGATGGGTAATTATTTTTCTATTTTATGACCTTACTTTTTAAA
TTGTGTTTTAGAATATTACTCTAGAATGATTATTTCCATCATAATTTTATAAGTAGTTATCTACTTTCCT
ATTACCCCACTTGCATTTTTCAATGTAGCATATGGTTTATGTGTCTTAATCATCTTTATACCCCCAAATT
CTAGGAAATATCTGTGAAATAAGTTAATGCTGATTTCATTTTGTCTTTATAAGTAAAATACATAACTACT
TGGATTTTTTCTTTAATCATTGGTATATATTTATTATACAGCATATTGGTATATATTTATTGTACACATT
ACAAATTTTATAATGTACTCATTATAAAATTTTCATACTTGTATAACTTTTTCTTTGCTTATACTGATGC
AACCCCAAACTACCCACAATATTGTCTTTCCTGCTACATTCTAGAATGCGTTAAAAAAAAAACAAATAGT
TCCTCCTGAAAATGTGCATGTATACACTTATATGTATATATAATATAGAAAAACGTGATTTTTAGTGTGA
CCTATTGCATTCATCATCATGAATTATAAATACATTAGTTTTCTTGCAAATGACATAATTTAATTCTTCT
TTATGGCTGAACAAACCTCCACCATGTATACATGCCATGGTTTCTCTATCCATTTGTCTGTGGATAGACA
TCTGGGGTGTCTCCACAACCTAGTTGTTGTGAGTAGCACTGTAATAAACAGATGTTCAGGGAACTCAAAT
AGTATATTGACACAGATTTTAGGGGGTATATGCTCTGCAAAAGCTGCTACCGCTACTACTTATGAGCCAG
ATCATACAGTAGTTGTCATTAAGAAAGAATAAAATATTTTAAAAATTAAACTGAAATTAATCAATTATTG
TGTATATTGCTAAATATTTCTTTTTAAACATTTCAACATTTGTTTTCTAGTTAATGAAAAGATAATACTA
GATTTTTAAAAGGTGATAAATTTTTAGTTTATTTTGTTTTATTTTGAGGTTCCATGATCACCACATTATT
TTTAGTATAATTTCAGCATCAGACAGTTAACTCAGCACCCATTATGAAATGCCATTAAAGTTAGGATTAT
TGGCCTAACATAATAGAAATCACCTTTCCTGTGAAATTGAAAGTATCTCTCATTAAAACAGTCTACTTTC
ATCCTAGTACAGCAATATCTACCTGTAATCCAGACACTGCTCTGAGACTGGAAAGCCAACAAAATCCAGC
AGTAGGAACCAGTTTATGCAACATATAGAACACTGATTTAGAAAACAAACTTTTTACTTCTATACATTTA
CTTTTAATTTTCTAAAAAAAAAAAAGACTAAGAAAGTAAAAATAATTTTAGTAAAGCAAATTTATTAAGA
ACTATATTTCACTAAATATTCACACTCAACATTTTATTTACCTATGGGACAAACAGGATGCAGAGCTGTT
TAATTAAAGAGAATGCATATATTTTAAAATAGGCAAAAGGAAAGTGAAAGTGATTACTATGAATTTTTAA
GATATTTTTTGAGGAGACATATTCAATTGTGATCCCAAATTTGGCAACTAAATAATTAAGGTAAGTCTCG
AGTCTACTAGTTTAAATGGCTAATAATCAATTCACAATCAATCAGATCTAGTGACTGAAGAAAGTTCTAC
ATGAGTTTTGATTCCAACCCACATATTGTTCGTTCAATTACATTTTATAAATATTTTATTATTTTTTGAA
AATTTGATATAATGTAAATCTGCCCTCCACTTCTCCATGTGACTCTCCGCAGATCCACCCCCACCTCACT
GCCTCCTCAGCTTCATGCTTTTATTCTTTTTTAAATGTAATAGCTCAGTCATTATAAGGCATGGTGTACC
TATACTACTGGGCTTGAATCCTTCTACCAGAACATGATAACTCTACCAGGACTCGAATAGAAAACTGAGT
GTCCCTCAAACAGAAGCCATCACTGCCCATAGGGCATCAGATGGGGATTGAGGCTAAGAAATCTCTTCAC
ACTCCATCCTAGAATGCTGCCATATAAAAAAACAATAAGAGGCCCCAAATAATAAATTTGAAGCATATAA
AACTTAAATAGAACATGAAAATTACTAAAGTTGTTCATATGTAGTTTGCAACAGCTAAATAATGTTAAGG
CTTTTGTGGTATTAATAGCTTGTTTATAATTTATATTCTATTGTATAAACTGACAAACTCTACTCATAAA
TGAAAGCTTATATAAATGCTGAACATCAATGATTTATGCTTGCTGTCAGCCTCATAAGGACACTAGTTAA
AATGACTTGTATCGATCACAGGTTAATCTCTACAGATAGAGAATTGCATGTTTGATTTGATAAAAATATA
TGAATACTAAAATTAATTTTAAAAGCCTAGAGGAAGAAGAAAGGGGGAAAATATTGCCACTTATTTATTT
CTTAACAGAATGATGTAGCAACAGGACAATTTCAGAAAAAAGTGAAGCAATTTATAAAAGCTTCACAATA
AGCAAGACTGAAATATACAAAGTTAATGAGAATTTAATGAAACTTTCAGATATATTGAAATAGTCATAAT
ATAATTTTGTTACCATAATGAGAATATATAATCAAAGAGATGGTAACTTTTATCAAAGGTGTGACTGCTA
TACAAATACATACCTTGAACCGCTAGAGAAAAAAACAATATTCTATGATGACATGAAGTGGCAAAGGAGG
GAATTGTATTGTGATAAAGGGAAACACTGAGTTTATAAAGACCCTTGTCAGCTGTAATGAACATTTGTTG
GGTAGATTTATATATACATGCTAGGTAGCAGAGTACAAGAAAATGCTTGCATTGCATATACAAGGCACTG
GGTTGATGTCCAGTACTAGAAAAAAAAATTAGTTTAGAAAACTAAAAATTTGCTTCCTAAAATTTTACTA
AACTAAAAACTAAAACTTAAATTTTACTTTCACTAAAGTAAAAATTTACTGGGCTGGCGAGATGGCTCAG
CGGGTAAGAGCACTGACTGTTCTTCCAGAGGTCCTGAGTTCAAATCCCAGCAACCACATGGTGGCTCACA
ACCATCTGTAATGAGATCTGACACCCTCTTCTGGTGTGTCTGAAGACAGCTACAGTGTACTTATGTATAA
TAATAAATAAATCTTTTTAAAAAGAAAAGAAAAAATTAATTTACAGTAAAAATTTACATTCACAGCAAAT
TTTGGTGACTCAACAGGTGTGAAGGTCTCAAAGATGACCCATGTGCCCCTGACACTATCACACTAGAATC
TGATTCAGATAGTTTCCCATCGCTGTTCCCATTCCTTTGGCTCTTGGGCTTGATGATTTCAGATTGCAGT
CAAGCCGACTTGAAGCTTCAGATGTTACTGAGTCATCTGTTTTGATTAATTTTCTGGCTATGGTAAACTT
CAGGTAATAATCTCTAGTAATAACCCACTCCTTCCAGGAGCCACTATCCTATTAGGCAGAGCATTCCCAT
CTCTTGCCTGATATTTTTCCACCAGTCACAGAAGGTAGATAAGGTAACTTAAATGACAATTAATAAAAGC
TGGCAGATGTTCTCCTCTGTTACTAATTTAGTAATTATTCGTCTTTCCTAATCATTAATGAAATAATTTC
ATAAATTAATGAATCATTTCTATCAATCCAAGATTTTCAAAATTGTTTGAATCAGTTAACACACACATAC
ACACAAACACACGAGAGAGAGAGAGAGAGAGAATATTTTTCTTGGAAATTCACAATGAAGTAAGGAAAAC
AAAAATGTGCCTCAAGTTTAAATAATTAAGACACATTCATAAAAACCAGCTCAATTAGTTGTAAGAGGAA
ATTTTATTTAGCTATTAGTAAGTTATTATTTATATATATATATATATTTTAGCAAATCCCAGTCATTTCT
TAGAAACTAGGACTTAGGAAAAAACATGGGTCTGAAAAAAAGCCAAACAGCTATGGTCTATGTTTTATAC
TAGTTTAAATTTGTAGAAACACCAACAAATAGGTCGAGTGAGGTAAAACCTTTCAGTCCCACTCTGTTTC
CTAGGATGTTCACAGATGGCTCTGATACAGCAAGCTGTGGTAGTCGTCTTTGTCCATGAGGAGTGGCTGC
CTTTCCTCCTGGGGTTGCTTCTTCTTCTTCTTCTTCTGAAGGCATAGCCTACTGCTAAGCCCAGAGAGAG
CTGCAGCAATAACAGCTCCCACCAGTGCTGCCCCAAGAAGCCATGGCCAGATACGACTGGCTTGTTCCAA
GTAAGGCTCAATATAATTTCTGTAAAAGCCTGGATCTGAAATAGAAAGAGATCAAGCTGTTTTCACAGAT
ATCACCAGCACCATCAGCAGCATTTTAGCATGCTACTTAGGAGTAAGAGGCTTGGGTTGTAATGCCAGCT
GTTTTGCTTAATAAAAAGAAAATCTTGGGGGAAAATTAACCTCTTCCTTCTCAAGCACCCTTTCCTCCCT
AGGAAGAAAAGAAAATAATTCTCTGCTTTTGGGATCTTTTGAAACTTGAATATAACCCTTGATGTGCAAT
ATTGTTAGGTACTATTGTTACAATTCCTTTTGATGATTATGTAATTATACTGCTGATCTATGAAACATAG
TTATATTATTAACTGTTGATGATCTGTTGATAATTTAAATTATTTGAGTAACACTGACTATACTGCTAGA
AGAAACTTTGTAGTCTCAGAGCATTCTCAAGAACACTACGACATTTGTACACTCTCTGTTCTTGCAGAGA
TCTGTGCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTACATTGACATGTGCATGTACA
TGCAGAATGCACCAAGGTAAAAAAGAGGGTGAATGTACCCCCGGAGCTAAAGCTACAAGTAGTTACAAGC
TGCCCATGTTGGTACTGAGATTTGAACTTCTTTCCTCTGTAAGAAAAGCAAACTCTTAACTGTTGAGATA
TGTCTCCAGTACTAAAATTTTCAGTCTTAAGACAATAGATTTTAGCCAAGAATATTTTAAAAATAATTTC
AAGTAAGGAAAACGTGTAGCCTTTGACCATCTATAATTACTTCAAACCACATAAGAAATTACAACTGGGT
TGAACAATTATGAGTTCTGCCACCCATAAATAAATTTCTACCTCCGAATCTTCTAGTACAGATAGTCTAA
CATACATATTTTGAAAAGAATGTACTTTTGATATTCCCCTGTACTTTTCCTAAAATTGTTCCTAGAGTCA
AATTTCACCTTTAGTTTCATGTGTTTCTTATAAGCATTTTTCCACTTTTTCTATTTAGTCCAAGAAACCC
TAAACATCTAAATGCTGTAAGTATAACATTTCTTCTACTATTACACCAACACATTGTATTAGAGTTACTA
ATTATATGTTTATGTTCTATATTATACTGACTCCTTGAAAACCCAAACTGTGGTGTGTAGAGATAATATC
TTCGGTACTGTGTGGAAGCATCACTTGACAATAAATATCTAATGGCCAATAAGCTGAGGAATGATTACAA
AGTGGGACACCCGGCAGAGAGAGATGAACTCTGGGAACTAGGCAATGCAGGATAGGAAGTTGAATGAGGT
AACCAGCCATGTGGCAAACATAGAATAGTATAAACAGGATAACTGAGTTACAGGCTAGTCAGAGAAGCTT
AGTTTAAGGTCCAGGCATTTATTAATATAATAATAAGCCTCCAAGTCATTTTTTGGGAACTGGGGTATGG
GTGGAATGCTGGTGGATACAATGAAGTAATCCTGAAATTTGGTAGAGTGCCTGAATCCCATGAGAAAAGT
AAATGTTTACTCCATGACTGAATGTATTATTACACTCCAAAAAGGTAATGAAGAAACATTAGGCCAATTG
GGAGAGATATTCAATAGATAGCAATGGAAAACAAATTATAAATTAGCCAGTATCTACTATGTTTTGAGGT
AAAACTTAGAGTTTATTTTTAAAATCAGGTATTGGTCATGATGTATTTTATATATATTAAAATAAAAATA
TGGAGCATTGGCTCTCAGAGAAAAAATATAAGAAATCACTATATCAGACAGATTCAGTGTAGAAAAATAA
CAAAAAATTCAAAATGTGTCTTTAAGTGACAGTCCCATATTGAAATGGTACAAATAAAATAGGTTTGTAA
GAGAAGTAAACTCATTTATACATGAAGACACCTGAGATAGACTTGATGAATAAAAAGATATTGCTATTTA
CATATTATTTGGAAACATGGAATAATTTTTAAAAATTTAGCTACACAAGTTATGGTAGCCGACTTGGGGC
ACTAACCTGGTGAAAGCATAAACATGGAAAGTGAAGTCATTGTTTTGGTATTTGGAAAAATCTAGCCTTT
AAAATTACACATATCGTTATTTGACAAAATGAAATTAAGAAACATGGTGAATGACATGATTTACATCTGA
GAATAAAATGTAAGCAGATACAAAATATAGACAAACATAAGCAGAGTGCATTATTTTCCAGCACTAAAAG
AAACTATAGCTTAAAAAATACATAAATATATTATAAAAATAGTACCTGGATTTTAAAACATACCTAAAGT
AAAAAATAAATAGTATGGTGAGACATGAATTATCAGATGATATATATTGAAGTAGTATGCTTTTGTAGAA
GTGAATCATATCAATTAATTATATATGAATATTAATTATATTAGAAAATTAGCTCAAAATAAATACAATT
AGAAAATAATAGTCTTGATATCACATATATACTTAAAGCATGCAGTATCTCAAAGAAACAGTTAAAATGT
ATTAATATTAATTATTAATATTCTGCTTATATTACAGACTACATAATAAACTTTAATTTTCAGGAAGCAA
AGAAAGGGTACATTGTATTATCTCAATAAACGTAGATAGATTGCTTATGGAAGGCAACTTCTGTATACTG
TCTTTTGTTTGGGTTGTTTAGATTGAATTCTGTTAAGAATATGAATAAGCCATCATAGATTATAGAATCC
CATGTAAACATTAAGTCTTAAAGAAGATTAAGGTCTAGTCTTCAAAATTATGGACTATTTTTTCAGTAGA
GTATCAAACACTAGCAAACAATTTATTTAAGTCACAAAATTTTAACTAGTGTTTTAGTATCTTTGCTATC
CACTTTTTAATCCCACCTCTGTTGAAGTGGAAATTTCAGTAATTCTTCCATGGTCACCTTTTTTAGGTAT
ACTTTACAGGATGTATAAATGTACAGGATGGATGAATGCCTGATTCATGATAGTTATTCCTAATCACTGT
TTGGAATGCACTATCCTGCAAACTAAGAAAGAGTGGATTCAGGAAATGAAGCCAGCACAATATAAGAAGC
AGAAAATCAAGAGCTGGAGAGAACTGAAGAAGACCTGGTTCTCTATATCTTTATCCTTCTTTGTCCTTTT
TGATCCTTTGAGTAGCCCCCTCATCTAATTTAATAATCAAATTATCTTTTCATCTAATCTCATTCCTATT
TATTTGCTGATAGTCAGTCTTCAAACGTTCTAATTACTTTGAGAAGTTAATTAACTGCTCATCCCATAAA
AATAAAAGATAAGTACTCATGGCATGCTGGAATGATAATTCTATATAAATAATTCACAGTGAAATTACAT
ATGTAAAACAAAGAAAAGGCAACATTTACTTATGAGGTATTTGGAGAGAAATGGATGTTTGTCTCACTTT
AGCTTGATAATGTTCAGAATGAATGACACAGGAATATTCTCTTTCAACTGGGGGATTTGACTAACTGCAT
ATTAAAGTTCAGTATTCAAAGAGGACAAAAATAGAACTTCTTTTTTTACTTAAGTGGTGACTATAGAGAT
AAGTAACTTTCCATCTTTTTTCTGTTTTTTTTCTTTACTTGTCTCTGAAAATCTTCTTAGAAGTTATGAA
GATAGTTTTAATGAAACCGATTGTTTGATTGTTTATCATCATTAGAAAATTTAAGAAATAACTGACATAA
AAACTGGAAATCTCTAGATTTGAGTGACATTAATGTATATAATAAAAATATGAGATCAATGGAAATGTGA
TATTTACTTTCAGTAATTCTGAAAATCACTCTTAAATACACTTAAAAAACATGTTTTGATAATGGGACTT
AAATGTCTAGATTCAATTACTCTTAGATATTCACATACATAGTTCATTTTAAATGTCTCCTCAATGTGTA
GCACATTGCATAATAAGTGCTATTTCTTTTATGTCCTGGGGATCAAAGAGAACAGCTAGTGCTCTTAAAT
ACTACGTCATCTCTCCATGCTAAGAAATAGCCTCACAGTGGAGAGGGGGTCCTCAGAGTGGTGTTTGAGA
ATGGTCAAAAAACAACTCAACATCAGTCATGGGTACAACTTACAGCTCAGTGTTCTGCTTGAGACAGCTT
TCCAGGCAGCTCAGGCTTGCCAAAAGAAAAAAAAAATCTAAAAGCTCTCTGGATAGTGCATGGATTTTCC
AGCCAGGGTCAGAAAGCTGCTAAAAAGAAAAAAAAAAAAAAAAATTCTTGGGTTTTCAGGCCTAAGTCAG
AAATTCTGCTAAAAATTTTTAAAAGGAGCTGTAACAGCTCCTTAGGATAGCTTTTGGGTTTTTTGACCAA
AGTCAGAAAATCTGCTAGAAAAAAACAAAAACAAAAACAAGCAAAACAAACAAACAAACCACCAACTTGG
GTGTTCTGACCAAGGTCAATAAAAAAAACAAAAACAAAAACAAAAAAACAAAACAAAACAAGAAAATTCT
AAAAGACCAATGTTTGCTCTCCAAACAGTTCTCTCTGGGTAGCTTTCTCTTGCAGACTAAAGCCCAGATT
AACATATCAATTCAGTCATTTACTCCATGTTCCTTTTTGATTATCTCATAAATCAGCAAGTACAATTTTT
TTCTTTCTTTTTATTTTTTATTTTTTTAACGTGGCAAACGAATTCAGAGATCTGCCTGCCTTTGTAAGCA
CAGACAATAAGCTACCTGGGTGAGATCCATCTCTGAGATCACCATTCCATCTTTACCTCTTTCTCTCTTT
TCTTAATATTTTTCTGTCAAGCTGGCTCATAGCGCAGTTGCCTTTGTTCTTCTAGGTCCATGAAGCCTTT
CTTATAATTCATTATGCTTCCCTATGTTTCGCATATTTGAGAAATTATACATTCTTGGATTCATGTTTTC
AGAAGATTTTTTGTTTTTGTTTTTGTTTTTTCTAACAGGCTGTCCTGAAGATCAGAGCATTTTAGTACAT
TAGACACACCCTGGTCTCCAGGACTATTGTGGTTTCTGATTATCAAGGGTCATTAACCTTGGCAAAGAAG
ACATTTCTCTGAAGGGGGAACCTAAAGTAATTATGTAGATTATTATACAAACAAGTCTCATGTGCACAGC
GGCCATTAATATACATTCTCTAGCATTAAGACATCAAGACTTCTGGAATCATATGCCAAAATAAACTCTC
TTTTGATGTTTCTCTCCTTGCCTTTTATCAGTTACCCCTGAAAGAAAATCACCTACTTCTCAGTTTTTAA
AGCATCACTGAATCTCATTACAAGAGAAAATGTTTGACAATTTCAGACATTAGCTGCCCTCTACAACAAA
ATACTTAAGTGATTATCAACATGAATACCTGAATGATGAATAATGACCCGCATGAACTAAATTATTGAAA
ACATTTAATATTTTTTTTAGAAATCTTGAAGTTTAGCAATGAATAGAGATGAATTTTAAGTACTTTGAAT
GCATAAACAATAATGAAGAATGGTTCATAAAATAGAAAATAGGCAATTTCTATTACTTATTTTAAAATCA
ACTTTCTCTAAATTTAACTGTGTAAATTCATAACTGTATAAAAGAGATAGTAAATCAGTAAAGCATTTCA
AATTAATACTGTTTATTTTGACATACTTAGAAAAATATATTCAACTTTCTATTAGGTTTTTTTGACCCTC
CTCTCTCATATAGATCTAAGGCCTAGGTGTCTGGAGCTTCAAGTTTTGGTACCATTTGCACTGAGAAATA
TTTACCCTGATGTTTCCTATCTTATTCTATCATAACAAAAATATGGATGTACCCCTTGTGTTTGGCCCTT
CTTTTATTATTGTTAAATATATCATTGAATTTTACTATAATGAATTTGCACCACAGGTTAAAAAGCTTCA
AAAGAGTCCTATAATCTCCGTTTTCTTCATTCAGTATATAACTTATTTGCCAATTTCTATGAGTTTTGTC
CTAAAAATGTAATGAGGAATAAAGTGATCCATGGATCATACCTAGACAATGCTGCAGTAATAAAAAGCAT
ATAATTTGTGATAACTTTTACAAAACATCTTAATCTTTTCAGTATTACTTTCTTTGTTGATAATAACCAA
TAGAAGAATTCAATATTTCATAAACACAGAGGTCATTTTGCTTTTTAGTCTTATTCTTTCAGGTTAAAAT
ATTTTCTGCCCTTTTCTATCTGCGGCCTACTAACTCGTCAAACATTGTAAAAGATGAATTGTATACAAAT
CAGTGCTTTCCTATCTGAATCTTTGTAAAATTTTGCTGTTCAGTCTTTGTATTTCCTTGCACAGTCTTTT
GGATTTTGTAGTGGTCTGAACATGCAAAGCACAGGGAGTGGAATTATCAGGAAGTGTGGCCTTTTTGGAG
AAGGTGTGGCCTTGGAAGAAGTGTGTCACTGTGAGGGTAGGCTTTAAGAATCTTGTCCTGGCTGCCTCAG
AGCCAGACTTTTCTTAGCTGCTTTGAAATCAGAGGTGGAATTCTCAGCCCCATGTATGTCTAGAAGCATC
CAACCTTGATGATAATCAACTGAACCTCTGAATTTGTAATCCAGGCCCAATTATATGTTGTCCGTTATGA
ATTGCCTTGGACATAGTGTCTGTTCACAGCAGTAAAACCCTAAGTAAGACAGACTTCTACTTTGGATTTG
GTCCTTACAGTGATTAGTCATTTCAGTGAAATGAAAGTTGATCATACGAGCTAGGTTTTATTGAGGATCA
CACATTTGTTCATTTCTCCTTATCTAATGAAAGTATTCAAGTTTCTTTCATGTAACAATTTGTAATTTTA
CATTGTATTCTTCTAGCCTTTATATAGAAGTCTTTATATGCTATAGTGAAAGCATAGTGTGCTAAGGGAA
CTGTCAAAACTTGCTTTCTATTTAACATTTAAGAAGTCATTTCAATTCTATAAGACTGGCATTCTCATCT
CTTTTATGGAAAATAATACCTATCTAGTGAATAATAAATTAAATGATGTAAATACATATAGTTCAACATA
CCCACACACCCAAAGACAAATGTTTAAAGGACTTAGTTGCCAGCTGATAGGTTTGACAATTTGTATCAGG
AGGATTCTGGCTACATTAATTGACTAATCAATTGATGGATTCCCAATATGATACACTAATTAGGACTTTC
TGGAAAGTAGAAAGTGAGGACTGATTGGAGGAATTAAGTCACTGGGAGTTTGCCTTTGAAGGATGCATCG
TAATTATAACTCCCTCTTTGTCTTTTCTACAAACCCCTAACATGATATTTCTATCTTGCCTCAACTTCAA
ACCCATAAAACCTGTTGATCATGGTCTGAAACCTCACCTTTTTTTAATGTGACTTTCTCAGTCATTTGTC
ATTGCAACAAATAGGTAGACTAGAATAGTAGGAAGATCCTGCGTGGATTAGGCTTTCTGGCTTTCTTTCT
TTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTCTTTTCATTTTTAT
TAGATATTTTCTCTATTTACATTTTAAATGTTATCCCCTTTACTGGTTTCTCCTCAGAAAACCTCCTATT
CCCTCCCCCCTCTCCCTGCTCACCAACCCACCCACTCCTGCTTCCTGTCCCTGGCATTCTCCTATACTGG
GGCATAGAACCTTCACAGGACCAAGGGCCTCTCCTCCCATTGATGACCTACTAGACCATCCTCTACTACA
TATGCAGCTAGAGTCATGAGTCCACCATGTATTTTCTTTGGTTAGTGGTTACAGAGACAAAGTGTGAAGC
AGAGACTGAAGGAATGACCATCCAGAGACTGCCCTACATGGGGATCCATCCCATATACAACCACCAAACC
CAGACACTATTGTGGATGCCAACATAGCTTGCTGACAGGAATCTGATAAAGCTGTCTCCTGAGACACTCT
GGCAGTGCCTGAAAAATATAGAAGTGGATGCTCACAGACATTCATTGGACAGAGCACAAGGTACCCAATG
AAGGAGCTAGAGAAAGTACTCAAGGGGCTGAAGGGGTTTGCAGCCCCATAGGAAGAACATGGACTAGGCT
TTTATTACTACCTATTCTTTCTTCATCAAGAAGATATTAGTGTAGTTCTGACTAGGAAGGCCAAAGCCCA
TAGCTACTTCCAGTCCTAAGGCTTTACATTATGCTTCTAGCCAAAGGTATAATAGTTAACATTAAAGAAT
TATTATGAAACCCAATATTAGTTCATTTTGAAAGTTTCCATTATTGCATTGGTAATCCTACCAAGAGTCT
CAAGATGGAAGATCACAAATTGTTAATACCATATGATTCGTAGACTGAATTCTTTAACCTGATTCAGAAA
AATACAGTTATTCCTATCTAAATATATAATGAATAAAATATGATTCACAGAATTGAAAGAATATCCCTAG
GTCATAAAACAGCTGACATAATTCATTGGAATTCATGGTTCAAAAGCTTCCCAATCCTATATTCTTCAAC
AATTTAACTGTATAAAATTCCTATACTAGATGGAATAGTTATAAATTTAGGAATCATTGAAATACAGTTC
TAGTTTACACAATTATAAATTGGCATAATATAGTTTCTTTAGAAGTTTTAGAAAAAAAATTGAGTATACA
GTAGGTGTTTTTAACTGCCCCCAAAGAGGTTACCCACATTGCATTCCATAGTTCATCTGAAGGCAACTGA
GCTTTACCTGACTCTTGGAGGTAGCTGTAGTCATATCCCAGATCCTTGGATGTTATGAAGAAATCACCAT
TTCTATAGAGCGGTATGAAAGGAACCATGTAAGAGTCTCTGTTATGGCCGATAGGTGCATTGGCTTCTGG
GTAAACTTCCAAAAGAGGGCGGTGCCTTCGCAGCCATTGTTCAAAAATACTACAGAGGGAAGGGTTACTC
AGAGTCAGGAACATTTTATTTATAAGGTGTAAATTTTAAGTTCTTAAAAGACAATTATTGATATCACAAG
ACTTGATCAAGTGCTATCTTCAAACTTTGACAAGTTACAATTTCATGTCCTGAAGAAGGTCATTCATCAG
AAGTAGTGTGAGGATAACTTCAAATTTTCCTTATGAAAATTAAACTTTTATAGATAGTATAGAGGTTTCA
GAATTCAACATTTGTTTTCATGAAATATTGTCATAATATTAAATATAACTTTAAAAATGCAAAGAAAGTC
AAAAGAAAAACCATATAAAACTAAATTGACAAAAGACTAGACCATAATCACTTTTTGTTTTTCTCTATAT
CAGGTATTTCAGTCTTTGTCTTATGGTTAGGAAAGATCATGTTTTTAAGGCAGAGCCTACCTTTAATGAT
AGAAGATGAAACAGCCCATTTCCAGCTTCCCATAAAGCTTTTATGTGACCACATGACTACTATTCAGGCA
ACAAGACAAAACCATTCTAGGAATAGGAAATAGCGACCAAAACAAAACAAACAAACAAACAAACAAACAA
ACCAAGGACAGTGGAAATCCATCCTAATGGTGGGCAATGACATTCTTTGGAATAGCATTGAGCAAATAAG
ATTGCCAGGTCAGATATGGACTTGTTAGAGGTAGAATGACATGGTTCCTGCCCCTGAATCAGGGCCAACA
GGCATGGGCCTTCATGAGTGTCAATGGCTGCTGTGGGAATATGGCTTGTTTGTATAACAATGTACATATT
TTCACATTCTTCTTTTAAAAAATGTCCTTCCTGTTAATGGTAAAGACTCCGATAATCAGAGATAGCATGA
ATCTGGCAGGTGATGGTGTGGCTAATATCTCACCAAAATGATAAACATTGGAATCTTCAGGATAGCCCTT
AATGCTGTGGAAGAGAACTCTAGAAACATGAGTTTGAAAATATATAATTTCTCAGCTATGTGAAATATAA
GGATATGATATGAATTGTTGGGAGGGGGCAGGAGTTTTTTAAAAGAACAAAACCAGCTGCACCCTGAACC
AATTTGTAAGAAAGACAGTAAGGAAGGAGATAAGGAGATTTAGGGAGTGGTGATCATAAGAGATCCCATC
CTGCTAAGTTTTTTGTTTAAGATTACAAAGGCAGACAGATTCCTGAGTTCAAGGTCAGCCTGGGACAGAG
GGAATTTAGGTCCAGGCCCAAGCATGAAGAAGTGATAATTTCAGGGCAGGGTCCCACCCAGCTAGCTTAT
AATTTGTACAGCTCTGCTGGCAGATCTTTGAATGATTTTGCAATGTTTAAAAAAAAATATTGTGCTTTGC
TGTATCCTAAGAATCAAGAGGCAAGGTCATGGGATAGTGATTTGTAGGATAATCAAAAGGGAACCTGGAG
AAAATGACTAGATTGATATGTACAATAAAAGACTGAGTTTATGATCTGTAAGATCTGAGGTATCCAGAGA
AATTTTTAGCAAGAACTGCTTGGTGAACAGTCTAAAGCAGAATACAGAGATGAGAGCTGCCTGGAGATCT
CCAGAGAAAAAAGATCAGAGAGAAAGCAATCTGGAAAGCTATCTCAAGTAGGCTACTGGTTTGGAACCAA
AATTTGACATCCAGTTGTTTCCTTCTCTCAGAATCTCCCTCAAAGCTGAGGTGATCCTTGGCAAAAGACA
GCTGTACCATGAAAGGAATCTATTCTGCACTAATCTGTTCTCTGGTATGTTTGCTCATGAGTTTGCCCCT
ATTCTGATCTGCCCCTGAGTTTGTTTCACAATAATTCTGTAAGCTAACTAAATTCCTTTTGGAACGTTCC
TACTAAAATAAGCCAATGTTAGTTTCTGTTAGACACAATAAAAATTAGTAACAATGCTTAAAAAAAATAA
AGGCATCAGAAGATTTCGAAAAATGAATTCTCAAATAGTAAGAGAATTTATAGAGAGCTCTTATAAGCAT
GAAAAAGAAATCAATTTGTGTTACAAGACTGGTTGACAGGGGAAGAACAAGAAACCTGGAGTTAATGAAC
TCTCCTTGAGCAGTACCTTTAGGTTTGAATCTCTCATGATTAAAACATAAATTAAAAATACAAAATTTAT
CCTTACTATCCAACTGATTCAAAACTCCAATGTTATAAATATTTATGAAAGTCCAAATAAGTTATTGCTA
ATTTTAAATGTAAGTTAGAAAGTCAGAAGGTAGTACATTGTAGAGATCAAGTTACATAAAAGGGAGACTG
TTAATACTTCAATAAATTTAAAAAAAATACAGTTTAAATTACAACAAACAGAACAAAAAGTCAAATAGAA
AAGAAAATAATAATTTTTTATGGTATAAAGCAATTCTATCACTTGAGATCTTGTTTTGGATAGCCCTGGG
ACTAATTATATTTGATATTAATTCCATTCTCCTGTGAGGGAATTCGAACTAGGAATGAGTCAGCACTCAG
GTGATTTCCTGTAAACCTGCTTCTCTTCTTAATTTATAAAATAAAGGAGAGCTGATGATTGGGCAGATAA
AAGTTAAGGTGGGGAGAGAGAGAAGAAGGAGAAAATGGAAGAGGAAGAGAAAGAGGAGGCATAGGAGGAG
GAGCAGAAGCACATGGCCTGGAGAAACCTCAAGTTATGAGGGGTCTCATAGATGTGGAAGATGGTAGTGT
AGTGGTAGAGCTGCCTAATCTAGGTGCACAGCATGTATTCCTATTAACTGAGTTGTGTTTTCATTGCTTG
GGCATATTTGGGTTGGAGATTTACCACAACGAGATCTGGATTTCAATCACTAGTCTAGTCAATATTTTAT
CTATATGTGAAACATGAAAATATGAATCATGACTAACAAAATTTTTCTAATTTTGGTTTATTATTAAATA
TATATAAGCCATATATTGCATGTCAACTTCTGCTAATTCAAAATGGAAATAACTTTTATGGTACAAAGAT
ACTGTGTAGATTAAAACAGCATCAGACACAGATTGTTGATAGTAGCATTTTTCCCGATCCCTTTTGCTAA
TCATCTTTCATATTATTATCAGTAAACTAGGAGAACTTTACAGCTGGTAAGAAAAAAAATATGCTGTGAC
AGAAATATGAAGGCCATATGCTTGAAGCCAGTTCTCTAATAATGGTCATCTTCTGGTAGGCAGAATTAGG
AAAGAGACCTCTGAAGGCTTGATATTCTTTTCCAGCTTTTTTACCCGAAAAAGATTAGAACTGATTTCTA
AACCCTAAGTCTCTCTAAGAGTTATAATTTTATGACTTTTTAAAAATATTAGCTTGTACTTTTATCTTCA
AAAAAGGCTTACTTGTTAACCACATTCAATTTAGAAAATACGAACAAGCCAAACATGAAAAGATCACATG
TAAATGCTATATATTTAGTTTTAAGATATGTACATATAATATTCTATATATACTTGAATCATATGGATAT
TATACTATTAACTTATATATATATGTGTGTGTGTGTATAATATTTTATTAGTTTGAAGCCTTATATTTTC
AACAAGTAAATATATATATATATATTAGGTATATGCAGAGTCTTTCACAATTGGCCCTTTCCCAAACCCT
CTTAACTTTGATATAGGAACAGGCCAATATGCAGAGGCTGAAGGAAAAATTTGTACCTGATTTCATCTGA
GAAAAATTACTATTATAGTTTAATTTATAAATAATCTTGTTTCTACTGAGAAATAAAAACAAAACTCTTA
CCTTAGTAGGACAAGGGCATCAATCCTTAGCTCCAGATTTAATGGATGTGACCATTAATTTGCTTACTAT
TTTATCAACTTATAAAAATGAAGGCATTAGTCTCGATTAAAATCGTCAGTGATAGTTTTCATCTTCAACT
AATTTCATGAAACTGTGTCTAGAATATGGTTTTCATTGAAATACTAATAGTAAACTGTATATTCACTGTG
ACAGTTTGGGTGGAAAATCTTATAAAAAATAAACCAAAAAACCCTCCCGTGTACTGAATCTGGATAGATT
ATTGAAAGTCTGAGAAATAGGGAGAGAGGTATTGTAGAACTAGGAAAAAGCCACCGTAGAGAGATAGCGT
GATAAGTTTTAAAGATAAACTTACCATAGACTATTTGGTTCTGGTCTAATATAAAGTCTTAGGTTGCTAT
TTTCTATGCAATAATAAAAAATAAAGTGGAAAATGAGCAACTTCTCTTGAATCCATAAGAAAATCGAGGT
TTCAGAACAAATTTCTTACCCTAAAGCTGTAGGTATATATGTATCCTAAAGAATATGACTAAAAATCTAT
CTACTAGGAGCCAATGCAACTGGGTCCATAAAATGATAACAACACCTAAACATTTCAGGAAAACTTAGAC
TTGGGTAATAGTGACAAACTTCTGGGGTAGCAGTCTCATGGATATTATAACACACATTATGACTTTACAT
CCAGGAATTCTACAAGGATTTCAGGATGAAGGTACAAGATCTTGTCTAACTCTGTCCATGCAAGCAATTA
TTGTGAAATATGTTGAGAACTTTTCCAATTAAGATAATGTCCACAATTTGTTTTACTGGAGAAACGGATT
TCTCCCAATCTACCTGCTGTTCTTATCTTATTCAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT
ATGTTTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGGAGGGGGGAGAGG
CCAAAGGGCCCAAGGCCTCCAGAAAATGTTTTTTGTACTGCTGAATCAAGGGAGGAGAAAATGGGTAAGG
TTAAAGAGGTTTAGAGACACAAGTTTGTAGCCATAGCACCCAGACATTGGTGTACTAAAAGTTACAAAAA
TTTCACAATCCAGACATTGGTGTACTAAAAGTTACAAAAATTTCACAATATGTTACATGACTTCCTGGCT
CTCTGACTGTAACATCACACCAACAAAGGTACAGTGTCAGACCAGAGATTACATCTAAAGGAACTACAAT
ATTCTGAGGAACAATATATATGTCCTTAAGAAAGGGATATGGGGAACTCCAAAACCAAAAGAAAAAACAT
CAAAGGTACTAGGGAAATCTGAAACCTATGCCAACTATGACCACATTAAATCAATGAAAGATTATTGGAT
GTTGAAAAAAAAAATAAATCTTCACGTTAACATTGTGTTTACCTCAGCTACTACAATTAAATAAAAACAA
AACATATCCAAAGTAATAAAACTTGTCTAAAGAGACAAAGCAATTATCAGAATTCCAAATACCATGTATA
CTTTTGGGATTATCAAACATAGAGCTCAAAACTATACTAATAATACGCTGAGTTTTAAAAGGAAATGTAA
ACAACTCACAATAAAAAACTCACAAGACAAGATGATATATGTAAGCAGATGTACAAACTCTAATAAAGAA
TCAAAGAAAACTTCAGAAATAAAATAATATCTACAATAGAAATGAAGGATATCTTCAGTGAGTTGATGAA
TATACTTAATATAGATGAGGAATACGTTAGAAAATTTAAAGATGACTTAGCAGAAACTTCTCAAACCCAA
ATGGATAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGATACAG
ACAGACAGATAGACAGACAGAGAGAGACAGAGAGAGAGACAGAGAGAGAGACAGAGAGAGAGAGAGAGCG
AAGAATCAAGGGAGAAGCAGAGAAAGAAGAAATAAAAAACAAAACAAATGATCCAAATGAAAATTGTTGA
GTAATTTTAAAGATGAAGCATAATCATAACTGGAACACCAGAATATAAGATTGAACAAATCAGATAAATT
CCAAGAGAATAACTTGTGGTTTTTGTCTTGTCTTGTTTTGTTTTGTTTTGTTTTGTTTTGTTTTGTCATG
GTGGCAAATGAATATGAATTCCCTGTATGAATACCATGTAGTGGCATAGAGTAAGGATATGATTAAAGAC
AGAAATATTTATTATAACATACACACAGATACAGACACACACAGGAAGGGGAGAGAAGAGAGAGCAAGAG
AGCAAGAGAACGAGAGAGAGCAAGAGTGAGAGTGAGAGAGAGAGAGAGAGAGAAATATTTCAGGACAAGG
ATCAAACTGAAATTGTTCACAGTTGCTACATATGGAGCAATTTAAATTAAAATACTAGGTATTATTGGTT
TATAGTCCAAACTATAAAATAAAGGAGGTATATTTACACTAATATAAATGAATTAATAAGTAGGAGCAAT
TTACAATATCAAATACTTTCAAATAATAATTTTTTTTTCTGCAGATATTCTATAAGGACTTCCTTCTGAA
GTGCATTATCAGATAGTAGAGAGATTTAACAGTTTGAGAAACCTGTCAGAAACCACCTGTACCAGAAAAC
ATATGCTATTAACAGTGGCATGTCCTTGATATGATTTGAAGCACATAGCACTTTACTTCTGTAATATTCT
TACAATACAAAACTTATATCCAATAAGAATCAAGTTCTGTTAAGGGACATTATATAAGACACCTGAGTAG
GACTCCAATATGTCAAGATTAATAAATGGAAGTGAGAAAAACTATCATAGCTGAGAATAGGAAAGCTTGG
TGAATAATGGTAAGATAGGATCTTAGTCACAGCACAGGTCCAAGAATTACATTGGGTCACTTCTAATATG
GACTTTGCCTATGTAATTTATCAGTGTTGGCTTGCTAACTGCAACAACAGTTCCATACTCTTTTAAGATG
TTATTGATTCAATAAACAAGGTATGATGCATGCCAAACCCCAGTATTTTATCTAATTAGTGAAACTATTT
TAAAACAAAACATAAGTTTATTAAACAAAATTAACAGAAGGGCCGTAAAAAAGTTGAGTGTTTAAGAATC
AATTTTAGAACATCCACTAGTAATAACAAAATGTAACAAAATGTTGTATATACAAATATAAGACATTTTA
TTCTTAAAATTCATTCATTTAAAATGGGTGAATTCCTCTGAAAAGTTTTCAGCATTTATAATACCCCCTT
TTTTTTTTTTTCTGGTCAAAGCATTAGTGAAATCCTCTGCCCTGTGGTTCTTAACAGTATAGTGGTAGAT
TTAAACATCCTAAAGAGTAATTTTAGAAATATCTTTGTAATTATACAATAGAAAATTTTACAAAAGAATT
CTATATAAAGAAGTCCTGATTCATGGTTATAGGGTTCTCTAAGTGTGCAAACTCAAAGAAAGATTTTGAT
GGTATTTTTAAGCTCAGAGTTGAAGAATGAGTATCCAGGGGAAAGAATGAAGAGGAACAGGTATACAGCA
AATCACACGCACTTAGTGTGTGACATAGTTGTTCATAAGGGTCAAGGAGGGAATATTTTTGGATGATATT
GGAGAACAAAAACCTGGGTTTCAGCCATCAAGAATAGCAAATGTCATGTGTCGGAATTTTGCATATTTTC
CCTCTATGAGCAGTAGGAAGTAGCTCTTCAAATTTGGCGTGGTGAATGAGGGCATTAACAAATAAGCGTT
TTGACAGATTATGCAGATTACTTTGTGGATGATAGATAAAAGATAATGCTATCGTTTGAATGTATCCCCC
CAAAGTTATATTGAATTTTGACCCTCAATCTGGAAGTATTGAATGTCAAAGCAAATATCAGAGATGAGCT
CACAAGAGTTCTGCCCTCAAAAACGGATTAATGTTGGAGTGAGATAATTTCCCTAGGTCTGTGTTTGTTA
TGAAAAAAAAGTTGTCTCTCTCTTGTTCTTGTTCTCTTGTTCTATTTGAGCATGAATCTTGTCACATTGG
ATGTCAATTCAAGAAAAGAATACCCTAAACCCTCAACCCATAGCCTAAGAACTGTAAGAAACACATGTGT
TACTTAATCAGCCAGTCTCAAGTATTCTATTTTAACACAATCATGGACTAAATCATATAATAAAACTTGG
TAGACATATATGAGTAAAGTTTAAATTTCTCAGAGAGGAAATCTATGTATAAGAAGAAAGAGCTGGGCAT
GTTAGTGCACACCTTTAATCCCAGCACTTGGGAGGCAGATTTCTGAGTTAGAGGCCAGCCTGGTCTAAAA
AGTGAGCTCCAGGACAACCAGGGCTATACAGAGAAACCCTATCTCGAAAACACACACATACAAACAACAA
CAACAACAACAAAACAAAAACAAACAAACAAAAAACCAAAAAAAAACAAAAAACAAAATAAAAGAAGAGG
TGTAGAAACAAGAACTACTGAATGGTGAGATGCTACATAGGACTTTACATATTATGTCTCATGCTTCTGG
GCAAAAGATTTTCACTCTCAAACAAATAGAACTCTAGAAAAGTGGTGAATGTATTACAAGATTTAATATC
ATAGTATGAATTCTCCATTAAATGTAAAGGAATCTCTCTGGAATTTTGAGATAAAATATTGAAGTAATGT
GTAAGACTGACTATTGTACACTCAACTAGAATGTGCTAAAATTATCTGGGATTTCATATCATATTCTGTG
ATGTACAGCTATACCTAAGTTTAATACTTTTCTGGTAATATGCAAGAAATTCCTTAGCAATTAGAAAGTA
AAGTAGATAGTTAAACAAAACTTTAATGTTTTGTGTCAAAAGGTAGAAAACCTTTTTATTTGTGCATGTG
TAGGGTGTTAAAAGTCTAAAGTAGACATCTTCAGTCAGTAATTCTTACACGAGAAATGGATTTTTTATCA
TAAAATAACCTTCAGATGGCAGAAAAGAGATGAATTCGTAATTGTAAAATACAAGGCTAAAGATGTGTGT
GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTTTATAATTGAAACTCAGTTTTCCTTCTT
GTACTACAGGGACCCAGAATTCAGTACCGAGAATTCCAGAGATAGACACTGACATGGGATTTTCTAATGA
ATAGCTTGAGATTCCTTTTTTAGGGAGGCTTGTGAGTGTCCATGAAGTGACTCCCAAATTGCTTAGTGTT
TTCTAGACAGTGCATATCCAAAGCAGGTAGGTGTGAGTGGAAAGAGTTAAGGAAAAGAATAACAGTACAA
TCTATCAATATTGTATCTATCAATGCTGCAGGATGAACAGATGAGAAGAAAATATGTGCTCTGTGGTGTG
TGGGCAAGGAGAAAACTGCAAAATATAGACATTTTGTTTCAAATTGTGTGTGTGTGTGTGTGTGTGTGTG
TGTGTGTGTGTGTGTGTGTGTGTAAAACAACAAATTGTTTTTCCTGGTTTCAGTTTCCTTGTGTGTAAAG
TGTACCTAATAACAAAGTCAAAAGCTTGTGAGAAACCAATGAGCTAGGTGTGCAATGTGCCCTAGACAGT
CTATTAGGCACCCAAACTGATTAGTTGTGGCTATTCTTTTACATGGCAGAAACTACCCATTTTACTTCAT
AAAAGAGCTAATATTAATATTTTTGAAATAAATATTCTACATTTTGGATCTGGGGTTATATTTGATATAC
TATGGACAAGATATCATTGTTTGGTTTCTCAAACAATGTTTTATTTTGTACCTTTATTAATGATTAAAAA
CATTTCATTATTTATATGTACATATAATGTGTTATATGAAAGACTCTAACCTCCATTATCTTCCATTATC
TCTCTTCCAATTACTCCTCATTCCTCCCTCACTTTTCTTTCCCAATATCCTGATCTATCTCTCTCTCTCT
CTCTCTCTCTCTCTCTCTCTCTCCCTCTCTCTCTCACTCTCCAATCCCATACATACTGAGTCCATTTAAC
ATTGCTTGTACGTGCGTGGGTGTGGGGCCACCTACTGGAGGTTGGGTAACTTCCCAGGTCCCCACAAAAT
TATTATTAAGAAAGCTAAGAAATATTTTTTAAATTGAGAAAAACAATTGAAGATGGGCTTCAGGGTGATT
TAGTCAGTAGAGTACTTGTTATACAAGCATGATGAACTGGGTCTAGATACCCAGCAGCCATTCAGAAGGA
GAGTGCAATATAAATTACATTGGTAAATTGTCATGTCATTTGCGCTTATTAAGAACAGAATCTGGGAACA
AGATGGACCCTTTGTTTCAGACTTAAATATATTTATATCAAGTCCTCTGAGACCCTTTCCTGAGGCTACC
TGTCCAGCTAGTCTTGCCAAGTGGCACTCTCCAGGTTTATTGAGATCTTTTCTCAGAAAATAAAGTGAAA
AGGTAGAGAAAAACATGCAAGCCTCTAACATCCACATGCATGAGCACACCATTAAACACACAAACACATA
TGTATGCATAATGAATATAAAATAAAAATCTGCAGGGTGAGCACTTTGTAGAGGATTAGGAAGAAATTCT
GAGGGTCTTCAGCTGGAAATTTAGATTCAGAGTACTGTAAGAATAACTCTAGAAATATGGGTAACCTACT
TAAGCTGTGACGATGCTAGTTTCATTTTGGTGAAACAGAGTATAACAGTATTGGATGAACCATTTCAGCC
ACAAAGTTCAAATGGTGAGGGAACTCCTAGAACCCTGGTGACTACATTAGAAAATGAGTTTAAACAAAAA
TGATTGACATAAAATGAATCATGAGACCATCACAGACTAATGACATCCTCAGGAGAAGAAGATTTCAACT
CAGAGACAGAGGGAAAACTGTGAAGTTATCTTTCATCACAAAAAAAGGCCTTAGAAGAAACATCCTTGCT
GTCTCTTTCAGCAGATTTCTAACCTCCAGTGCTGTAAGTAAGCAAAAAATGTAATACCTGGTATAAAAGA
TTATAATTATTGATATTGGTATTAGCATTATAATTTGATTTAAGGACTTTATAATATATATGTTTTTCTA
CTTTATCTTTTGCTCCAACAATGTGTAGGTCAAATACCACTTCCATGAGAACTTCACTTTCCTCACTTGA
TTATTACATTATGATAATTTTTGAATATGTGTTCAATACTTAAAATCCATTCATTATTACTTCTCAGGCT
TTTGTCTAATATTATATGTACAGAATTCAAATAAAGCAATTAATCACCTCTTTAGTTATTATATACCATA
TATTTACATAGTGCCTGCTCACAAACCAGATGGGTATTTGAATCATTCATAATCACCCATAAAATTTAAA
GGAAATTACAGAAACTATGCATTTTATTGGAAAACCACAATTTTTCCAAATTCTTAAAGTGGATATAAAG
TAACTCTTTTAGGAATTACTAGTTGATGATCAGAGGTGATTTTAAAAAATCTGAGATATGCTGGTGATTG
TAAATATTTCCTAACTGAACCATTCACTGAACTTCACCATGTGATCAGCTTGAAGCCTGATGCTGGAAAT
ACAAAACCCAGAGAAGAACTACCCTTGTCTTCCAAGAAGCTGAAGTTGGGTCCACAATTCAAAACAGCAT
AATATGAATGGCAAACAATAGTCAAAATATTTTATACATTAGGAGAACTGTGAAAAGACAGATAGATTAT
GCTTGAGGAGGGATGTACAAAGTAAGAGGACCCTTGAGTGACATTTGAACATTCTTTCAAGAAGTAACTG
ATAGAAATCTTGCAACATAACAGAAAGAGAAAAGGCAGCCAAAACAGACTCAAGAATAAAGGAGCCCAGG
ACAGTAAGTTGCTCAGTATGAAAAGGGAATGTGGATGCCAGTACATATGCTATAACAGATACTTGCAAGG
AAGCAACTGAGTCTAAATAGTACTGTGTCCCTATGAGCTTTCACAGGGTAGTTTAGGCAATGGAATGGCA
GTCACATTACCTGGTATAGAAGTGTATGGAGAGTCAAGTTTGTGGGATTAGGAGGAGTGATCTTTGACTA
AATAAACAGTCTATCTGAATGGAGACCATGTACGGCAGAGGTGGGGAGGCATGAGCCTCTGTTTGCATGG
GAAGTAACAGTGCTTCATTGCTTCTATTTTCTAGTGTTCTTCAATAATCATGGAACCGATTGGGCAAGTA
TTCAGAAAGTATTCATGAAAGCATTCCTTTTAATAGAGATTCACATTTTAAGAGGATATATTGTCAGATA
TGAATAATTTTAAATGAAAATTTCATAAAGGAACTATGAAATTCAACAGAGCCCAATGTCAACTGACCAC
CATTTCAAGTACCTATTTTAAAACTGTCTAGCTTAGTTAAAGAAAGTATTAAGCAATTCCTAGGGAATGG
CAAGGAATTAAGATGAGATTAAAATCACTTAAACTGATGAATAAACCTGGGGGAACTTAGCATAAGAATT
GAAAAGAGAAGTAAGGATGAAGGTCAAGAAAACAAAAGCAGTGATCTAATTTTCCTTTCCCAGAGATACT
TAAGCATATATGTAGGTAGTAGGCTACACTGTGGACAATTTGGAAGAGAAGATGGTTATAATTTGCAATT
AAATTGAAAGAATTTAGGGTGAATAGAAACTAAATTCAAGTCAAACTAATTAAACTATACTCATGAAGCA
CAGTCAGTGTGAATCTATGAAATGGGTTCATAAAGAGCTAGCCCCTCCCCCTGCTCAGACTGTGCTGAAT
AGAGGTAGGAGATTGGCTCTACATTTATTTCTCAGTAGAAAATGTTATCTGTTTTTAAAACCTCAGTGTT
CCAATATCTAAAATCATAATAATGAAGCTTTCCTTATCCCTCTCACTAAGGTCCTCACTAATTTTTCAAT
ACATTTTCTATCATGCACCCATTATTTGTCAAATTCCAAGAGTAGTTATAGTTGTCTATGGTTTTGCAGA
CAACATTTTGTGTAGTGATAAAGGAGCATATGAAAATCCAAACAACGTAAGTGCTACAAGATCAAAGGTG
AGAACAAAGGGAGTTTCTCAGAAGTAAGGACTTAAATCAGGAAAATTATGGAGAAGAAGTTGACTGCATT
CCAATTACATCCTTACAGGAAGTTGAGAAACAATAACTGGAAAGTAAAAGTAGCTAAGTATGGAAGGTAA
TATTGAATAGTACAGGGTCAATGAGAAATGAGCCTAGAAAGATTAGAATGATTTTGGAAAGCCTTATGTG
AATAATGAGAGAGTGTGGATTGAACTTGAGGGTCCATCTTCTGTGTATGTACAACAAAGAAGGTGTGGTT
GTTATTGGATTTTAAATTTCTAATTATGGTTATATTGATTATATGTGTTATGTATATTTCTATGTTGAAT
TACCTAGTATAGTATATGATAGGACCAATAATAAACAAAGTCAATGATTCTATGTGAAAATAAGCATAAC
TAGCTAATCTTATCTAAACTCCCACATCTATGAATTCAACAACCTAAGGATTAGAAATATGAGTTTTTGG
TATATATACTGAAGACGTGTAACCTTTTTCCTTCTCTAGCAACAATGGAGGATAAAGAAAAAACACTAAA
CACTGTTAGATATAAACAAACCCTGAATGATAAAAGTCAATGAGACGATGTTTTAATTTATGCTCAAGTA
ACACAGCATTGTATGTGAGAGACTTCAGCATCTGTGTGTATGCGTATCCTCCTAAAAACCCAGGTCAACT
CTATTGCTTTCCTAAGATAGTTATTTTGCAATTCTTTTTTATTATTATTGTTGATTTTTTGTTTACATTT
CAAATATTGTCCCCCTTCCGTGTCTCCCCTCCATGAGCCCCCAATCCTTCCCCCTCCACTTTGCCTCTAA
GAGGATGCTCACCCACCCACCCACCCACCCACACCTACCTCACCCCTCTAACATCCTCCTTCTCTGGGAT
ATCAAACCTCTACAGGATCAAGTGCTTCCCCTTCCACTGTTGCCAGATAAGGCAGTCCTCTACTACGTAT
GTAGCAGAAGCTATGGATCAGCCATGATAAATGCCTGGTGGTTTAGTCACTGGGATATACTTTTTGGTTA
GTGGTTTAGTCACTGGGATCTCTGAGGGGTCCGGTTAGTTGATATTGTTATTCTTCCTATGGGTTGCAAT
CCCCTTCTGCTTCTTTAGTTTCTCCCCTAACTTTTCTTTTGGGGGTCCCCGGGTTCAGTTCAATGATTGG
TTCTGAGTTTCGACATCTCTCTTAATCAGGTGCTGGCAAAGCCTCTTCTGCAATTCTTAACCATCATTAA
TTGTAATAAAAAGTAAATAACTTCAAGATGGACTTAGTATAGACACACTCTTAACACAACATTTCCACCA
AGAGTGACAGAAAAAAAACACTCTTTATCCTTATTCAGAGGTTCCCATTACTATACCAACTCTTTATACA
TCATTAGCTTCCTTACTTCTTTTCCACTTGTGATAGATTGTACTAAGCCCTCTCCCAACACCCAGGATTG
CAATGGATAAGTTCATCATGATGGGCTCTTTGTTTGTGTTGGTGACTATTTACTACACACCACAGTACAT
ATGACATTTCATATGTAATATTTAACCTTTATAGTCTCACAAGTAAATAGCATGTCTATATGAAAATTCA
AAGACACCATCCCTCCAACTGATAACCTACTAAGAGACAGAAGATAAGTGTAGTTGCAGTTGCATAAAGC
CAACAATTCACAGTCATTGATCCTCTTACTGCATGCATTATCAGTATATTCTTTATTTTCTTTATAGTCC
TAGATTCTTTGTCAATAAAAATTACAAGAAGTATCATTTATCATTTTAGATCATTGGTAGGCTACATGCC
AATTAATCTATATTCTTTCCTTTCTGTAAATCCCCAATTTCCACCTCATTTATTTGAAAAACAAATTATT
TTATTTGAAAAATAAAAATAACATAAACACTTTCATTTTGTTTATTCTTATTAAAAATTAGCACAGGAAT
GGTGACTTGAATTAAACAGGAAGAAGTATGAATGTTTGTCAGAGGACTTTAAATTAATTTTGGATGCAGT
GGGAGATGTAGTTACCATTTGATCAAAGGGATGGTGTAAAAAACTTGACTTCATGAAACATTTATTTGAG
AATTTTATACAGAATTTGCTTTTTAAAACTTGAGCTATGGTCCATATGACATAGTTTAGTACCAAGTGCT
TATACTAATCGTAGTAGCAGTTAGAAGTAATGCATGAGGATATAAAGAATTTCACAGATGTTTCAACACC
AGGATGATATTTATATAGAGAAAATTCCCTATAAACTCAAATGTTTTTTCCAACTAACAGAAAATGTTCT
ATGTATGCCTCATCATATTTATAGTGCATATGGAGTATGAATACACAAATAATTTATACAGTGATAATAC
TATTATCATTGGAATTTCAATGACAAAAGTAGTGTGTTTATGCTAGTGTAACTAATGAAAAAGCATTCTT
CAGAACATGAATTGAGGGCTGGAGAGATGGCTCAGAGGTTAAGAGCACTACTGTTCTTGCGAAGGTCCTG
AGTTCGAATCCTAGCAACCACATGGTGGCTCACAACCATCTGTAATGAGATCTGACACCTTCTTCTTGTG
CATCTAAAGATAGCTACAGTGTATTTAGACATAATAATAAATAAGTCTTTAGGCCAGTGTGAAAGGGGTC
TACCAGAGTGAGCAATCTTCATTCCCAGCAAACACATGATGGCTCACAGCCATCAGTAAAGCTACAGTCT
ACAGTCTAGAGTGTACTCATATACATAAAATAAATAAGTAAATCTTTACAAAATGAAAAAAAAAAACATG
AAAAGCATGAATTGATCCAGGCAGCAGGCTGACACTTAAACCACAACAAATCATTCTTACCACTGGAAAG
ATAAACTCAAAAATGCACAGATGAAAGGCTGAAAACCACATTTGTGTGTGTGTGTTTTGCTCTCTCTATC
TTCCCGCTTGTCGCTATCATTTTCCTGTAGTGAGGATATTCATCTATTCATAAATTCCCTTTTCTGCTCA
TTTAATTGTCTCTTTCAACTGAAGTAATTGAAAACTAAAGTTATTCCTTAAAAATAACTTCTTCATTTGT
GTGTCAATTAATCACGAGTTTAAAATATGTAAACTGTCAAGTTAAGCAAAAGAGAAAACTCTTTTTTTTT
AATTAGATATTTTCTTTATATACATTTCAAATGCTATCCCGAAAGTTCCCTATGCCTTTCTTCCGCCCTG
CTCCCCTACCCACCCACTCCCACTTCTTGGCCCTGGCGTTCCCCTGTATTGGGGCATATAAAGTTTGCAA
TACCAAGGGGCCTCTCTTCTCAGTGATGGCCAACTAGGCCATCTTCTGCTACATATGCAGCTAGAGATAT
GAGCTCTGGGGGTACTGGTTAGTTCAGATTGTTGTTCCACCTATAGGGTAGCAGACCCCTTCAGCTCCTT
GGGTGCTTTCTCTAGCTTCTCCTTTGAGGGCCCTGTGTTCCATCTTATAGATGAGTGTGAGCATCCACTT
CTGTATTTTCCAGGCACTGGCATAGCCTCATACAAGACAGCAATACCTCTCCTGGGCATATACCCAGAAG
AAGTTCCAACTGGTAATAAGGACAAATGCTCCACTATGTTCATAGCAGCCTTATTTATAATTGCCAGAAC
CTGGAAAGAACCCAGATGTCCCTCAACAGAAGAATGGATACAGAAAATGTGGTACATTTACACAATGGAG
TACTACTTAGCAATTAAAAACAATGGATTTATGAAATTATTGGGCAAATAGATGTATCTGGAGAATATCA
TCTTTAGTGAGGTAACCCAATCACAAAAGAAGTCATTAGATATGCACTCAATGATAAGTGGATATTAGCC
CAGAAACATGGAACACCCAAGATACAATTTACAGAACACAAGAAAATCAAATCAAGAGGAGGGAAGACCA
ATGGGTGGATACTTCATTCCTCATTAGAATAGGGAACAAAATACCCATGAAAGGAGTTATAATGACAAAG
TTTGGAGCTAAGATGAAAGGATGGACTATCCAGAGATTACCCCACCCGGGGATCCATCCCATAATCAGCA
ACGAAACCCAGACACTATTGCACAATGTCAGAAAGATTTTGCTGAAGGAGAAACCTCTTAACTTCCTTGA
ATTTTTATTATGGGAAGGAAATAATAAGAAGGAAATAATTTCTATTTATTGTGCTAAAGAATAATCTTTA
TATAAGTAAAGATTAGTGAAAATAAATAATGAATCAATGGGTAGAATACCAAGAAAGTCAATAGGGATCA
TCTGGAGAAGAGGCAGAGACGTGGGCCCAAGGGAACTGTGAAATTCTCATAAATGTCACAAGTTGCTATC
AATTTTTGCCAGTTTTCCTTTACGTGGTTAGCTGTGAAATTTATGAAGCTTAAAGTACCTAATTAAGTAA
CATTAAGGAAAAAGGAACTATGGAAAAATATTCAGCCTAAAACTCAGGGGCTTGGTGGAGGTAATTTTGG
AAGATAAAATCAACATGACAGCTACTTGCAAAGCCCTCCTTAAATCCATCTTATAACTTCTATAAAGGTT
AAAGGCATGATTTTCCTGTCTGAAGTCTGTTCTAGCTGCTTATGTATTATGTCATTTACATATAATAATT
TTATTTACTATCAATTCCCTCTAGCTTTAAAATATCCTTGCTTCTTTTAAAAATGTGAGTTATTTCAATA
AATGTCCAACTCACCACTATCTGTTTGTGCTGAAAACACTGAGGCACTCTTGTGGTACTGAAAGAATAGA
TATAAGCAGTCAAGAATTGTAACAAAATCCCCGTGGATTTACTGTATAATAGGTCTGAGCTTAAAACTGA
TAGAGATGAATGAAACTTGAAAACAATCAAACATGCATTTAGCACATTGGAATCCCTTAATGGAGGAGAA
ACAAATCCATCTTTCTTGAAGCAATGGAAAGAAAATGACACTATCAAAAAGCAATTTTCTTCAGAAAGGA
GAATTCTTACATATGTAGTATATTTTACATATGACAGAATATTGTAGCTTGAAGTAATATTGTCATTTAC
TGAGATGATAAATATTTACCCTTGGTTCATCATAATTTCCAAGAATTTCCCATGCAAATGGACAATCGAT
CAAAAAGAGCACAGTTTTAACTATGTATACATTAGCGTGTCCTTGATACAGAATTGAAATAAAGTGCCGT
GTGTTTCTACTTTTGCTATTTTGCAGAAAAAAAAATATAGCTAGGAAAAATTATGAGATAAAACTATCAT
TTAGCCTTAGACATTGTCTAATGGCATTCTTAAAAGTAAGAAACCATTATTCAAGAAAATCTTATAAACA
TTAAGAACTCTGAGTGTGTGTGCCATGTGACTGGATTATATCACTTCCTCCCATTTAACTGCGATAATAC
TGAAAACAAATCATTTTAGAGAATCTGATCATTTTAACAGGAAGTTAAATTGATGAGCAAGAGATATCTA
TTAATTTCAGAGATTTATTAAATTTACTTTAATACTGTTTCTGTACCTTTCAGCATATAAATCATGCTTT
TTTGAATTAAAACTATTCCTAACTTTTATCCCAGTGGTGCTGCAGTCTGAATCAGGAGAAATACTGATTC
CTGATACTATTCCTAAACGACAGCCAAGAACAGTTGATTTAGTATGAGATCTGGTATTCGGGGTCATATA
GGTGGCTAAGAGTATACTTTTATGAAACGAGCCGGCATGACTTTTTTTTTTTAAAGAAAAAAGTTTACAA
AGTGTCAATCCTCTTAGGAAGATTTTGAGACTAGGCAAAATATGAATGGTTTGATTCAAATAGTCTGTAC
TATAGGGCACCTGATTTGTAACATCAAAATAGTATTAAGCTTGTAAAAAATTTATTTGTGTGGAAAATGA
GTTCAAAGTATGCTATACATCAAGAACTACCTGCATTATTAGGATTAATTCATATTTGTACTTTGTGGTT
GTGTATATATTCCTAATTCCAGGCTTACCAATTGTATGCATGAATACACTTCATCCTTAAATTCATTTAA
GTATGGATACCCAGACTTCTACATATGCTACTTCAGCATCACTGTGTGTGTGTTTTACACATGATACTCC
TTAGTAATTGATCTATATATCAAGGAATATGTGAAGCTTTGGCAGTAGATTACCTATTCTTTTGGATTTT
AAAATAAAAATGAGACAGATGTTGAATGGAATACATGAGCTACCTCAATCTATGCAAAGCTGGAAAAAAC
ACTAGGGGAGTAACTAAAAAGAAAAACACATTTATATTCTTTATATAACCCAGTAATGTGAAATTGTAAT
TGTGGTACAAATAAAGTTTCTATCAATTATCGTAATTAAATCAACATCACTTATTTGTTAAAATTATCTC
TTTTATTTGTGAGATTATAATTACATCTCTCTTTTCCTTCTCTGTCTTCCCATCAAACCTTGCCTTATTT
AAAATTCATGGCTGACCATTTGCTATTGGATAACCAGAGTGCTCTACCCTAGAGAAGACCATTTCTCCTG
CTCCGAGCAGGAGAATGTGTAGAGTCAAGCACTCTGGTCTACCCCACCTGCCTATCCATTAGGGAAGGCC
AGTTGTTCTCAGGGATACAGAAGAAAAGGCAGAAAAATTATAAGACTCAGGGATCGAAGAGTCAGGGTGT
TTCTTGTATGTTTGTGTTGTATAATTGTGTTAGAAGATATATCCATAACTCTCATAAGCATGACTACATA
AATTTGAGCTAAACAAGAAAATAATGTATTTTATACATAAATGAGTTAAATATCAACAACCCAGTTAGAC
TAAAAGCTATGGAATAGTTAGAATTCCGAAGACTGCAATCCTGAGAAAAGTACACAGCCACTTAGCACTG
CTTTTCTGTAGACAATTTATTGGTTGCTCATGAGAAAAATTAGGAAGCAGTGGTAAGATGTACTGGCCTT
TTCTTATCAGAAGAAGAGTCATGCATGTCTGCAGAAGCCAATACACTGTTGACAGCAATAGCACAGTTTA
TTAATGGGCAACTGATGAAGCATAGGTATAAGATCGGCTCTTGTTATGCTTCTTTACATAATATAAAGCC
AAAAGATCAGCTGCTTATAAAAGGGTCCCTGCCTTTTTACTAGAAAGAGTAGCTCTGTCCTTGTAAAATG
TCTGGGACTTTGTCCACAGACTCCACGATATAGTGACATGAGGTATAAACAGTTTGTACTGGTCCAAACA
GCACCTATGTTCGATTCCAGAATCTCACATTGACAAAAACTAAATCTTTCTTCTGATAGAAAGGAGGCAA
AACATGCATTCAAGCTCTTCAGCAAAACAGTTTCAGTGCCATGTATATACATAAATACACACACACACAC
ACACACATACACACACAAACACACACAAACACACACACACACACACACACACACACACACACACACACAC
ACATACACATATAAATATATATAAAGCCTGCTTAAAGCTTTGGCTATAGCCAAGACATTATAACACTCTA
GCAACCCAAATGTTAAATACCTTCAAAAAATAATGTTAAGTCATAACTTGAAGGATTTAAAGATAGTGAT
TTATCAAAGATAACCATAATCTCAATAGTATACAAACTGATAGGGAAAATTAATTAAATGTTTTACTGTA
AAATTGTAATGTAGAGGATATTTGTTCTTGTCTCTGGAAATAAATGTTATTTACCTAAATATTAATTATT
CTTTTATATCATGTCTGTCAGTTATATATTACTTATAAAACACTATGAAATAATTATACTACAACACACA
CTTATGCACGCATCACTTTGTCAAAGTATTAAAAATCAAAACAACAACAACAAAAAAGAAACCCTAAAGA
TTAAATAAAAGTCAAAGACTGAGAAAGCCCACAGATTGATATTATAAGATAGACTTCTAAAAGTAATTTT
AAACAAATAACTATGAAGATGAAAGACAGATTTACAGGAACCTCAGAATTACAAAATAATTTTTTTAGTC
TTAACCATGGACCCAAGCCCTTCATTTCTGTTGCGATCTAGCCATTAATTTACACGAACTAAAATCCTAA
TAGGCAAAAAACAGGAACAGGCTTAATTTTAAATGTAATGATACTTCCAGTTTCTCTTCCCAAAATATGC
CTGAGCATAGAAGTTTGAGGTTCAGCTATCCATGTGTAATAATATTTATAAATGTGAAATAATATTTATT
GTAAAATTTCTTAAAGCTTTATCTGTTACTCTAAAGAGAATGTGACACCTCAGATTTGTGTCATTTTAAA
CCATTTTTTTCTAATTTATTTTCATTGCTTTGTACTCATTTTCTTTTAGTACTTTGTATCTATGTTCCTT
CTCCCACTCTGCCAAACATCACTTCACTCTCTCTTTCAGAGTCACACAACTTTGTGTGATGTTGTGTTTT
CTTTAAACCCATCAAGTTCAGTTAAGGTGCCCATTGATTTTTGGATTTGTGGCCTATCACCTGAGTAGTC
AACTTACCAGGGGCCACAACCTTAATAAAAACTGACCCCTTCTCACCCACCTGTCAGTCAGTTGCCAGTG
TCTCCTCAGCTAGAGATGGAATATCTAATAACTTAGTATCTTTCTGGAACACAGAGCCTTCTATGCCTTA
TAATTACACAAACTGTAGATTTAAAATTATAAATGTCATTTTCTTAAAACAAGTGAAATGTCTTCTCTTC
CTTATAGCACATGAGAAATGAGACATTTGCAATATAAAAAATAACAGAAAGAGAGGACATACTAACTGTA
TGTAAGGAACTGGACCTGGACAACAGGTGGATTTTAAGGATGCTCTGCTGTTTGCTGAGTCTCTTTACAC
AGTGTGTTTATACAGAGTTGTTTGTTCACAGTTCAGTGGAGTACGCGAGGACTCTAATGGCTTTGTATCC
ATAGAACTCAGACAAGAAGATCACTGTGGTTTAGGGATTATTTGTGATTTCTCTTCCCCAAAGGATTTTA
CTTCTGGTTTGTTAAGGAAAACATGGTAATGTCAATCTTGAATTTTGTTCTGTGGCTTGTCTTTTTATTT
TTCTCTGTCTCTAAGATTAAGGAAGTTCTACTGTCTCATTTTTTTCTTGTGAGAAAAATCACATTTAAAC
AAATCTTACTCTTTTGATAAATATAAACATTGCTATCCTGATGCAGTTAAAGAAAACTGGCATTTATCTC
TGAGTTACTGGGCATAGTAATATGTCTTTTTCAACATCCAACAGCACTGTATCCTTTGCTATTTGAGATT
ACGTGACAGTTTGTACTCCACAGATGCATCTTGGCTTGCTGATAGAATGGAAATGACATTTGAATTATGA
ATTCTTGCTTTCTTCTGTTTTGCCAAAAGTACATGAAGAAATTTTGTTTTGACGCTTTCAGAAACACACA
AGACATCAGAATCCTATTAATAACATAAATTAATGAAATTAAAAATATCAGAAATAAAATGTAAAATTAG
CATTTCTTGTGGATATGTTATACTTTAGCAGTTATTATTGGCTTTATTTTGTATTTAAGAACAATTTGGA
AATGTTTTCCTTTTAAGACTGCCATATCCAGAGATCCATCCCATAATTAGCCTCCAAACGATGACACCAT
TGCATACACTAGCAAGCGTTTGGTGCAAGGACCGTGATATAGCTGTCTCTTGTGAGACTAGGCCGGGGCC
TAGCAAACACATAAGTAGATGCTCACAGTCAGCTATTGGATGGAGCACAGGGACCCCAATGGAGGAGCTA
GAGAATGTATCCAAGGAGCTAAAGAGATCTGCAACCCTGTAGGTGCAACAACATTATGAACTAACCAGTA
CCCCGGAGGTCTTGACTCTAGCTGCATATGTATCAAAAGATGGCCTAGTCGGCCATCACTGGAAAGAGAG
GCCCATTGGACACGCAAACTTTATATGCCCCAGTACAGGGGAATGCCAGGGCCAAAAAATGGGAATGGGT
GGGTAGGGAAGTGGGGGGGAGGTTATGGGGGACTTTTGGGATAGCATTCTAAATGTAACTGAGGAAAATA
CATAATAATAAAAAATATTAAAAATAGTGTTTAAATTGAAGCCATGTAATTTTTCATAATTTGAGTTTTA
AAGCAGATCAATGTTCTTCATTTCTAGTGATTTTTGTACCATTTCATTGGCAAAATATTCCCGTAAATTC
TAACACCAGCAACCTGCCATTTGGAACTAAAAATCTGTTTTAAGAATTATTTTTCTTCTTACTCTTGCTA
TCACATTATTAAAATCTCTACTTTAGTTCAACAATTTCTATTACTATTCTATCTTCCTTCAGTCTACAGT
TTAATTTTTCTTTGTACCAATCTTAAAGATTAAATGGGCCCTCACACCCAAATCAATAATATATTGAACT
ACTAATCCCCAGAACCTCATGGTGTTACTGGATTTAAAGACAAAGTCAGAGACTGGCAATTAAGTTAAGT
AAGTCATTAGTGGGAGCTACAATCAGATATGACCAATGTCTGGAGAAGAAATACATACAGGACACAGATG
CACACAGAAAGTATTCTACATCAGCACACAGGAAAAGGATAGCTCTGTCCAAACCAAGGACAGAAATCCT
CAGGAGAATTTGATTCTCTTGACATTGATTTGGGGCATTTATTCTTGAAACTATGTTAGTATAAATGTCT
GTTCTTAAGCTACTAGACTGTGGTATTATTCTGTGGCAATAAAAACTTGAATTTGTTTCTTGGGAGGCTA
AATTTTTAATTTTATTATCCTTGAAGTCAGAACTGATTAATGACAGACTTAGGAGATGATAATTCCAAAT
AATACAGAGGTCAACTGAAATCCTGACAGTTGACTATTAGCTTCTGACTGTGAATTTACAAATCTTAAAT
AAAAGTTATAATCCATACATTTAATGGGTGATATATATATTACACATATACATGTACACACATATACACA
CATATATGTATATATATATATATATGTACTTCGTGGTATCAAACAGGTTGTAAAGAACTGCATTATGTTG
TAGAACTTTCCCACACCAGTACATTTCTTAAATTCAACAACCTACTTGATGTACTGAGTTACATAAAGAA
AAAAATTTCCTAAAACTTTTATAAAGTCTTGTTTTTCCATCTTCTCCTCCCGAGAAGTCATCACCAAATT
TAAAGGTGATGAGCACCAATGCCATTGAATGGAATAGTACATAAAAACAGGAACGACACTAAAATACAAT
CAAAATACCTCAACACTACATTTGTACACATATATGCACTTATTATCTATCTTTTCTTTCTAAATGTGCA
GAAGTCAGGAATATCTCACAGGAGGGCTTCACTGATTCCTTGTCTTCAAACCTCAAACATTAGTATGATT
ATTTGAATAAGAACAACTTCCTATAGGCTTTTATATTTAAATGTTTAGGTACCAGATTGTGGAACTATTT
TCGAAGGATTAGGAGATGTGACCTTGTTAGAAAGGTTCAGCCTTGGAGGAGGTGTGTCACTGGAAAAGGG
CTTTCAGATTTCAAAGGTCCATGCCAGCCCCAACCCTGTTTTCTACTGAAGATTAAGATGTAGAACTTTC
TGCTTCTGCTCTCCTGTCATGGCCATCTGCTTCCTGCCATGATGATCATGAACTCCATTGTCCTCTGGGA
CCATGAGCCTCAAATTAATCTTTTATAAGAGTTGCCATGGTGTGTCTTTACAGCAATAGAACAGCAGCTA
AGACGGTCAATCAACATGCATAGGTGCTTTTCTCACTTTCCCTCTGTATCTCCTTATACCACTTAACCTC
CTAAGAGCTTCTTCTTACACACCCTATCCCACTTCTCATTAGAAAACTTTGCAAAGAATTGTTCTGAAAC
TCCCATTCTGACTTCCTGTATTCTGAGCAGCTACCAAATCTGCTGTCGCCTGGGTAACTACCAGGCCCAA
TAACATCATGTAATTGATCTTTTTAGAGCAGTAGATATATTTGTTGGTAGCCTTTCTTTGTTTCTTTTTG
TTGCTGTTGTTGTTGGTGGTGGTGTTGCTGTTTGTTTTGTTTGTTCATGTTCTTAAATGGATCTTAGAAC
TTCATATGCTGGTTTTTCCTCCTTTGTCCCCTGTTGATTCTCTCACTTGCTAATCTGTATATGTTTATCC
TCTTAAATAATGGTATAGGTGAGATAGGTGATACTTTGTGTTCCCAACCTGGAAATTGGAGGAGACCACA
AGGAAAGCAAGAAGGTGGAGGAGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGA
GGAAGAGACAGAGGAAGACACCATGTGTTAGAAATCTAGAAAGAATGGATCTGAGGACCAACCAATTGGA
GTTAAGAACAGCTCACATGAAGCATAGTAAGTAATAACTCTAGGTTATCTGTAGGAAGTAGATTTTAATA
GCACAGAGGGTAGATCTCTGCTAAGCTCTAGTGCTGATTAAGGCTTATTGTAAAAATAAAGATTGTATGT
GTCTTTTATCCTGGAACTAAATGGTCAAAGGCGGAGTAGAATTCCTGGAATGGATTTAAATGATCTCTAC
AACAAAATAGCACTTGAATTATGTCAGTTAAAACGCAAGTTTACAACCTAAAAGGGCCCGGTAAAAGTGG
GTGGGGAGAGTCAGGCTAAGCAACACAAGAGGTCTATTTTCTTTAAGTTAATCAATCAATCAATCAATCA
ATCAATCAATCAGACCAATTCAAATGAAGATAAATACAGAAAATAATATTAATTTAATTTATATGAATAA
AAGGGTATATAAATATATTTACCCACAGAGATATTAATCTCTAAAGAAGGGAGATATAAATGGAAATTGA
TATAAATGTTTCTAAGAATACATAGATGAATGACTAAATCCAGGCCTTTGATCACAGTTGCTTAGGAGAG
AAAGGCAAGGAAAGTGAGGTTTCTTGTGAATTTTAGTGTTAGCATTCCTTGTAGGCTCCTCCCACACACA
GTCACCTGGCAACATCCAGCTATGCATTATTCACTATAAAAGGGACTGTTTGCCCCCTCCTCACTCTCTT
ACCCCCTTACTCTCTTCCCCTCTCCCCCTTTTACTCTCTTCCCCTCTCTGTCCCTTCTTTCCCCATGTTC
CCCTCCCCATTCTCTCCACATGGTTATAGTCAGCCTCTGCTCTCTCTTTCTCTCTCCTGTCTCTCTGACT
CTATTGGTCTCTGTCTCTGTCTCTCTCTCTCTGCCTTTCTCTGTCTCTACTCCATTCTCAGCTCCCCTCC
CCATACCCTGTATAAAAAGAAGAGATGTCTCAACGTGGGCCCACAGAGGCACCCCATTCCACCTCACCAT
TCCATGCCTCTACAAAATATATCCTGTTTCATTTTTATAAAACACAACACTGAGGCCAACATAATCTACA
GACAAATCCAGGTCAGCTCTGGCTACACAGAGAAATCCTATCTCAATAAACTCTGGAATGGGATTAAACG
ATTTCTACAATAGATCTCTGGCTGGTTGGTTCACTTCAGCTCTTCTGTCTCAATCTCCCCTTCAAACTGA
CTGATTCAAACTGATTCAAACTGGTTCCTCTAAGTTTTTGACTGAATTGCCATGCTTGGCCTCAGACTAA
TGTTAGCAATCTGTTGTGACCTTCTGGTTCCTTCTCATTCTCTGGATGATTTTGTCTTCACCTGTGTCTA
TCTTGTTCTTTCTACAGCCTGTGTATTTTTTTCACATCTTTCCCTGATTCTTCACTTTGTCTGTCCCTCA
ATTAGATATCACTTTCAAAATGGCTGCTTTCTTCTACAGAATAATCTTGCCTACATTGCTTGAAATTAAA
GGTGTGTACTAAATGTGTGTCTATATTCCAGCCAAAGGAATTTAAGGTCTGTGACATTTCTGCATTCCAG
CCAGATCACACAGACTTAGGAAGTGTTTGGATGTAATCCCTTGCCAGAGCAGCCATGTTGCTGCATTAAA
ATTCCTCTACATTGATGAGTGTGCAATGATTTATTTTTCACTGAATTTATTACTTCTGTTGTCTATTTGC
ATTCTTTTATAGTATTATTCCTTCTTCTACTGATCTTCATCCTGAGTATCCTTGGGTTTTCCTTACTTTT
TAAGTTATTATTTCTAGTTACATCAATATCATCATATATTACAAGATAACTTCTGTTGATTTTACCTCTG
AAATACACACGAGCGGTTTTCTTCCCATCAAACCTCTAGCTGATAACATTAATTAATGCCACAGAATTGT
CCCATCCGTAGTTTTCTTCCAATAATCATTTGTCTCAGCAAGCAAAGTAACTTGAAAAATACCTACACAT
TAATAATAAAGTCCAATCATGTCCCCCTTAGATGACATGCGCAACAGTGGGGAGAGGAAATTTGTAGAGT
CCATCTCCAATAGAAAGACAAGGCATCAAGTGGAGAGATGGGGTTGTAATTCCACAGTCAAAAATTCTGA
CCCGGAATTGTGCCTGTCTGAAAGAACTGTAGGGACAAAAATGGGGAAGAGCATAAAAGAAAGGAGGGTC
AGTGACTAGTCCAAATTGGAATTAATTTCAAAGGGAAGCTCCAAGGCCTGACATTATTAATGATGCTATG
ATGTGCTTCCAGACAACAACCTAGCCTTCTGCCCTCCAAGAGGCCCAACAAGCGGCTAAAAGAGTCAGAT
GCAGATACTTACACTCAAGCAATAGACAGAAGTCAGGGACCCCTGGGGTTGAATTAGGGAAAAGCTGGAA
GAAGCTGAGGAGGGTAACCCCATAGTAAGACCAGCAATCTCATCTAACCTGGACACCTGAGATCTCTCAG
ACACTAAGCCACCAACCAGGCAGCATACACTAGCTGATATGAGGCCTCAGATACATATCCAGCTGAGGAC
CTCCTGGTCTGGTCTCAGTGAAAGAAGGTGCACCTAACCCTCAAGAGACTTAAGGTTCCAGGGAGTGGGG
AGGACTGGTAGGGTGGGGTTGGGGGGTATAAGGATATGCTCTTGGAGAAGAGGGGAGGAGGAATGGGATG
AGGGCAGATGTTGGAGAGCATACAAGGAGGGGGATAATGACTGAATTGTAAAAAAAAAAATTAAATAATA
ATAATACCGGCAGCATTGGGTGGTCGAGTCAAAGCAGAGCTGCAGAGTTTGCCCTTGTATTGCTCATAAG
AGAAAGCCAGGGTGCTGATCTGCTCAGTAACCCCCCAGGCCCAAATCCAGGACTTTTAGATAGCACATTC
CAAAATCTGAATGATCTGTTAATGATCAGGACCAGTGTAAGAGCCAGTCCTGTTGACCCAAAGCTTTAGG
ATCTCCATGACCCAGGGCAACAACAGGAGTCCTGATCAGGATACAATATTGATGCTATCACAGAAGCCAG
AGACCTTGACCCAGACCAATAGCTCATTGCAATGAACATGTATGTGTAAGTGAGGATGTGTGGACAGAGG
AATATGACACATTACAGATGATGAGATATTTCTCTGATTTTTTTCTTTCTCTCTCTCTCTCCTCTCTCTC
TCTCTCTCTTCCTGTCTCCCTCCCCCCATGTGTGTGTGTGTGTGTGTGTGTGTGGGAGAGAGAGAGAGAG
AGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAATGTGCCAGTGGGAGAGAGGTTGCAAGAT
AGAGGGCAGATATGAAGGGATGGGGAGATGAGCAGGACTAGGGTGTATGATGGGAAATGTAAAACTCGCA
AAGAATAACAAGTAAAAGACAGAAAACAAAAACTAAAACGCATGCTCAACAAGCCTCGGGGAGCAAGCCA
GTAAACAGTTTTTCATGCCCTCTGTGTCAGATGCTGTGACCAAGTTCCTACCTCTAGTTGCTACCCTGAA
TGAATTCCCTTAGTGTTAGATTGTGACACAAGAGTTTTAAGATGAAATAACCCCCTCCCAGAAATAAAAA
AGCCTAAGTATCACGTTGAACCCAAAAAATATTGGGGTTGGGTGTGAACCTCGGTAACAAAGCACTTGAA
TTGCACAAGGTCATGAATTCCATCCACAATACCACACACAAACACATAAAATATTGAAGCTATAACTTCA
TACAGATACTAATATTTAAACCATTTTCTGCCTTAGTAAAGGAAGGTTATATAATAGCAAGTAATGTAGT
AAAGATCATAAAAATGGATAATTTCAAATCAGGCATGTGTAGTATTAATTATAGTGTCTTAATCATAAGA
TTTATGATCCCCAGGGATTCTGTTTTCTGGCAGTTGGAATCACTTAGTAGCTCTCTTGGATCTGCTATTT
GGTATTATTAAAGAAGTTCTTTTTGACCTTTGCTGTCTAAGTATGAAAGCTGAGGGCCTTTTCTTTAGTC
CTACTGCTTCTGCTTGACTTGGTTAAATAACCTTTTGCTATGTTAAGTAGTCTGCACTACCTCCTGGGAG
CTGATAGTTTCAATTCCTCTTTGTTTGTTTGTTTGTTTGTTTACTTATTTATTTATTTTCAGAAAACTCT
GTGGGAGGATTGCCTTGCTTGTGCCTTTAAAGAGTTTCATGCATGAATTTAAGATTCTTTTTCAGACCTA
CTTTTCTTCCTAGTGTTGCCAGTAAAATATTTAGGTTAACAATATTGTAATTCTCCTAATTCTAAATCAC
ATCAATCCTAAAACGAGTTGAGAGATTTTCTTCATTATAAGACATGCTTAAGGTTACTTGTCATAGCAAC
TGATTTCTTTATCACAAGATAGAGTACAATTCAATGTCCCTGGGTGAATATTTTATCTCAAAACAAAATG
TTATTGATAACCCATAGTGGCTGACTGCTCAAAATTATCAATTACATGACACTTTAGGAAGTCTTAGTGG
ATGGTTTCTATGTGTAATGGACAGTATTAGATGCCAGAGGTGATCAATATATAGACCCTGTCAGCAGAGA
GCTCAAGATTTACTGGGAGAGACACACATGAATCAATCTAACAAAGACAAACTGTTTTAGGAGCTAAATC
TAACAGGAAAAGCAGCTGGGGGAGTACGGTTGAATATGATTATAATGGTACAATAGCAATTGGTTATAGG
GAATGAATTCTGATTCAGAAAGCAAGTAAGCATTGTAAACTGGGTTGTAGGCCAATAATAAGAAAAGCAG
CACACAGAGAGCAGGTTCCCCTCTGACATCCCATCTGATGGCAAATGCAGACTTGAAGATATATCTCTGA
TTTCTGAGATGATTCCCTTTCATAACCCTGATATTTCTACCTTTCTGAGCAAGCTTTGGCCTCCAGTCAC
CAGTCAGGAAGCAATCTTCTGTTCATTCCTGAAATGCCAGGGACCTGTCTTGCTCCACTCTTCTGCCTGG
ACTACTCTGCTGACAATTTGGTACAGCATCTCCTTCGGGCAACCTCCTTAGCATGCTGGCCCAGGGTACA
CTTGGTGAGTAGAGTGGAAGGAAAATACATCCAAGAAAACACTGCAGGAGAGGTAATTATCTGTAGCTGA
GGACCAAGGCAGAATCACTATTTCTAGGATGCATTAGTTCATGTTTGCACTTAGCCAGGATTTTTCCTAC
CCTCAAAAGGCAGGCTTCAGAGACTTGCTGAAGGCGTGTTACCTTACTGGAGAGCACTGAGAAAATAGTA
AATAGAGATGATGTCGCCACTTTTAAATATCCTCCTTATTTCTTATGAGAGTTAGTCTTTGTATGCTGTG
TTATAATTTGTAAAATGGAGATACATTATACTGAAGAAGGTTCATTAACATCATTTTGTACGTGAGAAGA
CATAGGTCCAGAGAGGTCTAACAGCTTTTCCAATCTCACATAAGATTCACTGAACATTACTAGAATTTTC
TCATGGGCTCTGACTCCAGAGCTAATGATTTTTCTATCACACAGTTTATTTTTATATTTAGGTTCTGGAG
TTTTAAATATGAACTACTACTGGTGAATATTTTATCCTGTTTCTTTTCCTCTGCTCATTTGGCTCACCAG
TCAGTCTGTTCCCACTGTCTTACCATTATACACAATGATATCAGACTAGGATTTGAGAATCAGTTGAAAT
GGCTGGTCTAAACTGGGAAGGAAAAATGGCAACAGGACCATCTTGGTCATTCTGGTTTCAGATTGCCAAT
GTTTTGTAGTTCATTCTACTTGAATAATGTCTTCTGTAGCAATCACACTACTTGGCTACTGTTAAAACAA
CCACTGTAATGATGTTTTAAATTTTCTCACTGGCTGAAGACTATTCTCTCTTTGTCTATTAATACATATA
CCTTATATTAAGTATTTTATGAAGCAGATTTATACCGGTTGACTTAAACTCTTTAATTATGTTTTTTATC
TGTAACGTAATGACATGGCACTTAACTGATAAGATGGTAGAATCTGTAGATATGAAATGAGTCCCCTTAT
GCAACATACAAAGAATTCAGCATACATCTCGTTTCTTACAAATGTTACTTGTGATTTCAATACTTTAGTA
GATTTTTGTAATAATTGGAGTTAATATGAACCTTCTCTAACTGCAAACTTCTTTATGAGTTTTTTTAGCT
ATAGTGTGAGCATTTTTCCTTCCAAGTTCCACCAATTAAAATTGTATCTATATTTCAAGAAGTCTACATT
CATAAGTATATTCCATAACTAGTGGATATTTCCATTGTGACAGTCACAATTTGAGGATTGTGAGTCATAG
GCTAAAAAGGATGCCTGTTTGTCCTTACTTCAATCGTGTTCTTTTCTTCACTCCCAAATGTCCTTGCCTA
TTAAGTCACAATTACCAAAGGAGCTACATTTTACTATATGTTACTTAATTTACATTATATAGCTTGGGTG
GAAACAGGTGGAGATGAGAAATATATAGTGATTGCTGCCTGCTCAATTCTAATATGGCATATATAGAATA
TAAAAGTTACTTTGAATGTACAGATAATCTGATGTATGTGTGCAGAAGTGTGTTTGCTTTTGCTCATCTA
AGCCTTGAGTTGTAAACTGAACAGCATAACAATATCTTAATAAAGCTCCCTCTTTGTTCCCAAACATTTG
TCTATGCTCTGTGCTACCCACCAACAATCTATTATTGCCTGAGGAAGTCATCATTTTCTCAAAGGTTGAA
AATAGAAACACTTTTACCAAACTAAATCACATCAAAGTAAAGCATGGATTTGTAAGCCTTAACACATACA
ATTTCCATAAGAGAAATTGAATATCAGCTCATATAGAAAGTTGATAGGAGCATTGCATGTAGAGGCCTCA
CCATGGCATGCTGTGCCAAGATGGGAAGACATCCCAGAAGCCAAGGCTAGAGAGATATCATGTAATATAT
AATAACACTAGACAGGACTTTGAGCTGAATTGCCAGGAAGTCTTCATTAAACCAACCTGTGGAGAGAAGG
CTTCAAAATAAATATTTCACCAGGAATCACTTTGATAAAAACTCATAAGAAATAAACATTTCTAATATAT
CTTAAGAGTTATAGGGAAACAAATGCCCATCTCCTTCCATTCTTTTCATTTTTCAGGACTTATTTTATCA
TTGGTATTATTGAACAAGTATAGTCATCCATTTTGAGATATTAAAAAATTTTTTAAAAACTAATAAGATT
GTGTCTAACCACAAATCAGAGATAGTTCACTAATATTTGTTTATACTTGCCTCTCATTTATTAATAGGCA
TATTCATACATATTAAGACACATATGCAGTTGAAGTACTAAATATCATGTAGCCTCCATTCCTCATTTTA
AAATATAAATGATATTGTAAAACTCATCAAGTGTAGATACATTGGCATTATTTTAATGCCCTCTAAATTT
CCCTTACCATTCAAGAGCTCACTACAATTTATTTTGTGAAAGAACAATAGGAAATGCATTCAGCCAGTTC
TTCTACTCAATTTTAAAAATTAGAATATCTTAGTTATACATTCCAATTCTTCATTTATTCCCTCAACTAC
ACATTACATGTTGTCATGCTGATTACTGGGTAACAAGTCATGATTGATAAAATAAAACTTGAACTAATGA
CTTGAACTAATGAGTCAAGATGTGTTTAAACTAGCACTTTGATGATTATGATACAATGAATTAAGTTCTA
TAGGAAAGAGAAGAACACAAATTTCTGAAGACATAAGATAACTCAATAAGCTCCTTGGAGAAATGGAGAG
AATTGTATAGTGAGGAATGTACCTAAAATAACCCTTGACTTCTAAATATTGGTACAGACCATTGTTCCAT
GCTTTTAACAAGCTCAGTTATGAAAAGAGTACAGGGAGTGCAAAATGCATTATAATTATTTCTTGAATAA
ACATTAATGAATATATAAAATTAAGGAAACATCCTAAAATGTTTTTATGTAGTAATATTGAAAAAGTTTG
CAAGAAATCTCCAATATCTCAATAATTTACTCTGTTTCTTTATAGTATCATTTTTGGTATCATTTTTAAT
ATTCAAACTTTTAAAAATAATGCACTACTGAACAATTATTCAAATTGCTAGATAATAAGAATATAATAGC
TCACTAATATAGAATATCATTAAATATTATTACTTCTACCACTCAGCATTATGACCAAAGTGATATTATA
ATAATTCTTCCATTATATATGTACCCCAGAGGCTGTATGCTTGTCATCAAGTTAGCCATAACTTATATGT
GCTGCCTACTGTTAACACACAACTGTTTAGTTAGTTTCATAGCTTGTTTGTTTTTAATAACCTCTGTATT
CTTCATAACATCTTCTAAAGACCATGTTTAAAGATAAGAAAAGAAAAACTCAGTGATTTGCCTAAACTTC
CAAGGATACTTATAATTATTTATATTTATTTGCATCCAGTGATCCATGAGAGTACTAACCATCCCCAACA
CATTGTTATTTCTGTGCAAATTCTGAAATAGTAAATATCAGGATATATTACAGCTGATTATCTAAGGTCT
AAATGACTAACACCGTTACCTAAGTCCTCTCACATCCACTTAGTTAGCTTTAAAATTAGTAAAAAGATTA
GTTACAAACCATGCAAATTCCTATGAAACAATAATATGTGTTCATCTCTTCCATGAAAACTGTCACTTTT
TTCCTCGTTCCATACACAGTAGATTCCCTATATTCATATTTTTACTCTTAACCAAAAATGTCTACAAGCT
TTCAAATTCAGAACTAGAACCACATAGCCTCATGTACTATGAGGAATCCAACTAGTAGTTGGGAGTTCTG
CATCTACTGTGTAAAGTCAACGTGTAGCTATTGACTCTCTACTATTAGATTAAAAATTTATTCCTTTGTC
CTATTCTAATATCAAATAAAGAATACCCTAAACTGTCCCAAGACATGGCTGTATTTGACTCCTAAACTTT
TATTGTAGCTTAACATGAAAATTTCTATTTCCTTATCATAGCTTACACCTTACTGGTTTCTCTTCAGTAA
ATACTACTTTAATAAATCATTTGAAATTTTAGGATTAATTTAGGTTCTCTCAAAATAGCAAACCACCATA
ATTTATAAGAATTGGTATGATAAAGTCACATTTGAAACACACGTTGATAATACATTTAAATGCAATAAAT
GCATAATTTATGAGGAAATGTCAACCAACCTGTCCACAAAAGCATGGTGAAGAAGAAAAATGGGATCGTT
GGCCGATCCCTGTACTTGGGACATTGTTCCATTCATAAAGATATGTAAGGCATTGTGCATGCTACTTTGA
GAAGGATCTGCTATCCCTGTGAGTGGACTGGCAAATCCTGTTGAAATAAAGGGAAATTTAAAAAAAAATT
AGTTTTTCTAAATGATTGAAAATCTCACTAATTATCTCATCTAATCTACAACTCCAGAGGAAAAATCATG
ATTTCAAGTAAAGAAAATCAATAAGAAAACTCATTTGATATTGGGATTCTGAATATTCATTTAGATCTCT
TCAGAACTGAAAGATATTAGGTTTTGTACACTGTGAGATAGGTTAAGCAGTGAGATAGGCTGGGCCAATA
TGGACCTCTTAACAGTACATCTCTCTTAAGTCCTTTGAATACTGAAAAGTCCCAAGAACCTTTGCAATAA
ATAATAAGCCTTCACTCTCATTTAAATATAAAAATGTACAAAATATATCAACAACATATTAAGAAAATAA
CCCTGAGAGGTATCCTTTGCAGTCTACTTATTTTCTCTTGCTTTCTGGTTCTAAAAAATATTTAAATTTT
GGATCCTGGTTCCAGAAAAAGGACAAACTTTGTGGTCAACCTTATACTCATTCATCCCTAATGGTCCTAG
GGACAGCAAATCATAATGTTTTTAATTTTGTAGAACGTTCATTTCACAGATGATTGCAACCCTATAGGAG
GAACAACAATATGAACTAACCAGTACCCCCCAGAGCATGTGTCTCTAGTTGCATATAGAGCAGAGGATGG
CCTAGTCAGTCATCAATTGGAGGAGAGGCCCTTGGTCTTGTGAAGATTATATGCCCCAGTACAGGGGAAT
GCCAGGGCCAGGAAGCAGGAGTGGGTGTGTTGGGGAGCAGGGCAGGGGGAGGGTATAGGAGACTTTCAGA
GCGGAAACTAGGAAAGGGGATAGCATTTGAAAGGTAAATGAAGAAAATATCTATCTAAACTCATTTCAAA
AACAACATCAAGTCCTCATCTCTGTACATTCACCGTAAGATCATATAATAGTCTCTTCTGTCCTTTCTTG
TCTATAAGGATTGGGGGTGCATATTTCTAAGAACTTGACATTATTTATTTCATATGTTTCAGAATCATCA
TACATATTACTTCTTTTCTTTATCATAGATTTCAAATACAAGGCTTAGCGTACTAAAGAACTGCATATGT
TTATGTATAGAAACAGGGATTGGAAGATAAACCTGTTTAATTAAAGAGTTTAAGCTTTCCTATGCAATAG
TTTATTGTCTTTCCCATGTAGCAACATACTGTGCATCACTGAAGAGTATAGTCTATATAAGAAGAGACGT
CAAGTTTTAGTTTTAATCATAATCATAGCATCAAATGAAAGCTTTAGAACTTCATTTCATGTTCGGTCTT
AGATAATTTTAAGTGCAACTTAATTATTTTTGCCAGAGATATAAATATATTTTGAGGAATAATTTAGAGA
TATTGCAAATAGTATTAAAATTAAAGGTAATGTAGTTTTGAAGAGAACCACCTTAAGGATTTAAATGTGA
AATTCATATTTAAGTATCAAAATAGACTCATATGTCTTAGTAGTTTATAATTTCTTTTATGTGCCTCCTT
AATTCATTACTACAGAATTATTAACCTAAATGTTACACATTCTATGGTGGAGATTTTTTCAGGTTGGTGA
AGTTTAGGGCTATACTAGTCAAATAAAATTTATGTTGGTGGGAAAGAATAAGGCAGGGAGATAAACAGAG
ATCATGACAGCAACTGTACATCACAGTGCATAGTACACATGGAAATTGCTAAGAACAAAGATTGCAAACA
TTCACAGCAAGGAATTTAAGCAGGGCAGTGGTGACGCACACCTTCAGTCCCAGCACTTGGGAGGCAGAAG
CAGGTGGATTTCCAAGTTCGAGGCCAGCCTGGTCTACAGAGTGAGTTTCAGGATAGCCAGGGCTACACAG
AGAAACTCTGTCTTAAAAATAAAACAAACAAACAAACAAACAAAAAAGGAATAGTAAGTATAAAAGACAG
CAGACATGATGTTTAATTTTGTTTCGTTATTATATAATGTATCTAAAATATCAAAATATCATTTACCATA
AATATATGTAATTTTTTCTTGTCAACTTTCACCCCAATGTTTATAATATCTTTGTTTTTAAAATCATAGA
AATTTTCACCTCCCCTTGAAAATGCTAAAATAAAAGTGGAAGCAATATGATAGTTTTTGTGAATATAATT
ATACAAAGTGAATACACACACACACACACACACATATATGGGATTGCAAAGTACAGTAGTGTCAGAAGAC
CTTCGGTAACCTCTCAGTCTGATGTGTTTTAGACAATTATAGTATAATACGTTATAGCAGAATAATGACT
GGCAAATAAATTCCCTTCAAATTCTCTGTGTTTTTGATTCTTCTGAGATCCTAAAGCACTGTGTCTAGCT
AGTCCTCTTTCAAGACCCTGCTGTAAAGGGCTAAGTAAACTTGGCTTTAACTTCTAGGTTACTTACAAGA
AAGAAGTATAGTATTTGTCAATTTAGGTAACTATTTTTTGCTTTGCTTTTGTCATTGATATAATAGAAGC
TAGGTAAACACATTTCTTAAGATTTAACAGATAATTCTGATAGCTAGTATGAAAGCATCTAGCATTCATC
TGATACCAGTGGTAGTTTTCTGAGTAATAATAACAGCTCTTTATGTTGTCAGATTTAGTTGATAAATGAG
TGCCCAGTCTCAAAGCTGCTAACCAAAAATATGCATGCCTTTTCTGTGTGTATCCAGCAGAGGTGGGCAA
TAAGAAAGGCAGTCTTCTCATTAAAACCCAATGGACCATTAAAGTTTTATAATGTGGTATTTGCCAATGA
AAATACTATTAGAGATTAAAATGATATTAACATAAAAATAAACTATTTTATATTTTACTTCTTTACAGTT
CATTTGGAAATATAAGGGGAGATTATGACTTCTGAAATTATCTTTATAAAATAAAAATGATTACTCTGTT
AATTTCATTTCTTGTTGCATTTTGCTCTTTCCTGAAAGAAAAATCCCAATACTTTCATAAATCCAGGCAT
TCAAATATCATTCGTGTACATAATCTGATTTTAGTAACAGGATTTTTTGACATTTGACAATATTGCTTTC
CTTGTCCCAATTTTACTAATGATGAAACACCAGTTTAAAGAATTAATGTAACACATCTAAATTCAAACTA
GCATTTAAGGAACAAAAAACTTAAACATAACTGTGATTGTCTTGAAACCTGTGATCTTTACCAAATAGCA
GGTTGGATTTCTTCAAAAAGAGATCAGAAATGACTCCAAAGTGAGATCAAATAATTTACTTTGACTTTTT
ATAAACAAAGCTTGAGTTTCAAATGTTTCTGTATTTAAAAGAAAATTATCCAACAGAGATTGAGAATAAC
AAAGATAATCTTCCCCATTAAATCTAAAATGTTACGTATGAACTGGTCAATACACCTCAGACATCTCTTT
GTGTAGTGTTCTTGAATTTGTTTGTACACTTGCAATGGTCAAAACCATTACAGGAAGGTACAGGATGTTA
GGATGATATTACTCTTGCTTGTTCTTAAATTCCCCCTGGACAGATCATCCAGCAAGCCAGTAGGGATCAT
GTTAGCAACCTAAATTCCAAAACAACTCAAAGTTCTTTGCAAAGGGCAGCAACAATGGCTCCAATTATTG
AGAGTTGTGTCTTTAAGTCTCATAGGAATCTGTATTATTCCAATGAGAAATTTTAGGAGCATTTCACATG
GATGACAAAAGGGAGTTTCAATTTGTCAATCCATATTCTTTACTCTTTTATTTCTCCCCCAATTCTCCTC
TAGAGATGTTTGGGTTATTTGTTTTAGATATTGATGTTTATCTCTGATACCTGGAGATTTGGATTTAATT
GTTTTAGAATTGAACTCAGTCACTTATAGTCTTAAAAGCCCCTAAGTGATTCTAATGTGCAATCAGGGTT
GAAGTTTCCTGAATTTGACTAAATTGTTCTTTGTTTCCTCACCATAAACCTTCACTTCAAACTATTTTCT
TCTGATCATATTATTTCCTTCAGGTGAACTTTTCCTCTTCTATATTTTGGTATCAAAAGAACCAATAACC
ATTCTACCTTTAAAACCTCGCTCTGCAAACTTATGATGTGAAATAATTTCTTAGAAGTAGCTGCTAATAT
TTACTTGAAAATAAGTTAGCTACTATATTATGGCAGGTAATGCAAAGACATTTTCATGTGTATTTTCTTG
TTTGATTAGACTCTTTTCTTTCCAGGATGTAGGATCATAGGTGGTGTTGAACTTACATGGTTAAGCCTGC
TCAGTTTTGAAGTGTGAAAAAACAAGTGACTAAGTTTTCACTAGAGAGAAGCACATTTAATTTTTTGGTT
ATATTTAAACTGGTGCTAATATTAAAATTATATTAATCATTAAAAATGATTTGGAAATAGAAATAAAGAA
ATAAACAAGATAGCAAACTCATCTTAGTGCCCATGAGGAGCTATGAGGTTTCATTCCAGGGATGAAGGGA
TGGCTTAATACACGAAAATCCATCAACGTAATCCATTACATAAACAAACTCAAAGACAAAATCATCTCAT
TAGATGTGGAGAAAACATTTGACAAAATCAACACCCATTTATGATATAAGTCTTGGAAAGATCAGGAATT
CAAGGCCCATACCTAACATGATAAAAGCAATCTACAGCATACCAGTAGCCAACATCAAAGTAAATGGGGA
GAACCTGAAAACAACCCACTAAAATCAGGGACTAGACGAGGCTGCCCACTTTCTCCCTACCTTTTCAACA
TAGTACTTGAAGTATTAGCCAGAGCAATTCGACAACAAAAGGAGATCAAGGGGATACAAATTGGAAAAGA
GGAAGTCAAAATATCACTTTTTGCAGATGATATGATAGTATATATAAGTGACCCTAAAAATTCTACCAGA
GAACTCCTAAACCTGATAAACAGCTTCGGTGAAGTAGCTGGATATAAAATAAACTCAAACAAGTCAATGG
CCTTTCTCTATACAAAGAATAAACAGGCTGAGAAAGAAATTAGGGAAACAACACCCTTCTCAATAGTCAC
AAATAATATAAAATATCTTGGCGTGACTCTAACTAAGGAGGAGAAGATGTAATCTTAAAGCCATAAATGG
AATTTATTTTCATTTTTATTTATTGGAACTCCTTTTAAAAAAATCATTCTTTCTCTGTCTCTCTCTGCCT
GCCTCTGTCTCTGTCTCTGTCTCTCTCTCTGTCTTTGTGTGTATGTGTATATGTGTGTATATGTGTGTGT
GTGTGTGTGTGTGTGTGTGTGTGTGTATTACGTGGTGAAAATGTAGAGATACATTCCTGTAGAGATCAGA
GGACAAGTTGGTATGTTGGGTCTTCCCCTAAAAGTTGTTTGAAGCAGGCTATTTTGTTTAATATTGTATG
TGGAAATGATATGGTCATGAGCTTCCTAGGGTCTTTTCATCTCATCGTGGGTGTGGTGGTATTAAGACTT
CTGGCCTTTTGTGGATTAAATAAGCATATATTTTCTAATGCTTGTGCAGTAAGTATTTTGCTCACTGATC
CATCTCCTCTGTTACAGAAATAATTTAATTTGATTTAATACTACTGTCCAATTGTACCATTGTAGTGTAG
TGTTTGGAAGTGTTTTTCAATATGCAAATACTATGAGTGAAAATCATGATTTTTTTCTTTTTTAAATTTA
GTCACAGATCCAGCACCACTACCTATAACACTCAAATGCTCTGGACCTCACTGAGAAAGACACAGTCAAA
AAGGGATGGAGCTTGTCAAGCAAGGCAGCAGGTGCTGGCCATGACTTTCATGCATATTCAGGTTTTAGAT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGGTTTTCCTAGACATGGTTTCTCTGTGTAGCCCTGGCTGG
CCTGGAACTCACTTTGTAGACCAGGCTGGCCTCGAACTCAGAAATCTGCCTGTCTCTGCCTTCCAAGTGC
TAGGATTAAAGGCATGTGCCACTTCTGCCTGGCGATTCTTTTTTTCTAATTCTGGTTATTGTAAGTCATG
ATAATATAAATAAACTCACATAAGTAATTCAGTACATTTTTTTTTCAAAATTGTAGTTTTAAATTATCAC
AATAAGCACTAGACTAGCTTCTTGGAAATTTGGAAACACTAGTATACATTTGTTTATTCTCCAGCCATGT
TATCAATACACAGTATTCACATAACTGTAAAACTTTCAATATATCCATAATGCAATATTCCACTGCAAAG
ATAATGGACAATGTATTTATTTAAATTTATTTCTGAAACTTATTTTAAATTGTTAAATGTTTTTAGTGTT
TAATGTTTTAAAAGTTTATGATAGCTACTTATACTCCTTTAAAGCCTTTTTTGTGCGTGCAGAACCACAG
ACATACTATATTATATAGCAATTAATTACAAAAATATAACAACAGAAAAATAAAAGATCTCTGTAAGTAA
ATTTTTATTTATGTTTTCTTCTCCTTCCTATTCTTCAATTTTGGTTCAATTAATTGTGCCTAGTTCATTT
GGCATAGTTTATATATTGTACTAATACTCTGATAATTTATTAATGATAATGCTAATTATTTTTGAAACAA
GCTTAAGTAATCAGCCATGCCACAACACTTTGCCTGAGGCAACACTTTTTGTTTGTTTGTTTCCCCAAAG
CAGCATTTATTTACTCTTTTAAGTCCAAAACATTTATTTTAGCAGTCTGGCATTTCATAACCACCCATCA
TGATTGACATAGGTTGACACACATGATGCTGTCAGGGTACACAAGAGCAATAGCCAAAGAGTTACAAAAA
AAATAAATCCATGATTCTTAATCAGAATCCAAAAAAAAAGTTACACATATCAAAAACTTCTGATGCATTG
TATTAAAAAGAAGGTGTGCACACATCATAAGTTAAAGAGGCACAGCAAGGGCTGCTGAAACCTCACAAGA
AACAGTCTATAAAGCTAGCGGTGAAGGAGTTGTCACTGTGTCAGTTCCCATTAGCTGAAGGGAGGGGTGA
GAGGGTCAAATTCATTTTTGCATGCACAAGATGTATTGCTTAACAAAACACTATCAGCTTGTTTTAAATA
GCAGTCACAGCCTGTTTGGCTAATTCTCCTTTCTATATTCAATTAACATCACCTGAATTTGCTAGAGATC
AACAGACATAATAGAATGCTTTGTTCAGAACACACTTCTCTGCACAATTCAAAAAGGGAGTGCCCTGTGA
CTCAAAGCAACCATAAGTCCAGCAAATTCCCATGAGGGTTTATCTGAAGCTGCTTCCCAAGGGACAGAAG
GGCAGATCTGAATAGCTGTGCTGCCAATACAGATAGGTTTAGCACTAGATATAGTGATCGTGGCAAGAAA
GAATCAGTGATAATGGGGGTGGTGAGTGAAGGAAGGGCCAGGGACCTGAAGGGTCTTCAGTTGCCTTTTC
CTGCTTCTTCATCCTGCTGGTCACTAGTGCAGATGGTGAGGTTGCTGAGGCAACACTTTATTTTTAGAAT
TTAAAACCCTGTGTTCTTGGTACAGTTGGCTTTATACAGAGACAAATGAGTGTTGCTCAAGAATAACAAG
AACCGCTCATACTTGATACATTCAGTAATTTTTCAACAAGGTGATTGCTTTGCTTTGAATGAGAATGGCT
CCCTTAGGCTCATATATTTAAATGCTTAGTCATAAATTGATAGAAATGTTTTAAAAGGATTAGGAAGTGA
AGCCTTGTGAAATGATGTGTGTTACTGGAGGATAGACTCTGAAACAAAACTCTCTCCCTCTTTCCCTTCC
CCCTCTCTCTCTTCCTCTCTCCCTCCCTCCCTTTCTCTCTCATGCCTGTGAATAAGAATGTAAGCTCTCA
CCTGCTACTCTAGTGGAATGTGTACCTGTCTGTACTCATGCTCCTTGCTATGGTGGCCATGGACCTGATC
TTTATAACTGTAAGCCCCAGCAAACTCTTTTCTCTCTATGCTGTTCTAGAAGTGATATCTTCACAGCAAT
AGAGAAGTAACTAAGACAGTGAATCATATTTTTATAGTTTACTGGCATCTGAAAATTATGTATTTGATGA
TCATCTTGGTCTTGGAAAATGCCAGTCTTACTAAATAAAGACGGAAGGGAATCATTGTGACATATCATGT
GTTCTGTATCTTTAAAATGTCAATGCTAGAATTTTATCCATAAATATTAGTTATACTTTTTGAGGAATTG
CAACTAGCACTTCATGCTAGACAAGGACTCTACTCACAAAATATGTTCCTTCTCCTATTTAACAATTTTT
CTTTCTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCCTTCCTTCCTTCCTTCCTTTCCTCCC
TCCCCCCCTCTCTTTCCCTCCTTCCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCT
TTCTTTCTTTCTTTCTTCTTTCTTTCTCTCTTTCAACCACACCACAATAAAAAATACTGCGATTCCTGTA
CTTTATCCTCCCATACAGTTAGTACTATAATATGTTTCTGTATGCTTTTATGGAACTGAATCCTCATTGA
AACTCTGGAAACATGAAATGGTTTAATGAGGTTTCAGGTAATAAAATGAAAATTCAAAGAAGCTAAGTGC
TTTGTTCTACATATTTTAGCTGTGCCAGATTGAAATTTGTTTCAATTATGTGACAGGCATCAAAACTCTG
ACCTTTATTATAGTCTCTCTCTCTCTCTCCCTCTCTCTCTCTCTCTCCATCTCTCTCTAGCTTTGTGAAG
CTATTATTTGTGTAAAAATTGAAATGGGAAATAAATGTTCTGGTCATGTTATGTTTTTCATAATAGTTAT
CATGCTCATTGGAATGAAAGCTGAAGCCCTCTTTTCAAATTATCAGGATAGGCAAGGCCCTCTTGTGATG
AGTCCTTATTCAGATAAATTTTTCAAGGTTCATGTCACAGGACAACCAGCCCTTGATTGGGAATATTTTT
CTAAGCAGTAGCATCACTATCTAAAGAATTTTTTCCCTCTCTTTGTGAATGATTACTTCAACATGAGCTA
GTTGTTAACTAGATTATAAGTAAAAAATCTGCATTATATTCAATATTTATTCTTAATTTCTATAGAAAAT
CTCTTGTAACTATTTCATTCTCTATGACCCTTTTTATGAATAATCAAAACATTTATTTACTTTGTAAAAT
GTATATGGAGTTTTAGGTATGCTGGTAGTCTTTGCCCTGCTCAGTCACTGTACTCTTAAAGCTGATACCT
TTGTTTCCTCTGATGAACATTTACAGCTATAAATACATCGATTTGTAAATATATTCAGATATATGATTTT
AAATCTAAGTCTGATGTATGAGGAACATTGTTGGTGTTGTCTTTAGGAGCCTGATTTATTTCATTTAATA
ATTTCCATTTTCATCCATTTTCCTGTAAGTGTAAGGATTTAAATTTTCTTTATGACTTCATACATTTCTA
TTGCTCATAGGCAAGACAAAATATTAGGGAAGACAGTGAGATCTGGAAGTCCTTTCATAATAGCTGTATA
ATTAGCATGGGAGATAAAGCTGTTGTCCAAGAGCAAGGCTGGGCACCATAGCCCACGGTCATCATGTAAC
AGATAAAACATGCTGCAAAAAAGCCAGTGCTACCAAAGTAAGCCAGAACTCCCATAAAATGTGATCATTG
TGTAGTATTGCTGTTGTGCTCCCAAGCCTTTGCTATCTTGGGACCAGTTCTGATAGAGAAAGTATTTCTC
TTCTAATAACTGTGCTTCTGCTTTAAACCATGAATCTTTATCTAATTCTCTGTTTAGAAATACAAGAACA
TGCAACTCTACAGAGATCCCCCTCAAACCACTGTATCTGAAATTCTATTTACAGTATTGTCTACTCTCAG
CCAATTCATGAACTGTATTGGTCATCAGAATATGATGGAAAGAATGTCCTTCAACAATACCTTAAACAAA
ACAGGTACAGGTTAGGGGCTACCAATTAGTCAGTGACCAAACATAACCTTATTTTTTGACATTTCAAAAT
CTGTCTTCCCCTTTTCAGGAGAGCATAATGACGGCATCTATAGAAGATATTTGTAAAGTTTGGTACATCA
TATAGAGGAGTTAGCAGGGTGTTCTGGACCTAGCTATTACTTTTAAAGGCATCATTTTATTGCTGTAAGA
GAAAAAAATATGAATTTTATCTTAACATCGGTCATCAAAGTCTATCTTTAAGGTGGCTTTTCTTTACCTA
TGGGTGTAAATCTTTAGAATTATGTCTTGGGATGAGAGAAGAAGAAGAAATATTAGCTAGGGCTATATAC
TTTTGTAAAGTCCCCTCATTATGGTTGAACCATGAGACTTTCCATAGCTAAATAAGCAAAGTGTGCTGTT
TCTCTAACTTCTTGCCTGGCCTACACCAAAGACCCAGGCAATGGCCATCCAGGATGTTTCTCAATCACTT
ACCTTTATTTTACTGACTACTCAATGGTTACCCATAGCAATGGCAAATTTTGTGACAAAAAGTAAACATT
TTAATCTTATTCCTCTCCTTTTTTCCCTAGAATTATTGCCACTTCTAATTAATTAATGAATTAACTGCCC
CATTTCCTAGTCTCCCCCTCACAGAGTCATAACCCTCATACCCCTTTCTACTCTCCTTTGAGAGGGTGTG
GCCTCCTTTAGTATCCCCTATGATAGTGCATCAAGTCTCTGGAGGATTAGGCACATCCTCTCCCACTGAG
GACAGAAAAGGCATCCCTACTGGGGAACAGTCAGTCTACTTTTGCTGACTTTTCAAAAGAGACAGTAAAC
TCACCCCATAAGCAGAAGAACAAAAGTTAGGATAAAACATGCTAAAATTCAAAGAGAAAAGTTTAAAAAG
ATTCACTCTTGGAAGAAAAAAAGATTTTCTATATGAAAGATTGTGAAGAACTTTTAATAATATTTGGTAG
GTAATTTCTGTAAGTGTTGTTGGAGGTTATCCCCAATGTTTGCTCGTGTATGAATCTGGGGCTTGAGGGG
TCTTCCCTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCC
CTTCCCTTCCCTTCCCTTCCCTTTCCTTTTCTTTCCTTTCCTTCGCTTCCCTTTCCCTTTTATATCACTA
AATTTCTGGAGTATAGTGAGATACTCTATGCTAGCTAAGTTTACTATCACCATGGGTATAATTGAAGCAT
AACATTTCAAAACTCACAAAATTTTAAATTATAAACATCTCTGAGCCCAGAATTTCTGAAAAGAAATTAT
AAATTAAAAAAAATCAAAATTAATGAACACAAGGATATTACCTTCCAGTGTGTTTCTAAAGCTGAAATTG
GCAGTTCTATCCATTGATCCAGATTCATACTGGGTCAAACTCAGACAAAATTCCACATCTGCTGAAGATG
GGAGCCTGGGGGTTTTGGCTTTGTCATGGTTTCCAGGATTACGTAATAGTGGTCCCTCAGGTGTTCCATC
GCATAAAACCTGATGGCTATTATACTCTTCTGATCTGCTACAAATGATCTGTGAAAAACAATTTATGTTA
AATGAGTTACTTCTGAGACAAGAGAAAGATGTTGAAATTGCACATCAGTATCATTCAGCTTTCTGGCAGT
TAGATGAAAGTGAACTTAACCTACCATGCTAGGCATTTATTATTATTGTGGCTGGCACTCGCTAGTCTAA
TTTGTGTTCAGAAACTATATATATCAAACTATAGCTTGAGCTATTAACAGTTGTAATTCATAAAATGGAA
CCATATTTCTTTTTTGTGACTTGGGGGAATTTGTCACTAGTGACTCTGCCTCCCAGATATTCTCCAAAGT
CACCTCTTAGTTCAGTCTGTTTTCTTTTCTTCTTCCTTTTCCTTTTCCAAATACAAAATTTGTATTATTA
GCAATTCTTTGTTCCAGTAAACAAGTTTTATTTCACACTGTTGTATCTTGACTAACAAAAACATGCAAAC
TAAATCAGGAACTGGAAATCCCCTGTTCATTTTAACATAGAAGTGATGTAAAAACATTGGCTGCTGAACT
CTTTTGCAGGAGTTATAAATGAAAGGACACAGAAAAGGGCAATGGCTCAGTGGGTAAAATACTTGCAATG
TAAACTTAAGAACTGGAAATCAGATAACCAGCACCCTCTTAATTCCAAAATATGAGTAGTAGATTTCTGT
TAGTATCCTGGTGCTTGTAAAATGCAAACAGAAATTGCCAGAGCAAGCTAGATAATGAAACTAGCCATAT
TAATGAGTGTTGTTCCAGTCAGAGACCATGCCTTCATGTGTACCATAGTGTGTAACTGAGAAAGACACTC
AACATCAACCTGTGGTCTTCATAAGCATACACAAACATGCATATGTGCAAGTACACCTGCAGATACACAT
ATACCTACCGTCATGTAAACACATACTTGTGTGCAGACATGCAATGTGTGCCACATACATATAATGCACA
TGTCAATAAGAGTAAATAAACAAATAACTGCACAGGGTACAATAAAGTTGGAGCTGAAAAACTTGGTTGG
TATTGGAAGGACAGTCTTTTATCTTCCAACTATCACTTACCCTTTCTGACCCTCAGTTTTCTTATTAATA
TGGAAAATATTACCACATGACTTAAATGAAACATTTCATACAACCTAACTCCTTAAAATATTTCCTATAA
AATGTGAAGAACTGTGATTTAAAAAAAATAATGATGATGATAATCTGCCAGCGTAACATAGAAATCAGCG
AAACTGCTAGGTTTTGAAATTCTCTAAAAGGAAGACTATGCTTTATATCAAGGCAGACATTAACAATGGA
TCTGTTATGACAAAACGAAAAACCATGAAGTGGGATAATCACCAGTCTTAGCACTGTCAAAGGACGGAGT
GGAGGTTGCAGGAGAAGGGATGGAATGTCAAACACAGGGTGGCATTCCAGTCCTAGATCTAATGCCTTAG
GTTTTCTATGGGTTACACATTAAATTGTGATGAAAATGAGGTCTTTATGTAAATATTTGTAATAGAATTA
GTTAATGAAACCTTTATTATATTTAACTGCCATTTCCCCATGGCTTCACTATGAAACAAAAATTCACAGC
TAAAATTGTTCTGAATTTCAAGACAAAAATAACAAGGTGATAAATTCTCAAAACTTTGGCCTATTTCTAG
CATTGTATACTACATTCGATATACGGATATATGCCCAAAGATGGTACTGGCCATTACCATATAAATTAGC
AATCAAAAAAGTTCTCTATTAAAACGCCAACATGACAATCTGTATGAAGAAATTACTTAGTTGAGTTCCC
CTTCCTAAGTATGTCCAAGTTCATGTAAAACTGACAAAAAAAAAAAACAAAAACAAAAACAAAAACAAAA
ACAAAAAACAAAAGAAAACAAAAAAAAACCTAACTAGCCCGACCCTGAAGGTGGGCTTGGTGTAGAACTC
AGGTTTACACACTCTTTCTATCTTTCTTTTTGTATTCTTTGGCTGCCTTTATGAGTGAGTTTCATGACCT
ACTCACAAATTATGTTCATGAAAATTCTCATATTCTAAACACATGCATCTGTTTATGACTTAAAATTTCA
ACACAGTTTTCATAAATCACATATATACTTACAACAATAGATTCATTCCTTTCTCTTTTCTTTCGCACCA
TGCAGTCTGCAGCTAAAGGCTGAAAGCAGTGGGTTTTATTTTGTATGGTGCCCTTCTTTGCTTTTATCAC
ATTGACTATTTCAAACATTGTTTTCAATTCTCCCTCCAAAATATGTTTTTAACCTGGCCTGTGTTCGACA
TGAGCTTTTATCCCATGTGATCCTGCTGCTGAAGTCACACTGCCTTTTCTACTGCATGCTGCTCATGTTT
GTCTGTACTCCATGTTTCTGCCCATGCCTAAACACAGATGTATTTGCATCCTGGGGTCCAAGATCCTGCA
TAGTCTTCAAGAACAAGGGAGAGCTTAGTAACAAAGAAAAAAGAATCCTGTTACATGATTGACTCAATAT
GTTTGACTAAGAATGGAAATAGTCCTAGAAACCCATTCAAATCACGCTGCCTATGCAGCCTCAGAATCCG
AATCCAAAAATTCAAAATCCAGAATGTTGAAACTAAAATGCCTTGATTTCTTTAAGTGGAAATTCCAAAT
TTCACTTCATATGACAGAAGCAGGGAAAAATATGTAGGCTAAAATTGTATAAAATTATCTGCAAGCTATA
TGTGTAAAGGACATGTGAAACATAAATGCTTATTTAGACAGCTCTCTTCCTTAAAATATCAATTTCTTCA
CATATGAAGATATTTGAAAATCCATAAATACAGAATTTATGATTCTAAAGCTTTATCTATTTCATTTGTT
TTTCCATATTAATAACTTGTGAATGGTTTTATAAAACTAGTTCAGCTTCTGCTATGAATGTAACAGGTTG
GATGACTTTGCATTGTTGGTTGACTGGTCTACCAATTCAGTGCCACTGAGGAAGTAATTTTCATTCCTCT
TTGACTAATGGTCCTCAGGATACGCCCAAAAGATCGCTTGGCCAAAAAGACACCTACAGCAGATTCATTT
ACATTAGAGAGGTTGGAGGAAACCATTTTTTTTTTCTGAAATACCAACTGCCATTTGACTAAGTGTTCAG
TTGATGAAGACATTAGTGATGCACAATAATAACTGGTTGCAGAAATAATGTAAAAAATGTAGCTTCAATT
TGTTGTCTTTATGTTTAATTTAGGGCAAGAAGCAAGAATAGAGAAACTGTCATTACAGTCCTGGAGATTA
CAGTCAGAAAGATAGTTTCTAATATAGATTCTATTAAATCCATGGTCCCAAGCAGGTTGGCCTGCCTCTC
TATTAGAGCTCTATTTCTCTAAGTAGAGAGCATTATTCAGGATCAAATAGTCTGATCCTGATGTATCATT
TAGAGAACTTCTCAAAGATGGGACTCAAAACTATATGGCAAACAATACTAAACAAGTAATTTTCCATGAA
TTGACTTCTTTAAATTGTTTCATAATAATATTGTATTGAGCTATTGTATTTTTTAGAAACCAAAATGTCT
CTAAAATATTTAAGTAACTTCCTGGGGGTCTTATAGGTATGTTAGAGAAATAATATTAGTTTATGATTAT
GTGAGTCAAGAGAAAATTGCTTTTATAGTATAGTACATTGTTTTCTACTCCATTTGGTTCTCTCATTAGC
ATAGAAAACAATCATATATAATAACAACAGGGTTTTGTTGTTGTTGTTGTTGTTGTTACAAAATTCTAAT
GGCTTGTGTAGTAGTGTTTTGCAAATGGCAAAAATGGACTGAGCCCATGTCTTCTGGTTAAACTTTGATT
CTTTCTCCTTCTAACCACAAATGATTTGTAGCATAGTCAAACATGCAAATACAAAAAAACAAAGAAAGGA
ACAAAAGAAACAGATGTAAACAGATGTATTAATACTGAAGGTGAAGCATGATAGTGTTCTATTAAATTTA
GGAAGTAGCAATAAACTACCAGCTCTTAAAGGTTTTCAGGGGCAAAGATTTTATTGTGGTATTTATGTTT
CTTTTTTTCCTGAAAAACAAACAAACAATCAAAAACCAAAAAAGCCTAAACCATATGACATTCCACAAAA
TCTTTTTTATAGAGAAAAAGGAGCTGTTATTTCATAGAGCAGTTGTCATGGTTACCTAAACCCGTGACTT
TCTGCTGAAATATGACTGTTTTTCTTCCCCCTGTGGCTTCCATGTGATACGCTTTCCACCTAATGAGTGA
ATTCCCTGGCTGAAGTTCACTCATATCTATCATCAGAAATGTTTTCCTGTCCACTCTGATCTATCACGAC
AGTTCCCTTTAACACACCTTTGCTTCTTAGGTTAGGGTCTCTGTTGATTGCATAACCAACATATCTAATA
GTGTTGAACACAGGTATTTTGTACTTAAATGTCATCCAGTACCCTCCAAGAAAAGCAAAACAAAACAAAA
ACCTGTGGACTATTTTAATAGTTCTACTTGAAAAATATTTTGAAAATAATCAAACAAGTAGATGAATAAC
AAGCTTAAAAAAAGACTGATTGCATATTAAACTCTCCTTAAACAATTAACATTAATTACAAGATTTTATA
TACTGTCCTCTGTCAGAAAAAAACATGTCAAGTAATAATCAAGTCACATAATACTTAGATGTATTATGAT
TTATAAACCATATATTTTCATGTACACATTCTCTCTCTCTCTCTCTCTCTCTCTCTCACTCACTCACTCT
CTCTCCTCTTATGTAAACCAGCAAGTACTGCACAAGATATTGTTCAAGCAAGAGCTATCTGCTGGAATTA
TTGTGTATTCTGCATCAAGATTCCAATGCTGTAAACTATGGGCTGAAACCTCAGAAATCCACATAGGGAA
AGATTTAAAATTATCTGATTTGTATTTTTGTTTAACTCAGCATGTTTTTATAAAGTCCATTCTGTGAGTA
TAACATAGCCCCTCCGTATATGGCTACAAATGTATTTATAAATAGTTTCCACTTTGGAAAATCTGATAGT
GGTAGACAGAAATAAGTTTAATAAACCATTCATATGTTCTGAAATATTATAGAAGTTATGCAATAAATCT
TCACAAAATGTAGAACAAAGAGGAGGAAATCAATTCTCAGATAGAAATAGAAATACCTGTCTTCCCCAGG
CTGTCTGGTTCATGTGATTTTTTTTTTTAATGCACATGGTGTTTTCATTAATGGGAAGTCCATGGACCCT
GTGTGTGCCTAGTGATCATAGGGGACAGAAGATGTCAGATCTTCAAGGACTGGCATTACAAATAGCTGTA
AGCCATCTTGTGGGTTCTGGGAATCACATCTGAGTCAACTGGACGAGAACTCAAAACAAGTAAAAGTAAC
TACCTGGCAAATTATGCATACATACATTTGTTTTTAGACCTGCTTTAAGCCTAAGTCAATGCATTTACAT
AAATGGCAATGAATACATACTGACTTGGGTTCTGTCCTCAACTGGTTACTTTAGACAAATCCTCCTGCTC
GTTGAGACCTATCATTTATAAAATGTGAGCACTCCATGAGATATCACAAAAAATCTTTCAGCTTAGACTG
GGTAAAGACCATCAAAGCTCCTTTTCTCAAGGAGGAAGATATTGGAAGTCACGCAAGGGTAGAAGCCTGT
ATGAAATAGCTACAGCCTAGGTAATTTGGAAGGTATTAATGAGTTCATTTTAACTTGGAAGCTATTTGAT
CTCATCTAACACAAAATAGTCTAGTTTTTAATTTAAATGTTTAATTTAGACAAAAGCGTTCAAATTAATG
GTGTGTTCATTACGGAAACTCTATTTTCATAAAGGAAAGTAAAGAGATAACTAAACAATCTCCATATTAA
TTAAATCTATGCATCTCAGTGCTGACTGCACATTAGAACCGCATTAAGAGTCTTAAAAGTATAAACACCC
TTGGGAGGCTGAAGGCAGGAGGATTGCTGAGATTTGGAGGCCAGCCTAGGTTGTAGAGTAAGTTCTAAGT
TAGTCTAGGGTTACAGTGTTAAACCTCTTCCTCAAATAGACAAAGAACACAGACACTGGAGATTTACAAT
AGACTCATTGATTCTTTGTTTCCAGTATGTAGTTGGATGATTGATTTTCAAGCAACTACAGAACAATAGA
TTGTAGGTGATCATAATATTGACAGTAATTGAATTAAAGCACTGTAAACATGCATTATTTATTAGTTCAT
TTATTAATTTATTATTTACTGTCTAAGGGTGTTTTGTTGACATGTATGTCTGTATACCATATGTGTGCCT
GGCTCTCAGAGTGGTCAAAAGTGGCTATCAGACCCCCAAGAACTGGAGTTACAAGTGGCTGTAAAATACC
ATCTGAGTTTTGGGAACTGAACCAAGTTTGTCTGAAAGAATTAACCAGTGCTCTTAAATTCTGAGCCATC
TTTCCAGGCCAGAACAGTCAAATTTGCTTTGTTTCATTTCTGTAAGTCATTATTCACTTTTCTTTTGAAA
TGGTACATATTCTTTTTCTTCAGCACATATTCACTGAACAGGGTTTCATAAAGCCACATTCATCTACACA
TATCATCTGATTTGACAATATCCCTTTATTCATGCTCTCTAAACTTCCTCTAATGGGAAATGAGGAGGAG
AAAAAAAGTCTTCATTTTAGAAGGATTTTAACAAGACAGGTTGTGTGAATAAAGAAAACAGACAAGCAGA
ATTAGCTTATTTGTTATGTCTGCAACTGTTTATCCCTGGACAGTGCAAAACTTAAGTATATAGAGCAAAC
TGTATTCATTTGACCTCATTTTAAAATAATGTTGTTTGTTTGCAAAGTTATTGTTGTTTTGTTAATTATC
TTTTTTCAAATTTTGCTTGCTTTTCTTAGTGATTTTTTCCCCCTCTACTTTCTAATTTTACATAAAAAGT
CCTTTTCCTCCATAGCCCTATAAATGCAATACAAGGTTGTAGGCAATATTTTAGCAGTTATACATCAGGA
CTTACTACAATAGGCAAGTCTGCTGTGGTTTTATTGCAACTTTTGATAATTTCAATAATCCTTCAGACTT
TCTGCATCAAGTAATGCTATATAACAAATCGAATATTGTAACTGAGAGAATTCCACACCTGAGCCTGATA
GAACTTAAAGCAATAGCTAGAGAAGTAAAAAGCTAGATGAGAGTTTTGCAGTTCATGAATTAAGGTAGAA
TGACTGAAAATATACAGCAATGTTACTTCGCAGCAGAGCCCCATGCTATAAAGTACTCACTAGGTTTAGT
AAACACTTATCACCATTGGCACCAGGAATTAGCAGCTGTAATTTACAGTGGCCCTTTAAAGGTTTCCATT
TTGGAAGTGTTAGACCAGCAGAGACAGAGGACATTCATATTTCAAAATTTCAAGTGTGGGGTAGCCTATG
TTCTTTTTTCCCCATTTGAACTGGTAATCAGAATAGTTGCAATAGAAAATTTTACAAGATAGGCAGAAAA
ACATATTTCACATTTGTGTTCATTTAAAGGAAAACAATTTAACATATATTTCTTTCTTCATCTTTTGCTT
CCATTCCAGAATGAGGAAAAATAATAGGAGAAAAGAAAATTTAATCTCAAAATAACAATCCCTTAATTCT
ATGTCTAACATTTTTAAAGTAGGAAGAAGGCTAATTTTTCTCCATCCTAGAGAAAAAAAGTTAGAAAGTG
CCCATTCCTTAAAAAGGACTGTCTTCTCCCTGAACATAACGTAAGTTAGCCAGACAGCCCTTGTAATCAT
TAGCAAATATCACCTTTGCTATTTACCAACAATGCTATCAAAAAATAATTTTTAACAAATTAAGTAGTAT
CTTATGACTGTAAAATAGAAGTCTGTTTATATTAATTGTACAATAAATTCTTTCAATAGGTATTCACATA
TTCTAAATACACAGCAGGCTTTAACTCTTTTATTACTTAACTGTTTGAGAGTCAGCAACGTTTAAAATTT
AAGCAACTGAAGATTTTTTTGTGTGTGTGTAATCATTTTTTCTATCAGGCAATCATGTAATAAAGGTCAT
CTCTGATACTTAGTGAATTATCTCAGCACTTTCTCTTGAAGATCCTGAATAATAAGTCTTGGTTTTGGCC
AGAGATTTATATTTTAAAGTAGCATACTTATGGATTTTACTGTTAATATTAATTTTAATATTACTCAGAA
ACATGAACTAAGATAATCTGGTTTCTCATCCATTCTTAAATAACTGAGTTACTGTTTATTCCAGATACCA
TAGGAGGTGCTAACAATACAGTGGTGAACCAATCAGTCCTTGTTTATAGCAGCTTAGAAATCTAACTAAG
CTGTTAGATATTAAGACAAATAAGCACATAGATATTTGTTTAATAACAACTTTGAAGAGTTCTCAAAAGA
GAAAAAGAAATCAAGAAGCATTAACATCTGTTAGTAAGGCACATTTTCTGCCCTGAGATATTATCAGAGA
TGCTCACAGAGCATGAAAATGTGGCTGCTGAAGTACCAGTCTTTGCAACTCTCTCTATATAGTGCATCTT
ACCTGCCAGGAGGAGAAGAAGGATGCTGGGCTGAGTAAGTTAGGATTTTCAGGGTGACGACCTCCCAAGT
ACTCATCTGTGCAAATGTCACAGTTTTCTGCATCTCTCCAATCCCAGTATGGAACAGTGAAGTTCTCATC
CCCAGTTAGTTCTCGAATTTCTTGTTCCCACAATAACAAGAAAAGTCTGTGCCAAGGCAGAAACCCTGGT
GCTTCATGGGCAAAATCAATGTCCCTCCATATTTCAGAGCCCCCAAGCAGTGTGTCCCTTGACACATAGT
AATGCATCCATACAAAGAGGTCGTAGATGTTGATATCATTAAACATGGGTGTTGACCCATTGTTCATTTG
GCCATAGGTGCCTGTGGGGATGACATAGACTGAGCTGATAGTATGTTTTGCTAAAGTGAGGTAAGAAAAG
AACTTATTCTTTTCGGAGACACTCAAATCAAAAATGTTTCTTCTAATCAAGACTCGCTTCTCTGTACAAT
TTGGGCCCCCAAATCCAAACTTACAGTTTCCGCAGTTGAAACCCATGAAGTTGCCTGAGCACTGGCAGGT
CCTATTATAAAACACAGAGGGCCAGGACTCACGGTCATCCACCCCTTTGAAGGGGAACTGAGGTCCAGAT
GGTGCACTGGACAGAAGGATATCCTGGCAGGAACCTCTGCCTGAAAGCTGGCCGCAGGGACTCCCATCAC
CCATCCATGGTGGGCAGCATTCTTTTGCCAACAAGTTCTTAGAGGAGGCACAGGCTCGAGGAAAATGGCC
ATCAGAGATCTGGAAACTCCACAGAAGGCAATACAAAACAGCCAAGAACATTTTCTCCTTTAGATCATAC
AAAATCTGCACCAATAGGTTAATGAGTGTCACAGACTTCTTTTCCAGCAACCCCTGGAGTGACTATCACA
TGTTTTGGCTAAGACCTATATAACCACTCCCCTTCTTACATCAAATACTCTCAGCCTGTTTTACACTAAG
CT

</dna_sequence>
        <protein_sequence>>NP_001304326.1 tyrosinase isoform 2 precursor [Mus musculus]
MFLAVLYCLLWSFQISDGHFPRACASSKNLLAKECCPPWMGDGSPCGQLSGRGSCQDILLSSAPSGPQFP
FKGVDDRESWPSVFYNRTCQCSGNFMGFNCGNCKFGFGGPNCTEKRVLIRRNIFDLSVSEKNKFFSYLTL
AKHTISSVYVIPTGTYGQMNNGSTPMFNDINIYDLFVWMHYYVSRDTLLGGSEIWRDIDFAHEAPGFLPW
HRLFLLLWEQEIRELTGDENFTVPYWDWRDAENCDICTDEYLGGRHPENPNLLSPASFFSSWQIICSRSE
EYNSHQVLCDGTPEGPLLRNPGNHDKAKTPRLPSSADVEFCLSLTQYESGSMDRTANFSFRNTLEVFLNN
GCEGTALFWKFTQKPMHLSAITETLTWFLSYRSIEMVISS

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene293">
        <gene_name>TYRP1</gene_name>
        <strain>Homo sapiens</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>7306</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>4507757</ncbi_protein_id>
        <gene_locus_tag>RP11-3L8.1</gene_locus_tag>
        <gene_refseq>AF001295</gene_refseq>
        <protein_refseq>NP_000541</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:144010
CCDS:CCDS34990.1
HGNC:12450
HPRD:00283
MIM:115501</xrefs>
        <taxonomy_id>9606</taxonomy_id>
        <chromosome>9</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>12693374</gene_start>
        <gene_end>12710265</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>transcript variant X1</protein_name>
        <protein_pi>5.86</protein_pi>
        <protein_weight>57448.63</protein_weight>
        <protein_length>537</protein_length>
        <protein_note>Also known as TRP; CAS2; CATB; GP75; TYRP; b-PROTEIN</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_000009.12:12693374-12710265 Homo sapiens chromosome 9, GRCh38.p12 Primary Assembly
CACATGCACTTAACAGTTCTGACGTGAGAGGACAAGAAACACAAGCAAATATAAAACATTCAATTCTAAG
AGAAGTTCATCAGAGACATCCTTCAGGATTGTGAGGTACTGGAAAGAAGTCCTATGGGGAGTGGGTGGAC
ACGTGCCAAAACTCCATTAGTGTAAGGGACTTTAAATCACAGAAATTAACTTGCTGGAAATCTGTTCCCA
ATTCTTCCTTCAGCTCCAAGGTTAAATTAAATGTAATTAATGATGGTGACCTGCTAATTCATGCTTTTGA
TAACTGATATCTAGTATGTATATATATATAAACAAAATGACGAGGACAGGGAATTTAATTATTTGGGTAT
CACACATGCAGGTGTTATATATGCCAAATTTTAAAGGTAAAATTTGTGTGAAATGTCACACTTTTATTAT
TTGTGTGAAATGTCATTTTACATATGGGTTCCATTTTGAAAGTGGTTTGGGAAGGGGGCATACCATTTTA
AGTACCAAGAAAAACTTGCATAATCTCATTTTACTTTCTCTTTTTCAGCTGGATTTTCCTCTACGTGCTT
CAGTCTTCTCTACACAAAGAGCTGCAAACCAGGTCTTTGTTTTGCACTCTTATTTCAAGCAGAATGAGTG
CTCCTAAACTCCTCTCTCTGGGCTGTATCTTCTTCCCCTTGCTACTTTTTCAGCAGGCCCGGGCTCAATT
CCCAAGACAGTGTGCCACTGTTGAGGCTTTGAGAAGTGGTATGTGTTGCCCAGACCTGTCCCCTGTGTCT
GGGCCTGGGACAGACCGCTGTGGCTCATCATCAGGGAGGGGCAGATGTGAGGCAGTGACTGCAGACTCCC
GGCCCCACAGCCCTCAGTATCCCCATGATGGCAGAGATGATCGGGAGGTCTGGCCCTTGCGCTTCTTCAA
TAGGACATGTCACTGCAACGGCAATTTCTCAGGACACAACTGTGGGACGTGCCGTCCTGGCTGGAGAGGA
GCTGCCTGTGACCAGAGGGTTCTCATAGGTAAGTGGAGATATGAATGAGTTCATAAGTCCTGCATGAGAC
TCAAGGCTCTTAATAAAATCTTAAATCATTTGAGCTGGAGGAATACCTGGAAATCATATAGCTCAACCCT
CTCTTTTCATAGTTGAGGAAACTGAGGCTTAGAAAGGTTAAGAAACTTGTTTAATGTAAAGGGTTGGAGT
TGAAGCTCAGAACTTCTGATCAATATTTTATTCTGAAACATTTATTGAGCAACCACTATATCCTAGGAAC
TGTGTTAGGTATTATGACTAGTCAATTCAGTAACTCCTTCAGGTAAACATGTTAATTGTCATAGATGAGG
TTCAGAAAGTTCAAATCCACACAGGTGATATTTAGTAAACCTGGAATTCATGCTGAGATCTACCTAGCCC
TTATATTTTAGTTCTGCAACTACCCCTGCTGACCCTTAAAGAAGTTTCCCACCATGATGATCAAATTCAG
CATTTGAGATGAAGAGTTTGGCCTGCAGACTAAATAGCATTAAATAACAAAGCACTAAACAGTAACAGCC
AACAATATTTGATTGTGTTCTATGTGCGAGATAGTAGACTAAGGGTTTAAATGAACATGTATTGAGTCCT
TACTATGAGTTAGGCCTTGGGCTAATTGCTTTTTATGTGTGTGGTCTTTGAACTTTCAATTCTGTAAAGC
AAGTATTATTTTTATCCACATTTTAATGATTAAAAAAAAACTAAGACTTGGAAAAATGTGCCCAAAGTCA
TAGAATAATTCTCTGGTCTTAACTACTATGTTATATCACCTAATTTTCAAAGATTTATAATGTTAAAAAG
ACAGAAAATTCCAACAAAAATGCCAACAGTGGGCAGAAATCAACATGACAAGGTCACAGAAACATAAAAT
CCATAGGTAAGATTAAAGAAAGGTAATATAAATCATGCAGTAAATTGGAGAGAGAAAAGGGAAGAAAGAG
AGAGAAAGCAGGCTTGAAGAAAGGGTTTTAGTTAAGGATATTTTTAAAAGTGTAAAATAATTTAAAACAC
ATTTGAACAGATGGATAAATGGGTCGTGGTGTGTTACAAGATGATTATGCTCTTTCTCTACCCATCCCCG
CAAGGCAGATGTTTTCATGCTTGAATTTTGTATCCCTAAAGTCAGGAGAAATCTTCTGGACTTAAGTAAA
GAAGAAAAGAACCACTTTGTCCGGGCCCTGGATATGGCAAAGCGCACAACTCACCCTTTATTTGTCATTG
CCACCAGGAGATCAGAAGAAATACTGGGGCCAGATGGCAACACGCCACAATTTGAGAACATTTCCATTTA
TAACTACTTTGTTTGGACACACTATTACTCAGTCAAAAAGACTTTCCTTGGGGTAGGACAGGAAAGCTTT
GGTGAAGTGGATTTCTCTCATGAGGGACCAGCTTTTCTCACATGGCACAGGTACCACCTCCTGCGTCTGG
AGAAAGACATGCAGGTATGTAAGAAGCATTTCAGTTTGCAGACTCTTTACAGACAAGATGCCTTGTTTGT
AAGTGATTTTAATTCACTAGTTTTCAGAATCATCAGAACATTTGATGAAAAAGCAATTTTATGTTACTAA
CCTGTCTTTGGCATTTCGTTTTCTCCTTATTTTGGTTACTTGTTAATTAATCTTTATCTTGGTGAAGTGA
AAATAAAGCAAAATCAATAATGAGCAAAATGAGACATTTGCAGGAATGAATTAAAAGTTTAAAAATATTT
TGCAGTTTCATTGAAAACATGACTTTCATAAAGCTTGAAACAGAAGAATCTCATTTGCATGTCTTCCTTC
TCTACTAAATATAAGCAGATTCCTCCTCCTGGTCAAGTGATGTGGGTTAGAGACTTCTCAATCTTTCCAG
TCCTAAATGTATATCTCATCATTCCAGCGATGATTCCCTCCAACATGGTATAGGGTTTAAATCATGAAAA
ATAATTCCTTTCAATTTAGACTCTCATATTTTCATTGAACTATATTTTTCCACGTTCCCTACCCTTTGAG
TCTTACAGAAGAAACCTATTAAAATATCACATCACTATATAAGAGGACAGATATTTTAATTTGCTTGGCT
ATAGTAATCACTTTACTATGTATATTTATATCAAAGCACCATGTTGTACACCTAAAATATGTAAAATTTG
AAAAAAAGTTGAAAAATATCAAAATAATTATATCAGTCAGGCAATATTTTTAGTGAAAAGACATTGGCTT
TTTATTTGGCACAAAGTGAACCTCAACTCAAGCAGTTATTTCATGCTTATTTTCTAAGCAGATAAGCTTC
AAACATATTAAAGTATCTAGTTACGTAGATTCTTTACTCTTATTTCTTTTACCAACTGCTCTGTTCCTTG
AGAAAAATATGGAAATTTTAAAATAAAAGTTTAAGTTGTTAGATCTCAACTAGGAAATCCACAAAGTAAA
CCTGTTTTCTATGTGAAATAACAGCAATGAATCTCCCCCTTCAAGTTAAGATATAAAAATTAAGCTAAAA
ATATCTGAAGAAGGGAAAGGCGTTTAGATTCATTTATTAATTTGCAGAATGCTGTGCCAGCATTATTCCG
AGAAAAAATAAATGGTTAGAAGAGAGAGAATTAATGCACTAACATACAGGATAAAATATTCTTTTGAAAG
TACACTATCCATTTGCAGTTTGAGAGTGATTAAATGAATTCATCTGATACTCTGAACGTCATATTTTATA
GCTCTGATTGCAAGTAAGACATTTAGTAGATTATAGATAAATCTGTCATTTGTAATTGACTGCAGATCTT
CATGCCTTCAAGTCATTTTCTCATGGGCACACCAAAATGAAAGGGCAGGTGGAAAGTATCTAAAAGCTTC
AATTTTGCCTGTGTAAACTTCAACCTCTATGACTTACATTTTAAAGACCCAACAGCACAAGGGATGCAAC
AAATTAGAATTTAAATGTAATTCGTGGTTGAAATGCCACATGAATATGCTCTGGCTCCCAAATGTCAGTT
GCTGAACCACAAACCGATTCTTAATGATCCCTTGGAAGCTGTCACTAATTTTTGTGAACCACAATGATGG
CTTCTAAAGGAGGACTACAAACCCCTGGAGACCAATAACTGGGGATAACTTGGAAAGCTTTTGGCTCTCT
AAAACACCCAAGGATAAGAAAATGCTTCCTAGGAAGGGATTTAAAGTGAAAAAGTAGAAATATACTGAGT
GCTTGAGAGATAAGATAAAACAATTGCAATCCCTACATTTAAATCCCATACCATAAATAGAACTTCTCAA
GGCACCAAAGAAATGAGAAATAACAAGGAAATGTATGTTTTAAAGAACCGAATGAAATAAGCATGTGATC
TTGAGGCCAGCATTTTTAAAAATGTGAGATCAGCTTTGAATGGAAACTAGGTCTCTGATCTAAAAAACAA
TGGGCAGAAAGATTTACTCTGCTTCTGTTTAGCATTTTTATCAGTATAAATTTAGGCAGAAGCCTGAGTC
TTAAAAGTTTAGATTCTAAGGCAGGGTTCCCTAAATAAAACACCTTCCGTGCTCAGTGTGAAAGAGTCCA
TTGGCCTGTTGCCAAACCAGAATCTAAATGCCTAGTCATTCAAATTAAATTTAAAAACAGAAGCAAAACA
AAAATTAGCACTCCACAAAACATATTTTAAGGCTGGATCTGGCTCCAGACTAAGAGTTAATGATGCTTGA
ATTAAAGATAGGAAAATGGAAGAAGGTGGAAATGCCAAGAAGTGGATGTTGTTATTGATAACTTTTTTGT
ATAACCAATATAAATGTAATTATCTGCCTAAAAAAGAAAAAGAAGACCCTTTATCCCTTTAAATCATTTT
CAGAAATGTCTGCATAATGAGTTGAGTTTCATTCCCTCTAATGCCTAAATGACACCTTGTAATAAATTAC
CAGCTTTGTTAAATAAGGTTTTAACTCCTCTGGGCCCCTCAGACACCGTTGATATACTAACCAGTACCTT
ATTGTCTGAAGAGAGCTAATAGAAATAGACTGTCAGAGAGTAGACCAAACAGAAATGAATAATTGTAAAC
AGAAGCAGAGAGTATTAATGTGGTTTCTGTGATCTAGGAAATGTTGCAAGAGCCTTCTTTCTCCCTTCCT
TACTGGAATTTTGCAACGGGGAAAAATGTCTGTGATATCTGCACGGATGACTTGATGGGATCCAGAAGCA
ACTTTGATTCCACTCTAATAAGCCCAAACTCTGTCTTTTCTCAATGGCGAGTGGTCTGTGACTCCTTGGA
AGATTATGATACCCTGGGAACACTTTGTAACAGTAAGTTCCAAATGATAGCTTGGAGTCAGAATTTCTTT
TTAGATAAAGAGATTAAATATGTTGCCTGAAAGGCCCTTCATTCTACTAGAGAATTCAGACTAAAATCTA
CTTTTATTATAGAGTAACAGTGTACCAGGCATTCATTAAACACCTAGAATGTTCAAGGTACTCTAGAAGT
TGCTCCAGGGGAAACAGAAAGTGCCTACACATTTTTACACTGCCTTTCTTGAGTAGTTTGGTCAATATCT
TGCTAACTTTCTTATTTTGGAAATGTCTAGTTGTATAAACTAATCCTCTTAGTTTTCTTAGCACTACTTA
GAAGTCATGTGTCTTGTGTTGGAATTTCACAGAAAATGTTTCCTAAGAAAATGTGAAAAATAGGCAAAAA
GTTGGAAATGCCCTGGGAAGAAAAAAAAGAAAAGAAGCAAACCAAATGTATGCTTGCAGTTATAAAGTTA
GAAAACAAAAGCTGATATGGGGGATAGTTTTCAGAAAAGGAGTATATTGTACTGATGTCTGCCCCCTAGC
TGCTTTCCAGCTCTTCCAAAGTGAACACAGTAAGAGTACGCCTAATCAGTTGTCCCAGCATCCTTTCTCC
AGTGATCTGAATGCCACCACTGTCACAGGTCAAGTTTCTGCCACATGTAGATCTCTTCCTGAGCTTTCTG
TTCTCCTCCTTGGATCATATTATTATTTGTGCCTGTGGTAGTAACACAAGGTTTAATTATTAGACACCCC
CTACCTCATCTTATTTTTCTTCTTCAGGCATGTATGGCTCTTTTGATTGTTCTTCCATATAAAAATAAGA
GTTATGTGAATTTGTTTTCTTATTATAATCACCACATACTTATTCTACATGTATTATTTTATGCATCAAG
TATTATTTTATGAACTTAAATAAGAAATACTCTAAATAAATCAGCAGGAATTAGATACATATTTTCACCA
TTAGATTATTTAGCAATGTATAGGAATAAGAGAAGTGATAATATATGAAAATTTCCTCTGTAGAAGTTTA
AAACTTAGAATAAATTTGTATTTGTTTGGTATGCTGAATGCATGATCCCACCTTGTGGCAGAGAACTGAA
ATTGAGGATCAGGATGTCTGCAGATGCCAAAATGTTTATACTCTTTGTGACCAGGCCATTGTATTTTGGC
CTGAGAGTTTTCTAGACATTTCCCAATCACCCTGATGATTGGATACCAAAATAAAACACAGTTTAAATGA
GTGAATGCAATCATAGCACAGGAGGGGGAAGAAAGAGGAAGAGATTTTCTTTTCATCATAATTTTTCTTG
TCAATTAATATAACAAGTCTCCTAACTCAGACACATAGTCTCATGACAAATTGAAGAATATTTATTTTAG
GTTAAAATATTTTTAAGATTATCCCTTGTCTCACTGCAAGAGATAAATGGCAGACATTTTATTTATAAGG
CAAAGGAAAGGGAAAAACTATCATTTTATTGAACATATATTATGTATCTGATATAGTATGAAATGCATTG
ATATAGTATCCTATTTAGTCTTCATAACAATTCTCTCTTCTATTACTGTTCTTCTTTAATGATCTTGTCC
ATTTCTGTAGTTCCATTCGTCATCTTTTACTGGAGACCCACACGTTTCCACCTTTAGATAAAACCTTCTT
TCTTTAAATATTCCATACCCATGTCTTCACATGCTTGTTGCATAGTATTTCTCCAATATTCAAAATTAAT
GCGCCAAACTTGGTGGATTGAAAATAGTTAATATTTTATTGCAGCTAACGTTCTTCCAGCCACCAAAATA
CCATCTTTGAATCAACATAGAAAAACACTGTTCTTTATTCACAGTACTTCTCAAATATATTTTCTTCTTC
AGACATGGGCAACTTTCCATTTATTTTTATGTGGAAATTCCACAGGACTTTGGTCCATAGGATGTTAGGT
GCAATGGCAGAGTTTGTCCATATGCAAACAAATTTAAGAATCACTGGAATAAAAAACAAACTGGTTTATT
TTTTATATAAACTAGTTTCTTTACTGTCAGCATTTTCTACAATGGAACTCTGTGAGGGCAAATTAGAATG
TAATGTTTTGAAACTCAAGTAATTAATATTTGTTTCTTGGGATTTATTGATAGCTTCCTGAGCAGTAATC
CCCAAAACATCAGCTTGAATTGATAGTCTAGCTAGTGATGGTGAAAGTTTTGGGTGATAATGTACACTCA
ATAAATAGTTTCCAATCCCACCTGAGGCATATGTTTTAGTTACATATTATTTAAATTTCATTATGCTAAC
TTAACAGGTTCTGATTATTACGTTAATTATAAAGCATAGAACATGGGAGGCTTTCTGAATGAAGGAAAAG
GAATATGAGTTGAAGTTGTAAAATTATCTCTCACCAGCTTAGTGGATTGTTTTGCTTGTCCCTTTACGGT
ACATATATTCCTTTCTGGAGACCACTGGGACAGAATGATGCAAAATTTTCCTAACCAATCACCTCTCCTC
CCACCCATCTAAGGTTTTGACTTCTCTCCACTTCCTAATAAATCACACATAACTTTCTTATCTTGATACT
TGATTTTTTTTTCACAATATAGCTCTGGTCTAGCTTCTTTTCTTTCCTACAGTCCACTACTATCCTGGCA
CATACTCCAGGCAAACTATTTCCCAAACAGGCCCTCCCCCTTTTTTTGTTTATTTTACAGCTAACATGAT
CTTTTCCATATAATGACAGGCACCAAACAACTCTTCAGCACCTATTCAATGCCAGGTACTGTGCCAAGTC
TGTGGGATACAAAGTTTTTTTTTGTTACAGATAGGGGGTGTTATAGACAGAAGAAAGTGTATCATCTCTT
GCCATTTCCTCTGCCTAAAATGTTTGTCTTGTAAAATTTATTTCACCTAAGAAAATTTTTCTTAATCCTA
TGGGGCTTTGTGTAAATCTCTCTTCTTTATAAAGCCTTTCTGGAGATCTGACTGGGCAGGATCTCTCTCT
CTCTTTCCCTGCTCCCTCCCACCATCTCTCTTCTTTAAGGCTCCTATCATATTATCTATCCCTAGTATCA
CAGTTCTTTGTTTGTTACTGCCCTTCACAAAGTTTCATTATTTCTCACATTAATTGCTGAAAAAGTTGAA
AAATGTGTGTTGGTTGACATATGTATCACTTTCCAAAGAAATGTAAGGGTTTTTTTTTCCTTATTTCTCT
GAAGGTTTAAATAGACAGCATTTGCATACAAAATATCACATATATGTGACATAAAGATTTTAGTGTAGAA
CTAGATTTATGAGATTATTTTGGCAAAATTCAATTTTCCATGGAATTTTCATTTTAATACATTCTTGTGG
AAGAAGCATATATTGATTTAACAAATATCAACACCTGTATCTGTTAGTGTGATTCTTTTTTTTCCTTCAG
ATACTTTTATGTATCTCATATCTACTTGATTCAAAGAAATGGGACATGGTAACTTAGATTTTCTCATTTT
AATGCTACCAAGTATGCATTTTTAAATTTTCTTTTCTACCAAGGAAAACCTATATTTCATATTCATGCTA
TGTATAAAGTTTTAAAGAGCGACAATAAGAACTCCAAACATTGTGTAAATGTTTCCACATCCCATTTTTT
TCTGCAGGCACCGAGGATGGGCCAATTAGGAGAAATCCAGCTGGAAATGTGGCCAGACCAATGGTGCAAC
GTCTTCCTGAACCACAGGATGTCGCTCAGTGCTTGGAAGTTGGTTTATTTGACACGCCTCCTTTTTATTC
CAACTCTACAAACAGTTTCCGAAACACAGTGGAAGGCAAGTAAATGAAATCAGTATTTTTAAAAGATCTA
GTTATCAGAGAAAACTGAATTATTCAAAAGCAAGTTTCTTTGAGAAGGCTTTGAATAGTATATTAATCCT
GTGTGTTTATGTGAATGAGATTTTCTATTATGATACACCTGCTTGAAAAAGGAACTTTCTTAAAAAGAAG
AGTCAACCATGAAGCTCTTTTCATTATAGGTGAAGCCCTTGGAAATCATGCTCTAATTTCTTAAACACCC
AAAAACTTTTTAAATTCAAATTTCTGGTAGCTAGCTGGCCAATATGTAACTATATCAAGGTCTCTAGCAT
TGGCAAACAATATTCAAGACTTTGACAGTGTATTAAATTAGTTTAGTTTTTTTTTTAAATAGAGTAATAA
AAAAAATTCCAAACAATTAGTTGACACTGAGTAAAGCCTTGCTTGCGCATATGTTTTATTTAGGTCCGTA
TTAACCTGTAACTTTTTTCAAAGGTCTGTACAAATTCAAATTAGCATCTACTGATGCTTAACTTGGTTTT
CCTTATTTCACACAAAGTATTTTAAAGCTGAGGAAAGTGAGGTATAAACAGGTAAAATTACTATCACAAG
ATATTCAGCTAGTTACTAACAGAGCGTAGGTTCAAATTCAAGTTTTCAAAATCCAGTGTCTTTGTATAAT
AAATTTTGATACCTCCAAATGATGCTTGATATATATATATATTTAAAGTCTTCAAAAGAATATAATTACT
TTTATCTTATAAACTTGTTATTGTTAAATTTTTACCTTCAATATAGCATTGTCCATGTCTAATGCATCCC
ATCTCCCCAAAAAATGCAAATACATTTCTCTGCCCTATGATCAGAGATACTTGGTATACAAATCTAATAA
TTATTTTTAATTCTCTCACCTTTTAGTCTCAAAATTATATGCCATATTAACCTATTTTTGATCATTTTAA
TAACTACCTGAATGCACTGATTTGAATATGATTCAATAAAAAAAATCACTATATTTTGGCTAATCTGTAA
ACTAAGGCCATCAGCACTGATGTTTTAAAAAATGTACAGATTGTGTCTTCTTAATGCCCAATCAGAAGAC
AATTATACTTATTTCCTGACAAAATGTATAAAAAGACGAGTGTCAAGCCACGTTCCATATATATCACAGA
CAATCTTTAAATGTTTTTGAGTCAAATAACAATGGAATAGATGCTTGAAAAAATGCATAGGTGGCTAAAT
AAGTGGCTACAACTATACAATTCATCTTAGATGAAGAGAGAACTGGTTAACATATTTTAAATTCTGATTT
CATTTTATAATGCACAACAATTCCCTGATCTCAACCCTCTGGTCCTTCAACCCAATTAGACAGCCTACAT
TATAGACCCTCCATTTTTATTTATGACCTGTCTTATACCAATCCTTGTTTTCTCCCTTATATATGGAATA
TATATATATATGTGTGTGTGTGTGTGTGTGTGTGTGTATATATGTGTGTGTATATGTATATATGGAATTG
AGATATTTATCAAAAGCTGTATAAATGTTTTGACAGTAGGTTTTCCCGATGTTTAAAACTAGCACAAAGA
TGGAAAGAAAGCCCTGAGGAATTGTAGCTTCCCCACAAAAAATAGTTTTCCAAAAATAAACGTGCTAACA
GTCATTCAAAAATAAGGTAGGAGGCTGAAGTAACATCTGGCAACTTAAGTTCCAAGACAACCAGAGCATT
CTTCTCCCAATTGTGTCAGCAGTTTTTAGCAGAAACTGGAGATTTTCACTATCTTTATTCCCATGTAGAA
CAATGTCTGCCTTGTCAAATAGAGTGTCTATATATTTTGACTGGTATCCTTTGCAGGTCATTATTTTTAA
CCTGGAGGCTACATTTAGAATGTCATGCCACTAGCATAAAACCAGCCTAGCTCTGGGTATAGCAAACAAA
TGTCATCAACCATAGGTACAGAGAAGCAGTGCTGTTATATTAAGGCAAAAATTGGCCTGACGAGCCTTGA
AAAAATTGTTTCCCAATATAATCATTGCTATTACCTGGAAAAGTGAAATATTTGCAATAGTTTTACTATT
CTCCTCCTTACCATGTGTCTAGGTTACAGTGACCCCACGGGAAAGTATGACCCTGCTGTTCGAAGTCTTC
ACAATTTGGCTCATCTATTCCTGAATGGAACAGGGGGACAAACCCATTTGTCTCCAAATGATCCTATTTT
TGTCCTCCTGCACACCTTCACAGATGCAGTCTTTGATGAATGGCTGAGGAGATACAATGCTGGTAAGACA
TTTTCATATGCCTTTTGCATGCTCAGCTGGGCGGATTGTTTAGATGGCATAGTTATCAGTTCAAGCTGAG
CACTCAGCGCATAAAAACACTTTCAAAATAAGGATAGCATAGCTGTAATATCAAGTCACTTCCAGACATT
CAATTCTACTTTGAAAATGCAGGCAAGAAGTCTCTCCAAATAGTTATTATAGGATGATATTTTTAACCAT
TTGCTGGGACTAACCAAATCATCTCTCCTAATTTTTGCTACGAAAAAATGGCTACTATGTTTCACAAATT
GTTCTTACCCTCATCTTCCAACATAAATTCTCATTACTTTTAAATATAAATGAGGAAAACCTTATAGAGC
TCTTCTTTGATATCCCAAAAGACTAAAAATTTTATACCCATAATCCACAGTTCTTATTTTTATTACTTAA
TGGCCCCTCACAAATAGAAATTGTGTTCCACTTGAAAAGTTAATGTTGGCTTTTATATCACACTATAGGA
AATCTCTTTTAAGTTCATTTCAATGCATTCTTTAAAATACTATTTAAAAGGCCTCTTTCTCTGCCTTCCT
ATGCAGCTGAGAGGCTAGCATTATTTTTCAAACAATAAAAGTGCTTCCACTGGTTAAAACATCGCAAATT
TTCATAGGTTGAAAGCATTCTAAATTTTGGCTTTTGTGCCTTTAGCTCATAACGCACATAAACCTGATAT
TGTAGCTTAACTACCTATTGATTTATGTATCCATTAGGCATGCTTTCATTTCTATGTGTGTATGTGTGCA
ATAACGTCCTCTAATCCAACCTAATTAGGACCATTAATTGATGAAATTGATGAAAATAGTTTGTTCCATC
AAAAATTATTTAAGAAACAACTTACACATAAGCCTGTAATCGCAGCACTTTGGGAAGCCGAGATGTGGGG
ATCACTTGAGCCCAAGAGTTTGAGACCAGCCTGGTCAACATGGTGAAACCCCGTCTCTACTAAAAATACA
AAAATTAGCCAGGCATGGTCATGGGCACCTGTAATCCCACCTACTGGGGAGGCTGAGGCAGGAGAATCAC
TTGACCCTAGGAGGTAGAGGTTGCAGTTAGCCAAGATCACACCACTGCACTCTAGCCTGGCTGACAGAGA
CAGAGTTAGTTTTCAATCAGTTATGAATTCAGTTATTGCAGTTTCATCTCATTTTCATGTGTATTTATAT
ACATAATGACAACCATAAATCTATAATTTACACTGTCAGCTTTTTTAAAAGTGAAACAATAAATGAGTGA
CTTTTGAAATACAATATGAGGGCAAATATTTTAGCCATACACCTTTAACAAATCTTTCCAAAATGTTCAA
TTTACATACTATAAAAACAACATCCTTCTCTTTGTTTTACAGTCATGATGACCACTTTATGTTTGTTTAA
CTAGATTACTTTTATTACAGTAATGAGTAAACTCAAATTAATAGGTTTAGGAATTAACAAAACCAGCTTT
TGTTAAACATGCACTTCTGGGAACTACATGGCAATGTTCAAGTTGTATTTATTCAGTTATTCACAATGCC
GTGGGTGTTAGTAAACTTTTTAGAGGAAATGGAGACTATTCAGTAACCTGGCAAGTCTCTTAAGTGGAGT
TTTCTTTCACCTATGAAAGAAAGGAAAGATATTCCTTCACCTTGTGTATCTTGGCTGAAAATATAATTAT
TTCACATTGATAGCAAGTTGTTAAAGGTTCTCCAGATTTTAACTTAAAGGTCATTGATGAACCAGAAAAA
TACCTTTTGAACATTTTTTTCTGACATTTTCTTTGTTTGCAATATGTGTAGCATAAGGTTTCTCAGTAAC
TTGAATTGTAGTGGGAAGAGAAATACCGTAAATAAAAAATAGGAAACTACCCTGCAGCACATTTCTGATA
AAATGTGGCCATAAAATTATAGGATAGGTCAATGTAAACACTTGCAAACTGCATGAAAGCTAAGCTGAAA
CAATTAGCCTCCTTCTTAAATATTCCTTGTACCTGCAAATACGTTTTAGAAATCAGTGTCATAAAACAAC
TGTGAAGAAGAGAAAGAAAAATTAGAAAGATTAAAAAAATTTATAAAACTGTCTGTAAAGCAAGAGTCTT
GTTTAAAATAAGTCTAGGAGTGGAGGGATGGAATTCTTTTTCAAAATGATTGAAAGGTTTTTACAAATAT
AGAAAGCTCTTTACAAATTGCAGAATAATAGAATTATTAGGCTTGGAAAGGAACAAAAATTACACTTTAC
AGATAAAGAAAAGTGGAGTCATTCAAATATTAATGTCCATTACAGGTTCCTTTCATTAGACATGAAATAG
TACAATTGAGAGCATCCAAACTCTAGTTACTACCATGTTAATTTCTATTTACTAACATTTCTGATCTATA
TACACATTCAATTCAATTCCTTCTCTTTTATTTCAACTGAGAATTATATGAATTAAGTTTTAAATATAGC
AGCCCAGAAGTTCAGTGTATTTTCAGAAGAAGCAGTTTATACGTTTCCAAGAGTGATCACTACTTTACTT
TTTGAGCTGTGAGAGAAATGAAGTAATCACACGTACACTTAAGTCTTTTCATATATATTATTTTCAAATC
TACTATTTCCTGGTCAGTATTCAAGGTACCAGAAATACGATGCTATACAAAATTCACCAACAAATTTTCT
TCCTGAAACTTTTCTTCCTGTTGATAAAATTGACAATAACCATATGTAAATACATATACAGCATGTTAGA
TGGTGGAAGTCTCTATAGACAAATAAAATCAGGAAATAGGATAGGCAGTACTGTGTAGATATATGGAAGA
AGAATGTCCTAAGACAAAGGAACAGGGAGCCAACTGTGGCTGGAGTAGAGTGGGGTCTGGGGAGAGAGTG
GTGAGAGATAGTAAGGTCAAAGGGATAACAGGAGGCAGAGCTGTATGCCACAGCAAATTACAGGTTTATG
TTTTCTTTGGCTTTGAAAAATACATTTAATGAATTTTATTCAAATTGCTTTATGTAATTTTTAAAAATTA
TTCAAGATCACCATAGGTGATGAAATACTAAAACTCCCCTGCTTTTAAACTCTCTTTTTTATTAAGTGGT
ATATTGGTACTGTATTCAAAGCATTTTCTGTTTTATGTAATTTCTCATCCTGCTGTAGTGAAACTTCATA
TCTTTATTCAGTGTAAAATAAGAATAAAATTTTTTCAGGTTCTCCTTGAATATTGGATGCCTTTAGAACT
CAATAATGATAGGAATATTAATTTTATTATGTTTATTAATACGTTGTCTTTGGAATAATTTAGATATATC
CACATTTCCATTGGAAAATGCCCCTATTGGACATAATAGACAATACAACATGGTGCCATTCTGGCCCCCA
GTCACCAACACAGAAATGTTTGTTACTGCTCCAGACAACCTGGGATACACTTATGAAATTCAATGGCCAA
GTGAGTGTTGAAAGTGTATTTTTACTGTGATAATTTCCAAAAGCAAATGTGTTATCTTTCAAGTAGAGTA
ATCACGGTATTCTGAAGCTATGTTTTCCATTTGGACTTGGAAACTTTCATTTGTACTTTTATTTGAGGAT
AAGGGAAGGAATTTGATATTTGTTGAGAGTCCACACTAAGCTGATATTGATCTTATTGTACAGCACCCTA
TCTCATTTAATCCTCACAATGCTTTGGGGTGAGTATGAAAATCTTCATTTCACAAATAAGGAAGCTGAGG
CTTAAATAGGTTAACTGTTACAGATTCACATTTCTAATGAGGGAAGAGAATGAGTTTGAGCTTAGGCCCA
TGGAATATGCCCCAATTTTTCTACTATACCATATTGCCTGCATTTATCTATCTTAAAGGAAAAGGGAGTG
AGATACTCTTAGGTATTTTTCTGAGATTTTGAAGTTCAAAAGTTTTTTGTTTAAATCTTTTCCCCAACAA
AGGCAGTAGGGCATAGTGGAAAAGTACAAGACTTATATTCTAAAATATCCGGGCTCCAAAGCCAACTTTA
TTGCTTACCAACCAAGTGACCTGGGTAAGTGACTCAGACTCATTGAGTCATCATTCTCTCACTTTCACAA
AATGAAATGGAAATAACAATGACTATCCCAATAGGGTCCACTCATTAAAAGAAATCAGGAAGTGGCTTCA
AGGCCATGTGGCCAATGTAAATTAAATATGAGGATTTCTGTTAAAATAGACATTTCTAAATTTCATCTGT
CCACTTTTTGGTGATAACTATTTTAATATTTGTCTTTTTATTTTTATCTTCCTTTCCAAATAGGTCGGGA
GTTTAGTGTACCTGAGATAATTGCCATAGCAGTAGTTGGCGCTTTGTTACTGGTTGCACTCATTTTTGGG
ACTGCTTCTTATCTGATTCGTGCCAGACGCAGTATGGATGAAGCTAACCAGCCTCTCCTCACTGATCAGT
ATCAATGCTATGCTGAAGAATATGAAAAACTCCAGAATCCTAATCAGTCTGTGGTCTAACAAATGCCCTA
CTCTCTTATGCATTAGTATCACAAAACCACCTGGTTGAATATAATAGATTGAGTTATTAACTGTATTTTC
TTTCACTTTATTACCTTCTTTCTAATACAAGCATATGTTAGCATTAAAGTTCTAGGCATACTTTTCAAAG
CTGGGAAGACCCTTTCAGAATCTTTTCAATGGGTTTTAATTTTCAGTTCTATTTAAAATGGTGAATGACA
CTAAACTCCATGATATTTAAGGATAGTGTGAAGATCTTTGGCATGATTTAAAGGTTGAGTATGTGAAGAT
ATAAGTAAGTGAACTACCATGCTTTGTTTACGTGTAAAGGAAAATAATGTTTGATAGTAAATGTCCACTT
AAAATACATGAATGGGCATTTCTAAAATGTTAAAACATAAACACATTTCCATTCATGGATATTTGTCAAC
AGATTTAAAGAAAACCACAGTTATTAATTAAAGAAAATTAATTATGTGTAGTTATAAACCAATGAAATTT
TGATTAACCTTTTCAAATTAATGTTCCAGTTTGAAGACCAATCAAATATATTATTTAGTCAACATATACT
ATTTAGTCTCAGGTTCAAGGCTACAACAAAAATCACCATCTTTGTCAAACTTTGGAGAGGGAAAATCTTC
ACTTTCTTAAGCAACAATGGATATTGCCTGTGTTTGCCACTGTGTTTCCCTGCCTCTCAATTCGCTGAAA
AAGGAACTACCTATCCTTACATTTCACCTACTAATGTCTCTTCTAACATCTTAGAGGTCCATGGAGAAGG
CATATGGAGAACATGTTTTATACTGCTCTATAAATAGTATTCCAATCACTGTGCTTAATTTAAATAGCAT
TATCTTATCATTTATCAGCCTTTTATGTATTTTCCAAGTAAAATATTAACATATTATTTCATTGGTCTTC
TTTTTTATCTGGTTCTATATGAATGCTATTTTTTCCCTTCTCTTCTAACATGAAATATATTTTCTCTTTT
TGATCTTGTGCTATGAAACAATCTTCCAAAGAACTGTATAAGGTGGTCATAAGTGAATATTTTAATTAAA
ATTGGTAAAAATAAATAATAAC

</dna_sequence>
        <protein_sequence>>NP_000541.1 5,6-dihydroxyindole-2-carboxylic acid oxidase precursor [Homo sapiens]
MSAPKLLSLGCIFFPLLLFQQARAQFPRQCATVEALRSGMCCPDLSPVSGPGTDRCGSSSGRGRCEAVTA
DSRPHSPQYPHDGRDDREVWPLRFFNRTCHCNGNFSGHNCGTCRPGWRGAACDQRVLIVRRNLLDLSKEE
KNHFVRALDMAKRTTHPLFVIATRRSEEILGPDGNTPQFENISIYNYFVWTHYYSVKKTFLGVGQESFGE
VDFSHEGPAFLTWHRYHLLRLEKDMQEMLQEPSFSLPYWNFATGKNVCDICTDDLMGSRSNFDSTLISPN
SVFSQWRVVCDSLEDYDTLGTLCNSTEDGPIRRNPAGNVARPMVQRLPEPQDVAQCLEVGLFDTPPFYSN
STNSFRNTVEGYSDPTGKYDPAVRSLHNLAHLFLNGTGGQTHLSPNDPIFVLLHTFTDAVFDEWLRRYNA
DISTFPLENAPIGHNRQYNMVPFWPPVTNTEMFVTAPDNLGYTYEIQWPSREFSVPEIIAIAVVGALLLV
ALIFGTASYLIRARRSMDEANQPLLTDQYQCYAEEYEKLQNPNQSVV

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Preimmunization of mice with intradermal Ad.gp75 (TYRP1) provided dramatic reduction in the number of lung metastases.  Adoptive transfer of macrophage-depleted splenocytes from Ad.gp75-immunized mice similarly afforded significant protection against B16 tumor cell challenge.  hese results suggest that immunization with Ad.gp75 induces cellular immune responses that are capable of rejecting B16 melanoma in a host that is usually tolerant to gp75 antigen [Ref953:Hirschowitz et al., 1998].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1345">
        <gene_name>Ubiquitin</gene_name>
        <strain>Mus musculus</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>55118</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:176398
GDB:120478
GDB:133775
GOA:P0CG49
InterPro:IPR000626
InterPro:IPR019954
InterPro:IPR019955
InterPro:IPR019956
UniProtKB/Swiss-Prot:P0CG49</xrefs>
        <taxonomy_id>10090</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>ubiquitin</protein_name>
        <protein_pi>7.66</protein_pi>
        <protein_weight>33156.94</protein_weight>
        <protein_length>348</protein_length>
        <protein_note>Ubiquitin; cd01803</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>CAA35999.1 ubiquitin [Mus musculus]
MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLV
LRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKE
STLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSD
YNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLED
GRTLSDYNIQKESTLHLVLRLRGGY

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<reference reference_id="reference2972">
		<reference_name>Aarntzen et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, van Rossum MM, Blokx WA, Jacobs JF, Duiveman-de Boer T, Schuurhuis DH, Mus R, Thielemans K, de Vries IJ, Figdor CG, Punt CJ, Adema GJ</authors>
		<title>Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients</title>
		<year>2012</year>
		<volume>18</volume>
		<issue>19</issue>
		<pages>5460-5470</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3011">
		<reference_name>Aarntzen et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Aarntzen EH, Srinivas M, Bonetto F, Cruz LJ, Verdijk P, Schreibelt G, van de Rakt M, Lesterhuis WJ, van Riel M, Punt CJ, Adema GJ, Heerschap A, Figdor CG, Oyen WJ, de Vries IJ</authors>
		<title>Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells</title>
		<year>2013</year>
		<volume>19</volume>
		<issue>6</issue>
		<pages>1525-1533</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3908">
		<reference_name>Abate-Daga et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Abate-Daga D, Hanada K, Davis JL, Yang JC, Rosenberg SA, Morgan RA</authors>
		<title>Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes</title>
		<year>2013</year>
		<volume>122</volume>
		<issue>8</issue>
		<pages>1399-1410</pages>
		<journal_book_name>Blood</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2989">
		<reference_name>Abkin et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Abkin SV, Pankratova KM, Komarova EY, Guzhova IV, Margulis BA</authors>
		<title>Hsp70 chaperone-based gel composition as a novel immunotherapeutic anti-tumor tool</title>
		<year>2013</year>
		<volume>18</volume>
		<issue>3</issue>
		<pages>391-396</pages>
		<journal_book_name>Cell stress &amp; chaperones</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3912">
		<reference_name>Adamina et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Adamina M, Rosenthal R, Weber WP, Frey DM, Viehl CT, Bolli M, Huegli RW, Jacob AL, Heberer M, Oertli D, Marti W, Spagnoli GC, Zajac P</authors>
		<title>Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma</title>
		<year>2010</year>
		<volume>18</volume>
		<issue>3</issue>
		<pages>651-659</pages>
		<journal_book_name>Molecular therapy : the journal of the American Society of Gene Therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1915">
		<reference_name>Adams et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, Cruz CM, Angiulli A, Angiulli F, Ritter E, Holman RM, Shapiro RL, Berman RS, Berner N, Shao Y, Manches O, Pan L, Venhaus RR, Hoffman EW, Jungbluth A, Gnjatic S, Old L, Pavlick AC, Bhardwaj N</authors>
		<title>Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant</title>
		<year>2008</year>
		<volume>181</volume>
		<issue>1</issue>
		<pages>776-784</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2915">
		<reference_name>Agarwala et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Agarwala SS, Neuberg D, Park Y, Kirkwood JM</authors>
		<title>Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group</title>
		<year>2004</year>
		<volume>100</volume>
		<issue>8</issue>
		<pages>1692-1698</pages>
		<journal_book_name>Cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3902">
		<reference_name>Ahlers et al., 1993</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ahlers JD, Pendleton CD, Dunlop N, Minassian A, Nara PL, Berzofsky JA</authors>
		<title>Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations</title>
		<year>1993</year>
		<volume>150</volume>
		<issue>12</issue>
		<pages>5647-5665</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3976">
		<reference_name>Ahlers et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ahlers CM, Camphausen K, Citrin D, Arlen PM, Gulley JL</authors>
		<title>A pilot trial of a carcinoembryonic antigen/ TRICOM-based vaccine and radiation to liver metastases in patients with carcinoembryonic antigen-positive solid tumors</title>
		<year>2006</year>
		<volume>6</volume>
		<issue>1</issue>
		<pages>72-75</pages>
		<journal_book_name>Clinical colorectal cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2377">
		<reference_name>Ahmad et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC</authors>
		<title>Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth</title>
		<year>2009</year>
		<volume>17</volume>
		<issue>6</issue>
		<pages>1101-1108</pages>
		<journal_book_name>Molecular therapy : the journal of the American Society of Gene Therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1308">
		<reference_name>Ahmad et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC</authors>
		<title>Optimised electroporation mediated DNA vaccination for treatment of prostate cancer</title>
		<year>2010</year>
		<volume>8</volume>
		<issue>1</issue>
		<pages>1</pages>
		<journal_book_name>Genetic vaccines and therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3895">
		<reference_name>Akagi et al., 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Akagi J, Hodge JW, McLaughlin JP, Gritz L, Mazzara G, Kufe D, Schlom J, Kantor JA</authors>
		<title>Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7</title>
		<year>1997</year>
		<volume>20</volume>
		<issue>1</issue>
		<pages>38-47</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4007">
		<reference_name>Akbulut et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Akbulut H, Tang Y, Akbulut KG, Maynard J, Deisseroth A</authors>
		<title>Addition of adenoviral vector targeting of chemotherapy to the MUC-1/ecdCD40L VPPP vector prime protein boost vaccine prolongs survival of mice carrying growing subcutaneous deposits of Lewis lung cancer cells</title>
		<year>2010</year>
		<volume>17</volume>
		<issue>11</issue>
		<pages>1333-1340</pages>
		<journal_book_name>Gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5117">
		<reference_name>Alvarez et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Alvarez RD, Huh WK, Bae S, Lamb LS Jr, Conner MG, Boyer J, Wang C, Hung CF, Sauter E, Paradis M, Adams EA, Hester S, Jackson BE, Wu TC, Trimble CL</authors>
		<title>A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3)</title>
		<year>2016</year>
		<volume>140</volume>
		<issue>2</issue>
		<pages>245-252</pages>
		<journal_book_name>Gynecologic oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5213">
		<reference_name>Alvarez-Salas, 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Alvarez-Salas LM</authors>
		<title>Amolimogene bepiplasmid, a DNA-based therapeutic encoding the E6 and E7 epitopes from HPV, for cervical and anal dysplasia</title>
		<year>2008</year>
		<volume>10</volume>
		<issue>6</issue>
		<pages>622-628</pages>
		<journal_book_name>Current opinion in molecular therapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5300">
		<reference_name>Alves et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Alves PM, Faure O, Graff-Dubois S, Gross DA, Cornet S, Chouaib S, Miconnet I, Lemonnier FA, Kosmatopoulos K</authors>
		<title>EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes</title>
		<year>2003</year>
		<volume>63</volume>
		<issue>23</issue>
		<pages>8476-8480</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5155">
		<reference_name>Angsantikul et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Angsantikul P, Fang RH, Zhang L</authors>
		<title>Toxoid Vaccination against Bacterial Infection Using Cell Membrane-Coated Nanoparticles</title>
		<year>2018</year>
		<volume>29</volume>
		<issue>3</issue>
		<pages>604-612</pages>
		<journal_book_name>Bioconjugate chemistry</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4019">
		<reference_name>Aragon-Ching et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Aragon-Ching JB, Williams KM, Gulley JL</authors>
		<title>Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer</title>
		<year>2007</year>
		<volume>12</volume>
		<issue></issue>
		<pages>4957-4971</pages>
		<journal_book_name>Frontiers in bioscience : a journal and virtual library</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5233">
		<reference_name>Ardon et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G, Demaerel P, Bijttebier P, Claes L, Goffin J, Van Calenbergh F, De Vleeschouwer S</authors>
		<title>Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study</title>
		<year>2010</year>
		<volume>99</volume>
		<issue>2</issue>
		<pages>261-272</pages>
		<journal_book_name>Journal of neuro-oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4016">
		<reference_name>Arlen et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Arlen PM, Gulley JL, Palena C, Marshall J, Schlom J, Tsang KY</authors>
		<title>A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1</title>
		<year>2003</year>
		<volume>279</volume>
		<issue>1-2</issue>
		<pages>183-192</pages>
		<journal_book_name>Journal of immunological methods</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5326">
		<reference_name>Ascher et al., 1979</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ascher NL, Ahrenholz DH, Simmons RL, Weiblen B, Gomez L, Forstrom LA, Frick MP, Henke C, McCullough J</authors>
		<title>Indium 111 autologous tagged leukocytes in the diagnosis of intraperitoneal sepsis</title>
		<year>1979</year>
		<volume>114</volume>
		<issue>4</issue>
		<pages>386-392</pages>
		<journal_book_name>Archives of surgery (Chicago, Ill. : 1960)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3827">
		<reference_name>Aspord et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Aspord C, Charles J, Leccia MT, Laurin D, Richard MJ, Chaperot L, Plumas J</authors>
		<title>A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells</title>
		<year>2010</year>
		<volume>5</volume>
		<issue>5</issue>
		<pages>e10458</pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3929">
		<reference_name>Aspord et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Aspord C, Leccia MT, Salameire D, Laurin D, Chaperot L, Charles J, Plumas J</authors>
		<title>HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients</title>
		<year>2012</year>
		<volume>132</volume>
		<issue>10</issue>
		<pages>2395-2406</pages>
		<journal_book_name>The Journal of investigative dermatology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3882">
		<reference_name>Atencio et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Atencio IA, Grace M, Bordens R, Fritz M, Horowitz JA, Hutchins B, Indelicato S, Jacobs S, Kolz K, Maneval D, Musco ML, Shinoda J, Venook A, Wen S, Warren R</authors>
		<title>Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial</title>
		<year>2006</year>
		<volume>13</volume>
		<issue>2</issue>
		<pages>169-181</pages>
		<journal_book_name>Cancer gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5189">
		<reference_name>Avril et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Avril T, Vauleon E, Hamlat A, Saikali S, Etcheverry A, Delmas C, Diabira S, Mosser J, Quillien V</authors>
		<title>Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells</title>
		<year>2012</year>
		<volume>22</volume>
		<issue>2</issue>
		<pages>159-174</pages>
		<journal_book_name>Brain pathology (Zurich, Switzerland)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5148">
		<reference_name>Ayyoub et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ayyoub M, Migliaccio M, Guillaume P, LiÃ©nard D, Cerottini JC, Romero P, LÃ©vy F, Speiser DE, Valmori D</authors>
		<title>Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing</title>
		<year>2001</year>
		<volume>31</volume>
		<issue>9</issue>
		<pages>2642-2651</pages>
		<journal_book_name>European journal of immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1295">
		<reference_name>Bae et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bae MY, Cho NH, Seong SY</authors>
		<title>Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli</title>
		<year>2009</year>
		<volume>157</volume>
		<issue>1</issue>
		<pages>128-138</pages>
		<journal_book_name>Clinical and experimental immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5310">
		<reference_name>Bae et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bae J, Smith R, Daley J, Mimura N, Tai YT, Anderson KC, Munshi NC</authors>
		<title>Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders</title>
		<year>2012</year>
		<volume>18</volume>
		<issue>17</issue>
		<pages>4850-4860</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2936">
		<reference_name>Baghdadi et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Baghdadi M, Nagao H, Yoshiyama H, Akiba H, Yagita H, Dosaka-Akita H, Jinushi M</authors>
		<title>Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas</title>
		<year>2013</year>
		<volume>62</volume>
		<issue>4</issue>
		<pages>629-637</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5114">
		<reference_name>Bahy et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bahy RH, Hamouda HM, Shahat AS, Yassin AS, Amin MA</authors>
		<title>Development and evaluation of a novel vaccine against prevalent invasive multi-drug resistant strains of <i>Streptococcus pneumoniae</i></title>
		<year>2016</year>
		<volume>4</volume>
		<issue></issue>
		<pages>e2737</pages>
		<journal_book_name>PeerJ</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2968">
		<reference_name>Baird et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik DJ, Bosenberg M, Mullins DW, Turk MJ, Fiering S</authors>
		<title>Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge</title>
		<year>2013</year>
		<volume>190</volume>
		<issue>1</issue>
		<pages>469-478</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2880">
		<reference_name>Baldueva et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Baldueva IA, Novik AV, Moiseenko VM, Nekhaeva TL, Danilova AB, Danilov AO, Protsenko SA, Petrova TIu, UleÃ„Â­skaia GI, Shchekina LA, Semenova AI, MikhaÃ„Â­lichenko TD, Teletaeva GM, Zhabina AS, Volkov NV, Komarov IuI</authors>
		<title>[Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients]</title>
		<year>2012</year>
		<volume>58</volume>
		<issue>2</issue>
		<pages>212-221</pages>
		<journal_book_name>Voprosy onkologii</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3995">
		<reference_name>Bartal and Robinson, 1987</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bartal AH, Robinson E</authors>
		<title>Novel approach to MER/BCG administration in cancer patients</title>
		<year>1987</year>
		<volume>5</volume>
		<issue>1</issue>
		<pages>1-5</pages>
		<journal_book_name>Cancer investigation</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4014">
		<reference_name>Bartholomew et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R</authors>
		<title>Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo</title>
		<year>2002</year>
		<volume>30</volume>
		<issue>1</issue>
		<pages>42-48</pages>
		<journal_book_name>Experimental hematology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1900">
		<reference_name>Basak et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Basak S, Eck S, Gutzmer R, Smith AJ, Birebent B, Purev E, Staib L, Somasundaram R, Zaloudik J, Li W, Jacob L, Mitchell E, Speicher D, Herlyn D</authors>
		<title>Colorectal cancer vaccines: antiidiotypic antibody, recombinant protein, and viral vector</title>
		<year>2000</year>
		<volume>910</volume>
		<issue></issue>
		<pages>237-252</pages>
		<journal_book_name>Annals of the New York Academy of Sciences</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5237">
		<reference_name>Battiwalla and Hematti, 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Battiwalla M, Hematti P</authors>
		<title>Mesenchymal stem cells in hematopoietic stem cell transplantation</title>
		<year>2009</year>
		<volume>11</volume>
		<issue>5</issue>
		<pages>503-515</pages>
		<journal_book_name>Cytotherapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5241">
		<reference_name>Baudard et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Baudard M, Comte F, Conge AM, Mariano-Goulart D, Klein B, Rossi JF</authors>
		<title>Importance of [18F]fluorodeoxyglucose-positron emission tomography scanning for the monitoring of responses to immunotherapy in follicular lymphoma</title>
		<year>2007</year>
		<volume>48</volume>
		<issue>2</issue>
		<pages>381-388</pages>
		<journal_book_name>Leukemia &amp; lymphoma</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3833">
		<reference_name>Baxter et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Baxter R, Hansen J, Timbol J, Pool V, Greenberg DP, Johnson DR, Decker MD</authors>
		<title>Post-licensure safety surveillance study of routine use of tetanus toxoid, reduced diphtheria toxoid and 5-component acellular pertussis vaccine</title>
		<year>2016</year>
		<volume>12</volume>
		<issue>11</issue>
		<pages>2742-2748</pages>
		<journal_book_name>Human vaccines &amp; immunotherapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4022">
		<reference_name>Beachler et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Beachler DC, Kreimer AR, Schiffman M, Herrero R, Wacholder S, Rodriguez AC, Lowy DR, Porras C, Schiller JT, Quint W, Jimenez S, Safaeian M, Struijk L, Schussler J, Hildesheim A, Gonzalez P</authors>
		<title>Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection</title>
		<year>2016</year>
		<volume>108</volume>
		<issue>1</issue>
		<pages></pages>
		<journal_book_name>Journal of the National Cancer Institute</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1291">
		<reference_name>Becker et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG</authors>
		<title>DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer</title>
		<year>2010</year>
		<volume>33</volume>
		<issue>6</issue>
		<pages>639-647</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3985">
		<reference_name>Beebe et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Beebe M, Qin M, Moi M, Wu S, Heiati H, Walker L, Newman M, Fikes J, Ishioka GY</authors>
		<title>Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy</title>
		<year>2008</year>
		<volume>4</volume>
		<issue>3</issue>
		<pages>210-218</pages>
		<journal_book_name>Human vaccines</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3006">
		<reference_name>Benteyn et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Benteyn D, Van Nuffel AM, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A</authors>
		<title>Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL)</title>
		<year>2013</year>
		<volume>2013</volume>
		<issue></issue>
		<pages>976383</pages>
		<journal_book_name>BioMed research international</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference955">
		<reference_name>Benvenuti et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Benvenuti F, Burrone OR, Efremov DG</authors>
		<title>Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection</title>
		<year>2000</year>
		<volume>7</volume>
		<issue>7</issue>
		<pages>605-611</pages>
		<journal_book_name>Gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2928">
		<reference_name>Berd et al., 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Berd D, Maguire HC Jr, Schuchter LM, Hamilton R, Hauck WW, Sato T, Mastrangelo MJ</authors>
		<title>Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases</title>
		<year>1997</year>
		<volume>15</volume>
		<issue>6</issue>
		<pages>2359-2370</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3868">
		<reference_name>Berd et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Berd D, Sato T, Cohn H, Maguire HC Jr, Mastrangelo MJ</authors>
		<title>Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases</title>
		<year>2001</year>
		<volume>94</volume>
		<issue>4</issue>
		<pages>531-539</pages>
		<journal_book_name>International journal of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3905">
		<reference_name>Berd et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ</authors>
		<title>Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine</title>
		<year>2004</year>
		<volume>22</volume>
		<issue>3</issue>
		<pages>403-415</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2349">
		<reference_name>Bergman et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, Wulderk M, Jeffers Y, Sadelain M, Hohenhaus AE, Segal N, Gregor P, Engelhorn M, Riviere I, Houghton AN, Wolchok JD</authors>
		<title>Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial</title>
		<year>2003</year>
		<volume>9</volume>
		<issue>4</issue>
		<pages>1284-1290</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4023">
		<reference_name>Berinstein et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, Weir GM, Stanford MM, Mansour M</authors>
		<title>First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients</title>
		<year>2012</year>
		<volume>10</volume>
		<issue></issue>
		<pages>156</pages>
		<journal_book_name>Journal of translational medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1294">
		<reference_name>Bernhardt et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bernhardt SL, Gjertsen MK, Trachsel S, MÃ¸ller M, Eriksen JA, Meo M, Buanes T, Gaudernack G</authors>
		<title>Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study</title>
		<year>2006</year>
		<volume>95</volume>
		<issue>11</issue>
		<pages>1474-1482</pages>
		<journal_book_name>British journal of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5139">
		<reference_name>Bernstein et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bernstein MB, Chakraborty M, Wansley EK, Guo Z, Franzusoff A, MostbÃ¶ck S, Sabzevari H, Schlom J, Hodge JW</authors>
		<title>Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells</title>
		<year>2008</year>
		<volume>26</volume>
		<issue>4</issue>
		<pages>509-521</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5273">
		<reference_name>Bertino et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bertino P, Panigada M, Soprana E, Bianchi V, Bertilaccio S, Sanvito F, Rose AH, Yang H, Gaudino G, Hoffmann PR, Siccardi A, Carbone M</authors>
		<title>Fowlpox-based survivin vaccination for malignant mesothelioma therapy</title>
		<year>2013</year>
		<volume>133</volume>
		<issue>3</issue>
		<pages>612-623</pages>
		<journal_book_name>International journal of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3862">
		<reference_name>Berzofsky et al., 1991</reference_name>
		<reference_type>journal</reference_type>
		<authors>Berzofsky JA, Pendleton CD, Clerici M, Ahlers J, Lucey DR, Putney SD, Shearer GM</authors>
		<title>Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types</title>
		<year>1991</year>
		<volume>88</volume>
		<issue>3</issue>
		<pages>876-884</pages>
		<journal_book_name>The Journal of clinical investigation</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3889">
		<reference_name>Berzofsky et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Berzofsky JA, Ahlers JD, Belyakov IM</authors>
		<title>Strategies for designing and optimizing new generation vaccines</title>
		<year>2001</year>
		<volume>1</volume>
		<issue>3</issue>
		<pages>209-219</pages>
		<journal_book_name>Nature reviews. Immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5194">
		<reference_name>Berzofsky et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC</authors>
		<title>Progress on new vaccine strategies for the immunotherapy and prevention of cancer</title>
		<year>2004</year>
		<volume>113</volume>
		<issue>11</issue>
		<pages>1515-1525</pages>
		<journal_book_name>The Journal of clinical investigation</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2923">
		<reference_name>Bettinotti et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bettinotti MP, Panelli MC, Ruppe E, Mocellin S, Phan GQ, White DE, Marincola FM</authors>
		<title>Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178</title>
		<year>2003</year>
		<volume>105</volume>
		<issue>2</issue>
		<pages>210-216</pages>
		<journal_book_name>International journal of cancer. Journal international du cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2949">
		<reference_name>Bilgi et al., 1979</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bilgi C, Brown NE, McPherson TA, Lentle B</authors>
		<title>Pulmonary manifestations in patients with malignant melanoma during BCG immunotherapy. A preliminary report</title>
		<year>1979</year>
		<volume>75</volume>
		<issue>6</issue>
		<pages>685-687</pages>
		<journal_book_name>Chest</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3959">
		<reference_name>Bjoern et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bjoern J, Iversen TZ, Nitschke NJ, Andersen MH, Svane IM</authors>
		<title>Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab</title>
		<year>2016</year>
		<volume>18</volume>
		<issue>8</issue>
		<pages>1043-1055</pages>
		<journal_book_name>Cytotherapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4046">
		<reference_name>Boczkowski et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Boczkowski D, Lee J, Pruitt S, Nair S</authors>
		<title>Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy</title>
		<year>2009</year>
		<volume>16</volume>
		<issue>12</issue>
		<pages>900-911</pages>
		<journal_book_name>Cancer gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5180">
		<reference_name>Bollard et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bollard CM, Gottschalk S, Helen Huls M, Leen AM, Gee AP, Rooney CM</authors>
		<title>Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma</title>
		<year>2011</year>
		<volume>13</volume>
		<issue>5</issue>
		<pages>518-522</pages>
		<journal_book_name>Cytotherapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5246">
		<reference_name>Borch et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Borch TH, Engell-Noerregaard L, Zeeberg Iversen T, Ellebaek E, Met Ã–, Hansen M, Andersen MH, Thor Straten P, Svane IM</authors>
		<title>mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma</title>
		<year>2016</year>
		<volume>5</volume>
		<issue>9</issue>
		<pages>e1207842</pages>
		<journal_book_name>Oncoimmunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3944">
		<reference_name>Borrello et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Borrello IM, Levitsky HI, Stock W, Sher D, Qin L, DeAngelo DJ, Alyea EP, Stone RM, Damon LE, Linker CA, Maslyar DJ, Hege KM</authors>
		<title>Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)</title>
		<year>2009</year>
		<volume>114</volume>
		<issue>9</issue>
		<pages>1736-1745</pages>
		<journal_book_name>Blood</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3826">
		<reference_name>Bramante et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bramante S, Koski A, Kipar A, Diaconu I, Liikanen I, Hemminki O, Vassilev L, Parviainen S, Cerullo V, Pesonen SK, Oksanen M, Heiskanen R, Rouvinen-Lagerstrï¿½m N, Merisalo-Soikkeli M, Hakonen T, Joensuu T, Kanerva A, Pesonen S, Hemminki A</authors>
		<title>Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans</title>
		<year>2014</year>
		<volume>135</volume>
		<issue>3</issue>
		<pages>720-730</pages>
		<journal_book_name>International journal of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3867">
		<reference_name>Braun et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Braun M, Jandus C, Maurer P, Hammann-Haenni A, Schwarz K, Bachmann MF, Speiser DE, Romero P</authors>
		<title>Virus-like particles induce robust human T-helper cell responses</title>
		<year>2012</year>
		<volume>42</volume>
		<issue>2</issue>
		<pages>330-340</pages>
		<journal_book_name>European journal of immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5173">
		<reference_name>Brayer et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Brayer J, Lancet JE, Powers J, List A, Balducci L, Komrokji R, Pinilla-Ibarz J</authors>
		<title>WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides</title>
		<year>2015</year>
		<volume>90</volume>
		<issue>7</issue>
		<pages>602-607</pages>
		<journal_book_name>American journal of hematology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3957">
		<reference_name>Brockstedt et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, Liu W, Cook DN, Portnoy DA, Dubensky TW Jr</authors>
		<title>Listeria-based cancer vaccines that segregate immunogenicity from toxicity</title>
		<year>2004</year>
		<volume>101</volume>
		<issue>38</issue>
		<pages>13832-13837</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1937">
		<reference_name>Brockstedt et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Brockstedt DG, Bahjat KS, Giedlin MA, Liu W, Leong M, Luckett W, Gao Y, Schnupf P, Kapadia D, Castro G, Lim JY, Sampson-Johannes A, Herskovits AA, Stassinopoulos A, Bouwer HG, Hearst JE, Portnoy DA, Cook DN, Dubensky TW Jr</authors>
		<title>Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity</title>
		<year>2005</year>
		<volume>11</volume>
		<issue>8</issue>
		<pages>853-860</pages>
		<journal_book_name>Nature medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1297">
		<reference_name>Broder et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Broder H, Anderson A, Odesa SK, Kremen TJ, Liau LM</authors>
		<title>Recombinant adenovirus-transduced dendritic cell immunization in a murine model of central nervous system tumor</title>
		<year>2000</year>
		<volume>9</volume>
		<issue>6</issue>
		<pages>e6</pages>
		<journal_book_name>Neurosurgical focus</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5172">
		<reference_name>Brooks et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Brooks SE, Bonney SA, Lee C, Publicover A, Khan G, Smits EL, Sigurdardottir D, Arno M, Li D, Mills KI, Pulford K, Banham AH, van Tendeloo V, Mufti GJ, Rammensee HG, Elliott TJ, Orchard KH, Guinn BA</authors>
		<title>Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis</title>
		<year>2015</year>
		<volume>10</volume>
		<issue>10</issue>
		<pages>e0140483</pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5266">
		<reference_name>Brun et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Brun JL, Rajaonarison J, Nocart N, Hoarau L, Brun S, Garrigue I</authors>
		<title>Targeted immunotherapy of high-grade cervical intra-epithelial neoplasia: Expectations from clinical trials</title>
		<year>2018</year>
		<volume>8</volume>
		<issue>2</issue>
		<pages>227-235</pages>
		<journal_book_name>Molecular and clinical oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2339">
		<reference_name>Buchan et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Buchan S, GrÃƒÂ¸nevik E, Mathiesen I, King CA, Stevenson FK, Rice J</authors>
		<title>Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen</title>
		<year>2005</year>
		<volume>174</volume>
		<issue>10</issue>
		<pages>6292-6298</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3893">
		<reference_name>Burke et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, Aimi J, Lerner S, Yeung AW, Kazarian T, Maslyar DJ, McKiernan JM</authors>
		<title>A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer</title>
		<year>2012</year>
		<volume>188</volume>
		<issue>6</issue>
		<pages>2391-2397</pages>
		<journal_book_name>The Journal of urology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5251">
		<reference_name>Burkhardt et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Burkhardt UE, Hainz U, Stevenson K, Goldstein NR, Pasek M, Naito M, Wu D, Ho VT, Alonso A, Hammond NN, Wong J, Sievers QL, Brusic A, McDonough SM, Zeng W, Perrin A, Brown JR, Canning CM, Koreth J, Cutler C, Armand P, Neuberg D, Lee JS, Antin JH, Mulligan RC, Sasada T, Ritz J, Soiffer RJ, Dranoff G, Alyea EP, Wu CJ</authors>
		<title>Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells</title>
		<year>2013</year>
		<volume>123</volume>
		<issue>9</issue>
		<pages>3756-3765</pages>
		<journal_book_name>The Journal of clinical investigation</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5195">
		<reference_name>Butterfield et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, McBride WH, Finn R, Glaspy JA, Economou JS</authors>
		<title>A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides</title>
		<year>2006</year>
		<volume>12</volume>
		<issue>9</issue>
		<pages>2817-2825</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3884">
		<reference_name>Butterfield et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy JA, Economou JS, Ribas A</authors>
		<title>Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma</title>
		<year>2008</year>
		<volume>31</volume>
		<issue>3</issue>
		<pages>294-309</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3903">
		<reference_name>Butterfield et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Butterfield LH, Economou JS, Gamblin TC, Geller DA</authors>
		<title>Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients</title>
		<year>2014</year>
		<volume>12</volume>
		<issue></issue>
		<pages>86</pages>
		<journal_book_name>Journal of translational medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2959">
		<reference_name>Byrne et al., 1983</reference_name>
		<reference_type>journal</reference_type>
		<authors>Byrne MJ, Van Hazel G, Reynolds PM, Lemish WM, Holman CD</authors>
		<title>Adjuvant immunotherapy with BCG in stage II malignant melanoma</title>
		<year>1983</year>
		<volume>23</volume>
		<issue>2</issue>
		<pages>114-116</pages>
		<journal_book_name>Journal of surgical oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3909">
		<reference_name>Cacciavillano et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cacciavillano W, Sampor C, Venier C, Gabri MR, de Dï¿½vila MT, Galluzzo ML, Guthmann MD, Fainboim L, Alonso DF, Chantada GL</authors>
		<title>A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies</title>
		<year>2015</year>
		<volume>62</volume>
		<issue>12</issue>
		<pages>2120-2124</pages>
		<journal_book_name>Pediatric blood &amp; cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference952">
		<reference_name>Campbell et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Campbell I, Moyana T, Carlsen S, Zheng C, Xiang J</authors>
		<title>Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth</title>
		<year>2000</year>
		<volume>7</volume>
		<issue>1</issue>
		<pages>37-44</pages>
		<journal_book_name>Cancer gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2942">
		<reference_name>Campisano et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Campisano S, Mac Keon S, Gazzaniga S, Ruiz MS, Traian MD, Mordoh J, Wainstok R</authors>
		<title>Anti-melanoma vaccinal capacity of CD11c-positive and -negative cell populations present in GM-CSF cultures derived from murine bone marrow precursors</title>
		<year>2013</year>
		<volume>31</volume>
		<issue>2</issue>
		<pages>354-361</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5254">
		<reference_name>Carbone et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Carbone DP, Ciernik IF, Kelley MJ, Smith MC, Nadaf S, Kavanaugh D, Maher VE, Stipanov M, Contois D, Johnson BE, Pendleton CD, Seifert B, Carter C, Read EJ, Greenblatt J, Top LE, Kelsey MI, Minna JD, Berzofsky JA</authors>
		<title>Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome</title>
		<year>2005</year>
		<volume>23</volume>
		<issue>22</issue>
		<pages>5099-5107</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2367">
		<reference_name>Carpentier et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Carpentier AF, Rosenfeld MR, Delattre JY, Whalen RG, Posner JB, Dalmau J</authors>
		<title>DNA vaccination with HuD inhibits growth of a neuroblastoma in mice</title>
		<year>1998</year>
		<volume>4</volume>
		<issue>11</issue>
		<pages>2819-2824</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2993">
		<reference_name>Carreno et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Carreno BM, Becker-Hapak M, Huang A, Chan M, Alyasiry A, Lie WR, Aft RL, Cornelius LA, Trinkaus KM, Linette GP</authors>
		<title>IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity</title>
		<year>2013</year>
		<volume>123</volume>
		<issue>8</issue>
		<pages>3383-3394</pages>
		<journal_book_name>The Journal of clinical investigation</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4040">
		<reference_name>Carter and Plosker, 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Carter NJ, Plosker GL</authors>
		<title>Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus</title>
		<year>2008</year>
		<volume>22</volume>
		<issue>5</issue>
		<pages>279-292</pages>
		<journal_book_name>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5283">
		<reference_name>Cassaday et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cassaday RD, Sondel PM, King DM, Macklin MD, Gan J, Warner TF, Zuleger CL, Bridges AJ, Schalch HG, Kim KM, Hank JA, Mahvi DM, Albertini MR</authors>
		<title>A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients</title>
		<year>2007</year>
		<volume>13</volume>
		<issue>2 Pt 1</issue>
		<pages>540-549</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2943">
		<reference_name>Cassel et al., 1983</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cassel WA, Murray DR, Phillips HS</authors>
		<title>A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate</title>
		<year>1983</year>
		<volume>52</volume>
		<issue>5</issue>
		<pages>856-860</pages>
		<journal_book_name>Cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2939">
		<reference_name>Castel et al., 1991</reference_name>
		<reference_type>journal</reference_type>
		<authors>Castel T, EstapÃƒÂ© J, ViÃƒÂ±olas N, MascarÃƒÂ³ JM, Castro J, Vilalta A, GratacÃƒÂ³s R, Daniels M, Palou J, Grau JJ</authors>
		<title>Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy</title>
		<year>1991</year>
		<volume>183</volume>
		<issue>1</issue>
		<pages>25-30</pages>
		<journal_book_name>Dermatologica</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3981">
		<reference_name>Chaise et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Chaise C, Buchan SL, Rice J, Marquet J, Rouard H, Kuentz M, Vittes GE, Molinier-Frenkel V, Farcet JP, Stauss HJ, Delfau-Larue MH, Stevenson FK</authors>
		<title>DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance</title>
		<year>2008</year>
		<volume>112</volume>
		<issue>7</issue>
		<pages>2956-2964</pages>
		<journal_book_name>Blood</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3928">
		<reference_name>Charoensit et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Charoensit P, Kawakami S, Higuchi Y, Hashida M</authors>
		<title>Incorporation of all-trans retinoic acid into lipoplexes inhibits nuclear factor kappaB activation mediated liver injury induced by lipoplexes in mice</title>
		<year>2008</year>
		<volume>10</volume>
		<issue>1</issue>
		<pages>61-69</pages>
		<journal_book_name>The journal of gene medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference970">
		<reference_name>Chen et al., 1994</reference_name>
		<reference_type>journal</reference_type>
		<authors>Chen L, McGowan P, Ashe S, Johnston JV, HellstrÃ¶m I, HellstrÃ¶m KE</authors>
		<title>B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum</title>
		<year>1994</year>
		<volume>54</volume>
		<issue>20</issue>
		<pages>5420-5423</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference958">
		<reference_name>Chen et al., 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Chen K, Braun S, Lyman S, Fan Y, Traycoff CM, Wiebke EA, Gaddy J, Sledge G, Broxmeyer HE, Cornetta K</authors>
		<title>Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model</title>
		<year>1997</year>
		<volume>57</volume>
		<issue>16</issue>
		<pages>3511-3516</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2912">
		<reference_name>Chen et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Chen J, Zhang L, Wen W, Hao J, Zeng P, Qian X, Zhang Y, Yin Y</authors>
		<title>Induction of HCA587-specific antitumor immunity with HCA587 protein formulated with CpG and ISCOM in mice</title>
		<year>2012</year>
		<volume>7</volume>
		<issue>10</issue>
		<pages>e47219</pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3935">
		<reference_name>Chen et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram JN, Dauses T, Fetting J, Duus EM, Atay-Rosenthal S, Ye X, Wolff AC, Stearns V, Jaffee EM, Emens LA</authors>
		<title>A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer</title>
		<year>2014</year>
		<volume>2</volume>
		<issue>10</issue>
		<pages>949-961</pages>
		<journal_book_name>Cancer immunology research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3844">
		<reference_name>Chen et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Chen JL, Dawoodji A, Tarlton A, Gnjatic S, Tajar A, Karydis I, Browning J, Pratap S, Verfaille C, Venhaus RR, Pan L, Altman DG, Cebon JS, Old LL, Nathan P, Ottensmeier C, Middleton M, Cerundolo V</authors>
		<title>NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus</title>
		<year>2015</year>
		<volume>136</volume>
		<issue>6</issue>
		<pages>E590-601</pages>
		<journal_book_name>International journal of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5278">
		<reference_name>Chen et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Chen J, Guo XZ, Li HY, Zhao JJ, Xu WD</authors>
		<title>Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer <i>in vitro</i></title>
		<year>2017</year>
		<volume>23</volume>
		<issue>5</issue>
		<pages>817-829</pages>
		<journal_book_name>World journal of gastroenterology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5232">
		<reference_name>Chiappori et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI</authors>
		<title>INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect</title>
		<year>2010</year>
		<volume>10</volume>
		<issue>6</issue>
		<pages>983-991</pages>
		<journal_book_name>Expert opinion on biological therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5225">
		<reference_name>Chodon et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A</authors>
		<title>Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma</title>
		<year>2014</year>
		<volume>20</volume>
		<issue>9</issue>
		<pages>2457-2465</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1306">
		<reference_name>Choi et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Choi Y, Jeon YH, Kang JH, Chung JK, Schmidt M, Kim AC</authors>
		<title>MIDGE/hNIS vaccination generates antigen-associated CD8+IFN-gamma+ T cells and enhances protective antitumor immunity</title>
		<year>2007</year>
		<volume>120</volume>
		<issue>9</issue>
		<pages>1942-1950</pages>
		<journal_book_name>International journal of cancer. Journal international du cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2350">
		<reference_name>Chudley et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Chudley L, McCann K, Mander A, Tjelle T, Campos-Perez J, Godeseth R, Creak A, Dobbyn J, Johnson B, Bass P, Heath C, Kerr P, Mathiesen I, Dearnaley D, Stevenson F, Ottensmeier C</authors>
		<title>DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time</title>
		<year>2012</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3986">
		<reference_name>Clark et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I</authors>
		<title>Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine</title>
		<year>2009</year>
		<volume>361</volume>
		<issue>25</issue>
		<pages>2424-2435</pages>
		<journal_book_name>The New England journal of medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4011">
		<reference_name>Clerici et al., 1991</reference_name>
		<reference_type>journal</reference_type>
		<authors>Clerici M, Lucey DR, Zajac RA, Boswell RN, Gebel HM, Takahashi H, Berzofsky JA, Shearer GM</authors>
		<title>Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals</title>
		<year>1991</year>
		<volume>146</volume>
		<issue>7</issue>
		<pages>2214-2219</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2958">
		<reference_name>Clunie et al., 1980</reference_name>
		<reference_type>journal</reference_type>
		<authors>Clunie GJ, Gough IR, Dury M, Furnival CM, Bolton PM</authors>
		<title>A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results</title>
		<year>1980</year>
		<volume>46</volume>
		<issue>3</issue>
		<pages>475-479</pages>
		<journal_book_name>Cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5284">
		<reference_name>Cochlovius et al., 1999</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cochlovius B, Linnebacher M, Zewe-Welschof M, ZÃ¶ller M</authors>
		<title>Recombinant gp100 protein presented by dendritic cells elicits a T-helper-cell response in vitro and in vivo</title>
		<year>1999</year>
		<volume>83</volume>
		<issue>4</issue>
		<pages>547-554</pages>
		<journal_book_name>International journal of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2361">
		<reference_name>Cochlovius et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cochlovius B, Stassar MJ, Schreurs MW, Benner A, Adema GJ</authors>
		<title>Oral DNA vaccination: antigen uptake and presentation by dendritic cells elicits protective immunity</title>
		<year>2002</year>
		<volume>80</volume>
		<issue>2</issue>
		<pages>89-96</pages>
		<journal_book_name>Immunology letters</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2945">
		<reference_name>Cochran et al., 1981</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cochran AJ, Buyse ME, Lejeune FJ, Macher E, Revuz J, RÃƒÂ¼mke P</authors>
		<title>Adjuvant reactivity predicts survival in patients with "high-risk" primary malignant melanoma treated with systemic BCG. EORTC Malignant Melanoma Cooperative Group Writing Committee</title>
		<year>1981</year>
		<volume>28</volume>
		<issue>5</issue>
		<pages>543-550</pages>
		<journal_book_name>International journal of cancer. Journal international du cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5376">
		<reference_name>Cohen and Rudin, 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cohen EE, Rudin CM</authors>
		<title>ONYX-015. Onyx Pharmaceuticals</title>
		<year>2001</year>
		<volume>2</volume>
		<issue>12</issue>
		<pages>1770-1775</pages>
		<journal_book_name>Current opinion in investigational drugs (London, England : 2000)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2953">
		<reference_name>Cohen et al., 1978</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cohen MH, Jessup JM, Felix EL, Weese JL, Herberman RB</authors>
		<title>Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene</title>
		<year>1978</year>
		<volume>41</volume>
		<issue>6</issue>
		<pages>2456-2463</pages>
		<journal_book_name>Cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5217">
		<reference_name>Cohen et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cohen CJ, Zheng Z, Bray R, Zhao Y, Sherman LA, Rosenberg SA, Morgan RA</authors>
		<title>Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR</title>
		<year>2005</year>
		<volume>175</volume>
		<issue>9</issue>
		<pages>5799-5808</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference954">
		<reference_name>Cohen et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, Sakaguchi S, Houghton AN</authors>
		<title>Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity</title>
		<year>2006</year>
		<volume>66</volume>
		<issue>9</issue>
		<pages>4904-4912</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2342">
		<reference_name>Conry et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Conry RM, Curiel DT, Strong TV, Moore SE, Allen KO, Barlow DL, Shaw DR, LoBuglio AF</authors>
		<title>Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients</title>
		<year>2002</year>
		<volume>8</volume>
		<issue>9</issue>
		<pages>2782-2787</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5355">
		<reference_name>Cornelissen et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Cornelissen R, Hegmans JP, Maat AP, Kaijen-Lambers ME, Bezemer K, Hendriks RW, Hoogsteden HC, Aerts JG</authors>
		<title>Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma</title>
		<year>2016</year>
		<volume>193</volume>
		<issue>9</issue>
		<pages>1023-1031</pages>
		<journal_book_name>American journal of respiratory and critical care medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4006">
		<reference_name>Corrales-Rodriguez et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Corrales-Rodriguez L, Blais N, Souliï¿½res D</authors>
		<title>Emepepimut-S for non-small cell lung cancer</title>
		<year>2011</year>
		<volume>11</volume>
		<issue>8</issue>
		<pages>1091-1097</pages>
		<journal_book_name>Expert opinion on biological therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5123">
		<reference_name>Correale et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY</authors>
		<title>Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide</title>
		<year>1998</year>
		<volume>161</volume>
		<issue>6</issue>
		<pages>3186-3194</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3968">
		<reference_name>Correale et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete SP, Tsang KY, Micheli L, Nencini C, La Placa M, Montagnani F, Terrosi C, Caraglia M, Formica V, Giorgi G, Bonmassar E, Francini G</authors>
		<title>Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro</title>
		<year>2005</year>
		<volume>175</volume>
		<issue>2</issue>
		<pages>820-828</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3898">
		<reference_name>Crum et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Crum CP, Beach KJ, Hedley ML, Yuan L, Lee KR, Wright TC, Urban RG</authors>
		<title>Dynamics of human papillomavirus infection between biopsy and excision of cervical intraepithelial neoplasia: results from the ZYC101a protocol</title>
		<year>2004</year>
		<volume>189</volume>
		<issue>8</issue>
		<pages>1348-1354</pages>
		<journal_book_name>The Journal of infectious diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2963">
		<reference_name>Culos and Cuellar, 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Culos KA, Cuellar S</authors>
		<title>Novel targets in the treatment of advanced melanoma: new first-line treatment options</title>
		<year>2013</year>
		<volume>47</volume>
		<issue>4</issue>
		<pages>519-526</pages>
		<journal_book_name>The Annals of pharmacotherapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3954">
		<reference_name>Curigliano et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Curigliano G, Romieu G, Campone M, Dorval T, Duck L, Canon JL, Roemer-Becuwe C, Roselli M, Neciosup S, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF</authors>
		<title>A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer</title>
		<year>2016</year>
		<volume>156</volume>
		<issue>2</issue>
		<pages>301-310</pages>
		<journal_book_name>Breast cancer research and treatment</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2956">
		<reference_name>Currie and McElwain, 1975</reference_name>
		<reference_type>journal</reference_type>
		<authors>Currie GA, McElwain TJ</authors>
		<title>Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study</title>
		<year>1975</year>
		<volume>31</volume>
		<issue>2</issue>
		<pages>143-156</pages>
		<journal_book_name>British journal of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3919">
		<reference_name>Czerniecki et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Czerniecki BJ, Roses RE, Koski GK</authors>
		<title>Development of vaccines for high-risk ductal carcinoma in situ of the breast</title>
		<year>2007</year>
		<volume>67</volume>
		<issue>14</issue>
		<pages>6531-6534</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3998">
		<reference_name>Czerniecki et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, Weinstein S, Orel SG, Vonderheide R, Coukos G, DeMichele A, Araujo L, Spitz FR, Rosen M, Levine BL, June C, Zhang PJ</authors>
		<title>Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion</title>
		<year>2007</year>
		<volume>67</volume>
		<issue>4</issue>
		<pages>1842-1852</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3996">
		<reference_name>D'Souza et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>D'Souza G, Westra WH, Wang SJ, van Zante A, Wentz A, Kluz N, Rettig E, Ryan WR, Ha PK, Kang H, Bishop J, Quon H, Kiess AP, Richmon JD, Eisele DW, Fakhry C</authors>
		<title>Differences in the Prevalence of Human Papillomavirus (HPV) in Head and Neck Squamous Cell Cancers by Sex, Race, Anatomic Tumor Site, and HPV Detection Method</title>
		<year>2016</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name>JAMA oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5178">
		<reference_name>Dalet et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Dalet A, Stroobant V, Vigneron N, Van den Eynde BJ</authors>
		<title>Differences in the production of spliced antigenic peptides by the standard proteasome and the immunoproteasome</title>
		<year>2011</year>
		<volume>41</volume>
		<issue>1</issue>
		<pages>39-46</pages>
		<journal_book_name>European journal of immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4034">
		<reference_name>Daley et al., 1978</reference_name>
		<reference_type>journal</reference_type>
		<authors>Daley MJ, Gebel HM, Lynch RG</authors>
		<title>Idiotype-specific transplantation resistance to MOPC-315: abrogation by post-immunization thymectomy</title>
		<year>1978</year>
		<volume>120</volume>
		<issue>5</issue>
		<pages>1620-1624</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3853">
		<reference_name>Date et al., 1996</reference_name>
		<reference_type>journal</reference_type>
		<authors>Date Y, Kimura A, Kato H, Sasazuki T</authors>
		<title>DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese</title>
		<year>1996</year>
		<volume>47</volume>
		<issue>2</issue>
		<pages>93-101</pages>
		<journal_book_name>Tissue antigens</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4001">
		<reference_name>Dauer et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Dauer M, Herten J, Bauer C, Renner F, Schad K, Schnurr M, Endres S, Eigler A</authors>
		<title>Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells</title>
		<year>2005</year>
		<volume>28</volume>
		<issue>4</issue>
		<pages>332-342</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5244">
		<reference_name>de et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>de Rosa F, Ridolfi L, Ridolfi R, Gentili G, Valmorri L, Nanni O, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Riccobon A, Parisi E, Romeo A, Turci L, Guidoboni M</authors>
		<title>Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-Î± in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study</title>
		<year>2014</year>
		<volume>12</volume>
		<issue></issue>
		<pages>209</pages>
		<journal_book_name>Journal of translational medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5262">
		<reference_name>Deacon et al., 1982</reference_name>
		<reference_type>journal</reference_type>
		<authors>Deacon SP, Langford DT, Shepherd WM, Knight PA</authors>
		<title>A comparative clinical study of Adsorbed Tetanus Vaccine and Adult-type Tetanus-Diphtheria Vaccine</title>
		<year>1982</year>
		<volume>89</volume>
		<issue>3</issue>
		<pages>513-519</pages>
		<journal_book_name>The Journal of hygiene</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4030">
		<reference_name>Deans and Moseley, 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Deans RJ, Moseley AB</authors>
		<title>Mesenchymal stem cells: biology and potential clinical uses</title>
		<year>2000</year>
		<volume>28</volume>
		<issue>8</issue>
		<pages>875-884</pages>
		<journal_book_name>Experimental hematology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5299">
		<reference_name>Delhem et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Delhem N, Hadida F, Gorochov G, Carpentier F, de Cavel JP, AndrÃ©ani JF, Autran B, Cesbron JY</authors>
		<title>Primary Th1 cell immunization against HIVgp160 in SCID-hu mice coengrafted with peripheral blood lymphocytes and skin</title>
		<year>1998</year>
		<volume>161</volume>
		<issue>4</issue>
		<pages>2060-2069</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5337">
		<reference_name>Deng et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Deng W, Lira V, Hudson TE, Lemmens EE, Hanson WG, Flores R, Barajas G, Katibah GE, Desbien AL, Lauer P, Leong ML, Portnoy DA, Dubensky TW Jr</authors>
		<title>Recombinant <i>Listeria</i> promotes tumor rejection by CD8<sup>+</sup> T cell-dependent remodeling of the tumor microenvironment</title>
		<year>2018</year>
		<volume>115</volume>
		<issue>32</issue>
		<pages>8179-8184</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4044">
		<reference_name>Derrï¿½ et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Derrï¿½ L, Cesson V, Lucca I, Cerantola Y, Valerio M, Fritschi U, Vlamopoulos Y, Burruni R, Legris AS, Dartiguenave F, Gharbi D, Martin V, Vaucher L, Speiser DE, Romero P, Jichlinski P, Nardelli-Haefliger D</authors>
		<title>Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients</title>
		<year>2016</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5203">
		<reference_name>Desai et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Desai S, Rathi N, Kawade A, Venkatramanan P, Kundu R, Lalwani SK, Dubey AP, Venkateswara Rao J, Narayanappa D, Ghildiyal R, Gogtay NJ, Venugopal P, Palkar S, Munshi R, Bavdekar A, Juvekar S, Ganguly N, Niyogi P, Uttam KG, Kondekar A, Kumbhar D, Mohanlal S, Agarwal MC, Shetty P, Antony K, Gunale B, Dharmadhikari A, Deshpande J, Nalavade U, Sharma D, Bansal A, Tang Y, Flores J, Kulkarni PS</authors>
		<title>Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIILÂ® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine</title>
		<year>2018</year>
		<volume>36</volume>
		<issue>37</issue>
		<pages>5519-5523</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3958">
		<reference_name>Dessy et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, Pinto LA, Wettendorff MA</authors>
		<title>Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine</title>
		<year>2008</year>
		<volume>4</volume>
		<issue>6</issue>
		<pages>425-434</pages>
		<journal_book_name>Human vaccines</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3865">
		<reference_name>Dharmasena et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Dharmasena MN, Feuille CM, Starke CE, Bhagwat AA, Stibitz S, Kopecko DJ</authors>
		<title>Development of an Acid-Resistant Salmonella Typhi Ty21a Attenuated Vector For Improved Oral Vaccine Delivery</title>
		<year>2016</year>
		<volume>11</volume>
		<issue>9</issue>
		<pages>e0163511</pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4045">
		<reference_name>Di et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Di Y, Seymour L, Fisher K</authors>
		<title>Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood</title>
		<year>2014</year>
		<volume>21</volume>
		<issue>4</issue>
		<pages>440-443</pages>
		<journal_book_name>Gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3936">
		<reference_name>Dijkgraaf et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VT, Daemen TA, van der Hoeven JJ, Melief CJ, Welters MJ, Kroep JR, van der Burg SH</authors>
		<title>A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer</title>
		<year>2015</year>
		<volume>6</volume>
		<issue>31</issue>
		<pages>32228-32243</pages>
		<journal_book_name>Oncotarget</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5133">
		<reference_name>DiPaola et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, Manson K, Schuetz T</authors>
		<title>A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer</title>
		<year>2006</year>
		<volume>4</volume>
		<issue></issue>
		<pages>1</pages>
		<journal_book_name>Journal of translational medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5163">
		<reference_name>Downs-Canner et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Downs-Canner S, Guo ZS, Ravindranathan R, Breitbach CJ, O'Malley ME, Jones HL, Moon A, McCart JA, Shuai Y, Zeh HJ, Bartlett DL</authors>
		<title>Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers</title>
		<year>2016</year>
		<volume>24</volume>
		<issue>8</issue>
		<pages>1492-1501</pages>
		<journal_book_name>Molecular therapy : the journal of the American Society of Gene Therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2298">
		<reference_name>Drake, 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Drake CG</authors>
		<title>Update on prostate cancer vaccines</title>
		<year>2011</year>
		<volume>17</volume>
		<issue>5</issue>
		<pages>294-299</pages>
		<journal_book_name>Cancer journal (Sudbury, Mass.)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3860">
		<reference_name>Drugs R D, 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors></authors>
		<title>INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201</title>
		<year>2007</year>
		<volume>8</volume>
		<issue>3</issue>
		<pages>176-187</pages>
		<journal_book_name>Drugs in R&amp;D</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference960">
		<reference_name>Duan et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Duan HF, Hu XW, Chen JL, Gao LH, Xi YY, Lu Y, Li JF, Zhao SR, Xu JJ, Chen HP, Chen W, Wu CT</authors>
		<title>Antitumor activities of TEM8-Fc: an engineered antibody-like molecule targeting tumor endothelial marker 8</title>
		<year>2007</year>
		<volume>99</volume>
		<issue>20</issue>
		<pages>1551-1555</pages>
		<journal_book_name>Journal of the National Cancer Institute</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3921">
		<reference_name>Duggan et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Duggan MC, Jochems C, Donahue RN, Richards J, Karpa V, Foust E, Paul B, Brooks T, Tridandapani S, Olencki T, Pan X, Lesinski GB, Schlom J, Carson Iii WE</authors>
		<title>A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-?-2b in patients with CEA-expressing carcinomas</title>
		<year>2016</year>
		<volume>65</volume>
		<issue>11</issue>
		<pages>1353-1364</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2969">
		<reference_name>DurÃƒÂ¡n-Aniotz et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>DurÃƒÂ¡n-Aniotz C, Segal G, Salazar L, Pereda C, FalcÃƒÂ³n C, Tempio F, Aguilera R, GonzÃƒÂ¡lez R, PÃƒÂ©rez C, Tittarelli A, CatalÃƒÂ¡n D, Nervi B, Larrondo M, Salazar-Onfray F, LÃƒÂ³pez MN</authors>
		<title>The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses</title>
		<year>2013</year>
		<volume>62</volume>
		<issue>4</issue>
		<pages>761-772</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5141">
		<reference_name>Eder et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW</authors>
		<title>A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer</title>
		<year>2000</year>
		<volume>6</volume>
		<issue>5</issue>
		<pages>1632-1638</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5363">
		<reference_name>Eger et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Eger C, Siebert N, Seidel D, Zumpe M, JÃ¼ttner M, Brandt S, MÃ¼ller HP, Lode HN</authors>
		<title>Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma</title>
		<year>2016</year>
		<volume>11</volume>
		<issue>3</issue>
		<pages>e0150479</pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2961">
		<reference_name>El-Domeiri et al., 1978</reference_name>
		<reference_type>journal</reference_type>
		<authors>El-Domeiri AA, Das Gupta TK, Trippon M, Simo C, Sabet TY, Crispen R</authors>
		<title>Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma</title>
		<year>1978</year>
		<volume>146</volume>
		<issue>2</issue>
		<pages>230-232</pages>
		<journal_book_name>Surgery, gynecology &amp; obstetrics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2930">
		<reference_name>Elias et al., 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Elias EG, Suter CM, Fabian DS</authors>
		<title>Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide</title>
		<year>1997</year>
		<volume>64</volume>
		<issue>1</issue>
		<pages>17-22</pages>
		<journal_book_name>Journal of surgical oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5250">
		<reference_name>Elster et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Elster JD, Krishnadas DK, Lucas KG</authors>
		<title>Dendritic cell vaccines: A review of recent developments and their potential pediatric application</title>
		<year>2016</year>
		<volume>12</volume>
		<issue>9</issue>
		<pages>2232-2239</pages>
		<journal_book_name>Human vaccines &amp; immunotherapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3994">
		<reference_name>Embree et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Embree J, Law B, Voloshen T, Tomovici A</authors>
		<title>Immunogenicity, safety, and antibody persistence at 3, 5, and 10 years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1 month apart</title>
		<year>2015</year>
		<volume>22</volume>
		<issue>3</issue>
		<pages>282-290</pages>
		<journal_book_name>Clinical and vaccine immunology : CVI</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3838">
		<reference_name>Erbs et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Erbs P, Findeli A, Kintz J, Cordier P, Hoffmann C, Geist M, Balloul JM</authors>
		<title>Modified vaccinia virus Ankara as a vector for suicide gene therapy</title>
		<year>2008</year>
		<volume>15</volume>
		<issue>1</issue>
		<pages>18-28</pages>
		<journal_book_name>Cancer gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2352">
		<reference_name>Eschenburg et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Eschenburg G, Stermann A, Preissner R, Meyer HA, Lode HN</authors>
		<title>DNA vaccination: using the patient's immune system to overcome cancer</title>
		<year>2010</year>
		<volume>2010</volume>
		<issue></issue>
		<pages>169484</pages>
		<journal_book_name>Clinical &amp; developmental immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5196">
		<reference_name>EscribÃ -Garcia et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>EscribÃ -Garcia L, Alvarez-FernÃ¡ndez C, Tellez-Gabriel M, Sierra J, Briones J</authors>
		<title>Dendritic cells combined with tumor cells and Î±-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma</title>
		<year>2017</year>
		<volume>15</volume>
		<issue>1</issue>
		<pages>115</pages>
		<journal_book_name>Journal of translational medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2904">
		<reference_name>Eton et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Eton O, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Ellerhorst JA, Bedikian AY, Lee JE</authors>
		<title>Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma</title>
		<year>2010</year>
		<volume>8</volume>
		<issue></issue>
		<pages>9</pages>
		<journal_book_name>Journal of translational medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5179">
		<reference_name>Fagerberg et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Fagerberg L, HallstrÃ¶m BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S, Danielsson A, Edlund K, Asplund A, SjÃ¶stedt E, Lundberg E, Szigyarto CA, Skogs M, Takanen JO, Berling H, Tegel H, Mulder J, Nilsson P, Schwenk JM, Lindskog C, Danielsson F, Mardinoglu A, Sivertsson A, von Feilitzen K, Forsberg M, Zwahlen M, Olsson I, Navani S, Huss M, Nielsen J, Ponten F, UhlÃ©n M</authors>
		<title>Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics</title>
		<year>2014</year>
		<volume>13</volume>
		<issue>2</issue>
		<pages>397-406</pages>
		<journal_book_name>Molecular &amp; cellular proteomics : MCP</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3946">
		<reference_name>Fakhrai et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Fakhrai H, Mantil JC, Liu L, Nicholson GL, Murphy-Satter CS, Ruppert J, Shawler DL</authors>
		<title>Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma</title>
		<year>2006</year>
		<volume>13</volume>
		<issue>12</issue>
		<pages>1052-1060</pages>
		<journal_book_name>Cancer gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2355">
		<reference_name>Fang et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Fang J, Lu Y, Ouyang K, Wu G, Zhang H, Liu Y, Chen Y, Lin M, Wang H, Jin L, Cao R, Roque RS, Zong L, Liu J, Li T</authors>
		<title>Specific antibodies elicited by a novel DNA vaccine targeting gastrin-releasing peptide inhibit murine melanoma growth in vivo</title>
		<year>2009</year>
		<volume>16</volume>
		<issue>7</issue>
		<pages>1033-1039</pages>
		<journal_book_name>Clinical and vaccine immunology : CVI</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2906">
		<reference_name>Faries et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL</authors>
		<title>Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine</title>
		<year>2009</year>
		<volume>15</volume>
		<issue>22</issue>
		<pages>7029-7035</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference767">
		<reference_name>FDA: TICE BCG</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>FDA TICE BCG information</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM163039.pdf</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3937">
		<reference_name>Felizardo et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Felizardo TC, Wang JC, McGray RA, Evelegh C, Spaner DE, Fowler DH, Bramson JL, Medin JA</authors>
		<title>Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model</title>
		<year>2011</year>
		<volume>18</volume>
		<issue>10</issue>
		<pages>986-995</pages>
		<journal_book_name>Gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5308">
		<reference_name>Fenoglio et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Fenoglio D, Traverso P, Parodi A, Tomasello L, Negrini S, Kalli F, Battaglia F, Ferrera F, Sciallero S, Murdaca G, Setti M, Sobrero A, Boccardo F, Cittadini G, Puppo F, Criscuolo D, Carmignani G, Indiveri F, Filaci G</authors>
		<title>A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer</title>
		<year>2013</year>
		<volume>62</volume>
		<issue>6</issue>
		<pages>1041-1052</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference973">
		<reference_name>Fenton et al., 1993</reference_name>
		<reference_type>journal</reference_type>
		<authors>Fenton RG, Taub DD, Kwak LW, Smith MR, Longo DL</authors>
		<title>Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes</title>
		<year>1993</year>
		<volume>85</volume>
		<issue>16</issue>
		<pages>1294-1302</pages>
		<journal_book_name>Journal of the National Cancer Institute</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3840">
		<reference_name>Ferguson et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ferguson PJ, Sykelyk A, Figueredo R, Koropatnick J</authors>
		<title>Synergistic cytotoxicity against human tumor cell lines by oncolytic adenovirus dl1520 (ONYX-015) and melphalan</title>
		<year>2016</year>
		<volume>102</volume>
		<issue>1</issue>
		<pages>31-39</pages>
		<journal_book_name>Tumori</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1871">
		<reference_name>Fernando et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Fernando GJ, Stewart TJ, Tindle RW, Frazer IH</authors>
		<title>Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model</title>
		<year>1998</year>
		<volume>161</volume>
		<issue>5</issue>
		<pages>2421-2427</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3901">
		<reference_name>Fernando et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C</authors>
		<title>The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells</title>
		<year>2010</year>
		<volume>120</volume>
		<issue>2</issue>
		<pages>533-544</pages>
		<journal_book_name>The Journal of clinical investigation</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3965">
		<reference_name>Ferrara et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ferrara TA, Hodge JW, Gulley JL</authors>
		<title>Combining radiation and immunotherapy for synergistic antitumor therapy</title>
		<year>2009</year>
		<volume>11</volume>
		<issue>1</issue>
		<pages>37-42</pages>
		<journal_book_name>Current opinion in molecular therapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2902">
		<reference_name>Filipazzi et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, Maurichi A, Cova A, Rigamonti G, Giardino F, Di Florio A, Asioli M, Frati P, Sovena G, Squarcina P, Maio M, Danielli R, Chiarion-Sileni V, Villa A, Lombardo C, Tragni G, Santinami M, Parmiani G, Rivoltini L</authors>
		<title>Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides</title>
		<year>2012</year>
		<volume>18</volume>
		<issue>23</issue>
		<pages>6485-6496</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2909">
		<reference_name>Finocchiaro and Glikin, 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Finocchiaro LM, Glikin GC</authors>
		<title>Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up</title>
		<year>2012</year>
		<volume>19</volume>
		<issue>12</issue>
		<pages>852-861</pages>
		<journal_book_name>Cancer gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3877">
		<reference_name>Fishman et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee JH, Cantor A, Messina J, Seigne J, Pow-Sang J, Janssen W, Antonia SJ</authors>
		<title>Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma</title>
		<year>2008</year>
		<volume>31</volume>
		<issue>1</issue>
		<pages>72-80</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5177">
		<reference_name>Flickinger et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Flickinger JC Jr, Rodeck U, Snook AE</authors>
		<title><i>Listeria monocytogenes</i> as a Vector for Cancer Immunotherapy: Current Understanding and Progress</title>
		<year>2018</year>
		<volume>6</volume>
		<issue>3</issue>
		<pages></pages>
		<journal_book_name>Vaccines</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3922">
		<reference_name>Flores et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Flores RM, Zakowski M, Venkatraman E, Krug L, Rosenzweig K, Dycoco J, Lee C, Yeoh C, Bains M, Rusch V</authors>
		<title>Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center</title>
		<year>2007</year>
		<volume>2</volume>
		<issue>10</issue>
		<pages>957-965</pages>
		<journal_book_name>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1298">
		<reference_name>Fontana et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Fontana R, Bregni M, Cipponi A, Raccosta L, Rainelli C, Maggioni D, Lunghi F, Ciceri F, Mukenge S, Doglioni C, Colau D, Coulie PG, Bordignon C, Traversari C, Russo V</authors>
		<title>Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients</title>
		<year>2009</year>
		<volume>113</volume>
		<issue>8</issue>
		<pages>1651-1660</pages>
		<journal_book_name>Blood</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3847">
		<reference_name>Fotin-Mleczek et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojki?-Zrna S, Probst J, Kallen KJ</authors>
		<title>Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity</title>
		<year>2011</year>
		<volume>34</volume>
		<issue>1</issue>
		<pages>1-15</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2911">
		<reference_name>Fourcade et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, Krieg A, Donnenberg A, Shen H, Kirkwood JM, Zarour HM</authors>
		<title>Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients</title>
		<year>2008</year>
		<volume>31</volume>
		<issue>8</issue>
		<pages>781-791</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3883">
		<reference_name>Frankowski et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Frankowski DJ, Raez J, Manners I, Winnik MA, Khan SA, Spontak RJ</authors>
		<title>Formation of dispersed nanostructures from poly(ferrocenyldimethylsilane-b-dimethylsiloxane) nanotubes upon exposure to supercritical carbon dioxide</title>
		<year>2004</year>
		<volume>20</volume>
		<issue>21</issue>
		<pages>9304-9314</pages>
		<journal_book_name>Langmuir : the ACS journal of surfaces and colloids</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5379">
		<reference_name>Freeman et al., 1995</reference_name>
		<reference_type>journal</reference_type>
		<authors>Freeman SM, McCune C, Robinson W, Abboud CN, Abraham GN, Angel C, Marrogi A</authors>
		<title>The treatment of ovarian cancer with a gene modified cancer vaccine: a phase I study</title>
		<year>1995</year>
		<volume>6</volume>
		<issue>7</issue>
		<pages>927-939</pages>
		<journal_book_name>Human gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3906">
		<reference_name>Freytag et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Freytag SO, Barton KN, Zhang Y</authors>
		<title>Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer</title>
		<year>2013</year>
		<volume>20</volume>
		<issue>12</issue>
		<pages>1131-1139</pages>
		<journal_book_name>Gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3869">
		<reference_name>Freytag et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Freytag SO, Zhang Y, Siddiqui F</authors>
		<title>Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer</title>
		<year>2015</year>
		<volume>2</volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name>Molecular therapy oncolytics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5169">
		<reference_name>Fromm et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Fromm G, de Silva S, Giffin L, Xu X, Rose J, Schreiber TH</authors>
		<title>Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination</title>
		<year>2016</year>
		<volume>4</volume>
		<issue>9</issue>
		<pages>766-778</pages>
		<journal_book_name>Cancer immunology research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5125">
		<reference_name>Fujio et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Fujio K, Watanabe M, Ueki H, Li SA, Kinoshita R, Ochiai K, Futami J, Watanabe T, Nasu Y, Kumon H</authors>
		<title>A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment</title>
		<year>2015</year>
		<volume>33</volume>
		<issue>4</issue>
		<pages>1585-1592</pages>
		<journal_book_name>Oncology reports</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3988">
		<reference_name>Fulco et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Fulco I, Largo RD, Miot S, Wixmerten A, Martin I, Schaefer DJ, Haug MD</authors>
		<title>Toward clinical application of tissue-engineered cartilage</title>
		<year>2013</year>
		<volume>29</volume>
		<issue>2</issue>
		<pages>99-105</pages>
		<journal_book_name>Facial plastic surgery : FPS</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3917">
		<reference_name>Fulco et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Fulco I, Miot S, Haug MD, Barbero A, Wixmerten A, Feliciano S, Wolf F, Jundt G, Marsano A, Farhadi J, Heberer M, Jakob M, Schaefer DJ, Martin I</authors>
		<title>Engineered autologous cartilage tissue for nasal reconstruction after tumour resection: an observational first-in-human trial</title>
		<year>2014</year>
		<volume>384</volume>
		<issue>9940</issue>
		<pages>337-346</pages>
		<journal_book_name>Lancet (London, England)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3880">
		<reference_name>FUTURE II Study Group., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors></authors>
		<title>Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions</title>
		<year>2007</year>
		<volume>356</volume>
		<issue>19</issue>
		<pages>1915-1927</pages>
		<journal_book_name>The New England journal of medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5277">
		<reference_name>GahÃ©ry-SÃ©gard et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>GahÃ©ry-SÃ©gard H, Pialoux G, Figueiredo S, IgÃ©a C, Surenaud M, Gaston J, Gras-Masse H, LÃ©vy JP, Guillet JG</authors>
		<title>Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized</title>
		<year>2003</year>
		<volume>77</volume>
		<issue>20</issue>
		<pages>11220-11231</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5362">
		<reference_name>Gajdosik, 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Gajdosik Z</authors>
		<title>Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer</title>
		<year>2014</year>
		<volume>50</volume>
		<issue>4</issue>
		<pages>301-307</pages>
		<journal_book_name>Drugs of today (Barcelona, Spain : 1998)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5205">
		<reference_name>Gall et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Gall JM, Davol PA, Grabert RC, Deaver M, Lum LG</authors>
		<title>T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro</title>
		<year>2005</year>
		<volume>33</volume>
		<issue>4</issue>
		<pages>452-459</pages>
		<journal_book_name>Experimental hematology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5228">
		<reference_name>Gao et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Gao D, Li C, Xie X, Zhao P, Wei X, Sun W, Liu HC, Alexandrou AT, Jones J, Zhao R, Li JJ</authors>
		<title>Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients</title>
		<year>2014</year>
		<volume>9</volume>
		<issue>4</issue>
		<pages>e93886</pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3845">
		<reference_name>Gao et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Gao S, Zeng L, Zhang X, Wu Y, Cui J, Song Z, Sun X, Wang H, Yin Y, Xu W</authors>
		<title>Attenuated Streptococcus pneumoniae vaccine candidate SPY1 promotes dendritic cell activation and drives a Th1/Th17 response</title>
		<year>2016</year>
		<volume>179</volume>
		<issue></issue>
		<pages>47-55</pages>
		<journal_book_name>Immunology letters</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3945">
		<reference_name>Garcia et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP, Magill M, Silverman M, Urban RG, Hedley ML, Beach KJ</authors>
		<title>ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial</title>
		<year>2004</year>
		<volume>103</volume>
		<issue>2</issue>
		<pages>317-326</pages>
		<journal_book_name>Obstetrics and gynecology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2386">
		<reference_name>Garcia-Hernandez et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM</authors>
		<title>In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer</title>
		<year>2007</year>
		<volume>67</volume>
		<issue>3</issue>
		<pages>1344-1351</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2376">
		<reference_name>Garcia-Hernandez et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM</authors>
		<title>Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity</title>
		<year>2008</year>
		<volume>68</volume>
		<issue>3</issue>
		<pages>861-869</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5211">
		<reference_name>Garfall and Stadtmauer, 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Garfall AL, Stadtmauer EA</authors>
		<title>Cellular and vaccine immunotherapy for multiple myeloma</title>
		<year>2016</year>
		<volume>2016</volume>
		<issue>1</issue>
		<pages>521-527</pages>
		<journal_book_name>Hematology. American Society of Hematology. Education Program</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3850">
		<reference_name>Garland et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Garland SM, Cheung TH, McNeill S, Petersen LK, Romaguera J, Vazquez-Narvaez J, Bautista O, Shields C, Vuocolo S, Luxembourg A</authors>
		<title>Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine</title>
		<year>2015</year>
		<volume>33</volume>
		<issue>48</issue>
		<pages>6855-6864</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3855">
		<reference_name>Gathuru et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Gathuru JK, Koide F, Ragupathi G, Adams JL, Kerns RT, Coleman TP, Livingston PO</authors>
		<title>Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity</title>
		<year>2005</year>
		<volume>23</volume>
		<issue>39</issue>
		<pages>4727-4733</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4037">
		<reference_name>Gatson et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Gatson NT, Weathers SP, de Groot JF</authors>
		<title>ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma</title>
		<year>2016</year>
		<volume>5</volume>
		<issue>1</issue>
		<pages>11-26</pages>
		<journal_book_name>CNS oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3831">
		<reference_name>Germain and Margulies, 1993</reference_name>
		<reference_type>journal</reference_type>
		<authors>Germain RN, Margulies DH</authors>
		<title>The biochemistry and cell biology of antigen processing and presentation</title>
		<year>1993</year>
		<volume>11</volume>
		<issue></issue>
		<pages>403-450</pages>
		<journal_book_name>Annual review of immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3873">
		<reference_name>Giaccone et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, Thiberville L, D'addario G, Coens C, Rome LS, Zatloukal P, Masso O, Legrand C</authors>
		<title>Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)</title>
		<year>2005</year>
		<volume>23</volume>
		<issue>28</issue>
		<pages>6854-6864</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2988">
		<reference_name>Gomez et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Gomez B, He L, Tsai YC, Wu TC, Viscidi RP, Hung CF</authors>
		<title>Creation of a Merkel cell polyomavirus small T antigen-expressing murine tumor model and a DNA vaccine targeting small T antigen</title>
		<year>2013</year>
		<volume>3</volume>
		<issue>1</issue>
		<pages>29</pages>
		<journal_book_name>Cell &amp; bioscience</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3940">
		<reference_name>Greenberg et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL</authors>
		<title>Response to a monovalent 2009 influenza A (H1N1) vaccine</title>
		<year>2009</year>
		<volume>361</volume>
		<issue>25</issue>
		<pages>2405-2413</pages>
		<journal_book_name>The New England journal of medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2119">
		<reference_name>Gribben et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D, Nadler LM</authors>
		<title>Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy</title>
		<year>2005</year>
		<volume>11</volume>
		<issue>12</issue>
		<pages>4430-4436</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5116">
		<reference_name>Griguolo et al., 2019</reference_name>
		<reference_type>journal</reference_type>
		<authors>Griguolo G, Pascual T, Dieci MV, Guarneri V, Prat A</authors>
		<title>Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer</title>
		<year>2019</year>
		<volume>7</volume>
		<issue>1</issue>
		<pages>90</pages>
		<journal_book_name>Journal for immunotherapy of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference965">
		<reference_name>Grossmann et al., 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Grossmann ME, Brown MP, Brenner MK</authors>
		<title>Antitumor responses induced by transgenic expression of CD40 ligand</title>
		<year>1997</year>
		<volume>8</volume>
		<issue>16</issue>
		<pages>1935-1943</pages>
		<journal_book_name>Human gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3984">
		<reference_name>Gruslova et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Gruslova A, Cavazos DA, Miller JR, Breitbart E, Cohen YC, Bangio L, Yakov N, Soundararajan A, Floyd JR, Brenner AJ</authors>
		<title>VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme</title>
		<year>2015</year>
		<volume>124</volume>
		<issue>3</issue>
		<pages>365-372</pages>
		<journal_book_name>Journal of neuro-oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3203">
		<reference_name>Gu et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Gu R, Shampang A, Nashar T, Patil M, Fuller DH, Ramsingh AI</authors>
		<title>Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses</title>
		<year>2010</year>
		<volume>5</volume>
		<issue>9</issue>
		<pages></pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference950">
		<reference_name>Guinn et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL, Watts TH</authors>
		<title>4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors</title>
		<year>2001</year>
		<volume>210</volume>
		<issue>1</issue>
		<pages>56-65</pages>
		<journal_book_name>Cellular immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5200">
		<reference_name>Gulley et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, Remondo C, Cereda V, Jones JL, Pazdur MP, Higgins JP, Hodge JW, Steinberg SM, Kotz H, Dahut WL, Schlom J</authors>
		<title>Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma</title>
		<year>2008</year>
		<volume>14</volume>
		<issue>10</issue>
		<pages>3060-3069</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5143">
		<reference_name>Guo et al., 2019</reference_name>
		<reference_type>journal</reference_type>
		<authors>Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z, Bartlett DL</authors>
		<title>Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics</title>
		<year>2019</year>
		<volume>7</volume>
		<issue>1</issue>
		<pages>6</pages>
		<journal_book_name>Journal for immunotherapy of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5187">
		<reference_name>Gyurkocza et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Gyurkocza B, Lazarus HM, Giralt S</authors>
		<title>Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy</title>
		<year>2017</year>
		<volume>52</volume>
		<issue>8</issue>
		<pages>1083-1090</pages>
		<journal_book_name>Bone marrow transplantation</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5320">
		<reference_name>Haight et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Haight AE, Bowman LC, Ng CY, Vanin EF, Davidoff AM</authors>
		<title>Humoral response to vaccination with interleukin-2-expressing allogeneic neuroblastoma cells after primary therapy</title>
		<year>2000</year>
		<volume>35</volume>
		<issue>6</issue>
		<pages>712-715</pages>
		<journal_book_name>Medical and pediatric oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3009">
		<reference_name>Hailemichael et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, Liu C, Lou Y, Wang Z, Ma W, Rabinovich B, Sowell RT, Schluns KS, Davis RE, Hwu P, Overwijk WW</authors>
		<title>Persistent antigen at vaccination sites induces tumor-specific CD8Ã¢ÂÂº T cell sequestration, dysfunction and deletion</title>
		<year>2013</year>
		<volume>19</volume>
		<issue>4</issue>
		<pages>465-472</pages>
		<journal_book_name>Nature medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5135">
		<reference_name>Halin et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, Zardi L, Neri D</authors>
		<title>Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha</title>
		<year>2003</year>
		<volume>63</volume>
		<issue>12</issue>
		<pages>3202-3210</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5263">
		<reference_name>Halperin et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Halperin SA, McNeil S, Langley J, Blatter M, Dionne M, Embree J, Johnson R, Latiolais T, Meekison W, Noya F, Senders S, Zickler P, Johnson DR</authors>
		<title>Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose</title>
		<year>2011</year>
		<volume>29</volume>
		<issue>46</issue>
		<pages>8459-8465</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5325">
		<reference_name>Halpern et al., 1992</reference_name>
		<reference_type>journal</reference_type>
		<authors>Halpern SE, Dillman RO, Amox D, Hagan PL, Burks R, Dillman J, Perdikakis B, Merchant B, Frincke J, Schweighardt S</authors>
		<title>Detection of occult tumor using indium 111-labeled anticarcinoembryonic antigen antibodies</title>
		<year>1992</year>
		<volume>127</volume>
		<issue>9</issue>
		<pages>1094-1100</pages>
		<journal_book_name>Archives of surgery (Chicago, Ill. : 1960)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5122">
		<reference_name>Hannu et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hannu K, Johanna M, Ulf-HÃ¥kan S</authors>
		<title>KLK-targeted Therapies for Prostate Cancer</title>
		<year>2014</year>
		<volume>25</volume>
		<issue>2</issue>
		<pages>207-218</pages>
		<journal_book_name>EJIFCC</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3004">
		<reference_name>Hanwell et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hanwell DG, McNeil B, Visan L, Rodrigues L, Dunn P, Shewen PE, Macallum GE, Turner PV, Vogel TU</authors>
		<title>Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4</title>
		<year>2013</year>
		<volume>36</volume>
		<issue>4</issue>
		<pages>238-247</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5119">
		<reference_name>Hardwick et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hardwick NR, Frankel P, Ruel C, Kilpatrick J, Tsai W, Kos F, Kaltcheva T, Leong L, Morgan R, Chung V, Tinsley R, Eng M, Wilczynski S, Ellenhorn JDI, Diamond DJ, Cristea M</authors>
		<title>p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy</title>
		<year>2018</year>
		<volume>24</volume>
		<issue>6</issue>
		<pages>1315-1325</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference951">
		<reference_name>Harrop et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Harrop R, Ryan MG, Myers KA, Redchenko I, Kingsman SM, Carroll MW</authors>
		<title>Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated</title>
		<year>2006</year>
		<volume>55</volume>
		<issue>9</issue>
		<pages>1081-1090</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5219">
		<reference_name>Harzstark and Small, 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Harzstark AL, Small EJ</authors>
		<title>Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge)</title>
		<year>2007</year>
		<volume>7</volume>
		<issue>8</issue>
		<pages>1275-1280</pages>
		<journal_book_name>Expert opinion on biological therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2365">
		<reference_name>Hawkins et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hawkins WG, Gold JS, Blachere NE, Bowne WB, Hoos A, Lewis JJ, Houghton AN</authors>
		<title>Xenogeneic DNA immunization in melanoma models for minimal residual disease</title>
		<year>2002</year>
		<volume>102</volume>
		<issue>2</issue>
		<pages>137-143</pages>
		<journal_book_name>The Journal of surgical research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2998">
		<reference_name>He et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>He X, Wang J, Zhao F, Chen D, Chen J, Zhang H, Yang C, Liu Y, Dou J</authors>
		<title>ESAT-6-gpi DNA vaccine augmented the specific antitumour efficacy induced by the tumour vaccine B16F10-ESAT-6-gpi/IL-21 in a mouse model</title>
		<year>2013</year>
		<volume>78</volume>
		<issue>1</issue>
		<pages>69-78</pages>
		<journal_book_name>Scandinavian journal of immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3967">
		<reference_name>Hegmans et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hegmans JP, Hemmes A, Aerts JG, Hoogsteden HC, Lambrecht BN</authors>
		<title>Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells</title>
		<year>2005</year>
		<volume>171</volume>
		<issue>10</issue>
		<pages>1168-1177</pages>
		<journal_book_name>American journal of respiratory and critical care medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4005">
		<reference_name>Hegmans et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hegmans JP, Veltman JD, Lambers ME, de Vries IJ, Figdor CG, Hendriks RW, Hoogsteden HC, Lambrecht BN, Aerts JG</authors>
		<title>Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma</title>
		<year>2010</year>
		<volume>181</volume>
		<issue>12</issue>
		<pages>1383-1390</pages>
		<journal_book_name>American journal of respiratory and critical care medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3978">
		<reference_name>Heimberger et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH</authors>
		<title>Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors</title>
		<year>2003</year>
		<volume>9</volume>
		<issue>11</issue>
		<pages>4247-4254</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4029">
		<reference_name>Heiser et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J</authors>
		<title>Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors</title>
		<year>2002</year>
		<volume>109</volume>
		<issue>3</issue>
		<pages>409-417</pages>
		<journal_book_name>The Journal of clinical investigation</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2932">
		<reference_name>Henz et al., 1996</reference_name>
		<reference_type>journal</reference_type>
		<authors>Henz BM, Macher E, BrÃƒÂ¶cker EB, Suciu S, Steerenberg PA, Jung E, RÃƒÂ¼mke P</authors>
		<title>Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781)</title>
		<year>1996</year>
		<volume>193</volume>
		<issue>2</issue>
		<pages>105-109</pages>
		<journal_book_name>Dermatology (Basel, Switzerland)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5276">
		<reference_name>Herbert et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Herbert N, Haferkamp A, Schmitz-Winnenthal HF, ZÃ¶ller M</authors>
		<title>Concomitant tumor and autoantigen vaccination supports renal cell carcinoma rejection</title>
		<year>2010</year>
		<volume>185</volume>
		<issue>2</issue>
		<pages>902-916</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5170">
		<reference_name>Hersey et al., 1986</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hersey P, Edwards A, D'Alessandro G, MacDonald M</authors>
		<title>Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leucocyte dependent antibody activity: immunological effects of VMCL in melanoma patients</title>
		<year>1986</year>
		<volume>22</volume>
		<issue>3</issue>
		<pages>221-231</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2926">
		<reference_name>Hersey et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar RW, McLeod R, Gill PG, Coventry BJ, McMullen A, Dillon H, Simes RJ</authors>
		<title>Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial</title>
		<year>2002</year>
		<volume>20</volume>
		<issue>20</issue>
		<pages>4181-4190</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2913">
		<reference_name>Hersey et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hersey P, Menzies SW, Coventry B, Nguyen T, Farrelly M, Collins S, Hirst D, Johnson H</authors>
		<title>Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma</title>
		<year>2005</year>
		<volume>54</volume>
		<issue>3</issue>
		<pages>208-218</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2937">
		<reference_name>Hersey, 1992</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hersey P</authors>
		<title>Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma</title>
		<year>1992</year>
		<volume>16</volume>
		<issue>2</issue>
		<pages>251-260</pages>
		<journal_book_name>World journal of surgery</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3964">
		<reference_name>Higashihara et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Higashihara Y, Kato J, Nagahara A, Izumi K, Konishi M, Kodani T, Serizawa N, Osada T, Watanabe S</authors>
		<title>Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer</title>
		<year>2014</year>
		<volume>44</volume>
		<issue>3</issue>
		<pages>662-668</pages>
		<journal_book_name>International journal of oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5369">
		<reference_name>Hillman et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hillman GG, Reich LA, Rothstein SE, Abernathy LM, Fountain MD, Hankerd K, Yunker CK, Rakowski JT, Quemeneur E, Slos P</authors>
		<title>Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen</title>
		<year>2017</year>
		<volume>5</volume>
		<issue></issue>
		<pages>4</pages>
		<journal_book_name>Journal for immunotherapy of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference953">
		<reference_name>Hirschowitz et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hirschowitz EA, Leonard S, Song W, Ferris B, Leopold PL, Lewis JJ, Bowne WB, Wang S, Houghton AN, Crystal RG</authors>
		<title>Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma</title>
		<year>1998</year>
		<volume>5</volume>
		<issue>7</issue>
		<pages>975-983</pages>
		<journal_book_name>Gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4003">
		<reference_name>Hirschowitz et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J</authors>
		<title>Autologous dendritic cell vaccines for non-small-cell lung cancer</title>
		<year>2004</year>
		<volume>22</volume>
		<issue>14</issue>
		<pages>2808-2815</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4021">
		<reference_name>Hirschowitz et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hirschowitz EA, Hiestand DM, Yannelli JR</authors>
		<title>Vaccines for lung cancer</title>
		<year>2006</year>
		<volume>1</volume>
		<issue>1</issue>
		<pages>93-104</pages>
		<journal_book_name>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3982">
		<reference_name>Hirschowitz et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hirschowitz EA, Mullins A, Prajapati D, Baeker T, Kloecker G, Foody T, Damron K, Love C, Yannelli JR</authors>
		<title>Pilot study of 1650-G: a simplified cellular vaccine for lung cancer</title>
		<year>2011</year>
		<volume>6</volume>
		<issue>1</issue>
		<pages>169-173</pages>
		<journal_book_name>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3999">
		<reference_name>Hodge et al., 1999</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J</authors>
		<title>A triad of costimulatory molecules synergize to amplify T-cell activation</title>
		<year>1999</year>
		<volume>59</volume>
		<issue>22</issue>
		<pages>5800-5807</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5132">
		<reference_name>Hodge et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J</authors>
		<title>Vaccine therapy of established tumors in the absence of autoimmunity</title>
		<year>2003</year>
		<volume>9</volume>
		<issue>5</issue>
		<pages>1837-1849</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3848">
		<reference_name>Hodge et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hodge JW, Guha C, Neefjes J, Gulley JL</authors>
		<title>Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges</title>
		<year>2008</year>
		<volume>22</volume>
		<issue>9</issue>
		<pages>1064-1070</pages>
		<journal_book_name>Oncology (Williston Park, N.Y.)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1300">
		<reference_name>Hodi, 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hodi FS</authors>
		<title>Overcoming immunological tolerance to melanoma: Targeting CTLA-4</title>
		<year>2010</year>
		<volume>6 Suppl 1</volume>
		<issue></issue>
		<pages>S16-23</pages>
		<journal_book_name>Asia-Pacific journal of clinical oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5193">
		<reference_name>Hofman et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hofman FM, Stathopoulos A, Kruse CA, Chen TC, Schijns VE</authors>
		<title>Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells</title>
		<year>2010</year>
		<volume>10</volume>
		<issue>6</issue>
		<pages>462-470</pages>
		<journal_book_name>Anti-cancer agents in medicinal chemistry</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5146">
		<reference_name>Holmberg and Sandmaier, 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Holmberg LA, Sandmaier BM</authors>
		<title>Theratope vaccine (STn-KLH)</title>
		<year>2001</year>
		<volume>1</volume>
		<issue>5</issue>
		<pages>881-891</pages>
		<journal_book_name>Expert opinion on biological therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5321">
		<reference_name>Holt et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Holt GE, Podack ER, Raez LE</authors>
		<title>Immunotherapy as a strategy for the treatment of non-small-cell lung cancer</title>
		<year>2011</year>
		<volume>8</volume>
		<issue>1</issue>
		<pages>43-54</pages>
		<journal_book_name>Therapy (London, England : 2004)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3872">
		<reference_name>Hong et al., 1993</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hong WK, Lippman SM, Wolf GT</authors>
		<title>Recent advances in head and neck cancer--larynx preservation and cancer chemoprevention: the Seventeenth Annual Richard and Hinda Rosenthal Foundation Award Lecture</title>
		<year>1993</year>
		<volume>53</volume>
		<issue>21</issue>
		<pages>5113-5120</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3856">
		<reference_name>Hoogsteder et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hoogsteder PH, Kotz D, van Spiegel PI, Viechtbauer W, van Schayck OC</authors>
		<title>Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial</title>
		<year>2014</year>
		<volume>109</volume>
		<issue>8</issue>
		<pages>1252-1259</pages>
		<journal_book_name>Addiction (Abingdon, England)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2917">
		<reference_name>Hsueh and Morton, 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hsueh EC, Morton DL</authors>
		<title>Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine</title>
		<year>2003</year>
		<volume>13</volume>
		<issue>6</issue>
		<pages>401-407</pages>
		<journal_book_name>Seminars in cancer biology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2925">
		<reference_name>Hsueh et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hsueh EC, Essner R, Foshag LJ, Ollila DW, Gammon G, O'Day SJ, Boasberg PD, Stern SL, Ye X, Morton DL</authors>
		<title>Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine</title>
		<year>2002</year>
		<volume>20</volume>
		<issue>23</issue>
		<pages>4549-4554</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3897">
		<reference_name>Huang et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, Madan RA, Gulley JL, Schlom J</authors>
		<title>Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role</title>
		<year>2012</year>
		<volume>120</volume>
		<issue>15</issue>
		<pages>3030-3038</pages>
		<journal_book_name>Blood</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2369">
		<reference_name>Huebener et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Huebener N, Fest S, Strandsby A, Michalsky E, Preissner R, Zeng Y, Gaedicke G, Lode HN</authors>
		<title>A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity</title>
		<year>2008</year>
		<volume>7</volume>
		<issue>7</issue>
		<pages>2241-2251</pages>
		<journal_book_name>Molecular cancer therapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5368">
		<reference_name>Hui et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, Wong WL, Wilson S, Johnson BF, Edwards C, Stocken DD, Rickinson AB, Steven NM, Chan AT</authors>
		<title>Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients</title>
		<year>2013</year>
		<volume>73</volume>
		<issue>6</issue>
		<pages>1676-1688</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5338">
		<reference_name>Hung et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hung CF, Wu TC, Monie A, Roden R</authors>
		<title>Antigen-specific immunotherapy of cervical and ovarian cancer</title>
		<year>2008</year>
		<volume>222</volume>
		<issue></issue>
		<pages>43-69</pages>
		<journal_book_name>Immunological reviews</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2962">
		<reference_name>Hunter-Craig et al., 1970</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hunter-Craig I, Newton KA, Westbury G, Lacey BW</authors>
		<title>Use of vaccinia virus in the treatment of metastatic malignant melanoma</title>
		<year>1970</year>
		<volume>2</volume>
		<issue>5708</issue>
		<pages>512-515</pages>
		<journal_book_name>British medical journal</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5358">
		<reference_name>Hutchins et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hutchins LF, Makhoul I, Emanuel PD, Pennisi A, Siegel ER, Jousheghany F, Guo X, Pashov AD, Monzavi-Karbassi B, Kieber-Emmons T</authors>
		<title>Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects</title>
		<year>2017</year>
		<volume>8</volume>
		<issue>58</issue>
		<pages>99161-99178</pages>
		<journal_book_name>Oncotarget</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3991">
		<reference_name>Hutson et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hutson TE, Figlin RA, Kuhn JG, Motzer RJ</authors>
		<title>Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies</title>
		<year>2008</year>
		<volume>13</volume>
		<issue>10</issue>
		<pages>1084-1096</pages>
		<journal_book_name>The oncologist</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5161">
		<reference_name>Iinuma et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Iinuma H, Fukushima R, Inaba T, Tamura J, Inoue T, Ogawa E, Horikawa M, Ikeda Y, Matsutani N, Takeda K, Yoshida K, Tsunoda T, Ikeda T, Nakamura Y, Okinaga K</authors>
		<title>Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients</title>
		<year>2014</year>
		<volume>12</volume>
		<issue></issue>
		<pages>84</pages>
		<journal_book_name>Journal of translational medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3904">
		<reference_name>Illiano et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Illiano E, Bissa M, Paolini F, Zanotto C, De Giuli Morghen C, Franconi R, Radaelli A, Venuti A</authors>
		<title>Prime-boost therapeutic vaccination in mice with DNA/DNA or DNA/Fowlpox virus recombinants expressing the Human Papilloma Virus type 16 E6 and E7 mutated proteins fused to the coat protein of Potato virus X</title>
		<year>2016</year>
		<volume>225</volume>
		<issue></issue>
		<pages>82-90</pages>
		<journal_book_name>Virus research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3910">
		<reference_name>Insaidoo et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Insaidoo FK, Borbulevych OY, Hossain M, Santhanagopolan SM, Baxter TK, Baker BM</authors>
		<title>Loss of T cell antigen recognition arising from changes in peptide and major histocompatibility complex protein flexibility: implications for vaccine design</title>
		<year>2011</year>
		<volume>286</volume>
		<issue>46</issue>
		<pages>40163-40173</pages>
		<journal_book_name>The Journal of biological chemistry</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2920">
		<reference_name>Irie et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Irie RF, Ollila DW, O'Day S, Morton DL</authors>
		<title>Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma</title>
		<year>2004</year>
		<volume>53</volume>
		<issue>2</issue>
		<pages>110-117</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4043">
		<reference_name>Ishizaki et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H</authors>
		<title>Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1</title>
		<year>2006</year>
		<volume>12</volume>
		<issue>19</issue>
		<pages>5841-5849</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3950">
		<reference_name>James et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>James BR, Anderson KG, Brincks EL, Kucaba TA, Norian LA, Masopust D, Griffith TS</authors>
		<title>CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma</title>
		<year>2014</year>
		<volume>63</volume>
		<issue>11</issue>
		<pages>1213-1227</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4004">
		<reference_name>Jamshed et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Jamshed S, Walsh EE, Dimitroff LJ, Santelli JS, Falsey AR</authors>
		<title>Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: A pilot randomized clinical trial</title>
		<year>2016</year>
		<volume>34</volume>
		<issue>5</issue>
		<pages>630-635</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2881">
		<reference_name>Jha et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Jha G, Miller JS, Curtsinger JM, Zhang Y, Mescher MF, Dudek AZ</authors>
		<title>Randomized Phase II Study of IL-2 With or Without an Allogeneic Large Multivalent Immunogen Vaccine for the Treatment of Stage IV Melanoma</title>
		<year>2012</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name>American journal of clinical oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5222">
		<reference_name>Jia et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Jia YY, Tan WJ, Duan FF, Pan ZM, Chen X, Yin YL, Jiao XA</authors>
		<title>A Genetically Modified attenuated <i>Listeria</i> Vaccine Expressing HPV16 E7 Kill Tumor Cells in Direct and Antigen-Specific Manner</title>
		<year>2017</year>
		<volume>7</volume>
		<issue></issue>
		<pages>279</pages>
		<journal_book_name>Frontiers in cellular and infection microbiology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2374">
		<reference_name>Johnson et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, McNeel DG</authors>
		<title>Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP)</title>
		<year>2006</year>
		<volume>24</volume>
		<issue>3</issue>
		<pages>293-303</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5126">
		<reference_name>Johnson et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG</authors>
		<title>Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells</title>
		<year>2007</year>
		<volume>56</volume>
		<issue>6</issue>
		<pages>885-895</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5224">
		<reference_name>Johnson et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA</authors>
		<title>Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen</title>
		<year>2009</year>
		<volume>114</volume>
		<issue>3</issue>
		<pages>535-546</pages>
		<journal_book_name>Blood</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2931">
		<reference_name>Jones et al., 1996</reference_name>
		<reference_type>journal</reference_type>
		<authors>Jones RC, Kelley M, Gupta RK, Nizze JA, Yee R, Leopoldo Z, Qi K, Stern S, Morton DL</authors>
		<title>Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model</title>
		<year>1996</year>
		<volume>3</volume>
		<issue>5</issue>
		<pages>437-445</pages>
		<journal_book_name>Annals of surgical oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4039">
		<reference_name>Juric et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Juric D, Mahovli? V, Rajhvajn S, Ovanin-Raki? A, Skopljanac-Macina L, Barisi? A, Proji? IS, Babi? D, Susa M, Corusi? A, Oreskovi? S</authors>
		<title>Liquid-based cytology--new possibilities in the diagnosis of cervical lesions</title>
		<year>2010</year>
		<volume>34</volume>
		<issue>1</issue>
		<pages>19-24</pages>
		<journal_book_name>Collegium antropologicum</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4009">
		<reference_name>Kafi et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kafi K, Betting DJ, Yamada RE, Bacica M, Steward KK, Timmerman JM</authors>
		<title>Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines</title>
		<year>2009</year>
		<volume>46</volume>
		<issue>3</issue>
		<pages>448-456</pages>
		<journal_book_name>Molecular immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5183">
		<reference_name>Kakudo et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kakudo N, Tanaka Y, Morimoto N, Ogawa T, Kushida S, Hara T, Kusumoto K</authors>
		<title>Adipose-derived regenerative cell (ADRC)-enriched fat grafting: optimal cell concentration and effects on grafted fat characteristics</title>
		<year>2013</year>
		<volume>11</volume>
		<issue></issue>
		<pages>254</pages>
		<journal_book_name>Journal of translational medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2999">
		<reference_name>Kalli et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kalli F, Machiorlatti R, Battaglia F, Parodi A, Conteduca G, Ferrera F, Proietti M, Tardito S, Sanguineti M, Millo E, Fenoglio D, De Palma R, Inghirami G, Filaci G</authors>
		<title>Comparative analysis of cancer vaccine settings for the selection of an effective protocol in mice</title>
		<year>2013</year>
		<volume>11</volume>
		<issue></issue>
		<pages>120</pages>
		<journal_book_name>Journal of translational medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5367">
		<reference_name>Kalli et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kalli KR, Block MS, Kasi PM, Erskine CL, Hobday TJ, Dietz A, Padley D, Gustafson MP, Shreeder B, Puglisi-Knutson D, Visscher DW, Mangskau TK, Wilson G, Knutson KL</authors>
		<title>Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients</title>
		<year>2018</year>
		<volume>24</volume>
		<issue>13</issue>
		<pages>3014-3025</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2359">
		<reference_name>Kamata et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kamata M, Denda-Nagai K, Kubota N, Aida S, Takeda K, Irimura T</authors>
		<title>Vaccination of mice with MUC1 cDNA suppresses the development of lung metastases</title>
		<year>2002</year>
		<volume>19</volume>
		<issue>8</issue>
		<pages>689-696</pages>
		<journal_book_name>Clinical &amp; experimental metastasis</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5343">
		<reference_name>Kampf et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kampf G, Steinmann J, Rabenau H</authors>
		<title>Suitability of vaccinia virus and bovine viral diarrhea virus (BVDV) for determining activities of three commonly-used alcohol-based hand rubs against enveloped viruses</title>
		<year>2007</year>
		<volume>7</volume>
		<issue></issue>
		<pages>5</pages>
		<journal_book_name>BMC infectious diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5317">
		<reference_name>Kamran et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kamran N, Calinescu A, Candolfi M, Chandran M, Mineharu Y, Asad AS, Koschmann C, Nunez FJ, Lowenstein PR, Castro MG</authors>
		<title>Recent advances and future of immunotherapy for glioblastoma</title>
		<year>2016</year>
		<volume>16</volume>
		<issue>10</issue>
		<pages>1245-1264</pages>
		<journal_book_name>Expert opinion on biological therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5247">
		<reference_name>Kandalaft et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kandalaft LE, Powell DJ Jr, Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA, June CH, Coukos G</authors>
		<title>Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer</title>
		<year>2013</year>
		<volume>2</volume>
		<issue>1</issue>
		<pages>e22664</pages>
		<journal_book_name>Oncoimmunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3934">
		<reference_name>Kanehira et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kanehira M, Harada Y, Takata R, Shuin T, Miki T, Fujioka T, Nakamura Y, Katagiri T</authors>
		<title>Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis</title>
		<year>2007</year>
		<volume>26</volume>
		<issue>44</issue>
		<pages>6448-6455</pages>
		<journal_book_name>Oncogene</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2413">
		<reference_name>Kaplan et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kaplan CD, KrÃƒÂ¼ger JA, Zhou H, Luo Y, Xiang R, Reisfeld RA</authors>
		<title>A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma</title>
		<year>2006</year>
		<volume>24</volume>
		<issue>47-48</issue>
		<pages>6994-7002</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5312">
		<reference_name>Karamitros et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Karamitros D, Stoilova B, Aboukhalil Z, Hamey F, Reinisch A, Samitsch M, Quek L, Otto G, Repapi E, Doondeea J, Usukhbayar B, Calvo J, Taylor S, Goardon N, Six E, Pflumio F, Porcher C, Majeti R, GÃ¶ttgens B, Vyas P</authors>
		<title>Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells</title>
		<year>2018</year>
		<volume>19</volume>
		<issue>1</issue>
		<pages>85-97</pages>
		<journal_book_name>Nature immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5377">
		<reference_name>Karkada et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Karkada M, Weir GM, Quinton T, Sammatur L, MacDonald LD, Grant A, Liwski R, Juskevicius R, Sinnathamby G, Philip R, Mansour M</authors>
		<title>A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses</title>
		<year>2010</year>
		<volume>33</volume>
		<issue>3</issue>
		<pages>250-261</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5159">
		<reference_name>Karyampudi and Ghosh, 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Karyampudi L, Ghosh SK</authors>
		<title>Mycobacterial HSP70 as an adjuvant in the design of an idiotype vaccine against a murine lymphoma</title>
		<year>2008</year>
		<volume>254</volume>
		<issue>1</issue>
		<pages>74-80</pages>
		<journal_book_name>Cellular immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5131">
		<reference_name>Kass et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW</authors>
		<title>Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant</title>
		<year>2001</year>
		<volume>61</volume>
		<issue>1</issue>
		<pages>206-214</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5365">
		<reference_name>Kato, 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kato Y</authors>
		<title>[Efficacy of WT1 peptide-/MUC-1 peptide-pulsed dendritic cell therapy in 313 patients with a wide range of cancers]</title>
		<year>2014</year>
		<volume>41</volume>
		<issue>10</issue>
		<pages>1280-1282</pages>
		<journal_book_name>Gan to kagaku ryoho. Cancer &amp; chemotherapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5198">
		<reference_name>Kaufman et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kaufman HL, Lenz HJ, Marshall J, Singh D, Garett C, Cripps C, Moore M, von Mehren M, Dalfen R, Heim WJ, Conry RM, Urba WJ, Benson AB 3rd, Yu M, Caterini J, Kim-Schulze S, Debenedette M, Salha D, Vogel T, Elias I, Berinstein NL</authors>
		<title>Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer</title>
		<year>2008</year>
		<volume>14</volume>
		<issue>15</issue>
		<pages>4843-4849</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3878">
		<reference_name>Kawakami et al., 1994</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA</authors>
		<title>Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor</title>
		<year>1994</year>
		<volume>91</volume>
		<issue>9</issue>
		<pages>3515-3519</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3842">
		<reference_name>Kawakami et al., 1994</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA</authors>
		<title>Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection</title>
		<year>1994</year>
		<volume>91</volume>
		<issue>14</issue>
		<pages>6458-6462</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3836">
		<reference_name>Kawakami et al., 1994</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA</authors>
		<title>Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes</title>
		<year>1994</year>
		<volume>180</volume>
		<issue>1</issue>
		<pages>347-352</pages>
		<journal_book_name>The Journal of experimental medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5291">
		<reference_name>Keehn et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Keehn A, Gartrell B, Schoenberg MP</authors>
		<title>Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer</title>
		<year>2016</year>
		<volume>12</volume>
		<issue>23</issue>
		<pages>2673-2682</pages>
		<journal_book_name>Future oncology (London, England)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4020">
		<reference_name>Keller et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Keller M, Ebstein F, Bï¿½rger E, Textoris-Taube K, Gorny X, Urban S, Zhao F, Dannenberg T, Sucker A, Keller C, Saveanu L, Krï¿½ger E, Rothkï¿½tter HJ, Dahlmann B, Henklein P, Voigt A, Kuckelkorn U, Paschen A, Kloetzel PM, Seifert U</authors>
		<title>The proteasome immunosubunits, PA28 and ER-aminopeptidase 1 protect melanoma cells from efficient MART-126-35 -specific T-cell recognition</title>
		<year>2015</year>
		<volume>45</volume>
		<issue>12</issue>
		<pages>3257-3268</pages>
		<journal_book_name>European journal of immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3863">
		<reference_name>Kelsen et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG</authors>
		<title>Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer</title>
		<year>2007</year>
		<volume>25</volume>
		<issue>24</issue>
		<pages>3719-3725</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3930">
		<reference_name>Kemp et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA</authors>
		<title>HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection</title>
		<year>2011</year>
		<volume>29</volume>
		<issue>11</issue>
		<pages>2011-2014</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5158">
		<reference_name>Khan et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Khan MI, Pach A 3rd, Khan GM, Bajracharya D, Sahastrabuddhe S, Bhutta W, Tahir R, Soofi S, Thapa CB, Joshi N, Puri MK, Shrestha P, Upreti SR, Clemens JD, Bhutta Z, Ochiai RL</authors>
		<title>Typhoid vaccine introduction: An evidence-based pilot implementation project in Nepal and Pakistan</title>
		<year>2015</year>
		<volume>33 Suppl 3</volume>
		<issue></issue>
		<pages>C62-67</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4035">
		<reference_name>Kharfan-Dabaja et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, Guterwill DF, Smith LR, Rolland AP, Kenney RT</authors>
		<title>A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial</title>
		<year>2012</year>
		<volume>12</volume>
		<issue>4</issue>
		<pages>290-299</pages>
		<journal_book_name>The Lancet. Infectious diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3943">
		<reference_name>Khong et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Khong HT, Yang JC, Topalian SL, Sherry RM, Mavroukakis SA, White DE, Rosenberg SA</authors>
		<title>Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen</title>
		<year>2004</year>
		<volume>27</volume>
		<issue>6</issue>
		<pages>472-477</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5256">
		<reference_name>Kim and Liau, 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kim W, Liau LM</authors>
		<title>Dendritic cell vaccines for brain tumors</title>
		<year>2010</year>
		<volume>21</volume>
		<issue>1</issue>
		<pages>139-157</pages>
		<journal_book_name>Neurosurgery clinics of North America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference971">
		<reference_name>Kim and Sin, 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kim MS, Sin JI</authors>
		<title>Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model</title>
		<year>2005</year>
		<volume>116</volume>
		<issue>2</issue>
		<pages>255-266</pages>
		<journal_book_name>Immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3875">
		<reference_name>Kim et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kim SK, Ragupathi G, Cappello S, Kagan E, Livingston PO</authors>
		<title>Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates</title>
		<year>2000</year>
		<volume>19</volume>
		<issue>4-5</issue>
		<pages>530-537</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2378">
		<reference_name>Kim et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kim JJ, Yang JS, Nottingham LK, Tang W, Dang K, Manson KH, Wyand MS, Wilson DM, Weiner DB</authors>
		<title>Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen</title>
		<year>2001</year>
		<volume>20</volume>
		<issue>33</issue>
		<pages>4497-4506</pages>
		<journal_book_name>Oncogene</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2379">
		<reference_name>Kim et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kim JJ, Yang JS, Dang K, Manson KH, Weiner DB</authors>
		<title>Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants</title>
		<year>2001</year>
		<volume>7</volume>
		<issue>3 Suppl</issue>
		<pages>882s-889s</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5305">
		<reference_name>Kim et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kim TJ, Jin HT, Hur SY, Yang HG, Seo YB, Hong SR, Lee CW, Kim S, Woo JW, Park KS, Hwang YY, Park J, Lee IH, Lim KT, Lee KH, Jeong MS, Surh CD, Suh YS, Park JS, Sung YC</authors>
		<title>Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients</title>
		<year>2014</year>
		<volume>5</volume>
		<issue></issue>
		<pages>5317</pages>
		<journal_book_name>Nature communications</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5267">
		<reference_name>Kim et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kim JH, Lee JO, Kim N, Lee HJ, Lee YW, Kim HI, Kim SJ, Park SH, Kim HS</authors>
		<title>Paclitaxel suppresses the viability of breast tumor MCF7 cells through the regulation of EF1Î± and FOXO3a by AMPK signaling</title>
		<year>2015</year>
		<volume>47</volume>
		<issue>5</issue>
		<pages>1874-1880</pages>
		<journal_book_name>International journal of oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5349">
		<reference_name>Kim et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kim SW, Goedegebuure P, Gillanders WE</authors>
		<title>Mammaglobin-A is a target for breast cancer vaccination</title>
		<year>2016</year>
		<volume>5</volume>
		<issue>2</issue>
		<pages>e1069940</pages>
		<journal_book_name>Oncoimmunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5323">
		<reference_name>Kim et al., 2019</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kim KH, Kim CS, Kim HM, Kim JD, Ma SH, Kim DH, Hwang PH, Han JW, Lee TJ, Kim JH, Karkada N, Mesaros N, Sohn WY, Kim JH</authors>
		<title>Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study</title>
		<year>2019</year>
		<volume>15</volume>
		<issue>2</issue>
		<pages>317-326</pages>
		<journal_book_name>Human vaccines &amp; immunotherapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5332">
		<reference_name>Kitawaki et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kitawaki T, Kadowaki N, Fukunaga K, Kasai Y, Maekawa T, Ohmori K, Itoh T, Shimizu A, Kuzushima K, Kondo T, Ishikawa T, Uchiyama T</authors>
		<title>Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia</title>
		<year>2011</year>
		<volume>39</volume>
		<issue>4</issue>
		<pages>424-433.e2</pages>
		<journal_book_name>Experimental hematology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3830">
		<reference_name>Ko et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH</authors>
		<title>Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients</title>
		<year>2009</year>
		<volume>15</volume>
		<issue>6</issue>
		<pages>2148-2157</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5171">
		<reference_name>Kobayashi et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kobayashi H, Nagato T, Aoki N, Sato K, Kimura S, Tateno M, Celis E</authors>
		<title>Defining MHC class II T helper epitopes for WT1 tumor antigen</title>
		<year>2006</year>
		<volume>55</volume>
		<issue>7</issue>
		<pages>850-860</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5174">
		<reference_name>Kobayashi et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kobayashi Y, Sakura T, Miyawaki S, Toga K, Sogo S, Heike Y</authors>
		<title>A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia</title>
		<year>2017</year>
		<volume>66</volume>
		<issue>7</issue>
		<pages>851-863</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1292">
		<reference_name>Koido et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J</authors>
		<title>Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA</title>
		<year>2000</year>
		<volume>165</volume>
		<issue>10</issue>
		<pages>5713-5719</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2950">
		<reference_name>KolariÃ„â€¡ et al., 1979</reference_name>
		<reference_type>journal</reference_type>
		<authors>KolariÃ„â€¡ K, Malenica B, Roth A</authors>
		<title>A preliminary report of a pilot trial in adjuvant chemotherapy of primary melanoma</title>
		<year>1979</year>
		<volume>65</volume>
		<issue>2</issue>
		<pages>229-236</pages>
		<journal_book_name>Tumori</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3010">
		<reference_name>Komatsu et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Komatsu N, Jackson HM, Chan KF, Oveissi S, Cebon J, Itoh K, Chen W</authors>
		<title>Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein</title>
		<year>2013</year>
		<volume>54</volume>
		<issue>3-4</issue>
		<pages>465-471</pages>
		<journal_book_name>Molecular immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5279">
		<reference_name>Kong et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kong Z, Wang Y, Ma W</authors>
		<title>Vaccination in the immunotherapy of glioblastoma</title>
		<year>2018</year>
		<volume>14</volume>
		<issue>2</issue>
		<pages>255-268</pages>
		<journal_book_name>Human vaccines &amp; immunotherapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3980">
		<reference_name>Koski et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Koski GK, Koldovsky U, Xu S, Mick R, Sharma A, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Czerniecki BJ</authors>
		<title>A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer</title>
		<year>2012</year>
		<volume>35</volume>
		<issue>1</issue>
		<pages>54-65</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3849">
		<reference_name>Kouiavskaia et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kouiavskaia DV, Berard CA, Datena E, Hussain A, Dawson N, Klyushnenkova EN, Alexander RB</authors>
		<title>Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer</title>
		<year>2009</year>
		<volume>32</volume>
		<issue>6</issue>
		<pages>655-666</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4032">
		<reference_name>Krishnadas et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Krishnadas DK, Shusterman S, Bai F, Diller L, Sullivan JE, Cheerva AC, George RE, Lucas KG</authors>
		<title>A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma</title>
		<year>2015</year>
		<volume>64</volume>
		<issue>10</issue>
		<pages>1251-1260</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2952">
		<reference_name>Krown et al., 1978</reference_name>
		<reference_type>journal</reference_type>
		<authors>Krown SE, Hilal EY, Pinsky CM, Hirshaut Y, Wanebo HJ, Hansen JA, Huvos AG, Oettgen HF</authors>
		<title>Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma</title>
		<year>1978</year>
		<volume>42</volume>
		<issue>6</issue>
		<pages>2648-2660</pages>
		<journal_book_name>Cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2990">
		<reference_name>Kruit et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U</authors>
		<title>Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma</title>
		<year>2013</year>
		<volume>31</volume>
		<issue>19</issue>
		<pages>2413-2420</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5236">
		<reference_name>Kubuschok et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kubuschok B, Cochlovius C, Jung W, Schmits R, TrÃ¼mper L, Hartmann F, Renner C, Pfreundschuh M</authors>
		<title>Gene-modified spontaneous Epstein-Barr virus-transformed lymphoblastoid cell lines as autologous cancer vaccines: mutated p21 ras oncogene as a model</title>
		<year>2000</year>
		<volume>7</volume>
		<issue>9</issue>
		<pages>1231-1240</pages>
		<journal_book_name>Cancer gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3983">
		<reference_name>Kudela et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kudela P, Sun Z, Fourcade J, Janjic B, Kirkwood JM, Maillere B, Zarour HM</authors>
		<title>Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1</title>
		<year>2011</year>
		<volume>186</volume>
		<issue>1</issue>
		<pages>312-322</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5190">
		<reference_name>Kwiatkowska-Borowczyk et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kwiatkowska-Borowczyk E, CzerwiÅ„ska P, Mackiewicz J, Gryska K, Kazimierczak U, Tomela K, PrzybyÅ‚a A, KozÅ‚owska AK, Galus Å, Kwinta Å, Dondajewska E, GÄ…bka-Buszek A, Å»akowska M, Mackiewicz A</authors>
		<title>Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients</title>
		<year>2018</year>
		<volume>7</volume>
		<issue>11</issue>
		<pages>e1509821</pages>
		<journal_book_name>Oncoimmunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5311">
		<reference_name>Kyte et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kyte JA, Aamdal S, Dueland S, SÃ¦bÃ¸e-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G</authors>
		<title>Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells</title>
		<year>2016</year>
		<volume>5</volume>
		<issue>11</issue>
		<pages>e1232237</pages>
		<journal_book_name>Oncoimmunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3896">
		<reference_name>La et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>La Rosa C, Longmate J, Lacey SF, Kaltcheva T, Sharan R, Marsano D, Kwon P, Drake J, Williams B, Denison S, Broyer S, Couture L, Nakamura R, Dadwal S, Kelsey MI, Krieg AM, Diamond DJ, Zaia JA</authors>
		<title>Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant</title>
		<year>2012</year>
		<volume>205</volume>
		<issue>8</issue>
		<pages>1294-1304</pages>
		<journal_book_name>The Journal of infectious diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4013">
		<reference_name>La et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>La Rosa C, Longmate J, Martinez J, Zhou Q, Kaltcheva TI, Tsai W, Drake J, Carroll M, Wussow F, Chiuppesi F, Hardwick N, Dadwal S, Aldoss I, Nakamura R, Zaia JA, Diamond DJ</authors>
		<title>MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults</title>
		<year>2017</year>
		<volume>129</volume>
		<issue>1</issue>
		<pages>114-125</pages>
		<journal_book_name>Blood</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5318">
		<reference_name>Lacy et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lacy MQ, Mandrekar S, Dispenzieri A, Hayman S, Kumar S, Buadi F, Dingli D, Litzow M, Wettstein P, Padley D, Kabat B, Gastineau D, Rajkumar SV, Gertz MA</authors>
		<title>Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival</title>
		<year>2009</year>
		<volume>84</volume>
		<issue>12</issue>
		<pages>799-802</pages>
		<journal_book_name>American journal of hematology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3238">
		<reference_name>Lange et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lange S, Lampe J, Bossow S, Zimmermann M, Neubert W, Bitzer M, Lauer UM</authors>
		<title>A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma</title>
		<year>2013</year>
		<volume>24</volume>
		<issue>5</issue>
		<pages>554-564</pages>
		<journal_book_name>Human gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5144">
		<reference_name>Lattanzi et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lattanzi M, Han J, Moran U, Utter K, Tchack J, Sabado RL, Berman R, Shapiro R, Huang HH, Osman I, Bhardwaj N, Pavlick AC</authors>
		<title>Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis</title>
		<year>2018</year>
		<volume>6</volume>
		<issue>1</issue>
		<pages>38</pages>
		<journal_book_name>Journal for immunotherapy of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5333">
		<reference_name>Lauer et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lauer UM, Schell M, Beil J, Berchtold S, KoppenhÃ¶fer U, Glatzle J, KÃ¶nigsrainer A, MÃ¶hle R, Nann D, Fend F, Pfannenberg C, Bitzer M, Malek NP</authors>
		<title>Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis</title>
		<year>2018</year>
		<volume>24</volume>
		<issue>18</issue>
		<pages>4388-4398</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3841">
		<reference_name>Lawatscheck et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lawatscheck R, Aleksaite E, Schenk JA, Micheel B, Jandrig B, Holland G, Sasnauskas K, Gedvilaite A, Ulrich RG</authors>
		<title>Chimeric polyomavirus-derived virus-like particles: the immunogenicity of an inserted peptide applied without adjuvant to mice depends on its insertion site and its flanking linker sequence</title>
		<year>2007</year>
		<volume>20</volume>
		<issue>3</issue>
		<pages>453-460</pages>
		<journal_book_name>Viral immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3846">
		<reference_name>Lazarus et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR Jr, Moseley AB, Bacigalupo A</authors>
		<title>Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients</title>
		<year>2005</year>
		<volume>11</volume>
		<issue>5</issue>
		<pages>389-398</pages>
		<journal_book_name>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4017">
		<reference_name>Le et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Le DT, Dubenksy TW Jr, Brockstedt DG</authors>
		<title>Clinical development of Listeria monocytogenes-based immunotherapies</title>
		<year>2012</year>
		<volume>39</volume>
		<issue>3</issue>
		<pages>311-322</pages>
		<journal_book_name>Seminars in oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5294">
		<reference_name>Le et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM, Laheru DA</authors>
		<title>Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer</title>
		<year>2013</year>
		<volume>36</volume>
		<issue>7</issue>
		<pages>382-389</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1302">
		<reference_name>Lee et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E</authors>
		<title>Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts</title>
		<year>2005</year>
		<volume>65</volume>
		<issue>23</issue>
		<pages>11156-11163</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5329">
		<reference_name>Lee et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lee ST, Neelapu SS, Kwak LW</authors>
		<title>Therapeutic vaccine for lymphoma</title>
		<year>2007</year>
		<volume>48</volume>
		<issue>1</issue>
		<pages>1-10</pages>
		<journal_book_name>Yonsei medical journal</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5231">
		<reference_name>Lee et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Park SJ, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Lee G, Wallace WD, Lee S, Zeng G, Elashoff DA, Sharma S, Dubinett SM</authors>
		<title>Phase I Trial of Intratumoral Injection of <i>CCL21</i> Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8<sup>+</sup> T-cell Infiltration</title>
		<year>2017</year>
		<volume>23</volume>
		<issue>16</issue>
		<pages>4556-4568</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5118">
		<reference_name>Lee et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lee SJ, Kim HJ, Huh YM, Kim IW, Jeong JH, Kim JC, Kim JD</authors>
		<title>Functionalized Magnetic PLGA Nanospheres for Targeting and Bioimaging of Breast Cancer</title>
		<year>2018</year>
		<volume>18</volume>
		<issue>3</issue>
		<pages>1542-1547</pages>
		<journal_book_name>Journal of nanoscience and nanotechnology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2343">
		<reference_name>Leitner et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Leitner WW, Hwang LN, deVeer MJ, Zhou A, Silverman RH, Williams BR, Dubensky TW, Ying H, Restifo NP</authors>
		<title>Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways</title>
		<year>2003</year>
		<volume>9</volume>
		<issue>1</issue>
		<pages>33-39</pages>
		<journal_book_name>Nature medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5253">
		<reference_name>Leitner et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Leitner WW, Hwang LN, Bergmann-Leitner ES, Finkelstein SE, Frank S, Restifo NP</authors>
		<title>Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines</title>
		<year>2004</year>
		<volume>22</volume>
		<issue>11-12</issue>
		<pages>1537-1544</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2357">
		<reference_name>Leslie et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Leslie MC, Zhao YJ, Lachman LB, Hwu P, Wu GJ, Bar-Eli M</authors>
		<title>Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis</title>
		<year>2007</year>
		<volume>14</volume>
		<issue>4</issue>
		<pages>316-323</pages>
		<journal_book_name>Gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5259">
		<reference_name>Lesterhuis et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lesterhuis WJ, de Vries IJ, Schuurhuis DH, Boullart AC, Jacobs JF, de Boer AJ, Scharenborg NM, Brouwer HM, van de Rakt MW, Figdor CG, Ruers TJ, Adema GJ, Punt CJ</authors>
		<title>Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests</title>
		<year>2006</year>
		<volume>17</volume>
		<issue>6</issue>
		<pages>974-980</pages>
		<journal_book_name>Annals of oncology : official journal of the European Society for Medical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5184">
		<reference_name>Li et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Li L, Yang G, Ren C, Tanimoto R, Hirayama T, Wang J, Hawke D, Kim SM, Lee JS, Goltsov AA, Park S, Ittmann MM, Troncoso P, Thompson TC</authors>
		<title>Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2</title>
		<year>2013</year>
		<volume>7</volume>
		<issue>3</issue>
		<pages>484-496</pages>
		<journal_book_name>Molecular oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4036">
		<reference_name>Li et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Li Y, Li RC, Ye Q, Li C, Liu YP, Ma X, Li Y, Zhao H, Chen X, Assudani D, Karkada N, Han HH, Van Der Meeren O, Mesaros N</authors>
		<title>Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants</title>
		<year>2016</year>
		<volume></volume>
		<issue></issue>
		<pages>1-11</pages>
		<journal_book_name>Human vaccines &amp; immunotherapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5149">
		<reference_name>Li et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Li J, Chen J, Li X, Qian Y</authors>
		<title>Vaccination efficacy with marrow mesenchymal stem cell against cancer was enhanced under simulated microgravity</title>
		<year>2017</year>
		<volume>485</volume>
		<issue>3</issue>
		<pages>606-613</pages>
		<journal_book_name>Biochemical and biophysical research communications</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2348">
		<reference_name>Liao et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Liao JC, Gregor P, Wolchok JD, Orlandi F, Craft D, Leung C, Houghton AN, Bergman PJ</authors>
		<title>Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma</title>
		<year>2006</year>
		<volume>6</volume>
		<issue></issue>
		<pages>8</pages>
		<journal_book_name>Cancer immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2955">
		<reference_name>Lieberman et al., 1975</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lieberman R, Wybran J, Epstein W</authors>
		<title>The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma</title>
		<year>1975</year>
		<volume>35</volume>
		<issue>3</issue>
		<pages>756-777</pages>
		<journal_book_name>Cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2907">
		<reference_name>Lienard et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lienard D, Avril MF, Le Gal FA, Baumgaertner P, Vermeulen W, Blom A, Geldhof C, Rimoldi D, Pagliusi S, Romero P, Dietrich PY, Corvaia N, Speiser DE</authors>
		<title>Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant</title>
		<year>2009</year>
		<volume>32</volume>
		<issue>8</issue>
		<pages>875-883</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5162">
		<reference_name>Lilleby et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, Hole KH, Inderberg EM</authors>
		<title>Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer</title>
		<year>2017</year>
		<volume>66</volume>
		<issue>7</issue>
		<pages>891-901</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3916">
		<reference_name>Lin et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lin HC, Chao YH, Wu KH, Yen TY, Hsu YL, Hsieh TH, Wei HM, Wu JL, Muo CH, Hwang KP, Peng CT, Lin CC, Li TC</authors>
		<title>Increased risk of herpes zoster in children with cancer: A nationwide population-based cohort study</title>
		<year>2016</year>
		<volume>95</volume>
		<issue>30</issue>
		<pages>e4037</pages>
		<journal_book_name>Medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2340">
		<reference_name>Lindencrona et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lindencrona JA, Preiss S, Kammertoens T, SchÃƒÂ¼ler T, Piechocki M, Wei WZ, Seliger B, Blankenstein T, Kiessling R</authors>
		<title>CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells</title>
		<year>2004</year>
		<volume>109</volume>
		<issue>2</issue>
		<pages>259-264</pages>
		<journal_book_name>International journal of cancer. Journal international du cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5350">
		<reference_name>Lindsey et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lindsey KR, Gritz L, Sherry R, Abati A, Fetsch PA, Goldfeder LC, Gonzales MI, Zinnack KA, Rogers-Freezer L, Haworth L, Mavroukakis SA, White DE, Steinberg SM, Restifo NP, Panicali DL, Rosenberg SA, Topalian SL</authors>
		<title>Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma</title>
		<year>2006</year>
		<volume>12</volume>
		<issue>8</issue>
		<pages>2526-2537</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2944">
		<reference_name>Lipton et al., 1983</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lipton A, Harvey HA, Lawrence B, Gottlieb R, Kukrika M, Dixon R, Graham W, Miller S, Heckard R, Schelzel D, White DS</authors>
		<title>Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma</title>
		<year>1983</year>
		<volume>51</volume>
		<issue>1</issue>
		<pages>57-60</pages>
		<journal_book_name>Cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2940">
		<reference_name>Lipton et al., 1991</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lipton A, Harvey HA, Balch CM, Antle CE, Heckard R, Bartolucci AA</authors>
		<title>Corynebacterium parvum versus bacille Calmette-GuÃƒÂ©rin adjuvant immunotherapy of stage II malignant melanoma</title>
		<year>1991</year>
		<volume>9</volume>
		<issue>7</issue>
		<pages>1151-1156</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2991">
		<reference_name>Liu et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Liu H, Geng S, Feng C, Xie X, Wu B, Chen X, Zou Q, Wang S, Cui J, Xing R, Li W, Lu Y, Wang B</authors>
		<title>A DNA vaccine targeting p42.3 induces protective antitumor immunity via eliciting cytotoxic CD8+T lymphocytes in a murine melanoma model</title>
		<year>2013</year>
		<volume>9</volume>
		<issue>10</issue>
		<pages>2196-2202</pages>
		<journal_book_name>Human vaccines &amp; immunotherapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5375">
		<reference_name>Liu et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Liu Z, Yang Y, Zhang X, Wang H, Xu W, Wang H, Xiao F, Bai Z, Yao H, Ma X, Jin L, Wu C, Seth P, Zhang Z, Wang L</authors>
		<title>An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation</title>
		<year>2017</year>
		<volume>28</volume>
		<issue>8</issue>
		<pages>667-680</pages>
		<journal_book_name>Human gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1313">
		<reference_name>Lladser et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lladser A, Ljungberg K, Tufvesson H, Tazzari M, Roos AK, Quest AF, Kiessling R</authors>
		<title>Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma</title>
		<year>2010</year>
		<volume>59</volume>
		<issue>1</issue>
		<pages>81-92</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2368">
		<reference_name>Lode et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lode HN, Pertl U, Xiang R, Gaedicke G, Reisfeld RA</authors>
		<title>Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma</title>
		<year>2000</year>
		<volume>35</volume>
		<issue>6</issue>
		<pages>641-646</pages>
		<journal_book_name>Medical and pediatric oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5191">
		<reference_name>LoGuidice et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>LoGuidice A, Houlihan A, Deans R</authors>
		<title>Multipotent adult progenitor cells on an allograft scaffold facilitate the bone repair process</title>
		<year>2016</year>
		<volume>7</volume>
		<issue></issue>
		<pages>2041731416656148</pages>
		<journal_book_name>Journal of tissue engineering</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5322">
		<reference_name>Lohmueller et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lohmueller JJ, Sato S, Popova L, Chu IM, Tucker MA, Barberena R, Innocenti GM, Cudic M, Ham JD, Cheung WC, Polakiewicz RD, Finn OJ</authors>
		<title>Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential</title>
		<year>2016</year>
		<volume>6</volume>
		<issue></issue>
		<pages>31740</pages>
		<journal_book_name>Scientific reports</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5373">
		<reference_name>Lopes et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lopes L, Fletcher K, Ikeda Y, Collins M</authors>
		<title>Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy</title>
		<year>2006</year>
		<volume>55</volume>
		<issue>8</issue>
		<pages>1011-1016</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3952">
		<reference_name>Lotem et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lotem M, Shiloni E, Pappo I, Drize O, Hamburger T, Weitzen R, Isacson R, Kaduri L, Merims S, Frankenburg S, Peretz T</authors>
		<title>Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma</title>
		<year>2004</year>
		<volume>90</volume>
		<issue>4</issue>
		<pages>773-780</pages>
		<journal_book_name>British journal of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5287">
		<reference_name>Lotem et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lotem M, Machlenkin A, Hamburger T, Nissan A, Kadouri L, Frankenburg S, Gimmon Z, Elias O, David IB, Kuznetz A, Shiloni E, Peretz T</authors>
		<title>Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells</title>
		<year>2009</year>
		<volume>15</volume>
		<issue>15</issue>
		<pages>4968-4977</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5272">
		<reference_name>Lu et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lu Y, Xu LC, Parker N, Westrick E, Reddy JA, Vetzel M, Low PS, Leamon CP</authors>
		<title>Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate-targeted immunotherapy in hapten-immunized mice</title>
		<year>2006</year>
		<volume>5</volume>
		<issue>12</issue>
		<pages>3258-3267</pages>
		<journal_book_name>Molecular cancer therapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3899">
		<reference_name>Lu et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lu Y, Klein PJ, Westrick E, Xu LC, Santhapuram HK, Bloomfield A, Howard SJ, Vlahov IR, Ellis PR, Low PS, Leamon CP</authors>
		<title>Strategy to prevent drug-related hypersensitivity in folate-targeted hapten immunotherapy of cancer</title>
		<year>2009</year>
		<volume>11</volume>
		<issue>3</issue>
		<pages>628-638</pages>
		<journal_book_name>The AAPS journal</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3947">
		<reference_name>Lu et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lu S, Ren J, Li Q, Jiang Z, Chen Y, Xu K, Ruan B, Yang S, Xie T, Yang L, Li J, Yao J</authors>
		<title>Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization</title>
		<year>2016</year>
		<volume></volume>
		<issue></issue>
		<pages>0</pages>
		<journal_book_name>Human vaccines &amp; immunotherapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5182">
		<reference_name>Lubaroff et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lubaroff DM, Konety BR, Link B, Gerstbrein J, Madsen T, Shannon M, Howard J, Paisley J, Boeglin D, Ratliff TL, Williams RD</authors>
		<title>Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results</title>
		<year>2009</year>
		<volume>15</volume>
		<issue>23</issue>
		<pages>7375-7380</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5239">
		<reference_name>Lutz et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S, Onners B, Tartakovsky I, Choi M, Sharma R, Illei PB, Hruban RH, Abrams RA, Le D, Jaffee E, Laheru D</authors>
		<title>A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation</title>
		<year>2011</year>
		<volume>253</volume>
		<issue>2</issue>
		<pages>328-335</pages>
		<journal_book_name>Annals of surgery</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3927">
		<reference_name>Luxembourg et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Luxembourg A, Moreira ED Jr, Samakoses R, Kim KH, Sun X, Maansson R, Moeller E, Christiano S, Chen J</authors>
		<title>Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine</title>
		<year>2015</year>
		<volume>11</volume>
		<issue>6</issue>
		<pages>1306-1312</pages>
		<journal_book_name>Human vaccines &amp; immunotherapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3992">
		<reference_name>Luxembourg et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Luxembourg A, Brown D, Bouchard C, Giuliano AR, Iversen OE, Joura EA, Penny ME, Restrepo JA, Romaguera J, Maansson R, Moeller E, Ritter M, Chen J</authors>
		<title>Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine</title>
		<year>2015</year>
		<volume>11</volume>
		<issue>6</issue>
		<pages>1313-1322</pages>
		<journal_book_name>Human vaccines &amp; immunotherapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2966">
		<reference_name>Ly et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ly LV, Sluijter M, van der Burg SH, Jager MJ, van Hall T</authors>
		<title>Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma</title>
		<year>2013</year>
		<volume>190</volume>
		<issue>1</issue>
		<pages>489-496</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5257">
		<reference_name>Ma et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ma Y, Xu YC, Tang L, Zhang Z, Wang J, Wang HX</authors>
		<title>Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety</title>
		<year>2012</year>
		<volume>1</volume>
		<issue>1</issue>
		<pages>11</pages>
		<journal_book_name>Experimental hematology &amp; oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2948">
		<reference_name>MacGregor et al., 1977</reference_name>
		<reference_type>journal</reference_type>
		<authors>MacGregor AB, Falk RE, Landi S, Ambus U, Samuel ES, Langer B</authors>
		<title>Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-GuÃƒÂ©rin</title>
		<year>1977</year>
		<volume>20</volume>
		<issue>1</issue>
		<pages>25-30</pages>
		<journal_book_name>Canadian journal of surgery. Journal canadien de chirurgie</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5374">
		<reference_name>Mahipal et al., 2019</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mahipal A, Ejadi S, Gnjatic S, Kim-Schulze S, Lu H, Ter Meulen JH, Kenney R, Odunsi K</authors>
		<title>First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1</title>
		<year>2019</year>
		<volume>68</volume>
		<issue>7</issue>
		<pages>1211-1222</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5221">
		<reference_name>Mahmud et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mahmud SM, Bozat-Emre S, MostaÃ§o-Guidolin LC, Marrie RA</authors>
		<title>Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada</title>
		<year>2018</year>
		<volume>24</volume>
		<issue>7</issue>
		<pages>1267-1274</pages>
		<journal_book_name>Emerging infectious diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5197">
		<reference_name>Mailliard et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P</authors>
		<title>alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity</title>
		<year>2004</year>
		<volume>64</volume>
		<issue>17</issue>
		<pages>5934-5937</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3227">
		<reference_name>Mandl et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mandl S, Sigal LJ, Rock KL, Andino R</authors>
		<title>Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen</title>
		<year>1998</year>
		<volume>95</volume>
		<issue>14</issue>
		<pages>8216-8221</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3932">
		<reference_name>Manegold and Thatcher, 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Manegold C, Thatcher N</authors>
		<title>Survival improvement in thoracic cancer: progress from the last decade and beyond</title>
		<year>2007</year>
		<volume>57 Suppl 2</volume>
		<issue></issue>
		<pages>S3-5</pages>
		<journal_book_name>Lung cancer (Amsterdam, Netherlands)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2401">
		<reference_name>Manley et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Manley CA, Leibman NF, Wolchok JD, RiviÃƒÂ¨re IC, Bartido S, Craft DM, Bergman PJ</authors>
		<title>Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs</title>
		<year>2011</year>
		<volume>25</volume>
		<issue>1</issue>
		<pages>94-99</pages>
		<journal_book_name>Journal of veterinary internal medicine / American College of Veterinary Internal Medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1321">
		<reference_name>Maraskovsky et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Maraskovsky E, SjÃ¶lander S, Drane DP, Schnurr M, Le TT, Mateo L, Luft T, Masterman KA, Tai TY, Chen Q, Green S, SjÃ¶lander A, Pearse MJ, Lemonnier FA, Chen W, Cebon J, Suhrbier A</authors>
		<title>NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors</title>
		<year>2004</year>
		<volume>10</volume>
		<issue>8</issue>
		<pages>2879-2890</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3933">
		<reference_name>Marshall et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L, Park S, Panicali D, Schlom J</authors>
		<title>Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas</title>
		<year>2005</year>
		<volume>23</volume>
		<issue>4</issue>
		<pages>720-731</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5201">
		<reference_name>Marshall, 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Marshall J</authors>
		<title>Carcinoembryonic antigen-based vaccines</title>
		<year>2003</year>
		<volume>30</volume>
		<issue>3 Suppl 8</issue>
		<pages>30-36</pages>
		<journal_book_name>Seminars in oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference976">
		<reference_name>Maruyama et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Maruyama H, Zaloudik J, Li W, Sperlagh M, Koido T, Somasundaram R, Scheck S, Prewett M, Herlyn D</authors>
		<title>Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine</title>
		<year>2000</year>
		<volume>49</volume>
		<issue>3</issue>
		<pages>123-132</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5245">
		<reference_name>Mastelic-Gavillet et al., 2019</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon PO, Kandalaft LE</authors>
		<title>Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results</title>
		<year>2019</year>
		<volume>10</volume>
		<issue></issue>
		<pages>766</pages>
		<journal_book_name>Frontiers in immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5255">
		<reference_name>Matheson and Goa, 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Matheson AJ, Goa KL</authors>
		<title>Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection</title>
		<year>2000</year>
		<volume>2</volume>
		<issue>2</issue>
		<pages>139-159</pages>
		<journal_book_name>Paediatric drugs</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2929">
		<reference_name>Mattarollo et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mattarollo SR, Steegh K, Li M, Duret H, Foong Ngiow S, Smyth MJ</authors>
		<title>Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells</title>
		<year>2013</year>
		<volume>91</volume>
		<issue>1</issue>
		<pages>105-114</pages>
		<journal_book_name>Immunology and cell biology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5214">
		<reference_name>McCaffery et al., 1996</reference_name>
		<reference_type>journal</reference_type>
		<authors>McCaffery M, Yao TJ, Williams L, Livingston PO, Houghton AN, Chapman PB</authors>
		<title>Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant</title>
		<year>1996</year>
		<volume>2</volume>
		<issue>4</issue>
		<pages>679-686</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5186">
		<reference_name>McCormick et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>McCormick KA, Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG</authors>
		<title>Pancreatic cancer: Update on immunotherapies and algenpantucel-L</title>
		<year>2016</year>
		<volume>12</volume>
		<issue>3</issue>
		<pages>563-575</pages>
		<journal_book_name>Human vaccines &amp; immunotherapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5137">
		<reference_name>McKenzie et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>McKenzie IF, Apostolopoulos V, Lees C, Xing PX, Lofthouse S, Osinski C, Popovski V, Acres B, Pietersz G</authors>
		<title>Oxidised mannan antigen conjugates preferentially stimulate T1 type immune responses</title>
		<year>1998</year>
		<volume>63</volume>
		<issue>1-2</issue>
		<pages>185-190</pages>
		<journal_book_name>Veterinary immunology and immunopathology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1403">
		<reference_name>McNeel et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G</authors>
		<title>Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer</title>
		<year>2009</year>
		<volume>27</volume>
		<issue>25</issue>
		<pages>4047-4054</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3837">
		<reference_name>McNeil et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>McNeil SA, Noya F, Dionne M, Predy G, Meekison W, Ojah C, Ferro S, Mills EL, Langley JM, Halperin SA</authors>
		<title>Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults</title>
		<year>2007</year>
		<volume>25</volume>
		<issue>17</issue>
		<pages>3464-3474</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3914">
		<reference_name>Mehendale et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mehendale S, van Lunzen J, Clumeck N, Rockstroh J, Vets E, Johnson PR, Anklesaria P, Barin B, Boaz M, Kochhar S, Lehrman J, Schmidt C, Peeters M, Schwarze-Zander C, Kabamba K, Glaunsinger T, Sahay S, Thakar M, Paranjape R, Gilmour J, Excler JL, Fast P, Heald AE</authors>
		<title>A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine</title>
		<year>2008</year>
		<volume>24</volume>
		<issue>6</issue>
		<pages>873-880</pages>
		<journal_book_name>AIDS research and human retroviruses</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5342">
		<reference_name>Meleshko et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Meleshko AN, Petrovskaya NA, Savelyeva N, Vashkevich KP, Doronina SN, Sachivko NV</authors>
		<title>Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma</title>
		<year>2017</year>
		<volume>13</volume>
		<issue>6</issue>
		<pages>1-6</pages>
		<journal_book_name>Human vaccines &amp; immunotherapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5353">
		<reference_name>Melssen et al., 2019</reference_name>
		<reference_type>journal</reference_type>
		<authors>Melssen MM, Petroni GR, Chianese-Bullock KA, Wages NA, Grosh WW, Varhegyi N, Smolkin ME, Smith KT, Galeassi NV, Deacon DH, Gaughan EM, Slingluff CL Jr</authors>
		<title>A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients</title>
		<year>2019</year>
		<volume>7</volume>
		<issue>1</issue>
		<pages>163</pages>
		<journal_book_name>Journal for immunotherapy of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4025">
		<reference_name>Meng et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Meng WS, Butterfield LH, Ribas A, Dissette VB, Heller JB, Miranda GA, Glaspy JA, McBride WH, Economou JS</authors>
		<title>alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination</title>
		<year>2001</year>
		<volume>61</volume>
		<issue>24</issue>
		<pages>8782-8786</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5304">
		<reference_name>Mevorach et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mevorach D, Zuckerman T, Reiner I, Shimoni A, Samuel S, Nagler A, Rowe JM, Or R</authors>
		<title>Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial</title>
		<year>2014</year>
		<volume>20</volume>
		<issue>1</issue>
		<pages>58-65</pages>
		<journal_book_name>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2354">
		<reference_name>Meyer et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Meyer RG, Britten CM, Siepmann U, Petzold B, Sagban TA, Lehr HA, Weigle B, Schmitz M, Mateo L, Schmidt B, Bernhard H, Jakob T, Hein R, Schuler G, Schuler-Thurner B, Wagner SN, Drexler I, Sutter G, Arndtz N, Chaplin P, Metz J, Enk A, Huber C, WÃƒÂ¶lfel T</authors>
		<title>A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)</title>
		<year>2005</year>
		<volume>54</volume>
		<issue>5</issue>
		<pages>453-467</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2965">
		<reference_name>Miguel et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Miguel A, Herrero MJ, Sendra L, Botella R, AlgÃƒÂ¡s R, SÃƒÂ¡nchez M, AliÃƒÂ±o SF</authors>
		<title>Comparative antitumor effect of preventive versus therapeutic vaccines employing B16 melanoma cells genetically modified to express GM-CSF and B7.2 in a murine model</title>
		<year>2012</year>
		<volume>4</volume>
		<issue>11</issue>
		<pages>1058-1081</pages>
		<journal_book_name>Toxins</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2992">
		<reference_name>Miguel et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Miguel A, Herrero MJ, Sendra L, Botella R, AlgÃƒÂ¡s R, SÃƒÂ¡nchez M, AliÃƒÂ±o SF</authors>
		<title>Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines</title>
		<year>2013</year>
		<volume>20</volume>
		<issue>10</issue>
		<pages>576-581</pages>
		<journal_book_name>Cancer gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3962">
		<reference_name>Miller et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Miller MJ, Foy KC, Overholser JP, Nahta R, Kaumaya PT</authors>
		<title>HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells</title>
		<year>2014</year>
		<volume>3</volume>
		<issue>11</issue>
		<pages>e956012</pages>
		<journal_book_name>Oncoimmunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5248">
		<reference_name>Millman and Pagliuca, 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Millman JR, Pagliuca FW</authors>
		<title>Autologous Pluripotent Stem Cell-Derived Î²-Like Cells for Diabetes Cellular Therapy</title>
		<year>2017</year>
		<volume>66</volume>
		<issue>5</issue>
		<pages>1111-1120</pages>
		<journal_book_name>Diabetes</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2297">
		<reference_name>Mincheff et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S, Meryman HT</authors>
		<title>Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial</title>
		<year>2000</year>
		<volume>38</volume>
		<issue>2</issue>
		<pages>208-217</pages>
		<journal_book_name>European urology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2371">
		<reference_name>Mincheff et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mincheff M, Zoubak S, Makogonenko Y</authors>
		<title>Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals</title>
		<year>2006</year>
		<volume>13</volume>
		<issue>4</issue>
		<pages>436-444</pages>
		<journal_book_name>Cancer gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5352">
		<reference_name>Mitchell et al., 1994</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mitchell MS, Jakowatz J, Harel W, Dean G, Stevenson L, Boswell WD, Groshen S</authors>
		<title>Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma</title>
		<year>1994</year>
		<volume>12</volume>
		<issue>2</issue>
		<pages>402-411</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5113">
		<reference_name>Mitchell et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mitchell D, Chintala S, Dey M</authors>
		<title>Plasmacytoid dendritic cell in immunity and cancer</title>
		<year>2018</year>
		<volume>322</volume>
		<issue></issue>
		<pages>63-73</pages>
		<journal_book_name>Journal of neuroimmunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2933">
		<reference_name>Mittelman et al., 1995</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mittelman A, Chen GZ, Wong GY, Liu C, Hirai S, Ferrone S</authors>
		<title>Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma</title>
		<year>1995</year>
		<volume>1</volume>
		<issue>7</issue>
		<pages>705-713</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3975">
		<reference_name>Mittendorf et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mittendorf EA, Alatrash G, Xiao H, Clifton GT, Murray JL, Peoples GE</authors>
		<title>Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials</title>
		<year>2011</year>
		<volume>10</volume>
		<issue>6</issue>
		<pages>755-774</pages>
		<journal_book_name>Expert review of vaccines</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3861">
		<reference_name>Miyauchi et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Miyauchi M, Murata M, Shibuya K, Koga-Yamakawa E, Uenishi Y, Kusunose N, Sunagawa M, Yano I, Kashiwazaki Y</authors>
		<title>Arabino-mycolates derived from cell-wall skeleton of Mycobacterium bovis BCG as a prominent structure for recognition by host immunity</title>
		<year>2011</year>
		<volume>5</volume>
		<issue>3</issue>
		<pages>130-135</pages>
		<journal_book_name>Drug discoveries &amp; therapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3900">
		<reference_name>Miyauchi et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Miyauchi M, Murata M, Fukushima A, Sato T, Nakagawa M, Fujii T, Koseki N, Chiba N, Kashiwazaki Y</authors>
		<title>Optimization of cell-wall skeleton derived from Mycobacterium bovis BCG Tokyo 172 (SMP-105) emulsion in delayed-type hypersensitivity and antitumor models</title>
		<year>2012</year>
		<volume>6</volume>
		<issue>4</issue>
		<pages>218-225</pages>
		<journal_book_name>Drug discoveries &amp; therapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5097">
		<reference_name>Moehler et al., 2019</reference_name>
		<reference_type>journal</reference_type>
		<authors>Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, Yim HJ, Byun KS, Baron A, Ungerechts G, Jonker D, Ruo L, Cho M, Kaubisch A, Wege H, Merle P, Ebert O, Habersetzer F, Blanc JF, Rosmorduc O, Lencioni R, Patt R, Leen AM, Foerster F, Homerin M, Stojkowitz N, Lusky M, Limacher JM, Hennequi M, Gaspar N, McFadden B, De Silva N, Shen D, Pelusio A, Kirn DH, Breitbach CJ, Burke JM</authors>
		<title>Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)</title>
		<year>2019</year>
		<volume>8</volume>
		<issue>8</issue>
		<pages>1615817</pages>
		<journal_book_name>Oncoimmunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5121">
		<reference_name>Mohammadzadeh et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mohammadzadeh M, Shirmohammadi M, Ghojazadeh M, Nikniaz L, Raeisi M, Aghdas SAM</authors>
		<title>Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis</title>
		<year>2018</year>
		<volume>6</volume>
		<issue>4</issue>
		<pages>119-125</pages>
		<journal_book_name>Prostate international</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference956">
		<reference_name>Mohanty et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mohanty K, Saha A, Pal S, Mallick P, Chatterjee SK, Foon KA, Bhattacharya-Chatterjee M</authors>
		<title>Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu</title>
		<year>2007</year>
		<volume>104</volume>
		<issue>1</issue>
		<pages>1-11</pages>
		<journal_book_name>Breast cancer research and treatment</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5336">
		<reference_name>Mohn et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mohn KG, Smith I, Sjursen H, Cox RJ</authors>
		<title>Immune responses after live attenuated influenza vaccination</title>
		<year>2018</year>
		<volume>14</volume>
		<issue>3</issue>
		<pages>571-578</pages>
		<journal_book_name>Human vaccines &amp; immunotherapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2967">
		<reference_name>Mordoh et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mordoh J, Tapia IJ, Barrio MM</authors>
		<title>A word of caution: do not wake sleeping dogs; micrometastases of melanoma suddenly grew after progesterone treatment</title>
		<year>2013</year>
		<volume>13</volume>
		<issue></issue>
		<pages>132</pages>
		<journal_book_name>BMC cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3990">
		<reference_name>Moreira et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Qi H, Hyatt D, Martin J, Moeller E, Ritter M, Baudin M, Luxembourg A</authors>
		<title>Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials</title>
		<year>2016</year>
		<volume>138</volume>
		<issue>2</issue>
		<pages></pages>
		<journal_book_name>Pediatrics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1304">
		<reference_name>Morera et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Morera Y, Bequet-Romero M, Ayala M, LamdÃ¡n H, Agger EM, Andersen P, Gavilondo JV</authors>
		<title>Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants</title>
		<year>2008</year>
		<volume>11</volume>
		<issue>4</issue>
		<pages>381-393</pages>
		<journal_book_name>Angiogenesis</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3854">
		<reference_name>Morse et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Morse MA, Chaudhry A, Gabitzsch ES, Hobeika AC, Osada T, Clay TM, Amalfitano A, Burnett BK, Devi GR, Hsu DS, Xu Y, Balcaitis S, Dua R, Nguyen S, Balint JP Jr, Jones FR, Lyerly HK</authors>
		<title>Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients</title>
		<year>2013</year>
		<volume>62</volume>
		<issue>8</issue>
		<pages>1293-1301</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3828">
		<reference_name>Morse et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, Osada T, Onaitis M, Clary BM, Hsu D, Devi GR, Bulusu A, Annechiarico RP, Chadaram V, Clay TM, Lyerly HK</authors>
		<title>A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer</title>
		<year>2013</year>
		<volume>258</volume>
		<issue>6</issue>
		<pages>879-886</pages>
		<journal_book_name>Annals of surgery</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2934">
		<reference_name>Morton et al., 1992</reference_name>
		<reference_type>journal</reference_type>
		<authors>Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R</authors>
		<title>Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine</title>
		<year>1992</year>
		<volume>216</volume>
		<issue>4</issue>
		<pages>463-482</pages>
		<journal_book_name>Annals of surgery</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3920">
		<reference_name>Moulton et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL</authors>
		<title>Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival</title>
		<year>2002</year>
		<volume>8</volume>
		<issue>7</issue>
		<pages>2044-2051</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5265">
		<reference_name>Mpendo et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mpendo J, Mutua G, Nyombayire J, Ingabire R, Nanvubya A, Anzala O, Karita E, Hayes P, Kopycinski J, Dally L, Hannaman D, Egan MA, Eldridge JH, Syvertsen K, Lehrman J, Rasmussen B, Gilmour J, Cox JH, Fast PE, Schmidt C</authors>
		<title>A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults</title>
		<year>2015</year>
		<volume>10</volume>
		<issue>8</issue>
		<pages>e0134287</pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3931">
		<reference_name>Muderspach et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J</authors>
		<title>A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive</title>
		<year>2000</year>
		<volume>6</volume>
		<issue>9</issue>
		<pages>3406-3416</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5296">
		<reference_name>Mullane et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mullane KM, Winston DJ, Wertheim MS, Betts RF, Poretz DM, Camacho LH, Pergam SA, Mullane MR, Stek JE, Sterling TM, Zhao Y, Manoff SB, Annunziato PW</authors>
		<title>Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults</title>
		<year>2013</year>
		<volume>208</volume>
		<issue>9</issue>
		<pages>1375-1385</pages>
		<journal_book_name>The Journal of infectious diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5314">
		<reference_name>Muthumani et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Muthumani K, Marnin L, Kudchodkar SB, Perales-Puchalt A, Choi H, Agarwal S, Scott VL, Reuschel EL, Zaidi FI, Duperret EK, Wise MC, Kraynyak KA, Ugen KE, Sardesai NY, Joseph Kim J, Weiner DB</authors>
		<title>Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody</title>
		<year>2017</year>
		<volume>66</volume>
		<issue>12</issue>
		<pages>1577-1588</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3974">
		<reference_name>Nagabhushan et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Nagabhushan TL, Maneval DC, Benedict WF, Wen SF, Ihnat PM, Engler H, Connor RJ</authors>
		<title>Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer</title>
		<year>2007</year>
		<volume>18</volume>
		<issue>5-6</issue>
		<pages>389-394</pages>
		<journal_book_name>Cytokine &amp; growth factor reviews</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5166">
		<reference_name>Nagayama et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Nagayama H, Matsumoto K, Isoo N, Ohno H, Takahashi N, Nakaoka T, Shinozaki M, Watanabe M, Inoue Y, Nagamura F, Oyaizu N, Yamashita N</authors>
		<title>Gastrointestinal bleeding during anti-angiogenic peptide vaccination in combination with gemcitabine for advanced pancreatic cancer</title>
		<year>2010</year>
		<volume>3</volume>
		<issue>6</issue>
		<pages>307-317</pages>
		<journal_book_name>Clinical journal of gastroenterology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1319">
		<reference_name>Narayanan et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Narayanan K, Jaramillo A, Benshoff ND, Campbell LG, Fleming TP, Dietz JR, Mohanakumar T</authors>
		<title>Response of established human breast tumors to vaccination with mammaglobin-A cDNA</title>
		<year>2004</year>
		<volume>96</volume>
		<issue>18</issue>
		<pages>1388-1396</pages>
		<journal_book_name>Journal of the National Cancer Institute</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5354">
		<reference_name>Nasser et al., 2020</reference_name>
		<reference_type>journal</reference_type>
		<authors>Nasser R, Rakedzon S, Dickstein Y, Mousa A, Solt I, Peterisel N, Feldman T, Neuberger A</authors>
		<title>Are all vaccines safe for the pregnant traveller? A systematic review and meta-analysis</title>
		<year>2020</year>
		<volume>27</volume>
		<issue>2</issue>
		<pages></pages>
		<journal_book_name>Journal of travel medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4027">
		<reference_name>Nau, 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Nau JY</authors>
		<title>[Zona vaccine, molecular screening of lung cancer]</title>
		<year>2015</year>
		<volume>11</volume>
		<issue>477</issue>
		<pages>1258-1259</pages>
		<journal_book_name>Revue medicale suisse</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4047">
		<reference_name>NCIt: C48373</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>NCIt vaccine â€˜Alpha Fetoprotein Plasmid DNA Vaccineâ€™</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48373</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4294">
		<reference_name>NCIT_C100099</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C100099</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4549">
		<reference_name>NCIT_C101094</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C101094</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4132">
		<reference_name>NCIT_C101262</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C101262</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4256">
		<reference_name>NCIT_C101777</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C101777</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4498">
		<reference_name>NCIT_C101891</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C101891</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4497">
		<reference_name>NCIT_C101892</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C101892</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4372">
		<reference_name>NCIT_C102541</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C102541</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4590">
		<reference_name>NCIT_C102751</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C102751</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4591">
		<reference_name>NCIT_C102753</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C102753</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4542">
		<reference_name>NCIT_C102782</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C102782</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4541">
		<reference_name>NCIT_C102787</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C102787</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4559">
		<reference_name>NCIT_C102879</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C102879</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4560">
		<reference_name>NCIT_C102978</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C102978</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4601">
		<reference_name>NCIT_C102982</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C102982</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4557">
		<reference_name>NCIT_C103192</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C103192</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4592">
		<reference_name>NCIT_C103823</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C103823</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4428">
		<reference_name>NCIT_C103830</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C103830</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4159">
		<reference_name>NCIT_C104419</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C104419</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4205">
		<reference_name>NCIT_C104734</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C104734</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4206">
		<reference_name>NCIT_C104737</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C104737</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4200">
		<reference_name>NCIT_C104738</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C104738</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4573">
		<reference_name>NCIT_C104743</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C104743</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4662">
		<reference_name>NCIT_C104747</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C104747</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4492">
		<reference_name>NCIT_C105806</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C105806</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4380">
		<reference_name>NCIT_C106242</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C106242</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4545">
		<reference_name>NCIT_C106257</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C106257</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4526">
		<reference_name>NCIT_C107159</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C107159</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4420">
		<reference_name>NCIT_C107243</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C107243</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4305">
		<reference_name>NCIT_C111036</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C111036</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4525">
		<reference_name>NCIT_C111037</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C111037</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4494">
		<reference_name>NCIT_C111688</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C111688</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4261">
		<reference_name>NCIT_C111900</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C111900</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4262">
		<reference_name>NCIT_C111903</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C111903</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4227">
		<reference_name>NCIT_C111991</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C111991</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4229">
		<reference_name>NCIT_C111998</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C111998</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4339">
		<reference_name>NCIT_C112005</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C112005</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4146">
		<reference_name>NCIT_C112206</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C112206</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4371">
		<reference_name>NCIT_C1126</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C1126</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4617">
		<reference_name>NCIT_C113174</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C113174</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4275">
		<reference_name>NCIT_C113296</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C113296</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4338">
		<reference_name>NCIT_C113432</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C113432</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4192">
		<reference_name>NCIT_C113647</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C113647</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4337">
		<reference_name>NCIT_C113651</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C113651</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4336">
		<reference_name>NCIT_C113653</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C113653</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4332">
		<reference_name>NCIT_C113786</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C113786</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4177">
		<reference_name>NCIT_C113794</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C113794</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4241">
		<reference_name>NCIT_C113807</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C113807</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4665">
		<reference_name>NCIT_C114285</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C114285</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4660">
		<reference_name>NCIT_C114289</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C114289</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4210">
		<reference_name>NCIT_C114293</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C114293</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4512">
		<reference_name>NCIT_C114295</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C114295</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4279">
		<reference_name>NCIT_C114380</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C114380</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4280">
		<reference_name>NCIT_C114385</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C114385</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4438">
		<reference_name>NCIT_C114496</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C114496</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4130">
		<reference_name>NCIT_C114755</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C114755</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4540">
		<reference_name>NCIT_C114990</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C114990</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4639">
		<reference_name>NCIT_C115101</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C115101</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4457">
		<reference_name>NCIT_C115105</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C115105</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4460">
		<reference_name>NCIT_C115106</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C115106</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4602">
		<reference_name>NCIT_C1159</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C1159</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4625">
		<reference_name>NCIT_C115976</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C115976</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4575">
		<reference_name>NCIT_C116067</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C116067</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4251">
		<reference_name>NCIT_C116321</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C116321</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4386">
		<reference_name>NCIT_C116331</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C116331</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4385">
		<reference_name>NCIT_C116332</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C116332</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4634">
		<reference_name>NCIT_C116709</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C116709</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4452">
		<reference_name>NCIT_C116736</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C116736</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4140">
		<reference_name>NCIT_C116740</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C116740</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4318">
		<reference_name>NCIT_C116777</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C116777</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4409">
		<reference_name>NCIT_C116847</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C116847</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4278">
		<reference_name>NCIT_C116848</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C116848</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4474">
		<reference_name>NCIT_C116868</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C116868</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4316">
		<reference_name>NCIT_C116879</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C116879</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4623">
		<reference_name>NCIT_C116880</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C116880</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4620">
		<reference_name>NCIT_C116888</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C116888</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4458">
		<reference_name>NCIT_C116893</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C116893</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4658">
		<reference_name>NCIT_C116920</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C116920</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4231">
		<reference_name>NCIT_C117235</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C117235</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4116">
		<reference_name>NCIT_C117725</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C117725</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4582">
		<reference_name>NCIT_C118364</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C118364</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4162">
		<reference_name>NCIT_C11845</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C11845</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4242">
		<reference_name>NCIT_C118851</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C118851</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4243">
		<reference_name>NCIT_C118852</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C118852</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4128">
		<reference_name>NCIT_C11915</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C11915</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4612">
		<reference_name>NCIT_C119614</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C119614</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4630">
		<reference_name>NCIT_C119616</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C119616</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4324">
		<reference_name>NCIT_C119617</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C119617</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4584">
		<reference_name>NCIT_C119664</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C119664</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4657">
		<reference_name>NCIT_C119745</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C119745</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4499">
		<reference_name>NCIT_C119759</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C119759</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4480">
		<reference_name>NCIT_C120039</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C120039</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4272">
		<reference_name>NCIT_C120118</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C120118</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4167">
		<reference_name>NCIT_C120129</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C120129</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4586">
		<reference_name>NCIT_C120183</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C120183</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4282">
		<reference_name>NCIT_C121544</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C121544</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4144">
		<reference_name>NCIT_C121570</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C121570</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4228">
		<reference_name>NCIT_C121640</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C121640</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4117">
		<reference_name>NCIT_C121777</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C121777</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4605">
		<reference_name>NCIT_C121848</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C121848</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4441">
		<reference_name>NCIT_C121856</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C121856</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4232">
		<reference_name>NCIT_C121947</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C121947</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4481">
		<reference_name>NCIT_C122396</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C122396</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4546">
		<reference_name>NCIT_C122399</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C122399</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4653">
		<reference_name>NCIT_C122678</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C122678</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4514">
		<reference_name>NCIT_C123283</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C123283</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4666">
		<reference_name>NCIT_C123378</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C123378</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4129">
		<reference_name>NCIT_C123381</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C123381</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4333">
		<reference_name>NCIT_C123918</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C123918</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4334">
		<reference_name>NCIT_C123919</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C123919</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4419">
		<reference_name>NCIT_C123921</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C123921</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4312">
		<reference_name>NCIT_C123923</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C123923</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4415">
		<reference_name>NCIT_C123928</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C123928</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4585">
		<reference_name>NCIT_C123930</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C123930</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4145">
		<reference_name>NCIT_C124054</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C124054</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4621">
		<reference_name>NCIT_C124652</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C124652</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4382">
		<reference_name>NCIT_C125631</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C125631</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4265">
		<reference_name>NCIT_C125692</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C125692</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4516">
		<reference_name>NCIT_C126797</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C126797</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4650">
		<reference_name>NCIT_C1325</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C1325</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4255">
		<reference_name>NCIT_C1455</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C1455</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4551">
		<reference_name>NCIT_C1479</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C1479</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4454">
		<reference_name>NCIT_C1643</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C1643</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4453">
		<reference_name>NCIT_C1648</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C1648</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4374">
		<reference_name>NCIT_C1690</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C1690</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4417">
		<reference_name>NCIT_C1830</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C1830</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4501">
		<reference_name>NCIT_C1977</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C1977</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4496">
		<reference_name>NCIT_C1978</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C1978</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4495">
		<reference_name>NCIT_C1979</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C1979</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4463">
		<reference_name>NCIT_C1980</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C1980</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4464">
		<reference_name>NCIT_C1981</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C1981</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4465">
		<reference_name>NCIT_C1982</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C1982</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4466">
		<reference_name>NCIT_C1983</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C1983</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4461">
		<reference_name>NCIT_C1985</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C1985</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4462">
		<reference_name>NCIT_C1986</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C1986</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4468">
		<reference_name>NCIT_C1988</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C1988</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4378">
		<reference_name>NCIT_C2023</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2023</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4608">
		<reference_name>NCIT_C2055</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2055</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4606">
		<reference_name>NCIT_C2057</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2057</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4450">
		<reference_name>NCIT_C2060</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2060</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4449">
		<reference_name>NCIT_C2063</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2063</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4610">
		<reference_name>NCIT_C2195</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2195</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4341">
		<reference_name>NCIT_C2204</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2204</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4203">
		<reference_name>NCIT_C2214</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2214</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4661">
		<reference_name>NCIT_C2227</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2227</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4515">
		<reference_name>NCIT_C2232</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2232</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4518">
		<reference_name>NCIT_C2235</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2235</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4517">
		<reference_name>NCIT_C2236</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2236</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4238">
		<reference_name>NCIT_C2237</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2237</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4403">
		<reference_name>NCIT_C2241</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2241</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4360">
		<reference_name>NCIT_C2339</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2339</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4443">
		<reference_name>NCIT_C2341</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2341</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4552">
		<reference_name>NCIT_C2382</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2382</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4664">
		<reference_name>NCIT_C2384</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2384</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4522">
		<reference_name>NCIT_C2403</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2403</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4383">
		<reference_name>NCIT_C2419</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2419</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4245">
		<reference_name>NCIT_C2423</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2423</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4247">
		<reference_name>NCIT_C2424</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2424</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4246">
		<reference_name>NCIT_C2426</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2426</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4250">
		<reference_name>NCIT_C2428</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2428</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4636">
		<reference_name>NCIT_C2430</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2430</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4637">
		<reference_name>NCIT_C2433</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2433</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4640">
		<reference_name>NCIT_C2436</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2436</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4642">
		<reference_name>NCIT_C2438</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2438</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4641">
		<reference_name>NCIT_C2439</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2439</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4485">
		<reference_name>NCIT_C2442</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2442</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4483">
		<reference_name>NCIT_C2445</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2445</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4173">
		<reference_name>NCIT_C2464</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2464</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4174">
		<reference_name>NCIT_C2465</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2465</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4578">
		<reference_name>NCIT_C2471</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2471</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4580">
		<reference_name>NCIT_C2473</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2473</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4576">
		<reference_name>NCIT_C2474</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2474</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4406">
		<reference_name>NCIT_C2485</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2485</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4276">
		<reference_name>NCIT_C2492</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2492</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4416">
		<reference_name>NCIT_C2493</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2493</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4273">
		<reference_name>NCIT_C2497</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2497</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4166">
		<reference_name>NCIT_C2501</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2501</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4323">
		<reference_name>NCIT_C2510</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2510</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4321">
		<reference_name>NCIT_C2512</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2512</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4489">
		<reference_name>NCIT_C2520</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2520</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4488">
		<reference_name>NCIT_C2521</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2521</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4479">
		<reference_name>NCIT_C2531</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2531</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4486">
		<reference_name>NCIT_C2534</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2534</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4672">
		<reference_name>NCIT_C2540</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2540</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4607">
		<reference_name>NCIT_C2545</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2545</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4405">
		<reference_name>NCIT_C2569</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2569</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4568">
		<reference_name>NCIT_C2576</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2576</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4204">
		<reference_name>NCIT_C2606</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2606</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4593">
		<reference_name>NCIT_C2619</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2619</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4502">
		<reference_name>NCIT_C2620</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2620</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4503">
		<reference_name>NCIT_C2622</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2622</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4506">
		<reference_name>NCIT_C2628</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2628</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4120">
		<reference_name>NCIT_C2640</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2640</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4119">
		<reference_name>NCIT_C2643</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2643</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4399">
		<reference_name>NCIT_C26444</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C26444</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4398">
		<reference_name>NCIT_C26445</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C26445</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4397">
		<reference_name>NCIT_C26446</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C26446</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4401">
		<reference_name>NCIT_C26449</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C26449</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4266">
		<reference_name>NCIT_C26450</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C26450</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4126">
		<reference_name>NCIT_C2648</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2648</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4530">
		<reference_name>NCIT_C2650</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2650</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4527">
		<reference_name>NCIT_C2657</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2657</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4431">
		<reference_name>NCIT_C2660</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2660</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4613">
		<reference_name>NCIT_C26645</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C26645</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4429">
		<reference_name>NCIT_C2666</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2666</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4430">
		<reference_name>NCIT_C2667</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2667</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4370">
		<reference_name>NCIT_C26680</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C26680</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4369">
		<reference_name>NCIT_C26681</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C26681</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4287">
		<reference_name>NCIT_C2674</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2674</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4286">
		<reference_name>NCIT_C2675</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2675</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4348">
		<reference_name>NCIT_C2680</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2680</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4349">
		<reference_name>NCIT_C2686</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2686</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4356">
		<reference_name>NCIT_C2709</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2709</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4531">
		<reference_name>NCIT_C2710</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2710</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4529">
		<reference_name>NCIT_C2718</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2718</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4215">
		<reference_name>NCIT_C2732</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2732</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4426">
		<reference_name>NCIT_C2740</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2740</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4425">
		<reference_name>NCIT_C2741</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2741</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4424">
		<reference_name>NCIT_C2742</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2742</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4423">
		<reference_name>NCIT_C2743</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2743</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4421">
		<reference_name>NCIT_C2746</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2746</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4588">
		<reference_name>NCIT_C2754</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2754</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4589">
		<reference_name>NCIT_C2757</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2757</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4122">
		<reference_name>NCIT_C2760</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2760</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4121">
		<reference_name>NCIT_C2761</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2761</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4124">
		<reference_name>NCIT_C2762</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2762</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4123">
		<reference_name>NCIT_C2763</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2763</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4125">
		<reference_name>NCIT_C2764</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2764</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4127">
		<reference_name>NCIT_C2766</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2766</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4163">
		<reference_name>NCIT_C2767</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2767</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4290">
		<reference_name>NCIT_C2771</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2771</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4288">
		<reference_name>NCIT_C2772</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2772</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4289">
		<reference_name>NCIT_C2773</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2773</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4292">
		<reference_name>NCIT_C2774</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2774</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4293">
		<reference_name>NCIT_C2775</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2775</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4291">
		<reference_name>NCIT_C2776</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2776</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4213">
		<reference_name>NCIT_C2781</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2781</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4376">
		<reference_name>NCIT_C2783</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2783</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4511">
		<reference_name>NCIT_C2786</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2786</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4510">
		<reference_name>NCIT_C2787</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2787</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4131">
		<reference_name>NCIT_C2798</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2798</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4411">
		<reference_name>NCIT_C2805</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2805</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4412">
		<reference_name>NCIT_C2806</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2806</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4304">
		<reference_name>NCIT_C2807</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2807</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4418">
		<reference_name>NCIT_C2809</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2809</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4659">
		<reference_name>NCIT_C2811</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2811</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4254">
		<reference_name>NCIT_C2814</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2814</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4253">
		<reference_name>NCIT_C2815</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2815</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4252">
		<reference_name>NCIT_C2816</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2816</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4646">
		<reference_name>NCIT_C2821</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2821</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4645">
		<reference_name>NCIT_C2822</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2822</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4643">
		<reference_name>NCIT_C2824</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2824</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4487">
		<reference_name>NCIT_C2830</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C2830</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4152">
		<reference_name>NCIT_C28330</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C28330</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4391">
		<reference_name>NCIT_C28503</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C28503</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4456">
		<reference_name>NCIT_C28549</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C28549</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4368">
		<reference_name>NCIT_C28550</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C28550</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4624">
		<reference_name>NCIT_C28551</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C28551</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4147">
		<reference_name>NCIT_C28682</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C28682</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4598">
		<reference_name>NCIT_C28775</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C28775</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4597">
		<reference_name>NCIT_C28776</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C28776</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4271">
		<reference_name>NCIT_C28780</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C28780</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4325">
		<reference_name>NCIT_C28784</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C28784</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4319">
		<reference_name>NCIT_C28810</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C28810</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4195">
		<reference_name>NCIT_C28860</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C28860</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4350">
		<reference_name>NCIT_C28877</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C28877</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4260">
		<reference_name>NCIT_C28878</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C28878</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4299">
		<reference_name>NCIT_C29065</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29065</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4329">
		<reference_name>NCIT_C29068</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29068</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4364">
		<reference_name>NCIT_C29086</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29086</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4564">
		<reference_name>NCIT_C29088</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29088</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4534">
		<reference_name>NCIT_C29090</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29090</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4533">
		<reference_name>NCIT_C29091</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29091</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4500">
		<reference_name>NCIT_C29112</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29112</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4211">
		<reference_name>NCIT_C29187</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29187</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4599">
		<reference_name>NCIT_C29192</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29192</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4587">
		<reference_name>NCIT_C29316</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29316</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4472">
		<reference_name>NCIT_C29317</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29317</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4234">
		<reference_name>NCIT_C29334</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29334</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4410">
		<reference_name>NCIT_C29337</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29337</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4237">
		<reference_name>NCIT_C29338</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29338</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4451">
		<reference_name>NCIT_C29401</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29401</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4448">
		<reference_name>NCIT_C29402</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29402</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4444">
		<reference_name>NCIT_C29409</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29409</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4301">
		<reference_name>NCIT_C29476</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29476</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4614">
		<reference_name>NCIT_C29555</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29555</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4317">
		<reference_name>NCIT_C29558</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29558</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4616">
		<reference_name>NCIT_C29559</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29559</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4446">
		<reference_name>NCIT_C29560</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29560</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4445">
		<reference_name>NCIT_C29561</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29561</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4447">
		<reference_name>NCIT_C29563</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29563</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4442">
		<reference_name>NCIT_C29564</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29564</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4490">
		<reference_name>NCIT_C29566</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29566</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4572">
		<reference_name>NCIT_C29778</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29778</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4427">
		<reference_name>NCIT_C29785</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29785</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4347">
		<reference_name>NCIT_C29786</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29786</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4603">
		<reference_name>NCIT_C29908</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29908</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4633">
		<reference_name>NCIT_C29910</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29910</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4436">
		<reference_name>NCIT_C29918</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29918</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4143">
		<reference_name>NCIT_C29945</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29945</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4138">
		<reference_name>NCIT_C29982</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C29982</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4357">
		<reference_name>NCIT_C30000</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C30000</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4235">
		<reference_name>NCIT_C37448</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C37448</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4627">
		<reference_name>NCIT_C37515</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C37515</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4249">
		<reference_name>NCIT_C38117</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C38117</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4248">
		<reference_name>NCIT_C38119</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C38119</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4190">
		<reference_name>NCIT_C38121</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C38121</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4189">
		<reference_name>NCIT_C38122</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C38122</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4188">
		<reference_name>NCIT_C38123</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C38123</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4187">
		<reference_name>NCIT_C38124</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C38124</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4548">
		<reference_name>NCIT_C38132</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C38132</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4182">
		<reference_name>NCIT_C38587</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C38587</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4651">
		<reference_name>NCIT_C38681</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C38681</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4635">
		<reference_name>NCIT_C38708</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C38708</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4629">
		<reference_name>NCIT_C38715</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C38715</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4230">
		<reference_name>NCIT_C38761</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C38761</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4320">
		<reference_name>NCIT_C48368</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48368</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4475">
		<reference_name>NCIT_C48371</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48371</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4477">
		<reference_name>NCIT_C48372</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48372</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4618">
		<reference_name>NCIT_C48373</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48373</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4257">
		<reference_name>NCIT_C48376</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48376</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4478">
		<reference_name>NCIT_C48377</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48377</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4558">
		<reference_name>NCIT_C48390</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48390</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4556">
		<reference_name>NCIT_C48393</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48393</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4555">
		<reference_name>NCIT_C48394</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48394</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4554">
		<reference_name>NCIT_C48395</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48395</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4553">
		<reference_name>NCIT_C48396</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48396</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4355">
		<reference_name>NCIT_C48410</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48410</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4154">
		<reference_name>NCIT_C48411</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48411</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4155">
		<reference_name>NCIT_C48412</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48412</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4156">
		<reference_name>NCIT_C48414</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48414</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4343">
		<reference_name>NCIT_C48418</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48418</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4345">
		<reference_name>NCIT_C48419</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48419</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4622">
		<reference_name>NCIT_C48465</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48465</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4667">
		<reference_name>NCIT_C48632</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48632</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4668">
		<reference_name>NCIT_C48637</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48637</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4669">
		<reference_name>NCIT_C48638</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48638</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4670">
		<reference_name>NCIT_C48639</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48639</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4649">
		<reference_name>NCIT_C48640</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48640</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4221">
		<reference_name>NCIT_C48816</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C48816</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4581">
		<reference_name>NCIT_C49023</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C49023</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4331">
		<reference_name>NCIT_C49042</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C49042</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4579">
		<reference_name>NCIT_C49063</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C49063</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4577">
		<reference_name>NCIT_C49064</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C49064</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4277">
		<reference_name>NCIT_C49082</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C49082</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4274">
		<reference_name>NCIT_C49087</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C49087</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4422">
		<reference_name>NCIT_C49177</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C49177</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4169">
		<reference_name>NCIT_C49275</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C49275</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4619">
		<reference_name>NCIT_C49289</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C49289</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4224">
		<reference_name>NCIT_C49290</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C49290</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4384">
		<reference_name>NCIT_C51978</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C51978</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4137">
		<reference_name>NCIT_C53290</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C53290</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4482">
		<reference_name>NCIT_C53410</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C53410</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4185">
		<reference_name>NCIT_C53443</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C53443</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4151">
		<reference_name>NCIT_C61073</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C61073</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4149">
		<reference_name>NCIT_C61076</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C61076</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4148">
		<reference_name>NCIT_C61077</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C61077</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4191">
		<reference_name>NCIT_C61082</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C61082</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4193">
		<reference_name>NCIT_C61087</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C61087</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4186">
		<reference_name>NCIT_C61088</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C61088</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4335">
		<reference_name>NCIT_C61098</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C61098</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4626">
		<reference_name>NCIT_C61146</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C61146</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4202">
		<reference_name>NCIT_C61327</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C61327</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4366">
		<reference_name>NCIT_C61434</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C61434</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4535">
		<reference_name>NCIT_C61442</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C61442</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4208">
		<reference_name>NCIT_C61495</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C61495</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4327">
		<reference_name>NCIT_C62452</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C62452</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4570">
		<reference_name>NCIT_C62478</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C62478</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4571">
		<reference_name>NCIT_C62479</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C62479</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4342">
		<reference_name>NCIT_C62527</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C62527</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4504">
		<reference_name>NCIT_C62531</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C62531</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4322">
		<reference_name>NCIT_C62756</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C62756</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4408">
		<reference_name>NCIT_C62767</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C62767</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4407">
		<reference_name>NCIT_C62768</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C62768</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4467">
		<reference_name>NCIT_C62801</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C62801</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4315">
		<reference_name>NCIT_C64635</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C64635</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4263">
		<reference_name>NCIT_C64773</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C64773</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4396">
		<reference_name>NCIT_C64785</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C64785</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4300">
		<reference_name>NCIT_C64846</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C64846</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4507">
		<reference_name>NCIT_C66972</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C66972</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4377">
		<reference_name>NCIT_C66985</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C66985</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4223">
		<reference_name>NCIT_C67082</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C67082</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4236">
		<reference_name>NCIT_C67085</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C67085</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4225">
		<reference_name>NCIT_C67086</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C67086</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4226">
		<reference_name>NCIT_C67089</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C67089</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4361">
		<reference_name>NCIT_C67098</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C67098</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4244">
		<reference_name>NCIT_C68839</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C68839</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4537">
		<reference_name>NCIT_C68842</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C68842</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4543">
		<reference_name>NCIT_C68999</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C68999</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4400">
		<reference_name>NCIT_C69076</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C69076</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4491">
		<reference_name>NCIT_C70644</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C70644</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4393">
		<reference_name>NCIT_C70674</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C70674</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4295">
		<reference_name>NCIT_C70968</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C70968</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4170">
		<reference_name>NCIT_C70985</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C70985</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4139">
		<reference_name>NCIT_C71162</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C71162</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4435">
		<reference_name>NCIT_C71520</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C71520</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4538">
		<reference_name>NCIT_C71526</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C71526</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4153">
		<reference_name>NCIT_C71533</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C71533</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4652">
		<reference_name>NCIT_C71723</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C71723</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4296">
		<reference_name>NCIT_C71741</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C71741</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4611">
		<reference_name>NCIT_C71748</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C71748</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4675">
		<reference_name>NCIT_C71757</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C71757</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4222">
		<reference_name>NCIT_C71758</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C71758</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4302">
		<reference_name>NCIT_C71760</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C71760</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4303">
		<reference_name>NCIT_C71761</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C71761</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4270">
		<reference_name>NCIT_C73438</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C73438</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4363">
		<reference_name>NCIT_C73995</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C73995</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4362">
		<reference_name>NCIT_C73997</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C73997</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4528">
		<reference_name>NCIT_C73998</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C73998</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4359">
		<reference_name>NCIT_C73999</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C73999</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4168">
		<reference_name>NCIT_C74000</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C74000</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4285">
		<reference_name>NCIT_C74015</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C74015</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4326">
		<reference_name>NCIT_C74016</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C74016</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4402">
		<reference_name>NCIT_C74023</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C74023</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4569">
		<reference_name>NCIT_C74036</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C74036</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4671">
		<reference_name>NCIT_C74042</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C74042</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4269">
		<reference_name>NCIT_C74056</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C74056</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4268">
		<reference_name>NCIT_C74057</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C74057</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4392">
		<reference_name>NCIT_C74064</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C74064</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4340">
		<reference_name>NCIT_C74066</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C74066</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4240">
		<reference_name>NCIT_C74070</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C74070</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4594">
		<reference_name>NCIT_C74087</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C74087</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4595">
		<reference_name>NCIT_C74088</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C74088</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4596">
		<reference_name>NCIT_C74089</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C74089</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4201">
		<reference_name>NCIT_C74090</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C74090</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4532">
		<reference_name>NCIT_C76227</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C76227</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4365">
		<reference_name>NCIT_C77863</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C77863</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4539">
		<reference_name>NCIT_C77867</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C77867</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4367">
		<reference_name>NCIT_C77869</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C77869</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4196">
		<reference_name>NCIT_C77874</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C77874</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4199">
		<reference_name>NCIT_C77877</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C77877</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4194">
		<reference_name>NCIT_C77878</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C77878</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4358">
		<reference_name>NCIT_C77895</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C77895</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4281">
		<reference_name>NCIT_C77900</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C77900</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4283">
		<reference_name>NCIT_C77907</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C77907</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4505">
		<reference_name>NCIT_C77909</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C77909</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4258">
		<reference_name>NCIT_C77910</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C77910</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4519">
		<reference_name>NCIT_C78193</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C78193</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4219">
		<reference_name>NCIT_C78448</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C78448</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4437">
		<reference_name>NCIT_C78466</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C78466</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4434">
		<reference_name>NCIT_C78487</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C78487</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4433">
		<reference_name>NCIT_C78489</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C78489</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4544">
		<reference_name>NCIT_C78819</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C78819</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4654">
		<reference_name>NCIT_C78820</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C78820</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4655">
		<reference_name>NCIT_C78821</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C78821</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4264">
		<reference_name>NCIT_C78830</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C78830</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4150">
		<reference_name>NCIT_C78861</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C78861</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4313">
		<reference_name>NCIT_C78862</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C78862</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4354">
		<reference_name>NCIT_C78865</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C78865</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4164">
		<reference_name>NCIT_C79799</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C79799</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4284">
		<reference_name>NCIT_C79832</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C79832</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4536">
		<reference_name>NCIT_C79833</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C79833</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4414">
		<reference_name>NCIT_C79842</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C79842</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4663">
		<reference_name>NCIT_C80055</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C80055</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4476">
		<reference_name>NCIT_C80834</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C80834</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4212">
		<reference_name>NCIT_C82352</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C82352</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4344">
		<reference_name>NCIT_C82361</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C82361</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4520">
		<reference_name>NCIT_C82371</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C82371</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4674">
		<reference_name>NCIT_C82381</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C82381</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4673">
		<reference_name>NCIT_C82388</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C82388</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4521">
		<reference_name>NCIT_C82407</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C82407</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4346">
		<reference_name>NCIT_C82416</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C82416</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4413">
		<reference_name>NCIT_C82420</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C82420</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4459">
		<reference_name>NCIT_C82654</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C82654</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4379">
		<reference_name>NCIT_C82661</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C82661</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4239">
		<reference_name>NCIT_C82675</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C82675</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4632">
		<reference_name>NCIT_C82688</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C82688</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4395">
		<reference_name>NCIT_C84755</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C84755</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4306">
		<reference_name>NCIT_C84844</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C84844</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4524">
		<reference_name>NCIT_C84845</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C84845</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4351">
		<reference_name>NCIT_C84854</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C84854</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4404">
		<reference_name>NCIT_C85445</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C85445</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4638">
		<reference_name>NCIT_C85450</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C85450</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4267">
		<reference_name>NCIT_C85451</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C85451</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4259">
		<reference_name>NCIT_C85452</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C85452</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4470">
		<reference_name>NCIT_C85456</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C85456</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4171">
		<reference_name>NCIT_C85462</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C85462</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4172">
		<reference_name>NCIT_C85463</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C85463</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4176">
		<reference_name>NCIT_C85464</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C85464</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4175">
		<reference_name>NCIT_C85466</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C85466</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4330">
		<reference_name>NCIT_C85470</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C85470</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4328">
		<reference_name>NCIT_C85479</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C85479</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4567">
		<reference_name>NCIT_C87436</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C87436</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4142">
		<reference_name>NCIT_C88279</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C88279</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4310">
		<reference_name>NCIT_C88288</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C88288</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4309">
		<reference_name>NCIT_C88289</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C88289</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4308">
		<reference_name>NCIT_C88320</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C88320</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4209">
		<reference_name>NCIT_C88326</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C88326</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4583">
		<reference_name>NCIT_C88334</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C88334</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4550">
		<reference_name>NCIT_C88341</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C88341</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4141">
		<reference_name>NCIT_C90540</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C90540</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4628">
		<reference_name>NCIT_C90542</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C90542</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4473">
		<reference_name>NCIT_C90555</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C90555</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4471">
		<reference_name>NCIT_C90558</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C90558</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4314">
		<reference_name>NCIT_C90560</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C90560</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4311">
		<reference_name>NCIT_C90569</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C90569</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4160">
		<reference_name>NCIT_C90570</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C90570</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4161">
		<reference_name>NCIT_C90571</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C90571</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4158">
		<reference_name>NCIT_C90572</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C90572</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4394">
		<reference_name>NCIT_C90592</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C90592</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4439">
		<reference_name>NCIT_C91076</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C91076</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4440">
		<reference_name>NCIT_C91077</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C91077</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4656">
		<reference_name>NCIT_C91085</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C91085</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4178">
		<reference_name>NCIT_C91373</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C91373</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4181">
		<reference_name>NCIT_C91377</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C91377</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4184">
		<reference_name>NCIT_C91378</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C91378</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4183">
		<reference_name>NCIT_C91379</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C91379</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4609">
		<reference_name>NCIT_C91707</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C91707</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4214">
		<reference_name>NCIT_C91710</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C91710</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4676">
		<reference_name>NCIT_C91714</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C91714</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4615">
		<reference_name>NCIT_C91715</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C91715</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4218">
		<reference_name>NCIT_C91716</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C91716</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4217">
		<reference_name>NCIT_C91717</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C91717</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4220">
		<reference_name>NCIT_C91718</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C91718</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4118">
		<reference_name>NCIT_C91719</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C91719</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4207">
		<reference_name>NCIT_C92573</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C92573</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4565">
		<reference_name>NCIT_C94210</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C94210</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4563">
		<reference_name>NCIT_C94215</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C94215</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4562">
		<reference_name>NCIT_C94216</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C94216</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4561">
		<reference_name>NCIT_C94217</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C94217</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4566">
		<reference_name>NCIT_C94218</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C94218</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4600">
		<reference_name>NCIT_C95024</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C95024</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4134">
		<reference_name>NCIT_C95211</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C95211</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4135">
		<reference_name>NCIT_C95212</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C95212</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4136">
		<reference_name>NCIT_C95213</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C95213</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4631">
		<reference_name>NCIT_C95705</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C95705</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4373">
		<reference_name>NCIT_C95722</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C95722</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4375">
		<reference_name>NCIT_C95727</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C95727</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4133">
		<reference_name>NCIT_C95741</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C95741</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4297">
		<reference_name>NCIT_C95751</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C95751</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4298">
		<reference_name>NCIT_C95759</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C95759</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4604">
		<reference_name>NCIT_C95771</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C95771</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4179">
		<reference_name>NCIT_C96041</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C96041</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4180">
		<reference_name>NCIT_C96042</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C96042</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4389">
		<reference_name>NCIT_C96391</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C96391</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4390">
		<reference_name>NCIT_C96392</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C96392</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4157">
		<reference_name>NCIT_C96393</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C96393</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4165">
		<reference_name>NCIT_C96397</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C96397</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4387">
		<reference_name>NCIT_C96398</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C96398</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4388">
		<reference_name>NCIT_C96399</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C96399</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4647">
		<reference_name>NCIT_C96402</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C96402</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4648">
		<reference_name>NCIT_C96405</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C96405</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4307">
		<reference_name>NCIT_C96519</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C96519</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4352">
		<reference_name>NCIT_C96737</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C96737</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4353">
		<reference_name>NCIT_C96738</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C96738</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4484">
		<reference_name>NCIT_C96739</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C96739</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4216">
		<reference_name>NCIT_C97122</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C97122</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4513">
		<reference_name>NCIT_C97123</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C97123</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4508">
		<reference_name>NCIT_C97126</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C97126</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4509">
		<reference_name>NCIT_C97127</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C97127</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4469">
		<reference_name>NCIT_C97265</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C97265</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4493">
		<reference_name>NCIT_C97344</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C97344</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4198">
		<reference_name>NCIT_C97665</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C97665</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4197">
		<reference_name>NCIT_C97666</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C97666</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4523">
		<reference_name>NCIT_C97951</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C97951</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4381">
		<reference_name>NCIT_C98287</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C98287</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4455">
		<reference_name>NCIT_C99116</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C99116</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4547">
		<reference_name>NCIT_C99129</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C99129</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4233">
		<reference_name>NCIT_C99228</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C99228</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4432">
		<reference_name>NCIT_C99378</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C99378</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4574">
		<reference_name>NCIT_C99902</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C99902</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4644">
		<reference_name>NCIT_C99903</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;code=C99903</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3680">
		<reference_name>NCT00001386</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00001386</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3725">
		<reference_name>NCT00001512</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00001512</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3663">
		<reference_name>NCT00001561</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00001561</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3660">
		<reference_name>NCT00001564</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00001564</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3702">
		<reference_name>NCT00001564</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00001564/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3661">
		<reference_name>NCT00001565</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00001565</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3711">
		<reference_name>NCT00001703</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00001703/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3699">
		<reference_name>NCT00001705</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00001705</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3632">
		<reference_name>NCT00002767</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00002767</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3597">
		<reference_name>NCT00002787</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00002787?term=Autologous+Immunoglobulin+Idiotype-Keyhole+Limpet+Hemocyanin+Conjugate+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3544">
		<reference_name>NCT00002817</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00002817/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3674">
		<reference_name>NCT00002916</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00002916</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3695">
		<reference_name>NCT00002960</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00002960?term=Recombinant+Adenovirus+p53+SCH+58500&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3601">
		<reference_name>NCT00003023</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00003023</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3486">
		<reference_name>NCT00003167</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00003167</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3606">
		<reference_name>NCT00003184</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00003184</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3444">
		<reference_name>NCT00003556</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00003556?term=Canarypox-hIL-12+Melanoma+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3567">
		<reference_name>NCT00003556</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00003556?term=ALVAC-hB7.1&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3736">
		<reference_name>NCT00003638</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00003638</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3400">
		<reference_name>NCT00003761</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00003761?term=Recombinant+Vaccinia+DF3%2FMUC1+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3587">
		<reference_name>NCT00003871</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00003871?term=FOWLVAC&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3636">
		<reference_name>NCT00003871</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00003871?term=Fowlpox+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3499">
		<reference_name>NCT00003877</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00003877/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3452">
		<reference_name>NCT00003895</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00003895</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3416">
		<reference_name>NCT00004032</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00004032</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3746">
		<reference_name>NCT00004156</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00004156?term=MUC1-KLH+Vaccine%2FQS21&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3529">
		<reference_name>NCT00004184</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00004184</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3528">
		<reference_name>NCT00004211</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00004211</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3665">
		<reference_name>NCT00004604</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00004604</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3704">
		<reference_name>NCT00004918</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00004918/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3508">
		<reference_name>NCT00005039</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00005039/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3647">
		<reference_name>NCT00005039</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00005039?term=Recombinant+Fowlpox-Prostate+Specific+Antigen+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3542">
		<reference_name>NCT00005057</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00005057</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3502">
		<reference_name>NCT00005629</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00005629</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3658">
		<reference_name>NCT00006041</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00006041?term=MUC1-KLH+Conjugate+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3491">
		<reference_name>NCT00006066</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00006066</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3455">
		<reference_name>NCT00006106</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00006106?term=ONYX-015&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3409">
		<reference_name>NCT00006216</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00006216</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3715">
		<reference_name>NCT00006243</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00006243?term=MART-1%3A27-35+Peptide&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3404">
		<reference_name>NCT00006352</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00006352</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3599">
		<reference_name>NCT00006470</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00006470</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3525">
		<reference_name>NCT00007826</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00007826</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3741">
		<reference_name>NCT00008099</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00008099?term=MUC1+Antigen%2FSB+AS-2&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3436">
		<reference_name>NCT00015977</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00015977</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3638">
		<reference_name>NCT00016146</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00016146?term=MUC-2-Globo+H-KLH+Conjugate+Vaccine&amp;rank=2</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3469">
		<reference_name>NCT00019006</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00019006/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3372">
		<reference_name>NCT00019110</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00019110</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3500">
		<reference_name>NCT00019383</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00019383/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3532">
		<reference_name>NCT00019734</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00019734/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3545">
		<reference_name>NCT00019890</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00019890</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3624">
		<reference_name>NCT00019916</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00019916?term=p53+Peptide+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3671">
		<reference_name>NCT00020475</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00020475?term=MART-1%3A26-35+%2827L%29&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3700">
		<reference_name>NCT00022438</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00022438/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3574">
		<reference_name>NCT00023647</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00023647</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3371">
		<reference_name>NCT00028496</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00028496?term=Recombinant+Fowlpox-CEA%286D%29%2FTRICOM+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3742">
		<reference_name>NCT00030693</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00030693?term=Recombinant+Fowlpox-B7.1+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3401">
		<reference_name>NCT00030823</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00030823?term=Globo-H-GM2-Lewis-y-MUC1-32%28aa%29-sTn%28c%29-TF%28c%29-Tn%28c%29-KLH+Conjugate+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3613">
		<reference_name>NCT00031564</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00031564</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3493">
		<reference_name>NCT00033228</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00033228</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3737">
		<reference_name>NCT00033748</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00033748</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3494">
		<reference_name>NCT00039325</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00039325</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3701">
		<reference_name>NCT00039325</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00039325?term=MART-1+Adenovirus+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3754">
		<reference_name>NCT00040170</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00040170/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3752">
		<reference_name>NCT00049218</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00049218</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3524">
		<reference_name>NCT00054535</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00054535?term=Recombinant+Fowlpox-Tyrosinase+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3481">
		<reference_name>NCT00057915</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00057915</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3682">
		<reference_name>NCT00058747</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00058747</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3537">
		<reference_name>NCT00062907</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00062907?term=Recombinant+Adenovirus+L523S+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3612">
		<reference_name>NCT00062907</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00062907</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3561">
		<reference_name>NCT00066404</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00066404?term=Recombinant+Adenovirus-hIFN-beta&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3497">
		<reference_name>NCT00069940</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00069940/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3374">
		<reference_name>NCT00071942</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00071942/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3763">
		<reference_name>NCT00071981</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00071981</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3687">
		<reference_name>NCT00072085</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00072085</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3679">
		<reference_name>NCT00072137</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00072137?term=Recombinant+Fowlpox+GM-CSF+Vaccine+Adjuvant&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3377">
		<reference_name>NCT00074295</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00074295</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3483">
		<reference_name>NCT00078494</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00078494?term=LMP-2%3A340-349+Peptide+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3568">
		<reference_name>NCT00078520</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00078520</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3734">
		<reference_name>NCT00080353</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00080353?term=Recombinant+Fowlpox-gp100p209&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3514">
		<reference_name>NCT00081848</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00081848/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3731">
		<reference_name>NCT00085462</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00085462?term=gp100-Fowlpox+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3692">
		<reference_name>NCT00087373</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00087373?term=Recombinant+Fowlpox-TRICOM+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3547">
		<reference_name>NCT00089778</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00089778</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3422">
		<reference_name>NCT00091104</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00091104</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3512">
		<reference_name>NCT00091273</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00091273</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3442">
		<reference_name>NCT00092534</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00092534</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3760">
		<reference_name>NCT00093548</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00093548</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3570">
		<reference_name>NCT00096629</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00096629</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3750">
		<reference_name>NCT00098917</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00098917</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3402">
		<reference_name>NCT00100971</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00100971</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3427">
		<reference_name>NCT00101309</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00101309</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3749">
		<reference_name>NCT00103142</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00103142/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3419">
		<reference_name>NCT00107159</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00107159</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3668">
		<reference_name>NCT00108732</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00108732?term=Fowlpox-PSA-TRICOM+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3386">
		<reference_name>NCT00108875</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00108875?term=Survivin+Peptide+Vaccine&amp;rank=2</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3393">
		<reference_name>NCT00109655</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00109655?term=CG0070&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3485">
		<reference_name>NCT00109811</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00109811/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3690">
		<reference_name>NCT00110526</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00110526</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3551">
		<reference_name>NCT00112957</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00112957/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3728">
		<reference_name>NCT00112957</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00112957?term=rF-NY-ESO-1&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3424">
		<reference_name>NCT00116363</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00116363</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3480">
		<reference_name>NCT00116467</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00116467</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3759">
		<reference_name>NCT00116597</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00116597/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3408">
		<reference_name>NCT00121173</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00121173</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3716">
		<reference_name>NCT00128661</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00128661</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3468">
		<reference_name>NCT00136903</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00136903</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3573">
		<reference_name>NCT00140738</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00140738/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3672">
		<reference_name>NCT00145145</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00145145?term=MAGE-3.A1&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3429">
		<reference_name>NCT00145158</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00145158?term=Peptides%2FMontanide+ISA-51&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3445">
		<reference_name>NCT00146835</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00146835</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3614">
		<reference_name>NCT00197860</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00197860</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3623">
		<reference_name>NCT00199849</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00199849</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3543">
		<reference_name>NCT00203866</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00203866</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3479">
		<reference_name>NCT00203892</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00203892</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3662">
		<reference_name>NCT00217373</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00217373/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3727">
		<reference_name>NCT00227474</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00227474/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3476">
		<reference_name>NCT00257465</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00257465</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3554">
		<reference_name>NCT00257738</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00257738?term=MAGE-A3+Peptide+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3430">
		<reference_name>NCT00264732</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00264732</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3588">
		<reference_name>NCT00273910</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00273910</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3406">
		<reference_name>NCT00278200</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00278200</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3654">
		<reference_name>NCT00285259</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00285259</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3440">
		<reference_name>NCT00298298</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00298298</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3472">
		<reference_name>NCT00304096</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00304096/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3450">
		<reference_name>NCT00306566</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00306566?term=Melan-A+VLP+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3383">
		<reference_name>NCT00307229</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00307229</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3488">
		<reference_name>NCT00312286</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00312286</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3566">
		<reference_name>NCT00313508</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00313508</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3608">
		<reference_name>NCT00323557</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00323557?term=Streptococcus+pneumoniae+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3530">
		<reference_name>NCT00329368</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00329368?term=KLH-FITC&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3648">
		<reference_name>NCT00379977</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00379977?term=Haemophilus+Influenzae+B+Vaccine&amp;rank=4</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3579">
		<reference_name>NCT00381875</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00381875</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3558">
		<reference_name>NCT00389610</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00389610</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3589">
		<reference_name>NCT00393029</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00393029</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3438">
		<reference_name>NCT00398073</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00398073</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3453">
		<reference_name>NCT00399529</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00399529</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3526">
		<reference_name>NCT00404339</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00404339</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3610">
		<reference_name>NCT00405327</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00405327</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3399">
		<reference_name>NCT00411749</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00411749?term=V501&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3685">
		<reference_name>NCT00418574</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00418574</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3428">
		<reference_name>NCT00423254</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00423254/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3549">
		<reference_name>NCT00423254</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00423254</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3652">
		<reference_name>NCT00433914</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00433914</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3625">
		<reference_name>NCT00436254</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00436254</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3758">
		<reference_name>NCT00450619</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00450619?term=TRICOM+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3747">
		<reference_name>NCT00457249</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00457249?term=DECAVAC&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3676">
		<reference_name>NCT00458653</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00458653</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3490">
		<reference_name>NCT00458679</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00458679</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3478">
		<reference_name>NCT00470379</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00470379?term=NY-ESO-1b+Peptide+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3594">
		<reference_name>NCT00471133</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00471133</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3628">
		<reference_name>NCT00477906</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00477906</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3505">
		<reference_name>NCT00480025</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00480025?term=GSK1572932A&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3555">
		<reference_name>NCT00482027</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00482027</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3583">
		<reference_name>NCT00493545</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00493545/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3726">
		<reference_name>NCT00499577</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00499577?term=hTERT+I540%2FR572Y%2FD988Y+Multipeptide+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3739">
		<reference_name>NCT00499577</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00499577/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3473">
		<reference_name>NCT00505063</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00505063</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3492">
		<reference_name>NCT00505713</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00505713</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3651">
		<reference_name>NCT00509288</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00509288</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3380">
		<reference_name>NCT00509496</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00509496</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3762">
		<reference_name>NCT00510133</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00510133</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3745">
		<reference_name>NCT00514072</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00514072</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3753">
		<reference_name>NCT00516685</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00516685/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3580">
		<reference_name>NCT00521261</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00521261/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3637">
		<reference_name>NCT00523159</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00523159/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3646">
		<reference_name>NCT00524277</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00524277</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3546">
		<reference_name>NCT00534209</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00534209</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3603">
		<reference_name>NCT00551187</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00551187</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3466">
		<reference_name>NCT00574977</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00574977</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3706">
		<reference_name>NCT00580060</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00580060</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3484">
		<reference_name>NCT00589186</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00589186</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3407">
		<reference_name>NCT00612001</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00612001</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3620">
		<reference_name>NCT00612222</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00612222?term=ALVAC-MART-1+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3387">
		<reference_name>NCT00613509</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00613509?term=ALVAC%282%29+Melanoma+Multi-antigen+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3446">
		<reference_name>NCT00616135</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00616135/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3417">
		<reference_name>NCT00616291</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00616291?term=NY-ESO-1%2FLAGE-1+Peptide+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3475">
		<reference_name>NCT00616720</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00616720</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3667">
		<reference_name>NCT00624182</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00624182/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3703">
		<reference_name>NCT00626015</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00626015?term=PEP-3-KLH&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3384">
		<reference_name>NCT00629057</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00629057/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3595">
		<reference_name>NCT00633724</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00633724?term=HLA-A*2402-Restricted+VEGFR1+VEGFR2&amp;rank=3</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3732">
		<reference_name>NCT00639925</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00639925/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3477">
		<reference_name>NCT00654030</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00654030</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3536">
		<reference_name>NCT00660101</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00660101</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3584">
		<reference_name>NCT00669136</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00669136</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3743">
		<reference_name>NCT00669734</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00669734?term=Falimarev&amp;rank=2</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3425">
		<reference_name>NCT00674791</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00674791?term=IMT-1012+Immunotherapeutic+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3590">
		<reference_name>NCT00676507</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00676507</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3550">
		<reference_name>NCT00677859</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00677859/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3448">
		<reference_name>NCT00681421</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00681421</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3504">
		<reference_name>NCT00685412</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00685412</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3507">
		<reference_name>NCT00694551</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00694551/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3513">
		<reference_name>NCT00698711</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00698711?term=MUC-2-KLH+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3565">
		<reference_name>NCT00703222</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00703222</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3382">
		<reference_name>NCT00716495</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00716495</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3553">
		<reference_name>NCT00722839</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00722839?term=PADRE-CMV+Fusion+Peptide+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3626">
		<reference_name>NCT00722839</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00722839/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3713">
		<reference_name>NCT00725283</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00725283/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3373">
		<reference_name>NCT00726739</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00726739</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3677">
		<reference_name>NCT00727441</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00727441</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3618">
		<reference_name>NCT00753415</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00753415?term=V934%2FV935&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3447">
		<reference_name>NCT00784524</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00784524</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3571">
		<reference_name>NCT00791570</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00791570?</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3548">
		<reference_name>NCT00793208</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00793208</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3426">
		<reference_name>NCT00798629</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00798629?term=gp100+Adenovirus+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3694">
		<reference_name>NCT00798629</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00798629</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3586">
		<reference_name>NCT00807781</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00807781</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3410">
		<reference_name>NCT00831467</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00831467/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3411">
		<reference_name>NCT00831753</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00831753</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3482">
		<reference_name>NCT00836199</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00836199?term=NicVax&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3616">
		<reference_name>NCT00844506</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00844506?term=P53-Synthetic+Long+Peptides+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3398">
		<reference_name>NCT00849290</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00849290</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3463">
		<reference_name>NCT00859729</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00859729</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3596">
		<reference_name>NCT00868595</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00868595</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3369">
		<reference_name>NCT00874588</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00874588?term=HLA-A*2402-Restricted+VEGFR1+Peptide+Vaccine&amp;rank=2</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3708">
		<reference_name>NCT00880464</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00880464</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3627">
		<reference_name>NCT00886613</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00886613</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3659">
		<reference_name>NCT00890110</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00890110</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3697">
		<reference_name>NCT00891137</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00891137/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3634">
		<reference_name>NCT00895466</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00895466</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3718">
		<reference_name>NCT00897923</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00897923/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3489">
		<reference_name>NCT00900809</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00900809/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3707">
		<reference_name>NCT00923195</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00923195</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3520">
		<reference_name>NCT00927381</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00927381</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3458">
		<reference_name>NCT00935597</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00935597</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3390">
		<reference_name>NCT00937183</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00937183</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3437">
		<reference_name>NCT00943722</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00943722</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3527">
		<reference_name>NCT00944580</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00944580?term=MAGE-A1%2FMAGE-A3%2FNY-ESO-1+Peptides+Vaccine&amp;rank=2</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3388">
		<reference_name>NCT00972309</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00972309/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3460">
		<reference_name>NCT00978107</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00978107/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3602">
		<reference_name>NCT00978913</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT00978913</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3509">
		<reference_name>NCT00988559</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT00988559</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3394">
		<reference_name>NCT01008813</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01008813</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3396">
		<reference_name>NCT01016548</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01016548</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3487">
		<reference_name>NCT01022346</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01022346/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3375">
		<reference_name>NCT01045460</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01045460</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3622">
		<reference_name>NCT01047345</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01047345</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3391">
		<reference_name>NCT01048151</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01048151?term=Golnerminogene+Pradenovec&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3733">
		<reference_name>NCT01058850</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01058850?</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3640">
		<reference_name>NCT01064375</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01064375</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3415">
		<reference_name>NCT01066390</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01066390</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3604">
		<reference_name>NCT01082198</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01082198</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3523">
		<reference_name>NCT01088789</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01088789</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3576">
		<reference_name>NCT01094548</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01094548</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3714">
		<reference_name>NCT01095848</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01095848</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3757">
		<reference_name>NCT01143545</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01143545</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3559">
		<reference_name>NCT01146262</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01146262</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3591">
		<reference_name>NCT01147965</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01147965</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3645">
		<reference_name>NCT01171729</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01171729</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3577">
		<reference_name>NCT01176461</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01176461</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3538">
		<reference_name>NCT01176462</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01176462</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3506">
		<reference_name>NCT01213472</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01213472</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3730">
		<reference_name>NCT01216436</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01216436</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3533">
		<reference_name>NCT01219348</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01219348?term=IDO+Peptide+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3517">
		<reference_name>NCT01220128</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01220128/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3461">
		<reference_name>NCT01241682</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01241682</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3420">
		<reference_name>NCT01242618</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01242618/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3698">
		<reference_name>NCT01250470</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01250470?term=Montanide+ISA-51%2FSurvivin+Peptide+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3617">
		<reference_name>NCT01253837</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01253837</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3635">
		<reference_name>NCT01265368</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01265368</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3765">
		<reference_name>NCT01270503</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01270503?term=Menactra&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3418">
		<reference_name>NCT01280552</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01280552</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3459">
		<reference_name>NCT01307618</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01307618?term=NA17.A2&amp;rank=2</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3669">
		<reference_name>NCT01308294</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01308294?term=Melan-A%2FMAGE-3.DP4+Peptide+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3412">
		<reference_name>NCT01322802</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01322802</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3615">
		<reference_name>NCT01334047</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01334047</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3421">
		<reference_name>NCT01334060</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01334060</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3631">
		<reference_name>NCT01353222</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01353222</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3673">
		<reference_name>NCT01380600</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01380600</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3392">
		<reference_name>NCT01398124</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01398124</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3385">
		<reference_name>NCT01400672</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01400672</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3471">
		<reference_name>NCT01405521</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01405521?term=Ty21a&amp;rank=2</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3611">
		<reference_name>NCT01437280</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01437280?term=CGTG-102&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3585">
		<reference_name>NCT01453361</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01453361</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3439">
		<reference_name>NCT01488188</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01488188</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3423">
		<reference_name>NCT01498328</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01498328</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3552">
		<reference_name>NCT01525017</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01525017</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3720">
		<reference_name>NCT01526473</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01526473?term=AVX901&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3433">
		<reference_name>NCT01536054</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01536054?term=ALVAC%282%29-NY-ESO-1+%28M%29%2FTRICOM+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3405">
		<reference_name>NCT01556789</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01556789?term=ONT-10&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3560">
		<reference_name>NCT01559597</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01559597?term=Tetanus+Toxoid+Vaccine&amp;rank=3</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3644">
		<reference_name>NCT01598454</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01598454</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3653">
		<reference_name>NCT01606241</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01606241?term=FR+Alpha+Peptide+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3503">
		<reference_name>NCT01621542</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01621542/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3434">
		<reference_name>NCT01624701</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01624701/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3522">
		<reference_name>NCT01639612</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01639612/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3464">
		<reference_name>NCT01660529</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01660529?term=hTERT%2FSurvivin%2FCMV+Multipeptide+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3688">
		<reference_name>NCT01666782</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01666782</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3689">
		<reference_name>NCT01666783</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01666783</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3443">
		<reference_name>NCT01690377</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01690377</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3535">
		<reference_name>NCT01697527</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01697527</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3516">
		<reference_name>NCT01711970</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01711970</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3403">
		<reference_name>NCT01744171</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01744171</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3643">
		<reference_name>NCT01748747</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01748747</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3541">
		<reference_name>NCT01766739</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01766739/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3633">
		<reference_name>NCT01767467</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01767467</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3619">
		<reference_name>NCT01784913</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01784913/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3609">
		<reference_name>NCT01795313</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01795313?term=HLA-A2-Restricted+Synthetic+Glioma+Antigen+Peptides+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3501">
		<reference_name>NCT01800071</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01800071/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3598">
		<reference_name>NCT01823978</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01823978</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3729">
		<reference_name>NCT01827137</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01827137/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3389">
		<reference_name>NCT01828762</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01828762</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3462">
		<reference_name>NCT01836432</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01836432</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3719">
		<reference_name>NCT01842139</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01842139/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3764">
		<reference_name>NCT01853878</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01853878</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3467">
		<reference_name>NCT01854099</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01854099/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3563">
		<reference_name>NCT01863108</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01863108</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3755">
		<reference_name>NCT01957956</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01957956</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3449">
		<reference_name>NCT01961115</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01961115?term=MELITAC+12.1+Peptide+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3650">
		<reference_name>NCT01961882</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01961882/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3562">
		<reference_name>NCT01966289</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01966289</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3539">
		<reference_name>NCT01967758</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01967758</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3395">
		<reference_name>NCT01972737</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01972737</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3367">
		<reference_name>NCT01972737, ClinicalTrials.gov</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT01972737</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3593">
		<reference_name>NCT01994369</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01994369?term=EC17&amp;rank=2</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3600">
		<reference_name>NCT01995708</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT01995708</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3681">
		<reference_name>NCT02010203</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02010203</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3556">
		<reference_name>NCT02015416</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02015416</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3717">
		<reference_name>NCT02017678</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02017678/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3582">
		<reference_name>NCT02028442</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02028442</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3495">
		<reference_name>NCT02033616</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02033616</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3518">
		<reference_name>NCT02035358</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02035358</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3630">
		<reference_name>NCT02040636</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02040636</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3629">
		<reference_name>NCT02040637</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02040637</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3592">
		<reference_name>NCT02045836</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02045836</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3738">
		<reference_name>NCT02049489</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02049489</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3397">
		<reference_name>NCT02061423</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02061423</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3515">
		<reference_name>NCT02063724</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02063724</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3722">
		<reference_name>NCT02065973</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02065973?term=PDS0101&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3607">
		<reference_name>NCT02078648</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02078648</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3534">
		<reference_name>NCT02079324</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02079324/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3621">
		<reference_name>NCT02103426</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02103426</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3696">
		<reference_name>NCT02107404</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02107404</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3735">
		<reference_name>NCT02107950</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02107950</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3581">
		<reference_name>NCT02111941</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02111941</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3432">
		<reference_name>NCT02122861</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02122861?term=Dendritic+Cell-targeting+Lentiviral+Vector+ID-LV305&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3723">
		<reference_name>NCT02126579</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02126579?term=LPV7&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3761">
		<reference_name>NCT02128126</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02128126/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3496">
		<reference_name>NCT02140996</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02140996</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3657">
		<reference_name>NCT02149225</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02149225/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3575">
		<reference_name>NCT02157051</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02157051</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3751">
		<reference_name>NCT02159950</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02159950</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3465">
		<reference_name>NCT02170389</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02170389</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3693">
		<reference_name>NCT02179515</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02179515/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3740">
		<reference_name>NCT02193347</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02193347?term=PEPIDH1M+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3756">
		<reference_name>NCT02203357</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02203357?term=Hepatitis+B+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3435">
		<reference_name>NCT02204085</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02204085?term=GO-203-2C&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3376">
		<reference_name>NCT02223312</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02223312</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3521">
		<reference_name>NCT02237638</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02237638?term=hVEGF26-104%2FRFASE&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3605">
		<reference_name>NCT02241369</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02241369</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3456">
		<reference_name>NCT02264236</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02264236?term=Mimotope-P10s-PADRE+Peptide+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3712">
		<reference_name>NCT02285816</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02285816?term=AdMA3&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3540">
		<reference_name>NCT02293707</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02293707?term=GX+301&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3642">
		<reference_name>NCT02293850</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02293850?term=OBP-301&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3691">
		<reference_name>NCT02310464</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02310464?term=Globo+H-DT+Vaccine+OBI-833&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3379">
		<reference_name>NCT02316457</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02316457</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3381">
		<reference_name>NCT02323230</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02323230/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3710">
		<reference_name>NCT02327468</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02327468</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3414">
		<reference_name>NCT02334865</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02334865/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3431">
		<reference_name>NCT02390063</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02390063</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3572">
		<reference_name>NCT02410733</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02410733</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3474">
		<reference_name>NCT02411019</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02411019</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3569">
		<reference_name>NCT02411786</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02411786</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3454">
		<reference_name>NCT02423928</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02423928</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3578">
		<reference_name>NCT02427581</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02427581</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3724">
		<reference_name>NCT02439450</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02439450</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3684">
		<reference_name>NCT02454634</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02454634?term=IDH1R132H-specific+Peptide+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3451">
		<reference_name>NCT02460367</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02460367</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3370">
		<reference_name>NCT02479230</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02479230</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3511">
		<reference_name>NCT02499835</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02499835</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3748">
		<reference_name>NCT02501278</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02501278</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3649">
		<reference_name>NCT02503150</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02503150</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3656">
		<reference_name>NCT02506933</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02506933?term=CMV-MVA+Triplex+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3683">
		<reference_name>NCT02514213</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02514213</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3413">
		<reference_name>NCT02528682</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02528682</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3639">
		<reference_name>NCT02529930</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02529930</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3709">
		<reference_name>NCT02550678</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02550678?term=Interferon-gamma-expressing+Adenovirus+Vaccine+ASN-002&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3531">
		<reference_name>NCT02555397</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02555397</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3664">
		<reference_name>NCT02568566</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02568566?term=Recombinant+Human+Papillomavirus+Nonavalent+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3498">
		<reference_name>NCT02587520</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02587520?term=Bordetella+pertussis+Vaccine+Adsorbed&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3510">
		<reference_name>NCT02587520</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02587520?term=Diphtheria+Toxoid+Tetanus+Toxoid+Vaccine+Adsorbed&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3564">
		<reference_name>NCT02601040</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02601040</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3678">
		<reference_name>NCT02615574</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02615574/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3705">
		<reference_name>NCT02625857</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02625857</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3686">
		<reference_name>NCT02636582</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02636582?term=Nelipepimut-S+Plus+GM-CSF+Vaccine&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3457">
		<reference_name>NCT02648282</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02648282</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3721">
		<reference_name>NCT02649439</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02649439/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3378">
		<reference_name>NCT02654587</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02654587</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3670">
		<reference_name>NCT02693236</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02693236/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3655">
		<reference_name>NCT02718443</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02718443</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3675">
		<reference_name>NCT02772562</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02772562/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3470">
		<reference_name>NCT02773849</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02773849?term=Instiladrin&amp;rank=1</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3744">
		<reference_name>NCT02795988</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/ct2/show/NCT02795988</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3641">
		<reference_name>NCT02822079</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02822079</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3666">
		<reference_name>NCT02826434</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02826434/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3441">
		<reference_name>NCT02848911</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02848911/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3519">
		<reference_name>NCT02935790</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/NCT02935790/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3851">
		<reference_name>Nelson et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Nelson HH, Pawlita M, Michaud DS, McClean M, Langevin SM, Eliot MN, Kelsey KT</authors>
		<title>Immune Response to HPV16 E6 and E7 Proteins and Patient Outcomes in Head and Neck Cancer</title>
		<year>2016</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name>JAMA oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3835">
		<reference_name>Nemunaitis et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, Fakhrai H</authors>
		<title>Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer</title>
		<year>2006</year>
		<volume>24</volume>
		<issue>29</issue>
		<pages>4721-4730</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3859">
		<reference_name>Nemunaitis et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, Kumar P, Pappen B, Maples PB, Shawler D, Fakhrai H</authors>
		<title>Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients</title>
		<year>2009</year>
		<volume>16</volume>
		<issue>8</issue>
		<pages>620-624</pages>
		<journal_book_name>Cancer gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5293">
		<reference_name>Nemunaitis, 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Nemunaitis J</authors>
		<title>GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer</title>
		<year>2003</year>
		<volume>91</volume>
		<issue>1-2</issue>
		<pages>225-231</pages>
		<journal_book_name>Journal of controlled release : official journal of the Controlled Release Society</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1950">
		<reference_name>Nicholaou et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Nicholaou T, Ebert LM, Davis ID, McArthur GA, Jackson H, Dimopoulos N, Tan B, Maraskovsky E, Miloradovic L, Hopkins W, Pan L, Venhaus R, Hoffman EW, Chen W, Cebon J</authors>
		<title>Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma</title>
		<year>2009</year>
		<volume>15</volume>
		<issue>6</issue>
		<pages>2166-2173</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2921">
		<reference_name>Nicholson et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Nicholson S, Guile K, John J, Clarke IA, Diffley J, Donnellan P, Michael A, Szlosarek P, Dalgleish AG</authors>
		<title>A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma</title>
		<year>2003</year>
		<volume>13</volume>
		<issue>4</issue>
		<pages>389-393</pages>
		<journal_book_name>Melanoma research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3879">
		<reference_name>Niethammer et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA</authors>
		<title>A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth</title>
		<year>2002</year>
		<volume>8</volume>
		<issue>12</issue>
		<pages>1369-1375</pages>
		<journal_book_name>Nature medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference963">
		<reference_name>Nigro et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Nigro EA, Brini AT, Soprana E, Ambrosi A, Dombrowicz D, Siccardi AG, Vangelista L</authors>
		<title>Antitumor IgE adjuvanticity: key role of Fc epsilon RI</title>
		<year>2009</year>
		<volume>183</volume>
		<issue>7</issue>
		<pages>4530-4536</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5327">
		<reference_name>Nitschke et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Nitschke NJ, Bjoern J, Iversen TZ, Andersen MH, Svane IM</authors>
		<title>Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma</title>
		<year>2017</year>
		<volume>4</volume>
		<issue></issue>
		<pages>77</pages>
		<journal_book_name>Stem cell investigation</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5176">
		<reference_name>Nooka et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Nooka AK, Wang ML, Yee AJ, Kaufman JL, Bae J, Peterkin D, Richardson PG, Raje NS</authors>
		<title>Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial</title>
		<year>2018</year>
		<volume>4</volume>
		<issue>12</issue>
		<pages>e183267</pages>
		<journal_book_name>JAMA oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5297">
		<reference_name>Nothdurft, 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Nothdurft HD</authors>
		<title>Hepatitis A vaccines</title>
		<year>2008</year>
		<volume>7</volume>
		<issue>5</issue>
		<pages>535-545</pages>
		<journal_book_name>Expert review of vaccines</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5270">
		<reference_name>Nowicki et al., 2019</reference_name>
		<reference_type>journal</reference_type>
		<authors>Nowicki TS, Berent-Maoz B, Cheung-Lau G, Huang RR, Wang X, Tsoi J, Kaplan-Lefko P, Cabrera P, Tran J, Pang J, Macabali M, Garcilazo IP, Carretero IB, Kalbasi A, Cochran AJ, Grasso CS, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, Singh A, Ribas A</authors>
		<title>A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab</title>
		<year>2019</year>
		<volume>25</volume>
		<issue>7</issue>
		<pages>2096-2108</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2960">
		<reference_name>O'Connor et al., 1978</reference_name>
		<reference_type>journal</reference_type>
		<authors>O'Connor TP, Labandter HP, Hiles RW, Bodenham DC</authors>
		<title>A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma</title>
		<year>1978</year>
		<volume>31</volume>
		<issue>4</issue>
		<pages>317-322</pages>
		<journal_book_name>British journal of plastic surgery</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4008">
		<reference_name>Ochiai et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ochiai RL, Khan MI, Soofi SB, Sur D, Kanungo S, You YA, Habib MA, Sahito SM, Manna B, Dutta S, Acosta CJ, Ali M, Bhattacharya SK, Bhutta ZA, Clemens JD</authors>
		<title>Immune responses to Vi capsular polysaccharide typhoid vaccine in children 2 to 16 years old in Karachi, Pakistan, and Kolkata, India</title>
		<year>2014</year>
		<volume>21</volume>
		<issue>5</issue>
		<pages>661-666</pages>
		<journal_book_name>Clinical and vaccine immunology : CVI</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference972">
		<reference_name>Odin et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Odin L, Favrot M, Poujol D, Michot JP, Moingeon P, Tartaglia J, Puisieux I</authors>
		<title>Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53</title>
		<year>2001</year>
		<volume>8</volume>
		<issue>2</issue>
		<pages>87-98</pages>
		<journal_book_name>Cancer gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5371">
		<reference_name>Odunsi et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S</authors>
		<title>Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer</title>
		<year>2007</year>
		<volume>104</volume>
		<issue>31</issue>
		<pages>12837-12842</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5275">
		<reference_name>Odunsi et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, Lele S, duPont N, Edwards R, Shrikant P, Old LJ, Gnjatic S, JÃ¤ger E</authors>
		<title>Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients</title>
		<year>2012</year>
		<volume>109</volume>
		<issue>15</issue>
		<pages>5797-5802</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3948">
		<reference_name>Oertli et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Oertli D, Marti WR, Zajac P, Noppen C, Kocher T, Padovan E, Adamina M, Schumacher R, Harder F, Heberer M, Spagnoli GC</authors>
		<title>Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo</title>
		<year>2002</year>
		<volume>13</volume>
		<issue>4</issue>
		<pages>569-575</pages>
		<journal_book_name>Human gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1305">
		<reference_name>Oka et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Oka Y, Tsuboi A, Kawakami M, Elisseeva OA, Nakajima H, Udaka K, Kawase I, Oji Y, Sugiyama H</authors>
		<title>Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers</title>
		<year>2006</year>
		<volume>13</volume>
		<issue>20</issue>
		<pages>2345-2352</pages>
		<journal_book_name>Current medicinal chemistry</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5264">
		<reference_name>Okada et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, Zeh H, Holtzman MP, Reinhart TA, Whiteside TL, Butterfield LH, Hamilton RL, Potter DM, Pollack IF, Salazar AM, Lieberman FS</authors>
		<title>Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma</title>
		<year>2011</year>
		<volume>29</volume>
		<issue>3</issue>
		<pages>330-336</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4041">
		<reference_name>Olivares et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Olivares J, Kumar P, Yu Y, Maples PB, Senzer N, Bedell C, Barve M, Tong A, Pappen BO, Kuhn J, Magee M, Wallraven G, Nemunaitis J</authors>
		<title>Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine</title>
		<year>2011</year>
		<volume>17</volume>
		<issue>1</issue>
		<pages>183-192</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5124">
		<reference_name>Onaitis et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Onaitis M, Kalady MF, Pruitt S, Tyler DS</authors>
		<title>Dendritic cell gene therapy</title>
		<year>2002</year>
		<volume>11</volume>
		<issue>3</issue>
		<pages>645-660</pages>
		<journal_book_name>Surgical oncology clinics of North America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5302">
		<reference_name>Osanto, 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Osanto S</authors>
		<title>Vaccine Trials for the Clinician: Prospects for Tumor Antigens</title>
		<year>1997</year>
		<volume>2</volume>
		<issue>5</issue>
		<pages>284-299</pages>
		<journal_book_name>The oncologist</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2364">
		<reference_name>Overwijk et al., 1999</reference_name>
		<reference_type>journal</reference_type>
		<authors>Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP</authors>
		<title>Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes</title>
		<year>1999</year>
		<volume>96</volume>
		<issue>6</issue>
		<pages>2982-2987</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3953">
		<reference_name>Paff et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Paff M, Alexandru-Abrams D, Hsu FP, Bota DA</authors>
		<title>The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients</title>
		<year>2014</year>
		<volume>10</volume>
		<issue>11</issue>
		<pages>3322-3331</pages>
		<journal_book_name>Human vaccines &amp; immunotherapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5223">
		<reference_name>Pal et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pal R, Venzon D, Santra S, Kalyanaraman VS, Montefiori DC, Hocker L, Hudacik L, Rose N, Nacsa J, Edghill-Smith Y, Moniuszko M, Hel Z, Belyakov IM, Berzofsky JA, Parks RW, Markham PD, Letvin NL, Tartaglia J, Franchini G</authors>
		<title>Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels</title>
		<year>2006</year>
		<volume>80</volume>
		<issue>8</issue>
		<pages>3732-3742</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5167">
		<reference_name>Palefsky et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Palefsky JM, Berry JM, Jay N, Krogstad M, Da Costa M, Darragh TM, Lee JY</authors>
		<title>A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals</title>
		<year>2006</year>
		<volume>20</volume>
		<issue>8</issue>
		<pages>1151-1155</pages>
		<journal_book_name>AIDS (London, England)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5261">
		<reference_name>Panelli et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Panelli MC, Wunderlich J, Jeffries J, Wang E, Mixon A, Rosenberg SA, Marincola FM</authors>
		<title>Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100</title>
		<year>2000</year>
		<volume>23</volume>
		<issue>4</issue>
		<pages>487-498</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5128">
		<reference_name>Park et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Park MY, Kim DR, Jung HW, Yoon HI, Lee JH, Lee CT</authors>
		<title>Genetic immunotherapy of lung cancer using conditionally replicating adenovirus and adenovirus-interferon-beta</title>
		<year>2010</year>
		<volume>17</volume>
		<issue>5</issue>
		<pages>356-364</pages>
		<journal_book_name>Cancer gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5220">
		<reference_name>Park et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Park MH, Yang DH, Kim MH, Jang JH, Jang YY, Lee YK, Jin CJ, Pham TN, Thi TA, Lim MS, Lee HJ, Hong CY, Yoon JH, Lee JJ</authors>
		<title>Alpha-Type 1 Polarized Dendritic Cells Loaded with Apoptotic Allogeneic Breast Cancer Cells Can Induce Potent Cytotoxic T Lymphocytes against Breast Cancer</title>
		<year>2011</year>
		<volume>43</volume>
		<issue>1</issue>
		<pages>56-66</pages>
		<journal_book_name>Cancer research and treatment : official journal of Korean Cancer Association</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5364">
		<reference_name>Parker et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Parker LL, Do MT, Westwood JA, Wunderlich JR, Dudley ME, Rosenberg SA, Hwu P</authors>
		<title>Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer</title>
		<year>2000</year>
		<volume>11</volume>
		<issue>17</issue>
		<pages>2377-2387</pages>
		<journal_book_name>Human gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5242">
		<reference_name>Parkhurst et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Parkhurst MR, DePan C, Riley JP, Rosenberg SA, Shu S</authors>
		<title>Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules</title>
		<year>2003</year>
		<volume>170</volume>
		<issue>10</issue>
		<pages>5317-5325</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5206">
		<reference_name>Parkhurst et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA</authors>
		<title>T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis</title>
		<year>2011</year>
		<volume>19</volume>
		<issue>3</issue>
		<pages>620-626</pages>
		<journal_book_name>Molecular therapy : the journal of the American Society of Gene Therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3951">
		<reference_name>Parkinson and Sznol, 1995</reference_name>
		<reference_type>journal</reference_type>
		<authors>Parkinson DR, Sznol M</authors>
		<title>High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma</title>
		<year>1995</year>
		<volume>22</volume>
		<issue>1</issue>
		<pages>61-66</pages>
		<journal_book_name>Seminars in oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3989">
		<reference_name>Parmiani et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Parmiani G, Pilla L, Corti A, Doglioni C, Cimminiello C, Bellone M, Parolini D, Russo V, Capocefalo F, Maccalli C</authors>
		<title>A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma</title>
		<year>2014</year>
		<volume>3</volume>
		<issue>11</issue>
		<pages>e963406</pages>
		<journal_book_name>Oncoimmunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5372">
		<reference_name>Parvanova et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Parvanova I, Rettig L, Knuth A, Pascolo S</authors>
		<title>The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination</title>
		<year>2011</year>
		<volume>29</volume>
		<issue>22</issue>
		<pages>3832-3836</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3970">
		<reference_name>Patel et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R</authors>
		<title>PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer</title>
		<year>2013</year>
		<volume>31</volume>
		<issue>34</issue>
		<pages>4349-4357</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2344">
		<reference_name>Pavlenko et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, HellstrÃƒÂ¶m M, Kiessling R, Masucci G, WersÃƒÂ¤ll P, Nilsson S, Pisa P</authors>
		<title>A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer</title>
		<year>2004</year>
		<volume>91</volume>
		<issue>4</issue>
		<pages>688-694</pages>
		<journal_book_name>British journal of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5331">
		<reference_name>Peethambaram et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Peethambaram PP, Melisko ME, Rinn KJ, Alberts SR, Provost NM, Jones LA, Sims RB, Lin LR, Frohlich MW, Park JW</authors>
		<title>A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu</title>
		<year>2009</year>
		<volume>15</volume>
		<issue>18</issue>
		<pages>5937-5944</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5152">
		<reference_name>Pektor et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pektor S, Hilscher L, Walzer KC, Miederer I, Bausbacher N, Loquai C, Schreckenberger M, Sahin U, Diken M, Miederer M</authors>
		<title>In vivo imaging of the immune response upon systemic RNA cancer vaccination by FDG-PET</title>
		<year>2018</year>
		<volume>8</volume>
		<issue>1</issue>
		<pages>80</pages>
		<journal_book_name>EJNMMI research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5316">
		<reference_name>Pellegatta et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pellegatta S, Valletta L, Corbetta C, PatanÃ¨ M, Zucca I, Riccardi Sirtori F, Bruzzone MG, Fogliatto G, Isacchi A, Pollo B, Finocchiaro G</authors>
		<title>Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma</title>
		<year>2015</year>
		<volume>3</volume>
		<issue></issue>
		<pages>4</pages>
		<journal_book_name>Acta neuropathologica communications</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5356">
		<reference_name>Perloff et al., 1977</reference_name>
		<reference_type>journal</reference_type>
		<authors>Perloff M, Holland JF, Lumb GJ, Bekesi JG</authors>
		<title>Effects of methanol extraction residue of Bacillus calmette-GuÃ©rin in humans</title>
		<year>1977</year>
		<volume>37</volume>
		<issue>4</issue>
		<pages>1191-1196</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5282">
		<reference_name>Perricone et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Perricone MA, Smith KA, Claussen KA, Plog MS, Hempel DM, Roberts BL, St George JA, Kaplan JM</authors>
		<title>Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes</title>
		<year>2004</year>
		<volume>27</volume>
		<issue>4</issue>
		<pages>273-281</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2370">
		<reference_name>Pertl et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pertl U, Wodrich H, Ruehlmann JM, Gillies SD, Lode HN, Reisfeld RA</authors>
		<title>Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma</title>
		<year>2003</year>
		<volume>101</volume>
		<issue>2</issue>
		<pages>649-654</pages>
		<journal_book_name>Blood</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5290">
		<reference_name>Phan et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Phan GQ, Touloukian CE, Yang JC, Restifo NP, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE, Rosenberg SA</authors>
		<title>Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens</title>
		<year>2003</year>
		<volume>26</volume>
		<issue>4</issue>
		<pages>349-356</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5380">
		<reference_name>Pinto et al., 1999</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pinto LA, Berzofsky JA, Fowke KR, Little RF, Merced-Galindez F, Humphrey R, Ahlers J, Dunlop N, Cohen RB, Steinberg SM, Nara P, Shearer GM, Yarchoan R</authors>
		<title>HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients</title>
		<year>1999</year>
		<volume>13</volume>
		<issue>15</issue>
		<pages>2003-2012</pages>
		<journal_book_name>AIDS (London, England)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3230">
		<reference_name>Pol et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pol JG, Zhang L, Bridle BW, Stephenson KB, RessÃ©guier J, Hanson S, Chen L, Kazdhan N, Bramson JL, Stojdl DF, Wan Y, Lichty BD</authors>
		<title>Maraba virus as a potent oncolytic vaccine vector</title>
		<year>2014</year>
		<volume>22</volume>
		<issue>2</issue>
		<pages>420-429</pages>
		<journal_book_name>Molecular therapy : the journal of the American Society of Gene Therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5347">
		<reference_name>Pol et al., 2019</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pol JG, Acuna SA, Yadollahi B, Tang N, Stephenson KB, Atherton MJ, Hanwell D, El-Warrak A, Goldstein A, Moloo B, Turner PV, Lopez R, LaFrance S, Evelegh C, Denisova G, Parsons R, Millar J, Stoll G, Martin CG, Pomoransky J, Breitbach CJ, Bramson JL, Bell JC, Wan Y, Stojdl DF, Lichty BD, McCart JA</authors>
		<title>Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials</title>
		<year>2019</year>
		<volume>8</volume>
		<issue>1</issue>
		<pages>e1512329</pages>
		<journal_book_name>Oncoimmunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3843">
		<reference_name>Pollack et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H</authors>
		<title>Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study</title>
		<year>2016</year>
		<volume>130</volume>
		<issue>3</issue>
		<pages>517-527</pages>
		<journal_book_name>Journal of neuro-oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1892">
		<reference_name>Pope et al., 1994</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pope BL, Sigindere J, Chourmouzis E, MacIntyre P, Goodman MG</authors>
		<title>7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine</title>
		<year>1994</year>
		<volume>38</volume>
		<issue>2</issue>
		<pages>83-91</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3888">
		<reference_name>Posner et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Posner MC, Niedzwiecki D, Venook AP, Hollis DR, Kindler HL, Martin EW, Schilsky RL, Goldberg RM, Mayer RJ</authors>
		<title>A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903</title>
		<year>2008</year>
		<volume>15</volume>
		<issue>1</issue>
		<pages>158-164</pages>
		<journal_book_name>Annals of surgical oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3977">
		<reference_name>Prince et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Prince HE, Seaton BL, Matud JL, Batterman HJ</authors>
		<title>Chikungunya virus RNA and antibody testing at a National Reference Laboratory since the emergence of Chikungunya virus in the Americas</title>
		<year>2015</year>
		<volume>22</volume>
		<issue>3</issue>
		<pages>291-297</pages>
		<journal_book_name>Clinical and vaccine immunology : CVI</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3839">
		<reference_name>Prins et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B, Everson R, Yong WH, Lai A, Li G, Cloughesy TF, Liau LM</authors>
		<title>Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients</title>
		<year>2013</year>
		<volume>36</volume>
		<issue>2</issue>
		<pages>152-157</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5188">
		<reference_name>Procaccio et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete AA, Intini R, Manai C, Dadduzio V, Boscolo A, Zagonel V, Lonardi S</authors>
		<title>Immunotherapy in Gastrointestinal Cancers</title>
		<year>2017</year>
		<volume>2017</volume>
		<issue></issue>
		<pages>4346576</pages>
		<journal_book_name>BioMed research international</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3886">
		<reference_name>Pruitt et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pruitt SK, Boczkowski D, de Rosa N, Haley NR, Morse MA, Tyler DS, Dannull J, Nair S</authors>
		<title>Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells</title>
		<year>2011</year>
		<volume>41</volume>
		<issue>12</issue>
		<pages>3553-3563</pages>
		<journal_book_name>European journal of immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3942">
		<reference_name>Pujol et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pujol JL, De Pas T, Rittmeyer A, Valliï¿½res E, Kubisa B, Levchenko E, Wiesemann S, Masters GA, Shen R, Tjulandin SA, Hofmann HS, Vanhoutte N, Salaun B, Debois M, Jarnjak S, De Sousa Alves PM, Louahed J, Brichard VG, Lehmann FF</authors>
		<title>Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study</title>
		<year>2016</year>
		<volume>11</volume>
		<issue>12</issue>
		<pages>2208-2217</pages>
		<journal_book_name>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2922">
		<reference_name>Pullarkat et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pullarkat V, Lee PP, Scotland R, Rubio V, Groshen S, Gee C, Lau R, Snively J, Sian S, Woulfe SL, Wolfe RA, Weber JS</authors>
		<title>A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma</title>
		<year>2003</year>
		<volume>9</volume>
		<issue>4</issue>
		<pages>1301-1312</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5235">
		<reference_name>Purner et al., 1994</reference_name>
		<reference_type>journal</reference_type>
		<authors>Purner MB, Berens RL, Krug EC, Curiel TJ</authors>
		<title>Epstein-Barr virus-transformed B cells, a potentially convenient source of autologous antigen-presenting cells for the propagation of certain human cytotoxic T lymphocytes</title>
		<year>1994</year>
		<volume>1</volume>
		<issue>6</issue>
		<pages>696-700</pages>
		<journal_book_name>Clinical and diagnostic laboratory immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5120">
		<reference_name>Qazilbash et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ</authors>
		<title>PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies</title>
		<year>2017</year>
		<volume>31</volume>
		<issue>3</issue>
		<pages>697-704</pages>
		<journal_book_name>Leukemia</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3134">
		<reference_name>Qi et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Qi H, Li YH, Zheng SB</authors>
		<title>[Oral gene therapy via live attenuated Salmonella leads to tumor regression and survival prolongation in mice]</title>
		<year>2006</year>
		<volume>26</volume>
		<issue>12</issue>
		<pages>1738-1741</pages>
		<journal_book_name>Nan fang yi ke da xue xue bao = Journal of Southern Medical University</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5226">
		<reference_name>Qi et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Qi CJ, Ning YL, Han YS, Min HY, Ye H, Zhu YL, Qian KQ</authors>
		<title>Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer</title>
		<year>2012</year>
		<volume>61</volume>
		<issue>9</issue>
		<pages>1415-1424</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4028">
		<reference_name>Qiao et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Qiao H, Qian XP, Zhang HG, Tian C, Chen WF</authors>
		<title>[Estimation of an NY-ESO-1 expressing HCC cell line by NY-ESO-1b specific CD8+T cells in vitro induced by HLA-A2 restricted NY-ESO-1b peptide]</title>
		<year>2005</year>
		<volume>37</volume>
		<issue>6</issue>
		<pages>565-568</pages>
		<journal_book_name>Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5164">
		<reference_name>Qin and Chatterjee, 1996</reference_name>
		<reference_type>journal</reference_type>
		<authors>Qin H, Chatterjee SK</authors>
		<title>Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF</title>
		<year>1996</year>
		<volume>7</volume>
		<issue>15</issue>
		<pages>1853-1860</pages>
		<journal_book_name>Human gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2373">
		<reference_name>Qin et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Qin H, Zhou C, Wang D, Ma W, Liang X, Lin C, Zhang Y, Zhang S</authors>
		<title>Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens</title>
		<year>2005</year>
		<volume>99</volume>
		<issue>1</issue>
		<pages>85-93</pages>
		<journal_book_name>Immunology letters</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5340">
		<reference_name>Quandt et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Quandt J, Schlude C, Bartoschek M, Will R, Cid-Arregui A, SchÃ¶lch S, Reissfelder C, Weitz J, Schneider M, Wiemann S, Momburg F, Beckhove P</authors>
		<title>Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses</title>
		<year>2018</year>
		<volume>7</volume>
		<issue>12</issue>
		<pages>e1500671</pages>
		<journal_book_name>Oncoimmunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2938">
		<reference_name>Quirt et al., 1991</reference_name>
		<reference_type>journal</reference_type>
		<authors>Quirt IC, Shelley WE, Pater JL, Bodurtha AJ, McCulloch PB, McPherson TA, Paterson AH, Prentice R, Silver HK, Willan AR</authors>
		<title>Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group</title>
		<year>1991</year>
		<volume>9</volume>
		<issue>5</issue>
		<pages>729-735</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4031">
		<reference_name>Raez et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Raez LE, Cassileth PA, Schlesselman JJ, Padmanabhan S, Fisher EZ, Baldie PA, Sridhar K, Podack ER</authors>
		<title>Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma</title>
		<year>2003</year>
		<volume>10</volume>
		<issue>11</issue>
		<pages>850-858</pages>
		<journal_book_name>Cancer gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5154">
		<reference_name>Ragupathi et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ragupathi G, Koganty RR, Qiu D, Lloyd KO, Livingston PO</authors>
		<title>A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm</title>
		<year>1998</year>
		<volume>15</volume>
		<issue>3</issue>
		<pages>217-221</pages>
		<journal_book_name>Glycoconjugate journal</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3961">
		<reference_name>Ragupathi et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO</authors>
		<title>Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21</title>
		<year>2000</year>
		<volume>85</volume>
		<issue>5</issue>
		<pages>659-666</pages>
		<journal_book_name>International journal of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5330">
		<reference_name>Ragupathi et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ragupathi G, Damani P, Srivastava G, Srivastava O, Sucheck SJ, Ichikawa Y, Livingston PO</authors>
		<title>Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine</title>
		<year>2009</year>
		<volume>58</volume>
		<issue>9</issue>
		<pages>1397-1405</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5168">
		<reference_name>Rahma et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rahma OE, Ashtar E, Ibrahim R, Toubaji A, Gause B, Herrin VE, Linehan WM, Steinberg SM, Grollman F, Grimes G, Bernstein SA, Berzofsky JA, Khleif SN</authors>
		<title>A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma</title>
		<year>2010</year>
		<volume>8</volume>
		<issue></issue>
		<pages>8</pages>
		<journal_book_name>Journal of translational medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2360">
		<reference_name>Rakhmilevich et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rakhmilevich AL, Imboden M, Hao Z, Macklin MD, Roberts T, Wright KM, Albertini MR, Yang NS, Sondel PM</authors>
		<title>Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor</title>
		<year>2001</year>
		<volume>7</volume>
		<issue>4</issue>
		<pages>952-961</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4002">
		<reference_name>Ramesh et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ramesh R, Ioannides CG, Roth JA, Chada S</authors>
		<title>Adenovirus-mediated interleukin (IL)-24 immunotherapy for cancer</title>
		<year>2010</year>
		<volume>651</volume>
		<issue></issue>
		<pages>241-270</pages>
		<journal_book_name>Methods in molecular biology (Clifton, N.J.)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3923">
		<reference_name>Rapoport et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L, Janofsky S, Chew A, Storek J, Akpek G, Badros A, Yanovich S, Tan MT, Veloso E, Pasetti MF, Cross A, Philip S, Murphy H, Bhagat R, Zheng Z, Milliron T, Cotte J, Cannon A, Levine BL, Vonderheide RH, June CH</authors>
		<title>Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma</title>
		<year>2011</year>
		<volume>117</volume>
		<issue>3</issue>
		<pages>788-797</pages>
		<journal_book_name>Blood</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5346">
		<reference_name>Rapoport et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, Cai L, Fang HB, Weiss BM, Badros A, Yanovich S, Akpek G, Tsao P, Cross A, Mann D, Philip S, Kerr N, Brennan A, Zheng Z, Ruehle K, Milliron T, Strome SE, Salazar AM, Levine BL, June CH</authors>
		<title>Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells</title>
		<year>2014</year>
		<volume>20</volume>
		<issue>5</issue>
		<pages>1355-1365</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5216">
		<reference_name>Rapoport et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH</authors>
		<title>NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma</title>
		<year>2015</year>
		<volume>21</volume>
		<issue>8</issue>
		<pages>914-921</pages>
		<journal_book_name>Nature medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5157">
		<reference_name>Ravindranathan et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ravindranathan S, Nguyen KG, Kurtz SL, Frazier HN, Smith SG, Koppolu BP, Rajaram N, Zaharoff DA</authors>
		<title>Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines</title>
		<year>2018</year>
		<volume>20</volume>
		<issue>1</issue>
		<pages>126</pages>
		<journal_book_name>Breast cancer research : BCR</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference962">
		<reference_name>Reali et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Reali E, Greiner JW, Corti A, Gould HJ, Bottazzoli F, Paganelli G, Schlom J, Siccardi AG</authors>
		<title>IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines</title>
		<year>2001</year>
		<volume>61</volume>
		<issue>14</issue>
		<pages>5517-5522</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5243">
		<reference_name>Reed et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Reed CM, Cresce ND, Mauldin IS, Slingluff CL Jr, Olson WC</authors>
		<title>Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival</title>
		<year>2015</year>
		<volume>21</volume>
		<issue>17</issue>
		<pages>3879-3887</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2724">
		<reference_name>Reid et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Reid Y, Storts D, Riss T, Minor L</authors>
		<title>Authentication of Human Cell Lines by STR DNA Profiling Analysis</title>
		<year>2004</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3941">
		<reference_name>Reinartz et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Reinartz S, Kï¿½hler S, Schlebusch H, Krista K, Giffels P, Renke K, Huober J, Mï¿½bus V, Kreienberg R, DuBois A, Sabbatini P, Wagner U</authors>
		<title>Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II)</title>
		<year>2004</year>
		<volume>10</volume>
		<issue>5</issue>
		<pages>1580-1587</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5301">
		<reference_name>Reker et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH</authors>
		<title>HLA-B35-restricted immune responses against survivin in cancer patients</title>
		<year>2004</year>
		<volume>108</volume>
		<issue>6</issue>
		<pages>937-941</pages>
		<journal_book_name>International journal of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5309">
		<reference_name>Relitti et al., 2020</reference_name>
		<reference_type>journal</reference_type>
		<authors>Relitti N, Saraswati AP, Federico S, Khan T, Brindisi M, Zisterer D, Brogi S, Gemma S, Butini S, Campiani G</authors>
		<title>Telomerase-based cancer therapeutics: a review on their clinical trials</title>
		<year>2020</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name>Current topics in medicinal chemistry</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5204">
		<reference_name>Reusch et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, Eser M, McAleese F, Molkenthin V, Gall FL, Topp M, Little M, Zhukovsky EA</authors>
		<title>A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells</title>
		<year>2015</year>
		<volume>7</volume>
		<issue>3</issue>
		<pages>584-604</pages>
		<journal_book_name>mAbs</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3874">
		<reference_name>Reuschenbach et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Reuschenbach M, Pauligk C, Karbach J, Rafiyan MR, Kloor M, Prigge ES, Sauer M, Al-Batran SE, Kaufmann AM, Schneider A, Jï¿½ger E, von Knebel Doeberitz M</authors>
		<title>A phase 1/2a study to test the safety and immunogenicity of a p16(INK4a) peptide vaccine in patients with advanced human papillomavirus-associated cancers</title>
		<year>2016</year>
		<volume>122</volume>
		<issue>9</issue>
		<pages>1425-1433</pages>
		<journal_book_name>Cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3832">
		<reference_name>Ribas et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ribas A, Camacho LH, Lee SM, Hersh EM, Brown CK, Richards JM, Rodriguez MJ, Prieto VG, Glaspy JA, Oseguera DK, Hernandez J, Villanueva A, Chmielowski B, Mitsky P, Bercovici N, Wasserman E, Landais D, Ross MI</authors>
		<title>Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma</title>
		<year>2010</year>
		<volume>8</volume>
		<issue></issue>
		<pages>89</pages>
		<journal_book_name>Journal of translational medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2346">
		<reference_name>Rice et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rice J, Buchan S, Dewchand H, Simpson E, Stevenson FK</authors>
		<title>DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire</title>
		<year>2004</year>
		<volume>173</volume>
		<issue>7</issue>
		<pages>4492-4499</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3997">
		<reference_name>Rice et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rice J, Ottensmeier CH, Stevenson FK</authors>
		<title>DNA vaccines: precision tools for activating effective immunity against cancer</title>
		<year>2008</year>
		<volume>8</volume>
		<issue>2</issue>
		<pages>108-120</pages>
		<journal_book_name>Nature reviews. Cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3005">
		<reference_name>Ricupito et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ricupito A, Grioni M, Calcinotto A, Hess Michelini R, Longhi R, Mondino A, Bellone M</authors>
		<title>Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings</title>
		<year>2013</year>
		<volume>73</volume>
		<issue>12</issue>
		<pages>3545-3554</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5258">
		<reference_name>Ridolfi et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ridolfi L, de Rosa F, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Bulgarelli J, Riccobon A, Gentili G, Nanni O, Framarini M, Tauceri F, Guidoboni M</authors>
		<title>Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)</title>
		<year>2018</year>
		<volume>8</volume>
		<issue>8</issue>
		<pages>e021701</pages>
		<journal_book_name>BMJ open</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5127">
		<reference_name>Rijnkels and Rosen, 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rijnkels M, Rosen JM</authors>
		<title>Adenovirus-Cre-mediated recombination in mammary epithelial early progenitor cells</title>
		<year>2001</year>
		<volume>114</volume>
		<issue>Pt 17</issue>
		<pages>3147-3153</pages>
		<journal_book_name>Journal of cell science</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference957">
		<reference_name>Rinaldi et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rinaldi M, Fioretti D, Iurescia S, Signori E, Pierimarchi P, Seripa D, Tonon G, Fazio VM</authors>
		<title>Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model</title>
		<year>2008</year>
		<volume>370</volume>
		<issue>2</issue>
		<pages>279-284</pages>
		<journal_book_name>Biochemical and biophysical research communications</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5160">
		<reference_name>Rini et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, Weikert S, Bracarda S, Crabb SJ, Bedke J, Ludwig J, Maurer D, Mendrzyk R, Wagner C, Mahr A, Fritsche J, Weinschenk T, Walter S, Kirner A, Singh-Jasuja H, Reinhardt C, Eisen T</authors>
		<title>IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial</title>
		<year>2016</year>
		<volume>17</volume>
		<issue>11</issue>
		<pages>1599-1611</pages>
		<journal_book_name>The Lancet. Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4018">
		<reference_name>Rivoltini et al., 1999</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rivoltini L, Squarcina P, Loftus DJ, Castelli C, Tarsini P, Mazzocchi A, Rini F, Viggiano V, Belli F, Parmiani G</authors>
		<title>A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy</title>
		<year>1999</year>
		<volume>59</volume>
		<issue>2</issue>
		<pages>301-306</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5271">
		<reference_name>Robbins et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Li YF, El-Gamil M, Rosenberg SA</authors>
		<title>A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response</title>
		<year>2015</year>
		<volume>21</volume>
		<issue>5</issue>
		<pages>1019-1027</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2970">
		<reference_name>Robert et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S</authors>
		<title>Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control</title>
		<year>2013</year>
		<volume>19</volume>
		<issue>8</issue>
		<pages>2232-2239</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5140">
		<reference_name>Rochlitz et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R, Tartour E, Zhao Y, Bizouarne N, Baudin M, Acres B</authors>
		<title>Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer</title>
		<year>2003</year>
		<volume>5</volume>
		<issue>8</issue>
		<pages>690-699</pages>
		<journal_book_name>The journal of gene medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5298">
		<reference_name>RoldÃ£o et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>RoldÃ£o A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM</authors>
		<title>Virus-like particles in vaccine development</title>
		<year>2010</year>
		<volume>9</volume>
		<issue>10</issue>
		<pages>1149-1176</pages>
		<journal_book_name>Expert review of vaccines</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5295">
		<reference_name>Roohvand and Kossari, 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Roohvand F, Kossari N</authors>
		<title>Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities</title>
		<year>2012</year>
		<volume>22</volume>
		<issue>4</issue>
		<pages>391-415</pages>
		<journal_book_name>Expert opinion on therapeutic patents</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2372">
		<reference_name>Roos et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Roos AK, Pavlenko M, Charo J, Egevad L, Pisa P</authors>
		<title>Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine</title>
		<year>2005</year>
		<volume>62</volume>
		<issue>3</issue>
		<pages>217-223</pages>
		<journal_book_name>The Prostate</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2927">
		<reference_name>Rosenberg et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE</authors>
		<title>Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma</title>
		<year>1998</year>
		<volume>4</volume>
		<issue>3</issue>
		<pages>321-327</pages>
		<journal_book_name>Nature medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5142">
		<reference_name>Rosenberg et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, Gritz L, Panicali DL, White DE</authors>
		<title>Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma</title>
		<year>2003</year>
		<volume>9</volume>
		<issue>8</issue>
		<pages>2973-2980</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5234">
		<reference_name>Rosenblatt et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, Yuan YE, Francoeur K, Fitzgerald D, Richardson P, Weller E, Anderson K, Kufe D, Munshi N, Avigan D</authors>
		<title>Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma</title>
		<year>2011</year>
		<volume>117</volume>
		<issue>2</issue>
		<pages>393-402</pages>
		<journal_book_name>Blood</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3257">
		<reference_name>Roth et al., 1996</reference_name>
		<reference_type>journal</reference_type>
		<authors>Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E, Levine AJ</authors>
		<title>p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge</title>
		<year>1996</year>
		<volume>93</volume>
		<issue>10</issue>
		<pages>4781-4786</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5227">
		<reference_name>Rousseau et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rousseau RF, Biagi E, Dutour A, Yvon ES, Brown MP, Lin T, Mei Z, Grilley B, Popek E, Heslop HE, Gee AP, Krance RA, Popat U, Carrum G, Margolin JF, Brenner MK</authors>
		<title>Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation</title>
		<year>2006</year>
		<volume>107</volume>
		<issue>4</issue>
		<pages>1332-1341</pages>
		<journal_book_name>Blood</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4042">
		<reference_name>Rouxel et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rouxel RN, Mï¿½rour E, Biacchesi S, Brï¿½mont M</authors>
		<title>Complete Protection against Influenza Virus H1N1 Strain A/PR/8/34 Challenge in Mice Immunized with Non-Adjuvanted Novirhabdovirus Vaccines</title>
		<year>2016</year>
		<volume>11</volume>
		<issue>10</issue>
		<pages>e0164245</pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1303">
		<reference_name>Ruan et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ruan Z, Yang Z, Wang Y, Wang H, Chen Y, Shang X, Yang C, Guo S, Han J, Liang H, Wu Y</authors>
		<title>DNA vaccine against tumor endothelial marker 8 inhibits tumor angiogenesis and growth</title>
		<year>2009</year>
		<volume>32</volume>
		<issue>5</issue>
		<pages>486-491</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5252">
		<reference_name>Rubinstein et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rubinstein A, Mizrachi Y, Bernstein L, Shliozberg J, Golodner M, Liu GQ, Ochs HD</authors>
		<title>Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage phi X174 in asymptomatic HIV-1 infected patients</title>
		<year>2000</year>
		<volume>14</volume>
		<issue>4</issue>
		<pages>F55-62</pages>
		<journal_book_name>AIDS (London, England)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1299">
		<reference_name>Russo et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Russo V, Cipponi A, Raccosta L, Rainelli C, Fontana R, Maggioni D, Lunghi F, Mukenge S, Ciceri F, Bregni M, Bordignon C, Traversari C</authors>
		<title>Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity</title>
		<year>2007</year>
		<volume>117</volume>
		<issue>10</issue>
		<pages>3087-3096</pages>
		<journal_book_name>The Journal of clinical investigation</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2957">
		<reference_name>Russo et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Russo V, Pilla L, Lunghi F, Crocchiolo R, Greco R, Ciceri F, Maggioni D, Fontana R, Mukenge S, Rivoltini L, Rigamonti G, Mercuri SR, Nicoletti R, Maschio AD, Gianolli L, Fazio F, MarchianÃƒÂ² A, Florio AD, Maio M, Salomoni M, Gallo-Stampino C, Fiacco MD, Lambiase A, Coulie PG, Patuzzo R, Parmiani G, Traversari C, Bordignon C, Santinami M, Bregni M</authors>
		<title>Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes</title>
		<year>2013</year>
		<volume>132</volume>
		<issue>11</issue>
		<pages>2557-2566</pages>
		<journal_book_name>International journal of cancer. Journal international du cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3973">
		<reference_name>Sabbatini et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, Iasonos A, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K</authors>
		<title>Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer</title>
		<year>2006</year>
		<volume>12</volume>
		<issue>18</issue>
		<pages>5503-5510</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5280">
		<reference_name>Sabbatini et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A, Hensley ML, Spassova MK, Ouerfelli O, Spriggs DR, Tew WP, Konner J, Clausen H, Abu Rustum N, Dansihefsky SJ, Livingston PO</authors>
		<title>Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer</title>
		<year>2007</year>
		<volume>13</volume>
		<issue>14</issue>
		<pages>4170-4177</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3987">
		<reference_name>Saeki et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Saeki A, Nakao K, Nagayama Y, Yanagi K, Matsumoto K, Hayashi T, Ishikawa H, Hamasaki K, Ishii N, Eguchi K</authors>
		<title>Diverse efficacy of vaccination therapy using the alpha-fetoprotein gene against mouse hepatocellular carcinoma</title>
		<year>2004</year>
		<volume>13</volume>
		<issue>1</issue>
		<pages>111-116</pages>
		<journal_book_name>International journal of molecular medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5185">
		<reference_name>Saeterdal et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Saeterdal I, BjÃ¸rheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, MÃ¸ller M, Lindblom A, Gaudernack G</authors>
		<title>Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer</title>
		<year>2001</year>
		<volume>98</volume>
		<issue>23</issue>
		<pages>13255-13260</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference975">
		<reference_name>Saha et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Saha A, Chatterjee SK, Foon KA, Primus FJ, Sreedharan S, Mohanty K, Bhattacharya-Chatterjee M</authors>
		<title>Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice</title>
		<year>2004</year>
		<volume>64</volume>
		<issue>14</issue>
		<pages>4995-5003</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5361">
		<reference_name>Saha et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Saha A, Baral RN, Chatterjee SK, Mohanty K, Pal S, Foon KA, Primus FJ, Krieg AM, Weiner GJ, Bhattacharya-Chatterjee M</authors>
		<title>CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice</title>
		<year>2006</year>
		<volume>55</volume>
		<issue>5</issue>
		<pages>515-527</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5181">
		<reference_name>Saito et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Saito H, Kitagawa K, Yoneda T, Fukui Y, Fujsawa M, Bautista D, Shirakawa T</authors>
		<title>Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro</title>
		<year>2017</year>
		<volume>24</volume>
		<issue>7</issue>
		<pages>289-296</pages>
		<journal_book_name>Cancer gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3000">
		<reference_name>Salerno et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Salerno EP, Shea SM, Olson WC, Petroni GR, Smolkin ME, McSkimming C, Chianese-Bullock KA, Slingluff CL Jr</authors>
		<title>Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide</title>
		<year>2013</year>
		<volume>62</volume>
		<issue>7</issue>
		<pages>1149-1159</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5150">
		<reference_name>SAUER and TUCKER, 1954</reference_name>
		<reference_type>journal</reference_type>
		<authors>SAUER LW, TUCKER WH</authors>
		<title>Immune responses to diphtheria, tetanus, and pertussis, aluminum phosphate adsorbed</title>
		<year>1954</year>
		<volume>44</volume>
		<issue>6</issue>
		<pages>784-788</pages>
		<journal_book_name>American journal of public health and the nation's health</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5240">
		<reference_name>Savvateeva et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Savvateeva LV, Schwartz AM, Gorshkova LB, Gorokhovets NV, Makarov VA, Reddy VP, Aliev G, Zamyatnin AA Jr</authors>
		<title>Prophylactic Admission of an In Vitro Reconstructed Complexes of Human Recombinant Heat Shock Proteins and Melanoma Antigenic Peptides Activates Anti-Melanoma Responses in Mice</title>
		<year>2015</year>
		<volume>15</volume>
		<issue>5</issue>
		<pages>462-468</pages>
		<journal_book_name>Current molecular medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2382">
		<reference_name>Sawada et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, Nakagohri T, Takahashi S, Gotohda N, Takayama T, Yamao K, Uesaka K, Furuse J, Kinoshita T, Nakatsura T</authors>
		<title>Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival</title>
		<year>2012</year>
		<volume>18</volume>
		<issue>13</issue>
		<pages>3686-3696</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5281">
		<reference_name>Sawada et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sawada Y, Yoshikawa T, Fujii S, Mitsunaga S, Nobuoka D, Mizuno S, Takahashi M, Yamauchi C, Endo I, Nakatsura T</authors>
		<title>Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: an autopsy case</title>
		<year>2013</year>
		<volume>9</volume>
		<issue>6</issue>
		<pages>1228-1233</pages>
		<journal_book_name>Human vaccines &amp; immunotherapeutics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5249">
		<reference_name>Saxena and Bhardwaj, 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Saxena M, Bhardwaj N</authors>
		<title>Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment</title>
		<year>2018</year>
		<volume>4</volume>
		<issue>2</issue>
		<pages>119-137</pages>
		<journal_book_name>Trends in cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5351">
		<reference_name>SchÃ¼tz et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>SchÃ¼tz A, Oertli D, Marti WR, Noppen C, Padovan E, Spagnoli GC, Heberer M, Zajac P</authors>
		<title>Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen</title>
		<year>2001</year>
		<volume>8</volume>
		<issue>9</issue>
		<pages>655-661</pages>
		<journal_book_name>Cancer gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5165">
		<reference_name>Schmitz-Winnenthal et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, Springer M, Wieckowski S, Breiner KM, Mikus G, BÃ¼chler MW, Keller AV, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P</authors>
		<title>A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer</title>
		<year>2018</year>
		<volume>7</volume>
		<issue>4</issue>
		<pages>e1303584</pages>
		<journal_book_name>Oncoimmunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3834">
		<reference_name>Schneble et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Schneble EJ, Berry JS, Trappey FA, Clifton GT, Ponniah S, Mittendorf E, Peoples GE</authors>
		<title>The HER2 peptide nelipepimut-S (E75) vaccine (NeuVaxï¿½) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response</title>
		<year>2014</year>
		<volume>6</volume>
		<issue>5</issue>
		<pages>519-531</pages>
		<journal_book_name>Immunotherapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3939">
		<reference_name>Schoof et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Schoof DD, Smith JW 2nd, Disis ML, Brant-Zawadski P, Wood W, Doran T, Johnson E, Urba WJ</authors>
		<title>Immunization of metastatic breast cancer patients with CD80-modified breast cancer cells and GM-CSF</title>
		<year>1998</year>
		<volume>451</volume>
		<issue></issue>
		<pages>511-518</pages>
		<journal_book_name>Advances in experimental medicine and biology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5378">
		<reference_name>Schuler et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, Argiris A, Gooding W, Butterfield LH, Whiteside TL, Ferris RL</authors>
		<title>Phase I dendritic cell p53 peptide vaccine for head and neck cancer</title>
		<year>2014</year>
		<volume>20</volume>
		<issue>9</issue>
		<pages>2433-2444</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2895">
		<reference_name>Schwartzentruber et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P</authors>
		<title>gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma</title>
		<year>2011</year>
		<volume>364</volume>
		<issue>22</issue>
		<pages>2119-2127</pages>
		<journal_book_name>The New England journal of medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3971">
		<reference_name>Sears et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sears AK, Perez SA, Clifton GT, Benavides LC, Gates JD, Clive KS, Holmes JP, Shumway NM, Van Echo DC, Carmichael MG, Ponniah S, Baxevanis CN, Mittendorf EA, Papamichail M, Peoples GE</authors>
		<title>AE37: a novel T-cell-eliciting vaccine for breast cancer</title>
		<year>2011</year>
		<volume>11</volume>
		<issue>11</issue>
		<pages>1543-1550</pages>
		<journal_book_name>Expert opinion on biological therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1316">
		<reference_name>Seavey et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Seavey MM, Maciag PC, Al-Rawi N, Sewell D, Paterson Y</authors>
		<title>An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model</title>
		<year>2009</year>
		<volume>182</volume>
		<issue>9</issue>
		<pages>5537-5546</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference961">
		<reference_name>Seino et al., 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Seino K, Kayagaki N, Okumura K, Yagita H</authors>
		<title>Antitumor effect of locally produced CD95 ligand</title>
		<year>1997</year>
		<volume>3</volume>
		<issue>2</issue>
		<pages>165-170</pages>
		<journal_book_name>Nature medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3885">
		<reference_name>Senzer et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, Lifshitz S, Magee M, Oh J, Mill SW, Bedell C, Higgs C, Kumar P, Yu Y, Norvell F, Phalon C, Taquet N, Rao DD, Wang Z, Jay CM, Pappen BO, Wallraven G, Brunicardi FC, Shanahan DM, Maples PB, Nemunaitis J</authors>
		<title>Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer</title>
		<year>2012</year>
		<volume>20</volume>
		<issue>3</issue>
		<pages>679-686</pages>
		<journal_book_name>Molecular therapy : the journal of the American Society of Gene Therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5319">
		<reference_name>Seo et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Seo SH, Kim KS, Park SH, Suh YS, Kim SJ, Jeun SS, Sung YC</authors>
		<title>The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity</title>
		<year>2011</year>
		<volume>18</volume>
		<issue>5</issue>
		<pages>488-495</pages>
		<journal_book_name>Gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3871">
		<reference_name>Shapiro et al., 1993</reference_name>
		<reference_type>journal</reference_type>
		<authors>Shapiro DN, Sublett JE, Li B, Downing JR, Naeve CW</authors>
		<title>Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma</title>
		<year>1993</year>
		<volume>53</volume>
		<issue>21</issue>
		<pages>5108-5112</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3993">
		<reference_name>Sharma et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Koski G, Czerniecki BJ</authors>
		<title>HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ</title>
		<year>2012</year>
		<volume>118</volume>
		<issue>17</issue>
		<pages>4354-4362</pages>
		<journal_book_name>Cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3557">
		<reference_name>show</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title></title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>https://clinicaltrials.gov/show/</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5328">
		<reference_name>Siegel et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Siegel F, Lu M, Roggendorf M</authors>
		<title>Coadministration of gamma interferon with DNA vaccine expressing woodchuck hepatitis virus (WHV) core antigen enhances the specific immune response and protects against WHV infection</title>
		<year>2001</year>
		<volume>75</volume>
		<issue>11</issue>
		<pages>5036-5042</pages>
		<journal_book_name>Journal of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5292">
		<reference_name>Simons and Sacks, 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Simons JW, Sacks N</authors>
		<title>Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer</title>
		<year>2006</year>
		<volume>24</volume>
		<issue>5</issue>
		<pages>419-424</pages>
		<journal_book_name>Urologic oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3864">
		<reference_name>Sirisinha and Eisen, 1971</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sirisinha S, Eisen HN</authors>
		<title>Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins</title>
		<year>1971</year>
		<volume>68</volume>
		<issue>12</issue>
		<pages>3130-3135</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3892">
		<reference_name>Siurala et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Siurala M, Bramante S, Vassilev L, Hirvinen M, Parviainen S, Tï¿½htinen S, Guse K, Cerullo V, Kanerva A, Kipar A, Vï¿½hï¿½-Koskela M, Hemminki A</authors>
		<title>Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma</title>
		<year>2015</year>
		<volume>136</volume>
		<issue>4</issue>
		<pages>945-954</pages>
		<journal_book_name>International journal of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2919">
		<reference_name>Slingluff et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH</authors>
		<title>Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells</title>
		<year>2003</year>
		<volume>21</volume>
		<issue>21</issue>
		<pages>4016-4026</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2910">
		<reference_name>Slingluff et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Slingluff CL Jr, Petroni GR, Olson W, Czarkowski A, Grosh WW, Smolkin M, Chianese-Bullock KA, Neese PY, Deacon DH, Nail C, Merrill P, Fink R, Patterson JW, Rehm PK</authors>
		<title>Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens</title>
		<year>2008</year>
		<volume>26</volume>
		<issue>30</issue>
		<pages>4973-4980</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2900">
		<reference_name>Slingluff et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, von Mehren M, Grosh WW</authors>
		<title>Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine</title>
		<year>2011</year>
		<volume>29</volume>
		<issue>21</issue>
		<pages>2924-2932</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3001">
		<reference_name>Slingluff et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Slingluff CL Jr, Lee S, Zhao F, Chianese-Bullock KA, Olson WC, Butterfield LH, Whiteside TL, Leming PD, Kirkwood JM</authors>
		<title>A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602)</title>
		<year>2013</year>
		<volume>19</volume>
		<issue>15</issue>
		<pages>4228-4238</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3955">
		<reference_name>Slovin et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Slovin SF, Ragupathi G, Fernandez C, Jefferson MP, Diani M, Wilton AS, Powell S, Spassova M, Reis C, Clausen H, Danishefsky S, Livingston P, Scher HI</authors>
		<title>A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21</title>
		<year>2005</year>
		<volume>23</volume>
		<issue>24</issue>
		<pages>3114-3122</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2914">
		<reference_name>Smith et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Smith CL, Dunbar PR, Mirza F, Palmowski MJ, Shepherd D, Gilbert SC, Coulie P, Schneider J, Hoffman E, Hawkins R, Harris AL, Cerundolo V</authors>
		<title>Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence</title>
		<year>2005</year>
		<volume>113</volume>
		<issue>2</issue>
		<pages>259-266</pages>
		<journal_book_name>International journal of cancer. Journal international du cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5285">
		<reference_name>Smith et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Smith FO, Klapper JA, Wunderlich JR, Rosenberg SA, Dudley ME</authors>
		<title>Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma</title>
		<year>2009</year>
		<volume>32</volume>
		<issue>8</issue>
		<pages>870-874</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3918">
		<reference_name>Snape et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, Findlow J, Yu LM, Borrow R, Ypma E, Toneatto D, Pollard AJ</authors>
		<title>Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial</title>
		<year>2010</year>
		<volume>29</volume>
		<issue>11</issue>
		<pages>71-79</pages>
		<journal_book_name>The Pediatric infectious disease journal</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3913">
		<reference_name>Snook et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Snook AE, Stafford BJ, Li P, Tan G, Huang L, Birbe R, Schulz S, Schnell MJ, Thakur M, Rothstein JL, Eisenlohr LC, Waldman SA</authors>
		<title>Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity</title>
		<year>2008</year>
		<volume>100</volume>
		<issue>13</issue>
		<pages>950-961</pages>
		<journal_book_name>Journal of the National Cancer Institute</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2022">
		<reference_name>Soares et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Soares MM, Mehta V, Finn OJ</authors>
		<title>Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection</title>
		<year>2001</year>
		<volume>166</volume>
		<issue>11</issue>
		<pages>6555-6563</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2916">
		<reference_name>Sondak and Sosman, 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sondak VK, Sosman JA</authors>
		<title>Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine</title>
		<year>2003</year>
		<volume>13</volume>
		<issue>6</issue>
		<pages>409-415</pages>
		<journal_book_name>Seminars in cancer biology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5359">
		<reference_name>Song et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Song GY, Srivastava T, Ishizaki H, Lacey SF, Diamond DJ, Ellenhorn JD</authors>
		<title>Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion</title>
		<year>2011</year>
		<volume>29</volume>
		<issue>8</issue>
		<pages>501-510</pages>
		<journal_book_name>Cancer investigation</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5230">
		<reference_name>Sonpavde et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sonpavde G, McMannis JD, Bai Y, Seethammagari MR, Bull JMC, Hawkins V, Dancsak TK, Lapteva N, Levitt JM, Moseley A, Spencer DM, Slawin KM</authors>
		<title>Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer</title>
		<year>2017</year>
		<volume>66</volume>
		<issue>10</issue>
		<pages>1345-1357</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5288">
		<reference_name>Sosman et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sosman JA, Carrillo C, Urba WJ, Flaherty L, Atkins MB, Clark JI, Dutcher J, Margolin KA, Mier J, Gollob J, Kirkwood JM, Panka DJ, Crosby NA, O'Boyle K, LaFleur B, Ernstoff MS</authors>
		<title>Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma</title>
		<year>2008</year>
		<volume>26</volume>
		<issue>14</issue>
		<pages>2292-2298</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2901">
		<reference_name>Speiser et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Speiser DE, Schwarz K, Baumgaertner P, Manolova V, Devevre E, Sterry W, Walden P, Zippelius A, Conzett KB, Senti G, Voelter V, Cerottini JP, Guggisberg D, Willers J, Geldhof C, Romero P, KÃƒÂ¼ndig T, Knuth A, Dummer R, Trefzer U, Bachmann MF</authors>
		<title>Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients</title>
		<year>2010</year>
		<volume>33</volume>
		<issue>8</issue>
		<pages>848-858</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3979">
		<reference_name>Stadtmauer et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Stadtmauer EA, Vogl DT, Luning Prak E, Boyer J, Aqui NA, Rapoport AP, McDonald KR, Hou X, Murphy H, Bhagat R, Mangan PA, Chew A, Veloso EA, Levine BL, Vonderheide RH, Jawad AF, June CH, Sullivan KE</authors>
		<title>Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial</title>
		<year>2011</year>
		<volume>117</volume>
		<issue>1</issue>
		<pages>63-71</pages>
		<journal_book_name>Blood</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3891">
		<reference_name>Stahl et al., 1992</reference_name>
		<reference_type>journal</reference_type>
		<authors>Stahl M, Wilke HJ, Seeber S, Schmoll HJ</authors>
		<title>Cytokines and cytotoxic agents in renal cell carcinoma: a review</title>
		<year>1992</year>
		<volume>19</volume>
		<issue>2 Suppl 4</issue>
		<pages>70-79</pages>
		<journal_book_name>Seminars in oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2898">
		<reference_name>Stebbing et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Stebbing J, Dalgleish A, Gifford-Moore A, Martin A, Gleeson C, Wilson G, Brunet LR, Grange J, Mudan S</authors>
		<title>An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma</title>
		<year>2012</year>
		<volume>23</volume>
		<issue>5</issue>
		<pages>1314-1319</pages>
		<journal_book_name>Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2935">
		<reference_name>Steitz and TÃƒÂ¼ting, 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Steitz J, TÃƒÂ¼ting T</authors>
		<title>Biolistic DNA vaccination against melanoma</title>
		<year>2013</year>
		<volume>940</volume>
		<issue></issue>
		<pages>317-337</pages>
		<journal_book_name>Methods in molecular biology (Clifton, N.J.)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3881">
		<reference_name>Stern and Wiley, 1994</reference_name>
		<reference_type>journal</reference_type>
		<authors>Stern LJ, Wiley DC</authors>
		<title>Antigenic peptide binding by class I and class II histocompatibility proteins</title>
		<year>1994</year>
		<volume></volume>
		<issue>94</issue>
		<pages>1-10</pages>
		<journal_book_name>Behring Institute Mitteilungen</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3876">
		<reference_name>Steuerwald et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Steuerwald MT, Gabbard SR, Beauchamp GA, Riddle MK, Otten EJ</authors>
		<title>Administration of CroFab Antivenom by a Helicopter Emergency Medical Service Team</title>
		<year>2016</year>
		<volume>35</volume>
		<issue>6</issue>
		<pages>371-373</pages>
		<journal_book_name>Air medical journal</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2347">
		<reference_name>Stevenson et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Stevenson FK, Ottensmeier CH, Johnson P, Zhu D, Buchan SL, McCann KJ, Roddick JS, King AT, McNicholl F, Savelyeva N, Rice J</authors>
		<title>DNA vaccines to attack cancer</title>
		<year>2004</year>
		<volume>101 Suppl 2</volume>
		<issue></issue>
		<pages>14646-14652</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2947">
		<reference_name>Storm et al., 1979</reference_name>
		<reference_type>journal</reference_type>
		<authors>Storm FK, Sparks FC, Morton DL</authors>
		<title>Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette GuÃƒÂ©rin and hyperthermic perfusion</title>
		<year>1979</year>
		<volume>149</volume>
		<issue>1</issue>
		<pages>17-21</pages>
		<journal_book_name>Surgery, gynecology &amp; obstetrics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5175">
		<reference_name>Sugiyama, 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sugiyama H</authors>
		<title>Cancer immunotherapy targeting Wilms' tumor gene WT1 product</title>
		<year>2005</year>
		<volume>4</volume>
		<issue>4</issue>
		<pages>503-512</pages>
		<journal_book_name>Expert review of vaccines</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5129">
		<reference_name>Sugiyama, 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sugiyama H</authors>
		<title>WT1 peptide cancer vaccine</title>
		<year>2017</year>
		<volume>75</volume>
		<issue>2</issue>
		<pages>263-269</pages>
		<journal_book_name>Nihon rinsho. Japanese journal of clinical medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2356">
		<reference_name>Sun et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sun X, Hodge LM, Jones HP, Tabor L, Simecka JW</authors>
		<title>Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination</title>
		<year>2002</year>
		<volume>20</volume>
		<issue>9-10</issue>
		<pages>1466-1474</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3857">
		<reference_name>Sun et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sun P, Dong L, MacDonald AI, Akbari S, Edward M, Hodgins MB, Johnstone SR, Graham SV</authors>
		<title>HPV16 E6 Controls the Gap Junction Protein Cx43 in Cervical Tumour Cells</title>
		<year>2015</year>
		<volume>7</volume>
		<issue>10</issue>
		<pages>5243-5256</pages>
		<journal_book_name>Viruses</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5339">
		<reference_name>Sun et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sun L, Hao Y, Wang Z, Zeng Y</authors>
		<title>Constructing TC-1-GLUC-LMP2 Model Tumor Cells to Evaluate the Anti-Tumor Effects of LMP2-Related Vaccines</title>
		<year>2018</year>
		<volume>10</volume>
		<issue>4</issue>
		<pages></pages>
		<journal_book_name>Viruses</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2995">
		<reference_name>Suriano et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Suriano R, Rajoria S, L George A, Geliebter J, Wallack M, Tiwari RK</authors>
		<title>Ex vivo derived primary melanoma cells: implications for immunotherapeutic vaccines</title>
		<year>2013</year>
		<volume>4</volume>
		<issue>5</issue>
		<pages>371-382</pages>
		<journal_book_name>Journal of Cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5307">
		<reference_name>Suso et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, Gaudernack G</authors>
		<title>hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes</title>
		<year>2011</year>
		<volume>60</volume>
		<issue>6</issue>
		<pages>809-818</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3907">
		<reference_name>Suzuki et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Suzuki N, Hazama S, Iguchi H, Uesugi K, Tanaka H, Hirakawa K, Aruga A, Hatori T, Ishizaki H, Umeda Y, Fujiwara T, Ikemoto T, Shimada M, Yoshimatsu K, Shimizu R, Hayashi H, Sakata K, Takenouchi H, Matsui H, Shindo Y, Iida M, Koki Y, Arima H, Furukawa H, Ueno T, Yoshino S, Nakamura Y, Oka M, Nagano H</authors>
		<title>Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study</title>
		<year>2017</year>
		<volume>108</volume>
		<issue>1</issue>
		<pages>73-80</pages>
		<journal_book_name>Cancer science</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5115">
		<reference_name>Suzuki et al., 2019</reference_name>
		<reference_type>journal</reference_type>
		<authors>Suzuki S, Osato R, Wajima T, Hasebe T, Ishikawa H, Mitsumori H, Nakaminami H, Noguchi N</authors>
		<title>Impact of the introduction of a 13-valent pneumococcal vaccine on pneumococcal serotypes in non-invasive isolates from 2007 to 2016 at a teaching hospital in Japan</title>
		<year>2019</year>
		<volume>68</volume>
		<issue>6</issue>
		<pages>903-909</pages>
		<journal_book_name>Journal of medical microbiology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3915">
		<reference_name>Svane et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Svane IM, Pedersen AE, Johnsen HE, Nielsen D, Kamby C, Gaarsdal E, Nikolajsen K, Buus S, Claesson MH</authors>
		<title>Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study</title>
		<year>2004</year>
		<volume>53</volume>
		<issue>7</issue>
		<pages>633-641</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5153">
		<reference_name>Svatek et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Svatek RS, Tangen C, Delacroix S, Lowrance W, Lerner SP</authors>
		<title>Background and Update for S1602 "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-naÃ¯ve High-grade Non-muscle-invasive Bladder Cancer</title>
		<year>2018</year>
		<volume>4</volume>
		<issue>4</issue>
		<pages>522-524</pages>
		<journal_book_name>European urology focus</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2530">
		<reference_name>Syrengelas et al., 1996</reference_name>
		<reference_type>journal</reference_type>
		<authors>Syrengelas AD, Chen TT, Levy R</authors>
		<title>DNA immunization induces protective immunity against B-cell lymphoma</title>
		<year>1996</year>
		<volume>2</volume>
		<issue>9</issue>
		<pages>1038-1041</pages>
		<journal_book_name>Nature medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3866">
		<reference_name>Tagawa et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, Hickingbottom B, Smith J, Johnson D, Weber JS</authors>
		<title>Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma</title>
		<year>2003</year>
		<volume>98</volume>
		<issue>1</issue>
		<pages>144-154</pages>
		<journal_book_name>Cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4010">
		<reference_name>Tamminga et al., 1985</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tamminga CA, Foster NL, Chase TN</authors>
		<title>Reduced brain somatostatin levels in Alzheimer's disease</title>
		<year>1985</year>
		<volume>313</volume>
		<issue>20</issue>
		<pages>1294-1295</pages>
		<journal_book_name>The New England journal of medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1318">
		<reference_name>Tan et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tan GH, Li YN, Huang FY, Wang H, Bai RZ, Jang J</authors>
		<title>Combination of recombinant xenogeneic endoglin DNA and protein vaccination enhances anti-tumor effects</title>
		<year>2007</year>
		<volume>36</volume>
		<issue>4</issue>
		<pages>423-440</pages>
		<journal_book_name>Immunological investigations</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2997">
		<reference_name>Tan et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tan C, Reddy V, Dannull J, Ding E, Nair SK, Tyler DS, Pruitt SK, Lee WT</authors>
		<title>Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model</title>
		<year>2013</year>
		<volume>11</volume>
		<issue></issue>
		<pages>148</pages>
		<journal_book_name>Journal of translational medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2971">
		<reference_name>Tanaka et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tanaka A, Jensen JD, Prado R, Riemann H, Shellman YG, Norris DA, Chin L, Yee C, Fujita M</authors>
		<title>Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma</title>
		<year>2011</year>
		<volume>18</volume>
		<issue>8</issue>
		<pages>827-834</pages>
		<journal_book_name>Gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2381">
		<reference_name>Tanaka et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tanaka K, Ishikawa S, Matsui Y, Kawanishi T, Tamesada M, Harashima N, Harada M</authors>
		<title>Combining a peptide vaccine with oral ingestion of Lentinula edodes mycelia extract enhances anti-tumor activity in B16 melanoma-bearing mice</title>
		<year>2012</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5156">
		<reference_name>Tang et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tang Y, Lin Z, Ni B, Wei J, Han J, Wang H, Wu Y</authors>
		<title>An altered peptide ligand for naÃ¯ve cytotoxic T lymphocyte epitope of TRP-2(180-188) enhanced immunogenicity</title>
		<year>2007</year>
		<volume>56</volume>
		<issue>3</issue>
		<pages>319-329</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5366">
		<reference_name>Tang et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tang Y, Cui X, Xiao H, Qi S, Hu X, Yu Q, Shi G, Zhang X, Gu J, Yu Y, Wang L, Li Y</authors>
		<title>Binding of circulating anti-MUC1 antibody and serum MUC1 antigen in stage IV breast cancer</title>
		<year>2017</year>
		<volume>15</volume>
		<issue>5</issue>
		<pages>2659-2664</pages>
		<journal_book_name>Molecular medicine reports</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2924">
		<reference_name>Tarhini et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tarhini AA, Butterfield LH, Shuai Y, Gooding WE, Kalinski P, Kirkwood JM</authors>
		<title>Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-ÃŽÂ± or TLR-9 agonist and GM-CSF with peptide vaccination</title>
		<year>2012</year>
		<volume>35</volume>
		<issue>9</issue>
		<pages>702-710</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3926">
		<reference_name>Tarhini et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tarhini AA, Leng S, Moschos SJ, Yin Y, Sander C, Lin Y, Gooding WE, Kirkwood JM</authors>
		<title>Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma</title>
		<year>2012</year>
		<volume>35</volume>
		<issue>4</issue>
		<pages>359-366</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3870">
		<reference_name>Tashani et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tashani M, Alfelali M, Barasheed O, Alqahtani AS, Heron L, Wong M, Rashid H, Booy R</authors>
		<title>Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: A randomised controlled trial</title>
		<year>2016</year>
		<volume>34</volume>
		<issue>48</issue>
		<pages>5929-5937</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2954">
		<reference_name>Thatcher and Crowther, 1977</reference_name>
		<reference_type>journal</reference_type>
		<authors>Thatcher N, Crowther D</authors>
		<title>Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients</title>
		<year>1977</year>
		<volume>38</volume>
		<issue></issue>
		<pages>449-453</pages>
		<journal_book_name>Developments in biological standardization</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2295">
		<reference_name>Thirdborough et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Thirdborough SM, Radcliffe JN, Friedmann PS, Stevenson FK</authors>
		<title>Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma</title>
		<year>2002</year>
		<volume>62</volume>
		<issue>6</issue>
		<pages>1757-1760</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5199">
		<reference_name>Thomas et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J</authors>
		<title>NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives</title>
		<year>2018</year>
		<volume>9</volume>
		<issue></issue>
		<pages>947</pages>
		<journal_book_name>Frontiers in immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5289">
		<reference_name>Thompson et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Thompson LW, Garbee CF, Hibbitts S, Brinckerhoff LH, Pierce RA, Chianese-Bullock KA, Deacon DH, Engelhard VH, Slingluff CL Jr</authors>
		<title>Competition among peptides in melanoma vaccines for binding to MHC molecules</title>
		<year>2004</year>
		<volume>27</volume>
		<issue>6</issue>
		<pages>425-431</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5344">
		<reference_name>Thurner et al., 1999</reference_name>
		<reference_type>journal</reference_type>
		<authors>Thurner B, Haendle I, RÃ¶der C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, BrÃ¶cker EB, Steinman RM, Enk A, KÃ¤mpgen E, Schuler G</authors>
		<title>Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma</title>
		<year>1999</year>
		<volume>190</volume>
		<issue>11</issue>
		<pages>1669-1678</pages>
		<journal_book_name>The Journal of experimental medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2341">
		<reference_name>Timmerman et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R</authors>
		<title>Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma</title>
		<year>2002</year>
		<volume>62</volume>
		<issue>20</issue>
		<pages>5845-5852</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5260">
		<reference_name>Timmerman et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Timmerman JM, Vose JM, Czerwinski DK, Weng WK, Ingolia D, Mayo M, Denney DW, Levy R</authors>
		<title>Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma</title>
		<year>2009</year>
		<volume>50</volume>
		<issue>1</issue>
		<pages>37-46</pages>
		<journal_book_name>Leukemia &amp; lymphoma</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3949">
		<reference_name>Tolcher et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tolcher AW, Hao D, de Bono J, Miller A, Patnaik A, Hammond LA, Smetzer L, Van Wart Hood J, Merritt J, Rowinsky EK, Takimoto C, Von Hoff D, Eckhardt SG</authors>
		<title>Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer</title>
		<year>2006</year>
		<volume>24</volume>
		<issue>13</issue>
		<pages>2052-2058</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3858">
		<reference_name>Tomillero and Moral, 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tomillero A, Moral MA</authors>
		<title>Gateways to clinical trials</title>
		<year>2009</year>
		<volume>31</volume>
		<issue>10</issue>
		<pages>661-700</pages>
		<journal_book_name>Methods and findings in experimental and clinical pharmacology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5341">
		<reference_name>Tomita et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, Imamura Y, Yatsuda J, Sayem MA, Irie A, Hamada A, Jono H, Yoshida K, Tsunoda T, Daigo Y, Kohrogi H, Yoshitake Y, Nakamura Y, Shinohara M, Nishimura Y</authors>
		<title>Identification of immunogenic LY6K long peptide encompassing both CD4<sup>+</sup> and CD8<sup>+</sup> T-cell epitopes and eliciting CD4<sup>+</sup> T-cell immunity in patients with malignant disease</title>
		<year>2014</year>
		<volume>3</volume>
		<issue></issue>
		<pages>e28100</pages>
		<journal_book_name>Oncoimmunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3963">
		<reference_name>Toretsky et al., 1995</reference_name>
		<reference_type>journal</reference_type>
		<authors>Toretsky JA, Neckers L, Wexler LH</authors>
		<title>Detection of (11;22)(q24;q12) translocation-bearing cells in peripheral blood progenitor cells of patients with Ewing's sarcoma family of tumors</title>
		<year>1995</year>
		<volume>87</volume>
		<issue>5</issue>
		<pages>385-386</pages>
		<journal_book_name>Journal of the National Cancer Institute</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2903">
		<reference_name>Trepiakas et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Trepiakas R, Berntsen A, Hadrup SR, BjÃƒÂ¸rn J, Geertsen PF, Straten PT, Andersen MH, Pedersen AE, Soleimani A, Lorentzen T, Johansen JS, Svane IM</authors>
		<title>Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial</title>
		<year>2010</year>
		<volume>12</volume>
		<issue>6</issue>
		<pages>721-734</pages>
		<journal_book_name>Cytotherapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4015">
		<reference_name>Trimble et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Pardoll D, Wu TC</authors>
		<title>A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3</title>
		<year>2009</year>
		<volume>15</volume>
		<issue>1</issue>
		<pages>361-367</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5202">
		<reference_name>Triozzi et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Triozzi PL, Allen KO, Carlisle RR, Craig M, LoBuglio AF, Conry RM</authors>
		<title>Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma</title>
		<year>2005</year>
		<volume>11</volume>
		<issue>11</issue>
		<pages>4168-4175</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5208">
		<reference_name>Triozzi et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Triozzi PL, Bolger GB, Neidhart J, Rinehart JJ, Saleh M, Allen KO, Sellers S, Waddell MJ</authors>
		<title>Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer</title>
		<year>2005</year>
		<volume>65</volume>
		<issue>4</issue>
		<pages>316-321</pages>
		<journal_book_name>The Prostate</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3960">
		<reference_name>Trï¿½ck et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Trï¿½ck J, Snape MD, Tatangeli F, Voysey M, Yu LM, Faust SN, Heath PT, Finn A, Pollard AJ</authors>
		<title>Pneumococcal serotype-specific antibodies persist through early childhood after infant immunization: follow-up from a randomized controlled trial</title>
		<year>2014</year>
		<volume>9</volume>
		<issue>3</issue>
		<pages>e91413</pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5274">
		<reference_name>Tsang et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tsang KY, Palena C, Yokokawa J, Arlen PM, Gulley JL, Mazzara GP, Gritz L, Yafal AG, Ogueta S, Greenhalgh P, Manson K, Panicali D, Schlom J</authors>
		<title>Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules</title>
		<year>2005</year>
		<volume>11</volume>
		<issue>4</issue>
		<pages>1597-1607</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3972">
		<reference_name>Tummers et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tummers QR, Hoogstins CE, Gaarenstroom KN, de Kroon CD, van Poelgeest MI, Vuyk J, Bosse T, Smit VT, van de Velde CJ, Cohen AF, Low PS, Burggraaf J, Vahrmeijer AL</authors>
		<title>Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17</title>
		<year>2016</year>
		<volume>7</volume>
		<issue>22</issue>
		<pages>32144-32155</pages>
		<journal_book_name>Oncotarget</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5324">
		<reference_name>Turner et al., 1970</reference_name>
		<reference_type>journal</reference_type>
		<authors>Turner GS, Squires EJ, Murray HG</authors>
		<title>Inactivated smallpox vaccine. A comparison of inactivation methods</title>
		<year>1970</year>
		<volume>68</volume>
		<issue>2</issue>
		<pages>197-210</pages>
		<journal_book_name>The Journal of hygiene</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5138">
		<reference_name>Tykodi and Thompson, 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tykodi SS, Thompson JA</authors>
		<title>Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer</title>
		<year>2008</year>
		<volume>8</volume>
		<issue>12</issue>
		<pages>1947-1953</pages>
		<journal_book_name>Expert opinion on biological therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5303">
		<reference_name>Ueda et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ueda R, Ohkusu-Tsukada K, Fusaki N, Soeda A, Kawase T, Kawakami Y, Toda M</authors>
		<title>Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy</title>
		<year>2010</year>
		<volume>126</volume>
		<issue>4</issue>
		<pages>919-929</pages>
		<journal_book_name>International journal of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5360">
		<reference_name>Ullenhag et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ullenhag GJ, Spendlove I, Watson NF, Kallmeyer C, Pritchard-Jones K, Durrant LG</authors>
		<title>T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55</title>
		<year>2008</year>
		<volume>128</volume>
		<issue>2</issue>
		<pages>148-154</pages>
		<journal_book_name>Clinical immunology (Orlando, Fla.)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4026">
		<reference_name>van et al., 1991</reference_name>
		<reference_type>journal</reference_type>
		<authors>van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T</authors>
		<title>A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma</title>
		<year>1991</year>
		<volume>254</volume>
		<issue>5038</issue>
		<pages>1643-1647</pages>
		<journal_book_name>Science (New York, N.Y.)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3911">
		<reference_name>Van et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Van Damme P, Olsson SE, Block S, Castellsague X, Gray GE, Herrera T, Huang LM, Kim DS, Pitisuttithum P, Chen J, Christiano S, Maansson R, Moeller E, Sun X, Vuocolo S, Luxembourg A</authors>
		<title>Immunogenicity and Safety of a 9-Valent HPV Vaccine</title>
		<year>2015</year>
		<volume>136</volume>
		<issue>1</issue>
		<pages>e28-39</pages>
		<journal_book_name>Pediatrics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5357">
		<reference_name>van et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>van der Waart AB, Fredrix H, van der Voort R, Schaap N, Hobo W, Dolstra H</authors>
		<title>siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice</title>
		<year>2015</year>
		<volume>64</volume>
		<issue>5</issue>
		<pages>645-654</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3938">
		<reference_name>Van et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Van Damme P, Bonanni P, Bosch FX, Joura E, Kjaer SK, Meijer CJ, Petry KU, Soubeyrand B, Verstraeten T, Stanley M</authors>
		<title>Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines</title>
		<year>2016</year>
		<volume>34</volume>
		<issue>6</issue>
		<pages>757-761</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3887">
		<reference_name>Vardas et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Vardas E, Kaleebu P, Bekker LG, Hoosen A, Chomba E, Johnson PR, Anklesaria P, Birungi J, Barin B, Boaz M, Cox J, Lehrman J, Stevens G, Gilmour J, Tarragona T, Hayes P, Lowenbein S, Kizito E, Fast P, Heald AE, Schmidt C</authors>
		<title>A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus</title>
		<year>2010</year>
		<volume>26</volume>
		<issue>8</issue>
		<pages>933-942</pages>
		<journal_book_name>AIDS research and human retroviruses</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2946">
		<reference_name>Varella et al., 1981</reference_name>
		<reference_type>journal</reference_type>
		<authors>Varella AD, Bandiera DC, de Amorim AR Sr, Calvis LA, Santos IO, Escaleira N, Gentil F</authors>
		<title>Treatment of disseminated malignant melanoma with high-dose oral BCG</title>
		<year>1981</year>
		<volume>48</volume>
		<issue>6</issue>
		<pages>1353-1362</pages>
		<journal_book_name>Cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4000">
		<reference_name>Veltman et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Veltman JD, Lambers ME, van Nimwegen M, de Jong S, Hendriks RW, Hoogsteden HC, Aerts JG, Hegmans JP</authors>
		<title>Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity</title>
		<year>2010</year>
		<volume>2010</volume>
		<issue></issue>
		<pages>798467</pages>
		<journal_book_name>Journal of biomedicine &amp; biotechnology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3003">
		<reference_name>Vence et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, Bedikian AY, Homsi J, Hwu WJ, Boyd R, Radvanyi L, Hwu P</authors>
		<title>Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination</title>
		<year>2013</year>
		<volume>36</volume>
		<issue>4</issue>
		<pages>276-286</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5313">
		<reference_name>Vesikari et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Vesikari T, Brodszki N, van Damme P, Diez-Domingo J, Icardi G, Petersen LK, Tran C, Thomas S, Luxembourg A, Baudin M</authors>
		<title>A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus GardasilÂ® in 9-15-Year-Old Girls</title>
		<year>2015</year>
		<volume>34</volume>
		<issue>9</issue>
		<pages>992-998</pages>
		<journal_book_name>The Pediatric infectious disease journal</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5334">
		<reference_name>Vici et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Vici P, Pizzuti L, Mariani L, Zampa G, Santini D, Di Lauro L, Gamucci T, Natoli C, Marchetti P, Barba M, Maugeri-SaccÃ  M, Sergi D, Tomao F, Vizza E, Di Filippo S, Paolini F, Curzio G, Corrado G, Michelotti A, Sanguineti G, Giordano A, De Maria R, Venuti A</authors>
		<title>Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies</title>
		<year>2016</year>
		<volume>15</volume>
		<issue>10</issue>
		<pages>1327-1336</pages>
		<journal_book_name>Expert review of vaccines</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5370">
		<reference_name>Vivier et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S</authors>
		<title>Functions of natural killer cells</title>
		<year>2008</year>
		<volume>9</volume>
		<issue>5</issue>
		<pages>503-510</pages>
		<journal_book_name>Nature immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4033">
		<reference_name>Vogel et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Vogel TU, Visan L, Ljutic B, Gajewska B, Caterini J, Salha D, Wen T, He L, Parrington M, Cao SX, McNeil B, Sandhu D, Scollard N, Zhang L, Bradley B, Tang M, Lovitt C, Oomen R, Dunn P, Tartaglia J, Berinstein NL</authors>
		<title>Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma</title>
		<year>2010</year>
		<volume>33</volume>
		<issue>8</issue>
		<pages>743-758</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference974">
		<reference_name>Vollmer et al., 1999</reference_name>
		<reference_type>journal</reference_type>
		<authors>Vollmer CM Jr, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, Montejo LD, Lee MC, Andrews KJ, McBride WH, Glaspy JA, Economou JS</authors>
		<title>Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma</title>
		<year>1999</year>
		<volume>59</volume>
		<issue>13</issue>
		<pages>3064-3067</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5192">
		<reference_name>Volz et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Volz B, Schmidt M, Heinrich K, Kapp K, Schroff M, Wittig B</authors>
		<title>Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist</title>
		<year>2016</year>
		<volume>3</volume>
		<issue></issue>
		<pages>15023</pages>
		<journal_book_name>Molecular therapy oncolytics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5212">
		<reference_name>von et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM</authors>
		<title>The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma</title>
		<year>2001</year>
		<volume>7</volume>
		<issue>5</issue>
		<pages>1181-1191</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3852">
		<reference_name>Wada et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H</authors>
		<title>Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2</title>
		<year>2005</year>
		<volume>65</volume>
		<issue>11</issue>
		<pages>4939-4946</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2362">
		<reference_name>Wagner et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wagner SN, Wagner C, LÃƒÂ¼hrs P, Weimann TK, Kutil R, Goos M, Stingl G, Schneeberger A</authors>
		<title>Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo</title>
		<year>2000</year>
		<volume>115</volume>
		<issue>6</issue>
		<pages>1082-1087</pages>
		<journal_book_name>The Journal of investigative dermatology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4024">
		<reference_name>Wagner et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wagner U, Kï¿½hler S, Reinartz S, Giffels P, Huober J, Renke K, Schlebusch H, Biersack HJ, Mï¿½bus V, Kreienberg R, Bauknecht T, Krebs D, Wallwiener D</authors>
		<title>Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001</title>
		<year>2001</year>
		<volume>7</volume>
		<issue>5</issue>
		<pages>1154-1162</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1471">
		<reference_name>Wagner et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wagner S, Jasinska J, Breiteneder H, Kundi M, Pehamberger H, Scheiner O, Zielinski CC, Wiedermann U</authors>
		<title>Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice</title>
		<year>2007</year>
		<volume>106</volume>
		<issue>1</issue>
		<pages>29-38</pages>
		<journal_book_name>Breast cancer research and treatment</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2941">
		<reference_name>Wallack et al., 1986</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wallack MK, McNally K, Michaelides M, Bash J, Bartolucci A, Siegler H, Balch C, Wanebo H</authors>
		<title>A phase I/II SECSG (Southeastern Cancer Study Group) pilot study of surgical adjuvant immunotherapy with vaccinia melanoma oncolysates (VMO)</title>
		<year>1986</year>
		<volume>52</volume>
		<issue>3</issue>
		<pages>148-151</pages>
		<journal_book_name>The American surgeon</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5130">
		<reference_name>Wang et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wang T, Fan L, Watanabe Y, McNeill PD, Moulton GG, Bangur C, Fanger GR, Okada M, Inoue Y, Persing DH, Reed SG</authors>
		<title>L523S, an RNA-binding protein as a potential therapeutic target for lung cancer</title>
		<year>2003</year>
		<volume>88</volume>
		<issue>6</issue>
		<pages>887-894</pages>
		<journal_book_name>British journal of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5136">
		<reference_name>Wang et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wang XY, Chen X, Manjili MH, Repasky E, Henderson R, Subjeck JR</authors>
		<title>Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100</title>
		<year>2003</year>
		<volume>63</volume>
		<issue>10</issue>
		<pages>2553-2560</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2358">
		<reference_name>Wang et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wang YJ, Hou Y, Huang H, Liu GR, White AP, Liu SL</authors>
		<title>Two oral HBx vaccines delivered by live attenuated Salmonella: both eliciting effective anti-tumor immunity</title>
		<year>2008</year>
		<volume>263</volume>
		<issue>1</issue>
		<pages>67-76</pages>
		<journal_book_name>Cancer letters</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2908">
		<reference_name>Wang et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wang J, Wang X, Chen Y, Wan M, Xiang Z, Wu X, Wei H, Wang L, Zhang P, Wang L, Yu Y</authors>
		<title>Immunization with a HSP65-HER2 fusion peptide selectively eliminates HER2(+) B16 melanoma cells in a xenograft tumor mouse model</title>
		<year>2013</year>
		<volume>34</volume>
		<issue>1</issue>
		<pages>193-201</pages>
		<journal_book_name>Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3002">
		<reference_name>Wang et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wang Z, You H, Song S</authors>
		<title>[Inhibiting effect of IL-10 in tumor microenvironment on anti-tumor activity of SOCS1-silenced DC vaccine]</title>
		<year>2013</year>
		<volume>29</volume>
		<issue>4</issue>
		<pages>379-383</pages>
		<journal_book_name>Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1293">
		<reference_name>Watson and Gilliam, 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Watson SA, Gilliam AD</authors>
		<title>G17DT--a new weapon in the therapeutic armoury for gastrointestinal malignancy</title>
		<year>2001</year>
		<volume>1</volume>
		<issue>2</issue>
		<pages>309-317</pages>
		<journal_book_name>Expert opinion on biological therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2951">
		<reference_name>WÃƒÂ¤tzig and Knopf, 1979</reference_name>
		<reference_type>journal</reference_type>
		<authors>WÃƒÂ¤tzig V, Knopf B</authors>
		<title>[Clinical administration of BCG-immunotherapy in malignant melanoma (author's transl)]</title>
		<year>1979</year>
		<volume>49</volume>
		<issue>2</issue>
		<pages>140-145</pages>
		<journal_book_name>Archiv fur Geschwulstforschung</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2363">
		<reference_name>Weber et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Weber LW, Bowne WB, Wolchok JD, Srinivasan R, Qin J, Moroi Y, Clynes R, Song P, Lewis JJ, Houghton AN</authors>
		<title>Tumor immunity and autoimmunity induced by immunization with homologous DNA</title>
		<year>1998</year>
		<volume>102</volume>
		<issue>6</issue>
		<pages>1258-1264</pages>
		<journal_book_name>The Journal of clinical investigation</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3925">
		<reference_name>Weber et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S, Lee PP</authors>
		<title>Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma</title>
		<year>2003</year>
		<volume>97</volume>
		<issue>1</issue>
		<pages>186-200</pages>
		<journal_book_name>Cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2353">
		<reference_name>Weber et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M, Miles S, Liu X, Obrocea M, Qiu Z, Bot A</authors>
		<title>Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma</title>
		<year>2008</year>
		<volume>31</volume>
		<issue>2</issue>
		<pages>215-223</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5147">
		<reference_name>Weber et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Weber JS, Vogelzang NJ, Ernstoff MS, Goodman OB, Cranmer LD, Marshall JL, Miles S, Rosario D, Diamond DC, Qiu Z, Obrocea M, Bot A</authors>
		<title>A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors</title>
		<year>2011</year>
		<volume>34</volume>
		<issue>7</issue>
		<pages>556-567</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3969">
		<reference_name>Weber et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA</authors>
		<title>Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma</title>
		<year>2013</year>
		<volume>31</volume>
		<issue>34</issue>
		<pages>4311-4318</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5268">
		<reference_name>Wei et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wei H, Bera TK, Wayne AS, Xiang L, Colantonio S, Chertov O, Pastan I</authors>
		<title>A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene</title>
		<year>2013</year>
		<volume>288</volume>
		<issue>17</issue>
		<pages>12305-12312</pages>
		<journal_book_name>The Journal of biological chemistry</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5345">
		<reference_name>Wei et al., 2019</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wei X, Chen F, Xin K, Wang Q, Yu L, Liu B, Liu Q</authors>
		<title>Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects</title>
		<year>2019</year>
		<volume>12</volume>
		<issue>5</issue>
		<pages>733-738</pages>
		<journal_book_name>Translational oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5096">
		<reference_name>Weide et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries IJ, Sucker A, Schadendorf D, BÃ¼ttner P, Garbe C, Pawelec G</authors>
		<title>Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis</title>
		<year>2012</year>
		<volume>30</volume>
		<issue>15</issue>
		<pages>1835-1841</pages>
		<journal_book_name>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5229">
		<reference_name>Weinstock et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Weinstock M, Rosenblatt J, Avigan D</authors>
		<title>Dendritic Cell Therapies for Hematologic Malignancies</title>
		<year>2017</year>
		<volume>5</volume>
		<issue></issue>
		<pages>66-75</pages>
		<journal_book_name>Molecular therapy. Methods &amp; clinical development</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5315">
		<reference_name>Wentink et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wentink MQ, Hackeng TM, Tabruyn SP, Puijk WC, Schwamborn K, Altschuh D, Meloen RH, Schuurman T, Griffioen AW, Timmerman P</authors>
		<title>Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity</title>
		<year>2016</year>
		<volume>113</volume>
		<issue>44</issue>
		<pages>12532-12537</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5210">
		<reference_name>Wettendorff et al., 1989</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wettendorff M, Iliopoulos D, Tempero M, Kay D, DeFreitas E, Koprowski H, Herlyn D</authors>
		<title>Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A</title>
		<year>1989</year>
		<volume>86</volume>
		<issue>10</issue>
		<pages>3787-3791</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1475">
		<reference_name>Wiki:  Cancer</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>Cancer</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://en.wikipedia.org/wiki/Cancer</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2879">
		<reference_name>Wilgenhof et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wilgenhof S, Van Nuffel AM, Corthals J, Heirman C, Tuyaerts S, Benteyn D, De Coninck A, Van Riet I, Verfaillie G, Vandeloo J, Bonehill A, Thielemans K, Neyns B</authors>
		<title>Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma</title>
		<year>2011</year>
		<volume>34</volume>
		<issue>5</issue>
		<pages>448-456</pages>
		<journal_book_name>Journal of immunotherapy (Hagerstown, Md. : 1997)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4012">
		<reference_name>Wilgenhof et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wilgenhof S, Van Nuffel AM, Benteyn D, Corthals J, Aerts C, Heirman C, Van Riet I, Bonehill A, Thielemans K, Neyns B</authors>
		<title>A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients</title>
		<year>2013</year>
		<volume>24</volume>
		<issue>10</issue>
		<pages>2686-2693</pages>
		<journal_book_name>Annals of oncology : official journal of the European Society for Medical Oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5209">
		<reference_name>Wilkinson et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wilkinson RW, Ross EL, Lee-MacAry AE, Laylor R, Burchell J, Taylor-Papadimitriou J, Snary D</authors>
		<title>A transgenic mouse model for tumour immunotherapy: induction of an anti-idiotype response to human MUC1</title>
		<year>2000</year>
		<volume>83</volume>
		<issue>9</issue>
		<pages>1202-1208</pages>
		<journal_book_name>British journal of cancer</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2296">
		<reference_name>Williams et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Williams BB, Wall M, Miao RY, Williams B, Bertoncello I, Kershaw MH, Mantamadiotis T, Haber M, Norris MD, Gautam A, Darcy PK, Ramsay RG</authors>
		<title>Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer</title>
		<year>2008</year>
		<volume>57</volume>
		<issue>11</issue>
		<pages>1635-1645</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5151">
		<reference_name>Winthrop et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Winthrop KL, Korman N, Abramovits W, Rottinghaus ST, Tan H, Gardner A, Mukwaya G, Kaur M, Valdez H</authors>
		<title>T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment</title>
		<year>2018</year>
		<volume>78</volume>
		<issue>6</issue>
		<pages>1149-1155.e1</pages>
		<journal_book_name>Journal of the American Academy of Dermatology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2896">
		<reference_name>Wolchok et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wolchok JD, Weber JS, Hamid O, LebbÃƒÂ© C, Maio M, Schadendorf D, de Pril V, Heller K, Chen TT, Ibrahim R, Hoos A, O'Day SJ</authors>
		<title>Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials</title>
		<year>2010</year>
		<volume>10</volume>
		<issue></issue>
		<pages>9</pages>
		<journal_book_name>Cancer immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3007">
		<reference_name>Wolfraim et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wolfraim LA, Takahara M, Viley AM, Shivakumar R, Nieda M, Maekawa R, Liu LN, Peshwa MV</authors>
		<title>Clinical scale electroloading of mature dendritic cells with melanoma whole tumor cell lysate is superior to conventional lysate co-incubation in triggering robust in vitro expansion of functional antigen-specific CTL</title>
		<year>2013</year>
		<volume>15</volume>
		<issue>3</issue>
		<pages>488-497</pages>
		<journal_book_name>International immunopharmacology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2994">
		<reference_name>Woods and Cebon, 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Woods K, Cebon J</authors>
		<title>Tumor-specific T-cell help is associated with improved survival in melanoma</title>
		<year>2013</year>
		<volume>19</volume>
		<issue>15</issue>
		<pages>4021-4023</pages>
		<journal_book_name>Clinical cancer research : an official journal of the American Association for Cancer Research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2964">
		<reference_name>Wu et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wu H, Han Y, Qin Y, Cao C, Xia Y, Liu C, Wang Y</authors>
		<title>Whole-cell vaccine coated with recombinant calreticulin enhances activation of dendritic cells and induces tumour-specific immune responses</title>
		<year>2013</year>
		<volume>29</volume>
		<issue>2</issue>
		<pages>529-534</pages>
		<journal_book_name>Oncology reports</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2414">
		<reference_name>Xiang et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Xiang R, Luo Y, Niethammer AG, Reisfeld RA</authors>
		<title>Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis</title>
		<year>2008</year>
		<volume>222</volume>
		<issue></issue>
		<pages>117-128</pages>
		<journal_book_name>Immunological reviews</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2905">
		<reference_name>Xie et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Xie Y, Wang L, Freywald A, Qureshi M, Chen Y, Xiang J</authors>
		<title>A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling</title>
		<year>2013</year>
		<volume>10</volume>
		<issue>1</issue>
		<pages>72-77</pages>
		<journal_book_name>Cellular &amp; molecular immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5134">
		<reference_name>Xing et al., 2018</reference_name>
		<reference_type>journal</reference_type>
		<authors>Xing P, Wang H, Yang S, Han X, Sun Y, Shi Y</authors>
		<title>Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer</title>
		<year>2018</year>
		<volume>19</volume>
		<issue>1</issue>
		<pages>14</pages>
		<journal_book_name>BMC immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2996">
		<reference_name>Xu et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Xu G, Smith T, Grey F, Hill AB</authors>
		<title>Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice</title>
		<year>2013</year>
		<volume>437</volume>
		<issue>2</issue>
		<pages>287-291</pages>
		<journal_book_name>Biochemical and biophysical research communications</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3008">
		<reference_name>Xu et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Xu M, Xing Y, Zhou L, Yang X, Yao W, Xiao W, Ge C, Ma Y, Yang J, Wu J, Cao R, Li T, Liu J</authors>
		<title>Improved efficacy of therapeutic vaccination with viable human umbilical vein endothelial cells against murine melanoma by introduction of OK432 as adjuvant</title>
		<year>2013</year>
		<volume>34</volume>
		<issue>3</issue>
		<pages>1399-1408</pages>
		<journal_book_name>Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5145">
		<reference_name>Yaddanapudi and Eaton, 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Yaddanapudi K, Eaton JW</authors>
		<title>Multi-peptide immunotherapeutic vaccine for renal cell carcinoma: getting the troops all worked up</title>
		<year>2012</year>
		<volume>1</volume>
		<issue>4</issue>
		<pages>229-233</pages>
		<journal_book_name>Translational andrology and urology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference964">
		<reference_name>Yang et al., 1995</reference_name>
		<reference_type>journal</reference_type>
		<authors>Yang G, HellstrÃ¶m KE, HellstrÃ¶m I, Chen L</authors>
		<title>Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules</title>
		<year>1995</year>
		<volume>154</volume>
		<issue>6</issue>
		<pages>2794-2800</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5286">
		<reference_name>Yang et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Yang S, Linette GP, Longerich S, Haluska FG</authors>
		<title>Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity</title>
		<year>2002</year>
		<volume>169</volume>
		<issue>1</issue>
		<pages>531-539</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3890">
		<reference_name>Yano et al., 2016</reference_name>
		<reference_type>journal</reference_type>
		<authors>Yano S, Takehara K, Tazawa H, Kishimoto H, Urata Y, Kagawa S, Fujiwara T, Hoffman RM</authors>
		<title>Efficacy of a Cell-Cycle Decoying Killer Adenovirus on 3-D Gelfoamï¿½-Histoculture and Tumor-Sphere Models of Chemo-Resistant Stomach Carcinomatosis Visualized by FUCCI Imaging</title>
		<year>2016</year>
		<volume>11</volume>
		<issue>9</issue>
		<pages>e0162991</pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3924">
		<reference_name>Yoo et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Yoo GH, Moon J, Leblanc M, Lonardo F, Urba S, Kim H, Hanna E, Tsue T, Valentino J, Ensley J, Wolf G</authors>
		<title>A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group</title>
		<year>2009</year>
		<volume>135</volume>
		<issue>9</issue>
		<pages>869-874</pages>
		<journal_book_name>Archives of otolaryngology--head &amp; neck surgery</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5348">
		<reference_name>Yu et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ</authors>
		<title>Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma</title>
		<year>2004</year>
		<volume>64</volume>
		<issue>14</issue>
		<pages>4973-4979</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3012">
		<reference_name>Yu et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Yu X, Guo C, Yi H, Qian J, Fisher PB, Subjeck JR, Wang XY</authors>
		<title>A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity</title>
		<year>2013</year>
		<volume>73</volume>
		<issue>7</issue>
		<pages>2093-2103</pages>
		<journal_book_name>Cancer research</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5215">
		<reference_name>Yuan et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD</authors>
		<title>CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit</title>
		<year>2008</year>
		<volume>105</volume>
		<issue>51</issue>
		<pages>20410-20415</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference4038">
		<reference_name>Zachariae et al., 1991</reference_name>
		<reference_type>journal</reference_type>
		<authors>Zachariae H, Aslam HM, Bjerring P, Sï¿½gaard H, Zachariae E, Heickendorff L</authors>
		<title>Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis</title>
		<year>1991</year>
		<volume>25</volume>
		<issue>1 Pt 1</issue>
		<pages>50-53</pages>
		<journal_book_name>Journal of the American Academy of Dermatology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5207">
		<reference_name>Zaidi et al., 2019</reference_name>
		<reference_type>journal</reference_type>
		<authors>Zaidi N, Quezada SA, Kuroiwa JMY, Zhang L, Jaffee EM, Steinman RM, Wang B</authors>
		<title>Anti-CTLA-4 synergizes with dendritic cell-targeted vaccine to promote IL-3-dependent CD4<sup>+</sup> effector T cell infiltration into murine pancreatic tumors</title>
		<year>2019</year>
		<volume>1445</volume>
		<issue>1</issue>
		<pages>62-73</pages>
		<journal_book_name>Annals of the New York Academy of Sciences</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3966">
		<reference_name>Zajac et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Zajac P, Oertli D, Marti W, Adamina M, Bolli M, Guller U, Noppen C, Padovan E, Schultz-Thater E, Heberer M, Spagnoli G</authors>
		<title>Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients</title>
		<year>2003</year>
		<volume>14</volume>
		<issue>16</issue>
		<pages>1497-1510</pages>
		<journal_book_name>Human gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3829">
		<reference_name>Zandberg et al., 2015</reference_name>
		<reference_type>journal</reference_type>
		<authors>Zandberg DP, Rollins S, Goloubeva O, Morales RE, Tan M, Taylor R, Wolf JS, Schumaker LM, Cullen KJ, Zimrin A, Ord R, Lubek JE, Suntharalingam M, Papadimitriou JC, Mann D, Strome SE, Edelman MJ</authors>
		<title>A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)</title>
		<year>2015</year>
		<volume>64</volume>
		<issue>3</issue>
		<pages>367-379</pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3956">
		<reference_name>Zangwill et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Zangwill KM, Eriksen E, Lee M, Lee J, Marcy SM, Friedland LR, Weston W, Howe B, Ward JI</authors>
		<title>A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization</title>
		<year>2008</year>
		<volume>122</volume>
		<issue>6</issue>
		<pages>1179-1185</pages>
		<journal_book_name>Pediatrics</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5269">
		<reference_name>Zebertavage et al., 2019</reference_name>
		<reference_type>journal</reference_type>
		<authors>Zebertavage L, Bambina S, Shugart J, Alice A, Zens KD, Lauer P, Hanson B, Gough MJ, Crittenden MR, Bahjat KS</authors>
		<title>A microbial-based cancer vaccine for induction of EGFRvIII-specific CD8+ T cells and anti-tumor immunity</title>
		<year>2019</year>
		<volume>14</volume>
		<issue>1</issue>
		<pages>e0209153</pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference959">
		<reference_name>Zhai et al., 1996</reference_name>
		<reference_type>journal</reference_type>
		<authors>Zhai Y, Yang JC, Kawakami Y, Spiess P, Wadsworth SC, Cardoza LM, Couture LA, Smith AE, Rosenberg SA</authors>
		<title>Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy</title>
		<year>1996</year>
		<volume>156</volume>
		<issue>2</issue>
		<pages>700-710</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3894">
		<reference_name>Zhai et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Zhai SQ, Guo W, Hu YY, Yu N, Chen Q, Wang JZ, Fan M, Yang WY</authors>
		<title>Protective effects of brain-derived neurotrophic factor on the noise-damaged cochlear spiral ganglion</title>
		<year>2011</year>
		<volume>125</volume>
		<issue>5</issue>
		<pages>449-454</pages>
		<journal_book_name>The Journal of laryngology and otology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2366">
		<reference_name>Zhang et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Zhang M, Obata C, Hisaeda H, Ishii K, Murata S, Chiba T, Tanaka K, Li Y, Furue M, Chou B, Imai T, Duan X, Himeno K</authors>
		<title>A novel DNA vaccine based on ubiquitin-proteasome pathway targeting 'self'-antigens expressed in melanoma/melanocyte</title>
		<year>2005</year>
		<volume>12</volume>
		<issue>13</issue>
		<pages>1049-1057</pages>
		<journal_book_name>Gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2375">
		<reference_name>Zhang et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Zhang X, Yu C, Zhao J, Fu L, Yi S, Liu S, Yu T, Chen W</authors>
		<title>Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice</title>
		<year>2007</year>
		<volume>9</volume>
		<issue>8</issue>
		<pages>715-726</pages>
		<journal_book_name>The journal of gene medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2351">
		<reference_name>Zhang et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Zhang H, Wang Y, Liu C, Zhang L, Xia Q, Zhang Y, Wu J, Jiang C, Chen Y, Wu Y, Zha X, Yu X, Kong W</authors>
		<title>DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model</title>
		<year>2012</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name>Cancer immunology, immunotherapy : CII</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5218">
		<reference_name>Zhang et al., 2017</reference_name>
		<reference_type>journal</reference_type>
		<authors>Zhang X, Sharma PK, Peter Goedegebuure S, Gillanders WE</authors>
		<title>Personalized cancer vaccines: Targeting the cancer mutanome</title>
		<year>2017</year>
		<volume>35</volume>
		<issue>7</issue>
		<pages>1094-1100</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3277">
		<reference_name>Zhi et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Zhi H, Han L, Ren J, Tian H, Luo W, Liang Y, Ruan L</authors>
		<title>[Construction of recombinant vaccinia virus co-expressing mutant E6 plus E7 proteins and detection of its immunogenicity and antitumor response]</title>
		<year>2002</year>
		<volume>16</volume>
		<issue>4</issue>
		<pages>341-344</pages>
		<journal_book_name>Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference5306">
		<reference_name>Zhu et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Zhu Y, Zheng Y, Mei L, Liu M, Li S, Xiao H, Zhu H, Wu S, Chen H, Huang L</authors>
		<title>Enhanced immunotherapeutic effect of modified HPV16 E7-pulsed dendritic cell vaccine by an adeno-shRNA-SOCS1 virus</title>
		<year>2013</year>
		<volume>43</volume>
		<issue>4</issue>
		<pages>1151-1159</pages>
		<journal_book_name>International journal of oncology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
</VIOLIN>


